

## 参考文献

### 上卷

#### 第1章

1. Eyler JM. The changing assessments of John Snow's and William Farr's cholera studies. *Soz Praventivmed*. 2001;46:225-232.
2. Haynes RB, Sackett DL, Gray JM, et al. Transferring evidence from research into practice: 1. The role of clinical care research evidence in clinical decisions. *ACP J Club*. 1996;125:A14-A16.
3. Dawber TR, Kannel WB. The Framingham study. An epidemiological approach to coronary heart disease. *Circulation*. 1966;34:553-555.
4. Kannel WB, Castelli WP, McNamara PM. Cigarette smoking and risk of coronary heart disease. Epidemiologic clues to pathogenesis. The Framingham Study. *Natl Cancer Inst Monogr*. 1968;28:9-20.
5. Freedman B. Equipoise and the ethics of clinical research. *N Engl J Med*. 1987;317:141-145.
6. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. *BMJ*. 2003;327:1459-1461.
7. Smith ML, Glass GV. Meta-analysis of psychotherapy outcome studies. *Am Psychol*. 1977;32:752-760.
8. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA*. 2000;283:2008-2012.
9. Jones DR. Meta-analysis of observational epidemiological studies: A review. *J R Soc Med*. 1992;85:165-168.
10. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*. 1994;50:1088-1101.
11. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315:629-634.
12. Nguyen LL, Conte MS, Menard MT, et al. Infrainguinal vein bypass graft revision: factors affecting long-term outcome. *J Vasc Surg*. 2004;40:916-923.
13. Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. *J Vasc Surg*. 2006;43:742-751, discussion 751.
14. McDermott MM, Mehta S, Liu K, et al. Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease. *J Gen Intern Med*. 1999;14:173-181.
15. Allison MA, Hiatt WR, Hirsch AT, et al. A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life. *J Am Coll Cardiol*. 2008;51:1292-1298.
16. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. *Can Med Assoc J*. 1985;132:919-923.
17. Montgomery PS, Gardner AW. The clinical utility of a six-minute walk test in peripheral arterial occlusive disease patients. *J Am Geriatr Soc*. 1998;46:706-711.
18. Le Faucheur A, Abraham P, Jaquinandi V, et al. Measurement of walking distance and speed in patients with peripheral arterial disease: a novel method using a global positioning system. *Circulation*. 2008;117:897-904.
19. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992;30:473-483.
20. Rabin R, de Charro F. EQ-5D: A measure of health status from the EuroQol Group. *Ann Med*. 2001;33:337-343.
21. Regensteiner JG, Steiner JF, Panzer RJ, et al. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. *J Vasc Med Biol*. 1990;2:142-150.
22. Morgan MB, Crayford T, Murrin B, et al. Developing the Vascular Quality of Life Questionnaire: a new disease-specific

- quality of life measure for use in lower limb ischemia. *J Vasc Surg.* 2001;33:679-687.
23. Nguyen LL, Moneta GL, Conte MS, et al. Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia. *J Vasc Surg.* 2006;44:977-983.

## 第 2 章

1. Carlson BM. *Human Embryology and Developmental Biology*. 4th ed. Philadelphia: Elsevier; 2009:116-119.
2. Zhan W, Yatskievych TA, Baker RK, Antin PB. Regulation of Hex gene expression and initial stages of avian hepatogenesis by Bmp and Fgf signaling. *Dev Biol.* 2004;268:312-326.
3. Lin FJ, Tsai M-J, Tsai SY. Artery and vein formation: a tug of war between different forces. *EMBO Rep.* 2007;8:920-924.
4. Red-Horse K, Crawford Y, Shojaei F, Ferrara N. Endothelium-microenvironment interactions in the developing embryo and in the adult. *Dev Cell.* 2007;12:181-194.
5. Carlson BM. *Human Embryology and Developmental Biology*. 4th ed. Philadelphia: Elsevier; 2009:437-483.
6. Kadir S. Regional anatomy of the thoracic aorta. In: Kadir S, ed. *Atlas of Normal and Variant Angiographic Anatomy*. Philadelphia: WB Saunders; 1991:19-54.
7. Arciniegas E, Hakimi M, Hertzler JH, et al. Surgical management of congenital vascular rings. *J Thorac Cardiovasc Surg.* 1979;77:721-727.
8. Mahoney EB, Manning JA. Congenital abnormalities of the aortic arch. *Surgery.* 1964;55:1-14.
9. Richardson JV, Doty DB, Rossi NP, Ehrenhaft JL. Operation for aortic arch anomalies. *Ann Thorac Surg.* 1981;31:426-432.
10. Binet JP, Longlois J. Aortic arch anomalies in children and infants. *J Thorac Cardiovasc Surg.* 1977;73:248-253.
11. Lincoln JC, Deverall PB, Stark J, et al. Vascular anomalies compressing the esophagus and trachea. *Thorax.* 1969;24:295-306.
12. Davies M, Guest PJ. Developmental abnormalities of the great vessels of the thorax and their embryological basis. *Br J Radiol.* 2003;76:491-502.
13. Jaffe RB. Complete interruption of the aortic arch. 2. Characteristic angiographic features with emphasis on collateral circulation to the descending aorta. *Circulation.* 1976;53:161-168.
14. Merklin RJ, Michaels NA. The variant renal and suprarenal blood supply with data on inferior phrenic, ureteral, and gonadal arteries: a statistical analysis based on 185 dissections and review of the literature. *J Int Coll Surg.* 1958;29:41-76.
15. Ridley JH. The kidney and ureter. In: Gray SW, Skandalakis JE, eds. *Embryology for Surgeons. The Embryologic Basis for the Treatment of Congenital Defects*. Philadelphia: WB Saunders; 1972:443-552.
16. Anson BJ, Richardson GA, Minear WL. Variations in the number and arrangement of the renal vessels. A study of the blood supply of four hundred kidneys. *J Urol.* 1936;36:211-219.
17. Carlson BM. *Human Embryology and Developmental Biology*. 4th ed. Philadelphia: Elsevier; 2009:230-233.
18. Rodriguez-Niedenfuhr M, Burton GJ, Deu J, Sanudo JR. Development of the arterial pattern in the upper limb of staged human embryos: normal development and anatomic variations. *J Anat.* 2001;199:407-417.
19. Senior HD. The development of the arteries of the human lower extremity. *Am J Anat.* 1919;25:55-95.
20. Mayschak DT, Flye WM. Treatment of the persistent sciatic artery. *Ann Surg.* 1984;199:69-74.
21. McLellan GL, Moretti LB. Persistent sciatic artery: clinical, surgical, and angiographic aspects. *Arch Surg.* 1982;117:817-822.
22. Brantley SK, Rigdon EE, Raju S. Persistent sciatic artery: embryology, pathology, and treatment. *J Vasc Surg.* 1993;18:242-248.
23. Gibson MH, Mills JG, Johnson GE, Downs AR. Popliteal entrapment syndrome. *Ann Surg.* 1977;185:341-348.
24. Carlson BM. *Human Embryology and Developmental Biology*. 4th ed. Philadelphia: Elsevier; 2009:449-453.
25. Larsen WJ. *Human Embryology*. 3rd ed. Philadelphia: Churchill Livingstone; 2001, pp 209-217.
26. Nandy K, Blair CB Jr. Double superior venae cavae with completely paired azygous veins. *Anat Rec.* 1965;151:161-172.

27. Winter FS. Persistent left superior vena cava: survey of world literature and report of thirty additional cases. *Angiology*. 1954;5:90-132.
28. Babaian RJ, Johnson DE. Major venous anomalies complicating retroperitoneal surgery. *South Med J*. 1979;72:1254-1258.
29. Chuang VP, Mena CE, Hoskins PA. Congenital anomalies of the left renal vein: angiographic consideration. *Br J Radiol*. 1974;47:214-218.
30. Dardik H, Loop FD, Cox PA, Keshishian JM. "C-pattern" inferior vena cava. Embryogenesis and clinical implications. *JAMA*. 1967;200:248-249.
31. Kolbenstvedt A, Kolmannskog F, Lien HH. The anomalous inferior vena cava—another structure between the aorta and the superior mesenteric artery. *Br J Radiol*. 1981;54:423.
32. Brener BJ, Darling RC, Frederick PL, Linton RR. Major venous anomalies complicating abdominal aortic surgery. *Arch Surg*. 1974;108:159-165.
33. Mayo J, Gray R, St Louis E, et al. Anomalies of the inferior vena cava. *AJR Am J Roentgenol*. 1983;140:339-345.
34. Giordano JM, Trout HH III. Anomalies of the inferior vena cava. *J Vasc Surg*. 1986;3:924-928.

### 第 3 章

1. Rutherford RB, ed. *Vascular Surgery*. 4th ed. Philadelphia, PA: WB Saunders; 1995.
2. Sidawy A, Sumpio B, DePalma R, eds. *The Basic Science of Vascular Disease*. Armonk, NY: Futura; 1997.
3. Aird W. Phenotypic heterogeneity of the endothelium I. Structure, function, and mechanisms. *Circ Res*. 2007;100:158-173.
4. Clark J, Glagov S. Luminal surface of distended arteries, eliminating configurational and technical artefacts. *Br J Exp Pathol*. 1976;57:129-135.
5. Levy B, Tedgui A, eds. *Biology of the Arterial Wall*. Norwell, MA: Kluwer Academic; 1999.
6. van den Berg B, Vink H, Spaan J. The endothelial glycocalyx protects against myocardial edema. *Circ Res*. 2003;92:592-594.
7. Smith M, Long D, Damiano E, et al. Near-wall micro-PIV reveals a hydrodynamically relevant endothelial surface layer in venules in vivo. *Biophys J*. 2003;85:637-645.
8. Marchesi V. The role of pinocytic vesicles in the transport of materials across the walls of small blood vessels. *Invest Ophthalmol Vis Sci*. 1965;4:1111-1121.
9. Rostgaard J, Qvortrup K. Electron microscopic demonstrations of filamentous molecular sieve plugs in capillary fenestrae. *Microvasc Res*. 1997;53:1-13.
10. Simionescu M, Simionescu N, Palade G. Morphometric data on the endothelium of blood capillaries. *J Cell Biol*. 1974;60:128-152.
11. Wisse E. An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. *J Ultrastructure Res*. 1970;31:125-150.
12. Kramer R, Bensch K, Davison P, et al. Basal lamina formation by cultured microvascular endothelial cells. *J Cell Biol*. 1984;99:692-698.
13. Wang C, Shuaib A. Critical role of microvasculature basal lamina in ischemic brain injury. *Prog Neurobiol*. 2007;83:140-148.
14. Ts'ao C, Glagov S. Basal endothelial attachment: tenacity at cytoplasmic dense zone in the rabbit aorta. *Lab Invest*. 1970;23:510-516.
15. Schnittler H, Franke R, Akbay U, et al. Improved in vitro rheological system for studying the effect of fluid shear stress on cultured cells. *Am J Physiol*. 1993;265:C289-C298.
16. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases for arterial stiffness. *Hypertension*. 2005;45:1050-1055.
17. Wight T. Cell biology of arterial proteoglycans. *Arteriosclerosis*. 1989;9:1-20.
18. Merwin J, Anderson J, Kocher O, et al. Transforming growth factor  $\beta$ 1 modulates extracellular matrix organization and

- cell-cell junctional complex formation during in vitro angiogenesis. *J Cell Physiol.* 1990;142:117-128.
19. Kocher O, Madri J. Modulation of actin mRNAs in cultured capillary endothelial and aortic endothelial and smooth muscle cells by matrix components and TGF- $\beta$ 1. *In Vitro.* 1989;25:424-434.
  20. Grand D, Lelkes P, Fukuda K, et al. Intracellular mechanisms involved in basement membrane-induced blood vessel differentiation in vitro. *In Vitro Cell Dev Biol.* 1991;27A:327-336.
  21. Madri J, Pratt B. Endothelial cell matrix-interactions: in vitro models of angiogenesis. *J Histochem Cytochem.* 1986;34:85-91.
  22. Ingber D, Folkman J. Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. *J Cell Biol.* 1989;109:317-330.
  23. Mecham R, Maradras J, McDonald J, et al. Elastin production by cultured calf pulmonary artery endothelial cells. *J Cell Physiol.* 1963;116:282-288.
  24. Damiano V, Tsona A, Kueich U, et al. Immuno electron microscopic studies on cells synthesizing elastin. *Connect Tissue Res.* 1981;8:185-188.
  25. Sims F. The initiation of intimal thickening in human arteries. *Pathology.* 2000;32:171-175.
  26. Tada S, Tarbell J. Fenestral power size in the internal elastic lamina affects the flow distribution in the artery wall. *Ann Biomed Eng.* 2002;29:456-466.
  27. Clark J, Glagov S. Structural integration of the arterial wall. I: Relationships and attachments of medial smooth muscle cells in normally distended and hyperdistended aortas. *Lab Invest.* 1979;40:587-602.
  28. Davis E. Smooth muscle cell to elastic lamina connections in developing mouse aorta. Role in aortic medial organization. *Lab Invest.* 1993;68:89-99.
  29. Berry C, Sosa-Melgarejo J, Greenwald S. The relationship between wall tension, lamellar thickness, and intercellular junctions in the fetal and adult aorta: its relevance to the pathology of dissecting aneurysm. *J Pathol.* 1993;169:15-20.
  30. Johnson J, Jackson C. Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. *Atherosclerosis.* 2001;154:399-406.
  31. Sims F, Gavin J, Koelmeyer S, et al. Comparison of the endothelial surface and the subjacent elastic lamina of the anterior descending coronary arteries at the location of the atheromatous lesions with internal thoracic arteries of the same subjects: a scanning electron microscopic study. *Pathology.* 2002;34:433-441.
  32. Guo ZY, Yan ZQ, Bai L, et al. Flow shear stress affects macromolecular accumulation through modulation of internal elastic lamina fenestrae. *Clin Biomech (Bristol, Avon).* 2008;23(Suppl 1):S104-S111.
  33. Penn M, Saidel G, Chisolm G. Relative significance of endothelium and internal elastic lamina in regulating the entry of macromolecules into arteries in vivo. *Circ Res.* 1994;74:74-82.
  34. Avolio A, Jones D, Tafazzoli-Shadpour M. Quantification of alterations in structure and function of elastin in the arterial media. *Hypertension.* 1998;32:170-175.
  35. Dobrin P. Distribution of lamellar deformations: implications for properties of the arterial media. *Hypertension.* 1999;33:806-810.
  36. Thyberg J. Differentiated properties and proliferation of arterial smooth muscle cells in culture. *Int Rev Cytol.* 1996;169:183-265.
  37. Cai W, Kocsis E, Wu X, et al. Remodeling of the vascular tunica media is essential for the development of collateral vessels in the canine heart. *Mol Cell Biochem.* 2004;264:201-210.
  38. Clark J, Glagov S. Transmural organization of the arterial media: the lamellar unit revisited. *Arteriosclerosis.* 1985;5:19-34.
  39. Wolinsky H, Glacov S. A lamellar unit of aortic medial structure and function in mammals. *Circ Res.* 1967;20:99-111.
  40. Gore R, Bohlen H. Pressure regulation in the microcirculation. *Fed Procs.* 1975;34:2031-2037.
  41. Grow B. Circulatory correlates: vascular impedance, resistance, and capacitance. In: Bohr DF, Somlyo AP, Sparks HV, eds. *The Cardiovascular System, Vol II. Vascular Smooth Muscle.* Baltimore, MD: American Physiological Society (Williams



- & Wilkins); 1980: 353-408.
42. Hughes A, Thom S, Martin G, et al. Size and site-dependent heterogeneity of human vascular responses in vitro. *J Hypertens*. 1988;6:S173-S175.
  43. Aars H. Diameter and elasticity of the ascending aorta during infusion of noradrenaline. *Acta Physiol Scand*. 1971;83:133-138.
  44. Owen M. Phentolamine-resistant neurogenic constriction occurs in small arteries at higher frequencies. *Am J Physiol*. 1985;249:H404-H414.
  45. Mulvany M, Aalkjaer C. Structure and function of small arteries. *Physiol Rev*. 1990;70:922-946.
  46. Griffith S, Crowe J, Lincoln A, et al. Regional differences in the density of perivascular nerves and varicosities, noradrenaline content and responses to nerve stimulation in the rabbit ear artery. *Blood Vessels*. 1982;19:41-52.
  47. Carlson E, Burrows M, Johnson P. Electron microscopic studies of cat mesenteric arterioles, a structure-function analysis. *Microvasc Res*. 1982;24:123-141.
  48. Boutouyrie P, Lacolley P, Girerd X, et al. Sympathetic activation decreases radial artery compliance in humans. *Am J Physiol*. 1994;267:H1368-H1376.
  49. Sumpio B, ed. *Hemodynamic Forces and Vascular Cell Biology*. Austin, TX: RG Landes; 1993.
  50. Shimokawa H, Yasutake H, Fujii K, et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. *J Cardiovasc Pharmacol*. 1996;28:703-711.
  51. Scotland R, Madhani M, Chauhan S, et al. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice. *Circulation*. 2005;111:796-803.
  52. Ryan U, Rubanyi G, eds. *Endothelial Regulation of Vascular Tone*. New York, NY: Marcel Dekker; 1992.
  53. Colden-Stanfield M, Schilling W, Ritchie A, et al. Bradykinin-induced increases in cytosolic calcium and ionic current in cultured bovine aortic endothelial cells. *Circ Res*. 1987;61:632-640.
  54. Rhee S, Suh P, Ryu S, et al. Studies of inositol phospholipid-specific phospholipase C. *Science*. 1989;244:546-550.
  55. Katada T, Gilman A, Watanabe Y, et al. Protein kinase C phosphorylates the inhibitory guanine-nucleotide-binding regulatory component and apparently suppresses its function in hormonal inhibition of adenylate cyclase. *Eur J Biochem*. 1985;151:431-437.
  56. Bennet C, Crooke S. Purification and characterization of a phosphoinositide-specific phospholipase C from guinea pig uterus. *J Biol Chem*. 1987;262:13789-13797.
  57. Jaken S. Diacylglycerol: the role of stimulated production in activation of protein kinase C. In: Iyengar R, Birnbaumer L, eds. *G-Proteins*. San Diego, CA: Academic Press; 1990:163-178.
  58. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. *Nature*. 1988;334:661-665.
  59. Phillips W, Fujiki T, Rossi M, et al. Influence of calcium on the subcellular distribution of protein kinase C in human neutrophils. *J Biol Chem*. 1989;264:8361-8365.
  60. Gertler J, Abbott W. Current research review: prothrombotic and fibrinolytic function of normal and perturbed endothelium. *J Surg Res*. 1992;52:89-95.
  61. Luscher T, Vanhoutte P, eds. *The Endothelium: Modulator of Cardiovascular Function*. Boston, MA: CRC Press; 1990.
  62. Vanhoutte P. Endothelium and control of vascular function. State of the art lecture. *Hypertension*. 1989;13:658-667.
  63. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. *N Engl J Med*. 1978;299:53.
  64. Moncada S. Prostacyclin and arterial wall biology. *Arterioscl Thromb Vasc Biol*. 1982;2:193-207.
  65. Macintyre D, Pearson J, Gordon J. Localisation and stimulation of prostacyclin production in vascular cells. *Nature*. 1978;271:549-551.
  66. Vallance P, Webb D, eds. *Vascular Endothelium in Human Physiology and Pathophysiology*. Amsterdam, Netherlands:

Harwood Academic Publishers; 2000.

67. Best L, Martin T, Russell R, et al. Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets. *Nature*. 1977;267:850-851.
68. Moncada S, Gryglewski R, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. *Nature*. 1976;263:663-665.
69. Gorman R, Bunting S, Miller O. Modulation of human platelet adenylate cyclase by proxtacyclin (PGX). *Prostaglandins*. 1977;13:377-388.
70. Radomski M, Moncada S. Biologic role of nitric oxide in platelet function. In: Moncada S, Higgs EA, Berrazueta S, eds. *Clinical Relevance of Nitric Oxide in the Cardiovascular System*. Madrid: EDICOMPLET; 1991:45-56.
71. Moncada S, Higgs A. The l-arginine–nitric oxide pathway. *N Engl J Med*. 1993;329:2002-2012.
72. Spiecker M, Pend H, Liao J. Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of I $\kappa$ -B $\alpha$ . *J Biol Chem*. 1997;272:30969-30974.
73. Tsao P, Wang B, Buitrago R, et al. Nitric oxide regulates monocyte chemotactic protein-1. *Circulation*. 1997;96:934-940.
74. Katsuyama K, Shichiri M, Marumo F, et al. NO inhibits cytokine-induced iNOS expression and NF- $\kappa$ B activation by interfering with phosphorylation and degradation of I $\kappa$ B $\alpha$ . *Arterioscler Thromb Vasc Biol*. 1998;18:1796-1802.
75. Kubes P, Suzuki M, Granger D. Nitric oxide: an endogenous modulator of leukocyte adhesion. *Proc Natl Acad Sci U S A*. 1991;88:4651-4655.
76. Nakaki T, Nakayama M, Kato R. Inhibition by nitric oxide and nitric oxide–producing vasodilators of DNA synthesis in vascular smooth muscle cells. *Eur J Pharmacol*. 1990;189:347-353.
77. Sarkar R, Meinberg E, Stanley J, et al. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. *Circ Res*. 1996;78:225-230.
78. Lee J, Adrie C, Jacob H, et al. Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury. *Circ Res*. 1996;78:337-342.
79. Naruse K, Simizu K, Muramatsu M, et al. Long-term inhibition of NO synthesis promotes atherosclerosis in hypercholesterolaemic rabbit thoracic aorta: PGH<sup>2</sup> does not contribute to impaired endothelium-dependent relaxation. *Arterioscler Thromb Vasc Biol*. 1994;14:746-752.
80. Ignarro L. Haem-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: a unique transduction mechanism for transcellular signaling. *Pharmacol Toxicol*. 1990;67:1-7.
81. Hobbs A. Soluble guanylate cyclase: the forgotten sibling. *Trends Pharmacol Sci*. 1997;18:484-490.
82. Bolotina V, Najibi S, Palacino J, et al. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. *Nature*. 1994;368:850-853.
83. Jia L, Bonaventura C, Bonaventura J, et al. S-Nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. *Nature*. 1996;380:221-226.
84. Boulanger C, Luscher T. Release of endothelin from the porcine aorta. Inhibition of endothelium derived nitric oxide. *J Clin Invest*. 1990;85:587-590.
85. Rees D, Palmer R, Schulz R, et al. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. *Br J Pharmacol*. 1990;101:746-751.
86. Hassid A, Arabshahi H, Bourcier T, et al. Nitric oxide selectively amplifies FGF-2-induced mitogenesis in primary aortic smooth muscle cells. *Am J Physiol*. 1994;267:H1040-H1048.
87. Fish JE, Marsden PA. Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium. *Cell Mol Life Sci*. 2006;63:144-162.
88. Bult H, Boeckxstaens G, Pelckmans P, et al. Nitric oxide as an inhibitory non-adrenergic non-cholinergic neurotransmitter. *Nature*. 1990;345:346-347.
89. Schmidt K, Werner E, Mayer B, et al. Tetrahydrobiopterin-dependent formation of endothelium-derived relaxing factor

- (nitric oxide) in aortic endothelial cells. *Biochem J*. 1992;281:297-300.
90. Vallance P, Leane A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. *Lancet*. 1992;339:572-575.
  91. Boger R, Bode-Boger S, Brandes R, et al. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. *Circulation*. 1997;96:1282-1290.
  92. Busse R, Mulsch A, Fleming I, et al. Mechanisms of nitric oxide release from the vascular endothelium. *Circulation*. 1993;87:V18-V25.
  93. Uematsu M, Ohara Y, Navas J, et al. Regulation of endothelial cell nitric oxide synthase mRNA expression by shear stress. *Am J Physiol*. 1995;269:C1371-C1378.
  94. Papapetropoulos A, Garcia-Cardena G, Madri J, et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. *J Clin Invest*. 1997;100:3131-3139.
  95. Rosenkranz-Weiss P, Sessa W, Milstien S, et al. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. *J Clin Invest*. 1994;93:2236-2243.
  96. Liao J, Shin W, Lee W, et al. Oxidized low-density lipoproteins decrease the expression of endothelial nitric oxide synthase. *J Biol Chem*. 1995;270:319-324.
  97. Anderson H, Rahmutula D, Gardner D. Tumor necrosis factor- $\alpha$  inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. *J Biol Chem*. 2004;279:963-969.
  98. McQuillan L, Leung G, Marsden P, et al. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. *Am J Physiol*. 1994;267:H1921-H1927.
  99. Wilcox J, Subramanian R, Sundell C, et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. *Arterioscler Thromb Vasc Biol*. 1997;17:2479-2488.
  100. Spagnoli LG, Villaschi S, Neri L, et al. Gap junctions in myo-endothelial bridges of rabbit carotid arteries. *Experientia*. 1982;38:124-125.
  101. Mombouli J, Vanhoutte P. Endothelium-derived hyperpolarizing factor(s): updating the unknown. *Trends Pharmacol Sci*. 1997;18:252-256.
  102. Wagner O, Christ G, Wojta J. Polar secretion of endothelin-1 by cultured endothelial cells. *J Biol Chem*. 1992;267:16066-16068.
  103. Stewart D, Langleben D, Cernacek P. Endothelin release is inhibited by coculture of endothelial cells with cells of vascular media. *Am J Physiol*. 1990;259:H1928-H1932.
  104. Rensen S, Doevendans R, van Eys GJ. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. *Neth Heart J*. 2007;15:100-108.
  105. Mombouli J, Bissirou I, Agboton D, et al. Bioassay of endothelium-derived hyperpolarizing factor. *Biochem Biophys Res Commun*. 1996;221:484-488.
  106. Taylor S, Southerton J, Weston A, et al. Endothelium-dependent effects of acetylcholine in rat aorta: a comparison with sodium nitroprusside and cromakalim. *Br J Pharmacol*. 1988;94:853-863.
  107. Owen N. Regulation of Na/K/CL cotransport in vascular smooth muscle cells. *Biochem Biophys Res Commun*. 1984;125:500-508.
  108. O'Donnell M, Owen N. Role of cyclic GMP in atrial natriuretic factor stimulation of Na<sup>+</sup>, K<sup>+</sup>, Cl<sup>-</sup> cotransport in vascular smooth muscle cells. *J Biol Chem*. 1986;261:15461-15466.
  109. Archer SL, Huang JM, Hampl V, et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. *Proc Natl Acad Sci U S A*. 1994;91:7583-7587.
  110. Morgan J, Morgan K. Alteration of cytoplasmic ionized calcium levels in smooth muscle by vasodilators in the ferret. *J Physiol*. 1984;357:539-551.
  111. Rapaport R, Murad F. Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through

- cGMP. *Circ Res*. 1983a;52:352-357.
112. Feletou M, Vanhoutte P. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. *Br J Pharmacol*. 1988;93:515-524.
  113. Kausar K, Stekiel W, Rubanyi G, et al. Mechanism of action of EDRF on pressurized arteries: effect of K<sup>+</sup> conductance. *Circ Res*. 1989;65:199-204.
  114. Seo B, Oemar B, Siebenmann R. Both ET<sub>A</sub> and ET<sub>B</sub> receptors mediate contraction to endothelin-1 in human blood vessels. *Circulation*. 1994;89:1203.
  115. Bomberger R, Zarins C, Taylor K, et al. Effect of hypotension on atherogenesis and aortic wall composition. *J Surg Res*. 1980;28:401-409.
  116. Rubanyi G, Romero C, Vanhoutte P. Flow-induced release of endothelium-derived relaxing factor. *Am J Physiol*. 1986;250:H1145-H1149.
  117. Pohl U, Holtz J, Busse R, et al. Crucial role of endothelium in the vasodilator response to increase in flow in vivo. *Hypertension*. 1986;8:37-44.
  118. Cheng G, Libby P, Grodzinsky A, et al. Induction of DNA synthesis by a single transient mechanical stimulus of human vascular smooth muscle cells: role of fibroblast growth factor-2. *Circulation*. 1996;93:99-105.
  119. Langille B, Bendec M, Keeley F. Adaptations of carotid arteries of young and mature rabbits to reduced carotid blood flow. *Am J Physiol*. 1989;256:H931-H939.
  120. Levy B, Durize M, Phillip M, et al. Effect of chronic dihydropyridine on the large arterial wall of spontaneously hypertensive rats. *Circulation*. 1994;90:3024-3033.
  121. Helmlinger G, Geiger R, Schreck S, et al. Effects of pulsatile flow on cultured vascular endothelial cell morphology. *J Biomech Eng*. 1991;113:123-131.
  122. Sato M, Ohshima N. Flow-induced changes in shape and cytoskeletal structure of vascular endothelial cells. *Biorheology*. 1993;31:143-153.
  123. Davies P, Tripathi S. Mechanical stress mechanisms and the cell. An endothelial paradigm. *Circ Res*. 1993;72:239-245.
  124. Davies P. Flow-mediated endothelial mechanotransduction. *Physiol Rev*. 1995;75:519-560.
  125. Gimbrone M, Topper J. Biology of the vessel wall. In: Chien KR, ed. *Molecular Basis of Cardiovascular Disease*. Philadelphia, PA: WB Saunders; 1999:331-348.
  126. Resnick N, Gimbrone M Jr. Hemodynamic forces are complex regulators of endothelial gene expression. *FASEB J*. 1995;9:874-882.
  127. Dull R, Davies P. Flow modulation of agonist (ATP)-response (Ca<sup>2+</sup>) coupling in vascular endothelial cells. *Am J Physiol*. 1991;261:H149-H154.
  128. Mo M, Eskin S, Schilling W. Flow-induced changes in Ca<sup>2+</sup> signaling of vascular endothelial cells: effect of shear stress and ATP. *Am J Physiol*. 1991;260:H1698-H1707.
  129. Nollert M, Diamond S, McIntire L. Hemodynamic shear stress and mass transport modulation of endothelial cell metabolism. *Biotechnol Bioeng*. 1991;38:588-602.
  130. Nollert M, Panaro N, McIntire L. Regulation of genetic expression in shear stress-stimulated endothelial cells. *Ann N Y Acad Sci*. 1992;665:94-104.
  131. Qu, M, Liu B, Qang H, et al. Frequency-dependent phenotype modulation of vascular smooth muscle cells under cyclic mechanical strain. *J Vasc Res*. 2007;44:345-353.
  132. Iba T, Shin T, Sonoda T, et al. Stimulation of endothelial secretion of tissue-type plasminogen activator by repetitive stretch. *J Surg Res*. 1991;50:457-460.
  133. Smith P, Tokui T, Ikebe M. Mechanical strain increases contractile enzyme activity in cultured airway smooth muscle cells. *Am J Physiol*. 1995;268:L999-L1005.
  134. Rubanyi G, Vanhoutte P. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. *Am J Physiol*.

1986;250:H822-H887.

135. Beckman J, Koppenol W. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. *Am J Physiol.* 1996;271:C1424-C1437.
136. Cooke J. Does ADMA cause endothelial dysfunction? *Arterioscler Thromb Vasc Biol.* 2000;20:2032-2037.
137. Vanhoutte P, ed. *Relaxing and Contracting Factors: Biological and Clinical Research*. Clifton, New Jersey: Humana; 1988.
138. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vasomotor tone. *J Clin Invest.* 1996;97:1916-1923.
139. Fukui T, Ishizaka N, Rajagopalan S, et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. *Circ Res.* 1997;80:45-51.
140. Panza J, Cannon R, eds. *Endothelium, Nitric Oxide, and Atherosclerosis: From Basic Mechanisms to Clinical Implications*. Armonk, NY: Futura; 1999.
141. Alexander R. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. *Hypertension.* 1995;25:155-161.
142. Mugge A, Elwell J, Peterson T, et al. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. *Am J Physiol.* 1991;260:C219-C225.
143. Thomson L, Trujillo M, Telleri R, et al. Kinetics of cytochrome c2+ oxidation by peroxynitrite: implications for superoxide measurements in nitric oxide-producing biological systems. *Arch Biochem Biophys.* 1995;319:491-497.
144. Harrison D. Perspective series: nitric oxide and nitric oxide synthases. Cellular and molecular mechanisms of endothelial cell dysfunction. *J Clin Invest.* 1997;199:2153-2157.
145. Beckman J, Beckman T, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and peroxide. *Proc Natl Acad Sci U S A.* 1990;87:1620-1624.
146. Harrison D. Endothelial function and oxidant stress. *Clinl Cardi.* 1997;29:III11-III17.
147. Howard B, Alexander R, Nerem R, et al. Cyclic strain induces an oxidative stress in endothelial cells. *Am J Physiol.* 1997;272:C421-C427.
148. DeKeulenaer G, Chappell D, Ishizaka N, et al. Oscillatory and steady laminar shear stress differentially affect human endothelial redox state. *Circ Res.* 1998;82:1094-1101.
149. Inoue N, Ramaswamy S, Fukai R, et al. Shear stress modulates expression of Cu/Zn superoxide dismutase in human aortic endothelial cells. *Circ Res.* 1996;79:32-37.
150. Griendling K, Minieri C, Ollerenshaw J, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. *Circ Res.* 1994;74:1141-1148.
151. Ushio-Fukai M, Zafari A, Fukui T, et al. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. *J Biol Chem.* 1996;271:23317-23321.
152. Ushio-Fukai M, Alexander R, Akers M, et al. p38 MAP kinase is a critical component of the redox-sensitive signaling pathways by angiotensin II: role in vascular smooth muscle cell hypertrophy. *J Biol Chem.* 1998;273:15022-15029.
153. Pollman M, Yamada T, Horiuchi M, et al. Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. *Circ Res.* 1996;79:748-756.
154. Borg-Capra C, Fournet-Bourguignon M, Janiak P, et al. Morphological heterogeneity with normal expression but altered function of G<sub>i</sub> proteins in culture regenerated porcine coronary endothelial cells. *Br J Pharmacol.* 1997;122:999-1008.
155. Shimokawa H, Vanhoutte P. Angiographic demonstration of hyperconstriction induced by serotonin and aggregating platelets in porcine coronary arteries with regenerated endothelium. *J Am Coll Cardiol.* 1991;17:1197-1202.
156. Shimokawa H, Vanhoutte P. Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive

- substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. *Circ Res*. 1989;64:900-914.
157. Ishikawa S, Miyauchi T, Salcai S, et al. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. *J Thorac Cardiovasc Surg*. 1996;110:217-273.
  158. Goerre S, Wenk M, Bartsch P, et al. Endothelin-1 in pulmonary hypertension associated with high altitude. *Circulation*. 1995;91:359-364.
  159. Tanner F, Noll G, Boulanger C, et al. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. *Circulation*. 1991;83:2012-2020.
  160. Huang C, Voisard R, Lenich A, et al. Increased endothelin release by cultured human smooth muscle cells from atherosclerotic coronary arteries. *Cardiovasc Res*. 1996;31:807-813.
  161. Timm M, Kaski J, Dashwood M. Endothelin-like immunoreactivity in atherosclerotic human coronary arteries. *J Cardiovasc Pharmacol*. 1996;127:147-153.
  162. Shibano T, Codina J, Birnbaumer L. Pertussis toxin-sensitive G-proteins in regenerated endothelial cells after balloon denudation of porcine coronary artery. *Am J Physiol*. 1994;267:H979-H981.
  163. Flavahan N, Vanhoutte P. Endothelial cell signaling and endothelial dysfunction. *Am J Hypertens*. 1995;8:28S-41S.
  164. Shimokawa H, Aarhus L, Vanhoutte P. Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin. *Circ Res*. 1987;61:256-270.
  165. Shimokawa H, Flavahan N, Vanhoutte P. Natural course of the impairment of endothelium-dependent relaxations after balloon endothelial removal in porcine coronary arteries. Possible dysfunction of a pertussis toxin-sensitive G protein. *Circ Res*. 1989;65:740-753.
  166. Minor R Jr, Myers P, Guerra R Jr, et al. Diet induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. *J Clin Invest*. 1990;86:2109-2116.
  167. Sakai S, Miyauchi T, Sakurai T, et al. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. *J Am Coll Cardiol*. 1996;28:1580-1588.
  168. Love M, Haynes W, Gray G. Vasodilator effects of endothelin-1-mediated vasoconstriction in severe chronic heart failure. *Lancet*. 1995;346:732-736.
  169. Steward D, Kubac G, Costello K. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. *J Am Coll Cardiol*. 1991;18:38-43.
  170. Omland T, Terje Lie R, Askvaag A, et al. Plasma endothelin determination as a prognostic indicator of a 1-year mortality after acute myocardial infarction. *Circulation*. 1994;89:1573-1579.

## 第 4 章

1. Bonow RO, Smaha LA, Smith Jr SC, et al. World Heart Day 2002: The international burden of cardiovascular disease: responding to the emerging global epidemic. *Circulation*. 2002;106:1602-1605.
2. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. *N Engl J Med*. 2007;356:2388-2398.
3. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2008;117:e25-e146.
4. McGill Jr HC, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. *Circulation*. 2008;117:1216-1227.
5. Hayman LL, Meininger JC, Daniels SR, et al. Primary prevention of cardiovascular disease in nursing practice: focus on children and youth: a scientific statement from the American Heart Association Committee on Atherosclerosis,

- Hypertension, and Obesity in Youth of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity, and Metabolism. *Circulation*. 2007;116:344-357.
6. Lieberman EH, Gerhard MD, Uehata A, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. *Am J Cardiol*. 1996;78:1210-1214.
  7. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. *Lancet*. 1992;340:1111-1115.
  8. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. *Circulation*. 1995;91:1314-1319.
  9. Camejo G, Hurt-Camejo E, Wiklund O, et al. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. *Atherosclerosis*. 1998;139:205-222.
  10. Camejo G, Fager G, Rosengren B, et al. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. *J Biol Chem*. 1993;268:14131-14137.
  11. Pentikainen MO, Oorni K, Lassila R, et al. The proteoglycan decorin links low density lipoproteins with collagen type I. *J Biol Chem*. 1997;272:7633-7638.
  12. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2008;28:812-819.
  13. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. *Physiol Rev*. 2004;84:767-801.
  14. Ang AH, Tachas G, Campbell JH, et al. Collagen synthesis by cultured rabbit aortic smooth-muscle cells. Alteration with phenotype. *Biochem J*. 1990;265:461-469.
  15. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque: Part I: evolving concepts. *J Am Coll Cardiol*. 2005;46:937-954.
  16. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Arterioscler Thromb Vasc Biol*. 1995;15:1512-1531.
  17. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation*. 1994;89:2462-2478.
  18. Faggiotto A, Ross R. Studies of hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. *Arteriosclerosis*. 1984;4:341-356.
  19. Faggiotto A, Ross R, Harker L. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. *Arteriosclerosis*. 1984;4:423-440.
  20. Bruschke AV, Kramer Jr JR, Bal ET, et al. The dynamics of progression of coronary atherosclerosis studied in 168 medically treated patients who underwent coronary arteriography three times. *Am Heart J*. 1989;117:296-305.
  21. Yokoya K, Takatsu H, Suzuki T, et al. Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: a study based on four serial coronary arteriograms per year. *Circulation*. 1999;100:903-909.
  22. Newman WP 3rd, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. *N Engl J Med*. 1986;314:138-144.
  23. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. *N Engl J Med*. 1998;338:1650-1656.
  24. McGill Jr HC, McMahan CA, Zieske AW, et al. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. *Circulation*. 2001;103:1546-1550.
  25. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young

- adults: evidence from intravascular ultrasound. *Circulation*. 2001;103:2705-2710.
26. Nakashima Y, Chen YX, Kinukawa N, et al. Distributions of diffuse intimal thickening in human arteries: preferential expression in atherosclerosis-prone arteries from an early age. *Virchows Arch*. 2002;441:279-288.
  27. Libby P, Theroux P. Pathophysiology of coronary artery disease. *Circulation*. 2005;111:3481-3488.
  28. van der Wal AC, Becker AE, van der Loos CM, et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. *Circulation*. 1994;89:36-44.
  29. Hong MK, Mintz GS, Lee CW, et al. A three-vessel virtual histology intravascular ultrasound analysis of frequency and distribution of thin-cap fibroatheromas in patients with acute coronary syndrome or stable angina pectoris. *Am J Cardiol*. 2008;101:568-572.
  30. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. *Science*. 1986;232:34-47.
  31. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part I. *J Lipid Res*. 2004;45:1583-1593.
  32. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part II: the early evidence linking hypercholesterolemia to coronary disease in humans. *J Lipid Res*. 2005;46:179-190.
  33. Gofman JW, Lindgren FT, Elliott H. Ultracentrifugal studies of lipoproteins of human serum. *J Biol Chem*. 1949;179:973-979.
  34. Gofman JW, Jones HB, Lyon TP, et al. Atherosclerosis, lipoproteins, and coronary artery disease. *Wisc Med J*. 1952;51:687-689.
  35. Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. *Proc Natl Acad Sci U S A*. 1973;70:2804-2808.
  36. Brown MS, Dana SE, Goldstein JL. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. *J Biol Chem*. 1974;249:789-796.
  37. Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. *Proc Natl Acad Sci U S A*. 1974;71:788-792.
  38. Robertson TL, Kato H, Gordon T, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Coronary heart disease risk factors in Japan and Hawaii. *Am J Cardiol*. 1977;39:244-249.
  39. Robertson TL, Kato H, Rhoads GG, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Incidence of myocardial infarction and death from coronary heart disease. *Am J Cardiol*. 1977;39:239-243.
  40. Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. *Ann Intern Med*. 1961;55:33-50.
  41. Dayton S, Pearce ML, Goldman H, et al. Controlled trial of a diet high in unsaturated fat for prevention of atherosclerotic complications. *Lancet*. 1968;2:1060-1062.
  42. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. *JAMA*. 1984;251:365-374.
  43. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. *JAMA*. 1984;251:351-364.
  44. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344:1383-1389.



45. Duguid JB. Pathogenesis of atherosclerosis. *Lancet*. 1949;2:925-927.
46. Poole JC, Florey HW. Changes in the endothelium of the aorta and the behaviour of macrophages in experimental atheroma of rabbits. *J Pathol Bacteriol*. 1958;75:245-251.
47. French JE. Atherosclerosis in relation to the structure and function of the arterial intima, with special reference to the endothelium. *Int Rev Exp Pathol*. 1966;5:253-353.
48. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. *Science*. 1973;180:1332-1339.
49. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature*. 1993;362:801-809.
50. Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts). *N Engl J Med*. 1976;295:420-425.
51. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). *N Engl J Med*. 1976;295:369-377.
52. Ross R. The pathogenesis of atherosclerosis—an update. *N Engl J Med*. 1986;314:488-500.
53. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med*. 1999;340:115-126.
54. Ross R, Glomset J, Kariya B, et al. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. *Proc Natl Acad Sci U S A*. 1974;71:1207-1210.
55. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. *Cell*. 1986;46:155-169.
56. Nievelstein PF, Fogelman AM, Mottino G, et al. Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein. A deep-etch and immunolocalization study of ultrarapidly frozen tissue. *Arterioscler Thromb*. 1991;11:1795-1805.
57. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. *Arteriosclerosis*. 1989;9:908-918.
58. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions. *Arteriosclerosis*. 1989;9:895-907.
59. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. *Circulation*. 2007;116:1832-1844.
60. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. *Arterioscler Thromb Vasc Biol*. 1995;15:551-561.
61. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. *Proc Natl Acad Sci U S A*. 1973;70:1753-1756.
62. Linder D, Gartler SM. Glucose-6-phosphate dehydrogenase mosaicism: utilization as a cell marker in the study of leiomyomas. *Science*. 1965;150:67-69.
63. Fialkow PJ. Use of genetic markers to study cellular origin and development of tumors in human females. *Adv Cancer Res*. 1972;15:191-226.
64. Fialkow PJ. The origin and development of human tumors studied with cell markers. *N Engl J Med*. 1974;291:26-35.
65. Sary HC. Changes in components and structure of atherosclerotic lesions developing from childhood to middle age in coronary arteries. *Basic Res Cardiol*. 1994;89(Suppl 1):17-32.
66. Sary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Arterioscler Thromb*. 1994;14:840-856.
67. Taylor KE, Glagov S, Zarins CK. Preservation and structural adaptation of endothelium over experimental foam cell lesions. Quantitative ultrastructural study. *Arteriosclerosis*. 1989;9:881-894.
68. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. *Nature*. 2002;417:750-754.
69. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. *J Clin Invest*. 1989;84:1086-1095.

70. Gerrity RG. The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. *Am J Pathol.* 1981;103:191-200.
71. Gerrity RG. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. *Am J Pathol.* 1981;103:181-190.
72. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. *Blood.* 2003;101:2661-2666.
73. Cybulsky MI, Gimbrone Jr MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. *Science.* 1991;251:788-791.
74. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. *J Clin Invest.* 2001;107:1255-1262.
75. Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. *Circulation.* 2000;101:2290-2295.
76. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. *Mol Cell.* 1998;2:275-281.
77. Holvoet P, Davey PC, De Keyser D, et al. Oxidized low-density lipoprotein correlates positively with toll-like receptor 2 and interferon regulatory factor-1 and inversely with superoxide dismutase-1 expression: studies in hypercholesterolemic swine and THP-1 cells. *Arterioscler Thromb Vasc Biol.* 2006;26:1558-1565.
78. Quehenberger O. Thematic review series: the immune system and atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis. *J Lipid Res.* 2005;46:1582-1590.
79. Endemann G, Stanton LW, Madden KS, et al. CD36 is a receptor for oxidized low density lipoprotein. *J Biol Chem.* 1993;268:11811-11816.
80. Smith JD, Trogan E, Ginsberg M, et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. *Proc Natl Acad Sci U S A.* 1995;92:8264-8268.
81. Rajavashisth T, Qiao JH, Tripathi S, et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice. *J Clin Invest.* 1998;101:2702-2710.
82. Kume N, Cybulsky MI, Gimbrone Jr MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. *J Clin Invest.* 1992;90:1138-1144.
83. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. *Circulation.* 1995;92:1084-1088.
84. Sun J, Sukhova GK, Wolters PJ, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. *Nat Med.* 2007;13:719-724.
85. Schonbeck U, Libby P. CD40 signaling and plaque instability. *Circ Res.* 2001;89:1092-1103.
86. Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. *Arterioscler Thromb Vasc Biol.* 2002;22:1370-1380.
87. Johnson KA, Polewski M, Terkeltaub RA. Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. *Circ Res.* 2008;102:529-537.
88. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet.* 2005;366:1267-1278.
89. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet.* 2002;360:7-22.
90. Mills GL, Taylaur CE. The distribution and composition of serum lipoproteins in eighteen animals. *Comp Biochem Physiol B.* 1971;40:489-501.
91. Heart Protection Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk

- conditions. *J Vasc Surg*. 2007;45:645-654, discussion 655-664.
92. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106:3143-3421.
  93. Assmann G, Schulte H, von Eckardstein A, et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. *Atherosclerosis*. 1996;124(Suppl):S11-S20.
  94. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998;97:1837-1847.
  95. Warnick GR, Myers GL, Cooper GR, et al. Impact of the third cholesterol report from the adult treatment panel of the national cholesterol education program on the clinical laboratory. *Clin Chem*. 2002;48:11-17.
  96. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? *Nat Rev Drug Discov*. 2008;7:143-155.
  97. Glomset JA. The plasma lecithins: cholesterol acyltransferase reaction. *J Lipid Res*. 1968;9:155-167.
  98. Rader DJ. Molecular regulation of HDL metabolism and function: Implications for novel therapies. *J Clin Invest*. 2006;116:3090-3100.
  99. Tall AR, Jiang X, Luo Y, et al. 1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. *Arterioscler Thromb Vasc Biol*. 2000;20:1185-1188.
  100. Mineo C, Deguchi H, Griffin JH, et al. Endothelial and antithrombotic actions of HDL. *Circ Res*. 2006;98:1352-1364.
  101. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. *Circ Res*. 2004;95:764-772.
  102. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. *JAMA*. 2007;298:786-798.
  103. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. *Am J Clin Nutr*. 1992;56:320-328.
  104. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. *N Engl J Med*. 2004;350:1505-1515.
  105. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. *Arterioscler Thromb Vasc Biol*. 2004;24:490-497.
  106. Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. *J Lipid Res*. 2007;48:1263-1272.
  107. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med*. 2007;357:2109-2122.
  108. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. *N Engl J Med*. 2007;356:1620-1630.
  109. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. *N Engl J Med*. 2007;356:1304-1316.
  110. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. *Hypertension*. 2001;37:1236-1241.
  111. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. *Circulation*. 2003;107:2864-2869.
  112. Ziemann SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. *Arterioscler Thromb Vasc Biol*. 2005;25:932-943.
  113. Meaume S, Benetos A, Henry OF, et al. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. *Arterioscler Thromb Vasc Biol*. 2001;21:2046-2050.
  114. O'Rourke M, Frohlich ED. Pulse pressure: is this a clinically useful risk factor? *Hypertension*. 1999;34:372-374.
  115. Mitchell GF, DeStefano AL, Larson MG, et al. Heritability and a genome-wide linkage scan for arterial stiffness, wave

- reflection, and mean arterial pressure: the Framingham Heart Study. *Circulation*. 2005;112:194-199.
116. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. *Arterioscler Thromb Vasc Biol*. 2003;23:554-566.
  117. Dzau VJ. Significance of the vascular renin-angiotensin pathway. *Hypertension*. 1986;8:553-559.
  118. Huang F, Thompson JC, Wilson PG, et al. Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. *J Lipid Res*. 2008;49:521-530.
  119. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*. 2000;342:145-153.
  120. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*. 2003;362:782-788.
  121. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002;359:995-1003.
  122. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002;288:2981-2997.
  123. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. *JAMA*. 2004;292:2217-2225.
  124. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*. 2003;362:1527-1535.
  125. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002;360:1903-1913.
  126. Creager MA, Luscher TF, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. *Circulation*. 2003;108:1527-1532.
  127. Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. *JAMA*. 2003;290:1884-1890.
  128. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Health Study (CHS) Collaborative Research Group. *Circulation*. 1993;88:837-845.
  129. Jude EB, Oyibo SO, Chalmers N, et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. *Diabetes Care*. 2001;24:1433-1437.
  130. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature*. 2001;414:813-820.
  131. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature*. 2000;404:787-790.
  132. Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. *Proc Natl Acad Sci U S A*. 2000;97:12222-12226.
  133. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. *J Clin Invest*. 1991;87:1643-1648.
  134. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. *Circulation*. 1998;97:1695-1701.
  135. Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. *Circulation*. 2001;103:1282-1288.
  136. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. *J Am Coll Cardiol*. 1996;27:567-574.
  137. Nugent AG, McGurk C, Hayes JR, et al. Impaired vasoconstriction to endothelin 1 in patients with NIDDM. *Diabetes*.

1996;45:105-107.

138. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. *N Engl J Med.* 2000;342:381-389.
139. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med.* 1993;329:977-986.
140. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2008;358:2560-2572.
141. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med.* 2008;358:2545-2559.
142. Glantz SA, Parmley WW. Passive smoking and heart disease. Epidemiology, physiology, and biochemistry. *Circulation.* 1991;83:1-12.
143. Smith CJ, Fischer TH, Sears SB. Environmental tobacco smoke, cardiovascular disease, and the nonlinear dose-response hypothesis. *Toxicol Sci.* 2000;54:462-472.
144. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: An update. *J Am Coll Cardiol.* 2004;43:1731-1737.
145. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. *Circulation.* 1993;88:2149-2155.
146. Barua RS, Ambrose JA, Eales-Reynolds LJ, et al. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. *Circulation.* 2001;104:1905-1910.
147. Kugiyama K, Yasue H, Ohgushi M, et al. Deficiency in nitric oxide bioactivity in epicardial coronary arteries of cigarette smokers. *J Am Coll Cardiol.* 1996;28:1161-1167.
148. Tracy RP, Psaty BM, Macy E, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. *Arterioscler Thromb Vasc Biol.* 1997;17:2167-2176.
149. Mazzone A, Cusa C, Mazzucchelli I, et al. Cigarette smoking and hypertension influence nitric oxide release and plasma levels of adhesion molecules. *Clin Chem Lab Med.* 2001;39:822-826.
150. Rosenberg L, Kaufman DW, Helmrach SP, et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. *N Engl J Med.* 1985;313:1511-1514.
151. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. *Circulation.* 1997;96:1089-1096.
152. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. *J Am Coll Cardiol.* 1986;8:1245-1255.
153. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA.* 2002;288:321-333.
154. Sattler AM, Soufi M, Maisch B, et al. Lipids and lipoproteins in women. *Herz.* 2005;30:368-374, quiz 429-430.
155. Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. *Arch Pathol Lab Med.* 2007;31:872-884.
156. Wilson PW. Homocysteine and coronary heart disease: how great is the hazard? *JAMA.* 2002;288:2042-2043.
157. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. *JAMA.* 2002;288:2023-2031.
158. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. *JAMA.* 2002;288:2015-2022.
159. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. *BMJ.* 1998;316:894-898.

160. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. *JAMA*. 2007;298:1163-1170.
161. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. *JAMA*. 2003;290:898-904.
162. Corvol JC, Bouzamondo A, Sirol M, et al. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. *Arch Intern Med*. 2003;163:669-676.
163. Mega JL, Morrow DA, Cannon CP, et al. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. *J Thromb Thrombolysis*. 2006;22:71-76.
164. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. *Stroke*. 2001;32:2575-2579.
165. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med*. 2002;347:1557-1565.
166. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med*. 2000;342:836-843.
167. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. *Ann Intern Med*. 2006;45:21-29.
168. Boekholdt SM, Hack CE, Sandhu MS, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. *Atherosclerosis*. 2006;187:415-422.
169. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med*. 2005;352:20-28.
170. Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. *Circulation*. 2006;114:281-288.
171. Park R, Detrano R, Xiang M, et al. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. *Circulation*. 2002;106:2073-2077.
172. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. *JAMA*. 2005;294:1799-1809.
173. Scanu AM, Nakajima K, Edelstein C. Apolipoprotein(a): structure and biology. *Front Biosci*. 2001;6:D546-D554.
174. Scanu AM. Lp(a) lipoprotein—coping with heterogeneity. *N Engl J Med*. 2003;349:2089-2090.
175. Tseng CH. Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan. *Diabetes Care*. 2004;27:517-521.
176. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. *Arch Intern Med*. 2008;168:598-608.
177. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. *Circulation*. 1997;96:4095-4103.
178. Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis. *Eur Heart J*. 1993;14(Suppl K):30-38.
179. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. *JAMA*. 1989;261:3561-3566.
180. Cannon CP, Braunwald E, McCabe CH, et al. Antibiotic treatment of *Chlamydia pneumoniae* after acute coronary syndrome. *N Engl J Med*. 2005;352:1646-1654.
181. Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. *N Engl J Med*. 2005;352:1637-1645.
182. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. *JAMA*. 2003;290:1459-1466.

183. Schwartz SM, Benditt EP. Cell replication in the aortic endothelium: a new method for study of the problem. *Lab Invest.* 1973;28:699-707.
184. Wright HP. Mitosis patterns in aortic endothelium. *Atherosclerosis.* 1972;15:93-100.
185. Spaet TH, Lejnieks I. Mitotic activity of rabbit blood vessels. *Proc Soc Exp Biol Med.* 1967;125:1197-1201.
186. Insull W Jr., Bartsch GE. Cholesterol, triglyceride, and phospholipid content of intima, media, and atherosclerotic fatty streak in human thoracic aorta. *J Clin Invest.* 1966;45:513-523.
187. Collins T, Cybulsky MI. NF- $\kappa$ B: Pivotal mediator or innocent bystander in atherogenesis? *J Clin Invest.* 2001;107:255-264.
188. Guttridge DC, Albanese C, Reuther JY, et al. NF- $\kappa$ B controls cell growth and differentiation through transcriptional regulation of cyclin D1. *Mol Cell Biol.* 1999;19:5785-5799.
189. Akimoto S, Mitsumata M, Sasaguri T, et al. Laminar shear stress inhibits vascular endothelial cell proliferation by inducing cyclin-dependent kinase inhibitor p21 (Sdi1/Cip1/Waf1). *Circ Res.* 2000;86:185-190.
190. DePalma RG, Hubay CA, Insull Jr W, et al. Progression and regression of experimental atherosclerosis. *Surg Gynecol Obstet.* 1970;131:633-647.
191. DePalma RG, Insull Jr W, Bellon EM, et al. Animal models for the study of progression and regression of atherosclerosis. *Surgery.* 1972;72:268-278.
192. DePalma RG, Bellon EM, Koletsky S, et al. Atherosclerotic plaque regression in rhesus monkeys induced by bile acid sequestrant. *Exp Mol Pathol.* 1979;31:423-439.
193. DePalma RG, Klein L, Bellon EM, et al. Regression of atherosclerotic plaques in rhesus monkeys. Angiographic, morphologic, and angiochemical changes. *Arch Surg.* 1980;115:1268-1278.
194. Lichtlen PR, Nikutta P, Jost S, et al. Anatomical progression of coronary artery disease in humans as seen by prospective, repeated, quantitated coronary angiography. Relation to clinical events and risk factors. The INTACT Study Group. *Circulation.* 1992;86:828-838.
195. Asada Y, Hara S, Tsuneyoshi A, et al. Fibrin-rich and platelet-rich thrombus formation on neointima: recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta. *Thromb Haemost.* 1998;80:506-511.
196. Courtman DW, Schwartz SM, Hart CE. Sequential injury of the rabbit abdominal aorta induces intramural coagulation and luminal narrowing independent of intimal mass: extrinsic pathway inhibition eliminates luminal narrowing. *Circ Res.* 1998;82:996-1006.
197. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. *Circulation.* 2001;103:934-940.
198. Arnett EN, Isner JM, Redwood DR, et al. Coronary artery narrowing in coronary heart disease: comparison of cineangiographic and necropsy findings. *Ann Intern Med.* 1979;91:350-356.
199. Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol.* 2001;37:1478-1492.
200. Clarkson TB, Prichard RW, Morgan TM, et al. Remodeling of coronary arteries in human and nonhuman primates. *JAMA.* 1994;271:289-294.
201. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. *N Engl J Med.* 1987;316:1371-1375.
202. Hagenaaers T, Gussenhoven EJ, Kranendonk SE, et al. Progression of atherosclerosis at one-year follow-up seen with volumetric intravascular ultrasound in femoropopliteal arteries. *Am J Cardiol.* 2000;85:226-231.
203. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. *JAMA.* 2006;295:1556-1565.

204. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. *JAMA*. 2004;291:1071-1080.
205. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med*. 2004;350:1495-1504.
206. Montauban van Swijndregt AD, Elbers HR, Moll FL, et al. Cerebral ischemic disease and morphometric analyses of carotid plaques. *Ann Vasc Surg*. 1999;13:468-474.
207. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? *Circulation*. 1988;78:1157-1166.
208. Fuster V, Badimon L, Cohen M, et al. Insights into the pathogenesis of acute ischemic syndromes. *Circulation*. 1988;77:1213-1220.
209. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. *J Am Coll Cardiol*. 1988;12:56-62.
210. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. *Br Heart J*. 1983;50:127-134.
211. Davies MJ, Thomas T. The pathological basis and microanatomy of occlusive thrombus formation in human coronary arteries. *Philos Trans R Soc Lond B Biol Sci*. 1981;294:225-229.
212. Maseri A, Fuster V. Is there a vulnerable plaque? *Circulation*. 2003;107:2068-2071.
213. Kaartinen M, Penttilä A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. *Circulation*. 1994;90:1669-1678.
214. Shah PK, Galis ZS. Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. *Circulation*. 2001;104:1878-1880.
215. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. *Circulation*. 1995;92:1565-1569.
216. Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. *Circulation*. 1997;96:396-399.
217. Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. *Proc Natl Acad Sci U S A*. 1997;94:1931-1936.
218. Schonbeck U, Mach F, Bonnefoy JY, et al. Ligation of CD40 activates interleukin 1 $\beta$ -converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1 $\beta$ . *J Biol Chem*. 1997;272:19569-19574.
219. Schonbeck U, Mach F, Sukhova GK, et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? *Circ Res*. 1997;81:448-454.
220. Edelberg JM, Christie PD, Rosenberg RD. Regulation of vascular bed-specific prothrombotic potential. *Circ Res*. 2001;89:117-124.
221. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. *J Clin Invest*. 1993;91:2546-2551.
222. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. *Am J Physiol*. 1992;263:H321-H326.
223. Creager MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. *J Clin Invest*. 1990;86:228-234.
224. Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. *Circulation*. 1996;93:1354-1363.



225. Sugiyama S, Kugiyama K, Aikawa M, et al. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. *Arterioscler Thromb Vasc Biol.* 2004;24:1309-1314.
226. Hazen SL. Myeloperoxidase and plaque vulnerability. *Arterioscler Thromb Vasc Biol.* 2004;24:1143-1146.
227. Dalager S, Paaske WP, Kristensen IB, et al. Artery-related differences in atherosclerosis expression: implications for atherogenesis and dynamics in intima-media thickness. *Stroke.* 2007;38:2698-2705.
228. Chatzizisis YS, Jonas M, Coskun AU, et al. Prediction of the localization of high-risk coronary atherosclerotic plaques on the basis of low endothelial shear stress: an intravascular ultrasound and histopathology natural history study. *Circulation.* 2008;117:993-1002.
229. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol.* 2002;39:257-265.
230. Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. *Circulation.* 2000;102:1000-1006.
231. Brevetti G, Silvestro A, Di Giacomo S, et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. *J Vasc Surg.* 2003;38:374-379.
232. Cleland SJ, Sattar N, Petrie JR, et al. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. *Clin Sci (Lond).* 2000;98:531-535.
233. Brevetti G, Silvestro A, Schiano V, et al. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. *Circulation.* 2003;108:2093-2098.
234. Gokce N, Keaney Jr JF, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. *Circulation.* 2002;105:1567-1572.
235. Gokce N, Keaney Jr JF, Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. *J Am Coll Cardiol.* 2003;41:1769-1775.
236. Amirbekian V, Lipinski MJ, Briley-Saebo KC, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. *Proc Natl Acad Sci U S A.* 2007;104:961-966.
237. Hyafil F, Cornily JC, Feig JE, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. *Nat Med.* 2007;13:636-641.
238. Kaufmann BA, Sanders JM, Davis C, et al. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. *Circulation.* 2007;116:276-284.

## 第 5 章

1. Ross R. The pathogenesis of atherosclerosis: An update. *N Engl J Med.* 1986;314:488-500.
2. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I: Smooth muscle cell growth in the absence of endothelium. *Lab Invest.* 1983;49:327-333.
3. Perlman H, Maillard L, Krasinski K, et al. Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. *Circulation.* 1997;95:981-987.
4. Grassl ED, Bischof JC. In vitro model systems for evaluation of smooth muscle cell response to cryoplasty. *Cryobiology.* 2005;50:162-173.
5. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle cell migration in the injured rat carotid artery. *Circ Res.* 1985;56:139-145.
6. Hanke H, Strohschneider T, Oberhoff M, et al. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. *Circ Res.* 1990;67:651-659.

7. Majesky MW, Schwartz SM, Clowes MM, et al. Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. *Circ Res*. 1987;61:296-300.
8. More RS, Ruttly G, Underwood MJ, et al. Assessment of myointimal cellular kinetics in a model of angioplasty by means of proliferating cell nuclear antigen expression. *Am Heart J*. 1994;128:681-686.
9. Waksman R, Rodriguez JC, Robinson KA, et al. Effect of intravascular irradiation on cell proliferation, apoptosis and vascular remodeling after balloon overstretch injury of porcine coronary arteries. *Circulation*. 1997;96:1944-1952.
10. Ferns GA, Raines EW, Sprugel KH, et al. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. *Science*. 1991;253:1129-1132.
11. Scott NA, Martin F, Simonet L, et al. Contribution of adventitial myofibroblasts to vascular remodeling and lesion formation after experimental angioplasty in pig coronaries [abstract]. *FASEB J*. 1995;9:A845.
12. Ferrer P, Valentine M, Jenkins-West T, et al. Periadventitial changes in the balloon injured rat carotid artery [abstract]. *FASEB J*. 1996;10:A618.
13. O'Brien ER, Alpers CE, Stewart DK, et al. Proliferation in primary and restenotic coronary atherectomy tissue: implications for antiproliferative therapy. *Circ Res*. 1993;73:223-231.
14. Bauriedel G, Windstetter U, DeMaio SJJ, et al. Migratory activity of human smooth muscle cells cultivated from coronary and peripheral primary and restenotic lesions removed by percutaneous atherectomy. *Circulation*. 1992;85:554-564.
15. Rekhater MD, Schwartz SM, O'Brien E, et al. Collagen I gene expression in human coronary lesions, primary atherosclerotic versus restenosis [abstract]. *Circulation*. 1993;88:I-228.
16. Sarembock IJ, LaVeau PJ, Sigal SL, et al. Influence of inflation pressure and balloon size on the development of intimal hyperplasia after balloon angioplasty. A study in the atherosclerotic rabbit. *Circulation*. 1989;80:1029-1040.
17. VanErven L, Post MJ, Velema E, et al. In the normal rabbit femoral artery increasing arterial wall injury does not lead to increased intimal hyperplasia. *J Vasc Res*. 1994;31:153-162.
18. Sakamoto H, Nozaki S, Misumi K, et al. Smooth muscle cell proliferation in the arterial intima after stretch injury—relationship between severity of stretching and intimal hyperplasia in the New Zealand White rabbits. *Jikken Dobutsu [Experimental Animals]*. 1996;45:89-93.
19. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. *Lab Invest*. 1983;49:208-215.
20. Clowes AW, Clowes MM, Fingerle J, et al. Regulation of smooth muscle cell growth in injured artery. *J Cardiovasc Pharmacol*. 1989;14(Suppl 6):S12-S15.
21. Andersen HR, Maeng M, Thorwest M, et al. Remodeling rather than neointimal formation explains luminal narrowing after deep vessel wall injury—insights from a porcine coronary (re)stenosis model. *Circulation*. 1996;93:1716-1724.
22. Moornekamp FN, Borst C, Post MJ. Endothelial cell coverage and intimal hyperplasia after endothelium removal with or without smooth muscle cell necrosis in the rabbit carotid artery. *J Vasc Res*. 1996;33:146-155.
23. Wilentz JR, Sanborn TA, Haudenschild CC, et al. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. *Circulation*. 1987;75:635-642.
24. Kaplan AV, Leung L-K, Leung W-H, et al. Roles of thrombin and platelet membrane glycoprotein IIb/IIIa in platelet-subendothelial deposition after angioplasty in an ex-vivo whole artery model. *Circulation*. 1991;84:1279-1288.
25. Bates ER, McGillem MJ, Mickelson JK, et al. A monoclonal antibody to the platelet receptor GPIIb/IIIa prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. *Circulation*. 1991;84:2463-2469.
26. Bates ER, Walsh DG, Mu D-X, et al. Sustained inhibition of the vessel wall—platelet interaction after deep coronary artery injury by temporary inhibition of the platelet glycoprotein IIb/IIIa receptor. *Coron Artery Dis*. 1992;3:67-76.
27. Fingerle J, Johnson R, Clowes AW, et al. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. *Proc Natl Acad Sci U S A*. 1989;86:8412-8416.
28. Schmaier AH. Contact activation: a revision. *Thromb Haemost*. 1997;78:101-107.
29. Marmur JD, Guha A, Nemerson Y, et al. Arterial smooth muscle expresses tissue factor in response to balloon injury and

- growth factors [abstract]. *Circulation*. 1992;86(Suppl I):I-20.
30. Hatakeyama K, Asada Y, Marutsuka K, et al. Expression of tissue factor in the rabbit aorta after balloon injury. *Atherosclerosis*. 1998;139:265-271.
  31. Hasentab D, Lea H, Hart CE, et al. Tissue factor overexpression in rat arterial neointima models thrombosis and progression of advanced atherosclerosis. *Circulation*. 2000;101:2651-2657.
  32. Speidel CM, Eisenberg PR, Ruf W, et al. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon injured aortas in rabbits. *Circulation*. 1995;92:3323-3330.
  33. Marmur JD, Rossikhina M, Guha A, et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. *J Clin Invest*. 1993;91:2253-2259.
  34. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor. *Arterioscler Thromb Vasc Biol*. 2002;22:539-548.
  35. Oltrona L, Speidel CM, Rechia D, et al. Inhibition of tissue factor mediated coagulation markedly attenuates stenosis after balloon induced arterial injury in minipigs. *Circulation*. 1997;96:646-652.
  36. Khouri RK, Brown DM, Choi ET, et al. Local application of TFPI inhibits intimal hyperplasia induced by arterial interventions. *Surg Forum*. 1996;47:389-391.
  37. Ragni M, Golino P, Scognamiglio A, et al. Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury. *Circulation*. 2000;102:113-117.
  38. Jang Y, Guzman LA, Lincoff AM, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. *Circulation*. 1995;92:3041-3050.
  39. Ragosta M, Gimple LW, Gertz SD, et al. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. *Circulation*. 1994;89:1262-1271.
  40. Schwartz RS, Holder DJ, Holmes DR, et al. Neointimal thickening after severe coronary injury is limited by short-term administration of factor Xa inhibitor in a porcine model. *Circulation*. 1996;93:1543-1548.
  41. Bar-Shavit R, Eldor A, Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. *J Clin Invest*. 1989;84:1096-1104.
  42. Ozazaki H, Majesky MW, Harker LA, et al. Regulation of platelet-derived growth factor ligand and receptor gene expression by alpha-thrombin in vascular smooth muscle cells. *Circ Res*. 1992;71:1285-1293.
  43. Wilcox JN, Rodriguez J, Subramanian RR, et al. Characterization of thrombin receptor expression during vascular lesion formation. *Circ Res*. 1994;75:1029-1038.
  44. Tollefsen DM. Heparin cofactor II modulates the response to vascular injury. *Arterioscler Thromb Vasc Biol*. 2007;27:454-460.
  45. Takamori N, Azuma H, Kato M, et al. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. *Circulation*. 2004;109:481-486.
  46. Schillinger M, Exner M, Sabeti S, et al. High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting. *Thromb Haemost*. 2004;92:1108-1113.
  47. Witmer MR, Hatton MWC. Antithrombin III- $\beta$  associates more readily than antithrombin III- $\alpha$  with uninjured and de-endothelialized aortic wall in vitro and in vivo. *Arterioscler Thromb*. 1991;11:530-539.
  48. Serruys RW, Herrman J-P, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. *N Engl J Med*. 1995;333:757-763.
  49. Tanaka H, Sukhova G, Swanson SJ, et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. *Circulation*. 1993;88:1788-1803.
  50. Yasukawa H, Imaizumi T, Matsuoka H, et al. Inhibition of intimal hyperplasia after balloon injury by antibodies to ICAM-1 and LFA-1. *Circulation*. 1997;95:1515-1522.
  51. Landry DB, Couper LL, Bryant SR, et al. Activation of the NF $\kappa$ B and I $\kappa$ B system in smooth muscle cells after rat arterial

- injury: induction of VCAM-1 and MCP-1. *Am J Pathol.* 1997;151:1085-1095.
52. Cole EW, Hagen P-O, Mikat E, et al. Association of polymorphonuclear leukocytes with sites of aortic catheter-induced injury in rabbits. *Arteriosclerosis.* 1987;67:229-236.
  53. Lucas JF, Makhoul RG, Cole EW, et al. Mononuclear cells adhere to sites of vascular balloon catheter injury. *Curr Surg.* 1986;43:112-115.
  54. Schwartz RS, Edwards WD, Camrud AR, et al. Developmental stages of restenotic neointimal hyperplasia following porcine coronary artery injury: a morphologic review. *J Vasc Med Biol.* 1993;4:70-78.
  55. Kling D, Fingerle J, Harlan JM. Inhibition of leukocyte extravasation with a monoclonal antibody to CD18 during formation of experimental intimal thickening in rabbit carotid arteries. *Arterioscler Thromb.* 1992;12:997-1007.
  56. Guzman LA, Whitlow PL, Beall CJ, et al. Monocyte chemotactic protein antibody inhibits restenosis in the rabbit atherosclerotic model [abstract]. *Circulation.* 1993;88:I-371.
  57. Kamenz J, Hanke H, Ulmer A, et al. Occurrence of intimal macrophage following experimental balloon angioplasty: relation to the proliferative response of smooth muscle cells [abstract]. *Circulation.* 1992;86(Suppl I):I-847.
  58. Verheyen AK, Vlamincz EM, Lauwers FM, et al. Identification of macrophages in intimal thickening of rat carotid arteries by cytochemical localization of purine nucleoside phosphorylase. *Arteriosclerosis.* 1988;8:759-767.
  59. Schober A, Zerneck A. Chemokines in vascular remodeling. *Thromb Haemost.* 2007;97:730-737.
  60. Klagsbrun M, Edelman ER. Biological and biochemical properties of fibroblast growth factors. *Arteriosclerosis.* 1989;9:269-278.
  61. Gospodarowicz D, Ferrara N, Schweigerer L, et al. Structural characterization and biological functions of fibroblast growth factor. *Endocr Rev.* 1987;8:95-114.
  62. Casscells W, Lappi D, Shrivastav S, et al. Regulation of the fibroblast growth factor system in vascular injury [abstract]. *Circulation.* 1992;86(Suppl I):I-84.
  63. Lindner V, Majack RA, Reidy MA. Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. *J Clin Invest.* 1990;85:2004-2008.
  64. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. *Proc Natl Acad Sci U S A.* 1991;88:3739-3743.
  65. Olsen NE, Chao S, Lindner V, et al. Intimal smooth muscle cells proliferation after balloon catheter injury. The role of basic fibroblast growth factor. *Am J Pathol.* 1992;140:1017-1023.
  66. Lindner V, Reidy MA. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study. *Circ Res.* 1993;73:589-595.
  67. Bjornsson TD, Dryjski M, Tluczek J, et al. Acidic fibroblast growth factor promotes vascular repair. *Proc Natl Acad Sci U S A.* 1991;88:8651-8655.
  68. Nabel EG, Yang ZY, Plautz G, et al. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. *Nature.* 1993;362:844-846.
  69. Dzau VJ. Evolving concepts of the renin-angiotensin system. *Am J Hypertens.* 1988;1:334S-337S.
  70. Dzau VJ. Implications of local angiotensin production in cardiovascular physiology and pharmacology. *Am J Cardiol.* 1987;59:59A-65A.
  71. Rakugi H, Dzau VJ, Pratt RE. Importance of tissue angiotensin converting enzyme (ACE) in neointimal hyperplasia [abstract]. *Circulation.* 1992;86(Suppl I):I-169.
  72. Powell JS, Clozel JP, Muller RKM, et al. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. *Science.* 1989;245:186-188.
  73. Miyauchi K, Kawai S, Okado R, et al. Limitation of angiotensin converting enzyme (ACE) inhibitor in restenosis of deep arterial injury models [abstract]. *Circulation.* 1992;86(Suppl I):I-187.
  74. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin angiotensin system. *Circulation.*

1993;87:1816-1828.

75. Itoh H, Pratt RE, Gibbons G, et al. Angiotensin II modulates proliferation of vascular smooth muscle cells (VSMC) via dual autocrine loops of TGF- $\beta$  and bFGF. *Hypertension*. 1991;18:396.
76. Daemon M, Lombardi DM, Bosman FT, et al. Angiotensin II induces smooth muscle cell proliferation in the normal and injured arterial wall. *Circ Res*. 1991;68:450-456.
77. Kauffman RF, Bean JS, Zimmerman KM, et al. Losartan, a nonpeptide angiotensin II receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. *Life Sci*. 1991;49:223-228.
78. Bilazarian SD, Currier JW, Kakuta T, et al. Angiotensin II antagonism does not prevent restenosis after rabbit iliac angioplasty [abstract]. *Circulation*. 1992;86(Suppl I):I-187.
79. Janiak P, Pillon A, Prost JF, Vilaine JP. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. *Hypertension*. 1992;20:737-745.
80. Casscells W. Migration of smooth muscle and endothelial cells. *Circulation*. 1992;86:723-729.
81. Bornfeldt KE, Raines EW, Graves LM, et al. PDGF. Distinct signal transduction pathways associated with migration versus proliferation. *Ann N Y Acad Sci*. 1995;766:416-430.
82. Ross R. Platelet-derived growth factor. *Lancet*. 1989;1:1179-1182.
83. Hart CE, Kraiss LW, Vergel S, et al. PDGF beta receptor blockade inhibits intimal hyperplasia in the baboon. *Circulation*. 1999;99:564-569.
84. Koyama N, Hart CE, Clowes AW. Different functions of the PDGF  $\alpha$  and  $\beta$  receptors in the migration and proliferation of cultured baboon smooth muscle cells. *Circ Res*. 1994;75:682-691.
85. Inui H, Kitami Y, Tani M, et al. Differences in signal transduction between PDGF alpha and beta receptors in vascular smooth muscle cells. PDGF-BB is a potent mitogen but PDGF-AA promotes protein synthesis without activation of DNA synthesis. *J Biol Chem*. 1994;269:30546-30552.
86. Koyama N, Morisaki N, Saito Y, et al. Regulatory effects of PDGF-AA homodimer on migration of vascular smooth muscle cells. *J Biol Chem*. 1992;267:22806-22812.
87. Davies MG, Owens EL, Lea H, et al. Effect of PDGF receptor- $\alpha$  and - $\beta$  blockade on flow induced neointimal formation in endothelialized baboon vascular grafts. *Circ Res*. 2000;86:779-786.
88. Majesky MW, Reidy MA, Bowen-Pope DF, et al. PDGF ligand and receptor gene expression during repair of arterial injury. *J Cell Biol*. 1990;111:2149-2158.
89. Walker LN, Bowen-Pope DF, Ross R, et al. Production of platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury. *Proc Natl Acad Sci U S A*. 1986;83:7311-7315.
90. Consigny PM, Bilder GE. Expression and release of smooth muscle cell mitogens in the arterial wall after balloon angioplasty. *J Vasc Med Biol*. 1993;4:1-8.
91. Bowen-Pope DF, Hart CE, Seifert RA. Sera and conditioned media contain different isoforms of platelet-derived growth factors (PDGF) which bind to different classes of PDGF receptors. *J Biol Chem*. 1989;264:2502-2508.
92. Nabel EG, Yang ZY, Liptay S, et al. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivo. *J Clin Invest*. 1993;91:1822-1829.
93. Jawien A, Bowen-Pope DF, Lindner V, et al. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. *J Clin Invest*. 1992;89:507-511.
94. Serruys PW, Heyndrickx GR, Patel J, et al. Effect of an anti-PDGF-beta-receptor-blocking antibody on restenosis in patients undergoing elective stent placement. *Int J Cardiovasc Intervent*. 2003;5:214-222.
95. Nagase H, Woessner JF. Matrix metalloproteinases. *J Biol Chem*. 1999;274:21491-21494.
96. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. *Curr Opin Cell Biol*. 1995;7:728-735.
97. Carmeliet P, Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. *Thromb Res*. 1998;91:255-285.

98. Lijnen HR, Collen D. Mechanisms of physiological fibrinolysis. *Baillieres Clin Haematol*. 1995;8:277-290.
99. VanLeeuwen RTJ. Extracellular proteolysis and the migrating vascular smooth muscle cell. *Fibrinolysis*. 1996;10:59-74.
100. Lijnen HR. Molecular interactions between the plasminogen/plasmin and matrix metalloproteinase systems. *Fibrinolysis Proteolysis*. 2000;14:175-181.
101. Strauss BH, Lau HK, Bowman KA, et al. Plasma urokinase antigen and PAI-1 antigen levels predict angiographic coronary restenosis. *Circulation*. 1999;100:1616-1622.
102. Clowes AW, Reidy MA, Clowes MM, et al. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid. *Circ Res*. 1990;67:61-67.
103. Bendeck MP, Zempo N, Clowes AW, et al. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. *Circ Res*. 1994;75:539-545.
104. Plekhanova OS, Parfenova EV, Bibilashvily RS, et al. Urokinase plasminogen activator enhances neointima growth and reduces lumen size in carotid arteries. *J Hypertens*. 2000;18:10065-10069.
105. Kanamasa K, Otani N, Ishida N, et al. Suppression of cell proliferation by tPA during the early phase after balloon injury minimizes intimal hyperplasia in hypercholesterolemic rabbits. *J Cardiovasc Pharmacol*. 2001;37:155-162.
106. Hasentaub D, Forough R, Clowes AW. Plasminogen activator inhibitor type I and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats. *Circ Res*. 1997;80:490-496.
107. Hamdan AD, Quist WC, Gagne JB, et al. ACE inhibition suppresses PAI-1 expression in the neointima of balloon injured rat aorta. *Circulation*. 1996;93:1073-1078.
108. Hasentaub D, Lea H, Clowes AW. Local plasminogen activator inhibitor type 1 overexpression in rat carotid artery enhances thrombosis and endothelial regeneration while inhibiting intimal thickening. *Arterioscler Thromb Vasc Biol*. 2000;20:853-859.
109. Shen GX. Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders. *Int J Mol Med*. 1998;1:399-408.
110. Zempo N, Kenagy RD, Au YP, et al. Matrix metalloproteinase of vascular wall cells are increased in balloon injured rat carotid artery. *J Vasc Surg*. 1994;20:209-217.
111. Southgate KM, Fisher M, Banning A, et al. Upregulation of basement membrane degrading metalloproteinase secretion after balloon injury of pig carotid arteries. *Circ Res*. 1996;79:1177-1187.
112. Lijnen HR, VanHoef B, Lupu F, et al. Function of the plasminogen/plasmin and MMP systems after vascular injury in mice with targeted inactivation of fibrinolytic genes. *Arterioscler Thromb Vasc Biol*. 1998;18:1035-1045.
113. Jenkins GM, Crow MT, Bilato C, et al. Increased expression of MT-MMP and preferential localization of matrix metalloproteinase-2 to the neointima of balloon injured rat carotid arteries. *Circulation*. 1998;97:82-90.
114. Bassiouny HS, Song RH, Hong XF, et al. Reduced flow enhances in vivo collagenase IV transcription after arterial injury [abstract]. *Circulation*. 1996;94(Suppl):I-349.
115. Sluijter JP, Verloop RE, Pulskens WP, et al. Involvement of furin-like proprotein convertases in the arterial response to injury. *Cardiovasc Res*. 2005;68:136-143.
116. DeSmet BJ, VanderHelm Y, Horowitz A, et al. Matrix remodeling in balloon dilated and stented arteries in atherosclerotic Yucatan micropigs: procollagen alpha1(I) alpha1(III) and MMP1 expression over time [abstract]. *Circulation*. 1996;94(Suppl):I-403.
117. Natarajan MK, Robinson R, Thompson KE, et al. Increased elastolytic activity after balloon angioplasty [abstract]. *Circulation*. 1996;94(Suppl):I-349.
118. Cheng XW, Kuzuya M, Sasaki T, et al. Green tea catechins inhibit neointimal hyperplasia in a rat carotid arterial injury model by TIMP-2 overexpression. *Cardiovasc Res*. 2004;62:594-602.
119. Webb KE, Henney AM, Anglin S, et al. Expression of MMP and their inhibitor TIMP-1 in the rat carotid artery after balloon injury. *Arterioscler Thromb Vasc Biol*. 1997;17:1837-1844.

120. Dollery CM, Mewan JR, Wang M, et al. TIMP-4 is regulated by vascular injury in rats. *Circ Res.* 1999;84:498-504.
121. Forough R, Koyama N, Hasentaub D, et al. Overexpression of TIMP-1 inhibits vascular smooth muscle cell formation in vitro and in vivo. *Circ Res.* 1996;79:812-820.
122. Forough R, Lea H, Starcher B, et al. Metalloproteinase blockade by local overexpression of TIMP-1 increase elastin accumulation in rat carotid artery intima. *Arterioscler Thromb Vasc Biol.* 1998;18:803-807.
123. Furman C, Luo Z, Walsh K, et al. Systemic tissue inhibitor of metalloproteinase-1 gene delivery reduces neointimal hyperplasia in balloon-injured rat carotid artery. *FEBS Lett.* 2002;531:122-126.
124. Cheng XW, Kuzuya M, Sasaki T, et al. Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. *Am J Pathol.* 2004;164:243-251.
125. Yamamoto M, Yamamoto K, Noumura T. Type I collagen promotes modulation of cultured rabbit arterial smooth muscle cells from a contractile to synthetic phenotype. *Exp Cell Res.* 1993;204:121-129.
126. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. *Arterioscler Thromb.* 1991;11:1223-1230.
127. Thie M, Schlumberger W, Semich R, et al. Aortic smooth muscle cells in collagen lattice culture: effects on ultrastructure, proliferation and collagen synthesis. *Eur J Cell Biol.* 1991;55:295-304.
128. Thie M, Harrach B, Schonhert E, et al. Responsiveness of aortic smooth muscle cells to soluble growth mediators is influenced by cell matrix contact. *Arterioscler Thromb.* 1993;13:994-1003.
129. Redecker-Beuke B, Thie M, Rauterberg J, et al. Aortic smooth muscle cells in a three dimensional collagen lattice culture: evidence for post translational regulation of collagen synthesis. *Arterioscler Thromb.* 1993;13:1572-1579.
130. Paye M, Nusgens B, Lapiere C. Modulation of cellular biosynthetic activity in the retracting collagen lattice. *Eur J Cell Biol.* 1987;45:44-50.
131. Gillery P, Leperre A, Coustry F, et al. Different regulation of collagen I gene transcription in three dimensional lattice cultures. *FEBS Lett.* 1992;296:297-299.
132. Nuthakki VK, Fleser PS, Malinzak LE, et al. Lysyl oxidase expression in a rat model of arterial balloon injury. *J Vasc Surg.* 2004;40:123-129.
133. Wight TN. Cell biology of arterial proteoglycans. *Arteriosclerosis.* 1989;9:1-20.
134. Alvani M, Moore S. Glycosaminoglycans composition and biosynthesis in the endothelium-covered neointima and de-endothelialized rabbit aorta. *Exp Mol Pathol.* 1985;42:389-400.
135. Clowes AW, Karnovsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. *Nature.* 1979;265:625-627.
136. Castellot JJ, Favreau LV, Karnovsky MJ, et al. Inhibition of vascular smooth muscle cell growth by endothelium cell-derived heparin. *J Biol Chem.* 1982;257:11256-11260.
137. Majack RA, Clowes AW. Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans. *J Cell Physiol.* 1984;118:253-256.
138. Majack RA, Coates-Cook S, Bernstein P. Platelet derived growth factor and heparin-like glycosaminoglycans regulate thrombospondin synthesis and deposition in the matrix by smooth muscle cells. *J Cell Biol.* 1985;105:1059-1070.
139. Li Z, Alavi M, Wasty F, et al. Collagen biosynthesis by neointimal smooth muscle cells in vitro [abstract]. *FASEB J.* 1993;7:A798.
140. Nikkari ST, Jarvelainen HT, Wight TN, et al. Smooth muscle cell expression of extracellular matrix genes after arterial injury. *Am J Pathol.* 1994;144:1348-1356.
141. Strauss BH, Chisholm RJ, Keley FW, et al. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. *Circ Res.* 1994;75:650-658.
142. Strauss BH, Robinson R, Batchelor WB, et al. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinase. *Circulation.* 1996;79:541-550.

143. Riessen R, Wight TN, Pastore C, et al. Distribution of hyaluron during extracellular matrix remodeling in human restenotic arteries and balloon injured rat carotid arteries. *Circulation*. 1996;93:1141-1147.
144. Tran PK, Tran-Lundmark K, Soininen R, et al. Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfate-deficient perlecan. *Circ Res*. 2004;94:550-558.
145. Suzuki H, Sunayama S, Kawal S, et al. ECM remodelling in restenotic human coronary atherosclerotic plaque of balloon angioplasty [abstract]. *J Am Coll Cardiol*. 1997;29:421A.
146. Wight TN, Lara S, Riessen R, et al. Selective deposits of versican in the ECM of restenotic lesions from human peripheral arteries. *Am J Pathol*. 1997;151:963-974.
147. Graf K, Meehan WP, Chen JZ, et al. Upregulation of  $\alpha_v$ ,  $\beta_3$ - and  $\beta_5$ -integrin mRNA during neointima formation in rat aorta after balloon injury [abstract]. *Circulation*. 1996;94(Suppl):I-41.
148. Srivatsa SS, Tsao P, Holmes DR, et al. Temporal and spatial variation in  $\alpha_v\beta_3$  integrin expression following deep arterial injury in the porcine coronary restenosis model [abstract]. *J Am Coll Cardiol*. 1997;29:153A.
149. Choi ET, Sun S, Parks W, et al. Early role of collagen type I on smooth muscle cell phenotype change and intimal hyperplasia. *Surg Forum*. 1993;44:349-351.
150. Stouffer GA, Sajid M, Nakada MT, et al.  $\beta_3$  Integrins are upregulated following vascular injury and mediate proliferation of cultured SMC [abstract]. *J Am Coll Cardiol*. 1997;29(Suppl A):3A.
151. Liaw L, Lindner V, Schwartz S, et al. Osteopontin and  $\beta_3$  integrin are co-ordinately expressed during endothelial regeneration in rat arteries [abstract]. *FASEB J*. 1995;9:A846.
152. Corjay MH, Stoltenberg JK, Diamond SM, et al.  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins and osteopontin are spatially and temporally regulated during early timepoints in a rabbit model of neointima formation [abstract]. *Circulation*. 1996;94(Suppl):I-517.
153. Loudon C, Zimmerman D, Wang X, et al. Expression of osteopontin in PDGF stimulated vascular smooth muscle cells and in rat carotid arteries [abstract]. *FASEB J*. 1996;10:A72.
154. Koyama N, Seki J, Vergel S, et al. Regulation and function of an activation dependent epitope of the  $\beta_1$  integrin in vascular cells after balloon injury in baboon arteries and in vitro. *Am J Pathol*. 1996;148:749-761.
155. Khan R, Agrotis A, Bobik A. Understanding the role of transforming growth factor- $\beta_1$  in intimal thickening after vascular injury. *Cardiovasc Res*. 2007;74:223-234.
156. McCaffrey TA. TGF- $\beta$  and TGF- $\beta$  receptors in atherosclerosis. *Cytokine Growth Factor Rev*. 2000;11:103-114.
157. Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor- $\beta$  regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. *J Biol Chem*. 1991;266:9419-9427.
158. Ignatz RA, Massague J. Transforming growth factor- $\beta$  stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. *J Biol Chem*. 1986;261:4337-4345.
159. Kobayashi K, Yokote K, Fujimoto M, et al. Targeted disruption of TGF-beta-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury. *Circ Res*. 2005;96:904-912.
160. Wang M, Zhao D, Spinetti G, et al. Matrix metalloproteinase 2 activation of transforming growth factor- $\beta_1$  (TGF- $\beta_1$ ) and TGF- $\beta_1$ -type II receptor signaling within the aged arterial wall. *Arterioscler Thromb Vasc Biol*. 2006;26:1503-1509.
161. Majesky MW, Lindner V, Twardzik DR, et al. Production of transforming growth factor  $\beta_1$  during repair of arterial injury. *J Clin Invest*. 1991;88:904-910.
162. Kanzaki T, Tamura K, Takahashi K, et al. In vivo effect of TGF- $\beta_1$ : Enhanced intimal thickening by administration of TGF- $\beta_1$  in rabbit arteries injured with a balloon catheter. *Arterioscler Thromb*. 1995;15:1951-1957.
163. Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against TGF- $\beta_1$  suppress intimal hyperplasia in a rat model. *J Clin Invest*. 1994;93:1172-1178.
164. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. *Circulation*. 1992;86(Suppl III):43-46.
165. Nabel EG, Shum L, Pompili VJ, et al. Direct gene transfer of transforming growth factor- $\beta_1$  in the arterial wall stimulates



- fibrocellular hyperplasia [abstract]. *Proc Natl Acad Sci U S A*. 1993;90:10759-10763.
166. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng*. 2001;7:211-228.
  167. Kashiwakura Y, Katoh Y, Tamayose K, et al. Isolation of bone marrow stromal cell-derived smooth muscle cells by a human SM22 $\alpha$  promoter: in vitro differentiation of putative smooth muscle progenitor cells of bone marrow. *Circulation*. 2003;107:2078-2081.
  168. Matsumura G, Niagara-Tomita S, Shin'oka T, et al. First evidence that bone marrow cells contribute to the construction of tissue-engineered vascular autografts in vivo. *Circulation*. 2003;108:1729-1734.
  169. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. *Nat Med*. 2002;8:403-409.
  170. Sata M. Molecular strategies to treat vascular diseases. *Circ J*. 2003;67:983-991.
  171. Saiura A, Sata M, Hirata Y, et al. Circulating smooth muscle progenitor cells contribute to atherosclerosis. *Nat Med*. 2001;7:382-383.
  172. Tanaka K, Sata M, Hirata Y, Nagai R. Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. *Circ Res*. 2003;93:783-790.
  173. Caplice NM, Bunch TJ, Stalboerger PG, et al. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. *Proc Natl Acad Sci U S A*. 2003;100:4754-4759.
  174. Gulati R, Jevremovic D, Peterson TE, et al. Autologous culture-modified mononuclear cells confer vascular protection after arterial injury. *Circulation*. 2003;108:1520-1526.
  175. Griese DP, Ehsan A, Melo LG, et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. *Circulation*. 2003;108:2710-2715.
  176. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. *N Engl J Med*. 2005;353:999-1007.
  177. Xu Q, Zhang Z, Davison F, Hu Y. Circulating progenitor cells regenerate endothelium of vein graft atherosclerosis, which is diminished in ApoE-deficient mice. *Circ Res*. 2003;93:e76-e86.
  178. Strehlow K, Werner N, Berweiler J, et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. *Circulation*. 2003;107:3059-3065.
  179. Iwakura A, Luedemann C, Shastry S, et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. *Circulation*. 2003;108:3115-3121.
  180. Bahlmann FH, De Groot K, Spandau JM, et al. Erythropoietin regulates endothelial progenitor cells. *Blood*. 2004;103:921-926.
  181. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med*. 2003;348:593-600.
  182. Laufs U, Werner N, Link A, et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. *Circulation*. 2004;109:220-226.
  183. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. *Circulation*. 2002;105:3017-3024.
  184. Werner N, Priller J, Laufs U, et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition. *Arterioscler Thromb Vasc Biol*. 2002;22:1567-1572.
  185. Banerjee S, Brilakis E, Zhang S, et al. Endothelial progenitor cell mobilization after percutaneous coronary intervention. *Atherosclerosis*. 2006;189:70-75.
  186. Kong D, Melo LG, Mangi AA, et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial

- progenitor cells. *Circulation*. 2004;109:1769-1775.
187. Powell TM, Paul JD, Hill JM, et al. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. *Arterioscler Thromb Vasc Biol*. 2005;25:296-301.
  188. Li M, Takenaka H, Asai J, et al. Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. *Circ Res*. 2006;98:697-704.
  189. Clowes AW, Clowes MM, Fingerle J, et al. Kinetics of cellular proliferation after arterial injury. V: role of acute distension in the induction of smooth muscle cell proliferation. *Lab Invest*. 1989;60:360-364.
  190. Yang Z, VonSegesser L, Stulz P, et al. Pulsatile stretch and platelet-derived growth factor (PDGF): important mechanisms for coronary venous graft disease [abstract]. *Circulation*. 1992;86(Suppl I):I-84.
  191. Slepian MJ, Gaballa MA. Vascular wall hydraulic conductivity increases following non dissecting balloon stretch injury [abstract]. *Circulation*. 1992;86(Suppl I):I-85.
  192. Glagov S, Zarins CK, Masawa N, et al. Mechanical and functional role of non-atherosclerotic intimal thickening. *Front Med Biol Eng*. 1993;5:37-43.
  193. Hehrlein C, Chuang CH, Tuntelder JR, et al. Effects of vascular runoff on myointimal hyperplasia after mechanical balloon or thermal laser arterial injury in dogs. *Circulation*. 1991;84:884-890.
  194. Dobrin PB, Littooy FN, Endean ED. Mechanical factors predisposing to intimal hyperplasia and medial thickening in autogenous vein grafts. *Surgery*. 1989;105:393-400.
  195. Kohler TR, Kirkman TR, Kraiss LW, et al. Increased blood flow inhibits neointimal hyperplasia in endothelialized vascular grafts. *Circ Res*. 1991;69:1557-1565.
  196. Kohler TR, Jawien A. Flow affects development of intimal hyperplasia after arterial injury in rats. *Arterioscler Thromb*. 1992;12:963-971.
  197. Reis GJ, Kuntz RE, Silverman DI, et al. Effects of serum lipid levels on restenosis after coronary angioplasty. *Am J Cardiol*. 1991;68:1431-1435.
  198. Rapp JH, Ovarfordt P, Krupski WC, et al. Hypercholesterolemia and early restenosis after carotid endarterectomy. *Surgery*. 1987;101:277-282.
  199. Quigley PJ, Hiattky MA, Hinohara T, et al. Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent stenosis. *Am J Cardiol*. 1989;63:409-413.
  200. Carrozza JPI, Kuntz RE, Fishman RF, et al. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. *Ann Intern Med*. 1993;118:344-349.
  201. Law MM, Gelabert HA, Moore WS, et al. Cigarette smoking increases the development of intimal hyperplasia after vascular injury. *J Vasc Surg*. 1996;23:401-409.
  202. Sahni R, Maniet AR, Voci G, et al. Prevention of restenosis by lovastatin after successful angioplasty. *Am Heart J*. 1991;121:1600-1608.
  203. Gellman J, Ezekowitz MD, Sarembock IJ, et al. Effect of lovastatin after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit. *J Am Coll Cardiol*. 1991;17:251-259.
  204. Lovostatin Restenosis Trial Group: Lovostatin Restenosis Trial: final results [abstract]. *Circulation*. 1993;88:I-506.
  205. Weidinger FF, McLenachen JM, Cybulsky MJ, et al. Hypercholesterolemia enhances macrophage recruitment and dysfunction of regenerated endothelium after balloon injury of the rabbit iliac artery. *Circulation*. 1991;84:755-767.
  206. Kisanuki A, Asada Y, Hatakeyama K, et al. Contribution of the endothelium to intimal thickening in normocholesterolemic and hypercholesterolemic rabbits. *Arterioscler Thromb*. 1992;12:1198-1205.
  207. Stevens SL, Hilgarth K, Ryan US, et al. The synergistic effect of hypercholesterolemia and mechanical injury on intimal hyperplasia. *Ann Vasc Surg*. 1992;6:55-61.
  208. Trachtenberg J, Choi E, Sun S, et al. Hypercholesterolemia causes increased smooth muscle cell proliferation following arterial injury [abstract]. Paper presented at the 26th Annual Meeting of the Association for Academic Surgery, 1992,

Montreal, McGill University, p 57.

209. Chang MY, Lees AM, Lees RS. Time course of <sup>125</sup>I labelled LDL accumulation in the healing balloon de-endothelialized rabbit aorta. *Arterioscler Thromb.* 1992;12:1088-1098.
210. Srinivasan SR, Xu J-H, Vijayagonal P, et al. Injury to the arterial wall produces proteoglycan variants with enhanced low density lipoprotein binding activity. *Circulation.* 1992;86(Suppl 1):I-156.
211. Guarda E, Katwa LC, Campbell SE, et al. Extracellular matrix collagen synthesis and degradation following coronary balloon angioplasty. *J Mol Cell Cardiol.* 1996;28:699-706.
212. Oberhoff M, Hanke H, Hassenstein S, et al. Difference in the proliferative response of smooth muscle cells in normal and atherosclerotic rabbit carotid arteries after balloon angioplasty [abstract]. *Arterioscler Thromb.* 1991;11:1528a.
213. Stadius ML, Gown AM, Kernoff R, et al. Does sequential balloon injury of an artery lead to a different outcome than a single injury? An experimental study of angioplasty. *Coron Artery Dis.* 1996;7:247-255.
214. Murcia AM, Fallon JT, Fuster V. Smooth muscle cell proliferation does not account for restenosis in diabetic patients [abstract]. *Circulation.* 1996;94(Suppl):I-619.
215. Manciet LH, Copeland JG, Chavez RA, et al. Development of neointimal hyperplasia in balloon injured carotid arteries of normal and streptozocin induced diabetic rats [abstract]. *FASEB J.* 1996;10:A619.
216. Aronson D. Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. *Med Hypotheses.* 2002;59:297-301.
217. Cwikiel W. Restenosis after balloon angioplasty and/or stent insertion—origin and prevention. *Acta Radiol.* 2002;43:442-454.
218. Lowe HC, Oesterle SN, Khachigan LM. Coronary in stent restenosis: current status and future strategies. *J Am Coll Cardiol.* 2002;39:183-193.
219. Mehran R, Dangas G, Abizaid A, et al. Angiographic patterns of in stent restenosis: classification and implications for longterm outcome. *Circulation.* 1999;100:1872-1878.
220. Hoffman R, Mintz GS, Dussaillant RG, et al. Patterns and mechanisms of in stent restenosis: a serial intravascular ultrasound study. *Circulation.* 1996;94:1247-1254.
221. Moreno PR, Palacios IF, Leon MN, et al. Histopathologic comparison of human coronary in stent and post balloon angioplasty restenotic tissue. *Am J Cardiol.* 1999;84:462-466.
222. Virmani R, Farb A. Pathology of in stent restenosis. *Curr Opin Lipidol.* 1999;10:499-506.
223. Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late outcomes following coronary stent implantation. *J Am Coll Cardiol.* 1998;32:584-589.
224. Carter AJ, Bailey L, Devries J, et al. The effects of uncontrolled hyperglycemia on thrombosis and formation of neointima after coronary stent placement in a novel diabetic porcine model of restenosis. *Coron Artery Dis.* 2000;11:473-479.
225. Baier RE, Dutton RC. Initial events in interaction of blood with a foreign surface. *J Biomed Mater Res.* 1969;3:191-206.
226. Emn áis H, Stenram U. Metal implants in the human body. *Acta Orthop Scand.* 1965;36:116-129.
227. Pärsson H, Cwikiel W, Johansson K, et al. Deposition of platelets and neutrophils on porcine iliac arteries and angioplasty and Wallstent placement compared with angioplasty alone. *Cardiovasc Intervent Radiol.* 1994;17:190-196.
228. Bai H, Masuda J, Sawa Y, et al. Neointima formation after vascular stent implantation: spatial and chronological distribution of smooth muscle cell proliferation and phenotypic modulation. *Arterioscler Thromb.* 1994;14:1846-1853.
229. Schwartz RS, Huber KC, Murphy JIG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. *J Am Coll Cardiol.* 1992;19:267-274.
230. Kornowski R, Hong MK, Fermin OT, et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointima hyperplasia. *J Am Coll Cardiol.* 1998;31:224-230.
231. Sanada JI, Matsui O, Yoshikawa J, et al. An experimental study of endovascular stenting with special reference to the effects on the aortic vasa vasorum. *Cardiovasc Intervent Radiol.* 1998;21:45-49.

232. Farb AS, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. *Circulation*. 1999;99:44-52.
233. Farb A, Kolodgie FD, Hwang JY, et al. Extracellular matrix changes in stented human coronary arteries. *Circulation*. 2004;110:940-947.
234. Garc ía-Garc ía HM, Vaina S, Tsuchida K, et al. Drug-eluting stents. *Arch Cardiol Mex*. 2006;76:297-319.
235. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. *J Am Coll Cardiol*. 2006;48:193-202.
236. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. *Arterioscler Thromb Vasc Biol*. 2007;27:1500-1510.
237. Steffel J, Tanner FC. Biological effects of drug-eluting stents in the coronary circulation. *Herz*. 2007;32:268-273.
238. Nakazawa G, Finn AV, Virmani R. Vascular pathology of drug-eluting stents. *Herz*. 2007;32:274-280.
239. Giannoukas AD, Labropoulos N, Stavridis G, et al. Pre-bypass quality assessment of the long saphenous vein wall with ultrasound and histology. *Eur J Vasc Endovasc Surg*. 1997;14:37-40.
240. Wilson YG, Davies AH, Currie IC, et al. Angioscopy for quality control of saphenous vein during bypass grafting. *Eur J Vasc Endovasc*. 1996;11:12-18.
241. Panetta TF, Marin ML, Veith FJ, et al. Unsuspected pre-existing saphenous vein disease: an unrecognized cause of vein bypass failure. *J Vasc Surg*. 1992;15:102-112.
242. Varty K, Allen KE, Bell PRF, et al. Infrainguinal vein graft stenosis. *Br J Surg*. 1993;80:825-833.
243. Xu Q, Zhang Z, Davison F, Hu Y. Circulating progenitor cells regenerate endothelium of vein graft atherosclerosis, which is diminished in ApoE-deficient mice. *Circ Res*. 2003;93:E76-E86.
244. Chervu A, Moore WS. An overview of intimal hyperplasia. *Surg Gynecol Obstet*. 1990;171:433-447.
245. Ip JH, Fuster V, Badimon L, et al. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. *J Am Coll Cardiol*. 1990;15:1667-1687.
246. Sayers RD, Jones L, Varty K, et al. The histopathology of infrainguinal vein graft stenoses. *Eur J Vasc Surg*. 1993;7:16-20.
247. Berkowitz HD, Fox AD, Deaton DH. Reversed vein graft stenosis: Early diagnosis and management. *J Vasc Surg*. 1992;15:130-142.
248. Mills JL, Bandyk DF, Gahtan V, et al. The origin of infrainguinal vein graft stenosis—prospective study based on duplex surveillance. *J Vasc Surg*. 1995;21:16-25.
249. Moody AP, Edwards PR, Harris PL. The etiology of vein graft strictures: a prospective marker study. *Eur J Vasc Surg*. 1992;6:509-511.
250. Adcock GD. Vein grafts: implantation injury. *J Vasc Surg*. 1989;10:587-589.
251. Quist WC, LoGerfo FW. Prevention of smooth muscle cell phenotypic modulation in vein grafts: a histomorphometric study. *J Vasc Surg*. 1992;16:225-231.
252. Cavaliari N, Abebe W, Hunter WJ, et al. University of Wisconsin solution prevents intimal proliferation in canine autogenous vein grafts [abstract]. Paper presented at the 7th Annual Meeting of the European Society for Vascular Surgery, 1993, Barcelona, Spain, p 44.
253. Davies MG, Hagen P-O: Influence of perioperative storage solutions on long term vein graft function and morphology. *Ann Vasc Surg*. 1994;8:150-157.
254. Davies MG, Klyachkin ML, Dalen H, et al. The integrity of experimental vein graft endothelium: implications on the etiology of early graft failure. *Eur J Vasc Surg*. 1993;7:156-165.
255. Carson SD, Bronza JP. The role of tissue factor in the production of thrombin. *Blood Coagul Fibrinolysis*. 1993;4:281-292.
256. Channon KM, Fulton GJ, Davies MG, et al. Intimal tissue factor protein expression precedes intimal hyperplasia in experimental venous bypass grafts. *Arterioscler Thromb Vasc Biol*. 1997;17:1313-1319.
257. Huynh TTT, Davies MG, Hagen P-O, et al. Local treatment with tissue factor pathway inhibitor reduces the development

- of intimal hyperplasia in experimental vein grafts [abstract]. *Circulation*. 1997;96(Suppl):I-41.
258. Kim AY, Walinsky PL, Kolodgie FD, et al. Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure. *Circ Res*. 2002;90:205-212.
  259. Sperry JL, Deming CB, Bian C, et al. Wall tension is a potent negative regulator of in vivo thrombomodulin expression. *Circ Res*. 2003;92:41-47.
  260. Solymoss BC, Nadeau P, Millette D, et al. Late thrombosis of saphenous vein coronary bypass graft related to risk factors [abstract]. *Circulation*. 1988;78(Suppl II):140.
  261. Davies MG, Klyachkin ML, Dalen H, et al. The early morphology of veno-venous bypass grafts. *Cardiovasc Surg*. 1997;5:82-91.
  262. Stark VK, Warner TF, Hoch JR. An ultrastructural study of progressive intimal hyperplasia in rat vein grafts. *J Vasc Surg*. 1997;26:94-103.
  263. Hoch JR, Stark VK, Hullett DA, et al. Vein graft intimal hyperplasia—leukocytes and cytokine gene expression. *Surgery*. 1994;116:463-471.
  264. Hoch JR, Stark VK, Turnipseed WD. The temporal relationship between the development of vein graft intimal hyperplasia and growth factor gene expression. *J Vasc Surg*. 1995;22:51-58.
  265. Hoch JR, Stark VK. Apoptosis in vein graft intimal hyperplasia. *Surg Forum*. 1996;47:357-360.
  266. Hoch JR, Stark VK, VanRooijen N, et al. Macrophage depletion alters vein graft intimal hyperplasia. *Surgery*. 1999;126:428-437.
  267. Stark VK, Hoch JR, Warner TF, et al. Monocyte chemotactic protein-1 expression is associated with the development of vein graft intimal hyperplasia. *Arterioscler Thromb Vasc Biol*. 1997;17:1614-1621.
  268. Schwartz LB, Pence JC, Kerns BJ, et al. Kinetics of vein graft cell division and function. *Surg Forum*. 1991;42:362-365.
  269. Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperplasia: Association with tangential stress. *J Vasc Surg*. 1987;5:126-136.
  270. Angelini GD, Bryan AJ, Williams HMJ, et al. Time course of medial and intimal thickening in pig venous arterial grafts: relationship to endothelial injury and cholesterol accumulation. *J Thorac Cardiovasc Surg*. 1992;103:1093-1103.
  271. Davies MG, Ramkumar V, Hagen P-O. Temporal expression of G-proteins in intimal hyperplasia. *J Surg Res*. 1996;63:115-122.
  272. Golden MA, Kariko K, David ML, et al. Increased urokinase receptor expression in proliferating vascular smooth muscle cells and in arterialized vein grafts in rabbits. *Surg Forum*. 1995;46:384-386.
  273. Faries PL, Marin ML, Veith FJ, et al. Immunolocalization and temporal distribution of cytokine expression during the development of vein graft intimal hyperplasia in an experimental model. *J Vasc Surg*. 1996;24:463-471.
  274. Faries PL, Gorden RE, Veith FJ, et al. Spatial and temporal distribution of cytokines during the development of vein graft intimal hyperplasia [abstract]. *FASEB J*. 1995;9:A611.
  275. Francis SE, Hunter S, Holt CM, et al. Release of PDGF activity from pig venous arterial grafts. *J Thorac Cardiovasc Surg*. 1994;108:540-548.
  276. Sterpetti AV, Cucina A, Lepidi S, et al. Progression and regression of myointimal hyperplasia in experimental vein grafts depends on PDGF and bFGF production. *J Vasc Surg*. 1996;23:568-575.
  277. Sterpetti AV, Lepidi S, Cucina A, et al. Growth factor production after PTFE and vein arterial grafting—an experimental study. *J Vasc Surg*. 1996;23:453-460.
  278. Lepidi S, Sterpetti AV, Cucina A, et al. bFGF release is dependent on flow conditions in experimental vein grafts. *Eur J Vasc Endovasc Surg*. 1995;10:450-458.
  279. Sterpetti AV, Cucina A, Lepidi S, et al. Formation of myointimal hyperplasia and cytokine production in experimental vein grafts. *Surgery*. 1998;123:461-469.
  280. Brauner R, Laks L, Wu L, et al. Structural and vasomotor effects of adenovirus mediated transfer of the TGF- $\beta$ 1 gene in

- normcholesterolemic and hypercholesterolemic arterialized vein grafts [abstract]. *Circulation*. 1996;94(Suppl):I-466.
281. Wolff RA, Ryomoto M, Stark VE, et al. Antisense to transforming growth factor- $\beta$ 1 messenger RNA reduces vein graft intimal hyperplasia and monocyte chemotactic protein 1. *J Vasc Surg*. 2005;41:498-508.
  282. Heaton NS, Wolff RA, Malinowski JR, et al. Antisense to transforming growth factor- $\beta$ 1 facilitates the apoptosis of macrophages in rat vein grafts. *J Vasc Res*. 2008;45:365-374.
  283. George SJ, Zaltsman AB, Newby AC. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. *Cardiovasc Res*. 1997;33:447-449.
  284. Johnson JL, vanEys GJ, Angelini GD, et al. Injury induces dedifferentiation of smooth muscle cells and increased matrix-degrading metalloproteinase activity in human saphenous vein. *Arterioscler Thromb Vasc Biol*. 2001;21:1146-1151.
  285. Meng X, Mavromatis K, Galis ZS. Mechanical stretching of human saphenous vein grafts induces expression and activation of matrix-degrading enzymes associated with vascular tissue injury and repair. *Exp Mol Pathol*. 1999;66:227-237.
  286. Mavromatis K, Fukai T, Tate M, et al. Early effects of arterial hemodynamic conditions on human saphenous veins perfused ex vivo. *Arterioscler Thromb Vasc Biol*. 2000;20:1889-1895.
  287. Berceli SA, Jiang Z, Klingman NV, et al. Differential expression and activity of matrix metalloproteinases during flow-modulated vein graft remodeling. *J Vasc Surg*. 2004;39:1084-1090.
  288. Kranzhofer A, Baker AH, George SJ, et al. Expression of TIMP-1, -2 and -3 during neointima formation in organ cultures of human saphenous vein. *Arterioscler Thromb Vasc Biol*. 1999;19:255-265.
  289. Crook MF, Newby AC, Smithgate KM. Expression of intercellular adhesion molecules in human saphenous veins: effects of inflammatory cytokines and neointima formation in culture. *Atherosclerosis*. 2000;150:33-41.
  290. Leville CD, Dassow MS, Seabrook GR, et al. All-*trans*-retinoic acid decreases vein graft intimal hyperplasia and matrix metalloproteinase activity in vivo. *J Surg Res*. 2000;90:183-190.
  291. Southgate KM, Mehta D, Izzat MB, et al. Increased secretion of basement membrane degrading metalloproteinases in pig saphenous vein into carotid artery interposition grafts. *Arterioscler Thromb Vasc Biol*. 1999;19:1640-1649.
  292. George SJ, Johnson JL, Angelini GD, et al. Adenovirus-mediated gene transfer of human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. *Hum Gene Ther*. 1998;9:567-577.
  293. George SJ, Baker AH, Angelini GD, et al. Gene transfer of human TIMP-2 inhibits MMP activity and neointimal formation in human saphenous veins. *Gene Ther*. 1998;5:1552-1560.
  294. George SJ, Llyod CT, Angelini GD, et al. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of TIMP-3. *Circulation*. 2000;101:296-304.
  295. George J, Johnson JL, Smith MA, et al. Plasmin-mediated fibroblast growth factor-2 mobilization supports smooth muscle cells proliferation in human saphenous vein. *J Vasc Res*. 2001;38:492-501.
  296. Javed Q, Swanson N, Warner EL, et al. Plasminogen activator and plasminogen activator inhibitor gene expression in human saphenous vein organ culture. *Exp Mol Pathol*. 2001;70:146-153.
  297. Redmond EM, Cahill PA, Hirsch M, et al. Effect of pulse pressure on vascular smooth muscle cell migration: the role of urokinase and matrix metalloproteinase. *Thromb Haemost*. 1999;81:293-300.
  298. Hu Y, Baker AH, Zou Y, et al. Local gene transfer of TIMP-2 influences vein graft remodelling in a mouse model. *Arterioscler Thromb Vasc Biol*. 2001;21:1275-1280.
  299. Kohler TR, Kirkman TR, Gordon D, et al. Mechanism of longterm degeneration of arterialized vein graft. *Am J Surg*. 1990;160:257-261.
  300. Zhang W-D, Bai H-Z, Sawa Y, et al. Association of smooth muscle cell phenotypic modulation with extracellular matrix alterations during neointima formation in rabbit vein grafts. *J Vasc Surg*. 1999;30:169-183.
  301. Dattilo JB, Dattilo MP, Yager DR, et al. Hypercholesterolemia alters gene expression of novel components of the ECM in experimental vein grafts. *Ann Vasc Surg*. 1998;12:168-173.

302. Brody WR, Kosek JG, Angell WV. Changes in vein grafts following aorto-coronary bypass induced by pressure and ischemia. *J Thorac Cardiovasc Surg.* 1972;64:847-854.
303. Kennedy JH, Wieting DW, Hwang NHC, et al. Hydraulic and morphologic study of fibrous intimal hyperplasia in autogenous saphenous vein bypass grafts. *J Thorac Cardiovasc Surg.* 1974;67:805-813.
304. Faulkner SL, Fischer RD, Conkle DM, et al. Effect of blood flow rate on subendothelial proliferation in venous autografts used as arterial substitutes [abstract]. *Circulation.* 1975;52(Suppl I):163.
305. Rittgers SE, Karayannacos PE, Guy JF, et al. Velocity distribution and intimal proliferation in autologous vein grafts in dogs. *Circ Res.* 1978;42:792-801.
306. Berguer R, Higgins RF, Reddy DJ. Intimal hyperplasia: an experimental study. *Arch Surg.* 1980;115:332-338.
307. Kamiya A, Togawa T. Adaptive regulation of wall shear stress on intimal thickening of arterially transplanted autogenous veins in dogs. *Am J Physiol.* 1980;239:14-21.
308. Karayannacos PE, Rittgers SE, Kakos GS, et al. Potential role of velocity and wall tension in vein graft failure. *J Cardiovasc Surg.* 1980;21:171-178.
309. Morinaga K, Okadome K, Kuroki M, et al. Effect of wall shear stress on intimal thickening of arterially transplanted autologous veins in dogs. *J Vasc Surg.* 1985;2:430-433.
310. Dobrin PB, Littooy FN, Golan J, et al. Mechanical and histologic changes in canine vein grafts. *J Surg Res.* 1988;14:259-260.
311. Morinaga K, Eguchi H, Miyazaki T, et al. Development and regression of intimal thickening of arterially transplanted autologous vein grafts in dogs. *J Vasc Surg.* 1987;5:19-30.
312. Schwartz LB, O'Donohoe MK, Purut CM, et al. Myointimal thickening in experimental vein grafts is dependent on wall tension. *J Vasc Surg.* 1992;15:176-186.
313. Davies AH, Magee TR, Baird RN, et al. Vein compliance: a preoperative indicator of vein morphology and of veins at risk of vascular graft stenosis. *Br J Surg.* 1992;79:1019-1021.
314. Galt SW, Zwolak RM, Wagner RJ, et al. Differential response of arteries and vein grafts to blood flow reduction. *J Vasc Surg.* 1993;17:563-570.
315. Itoh H, Komori K, Funahashi S, et al. Intimal hyperplasia of experimental autologous vein graft in hyperlipidemic rabbits with poor distal runoff. *Atherosclerosis.* 1994;110:259-270.
316. Yamamura S, Okadome K, Onohara T, et al. Blood flow and kinetics of smooth muscle cell proliferation in canine autogenous vein grafts: in vivo BrdU incorporation. *J Surg Res.* 1994;56:155-161.
317. Lee RT, Lorse HM, Fishbein MC. High stress regions in saphenous vein bypass graft atherosclerotic lesions. *J Am Coll Cardiol.* 1994;24:1639-1644.
318. Karayannacos PE, Geer J, Gast M, et al. Wall strain in arterial vein grafts [abstract]. *Clin Res.* 1973;21:813.
319. Barra JA, Volant A, Leroy JP, et al. Constrictive perivenous mesh prosthesis for preservation of vein integrity. *J Thorac Cardiovasc Surg.* 1986;92:330-336.
320. Kohler TR, Kirkman TR, Clowes AW. The effect of rigid external support on vein graft adaptation to the arterial circulation. *J Vasc Surg.* 1989;9:277-285.
321. Hopson SB, Lust RM, Zeri RS, et al. The effects of wall tension on the development of intimal hyperplasia in vein grafts. Paper presented at the 21st World Congress of the International Society for Cardiovascular Surgery, 1993, Lisbon, Portugal, p 106.
322. Bamberg LS, Moczar M, Lecerf L, et al. External biodegradable supporting conduit protects endothelium in vein graft in arterial interposition. *Int J Artif Organs.* 1997;20:397-406.
323. Angelini GD, Izzat MB, Bryan AJ, et al. External stenting reduces early medial and neointimal thickening in a pig model of arteriovenous bypass grafting. *J Thorac Cardiovasc Surg.* 1996;112:79-84.
324. Violaris AG, Newby AC, Angelini GD. Effects of external stenting on wall thickening in arteriovenous bypass grafts. *Ann*

*Thorac Surg.* 1993;55:667-671.

325. Vijayan V, Shukla N, Johnson JL, et al. Long-term reduction of medial and intimal thickening in porcine saphenous vein grafts with a polyglactin biodegradable external sheath. *J Vasc Surg.* 2004;40:1011-1019.
326. Davies MG, Klyachkin ML, Dalen H, et al. Regression of intimal hyperplasia with restoration of EDRF-mediated relaxation in experimental vein grafts. *Surgery.* 1993;114:258-271.
327. Fann JL, Sokoloff MH, Sarris GE, et al. The reversibility of canine vein graft arterialization. *Circulation.* 1990;82(Suppl IV):9-18.
328. Zhang L, Freedman NJ, Brian L, et al. Graft-extrinsic cells predominate in vein graft arterialization. *Arterioscler Thromb Vasc Biol.* 2004;24:470-476.
329. Hu Y, Zhang Z, Torsney E, et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. *J Clin Invest.* 2004;113:1258-1265.
330. Hu Y, Mayr M, Metzler B, et al. Both donor and recipient origins of smooth muscle cells in vein graft atherosclerotic lesions. *Circ Res.* 2002;91:e13-e20.
331. Neitzel GF, Barboriak JJ, Pintar K, et al. Atherosclerosis in aortocoronary bypass grafts. Morphologic study and risk factor analysis 6 to 12 years after surgery. *Arteriosclerosis.* 1986;6:594-600.
332. Atkinson JB, Forman MB, Vaughn WK, et al. Morphologic changes in longterm saphenous vein bypass grafts. *Chest.* 1985;88:341-348.
333. Virami R, Atkinson JB, Forman MB. Aortocoronary saphenous vein bypass grafts. *Cardiovasc Clin.* 1988;18:41-59.
334. O'Donohoe MK, Radic ZS, Schwartz LB, et al. Systemic hypertension alters vasomotor function in experimental vein grafts. *J Vasc Surg.* 1991;14:30-39.
335. Landymore RW, Kinley CE, Cameron CA. Intimal hyperplasia in autogenous vein grafts used for arterial bypass: a canine model. *Cardiovasc Res.* 1985;19:589-592.
336. Klyachkin ML, Davies MG, Svendsen E, et al. Hypercholesterolemia and experimental vein grafts. Accelerated development of intimal hyperplasia and abnormal vasomotor function. *J Surg Res.* 1993;54:451-468.
337. Rosenblatt MS, Quist WC, Sidawy AN, et al. Results of vein graft reconstruction of the lower extremity in diabetic and non-diabetic patients. *Surg Gynecol Obstet.* 1990;171:331-335.
338. Davies MG, Hagen P-O. Modelling the pathophysiology of vein graft failure. *J Vasc Surg.* 1994;20:139-140.
339. Amano J, Suzuki A, Sunamori M, et al. Cytokinetic study of aortocoronary bypass vein grafts in place for less than six months. *Am J Cardiol.* 1991;67:1234-1236.
340. Fuchs JCA, Hagen P-O, Oldham HNJ, et al. Lipid composition in venous arterial bypass grafts. *Surg Forum.* 1972;23:139-141.
341. Scott HW Jr, Morgan CV, Bolasny BL, et al. Experimental atherosclerosis in autogenous venous grafts. *Arch Surg.* 1970;101:677-682.
342. Angelini GD, Bryan AJ, Hunter S, et al. A surgical technique that preserves human saphenous vein functional integrity. *Ann Thorac Surg.* 1992;53:871-874.
343. Zwolak RM, Kirkman TR, Clowes AW. Atherosclerosis in rabbit vein grafts. *Arteriosclerosis.* 1989;9:374-379.
344. Ohki T. Localized intimal hyperplasia in autologous vein graft: does presence of the valve induce obliteration. *Nippon Geka Gakkai Zasshi [J Jpn Surg Soc].* 1993;94:302-310.
345. Chaux A, Ruan X-M, Fishbein MC, et al. Influence of vein valves on the development of arteriosclerosis in venoarterial grafts in the rabbit. *J Thorac Cardiovasc Surg.* 1995;110:1382-1390.
346. Lenz M, Hughes H, Raya J, et al. Vascular smooth muscle cell-mediated LDL oxidation: loss of polyunsaturated fatty acids and formation of specific lipid peroxidation products [abstract]. *FASEB J.* 1992;6:A1323.
347. Tappel A. Measurement of and protection from in vivo lipid peroxidation. In: Pryor W (ed): *Free Radicals in Biology*. San Diego, CA: Academic Press; 1980:1-47.



348. Piotrowski JJ, Hunter GC, Eskelson CD, et al. Lipid peroxidation: a possible factor in late graft failure of coronary artery bypass grafts. *J Vasc Surg.* 1991;13:652-657.
349. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production of peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci U S A.* 1990;87:1620-1624.
350. Rubanyi G. Vascular effects of oxygen derived free radicals. *Free Radic Biol Med.* 1988;4:107-120.
351. Galle J, Bassange E, Busse R. Oxidized low density lipoproteins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. *Circ Res.* 1990;66:1287-1293.
352. Sachinidis A, Mengden T, Locher R, et al. Novel cellular activities for low density lipoproteins in vascular smooth muscle cells. *Hypertension.* 1990;15:704-711.
353. Fuster V. Progression-regression of atherosclerosis: molecular, cellular and clinical bases. *Circulation.* 1992;86(Suppl III):1-123.
354. Menchaca HJ, Morris TJ, Bourdages H, et al. Role of the mechanism of cholesterol reduction on vein graft atherosclerosis. *Surg Forum.* 1992;43:351-352.
355. Klyachkin ML, Davies MG, Kim JH, et al. Post-operative reduction of high serum cholesterol concentrations and experimental vein bypass grafts: effect on the development of intimal hyperplasia and abnormal vasomotor function. *J Thorac Cardiovasc Surg.* 1994;107:556-566.
356. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. *JAMA.* 1987;257:3233-3240.
357. Mann MJ, Gibbons GH, Tsao PS, et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. *J Clin Invest.* 1997;99:1295-1301.
358. Sladen JG, Gilmour JL. Vein graft stenosis: characteristics and effect of treatment. *Am J Surg.* 1981;141:549-553.
359. Hicks RCJ, Ellis M, Mirhasseine R, et al. The influence of fibrinogen concentrations on the development of vein graft stenoses. *Eur J Vasc Endovasc Surg.* 1995;9:415-420.
360. Irvine G, Wilson YG, Currie C, et al. Hyperhomocysteinaemia is a risk factor for vein graft stenosis. *Eur J Vasc Endovasc Surg.* 1996;12:304-309.
361. Nielsen TG, VonJessen F, Andreassen JJ, et al. Antibodies to cardiolipin increase the risk of failure of infrainguinal vein bypasses. *Eur J Vasc Endovasc Surg.* 1997;14:177-184.
362. Hoff HF, Beck GJ, Skibinski CJ, et al. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. *Circulation.* 1988;77:1238-1244.
363. Cheshire NJ, Wolfe JH, Barradas M, et al. Smoking and platelet activity predict infrainguinal graft stenosis. *Br J Surg.* 1993;80:520.
364. Cheshire NJW, Wolfe JHN, Barradas MA, et al. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis. *Eur J Vasc Endovasc Surg.* 1996;11:479-486.
365. Eritsland J, Arnesen H, Seljeflot I, et al. Influence of serum lipoprotein (a) and homocysteine levels on graft patency after coronary artery bypass grafting. *Am J Cardiol.* 1994;74:1099-1102.
366. Daida H, Yokoi H, Miyano H, et al. Relation of saphenous vein graft obstruction to serum cholesterol levels. *J Am Coll Cardiol.* 1995;25:193-197.
367. Kawasuji M, Sakakibara N, Takemura H, et al. Coronary artery bypass grafting in familial hypercholesterolemia. *J Thorac Cardiovasc Surg.* 1995;109:364-369.
368. Campeau L, Knatterud G, Hunninghake D, et al. The effect of aggressive lowering of low density lipoprotein cholesterol levels and low dose anticoagulation on obstructing changes in saphenous vein coronary artery bypass grafts. *N Engl J Med.* 1997;336:153-162.
369. Frick MH, Syvanne M, Nieminen MS. Prevention of the angiographic progression of coronary and vein graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. *Lipid Coronary Angiography*

- Trial (LOCAL) Study Group. *Circulation*. 1997;96:2137-2143.
370. Buckley BH, Hutchins GM. Accelerated atherosclerosis: A morphological study of 97 saphenous vein coronary artery bypass grafts. *Circulation*. 1977;50:163-169.
  371. Lorenz RL, Weber M, Kotzur J, et al. Improved aortocoronary bypass patency by low dose aspirin: effect on platelet aggregation and thromboxane formation. *Lancet*. 1984;1:1261-1264.
  372. Bourassa MG, Campeau L, Lesperance J, et al. Changes in grafts and coronary arteries after saphenous vein aortocoronary bypass surgery: results at repeat angiography. *Circulation*. 1982;65(Suppl II):90-97.
  373. Campeau L, Enjalbert M, Lesperance J, et al. Atherosclerosis and late closure of aortocoronary saphenous vein grafts: sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years and 10 to 12 years after surgery. *Circulation*. 1983;68(Suppl I):1-7.
  374. Olofason P, Rabahie GN, Matsumoto K, et al. Histopathological characterization of explanted human prosthetic arterial grafts: implications for the prevention and management of graft infection. *Eur J Vasc Endovasc*. 1995;9:143-151.
  375. Guidoin R, Chakf'e N, Maurel S, et al. ePTFE arterial prostheses in humans: histopathological study of 298 surgically excised grafts. *Biomaterials*. 1993;14:678-693.
  376. Swedberg SH, Brown BC, Sigley R, et al. Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients: clinical immunocytochemical light and electron microscopic assessment. *Circulation*. 1989;80:1726-1736.
  377. Cho JS, Ouriel K, DeWeese JA, et al. Thrombus formation on PTFE surfaces: the importance of vWF. *Cardiovasc Surg*. 1995;3:645-691.
  378. Formichi MJ, Guidoin RG, Jausseran JM, et al. Expanded PTFE prostheses as arterial substitutes in humans: late pathological findings in 73 excised grafts. *Ann Vasc Surg*. 1988;2:14-27.
  379. Delman SH, Rhoddes RS, Andersonn JM, et al. Atheromatous changes in ePTFE grafts. *Surgery*. 1980;67:630-637.
  380. Urayama H, Kasashima F, Kawakami T, et al. An immunohistochemical analysis of implanted woven Dacron and ePTFE grafts in humans. *Artif Organs*. 1996;20:24-29.
  381. Golden MA, Hanson SR, Kirkman TR, et al. Healing of polytetrafluoroethylene arterial grafts is influenced by graft porosity. *J Vasc Surg*. 1990;11:838-844.
  382. Golden MA, Au YPT, Kenagy RD, et al. Growth factor gene expression by intimal cells in healing polytetrafluoroethylene grafts. *J Vasc Surg*. 1990;11:580-585.
  383. Reidy M, Chao S, Kirkman TR, et al. Endothelial regeneration VI: chronic nondenuding injury in baboon vascular grafts. *Am J Pathol*. 1986;123:432-439.
  384. Tsuchida H, Wilson SE, Ishimaru S. Healing mechanisms of high porosity PTFE grafts: significance of transmural structure. *J Surg Res*. 1997;71:187-195.
  385. Shi Q, Wu MH, Hayashida N, et al. Proof of fallout endothelialization of impervious Dacron grafts in the aorta and inferior vena cava of the dog. *J Vasc Surg*. 1994;20:546-556.
  386. Lanzetta M, Owen ER. Neoendothelialisation of PTFE microvascular grafts: a five year experience. *Microsurgery*. 1995;16:404-411.
  387. Kohler TR, Ferguson MS, Kirkman TR. Thrombosis contributes to intimal hyperplasia in a sheep model of dialysis access fistula [abstract]. *J Vasc Res*. 1996;33(Suppl 1):51.
  388. Clowes AW, Kirkman TR, Reidy MA. Mechanisms of arterial graft healing. Rapid transmural capillary ingrowth provides a source of intimal endothelium and smooth muscle in porous PTFE prostheses. *Am J Pathol*. 1986;123:220-230.
  389. Cordero JA, Quist M, LoGerfo FW. VEGF expression in healing PTFE vascular grafts [abstract]. *J Vasc Res*. 1996;33(Suppl 1):44.
  390. Mesh CL, Majors A, Mistele D, et al. Graft smooth muscle cells specifically synthesize increased collagen. *J Vasc Surg*. 1995;22:142-149.

391. Zacharias RK, Kirkman TR, Kenagy RD, et al. Growth factor production by PTFE vascular grafts. *J Vasc Surg.* 1988;7:606-610.
392. Kraiss LW, Geary RL, Mattsson EJR, et al. Acute reductions in blood flow and shear stress induce platelet-derived growth factor-A expression in baboon prosthetic grafts. *Circ Res.* 1996;79:45-53.
393. Lepidi S, Sterpetti AV, Cucina A, et al. The degree of porosity influences the release of growth factors by healing PTFE grafts. *Eur J Vasc Endovasc Surg.* 1996;11:36-41.
394. Randone B, Cucina A, Corvino V, et al. Suppression of smooth muscle cell proliferation after experimental PTFE arterial grafting: a role for polyclonal antibasic fibroblastic growth factor (bFGF) antibody. *Eur J Vasc Endovasc Surg.* 1998;16:401-407.
395. Um JW, Kim JM, Min BW, et al. Transforming growth factor- $\beta$ 1 expression and the role of angiotensin-converting enzyme inhibitor on perianastomotic intimal hyperplasia in polytetrafluoroethylene graft implanted in rabbit carotid artery. *Kurume Med J.* 2004;51:235-243.
396. Jin D, Ueda H, Takai S, et al. Roles of chymase in stenosis occurring after polytetrafluoroethylene graft implantations. *Life Sci.* 2007;81:1291-1300.
397. Geary RL, Kohler TR, Vergal S, et al. Time course of flow-induced smooth muscle cell proliferation and intimal thickening in endothelialized baboon vascular grafts. *Circ Res.* 1993;74:14-23.
398. Kraiss LW, Kirkman TR, Kohler TR, et al. Shear stress regulates smooth muscle proliferation and neointimal thickening in porous PTFE grafts. *Arterioscler Thromb.* 1991;11:1844-1852.
399. Mattsson EJR, Kohler TR, Vergel SM, et al. Increased blood flow induces regression of intimal hyperplasia. *Arterioscler Thromb Vasc Biol.* 1997;17:2245-2249.
400. Gillis-Haegerstrand C, Frebelius S, Haegerstrand A, et al. Cultured human endothelial cells seeded on ePTFE support thrombin-mediated activation of protein C. *J Vasc Surg.* 1996;24:226-234.
401. Kovekar GB, Burkel WE, Graham LM, et al. Endothelial cell seeding of expanded PTFE vena cava conduits: effects on luminal production of prostacyclin, platelet adherence and fibrinogen accumulation. *J Vasc Surg.* 1988;7:600-605.
402. Walluscheck KP, Steinhoff G, Kelm S, et al. Improved endothelial cell attachment on ePTFE grafts pretreated with synthetic RGD containing peptides. *Eur J Vasc Endovasc Surg.* 1996;12:321-330.
403. Greisler HP, Cziperle DJ, Kim DU, et al. Enhanced endothelialization of ePTFE grafts by FGF-1 pretreatment. *Surgery.* 1992;112:244-254.
404. Gray JL, Kang SS, Zenni GC, et al. FGF-1 affixation stimulates ePTFE endothelialization without intimal hyperplasia. *J Surg Res.* 1994;57:596-612.
405. Wakefield TW, Earley EM, Brother TE, et al. Karyotype analysis of cell sex to determine the source of vascular graft luminal linings following autologous and non autologous endothelial cell seeding. *ASAIO Trans.* 1988;34:864-867.
406. Kaufman BR, Delucca DJ, Folsom DL, et al. Elevated PDGF production by aortic grafts implanted on a long term basis in a canine model. *J Vasc Surg.* 1992;15:806-815.
407. Dichek DA, Anderson J, Kelly AB, et al. Enhanced in vivo antithrombotic effects of EC expressing recombinant plasminogen activators transduced with retroviral vectors. *Circulation.* 1996;93:301-309.
408. Dunn PF, Newman KD, Jones M, et al. Seeding of vascular grafts with genetically modified EC secretion of recombinant t-PA results in decreased seeded cell retention in vitro and in vivo. *Circulation.* 1996;93:1439-1446.
409. Kohler TR. Making hemodialysis grafts work. *J Vasc Surg.* 1997;25:1111-1112.
410. Brothers TE, Vincent CK, Darvishian D, et al. Effects of duration of acetylsalicylic acid administration on patency and anastomotic hyperplasia of ePTFE grafts. *ASAIO Trans.* 1989;35:558-560.
411. Graham LM, Brothers TE, Darvishian D, et al. Effects of thromboxane synthase inhibition on patency and anastomotic hyperplasia of vascular grafts. *J Surg Res.* 1989;46:611-615.
412. Hanson SR, Powell JS, Dodson T, et al. Effects of angiotensin converting enzyme inhibition with cilazapril on intimal

hyperplasia in injured arteries and vascular grafts in the baboon. *Hypertension*. 1991;18(Suppl II):II70-II76.

413. Lundell A, Marijjanowski M, Keffer LK, et al. A locally infused novel fast acting NO donor reduces neointima formation at vascular graft anastomoses in baboons [abstract]. *Cardiovasc Surg*. 1997;5(Suppl 1):145.
414. Jones GT, VanRij AM, Thomson IA, et al. Inhibition of vascular graft intimal hyperplasia using an orally active ET-A and ET-B receptor antagonist [abstract]. *J Vasc Res*. 1996;33(Suppl 1):44.
415. Lumsden AB, Chen C, Coyle KA, et al. Nonporous silicone polymer coating of expanded PTFE grafts reduces graft neointimal hyperplasia in dog and baboon models. *J Vasc Surg*. 1996;24:825-833.
416. Chen C, Lumsden AB, Ofenloch JC, et al. Phosphorylcholine coating of ePTFE grafts reduces neointimal hyperplasia in canine model. *Ann Vasc Surg*. 1997;11:74-79.
417. Chen C, Mattar SG, Hughes JD, et al. Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic intimal hyperplasia in the arteriovenous graft. *Circulation*. 1996;94:1989-1995.
418. Zarge JI, Gosselin C, Huang P, et al. Platelet deposition on ePTFE coated with fibrin glue with or without FGF-1 and heparin. *J Surg Res*. 1997;67:4-8.
419. Gosselin C, Ren D, Ellinger J, et al. In vivo platelet deposition on PTFE coated with fibrin glue containing FGF-1 and heparin in a canine mode. *Am J Surg*. 1995;170:126-130.
420. Greisler HP, Kiosak JJ, Steinam SJ, et al. Effects of class I heparin binding growth factor and fibronectin on platelet adhesion and aggregation. *J Vasc Surg*. 1990;11:665-674.
421. Delorme JM, Guidoin R, Canizales S, et al. Vascular access for hemodialysis: pathologic features of surgical excised ePTFE grafts. *Ann Vasc Surg*. 1992;6:517-524.
422. Koga N, Sato T, Baba T, et al. Angioscopy in transluminal balloon and laser angioplasty in the management of chronic hemodialysis fistulae. *ASAIO J*. 1989;35:193-196.
423. Bassiouny HS, White S, Glagov S, et al. Anastomotic intimal hyperplasia: mechanical injury or flow induced. *J Vasc Surg*. 1992;15:708-717.
424. Kanterman RY, Vesely TM, Pilgram TR, et al. Dialysis access grafts: anatomic location of venous stenosis and results of angioplasty. *Radiology*. 1995;195:135-139.
425. Hofstra L, Bergmans DC, Leunissen KM, et al. Prosthetic arteriovenous fistula and venous anastomotic stenosis: influence of a high velocity on development of intimal hyperplasia. *Blood Purif*. 1996;14:345-349.
426. Hofstra L, Bergmans DC, Leunissen KM, et al. Anastomotic intimal hyperplasia in prosthetic arteriovenous fistulas for hemodialysis is associated with initial high flow velocity and not with mismatch in elastic properties. *J Am Soc Nephrol*. 1995;6:1625-1633.
427. Fillinger MF, Reinitz ER, Schwartz RA, et al. Graft geometry and venous intimal-medial hyperplasia in arteriovenous loop grafts. *J Vasc Surg*. 1990;11:556-566.
428. Fillinger MF, Reinitz ER, Schwartz RA, et al. Beneficial effects of banding on venous intimal-medial hyperplasia in arteriovenous loop grafts. *Am J Surg*. 1989;158:87-94.
429. Roy-Chaudhury P, Kelly BS, Miller MA, et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. *Kidney Int*. 2001;59:2325-2334.
430. Misra S, Fu AA, Rajan DK, et al. Expression of hypoxia inducible factor-1 $\alpha$ , macrophage migration inhibition factor, matrix metalloproteinase-2 and -9, and their inhibitors in hemodialysis grafts and arteriovenous fistulas. *J Vasc Interv Radiol*. 2008;19:252-259.
431. Misra S, Lee N, Fu AA, et al. Increased expression of a disintegrin and metalloproteinase thrombospondin 1 in thrombosed hemodialysis grafts. *J Vasc Interv Radiol*. 2008;19:111-119.
432. Nugent HM, Sjin RT, White D, et al. Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts. *J Vasc Surg*. 2007;46:548-556.
433. Rotmans JI, Velema E, Verhagen HJ, et al. Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine

- arteriovenous-graft model. *J Vasc Surg*. 2004;39:432-439.
434. Luo Z, Akita GY, Date T, et al. Adenovirus-mediated expression of beta-adrenergic receptor kinase C-terminus reduces intimal hyperplasia and luminal stenosis of arteriovenous polytetrafluoroethylene grafts in pigs. *Circulation*. 2005;111:1679-1684.
  435. Cagiannos C, Abul-Khoudoud OR, DeRijk W, et al. Rapamycin-coated expanded polytetrafluoroethylene bypass grafts exhibit decreased anastomotic neointimal hyperplasia in a porcine model. *J Vasc Surg*. 2005;42:980-988.
  436. DeMarchi S, Falleti E, Giacomelio R, et al. Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. *J Am Soc Nephrol*. 1996;7:1169-1177.
  437. DeMarchi S, Cecchin E, Falleti E, et al. Long term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. *J Am Soc Nephrol*. 1997;8:1147-1156.
  438. Taber TE, Maikranz PS, Haag BW, et al. Maintenance of adequate hemodialysis access. Prevention of neointimal hyperplasia. *ASAIO J*. 1995;41:842-846.
  439. Louridas C, Botha JR, Levien L, et al. Vascular access for hemodialysis—experience at Johannesburg hospital. *S Afr Med J*. 1984;66:637-640.
  440. Choudhury D, Lee J, Elivera HS, et al. Correlation of venography, venous pressure and hemoaccess function. *Am J Kidney Dis*. 1995;25:269-275.
  441. Rekhter MN, Nicholls S, Ferguson M, et al. Cell proliferation in human arteriovenous fistulas used for hemodialysis. *Arterioscler Thromb*. 1993;13:609-617.
  442. Chen C, Ku DN, Kikeri D, Lumsden AB. Tenascin: a potential role in human arteriovenous PTFE graft failure. *J Surg Res*. 1996;60:409-416.

## 第 6 章

1. Haimovici H. Arterial embolism with acute massive ischemic myopathy and myoglobinuria: evaluation of a hitherto unreported syndrome with report of two cases. *Surgery*. 1960;47:739-747.
2. Cerra FB, Lajos TZ, Montes M, et al. Hemorrhagic infarction: a reperfusion injury following prolonged myocardial ischemic anoxia. *Surgery*. 1975;78:95-104.
3. Ames A 3rd, Wright RL, Kowada M, et al. Cerebral ischemia. II. The no-reflow phenomenon. *Am J Pathol*. 1968;52:437-453.
4. May Jr JW, Chait LA, O'Brien BM, et al. The no-reflow phenomenon in experimental free flaps. *Plast Reconstr Surg*. 1978;61:256-267.
5. Olding M, Jeng JC. Ischemic tolerance of canine jejunal flaps. *Plast Reconstr Surg*. 1994;94:167-173.
6. Gustafsson AB, Gottlieb RA. Heart mitochondria: gates of life and death. *Cardiovasc Res*. 2008;77:334-343.
7. Chaitanya GV, Babu PP. Activation of calpain, cathepsin-B and caspase-3 during transient focal cerebral ischemia in rat model. *Neurochem Res*. 2008;33:2178-2186.
8. Stein I, Itin A, Einat P, et al. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: Implications for translation under hypoxia. *Mol Cell Biol*. 1998;18:3112-3119.
9. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. *Mol Cell Biol*. 1996;16:4604-4613.
10. Sutter CH, Laughner E, Semenza GL. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. *Proc Natl Acad Sci U S A*. 2000;97:4748-4753.
11. Semenza GL. HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. *J Appl Physiol*. 2000;88:1474-1480.
12. Kong T, Eltzschig HK, Karhausen J, et al. Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction

- of beta2 integrin gene expression. *Proc Natl Acad Sci U S A*. 2004;101:10440-10445.
13. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. *Cell*. 1994;76:301-314.
  14. Tamura DY, Moore EE, Partrick DA, et al. Acute hypoxemia in humans enhances the neutrophil inflammatory response. *Shock*. 2002;17:269-273.
  15. Collard CD, Park KA, Montalto MC, et al. Neutrophil-derived glutamate regulates vascular endothelial barrier function. *J Biol Chem*. 2002;277:14801-14811.
  16. Eltzschig HK, Collard CD. Vascular ischaemia and reperfusion injury. *Br Med Bull*. 2004;70:71-86.
  17. Eltzschig HK, Thompson LF, Karhausen J, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. *Blood*. 2004;104:3986-3992.
  18. Eltzschig HK, Ibla JC, Furuta GT, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A<sub>2B</sub> receptors. *J Exp Med*. 2003;198:783-796.
  19. Gautam N, Olofsson AM, Herwald H, et al. Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. *Nat Med*. 2001;7:1123-1127.
  20. Parks DA, Granger DN. Xanthine oxidase: biochemistry, distribution and physiology. *Acta Physiol Scand Suppl*. 1986;548:87-99.
  21. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. *N Engl J Med*. 1985;312:159-163.
  22. Parks DA, Williams TK, Beckman JS. Conversion of xanthine dehydrogenase to oxidase in ischemic rat intestine: a reevaluation. *Am J Physiol*. 1988;254:G768-G774.
  23. Bonheur JA, Albadawi H, Patton GM, et al. A noninvasive murine model of hind limb ischemia-reperfusion injury. *J Surg Res*. 2004;116:55-63.
  24. Ratych RE, Chuknyiska RS, Bulkley GB. The primary localization of free radical generation after anoxia/reoxygenation in isolated endothelial cells. *Surgery*. 1987;102:122-131.
  25. Fuh KC, Meneshian A, Patel CB, et al. Signal transduction by reactive oxygen species: alternative paradigms for signaling specificity. *Surgery*. 2002;131:601-612.
  26. Watkins MT, al-Badawi H, Cardenas R, et al. Endogenous reactive oxygen metabolites mediate sublethal endothelial cell dysfunction during reoxygenation. *J Vasc Surg*. 1996;23:95-103.
  27. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci U S A*. 1990;87:1620-1624.
  28. Ogawa S, Koga S, Kuwabara K, et al. Hypoxia-induced increased permeability of endothelial monolayers occurs through lowering of cellular cAMP levels. *Am J Physiol*. 1992;262:C546-C554.
  29. Albadawi H, Patton GM, Bratton CF, et al. Human microvascular endothelial synthesis of interleukin-8 during in vitro ischemia and reperfusion. *J Cell Biochem*. 2007;100:412-420.
  30. Watkins MT, Al-Badawi H, Russo AL, et al. Human microvascular endothelial cell prostaglandin E<sub>1</sub> synthesis during in vitro ischemia-reperfusion. *J Cell Biochem*. 2004;92:472-480.
  31. Belkin M, LaMorte WL, Wright JG, et al. The role of leukocytes in the pathophysiology of skeletal muscle ischemic injury. *J Vasc Surg*. 1989;10:14-18; discussion 18-19.
  32. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. *J Pathol*. 2000;190:255-266.
  33. Alexander JS, Alexander BC, Eppihimer LA, et al. Inflammatory mediators induce sequestration of VE-cadherin in cultured human endothelial cells. *Inflammation*. 2000;24:99-113.
  34. Colgan SP, Dzus AL, Parkos CA. Epithelial exposure to hypoxia modulates neutrophil transepithelial migration. *J Exp Med*. 1996;184:1003-1015.
  35. Weiss SJ. Tissue destruction by neutrophils. *N Engl J Med*. 1989;320:365-376.
  36. Carter JM, Buerke U, Rossner E, et al. Anti-inflammatory actions of aprotinin provide dose-dependent cardioprotection

- from reperfusion injury. *Br J Pharmacol*. 2008;155:93-102.
37. Day JR, Taylor KM, Lidington EA, et al. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. *J Thorac Cardiovasc Surg*. 2006;131:21-27.
  38. Gupta S. Molecular signaling in death receptor and mitochondrial pathways of apoptosis. *Int J Oncol*. 2003;22:15-20.
  39. Aleo E, Henderson CJ, Fontanini A, et al. Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. *Cancer Res*. 2006;66:9235-9244.
  40. Schulz JB, Weller M, Moskowitz MA. Caspases as treatment targets in stroke and neurodegenerative diseases. *Ann Neurol*. 1999;45:421-429.
  41. Kim JS, Qian T, Lemasters JJ. Mitochondrial permeability transition in the switch from necrotic to apoptotic cell death in ischemic rat hepatocytes. *Gastroenterology*. 2003;124:494-503.
  42. Iwata A, Harlan JM, Vedder NB, et al. The caspase inhibitor z-VAD is more effective than CD18 adhesion blockade in reducing muscle ischemia-reperfusion injury: implication for clinical trials. *Blood*. 2002;100:2077-2080.
  43. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. *Circ Res*. 2001;88:877-887.
  44. Chandrasekar B, Colston JT, Geimer J, et al. Induction of nuclear factor  $\kappa$ B but not  $\kappa$ B-responsive cytokine expression during myocardial reperfusion injury after neutropenia. *Free Radic Biol Med*. 2000;28:1579-1588.
  45. Park JW, Qi WN, Cai Y, et al. Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor- $\kappa$ B activation. *Plast Reconstr Surg*. 2007;120:1808-1818.
  46. Tian XF, Yao JH, Li YH, et al. Protective effect of pyrrolidine dithiocarbamate on liver injury induced by intestinal ischemia-reperfusion in rats. *Hepatobiliary Pancreat Dis Int*. 2006;5:90-95.
  47. Tian XF, Yao JH, Li YH, et al. Effect of nuclear factor kappa B on intercellular adhesion molecule-1 expression and neutrophil infiltration in lung injury induced by intestinal ischemia/reperfusion in rats. *World J Gastroenterol*. 2006;12:388-392.
  48. Tian XF, Zhang XS, Li YH, et al. Proteasome inhibition attenuates lung injury induced by intestinal ischemia reperfusion in rats. *Life Sci*. 2006;79:2069-2076.
  49. Lentsch AB, Yoshidome H, Cheadle WG, et al. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and KC. *Hepatology*. 1998;27:1172-1177.
  50. Conrad MF, Stone DH, Albadawi H, et al. Local inflammatory and thrombotic responses differ in a murine model of partial and complete hindlimb ischemia/reperfusion. *Surgery*. 2005;138:375-381.
  51. Hua HT, Al-Badawi H, Entabi F, et al. CXC chemokine expression and synthesis in skeletal muscle during ischemia/reperfusion. *J Vasc Surg*. 2005;42:337-343.
  52. Seekamp A, Warren JS, Remick DG, et al. Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. *Am J Pathol*. 1993;143:453-463.
  53. Colletti LM, Green M. Lung and liver injury following hepatic ischemia/reperfusion in the rat is increased by exogenous lipopolysaccharide which also increases hepatic TNF production in vivo and in vitro. *Shock*. 2001;16:312-319.
  54. Wakai A, Winter DC, Street JT, et al. Inosine attenuates tourniquet-induced skeletal muscle reperfusion injury. *J Surg Res*. 2001;99:311-315.
  55. Kang J, Albadawi H, Patel VI, et al. Apolipoprotein E(-/-) mice have delayed skeletal muscle healing after hind limb ischemia-reperfusion. *J Vasc Surg*. 2008;48:701-708.
  56. Seekamp A, Ward PA. Ischemia-reperfusion injury. *Agents Actions Suppl*. 1993;41:137-152.
  57. Conrad MF, Albadawi H, Stone DH, et al. Local administration of the poly ADP-ribose polymerase (PARP) inhibitor, PJ34 during hindlimb ischemia modulates skeletal muscle reperfusion injury. *J Surg Res*. 2006;135:233-237.
  58. Hua HT, Albadawi H, Entabi F, et al. Polyadenosine diphosphate-ribose polymerase inhibition modulates skeletal muscle injury following ischemia reperfusion. *Arch Surg*. 2005;140:344-351; discussion 351-352.
  59. Akuzawa S, Kazui T, Shi E, et al. Interleukin-1 receptor antagonist attenuates the severity of spinal cord ischemic injury in

- rabbits. *J Vasc Surg*. 2008;48:694-700.
60. Rusai K, Huang H, Sayed N, et al. Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury. *Transpl Int*. 2008;21:572-580.
  61. Shireman PK, Contreras-Shannon V, Ochoa O, et al. MCP-1 deficiency causes altered inflammation with impaired skeletal muscle regeneration. *J Leukoc Biol*. 2007;81:775-785.
  62. Persy VP, Verhulst A, Ysebaert DK, et al. Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. *Kidney Int*. 2003;63:543-553.
  63. Trueblood NA, Xie Z, Communal C, et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. *Circ Res*. 2001;88:1080-1087.
  64. Suezawa C, Kusachi S, Murakami T, et al. Time-dependent changes in plasma osteopontin levels in patients with anterior-wall acute myocardial infarction after successful reperfusion: correlation with left-ventricular volume and function. *J Lab Clin Med*. 2005;145:33-40.
  65. Kossmehl P, Schonberger J, Shakibaei M, et al. Increase of fibronectin and osteopontin in porcine hearts following ischemia and reperfusion. *J Mol Med*. 2005;83:626-637.
  66. Cairns C. Rude unhinging of the machinery of life: Metabolic approaches to hemorrhagic shock. *Curr Opin Crit Care*. 2001;7:437-443.
  67. Taegmayer H, Roberts A, Raine A. Energy metabolism in reperfused heart muscle: metabolic correlates to return of function. *J Am Coll Card*. 1995;6:864-870.
  68. Cairns C, Ferroggiaro A, Walther J, et al. Post ischemic administration of succinate reverses the impairment of oxidative phosphorylation after ischemia reperfusion injury. *Circulation*. 1997;96(Suppl II):260-265.
  69. Schaefer C, Biber B, Lerner M, et al. Rapid reduction of intestinal cytochrome a,a<sub>3</sub> during lethal endotoxemia. *J Surg Res*. 1991;51:382-391.
  70. Fink MP. Bench-to-bedside review: cytopathic hypoxia. *Crit Care*. 2002;6:491-499.
  71. Casey PJ, Black JH, Szabo C, et al. Poly(adenosine diphosphate ribose) polymerase inhibition modulates spinal cord dysfunction after thoracoabdominal aortic ischemia-reperfusion. *J Vasc Surg*. 2005;41:99-107.
  72. Glantzounis G, Rocks S, Sheth H, et al. Formation and role of plasma S-nitrosothiols in liver ischemia-reperfusion injury. *Free Radic Biol Med*. 2007;42:882-892.
  73. Zhao X, He G, Chen Y, et al. Endothelium-derived nitric oxide regulates postischemic myocardial oxygenation and oxygen consumption by modulation of mitochondrial electron transport. *Circulation*. 2005;111:2966-2972.
  74. Rabkin SW, Klassen SS. Metalloporphyrins as a therapeutic drug class against peroxynitrite in cardiovascular diseases involving ischemic reperfusion injury. *Eur J Pharmacol*. 2008;586:1-8.
  75. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. *Annu Rev Physiol*. 1998;60:619-642.
  76. Kuwana T, Mackey MR, Perkins G, et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. *Cell*. 2002;111:331-342.
  77. Chen Z, Chua CC, Ho Y-S, et al. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. *Am J Physiol Heart Circ Physiol*. 2001;280: H2313-H2320.
  78. Arumugam TV, Magnus T, Woodruff TM, et al. Complement mediators in ischemia-reperfusion injury. *Clin Chim Acta*. 2006;374:33-45.
  79. Wong MS, Lara TM, Kobzik L, et al. Hindlimb ischemia-reperfusion increases complement deposition and glycolysis. *J Surg Res*. 1999;85:130-135.
  80. Fleming SD, Shea-Donohue T, Guthridge JM, et al. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. *J Immunol*. 2002;169:2126-2133.
  81. Austen WG, Zhang M, Chan R, et al. Murine hindlimb reperfusion injury can be initiated by a self-reactive monoclonal



- IgM. *Surgery*. 2004;136:401-406.
82. Chan RK, Verna N, Afnan J, et al. Attenuation of skeletal muscle reperfusion injury with intravenous 12 amino acid peptides that bind to pathogenic IgM. *Surgery*. 2006;139:236-243.
  83. Toomayan C, Chen L, Jiang H, et al. C1-esterase inhibitor and a novel peptide inhibitor improve contractile function in reperfused skeletal muscle. *Microsurgery*. 2003;23:561-567.
  84. Kyriakides C, Austen Jr W, Wang Y, et al. Skeletal muscle reperfusion injury is mediated by neutrophils and the complement membrane attack complex. *Am J Physiol Cell Physiol*. 1999;277:C1263-C1268.
  85. Beckman JS. Ischaemic injury mediator. *Nature*. 1990;345:27-28.
  86. Beckman JS. The double-edged role of nitric oxide in brain function and superoxide-mediated injury. *J Dev Physiol*. 1991;15:53-59.
  87. Nathan C. Nitric oxide and biopterin: a study in Chiaroscuro. *J Clin Invest*. 1994;93:1875-1876.
  88. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. *J Biol Chem*. 1994;269:13725-13728.
  89. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiol Rev*. 2007;87:315-424.
  90. Avila MA, Sell SL, Kadoi Y, et al. L-Arginine decreases fluid-percussion injury-induced neuronal nitrotyrosine immunoreactivity in rats. *J Cereb Blood Flow Metab*. 2008;28:1733-1741.
  91. Matata BM, Galinanes M. Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor-kappa B DNA binding activity. *J Biol Chem*. 2002;277:2330-2335.
  92. Park SW, Huq MD, Hu X, et al. Tyrosine nitration on p65: A novel mechanism to rapidly inactivate nuclear factor- $\kappa$ B. *Mol Cell Proteomics*. 2005;4:300-309.
  93. Park SW, Wei LN. Regulation of c-myc gene by nitric oxide via inactivating NF-kappa B complex in P19 mouse embryonal carcinoma cells. *J Biol Chem*. 2003;278:29776-29782.
  94. Greco R, Amantea D, Blandini F, et al. Neuroprotective effect of nitroglycerin in a rodent model of ischemic stroke: evaluation of Bcl-2 expression. *Int Rev Neurobiol*. 2007;82:423-435.
  95. Katsumi H, Nishikawa M, Yamashita F, et al. Prevention of hepatic ischemia/reperfusion injury by prolonged delivery of nitric oxide to the circulating blood in mice. *Transplantation*. 2008;85:264-269.
  96. Namazi H. Sodium nitroprusside as a nitric oxide donor in a rat intestinal ischemia reperfusion model: a novel molecular mechanism. *Clinics*. 2008;63:405.
  97. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. *J Clin Invest*. 1995;96:60-68.
  98. Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. *J Biol Chem*. 1995;270:14214-14219.
  99. Rubbo H, O'Donnell V. Nitric oxide, peroxynitrite and lipoxygenase in atherogenesis: mechanistic insights. *Toxicology*. 2005;208:305-317.
  100. Kubes P. Polymorphonuclear leukocyte-endothelium interactions: a role for pro-inflammatory and anti-inflammatory molecules. *Can J Physiol Pharmacol*. 1993;71:88-97.
  101. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. *Proc Natl Acad Sci U S A*. 1991;88:4651-4655.
  102. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. *Lancet*. 1987;2:1057-1058.
  103. Tuor UI, Simone CS, Barks JD, et al. Dexamethasone prevents cerebral infarction without affecting cerebral blood flow in neonatal rats. *Stroke*. 1993;24:452-457.
  104. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature*. 1988;332:411-415.

105. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. *Proc Natl Acad Sci U S A*. 1989;86:2863-2867.
106. Mallick IH, Yang W, Winslet MC, et al. Ischemia-reperfusion injury of the intestine and protective strategies against injury. *Dig Dis Sci*. 2004;49:1359-1377.
107. Clozel M, Gray GA, Breu V, et al. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. *Biochem Biophys Res Commun*. 1992;186:867-873.
108. Haynes WG, Webb DJ. Endothelium-dependent modulation of responses to endothelin-I in human veins. *Clin Sci (Lond)*. 1993;84:427-433.
109. Sargent CA, Liu EC, Chao CC, et al. Role of endothelin receptor subtype B (ET-B) in myocardial ischemia. *Life Sci*. 1994;55:1833-1844.
110. Henrion D, Laher I. Potentiation of norepinephrine-induced contractions by endothelin-1 in the rabbit aorta. *Hypertension*. 1993;22:78-83.
111. Gupta SK, Saxena A, Singh U, et al. Bosentan, the mixed ETA-ETB endothelin receptor antagonist, attenuated oxidative stress after experimental myocardial ischemia and reperfusion. *Mol Cell Biochem*. 2005;275:67-74.
112. McMurdo L, Thiemeermann C, Vane JR. The effects of the endothelin ETA receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion. *Br J Pharmacol*. 1994;112:75-80.
113. Ozdemir R, Parlakpınar H, Polat A, et al. Selective endothelin A (ETA) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury. *Toxicology*. 2006;219:142-149.
114. Kuro T, Kohnou K, Kobayashi Y, et al. Selective antagonism of the ETA receptor, but not the ETB receptor, is protective against ischemic acute renal failure in rats. *Jpn J Pharmacol*. 2000;82:307-316.
115. Matsuo Y, Mihara S, Ninomiya M, et al. Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. *Stroke*. 2001;32:2143-2148.
116. Uhlmann D, Glasser S, Gaebel G, et al. Improvement of postischemic hepatic microcirculation after endothelin A receptor blockade—endothelin antagonism influences platelet-endothelium interactions. *J Gastrointest Surg*. 2005;9:187-197.
117. Andrasi TB, Kekesi V, Blazovics A, et al. ET(A) receptor blockade protects the small intestine against ischaemia/reperfusion injury in dogs via an enhancement of antioxidant defences. *Clin Sci (Lond)*. 2002;103(Suppl 48):59S-63S.
118. Sato W, Kadomatsu K, Yuzawa Y, et al. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. *J Immunol*. 2001;167:3463-3469.
119. Sato W, Takei Y, Yuzawa Y, et al. Midkine antisense oligodeoxynucleotide inhibits renal damage induced by ischemic reperfusion. *Kidney Int*. 2005;67:1330-1339.
120. Sato W, Yuzawa Y, Kadomatsu K, et al. Midkine expression in the course of nephrogenesis and its role in ischaemic reperfusion injury. *Nephrol Dial Transplant*. 2002;17(Suppl 9):52-54.
121. Horiba M, Kadomatsu K, Yasui K, et al. Midkine plays a protective role against cardiac ischemia/reperfusion injury through a reduction of apoptotic reaction. *Circulation*. 2006;114:1713-1720.
122. Jennings RB, Reimer KA, Hill ML, et al. Total ischemia in dog hearts, in vitro. 1. Comparison of high energy phosphate production, utilization, and depletion, and of adenine nucleotide catabolism in total ischemia in vitro vs. severe ischemia in vivo. *Circ Res*. 1981;49:892-900.
123. Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. *Cardiovasc Drug Rev*. 2006;24:116-147.
124. Yaar R, Jones MR, Chen JF, et al. Animal models for the study of adenosine receptor function. *J Cell Physiol*. 2005;202:9-20.
125. Berne RM. The role of adenosine in the regulation of coronary blood flow. *Circ Res*. 1980;47:807-813.
126. Conti A, Monopoli A, Gamba M, et al. Effects of selective A<sub>1</sub> and A<sub>2</sub> adenosine receptor agonists on cardiovascular tissues.

*Naunyn Schmiedebergs Arch Pharmacol.* 1993;348:108-112.

127. Pasque MK, Spray TL, Pellom GL, et al. Ribose-enhanced myocardial recovery following ischemia in the isolated working rat heart. *J Thorac Cardiovasc Surg.* 1982;83:390-398.
128. Gross GJ, Auchampach JA. Role of ATP dependent potassium channels in myocardial ischaemia. *Cardiovasc Res.* 1992;26:1011-1016.
129. Cronstein BN, Rosenstein ED, Kramer SB, et al. Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A<sub>2</sub> receptor on human neutrophils. *J Immunol.* 1985;135:1366-1371.
130. Quintana M, Kahan T, Hjerdahl P. Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent. *Am J Cardiovasc Drugs.* 2004;4:159-167.
131. Zheng J, Wang R, Zambraski E, et al. Protective roles of adenosine A<sub>1</sub>, A<sub>2A</sub>, and A<sub>3</sub> receptors in skeletal muscle ischemia and reperfusion injury. *Am J Physiol Heart Circ Physiol.* 2007;293: H3685-H3691.
132. Reece TB, Tribble CG, Okonkwo DO, et al. Early adenosine receptor activation ameliorates spinal cord reperfusion injury. *J Cardiovasc Med (Hagerstown).* 2008;9:363-367.
133. Okusa MD, Linden J, Huang L, et al. A(2A) adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. *Am J Physiol Renal Physiol.* 2000;279:F809-F818.
134. Koti RS, Seifalian AM, Davidson BR. Protection of the liver by ischemic preconditioning: a review of mechanisms and clinical applications. *Dig Surg.* 2003;20:383-396.
135. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. *Biochem Biophys Res Commun.* 1993;192:553-560.
136. Pio R, Martinez A, Unsworth EJ, et al. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. *J Biol Chem.* 2001;276:12292-12300.
137. Shimekake Y, Nagata K, Ohta S, et al. Adrenomedullin stimulates two signal transduction pathways, cAMP accumulation and Ca<sup>2+</sup> mobilization, in bovine aortic endothelial cells. *J Biol Chem.* 1995;270:4412-4417.
138. Harrison RA, Lachmann PJ. The physiological breakdown of the third component of human complement. *Mol Immunol.* 1980;17:9-20.
139. DiScipio RG, Daffern PJ, Schraufstatter IU, et al. Human polymorphonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18). *J Immunol.* 1998;160:4057-4066.
140. Carrizo GJ, Wu R, Cui X, et al. Adrenomedullin and adrenomedullin-binding protein-1 downregulate inflammatory cytokines and attenuate tissue injury after gut ischemia-reperfusion. *Surgery.* 2007;141:245-253.
141. Lien YH, Lai LW, Silva AL. Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice. *Life Sci.* 2003;74:543-552.
142. Kerem M, Bedirli A, Pasaoglu H, et al. Effect of adrenomedullin on hepatic damage in hepatic ischemia reperfusion injury in rats. *Liver Int.* 2008: Epub PMID 18435717.
143. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. *Proc Natl Acad Sci U S A.* 1968;61:748-755.
144. Maines MD, Mayer RD, Ewing JF, et al. Induction of kidney heme oxygenase-1 (HSP32) mRNA and protein by ischemia/reperfusion: Possible role of heme as both promotor of tissue damage and regulator of HSP32. *J Pharmacol Exp Ther.* 1993;264:457-462.
145. Ferrandiz ML, Devesa I. Inducers of heme oxygenase-1. *Curr Pharm Des.* 2008;14:473-486.
146. Ryter SW, Morse D, Choi AM. Carbon monoxide and bilirubin: Potential therapies for pulmonary/vascular injury and disease. *Am J Respir Cell Mol Biol.* 2007;36:175-182.
147. Misra HP, Fridovich I. The generation of superoxide radical during the autoxidation of hemoglobin. *J Biol Chem.* 1972;247:6960-6962.
148. Hayashi S, Takamiya R, Yamaguchi T, et al. Induction of heme oxygenase-1 suppresses venular leukocyte adhesion

- elicited by oxidative stress: role of bilirubin generated by the enzyme. *Circ Res.* 1999;85:663-671.
149. Christova T, Diankova Z, Setchenska M. Heme oxygenase–carbon monoxide signalling pathway as a physiological regulator of vascular smooth muscle cells. *Acta Physiol Pharmacol Bulg.* 2000;25:9-17.
  150. Zhang X, Shan P, Otterbein LE, et al. Carbon monoxide inhibition of apoptosis during ischemia-reperfusion lung injury is dependent on the p38 mitogen–activated protein kinase pathway and involves caspase 3. *J Biol Chem.* 2003;278:1248-1258.
  151. Kaizu T, Ikeda A, Nakao A, et al. Protection of transplant-induced hepatic ischemia/reperfusion injury with carbon monoxide via MEK/ERK1/2 pathway downregulation. *Am J Physiol Gastrointest Liver Physiol.* 2008;294:G236-G244.
  152. Morse D, Sethi J, Choi AM. Carbon monoxide–dependent signaling. *Crit Care Med.* 2002;30:S12-S17.
  153. Hobson RW 2nd, Wright JG, Fox D, et al. Heparinization reduces endothelial permeability and hydrogen ion accumulation in a canine skeletal muscle ischemia-reperfusion model. *J Vasc Surg.* 1988;7:585-591.
  154. Abbruzzese TA, Albadawi H, Kang J, et al. Enoxaparin does not ameliorate limb ischemia-reperfusion injury. *J Surg Res.* 2008;147:260-266.
  155. Stutzmann JM, Mary V, Wahl F, et al. Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury in rats: a review. *CNS Drug Rev.* 2002;8:1-30.
  156. Levi M, Choi G, Schoots I, et al. Beyond sepsis: activated protein C and ischemia-reperfusion injury. *Crit Care Med.* 2004;32: S309-312.
  157. Roemisch J, Gray E, Hoffmann JN, et al. A new look at the actions of a serine protease inhibitor. *Blood Coagul Fibrinolysis.* 2002;13:657-670.
  158. Laszik Z, Carson CW, Nadasdy T, et al. Lack of suppressed renal thrombomodulin expression in a septic rat model with glomerular thrombotic microangiopathy. *Lab Invest.* 1994;70:862-867.
  159. Duru S, Koca U, Oztekin S, et al. Antithrombin III pretreatment reduces neutrophil recruitment into the lung and skeletal muscle tissues in the rat model of bilateral lower limb ischemia and reperfusion: a pilot study. *Acta Anaesthesiol Scand.* 2005;49:1142-1148.
  160. Wright JG, Kerr JC, Valeri CR, et al. Regional hypothermia protects against ischemia-reperfusion injury in isolated canine gracilis muscle. *J Trauma.* 1988;28:1026-1031.
  161. Motoyoshi N, Sakurai M, Hayashi T, et al. Establishment of a local cooling model against spinal cord ischemia representing prolonged induction of heat shock protein. *J Thorac Cardiovasc Surg.* 2001;122:351-357.
  162. Black JH, Davison JK, Cambria RP. Regional hypothermia with epidural cooling for prevention of spinal cord ischemic complications after thoracoabdominal aortic surgery. *Semin Thorac Cardiovasc Surg.* 2003;15:345-352.
  163. Cambria RP, Davison JK, Carter C, et al. Epidural cooling for spinal cord protection during thoracoabdominal aneurysm repair: a five-year experience. *J Vasc Surg.* 2000;31:1093-1102.
  164. Davison JK, Cambria RP, Vierra DJ, et al. Epidural cooling for regional spinal cord hypothermia during thoracoabdominal aneurysm repair. *J Vasc Surg.* 1994;20:304-310.
  165. El-Wahsh M. Liver graft preservation: an overview. *Hepatobiliary Pancreat Dis Int.* 2007;6:12-16.
  166. Coselli JS, Bozinovski J, Cheung C. Hypothermic circulatory arrest: safety and efficacy in the operative treatment of descending and thoracoabdominal aortic aneurysms. *Ann Thorac Surg.* 2008;85:956-963; discussion 964.
  167. Kazui T, Bashar AH. The safety of moderate hypothermic circulatory arrest with selective cerebral perfusion. *J Thorac Cardiovasc Surg.* 2008;135:715; author reply 715-716.
  168. Khaladj N, Shrestha M, Meck S, et al. Hypothermic circulatory arrest with selective antegrade cerebral perfusion in ascending aortic and aortic arch surgery: a risk factor analysis for adverse outcome in 501 patients. *J Thorac Cardiovasc Surg.* 2008;135:908-914.
  169. Bernik TR, Friedman SG, Ochani M, et al. Cholinergic antiinflammatory pathway inhibition of tumor necrosis factor during ischemia reperfusion. *J Vasc Surg.* 2002;36:1231-1236.

170. Czura CJ, Friedman SG, Tracey KJ. Neural inhibition of inflammation: the cholinergic anti-inflammatory pathway. *J Endotoxin Res.* 2003;9:409-413.
171. Wang X, Xu L, Wang H, et al. Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats. *Stroke.* 2003;34:468-474.
172. Mioni C, Bazzani C, Giuliani D, et al. Activation of an efferent cholinergic pathway produces strong protection against myocardial ischemia/reperfusion injury in rats. *Crit Care Med.* 2005;33:2621-2628.
173. Uemura K, Li M, Tsutsumi T, et al. Efferent vagal nerve stimulation induces tissue inhibitor of metalloproteinase-1 in myocardial ischemia-reperfusion injury in rabbit. *Am J Physiol Heart Circ Physiol.* 2007;293:H2254-H2261.
174. Borovikova LV, Ivanova S, Nardi D, et al. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. *Auton Neurosci.* 2000;85:141-147.
175. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature.* 2000;405:458-462.
176. Yeboah MM, Xue X, Duan B, et al. Cholinergic agonists attenuate renal ischemia-reperfusion injury in rats. *Kidney Int.* 2008;74:62-69.
177. Gourgiotis S, Villias C, Germanos S, et al. Acute limb compartment syndrome: a review. *J Surg Educ.* 2007;64:178-186.
178. Tiwari A, Haq AI, Myint F, et al. Acute compartment syndromes. *Br J Surg.* 2002;89:397-412.
179. Heemskerk J, Kitslaar P. Acute compartment syndrome of the lower leg: retrospective study on prevalence, technique, and outcome of fasciotomies. *World J Surg.* 2003;27:744-747.
180. Rush DS, Frame SB, Bell RM, et al. Does open fasciotomy contribute to morbidity and mortality after acute lower extremity ischemia and revascularization? *J Vasc Surg.* 1989;10:343-350.
181. Laky D, Parascan L, Candea V. Myocardial stunning. Morphological studies in acute experimental ischemia and intraoperative myocardial biopsies. *Rom J Morphol Embryol.* 2008;49:153-158.
182. Page B, Young R, Iyer V, et al. Persistent regional downregulation in mitochondrial enzymes and upregulation of stress proteins in swine with chronic hibernating myocardium. *Circ Res.* 2008;102:103-112.
183. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. *Am J Physiol Cell Physiol.* 2002;282:C227-241.
184. Maxwell SR, Lip GY. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. *Int J Cardiol.* 1997;58:95-117.
185. Forman MB, Jackson EK. Importance of tissue perfusion in ST segment elevation myocardial infarction patients undergoing reperfusion strategies: role of adenosine. *Clin Cardiol.* 2007;30:583-585.
186. Pereda D, Castella M, Pomar JL, et al. Elective cardiac surgery using Celsior or St. Thomas No. 2 solution: a prospective, single-center, randomized pilot study. *Eur J Cardiothorac Surg.* 2007;32:501-506.
187. Richling N, Herkner H, Holzer M, et al. Thrombolytic therapy vs primary percutaneous intervention after ventricular fibrillation cardiac arrest due to acute ST-segment elevation myocardial infarction and its effect on outcome. *Am J Emerg Med.* 2007;25:545-550.
188. Yamazaki S, Fujibayashi Y, Rajagopalan RE, et al. Effects of staged versus sudden reperfusion after acute coronary occlusion in the dog. *J Am Coll Cardiol.* 1986;7:564-572.
189. Cerqueira NF, Hussni CA, Yoshida WB. Pathophysiology of mesenteric ischemia/reperfusion: a review. *Acta Cir Bras.* 2005;20:336-343.
190. Oldenburg WA, Lau LL, Rodenberg TJ, et al. Acute mesenteric ischemia: A clinical review. *Arch Intern Med.* 2004;164:1054-1062.
191. Kaminsky O, Yampolski I, Aranovich D, et al. Does a second-look operation improve survival in patients with peritonitis due to acute mesenteric ischemia? A five-year retrospective experience. *World J Surg.* 2005;29:645-648.
192. Park WM, Gloviczki P, Cherry KJ Jr, et al. Contemporary management of acute mesenteric ischemia: factors associated

- with survival. *J Vasc Surg.* 2002;35:445-452.
193. Yanar H, Taviloglu K, Ertekin C, et al. Planned second-look laparoscopy in the management of acute mesenteric ischemia. *World J Gastroenterol.* 2007;13:3350-3353.
  194. Tang PS, Mura M, Seth R, et al. Acute lung injury and cell death: how many ways can cells die? *Am J Physiol Lung Cell Mol Physiol.* 2008;294:L632-L641.
  195. Landis C. Why the inflammatory response is important to the cardiac surgical patient. *J Extra Corpor Technol.* 2007;39:281-284.
  196. Menger MD, Vollmar B. Pathomechanisms of ischemia-reperfusion injury as the basis for novel preventive strategies: is it time for the introduction of pleiotropic compounds? *Transplant Proc.* 2007;39:485-488.
  197. MEND-CABG II Investigators, Alexander JH, Emery Jr RW, Carrier M, et al. Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. *JAMA.* 2008;299:1777-1787.
  198. Mentzer Jr RM, Bartels C, Bolli R, et al. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. *Ann Thorac Surg.* 2008;85:1261-1270.
  199. Lees KR, Davalos A, Davis SM, et al. Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial. *Stroke.* 2006;37:2970-2978.
  200. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. *N Engl J Med.* 2006;354:588-600.
  201. Koziol JA, Feng AC. On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke. *Stroke.* 2006;37:2644-2647.
  202. Basu S, Meisert I, Eggensperger E, et al. Time course and attenuation of ischaemia-reperfusion induced oxidative injury by propofol in human renal transplantation. *Redox Rep.* 2007;12:195-202.
  203. Lang Jr JD, Teng X, Chumley P, et al. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. *J Clin Invest.* 2007;117:2583-2591.
  204. Graor R, Comerota A, Dlouville Y, for the STILE Investigators: Results of a prospective randomized trial evaluating surgery vs thrombolysis for ischemia of the lower extremities. *Ann Surg.* 1994;220:251-268.
  205. Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. *J Vasc Surg.* 1994;19:1021-1030.
  206. Ouriel K, Veith F, Sasahara A. Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators. *J Vasc Surg.* 1996;23:64-73.
  207. Ouriel K, Veith F, Sasahara A. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. *N Engl J Med.* 1998;339:1105-1111.
  208. Walker PM, Romaschin AD, Davis S, et al. Lower limb ischemia: phase 1 results of salvage perfusion. *J Surg Res.* 1999;84:193-198.
  209. Wilhelm MP, Schlensak C, Hoh A, et al. Controlled reperfusion using a simplified perfusion system preserves function after acute and persistent limb ischemia: a preliminary study. *J Vasc Surg.* 2005;42:690-694.
  210. Blaisdell FW. The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: a review. *Cardiovasc Surg.* 2002;10:620-630.
  211. Blaisdell FW, Steele M, Allen R. Management of acute lower extremity arterial ischemia due to embolism and thrombosis. *Surgery.* 1978;84:822-834.

## 第 7 章

1. Grundmann S, Piek JJ, Pasterkamp G, et al. Arteriogenesis: basic mechanisms and therapeutic stimulation. *Eur J Clin*

- Invest.* 2007;37:755-766.
2. Hoefer IE, van Royen N, Jost MM. Experimental models of arteriogenesis: differences and implications. *Lab Anim (N Y)*. 2006;35:36-44.
  3. Peirce SM, Skalak TC. Microvascular remodeling: a complex continuum spanning angiogenesis to arteriogenesis. *Microcirculation*. 2003;10:99-111.
  4. Heil M, Eitenmuller I, Schmitz-Rixen T, et al. Arteriogenesis versus angiogenesis: similarities and differences. *J Cell Mol Med*. 2006;10:45-55.
  5. Burri PH, Hlushchuk R, Djonov V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. *Dev Dyn*. 2004;231:474-488.
  6. Moldovan L, Moldovan NI. Role of monocytes and macrophages in angiogenesis. *EXS*. 2005;94:127-146.
  7. Schaper W, Scholz D. Factors regulating arteriogenesis. *Arterioscler Thromb Vasc Biol*. 2003;23:1143-1151.
  8. Ritter R. *Collateral circulation in clinical practice*. In: Schaper W, Schaper J, eds. Arteriogenesis (Basic Science for the Cardiologist). Dordrecht, Germany: Kluwer; 2004:353-358.
  9. Hossmann KA. *Collateral circulation of the brain*. In: Schaper W, Schaper J, eds. Collateral Circulation: Heart, Brain, Kidney, Limbs. Dordrecht, Germany: Kluwer; 1993:291-315.
  10. Yamaguchi K, Sweet FA, Bindra R, et al. The extraosseous and intraosseous arterial anatomy of the adult elbow. *J Bone Joint Surg Am*. 1997;79:1653-1662.
  11. McCready RA. Upper-extremity vascular injuries. *Surg Clin North Am*. 1988;68:725-740.
  12. Ciervo A, Kahn M, Pangilinan AJ, et al. Absence of the brachial artery: report of a rare human variation and review of upper extremity arterial anomalies. *J Vasc Surg*. 2001;33:191-194.
  13. Gourley EJ, Gering SA. The meandering mesenteric artery: a historic review and surgical implications. *Dis Colon Rectum*. 2005;48:996-1000.
  14. Douard R, Chevallier JM, Delmas V, et al. Clinical interest of digestive arterial trunk anastomoses. *Surg Radiol Anat*. 2006;28:219-227.
  15. Muller RF, Figley MM. The arteries of the abdomen, pelvis, and thigh. I. Normal roentgenographic anatomy. II. Collateral circulation in obstructive arterial disease. *Am J Roentgenol Radium Ther Nucl Med*. 1957;77:296-311.
  16. Bron KM. Thrombotic occlusion of the abdominal aorta. Associated visceral artery lesions and collateral circulation. *Am J Roentgenol Radium Ther Nucl Med*. 1966;96:887-895.
  17. Yurdakul M, Tola M, Ozdemir E, et al. Internal thoracic artery–inferior epigastric artery as a collateral pathway in aortoiliac occlusive disease. *J Vasc Surg*. 2006;43:707-713.
  18. Takahashi S, Kaneda H, Saito S. Winslow's pathway in 64-slice multi-detector computed tomography. *Eur Heart J*. 2007;28:2437.
  19. Barral X, Salari GR, Toursarkissian B, et al. Bypass to the perigeniculate collateral vessels. A useful technique for limb salvage: preliminary report on 22 patients. *J Vasc Surg*. 1998;27:928-935.
  20. de Latour B, Nourissat G, Duprey A, et al. Bypass to the perigeniculate collateral arteries: mid-term results. *Eur J Vasc Endovasc Surg*. 2008;35:473-479.
  21. Shireman PK, Quinones MP. Differential necrosis despite similar perfusion in mouse strains after ischemia. *J Surg Res*. 2005;129:242-250.
  22. Mees B, Wagner S, Ninci E, et al. Endothelial nitric oxide synthase activity is essential for vasodilation during blood flow recovery but not for arteriogenesis. *Arterioscler Thromb Vasc Biol*. 2007;27:1926-1933.
  23. Scholz D, Ziegelhoeffer T, Helisch A, et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. *J Mol Cell Cardiol*. 2002;34:775-787.
  24. Ito WD, Arras M, Scholz D, et al. Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion. *Am J Physiol*. 1997;273:H1255-H1265.

25. Buschmann I, Schaper W. The pathophysiology of the collateral circulation (arteriogenesis). *J Pathol.* 2000;190:338-342.
26. Topper JN, Gimbrone Jr MA. Blood flow and vascular gene expression: fluid shear stress as a modulator of endothelial phenotype. *Mol Med Today.* 1999;5:40-46.
27. Deindl E. Arteriogenesis: A focus on signal transduction cascades and transcription factors. *Thromb Haemost.* 2007;98:940-943.
28. Nagel T, Resnick N, Atkinson WJ, et al. Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. *J Clin Invest.* 1994;94:885-891.
29. Chappell DC, Varner SE, Nerem RM, et al. Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium. *Circ Res.* 1998;82:532-539.
30. Eischen A, Vincent F, Bergerat JP, et al. Long term cultures of human monocytes in vitro. Impact of GM-CSF on survival and differentiation. *J Immunol Methods.* 1991;143:209-221.
31. Schaper W, Buschmann I. Collateral circulation and diabetes. *Circulation.* 1999;99:2224-2226.
32. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O<sub>2</sub> tension. *Proc Natl Acad Sci U S A.* 1995;92:5510-5514.
33. Semenza G. Signal transduction to hypoxia-inducible factor 1. *Biochem Pharmacol.* 2002;64:993-998.
34. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: Role of the HIF system. *Nat Med.* 2003;9:677-684.
35. Milkiewicz M, Ispanovic E, Doyle JL, et al. Regulators of angiogenesis and strategies for their therapeutic manipulation. *Int J Biochem Cell Biol.* 2006;38:333-357.
36. Tammela T, Enholm B, Alitalo K, et al. The biology of vascular endothelial growth factors. *Cardiovasc Res.* 2005;65:550-563.
37. Deindl E, Buschmann I, Hoefer IE, et al. Role of ischemia and of hypoxia-inducible genes in arteriogenesis after femoral artery occlusion in the rabbit. *Circ Res.* 2001;89:779-786.
38. Lee CW, Stabile E, Kinnaird T, et al. Temporal patterns of gene expression after acute hindlimb ischemia in mice: insights into the genomic program for collateral vessel development. *J Am Coll Cardiol.* 2004;43:474-482.
39. Hanze J, Weissmann N, Grimminger F, et al. Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. *Thromb Haemost.* 2007;97:774-787.
40. Semenza GL. Regulation of tissue perfusion in mammals by hypoxia-inducible factor 1. *Exp Physiol.* 2007;92:988-991.
41. Sarateanu CS, Retuerto MA, Beckmann JT, et al. An Egr-1 master switch for arteriogenesis: studies in Egr-1 homozygous negative and wild-type animals. *J Thorac Cardiovasc Surg.* 2006;131:138-145.
42. Yan SF, Fujita T, Lu J, et al. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. *Nat Med.* 2000;6:1355-1361.
43. Khachigian LM, Collins T. Inducible expression of Egr-1-dependent genes. A paradigm of transcriptional activation in vascular endothelium. *Circ Res.* 1997;81:457-461.
44. Silverman ES, Collins T. Pathways of Egr-1-mediated gene transcription in vascular biology. *Am J Pathol.* 1999;154:665-670.
45. Lee YS, Jang HS, Kim JM, et al. Adenoviral-mediated delivery of early growth response factor-1 gene increases tissue perfusion in a murine model of hindlimb ischemia. *Mol Ther.* 2005;12:328-336.
46. Zachary I. VEGF signalling: Integration and multi-tasking in endothelial cell biology. *Biochem Soc Trans.* 2003;31:1171-1177.
47. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. *Endocr Rev.* 2004;25:581-611.
48. Tchaikovski V, Fellbrich G, Waltenberger J. The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. *Arterioscler Thromb Vasc Biol.* 2008;28:322-328.
49. Bauters C, Asahara T, Zheng LP, et al. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. *J Vasc Surg.* 1995;21:314-324, discussion 324-315.



50. Bauters C, Asahara T, Zheng LP, et al. Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. *Am J Physiol.* 1994;267:H1263-H1271.
51. Baffour R, Berman J, Garb JL, et al. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. *J Vasc Surg.* 1992;16:181-191.
52. Takeshita S, Pu LQ, Stein LA, et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. *Circulation.* 1994;90:II228-II234.
53. Unger EF, Banai S, Shou M, et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. *Am J Physiol.* 1994;266:H1588-H1595.
54. Galzie Z, Kinsella AR, Smith JA. Fibroblast growth factors and their receptors. *Biochem Cell Biol.* 1997;75:669-685.
55. Arras M, Ito WD, Scholz D, et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. *J Clin Invest.* 1998;101:40-50.
56. Deindl E, Hoefer IE, Fernandez B, et al. Involvement of the fibroblast growth factor system in adaptive and chemokine-induced arteriogenesis. *Circ Res.* 2003;92:561-568.
57. Werner GS, Jandt E, Krack A, et al. Growth factors in the collateral circulation of chronic total coronary occlusions: relation to duration of occlusion and collateral function. *Circulation.* 2004;110:1940-1945.
58. Vogel S, Kubin T, von der Ahe D, et al. MEK hyperphosphorylation coincides with cell cycle shut down of cultured smooth muscle cells. *J Cell Physiol.* 2006;206:25-34.
59. Yang HT, Deschenes MR, Ogilvie RW, et al. Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. *Circ Res.* 1996;79:62-69.
60. Allen LA, Terjung RL, Yang HT. Exogenous basic fibroblast growth factor increases collateral blood flow in female rats with femoral artery occlusion. *J Cardiovasc Pharmacol.* 2006;47:146-154.
61. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. *Nat Med.* 2003;9:604-613.
62. Yang HT, Feng Y. bFGF increases collateral blood flow in aged rats with femoral artery ligation. *Am J Physiol Heart Circ Physiol.* 2000;278:H85-H93.
63. Lutgens E, Gijbels M, Smook M, et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. *Arterioscler Thromb Vasc Biol.* 2002;22:975-982.
64. Boengler K, Pipp F, Fernandez B, et al. Arteriogenesis is associated with an induction of the cardiac ankyrin repeat protein (carp). *Cardiovasc Res.* 2003;59:573-581.
65. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. *EMBO J.* 2002;21:1743-1753.
66. van Royen N, Hoefer I, Buschmann I, et al. Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. *FASEB J.* 2002;16:432-434.
67. Hoefer IE, van Royen N, Reichenwald JE, et al. Direct evidence for tumor necrosis factor-alpha signaling in arteriogenesis. *Circulation.* 2002;105:1639-1641.
68. Luo D, Luo Y, He Y, et al. Differential functions of tumor necrosis factor receptor 1 and 2 signaling in ischemia-mediated arteriogenesis and angiogenesis. *Am J Pathol.* 2006;169:1886-1898.
69. Kaminski A, Ma N, Donndorf P, et al. Endothelial NOS is required for SDF-1alpha/CXCR4-mediated peripheral endothelial adhesion of c-kit<sup>+</sup> bone marrow stem cells. *Lab Invest.* 2008;88:58-69.
70. Buschmann IR, Hoefer IE, van Royen N, et al. GM-CSF: A strong arteriogenic factor acting by amplification of monocyte function. *Atherosclerosis.* 2001;159:343-356.
71. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial

- progenitor cells for neovascularization. *Nat Med*. 1999;5:434-438.
72. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. *N Engl J Med*. 2006;354:610-621.
  73. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. *Circ Res*. 2004;95:858-866.
  74. Bernardini G, Ribatti D, Spinetti G, et al. Analysis of the role of chemokines in angiogenesis. *J Immunol Methods*. 2003;273:83-101.
  75. Rosenkilde MM, Schwartz TW. The chemokine system—a major regulator of angiogenesis in health and disease. *APMIS*. 2004;112:481-495.
  76. Shireman PK. The chemokine system in arteriogenesis and hind limb ischemia. *J Vasc Surg*. 2007;45:48A-56A.
  77. Heil M, Schaper W. Arteriogenic growth factors, chemokines and proteases as a prerequisite for arteriogenesis. *Drug News Perspect*. 2005;18:317-322.
  78. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. *Pharmacol Rev*. 2000;52:145-176.
  79. Ito WD, Arras M, Winkler B, et al. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. *Circ Res*. 1997;80:829-837.
  80. Hoefer IE, van Royen N, Rectenwald JE, et al. Arteriogenesis proceeds via ICAM-1/Mac-1– mediated mechanisms. *Circ Res*. 2004;94:1179-1185.
  81. Scholz D, Ito W, Fleming I, et al. Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis). *Virchows Arch*. 2000;436:257-270.
  82. Waeckel L, Mallat Z, Potteaux S, et al. Impairment in postischemic neovascularization in mice lacking the CXC chemokine receptor 3. *Circ Res*. 2005;96:576-582.
  83. Voskuil M, Hoefer IE, van Royen N, et al. Abnormal monocyte recruitment and collateral artery formation in monocyte chemoattractant protein-1 deficient mice. *Vasc Med*. 2004;9:287-292.
  84. Shireman PK, Contreras-Shannon V, Ochoa O, et al. MCP-1 deficiency causes altered inflammation with impaired skeletal muscle regeneration. *J Leukoc Biol*. 2007;81:775-785.
  85. Heil M, Ziegelhoeffer T, Wagner S, et al. Collateral artery growth (arteriogenesis) after experimental arterial occlusion is impaired in mice lacking CC-chemokine receptor-2. *Circ Res*. 2004;94:671-677.
  86. Contreras-Shannon V, Ochoa O, Reyes-Reyna SM, et al. Fat accumulation with altered inflammation and regeneration in skeletal muscle of CCR2<sup>-/-</sup> mice following ischemic injury. *Am J Physiol Cell Physiol*. 2007;292:C953-C967.
  87. Tang G, Charo DN, Wang R, et al. CCR2<sup>-/-</sup> knockout mice revascularize normally in response to severe hindlimb ischemia. *J Vasc Surg*. 2004;40:786-795.
  88. Schechter AD, Berman AB, Yi L, et al. MCP-1–dependent signaling in CCR2<sup>(-/-)</sup> aortic smooth muscle cells. *J Leukoc Biol*. 2004;75:1079-1085.
  89. Contreras-Shannon V, Ochoa O, Reyes-Reyna SM, et al. Fat accumulation with altered inflammation and regeneration in skeletal muscle of CCR2<sup>-/-</sup> mice following ischemic injury. *Am J Physiol Cell Physiol*. 2007;292:C953-C967.
  90. Garcia-Cardena G, Comander J, Anderson KR, et al. Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. *Proc Natl Acad Sci U S A*. 2001;98:4478-4485.
  91. Gimbrone MA Jr, Nagel T, Topper JN. Biomechanical activation: An emerging paradigm in endothelial adhesion biology. *J Clin Invest*. 1997;99:1809-1813.
  92. Pipp F, Boehm S, Cai WJ, et al. Elevated fluid shear stress enhances postocclusive collateral artery growth and gene expression in the pig hind limb. *Arterioscler Thromb Vasc Biol*. 2004;24:1664-1668.
  93. Tzima E, Irani-Tehrani M, Kiosses WB, et al. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. *Nature*. 2005;437:426-431.
  94. Resnick N, Yahav H, Shay-Salit A, et al. Fluid shear stress and the vascular endothelium: For better and for worse. *Prog*

*Biophys Mol Biol.* 2003;81:177-199.

95. Pipp F, Heil M, Issbrucker K, et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: Evidence for a monocyte-mediated mechanism. *Circ Res.* 2003;92:378-385.
96. Davies PF, Barbee KA, Volin MV, et al. Spatial relationships in early signaling events of flow-mediated endothelial mechanotransduction. *Annu Rev Physiol.* 1997;59:527-549.
97. Massova I, Kotra LP, Fridman R, et al. Matrix metalloproteinases: Structures, evolution, and diversification. *FASEB J.* 1998;12:1075-1095.
98. Menshikov M, Elizarova E, Plakida K, et al. Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis. *Biochem J.* 2002;367:833-839.
99. Hobeika MJ, Edlin RS, Muhs BE, et al. Matrix metalloproteinases in critical limb ischemia. *J Surg Res.* 2008;149:148-154.
100. van Royen N, Hoefer I, Bottinger M, et al. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. *Circ Res.* 2003;92:218-225.
101. van Royen N, Hoefer I, Buschmann I, et al. Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits. *Cardiovasc Res.* 2003;57:178-185.
102. Anghelina M, Krishnan P, Moldovan L, et al. Monocytes/macrophages cooperate with progenitor cells during neovascularization and tissue repair: conversion of cell columns into fibrovascular bundles. *Am J Pathol.* 2006;168:529-541.
103. Anghelina M, Krishnan P, Moldovan L, et al. Monocytes and macrophages form branched cell columns in matrigel: Implications for a role in neovascularization. *Stem Cells Dev.* 2004;13:665-676.
104. Cai W, Vosschulte R, Afsah-Hedjri A, et al. Altered balance between extracellular proteolysis and antiproteolysis is associated with adaptive coronary arteriogenesis. *J Mol Cell Cardiol.* 2000;32:997-1011.
105. Cai WJ, Kocsis E, Wu X, et al. Remodeling of the vascular tunica media is essential for development of collateral vessels in the canine heart. *Mol Cell Biochem.* 2004;264:201-210.
106. Mochizuki S, Brassart B, Hinek A. Signaling pathways transduced through the elastin receptor facilitate proliferation of arterial smooth muscle cells. *J Biol Chem.* 2002;277:44854-44863.
107. Helisch A, Schaper W. Arteriogenesis: The development and growth of collateral arteries. *Microcirculation.* 2003;10:83-97.
108. Deindl E, Schaper W. The art of arteriogenesis. *Cell Biochem Biophys.* 2005;43:1-16.
109. Silvestre JS, Mallat Z, Tedgui A, et al. Post-ischaemic neovascularization and inflammation. *Cardiovasc Res.* 2008;78:242-249.
110. Hoefer IE, Grundmann S, van Royen N, et al. Leukocyte subpopulations and arteriogenesis: specific role of monocytes, lymphocytes and granulocytes. *Atherosclerosis.* 2005;181:285-293.
111. Sunderkotter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. *J Leukoc Biol.* 1994;55:410-422.
112. Schaper J, Konig R, Franz D, et al. The endothelial surface of growing coronary collateral arteries. Intimal margination and diapedesis of monocytes. A combined SEM and TEM study. *Virchows Arch A Pathol Anat Histol.* 1976;370:193-205.
113. Luster AD. Chemokines—chemotactic cytokines that mediate inflammation. *N Engl J Med.* 1998;338:436-445.
114. Kim CH. Chemokine-chemokine receptor network in immune cell trafficking. *Curr Drug Targets Immune Endocr Metabol Disord.* 2004;4:343-361.
115. Bergmann CE, Hoefer IE, Meder B, et al. Arteriogenesis depends on circulating monocytes and macrophage accumulation and is severely depressed in op/op mice. *J Leukoc Biol.* 2006;80:59-65.
116. Heil M, Ziegelhoeffer T, Pipp F, et al. Blood monocyte concentration is critical for enhancement of collateral artery growth. *Am J Physiol Heart Circ Physiol.* 2002;283:H2411-H2419.
117. Couffignal T, Silver M, Kearney M, et al. Impaired collateral vessel development associated with reduced expression of

- vascular endothelial growth factor in ApoE<sup>-/-</sup> mice. *Circulation*. 1999;99:3188-3198.
118. Iwaguro H, Yamaguchi J, Kalka C, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. *Circulation*. 2002;105:732-738.
  119. Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovascularogenesis. *Arterioscler Thromb Vasc Biol*. 2004;24:288-293.
  120. Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. *Circulation*. 2003;107:1322-1328.
  121. Murasawa S, Llevadot J, Silver M, et al. Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. *Circulation*. 2002;106:1133-1139.
  122. Kalka C, Masuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc Natl Acad Sci U S A*. 2000;97:3422-3427.
  123. Masaki I, Yonemitsu Y, Yamashita A, et al. Angiogenic gene therapy for experimental critical limb ischemia: Acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. *Circ Res*. 2002;90:966-973.
  124. Schatteman GC, Hanlon HD, Jiao C, et al. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. *J Clin Invest*. 2000;106:571-578.
  125. Harraz M, Jiao C, Hanlon HD, et al. CD34<sup>+</sup> blood-derived human endothelial cell progenitors. *Stem Cells*. 2001;19:304-312.
  126. Urbich C, Heeschen C, Aicher A, et al. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. *Circulation*. 2003;108:2511-2516.
  127. Stabile E, Burnett MS, Watkins C, et al. Impaired arteriogenic response to acute hindlimb ischemia in CD4<sup>-</sup> knockout mice. *Circulation*. 2003;108:205-210.
  128. Stabile E, Kinnaird T, la Sala A, et al. CD8<sup>+</sup> T lymphocytes regulate the arteriogenic response to ischemia by infiltrating the site of collateral vessel development and recruiting CD4<sup>+</sup> mononuclear cells through the expression of interleukin-16. *Circulation*. 2006;113:118-124.
  129. van Weel V, Toes RE, Seghers L, et al. Natural killer cells and CD4<sup>+</sup> T-cells modulate collateral artery development. *Arterioscler Thromb Vasc Biol*. 2007;27:2310-2318.
  130. Sayed BA, Christy A, Quirion MR, et al. The master switch: the role of mast cells in autoimmunity and tolerance. *Annu Rev Immunol*. 2008;26:705-739.
  131. Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological properties and role in health and disease. *Clin Exp Allergy*. 2008;38:709-750.
  132. Wolf C, Cai WJ, Vosschulte R, et al. Vascular remodeling and altered protein expression during growth of coronary collateral arteries. *J Mol Cell Cardiol*. 1998;30:2291-2305.
  133. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. *Nat Med*. 2003;9:1370-1376.
  134. Shintani S, Murohara T, Ikeda H, et al. Augmentation of postnatal neovascularization with autologous bone marrow transplantation. *Circulation*. 2001;103:897-903.
  135. Alobaid N, Alnaeb ME, Sales KM, et al. Endothelial progenitor cells and their potential clinical applications in peripheral arterial disease. *Endothelium*. 2005;12:243-250.
  136. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. *Arterioscler Thromb Vasc Biol*. 2003;23:1185-1189.
  137. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res*. 1999;85:221-228.
  138. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. *Science*.

1997;275:964-967.

139. Kopp HG, Ramos CA, Rafii S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. *Curr Opin Hematol.* 2006;13:175-181.
140. Caplice NM, Doyle B. Vascular progenitor cells: Origin and mechanisms of mobilization, differentiation, integration, and vasculogenesis. *Stem Cells Dev.* 2005;14:122-139.
141. Sata M. Role of circulating vascular progenitors in angiogenesis, vascular healing, and pulmonary hypertension: lessons from animal models. *Arterioscler Thromb Vasc Biol.* 2006;26:1008-1014.
142. Miller-Kasprzak E, Jagodzinski PP. Endothelial progenitor cells as a new agent contributing to vascular repair. *Arch Immunol Ther Exp (Warsz).* 2007;55:247-259.
143. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. *Circulation.* 2001;103:2776-2779.
144. Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. *Circ Res.* 2001;88:167-174.
145. Urbich C, Aicher A, Heeschen C, et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. *J Mol Cell Cardiol.* 2005;39:733-742.
146. Jin DK, Shido K, Kopp HG, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4<sup>+</sup> hemangiocytes. *Nat Med.* 2006;12:557-567.
147. Ziegelhoeffer T, Fernandez B, Kostin S, et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. *Circ Res.* 2004;94:230-238.
148. O'Neill TJ, Wamhoff BR, Owens GK, et al. Mobilization of bone marrow-derived cells enhances the angiogenic response to hypoxia without transdifferentiation into endothelial cells. *Circ Res.* 2005;97:1027-1035.
149. Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. *Circ Res.* 2004;94:678-685.
150. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. *Nat Med.* 2000;6:389-395.
151. Selzman CH, Miller SA, Zimmerman MA, et al. Monocyte chemoattractant protein-1 directly induces human vascular smooth muscle proliferation. *Am J Physiol Heart Circ Physiol.* 2002;283:H1455-H1461.
152. Streblov DN, Soderberg-Naucler C, Vieira J, et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. *Cell.* 1999;99:511-520.
153. Hayes IM, Jordan NJ, Towers S, et al. Human vascular smooth muscle cells express receptors for CC chemokines. *Arterioscler Thromb Vasc Biol.* 1998;18:397-403.
154. Schecter AD, Rollins BJ, Zhang YJ, et al. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. *J Biol Chem.* 1997;272:28568-28573.
155. Kinnaird T, Stabile E, Zbinden S, et al. Cardiovascular risk factors impair native collateral development and may impair efficacy of therapeutic interventions. *Cardiovasc Res.* 2008;78:257-264.
156. Semenza GL. Vasculogenesis, angiogenesis, and arteriogenesis: Mechanisms of blood vessel formation and remodeling. *J Cell Biochem.* 2007;102:840-847.
157. Hessler JR, Robertson AL Jr, Chisolm GM 3rd. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. *Atherosclerosis.* 1979;32:213-229.
158. Reed MJ, Edelberg JM. Impaired angiogenesis in the aged. *Sci Aging Knowledge Environ.* 2004;2004:pe7.
159. Sadoun E, Reed MJ. Impaired angiogenesis in aging is associated with alterations in vessel density, matrix composition, inflammatory response, and growth factor expression. *J Histochem Cytochem.* 2003;51:1119-1130.
160. Rivard A, Silver M, Chen D, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. *Am J Pathol.* 1999;154:355-363.

161. Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-A–induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals. *Circulation*. 2000;102:185-190.
162. Czepluch FS, Bergler A, Waltenberger J. Hypercholesterolaemia impairs monocyte function in CAD patients. *J Intern Med*. 2007;261:201-204.
163. Rivard A, Fabre JE, Silver M, et al. Age-dependent impairment of angiogenesis. *Circulation*. 1999;99:111-120.
164. Ebskov B, Josephsen P. Incidence of reamputation and death after gangrene of the lower extremity. *Prosthet Orthot Int*. 1980;4:77-80.
165. Abaci A, Oguzhan A, Kahraman S, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. *Circulation*. 1999;99:2239-2242.
166. Zbinden R, Zbinden S, Billinger M, et al. Influence of diabetes mellitus on coronary collateral flow: an answer to an old controversy. *Heart*. 2005;91:1289-1293.
167. Kyriakides ZS, Psychari S, Chrysomallis N, et al. Type II diabetes does not prevent the recruitment of collateral vessels and the normal reduction of myocardial ischaemia on repeated balloon inflations during angioplasty. *Heart*. 2002;87:61-66.
168. Abbott RD, Donahue RP, Kannel WB, et al. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. *JAMA*. 1988;260:3456-3460.
169. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med*. 2003;348:593-600.
170. American Diabetes Association. Peripheral arterial disease in people with diabetes. *Diabetes Care*. 2003;26:3333-3341.
171. Bucay M, Nguy J, Barrios R, et al. Impaired adaptive vascular growth in hypercholesterolemic rabbit. *Atherosclerosis*. 1998;139:243-251.
172. Tirziu D, Moodie KL, Zhuang ZW, et al. Delayed arteriogenesis in hypercholesterolemic mice. *Circulation*. 2005;112:2501-2509.
173. Resar JR, Roguin A, Voner J, et al. Hypoxia-inducible factor 1 $\alpha$  polymorphism and coronary collaterals in patients with ischemic heart disease. *Chest*. 2005;128:787-791.
174. Epstein SE, Fuchs S, Zhou YF, et al. Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards. *Cardiovasc Res*. 2001;49:532-542.
175. Grundmann S, van Royen N, Pasterkamp G, et al. A new intra-arterial delivery platform for pro-arteriogenic compounds to stimulate collateral artery growth via transforming growth factor- $\beta$ 1 release. *J Am Coll Cardiol*. 2007;50:351-358.
176. Makinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. *Mol Ther*. 2002;6:127-133.
177. Rajagopalan S, Mohler ER 3rd, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. *Circulation*. 2003;108:1933-1938.
178. Rajagopalan S, Olin J, Deitcher S, et al. Use of a constitutively active hypoxia-inducible factor-1 $\alpha$  transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. *Circulation*. 2007;115:1234-1243.
179. Lazarous DF, Unger EF, Epstein SE, et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. *J Am Coll Cardiol*. 2000;36:1239-1244.
180. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. *Lancet*. 2002;359:2053-2058.
181. van Royen N, Schirmer SH, Atasever B, et al. START Trial: A pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular

- disease. *Circulation*. 2005;112:1040-1046.
182. Van Tongeren RB, Hamming JF, Fibbe WE, et al. Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. *J Cardiovasc Surg (Torino)*. 2008;49:51-58.
  183. Miura S, Saku K: Regulation of angiogenesis and angiogenic factors by cardiovascular medications. *Curr Pharm Des*. 2007;13:2113-2117.
  184. Pourati I, Kimmelstiel C, Rand W, et al. Statin use is associated with enhanced collateralization of severely diseased coronary arteries. *Am Heart J*. 2003;146:876-881.
  185. Zbinden S, Brunner N, Wustmann K, et al. Effect of statin treatment on coronary collateral flow in patients with coronary artery disease. *Heart*. 2004;90:448-449.
  186. Hoefer IE, Grundmann S, Schirmer S, et al. Aspirin, but not clopidogrel, reduces collateral conductance in a rabbit model of femoral artery occlusion. *J Am Coll Cardiol*. 2005;46:994-1001.
  187. Emanuelli C, Salis MB, Stacca T, et al. Angiotensin AT(1) receptor signalling modulates reparative angiogenesis induced by limb ischaemia. *Br J Pharmacol*. 2002;135:87-92.
  188. Fabre JE, Rivard A, Magner M, et al. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. *Circulation*. 1999;99:3043-3049.
  189. Lee TM, Su SF, Tsai CH, Lee et al. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. *Clin Sci (Lond)*. 2001;101:305-311.
  190. Hashimoto A, Miyakoda G, Hirose Y, et al. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. *Atherosclerosis*. 2006;189:350-357.
  191. Gude RP, Binda MM, Boquete AL, Bonfil RD. Inhibition of endothelial cell proliferation and tumor-induced angiogenesis by pentoxifylline. *J Cancer Res Clin Oncol*. 2001;127:625-630.
  192. Amirkhosravi A, Meyer T, Warnes G, et al. Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor. *Thromb Haemost*. 1998;80:598-602.

## 第 8 章

1. Tilson MD. Aortic aneurysms and atherosclerosis. *Circulation*. 1992;85:378.
2. Brady AR, Thompson SG, Fowkes FGR, et al. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. *Circulation*. 2004;110:16.
3. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. *Arterioscler Thromb Vasc Biol*. 2006;26:987.
4. Wolinsky H, Glagov S. Nature of species differences in the medial distribution of aortic vasa vasorum in mammals. *Circ Res*. 1967;20:409.
5. Choke E, Thompson MM, Dawson J, et al. Abdominal aortic aneurysm rupture is associated with increased medial neovascularization and overexpression of proangiogenic cytokines. *Arterioscler Thromb Vasc Biol*. 2006;26:2077.
6. Lederle FA. A summary of the contributions of the VA cooperative studies on abdominal aortic aneurysms. *Ann N Y Acad Sci*. 2006;1085:29.
7. Iribarren C, Darbinian JA, Go AS, et al. Traditional and novel risk factors for clinically diagnosed abdominal aortic aneurysm: the Kaiser Multiphasic Health Checkup Cohort Study. *Ann Epidemiol*. 2007;17:669.
8. Jamrozik K, Norman PE, Spencer CA, et al. Screening for abdominal aortic aneurysm: lessons from a population-based study. *Med J Aust*. 2000;173:345.
9. Goessens BMB, Visseren FLJ, Algra A, et al. Screening for asymptomatic cardiovascular disease with noninvasive imaging in patients at high-risk and low-risk according to the European Guidelines on Cardiovascular Disease Prevention: the

- SMART study. *J Vasc Surg.* 2006;43:525.
10. Mofidi R, Goldie VJ, Kelman J, et al. Influence of sex on expansion rate of abdominal aortic aneurysms. *Br J Surg.* 2007;94:310.
  11. Lederle FA, Johnson GR, Wilson SE, et al. Relationship of age, gender, race, and body size to infrarenal aortic diameter. The Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Investigators. *J Vasc Surg.* 1997;26:595.
  12. Lederle FA, Johnson GR, Wilson SE, et al. Yield of repeated screening for abdominal aortic aneurysm after a 4-year interval. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. *Arch Intern Med.* 2000;160:1117.
  13. Singh K, Børnaa KH, Jacobsen BK, et al. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: the Tromsø Study. *Am J Epidemiol.* 2001;154:236.
  14. Blanchard JF, Armenian HK, Friesen PP. Risk factors for abdominal aortic aneurysm: results of a case-control study. *Am J Epidemiol.* 2000;151:575.
  15. Lederle FA, Nelson DB, Joseph AM. Smokers' relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. *J Vasc Surg.* 2003;38:329.
  16. Golledge J, Clancy P, Jamrozik K, Norman PE. Obesity, adipokines, and abdominal aortic aneurysm: Health in Men study. *Circulation.* 2007;116:2275.
  17. Norman PE, Davis TME, Le MTQ, Golledge J. Matrix biology of abdominal aortic aneurysms in diabetes: mechanisms underlying the negative association. *Connect Tissue Res.* 2007;48:125.
  18. Golledge J, Karan M, Moran CS, et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. *Eur Heart J.* 2008;29:665.
  19. Le MTQ, Jamrozik K, Davis TME, Norman PE. Negative association between infra-renal aortic diameter and glycaemia: the Health in Men Study. *Eur J Vasc Endovasc Surg.* 2007;33:599.
  20. Moroz P, Le MTQ, Norman PE. Homocysteine and abdominal aortic aneurysms. *Aust N Z J Surg.* 2007;77:329.
  21. Helgadottir A, Thorleifsson G, Magnusson KP, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. *Nat Genet.* 2008;40:217.
  22. Ogata T, Shibamura H, Tromp G, et al. Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms. *J Vasc Surg.* 2005;41:1036.
  23. Isselbacher EM. Thoracic and abdominal aortic aneurysms. *Circulation.* 2005;111:816.
  24. Verloes A, Sakalihasan N, Koulischer L, Limet R. Aneurysms of the abdominal aorta: familial and genetic aspects in three hundred thirteen pedigrees. *J Vasc Surg.* 1995;21:646.
  25. Kuivaniemi H, Platsoucas CD, Tilson MD. Aortic aneurysms: an immune disease with a strong genetic component. *Circulation.* 2008;117:242.
  26. Absi TS, Sundt TM, Tung WS, et al. Altered patterns of gene expression distinguishing ascending aortic aneurysms from abdominal aortic aneurysms: complementary DNA expression profiling in the molecular characterization of aortic disease. *J Thorac Cardiovasc Surg.* 2003;126:344.
  27. Powell JT, Bashir A, Dawson S, et al. Genetic variation on chromosome 16 is associated with abdominal aortic aneurysm. *Clin Sci.* 1990;78:13.
  28. Ruigrok YM, Elias R, Wijmenga C, Rinkel GJJE. A comparison of genetic chromosomal loci for intracranial, thoracic aortic, and abdominal aortic aneurysms in search of common genetic risk factors. *Cardiovasc Pathol.* 2008;17:40.
  29. Hirose H, Takagi M, Miyagawa N, et al. Genetic risk factor for abdominal aortic aneurysm: HLA-DR2(15), a Japanese study. *J Vasc Surg.* 1998;27:500.
  30. Rasmussen TE, Hallett JW, Metzger RL, et al. Genetic risk factors in inflammatory abdominal aortic aneurysms: polymorphic residue 70 in the HLA-DR B1 gene as a key genetic element. *J Vasc Surg.* 1997;25:356.
  31. Gerdes LU, Lindholt JS, Vammen S, et al. Apolipoprotein E genotype is associated with differential expansion rates of small



- abdominal aortic aneurysms. *Br J Surg*. 2000;87:760.
32. Fatini C, Pratesi G, Sofi F, et al. ACE DD genotype: a predisposing factor for abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg*. 2005;29:227.
  33. Pola R, Gaetani E, Santoliquido A, et al. Abdominal aortic aneurysm in normotensive patients: association with angiotensin-converting enzyme gene polymorphism. *Eur J Vasc Endovasc Surg*. 2001;21:445.
  34. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. *Lancet*. 2006;368:659.
  35. Jones GT, Phillips VL, Harris EL, et al. Functional matrix metalloproteinase-9 polymorphism (C-1562T) associated with abdominal aortic aneurysm. *J Vasc Surg*. 2003;38:1363.
  36. Rossaak JI, Van Rij AM, Jones GT, Harris EL. Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms. *J Vasc Surg*. 2000;31:1026.
  37. Jones K, Powell J, Brown L, et al. The influence of 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene promoter on the incidence, growth and operative risk of abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg*. 2002;23:421.
  38. Sandford RM, Bown MJ, London NJ, Sayers RD. The genetic basis of abdominal aortic aneurysms: a review. *Eur J Vasc Endovasc Surg*. 2007;33:381.
  39. Ghilardi G, Biondi ML, Battaglioli L, et al. Genetic risk factor characterizes abdominal aortic aneurysm from arterial occlusive disease in human beings: CCR5 Delta 32 deletion. *J Vasc Surg*. 2004;40:995.
  40. Fatini C, Sofi F, Sticchi E, et al. eNOS G894T polymorphism as a mild predisposing factor for abdominal aortic aneurysm. *J Vasc Surg*. 2005;42:415.
  41. Schillinger M, Exner M, Mlekusch W, et al. Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. *Thromb Res*. 2002;106:131.
  42. Thompson AR, Drenos F, Hafez H, Humphries SE. Candidate gene association studies in abdominal aortic aneurysm disease: a review and meta-analysis. *Eur J Vasc Endovasc Surg*. 2008;35:19.
  43. Robinson PN, Arteaga-Solis E, Baldock C, et al. The molecular genetics of Marfan syndrome and related disorders. *J Med Genet*. 2006;43:769.
  44. Müller J, Sahni O, Li X, et al. Anisotropic adaptive finite element method for modeling blood flow. *Comput Methods Biomech Biomed Engin*. 2005;8:295.
  45. Gimbrone MA Jr, Topper JN, Nagel T, et al. Endothelial dysfunction, hemodynamic forces, and atherogenesis. *Ann N Y Acad Sci*. 2000;902:230.
  46. Ailawadi G, Knipp BS, Lu G, et al. A nonintrinsic regional basis for increased infrarenal aortic MMP-9 expression and activity. *J Vasc Surg*. 2003;37:1059.
  47. Hoshina K, Sho E, Sho M, et al. Wall shear stress and strain modulate experimental aneurysm cellularity. *J Vasc Surg*. 2003;37:1067.
  48. Greve JM, Les AS, Tang BT, et al. Allometric scaling of wall shear stress from mice to humans: quantification using cine phase-contrast MRI and computational fluid dynamics. *Am J Physiol Heart Circ Physiol*. 2006;291:H1700.
  49. Vollmar JF, Paes E, Pauschinger P, et al. Aortic aneurysms as late sequelae of above-knee amputation. *Lancet*. 1989;2:834.
  50. Yeung JJ, Kim HJ, Abbruzzese TA, et al. Aortoiliac hemodynamic and morphologic adaptation to chronic spinal cord injury. *J Vasc Surg*. 2006;44:1254.
  51. Dalman RL, Tedesco MM, Myers J, Taylor CA. AAA disease: mechanism, stratification, and treatment. *Ann N Y Acad Sci*. 2006;1085:92.
  52. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. *Arterioscler Thromb Vasc Biol*. 2004;24:429.
  53. Saraff K, Babamusta F, Cassis LA, Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol*. 2003;23:1621.

54. Petrincec D, Liao S, Holmes DR, et al. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. *J Vasc Surg.* 1996;23:336.
55. McMillan WD, Tamarina NA, Cipollone M, et al. Size matters: the relationship between MMP-9 expression and aortic diameter. *Circulation.* 1997;96:2228.
56. Lorelli DR, Jean-Claude JM, Fox CJ, et al. Response of plasma matrix metalloproteinase-9 to conventional abdominal aortic aneurysm repair or endovascular exclusion: implications for endoleak. *J Vasc Surg.* 2002;35:916.
57. Irizarry E, Newman KM, Gandhi RH, et al. Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. *J Surg Res.* 1993;54:571-574.
58. Annabi B, Shérid D, Ghosn P, et al. Differential regulation of matrix metalloproteinase activities in abdominal aortic aneurysms. *J Vasc Surg.* 2002;35:539-546.
59. Davis V, Persidskaia R, Baca-Regen L, et al. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. *Arterioscler Thromb Vasc Biol.* 1998;18:1625-1633.
60. Carrell TWG, Burnand KG, Wells GMA, et al. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. *Circulation.* 2002;105:477-482.
61. Sangiorgi G, D'Averio R, Mauriello A, et al. Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. *Circulation.* 2001;104(12 Suppl 1):I288-I295.
62. Wilson WRW, Anderton M, Schwalbe EC, et al. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. *Circulation.* 2006;113:438-445.
63. McMillan WD, Pearce WH. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. *J Vasc Surg.* 1999;29:122-127; discussion 127.
64. McMillan WD, Patterson BK, Keen RR, et al. In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta. *Arterioscler Thromb Vasc Biol.* 1995;15:1139-1144.
65. Watanabe T, Sato A, Sawai T, et al. The elevated level of circulating matrix metalloproteinase-9 in patients with abdominal aortic aneurysms decreased to levels equal to those of healthy controls after an aortic repair. *Ann Vasc Surg.* 2006;20:317-321.
66. Curci JA, Liao S, Huffman MD, et al. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. *J Clin Invest.* 1998;102:1900-1910.
67. Tromp G, Gatalica Z, Skunca M, et al. Elevated expression of matrix metalloproteinase-13 in abdominal aortic aneurysms. *Ann Vasc Surg.* 2004;18:414-420.
68. Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. *J Clin Invest.* 2002;110:625.
69. Lindholt JS, Shi GP. Chronic inflammation, immune response, and infection in abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg.* 2006;31:453.
70. Miller FJ Jr, Sharp WJ, Fang X, et al. Oxidative stress in human abdominal aortic aneurysms: a potential mediator of aneurysmal remodeling. *Arterioscler Thromb Vasc Biol.* 2002;22:560.
71. Schönbeck U, Sukhova GK, Gerdes N, Libby P. T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm. *Am J Pathol.* 2002;161:499.
72. Xiong W, Zhao Y, Prall A, et al. Key roles of CD4<sup>+</sup> T cells and IFN-gamma in the development of abdominal aortic aneurysms in a murine model. *J Immunol.* 2004;172:2607.
73. Middleton RK, Lloyd GM, Bown MJ, et al. The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. *J Vasc Surg.* 2007;45:574.
74. Armstrong PJ, Franklin DP, Carey DJ, Elmore JR. Suppression of experimental aortic aneurysms: comparison of inducible

- nitric oxide synthase and cyclooxygenase inhibitors. *Ann Vasc Surg*. 2005;19:248.
75. Yoshimura K, Aoki H, Ikeda Y, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. *Nat Med*. 2005;11:1330.
  76. Köbel T, Strandberg K, Donath T, et al. Activated protein C–protein C inhibitor complex in patients with abdominal aortic aneurysms: is it associated with diameter and growth rate? *Vasc Endovasc Surg*. 2008;42:135.
  77. Golledge J, Muller J, Shephard N, et al. Association between osteopontin and human abdominal aortic aneurysm. *Arterioscler Thromb Vasc Biol*. 2007;27:655.
  78. Brummer D, Collins AR, Noh G, et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. *J Clin Invest*. 2003;112:1318.
  79. Norman P, Spencer CA, Lawrence-Brown MM, Jamrozik K. C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysms in men. *Circulation*. 2004;110:862.
  80. Sodeck G, Domanovits H, Khanakah G, et al. The role of *Chlamydia pneumoniae* in human aortic disease—a hypothesis revisited. *Eur J Vasc Endovasc Surg*. 2004;28:547.
  81. Sho E, Sho M, Nanjo H, et al. Hemodynamic regulation of CD34<sup>+</sup> cell localization and differentiation in experimental aneurysms. *Arterioscler Thromb Vasc Biol*. 2004;24:1916.
  82. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. *Circulation*. 2008 Apr 8;117:1883-1889.
  83. Benenson S, Raveh D, Schlesinger Y, et al. The risk of vascular infection in adult patients with nontyphi *Salmonella* bacteremia. *Am J Med* 2001;110:60.

## 第 9 章

1. Gauer OH, Thron HL. Postural changes in the circulation. In: Hamilton WF, Dow P, eds. *Handbook of Physiology*. Sect 2: Circulation, vol III. Washington, DC: American Physiological Society; 1965:2409.
2. Guyton AC. Venous return. In: Hamilton WF, Dow P, eds. *Handbook of Physiology*. Sect 2: Circulation, vol II. Washington, DC: American Physiological Society; 1963:1099.
3. Daily JW, Harleman DRF. Fluid Dynamics. Reading, MA: Addison-Wesley; 1966.
4. Burton AC. *Physiology and Biophysics of the Circulation*. 2nd ed. Chicago: Year Book; 1972.
5. Rijsterborgh H, Roelandt J. Doppler assessment of aortic stenosis: Bernoulli revisited. *Ultrasound Med Biol*. 1987;13:241.
6. Pedersen EM, Hjørtdal JØ, Hjørtdal VE, et al. Three-dimensional visualization of velocity profiles in the porcine abdominal aortic trifurcation. *J Vasc Surg*. 1992;15:194.
7. Vieli A, Moser U, Maier S, et al. Velocity profiles in the normal human abdominal aorta: a comparison between ultrasound and magnetic resonance data. *Ultrasound Biol Med*. 1989;15:113.
8. Malcome AD, Roach MR. Flow disturbances at the apex and lateral angles of a variety of bifurcation models and their role in the development and manifestations of arterial disease. *Stroke*. 1979;10:335.
9. Segadal L, Matre K. Blood velocity distribution in the human ascending aorta. *Circulation*. 1987;76:90.
10. Schultz DL. Pressure and flow in large arteries. In: Bergel DH, ed. *Cardiovascular Fluid Dynamics*. Vol I. New York: Academic Press; 1972:287.
11. Attinger EO. Flow patterns and vascular geometry. In: *Pulsatile Blood Flow*. New York: McGraw-Hill; 1964:179.
12. Yellin EL. Laminar-turbulent transition process in pulsation flow. *Circ Res*. 1966;19:791.
13. Streeter VC, Keitzer WF, Bohr DF. Pulsatile pressure and flow through distensible vessels. *Circ Res*. 1963;13:3.
14. Berguer R, Hwang NHC. Critical arterial stenosis: a theoretical and experimental solution. *Ann Surg*. 1974;180:39.
15. O'Rourke MF. Steady and pulsatile energy losses in the systemic circulation under normal conditions and in simulated arterial disease. *Cardiovasc Res*. 1967;1:313.
16. McDonald DA. *Blood Flow in Arteries*. 2nd ed. Baltimore: Williams & Wilkins; 1974.

17. Attinger EO, Sugawara H, Navarro A, et al. Pressure flow relations in dog arteries. *Circ Res.* 1966;19:230.
18. Ling SC, Atabek HB, Letzing WG, et al. Non-linear analysis of aortic flow in living dogs. *Circ Res.* 1973;33:198.
19. Milnor WR. Pulsatile blood flow. *N Engl J Med.* 1972;287:27.
20. Byar D, Fiddian RV, Quereau M, et al. The fallacy of applying Poiseuille equation to segmented arterial stenosis. *Am Heart J.* 1965;70:216.
21. Fiddian RV, Byar D, Edwards EA. Factors affecting flow through a stenosed vessel. *Arch Surg.* 1964;88:105.
22. Kindt GW, Youmans JR. The effect of stricture length on critical arterial stenosis. *Surg Gynecol Obstet.* 1969;128:729.
23. May AG, DeWeese JA, Rob CA. Hemodynamic effects of arterial stenosis. *Surgery.* 1963;53:513.
24. Strandness DE Jr, Sumner DS. *Hemodynamics for Surgeons.* New York: Grune & Stratton; 1975.
25. Young DF, Tsai FY. Flow characteristics of models of arterial stenosis. II: Unsteady flow. *J Biomech.* 1973;6:547.
26. Young DF, Tsai FY. Flow characteristics in models of arterial stenoses. I: Steady flow. *J Biomech.* 1973;6:395.
27. May AG, Van deBerg L, DeWeese JA, et al. Critical arterial stenosis. *Surgery.* 1963;54:250.
28. Moore WS, Malone JM. Effect of flow rate and vessel caliber on critical arterial stenosis. *J Surg Res.* 1979;26:1.
29. Moore WS, Sydorak GR, Newcomb L, et al. Blood pressure gradient to estimate flow changes with progressive arterial stenosis. *Surg Forum.* 1973;24:248.
30. Sydorak GR, Moore WS, Newcomb L, et al. Effect of increasing flow rates and arterial caliber on critical arterial stenoses. *Surg Forum.* 1972;23:243.
31. Van deBerg L, DeWeese JA, Rob CG. The effect of arterial stenosis and sympathectomy on blood flow and the ergogram. *Ann Surg.* 1964;159:623.
32. Carter SA. Response of ankle systolic pressure to leg exercise in mild or questionable arterial disease. *N Engl J Med.* 1972;287:578.
33. Strandness DE Jr. Abnormal exercise response after successful reconstructive arterial surgery. *Surgery.* 1966;59:325.
34. Strandness DE Jr, Bell JW. An evaluation of the hemodynamic response of the claudicating extremity to exercise. *Surg Gynecol Obstet.* 1964;119:1237.
35. Moore WS, Hall AD. Unrecognized aortoiliac stenosis: a physiologic approach to the diagnosis. *Arch Surg.* 1971;103:633.
36. Wesolowski SA, Martinez A, Domingo RT, et al. Indications for aortofemoral arterial reconstruction: a study of borderline risk patients. *Surgery.* 1966;60:288.
37. Brice JG, Dowsett DJ, Lowe RD. Hemodynamic effects of carotid artery stenosis. *BMJ.* 1964;2:1363.
38. Vonruden WJ, Blaisdell FW, Hall AD, et al. Multiple arterial stenosis: effect on blood flow. *Arch Surg.* 1964;89:307.
39. Flanigan DP, Tullis JP, Streeter VL, et al. Multiple subcritical arterial stenoses: effect on poststenotic pressure and flow. *Ann Surg.* 1977;186:663.
40. Karayannacos PE, Talukder N, Nerem RM, et al. The role of multiple noncritical arterial stenoses in the pathogenesis of ischemia. *J Thorac Cardiovasc Surg.* 1977;73:458.
41. Dundas P, Hillestad LK. Profunda revascularization: the early postoperative effect upon calf blood flow. *Scand J Thorac Cardiovasc Surg.* 1971;5:275.
42. Martin P, Frawley JE, Barabas AP, et al. On the surgery of atherosclerosis of the profunda femoris artery. *Surgery.* 1972;71:182.
43. Morris GC Jr, Edwards W, Cooley DA, et al. Surgical importance of the profunda femoris artery. *Arch Surg.* 1961;82:32.
44. Strandness DE Jr. Functional results after revascularization of the profunda femoris artery. *Am J Surg.* 1970;119:240.
45. Cobb LA, Smith PH, Lwai S, et al. External iliac vein flow: Its response to exercise and relation to lactate production. *J Appl Physiol.* 1969;26:606.
46. Folse JR. Application of the sudden injection dye dilution principle to the study of the femoral circulation. *Surg Gynecol Obstet.* 1965;120:1194.
47. Lewis P, Psaila JV, Morgan RH, et al. Common femoral artery volume flow in peripheral vascular disease. *Br J Surg.*

1990;77:183.

48. Wahren J, Jorfeldt L. Determinations of leg blood flow during exercise in man: an indicator-dilution technique based on femoral venous dye infusion. *Clin Sci Mol Med*. 1973;45:135.
49. Hillestad LK. The peripheral blood flow in intermittent claudication. V: Plethysmographic studies: the significance of the calf blood flow at rest and in response to timed arrest of the circulation. *Acta Med Scand*. 1963;174:23.
50. Strandell T, Wahren J. Circulation in the calf at rest, after arterial occlusion and after exercise in normal subjects and in patients with intermittent claudication. *Acta Med Scand*. 1963;173:99.
51. Lassen NA, Lindberg IF, Dahn I. Validity of the xenon <sup>133</sup>Xe method for measurement of muscle blood flow evaluated by simultaneous venous occlusion plethysmography: observations in the calf of normal man and in patients with occlusive vascular disease. *Circ Res*. 1965;16:287.
52. Snell ES, Eastcott HHG, Hamilton M. Circulation in lower limb before and after reconstruction of obstructed main artery. *Lancet*. 1960;1:242.
53. Lassen NA, Kampp M. Calf muscle blood flow during walking studied by the <sup>133</sup>Xe method in normals and in patients with intermittent claudication. *Scand J Clin Lab Invest*. 1965;17:447.
54. Pentecost BL. The effect of exercise on the external iliac vein blood flow and local oxygen consumption in normal subjects, and in those with occlusive arterial disease. *Clin Sci*. 1964;27:437.
55. Remington JW, Wood EH. Formation of peripheral pulse contour in man. *J Appl Physiol*. 1956;9:433.
56. Yao ST. Haemodynamic studies in peripheral arterial disease. *Br J Surg*. 1970;57:761.
57. Stahler C, Strandness DE Jr. Ankle blood pressure response to gradual treadmill exercise. *Angiology*. 1967;18:237.
58. Shepherd JT. *Physiology of the Circulation in Human Limbs in Health and Disease*. Philadelphia: WB Saunders; 1963.
59. Kjellmer I. On the competition between metabolic vasodilatation and neurogenic vasoconstriction in skeletal muscle. *Acta Physiol Scand*. 1965;63:450.
60. Remensnyder JP, Mitchell JH, Sarnoff SJ. Functional sympatholysis during muscular activity. *Circ Res*. 1962;11:370.
61. Beiser GD, Zelis R, Epstein SE, et al. The role of skin and muscle resistance vessels in reflexes mediated by the baroreceptor system. *J Clin Invest*. 1970;49:225.
62. James IM, Millar RA, Purves MY. Observations on the extrinsic neural control of cerebral blood flow in the baboon. *Circ Res*. 1969;25:77.
63. Johnson PC. Review of previous studies and current theories of autoregulation. *Circ Res*. 1964;14:15.
64. Jones RD, Berne RM. Intrinsic regulation of skeletal muscle blood flow. *Circ Res*. 1964;14:126.
65. Lassen NA. Cerebral blood flow and oxygen consumption in man. *Physiol Rev*. 1959;39:183.
66. Korner PI. Control of blood flow to special vascular areas: brain, kidney, muscle, skin, liver and intestine. In: Guyton AC, Jones CE, eds. MTP International Review of Science. *Physiology: Series 1, vol 1: Cardiovascular Physiology*. London: Butterworths; 1974.
67. Gutstein WH, Schneck DJ, Marks JO. In vitro studies of local blood flow disturbance in a region of separation. *J Atheroscler Res*. 1968;8:381.
68. Logerfo FW, Soncrant T, Teel T, et al. Boundary layer separation in models of side-to-end arterial anastomoses. *Arch Surg*. 1979;114:1364.
69. Ku DN, Giddens DP, Phillips DJ, et al. Hemodynamics of the normal human carotid bifurcation—in vitro and in vivo studies. *Ultrasound Med Biol*. 1985;1:13.
70. Phillips DJ, Greene FM Jr, Langlois Y, et al. Flow velocity patterns in the carotid bifurcations of young, presumed normal subjects. *Ultrasound Med Biol*. 1983;1:39.
71. Fox JA, Hugh AE. Localization of atheroma: a theory based on boundary layer separation. *Br Heart J*. 1966;28:388.
72. Westerhof N, Sipkema P, Van Den Bos GC, et al. Forward and backward waves in the arterial system. *Cardiovasc Res*. 1972;6:648.

73. Rittenhouse EA, Maxiner W, Burr JW, et al. Directional arterial flow velocity: a sensitive index of changes in peripheral vascular resistance. *Surgery*. 1976;79:359.
74. Mozersky DJ, Sumner DS, Hokanson DE, et al. Transcutaneous measurement of the elastic properties of the human femoral artery. *Circulation*. 1972;46:948.
75. Sumner DS, Strandness DE Jr. The effect of exercise on resistance to blood flow in limbs with an occluded superficial femoral artery. *Vasc Surg*. 1970;4:229.
76. Longland CJ. The collateral circulation of the limb. *Ann R Coll Surg Engl*. 1953;13:161.
77. Conrad MC, Anderson JL III, Garrett JB Jr. Chronic collateral growth after femoral artery occlusion in the dog. *J Appl Physiol*. 1971;31:550.
78. John HT, Warren R. The stimulus to collateral circulation. *Surgery*. 1961;49:14.
79. Rosenthal SL, Guyton AC. Hemodynamics of collateral vasodilatation following femoral artery occlusion in anesthetized dogs. *Circ Res*. 1968;23:239.
80. Winblad JN, Reemtsma K, Vernhet JL, et al. Etiologic mechanisms in the development of collateral circulation. *Surgery*. 1959;45:105.
81. Holman E. Problems in the dynamics of blood flow. I: Conditions controlling collateral circulation in the presence of an arteriovenous fistula and following ligation of an artery. *Surgery*. 1949;26:880.
82. Keenan RL, Rodbard S. Competition between collateral vessels. *Cardiovasc Res*. 1973;7:670.
83. Ludbrook J. Collateral artery resistance in the human lower limb. *J Surg Res*. 1966;6:423.
84. Beaconsfield PA. A. Effect of exercise on muscle blood flow in normal and sympathectomized limbs. B. Collateral circulation before and after sympathectomy. *Ann Surg*. 1954;140:786.
85. Dornhorst AC, Sharpey-Schafer EP. Collateral resistance in limbs with arterial obstruction: spontaneous changes and effects of sympathectomy. *Clin Sci*. 1951;10:371.
86. Folse R. Alterations in femoral blood flow and resistance during rhythmic exercise and sustained muscular contractions in patients with arteriosclerosis. *Surg Gynecol Obstet*. 1965;121:767.
87. Wolf EA Jr, Sumner DS, Strandness DE Jr. Correlation between nutritive blood flow and pressure in limbs of patients with intermittent claudication. *Surg Forum*. 1972;23:238.
88. Angelides NS, Nicolaides AN. Simultaneous isotope clearance from the muscles of the calf and thigh. In: Puel P, Boccalon H, Enjalbert A, eds. *Hemodynamics of the Limbs: I*. Toulouse: GEPESC; 1979:547.
89. Lewis JD, Papathanasiou C, Yao ST, et al. Simultaneous flow and pressure measurements in intermittent claudication. *Br J Surg*. 1972;59:418.
90. Sumner DS, Strandness DE Jr. The relationship between calf blood flow and ankle blood pressure in patients with intermittent claudication. *Surgery*. 1969;65:763.
91. DeWeese JA. Pedal pulses disappearing with exercise: A test for intermittent claudication. *N Engl J Med*. 1960;262:1214.
92. DeWeese JA, Van deBerg L, May AG, et al. Stenoses of arteries of the lower extremity. *Arch Surg*. 1964;89:806.
93. Farrar DJ, Malindzak GS Jr, Johnson G Jr. Large vessel impedance in peripheral atherosclerosis. *Circulation*. 1977;56(Suppl 2):171.
94. Ehrenfeld WK, Harris JD, Wylie EJ. Vascular "steal" phenomenon—an experimental study. *Am J Surg*. 1968;116:192.
95. Shin CS, Chaudhry AG. The hemodynamics of extraanatomic bypass grafts. *Surg Gynecol Obstet*. 1979;148:567.
96. Sumner DS, Strandness DE Jr. The hemodynamics of the femorofemoral shunt. *Surg Gynecol Obstet*. 1972;134:629.
97. Mozersky DJ, Sumner DS, Barnes RW, et al. The hemodynamics of the axillary-axillary bypass. *Surg Gynecol Obstet*. 1972;135:925.
98. Edholm OG, Howarth S, Sharpey-Schafer EP. Resting blood flow and blood pressure in limbs with arterial obstruction. *Clin Sci*. 1951;10:361.
99. Keitzer WF, Fry WJ, Kraft RO, et al. Hemodynamic mechanism for pulse changes seen in occlusive vascular disease.

- Surgery*. 1965;57:163.
100. Conrad MC, Green HD. Hemodynamics of large and small vessels in peripheral vascular disease. *Circulation*. 1964;29:847.
  101. Darling RC, Raines JK, Brener BJ, et al. Quantitative segmental pulse and volume recorder: a clinical tool. *Surgery*. 1973;72:873.
  102. Strandness DE Jr, Bell JW. Peripheral vascular disease: Diagnosis and objective evaluation using a mercury strain gauge. *Ann Surg*. 1965;161(Suppl):1.
  103. Baird RN, Bird DR, Clifford PC, et al. Upstream stenosis, its diagnosis by Doppler signals from the femoral artery. *Arch Surg*. 1980;115:1316.
  104. Evans DH, Barrie WW, Asher MJ, et al. The relationship between ultrasonic pulsatility index and proximal arterial stenosis in a canine model. *Circ Res*. 1980;46:470.
  105. Fronck A, Johansen KH, Dilley RB, et al. Non-invasive physiologic tests in the diagnosis and characterization of peripheral arterial occlusive disease. *Am J Surg*. 1973;126:205.
  106. Gosling RG, Dunbar G, King DH, et al. The quantitative analysis of occlusive peripheral arterial disease by a noninvasive ultrasonic technique. *Angiology*. 1971;22:52.
  107. Nicolaides AN, Gordon-Smith DC, Dayandas J, et al. The value of Doppler blood velocity tracings in the detection of aortoiliac disease in patients with intermittent claudication. *Surgery*. 1976;80:774.
  108. Strandness DE Jr, Schultz RD, Sumner DS, et al. Ultrasonic flow detection: a useful technique in the evaluation of peripheral vascular disease. *Am J Surg*. 1967;113:311.
  109. Yao ST, Hobbs JT, Irvine WT. Pulse examination by an ultrasonic method. *BMJ*. 1968;4:555.
  110. Cousins MJ, Wright CJ. Graft, muscle, skin blood flow after epidural block in vascular surgical procedures. *Surg Gynecol Obstet*. 1971;133:59.
  111. Hoffman DC, Jepson RP. Muscle blood flow and sympathectomy. *Surg Gynecol Obstet*. 1968;127:12.
  112. Rutherford RB, Valenta J. Extremity blood flow and distribution: the effects of arterial occlusion, sympathectomy, and exercise. *Surgery*. 1971;69:332.
  113. Schwartz LB, Purut CM, Craig DM, et al. Input impedance of revascularized skeletal muscle, renal, and mesenteric vascular beds. *Vasc Surg*. 1966;30:459.
  114. Coffman JD, Mannick JA. Failure of vasodilator drugs in arteriosclerosis obliterans. *Ann Intern Med*. 1972;76:35.
  115. Weissenhofer W, Schenk WG Jr. Hemodynamic response to vasodilation and exercise in "critical" arterial stenosis. *Arch Surg*. 1974;108:712.
  116. Cronenwett JL, Lindenaum SM. Hemodynamic effects of sympathectomy in ischemic canine hind limbs. *Surgery*. 1980;87:417.
  117. Strandness DE Jr, Bell JW. Critical evaluation of the results of lumbar sympathectomy. *Ann Surg*. 1964;160:1021.
  118. Cronenwett JL, Zelenock GB, Whitehouse WM Jr, et al. The effect of sympathetic innervation on canine muscle and skin blood flow. *Arch Surg*. 1983;118:420.
  119. van Dielen FMH, Kurvers HAJM, Dammers R, et al. Effects of surgical sympathectomy on skin blood flow in a rat model of chronic limb ischemia. *World J Surg*. 1998;22:807.
  120. Larsen OA, Lassen NA. Medical treatment of occlusive arterial disease of the legs: walking exercise and medically induced hypertension. *Angiologica*. 1969;6:288.
  121. Skinner JS, Strandness DE Jr. Exercise and intermittent claudication. II: Effect of physical training. *Circulation*. 1967;36:23.
  122. Feinberg RL, Gregory RT, Wheeler JR, et al. The ischemic window: a method for the objective quantitation of the training effect in exercise therapy for intermittent claudication. *J Vasc Surg*. 1992;16:244.
  123. Johnson EC, Voyles WF, Atterbom HA, et al. Effects of exercise training on common femoral artery blood flow in patients

- with intermittent claudication. *Circulation*. 1989;80:III59.
124. Lassen NA, Larsen OA, Sørensen AWS, et al. Conservative treatment of gangrene using mineral corticoid-induced moderate hypertension. *Lancet*. 1968;1:606.
  125. Scheffler A, Rieger H. A comparative analysis of transcutaneous oximetry (tcPo<sub>2</sub>) during oxygen inhalation and leg dependency in severe peripheral arterial occlusive disease. *J Vasc Surg*. 1992;16:218.
  126. Dormandy JA. Significance of hemorrheology in the management of the ischemic limb. *World J Surg*. 1983;7:319.
  127. LeVeen HH, Moon I, Ahmed N, et al. Lowering blood viscosity to overcome vascular resistance. *Surg Gynecol Obstet*. 1980;150:139.
  128. Wolfe JHN, Waller DG, Chapman MB, et al. The effect of hemodilution upon patients with intermittent claudication. *Surg Gynecol Obstet*. 1985;160:347.
  129. Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive disease patients. *Am Heart J*. 1982;104:66.
  130. Sanders RJ, Kempczinski RF, Hammond W, et al. The significance of graft diameter. *Surgery*. 1980;88:856.
  131. Buxton B, Lambert RP, Pitt TTE. The significance of vein wall thickness and diameter in relation to the patency of femoropopliteal saphenous vein bypass grafts. *Surgery*. 1980;87:425.
  132. Edwards WS, Holdefer WF, Mohtashemi M. The importance of proper caliber of lumen in femoral-popliteal artery reconstruction. *Surg Gynecol Obstet*. 1966;122:37.
  133. Ojha M, Ethier CR, Johnston KW, et al. Steady and pulsatile flow fields in an end-to-side arterial anastomosis model. *J Vasc Surg*. 1990;12:747.
  134. Wengerter KR, Veith FJ, Gupta SK, et al. Influence of vein size (diameter) on infrapopliteal reversed vein graft patency. *J Vasc Surg*. 1990;11:525.
  135. Schultz RD, Hokanson DE, Strandness DE Jr. Pressure-flow relations of the end-side anastomosis. *Surgery*. 1967;62:319.
  136. Schneider JR, Zwolak RM, Walsh DB, et al. Lack of diameter effect on short-term patency of size-matched Dacron aortofemoral grafts. *J Vasc Surg*. 1991;13:785.
  137. Berguer R, Higgins RF, Reddy DJ. Intimal hyperplasia: an experimental study. *Arch Surg*. 1980;115:332.
  138. Lye CR, Sumner DS, Strandness DE Jr. The transcutaneous measurement of the elastic properties of the human saphenous vein femoropopliteal bypass graft. *Surg Gynecol Obstet*. 1975;141:891.
  139. Okadone K, Yukizane T, Mii S, et al. Ultrastructural evidence of the effects of shear stress variation on intimal thickening in dogs with arterially transplanted autologous grafts. *J Cardiovasc Surg*. 1990;31:719.
  140. Fillinger MF, Cronenwett JL, Besso S, et al. Vein adaptation to the hemodynamic environment of infrainguinal grafts. *J Vasc Surg*. 1994;19:970.
  141. Golledge J, Hicks RCJ, Ellis M, et al. Dilatation of saphenous vein grafts by nitric oxide. *Eur J Vasc Endovasc Surg*. 1977;14:41.
  142. Cambria RA, Lowell RC, Głowiczki P, et al. Chronic changes in blood flow alter endothelium-dependent responses in autogenous vein grafts in dogs. *J Vasc Surg*. 1994;20:765.
  143. Park TC, Harker CT, Edwards JM, et al. Human saphenous vein grafts explanted from the arterial circulation demonstrate altered smooth-muscle and endothelial responses. *J Vasc Surg*. 1993;18:61.
  144. Lye CR, Sumner DS, Strandness DE Jr. Hemodynamics of the retrograde cross-pubic anastomosis. *Surg Forum*. 1975;26:298.
  145. Bassiouny HS, White S, Glagov S, et al. Anastomotic intimal hyperplasia: mechanical injury or flow-induced? *J Vasc Surg*. 1992;15:708.
  146. Crawshaw HM, Quist WC, Sarrallach E, et al. Flow disturbance at the distal end-to-side anastomosis: effect of patency of the proximal outflow segment and angle of anastomosis. *Arch Surg*. 1980;115:1280.
  147. McMillan DE. Blood flow and the localization of atherosclerotic plaques. *Stroke*. 1985;16:582.



148. Zarins CK, Giddens DP, Bharadvaj BK, et al. Carotid bifurcation atherosclerosis: quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. *Circ Res*. 1983;53:502.
149. LoGerfo FW, Quist WC, Nowak MD, et al. Downstream anastomotic hyperplasia: a mechanism of failure of Dacron arterial grafts. *Ann Surg*. 1983;197:479.
150. Abbott WM, Bouchier-Hayes DJ. The role of mechanical properties in graft design. In: Dardik H, ed. *Graft Materials in Vascular Surgery*. Miami: Symposia Specialist; 1978:59.
151. Hokanson DE, Strandness DE Jr. Stress-strain characteristics of various arterial grafts. *Surg Gynecol Obstet*. 1968;127:57.
152. Mehigan DG, Fitzpatrick B, Browne HI, et al. Is compliance mismatch the major cause of anastomotic arterial aneurysms? *J Cardiovasc Surg*. 1985;26:147.
153. Walden R, L'Italien GJ, Megerman J, et al. Matched elastic properties and successful arterial grafting. *Arch Surg*. 1980;115:1166.
154. Dobrin PB, Mirande R, Kang S, et al. Mechanics of end-to-end artery-to-PTFE graft anastomoses. *Ann Vasc Surg*. 1998;12:317.
155. Kinley CE, Marble AE. Compliance: a continuing problem with vascular grafts. *J Cardiovasc Surg*. 1980;21:163.
156. Nichols WK, Stanton M, Silver D, et al. Anastomotic aneurysms following lower extremity revascularization. *Surgery*. 1980;88:366.
157. Kinley CE, Paasche PE, MacDonald AS, et al. Stress at vascular anastomosis in relation to host artery: synthetic graft diameter. *Surgery*. 1974;75:28.
158. Paasche PE, Kinley CE, Dolan FG, et al. Consideration of suture line stresses in the selection of synthetic grafts for implantation. *J Biomech*. 1973;6:253.
159. Newman DL, Gosling RG, Bowden NLR, et al. Pressure amplitude increase on unmatching the aorto-iliac junction of the dog. *Cardiovasc Res*. 1973;7:6.
160. Dobrin PB. Mechanics of normal and diseased blood vessels. *Ann Vasc Surg*. 1988;2:283.
161. Sumner DS, Hokanson DE, Strandness DE Jr. Arterial walls before and after endarterectomy, stress-strain characteristics and collagen-elastic content. *Arch Surg*. 1969;99:606.
162. Sumner DS, Hokanson DE, Strandness DE Jr. Stress-strain characteristics and collagen-elastic content of abdominal aortic aneurysms. *Surg Gynecol Obstet*. 1970;130:459.

## 第 10 章

1. Caggiati A, Bergan JJ, Gloviczki P. Nomenclature of the veins of the lower limb: an international interdisciplinary consensus statement. *J Vasc Surg*. 2002;36:416-422.
2. Caggiati A. Fascial relationships of the long saphenous vein. *Circulation*. 1999;100:2547-2549.
3. Caggiati A. Fascial relationships of the short saphenous vein. *J Vasc Surg*. 2001;34:241-246.
4. Meissner MH, Moneta G, Burnand K, et al. The hemodynamics and diagnosis of venous disease. *J Vasc Surg*. 2007;46:4S-24S.
5. Alimi YS, Barthelemy P, Juhan C. Venous pump of the calf: a study of venous and muscular pressures. *J Vasc Surg*. 1994;20:728-735.
6. Ludbrook J. The musculovenous pumps of the human lower limb. *Am Heart J*. 1966;71:635-641.
7. Pollack AA, Wood EH. Venous pressure in the saphenous vein at the ankle in man during exercise and changes in posture. *J Appl Physiol*. 1949;1:649-662.
8. White JV, Katz ML, Cisek P, Kreithen J. Venous outflow of the leg: anatomy and physiologic mechanism of the plantar venous plexus. *J Vasc Surg*. 1996;24:819-824.
9. Burnand KG. The physiology and hemodynamics of chronic venous insufficiency of the lower limb. In: Gloviczki P, Yao JST, eds. *Handbook of Venous Disorders. Guidelines of the American Venous Forum*. 2nd ed. London: Arnold; 2001:49-57.

10. Rothe CF. Physiology of venous return. *Arch Intern Med.* 1986;146:977-982.
11. Shepherd JT. Role of the veins in the circulation. *Circulation.* 1966;33:484-491.
12. Tyberg JV. How changes in venous capacitance modulate cardiac output. *Pflugers Arch Eur J Physiol.* 2002;445:10-17.
13. Rothe CF. Mean circulatory filling pressure: its meaning and measurement. *J Appl Physiol.* 1993;74:499-509.
14. Rothe CF. Reflex control of veins and vascular capacitance. *Physiol Rev.* 1983;63:1281-1342.
15. Moreno AH, Katz AI, Gold LD, Reddy RV. Mechanics of distension of dog veins and other thin-walled tubular structures. *Circ Res.* 1970;27:1069-1080.
16. Attinger EO. Wall properties of veins. *IEEE Trans Biomed Eng.* 1969;16:253-261.
17. Lye CR, Sumner DS, Hokanson DE, Strandness DE Jr. The transcutaneous measurement of the elastic properties of the human saphenous vein femoropopliteal bypass graft. *Surg Gynecol Obstet.* 1975;141:891-895.
18. Strandness DE Jr, Sumner DS. *Hemodynamics for Surgeons.* New York: Grune & Stratton; 1975.
19. Brooksby GA, Donald DE. Release of blood from the splanchnic circulation in dogs. *Circ Res.* 1972;31:105-118.
20. Sumner DS, Zierler RE. Vascular physiology: essential hemodynamic principles. In: Rutherford RB, ed. *Vascular Surgery.* 6th ed. Philadelphia: WB Saunders; 2005:75-123.
21. Stegall HR. Muscle pumping in the dependent leg. *Circ Res.* 1966;19:180-190.
22. Arnoldi CC, Linderholm H. Venous blood pressures in the lower limb at rest and during exercise in patients with idiopathic dysfunction of the venous pump of the calf. *Acta Chir Scand.* 1969;135:601-609.
23. Almen T, Nylander G. Serial phlebography of the normal leg during muscular contraction and relaxation. *Acta Radiol.* 1962;57:264-272.
24. Hjelmstedt A. The pressure in the veins of the dorsum of the foot in quiet standing and during exercise in limbs without signs of venous disorder. *Acta Chir Scand.* 1968;134:235-244.
25. Hojensgard IC, Sturup H. Static and dynamic pressures in the superficial and deep veins of the lower extremity in man. *Acta Physiol Scand.* 1952;27:49-67.
26. Criado E, Passman MA. Physiological assessment of the venous system. In: Rutherford RB, ed. *Vascular Surgery.* 3rd ed. Philadelphia: WB Saunders, 1989:175-177.
27. Nicolaides AN, Hussein MK, Szendro G, et al. The relationship of venous ulceration with ambulatory venous pressure measurements. *J Vasc Surg.* 1993;17:414-419.
28. Ellwood RA, Lee WB. Pedal venous pressure: correlation with presence and site of deep-venous abnormalities. *Radiology.* 1979;131:73-74.
29. Husni EA, Ximenes JOC, Goyette EM. Elastic support of the lower limbs in hospital patients—a critical study. *JAMA.* 1970;214:1456-1462.
30. Barnes RW, Collicott PE, Mozersky DJ, et al. Noninvasive quantitation of maximum venous outflow in acute thrombophlebitis. *Surgery.* 1972;72:971-979.
31. Cooke ED, Picher MF. Thrombosis: Preclinical diagnosis by deep vein thermography. *Br J Surg.* 1974;61:971-978.
32. Hallbook T, Gothlin J. Strain gauge plethysmography and phlebography in diagnosis of deep venous thrombosis. *Acta Chir Scand.* 1971;137:37-52.
33. Barnes RW, Hokanson DE, Wu KK, Hoak JC. Detection of deep vein thrombosis with an automatic electrically calibrated strain gauge plethysmograph. *Surgery.* 1977;82:219-223.
34. Zufferey P, Pararas C, Monti M, Depairon M. Assessment of acute and old deep venous thrombosis in upper extremity by venous strain gauge plethysmography. *Vasa.* 1992;21:263-267.
35. Raju S, Fredericks RK, Hudson CA, et al. Venous valve station changes in “primary” and post-thrombotic reflux: an analysis of 149 cases. *Ann Vasc Surg.* 2000;14:193-199.
36. Labropoulos N, Leon M, Nicolaides AN, et al. Superficial venous insufficiency: correlation of anatomic extent of reflux with clinical symptoms and signs. *J Vasc Surg.* 1994;20:953-958.

37. Meissner MH, Eklof B, Coleridge-Smith P, et al. Secondary chronic venous disorders. *J Vasc Surg.* 2007;46:S68-S83.
38. Clarke H, Smith SR, Vasdekis SN, et al. Role of venous elasticity in the development of varicose veins. *Br J Surg.* 1989;76:577-580.
39. Somers P, Knaapen M. The histopathology of varicose vein disease. *Angiology.* 2006;57:546-555.
40. Raffetto J, Khalil R. Mechanisms of varicose vein formation: valve dysfunction and wall dilation. *Phlebology* 2008;23:85-98.
41. Takase S, Pascarella L, Bergan JJ, Schmid-Schonbein GW. Hypertension-induced venous valve remodeling. *J Vasc Surg.* 2004;39:1329-1334.
42. Pascarella L, Schmid-Schonbein GW, Bergan J. An animal model of venous hypertension: the role of inflammation in venous valve failure. *J Vasc Surg.* 2005;41:303-311.
43. Bergan JJ, Schmid-Schonbein GW, Coleridge-Smith PD, et al. Chronic venous disease. *N Engl J Med.* 2006;355:488-498.
44. Qui Y, Quijano RC, Wang SK, Hwang NH. Fluid dynamics of venous valve closure. *Ann Biomed Eng.* 1995;23:750-759.
45. Yamaki T, Sasaki K, Nozaki M. Preoperative duplex-derived parameters and angioscopic evidence of valvular incompetence associated with superficial venous insufficiency. *J Endovasc Ther.* 2002;9:229-233.
46. Sales CM, Rosenthal D, Petrillo KA, et al. The valvular apparatus in venous insufficiency: a problem of quantity? *Ann Vasc Surg.* 1998;12:153-155.
47. Bauer G. The etiology of leg ulcers and their treatment by resection of the popliteal vein. *J Int Chir.* 1948;8:937-967.
48. Killewich LA, Bedford GR, Beach KW, Strandness DE Jr. Spontaneous lysis of deep venous thrombi: rate and outcome. *J Vasc Surg.* 1989;9:89-97.
49. Myers KA, Ziegenbein RW, Xeng GH, Matthews PG. Duplex ultrasonography scanning for chronic venous disease: patterns of venous reflux. *J Vasc Surg.* 1995;21:605-612.
50. Welch HJ, Young CM, Semegran AB, et al. Duplex assessment of venous reflux and chronic venous insufficiency: the significance of deep venous reflux. *J Vasc Surg.* 1996;24:755-762.
51. O'Shaughnessy A, Fitzgerald DE. The patterns and distribution of residual abnormalities between the individual proximal venous segments after an acute deep vein thrombosis. *J Vasc Surg.* 2001;33:379-384.
52. Ibegbuna V, Delis KT, Nicolaides AN. Haemodynamic and clinical impact of superficial, deep and perforator vein incompetence. *Eur J Vasc Endovasc Surg.* 2006;31:535-541.
53. Neglen P, Thrasher TL, Raju S. Venous outflow obstruction: an underestimated contributor to chronic venous disease. *J Vasc Surg.* 2003;38:879-885.
54. Christopoulos DG, Nicolaides AN, Szendro G, et al. Air-plethysmography and the effect of elastic compression on venous hemodynamics of the leg. *J Vasc Surg.* 1987;5:148-159.
55. Christopoulos D, Nicolaides AN, Cook A, et al. Pathogenesis of venous ulceration in relation to the calf muscle pump function. *Surgery.* 1989;106:829-835.
56. Criado E, Farber MA, Marston WA, et al. The role of air-plethysmography in the diagnosis of chronic venous insufficiency. *J Vasc Surg.* 1998;27:660-670.
57. van Bemmelen PS, Beach K, Bedford G, Strandness DE Jr. The mechanism of venous valve closure: its relationship to the velocity of reverse flow. *Arch Surg.* 1990;125:617-619.
58. Labropoulos N, Tiongson J, Pryor L, et al. Definition of venous reflux in lower extremity veins. *J Vasc Surg.* 2003;38:793-798.
59. Delis KT, Husmann M, Kalodiki E, et al. In situ hemodynamics of perforating veins in chronic venous insufficiency. *J Vasc Surg.* 2001;33:773-782.
60. Browse NL, Burnand KG. The cause of venous ulceration. *Lancet.* 1982;2:243-245.
61. Gloviczki P, Bergan JJ, Rhodes MJ, et al. Mid-term results of endoscopic perforator vein interruption for chronic venous insufficiency: lessons learned from the North American subfascial endoscopic perforator surgery registry. *J Vasc Surg.*

- 1999;29:489-502.
62. Nicolaides AN, Zukowski AJ. The value of dynamic venous pressure measurements. *World J Surg.* 1986;10:919-924.
63. Nicolaides AN. Noninvasive assessment of primary and secondary varicose veins. In: Bernstein EF, ed. *Noninvasive Diagnostic Techniques in Vascular Disease*. 2nd ed. St Louis: CV Mosby; 1982:575-586.
64. Araki CT, Back TL, Padberg FT, et al. The significance of calf muscle pump function in venous ulceration. *J Vasc Surg.* 1994;20:872-877.
65. Back TL, Padberg FT, Araki CT, et al. Limited range of motion is a significant factor in venous ulceration. *J Vasc Surg.* 1995; 22: 519-523.
66. Padberg FT, Johnston MV, Sisto SA. Structured exercise improves calf muscle pump function in chronic venous insufficiency: a randomized trial. *J Vasc Surg.* 2004;39:79-87.
67. Starling EH. On the absorption of fluids from the connective tissue spaces. *J Physiol.* 1896;19:312-326.
68. Taylor AE. Capillary fluid filtration. Starling forces and lymph flow. *Circ Res.* 1981;49:557-575.
69. DeWeese JA, Rogoff SM. Phlebographic patterns of acute deep venous thrombosis of the leg. *Surgery.* 1963;53:99-108.
70. Snyder MA, Adams JT, Schwartz SI. Hemodynamics of phlegmasia cerulea dolens. *Surg Gynecol Obstet.* 1967;125:342-346.
71. van Ramshorst B, van Bemmelen PS, Hoeneveld H, et al. Thrombus regression in deep venous thrombosis: quantification of spontaneous thrombolysis with duplex scanning. *Circulation.* 1992;86:414-419.
72. Killewich LA, Macko RF, Cox K, et al. Regression of proximal deep venous thrombosis is associated with fibrinolytic enhancement. *J Vasc Surg.* 1997;26:861-868.
73. Meissner JH, Zierler BK, Bergelin RO, et al. Coagulation, fibrinolysis, and recanalization after acute deep venous thrombosis. *J Vasc Surg.* 2002;35:278-285.
74. Caps MT, Manzo RA, Bergelin RO, et al. Venous valvular reflux in veins not involved at the time of acute deep vein thrombosis. *J Vasc Surg.* 1995;22:524-531.
75. Markel A, Manzo RA, Bergelin RO, Strandness DE Jr. Valvular reflux after deep vein thrombosis: incidence and time of occurrence. *J Vasc Surg.* 1992;15:377-382.
76. van Haarst EP, Liasis N, van Ramshorst B, Moll FL. The development of duplex scanning. *Eur J Vasc Endovasc Surg.* 1996;12:295-299.
77. Coleridge Smith P. The causes of skin damage and leg ulceration in chronic venous disease. *Lower extremity wounds.* 2006;5:160-168.
78. Killewich LA, Martin R, Cramer M, et al. Pathophysiology of venous claudication. *J Vasc Surg.* 1984;1:507-511.
79. Delis KT, Bountouroglou D, Mansfield A. Venous claudication in iliofemoral thrombosis: long-term effects on venous hemodynamics, clinical status, and quality of life. *Ann Surg.* 2004;239:118-126.
80. Meissner MH, Gloviczki P, Bergan J, et al. Primary chronic venous disorders. *J Vasc Surg.* 2007;46:S54-S67.
81. Labropoulos N, Giannoukas AD, Delis K, et al. Where does venous reflux start? *J Vasc Surg.* 1997;26:736-742.
82. Kerr MG, Scott DB, Samuel E. Studies of the inferior vena cava in late pregnancy. *BMJ.* 1964;1:532-533.
83. Sumner DS. Venous dynamics—varicosities. *Clin Obstet Gynecol.* 1981;24:743-760.
84. Ueland K. Pregnancy and cardiovascular disease. *Med Clin North Am.* 1977; 61:17-41.
85. Barwin BN, Roddie IG. Venous distensibility during pregnancy determined by graded venous congestion. *Am J Obstet Gynecol.* 1976;125:921-923.
86. Henry M, Corless C. The incidence of varicose veins in Ireland. *Phlebology.* 1989;4:133-136.
87. Bergan JJ. Causes of venous varicosities and telangiectasias: implications for treatment. *J Vasc Biol Med.* 1995;85:1101-1106.
88. Evans CJ, Fowkes FGR, Hajivassiliou C. Epidemiology of varicose veins: a review. *Int Angiol.* 1994;13:263-270.
89. Boivin P, Cornu-Thenard A, Charpak Y. Pregnancy-induced changes in lower extremity superficial veins: an ultrasound

- scan study. *J Vasc Surg.* 2000;32:570-574.
90. Sustrell C, Thulin I, Norgeren L. The effects of long-term graduated compression treatment on venous function during pregnancy. *Phlebology.* 1995;10:165-168.

## 第 11 章

1. Holderfield MT, Hughes CC. Crosstalk between vascular endothelial growth factor, Notch, and transforming growth factor- $\beta$  in vascular morphogenesis. *Circ Res.* 2008;102:637-652.
2. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. *Circ Res.* 2007;100:158-173.
3. You LR, Lin FJ, Lee CT, et al. Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. *Nature.* 2005;435:98-104.
4. Delot EC, Shneyder N, Zhang H, et al. Abnormal venous and arterial patterning in Chordin mutants. *Dev Dyn.* 2007;236:2586-2593.
5. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. *Circ Res.* 2005;97:1093-1107.
6. Eriksson EE, Karlof E, Lundmark K, et al. Powerful inflammatory properties of large vein endothelium in vivo. *Arterioscler Thromb Vasc Biol.* 2005;25:723-728.
7. Archie JP Jr, Green JJ Jr. Saphenous vein rupture pressure, rupture stress, and carotid endarterectomy vein patch reconstruction. *Surgery.* 1990;107:389-396.
8. Deatrick KB, Eliason JL, Lynch EM, et al. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model. *J Vasc Surg.* 2005;42:140-148.
9. Henke PK, Varma MR, Moaveni DK, et al. Fibrotic injury after experimental deep vein thrombosis is determined by the mechanism of thrombogenesis. *Thromb Haemost.* 2007;98:1045-1055.
10. De Mey JG, Vanhoutte PM. Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. *Circ Res.* 1982;51:439-447.
11. Vanhoutte PM, Luscher TF, Graser T. Endothelium-dependent contractions. *Blood Vessels.* 1991;28:74-83.
12. Hiremath AN, Pershe RA, Hoffman BB, et al. Comparison of age-related changes in prostaglandin E1 and beta-adrenergic responsiveness of vascular smooth muscle in adult males. *J Gerontol.* 1989;44:M13-M17.
13. Bevan JA, Joyce EH. Comparable sensitivity of flow contraction and relaxation to Na reduction may reflect flow-sensor characteristics. *Am J Physiol.* 1992;263:H182-H187.
14. Simon G. Increased vascular wall sodium in hypertension: where is it, how does it get there and what does it do there? *Clin Sci (Lond).* 1990;78:533-540.
15. Heit JA, Cohen AT, Anderson FJ. Estimated annual number of incident and recurrent, non-fatal venous thromboembolism (VTE) events in the US [abstract 910]. *Blood.* 2005;106:267a.
16. Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. *J Vasc Surg.* 2007;45:335-341; discussion 341-332.
17. Meissner MH, Wakefield TW, Ascher E, et al. Acute venous disease: venous thrombosis and venous trauma. *J Vasc Surg.* 2007;46(Suppl S):25S-53S.
18. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. *Arterioscler Thromb Vasc Biol.* 2007;27:1687-1693.
19. Mackman N. Tissue-specific hemostasis in mice. *Arterioscler Thromb Vasc Biol.* 2005;25:2273-2281.
20. Savage B, Ruggeri ZM. Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets. *J Biol Chem.* 1991;266:11227-11233.
21. Ferguson JJ, Waly HM, Wilson JM. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. *Eur Heart J.*

1998;19(Suppl D):D3-D9.

22. Dahlback B. Blood coagulation. *Lancet*. 2000;355:1627-1632.
23. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. *Biochemistry*. 1991;30:10363-10370.
24. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. *J Biol Chem*. 1991;266:7353-7358.
25. Marlar RA, Kleiss AJ, Griffin JH. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. *Blood*. 1982;59:1067-1072.
26. Corral J, Aznar J, Gonzalez-Conejero R, et al. Homozygous deficiency of heparin cofactor II: Relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. *Circulation*. 2004;110:1303-1307.
27. Adelman B, Michelson AD, Loscalzo J, et al. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. *Blood*. 1985;65:32-40.
28. Sidelmann JJ, Gram J, Jespersen J, et al. Fibrin clot formation and lysis: basic mechanisms. *Semin Thromb Hemost*. 2000;26:605-618.
29. Esmon CT. The regulation of natural anticoagulant pathways. *Science*. 1987;235:1348-1352.
30. Hassouna HI. Laboratory evaluation of hemostatic disorders. *Hematol Oncol Clin North Am*. 1993;7:1161-1249.
31. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. *N Engl J Med*. 2006;355:1780-1789.
32. Ljungner H, Bergqvist D. Decreased fibrinolytic activity in the bottom of human vein valve pockets. *Vasa*. 1983;12:333-336.
33. Dano K, Andreasen PA, Grondahl-Hansen J, et al. Plasminogen activators, tissue degradation, and cancer. *Adv Cancer Res*. 1985;44:139-266.
34. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. *J Clin Invest*. 1991;88:1067-1072.
35. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. *N Engl J Med*. 2000;342:1792-1801.
36. Booth NA, Simpson AJ, Croll A, et al. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. *Br J Haematol*. 1988;70:327-333.
37. Schulman S, Wiman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group. *Thromb Haemost*. 1996;75:607-611.
38. Crowther MA, Roberts J, Roberts R, et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. *Thromb Haemost*. 2001;85:390-394.
39. Segui R, Estelles A, Mira Y, et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. *Br J Haematol*. 2000;111:122-128.
40. Zoller B, Garcia de Frutos P, Dahlback B. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. *Thromb Haemost*. 1998;79:802-807.
41. Becker MD, O'Rourke LM, Blackman WS, et al. Reduced leukocyte migration, but normal rolling and arrest, in interleukin-8 receptor homologue knockout mice. *Invest Ophthalmol Vis Sci*. 2000;41:1812-1817.
42. Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. *Circulation*. 2000;101:2144-2148.
43. Gross PL, Aird WC. The endothelium and thrombosis. *Semin Thromb Hemost*. 2000;26:463-478.
44. Stewart GJ. Neutrophils and deep venous thrombosis. *Haemostasis*. 1993;23(Suppl 1):127-140.
45. Esmon CT. Inflammation and thrombosis. *J Thromb Haemost*. 2003;1:1343-1348.
46. Myers D Jr, Farris D, Hawley A, et al. Selectins influence thrombosis in a mouse model of experimental deep venous

thrombosis. *J Surg Res.* 2002;108:212-221.

47. Gilbert GE, Sims PJ, Wiedmer T, et al. Platelet-derived microparticles express high affinity receptors for factor VIII. *J Biol Chem.* 1991;266:17261-17268.
48. Mesri M, Altieri DC. Endothelial cell activation by leukocyte microparticles. *J Immunol.* 1998;161:4382-4387.
49. Sabatier F, Roux V, Anfosso F, et al. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. *Blood.* 2002;99:3962-3970.
50. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. *J Exp Med.* 2003;197:1585-1598.
51. Martinez MC, Tesse A, Zobairi F, et al. Shed membrane microparticles from circulating and vascular cells in regulating vascular function. *Am J Physiol Heart Circ Physiol.* 2005;288:H1004-H1009.
52. Osterud B. The role of platelets in decrypting monocyte tissue factor. *Semin Hematol.* 2001;38:2-5.
53. Ahn ER, Lander G, Jy W, et al. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. *Thromb Res.* 2004;114:143-148.
54. Myers DD, Hawley AE, Farris DM, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. *J Vasc Surg.* 2003;38:1075-1089.
55. Myers DD, Wakefield TW. Inflammation-dependent thrombosis. *Front Biosci.* 2005;10:2750-2757.
56. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. *J Thromb Haemost.* 2005;3:1590-1596.
57. Siddiqui FA, Desai H, Amirkhosravi A, et al. The presence and release of tissue factor from human platelets. *Platelets.* 2002;13:247-253.
58. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. *Proc Natl Acad Sci U S A.* 1999;96:2311-2315.
59. Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. *Proc Natl Acad Sci U S A.* 1994;91:8767-8771.
60. Hrachovinova I, Cambien B, Hafezi-Moghadam A, et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. *Nat Med.* 2003;9:1020-1025.
61. Andre P, Hartwell D, Hrachovinova I, et al. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. *Proc Natl Acad Sci U S A.* 2000;97:13835-13840.
62. Jy W, Horstman LL, Wang F, et al. Platelet factor 3 in plasma fractions: its relation to microparticle size and thromboses. *Thromb Res.* 1995;80:471-482.
63. Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. *Blood.* 2005;105:192-198.
64. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. *Nature.* 1998;391:591-594.
65. Horrevoets AJ. Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance. *Br J Haematol.* 2004;125:12-23.
66. Podor TJ, Singh D, Chindemi P, et al. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. *J Biol Chem.* 2002;277:7529-7539.
67. Meissner MH, Manzo RA, Bergelin RO, et al. Deep venous insufficiency: the relationship between lysis and subsequent reflux. *J Vasc Surg.* 1993;18:596-605; discussion 606-598.
68. Killewich LA, Macko RF, Cox K, et al. Regression of proximal deep venous thrombosis is associated with fibrinolytic enhancement. *J Vasc Surg.* 1997;26:861-868.
69. Wakefield TW, Strieter RM, Wilke CA, et al. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. *Arterioscler Thromb Vasc Biol.* 1995;15:258-268.
70. Varma MR, Varga AJ, Knipp BS, et al. Neutropenia impairs venous thrombosis resolution in the rat. *J Vasc Surg.*

2003;38:1090-1098.

71. Varma MR, Moaveni DM, Dewyer NA, et al. Deep vein thrombosis resolution is not accelerated with increased neovascularization. *J Vasc Surg.* 2004;40:536-542.
72. Hogaboam CM, Steinhauser ML, Chensue SW, et al. Novel roles for chemokines and fibroblasts in interstitial fibrosis. *Kidney Int.* 1998;54:2152-2159.
73. Humphries J, McGuinness CL, Smith A, et al. Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi. *J Vasc Surg.* 1999;30:894-899.
74. Henke PK, Pearce CG, Moaveni DM, et al. Targeted deletion of CCR2 impairs deep vein thrombosis resolution in a mouse model. *J Immunol.* 2006;177:3388-3397.
75. Myers Jr DD, Henke PK, Bedard PW, et al. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. *J Vasc Surg.* 2006;44:625-632.
76. Moaveni DK, Lynch EM, Luke C, et al. Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin. *J Vasc Surg.* 2008;47:616-624.
77. Stenberg B, Bylock A, Risberg B. Effect of venous stasis on vessel wall fibrinolysis. *Thromb Haemost.* 1984;51:240-242.
78. Grainger DJ, Wakefield L, Bethell HW, et al. Release and activation of platelet latent TGF $\beta$  in blood clots during dissolution with plasmin. *Nat Med.* 1995;1:932-937.
79. Delis KT, Bountouroglou D, Mansfield AO. Venous claudication in iliofemoral thrombosis: long-term effects on venous hemodynamics, clinical status, and quality of life. *Ann Surg.* 2004;239:118-126.
80. Franzeck UK, Schalch I, Bollinger A. On the relationship between changes in the deep veins evaluated by duplex sonography and the postthrombotic syndrome 12 years after deep vein thrombosis. *Thromb Haemost.* 1997;77:1109-1112.
81. Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. *J Vasc Surg.* 2004;40:1248-1252.
82. Lalka SG, Unthank JL, Nixon JC. Elevated cutaneous leukocyte concentration in a rodent model of acute venous hypertension. *J Surg Res.* 1998;74:59-63.
83. Pappas PJ, Fallek SR, Garcia A, et al. Role of leukocyte activation in patients with venous stasis ulcers. *J Surg Res.* 1995;59:553-559.
84. Homans J. The etiology and treatment of varicose ulcer of the leg. *Surg Gynecol Obstet.* 1917;24:300-311.
85. Blalock A. Oxygen content of blood in patients with varicose veins. *Arch Surg.* 1929;19:898-905.
86. Lindemayr W, Lofferer O, Mostbeck A, et al. Arteriovenous shunts in primary varicosis? A critical essay. *Vasc Surg.* 1972;6:9-13.
87. Browse NL, Burnand KG. The cause of venous ulceration. *Lancet.* 1982;2:243-245.
88. Coleridge Smith PD, Thomas P, et al. Causes of venous ulceration: A new hypothesis. *Br Med J (Clin Res Ed).* 1988;296:1726-1727.
89. Scott HJ, Coleridge Smith PD, Scurr JH. Histological study of white blood cells and their association with lipodermatosclerosis and venous ulceration. *Br J Surg.* 1991;78:210-211.
90. Pappas PJ, DeFouw DO, Venezia LM, et al. Morphometric assessment of the dermal microcirculation in patients with chronic venous insufficiency. *J Vasc Surg.* 1997;26:784-795.
91. Burnand KG, Whimster I, Clemenson G, et al. The relationship between the number of capillaries in the skin of the venous ulcer-bearing area of the lower leg and the fall in foot vein pressure during exercise. *Br J Surg.* 1981;68:297-300.
92. Clyne CA, Ramsden WH, Chant AD, et al. Oxygen tension on the skin of the gaiter area of limbs with venous disease. *Br J Surg.* 1985;72:644-647.
93. Herrick SE, Sloan P, McGurk M, et al. Sequential changes in histologic pattern and extracellular matrix deposition during the healing of chronic venous ulcers. *Am J Pathol.* 1992;141:1085-1095.
94. Labropoulos N, Giannoukas AD, Delis K, et al. Where does venous reflux start? *J Vasc Surg.* 1997;26:736-742.



95. Sadick NS. Predisposing factors of varicose and telangiectatic leg veins. *J Dermatol Surg Oncol.* 1992;18:883-886.
96. Gundersen J, Hauge M. Hereditary factors in venous insufficiency. *Angiology.* 1969;20:346-355.
97. Cornu-Thenard A, Boivin P, Baud JM, et al. Importance of the familial factor in varicose disease. Clinical study of 134 families. *J Dermatol Surg Oncol.* 1994;20:318-326.
98. Badier-Commander C, Couvelard A, Henin D, et al. Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study. *J Pathol.* 2001;193:398-407.
99. Niebes P. Vessel wall modification in venous pathology. Application to the study of phlebotonic drugs. *Int Angiol.* 1996;15:88-92.
100. Gandhi RH, Irizarry E, Nackman GB, et al. Analysis of the connective tissue matrix and proteolytic activity of primary varicose veins. *J Vasc Surg.* 1993;18:814-820.
101. Waksman Y, Mashiah A, Hod I, et al. Collagen subtype pattern in normal and varicose saphenous veins in humans. *Isr J Med Sci.* 1997;33:81-86.
102. Sansilvestri-Morel P, Rupin A, Badier-Commander C, et al. Imbalance in the synthesis of collagen type I and collagen type III in smooth muscle cells derived from human varicose veins. *J Vasc Res.* 2001;38:560-568.
103. Sansilvestri-Morel P, Nonotte I, Fournet-Bourguignon MP, et al. Abnormal deposition of extracellular matrix proteins by cultured smooth muscle cells from human varicose veins. *J Vasc Res.* 1998;35:115-123.
104. Porto LC, Ferreira MA, Costa AM, et al. Immunolabeling of type IV collagen, laminin, and alpha-smooth muscle actin cells in the intima of normal and varicose saphenous veins. *Angiology.* 1998;49:391-398.
105. Sansilvestri-Morel P, Rupin A, Jaisson S, et al. Synthesis of collagen is dysregulated in cultured fibroblasts derived from skin of subjects with varicose veins as it is in venous smooth muscle cells. *Circulation.* 2002;106:479-483.
106. Somers P, Knaapen M. The histopathology of varicose vein disease. *Angiology.* 2006;57:546-555.
107. Shireman PK, McCarthy WJ, Pearce WH, et al. Plasminogen activator levels are influenced by location and varicosity in greater saphenous vein. *J Vasc Surg.* 1996;24:719-724.
108. Parra JR, Cambria RA, Hower CD, et al. Tissue inhibitor of metalloproteinase-1 is increased in the saphenofemoral junction of patients with varices in the leg. *J Vasc Surg.* 1998;28:669-675.
109. Badier-Commander C, Verbeuren T, Lebard C, et al. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. *J Pathol.* 2000;192:105-112.
110. Woodside KJ, Hu M, Burke A, et al. Morphologic characteristics of varicose veins: possible role of metalloproteinases. *J Vasc Surg.* 2003;38:162-169.
111. Kosugi I, Urayama H, Kasashima F, et al. Matrix metalloproteinase-9 and urokinase-type plasminogen activator in varicose veins. *Ann Vasc Surg.* 2003;17:234-238.
112. Rizzi A, Quaglio D, Vasquez G, et al. Effects of vasoactive agents in healthy and diseased human saphenous veins. *J Vasc Surg.* 1998;28:855-861.
113. Barber DA, Wang X, Gloviczki P, Miller VM. Characterization of endothelin receptors in human varicose veins. *J Vasc Surg.* 1997;26:61-69.
114. Nemcova S, Gloviczki P, Rud KS, et al. Cyclic nucleotides and production of prostanoids in human varicose veins. *J Vasc Surg.* 1999;30:876-883.
115. Raffetto JD, Ross RL, Khalil RA. Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K<sup>+</sup> channels: relevance to varicose vein formation. *J Vasc Surg.* 2007;45:373-380.
116. Cheattle TR, Sarin S, Coleridge Smith PD, et al. The pathogenesis of skin damage in venous disease: a review. *Eur J Vasc Surg.* 1991;5:115-123.
117. O'Kane S, Ferguson MW. Transforming growth factor betas and wound healing. *Int J Biochem Cell Biol.* 1997;29:63-78.
118. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. *N Engl J Med.* 1994;331:1286-1292.
119. Pappas PJ, You R, Rameshwar P, et al. Dermal tissue fibrosis in patients with chronic venous insufficiency is associated

- with increased transforming growth factor-beta1 gene expression and protein production. *J Vasc Surg.* 1999;30:1129-1145.
120. Peschen M, Grenz H, Brand-Saberi B, et al. Increased expression of platelet-derived growth factor receptor alpha and beta and vascular endothelial growth factor in the skin of patients with chronic venous insufficiency. *Arch Dermatol Res.* 1998;290:291-297.
  121. Nicolaides AN. Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. *Angiology.* 2005;56(Suppl 1):S11-S19.
  122. Saharay M, Shields DA, Georgiannos SN, et al. Endothelial activation in patients with chronic venous disease. *Eur J Vasc Endovasc Surg.* 1998;15:342-349.
  123. Nicolaides AN. Investigation of chronic venous insufficiency: a consensus statement (France, March 5-9, 1997). *Circulation.* 2000;102:E126-E163.
  124. Shields DA, Andaz SK, Sarin S, et al. Plasma elastase in venous disease. *Br J Surg.* 1994;81:1496-1499.
  125. Wilkinson LS, Bunker C, Edwards JC, et al. Leukocytes: their role in the etiopathogenesis of skin damage in venous disease. *J Vasc Surg.* 1993;17:669-675.
  126. Raffetto JD, Mendez MV, Marien BJ, et al. Changes in cellular motility and cytoskeletal actin in fibroblasts from patients with chronic venous insufficiency and in neonatal fibroblasts in the presence of chronic wound fluid. *J Vasc Surg.* 2001;33:1233-1241.
  127. Hasan A, Murata H, Falabella A, et al. Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-beta 1. *J Dermatol Sci.* 1997;16:59-66.
  128. Lal BK, Saito S, Pappas PJ, et al. Altered proliferative responses of dermal fibroblasts to TGF-beta1 may contribute to chronic venous stasis ulcer. *J Vasc Surg.* 2003;37:1285-1293.
  129. Stanley AC, Park HY, Phillips TJ, et al. Reduced growth of dermal fibroblasts from chronic venous ulcers can be stimulated with growth factors. *J Vasc Surg.* 1997;26:994-999; discussion 999-1001.
  130. Ackerman Z, Seidenbaum M, Loewenthal E, et al. Overload of iron in the skin of patients with varicose ulcers. Possible contributing role of iron accumulation in progression of the disease. *Arch Dermatol.* 1988;124:1376-1378.
  131. Zamboni P, Tognazzo S, Izzo M, et al. Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. *J Vasc Surg.* 2005;42:309-314.
  132. Calligaro KD, Ahmad S, Dandora R, et al. Venous aneurysms: Surgical indications and review of the literature. *Surgery.* 1995;117:1-6.
  133. Gillespie DL, Villavicencio JL, Gallagher C, et al. Presentation and management of venous aneurysms. *J Vasc Surg.* 1997;26:845-852.
  134. Winchester D, Pearce WH, McCarthy WJ, et al. Popliteal venous aneurysms. *Surgery.* 1993;114:600-607.
  135. Jorgensen JO, Hanel KC, Morgan AM, et al. The incidence of deep venous thrombosis in patients with superficial thrombophlebitis of the lower limbs. *J Vasc Surg.* 1993;18:70-73.
  136. Woodhouse CR. Infusion thrombophlebitis: the histological and clinical features. *Ann R Coll Surg Engl.* 1980;62:364-368.
  137. Luis Rodriguez-Peralto J, Carrillo R, Rosales B, et al. Superficial thrombophlebitis. *Semin Cutan Med Surg.* 2007;26:71-76.
  138. Tapper H, Herwald H. Modulation of hemostatic mechanisms in bacterial infectious diseases. *Blood.* 2000;96:2329-2337.
  139. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. *J Pharmacol Exp Ther.* 2002;300:729-735.
  140. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. *N Engl J Med.* 2003;348:1435-1441.
  141. Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. *Circulation.* 2008;117:93-102.
  142. Prandoni P, Ghirarduzzi A, Prins MH, et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. *J Thromb Haemost.* 2006;4:1891-1896.

143. Glynn RJ, Ridker PM, Goldhaber SZ, et al. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. *Ann Intern Med.* 2007;147:525-533.
144. Ray JG, Mamdani M, Tsuyuki RT, et al. Use of statins and the subsequent development of deep vein thrombosis. *Arch Intern Med.* 2001;161:1405-1410.

## 第 12 章

1. Kanter MA. The lymphatic system: an historical perspective. *Plast Reconstr Surg.* 1987;79:131-139.
2. Rusznyák I, Földi M, Szabo G. History of the discovery of lymphatics and lymph circulation. In: *Lymphatics and Lymph Circulation*. 2nd ed. Oxford: Pergamon Press; 1967:15-24.
3. Földi M. Lymphogenous encephalopathy. In: *Diseases of Lymphatics and Lymph Circulation*. Springfield, IL: Charles C Thomas; 1969:91-117.
4. Bradbury MWB, Westrop RJ. Factors influencing exit of substances from cerebrospinal fluid into deep cervical lymph of the rabbit. *J Physiol.* 1983;339:519-534.
5. Leeds SE, Kong AK, Wise BL. Alternative pathways for drainage of cerebrospinal fluid in the canine brain. *Lymphology.* 1989;22:144-146.
6. Witte MH, Dellinger MT, Bernas MJ, et al. Molecular lymphology and genetics of lymphedema-angiodysplasia syndromes. In: Földi M, Földi E, eds. *Textbook of Lymphology*. 6th ed. Munich: Urban & Fischer; 2006:497-523.
7. Sabin FR. On the origin and development of the lymphatic system from the veins and the development of the lymph hearts and the thoracic duct in the pig. *Am J Anat.* 1902;1:367.
8. Kampmeier OF, ed. *Evolution and Comparative Morphology of the Lymphatic System*. Springfield, IL: Charles C Thomas; 1969.
9. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. *Cell.* 1999;98:769-778.
10. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. *Proc Natl Acad Sci U S A.* 1995;92:3566-3570.
11. Wilting J, Papoutsi M, Schneider M, Christ B. The lymphatic endothelium of the avian wing is of somitic origin. *Dev Dynam.* 2000;217:271-278.
12. Witte MH, Bernas M, Martin C, Witte CL. Lymphangiogenesis and lymphangiodysplasias: from molecular to clinical lymphology. *Microscop Res Tech.* 2001;55:122-145.
13. Casley-Smith JR. Lymph and lymphatics. In: Kaley G, Altura BM, eds. *Microcirculation*. Vol 1. Baltimore: University Park Press; 1977:423-502.
14. Leak LV. Physiology of the lymphatic system. In: Abramson DI, Dobrin PB, eds. *Blood Vessels and Lymphatics in Organ Systems*. Orlando, FL: Academic Press; 1984:134-164.
15. Way D, Hendrix M, Witte MH, et al. Lymphatic endothelial cell line (CH3) from a recurrent retroperitoneal lymphangioma. *In Vitro Cell Dev Biol.* 1987;23:647-652.
16. Gnepp DR, Chandler W. Tissue culture of human and canine thoracic duct endothelium. *In Vitro Cell Dev Biol.* 1985;21:200-206.
17. Johnston MG, Walker MA. Lymphatic endothelial and smooth-muscle cells in tissue culture. *In Vitro.* 1984;20:566-572.
18. Breiteneder-Geleff S, Soleiman A, Amann G, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. *Am J Pathol.* 1999;154:385-394.
19. Banerji S, Ni J, Wang S-X, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. *J Cell Biol.* 1999;144:789-801.
20. Jussila L, Valtola R, Partanen TA, et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. *Cancer Res.* 1998;58:1559-1604.

21. Lymboussaki A, Partanen TA, Olofsson B, et al. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. *Am J Pathol.* 1998;153:395-403.
22. Kato S, Ji R, Miura M. Histochemical characteristics of endothelial cells of the subcapsular sinus in the monkey mesenteric lymph node. *Lymphology.* 1998;31(Suppl):39-74.
23. Jackson DG. Biology of the lymphatic marker LYVE-1 and applications in research into trafficking and lymphangiogenesis. *APMIS.* 2004;112:526-538.
24. Wetterwald A, Hoffstetter W, Cecchini MG, et al. Characterization and cloning of the e11 antigen, a marker expressed by rat osteoblasts and osteocytes. *Bone.* 1996;18:125-132.
25. Schacht V, Dadrass SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. *Am J Pathol.* 2005;166:913-921.
26. Mohammed RA, Martin SG, Gill MS, et al. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. *Am J Surg Pathol.* 2007;31:1825-1833.
27. Kato S, Yasunaga A, Uchida Y. Enzyme-histochemical method for identification of lymphatic capillaries. *Lymphology.* 1991;24:125-129.
28. Yuan L, Moyon D, Pardanaud L, et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. *Development.* 2002;129:4797-4806;
29. Cueni LN, Detmar M. New insights into the molecular control of the lymphatic vascular system and its role in disease. *J Invest Dermatol.* 2006;126:2167-2177.
30. Karpanen T, Alitalo K. Molecular biology and pathology of lymphangiogenesis. *Annu Rev Pathol Mech Dis.* 2008;3:367-397.
31. Casley-Smith JR. The lymphatic system. In: Földi M, Casley-Smith JR, eds. *Lymphangiology.* Stuttgart, Germany: FK Schattauer-Verlag; 1983:89-164.
32. Leak LV, Burke JF. Fine structure of the lymphatic capillary and the adjoining connective tissue area. *Am J Anat.* 1966;118:785-809.
33. Leak LV, Burke JF. Ultrastructural studies on the lymphatic anchoring filaments. *J Cell Biol.* 1968;36:129-149.
34. Casley-Smith JR, Florey HW. The structure of normal small lymphatics. *Q J Exp Physiol.* 1961;46:101-106.
35. Leak LV. Electron microscopic observation on lymphatic capillaries and the structural components of the connective tissue-lymph interface. *Microvasc Res.* 1970;2:361-391.
36. Mislin H. The lymphangion. In: Földi M, Casley-Smith JR, eds. *Lymphangiology.* Stuttgart, Germany: FK Schattauer-Verlag; 1983:165-175.
37. Asellius G. De Lactibus sive Lacteis Venis Quarto Vasorum Mesaraicorum Genere Novo Inuento. Mediolani: JB Biddellium; 1627.
38. Nuck A. Adenographia curiosa et uteri foemineri anatome nova. Luduni Batavorum: P. Vander Aa; 1692.
39. Mascagni P. Vasorum Lymphaticorum Corporis Humani Historia et Ichnographia. Senis: Pazzini Carli; 1787;138.
40. Sappey PC. Anatomie, physiologie, pathologie des vaisseaux lymphatiques. Paris: Adrien Delahaye; 1874.
41. von Recklinghausen F. Die Lymphgefäße und ihre Beziehungen zum Bindegewebe. Berlin: Hirschwald; 1862.
42. Gerota. Zur technik der lymphgefäßinsektion. *Anat Anzeiger.* 1896;12:216.
43. Hudack SS, McMaster PD. The lymphatic participation in human cutaneous phenomena. *J Exp Med.* 1933;57:751-774.
44. Kinmonth JB. *The lymphatic Diseases, Lymphography, and Surgery.* Baltimore: Williams & Wilkins; 1972.
45. Witte CL, Witte MH, Unger EC, et al. Advances in imaging of lymph flow disorders. *Radiographics.* 2000;20:1697-1719.
46. Bollinger A, Amann-Vesti BR. Fluorescence microlymphography: diagnostic potential in lymphedema and basis for the measurement of lymphatic pressure and flow velocity. *Lymphology.* 2007;40:52-62.
47. Kobayashi H, Kawamoto S, Choyke PL, et al. Comparison of dendrimer-based macromolecular contrast agents for

- dynamic micro-magnetic resonance lymphangiography. *Magn Res Med*. 2003;50:758-766.
48. Ogata F, Azuma R, Kikuchi M, et al. Novel lymphography using green dye for near-infrared fluorescence labeling. *Ann Plast Surg*. 2007;58:652-655.
  49. Richards G, Bernas M, Hunter R, et al. Rhodamine-based optical imaging of the murine lymphatic system. *Lymphology*. 2007;39:164-165.
  50. Hama Y, Koyama Y, Urano Y, et al. Two-color lymphatic mapping using Ig-conjugated near infrared optical probes. *J Invest Dermatol*. 2007;127:2351-2356.
  51. Goldberg BB, Merton DA, Liu J-B, et al. Contrast-enhanced sonographic imaging of lymphatic channels and sentinel lymph nodes. *J Ultrasound Med*. 2005;24:953-965.
  52. Barrett T, Choyke PL, Kobayashi H. Imaging of the lymphatic system: New horizons. *Contrast Med Mol Imaging*. 2006;1:230-245.
  53. Lohrmann C, Földi E, Bartholomä JP, et al. MR imaging of the lymphatic system: distribution and contrast enhancement of gadodiamide after intradermal injection. *Lymphology*. 2006;39:156-163.
  54. Starling EH. Physiologic factors involved in the causation of dropsy. *Lancet*. 1896;1:1267-1270.
  55. Starling EH. The Fluids of the Body. The Herter Lectures. Chicago: WT Keener; 1909:81.
  56. Hall JG, Morris B, Woolley G. Intrinsic rhythmic propulsion of lymph in the unanaesthetised sheep. *J Physiol (Lond)*. 1965;180:336-349.
  57. Mawhinney HJD, Roddie IC. Spontaneous activity in isolated bovine mesenteric lymphatics. *J Physiol*. 1973;229:339-348.
  58. Olszewski WL, Engeset A. Intrinsic contractility of prenodal lymph vessels and lymph flow in the human leg. *Am J Physiol*. 1980;239:H775-H783.
  59. Gnepp DR. Lymphatics. In: Staub NC, Taylor AE, eds. *Edema*. New York: Raven Press; 1984:263-298.
  60. McHale NG, Roddie IC. The effect of transmural pressure on pumping activity in isolated bovine lymphatic vessels. *J Physiol*. 1976;261:255-269.
  61. McHale NG, Roddie IC. The effect of intravenous adrenaline and noradrenaline infusion on peripheral lymph flow in the sheep. *J Physiol*. 1983;341:517-526.
  62. Johnston MG. The intrinsic lymph pump: progress and problems. *Lymphology*. 1989;22:116-122.
  63. Sinzinger H, Kaliman J, Mannheimer E. Regulation of human lymph contractility by prostaglandins and thromboxane. *Lymphology*. 1984;17:43-45.
  64. Johnston MG, Gordon JL. Regulation of lymphatic contractility by arachidonate metabolites. *Nature*. 1981;293:294-297.
  65. Johnston MG, Feuer C. Suppression of lymphatic vessel contractility with inhibitors of arachidonic acid metabolism. *J Pharmacol Exp Ther*. 1983;226:603-607.
  66. Ohhashi T, Kawai Y, Azuma T. The response of lymphatic smooth muscles to vasoactive substances. *Pflügers Arch*. 1978;375:183-188.
  67. McHale NG, Roddie IC, Thornbury K. Nervous modulation of spontaneous contractions in bovine mesenteric lymphatics. *J Physiol*. 1980;309:461-472.
  68. McGeown JG, McHale NG, Thornbury K. Popliteal efferent lymph flow response to stimulation of the sympathetic chain in the sheep. *J Physiol*. 1987;387:55P.
  69. Sjöberg T, Alm P, Andersson KE, et al. Contractile response in isolated human groin lymphatics. *Lymphology*. 1987;20:152-160.
  70. Sjöberg T, Steen S. Contractile properties of lymphatics from the human lower leg. *Lymphology*. 1991;24:16-21.
  71. Swemer RL, Foglia VG. Fatal loss of plasma volume after lymph heart destruction in toads. *Proc Soc Exp Biol Med*. 1943;53:14-17.
  72. Conklin R. The formation and circulation of lymph in the frog: I. The rate of lymph production. *Am J Physiol*. 1930;95:79-90.

73. Kinmonth JB, Wolfe JH. Fibrosis in the lymph nodes in primary lymphedema. *Ann R Coll Surg*. 1980;62:344-354.
74. Olszewski W. On the pathomechanism of development of post surgical lymphedema. *Lymphology*. 1973;6:35-51.
75. Witte MH, Jones K, Wilting J, et al. Structure-function relationships in the lymphatic system and implications for cancer biology. *Cancer Metastasis Rev*. 2006;25:159-184.
76. Zweifach BW, Prather JW. Micromanipulation of pressure in terminal lymphatics in the mesentery. *Am J Physiol*. 1975;228:1326-1335.
77. Pippard C, Roddie IC. Resistance in the sheep's lymphatic system. *Lymphology*. 1987;20:230-234.
78. Olszewski WL. Lymph pressure and flow in limbs. In: Olszewski WL, ed. *Lymph Stasis: Pathophysiology, Diagnosis and Treatment*. Boca Raton, FL: CRC Press; 1991:109-156.
79. McHale NG. Influence of autonomic nerves on lymph flow. In: Olszewski WL, ed. *Lymph Stasis: Pathophysiology, Diagnosis and Treatment*. Boca Raton, FL: CRC Press; 1991:85-107.
80. Pippard C, Roddie IC. Comparison of fluid transport systems in lymphatics and veins. *Lymphology*. 1987;20:224-229.
81. Yoffey JM, Courtice FC. *Lymphatics, Lymph, and Lymphoid Tissue*. London: Butler & Tanner; 1956.
82. Morris B, Courtice FC. Cells and immunoglobulins in lymph. *Lymphology*. 1977;10:62-70.
83. Courtice FC. Lymph and plasma proteins: Barriers to their movement throughout the extracellular fluid. *Lymphology*. 1971;4:9-17.
84. Witte MH, Horowitz L, Dumont AE. Use of thoracic duct cannulation in the diagnosis of tuberculosis enteritis. *N Engl J Med*. 1963;268:1125-1126.
85. Cole WR, Witte MH, Witte CL. Lymph culture: a new tool for the investigation of human infections. *Ann Surg*. 1969;170:705-714.
86. Witte MH, Witte CL. Ignorance in infectious diseases: the case of AIDS, Kaposi sarcoma, and lymphology. *Lymphology*. 2000;33:95-121.
87. Abernethy NJ, Hay JB. The recirculation of lymphocytes from blood to lymph: physiological considerations and molecular mechanisms. *Lymphology*. 1992;25:1-30.
88. Folkman J, Haudenschild C. Angiogenesis in vitro. *Nature*. 1980;288:551-556.
89. Folkman J. Clinical applications of research on angiogenesis. *N Engl J Med*. 1995;26:1757-1763.
90. Witte MH, Witte CL. Lymphatics and blood vessels, lymphangiogenesis and hemangiogenesis. From cell biology to clinical medicine. *Lymphology*. 1987;20:257-266.
91. Witte MH, Dellinger MT, Bernas MJ, et al. Hem/lymph vasculogenesis, -angiogenesis, -angiogenitorogenesis, and tumor hem/lymphangiogenesis: need for terminology adjustment. In: Leong S, ed. *Cancer Metastasis: From Local Proliferation to Distant Sites through the Lymphovascular System*. Current Clinical Oncology Series. New York: Humana Press; 2009:77-92.
92. Clark ER, Clark EL. Observations on the new growth of lymphatic vessels as seen in transparent chambers introduced into the rabbit's ear. *Am J Anat*. 1932;51:49-87.
93. Pullinger DB, Florey HW. Proliferation of lymphatics in inflammation. *J Pathol Bacteriol*. 1937;45:157-170.
94. Reichert FL. The regeneration of the lymphatics. *Arch Surg*. 1926;13:871-881.
95. Casley-Smith JR. The regenerative capacity of the lymphovascular system. In: Fädi M, Casley-Smith JR, eds. *Lymphangiology*. Stuttgart, Germany: FK Schattauer-Verlag; 1983:276.
96. Bellman S, Odén B. Regeneration of surgically divided lymph vessels: an experimental study on the rabbit's ear. *Acta Chir Scand*. 1959;116:99-117.
97. Odén B. A microlymphangiographic study of experimental wound healing by second intention. *Acta Chir Scand*. 1960;120:100-114.
98. Magari S, Asano S. Regeneration of the deep cervical lymphatics—light and electron microscopic observations. *Lymphology*. 1978;11:57-61.

99. Magari S. Comparison of fine structure of lymphatics and blood vessels in normal conditions and during embryotic development and regeneration. *Lymphology*. 1987;20:189-195.
100. Leak L. Interaction of the peritoneal cavity to intraperitoneal stimulation: a peritoneal nodal system to monitor cellular and extracellular events in the formation of granulation tissue. *Am J Anat*. 1985;173:171-183.
101. Jaffe EA. Cell biology of endothelial cells. *Hum Pathol*. 1987;18:234-239.
102. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. *Br J Radiol*. 1993;66:181-196.
103. Junghans BM, Collin HB. Limbal lymphangiogenesis after corneal injury: an autoradiographic study. *Curr Eye Res*. 1989;8:91-100.
104. Travella W, Dugan MC. Endothelial interactions. In: Nishi M, Uchino S, Yabuki S, eds. *Progress in Lymphology XII*. Amsterdam: Elsevier; 1990:269.
105. Bowman C, Witte MH, Witte CL, et al. Cystic hygroma reconsidered: Hamartoma or neoplasm? Primary culture of an endothelial cell line from a massive cervicomediastinal cystic hygroma with bony lymphangiomatosis. *Lymphology*. 1984;17:15-22.
106. Hirakawa S, Hong Y-K, Harvey N, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. *Am J Pathol*. 2003;162:575-586.
107. Leak LV, Jones M. Lymphatic endothelium isolation, characterization and long-term culture. *Anat Rec*. 1993;236:641-652.
108. Nicosia RF. Angiogenesis and the formation of lymphatic-like channels in cultures of thoracic duct. *In Vitro Cell Dev Biol*. 1987;23:167-174.
109. Witte MH, Way DL, Witte CL, Bernas M. Lymphangiogenesis: mechanisms, significance and clinical implications. In: Goldberg IV, Rosen EM, eds. *Regulation of Angiogenesis*. Basel: Birkhäuser; 1997:65.
110. Greenlee R, Hoyme H, Witte M, et al. Developmental disorders of the lymphatic system. *Lymphology*. 1993;26:156-168.
111. Witte MH, Erickson R, Reiser FA, Witte CL. Genetic alterations in lymphedema. *Phlebolympology*. 1997;16:19-25.
112. Northup KA, Witte MH, Witte CL. Syndromic classification of hereditary lymphedema. *Lymphology*. 2003;36:162-189.
113. Karkkainen MJ, Ferrell RE, Lawrence EC, et al. Missense mutations interfere with vascular endothelial growth factor receptor-3 signaling in primary lymphedema. *Nat Genet*. 2000;25:153-159.
114. Irrthum A, Devriend K, Chitayat D, et al. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasis. *Am J Hum Genet*. 2003;72:1470-1478.
115. Fang J, Dagenais SL, Erickson RP, et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. *Am J Hum Genet*. 2000;67:1382-1388.
116. Kriederman BM, Myloyde TL, Witte MH, et al. Foxc2 haploinsufficient mice are a model for human autosomal dominant lymphedema-distichiasis syndrome. *Hum Mol Genet*. 2003;12:1179-1185.
117. Dellinger MT, Hunter RJ, Bernas MJ, et al. Chy-3 mice are Vegfc haploinsufficient and exhibit defective dermal superficial to deep lymphatic transition and dermal lymphatic hypoplasia. *Dev Dyn*. 2007;236:2346-2355.
118. Dellinger MT, Hunter R, Bernas M, et al. Defective remodeling and maturation of the lymphatic vasculature in angiopoietin-2 deficient mice. *Dev Bio*. 2008;319:309-320.
119. Blalock A, Robinson CS, Cunningham RS, Gray ME. Experimental studies on lymphatic blockade. *Arch Surg*. 1937;34:1049-1071.
120. Halsted WS. The swelling of the arm after operations for cancer of the breast: elephantiasis chirurgica: its cause and prevention. *Johns Hopkins Hosp Bull*. 1921;32:309-313.
121. Drinker CK, Field MJ, Homans J. The experimental production of edema and elephantiasis as a result of lymphatic obstruction. *Am J Physiol*. 1934;108:509-520.
122. Danese CA, Georgalas-Bertakis M, Morales LE. A model of chronic postsurgical lymphedema in dogs' limbs. *Surgery*. 1968;64:814-820.

123. Clodius L, Altorfer J. Experimental chronic lymphostasis of extremities. *Folia Angiol.* 1977;25:137-140.
124. Lee-Donaldson L, Witte MH, Bernas M, et al. Refinement of a rodent model of peripheral lymphedema. *Lymphology.* 1999;32:111-117.
125. Kanter MA, Slavin SA, Kaplan WK. An experimental model for chronic lymphedema. *Plast Reconstr Surg.* 1999;85:573-580.
126. Case T, Leis B, Witte M, et al. Vascular abnormalities in experimental and human lymphatic filariasis. *Lymphology.* 1991;24:174-183.
127. Földi M. Lymphoedema. In: Földi M, Casley-Smith JR, eds. *Lymphangiology*. Stuttgart, Germany: FK Schattauer-Verlag; 1983:668-670.
128. Cruikshank W. *The Anatomy of the Absorbing Vessels*. 2nd ed. London: G Nicol Pall Mall; 1790.
129. Busey SC. *Congenital Occlusion and Dilation of Lymph Channels*. New York: William Wood & Co; 1878.
130. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. *Dev Cell.* 2002;3:411-423.
131. Edwards EA. Recurrent febrile episodes and lymphedema. *JAMA.* 1963;184:858-862.
132. Sasisekhar B, Aparna M, Augustin DJ, et al. Diminished monocyte function in microfilaremic patients with lymphatic filariasis and its relationship to altered lymphoproliferative responses. *Infect Immun.* 2005;73:3385-3393.
133. Casley-Smith JR, Casley-Smith JR. *High-Protein Oedemas and the Benzo-pyrones*. Sydney, Australia: JB Lippincott; 1986:126-152.
134. Ehrich WE, Seifter J, Album HE, Begamy AJ. Heparin and heparinocytes in elephantiasis scroti. *Proc Soc Exp Biol Med.* 1949;70:183.
135. Dumont AE, Fazzini E, Jamal S. Metachromatic cells in filarial lymphoedema. *Lancet.* 1983;2:1021.
136. Gaffney RM, Casley-Smith JR. Lymphedema without lymphostasis: excess proteins as the cause of chronic inflammation. In: *Progress in Lymphology. Proceedings of the VII International Congress*. Prague: Avicenum; 1981:213-216.
137. Poslethwaite AE, Keski-Oja J, Balian G, Kang AH. Induction of fibroblast chemotaxis by fibronectin. *J Exp Med.* 1981;153:494-499.
138. Földi M. Insufficiency of lymph flow. In: Földi M, Casley-Smith JR, eds. *Lymphangiology*. Stuttgart, Germany: FK Schattauer-Verlag; 1983:195.
139. Harvey NL, Srinivasan RS, Dillard ME, et al. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. *Nat Genet.* 2005;37:1072-1081.
140. Schneider M, Conway EM, Carmeliet P. Lymph makes you fat. *Nat Genet.* 2005;37:1023-1024.
141. Prins JB, O'Rahilly S. Regulation of adipose cell number in man. *Clin Sci (London).* 1997;92:3-11.
142. Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. *J Am Acad Dermatol.* 2007;56:901-916.
143. Tavakkolizadeh A, Wolfe KQ, Kangesu L. Cutaneous lymphatic malformation with secondary fat hypertrophy. *Br J Plast Surg.* 2001;54:367-369.
144. Boos AM, Fiedler U, Földi E, et al. The ratio of lymphatic and blood endothelial cells in a medium conditioned with preadipocytes. *Lymphology.* 2007;40(Suppl):42-48.
145. Nougues J, Reyne Y, Duplor JP. Differentiation of rabbit adipocyte precursors in primary culture. *Int J Obes.* 1988;12:321-333.
146. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. *Science.* 1999;184:143-147.
147. Brorson H, Svensson H. Complete reduction of lymphedema of the arm by liposuction after breast cancer. *Scand J Plast Reconstr Surg Hand Surg.* 1997;31:137-143.
148. Stewart FW, Treves N. Lymphangiosarcoma in post mastectomy lymphedema: a report of six cases in elephantiasis



- chirurgica. *Cancer*. 1948;1:64-81.
149. Unruh H, Robertson DI, Karasewich E. Post mastectomy lymphangiosarcoma. *Can J Surg*. 1979;22:586-590.
  150. Woodward AH, Ivins JC, Soule EH. Lymphangiosarcoma arising in chronic lymphedematous extremities. *Cancer*. 1972;30:562-572.
  151. Dorfman RF. Kaposi's sarcoma: Evidence supporting its origin from the lymphatic system. *Lymphology*. 1988;21:45-52.
  152. Witte MH, Stuntz M, Witte CL. Kaposi's sarcoma: a lymphologic perspective. *Int J Dermatol*. 1989;28:561-570.
  153. Witte MH, Fiala M, McNeill GC, et al. Lymphangioscintigraphy in AIDS-associated Kaposi sarcoma. *AJR Am J Roentgenol*. 1990;155:311-315.
  154. Beckstead JH, Wood GS, Fletcher V. Evidence for the origin of Kaposi's sarcoma from lymphatic endothelium. *Am J Pathol*. 1985;119:294-300.
  155. Folkman J. Tumor angiogenesis: therapeutic implications. *N Eng J Med*. 1971;285:1182-1186.
  156. Zwaans BM, Bielenberg DR. Potential therapeutic strategies for lymphatic metastasis. *Microvasc Res*. 2007;74:145-158.
  157. Tobler NE, Detmar M. Tumor and lymph node lymphangiogenesis—impact on cancer metastasis. *J Leukoc Biol*. 2006;80:691-696.
  158. Witte M, Witte C. On tumor (and other) lymphangiogenesis. *Lymphology*. 1997;30:1-2.
  159. Sleeman JP. The relationship between tumors and the lymphatics: what more is there to know? *Lymphology*. 2006;39:62-68.
  160. Kirk RM. Capillary filtration rates in normal and lymphedematous legs. *Clin Sci*. 1964;27:363.

## 第 13 章

1. Beckman JA, Creager MA. Clinical examination of the vascular system. In: Hobson RW, Wilson SE, Veith FJ, eds. *Vascular Surgery: Principles and Practice*. 3rd ed, revised and expanded. New York, NY: Marcel Dekker; 2004:103-112.
2. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery,\* Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *Circulation*. 2005;113:e463-e654.
3. Lerich R. De la resection du carrefour aortico-iliaque avec double sympathectomie lombaire pour thrombose arteritique de l'aorte. Le syndrome de l'obliteration termino-aortique par arterite. *Presse Med*. 1940;48:601.
4. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease. Associated clinic characteristic and functional impairment. *JAMA*. 2001;286:1599-1606.
5. Newman AB, Naydeck BL, Sutton-Tyrrell K, et al. For the Cardiovascular Study Research Group. The role of comorbidity in the assessment of intermittent claudication in older adults. *J Clin Epidemiol*. 2001;54:294-300.
6. Wang JC, Criqui MH, Denenber JO, et al. Exertional leg pain in patients with and without peripheral arterial disease. *Circulation*. 2005;112:3501-3508.
7. Turnipseed WD. Popliteal entrapment syndrome. *J Vasc Surg*. 2002;35:910-915.
8. Turnipseed WD. Clinical review of patients treated for atypical claudication: a 28-year experience. *J Vasc Surg*. 2004;40:79-85.
9. Gibbs MB, English JC, Zirwas MJ. Livedo reticularis: an update. *J Am Acad Dermatol*. 2005;52:1009-1019.
10. Gloviczki P, Wahner HW. Clinical diagnosis and evaluation of lymphedema. In: Rutherford R, ed. *Vascular Surgery*. 6th ed. Philadelphia, PA: Elsevier Saunders; 2005:2396-2415.

11. Miller TA, Turk AE. The lymphatic system. In: Hobson RW, Wilson SE, Veith FJ, eds. *Vascular Surgery: Principles and Practice*. 3rd ed, revised and expanded. New York, NY: Marcel Dekker; 2004:1037-1048.
12. Schirger A, Peterson LFA. Lymphedema. In: Juergens JL, Spittell JA, Fairbairn JF, eds. *Peripheral Vascular Diseases*. 5th ed. Philadelphia, PA: WB Saunders; 1980:823-851.
13. Homans J. Thrombophlebitis of the lower extremities. *Ann Surg*. 1928;87:641-651.
14. Porter JM, Moneta GL. Reporting standards in venous disease. An update. International Consensus Committee on Chronic Venous Disease. *J Vasc Surg*. 1995;21:635-645.

## 第 14 章

1. Hodgson KJ, Sumner DS. Noninvasive assessment of lower extremity arterial disease. *Ann Vasc Surg*. 1988;2:174-184.
2. Newman AB, Sutton-Tyrrell K, Vogt MT, et al. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. *JAMA*. 1993;270:487-489.
3. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. *Atherosclerosis*. 1991;87:119-128.
4. Carter SA. Clinical measurement of systolic pressures in limbs with arterial occlusive disease. *JAMA*. 1969;207:1869-1874.
5. Beckman JA, Higgins CO, Gerhard-Herman M. Automated oscillometric determination of the ankle-brachial index provides accuracy necessary for office practice. *Hypertension*. 2006;47:35-38.
6. Baker JD, Dix DE. Variability of Doppler ankle pressures with arterial occlusive disease: an evaluation of ankle index and brachial-ankle pressure gradient. *Surgery*. 1981;89:134-137.
7. Lijmer JG, Hunink MG, van den Dungen JJ, et al. ROC analysis of noninvasive tests for peripheral arterial disease. *Ultrasound Med Biol*. 1996;22:391-398.
8. Feigelson HS, Criqui MH, Fronek A, et al. Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of noninvasive tests in a defined population. *Am J Epidemiol*. 1994;140:526-534.
9. Schroder F, Diehm N, Kareem S, et al. A modified calculation of ankle-brachial pressure index is far more sensitive in the detection of peripheral arterial disease. *J Vasc Surg*. 2006;44:531-536.
10. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *Circulation*. 2006;113:e463-e465.
11. Flanagan DP, Ballard JL, Robinson D, et al. Duplex ultrasound of the superficial femoral artery is a better screening tool than ankle-brachial index to identify at risk patients with lower extremity atherosclerosis. *J Vasc Surg*. 2008;47:789-793.
12. Jelnes R, Gaardsting O, Hougaard Jensen K, et al. Fate in intermittent claudication: outcome and risk factors. *Br Med J (Clin Res Ed)* 1986;293:1137-1140.
13. Aquino R, Johnnides C, Makaroun M, et al. Natural history of claudication: long-term serial follow-up study of 1244 claudicants. *J Vasc Surg*. 2001;34:962-970.
14. Feringa HH, Karagiannis SE, Schouten O, et al. Prognostic significance of declining ankle-brachial index values in patients with suspected or known peripheral arterial disease. *Eur J Vasc Endovasc Surg*. 2007;34:206-213.
15. Turnipseed WD. Clinical review of patients treated for atypical claudication: a 28-year experience. *J Vasc Surg*. 2004;40:79-85.
16. Turnipseed WD, Pozniak M. Popliteal entrapment as a result of neurovascular compression by the soleus and plantaris

- muscles. *J Vasc Surg*. 1992;15:285-293; discussion 93-94.
17. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans: an AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee. *J Clin Hypertens (Greenwich)*. 2005;7:102-109.
  18. Gale SS, Scissons RP, Salles-Cunha SX, et al. Lower extremity arterial evaluation: are segmental arterial blood pressures worthwhile? *J Vasc Surg*. 1998;27:831-838; discussion 838-839.
  19. Ramsey DE, Manke DA, Sumner DS. Toe blood pressure. A valuable adjunct to ankle pressure measurement for assessing peripheral arterial disease. *J Cardiovasc Surg (Torino)*. 1983;24:43-48.
  20. DePalma RG, Olding M, Yu GW, et al. Vascular interventions for impotence: lessons learned. *J Vasc Surg*. 1995;21:576-584; discussion 84-85.
  21. Strandness DE Jr, Schultz RD, Sumner DS, et al. Ultrasonic flow detection. A useful technic in the evaluation of peripheral vascular disease. *Am J Surg*. 1967;113:311-320.
  22. Bascom PA, Johnston KW, Cobbold RS, et al. Defining the limitations of measurements from Doppler spectral recordings. *J Vasc Surg*. 1996;24:34-44; discussion 44-45.
  23. Thiele BL, Hutchinson KJ, Greene FM, et al. Pulsed Doppler waveform patterns produced by smooth stenosis in the dog thoracic aorta. In: Taylor DM, Stevens AL, eds. *Blood Flow, Theory and Practice*. San Diego, MA: Academic Press; 1983:85-104.
  24. Thiele BL, Bandyk DF, Zierler RE, et al. A systematic approach to the assessment of aortoiliac disease. *Arch Surg*. 1983;118:477-481.
  25. Johnston KW, Taraschuk I. Validation of the role of pulsatility index in quantitation of the severity of peripheral arterial occlusive disease. *Am J Surg*. 1976;131:295-297.
  26. Strandness DE Jr, Bell JW. Peripheral vascular disease: diagnosis and objective evaluation using a mercury strain gauge. *Ann Surg*. 1965;161(Suppl 4):4-35.
  27. Raines JK. The pulse volume recorder in peripheral arterial disease. In: Bernstein EF, ed. *Noninvasive Diagnostic Techniques in Vascular Disease*. St. Louis, MO: CV Mosby; 1985:513-544.
  28. Raines JK, Darling RC, Buth J, et al. Vascular laboratory criteria for the management of peripheral vascular disease of the lower extremities. *Surgery*. 1976;79:21-29.
  29. Rutherford RB, Lowenstein DH, Klein MF. Combining segmental systolic pressures and plethysmography to diagnose arterial occlusive disease of the legs. *Am J Surg*. 1979;138:211-218.
  30. Abularrage CJ, Sidawy AN, Aidinian G, et al. Evaluation of the microcirculation in vascular disease. *J Vasc Surg*. 2005;42:574-581.
  31. Rich K. Transcutaneous oxygen measurements: implications for nursing. *J Vasc Nurs*. 2001;19:55-59; quiz 60-61.
  32. Quigley FG, Faris IB. Transcutaneous oxygen tension measurements in the assessment of limb ischaemia. *Clin Physiol*. 1991;11:315-320.
  33. Rich K. Effects of leg and body position on transcutaneous oxygen measurements in healthy subjects and subjects with peripheral artery disease after lower-extremity arterial revascularization: a pilot study. *J Vasc Nurs*. 2002;20:125-135; quiz 36-37.
  34. Moosa HH, Peitzman AB, Makaroun MS, et al. Transcutaneous oxygen measurements in lower extremity ischemia: effects of position, oxygen inhalation, and arterial reconstruction. *Surgery*. 1988;103:193-198.
  35. Harward TR, Volny J, Golbranson F, et al. Oxygen inhalation-induced transcutaneous PO<sub>2</sub> changes as a predictor of amputation level. *J Vasc Surg*. 1985;2:220-227.
  36. Humeau A, Steenbergen W, Nilsson H, et al. Laser Doppler perfusion monitoring and imaging: novel approaches. *Med Biol Eng Comput*. 2007;45:421-435.
  37. Castronuovo JJ Jr, Adera HM, Smiell JM, et al. Skin perfusion pressure measurement is valuable in the diagnosis of critical

limb ischemia. *J Vasc Surg.* 1997;26:629-637.

## 第 15 章

1. Barber FE, Baker DW, Strandness DEJ, et al. Duplex scanner II: For simultaneous imaging of artery tissues and flow. 1974 Ultrasonic Symposium Proceedings. *IEEE.* 1974; #74 CH0 896-ISU:744-748.
2. Blackshear WM, Phillips DJ, Chikos PM, et al. Carotid artery velocity patterns in normal and stenotic vessels. *Stroke.* 1980;11:67-71.
3. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. *JAMA.* 1995;273:1421-1428.
4. Moneta GL, Edwards JM, Chitwood RW, et al. Correlation of North American Symptomatic Carotid Endarterectomy Trial (NASCET) angiographic definition of 70% to 99% internal carotid artery stenosis with duplex scanning. *J Vasc Surg.* 1993;17:152-159.
5. Faught WE, Mattos MA, van Bemmelen PS, et al. Color-flow duplex scanning of carotid arteries: new velocity criteria based on receiver operator characteristic analysis for threshold stenoses used in the symptomatic and asymptomatic carotid trials. *J Vasc Surg.* 1994;19:818-828.
6. Neale ML, Chambers JL, Kelly AT, et al. Reappraisal of duplex criteria to assess significant carotid stenosis with special reference to reports from the North American Symptomatic Carotid Endarterectomy Trial and the European Carotid Surgery Trial. *J Vasc Surg.* 1994;20:642-649.
7. Moneta GL, Edwards JM, Papanicolaou G, et al. Screening for asymptomatic internal carotid artery stenosis: duplex criteria for discriminating 60% to 99% stenosis. *J Vasc Surg.* 1995;21:989-994.
8. Fillinger MF, Baker RJ, Zwolak RM, et al. Carotid duplex criteria for a 60% or greater angiographic stenosis: variation according to equipment. *J Vasc Surg.* 1996;24:856-864.
9. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. *N Engl J Med.* 1991;325:445-453.
10. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *N Engl J Med.* 1998;339:1415-1425.
11. Grant EG, Benson CB, Moneta GL, et al. Carotid artery stenosis: Gray-scale and Doppler US diagnosis. Society of Radiologists in Ultrasound consensus conference. *Radiology.* 2003;229:340-346.
12. Back MR, Wilson JS, Rushing G, et al. Magnetic resonance angiography is an accurate imaging adjunct to duplex ultrasound in patient selection for carotid endarterectomy. *J Vasc Surg.* 2000;32:429-440.
13. Primozich JC. Extracranial arterial system. In: Strandness DE, ed. *Duplex Scanning in Vascular Disorders.* Philadelphia, PA: Lippincott Williams & Wilkins; 2002:191-231.
14. Verlato F, Grego F, Avruscio GP, et al. Diagnosis of high-grade stenosis of innominate artery. *Angiology.* 1993;44:845-851.
15. Abou-Zamzam AM Jr, Moneta GL, Edwards JM, et al. Is a single preoperative duplex scan sufficient for planning bilateral carotid endarterectomy? *J Vasc Surg.* 2000;31:282-288.
16. Fujitani RM, Mills JL, Wang LM, et al. The effect of unilateral internal carotid artery occlusion upon contralateral duplex study: Criteria for accurate interpretation. *J Vasc Surg.* 1992;16:459-468.
17. Welch HJ, Murphy MC, Raftery KB, et al. Carotid duplex with contralateral disease: the influence of vertebral artery blood flow. *Ann Vasc Surg.* 2000;14:82-88.
18. Bendick PJ, Jackson VP. Evaluation of the vertebral arteries with duplex sonography. *J Vasc Surg.* 1986;3:523-530.
19. Bartels E, Flugel KA. Evaluation of extracranial vertebral artery dissection with duplex color-flow imaging. *Stroke.* 1996;27:290-295.

20. Roth SM, Back MR, Bandyk DF, et al. A rational algorithm for duplex surveillance following carotid endarterectomy. *J Vasc Surg.* 1999;30:453-460.
21. Dawson DL, Zierler RE, Kohler TR. Role of arteriography in the preoperative evaluation of carotid artery disease. *Am J Surg.* 1991;16:619-624.
22. Wagner WH, Treiman RL, Cossman DV, et al. The diminishing role of diagnostic arteriography in carotid artery disease: duplex scanning as definitive preoperative study. *Ann Vasc Surg.* 1991;5:105-110.
23. Mattos MA, Hodgson KJ, Faught WE, et al. Carotid endarterectomy without angiography: Is color-flow duplex scanning insufficient? *Surgery.* 1994;116:776-783.
24. Muto PM, Welch HJ, Mackey WC, et al. Evaluation of carotid artery stenosis: Is duplex ultrasonography sufficient? *J Vasc Surg.* 1996;24:17-24.
25. Schwartz SW, Chambless LE, Baker WH, et al. Consistency of Doppler parameters in predicting arteriographically confirmed carotid stenosis. *Stroke.* 1997;28:343-347.
26. Spadone DP, Barkmeier LD, Hodgson KJ, et al. Contralateral internal carotid artery stenosis or occlusion: Pitfall of correct ipsilateral classification: a study performed with color-flow imaging. *J Vasc Surg.* 1990;11:642-649.
27. Fujitani RM, Mills JL, Wang LM, et al. The effect of unilateral internal carotid artery occlusion upon contralateral duplex study: criteria for accurate interpretation. *J Vasc Surg.* 1992;16:459-468.
28. Welch HJ, Murphy MC, Raftery KB, et al. Carotid duplex with contralateral disease: the influence of vertebral artery blood flow. *Ann Vasc Surg.* 2000;14:82-88.
29. Bandyk DF, Kaebnick HW, Adams MB, et al. Turbulence occurring after carotid bifurcation endarterectomy: a harbinger of residual and recurrent carotid stenosis. *J Vasc Surg.* 1988;7:261-274.
30. Baker WH, Koustas G, Burke K, et al. Intraoperative duplex scanning and late carotid artery stenosis. *J Vasc Surg.* 1994;19:829-833.
31. Lipski DA, Bergamini TM, Garrison RN, et al. Intraoperative duplex scanning reduces the incidence of residual stenosis after carotid endarterectomy. *J Surg Res.* 1996;60:317-320.
32. Bandyk DF, Mills JL, Gahtan V, et al. Intraoperative duplex scanning of arterial reconstructions: fate of repaired and unrepaired defects. *J Vasc Surg.* 1994;20:426-433.
33. Ascher E, Markevich N, Kallakuri S, et al. Intraoperative carotid artery duplex scanning in a modern series of 650 consecutive primary endarterectomy procedures. *J Vasc Surg.* 2004;39:416-420.
34. Lal BK, Hobson RW 2nd, Goldstein J, et al. Carotid artery stenting: is there a need to revise ultrasound velocity criteria? *J Vasc Surg.* 2004;39:58-66.
35. Armstrong PA, Bandyk DF, Johnson BL, et al. Duplex scan surveillance after carotid angioplasty and stenting: a rational definition of stent stenosis. *J Vasc Surg.* 2007;46:460-466.
36. Aaslid R, Markwalder TM, Nornes H. Noninvasive transcranial Doppler ultrasound recording of flow velocity in basal cerebral arteries. *J Neurosurg.* 1982;57:769-774.
37. Lee MT, Piomelli S, Granger S, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. *Blood.* 2006;108:847-852.
38. Kassab MY, Majid A, Farooq MU, et al. Transcranial Doppler: An introduction for primary care physicians. *J Am Board Fam Med.* 2007;20:67-71.
39. Gaunt ME, Martin PJ, Smith JL, et al. Clinical relevance of intraoperative embolization detected by transcranial Doppler ultrasonography during carotid endarterectomy: a prospective study of 100 patients. *Br J Surg.* 1994;81:1435-1439.
40. Ackerstaff RG, Jansen C, Moll FL, et al. The significance of microemboli detection by means of transcranial Doppler ultrasonography monitoring in carotid endarterectomy. *J Vasc Surg.* 1995;21:963-969.
41. Arnold M, Sturzenegger M, Schaffler L, et al. Continuous intraoperative monitoring of middle cerebral artery blood flow velocities and electroencephalography during carotid endarterectomy: a comparison of the two methods to detect cerebral

ischemia. *Stroke*. 1997;28:1345-1350.

42. Cao P, Giordano G, Zannetti S, et al. Transcranial Doppler monitoring during carotid endarterectomy: is it appropriate for selecting patients in need of a shunt? *J Vasc Surg*. 1997;26:973-980.
43. Spencer MP. Transcranial Doppler monitoring and causes of stroke from carotid endarterectomy. *Stroke*. 1997;28:685-691.
44. Smith WB. Transcranial Doppler monitoring for carotid endarterectomy. In: Strandness DE Jr, ed. *Duplex Scanning in Vascular Surgery*. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:244-248.
45. Jorgensen LG, Schroeder TV. Defective cerebrovascular autoregulation after carotid endarterectomy. *Eur J Vasc Surg*. 1993;7:370-379.
46. Hansen C, Sprengers AM, Moll FL, et al. Prediction of intracerebral hemorrhage after carotid endarterectomy by clinical criteria and intraoperative transcranial Doppler monitoring: results of 233 operations. *Eur J Vasc Surg*. 1994;8:220-225.
47. Newell DW, Winn HR. Transcranial Doppler in cerebral vasospasm. *Neurosurg Clin North Am*. 1990;1:319-328.
48. van Zuilen EV, Moll FL, Vermeulen FEE, et al. Detection of cerebral microemboli by means of transcranial Doppler monitoring before and after carotid endarterectomy. *Stroke*. 1995;26:210-213.
49. Jager KA, Phillips DJ, Martin RL, et al. Noninvasive mapping of lower limb arterial lesions. *Ultrasound Med Biol*. 1985;11:515-521.
50. Kohler TR, Nance DR, Cramer MM, et al. Duplex scanning for diagnosis of aortoiliac and femoropopliteal disease: a prospective study. *Circulation*. 1987;76:1074-1080.
51. Cossman DV, Ellison JE, Wagner WH, et al. Comparison of contrast arteriography to arterial mapping with color-flow duplex imaging in the lower extremities. *J Vasc Surg*. 1989;10:522-529.
52. Kohler TR, Andros G, Porter JM, et al. Can duplex scanning replace arteriography for lower extremity arterial disease? *Ann Vasc Surg*. 1990;4:280-287.
53. Grassbaugh JA, Nelson PR, Rzucidlo EM, et al. Blinded comparison of preoperative duplex ultrasound scanning and contrast arteriography for planning revascularization at the level of the tibia. *J Vasc Surg*. 2003;37:1186-1190.
54. Wilson YG, George JK, Wilkins DC, et al. Duplex assessment of run-off before femorocrural reconstruction. *Br J Surg*. 1997;84:1360-1363.
55. Currie IC, Jones AJ, Wakeley CJ, et al. Non-invasive aortoiliac assessment. *Eur J Vasc Endovasc Surg*. 1995;9:24-28.
56. Proia RR, Walsh DB, Nelson PR, et al. Early results of infragenicular revascularization based solely on duplex arteriography. *J Vasc Surg*. 2001;33:1165-1170.
57. Moneta GL, Yeager RA, Antonovic R, et al. Accuracy of lower extremity arterial duplex mapping. *J Vasc Surg*. 1992;15:275-284.
58. Legemate DA, Teeuwen C, Hoeneveld H, et al. Value of duplex scanning compared with angiography and pressure measurement in the assessment of aortoiliac arterial lesions. *Br J Surg*. 1991;78:1003-1008.
59. Paulson EK, Kliever MA, Hertzberg BS, et al. Color Doppler sonography of groin complications following femoral artery catheterization. *AJR Am J Roentgenol*. 1995;165:439-444.
60. Liao C, Ho F, Chen M, et al. Treatment of iatrogenic femoral artery pseudoaneurysm with percutaneous thrombin injection. *J Vasc Surg*. 1997;26:18-23.
61. Kang SS, Labropoulos N, Mansour A, et al. Percutaneous ultrasound guided thrombin injection: a new method for treating postcatheterization femoral pseudoaneurysms. *J Vasc Surg*. 1998;27:1032-1038.
62. Moneta GL, Yeager RA, Lee RW, et al. Noninvasive localization of arterial occlusive disease: a comparison of segmental Doppler pressures and arterial duplex mapping. *J Vasc Surg*. 1993;17:578-582.
63. Lederle FA, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med*. 2002;346:1437-1444.
64. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance of small aneurysms. The UK Small Aneurysm Trial Participants. *Lancet*. 1998;352:1649-1655.

65. Heilberger P, Schunn C, Ritter W. Postoperative color flow duplex scanning in aortic endografting. *J Endovasc Surg.* 1997;4:262-271.
66. Bendick PJ, Bove PG, Long GW, et al. Efficacy of ultrasound scan contrast agents in the noninvasive follow-up of aortic stent grafts. *J Vasc Surg.* 2003;37:381-385.
67. Sato DT, Goff CD, Gregory RT. Endoleak after aortic stent graft repair: diagnosis by color duplex ultrasound scan versus computed tomography scan. *J Vasc Surg.* 1998;28:657-663.
68. Wolf RA, Johnson BL, Hill BB. Duplex ultrasound scanning vs. computed tomographic angiography for postoperative evaluation of endovascular abdominal aortic aneurysm repair. *J Vasc Surg.* 2000;32:1142-1148.
69. Arko FR, Konstantinos A, Siedel SA, et al. Intrasc flow velocities predict sealing of type II endoleaks after endovascular abdominal aortic aneurysm repair. *J Vasc Surg.* 2003;37:8-15.
70. Norgren I, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Intersociety consensus for the management of peripheral arterial disease (TASC II). *J Vasc Surg.* 2007;45:S5A-S67A.
71. Mewissen MW, Kinney EV, Bandyk DF, et al. The role of duplex scanning versus angiography in predicting outcome after balloon angioplasty in the femoropopliteal artery. *J Vasc Surg.* 1992;15:860-866.
72. Gonsalves C, Bandyk DF, Avino A, et al. Duplex features of vein graft stenosis and the success of percutaneous transluminal angioplasty. *J Endovasc Surg.* 1999;6:66-72.
73. Ascher E, Marks NA, Hingorani AP, et al. Duplex-guided endovascular treatment of occlusive and stenotic lesions of the femoral popliteal arterial segment. a comparative study in the first 253 cases. *J Vasc Surg.* 2006;38:251-258.
74. Hatsukami TS, Primoich JF, Zierler RE, et al. Color Doppler imaging of infrainguinal arterial occlusive disease. *J Vasc Surg.* 1992;16:527-533.
75. Sensier Y, Hartshorne T, Thrush A, et al. The effect of adjacent segment disease on the accuracy of colour duplex scanning for the diagnosis of lower limb arterial disease. *Eur J Vasc Endovasc Surg.* 1996;12:238-242.
76. Moody P, Gould DA, Harris PL. Vein graft surveillance improves patency in femoropopliteal bypass. *Eur J Vasc Surg.* 1990;4:117-121.
77. Idu MM, Blankenstein JD, de Gier P, et al. Impact of a color-flow duplex surveillance program on infrainguinal vein graft patency: a five-year experience. *J Vasc Surg.* 1993;17:42-53.
78. Bandyk DF, Cato RF, Towne JB. A low flow velocity predicts failure of femoropopliteal and femorotibial bypass grafts. *Surgery.* 1985;98:799-809.
79. Mills JL, Harris EJ, Taylor LM Jr, et al. The importance of routine surveillance of distal bypass grafts with duplex scanning: a study of 379 reversed vein grafts. *J Vasc Surg.* 1990;12:379-389.
80. Johnson BL, Bandyk DF, Back MR, et al. Intraoperative duplex monitoring of infrainguinal vein bypass procedures. *J Vasc Surg.* 2000;31:678-690.
81. Chalmers RT, Hoballah JJ, Kresowik TF, et al. The impact of color duplex surveillance on the outcome of lower limb bypass with segments of arm veins. *J Vasc Surg.* 1994;19:279-288.
82. Caps MT, Cantwell-Gab K, Bergelin RO, et al. Vein graft lesions: time of onset and rate of progression. *J Vasc Surg.* 1995;22:466-475.
83. Bandyk DF, Johnson BL, Gupta AK, et al. Nature and management of duplex abnormalities encountered during infrainguinal vein bypass grafting. *J Vasc Surg.* 1996;24:430-438.
84. Gupta AK, Bandyk DF, Cheanvechai D, et al. Natural history of infrainguinal vein graft stenosis relative to bypass grafting technique. *J Vasc Surg.* 1997;25:211-225.
85. Westerband A, Mills JL, Kistler S, et al. Prospective validation of threshold criteria for intervention in infrainguinal vein grafts undergoing duplex surveillance. *Ann Vasc Surg.* 1997;11:44-48.
86. Armstrong PA, Bandyk DF, Wilson JS, et al. Optimizing infrainguinal arm vein bypass patency with duplex ultrasound surveillance and endovascular therapy. *J Vasc Surg.* 2004;40:724-730; discussion 730-731.

87. Brumberg SR, Back MR, Armstrong PA, et al. The relative importance of graft surveillance and warfarin therapy in infrainguinal prosthetic bypass failure. *J Vasc Surg.* 2007;46:1160-1166.
88. Stone PA, Armstrong PA, Bandyk DF, et al. The value of duplex surveillance after open and endovascular popliteal aneurysm repair. *J Vasc Surg.* 2005;41:936-941.
89. Zierler BK, Kirkman TR, Kraiss LW, et al. Accuracy of duplex scanning for measurement of arterial volume flow. *J Vasc Surg.* 1999;16:520-526.
90. Back MR, Bandyk DF. Current status of surveillance of hemodialysis access grafts. *Ann Vasc Surg.* 2001;15:491-502.
91. Norris CS, Pfeiffer JS, Rittgers SE, et al. Noninvasive evaluation of renal artery stenosis and renovascular resistance. *J Vasc Surg.* 1984;1:192-201.
92. Cantwell-Gab K. Renal artery evaluation. In: Strandness DE Jr, ed. *Duplex Scanning in Vascular Disease*. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:300-318.
93. Kohler TR, Zierler RE, Martin RL, et al. Noninvasive diagnosis of renal artery stenosis by ultrasonic duplex scanning. *J Vasc Surg.* 1986;4:450-456.
94. Taylor DC, Kettler MD, Moneta GL, et al. Duplex ultrasound scanning in the diagnosis of renal artery stenosis: a prospective evaluation. *J Vasc Surg.* 1988;7:363-369.
95. Hansen KJ, Tribble RW, Reavis SW, et al. Renal duplex sonography: evaluation of clinical utility. *J Vasc Surg.* 1990;12:227-236.
96. Martin RL, Nanra RS, Wlodarczyk J, et al. Renal hilar Doppler analysis in the detection of renal artery stenosis. *J Vasc Tech.* 1989;15:173-180.
97. Schwerk WB, Restrepo IK, Stellwaag M, et al. Renal artery stenosis: grading with image-directed Doppler US evaluation of renal resistive index. *Radiology.* 1994;190:785-790.
98. McLeary MS, Rouse GA. Tardus-parvus Doppler signals in the renal arteries: a sign of pediatric thoracoabdominal aortic coarctations. *Am J Radiol.* 1996;167:521-523.
99. Taylor DC, Houston TM, Anderson C, et al. Follow-up of renal and mesenteric artery revascularization with duplex ultrasonography. *Can J Surg.* 1996;39:17-20.
100. Radermacher J, Vitzthum A, Stoess B. Resistive index and improvement of renal function after correction of renal artery stenosis [abstract]. *J Am Soc Nephrol.* 1996;7:1554.
101. Radermacher J, Chavan A, Bleck J, et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. *N Engl J Med.* 2001;344:410-417.
102. Neumyer MM. Ultrasonographic assessment of renal and pancreatic transplants. *J Vasc Tech.* 1991;19:321-329.
103. Frauchiger B, Bock A, Eichlisberger R, et al. The values of different resistive parameters in distinguishing biopsy-proved dysfunction of renal allografts. *Nephrol Dial Transplant.* 1995;10:527-532.
104. Radermacher J, Mengel M, Ellis S, et al. The renal arterial resistance index and renal allograft survival. *N Engl J Med.* 2003;349:115-124.
105. Jager KA, Fortner GS, Thiele BL, et al. Noninvasive diagnosis of intestinal angina. *J Clin Ultrasound.* 1984;12:588-591.
106. Bowersox JC, Zwolak RM, Walsh DB, et al. Duplex ultrasonography in the diagnosis of celiac and mesenteric artery occlusive disease. *J Vasc Surg.* 1991;14:780-790.
107. Moneta GL, Yeager RA, Dalman R, et al. Duplex ultrasound criteria for diagnosis of splanchnic artery stenosis or occlusion. *J Vasc Surg.* 1991;14:511-520.
108. Zwolak RM, Fillingner MF, Walsh DB, et al. Mesenteric and celiac duplex scanning: a validation study. *J Vasc Surg.* 1998;27:1078-1088.
109. LaBombard FE, Musson A, Bowersox JC, et al. Hepatic artery duplex as an adjunct in the evaluation of chronic mesenteric ischemia. *J Vasc Tech.* 1992;16:7-11.
110. Moneta GL, Lee RW, Yeager RA, et al. Mesenteric duplex scanning: a blinded prospective study. *J Vasc Surg.*



1993;17:79-86.

111. Perko MJ, Just S, Schroeder TV. Importance of diastolic velocities in the detection of celiac and mesenteric artery disease by duplex ultrasound. *J Vasc Surg.* 1997;26:288-293.

## 第 16 章

1. Meissner MH, Gloviczki P, Bergan J, et al. Primary chronic venous disorders. *J Vasc Surg.* 2007;46(Suppl S):54S-67S.
2. Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. *J Vasc Surg.* 2004;40:1248-1252.
3. Danielsson G, Norgren L, Jungbeck C, et al. Global venous function correlates better than duplex derived reflux to clinical class in the evaluation of chronic venous disease. *Int Angiol.* 2003;22:177-181.
4. Bays RA, Healy DA, Atnip RG, et al. Validation of air plethysmography, photoplethysmography, and duplex ultrasonography in the evaluation of severe venous stasis. *J Vasc Surg.* 1994;20:721-727.
5. McDaniel HB, Marston WA, Farber MA, et al. Recurrence of chronic venous ulcers on the basis of clinical, etiologic, anatomic, and pathophysiologic criteria and air plethysmography. *J Vasc Surg.* 2002;35:723-728.
6. Pollack AA, Wood EH. Venous pressure in the saphenous vein at the ankle in man during exercise and changes in posture. *J Appl Physiol.* 1949;1:649-662.
7. Arnoldi CC, Greitz T, Linderholm H. Variations in cross sectional area and pressure in the veins of the normal human leg during rhythmic muscular exercise. *Acta Chir Scand.* 1966;132:507-522.
8. Nicolaides AN, Hussein MK, Szendro G, et al. The relation of venous ulceration with ambulatory venous pressure measurements. *J Vasc Surg.* 1993;17:414-419.
9. Nicolaides AN, Zukowski AJ. The value of dynamic venous pressure measurements. *World J Surg.* 1986;10:919-924.
10. Raju S, Fredericks R. Hemodynamic basis of stasis ulceration—a hypothesis. *J Vasc Surg.* 1991;13:491-495.
11. Payne SP, London NJ, Newland CJ, et al. Ambulatory venous pressure: correlation with skin condition and role in identifying surgically correctable disease. *Eur J Vasc Endovasc Surg.* 1996;11:195-200.
12. Neglen P, Raju S. Ambulatory venous pressure revisited. *J Vasc Surg.* 2000;31:1206-1213.
13. Whitney RJ. The measurement of volume changes in human limbs. *J Physiol.* 1953;121:1-27.
14. Mansour M, Sumner D. Overview: Plethysmographic techniques in the diagnosis of venous disease. In: AbuRahma A, Bergan J, eds. *Non-invasive Vascular Diagnosis*. 2nd ed. London: Springer-Verlag; 2007:375-384.
15. Barnes RW, Collicott PE, Mozersky DJ, et al. Noninvasive quantitation of maximum venous outflow in acute thrombophlebitis. *Surgery.* 1972;72:971-979.
16. Jorfeldt L, Vedung T, Forsstrom E, et al. Influence of leg position and environmental temperature on segmental volume expansion during venous occlusion plethysmography. *Clin Sci.* 2003;104:599-605.
17. Hull R, Taylor DW, Hirsh J, et al. Impedance plethysmography: the relationship between venous filling and sensitivity and specificity for proximal vein thrombosis. *Circulation.* 1978;58:898-902.
18. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis. A randomized trial. *Ann Intern Med.* 1985;102:21-28.
19. Agnelli G, Cosmi B, Radicchia S, et al. Features of thrombi and diagnostic accuracy of impedance plethysmography in symptomatic and asymptomatic deep vein thrombosis. *Thromb Haemost.* 1993;70:266-269.
20. Abramowitz HB, Queral LA, Finn WR, et al. The use of photoplethysmography in the assessment of venous insufficiency: a comparison to venous pressure measurements. *Surgery.* 1979;86:434-441.
21. Sarin S, Shields DA, Scurr JH, et al. Photoplethysmography: a valuable noninvasive tool in the assessment of venous dysfunction? *J Vasc Surg.* 1992;16:154-162.
22. Labropoulos N, Leon L. Evaluation of chronic venous disease. In: Mansour M, Labropoulos N, eds. *Vascular Diagnosis*. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2005:447-461.

23. Nicolaides AN, Miles C. Photoplethysmography in the assessment of venous insufficiency. *J Vasc Surg.* 1987;5:405-412.
24. Rosfors S. Venous photoplethysmography: relationship between transducer position and regional distribution of venous insufficiency. *J Vasc Surg.* 1990;11:436-440.
25. Christopoulos D, Nicolaides AN, Szendro G. Venous reflux: quantification and correlation with the clinical severity of chronic venous disease. *Br J Surg.* 1988;75:352-356.
26. Criado E, Farber MA, Marston WA, et al. The role of air plethysmography in the diagnosis of chronic venous insufficiency. *J Vasc Surg.* 1998;27:660-670.
27. Eberhardt RT, Raffetto JD. Chronic venous insufficiency. *Circulation.* 2005;111:2398-2409.
28. Labropoulos N, Giannoukas AD, Nicolaides AN, et al. The role of venous reflux and calf muscle pump function in nonthrombotic chronic venous insufficiency. Correlation with severity of signs and symptoms. *Arch Surg.* 1996;131:403-406.
29. Nicolaides A, Sumner D. *Investigation of patients with deep vein thrombosis and chronic venous insufficiency.* In: Nicolaides A, Sumner D, eds. London, UK: Med-Orion; 1991:39-43.
30. Nicolaides AN. Investigation of chronic venous insufficiency: a consensus statement (France, March 5-9, 1997). *Circulation.* 2000;102:E126-E163.
31. Gillespie DL, Cordts PR, Hartono C, et al. The role of air plethysmography in monitoring results of venous surgery. *J Vasc Surg.* 1992;16:674-678.
32. Owens LV, Farber MA, Young ML, et al. The value of air plethysmography in predicting clinical outcome after surgical treatment of chronic venous insufficiency. *J Vasc Surg.* 2000;32:961-968.

## 第 17 章

1. Meissner MH. Venous duplex scanning. In: Rutherford RB, ed. *Vascular Surgery.* 6<sup>th</sup> ed. Philadelphia: Elsevier Saunders; 2005.
2. Talbot SR. Use of real-time imaging in identifying deep venous obstruction: a preliminary report. *Bruit.* 1982;7:41-42.
3. Cronan JJ. History of venous ultrasound. *J Ultrasound Med.* 2003;22:1143-1146.
4. Effenev DJ, Friedman MB, Gooding GA. Iliofemoral venous thrombosis: real-time ultrasound diagnosis, normal criteria, and clinical application. *Radiology.* 1984;150:787-792.
5. Raghavendra BN, Rosen RJ, Lam S, et al. Deep venous thrombosis: detection by high-resolution real-time ultrasonography. *Radiology.* 1984;152:789-793.
6. Raghavendra BN, Horii SC, Hilton S, et al. Deep venous thrombosis: detection by probe compression of veins. *J Ultrasound Med.* 1986;5:89-95.
7. Markel A, Manzo R, Bergelin R, et al. Pattern and distribution of thrombi in acute deep venous thrombosis. *Arch Surg.* 1992;127:305-309.
8. Criado E, Burnham CB. Predictive value of clinical criteria for the diagnosis of deep vein thrombosis. *Surgery.* 1997;122:578-583.
9. Glover JL, Bendick PJ. Appropriate indications for venous duplex ultrasonic examinations. *Surgery.* 1996;120:725-730.
10. Hill S, Holtzman G, Martin D, et al. Selective use of the duplex scan in diagnosis of deep venous thrombosis. *Am J Surg.* 1995;170:201-205.
11. Naidich JB, Torre JR, Pellerito JS, et al. Suspected deep venous thrombosis: is US of both legs necessary? *Radiology.* 1996;200:429-431.
12. Vogel P, Laing FC, Jeffrey RB, et al. Deep venous thrombosis of the lower extremity: US evaluation. *Radiology.* 1987;163:747-751.
13. Coleridge-Smith P, Labropoulos N, Partsch H, et al. Duplex ultrasound investigation of the veins in chronic venous disease of the lower limbs—UIP consensus document. Part I. Basic principles. *Eur J Vasc Endovasc Surg.* 2006;31:83-92.

14. Cavezzi A, Labropoulos N, Partsch H, et al. Duplex ultrasound investigation of the veins in chronic venous disease of the lower limbs—UIP consensus document. Part II. Anatomy. *Eur J Vasc Endovasc Surg*. 2006;31:288-299.
15. Available at [http://apdvs.vascularweb.org/APDVS\\_Contribution\\_Pages/Curriculum/Clinical/16-Diagnostic\\_Techniques.html](http://apdvs.vascularweb.org/APDVS_Contribution_Pages/Curriculum/Clinical/16-Diagnostic_Techniques.html).
16. van Bemmelen PS, Kelly P, Blebea J. Improvement in the visualization of superficial arm veins being evaluated for access and bypass. *J Vasc Surg*. 2005;42:957-962.
17. León LR, Labropoulos N. Diagnosis of deep venous thrombosis. In: Davies AH, ed. *Vascular Surgery Highlights 2003-04*. Oxford: Health Press Limited; 2004:45-52.
18. Barnes RW, Hoac JC. The fallibility of the clinical diagnosis of venous thrombosis. *JAMA*. 1975;234:605-607.
19. Haeger K. Problems of acute deep venous thrombosis, the interpretation of signs and symptoms. *Angiology*. 1969;20:219-226.
20. Hirsh J, Hull RD, Raskob GJ. Clinical features and diagnosis of venous thrombosis. *J Am Coll Cardiol*. 1986;8:114B-127B.
21. Persson AV, Jones C, Zide R, et al. Use of the triplex scanner in diagnosis of deep venous thrombosis. *Arch Surg*. 1989;124:593-596.
22. Schindler JM, Kaiser M, Vuillienet A, et al. Colour coded sonography in suspected deep vein thrombosis of the leg. *BMJ*. 1990;301:1369-1370.
23. Foley WD, Middleton WD, Lawson TL, et al. Color Doppler ultrasound imaging of lower extremity venous disease. *AJR Am J Roentgenol*. 1989;152:371-376.
24. Rose SC, Zwiebel WJ, Nelson BD, et al. Symptomatic lower extremity deep venous thrombosis: accuracy, limitations, and role of colour duplex flow imaging in diagnosis. *Radiology*. 1990;175:639-644.
25. Mattos MA, Londrey GL, Leutz DW, et al. Color-flow duplex scanning for the surveillance and diagnosis of acute deep venous thrombosis. *J Vasc Surg*. 1992;15:366-376.
26. Lee HY, Lee W, Cho YK, et al. Superficial venous aneurysm: reports of 3 cases and literature review. *J Ultrasound Med*. 2006;25:771-776.
27. Kim-Gavino CS, Vade A, Lim-Dunham J. Unusual appearance of a popliteal venous aneurysm in a 16-year-old patient: sonographic findings. *J Ultrasound Med*. 2006;25:1615-1618.
28. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. *Chest*. 2001;119(1 Suppl):132S-175S.
29. Labropoulos N, Patel PJ, Tiongson JE, et al. Patterns of venous reflux and obstruction in patients with skin damage due to chronic venous disease. *Vasc Endovascular Surg*. 2007;41:33-40.
30. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep vein thrombosis. *Ann Intern Med*. 1996;125:1-7.
31. Kearon C, Julian JA, Newman TE, et al. Noninvasive diagnosis of deep venous thrombosis. McMaster diagnostic imaging practice guidelines initiative. *Ann Intern Med*. 1998;128:663-677.
32. Labropoulos N, León LR, Rahman A, et al. Clinical significance of the venous anatomic variations of the lower body veins. Abstract Book. Paper presented at the 16th Annual Meeting of the American Venous Forum, Orlando, FL, 2004.
33. Labropoulos N, Webb KM, Kang SS, et al. Patterns and distribution of isolated calf deep vein thrombosis. *J Vasc Surg*. 1999;30:787-791.
34. Labropoulos N, Borge M, Pierce K, et al. Criteria for defining significant central vein stenosis with duplex ultrasound. *J Vasc Surg*. 2007;46:101-107.
35. Labropoulos N, Leon M, Kalodiki E, et al. Colour flow duplex scanning in suspected acute deep vein thrombosis; experience with routine use. *Eur J Vasc Endovasc Surg*. 1995;9:49-52.
36. Emelianov SY, Chen X, O'Donnell M, et al. Triplex ultrasound: elasticity imaging to age deep venous thrombosis. *Ultrasound Med Biol*. 2002;28:757-767.
37. Moody AR, Pollock JG, O'Connor AR, et al. Lower-limb deep venous thrombosis: direct MR imaging of the thrombus.

- Radiology*. 1998;209:349-355.
38. Fowlkes JB, Strieter RM, Downing LJ, et al. Ultrasound echogenicity in experimental venous thrombosis. *Ultrasound Med Biol*. 1998;24:1175-1182.
  39. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. *Arch Intern Med*. 2000;160:769-764.
  40. Douketis JD, Crowther MA, Foster GA, et al. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? *Am J Med*. 2001;110:515-519.
  41. Linkins LA, Pasquale P, Paterson S, et al. Change in thrombus length on venous ultrasound and recurrent deep vein thrombosis. *Arch Intern Med*. 2004;164:1793-1796.
  42. Linkins LA, Stretton R, Probyn L, et al. Interobserver agreement on ultrasound measurements of residual vein diameter, thrombus echogenicity and Doppler venous flow in patients with previous venous thrombosis. *Thromb Res*. 2006;117:241-247.
  43. León LR, Giannoukas AD, Dodd D, et al. Clinical significance of superficial vein thrombosis. *Eur J Vasc Endovasc Surg*. 2005;29:10-17.
  44. Martinelli I, Cattaneo M, Taioli E, et al. Genetic risk factors for superficial vein thrombosis. *Thromb Haemost*. 1999;82:1215-1217.
  45. de Moerloose P, Wutschert R, Heinzmann M, et al. Superficial vein thrombosis of the lower limb: influence of factor V Leiden, factor II G20210A and overweight. *Thromb Haemost*. 1998;80:239-241.
  46. Hanson JN, Ascher E, DePippo P, et al. Saphenous vein thrombophlebitis (SVT): a deceptively benign disease. *J Vasc Surg*. 1998;27:677-680.
  47. Schonauer V, Kyrle PA, Weltermann A, et al. Superficial thrombophlebitis and risk for recurrent venous thromboembolism. *J Vasc Surg*. 2003;37:834-838.
  48. de Godoy JM, Batigalia F, Braile M. Superficial thrombophlebitis and anticardiolipin antibodies—report of association. *Angiology*. 2001;52:127-129.
  49. Engesser L, Broekmans AW, Briet E, et al. Hereditary protein S deficiency: clinical manifestations. *Ann Intern Med*. 1987;106:677-682.
  50. Lohr JM, Muck PE, Oliverio EA, et al. Superficial vein thrombophlebitis: a clinical marker of a hypercoagulable state. Paper presented at the American Venous Forum, 1992, San Diego, CA.
  51. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft für Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. *Arterioscler Thromb Vasc Biol*. 1996;16:742-748.
  52. de Godoy JM, Braile DM. Protein S deficiency in repetitive superficial thrombophlebitis. *Clin Appl Thromb Hemost*. 2003;9:61-62.
  53. Labropoulos N, Bekelis K, Leon LR. Thrombosis in unusual sites of the lower extremity veins. *J Vasc Surg*. 2008;47:1022-1027.
  54. Labropoulos N, Manalo D, Patel NP, et al. Uncommon leg ulcers in the lower extremity. *J Vasc Surg*. 2007;45:568-573.
  55. Labropoulos N, Tassiopoulos AK. Vascular diagnosis of venous thrombosis. In: Mansour AM, Labropoulos N, eds. *Vascular Diagnosis*. Philadelphia: WB Saunders; 2005:429-438.
  56. Muñoz FJ, Mismetti P, Poggio R, et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. *Chest*. 2008;133:143-148.
  57. Prandoni P, Polistena P, Bernardi E, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. *Arch Intern Med*. 1997;157:57-62.
  58. Prandoni P, Bernardi E, Marchiori A, et al. The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. *BMJ*. 2004;329:484-485.

59. Chin EE, Zimmerman PT, Grant EG. Sonographic evaluation of upper extremity deep venous thrombosis. *J Ultrasound Med.* 2005;24:829-838.
60. Rodríguez-Niedenführ M, Vázquez T, Nearn L, et al. Variations of the arterial pattern in the upper limb revisited: a morphological and statistical study, with a review of the literature. *J Anat.* 2001;199:547-566.
61. Jeanneret C, Jäger KA, Zaugg CE, et al. Venous reflux and venous distensibility in varicose and healthy veins. *Eur J Vasc Endovasc Surg.* 2007;34:236-242.
62. Labropoulos N, Tiongson J, Pryor L, et al. Definition of venous reflux in lower-extremity veins. *J Vasc Surg.* 2003;38:793-798.
63. Jeanneret C, Labs KH, Aschwanden M, et al. Physiological reflux and venous diameter change in the proximal lower limb veins during a standardised Valsalva manoeuvre. *Eur J Vasc Endovasc Surg.* 1999;17:398-403.
64. Lagattolla NR, Donald A, Lockhart S, et al. Retrograde flow in the deep veins of subjects with normal venous function. *Br J Surg.* 1997;84:36-39.
65. Markel A, Meissner MH, Manzo RA, et al. A comparison of the cuff deflation method with Valsalva's maneuver and limb compression in detecting venous valvular reflux. *Arch Surg.* 1994;129:701-705.
66. Masuda EM, Kistner RL, Eklof B. Prospective study of duplex scanning for venous reflux: comparison of Valsalva and pneumatic cuff techniques in the reverse Trendelenburg and standing positions. *J Vasc Surg.* 1994;20:711-720.
67. Sarin S, Sommerville K, Farrah J, et al. Duplex ultrasonography for assessment of venous valvular function of the lower limb. *Br J Surg.* 1994;81:1591-1595.
68. Araki CT, Back TL, Padberg FT Jr, et al. Refinements in the ultrasonic detection of popliteal vein reflux. *J Vasc Surg.* 1993;18:742-748.
69. Van Bemmelen PS, Beach K, Bedford G, et al. The mechanism of venous valve closure. Its relationship to the velocity of reverse flow. *Arch Surg.* 1990;125:617-619.
70. Van Bemmelen PS, Bedford G, Beach K, et al. Quantitative segmental evaluation of venous valvular reflux with duplex ultrasound scanning. *J Vasc Surg.* 1989;10:425-431.
71. Kistner RL, Eklof B, Masuda EM. Diagnosis of chronic venous disease of the lower extremities: the "CEAP" classification. *Mayo Clin Proc.* 1996;71:338-345.
72. Labropoulos N. CEAP in clinical practice. *Vasc Surg.* 1997;31:224-225.
73. Van Bemmelen PS, Bedford G, Beach K, et al. Quantitative segmental evaluation of venous valvular reflux with duplex ultrasound scanning. *J Vasc Surg.* 1989;10:425-431.
74. Caggiati A. Fascial relationships of the long saphenous vein. *Circulation* 1999;100:2547-2549.
75. Caggiati A, Bergan JJ, Gloviczki P. International Interdisciplinary Consensus Committee on Venous Anatomical Terminology. Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus statement. *J Vasc Surg* 2002;36:416-622.
76. Caggiati A. Fascial relationships of the short saphenous vein. *J Vasc Surg.* 2001;34:241-246.
77. Caggiati A, Ricci S. The caliber of the human long saphenous vein and its congenital variations. *Anat Anz.* 2000;182:195-201.
78. Caggiati A, Mendoza E. Segmental hypoplasia of the great saphenous vein and varicose disease. *Eur J Vasc Endovasc Surg.* 2004;28:257-261.
79. Labropoulos N, Giannoukas AD, Delis K, et al. The impact of isolated lesser saphenous vein system incompetence on clinical signs and symptoms of chronic venous disease. *J Vasc Surg.* 2000;32:954-960.
80. van Limborgh J. L'anatomie du système veineux de l'extrémité inférieure en relation avec la pathologie variqueuse. *Folia Angiol.* 1961;8: 240-257.
81. Johnson BF, Manzo RA, Bergelin RO, et al. Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one- to six-year follow-up. *J*

- Vasc Surg.* 1995;21:307-312.
82. Sandri JL, Barros FS, Pontes S, et al. Diameter-reflux relationship in perforating veins of patients with varicose veins. *J Vasc Surg.* 1999;30:867-874.
  83. Labropoulos N, Mansour MA, Kang SS, et al. New insights into perforator vein incompetence. *Eur J Vasc Endovasc Surg.* 1999;18:228-234.
  84. Labropoulos N, Tiongson J, Pryor L, et al. Nonsaphenous superficial vein reflux. *J Vasc Surg.* 2001;34:872-877.
  85. Labropoulos N, Abai B. Reflux testing and imaging for endovenous ablation. *Perspect Vasc Surg Endovasc Ther.* 2007;19:67-70.
  86. Johnson CM, McLafferty RB. Endovenous laser ablation of varicose veins: review of current technologies and clinical outcome. *Vascular.* 2007;15:250-254.
  87. Myers KA, Jolley D, Clough A, et al. Outcome of ultrasound-guided sclerotherapy for varicose veins: medium-term results assessed by ultrasound surveillance. *Eur J Vasc Endovasc Surg.* 2007;33:116-121.
  88. Guex JJ. Foam sclerotherapy: an overview of use for primary venous insufficiency. *Semin Vasc Surg.* 2005;18:25-29.
  89. Smith PC. Chronic venous disease treated by ultrasound guided foam sclerotherapy. *Eur J Vasc Endovasc Surg.* 2006;32:577-583.
  90. Neglén P, Hollis KC, Olivier J, et al. Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic result. *J Vasc Surg.* 2007;46:979-990.
  91. Corriere MA, Passman MA, Guzman RJ, et al. Comparison of bedside transabdominal duplex ultrasound versus contrast venography for inferior vena cava filter placement: what is the best imaging modality? *Ann Vasc Surg.* 2005;19:229-234.
  92. Perrin M, Guex JJ, Ruckley CV, et al. Recurrent varices after surgery (REVAS): a consensus document. *Cardiovasc Surg.* 2000;8:233-245.
  93. van Rij AM, Jiang P, Solomon C, et al. Recurrence after varicose vein surgery: a prospective long-term clinical study with duplex ultrasound scanning and air plethysmography. *J Vasc Surg.* 2003;38: 935-943.
  94. Porter JM, Moneta GL. Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. *J Vasc Surg.* 1995;21:635-645.
  95. Perrin MR, Labropoulos N, Leon LR Jr. Presentation of the patient with recurrent varices after surgery (REVAS). *J Vasc Surg.* 2006;43:327-334.

## 第 18 章

1. Mell M, Girma T, Thornton F, et al. Clinical utility of time-resolved imaging of contrast kinetics (TRICKS) magnetic resonance angiography for infrageniculate arterial occlusive disease. *J Vasc Surg.* 2007;45:543-548.
2. Schlager O, Francesconi M, Haumer M, et al. Duplex sonography versus angiography for assessment of femoropopliteal arterial disease in a “real-world” setting. *J Endovasc Ther.* 2007;14:452-459.
3. Gjonnaess E, Morken B, Sandbaek G, et al. Gadolinium-enhanced magnetic resonance angiography, colour duplex and digital subtraction angiography of the lower limb arteries from the aorta to the tibio-peroneal trunk in patients with intermittent claudication. *Eur J Endovasc Surg.* 2006;31:53-58.
4. U-King-Im JM, Trivedi RA, Graves MJ, et al. Contrast-enhanced MR angiography for carotid disease. *Neurology.* 2004;62:1282-1290.
5. Nederkorn PJ, van der Graaf Y, Hunink M. Duplex ultrasound and magnetic resonance angiography compared with digital subtraction angiography in carotid artery stenosis. *Stroke.* 2003;34:1324-1332.
6. Randoux B, Marro B, Koskas F, et al. Carotid artery stenosis: prospective comparison of CT, three-dimensional gadolinium-enhanced MR, and conventional angiography. *Radiology.* 2001;220:179-185.
7. Mills JL. Infrainguinal vein graft surveillance: how and when. *Semin Vasc Surg.* 2001;14:169-176.
8. Bergamini TM, George SM, Massey HT, et al. Intensive surveillance of femoropopliteal-tibial autogenous vein bypass

- improves long-term graft patency and limb salvage. *Ann Surg.* 1995;221:507-516.
9. Lundell A, Lindblad B, Bergqvist D, et al. Femoropopliteal-crural graft patency is improved by an intensive surveillance program: a prospective randomized study. *J Vasc Surg.* 1995;21:26-34.
  10. Weaver FA, Pentecost MJ, Yellin AE, et al. Clinical applications of carbon dioxide/digital subtraction angiography. *J Vasc Surg.* 1991;13:266-273.
  11. Seeger JM, Self S, Harward TR, et al. Carbon dioxide gas as an arterial contrast agent. *Ann Surg.* 1993;217:688-697.
  12. Smith D, Yahiku PY, Maloney MD, et al. Three new low-osmolality contrast agents: a comparative study of patient discomfort. *Am J Neuroradiol.* 1988;9:137-139.
  13. Bettmann MA. Contrast agents. In: Kim D, Orron DE, eds. *Peripheral Vascular Imaging and Intervention*. St. Louis: Mosby-Year Book; 1992.
  14. Podrid PJ. Role of higher nervous activity in ventricular arrhythmia and sudden cardiac death: implication for alternative antiarrhythmic therapy. *Ann N Y Acad Sci.* 1984;432:296-313.
  15. Lasser EC. Pretreatment with corticosteroids to prevent reactions to i.v. contrast material: overview and implications. *AJR Am J Roentgenol.* 1988;150:257-259.
  16. Lasser EC, Berry CC, Mishkin MM, et al. Pretreatment with corticosteroids to prevent adverse reactions to nonionic contrast media. *AJR Am J Roentgenol.* 1994;162:523-526.
  17. Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. *N Engl J Med.* 1987;317:845-849.
  18. Lasser EC, Berry CC, Talner LB, et al. Protective effects of corticosteroids in contrast material anaphylaxis. *Invest Radiol.* 1988;23(Suppl 1):S193-S194.
  19. Lasser EC, Lang J, Sovak M, et al. Steroids: theoretical and experimental basis for utilization in prevention of contrast media reactions. *Radiology.* 1977;125:1-9.
  20. Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. *J Allergy Clin Immunol.* 1991;87:867-872.
  21. Greenberger PA, Patterson R, Tapio CM. Prophylaxis against repeated radiocontrast media reactions in 857 cases: adverse experience with cimetidine and safety of beta-adrenergic antagonists. *Arch Intern Med.* 1985;145:2197-2200.
  22. Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and nonionic contrast media: a report from the Japanese Committee on the Safety of Contrast Media. *Radiology.* 1990;175:621-628.
  23. Freed KS, Leder RA, Alexander C, et al. Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication. *AJR Am J Roentgenol.* 2001;176:1389-1392.
  24. Morris TW, Sahler LG, Violante M, et al. Work in progress: reduction of calcium activity by radiopaque contrast media. *Radiology.* 1983;148:55-59.
  25. Dawson P. Cardiovascular effects of contrast agents. *Am J Cardiol.* 1989;64:2E-9E.
  26. Farrehi PM, Zhu Y, Fay WP. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents. *J Thromb Thrombolysis.* 2001;12:273-281.
  27. Kopko PM, Smith DC, Bull BS. Thrombin generation in nonclottable mixtures of blood and nonionic contrast agents. *Radiology.* 1990;174:459-461.
  28. Bettmann M. Ionic versus nonionic contrast agents and their effects on blood components: clinical summary and conclusions. *Invest Radiol.* 1988;23(Suppl 2):S378-S380.
  29. Waybill MM, Waybill PN. Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. *J Vasc Interv Radiol.* 2001;12:3-9.
  30. Agrawal M, Stouffer GA. Cardiology grand rounds from the University of North Carolina at Chapel Hill: contrast induced nephropathy after angiography. *Am J Med Sci.* 2002;323:252-258.
  31. Manske CL, Sprafka JM, Strony JT, et al. Contrast nephropathy in azotemic diabetic patients undergoing coronary

- angiography. *Am J Med.* 1990;89:615-620.
32. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: Results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. *J Am Coll Cardiol.* 1999;33:403-411.
  33. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. *Kidney Int.* 1994;45:259-265.
  34. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: A prospective controlled study. *N Engl J Med.* 1989;320:143-149.
  35. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older: a prospective study. *Arch Intern Med.* 1990;150:1237-1242.
  36. Gomes AS, Lois JF, Baker JD, et al. Acute renal dysfunction in high-risk patients after angiography: comparison of ionic and nonionic contrast media. *Radiology.* 1989;170:65-68.
  37. Miller DL, Chang R, Wells WT, et al. Intravascular contrast media: effect of dose on renal function. *Radiology.* 1988;167:607-611.
  38. Schwab SJ, Hlatky MA, Pieper KS, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. *N Engl J Med.* 1989;320:149-153.
  39. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. *Kidney Int.* 1995;47:254-261.
  40. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. *Radiology.* 1993;188:171-178.
  41. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. *Br J Radiol.* 1999;72:701-703.
  42. Donadio C, Tramonti G, Lucchesi A, et al. Tubular toxicity is the main renal effect of contrast media. *Ren Fail.* 1996;18:647-656.
  43. Hall KA, Wong RW, Hunter GC, et al. Contrast-induced nephrotoxicity: the effects of vasodilator therapy. *J Surg Res.* 1992;53:317-320.
  44. Harkonen S, Kjellstrand CM. Exacerbation of diabetic renal failure following intravenous pyelography. *Am J Med.* 1977;63:939-946.
  45. Shieh SD, Hirsch SR, Boshell BR, et al. Low risk of contrast media-induced acute renal failure in nonazotemic type 2 diabetes mellitus. *Kidney Int.* 1982;21:739-743.
  46. Weinrauch LA, Healy RW, Leland Jr OS, et al. Coronary angiography and acute renal failure in diabetic azotemic nephropathy. *Ann Intern Med.* 1977;86:56-59.
  47. Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. *Br J Radiol.* 2003;76:513-518.
  48. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. *N Engl J Med.* 1994;331:1416-1420.
  49. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. *Nephron Clin Pract.* 2003;93:C29-C34.
  50. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. *Arch Intern Med.* 2002;162:329-336.
  51. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. *JAMA.* 2004;291:2328-2334.
  52. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. *J Am Coll Cardiol.* 2002;40:298-303.
  53. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal



- function by acetylcysteine. *N Engl J Med*. 2000;343:180-184.
54. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. *JAMA*. 2003;289:553-558.
  55. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). *Am J Cardiol*. 2002;89:356-358.
  56. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. *J Am Coll Cardiol*. 2002;40:1383-1388.
  57. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of *N*-acetylcysteine to prevent contrast nephropathy in cardiac angiography. *Kidney Int*. 2002;62:2202-2207.
  58. Hoffmann U, Fischereder M, Kruger B, et al. The value of *N*-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. *J Am Soc Nephrol*. 2004;15:407-410.
  59. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. *Nephron*. 1992;62:413-415.
  60. Shammas NW, Kapalis MJ, Harris M, et al. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. *J Invasive Cardiol*. 2001;13:738-740.
  61. Gupta RK, Kapoor A, Tewari S, et al. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. *Indian Heart J*. 1999;51:521-526.
  62. Sketch Jr MH, Whelton A, Schollmayer E, et al. Prevention of contrast media-induced renal dysfunction with prostaglandin E<sub>1</sub>: a randomized, double-blind, placebo-controlled study. *Am J Ther*. 2001;8:155-162.
  63. Huber W, Schiepek C, Ilgmann K, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. *Am J Cardiol*. 2003;91:1157-1162.
  64. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of *N*-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. *Catheter Cardiovasc Interv*. 2002;57:279-283.
  65. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. *JAMA*. 2003;290:2284-2291.
  66. Erley CM, Duda SH, Rehfuss D, et al. Prevention of radiocontrast-media induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. *Nephrol Dial Transplant*. 1999;14:1146-1149.
  67. Koch JA, Plum J, Grabensee B, et al. Prostaglandin E<sub>1</sub>: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE<sub>1</sub> Study Group. *Nephrol Dial Transplant*. 2000;15:43-49.
  68. Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. *Kidney Int*. 2000;57:1675-1680.
  69. Neumayer HH, Junge W, Kufner A, et al. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. *Nephrol Dial Transplant*. 1989;4:1030-1036.
  70. Carraro M, Mancini W, Artero M, et al. Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. *Nephrol Dial Transplant*. 1996;11:444-448.
  71. Rodicio JL, Morales JM, Alcazar JM, et al. Calcium antagonists and renal protection. *J Hypertens Suppl*. 1993;11:S49-S53.
  72. Spangberg-Viklund B, Berglund J, Nikonoff T, et al. Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? *Scand J Urol Nephrol*. 1996;30:63-68.
  73. Esnault VL. Radiocontrast media-induced nephrotoxicity in patients with renal failure: rationale for a new double-blind, prospective, randomized trial testing calcium channel antagonists. *Nephrol Dial Transplant*. 2002;17:1362-1364.
  74. Hans SS, Hans BA, Dhillon R, et al. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. *Am Surg*. 1998;64:432-436.

75. Kapoor A, Sinha N, Sharma RK, et al. Use of dopamine in prevention of contrast induced acute renal failure—a randomised study. *Int J Cardiol.* 1996;53:233-236.
76. Gare M, Haviv YS, Ben-Yehuda A, et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. *J Am Coll Cardiol.* 1999;3:1682-1688.
77. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. *Am J Cardiol.* 1999;83:260-263, A5.
78. Gahlen J, Hansmann J, Schumacher H, et al. Carbon dioxide angiography for endovascular grafting in high-risk patients with infrarenal abdominal aortic aneurysms. *J Vasc Surg.* 2001;33:646-649.
79. Caridi JG, Hawkins Jr IF, Cho K, et al. CO<sub>2</sub> splenoportography: preliminary results. *AJR Am J Roentgenol.* 2003;180:1375-1378.
80. Lang EV, Gossler AA, Fick LJ, et al. Carbon dioxide angiography: effect of injection parameters on bolus configurations. *J Vasc Interv Radiol.* 1999;10:41-49.
81. Hawkins Jr IF, Caridi JG, Klioze SD, et al. Modified plastic bag system with O-ring fitting connection for carbon dioxide angiography. *AJR Am J Roentgenol.* 2001;176:229-232.
82. Rundback JH, Shah PM, Wong J, et al. Livedo reticularis, rhabdomyolysis, massive intestinal infarction, and death after carbon dioxide arteriography. *J Vasc Surg.* 1997;26:337-340.
83. Caridi JG, Hawkins Jr IF, Klioze SD, et al. Carbon dioxide digital subtraction angiography: the practical approach. *Tech Vasc Interv Radiol.* 2001;4:57-65.
84. Coffey R, Quisling RG, Mickle JP, et al. The cerebrovascular effects of intraarterial CO<sub>2</sub> in quantities required for diagnostic imaging. *Radiology.* 1984;151:405-410.
85. Shifrin EG, Plich MB, Verstandig AG, et al. Cerebral angiography with gaseous carbon dioxide. *J Cardiovasc Surg (Torino).* 1990;31:603-606.
86. Dimakakos PB, Stefanopoulos T, Doufas AG, et al. The cerebral effects of carbon dioxide during digital subtraction angiography in the aortic arch and its branches in rabbits. *AJNR Am J Neuroradiol.* 1998;19:261-266.
87. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? *Nephrol Dial Transplant.* 2006;21:1104-1108.
88. Murphy KP, Szopinski KT, Cohan RH, et al. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors. *Acad Radiol.* 1999;6:656-664.
89. U-King-Im JM, Graves MJ, Cross JJ, et al. Internal carotid artery stenosis: accuracy of subjective visual impression for evaluation with digital subtraction angiography and contrast-enhanced MR angiography. *Radiology.* 2007;244:213-222.

## 第 19 章

1. Bauer G. A venographic study of thromboembolic problems. *Acta Chir Scand.* 1940;84(Suppl 61):1-75.
2. Hager K. Problems of acute deep venous thrombosis: I. The interpretation of signs and symptoms. *Angiology.* 1969;20:219-223.
3. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis of the leg. *Arch Surg.* 1972;104:134-144.
4. Welch CE, Faxon HH, McGahey CE. The application of phlebography to the therapy of thrombosis and embolism. *Surgery.* 1942;12:162.
5. Wheeler HB, Hirsch J, Wells P, et al. Diagnostic tests for deep vein thrombosis: clinical usefulness depends on probability of disease. *Arch Intern Med.* 1994;154:1921-1928.
6. Huisman MV, Buller HR, ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. *N Engl J Med.* 1986;314:823-828.
7. Lea Thomas M. Techniques of phlebography: a review. *Eur J Radiol.* 1990;11:125-130.

8. McLachlan MS, Thomson JG, Taylor DW, et al. Observer variation in the interpretation of lower limb venograms. *AJR Am J Roentgenol.* 1979;132:227-229.
9. Thomas ML, Bowles JN. Incompetent perforating veins: comparison of varicography and ascending phlebography. *Radiology.* 1985;154:619-623.
10. Aldridge SC, Comerota AJ, Katz ML, et al. Popliteal venous aneurysm: report of two cases and review of the world literature. *J Vasc Surg.* 1993;18:708-715.
11. Gloviczki P, Stanson AW, Stickler GB, et al. Klippel-Trenaunay syndrome: the risks and benefits of vascular interventions. *Surgery.* 1991;110:469-479.
12. Chahlaoui J, Julien M, Nadeau P, et al. Popliteal venous aneurysm: a source of pulmonary embolism. *AJR Am J Roentgenol.* 1981;136:415-416.
13. Gillespie DL, Villavicencio JL, Gallagher C, et al. Presentation and management of venous aneurysms. *J Vasc Surg.* 1997;26:845-852.
14. Braun SD, Moore AV Jr, Mills SR, et al. Closed-system venography in the evaluation of angiodysplastic lesions of the extremities. *AJR Am J Roentgenol.* 1983;141:1307-1310.
15. Baldt MM, Bohler K, Zontsich T, et al. Preoperative imaging of lower extremity varicose veins: color coded duplex sonography or venography. *J Ultrasound Med.* 1996;15:143-154.
16. Kistner RL, Ferris EB, Randhawa G, Kamida C. A method of performing descending venography. *J Vasc Surg.* 1986;4:464-468.
17. Herman RJ, Neiman HL, Yao JS, et al. Descending venography: a method of evaluating lower extremity venous valvular function. *Radiology.* 1980;137:63-69.
18. Morano JU, Raju S. Chronic venous insufficiency: assessment with descending venography. *Radiology.* 1990;174:441-444.
19. Raju S, Fredericks R. Valve reconstruction procedures for nonobstructive venous insufficiency: rationale, techniques, and results in 107 procedures with two- to eight-year follow-up. *J Vasc Surg.* 1988;7:301-310.
20. Danetz JS, McLafferty RB, Ayerdi J, et al. Selective venography versus nonselective venography before vena cava filter placement: evidence for more, not less. *J Vasc Surg.* 2003;38:928-934.
21. Rosenthal D, Wellons ED, Hancock SM, Burkett AB. Retrieval of the Gunther Tulip vena cava filter after dwell times longer than 180 days in patients with multiple trauma. *J Endovasc Ther.* 2007;14:406-410.
22. Broholm R, Baekgaard N, Just SR, Jorgensen M. [Endovascular treatment of chronic iliac vein obstruction in patients with venous claudication]. *Ugeskr Laeger.* 2007;169:1564-1568.
23. Delis KT, Bjarnason H, Wennberg PW, et al. Successful iliac vein and inferior vena cava stenting ameliorates venous claudication and improves venous outflow, calf muscle pump function, and clinical status in post-thrombotic syndrome. *Ann Surg.* 2007;245:130-139.
24. Elson JD, Becker GJ, Wholey MH, Ehrman KO. Vena caval and central venous stenoses: management with Palmaz balloon-expandable intraluminal stents. *J Vasc Interv Radiol.* 1991;2:215-223.
25. Hartung O, Otero A, Boufi M, et al. Mid-term results of endovascular treatment for symptomatic chronic nonmalignant ilioacaval venous occlusive disease. *J Vasc Surg.* 2005;42:1138-1144.
26. Heniford BT, Senler SO, Olsofka JM, et al. May-Thurner syndrome: management by endovascular surgical techniques. *Ann Vasc Surg.* 1998;12:482-486.
27. Hurst DR, Forauer AR, Bloom JR, et al. Diagnosis and endovascular treatment of ilioacaval compression syndrome. *J Vasc Surg.* 2001;34:106-113.
28. Husmann MJ, Heller G, Kalka C, et al. Stenting of common iliac vein obstructions combined with regional thrombolysis and thrombectomy in acute deep vein thrombosis. *Eur J Vasc Endovasc Surg.* 2007;34:87-91.
29. Knipp BS, Ferguson E, Williams DM, et al. Factors associated with outcome after interventional treatment of symptomatic iliac vein compression syndrome. *J Vasc Surg.* 2007;46:743-749.

30. Kwak HS, Han YM, Lee YS, et al. Stents in common iliac vein obstruction with acute ipsilateral deep venous thrombosis: early and late results. *J Vasc Interv Radiol*. 2005;16:815-822.
31. Mickley V, Schwagierek R, Rilinger N, et al. Left iliac venous thrombosis caused by venous spur: treatment with thrombectomy and stent implantation. *J Vasc Surg*. 1998;28:492-497.
32. Mussa FF, Peden EK, Zhou W, et al. Iliac vein stenting for chronic venous insufficiency. *Tex Heart Inst J*. 2007;34:60-66.
33. Neglen P, Raju S. Balloon dilation and stenting of chronic iliac vein obstruction: technical aspects and early clinical outcome. *J Endovasc Ther*. 2000;7:79-91.
34. Neglen P, Raju S. Proximal lower extremity chronic venous outflow obstruction: recognition and treatment. *Semin Vasc Surg*. 2002;15:57-64.
35. Neglen P, Thrasher TL, Raju S. Venous outflow obstruction: an underestimated contributor to chronic venous disease. *J Vasc Surg*. 2003;38:879-885.
36. Neglen P, Raju S. In-stent recurrent stenosis in stents placed in the lower extremity venous outflow tract. *J Vasc Surg*. 2004;39:181-187.
37. Neglen P, Hollis KC, Raju S. Combined saphenous ablation and iliac stent placement for complex severe chronic venous disease. *J Vasc Surg*. 2006;44:828-833.
38. Neglen P, Hollis KC, Olivier J, Raju S. Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic result. *J Vasc Surg*. 2007;46:979-990.
39. O'Sullivan GJ, Semba CP, Bittner CA, et al. Endovascular management of iliac vein compression (May-Thurner) syndrome. *J Vasc Interv Radiol*. 2000;11:823-836.
40. Raju S, Owen S Jr, Neglen P. Reversal of abnormal lymphoscintigraphy after placement of venous stents for correction of associated venous obstruction. *J Vasc Surg*. 2001;34:779-784.
41. Raju S, Owen S Jr, Neglen P. The clinical impact of iliac venous stents in the management of chronic venous insufficiency. *J Vasc Surg*. 2002;35:8-15.
42. Raju S, Hollis K, Neglen P. Obstructive lesions of the inferior vena cava: clinical features and endovenous treatment. *J Vasc Surg*. 2006;44:820-827.
43. Raju S. Endovenous treatment of patients with iliac-caval venous obstruction. *J Cardiovasc Surg (Torino)*. 2008;49:27-33.
44. Sawada S, Fujiwara Y, Koyama T, et al. Application of expandable metallic stents to the venous system. *Acta Radiol*. 1992;33:156-159.
45. Tacke J, Antonucci F, Stuckmann G, et al. [The palliative treatment of venous stenoses in tumor patients with self-expanding vascular prostheses]. *Rofo*. 1994;160:433-440.
46. Raju S, McAllister S, Neglen P. Recanalization of totally occluded iliac and adjacent venous segments. *J Vasc Surg*. 2002;36:903-911.
47. Neglen P, Raju S. Balloon dilation and stenting of chronic iliac vein obstruction: technical aspects and early clinical outcome. *J Endovasc Ther*. 2000;7:79-91.
48. Neglen P, Raju S. Detection of outflow obstruction in chronic venous insufficiency. *J Vasc Surg*. 1993;17:583-589.
49. Ing FF, Fagan TE, Grifka RG, et al. Reconstruction of stenotic or occluded iliofemoral veins and inferior vena cava using intravascular stents: re-establishing access for future cardiac catheterization and cardiac surgery. *J Am Coll Cardiol*. 2001;37:251-257.
50. Chang TC, Zaleski GX, Lin BH, et al. Treatment of inferior vena cava obstruction in hemodialysis patients using Wallstents: early and intermediate results. *AJR Am J Roentgenol*. 1998;171:125-128.
51. Neglen P, Raju S. Detection of outflow obstruction in chronic venous insufficiency. *J Vasc Surg*. 1993;17:583-589.
52. Neglen P, Raju S. Intravascular ultrasound scan evaluation of the obstructed vein. *J Vasc Surg*. 2002;35:694-700.
53. Zerhouni EA, Siegelman SS, Walsh PC, White RI. Elevated pressure in the left renal vein in patients with varicocele: preliminary observations. *J Urol*. 1980;123:512-513.

54. Beinart C, Sniderman KW, Tamura S, et al. Left renal to inferior vena cava pressure relationship in humans. *J Urology*. 1982;127:1070-1071.
55. Hobbs JT. The pelvic congestion syndrome. *Br J Hosp Med*. 1990;43:200-206.
56. Beard RW, Highman JH, Pearce S, Reginald PW. Diagnosis of pelvic varicosities in women with chronic pelvic pain. *Lancet*. 1984;2:946-949.
57. Belenky A, Bartal G, Atar E, et al. Ovarian varices in healthy female kidney donors: incidence, morbidity, and clinical outcome. *AJR Am J Roentgenol*. 2002;179:625-627.
58. Scultetus AH, Villavicencio JL, Gillespie DL. The nutcracker syndrome: its role in the pelvic venous disorders. *J Vasc Surg*. 2001;34:812-819.
59. O'Dea MJ, Malek RS, Tucker RM, Fulton RE. Renal vein thrombosis. *J Urol*. 1976;116:410-414.
60. Martin EC, Gordon DH. Selective renal venography in patients with primary renal disease and the nephrotic syndrome. *Cardiovasc Intervent Radiol*. 1980;3:175-179.
61. Beckmann CF, Abrams HL. Renal venography: anatomy, technique, applications, analysis of 132 venograms, and a review of the literature. *Cardiovasc Intervent Radiol*. 1980;3:45-70.
62. Gertsch P, Matthews J, Lerut J, et al. Acute thrombosis of the splanchnic veins. *Arch Surg*. 1993;128:341-345.
63. Ozkan U, Oguzkurt L, Tercan F, Tokmak N. Percutaneous transhepatic thrombolysis in the treatment of acute portal venous thrombosis. *Diagn Interv Radiol*. 2006;12:105-107.
64. Rosen MP, Sheiman R. Transhepatic mechanical thrombectomy followed by infusion of TPA into the superior mesenteric artery to treat acute mesenteric vein thrombosis. *J Vasc Interv Radiol*. 2000;11:195-198.
65. Rösch J, Hanafee WN, Snow H. Transjugular portal venography and radiologic portacaval shunt: an experimental study. *Radiology*. 1969;92:1112-1114.
66. Rösch J, Hanafee W, Snow H, et al. Transjugular intrahepatic portacaval shunt. An experimental work. *Am J Surg*. 1971;121:588-592.
67. Rösch J, Antonovic R, Dotter CT. Transjugular approach to the liver, biliary system, and portal circulation. *Am J Roentgenol Radium Ther Nucl Med*. 1975;125:602-608.
68. Rösch J, Uchida BT, Barton RE, Keller FS. Coaxial catheter-needle system for transjugular portal vein entrance. *J Vasc Interv Radiol*. 1993;4:145-147.
69. Hebbard GS, Fitt G, Thomson KR, et al. Transjugular intrahepatic portal-systemic shunts (TIPS)—initial experience and clinical outcome. *Aust N Z J Med*. 1994;24:141-148.
70. Ferro C, Rossi UG, Bovio G, et al. Transjugular intrahepatic portosystemic shunt, mechanical aspiration thrombectomy, and direct thrombolysis in the treatment of acute portal and superior mesenteric vein thrombosis. *Cardiovasc Intervent Radiol*. 2007;30:1070-1074.
71. Dilawari JB, Bamberg P, Chawla Y, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. *Medicine (Baltimore)*. 1994;73:21-36.
72. Rosa P, Gillespie DL. Budd-Chiari syndrome: case report and review of the literature. *Vasc Surg*. 2000;34:591-595.
73. Phibbs B, Marriott HJ. Complications of permanent transvenous pacing. *N Engl J Med*. 1985;312:1428-1432.
74. Warden GD, Wilmore DW, Pruitt BA Jr. Central venous thrombosis: a hazard of medical progress. *J Trauma*. 1973;13:620-626.
75. Thomas ML, Andress MR. Axillary phlebography. *Am J Roentgenol Radium Ther Nucl Med*. 1971;113:713-721.
76. Natsu SS, Sequeira JC, Weitzman AF. An improved technique for axillary phlebography. *Radiology*. 1982;142:529-530.
77. Andrews JC, Williams DM, Cho KJ. Digital subtraction venography of the upper extremity. *Clin Radiol*. 1987;38:423-424.
78. Shimm DS, Logue GL, Rigsby LC. Evaluating the superior vena cava syndrome. *JAMA*. 1981;245:951-953.
79. Hudson GW. Venography in superior vena caval obstruction. *Radiology*. 1957;68:499-506.
80. Rutherford RB, Hurlbert SN. Primary subclavian-axillary vein thrombosis: consensus and commentary. *Cardiovasc Surg*.

1996;4:420-423.

81. Sharma RP, Keller CE, Shetty PC, Burke MW. Superior vena cava obstruction: evaluation with digital subtraction angiography. *Radiology*. 1986;160:845.
82. Ruiz Y, Caballero P, Caniego JL, et al. Prospective comparison of helical CT with angiography in pulmonary embolism: global and selective vascular territory analysis. Interobserver agreement. *Eur Radiol*. 2003;13:823-829.

## 第 20 章

1. Lipsitz EC, Veith FJ, Ohki T, et al. Does the endovascular repair of aortoiliac aneurysms pose a radiation safety hazard to vascular surgeons? *J Vasc Surg*. 2000;32:704-710.
2. Ho P, Cheng SWK, Wu PM, et al. Ionizing radiation absorption of vascular surgeons during endovascular procedures. *J Vasc Surg*. 2007;46:455-459.

## 第 21 章

1. Hingorani A, Ascher E, Marks N. Preprocedural imaging: new options to reduce need for contrast angiography. *Semin Vasc Surg*. 2007;20:15-28.
2. Simoni G, Perrone R, Cittadini G Jr, et al. Helical CT for the study of abdominal aortic aneurysms in patients undergoing conventional surgical repair. *Eur J Vasc Endovasc Surg*. 1996;12:354-358.
3. Wyers MC, Fillinger MF, Schermerhorn ML, et al. Endovascular repair of abdominal aortic aneurysm without preoperative arteriography. *J Vasc Surg*. 2003;38:730-738.
4. Grassbaugh JA, Nelson PR, Rzucidlo EM, et al. Blinded comparison of preoperative duplex ultrasound scanning and contrast arteriography for planning revascularization at the level of the tibia. *J Vasc Surg*. 2003;37:1186-1190.
5. Back MR, Rogers GA, Wilson JS, et al. Magnetic resonance angiography minimizes need for arteriography after inadequate carotid duplex ultrasound scanning. *J Vasc Surg*. 2003;38:422-430.
6. Collins R, Burch J, Cranny G, et al. Duplex ultrasonography, magnetic resonance angiography, and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review. *BMJ*. 2007;334:1257.
7. Hounsfield GN. Computerized transverse axial scanning (tomography). 1. Description of system. *Br J Radiol*. 1973;46:1016-1022.
8. Prokop M. CT angiography of the abdominal arteries. *Abdom Imaging*. 1998;23:462-468.
9. Wintersperger BJ, Nikolaou K, Becker CR. Multidetector-row CT angiography of the aorta and visceral arteries. *Semin Ultrasound CT MR*. 2004;25:25-40.
10. Knez A, Becker CR, Leber A, et al. Usefulness of multislice spiral computed tomography angiography for determination of coronary artery stenoses. *Am J Cardiol*. 2001;88:1191-1194.
11. Kachelriess M, Ulzheimer S, Kalender WA. ECG-correlated imaging of the heart with subsecond multislice spiral CT. *IEEE Trans Med Imaging*. 2000;19:888-901.
12. Roberts WT, Bax JJ, Davies LC. Cardiac CT and CT coronary angiography: technology and application. *Heart*. 2008;94:781-792.
13. Ibukuro K, Charnsangavej C, Chasen MH, et al. Helical CT angiography with multiplanar reformation: techniques and clinical applications. *Radiographics*. 1995;15:671-682.
14. Fillinger MF, Racusin J, Baker RK, et al. Anatomic characteristics of ruptured abdominal aortic aneurysm on conventional CT scans: implications for rupture risk. *J Vasc Surg*. 2004;39:1243-1252.
15. Broeders IA, Blankensteijn JD, Olree M, et al. Preoperative sizing of grafts for transfemoral endovascular aneurysm management: a prospective comparative study of spiral CT angiography, arteriography, and conventional CT imaging. *J Endovasc Surg*. 1997;4:252-261.

16. Sprouse LR, Meier GH III, Parent FN, et al. Is three-dimensional computed tomography reconstruction justified before endovascular aortic aneurysm repair? *J Vasc Surg.* 2004;40:443-447.
17. Beebe HG, Kritpracha B. Computed tomography scanning for endograft planning: evolving toward three-dimensional, single source imaging. *Semin Vasc Surg.* 2004;17:126-134.
18. Parker MV, O'Donnell SD, Chang AS, et al. What imaging studies are necessary for abdominal aortic endograft sizing? A prospective blinded study using conventional computed tomography, aortography, and three-dimensional computed tomography. *J Vasc Surg.* 2005;41:199-205.
19. Riccabona M, Nelson TR, Pretorius DH, Davidson TE. In vivo three-dimensional sonographic measurement of organ volume: validation in the urinary bladder. *J Ultrasound Med.* 1996;15:627-632.
20. Wheatley JM, Rosenfield NS, Heller G, et al. Validation of a technique of computer-aided tumor volume determination. *J Surg Res.* 1995;59:621-626.
21. Bargellini I, Cioni R, Petruzzi P, et al. Endovascular repair of abdominal aortic aneurysms: analysis of aneurysm volumetric changes at mid-term follow-up. *Cardiovasc Intervent Radiol.* 2005;28:426-433.
22. Wever JJ, Blankensteijn JD, Mali WP, Eikelboom BC. Maximal aneurysm diameter follow-up is inadequate after endovascular abdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg.* 2000;20:177-182.
23. Fillinger MF. New imaging techniques in endovascular surgery. *Surg Clin North Am.* 1999;79:451-475.
24. Lee JT, Aziz IN, Lee JT, et al. Volume regression of abdominal aortic aneurysms and its relation to successful endoluminal exclusion. *J Vasc Surg.* 2003;38:1254-1263.
25. White RA, Donayre CE, Walot I, et al. Computed tomography assessment of abdominal aortic aneurysm morphology after endograft exclusion. *J Vasc Surg.* 2001;33(2 Suppl):S1-S10.
26. Prinssen M, Verhoeven EL, Verhagen HJ, Blankensteijn JD. Decision-making in follow-up after endovascular aneurysm repair based on diameter and volume measurements: a blinded comparison. *Eur J Vasc Endovasc Surg.* 2003;26:184-187.
27. Pollock JG, Travis SJ, Whitaker SC, et al. Endovascular AAA repair: classification of aneurysm sac volumetric change using spiral computed tomographic angiography. *J Endovasc Ther.* 2002;9:185-193.
28. Torsello GB, Klenk E, Kasprzak B, Umscheid T. Rupture of abdominal aortic aneurysm previously treated by endovascular stentgraft. *J Vasc Surg.* 1998;28:184-187.
29. Lee LK, Faries PL. Assessing the effectiveness of endografts: clinical and experimental perspectives. *J Vasc Surg.* 2007;45(Suppl):A123-A130.
30. Balm R, Kaatee R, Blankensteijn JD, et al. CT-angiography of abdominal aortic aneurysms after transfemoral endovascular aneurysm management. *Eur J Vasc Endovasc Surg.* 1996;12:182-188.
31. Qanadli SD, Mesurolle B, Coggia M, et al. Abdominal aortic aneurysm: pretherapy assessment with dual-slice helical CT angiography. *AJR Am J Roentgenol.* 2000;174:181-187.
32. Broeders IA, Blankensteijn JD. Preoperative imaging of the aortoiliac anatomy in endovascular aneurysm surgery. *Semin Vasc Surg.* 1999;12:306-314.
33. Primak AN, McCollough CH, Bruesewitz MR, et al. Relationship between noise, dose, and pitch in cardiac multi-detector row CT. *Radiographics.* 2006;26:1785-1794.
34. Wang G, Vannier MW. Optimal pitch in spiral computed tomography. *Med Phys.* 1997;24:1635-1639.
35. Verdun FR, Noel A, Meuli R, et al. Influence of detector collimation on SNR in four different MDCT scanners using a reconstructed slice thickness of 5 mm. *Eur Radiol.* 2004;14:1866-1872.
36. Gomori JM, Steiner I. Non-linear CT windows. *Comput Radiol.* 1987;11:21-27.
37. Gawenda M, Gossmann A, Kruger K, et al. Comparison of magnetic resonance imaging and computed tomography of 8 aortic stent-graft models. *J Endovasc Ther.* 2004;11:627-634.
38. Siewerdsen JH, Moseley DJ, Burch S, et al. Volume CT with a flat-panel detector on a mobile, isocentric C-arm: pre-clinical investigation in guidance of minimally invasive surgery. *Med Phys.* 2005;32:241-254.

39. Brenner DJ, Hall DJ. Computed tomography—an increasing source of radiation exposure. *N Engl J Med*. 2007;357:2277-2284.
40. Soma VR, Cavusoglu E, Vidhun R, et al. Contrast-associated nephropathy. *Heart Dis*. 2002;4:372-379.
41. Thomsen HA, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) Guidelines. *Br J Radiol*. 2003;76:513-518.
42. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. *Arch Intern Med*. 1990;150:1237-1242.
43. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation*. 2002;105:2259-2264.
44. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. *Kidney Int*. 1994;45:259-265.
45. Oudemans-van Straaten HM. Contrast nephropathy, pathophysiology and prevention. *Int J Artif Organs*. 2004;27:1054-1065.
46. Ogawa M, Ishino S, Mukai T, et al. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. *J Nucl Med*. 2004;45:1245-1250.
47. Defawe OD, Hustinx R, Defraigne JO, et al. Distribution of F-18 fluorodeoxyglucose (F-18 FDG) in abdominal aortic aneurysm: high accumulation in macrophages seen on PET imaging and immunohistology. *Clin Nucl Med*. 2005;30:340-341.
48. Eide KR, Odegard A, Myhre HO, Haraldseth O. Initial observations of endovascular aneurysm repair using Dyna-CT. *J Endovasc Ther*. 2007;14:50-53.
49. Wallace MJ, Kuo MD, Glaiberman C, et al. Three-dimensional C-arm cone-beam CT: applications in the interventional suite. *J Vasc Interv Radiol*. 2008;19:799-813.

## 第 22 章

1. Tan KT, van Beek EJ, Brown PW, et al. Magnetic resonance angiography for the diagnosis of renal artery stenosis: a meta-analysis. *Clin Radiol*. 2002;57:617-624.
2. Meaney JF. Magnetic resonance angiography of the peripheral arteries: Current status. *Eur Radiol*. 2003;13:836-852.
3. Hood MN, Ho VB, Foo TK, et al. High-resolution gadolinium-enhanced 3D MRA of the infrapopliteal arteries. Lessons for improving bolus-chase peripheral MRA. *Magn Reson Imaging*. 2002;20:543-549.
4. Sharafuddin MJ, Stolpen AH, Sun S, et al. High-resolution multiphase contrast-enhanced three-dimensional MR angiography compared with two-dimensional time-of-flight MR angiography for the identification of pedal vessels. *J Vasc Interv Radiol*. 2002;13:695-702.
5. Johnson DB, Lerner CA, Prince MR, et al. Gadolinium-enhanced magnetic resonance angiography of renal transplants. *Magn Reson Imaging*. 1997;15:13-20.
6. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal dialysis patients. *Lancet*. 2000;356:1000-1001.
7. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? *Nephrol Dial Transplant*. 2006;21:1104-1108.
8. Foo TK, Ho VB, Marcos HB, et al. MR angiography using steady-state free precession. *Magn Reson Med*. 2002;48:699-706.
9. Spuentrup E, Manning WJ, Bärnert P, et al. Renal arteries: navigator-gated balanced fast field-echo projection MR angiography with aortic spin labeling: Initial experience. *Radiology*. 2002;225:589-596.
10. Miyazaki M, Takai H, Sugiura S, et al. Peripheral MR angiography: separation of arteries from veins with flow-spoiled gradient pulses in electrocardiography-triggered three-dimensional half-Fourier fast spin-echo imaging. *Radiology*.



2003;227:890-896.

11. Gebker R, Gomaa O, Schnackenburg B, et al. Comparison of different MRI techniques for the assessment of thoracic aortic pathology: 3D contrast enhanced MR angiography, turbo spin echo and balanced steady state free precession. *Int J Cardiovasc Imaging*. 2007;23:747-756.
12. François CJ, Tuite D, Deshpande V, et al. Unenhanced MR angiography of the thoracic aorta: initial clinical evaluation. *AJR Am J Roentgenol*. 2008;190:902-906.
13. Zavodni AE, Emery DJ, Wilman AH. Performance of steady-state free precession for imaging carotid artery disease. *J Magn Reson Imaging*. 2005;21:86-90.
14. Maki JH, Wilson GJ, Eubank WB, et al. Steady-state free precession MRA of the renal arteries: breath-hold and navigator-gated techniques vs. CE-MRA. *J Magn Reson Imaging*. 2007;26:966-973.
15. Spinosa DJ, Angle JF, Hartwell GD, et al. Gadolinium-based contrast agents in angiography and interventional radiology. *Radiol Clin North Am*. 2002;40:693-710.
16. Srodon P, Matson M, Ham R. Contrast nephropathy in lower limb angiography. *Ann R Coll Surg Engl*. 2003;85:187-191.
17. Rieger J, Sitter T, Toepfer M, et al. Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. *Nephrol Dial Transplant*. 2002;17:824-828.
18. Freed KS, Leder RA, Alexander C, et al. Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication. *AJR Am J Roentgenol*. 2001;176:1389-1392.
19. Lieberman PL, Seigle RL. Reactions to radiocontrast material. Anaphylactoid events in radiology. *Clin Rev Allergy Immunol*. 1999;17:469-496.
20. Sun Y, Parker DL. Performance analysis of maximum intensity projection algorithm for display of MRA images. *IEEE Trans Med Imaging*. 1999;18:1154-1169.
21. Johnson PT, Halpern EJ, Kuszyk BS, et al. Renal artery stenosis: CT angiography—comparison of real-time volume-rendering and maximum intensity projection algorithms. *Radiology*. 1999;211:337-343.
22. Baskaran V, Pereles FS, Nemcek AA Jr, et al. Gadolinium-enhanced 3-D MR angiography of renal artery stenosis: a pilot comparison of maximum intensity projection, multi-planar reformatting, and 3-D volume rendering post-processing algorithms. *Proc Int Soc Magn Reson Med*. 2001;9:1935.
23. Vogt FM, Ajaj W, Hunold P, et al. Venous compression at high-spatial-resolution three-dimensional MR angiography of peripheral arteries. *Radiology*. 2004;233:913-920.
24. Marcos HB, Choyke PL. Magnetic resonance angiography of the kidney. *Semin Nephrol*. 2000;20:450-455.
25. Hussain SM, Kock MC, Jzermans JN, et al. MR imaging: a “one-stop shop” modality for preoperative evaluation of potential living kidney donors. *Radiographics*. 2003;23:505-520.
26. Israel GM, Lee VS, Edye M, et al. Comprehensive MR imaging in the preoperative evaluation of living donor candidates for laparoscopic nephrectomy: initial experience. *Radiology*. 2002;225:427-432.
27. Monroy-Cuadros M, McLaughlin K, Salazar A, et al. Assessment of live kidney donors by magnetic resonance angiography: reliability and impact on outcomes. *Clin Transplant*. 2008;22:29-34.
28. He J, Klag MJ, Appel LJ, et al. Seven-year incidence of hypertension in a cohort of middle-aged African Americans and whites. *Hypertension*. 1998;31:1130-1135.
29. Derckx FHM, Schalekamp MADH. Renal artery stenosis and hypertension. *Lancet*. 1994;344:237-239.
30. Baumgartner I, von Aesch K, Do DD, et al. Stent placement in ostial and nonostial atherosclerotic renal arterial stenoses: a prospective follow-up study. *Radiology*. 2000;216:498-505.
31. Bush RL, Najibi S, MacDonald MJ, et al. Endovascular revascularization of renal artery stenosis: technical and clinical results. *J Vasc Surg*. 2001;33:1041-1049.
32. Henry M, Amor M, Henry I, et al. Stents in the treatment of renal artery stenosis: long-term follow-up. *J Endovasc Surg*. 1999;6:42-51.

33. Sharafuddin MJ, Stolpen AH, Dixon BS, et al. Value of MR angiography before percutaneous transluminal renal artery angioplasty and stent placement. *J Vasc Interv Radiol.* 2002;13:901-908.
34. Kaatee R, Beek FJ, Verschuyt EJ, et al. Atherosclerotic renal artery stenosis: ostial or truncal? *Radiology.* 1996;199:637-640.
35. Birrer M, Do DD, Mahler F, et al. Treatment of renal artery fibromuscular dysplasia with balloon angioplasty: a prospective follow-up study. *Eur J Vasc Endovasc Surg.* 2002;23:146-152.
36. Gilfeather M, Holland GA, Siegelman ES, et al. Gadolinium-enhanced ultrafast three-dimensional spoiled gradient-echo MR imaging of the abdominal aorta and visceral and iliac vessels. *Radiographics.* 1997;17:423-432.
37. Debatin JF, Sostman HD, Knelson M, et al. Renal magnetic resonance angiography in the preoperative detection of supernumerary renal arteries in potential kidney donors. *Invest Radiol.* 1993;28:882-889.
38. Nelson HA, Gilfeather M, Holman JM, et al. Gadolinium-enhanced breathhold three-dimensional time-of-flight renal MR angiography in the evaluation of potential renal donors. *J Vasc Interv Radiol.* 1999;10:175-181.
39. Dillavou E, Kahn MB. Peripheral vascular disease. Diagnosing and treating the 3 most common peripheral vasculopathies. *Geriatrics.* 2003;58:37-42.
40. Sharafuddin MJ, Wroblecka JT, Sun S, et al. Percutaneous vascular intervention based on gadolinium-enhanced MR angiography. *J Vasc Interv Radiol.* 2000;11:739-746.
41. Carpenter JP, Baum RA, Holland GA, et al. Peripheral vascular surgery with magnetic resonance angiography as the sole preoperative imaging modality. *J Vasc Surg.* 1994;20:861-869; discussion 869-871.
42. Khilnani NM, Winchester PA, Prince MR, et al. Peripheral vascular disease: combined 3D bolus chase and dynamic 2D MR angiography compared with x-ray angiography for treatment planning. *Radiology.* 2002;224:63-74.
43. Carpenter JP, Owen RS, Holland GA, et al. Magnetic resonance angiography of the aorta, iliac, and femoral arteries. *Surgery.* 1994;116:17-23.
44. Steffens JC, Schafer FK, Oberscheid B, et al. Bolus-chasing contrast-enhanced 3D MRA of the lower extremity. Comparison with intraarterial DSA. *Acta Radiol.* 2003;44:185-192.
45. Owen RS, Carpenter JP, Baum RA, et al. Magnetic resonance imaging of angiographically occult runoff vessels in peripheral arterial occlusive disease. *N Engl J Med.* 1992;326:1577-1581.
46. Visser K, Kuntz KM, Donaldson MC, et al. Pretreatment imaging workup for patients with intermittent claudication: a cost-effectiveness analysis. *J Vasc Interv Radiol.* 2003;14:53-62.
47. Yin D, Baum RA, Carpenter JP, et al. Cost-effectiveness of MR angiography in cases of limb-threatening peripheral vascular disease. *Radiology.* 1995;194:757-764.
48. Konkus CJ, Czum JM, Jacobacci JT. Contrast-enhanced MR angiography of the aorta and lower extremities with routine inclusion of the feet. *AJR Am J Roentgenol.* 2002;179:115-117.
49. Morasch MD, Collins J, Pereles FS, et al. Lower extremity stepping-table magnetic resonance angiography with multilevel contrast timing and segmented contrast infusion. *J Vasc Surg.* 2003;37:62-71.
50. Hofmann WJ, Forstner R, Kofler B, et al. Pedal artery imaging—a comparison of selective digital subtraction angiography, contrast enhanced magnetic resonance angiography and duplex ultrasound. *Eur J Vasc Endovasc Surg.* 2002;24:287-292.
51. Heverhagen JT, Wagner HJ, Bandorski D, et al. Magnetic resonance phase contrast velocity measurement for non-invasive follow up after percutaneous transluminal angioplasty. *Vasa.* 2002;31:235-240.
52. Heverhagen JT, Kalinowski M, Schwarz U, et al. Quantitative human in vivo evaluation of high resolution MRI for vessel wall morphometry after percutaneous transluminal angioplasty. *Magn Reson Imaging.* 2000;18:985-989.
53. Coulden RA, Moss H, Graves MJ, et al. High resolution magnetic resonance imaging of atherosclerosis and the response to balloon angioplasty. *Heart.* 2000;83:188-191.
54. Nederkoorn PJ, van der Graaf Y, Hunink MG. Duplex ultrasound and magnetic resonance angiography compared with digital subtraction angiography in carotid artery stenosis: a systematic review. *Stroke.* 2003;34:1324-1332.

55. Lenhart M, Framme N, Volk M, et al. Time-resolved contrast-enhanced magnetic resonance angiography of the carotid arteries: diagnostic accuracy and inter-observer variability compared with selective catheter angiography. *Invest Radiol.* 2002;37:535-541.
56. Westwood ME, Kelly S, Berry E, et al. Use of magnetic resonance angiography to select candidates with recently symptomatic carotid stenosis for surgery: Systematic review. *BMJ.* 2002;324:198-222.
57. Cosottini M, Pingitore A, Puglioli M, et al. Contrast-enhanced three-dimensional magnetic resonance angiography of atherosclerotic internal carotid stenosis as the noninvasive imaging modality in revascularization decision making. *Stroke.* 2003;34:660-664.
58. Roberts DA. Magnetic resonance imaging of thoracic aortic aneurysm and dissection. *Semin Roentgenol.* 2001;36:295-308.
59. Carr JC, Finn JP. MR imaging of the thoracic aorta. *Magn Reson Imaging Clin N Am.* 2003;11:135-148.
60. Ho VB, Corse WR. MR angiography of the abdominal aorta and peripheral vessels. *Radiol Clin North Am.* 2003;41:115-144.
61. Vogt FM, Goyen M, Debatin JF. MR angiography of the chest. *Radiol Clin North Am.* 2003;41:29-41.
62. Carpenter JP, Holland GA, Golden MA, et al. Magnetic resonance angiography of the aortic arch. *J Vasc Surg.* 1997;25:145-151.
63. Fernandez GC, Tardaguila FM, Duran D, et al. Dynamic 3-dimensional contrast-enhanced magnetic resonance angiography in acute aortic dissection. *Curr Probl Diagn Radiol.* 2002;31:134-145.
64. Leiner T, Elenbaas TW, Kaandorp DW, et al. Magnetic resonance angiography of an aortic dissection. *Circulation.* 2001;103:E76-E78.
65. Hartnell GG. Imaging of aortic aneurysms and dissection: CT and MRI. *J Thorac Imaging.* 2001;16:35-46.
66. Anbarasu A, Harris PL, McWilliams RG. The role of gadolinium-enhanced MR imaging in the preoperative evaluation of inflammatory abdominal aortic aneurysm. *Eur Radiol.* 2002;12(Suppl 3):S192-S195.
67. Kawamoto S, Bluemke DA, Traill TA, et al. Thoracoabdominal aorta in Marfan syndrome: MR imaging findings of progression of vasculopathy after surgical repair. *Radiology.* 1997;203:727-732.
68. Engellau L, Albrechtsson U, Dahlstrom N, et al. Measurements before endovascular repair of abdominal aortic aneurysms. MR imaging with MRA vs. angiography and CT. *Acta Radiol.* 2003;44:177-184.
69. Neschis DG, Velazquez OC, Baum RA, et al. The role of magnetic resonance angiography for endoprosthetic design. *J Vasc Surg.* 2001;33:488-494.
70. Cejna M, Loewe C, Schoder M, et al. MR angiography vs CT angiography in the follow-up of nitinol stent grafts in endoluminally treated aortic aneurysms. *Eur Radiol.* 2002;12:2443-2450.
71. Insko EK, Kulzer LM, Fairman RM, et al. MR imaging for the detection of endoleaks in recipients of abdominal aortic stent-grafts with low magnetic susceptibility. *Acad Radiol.* 2003;10:509-513.
72. Chow LC, Chan FP, Li KC. A comprehensive approach to MR imaging of mesenteric ischemia. *Abdom Imaging.* 2002;27:507-516.
73. Cagnet F, Salem DB, Dransart M, et al. Chronic mesenteric ischemia: imaging and percutaneous treatment. *Radiographics.* 2002;22:863-879; discussion 879-880.
74. Carlos RC, Stanley JC, Stafford-Johnson D, et al. Interobserver variability in the evaluation of chronic mesenteric ischemia with gadolinium-enhanced MR angiography. *Acad Radiol.* 2001;8:879-887.
75. Lee VS, Morgan JN, Tan AGS, et al. Celiac artery compression by the median arcuate ligament: a pitfall of end-expiratory MR imaging. *Radiology.* 2003;228:437-442.
76. Bradbury MS, Kavanagh PV, Bechtold RE, et al. Mesenteric venous thrombosis: diagnosis and noninvasive imaging. *Radiographics.* 2002;22:527-541.
77. Kroencke TJ, Taupitz M, Arnold R, et al. Three-dimensional gadolinium-enhanced magnetic resonance venography in suspected thrombo-occlusive disease of the central chest veins. *Chest.* 2001;120:1570-1576.

78. Thornton MJ, Ryan R, Varghese JC, et al. A three-dimensional gadolinium-enhanced MR venography technique for imaging central veins. *AJR Am J Roentgenol*. 1999;173:999-1003.
79. Stern JB, Abehsera M, Grenet D, et al. Detection of pelvic vein thrombosis by magnetic resonance angiography in patients with acute pulmonary embolism and normal lower limb compression ultrasonography. *Chest*. 2002;122:115-121.
80. Spritzer CE, Arata MA, Freed KS. Isolated pelvic deep venous thrombosis: relative frequency as detected with MR imaging. *Radiology*. 2001;219:521-525.
81. Evans AJ, Sostman HD, Witty LA, et al. Detection of deep venous thrombosis: prospective comparison of MR imaging and sonography. *J Magn Reson Imaging*. 1996;6:44-51.
82. Demondion X, Bacqueville E, Paul C, et al. Thoracic outlet: assessment with MR imaging in asymptomatic and symptomatic populations. *Radiology*. 2003;227:461-468.
83. Fang YC, Siegelman ES. Complications of renal transplantation: MR findings. *J Comput Assist Tomogr*. 2001;25:836-842.
84. Atalay MK, Bluemke DA. Magnetic resonance imaging of large vessel vasculitis. *Curr Opin Rheumatol*. 2001;13:41-47.
85. Goyen M, Ruehm SG, Jagenburg A, et al. Pulmonary arteriovenous malformation: characterization with time-resolved ultrafast 3D MR angiography. *J Magn Reson Imaging*. 2001;13:458-460.
86. Maki DD, Siegelman ES, Roberts DA, et al. Pulmonary arteriovenous malformations: three-dimensional gadolinium-enhanced MR angiography—initial experience. *Radiology*. 2001;219:243-246.
87. Siegelman ES, Charafeddine R, Stolpen AH, et al. Suppression of intravascular signal on fat-saturated contrast-enhanced thoracic MR arteriograms. *Radiology*. 2000;217:115-118.
88. Tirkes AT, Rosen MA, Siegelman ES. Gadolinium susceptibility artifact causing false positive stenosis isolated to the proximal common carotid artery in 3D dynamic contrast medium enhanced MR angiography of the thorax—a brief review of causes and prevention. *Int J Cardiovasc Imaging*. 2003;19:151-155.
89. Neimatallah MA, Chenevert TL, Carlos RC, et al. Subclavian MR arteriography: reduction of susceptibility artifact with short echo time and dilute gadopentetate dimeglumine. *Radiology*. 2000;217:581-586.
90. Insko EK, Siegelman ES, Stolpen AH. Subacute clot mimicking flow in a thrombosed arterial bypass graft on two-dimensional time-of-flight and three-dimensional contrast-enhanced MRA. *J Magn Reson Imaging*. 2000;11:192-194.
91. Sam AD 2nd, Morasch MD, Collins J, et al. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. *J Vasc Surg*. 2003;38:313-318.
92. Erley CM, Bader BD, Berger ED, et al. Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients. *Nephrol Dial Transplant*. 2004;19:2526-2531.
93. Henson JW, Nogueira RG, Covarrubias DJ, et al. Gadolinium-enhanced CT angiography of the circle of Willis and neck. *AJNR Am J Neuroradiol*. 2004;25:969-972.
94. Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis—implications for nephrologists. *Eur J Radiol*. 2008;66:208-212.
95. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. *Eur J Radiol*. 2008;66:230-234.
96. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med*. 1999;130:461-470.
97. Bongartz G, Mayr M, Bilecen D. Magnetic resonance angiography (MRA) in renally impaired patients: when and how. *Eur J Radiol*. 2008;66:213-219.
98. Dempsey MF, Condon B, Hadley DM. MRI safety review. *Semin Ultrasound CT MR*. 2002;23:392-401.
99. McNeil DG Jr. M.R.I.'s Strong Magnets Cited in Accidents. The New York Times, August 19, 2005.
100. Shellock FG, Kanal E. *Magnetic Resonance: Bioeffects, Safety, and Patient Management*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1996.
101. Shellock FG. Magnetic resonance safety update 2002: implants and devices. *J Magn Reson Imaging*. 2002;16:485-496.

<<http://www.fda.gov/cdrh/safety/mrisafety.html>>.

103. Martin ET, Coman JA, Shellock FG, et al. Magnetic resonance imaging and cardiac pacemaker safety at 1.5-Tesla. *J Am Coll Cardiol.* 2004;43:1315-1324.
104. Roguin A, Zviman MM, Meininger GR, et al. Modern pacemaker and implantable cardioverter/defibrillator systems can be magnetic resonance imaging safe: in vitro and in vivo assessment of safety and function at 1.5 T. *Circulation.* 2004;110:475-482.
105. Sommer T, Naehle CP, Yang A, et al. Strategy for safe performance of extrathoracic magnetic resonance imaging at 1.5 tesla in the presence of cardiac pacemakers in non-pacemaker-dependent patients: a prospective study with 115 examinations. *Circulation.* 2006;114:1285-1292.
106. Nazarian S, Roguin A, Zviman MM, et al. Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1.5 tesla. *Circulation.* 2006;114:1277-1284.
107. Naehle CP, Sommer T, Meyer C, et al. Strategy for safe performance of magnetic resonance imaging on a patient with implantable cardioverter defibrillator. *Pacing Clin Electrophysiol.* 2006;29:113-116.
108. American Society for Testing and Materials (ASTM) International: ASTM F2503-05: Standard Practice for Marking Medical Devices and Other Items for Safety in the Magnetic Resonance Environment. West Conshohocken, PA, ASTM International. Available at <<http://www.astm.org/>>; 2005 Accessed 03.05.08.
109. Shellock FS. <<http://www.mrisafety.com/>>; Accessed May 3, 2008.
110. Hiramoto JS, Reilly LM, Schneider DB, et al. The effect of magnetic resonance imaging on stainless-steel Z-stent-based abdominal aortic prosthesis. *J Vasc Surg.* 2007;45:472-474.
111. Levine GN, Gomes AS, Arai AE, et al. Safety of magnetic resonance imaging in patients with cardiovascular devices: an American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention: Endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance. *Circulation.* 2007;116:2878-2891.
112. Hecht EM, Lee RF, Taouli B, et al. Perspectives on body MR imaging at ultrahigh field. *Magn Reson Imaging Clin N Am.* 2007;15:449-465.
113. DeLano MC, Fisher C. 3T MR imaging of the brain. *Magn Reson Imaging Clin N Am.* 2006;14:77-88.
114. Mosher TJ. Musculoskeletal imaging at 3T: Current techniques and future applications. *Magn Reson Imaging Clin N Am.* 2006;14:63-76.
115. Merkle EM, Dale BM, Paulson EK. Abdominal MR imaging at 3T. *Magn Reson Imaging Clin N Am.* 2006;14:17-26.
116. Michaely HJ, Attenberger UI, Kramer H, et al. Abdominal and pelvic MR angiography. *Magn Reson Imaging Clin N Am.* 2007;15:301-314.
117. DeMarco JK, Huston J 3rd, Nash AK. Extracranial carotid MR imaging at 3T. *Magn Reson Imaging Clin N Am.* 2006;14:109-121.
118. Diehm N, Kickuth R, Baumgartner I, et al. Magnetic resonance angiography in infrapopliteal arterial disease: prospective comparison of 1.5 and 3 tesla magnetic resonance imaging. *Invest Radiol.* 2007;42:467-476.
119. Lin W, An H, Chen Y, et al. Practical consideration for 3T imaging. *Magn Reson Imaging Clin N Am.* 2003;11:615-639.
120. Tanenbaum LN. Clinical 3T MR imaging: mastering the challenges. *Magn Reson Imaging Clin N Am.* 2006;14:1-15.
121. Heidemann RM, Ozsarlak O, Parizel PM, et al. A brief review of parallel magnetic resonance imaging. *Eur Radiol.* 2003;13:2323-2337.
122. Larkman DJ, Nunes RG. Parallel magnetic resonance imaging. *Phys Med Biol.* 2007;52:R15-R55.
123. Niendorf T, Sodickson DK. Parallel imaging in cardiovascular MRI: methods and applications. *NMR Biomed.* 2006;19:325-341.
124. Blaimer M, Breuer F, Mueller M, et al. SMASH, SENSE, PILS, GRAPPA: how to choose the optimal method. *Top Magn*

*Reson Imaging*. 2004;15:223-236.

125. Breuer FA, Kellman P, Griswold MA, et al. Dynamic autocalibrated parallel imaging using temporal GRAPPA (TGRAPPA). *Magn Reson Med*. 2005;53:981-985.
126. Huang F, Akao J, Vijayakumar S, et al. k-t GRAPPA: a k-space implementation for dynamic MRI with high reduction factor. *Magn Reson Med*. 2005;54:1172-1184.
127. Kruger DG, Riederer SJ, Grimm RC, et al. Continuously moving table data acquisition method for long FOV contrast-enhanced MRA and whole-body MRI. *Magn Reson Med*. 2002;47:224-231.
128. Zenge MO, Vogt FM, Brauck K, et al. High-resolution continuously acquired peripheral MR angiography featuring partial parallel imaging GRAPPA. *Magn Reson Med*. 2006;56:859-865.
129. Andreisek G, Pfammatter T, Goepfert K, et al. Peripheral arteries in diabetic patients: standard bolus-chase and time-resolved MR angiography. *Radiology*. 2007;242:610-620.
130. Bremerich J, Bilecen D, Reimer P. MR angiography with blood pool contrast agents. *Eur Radiol*. 2007;17:3017-3024.
131. Rapp JH, Wolff SD, Quinn SF, et al. Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography—multicenter comparative phase III study. *Radiology*. 2005;236:71-78.
132. Leiner T, Schoenberg SO. Current status of renal artery magnetic resonance imaging: theoretical and practical considerations and the potential role of blood-pool contrast agents. *Eur Radiol*. 2007;17(Suppl 2):B13-B17.
133. Maki JH, Wilson GJ, Eubank WB, et al. Navigator-gated MR angiography of the renal arteries: a potential screening tool for renal artery stenosis. *AJR Am J Roentgenol*. 2007;188:540-546.
134. Fayad ZA. MR imaging for the noninvasive assessment of atherothrombotic plaques. *Magn Reson Imaging Clin N Am*. 2003;11:101-113.
135. Yuan C, Mitsumori LM, Ferguson MS, et al. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. *Circulation*. 2001;104:2051-2056.
136. Cai JM, Hatsukami TS, Ferguson MS, et al. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. *Circulation*. 2002;106:1368-1373.
137. Mitsumori LM, Hatsukami TS, Ferguson MS, et al. In vivo accuracy of multisequence MR imaging for identifying unstable fibrous caps in advanced human carotid plaques. *J Magn Reson Imaging*. 2003;17:410-420.
138. Fayad ZA, Nahar T, Fallon JT, et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. *Circulation*. 2000;101:2503-2509.
139. Botnar RM, Stuber M, Kissinger KV, et al. Noninvasive coronary vessel wall and plaque imaging with magnetic resonance imaging. *Circulation*. 2000;102:2582-2587.
140. Wasserman BA, Smith WI, Trout HH III, et al. Carotid artery atherosclerosis: in vivo morphologic characterization with gadolinium-enhanced double-oblique MR imaging initial results. *Radiology*. 2002;223:566-573.
141. Yuan C, Kerwin WS, Ferguson MS, et al. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. *J Magn Reson Imaging*. 2002;15:62-67.
142. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. *Circulation*. 2003;107:2453-2458.
143. Maki JH, Wilson GJ, Lauffer RB, et al. Apparent vessel wall inflammation detected using MS-325, a blood pool contrast agent. *Proc Int Soc Mag Reson Med*. 2001;9:639.
144. Winter PM, Morawski AM, Caruthers SD, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. *Circulation*. 2003;108:2270-2274.
145. Meyer BC, Oldenburg A, Frericks BB, et al. Quantitative and qualitative evaluation of the influence of different table feeds on visualization of peripheral arteries in CT angiography of aortoiliac and lower extremity arteries. *Eur Radiol*. 2008;18:1546-1555.

146. International Commission on Radiological Protection. Managing Patient Dose in Computed Tomography, ICRP Publication 87. *Annals of the ICRP*. 2001;30.
147. Liu X, Zhao X, Huang J, et al. Comparison of 3D free-breathing coronary MR angiography and 64-MDCT angiography for detection of coronary stenosis in patients with high calcium scores. *AJR Am J Roentgenol*. 2007;189:1326-1332.
148. Amano Y, Ishihara M, Hayashi H, et al. Metallic artifacts of coronary and iliac arteries stents in MR angiography and contrast-enhanced CT. *Clin Imaging*. 1999;23:85-89.
149. Maintz D, Fischbach R, Juergens KU, et al. Multislice CT angiography of the iliac arteries in the presence of various stents: in vitro evaluation of artifacts and lumen visibility. *Invest Radiol*. 2001;36:699-704.
150. Willoteaux S, Negawi Z, Lions C, et al. Observations from multidetector CT imaging of different types of renal artery stents. *J Endovasc Ther*. 2004;11:560-569.
151. Lefourneau-Guillon L, Soulez G, Beaudoin G, et al. CT and MR imaging of nitinol stents with radiopaque distal markers. *J Vasc Interv Radiol*. 2004;15:615-624.
152. Sagara Y, Kiyosue H, Hori Y, et al. Limitations of three-dimensional reconstructed computerized tomography angiography after clip placement for intracranial aneurysms. *J Neurosurg*. 2005;103:656-661.
153. van der Schaaf I, van Leeuwen M, Vlassenbroek A, et al. Minimizing clip artifacts in multi CT angiography of clipped patients. *AJNR Am J Neuroradiol*. 2006;27:60-66.
154. Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. *N Engl J Med*. 2007;357:2277-2284.
155. Einstein AJ, Henzlova MJ, Rajagopalan S. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. *JAMA*. 2007;298:317-323.

## 第 23 章

1. Cieszynski T. Intracardiac method for investigation of structure of the heart with the aid of ultrasonics. *Arch Immun Ter Dow*. 1960;8:551-557.
2. Wells PNT. Development in medical ultrasonics. *World Med Electron*. 1966;66:272-277.
3. Nissen SE, Gurley JC, Grines CL, et al. Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary disease. *Circulation*. 1991;84:1087-1099.
4. The SHK, Gussenhoven EJ, Zhong Y, et al. Effect of balloon angioplasty on femoral artery evaluated with intravascular ultrasound imaging. *Circulation*. 1992;86:483-493.
5. Kopchok GE, Donayre CE, White RA. Principles and devices. *Semin Vasc Surg*. 2006;19:128-131.
6. Saket RR, Razavi MK, Padidar A, et al. Novel intravascular ultrasound-guided method to create transintimal arterial communications. *J Endovasc Ther*. 2004;11:274-280.
7. Di Mario C, The SHK, Madretsma S, et al. Detection and characterization of vascular lesions by intravascular ultrasound: an in vitro study correlated with histology. *J Am Soc Echocardiogr*. 1992;5:135-146.
8. Gussenhoven EJ, Essed CE, Lancé CT, et al. Arterial wall characteristics determined by intravascular ultrasound imaging: an in vitro study. *J Am Coll Cardiol*. 1989;14:947-952.
9. Nishimura RA, Edwards WD, Warnes CA, et al. Intravascular ultrasound imaging: in vitro validation and pathologic correlation. *J Am Coll Cardiol*. 1990;16:145-154.
10. Chong WK, Lawrence R, Gardener J, et al. The appearance of normal and abnormal arterial morphology on intravascular ultrasound. *Clin Radiol*. 1993;48:301-306.
11. Tabbara M, White R, Cavaye D, et al. In vivo comparison of intravascular ultrasound and angiography. *J Vasc Surg*. 1991;14:496-504.
12. Bartorelli AL, Neville RF, Keren G, et al. In vitro and in vivo intravascular ultrasound imaging. *Eur Heart J*. 1992;13:102-108.

13. Mallery JA, Tobis JM, Griffith J, et al. Assessment of normal and atherosclerotic arterial wall thickness with an intravascular imaging catheter. *Am Heart J*. 1990;119:1392-1400.
14. Bolz KD, Teit K, Nordby A, et al. Intravascular ultrasonographic appearance of angiographically normal arteries related to age and the occurrence of vascular disease. *Acta Radiol*. 1992;33:532-538.
15. Gussenhoven EJ, Essed CE, Frietman P, et al. Intravascular ultrasonic imaging: histologic and echographic correlation. *Eur J Vasc Surg*. 1989;3:571-576.
16. Jeremy R, Hasche E, Sinclair E, et al. Visualisation of arterial structure in vivo with intravascular ultrasound. *Aust N Z J Med*. 1993;23:362-369.
17. Potkin BN, Bartorelli AL, Gessert JM, et al. Coronary artery imaging with intravascular high-frequency ultrasound. *Circulation*. 1990;81:1575-1585.
18. Tobis JM, Mallery JA, Gessert J, et al. Intravascular ultrasound imaging of human coronary arteries in vivo. *Circulation*. 1991;83:913-926.
19. Vince G, Davies SC. Peripheral application of intravascular ultrasound virtual histology. *Semin Vasc Surg*. 2004;17:119-125.
20. Dietrich EB, Margolis P, Reid DB, et al. Virtual histology intravascular ultrasound assessment of carotid artery disease. *J Endovasc Ther*. 2007;14:676-686.
21. Nair A, Kuban BD, Tuzcu M, et al. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. *Circulation*. 2002;106:2200-2206.
22. DeMaria AN, Narula J, Mahmud E, et al. Imaging vulnerable plaque by ultrasound. *J Am Coll Cardiol*. 2006;47:C32-C39.
23. Schoenhagen P, Tuzcu M, Apperson-Hansen C, et al. Determinants of arterial wall remodeling during lipid-lowering therapy. *Circulation*. 2006;113:2826-2834.
24. Irshad K, Reid D, Miller P, et al. Early clinical experience with color three dimensional intravascular ultrasound in peripheral interventions. *J Endovasc Ther*. 2001;8:329-338.
25. Thrush AJ, Bonnett DE, Elliott MR, et al. An evaluation of the potential and limitations of three-dimensional reconstructions from intravascular ultrasound images. *Ultrasound Med Biol*. 1997;23:437-445.
26. Klingensmith JD, Schoenhagen P, Tajaddini A, et al. Automated three-dimensional assessment of coronary artery anatomy with intravascular ultrasound scanning. *Am Heart J*. 2003;145:795-805.
27. Reid DB, Douglas M, Dietrich EB. The clinical value of three-dimensional intravascular ultrasound imaging. *J Endovasc Surg*. 1995;2:356-364.
28. Finet G, Maurincomme E, Tabib A, et al. Artefacts in intravascular ultrasound imaging: analyses and implications. *Ultrasound Med Biol*. 1993;19:533-547.
29. Lyon RT, Zarins CK, Lu C-T, et al. Vessel, plaque and lumen morphology after transluminal balloon angioplasty. *Arteriosclerosis*. 1987;7:306-314.
30. Pasterkamp G, Borst C, Gussenhoven EJ, et al. Remodeling of de novo atherosclerotic lesions in femoral arteries: impact on mechanism of balloon angioplasty. *J Am Coll Cardiol*. 1995;26:422-428.
31. van der Lugt A, Gussenhoven EJ, Mali WPTM, et al. Effect of balloon angioplasty in femoropopliteal arteries assessed by intravascular ultrasound. *Eur J Vasc Endovasc Surg*. 1997;13:549-556.
32. Vogt KC, Just S, Rasmussen JG, et al. Prediction of outcome of femoropopliteal balloon angioplasty by intravascular ultrasound. *Eur J Vasc Endovasc Surg*. 1997;13:563-568.
33. Gussenhoven EJ, van der Lugt A, Pasterkamp G, et al. Intravascular ultrasound predictors of outcome after peripheral balloon angioplasty. *Eur J Vasc Endovasc Surg*. 1995;10:279-288.
34. van der Lugt A, Gussenhoven EJ, Pasterkamp G, et al. Intravascular ultrasound predictors of restenosis after balloon angioplasty of the femoropopliteal artery. *Eur J Endovasc Surg*. 1998;16:110-119.
35. Mintz GS, Popma JJ, Pichard AD, et al. Intravascular ultrasound predictors of restenosis after PTCA. *J Am Coll Cardiol*. 1996;27:1678-1687.



36. van der Lugt A, Gussenhoven EJ, Stijnen T, et al. Comparison of intravascular ultrasound findings after coronary balloon angioplasty evaluated in vitro with histology. *Am J Cardiol.* 1995;76:661-666.
37. Tobis JM, Mallory JA, Gessert J, et al. Intravascular ultrasound cross-sectional arterial imaging before and after balloon angioplasty in vitro. *Circulation.* 1989;80:873-882.
38. Coy KM, Park JC, Fishbein MC, et al. In vitro validation of three-dimensional intravascular ultrasound for the evaluation of arterial injury after balloon angioplasty. *J Am Coll Cardiol.* 1992;20:692-700.
39. Peters RJG, Kok WEM, van der Wal A, et al. In vitro validation of intravascular ultrasound imaging after balloon angioplasty of coronary artery stenoses. *Ultrasound Med Biol.* 1996;22:999-1005.
40. Slepian MJ. Application of intraluminal ultrasound imaging to vascular stenting. *Int J Card Imaging.* 1991;6:285-311.
41. Kuribayashi S, Takamiya M, Homma S. Intravascular ultrasound observations during iliac stent deployment. *Int Angiol.* 1999;18:263-290.
42. Ge J, Erbel R, Zamorano J, et al. Improvement of coronary morphology and blood flow after stenting. *Int J Card Imaging.* 1995;11:81-87.
43. Buckley CJ, Arko FR, Lee S, et al. Intravascular ultrasound scanning improves long-term patency of iliac lesions treated with balloon angioplasty and primary stenting. *J Vasc Surg.* 2002;35:316-323.
44. Post MJ, de Smet BJGL, van der Helm Y, et al. Arterial remodeling after balloon angioplasty and stenting in an atherosclerotic experimental model. *Circulation.* 1997;96:996-1003.
45. Clark DJ, Lessio S, O'Donoghue M, et al. Mechanisms and predictors of carotid artery stent restenosis. *J Am Coll Cardiol.* 2006;47:2390-2396.
46. van Essen JA, Gussenhoven EJ, van der Lugt A, et al. Accurate assessment of abdominal aortic aneurysm by intravascular ultrasound: validation with computed tomographic angiography. *J Vasc Surg.* 1999;29:631-638.
47. Verbin C, Scoccianti M, Kopchok G, et al. Comparison of the utility of CT scans and intravascular ultrasound in endovascular aortic grafting. *Ann Vasc Surg.* 1995;9:434-440.
48. Vogt KC, Brunckwall J, Malina M, et al. The use of intravascular ultrasound as control procedure for the deployment of endovascular stented grafts. *Eur J Endovasc Surg.* 1997;13:592-596.
49. White RA, Verbin C, Kopchok G, et al. The role of cinefluoroscopy and intravascular ultrasonography in evaluating the deployment of experimental endovascular prosthesis. *J Vasc Surg.* 1995;21:365-374.
50. Koschyk DH, Nienaber CA, Knap M, et al. How to guide stent-graft implantation in type B aortic dissection: comparison of angiography, transesophageal echocardiography and intravascular ultrasound. *Circulation.* 2005;112:I260-I264.
51. Ohki T. Pros and cons of IVUS imaging for endovascular procedures. *J Endovasc Today.* 2008;80-82.
52. Nishanian G, Kopchok GE, Donayre CE, et al. The impact of IVUS on endovascular interventions. *Semin Vasc Surg.* 1999;12:285.
53. Song TK, Donayre CE, Kopchok GE, White RA. Intravascular ultrasound use in the treatment of thoracoabdominal dissections, aneurysms and transections. *Semin Vasc Surg.* 2006;19:145-149.
54. Husmann MJ, Kickuth R, Ludwig K, et al. Intravascular ultrasound-guided creation of re-entry sites to improve intermittent claudication in patients with aortic dissection. *J Endovasc Ther.* 2006;13:424-428.
55. Marty B, Tozzi P, Ruchat P, et al. An IVUS-based approach to traumatic aortic rupture with a look at the lesion from inside. *J Endovasc Ther.* 2007;14:689-697.
56. Tielbeck AV, Vroegindeweij D, Buth J, et al. Comparison of intravascular ultrasonography and intraarterial digital subtraction angiography after directional atherectomy of short lesions in femoropopliteal arteries. *J Vasc Surg.* 1996;23:436-445.
57. Vogt KC, Sillesen H, Schroeder TV. The use of intravascular ultrasound for intraoperative assessment during semiclosed thromboendarterectomy. *Ultrasound Med Biol.* 1998;24:21-25.
58. Kastelein JJP, de Groot E. Ultrasound imaging techniques for the evaluation of cardiovascular therapies. *Eur Heart J.*

- 2008;29:849-858.
59. Berry C, L'Allier PL, Grégoire J, et al. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. *Circulation*. 2007;115:1851-1857.
  60. Gerber R, Colombo A. Does IVUS guidance of coronary interventions affect outcome? A prime example of the failure of randomized clinical trials. *Catheter Cardiovasc Interv*. 2008;71:646-654.
  61. Arbab-Zabed A, Mehta RL, Ziegler TW, et al. Hemodialysis access assessment with intravascular ultrasound. *Am J Kidney Dis*. 2002;39:813-823.
  62. Petersen B. Intravascular ultrasound-guided direct intrahepatic portacaval shunt: description of technique and technical refinements. *J Vasc Interv Radiol*. 2003;14:21-32.
  63. Kardys CM, Stoner MC, Manwaring ML, et al. The use of intravascular ultrasound imaging to improve use of inferior vena cava filters in a high bariatric population. *J Vasc Surg*. 2007;46:1248-1256.
  64. Neglón P, Raju S. Intravascular ultrasound scan evaluation of the obstructed vein. *J Vasc Surg*. 2002;35:694-700.
  65. Forauer AR, Gemmete JJ, Dasika NL, et al. Intravascular ultrasound in the diagnosis and treatment of iliac vein compression (May-Thurner) syndrome. *J Vasc Interv Radiol*. 2002;13:523-527.
  66. Neglón P, Hollis KC, Olivier J, et al. Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical and hemodynamic result. *J Vasc Surg*. 2007;46:979-990.
  67. van der Lugt A, Gussenhoven EJ, The SHK, et al. Femorodistal venous bypass evaluated with intravascular ultrasound. *Eur J Vasc Endovasc Surg*. 1995;9:394-402.

## 第 24 章

1. Vuu K, Xie J, McDonald MA, et al. Gadolinium-rhodamine nanoparticles for cell labeling and tracking via magnetic resonance and optical imaging. *Bioconjug Chem*. 2005;16:995-999.
2. Chiang S, ed. PET-CT. In: Paulino AC, Teh BS, eds. *Radiotherapy Treatment Planning*. Philadelphia, PA: Saunders-Elsevier; 2008.
3. van der Vaart MG, Meerwaldt R, Slart RH, et al. Application of PET/SPECT imaging in vascular disease. *Eur J Vasc Endovasc Surg*. 2008;35:507-513.
4. Husmann L, Wiegand M, Valenta I, et al. Diagnostic accuracy of myocardial perfusion imaging with single photon emission computed tomography and positron emission tomography: a comparison with coronary angiography. *Int J Cardiovasc Imaging*. 2008;24:511-518.
5. Rispler S, Keidar Z, Ghersin E, et al. Integrated single-photon emission computed tomography and computed tomography coronary angiography for the assessment of hemodynamically significant coronary artery lesions. *J Am Coll Cardiol*. 2007;49:1059-1067.
6. Stewart RE, Schwaiger M, Molina E, et al. Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease. *Am J Cardiol*. 1991;67:1303-1310.
7. Go RT, Marwick TH, MacIntyre WJ, et al. A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease. *J Nucl Med*. 1990;31:1899-1905.
8. Bateman TM, Heller GV, McGhie AI, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. *J Nucl Cardiol*. 2006;13:24-33.
9. Di Carli MF, Dorbala S, Meserve J, et al. Clinical myocardial perfusion PET/CT. *J Nucl Med*. 2007;48:783-793.
10. Chaudhry FA, Tauke JT, Alessandrini RS, et al. Enhanced detection of ischemic myocardium by transesophageal dobutamine stress echocardiography: comparison with simultaneous transthoracic echocardiography. *Echocardiography*. 2000;17:241-253.
11. Duet M, Virally M, Bailliar O, et al. Whole-body (201)Tl scintigraphy can detect exercise lower limb perfusion

- abnormalities in asymptomatic diabetic patients with normal Doppler pressure indices. *Nucl Med Commun*. 2001;22:949-954.
12. Bajnok L, Kozlovsky B, Varga J, et al. Technetium-99m sestamibi scintigraphy for the assessment of lower extremity ischaemia in peripheral arterial disease. *Eur J Nucl Med*. 1994;21:1326-1332.
  13. Penuelas I, Aranguren XL, Abizanda G, et al. (13)N-ammonia PET as a measurement of hindlimb perfusion in a mouse model of peripheral artery occlusive disease. *J Nucl Med*. 2007;48:1216-1223.
  14. Hamanaka D, Odori T, Maeda H, et al. A quantitative assessment of scintigraphy of the legs using <sup>201</sup>Tl. *Eur J Nucl Med*. 1984;9:12-16.
  15. Miles KA, Barber RW, Wraight EP, et al. Leg muscle scintigraphy with <sup>99m</sup>Tc-MIBI in the assessment of peripheral vascular (arterial) disease. *Nucl Med Commun*. 1992;13:593-603.
  16. Celen YZ, Zincirkeser S, Akdemir I, et al. Investigation of perfusion reserve using 99Tc(m)-MIBI in the lower limbs of diabetic patients. *Nucl Med Commun*. 2000;21:817-822.
  17. Lin CC, Ding HJ, Chen YW, et al. Usefulness of thallium-201 muscle perfusion scan to investigate perfusion reserve in the lower limbs of type 2 diabetic patients. *J Diabetes Complications*. 2004;18:233-236.
  18. Lüdemann L, Warmuth C, Plotkin M, et al. Brain tumor perfusion: comparison of dynamic contrast enhanced magnetic resonance imaging using T1, T2, and T2\* contrast, pulsed arterial spin labeling, and H2(15)O positron emission tomography. *Eur J Radiol*. 2009;70:465-474.
  19. Vernon MR, Maheshwari M, Schultz CJ, et al. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. *Int J Radiat Oncol Biol Phys*. 2008;70:678-684.
  20. Weiner SM, Vaith P, Walker UA, et al. Detection of alterations in brain glucose metabolism by positron emission tomography in Takayasu's arteritis. *Eur J Nucl Med Mol Imaging*. 2004;31:300-302.
  21. Takasawa M, Jones PS, Guadagno JV, et al. How reliable is perfusion MR in acute stroke? Validation and determination of the penumbra threshold against quantitative PET. *Stroke*. 2008;39:870-877.
  22. Gould KL, Pan T, Loghin C, et al. Frequent diagnostic errors in cardiac PET/CT due to misregistration of CT attenuation and emission PET images: a definitive analysis of causes, consequences, and corrections. *J Nucl Med*. 2007;48:1112-1121.
  23. Schmidt WA, Blockmans D. Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. *Curr Opin Rheumatol*. 2005;17:9-15.
  24. Schillaci O. Hybrid SPECT/CT: a new era for SPECT imaging? *Eur J Nucl Med Mol Imaging*. 2005;32:521-524.
  25. Akincioglu C, Belhocine T, Gambhir S, et al. Complementary roles of low-dose SPECT-CT and high-resolution volume CT for detection of coronary artery disease. *Clin Nucl Med*. 2008;33:285-287.
  26. Walter MA. [(18)F]fluorodeoxyglucose PET in large vessel vasculitis. *Radiol Clin North Am*. 2007;45:735-744, viii.
  27. Hoffmann M, Corr P, Robbs J. Cerebrovascular findings in Takayasu disease. *J Neuroimaging*. 2000;10:84-90.
  28. Tato F, Hoffmann U. Clinical presentation and vascular imaging in giant cell arteritis of the femoropopliteal and tibioperoneal arteries. Analysis of four cases. *J Vasc Surg*. 2006;44:176-182.
  29. Kobayashi Y, Ishii K, Oda K, et al. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. *J Nucl Med*. 2005;46:917-922.
  30. Yun M, Yeh D, Araujo LI, et al. F-18 FDG uptake in the large arteries: a new observation. *Clin Nucl Med*. 2001;26:314-319.
  31. Andrews J, Mason JC. Takayasu's arteritis—recent advances in imaging offer promise. *Rheumatology (Oxford)*. 2007;46:6-15.
  32. Blockmans D, Stroobants S, Maes A, et al. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. *Am J Med*. 2000;108:246-249.
  33. Young JJ, Phillips HR, Marso SP, et al. Vulnerable plaque intervention: state of the art. *Catheter Cardiovasc Interv*. 2008;71:367-374.
  34. Saam T, Hatsukami TS, Takaya N, et al. The vulnerable, or high-risk, atherosclerotic plaque: noninvasive MR imaging for

- characterization and assessment. *Radiology*. 2007;244:64-77.
35. Davies JR, Rudd JH, Fryer TD, et al. Identification of culprit lesions after transient ischemic attack by combined <sup>18</sup>F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. *Stroke*. 2005;36:2642-2647.
  36. Sakalihasan N, Hustinx R, Limet R. Contribution of PET scanning to the evaluation of abdominal aortic aneurysm. *Semin Vasc Surg*. 2004;17:144-153.
  37. Rudd JH, Myers KS, Bansilal S, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. *J Am Coll Cardiol*. 2007;50:892-896.
  38. Rakita D, Newatia A, Hines JJ, et al. Spectrum of CT findings in rupture and impending rupture of abdominal aortic aneurysms. *Radiographics*. 2007;27:497-507.
  39. Truijers M, Pol JA, Schultzekool LJ, et al. Wall stress analysis in small asymptomatic, symptomatic and ruptured abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg*. 2007;33:401-407.
  40. Boules TN, Compton CN, Stanziale SF, et al. Can computed tomography scan findings predict "impending" aneurysm rupture? *Vasc Endovasc Surg*. 2006;40:41-47.
  41. Defawe OD, Hustinx R, Defraigne JO, et al. Distribution of F-18 fluorodeoxyglucose (F-18 FDG) in abdominal aortic aneurysm: high accumulation in macrophages seen on PET imaging and immunohistology. *Clin Nucl Med*. 2005;30:340-341.
  42. Kuehl H, Eggebrecht H, Boes T, et al. Detection of inflammation in patients with acute aortic syndrome: comparison of FDG-PET/CT imaging and serologic markers of inflammation. *Heart*. 2008;94:1472-1477.
  43. Wagner S, Breyholz HJ, Law MP, et al. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors *N*-hydroxy-2(R)-[[[4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET. *J Med Chem*. Nov 15 2007;50:5752-5764.
  44. Tegler G, Sorensen J, Bjorck M, et al. Detection of aortic graft infection by 18-fluorodeoxyglucose positron emission tomography combined with computed tomography. *J Vasc Surg*. 2007;45:828-830.
  45. Fukuchi K, Ishida Y, Higashi M, et al. Detection of aortic graft infection by fluorodeoxyglucose positron emission tomography: comparison with computed tomographic findings. *J Vasc Surg*. 2005;42:919-925.
  46. Orton DF, LeVeen RF, Saigh JA, et al. Aortic prosthetic graft infections: radiologic manifestations and implications for management. *Radiographics*. 2000;20:977-993.
  47. LaMuraglia GM, Fischman AJ, Strauss HW, et al. Utility of the indium 111-labeled human immunoglobulin G scan for the detection of focal vascular graft infection. *J Vasc Surg*. 1989;10:20-27; discussion 27-28.
  48. Shahidi S, Eskil A, Lundof E, et al. Detection of abdominal aortic graft infection: comparison of magnetic resonance imaging and indium-labeled white blood cell scanning. *Ann Vasc Surg*. 2007;21:586-592.
  49. Branstetter BF, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? *Radiology*. 2005;235:580-586.
  50. Benvenuti L, Chibbaro S, Carnesecchi S, et al. Automated three-dimensional volume rendering of helical computed tomographic angiography for aneurysms: an advanced application of neuronavigation technology. *Neurosurgery*. 2005;57(1 Suppl):69-77; discussion 69-77.
  51. Chibbaro S, Tacconi L. Image-guided microneurosurgical management of vascular lesions using navigated computed tomography angiography. An advanced IGS technology application. *Int J Med Robot*. 2006;2:161-167.
  52. Gutierrez LF, Silva R, Ozturk C, et al. Technology preview: x-ray fused with magnetic resonance during invasive cardiovascular procedures. *Catheter Cardiovasc Interv*. 2007;70:773-782.
  53. Bladin CF, Bingham L, Grigg L, et al. Transcranial Doppler detection of microemboli during percutaneous transluminal coronary angioplasty. *Stroke*. 1998;29:2367-2370.

## 第 25 章

1. Haimovici H, DePalma RC. Atherosclerosis. Biologic and surgical considerations. In: Haimovici H, Ascer E, Hollier LH, et al, eds. *Vascular Surgery Principles and Techniques*. 4th ed. Cambridge, MA: Blackwell Science; 1996:127.
2. McMillan GC. Nature and definitions of atherosclerosis. *Ann N Y Acad Sci*. 1985;454:1.
3. Mackey RH, Venkitachalam L, Sutton-Tyrrell K. Calcifications, arterial stiffness and atherosclerosis. *Adv Cardiol*. 2007;44:234-244.
4. Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease—six year follow-up experience: the Framingham study. *Ann Intern Med*. 1961;55:33.
5. Liapis CD, Balzer K, Fernandes e Fernandes J, et al. *Vascular Surgery*. Berlin: Springer-Verlag; 2007.
6. Holtzman JL. *Atherosclerosis and Oxidant Stress, a New Perspective*. New York: Springer Science+Business Media, LLC; 2008.
7. Kumar V, Abbas AK, Fausto N, et al. *Robbins Basic Pathology*. 8th ed. Philadelphia: Elsevier Saunders; 2007.
8. Topper JN, Cai J, Falb D, et al. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. *Proc Natl Acad Sci U S A*. 1996;93:10417.
9. Vogel RA. Cholesterol lowering and endothelial function. *Am J Med*. 1999;107:479.
10. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II—mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. *J Clin Invest*. 1996;97:1916.
11. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. *J Clin Invest*. 1993;91:2546.
12. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. *Am J Physiol*. 1992;263:H321.
13. Tsao PS, Buitrago R, Chang H, et al. Effects of diabetes on monocyte-endothelial interactions and endothelial superoxide production in fructose-induced insulin-resistant and hypertensive rats. *Circulation*. 1995;92:A2666.
14. Cooke JP. Does ADMA cause endothelial dysfunction? *Arterioscler Thromb Vasc Biol*. 2000;20:2032.
15. Flavahan NA. Atherosclerosis or lipoprotein induced endothelial dysfunction: potential mechanisms underlying reduction in EDRF/nitric oxide activity. *Circulation*. 1992;85:1927.
16. Gounopoulos P, Merki E, Hansen LF, et al. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. *Minerva Cardioangiol*. 2007;55:821.
17. Cybulsky MI, Gimbrone MAJ. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. *Science*. 1991;251:788.
18. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. *Circulation*. 1995;91:2488.
19. Tsao PS, Buitrago R, Chan JR, et al. Fluid flow inhibits endothelial adhesiveness: nitric oxide and transcriptional regulation of VCAM-1. *Circulation*. 1996;94:1682.
20. Tsao PS, Wang B, Buitrago R, et al. Nitric oxide regulates monocyte chemotactic protein-1. *Circulation*. 1997;96:934.
21. Ross R. Cellular and molecular studies of atherosclerosis. *Atherosclerosis*. 1997;131:S3.
22. Berliner JA, Territo MC, Sevanian A, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. *J Clin Invest*. 1990;85:1260.
23. Ross R. Cell biology of atherosclerosis. *Annu Rev Physiol*. 1995;57:791.
24. Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix

metalloproteinase activity in vascular tissue. *FASEB J*. 1995;9:974.

25. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. *Circulation*. 1995;92:1565.
26. Lendon CL, Davies MJ, Born GV, et al. Atherosclerotic plaque caps are locally weakened when macrophage density is increased. *Atherosclerosis*. 1991;87:87.
27. Hansson GK, Robertson AKL, Söderberg-Nauclé C. Inflammation and atherosclerosis. *Annu Rev Pathol*. 2006;1:297.
28. Taleb S, Tedgui A, Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. *J Intern Med*. 2008;263:489.
29. Kuiper J, van Puijvelde GH, van Wanrooij EJ, et al. Immunomodulation of the inflammatory response in atherosclerosis. *Curr Opin Lipidol*. 2007;18:521.
30. Torzewski J, Bowyer DE, Waltenberger J, et al. Processes in atherosclerosis: complement activation. *Atherosclerosis*. 1997;132:131.
31. Lindemann S, Kraemer B, Daub K, et al. Molecular pathways used by platelets to initiate and accelerate atherogenesis. *Curr Opin Lipidol*. 2007;18:566.
32. May AE, Seizer P, Gawaz M. Platelets: inflammatory firebugs of vascular walls. *Arterioscler Thromb Vasc Biol*. 2008;28:5.
33. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2008;28:812.
34. Golledge J, Greenhalgh RM, Davies AH. The symptomatic carotid plaque. *Stroke*. 2000;31:774.
35. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*. 2005;352:1685.
36. Daskalopoulou SS, Daskalopoulos ME, Perrea D, et al. Carotid artery atherosclerosis: what is the evidence for drug action? *Curr Pharm Des*. 2007;13:1141.
37. Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. *Arterioscler Thromb Vasc Biol*. 2000;20:1177.
38. Davies JR, Rudd JF, Fryer TD, et al. Targeting the vulnerable plaque: the evolving role of nuclear imaging. *J Nucl Cardiol*. 2005;12:234.
39. Rosner D, Stoneman V, Littlewood T, et al. Interferon-gamma induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K- and Akt-dependent mechanism. *Am J Pathol*. 2006;168:2054.
40. Falk E. Why do plaques rupture? *Circulation*. 1992;86:SI11-30.
41. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. *Circulation*. 1997;96:4095.
42. Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation*. 1999;100:1481.
43. Smith SC Jr, Greenland P, Grundy SM. Prevention conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary. *Circulation*. 2000;101:111.
44. Kullo IJ, Ballantyne CM. Conditional risk factors for atherosclerosis. *Mayo Clin Proc*. 2005;80:219.
45. Vidula H, Tian L, Liu K, et al. Biomarkers of inflammation and thrombosis as predictors of near term mortality in patients with peripheral arterial disease: a cohort study. *Ann Intern Med*. 2008;148:85.
46. Bartholomew JR, Olin JW. Pathophysiology of peripheral arterial disease and risk factors for its development. *Clev Clin J Med*. 2006;73:8.
47. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. *JAMA*. 2003;290:932.
48. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease. Application to

- clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation*. 2003;107:499.
49. Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication. A risk profile from the Framingham Heart Study. *Circulation*. 1997;96:44.
  50. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Health Study (CHS) Collaborative Research Group. *Circulation*. 1993;88:837.
  51. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. *JAMA*. 2001;286:1317.
  52. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. *Circulation*. 2004;110:738.
  53. Wattanakit K, Folsom AR, Selvin E, et al. Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. *Atherosclerosis*. 2005;180:389.
  54. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease: the San Luis Valley Diabetes Study. *Circulation*. 1995;91:1472.
  55. Joensuu T, Salonen R, Winblad I, et al. Determinants of femoral and carotid artery atherosclerosis. *J Intern Med*. 1994;236:79.
  56. Vogt MT, Cauley JA, Kuller LH, et al. Prevalence and correlates of lower extremity arterial disease in elderly women. *Am J Epidemiol*. 1993;137:559.
  57. Hobson RW II, Wilson SE, Veith FJ. *Vascular Surgery. Principles and Practice*. New York: Marcel Dekker; 2004.
  58. Meyers MR, Gocke N. Endothelial dysfunction in obesity: etiological role in atherosclerosis. *Curr Opin Endocrinol Diabetes Obes*. 2007;14:365.
  59. Brook RD. Obesity, weight loss and vascular function. *Endocrine*. 2006;29:21.
  60. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. *Am J Epidemiol*. 1990;132:612.
  61. Fletcher GF. The antiatherosclerotic effect of exercise and development of an exercise prescription. *Cardiol Clin*. 1996;14:85.
  62. Kadooglou NPE, Iliadis F, Liapis CD, et al. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes. *Diabetes Care*. 2007;30:2242.
  63. Kadooglou NP, Iliadis F, Liapis CD. Exercise and carotid atherosclerosis. *Eur J Vasc Endovasc Surg*. 2008;35:264.
  64. Vitale C, Miceli M, Rosano GM. Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention. *Climacteric*. 2007;10:16.
  65. Chen Y, Rollins J, Paigen B, et al. Genetic and genomic insights into the molecular basis of atherosclerosis. *Cell Metab*. 2007;6:164.
  66. Topol EJ. The genomic basis of myocardial infarction. *J Am Coll Cardiol*. 2005;46:1456.
  67. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. *Nat Genet*. 2004;36:233.
  68. Miller DT, Ridker PM, Libby P, et al. Atherosclerosis. The path from genomics to therapeutics. *J Am Coll Cardiol*. 2007;49:1589.
  69. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. *Circulation*. 1999;99:2192.
  70. Morland K, Wing S, Diez Roux A. The contextual effect of the local food environment on residents' diets: the Atherosclerosis Risk in Communities study. *Am J Public Health*. 2002;92:1761.
  71. Diez Roux AV, Jacobs DR, Kiefe CI. Neighborhood characteristics and components of the insulin resistance syndrome in young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) study. *Diabetes Care*. 2002;25:1976.

72. Wadsworth ME. Health inequalities in the life course perspective. *Soc Sci Med.* 1997;44:859.
73. Pollitt RA, Rose KM, Kaufman JS. Evaluating the evidence for models of life course socioeconomic factors and cardiovascular outcomes: a systematic review. *BMC Public Health.* 2005;5:7.
74. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. *Circulation.* 2004;110:738.
75. Saunders E, Ofili E. Epidemiology of atherothrombotic disease and the effectiveness and risks of antiplatelet therapy: race and ethnicity considerations. *Cardiol Rev.* 2008;16:82.
76. Criqui MH, Vargass V, Denenberg JO, et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. *Circulation.* 2005;112:2703.
77. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. *N Engl J Med.* 1998;338:1042.
78. D Angelo A, Mazzola G, Fermo I. Gene-gene and gene environment interactions in mild hyperhomocysteinemia. *Pathophysiol Hemost Thromb.* 2003;33:337.
79. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. *N Engl J Med.* 1991;324:1149.
80. Brattstrom L, Israelson B, Norrving B, et al. Impaired homocysteine metabolism in early onset cerebral and arterial occlusive disease. *Atherosclerosis.* 1990;81:51.
81. Darius H, Pittrow D, Haberl R, et al. Are elevated homocysteine plasma levels related to peripheral arterial disease? Results from a cross-sectional study of 6880 primary care patients. *Eur J Clin Invest.* 2003;33:751.
82. Guillard JC, Favier A, Potier de Courcy G, et al. Hyperhomocysteinemia: an independent risk factor or a simple marker of vascular disease? *Pathol Biol.* 2003;51:111.
83. Undas A, Brozec J, Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. *Thromb Haemost.* 2005;94:907.
84. Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. *Arch Pathol Lab Med.* 2007;131:872.
85. Carmody BJ, Arora S, Avena R, et al. Folic acid inhibits homocysteine-induced proliferation of human arterial smooth muscle cells. *J Vasc Surg.* 1999;30:1121.
86. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. *N Engl J Med.* 1998;338:1009.
87. Volanakis JE. Human C-reactive protein: expression, structure, and function. *Mol Immunol.* 2001;38:189.
88. Pietila K, Harmoinen A, Hermens W, et al. Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. *Eur Heart J.* 1993;14:915.
89. Paffen E, Vos HL, Bertina RM. C-reactive protein does not directly induce tissue factor in human monocytes. *Arterioscler Thromb Vasc Biol.* 2004;24:975.
90. Giannakis E, Male DA, Ormsby RJ, et al. Multiple ligand binding sites on domain seven of human complement factor H. *Int Immunopharmacol.* 2001;1:433.
91. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. *Circulation.* 2002;106:1439.
92. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. *Circulation.* 2004;109:2058.
93. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. *Circulation.* 2003;107:1783.
94. Pasceri V, Chang J, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. *Circulation.* 2001;103:2531.
95. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. *Cardiovasc Res.*



2003;58:186.

96. Ikonomidis I, Stamatelopoulos K, Lekakis J, et al. Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. *Atherosclerosis*. 2008;199:3.
97. Wilhelmssen L, Svärdsudd K, Korsan-Bengtson K, et al. Fibrinogen as a risk factor for stroke and myocardial infarction. *N Engl J Med*. 1984;311:501.
98. Meade TO, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. *Lancet*. 1986;2:533.
99. Thompson SG, Keinast J, Pyke SDM, et al. for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. *N Engl J Med*. 1995;332:635.
100. Kofoed SC, Wittrup HH, Sillesen H, et al. Fibrinogen predicts ischaemic stroke and advanced atherosclerosis, but not echolucent, rupture-prone carotid plaques. *Eur Heart J*. 2003;24:567.
101. The Bezafibrate Infarction Prevention (BIP) Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. *Circulation*. 2000;102:21.
102. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. *Circulation*. 1999;99:855.
103. Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation (WISE). *Circulation*. 2004;109:726.
104. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. *JAMA*. 1998;279:1477.
105. Tzoulaki I, Murray GD, Lee AJ, et al. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. *Circulation*. 2005;112:976.
106. McDermott MM, Guralnik JM, Corsi A, et al. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. *Am Heart J*. 2005;150:276.
107. Allison MA, Criqui MH, McClelland RL, et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). *J Am Coll Cardiol*. 2006;48:1190.
108. Mallat Z, Corbaz A, Scoazec A, et al. Interleukin-18/interleukin-18 binding protein signalling modulates atherosclerotic lesion development and stability. *Circ Res*. 2001;89:E41.
109. Elhage R, Jawien J, Rudling M, et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E–knockout mice. *Cardiovasc Res*. 2003;59:234.
110. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. *Circulation*. 2001;104:1598.
111. Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. *Thromb Haemost*. 2002;88:554.
112. Taubman MB, Fallon JT, Schechter AD, et al. Tissue factor in the pathogenesis of atherosclerosis. *Thromb Haemost*. 1997;78:200.
113. Hoogeveen RC, Morrison A, Boerwinkle E, et al. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. *Atherosclerosis*. 2005;183:301.
114. Chung HK, Lee IK, Kang H, et al. Statin inhibits interferon gamma–induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. *Exp Mol Med*. 2002;34:451.
115. André P, Nannizzi-Alaimo L, Prasad SK, et al. Platelet derived CD40L. The switch hitting player of cardiovascular disease. *Circulation*. 2002;106:896.
116. Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. *Circulation*. 1999;100:614.

117. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. *Arterioscler Thromb Vasc Biol.* 2007;27:27.
118. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A<sub>2</sub> activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. *Circulation.* 2005;111:570.
119. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor- $\alpha$ , in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation.* 2003;107:3133.
120. Muller-Ehmsen J, Schwinger RH. TNF and congestive heart failure: therapeutic possibilities. *Expert Opin Ther Targets.* 2004;8:203.
121. Leu HB, Wu CC, Wu TC, et al. Fluvastatin reduces oxidative stress, decreases serum monocyte chemotactic protein-1 level and improves endothelial function in patients with hypercholesterolemia. *J Formos Med Assoc.* 2004;103:914.
122. DePalma RG, Hayes VW, May PE, et al. Statins and biomarkers in claudicants with peripheral arterial disease: cross-sectional study. *Vascular.* 2006;14:193.
123. Jiang C, Ting AT, Seed B. PPAR- $\gamma$  agonists inhibit production of monocyte inflammatory cytokines. *Nature.* 1998;391:82.
124. Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor- $\gamma$  activators. *Circulation.* 2000;101:235.
125. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel *Chlamydia*, TWAR, with chronic coronary heart disease and acute myocardial infarction. *Lancet.* 1988;2:983.
126. Arcari CM, Gaydos CA, Nieto FJ, et al. Association between *Chlamydia pneumoniae* and acute myocardial infarction in young men in the United States military: the importance of timing of exposure measurement. *Clin Infect Dis.* 2005;40:1123.
127. Grayston JT, Kuo CC, Coulson AS, et al. *Chlamydia pneumoniae* (TWAR) in atherosclerosis of the carotid artery. *Circulation.* 1995;92:3397.
128. Kaperonis EA, Liapis CD, Kakisis JD, et al. The association of carotid plaque inflammation and *Chlamydia pneumoniae* infection with cerebrovascular symptomatology. *J Vasc Surg.* 2006;44:1198.
129. Sessa R, Di Pietro M, Schiavoni G, et al. *Chlamydia pneumoniae* DNA in patients with symptomatic carotid atherosclerotic disease. *J Vasc Surg.* 2003;37:1027.
130. Kaperonis EA, Liapis CD, Kakisis JD, et al. Inflammation and *Chlamydia pneumoniae* infection correlate with the severity of peripheral arterial disease. *Eur J Vasc Endovasc Surg.* 2006;31:509.
131. Lindholt JS, Ashton HA, Scott RA. Indicators of infection with *Chlamydia pneumoniae* are associated with expansion of abdominal aortic aneurysms. *J Vasc Surg.* 2001;34:212.
132. Muhlestein JB, Home BD, Carlquist JF, et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. *Circulation.* 2000;102:1817.
133. Smieja M, Gnarp J, Lonn E, et al. Multiple infections and subsequent cardiovascular events in the Heart Outcome Prevention Evaluation (HOPE) study. *Circulation.* 2003;107:251.
134. Vercellotti GM. Effect of viral activation of the vessel wall on inflammation and thrombosis. *Blood Coagul Fibrinolysis.* 1998;9:S3.
135. Zhou YF, Shou M, Guetta E, et al. Cytomegalovirus infection of rats increases neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall. *Circulation.* 1999;100:1569.
136. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. *Circulation.* 1999;100:e20.
137. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. *JAMA.* 2005;293:2641.
138. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. *Arterioscler Thromb Vasc*

*Biol.* 2004;24:1161.

139. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. *Circ Res.* 2006;99:1044.
140. O'Brien ER, Garvin MR, Stewart DK, et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. *Arterioscler Thromb.* 1994;14:1648.
141. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. *Arterioscler Thromb Vasc Biol.* 2002;22:549.
142. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. *Circulation.* 2004;109:2175.
143. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. *Circulation.* 2002;106:1192.
144. Ohmori R, Momiyama Y, Taniguchi H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. *Atherosclerosis.* 2003;170:333.
145. Kurata M, Okura T, Watanabe S, et al. Osteopontin and carotid atherosclerosis in patients with essential hypertension. *Clin Sci (Lond).* 2006;111:319.
146. Golledge J, McCann M, Mangan S, et al. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. *Stroke.* 2004;35:1636.
147. Kadoglou NPE, Gerasimidis T, Golemati S, et al. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. *J Vasc Surg.* 2008;47:55.
148. Kadoglou NPE, Gerasimidis T, Moutzouoglou A, et al. Intensive lipid-lowering therapy ameliorates novel inflammatory and calcification markers and GSM score in patients with carotid stenosis. *Eur J Vasc Endovasc Surg.* 2008;35:661.
149. Lowe GD, Danesh J. Classical and emerging risk factors for cardiovascular disease. *Semin Vasc Med.* 2002;2:353.
150. Smith A, Patterson C, Yarnell J, et al. Which hemostatic markers add to the predictive value of conventional risk factors for CHD and ischaemic stroke? The Caerphilly study. *Circulation.* 2005;112:3080.
151. Tzoulaki I, Murray GD, Lee AJ, et al. Relative value of inflammatory, hemostatic and rheological factors for incident myocardial infarction and stroke. *Circulation.* 2007;115:2119.
152. Lee AJ, Fowkes FGR, Lowe GDO, et al. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. *Thromb Haemost.* 1995;3:828.
153. Martiskainen M, Mikkelsen J, Mantyla R, et al. Fibrinogen gene promoter -455A allele as a risk factor for macular stroke. *Stroke.* 2003;34:886.
154. Al Zahrani H, Lowe GDO, Douglas JT, et al. Increased fibrin turnover in peripheral arterial disease: comparison with a population study. *Clin Hemorheol.* 1992;12:867.
155. Foley PWX, Irvine CD, Standen GR, et al. Activated protein C resistance, factor V Leiden and peripheral arterial disease. *Card Surg.* 1997;5:157.
156. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, et al. Prevalence of prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. *Thromb Haemost.* 1997;78:1430.
157. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. *N Engl J Med.* 2000;342:1792.
158. Strano A, Hoppensteadt D, Walenga JM, et al. Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease. *Semin Thromb Haemost.* 1996;22:35.
159. McDermott MM, Green D, Greenland P, et al. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. *Am J Cardiol.* 2003;92:194.
160. Sofi F, Lari B, Rogolino A, et al. Thrombophilic risk factors for symptomatic peripheral arterial disease. *J Vasc Surg.* 2005;41:255.
161. Stein JH, Rosenson RS. Lp(a) excess and coronary heart disease. *Arch Intern Med.* 1997;157:1170.

162. Misirli H, Somay G, Ozbal N, et al. Relation of lipid and Lp(a) to ischemic stroke. *J Clin Neurosci*. 2002;2:127.
163. Sutton-Tyrrell K, Evans RW, Meilahn E, et al. Lipoprotein (a) and peripheral atherosclerosis in older adults. *Atherosclerosis*. 1996;122:11.
164. Valentine JR, Grayburn PA, Vega GL, et al. Lp(a) lipoprotein is an independent discriminating risk factor for premature peripheral atherosclerosis among white men. *Arch Intern Med*. 1994;154:801.
165. Puisieux F, de Groote P, Masy E, et al. Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease. *Am J Med*. 2000;109:635.
166. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. *Circ Res*. 2003;92:827.
167. Nagase H, Woessne JF Jr. Matrix metalloproteinases. *J Biol Chem*. 1999;274:21491.
168. Plutsky J. The vascular biology of atherosclerosis. *Am J Med*. 2003;115:55S.
169. Lijnen HR. Metalloproteinases in development and progression of vascular disease. *Pathophysiol Haemost Thromb*. 2003;33:275.
170. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. *Circ Res*. 2002;90:251.
171. Alvarez B, Ruiz C, Chacon P, et al. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. *J Vasc Surg*. 2004;40:469.
172. Jiang X, Zeng HS, Guo Y, et al. The expression of matrix metalloproteinases-9, transforming growth factor-beta1 and transforming growth factor-beta receptor I in human atherosclerotic plaque and their relationship with plaque stability. *Chin Med J (Engl)*. 2004;117:1825.
173. Kadoglou NP, Daskalopoulou SS, Perrea D, et al. Matrix metalloproteinases and diabetic vascular complications. *Angiology*. 2005;56:173.
174. Kadoglou NP, Liapis CD. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. *Curr Med Res Opin*. 2004;20:419.
175. Furman C, Copin C, Kandoussi M, et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. *Atherosclerosis*. 2004;174:93.
176. Paraskevas KI, Liapis CD, Mikhailidis DP. Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. *Curr Drug Targets*. 2006;7:761.
177. Beltowski J. Leptin and atherosclerosis. *Atherosclerosis*. 2006;189:47.
178. Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. *Arterioscler Thromb Vasc Biol*. 2007;27:996.
179. Considine RV. Human leptin: an adipocyte hormone with weight-regulatory and endocrine functions. *Semin Vasc Med*. 2005;5:15.
180. Stefan N, Voarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. *Diabetes*. 2002;51:1884.
181. Kantartzis K, Rittig K, Balletshofer B, et al. The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity. *Clin Chem*. 2006;52:1934.
182. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. *Clin Chim Acta*. 2007;380:24.
183. Gable DR, Hurel SJ, Humphries SE. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. *Atherosclerosis*. 2006;188:231.
184. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun*. 1999;257:79.
185. Im JA, Kim SH, Lee JW, et al. Association between hypoadiponectinemia and cardiovascular risk factors in nonobese

healthy adults. *Metabolism*. 2006;55:1546.

186. Rothenbacher D, Brenner H, Marz W, et al. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. *Eur Heart J*. 2005;26:1640.
187. Zyriax BC, Algenstaedt P, Hess UF, et al. Factors contributing to the risk of cardiovascular disease reflected by plasma adiponectin: data from the coronary risk factors for atherosclerosis in women (CORA) study. *Atherosclerosis*. 2008;200:403.
188. Shantsila E, Timothy Watson T, Lip GYH. Endothelial progenitor cells in cardiovascular disorders. *J Am Coll Surg*. 2007;49:741.
189. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res*. 2001;89:E1.
190. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med*. 2003;348:593.
191. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. *J Clin Invest*. 2001;108:391.
192. Laufs U, Werner N, Link A, et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. *Circulation*. 2004;109:220.
193. Strehlow K, Werner N, Berweiler J, et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. *Circulation*. 2003;107:3059.
194. Mlekusch W, Exner M, Sabeti S, et al. Serum creatinine predicts mortality in patients with peripheral artery disease: influence of diabetes and hypertension. *Atherosclerosis*. 2004;175:361.
195. Daskalopoulou SS, Daskalopoulos ME, Liapis CD, et al. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. *Curr Med Chem*. 2005;12:763.
196. Daskalopoulou SS, Athyros VG, Elisaf M, et al. Uric acid levels and vascular disease. *Curr Med Res Opin*. 2004;20:951.
197. Langlois M, De Bacquer D, Duprez D, et al. Serum uric acid in hypertensive patients with and without peripheral arterial disease. *Atherosclerosis*. 2003;168:163.
198. Tseng CH, Tseng CP, Tai TY, et al. Effect of angiotensin blockade on the association between albuminuria and peripheral arterial disease in elderly Taiwanese patients with type 2 diabetes mellitus. *Circ J*. 2005;69:965.
199. Wattanakit K, Folsom AR, Criqui MH, et al. Albuminuria and peripheral arterial disease: results from the Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*. 2008 (in press).
200. Ylä-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. *J Clin Invest*. 1989;84:1086.
201. Dunn S, Vohra RS, Murphy JE, et al. The lectin-like oxidized low-density-lipoprotein receptor: a pro-inflammatory factor in vascular disease. *Biochem J*. 2008;409:349.
202. Tsimikas S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. *Am J Cardiol*. 2006;98:9p.
203. Steinberg D, Pearson TA, Kuller LH. Alcohol and atherosclerosis. *Ann Intern Med*. 1991;114:967.
204. Notzon FC, Komarov YM, Ermakov SP, et al. Causes of declining life expectancy in Russia. *JAMA*. 1998;279:793.
205. Mukamal KJ, Conigrave KM, Mittleman MA, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. *N Engl J Med*. 2003;348:109.
206. Donnan PT, Thomson M, Fowkes FGR, et al. Diet as a risk factor for peripheral arterial disease in the general population: the Edinburgh Artery Study. *Am J Clin Nutr*. 1993;57:917.
207. Langlois M, Duprez D, Delanghe J, et al. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. *Circulation*. 2001;103:1863.
208. Salonen RM, Nyyssönen K, Kaikkonen J, et al. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. *Circulation*.

2003;107:947.

209. Barter P. The role of HDL-cholesterol in preventing atherosclerotic disease. *Eur Heart J Supplements*. 2005;7:F4.
210. Zimmerman GA, McIntyre TM, Prescott SM. Adhesion and signaling in vascular cell-cell interactions. *J Clin Invest*. 1997;100:S3.
211. Krone W, Müller-Wieland D, Nägele H, et al. Effects of calcium antagonists and adrenergic antihypertensive drugs on plasma lipids and cellular cholesterol metabolism. *J Cardiovasc Pharmacol*. 1987;10:S199.
212. Vaughan DE. The renin-angiotensin system and fibrinolysis. *Am J Cardiol*. 1997;79:12.
213. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. *Annu Rev Med*. 1997;48:489.
214. Tsao PS, Wang B, Buitrago R, et al. Nitric oxide regulates monocyte chemotactic protein-1. *Circulation*. 1997;96:934.
215. Mostafa Mtairag E, Chollet-Martin S, Oudghiri M, et al. Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. *Cardiovasc Res*. 2001;49:882.
216. Daskalopoulou SS, Daskalopoulos ME, Theocharis S, et al. Metallothionein expression in the high-risk carotid atherosclerotic plaque. *Curr Med Res Opin*. 2007;23:659.
217. Drexler H, Fischell TA, Pinto FJ, et al. Effect of l-arginine on coronary endothelial function in cardiac transplant recipients: relation to vessel wall morphology. *Circulation*. 1994;89:1615.
218. Clarkson P, Adams MR, Powe AJ, et al. Oral l-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. *J Clin Invest*. 1996;97:1989.
219. Lerman A, Burnett JC Jr, Higano ST, et al. Long-term l-arginine supplementation improves small-vessel coronary endothelial function in humans. *Circulation*. 1998;97:2123.
220. Bode-Böger SM, Böger RH, Alfke H, et al. L-Arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. *Circulation*. 1996;93:85.
221. Cooke JP, Singer AH, Tsao P, et al. Antiatherogenic effects of l-arginine in the hypercholesterolemic rabbit. *J Clin Invest*. 1992;90:1168.
222. Wang BY, Singer AH, Tsao PS, et al. Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit. *J Am Coll Cardiol*. 1994;23:452.
223. Böger RH, Bode-Böger SM, Mügge A, et al. Supplementation of hypercholesterolaemic rabbits with l-arginine reduces the vascular release of superoxide anions and restores NO production. *Atherosclerosis*. 1995;117:273.
224. Tsao PS, McEvoy LM, Drexler H, et al. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by l-arginine. *Circulation*. 1994;89:2176.
225. Candipan RC, Wang BY, Buitrago R, et al. Regression or progression. Dependency on vascular nitric oxide. *Arterioscler Thromb Vasc Biol*. 1996;16:44.
226. Stern N, Osher E, Greenman Y. Hypoadiponectinemia as a marker of adipocyte dysfunction—Part I: the biology of adiponectin. *J Cardiometaab Syndr*. 2007;2:174.
227. Fadini GP, Agostini C, Sartore S, et al. Endothelial progenitor cells in the natural history of atherosclerosis. *Atherosclerosis*. 2007;194:46.
228. Wu Y, Ip JE, Huang J, et al. Essential role of ICAM-1/CD18 in mediating EPC recruitment, angiogenesis and repair to the infarcted myocardium. *Circ Res*. 2006;99:315.
229. Duan H, Cheng L, Sun X, et al. LFA-1 and VLA-4 involved in human high proliferative potential-endothelial progenitor cells homing to ischemic tissue. *Thromb Haemost*. 2006;96:807.
230. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. *Nat Med*. 2004;10:858.
231. Willich SN. Circadian variation and triggering of cardiovascular events. *Vasc Med*. 1999;4:41.
232. Willich SN, Löwel H, Lewis M, et al. Weekly variation of acute myocardial infarction. Increased Monday risk in the working population. *Circulation*. 1994;90:87.

233. Liapis C, Sechas M, Iliopoulos D, et al. Seasonal variation in the incidence of ruptured abdominal aortic aneurysm. *Eur J Vasc Surg*. 1992;6:416.
234. Saposnik G, Baibergenova A, Dang J, et al. Does a birthday predispose to vascular events? *Neurology*. 2006;67:300.
235. Witte DR, Bots ML, Hoes AW, et al. Cardiovascular mortality in Dutch men during 1996 European football championship: longitudinal population study. *BMJ*. 2000;321:1552.
236. Callahan KP, Malinin AI, Atar D, et al. Platelet activation as a universal trigger in the pathogenesis of acute coronary events after cocaine abuse. *Swiss Med Wkly*. 2001;131:487.
237. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. *N Engl J Med*. 2004;351:2611.
238. Anderson RA, Jones CJ, Goodfellow J. Is the fatty meal a trigger for acute coronary syndromes. *Atherosclerosis*. 2001;159:9.

## 第 26 章

1. Centers for Disease Control and Prevention (CDC). Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1997-2001. *MMWR Morb Mortal Wkly Rep*. 2005;54:625-628.
2. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults—United States, 1998. *MMWR Morb Mortal Wkly Rep*. 2000;49:882-884.
3. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults—2006. *MMWR Morb Mortal Wkly Rep*. 2007;56:1157-1161.
4. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults—United States, 2000. *MMWR Morb Mortal Wkly Rep*. 2003;51:642-645.
5. Centers for Disease Control and Prevention (CDC). Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1995-1999. *MMWR Morb Mortal Wkly Rep*. 2002;51:300-303.
6. Capehart TC. *Electronic Outlook Report from the Economic Research Service: Tobacco Situation and Outlook Yearbook, TBS-2006*. Washington, DC: U.S. Department of Agriculture; December 2006.
7. Centers for Disease Control and Prevention (CDC). Prevalence of current smoking among adults aged 18 years and over: United States, 1997-September 2007. Early release of selected estimates based on data from the January-September 2007 National Health Interview Survey; 2008.
8. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults—United States, 2006. *MMWR Morb Mortal Wkly Rep*. 2007;56:1157-1161.
9. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. *Nature*. 2008;452:638-642.
10. Kannel WB, Shurtleff D. The Framingham Study. Cigarettes and the development of intermittent claudication. *Geriatrics*. 1973;28:61-68.
11. National Cancer Institute. *Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine. Smoking and Tobacco Control Monograph 13 (NIH Publication No. 02-5974)*. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2001.
12. Hammond EC, Garfinkel L, Seidman H, et al. "Tar" and nicotine content of cigarette smoke in relation to death rates. *Environ Res*. 1976;12:263-274.
13. Tang JL, Morris JK, Wald NJ, et al. Mortality in relation to tar yield of cigarettes: a prospective study of four cohorts. *BMJ*. 1995;311:1530-1533.
14. Petitti DB, Friedman GD. Cardiovascular and other diseases in smokers of low yield cigarettes. *J Chronic Dis*. 1985;38:581-588.
15. Parish S, Collins R, Peto R, et al. Cigarette smoking, tar yields, and non-fatal myocardial infarction: 14,000 cases and

- 32,000 controls in the United Kingdom. The International Studies of Infarct Survival (ISIS) Collaborators. *BMJ*. 1995;311:471-477.
16. Castelli WP, Garrison RJ, Dawber TR, et al. The filter cigarette and coronary heart disease: the Framingham Study. *Lancet*. 1981;2:109-113.
  17. Kaufman DW, Helmrich SP, Rosenberg L, et al. Nicotine and carbon monoxide content of cigarette smoke and the risk of myocardial infarction in young men. *N Engl J Med*. 1983;308:409-413.
  18. Palmer JR, Rosenberg L, Shapiro S. "Low yield" cigarettes and the risk of nonfatal myocardial infarction in women. *N Engl J Med*. 1989;320:1569-1573.
  19. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. *Lancet*. 1990;336:65-71.
  20. Negri E, Franzosi MG, La Vecchia C, et al. Tar yield of cigarettes and risk of acute myocardial infarction. GISSI-EFRIM Investigators. *BMJ*. 1993;306:1567-1570.
  21. Pittilo RM. Cigarette smoking and endothelial injury: a review. *Adv Exp Med Biol*. 1990;273:61-78.
  22. Campbell SC, Moffatt RJ, Stamford BA. Smoking and smoking cessation—the relationship between cardiovascular disease and lipoprotein metabolism: a review. *Atherosclerosis*. 2008;201:225-235.
  23. Krupski WC. The peripheral vascular consequences of smoking. *Ann Vasc Surg*. 1991;5:291-304.
  24. Hutchison S. Smoking as a risk factor for endothelial dysfunction. *Can J Cardiol*. 1998;14(Suppl D):20D-22D.
  25. Miller GJ, Bauer KA, Cooper JA, et al. Activation of the coagulant pathway in cigarette smokers. *Thromb Haemost*. 1998;79:549-553.
  26. Rahman MM, Laher I. Structural and functional alteration of blood vessels caused by cigarette smoking: an overview of molecular mechanisms. *Curr Vasc Pharmacol*. 2007;5:276-292.
  27. Zevin S, Saunders S, Gourlay SG, et al. Cardiovascular effects of carbon monoxide and cigarette smoking. *J Am Coll Cardiol*. 2001;38:1633-1638.
  28. Allen DR, Browse NL, Rutt DL, et al. The effect of cigarette smoke, nicotine, and carbon monoxide on the permeability of the arterial wall. *J Vasc Surg*. 1988;7:139-152.
  29. Lakier JB. Smoking and cardiovascular disease. *Am J Med*. 1992;93:8S-12S.
  30. Asmussen I, Kjeldsen K. Intimal ultrastructure of human umbilical arteries. Observations on arteries from newborn children of smoking and nonsmoking mothers. *Circ Res*. 1975;36:579-589.
  31. Pittilo RM, Clarke JM, Harris D, et al. Cigarette smoking and platelet adhesion. *Br J Haematol*. 1984;58:627-632.
  32. Lehr HA. Adhesion-promoting effects of cigarette smoke on leukocytes and endothelial cells. *Ann N Y Acad Sci*. 1993;686:112-118; discussion 118-119.
  33. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. *Circulation*. 1993;88:2149-2155.
  34. Heitzer T, Yla-Herttuala S, Luoma J, et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. *Circulation*. 1996;93:1346-1353.
  35. Heiss C, Amabile N, Lee AC, et al. Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained vascular injury and blunted nitric oxide production. *J Am Coll Cardiol*. 2008;51:1760-1771.
  36. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. *Circulation*. 1996;94:6-9.
  37. Beckman JA, Liao JK, Hurley S, et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. *Circ Res*. 2004;95:217-223.
  38. Kaufmann PA, Gnecci-Ruscone T, di Terlizzi M, et al. Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. *Circulation*. 2000;102:1233-1238.



39. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. *N Engl J Med.* 1989;320:915-924.
40. Frei B, Forte TM, Ames BN, et al. Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid. *Biochem J.* 1991;277:133-138.
41. Fusegawa Y, Goto S, Handa S, et al. Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. *Thromb Res.* 1999;93:271-278.
42. Davis JW, Shelton L, Eigenberg DA, et al. Effects of tobacco and non-tobacco cigarette smoking on endothelium and platelets. *Clin Pharmacol Ther.* 1985;37:529-533.
43. Saba SR, Mason RG. Some effects of nicotine on platelets. *Thromb Res.* 1975;7:819-824.
44. Eliasson B, Hjalmarson A, Kruse E, et al. Effect of smoking reduction and cessation on cardiovascular risk factors. *Nicotine Tob Res.* 2001;3:249-255.
45. Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. *Lancet.* 1987;2:986-988.
46. Matetzky S, Tani S, Kangavari S, et al. Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. *Circulation.* 2000;102:602-604.
47. Newby DE, McLeod AL, Uren NG, et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. *Circulation.* 2001;103:1936-1941.
48. Newby DE, Wright RA, Labinjoh C, et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. *Circulation.* 1999;99:1411-1415.
49. Ernst E, Matrai A, Schmolzl C, et al. Dose-effect relationship between smoking and blood rheology. *Br J Haematol.* 1987;65:485-487.
50. Rothwell M, Rampling MW, Cholerton S, et al. Haemorheological changes in the very short term after abstention from tobacco by cigarette smokers. *Br J Haematol.* 1991;79:500-503.
51. Cryer PE, Haymond MW, Santiago JV, et al. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. *N Engl J Med.* 1976;295:573-577.
52. Narkiewicz K, van de Borne PJ, Hausberg M, et al. Cigarette smoking increases sympathetic outflow in humans. *Circulation.* 1998;98:528-534.
53. Koch A, Hoffmann K, Steck W, et al. Acute cardiovascular reactions after cigarette smoking. *Atherosclerosis.* 1980;35:67-75.
54. Wolk R, Shamsuzzaman AS, Svatikova A, et al. Hemodynamic and autonomic effects of smokeless tobacco in healthy young men. *J Am Coll Cardiol.* 2005;45:910-914.
55. Gupta R, Gurm H, Bartholomew JR. Smokeless tobacco and cardiovascular risk. *Arch Intern Med.* 2004;164:1845-1849.
56. Lao XQ, Jiang CQ, Zhang WS, et al. Smoking, smoking cessation and inflammatory markers in older Chinese men: the Guangzhou Biobank Cohort Study. *Atherosclerosis.* 2008;203:304-310.
57. Facchini FS, Hollenbeck CB, Jeppesen J, et al. Insulin resistance and cigarette smoking. *Lancet.* 1992;339:1128-1130.
58. Farin HM, Abbasi F, Kim SH, et al. The relationship between insulin resistance and dyslipidaemia in cigarette smokers. *Diabetes Obes Metab.* 2007;9:65-69.
59. Reaven G, Tsao PS. Insulin resistance and compensatory hyperinsulinemia: the key player between cigarette smoking and cardiovascular disease? *J Am Coll Cardiol.* 2003;41:1044-1047.
60. Price JF, Mowbray PI, Lee AJ, et al. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. *Eur Heart J.* 1999;20:344-353.
61. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. *J Am Geriatr Soc.* Jan 1985;33:13-18.

62. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. *Circulation*. 1990;82:1925-1931.
63. Bowlin SJ, Medalie JH, Flocke SA, et al. Epidemiology of intermittent claudication in middle-aged men. *Am J Epidemiol*. 1994;140:418-430.
64. Fowkes FG, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. *Am J Epidemiol*. 1992;135:331-340.
65. Powell JT, Edwards RJ, Worrell PC, et al. Risk factors associated with the development of peripheral arterial disease in smokers: a case-control study. *Atherosclerosis*. 1997;129:41-48.
66. Cole CW, Hill GB, Farzad E, et al. Cigarette smoking and peripheral arterial occlusive disease. *Surgery*. 1993;114:753-756; discussion 756-757.
67. Olin JW. Thromboangiitis obliterans (Buerger's disease). *N Engl J Med*. 2000;343:864-869.
68. Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. *Ann Intern Med*. 1997;126:441-449.
69. Brady AR, Thompson SG, Fowkes FG, et al. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. *Circulation*. 2004;110:16-21.
70. Salonen R, Salonen JT. Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. *Atherosclerosis*. 1990;81:33-40.
71. Howard G, Wagenknecht LE, Burke GL, et al. Cigarette smoking and progression of atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. *JAMA*. 1998;279:119-124.
72. Fowler B, Jamrozik K, Norman P, et al. Prevalence of peripheral arterial disease: persistence of excess risk in former smokers. *Aust N Z J Public Health*. 2002;26:219-224.
73. He Y, Jiang Y, Wang J, et al. Prevalence of peripheral arterial disease and its association with smoking in a population-based study in Beijing, China. *J Vasc Surg*. 2006;44:333-338.
74. Yataco AR, Gardner AW. Acute reduction in ankle/brachial index following smoking in chronic smokers with peripheral arterial occlusive disease. *Angiology*. 1999;50:355-360.
75. Smith FB, Lowe GD, Lee AJ, et al. Smoking, hemorheologic factors, and progression of peripheral arterial disease in patients with claudication. *J Vasc Surg*. 1998;28:129-135.
76. Gardner AW. The effect of cigarette smoking on exercise capacity in patients with intermittent claudication. *Vasc Med*. 1996;1:181-186.
77. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. *Acta Med Scand*. 1987;221:253-260.
78. Cahan MA, Montgomery P, Otis RB, et al. The effect of cigarette smoking status on six-minute walk distance in patients with intermittent claudication. *Angiology*. 1999;50:537-546.
79. Quick CR, Cotton LT. The measured effect of stopping smoking on intermittent claudication. *Br J Surg*. 1982;69(Suppl):S24-S26.
80. Juergens JL, Barker NW, Hines EA Jr. Arteriosclerosis obliterans: review of 520 cases with special reference to pathogenic and prognostic factors. *Circulation*. 1960;21:188-195.
81. Willigendael EM, Teijink JA, Bartelink ML, et al. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. *J Vasc Surg*. 2005;42:67-74.
82. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. *Med J Aust*. 1983;1:217-219.
83. Lassila R, Lepantalo M. Cigarette smoking and the outcome after lower limb arterial surgery. *Acta Chir Scand*.

1988;154:635-640.

84. Kenfield SA, Stampfer MJ, Rosner BA, et al. Smoking and smoking cessation in relation to mortality in women. *JAMA*. 2008;299:2037-2047.
85. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Executive summary, a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *J Am Coll Cardiol*. 2006;47:1239-1312.
86. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg*. 2007;45(Suppl S):S5-S67.
87. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults—United States, 2000. *MMWR Morb Mortal Wkly Rep*. 2002;51:642-645.
88. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence: Quick Reference Guide for Clinicians. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2000.
89. Guideline Update Panel P. Treating Tobacco Use and Dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. *Respir Care*. 2008;53:1217-1222.
90. Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. *N Engl J Med*. Feb 14 2002;346:506-512.
91. GlaxoSmithKline. Nicorette gum package insert. 1998. Available at <[http://www.fda.gov/cder/foi/nda/98/18-612S025\\_Nicorette\\_prntlbl.pdf](http://www.fda.gov/cder/foi/nda/98/18-612S025_Nicorette_prntlbl.pdf)>; Accessed October 1, 2008.
92. GlaxoSmithKline. Commit Nicotine Lozenge package insert. 2004. Available at <[http://www.fda.gov/cder/foi/label/2004/21330scf002\\_committ\\_lbl.pdf](http://www.fda.gov/cder/foi/label/2004/21330scf002_committ_lbl.pdf)>; Accessed October 1, 2008.
93. Pfizer. Nicotrol Inhaler Physician Prescribing Information. Available at <[http://media.pfizer.com/files/products/uspi\\_nicotrol\\_inhaler.pdf](http://media.pfizer.com/files/products/uspi_nicotrol_inhaler.pdf)>; Accessed October 1, 2008.
94. Pfizer. Nicotrol Package Insert. 2005. Available at <[http://media.pfizer.com/files/products/ppi\\_nicotrol.pdf](http://media.pfizer.com/files/products/ppi_nicotrol.pdf)>; Accessed October 1, 2008.
95. GlaxoSmithKline. Nicoderm CQ package insert. 2006. Available at <[http://www.fda.gov/medwatch/SAFETY/2007/Apr\\_PI/NicoDermCQ\\_PPI.pdf](http://www.fda.gov/medwatch/SAFETY/2007/Apr_PI/NicoDermCQ_PPI.pdf)>.
96. Health NC. Habitrol Package Insert. 2002. Available at <<http://www.fda.gov/cder/foi/label/2002/20076s21lbl.pdf>>; Accessed October 1, 2008.
97. GlaxoSmithKline. Zyban Package Insert. 2001. Available at <[http://us.gsk.com/products/assets/us\\_zyban.pdf](http://us.gsk.com/products/assets/us_zyban.pdf)>; Accessed October 1, 2008.
98. Ascher JA, Cole JO, Colin JN, et al. Bupropion: A review of its mechanism of antidepressant activity. *J Clin Psychiatry*. 1995;56:395-401.
99. Pfizer. Chantix (varenicline) Tablets. January, 2008. Package Insert. Available at <[http://www.pfizer.com/files/products/uspi\\_chantix.pdf](http://www.pfizer.com/files/products/uspi_chantix.pdf)>; Accessed May 7, 2008.
100. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. *Cochrane Database Syst Rev*. 2008;1:CD000146.
101. Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. *Tob Control*. 2006;15:280-285.
102. Shiffman S, Fant RV, Buchhalter AR, et al. Nicotine delivery systems. *Expert Opin Drug Deliv*. 2005;2:563-577.
103. D'Orlando KJ, Fox BS. Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw, a novel

- nicotine replacement product. *Nicotine Tob Res.* 2004;6:63-70.
104. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med.* 1999;340:685-691.
  105. GlaxoSmithKline. Zyban (bupropion hydrochloride) Sustained Release Tablets. Package Insert, 2007. Available at <[http://us.gsk.com/products/assets/us\\_zyban.pdf](http://us.gsk.com/products/assets/us_zyban.pdf)>; Accessed May 2008.
  106. Hayford KE, Patten CA, Rummans TA, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. *Br J Psychiatry.* 1999;174:173-178.
  107. Coe JW, Brooks PR, Wirtz MC, et al. 3,5-Bicyclic aryl piperidines: A novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. *Bioorg Med Chem Lett.* 2005;15:4889-4897.
  108. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA.* 2006;296:47-55.
  109. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA.* 2006;296:56-63.
  110. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. *JAMA.* 2006;296:64-71.
  111. Food and Drug Administration. February 2008. Available at <<http://www.fda.gov/cder/drug/infopage/varenicline/default.htm>>; Accessed April 28, 2008.
  112. Saul S. F.A.A. bans antismoking drug, citing side effects. New York Times, May 22, 2008.
  113. FMCSA Administration. Statement from Administrator John H. Hill. Available at <<http://www.fmcsa.dot.gov/statement-5-23-08.htm?printer=true>>; Accessed October 5, 2008.
  114. Hall SM, Reus VI, Munoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. *Arch Gen Psychiatry.* 1998;55:683-690.
  115. Prochazka AV, Weaver MJ, Keller RT, et al. A randomized trial of nortriptyline for smoking cessation. *Arch Intern Med.* 1998;158:2035-2039.
  116. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. *Cochrane Database Syst Rev.* 2004;3:CD000058.
  117. Cinciripini PM, Aubin H-J, Dale LC, et al. STRATUS-EU. Pooled analysis of three short-term, randomised, double-blind, placebo-controlled trials with rimonabant 20mg/d in smoking cessation [PI-TS-o1]. Society for Research on Nicotine and Tobacco. Paper presented at the Eighth European Conference, September 2006, Kusadasi, Turkey.
  118. Anthenelli RM, Depres J-P. Results from the STRATUS-US Trial (smoking cessation in smokers motivated to quit) and the RIO-LIPIDS Trial (weight reducing and metabolic effects in overweight/obese patients with dyslipidemia. Paper presented at the American College of Cardiology Annual Scientific Session. March 2004.
  119. Boyd ST, Fremming BA. Rimonabant—a selective CB1 antagonist. *Ann Pharmacother.* 2005;39:684-690.
  120. Niaura R. Long-term maintenance of abstinence from smoking with rimonabant: Results from the STRATUS Worldwide Trial. 1-year efficacy/safety results. Paper presented at the 2005 American Thoracic Society Conference, San Diego, CA.
  121. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. *Cochrane Database Syst Rev.* 2007;4:CD005353.
  122. Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints and Outcomes (CRESCENDO). Available at <[http://www.clinicaltrials.gov/ct2/show/NCT00263042?term=crescendo&rank=1&show\\_locs=Y#locn](http://www.clinicaltrials.gov/ct2/show/NCT00263042?term=crescendo&rank=1&show_locs=Y#locn)>; Accessed October 9, 2008.
  123. Press release: Sanofi-aventis to discontinue all clinical trials with rimonabant. Available at <[http://en.sanofiaventis.com/press/press\\_releases/2008/ppc\\_22683.asp](http://en.sanofiaventis.com/press/press_releases/2008/ppc_22683.asp)>.
  124. Maurer P, Jennings GT, Willers J, et al. A therapeutic vaccine for nicotine dependence: Preclinical efficacy, and phase I safety and immunogenicity. *Eur J Immunol.* 2005;35:2031-2040.

125. Heading CE. NicVAX (Nabi Biopharmaceuticals). *IDrugs*. 2003;6:1178-1181.
126. Trial watch: Xenova's TA-NIC vaccine shows promise. *Expert Rev Vaccines*. 2004;3:386.
127. Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. *Clin Pharmacol Ther*. 2005;78:456-467.
128. Nabi Biopharmaceuticals News Release. Nabi Biopharmaceuticals announces positive results of phase IIb trial of NicVAX, 2007. Available at <<http://www.nabi.com/pipeline/clinicaltrials.php#3>>; Accessed May 2, 2007.
129. Cytos Biotechnology AG. Vaccine to treat nicotine addiction achieves proof of efficacy in phase II clinical trial. Available at <[www.cytos.com/doc/Cytos\\_press\\_E\\_050514.pdf](http://www.cytos.com/doc/Cytos_press_E_050514.pdf)>; Accessed May 10, 2008.
130. O'Dell JR, Linder J, Markin RS, et al. Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. *Arthritis Rheum*. 1987;30:1054-1056.
131. Lawrence PF, Lund OI, Jimenez JC, et al. Substitution of smokeless tobacco for cigarettes in Buerger's disease does not prevent limb loss. *J Vasc Surg*. 2008;48:210-212.
132. Haddock CK, Weg MV, DeBon M, et al. Evidence that smokeless tobacco use is a gateway for smoking initiation in young adult males. *Prev Med*. 2001;32:262-267.
133. U.S. Department of Health and Human Services. *The Health Consequences of Using Smokeless Tobacco: A Report of the Advisory Committee to the Surgeon General (NIH Publication No. 86-2874)*. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service; 1986.
134. Jones RT. Cardiovascular system effects of marijuana. *J Clin Pharmacol*. 2002;42(11 Suppl):58S-63S.
135. Disdier P, Granel B, Serratrice J, et al. Cannabis arteritis revisited—ten new case reports. *Angiology*. 2001;52:1-5.
136. Santo-Tomas M, Lopez-Jimenez F, Machado H, et al. Effect of cigar smoking on endothelium-dependent brachial artery dilation in healthy young adults. *Am Heart J*. 2002;143:83-86.

## 第 27 章

1. Pearson WS. Ten-year comparison of estimates of overweight and obesity, diagnosed diabetes and use of office-based physician services for treatment of diabetes in the United States. *Prev Med*. 2007;45:353-357.
2. Zimmet PZ. Kelly West Lecture 1991. Diabetes epidemiology—from the west to the rest. *Diabetes Challenges Care*. 1992;15:232-252.
3. Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? *Ann J Hum*. 1962;14:353-362.
4. Expert Committee for the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*. 1997;20:1183-1197.
5. Harris MI. Prevalence of retinopathy since time of diagnosis of type 2 diabetes: WESDR Study, 1980-1988. *Consultant*. 1997;37(Suppl.):S9-S14.
6. Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. *Lancet*. 1997;350:1288-1293.
7. Clausen TD, Mathiesen ER, Hansen T, et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. *Diabetes Care*. 2008;31:340-346.
8. Eisenbarth GS. Type I diabetes mellitus—a chronic autoimmune disease. *N Engl J Med*. 1986;314:1360-1368.
9. Coutant R, Carel JC, Timsit J, et al. Insulin and the prevention of insulin-dependent diabetes mellitus. *Diabetes Metabol*. 1997;23(supplement 3):25-28.
10. Eisenbarth GS. Lilly lecture 1986. Genes, generator of diversity, glycoconjugates and autoimmune beta-cell insufficiency in type I diabetes. *Diabetes*. 1987;36:355-364.
11. Dahlquist GG. Primary and secondary prevention strategies of pre-type 1 diabetes. Potentials and pitfalls. *Diabetes Care*. 1999;22(Suppl. 2):B4-B6.
12. Rosenbloom AL, Joe JR, Young RS, et al. Emerging epidemic of type 2 diabetes in youth. *Diabetes Care*. 1999;22:345-354.

13. Gulli G, Ferrannini E, Stern M, et al. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. *Diabetes*. 1992;41:1575-1586.
14. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am J Physiol*. 1979;237:E214-E223.
15. DeFronzo RA. Lilly Lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. *Diabetes*. 1988;37:667-687.
16. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J Clin Invest*. 1999;104:787-794.
17. Rossetti L. Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. *Clin Invest Med*. 1995;18:225-260.
18. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. *Diabetes Care*. 1992;15:318-368.
19. Wrobel JS, Mayfield JA, Reiber GE. Geographic variation of lower-extremity major amputation in individuals with and without diabetes in the Medicare population. *Diabetes Care*. 2001;24:860-864.
20. Bernstein EF, Fronek A. Current status of non-invasive tests in the diagnosis of peripheral arterial disease. *Surg Clin North Am*. 1982;62:473-487.
21. Elhadd TA, Robb R, Jung RT, et al. Pilot study of prevalence of asymptomatic peripheral arterial occlusive disease in patients with diabetes attending a hospital clinic. *Pract Diabetes Int*. 1999;16:163-166.
22. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. *Circulation*. 1996;94:3026-3049.
23. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). *J Vasc Surg*. 2000;31:S1-S296.
24. Ram Z, Sadeh M, Walden R, et al. Vascular insufficiency quantitatively aggravates diabetic neuropathy. *Arch Neurol*. 1991;48:1239-1242.
25. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. *J Cardiovasc Risk*. 1994;1:3333-3339.
26. Eckel RH, Wassef M, Chait A, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. *Circulation*. 2002;105:e138-e143.
27. Veves A, Akbari CM, Primavera J, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. *Diabetes*. 1998;47:457-463.
28. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. *JAMA*. 2002;287:2570-2581.
29. Kaiser N, Sasson S, Feener EP, et al. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and muscle cells. *Diabetes*. 1993;42:80-89.
30. Muniyappa R, Quon MJ. Insulin action and insulin resistance in vascular endothelium. *Curr Opin Clin Nutr Metab Care*. 2007;10:523-530.
31. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. *Diabetologia*. 2002;45:623-634.
32. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. *Diabet Med*. 2001;18:945-959.
33. Montagnani M, Golovchenko I, Kim I, et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. *J Biol Chem*. 2002;277:1794-1799.
34. Tsao PS, Wang B, Buitrago R, et al. Nitric oxide regulates monocyte chemotactic protein-1. *Circulation*. 1997;96:934-940.
35. Libby P. Inflammation in atherosclerosis. *Nature*. 2002;420:868-874.
36. Jialal I, Devaraj S, Venugopal SK. Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha tocopherol

- therapy. *Free Radic Res.* 2002;36:1331-1336.
37. Ridker PM, Fonseca FA, Genest J, et al., for the JUPITER Trial Study Group. Baseline characteristics of participants in the JUPITER trial. *Am J Cardiol.* 2007;100:1659-1664.
  38. Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. *Arterioscler Thromb Vasc Biol.* 2002;22:1370-1380.
  39. Schneider DL, Sobel BE. Diabetes and thrombosis. In: Johnstone MT, Veves A, eds. *Diabetes and Cardiovascular Disease*. Totowa, NJ: Humana; 2001.
  40. Pande RL, Perlstein TS, Beckman JA, et al. Association of insulin resistance and inflammation with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999 to 2004. *Circulation.* 2008;118:33-41.
  41. Dolan NC, Liu K, Criqui MH, et al. Peripheral artery disease, diabetes, and reduced lower extremity functioning. *Diabetes Care.* 2002;25:113-120.
  42. McDaniel MD, Cronenwett JL. Basic data related to the natural history of intermittent claudication. *Ann Vasc Surg.* 1989;3:273-277.
  43. Jude EB, Oyibo SO, Chalmers N, et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. *Diabetes Care.* 2001;24:1433-1437.
  44. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. *Lancet.* 2002;360:7-22.
  45. Steg PG, Bhatt DL, Wilson PW, et al., for the REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. *JAMA.* 2007;297:1197-1206.
  46. American Diabetes Association. Standards of medical care in diabetes—2008. [http://care.diabetesjournals.org/content/31/supplement\\_1/s12.Full](http://care.diabetesjournals.org/content/31/supplement_1/s12.Full). Accessed 8/30/2009.
  47. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Trans-Atlantic Inter-Society Consensus; and Vascular Disease Foundation. *Circulation.* 2006;113:e463-e654.
  48. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet.* 1998;352:837-853.
  49. Holman RR. Prevalence of complications at time of diagnosis: UKPDS. *Consultant.* 1997;37(Suppl):S30-S36.
  50. The Action to Control Cardiovascular Risk in Diabetes Study Group. *N Engl J Med.* 2008;358:2545-2559.
  51. The ADVANCE Collaborative Group. *N Engl J Med.* 2008;358:2560-2572.
  52. Abaira C, Duckworth WC, Moritz T. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. *Diabetes Obes Metab.* 2008;11:L150-L156.
  53. Cefalu WT. Glycemic targets and cardiovascular disease. *N Engl J Med.* 2008;358:2633-2635.
  54. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med.* 2008;359:1577-1589.
  55. Nathan DM, Cleary PA, Backlund JY, et al., for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med.* 2005;353:2643-2653.
  56. Stokes J, Kannel WB, Wolf PA, et al. The relative importance of selected risk factors for various manifestations of

- cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. *Circulation*. 1987;75:V65-V73.
57. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). *BMJ*. 1998;317:703-713.
  58. American Diabetes Association. Treatment of hypertension in adults with diabetes (position statement). *Diabetes Care*. 2003;26:S80-S82.
  59. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*. 2000;342:145-153.
  60. Mehler PS, Coll JR, Estacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. *Circulation*. 2003;107:753-756.
  61. Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis. *Cochrane Database Syst Rev*. 2000;2:CD000123.
  62. Kjekshus J, Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). *Am J Cardiol*. 1995;76:64C-68C.
  63. Colhoun HM, Betteridge DJ, Durrington PN, et al., for the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*. 2004;364:685-696.
  64. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ*. 1994;308:81-106.
  65. American Diabetes Association. Aspirin therapy in diabetes (position statement). *Diabetes Care*. 2003;26(Suppl. 1):S87-S88.
  66. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet*. 1996;348:1329-1339.
  67. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. *Am J Cardiol*. 2002;90:625-628.
  68. Bhatt DL, Fox KA, Kacke W, et al., for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med*. 2006;354:1706-1717.
  69. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med*. 2003;348:383-393.
  70. Howard BV, Roman MJ, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. *JAMA*. 2008;299:1678-1689.
  71. Froehlich JB, Karavite D, Russman PL, et al. American College of Cardiology/American Heart Association preoperative assessment guidelines reduce resource utilization before aortic surgery. *J Vasc Surg*. 2002;36:758-763.
  72. Fleisher LA, Eagle KA. Screening for cardiac disease in patients having noncardiac surgery. *Ann Intern Med*. 1996;124:767-772.
  73. Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery: an abridged version of the report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Mayo Clin Proc*. 1997;72:524-531.
  74. Cohen MC, Curran PF, L' Italien GJ, et al. Long-term prognostic value of preoperative dipyridamole thallium imaging and clinical indexes in patients with diabetes mellitus undergoing peripheral vascular surgery. *Am J Cardiol*. 1999;83:1038-1042.
  75. Zarich SW, Cohen MC, Lane SE, et al. Routine perioperative dipyridamole <sup>201</sup>Tl imaging in diabetic patients undergoing vascular surgery. *Diabetes Care*. 1996;19:355-360.
  76. Mangano DT. Assessment of the patient with cardiac disease: an anesthesiologist's paradigm. *Anesthesiology*.



- 1999;91:1521-1526.
77. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. *N Engl J Med*. 2004;351:2795-2804.
  78. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. *N Engl J Med*. 1999;341:1789-1794.
  79. Monahan TS, Shrikhande GV, Pomposelli FB, et al. Preoperative cardiac evaluation does not improve or predict perioperative or late survival in asymptomatic diabetic patients undergoing elective infrainguinal arterial reconstruction. *J Vasc Surg*. 2005;41:38-45.
  80. Hamdan AD, Saltzberg SS, Sheahan M, et al. Lack of association of diabetes with increased postoperative mortality and cardiac morbidity: results of 6565 major vascular operations. *Arch Surg*. 2002;137:417-421.
  81. Mehta RH, Bossone E, Eagle KA. Perioperative cardiac risk assessment for noncardiac surgery. *Cardiology*. 1999;44:409-418.

## 第 28 章

1. Hirsch AT, Haskal ZJ, Hertzner NR, et al. *ACC/AHA 2005 Guidelines for the Management of Patients with Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report [trunc]*. Bethesda, MD: American College of Cardiology Foundation; 2005.
2. Howard BV, Howard WJ. The pathophysiology and treatment of lipid disorders in diabetes mellitus. In: Kahn C, Weis G, eds. *Joslin's Textbook of Diabetes*, 13th ed. Philadelphia: Lea & Febiger; 1994:372-376.
3. Brewer HB. Increasing HDL cholesterol levels. *N Engl J Med* 2004;350:1491-1494.
4. Libby P, Hansson GK, Pober JS. Atherogenesis and inflammation. In: Chien K, ed. *Molecular Basis of Cardiovascular Disease*. Philadelphia: WB Saunders; 1999:349-366.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA*. 2001;285:2486-2497.
6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106:3143-3421.
7. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. *Curr Atheroscler Rep*. 2004;6:381-387.
8. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. *Arch Intern Med* 148:36-69, 1988.
9. National Cholesterol Education Program: Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). *Circulation*. 1994;89:1333-1445.
10. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004;110:227-239.
11. Smith SC Jr, Allen J, Blair SN. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. *Circulation*. 2006;113:2363-2372.
12. Buchwald H, Varco RL, Matts JP. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). *N Engl J Med*. 1990;323:946-955.

13. Cashin-Hemphill L, Mack WJ, Pogoda JM. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. *JAMA*. 1990;264:3013-3017.
14. Buchwald H, Bourdages HR, Campos CT, et al. Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH). *Surgery*. 1996;120:672-679.
15. Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. *Circulation*. 1996;93:34-41.
16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344:1383-1389.
17. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). *Am J Cardiol*. 1998;81:333-335.
18. Heart Protection Study Collaborative Group. HPS randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular disease and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. *J Vasc Surg*. 2007;45:645-654.
19. Shepard J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*. 2002;360:1623-1630.
20. Mohler ER, Hiatt WR, Cramer MA, et al. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. *Circulation*. 2003;108:1481-1486.
21. Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. *Am J Med*. 2003;114:359-364.
22. Kinlay S, Plutzky J. Effect of lipid-lowering therapy on vasomotion and endothelial function. *Curr Cardiol Rep*. 1999;1:238-243.
23. Rehrling TF, Sandhoff BG, Stolepart RS, et al. Atherosclerotic risk factor control in patients with peripheral arterial disease. *J Vasc Surg*. 2005;41:816-822.
24. Gardner CD, Coulston AM, Chatterjee L, et al. The effect of a plant based diet on plasma lipids in hypercholesterolemic adults: a randomized trial. *Ann Intern Med*. 2005;142:725-733.
25. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesvelam in patients with primary hypercholesterolemia. *Am J Med*. 2001;110:352-360.
26. Kris-Etherton PM, Harris WS, Appel LJ. American Heart Association, Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation*. 2002;106:2742-2757.
27. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation*. 1999;99:779-785.
28. von Schacky C, Angerer P, Kothny W, et al. The effect of dietary  $\omega$ -3 fatty acids on coronary atherosclerosis: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 1999;130:554-562.
29. Report of the National Lipid Association's Safety Task Force: the nonstatins. *Am J Cardiol*. 2007;99:S1-S60.
30. McKenney P, Jones H, Bays R, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). *Atherosclerosis*. 2007;192:432-437.
31. Howard BV, Roman MJ, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes. The SANDS randomized trial. *JAMA*. 2008;299:1678-1689.
32. Clinical Trial: AIM HIGH. Niacin plus statin to prevent vascular events. Available at <http://www.clinicaltrials.gov/ct/show/NCT00120289>/Accessed 27 March 2008.
33. Clinical Trial: Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE. Available at <http://www.clinicaltrials.gov/ct2/show/NCT00461630/>?. Accessed 27 March 2008.
34. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. *Am J Cardiol*. 2008;101:625-630.

## 第 29 章

1. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. *Hypertension*. 2007;49:69-75.
2. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. *Hypertension*. 2004;44:398-404.
3. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. *Hypertension*. 1995;25:305-313.
4. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. *JAMA*. 2003;290:199-206.
5. Kaplan N. *Clinical Hypertension*. 9th ed. Philadelphia: Lippincott, Williams Wilkins; 2006.
6. Kullo IJ, Bailey KR, Kardia SLR, et al. Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. *Vasc Med*. 2003;8:237-242.
7. Osthege Y, Paulose-Ram R, Dillon CF, et al. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. *J Am Geriatr Soc*. 2007;55:583-589.
8. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease change with aging? The Framingham Heart Study. *Circulation*. 2001;103:1245.
9. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. *J Am Geriatr Soc*. 1985;33:13-18.
10. Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication. A risk profile from The Framingham Heart Study. *Circulation*. 1997;96:44-49.
11. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. *JAMA*. 2001;286:1599-1606.
12. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. *Circulation*. 2004;110:738-743.
13. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Health Study (CHS) Collaborative Research Group. *Circulation*. 1993;88:837-845.
14. Meijer WT, Hoes AW, Rutgers D, et al. Peripheral arterial disease in the elderly: the Rotterdam Study. *Arterioscler Thromb Vasc Biol*. 1998;18:185-192.
15. Selvin E, Hirsch AT. Contemporary risk factor control and walking dysfunction in individuals with peripheral arterial disease: NHANES 1999-2004. *Atherosclerosis*. 2008;201:425-433.
16. Hirsch AT, Hiatt WR, PARTNERS Steering Committee. PAD awareness, risk, and treatment: new resources for survival—the USA PARTNERS program. *Vasc Med*. 2001;6:9-12.
17. Violi F, Criqui MH, Longoni A, et al. Relationship between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. study. *Atherosclerosis*. 1996;120:25-35.
18. Palumbo PJ, O'Fallon WM, Osmundson PJ, et al. Progression of peripheral occlusive arterial disease in diabetes mellitus. What factors are predictive? *Arch Intern Med*. 1991;151:717-721.
19. Ozkan U, Oguzkurt L, Tercan F, et al. The prevalence and clinical predictors of incident atherosclerotic renal artery stenosis. *Eur J Radiol*. 2009;69:550-554.
20. Kikuya M, Hansen TW, Thijs L, et al. for the International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) Investigators: diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. *Circulation*. 2007;115:2145-2152.
21. Hansen TW, Kikuya M, Thijs L, et al. for the IDACO Investigators: prognostic superiority of daytime ambulatory over

- conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. *J Hypertens*. 2007;25:1554-1564.
22. Bjorklund K, Lind L, Zethelius B, et al. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. *Circulation*. 2003;107:1297-1302.
  23. Wofford MR, King DS, Wyatt SB, et al. Secondary hypertension: detection and management for the primary care provider. *J Clin Hypertens*. 2000;2:124-131.
  24. Lu H, Cassis LA, Daugherty A. Atherosclerosis and arterial blood pressure in mice. *Curr Drug Targets*. 2007;8:1181-1189.
  25. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. *J Clin Invest*. 2000;105:1605-1612.
  26. Nickenig G, Baumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. *Circulation*. 1999;100:2131-2134.
  27. Sarkar K, Sinha AK, Mehta JL. The role of statins in endothelial dysfunction in hypertension. *Curr Opin Cardiol*. 2006;21:316-321.
  28. Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. *J Cardiovasc Pharmacol*. 2000;35:549-555.
  29. Landmesser U, Drexel H. Endothelial function and hypertension. *Curr Opin Cardiol*. 2007;22:316-320.
  30. Yang XP, Liu YH, Shesely EG, et al. Endothelial nitric oxide gene knock-out mice: cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. *Hypertension*. 1999;34:24-30.
  31. Taddei S, Virdis A, Mattei P, et al. Defective l-arginine-nitric oxide pathway in offspring of essential hypertension patients. *Circulation*. 1996;94:1298-1303.
  32. Mohler ER III, O'Hare K, Darze ES, et al. Cardiovascular function in normotensive offspring of persons with essential hypertension and black race. *J Clin Hypertens*. 2007;9:506-512.
  33. Fava C, Minuz P, Patrignani P, et al. Renal artery stenosis and accelerated atherosclerosis: which comes first? *J Hypertens*. 2006;24:1687-1696.
  34. Chade AR, Krier JD, Rodriguez-Porcel M, et al. Comparison of acute and chronic antioxidant interventions in experimental renovascular disease. *Am J Physiol Renal Physiol*. 2004;286:F1079-F1086.
  35. Appel LJ, Champagne CM, Harsha DW, et al. for the Writing Group of the PREMIER Collaborative Research Group: Effects of comprehensive lifestyle modification on blood pressure control: Main results of the PREMIER clinical trial. *JAMA*. 2003;289:2083-2089.
  36. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;289:2560-2572.
  37. Sacks FM, Svetkey LP, Vollmer WM, et al. for the DASH-Sodium Collaborative Research Group: effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. *N Engl J Med*. 2001;344:3-10.
  38. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. *J Hypertens*. 2003;21:1055-1076.
  39. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*. 2003;362:1527-1535.
  40. Mehler PS, Coll JR, Eastacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. *Circulation*. 2003;107:753-756.
  41. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ*. 1998;317:703-713.
  42. Ahimastos AA, Lawler A, Reid CM, et al. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. *Ann Intern Med*. 2006;144:660-664.

43. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *J Am Coll Cardiol*. 2006;47:1239-1312.
44. Norgren L, Hiatt WR, Dormandy JA, et al. for the TASC II Working Group: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg*. 2007;45:S5-S67.
45. Julius S, Nesbitt SD, Egan BM, et al. for the Trial of Preventing Hypertension (TROPHY) Study Investigators: feasibility of treating prehypertension with an angiotensin-receptor blocker. *N Engl J Med*. 2006;354:1685-1697.
46. Lip GYH, Makin AJ. Treatment of hypertension in peripheral arterial disease. *Cochrane Database Syst Rev* 4:CD003075, 2003.
47. Brown MJ, Cruickshank JK, Dominiczak AF. Better blood pressure control: how to combine agents. *J Hum Hypertens*. 2003;17:81-86.
48. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group: Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Hypertension*. 2003;42:239-246.
49. Park JB, Schiffrin EL. Effects of antihypertensive therapy on hypertensive vascular disease. *Curr Hypertens Rep*. 2000;2:280-288.
50. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk. The Heart Outcomes Protection Evaluation Study Investigators. *N Engl J Med*. 2000;342:145-153.
51. Singer DR, Kite A. Management of hypertension in peripheral arterial disease: does choice of drugs matter? *Eur J Vasc Endovasc Surg*. 2008;35:701-798.
52. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first trimester exposure to ACE inhibitors. *N Engl J Med*. 2006;354:2451.
53. Dahlof B, Devereux RB, Kjeldsen SE, et al. for the LIFE Study Group: cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002;359:995.
54. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril or both in patients at high risk for vascular events. *N Engl J Med*. 2008;358:1547-1559.
55. Bagger JP, Helligsoe P, Randsbaek F, et al. Effect of verapamil in intermittent claudication. A randomized, double-blind, placebo-controlled, cross-over study after individual dose-response assessment. *Circulation*. 1997;95:411-414.
56. Weiss RJ, Weber MA, Carr AA, et al. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta blocker in patients with mild to moderate hypertension. *J Clin Hypertens*. 2007;9:667-676.
57. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: Is it a wise choice? *Lancet*. 2004;364:1684-1689.
58. Feringa HH, Bax JJ, Hoeks S, et al. A prognostic risk index for long-term mortality in patients with peripheral arterial disease. *Arch Intern Med*. 2007;167:2482-2489.
59. Solomon SA, Ramsay LE, Yeo WW, et al. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. *BMJ*. 1991;303:1100-1104.
60. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med*. 1999;341:709-717.

61. Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med*. 2003;348:1309-1321.
62. Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. *Hypertension*. 2003;41:64-68.
63. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. *JAMA*. 2000;283:1967-1975.
64. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *N Engl J Med*. 2004;351:2049-2057.
65. Gradman AH, Kad R. Renin inhibition in hypertension. *J Am Coll Cardiol*. 2008;51:519-528.
66. Black HR, Bakris GL, Weber MA, et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. *J Clin Hypertens*. 2007;9:760-769.
67. Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. *J Vasc Surg*. 2006;44:1213-1281.
68. Mohaupt MG, Schmidli J, Luft FC. Management of uncontrollable hypertension with a carotid sinus stimulation device. *Hypertension*. 2007;50:825-828.

## 第 30 章

1. Barkhordarian S, Dardik A. Preoperative assessment and management to prevent complications during high-risk vascular surgery. *Crit Care Med*. 2004;32(4 Suppl):S174-S185.
2. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. *N Engl J Med*. 1977;297:845-850.
3. Detsky AS, Abrams HB, McLaughlin JR, et al. Predicting cardiac complications in patients undergoing non-cardiac surgery. *J Gen Intern Med*. 1986;1:211-219.
4. Bronson DL, Halperin AK, Marwick TH. Evaluating cardiac risk in noncardiac surgery patients. *Cleve Clin J Med*. 1995;62:391-400.
5. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *J Am Coll Cardiol*. 2002;39:542-553.
6. Boersma E, Poldermans D, Bax JJ, et al. Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. *JAMA*. 2001;285:1865-1873.
7. Krupski WC, Nehler MR, Whitehill TA, et al. Negative impact of cardiac evaluation before vascular surgery. *Vasc Med*. 2000;5:3-9.
8. Eagle KA, Coley CM, Newell JB, et al. Combining clinical and thallium data optimizes preoperative assessment of cardiac risk before major vascular surgery. *Ann Intern Med*. 1989;110:859-866.
9. Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. *N Engl J Med*. 1996;335:1713-1720.
10. Back MR, Leo F, Cuthbertson D, et al. Long-term survival after vascular surgery: specific influence of cardiac factors and implications for preoperative evaluation. *J Vasc Surg*. 2004;40:752-760.
11. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. *N Engl J Med*. 2004;351:2795-2804.
12. Haimov M, Glabman S, Schupak E, et al. General surgery in patients on maintenance hemodialysis. *Ann Surg*. 1974;179:863-867.
13. Dardik A, Moesinger RC, Efron G, et al. Acute abdomen with colonic necrosis induced by Kayexalate-sorbitol. *South Med J*.

- 2000;93:511-513.
14. Hassen TA, Pearson S, Cowled PA, et al. Preoperative nutritional status predicts the severity of the systemic inflammatory response syndrome (SIRS) following major vascular surgery. *Eur J Vasc Endovasc Surg.* 2007;33:696-702.
  15. Westvik TS, Krause LK, Pradhan S, et al. Malnutrition after vascular surgery: are patients with chronic renal failure at increased risk? *Am J Surg.* 2006;192:e22-e27.
  16. Eneroth M, Apelqvist J, Larsson J, et al. Improved wound healing in transtibial amputees receiving supplementary nutrition. *Int Orthop.* 1997;21:104-108.
  17. King MS, Preoperative evaluation. *Am Fam Physician.* 2000;62:387-396.
  18. Santoso JT, Canada T, Latson B, et al. Prognostic nutritional index in relation to hospital stay in women with gynecologic cancer. *Obstet Gynecol.* 2000;95:844-846.
  19. Wu WC, Schiffner TL, Henderson WG, et al. Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. *JAMA.* 2007;297:2481-2488.
  20. Kendirci M, Trost L, Sikka SC, et al. The effect of vascular risk factors on penile vascular status in men with erectile dysfunction. *J Urol.* 2007;178:2516-2520; discussion 2520.
  21. Kapur V, Schwarz ER. The relationship between erectile dysfunction and cardiovascular disease. Part I: Pathophysiology and mechanisms. *Rev Cardiovasc Med.* 2007;8:214-219.
  22. Ramanathan R, Mulhall J, Rao S, et al. Predictive correlation between the International Index of Erectile Function (IIEF) and Sexual Health Inventory for Men (SHIM): implications for calculating a derived SHIM for clinical use. *J Sex Med.* 2007;4:1336-1344.
  23. Martin MJ, Heymann C, Neumann T, et al. Preoperative evaluation of chronic alcoholics assessed for surgery of the upper digestive tract. *Alcohol Clin Exp Res.* 2002;26:836-840.
  24. Pasetto LM, Lise M, Monfardini S. Preoperative assessment of elderly cancer patients. *Crit Rev Oncol Hematol.* 2007;64:10-18.
  25. Rosenthal RA, Kavic SM. Assessment and management of the geriatric patient. *Crit Care Med.* 2004;32(4 Suppl):S92-S105.
  26. Berman L, Dardik A, Bradley EH, et al. Informed consent for abdominal aortic aneurysm repair: assessing variations in surgeon opinion through a national survey. *J Vasc Surg.* 2008;47:287-295.

## 第 31 章

1. Cannon WB. Organization for physiological homeostasis. *Physiol Rev.* 1929;9:399.
2. Korner PI. Integrative neural cardiovascular control. *Physiol Rev.* 1971;51:312.
3. Gagliardino JJ. Physiological endocrine control of energy homeostasis and postprandial blood glucose levels. *Eur Rev Med Pharmacol Sci.* 2005;9:75.
4. Sapru HN. Carotid chemoreflex. Neural pathways and transmitters. *Adv Exp Med Biol.* 1996;410:357.
5. Romanovsky AA. Thermoregulation: some concepts have changed. Functional architecture of the thermoregulatory system. *Am J Physiol Regul Integr Comp Physiol.* 2007;292:R37.
6. Benarroch EE. Thermoregulation: recent concepts and remaining questions. *Neurology.* 2007;69:1293.
7. Dallman MF. Regulation of adrenocortical function following stress. In: Brown MR, Koob GF, Rivier C, eds. *Stress: Neurobiology and Neuroendocrinology*. New York: Marcel Dekker; 1991:173.
8. Fink G. Feedback systems. In: Fink G, ed. *Encyclopedia of Stress*. San Diego, CA: Academic Press; 2000:124.
9. Mekjavic IB, Eiken O. Contribution of thermal and nonthermal factors to the regulation of body temperature in humans. *J Appl Physiol.* 2006;100:2065.
10. Keller-Wood ME, Dallman MF. Corticosteroid inhibition of ACTH secretion. *Endocr Rev.* 1984;5:1.
11. Lilly MP, Jones RO, Putney DJ, et al. Post-surgical recovery and time-of-day mask potentiated responses of ACTH to repeated moderate hemorrhage in conscious rats. *J Endocrinol.* 2000;167:205.

12. Lilly MP. Effect of surgery on the pituitary-adrenal response to repeated hemorrhage. *Am J Physiol.* 1994;266:R1976.
13. Lilly MP, Cross JS, Shurtleff D, et al. Surgery increases the pituitary-adrenal response to hemorrhage and masks potentiated responses to repeated hemorrhage. *Endocrinology.* 1992;130:147A.
14. Lilly MP, Putney DJ, Carlson DE. Potentiated response of corticotropin (ACTH) to repeated moderate hemorrhage requires amygdalar neuronal processing. *Neuroendocrinology.* 2000;71:88.
15. Lilly MP, Gann DS. The hypothalamic-pituitary-adrenal-immune axis: a critical assessment. *Arch Surg.* 1992;127:1463.
16. Gann DS, Lilly MP. The neuroendocrine response to multiple trauma. *World J Surg.* 1983;7:101.
17. Lilly MP, Gann DS. The neuroendocrine response to injury. In: Border JR, Allgower M, Hansen ST, Ruedi TP, eds. *Blunt Multiple Trauma, Comprehensive Pathophysiology and Care.* New York: Marcel Dekker; 1990:167.
18. Gann DS, Amaral JF. Endocrine and metabolic responses to injury. In: Schwartz SI, Shires GT, Spencer FC, eds. *Principals of Surgery.* New York: McGraw-Hill; 1989.
19. Barton RN. The neuroendocrinology of physical injury. *Baillieres Clin Endocrinol Metab.* 1987;1:355.
20. American Society of Anesthesiologists Task Force on Sedation. Analgesia Practice guidelines for sedation and analgesia by non-anesthesiologists. *Anesthesiology.* 2002;96:1004.
21. Joint Commission on Accreditation of Healthcare Organizations. *Revisions to Anesthesia Care Standards: Comprehensive Accreditation Manual for Hospitals.* Oakbrook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations; 2001.
22. American Society of Anesthesiologists. *Statement on granting privileges for administration of moderate sedation to practitioners who are not anesthesia professionals.* Park Ridge, IL: American Society of Anesthesiologists; 2006.
23. Heavner JE. Pain mechanisms and local anesthetics: scientific foundations for clinical practice. In: Raj PP, ed. *Textbook of Regional Anesthesia.* New York: Churchill Livingstone; 2002:105.
24. Butterworth J. Clinical pharmacology of local anesthetics. In: Hadzic A, ed. *Textbook of Regional Anesthesia and Acute Pain Management.* New York: McGraw Hill; 2007:105.
25. Wildsmith JAW. Clinical use of local anesthetic drugs. In: Wildsmith JAW, Armitage EN, McClure JH, eds. *Principles and Practice of Regional Anesthesia.* London: Churchill Livingstone; 2003:65.
26. Lou L, Sabar R, Kaye AD. Local anesthetics. In: Raj PP, ed. *Textbook of Regional Anesthesia.* New York: Churchill Livingstone; 2002:177.
27. Lubarsky DA, Candiotti K, Harris E. Understanding modes of moderate sedation during gastrointestinal procedures: a current review of the literature. *J Clin Anesth.* 2007;19:397.
28. Gan TJ. Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation. *Clin Pharmacokinet.* 2006;45:855.
29. Kay J, Delmonte RJ, Greenberg PM. Ankle block. In: Hadzic A, ed. *Textbook of Regional Anesthesia and Acute Pain Management.* New York: McGraw Hill; 2007:545.
30. Vloka JD, Tsai T, Hadzic A. Cervical plexus block. In: Hadzic A, ed. *Textbook of Regional Anesthesia and Acute Pain Management.* New York: McGraw Hill; 2007:387.
31. Wildsmith JAW, Armitage EN, McClure JH. Principles and Practice of Regional Anesthesia. London: Churchill Livingstone; 2003.
32. Hadzic A. Textbook of Regional Anesthesia and Acute Pain Management. New York: McGraw Hill; 2007.
33. Raj PP. Textbook of Regional Anesthesia. New York: Churchill Livingstone; 2002.
34. Rooke GA, Freund PR, Jacobson AF. Hemodynamic response and change in organ blood volume during spinal anesthesia in elderly men with cardiac disease. *Anesth Analg.* 1997;85:99.
35. Lybecker H, Djernes M, Schmidt JF. Postdural puncture headache (PDPH): onset, duration, severity, and associated symptoms. An analysis of 75 consecutive patients with PDPH. *Acta Anaesthesiol Scand.* 1995;39:605.
36. Candido KD, Stevens RA. Post-dural puncture headache: pathophysiology, prevention and treatment. *Best Pract Res Clin*



*Anesthesiol.* 2003;17:451.

37. Oedit R, van Kooten F, Bakker SL, et al. Efficacy of the epidural blood patch for the treatment of post lumbar puncture headache BLOPP: a randomised, observer-blind, controlled clinical trial. *BMC Neurol.* 2005;5:12.
38. Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). *Reg Anesth Pain Med.* 2003;28:172.
39. Kaplan JA, Lake CL, Murray MJ. Vascular Anesthesia. Philadelphia: Churchill Livingstone; 2004.
40. Manikian B, Cantineau JP, Bertrand M, et al. Improvement of diaphragmatic function by a thoracic extradural block after upper abdominal surgery. *Anesthesiology.* 1988;68:379.
41. Norris EJ, Beattie C, Perler BA, et al. Double-masked randomized trial comparing alternate combinations of intraoperative anesthesia and postoperative analgesia in abdominal aortic surgery. *Anesthesiology.* 2001;95:1054.
42. Pronovost PJ, Jenckes MW, Dorman T, et al. Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery. *JAMA.* 1999;281:1310.
43. Baron JF, Bertrand M, Barré E, et al. Combined epidural and general anesthesia versus general anesthesia for abdominal aortic surgery. *Anesthesiology.* 1991;75:611.
44. Bode RH, Lewis KP, Zarich SW, et al. Cardiac outcome after peripheral vascular surgery. Comparison of general and regional anesthesia. *Anesthesiology.* 1996;84:3.
45. Liu S, Carpenter RL, Neal JM. Epidural anesthesia and analgesia. Their role in postoperative outcome. *Anesthesiology.* 1995;82:1474.
46. Tuman KJ, McCarthy RJ, March RJ, et al. Effects of epidural anesthesia and analgesia on coagulation and outcome after major vascular surgery. *Anesth Analg.* 1991;73:696.
47. Yeager MP, Glass DD, Neff RK, et al. Epidural anesthesia and analgesia in high-risk surgical patients. *Anesthesiology.* 1987;66:729.
48. Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. *BMJ.* 2000;321:1493.
49. Beattie WS, Badner NH, Choi P. Epidural analgesia reduces postoperative myocardial infarction: a meta-analysis. *Anesth Analg.* 2001;93:853.
50. Park WY, Thompson JS, Lee KK. Effect of epidural anesthesia and analgesia on perioperative outcome: a randomized, controlled Veterans Affairs cooperative study. *Ann Surg.* 2001;234:560.
51. Rigg JRA, Jamrozik K, Myles PS, et al. Epidural anaesthesia and analgesia and outcome of major surgery: a randomised trial. *Lancet.* 2002;359:1276.
52. Rigg JR, Jamrozik K, Myles PS, et al. Design of the multicenter Australian study of epidural anesthesia and analgesia in major surgery: the MASTER trial. *Controlled Clinl Trials.* 2000;21:244.
53. Norris EJ. Perioperative management of the patient undergoing aortic vascular surgery. In: Schwartz AJ, ed. *ASA Refresher Courses in Anesthesiology.* Philadelphia: Lippincott Williams & Wilkins; 2005:187.
54. Davies MJ, Silbert BS, Mooney PJ, et al. Combined epidural and general anaesthesia versus general anaesthesia for abdominal aortic surgery: a prospective randomised trial. *Anaesth Intensive Care.* 1993;21:790.
55. Garnett RL, MacIntyre A, Lindsay P, et al. Perioperative ischaemia in aortic surgery: combined epidural/general anaesthesia and epidural analgesia vs general anaesthesia and i.v. analgesia. *Can J Anaesth.* 1996;43:769.
56. Bois S, Couture P, Boudreault D, et al. Epidural analgesia and intravenous patient-controlled analgesia result in similar rates of postoperative myocardial ischemia after aortic surgery. *Anesth Analg.* 1997;85:1233.
57. Boylan JF, Katz J, Kavanagh BP, et al. Epidural bupivacaine-morphine analgesia versus patient-controlled analgesia following abdominal aortic surgery: analgesic, respiratory, and myocardial effects. *Anesthesiology.* 1998;89:585.
58. Ballantyne JC. Editorial II: Does epidural analgesia improve surgical outcome? *Br J Anaesth.* 2004;92:4.
59. Nishimori M, Ballantyne JC, Low JHS. Epidural pain relief versus systemic opioid-based pain relief for abdominal aortic

- surgery. *Cochrane Database Syst Rev*. 2006;3:CD005059.
60. Rivers SP, Scher LA, Sheehan E, et al. Epidural versus general anesthesia for infrainguinal arterial reconstruction. *J Vasc Surg*. 1991;14:764.
  61. Damask MC, Weissman C, Todd G. General versus epidural anesthesia for femoral-popliteal bypass surgery. *J Clin Anesth*. 1990;2:71.
  62. Pierce ET, Pomposelli FB, Stanley GD, et al. Anesthesia type does not influence early graft patency or limb salvage rates of lower extremity arterial bypass. *J Vasc Surg*. 1997;25:226.
  63. Gelman S. General versus regional anesthesia for peripheral vascular surgery. Is the problem solved? *Anesthesiology*. 1993;79:415.
  64. Christopherson R, Beattie C, Frank SM, et al. Perioperative morbidity in patients randomized to epidural or general anesthesia for lower extremity vascular surgery. Perioperative Ischemia Randomized Anesthesia Trial Study Group. *Anesthesiology*. 1993;79:422.
  65. Rosenfeld BA, Beattie C, Christopherson R, et al. The effects of different anesthetic regimens on fibrinolysis and the development of postoperative arterial thrombosis. Perioperative Ischemia Randomized Anesthesia Trial Study Group. *Anesthesiology*. 1993;79:435.
  66. Hahnenkamp K, Theilmeier G, Van Aken HK, et al. The effects of local anesthetics on perioperative coagulation, inflammation, and microcirculation. *Anesth Analg*. 2002;94:1441.
  67. Delis KT, Husmann MJ, Szendro G, et al. Haemodynamic effect of intermittent pneumatic compression of the leg after infrainguinal arterial bypass grafting. *Br J Surg*. 2004;91:429.
  68. Rerkasem K, Bond R, Rothwell PM. Local versus general anaesthesia for carotid endarterectomy. *Cochrane Database Syst Rev*. 2004;2:CD000126.
  69. Landesberg G, Mosseri M, Wolf Y, et al. Perioperative myocardial ischemia and infarction: identification by continuous 12-lead electrocardiogram with online ST-segment monitoring. *Anesthesiology*. 2002;96:264.
  70. Kates RA, Zaidan JR, Kaplan JA. Esophageal lead for intraoperative electrocardiographic monitoring. *Anesth Analg*. 1982;61:781.
  71. Machler HE, Lueger A, Rehak P, et al. A new high-resolution esophageal electrocardiography recording technique: an experimental approach for the detection of myocardial ischemia. *Anesth Analg*. 1998;86:34.
  72. Moller JT, Johannessen NW, Espersen K, et al. Randomized evaluation of pulse oximetry in 20,802 patients: II. Perioperative events and postoperative complications. *Anesthesiology*. 1993;78:445.
  73. Moller JT, Pedersen T, Rasmussen LS, et al. Randomized evaluation of pulse oximetry in 20,802 patients: I. Design, demography, pulse oximetry failure rate, and overall complication rate. *Anesthesiology*. 1993;78:436.
  74. Reich DL, Timcenko A, Bodian CA, et al. Predictors of pulse oximetry data failure. *Anesthesiology*. 1996;84:859.
  75. van Montfrans GA. Oscillometric blood pressure measurement: progress and problems. *Blood Press Monit*. 2001;6:287.
  76. Borow KM, Newburger JW. Noninvasive estimation of central aortic pressure using the oscillometric method for analyzing systemic artery pulsatile blood flow: comparative study of indirect systolic, diastolic, and mean brachial artery pressure with simultaneous direct ascending aortic pressure measurements. *Am Heart J*. 1982;103:879.
  77. Sfeir RR, Khoury SS, Khoury GG, et al. Ischaemia of the hand after radial artery monitoring. *Cardiovasc Surg*. 1996;4:456.
  78. Mozersky DJ, Buckley CJ, Hagood CO, et al. Ultrasonic evaluation of the palmar circulation. A useful adjunct to radial artery cannulation. *Am J Surg*. 1973;126:810.
  79. Shoemaker WC. Cardiorespiratory patterns of surviving and nonsurviving postoperative patients. *Surg Gynecol Obstet*. 1972;134:810.
  80. Shoemaker WC, Appel PL, Kram HB. Hemodynamic and oxygen transport responses in survivors and nonsurvivors of high-risk surgery. *Crit Care Med*. 1993;21:977.
  81. Shoemaker WC, Montgomery ES, Kaplan E, et al. Physiologic patterns in surviving and nonsurviving shock patients. Use

- of sequential cardiorespiratory variables in defining criteria for therapeutic goals and early warning of death. *Arch Surg.* 1973;106:630.
82. Shoemaker WC, Appel PL, Kram HB, et al. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. *Chest.* 1988;94:1176.
  83. Cooper AB, Doig GS, Sibbald WJ. Pulmonary artery catheters in the critically ill. An overview using the methodology of evidence-based medicine. *Crit Care Clin.* 1996;12:777.
  84. Gnaegi A, Feihl F, Perret C. Intensive care physicians' insufficient knowledge of right-heart catheterization at the bedside: time to act? *Crit Care Med.* 1997;25:213.
  85. Connors AF, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. *JAMA.* 1996;276:889.
  86. Polanczyk CA, Rohde LE, Goldman L, et al. Right heart catheterization and cardiac complications in patients undergoing noncardiac surgery: an observational study. *JAMA.* 2001;286:309.
  87. Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. *N Engl J Med.* 2003;348:5.
  88. Shah MR, Hasselblad V, Stevenson LW, et al. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. *JAMA.* 2005;294:1664.
  89. Barone JE, Tucker JB, Rassias D, et al. Routine perioperative pulmonary artery catheterization has no effect on rate of complications in vascular surgery: a meta-analysis. *Am Surg.* 2001;67:674.
  90. Berlaak JF, Abrams JH, Gilmour IJ, et al. Preoperative optimization of cardiovascular hemodynamics improves outcome in peripheral vascular surgery—A prospective, randomized clinical-trial. *Ann Surg.* 1991;214:289.
  91. Valentine RJ, Duke ML, Inman MH, et al. Effectiveness of pulmonary artery catheters in aortic surgery: a randomized trial. *J Vasc Surg.* 1998;27:203.
  92. Bender JS, Smith-Meek MA, Jones CE. Routine pulmonary artery catheterization does not reduce morbidity and mortality of elective vascular surgery: results of a prospective, randomized trial. *Ann Surg.* 1997;226:229.
  93. Harvey S, Young D, Brampton W, et al. Pulmonary artery catheters for adult patients in intensive care. *Cochrane Database Syst Rev.* 2006.
  94. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *Circulation.* 2007;116:1971.
  95. American Society of Anesthesiologists Task Force on Pulmonary Artery Catheterization. Practice guidelines for pulmonary artery catheterization: an updated report by the American Society of Anesthesiologists Task Force on Pulmonary Artery Catheterization. *Anesthesiology.* 2003;99:988.
  96. Tote SP, Grounds RM. Performing perioperative optimization of the high-risk surgical patient. *Br J Anaesth.* 2006;97:4.
  97. Joffe II, Jacobs LE, Lampert C, et al. Role of echocardiography in perioperative management of patients undergoing open heart surgery. *Am Heart J.* 1996;131:162.
  98. Click RL, Abel MD, Schaff HV. Intraoperative transesophageal echocardiography: 5-year prospective review of impact on surgical management. *Mayo Clin Proc.* 2000;75:241.
  99. Swenson JD, Bull D, Stringham J. Subjective assessment of left ventricular preload using transesophageal echocardiography: corresponding pulmonary artery occlusion pressures. *J Cardiothorac Vasc Anesth.* 2001;15:580.
  100. Gewertz BL, Kremser PC, Zarins CK, et al. Transesophageal echocardiographic monitoring of myocardial ischemia during

vascular surgery. *J Vasc Surg*. 1987;5:607.

101. Hofer CK, Zollinger A, Rak M, et al. Therapeutic impact of intra-operative transoesophageal echocardiography during noncardiac surgery. *Anaesthesia*. 2004;59:3.
102. Schulmeyer MC, Santelices E, Vega R, et al. Impact of intraoperative transesophageal echocardiography during noncardiac surgery. *J Cardiothorac Vasc Anesth*. 2006;20:768.
103. Urban MK, Gordon MA, Harris SN, et al. Intraoperative hemodynamic changes are not good indicators of myocardial ischemia. *Anesth Analg*. 1993;76:942.
104. Ellis JE, Shah MN, Briller JE, et al. A comparison of methods for the detection of myocardial ischemia during noncardiac surgery: automated ST-segment analysis systems, electrocardiography, and transesophageal echocardiography. *Anesth Analg*. 1992;75:764.
105. McGowan JE. Cost and benefit of perioperative antimicrobial prophylaxis: methods for economic analysis. *Rev Infect Dis*. 1991;13(Suppl 10):S879.
106. Burke JP. Infection control—a problem for patient safety. *N Engl J Med*. 2003;348:651.
107. Wong ES. The price of a surgical site infection: more than just excess length of stay. *Infect Control Hosp Epidemiol*. 1999;20:722.
108. Kirkland KB, Briggs JP, Trivette SL, et al. The impact of surgical site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. *Infect Control Hosp Epidemiol*. 1999;20:725.
109. Auerbach AD. Prevention of surgical site infections. In: Shojania KG, Duncan BW, McDonald KM, Wachter RF, eds. *Making Health Care Safer: A Critical Analysis of Patient Safety Practices*. Evidence Report/Technology Assessment No. 43. Rockville, MD: Agency for Healthcare Research and Quality; 2001:221.
110. Silver A, Eichorn A, Kral J, et al. Timeliness and use of antibiotic prophylaxis in selected inpatient surgical procedures. *Am J Surg*. 1996;171:548.
111. Poulsen KB, Wachmann CH, Bremmelgaard A, et al. Survival of patients with surgical wound infection: a case-control study of common surgical interventions. *Br J Surg*. 1995;82:208.
112. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. *Surgery*. 1961;50:161.
113. Polk HC, Lopez-Mayor JF. Postoperative wound infection: a prospective study of determinant factors and prevention. *Surgery*. 1969;66:97.
114. Polk HC, Trachtenberg L, Finn MP. Antibiotic activity in surgical incisions. The basis of prophylaxis in selected operations. *JAMA*. 1980;244:1353.
115. Page CP, Bohnen JM, Fletcher JR, et al. Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. *Arch Surg*. 1993;128:79.
116. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. *Am J Infect Control*. 1999;27:97.
117. Classen DC, Evans RS, Pestotnik SL, et al. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. *N Engl J Med*. 1992;326:281.
118. Bratzler DW, Houck PM, Richards C, et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. *Arch Surg*. 2005;140:174.
119. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. *Clin Infect Dis*. 2004;38:1706.
120. Stevens RD, Burri H, Tramèr MR. Pharmacologic myocardial protection in patients undergoing noncardiac surgery: a quantitative systematic review. *Anesth Analg*. 2003;97:623.
121. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive summary. A report of the American College of Cardiology/American Heart Association

Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *Circulation*. 2002;105:1257.

122. Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. *Anesthesiology*. 1998;88:7.
123. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. *N Engl J Med*. 1999;341:1789.
124. Juul AB, Wetterslev J, Gluud C, et al. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. *BMJ*. 2006;332:1482.
125. Yang H, Raymer K, Butler R, et al. The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. *Am Heart J*. 2006;152:983.
126. Feringa HHH, Bax JJ, Schouten O, et al. Beta-blockers improve in-hospital and long-term survival in patients with severe left ventricular dysfunction undergoing major vascular surgery. *Eur J Vasc Endovasc Surg*. 2006;31:351.
127. Feringa HHH, Bax JJ, Boersma E, et al. High-dose  $\beta$ -blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients. *Circulation*. 2006;114(1 Suppl):I344.
128. Wijeyundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. *Am J Med*. 2003;114:742.
129. Frank SM, Higgins MS, Fleisher LA, et al. Adrenergic, respiratory, and cardiovascular effects of core cooling in humans. *Am J Physiol*. 1997;272:R557.
130. Greif S, Laciny S, Rajek A, et al. Blood pressure response to thermoregulatory vasoconstriction during isoflurane and desflurane anesthesia. *Acta Anaesthesiol Scand*. 2003;47:847.
131. Sessler DI. Complications and treatment of mild hypothermia. *Anesthesiology*. 2001;95:531.
132. Frank SM, Beattie C, Christopherson R, et al. Unintentional hypothermia is associated with postoperative myocardial ischemia. The Perioperative Ischemia Randomized Anesthesia Trial Study Group. *Anesthesiology*. 1993;78:468.
133. Frank SM, Fleisher LA, Breslow MJ, et al. Perioperative maintenance of normothermia reduces the incidence of morbid cardiac events. A randomized clinical trial. *JAMA*. 1997;277:1127.
134. Hosokawa K, Nakajima Y, Umenai T, et al. Predictors of atrial fibrillation after off-pump coronary artery bypass graft surgery. *Br J Anaesth*. 2007;98:575.
135. Reed RL, Johnson TD, Hudson JD, et al. The disparity between hypothermic coagulopathy and clotting studies. *J Trauma*. 1992;33:465.
136. Rohrer MJ, Natale AM. Effect of hypothermia on the coagulation cascade. *Crit Care Med*. 1992;20:1402.
137. Valeri CR, Feingold H, Cassidy G, et al. Hypothermia-induced reversible platelet dysfunction. *Ann Surg*. 1987;205:175.
138. Michelson AD, MacGregor H, Barnard MR, et al. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. *Thromb Haemost*. 1994;71:633.
139. Schmied H, Reiter A, Kurz A, et al. Mild hypothermia increases blood loss and transfusion requirements during total hip arthroplasty. *Lancet*. 1996;347:289.
140. Rajagopalan S, Mascha E, Na J, et al. The effects of mild perioperative hypothermia on blood loss and transfusion requirement. *Anesthesiology*. 2008;108:71.
141. Winkler M, Akca O, Birkenberg B, et al. Aggressive warming reduces blood loss during hip arthroplasty. *Anesth Analg*. 2000;91:1978.
142. Widman J, Hammarqvist F, Selldén E. Amino acid infusion induces thermogenesis and reduces blood loss during hip arthroplasty under spinal anesthesia. *Anesth Analg*. 2002;95:1757.
143. Persson K, Lundberg J. Perioperative hypothermia and postoperative opioid requirements. *Eur J Anaesthesiol*. 2001;18:679.

144. Hofer CK, Worn M, Tavakoli R, et al. Influence of body core temperature on blood loss and transfusion requirements during off-pump coronary artery bypass grafting: a comparison of 3 warming systems. *J Thorac Cardiovasc Surg.* 2005;129:838.
145. Bock M, Müller J, Bach A, et al. Effects of preinduction and intraoperative warming during major laparotomy. *Br J Anaesth.* 1998;80:159.
146. Johansson T, Lisander B, Ivarsson I. Mild hypothermia does not increase blood loss during total hip arthroplasty. *Acta Anaesthesiol Scand.* 1999;43:1005.
147. Smith CE, Desai R, Gloriosio V, et al. Preventing hypothermia: convective and intravenous fluid warming versus convective warming alone. *J Clin Anesth.* 1998;10:380.
148. Mason DS, Sapala JA, Wood MH, et al. Influence of a forced air warming system on morbidly obese patients undergoing Roux-en-Y gastric bypass. *Obes Surg.* 1998;8:453.
149. Casati A, Fanelli G, Ricci A, et al. Shortening the discharging time after total hip replacement under combined spinal/epidural anesthesia by actively warming the patient during surgery. *Minerva Anesthesiol.* 1999;65:507.
150. Murat I, Bernière J, Constant I. Evaluation of the efficacy of a forced-air warmer (Bair Hugger) during spinal surgery in children. *J Clin Anesth.* 1994;6:425.
151. Hohn L, Schweizer A, Kalangos A, et al. Benefits of intraoperative skin surface warming in cardiac surgical patients. *Br J Anaesth.* 1998;80:318.
152. Nathan HJ, Parlea L, Dupuis J-Y, et al. Safety of deliberate intraoperative and postoperative hypothermia for patients undergoing coronary artery surgery: a randomized trial. *J Thorac Cardiovasc Surg.* 2004;127:1270.
153. Beilin B, Yehuda S, Razumovsky J, et al. Effects of mild perioperative hypothermia on cellular immune responses. *Anesthesiology.* 1998;89:1133.
154. Frohlich D, Wittmann S, Rothe G, et al. Mild hyperthermia down-regulates receptor-dependent neutrophil function. *Anesth Analg.* 2004;99:284.
155. Wenisch C, Narzt E, Sessler DI, et al. Mild intraoperative hypothermia reduces production of reactive oxygen intermediates by polymorphonuclear leukocytes. *Anesth Analg.* 1996;82:810.
156. Kurz A, Sessler DI, Lenhardt R, et al. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. *N Engl J Med.* 1996;334:1209.
157. Todd MM. Current status of hypothermia as a treatment modality. *Can J Anesth.* 2004;51:R8.
158. Alderson P, Gadkary C, Signorini DF. Therapeutic hypothermia for head injury. *Cochrane Database Syst Rev.* 2004;4:CD001048.
159. Samra SK, Giordani B, Caveney AF, et al. Recovery of cognitive function after surgery for aneurysmal subarachnoid hemorrhage. *Stroke.* 2007;38:1864.
160. Correia M, Silva M, Veloso M. Cooling therapy for acute stroke. *Cochrane Database Syst Rev.* 1999;2:CD001247.
161. Rees K, Beranek-Stanley M, Burke M, et al. Hypothermia to reduce neurological damage following coronary artery bypass surgery. *Cochrane Database Syst Rev.* 2001;1:CD002138.
162. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. *Mayo Clin Proc.* 2003;78:1471.
163. Latham R, Lancaster AD, Covington JF, et al. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. *Infect Control Hosp Epidemiol.* 2001;22:607.
164. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. *Diabetes Care.* 1998;21:518.
165. Turina M, Fry DE, Polk HC. Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. *Crit Care Med.* 2005;33:1624.
166. Coursin DB, Connery LE, Ketzler JT. Perioperative diabetic and hyperglycemic management issues. *Crit Care Med.*

2004;32:S116.

167. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. *N Engl J Med*. 2001;345:1359.
168. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. *Mayo Clin Proc*. 2004;79:992.
169. Furnary AP, Gao G, Grunkemeier GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. *J Thorac Cardiovasc Surg*. 2003;125:1007.
170. Thompson JF, Mullee MA, Bell PR, et al. Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: a Joint Vascular Research Group study. *Eur J Vasc Endovasc Surg*. 1996;12:86.
171. Mackman N. Triggers, targets and treatments for thrombosis. *Nature*. 2008;451:914.
172. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. *Arterioscler Thromb Vasc Biol*. 2008;28:380.
173. McAvoy TJ. Pharmacokinetic modeling of heparin and its clinical implications. *J Pharmacokinet Biopharm*. 1979;7:331.
174. Tremey B, Szekely B, Schlumberger S, et al. Anticoagulation monitoring during vascular surgery: accuracy of the Hemochron low range activated clotting time (ACT-LR). *Br J Anaesth*. 2006;97:453.
175. Mabry CD, Thompson BW, Read RC, et al. Activated clotting time monitoring of intraoperative heparinization: our experience and comparison of two techniques. *Surgery*. 1981;90:889.
176. Poisik A, Heyer EJ, Solomon RA, et al. Safety and efficacy of fixed-dose heparin in carotid endarterectomy. *Neurosurgery*. 1999;45:434.
177. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. *Circulation*. 2001;103:961.
178. Castellan L, Causin F, Danieli D, et al. Carotid stenting with filter protection. Correlation of ACT values with angiographic and histopathologic findings. *J Neuroradiol*. 2003;30:103.
179. Levy JH, Adkinson NF. Anaphylaxis during cardiac surgery: implications for clinicians. *Anesth Analg*. 2008;106:392.
180. Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126:609S.
181. Baldwin ZK, Spitzer AL, Ng VL, et al. Contemporary standards for the diagnosis and treatment of heparin-induced thrombocytopenia (HIT). *Surgery*. 2008;143:305.
182. He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. *JAMA*. 1998;280:1930.
183. Keller TT, Squizzato A, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. *Cochrane Database Syst Rev*. 2007;3:CD005158.
184. Nasser M, Kapeliovich M, Markiewicz W. Late thrombosis of sirolimus-eluting stents following noncardiac surgery. *Catheter Cardiovasc Interv*. 2005;65:516.
185. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. *Lancet*. 2004;364:1519.
186. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. *Circulation*. 2007;115:813.
187. Chassot PG, Delabays A, Spahn DR. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. *Br J Anaesth*. 2007;99:316.
188. Neilipovitz DT, Bryson GL, Nichol G. The effect of perioperative aspirin therapy in peripheral vascular surgery: a decision analysis. *Anesth Analg*. 2001;93:573.

189. Smout J, Stansby G. Current practice in the use of antiplatelet agents in the peri-operative period by UK vascular surgeons. *Ann R Coll Surg Engl*. 2003;85:97.
190. Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. *Crit Care Med*. 2001;29:2271.
191. Kapetanakis EI, Medlam DA, Petro KR, et al. Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae? *Circulation*. 2006;113:1667.
192. Levy JH, Tanaka KA. The anticoagulated patient: strategies for effective blood loss management. *Surgery*. 2007;142: S71.
193. Chu MWA, Wilson SR, Novick RJ, et al. Does clopidogrel increase blood loss following coronary artery bypass surgery? *Ann Thorac Surg*. 2004;78:1536.
194. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). *J Thromb Haemost*. 2003;1:682.
195. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. *Blood*. 1997;90:2515.
196. Carless PA, Henry DA, Moxey AJ, et al. Desmopressin for minimising perioperative allogeneic blood transfusion. *Cochrane Database Syst Rev*. 2004;1:CD001884.
197. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. *Lancet*. 1999;354:1940.
198. Goodnough LT, Lublin DM, Zhang L, et al. Transfusion medicine service policies for recombinant factor VIIa administration. *Transfusion*. 2004;44:1325.
199. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. *JAMA*. 2006;295:293.
200. Berridge DC, Kessel D, Robertson I. Surgery versus thrombolysis for acute limb ischaemia: initial management. *Cochrane Database Syst Rev*. 2002;3:CD002784.
201. Norem RF, Short DH, Kerstein MD. Role of intraoperative fibrinolytic therapy in acute arterial occlusion. *Surg Gynecol Obstet*. 1988;167:87.
202. Quinones-Baldrich WJ, Zierler RE, Hiatt JC. Intraoperative fibrinolytic therapy: an adjunct to catheter thromboembolectomy. *J Vasc Surg*. 1985;2:319.
203. Earnshaw JJ, Beard JD. Intraoperative use of thrombolytic agents. *BMJ*. 1993;307:638.
204. Gonzalez-Fajardo JA, Perez-Burkhardt JL, Mateo AM. Intraoperative fibrinolytic therapy for salvage of limbs with acute arterial ischemia: an adjunct to thromboembolectomy. *Ann Vasc Surg*. 1995;9:179.
205. Malone MD, Barber L, Comerota AJ. Clinical applications of thrombolytic therapy for arterial and graft occlusion. *Surg Clin North Am*. 1998;78:647.
206. Comerota AJ, Rao AK. Intraoperative intraarterial thrombolytic therapy. In: Comerota AJ, ed. *Thrombolytic Therapy for Peripheral Vascular Disease*. Philadelphia: JB Lippincott; 1995:313.
207. Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lower limb peripheral arterial occlusion—A consensus document. *J Vasc Interv Radiol*. 2003;14:S337.
208. Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lower limb peripheral arterial occlusion—A consensus document. *Am J Cardiol*. 1998;81:207.
209. Comerota AJ, White JV, Grosh JD. Intraoperative intra-arterial thrombolytic therapy for salvage of limbs in patients with distal arterial thrombosis. *Surg Gynecol Obstet*. 1989;169:283.
210. Beard JD, Gaines PA. The future of vascular surgery. *Br J Surg*. 1993;80:185.
211. Comerota AJ, Rao AK, Thom RC, et al. A prospective, randomized, blinded, and placebo-controlled trial of intraoperative intra-arterial urokinase infusion during lower extremity revascularization. Regional and systemic effects. *Ann Surg*. 1993;218:534.
212. Riggs P, Ouriel K. Thrombolysis in the treatment of lower extremity occlusive disease. *Surg Clin North Am*. 1995;75:633.



213. Gonzales-Fajardo JA, Perez-Burkhardt JL, Mateo AM. Intraoperative fibrinolytic therapy for salvage of limbs with acute arterial surgery: an adjunct to thromboembolectomy. *Ann Vasc Surg.* 1995;9:179.
214. Knaus J, Ris HB, Do D, et al. Intraoperative catheter thrombolysis as an adjunct to surgical revascularisation for infrainguinal limb-threatening ischaemia. *Eur J Vasc Surg.* 1993;7:507.
215. Earnshaw JJ, Birch P. Peripheral thrombolysis: state of the art. *Cardiovasc Surg.* 1995;3:357.
216. The STILE Trial Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. *Ann Surg.* 1994;220:251.
217. Ouriel K, Veith FJ, Sasahara AA. Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators. *J Vasc Surg.* 1996;23:64.
218. Levy PS, Kim SJ, Eckel PK, et al. Limit to cardiac compensation during acute isovolemic hemodilution: influence of coronary stenosis. *Am J Physiol.* 1993;265: H340.
219. Kreimeier U, Messmer K. Hemodilution in clinical surgery: state of the art 1996. *World J Surg.* 1996;20:1208.
220. Carson JL, Noveck H, Berlin JA, et al. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. *Transfusion.* 2002;42:812.
221. Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. *Lancet.* 1996;348:1055.
222. Viele MK, Weiskopf RB. What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. *Transfusion.* 1994;34:396.
223. Goldman M, Webert KE, Arnold DM, et al. Proceedings of a consensus conference: towards an understanding of TRALI. *Transfus Med Rev.* 2005;19:2.
224. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. *Transfusion.* 2004;44:1774.
225. Barrett NA, Kam PCA. Transfusion-related acute lung injury: a literature review. *Anaesthesia.* 2006;61:777.
226. Holness L, Knippen MA, Simmons L, et al. Fatalities caused by TRALI. *Transfus Med Rev.* 2004;18:184.
227. Goodnough LT. Risks of blood transfusion. *Crit Care Med.* 2003;31:S678.
228. Centers for Disease Control and Prevention (CDC). Red blood cell transfusions contaminated with *Yersinia enterocolitica*—United States, 1991-1996, and initiation of a national study to detect bacteria-associated transfusion reactions. *MMWR Morb Mortal Wkly Rep.* 1997;46:553.
229. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. *JAMA.* 2003;289:959.
230. Linden JV, Wagner K, Voytovich AE, et al. Transfusion errors in New York State: an analysis of 10 years' experience. *Transfusion.* 2000;40:1207.
231. Opelz G, Sengar DP, Mickey MR, et al. Effect of blood transfusions on subsequent kidney transplants. *Transplant Proc.* 1973;5:253.
232. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. *N Engl J Med.* 1978;299:799.
233. Vamvakas EC, Carven JH, Hibberd PL. Blood transfusion and infection after colorectal cancer surgery. *Transfusion.* 1996;36:1000.
234. Vamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. *Transfusion.* 1996;36:175.
235. Taylor RW, Manganaro L, O'Brien J, et al. Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. *Crit Care Med.* 2002;30:2249.
236. Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? *Blood.* 2001;97:1180.
237. Blajchman MA. Immunomodulation and blood transfusion. *Am J Ther.* 2002;9:389.

238. Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. *Transfusion*. 2001;41:691.
239. Sharma AD, Sreeram G, Erb T, et al. Leukocyte-reduced blood transfusions: perioperative indications, adverse effects, and cost analysis. *Anesth Analg*. 2000;90:1315.
240. Hebert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian Universal Leukoreduction Program for Red Blood Cell Transfusions. *JAMA*. 2003;289:1941.
241. Corwin HL, AuBuchon JP. Is leukoreduction of blood components for everyone? *JAMA*. 2003;289:1993.
242. van Hilten JA, van de Watering LMG, van Bockel JH, et al. Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery. *BMJ*. 2004;328:1281.
243. Vamvakas EC. White-blood-cell-containing allogeneic blood transfusion and postoperative infection or mortality: an updated meta-analysis. *Vox Sang*. 2007;92:224.
244. Blumberg N, Zhao H, Wang H, et al. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. *Transfusion*. 2007;47:573.
245. Tinmouth A, Chin-Yee I. The clinical consequences of the red cell storage lesion. *Transfus Med Revs*. 2001;15:91.
246. Greenwalt TJ, Zehner Sostok C, Dumaswala UJ. Studies in red blood cell preservation. 1. Effect of the other formed elements. *Vox Sang*. 1990;58:85.
247. Högman CF, Meryman HT. Storage parameters affecting red blood cell survival and function after transfusion. *Transfus Med Rev*. 1999;13:275.
248. Tinmouth A, Fergusson D, Yee IC, et al. Clinical consequences of red cell storage in the critically ill. *Transfusion*. 2006;46:2014.
249. Ho J, Sibbald WJ, Chin-Yee IH. Effects of storage on efficacy of red cell transfusion: when is it not safe? *Crit Care Med*. 2003;31:S687.
250. Zallen G, Offner PJ, Moore EE, et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. *Am J Surg*. 1999;178:570.
251. Purdy FR, Tweeddale MG, Merrick PM. Association of mortality with age of blood transfused in septic ICU patients. *Can J Anesth*. 1997;44:1256.
252. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. *N Engl J Med*. 2008;358:1229.
253. Goodnough LT. Transfusion triggers. *Surgery*. 2007;142:S67.
254. Rawn J. The silent risks of blood transfusion. *Curr Opin Anaesthesiol*. 2008;21:664.
255. Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications. *Br J Anaesth*. 2005;95:33.
256. Hebert PC, Tinmouth A, Corwin HL. Controversies in RBC transfusion in the critically ill. *Chest*. 2007;131:1583.
257. Carson JL, Duff A, Berlin JA, et al. Perioperative blood transfusion and postoperative mortality. *JAMA*. 1998;279:199.
258. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. *N Engl J Med*. 1999;340:409.
259. Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? *Crit Care Med*. 2001;29:227.
260. Hill SR, Carless PA, Henry DA, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev*. 2002;2:CD002042.
261. Hogue CW, Goodnough LT, Monk TG. Perioperative myocardial ischemic episodes are related to hematocrit level in patients undergoing radical prostatectomy. *Transfusion*. 1998;38:924.
262. Mangano DT, Browner WS, Hollenberg M, et al. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. *N Engl J Med*. 1990;323:1781.

263. Wu W-C, Schiffner TL, Henderson WG, et al. Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. *JAMA*. 2007;297:2481.
264. Goodnough LT, Despotis GJ, Hogue CW, et al. On the need for improved transfusion indicators in cardiac surgery. *Ann Thorac Surg*. 1995;60:473.
265. American College of Physicians. Practice strategies for elective red blood cell transfusion. *Ann Intern Med*. 1992;116:403.
266. Consensus conference. Perioperative red blood cell transfusion. *JAMA*. 1988;260:2700.
267. Practice Guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. *Anesthesiology*. 1996;84:732.
268. Guidelines for red blood cell and plasma transfusion for adults and children. *CMAJ*. 1997;156:1S.
269. Gardner TJ. To transfuse or not to transfuse. *Circulation*. 2007;116:458.
270. Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. *Transfusion*. 2003;43:668.
271. Wallis JP, Wells AW, Whitehead S, et al. Recovery from post-operative anaemia. *Transfus Med*. 2005;15:413.
272. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. *Blood*. 2000;96:823.
273. Goodnough LT. Erythropoietin therapy versus red cell transfusion. *Curr Opin Hematol*. 2001;8:405.
274. Bezwada HP, Nazarian DG, Henry DH, et al. Preoperative use of recombinant human erythropoietin before total joint arthroplasty *J Bone Joint Surg Am*. 2003;85:1795.
275. Martinez V, Monsaingeon-Lion A, Cherif K, et al. Transfusion strategy for primary knee and hip arthroplasty: impact of an algorithm to lower transfusion rates and hospital costs. *Br J Anaesth*. 2007;99:794.
276. Stowell CP, Chandler H, Jové M, et al. An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty. *Orthopedics*. 1999;22:s105.
277. Cohen JA, Brecher ME. Preoperative autologous blood donation: benefit or detriment? A mathematical analysis. *Transfusion*. 1995;35:640.
278. Brecher ME, Goodnough LT. The rise and fall of preoperative autologous blood donation. *Transfusion*. 2002;42:1618.
279. Bierbaum BE, Callaghan JJ, Galante JO, et al. An analysis of blood management in patients having a total hip or knee arthroplasty. *J Bone Joint Surg Am*. 1999;81:2.
280. Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. *N Engl J Med*. 1995;332:719.
281. Goodnough LT, Brecher ME, Kanter MH, et al. Transfusion medicine—blood transfusion—first of two parts. *N Engl J Med*. 1999;340:438.
282. Popovsky MA, Whitaker B, Arnold NL. Severe outcomes of allogeneic and autologous blood donation: frequency and characterization. *Transfusion*. 1995;35:734.
283. Goodnough LT, Despotis GJ, Merkel K, et al. A randomized trial comparing acute normovolemic hemodilution and preoperative autologous blood donation in total hip arthroplasty. *Transfusion*. 2000;40:1054.
284. Goodnough LT, Monk TG, Despotis GJ, et al. A randomized trial of acute normovolemic hemodilution compared to preoperative autologous blood donation in total knee arthroplasty. *Vox Sang*. 1999;77:11.
285. Monk TG, Goodnough LT, Brecher ME, et al. A prospective randomized comparison of three blood conservation strategies for radical prostatectomy. *Anesthesiology*. 1999;91:24.
286. Segal JB, Blasco-Colmenares E, Norris EJ, et al. Preoperative acute normovolemic hemodilution: a meta-analysis. *Transfusion*. 2004;44:632.
287. Torella F, Haynes SL, Kirwan CC, et al. Acute normovolemic hemodilution and intraoperative cell salvage in aortic surgery. *J Vasc Surg*. 2002;36:31.
288. Wong JCL, Torella F, Haynes SL, et al. Autologous versus allogeneic transfusion in aortic surgery: a multicenter

- randomized clinical trial. *Ann Surg.* 2002;235:145.
289. Williamson KR, Taswell HF. Intraoperative blood salvage: a review. *Transfusion.* 1991;31:662.
  290. McGill N, O'Shaughnessy D, Pickering R, et al. Mechanical methods of reducing blood transfusion in cardiac surgery: randomised controlled trial. *BMJ.* 2002;324:1299.
  291. Thompson JF, Webster JH, Chant AD. Prospective randomised evaluation of a new cell saving device in elective aortic reconstruction. *Eur J Vasc Surg.* 1990;4:507.
  292. Hu à C, Salmi LR, Fergusson D, et al. A meta-analysis of the effectiveness of cell salvage to minimize perioperative allogeneic blood transfusion in cardiac and orthopedic surgery. International Study of Perioperative Transfusion (ISPOT) Investigators. *Anesth Analg.* 1999;89:861.
  293. Carless P, Moxey A, O'Connell D, et al. Autologous transfusion techniques: a systematic review of their efficacy. *Transfus Med.* 2004;14:123.
  294. Carless PA, Henry DA, Moxey AJ, et al. Cell salvage for minimising perioperative allogeneic blood transfusion. *Cochrane Database Syst Rev.* 2006;4:CD001888.
  295. Spark JI, Chetter IC, Kester RC, et al. Allogeneic versus autologous blood during abdominal aortic aneurysm surgery. *Eur J Vasc Endovasc Surg.* 1997;14:482.
  296. Mercer KG, Spark JI, Berridge DC, et al. Randomized clinical trial of intraoperative autotransfusion in surgery for abdominal aortic aneurysm. *Br J Surg.* 2004;91:1443.
  297. Clagett GP, Valentine RJ, Jackson MR, et al. A randomized trial of intraoperative autotransfusion during aortic surgery. *J Vasc Surg.* 1999;29:22.
  298. Takagi H, Sekino S, Kato T, et al. Intraoperative autotransfusion in abdominal aortic aneurysm surgery: meta-analysis of randomized controlled trials. *Arch Surg.* 2007;142:1098.
  299. Alvarez GG, Fergusson DA, Neilipovitz DT, et al. Cell salvage does not minimize perioperative allogeneic blood transfusion in abdominal vascular surgery: a systematic review. *Can J Anesth.* 2004;51:425.
  300. Kelley-Patteson C, Ammar AD, Kelley H. Should the Cell Saver Autotransfusion Device be used routinely in all infrarenal abdominal aortic bypass operations? *J Vasc Surg.* 1993;18:261.
  301. Goodnough LT, Monk TG, Sicard G, et al. Intraoperative salvage in patients undergoing elective abdominal aortic aneurysm repair: an analysis of cost and benefit. *J Vasc Surg.* 1996;24:213.
  302. Tawes RL, Scribner RG, Duval TB, et al. The cell-saver and autologous transfusion: an underutilized resource in vascular surgery. *Am J Surg.* 1986;152:105.
  303. Reddy DJ, Ryan CJ, Shepard AD, et al. Intraoperative autotransfusion in vascular surgery. *Arch Surg.* 1990;125:1012.
  304. Cutler BS. Avoidance of homologous transfusion in aortic operations: the role of autotransfusion, hemodilution, and surgical technique. *Surgery.* 1984;95:717.
  305. Ouriel K, Shortell CK, Green RM, et al. Intraoperative autotransfusion in aortic surgery. *J Vasc Surg.* 1993;18:16.
  306. Huber TS, McGorray SP, Carlton LC, et al. Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: a decision analysis model. *J Vasc Surg.* 1997;25:984.
  307. Tawfick WA, O'Connor M, Hynes N, et al. Implementation of the Continuous AutoTransfusion System (C.A.T.S) in open abdominal aortic aneurysm repair: an observational comparative cohort study. *Vasc Endovasc Surg.* 2008;42:32.
  308. Hollyoak M, Woodruff P, Muller M, et al. Deep venous thrombosis in postoperative vascular surgical patients: a frequent finding without prophylaxis. *J Vasc Surg.* 2001;34:656.
  309. Olin JW, Graor RA, O'Hara P, et al. The incidence of deep venous thrombosis in patients undergoing abdominal aortic aneurysm resection. *J Vasc Surg.* 1993;18:1037.
  310. Killewich LA, Aswad MA, Sandager GP, et al. A randomized, prospective trial of deep venous thrombosis prophylaxis in aortic surgery. *Arch Surg.* 1997;132:499.
  311. Farkas JC, Chapuis C, Combe S, et al. A randomised controlled trial of a low-molecular-weight heparin (Enoxaparin) to

- prevent deep-vein thrombosis in patients undergoing vascular surgery. *Eur J Vasc Surg*. 1993;7:554.
312. Passman MA, Farber MA, Marston WA, et al. Prospective screening for postoperative deep venous thrombosis in patients undergoing infrainguinal revascularization. *J Vasc Surg*. 2000;32:669.
  313. Bani-Hani MG, Al-Khaffaf H, Titi MA, et al. Interventions for preventing venous thromboembolism following abdominal aortic surgery. *Cochrane Database Syst Rev*. 2008;1:CD005509.
  314. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126:338S.
  315. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. *Chest*. 2001;120:1964.
  316. Committee on Quality Health Care in America—Institute of Medicine. *To Err Is Human: Building a Safer Health System*. Washington, D.C: National Academy Press; 2000.
  317. Leape LL, Berwick DM, Bates DW. What practices will most improve safety?: evidence-based medicine meets patient safety. *JAMA*. 2002;288:501.
  318. Helmreich RL. On error management: lessons from aviation. *BMJ*. 2000;320:781.
  319. Muller M. Safety lessons taken from the airlines. *Br J Surg*. 2004;91:393.
  320. Cooper GE, White MD, Lauber JK. *Resource management on the flightdeck: proceedings of a NASA/Industry Workshop*. Moffett Field, Calif: NASA-Ames Research Center; 1980:225.
  321. Helmreich RL, Merritt AC, Wilhelm JA. The evolution of Crew Resource Management training in commercial aviation. *Int J Aviat Psychol*. 1999;9:19.
  322. Katz RI, Lagasse RS. Factors influencing the reporting of adverse perioperative outcomes to a quality management program. *Anesth Analg*. 2000;90:344.
  323. Leape LL. Reporting of adverse events. *N Engl J Med*. 2002;347:1633.
  324. Gawande AA, Zinner MJ, Studdert DM, et al. Analysis of errors reported by surgeons at three teaching hospitals. *Surgery*. 2003;133:614.
  325. Winters BD, Berenholtz SM, Pronovost P. Improving patient safety reporting systems. *Crit Care Med*. 2007;35:1206.
  326. Harris CB, Krauss MJ, Coopersmith CM, et al. Patient safety event reporting in critical care: a study of three intensive care units. *Crit Care Med*. 2007;35:1068.
  327. Catchpole KR, Giddings AEB, Wilkinson M, et al. Improving patient safety by identifying latent failures in successful operations. *Surgery*. 2007;142:102.
  328. Healy GB, Barker J, Madonna G. Error reduction through team leadership: applying aviation's CRM model in the OR. *Bull Am Coll Surg*. 2006;91:10.
  329. Kao LS, Thomas EJ. Navigating towards improved surgical safety using aviation-based strategies. *J Surg Res*. 2008;145:327.
  330. Healy GB, Barker J, Madonna G. Error reduction through team leadership: seven principles of CRM applied to surgery. *Bull Am Coll Surg*. 2006;91:24.
  331. Aziz F, Khalil A, Hall JC. Evolution of trends in risk management. *Aust N Z J Surg*. 2005;75:603.
  332. Trunkey DD, Botney R. Assessing competency: a tale of two professions. *J Am Coll Surg*. 2001;192:385.
  333. Cuschieri A. Nature of human error: implications for surgical practice. *Ann Surg*. 2006;244:642.
  334. Thorpe P. Training and patient safety. *Br J Surg*. 2004;91:391.
  335. McCafferty MH, Polk Jr HC. Patient safety and quality in surgery. *Surg Clin North Am*. 2007;87:867.
  336. Catchpole K, Mishra A, Handa A, et al. Teamwork and error in the operating room: analysis of skills and roles. *Ann Surg*. 2008;247:699.
  337. Thompson DA, Cowan J, Holzmüller C, et al. Planning and implementing a systems-based patient safety curriculum in medical education. *Am J Med Qual*. 2008;23:271.

338. Measures: Surgical Care Improvement Project. Available at <<http://www.qualitynet.org/dcs/ContentServer?cid=1137346750659&pagename=Medqic%2FMeasure%2FMeasuresHome&parentName=TopicCat&level3=Measures&c=MQParents>>; 2008. Accessed 23.09.08.
339. Shojania KG, Duncan BW, McDonald KM, et al. *Making healthcare safer: a critical analysis of patient safety practices*. Evidence Report/Technology Assessment No. 43. Rockville, MD: Agency for Healthcare Research and Quality; 2001.
340. The Joint Commission. *Universal Protocol for Preventing Wrong Site, Wrong Procedure, Wrong Person Surgery*. Oakbrook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations; 2003. Available at <<http://www.jointcommission.org/PatientSafety/UniversalProtocol/>>.
341. National Patient Safety Agency Patient Safety Alert 06. Correct Site Surgery. 2005.
342. Kwaan MR, Studdert DM, Zinner MJ, et al. Incidence, patterns, and prevention of wrong-site surgery. *Arch Surg*. 2006;141:353.
343. Michaels RK, Makary MA, Dahab Y, et al. Achieving the National Quality Forum's "Never Events": prevention of wrong site, wrong procedure, and wrong patient operations. *Ann Surg*. 2007;245:526.
344. Wilson IH, Walker IA. Theatre checklists and patient safety. *Anaesthesia*. 2008;63:921.
345. Resar R, Pronovost P, Haraden C, et al. Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia. *Jt Comm J Qual Patient Saf*. 2005;31:243.
346. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. *N Engl J Med*. 2006;355:2725.
347. Galpern D, Guerrero A, Tu A, et al. Effectiveness of a central line bundle campaign on line-associated infections in the intensive care unit. *Surgery*. 2008;144:492.
348. World Health Organization. *The Second Global Patient Safety Challenge: Safe Surgery Saves Lives—Background Paper*. Geneva: World Health Organization; 2006. Draft of background information circulated in preparation for the First International Consultation Meeting WHO Headquarters.
349. World Health Organization. *Safe Surgery Saves Lives: The Second Global Patient Safety Challenge*. Geneva: World Health Organization; 2008. Manual for the implementation of this initiative.
350. WHO Surgical Safety Checklist. 2008. Available at <[http://www.who.int/patientsafety/safesurgery/ss\\_checklist/en/index.html](http://www.who.int/patientsafety/safesurgery/ss_checklist/en/index.html)>; 2008. Accessed 23.09.08.

## 第 32 章

1. Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. *N Engl J Med*. 2005;353:349-361.
2. Lawlor DK, Lovell MB, DeRose G, et al. Is intensive care necessary after elective abdominal aortic aneurysm repair? *Can J Surg*. 2004;47:359-363.
3. Bastounis E, Filis K, Georgopoulos S, et al. Selective use of the intensive care unit after elective infrarenal abdominal aortic aneurysm repair. *Int Angiol*. 2003;22:308-316.
4. Dang D, Johantgen ME, Pronovost PJ, et al. Postoperative complications: does intensive care unit staff nursing make a difference? *Heart Lung*. 2002;31:219-228.
5. Pronovost PJ, Jenckes MW, Dorman T, et al. Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery. *JAMA*. 1999;281:1310-1317.
6. Zimmerman JE, Shortell SM, Rousseau DM, et al. Improving intensive care: observations based on organizational case studies in nine intensive care units: a prospective, multicenter study. *Crit Care Med*. 1993;21:1443-1451.
7. Carson SS, Stocking C, Podsadecki T, et al. Effects of organizational change in the medical intensive care unit of a teaching hospital: a comparison of 'open' and 'closed' formats. *JAMA*. 1996;276:322-328.
8. Pronovost PJ, Dang D, Dorman T, et al. Intensive care unit nurse staffing and the risk for complications after abdominal

aortic surgery. *Eff Clin Pract.* 2001;4:199-206.

9. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med.* 2001;345:1368-1377.
10. Ince C, Sinaasappel M. Microcirculatory oxygenation and shunting in sepsis and shock. *Crit Care Med.* 1999;27:1369-1377.
11. Marik PE, Baram M. Noninvasive hemodynamic monitoring in the intensive care unit. *Crit Care Clin.* 2007;23:383-400.
12. De BD, Creteur J, Preiser JC, et al. Microvascular blood flow is altered in patients with sepsis. *Am J Respir Crit Care Med.* 2002;166:98-104.
13. Lindert J, Werner J, Redlin M, et al. OPS imaging of human microcirculation: a short technical report. *J Vasc Res.* 2002;39:368-372.
14. Bellemare P, Goldberg P, Magder SA. Variations in pulmonary artery occlusion pressure to estimate changes in pleural pressure. *Intensive Care Med.* 2007;33:2004-2008.
15. Carter RS, Snyder JV, Pinsky MR. LV filling pressure during PEEP measured by nadir wedge pressure after airway disconnection. *Am J Physiol.* 1985;249:H770-H776.
16. Scheer B, Perel A, Pfeiffer UJ. Clinical review: complications and risk factors of peripheral arterial catheters used for haemodynamic monitoring in anaesthesia and intensive care medicine. *Crit Care.* 2002;6:199-204.
17. Frezza EE, Mezgebe H. Indications and complications of arterial catheter use in surgical or medical intensive care units: analysis of 4932 patients. *Am Surg.* 1998;64:127-131.
18. Courtois M, Fattal PG, Kovacs Jr SJ, et al. Anatomically and physiologically based reference level for measurement of intracardiac pressures. *Circulation.* 1995;92:1994-2000.
19. Wiener RS, Welch HG. Trends in the use of the pulmonary artery catheter in the United States, 1993-2004. *JAMA.* 2007;298:423-429.
20. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. *JAMA.* 2005;294:1625-1633.
21. Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. *N Engl J Med.* 2003;348:5-14.
22. Polanczyk CA, Rohde LE, Goldman L, et al. Right heart catheterization and cardiac complications in patients undergoing noncardiac surgery: an observational study. *JAMA.* 2001;286:309-314.
23. Lodato RF, Khan AR, Zembowicz MJ, et al. Roles of IL-1 and TNF in the decreased ileal muscle contractility induced by lipopolysaccharide. *Am J Physiol.* 1999;276:G1356-G1362.
24. Magder S. Invasive intravascular hemodynamic monitoring: technical issues. *Crit Care Clin.* 2007;23:401-414.
25. Slung HB, Scher KS. Complications of the Swan-Ganz catheter. *World J Surg.* 1984;8:76-81.
26. Beaulieu Y, Marik PE. Bedside ultrasonography in the ICU: part 1. *Chest.* 2005;128:881-895.
27. Beaulieu Y, Marik PE. Bedside ultrasonography in the ICU: part 2. *Chest.* 2005;128:1766-1781.
28. Duvall WL, Croft LB, Goldman ME. Can hand-carried ultrasound devices be extended for use by the noncardiology medical community? *Echocardiography.* 2003;20:471-476.
29. Spronk PE, Ince C, Gardien MJ, et al. Nitroglycerin in septic shock after intravascular volume resuscitation. *Lancet.* 2002;360:1395-1396.
30. Lefrant JY, Bruelle P, Aya AG, et al. Training is required to improve the reliability of esophageal Doppler to measure cardiac output in critically ill patients. *Intensive Care Med.* 1998;24:347-352.
31. Biffl WL, Moore EE, Burch JM, et al. Secondary abdominal compartment syndrome is a highly lethal event. *Am J Surg.* 2001;182:645-648.
32. Sugrue M. Abdominal compartment syndrome. *Curr Opin Crit Care.* 2005;11:333-338.
33. Lui F, Sangosanya A, Kaplan LJ. Abdominal compartment syndrome: clinical aspects and monitoring. *Crit Care Clin.*

2007;23:415-433.

34. Cheatham ML, Safcsak K, Block EF, et al. Preload assessment in patients with an open abdomen. *J Trauma*. 1999;46:16-22.
35. Collee GG, Lomax DM, Ferguson C, et al. Bedside measurement of intra-abdominal pressure (IAP) via an indwelling naso-gastric tube: clinical validation of the technique. *Intensive Care Med*. 1993;19:478-480.
36. Papia G, Klein D, Lindsay TF. Intensive care of the patient following open abdominal aortic surgery. *Curr Opin Crit Care*. 2006;12:340-345.
37. Gopalan PD, Burrows RC. Critical care of the vascular surgery patient. *Crit Care Clin*. 2003;19:109-125.
38. Haas CE, LeBlanc JM. Acute postoperative hypertension: a review of therapeutic options. *Am J Health Syst Pharm*. 2004;61:1661-1673.
39. Marik PE, Varon J. Hypertensive crises: challenges and management. *Chest*. 2007;131:1949-1962.
40. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;289:2560-2572.
41. Khan IA, Nair CK. Clinical, diagnostic, and management perspectives of aortic dissection. *Chest*. 2002;122:311-328.
42. Kanto J, Allonen H, Kleimola T, et al. Pharmacokinetics of labetalol in healthy volunteers. *Int J Clin Pharmacol Ther Toxicol*. 1981;19:41-44.
43. Estrera AL, Miller CC III, Safi HJ, et al. Outcomes of medical management of acute type B aortic dissection. *Circulation*. 2006;114(1 Suppl):I384-I389.
44. Chen K, Varon J, Wenker OC, et al. Acute thoracic aortic dissection: the basics. *J Emerg Med*. 1997;15:859-867.
45. McArdle PJ, Sanders KD. Postoperative care of vascular surgery patients. *Anesthesiol Clin North Am*. 2004;22:333-347, viii.
46. Michard F, Teboul JL. Predicting fluid responsiveness in ICU patients: a critical analysis of the evidence. *Chest*. 2002;121:2000-2008.
47. De Backer D, Heenen S, Piagnerelli M, et al. Pulse pressure variations to predict fluid responsiveness: influence of tidal volume. *Intensive Care Med*. 2005;31:517-523.
48. Babaev A, Frederick PD, Pasta DJ, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. *JAMA*. 2005;294:448-454.
49. Gurm HS, Bates ER. Cardiogenic shock complicating myocardial infarction. *Crit Care Clin*. 2007;23:759-777, vi.
50. Heintz KM, Hollenberg SM. Perioperative cardiac issues: postoperative arrhythmias. *Surg Clin North Am*. 2005;85:1103-1114, viii.
51. Johnston KW. Multicenter prospective study of nonruptured abdominal aortic aneurysm. Part II. Variables predicting morbidity and mortality. *J Vasc Surg*. 1989;9:437-447.
52. Hollenberg SM, Dellinger RP. Noncardiac surgery: postoperative arrhythmias. *Crit Care Med*. 2000;28(10 Suppl):N145-N150.
53. Valentine RJ, Rosen SF, Cigarroa JE, et al. The clinical course of new-onset atrial fibrillation after elective aortic operations. *J Am Coll Surg*. 2001;193:499-504.
54. Goodman S, Shirov T, Weissman C. Supraventricular arrhythmias in intensive care unit patients: short and long-term consequences. *Anesth Analg*. 2007;104:880-886.
55. Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. *Circulation*. 2004;110:364-367.
56. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. *JAMA*. 2004;292:2471-2477.
57. Daoud EG, Weiss R, Bahu M, et al. Effect of an irregular ventricular rhythm on cardiac output. *Am J Cardiol*. 1996;78:1433-1436.
58. Crawford TC, Oral H. Cardiac arrhythmias: management of atrial fibrillation in the critically ill patient. *Crit Care Clin*.



2007;23:855-872, vii.

59. Zimetbaum P. Amiodarone for atrial fibrillation. *N Engl J Med*. 2007;356:935-941.
60. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. *N Engl J Med*. 2001;344:1411-1420.
61. Mangano DT, Siliciano D, Hollenberg M, et al. Postoperative myocardial ischemia. Therapeutic trials using intensive analgesia following surgery. The Study of Perioperative Ischemia (SPI) Research Group. *Anesthesiology*. 1992;76:342-353.
62. Høbert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med*. 1999;340:409-417.
63. Stevens RD, Burri H, Tramer MR. Pharmacologic myocardial protection in patients undergoing noncardiac surgery: a quantitative systematic review. *Anesth Analg*. 2003;97:623-633.
64. Boersma E, Poldermans D, Bax JJ, et al. Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. *JAMA*. 2001;285:1865-1873.
65. Raby KE, Barry J, Creager MA, et al. Detection and significance of intraoperative and postoperative myocardial ischemia in peripheral vascular surgery. *JAMA*. 1992;268:222-227.
66. Mangano DT. Perioperative cardiac morbidity. *Anesthesiology*. 1990;72:153-184.
67. Kim LJ, Martinez EA, Faraday N, et al. Cardiac troponin I predicts short-term mortality in vascular surgery patients. *Circulation*. 2002;106:2366-2371.
68. Karve AM, Bossone E, Mehta RH. Acute ST-segment elevation myocardial infarction: critical care perspective. *Crit Care Clin*. 2007;23:685-707, v.
69. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). *J Am Coll Cardiol*. 2004;44:671-719.
70. Bhatheja R, Mukherjee D. Acute coronary syndromes: unstable angina/non-ST elevation myocardial infarction. *Crit Care Clin*. 2007;23:709-735, v.
71. Antman EM. Decision making with cardiac troponin tests. *N Engl J Med*. 2002;346:2079-2082.
72. Whitehead T, Slutsky AS. The pulmonary physician in critical care \* 7: ventilator induced lung injury. *Thorax*. 2002;57:635-642.
73. Adams AB, Simonson DA, Dries DJ. Ventilator-induced lung injury. *Respir Care Clin N Am*. 2003;9:343-362.
74. Brower RG, Rubenfeld GD. Lung-protective ventilation strategies in acute lung injury. *Crit Care Med*. 2003;31(4 Suppl):S312-S316.
75. Hickling KG. Permissive hypercapnia. *Respir Care Clin N Am*. 2002;8:155-169, v.
76. Kress JP, Pohlman AS, O'Connor MF, et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. *N Engl J Med*. 2000;342:1471-1477.
77. Epstein SK, Ciubotaru RL. Independent effects of etiology of failure and time to reintubation on outcome for patients failing extubation. *Am J Respir Crit Care Med*. 1998;158:489-493.
78. Esteban A, Anzueto A, Alia I, et al. How is mechanical ventilation employed in the intensive care unit? An international utilization review. *Am J Respir Crit Care Med*. 2000;161:1450-1458.
79. Yang KL, Tobin MJ. A prospective study of indexes predicting the outcome of trials of weaning from mechanical ventilation. *N Engl J Med*. 1991;324:1445-1450.
80. Eskandar N, Apostolakis MJ. Weaning from mechanical ventilation. *Crit Care Clin*. 2007;23:263-274, x.
81. Epstein SK, Ciubotaru RL, Wong JB. Effect of failed extubation on the outcome of mechanical ventilation. *Chest*. 1997;112:186-192.

82. Rothaar RC, Epstein SK. Extubation failure: magnitude of the problem, impact on outcomes, and prevention. *Curr Opin Crit Care*. 2003;9:59-66.
83. Diedrich DA, Keegan MT, Brown DR. Tracheostomy after major vascular surgery. *J Cardiothorac Vasc Anesth*. 2006;20:14-19.
84. Delaney A, Bagshaw SM, Nalos M. Percutaneous dilatational tracheostomy versus surgical tracheostomy in critically ill patients: a systematic review and meta-analysis. *Crit Care*. 2006;10:R55.
85. De Leyn P, Bedert L, Delcroix M, et al. Tracheotomy: clinical review and guidelines. *Eur J Cardiothorac Surg*. 2007;32:412-421.
86. Dagi TF. The management of postoperative bleeding. *Surg Clin North Am*. 2005;85:1191-1213.
87. Levy JH. Hemostatic agents. *Transfusion*. 2004;44(12 Suppl):58S-62S.
88. McKenna R. Abnormal coagulation in the postoperative period contributing to excessive bleeding. *Med Clin North Am*. 2001;85:1277-1310, viii.
89. Labelle CA, Kitchens CS. Disseminated intravascular coagulation: treat the cause, not the lab values. *Cleve Clin J Med*. 2005;72:377-378, 383-385, 390.
90. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med*. 2001;344:699-709.
91. Nisanevich V, Felsenstein I, Almog G, et al. Effect of intraoperative fluid management on outcome after intraabdominal surgery. *Anesthesiology*. 2005;103:25-32.
92. Brandstrup B, Tonnesen H, Beier-Holgersen R, et al. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. *Ann Surg*. 2003;238:641-648.
93. Bunn F, Trivedi D, Ashraf S. Colloid solutions for fluid resuscitation. *Cochrane Database Syst Rev* 2008;CD001319.
94. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. *JAMA*. 1994;271:777-781.
95. Goodnough LT, Shander A. Blood management. *Arch Pathol Lab Med*. 2007;131:695-701.
96. Goodnough LT, Shander AS. Recombinant factor VIIa: safety and efficacy. *Curr Opin Hematol*. 2007;14:504-509.
97. Shander A, Goodnough LT. Objectives and limitations of bloodless medical care. *Curr Opin Hematol*. 2006;13:462-470.
98. Ozier Y, Schlumberger S. Pharmacological approaches to reducing blood loss and transfusions in the surgical patient. *Can J Anaesth*. 2006;53(6 Suppl):S21-S29.
99. Mahdy AM, Webster NR. Perioperative systemic haemostatic agents. *Br J Anaesth*. 2004;93:842-858.
100. Frenes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. *Ann Thorac Surg*. 1994;58:1580-1588.
101. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. *Lancet*. 1999;354:1940-1947.
102. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. *Kidney Int*. 1996;50:235-242.
103. Wojciechowski PJ, Samol N, Walker J. Coagulopathy in massive transfusion. *Int Anesthesiol Clin*. 2005;43:1-20.
104. Valeri CR, Khabbaz K, Khuri SF, et al. Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass. *J Thorac Cardiovasc Surg*. 1992;104:108-116.
105. Nathens AB. Massive transfusion as a risk factor for acute lung injury: association or causation? *Crit Care Med*. 2006;34(5 Suppl):S144-S150.
106. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. *Transfusion*. 1985;25:573-577.

107. Friedrich JO, Adhikari N, Herridge MS, et al. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. *Ann Intern Med.* 2005;142:510-524.
108. Halpenny M, Rushe C, Breen P, et al. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. *Eur J Anaesthesiol.* 2002;19:32-39.
109. Miller Q, Peyton BD, Cohn EJ, et al. The effects of intraoperative fenoldopam on renal blood flow and tubular function following suprarenal aortic cross-clamping. *Ann Vasc Surg.* 2003;17:656-662.
110. Brezis M, Rosen S. Hypoxia of the renal medulla—its implications for disease. *N Engl J Med.* 1995;332:647-655.
111. Rahman SN, Kim GE, Mathew AS, et al. Effects of atrial natriuretic peptide in clinical acute renal failure. *Kidney Int.* 1994;45:1731-1738.
112. Champagne BJ, Darling RC III, Daneshmand M, et al. Outcome of aggressive surveillance colonoscopy in ruptured abdominal aortic aneurysm. *J Vasc Surg.* 2004;39:792-796.
113. Kehlet H, Moesgaard F. Prophylaxis against postoperative complications in gastroenterology. *Scand J Gastroenterol Suppl.* 1996;216:218-224.
114. Avrahami R, Cohen JD, Haddad M, et al. Gastric emptying after elective abdominal aortic aneurysm surgery: the case for early postoperative enteral feeding. *Eur J Vasc Endovasc Surg.* 1999;17:241-244.
115. Fraser RJ, Ritz M, Di Matteo AC, et al. Distal small bowel motility and lipid absorption in patients following abdominal aortic aneurysm repair surgery. *World J Gastroenterol.* 2006;12:582-587.
116. Heyland DK, Dhaliwal R, Drover JW, et al. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. *JPEN J Parenter Enteral Nutr.* 2003;27:355-373.
117. Kock M, Blomberg S, Emanuelsson H, et al. Thoracic epidural anesthesia improves global and regional left ventricular function during stress-induced myocardial ischemia in patients with coronary artery disease. *Anesth Analg.* 1990;71:625-630.
118. Bani-Hani MG, Al-Khaffaf H, Titi MA, Jaradat I. Interventions for preventing venous thromboembolism following abdominal aortic surgery. *Cochrane Database Syst Rev* 2008;CD005509.
119. Petralia GA, Kakkar AK. Venous thromboembolism prophylaxis for the general surgical patient: where do we stand? *Semin Respir Crit Care Med.* 2008;29:83-89.
120. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126(3 Suppl):338S-400S.
121. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. *N Engl J Med.* 2006;355:809-817.
122. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. *Arch Intern Med.* 2003;163:2518-2524.
123. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. *Am J Med.* 1999;106:629-635.
124. Warkentin TE, Roberts RS, Hirsh J, et al. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. *Chest.* 2005;127:1857-1861.
125. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. *Circulation.* 2001;103:1838-1843.
126. Dunn A. Perioperative management of oral anticoagulation: when and how to bridge. *J Thromb Thrombolysis.* 2006;21:85-89.
127. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126(3 Suppl):204S-233S.
128. Douketis JD, Crowther MA, Cherian SS, et al. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective noncardiac surgery. *Chest.* 1999;116:1240-1246.
129. Lieber CS. Alcohol and coronary heart disease. *N Engl J Med.* 2003;348:1719-1722.

130. Spies C, Tonnesen H, Andreasson S, et al. Perioperative morbidity and mortality in chronic alcoholic patients. *Alcohol Clin Exp Res*. 2001;25(5 Suppl ISBRA):164S-170S.
131. Tonnesen H, Kehlet H. Preoperative alcoholism and postoperative morbidity. *Br J Surg*. 1999;86:869-874.
132. Ntais C, Pakos E, Kyzas P, Ioannidis JP. Benzodiazepines for alcohol withdrawal. *Cochrane Database Syst Rev* 2005;CD005063.
133. Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. *Arch Intern Med*. 2004;164:1405-1412.
134. Gordon AJ, Olstein J, Conigliaro J. Identification and treatment of alcohol use disorders in the perioperative period. *Postgrad Med*. 2006;119:46-55.

## 第 33 章

1. Mann KG. Normal hemostasis. In: Kelley WN, ed. *Textbook of Internal Medicine*. Philadelphia, PA: JB Lippincott; 1992:1240-1245.
2. Brinkhous KM. A short history of hemophilia, with some comments on the word "hemophilia." In: Brinkhous KM, Hemker HC, eds. *Handbook of Hemophilia*. New York, NY: Elsevier; 1975.
3. Ratnoff OD. The evolution of knowledge about hemostasis. In: Ratnoff OD, Forbes CD, eds. *Disorders of Hemostasis*. Philadelphia, PA: WB Saunders, 1996:1-22.
4. Owen CA, Jr. In: Nichols WL, Bowie FJ, eds. *A History of Blood Coagulation*. Rochester, MN: Mayo Foundation for Medical Education and Research; 2001.
5. Owen CA. Older concepts of blood coagulation. In: Nichols WL, Bowie EJ, eds. *A History of Blood Coagulation*. Rochester, MN: Mayo Foundation for Medical Education and Research; 2001:7-16.
6. Morawitz P. Die Chemie der Blutgerinnung. *Ergebn Physiol*. 1905;4:307.
7. Wright IS. The nomenclature of blood clotting factor. *Thromb Diath Haemost*. 1962;7:381-388.
8. Girolami A, Scandellari R, Scapin M, et al. Congenital bleeding disorders of the vitamin K-dependent clotting factors. *Vitam Horm*. 2008;78:281-374.
9. Stafford DW. The vitamin K cycle. *J Thromb Haemost*. 2005;3:1873-1878.
10. Nelsestuen GL, Shah AM, Harvey SB. Vitamin K-dependent proteins. *Vitam Horm*. 2000;58:355-389.
11. Stenflo J. Contributions of Gla and EGF-like domains to the function of vitamin K-dependent coagulation factors. *Crit Rev Eukaryot Gene Expr*. 1999;9:59-88.
12. Sunnerhagen M, Olah GA, Stenflo J, et al. The relative orientation of Gla and EGF domains in coagulation factor X is altered by Ca<sup>2+</sup> binding to the first EGF domain. A combined NMR-small angle X-ray scattering study. *Biochemistry*. 1996;35:11547-11559.
13. Berkner KL. Vitamin K-dependent carboxylation. *Vitam Horm*. 2008;78:131-156.
14. Oldenburg J, Marinova M, Muller-Reible C, et al. The vitamin K cycle. *Vitam Horm*. 2008;78:35-62.
15. Nelsestuen GL, Kisiel W, Di Scipio RG. Interaction of vitamin K dependent proteins with membranes. *Biochemistry*. 1978;17:2134-2138.
16. Schwalbe RA, Ryan J, Stern DM, et al. Protein structural requirements and properties of membrane binding by gamma-carboxyglutamic acid-containing plasma proteins and peptides. *J Biol Chem*. 1989;264:20288-20296.
17. Schulman S, El Bouazzaoui B, Eikelboom JW, et al. Clinical factors influencing the sensitivity to warfarin when restarted after surgery. *J Intern Med*. 2008;263:412-419.
18. Cosgriff SW. The effectiveness of an oral vitamin K in controlling excessive hypoprothrombinemia during anticoagulant therapy. *Ann Intern Med*. 1956;45:14-22.
19. Hirsh J. Optimal intensity and monitoring warfarin. *Am J Cardiol*. 1995;75:39B-42B.
20. Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal

- therapeutic range. *Chest*. 1995;108(4 Suppl):231S-246S.
21. Joseph DR, Baker ME. Sex hormone-binding globulin, androgen-binding protein, and vitamin K-dependent protein S are homologous to laminin A, merosin, and *Drosophila* crumbs protein. *FASEB J*. 1992;6:2477-2481.
  22. Prowse CV, Esnouf MP. The isolation of a new warfarin-sensitive protein from bovine plasma. *Biochem Soc Trans*. 1977;5:255-256.
  23. Mann KG, Nesheim ME, Church WR, et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. *Blood*. 1990;76:1-16.
  24. Tracy PB, Eide LL, Bowie EJ, et al. Radioimmunoassay of factor V in human plasma and platelets. *Blood*. 1982;60:59-63.
  25. Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. *Biochemistry*. 1990;29:1118-1128.
  26. Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. *Blood*. 2003;101:20-30.
  27. Esmon CT. The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. *J Biol Chem*. 1979;254:964-973.
  28. Mann KG, Hockin MF, Begin KJ, et al. Activated protein C cleavage of factor Va leads to dissociation of the A2 domain. *J Biol Chem*. 1997;272:20678-20683.
  29. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. *Proc Natl Acad Sci U S A*. 1993;90:1004-1008.
  30. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature*. 1994;369:64-67.
  31. Leyte A, Verbeet MP, Brodniewicz-Proba T, et al. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII. *Biochem J*. 1989;257:679-683.
  32. Saenko EL, Shima M, Rajalakshmi KJ, et al. A role for the C2 domain of factor VIII in binding to von Willebrand factor. *J Biol Chem*. 1994;269:11601-11605.
  33. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. *J Biol Chem*. 1997;272:18007-18014.
  34. Foster PA, Fulcher CA, Houghten RA, et al. An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. *J Biol Chem*. 1988;263:5230-5234.
  35. Butenas S, van't Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. *J Biol Chem*. 1997;272:21527-21533.
  36. Jenny RJ, Pittman DD, Toole JJ, et al. Complete cDNA and derived amino acid sequence of human factor V. *Proc Natl Acad Sci U S A*. 1987;84:4846-4850.
  37. Mannucci PM, Tuddenham EGD. The hemophiliacs—from royal genes to gene therapy. *N Engl J Med*. 2001;344:1733-1779.
  38. Hoyer LW. Hemophilia A. *N Engl J Med*. 1994;330:38-47.
  39. Nemerson Y, Repke D. Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. *Thromb Res*. 1985;40:351-358.
  40. Butenas S, Orfeo T, Brummel-Ziedins KE, et al. Tissue factor in thrombosis and hemorrhage. *Surgery*. 2007;142(4 Suppl):S2-S14.
  41. Nemerson Y. Tissue factor and hemostasis [published erratum appears in *Blood* 1988;71:1178]. *Blood*. 1988;71:1-8.
  42. Edgington TS, Mackman N, Brand K, et al. The structural biology of expression and function of tissue factor. *Thromb Haemost*. 1991;66:67-79.
  43. Nakagaki T, Foster DC, Berkner KL, et al. Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VII. *Biochemistry*. 1991;30:10819-10824.

44. Toomey JR, Kratzer KE, Lasky NM, et al. Targeted disruption of the murine tissue factor gene results in embryonic lethality. *Blood*. 1996;88:1583-1587.
45. Morel O, Toti F, Hugel B, et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? *Arterioscler Thromb Vasc Biol*. 2006;26:2594-2604.
46. Butenas S, Bouchard BA, Brummel-Ziedins KE, et al. Tissue factor activity in whole blood. *Blood*. 2005;105:2764-2770.
47. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. *Proc Natl Acad Sci U S A*. 1999;96:2311-2315.
48. Osterud B. The role of platelets in decrypting monocyte tissue factor. *Semin Hematol*. 2001;38(4 Suppl 12):2-5.
49. Zillmann A, Luther T, Muller I, et al. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. *Biochem Biophys Res Commun*. 2001;281:603-609.
50. Santucci RA, Erlich J, Labriola J, et al. Measurement of tissue factor activity in whole blood. *Thromb Haemost*. 2000;83:445-454.
51. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. *J Biol Chem*. 1982;257:859-864.
52. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. *J Biol Chem*. 1994;269:26486-26491.
53. Bangalore N, Drohan WN, Orthner CL. High affinity binding sites for activated protein C and protein C on cultured human umbilical vein endothelial cells. Independent of protein S and distinct from known ligands. *Thromb Haemost*. 1994;72:465-474.
54. Hofsteenge J, Taguchi H, Stone SR. Effect of thrombomodulin on the kinetics of the interaction of thrombin with substrates and inhibitors. *Biochem J*. 1986;237:243-251.
55. Bourin MC, Boffa MC, Bjork I, et al. Functional domains of rabbit thrombomodulin. *Proc Natl Acad Sci U S A*. 1986;83:5924-5928.
56. Preissner KT, Delves U, Muller-Berghaus G. Binding of thrombin to thrombomodulin accelerates inhibition of the enzyme by antithrombin III. Evidence for a heparin-independent mechanism. *Biochemistry*. 1987;26:2521-2528.
57. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. *J Biol Chem*. 1994;269:31869-31880.
58. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. *Biochemistry*. 1986;25:505-512.
59. Nesheim M. Fibrinolysis and the plasma carboxypeptidase. *Curr Opin Hematol*. 1998;5:309-313.
60. Bajzar L, Jain N, Wang P, et al. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis. *Crit Care Med*. 2004;32(5 Suppl):S320-S324.
61. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. *Arterioscler Thromb Vasc Biol*. 2006;26:2445-2453.
62. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. *Mol Cell Biol*. 1988;8:5588-5592.
63. Hathaway WE, Belhasen LP, Hathaway HS. Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties. *Blood*. 1965;26:521-532.
64. Colman RW, Bagdasarian A, Talamo RC, et al. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. *J Clin Invest*. 1975;56:1650-1662.
65. Hoak JC, Swanson LW, Warner ED, et al. Myocardial infarction associated with severe factor-XII deficiency. *Lancet*.

- 1966;2:884-886.
66. Hoyer LW. Factor VIII. In: Colman RW, Hirsh J, Marder VJ, et al, eds. *Hemostasis and Thrombosis: Basic Principles and Clinical Practice*. Philadelphia, PA: JB Lippincott; 1987:48-59.
  67. Hoyer LW. Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors). *Hum Pathol*. 1987;18:153-161.
  68. Biggs R, Douglas AS, MacFarlane RG. Christmas disease: a condition previously mistaken for hemophilia. *Br Med J*. 1952;2:1384.
  69. Tefler TP, Denson KW, Wright DR. A "new" coagulation defect. *Br J Haematol*. 1956;2:308-312.
  70. Owren PA, Cooper T. Parahemophilia. *Arch Intern Med*. 1955;95:194-201.
  71. Roberts HR, Foster PA. *Inherited Disorders of Prothrombin Conversion*. Philadelphia, PA: JB Lippincott; 1987:162-181.
  72. Schmaier A, Silverberg M, Kaplan AP, et al. Contact activation and its abnormalities. In: Colman RW, Hirsh J, Marder VJ, et al, eds. *Hemostasis and Thrombosis; Basic Principles and Clinical Practice*. Philadelphia, PA: JB Lippincott; 1987:18-33.
  73. Rapaport SI, Proctor RR, Patch MJ. The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. *Blood*. 1961;18:149-155.
  74. Sidi A, Seligsohn U, Jonas P. Factor XI deficiency: detection and management during urological surgery. *J Urol*. 1978;119:528-530.
  75. Lawson JH, Kalafatis M, Stram S, et al. A model for the tissue factor pathway to thrombin. I. An empirical study. *J Biol Chem*. 1994;269:23357-23366.
  76. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. *Science*. 1991;253:909-912.
  77. Schmaier AH. Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. *Int Immunopharmacol*. 2008;8:161-165.
  78. Wiggins RC, Cochrane CC. The autoactivation of rabbit Hageman factor. *J Exp Med*. 1979;150:1122-1133.
  79. Silverberg M, Dunn JT, Garen L, et al. Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. *J Biol Chem*. 1980;255:7281-7286.
  80. Mandle RJ, Colman RW, Kaplan AP. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. *Proc Natl Acad Sci U S A*. 1976;73:4179-4183.
  81. Scott CF, Silver LD, Schapira M, et al. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. *J Clin Invest*. 1984;73:954-962.
  82. Scott CF, Silver LD, Purdon AD, et al. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. *J Biol Chem*. 1985;260:10856-10863.
  83. Bone R. Sepsis and multiple organ failure: consensus and controversy. In: Lamy M, Thijs LG, eds. *Mediators of Sepsis*. New York, NY: Springer-Verlag; 1992:3-12.
  84. Colman RW. Contact activation pathway: inflammatory, fibrinolytic, anticoagulant, antiadhesive and antiangiogenic activities. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. *Hemostasis and Thrombosis: Basic Principles & Clinical Practice*. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:103-121.
  85. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. *J Exp Med*. 2005;202:271-281.
  86. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. *J Exp Med*. 2006;203:513-518.
  87. Schousboe I. Pharmacological regulation of factor XII activation may be a new target to control pathological coagulation. *Biochem Pharmacol*. 2008;75:1007-1013.
  88. Schmaier AH. Plasma contact activation: a revised hypothesis. *Biol Res*. 1998;31:251-262.
  89. Rojckaer R, Hasan AA, Motta G, et al. Factor XII does not initiate prekallikrein activation on endothelial cells. *Thromb*

*Haemost.* 1998;80:74-81.

90. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. *J Biol Chem.* 1973;248:6490-6505.
91. Perry DJ, Carrell RW. Molecular genetics of human antithrombin deficiency. *Hum Mutat.* 1996;7:7-22.
92. Harper PL, Luddington RJ, Daly M, et al. The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease. *Br J Haematol.* 1991;77:360-364.
93. Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. *Methods Enzymol.* 1993;222:525-559.
94. Olson ST, Shore JD. Demonstration of a two-step reaction mechanism for inhibition of alpha-thrombin by antithrombin III and identification of the step affected by heparin. *J Biol Chem.* 1982;257:14891-14895.
95. Casu B, Oreste P, Torri G, et al. The structure of heparin oligosaccharide fragments with high anti-factor Xa activity containing the minimal antithrombin III-binding sequence. Chemical and <sup>13</sup>C nuclear-magnetic-resonance studies. *Biochem J.* 1981;197:599-609.
96. O'Reilly MS, Pirie-Shepherd S, Lane WS, et al. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. *Science.* 1999;285:1926-1928.
97. Olivera BM. E.E. Just Lecture, 1996. Conus venom peptides, receptor and ion channel targets, and drug design: 50 million years of neuropharmacology. *Mol Biol Cell.* 1997;8:2101-2109.
98. Broze GJ Jr, Lange GW, Duffin KL, et al. Heterogeneity of plasma tissue factor pathway inhibitor. *Blood Coagul Fibrinolysis.* 1994;5:551-559.
99. Novotny WF, Girard TJ, Miletich JP, et al. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. *J Biol Chem.* 1989;264:18832-18837.
100. Bajaj MS, Kuppuswamy MN, Saito H, et al. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. *Proc Natl Acad Sci U S A.* 1990;87:8869-8873.
101. Sanders NL, Bajaj SP, Zivelin A, et al. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. *Blood.* 1985;66:204-212.
102. Lesnik P, Vonica A, Guerin M, et al. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). *Arterioscler Thromb.* 1993;13:1066-1075.
103. Golino P, Ragni M, Cimmino G, et al. Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagulation. *Cardiovasc Drug Rev.* 2002;20:67-80.
104. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. *Arterioscler Thromb Vasc Biol.* 2002;22:539-548.
105. Broze GJ Jr. Tissue factor pathway inhibitor. *Thromb Haemost.* 1995;74:90-93.
106. Broze GJ Jr, Tollefen DM. Regulation of blood coagulation by protease inhibitors. In: Stamatoyanopolous G, Nienhuis AW, Majerus PW, eds. *The Molecular Basis of Blood Diseases*. Philadelphia, PA: WB Saunders; 1994:629-656.
107. Sandset PM. Tissue factor pathway inhibitor (TFPI)—an update. *Haemostasis.* 1996;26(Suppl 4):154-165.
108. Lindahl AK. Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle. *Cardiovasc Res.* 1997;33:286-291.
109. Schwartz AL, Broze GJ Jr. Tissue factor pathway inhibitor. *Trends Cardiovasc Med.* 1997;7:234-239.
110. Huang ZF, Higuchi D, Lasky N, et al. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. *Blood.* 1997;90:944-951.
111. Chan JC, Carmeliet P, Moons L, et al. Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit. *J Clin Invest.* 1999;103:475-482.
112. Westrick RJ, Bodary PF, Xu Z, et al. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis



in mice. *Circulation*. 2001;103:3044-3046.

113. Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. *Arterioscler Thromb Vasc Biol*. 2008;28:233-242.
114. Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. *J Biol Chem*. 1982;257:2162-2169.
115. Griffith MJ, Carraway T, White GC, et al. Heparin cofactor activities in a family with hereditary antithrombin III deficiency: evidence for a second heparin cofactor in human plasma. *Blood*. 1983;61:111-118.
116. Tollefsen DM, Pestka CA, Monafó WJ. Activation of heparin cofactor II by dermatan sulfate. *J Biol Chem*. 1983;258:6713-6716.
117. Parker KA, Tollefsen DM. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation. *J Biol Chem*. 1985;260:3501-3505.
118. Giri TK, Ahn CW, Wu KK, et al. Heparin cofactor II levels do not predict the development of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. *Arterioscler Thromb Vasc Biol*. 2005;25:2689-2690.
119. McGuire EA, Tollefsen DM. Activation of heparin cofactor II by fibroblasts and vascular smooth muscle cells. *J Biol Chem*. 1987;262:169-175.
120. Church FC, Pratt CW, Hoffman M. Leukocyte chemoattractant peptides from the serpin heparin cofactor II. *J Biol Chem*. 1991;266:704-709.
121. Andrew M, Mitchell L, Berry L, et al. An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. *J Clin Invest*. 1992;89:321-326.
122. Massouh M, Jatoti A, Gordon EM, et al. Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use. *J Lab Clin Med*. 1989;114:697-699.
123. Liu L, Dewar L, Song Y, et al. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. *Thromb Haemost*. 1995;73:405-412.
124. Andersson TR, Sie P, Pelzer H, et al. Elevated levels of thrombin-heparin cofactor II complex in plasma from patients with disseminated intravascular coagulation. *Thromb Res*. 1992;66:591-598.
125. Corral J, Aznar J, Gonzalez-Conejero R, et al. Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. *Circulation*. 2004;110:1303-1307.
126. Simioni P, Lazzaro AR, Coser E, et al. Hereditary heparin cofactor II deficiency and thrombosis: report of six patients belonging to two separate kindreds. *Blood Coagul Fibrinolysis*. 1990;1:351-356.
127. Weisdorf DJ, Edson JR. Recurrent venous thrombosis associated with inherited deficiency of heparin cofactor II [published erratum appears in Br J Haematol 1991 Mar;77(3):446]. *Br J Haematol*. 1991;77:125-126.
128. Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. *J Biol Chem*. 1983;258:163-168.
129. Laurell M, Christensson A, Abrahamsson PA, et al. Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system. *J Clin Invest*. 1992;89:1094-1101.
130. Laurell M, Stenflo J, Carlson TH. Turnover of \*I-protein C inhibitor and \*I-alpha 1-antitrypsin and their complexes with activated protein C. *Blood*. 1990;76:2290-2295.
131. Geiger M, Zechmeister-Machhart M, Uhrin P, et al. Protein C inhibitor (PCI). *Immunopharmacology*. 1996;32:53-56.
132. Seregni E, Botti C, Ballabio G, et al. Biochemical characteristics and recent biological knowledge on prostate-specific antigen. *Tumori*. 1996;82:72-77.
133. Heeb MJ, Espana F, Griffin JH. Inhibition and complexation of activated protein C by two major inhibitors in plasma. *Blood*. 1989;73:446-454.
134. Hoogendoorn H, Nesheim ME, Giles AR. A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model. *Blood*. 1990;75:2164-2171.

135. Espana F, Vicente V, Tabernero D, et al. Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. *Thromb Res.* 1990;59:593-608.
136. Mosnier LO, Elisen MG, Bouma BN, et al. Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation. *Thromb Haemost.* 2001;86:1057-1064.
137. Strandberg K, Astermark J, Bjorgell O, et al. Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis. *Thromb Haemost.* 2001;86:1400-1408.
138. Meijers JC, Kanters DH, Vlooswijk RA, et al. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. *Biochemistry.* 1988;27:4231-4237.
139. Griendling KK, Alexander RW. Endothelial control of the cardiovascular system: recent advances. *FASEB J.* 1996;10:283-292.
140. Rodgers GM. Endothelium and the regulation of hemostasis. In: Lee GR, Lickens J, Paraskevas F, et al, eds. *Wintrobe's Clinical Hematology*. Baltimore, MD: Williams & Wilkins; 1999:765-773.
141. Colman RW, Marder VJ, Salzman EW, et al. Overview of hemostasis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. *Hemostasis and Thrombosis: Basic Principles and Clinical Practice*. Philadelphia, PA: JB Lippincott; 1994:3-18.
142. Makrides SC, Ryan US. Overview of the endothelium. In: Schafer AI, Loscalzo J, eds. *Thrombosis and Hemorrhage*. Baltimore, MD: Williams & Wilkins; 1998:295-306.
143. Ware AG, Seegers WH. Procedure for the quantitative determination of prothrombin concentration. *Am J Clin Pathol.* 1949;19:471-482.
144. Weiss HJ. The role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium: Studies utilizing patients with quantitative and qualitative platelet defects. *J Clin Invest* 1986;78:1072-1082.
145. Bevilacqua MP, Pober JS, Majeau GR, et al. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. *J Exp Med.* 1984;160:618-623.
146. Tuszyński GP, Bevacqua SJ, Schmaier AH, et al. Factor XI antigen and activity in human platelets. *Blood.* 1982;59:1148-1156.
147. Bagdasarian A, Colman RW. Subcellular localization and purification of platelet alpha1-antitrypsin. *Blood.* 1978;51:139-156.
148. Novotny WF, Girard TJ, Miletich JP, et al. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. *Blood.* 1988;72:2020-2025.
149. Schwarz HP, Heeb MJ, Wencel-Drake JD, et al. Identification and quantitation of protein S in human platelets. *Blood.* 1985;66:1452-1455.
150. McDonagh J, McDonagh RP Jr, Delage JM, et al. Factor XIII in human plasma and platelets. *J Clin Invest.* 1969;48:940-946.
151. Erickson LA, Hekman CM, Loskutoff DJ. The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. *Proc Natl Acad Sci U S A.* 1985;82:8710-8714.
152. Plow EF, Collen D. The presence and release of alpha 2-antiplasmin from human platelets. *Blood.* 1981;58:1069-1074.
153. Holt JC, Niewiarowski S. Secretion of plasminogen by washed human platelets. *Circulation.* 1980;62:342.
154. Kruithof EK, Tran-Thang C, Bachmann F. Studies on the release of a plasminogen activator inhibitor by human platelets. *Thromb Haemost.* 1986;55:201-205.
155. Brass LF. Thrombin and platelet activation. *Chest.* 2003;124(3 Suppl):18S-25S.
156. White JG. Views of the platelet cytoskeleton at rest and at work. *Ann N Y Acad Sci.* 1987;509:156-176.
157. Parise LV, Boudignon-Proudhon C, Keely PJ, et al. Platelets in hemostasis and thrombosis. In: Foersten J, Lukens J, Paraskevas F et al, eds. *Wintrobe's Clinical Hematology*. Baltimore, MD: Williams & Wilkins; 1999:661-683.

158. Hartwig JH. Platelet Morphology. In: Lescalzo J, Schajen AI, eds. *Thrombosis and Hemorrhage*. Baltimore, MD: Williams & Wilkins; 1998:207-228.
159. Nurden AT. Human platelet membrane glycoproteins. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EG, eds. *Hemostasis and Thrombosis*. New York, NY: Churchill Livingstone; 1994:115-165.
160. Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. *Biochim Biophys Acta*. 1983;736:57-66.
161. Bouchard BA, Catcher CS, Thrash BR, et al. Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. *J Biol Chem*. 1997;272:9244-9251.
162. Altieri DC, Stamnes SJ. Protease-dependent T cell activation: ligation of effector cell protease receptor-1 (EPR-1) stimulates lymphocyte proliferation. *Cell Immunol*. 1994;155:372-383.
163. Altieri DC, Edgington TS. Identification of effector cell protease receptor-1. A leukocyte-distributed receptor for the serine protease factor Xa. *J Immunol*. 1990;145:246-253.
164. Altieri DC, Edgington TS. Sequential receptor cascade for coagulation proteins on monocytes. Constitutive biosynthesis and functional prothrombinase activity of a membrane form of factor V/Va. *J Biol Chem*. 1989;264:2969-2972.
165. Blomback B. Fibrinogen: evolution of the structure-function concept. Keynote address at Fibrinogen 2000 Congress. *Ann N Y Acad Sci*. 2001;936:1-10.
166. Doolittle RF, Yang Z, Mochalkin I. Crystal structure studies on fibrinogen and fibrin. *Ann N Y Acad Sci*. 2001;936:31-43.
167. Bailey K, Bettelheim FR, Lorand L, et al. Action of thrombin in the clotting of fibrinogen. *Nature*. 1951;167:233-234.
168. Blomback B. Studies on the action of thrombotic enzymes on bovine fibrinogen as measured by N-terminal analysis. *Arkiv Kemi*. 2003;12:321.
169. Laki K, Lóránd L. On the solubility of fibrin clots. *Science*. 1948;108:280.
170. Lorand L. A study on the solubility of fibrin clots in urea. *Acta Physiol Acad Sci Hung*. 1948;1:192-196.
171. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. *Ann N Y Acad Sci*. 2001;936:291-311.
172. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. *J Biol Chem*. 1997;272:14477-14482.
173. Wang W, Boffa MB, Bajzar L, et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. *J Biol Chem*. 1998;273:27176-27181.
174. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. *Blood*. 1996;88:3815-3823.
175. Marder VJ, Francis CW. Plasmin degradation of cross-linked fibrin. *Ann N Y Acad Sci*. 1983;408:397-406.
176. Bachmann F. Plasminogen-plasmin enzyme system. In: Colman RW, Hirsh J, Marder VJ, et al, eds. *Hemostasis and Thrombosis: Basic Principles and Clinical Practice*. Philadelphia, PA: Lippencott Williams & Wilkins; 2001:275-320.
177. Bugge TH, Flick MJ, Daugherty CC, et al. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. *Genes Dev*. 1995;9:794-807.
178. Ploplis VA, Carmeliet P, Vazirzadeh S, et al. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. *Circulation*. 1995;92:2585-2593.
179. Jenkins GR, Seiffert D, Parmer RJ, et al. Regulation of plasminogen gene expression by interleukin-6. *Blood*. 1997;89:2394-2403.
180. Petersen TE, Martzen MR, Ichinose A, et al. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. *J Biol Chem*. 1990;265:6104-6111.
181. Raum D, Marcus D, Alper CA, et al. Synthesis of human plasminogen by the liver. *Science*. 1980;208:1036-1037.
182. Collen D, Tytgat G, Claeys H, et al. Metabolism of plasminogen in healthy subjects: effect of tranexamic acid. *J Clin Invest*. 1972;51:1310-1318.

183. Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. *Semin Thromb Hemost.* 1987;13:50-68.
184. Violand BN, Castellino FJ. Mechanism of the urokinase-catalyzed activation of human plasminogen. *J Biol Chem.* 1976;251:3906-3912.
185. Claeys H, Vermeylen J. Physico-chemical and proenzyme properties of NH<sub>2</sub>-terminal glutamic acid and NH<sub>2</sub>-terminal lysine human plasminogen. Influence of 6-aminohexanoic acid. *Biochim Biophys Acta.* 1974;342:351-359.
186. Thorsen S, Astrup T. Substrate composition and the effect of epsilon-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis. *Thromb Diath Haemorrh.* 1974;32:306-324.
187. Violand BN, Byrne R, Castellino FJ. The effect of alpha-, omega-amino acids on human plasminogen structure and activation. *J Biol Chem.* 1978;253:5395-5401.
188. Booyse FM, Scheinbuks J, Radek J, et al. Immunological identification and comparison of plasminogen activator forms in cultured normal human endothelial cells and smooth muscle cells. *Thromb Res.* 1981;24:495-504.
189. Goldsmith GH Jr, Ziats NP, Robertson AL Jr. Studies on plasminogen activator and other proteases in subcultured human vascular cells. *Exp Mol Pathol.* 1981;35:257-264.
190. Levin EG, Loskutoff DJ. Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. *J Cell Biol.* 1982;94:631-636.
191. Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. *Proc Natl Acad Sci U S A.* 1983;80:6804-6808.
192. Allen RA, Pepper DS. Isolation and properties of human vascular plasminogen activator. *Thromb Haemost.* 1981;45:43-50.
193. Papadaki M, Ruef J, Nguyen KT, et al. Differential regulation of protease activated receptor-1 and tissue plasminogen activator expression by shear stress in vascular smooth muscle cells. *Circ Res.* 1998;83:1027-1034.
194. Wang Y, Hand AR, Wang YH, et al. Functional and morphologic evidence of the presence of tissue-plasminogen activator in vascular nerves: implications for a neurologic control of vessel wall fibrinolysis and rigidity. *J Neurosci Res.* 1998;53:443-453.
195. Brisson-Jeanneau C, Solberg LA Jr, Sultan Y. Presence of functionally active tissue plasminogen activator in human CFU-M derived megakaryocytes in vitro. *Fibrinolysis.* 1990;4:107-115.
196. Brisson-Jeanneau C, Nelles L, Rouer E, et al. Tissue-plasminogen activator RNA detected in megakaryocytes by in situ hybridization and biotinylated probe. *Histochemistry.* 1990;95:23-26.
197. Bankl HC, Grossschmidt K, Pikula B, et al. Mast cells are augmented in deep vein thrombosis and express a profibrinolytic phenotype. *Hum Pathol.* 1999;30:188-194.
198. Sillaber C, Baghestanian M, Bevec D, et al. The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. *J Immunol.* 1999;162:1032-1041.
199. Hart PH, Vitti GF, Burgess DR, et al. Human monocytes can produce tissue-type plasminogen activator. *J Exp Med.* 1989;169:1509-1514.
200. Tyagi SC, Lewis K, Pikes D, et al. Stretch-induced membrane type matrix metalloproteinase and tissue plasminogen activator in cardiac fibroblast cells. *J Cell Physiol.* 1998;176:374-382.
201. Collen D, Lijnen HR, Todd PA, et al. Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. *Drugs.* 1989;38:346-388.
202. Lucas RV, Miller ML. The fibrinolytic system. Recent advances. *Cleve Clin J Med.* 1988;55:531-541.
203. Rijcken DC, Juhan-Vague I, De Cock F, et al. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. *J Lab Clin Med.* 1983;101:274-284.
204. Stalder M, Hauert J, Kruithof EK, et al. Release of vascular plasminogen activator (v-PA) after venous stasis: electrophoretic-zymographic analysis of free and complexed v-PA. *Br J Haematol.* 1985;61:169-176.
205. Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. *Thromb Haemost.* 1985;54:684-687.

206. Nicoloso G, Hauert J, Kruithof EK, et al. Fibrinolysis in normal subjects—comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. *Thromb Haemost.* 1988;59:299-303.
207. Takada Y, Takada A. Plasma levels of t-PA free PAI-1 and a complex of t-PA with PAI-1 in human males and females at various ages. *Thromb Res.* 1989;55:601-609.
208. Booth NA, Walker E, Maughan R, et al. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. *Blood.* 1987;69:1600-1604.
209. Eitzman DT, Fay WP, Ginsburg D. Plasminogen activator inhibitor-1. In: Becker RC, ed. *Textbook of Coronary Thrombosis and Thrombolysis*. Boston, MA: Kluwer Academic; 1997:65-78.
210. Chandler WL, Alessi MC, Aillaud MF, et al. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. *Circulation.* 1997;96:761-768.
211. Garabedian HD, Gold HK, Leinbach RC, et al. Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. *Am J Cardiol.* 1986;58:673-679.
212. Carmeliet P, Schoonjans L, Kieckens L, et al. Physiological consequences of loss of plasminogen activator gene function in mice. *Nature.* 1994;368:419-424.
213. Carmeliet P, Collen D. Targeted gene manipulation and transfer of the plasminogen and coagulation systems in mice. *Fibrinolysis.* 1996;10:195-213.
214. Pohl G, Kallstrom M, Bergsdorf N, et al. Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences. *Biochemistry.* 1984;23:3701-3707.
215. Wallen P, Wiman B. Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. *Biochim Biophys Acta.* 1972;257:122-134.
216. Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. *J Biol Chem.* 1982;257:2920-2925.
217. Rijken DC, Groeneveld E. Isolation and functional characterization of the heavy and light chains of human tissue-type plasminogen activator. *J Biol Chem.* 1986;261:3098-3102.
218. Ranby M, Bergsdorf N, Nilsson T. Enzymatic properties of the one- and two-chain form of tissue plasminogen activator. *Thromb Res.* 1982;27:175-183.
219. Ny T, Elgh F, Lund B. The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. *Proc Natl Acad Sci U S A.* 1984;81:5355-5359.
220. Hoylaerts M, Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. *J Biol Chem.* 1982;257:2912-2919.
221. Zamarron C, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. *J Biol Chem.* 1984;259:2080-2083.
222. Loscalzo J. Structural and kinetic comparison of recombinant human single- and two-chain tissue plasminogen activator. *J Clin Invest.* 1988;82:1391-1397.
223. Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. *Blood.* 1989;74:222-228.
224. Diamond SL, Eskin SG, McIntire LV. Fluid flow stimulates tissue plasminogen activator secretion by cultured human endothelial cells. *Science.* 1989;243:1483-1485.
225. Emeis JJ. Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products. *Ann N Y Acad Sci.* 1992;667:249-258.
226. Eijnden-Schrauwen Y, Kooistra T, de Vries RE, et al. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: evidence for a dynamic storage pool. *Blood.* 1995;85:3510-3517.

227. Fay WP, Eitzman DT, Shapiro AD, et al. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1–dependent and –independent mechanisms. *Blood*. 1994;83:351-356.
228. Levi M, Biemond BJ, van Zonneveld AJ, et al. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. *Circulation*. 1992;85:305-312.
229. Braaten JV, Handt S, Jerome WG, et al. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. *Blood*. 1993;81:1290-1299.
230. Steffens GJ, Gunzler WA, Otting F, et al. The complete amino acid sequence of low molecular mass urokinase from human urine. *Hoppe Seylers Z Physiol Chem*. 1982;363:1043-1058.
231. Gunzler WA, Steffens GJ, Otting F, et al. The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. *Hoppe Seylers Z Physiol Chem*. 1982;363:1155-1165.
232. Husain SS, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. *Arch Biochem Biophys*. 1983;220:31-38.
233. Stump DC, Thienpont M, Collen D. Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex. *J Biol Chem*. 1986;261:1267-1273.
234. Shatos MA, Orfeo T, Doherty JM, et al. Alpha-thrombin stimulates urokinase production and DNA synthesis in cultured human cerebral microvascular endothelial cells. *Arterioscler Thromb Vasc Biol*. 1995;15:903-911.
235. van Hinsbergh VW. Regulation of the synthesis and secretion of plasminogen activators by endothelial cells. *Haemostasis*. 1988;18:307-327.
236. Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. *J Biol Chem*. 1982;257:3276-3283.
237. Stump DC, Lijnen HR, Collen D. Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures. *J Biol Chem*. 1986;261:1274-1278.
238. Darras V, Thienpont M, Stump DC, et al. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. *Thromb Haemost*. 1986;56:411-414.
239. Collen D, Zamarron C, Lijnen HR, et al. Activation of plasminogen by pro-urokinase. II. Kinetics. *J Biol Chem*. 1986;261:1259-1266.
240. Gurewich V, Pannell R, Broeze RJ, et al. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158). *J Clin Invest*. 1988;82:1956-1962.
241. Gurewich V, Pannell R. Fibrin binding and zymogenic properties of single-chain urokinase (pro-urokinase). *Semin Thromb Hemost*. 1987;13:146-151.
242. Pannell R, Gurewich V. Activation of plasminogen by single-chain urokinase or by two-chain urokinase—a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). *Blood*. 1987;69:22-26.
243. Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. *J Biol Chem*. 1986;261:3486-3489.
244. Kobayashi H, Schmitt M, Goretzki L, et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor–bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). *J Biol Chem*. 1991;266:5147-5152.
245. Nauland U, Rijken DC. Activation of thrombin-inactivated single-chain urokinase-type plasminogen activator by dipeptidyl peptidase I (cathepsin C). *Eur J Biochem*. 1994;223:497-501.
246. Schmitt M, Goretzki L, Chucholowski N, et al. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. *Fibrinolysis*. 1992;6(Suppl. 2):122.
247. Drag B, Petersen LC. Activation of pro-urokinase by cathepsin G in the presence of glucosaminoglycans. *Fibrinolysis*.

- 1994;8:192-199.
248. Stack MS, Johnson DA. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). *J Biol Chem.* 1994;269:9416-9419.
  249. Wolf BB, Vasudevan J, Henkin J, et al. Nerve growth factor-gamma activates soluble and receptor-bound single chain urokinase-type plasminogen activator. *J Biol Chem.* 1993;268:16327-16331.
  250. Brunner G, Simon MM, Kramer MD. Activation of pro-urokinase by the human T cell-associated serine proteinase HuTSP-1. *FEBS Lett.* 1990;260:141-144.
  251. Romisch J, Vermohlen S, Feussner A, et al. The FVII activating protease cleaves single-chain plasminogen activators. *Haemostasis.* 1999;29:292-299.
  252. Marcotte PA, Kozan IM, Dorwin SA, et al. The matrix metalloproteinase pump-1 catalyzes formation of low molecular weight (pro)urokinase in cultures of normal human kidney cells. *J Biol Chem.* 1992;267:13803-13806.
  253. Ugwu F, Van Hoef B, Bini A, et al. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). *Biochemistry.* 1998;37:7231-7236.
  254. Orgel D, Schroder W, Hecker-Kia A, et al. The cleavage of pro-urokinase type plasminogen activator by stromelysin-1. *Clin Chem Lab Med.* 1998;36:697-702.
  255. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. *Blood.* 1991;78:3114-3124.
  256. Lijnen HR. Elements of the fibrinolytic system. *Ann N Y Acad Sci.* 2001;936:226-236.
  257. Han B, Nakamura M, Mori I, et al. Urokinase-type plasminogen activator system and breast cancer. *Oncol Rep.* 2005;14:105-112.
  258. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. *Thromb Haemost.* 1999;82:298-304.
  259. Quax PH, van Leeuwen RT, Verspaget HW, et al. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines. *Cancer Res.* 1990;50:1488-1494.
  260. Evans DM, Sloan-Stakleff K, Arvan M, et al. Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride. *Clin Exp Metastasis.* 1998;16:353-357.
  261. Banerji A, Fernandes A, Bane S, et al. The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice. *Cancer Lett.* 1998;129:15-20.
  262. Kobayashi H, Gotoh J, Shinohara H, et al. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. *Thromb Haemost.* 1994;71:474-480.
  263. Xiao G, Liu YE, Gentz R, et al. Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells. *Proc Natl Acad Sci U S A.* 1999;96:3700-3705.
  264. Rabbani SA, Harakidas P, Davidson DJ, et al. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). *Int J Cancer.* 1995;63:840-845.
  265. Alonso DF, Tejera AM, Farias EF, et al. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. *Anticancer Res.* 1998;18:4499-4504.
  266. Alonso DF, Farias EF, Ladedá V, et al. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. *Breast Cancer Res Treat.* 1996;40:209-223.
  267. Jankun J, Keck RW, Skrzypczak-Jankun E, et al. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. *Cancer Res.* 1997;57:559-563.
  268. Robbins KC, Summaria L, Hsieh B, et al. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. *J Biol Chem.* 1967;242:2333-2342.
  269. Fleury V, Lijnen HR, Angles-Cano E. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. *J Biol Chem.* 1993;268:18554-18559.

270. Longstaff C, Clough AM, Gaffney PJ. Kinetics of plasmin activation of single chain urinary-type plasminogen activator (scu-PA) and demonstration of a high affinity interaction between scu-PA and plasminogen. *J Biol Chem.* 1992;267:173-179.
271. Lenich C, Pannell R, Gurewich V. The effect of the carboxy-terminal lysine of urokinase on the catalysis of plasminogen activation. *Thromb Res.* 1991;64:69-80.
272. Dieval J, Nguyen G, Gross S, et al. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. *Blood.* 1991;77:528-532.
273. Fay WP, Shapiro AD, Shih JL, et al. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. *N Engl J Med.* 1992;327:1729-1733.
274. Lee MH, Vosburgh E, Anderson K, et al. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. *Blood.* 1993;81:2357-2362.
275. Fay WP, Parker AC, Condrey LR, et al. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. *Blood.* 1997;90:204-208.
276. Minowa H, Takahashi Y, Tanaka T, et al. Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency. *Haemostasis.* 1999;29:286-291.
277. Declercq PJ, De Mol M, Alessi MC, et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). *J Biol Chem.* 1988;263:15454-15461.
278. Declercq PJ, Alessi MC, Verstreken M, et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. *Blood.* 1988;71:220-225.
279. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. *Semin Thromb Hemost.* 1990;16:207-216.
280. Stiko A, Hervio L, Loskutoff DJ. Plasminogen activator inhibitors. In: Colman RF, Hirsh J, Marder VJ et al, eds. *Hemostasis and Thrombosis: Basic Principles and Clinical Practice*. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:355-365.
281. Huber K. Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents. *J Thromb Thrombolysis.* 2001;11:195-202.
282. Alessi MC, Chomiki N, Berthier R, et al. Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization. *Thromb Haemost.* 1994;72:931-936.
283. Sharp AM, Stein PE, Pannu NS, et al. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. *Structure Fold Des.* 1999;7:111-118.
284. Madison EL, Goldsmith EJ, Gething MJ, et al. Restoration of serine protease-inhibitor interaction by protein engineering. *J Biol Chem.* 1990;265:21423-21426.
285. Madison EL, Goldsmith EJ, Gerard RD, et al. Serpin-resistant mutants of human tissue-type plasminogen activator. *Nature.* 1989;339:721-724.
286. Adams DS, Griffin LA, Nachajko WR, et al. A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor. *J Biol Chem.* 1991;266:8476-8482.
287. Wiman B, Almquist A, Sigurdardottir O, et al. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. *FEBS Lett.* 1988;242:125-128.
288. Naski MC, Lorand L, Shafer JA. Characterization of the kinetic pathway for fibrin promotion of alpha-thrombin-catalyzed activation of plasma factor XIII. *Biochemistry.* 1991;30:934-941.
289. Heeb MJ, Espana F, Geiger M, et al. Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. *J Biol Chem.* 1987;262:15813-15816.
290. Kruithof EK, Tran-Thang C, Gudinchet A, et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors.



*Blood*. 1987;69:460-466.

291. Kjoller L, Kanse SM, Kirkegaard T, et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. *Exp Cell Res*. 1997;232:420-429.
292. Waltz DA, Natkin LR, Fujita RM, et al. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. *J Clin Invest*. 1997;100:58-67.
293. Kanse SM, Kost C, Wilhelm OG, et al. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. *Exp Cell Res*. 1996;224:344-353.
294. Deng G, Curriden SA, Wang S, et al. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? *J Cell Biol*. 1996;134:1563-1571.
295. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. *Nature*. 1996;383:441-443.
296. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. *Eur J Biochem*. 1976;69:209-216.
297. Mullertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. *Biochem J*. 1976;159:545-553.
298. Moroi M, Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. *J Biol Chem*. 1976;251:5956-5965.
299. Collen D, De Cock F, Verstraete M. Immunochemical distinction between antiplasmin and alpha-antitrypsin. *Thromb Res*. 1975;7:245-249.
300. Favier R, Aoki N, de Moerloose P. Congenital alpha(2)-plasmin inhibitor deficiencies: a review. *Br J Haematol*. 2001;114:4-10.
301. Menoud PA, Sappino N, Boudal-Khoshbeen M, et al. The kidney is a major site of alpha(2)-antiplasmin production. *J Clin Invest*. 1996;97:2478-2484.
302. Collen D, Wiman B. Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. *Blood*. 1979;53:313-324.
303. Mast AE, Enghild JJ, Pizzo SV, et al. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin. *Biochemistry*. 1991;30:1723-1730.
304. Wiman B, Collen D. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. *Eur J Biochem*. 1977;78:19-26.
305. Holmes WE, Nelles L, Lijnen HR, et al. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). *J Biol Chem*. 1987;262:1659-1664.
306. Lijnen HR, Holmes WE, Van Hoef B, et al. Amino-acid sequence of human alpha 2-antiplasmin. *Eur J Biochem*. 1987;166:565-574.
307. Hortin GL, Gibson BL, Fok KF. Alpha 2-antiplasmin's carboxy-terminal lysine residue is a major site of interaction with plasmin. *Biochem Biophys Res Commun*. 1988;155:591-596.
308. Wiman B, Almquist A, Ranby M. The non-covalent interaction between plasmin and alpha2-antiplasmin. *Fibrinolysis*. 1989;3:231-235.
309. Sugiyama N, Sasaki T, Iwamoto M, et al. Binding site of alpha 2-plasmin inhibitor to plasminogen. *Biochim Biophys Acta*. 1988;952:1-7.
310. Hortin GL, Trimpe BL, Fok KF. Plasmin's peptide-binding specificity: characterization of ligand sites in alpha 2-antiplasmin. *Thromb Res*. 1989;54:621-632.
311. Tamaki T, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. *J Biol Chem*. 1982;257:14767-14772.
312. Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. *Eur J Biochem*.

1978;84:573-578.

313. Christensen U, Clemmensen I. Purification and reaction mechanisms of the primary inhibitor of plasmin from human plasma. *Biochem J*. 1978;175:635-641.
314. Sakata Y, Aoki N. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. *J Clin Invest*. 1982;69:536-542.
315. Eaton DL, Malloy BE, Tsai SP, et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. *J Biol Chem*. 1991;266:21833-21838.
316. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. *J Biol Chem*. 1996;271:16603-16608.
317. Redlitz A, Nicolini FA, Malycky JL, et al. Inducible carboxypeptidase activity. A role in clot lysis in vivo. *Circulation*. 1996;93:1328-1330.
318. Minnema MC, Friederich PW, Levi M, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. *J Clin Invest*. 1998;101:10-14.
319. Gresele P, Momi S, Berrettini M, et al. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. *J Clin Invest*. 1998;101:667-676.
320. Nagashima M, Yin ZF, Broze GJ Jr, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice. *Front Biosci*. 2002;7:d556-d568.
321. Franco RF, Fagundes MG, Meijers JC, et al. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. *Haematologica*. 2001;86:510-517.
322. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. *Blood*. 2000;95:2855-2859.
323. Mao SS, Cooper CM, Wood T, et al. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. *J Biol Chem*. 1999;274:35046-35052.
324. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. *J Biol Chem*. 1995;270:14477-14484.
325. Cote HF, Bajzar L, Stevens WK, et al. Functional characterization of recombinant human meizothrombin and meizothrombin (desF1). *J Biol Chem* 1997;272:6194-6200.
326. Bouma BN, Mosnier LO, Meijers JC, et al. Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation. *Thromb Haemost*. 1999;82:1703-1708.
327. Morrissey JH, Macik BG, Neuenschwander PF, et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. *Blood*. 1993;81:734-744.
328. Komiya Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. *Biochemistry*. 1990;29:9418-9425.
329. Jesty J, Silverberg SA. Kinetics of the tissue factor-dependent activation of coagulation factors IX and X in a bovine plasma system. *J Biol Chem*. 1979;254:12337-12345.
330. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. *Proc Natl Acad Sci U S A*. 1977;74:5260-5264.
331. Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. *Nature*. 1989;338:518-520.
332. Baugh RJ, Broze GJ Jr, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. *J Biol Chem*. 1998;273:4378-4386.
333. Novotny WF, Palmier M, Wun TC, et al. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. *Blood*. 1991;78:394-400.

334. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor–dependent blood coagulation. *Thromb Haemost.* 1991;66:6-15.
335. Coughlin SR, Vu TK, Hung DT, et al. Characterization of a functional thrombin receptor. Issues and opportunities. *J Clin Invest.* 1992;89:351-355.
336. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. *J Biol Chem.* 1991;266:7353-7358.
337. Lorand L, Konishi K. Activation of the fibrin-stabilizing factor of plasma by thrombin. *Arch Biochem Biophys.* 1964;105:58-67.
338. Brummel KE, Butenas S, Mann KG. An integrated study of fibrinogen during blood coagulation. *J Biol Chem.* 1999;274:22862-22870.
339. Blomback B, Hessel B, Hogg D, et al. A two-step fibrinogen-fibrin transition in blood coagulation. *Nature.* 1978;275:501-505.
340. Blomback B, Vestermark A. Isolation of fibrinopeptides by chromatography. *Arkiv Kemi.* 1958;12:173.
341. Shainoff JR, Page IH. Cofibrins and fibrin intermediates as indicators of thrombin activity in vivo. *Circ Res.* 1960;8:1013-1022.
342. Lawson JH, Mann KG. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. *J Biol Chem.* 1991;266:11317-11327.
343. Ahmad SS, Rawala-Sheikh R, Walsh PN. Components and assembly of the factor X activating complex. *Semin Thromb Hemost.* 1992;18:311-323.
344. van't Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. *J Biol Chem.* 1997;272:4367-4377.
345. Hockin MF, Jones KC, Everse SJ, et al. A model for the stoichiometric regulation of blood coagulation. *J Biol Chem.* 2002;277:18322-18333.
346. Cawthorn KM, van't Veer C, Lock JB, et al. Blood coagulation in hemophilia A and hemophilia C. *Blood.* 1998;91:4581-4592.
347. Butenas S, Brummel KE, Branda RF, et al. Mechanism of factor VIIa–dependent coagulation in hemophilia blood. *Blood.* 2002;99:923-930.
348. Tracy PB, Nesheim ME, Mann KG. Platelet factor Xa receptor. *Methods Enzymol.* 1992;215:329-360.
349. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. *Arterioscler Thromb Vasc Biol.* 2000;20:2511-2518.
350. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. *Blood.* 1996;88:2093-2100.
351. Francis CW, Marder VJ, Barlow GH. Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure. *J Clin Invest.* 1980;66:1033-1043.
352. Gaffney PJ, Brasher M. Subunit structure of the plasmin-induced degradation products of crosslinked fibrin. *Biochim Biophys Acta.* 1973;295:308-313.
353. Marder VJ. Physicochemical studies of intermediate and final products of plasmin digestion of human fibrinogen. *Thromb Diath Haemorrh.* 1970;80:187-195.
354. Larrieu MJ, Marder VJ, Inceman S. Effects of fibrinogen degradation products on platelets and coagulation. *Thromb Diath Haemorrh Suppl.* 1966;20:215-226.
355. Righini M, Perrier A, de Moerloose P, et al. D-dimer for venous thromboembolism diagnosis: twenty years later. *J Thromb Haemost.* 2008;6:1059-1071.
356. Loskutoff DJ. Type 1 plasminogen activator inhibitor and its potential influence on thrombolytic therapy. *Semin Thromb Hemost.* 1988;14:100-109.

357. Collen D. Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling. *Hematology (Am Soc Hematol Educ Program)*. 2001;1-9.
358. Ellis V, Pyke C, Eriksen J, et al. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. *Ann N Y Acad Sci*. 1992;667:13-31.
359. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. *Thromb Haemost*. 2001;86:324-333.
360. Brummel KE, Paradis SG, Butenas S, et al. Thrombin functions during tissue factor-induced blood coagulation. *Blood*. 2002;100:148-152.
361. Rand MD, Lock JB, van't Veer C, et al. Blood clotting in minimally altered whole blood. *Blood*. 1996;88:3432-3445.
362. Suh TT, Holmback K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. *Genes Dev*. 1995;9:2020-2033.
363. Holmback K, Danton MJ, Suh TT, et al. Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3. *EMBO J*. 1996;15:5760-5771.
364. Crabtree GR. The molecular biology of fibrinogen. In: Stamatoyanopolous G, Nienhuis AW, Leder P, Majerus PW, eds. *The Molecular Basis of Blood Diseases*. Philadelphia, PA: WB Saunders; 1987:631-661.
365. Neerman-Arbez M, Honsberger A, Antonarakis SE, et al. Deletion of the fibrinogen [correction of fibrogen] alpha-chain gene (FGA) causes congenital afibrinogenemia. *J Clin Invest*. 1999;103:215-218.
366. Quick AJ. The prothrombin time in haemophilia and in obstructive jaundice. *J Biol Chem*. 1935;109:73-74.
367. World Health Organization. *Expert Committee on Biological Standardisation, 33th Report*. Geneva, Switzerland: WHO Technical Report Series; 1983:81-105.
368. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests: a presumptive test of hemophilia and a single one-stage anti-hemophilic factor assay procedure. *J Lab Clin Med*. 1953;41:7637-7647.
369. Hattersley PG. Activated coagulation time of whole blood. *JAMA*. 1966;196:436-440.
370. Zucker ML, Koster A, Prats J, et al. Sensitivity of a modified ACT test to levels of bivalirudin used during cardiac surgery. *J Extra Corpor Technol*. 2005;37:364-368.
371. Martin ME, Kloecker GH, Laber DA. Argatroban for anticoagulation during cardiac surgery. *Eur J Haematol*. 2007;78:161-166.
372. Spinler SA, Wittkowsky AK, Nutescu EA, et al. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin. *Ann Pharmacother*. 2005;39:1275-1285.
373. Holmes MB, Schneider DJ, Hayes MG, et al. Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy. *Circulation*. 2000;102:2051-2057.
374. Hartert HS. Blutgerinnungsstudien mit der Thromboelastographie, einem neuen Untersuchungsverfahren. *Klin Wochenschr*. 1948;26:577-583.
375. Hartert HS. The physical and biological constants of thrombelastography. *Biorheology*. 1962;1:31-39.
376. Sorensen B, Johansen P, Christiansen K, et al. Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. *J Thromb Haemost*. 2003;1:551-558.
377. Mann KG, Whelihan MF, Cooley RB, et al. Citrate blood: a century of artifact. *Blood*. 2006;108:459a.
378. Luddington RJ. Thrombelastography/thromboelastometry. *Clin Lab Haematol*. 2005;27:81-90.
379. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. *Anesth Analg*. 1999;88:312-319.
380. Spiess BD, Gillies BS, Chandler W, et al. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. *J Cardiothorac Vasc Anesth*. 1995;9:168-173.
381. Kaufmann CR, Dwyer KM, Crews JD, et al. Usefulness of thrombelastography in assessment of trauma patient coagulation. *J Trauma*. 1997;42:716-720.
382. Avidan MS, Da Fonseca J, Parmar K, et al. The effects of aprotinin on thromboelastography with three different activators.

*Anesthesiology*. 2001;95:1169-1174.

383. Grosse H, Lobbes W, Frambach M, et al. The use of high dose aprotinin in liver transplantation: the influence on fibrinolysis and blood loss. *Thromb Res*. 1991;63:287-297.
384. Himmelreich G, Muser M, Neuhaus P, et al. Different aprotinin applications influencing hemostatic changes in orthotopic liver transplantation. *Transplantation*. 1992;53:132-136.
385. Ramsay MA, Randall HB, Burton EC. Intravascular thrombosis and thromboembolism during liver transplantation: antifibrinolytic therapy implicated? *Liver Transpl*. 2004;10:310-314.
386. Chavez JJ, Foley DE, Snider CC, et al. A novel thrombelastograph tissue factor/kaolin assay of activated clotting times for monitoring heparin anticoagulation during cardiopulmonary bypass. *Anesth Analg*. 2004;99:1290-1294.
387. Baird CW, Zurakowski D, Robinson B, et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. *Ann Thorac Surg*. 2007;83:912-919.
388. Tadros GM, Broder K, Bachour F. Intracoronary macrothrombus formation during percutaneous coronary intervention despite optimal activated clotting time using bivalirudin—a case report. *Angiology*. 2005;56:761-765.
389. Brener SJ, Moliterno DJ, Lincoff AM, et al. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. *Circulation*. 2004;110:994-998.

## 第 34 章

1. Libby P. Vascular biology of atherosclerosis: overview and state of the art. *Am J Cardiol*. 2003;91:3A-6A.
2. Nicolaides AN, Kakkar VV, Field ES, et al. The origin of deep vein thrombosis: a venographic study. *Br J Radiol*. 1971;44:653-663.
3. Hamer JD, Malone PC, Silver IA: The Po<sub>2</sub> in venous valve pockets: its possible bearing on thrombogenesis. *Br J Surg*. 1981;68:166-170.
4. Myers DD, Hawley AE, Farris DM, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. *J Vasc Surg*. 2003;38:1075-1089.
5. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? *Ann Intern Med*. 1981;94:439-444.
6. Freiman DG: The structure of thrombi. In: Colman RW, Hirsh J, Marder V, Salzman EW, eds. *Hemostasis and Thrombosis: Basic Principles and Clinical Practice*. 2nd ed. Philadelphia: J.B. Lippincott; 1987; pp 1123-1135.
7. Emmerich J, Meyer G, Decousus H, et al. Role of fibrinolysis and interventional therapy for acute venous thromboembolism. *Thromb Haemost*. 2006;96:251-257.
8. Gross PL, Aird WC. The endothelium and thrombosis. *Semin Thromb Haemost*. 2000;26:463-478.
9. Patrono C, Collier B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(3 Suppl):234S-264S.
10. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med*. 2005;352:1092-1102.
11. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. *Lancet*. 2004;364:2021-2029.
12. Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. *BMJ*. 1994;308:81-106.
13. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002;324:71-86.

14. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. *JAMA*. 2006;295:306-313.
15. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. *BMJ*. 2000;321:1183-1187.
16. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. *J Allergy Clin Immunol*. 2006;118:773-786.
17. Hankey GJ, Eikelboom JW. Aspirin resistance. *Lancet*. 2006;367:606-617.
18. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. *Circulation*. 2002;105:1650-1655.
19. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. *J Am Coll Cardiol*. 2003;41:961-965.
20. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y<sub>12</sub> adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. *Semin Thromb Haemost*. 2005;31:174-183.
21. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. *Lancet*. 1989;1:1215-1220.
22. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). *Lancet*. 1996;348:1329-1339.
23. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. *Lancet*. 2007;369:667-678.
24. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. *JAMA*. 2007;297:159-168.
25. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. *Circulation*. 2003;108:1682-1687.
26. Cooke GE, Goldschmidt-Clermont PJ. The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. *Expert Opin Drug Saf*. 2006;5:815-826.
27. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet*. 2004;364:331-337.
28. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med*. 2006;354:1706-1717.
29. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. *J Am Coll Cardiol*. 2005;45:1157-1164.
30. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. *Blood*. 2006;108:2244-2247.
31. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. *Arterioscler Thromb Vasc Biol*. 2006;26:1895-1900.
32. Michelson AD. Platelet function testing in cardiovascular diseases. *Circulation*. 2004;119:e489-e493.
33. Lenz TL, Hilleman DE. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. *Ann Pharmacother*. 2000;34:1283-1290.
34. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci*. 1996;143:1-13.

35. ESPRIT Study Group; Halkes PH, van Gijn J, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. *Lancet*. 2006;367:1665-1673.
36. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. *N Engl J Med*. 1995;332:1553-1559.
37. Rossi ML, Zavalloni D. Inhibitors of platelets glycoprotein IIb/IIIa (GPIIb/IIIa) receptor: rationale for their use in clinical cardiology. *Mini Rev Med Chem*. 2004;4:703-709.
38. Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(3 Suppl):576S-599S.
39. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(3 Suppl):513S-548S.
40. Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. *Chest*. 2005;127(2 Suppl):53S-59S.
41. Tantry US, Bliden KP, Gurbel PA. Prasugrel. *Expert Opin Investig Drugs*. 2006;15:1627-1633.
42. Cattaneo M. Platelet P2 receptors: Old and new targets for antithrombotic drugs. *Expert Rev Cardiovasc Ther*. 2007;5:45-55.
43. Lindahl U, Kusche M, Lidholt K, et al. Biosynthesis of heparin and heparan sulfate. *Ann N Y Acad Sci*. 1989;556:36-50.
44. Hirsh J. Heparin. *N Engl J Med*. 1991;324:1565-1574.
45. Andersson LO, Barrowcliffe TW, Holmer E, et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. *Thromb Res*. 1976;9:575-583.
46. Olson ST, Bjork I, Sheffer R, et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. *J Biol Chem*. 1992;267:12528-12538.
47. Olson ST, Bjork I. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects. *J Biol Chem*. 1991;266:6353-6364.
48. Danielsson A, Raub E, Lindahl U, et al. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. *J Biol Chem*. 1986;261:15467-15473.
49. Jordan RE, Oosta GM, Gardner WT, et al. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. *J Biol Chem*. 1980;255:10081-10090.
50. Altman R, Scazzioti A, Rouvier J. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor. *Haemostasis*. 1998;28:229-235.
51. Alban S, Gastpar R. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. *Thromb Haemost*. 2001;85:824-829.
52. Broze Jr GJ. Tissue factor pathway inhibitor. *Thromb Haemost*. 1995;74:90-93.
53. Young E, Prins M, Levine MN, et al. Heparin binding to plasma proteins, an important mechanism for heparin resistance. *Thromb Haemost*. 1992;67:639-643.
54. Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. *J Biol Chem*. 1983;258:3803-3808.
55. de Romeuf C, Mazurier C. Heparin binding assay of von Willebrand factor (vWF) in plasma milieu—evidence of the importance of the multimerization degree of vWF. *Thromb Haemost*. 1993;69:436-440.
56. Baruch D, Ajzenberg N, Denis C, et al. Binding of heparin fractions to von Willebrand factor: effect of molecular weight and affinity for antithrombin III. *Thromb Haemost*. 1994;71:141-146.
57. Denton J, Lane DA, Thunberg L, et al. Binding of platelet factor 4 to heparin oligosaccharides. *Biochem J*. 1983;209:455-460.
58. Eitzman DT, Chi L, Saggin L, et al. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. *Circulation*.

1994;89:1523-1529.

59. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. *N Engl J Med*. 1986;315:1109-1114.
60. Hull RD, Raskob GE, Brant RF, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. *Arch Intern Med*. 1997;157:2562-2568.
61. Anand SS, Yusuf S, Pogue J, et al. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. *Circulation*. 2003;107:2884-2888.
62. Lee MS, Wali AU, Menon V, et al. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. *J Thromb Thrombolysis*. 2002;14:91-101.
63. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. *Ann Intern Med*. 1993;119:104-109.
64. Bates SM, Weitz JI, Johnston M, et al. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. *Arch Intern Med*. 2001;161:385-391.
65. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. *Arch Intern Med*. 1994;154:49-56.
66. Chunilal SD, Young E, Johnston MA, et al. The APTT response of pregnant plasma to unfractionated heparin. *Thromb Haemost*. 2002;87:92-97.
67. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(3 Suppl):338S-400S.
68. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. *Arch Intern Med*. 1991;151:333-337.
69. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. *Ann Intern Med*. 1993;119:874-881.
70. Menon V, Berkowitz SD, Antman EM, et al. New heparin dosing recommendations for patients with acute coronary syndromes. *Am J Med*. 2001;110:641-650.
71. Hassan WM, Flaker GC, Feutz C, et al. Improved anticoagulation with a weight-adjusted heparin nomogram in patients with acute coronary syndromes: a randomized trial. *J Thromb Thrombolysis*. 1995;2:245-249.
72. Rezaie AR: Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. *Blood*. 2001;97:2308-2313.
73. Brufatto N, Nesheim ME. The use of prothrombin (S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation. *J Biol Chem*. 2001;276:17663-17671.
74. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. *Proc Natl Acad Sci U S A*. 1989;86:3619-3623.
75. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. *J Clin Invest*. 1990;86:385-391.
76. Eisenberg PR, Siegel JE, Abendschein DR, et al. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. *J Clin Invest*. 1993;91:1877-1883.
77. Kumar R, Beguin S, Hemker HC. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. *Thromb Haemost*. 1995;74:962-968.
78. Kumar R, Beguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation—evidence for feedback activation of the clotting system by clot bound thrombin. *Thromb Haemost*. 1994;72:713-721.
79. von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional



formation of thrombin that protects fibrin clots from fibrinolysis. *Blood*. 1995;86:3035-3042.

80. Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(3 Suppl):287S-310S.
81. Horrow JC. Protamine: a review of its toxicity. *Anesth Analg*. 1985;64:348-361.
82. Wakefield TW, Hantler CB, Wroblewski SK, et al. Effects of differing rates of protamine reversal of heparin anticoagulation. *Surgery*. 1996;119:123-128.
83. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia. Diagnosis, natural history, and treatment options. *Postgrad Med*. 1998;103:169-171.
84. Hughes M, Hayward CP, Warkentin TE, et al. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. *Blood*. 2000;96:188-194.
85. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. *N Engl J Med*. 2001;244:1286-1292.
86. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. *Arch Intern Med*. 2004;164:361-369.
87. Warkentin TE, Sikov WM, Lillicrap DP. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. *Am J Hematol*. 1999;62:44-48.
88. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. *Arch Intern Med*. 2004;164:66-70.
89. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. *Am J Obstet Gynecol*. 1993;168:1265-1270.
90. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. *Am J Obstet Gynecol*. 1994;170:862-869.
91. Dahlman TC, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. *Am J Obstet Gynecol*. 1994;170:1315-1320.
92. Douketis JD, Ginsberg JS, Burrows RF, et al. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. *Thromb Haemost*. 1996;75:254-257.
93. Bhandari M, Hirsh J, Weitz JI, et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. *Thromb Haemost*. 1998;80:413-417.
94. Muir JM, Andrew M, Hirsh J, et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. *Blood*. 1996;88:1314-1320.
95. Muir JM, Hirsh J, Weitz JI, et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. *Blood*. 1997;89:3236-3242.
96. Murray WJ, Lindo VS, Kakkar VV, et al. Long-term administration of heparin and heparin fractions and osteoporosis in experimental animals. *Blood Coagul Fibrinolysis*. 1995;6:113-118.
97. Dukes GE Jr, Sanders SW, Russo Jr J, et al. Transaminase elevations in patients receiving bovine or porcine heparin. *Ann Intern Med*. 1984;100:646-650.
98. Guevara A, Labarca J, Gonzalez-Martin G. Heparin-induced transaminase elevations: a prospective study. *Int J Clin Pharmacol Ther Toxicol*. 1993;31:137-141.
99. Weitz JI. Low-molecular-weight heparins. *N Engl J Med*. 1997;337:688-698.
100. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. *Haemostasis*. 1996;26(Suppl 2):24-38.
101. Cosmi B, Fredenburgh JC, Rischke J, et al. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. *Circulation*. 1997;95:118-124.
102. Young E, Cosmi B, Weitz J, et al. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. *Thromb Haemost*. 1993;70:625-630.

103. Young E, Wells P, Holloway S, et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. *Thromb Haemost.* 1994;71:300-304.
104. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. *N Engl J Med.* 1996;334:677-681.
105. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. *N Engl J Med.* 1996;334:682-687.
106. Belcaro G, Nicolaides AN, Cesarone MR, et al. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep vein thrombosis. *Angiology.* 1999;50:781-787.
107. Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. *Semin Thromb Haemost.* 2001;27:519-522.
108. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. *Ann Intern Med.* 1999;130:800-809.
109. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. *Ann Intern Med.* 2004;140:175-183.
110. Holst J, Lindblad B, Bergqvist D, et al. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers. *Blood Coagul Fibrinolysis.* 1994;5:795-803.
111. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. *N Engl J Med.* 1995;332:1330-1335.
112. Lindhoff-Last E, Nakov R, Misselwitz F, et al. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. *Br J Haematol.* 2002;118:1137-1142.
113. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. *Thromb Haemost.* 1998;80:292-297.
114. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. *Thromb Haemost.* 1992;67:545-549.
115. Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. *Thromb Haemost.* 1994;71:7-11.
116. Bauer KA. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. *Chest.* 2003;124(6 Suppl):364S-370S.
117. Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. *Clin Pharmacokinet.* 2002;41(Suppl 2):1-9.
118. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. *Ann Intern Med.* 2004;140:867-873.
119. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. *N Engl J Med.* 2003;349:1695-1702.
120. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators; Yusuf S, Mehta SR, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. *N Engl J Med.* 2006;354:1464-1476.
121. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute

- ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. *JAMA*. 2006;295:1519-1530.
122. Kuo KH, Kovacs MJ. Fondaparinux: a potential new therapy for HIT. *Hematology*. 2005;10:271-275.
  123. Lisman T, Bijsterveld NR, Adelmeijer J, et al. Recombinant factor VIIa reserves the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. *J Thromb Haemost*. 2003;1:2368-2373.
  124. Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future. *Circulation*. 2002;105:1004-1011.
  125. Fischer KG. Hirudin in renal insufficiency. *Semin Thromb Hemost*. 2002;28:467-482.
  126. Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. *Blood*. 2000;96:2373-2378.
  127. Sheth SB, DiCicco RA, Hursting MJ, et al. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. *Thromb Haemost*. 2001;85:435-440.
  128. Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for ischemic heart disease. *Circulation*. 1999;100:2049-2053.
  129. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. *Lancet*. 2002;349:294-302.
  130. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. *JAMA*. 2003;289:853-863.
  131. Mahaffey KW, Lewis BE, Wildermann NM, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: Main results. *J Invasive Cardiol*. 2003;15:611-616.
  132. Furie B, Furie BC. Molecular basis of vitamin K-dependent gamma-carboxylation. *Blood*. 1990;75:1753-1762.
  133. Nelsestuen GL, Zytkevich TH, Howard JB. The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. *J Biol Chem*. 1974;249:6347-6350.
  134. Stenflo J, Fernlund P, Egan W, et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. *Proc Natl Acad Sci U S A*. 1974;71:2730-2733.
  135. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. *Biochemistry*. 1978;17:1371-1377.
  136. Fasco MJ, Hildebrandt EF, Suttie JW. Evidence that warfarin anticoagulant action involves two distinct reductase activities. *J Biol Chem*. 1982;257:11210-11212.
  137. Friedman PA, Rosenberg RD, Hauschka PV, et al. A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. *Biochim Biophys Acta*. 1977;494:271-276.
  138. Hirsh J. Oral anticoagulant drugs. *N Engl J Med*. 1991;324:1865-1875.
  139. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. *Blood*. 2005;106:2329-2333.
  140. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. *Hum Genet*. 2007;121:23-34.
  141. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(3 Suppl):429S-456S.
  142. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. *N Engl J Med*. 2003;349:631-639.
  143. Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. *Lancet*. 2000;356:1551-1553.
  144. Ageno W, Crowther M, Steidl L, et al. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a

- randomized controlled trial. *Thromb Haemost.* 2002;88:48-51.
145. McGehee WG, Klotz TA, Epstein DJ, et al. Coumarin necrosis associated with hereditary protein C deficiency. *Ann Intern Med.* 1984;101:59-60.
  146. Berkompas DC. Coumadin skin necrosis in a patient with a free protein S deficiency: case report and literature review. *Indiana Med.* 1991;84:788-791.
  147. Bates SM, Greer IA, Hirsh J, et al. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126(3 Suppl):627S-644S.
  148. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. *N Engl J Med.* 2003;349:1133-1138.
  149. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). *J Thromb Haemost.* 2005;3:848-853.
  150. Bates SM, Weitz JI. The status of new anticoagulants. *Br J Haematol.* 2006;134:3-19.

## 第 35 章

1. CSL Behring. Dosing information for Streptase. March 2007.
2. Genentech Inc. Packet Insert for Activase. Dec 2005.
3. PDL BioPharma Inc. Packet Insert for Retevase. Nov 2006.
4. Genetech. Packet Insert for TNKase. Dec 2001.
5. ImaRx Therapeutics Inc. Packet Insert for Kinlytic. Available at ([http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/021846s101lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021846s101lbl.pdf)); 7/2008.
6. Falk A, Harbour K. Tenecteplase in the treatment of thrombosed hemodialysis grafts. *Cardiovasc Intervent Radiol.* 2005;28:472-475.
7. Sofocleous CT, Hinrichs CR, Weiss SH, et al. Alteplase for hemodialysis access graft thrombolysis. *J Vasc Interv Radiol.* 2002;13:775-784.
8. Falk A, Guller J, Nowakowski FS, et al. Reteplase in the treatment of thrombosed hemodialysis grafts. *J Vasc Interv Radiol.* 2001;12:1257-1262.
9. Sherry S, Tillet WS, Read CT. The use of streptokinase-streptodornase in the treatment of hemothorax. *J Thorac Surg.* 1950;20:393-417.
10. Eurvilaichit C, Tirapanich W, Thongborisute E. Renal artery embolism: therapy with intra-arterial streptokinase infusion. *J Med Assoc Thai.* 1999;82:978-983.
11. Ozdogan M, Gurer A, Gokakin AK, et al. Thrombolysis via an operatively placed mesenteric catheter for portal and superior mesenteric vein thrombosis: report of a case. *Surg Today.* 2006;36:846-848.
12. Morgagni JB. *De Sedibus et Causis Morborum per Anatomen Indagatis*, 2nd ed. 1761. Translated by Alexander B: The Seats and Causes of Diseases Investigated by Anatomy, vol 3, book 4. London: Miller; 1769.
13. Morawitz P. Ner einige postmortale Blutveränderungen beitz zur Chem. *Physiol Pathol.* 1906;8:1.
14. Milstone H. A factor in normal human blood which participates in streptococcal fibrinolysis. *J Immunol.* 1941;42:109-116.
15. Kaplan MH. Nature and role of lytic factor in hemolytic streptococcal fibrinolysis. *Proc Soc Exp Biol Med.* 1944;57:40-43.
16. Christensen LR. Streptococcal fibrinolysis: a proteolytic reaction due to a serum enzyme activated by streptococcal fibrinolysin. *J Gen Physiol.* 1945;28:363-383.
17. Christensen LR, MacLeod CM. A proteolytic enzyme of the serum: characterization, activation, and reaction with inhibitors. *J Gen Physiol.* 1945;28:559-583.
18. Albrechtsen OK. The fibrinolytic activity of human tissues. *Br J Haematol.* 1957;3:284-291.
19. Tillet WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. *J Exp Med.* 1933;58:458-502.

20. Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. *Tex Heart Inst J*. 2007;34:318-327.
21. Garner RL, Tillett WS. Biochemical studies on the fibrinolytic activity of hemolytic streptococci: I. Isolation and characterization of fibrinolysin. *J Exp Med*. 1934;60:239-254.
22. Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural exudations. *J Clin Invest*. 1949;28:173-190.
23. Sherry S, Titchener A, Gottesman L, et al. The enzymatic dissolution of experimental arterial thrombi in the dog by trypsin, chymotrypsin and plasminogen activators. *J Clin Invest*. 1954;33:1303-1313.
24. Tillett WS, Johnson AJ, McCarty WR. The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients. *J Clin Invest*. 1955;34:169-185.
25. Hansen F, Jorgensen M, Kjeldgaard NO, et al. Urokinase—an activator of plasminogen from human urine. Experiences with intravenous application on twenty-two patients. *Angiology*. 1961;12:367-371.
26. Boyles PW, Meyer WH, Graff J, et al. Comparative effectiveness of intravenous and intra-arterial fibrinolysin therapy. *Am J Cardiol*. 1960;6:439-446.
27. Berridge DC, Gregson RH, Hopkinson BR, et al. Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis. *Br J Surg*. 1991;78:988-995.
28. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease)—summary of recommendations. *J Vasc Interv Radiol*. 2006;17:1383-1397; quiz 1398.
29. Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral arterial occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133:815S-843S.
30. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133:454S-545S.
31. Valji K, Bookstein JJ, Roberts AC, et al. Pulse-spray pharmacomechanical thrombolysis of thrombosed hemodialysis access grafts: long-term experience and comparison of original and current techniques. *AJR Am J Roentgenol*. 1995;164:1495-1500; discussion 1501-1503.
32. Ouriel K. Endovascular techniques in the treatment of acute limb ischemia: Thrombolytic agents, trials, and percutaneous mechanical thrombectomy techniques. *Semin Vasc Surg*. 2003;16:270-279.
33. Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lower limb peripheral arterial occlusion—a consensus document. *J Vasc Interv Radiol*. 2003;14:S337-S349.
34. Semba CP, Murphy TP, Bakal CW, et al. Thrombolytic therapy with the use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. *J Vasc Interv Radiol*. 2000;11:149-161.
35. Vesely TM. Mechanical thrombectomy devices to treat thrombosed hemodialysis grafts. *Tech Vasc Interv Radiol*. 2003;6:35-41.
36. Vorwerk D. Mechanical thrombectomy is an alternative way to go: the European experience commentary on quality improvement guidelines for percutaneous management of acute limb ischemia. *Cardiovasc Intervent Radiol*. 2006;29:7-10.
37. Hirsch DR, Goldhaber SZ. Bleeding time and other laboratory tests to monitor the safety and efficacy of thrombolytic therapy. *Chest*. 1990;97:124S-131S.
38. Tracy RP, Bovill EG. Fibrinolytic parameters and hemostatic monitoring: identifying and predicting patients at risk for major hemorrhagic events. *Am J Cardiol*. 1992;69:52A-59A.
39. The National Institute of Neurological Disorders and Stroke Investigators. Tissue plasminogen activator for acute ischemic

- stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. *N Engl J Med*. 1995;333:1581-1587.
40. Pharmacy Healthcare Solutions. Thrombolytics: Therapeutic Class Review. Available at: (<http://www.pharmhs.com/Forms/Thrombolytic%20Review.pdf>); 12/8/2005.
  41. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. *N Engl J Med*. 1998;338:1105-1111.
  42. Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. *J Vasc Surg*. 1994;19:1021-1030.
  43. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. *Ann Surg*. 1994;220:251-266; discussion 266-268.
  44. Jackson KW, Tang J. Complete amino acid sequence of streptokinase and its homology with serine proteases. *Biochemistry*. 1982;21:6620-6625.
  45. Wu DH, Shi GY, Chuang WJ, et al. Coiled coil region of streptokinase gamma-domain is essential for plasminogen activation. *J Biol Chem*. 2001;276:15025-15033.
  46. Kim DM, Lee SJ, Kim IC, et al. Asp41-His48 region of streptokinase is important in binding to a substrate plasminogen. *Thromb Res*. 2000;99:93-98.
  47. Reddy KN, Markus G. Mechanism of activation of human plasminogen by streptokinase. Presence of active center in streptokinase-plasminogen complex. *J Biol Chem*. 1972;247:1683-1691.
  48. Brucato FH, Pizzo SV. Catabolism of streptokinase and polyethylene glycol-streptokinase: evidence for transport of intact forms through the biliary system in the mouse. *Blood*. 1990;76:73-79.
  49. Gouin I, Lecompte T, Morel MC, et al. In vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis. *Circulation*. 1992;85:935-941.
  50. Lee HS. How safe is the readministration of streptokinase? *Drug Saf*. 1995;13:76-80.
  51. Jennings K. Antibodies to streptokinase. *BMJ*. 1996;312:393-394.
  52. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. *Lancet*. 1988;2:349-360.
  53. Davies KA, Mathieson P, Winearls CG, et al. Serum sickness and acute renal failure after streptokinase therapy for myocardial infarction. *Clin Exp Immunol*. 1990;80:83-88.
  54. Verstraete M, Collen D. Thrombolytic therapy in the eighties. *Blood*. 1986;67:1529-1541.
  55. Estrada MP, Hernandez L, Perez A, et al. High level expression of streptokinase in *Escherichia coli*. *Biotechnology (N Y)*. 1992;10:1138-1142.
  56. Shantha Biotechnics PVT. LTD. Packet insert for Shankinase. Available at ([http://www.shanthabiotech.com/pack\\_insert\\_inhouse/Pack%20Insert%20shankinase.pdf](http://www.shanthabiotech.com/pack_insert_inhouse/Pack%20Insert%20shankinase.pdf)).
  57. Hermentin P, Cuesta-Linker T, Weisse J, et al. Comparative analysis of the activity and content of different streptokinase preparations. *Eur Heart J*. 2005;26:933-940.
  58. MacFarlane RG, Pinot JJ. Fibrinolytic activity of normal urine. *Nature*. 1947;159:779.
  59. Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. *J Biol Chem*. 1982;257:3276-3283.
  60. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. *Curr Pharm Des*. 2004;10:39-49.
  61. Bugge TH, Flick MJ, Danton MJ, et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. *Proc Natl Acad Sci U S A*. 1996;93:5899-5904.
  62. Collen D, Zamarron C, Lijnen HR, et al. Activation of plasminogen by pro-urokinase. II. Kinetics. *J Biol Chem*.

- 1986;261:1259-1266.
63. Lijnen HR, Zamarron C, Blaber M, et al. Activation of plasminogen by pro-urokinase. I. Mechanism. *J Biol Chem*. 1986;261:1253-1258.
  64. Sumi H, Robbins KC. A functionally active heavy chain derived from human high molecular weight urokinase. *J Biol Chem*. 1983;258:8014-8019.
  65. Gunzler WA, Steffens GJ, Otting F, et al. Structural relationship between human high and low molecular mass urokinase. *Hoppe Seylers Z Physiol Chem*. 1982;363:133-141.
  66. Gunzler WA, Steffens GJ, Otting F, et al. The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. *Hoppe Seylers Z Physiol Chem*. 1982;363:1155-1165.
  67. Bdeir K, Kuo A, Sachais BS, et al. The kringle stabilizes urokinase binding to the urokinase receptor. *Blood*. 2003;102:3600-3608.
  68. Riccio A, Grimaldi G, Verde P, et al. The human urokinase-plasminogen activator gene and its promoter. *Nucleic Acids Res*. 1985;13:2759-2771.
  69. Vetterlein D, Calton GJ. Purification of urokinase from complex mixtures using immobilized monoclonal antibody against urokinase light chain. *Thromb Haemost*. 1983;49:24-27.
  70. Hartnell GG, Gates J. The case of Abbokinase and the FDA: the events leading to the suspension of Abbokinase supplies in the United States. *J Vasc Interv Radiol*. 2000;11:841-847.
  71. Haire WD, Deitcher SR, Mullane KM, et al. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial. *Thromb Haemost*. 2004;92:575-582.
  72. Svoboda P, Barton RP, Barbarash OL, et al. Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: a multiple-center, international trial. *Crit Care Med*. 2004;32:1990-1996.
  73. Robbins KC, Tanaka Y. Covalent molecular weight approximately 92 000 hybrid plasminogen activator derived from human plasmin amino-terminal and urokinase carboxyl-terminal domains. *Biochemistry*. 1986;25:3603-3611.
  74. Maksimenko AV, Torchilin VP. Water-soluble urokinase derivatives of combined action. *Thromb Res*. 1985;38:277-288.
  75. Maksimenko AV, Torchilin VP. Water-soluble urokinase derivatives with increased affinity to the fibrin clot. *Thromb Res*. 1985;38:289-295.
  76. Gurewich V, Pannell R, Louie S, et al. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. *J Clin Invest*. 1984;73:1731-1739.
  77. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group. *Lancet*. 1989;1:863-868.
  78. Bar FW, Meyer J, Vermeer F, et al. Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. *Am J Cardiol*. 1997;79:727-732.
  79. Tebbe U, Michels R, Adgey J, et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators. *J Am Coll Cardiol*. 1998;31:487-493.
  80. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. *Stroke*. 1998;29:4-11.
  81. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. *JAMA*. 1999;282:2003-2011.
  82. Collen D, Rijken DC, Van Damme J, et al. Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo. *Thromb Haemost*. 1982;48:294-296.
  83. Smalling RW. Molecular biology of plasminogen activators: what are the clinical implications of drug design? *Am J Cardiol*. 1996;78:2-7.

84. Ponting CP, Marshall JM, Cederholm-Williams SA. Plasminogen: a structural review. *Blood Coagul Fibrinolysis*. 1992;3:605-614.
85. Rudolf J, Grond M, Prince WS, et al. Evidence of anaphylaxis after alteplase infusion. *Stroke*. 1999;30:1142-1143.
86. Pechlaner C, Knapp E, Wiedermann CJ. Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase. *Blood Coagul Fibrinolysis*. 2001;12:491-494.
87. Martin U, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. *J Am Coll Cardiol*. 1992;19:433-440.
88. Roche. Packet insert for Rapilysin. Feb 2006.
89. Smalling RW. A fresh look at the molecular pharmacology of plasminogen activators: from theory to test tube to clinical outcomes. *Am J Health Syst Pharm*. 1997;54(Suppl 1):S17-S22.
90. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. *Proc Natl Acad Sci U S A*. 1994;91:3670-3674.
91. Hansen L, Blue Y, Barone K, et al. Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator. *J Biol Chem*. 1988;263:15713-15719.
92. Kostis JB, Dockens RC, Thadani U, et al. Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction. *Clin Pharmacokinet*. 2002;41:445-452.
93. InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. *Eur Heart J*. 2000;21:2005-2013.
94. Lewis JH, Shirskawa M. Effects of fibrinolytic agents and heparin on blood coagulation in dogs. *Am J Physiol*. 1964;207:1049-1052.
95. Collen D, Van Hoef B, Schlott B, et al. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase. *Eur J Biochem*. 1993;216:307-314.
96. Collen D. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. *Nat Med*. 1998;4:279-284.
97. Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. *Circulation*. 1993;87:1850-1853.
98. Vanderschueren S, Barrios L, Kerdsinchai P, et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. *Circulation*. 1995;92:2044-2049.
99. Sako T, Tsuchida N. Nucleotide sequence of the staphylokinase gene from *Staphylococcus aureus*. *Nucleic Acids Res*. 1983;11:7679-7693.
100. Schlott B, Hartmann M, Guhrs KH, et al. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. *Biotechnology (N Y)*. 1994;12:185-189.
101. Sako T, Sawaki S, Sakurai T, et al. Cloning and expression of the staphylokinase gene of *Staphylococcus aureus* in *Escherichia coli*. *Mol Gen Genet*. 1983;190:271-277.
102. Behnke D, Gerlach D. Cloning and expression in *Escherichia coli*, *Bacillus subtilis*, and *Streptococcus sanguis* of a gene for staphylokinase—a bacterial plasminogen activator. *Mol Gen Genet*. 1987;210:528-534.
103. Laroche Y, Heymans S, Capaert S, et al. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. *Blood*. 2000;96:1425-1432.
104. Collen D, Sinnaeve P, Demarsin E, et al. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction. *Circulation*. 2000;102:1766-1772.
105. Armstrong PW, Burton J, Pakola S, et al. Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). *Am Heart J*. 2003;146:484-488.
106. ThromboGenics. From ThromboGenics website: products—staphylokinase. Jan 17, 2008.



107. Zavalova LL, Basanova AV, Baskova IP. Fibrinogen-fibrin system regulators from bloodsuckers. *Biochemistry (Mosc)*. 2002;67:135-142.
108. Hawkey C. Plasminogen activator in saliva of the vampire bat *Desmodus rotundus*. *Nature*. 1966;211:434-435.
109. Bringmann P, Gruber D, Liese A, et al. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. *J Biol Chem*. 1995;270:25596-25603.
110. Gardell SJ, Duong LT, Diehl RE, et al. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. *J Biol Chem*. 1989;264:17947-17952.
111. Kratzschmar J, Haendler B, Langer G, et al. The plasminogen activator family from the salivary gland of the vampire bat *Desmodus rotundus*: cloning and expression. *Gene*. 1991;105:229-237.
112. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. *Stroke*. 2005;36:66-73.
113. Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. *Stroke*. 2006;37:1227-1231.
114. Rising M. Lundbeck's stroke drug desmoteplase fails test. (<http://www.marketwatch.com>); June 1, 2007.
115. Randolph A, Chamberlain SH, Chu HL, et al. Amino acid sequence of fibrolase, a direct-acting fibrinolytic enzyme from *Agkistrodon contortrix contortrix* venom. *Protein Sci*. 1992;1:590-600.
116. Deitcher SR, Toombs CF. Non-clinical and clinical characterization of a novel acting thrombolytic: alfineprase. *Pathophysiol Haemost Thromb*. 2005;34:215-220.
117. Ouriel K, Cynamon J, Weaver FA, et al. A phase I trial of alfineprase for peripheral arterial thrombolysis. *J Vasc Interv Radiol*. 2005;16:1075-1083.
118. Moll S, Kenyon P, Bertoli L, et al. Phase II trial of alfineprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. *J Clin Oncol*. 2006;24:3056-3060.
119. Ouriel K. Safety and activity of alfineprase for catheter-directed thrombolysis in patients with lower extremity acute peripheral arterial occlusion: report of a phase 2, multi-center, multi-national, open-label, dose-escalation study (NAPA-1). Paper presented at the Transcatheter Cardiovascular Therapeutics Symposium, September 2004, Washington, DC.
120. Nagle M. Nuvelo restarts alfineprase development but Bayer bails out. 6/27/2007. Available at (<http://www.drugresearcher.com/news/ng.asp?id=77704>).
121. Martino M. Press release: Phase 3 trials of alfineprase misses primary endpoint. 12/10/2006. Available at (<http://www.fiercebiotech.com/node/4884>).
122. Silicon Valley/San Jose Business Journal. Nuvelo cuts staff, halts alfineprase development. March 17, 2008.
123. Watt DL, MacMillan RL. Evaluation of intravenous human fibrinolysin as a treatment for recent intravascular thrombosis. *Can Med Assoc J*. 1960;83:1436-1437.
124. Fletcher AP, Alkjaersig N, Sawyer WD, et al. Evaluation of human fibrinolysin (actase); lack of fibrinolytic activity after intravenous administration in man. *JAMA*. 1960;172:912-915.
125. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. *Thromb Haemost*. 1980;43:77-89.
126. Marder VJ, Landskroner K, Novokhatny V, et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. *Thromb Haemost*. 2001;86:739-745.
127. Clinical Trials. Gov. A dose escalation and safety study of plasmin (human) in acute lower extremity native artery or bypass graft occlusion (PRIORITY). March 25, 2008.
128. Talecris Biotherapeutics Inc. Information representing the continuing research and development program for plasmin (human). Paper presented at the 21st International Society for Thrombosis and Haemostasis (ISTH) Congress, Nov 7, 2007, Geneva.
129. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della

Streptochinasi nell'Infarto Miocardico (GISSI). *Lancet*. 1986;1:397-402.

130. Wilcox RG, von der Lippe G, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). *Lancet*. 1988;2:525-530.
131. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. *Circulation*. 1987;76:142-154.
132. GISSI-2. A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. *Lancet*. 1990;336:65-71.
133. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. *N Engl J Med*. 1993;329:673-682.
134. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. *N Engl J Med*. 1993;329:1615-1622.
135. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. *Circulation*. 1995;91:2725-2732.
136. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. *Lancet*. 1995;346:329-336.
137. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. *Circulation*. 1996;94:891-898.
138. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. *N Engl J Med*. 1997;337:1118-1123.
139. Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. *Circulation*. 1998;98:2805-2814.
140. Van de Werf F, Cannon CP, Luyten A, et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. *Am Heart J*. 1999;137:786-791.
141. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. *Lancet*. 1999;354:716-722.
142. Simon TL, Stengle JM, Sasahara AA. Urokinase in pulmonary embolism. *Lancet*. 1973;2:501.
143. Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study. *JAMA*. 1974;229:1606-1613.
144. De Takats G. The urokinase pulmonary embolism trial. *Am J Surg*. 1973;126:311-313.
145. The urokinase pulmonary embolism trial. A national cooperative study. *Circulation*. 1973;47:III-108.
146. Sasahara AA, Bell WR, Simon TL, et al. The phase II urokinase-streptokinase pulmonary embolism trial: a national cooperative study. *Thromb Diath Haemorrh*. 1975;33:464-476.
147. Bell WR, Simon TL, Stengle JM, et al. The urokinase-streptokinase pulmonary embolism trial (phase II) results. *Circulation*. 1974;50:1070-1071.
148. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. *Chest*. 1990;97:528-533.
149. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen

- activator in patients with acute pulmonary embolism. *Chest*. 1990;98:1473-1479.
150. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. *J Am Coll Cardiol*. 1992;20:520-526.
  151. Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. *Lancet*. 1988;2:293-298.
  152. Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. *J Am Coll Cardiol*. 1992;19:239-245.
  153. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. *J Am Coll Cardiol*. 1992;20:24-30.
  154. Tebbe U, Graf A, Kamke W, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. *Am Heart J*. 1999;138:39-44.
  155. Verstraete M, Miller GA, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. *Circulation*. 1988;77:353-360.
  156. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. *Chest*. 1994;106:718-724.
  157. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. *Lancet*. 1993;341:507-511.
  158. Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. *N Engl J Med*. 2002;347:1143-1150.
  159. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). *JAMA*. 1995;274:1017-1025.
  160. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. *Lancet*. 1998;352:1245-1251.
  161. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. *JAMA*. 1999;282:2019-2026.
  162. IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. *Stroke*. 2004;35:904-911.
  163. IMS II Study Investigators. The Interventional Management of Stroke (IMS) II Study. *Stroke*. 2007;38:2127-2135.
  164. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. *Stroke*. 1999;30:2598-2605.
  165. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133:630S-669S.
  166. McNamara TO, Fischer JR. Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase. *AJR Am J Roentgenol*. 1985;144:769-775.
  167. Sullivan KL, Gardiner GA Jr, Kandarpa K, et al. Efficacy of thrombolysis in infrainguinal bypass grafts. *Circulation*. 1991;83:199-205.
  168. Goldhaber SZ, Buring JE, Lipnick RJ, et al. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. *Am J Med*. 1984;76:393-397.
  169. Porter JM, Seaman AJ, Common HH, et al. Comparison of heparin and streptokinase in the treatment of venous thrombosis. *Am Surg*. 1975;41:511-519.

170. Janssen MC, Wollersheim H, Schultze-Kool LJ, et al. Local and systemic thrombolytic therapy for acute deep venous thrombosis. *Neth J Med.* 2005;63:81-90.
171. Mewissen MW, Seabrook GR, Meissner MH, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. *Radiology.* 1999;211:39-49.
172. Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. *Eur J Vasc Endovasc Surg.* 2002;24:209-214.
173. Rodkin RS, Bookstein JJ, Heeney DJ, et al. Streptokinase and transluminal angioplasty in the treatment of acutely thrombosed hemodialysis access fistulas. *Radiology.* 1983;149:425-428.
174. Marston WA, Criado E, Jaques PF, et al. Prospective randomized comparison of surgical versus endovascular management of thrombosed dialysis access grafts. *J Vasc Surg.* 1997;26:373-380; discussion 380-381.
175. Ponc D, Irwin D, Haire WD, et al. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial—the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. *J Vasc Interv Radiol.* 2001;12:951-955.
176. Semba CP, Deitcher SR, Li X, et al. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients. *J Vasc Interv Radiol.* 2002;13:1199-1205.
177. Schenk P, Rosenkranz AR, Wolfl G, et al. Recombinant tissue plasminogen activator is a useful alternative to heparin in priming Quinton Permcath. *Am J Kidney Dis.* 2000;35:130-136.
178. Clase CM, Crowther MA, Ingram AJ, et al. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review. *J Thromb Thrombolysis.* 2001;11:127-136.
179. Falk A, Samson W, Uribarri J, et al. Efficacy of reteplase in poorly functioning hemodialysis catheters. *Clin Nephrol.* 2004;61:47-53.
180. Svoboda P, Barton RP, Barbarash OL, et al. Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: a multiple-center, international trial. *Crit Care Med.* 2004;32:1990-1996.
181. US Food and Drug Administration Med Watch. Important safety information—letter: Dear hospital pharmacy and physician (AstraZeneca, Inc.). December 10, 1999.

## 第 36 章

1. The Gale Group I, ed. *Encyclopedia of Medicine* 3rd ed. Detroit: Thomson Gale; 2006.
2. Rapaport SI. Preoperative hemostatic evaluation: which tests, if any? *Blood.* 1983;61:229-231.
3. Stuart MJ, Miller ML, Davey FR, et al. The post-aspirin bleeding time: a screening test for evaluating haemostatic disorders. *Br J Haematol.* 1979;43:649-659.
4. Chuang J, Sadler MA, Witt DM. Impact of evacuated collection tube fill volume and mixing on routine coagulation testing using 2.5-ml (pediatric) tubes. *Chest.* 2004;126:1262-1266.
5. Hilpert K, Ackermann J, Banner DW, et al. Design and synthesis of potent and highly selective thrombin inhibitors. *J Med Chem.* 1994;37:3889-3901.
6. Schmaier AH. Contact activation: a revision. *Thromb Haemost.* 1997;78:101-107.
7. Achneck HE, Modi BP, Shaw C, et al. Ascending aortic aneurysm protects against systemic arteriosclerosis. Submitted to *American Journal of Cardiology.*
8. Jim RT. A study of the plasma thrombin time. *J Lab Clin Med.* 1957;50:45-60.
9. Conard J, Samama MM. Theoretic and practical considerations on laboratory monitoring of thrombolytic therapy. *Semin Thromb Hemost.* 1987;13:212-222.
10. Bowie EJ, Owen CA Jr. The bleeding time. *Prog Hemost Thromb.* 1974;2:249-271.
11. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. *Thromb Haemost.* 2000;84:160-174.

12. Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. *Thromb Haemost.* 1994;71:520-525.
13. Bush RW, Huff JW. Von Willebrand disease and severe gastrointestinal bleeding. Report of a kindred. *West J Med.* 1984;140:781-783.
14. Budde U, Schneppenheim R. Von Willebrand factor and von Willebrand disease. *Rev Clin Exp Hematol.* 2001;5:335-368; quiz following 431.
15. Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. *J Clin Invest.* 1971;50:244-254.
16. Howard MA, Sawers RJ, Firkin BG. Ristocetin: a means of differentiating von Willebrand disease into two groups. *Blood.* 1973;41:687-690.
17. Weiss HJ, Pietu G, Rabinowitz R, et al. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand disease. *J Lab Clin Med.* 1983;101:411-425.
18. Mhawech P, Saleem A. Inherited giant platelet disorders. Classification and literature review. *Am J Clin Pathol.* 2000;113:176-190.
19. Weiss HJ, Tschopp TB, Baumgartner HR, et al. Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis. *Am J Med.* 1974;57:920-925.
20. Lopez JA, Andrews RK, Afshar-Kharghan V, et al. Bernard-Soulier syndrome. *Blood.* 1998;91:4397-4418.
21. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. *Blood.* 1990;75:1383-1395.
22. Toogeh G, Sharifian R, Lak M, et al. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. *Am J Hematol.* 2004;77:198-199.
23. Tholouli E, Hay CR, O'Gorman P, et al. Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. *Br J Haematol.* 2004;127:209-213.
24. Levy-Toledano S, Caen JP, Breton-Gorius J, et al. Gray platelet syndrome: alpha-granule deficiency. Its influence on platelet function. *J Lab Clin Med.* 1981;98:831-848.
25. Weiss HJ, Lages B, Vivic W, et al. Heterogeneous abnormalities of platelet dense granule ultrastructure in 20 patients with congenital storage pool deficiency. *Br J Haematol.* 1993;83:282-295.
26. Shelley CS, Remold-O'Donnell E, Davis AE 3rd, et al. Molecular characterization of sialophorin (CD43), the lymphocyte surface sialoglycoprotein defective in Wiskott-Aldrich syndrome. *Proc Natl Acad Sci U S A.* 1989;86:2819-2823.
27. Marone G, Albini F, di Martino L, et al. The Wiskott-Aldrich syndrome: studies of platelets, basophils and polymorphonuclear leucocytes. *Br J Haematol.* 1986;62:737-745.
28. White GC 2nd, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. *Thromb Haemost.* 2001;85:560.
29. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. *Lancet.* 2003;361:1801-1809.
30. Keeling DM, Sukhu K, Kemball-Cook G, et al. Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954→Leu substitution in the factor VIII A3 domain. *Br J Haematol.* 1999;105:1123-1126.
31. Rodriguez NI, Hoots WK. Advances in hemophilia: experimental aspects and therapy. *Pediatr Clin North Am.* 2008;55:357-376, viii.
32. Weigert AL, Schafer AI. Uremic bleeding: pathogenesis and therapy. *Am J Med Sci.* 1998;316:94-104.

33. Gawaz MP, Dobos G, Spath M, et al. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. *J Am Soc Nephrol*. 1994;5:36-46.
34. Di Minno G, Martinez J, McKean ML, et al. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. *Am J Med*. 1985;79:552-559.
35. Remuzzi G, Perico N, Zoja C, et al. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. *J Clin Invest*. 1990;86:1768-1771.
36. Zeigler ZR, Megaludis A, Fraley DS. Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. *Am J Hematol*. 1992;39:90-95.
37. Esmon CT, Fukudome K, Mather T, et al. Inflammation, sepsis, and coagulation. *Haematologica*. 1999;84:254-259.
38. Gando S, Nanzaki S, Kemmotsu O. Disseminated intravascular coagulation and sustained systemic inflammatory response syndrome predict organ dysfunctions after trauma: application of clinical decision analysis. *Ann Surg*. 1999;229:121-127.
39. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. *Blood*. 2000;95:1124-1129.
40. Gordon SG, Mielski WP. Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. *Blood Coagul Fibrinolysis*. 1997;8:73-86.
41. Muller-Berghaus G, ten Cate H, Levi M. Disseminated intravascular coagulation: clinical spectrum and established as well as new diagnostic approaches. *Thromb Haemost*. 1999;82:706-712.
42. Feinstein DI. Treatment of disseminated intravascular coagulation. *Semin Thromb Hemost*. 1988;14:351-362.
43. Rocha E, Paramo JA, Montes R, et al. Acute generalized, widespread bleeding. Diagnosis and management. *Haematologica*. 1998;83:1024-1037.
44. Mannucci PM, Ruggeri ZM, Pareti FI, et al. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's diseases. *Lancet*. 1977;1:869-872.
45. Mannucci PM, Levi M. Prevention and treatment of major blood loss. *N Engl J Med*. 2007;356:2301-2311.
46. Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. *N Engl J Med*. 2008;358:784-793.
47. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. *Chest*. 2001;119(Suppl 1):64S-94S.
48. Van Ryn-McKenna J, Cai L, Ofosu FA, et al. Neutralization of enoxaparin-induced bleeding by protamine sulfate. *Thromb Haemost*. 1990;63:271-274.
49. Berry CN, Girardot C, Lecoffre C, et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. *Thromb Haemost*. 1994;72:381-386.
50. Gurewich V. Ximelagatran—promises and concerns. *JAMA*. 2005;293:736-739.
51. Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: the ximelagatran experience. *J Am Coll Cardiol*. 2005;46:1986-1995.
52. Huel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. *J Med Chem*. 2002;45:1757-1766.
53. Hirsch RL. Catheter-related venous thrombosis. *Am J Med*. 1995;98:99-100.
54. Mangano DT. Aspirin and mortality from coronary bypass surgery. *N Engl J Med*. 2002;347:1309-1317.
55. Dacey LJ, Munoz JJ, Johnson ER, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. *Ann Thorac Surg*. 2000;70:1986-1990.
56. Neilipovitz DT, Bryson GL, Nichol G. The effect of perioperative aspirin therapy in peripheral vascular surgery: a decision analysis. *Anesth Analg*. 2001;93:573-580.
57. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable

- angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non–ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *J Am Coll Cardiol*. 2007;50:e1-e157.
58. Tcheng JE, Kandzari DE, Grines CL, et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation*. 2003;108:1316-1323.
  59. Hamm CW. Anti-integrin therapy. *Annu Rev Med*. 2003;54:425-435.
  60. Levy JH. Massive transfusion coagulopathy. *Semin Hematol*. 2006;43(1 Suppl 1):S59-S63.
  61. Reed RL 2nd, Johnson TD, Hudson JD, et al. The disparity between hypothermic coagulopathy and clotting studies. *J Trauma*. 1992;33:465-470.
  62. Slovis CM, Bachvarov HL. Heated inhalation treatment of hypothermia. *Am J Emerg Med*. 1984;2:533-536.
  63. Eddy VA, Morris JA Jr, Cullinane DC. Hypothermia, coagulopathy, and acidosis. *Surg Clin North Am*. 2000;80:845-854.
  64. Engstrom M, Schott U, Romner B, et al. Acidosis impairs the coagulation: a thromboelastographic study. *J Trauma*. 2006;61:624-628.
  65. Adams RC, Lundy JS. Anesthesia in cases of poor surgical risk. *Surg Gynecol Obstet*. 1942;74:1011.
  66. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med*. 1999;340:409-417.
  67. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. *Anesthesiology*. 2006;105:198-208.
  68. Royal College of Physicians of Edinburgh consensus conference on platelet transfusion. *Transfus Med*. 1998;8:149-151.
  69. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. *Transfus Med Rev*. 2004;18:153-167.
  70. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). *J Thromb Haemost*. 2003;1:682-689.
  71. Carless PA, Henry DA, Moxey AJ, et al. Desmopressin for minimising perioperative allogeneic blood transfusion. *Cochrane Database Syst Rev*. 1:CD001884, 2004.
  72. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. *Lancet*. 1999;354:1940-1947.
  73. Woods K, Douketis JD, Kathirgamanathan K, et al. Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. *J Thromb Thrombolysis*. 2007;24:93-97.
  74. Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. *J Thromb Haemost*. 2008;6:622-631.
  75. Levy JH, Adkinson NF Jr. Anaphylaxis during cardiac surgery: implications for clinicians. *Anesth Analg*. 2008;106:392-403.
  76. Weiler JM, Gellhaus MA, Carter JG, et al. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. *J Allergy Clin Immunol*. 1990;85:713-719.
  77. Butenas S, Brummel KE, Branda RF, et al. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. *Blood*. 2002;99:923-930.
  78. Ranucci M, Isgro G, Soro G, et al. Efficacy and safety of recombinant activated factor VII in major surgical procedures:

systematic review and meta-analysis of randomized clinical trials. *Arch Surg*. 2008;143:296-304.

79. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. *JAMA*. 2006;295:293-298.
80. Katsaros D, Petricevic M, Snow NJ, et al. Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients. *Ann Thorac Surg*. 1996;61:1131-1135.
81. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. *N Engl J Med*. 2008;358:2319-2331.
82. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. *JAMA*. 2007;297:471-479.
83. Ray WA, Stein CM. The aprotinin story—is BART the final chapter? *N Engl J Med*. 2008;358:2398-2400.
84. O'Connor JL, Bloom DA, William T. Bovie and electrosurgery. *Surgery*. 1996;119:390-396.
85. Go PM, Goodman GR, Bruhn EW, et al. The argon beam coagulator provides rapid hemostasis of experimental hepatic and splenic hemorrhage in anticoagulated dogs. *J Trauma*. 1991;31:1294-1300.
86. Yim AP, Rendina EA, Hazelrigg SR, et al. A new technological approach to nonanatomical pulmonary resection: saline enhanced thermal sealing. *Ann Thorac Surg*. 2002;74:1671-1676.
87. Topp SA, McClurken M, Lipson D, et al. Saline-linked surface radiofrequency ablation: factors affecting steam popping and depth of injury in the pig liver. *Ann Surg*. 2004;239:518-527.
88. Schonauer C, Tessitore E, Barbagallo G, et al. The use of local agents: bone wax, gelatin, collagen, oxidized cellulose. *Eur Spine J*. 2004;13(Suppl 1):S89-S96.
89. Wilkinson HA, Baker S, Rosenfeld S. Gelfoam paste in experimental laminectomy and cranial trephination: hemostasis and bone healing. *J Neurosurg*. 1981;54:664-667.
90. Frantz VK. Absorbable cotton, paper and gauze: (oxidized cellulose). *Ann Surg*. 1943;118:116-126.
91. Tomizawa Y. Clinical benefits and risk analysis of topical hemostats: a review. *J Artif Organs*. 2005;8:137-142.
92. Ibrahim MF, Aps C, Young CP. A foreign body reaction to Surgicel mimicking an abscess following cardiac surgery. *Eur J Cardiothorac Surg*. 2002;22:489-490; author reply 90.
93. Tomizawa Y, Endo M, Kitamura M, et al. [Coronary artery bypass graft stenosis suspected to be due to hemostatic agents: a case report.] *Kyobu Geka*. 1991;44:764-766.
94. Igari T, Iwaya F, Abe T, et al. [A case of foreign body granuloma after aortic valve replacement.] *Kyobu Geka*. 1990;43:550-552.
95. Banerjee T, Goldschmidt K. "Surgiceloma" manifested as cauda equina syndrome. *South Med J*. 1998;91:481-483.
96. Brodbelt AR, Miles JB, Foy PM, et al. Intraspinal oxidised cellulose (Surgicel) causing delayed paraplegia after thoracotomy—a report of three cases. *Ann R Coll Surg Engl*. 2002;84:97-99.
97. Zucker WH, Mason RG. Ultrastructural aspects of interactions of platelets with microcrystalline collagen. *Am J Pathol*. 1976;82:129-142.
98. Wagner WR, Pachence JM, Ristich J, et al. Comparative in vitro analysis of topical hemostatic agents. *J Surg Res*. 1996;66:100-108.
99. Abbott WM, Austen WG. The effectiveness and mechanism of collagen-induced topical hemostasis. *Surgery*. 1975;78:723-729.
100. Sileshi B, Achneck HE, Lawson JH. Management of surgical hemostasis: topical agents. *Vascular*. 2008;16(Suppl 1):S22-S28.
101. Low RK, Moran ME, Goodnight JE Jr. Microfibrillar collagen hemostat during laparoscopically directed liver biopsy. *J Laparoendosc Surg*. 1993;3:415-420.
102. Lawson JH, Lynn KA, Vanmatre RM, et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. *Ann Thorac Surg*. 2005;79:1037-1038.



103. Schoenecker JG, Hauck RK, Mercer MC, et al. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose. *J Clin Immunol*. 2000;20:434-444.
104. Ortel TL, Mercer MC, Thames EH, et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. *Ann Surg*. 2001;233:88-96.
105. Sands JJ, Nudo SA, Ashford RG, et al. Antibodies to topical bovine thrombin correlate with access thrombosis. *Am J Kidney Dis*. 2000;35:796-801.
106. Sarfati MR, Dilorenzo DJ, Kraiss LW, et al. Severe coagulopathy following intraoperative use of topical thrombin. *Ann Vasc Surg*. 2004;18:349-351.
107. Savage WJ, Kickler TS, Takemoto CM. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. *Pediatr Blood Cancer*. 2007;49:1025-1029.
108. Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. *Transfusion*. 2002;42:18-26.
109. Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. *J Am Coll Surg*. 2007;205:256-265.
110. Rousou J, Levitsky S, Gonzalez-Lavin L, et al. Randomized clinical trial of fibrin sealant in patients undergoing re sternotomy or reoperation after cardiac operations. A multicenter study. *J Thorac Cardiovasc Surg*. 1989;97:194-203.
111. Shirai T, Shimota H, Chida K, et al. Anaphylaxis to aprotinin in fibrin sealant. *Intern Med (Tokyo)*. 2005;44:1088-1089.
112. Oz MC, Cosgrove DM 3rd, Badduke BR, et al. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. The Fusion Matrix Study Group. *Ann Thorac Surg*. 2000;69:1376-1382.
113. Richter F, Schnorr D, Deger S, et al. Improvement of hemostasis in open and laparoscopically performed partial nephrectomy using a gelatin matrix-thrombin tissue sealant (FloSeal). *Urology*. 2003;61:73-77.
114. Hong YM, Loughlin KR. The use of hemostatic agents and sealants in urology. *J Urol*. 2006;176:2367-2374.
115. Currie LJ, Sharpe JR, Martin R. The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review. *Plast Reconstr Surg*. 2001;108:1713-1726.
116. Spotnitz WD, Prabhu R. Fibrin sealant tissue adhesive—review and update. *J Long Term Eff Med Implants*. 2005;15:245-270.

## 第 37 章

### REFERENCES

1. Stanley JC, Barnes RW, Ernst CB, et al. Vascular surgery in the United States: workforce issues. Report of the Society for Vascular Surgery and the International Society for Cardiovascular Surgery, North American Chapter, Committee on Workforce Issues. *J Vasc Surg* 1996;23:172-181.
2. Goldhaber, S. *Thrombosis and Thromboembolism, Venous Thromboembolism: Clinical Impact and Multifactorial Etiology*. New York, NY: Marcel Dekker; 2002:211-224.
3. Jackson E, Skerret PJ, Ridker PM. Epidemiology of arterial thrombosis. In: Colman RW, Hirsh J, Marder VJ, et al., eds. *Hemostasis and Thrombosis; Basic Principles & Clinical Practice*. 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001:1179-1196.
4. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. *Arch Intern Med*. 1991;151:933.
5. Coon WW, Willis PW, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. *Circulation*. 1973;48:839.
6. Rosendaal FR. Venous thrombosis: a multicausal disease. *Lancet*. 1993;353:1167.
7. Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. *Ann Intern Med*. 2003;138:128.

8. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. *Blood*. 1997;90:1.
9. Frohlich J. Lipoproteins and homocyt(e)ine as risk factors for atherosclerosis: assessment and treatment. *Can J Cardiol*. 1995;11(Suppl C):18C.
10. Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. *N Engl J Med*. 2004;350:2673.
11. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease. *JAMA*. 2007;298:1163.
12. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death. The Vitamin Intervention for Stroke Prevention Randomized Controlled Trial. *JAMA*. 2004;291:565.
13. den Heijer M, Willems HPJ, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized placebo-controlled, double-blind trial. *Blood*. 2007;109:139.
14. De Stefano V, Leone G, Mastrangelo S, et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C and protein S. *Thromb Haemost*. 1994;72:352.
15. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C or protein S deficiency. *Arterioscler Thromb Vasc Biol*. 1996;16:742.
16. Bucciarelli P, Rosendaal FR, Tripodi A, et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency or activated protein C resistance. A multicenter collaborative study. *Arterioscler Thromb Vasc Biol*. 1999;19:1026.
17. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. *N Engl J Med*. 1995;332:912.
18. McCully KS. Vascular pathology of homocysteineuria: implications for the pathogenesis of atherosclerosis. *Am J Pathol*. 1969;56:111.
19. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. *Atherosclerosis*. 1994;106:9-19.
20. Scanu AM. Lipoprotein (a): a genetic risk factor for premature coronary heart disease. *JAMA*. 1992;267:3326.
21. Wu KK, Folsom AR, Heiss G, et al. Association of coagulation factors and inhibitors with carotid artery atherosclerosis. Early results of the Atherosclerosis Risk in Communities Study. *Ann Epidemiol*. 1992;2:471.
22. Tracy RP, Bovill EG, Yanez D, et al. Fibrinogen and factor VIII, but not factor VII are associated with measurements of subclinical cardiovascular disease in the elderly. Results from the Cardiovascular Health Study. *Arterioscler Thromb Vasc Biol*. 1995;15:1269.
23. Vossen CY, Conrad J, Fontcuberta J, et al. Familial thrombophilia and lifetime risk of venous thrombosis. *J Thromb Haemost*. 2004;2:1526.
24. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(Suppl 3):401S.
25. Hirsh J. Heparin. *N Engl J Med*. 1991;324:1565.
26. Wells PS, Blajchman MA, Henderson P, et al. Prevalence of antithrombin deficiency in healthy blood donors: a cross-sectional study. *Am J Hematol*. 1994;45:321.
27. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. *Br J Haematol*. 1994;87:106.
28. Ben-Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. *Thromb Haemost*. 1989;61:50.
29. Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected

- patients with venous thromboembolism. Results of the Spanish Multicentric Study on Thrombophilia (EMET-study). *Thromb Haemost.* 1997;77:444.
30. Cosgriff TM, Bishop DT, Hershgold EJ, et al. Familial antithrombin III deficiency: its natural history, genetics, diagnosis, and treatment. *Medicine (Baltimore)*. 1983;62:209.
  31. Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. *Thromb Haemost.* 1997;77:197.
  32. Bauters A, Zawadzki C, Bura A, et al. Homozygous variant of antithrombin with lack of affinity for heparin: management of severe thrombotic complications associated with intrauterine demise. *Blood Coagul Fibrinolysis*. 1996;7:705.
  33. Winter JH, Fenech A. Familial antithrombin III deficiency. *QJM*. 1982;51:373.
  34. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin deficiency: review of 404 cases [letter]. *Thromb Haemost.* 1987;58:1094.
  35. DeStefano V, Leone G. Mortality related to thrombosis in congenital antithrombin III deficiency. *Lancet*. 1991;337:847.
  36. Wilson C, Walker ID, Davidson JF, et al. Mesenteric venous thrombosis and antithrombin III deficiency. *J Clin Pathol*. 1987;40:906.
  37. Tuite P, Ahmad F, Grant I, et al. Cerebral vein thrombosis due to antithrombin III deficiency. *Can J Neurol Sci*. 1993;20:158.
  38. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. *Gynecol Obstet Invest*. 1982;14:127.
  39. Blondel-Hill E, Mant MJ. The pregnancy antithrombin III deficient patient: management without antithrombin III concentrate. *Thromb Res*. 1992;65:193.
  40. Schwartz RS, Bauer KA, Rosenberg RD, et al. Antithrombin III Study Group. Clinical experience with antithrombin III concentrate in the treatment of congenital acquired deficiency of antithrombin. *Am J Med*. 1989;87:53S.
  41. Liebman HA, McGehee WG, Patch MJ, et al. Severe depression of antithrombin III associated with disseminated intravascular coagulation of women with fatty liver of pregnancy. *Ann Intern Med*. 1983;98:330.
  42. Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. *J Clin Invest*. 1981;68:1370.
  43. Dahlback B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. *Thromb Res*. 1995;77:1.
  44. Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. *Thromb Haemost.* 1995;73:87.
  45. Pabinger I, Brucker S, Kyrle PA, et al. Hereditary deficiency of antithrombin III, protein C, and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. *Blood Coagul Fibrinolysis*. 1992;3:547.
  46. Reitsma PH, Bernardi F, Doig RG, et al. Protein C deficiency: a database of mutations 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. *Thromb Haemost.* 1995;73:876.
  47. Boekholdt SM, Kramer MHH. Arterial thrombosis and the role of thrombophilia. *Semin Thromb Hemost*. 2007;33:588.
  48. Estrelles A, Garcia Plaza I, Dasi A, et al. Severe "homozygous" protein C deficiency in a newborn infant. *Thromb Haemost.* 1984;52:53.
  49. McGehee WG, Klotz TA, Epstein DJ, et al. Coumadin necrosis associated with hereditary protein C deficiency. *Ann Intern Med*. 1984;101:59.
  50. Broekman AW, Bertina RM, Loeliger EA, et al. Protein C and the development of skin necrosis during anticoagulant therapy. *Thromb Haemost.* 1983;49:251.
  51. Borgel D, Gandrille S, Aiach M. Protein S deficiency. *Thromb Haemost.* 1997;78:351.

52. Comp PC, Nixon RR, Cooper MR, et al. Familial protein S deficiency is associated with recurrent thrombosis. *J Clin Invest.* 1984;74:2082.
53. Schwartz HP, Fischer M, Hopmeier P, et al. Plasma protein S deficiency in familial thrombotic disease. *Blood.* 1984;64:1297.
54. Comp PC. Laboratory evaluation of protein S status. *Semin Thromb Hemost.* 1990;16:177.
55. Faught W, Garner P, Jones G, et al. Changes in protein C and protein S levels in normal pregnancy. *Am J Obstet Gynecol.* 1995;172:147.
56. Comp PC, Thurnau GR, Welsh J, et al. Functional and immunologic protein S levels are decreased during pregnancy. *Blood.* 1986;68:881.
57. Kemkes-Matthes B. Acquired protein S deficiency. *Clin Invest Med.* 1992;70:529.
58. Vigano-D'Angelo S, D'Angelo A, Kaufman DE Jr, et al. Protein S deficiency occurs in the nephrotic syndrome. *Ann Intern Med.* 1987;107:42.
59. Levine AM, Vigen C, Gravink J, et al. Advancing prothrombotic state in women with advancing HIV disease. *J Acquir Immune Defic Syndr.* 2006;42:572.
60. Clark DA, Williams WL, Marlar RA. Mesenteric vein thrombosis associated with familial deficiency of free protein S. *Arch Pathol Lab Med.* 1991;115:617.
61. Sas G, Blasko G, Petro I, et al. A protein S deficient family with portal vein thrombosis. *Thromb Haemost.* 1985;54:724.
62. Vrethem M, Dahle C, Lindahl T, et al. Association between deficiency of free protein S and anticardiolipin antibodies in patients < 65 years of age with ischemic stroke and TIA. *Eur J Neurol.* 1998;5:491.
63. Anderson DR, Brill-Edwards P, Walker I. Warfarin induced skin necrosis in 2 patients with protein S deficiency: successful reinstatement of warfarin therapy. *Haemostasis.* 1992;22:124.
64. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism due to poor anticoagulant response to activated protein: prediction of a cofactor to activated protein C. *Proc Natl Acad Science U S A.* 1993;90:1004.
65. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature.* 1994;369:64.
66. Dahlback B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. *Proc Natl Acad Sci U S A.* 1994;91:1396.
67. Lee DH, Henderson PA, Blajchman MA. Prevalence of factor V Leiden in a Canadian blood donor population. *CMAJ.* 1996;155:285.
68. Rees DC. The population genetics of factor V Leiden (Arg506Gln). *Br J Haematol.* 1996;95:579.
69. Ridiker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. *JAMA.* 1997;277:1305.
70. Dulicek P, Maly J, Safarova M. Risk of thrombosis in patients homozygous for and heterozygous for factor V Leiden in the East Bohemian region. *Clin Appl Thromb Hemost.* 2000;6:87.
71. Simioni P, Prandoni P, Lensing AW, et al. The risk of venous thromboembolism in patients with an Arg506Gln mutation in the gene for factor V (factor V Leiden). *N Engl J Med.* 1997;336:399.
72. Price DT, Ridker PM. Factor V Leiden and the risk for thromboembolic disease: a clinical perspective. *Ann Intern Med.* 1997;127:895.
73. Vossen CY, Conard J, Fontcuberta J, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). *J Thromb Haemost.* 2005;3:459.
74. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. 1999;130:643.
75. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden.

*Blood*. 1995;85:1504.

76. Williamson D, Brown K, Luddington R, et al. Factor V Cambridge: a new mutation (Arg306Thr) associated with resistance to activated protein C. *Blood*. 1998;91:1140.
77. Zuber M, Toulon P, Marnet L, et al. Factor V Leiden in cerebral venous thrombosis. *Stroke*. 1996;27:1721.
78. Ma AD, Abrams CS. Activated protein C resistance and retinal vein occlusion. *Retina*. 1998;18:297.
79. Hirsch DR, Mikkola KM, Marks PW, et al. Pulmonary embolism and deep vein thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. *Am Heart J*. 1996;131:1145.
80. Hellgren M, Svensson PI, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. *Am J Obstet Gynecol*. 1995;173:210.
81. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. *Lancet*. 1994;344:1453.
82. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. *Lancet*. 1995;346:1593.
83. Brill-Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. *N Engl J Med*. 2000;343:1439.
84. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low intensity warfarin therapy for the prevention of recurrent venous thromboembolism. *N Engl J Med*. 2003;348:1425.
85. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. *Blood*. 1996;88:3698.
86. Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk of venous thrombosis in carriers of the prothrombin G-A20210 gene variant. *Ann Intern Med*. 1998;129:89.
87. Leroyer C, Mercier B, Oger E, et al. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. *Thromb Haemost*. 1998;80:49.
88. Brown K, Luddington R, Williamson D, et al. Risk of venous thromboembolism associated with the G to A transition at position 20210 in the 3'-untranslated region of the prothrombin gene. *Br J Haematol*. 1997;98:907.
89. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. *Thromb Haemost*. 1998;79:706.
90. Franco RF, Trip MD, ten Cate H, et al. The 20210 G to A mutation in the 3'-untranslated region of the prothrombin gene in different human populations. *Acta Haematol*. 1998;100:9.
91. Zivelin A, Mor-Cohen R, Kovalsky V, et al. Prothrombin 20210G→A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years ago. *Blood*. 1998;92:1119.
92. Markis M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. *Thromb Haemost*. 1997;78:1426.
93. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. *Circulation*. 1999;99:999.
94. Martinelli I, Taioli E, Bucciarelli P, et al. Interaction between G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. *Arterioscler Thromb Vasc Biol*. 1999;19:700.
95. Ferraresi P, Marchetti G, Legnani C, et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. *Arterioscler Thromb Vasc Biol*. 1997;17:2418.
96. Rosendaal FR, Siscovick DS, Schwartz SM, et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. *Blood*. 1997;90:1747.
97. Lindmarker P, Schulman S, Sten-Linder M, et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene.

- DURAC Trial Study Group. Duration of anticoagulation. *Thromb Haemost.* 1999;81:684.
98. Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. *N Engl J Med.* 1998;338:1793.
  99. Koster T, Blann AD, Briet E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. *Lancet.* 1995;345:152.
  100. O'Donnell JO, Tuddenham EGD, Manning R, et al. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to acute phase reaction. *Thromb Haemost.* 1997;77:825.
  101. Kamphusien PW, Eikenboom JCJ, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. *Arterioscler Thromb Vasc Biol.* 2001;21:731.
  102. Schambeck CM, Hinney K, Haubitz I, et al. Familial clustering of high factor VIII levels in patients with venous thromboembolism. *Arterioscler Thromb Vasc Biol.* 2001;21:289.
  103. Miller CH, Dilley A, Richardson L, et al. Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women. *Am J Hematol.* 2001;67:125.
  104. Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR, et al. Venous thrombosis, oral contraceptives and high factor VIII levels. *Thromb Haemost.* 1999;82:1024.
  105. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. *N Engl J Med.* 2000;343:457.
  106. van Hylckama Vlieg A, van der Linden IK, et al. High levels of factor IX increase the risk of venous thrombosis. *Blood.* 2000;95:3678.
  107. Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. *N Engl J Med.* 2000;342:696.
  108. Mansveld EPG, Laftan M, McVey JH, et al. Analysis of the F8 gene in individuals with high plasma factor VIII: C levels and associated venous thrombosis. *Thromb Haemost.* 1998;80:561.
  109. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. *Am J Pathol.* 1969;56:111.
  110. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocysteinuria due to cystathionine-beta-synthase deficiency. *Am J Hum Genet.* 1985;37:1.
  111. Arnesen E, Refsum H, Bonna KH, et al. Serum total homocysteine and coronary heart disease. *Int J Epidemiol.* 1995;24:704-709.
  112. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med.* 1997;337:230.
  113. Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. *Arch Intern Med.* 1998;158:862.
  114. Ridker PM, Manson JE, Buring JE, et al. Homocysteine and the risk of cardiovascular disease among postmenopausal women. *JAMA.* 1999;281:1817.
  115. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med.* 2000;342:836.
  116. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. *JAMA.* 1992;268:877.
  117. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation.* 1998;98:204.
  118. Falcon C, Cattaneo M, Panzeri D, et al. High incidence of hyperhomocysteinemia in juvenile venous thrombosis.

*Atheroscler Thromb.* 1994;14:1080.

119. Fermo I, Vigano D'Angelo V, Paroni R, et al. Prevalence of moderate hyperhomocysteinemia in patients with early onset venous and arterial occlusive disease. *Ann Intern Med.* 1995;123:747.
120. Simioni P, Prandoni P, Burlina A, et al. Hyperhomocysteinemia and deep-vein thrombosis: a case controlled study. *Thromb Haemost.* 1996;76:883.
121. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. *N Engl Med.* 1996;334:759.
122. den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. *Thromb Haemost.* 1998;80:874.
123. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. *Blood.* 1997;90:1.
124. Bezemer ID, Doggen CJM, Vos HL, et al. No association between the common MTHFR 677 C to T polymorphism and venous thrombosis. Results from the MEGA study. *Arch Intern Med.* 2007;167:497.
125. Angles-Cano E, de La Diaz A, Loyau S. Inhibition of fibrinolysis by lipoprotein (a). *Ann N Y Acad Sci.* 2001;931:261.
126. Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. *Arterioscler Thromb Vasc Biol.* 2006;26:2567.
127. Howard BV, Le NA, Beicher JD, et al. Concentrations of Lp(a) in black and white young adults: relations to risk factors for cardiovascular disease. *Ann Epidemiol.* 1994;4:341.
128. Slunga L, Johnson O, Dahlen GH, et al. Lipoprotein (a) and acute-phase proteins in myocardial infarction. *Scand J Clin Lab Invest.* 1992;52:95.
129. Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. *J Am Coll Cardiol.* 1993;22:933.
130. Balik O, Gur G, Lenk N, et al. Serum lipoprotein (a) levels and Behçet's disease: is there an association? *Int J Dermatol.* 2007;46:827.
131. Rhoads GG, Dahlen G, Berg K, et al. Lp(a) lipoprotein as a risk factor for myocardial infarction. *JAMA.* 1986;256:2540.
132. Kostner GM, Avogaro P, Cazzolato G, et al. Lipoprotein Lp(a) and the risk for myocardial infarction. *Atherosclerosis.* 1981;38:51.
133. Sandkamp M, Funke H, Schulte H, et al. Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. *Clin Chem.* 1990;36:20.
134. Rosengren A, Wilhelmsen L, Eriksson E, et al. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. *BMJ.* 1990;301:1248.
135. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. *Atherosclerosis.* 1991;89:59.
136. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischaemic heart disease: implications for screening. *Lancet.* 1994;343:75.
137. Schaefer EJ, Lamou-Fava S, Jenner JL, et al. Lipoprotein (a) levels and the risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. *JAMA.* 1994;271:999.
138. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL, cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study. *Eur J Clin Invest.* 1994;24:444.
139. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein (a) and the risk of myocardial infarction. *JAMA.* 1993;270:2195.
140. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein (a) and the risk of future stroke. *JAMA.* 1995;273:1269.
141. Marcucci R, Liotta AA, Cellai AP, et al. Increased plasma levels of lipoprotein (a) and the risk of idiopathic and recurrent venous thromboembolism. *Am J Med.* 2003;115:601.

142. Ignatescu M, Kostner K, Zorn G, et al. Plasma Lp (a) levels are increased in patients with chronic thromboembolic pulmonary hypertension. *Thromb Haemost.* 1998;80:231.
143. Vormittag R, Vukovich T, Stain M, et al. Lipoprotein (a) in patients with spontaneous venous thromboembolism. *Thromb Res.* 2007;120:15.
144. Mammen EF, Barnhart MI, Selik NR, et al. "Sticky platelet syndrome": a congenital platelet abnormality predisposing to thrombosis. *Folia Haematologica.* 1988;115:361.
145. Mammen EF. Ten years experience with the "sticky platelet syndrome." *Clin Appl Thromb Hemost.* 1995;1:66.
146. Frenkel EP, Mammen EF. Sticky platelet syndrome and thrombocythemia. *Hematol Oncol Clin North Am.* 2003;17:63.
147. Kubisz P, Ivankov J, Holly P, et al. The glycoprotein IIIa PL(A1/A2) polymorphism—a defect responsible for the sticky platelet syndrome? *Clin Appl Thromb Hemost.* 2006;12:117.
148. Fateh-Moghadam S, Htun P, Tomandl B, et al. Hyperresponsiveness of platelets in ischemic stroke. *Thromb Haemost.* 2007;97:974.
149. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid antibody syndrome: a systematic review of the literature. *Blood.* 2003;101:1827.
150. Lim W, Crowther MA. Antiphospholipid antibodies: a critical review of the literature. *Curr Opin Hematol.* 2007;14:494.
151. Sutherland DE, Weitz I, Liebman HA. Thromboembolic complications of cancer. Epidemiology, pathogenesis, diagnosis and treatment. *Am J Hematol.* 2003;73:43.
152. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. *JAMA.* 2005;293:715.
153. Geerts WH, Pineao GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126(Suppl 3):338S.
154. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment and prevention. *Chest.* 2004;126:311S.
155. Liebman HA, Kashani N, Sutherland D, et al. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. *Gastroenterology.* 1998;115:830.
156. Sakane T, Takeno M, Suzuki N, et al. Behçet's disease. *N Engl J Med.* 1999;341:1284.
157. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1000 patients. *Medicine (Baltimore).* 1999;78:167.
158. Long AA, Ginsberg JS, Brill-Edwards P, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. *Thromb Haemost.* 1991;66:520.
159. Silberberg JM, Gordon S, Zucker S. Identification of tissue factor in two human pancreatic tumor cell lines. *Cancer Res.* 1989;49:5443.
160. Rao LV. Tissue factor as a tumor procoagulant. *Cancer Metastasis Rev.* 1992;11:249.
161. Weidmer T, Hall SE, Ortel TL, et al. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. *Blood.* 1993;91:1192.
162. Liebman HA, Feinstein DI. Thrombosis in patients with paroxysmal nocturnal hemoglobinuria is associated with markedly elevated plasma levels of leukocyte tissue factor. *Thromb Res.* 2003;111:235.
163. Gruppo Italiano Studie Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studie Policitemia. *Ann Intern Med.* 1995;123:656.
164. Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in historical cohort of 100 patients with essential thrombocythemia. *J Clin Oncol.* 1990;8:556.
165. Hexner EO. JAK2 V617F: implications for thrombosis in myeloproliferative diseases. *Curr Opin Hematol.* 2007;14:450.
166. DeStefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. *J Thromb Haemost.* 2007;5:708.



167. Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. *Am J Med.* 1994;96:3.
168. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost.* 2006;4:295.
169. de Groot PG, Lutters B, Derksen RH, et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. *J Thromb Haemost.* 2005;3:1993.
170. Giannakopoulos B, Passam F, Rahgozar S, et al. Current concepts on the pathogenesis of the antiphospholipid syndrome. *Blood.* 2007;109:422.
171. Zhou H, Wolberg AS, Roubey RA. Characterization of monocytes tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. *Blood.* 2004;104:2352.
172. Dignat-George F, Camoin-Jau L, Sabatier F, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. *Thromb Haemost.* 2004;91:667.
173. Meroni P, Del Papa N, Raschi E, et al. Beta-2-glycoprotein I as a “cofactor” for anti-phospholipid reactivity with endothelial cells. *Lupus.* 1998;7(Suppl 2):S44.
174. Pierangeli SS, Girardi G, Vega-Ostertag M, et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. *Arthritis Rheum.* 2005;52:2120.
175. Turiel M, Sarzi-Puttini P, Peretti R, et al. Thrombotic risk factors in primary antiphospholipid syndrome. A 5-year prospective study. *Stroke.* 2005;36:1490.
176. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. *Ann Intern Med.* 1992;117:303.
177. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid antibody syndrome. *N Engl J Med.* 1995;332:993.
178. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for the first episode of idiopathic venous thromboembolism. *N Engl J Med.* 2003;349:631.
179. Schulman S, Svenungsson E, Granqvist S, Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. *Am J Med.* 1998;104:332.
180. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. *N Engl J Med.* 2003;349:1133.
181. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. *J Thromb Haemost.* 2005;3:848.
182. Cervera R, Bucciarella S, Espinosa G, et al. Catastrophic antiphospholipid syndrome: lessons from the “CAPS” registry. A tribute to the late Josep Font. *Ann N Y Acad Sci.* 2007;1108:448.
183. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. *Acta Haematol.* 2001;106:6.
184. Taubman MB. Tissue factor in cancer angiogenesis and coagulopathy. In: Khorana AA, Francis CW, eds. *Cancer-Associated Thrombosis.* New York, NY: Informa Healthcare; 2007:35-50.
185. Weitz I, Liebman HA. Chemotherapy-induced hemostatic activation and thrombosis in cancer. In: Khorana AA, Francis CW, eds. *Cancer-Associated Thrombosis.* New York, NY: Informa Healthcare; 2007:65-76.
186. Trousseau A. Phlegmasia alba dolen. In: *Clinique Médicale de l'Hôtel-Dieu de Paris.* Paris: JB Bailliere; 1865:654.
187. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. *Arch Intern Med.* 2000;160:809.
188. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. *Medicine (Baltimore).*

1999;78:285.

189. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors. Determination of frequency and characteristics. *Thromb Haemost.* 2002;87:575.
190. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. *Chest.* 1995;108:978.
191. O'Connell C, Boswell WD, Caton A, et al. Unsuspected pulmonary emboli in cancer patients: clinical correlates and significance. *J Clin Oncol.* 2006;24:4928.
192. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. *J Clin Oncol.* 2000;18:3078.
193. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. *Blood.* 2002;100:3484.
194. Lee AYY, Julian JA, Levine MN, et al. Long-term treatment with dalteparin low-molecular weight heparin (LMWH) may improve survival in patients with non-metastatic malignancy and venous thromboembolism. *J Clin Oncol.* 2005;23:2123.
195. Hull RD, Pineo GF, Brant RF, et al. LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. *Am J Med.* 2006, 119:1062.
196. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. *J Clin Oncol.* 2007;25:5490.
197. Scappaticci F, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. *J Natl Cancer Inst.* 2007;99:1232.
198. Rosen P, Armstrong D. Nonbacterial thrombotic endocarditis in patients with malignant neoplastic diseases. *Am J Med.* 1973;54:23.
199. Edoute Y, Haim N, Rinkevich D, et al. Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients. *Am J Med.* 1997;102:252.
200. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. *Medicine (Baltimore).* 1985;64:16.
201. Bedikian A, Valdivieso M, Luna M, et al. Nonbacterial thrombotic endocarditis: comparison of characteristics of patients with and without concomitant disseminated intravascular coagulation. *Med Pediatr Oncol.* 1978;4:149.
202. Rogers LR, Cho E-S, Kempin S, et al. Cerebral infarction from non-bacterial thrombotic endocarditis. Clinical and pathological study including the effects of anticoagulation. *Am J Med.* 1987;83:746.
203. Martinelli I, De Stefano V, Taioli E, et al. Inherited thrombophilia and the first thromboembolism during pregnancy and the puerperium. *Thromb Haemost.* 2002;87:791.
204. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and puerperium. *N Engl J Med.* 2000;342:374.
205. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30 year population-based study. *Ann Intern Med.* 2005;143:697.
206. Eldor A. Thrombophilia, thrombosis and pregnancy. *Thromb Haemost.* 2001;86:104.
207. Andersen BS, Steffensen FH, Sorensen HT, et al. The cumulative incidence of venous thromboembolism during pregnancy and the puerperium. *Acta Obstet Gynecol Scand.* 1998;77:170.
208. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. *Lancet.* 1999;353:1258.
209. Andres RL, Miles A. Venous thromboembolism and pregnancy. *Obstet Gynecol Clin North Am.* 2001;28:613.
210. James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. *Am J Obstet Gynecol.* 2005;193:216.
211. Hull RD, Raskob GF, Carter CJ. Serial IPG in pregnant patients with clinically suspected DVT: clinical validity of negative findings. *Ann Intern Med.* 1990;112:663.

212. Ginsberg J, Brill-Edwards P, Burrows RF, et al. DVT during pregnancy: leg and trimester presentation. *Thromb Haemost.* 1992;67:519.
213. Cockett FB, Thomas ML, Negus D. Iliac vein compression: its relation to iliofemoral thrombosis and the post-thrombotic syndrome. *BMJ.* 1967;2:14.
214. Inman WHW, Vessey MP, Westerholm B, et al. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the committee on safety of drugs. *BMJ.* 1970;2:203.
215. Meirik O. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: effect of different progestogens in low oestrogen oral contraceptive on venous thromboembolic disease. *Lancet.* 1995;346:1582.
216. Poulter NR. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. *Lancet.* 1995;346:1575.
217. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. *Arterioscler Thromb Vasc.* 2002;22:201.
218. Lewis MA. Myocardial infarction and stroke in young women: what is the impact of oral contraceptive? *Am J Obstet Gynecol.* 1996;179:S66.
219. Schwartz SM, Siscovick DS, Longstreth WT, et al. Use of low-dose oral contraceptives and stroke in young women. *Ann Intern Med.* 1997;127:596.
220. Petiti DB, Sidney S, Bernstein A, et al. Stroke in users of low-dose oral contraceptives. *N Engl J Med.* 1996;335:8.
221. Heinemann LA, Lewis MA, Thorogood M, et al. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from international study on oral contraceptives and health of young women. *BMJ.* 1997;315:1502.
222. Hannaford P. Health consequences of oral combination contraceptives. *Br Med Bull.* 2000;56:749.
223. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. *Thromb Haemost.* 2001;86:112.
224. WHO. Effect of different progestogens in low oestrogen contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. *Lancet.* 1995;346:1582.
225. Jick H, Jick S, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogens components. *Lancet.* 1995;346:1589.
226. Kemmeren J, Algra A, Grobbee D. Third generation oral contraceptives and the risk of venous thrombosis: meta-analysis. *BMJ.* 2001;323:131.
227. Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives and the risk of cerebral venous thrombosis: a meta-analysis. *Blood.* 2006;107:2766.
228. Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. *Hepatology.* 2005;41:603.
229. Pabinger I, Schneider B, GTH study group. Thrombotic risk of women with hereditary antithrombin III, protein C and protein S deficiency taking oral contraceptive medication. *Thromb Haemost.* 1994;71:548.
230. Van Vlijmen EFW, Brouwer JL, Veeger NJGM, et al. Oral contraceptives and absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. *Arch Intern Med.* 2007;167:282.
231. Martinelli I. Risk factors in venous thromboembolism. *Thromb Haemost.* 2001;86:395.
232. Daly E, Vessey M, Hawkins M, et al. Risk of venous thromboembolism in users of hormone replacement therapy. *Lancet.* 1996;348:977.
233. Jick H, Derby L, Myers M, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. *Lancet.* 1996;348:981.

234. Grady D, Wenger N, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/Progestin Replacement Study. *Ann Intern Med.* 2000;132:689.
235. Herrington D, Reboussin D, Broshnihan B. Effect of estrogen replacement on the progression of coronary-artery atherosclerosis. *N Engl J Med.* 2000;343:522.
236. Lowe G. Hormone replacement therapy and cardiovascular disease: increased risk of venous thromboembolism and stroke, and no protection from coronary heart disease. *J Intern Med.* 2004;256:361.
237. Miller J, Chan B, Nelson H. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force. *Ann Intern Med.* 2002;136:680.
238. Herrington D, Vittinghoff E, Howard R, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thrombosis. *Arterioscler Thromb Vasc Biol.* 2002;22:1012.
239. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER Study. *Circulation.* 2007;115:840.
240. Straczek C, Oger E, Yon de Jonage-Canonico M, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of route of estrogen administration. *Circulation.* 2005;112:3495.
241. Kelton JG. The pathophysiology of heparin-induced thrombocytopenia. Biological basis for treatment. *Chest.* 2005;127:9S.
242. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. *Chest.* 2005;127:35S.
243. Warkentin TE, Kelton JG. A 14 year study of heparin-induced thrombocytopenia. *Am J Med.* 1996;101:502.
244. Nand S, Wong W, Yuen B, et al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. *Am J Hematol.* 1998;56:12.
245. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. *Am J Med.* 1999;106:629.
246. Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. *AMA Arch Surg.* 1958;76:219.
247. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. *Surg Gynecol Obstet.* 1973;136:409.
248. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. *Thromb Haemost.* 1992;68:95.
249. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. *Blood.* 1994;83:3232.
250. Horsewood P, Warkentin TE, Hayward CP, et al. The epitope specificity of heparin-induced thrombocytopenia. *Br J Haematol.* 1996;95:161.
251. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. *Blood.* 1988;72:925.
252. Nieswandt B, Bergmeier W, Schulte V, et al. Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcR-gamma chain. *J Biol Chem.* 2000;275:23998.
253. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. *Blood.* 1994;84:3691.
254. Furie B, Furie BC. P-selectin induction of tissue factor biosynthesis. *Haemostasis.* 1996;26(Suppl 1):60.
255. Pouplard C, Iochmann S, Renard B, et al. Induction of monocytes tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. *Blood.* 2001;97:3300.
256. Liebman HA, Weitz IC. Disseminated intravascular coagulation. In: Hoffman R, Benz EJ, Shattil SJ, et al., eds. *Hematology: Basic Principles and Practice.* 4th ed. New York, NY: McGraw-Hill; 2004:2169-2182.
257. Jackson MR, Gillespie DL, Chang AS, et al. The incidence of heparin-induced antibodies in patients undergoing vascular surgery: A prospective study. *J Vasc Surg.* 1998;28:439.
258. Klein HG, Bell WR. Disseminated intravascular coagulation during heparin therapy. *Ann Intern Med.* 1974;80:477.

259. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. *Semin Hematol*. 1998;35(4 Suppl 5):9.
260. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. *Thromb Res*. 2003;110:73.
261. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. *N Engl J Med*. 2001;344:1286.
262. Hong AP, Cook DJ, Sigouin CS, et al. Central venous catheters and upper extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. *Blood*. 2003;101:3049.
263. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. *Blood*. 2003;101:2955.
264. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. *Arch Intern Med*. 2003;163:2514.
265. Lindhoff-Last E, Eichler P, Stein M, et al. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. *Thromb Res*. 2000;97:387.
266. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Recommendations of the College of American Pathologists. *Arch Pathol Lab Med*. 2002;126:1415.
267. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. *Heparin-Induced Thrombocytopenia*. 3rd ed. New York, NY: Marcel Dekker; 2004:107-148.
268. Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. *Ann Intern Med*. 1997;127:804.
269. Lubenow N, Kempf R, Eichner A, et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. *Chest*. 2002;122:37.

## 第 38 章

1. Hertzner NR, Beven EG, Young JR, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. *Ann Surg*. 1984;199:223-233.
2. Boersma E, Poldermans D, Bax JJ, et al. Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. *JAMA*. 2001;285:1865-1873.
3. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. *J Am Coll Cardiol*. 2007;50:2173-2195.
4. Devereaux PJ, Goldman L, Yusuf S, et al. Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review. *CMAJ*. 2005;173:779-788.
5. Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. *Circulation*. 2000;102:1216-1220.
6. Jaffe AS. Chasing troponin: How low can you go if you can see the rise? *J Am Coll Cardiol*. 2006;48:1763-1764.
7. Apple FS, Jesse RL, Newby LK, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. *Circulation*. 2007;115:e352-e355.
8. Macrae AR, Kavsak PA, Lustig V, et al. Assessing the requirement for the 6-hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. *Clin Chem*. 2006;52:812-818.
9. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. *Circulation*. 2007;115:e356-e375.
10. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. *Circulation*. 2007;116:2634-2653.
11. Sgarbossa EB, Pinski SL, Barbagelata A, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-I (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. *N Engl J Med*. 1996;334:481-487.

12. Wong CK, French JK, Aylward PE, et al. Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. *J Am Coll Cardiol.* 2005;46:29-38.
13. Landesberg G, Shatz V, Akopnik I, et al. Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. *J Am Coll Cardiol.* 2003;42:1547-1554.
14. Welten GM, Schouten O, Hoeks SE, et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. *J Am Coll Cardiol.* 2008;51:1588-1596.
15. Hoeks SE, Scholte Op Reimer WJ, van Urk H, et al. Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients. *Eur J Vasc Endovasc Surg.* 2007;33:13-19.
16. Krupski WC. Update on perioperative evaluation and management of cardiac disease in vascular surgery patients. *J Vasc Surg.* 2002;36:1292-1308.
17. Greenstein AJ, Chassin MR, Wang J, et al. Association between minor and major surgical complications after carotid endarterectomy: results of the New York Carotid Artery Surgery study. *J Vasc Surg.* 2007;46:1138-1144; discussion 1145-1146.
18. Stoner MC, Abbott WM, Wong DR, et al. Defining the high-risk patient for carotid endarterectomy: an analysis of the prospective National Surgical Quality Improvement Program database. *J Vasc Surg.* 2006;43:285-295; discussion 295-296.
19. Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. *N Engl J Med.* 2004;351:1493-1501.
20. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. *Lancet.* 2001;357:1729-1737.
21. Ringleb PA, Allenberg J, Bruckmann H, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. *Lancet.* 2006;368:1239-1247.
22. Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. *N Engl J Med.* 2006;355:1660-1671.
23. Ederle J, Featherstone RL, Brown MM. Percutaneous transluminal angioplasty and stenting for carotid artery stenosis. *Cochrane Database Syst Rev.* 4:CD000515, 2007.
24. Prinssen M, Verhoeven EL, Buth J, et al. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. *N Engl J Med.* 2004;351:1607-1618.
25. Drury D, Michaels JA, Jones L, et al. Systematic review of recent evidence for the safety and efficacy of elective endovascular repair in the management of infrarenal abdominal aortic aneurysm. *Br J Surg.* 2005;92:937-946.
26. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. *Lancet.* 2005;365:2179-2186.
27. Schermerhorn ML, O'Malley AJ, Jhaveri A, et al. Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population. *N Engl J Med.* 2008;358:464-474.
28. Buffon A, Biasucci LM, Liuzzo G, et al. Widespread coronary inflammation in unstable angina. *N Engl J Med.* 2002;347:5-12.
29. Mangano DT. Perioperative cardiac morbidity. *Anesthesiology.* 1990;72:153-184.
30. Mangano DT, Browner WS, Hollenberg M, et al. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. *N Engl J Med.* 1990;323:1781-1788.
31. Landesberg G, Luria MH, Cotev S, et al. Importance of long-duration postoperative ST-segment depression in cardiac morbidity after vascular surgery. *Lancet.* 1993;341:715-719.
32. Fleisher LA, Nelson AH, Rosenbaum SH. Postoperative myocardial ischemia: etiology of cardiac morbidity or manifestation of underlying disease? *J Clin Anesth.* 1995;7:97-102.

33. Landesberg G, Mosseri M, Shatz V, et al. Cardiac troponin after major vascular surgery: the role of perioperative ischemia, preoperative thallium scanning, and coronary revascularization. *J Am Coll Cardiol*. 2004;44:569-575.
34. London MJ, Hollenberg M, Wong MG, et al. Intraoperative myocardial ischemia: localization by continuous 12-lead electrocardiography. *Anesthesiology*. 1988;69:232-241.
35. Dawood MM, Gutpa DK, Southern J, et al. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. *Int J Cardiol*. 1996;57:37-44.
36. Cohen MC, Aretz TH. Histological analysis of coronary artery lesions in fatal postoperative myocardial infarction. *Cardiovasc Pathol*. 1999;8:133-139.
37. Feringa HH, Bax JJ, Boersma E, et al. High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients. *Circulation*. 2006;114(1 Suppl):I344-I349.
38. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. *N Engl J Med*. 1977;297:845-850.
39. Detsky AS, Abrams HB, McLaughlin JR, et al. Predicting cardiac complications in patients undergoing non-cardiac surgery. *J Gen Intern Med*. 1986;1:211-219.
40. Samy AK, Murray G, MacBain G. Glasgow aneurysm score. *Cardiovasc Surg*. 1994;2:41-44.
41. Klomp HM, Spincemille GH, Steyerberg EW, et al. Design issues of a randomised controlled clinical trial on spinal cord stimulation in critical limb ischaemia. ESES Study Group. *Eur J Vasc Endovasc Surg*. 1995;10:478-485.
42. L'Italien GJ, Paul SD, Hendel RC, et al. Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates. *J Am Coll Cardiol*. 1996;27:779-786.
43. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation*. 1999;100:1043-1049.
44. Kertai MD, Boersma E, Klein J, et al. Optimizing the prediction of perioperative mortality in vascular surgery by using a customized probability model. *Arch Intern Med*. 2005;165:898-904.
45. Dernellis J, Panaretou M. Assessment of cardiac risk before non-cardiac surgery: brain natriuretic peptide in 1590 patients. *Heart*. 2006;92:1645-1650.
46. Feringa HH, Bax JJ, Elhendy A, et al. Association of plasma N-terminal pro-B-type natriuretic peptide with postoperative cardiac events in patients undergoing surgery for abdominal aortic aneurysm or leg bypass. *Am J Cardiol*. 2006;98:111-115.
47. Gibson SC, Payne CJ, Byrne DS, et al. B-type natriuretic peptide predicts cardiac morbidity and mortality after major surgery. *Br J Surg*. 2007;94:903-909.
48. Weiss JS, Sumpio BE. Review of prevalence and outcome of vascular disease in patients with diabetes mellitus. *Eur J Vasc Endovasc Surg*. 2006;31:143-150.
49. O'Sullivan CJ, Hynes N, Mahendran B, et al. Haemoglobin A1c (HbA1C) in non-diabetic and diabetic vascular patients. Is HbA1C an independent risk factor and predictor of adverse outcome? *Eur J Vasc Endovasc Surg*. 2006;32:188-197.
50. Schreiner F, Bax JJ, Feringa HH, et al. Poor glycaemic control in diabetic patients prior to major vascular surgery is associated with an increased mortality. *Circulation*. 2005;112:II-828.
51. Noordzij PG, Boersma E, Schreiner F, et al. Increased preoperative glucose levels are associated with perioperative mortality in patients undergoing noncardiac, nonvascular surgery. *Eur J Endocrinol*. 2007;156:137-142.
52. Sarveswaran J, Ikponmwosa A, Asthana S, et al. Should cardiac troponins be used as a risk stratification tool for patients with chronic critical limb ischaemia? *Eur J Vasc Endovasc Surg*. 2007;33:703-707.
53. Kertai MD, Boersma E, Klein J, et al. Long-term prognostic value of asymptomatic cardiac troponin T elevations in patients after major vascular surgery. *Eur J Vasc Endovasc Surg*. 2004;28:59-66.
54. Kertai MD, Boersma E, Bax JJ, et al. Comparison between serum creatinine and creatinine clearance for the prediction of postoperative mortality in patients undergoing major vascular surgery. *Clin Nephrol*. 2003;59:17-23.

55. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *J Am Coll Cardiol*. 2007;50:1707-1732.
56. Poldermans D, Bax JJ, Schouten O, et al. Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control? *J Am Coll Cardiol*. 2006;48:964-969.
57. Noordzij PG, Boersma E, Bax JJ, et al. Prognostic value of routine preoperative electrocardiography in patients undergoing noncardiac surgery. *Am J Cardiol*. 2006;97:1103-1106.
58. Jeger RV, Probst C, Arsenic R, et al. Long-term prognostic value of the preoperative 12-lead electrocardiogram before major noncardiac surgery in coronary artery disease. *Am Heart J*. 2006;151:508-513.
59. Raby KE, Goldman L, Creager MA, et al. Correlation between preoperative ischemia and major cardiac events after peripheral vascular surgery. *N Engl J Med*. 1989;321:1296-1300.
60. Kertai MD, Boersma E, Bax JJ, et al. A meta-analysis comparing the prognostic accuracy of six diagnostic tests for predicting perioperative cardiac risk in patients undergoing major vascular surgery. *Heart*. 2003;89:1327-1334.
61. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). *J Am Coll Cardiol*. 2002;40:1531-1540.
62. Pellicka PA, Nagueh SF, Elhendy AA, et al. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. *J Am Soc Echocardiogr*. 2007;20:1021-1041.
63. Vlassak I, Rubin DN, Odabashian JA, et al. Contrast and harmonic imaging improves accuracy and efficiency of novice readers for dobutamine stress echocardiography. *Echocardiography*. 2002;19:483-488.
64. Poldermans D, Arnesen M, Fioretti PM, et al. Improved cardiac risk stratification in major vascular surgery with dobutamine-atropine stress echocardiography. *J Am Coll Cardiol*. 1995;26:648-653.
65. Sicari R, Ripoli A, Picano E, et al. Perioperative prognostic value of dipyridamole echocardiography in vascular surgery: a large-scale multicenter study in 509 patients. EPIC (Echo Persantine International Cooperative) Study Group. *Circulation*. 1999;100(19 Suppl):II269-II274.
66. Beattie WS, Abdelnaem E, Wijesundera DN, et al. A meta-analytic comparison of preoperative stress echocardiography and nuclear scintigraphy imaging. *Anesth Analg*. 2006;102:8-16.
67. Etchells E, Meade M, Tomlinson G, et al. Semiquantitative dipyridamole myocardial stress perfusion imaging for cardiac risk assessment before noncardiac vascular surgery: a meta-analysis. *J Vasc Surg*. 2002;36:534-540.
68. Eagle KA, Rihal CS, Mickel MC, et al. Cardiac risk of noncardiac surgery: Influence of coronary disease and type of surgery in 3368 operations. CASS Investigators and University of Michigan Heart Care Program. Coronary Artery Surgery Study. *Circulation*. 1997;96:1882-1887.
69. Hassan SA, Hlatky MA, Boothroyd DB, et al. Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Med*. 2001;110:260-266.
70. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. *N Engl J Med*. 2004;351:2795-2804.
71. Poldermans D, Schouten O, Vidakovic R, et al. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. *J Am Coll Cardiol*. 2007;49:1763-1769.



72. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. *N Engl J Med*. 1996;335:1713-1720.
73. Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. *Anesthesiology*. 1998;88:7-17.
74. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. *N Engl J Med*. 1999;341:1789-1794.
75. Brady AR, Gibbs JS, Greenhalgh RM, et al. Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial. *J Vasc Surg*. 2005;41:602-609.
76. Juul AB, Wetterslev J, Gluud C, et al. DIPOM Trial Group. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. *BMJ*. 2006;332:1482.
77. POISE Study Group, Devereaux PJ, Yang H, Yusuf S, et al. POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE Trial) in a randomized controlled trial. *Lancet* 371:1839-1847, 2008.
78. Raby KE, Brull SJ, Timimi F, et al. The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. *Anesth Analg*. 1999;88:477-482.
79. Maling TJ, Dollery CT. Changes in blood pressure, heart rate, and plasma noradrenaline concentration after sudden withdrawal of propranolol. *Br Med J*. 1979;2:366-367.
80. Redelmeier D, Scales D, Kopp A. Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study. *BMJ*. 2005;331:932.
81. Schouten O, Bax JJ, Dunkelgrun M, et al. Statins for the prevention of perioperative cardiovascular complications in vascular surgery. *J Vasc Surg*. 2006;44:419-424.
82. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. *Circulation*. 2003;107:1848-1851.
83. Kertai MD, Boersma E, Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. *Eur J Vasc Endovasc Surg*. 2004;28:343-352.
84. Lindenauer PK, Pekow P, Wang K, et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. *JAMA*. 2004;291:2092-2099.
85. O'Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. *J Am Coll Cardiol*. 2005;45:336-342.
86. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. *J Vasc Surg*. 2004;39:967-975; discussion 975-976.
87. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. *JAMA*. 2003;289:1681-1690.
88. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. *J Am Coll Cardiol*. 2002;40:567-572.
89. Schouten O, Kertai MD, Bax JJ, et al. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. *Am J Cardiol*. 2005;95:658-660.
90. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. *Clin Pharmacokinet*. 2004;43:963-981.
91. Burger W, Chemnitz JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation—review and meta-analysis. *J Intern Med*. 2005;257:399-414.

92. Schouten O, Van Domburg RT, Bax JJ, et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. *J Am Coll Cardiol.* 2007;49:122-124.
93. Ward HB, Kelly RF, Thottapurathu L, et al. Coronary artery bypass grafting is superior to percutaneous coronary intervention in prevention of perioperative myocardial infarctions during subsequent vascular surgery. *Ann Thorac Surg.* 2006;82:795-800; discussion 800-801.
94. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. *Eur Heart J.* 2007;28:1598-1660.
95. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J.* 2003;24:28-66.
96. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2008;51:210-247.
97. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *J Am Coll Cardiol.* 2007;50:e1-e157.
98. Sprung J, Abdelmalak B, Gottlieb A, et al. Analysis of risk factors for myocardial infarction and cardiac mortality after major vascular surgery. *Anesthesiology.* 2000;93:129-140.
99. Badner NH, Knill RL, Brown JE, et al. Myocardial infarction after noncardiac surgery. *Anesthesiology.* 1998;88:572-578.
100. Yeager RA, Moneta GL, Edwards JM, et al. Late survival after perioperative myocardial infarction complicating vascular surgery. *J Vasc Surg.* 1994;20:598-604; discussion 604-606.
101. Madras PN, Ward CA, Johnson WR, et al. Anastomotic hyperplasia. *Surgery.* 1981;90:922-923.
102. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Executive summary. A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *J Am Coll Cardiol.* 2006;47:1239-1312.
103. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S5-S67.

## 第 39 章

1. Lawrence VA, Hilsenbeck SG, Mulrow CD, et al. Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. *J Gen Intern Med.* 1995;10:671-678.
2. Pronovost PJ, Dang D, Dorman T, et al. Intensive care unit nurse staffing and the risk for complications after abdominal aortic surgery. *Eff Clin Pract.* 2001;4:199-206.
3. Pronovost PJ, Jenckes MW, Dorman T, et al. Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery. *JAMA.* 1999;281:1310-1317.

4. Qaseem A, Snow V, Fittelman N, et al. Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiac thoracic surgery. A Guideline from the American College of Physicians. *Ann Intern Med.* 2006;144:575-580.
5. Svensson LG, Hess KR, Coselli JS, et al. A prospective study of respiratory failure after high-risk surgery on the thoracoabdominal aorta. *J Vasc Surg.* 1991;14:271-282.
6. Gracey DR, Divertie MB, Didier EP. Preoperative pulmonary preparation of patients with chronic obstructive pulmonary disease: a prospective study. *Chest.* 1979;76:123-129.
7. Hall JC, Tarala RA, Hall JL, et al. A multivariate analysis of the risk of pulmonary complications after laparotomy. *Chest.* 1991;99:923-927.
8. Pedersen T. Complications and death following anaesthesia. A prospective study with special reference to the influence of patient-, anaesthesia-, and surgery-related risk factors. *Dan Med Bull.* 1994;41:319-331.
9. Smetana GW. Preoperative pulmonary evaluation. *N Engl J Med.* 1999;340:937-944.
10. Stein M, Cassara EL. Preoperative pulmonary evaluation and therapy for surgery patients. *JAMA.* 1970;211:787-790.
11. Compton CN, Dillavou ED, Sheehan MK, et al. Is abdominal aortic aneurysm repair appropriate in oxygen-dependent chronic obstructive pulmonary disease patients? *J Vasc Surg.* 2005;42:650-653.
12. Warner DO, Warner MA, Barnes RD, et al. Perioperative respiratory complications in patients with asthma. *Anesthesiology.* 1996;85:460-467.
13. Bluman LG, Mosca L, Newman N, et al. Preoperative smoking habits and postoperative pulmonary complications. *Chest.* 1998;113:883-889.
14. Moller AM, Maaloe R, Pedersen T. Postoperative intensive care admittance: the role of tobacco smoking. *Acta Anaesthesiol Scand.* 2001;45:345-348.
15. Nakagawa M, Tanaka H, Tsukuma H, et al. Relationship between the duration of the preoperative smoke-free period and the incidence of postoperative pulmonary complications after pulmonary surgery. *Chest.* 2001;120:705-710.
16. Warner MA, Offord KP, Warner ME, et al. Role of preoperative cessation of smoking and other factors in postoperative pulmonary complications: a blinded prospective study of coronary artery bypass patients. *Mayo Clin Proc.* 1989;64:609-616.
17. Brooks-Brunn JA. Predictors of postoperative pulmonary complications following abdominal surgery. *Chest.* 1997;111:564-571.
18. Pasulka PS, Bistran BR, Benotti PN, et al. The risks of surgery in obese patients. *Ann Intern Med.* 1986;104:540-546.
19. Thomas EJ, Goldman L, Mangione CM, et al. Body mass index as a correlate of postoperative complications and resource utilization. *Am J Med.* 1997;102:277-283.
20. Calligaro KD, Azurin DJ, Dougherty MJ, et al. Pulmonary risk factors of elective abdominal aortic surgery. *J Vasc Surg.* 1993;18:914-920; discussion 920-911.
21. Djokovic JL, Hedley-Whyte J. Prediction of outcome of surgery and anesthesia in patients over 80. *JAMA.* 1979;242:2301-2306.
22. Arozullah AM, Daley J, Henderson WG, et al. Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. The National Veterans Administration Surgical Quality Improvement Program. *Ann Surg.* 2000;232:242-253.
23. Polanczyk CA, Marcantonio E, Goldman L, et al. Impact of age on perioperative complications and length of stay in patients undergoing noncardiac surgery. *Ann Intern Med.* 2001;134:637-643.
24. Thomas DR, Ritchie CS. Preoperative assessment of older adults. *J Am Geriatr Soc.* 1995;43:811-821.
25. Etz CD, Di Luozzo G, Bello R, et al. Pulmonary complications after descending thoracic and thoracoabdominal aortic aneurysm repair: predictors, prevention, and treatment. *Ann Thorac Surg.* 2007;83:S870-S876; discussion S890-S892.
26. Mohr DN, Jett JR. Preoperative evaluation of pulmonary risk factors. *J Gen Intern Med.* 1988;3:277-287.

27. Ford GT, Whitelaw WA, Rosenal TW, et al. Diaphragm function after upper abdominal surgery in humans. *Am Rev Respir Dis.* 1983;127:431-436.
28. Xue FS, Li BW, Zhang GS, et al. The influence of surgical sites on early postoperative hypoxemia in adults undergoing elective surgery. *Anesth Analg.* 1999;88:213-219.
29. Garibaldi RA, Britt MR, Coleman ML, et al. Risk factors for postoperative pneumonia. *Am J Med.* 1981;70:677-680.
30. Kroenke K, Lawrence VA, Theroux JF, et al. Operative risk in patients with severe obstructive pulmonary disease. *Arch Intern Med.* 1992;152:967-971.
31. Pedersen T, Eliassen K, Henriksen E. A prospective study of risk factors and cardiopulmonary complications associated with anaesthesia and surgery: risk indicators of cardiopulmonary morbidity. *Acta Anaesthesiol Scand.* 1990;34:144-155.
32. Ballantyne JC, Carr DB, deFerranti S, et al. The comparative effects of postoperative analgesic therapies on pulmonary outcome: cumulative meta-analyses of randomized, controlled trials. *Anesth Analg.* 1998;86:598-612.
33. Christopherson R, Beattie C, Frank SM, et al. Perioperative morbidity in patients randomized to epidural or general anesthesia for lower extremity vascular surgery. Perioperative Ischemia Randomized Anesthesia Trial Study Group. *Anesthesiology.* 1993;79:422-434.
34. Major CP Jr, Greer MS, Russell WL, et al. Postoperative pulmonary complications and morbidity after abdominal aneurysmectomy: a comparison of postoperative epidural versus parenteral opioid analgesia. *Am Surg.* 1996;62:45-51.
35. Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. *BMJ.* 2000;321:1493.
36. Norris EJ, Beattie C, Perler BA, et al. Double-masked randomized trial comparing alternate combinations of intraoperative anesthesia and postoperative analgesia in abdominal aortic surgery. *Anesthesiology.* 2001;95:1054-1067.
37. Berg H, Roed J, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. *Acta Anaesthesiol Scand.* 1997;41:1095-1103.
38. Preoperative pulmonary function testing. American College of Physicians. *Ann Intern Med.* May 15 1990;112:793-794.
39. De Nino LA, Lawrence VA, Averyt EC, et al. Preoperative spirometry and laparotomy: blowing away dollars. *Chest.* 1997;111:1536-1541.
40. Lawrence VA, Page CP, Harris GD. Preoperative spirometry before abdominal operations. A critical appraisal of its predictive value. *Arch Intern Med.* 1989;149:280-285.
41. Zibrak JD, O'Donnell CR, Marton K. Indications for pulmonary function testing. *Ann Intern Med.* 1990;112:763-771.
42. Khan MA, Hussain SF. Pre-operative pulmonary evaluation. *J Ayub Med Coll Abbottabad.* 2005;17:82-86.
43. Gass GD, Olsen GN. Preoperative pulmonary function testing to predict postoperative morbidity and mortality. *Chest.* 1986;89:127-135.
44. Smetana GW, Lawrence VA, Cornell JE. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. *Ann Intern Med.* 2006;144:581-595.
45. Archer C, Levy AR, McGregor M. Value of routine preoperative chest x-rays: a meta-analysis. *Can J Anaesth.* 1993;40:1022-1027.
46. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. *N Engl J Med.* 1977;297:845-850.
47. Brooks-Brunn JA. Validation of a predictive model for postoperative pulmonary complications. *Heart Lung.* 1998;27:151-158.
48. Castillo R, Haas A. Chest physical therapy: comparative efficacy of preoperative and postoperative in the elderly. *Arch Phys Med Rehabil.* 1985;66:376-379.
49. Epstein SK, Faling LJ, Daly BD, et al. Predicting complications after pulmonary resection. Preoperative exercise testing vs a multifactorial cardiopulmonary risk index. *Chest.* 1993;104:694-700.

50. Melendez JA, Carlon VA. Cardiopulmonary risk index does not predict complications after thoracic surgery. *Chest*. 1998;114:69-75.
51. Johnson RG, Arozullah AM, Neumayer L, et al. Multivariable predictors of postoperative respiratory failure after general and vascular surgery: results from the patient safety in surgery study. *J Am Coll Surg*. 2007;204:1188-1198.
52. Rosenberg J, Rasmussen GI, Wojdemann KR, et al. Ventilatory pattern and associated episodic hypoxaemia in the late postoperative period in the general surgical ward. *Anaesthesia*. 1999;54:323-328.
53. Wahba RM. Airway closure and intraoperative hypoxaemia: twenty-five years later. *Can J Anaesth*. 1996;43:1144-1149.
54. Barone JE, Tucker JB, Rassias D, et al. Routine perioperative pulmonary artery catheterization has no effect on rate of complications in vascular surgery: a meta-analysis. *Am Surg*. 2001;67:674-679.
55. Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. *N Engl J Med*. 2003;348:5-14.
56. Warner DO, Warner MA, Offord KP, et al. Airway obstruction and perioperative complications in smokers undergoing abdominal surgery. *Anesthesiology*. 1999;90:372-379.
57. Guideline for prevention of nosocomial pneumonia. Centers for Disease Control and Prevention. *Respir Care*. 1994;39:1191-1236.
58. Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. *Am J Med*. 1993;94:281-288.
59. Arozullah AM, Khuri SF, Henderson WG, et al. Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major noncardiac surgery. *Ann Intern Med*. 2001;135:847-857.
60. Scheld WM, Mandell GL. Nosocomial pneumonia: pathogenesis and recent advances in diagnosis and therapy. *Rev Infect Dis*. 1991;13(Suppl 9):S743-S751.
61. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. *N Engl J Med*. 1998;338:791-797.
62. Cook DJ, Laine LA, Guyatt GH, et al. Nosocomial pneumonia and the role of gastric pH. A meta-analysis. *Chest*. 1991;100:7-13.
63. Swoboda SM, Dixon T, Lipsett PA. Can the clinical pulmonary infection score impact ICU antibiotic days? *Surg Infect (Larchmt)*. 2006;7:331-339.
64. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. *Ann Intern Med*. 2000;132:621-630.
65. Rubenfeld GD. Epidemiology of acute lung injury. *Crit Care Med*. 2003;31(4 Suppl):S276-S284.
66. Vincent JL, Sakr Y, Ranieri VM. Epidemiology and outcome of acute respiratory failure in intensive care unit patients. *Crit Care Med*. 2003;31(4 Suppl):S296-S299.
67. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med*. 1994;149:818-824.
68. Brun-Buisson C, Minelli C, Bertolini G, et al. Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. *Intensive Care Med*. 2004;30:51-61.
69. Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. *N Engl J Med*. 2003;348:683-693.
70. Pinhu L, Whitehead T, Evans T, et al. Ventilator-associated lung injury. *Lancet*. 2003;361:332-340.
71. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. *Am J Respir Crit Care Med*. 1995;152:S77-S121.
72. Tarhan S, Moffitt EA, Sessler AD, et al. Risk of anesthesia and surgery in patients with chronic bronchitis and chronic obstructive pulmonary disease. *Surgery*. 1973;74:720-726.

73. Sestini P, Renzoni E, Robinson S, et al. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2002(4):CD001495.
74. Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. National Asthma Education Program. Expert Panel Report. *J Allergy Clin Immunol.* 1991;88:425-534.
75. Kabalin CS, Yarnold PR, Grammer LC. Low complication rate of corticosteroid-treated asthmatics undergoing surgical procedures. *Arch Intern Med.* 1995;155:1379-1384.
76. Oh SH, Patterson R. Surgery in corticosteroid-dependent asthmatics. *J Allergy Clin Immunol.* 1974;53:345-351.
77. Pien LC, Grammer LC, Patterson R. Minimal complications in a surgical population with severe asthma receiving prophylactic corticosteroids. *J Allergy Clin Immunol.* 1988;82:696-700.
78. Thomas JA, McIntosh JM. Are incentive spirometry, intermittent positive pressure breathing, and deep breathing exercises effective in the prevention of postoperative pulmonary complications after upper abdominal surgery? A systematic overview and meta-analysis. *Phys Ther.* 1994;74:3-10; discussion 10-16.
79. Hulzebos E, Helder PJM, Favier NJ, et al. Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing CABG surgery. A randomized clinical trial. *JAMA* 2006;296:1851-1857
80. Overend TJ, Anderson CM, Lucy SD, et al. The effect of incentive spirometry on postoperative pulmonary complications: a systematic review. *Chest.* 2001;120:971-978.
81. Stock MC, Downs JB, Gauer PK, et al. Prevention of postoperative pulmonary complications with CPAP, incentive spirometry, and conservative therapy. *Chest.* 1985;87:151-157.
82. Celli BR, Rodriguez KS, Snider GL. A controlled trial of intermittent positive pressure breathing, incentive spirometry, and deep breathing exercises in preventing pulmonary complications after abdominal surgery. *Am Rev Respir Dis.* 1984;130:12-15.
83. Radu DM, Jauregui F, Seguin A, et al. Postoperative pneumonia after major pulmonary resections: an unsolved problem in thoracic surgery. *Ann Thorac Surg.* 2007;84:1669-1673.
84. Gastmeier P, Geffers C. Prevention of ventilator-associated pneumonia: analysis of studies published since 2004. *J Hosp Infect.* 2007;67:1-8.
85. Segers P, Spekenbrink RG, Ubbink DT, et al. Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial. *JAMA.* 2006;296:2460-2466.
86. MacIntyre NR, Cook DJ, Ely EW Jr, et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. *Chest.* 2001;120(6 Suppl):375S-395S.
87. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. *N Engl J Med.* 2001;345:1359-1367.
88. Kindgen-Milles D, Muller E, Buhl R, et al. Nasal-continuous positive airway pressure reduces pulmonary morbidity and length of hospital stay following thoracoabdominal aortic surgery. *Chest.* 2005;128:821-828.
89. van Nieuwenhoven CA, Buskens E, van Tiel FH, et al. Relationship between methodological trial quality and the effects of selective digestive decontamination on pneumonia and mortality in critically ill patients. *JAMA.* 2001;286:335-340.
90. Drakulovic MB, Torres A, Bauer TT, et al. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. *Lancet.* 1999;354:1851-1858.
91. Orozco-Levi M, Torres A, Ferrer M, et al. Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. *Am J Respir Crit Care Med.* 1995;152:1387-1390.
92. Torres A, Serra-Batlles J, Ros E, et al. Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: the effect of body position. *Ann Intern Med.* 1992;116:540-543.
93. Ramirez P, Ferrer M, Torres A. Prevention measures for ventilator-associated pneumonia: a new focus on the endotracheal

- tube. *Curr Opin Infect Dis*. 2007;20:190-197.
94. Smulders K, van der Hoeven H, Weers-Pothoff I, et al. A randomized clinical trial of intermittent subglottic secretion drainage in patients receiving mechanical ventilation. *Chest*. 2002;121:858-862.
  95. Kollef MH, Skubas NJ, Sundt TM. A randomized clinical trial of continuous aspiration of subglottic secretions in cardiac surgery patients. *Chest*. 1999;116:1339-1346.
  96. Shorr AF, O'Malley PG. Continuous subglottic suctioning for the prevention of ventilator-associated pneumonia: potential economic implications. *Chest*. 2001;119:228-235.
  97. Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. *JAMA*. 1999;282:54-61.
  98. Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. *N Engl J Med*. 1998;338:347-354.
  99. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. the Acute Respiratory Distress Syndrome Network. *N Engl J Med*. 2000;342:1301-1308.
  100. Nuckton TJ, Alonso JA, Kallet RH, et al. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. *N Engl J Med*. 2002;346:1281-1286.
  101. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. *Chest*. 1997;111:676-685.
  102. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med*. 2005;171:388-416.
  103. Liesching T, Kwok H, Hill NS. Acute applications of noninvasive positive pressure ventilation. *Chest*. 2003;124:699-713.
  104. Lightowler JV, Wedzicha JA, Elliott MW, et al. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. *BMJ*. 2003;326:185.
  105. Derdak S. High-frequency oscillatory ventilation for acute respiratory distress syndrome in adult patients. *Crit Care Med*. 2003;31(4 Suppl):S317-S323.

## 第 40 章

1. Freehally J, Floege J, Johnson R, eds. *Comprehensive Clinical Nephrology*. 3rd ed. Philadelphia, PA: Mosby Elsevier; 2007.
2. Kriz W, Elger M. Renal anatomy. In: Freehally J, Floege J, Johnson R, eds. *Comprehensive Clinical Nephrology*. 3rd ed. Philadelphia, PA: Mosby Elsevier; 2007:1-12.
3. Shirley DG, Copasso G, Unwin RJ. Renal physiology. In: Freehally J, Floege J, Johnson R, eds. *Comprehensive Clinical Nephrology*. 3rd ed. Philadelphia, PA: Mosby Elsevier; 2007:13-26.
4. Vander AJ, ed. *Renal Physiology*. 5th ed. New York: McGraw-Hill; 1995:1-23.
5. Robaczewski DL, Dean RH, Hansen KJ. Pathophysiology of renovascular hypertension. In: White RA, Hollier LH, eds. *Vascular Surgery: Basic Science and Clinical Considerations*. Armonk, NY: Futuna; 2005:180-191.
6. Valtin H, Seafer JA. *Renal Function: Mechanisms Preserving Fluid and Solute Balance in Health*. 3rd ed. Boston, MA: Little Brown; 1995.
7. Daniels EG, Hinman JW, Leach BE, et al. Identification of prostaglandin E<sub>2</sub> as the principal vasodepressor lipid of rabbit renal medulla. *Nature (Lond)*. 1967;215:1298.
8. McGiff JC, Crowshaw K, Terrango NA, et al. Prostaglandin-like substance appearing in canine renal venous blood during renal ischemia. *Circ Res*. 1970;27:765.
9. Myers SI, Zipser R, Needleman P. Peptide-induced prostaglandin biosynthesis in the renal vein constricted kidney.

*Biochem J.* 1981;198:357.

10. Nishikawa K, Morrison AR, Needleman P. Exaggerated prostaglandin biosynthesis and its influence on renal resistance in the isolated hydronephrotic rabbit kidney. *J Clin Invest.* 1977;59:1143.
11. Rothenbakh P, Turnage RH, Iglesias J, et al. Downstream effects of splanchnic ischemia-reperfusion injury on renal function and eicosanoid release. *J Appl Physiol.* 1997;82:530.
12. Cristol JP, Thiernemann C, Mitchell JA, et al. Support of renal blood flow after ischemic-reperfusion injury by endogenous formation of nitric oxide and of cyclooxygenase vasodilators metabolites. *Br J Pharmacol.* 1993;109:188.
13. Myers SI, Turnage RH, Casteneda A, et al. Autoregulation of renal and splanchnic blood flow following infra-renal aortic clamping is mediated by nitric oxide and vasodilator prostanoids. *J Cardiovasc Surg.* 1996;37:97.
14. LaNoue JL, Turnage RH, Kadesky KM, et al. The effect of intestinal reperfusion on renal function and perfusion. *J Surg Res.* 1996;64:19.
15. Myers SI, Hernandez R, Horton JW. Acute mesenteric ischemia/reperfusion down regulates renal PGE<sub>2</sub> synthesis. *Prostaglandins Leukot Essent Fatty Acids.* 1995;52:41.
16. Lieberthal W, McGarry AE, Sheils J, Valeri CR. NO inhibition in rats improves blood pressure and renal function during hypovolemic shock. *Am J Physiol.* 1991;261:F868.
17. Radermacher J, Klanke B, Kastner S, et al. Effect of arginine depletion of glomerular and tubular kidney function: studies in isolated perfused rat kidneys. *Am J Physiol.* 1991;261:F779.
18. Tolins JP, Palmer RMJ, Moncada S, Raj L. Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. *Am J Physiol.* 1990;258:H655.
19. Radermacher J, Klanke B, Kastner S, et al. Effect of arginine depletion of glomerular and tubular kidney function: studies in isolated perfused rat kidneys. *Am J Physiol.* 1991;261:F779.
20. Rademacher J, Forstermann U, Frolich JC. Endothelium-derived relaxing factor influences renal vascular resistance. *Am J Physiol.* 1990;259:F9.
21. Zatz R, DeNucci G. Effects of acute nitric oxide inhibition on rat glomerular microcirculation. *Am J Physiol.* 1991;261:F360.
22. Welsh WJ, Wilcox CS, Alsaka K, et al. Nitric oxide synthesis for L-arginine modulates renal vascular resistance in isolated perfused and intact rat kidney. *J Cardiovasc Pharmacol.* 1991;17:S165.
23. Zou AP, Cowley A Jr. Nitric oxide in renal cortex and medulla: an in vivo microdialysis study. *Am Heart Assoc.* 1997;29:194.
24. Brezis M, Rosen S, Epstein FH. Acute renal failure. In: Brenner BM, Rector FC, eds. *The Kidney*. 4th ed. Philadelphia, PA: WB Saunders; 1991:993-1061.
25. Bullock ML, Umen A, Finkelstein M, Keane WF. The assessment of risk factors in 462 patients with acute renal failure. *Am J Kidney Dis.* 1985;5:97.
26. Muther RS. Acute renal failure: Acute azotemia in the critically ill. In: Civetta JM, Taylor RW, Kirby RR, eds. *Critical Care*. 2nd ed. Philadelphia, PA: JB Lippincott; 1992:1583-1598.
27. Jefferson AJ, Schrier RW. In: Freehally J, Floege J, Johnson R, eds. *Comprehensive Clinical Nephrology*. 3rd ed. Philadelphia, PA: Mosby Elsevier; 2007:755-770.
28. Bush HC Jr. Renal failure following abdominal aortic reconstruction. *Surgery.* 1983;93:107.
29. Rice CL, Hobelman CF, John DA, et al. Central venous pressure or pulmonary capillary wedge pressure as the determinant of fluid replacement in aortic surgery. *Surgery.* 1978;84:437.
30. Hansen KJ, Tribble RW, Reavis SW, et al. Renal duplex sonography: evaluation of clinical utility. *J Vasc Surg.* 1990;12:227.
31. Molitoris BA. New insights into the cell biology of ischemic acute renal failure. *J Am Soc Nephrol.* 1991;1:1263.
32. Mason J, Joeris B, Welsch J, et al. Vascular congestion in ischemic renal failure: the role of cell swelling. *Miner Electrolyte*



*Metab.* 1989;15:114.

33. Mohaupt M, Kramer HJ. Acute ischemic renal failure: review of experimental studies on pathophysiology and potential protective interventions. *Ren Fail.* 1989;11:177.
34. Safi HJ, Harlin SA, Miller CC, et al. Predictive factors for acute renal failure in thoracic and thoracoabdominal aortic aneurysm surgery. *J Vasc Surg.* 1996;24:338.
35. Schepens MA, Defauw JJ, Hamerlijnck RP, et al. Risk assessment of acute renal failure after thoracoabdominal aortic aneurysm surgery. *Ann Surg.* 1994;219:400.
36. Breckwoldt WL, Mackay WC, Belkin M, et al. The effect of suprarenal cross-clamping on abdominal aortic aneurysm repair. *Arch Surg.* 1992;127:520.
37. Cambria RP, Clouse WD, Davison JK, et al. Thoracoabdominal aneurysm repair: results with 337 operations performed over a 15-year interval. *Ann Surg.* 2002;236:471.
38. Gardner RJ, Lancaster JR, Tarney TJ, et al. Five year history of surgically treated abdominal aortic aneurysms. *Surg Gynecol Obstet.* 1970;30:981.
39. O'Donnell D, Clarke G, Hurst P. Acute renal failure following surgery for abdominal aortic aneurysm. *Aust N Z J Surg.* 1989;59:405.
40. Thompson JE, Hollier JH, Patman RD, et al. Surgical management of abdominal aortic aneurysms: factors influencing mortality and morbidity—a 20-year experience. *Ann Surg.* 1970;181:654.
41. Bergqvist D, Olsson PO, Takolander R, et al. Renal failure as a complication to aortoiliac and iliac reconstructive surgery. *Acta Chir Scand.* 1983;149:37.
42. McCombs PR, Roberts B. Acute renal failure following resection of abdominal aortic aneurysm. *Surg Gynecol Obstet.* 1979;148:175.
43. Diehl JT, Cali RF, Hertzner NR, Beven EG. Complications of abdominal aortic reconstruction, an analysis of perioperative risk factors in 557 patients. *Ann Surg.* 1983;197:49.
44. Gornick CC Jr, Kjellstrand CM. Acute renal failure complicating aortic aneurysm surgery. *Nephron.* 1983;35:145.
45. Ouriel K. Renal artery embolism. In Ernst CB, Stanley JC, eds. *Current Therapy in Vascular Surgery*. 3rd ed. St Louis, MO, Mosby—Year Book, 1995:821.
46. Lye WC, Cheah JS, Sinniah R. Renal cholesterol embolic disease: case report and review of the literature. *Am J Nephrol.* 1993;13:489.
47. Blankenship JC. Cholesterol embolisation after thrombolytic therapy. *Drug Saf.* 1996;14:78.
48. Thadani RI, Camargo CA Jr, Xavier RJ. Atheroembolic renal failure after invasive procedures: natural history based on 52 histologically proven cases. *Medicine (Baltimore).* 1995;74:350.
49. Sakalayan MG, Gupta S, Suryaprasad A, et al. Incidence of atheroembolic renal failure after coronary angiography: a prospective study. *Angiology.* 1997;48:609.
50. Hansen KJ, Cherr GS, Craven TE, et al. Management of ischemic nephropathy: dialysis-free survival after surgical repair. *J Vasc Surg.* 2000;32:472.
51. Textor SC. Renal failure related to angiotensin converting enzyme inhibitors. *Semin Nephrol.* 1997;17:67.
52. Navis G. ACE inhibitors and the kidney: a risk benefit assessment. *Drug Saf.* 1996;15:200.
53. Toto RD. Renal insufficiency due to angiotensin-converting enzyme inhibitors. *Miner Electrolyte Metab.* 1944;20:193.
54. Kalra PA, Mamtara H, Holmes AM. Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor therapy. *QJM.* 1990;77:1013.
55. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. *Ann Intern Med.* 1984;100:352.
56. Boucher BA, Coffey BC, Kuhl DA, et al. Algorithm for assessing renal dysfunction risk in critically ill trauma patients receiving aminoglycosides. *Am J Surg.* 1990;160:473.

57. Lamerie N, VanBiesen W, Vanholder R. In: Freehally J, Floege J, Johnson R, eds. *Comprehensive Clinical Nephrology*. 3rd ed. Philadelphia, PA: Mosby Elsevier; 2007:771-785.
58. Eneas JF, Schoenfeld BY, Humphreys MH. The effect of infusion of mannitol-sodium bicarbonate on the clinical course of myoglobinuria. *Arch Intern Med*. 1979;139:801.
59. Briguori C, Tavano D, Columbo A. Contrast agent associated nephrotoxicity. *Prog Cardiovasc Dis*. 2003;45:493-503.
60. McCullough PA, Wolyn R, Roucher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. *Am J Med*. 1997;103:368.
61. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. *J Am Soc Nephrol*. 2000;11:177.
62. Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast-associated renal dysfunction: incidence and risk factors. *AJR Am J Roentgenol*. 1991;157:49.
63. Soloman R, Werner C, Mann D, et al. Effects of saline, mannitol and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. *N Engl J Med*. 1994;331:1416.
64. Soloman R. Contrast-medium-induced acute renal failure. *Kidney Int*. 1998;53:230.
65. Hou SH, Bushinsky DA, Wisch JB, et al. Hospital acquired renal insufficiency: a prospective study. *Am J Med*. 1983;74:243.
66. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. *Kidney Int*. 1995;47:254.
67. Levy EM, Viscoli CM, Horowitz RI. The effect of acute renal failure on mortality: a cohort analysis. *JAMA*. 1996;275:1489.
68. Bordet R, Gautier S, LeLouet H, et al. Analysis of the direct cost of adverse drug reactions in hospitalized patients. *Eur J Clin Pharmacol*. 2001;6:935.
69. Larson IS, Hudson K, Mertz ML, et al. Renal vasoconstriction responses to contrast medium. *J Lab Clin Med*. 1983;101:385.
70. Harkonen S, Kjellstrand CM. Exacerbation of diabetic renal failure following intravenous pyelography. *Am J Med*. 1977;63:939.
71. Shieh SD, Hirsch SR, Boshell BR, et al. Low risk of contrast media induced acute renal failure in nonazotemic type 2 diabetes mellitus. *Kidney Int*. 1982;21:739.
72. Barrett BJ. Contrast nephrotoxicity. *J Am Soc Nephrol*. 1994;5:125.
73. Hou SH, Burchinsky DA, Wish JB, et al. Hospital acquired renal insufficiency: a prospective study. *Am J Med*. 1983;74:243.
74. Palfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency or both. *N Engl J Med*. 1989;320:143.
75. Agnon Y, Pelig H, Greenfield Z, et al. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. *J Clin Invest*. 1994;94:1069.
76. Heyman SN, Goldfarb M, Carmeli F, et al. The effect of radiocontrast on intra-renal nitric oxide (NO) and NO synthase activity. *Exp Nephrol*. 1988;6:557.
77. Heyman SN, Fuchs S, Jaffe R, et al. Renal microcirculation and tissue damage during acute ureteral obstruction in the rat: effect of saline infusion, indomethacin and radiocontrast. *Kidney Int*. 1977;51:653.
78. Schwartz D, Blum M, Peer G, et al. Role of nitric oxide (EDRF) in radiocontrast acute renal failure in rats. *Am J Physiol*. 1994;267: F374.
79. Myers SI, Wang L, Fang L, Bartula LL. Suprarenal aortic clamping and reperfusion decreased medullary and cortical blood flow by decreased endogenous renal NO and PGE<sub>2</sub> synthesis. *J Vasc Surg*. 2005;42:524.
80. Myers SI, Wang L, Liu F, Bartula LL. Oxygen-radical regulation of renal blood flow following suprarenal aortic clamping. *J Vasc Surg*. 2006;43:577.

81. Myers SI, Wang L, Fang L, Bartula L. Iodinated contrast induced renal vasoconstriction is due in part to the down-regulation of renal cortical and medullary nitric oxide synthesis. *J Vasc Surg.* 2006;44:383.
82. Myers DJ, Wang L, Myers SI. Ionic and nonionic contrast media decreases renal microcirculation and renal function by different mechanisms. *J Vasc Surg* (in press).
83. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. *N Engl J Med.* 1994;331:1416.
84. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. *JAMA.* 2004;291:2328.
85. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. *Am J Med.* 1989;86:649.
86. Seager JM, Self S, Harward TR, et al. Carbon dioxide gas as an arterial contrast agent. *Ann Surg.* 1993;217:688.
87. Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic fibrosis. *J Magn Reson Imaging.* 2007;26:1190.
88. Tepel M, Van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. *N Engl J Med.* 2000;343:180.
89. Pannu N, Manns B, Lee H, Tonelli M. Systematic review on the impact of *N*-acetylcysteine on contrast nephropathy. *Kidney Int.* 2004;65:1366.
90. Birck R, Krzossk S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. *Lancet.* 2003;362:598.
91. Smilkstein MJ, Knapp GL, Kulig KW, Rumanck BH. Efficacy of oral *N*-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976-1985). *N Engl J Med.* 1988;319:1557.
92. Granger H, Dhar J, Chen HI, et al. Structure and function of the interstitium. In: *Proceedings of the Workshop on Albumin.* Bethesda, MD: National Institutes of Health; 1976:114.
93. Smeets HJ, Kievit J, Duffer FT, et al. Analysis of post-operative hypoalbuminemia: a clinical study. *Int Surg.* 1994;79:152.
94. Humes HD. Role of calcium in pathogenesis of acute renal failure. *Am J Physiol.* 1986;250:F579.
95. Lucas CE, Ledgerwood AM. The fluid problem in the critically ill. *Surg Clin North Am.* 1983;63:439.
96. Dawson CW, Lucas CE, Ledgerwood AM. Altered interstitial fluid space dynamics and post-resuscitation hypertension. *Arch Surg.* 1981;116:657.
97. Bomberger RA, McGregor B, Depalma RG. Optimal fluid management after aortic reconstruction: a prospective study of two crystalloid solutions. *J Vasc Surg.* 1984;4:164.
98. Nielsen OM, Engell HC. Effects of maintaining normal plasma colloid osmotic pressure on renal function and excretion of sodium and water after major surgery: a randomized study. *Dan Med Bull.* 1985;32:182.
99. Myers SI, Wang L, Myers DJ. Loss of renal function and microvascular blood flow after suprarenal aortic clamping and reperfusion (SPACR) above the superior mesenteric artery is greatly augmented compared to SPACR above the renal arteries. *J Vasc Surg.* 2007;45:357.
100. Svensson LG, Crawford ES, Hess KR, et al. Experience with 1509 patients undergoing thoracoabdominal and aortic operations. *J Vasc Surg.* 1993;17:357.
101. Kashyap VS, Cambria RP, Davison JF, et al. Renal failure after thoracoabdominal aortic surgery. *J Vasc Surg.* 1997;26:949.
102. Allen BT, Anderson CB, Rubin BG, et al. Preservation of renal function in juxtarenal and suprarenal abdominal aortic aneurysm repair. *J Vasc Surg.* 1993;17:948.
103. Chawla SK, Najafi H, Ing TS, et al. Acute renal failure complicating ruptured abdominal aortic aneurysm. *Arch Surg.* 1975;110:521.
104. Hicks GL, Eastland MW, DeWeese JA, et al. Survival improvement following aortic aneurysm resection. *Ann Surg.*

- 1975;181:863.
105. Fielding JL, Black J, Ashton F, et al. Ruptured aortic aneurysms: postoperative complications and their aetiology. *Br J Surg*. 1984;71:487.
  106. Gordon AC, Pryn S, Collin J. Outcome of patients who required renal support after surgery for ruptured abdominal aortic aneurysm. *Br J Surg*. 1994;81:836.
  107. Anderson RJ, Lines SL, Bents AS, et al. Non-oliguric acute renal failure. *N Engl J Med*. 1977;296:1134.
  108. Mann HI, Fuhs DW, Hemstrom CA. Acute renal failure. *Drug Intell Clin Pharm*. 1986;20:421.
  109. Myers BD, Moran SM. Hemodynamically mediated acute renal failure. *N Engl J Med*. 1986;314:97.
  110. Myers BD, Miller DC, Mehigan JT, et al. Nature of the renal injury following total renal ischemia in man. *J Clin Invest*. 1984;73:329.
  111. Moran SM, Myers BD. Course of acute renal failure studied by a model of creatinine kinetics. *Kidney Int*. 1985;27:928.
  112. Hilberman M, Myers BD, Carrie G, et al. Acute renal failure following cardiac surgery. *J Thorac Cardiovasc Surg*. 1979;77:880.
  113. Oliver J, MacDowell M, Tracy A. Pathogenesis of acute renal failure associated with traumatic and toxic injury: renal ischemia, nephrotoxic damage, and the ischemic episode. *J Clin Invest*. 1951;30:1305.
  114. Iliopoulos JI, Zdon MI, Crawford BG, et al. Renal microembolization syndrome: a cause for renal dysfunction after abdominal aortic reconstruction. *Am J Surg*. 1983;146:779.
  115. Smith MC, Chose MK, Henry AR. The clinical spectrum of renal cholesterol embolization. *Am J Med*. 1981;71:174.
  116. Miller DC, Myers BD. Pathophysiology and prevention of acute renal failure associated with thoracoabdominal or abdominal aortic surgery. *J Vasc Surg*. 1987;5:518.
  117. Abbott WM, Austen WG, Abel RM, Beck CH. The reversal of renal cortical ischemia during aortic occlusion by mannitol. *J Surg Res*. 1974;16:482.
  118. Hanley MJ, Davidson K. Prior mannitol and furosemide infusion in a model of ischemic acute renal failure. *Am J Physiol*. 1981;241:F556.
  119. Ochsner JL, Mills NL, Gardner PA. A technique for renal preservation during suprarenal abdominal aortic operations. *Surg Gynecol Obstet*. 1984;159:388.
  120. Hilberman M, Maseda J, Stinson EB, et al. The diuretic properties of dopamine in patients after open-heart operation. *Anesthesiology*. 1984;61:489.
  121. Lindner A, Cutler RE, Bell AI. Attenuation of nephrotoxic acute renal failure in the dog with angiotensin-converting enzyme inhibitor (SQ-20, 881). *Circ Res*. 1982;51:216.
  122. Salem MG, Crooke JW, McLoughlin GA, et al. The effect of dopamine on renal function during aortic cross clamping. *Ann R Coll Surg Engl*. 1988;170:9.
  123. Nicholson ML, Baker DM, Hopkinson BR, et al. Randomized control trial of the effect of mannitol on renal reperfusion injury during aortic aneurysm surgery. *Br J Surg*. 1996;83:1230.
  124. Paul MD, Mazer CD, Byrick RI, et al. Influence of mannitol and dopamine on renal function during elective infrarenal aortic clamping in man. *Am J Nephrol*. 1986;6:427.
  125. Denton MD, Chertow M, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. *Kidney Int*. 1996;50:4.
  126. DeLasson L, Hansen HE, Jugl B, et al. A randomized, clinical study of the effect of low-dose dopamine on central and renal haemodynamics in infrarenal aortic surgery. *Eur J Vasc Endovasc Surg*. 1995;10:82.
  127. Girbes AR, Lievever AG, Smit AJ, et al. Lack of specific renal haemodynamic effects of different doses of dopamine after infrarenal aortic surgery. *Br J Anaesth*. 1996;77:753.
  128. Baldwin L, Henderson A, Hickman P. Effect of postoperative low dose dopamine on renal function after elective major vascular surgery. *Ann Intern Med*. 1994;120:744.

129. Mathur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. *Crit Care Med.* 1999;27:1832.
130. Bakris GL, Lass NA, Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role for dopamine-1 receptors. *Kidney Int.* 1999;56:206.
131. Halpenny M, Markos F, Snow HM, et al. The effects of fenoldopam on renal blood flow and tubular function during aortic cross-clamping in anaesthetized dogs. *Eur J Anaesth.* 2000;17:491.
132. Goetz KL. Physiology and pathophysiology of atrial peptides. *Am J Physiol.* 1988;254:E1.
133. Kurnik BR, Allgren RL, Center FC, et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast induced nephropathy. *Am J Kidney Dis.* 1998;31:674.
134. Sward K, Valson F, Ricksten SE. Long-term infusion of atrial natriuretic peptide (ANP) improves renal blood flow and glomerular filtration rate in clinical acute renal failure. *Acta Anaesthesiol Scand.* 2001;45:536.
135. Hayashida N, Chihara S, Kashikie H, et al. Effects of intraoperative administration of atrial natriuretic peptide. *Ann Thorac Surg.* 2000;70:1319.
136. Halpenny M, Lakslami S, O'Donnell A, et al. Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass grafting. *Anaesthesia.* 2001;56:963.
137. Halpenny M, Rushe C, Breen P, et al. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. *Eur J Anaesthesiol.* 2002;19:32.
138. Von Oppell UD, Dunne TT, DeGroot KM, Zilla P. Spinal cord protection in the absence of collateral circulation: meta-analysis of mortality and paraplegia. *J Card Surg.* 1994;9:685.
139. Coselli JS. Thoracoabdominal aortic aneurysms: experience with 372 patients. *J Card Surg.* 1994;9:638.
140. Safi HJ, Harlin SA, Miller CC, et al. Predictive factors for acute renal failure in thoracic and thoracoabdominal aortic aneurysm surgery. *J Vasc Surg.* 1996;24:338.
141. Coselli JS, LeMaire SA, Miller CC 3rd, et al. Mortality and paraplegia after thoracoabdominal aortic aneurysm repair: a risk factor analysis. *Ann Thorac Surg.* 2000;69:409.
142. Pelkay TJ, Frank RS, Stanley JJ, et al. Minimal physiologic temperature variations during renal ischemia alter functional and morphologic outcome. *J Vasc Surg.* 1992;15:619.
143. El Kassi M, El Naha M. In: Freehally J, Floege J, Johnson R, eds. *Comprehensive Clinical Nephrology*. 3rd ed. Philadelphia, PA: Mosby Elsevier; 2007:813-821.
144. Haddad N, Brown C, Herbert LA. In: Freehally J, Floege J, Johnson R, eds. *Comprehensive Clinical Nephrology*. 3rd ed. Philadelphia, PA: Mosby Elsevier; 2007:823-830.
145. Ejaz AA, Paganini EP. In: Freehally J, Floege J, Johnson R, eds. *Comprehensive Clinical Nephrology*. 3rd ed. Philadelphia, PA: Mosby Elsevier; 2007:787-794.
146. Kotanko P, Kuhlmann MK, Levin NW. In: Freehally J, Floege J, Johnson R, eds. *Comprehensive Clinical Nephrology*. 3rd ed. Philadelphia, PA: Mosby Elsevier; 2007:953-966.
147. Rippe B. In: Freehally J, Floege J, Johnson R, eds. *Comprehensive Clinical Nephrology*. 3rd ed. Philadelphia, PA: Mosby Elsevier; 2007:979-990.

## 第 41 章

1. Bandyk DF. Vascular graft infections: Epidemiology, microbiology, pathogenesis, and prevention. In: Bernhard VM, Towne JB, eds. *Complications in Vascular Surgery*. St Louis: Quality Medical; 1991:223-234.
2. Bunt TJ. Synthetic vascular graft infections. *Surgery.* 1988;93:733.
3. Dean RH, Allen TR, Foster JH, et al. Aortoduodenal fistula: an uncommon but correctable cause of upper gastrointestinal bleeding. *Am Surg.* 1978;44:37.
4. Fry WJ, Lindenauer SM. Infection complicating the use of plastic arterial implants. *Arch Surg.* 1966;94:600.

5. Liekweg WG Jr, Greenfield LJ. Vascular prosthetic infections: collected experience and results of treatment. *Surgery*. 1977;81:335.
6. O'Hara PJ, Hertzner NR, Beven EG, et al. Surgical management of infected abdominal aortic grafts: review of a 25-year experience. *J Vasc Surg*. 1986;3:725.
7. Calligaro KD, Veith FJ, Schwartz ML, et al. Are gram-negative bacteria a contraindication to selective preservation of infected prosthetic arterial grafts? *J Vasc Surg*. 1992;16:337.
8. Campbell WB, Tambieur LJ, Geens VR. Local complications after arterial bypass grafting. *Ann R Coll Surg Engl*. 1994;76:127.
9. Geary KJ, Tomkiewicz ZM, Harrison HN, et al. Differential effects of a gram-negative and a gram-positive infection on autogenous and prosthetic grafts. *J Vasc Surg*. 1990;11:339.
10. Bandyk DF, Bergamini TM, Kinney EV, et al. In situ replacement of vascular prostheses infected by bacterial biofilms. *J Vasc Surg*. 1991;13:575.
11. Calligaro KD, Veith FJ, Schwartz ML, et al. Selective preservation of infected prosthetic grafts: analysis of a 20-year experience with 120 extra-cavitary infected grafts. *Ann Surg*. 1994;220:461.
12. Clagett GP, Valentine RJ, Hagino RT. Autogenous aortoiliac/femoral reconstruction from superficial femoral-popliteal veins: feasibility and durability. *J Vasc Surg*. 1997;25:25.
13. Daenens K, Fourneau I, Nevelsteen A. Ten-year experience in autogenous reconstruction with the femoral vein in the treatment of aortofemoral prosthetic infection. *Eur J Vasc Surg*. 2003;25:240.
14. Fujitani RM, Bassiouny HS, Gewertz BL, et al. Cryopreserved saphenous vein allogenic homografts: an alternative conduit in lower extremity arterial reconstruction in infected fields. *J Vasc Surg*. 1992;15:519.
15. Reilly LM, Stoney RJ, Goldstone J, et al. Improved management of aortic graft infection: the influence of operation sequence and staging. *J Vasc Surg*. 1987;5:421.
16. Schmitt DD, Seabrook GR, Bandyk DF, et al. Graft excision and extra-anatomic revascularization: the treatment of choice for the septic aortic prosthesis. *J Cardiovasc Surg*. 1990;31:327.
17. Yeager RA, Taylor LM, Moneta GL, et al. Improved results with conventional management of infrarenal aortic infection. *J Vasc Surg*. 1999;30:76.
18. Young RM, Cherry KJ Jr, Davis PM, et al. The results of in situ prosthetic replacement for infected aortic grafts. *Am J Surg*. 1999;178:136.
19. Bandyk DF, Berni GA, Thiele BL, et al. Aortofemoral graft infection due to *Staphylococcus epidermidis*. *Arch Surg*. 1984;119:102.
20. Batt M, Mange JL, Alric P, et al. In situ revascularization with silver coated polyester grafts to treat aortic infection: early and midterm results. *J Vasc Surg*. 2003;38:983.
21. Cherry KJ, Roland CF, Pairolero PC, et al. Infected femorodistal bypass: is graft removal mandatory? *J Vasc Surg*. 1992;15:295.
22. Ehrenfeld WK, Wilbur BG, Olcott CN, et al. Autogenous tissue reconstruction in the management of infected prosthetic grafts. *Surgery*. 1979;85:82.
23. Johnston KW. Multicenter prospective study of nonruptured abdominal aortic aneurysm: II. Variables predicting morbidity and mortality. *J Vasc Surg*. 1989;9:437.
24. Kieffer E, Bahnini A, Koskas F, et al. In situ allograft replacement of infected infrarenal aortic prosthetic grafts: results in 43 patients. *J Vasc Surg*. 1993;17:349.
25. Nevelsteen A, Lacroix H, Suy R. Autogenous reconstruction of the lower extremity deep veins: an alternative treatment of prosthetic infection after reconstructive surgery of aortoiliac disease. *J Vasc Surg*. 1995;22:129.
26. Vogt PR, Brunner-LaRocca HP, Lachat M, et al. Technical details with the use of cryopreserved arterial allografts for aortic infection: influence on early and midterm mortality. *J Vasc Surg*. 2002;35:80.

27. Durham JR, Rubin JR, Malone JM. Management of infected infrainguinal bypass grafts. In: Bergan JJ, Yao JST, eds. *Reoperative Arterial Surgery*. Orlando, FL: Grune & Stratton; 1986:359-373.
28. Goldstone J, Moore WS. Infection in vascular prostheses: clinical manifestations and surgical management. *Am J Surg*. 1974;128:225.
29. Lorentzen JE, Nielsen OM, Arendrup H, et al. Vascular graft infection: an analysis of sixty-two graft infections in 2411 consecutively implanted synthetic vascular grafts. *Surgery*. 1985;98:81.
30. Naylor AR, Payne D, London NJ, et al. Prosthetic patch infection after carotid endarterectomy. *Eur J Vasc Surg*. 2002;23:11.
31. Ohki T, Veith FJ, Shaw P, et al. Increasing incidence of midterm and long-term complications after endovascular graft repair of abdominal aortic aneurysms: a note of caution based on a 9-year experience. *Ann Surg*. 2001;234:323.
32. Rosenthal D, Archie JP, Garcia-Rinaldi R, et al. Carotid patch angioplasty: intermediate and long-term results. *J Vasc Surg*. 1990;12:326.
33. Szilagyi DE, Smith RF, Elliott JP, et al. Infection in arterial reconstruction with synthetic grafts. *Ann Surg*. 1972;176:321.
34. Hallett JW, Marshall DM, Petterson TM, et al. Graft-related complications after abdominal aortic aneurysm repair: population-based experience. *J Vasc Surg*. 1977;25:277.
35. Baker M, Uflacker R, Robinson J. Stent-graft infection after abdominal aortic aneurysm repair: a case report. *J Vasc Surg*. 2002;36:180.
36. Sharif MA, Lee B, Lau LL, et al. Prosthetic stent-graft infection after endovascular abdominal aortic aneurysm repair. *J Vasc Surg*. 2007;46:442.
37. Jimenez JC, Moore WS, Quinones-Baldrich WJ. Acute and chronic open conversion after endovascular aortic aneurysm repair. *J Vasc Surg*. 2007;46:642.
38. Kaebnick HW, Bandyk DF, Bergamini TM, et al. The microbiology of explanted vascular prostheses. *Surgery*. 1987;102:756.
39. Bandyk DF, Novotney ML, Back MR, et al. Expanded application of in situ replacement for prosthetic graft infection. *J Vasc Surg*. 2001;34:411.
40. Quinones-Baldrich WJ, Hernandez JJ, Moore WS. Long-term results following surgical management of aortic graft infection. *Arch Surg*. 1991;126:507.
41. Elek SD, Conen PE. The virulence of *Staphylococcus pyogenes* in man: a study of the problems of wound infection. *Br J Exp Pathol*. 1957;38:573.
42. Back MR, Klingman N, Schultz GS, et al. Arterial prosthetic grafts stimulate local production of tumor necrosis factor and matrix metalloproteases. *ACS Surg Forum*. 1997;158:395.
43. Zimmer W, Waldvogel FA, Vaudaux P, et al. Pathogenesis of foreign body infection: description and characteristics of an animal model. *J Infect Dis*. 1982;146:487.
44. Moore WS, Malone JM, Keown K. Prosthetic arterial graft material: influence on neointimal healing and bacteremic infectibility. *Arch Surg*. 1980;115:1379.
45. Armstrong PA, Back MR, Wilson J, et al. Improved outcomes in the recent management of secondary aortoenteric fistula. *J Vasc Surg*. 2005;42:660.
46. Durham JR, Malone JM, Bernhard VM. The impact of multiple operations on the importance of arterial wall cultures. *J Vasc Surg*. 1987;5:160.
47. Back MR. Infections and antibiotics in vascular surgery. In: White RA, Hollier LH, eds. *Vascular Surgery: Basic Science and Clinical Correlations*. 2nd ed. Malden, MA: Blackwell; 2005:477-492.
48. Bergamini TM, Bandyk DF, Govostis D, et al. Identification of *Staphylococcus epidermidis* vascular graft infections: a comparison of culture techniques. *J Vasc Surg*. 1989;9:665.
49. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant *Staphylococcus aureus*: a meta-analysis of prevalence and risk factors. *Clin Infect Dis*. 2003;36:131.

50. Bradley SF, Terpenning MS, Ramsey MA, et al. MRSA. Colonization and infection in a long-term care facility. *Ann Intern Med.* 1991;115:417.
51. Hsu CCS, Macaluso CP, Special L, et al. High rate of MRSA isolated from hospitalized nursing home patients. *Arch Intern Med.* 1988;148:569.
52. Nasim A, Thompson MM, Naylor AR, et al. The impact of MRSA on vascular surgery. *Eur J Vasc Endovasc Surg.* 2001;22:211.
53. Naylor AR, Hayes PD, Darke S. Joint Vascular Research Group: a prospective audit of complex wound and graft infections in Great Britain and Ireland: the emergence of MRSA. *Eur J Vasc Endovasc Surg.* 2001;21:289.
54. D'Addato M, Curti T, Freyrie A. Prophylaxis of graft infection with rifampicin-bonded Gelseal graft: 2-year follow-up of a prospective clinical trial. *Cardiovasc Surg.* 1996;4:200.
55. Braithwaite BD, Davies B, Heather BP, et al. Joint Vascular Research Group. Early results of a randomized trial of rifampicin-bonded Dacron grafts for extra-anatomic vascular reconstruction. *Br J Surg.* 1998;85:1378.
56. Calligaro KD, Veith FJ, Schwartz ML, et al. Differences in early versus late extracavitary arterial graft infections. *J Vasc Surg.* 1995;22:680.
57. Calligaro KD, Veith FJ, Yuan JG, et al. Intra-abdominal aortic graft infection: complete or partial graft preservation in patients at very high risk. *J Vasc Surg.* 2003;38:1199.
58. Calligaro KD, Westcott CJ, Buckley RM, et al. Infrainguinal anastomotic arterial graft infections treated by selective graft preservation. *Ann Surg.* 1993;216:74.
59. Seeger JM, Pretus HA, Welborn MB, et al. Long-term outcome after treatment of aortic graft infection with staged extra-anatomic bypass and aortic graft removal. *J Vasc Surg.* 2000;32:451.
60. Kieffer E, Gomes D, Chiche L, et al. Allograft replacement for infrarenal aortic graft infection: early and late results in 179 patients. *J Vasc Surg.* 2004;39:1009.
61. Seeger JM, Back MR, Albright JL, et al. Influence of patient characteristics and treatment options on outcome of patients with prosthetic aortic graft infection. *Ann Vasc Surg.* 1999;13:413.
62. Seeger JM, Wheeler JR, Gregory RT, et al. Autogenous graft replacement of infected prosthetic grafts in the femoral position. *Surgery.* 1983;93:39.
63. Clagett GP, Bowers BL, Lopez-Viego MA, et al. Creation of a neo-aortoiliac system from lower extremity deep and superficial veins. *Ann Surg.* 1993;218:239.
64. Beck AW, Murphy EH, Hocking JA, et al. Aortic reconstruction with femoro-popliteal vein: graft stenosis incidence, risk and reintervention. *J Vasc Surg.* 2008;47:36.
65. Jackson MR, Joiner DR, Clagett GP. Excision and autogenous revascularization of an infected aortic stent graft resulting from a urinary tract infection. *J Vasc Surg.* 2002;36:622.
66. Hayes PD, Nasim A, London NJM, et al. In situ replacement of infected aortic grafts with rifampicin bonded prostheses: the Leicester experience (1992-1998). *J Vasc Surg.* 1999;30:92.
67. Koshiko S, Sasajima T, Muraki S, et al. Limitations in the use of rifampicin-gelatin grafts against virulent organisms. *J Vasc Surg.* 2002;35:779.
68. Stone PA, Armstrong PA, Bandyk DF, et al. Use of antibiotic-loaded polymethylmethacrylate beads for the treatment of extra-cavitary prosthetic graft infection. *J Vasc Surg.* 2006;44:757.
69. Perler BA, Vanderkolk CA, Manson PM, et al. Rotational muscle flaps to treat localized prosthetic graft infection: long-term follow-up. *J Vasc Surg.* 1993;18:358.
70. Armstrong PA, Back MR, Bandyk DF, et al. Selective application of sartorius muscle flaps and aggressive staged surgical debridement can influence long-term outcomes of complex prosthetic graft infections. *J Vasc Surg.* 2007;46:71.
71. Budney PG, Fix RJ. Salvage of prosthetic grafts and joints in the lower extremity. *Clin Plast Surg.* 1991;18:583.
72. Mathes SSI, McGrow JB, Vasconez LO. Muscle transposition flaps for coverage of lower extremity deficits. *Anatomic*



- considerations. *Surg Clin North Am.* 1954;54:1337.
73. Deiparine MK, Ballard JL, Taylor FC, et al. Endovascular stent infection. *J Vasc Surg.* 1996;23:529.
  74. Dosluoglu HH, Curl GR, Doerr RJ, et al. Stent-related iliac artery and iliac vein infections: two unreported presentations and review of the literature. *J Endovasc Ther.* 2001;8:202.
  75. Pruitt A, Dodson TF, Najibi S, et al. Distal septic emboli and fatal brachiocephalic artery mycotic pseudoaneurysm as a complication of stenting. *J Vasc Surg.* 2002;36:625.
  76. Riesenman PJ, Farber MA, Mauro MA, et al. Aortoesophageal fistula after thoracic endovascular aortic repair and transthoracic embolization. *J Vasc Surg.* 2007;46:789.
  77. Abou-Zamzam AM Jr, Bianchi C, Mazraany W, et al. Aortoenteric fistula development following endovascular abdominal aortic aneurysm repair: a case report. *Ann Vasc Surg.* 2003;17:119.
  78. Alankar S, Barth MH, Shin DD, et al. Aortoduodenal fistula and associated rupture of abdominal aortic aneurysm after endoluminal stent-graft repair. *J Vasc Surg.* 2003;37:465.
  79. Eliason JL, Guzman RJ, Passman MA, et al. Infected endovascular graft secondary to coil embolization of endoleak; a demonstration of the importance of operative sterility. *Ann Vasc Surg.* 2002;16:562.
  80. Hulin SJ, Morris GE. Aortic endograft infection: open surgical management with endograft preservation. *Eur J Vasc Endovasc Surg.* 2007;34:191.
  81. Kirksey L, Brener BJ, Hertz S, et al. Prophylactic antibiotics prior to bacteremia decrease endovascular graft infection in dogs. *Vasc Endovasc Surg.* 2002;36:171.
  82. Paget DS, Bukhari RH, Zayyat EJ, et al. Infectibility of endovascular stents following antibiotic prophylaxis or after arterial wall incorporation. *Am J Surg.* 1999;178:219.
  83. Parsons RE, Sanchez LA, Marin ML, et al. Comparison of endovascular and conventional vascular prostheses in an experimental infection model. *J Vasc Surg.* 1996;24:920.
  84. Kan CD, Lee HL, Yang YJ. Outcome after endovascular stent-graft treatment for mycotic aortic aneurysm: a systematic review. *J Vasc Surg.* 2007;46:906.
  85. Wheatley GH 3rd, Nunez A, Preventza O, et al. Have we gone too far? Endovascular stent-graft repair of aortobronchial fistulas. *J Thorac Cardiovasc Surg.* 2007;133:1277.
  86. Deshpande A, Lovelock M, Mossop P, et al. Endovascular repair of an aortoenteric fistula in a high-risk patient. *J Endovasc Surg.* 1999;6:379.
  87. Eskandari MK, Makaroun MS, Abu-Elmagd KM, et al. Endovascular repair of an aortoduodenal fistula. *J Endovasc Ther.* 2000;7:328.
  88. Curti T, Freyrie A, Mirelli M, et al. Endovascular treatment of an ilioenteric fistula: a bridge to aortic homograft. *Eur J Vasc Endovasc Surg.* 2000;20:204.
  89. Chuter TAM, Lukaszewicz GC, Reilly LM, et al. Endovascular repair of a presumed aortoenteric fistula: late failure due to recurrent infection. *J Endovasc Ther.* 2000;7:240.
  90. Kieffer E, Sabatier J, Plissonnier D, et al. Prosthetic graft infection after descending thoracic/thoracoabdominal aortic aneurysmectomy: management with in situ arterial grafts. *J Vasc Surg.* 2001;33:671.
  91. Svensson LG, Crawford ES, Hess KR, et al. Experience with 1509 patients undergoing thoracoabdominal aortic operations. *J Vasc Surg.* 1993;17:357.
  92. Svensson LG, Crawford ES, Hess KR, et al. Variables predictive of outcome in 832 patients undergoing repairs of the descending thoracic aorta. *Chest.* 1993;104:1248.
  93. Coselli JS, Crawford ES, Williams TW, et al. Treatment of postoperative infection of ascending aorta and transverse aortic arch, including use of viable omentum and muscle flaps. *Ann Thorac Surg.* 1990;50:868.
  94. Rockman CB, Su WT, Domenig C, et al. Postoperative infection associated with polyester patch angioplasty after carotid endarterectomy. *J Vasc Surg.* 2003;38:251.

95. Zacharoulis DC, Gupta SK, Seymour P, et al. Use of muscle flap to cover infections of the carotid artery after carotid endarterectomy. *J Vasc Surg.* 1997;25:769.
96. Bergamini TM, Seabrook GR, Bandyk DF, et al. Symptomatic recurrent carotid stenosis and aneurysmal degeneration following endarterectomy. *Surgery.* 1993;113:580.

## 第 42 章

1. Cooper A. *The lectures of Sir Astley Cooper on the Principles and Practice of Surgery with Additional Notes and Cases by F. Tyrell.* 5th ed. Philadelphia, PA: Haswell, Barrington, and Haswell; 1939.
2. Brock RC. Aortic homografting: a report of six successful cases. *Guys Hosp Rep.* 1953;102:204.
3. Heberer A. Diagnosis and treatment of aneurysms of the abdominal aorta. *Ger Med Monatschr.* 1957;2:203.
4. MacKenzie RJ, Buell AH, Pearson SC. Aneurysm of aortic homograft with rupture into the duodenum. *Arch Surg.* 1958;77:965.
5. Dossa CD, Pipinos II, Shepard AD, et al. Primary aortoenteric fistula: Part I. *Ann Vasc Surg.* 1994;8:113.
6. Reckless JPD, McColl I, Taylor GW. Aortoenteric fistulae: an uncommon complication of abdominal aortic aneurysms. *Br J Surg.* 1972;59:458.
7. Dossa CD, Pipinos II, Shepard AD, et al. Primary aortoenteric fistula: Part II. Primary aortoenteric fistula. *Ann Vasc Surg.* 1994;8:207.
8. Lorimer JW, Goobie P, Rasuli P, et al. Primary aortogastric fistula: a complication of ruptured aortic aneurysm. *J Cardiovasc Surg.* 1996;37:363.
9. Vollmar JF, Kogel H. Aorto-enteric fistulas as postoperative complication. *J Cardiovasc Surg.* 1987;28:479.
10. Buchbinder D, Leather R, Shah D, et al. Pathologic interactions between prosthetic aortic grafts and the gastrointestinal tract. *Am J Surg.* 1980;140:192.
11. Bunt TJ. Synthetic vascular graft infections: II. Graft-enteric erosions and graft-enteric fistulas. *Surgery.* 1983;94:1.
12. Sweeney MS, Gadacz TR. Primary aortoduodenal fistula: manifestations, diagnosis, and treatment. *Surgery.* 1984;96:492.
13. Trout HH III, Kozloff L, Giordano JM. Priority of revascularization in patients with graft enteric fistulas, infected arteries, or infected arterial prostheses. *Ann Surg.* 1984;199:669.
14. Chaphery AD, Gupta RL, Currie RD. Carcinoma of head of pancreas with aortoduodenal fistula. *Am J Surg.* 1966;111:580.
15. Frosch HL, Horowitz W. Rupture of abdominal aorta into duodenum through sinus tract created by tuberculous mesenteric lymphadenitis. *Ann Intern Med.* 1944;21:481.
16. Morrow C, Safi H, Beall AC Jr. Primary aortoduodenal fistula caused by *Salmonella* aortitis. *J Vasc Surg.* 1987;6:415.
17. Sindelar WF, Mason GR. Aortocystoduodenal fistula: rare complication of pancreatic pseudocyst. *Arch Surg.* 1979;114:953.
18. Sternberg A, Nava HR, Irac AT, et al. Perforation of a benign gastric ulcer into the supradiaphragmatic aorta. *Am J Gastroenterol.* 1987;82:579.
19. Odze RD, Begin LR. Peptic ulcer induced aortoenteric fistula: report of case and review of the literature. *J Clin Gastroenterol.* 1991;113:682.
20. Campbell HC Jr, Ernst CB. Aortoenteric fistula following renal revascularization. *Am Surg.* 1978;44:155.
21. King RM, Sterioff S, Engen DE. Renal artery graft-to-duodenum fistula: unusual presentation of a recurrent flank abscess. *J Cardiovasc Surg.* 1985;26:509.
22. Sheil AGR, Reeve TS, Little JM, et al. Aortointestinal fistulas following operations on the abdominal aorta and iliac arteries. *Br J Surg.* 1969;56:840.
23. Donovan TJ, Bucknam CA. Aorto-enteric fistula. *Arch Surg.* 1967;95:810.
24. Humphries AW, Young JR, deWolfe VG, et al. Complications of abdominal aortic surgery. *Arch Surg.* 1963;86:43.
25. Hallett JW Jr, Marshall DM, Petterson TM, et al. Graft-related complications after abdominal aortic aneurysm repair:

- reassurance from a 36-year population-based experience. *J Vasc Surg.* 1997;25:277.
26. Thomas WEG, Baird RN. Secondary aorto-enteric fistulae: towards a more conservative approach. *Br J Surg.* 1986;73:875.
  27. O'Hara PJ, Hertzner NR, Beven EG, et al. Surgical management of infected abdominal aortic grafts: review of 25-year experience. *J Vasc Surg.* 1986;3:725.
  28. Elliott JP, Smith RF, Szilagyi DE. Aortoenteric and paraprosthesis-enteric fistulas. *Arch Surg.* 1974;108:479.
  29. Claytor H, Birch L, Cardwell ES, et al. Suture-line rupture of a nylon aortic bifurcation graft into the small bowel. *Arch Surg.* 1956;73:947.
  30. DeWeese MS, Fry WJ. Small bowel erosion following aortic resection. *JAMA.* 1962;179:882.
  31. Busuttil RN, Reese W, Baker JD, et al. Pathogenesis of aortoduodenal fistula: experimental and clinical correlates. *Surgery.* 1979;85:1.
  32. Higgins RSD, Steed DL, Zajko AB, et al. Computed tomographic scan confirmation of paraprosthesis enteric fistula. *Am J Surg.* 1991;162:36.
  33. Reilly LM, Ehrenfeld WK, Goldstone J, et al. Gastrointestinal tract involvement by prosthetic graft infection: the significance of gastrointestinal hemorrhage. *Ann Surg.* 1985;202:342.
  34. Lawrence PF. Management of infected aortic grafts. *Surg Clin North Am.* 1995;75:783.
  35. Conn JH, Hardy JD, Chavez CM, et al. Infected arterial grafts. *Ann Surg.* 1970;171:704.
  36. Fry WJ, Lindenauer SM. Infection complicating the use of plastic arterial implants. *Arch Surg.* 1967;94:600.
  37. Kleinman LH, Towne JB, Bernhard WM. A diagnostic and therapeutic approach to aorto-enteric fistulas: clinical experience with twenty patients. *Surgery.* 1979;86:868.
  38. Perdue GD Jr, Smith RB, Ansley JD, et al. Impending aortoenteric hemorrhage: the effect of early recognition on improved outcome. *Ann Surg.* 1980;192:237.
  39. Nelken N. Aortoenteric fistula. In: Callow AD, Ernst CB, eds. *Vascular Surgery: Theory and Practice.* Stamford, CT: Appleton & Lange; 1995:1311-1323.
  40. Bernhard VM. *Aortoenteric Fistula.* Orlando, FL: Grune & Stratton; 1985:513-525.
  41. O'Mara CS, Imbembo AL. Paraprosthesis enteric fistula. *Surgery.* 1977;81:556.
  42. Voorhoeve R, Moll FL, Bast TJ. The primary aortoenteric fistula in The Netherlands—the unpublished cases. *Eur J Vasc Endovasc Surg.* 1996;11:429.
  43. Abou-Zamzam AM, Bianchi C, Mazraany W, et al. Aortoenteric fistula development following endovascular abdominal aortic aneurysm repair: a case report. *Ann Vasc Surg.* 2003;17:119.
  44. Bertges DJ, Villela ER, Makaroun MS. Aortoenteric fistula due to endoleak coil embolization after endovascular AAA repair. *J Endovasc Ther.* 2003;10:130.
  45. French J, Simring D, Merrett N, et al. Aorto-enteric fistula following endoluminal aortic aneurysm repair. *Aust N Z J Surg.* 2004;74:397.
  46. Janne DB, Soula P, Otal P, et al. Aortoduodenal fistula after endovascular stent-graft of an abdominal aortic aneurysm. *J Vasc Surg.* 2000;31:190.
  47. Hausseger, K, Tiesenhausen K, Karaic R, et al. Aortoduodenal fistula: a late complication of intraluminal exclusion of infrarenal aortic aneurysm. *J Vasc Interv Radiol.* 1999;10:747.
  48. Hirst AE, Affeldt JE. Abdominal aortic aneurysm with rupture into the duodenum: a case report of eight cases. *Gastroenterology.* 1971;17:504.
  49. Daugherty M, Shearer GR, Ernst CB. Primary aortoduodenal fistula: extra-anatomic vascular reconstruction not required for successful management. *Surgery.* 1979;86:399.
  50. Voyles WR, Moretz WH. Rupture of aortic aneurysms into gastrointestinal tract. *Surgery.* 1958;43:666.
  51. Champion MC, Sullivan SN, Coles JC, et al. Aortoenteric fistula: incidence, presentation, recognition, and management. *Ann Surg.* 1982;195:314.

52. Crawford ES, Manning LG, Kelly TF. "Redo" surgery after operations for aneurysm and occlusion of the abdominal aorta. *Surgery*. 1977;81:41.
53. Fulenwider JT, Smith RB, Johnson RW, et al. Reoperative abdominal arterial surgery: a ten-year experience. *Surgery*. 1982;93:20.
54. Pabst TS III, Bernhard VM, McIntyre KE Sr, et al. Gastrointestinal bleeding following aortic surgery: the place of laparotomy to rule out aortoenteric fistula. *J Vasc Surg*. 1988;8:280.
55. Kuestner LM, Reilly LM, Jicha DL, et al. Secondary aortoenteric fistula: contemporary outcome with use of extraanatomic bypass and infected graft excision. *J Vasc Surg*. 1995;21:184.
56. Rosenthal D, Deterling RA Jr, O'Donnell TF, et al. Positive blood culture as an aid in the diagnosis of secondary aortoenteric fistula. *Arch Surg*. 1979;114:1041.
57. Gordon SL, Nicholas GG, Carter SL, et al. Aortoenteric fistula presenting as multicentric osteomyelitis. *Clin Orthop Relat Res*. 1978;131:255.
58. Baker BH, Baker MS, vander Reis L, et al. Endoscopy in the diagnosis of aortoduodenal fistula. *Gastrointest Endosc*. 1977;24:35.
59. Bunt TJ, Doerhoff CR. Endoscopic visualization of an intraluminal Dacron graft: definitive diagnosis of aortoduodenal fistula. *South Med J*. 1984;77:86.
60. Ott DJ, Kerr RM, Gelfand DW. Aortoduodenal fistula. *Gastrointest Endosc*. 1978;24:296.
61. Mir-Madjlessi SH, Sullivan BH Jr, Farmer RG, et al. Endoscopic diagnosis of aortoduodenal fistula. *Gastrointest Endosc*. 1973;19:187.
62. Kukora JS, Rushton FW, Cranston PE. New computed tomographic signs of aortoenteric fistula. *Arch Surg*. 1984;119:1073.
63. Gupta RK, Rogers KE. A unique case of aortoduodenal fistula following carcinoma of cervix. *Am J Obstet Gynecol*. 1978;131:110.
64. Low RN, Wall SD, Jeffrey RB, et al. Aortoenteric fistula and perigraft infection: evaluation with CT. *Radiology*. 1990;175:157.
65. Lemos DW, Raffetto JD, Moore TC, et al. Primary aortoduodenal fistula: a case report and review of the literature. *J Vasc Surg*. 2003;37:686.
66. Cunaat JS, Haaga JR, Rhodes R, et al. Periaortic fluid aspiration for recognition of infected graft: preliminary report. *AJR Am J Roentgenol*. 1982;139:251.
67. Katz BH, Black RA, Colley DP. CT-guided fine-needle aspiration of a perigraft collection. *J Vasc Surg*. 1987;5:762.
68. O'Donnell TF Jr, Scott G, Shepard A, et al. Improvements in the diagnosis and management of aortoenteric fistulas. *Am J Surg*. 1985;149:481.
69. Schütte HE. Angiographic signs of aortic graft-enteric fistulae. *Clin Radiol*. 1987;38:503.
70. Olofsson PA, Auffermann W, Higgins CB, et al. Diagnosis of prosthetic graft infection by magnetic resonance imaging (MRI) *J Vasc Surg*. 1988;8:99.
71. Lawrence PF, Dries DJ, Alazraki N, et al. Indium 111-labeled leukocyte scanning for detection of prosthetic graft infection. *J Vasc Surg*. 1985;2:165.
72. LaMuraglia GM, Fischman AJ, Strauss HW, et al. Utility of indium-111-labeled human immunoglobulin G scan for the detection of focal vascular graft infection. *J Vasc Surg*. 1989;10:20.
73. Ramo OJ, Vorne M, Lantto T, et al. Postoperative graft incorporation after aortic reconstruction—comparison between computerized tomography and Tc-99m-HMPAO labeled leucocyte imaging. *Eur J VascSurg*. 1993;7:122.
74. Alfrey EJ, Stanton C, Dunnington G, et al. Graft appendiceal fistulas. *J Vasc Surg*. 1988;7:814.
75. Dalinka MK, Reginato AJ, Berkowitz HD, et al. Hypertrophic osteoarthropathy as indication of aortic graft infection and aortoenteric fistula. *Arch Surg*. 1982;117:1355.

76. King JO. Localized clubbing in hypertrophic osteoarthropathy due to infection in an aortic prosthesis. *BMJ*. 1972;4:404.
77. Seeger JM, Back MR, Albright JL, et al. Influence of patient characteristics and treatment options on outcome of patients with prosthetic aortic graft infection. *Ann Vasc Surg*. 1999;13:413.
78. Reilly LM, Stoney RJ, Goldstone J, et al. Improved management of aortic graft infection: the influence of operative sequence and staging. *J Vasc Surg*. 1987;5:421.
79. Walker WE, Cooley DA, Duncan JM, et al. The management of aortoduodenal fistula by in situ replacement of the infected abdominal aortic graft. *Ann Surg*. 1987;205:727.
80. Taheri SA, Kulaylat MN, Grippi J, et al. Surgical treatment of primary aortoduodenal fistula. *Ann Vasc Surg*. 1991;5:265.
81. Belair M, Soulez G, Oliva VL, et al. Aortic graft infection: the value of percutaneous drainage. *AJR Am J Roentgenol*. 1998;171:119.
82. Bunt TJ. Vascular graft infections: a personal experience. *Cardiovasc Surg*. 1993;1:489.
83. Bergquist D, Alm A, Claes G, et al. Secondary aortoenteric fistulas—an analysis of 42 cases. *Eur J Vasc Surg*. 1987;1:11.
84. Shah DM, Buchbinder D, Leather RP, et al. Clinical use of the seromuscular jejunal patch for protection of the infected aortic stump. *Am J Surg*. 1983;146:198.
85. Reilly LM. Aortic graft infection: evolution in management. *Cardiovasc Surg*. 2002;10:372.
86. Clagett GP, Bowers BL, Lopez-Viejo MA, et al. Creation of a neo-aortoiliac system from lower extremity deep and superficial veins. *Ann Surg*. 1993;210:239.
87. Clagett GP, Valentine RJ, Hagino RT. Autogenous aortoiliac/femoral reconstruction from superficial femoral-popliteal veins: feasibility and durability. *J Vasc Surg*. 1997;25:255.
88. Kieffer E, Bahnini A, Koskas F, et al. In-situ allograft replacement of infected infrarenal aortic prosthetic grafts: results in forty-three patients. *J Vasc Surg*. 1993;17:349.
89. Young RM, Cherry KJ Jr, David PM, et al. The results of in situ prosthetic replacement for infected aortic grafts. *Am J Surg*. 1999;178:136.
90. Burks JA, Faries PL, Gravereaux EC, et al. Endovascular repair of bleeding aortoenteric fistulas: a 5 year experience. *J Vasc Surg*. 2001;34:1055.
91. Deshpande A, Lovelock M, Mossop P, et al. Endovascular repair of an aortoenteric fistula in a high-risk patient. *J Endovasc Surg*. 1999;6:379.
92. Tomlinson M, Gold B, Thomas M, et al. Endovascular stent graft repair of a recurrent aorto-enteric fistula. *Eur J Vasc Endovasc Surg*. 2002;24:459.
93. Brountzos E, Vasdekis S, Kostopanagiotou G, et al. Endovascular treatment of a bleeding secondary aorto-enteric fistula. A case report with 1 year follow-up. *Cardiovasc Intervent Radiol*. 2007;30:1037.
94. El Sakka K, Halawa M, Kotze C, et al. Complications of open abdominal aortic surgery: the endovascular solution. *Interact Cardiovasc Thorac Surg*. 2008;7:121.
95. Danneels M, Verhagen H, Teijink J, et al. Endovascular repair for aorto-enteric fistula: a bridge too far or a bridge to surgery. *Eur J Vasc Endovasc Surg*. 2006;32:27.
96. Chuter T, Lukaszewicz G, Reilly L, et al. Endovascular repair of a presumed aortoenteric fistula: late failure due to recurrent infection. *J Endovasc Ther*. 2000;7:240.
97. Sierra J, Kalangos A, Faidutti B, et al. Aorto-enteric fistula is a serious complication to aortic surgery. Modern trends in diagnosis and therapy. *Cardiovasc Surg*. 2003;11:185.
98. Moulton S, Adams M, Johansen K. Aortoenteric fistula: a 7 year experience. *Am J Surg*. 1986;151:607.
99. Harris JP, Sheil AGR, Stephen MS, et al. Lessons learnt in the management of aortoenteric fistula. *J Cardiovasc Surg*. 1987;28:449.
100. Yeager RA, Moneta GL, Taylor LM Jr, et al. Improving survival and limb salvage in patients with aortic graft infection. *Am J Surg*. 1990;159:466.

101. Higgins RSD, Steed DL, Julian TB, et al. The management of aortoenteric and paraprosthetic fistulae. *J Cardiovasc Surg.* 1990;31:81.
102. McCann RL, Schwartz LB, Georgiade GS. Management of abdominal aortic graft complications. *Ann Surg.* 1993;217:729.
103. van Baalen JM, Kluit AB, Maas J, et al. Diagnosis and therapy of aortic prosthetic fistulas: trends over a 30-year experience. *Br J Surg.* 1996;83:1729.
104. Bergquist D, Bjorkman H, Bolin T, et al. Secondary aortoenteric fistulae—changes from 1973 to 1993. *Eur J Vasc Endovasc Surg.* 1996;11:425.
105. Nevelsteen A, Feryn T, Lacroix H, et al. Experience with cryopreserved arterial allografts in the treatment of prosthetic graft infections. *Cardiovasc Surg.* 1998;6:378.
106. Kiernan PD, Pairolero PC, Hubert JP Jr, et al. Aortic graft-enteric fistula. *Mayo Clin Proc.* 1980;55:731.

## 第 43 章

1. Birch L, Cardwell ES, Claytor H, et al. Suture-line rupture of a nylon aortic bifurcation graft into the small bowel. *AMA Arch Surg.* 1954;73:947.
2. Goldstone J. Anastomotic aneurysms. In: Bernard VM, Towne JB, eds. *Complications in Vascular Surgery.* St Louis, MO: Quality Medical Publishing; 1991.
3. Szilagyi DE, Elliott JP, Smith RF, et al. A thirty-year survey of the reconstructive surgical treatment of aortoiliac occlusive disease. *J Vasc Surg.* 1986;3:421.
4. Sigala F, Georgopoulos S, Sigalas K, et al. Femoral anastomotic aneurysms in the modern era: a reappraisal of a continuing challenge. *Minerva Chir.* 2006;61:95.
5. Markovic DM, Davidovic LB, Kostic DM, et al. False anastomotic aneurysms. *Vascular.* 2007;15:141.
6. Skourtis G, Bountouris I, Papacharalambous G, et al. Anastomotic pseudoaneurysms: our experience with 49 cases. *Ann Vasc Surg.* 2006;20:582.
7. Schellack J, Salam A, Abouzeid MA, et al. Femoral anastomotic aneurysms: a continuing challenge. *J Vasc Surg.* 1987;6:308.
8. Youkey JR, Clagett GP, Rich NM, et al. Femoral anastomotic false aneurysms: an 11-year experience analyzed with a case control study. *Ann Surg.* 1984;199:703.
9. Demarche M, Waltregny D, van Damme H, et al. Femoral anastomotic aneurysms: pathogenic factors, clinical presentations and treatment. A study of 142 cases. *Cardiovasc Surg.* 1999;7:315.
10. Levi N, Schroeder TV. Anastomotic femoral aneurysms: increase in interval between primary operation and aneurysm formation. *Eur J Vasc Endovasc Surg.* 1996;11:207.
11. Dennis JW, Littooy FN, Greisler HP, et al. Anastomotic pseudoaneurysms: a continuing late complication of vascular reconstructive procedures. *Arch Surg.* 1986;121:314.
12. Sachdev U, Baril DT, Morrissey NJ, et al. Endovascular repair of para-anastomotic aortic aneurysms. *J Vasc Surg.* 2007;46:636.
13. Morrissey NJ, Yano OJ, Soundararajan K, et al. Endovascular repair of para-anastomotic aneurysms of the aorta and iliac arteries: preferred treatment for a complex problem. *J Vasc Surg.* 2001;33:503.
14. Van den Akker PJ, Brand R, van Schilfgaarde R, et al. False aneurysms after prosthetic reconstructions for aortoiliac obstructive disease. *Ann Surg.* 1989;210:658.
15. Conrad MF, Crawford RS, Pedraza JD, et al. Long-term durability of open abdominal aortic aneurysm repair. *J Vasc Surg.* 2007;46:669.
16. Hallett JW Jr, Marshall DM, Petterson TM, et al. Graft-related complications after abdominal aortic aneurysm repair: reassurance from a 36-year population-based experience. *J Vasc Surg.* 1996;25:277.
17. Gawenda M, Zaehring M, Brunkwall J. Open versus endovascular repair of para-anastomotic aneurysms in patients who

- were morphological candidates for endovascular treatment. *J Endovasc Ther.* 2003;10:745.
18. Mii SH, Mori A, Sakata H, et al. Para-anastomotic aneurysms: incidence, risk factors, treatment, and prognosis. *J Cardiovasc Surg.* 1998;39:259.
  19. Van Herwaarden JA, Waasdorp EJ, Bendermacher BLW, et al. Endovascular repair of paraanastomotic aneurysms after previous open aortic prosthetic reconstruction. *Ann Vasc Surg.* 2004;18:280.
  20. Edwards JM, Teefey SA, Zierler RE, et al. Intraabdominal paraanastomotic aneurysms after aortic bypass grafting. *J Vasc Surg.* 1992;15:344.
  21. Mulder EJ, van Bockel JH, Maas J, et al. Morbidity and mortality of reconstructive surgery of non-infected false aneurysms detected long after aortic prosthetic reconstruction. *Arch Surg.* 1998;133:45.
  22. Branch CL Jr, Davis CH Jr. False aneurysm complicating carotid endarterectomy. *Neurosurgery.* 1986;19:421.
  23. Zhou W, Lin PH, Bush RL, et al. Carotid artery aneurysm: evolution of management over two decades. *J Vasc Surg.* 2006;43:493.
  24. Borazjani BH, Wilson SE, Fujitani RM, et al. Postoperative complications of carotid patching: pseudoaneurysm and infection. *Ann Vasc Surg.* 2003;17:156.
  25. McCabe CJ, Moncure AC, Malt RA. Host-artery weakness in the etiology of femoral anastomotic false aneurysms. *Surgery.* 1984;95:150.
  26. Hollier LH, Batson RC, Cohn I Jr. Femoral anastomotic aneurysms. *Ann Surg.* 1980;191:715.
  27. Starr DS, Weatherford SC, Lawrie GM, et al. Suture material as a factor in the occurrence of anastomotic false aneurysms. *Arch Surg.* 1979;114:412.
  28. Calhoun TR, Kitten CM. Polypropylene suture—is it safe? *J Vasc Surg.* 1986;4:98.
  29. Zeebregts CJ, Kirsch WM, van den Dungen JJ, et al. Five years' world experience with nonpenetrating clips for vascular anastomoses. *Am J Surg.* 2004;187:751.
  30. Zeebregts CJ, Heijmen RH, van den Dungen JJ, et al. Non-suture methods of vascular anastomosis. *Br J Surg.* 2003;90:261.
  31. Mehigan DG, Fitzpatrick B, Browne HI, et al. Is compliance mismatch the major cause of anastomotic arterial aneurysms? Analysis of 42 cases. *J Cardiovasc Surg.* 1985;26:147.
  32. Gaylis H. Pathogenesis of anastomotic aneurysms. *Surgery.* 1981;90:509.
  33. Seabrook GR, Schmitt DD, Bandyk DF, et al. Anastomotic femoral pseudoaneurysms: an investigation of occult infection as an etiologic factor. *J Vasc Surg.* 1990;11:629.
  34. Ylönen K, Biancari F, Leo E, et al. Predictors of development of anastomotic femoral pseudoaneurysms after aortobifemoral reconstruction for abdominal aortic aneurysm. *Am J Surg.* 2004;187:83.
  35. Downs AR, Guzman R, Formichi M, et al. Etiology of prosthetic anastomotic false aneurysms: pathologic and structural evaluation in 26 cases. *Can J Surg.* 1991;34:53.
  36. Alpagut U, Ugurlucan M, Daytoglu E. Major arterial involvement and review of Behçet's disease. *Ann Vasc Surg.* 2007;21:232.
  37. Oderich GS, Panneton JM, Bower TC, et al. The spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV: a 30-year experience. *J Vasc Surg.* 2005;42:98.
  38. Szilagyi DE, Smith RF, Elliott JP, et al. Anastomotic aneurysms after vascular reconstruction: problems of incidence, etiology, and treatment. *Surgery.* 1975;78:800.
  39. Argifoglio G, Costantini A, Lorenzi G, et al. Femoral noninfected anastomotic aneurysms. *J Cardiovasc Surg.* 1990;31:453.
  40. Mestres CA, Ninot S, Mulet J. Erosion of lumbar vertebral bodies by an anastomotic false aneurysm late after implantation of a prosthetic aortic bifurcated graft. *Interact Cardiovasc Thorac Surg.* 2006;5:121.
  41. Baldwin ZK, Sokoloff MM, Gerber GS. Ureteroarterial fistula with ruptured anastomotic pseudoaneurysm: successful management with vascular exclusion, extra-anastomotic bypass and nephrectomy—a case report. *Vasc Endovasc Surg.* 2005;39:203.

42. Treiman GS, Weaver FA, Cossman DV, et al. Anastomotic false aneurysms of the abdominal aorta and the iliac arteries. *J Vasc Surg.* 1988;8:268.
43. Taylor LM Jr, Van Kolken RJ, Baur GM, et al. Precise diagnosis of aortic anastomotic aneurysm by computed tomographic scan. *Arch Surg.* 1981;116:1209.
44. Bastounis E, Georgopoulos S, Balas P. The validity of current vascular imaging methods in the evaluation of aortic anastomotic aneurysms developing after abdominal aortic aneurysm repair. *Ann Vasc Surg.* 1996;10:537.
45. Nevelsteen A, Suy R. Anastomotic false aneurysms of the abdominal aorta and the iliac arteries. *J Vasc Surg.* 1989;10:595.
46. Ochsner JL. Management of femoral pseudoaneurysms. *Surg Clin North Am.* 1982;62:431.
47. Levi N, Schroeder TV. True and anastomotic femoral artery aneurysms: is the risk of rupture and thrombosis related to the size of the aneurysm? *Eur J Vasc Surg.* 1999;18:111.
48. Abou-Zamzam AM Jr, Ballard JL. Management of sterile para-anastomotic aneurysms of the aorta. *Semin Vasc Surg.* 2001;14:282.
49. Taylor BV, Kalman PG. Saccular aortic aneurysms. *Ann Vasc Surg.* 1999;13:555.
50. Faggioli G, Freyrie A, Stella A, et al. Extracranial internal carotid artery aneurysms: results of a surgical series with long-term follow-up. *J Vasc Surg.* 1996;23:587.
51. Di Marzo L, Strandness EL, Schultz RD, et al. Reoperation for femoral anastomotic false aneurysm: a 15-year experience. *Ann Surg.* 1987;206:168.
52. Schache DJ, Englund R, Effenev DJ. Femoral false aneurysm: a recommendation for the method of repair. *Aust N Z J Surg.* 1988;58:377.
53. Chiesa R, Marone EM, Brioschi C, et al. Open repair of pararenal aortic aneurysms: operative management, early results, and risk factor analysis. *Ann Vasc Surg.* 2006;20:739.
54. Hertzner NR. Extracranial carotid aneurysms: a new look at an old problem. *J Vasc Surg.* 2000;31:823.
55. El-Sabroun R, Cooley DA. Extracranial carotid artery aneurysms: Texas Heart Institute experience. *J Vasc Surg.* 2000;31:702.
56. Derom A, Nout E. Treatment of femoral pseudoaneurysms with endograft in high-risk patients. *Eur J Vasc Endovasc Surg.* 2005;30:644.
57. Klonaris C, Katsargyris A, Matthaiou A, et al. Emergency stenting of a ruptured infected anastomotic femoral pseudoaneurysm. *Cardiovasc Intervent Radiol.* 2007;30:1238.
58. Liewald F, Kapfer X, Gorich J, et al. Endograft treatment of anastomotic aneurysms following conventional open surgery for infrarenal aortic aneurysms. *Eur J Vasc Endovasc Surg.* 2001;21:46.
59. Magnan PE, Albertini JN, Bartoli JM, et al. Endovascular treatment of anastomotic false aneurysms of the abdominal aorta. *Ann Vasc Surg.* 2003;17:365.
60. Piffaretti G, Tozzi M, Lomazzi C, et al. Endovascular treatment for para-anastomotic abdominal aortic and iliac aneurysms following aortic surgery. *J Cardiovasc Surg.* 2007;48:711.
61. Lagana D, Carrafiello G, Mangini M, et al. Endovascular treatment of anastomotic pseudoaneurysms after aorto-iliac surgical reconstruction. *Cardiovasc Intervent Radiol.* 2007;30:1185.
62. Curti T, Stella A, Rossi C, et al. Endovascular repair as first-choice treatment for anastomotic and true iliac aneurysms. *J Endovasc Ther.* 2001;8:139.
63. Zhou W, Bush RL, Bhama JK, et al. Repair of anastomotic abdominal aortic pseudoaneurysm utilizing sequential AneuRx aortic cuffs in an overlapping configuration. *Ann Vasc Surg.* 2006;20:17.
64. Verhoeven ELG, Muhs BE, Zeebregts CJAM, et al. Fenestrated and branched stent-grafting after previous surgery provides a good alternative to open redo surgery. *Eur J Vasc Endovasc Surg.* 2007;33:84.
65. Adam DJ, Berce M, Hartley DE, et al. Repair of juxtarenal para-anastomotic aortic aneurysms after previous open repair with fenestrated and branched endovascular stent grafts. *J Vasc Surg.* 2005;42:997.



66. Faries PL, Won J, Morrissey NJ, et al. Endovascular treatment of failed prior abdominal aortic aneurysm repair. *Ann Vasc Surg.* 2003;17:43.
67. El Sakka K, Halawa M, Kotze C, et al. Complications of open abdominal aortic surgery: the endovascular solution. *Interact Cardiovasc Thorac Surg.* 2008;7:121.
68. Yamagami T, Kanda K, Kato T, et al. Embolisation of proximal anastomotic pseudoaneurysm developing after surgical repair of abdominal aortic aneurysm with a bifurcated graft with *n*-butyl cyanoacrylate. *Br J Radiol.* 2006;79:e193.
69. Alzubaidi A, MacDonald S, Clement J, et al. Percutaneous closure of a para-anastomotic abdominal aortic graft leak. *Catheter Cardiovasc Interv.* 2006;68:799.
70. Fann JJ, Samuels S, Slonim S, et al. Treatment of abdominal aortic anastomotic pseudoaneurysm with percutaneous coil embolization. *J Vasc Surg.* 2002;35:811.
71. Yuan JG, Marin ML, Veith FJ, et al. Endovascular grafts for noninfected aortoiliac anastomotic aneurysms. *J Vasc Surg.* 1997;26:210.
72. Parsons RE, Marin ML, Veith FJ, et al. Midterm results of endovascular stented grafts for the treatment of isolated iliac artery aneurysms. *J Vasc Surg.* 1999;30:915.
73. Sanchez LA, Patel AV, Ohki T, et al. Midterm experience with the endovascular treatment of isolated iliac aneurysms. *J Vasc Surg.* 1999;30:907.
74. Criado E, Marston WA, Ligush J, et al. Endovascular repair of peripheral aneurysms, pseudoaneurysms, and arteriovenous fistulas. *Ann Vasc Surg.* 1997;11:256.
75. Hans SS, Khoury MD, Bove P, et al. Technical considerations in endovascular repair of large symptomatic iliac anastomotic aneurysms. *Ann Vasc Surg.* 2007;21:376.
76. Bush RL, Lin PH, Dodson TF, et al. Endoluminal stent placement and coil embolization for the management of carotid artery pseudoaneurysms. *J Endovasc Ther.* 2001;8:53.
77. Saatci I, Cekirge HS, Ozturk MH, et al. Treatment of internal carotid artery aneurysms with a covered stent: experience in 24 patients with mid-term follow-up results. *AJNR Am J Neuroradiol.* 2004;25:1742.
78. Allen RC, Schneider J, Longenecker L, et al. Paraanastomotic aneurysms of the abdominal aorta. *J Vasc Surg.* 1993;18:424.
79. Curl GR, Faggioli GL, Stella A, et al. Aneurysmal change at or above the proximal anastomosis after infrarenal aortic grafting. *J Vasc Surg.* 1992;16:855.
80. McCann RL, Schwartz LB, Georgiade GS. Management of abdominal aortic graft complications. *Ann Surg.* 1993;217:729.
81. Clarke AM, Poskitt KR, Baird RN, et al. Anastomotic aneurysms of the femoral artery: aetiology and treatment. *Br J Surg.* 1989;76:1014.
82. Ernst CB, Elliott JP, Ryan CJ, et al. Recurrent femoral anastomotic aneurysms: a 30-year experience. *Ann Surg.* 1988;208:401.
83. Carson SN, Hunter GC, Palmaz J, et al. Recurrence of femoral anastomotic aneurysms. *Am J Surg.* 1983;146:774.

## 第 44 章

1. Giswold ME, Landry GJ, Sexton GJ, et al. Modifiable patient factors are associated with reverse vein graft occlusion in the era of duplex scan surveillance. *J Vasc Surg.* 2003;37:47-53.
2. Watson HR, Schroeder TV, Simms MH, et al. Relationship of femorodistal bypass patency to clinical outcome. Iloprost Bypass International Study Group. *Eur J Vasc Endovasc Surg.* 1999;17:77-83.
3. Stept LL, Flinn WR, McCarthy WJ 3rd, et al. Technical defects as a cause of early graft failure after femorodistal bypass. *Arch Surg.* 1987;122:599-604.
4. Walsh DB, Zwolak RM, McDaniel MD, et al. Intragraft drug infusion as an adjunct to balloon catheter thrombectomy for salvage of thrombosed infragenicular vein grafts: a preliminary report. *J Vasc Surg.* 1990;11:753-759; discussion 60.
5. Wolfle KD, Bruijnen H, Mayer B, et al. [Follow-up of infra-inguinal bypass operations: value of the peak systolic velocity

- and arm-ankle index for evaluation of femorodistal reconstructions.] *Vasa*. 1994;23:349-356.
6. Mills JL, Fujitani RM, Taylor SM. The characteristics and anatomic distribution of lesions that cause reversed vein graft failure: a five-year prospective study. *J Vasc Surg*. 1993;17:195-204; discussion 204-206.
  7. O'Mara CS, Flinn WR, Johnson ND, et al. Recognition and surgical management of patent but hemodynamically failed arterial grafts. *Ann Surg*. 1981;193:467-476.
  8. Turnipseed WD, Acher CW. Postoperative surveillance. An effective means of detecting correctable lesions that threaten graft patency. *Arch Surg*. 1985;120:324-328.
  9. Veith FJ, Weiser RK, Gupta SK, et al. Diagnosis and management of failing lower extremity arterial reconstructions prior to graft occlusion. *J Cardiovasc Surg (Torino)*. 1984;25:381-384.
  10. Beard JD, Scott DJ, Skidmore R, et al. Operative assessment of femorodistal bypass grafts using a new Doppler flowmeter. *Br J Surg*. 1989;76:925-928.
  11. Schwartz LB, Belkin M, Donaldson MC, et al. Validation of a new and specific intraoperative measurement of vein graft resistance. *J Vasc Surg*. 1997;25:1033-1041; discussion 41-43.
  12. Liebman PR, Menzoian JO, Mannick JA, et al. Intraoperative arteriography in femoropopliteal and femorotibial bypass grafts. *Arch Surg*. 1981;116:1019-1021.
  13. Courbier R, Jausseran JM, Reggi M. Detecting complications of direct arterial surgery: the role of intraoperative arteriography. *Arch Surg*. 1977;112:1115-1118.
  14. Bandyk DF, Mills JL, Gahtan V, et al. Intraoperative duplex scanning of arterial reconstructions: fate of repaired and unrepaired defects. *J Vasc Surg*. 1994;20:426-432; discussion 32-33.
  15. Bredenberg CE, Iannetoni M, Rosenbloom M, et al. Operative angiography by intraarterial digital subtraction angiography: a new technique for quality control of carotid endarterectomy. *J Vasc Surg*. 1989;9:530-534.
  16. Mills JL, Fujitani RM, Taylor SM. Contribution of routine intraoperative completion arteriography to early infrainguinal bypass patency. *Am J Surg*. 1992;164:506-510; discussion 10-11.
  17. Bandyk DF, Zierler RE, Thiele BL. Detection of technical error during arterial surgery by pulsed Doppler spectral analysis. *Arch Surg*. 1984;119:421-428.
  18. Coelho JC, Sigel B, Flanagan DP, et al. An experimental evaluation of arteriography and imaging ultrasonography in detecting arterial defects at operation. *J Surg Res*. 1982;32:130-137.
  19. Kresowik TF, Hoballah JJ, Sharp WJ, et al. Intraoperative B-mode ultrasonography is a useful adjunct to peripheral arterial reconstruction. *Ann Vasc Surg*. 1993;7:33-38.
  20. Gaunt ME, Smith JL, Ratliff DA, et al. A comparison of quality control methods applied to carotid endarterectomy. *Eur J Vasc Endovasc Surg*. 1996;11:4-11.
  21. Machi J, Sigel B, Roberts A, et al. Operative color Doppler imaging for vascular surgery. *J Ultrasound Med*. 1992;11:65-71.
  22. Cull DL, Gregory RT, Wheeler JR, et al. Duplex scanning for the intraoperative assessment of infrainguinal arterial reconstruction: a useful tool? *Ann Vasc Surg*. 1992;6:20-24.
  23. Jackson MR, D'Addio VJ, Gillespie DL, et al. The fate of residual defects following carotid endarterectomy detected by early postoperative duplex ultrasound. *Am J Surg*. 1996;172:184-187.
  24. Yu A, Gregory D, Morrison L, et al. The role of intra-operative duplex imaging in arterial reconstructions. *Am J Surg*. 1996;171:500-501.
  25. Rzuclido EM, Walsh DB, Powell RJ, et al. Prediction of early graft failure with intraoperative completion duplex ultrasound scan. *J Vasc Surg*. 2002;36:975-981.
  26. Miller A, Stonebridge PA, Jepsen SJ, et al. Continued experience with intraoperative angioscopy for monitoring infrainguinal bypass grafting. *Surgery*. 1991;109:286-293.
  27. Wilson YG. Vein quality in infrainguinal revascularisation: assessment by angioscopy and histology. *Ann R Coll Surg Engl*. 1998;80:3-15.

28. Marcaccio EJ, Miller A, Tannenbaum GA, et al. Angioscopically directed interventions improve arm vein bypass grafts. *J Vasc Surg.* 1993;17:994-1002; discussion 3-4.
29. Sales CM, Marin ML, Veith FJ, et al. Saphenous vein angiography: a valuable method to detect unsuspected venous disease. *J Vasc Surg.* 1993;18:198-204; discussion 204-206.
30. Stonebridge PA, Miller A, Tsoukas A, et al. Angioscopy of arm vein infrainguinal bypass grafts. *Ann Vasc Surg.* 1991;5:170-175.
31. Lee G, Beerline D, Lee MH, et al. Hazards of angioscopic examination: documentation of damage to the arterial intima. *Am Heart J.* 1988;116:1530-1536.
32. Hashizume M, Yang Y, Galt S, et al. Intimal response of saphenous vein to intraluminal trauma by stimulated angioscopic insertion. *J Vasc Surg.* 1987;5:862-868.
33. Thorne J, Danielsson G, Danielsson P, et al. Intraoperative angioscopy may improve the outcome of in situ saphenous vein bypass grafting: a prospective study. *J Vasc Surg.* 2002;35:759-765.
34. Neville RF Jr, Yasuhara H, Watanabe BI, et al. Endovascular management of arterial intimal defects: an experimental comparison by arteriography, angioscopy, and intravascular ultrasonography. *J Vasc Surg.* 1991;13:496-502.
35. Neville RF, Hobson RW, 2nd, Jamil Z, et al. Intravascular ultrasonography: validation studies and preliminary intraoperative observations. *J Vasc Surg.* 1991;13:274-282; discussion 82-83.
36. Siegel RJ, Ariani M, Fishbein MC, et al. Histopathologic validation of angioscopy and intravascular ultrasound. *Circulation.* 1991;84:109-117.
37. Tabbara MR, Mehlinger CM, Cavaye DM, et al. Sequential intraluminal ultrasound evaluation of balloon angioplasty of an iliac artery lesion. *Ann Vasc Surg.* 1992;6:179-184.
38. Song TK, Donayre CE, Walot I, et al. Endograft exclusion of acute and chronic descending thoracic aortic dissections. *J Vasc Surg.* 2006;43:247-258.
39. Koschyk DH, Nienaber CA, Knap M, et al. How to guide stent-graft implantation in type B aortic dissection? Comparison of angiography, transesophageal echocardiography, and intravascular ultrasound. *Circulation.* 2005;112:I260-I264.
40. Saket RR, Razavi MK, Padidar A, et al. Novel intravascular ultrasound-guided method to create transintimal arterial communications: initial experience in peripheral occlusive disease and aortic dissection. *J Endovasc Ther.* 2004;11:274-280.
41. Diethrich EB. Endovascular treatment of abdominal aortic occlusive disease: the impact of stents and intravascular ultrasound imaging. *Eur J Vasc Surg.* 1993;7:228-236.
42. Ascer E, Veith FJ, Morin L, et al. Components of outflow resistance and their correlation with graft patency in lower extremity arterial reconstructions. *J Vasc Surg.* 1984;1:817-828.
43. Peterkin GA, LaMorte WW, Menzoian JO. Runoff resistance and early graft failure in infrainguinal bypass surgery. *Arch Surg.* 1988;123:1199-1201.
44. Wolfle KD, Bruijnen H, Morski A, et al. The importance of graft blood flow and peripheral outflow resistance for early patency in infrainguinal arterial reconstructions. *Vasa.* 1999;28:34-41.
45. Darling RC, 3rd, Chang BB, Shah DM, et al. Choice of peroneal or dorsalis pedis artery bypass for limb salvage. *Semin Vasc Surg.* 1997;10:17-22.
46. Singh N, Sidawy AN, Dezee KJ, et al. Factors associated with early failure of infrainguinal lower extremity arterial bypass. *J Vasc Surg.* 2008;47:556-561.
47. Robinson KD, Sato DT, Gregory RT, et al. Long-term outcome after early infrainguinal graft failure. *J Vasc Surg.* 1997;26:425-437; discussion 37-38.
48. Seeger JM, Pretus HA, Carlton LC, et al. Potential predictors of outcome in patients with tissue loss who undergo infrainguinal vein bypass grafting. *J Vasc Surg.* 1999;30:427-435.
49. Baldwin ZK, Pearce BJ, Curi MA, et al. Limb salvage after infrainguinal bypass graft failure. *J Vasc Surg.* 2004;39:951-957.
50. Singh N, Sidawy AN, Dezee K, et al. The effects of the type of anesthesia on outcomes of lower extremity infrainguinal

- bypass. *J Vasc Surg.* 2006;44:964-968; discussion 968-970.
51. Gibson KD, Caps MT, Gillen D, et al. Identification of factors predictive of lower extremity vein graft thrombosis. *J Vasc Surg.* 2001;33:24-31.
  52. Gentile AT, Mills JL, Gooden MA, et al. Identification of predictors for lower extremity vein graft stenosis. *Am J Surg.* 1997;174:218-221.
  53. Schanzer A, Hevelone N, Owens CD, et al. Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. *J Vasc Surg.* 2007;46:1180-1190; discussion 90.
  54. Schanzer A, Hevelone N, Owens CD, et al. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. *J Vasc Surg.* 2008;47:774-781.
  55. Bartlett ST, Olinde AJ, Flinn WR, et al. The reoperative potential of infrainguinal bypass: long-term limb and patient survival. *J Vasc Surg.* 1987;5:170-179.
  56. Assadian A, Knobl P, Hubl W, et al. Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial. *J Vasc Surg.* 2008;47:537-542.
  57. Curi MA, Skelly CL, Baldwin ZK, et al. Long-term outcome of infrainguinal bypass grafting in patients with serologically proven hypercoagulability. *J Vasc Surg.* 2003;37:301-306.
  58. Donaldson MC, Weinberg DS, Belkin M, et al. Screening for hypercoagulable states in vascular surgical practice: a preliminary study. *J Vasc Surg.* 1990;11:825-831.
  59. Desiron Q, Detry O, Van Damme H, et al. Comparison of results of carotid artery surgery after either direct closure or use of a vein patch. *Cardiovasc Surg.* 1997;5:295-303.
  60. Berceli SA, Hevelone ND, Lipsitz SR, et al. Surgical and endovascular revision of infrainguinal vein bypass grafts: analysis of midterm outcomes from the PREVENT III trial. *J Vasc Surg.* 2007;46:1173-1179.
  61. Bandyk DF. Surveillance after lower extremity arterial bypass. *Perspect Vasc Surg Endovasc Ther.* 2007;19:376-383.
  62. Brumberg RS, Back MR, Armstrong PA, et al. The relative importance of graft surveillance and warfarin therapy in infrainguinal prosthetic bypass failure. *J Vasc Surg.* 2007;46:1160-1166.
  63. Walsh DB. Management of the thrombosed infrainguinal vein graft. In: Whittemore AD, Bandyk DF, Cronenwett JL, eds. *Advances in Vascular Surgery.* Chicago, IL: Mosby-Year Book; 1998:181.
  64. Greenberg RK, Ouriel K. A multi-modal approach to the management of bypass graft failure. *Vasc Med.* 1998;3:215-220.
  65. Madhavan P, Sultan S, McDonnell CO, et al. Low dose intraarterial thrombolysis with tissue plasminogen activator: does it deliver as promised? *Vasc Endovasc Surg.* 2002;36:351-356.
  66. Nehler MR, Mueller RJ, McLafferty RB, et al. Outcome of catheter-directed thrombolysis for lower extremity arterial bypass occlusion. *J Vasc Surg.* 2003;37:72-78.
  67. Donaldson MC, Belkin M, Whittemore AD, et al. Impact of activated protein C resistance on general vascular surgical patients. *J Vasc Surg.* 1997;25:1054-1060.
  68. Fisher CM, Tew K, Appleberg M. Prevalence and outcome of activated protein C resistance in patients after peripheral arterial bypass grafts. *Cardiovasc Surg.* 1999;7:519-525.
  69. Nielsen TG, Nordestgaard BG, von Jessen F, et al. Antibodies to cardiolipin may increase the risk of failure of peripheral vein bypasses. *Eur J Vasc Endovasc Surg.* 1997;14:177-184.
  70. Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. *Semin Thromb Hemost.* 2008;34:86-96.
  71. Bartholomew JR. Heparin-induced thrombocytopenia: 2008 update. *Curr Treat Options Cardiovasc Med.* 2008;10:117-127.
  72. Goodney PP, Nolan BW, Schanzer A, et al. Factors associated with amputation or graft occlusion 1 year after lower extremity bypass. *Ann Vasc Surg.* 2009 (In press).
  73. Sauvage LR, Berger KE, Mansfield PB, et al. Future directions in the development of arterial prostheses for small and medium caliber arteries. *Surg Clin North Am.* 1974;54:213-228.

74. Schmitt DD, Seabrook GR, Bandyk DF, et al. Early patency of in situ saphenous vein bypasses as determined by intraoperative velocity waveform analysis. *Ann Vasc Surg.* 1990;4:270-275.
75. Berkowitz HD, Kee JC. Occluded infrainguinal grafts: when to choose lytic therapy versus a new bypass graft. *Am J Surg.* 1995;170:136-139.
76. Nackman GB, Walsh DB, Fillinger MF, et al. Thrombolysis of occluded infrainguinal vein grafts: predictors of outcome. *J Vasc Surg.* 1997;25:1023-1031; discussion 31-32.
77. Rickard MJ, Fisher CM, Soong CV, et al. Limitations of intra-arterial thrombolysis. *Cardiovasc Surg.* 1997;5:634-640.
78. Schwierz T, Gschwendtner M, Havlicek W, et al. Indications for directed thrombolysis or new bypass in treatment of occlusion of lower extremity arterial bypass reconstruction. *Ann Vasc Surg.* 2001;15:644-652.
79. Kawai S, Sasajima T, Satoh K, et al. Biologic degeneration of vein grafts after thrombotic occlusion: thrombectomy within 3 days results in better indices of viability. *J Vasc Surg.* 2003;38:305-312.
80. Nielsen TG, Jensen LP, Schroeder TV. Early vein bypass thrombectomy is associated with an increased risk of graft related stenoses. *Eur J Vasc Endovasc Surg.* 1997;13:134-138.
81. McMillan WD, McCarthy WJ, Lin SJ, et al. Perioperative low molecular weight heparin for infrageniculate bypass. *J Vasc Surg.* 1997;25:796-801; discussion 801-802.
82. Rutherford RB, Jones DN, Bergentz SE, et al. The efficacy of dextran 40 in preventing early postoperative thrombosis following difficult lower extremity bypass. *J Vasc Surg.* 1984;1:765-773.
83. Sarac TP, Huber TS, Back MR, et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. *J Vasc Surg.* 1998;28:446-457.
84. Rivers SP, Veith FJ, Ascer E, et al. Successful conservative therapy of severe limb-threatening ischemia: the value of nonsympathectomy. *Surgery.* 1986;99:759-762.
85. Sullivan TR Jr, Welch HJ, Iafrati MD, et al. Clinical results of common strategies used to revise infrainguinal vein grafts. *J Vasc Surg.* 1996;24:909-917; discussion 17-19.
86. De Frang RD, Edwards JM, Moneta GL, et al. Repeat leg bypass after multiple prior bypass failures. *J Vasc Surg.* 1994;19:268-276; discussion 76-77.
87. Sanchez LA, Suggs WD, Marin ML, et al. Is percutaneous balloon angioplasty appropriate in the treatment of graft and anastomotic lesions responsible for failing vein bypasses? *Am J Surg.* 1994;168:97-101.
88. Houghton AD, Todd C, Pardy B, et al. Percutaneous angioplasty for infrainguinal graft-related stenoses. *Eur J Vasc Endovasc Surg.* 1997;14:380-385.
89. Gray BH, Olin JW. Limitations of percutaneous transluminal angioplasty with stenting for femoropopliteal arterial occlusive disease. *Semin Vasc Surg.* 1997;10:8-16.
90. Stanley B, Teague B, Raptis S, et al. Efficacy of balloon angioplasty of the superficial femoral artery and popliteal artery in the relief of leg ischemia. *J Vasc Surg.* 1996;23:679-685.
91. Tarry WC, Walsh DB, Birkmeyer NJ, et al. Fate of the contralateral leg after infrainguinal bypass. *J Vasc Surg.* 1998;27:1039-1047; discussion 47-48.
92. Gentile AT, Lee RW, Moneta GL, et al. Results of bypass to the popliteal and tibial arteries with alternative sources of autogenous vein. *J Vasc Surg.* 1996;23:272-279; discussion 9-80.
93. Ascer E, Gennaro M, Pollina RM, et al. Complementary distal arteriovenous fistula and deep vein interposition: a five-year experience with a new technique to improve infrapopliteal prosthetic bypass patency. *J Vasc Surg.* 1996;24:134-143.
94. Farber A, Major K, Wagner WH, et al. Cryopreserved saphenous vein allografts in infrainguinal revascularization: analysis of 240 grafts. *J Vasc Surg.* 2003;38:15-21.
95. Parsons RE, Sanchez LA, Marin ML, et al. Comparison of endovascular and conventional vascular prostheses in an experimental infection model. *J Vasc Surg.* 1996;24:920-925; discussion 5-6.
96. Raptis S, Miller JH. Influence of a vein cuff on polytetrafluoroethylene grafts for primary femoropopliteal bypass. *Br J Surg.*

1995;82:487-491.

97. Faries PL, Leger FW, Arora S, et al. A comparative study of alternative conduits for lower extremity revascularization: all-autogenous conduit versus prosthetic grafts. *J Vasc Surg.* 2000;32:1080-1090.
98. Faries PL, Leger FW, Arora S, et al. Arm vein conduit is superior to composite prosthetic-autogenous grafts in lower extremity revascularization. *J Vasc Surg.* 2000;31:1119-1127.

## 第 45 章

1. DeRubertis BG, Faries PL, McKinsey JF, et al. Shifting paradigms in the treatment of lower extremity vascular disease: a report of 1000 percutaneous interventions. *Ann Surg.* 2007;246:415-422; discussion 422-424.
2. Omoigui NA, Califf RM, Pieper K, et al. Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). *J Am Coll Cardiol.* 1995;26:922-930.
3. Waksman R, King SB 3rd, Douglas JS, et al. Predictors of groin complications after balloon and new-device coronary intervention. *Am J Cardiol.* 1995;75:886-889.
4. Blankenship JC, Hellkamp AS, Aguirre FV, et al. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. *Am J Cardiol.* 1998;81:36-40.
5. Rosamond W, Flegal K, Furie K, et al. Heart Disease and Stroke Statistics—2008 Update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. *Circulation.* 2008;117:e25-e146.
6. Chandrasekar B, Doucet S, Bilodeau L, et al. Complications of cardiac catheterization in the current era: a single-center experience. *Catheter Cardiovasc Interv.* 2001;52:289-295.
7. Piper WD, Malenka DJ, Ryan TJ Jr, et al. Predicting vascular complications in percutaneous coronary interventions. *Am Heart J.* 2003;145:1022-1029.
8. Tavis DR, Gallauresi BA, Lin B, et al. Risk of local adverse events following cardiac catheterization by hemostasis device use and gender. *J Invasive Cardiol.* 2004;16:459-464.
9. Katzenschlager R, Ugurluoglu A, Ahmadi A, et al. Incidence of pseudoaneurysm after diagnostic and therapeutic angiography. *Radiology.* 1995;195:463-466.
10. Eichlisberger R, Frauchiger B, Schmitt H, Jager K. [Aneurysma spurium following arterial catheterization: diagnosis and follow-up.]. *Ultraschall Med.* 1992;13:54-58.
11. Kelm M, Perings SM, Jax T, et al. Incidence and clinical outcome of iatrogenic femoral arteriovenous fistulas: implications for risk stratification and treatment. *J Am Coll Cardiol.* 2002;40:291-297.
12. Meyerson SL, Feldman T, Desai TR, et al. Angiographic access site complications in the era of arterial closure devices. *Vasc Endovasc Surg.* 2002;36:137-144.
13. Prasad A, Compton PA, Roesle M, et al. Incidence and treatment of arterial access dissections occurring during cardiac catheterization. *J Interv Cardiol.* 2008;21:61-66.
14. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. *Circulation.* 1997;96:1445-1453.
15. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. *N Engl J Med.* 1998;339:436-443.
16. Sherev DA, Shaw RE, Brent BN. Angiographic predictors of femoral access site complications: implication for planned percutaneous coronary intervention. *Catheter Cardiovasc Interv.* 2005;65:196-202.
17. Applegate RJ, Sacrinty MT, Kutcher MA, et al. Vascular complications in women after catheterization and percutaneous coronary intervention 1998-2005. *J Invasive Cardiol.* 2007;19:369-374.

18. Fitts J, Ver Lee P, Hofmaster P, Malenka D. Fluoroscopy-guided femoral artery puncture reduces the risk of PCI-related vascular complications. *J Interv Cardiol.* 2008;21:273-278.
19. Pracyk JB, Wall TC, Longabaugh JP, et al. A randomized trial of vascular hemostasis techniques to reduce femoral vascular complications after coronary intervention. *Am J Cardiol.* 1998;81:970-976.
20. Yatskar L, Selzer F, Feit F, et al. Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: data from the National Heart, Lung, and Blood Institute Dynamic Registry. *Catheter Cardiovasc Interv.* 2007;69:961-966.
21. Horwitz PA, Berlin JA, Sauer WH, et al. Bleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad-based practice (results from the Society for Cardiac Angiography and Interventions Registry). *Am J Cardiol.* 2003;91:803-806.
22. Parmer SS, Carpenter JP, Fairman RM, et al. Femoral neuropathy following retroperitoneal hemorrhage: case series and review of the literature. *Ann Vasc Surg.* 2006;20:536-540.
23. Lumsden AB, Peden E, Bush RL, Lin PH. Complications of endovascular procedures. In: Rutherford RB, ed. *Vascular Surgery*. 6<sup>th</sup> ed. Philadelphia, PA: Elsevier; 2005.
24. Kresowik TF, Khoury MD, Miller BV, et al. A prospective study of the incidence and natural history of femoral vascular complications after percutaneous transluminal coronary angioplasty. *J Vasc Surg.* 1991;13:328-333; discussion 333-335.
25. Ricci MA, Trevisani GT, Pilcher DB. Vascular complications of cardiac catheterization. *Am J Surg.* 1994;167:375-378.
26. Kent KC, McArdle CR, Kennedy B, et al. Accuracy of clinical examination in the evaluation of femoral false aneurysm and arteriovenous fistula. *Cardiovasc Surg.* 1993;1:504-507.
27. Perings SM, Kelm M, Jax T, Strauer BE. A prospective study on incidence and risk factors of arteriovenous fistulae following transfemoral cardiac catheterization. *Int J Cardiol.* 2003;88:223-228.
28. Schaub F, Theiss W, Heinz M, et al. New aspects in ultrasound-guided compression repair of postcatheterization femoral artery injuries. *Circulation.* 1994;90:1861-1865.
29. Toursarkissian B, Allen BT, Petrinc D, et al. Spontaneous closure of selected iatrogenic pseudoaneurysms and arteriovenous fistulae. *J Vasc Surg.* 1997;25:803-808; discussion 808-809.
30. Ruebben A, Tettoni S, Muratore P, et al. Arteriovenous fistulas induced by femoral arterial catheterization: percutaneous treatment. *Radiology.* 1998;209:729-734.
31. Thalhhammer C, Kirchherr AS, Uhlich F, et al. Postcatheterization pseudoaneurysms and arteriovenous fistulas: repair with percutaneous implantation of endovascular covered stents. *Radiology.* 2000;214:127-131.
32. Waigand J, Uhlich F, Gross CM, et al. Percutaneous treatment of pseudoaneurysms and arteriovenous fistulas after invasive vascular procedures. *Catheter Cardiovasc Interv.* 1999;47:157-164.
33. Onal B, Kosar S, Gumus T, et al. Postcatheterization femoral arteriovenous fistulas: endovascular treatment with stent-grafts. *Cardiovasc Intervent Radiol.* 2004;27:453-458.
34. Onal B, Ilgit ET, Akpek S, Coskun B. Postcatheterization femoral arteriovenous fistula: endovascular treatment with N-butyl-cyanoacrylate embolization. *Cardiovasc Intervent Radiol.* 2006;29:276-278.
35. Kent KC, McArdle CR, Kennedy B, et al. A prospective study of the clinical outcome of femoral pseudoaneurysms and arteriovenous fistulas induced by arterial puncture. *J Vasc Surg.* 1993;17:125-131; discussion 131-133.
36. Oweida SW, Roubin GS, Smith RB 3rd, Salam AA. Postcatheterization vascular complications associated with percutaneous transluminal coronary angioplasty. *J Vasc Surg.* 1990;12:310-315.
37. Koreny M, Riedmuller E, Nikfardjam M, et al. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. *JAMA.* 2004;291:350-357.
38. Abu-Yousef MM, Wiese JA, Shamma AR. The "to-and-fro" sign: duplex Doppler evidence of femoral artery pseudoaneurysm. *AJR Am J Roentgenol.* 1988;150:632-634.
39. Coughlin BF, Paushter DM. Peripheral pseudoaneurysms: evaluation with duplex US. *Radiology.* 1988;168:339-342.
40. Fellmeth BD, Roberts AC, Bookstein JJ, et al. Postangiographic femoral artery injuries: nonsurgical repair with US-guided

- compression. *Radiology*. 1991;178:671-675.
41. Coley BD, Roberts AC, Fellmeth BD, et al. Postangiographic femoral artery pseudoaneurysms: further experience with US-guided compression repair. *Radiology*. 1995;194:307-311.
  42. Eisenberg L, Paulson EK, Kliewer MA, et al. Sonographically guided compression repair of pseudoaneurysms: further experience from a single institution. *AJR Am J Roentgenol*. 1999;173:1567-1573.
  43. Lange P, Houe T, Helgstrand UJ. The efficacy of ultrasound-guided compression of iatrogenic femoral pseudo-aneurysms. *Eur J Vasc Endovasc Surg*. 2001;21:248-250.
  44. Cope C, Zeit R. Coagulation of aneurysms by direct percutaneous thrombin injection. *AJR Am J Roentgenol*. 1986;147:383-387.
  45. La Perna L, Olin JW, Goines D, et al. Ultrasound-guided thrombin injection for the treatment of postcatheterization pseudoaneurysms. *Circulation*. 2000;102:2391-2395.
  46. Kang SS, Labropoulos N, Mansour MA, et al. Expanded indications for ultrasound-guided thrombin injection of pseudoaneurysms. *J Vasc Surg*. 2000;31:289-298.
  47. Calton WC Jr, Franklin DP, Elmore JR, Han DC. Ultrasound-guided thrombin injection is a safe and durable treatment for femoral pseudoaneurysms. *Vasc Surg*. 2001;35:379-383.
  48. Sheiman RG, Brophy DP. Treatment of iatrogenic femoral pseudoaneurysms with percutaneous thrombin injection: experience in 54 patients. *Radiology*. 2001;219:123-127.
  49. Mohler ER 3rd, Mitchell ME, Carpenter JP, et al. Therapeutic thrombin injection of pseudoaneurysms: a multicenter experience. *Vasc Med*. 2001;6:241-244.
  50. Paulson EK, Nelson RC, Mayes CE, et al. Sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms: further experience of a single institution. *AJR Am J Roentgenol*. 2001;177:309-316.
  51. Khoury M, Rebecca A, Greene K, et al. Duplex scanning-guided thrombin injection for the treatment of iatrogenic pseudoaneurysms. *J Vasc Surg*. 2002;35:517-521.
  52. Kruger K, Zahring M, Sohngen FD, et al. Femoral pseudoaneurysms: management with percutaneous thrombin injections—success rates and effects on systemic coagulation. *Radiology*. 2003;226:452-458.
  53. Sheiman RG, Mastromatteo M. Iatrogenic femoral pseudoaneurysms that are unresponsive to percutaneous thrombin injection: potential causes. *AJR Am J Roentgenol*. 2003;181:1301-1304.
  54. Etemad-Rezai R, Peck DJ. Ultrasound-guided thrombin injection of femoral artery pseudoaneurysms. *Can Assoc Radiol J*. 2003;54:118-120.
  55. Maleux G, Hendrickx S, Vaninbroux J, et al. Percutaneous injection of human thrombin to treat iatrogenic femoral pseudoaneurysms: short- and midterm ultrasound follow-up. *Eur Radiol*. 2003;13:209-212.
  56. Grewe PH, Mugge A, Gerding A, et al. Occlusion of pseudoaneurysms using human or bovine thrombin using contrast-enhanced ultrasound guidance. *Am J Cardiol*. 2004;93:1540-1542.
  57. Vazquez V, Reus M, Pinero A, et al. Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection. *AJR Am J Roentgenol*. 2005;184:1665-1671.
  58. Krueger K, Zahring M, Strohe D, et al. Postcatheterization pseudoaneurysm: results of US-guided percutaneous thrombin injection in 240 patients. *Radiology*. 2005;236:1104-1110.
  59. Schneider C, Malisius R, K  chler R, et al. A prospective study on ultrasound-guided percutaneous thrombin injection for treatment of iatrogenic post-catheterisation femoral pseudoaneurysms. *Int J Cardiol*. 2009;131:356-361.
  60. Pope M, Johnston KW. Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention. *J Vasc Surg*. 2000;32:190-191.
  61. Morgan R, Belli AM. Current treatment methods for postcatheterization pseudoaneurysms. *J Vasc Interv Radiol*. 2003;14:697-710.
  62. Webber GW, Jang J, Gustavson S, Olin JW. Contemporary management of postcatheterization pseudoaneurysms.



*Circulation*. 2007;115:2666-2674.

63. Lumsden AB, Miller JM, Kosinski AS, et al. A prospective evaluation of surgically treated groin complications following percutaneous cardiac procedures. *Am Surg*. 1994;60:132-137.
64. Perler BA. Surgical treatment of femoral pseudoaneurysm following cardiac catheterization. *Cardiovasc Surg*. 1993;1:118-121.
65. Kobeiter H, Lapeyre M, Becquemin JP, et al. Percutaneous coil embolization of postcatheterization arterial femoral pseudoaneurysms. *J Vasc Surg*. 2002;36:127-131.
66. Heenan SD, Grubnic S, Buckenham TM, Belli AM. Transbrachial arteriography: indications and complications. *Clin Radiol*. 1996;51:205-209.
67. Al-Mubarak N, Vitek JJ, Iyer SS, et al. Carotid stenting with distal-balloon protection via the transbrachial approach. *J Endovasc Ther*. 2001;8:571-575.
68. Chatzioannou A, Ladopoulos C, Mourikis D, et al. Complications of lower-extremity outpatient arteriography via low brachial artery. *Cardiovasc Intervent Radiol*. 2004;27:31-34.
69. Hildick-Smith DJ, Khan ZI, Shapiro LM, Petch MC. Occasional-operator percutaneous brachial coronary angiography: first, do no arm. *Catheter Cardiovasc Interv*. 2002;57:161-165; discussion 166.
70. Chitwood RW, Shepard AD, Shetty PC, et al. Surgical complications of transaxillary arteriography: a case-control study. *J Vasc Surg*. 1996;23:844-849; discussion 849-850.
71. Kent KC, Moscucci M, Gallagher SG, et al. Neuropathy after cardiac catheterization: incidence, clinical patterns, and long-term outcome. *J Vasc Surg*. 1994;19:1008-1013; discussion 1013-1014.
72. Molnar W, Paul DJ. Complications of axillary arteriotomies. An analysis of 1,762 consecutive studies. *Radiology*. 1972;104:269-276.
73. AbuRahma AF, Robinson PA, Boland JP, et al. Complications of arteriography in a recent series of 707 cases: factors affecting outcome. *Ann Vasc Surg*. 1993;7:122-129.
74. Lupattelli T, Clerissi J, Clerici G, et al. The efficacy and safety of closure of brachial access using the AngioSeal closure device: experience with 161 interventions in diabetic patients with critical limb ischemia. *J Vasc Surg*. 2008;47:782-788.
75. Cura FA, Kapadia SR, L'Allier PL, et al. Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade. *Am J Cardiol*. 2000;86:780-782, A9.
76. Dangas G, Mehran R, Kokolis S, et al. Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices. *J Am Coll Cardiol*. 2001;38:638-641.
77. Resnic FS, Blake GJ, Ohno-Machado L, et al. Vascular closure devices and the risk of vascular complications after percutaneous coronary intervention in patients receiving glycoprotein IIb-IIIa inhibitors. *Am J Cardiol*. 2001;88:493-496.
78. Dangas G, Mehran R, Fahy M, et al. Complications of vascular closure devices—not yet evidence based [reply]. *J Am Coll Cardiol*. 2002;39:1706-1708.
79. Exaire JE, Dauerman HL, Topol EJ, et al. Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices. *Am Heart J*. 2004;147:31-34.
80. Nikolsky E, Mehran R, Halkin A, et al. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. *J Am Coll Cardiol*. 2004;44:1200-1209.
81. Applegate RJ, Sacrinty M, Kutcher MA, et al. Vascular complications with newer generations of angioseal vascular closure devices. *J Interv Cardiol*. 2006;19:67-74.
82. Arora N, Matheny ME, Sepke C, Resnic FS. A propensity analysis of the risk of vascular complications after cardiac catheterization procedures with the use of vascular closure devices. *Am Heart J*. 2007;153:606-611.
83. Dauerman HL, Applegate RJ, Cohen DJ. Vascular closure devices: the second decade. *J Am Coll Cardiol*. 2007;50:1617-1626.
84. Castelli P, Caronno R, Piffaretti G, et al. Incidence of vascular injuries after use of the Angio-Seal closure device following

- endovascular procedures in a single center. *World J Surg*. 2006;30:280-284.
85. Cremonesi A, Castriota F, Tarantino F, et al. Femoral arterial hemostasis using the Angio-Seal feminine system after coronary and vascular percutaneous angioplasty and stenting. *J Invasive Cardiol*. 1998;10:464-469.
  86. Eidt JF, Habibipour S, Saucedo JF, et al. Surgical complications from hemostatic puncture closure devices. *Am J Surg*. 1999;178:511-516.
  87. Kirchhof C, Schickel S, Schmidt-Lucke C, Schmidt-Lucke JA. Local vascular complications after use of the hemostatic puncture closure device Angio-Seal. *Vasa*. 2002;31:101-106.
  88. Mukhopadhyay K, Puckett MA, Roobottom CA. Efficacy and complications of Angio-Seal in antegrade puncture. *Eur J Radiol*. 2005;56:409-412.
  89. Park Y, Roh HG, Choo SW, et al. Prospective comparison of collagen plug (Angio-Seal) and suture-mediated (the Closer S) closure devices at femoral access sites. *Korean J Radiol*. 2005;6:248-255.
  90. Thalhammer C, Aschwanden M, Jeanneret C, et al. Symptomatic vascular complications after vascular closure device use following diagnostic and interventional catheterisation. *Vasa*. 2004;33:78-81.
  91. Abando A, Hood D, Weaver F, Katz S. The use of the Angio-Seal device for femoral artery closure. *J Vasc Surg*. 2004;40:287-290.
  92. Rastan A, Sixt S, Schwarzwald U, et al. VIPER-2: a prospective, randomized single-center comparison of 2 different closure devices with a hemostatic wound dressing for closure of femoral artery access sites. *J Endovasc Ther*. 2008;15:83-90.
  93. Mackrell PJ, Kalbaugh CA, Langan EM 3rd, et al. Can the Perclose suture-mediated closure system be used safely in patients undergoing diagnostic and therapeutic angiography to treat chronic lower extremity ischemia? *J Vasc Surg*. 2003;38:1305-1308.
  94. Starnes BW, O'Donnell SD, Gillespie DL, et al. Percutaneous arterial closure in peripheral vascular disease: a prospective randomized evaluation of the Perclose device. *J Vasc Surg*. 2003;38:263-271.
  95. Steinkamp HJ, Werk M, Beck A, et al. Excimer laser-assisted recanalisation of femoral arterial stenosis or occlusion caused by the use of Angio-Seal. *Eur Radiol*. 2001;11:1364-1370.
  96. Johanning JM, Franklin DP, Elmore JR, Han DC. Femoral artery infections associated with percutaneous arterial closure devices. *J Vasc Surg*. 2001;34:983-985.
  97. Geary K, Landers JT, Fiore W, Riggs P. Management of infected femoral closure devices. *Cardiovasc Surg*. 2002;10:161-163.
  98. Jacobs DL, Motaganahalli RL, Cox DE, et al. True lumen re-entry devices facilitate subintimal angioplasty and stenting of total chronic occlusions: Initial report. *J Vasc Surg*. 2006;43:1291-1296.
  99. McDermott JC, Crummy AB, Voegeli DR, Starck EE. Complications of transluminal angioplasty. *Radiology*. 1987;162:286-288.
  100. Lam RC, Shah S, Faries PL, et al. Incidence and clinical significance of distal embolization during percutaneous interventions involving the superficial femoral artery. *J Vasc Surg*. 2007;46:1155-1159.
  101. Konig CW, Pusich B, Tepe G, et al. Frequent embolization in peripheral angioplasty: detection with an embolism protection device (AngioGuard) and electron microscopy. *Cardiovasc Intervent Radiol*. 2003;26:334-339.
  102. Zafar N, Prasad A, Mahmud E. Utilization of an aspiration thrombectomy catheter (Pronto) to treat acute atherothrombotic embolization during percutaneous revascularization of the lower extremity. *Catheter Cardiovasc Interv*. 2008;71:972-975.
  103. Canova CR, Schneider E, Fischer L, et al. Long-term results of percutaneous thrombo-embolectomy in patients with infrainguinal embolic occlusions. *Int Angiol*. 2001;20:66-73.
  104. Allaire E, Melliore D, Poussier B, et al. Iliac artery rupture during balloon dilatation: what treatment? *Ann Vasc Surg*. 2003;17:306-314.
  105. Hayes PD, Chokkalingam A, Jones R, et al. Arterial perforation during infrainguinal lower limb angioplasty does not

- worsen outcome: results from 1409 patients. *J Endovasc Ther.* 2002;9:422-427.
106. Cambria RP, Brewster DC, Lauterbach SR, et al. Evolving experience with thoracic aortic stent graft repair. *J Vasc Surg.* 2002;35:1129-1136.
  107. Makaroun MS, Dillavou ED, Kee ST, et al. Endovascular treatment of thoracic aortic aneurysms: results of the phase II multicenter trial of the GORE TAG thoracic endoprosthesis. *J Vasc Surg.* 2005;41:1-9.
  108. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. *Ann Surg.* 1994;220:251-266; discussion 266-268.
  109. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. *N Engl J Med.* 1998;338:1105-1111.
  110. Ouriel K, Veith FJ, Sasahara AA. Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators. *J Vasc Surg.* 1996;23:64-73; discussion 74-75.
  111. Marder VJ. Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy. *Am J Med.* 1987;83:15-19.
  112. Sullivan KL, Gardiner GA Jr, Kandarpa K, et al. Efficacy of thrombolysis in infrainguinal bypass grafts. *Circulation.* 1991;83(2 Suppl):I99-I105.
  113. Kieffer E, Sabatier J, Plissonnier D, et al. Prosthetic graft infection after descending thoracic/thoracoabdominal aortic aneurysmectomy: management with in situ arterial allografts. *J Vasc Surg.* 2001;33:671-678.
  114. O'Connor S, Andrew P, Batt M, Becquemin JP. A systematic review and meta-analysis of treatments for aortic graft infection. *J Vasc Surg.* 2006;44:38-45.
  115. Seeger JM, Pretus HA, Welborn MB, et al. Long-term outcome after treatment of aortic graft infection with staged extra-anatomic bypass grafting and aortic graft removal. *J Vasc Surg.* 2000;32:451-459; discussion 460-461.
  116. Ducasse E, Calisti A, Speziale F, et al. Aortoiliac stent graft infection: current problems and management. *Ann Vasc Surg.* 2004;18:521-526.
  117. Vogel TR, Symons R, Flum DR. The incidence and factors associated with graft infection after aortic aneurysm repair. *J Vasc Surg.* 2008;47:264-269.
  118. Sharif MA, Lee B, Lau LL, et al. Prosthetic stent graft infection after endovascular abdominal aortic aneurysm repair. *J Vasc Surg.* 2007;46:442-448.
  119. Hogg ME, Peterson BG, Pearce WH, et al. Bare metal stent infections: case report and review of the literature. *J Vasc Surg.* 2007;46:813-820.
  120. Mullens W, De Keyser J, Van Dorpe A, et al. Migration of two venous stents into the right ventricle in a patient with May-Thurner syndrome. *Int J Cardiol.* 2006;110:114-115.
  121. Taylor JD, Lehmann ED, Belli AM, et al. Strategies for the management of SVC stent migration into the right atrium. *Cardiovasc Intervent Radiol.* 2007;30:1003-1009.
  122. Streiff MB. Vena caval filters: a review for intensive care specialists. *J Intensive Care Med.* 2003;18:59-79.
  123. Haddadian B, Shaikh F, Djelmami-Hani M, Shalev Y. Sudden cardiac death caused by migration of a TrapEase inferior vena cava filter: case report and review of the literature. *Clin Cardiol.* 2008;31:84-87.
  124. Crochet DP, Brunel P, Trogrlic S, et al. Long-term follow-up of Vena Tech-LGM filter: predictors and frequency of caval occlusion. *J Vasc Interv Radiol.* 1999;10:137-142.

## 第 46 章

1. Vaughan BF, Slavotinek AH, Jepson RP. Edema of the lower limb after vascular operations. *Surg Gynecol Obstet.* 1970;133:282.
2. Porter JM, Lindell TD, Lakin PC. Leg edema following femoropopliteal autogenous vein bypass. *Arch Surg.* 1972;105:883.

3. Storen EJ, Myhre HO, Stiris G. Lymphangiographic findings in patients with leg oedema after arterial reconstructions. *Acta Chir Scand*. 1974;140:385.
4. Schmidt KR, Welter H, Pfeifer KJ, et al. Lymphographic investigations of oedema of the extremities following reconstructive vascular surgery in the femoropopliteal territory. *Rofo*. 1978;128:194.
5. Stillman RM, Fitzgerald JF, Varughese G, et al. Edema following femoropopliteal bypass: etiology and prevention. *Vasc Surg*. 1983;18:354.
6. Stranden E. Edema in the lower limb following arterial reconstruction for atherosclerosis: a study of pathogenetic mechanisms. *J Oslo City Hosp*. 1984;34:3.
7. Schubart PJ, Porter JM. Leg edema following femorodistal bypass. In: Bergan JJ, Yao JST, eds. *Reoperative Arterial Surgery*. Orlando, FL: Grune & Stratton; 1986:311.
8. Eickhoff JH. Local regulation of subcutaneous blood flow and capillary filtration in limbs with occlusive arterial disease: studies before and after arterial reconstruction. *Dan Med Bull*. 1986;33:111.
9. AbuRahma AF, Woodruff BA, Lucente FC. Edema after femoropopliteal bypass surgery: lymphatic and venous theories of causation. *J Vasc Surg*. 1990;11:461.
10. Persson NH, Takolander R, Bergqvist D. Edema after lower limb arterial reconstruction: influence of background factors, surgical technique and potentially prophylactic methods. *Vasa*. 1991;20:57.
11. Esato K, Ohara M, Seyama A, et al. <sup>99m</sup>Tc-HSA lymphoscintigraphy and leg edema following arterial reconstruction. *J Cardiovasc Surg*. 1991;32:741.
12. Stolzenberg J. Detection of lymphaticocutaneous fistula by radionuclide lymphangiography. *Arch Surg*. 1978;113:306.
13. Kwaan JHM, Berstein JM, Connolly JE. Management of lymph fistulae in the groin after arterial reconstruction. *Arch Surg*. 1979;114:1416.
14. Murphy JL, Cole WC, White PM, et al. Lymphatic fistula after vascular reconstruction: a case control study. *Can J Surg*. 1991;34:76.
15. Weaver FA, Yellin AE. Management of postoperative lymphatic leaks by use of isosulphan blue [letter]. *J Vasc Surg*. 1991;14:566.
16. Kalman PG, Walker PM, Johnston KW. Consequences of groin lymphatic fistulae after vascular reconstruction. *Vasc Surg*. 1991;25:210.
17. Khauli RB, Mosenthal AC, Caushaj PF. Treatment of lymphocele and lymphatic fistula following renal transplantation by laparoscopic peritoneal window. *J Urol*. 1992;147:1353.
18. Dillon ML, Postlethwait RW. The management of an abdominal mass recurring after resection of abdominal aortic aneurysm. *Surg Clin North Am*. 1970;50:1021.
19. Fitzer PM, Sallade RL, Graham WH. Computed tomography and the diagnosis of giant abdominal lymphocele. *Va Med Q*. 1980;107:448.
20. Patel BR, Burkhalter JL, Patel TB, et al. Interstitial lymphoscintigraphy for diagnosis of lymphocele. *Clin Nucl Med*. 1985;10:175.
21. Puyau FA, Adinolfi MF, Kerstein MD. Lymphocele around aortic femoral grafts simulating a false aneurysm. *Cardiovasc Intervent Radiol*. 1985;8:195.
22. Jensen SR, Voegeli DR, McDermott JC, et al. Lymphatic disruption following abdominal aortic surgery. *Cardiovasc Intervent Radiol*. 1986;9:199.
23. Pardy BJ, Harris P, Mourad K, et al. Case reports: upper abdominal lymphocele following urgent aortorenal bypass grafting. *J R Soc Med*. 1986;79:674.
24. Scott AR. A report on the management of a lymphocyst after vascular surgery. *Aust N Z J Surg*. 1987;57:205.
25. Garrett HE Jr, Richardson JW, Howard HS, et al. Retroperitoneal lymphocele after abdominal aortic surgery. *J Vasc Surg*. 1989;10:245.

26. Malovrh M, Kandus A, Buturovic-Ponikvar J, et al. Frequency and clinical influence of lymphoceles after kidney transplantation. *Transplant Proc.* 1990;22:1423.
27. Velanovich V, Mallory P, Collins PS. Lower extremity lymphocele development after saphenous vein harvesting. *Mil Med.* 1991;156:149.
28. Bradham RR, Gregorie HB, Wilson R. Chylous ascites following resection of an abdominal aortic aneurysm. *Am Surg.* 1970;36:238.
29. Klippel AP, Hardy DA. Postoperative chylous ascites. *Mo Med.* 1971;68:253.
30. DeBartolo TF, Etzkorn JR. Conservative management of chylous ascites after abdominal aortic aneurysm repair: case report. *Mo Med.* 1976;73:611.
31. Lopez-Enriquez E, Gonzalez A, Johnson CD, et al. Chylothorax and chyloperitoneum: a case report. *Bol Assoc Med P R.* 1979;71:54.
32. Meinke AH III, Estes NC, Ernst CB. Chylous ascites following abdominal aortic aneurysmectomy: management with total parenteral hyperalimentation. *Ann Surg.* 1979;190:631.
33. Stubbe LT, Terpstra JL. Chylous ascites after resection of an abdominal aortic aneurysm. *Arch Chir Neerl.* 1979;31:111.
34. McKenna R, Stevick CA. Chylous ascites following aortic reconstruction. *Vasc Surg.* 1983;17:143.
35. Savrin RA, High JR. Chylous ascites after abdominal aortic surgery. *Surgery.* 1985;98:866.
36. Sarazin WG, Sauter KE. Chylous ascites following resection of a ruptured abdominal aneurysm. *Arch Surg.* 1986;121:246.
37. Fleisher HL III, Oren JW, Sumner DS. Chylous ascites after abdominal aortic aneurysmectomy: successful management with a peritoneovenous shunt. *J Vasc Surg.* 1987;6:403.
38. Schwein M, Dawes PD, Hatchuel D, et al. Postoperative chylous ascites after resection of an abdominal aortic aneurysm: a case report. *S Afr J Surg.* 1987;25:39.
39. Williamson C, Provan JL. Chylous ascites following aortic surgery. *Br J Surg.* 1987;74:71.
40. Boyd WD, McPhail NV, Barber GC. Case report: chylous ascites following abdominal aortic aneurysmectomy: surgical management with a peritoneovenous shunt. *J Cardiovasc Surg.* 1989;30:627.
41. Heyl A, Veen HF. Iatrogenic chylous ascites: operative or conservative approach. *Neth J Surg.* 1989;41:5.
42. Ablan CJ, Littooy FN, Freeark RJ. Postoperative chylous ascites: diagnosis and treatment. *Arch Surg.* 1990;125:270.
43. Bahner DR Jr, Townsend R. Chylous ascites after ruptured abdominal aortic aneurysm. *Contemp Surg.* 1990;36:37.
44. Sultan S, Pauwels A, Poupon R, et al. Ascites chyleuses de l'adulte aspects étiologiques, thérapeutiques et évolutifs: a propos de 35 cas. *Ann Gastroenterol Hepatol (Paris).* 1990;26:187.
45. Williams RA, Vetto J, Quinones-Baldrich W, et al. Chylous ascites following abdominal aortic surgery. *Ann Vasc Surg.* 1991;5:247.
46. Sanger R, Wilmschurst CC, Clyne CA. Chylous ascites following aneurysm surgery: case report. *Eur J Vasc Surg.* 1991;5:689.
47. Mack JW, Heydorn WH, Pauling FW, et al. Postoperative chylous pseudocyst. *J Thorac Cardiovasc Surg.* 1979;77:773.
48. Kostianinen S, Meurala H, Mattila S, et al. Chylothorax: clinical experience in nine cases. *Scand J Thorac Cardiovasc Surg.* 1983;17:79.
49. Okabayashi H, Tamura N, Hirose N, et al. Aortic aneurysm associated with coarctation of the aorta. *Kyobu Geka.* 1989;42:1032.
50. Sachs PB, Zelch MG, Rice TG, et al. Diagnosis and localization of laceration of the thoracic duct: usefulness of lymphangiography and CT. *AJR Am J Roentgenol.* 1991;157:703.
51. Hallman GL, Bloodwell RD, Cooley DA. Coarctation of the thoracic aorta. *Surg Clin North Am.* 1966;46:893.
52. Bortolotti U, Faggian G, Livi U, et al. Postoperative chylothorax following repair of coarctation of the aorta: report of a case with unusual clinical manifestation. *Thorac Cardiovasc Surg.* 1982;30:319.
53. Fairfax AJ, McNabb WR, Spiro SG. Chylothorax: a review of 18 cases. *Thorax.* 1986;41:880.

54. Baudet E, Al-Qudah A. Late results of the subclavian flap repair of coarctation in infancy. *J Cardiovasc Surg.* 1989;30:445.
55. Cooper P, Paes ML. Bilateral chylothorax. *Br J Anaesth.* 1991;66:387.
56. Chun K, Colombani PM, Dudgeon DL. Diagnosis and management of congenital vascular rings: a 22 year experience. *Ann Thorac Surg.* 1992;53:597; discussion, 602.
57. Negroni CC, Ortiz VN. Chylothorax following high translumbar aortography: a case report and review of the literature. *Bol Assoc Med P R.* 1988;80:201.
58. Gloviczki P, Bergman RT. Lymphatic problems and revascularization edema. In: Bernhard VM, Towne JB, eds. *Complications in Vascular Surgery.* 2nd ed. St. Louis, MO: Quality Medical Publishing; 1991:366.
59. Simeone FA, Husni EA. The hyperemia of reconstructive arterial surgery. *Ann Surg.* 1959;150:575.
60. Campbell H, Harris PL. Albumin kinetics and oedema following reconstructive arterial surgery of the lower limb. *J Cardiovasc Surg.* 1985;26:110.
61. Taylor GW. Arterial grafting for gangrene. *Ann R Coll Surg Engl.* 1962;31:168.
62. Hamer JD. Investigation of oedema of the lower limb following successful femoropopliteal by-pass surgery: the role of phlebography in demonstrating venous thrombosis. *Br J Surg.* 1972;59:979.
63. Myhre HO, Dedichen H. Haemodynamic factors in the oedema of arterial reconstructions. *Scand J Thorac Cardiovasc Surg.* 1972;6:323.
64. Myhre HO, Storen EJ, Ongre A. The incidence of deep venous thrombosis in patients with leg oedema after arterial reconstruction. *Scand J Thorac Cardiovasc Surg.* 1974;8:73.
65. Husni EA. The edema of arterial reconstruction. *Circulation.* 1967;35(Suppl):I169.
66. Cass AJ, Jennings SA, Greenhalgh RM. Leg swelling after aortic surgery. *Int Angiol.* 1986;5:207.
67. Jordan WD, Voellinger DC, Schroeder PT, McDowell HA. Video-assisted saphenous vein harvest: the evolution of a new technique. *J Vasc Surg.* 1997;26:405.
68. Allen KB, Griffith GL, Heimansohn DA, et al. Endoscopic versus traditional saphenous vein harvesting: a prospective randomized trial. *Ann Thorac Surg.* 1998;66:26.
69. Puskas JD, Wright CE, Miller PK, et al. A randomized trial of endoscopic versus open saphenous vein harvest in coronary bypass surgery. *Ann Thorac Surg.* 1999;68:1509.
70. Jimenez JC, Lawrence PF, Rigberg DA, Quinones-Baldrich WJ. Technical modifications in endoscopic vein harvest techniques facilitate their use in lower extremity limb salvage procedures. *J Vasc Surg.* 2007;45:549.
71. Gazoni LM, Carty R, Skinner J, et al. Endoscopic versus open saphenous vein harvest for femoral to below the knee arterial bypass using saphenous vein graft. *J Vasc Surg.* 2006;44:282; discussion 287.
72. Skudder PA, Geary J. Lymphatic drainage from the groin following surgery of the femoral artery. *J Cardiovasc Surg (Torino).* 1987;28:460.
73. Johnston KW. Multicenter prospective study of nonruptured abdominal aortic aneurysm: II. Variables predicting morbidity and mortality. *J Vasc Surg.* 1989;9:437.
74. Gill IS, Hodge EE, Munch LC, et al. Transperitoneal marsupialization of lymphoceles: a comparison of laparoscopic and open techniques. *J Urol.* 1995;153:706.
75. Melvin WS, Bumgardner GL, Davies EA, et al. The laparoscopic management of post-transplant lymphocele: a critical review. *Surg Endosc.* 1997;11:245.
76. Doehn C, Fornara P, Fricke L, Jocham D. Laparoscopic fenestration of posttransplant lymphoceles. *Surg Endosc.* 2002;16:690.
77. Sawhney R, D'Agostino HB, Zinck S, et al. Treatment of postoperative lymphoceles with percutaneous drainage and alcohol sclerotherapy. *J Vasc Interv Radiol.* 1996;7:241.
78. Kerlan RK Jr, LaBerge JM, Gordon RL, Ring EJ. Bleomycin sclerosis of pelvic lymphoceles. *J Vasc Interv Radiol.* 1997;8:885.

79. Cannon L, Walker AJ. Sclerotherapy of a wound lymphocele using tetracycline. *Eur J Vasc Endovasc Surg.* 1997;14:505.
80. Seelig MH, Klingler PJ, Oldenburg WA. Treatment of a postoperative cervical chylous lymphocele by percutaneous sclerosing with povidone-iodine. *J Vasc Surg.* 1998;27:1148.
81. Caliendo MV, Lee DE, Queiroz R, Waldman DL. Sclerotherapy with use of doxycycline after percutaneous drainage of postoperative lymphoceles. *J Vasc Interv Radiol.* 2001;12:73.
82. Teiche PE, Pauer W, Schmid N. Use of talcum in sclerotherapy of pelvic lymphoceles. *Techn Urol.* 1999;5:52.
83. Michail PO, Griniatsos J, Kargakou M, et al. Treatment of persistent lymphorrhea using bleomycin sclerotherapy. *Plast Reconstr Surg.* 2001;107:890.
84. Chin A, Ragavendra N, Hilborne L, Gritsch HA. Fibrin sealant sclerotherapy for treatment of lymphoceles following renal transplantation. *J Urol.* 2003;170:380.
85. Servelle M, Nogues CL, Soulie J, et al. Spontaneous, postoperative and traumatic chylothorax. *J Cardiovasc Surg (Torino).* 1980;21:475.
86. Lefrou L, d'Alterroche L, Harchaoui Y, et al. Peritovenous shunt after failure of octreotide treatment for chylous ascites in lymphangioleiomyomatosis. *Dig Dis Sci.* 2007;52:3188.
87. Nishizawa K, Ito N, Yamamoto SH, et al. Successful laparoscopic management of chylous ascites following laparoscopic radical nephrectomy. *Int J Urol.* 2006;13:619.
88. Mitsunaga T, Yoshida H, Iwai J, et al. Successful surgical treatment of two cases of congenital chylous ascites. *J Pediatr Surg.* 2001;36:1717.
89. Jensen E, Weiss CA III. Management of chylous ascites after laparoscopic cholecystectomy using minimally invasive techniques: a case report and literature review. *Am Surg.* 2006;72:60.
90. Geary B, Wade B, Wollman W, El-Galley R. Laparoscopic repair of chylous ascites. *J Urol.* 2004;171:1231.
91. Browse NL, Allen DR, Wilson NM. Management of chylothorax. *Br J Surg.* 1997;84:1711.
92. Cerfolio RJ, Allen MS, Deschamps C, et al. Postoperative chylothorax. *J Thorac Cardiovasc Surg.* 1996;112:1361.
93. Sugura K, Tanabe Y, Ogawa T, Tokushima T. Localization of chyle leakage site in postoperative chylothorax by oral administration of I-123 BMIPP (case report). *Ann Nucl Med.* 2005;19:597.
94. Hirata N, Ueno T, Amemiya A, et al. Advantage of earlier thoracoscopic clipping of thoracic duct for post-operative chylothorax following thoracic aneurysm surgery. *Jpn J Thorac Cardiovasc Surg.* 2003;51:378.
95. Cope C, Kaiser LR. Management of unremitting chylothorax by percutaneous embolization and blockage of retroperitoneal lymphatic vessels in 42 patients. *J Vasc Interv Radiol.* 2002;13:1139.
96. Kumar K, Pawar A. Thoracoscopic management of thoracic duct injury: is there a place for conservatism (case report). *J Postgrad Med.* 2004;50:57.
97. Takeo S, Yamazaki K, Takagi M, Nakashima A. Thoracoscopic ultrasonic coagulation of thoracic duct in management of postoperative chylothorax. *Ann Thorac Surg.* 2002;74:263.
98. Ohtsuka T, Ninomiya M, Kobayashi J, Kaneko Y. VATS thoracic-duct division for aortic surgery-related chylous leakage. *Eur J Cardiothorac Surg.* 2005;27:153.
99. Khelif K, Maassarani F, Dassonville M, DeLaft MH. Thoracoscopic thoracic duct sealing with LigaSure in two children with refractory postoperative chylothorax. *J Laparoendosc Adv Surg Tech.* 2007;17:137.
100. Hayden J, Sue-Ling HM, Sarela AI, Dexter SPL. Minimally invasive management of chylous fistula after esophagectomy. *Dis Esoph.* 2007;20:251.
101. Cho DG, Cho KD, Jo MS. Thoracoscopic direct suture repair of thoracic duct injury after thoracoscopic mediastinal surgery (case report). *Surg Laparosc Endosc Percutan Tech.* 2007;17:60.
102. Watanabe A, Koyanagi T, Nakashima S, Higami T. Supradiaphragmatic thoracic duct clipping for chylothorax through left-sided video-assisted thoracoscopic surgery. *Cardiothorac Surg.* 2007;31:313.
103. Hirata N, Ueno T, Amemiya A, et al. Advantage of earlier thoracoscopic clipping of thoracic duct for post-operation

chylothorax following thoracic aneurysm surgery. *J Thorac Cardiovasc Surg.* 2003;51:3780.

## 第 47 章

1. Daube JR, Dyck PJ. *Diseases of the Peripheral Nervous System*. Philadelphia, PA: WB Saunders; 1984.
2. Lundborg G. The intrinsic vascularization of human peripheral nerves: structural and functional aspects. *J Hand Surg.* 1979;4:34.
3. Lundborg G. Intraneural microcirculation. *Orthop Clin North Am.* 1988;19:1.
4. Sunderland S. *Nerve and Nerve Injuries*. Edinburgh: Churchill Livingstone; 1978.
5. Lundborg G. Ischemic nerve injury. Experimental studies on intraneural microvascular pathophysiology and nerve function in a limb subjected to temporary circulatory arrest. *Scand J Plast Reconstr Surg Suppl.* 1970;6:3.
6. Eames RA, Lange LS. Clinical and pathological study of ischemic neuropathy. *J Neurol Neurosurg Psychiatry.* 1967;30:215.
7. Weinberg DH, Simovic D, Isner J, Ropper AH. Chronic ischemic monomelic neuropathy from critical limb ischemia. *Neurology.* 2001;57:1008.
8. Miglietta O, Lowenthal M. Nerve conduction velocity and refractory period in peripheral vascular disease. *J Appl Physiol.* 1962;17:837.
9. Hunter GC, Song GW, Nayak NN, et al. Peripheral nerve conduction abnormalities in lower extremity ischemia: the effects of revascularization. *J Surg Res.* 1988;45:96.
10. Laghi Pasini F, Pastorelli M, Beermann U, et al. Peripheral neuropathy associated with ischemic vascular disease of the lower limbs. *Angiology.* 1996;47:569.
11. Parry GJ, Cornblath DR, Brown MJ. Transient conduction block following acute peripheral nerve ischemia. *Muscle Nerve.* 1985;8:409.
12. Parry GJ, Linn DJ. Transient focal conduction block following experimental occlusion of the vasa nervorum. *Muscle Nerve.* 1986;9:345.
13. Leone J, Ochs S. Anoxic block and recovery of axoplasmic transport and electrical excitability of nerve. *J Neurobiol.* 1978;9:229.
14. Dyck PJ. Hypoxic neuropathy: does hypoxia play a role in diabetic neuropathy? *Neurology.* 1989;39:111.
15. Olsson Y. *Handbook of Clinical Neurology*. Vol XII. Amsterdam: North Holland Publishing; 1972.
16. Fox JL, Kenmore PI. The effect of ischemia on nerve conduction. *Exp Neurol.* 1967;17:403.
17. Farinon AM, Marbini A, Gemignani F, et al. Skeletal muscle and peripheral nerve changes caused by chronic arterial insufficiency—significance and clinical correlations—histological, histochemical and ultrastructural study. *Clin Neuropathol.* 1984;3:240.
18. Rodríguez-Sánchez C, Medina Sánchez M, Malik RA, et al. Morphological abnormalities in the sural nerve from patients with peripheral vascular disease. *Histol Histopathol.* 1991;6:63.
19. Nukada H, van Rij AM, Packer SG, McMorran PD. Pathology of acute and chronic ischaemic neuropathy in atherosclerotic peripheral vascular disease. *Brain.* 1996;119:1449.
20. Lacroix P, Aboyans V, Fournier S, et al. Ischemic neuropathy in occlusive lower limb arterial disease at the state of ischemia on effort. *Arch Mal Coeur Vaiss.* 1999;92:1471.
21. Schoen M, Rotter R, Gierer P, et al. Ischemic preconditioning prevents skeletal muscle tissue injury, but not nerve lesion upon tourniquet-induced ischemia. *J Trauma.* 2007;63:788.
22. Kim DH, Murovic JA, Tiel RL, Kline DG. Management and outcomes in 318 operative common peroneal nerve lesions at the Louisiana State University Health Sciences Center. *Neurosurgery.* 2004;54:1421.
23. Kim DH, Murovic JA, Tiel RL, Kline DG. Intrapelvic and thigh-level femoral nerve lesions: management and outcomes in 119 surgically treated cases. *J Neurosurg.* 2004;100:989.



24. Benezis I, Boutaud B, Leclerc J, et al. Lateral femoral cutaneous neuropathy and its surgical treatment: a report of 167 cases. *Muscle Nerve*. 2007;36:659.
25. Kim DH, Kline DG. Surgical outcome for intra- and extrapelvic femoral nerve lesions. *J Neurosurg*. 1995;83:783.
26. Thoma A, Fawcett S, Ginty M, Veltri K. Decompression of the common peroneal nerve: experience with 20 consecutive cases. *Plast Reconstr Surg*. 2001;107:1183.
27. Humphreys DB, Novak CB, Mackinnon SE. Patient outcome after common peroneal nerve decompression. *J Neurosurg*. 2007;107:314.
28. Garozzo D, Ferraresi S, Buffatti P. Surgical treatment of common peroneal nerve injuries: indications and results. A series of 62 cases. *J Neurosurg Sci*. 2004;48:105.
29. Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. *Diabetes*. 1989;38:1456.
30. Gordon Smith A, Robinson Singleton J. Idiopathic neuropathy, prediabetes and the metabolic syndrome. *J Neurol Sci*. 2006;242:9.
31. Pradeepa R, Rema M, Vignesh J, et al. Prevalence and risk factors for diabetic neuropathy in an urban south Indian population: the Chennai Urban Rural Epidemiology Study (CURES-55). *Diabet Med*. 2008;25:407.
32. Kles KA, Vinik AI. Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component. *Curr Diabetes Rev*. 2006;2:131.
33. Cardoso CR, Salles GF. Predictors of development and progression of microvascular complications in a cohort of Brazilian type 2 diabetic patients. *J Diabetes Complications*. 2008;22:164.
34. Wang Y, Kawamura N, Schmelzer JD, et al. Decreased peripheral nerve damage after ischemia-reperfusion injury in mice lacking TNF-alpha. *J Neurol Sci*. 2008;267:107.
35. Ramaglia V, Wolterman R, de Kok M, et al. Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injury. *Am J Pathol*. 2008;172:1043.
36. Smith DC, Mitchell DA, Peterson GW, et al. Medial brachial fascial compartment syndrome: anatomic basis of neuropathy after transaxillary arteriography. *Radiology*. 1989;173:149.
37. Tsao BE, Wilbourn AJ. The medial brachial fascial compartment syndrome following axillary arteriography. *Neurology*. 2003;61:1037.
38. Pillai AK, Bashir M, Ferral H, et al. Median nerve injury as a result of medial brachial fascial compartment syndrome. *J Vasc Interv Radiol*. 2007;18:1434.
39. Kennedy AM, Grocott M, Schwartz MS, et al. Median nerve injury: an underrecognised complication of brachial artery cardiac catheterisation? *J Neurol Neurosurg Psychiatry*. 1997;63:542.
40. Hye RJ, Wolf YG. Ischemic monomelic neuropathy: an under-recognized complication of hemodialysis access. *Ann Vasc Surg*. 1994;8:578.
41. Miles AM. Vascular steal syndrome and ischaemic monomelic neuropathy: two variants of upper limb ischaemia after haemodialysis vascular access surgery. *Nephrol Dial Transplant*. 1999;14:297.
42. Miles AM. Upper limb ischemia after vascular access surgery: differential diagnosis and management. *Semin Dial*. 2000;13:312.
43. Ikizler M, Ozkan S, Dernek S, et al. Does radial artery harvesting for coronary revascularization cause neurological injury in the forearm and hand? *Eur J Cardiothorac Surg*. 2005;28:420.
44. Ikizler M, Entok E, Ozdemir C, et al. Neurological status and tissue perfusion changes after radial artery harvesting for myocardial revascularization: importance of the Allen test. *Thorac Cardiovasc Surg*. 2007;55:99.
45. Kandemir O, Buyukates M, Emre U, et al. Effect of low dose electrocautery usage during radial artery harvesting on the neurological outcome of the forearm: a neuroelectrophysiological study. *Thorac Cardiovasc Surg*. 2008;56:24.
46. Guerra WK, Baldauf J, Schroeder HW. Long-term results after microsurgical repair of traumatic nerve lesions of the upper

- extremities. *Zentralbl Neurochir.* 2007;68:195.
47. Usubiaga JE, Kolodny J, Usubiaga LE. Neurologic complications of prevertebral surgery under regional anaesthesia. *Surgery.* 1970;68:304.
  48. Abdellaoui A, West NJ, Tomlinson MA, et al. Lower limb paralysis from ischaemic neuropathy of the lumbosacral plexus following aorto-iliac procedures. *Interact Cardiovasc Thorac Surg.* 2007;6:501.
  49. Gloviczki P, Cross SA, Stanson AW, et al. Ischemic injury to the spinal cord or lumbosacral plexus after aorto-iliac reconstruction. *Am J Surg.* 1991;162:131.
  50. Plecha EJ, Seabrook GR, Freischlag JA, Towne JB. Neurologic complications of reoperative and emergent abdominal aortic reconstruction. *Ann Vasc Surg.* 1995;9:95.
  51. Voulters L, Bolton C. Acute lumbosacral plexus neuropathy following vascular surgery. *Can J Neurol Sci.* 1983;10:153.
  52. D'Amour ML, Lebrun LH, Rabbat A, et al. Peripheral neurological complications of aortoiliac vascular disease. *Can J Neurol Sci.* 1987;14:127.
  53. Forester ND, Parry D, Kessel D, et al. Ischaemic sciatic neuropathy: an important complication of embolisation of a type II endoleak. *Eur J Vasc Endovasc Surg.* 2002;24:462.
  54. Kwok PC, Chung TK, Chong LC, et al. Neurologic injury after endovascular stent-graft and bilateral internal iliac artery embolization for infrarenal abdominal aortic aneurysm. *J Vasc Interv Radiol.* 2001;12:761.
  55. Kibria SG, Gough MJ. Ischaemic sciatic neuropathy: a complication of endovascular repair of abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg.* 1999;17:266.
  56. Xenos ES, Stevens SL, Freeman MB, et al. Erectile function after open or endovascular abdominal aortic aneurysm repair. *Ann Vasc Surg.* 2003;17:530.
  57. Luzzio CC, Waclawik AJ, Gallagher CL, Knechtle SJ. Iliac artery pseudoaneurysm following renal transplantation presenting as lumbosacral plexopathy. *Transplantation.* 1999;67:1077.
  58. Gardiner MD, Mangwani J, Williams WW. Aneurysm of the common iliac artery presenting as a lumbosacral plexopathy. *J Bone Joint Surg Am.* 2006;88:1524.
  59. Wider C, Kuntzer T, Von Segesser LK, et al. Bilateral compressive lumbosacral plexopathy due to internal iliac artery aneurysms. *J Neurol.* 2006;253:809.
  60. Turley JJE, Johnston KW. Ischemic neuropathy. In: Rutherford RB, ed. *Vascular Surgery*. 6th ed. Philadelphia, PA: Elsevier Saunders; 2005:915.
  61. Hall MC, Koch MO, Smith JA Jr. Femoral neuropathy complicating urologic abdominopelvic procedures. *Urology.* 1995;45:146.
  62. Walsh C, Walsh A. Postoperative femoral neuropathy. *Surg Gynecol Obstet.* 1992;174:255.
  63. Brasch RC, Bufo AJ, Kreienberg PF, Johnson GP. Femoral neuropathy secondary to the use of a self-retaining retractor. Report of three cases and review of the literature. *Dis Colon Rectum.* 1995;38:1115.
  64. Porzionato A, Macchi V, Fenato F, et al. Femoral nerve injury after gynecologic laparoscopy. *J Minim Invasive Gynecol.* 2008;15:105.
  65. Simmons C Jr, Izant TH, Rothman RH, et al. Femoral neuropathy following total hip arthroplasty. Anatomic study, case reports, and literature review. *J Arthroplasty.* 1991;6:S57.
  66. Ghani KR, McMillan R, Paterson-Brown S. Transient femoral nerve palsy following ilio-inguinal nerve blockade for day case inguinal hernia repair. *J R Coll Surg Edinb.* 2002;47:626.
  67. Mirovsky Y, Neuwirth M. Injuries to the lateral femoral cutaneous nerve during spine surgery. *Spine.* 2000;25:1266.
  68. Boontje AH, Haaxma R. Femoral neuropathy as a complication of aortic surgery. *J Cardiovasc Surg.* 1987;28:286.
  69. Moawad MR, Masannat YA, Alhamdani A, Gibbons CP. Nerve injury in lower limb vascular surgery. *Surgeon.* 2008;6:32.
  70. Caiati JM, Kaplan D, Gitlitz D, et al. The value of the oblique groin incision for femoral artery access during endovascular procedures. *Ann Vasc Surg.* 2000;14:248.

71. Watson DR, Tan J, Wiseman L, et al. Oblique groin incision for endovascular repair of abdominal aortic aneurysms. *Heart Surg Forum*. 2004;7:E515.
72. Parmer SS, Carpenter JP, Fairman RM, et al. Femoral neuropathy following retroperitoneal hemorrhage: case series and review of the literature. *Ann Vasc Surg*. 2006;20:536.
73. Rochman AS, Vitarbo E, Levi AD. Femoral nerve palsy secondary to traumatic pseudoaneurysm and iliacus hematoma. *J Neurosurg*. 2005;102:382.
74. Pirouzmand F, Midha R. Subacute femoral compressive neuropathy from iliacus compartment hematoma. *Can J Neurol Sci*. 2001;28:155.
75. Merrick HW, Zeiss J, Woldenberg LS. Percutaneous decompression for femoral neuropathy secondary to heparin-induced retroperitoneal hematoma: case report and review of the literature. *Am Surg*. 1991;57:706.
76. Kent KC, Moscucci M, Gallagher SG, et al. Neuropathy after cardiac catheterization: incidence, clinical patterns, and long-term outcome. *J Vasc Surg*. 1994;19:1008.
77. Jacobs MJ, Gregoric ID, Reul GJ. Profunda femoral artery pseudoaneurysm after percutaneous transluminal procedures manifested by neuropathy. *J Cardiovasc Surg*. 1992;33:729.
78. Chopra JS, Hurwitz LJ. Femoral nerve conduction in diabetes and chronic occlusive vascular disease. *J Neurol Neurosurg Psychiatry*. 1968;31:28.
79. Archie JP Jr. Femoral neuropathy due to common iliac artery occlusion. *South Med J*. 1983;76:1073.
80. McManis PG. Sciatic nerve lesions during cardiac surgery. *Neurology*. 1994;44:684.
81. Mackenzie DJ, Wagner WH, Kulber DA, et al. Vascular complications of the intra-aortic balloon pump. *Am J Surg*. 1992;164:517.
82. Hsin HT, Hwang JJ. Isolated femoral nerve neuropathy after intra-aortic balloon pump treatment. *J Formos Med Assoc*. 2007;106:S29.
83. Arafa OE, Pedersen TH, Svennevig JL, et al. Vascular complications of the intraaortic balloon pump in patients undergoing open heart operations: 15-year experience. *Ann Thorac Surg*. 1999;67:645.
84. Göl MK, Bayazit M, Emir M, et al. Vascular complications related to percutaneous insertion of intraaortic balloon pumps. *Ann Thorac Surg*. 1994;58:1476.
85. Belsh JM. Anterior femoral cutaneous nerve injury following femoral artery reconstructive surgery. *Arch Neurol*. 1991;48:230.
86. de Ridder VA, de Lange S, Popta JV. Anatomical variations of the lateral femoral cutaneous nerve and the consequences for surgery. *J Orthop Trauma*. 1999;13:207.
87. Chiu KM, Chen CL, Chu SH, Lin TY. Endoscopic harvest of saphenous vein: a lesson learned from 1,348 cases. *Surg Endosc*. 2008;22:183.
88. Wood JJ, Chant H, Laugharne M, et al. A prospective study of cutaneous nerve injury following long saphenous vein surgery. *Eur J Vasc Endovasc Surg*. 2005;30:654.
89. Morrison C, Dalsing MC. Signs and symptoms of saphenous nerve injury after greater saphenous vein stripping: prevalence, severity, and relevance for modern practice. *J Vasc Surg*. 2003;38:886.
90. Fernandez CF, Roizental M, Carvalho J. Combined endovenous laser therapy and microphlebectomy in the treatment of varicose veins: efficacy and complications of a large single center-experience. *J Vasc Surg*. 2008;48:947.
91. Subramonia S, Lees T. Sensory abnormalities and bruising after long saphenous vein stripping: impact on short-term quality of life. *J Vasc Surg*. 2005;42:510.
92. Drees C, Wilbourn AJ, Stevens GH. Main trunk tibial neuropathies. *Neurology*. 2002;59:1082.
93. Atkin GK, Round T, Vattipally VR, Das SK. Common peroneal nerve injury as a complication of short saphenous vein surgery. *Phlebology*. 2007;22:3.

## 第 48 章

1. Hull RD, Raskob GE, Hirsh J. Prophylaxis of venous thromboembolism. An overview. *Chest*. 1986;89(5 Suppl):374S-383S.
2. Biland L, Widmer LK. Varicose veins (VV) and chronic venous insufficiency (CVI). Medical and socio-economic aspects, Basle study. *Acta Chir Scand*. 1988;544:9-11.
3. Coon WW, Willis PW 3rd, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. *Circulation*. 1973;48:839-846.
4. Silva Mde C. Chronic venous insufficiency of the lower limbs and its socio-economic significance. *Int Angiol*. 1991;10:152-157.
5. Virchow RLK. "Thrombose und Embolie. Gefässentzündung und septische infektion." *Gesammelte Abhandlungen zur wissenschaftlichen Medicin*. Frankfurt am Main: Von Meidinger and John, 1856;219-732. Translation in Matzdorff AC, Bell WR (1998). Thrombosis and embolie (1846-1856). Canton, MA: Science History Publications.
6. Heit JA, Cohen AT, Anderson FJ. On behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal venous thromboembolism (VTE) events in the US [abstract]. *Blood*. 2005;106(11).
7. Heit JA, Petterson TM, Farmer SA, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 35-year population based study. *Blood*. 2006;108:403a.
8. Heit JA. The epidemiology of venous thromboembolism in the community. *Arterioscler Thromb Vasc Biol*. 2008;28:370-372.
9. Keenan CR, White RH. The effects of race/ethnicity and sex on the risk of venous thromboembolism. *Curr Opin Pulm Med*. 2007;13:377-383.
10. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thromb Haemost*. 2007;98:756-764.
11. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(3 Suppl):338S-400S.
12. Anderson FA Jr, Zayazny M, Heit JA, et al. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. *Am J Hematol*. 2007;82:777-782.
13. Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after major trauma. *N Engl J Med*. 1994;331:1601-1606.
14. Cook DJ, Crowther MA, Meade MO, et al. Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. *J Crit Care*. 2005;20:309-313.
15. Muscedere JG, Heyland DK, Cook D. Venous thromboembolism in critical illness in a community intensive care unit. *J Crit Care*. 2007;22:285-289.
16. Liebson CL, Petterson TM, Bailey KR, et al. Risk factors for venous thromboembolism in nursing home residents. *Mayo Clin Proc*. 2008;83:151-157.
17. Attia J, Ray JG, Cook DJ, et al. Deep vein thrombosis and its prevention in critically ill adults. *Arch Intern Med*. 2001;161:1268-1279.
18. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. *Arch Intern Med*. 2000;160:761-768.
19. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. *Thromb Haemost*. 2002;88:407-414.
20. Heit JA, Farmer SA, Petterson TM, et al. Venous thromboembolism event type (PE+/-DVT vs DVT alone) predicts recurrence type and survival. *Blood*. 2002;100:149a.
21. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. *BMJ*. 1991;302:709-711.

22. Kakkar VV, Howe CT, Flanc C, et al. Natural history of postoperative deep-vein thrombosis. *Lancet*. 1969;2:230-232.
23. Piccioli A, Prandoni P, Goldhaber SZ. Epidemiologic characteristics, management, and outcome of deep venous thrombosis in a tertiary-care hospital: the Brigham and Women's Hospital DVT registry. *Am Heart J*. 1996;132:1010-1014.
24. Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. *Arch Intern Med*. 1994;154:164-168.
25. Oger E, Leroyer C, Le Moigne E, et al. The value of a risk factor analysis in clinically suspected deep venous thrombosis. *Respiration*. 1997;64:326-330.
26. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. The prevalence of risk factors for venous thromboembolism among hospital patients. *Arch Intern Med*. 1992;152:1660-1664.
27. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. *Thromb Haemost*. 1997;78:1-6.
28. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. *Arch Intern Med*. 2000;160:809-815.
29. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. *Thromb Haemost*. 2001;86:452-463.
30. Nordstrom M, Lindblad B, Bergqvist D, et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. *J Intern Med*. 1992;232:155-160.
31. Hansson PO, Welin L, Tibblin G, et al. Deep vein thrombosis and pulmonary embolism in the general population. "The Study of Men Born in 1913." *Arch Intern Med*. 1997;157:1665-1670.
32. Tardy B, Tardy-Poncet B, Bara L, et al. Effects of long travels in sitting position in elderly volunteers on biological markers of coagulation activation and fibrinolysis. *Thromb Res*. 1996;83:153-160.
33. Gibbs NM. Venous thrombosis of the lower limbs with particular reference to bed-rest. *Br J Surg*. 1957;45:209-236.
34. McLachlin AD, McLachlin JA, Jory TA, et al. Venous stasis in the lower extremities. *Ann Surg*. 1960;152:678-685.
35. Rohrer MJ, Cutler BS, MacDougall E, et al. A prospective study of the incidence of deep venous thrombosis in hospitalized children. *J Vasc Surg*. 1996;24:46-49; discussion 50.
36. Sandoval JA, Sheehan MP, Stonerock CE, et al. Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: an increasing population at risk. *J Vasc Surg*. 2008;47:837-843.
37. Buck JR, Connors RH, Coon WW, et al. Pulmonary embolism in children. *J Pediatr Surg*. 1981;16:385-391.
38. Coon WW. Epidemiology of venous thromboembolism. *Ann Surg*. 1977;186:149-164.
39. Wise RC, Todd JK. Spontaneous, lower-extremity venous thrombosis in children. *Am J Dis Child*. 1973;126:766-769.
40. Leslie IJ, Dorgan JC, Bentley G, et al. A prospective study of deep vein thrombosis of the leg in children on halo-femoral traction. *J Bone Joint Surg Br*. 1981;63:168-170.
41. DeAngelis GA, McIlhenny J, Willson DF, et al. Prevalence of deep venous thrombosis in the lower extremities of children in the intensive care unit. *Pediatr Radiol*. 1996;26:821-824.
42. McBride WJ, Gadowski GR, Keller MS, et al. Pulmonary embolism in pediatric trauma patients. *J Trauma*. 1994;37:913-915.
43. Radecki RT, Gaebler-Spira D. Deep vein thrombosis in the disabled pediatric population. *Arch Phys Med Rehabil*. 1994;75:248-250.
44. Nguyen LT, Laberge JM, Guttman FM, et al. Spontaneous deep vein thrombosis in childhood and adolescence. *J Pediatr Surg*. 1986;21:640-643.
45. Bernstein D, Coupey S, Schonberg SK. Pulmonary embolism in adolescents. *Am J Dis Child*. 1986;140:667-671.
46. Sigel B, Ipsen J, Felix WR Jr. The epidemiology of lower extremity deep venous thrombosis in surgical patients. *Ann Surg*. 1974;179:278-290.
47. Warlow C, Ogston D, Douglas AS. Deep venous thrombosis of the legs after strokes. Part I—incidence and predisposing

- factors. *BMJ*. 1976;1:1178-1181.
48. Cruickshank JM, Gorlin R, Jennett B. Air travel and thrombotic episodes: the economy class syndrome. *Lancet*. 1988;2:497-498.
  49. Homans J. Thrombosis of the deep leg veins due to prolonged sitting. *N Engl J Med*. 1954;250:148-149.
  50. Ledermann JA, Keshavarzian A. Acute pulmonary embolism following air travel. *Postgrad Med J*. 1983;59:104-105.
  51. Thromboembolism and air travel. *Lancet*. 1988;2:797.
  52. Sarvesvaran R. Sudden natural deaths associated with commercial air travel. *Med Sci Law*. 1986;26:35-38.
  53. Symington I, Stack BHR. Pulmonary thromboembolism after travel. *Br J Dis Chest*. 1977;71:138-140.
  54. Wessler S. Thrombosis in the presence of vascular stasis. *Am J Med*. 1962;33:648-666.
  55. Landgraf H, Vanselow B, Schulte-Huermann D, et al. Economy class syndrome: rheology, fluid balance, and lower leg edema during a simulated 12-hour long distance flight. *Aviat Space Environ Med*. 1994;65:930-935.
  56. Eklof B. Air travel related venous thromboembolism—an existing problem that can be prevented? *Cardiovasc Surg*. 2002;10:95-97.
  57. Ferrari E, Chevallier T, Chapelier A, et al. Travel as a risk factor for venous thromboembolic disease: a case-control study. *Chest*. 1999;115:440-444.
  58. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. *Arch Intern Med*. 2000;160:3415-3420.
  59. Scurr JH, Machin SJ, Bailey-King S, et al. Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial. *Lancet*. 2001;357:1485-1489.
  60. Lapostolle F, Surget V, Borron SW, et al. Severe pulmonary embolism associated with air travel. *N Engl J Med*. 2001;345:779-783.
  61. Paganin F, Bourde A, Yvin JL, et al. Venous thromboembolism in passengers following a 12-h flight: a case-control study. *Aviat Space Environ Med*. 2003;74:1277-1280.
  62. Hughes RJ, Hopkins RJ, Hill S, et al. Frequency of venous thromboembolism in low to moderate risk long distance air travellers: the New Zealand Air Traveller's Thrombosis (NZATT) study. *Lancet*. 2003;362:2039-2044.
  63. Sevitt S. The vascularisation of deep-vein thrombi and their fibrous residue: a post mortem angio-graphic study. *J Pathol*. 1973;111:1-11.
  64. Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden). *N Engl J Med*. 1997;336:399-403.
  65. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. *N Engl J Med*. 1999;341:801-806.
  66. den Heijer M, Blom HJ, Gerrits WB, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? *Lancet*. 1995;345:882-885.
  67. Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. *Arch Intern Med*. 1991;151:1721-1731.
  68. Bergqvist D, Caprini JA, Dotsenko O, et al. Venous thromboembolism and cancer. *Curr Probl Surg*. 2007;44:157-216.
  68. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? *South Med J*. 1980;73:841-843.
  70. Cornuz J, Pearson SD, Creager MA, et al. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. *Ann Intern Med*. 1996;125:785-793.
  71. Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. *N Engl J Med*. 1992;327:1128-1133.
  72. Monreal M, Lafoz E, Casals A, et al. Occult cancer in patients with deep venous thrombosis. A systematic approach. *Cancer*. 1991;67:541-545.

73. Griffin MR, Stanson AW, Brown ML, et al. Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms. *Arch Intern Med.* 1987;147:1907-1911.
74. Nordstrom M, Lindblad B, Anderson H, et al. Deep venous thrombosis and occult malignancy: an epidemiological study. *BMJ.* 1994;308:891-894.
75. Sorensen HT, Mellekjaer L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. *N Engl J Med.* 1998;338:1169-1173.
76. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. *Cancer.* 2007;110:2339-2346.
77. Winter PC. The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology. *Hematol Oncol.* 2006;24:126-133.
78. Osborne NH, Wakefield TW, Henke PK. Venous thromboembolism in cancer patients undergoing major surgery. *Ann Surg Oncol* 2008;15:3567-3578.
79. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. *Lancet Oncol.* 2005;6:401-410.
80. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. *Thromb Res.* 2001;102:V215-V224.
81. Gordon SG, Cross BA. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. *Cancer Res.* 1990;50:6229-6234.
82. Nijziel MR, van Oerle R, Hillen HF, et al. From Trousseau to angiogenesis: the link between the haemostatic system and cancer. *Neth J Med.* 2006;64:403-410.
83. Nachman RL, Hajjar KA, Silverstein RL, et al. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. *J Exp Med.* 1986;163:1595-1600.
84. Falanga A, Barui T, Rickles FR, et al. Guidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and Haemostasis. *Thromb Haemost.* 1993;70:540-542.
85. Falanga A, Ofosu FA, Delaini F, et al. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions. *Blood Coagul Fibrinolysis.* 1994;5(Suppl 1):S19-S23; discussion 59-64.
86. Rickles FR, Levin M, Edwards RL. Hemostatic alterations in cancer patients. *Cancer Metastasis Rev.* 1992;11:237-248.
87. Edwards RL, Rickles FR, Moritz TE, et al. Abnormalities of blood coagulation tests in patients with cancer. *Am J Clin Pathol.* 1987;88:596-602.
88. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. *Blood.* 1983;62:14-31.
89. Falanga A, Ofosu FA, Cortelazzo S, et al. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. *Br J Haematol.* 1993;85:745-750.
90. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. *Ann Surg.* 1988;208:227-240.
91. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. *N Engl J Med.* 1988;318:404-407.
92. Doll DC, Ringenberg QS, Yarbrow JW. Vascular toxicity associated with antineoplastic agents. *J Clin Oncol.* 1986;4:1405-1417.
93. Clarke CS, Otridge BW, Carney DN. Thromboembolism. A complication of weekly chemotherapy in the treatment of non-Hodgkin's lymphoma. *Cancer.* 1990;66:2027-2030.
94. Edwards RL, Klaus M, Matthews W, et al. Heparin abolished the chemotherapy-induced increase in plasma fibrinogen levels. *Am J Med.* 1990;89:25-28.
95. Clagett GP, Anderson FA Jr, Heit J, et al. Prevention of venous thromboembolism. *Chest.* 1995;108(4 Suppl):312S-334S.

96. Mammen EF. Pathogenesis of venous thrombosis. *Chest*. 1992;102(6 Suppl):640S-644S.
97. Kakkar VV, Howe CT, Nicolaides AN, et al. Deep vein thrombosis of the leg. Is there a "high risk" group? *Am J Surg*. 1970;120:527-530.
98. Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. *Scott Med J*. 1996;41:83-86.
99. Scurr JH. How long after surgery does the risk of thromboembolism persist? *Acta Chir Scand*. 1990;556:22-24.
100. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. *Arch Intern Med*. 1999;159:445-453.
101. Tripolitis AJ, Bodily KC, Blackshear WM Jr, et al. Venous capacitance and outflow in the postoperative patient. *Ann Surg*. 1979;190:634-637.
102. Kambayashi J, Sakon M, Yokota M, et al. Activation of coagulation and fibrinolysis during surgery, analyzed by molecular markers. *Thromb Res*. 1990;60:157-167.
103. Sharrock NE, Go G, Harpel PC, et al. The John Charnley Award. Thrombogenesis during total hip arthroplasty. *Clin Orthop Relat Res*. 1995;319:16-27.
104. Eriksson BI, Eriksson E, Risberg B. Impaired fibrinolysis and postoperative thromboembolism in orthopedic patients. *Thromb Res*. 1991;62:55-64.
105. Kluft C, Verheijen JH, Jie AF, et al. The postoperative fibrinolytic shutdown; a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. *Scand J Clin Lab Invest*. 1985;45:605-610.
106. Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. *J Clin Pathol*. 1974;27:517-528.
107. Hamilton T, Angevine D. Fatal pulmonary embolism in 100 battle casualties. *Mil Surg*. 1946;99:450.
108. Burns GA, Cohn SM, Frumento RJ, et al. Prospective ultrasound evaluation of venous thrombosis in high-risk trauma patients. *J Trauma*. 1993;35:405-408.
109. Kundson MM, Collins JA, Goodman SB, et al. Thromboembolism following multiple trauma. *J Trauma*. 1992;32:2-11.
110. Knudson MM, Lewis FR, Clinton A, et al. Prevention of venous thromboembolism in trauma patients. *J Trauma*. 1994;37:480-487.
111. Napolitano LM, Farlapati VS, Heard SO, et al. Asymptomatic deep venous thrombosis in the trauma patient: is an aggressive screening protocol justified? *J Trauma*. 1995;39:651-657; discussion 657-659.
112. Satiani B, Falcone R, Shook L, et al. Screening for major deep vein thrombosis in seriously injured patients: a prospective study. *Ann Vasc Surg*. 1997;11:626-629.
113. Upchurch GR Jr, Demling RH, Davies J, et al. Efficacy of subcutaneous heparin in prevention of venous thromboembolic events in trauma patients. *Ann Surg*. 1995;61:749-755.
114. Hill SL, Berry RE, Ruiz AJ. Deep venous thrombosis in the trauma patient. *Am Surg*. 1994;60:405-408.
115. Dennis JW, Menawat S, Von Thron J, et al. Efficacy of deep venous thrombosis prophylaxis in trauma patients and identification of high-risk groups. *J Trauma*. 1993;35:132-138; discussion 138-139.
116. Sue LP, Davis JW, Parks SN. Iliofemoral venous injuries: an indication for prophylactic caval filter placement. *J Trauma*. 1995;39:693-695.
117. Knudson MM, Morabito D, Paiement GD, et al. Use of low molecular weight heparin in preventing thromboembolism in trauma patients. *J Trauma*. 1996;41:446-459.
118. Gando S, Tede I, Kubota M. Posttrauma coagulation and fibrinolysis. *Crit Care Med*. 1992;20:594-600.
119. Garcia Frade LJ, Landin L, Avello AG, et al. Changes in fibrinolysis in the intensive care patient. *Thromb Res*. 1987;47:593-599.
120. Kapsch DN, Metzler M, Harrington M, et al. Fibrinolytic response to trauma. *Surgery*. 1984;95:473-478.
121. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous blood. *Blood*. 1996;88:3698-3703.



122. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. *Thromb Haemost.* 1998;79:706-708.
123. Hillarp A, Zoller B, Svensson PJ, et al. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. *Thromb Haemost.* 1997;78:990-992.
124. Ferraresi P, Marchetti G, Legnani C, et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. *Arterioscler Thromb Vasc Biol.* 1997;17:2418-2422.
125. Franchini M, Veneri D, Salvagno GL, et al. Inherited thrombophilia. *Crit Rev Clin Lab Sci.* 2006;43:249-290.
126. Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. *Thromb Haemost.* 1997;78:1426-1429.
127. Leroyer C, Mercier B, Oger E, et al. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. *Thromb Haemost.* 1998;80:49-51.
128. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: predication of a cofactor to activated protein C. *Proc Natl Acad Sci U S A.* 1993;90:1004-1008.
129. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature.* 1994;369:64-67.
130. Dahlbäck B. Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism. *J Intern Med.* 1995;237:221-227.
131. Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. *Blood.* 1999;93:2552-2558.
132. Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. *Blood.* 1995;85:607-614.
133. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. *Lancet.* 1993;342:1503-1506.
134. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. *Lancet.* 1995;346:1133-1134.
135. Irani-Hakime N, Tamim H, Kreidy R, et al. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. *Am J Hematol.* 2000;65:45-49.
136. Ridker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. *JAMA.* 1997;277:1305-1307.
137. Ho WK, Hankey GJ, Quinlan DJ, et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. *Arch Intern Med.* 2006;166:729-736.
138. Buchanan GS, Rodgers GM, Ware Branch D. The inherited thrombophilias: genetics, epidemiology, and laboratory evaluation. *Best Pract Res.* 2003;17:397-411.
139. Rosendaal FR, Koster T, Vandenbrouche JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). *Blood.* 1995;85:1504-1508.
140. Bick RL. Prothrombin G20210A mutation, antithrombin, heparin cofactor II, protein C, and protein S defects. *Hematol Oncol Clin North Am.* 2003;17:9-36.
141. Esmon CT, Esmon NL. Protein C activation. *Semin Thromb Hemost.* 1984;10:122-130.
142. Walker FJ. Protein S and the regulation of activated protein C. *Semin Thromb Hemost.* 1984;10:131-138.
143. Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. *Thromb Haemost.* 1995;73:87-93.
144. Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism—results of the Spanish Multicenteric Study of Thrombophilia (EMET-Study).

*Thromb Haemost.* 1997;77:444-451.

145. Koster T, Rosendaal FR, Briet E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). *Blood*. 1995;85:2756-2761.
146. Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. *Semin Thromb Hemost.* 1990;16:229-309.
147. Viganò D'Angelo S, Comp PC, Esmon CT, et al. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. *J Clin Invest.* 1986;77:416-425.
148. McGehee WG, Klotz TA, Epstein DJ, et al. Coumarin necrosis associated with hereditary protein C deficiency. *Ann Intern Med.* 1984;101:59-60.
149. Fourrier F, Lestavel P, Chopin C, et al. Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. *Intensive Care Med.* 1990;16:121-124.
150. Gladson CL, Scharrer I, Hach V, et al. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. *Thromb Haemost.* 1988;59:18-22.
151. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. *Hum Genet.* 2001;109:369-384.
152. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. *Blood*. 1998;92:2353-2358.
153. Sallah S, Abdallah JM, Gagnon GA. Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency. *Haemostasis.* 1998;28:25-30.
154. Shafer AI, Levine MN, Konkle BA, et al. Thrombotic disorders: diagnosis and treatment. *Hematology Am Soc Hematol Educ Program.* 2003;520-539.
155. Rosendaal FR. Risk factors for venous thrombotic disease. *Thromb Haemost.* 1999;82:610-619.
156. Bick RL. Clinical relevance of antithrombin III. *Semin Thromb Hemost.* 1982;8:276-287.
157. Das M, Carrol SF. Antithrombin III deficiency: an etiology of Budd-Chiari syndrome. *Surgery.* 1985;97:242-246.
158. Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. *Ann Intern Med.* 2003;138:128-134.
159. Roberts HR, Stinchcomb TE, Gabriel DA. The dysfibrinogenemias. *Br J Haematol.* 2001;114:249-257.
160. Rosendaal FR. High levels of factor VIII and venous thrombosis. *Thromb Haemost.* 2000;83:1-2.
161. Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. *N Engl J Med.* 2000;342:696-701.
162. van Hylckama Vlieg A, van der Linden IK, Bertina RM, et al. High levels of factor IX increase the risk of venous thrombosis. *Blood.* 2000;95:3678-3682.
163. O'Donnell J, Laffan M. Elevated plasma factor VIII levels—a novel risk factor for venous thromboembolism. *Clin Lab.* 2001;47:1-6.
164. den Heijer M, Koster T, Bloom HJ. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. *N Engl J Med.* 1996;334:759-762.
165. Lee R, Frenkel EP. Hyperhomocysteinemia and thrombosis. *Hematol Oncol Clin North Am.* 2003;17:85-102.
166. Kujovich JL. Hormones and pregnancy: thrombotic risks for women. *Br J Haematol.* 2004;126:443-454.
167. James AH. Prevention and management of venous thromboembolism in pregnancy. *Am J Med.* 2007;120:S26-S34.
168. Freiderich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. *Ann Intern Med.* 1996;125:955-960.
169. Rutherford S, Montoro M, McGehee W, et al. Thromboembolic disease associated with pregnancy: an 11-year review [abstract]. *Am J Obstet Gynecol.* 1991;164S:286.
170. Bates SM, Greer IA, Hirsh J, et al. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126:627S-644S.

171. Ginsberg JS, Brill-Edwards PB, Burrows RF, et al. Venous thrombosis during pregnancy: leg and trimester of presentation. *Thromb Haemost* 1992;67:519-520.
172. Treffers PE, Huidekoper BL, Weenink GH, et al. Epidemiological observations of thromboembolic disease during pregnancy and in the puerperium, in 56,022 women. *Int J Gynecol Obstet*. 1983;21:327-331.
173. Eldor A. Thrombophilia and its treatment in pregnancy. *J Thromb Thrombolysis*. 2001;12:23-30.
174. Alving BM, Comp PC. Recent advances in understanding clotting and evaluating patients with recurrent thrombosis. *Am J Obstet Gynecol*. 1992;167:1184-1191.
175. Malm J, Laurell M, Dahlbäck B. Changes in plasma levels of vitamin K-dependent protein C and S and of C4b-binding protein during pregnancy and oral contraception. *Br J Haematol*. 1988;68:437-443.
176. Brenner B. Haemostatic changes in pregnancy. *Thromb Res*. 2004;114:409-414.
177. Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein C-, and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. *Thromb Haemost*. 1994;71:548-552.
178. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. *N Engl J Med*. 1996;335:108-114.
179. Vandenbrouke JP, van der Meer FJM, Helmerhorst FM, et al. Factor V Leiden: should we screen oral contraceptive users and pregnant women? *BMJ*. 1996;313:1127-1130.
180. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. *Thromb Haemost*. 1997;78:1183-1188.
181. Harvey D, Lowe GM. Factor V Leiden: association with venous thromboembolism in pregnancy and screening issues. *Br J Biomed Sci*. 2004;6:157-164.
182. Franchini M, Veneri D, Salvagno GL, et al. Inherited thrombophilia. *Crit Rev Clin Lab Sci*. 2006;43:249-290.
183. Tindall VR. Factors influencing puerperal thromboembolism. *J Obstet Gynaecol Br Commonw*. 1968;75:1324-1327.
184. Oral contraceptive use and venous thromboembolic disease, surgically confirmed gall-bladder disease, and breast tumors. Boston Collaborative Drug Surveillance Program. *Lancet*. 1973;1:1399-1404.
185. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. *Hemostasis and Thrombosis: Basic Principles and Clinical Practice*. 3rd ed. Philadelphia, PA: JB Lippincott; 1994:1275.
186. Sartwell PE, Masi AT, Arthes FG, et al. Thromboembolism and oral contraceptives: an epidemiologic case-control study. *Am J Epidemiol*. 1969;90:365-380.
187. Stolley PD, Tonascia JA, Tockman MS, et al. Thrombosis with low-estrogen oral contraceptives. *Am J Epidemiol*. 1975;102:197-208.
188. Koster T, Small RA, Rosendaal FR, et al. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. *J Intern Med*. 1995;238:31-37.
189. Farmer RD, Lawrenson RA, Thompson CR, et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. *Lancet*. 1997;349:83-88.
190. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. *BMJ*. 1968;2:199-205.
191. Inman WHW, Vessey MP. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. *BMJ*. 1968;2:193-199.
192. Greene GR, Sartwell PE. Oral contraceptive use in patients with thromboembolism following surgery, trauma, or infection. *Am J Public Health*. 1972;62:680-685.
193. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. *Lancet*. 1996;348:983-987.
194. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C, associated with oral contraceptive use: effect of formulations, duration of assumption, and doses of oestro-progestins. *Contraception*. 1996;54:149-152.

195. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. *Am J Obstet Gynecol.* 1995;173:210-213.
196. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestagen. *Lancet.* 1995;346:1593-1596.
197. Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR, et al. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. *Thromb Haemost.* 1997;78:327-333.
198. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KW, et al. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. *Am J Obstet Gynecol.* 1997;177:887-891.
199. Gerstman BB, Piper JM, Freiman JP, et al. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. *Int J Epidemiol.* 1990;19:931-936.
200. Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. *Am J Epidemiol.* 1991;133:32-37.
201. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. *Lancet.* 1996;348:977-980.
202. Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. *Lancet.* 1996;348:981-983.
203. Pérez Gutthann S, García Rodríguez LA, Castellsague J, et al. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. *BMJ.* 1997;314:796-800.
204. Varas-Lorenzo C, García-Rodríguez LA, Cattaruzzi C, et al. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. *Am J Epidemiol.* 1998;147:387-390.
205. Scarabin PY, Plu-Bureau G, Zitoun D, et al. Changes in haemostatic variables induced by oral contraceptives containing 50 µg or 30 µg oestrogen: absence of dose-dependent effect of PAI-1 activity. *Thromb Haemost.* 1995;74:928-932.
206. Quehenberger P, Loner U, Kapiotis S, et al. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. *Thromb Haemost.* 1996;76:729-734.
207. Von Kaulla E, Droegemueller W, Aoki N, et al. Antithrombin III depression and thrombin generation acceleration in women taking oral contraceptives. *Am J Obstet Gynecol.* 1971;109:868-873.
208. Winkler UH, Hädscher T, Schulte H, et al. Ethinylestradiol 20 versus 30 µg combined with 150 µg desogestrel: a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system. *Gynecol Endocrinol.* 1996;10:265-271.
209. Wautrecht JC, Galle C, Motte S, et al. The role of ABO blood groups in the incidence of deep vein thrombosis [letter]. *Thromb Haemost.* 1998;79:688.
210. Mourant AE, Kopec AC, Domaniewska-Sobczak K. Blood-groups and blood-clotting. *Lancet.* 1971;1:223-227.
211. Jick H, Slone D, Westerholm B, et al. Venous thromboembolic disease and ABO blood type. A cooperative study. *Lancet.* 1969;1:539-542.
212. Blann AD, Daly RJ, Amiral J. The influence of age, gender, and ABO blood group on soluble endothelial cell markers and adhesion markers. *Br J Haematol.* 1996;92:498-500.
213. Kniffin WD Jr, Baron JA, Barrett J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. *Arch Intern Med.* 1994;154:861-866.
214. Thomas WA, Davies JNP, O'Neal RM, et al. Incidence of myocardial infarction correlated with venous and pulmonary thrombosis and embolism. A geographic study based on autopsies in Uganda, East Africa and St. Louis, U.S.A. *Am J Cardiol.* 1960;5:41-47.
215. Gore I, Hirst AE, Tanaka K. Myocardial infarction and thromboembolism: a comparative study in Boston and in Kyushu, Japan. *Arch Intern Med.* 1964;113:323-330.

216. Aiach M, Gandrille S, Emmerich J. A review of mutations causing deficiencies of antithrombin, protein C, and protein S. *Thromb Haemost.* 1995;74:81-89.
217. Hingorani A, Ascher E, Lorensen E, et al. Upper extremity deep venous thrombosis and its impact on morbidity and mortality rates in a hospital-based population. *J Vasc Surg.* 1997;26:853-860.
218. Horattas MC, Wright DJ, Fenton AH, et al. Changing concepts of deep venous thrombosis of the upper extremity: report of a series and review of the literature. *Surgery.* 1988;104:561-567.
219. Meredith JW, Young JS, O'Neil EA, et al. Femoral catheters and deep venous thrombosis: a prospective evaluation with venous duplex sonography. *J Trauma.* 1993;35:187-190.
220. Xiang DZ, Verbeken EK, Van Lommel ATL, et al. Composition and formation of the sleeve enveloping a central venous catheter. *J Vasc Surg.* 1998;28:260-271.
221. Ross AH, Griffith CDM, Anderson JR, et al. Thromboembolic complications with silicone elastomer subclavian catheters. *JPN J Parenter Enteral Nutr.* 1982;6:61-63.
222. Monreal M, Raventos A, Lerma R, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines—a prospective study. *Thromb Haemost.* 1994;72:548-550.
223. Efsing HO, Lindblad B, Mark J, et al. Thromboembolic complications from central venous catheters: a comparison of three catheter materials. *World J Surg.* 1983;7:419-423.
224. Jackson LM, O'Gorman PJ, O'Connell J, et al. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. *Q J Med.* 1997;90:183-188.
225. Koenigs KP, McPhedran P, Spiro HM. Thrombosis in inflammatory bowel disease. *J Clin Gastroenterol.* 1987;9:627-631.
226. Vecchi M, Cattaneo M, de Franchis R, et al. Risk of thromboembolic complications in patients with inflammatory bowel disease: study of hemostasis measurements. *Int J Clin Lab Res.* 1991;21:165-170.
227. Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. *J Rheumatol.* 1986;13:486-489.
228. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. *Ann Intern Med.* 1990;112:682-698.
229. Wahl DG, Guillemin F, de Maistre E, et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—a meta-analysis. *Lupus.* 1997;6:467-473.
230. Nicolaides AN, Irving D. Clinical factors and the risk of deep venous thrombosis. In: Nicolaides AN, ed. *Thromboembolism: Aetiology, Advances in Prevention and Management.* Lancaster, UK: MTP Press; 1975.
231. Maurer BJ, Wray R, Shillingford JP. Frequency of venous thrombosis after myocardial infarction. *Lancet.* 1971;2:1385-1387.
232. Warlow C, Ogston D, Douglas AS. Deep venous thrombosis of the legs after strokes: Part I—Incidence and predisposing factors. *BMJ.* 1976;1:1178-1181.
233. Campbell B. Thrombosis, phlebitis, and varicose veins. *BMJ.* 1996;312:198-199.
234. May R, Thurner J. The cause of the predominately sinistral occurrence of thrombosis of the pelvic veins. *Angiology.* 1957;8:419-427.
235. Vichow R. Uber die erweiterung kleiner Degasse. *Arch Pathol Antol.* 1851;3:427.
236. Cockett F. The iliac compression syndrome. *Br J Surg.* 1965;52:816-821.
237. Knipp BS, Ferguson E, Williams DM, et al. Factors associated with outcome after interventional treatment of symptomatic iliac vein compression syndrome. *J Vasc Surg.* 2007;46:743-749.
238. Kibbe MR, Ujiki M, Goodwin AL, et al. Iliac vein compression in an asymptomatic patient population. *J Vasc Surg.* 2004;39:937-943.
239. Wolpert L. Magnetic resonance venography in the diagnosis and management of May-Thurner syndrome. *Vasc Endovasc Surg.* 2002;36:51-57.
240. Chung JW, Yoon CJ, Jung SI, et al. Acute iliofemoral deep vein thrombosis: evaluation of underlying anatomic

- abnormalities by spiral CT venography. *J Vasc Interv Radiol*. 2004;15:249-256.
241. Moreland NC, Ujiki M, Matsumura JS, et al. Decreased incidence of left common iliac vein compression in patients with abdominal aortic aneurysms. *J Vasc Surg*. 2006;44:595-600.
  242. Joffe HV, Goldhaber SZ. Upper-extremity deep vein thrombosis. *Circulation*. 2002;106:1874-1880.
  243. Thomas IH, Zierler BK. An integrative review of outcomes in patients with acute primary upper extremity deep venous thrombosis following no treatment or treatment with anticoagulation, thrombolysis, or surgical algorithms. *Vasc Endovasc Surg*. 2005;39:163-174.
  244. Shebel ND, Marin A. Effort thrombosis (Paget-Schroetter syndrome) in active young adults: current concepts in diagnosis and treatment. *J Vasc Nurs*. 2006;24:116-126.
  245. Paget J. Clinical Lectures and Assays. London: Longmans Green; 1875.
  246. von Schroetter L. *Handbuch der allgemeinen Pathologie und Therapie*. Nothnagel, Berlin: A Hirshwald; 1884:553.
  247. Oktar GL, Ergul EG. Paget-Schroetter syndrome. *Hong Kong Med J [Xianggang yi xue za zhi/Hong Kong Academy of Medicine]*. 2007;13:243-245.
  248. Melby SJ, Vedantham S, Narra VR, et al. Comprehensive surgical management of the competitive athlete with effort thrombosis of the subclavian vein (Paget-Schroetter syndrome). *J Vasc Surg*. 2008;47:809-820.
  249. Lee AY, Ginsberg JS. Venous thrombosis of the upper extremities. *Curr Treat Options Cardiovasc Med*. 2001;3:207-214.
  250. Elman EE, Kahn SR. The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review. *Thromb Res*. 2006;117:609-614.
  251. Murray A, Halliday M, Croft RJ. Popliteal artery entrapment syndrome. *Br J Surg*. 1991;78:1414-1419.
  252. Liu PT, Moyer AC, Huettl EA, et al. Popliteal vascular entrapment syndrome caused by a rare anomalous slip of the lateral head of the gastrocnemius muscle. *Skeletal Radiol*. 2005;34:359-363.
  253. Leconte D, Wagner JM, Maguin D, et al. [An uncommon syndrome: the trapped popliteal vein. Apropos of a case.]. *J Chir (Paris)*. 1986;123:358-361.
  254. Scarborough J, Porter JM, Beals RK, et al. Stenosis of the popliteal vein caused by an osteochondroma of the distal femur: a case report. *Diagn Imaging*. 1979;48:167-170.
  255. Gerkin TM, Beebe HG, Williams DM, et al. Popliteal vein entrapment presenting as deep venous thrombosis and chronic venous insufficiency. *J Vasc Surg*. 1993;18:760-766.
  256. Rodriguez HE, Pearce WH. The management of venous aneurysms. In: Gloviczki P, Dalsing MC, Eklof B, Monete GZ, Wokefield TW, eds. *Handbook of Venous Disorders*. London: Edward Arnold; 2009:604-616.
  257. Ruggeri M, Tosetto A, Castaman G, et al. Congenital absence of the inferior vena cava: a rare risk factor for idiopathic deep-vein thrombosis. *Lancet*. 2001;357:441.
  258. Chee YL, Culligan DJ, Watson HG. Inferior vena cava malformation as a risk factor for deep venous thrombosis in the young. *Br J Haematol*. 2001;114:878-880.
  259. Obernosterer A, Aschauer M, Schnedl W, et al. Anomalies of the inferior vena cava in patients with iliac venous thrombosis. *Ann Intern Med*. 2002;136:37-41.
  260. Gayer G, Luboshitz J, Hertz M, et al. Congenital anomalies of the inferior vena cava revealed on CT in patients with deep vein thrombosis. *AJR Am J Roentgenol*. 2003;180:729-732.
  261. Lensing AW, Prandoni P, Brandjes D, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. *N Engl J Med*. 1989;320:342-345.
  262. Nicolaiades AN, Kakkar VV, Renney JTC, et al. Myocardial infarction and deep venous thrombosis. *BMJ*. 1971;432-434.
  263. Kotilainen M, Ristola P, Ikkala E, et al. Leg vein thrombosis diagnosed by <sup>125</sup>I-fibrinogen test after acute myocardial infarction. *Ann Clin Res*. 1973;5:365-368.
  264. Simmons AV, Sheppard MA, Cox AF. Deep venous thrombosis after myocardial infarction: predisposing factors. *Br Heart J*. 1973;35:623-625.

265. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among medical intensive care. *JAMA*. 1995;274:335-337.
266. Stewart GJ. Neutrophils and deep venous thrombosis. *Haemostasis*. 1993;23(Suppl 1):127-140.
267. Stamatakis JD, Kakkar VV, Sagar S, et al. Femoral vein thrombosis and total hip replacement. *BMJ*. 1977;2:223-225.
268. Sevitt S, Gallagher N. Venous thrombosis and pulmonary embolism. A clinico-pathological study in injured and burned patients. *Br J Surg*. 1961;48:475-489.
269. Aronson DL, Thomas DP. Experimental studies on venous thrombosis: effect of coagulants, procoagulants and vessel contusion. *Thromb Haemost*. 1985;54:866-870.
270. Thomas DP, Merton RE, Wood RD, et al. The relationship between vessel wall injury and venous thrombosis: an experimental study. *Br J Haematol*. 1985;59:449-457.
271. Becker BF, Heindl B, Kupatt C, et al. Endothelial function and hemostasis. *Z Kardiol*. 2000;89:160-167.
272. Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. *Arterioscler Thromb Vasc Biol*. 2008;28:387-391.
273. Esmon CT. Inflammation and thrombosis. *J Thromb Haemost*. 2003;1:1343-1348.
274. Myers D Jr, Farris D, Hawley A, et al. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. *J Surg Res*. 2002;108:212-221.
275. Myers DD, Hawley AE, Farris DM, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. *J Vasc Surg*. 2003;38:1075-1089.
276. Myers DD, Wakefield TW. Inflammation-dependent thrombosis. *Front Biosci*. 2005;10:2750-2757.
277. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. *J Thromb Haemost*. 2005;3:1590-1596.
278. Hrachovinova I, Cambien B, Hafezi-Moghadam A, et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. *Nat Med*. 2003;9:1020-1025.
279. Andre P, Hartwell D, Hrachovinova I, et al. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. *Proc Natl Acad Sci U S A*. 2000;97:13835-13840.
280. Jy W, Horstman LL, Wang F, et al. Platelet factor 3 in plasma fractions: its relation to microparticle size and thromboses. *Thromb Res*. 1995;80:471-482.
281. Biro E, Sturk-Maquelin KN, Vogel GM, et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. *J Thromb Haemost*. 2003;1:2561-2568.
282. Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. *Blood*. 2005;105:192-198.
283. Rectenwald JE, Myers DD Jr, Hawley AE, et al. D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. *Thromb Haemost*. 2005;94:1312-1317.
284. Booth NA, Simpson AJ, Croll A, et al. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. *Br J Haematol*. 1988;70:327-333.
285. Podor TJ, Singh D, Chindemi P, et al. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. *J Biol Chem*. 2002;277:7529-7539.
286. Adelman B, Michelson AD, Loscalzo J, et al. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. *Blood*. 1985;65:32-40.
287. Dano K, Andreassen PA, Grondahl-Hansen J, et al. Plasminogen activators, tissue degradation, and cancer. *Adv Cancer Res*. 1985;44:139-266.
288. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. *J Clin Invest*. 1991;88:1067-1072.
289. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. *N Engl J Med*. 2000;342:1792-1801.
290. Schulman S, Wiman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism.

Duration of Anticoagulation (DURAC) Trial Study Group. *Thromb Haemost.* 1996;75:607-611.

291. Crowther MA, Roberts J, Roberts R, et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. *Thromb Haemost.* 2001;85:390-394.
292. Wakefield TW, Strieter RM, Wilke CA, et al. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. *Arterioscler Thromb Vasc Biol.* 1995;15:258-268.
293. Varma MR, Varga AJ, Knipp BS, et al. Neutropenia impairs venous thrombosis resolution in the rat. *J Vasc Surg.* 2003;38:1090-1098.
294. Hogaboam CM, Steinhauser ML, Chensue SW, et al. Novel roles for chemokines and fibroblasts in interstitial fibrosis. *Kidney Int.* 1998;54:2152-2159.
295. Humphries J, McGuinness CL, Smith A, et al. Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi. *J Vasc Surg.* 1999;30:894-899.
296. Henke PK, Pearce CG, Moaveni DM, et al. Targeted deletion of CCR2 impairs deep vein thrombosis resolution in a mouse model. *J Immunol.* 2006;177:3388-3397.
297. Henke PK, Varma MR, Moaveni DK, et al. Fibrotic injury after experimental deep vein thrombosis is determined by the mechanism of thrombogenesis. *Thromb Haemost.* 2007;98:1045-1055.
298. Deatrick KB, Eliason JL, Lynch EM, et al. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model. *J Vasc Surg.* 2005;42:140-148.
299. Myers DD Jr, Henke PK, Bedard PW, et al. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. *J Vasc Surg.* 2006;44:625-632.
300. Nicolaides AN, Kakkar VV, Field ES, et al. The origin of deep vein thrombosis: a venographic study. *Br J Radiol.* 1971;44:653-663.
301. Sevitt S. Organization of valve pocket thrombi and the anomalies of double thrombi and valve cusp involvement. *Br J Surg.* 1974;61:641-649.
302. Hamer JD, Malone PC, Silver IA. The Po<sub>2</sub> in venous valve pockets: its possible bearing on thrombogenesis. *Br J Surg.* 1981;68:166-170.
303. Shreeniwas R, Koga S, Karakurum M, et al. Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. *J Clin Invest.* 1992;90:2333-2339.
304. Thomas DP, Merton RE, Hockley DJ. The effect of stasis on the venous endothelium: an ultrastructural study. *Br J Haematol.* 1983;55:113-122.
305. Thomas D. Venous thrombogenesis. *Br Med Bull.* 1994;50:803-812.
306. Breddin HK. Thrombosis and Virchow's triad: what is established? *Semin Thromb Hemost.* 1989;15:237-239.
307. Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis-inducing activity in human serum. *J Appl Physiol.* 1959;14:943-946.
308. Amiral J, Fareed J. Thromboembolic diseases: biochemical mechanisms and new possibilities of biological diagnosis. *Semin Thromb Hemost.* 1996;22(Suppl 1):41-48.
309. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. *Blood.* 1987;70:343-350.
310. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. *N Engl J Med.* 2006;355:1780-1789.
311. Wakefield TW, Greenfield LJ, Rolfe MW, et al. Inflammatory and procoagulant mediator interactions in an experimental baboon model of venous thrombosis. *Thromb Haemost.* 1993;69:164-172.
312. Owen J, Kvam D, Nossel HL, et al. Thrombin and plasmin activity and platelet activation in the development of venous thrombosis. *Blood.* 1983;61:476-482.



313. Ridker PM, Glynn RJ, Miletich JP, et al. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. *Ann Intern Med.* 1997;126:528-531.
314. Karino T, Motomiya M. Flow through a venous valve and its implication for thrombus formation. *Thromb Res.* 1984;36:245-257.
315. Doouss TW. The clinical significance of venous thrombosis of the calf. *Br J Surg.* 1976;63:377-378.
316. Huisman MV, Buller HR, ten Cate JW. Utility of impedance plethysmography in the diagnosis of recurrent deep-vein thrombosis. *Arch Intern Med.* 1988;148:681-683.
317. Killewich LA, Bedford GR, Beach KW, et al. Spontaneous lysis of deep venous thrombi: rate and outcome. *J Vasc Surg.* 1989;9:89-97.
318. van Ramshorst B, van Bemmelen PS, Hoeneveld H, et al. Thrombus regression in deep venous thrombosis. Quantification of spontaneous thrombolysis with duplex scanning. *Circulation.* 1992;86:414-419.
319. Killewich LA, Macko RF, Cox K, et al. Regression of proximal deep venous thrombosis is associated with fibrinolytic enhancement. *J Vasc Surg.* 1997;26:861-868.
320. Prandoni P, Cogo A, Bernardi E, et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. *Circulation.* 1993;88:1730-1735.
321. Markel A, Manzo RA, Bergelin RO, et al. Valvular reflux after deep vein thrombosis: incidence and time of occurrence. *J Vasc Surg.* 1992;15:377-382; discussion 383-384.
322. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. *N Engl J Med.* 1986;315:1109-1114.
323. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. *N Engl J Med.* 1979;301:855-858.
324. Philbrick JT, Becker DM. Calf deep venous thrombosis. A wolf in sheep's clothing? *Arch Intern Med.* 1988;148:2131-2138.
325. Krupski WC, Bass A, Dilley RB, et al. Propagation of deep venous thrombosis identified by duplex ultrasonography. *J Vasc Surg.* 1990;12:467-474; discussion 474-475.
326. Meissner MH, Caps MT, Bergelin RO, et al. Propagation, rethrombosis and new thrombus formation after acute deep venous thrombosis. *J Vasc Surg.* 1995;22:558-567.
327. Buller HR, Sohne M, Middeldrop S. Treatment of venous thromboembolism. *J Thromb Haemost.* 2005;3:1554-1560.
328. Girolami A, Prandoni P, Simioni P, et al. The pathogenesis of venous thromboembolism. *Haematologica.* 1995;80(2 Suppl):25-35.
329. Raskob G. Calf-vein thrombosis. In: Hull RD, Raskob GE, Pineo GF, eds. *Venous Thromboembolism: An Evidence-based Atlas.* Armonk, NY: Futura; 1996:307.
330. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. *Lancet.* 1960;1:1309-1312.
331. Campbell CB, Chandler JG, Tegtmeyer CJ, et al. Axillary, subclavian, and brachiocephalic obstruction. *Surgery.* 1977;82:816-826.
332. Donayre CE, White GH, Mehringer SM, et al. Pathogenesis determines late morbidity of axillosubclavian vein thrombosis. *Am J Surg.* 1986;152:179-184.
333. Hingorani A, Ascher E, Hanson J, et al. Upper extremity versus lower extremity deep venous thrombosis. *Am J Surg.* 1997;174:214-217.
334. Huisman MV, Buller HR, ten Cate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. *Chest.* 1989;95:498-502.
335. Monreal M, Rey-Joly Barroso C, Ruiz Manzano J, et al. Asymptomatic pulmonary embolism in patients with deep vein thrombosis: is it useful to take a lung scan to rule out this condition? *J Cardiovasc Surg.* 1989;30:104-107.

336. Gosselin MV, Rubin GD, Leung AN, et al. Unsuspected pulmonary embolism: prospective detection on routine helical CT scans. *Radiology*. 1998;208:209-215.
337. Murphy JM. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. *AJR J Roentgenol*. 2007;189:162-170.
338. Dalen JE, Alpert JS. Natural history of pulmonary embolism. *Prog Cardiovasc Dis*. 1975;17:259-270.
339. Piovela F, D'Armini AM, Barone M, et al. Chronic thromboembolic pulmonary hypertension. *Semin Thromb Hemost*. 2006;32:848-855.
340. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med*. 2004;350:2257-2264.
341. McNeil K, Dunning J. Chronic thrombotic pulmonary hypertension (CTEPH). *Heart*. 2007;93:1152-1158.
342. Auger WR, Kerr KM, Kim NH, et al. Chronic thromboembolic pulmonary hypertension. *Cardiol Clin*. 2004;22:453-466.
343. Lindner DJ, Edwards JM, Phinney ES, et al. Long-term hemodynamic and clinical sequelae of lower extremity deep vein thrombosis. *J Vasc Surg*. 1986;4:436-442.
344. Monreal M, Martorell A, Callejas J, et al. Venographic assessment of deep vein thrombosis and risk of developing post-thrombotic syndrome: a prospective trial. *J Intern Med*. 1993;233:233-238.
345. Prandoni P, Lensing A, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. *Ann Intern Med*. 1996;125:1-7.
346. Prandoni P, Villalta S, Polistena P, et al. Symptomatic deep-vein thrombosis and the post-thrombotic syndrome. *Haematologica*. 1995;80(2 Suppl):42-48.
347. Strandness DE, Langlois Y, Cramer M, et al. Long-term sequelae of acute venous thrombosis. *JAMA*. 1983;250:1289-1292.
348. Meissner MH, Wakefield TW, Ascher E, et al. Acute venous disease: venous thrombosis and venous trauma. *J Vasc Surg*. 2007;46S:25S-53S.
349. Johnson BF, Manzo RA, Bergelin RO, et al. Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one- to six-year follow-up. *J Vasc Surg*. 1995;21:307-312.
350. Glas-Greenwalt P, Dalton BC, Astrup T. Localization of tissue plasminogen activator in relation to morphological changes in human saphenous veins used as coronary artery bypass autografts. *Ann Surg*. 1975;181:431-441.
351. Sevitt S. The mechanisms of canalisation in deep vein thrombosis. *J Pathol*. 1973;110:153-165.
352. Budd TW, Meenaghan MA, Wirth J, et al. Histopathology of veins and venous valves of patients with venous insufficiency syndrome: ultrastructure. *J Med*. 1990;21:181-199.
353. Browse NL, Clemenson G, Thomas ML. Is the postphlebotic leg always postphlebotic? Relation between phlebographic appearances of deep-vein thrombosis and late sequelae. *BMJ*. 1980;281:1167-1170.
354. Heldal M, Seem E, Sandset PM, et al. Deep vein thrombosis: a 7-year follow-up study. *J Intern Med*. 1993;234:71-75.
355. Meissner MH, Caps MT, Zierler BK, et al. Determinants of chronic venous disease after acute deep venous thrombosis. *J Vasc Surg*. 1998;28:826-833.
356. Ageno W, Piantanida E, Dentali F, et al. Body mass index is associated with the development of post-thrombotic syndrome. *Thromb Haemost*. 2003;89:305-309.
357. Meissner MH, Manzo RA, Bergelin RO, et al. Deep venous insufficiency: the relationship between lysis and subsequent reflux. *J Vasc Surg*. 1993;18:596-605, discussion 606-608.
358. Mohr DN, Silverstein MD, Heit JA, et al. The venous stasis syndrome after deep venous thromboembolism or pulmonary embolism: a population-based study. *Mayo Clin Proc*. 2000;75:1249-1256.
359. Piccioli A, Prandoni P, Goldhaber SZ. Epidemiologic characteristics, management, and outcome of deep venous thrombosis in a tertiary-care hospital: the Brigham and Women's Hospital DVT Registry. *Am Heart J*. 1996;132:1010-1014.

360. Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. *Lancet* 2003;362:523-526.
361. Tilney NL, Griffiths HJG, Edwards EA. Natural history of major venous thrombosis of the upper extremity. *Arch Surg.* 1970;101:792-796.
362. Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. *Lancet.* 1985;2:515-518.
363. Lohr JM, Kerr TM, Lutter KS, et al. Lower extremity calf thrombosis: to treat or not to treat? *J Vasc Surg.* 1991;14:618-623.
364. Kearon C. Natural history of venous thromboembolism. *Circulation.* 2003;107(23 suppl):I22-I30.
365. Menzoian JO, Sequeira JC, Doyle JE, et al. Therapeutic and clinical course of deep vein thrombosis. *Am J Surg.* 1983;146:581-585.
366. Passman MA, Montea GL, Taylor LM Jr, et al. Pulmonary embolism is associated with the combination of isolated calf vein thrombosis and respiratory symptoms. *J Vasc Surg.* 1997;25:39-45.
367. Kistner RL, Ball JJ, Nordyke RA, et al. Incidence of pulmonary embolism in the course of thrombophlebitis of the lower extremity. *Am J Surg.* 1972;124:160-176.
368. Monroo-Cabral R, Kistner RL, Nordyke RA. Importance of calf vein thrombophlebitis. *Surgery.* 1976;80:735-742.
369. Raskob G. Calf-vein thrombosis. In: Sull RD, Raskob GE, Pineo GF, eds. *Venous Thromboembolism: An Evidence-Based Atlas.* Armonk, NY: Futura; 1996:307.
370. Prandoni P, Villalta S, Polistena P, et al. Symptomatic deep-vein thrombosis and the post-thrombotic syndrome. *Haematologica.* 1995;80(2 Suppl):42-48.
371. McLafferty RB, Moneta GL, Passman MA, et al. Late clinical and hemodynamic sequelae of isolated calf vein thrombosis. *J Vasc Surg.* 1988;27:50-56.
372. Gillet JL, Perin MR, Alalet FA. Short-term and mid-term outcome of isolated symptomatic muscular calf vein thrombosis. *J Vasc Surg.* 2007;46:513-519.

## 第 49 章

1. Kearon C, Julian JA, Newman TE, et al. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. *Ann Intern Med.* 1998;128:663-677.
2. Strothman G, Blebea J, Fowl RJ, et al. Contralateral duplex scanning for deep venous thrombosis is unnecessary in patients with symptoms. *J Vasc Surg.* 1995;22:543-547.
3. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. *Arch Intern Med.* 1991;151:933-938.
4. Barnes RW, Wu KK, Hoak JC. Fallibility of the clinical diagnosis of venous thrombosis. *JAMA.* 1975;234:605-607.
5. Cranley JJ, Canos AJ, Sull WJ. The diagnosis of deep venous thrombosis. Fallibility of clinical symptoms and signs. *Arch Surg.* 1976;111:34-36.
6. Haeger K. Problems of acute deep venous thrombosis. I. The interpretation of signs and symptoms. *Angiology.* 1969;20:219-223.
7. Kakkar VV, Howe CT, Flanc C, et al. Natural history of postoperative deep-vein thrombosis. *Lancet.* 1969;2:230-232.
8. McLachlin J, Richards T, Paterson JC. An evaluation of clinical signs in the diagnosis of venous thrombosis. *Arch Surg.* 1962;85:738-744.
9. Sevitt S, Gallagher N. Venous thrombosis and pulmonary embolism. A clinico-pathological study in injured and burned patients. *Br J Surg.* 1961;48:475-489.
10. Hull R, Hirsh J, Sackett DL, et al. Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients

with symptomatic deep-vein thrombosis. *N Engl J Med*. 1981;304:1561-1567.

11. Cooperman M, Martin EW Jr, Satiani B, et al. Detection of deep venous thrombosis by impedance plethysmography. *Am J Surg*. 1979;137:252-254.
12. Peters SH, Jonker JJ, de Boer AC, et al. Home-diagnosis of deep venous thrombosis with impedance plethysmography. *Thromb Haemost*. 1982;48:297-300.
13. Johnson WC. Evaluation of newer techniques for the diagnosis of venous thrombosis. *J Surg Res*. 1974;16:473-481.
14. Criado E, Burnham CB. Predictive value of clinical criteria for the diagnosis of deep vein thrombosis. *Surgery*. 1997;122:578-583.
15. Nypaver TJ, Shepard AD, Kiell CS, et al. Outpatient duplex scanning for deep vein thrombosis: parameters predictive of a negative study result. *J Vasc Surg*. 1993;18:821-826.
16. Markel A, Manzo RA, Bergelin RO, et al. Acute deep vein thrombosis: diagnosis, localization, and risk factors. *J Vasc Med Biol*. 1991;3:432-439.
17. Donner-Banzhoff N. Limited value of patient history and physical examination in diagnosing deep vein thrombosis in primary care. *Fam Pract*. 2005;22:579.
18. Oudega R, Hoes AW, Moons KG. The Wells rule does not adequately rule out deep venous thrombosis in primary care patients. *Ann Intern Med*. 2005;143:100-107.
19. Goldhaber SZ, Buring JE, Hennekens CH. Cancer and venous thromboembolism. *Arch Intern Med*. 1987;147:216.
20. Barker NW, Nygard KK, Waters W, et al. A statistical study of post-operative venous thrombosis and pulmonary embolism: predisposing factors. *Proc Mayo Clin*. 1941;16:17-21.
21. Kakkar VV, Howe CT, Nicolaides AN, et al. Deep vein thrombosis of the leg. Is there a "high risk" group? *Am J Surg*. 1970;120:527-530.
22. Glover JL, Bendick PJ. Appropriate indications for venous duplex ultrasonographic examinations. *Surgery*. 1996;120:725-730; discussion 730-731.
23. Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. *Lancet*. 1997;350:1795-1798.
24. Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. *N Engl J Med*. 2003;349:1227-1235.
25. Smithline HA, Mader TJ, Ali FM, et al. Determining pretest probability of DVT: clinical intuition vs. validated scoring systems. *Am J Emerg Med*. 2003;21:161-162.
26. Miron MJ, Perrier A, Bounameaux H. Clinical assessment of suspected deep vein thrombosis: comparison between a score and empirical assessment. *J Intern Med*. 2000;247:249-254.
27. Wells PS, Owen C, Doucette S, et al. Does this patient have deep vein thrombosis? *JAMA*. 2006;295:199-207.
28. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. *Arch Surg*. 1972;104:134-144.
29. Bettmann MA, Robbins A, Braun SD, et al. Contrast venography of the leg: diagnostic efficacy, tolerance, and complication rates with ionic and nonionic contrast media. *Radiology*. 1987;165:113-116.
30. Lensing AW, Büller HR, Prandoni P, et al. Contrast venography, the gold standard for the diagnosis of deep-vein thrombosis: improvement in observer agreement. *Thromb Haemost*. 1992;67:8-12.
31. Terao M, Ozaki T, Sato T. Diagnosis of deep vein thrombosis after operation for fracture of the proximal femur: comparative study of ultrasonography and venography. *J Orthop Sci*. 2006;11:146-153.
32. Ozbudak O, Eroglu I, Oğuş C, et al. Doppler ultrasonography versus venography in the detection of deep vein thrombosis in patients with pulmonary embolism. *J Thromb Thrombolysis*. 2006;21:159-162.
33. de Valois JC, van Schaik CC, Verzijlbergen F, et al. Contrast venography: from gold standard to "golden backup" in clinically suspected deep vein thrombosis. *Eur J Radiol*. 1990;11:131-137.
34. Lensing AW, Prandoni P, Brandjes D, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. *N*

*Engl J Med.* 1989;320:342-345.

35. Cogo A, Lensing AW, Prandoni P, et al. Comparison of real-time B-mode ultrasonography and Doppler ultrasound with contrast venography in the diagnosis of venous thrombosis in symptomatic outpatients. *Thromb Haemost.* 1993;70:404-407.
36. Killewich LA, Bedford GR, Beach KW, et al. Diagnosis of deep venous thrombosis. A prospective study comparing duplex scanning to contrast venography. *Circulation.* 1989;79:810-814.
37. Goodacre S, Sampson F, Thomas S, et al. Systematic review and meta-analysis of the diagnostic accuracy of ultrasonography for deep vein thrombosis. *BMC Med Imaging.* 2005;5:6.
38. Heijboer H, Cogo A, Büller HR, et al. Detection of deep vein thrombosis with impedance plethysmography and real-time compression ultrasonography in hospitalized patients. *Arch Intern Med.* 1992;152:1901-1903.
39. Ascher E, Depippo PS, Hingorani A, et al. Does repeat duplex ultrasound for lower extremity deep vein thrombosis influence patient management? *Vasc Endovascular Surg.* 2004;38:525-531.
40. Birdwell BG, Raskob GE, Whitsett TL, et al. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. *Ann Intern Med.* 1998;128:1-7.
41. Cogo A, Lensing AW, Koopman MM, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. *BMJ.* 1998;316:17-20.
42. Kraaijenhagen RA, Piovella F, Bernardi E, et al. Simplification of the diagnostic management of suspected deep vein thrombosis. *Arch Intern Med.* 2002;162:907-911.
43. Andrews EJ Jr, Fleischer AC. Sonography for deep venous thrombosis: current and future applications. *Ultrasound Q.* 2005;21:213-225.
44. Tick LW, Ton E, van Voorthuizen T, et al. Practical diagnostic management of patients with clinically suspected deep vein thrombosis by clinical probability test, compression ultrasonography, and D-dimer test. *Am J Med.* 2002;113:630-635.
45. Bernardi E, Prandoni P, Lensing AW, et al. D-dimer testing as an adjunct to ultrasonography in patients with clinically suspected deep vein thrombosis: prospective cohort study. The Multicentre Italian D-dimer Ultrasound Study Investigators Group. *BMJ.* 1998;317:1037-1040.
46. Lewis BD, James EM, Welch TJ, et al. Diagnosis of acute deep venous thrombosis of the lower extremities: prospective evaluation of color Doppler flow imaging versus venography. *Radiology.* 1994;192:651-655.
47. Vaccaro JP, Cronan JJ, Dorfman GS. Outcome analysis of patients with normal compression US examinations. *Radiology.* 1990;175:645-649.
48. Mattos MA, Melendres G, Sumner DS, et al. Prevalence and distribution of calf vein thrombosis in patients with symptomatic deep venous thrombosis: a color-flow duplex study. *J Vasc Surg.* 1996;24:738-744.
49. Messina LM, Sarpa MS, Smith MA, et al. Clinical significance of routine imaging of iliac and calf veins by color flow duplex scanning in patients suspected of having acute lower extremity deep venous thrombosis. *Surgery.* 1993;114:921-927.
50. Wolf B, Nichols DM, Duncan JL. Safety of a single duplex scan to exclude deep venous thrombosis. *Br J Surg.* 2000;87:1525-1528.
51. Cogo A, Lensing AW, Prandoni P, et al. Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound. *Arch Intern Med.* 1993;153:2777-2780.
52. Philbrick JT, Becker DM. Calf deep venous thrombosis. A wolf in sheep's clothing? *Arch Intern Med.* 1988;148:2131-2138.
53. Lohr JM, James KV, Deshmukh RM, et al. Karmody Award. Calf vein thrombi are not a benign finding. *Am J Surg.* 1995;170:86-90.
54. Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. *Lancet.* 1985;2:515-518.

55. Hull RD, Hirsh J, Carter CJ, et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis. A randomized trial. *Ann Intern Med.* 1985;102:21-28.
56. Huisman MV, Büller HR, ten Cate JW, et al. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. *N Engl J Med.* 1986;314:823-828.
57. Fraser JD, Anderson DR. Deep venous thrombosis: recent advances and optimal investigation with US. *Radiology.* 1999;211:9-24.
58. Sluzewski M, Koopman MM, Schuur KH, et al. Influence of negative ultrasound findings on the management of in- and outpatients with suspected deep-vein thrombosis. *Eur J Radiol.* 1991;13:174-177.
59. Heijboer H, Büller HR, Lensing AW, et al. A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. *N Engl J Med.* 1993;329:1365-1369.
60. Intersocietal Commission for the Accreditation of Vascular Laboratories. Calf vein surveillance is no longer an option. *IAC Newsl.* 2008;8-9.
61. Moreno-Cabral R, Kistner RL, Nordyke RA. Importance of calf vein thrombophlebitis. *Surgery.* 1976;80:735-742.
62. Meissner MH, Caps MT, Bergelin RO, et al. Early outcome after isolated calf vein thrombosis. *J Vasc Surg.* 1997;26:749-756.
63. Elias A, Le Corff G, Bouvier JL, et al. Value of real time B mode ultrasound imaging in the diagnosis of deep vein thrombosis of the lower limbs. *Int Angiol.* 1987;6:175-182.
64. Badgett DK, Comerota MC, Khan MN, et al. Duplex venous imaging: role for a comprehensive lower extremity examination. *Ann Vasc Surg.* 2000;14:73-76.
65. Noren A, Lindmarker P, Rosfors S. A retrospective follow-up study of patients with suspected deep vein thrombosis and negative results of color duplex ultrasound. *Phlebography.* 1997;12:56-59.
66. Schellong SM, Schwarz T, Halbritter K, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. *Thromb Haemost.* 2003;89:228-234.
67. Elias A, Mallard L, Elias M, et al. A single complete ultrasound investigation of the venous network for the diagnostic management of patients with a clinically suspected first episode of deep venous thrombosis of the lower limbs. *Thromb Haemost.* 2003;89:221-227.
68. Noren A, Ottosson E, Rosfors S. Is it safe to withhold anticoagulation based on a single negative color duplex examination in patients with suspected deep venous thrombosis? A prospective 3-month follow-up study. *Angiology.* 2002;53:521-527.
69. Cornuz J, Pearson SD, Polak JF. Deep venous thrombosis: complete lower extremity venous US evaluation in patients without known risk factors—outcome study. *Radiology.* 1999;211:637-641.
70. Sheiman RG, McArdle CR. Bilateral lower extremity US in the patient with unilateral symptoms of deep venous thrombosis: assessment of need. *Radiology.* 1995;194:171-173.
71. Naidich JB, Torre JR, Pellerito JS, et al. Suspected deep venous thrombosis: is US of both legs necessary? *Radiology.* 1996;200:429-431.
72. Kim HM, Kuntz KM, Cronan JJ. Optimal management strategy for use of compression US for deep venous thrombosis in symptomatic patients: a cost-effectiveness analysis. *Acad Radiol.* 2000;7:67-76.
73. Hillner BE, Philbrick JT, Becker DM. Optimal management of suspected lower-extremity deep vein thrombosis. An evaluation with cost assessment of 24 management strategies. *Arch Intern Med.* 1992;152:165-175.
74. Butty S, Hagspiel KD, Leung DA, et al. Body MR venography. *Radiol Clin North Am.* 2002;40:899-919.
75. Carpenter JP, Holland GA, Baum RA, et al. Magnetic resonance venography for the detection of deep venous thrombosis: comparison with contrast venography and duplex Doppler ultrasonography. *J Vasc Surg.* 1993;18:734-741.
76. Laissy JP, Cinqualbre A, Loshkajian A, et al. Assessment of deep venous thrombosis in the lower limbs and pelvis: MR venography versus duplex Doppler sonography. *AJR Am J Roentgenol.* 1996;167:971-975.

77. Fraser DG, Moody AR, Morgan PS, et al. Diagnosis of lower-limb deep venous thrombosis: a prospective blinded study of magnetic resonance direct thrombus imaging. *Ann Intern Med.* 2002;136:89-98.
78. Fraser DG, Moody AR, Davidson IR, et al. Deep venous thrombosis: diagnosis by using venous enhanced subtracted peak arterial MR venography versus conventional venography. *Radiology.* 2003;226:812-820.
79. Cantwell CP, Craddock A, Bruzzi J, et al. MR venography with true fast imaging with steady-state precession for suspected lower-limb deep vein thrombosis. *J Vasc Interv Radiol.* 2006;17:1763-1769.
80. Larsson EM, Sundin P, Olsson CG, et al. MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage. *AJR Am J Roentgenol.* 2003;180:227-232.
81. Evans AJ, Sostman HD, Knelson MH, et al. 1992 ARRS Executive Council Award. Detection of deep venous thrombosis: prospective comparison of MR imaging with contrast venography. *AJR Am J Roentgenol.* 1993;161:131-139.
82. Heinrich MC, Kuhlmann MK, Kohlbacher S, et al. Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study. *Radiology.* 2007;242:425-434.
83. Centers for Disease Control and Prevention. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents—St. Louis, Missouri, 2002-2006. *MMWR Morb Mortal Wkly Rep.* 2007;56:137-141.
84. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. *AJR Am J Roentgenol.* 2007;188:586-592.
85. Kuo PH, Kanal E, Abu-Alfa AK, et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. *Radiology.* 2007;242:647-649.
86. Froehlich JB, Prince MR, Greenfield LJ, et al. "Bull's-eye" sign on gadolinium-enhanced magnetic resonance venography determines thrombus presence and age: a preliminary study. *J Vasc Surg.* 1997;26:809-816.
87. Spritzer CE, Arata MA, Freed KS. Isolated pelvic deep venous thrombosis: relative frequency as detected with MR imaging. *Radiology.* 2001;219:521-525.
88. Stern JB, Abehsera M, Grenet D, et al. Detection of pelvic vein thrombosis by magnetic resonance angiography in patients with acute pulmonary embolism and normal lower limb compression ultrasonography. *Chest.* 2002;122:115-121.
89. Loud PA, Grossman ZD, Klippenstein DL, et al. Combined CT venography and pulmonary angiography: a new diagnostic technique for suspected thromboembolic disease. *AJR Am J Roentgenol.* 1998;170:951-954.
90. Walsh G, Redmond S. Does addition of CT pelvic venography to CT pulmonary angiography protocols contribute to the diagnosis of thromboembolic disease? *Clin Radiol.* 2002;57:462-465.
91. Coche EE, Hamoir XL, Hammer FD, et al. Using dual-detector helical CT angiography to detect deep venous thrombosis in patients with suspicion of pulmonary embolism: diagnostic value and additional findings. *AJR Am J Roentgenol.* 2001;176:1035-1039.
92. Loud PA, Katz DS, Bruce DA, et al. Deep venous thrombosis with suspected pulmonary embolism: detection with combined CT venography and pulmonary angiography. *Radiology.* 2001;219:498-502.
93. Begemann PG, Bonacker M, Kemper J, et al. Evaluation of the deep venous system in patients with suspected pulmonary embolism with multi-detector CT: a prospective study in comparison to Doppler sonography. *J Comput Assist Tomogr.* 2003;27:399-409.
94. Peterson DA, Kazerooni EA, Wakefield TW, et al. Computed tomographic venography is specific but not sensitive for diagnosis of acute lower-extremity deep venous thrombosis in patients with suspected pulmonary embolus. *J Vasc Surg.* 2001;34:798-804.
95. Stover MD, Morgan SJ, Bosse MJ, et al. Prospective comparison of contrast-enhanced computed tomography versus magnetic resonance venography in the detection of occult deep pelvic vein thrombosis in patients with pelvic and acetabular fractures. *J Orthop Trauma.* 2002;16:613-621.
96. Anderson DR, Lensing AW, Wells PS, et al. Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis. *Ann Intern Med.* 1993;118:25-30.

97. Ginsberg JS, Wells PS, Hirsh J, et al. Reevaluation of the sensitivity of impedance plethysmography for the detection of proximal deep vein thrombosis. *Arch Intern Med.* 1994;154:1930-1933.
98. Kearon C, Hirsh J. Factors influencing the reported sensitivity and specificity of impedance plethysmography for proximal deep vein thrombosis. *Thromb Haemost.* 1994;72:652-658.
99. Muto P, Lastoria S, Varrella P, et al. Detecting deep venous thrombosis with technetium-99m-labeled synthetic peptide P280. *J Nucl Med.* 1995;36:1384-1391.
100. Pearson DA, Lister-James J, McBride WJ, et al. Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies. *J Med Chem.* 1996;39:1372-1382.
101. Carretta RF. Scintigraphic imaging of lower-extremity acute venous thrombosis. *Adv Ther.* 1998;15:315-322.
102. Taillefer R, Edell S, Innes G, et al. Acute thromboscintigraphy with (99m)Tc-apcitide: results of the phase 3 multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter Trial Investigators. *J Nucl Med.* 2000;41:1214-1223.
103. Bates SM, Lister-James J, Julian JA, et al. Imaging characteristics of a novel technetium Tc 99m-labeled platelet glycoprotein IIb/IIIa receptor antagonist in patients with acute deep vein thrombosis or a history of deep vein thrombosis. *Arch Intern Med.* 2003;163:452-456.
104. Horellou M-H, Conrad J, Samama MM. *Venous Thromboembolism: An Evidence Based Atlas.* Armonk, NY: Futura; 1996.
105. Kelly J, Hunt BJ. Role of D-dimers in diagnosis of venous thromboembolism. *Lancet.* 2002;359:456-458.
106. Gaffney PJ, Creighton LJ, Callus M, et al. Monoclonal antibodies to crosslinked fibrin degradation products (XL-FDP). II. Evaluation in a variety of clinical conditions. *Br J Haematol.* 1988;68:91-96.
107. Schutgens RE, Esseboom EU, Haas FJ, et al. Usefulness of a semiquantitative D-dimer test for the exclusion of deep venous thrombosis in outpatients. *Am J Med.* 2002;112:617-621.
108. Brotman DJ, Segal JB, Jani JT, et al. Limitations of D-dimer testing in unselected inpatients with suspected venous thromboembolism. *Am J Med.* 2003;114:276-282.
109. Larsen TB, Stoffersen E, Christensen CS, et al. Validity of D-dimer tests in the diagnosis of deep vein thrombosis: a prospective comparative study of three quantitative assays. *J Intern Med.* 2002;252:36-40.
110. Carter CJ, Doyle DL, Dawson N, et al. Investigations into the clinical utility of latex D-dimer in the diagnosis of deep venous thrombosis. *Thromb Haemost.* 1993;69:8-11, 24.
111. de Moerloose P. D-dimer assays for the exclusion of venous thromboembolism: which test for which diagnostic strategy? *Thromb Haemost.* 2000;83:180-181.
112. van der Graaf F, van den Borne H, van der Kolk M, et al. Exclusion of deep venous thrombosis with D-dimer testing—comparison of 13 D-dimer methods in 99 outpatients suspected of deep venous thrombosis using venography as reference standard. *Thromb Haemost.* 2000;83:191-198.
113. Anderson DR, Wells PS, Stiell I, et al. Management of patients with suspected deep vein thrombosis in the emergency department: combining use of a clinical diagnosis model with D-dimer testing. *J Emerg Med.* 2000;19:225-230.
114. Wåhländer K, Tengborn L, Hellström M, et al. Comparison of various D-dimer tests for the diagnosis of deep venous thrombosis. *Blood Coagul Fibrinolysis.* 1999;10:121-126.
115. Philbrick JT, Heim S. The d-dimer test for deep venous thrombosis: gold standards and bias in negative predictive value. *Clin Chem.* 2003;49:570-574.
116. Aschwanden M, Labs KH, Jeanneret C, et al. The value of rapid D-dimer testing combined with structured clinical evaluation for the diagnosis of deep vein thrombosis. *J Vasc Surg.* 1999;30:929-935.
117. Shitrit D, Levi H, Huerta M, et al. Appropriate indications for venous duplex scanning based on D-dimer assay. *Ann Vasc Surg.* 2002;16:304-308.
118. Keeling DM, Mackie IJ, Moody A, et al. for the The Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. The diagnosis of deep vein thrombosis in symptomatic outpatients and the potential for clinical



- assessment and D-dimer assays to reduce the need for diagnostic imaging. *Br J Haematol.* 2004;124:15-25.
119. Yamaki T, Nozaki M, Sakurai H, et al. Prospective evaluation of a screening protocol to exclude deep vein thrombosis on the basis of a combination of quantitative D-dimer testing and pretest clinical probability score. *J Am Coll Surg.* 2005;201:701-709.
  120. Fancher TL, White RH, Kravitz RL. Combined use of rapid D-dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review. *BMJ.* 2004;329:821.
  121. Diamond S, Goldbweber R, Katz S. Use of D-dimer to aid in excluding deep venous thrombosis in ambulatory patients. *Am J Surg.* 2005;189:23-26.
  122. Stevens SM, Gregory Elliott C, Woller SC, et al. The use of a fixed high sensitivity to evaluate five D-dimer assays' ability to rule out deep venous thrombosis: a novel approach. *Br J Haematol.* 2005;131:341-347.
  123. Wells PS, Anderson DR, Bormanis J, et al. Application of a diagnostic clinical model for the management of hospitalized patients with suspected deep-vein thrombosis. *Thromb Haemost.* 1999;81:493-497.
  124. Shields GP, Turnipseed S, Panacek EA, et al. Validation of the Canadian clinical probability model for acute venous thrombosis. *Acad Emerg Med.* 2002;9:561-566.
  125. Dryjski M, O'Brien-Irr MS, Harris LM, et al. Evaluation of a screening protocol to exclude the diagnosis of deep venous thrombosis among emergency department patients. *J Vasc Surg.* 2001;34:1010-1015.
  126. Schutgens RE, Ackermack P, Haas FJ, et al. Combination of a normal D-dimer concentration and a non-high pretest clinical probability score is a safe strategy to exclude deep venous thrombosis. *Circulation.* 2003;107:593-597.
  127. Bucek RA, Koca N, Reiter M, et al. Algorithms for the diagnosis of deep-vein thrombosis in patients with low clinical pretest probability. *Thromb Res.* 2002;105:43-47.
  128. Zierler BK. Screening for acute DVT: optimal utilization of the vascular diagnostic laboratory. *Semin Vasc Surg.* 2001;14:206-214.
  129. Perrier A, Desmarais S, Miron MJ, et al. Non-invasive diagnosis of venous thromboembolism in outpatients. *Lancet.* 1999;353:190-195.
  130. Wells PS, Hirsh J, Anderson DR, et al. A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. *J Intern Med.* 1998;243:15-23.
  131. Wells PS, Hirsh J, Anderson DR, et al. Accuracy of clinical assessment of deep-vein thrombosis. *Lancet.* 1995;345:1326-1330.
  132. Cornuz J, Ghali WA, Hayoz D, et al. Clinical prediction of deep venous thrombosis using two risk assessment methods in combination with rapid quantitative D-dimer testing. *Am J Med.* 2002;112:198-203.
  133. Bucek RA, Reiter M, Quehenberger P, et al. C-reactive protein in the diagnosis of deep vein thrombosis. *Br J Haematol.* 2002;119:385-389.
  134. Hull R, Hirsh J, Sackett DL, et al. Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis. *Circulation.* 1981;64:622-625.
  135. Sohne M, Kruip MJ, Nijkeuter M, et al. Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. *J Thromb Haemost.* 2006;4:1042-1046.
  136. van Belle A, Büller HR, Huisman MV, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. *JAMA.* 2006;295:172-179.
  137. Brown MD, Rowe BH, Reeves MJ, et al. The accuracy of the enzyme-linked immunosorbent assay D-dimer test in the diagnosis of pulmonary embolism: a meta-analysis. *Ann Emerg Med.* 2002;40:133-144.
  138. Baldt MM, Zontsich T, Stümpflen A, et al. Deep venous thrombosis of the lower extremity: efficacy of spiral CT venography compared with conventional venography in diagnosis. *Radiology.* 1996;200:423-428.
  139. Lim KE, Hsu WC, Hsu YY, et al. Deep venous thrombosis: comparison of indirect multidetector CT venography and

- sonography of lower extremities in 26 patients. *Clin Imaging*. 2004;28:439-444.
140. Kohler A, Hoffmann R, Platz A, et al. Diagnostic value of duplex ultrasound and liquid crystal contact thermography in preclinical detection of deep vein thrombosis after proximal femur fractures. *Arch Orthop Trauma Surg*. 1998;117:39-42.
141. Locker T, Goodacre S, Sampson F, et al. Meta-analysis of plethysmography and rheography in the diagnosis of deep vein thrombosis. *Emerg Med J*. 2006;23:630-635.
142. Tan YK, da Silva AF. Digital photoplethysmography in the diagnosis of suspected lower limb DVT: is it useful? *Eur J Vasc Endovasc Surg*. 1999;18:71-79.
143. Scarsbrook AF, Evans AL, Owen AR, et al. Diagnosis of suspected venous thromboembolic disease in pregnancy. *Clin Radiol*. 2006;61:1-12.
144. Lohr J. Bilateral lower extremity duplex scanning revisited. *Dis Mon*. 2005;51:79-85.
145. Mozes G, Gloviczki P. New discoveries in anatomy and new terminology of leg veins: clinical implications. *Vasc Endovascular Surg*. 2004;38:367-374.

## 第 50 章

1. Salinger MH, Feldman TE, Salinger MH, et al. Patent foramen ovale: the missing link between deep venous thrombotic disease and embolic stroke. *Dis Mon*. 2005;51:94-103.
2. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. *Chest*. 2001;119:132S-175S.
3. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. *Arch Intern Med*. 1991;151:933-938.
4. Clagett GP, Anderson FA Jr, Heit J, et al. Prevention of venous thromboembolism. *Chest*. 1995;108:312S-334S.
5. Kniffen WD Jr, Baron JA, Barrett J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. *Arch Intern Med*. 1994;154:861-866.
6. Heit J, Cohen A, Anderson F. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US [abstract 910]. *Blood*. 1995;106.
7. Schulman S, Lindmarker P, Holmstrom M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. *J Thromb Haemost*. 2006;4:734-742.
8. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med*. 2004;350:2257-2264.
9. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. *J Thromb Haemost*. 2005;3:1611-1617.
10. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. *Arch Intern Med*. 2000;160:761-768.
11. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. *Ann Intern Med*. 2003;139:19-25.
12. van Dongen CJ, Vink R, Hutten BA, et al. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. *Arch Intern Med*. 2003;163:1285-1293.
13. Borow M, Goldson H. Postoperative venous thrombosis. Evaluation of five methods of treatment. *Am J Surg*. 1981;141:245-251.
14. Borow M, Goldson HJ. Prevention of postoperative deep venous thrombosis and pulmonary emboli with combined modalities. *Am Surg*. 1983;49:599-605.
15. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. *Arch Intern Med*. 2004;164:17-26.
16. Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. *Arch Intern Med*. 2002;162:1144-1148.

17. Mohr DN, Silverstein MD, Heit JA, et al. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. *Mayo Clin Proc.* 2000;75:1249-1256.
18. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. *Ann Intern Med.* 1996;125:1-7.
19. Porter JM, Moneta GL. Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. *J Vasc Surg.* 1995;21:635-645.
20. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126:338S-400S.
21. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. *Ann Surg.* 2006;243:89-95.
22. Goldhaber SZ, Tapson VF, Committee DFS. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. *Am J Cardiol.* 2004;93:259-262.
23. Diamond GA, Denton TA. Alternative perspectives on the biased foundations of medical technology assessment. *Ann Intern Med.* 1993;118:455-464.
24. Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women: A meta-analysis. *Thromb Haemost.* 2008;99:338-342.
25. Dalen JE. Economy class syndrome: Too much flying or too much sitting? *Arch Intern Med.* 1993;163:2674-2676.
26. Ray JG, Mamdani M, Tsuyuki RT, et al. Use of statins and the subsequent development of deep vein thrombosis. *Arch Intern Med.* 2001;161:1405-1410.
27. Khorana AA, Francis CW, Culakowa E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. *J Thromb Haemost.* 2007;5:632-634.
28. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost.* 2006;4:295-306.
29. Oger E. Incidence of venous thromboembolism: A community-based study in western France. *Thromb Haemost* 2000;657-660.
30. Sugerman HJ, Sugerman EL, Wolfe L, et al. Risks and benefits of gastric bypass in morbidly obese patients with severe venous stasis disease. *Ann Surg.* 2001;234:41-46.
31. Rickles FR. Epidemiology of thrombosis and cancer. *Acta Haematol.* 2001;106:6-12.
32. Donati M. Cancer and thrombosis. *Haemostasis.* 1994;24:128-131.
33. Kroger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. *Ann Oncol.* 2006;17:297-303.
34. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. *Circulation.* 2003;107:19-16.
35. Caprini JA, Arcelus JJ, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. *Semin Hematol.* 2001;38:12-19.
36. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. *Dis Mon.* 2005;51:70-78.
37. Caprini JA, Arcelus JJ, Hasty JH, et al. Clinical assessment of venous thromboembolic risk in surgical patients. *Semin Thromb Hemost.* 1991;17(Suppl 3):304-312.
38. Arcelus JJ, Candocia S, Traverso CI, et al. Venous thromboembolism prophylaxis and risk assessment in medical patients. *Semin Thromb Hemost.* 1991;17(Suppl 3):313-318.
39. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study [summary for patients in *Ann Intern Med.* 2005;143:112; PMID: 16287785]. *Ann Intern Med.* 2005;143:697-706.
40. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. *Arch Intern Med.* 2000;160:809-815.

41. Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. *N Engl J Med*. 2005;352:969-977.
42. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. *J Thromb Haemost*. 2004;2:2156-2161.
43. Deheinzelin D, Braga AL, Martins LC, et al. Incorrect use of thromboprophylaxis for venous thromboembolism in medical and surgical patients: results of a multicentric, observational and cross-sectional study in Brazil. *J Thromb Haemost*. 2006;4:1266-1270.
44. Comerota AJ, Stewart GJ, Alburger PD, et al. Operative venodilation: a previously unsuspected factor in the cause of postoperative deep vein thrombosis. *Surgery*. 1989;106:301-308: discussion 8-9.
45. Summari L, Caprini JA, McMillan R, et al. Relationship between postsurgical fibrinolytic parameters and deep vein thrombosis in surgical patients treated with compression devices. *Am Surg*. 1988;54:156-160.
46. Sigel B, Edelstein AL, Savitch L, et al. Type of compression for reducing venous stasis. A study of lower extremities during inactive recumbency. *Arch Surg*. 1975;110:171-175.
47. Coleridge-Smith PD, Hasty JH, Scurr JH. Venous stasis and vein lumen changes during surgery. *Br J Surg*. 1990;77:1055-1059.
48. Porteous MJ, Nicholson EA, Morris LT, et al. Thigh length versus knee length stockings in the prevention of deep vein thrombosis. *Br J Surg*. 1989;76:296-297.
49. Williams AM, Davies PR, Sweetnam DI, et al. Knee-length versus thigh-length graduated compression stockings in the prevention of deep vein thrombosis. *Br J Surg*. 1996;83:1553.
50. Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. *Cochrane Database Syst Rev*. 2000;3:CD001484.
51. Wells PS, Lensing AW, Hirsh J. Graduated compression stockings in the prevention of postoperative venous thromboembolism. A meta-analysis. *Arch Intern Med*. 1994;154:67-72.
52. Agu O, Hamilton G, Baker D. Graduated compression stockings in the prevention of venous thromboembolism. *Br J Surg*. 1999;86:992-1004.
53. Nicolaides AN, Fernandes e Fernandes J, Pollock AV. Intermittent sequential pneumatic compression of the legs in the prevention of venous stasis and postoperative deep venous thrombosis. *Surgery*. 1980;87:69-76.
54. Kakkos SK, Szendro G, Griffin M, et al. The efficacy of the new SCD response compression system in the prevention of venous stasis. *J Vasc Surg*. 2000;32:932-940.
55. Summari L, Caprini JA, McMillan R, et al. Relationship between postsurgical fibrinolytic parameters and deep vein thrombosis in surgical patients treated with compression devices. *Am Surg*. 1988;54:156-160.
56. Chouhan VD, Comerota AJ, Sun L, et al. Inhibition of tissue factor pathway during intermittent pneumatic compression: a possible mechanism for antithrombotic effect. *Arterioscler Thromb Vasc Biol*. 1999;19:2812-2817.
57. Skillman JJ, Collins RE, Coe NP, et al. Prevention of deep vein thrombosis in neurosurgical patients: a controlled, randomized trial of external pneumatic compression boots. *Surgery*. 1978;83:354-358.
58. Clarke-Pearson DL, Creasman WT, Coleman RE, et al. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial. *Gynecol Oncol*. 1984;18:226-232.
59. Clarke-Pearson DL, Synan IS, Hinshaw WM, et al. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. *Obstet Gynecol*. 1984;63:92-98.
60. Salzman EW, Ploetz J, Bettmann M, et al. Intraoperative external pneumatic calf compression to afford long-term prophylaxis against deep vein thrombosis in urological patients. *Surgery*. 1980;87:239-242.
61. Hull RD, Raskob GE, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. *JAMA*. 1990;263:2313-2317.

62. Roderick P, Ferris G, Wilson K, et al. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. *Health Technol Assess*. 2005;9:iii-iv,ix-x,1-78.
63. Urbankova J, Quiroz R, Kucher N, et al. Intermittent pneumatic compression and deep vein thrombosis prevention. A meta-analysis in postoperative patients. *Thromb Haemost*. 2005;94:1181-1185.
64. Freedman KB, Brookenthal KR, Fitzgerald RH Jr, et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. *J Bone Joint Surg Am*. 2000;82:929-938.
65. Westrich GH, Haas SB, Mosca P, et al. Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty. *J Bone Joint Surg Br*. 2000;82:795-800.
66. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. *Lancet*. 2008;371:387-394.
67. Haddad FS, Kerry RM, McEwen JA, et al. Unanticipated variations between expected and delivered pneumatic compression therapy after elective hip surgery: a possible source of variation in reported patient outcomes. *J Arthroplasty*. 2001;16:37-46.
68. Brady D, Raingruber B, Peterson J, et al. The use of knee-length versus thigh-length compression stockings and sequential compression devices. *Crit Care Nurs Q*. 2007;30:255-262.
69. Warwick D, Harrison J, Glew D, et al. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. *J Bone Joint Surg Am*. 1998;80:1158-1166.
70. Norgren L, Toksvig-Larsen S, Magyar G, et al. Prevention of deep vein thrombosis in knee arthroplasty. Preliminary results from a randomized controlled study of low molecular weight heparin vs foot pump compression. *Int Angiol*. 1998;17:93-96.
71. Blanchard J, Meuwly JY, Leyvraz PF, et al. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. *J Bone Joint Surg Br*. 1999;81:654-659.
72. Kakkar VV, Corrigan TP, Fossard DP, et al. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial. *Lancet*. 1977;1:567-569.
73. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. *N Engl J Med*. 1988;318:1162-1173.
74. Hill J, Treasure T. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidance. *BMJ*. 2007;334:1053-1054.
75. Warkentin TE, Warkentin TE. Heparin-induced thrombocytopenia. *Dis Mon*. 2005;51:141-149.
76. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation*. 2004;110:874-879.
77. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. *Lancet*. 1992;340:152-156.
78. Leizorovicz A, Mismetti P, Leizorovicz A, et al. Preventing venous thromboembolism in medical patients. *Circulation*. 2004;110:IV13-IV19.
79. Mismetti P, Laporte S, Darmon JY, et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. *Br J Surg*. 2001;88:913-930.
80. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. *Thromb Haemost*. 2000;83:14-19.
81. Bergqvist D. Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery. *Br J*

*Surg.* 2004;91:965-974.

82. Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. *Br J Surg.* 1995;82:496-501.
83. Planes A, Vochelle N, Mazas F, et al. The use of enoxaparin in preventing deep venous thrombosis following total hip prosthesis. Randomized multicenter prospective trial. *Rev Chir Orthop Reparatrice Appar Mot.* 1988;74(Suppl 2):215-218.
84. Hull RD, Pineo GF. Low-molecular-weight heparins for the treatment of venous thromboembolism. *Ann Med.* 1993;25:457-462.
85. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. *Ann Intern Med.* 1996;124:619-626.
86. Monreal M, Lafoz E, Navarro A, et al. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. *J Trauma.* 1989;29:873-875.
87. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. *N Engl J Med.* 1999;341:793-800.
88. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation.* 2004;110:874-879.
89. Ma Q, Tobu M, Schultz C, et al. Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. *Thromb Res.* 2007;119:653-661.
90. Mesko JW, Brand RA, Iorio R, et al. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. *J Arthroplasty.* 2001;16:679-688.
91. Collaborative overview of randomised trials of antiplatelet therapy—III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. *BMJ.* 1994;308:235-246.
92. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. *Lancet.* 2000;355:1295-1302.
93. Turpie AG, Eriksson BI, Lassen MR, et al. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. *J South Orthop Assoc.* 2002;11:182-188.
94. Eriksson BI, Lassen MR; PENTasaccharide in Hip-FRActure Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. *Arch Intern Med.* 2003;163:1337-1342.
95. Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. *Br J Surg.* 2005;92:1212-1220.
96. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. *Circulation.* 2006;114:2374-2381.
97. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. *J Thromb Haemost.* 2006;4:121-128.
98. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. *Circulation.* 2007;116:552-560.
99. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. *J Thromb Haemost.* 2005;3:103-111.
100. Eriksson BI, Dahl OE, Rosenthal N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. *Lancet.* 2007;370:949-956.

101. Amaragiri S, Lees TA. Elastic compression stockings for the prevention of deep venous thrombosis. *Ann Intern Med.* 2004;141:249-256.
102. Wille-Jorgensen P, Rasmussen MS, Andersen BR, et al. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery.[update of Cochrane Database Syst Rev. 2001;(3):CD001217; PMID: 11686983]. *Cochrane Database Syst Rev.* 2003;(4):CD001217.
103. Ramos R, Salem BI, De Pawlikowski MP, et al. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. *Chest.* 1996;109:82-85.
104. Kamran SI, Downey D, Ruff RL, et al. Pneumatic sequential compression reduces the risk of deep vein thrombosis in stroke patients. *Neurology.* 1998;50:1683-1688.
105. Kakkos SK, Daskalopoulou SS, Daskalopoulos ME, et al. Review on the value of graduated elastic compression stockings after deep vein thrombosis. *Thromb Haemost.* 2006;96:441-445.
106. Turpie AG, Bauer KA, Caprini JA, et al. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. *J Thromb Haemost.* 2007;5:1854-1861.
107. Nicolaides AN, Arcelus J, Belcaro G, et al. Prevention of venous thromboembolism. European Consensus Statement, 1-5 November 1991, developed at Oakley Court Hotel, Windsor, UK. *Int Angiol.* 1992;11:151-159.
108. Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. *Int Angiol.* 2001;20:1-37.
109. Sagar S, Nairn D, Stamatakis JD, et al. Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement. *Lancet.* 1976;1:1151-1154.
110. Hill J, Treasure T. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidance. *BMJ.* 2007;334:1053-1054.
111. Aito S, Pieri A, D'Andrea M, et al. Primary prevention of deep venous thrombosis and pulmonary embolism in acute spinal cord injured patients. *Spinal Cord.* 2002;40:300-303.
112. Reilly MK, McCabe CJ, Abbott WM, et al. Deep venous thrombophlebitis following aortoiliac reconstructive surgery. *Arch Surg.* 1982;117:1210-1211.
113. Hollyoak M, Woodruff P, Muller M, et al. Deep venous thrombosis in postoperative vascular surgical patients: a frequent finding without prophylaxis. *J Vasc Surg.* 2001;34:656-660.
114. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. The prevalence of risk factors for venous thromboembolism among hospital patients. *Arch Intern Med.* 1992;152:1660-1664.
115. DeVivo MJ, Krause JS, Lammertse DP, et al. Recent trends in mortality and causes of death among persons with spinal cord injury. *Arch Phys Med Rehabil.* 1999;80:1411-1419.
116. Prevention of thromboembolism in spinal cord injury. Consortium for Spinal Cord Medicine. *J Spinal Cord Med.* 1997;20:259-283.
117. Beebe D. Evidence of venous stasis after abdominal insufflation for laparoscopic cholecystectomy. *Anesthesiology.* 1992;77:148.
118. Caprini JA, Arcelus JI, Laubach M, et al. Postoperative hypercoagulability and deep-vein thrombosis after laparoscopic cholecystectomy. *Surg Endosc.* 1995;9:304-309.
119. Lindberg F, Bergqvist D, Rasmussen I. Incidence of thromboembolic complications after laparoscopic cholecystectomy: review of the literature. *Surg Laparosc Endosc.* 1997;7:324-331.
120. Bounameaux H, Didier D, Polat O, et al. Antithrombotic prophylaxis in patients undergoing laparoscopic cholecystectomy. *Thromb Res.* 1997;86:271-273.
121. Caprini JA, Arcelus JI. Prevention of postoperative venous thromboembolism following laparoscopic cholecystectomy. *Surg Endosc.* 1994;8:741-747.

122. Milic DJ, Pejic VD, Zivic SS, et al. Coagulation status and the presence of postoperative deep vein thrombosis in patients undergoing laparoscopic cholecystectomy. *Surg Endosc.* 2007;21:1588-1592.
123. Ljungstrom KG. Is there a need for antithromboembolic prophylaxis during laparoscopic surgery? Not always. *J Thromb Haemost.* 2005;3:212-213.
124. Rasmussen MS. Is there a need for antithrombotic prophylaxis during laparoscopic surgery? Always. *J Thromb Haemost.* 2005;3:210-211.
125. Lindberg F, Bjorck M, Rasmussen I, et al. Low frequency of phlebographic deep vein thrombosis after laparoscopic cholecystectomy—a pilot study. *Clin Appl Thromb Hemost.* 2006;12:421-426.
126. Tincani E, Piccoli M, Turrini F, et al. Video laparoscopic surgery: is out-of-hospital thromboprophylaxis necessary? *J Thromb Haemost.* 2005;3:216-220.
127. Blaszyk H, Bjornsson J. Factor V leiden and morbid obesity in fatal postoperative pulmonary embolism. *Arch Surg.* 2000;135:1410-1413.
128. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. *Obes Surg.* 2002;12:19-24.
129. Nguyen NT, Owings JT, Gosselin R, et al. Systemic coagulation and fibrinolysis after laparoscopic and open gastric bypass. *Arch Surg.* 2001;136:909-916.
130. Rocha AT, de Vasconcellos AG, da Luz Neto ER, et al. Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. *Obes Surg.* 2006;16:1645-1655.
131. Gonzalez R, Haines K, Gallagher SF, et al. Does experience preclude leaks in laparoscopic gastric bypass? *Surg Endosc.* 2006;20:1687-1692.
132. Prystowsky JB, Morasch MD, Eskandari MK, et al. Prospective analysis of the incidence of deep venous thrombosis in bariatric surgery patients. *Surgery.* 2005;138:759-763; discussion 763-765.
133. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. *Obes Surg.* 2005;15:1368-1374.
134. Agnelli G, Caprini JA. The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options. *J Surg Oncol.* 2007;96:265-272.
135. Gallus AS, Hirsh J, O'Brien SE, et al. Prevention of venous thrombosis with small, subcutaneous doses of heparin. *JAMA.* 1976;235:1980-1982.
136. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. *Ann Surg.* 1988;208:227-240.
137. Bergqvist D, Caprini JA, Dotsenko O, et al. Venous thromboembolism and cancer. *Curr Probl Surg.* 2007;44:157-216.
138. Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. *J Bone Joint Surg Am.* 1999;81:932-940.
139. Colwell CW Jr, Hardwick ME. Rationale for low-molecular-weight heparin prophylaxis after total knee arthroplasty. *Clin Orthop Relat Res.* 2006;452:181-185.
140. Turpie AG, Eriksson BI, Bauer KA, et al. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. *Chest.* 2003;124:371S-378S.
141. Lassen MR, Borris LC, Nakov RLL. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. *N Engl J Med.* 2002;347:726-730.
142. Jorgensen PS, Warming T, Hansen K, et al. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venographic controlled study. *Thromb Res.* 2002;105:477-480.



143. Oda T, Fuji T, Kato Y, et al. Deep venous thrombosis after posterior spinal surgery. *Spine*. 2000;25:2962-2967.
144. Tetzlaff J, Yoon H, O'Hara J. Influence of anesthetic technique on the incidence of deep venous thrombosis after elective lumbar spine surgery [abstract]. *Reg Anesth Pain Med*. 1994;19:28.
145. Agnelli G. Prevention of venous thromboembolism after neurosurgery. *Thromb Haemost*. 1999;82:925-930.
146. Hamilton MG, Hull RD, Pineo GF. Venous thromboembolism in neurosurgery and neurology patients: a review. *Neurosurgery*. 1994;34:280-296; discussion 296.
147. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. *J Neurosurg*. 2007;106:601-608.
148. Goldhaber SZ, Dunn K, Gerhard-Herman M, et al. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. *Chest*. 2002;122:1933-1937.
149. Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors.[erratum appears in *J Clin Oncol*. 2006;24:2133]. *J Clin Oncol*. 2006;24:1310-1318.
150. Grande WJ, Trerotola SO, Reilly PM, et al. Experience with the recovery filter as a retrievable inferior vena cava filter. *J Vasc Interv Radiol*. 2005;16:1189-1193.
151. Nicolaides AN, Kakkar VV, Field ES, et al. Soleal veins and stasis during operation. *Br J Surg*. 1972;59:304.
152. Haas S, Wolf H, Kakkar AK, et al. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. *Thromb Haemost*. 2005;94:814-819.
153. Sharnoff JG, Rosen RL, Palazzo PJ, et al. Prevention of fatal pulmonary thromboembolism by small dose heparin prophylaxis in acute hip fracture surgery. *Br J Clin Pract*. 1981;35:390-392, 427.
154. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group [erratum appears in *J Bone Joint Surg Am*. 1994;76:4741]. *J Bone Joint Surg Am*. 1994;76:3-14.
155. Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. *J Bone Joint Surg Am*. 2001;83-A:900-906.
156. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. *Thromb Haemost*. 1988;60:407-410.
157. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. *Arch Intern Med*. 2000;160:2208-2215.
158. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. *N Engl J Med*. 2002;346:975-980.
159. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. *J Thromb Haemost*. 2006;4:2384-2390.
160. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. *N Engl J Med*. 1996;335:696-700.
161. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. *J Bone Joint Surg Am*. 2001;83:336-345.
162. Vandermeulen EP, Van Aken H, Vermeylen J. Anticoagulants and spinal-epidural anesthesia. *Anesth Analg*. 1994;79:1165-1177.
163. Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens,

- and guidelines for regional anesthetic management. *Anesth Analg*. 1997;85:874-885.
164. Caprini JA, Tapson VF, Hyers TM, et al. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. *J Vasc Surg*. 2005;42:726-733.
  165. Clagett GP, Anderson FA Jr, Levine MN, et al. Prevention of venous thromboembolism. *Chest*. 1992;102:391S-407S.
  166. Otero R, Uresandi F, Cayuela A, et al. Use of venous thromboembolism prophylaxis for surgical patients: a multicentre analysis of practice in Spain. *Eur J Surg*. 2001;167:163-167.
  167. Yu HT, Dylan ML, Lin J, et al. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. *Am J Health Syst Pharm*. 2007;64:69-76.
  168. Goldhaber SZ, Dunn K, MacDougall RC. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. *Chest*. 2000;118:1680-1684.
  169. Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients. *J Clin Pathol*. 1997;50:609-610.
  170. Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. *Br J Surg*. 1991;78:849-852.
  171. Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. *Ann Intern Med*. 2007;146:278-288.
  172. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. *BMJ*. 2006;332:325-329.
  173. Barritt DW, Jordan SC. Clinical features of pulmonary embolism. *Lancet*. 1961;1:729-732.
  174. Aschwanden M, Labs KH, Engel H, et al. Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism. *Thromb Haemost*. 2001;85:42-46.
  175. Partsch H, Blattler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. *J Vasc Surg*. 2000;32:861-869.
  176. Trujillo-Santos J, Perea-Milla E, Jimenez-Puente A, et al. Bed rest or ambulation in the initial treatment of patients with acute deep vein thrombosis or pulmonary embolism: findings from the RIETE registry. *Chest*. 2005;127:1631-1636.
  177. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126:401S-428S.
  178. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. *N Engl J Med*. 1990;322:1260-1264.
  179. Raskob GE, Hull RD. Diagnosis and management of pulmonary thromboembolism. *Q J Med*. 1990;76:787-797.
  180. Geerts W, Ray JG, Colwell CW, et al. Prevention of venous thromboembolism. *Chest*. 2005;128:3775-3776.
  181. Arcelus JJ, Caprini JA, Monreal M, et al. The management and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. *J Vasc Surg*. 2003;38:916-922.
  182. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. *Arch Intern Med*. 2000;160:181-188.
  183. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. *N Engl J Med*. 1996;334:677-681.
  184. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. *N Engl J Med*. 1996;334:682-687.
  185. Low molecular weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. *N Engl J Med*. 1997;337:657-662.

186. Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. *Ann Fam Med*. 2007;5:74-80.
187. van Dongen CJ, MacGillavry MR, Prins MH. Once versus twice daily LMWH for the initial treatment of venous thromboembolism [update of *Cochrane Database Syst Rev*. 2003;CD003074]. *Cochrane Database Syst Rev*. 2005;3:CD003074.
188. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. *Ann Intern Med*. 2004;140:867-873.
189. Arnesen H, Hoiseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis. Follow-up results of a prospective study. *Acta Med Scand*. 1982;211:65-68.
190. Elliot MS, Immelman EJ, Jeffery P, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. *Br J Surg*. 1979;66:838-843.
191. Mewissen MW, Seabrook GR, Meissner MH, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry [erratum appears in *Radiology*. 1999;213:930]. *Radiology*. 1999;211:39-49.
192. Molina J, Hunter D, Yedlina J. Thrombolytic therapy for iliofemoral venous thrombosis. *Vasc Surg*. 1992;20:244-254.
193. Raffini L, Raybagkar D, Cahill AM, et al. May-Thurner syndrome (iliac vein compression) and thrombosis in adolescents. *Pediatr Blood Cancer*. 2006;47:834-838.
194. Peden E, Zhou W, Bush RL, et al. The case for thrombolysis for iliofemoral venous thrombosis. *Semin Vasc Surg*. 2005;18:139-147.
195. Semba CP, Razavi MK, Kee ST, et al. Thrombolysis for lower extremity deep venous thrombosis. *Tech Vasc Interv Radiol*. 2004;7:68-78.
196. Comerota AJ. The role of fibrinolytic therapy in the treatment of venous thromboembolism. *Dis Mon*. 2005;51:124-134.
197. Comerota AJ, Gravett MH. Iliofemoral venous thrombosis. *J Vasc Surg*. 2007;46:1065-1076.
198. Bjarnason H, Kruse JR, Asinger DA, et al. Iliofemoral deep venous thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy. *J Vasc Interv Radiol*. 1997;8:405-418.
199. Comerota AJ. Quality-of-life improvement using thrombolytic therapy for iliofemoral deep venous thrombosis. *Rev Cardiovasc Med*. 2002;3(Suppl 2):S61-S67.
200. White RH. The epidemiology of venous thromboembolism. *Circulation*. 2003;107:I4-I8.
201. Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. *JAMA*. 1998;279:458-462.
202. Arcelus JJ, Caprini JA, Monreal M, et al. The management and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. *J Vasc Surg*. 2003;38:916-922.
203. Aujesky D, Perrier A, Roy PM, et al. Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism. *J Intern Med*. 2007;261:597-604.
204. Stein PD, Woodard PK, Weg JG, et al. Diagnostic pathways in acute pulmonary embolism: recommendations of the PIOPED II Investigators. *Radiology*. 2007;242:15-21.
205. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. *N Engl J Med*. 2003;349:1695-1702.
206. Nijkeuter M, Söhne M, Tick LW, et al. The natural course of hemodynamically stable pulmonary embolism: clinical outcome and risk factors in a large prospective cohort study. *Chest*. 2007;131:517-523.
207. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. *N Engl J Med*. 1998;338:409-415.
208. Young T, Tang H, Aukes J, et al. Vena caval filters for the prevention of pulmonary embolism [update of *Cochrane Database Syst Rev*. 2007;CD006212]. *Cochrane Database Syst Rev*. 2007;4:CD006212.

209. Greenfield LJ, Proctor MC. Recurrent thromboembolism in patients with vena cava filters. *J Vasc Surg.* 2001;33:510-514.
210. Martin MJ, Salim A. Vena cava filters in surgery and trauma. *Surg Clin North Am.* 2007;87:1229-1252.
211. Mismetti P, Rivron-Guillot K, Quenet S, et al. A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism. *Chest.* 2007;131:223-229.
212. Kaufman JA, Kinney TB, Streiff MB, et al. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology Multidisciplinary Consensus Conference. *J Vasc Interv Radiol.* 2006;17:449-459.
213. Karmy-Jones R, Jurkovich GJ, Velmahos GC, et al. Practice patterns and outcomes of retrievable vena cava filters in trauma patients: an AAST multicenter study. *J Trauma.* 2007;62:17-24; discussion 24-25.
214. Corriere MA, Sauve KJ, Ayerdi J, et al. Vena cava filters and inferior vena cava thrombosis [erratum appears in *J Vasc Surg.* 2007;45:1293. Note: Suave, Kenneth J corrected to Sauve, Kenneth J]. *J Vasc Surg.* 2007;45:789-794.
215. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med.* 2003;349:146-153.
216. Ost D, Tepper J, Mihara H, et al. Duration of anticoagulation following venous thromboembolism: a meta-analysis. *JAMA.* 2005;294:706-715.
217. Prandoni P, Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. *Ann Intern Med.* 2004;141:249-256.
218. Heit JA, Rooke TW, Silverstein MD, et al. Trends in the incidence of venous stasis syndrome and venous ulcer: a 25-year population-based study. *J Vasc Surg.* 2001;33:1022-1027.
219. Kahn SR, Elman E, Rodger MA, et al. Use of elastic compression stockings after deep venous thrombosis: a comparison of practices and perceptions of thrombosis physicians and patients. *J Thromb Haemost.* 2003;1:500-506.
220. Puggioni A, Kalra M, Gloviczki P. Practical aspects of the postthrombotic syndrome. *Dis Mon.* 2005;51:166-175.
221. Brandjes DP, Buller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. *Lancet.* 1997;349:759-762.
222. Partsch H. Immediate ambulation and leg compression in the treatment of deep vein thrombosis. *Dis Mon.* 2005;51:135-140.

## 第 51 章

1. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: ACCP evidence-based clinical practice guidelines (8th ed). *Chest.* 2008;133:454S-545S.
2. Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. *Arch Intern Med.* 2002;162:1144-1148.
3. Kahn SR, Kearon C, Julian JA, et al. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. *J Thromb Haemost.* 2005;3:718-723.
4. Delis KT, Bountouroglou D, Mansfield AO. Venous claudication in iliofemoral thrombosis: long-term effects on venous hemodynamics, clinical status, and quality of life. *Ann Surg.* 2004;239:118-126.
5. O'Donnell TF, Browse NL, Burnand KG, et al. The socioeconomic effects of an iliofemoral venous thrombosis. *J Surg Res.* 1977;22:483-488.
6. Akesson H, Brudin L, Dahlstrom JA, et al. Venous function assessed during a 5 year period after acute ilio-femoral venous thrombosis treated with anticoagulation. *Eur J Vasc Surg.* 1990;4:43-48.
7. Comerota AJ, Gravett MH. Iliofemoral venous thrombosis. *J Vasc Surg.* 2007;46:1065-1076.
8. Comerota AJ, Paolini D. Treatment of acute iliofemoral deep venous thrombosis: a strategy of thrombus removal. *Eur J Vasc Endovasc Surg.* 2007;33:351-360.
9. Shull KC, Nicolaides AN, Fernandes e Fernandes J, et al. Significance of popliteal reflux in relation to ambulatory venous

- pressure and ulceration. *Arch Surg*. 1979;114:1304-1306.
10. Nicolaides AN, Schull K, Fernandes E. Ambulatory venous pressure: new information. In: Nicolaides AN, Yao JS, eds. *Investigation of Vascular Disorders*. New York, NY: Churchill Livingstone; 1981:488-494.
  11. Welkie JF, Comerota AJ, Katz ML, et al. Hemodynamic deterioration in chronic venous disease. *J Vasc Surg*. 1992;16:733-740.
  12. Johnson BF, Manzo RA, Bergelin RO, et al. Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one- to six-year follow-up. *J Vasc Surg*. 1995;21:307-312.
  13. Cho JS, Martelli E, Mozes G, et al. Effects of thrombolysis and venous thrombectomy on valvular competence, thrombogenicity, venous wall morphology, and function. *J Vasc Surg*. 1998;28:787-799.
  14. Rhodes JM, Cho JS, Gloviczki P, et al. Thrombolysis for experimental deep venous thrombosis maintains valvular competence and vasoreactivity. *J Vasc Surg*. 2000;31:1193-1205.
  15. Killewich LA, Bedford GR, Beach KW, et al. Spontaneous lysis of deep venous thrombi: rate and outcome. *J Vasc Surg*. 1989;9:89-97.
  16. Meissner MH, Manzo RA, Bergelin RO, et al. Deep venous insufficiency: the relationship between lysis and subsequent reflux. *J Vasc Surg*. 1993;18:596-605.
  17. Markel A, Manzo RA, Bergelin RO, et al. Valvular reflux after deep vein thrombosis: incidence and time of occurrence. *J Vasc Surg*. 1992;15:377-382.
  18. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126:401S-428S.
  19. Lansing AM, Davis WM. Five-year follow-up study of iliofemoral venous thrombectomy. *Ann Surg*. 1968;168:620-628.
  20. Plate G, Einarsson E, Ohlin P, et al. Thrombectomy with temporary arteriovenous fistula: the treatment of choice in acute iliofemoral venous thrombosis. *J Vasc Surg*. 1984;1:867-876.
  21. Plate G, Akesson H, Einarsson E, et al. Long-term results of venous thrombectomy combined with a temporary arterio-venous fistula. *Eur J Vasc Surg*. 1990;4:483-489.
  22. Plate G, Eklof B, Norgren L, et al. Venous thrombectomy for iliofemoral vein thrombosis—10-year results of a prospective randomised study. *Eur J Vasc Endovasc Surg*. 1997;14:367-374.
  23. Mewissen MW, Seabrook GR, Meissner MH, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. *Radiology*. 1999;211:39-49.
  24. Bjarnason H, Kruse JR, Asinger DA, et al. Iliofemoral deep venous thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy. *J Vasc Interv Radiol*. 1997;8:405-418.
  25. Comerota AJ, Kagan SA. Catheter-directed thrombolysis for the treatment of acute iliofemoral deep venous thrombosis. *Phlebology*. 2001;15:149-155.
  26. Comerota AJ, Throm RC, Mathias SD, et al. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. *J Vasc Surg*. 2000;32:130-137.
  27. Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. *Eur J Vasc Endovasc Surg*. 2002;24:209-214.
  28. Comerota AJ, Gale SS. Technique of contemporary iliofemoral and infrainguinal venous thrombectomy. *J Vasc Surg*. 2006;43:185-191.
  29. Elliot MS, Immelman EJ, Jeffery P, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. *Br J Surg*. 1979;66:838-843.
  30. Arnesen H, Hoiseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis. Follow-up results of a prospective study. *Acta Med Scand*. 1982;211:65-68.
  31. Jeffery P, Immelman EJ, Amooore J. Treatment of deep vein thrombosis with heparin or streptokinase: long-term venous

- function assessment [Abstract No. S20.3]. Proceedings of the Second International Vascular Symposium, London, 1989.
32. Semba CP, Dake MD. Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis. *Radiology*. 1994;191:487-494.
  33. Semba CP, Dake MD. Catheter-directed thrombolysis for iliofemoral venous thrombosis. *Semin Vasc Surg*. 1996;9:26-33.
  34. Verhaeghe R, Stockx L, Lacroix H, et al. Catheter-directed lysis of iliofemoral vein thrombosis with use of rt-PA. *Eur Radiol*. 1997;7:996-1001.
  35. Horne MK III, Mayo DJ, Cannon RO III, et al. Intraclot recombinant tissue plasminogen activator in the treatment of deep venous thrombosis of the lower and upper extremities. *Am J Med*. 2000;108:251-255.
  36. Kasirajan K, Gray B, Ouriel K. Percutaneous AngioJet thrombectomy in the management of extensive deep venous thrombosis. *J Vasc Interv Radiol*. 2001;12:179-185.
  37. AbuRahma AF, Perkins SE, Wulu JT, et al. Iliofemoral deep vein thrombosis: conventional therapy versus lysis and percutaneous transluminal angioplasty and stenting. *Ann Surg*. 2001;233:752-760.
  38. Vedantham S, Vesely TM, Parti N, et al. Lower extremity venous thrombolysis with adjunctive mechanical thrombectomy. *J Vasc Interv Radiol*. 2002;13:1001-1008.
  39. Castaneda F, Li R, Young K, et al. Catheter-directed thrombolysis in deep venous thrombosis with use of reteplase: immediate results and complications from a pilot study. *J Vasc Interv Radiol*. 2002;13:577-580.
  40. Grunwald MR, Hofmann LV. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis. *J Vasc Interv Radiol*. 2004;15:347-352.
  41. Laiho MK, Oinonen A, Sugano N, et al. Preservation of venous valve function after catheter-directed and systemic thrombolysis for deep venous thrombosis. *Eur J Vasc Endovasc Surg*. 2004;28:391-396.
  42. Sillesen H, Just S, Jorgensen M, et al. Catheter-directed thrombolysis for treatment of ilio-femoral deep venous thrombosis is durable, preserves venous valve function and may prevent chronic venous insufficiency. *Eur J Vasc Endovasc Surg*. 2005;30:556-562.
  43. Jackson LS, Wang XJ, Dudrick SJ, et al. Catheter-directed thrombolysis and/or thrombectomy with selective endovascular stenting as alternatives to systemic anticoagulation for treatment of acute deep vein thrombosis. *Am J Surg*. 2005;190:864-868.
  44. Ogawa T, Hoshino S, Midorikawa H, et al. Intermittent pneumatic compression of the foot and calf improves the outcome of catheter-directed thrombolysis using low-dose urokinase in patients with acute proximal venous thrombosis of the leg. *J Vasc Surg*. 2005;42:940-944.
  45. Kim HS, Patra A, Paxton BE, et al. Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic outcomes. *J Vasc Interv Radiol*. 2006;17:1099-1104.
  46. Lin PH, Zhou W, Dardik A, et al. Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis. *Am J Surg*. 2006;192:782-788.
  47. Protack CD, Bakken AM, Patel N, et al. Long-term outcomes of catheter directed thrombolysis for lower extremity deep venous thrombosis without prophylactic inferior vena cava filter placement. *J Vasc Surg*. 2007;45:992-997.
  48. Goldenberg NA, Durham JD, Knapp-Clevenger R, et al. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. *Blood*. 2007;110:45-53.
  49. Chang R, Cannon RO III, Chen CC, et al. Daily catheter-directed single dosing of t-PA in treatment of acute deep venous thrombosis of the lower extremity. *J Vasc Interv Radiol*. 2001;12:247-252.
  50. Mathias SD, Prebil LA, Putterman CG, et al. A health-related quality of life measure in patients with deep vein thrombosis: a validation study. *Drug Inf J*. 1999;33:1173-1187.
  51. Enden T, Sandvik L, Klow NE, et al. Catheter-directed venous thrombolysis in acute iliofemoral vein thrombosis—the CaVenT study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771). *Am Heart J*. 2007;154:808-814.

52. Vedantham S, Goldhaber SZ, Kearon C. Acute venous thrombosis: thrombus removal with adjunctive catheter-directed thrombolysis (ATTRACT) [protocol]. 2008, unpublished work.
53. Parikh S, Motarjeme A, McNamara T, et al. Ultrasound-accelerated thrombolysis for the treatment of deep vein thrombosis: initial clinical experience. *J Vasc Interv Radiol*. 2008;19:521-528.
54. Martinez J, Comerota AJ, Kazanjian S, et al. The quantitative benefit of isolated, segmental, pharmacomechanical thrombolysis for iliofemoral DVT. *J Vasc Surg*. 2008;48:1532-1537.
55. O'Sullivan GJ, Lohan DG, Gough N, et al. Pharmacomechanical thrombectomy of acute deep vein thrombosis with the Trellis-8 isolated thrombolysis catheter. *J Vasc Interv Radiol*. 2007;18:715-724.
56. Eklof B, Juhan C. Revival of thrombectomy in the management of acute iliofemoral venous thrombosis. *Contemp Surg*. 1992;40:21.
57. Einarsson E, Albrechtsson U, Eklof B, et al. Follow-up evaluation of venous morphologic factors and function after thrombectomy and temporary arteriovenous fistula in thrombosis of iliofemoral vein. *Surg Gynecol Obstet*. 1986;163:111-116.
58. Ganger KH, Nachbur BH, Ris HB, et al. Surgical thrombectomy versus conservative treatment for deep venous thrombosis: functional comparison of long-term results. *Eur J Vasc Surg*. 1989;3:529-538.
59. Neglen P, al-Hassan HK, Endrys J, et al. Iliofemoral venous thrombectomy followed by percutaneous closure of the temporary arteriovenous fistula. *Surgery*. 1991;110:493-499.
60. Kniemeyer HW, Sandmann W, Schwindt C, et al. Thrombectomy with arteriovenous fistula for embolizing deep venous thrombosis: an alternative therapy for prevention of recurrent pulmonary embolism. *Clin Invest*. 1993;72:40-45.
61. Juhan C, Alimi Y, Di Mauro P, et al. Surgical venous thrombectomy. *Cardiovasc Surg*. 1999;7:586-590.
62. Meissner AJ, Huszcza S. Surgical strategy for management of deep venous thrombosis of the lower extremities. *World J Surg*. 1996;20:1149-1155.
63. Brandjes DP, Buller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. *Lancet*. 1997;349:759-762.
64. Prandoni P, Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. *Ann Intern Med*. 2004;141:249-256.
65. Monreal M, Rey-Joly BC, Ruiz MJ, et al. Asymptomatic pulmonary embolism in patients with deep vein thrombosis. Is it useful to take a lung scan to rule out this condition? *J Cardiovasc Surg (Torino)*. 1989;30:104-107.
66. Martinez J, Paolini D, Comerota AJ. Chest and abdominopelvic CT scans are important tools for evaluating patients with iliofemoral venous thrombosis. Paper presented at: Peripheral Vascular Surgery Society; June 7, 2008; San Diego, CA.
67. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med*. 2004;350:2257-2264.
68. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, et al. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. *Am Heart J*. 1997;134:479-487.
69. Aklog L, Williams CS, Byrne JG, et al. Acute pulmonary embolectomy: a contemporary approach. *Circulation*. 2002;105:1416-1419.
70. Yalamanchili K, Fleisher AG, Lehrman SG, et al. Open pulmonary embolectomy for treatment of major pulmonary embolism. *Ann Thorac Surg*. 2004;77:819-823.
71. Greenfield LJ, Bruce TA, Nichols NB. Transvenous pulmonary embolectomy by catheter device. *Ann Surg*. 1971;174:881-886.
72. Scoggins WG, Greenfield LJ. Transvenous pulmonary embolectomy for acute massive pulmonary embolism. *Chest*. 1977;71:213-216.
73. Greenfield LJ, Zocco JJ. Intraluminal management of acute massive pulmonary thromboembolism. *J Thorac Cardiovasc Surg*. 1979;77:402-410.

74. Moore JH Jr, Koolpe HA, Carabasi RA, et al. Transvenous catheter pulmonary embolectomy. *Arch Surg.* 1985;120:1372-1375.
75. Nakasaki Y, Tsujiyama S, Higo M, et al. [A case of acute massive pulmonary embolism successfully treated with transvenous pulmonary embolectomy by catheter.] *Kokyu To Junkan.* 1989;37:1363-1366.
76. Timsit JF, Reynaud P, Meyer G, et al. Pulmonary embolectomy by catheter device in massive pulmonary embolism. *Chest.* 1991;100:655-658.
77. Greenfield LJ, Proctor MC, Williams DM, et al. Long-term experience with transvenous catheter pulmonary embolectomy. *J Vasc Surg.* 1993;18:450-457.
78. Hiramatsu S, Ogihara A, Kitano Y, et al. Clinical outcome of catheter fragmentation and aspiration therapy in patients with acute pulmonary embolism. *J Cardiol.* 1999;34:71-78.
79. Tajima H, Murata S, Kumazaki T, et al. Manual aspiration thrombectomy with a standard PTCA guiding catheter for treatment of acute massive pulmonary thromboembolism. *Radiat Med.* 2004;22:168-172.
80. Koning R, Cribier A, Gerber L, et al. A new treatment for severe pulmonary embolism: percutaneous rheolytic thrombectomy. *Circulation.* 1997;96:2498-2500.
81. Voigtlander T, Rupprecht HJ, Nowak B, et al. Clinical application of a new rheolytic thrombectomy catheter system for massive pulmonary embolism. *Catheter Cardiovasc Interv.* 1999;47:91-96.
82. Zeni PT Jr, Blank BG, Peeler DW. Use of rheolytic thrombectomy in treatment of acute massive pulmonary embolism. *J Vasc Interv Radiol.* 2003;14:1511-1515.
83. Chiam P, Kwok V, Johan BA, et al. Major pulmonary embolism treated with a rheolytic thrombectomy catheter. *Singapore Med J.* 2005;46:479-482.
84. Siablis D, Karnabatidis D, Katsanos K, et al. AngioJet rheolytic thrombectomy versus local intrapulmonary thrombolysis in massive pulmonary embolism: a retrospective data analysis. *J Endovasc Ther.* 2005;12:206-214.
85. Chauhan MS, Kawamura A. Percutaneous rheolytic thrombectomy for large pulmonary embolism: a promising treatment option. *Catheter Cardiovasc Interv.* 2007;70:121-128.
86. Margheri M, Vittori G, Vecchio S, et al. Early and long-term clinical results of AngioJet rheolytic thrombectomy in patients with acute pulmonary embolism. *Am J Cardiol.* 2008;101:252-258.
87. Brady AJ, Crake T, Oakley CM. Percutaneous catheter fragmentation and distal dispersion of proximal pulmonary embolus. *Lancet.* 1991;338:1186-1189.
88. Sigmund M, Rubart M, Vom DJ, et al. Successful treatment of massive pulmonary embolism by combined mechanical and thrombolytic therapy. *J Interv Cardiol.* 1991;4:63-68.
89. Rafique M, Middlemost S, Skoularigis J, et al. Simultaneous mechanical clot fragmentation and pharmacologic thrombolysis in acute massive pulmonary embolism. *Am J Cardiol.* 1992;69:427-430.
90. Manthey J, Frohlich G, Mautner JP, et al. [Mechanical recanalization and local thrombolysis in a patient with fulminant pulmonary embolism and craniocerebral trauma.] *Anesthesiol Intensivmed Notfallmed Schmerzther.* 1994;29:446-449.
91. Fava M, Loyola S, Flores P, et al. Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism. *J Vasc Interv Radiol.* 1997;8:261-266.
92. Stock KW, Jacob AL, Schnabel KJ, et al. Massive pulmonary embolism: treatment with thrombus fragmentation and local fibrinolysis with recombinant human-tissue plasminogen activator. *Cardiovasc Intervent Radiol.* 1997;20:364-368.
93. Schmitz-Rode T, Janssens U, Schild HH, et al. Fragmentation of massive pulmonary embolism using a pigtail rotation catheter. *Chest.* 1998;114:1427-1436.
94. Wong PS, Singh SP, Watson RD, et al. Management of pulmonary thrombo-embolism using catheter manipulation: a report of four cases and review of the literature. *Postgrad Med J.* 1999;75:737-741.
95. Murphy JM, Mulvihill N, Mulcahy D, et al. Percutaneous catheter and guidewire fragmentation with local administration of recombinant tissue plasminogen activator as a treatment for massive pulmonary embolism. *Eur Radiol.* 1999;9:959-964.



96. Schmitz-Rode T, Janssens U, Duda SH, et al. Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter. *J Am Coll Cardiol*. 2000;36:375-380.
97. Schmitz-Rode T, Janssens U, Hanrath P, et al. Fragmentation of massive pulmonary embolism by pigtail rotation catheter: possible complication. *Eur Radiol*. 2001;11:2047-2049.
98. Prokubovski VI, Kapranov SA, Bobrov BI. Endovascular rotary fragmentation in the treatment of massive pulmonary thromboembolism. *Angiol Sosud Khir*. 2003;9:31-39.
99. Tajima H, Murata S, Kumazaki T, et al. Hybrid treatment of acute massive pulmonary thromboembolism: mechanical fragmentation with a modified rotating pigtail catheter, local fibrinolytic therapy, and clot aspiration followed by systemic fibrinolytic therapy. *AJR Am J Roentgenol*. 2004;183:589-595.
100. De Gregorio MA, Gimeno MJ, Mainar A, et al. Mechanical and enzymatic thrombolysis for massive pulmonary embolism. *J Vasc Interv Radiol*. 2002;13:163-169.
101. Uflacker R, Strange C, Vujic I. Massive pulmonary embolism: preliminary results of treatment with the Amplatzer thrombectomy device. *J Vasc Interv Radiol*. 1996;7:519-528.
102. Peuster M, Bertram H, Windhagen-Mahnert B, et al. [Mechanical recanalization of venous thrombosis and pulmonary embolism with the Clotbuster thrombectomy system in a 12-year-old boy.] *Z Kardiol*. 1998;87:283-287.
103. Muller-Hulsbeck S, Brossmann J, Jahnke T, et al. Mechanical thrombectomy of major and massive pulmonary embolism with use of the Amplatzer thrombectomy device. *Invest Radiol*. 2001;36:317-322.
104. Michalis LK, Tsetis DK, Rees MR. Case report: percutaneous removal of pulmonary artery thrombus in a patient with massive pulmonary embolism using the hydrolyser catheter: the first human experience. *Clin Radiol*. 1997;52:158-161.
105. Fava M, Loyola S, Huete I. Massive pulmonary embolism: treatment with the hydrolyser thrombectomy catheter. *J Vasc Interv Radiol*. 2000;11:1159-1164.
106. Reekers JA, Baarslag HJ, Koolen MG, et al. Mechanical thrombectomy for early treatment of massive pulmonary embolism. *Cardiovasc Intervent Radiol*. 2003;26:246-250.
107. Rocek M, Peregrin J, Velimsky T. Mechanical thrombectomy of massive pulmonary embolism using an Arrow-Trerotola percutaneous thrombolytic device. *Eur Radiol*. 1998;8:1683-1685.
108. Lang EV, Barnhart WH, Walton DL, et al. Percutaneous pulmonary thrombectomy. *J Vasc Interv Radiol*. 1997;8:427-432.
109. Agnelli G, Becattini C, Kirschstein T. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. *Arch Intern Med*. 2002;162:2537-2541.
110. Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. *N Engl J Med*. 2002;347:1143-1150.
111. Urokinase Pulmonary Embolism Trial. A national cooperative study. *Circulation*. 1973;47:III-III08.
112. Dong B, Jirong Y, Liu G, et al. Thrombolytic therapy for pulmonary embolism. *Cochrane Database Syst Rev*. 2006;(2)CD004437.
113. Wan S, Quinlan DJ, Agnelli G, et al. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. *Circulation*. 2004;110:744-749.
114. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen Activator Italian Multicenter Study 2. *J Am Coll Cardiol*. 1992;20:520-526.
115. Dotter CT, Seaman AJ, Rosch J, et al. Streptokinase and heparin in the treatment of pulmonary embolism: a randomized comparison. *Vasc Endovasc Surg*. 1979;13:42-52.
116. Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes GM, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. *J Thromb Thrombolysis*. 1995;2:227-229.
117. Ly B, Arnesen H, Eie H, et al. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. *Acta Med Scand*. 1978;203:465-470.
118. Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clinical trial of streptokinase and heparin in

treatment of life-threatening pulmonary embolism. *BMJ*. 1974;1:343-347.

119. PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. *Chest*. 1990;97:528-533.
120. Urokinase Pulmonary Embolism Trial Study Group. Urokinase pulmonary embolism trial: phase I results. *JAMA*. 1970;214:2163-2172.
121. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. *Lancet*. 1993;341:507-511.

## 第 52 章

1. White RH. The epidemiology of venous thromboembolism. *Circulation*. 2003;107:14-8.
2. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. *Thromb Haemost*. 2001;86:452-463.
3. Fuller CH, Willbanks OL. Incidental prophylactic inferior vena cava clipping. *Arch Surg*. 1971;102:440-441.
4. Leather RP, Clark WR Jr, Powers SR Jr, et al. Five-year experience with the Moretz vena caval clip in 62 patients. *Arch Surg*. 1968;97:357-364.
5. Lindenauer SM. Prophylactic staple plication of the inferior vena cava. *Arch Surg*. 1973;107:669-675.
6. Spencer FC, Quattlebaum JK, Quattlebaum JK Jr, et al. Plication of the inferior vena cava for pulmonary embolism: a report of 20 cases. *Ann Surg*. 1962;155:827-837.
7. Kaufman JA, Kinney TB, Streiff MB, et al. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology Multidisciplinary Consensus Conference. *J Vasc Interv Radiol*. 2006;17:449-459.
8. Greenfield LJ, McCurdy JR, Brown PP, et al. A new intracaval filter permitting continued flow and resolution of emboli. *Surgery*. 1973;73:599-606.
9. Proctor MC, Greenfield LJ. Form and function of vena cava filters: How do optional filters measure up? *Vascular*. 2008;16:10-16.
10. Verstraete M. Thrombolytic treatment. *BMJ*. 1995;311:582-583.
11. Greenfield LJ, Proctor MC, Roberts KR. An improved process for development and testing of vena caval filters: the percutaneous steel Greenfield filter. *Surgery*. 1997;121:50-57.
12. Hammer FD, Rousseau HP, Joffe FG, et al. In vitro evaluation of vena cava filters. *J Vasc Interv Radiol*. 1994;5:869-876.
13. Greenfield LJ, Proctor MC. Twenty-year clinical experience with the Greenfield filter. *Cardiovasc Surg*. 1995;3:199-205.
14. Athanasoulis CA, Kaufman JA, Halpern EF, et al. Inferior vena caval filters: review of a 26-year single-center clinical experience. *Radiology*. 2000;216:54-66.
15. Kantor A, Glanz S, Gordon DH, et al. Percutaneous insertion of the Kimray-Greenfield filter: incidence of femoral vein thrombosis. *AJR Am J Roentgenol*. 1987;149:1065-1066.
16. Greenfield LJ, Zocco J, Wilk J, et al. Clinical experience with the Kim-Ray Greenfield vena caval filter. *Ann Surg*. 1977;185:692-698.
17. Greenfield LJ, Cho KJ, Tauscher JR. Evolution of hook design for fixation of the titanium Greenfield filter. *J Vasc Surg*. 1990;12:345-353.
18. Greenfield LJ, Cho KJ, Proctor MC, et al. Results of a multicenter study of the modified hook-titanium Greenfield filter. *J Vasc Surg*. 1991;14:253-257.
19. Greenfield LJ, Proctor MC, Cho KJ, et al. Extended evaluation of the titanium Greenfield vena caval filter. *J Vasc Surg*. 1994;20:458-464.
20. Sweeney TJ, Van Aman ME. Deployment problems with the titanium Greenfield filter. *J Vasc Interv Radiol*. 1993;4:691-694.

21. Greenfield LJ, Proctor MC. Experimental embolic capture by asymmetric Greenfield filters. *J Vasc Surg.* 1992;16:436-443; discussion 443-444.
22. Greenfield LJ, Proctor MC, Cho KJ, et al. Limb asymmetry in titanium Greenfield filters: clinically significant? *J Vasc Surg.* 1997;26:770-775.
23. Greenfield LJ, Savin MA. Comparison of titanium and stainless steel, Greenfield vena caval filters. *Surgery.* 1989;106:820-828.
24. Greenfield LJ, Proctor MC. Twenty-year clinical experience with the Greenfield filter. *Cardiovasc Surg.* 1995;3:199-205
25. Greenfield LJ, Tauscher JR, Marx MV. Evaluation of a new percutaneous stainless steel Greenfield filter by intravascular ultrasonography. *Surgery.* 1991;109:722-729.
26. Johnson SP, Raiken DP, Grebe PJ, et al. Single institution prospective evaluation of the over-the-wire Greenfield vena caval filter. *J Vasc Interv Radiol.* 1998;9:766-773.
27. Kinney TB, Rose SC, Weingarten KE, et al. IVC filter tilt and asymmetry: comparison of the over-the-wire stainless-steel and titanium Greenfield IVC filters. *J Vasc Interv Radiol.* 1997;8:1029-1037.
28. Roehm JO Jr, Gianturco C, Barth MH, et al. Percutaneous transcatheter filter for the inferior vena cava. A new device for treatment of patients with pulmonary embolism. *Radiology.* 1984;150:255-257.
29. Roehm JO Jr. The bird's nest filter: a new percutaneous transcatheter inferior vena cava filter. *J Vasc Surg.* 1984;1:498-501.
30. Roehm JO Jr, Thomas JW. The twist technique: a method to minimize wire prolapse during Bird's Nest filter placement. *J Vasc Interv Radiol.* 1995;6:455-459.
31. Wojtowycz MM, Stoehr T, Crummy AB, et al. The Bird's Nest inferior vena caval filter: review of a single-center experience. *J Vasc Interv Radiol.* 1997;8:171-179.
32. Roehm JO Jr, Johnsrude IS, Barth MH, et al. The bird's nest inferior vena cava filter: progress report. *Radiology.* 1988;168:745-749.
33. Athanasoulis CA, Kaufman JA, Halpern EF, et al. Inferior vena caval filters: review of a 26-year single-center clinical experience. *Radiology.* 2000;216:54-66.
34. Thomas JH, Cornell KM, Siegel EL, et al. Vena caval occlusion after bird's nest filter placement. *Am J Surg.* 1998;176:598-600.
35. Nicholson AA, Ettles DF, Paddon AJ, et al. Long-term follow-up of the Bird's Nest IVC Filter. *Clin Radiol.* 1999;54:759-764.
36. Ferris EJ, McCowan TC, Carver DK, et al. Percutaneous inferior vena cava filters: follow-up of seven designs in 320 patients. *Radiology.* 1993;188:851-856.
37. Murphy TP, Dorfman GS, Yedlicka JW, et al. LGM vena cava filter: objective evaluation of early results. *J Vasc Interv Radiol.* 1991;2:107-115.
38. Reed RA, Teitelbaum GP, Taylor FC, et al. Incomplete opening of LGM (Vena Tech) filters inserted via the transjugular approach. *J Vasc Interv Radiol.* 1991;2:441-445.
39. Crochet DP, Brunel P, Trogrlic S, et al. Long-term follow-up of Vena Tech-LGM filter: predictors and frequency of caval occlusion. *J Vasc Interv Radiol.* 1999;10:137-142.
40. LeBlanche AF, Benazzoos A, Reynaud P, et al. The VenaTech LP permanent caval filter: effectiveness and safety in the prevention of pulmonary embolism—A European multicenter Study. *J Vasc Interv Radiol.* 2008;19:509-515.
41. Simon M, Athanasoulis CA, Kim D, et al. Simon nitinol inferior vena cava filter: initial clinical experience. Work in progress. *Radiology.* 1989;172:99-103.
42. Leask RL, Johnston KW, Ojha M. In vitro hemodynamic evaluation of a Simon nitinol vena cava filter: possible explanation of IVC occlusion. *J Vasc Interv Radiol.* 2001;12:613-618.
43. Poletti PA, Becker CD, Prina L, et al. Long-term results of the Simon nitinol inferior vena cava filter. *Eur Radiol.*

1998;8:289-294.

44. Aswad MA, Sandager GP, Pais SO, et al. Early duplex scan evaluation of four vena caval interruption devices. *J Vasc Surg.* 1996;24:809-818.
45. Oliva VL, Sztatmari F, Giroux MF, et al. The Jonas Study: evaluation of the retrievability of the Cordis OptEase inferior vena cava filter. *J Vasc Interv Radiol.* 2005;16:1423-1425.
46. Rousseau H, Perreault P, Otal P, et al. The 6-F nitinol TrapEase inferior vena cava filter: results of a prospective multicenter trial. *J Vasc Interv Radiol.* 2001;12:299-304.
47. Rousseau HP, Perreault P, Otal P, et al. First clinical experience with a new 6F nitinol inferior vena cava filter: results from a European multicenter trial. *J Vasc Interv Radiol.* 2000;11:196.
48. Kalva SP, Wicky S, Waltman AC, et al. TrapEase vena cava filter: experience in 751 patients. *J Endovasc Ther.* 2006;13:365-372.
49. Leask RL, Johnston KW, Ojha M. Hemodynamic effects of clot entrapment in the TrapEase inferior vena cava filter. *J Vasc Interv Radiol.* 2004;15:485-490.
50. Schutzer R, Ascher E, Hingorai A, et al. Preliminary results of the new 6F TrapEase inferior vena cava filter. *Ann Vasc Surg.* 2003;17:103-106.
51. Corriere MA, Sauve KJ, Ayerdi J, et al. Vena cava filters and inferior vena cava thrombosis. *J Vasc Surg.* 2007;45:789-794.
52. Mahrer A, Zippel D, Garniek A, et al. Retrievable vena cava filters in major trauma patients: prevalence of thrombus within the filter. *Cardiovasc Intervent Radiol.* 2008;31:785-789.
53. Asch MR. Initial experience in humans with a new retrievable inferior vena cava filter. *Radiology.* 2002;225:835-844.
54. Binkert CA, Sasadeusz K, Stavropoulos SW. Retrievability of the recovery vena cava filter after dwell times longer than 180 days. *J Vasc Interv Radiol.* 2006;17:299-302.
55. Lipman JC. Removal of vena caval filter at 224 days. *South Med J.* 2005;98:556-558.
56. Grande WJ, Trerotola SO, Reilly PM, et al. Experience with the recovery filter as a retrievable inferior vena cava filter. *J Vasc Interv Radiol.* 2005;16:1189-1193.
57. <http://www.fda.gov/cdrh/pdf7/K073090.pdf>.
58. <http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00556426>.
59. Turba UC, Glaiberman C, Picus D, et al. Management of severe vena cava filter tilting: experience with Bard G-2 filters. *J Vasc Interv Radiol.* 2008;19:449-453.
60. Kuo WT, Loh CT, Sze DY. Emergency retrieval of a G2 filter after complete migration into the right ventricle. *J Vasc Interv Radiol.* 2007;18:1177-1182.
61. Bui JT, West DL, Pinto C, et al. Right ventricular migration and endovascular removal of an inferior vena cava filter. *J Vasc Interv Radiol.* 2008;19:141-144.
62. Rosenthal D, Wellons Ed, Hancock SM, et al. Retrievability of the Günther Tulip vena cava filter after dwell times longer than 180 days in patients with multiple trauma. *J Endovasc Ther.* 2007;14:406-410.
63. Millward SF. Günther Tulip retrievable filter: why, when and how? *Can Assoc Radiol J.* 2001;52:188-192.
64. Millward SF, Bhargava A, Aquino J Jr, et al. Günther Tulip filter: preliminary clinical experience with retrieval. *J Vasc Interv Radiol.* 2000;11:75-82.
65. Van Ha TG, Chien AS, Funaki BS, et al. Use of retrievable compared to permanent inferior vena cava filters: a single-institution experience. *Cardiovasc Intervent Radiol.* 2008;31:308-315.
66. Keller IS, Meier C, Pfiffner R, et al. Clinical comparison of two optional vena cava filters. *J Vasc Interv Radiol.* 2007;18:505-511.
67. Looby S, Given M, Geoghegan T, et al. Günther Tulip retrievable inferior vena caval filters: indications, efficacy, retrieval, and complications. *Cardiovasc Intervent Radiol.* 2007;30:59-65.

68. Millward SF, Oliva VL, Bell SD, et al. Günther Tulip retrievable vena cava filter: results from the registry of the Canadian Interventional Radiology Association. *J Vasc Interv Radiol*. 2001;12:1053-1058.
69. Tay KH, Martin ML, Fry PD, et al. Repeated Günther Tulip inferior vena cava filter repositioning to prolong implantation time. *J Vasc Interv Radiol*. 2002;13:509-512.
70. Günther RW, Neuerburg J, Mossdorf A, et al. New optional IVC filter for percutaneous retrieval—in vitro evaluation of embolus capturing efficiency. *Rofo*. 2005; 177:632-636.
71. <http://www.fda.gov/cdrh/pdf7/K073374.pdf>.
72. <http://clinicaltrials.gov/ct2/show/NCT00470626?term=celect&rank=1>.
73. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133(6 Suppl):454S-545S.
74. Stein PD, Kayali F, Olson RE. Twenty-one year trends in the use of inferior vena cava filters. *Arch Intern Med*. 2004;164:1541-1545.
75. Jaff MR, Goldhaber SZ, Tapson VF. High utilization rate of vena cava filters in deep vein thrombosis. *Thromb Haemost*. 2005;93:1117-1119.
76. Greenfield LJ, Rutherford RB, and participants in the Vena Caval Filter Consensus Conference. Recommended reporting standards for vena caval filter placement and patient followup. *J Vasc Surg*. 1999;30:573-579.
77. Grassi CJ, Swan TL, Cardella JF, et al. Quality improvement guidelines for percutaneous permanent inferior vena cava filter placement for the prevention of pulmonary embolism. *J Vasc Interv Radiol*. 2003;14:S271-S275.
78. Millward SF, Grassi CJ, Kinney TB, et al. Reporting standards for inferior vena caval filter placement and patient follow-up: supplement for temporary and retrievable/optional filters. *J Vasc Interv Radiol*. 2005;16:441-443.
79. Ray CE, Kaufman JA. Complications of inferior vena cava filters. *Abdom Imaging*. 1996;21:368-374.
80. Ballew KA, Phillbrick JT, Becker DM. Vena cava filter devices. *Clin Chest Med*. 1995;16:295-305.
81. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. *N Engl J Med*. 1998;338:409-415.
82. PREPIC Study Group. Eight year follow-up of patients with permanent vena cava filters in the prevention of PE. The PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study) randomized study. *Circulation*. 2005;112:416-422.
83. Becker DM, Philbrick JT, Selby JB, et al. Inferior vena cava filters: indications, safety, effectiveness. *Arch Intern Med*. 1992;152:1985-1992.
84. Streiff MB. Vena caval filters: a comprehensive review. *Blood*. 2000;95:3669-3677.
85. Young T, Tang H, Aukes J, et al. Vena cava filters for the prevention of pulmonary embolism. *Cochrane Database Syst Rev*. 2007;4:CD006212.
86. Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. *Blood Rev*. 2005;19:179-202.
87. Binkert CA, Bansal A, Gates JD. Inferior vena caval filter removal after 317 day implantation. *J Vasc Interv Radiol*. 2005;16:1156-1158.
88. Velmahos GC, Kern J, Chan LS, et al. Prevention of venous thromboembolism after injury: an evidence-based report. Part I: Analysis of risk factors and evaluation of the role of vena caval filters. *J Trauma*. 2000;49:132-139.
89. Velmahos GC, Kern J, Chan LS, et al. Prevention of venous thromboembolism after injury: an evidence-based report. Part II: Analysis of risk factors and evaluation of the role of vena caval filters. *J Trauma*. 2000;49:140-144.
90. Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after major trauma. *N Engl J Med*. 1994;331:1601-1606.
91. Meyer CS, Blebea J, Davis K, et al. Surveillance venous scans for deep venous thrombosis in multiple trauma patients. *Ann*

- Vasc Surg.* 1995;9:109-114.
92. Geerts WH, Bergqvist D, Pineo GF, et al. American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008;133(6 Suppl):381S-453S.
  93. Rogers FB, Cipolle MD, Velmahos G, et al. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST Practice Management Guidelines Work Group. *J Trauma.* 2002;53:142-164.
  94. Khansarinia S, Dennis JW, Velden HC, et al. Prophylactic Greenfield filter placement in selected high-risk trauma patients. *J Vasc Surg.* 1995;22:231-236.
  95. Sing RF, Cicci CK, Smith CH, et al. Bedside insertion of inferior vena cava filters in the intensive care unit. *J Trauma.* 1999;47:1104-1107.
  96. Tola JC, Holtzmann R, Lottenberg L. Bedside placement of inferior vena cava filters in the intensive care unit. *Am Surg.* 1999;65:833-837.
  97. Carlin AM, Tyburski JG, Wilson RF, et al. Prophylactic and therapeutic inferior vena cava filters to prevent pulmonary emboli in trauma patients. *Arch Surg.* 2002;137:521-527.
  98. Winchell RJ, Hoyt DB, Walsh JC, et al. Risk factors associated with pulmonary embolism despite routine prophylaxis: implications for improved protection. *J Trauma.* 1994;37:600-606.
  99. Rodriguez JL, Lopez JM, Proctor MC, et al. Early placement of prophylactic vena caval filters in injured patients at high risk for pulmonary embolism. *J Trauma.* 1996;40:797-802.
  100. Rogers FB, Strindberg G, Shackford SR, et al. Five-year follow-up of prophylactic vena cava filters in high risk trauma patients. *Arch Surg.* 1998;133:406-412.
  101. Sing RF, Camp SM, Heniford BT, et al. Timing of pulmonary emboli after trauma: implications for retrievable vena cava filters. *J Trauma.* 2006;60:732-735.
  102. Karny-Jones R, Jurkovich GJ, Velmahos GC, et al. Practice patterns and outcomes of retrievable vena cava filters in trauma patients: an AAST multicenter study. *J Trauma.* 2007;62:17-25.
  103. Meier C, Keller IS, Pfiffner R, et al. Early experience with the retrievable OptEase vena cava filter in high-risk trauma patients. *Eur J Vasc Endovasc Surg.* 2006;32:589-595.
  104. Rosenthal D, Wellons ED, Lai KM, et al. Retrievable inferior vena cava filters: early clinical experience. *J Cardiovasc Surg.* 2005;46:163-169.
  105. McMurty AL, Owings JT, Anderson JT, et al. Increased use of prophylactic vena cava filters in trauma patients failed to decrease overall incidence of pulmonary embolism. *J Am Coll Surg.* 1999;189:314-320.
  106. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. *JAMA.* 1997;277:642-645.
  107. Blaszyk H, Wollan PC, Witkiewicz AK, et al. Death from pulmonary thromboembolism in severe obesity: lack of association with established genetic and clinical risk factors. *Virchows Arch.* 1999;434:529-532.
  108. Prystowsky J, Morasch M, Eskandari MK, et al. Prospective analysis of the incidence of deep venous thrombosis in bariatric surgery patients. *Surgery.* 2005;138:759-765.
  109. Wu E, Barba C. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. *Obes Surg.* 2000;10:7-14.
  110. Scholten D, Hoedema R, Scholten R. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. *Obes Surg.* 2002;12:19-24.
  111. Kalfarentzos F, Stavropoulou F, Yarmenitis S, et al. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. *Obes Surg.* 2001;11:670-676.

112. Shepherd M, Rosborough T, Schwartz M. Heparin thromboprophylaxis in gastric bypass surgery. *Obes Surg.* 2003;13:249-253.
113. Gonzalez Q, Tishler D, Plata-Munoz J, et al. Incidence of clinically evident deep venous thrombosis after laparoscopic Roux-en-Y gastric bypass. *Surg Endosc.* 2004;18:1082-1084.
114. Huber O, Bounameaux H, Borst F, et al. Postoperative pulmonary embolism after hospital discharge: an underestimated risk. *Arch Surg.* 1992;127:310-313.
115. Carmody BJ, Sugerman HJ, Kellum JM, et al. Pulmonary embolism complicating bariatric surgery: detailed analysis of a single institution's 24-year experience. *J Am Coll Surg.* 2006;203:831-837.
116. Hamad GG, Bergqvist D. Venous thromboembolism in bariatric surgery patients: an update of risk and prevention. *Surg Obes Relat Dis.* 2007;3:97-102.
117. Obeid FN, Bowling WM, Fike JS, et al. Efficacy of prophylactic inferior vena cava filter placement in bariatric surgery. *Surg Obes Relat Dis.* 2007;3:606-610.
118. Gargiulo NJ 3rd, Veith FJ, Lipsitz EC, et al. Experience with inferior vena cava filter placement in patients undergoing open gastric bypass procedures. *J Vasc Surg.* 2006;44:1301-1305.
119. Triquilio-Black CM, Ringley CD, McBride CL, et al. Inferior vena cava filter placement for pulmonary embolism risk reduction in super morbidly obese undergoing bariatric surgery. *Surg Obes Relat Dis.* 2007;3:461-464.
120. Piano G, Ketteler ER, Prachand V, et al. Safety, feasibility, and outcome of retrievable vena cava filters in high-risk surgical patients. *J Vasc Surg.* 2007;45:784-788.
121. Halmi D, Kolesnikov E. Preoperative placement of retrievable inferior vena cava filters in bariatric surgery. *Surg Obes Relat Dis.* 2007;3:602-605.
122. Anderson FA Jr, Hirsh J, White K, et al; Hip and Knee Registry Investigators. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. *Chest.* 2003;124(6 Suppl):349S-356S.
123. Seagroatt V, Tan HS, Goldacre M. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. *BMJ.* 1991;303:1431-1435.
124. Turpie AGG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. *Arch Intern Med.* 2002;162:1833-1840.
125. Warwick DJ, Whitehouse S. Symptomatic venous thromboembolism after total knee replacement. *J Bone Joint Surg Br.* 1997;78:780-786.
126. Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. *Acta Orthop Scand.* 2000;71:47-50.
127. Anderson DR, Wilson SJ, Blundell J, et al. Comparison of a nomogram and physician-adjusted dosage of warfarin for prophylaxis against deep-vein thrombosis after arthroplasty. *J Bone Joint Surg Am.* 2002;84:1992-1997.
128. Austin MS, Parvizi J, Grossman S, et al. The inferior vena cava filter is effective in preventing fatal pulmonary embolus after hip and knee arthroplasties. *J Arthroplasty.* 2007;22:343-348.
129. Golueke PJ, Garrett WV, Thompson JE, et al. Interruption of the vena cava by means of the Greenfield filter: expanding the indications. *Surgery.* 1988;103:111-117.
130. Vaughn BK, Knezevich S, Lombardi AV Jr, et al. Use of the Greenfield filter to prevent fatal pulmonary embolism associated with total hip and knee arthroplasty. *J Bone Joint Surg Am.* 1989;71:1542.
131. Strauss EJ, Egol KA, Alaia M, et al. The use of retrievable inferior vena cava filter in orthopaedic patients. *J Bone Joint Surg Br.* 2008;90:662-667.
132. Krauth D, Holden A, Knapic N, et al. Safety and efficacy of long-term oral anticoagulation in cancer patients. *Cancer.* 1987;59:983-985.
133. Gitter MJ, Jaeger TM, Petterson TM, et al. Bleeding and thromboembolism during anticoagulant therapy: a population

- based study in Rochester, Minnesota. *Mayo Clin Proc.* 1995;70:725-733.
134. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. *Blood.* 2002;100:3484-3488.
  135. Lin J, Proctor MC, Varma M, et al. Factors associated with recurrent venous thromboembolism in patients with malignant disease. *J Vasc Surg.* 2003;37:976-983.
  136. Moore FD, Osteen RT, Karp DD, et al. Anticoagulants, venous thromboembolism, and the cancer patient. *Arch Surg.* 1981;116:405-407.
  137. Calligaro KD, Bergen WS, Haut MJ, et al. Thromboembolic complications in patients with advanced cancer: anticoagulation versus Greenfield filter placement. *Ann Vasc Surg.* 1991;5:186-189.
  138. Greenfield LJ, Proctor MC, Saluja A. Clinical results of Greenfield filter use in patients with cancer. *Cardiovasc Surg.* 1997;5:145-149.
  139. Cohen JR, Tenenbaum N, Citron M. Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. *Surgery.* 1991;109:12-15.
  140. Levine M, Hirsh J. The diagnosis and treatment of thrombosis in the cancer patient. *Semin Oncol.* 1990;17:160-171.
  141. Wallace MJ, Jean JL, Gupta S, et al. Use of vena caval filters and survival in patients with malignancy. *Cancer.* 2004;101:1902-1907.
  142. Sarasin FP, Eckman MH. Management and prevention of thromboembolic events in patients with cancer-related hypercoagulable states: a risky business. *J Gen Intern Med.* 1993;8:476-486.
  143. Marcy PY, Magne N, Gallard JC, et al. Cost-benefit assessment of inferior vena cava filter placement in advanced cancer patients. *Support Care Cancer.* 2002;10:76-80.
  144. Chau Q, Cantor SB, Caramel E, et al. Cost-effectiveness of the bird's nest filter for preventing pulmonary embolism among patients with malignant brain tumors and deep thrombosis of the lower extremities. *Support Care Cancer.* 2003;11:795-799.
  145. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. *Cancer.* 1994;73:493-498.
  146. Cohen JR, Grella L, Citron M. Greenfield filter instead of heparin as primary treatment for deep venous thrombosis or pulmonary embolism in patients with cancer. *Cancer.* 1992;70:1993-1996.
  147. Olin JW, Young JR, Graor RA, et al. Treatment of deep venous thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. *Arch Intern Med.* 1987;147:2177-2179.
  148. Inhat DM, Mills JL, Hughes JD, et al. Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine? *J Vasc Surg.* 1998;28:800-807.
  149. Jarrett BP, Dougherty MJ, Calligaro KD. Inferior vena cava filters in malignant disease. *J Vasc Surg.* 2002;36:704-707.
  150. Nicolaides A, Irving D, Pretzell M, et al. The risk of deep-vein thrombosis in surgical patients. *Br J Surg.* 1973;60:312.
  151. Wille-Jorgensen P, Ott P. Predicting failure of low-dose heparin in general surgical procedures. *Surg Gynecol Obstet.* 1990;171:126-130.
  152. Huber O, Bounameaux H, Borst F, et al. Postoperative pulmonary embolism after hospital discharge: an underestimated risk. *Arch Surg.* 1992;127:310-313.
  153. Flordal PA, Bergqvist D, Burmark US, et al. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. *Eur J Surg.* 1996;162:783-789.
  154. Mamdani MM, Weingarten CM, Stevenson JG. Thromboembolic prophylaxis in moderate-risk patients undergoing selective abdominal surgery: decision and cost-effectiveness analyses. *Pharmacotherapy.* 1996;16:1111-1127.
  155. Scurr JH, Coleridge-Smith PD, Hasty JH. Deep venous thrombosis: a continuing problem. *BMJ.* 1988;297:28.
  156. Seddighzadeh A, Zurawska U, Shetty R, et al. Venous thromboembolism in patients undergoing surgery: low rates of prophylaxis and high rates of filter insertion. *Thromb Haemost.* 2007;98:1220-1225.



157. Krivak TC, Zorn KK. Venous thromboembolism in obstetrics gynecology. *Obstet Gynecol.* 2007;109:761-777.
158. Matchett WJ, Jones MP, McFarland DR, et al. Suprarenal vena caval filter placement: follow-up of four filter types in 22 patients. *J Vasc Interv Radiol.* 1998;9:588-593.
159. AbuRahma AF, Mullins DA. Endovascular caval interruption in pregnant patients with deep vein thrombosis of the lower extremity. *J Vasc Surg.* 2001;33:375-378.
160. Bovyn G, Ricco JB, Reynaud P, et al. Long-duration temporary vena cava filter: a prospective 104-case multicenter study. *J Vasc Surg.* 2006;43:1222-1229.
161. Köcher M, Krcova V, Cerna M, et al. Retrievable Günther Tulip vena cava filter in the prevention of pulmonary embolism in patients with acute deep venous thrombosis in perinatal period. *Eur J Radiol.* 2009;70:165-169.
162. Gayer G, Luboshitz J, Hertz M, et al. Congenital anomalies of the inferior vena cava revealed on CT in patients with deep vein thrombosis. *AJR Am J Roentgenol.* 2004;180:729-732.
163. Artico M, Lorenzini D, Mancini P, et al. Radiological evidence of anatomical variation of the inferior vena cava: report of two cases. *Surg Radiol Anat.* 2004;26:153-156.
164. Bass JE, Redwine MD, Kramer LA, et al. Spectrum of congenital anomalies of the inferior vena cava: cross-sectional imaging findings. *Radiographics.* 2000;20:639-652.
165. Rohrer MJ, Cutler BS. Placement of two Greenfield filters in a duplicated vena cava. *Surgery.* 1988;104:572-574.
166. Yilmaz E, Guleu A, Sal S, et al. Interruption of the inferior vena cava with azygos/hemiazygos continuation accompanied by distinct renal vein anomalies: MRA and CT assessment. *Abdom Imaging.* 2003;28:392-394.
167. Cho BC, Choi HJ, Kang SM, et al. Congenital absence of inferior vena cava as a rare cause of pulmonary thromboembolism. *Yonsei Med J.* 2004;45:947-951.
168. Tanju S, Dusunceli E, Sancak T. Placement of an inferior vena cava filter in a patient with azygos continuation complicated by pulmonary embolism. *Cardiovasc Intervent Radiol.* 2006;29:681-684.
169. Ray CE, Kaufman JA Jr. Complications of inferior vena cava filters. *Abdom Imaging.* 1996;21:368-374.
170. Streiff MB. Vena cava filters: a review for intensive care specialists. *J Intensive Care Med.* 2003;18:59-79.
171. Mohan CR, Hoballah JJ, Sharp WJ, et al. Comparative efficacy and complications of vena cava filters. *J Vasc Surg.* 1995;21:235-245.
172. Matchett WJ, Jones MP, McFarland DR, et al. Suprarenal vena caval filter placement: follow-up of four filter types in 22 patients. *J Vasc Interv Radiol.* 1998;9:588-593.
173. Greenfield LJ, Proctor MC. Suprarenal filter placement. *J Vasc Surg.* 1998;28:432-438.
174. Nunn C, Neuzil D, Naslund T, et al. Cost-effective method for bedside insertion of vena cava filters in trauma patients. *J Trauma.* 1997;43:753-758.
175. Neuzil DF, Garrard CL, Berkman RA, et al. Duplex-directed vena cava filter placement (report of initial experience). *Surgery.* 1998;123:470-474.
176. Ebaugh JL, Chiou AC, Morasch MD, et al. Bedside vena cava filter placement guided with intravascular ultrasound. *J Vasc Surg.* 2001;34:21-26.
177. Oppat WF, Chiou AC, Matsumura JS. Intravascular ultrasound-guided vena cava filter placement. *J Endovasc Surg.* 1999;6:285-287.
178. Stearley HE. Patients' outcomes: intrahospital transportation and monitoring of critically ill patients by a specially trained ICU nursing staff. *Am J Crit Care.* 1998;7:282-287.
179. Szem JW, Hydo LF, Fischer E, et al. High-risk intrahospital transport of critically ill patients: safety and outcome of the necessary "road trip." *Crit Care Med.* 1995;23:1660-1666.
180. Connors M, Becker S, Guzman R, et al. Duplex scan-directed placement of inferior vena cava filters: a five year institutional experience. *J Vasc Surg.* 2002;35:286-291.
181. Garrett J, Passman MA, Guzman RJ, et al. Expanding options for bedside placement of inferior vena cava filters with

- intravascular ultrasound when trans-abdominal duplex ultrasound imaging is inadequate. *Ann Vasc Surg.* 2004;18:329-334.
182. Corriere MA, Passman MA, Dattilo JB, et al. Comparison of bedside trans-abdominal duplex ultrasound versus contrast venography for inferior vena cava filter placement: what is the best imaging modality? *Ann Vasc Surg.* 2005;19:229-234.
  183. Corriere MC, Passman MA, Guzman RJ, et al. Retrieving “non-retrievable” inferior vena caval Greenfield filters: a therapeutic option for filter malpositioning. *Ann Vasc Surg.* 2004;18:629-634.
  184. Greenfield LJ. Technical considerations for insertion of vena caval filters. *Surg Gynecol Obstet.* 1979;148:422-426.
  185. Otchy DP, Elliott BM. The malpositioned Greenfield filter: lessons learned. *Am Surg.* 1987;53:580-583.
  186. Danetz JS, McLafferty RB, Ayerdi J, et al. Selective venography versus nonselective venography before vena cava filter placement: evidence for more, not less. *J Vasc Surg.* 2003;38:928-934.
  187. Hicks ME, Maiden ES, Vesely TM, et al. Prospective anatomic study of the inferior vena cava and renal veins: comparison of selective renal venography with cavography and relevance in filter placement. *J Vasc Interv Radiol.* 1995;6:721-729.
  188. Martin KD, Kempczinski RF, Fowl RJ. Are routine vena cavograms necessary before Greenfield filter placement? *Surgery.* 1989;106:647-651.
  189. Mejia EA, Saroyan RM, Balkin PW, et al. Analysis of inferior venacavography before Greenfield filter placement. *Ann Vasc Surg.* 1989;3:232-235.
  190. Passman MA, Dattilo JB, Guzman RJ, et al. Bedside placement of inferior vena cava filters by using transabdominal duplex ultrasonography and intravascular ultrasound imaging. *J Vasc Surg.* 2005;42:1027-1032.
  191. Jacobs DL, Motaganahalli RL, Peterson BG. Bedside vena cava filter placement with intravascular ultrasound: a simple, accurate, single venous access method. *J Vasc Surg.* 2007;46:1284-1286.
  192. Wellons ED, Rosenthal D, Shuler FW, et al. Real-time intravascular ultrasound-guided placement of a removable inferior vena cava filter. *J Trauma.* 2004;57:20-25.
  193. Rosenthal D, Wellons ED, Levitt AB, et al. Role of prophylactic temporary inferior vena cava filters placed at the ICU bedside under intravascular ultrasound guidance in patients with multiple trauma. *J Vasc Surg.* 2004;40:958-964.
  194. Burke CT, Dixon RG, Stavos JM. Use of rigid bronchoscopic forceps in the difficult retrieval of the Günther Tulip inferior vena cava filter. *J Vasc Interv Radiol.* 2007;18:1319-1323.
  195. Campbell CB, Chandler JG, Tegremeyer CJ, et al. Axillary, subclavian and brachiocephalic vein obstruction. *Surgery.* 1977;82:816-826.
  196. Kooij JD, van der Zant FM, van Beek EJ, et al. Pulmonary embolism in deep venous thrombosis of the upper extremity: more often in catheter-related thrombosis. *Neth J Med.* 1997;50:238-242.
  197. Hingorani A, Ascher E, Markevich N, et al. Risk factors for mortality in patients with upper extremity and internal jugular deep venous thrombosis. *Vasc Surg.* 2005;41:476-478.
  198. Horattas MC, Wright DJ, Fenton AH, et al. Changing concepts of deep venous thrombosis of the upper extremity: report of a series and review of the literature. *Surgery.* 1988;104:561-567.
  199. Monreal M, Lafoz E, Ruiz J, et al. Upper extremity deep venous thrombosis and pulmonary embolism: a prospective study. *Chest.* 1991;99:280-283.
  200. Langan MR Jr, Etheridge JC, Curte SL, et al. Experimental superior vena caval placement of the Greenfield filter. *J Vasc Surg.* 1985;2:794-798.
  201. Pais SO, De Orchis DF, Mirvis SE. Superior vena caval placement of Kimray-Greenfield filter. *Radiology.* 1987;165:385-386.
  202. Hirano Y, Kasashima F, Abe Y, et al. The use of a Greenfield filter to treat a pregnant woman for internal jugular venous thrombosis: report of a case. *Surg Today.* 2002;32:635-637.
  203. Kanda Y, Yamamoto R, Chizuka A, et al. Treatment of deep vein thrombosis using temporary vena caval filters after allogeneic bone marrow transplantation. *Leuk Lymphoma.* 2002;38:429-433.
  204. Owen EW Jr, Schoettle GP Jr, Harrington OB. Placement of a Greenfield filter in the superior vena cava. *Ann Thorac Surg.*

- 1992;53:896-897.
205. Nadkarni S, Macdonald S, Cleveland TJ, et al. Placement of a retrievable Günther Tulip filter in the superior vena cava for upper extremity deep venous thrombosis. *Cardiovasc Intervent Radiol*. 2002;25:524-526.
  206. Spence LD, Girona MG, Malde HM, et al. Acute upper extremity deep venous thrombosis: safety and effectiveness of superior vena caval filters. *Radiology*. 1999;210:53-58.
  207. Ascer E, Gennaro M, Lorenson E, et al. Superior vena caval Greenfield filter: indications, techniques, and results. *J Vasc Surg*. 1996;23:498-503.
  208. Ascher E, Hingorani A, Gade P, et al. Clinical experience with superior vena caval Greenfield filters. *J Endovasc Surg*. 1999;6:365-369.
  209. Rajan DK, Sniderman KW, Rubin BB. Retrieval of the Bard recovery filter from the superior vena cava. *J Vasc Interv Radiol*. 2004;15:1169-1171.
  210. Watanabe S, Shimokawa S, Shibuya H, et al. Superior vena caval placement of a temporary filter. *Vasc Surg*. 2001;35:59-62.
  211. Hussain SM, McLafferty RB, Schmittling ZC, et al. Superior vena cava perforation and cardiac tamponade after filter placement in the superior vena cava. *Vasc Endovasc Surg*. 2005;39:367-370.
  212. Beslic S, Dalagija F. Diagnosis of duplicate superior vena cava. *Med Arch*. 1996;50:95-97.
  213. Mir MA. Superior vena cava filters: hindsight, insight, foresight. *J Thromb Thrombolysis*. 2008;26:257-261.
  214. Meissner MH, Wakefield TW, Ascher E, et al. Proceedings of the International Summit of the 5th Pacific Vascular Symposium. Acute venous disease: venous thrombosis and venous trauma. *J Vasc Surg*. 2007;46:S25-S53.

## 第 53 章

1. Beebe-Dimmer JL, Pfeifer JR, Engle JS, et al. The epidemiology of chronic venous insufficiency and varicose veins. *Ann Epidemiol*. 2005;15:175-184.
2. McLafferty RB, Lohr JM, Caprini JA, et al. Results of the national pilot screening program for venous disease by the American Venous Forum. *J Vasc Surg*. 2007;45:142-148.
3. Cesarone MR, Belcaro G, Nicolaides AN, et al. Real epidemiology of varicose veins and chronic venous disease: the San Valentino Vascular Screening Project. *Angiology*. 2002;53:119-130.
4. Brand FN, Dannenberg AL, Abbott RD, et al. The epidemiology of varicose veins: the Framingham Study. *Am J Prev Med*. 1988;4:96-101.
5. Criqui MH, Jamosmos M, Fronck A, et al. Chronic venous disease in an ethnically diverse population: the San Diego Population Study. *Am J Epidemiol*. 2003;158:448-456.
6. Evans CJ, Fowkes FG, Ruckley CV, et al. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. *J Epidemiol Community Health*. 1999;53:149-153.
7. Ruckley CV, Evans CJ, Allan PL, et al. Chronic venous insufficiency: clinical and duplex correlations. The Edinburgh Vein Study of venous disorders in the general population. *J Vasc Surg*. 2002;36:520-525.
8. Jawien A. The influence of environmental factors in chronic venous insufficiency. *Angiology*. 2003;54:S19-S31.
9. Criqui MH, Denenberg JO, Bergan J, et al. Risk factors for chronic venous disease: the San Diego Population Study. *J Vasc Surg*. 2007;46:331-337.
10. Lacroix P, Aboyans V, Preux PM, et al. Epidemiology of venous insufficiency in an occupational population. *Int Angiol*. 2003;27:172-176.
11. Berard A, Abenhaim L, Platt R, et al. Risk factors for the first-time development of venous ulcers of the lower limbs: the influence of heredity and physical activity. *Angiology*. 2002;53:647-657.
12. Etufugh CN, Phillips TJ. Venous ulcers. *Clin Dermatol*. 2007;25:121-130.
13. Callam MJ, Harper DR, Dale JJ, et al. Chronic ulcer of the leg: clinical history. *BMJ*. 1987;294:1389-1391.

14. Scott TE, LaMorte WW, Gorin DR, et al. Risk factors for chronic venous insufficiency: a dual case-control study. *J Vasc Surg.* 1995;22:622-628.
15. DaSilva A, Navarro MF, Batalheiro J. The importance of chronic venous insufficiency: various preliminary data on its medico-social consequences. *Phlebologie.* 1992;45:439-443.
16. McGuckin M, Waterman R, Brooks J, et al. Validation of venous leg ulcer guidelines in the United States and United Kingdom. *Am J Surg.* 2002;183:132-137.
17. Ruckley CV. Socioeconomic impact of chronic venous insufficiency and leg ulcers. *Angiology.* 1997;48:67-69.
18. Burnand KG. The physiology and hemodynamics of chronic venous insufficiency of the lower limb. In: Gloviczki P, Yao JS, eds. *Handbook of Venous Disorders.* 2nd ed. New York: Arnold; 2001:49-57.
19. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. *Arch Intern Med.* 2004;164:17-26.
20. Delis KT, Husmann M, Kalodiki E, et al. In situ hemodynamics of perforating veins in chronic venous insufficiency. *J Vasc Surg.* 2001;33:773-782.
21. Labropoulos N, Mansour MA, Kang SS, et al. New insight into perforator vein incompetence. *Euro J Vasc Surg.* 1999;18:228-234.
22. Caggiati A, Rosi C, Heyen R, et al. Age-related variations of varicose veins anatomy. *J Vasc Surg.* 2006;44:1291-1295.
23. Carandina S, Mari C, De Palma M, et al. Varicose vein stripping vs haemodynamic correction (CHIVA): a long term randomised trial. *Eur J Vasc Endovasc Surg.* 2008;35:230-237.
24. Labropoulos N, Giannoukas AD, Delis K, et al. Where does venous reflux start? *J Vasc Surg.* 1997;26:736-742.
25. Labropoulos N, Kang SS, Mansour MA, et al. Primary superficial vein reflux with competent saphenous trunk. *Eur J Vasc Endovasc Surg.* 1999;18:201-206.
26. Neglón P, Thrasher TL, Raju S. Venous outflow obstruction: an underestimated contributor to chronic venous disease. *J Vasc Surg.* 2003;38:879-885.
27. Christopoulos D, Nicolaides AN, Cook A, et al. Pathogenesis of venous ulceration in relation to the muscle pump function. *Surgery.* 1989;106:829-835.
28. Araki CT, Back TL, Padberg FT, et al. The significance of calf muscle pump function in venous ulceration. *J Vasc Surg.* 1994;20:872-877.
29. Cornu-Thenard A, Boivin P, Baud MM, et al. Importance of the familial factor in varicose disease: clinical study of 134 families. *J Derm Surg Oncol.* 1994;20:318-326.
30. Brice G, Mansour S, Bell R, et al. Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. *J Med Genet.* 2002;39:478-483.
31. Ng MY, Andrew T, Spector TD, et al. Lymphoedema Consortium. Linkage to the FOXC2 region of chromosome 16 for varicose veins in otherwise healthy, unselected sibling pairs. *J Med Genet.* 2005;42:235-239.
32. Saiki S, Sakai K, Saiki M, et al. Varicose veins associated with CADASIL result from a novel mutation in the Notch3 gene. *Neurology.* 2006;67:337-339.
33. Lee S, Lee W, Choe Y, et al. Gene expression profiles in varicose veins using complementary DNA microarray. *Dermatol Surg.* 2005;31:391-395.
34. Dalal A, Phadke SR. Hemihyperplasia with Ehlers-Danlos syndrome like skin changes. *Clin Dysmorphol.* 2005;14:207-208.
35. Badauy CM, Gomes SS, Sant'ana Filho M, et al. Ehlers-Danlos Syndrome (EDS) type IV. Review of the literature. *Clin Oral Investig.* 2007;11:183-187.
36. McKusick VA. The defect in Marfan syndrome. *Nature.* 1991;352:279-281.
37. Zamboni P, Scapoli GL, Lanzara V, et al. Serum iron and matrix metalloproteinase-9 in limbs affected by chronic venous disease and venous leg ulcers. *Dermatol Surg.* 2005;31:644-649.

38. Zamboni P, Izzo M, Tognazzo S, et al. The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis. *Free Radic Biol Med*. 2006;40:1869-1873.
39. Zamboni P, De Mattei M, Ongaro A, et al. Factor XIII contrasts the effects of metalloproteinases in human dermal fibroblast cultured cells. *Vasc Endovasc Surg*. 2004;38:431-438.
40. Zamboni P, Tognazzo S, Izzo M, et al. Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. *J Vasc Surg*. 2005;42:309-314.
41. Tognazzo S, Gemmati D, Pallazzo A, et al. Prognostic role of factor XIII gene variants in nonhealing venous leg ulcers. *J Vasc Surg*. 2006;44:815-819.
42. Gemmati D, Tognazzo S, Catozzi L, et al. Influence of gene polymorphisms in ulcer healing process after superficial venous surgery. *J Vasc Surg*. 2006;44:554-562.
43. Gloviczki P, Stanson AW, Stikler GB, et al. Klippel-Trenaunay syndrome: the risks and benefits of vascular interventions. *Surgery*. 1991;110:469-479.
44. Noel AA, Gloviczki P, Cherry KJ, et al. Surgical treatment of venous malformations in Klippel-Trenaunay syndrome. *J Vasc Surg*. 2000;32:840-847.
45. Delis KT, Gloviczki P, Wennberg PW, et al. Hemodynamic impairment, venous segmental disease, and clinical severity scoring in limbs with Klippel-Trenaunay syndrome. *J Vasc Surg*. 2007;45:561-567.
46. Pappas PJ, Durán WN, Hobson RW. Pathology and cellular physiology of chronic venous insufficiency. In: Gloviczki P, Yao JS, eds. *Handbook of Venous Disorders*. 2nd ed. New York: Arnold; 2001:58-67.
47. Gschwandtner ME, Ehringer H. Microcirculation in chronic venous insufficiency. *Vascular Med*. 2001;6:169-179.
48. Burnand KG, Whimster I, Naidoo A, et al. Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and venous ulceration. *BMJ*. 1982;285:1071-1072.
49. Coleridge Smith PD, Thomas P, Scurr JH, et al. Causes of venous ulceration: a new hypothesis. *BMJ*. 1988;296:1726-1727.
50. Falanga V, Eaglstein WH. The "trap" hypothesis of venous ulceration. *Lancet*. 1993;341:1006-1008.
51. Eberhardt RT, Raffetto JD. Contemporary review in cardiovascular medicine. Chronic venous insufficiency. *Circulation*. 2005;111:2398-2409.
52. Bradbury A, Ruckley CV. Clinical assessment of patients with venous disease. In: Gloviczki P, Yao JS, eds. *Handbook of Venous Disorders*. 2nd ed. New York: Arnold; 2001:71-83.
53. Folse R, Alexander RH. Directional flow detection for the localizing venous valvular incompetence. *Surgery*. 1970;67:114-121.
54. Porter JM, Moneta GL. Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. *J Vasc Surg*. 1995;21:635-645.
55. Antignani PL, Cornu-Thénard A, Allegra C, et al for the European Working Group on Venous Classification under the Auspices of the International Union of Phlebology. Results of a questionnaire regarding improvement of 'C' in the CEAP classification. *Eur J Vasc Endovasc Surg*. 2004;28:177-181.
56. Carpentier PH, Cornu-Thénard A, Uhl JF, et al for the Société Française de Médecine Vasculaire; European Working Group on the Clinical Characterization of Venous Disorders. Appraisal of the information content of the C classes of CEAP clinical classification of chronic venous disorders: A multicenter evaluation of 872 patients. *J Vasc Surg*. 2003;37:827-833.
57. Eklöf B, Rutherford RB, Bergan JJ, et al for the American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. *J Vasc Surg*. 2004;40:1248-1252.
58. Rutherford RB, Padberg FT Jr, Comerota AJ, et al. Venous severity scoring: an adjunct to venous outcome assessment. *J Vasc Surg*. 2000;31:1307-1312.
59. Meissner MH, Natiello C, Nicholls SC. Performance characteristics of the venous clinical severity score. *J Vasc Surg*. 2002;36:889-895.

60. Kakkos SK, Rivera MA, Matsagas MI, et al. Validation of the new venous severity scoring system in varicose vein surgery. *J Vasc Surg.* 2003;38:224-228.
61. Vasquez MA, Wang J, Mahathanaruk M, et al. The utility of the Venous Clinical Severity Score in 682 limbs treated by radiofrequency saphenous vein ablation. *J Vasc Surg.* 2007;45:1008-1014.
62. Smith JJ, Garratt AM, Guest M, et al. Evaluating and improving health-related quality of life in patients with varicose veins. *J Vasc Surg.* 1999;30:710-719.
63. Davies A, Rudarakanchana N. Quality of life and outcome assessment in patients with varicose veins. In: Davies AH, Lees TA, Lane IF, eds. *Venous Disease Simplified*. Shrewsbury, Shropshire, England: TFM Publishing; 2006.
64. Launois R, Reboul-Marty J, Henry B. Construction and validation of a quality of life questionnaire in chronic lower limb venous insufficiency (CIVIQ). *Qual Life Res.* 1996;5:539-554.
65. Neglen P, Hollis K, Olivier J, et al. Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic results. *J Vasc Surg.* 2007;46:979-990.
66. Lamping DL, Schroter S, Kurz X, et al. Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. *J Vasc Surg.* 2003;37:410-419.
67. Kahn SR, M'lan CE, Lamping DL, et al for the VEINES Study Group. Relationship between clinical classification of chronic venous disease and patient-reported quality of life: results from an international cohort study. *J Vasc Surg.* 2004;39:823-828.
68. Kahn SR, Lamping DL, Ducruet T, et al for the VETO Study investigators. VEINES-QOL/Sym questionnaire was a reliable and valid disease-specific quality of life measure for deep venous thrombosis. *J Clin Epidemiol.* 2006;59:1049-1056.
69. Smith JJ, Guest MG, Greenhalgh RM, et al. Measuring the quality of life in patients with venous ulcers. *J Vasc Surg.* 2000;31:642-649.
70. Mattos MA, Sumner DS. Direct noninvasive tests (duplex scan) for the evaluation of chronic venous obstruction and valvular incompetence. In: Głowiczki P, Yao JS, eds. *Handbook of Venous Disorders*. 2nd ed. New York: Arnold; 2001:120-131.
71. Marston WA. PPG, APG, Duplex: Which noninvasive tests are most appropriate for the management of patients with chronic venous insufficiency? *Semin Vasc Surg.* 2002;15:13-20.
72. Markel A, Meissner MH, Manzo RA, et al. A comparison of the cuff deflation method with Valsalva's maneuver and limb compression in detecting venous valvular reflux. *Arch Surg.* 1994;129:701-705.
73. Labropoulos N, Tionson J, Pryor L, et al. Definition of venous reflux in the lower-extremity veins. *J Vasc Surg.* 2003;38:793-798.
74. Neglen P, Egger JF, Olivier J, Raju S. Hemodynamic and clinical impact of ultrasound-derived venous reflux parameters. *J Vasc Surg.* 2004;40:303-310.
75. Nicolaides AN, Miles C. Photoplethysmography in the assessment of venous insufficiency. *J Vasc Surg.* 1987;5:405-412.
76. Abramowitz HB, Queral LA, Finn WR, et al. The use of photoplethysmography in the assessment of venous insufficiency: a comparison to venous pressure measurements. *Surgery.* 1979;86:434-441.
77. Nicolaides AN. Investigation of chronic venous insufficiency: a consensus statement. *Circulation.* 2000;102:e126-e163.
78. Christopoulos D, Nicolaides AN, Szendro G. Venous reflux: quantification and correlation with clinical severity. *Br J Surg.* 1988;75:352-356.
79. Criado E, Farber MA, Marston WA, et al. The role of air plethysmography in the diagnosis of chronic venous insufficiency. *J Vasc Surg.* 1998;27:660-670.
80. Harada R, Katz M, Comerota A. A non-invasive screening test to detect "critical" deep venous reflux. *J Vasc Surg.* 1995;22:532-537.
81. Criado E, Daniel PF, Marston W, et al. Physiologic variation in lower extremity venous valvular function. *Ann Vasc Surg.*

- 1995;9:102-108.
82. Gillespie DL, Cordts PR, Hartono C, et al. The role of air plethysmography in monitoring results of venous surgery. *J Vasc Surg.* 1992;16:674-678.
  83. Owens LV, Farber MA, Young ML. The value of air plethysmography in predicting clinical outcome after surgical treatment of chronic venous insufficiency. *J Vasc Surg.* 2000;32:961-968.
  84. Meissner MH, Moneta G, Burnand K, et al. The hemodynamics and diagnosis of venous disease. *J Vasc Surg.* 2007;46:4S-24S.
  85. Danielsson G, Norgren L, Jungbeck C, et al. Global venous function correlates better than duplex derived reflux to clinical class in the evaluation of chronic venous disease. *Int Angiol.* 2003;22:177-181.
  86. Kistner RL, Kamida CB. 1994 update on phlebography and varicography. *Dermatol Surg.* 1995;21:71-76.
  87. Kamida CB, Kistner RL, Eklof B, et al. Lower extremity ascending and descending venography. In: Gloviczki P, Yao JS, eds. *Handbook of Venous Disorders*. 2nd ed. New York: Arnold; 2001:132-139.
  88. Masuda EM, Arfvidsson B, Eklof B, et al. Direct venous pressure: Role in the assessment of venous disease. In: Gloviczki P, Yao JS, eds. *Handbook of Venous Disorders*. 2nd ed. New York: Arnold; 2001:140-145.
  89. Nicolaides AN, Hussein MK, Szendro G, et al. The relation of venous ulceration with ambulatory venous pressure measurements. *J Vasc Surg.* 1993;17:414-419.
  90. Neglen P, Raju S. Ambulatory venous pressure revisited. *J Vasc Surg.* 2000;31:1206-1213.
  91. Fronek A, Kim R, Curran B. Non-invasively determined ambulatory venous pressure. *Vascular Med.* 2000;5:213-216.
  92. Neglen P, Raju S. Intravascular ultrasound scan evaluation of the obstructed vein. *J Vasc Surg.* 2002;35:694-700.
  93. Cullum N, Nelson EA, Fletcher AW, et al. Compression for venous leg ulcers. *Cochrane Database Syst Rev.* 2000;3:CD000265.
  94. Motykie GD, Caprini JA, Arcelus JI, et al. Evaluation of therapeutic compression stockings in the treatment of chronic venous insufficiency. *Dermatol Surg.* 1999;25:116-120.
  95. Nelson EA, Bell-Syer SE, Cullum NA. Compression for preventing recurrence of venous ulcers. *Cochrane Database Syst Rev.* 2000;4:CD002303.
  96. Mayberry JC, Moneta GL, Taylor LM, et al. Fifteen-year results of ambulatory compression therapy for chronic venous ulcers. *Surgery.* 1991;109:575-581.
  97. Ibegbuna V, Delis KT, Nicolaides AN, et al. Effect of elastic compression stockings on venous hemodynamics during walking. *J Vasc Surg.* 2003;37:420-425.
  98. Zajkowski PJ, Proctor MC, Wakefield TW, et al. Compression stockings and venous function. *Arch Surg.* 2002;137:1064-1068.
  99. Karlsmark T, Agerslev RH, Bendz SH, et al. Clinical performance of a new silver dressing, Contreet Foam, for chronic exuding venous leg ulcers. *J Wound Care.* 2003;12:351-354.
  100. Jones SA, Bowler PG, Walker M, et al. Controlling wound bioburden with a novel silver-containing Hydrofiber dressing. *Wound Repair Regen.* 2004;12:288-294.
  101. Colletta V, Dioguardi D, Di Lonardo A, et al. A trial to assess the efficacy and tolerability of Hyalofill-F in non-healing venous leg ulcers. *J Wound Care.* 2003;12:357-360.
  102. Jones KR, Fennie K, Lenihan A. Evidence-based management of chronic wounds. *Adv Skin Wound Care.* 2007;20:591-600.
  103. Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. *Wound Repair Regen.* 1999;7:201-217.
  104. Mostow EN, Haraway GD, Dalsing M, et al for the OASIS Venous Ulcer Study Group. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. *J Vasc Surg.* 2005;41:837-843.

105. Nicolaides AN. From symptoms to leg edema: efficacy of Daflon 500 mg. *Angiology*. 2003;54:S33-S44.
106. Vanscheidt W, Rabe E, Naser-Hijazi B, et al. The efficacy and safety of coumarin-troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomized study. *Vasa*. 2002;31:185-190.
107. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: A meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. *Eur J Vasc Endovasc Surg*. 2005;30:198-208.
108. Siebert U, Brach M, Sroczynski G, et al. Efficacy, routine effectiveness, and safety of horse chestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. *Int Angiol*. 2002;21:305-315.
109. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. *Cochrane Database Syst Rev*. 2004;2:CD003230.
110. Colgan M-P, Dormandy JA, Jones PW, et al. Oxpentifylline treatment of venous ulcers of the leg. *BMJ*. 1990;300:972-975.
111. Dale JJ, Ruckley CV, Harper DR, et al. Randomised, double blind placebo controlled trial of pentoxifylline in the treatment of venous leg ulcers. *BMJ*. 1999;319:875-878.
112. Falanga V, Fujitani RM, Diaz C, et al. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial. *Wound Repair Regen*. 1999;7:208-213.
113. Padberg FT, Johnston MV, Sisto SA. Structured exercise improves calf muscle pump function in chronic venous insufficiency: a randomized trial. *J Vasc Surg*. 2004;39:79-87.
114. Kahle B, Leng K. Efficacy of sclerotherapy in varicose veins: prospective, blinded, placebo-controlled study. *Dermatol Surg*. 2004;30:723-728.
115. Breu FX, Guggenbichler S. European consensus meeting on foam sclerotherapy, April 4-6, 2003, Tegernsee, Germany. *Dermatol Surg*. 2004;30:709-717.
116. Rabe E, Pannier-Fischer F, Gerlach H, et al for the German Society of Phlebology. Guidelines for sclerotherapy of varicose veins (ICD 10: I83.0, I83.1, I83.2, and I83.9). *Dermatol Surg*. 2004;30:687-693.
117. Bergan J, Pascarella L, Mekenas L. Venous disorders: treatment with sclerosant foam. *J Cardiovasc Surg (Torino)*. 2006;47:9-18.
118. Scultetus AH, Villavicencio JL, Kao TC, et al. Microthrombectomy reduces postsclerotherapy pigmentation: multicenter randomized trial. *J Vasc Surg*. 2003;38:896-903.
119. Merchant RF, Pichot O; Closure Study Group. Long-term outcomes of endovenous radiofrequency obliteration of saphenous reflux as a treatment for superficial venous insufficiency. *J Vasc Surg*. 2005;42:502-509.
120. Min RJ, Khilnani N, Zimmet SE. Endovenous laser treatment of saphenous vein reflux: long-term results. *J Vasc Interv Radiol*. 2003;14:991-996.
121. Kabnick LS. Outcome of different endovenous laser wavelengths for great saphenous vein ablation. *J Vasc Surg*. 2006;43:88-93.
122. Rasmussen LH, Bjoern L, Lawaetz M, et al. Randomized trial comparing endovenous laser ablation of the great saphenous vein with high ligation and stripping in patients with varicose veins: short-term results. *J Vasc Surg*. 2007;46:308-315.
123. Lurie F, Creton D, Eklof B, et al. Prospective randomised study of endovenous radiofrequency obliteration (closure) versus ligation and vein stripping (EVOLVEs): Two-year follow-up. *Eur J Vasc Endovasc Surg*. 2005;29:67-73.
124. Darwood RJ, Theivacumar N, Dellagrammaticas D, et al. Randomized clinical trial comparing endovenous laser ablation with surgery for the treatment of primary great saphenous varicose veins. *Br J Surg*. 2008;95:294-301.
125. Danza R, Navarro T, Baldizan J. Reconstructive surgery in chronic venous obstruction of the lower limbs. *J Cardiovasc Surg*. 1991;32:98-103.
126. Neglen P, Raju S. In-stent recurrent stenosis in stents placed in the lower extremity venous outflow tract. *J Vasc Surg*. 2004;39:181-188.
127. Sarin S, Scurr JH, Coleridge Smith PD. Stripping of the long saphenous vein in the treatment of primary varicose veins. *Br*



- J Surg.* 1994;81:1455-1458.
128. Aremu MA, Mahendran B, Butcher W, et al. Prospective randomised controlled trial: conventional versus powered phlebectomy. *J Vasc Surg.* 2004;39:88-94.
  129. Padberg FT Jr, Pappas PJ, Araki CT, et al. Hemodynamic and clinical improvement after superficial vein ablation in primary combined insufficiency with ulceration. *J Vasc Surg.* 1996;24:711-718.
  130. MacKenzie RK, Allan PL, Ruckley CV, et al. The effect of long saphenous vein stripping on deep venous reflux. *Eur J Vasc Endovasc Surg.* 2004;28:104-107.
  131. Barwell JR, Davies CE, Deacon J, et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomized controlled trial. *Lancet.* 2004;363:1854-1859.
  132. Gloviczki P, Bergan JJ, Rhodes JM, et al. Mid-term results of endoscopic perforator vein interruption for chronic venous insufficiency: lessons learned from the North American subfascial endoscopic perforator surgery registry. The North American Study Group. *J Vasc Surg.* 1999;29:489-502.
  133. Bianchi C, Ballard JL, Abou-Zamzam AM, et al. Subfascial endoscopic perforator vein surgery combined with saphenous vein ablation: results and critical analysis. *J Vasc Surg.* 2003;38:67-71.
  134. Tawes RL, Barron ML, Coello AA, et al. Optimal therapy for advanced chronic venous insufficiency. *J Vasc Surg.* 2003;37:545-551.
  135. Kistner RL. Surgical repair of the incompetent femoral vein valve. *Arch Surg.* 1975;110:1336-1342.
  136. Raju S, Berry MA, Neglen P. Transcommissural valvuloplasty: technique and results. *J Vasc Surg.* 2000;32:969-976.
  137. Neglen P, Raju S. Venous reflux repair with cryopreserved vein valves. *J Vasc Surg.* 2003;38:1139-1140.
  138. Dalsing MC, Raju S, Wakefield TW, et al. A multicenter, phase I evaluation of cryopreserved venous valve allografts for the treatment of chronic deep venous insufficiency. *J Vasc Surg.* 1999;30:854-864.
  139. Pavcnik D, Yin Q, Uchida B, et al. Percutaneous autologous venous valve transplantation: short-term feasibility study in an ovine model. *J Vasc Surg.* 2007;46:338-345.
  140. Maleti O, Lugli M. Neovalve construction in postthrombotic syndrome. *J Vasc Surg.* 2006;43:794-799.

## 第 54 章

1. Ludbrook J. *Aspects of Venous Function in the Lower Limbs*. Springfield, IL: Charles C Thomas; 1966.
2. Partsch B, Partsch H. Calf compression pressure required to achieve venous closure from supine to standing positions. *J Vasc Surg.* 2005;42:734-738.
3. Thomas S, Fram P. An evaluation of a new type of compression bandaging system. Available from <<http://www.worldwidewounds.com/2003>>; (online version in World Wide Wounds).
4. Delis KT, Azizi ZA, Stevens RJ, et al. Optimum intermittent pneumatic compression stimulus for lower-limb venous emptying. *Eur J Vasc Endovasc Surg.* 2000;19:261-269.
5. Abenhaim L, Clement D, Norgren L, et al. The management of chronic venous disorders of the leg: an evidence-based report of an international task force. *Phlebology.* 1999;14(Suppl 1):1-126.
6. Partsch H, Menzinger G, Mostbeck A. Inelastic leg compression is more effective to reduce deep venous refluxes than elastic bandages. *Dermatol Surg.* 1999;25:695-700.
7. Partsch H. Improvement of venous pumping function in chronic venous insufficiency by compression depending on pressure and material. *Vasa.* 1984;13:58-64.
8. Partsch H, Clark M, Bassez S, et al. Measurement of lower leg compression in vivo: recommendations for the performance of measurements of interface pressure and stiffness. *Dermatol Surg.* 2006;32:229-238.
9. Nehler MR, Moneta GL, Woodard DM, et al. Perimalleolar subcutaneous tissue pressure effects of elastic compression stockings. *J Vasc Surg.* 1993;18:783-788.
10. Nehler MR, Moneta GL, Porter JM. The lower extremity venous system. Part II: The pathophysiology of chronic venous

- insufficiency. *Perspect Vasc Surg.* 1992;5:81-97.
11. Murphy MA, Joyce WP, Condrón C, et al. A reduction in serum cytokine levels parallels healing of venous ulcers in patients undergoing compression therapy. *Eur J Vasc Endovasc Surg.* 2002;23:349-352.
  12. Humphreys ML, Stewart AHR, Gohel MS, et al. Management of mixed arterial and venous leg ulcers. *Br J Surg.* 2007;94:1104-1107.
  13. Callum MJ, Ruckley CV, Dale JJ, et al. Hazards of compression treatment of the leg: an estimate from Scottish surgeons. *Br Med J (Clin Res Ed).* 1987;295:1382.
  14. Mayberry JC, Moneta GL, Taylor LM Jr, et al. Fifteen-year results of ambulatory compression therapy for chronic venous ulcers. *Surgery.* 1991;109:575-581.
  15. Motykie GD, Caprini JA, Arcelus JJ, et al. Evaluation of therapeutic compression stockings in the treatment of chronic venous insufficiency. *Dermatol Surg.* 1999;25:116-120.
  16. Franks PJ, Oldroyd MI, Dickson D, et al. Risk factors for leg ulcer recurrence: a randomized trial of two types of compression stockings. *Age Aging.* 1994;24:490-494.
  17. Korn P, Patel ST, Heller JA, et al. Why insurers should reimburse for compression stockings in patients with chronic venous stasis. *J Vasc Surg.* 2002;35:950-957.
  18. Lippmann HI, Fishman LM, Farrar RH, et al. Edema control in the management of disabling chronic venous insufficiency. *Arch Phys Med Rehabil.* 1994;75:436-441.
  19. Rubin JR, Alexander J, Plecha EJ, et al. Unna's boot vs. polyurethane foam dressings for the treatment of venous ulceration. *Arch Surg.* 1990;125:489-493.
  20. Partsch H, Clark M, Mosti G, et al. Classification of compression bandages: practical aspects. *Dermatol Surg.* 2008;34:600-609.
  21. Partsch H, Partsch B, Braun W. Interface pressure and stiffness of ready made compression stockings: comparison of in vivo and in vitro measurements. *J Vasc Surg.* 2006;44:809-814.
  22. Partsch H. The static stiffness index: a simple method to assess the elastic property of compression material in vivo. *Dermatol Surg.* 2005;31:625-630.
  23. Cullum N, Nelson EA, Fletcher AW, et al. Compression for venous leg ulcers. *Cochrane Database Syst Rev.* 2002;2:CD000265.
  24. Blair SD, Wright DD, Backhouse LM, et al. Sustained compression and healing of chronic venous ulcers. *BMJ.* 1988;297:1159-1161.
  25. Meyer FJ, Burnand KG, Lagattolla RF, et al. Randomized clinical trial comparing the efficacy of two bandaging regimens in the treatment of venous leg ulcers. *Br J Surg.* 2002;89:40-44.
  26. Nelson EA, Iglesias CP, Cullum N, et al. Randomized clinical trial of four-layer and short-stretch compression bandages for venous leg ulcers (VenUS I). *Br J Surg.* 2004;91:1292-1299.
  27. Milic DJ, Zivic SS, Bogdanovic DC, et al. A randomized trial of the Tubulcus multilayer bandaging system in the treatment of extensive venous ulcers. *J Vasc Surg.* 2007;46:750-755.
  28. Spence RK, Cahall E. Inelastic versus elastic compression in chronic venous insufficiency: a comparison of limb size and venous hemodynamics. *J Vasc Surg.* 1996;24:783-787.
  29. Pekkanmaki K, Kolarí PJ, Kiistala U. Intermittent pneumatic compression treatment for postthrombotic leg ulcers. *Clin Exp Dermatol.* 1987;12:350-356.
  30. Coleridge-Smith P, Sarin S, Hasty J, et al. Sequential gradient pneumatic compression enhances venous ulcer healing: a randomized trial. *Surgery.* 1990;108:871-877.
  31. Fletcher A, Cullum N, Sheldon TA. A systematic review of compression treatment for venous leg ulcers. *BMJ.* 1997;315:576-580.
  32. Palfreyman S, Nelson EA, Michaels JA. Dressings for venous leg ulcers: systematic review and meta-analysis. *BMJ.*

- 2007;335:7613-7617.
33. Zamboni P, Ciso C, Marchetti F, et al. Minimally invasive surgical management of primary venous ulcers vs. compression treatment: a randomized clinical trial. *Eur J Vasc Endovasc Surg*. 2003;25:313-318.
  34. Guest M, Smith JJ, Tripuraneni G, et al. Randomized clinical trial of varicose vein surgery with compression versus compression alone for the treatment of venous ulceration. *Phlebology*. 2003;18:130-136.
  35. Gohel MS, Barwell JR, Earnshaw JJ, et al. Randomized trial of compression plus surgery versus compression alone in chronic venous ulceration (ESCHAR study)—haemodynamic and anatomical changes. *Br J Surg*. 2005;92:291-297.
  36. Gohel MS, Barwell JR, Earnshaw JJ, et al. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR study): randomized controlled trial. *BMJ*. 2007;335:55-56.
  37. Uber A. The socioeconomic profile of patients treated by phlebotropic drugs in Germany. *Angiology*. 1997;48:595-607.
  38. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. *Clin Hemorheol Microcirc*. 2005;33:309-319.
  39. Martinez MJ, Bonfill X, Moreno RM, et al. Phlebotonics for venous insufficiency. *Cochrane Database Syst Rev*. 2005;3:CD003229.
  40. Graves MW, Boyde TR. Plasma zinc concentrations in patients with psoriasis, other dermatoses, and venous leg ulceration. *Lancet*. 1967;2:1019-1020.
  41. Withers AF, Baker H, Musa M, et al. Plasma zinc in psoriasis. *Lancet*. 1968;2:278.
  42. Hallbook T, Lanner E. Serum-zinc and healing of venous leg ulcers. *Lancet*. 1972;2:780-782.
  43. Myers MB, Cherry G. Zinc and the healing of chronic ulcers. *Am J Surg*. 1970;120:77-81.
  44. Phillips A, Davidson M, Greaves MW. Venous leg ulceration: evaluation of zinc treatment, serum zinc and rate of healing. *Clin Exp Dermatol*. 1977;2:395-399.
  45. Burnand K, Lemenson G, Morland M, et al. Venous lipodermatosclerosis: treatment by fibrinolytic enhancement and elastic compression. *BMJ*. 1980;280:7-11.
  46. McMullin GM, Watkin GT, Coleridge Smith PD, et al. The efficacy of fibrinolytic enhancement with stanazolol in the treatment of venous insufficiency. *Aust N Z J Surg*. 1991;61:306-309.
  47. Layer GT, Stacey MC, Burnand KG. Stanazolol and the treatment of venous ulceration—an interim report. *Phlebology*. 1986;1:197-203.
  48. Colgan M, Dormandy JA, Jones PW, et al. Oxpentifylline treatment of venous ulcers of the leg. *BMJ*. 1990;300:972-975.
  49. Ramelet A-A. Daflon 500mg: symptoms and edema clinical update. *Angiology*. 2005;56:S25-S32.
  50. Balmer A, Limoni C. Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients. *Vasa*. 1980;9:76-86.
  51. Jantet G, the RELIEF Study Group. Chronic venous insufficiency: worldwide results of the RELIEF study. *Angiology*. 2002;53:245-256.
  52. Pulvertaft TB. General practice treatment of symptoms of venous insufficiency with oxyretins. Results of a 660 patient multicentre study in the UK. *Vasa*. 1983;12:373-376.
  53. Mann RJ. A double-blind trial of oral O. B-hydroxyethyl rutosides for stasis leg ulcers. *Br J Clin Pract*. 1981;35:79-81.
  54. Coleridge-Smith P, Lok C, Ramelet A-A. Venous leg ulcer: a meta analysis of adjunctive therapy with MPFF. *Eur J Vasc Endovasc Surg*. 2005;30:198-208.
  55. Casley-Smith JR, Casley-Smith JR. The effects of calcium dobesilate on acute lymphoedema (with and without macrophages) and on burn edema. *Lymphology*. 1985;18:37-45.
  56. Casley-Smith JR. The effect of variations in tissue protein concentration and tissue hydrostatic pressure on fluid and protein uptake by the initial lymphatics, and the action of calcium dobesilate. *Microcirc Endothelium Lymphatics*. 1985;2:385-415.
  57. Casley-Smith JR. A double-blind trial of calcium dobesilate in chronic venous insufficiency. *Angiology*. 1988;39:853-857.
  58. Martinez-Zapata MJ, Moreno RM, Gich I, et al. A randomized double-blind multicentre clinical trial comparing the efficacy

- of calcium dobesilate with placebo in the treatment of chronic venous disease. *Eur J Vasc Endovasc Surg*. 2007;35:358-365.
59. Sullivan GW, Carper HT, Novick WJ Jr, et al. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. *Infect Immunol*. 1988;56:1722-1729.
  60. Jull A, Waters J, Arroll B. Pentifylline for treatment of venous leg ulcers: a systematic review. *Lancet*. 2002;359:1550-1554.
  61. Layton AM, Ibbotson SH, Davies JA, et al. The effect of oral aspirin in the treatment of chronic venous leg ulcers. *Lancet*. 1994;344:164-165.
  62. Ibbotson SH, Layton AM, Davies JA, et al. The effect of aspirin on haemostatic activity in the treatment of chronic venous leg ulceration. *Br J Dermatol*. 1995;132:422-426.
  63. Sinzinger H, Virgolini I, Fitscha P. Pathomechanisms of atherosclerosis beneficially affected by prostaglandin E<sub>1</sub> (PGE<sub>1</sub>)—an update. *Vasa Suppl*. 1989;28:6-13.
  64. Rudofsky G. Intravenous prostaglandin E<sub>1</sub> in the treatment of venous ulcers—a double-blind, placebo controlled trial. *Vasa Suppl*. 1989;28:39-43.
  65. Diehm C, Trampisch HJ, Lange S, et al. Comparison of leg compression stocking and oral horse-chestnut seed extract in patients with chronic venous insufficiency. *Lancet*. 1996;347:292-294.
  66. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. *Cochrane Database Syst Rev*. 2006;1:CD003230.
  67. Gilchrist B, Reed C. The bacteriology of chronic venous ulcers treated with occlusive hydrocolloid dressings. *Br J Dermatol*. 1989;121:337-344.
  68. Lineaweaver W, Howard R, Souey D, et al. Topical antimicrobial toxicity. *Arch Surg*. 1985;120:267-270.
  69. Roelens P. Double-blind placebo-controlled study with topical 2% ketanserin ointment in the treatment of venous ulcers. *Dermatologica*. 1989;178:98-102.
  70. Alvarez OM, Mertz PM, Eaglstein WH. The effect of occlusive dressings on collagen synthesis and re-epithelialization in superficial wounds. *J Surg Res*. 1983;35:142-148.
  71. Kitka MJ, Schuler JJ, Meyer JP, et al. A prospective, randomized trial of Unna's boots versus hydroactive dressing in the treatment of venous stasis ulcers. *J Vasc Surg*. 1988;7:478-483.
  72. Wilkins LM, Watson SR, Prosky SJ, et al. Development of a bilayered living skin construct for clinical applications. *Biotechnol Bioeng*. 1994;43:747-756.
  73. Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogenic cultured human skin equivalent. *Arch Dermatol*. 1998;134:293-302.

## 第 55 章

1. Brand FN, Dannenberg AL, Abbott RD, Kannel WB. The epidemiology of varicose veins: the Framingham Study. *Am J Prev Med*. 1988;4:96-101.
2. Trendelenburg F. Über Die Unterbindung der Vena Saphena Magna bei Unterschenkelvaricen. *Berl Klin Chir*. 1890;7:195.
3. Moore W. The operative treatment of varicose veins: a special reference to a modification of the Trendelenburg operation. *Intercolonial Med J Aust*. 1896;1:393.
4. Homans J. The operative treatment of varicose veins and ulcers based upon a classification of these lesions. *Surg Gynecol Obstet*. 1916;22:143.
5. Mayo C. The surgical treatment of varicose veins. *Saint Paul Med J*. 1904;6:695.
6. Mayo C. Treatment of varicose veins. *Surg Gynecol Obstet*. 1906;2:385.
7. Babcock W. A new operation for the extripation of varicose veins of the legs. *N Y Med J*. 1907;86:153.
8. Survey NH. 1935-1936 Washington DC. US Department of Health, Education & Welfare, 1938.
9. Logan W, Brooke E. Studies in medical population subjects #12. The Survey of Sickness General Register Office, 1957.
10. The sickness survey of Denmark, Copenhagen. The committee on national morbidity survey. 1960.

11. Allan PL, Bradbury AW, Evans CJ, et al. Patterns of reflux and severity of varicose veins in the general population—Edinburgh Vein Study. *Eur J Vasc Endovasc Surg*. 2000;20:470-477.
12. White G. Chronic venous insufficiency. In: Hobson RW, Veith F, eds. *Vascular Surgery*. New York, NY: McGraw Hill; 1993.
13. Callam M. Epidemiology of varicose veins. *Br J Surg*. 1994;81:167-173.
14. Lin JC, Iafrati MD, O'Donnell TF Jr, et al. Correlation of duplex ultrasound scanning-derived valve closure time and clinical classification in patients with small saphenous vein reflux: is lesser saphenous vein truly lesser? *J Vasc Surg*. 2004;39:1053-1058.
15. Myers KA, Ziegenbein RW, Zeng GH, Matthews PG. Duplex ultrasonography scanning for chronic venous disease: patterns of venous reflux. *J Vasc Surg*. 1995;21:605-612.
16. Labropoulos N, Delis K, Nicolaides AN, et al. The role of the distribution and anatomic extent of reflux in the development of signs and symptoms in chronic venous insufficiency. *J Vasc Surg*. 1996;23:504-510.
17. Labropoulos N, Giannoukas AD, Delis K, et al. The impact of isolated lesser saphenous vein system incompetence on clinical signs and symptoms of chronic venous disease. *J Vasc Surg*. 2000;32:954-960.
18. Ruckley CV, Evans CJ, Allan PL, et al. Chronic venous insufficiency: clinical and duplex correlations. The Edinburgh Vein Study of venous disorders in the general population. *J Vasc Surg*. 2002;36:520-525.
19. Crotty T. The roles of turbulence and vasorum in the aetiology of varicose veins. *Med Hypotheses*. 1991;34:41-48.
20. Rose SS, Ahmed A. Some thoughts on the aetiology of varicose veins. *J Cardiovasc Surg (Torino)*. 1986;27:534-543.
21. Ludbrook J. Valvular defect in primary varicose veins: cause or effect? *Lancet*. 1963;2:1289-1292.
22. Varicose veins: pathology. In: Browse NL, Burnand KG, Thomas ML, eds. *Diseases of the Veins*. London: Edward Arnold, a division of Hodder & Stoughton; 1988:151-165.
23. Labropoulos N, Giannoukas AD, Delis K, et al. Where does venous reflux start? *J Vasc Surg*. 1997;26:736-742.
24. Psaila JV, Melhuish J. Viscoelastic properties and collagen content of the long saphenous vein in normal and varicose veins. *Br J Surg*. 1989;76:37-40.
25. Reporting standards in venous disease. Prepared by the Subcommittee on Reporting Standards in Venous Disease, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery. *J Vasc Surg*. 1988;8:172-181.
26. Eklöf B, Rutherford RB, Bergan JJ, et al., for the American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. *J Vasc Surg*. 2004;40:1248-1252.
27. Caggiati A, Bergan JJ, Gloviczki P, et al., for the International Interdisciplinary Consensus Committee on Venous Anatomical Terminology. Nomenclature of the veins of the lower limbs: An international interdisciplinary consensus statement. *J Vasc Surg*. 2002;36:416-422.
28. Donald T, Steed SA. Chronic venous insufficiency. In: Jarret F, Hirsh S, eds. *Vascular Surgery of the Lower Extremities*. St. Louis, MO: CV Mosby; 1985.
29. O'Donnell TF Jr, Burnand KG, Clemenson G, et al. Doppler examination vs clinical and phlebographic detection of the location of incompetent perforating veins: a prospective study. *Arch Surg*. 1977;112:31-35.
30. Padberg FT. Classification and clinical and diagnostic evaluation of patients with chronic venous disorders. In: Rutherford RB, ed. *Vascular Surgery*. 6th ed. Philadelphia, PA: Elsevier Saunders; 2005:2230.
31. DePalma RGR, Menawat SS, Bergan JJ. Treatment of varicosities of the saphenous origin: a dialogue. In: Goldman MP, Weiss RA, Bergan JJ, eds. *In Varicose Veins and Telangiectases: Diagnosis and Treatment*. St. Louis, MO: Quality Medical Publishing; 1993:166-188.
32. van Bemmelen PS, Bedford G, Beach K, Strandness DE. Quantitative segmental evaluation of venous valvular reflux with duplex ultrasound scanning. *J Vasc Surg*. 1989;10:425-431.

33. Nicolaides AN, Miles C. Photoplethysmography in the assessment of venous insufficiency. *J Vasc Surg.* 1987;5:405-412.
34. Fernandes JF, Horner J, Needham T, Nicolaides A. Ambulatory calf volume plethysmography in the assessment of venous insufficiency. *Br J Surg.* 1979;66:327-330.
35. Abramowitz HB, Queral LA, Finn WR, et al. The use of photoplethysmography in the assessment of venous insufficiency: a comparison to venous pressure measurements. *Surgery.* 1979;86:434-441.
36. Christopoulos D, Nicolaides AN, Galloway JM, Wilkinson A. Objective noninvasive evaluation of venous surgical results. *J Vasc Surg.* 1988;8:683-687.
37. Sarin S, Shields DA, Scurr JH, et al. Photoplethysmography: a valuable noninvasive tool in the assessment of venous dysfunction? *J Vasc Surg.* 1992;16:154-162.
38. Goren G, Yellin AE. Primary varicose veins: topographic and hemodynamic correlations. *J Cardiovasc Surg (Torino).* 1990;31:672-677.
39. Hanrahan LM, Kechejian GJ, Cordts PR, et al. Patterns of venous insufficiency in patients with varicose veins. *Arch Surg.* 1991;126:687-690; discussion 690-691.
40. Callam MJ. Epidemiology of varicose veins. *Br J Surg.* 1994;81:167-173.
41. Cullum N, North EA, Fletcher AW, Sheldon TA. Compression for venous leg ulcers. *Cochrane Database Syst Rev.* 2001;2:CD000265.
42. Kupinski AM, Evans SM, Khan AM, et al. Ultrasonic characterization of the saphenous vein. *Cardiovasc Surg.* 1993;1:513-517.
43. Hobbs JT, Vandendriessche MAW. Perioperative venography to ensure accurate sapheno-popliteal vein ligation. *Br Med J.* 1980;280:1578-1579.
44. Kosinski C. Observations on the superficial venous system of the lower extremity. *J Anat.* 1926;60:131-142.
45. Hobbs JTV, Vandendriessche MAW. Incompetence of the gastrocnemius vein. *Phlebology.* 2004;19:57-64.
46. Gillet JL, Perrin M, Hiltbrand B, et al. Pre- and postoperative contribution of Doppler ultrasonography in superficial venous surgery of the popliteal fossa. *J Mal Vasc.* 1997;22:330-335.
47. Delis KT, Knaggs AL, Khodabakhsh P. Prevalence, anatomic patterns, valvular competence, and clinical significance of the Giacomini vein. *J Vasc Surg.* 2004;40:1174-1183.
48. Zierau UT, Kullmer A, Kunkel HP. Stripping the Giacomini vein—pathophysiologic necessity or phlebosurgical games? *Vasa.* 1996;25:142-147.
49. Delis KT, Knaggs AL, Hobbs JT, Vandendriessche MA. The nonsaphenous vein of the popliteal fossa: prevalence, patterns of reflux, hemodynamic quantification, and clinical significance. *J Vasc Surg.* 2006;44:611-619.
50. Dodd H. The varicose tributaries of the popliteal vein. *Br J Surg.* 1965;52:350-354.
51. Mozes G, Gloviczki P, Menawat SS, et al. Surgical anatomy for endoscopic subfascial division of perforating veins. *J Vasc Surg.* 1996;24:800-808.
52. Neglan P. Cosmetic excision and stripping of varices. In: Raju S, Villavicencio JL, eds. *Surgical Management of Venous Disease.* Baltimore, MD: Williams & Wilkins; 1997:269.
53. Eger M, Golcman L, Torok G, Hirsch M. Inadvertent arterial stripping in the lower limb: problems of management. *Surgery.* 1973;73:23-27.
54. Luke JC, Miller GG. Disasters following the operation of ligation and retrograde injection of varicose veins. *Ann Surg.* 1948;127:426-431.
55. Fischer R, Chandler JG, De Maeseneer MG, et al. The unresolved problem of recurrent saphenofemoral reflux. *J Am Coll Surg.* 2002;195:80-94.
56. Rivlin S. The surgical cure of primary varicose veins. *Br J Surg.* 1975;62:913-917.
57. Lofgren KA. Management of varicose veins: Mayo Clinic experience. In: Bergan JJ, Yao JST, eds. *Venous Problems.* Chicago, IL: Year-Book Medical Publishers; 1978:71-83.

58. Iafrati MD, O'Donnell OD, Kunkemueller TF, et al. Clinical examination, duplex ultrasound and plethysmography for varicose veins. *Phlebology*. 1994;9:114-118.
59. Goren G, Yellin AE. Primary varicose veins: topographic and hemodynamic correlations. *J Cardiovasc Surg*. 1990;31:672-677.
60. Jacobsen BH, Wallin L. Proximal or distal extraction of the internal saphenous vein? *Vasa*. 1975;4:240-242.
61. Holme JB, Skajaa K, Holme K. Incidence of lesions of the saphenous nerve after partial or complete stripping of the long saphenous vein. *Acta Chir Scand*. 1990;156:145-148.
62. Negus D. Should the incompetent saphenous vein be stripped to the ankle? *Phlebology*. 1986;1:33-36.
63. Bergan JJ. Varicose veins: treatment by intervention including sclerotherapy. In: Rutherford RB, ed. *Vascular Surgery*, 6th ed. Philadelphia, PA: Elsevier Saunders; 2005:2257.
64. Conrad P, Gassner P. Invagination stripping of the long and short saphenous vein using the PIN stripper. *Aust N Z J Surg*. 1996;66:394-396.
65. Goren G, Yellin AE. Invaginated axial saphenectomy by a semirigid stripper: perforate-invaginate stripping. *J Vasc Surg*. 1994;20:970-977.
66. Bergan JJ. Surgical procedures for varicose veins: Axial stripping and stab avulsion. In: Bergan JJK, Kistner RL, eds. *Atlas of Venous Surgery*. Philadelphia, PA: WB Saunders; 1992:61-75.
67. Darke SG, Andress MR. The value of venography in the management of chronic venous disorders of the lower limb. In: Greenhalgh RME, ed. *Diagnostic Techniques and Assessment Procedures in Vascular Surgery*. London: Grune & Stratton; 1985.
68. Bass A, Chayen D, Weinmann EE, Ziss M. Lateral venous ulcer and short saphenous vein insufficiency. *J Vasc Surg*. 1997;25:654-657.
69. Iafrati MD, Pare GJ, O'Donnell TF, Estes J. Is the nihilistic approach to surgical reduction of superficial and perforator vein incompetence for venous ulcer justified? *J Vasc Surg*. 2002;36:1167-1174.
70. Winterborn RJ, Campbell WB, Heather BP, Earnshaw JJ. The management of short saphenous varicose veins: a survey of the members of the vascular surgical society of Great Britain and Ireland. *Eur J Vasc Endovasc Surg*. 2004;28:400-403.
71. Goren G, Yellin AE. Ambulatory stab evulsion phlebectomy for truncal varicose veins. *Am J Surg*. 1991;162:166-174.
72. Ricci SG, Georgiev M, Goldman M. In: Shalita A, ed. *Ambulatory Phlebectomy*. 2nd ed. Boca Raton, FL: Taylor & Francis; 2005:109.
73. Barwell JR, Davies CE, Deacon J, et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. *Lancet*. 2004;363:1854-1859.
74. Michaels JA, Brazier JE, Campbell WB, et al. Randomized clinical trial comparing surgery with conservative treatment for uncomplicated varicose veins. *Br J Surg*. 2006;93:175-181.
75. Rasmussen LH, Bjoern L, Lawaetz M, et al. Randomized trial comparing endovenous laser ablation of the great saphenous vein with high ligation and stripping in patients with varicose veins: short-term results. *J Vasc Surg*. 2007;46:308-315.
76. Darwood RJ, Theivacumar N, Dellagrammaticas D, et al. Randomized clinical trial comparing endovenous laser ablation with surgery for the treatment of primary great saphenous varicose veins. *Br J Surg*. 2008;95:294-301.
77. Kalteis M, Berger I, Messie-Werndl S, et al. High ligation combined with stripping and endovenous laser ablation of the great saphenous vein: early results of a randomized controlled study. *J Vasc Surg*. 2008;47:822-829; discussion 829.
78. Rautio T, Ohinmaa A, Perä J, et al. Endovenous obliteration versus conventional stripping operation in the treatment of primary varicose veins: a randomized controlled trial with comparison of the costs. *J Vasc Surg*. 2002;35:958-965.
79. Lurie F, Creton D, Eklof B, et al. Prospective randomized study of endovenous radiofrequency obliteration (closure procedure) versus ligation and stripping in a selected patient population (EVOLVE Study). *J Vasc Surg*. 2003;38:207-214.
80. Perä J, Rautio T, Biancari F, et al. Radiofrequency endovenous obliteration versus stripping of the long saphenous vein in the management of primary varicose veins: 3-year outcome of a randomized study. *Ann Vasc Surg*. 2005;19:669-672.

81. Lurie F, Creton D, Eklof B, et al. Prospective randomised study of endovenous radiofrequency obliteration (closure) versus ligation and vein stripping (EVOLVEs): two-year follow-up. *Eur J Vasc Endovasc Surg.* 2005;29:67-73.
82. Tong Y, Royle J. Recurrent varicose veins after short saphenous vein surgery: a duplex ultrasound study. *Cardiovasc Surg.* 1996;4:364-367.
83. Mitchell GR, Edwards S, de Cossart P, Simitri L. Recurrence is common after short saphenous vein surgery. Paper presented at the American Venous Forum. Miami, FL; 2006.
84. Creton D. 125 reinterventions for recurrent popliteal varicose veins after excision of the short saphenous vein. Anatomical and physiological hypotheses of the mechanism of recurrence. *J Mal Vasc.* 1999;24:30-36.
85. De Maeseneer MG, De Hert SG, Van Schils PE, et al. Preoperative colour-coded duplex examination of the saphenopopliteal junction in recurrent varicosity of the short saphenous vein. *Cardiovasc Surg.* 1993;1:680-683; discussion 684-685.
86. Rettori R. Postoperative recurrence of varicosities at the level of the popliteal fossa. Anatomic data guiding the ultrasonographic exploration and surgical sequelae. *J Mal Vasc.* 1998;23:54-60.

## 第 56 章

1. Beebe-Dimmer JL, Pfeifer JR, Engle JS. The epidemiology of chronic venous insufficiency and varicose veins. *Ann Epidemiol.* 2005;15:175-184.
2. Criqui MH, Jamosmos M, Fronek A, et al. Chronic venous disease in an ethnically diverse population. *Am J Epidemiol.* 2003;158:448-456.
3. Kostas TT, Ioannou CV, Veligantakis M, et al. The appropriate length of great saphenous vein stripping should be based on the extent of reflux and not on the intent to avoid saphenous nerve injury. *J Vasc Surg.* 2007;46:1234-1241.
4. Allegra C, Antignani PL, Carlizza A. Recurrent varicose veins following surgical treatment: our experience with five years follow-up. *Eur J Vasc Endovasc Surg.* 2007;33:751-756.
5. Rautio T, Ohinmaa A, Pera J, et al. Endovenous obliteration versus conventional stripping operation in the treatment of primary varicose veins: a randomized controlled trial with comparison of the costs. *J Vasc Surg.* 2002;35:958-965.
6. Navarro S. Endolaser—a three year follow-up report: Implication on crossectomy and ligation and stripping. Paper presented at the 16th Annual Congress American College of Phlebology, Nov 2002, Fort Lauderdale, FL.
7. Rautio T, Ohinmaa A, Pera J, et al. Endovenous obliteration versus conventional stripping operation in the treatment of primary varicose veins: a randomized controlled trial with comparison of costs. *J Vasc Surg.* 2002;35:958-965.
8. Boné C. Tratamiento endoluminal de las varices con laser de diodo: estudio preliminar. *Rev Patol Vasc.* 1999;5:35-46.
9. Navarro L, Min RJ, Bone C. Endovenous laser: a new minimally invasive method of treatment for varicose veins—preliminary observations using an 810 nm diode laser. *Dermatol Surg.* 2001;27:117-122.
10. Min RJ, Zimmet SE, Isaacs MN, et al. Endovenous laser treatment of the incompetent greater saphenous vein. *J Vasc Interv Radiol.* 2001;12:1167-1171.
11. Proebstle TM, Moehler T, Gul D, et al. Endovenous treatment of the great saphenous vein using a 1,320-nm Nd:YAG laser causes fewer side effects than using a 940-nm diode laser. *Dermatol Surg.* 2005;31:1678-1684.
12. Kabnick LS, Caruso JA. Jacket-tip laser fiber vs. bare-tip laser fiber for endothermal venous ablation of the great saphenous vein: are the results the same? Paper presented at the 16th Annual Controversies and Updates in Vascular Surgery, Jan 18-19, 2008, Paris.
13. Min RJ, Khilnani N, Zimmet SE. Endovenous laser treatment of saphenous vein reflux: long-term results. *J Vasc Interv Radiol.* 2003;14:991-996.
14. Babilas P, Shafirstein G, Baumler W, et al. Selective photothermolysis of blood vessels following flashlamp-pumped pulsed dye laser irradiation: in vivo results and mathematical modeling are in agreement. *J Invest Dermatol.* 2005;125:343-352.
15. Bergan JJ, Feied CF. Venous anatomy and pathophysiology. In: Fronek HS, ed. *The Fundamentals of Phlebology: Venous*



*Disease for Clinicians*. London: Royal Society of Medicine Press; 2008.

16. Cavezzi A, Labropoulos N, Partsch H, et al. Duplex ultrasound investigation of the veins in chronic venous disease of the lower limbs—UIP Consensus Document. Part II. Anatomy. *Eur J Vasc Endovasc Surg*. 2006;31:288-299.
17. Pieri A, Vannuzzi A, Duranti A, et al. Role central de la valvule pre-ostiale de la veine saphène interne dans la genèse des varices tronculaires des membres inférieures. *Phlebologie*. 1995;48:227-239.
18. Mozes G, Gloviczki P. New discoveries in anatomy and new terminology of leg veins: clinical implications. *Vasc Endovasc Surg*. 2004;38:367-374.
19. Min R, Khilnani N, Golia P. Duplex ultrasound evaluation of lower extremity venous insufficiency. *J Vasc Interv Radiol*. 2003;14:1233-1241.
20. Ricci S, Caggiati A. Does a double long saphenous vein exist? *Phlebology*. 1999;14:59-64.
21. Ricci S, Georgiev M. Ultrasound anatomy of the superficial veins of the lower limb. *J Vasc Technol*. 2002;26:183-199.
22. Meissner MH. Lower extremity venous anatomy. *Semin Interv Radiol*. 2005;22:147-156.
23. Caggiati A. Fascial relationships of the long saphenous vein. *Circulation*. 1999;100:2547-2549.
24. Caggiati A, Bergan JJ, Gloviczki P, et al. Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus statement. *J Vasc Surg*. 2002;36:416-422.
25. Weiss RA, Feied CF, Weiss MA. *Vein Diagnosis and Treatment: A Comprehensive Approach*. New York: McGraw-Hill; 2001:211-221.
26. Limborgh J, van Hage RW. Anatomical features of those perforating veins of the leg which frequently or infrequently become incompetent. In: May R, Partsch H, Staubesand J, eds. *Perforating Veins*. Munich: Urban & Schwarzenberg; 1981:49-59.
27. Bergan JJ, Pascarella L. Venous anatomy, physiology, and pathophysiology. In: Bergan JJ, ed. *The Vein Book*. Boston: Elsevier; 2007.
28. Allegra C, Antignani P-L, Bergan JJ, et al. The “C” of CEAP: suggested definitions and refinements. An International Union of Phlebology conference of experts. *J Vasc Surg*. 2003;37:129-131.
29. Albanese AR, Albanese AM, Albanese EF. Lateral subdermic varicose vein system of the legs: its surgical treatment by the chiseling tube method. *Vasc Surg*. 1969;3:81-89.
30. Weiss RA, Weiss MA. Doppler ultrasound findings in reticular veins of the thigh subdermic lateral venous system and implications for sclerotherapy. *J Dermatol Surg Oncol*. 1993;19:947-951.
31. Rutherford RB. *Vascular Surgery*. 6th ed. Philadelphia: Elsevier; 2005.
32. Goldman MP, Bergan JJ. *Sclerotherapy Treatment of Varicose and Telangiectatic Leg Veins*. 3rd ed. St Louis: CV Mosby; 2001.
33. Meissner MH, Gloviczki P, Bergan J, et al. Primary chronic venous disorders. *J Vasc Surg*. 2007;46:54S-67S.
34. Society for Vascular Ultrasound. *Vascular Technology Performance Guidelines: Lower Extremity Venous Insufficiency Guidelines*. Lanham, MD: Society for Vascular Ultrasound; 2007.
35. Min R, Khilnani N, Golia P. Duplex ultrasound evaluation of lower extremity venous insufficiency. *J Vasc Interv Radiol*. 2003;14:1233-1241.
36. Eklöf B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. *J Vasc Surg*. 2004;40:1248-1252.
37. Bergan JJ. Surgical procedures for varicose veins: axial stripping and stab avulsion. In: Bergan JJ, Kistner RL, eds. *Atlas of Venous Surgery*. Philadelphia: WB Saunders; 1992.
38. Wong JK, Duncan JL, Nichols DM. Whole-leg duplex mapping for varicose veins: observations on patterns of reflux in recurrent and primary legs, with clinical correlation. *Eur J Endovasc Surg*. 2003;25:267-275.
39. Guex JJ, Hiltbrand B, Bayon JM, et al. Anatomical patterns in varicose vein disease. *Phlebology*. 1995;10:94-97.
40. Mekako A, Hatfield J, Bryce M, et al. Combined endovenous laser therapy and ambulatory phlebectomy: refinement of a

new technique. *Eur J Vasc Endovasc Surg*. 2006;32:725-729.

41. Welch H. Endovenous ablation of the great saphenous vein may avert phlebectomy for branch varicose veins. *J Vasc Surg*. 2006;44:601-605.
42. VNUS Medical Technologies, Inc. *VNUS ClosureFAST Radiofrequency brochure*. San Jose, CA: VNUS Medical Technologies, Inc; 2006 [VN25-91-A].
43. Merchant RF, Min RJ, Morrison N, et al. Endovenous thermal ablation in the management of varicose veins. In: Fronek HS, ed. *The Fundamentals of Phlebology: Venous Disease for Clinicians*. London: Royal Society of Medicine Press; 2008.
44. Proebstle TM, Vago B, Alm J, et al. Treatment of the incompetent great saphenous vein by endovenous radiofrequency powered segmental thermal ablation: first clinical experience. *J Vasc Surg*. 2008;47:151-156.
45. Roth SM. Endovenous radiofrequency ablation of superficial and perforator veins. *Surg Clin North Am*. 2007;87:1267-1284.
46. VNUS Medical Technologies, Inc. *VNUS ClosureFAST catheter instructions for use*. San Jose, CA: VNUS Medical Technologies, Inc; 2007 [RM55-529-01 Rev B].
47. Klein JA. Tumescence technique chronicles: local anesthesia, liposuction, and beyond. *Dermatol Surg*. 1995;21:449-457.
48. Lumsden AB, Peden EK. Clinical use of the new ClosureFAST radiofrequency catheter: segmental ablation technique facilitates quick and simple procedures. *Endovasc Today*. January 2007, Supplement.
49. Proebstle TM. Comparison of endovenous ablation techniques: new technologies and techniques allow more choice in endovenous ablation. *Endovasc Today*. January 2007, Supplement.
50. Merchant RF, Pichot O, Myers KA. Four-year follow-up on endovascular radiofrequency obliteration of great saphenous reflux. *Dermatol Surg*. 2005;31:129-134.
51. Morrison N. VNUS closure of the saphenous vein. In: Bergan JJ, ed. *The Vein Book*. Boston: Elsevier; 2007.
52. Food and Drug Administration. Search of the MAUDE adverse event reporting system. Available at (<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM>); 2008 Accessed April 13.
53. Hingorani AP, Ascher E, Markevich N, et al. Deep venous thrombosis after radiofrequency ablation of greater saphenous vein: a word of caution. *J Vasc Surg*. 2004;40:500-504.
54. Proebstle TM. ClosureFAST: One-year clinical outcomes. Paper presented at the 20th Annual Meeting of the American Venous Forum, Feb 23, 2008, Charleston, SC.
55. Dietzek A. ClosureFAST is better than first generation radiofrequency ablation—a quantum leap forward. Paper presented at the 34th Veith Symposium, Nov 14-18, 2007, New York.
56. Kistner RL. Endovenous obliteration of the greater saphenous vein: The Closure procedure. *Jpn J Phlebol*. 2002;13:325-333.
57. Whiteley MS, Holstock JM, Price BA, et al. Radiofrequency ablation of refluxing great systems, Giacomini veins, and incompetent perforating veins using VNUS Closure and TRLOP technique. *J Endovasc Ther*. 2003;10:1-46.
58. Lurie F, Creton D, Eklof B, et al. Prospective randomised study of endovenous radiofrequency obliteration (Closure) versus ligation and vein stripping (EVOLVEs): two-year follow-up. *Eur J Vasc Endovasc Surg*. 2005;29:67-73.
59. Proebstle TM, Lehr HA, Kargl A, et al. Endovenous treatment of the greater saphenous vein with a 940 nm diode laser: thrombotic occlusion after endoluminal thermal damage by laser generated steam bubbles. *J Vasc Surg*. 2002;35:729-736.
60. Perrin M. Endovenous treatment of lower-limb varices by laser and radiofrequency. *Phlebology*. 2005;48:337-346.
61. Proebstle TM, Sandhofer M, Kargl A, et al. Thermal damage of the inner vein wall during endovenous treatment: key role of energy absorption by intravascular blood. *Dermatol Surg*. 2002;28:596-600.
62. Goldman MP. Intravascular lasers in the treatment of varicose veins. *J Cosmetic Dermatol*. 2004;3:162-166.
63. Proebstle TM. PowerPoint Presentation: Endovenous laser: comparison of different lasers. Available at ([http://bibamed.agcl.com/cx\\_2006/Sat1340Proebstle.pdf](http://bibamed.agcl.com/cx_2006/Sat1340Proebstle.pdf)); 2008 Accessed April 18.
64. Kabnick LS. Outcome of different endovenous laser wavelengths for great saphenous vein ablation. *J Vasc Surg*.

2006;43:88-93.

65. Dornier MedTech. Medilas D Multibeam Technology: Ideal wavelength. Available at ([http://www.dornier.com/americas/english\\_gb/products/lasers/compactDiode/technology.htm](http://www.dornier.com/americas/english_gb/products/lasers/compactDiode/technology.htm)); 2008 Accessed April 15.
66. CoolTouch, Inc. *Laser Endovenous Treatment for Varicose Veins Brochure*. Roseville, CA: CoolTouch, Inc; 2004 [7110-0049 Rev. A].
67. Biolitec, Inc. *ELVeS PL: The Gentle Standard in Endovenous Therapies brochure*. East Longmeadow, MA: Biolitec, Inc; 2008 [ML-290 Rev B].
68. Mackey EG, Almeida JI, Raines JK. Saphenous vein ablation: do different laser wavelengths translate into different patient experiences? *Endovasc Today*. March 2006;45-48.
69. Theivacumar NS, Dellagrammaticas D, Beale RJ, et al. Factors influencing the effectiveness of endovenous laser ablation (EVLA) in the treatment of great saphenous vein reflux. *Eur J Vasc Endovasc Surg*. 2008;35:119-123.
70. Perkowski P, Ravi R, Gowda RCN, et al. Endovenous laser ablation of the saphenous vein for treatment of venous insufficiency and varicose veins: early results from a large single-center experience. *J Endovasc Ther*. 2004;11:132-138.
71. Timperman PE, Sichlau M, Ryu RK. Greater energy delivery improves treatment success of endovenous laser treatment of incompetent saphenous veins. *J Vasc Interv Radiol*. 2004;15:1061-1063.
72. Timperman PE. Prospective evaluation of higher energy great saphenous vein endovenous laser treatment. *J Vasc Interv Radiol*. 2005;16:791-794.
73. Desmytère J, Grard C, Wassmer B, et al. Endovenous 980-nm laser treatment of saphenous veins in a series of 500 patients. *J Vasc Surg*. 2007;46:1242-1247.
74. AngioDynamics, Inc. *VenaCure Procedure Kit Featuring NeverTouch Gold-Tipped Fiber Instructions For Use*. Queensbury, NY: AngioDynamics, Inc; 2007 [IC 064 Rev. A].
75. Roizental M, Fernandez CF. EVLT of the GSV: Experience in 376 patients using EVLT of the GSV and miniphelectomy for collateral varicose veins. *Endovasc Today*. November/December 2004, Supplement.
76. Kim HS, Paxton BE. Endovenous laser ablation of the great saphenous vein with a 980-nm diode laser in continuous mode: early treatment failures and successful repeat treatments. *J Vasc Interv Radiol*. 2006;17:1449-1455.
77. Vascular Solutions, Inc. *VariLase Bright Tip Fiber brochure*. Vascular Solutions: Minneapolis; 2007 [ML1739 Rev. B].
78. AngioDynamics, Inc. *NeverTouch VenaCure Kit Featuring Gold Tip Technology brochure*. Queensbury, NY: AngioDynamics; 2007 [MLC 201 Rev. D].
79. Thibault P. Sclerotherapy and ultrasound-guided sclerotherapy. In: Bergan J, ed. *The Vein Book*. Boston: Elsevier; 2007.
80. Baccaglini U, Spreafico G, Castoro C, et al. Consensus conference on sclerotherapy or varicose veins of the lower limbs. *Phlebology*. 1997;12:2-16.
81. Omega Laboratories. Sclerodex Description. Available at (<http://www.omegalaboratory.com/eng/prodall.asp>); 2008 Accessed April 18.
82. Feied C. Sclerosing solutions. In: Bergan J, ed. *The Vein Book*. Boston: Elsevier; 2007.
83. Kern P, Ramelet AA, Wütschert R, et al. Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. *Dermatol Surg*. 2004;3:367-372.
84. Lewis KM. Anaphylaxis due to sodium morrhuate. *JAMA*. 1936;107:1298-1299.
85. Goldman MP. Sodium tetradecyl sulfate for sclerotherapy treatment of veins: is compounding pharmacy solution safe? *Dermatol Surg*. 2004;30:1454-1456.
86. Bioniche Pharma Group. *FDA Submission: Sotradecol (sodium tetradecyl sulfate injection 1%, 3%)*. Belleville, Ontario, Canada: Bioniche Pharma Group; 2004.
87. Rabe E, Pannier-Fischer F, Gerlach H, et al. Guidelines for sclerotherapy of varicose veins (ICD 10: 183.0, 183.1, 183.2, and 183.9). *Dermatol Surg*. 2004;30:687-693.
88. BioForm Medical, Inc. Aethoxysklerol Sclerosing Agent. Available at

(<http://www.bioform.com/products/aethoxysklerol.html>); 2008 Accessed March 20.

89. BTG International LTG. Product pipeline: Varisolve. Available at (<http://www.btgplc.com/BTGDevelopmentProgrammes/228/Varisolvesupregsup.html>); 2008 Accessed April 20.
90. Goldman MP. Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between Aethoxysklerol and Sotradecol. *Dermatol Surg.* 2002;28:52-55.
91. Carlin MC, Ratz JL. Treatment of telangiectasia: Comparison of sclerosing agents. *J Dermatol Surg Oncol.* 1987;13:1181-1184.
92. Kabnick L. Should we consider a paradigm shift for the treatment of GSV and branch varicosities? [Abstract] Paper presented at the UIP World Congress Phlebology Chapter Meeting, August, 2003, San Diego, CA.
93. Zimmet SE. Sclerotherapy treatment of telangiectasias and varicose veins. *Tech Vasc Interv Radiol.* 2003;6:116-120.
94. Sadick NS. Sclerotherapy of varicose and telangiectatic leg veins: Minimal sclerosant concentration of hypertonic saline and its relationship to vessel diameter. *J Dermatol Surg Oncol.* 1991;18:47-52.
95. Bergan J. Overview: Treatment of venous insufficiency. In Bergan J, ed. *The Vein Book*. Boston: Elsevier; 2007.
96. Weiss RA, Weiss MA. Sclerotherapy treatment of telangiectasias. In: Bergan J, ed. *The Vein Book*. Boston: Elsevier; 2007.
97. Kabnick L. Sclerosants: Spiders and superficial veins: results and Techniques. Paper presented at a Society of Interventional Radiology Meeting, March 2007, Seattle, WA.
98. Sadick NS. Sclerotherapy of telangiectasias and reticular veins. In: Fronek HS, ed. *The Fundamentals of Phlebology: Venous Disease for Clinicians*. London: Royal Society of Medicine Press; 2008.
99. American Academy of Dermatology. Guidelines of care for sclerotherapy treatment of varicose and telangiectatic leg veins. *J Am Acad Dermatol.* 1996;34:523-528.
100. Monfreux A. Traitement sclerosant des troncs saphenies et leurs collaterals de gros caliber par la method. *MUS Phlebologie.* 1997;50:351-353.
101. Cabrera J, Cabrera J Jr, Garcia-Olmedo MA. Sclerosants in microfoam: A new approach in angiology. *Int Angiol.* 2001;20:322-329.
102. Sadoun S, Benigni JP. The treatment of varicosities and telangiectasias with TDS or Lauromacrogol foam [abstract]. Paper presented at the 13th World Congress of Phlebology, Sept 6-11, 1998, Sydney, Australia, p 327.
103. Tessari L. Nouvelle technique d'obtention de la sclero-mousse. *Phlebologie.* 2000;53:129.
104. Frullini A, Cavezzi A. Sclerosing foam in the treatment of varicose veins and telangiectasias: history and analysis of safety and complications. *Dermatol Surg.* 2002;28:11-15.
105. Cavezzi A, Frullini A, Ricci S, et al. Treatment of varicose veins by foam sclerotherapy: two clinical series. *Phlebology.* 2002;17:13-18.
106. Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. *Dermatol Surg.* 2001;27:58-60.
107. Barrett JM, Allen B, Ockelford A, et al. Microfoam ultrasound-guided sclerotherapy of varicose veins in 100 legs. *Dermatol Surg.* 2004;30:6-12.
108. Guex JJ. Overview: Sclerofoam for treatment of varicose veins. In: Bergan J, ed. *The Vein Book*. Boston: Elsevier; 2007.
109. Kanter A. Clinical determinants of ultrasound-guided sclerotherapy outcome. Part I. The effects of age, gender, and vein size. *Dermatol Surg.* 1998;24:131-135.
110. Kolbel T, Hinchliffe RJ, Lindblad B. Catheter-directed foam sclerotherapy of axial saphenous reflux: early results. *Phlebology.* 2007;22:219-222.
111. Min RJ, Navarro L. Transcatheter duplex ultrasound-guided sclerotherapy for treatment of greater saphenous vein reflux: preliminary report. *Dermatol Surg.* 2000;26:10-14.
112. Kern P, Ramelet AA, Wütschert R, et al. Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. *J Vasc Surg.* 2007;45:1212-1216.

113. Weiss RA, Sadick NS, Goldman MP, et al. Post-sclerotherapy compression: controlled comparative study of duration of compression and its effects on clinical outcome. *Dermatol Surg.* 1999;25:105-108.
114. Munavalli GS, Weiss RA. Complications of sclerotherapy. *Semin Cutan Med Surg.* 2007;26:22-28.
115. Goldman MP, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting, and hyperpigmentation following sclerotherapy. etiology, prevention, and treatment. *Dermatol Surg.* 1995;21:19-29.
116. Davis LT, Duffy DM. Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity: a retrospective analysis. *J Dermatol Surg Oncol.* 1990;16:327-330.
117. Bergan J, Pascarella L, Mekenas LJ. Venous disorders: treatment with sclerosant foam. *Cardiovasc Surg (Torino).* 2006;47:9-18.
118. Belcaro G, Cesarone MR, Di Renzo A, et al. Foam sclerotherapy, surgery, sclerotherapy, and combined treatment for varicose veins: a 10-year, prospective, randomized, controlled, trial (VEDICO trial). *Angiology.* 2003;54:307-315.
119. Yamaki T, Nozaki M, Iwasaka S. Comparative study of duplex-guided foam sclerotherapy and duplex-guided liquid sclerotherapy for the treatment of superficial venous insufficiency. *Dermatol Surg.* 2004;30:718-722.
120. Bergan J, Pascarella L, Mekenas L. Venous disorders: treatment with sclerosant foam. *J Cardiovasc Surg.* 2006;47:115-124.
121. Almeida JJ, Raines JK. FDA-approved sodium tetradecyl sulfate (STS) versus compounded STS for venous sclerotherapy. *Dermatol Surg.* 2007;33:1037-1044.
122. Kauvar A. The role of lasers in the treatment of leg veins. *Semin Surg Cutan Med.* 2000;19:245-252.
123. Sadick NS. Laser treatment of leg veins. *Skin Therapy Letter.* 2004;9.
124. Passeron T, Ollivier V, Duteil L, et al. The new 940 nanometer diode laser. An effective treatment for leg venulectasia. *J Am Acad Dermatol.* 2003;48:768-774.
125. Fournier N, Brisot P, Murdon S. Treatment of leg telangiectasias with a 532 nm KTP laser in multi-pulse model. *Dermatol Surg.* 2002;28:564-571.
126. Anderson RR, Jaenicke KF, Parrish JA. Mechanisms of selective vascular changes caused by dye lasers. *Lasers Surg Med.* 1983;3:211-215.
127. Sadick N, Sorhaindo L. Laser treatment of telangiectasias and reticular veins. In: Bergan J, ed. *The Vein Book*. Boston: Elsevier; 2007.
128. Lupton J, Alster T, Romero P. Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectasias. *Dermatol Surg.* 2002;28:694-697.
129. Goldberg D. Evaluation of KTP/532nm laser with StarPulse for treatment of leg telangiectasia. Available at (<http://www.irindex.com/pdf/ktpevaluation.pdf>); 2008 Accessed April 24.
130. Goldman MP, Fitzpatrick R. Pulse-dye laser treatment of leg telangiectasia: with and without simultaneous sclerotherapy. *J Dermatol Surg.* 1990;16:338-344.
131. Eremia S, Li C, Umar SH. A side-by-side comparative study of 1064 nm Nd : YAG, 810 nm diode and 755 nm alexandrite lasers for treatment of 0.3-3 mm leg veins. *Dermatol Surg.* 2002;28:224-230.
132. Trelles MA, Allones I, Alvarez J, et al. The 800-nm diode laser in the treatment of leg veins: assessment at 6 months. *J Am Acad Dermatol.* 2006;54:282-289.
133. Weiss RA, Weiss MA. Early clinical results with a multiple synchronized pulse 1064 nm laser for leg telangiectasias and reticular veins. *Dermatol Surg.* 1999;25:399-402.
134. Sadick NS. Laser treatment with a 1064-nm laser for lower extremity class I-III veins employing variable spots and pulse width parameters. *Dermatol Surg.* 2003;29:916-919.
135. Weiss RA, Weiss MA, Marwaha S, et al. Non-coherent filtered flashlamp intense pulsed light source for leg telangiectasias: long pulse durations for improved results. *Lasers Surg Med.* 1998;10(Suppl):40.
136. Dover JS, Sadick NS, Goldman MP. The role of lasers and light sources in the treatment of leg veins. *Dermatol Surg.*

- 1999;24:328-336.
137. Sadick NS, Weiss RA, Goldman MP. Advances in laser surgery for leg veins: bimodal wavelength approach to lower extremity vessels, new cooling techniques, and longer pulse durations. *Dermatol Surg.* 2002;28:16-20.
  138. Hohenleutner U, Walther T, Wenig M, et al. Leg telangiectasia treatment with a 1.5 ms pulsed dye laser, ice cube cooling of the skin and 595 vs 600 nm: preliminary results. *Lasers Surg Med.* 1998;23:72-78.
  139. Anvari B, Milner TE, Tanenbaum BS, et al. A comparative study of human skin thermal response to sapphire contact and cryogen spray cooling. *IEEE Trans Biomed Eng.* 1998;45:934-941.
  140. Rogachefsky AS, Silapunt S, Goldberg DJ. Nd : YAG laser (1064 nm) irradiation for lower extremity telangiectases and small reticular veins: efficacy as measured by vessel color and size. *Dermatol Surg.* 2002;28:220-223.
  141. Dawson E, Willey A, Lee K. Adverse events associated with nonablative cutaneous laser, radiofrequency, and light-based devices. *Semin Cutan Med Surg.* 2007;26:15-21.
  142. Willey A, Anderson RR, Azpiazu JL, et al. Complications of laser dermatologic surgery. *Lasers Surg Med.* 2006;38:1-15.
  143. McMeekin TO. Treatment of spider veins of the leg using a long-pulsed Nd:YAG laser (VersaPulse) at 532 nm. *J Cutan Laser Ther.* 1999;1:179-180.
  144. Reichert D. Evaluation of the long-pulse dye laser for the treatment of telangiectasias. *Dermatol Surg.* 1998;24:737-740.
  145. Schroeter CA, Wilder D, Reineke T, et al. Clinical significance of an intense, pulsed light source on leg telangiectasias of up to 1 mm diameter. *Eur J Dermatol.* 1997;7:38.
  146. Goldman MP, Eckhouse S, Photoderm VL. Cooperative Study Group: photothermal sclerosis of leg veins. *Dermatol Surg.* 1996;22:323-330.
  147. Adrian RM. Treatment of leg telangiectasias using a long-pulse frequency-doubled neodymium : YAG laser at 532 nm. *Dermatol Surg.* 1998;24:19-23.
  148. Quintana AT, Grossman MG, Kauvar ANB, et al. Removal of leg veins with Laserscope potassium titanyl phosphate-532nm and Dermastat 2mm handpiece. Paper presented at the 18th Annual Meeting of the American Society of Laser Medicine and Surgery, April 5-7, 1998, San Diego, CA.
  149. Bernstein EF, Kornbluth S, Brown DB, et al. Treatment of spider veins using a 10 millisecond pulse-duration frequency-doubled neodymium:YAG laser. *Dermatol Surg.* 1999;25:316-323.
  150. Kauvar ANB, Lou WW. Pulsed alexandrite laser for the treatment of leg telangiectasia and reticular veins. *Arch Dermatol.* 2000;136:1371-1375.
  151. Schroeter CA, Wilder D, Reineke T, et al. Clinical significance of an intense, pulsed light source on leg telangiectasias of up to 1 mm diameter. *Eur J Dermatol.* 1997;7:38.

## 第 57 章

1. Caggiati A, Mendoza E. The discovery of perforating veins. *Ann Vasc Surg.* 2004;18:502-503.
2. Gay J. *On varicose disease of the lower extremities and its allied disorders: skin discoloration, induration and ulcer. Lettsomian lectures delivered before the Medical Society of London in 1867, by John Gay.* London: John Churchill & Sons; 1868.
3. Thomson H. The surgical anatomy of the superficial and perforating veins of the lower limb. *Ann R Coll Surg Engl.* 1979;61:198-205.
4. Pirner F. On the valves of the perforating veins. In: Robert May, ed. *Perforating Veins.* Munchen: Urban & Schwarzenberg; 1981:46-48.
5. Cotton LT. Varicose veins. Gross anatomy and development. *Br J Surg.* 1961;48:589-598.
6. Labropoulos N, Delis KT, Nicolaides AN. Venous reflux in symptom-free vascular surgeons. *J Vasc Surg.* 1995;22:150-154.
7. Cooper DG, Hillman-Cooper CS, Barker SG, et al. Primary varicose veins: the sapheno-femoral junction, distribution of varicosities and patterns of incompetence. *Eur J Vasc Endovasc Surg.* 2003;25:53-59.

8. Sakurai T, Matsushita M, Nishikimi N, et al. Hemodynamic assessment of femoropopliteal venous reflux in patients with primary varicose veins. *J Vasc Surg.* 1997;26:260-264.
9. Guex JJ. Ultrasound guided sclerotherapy (USGS) for perforating veins (PV). *Hawaii Med J.* 2000;59:261-262.
10. Masuda EM, Kessler DM, Lurie F, et al. The effect of ultrasound-guided sclerotherapy of incompetent perforator veins on venous clinical severity and disability scores. *J Vasc Surg.* 2006;43:551-556.
11. Almgren B, Eriksson I. Valvular incompetence in superficial, deep and perforator veins of limbs with varicose veins. *Acta Chir Scand.* 1990;156:69-74.
12. Labropoulos N, Tassiopoulos AK, Bhatti AF, et al. Development of reflux in the perforator veins in limbs with primary venous disease. *J Vasc Surg.* 2006;43:558-562.
13. Sarin S, Shields DA, Farrah J, et al. Does venous function deteriorate in patients waiting for varicose vein surgery? *J R Soc Med.* 1993;86:21-23.
14. Gohel MS, Barwell JR, Wakely C, et al. The influence of superficial venous surgery and compression on incompetent calf perforators in chronic venous leg ulceration. *Eur J Vasc Endovasc Surg.* 2005;29:78-82.
15. Stuart WP, Lee AJ, Allan PL, et al. Most incompetent calf perforating veins are found in association with superficial venous reflux. *J Vasc Surg.* 2001;34:774-778.
16. Mendes RR, Marston WA, Farber MA, et al. Treatment of superficial and perforator venous incompetence without deep venous insufficiency: is routine perforator ligation necessary? *J Vasc Surg.* 2003;38:891-895.
17. Gohel MS, Barwell JR, Earnshaw JJ, et al. Randomized clinical trial of compression plus surgery versus compression alone in chronic venous ulceration (ESCHAR study): haemodynamic and anatomical changes. *Br J Surg.* 2005;92:291-297.
18. Puggioni A, Lurie F, Kistner RL, et al. How often is deep venous reflux eliminated after saphenous vein ablation? *J Vasc Surg.* 2003;38:517-521.
19. Stuart WP, Adam DJ, Allan PL, et al. Saphenous surgery does not correct perforator incompetence in the presence of deep venous reflux. *J Vasc Surg.* 1998;28:834-838.
20. Bjordal RI. Circulation patterns in incompetent perforating veins in the calf and in the saphenous system in primary varicose veins. *Acta Chir Scand.* 1972;138:251-261.
21. Neglen P, Raju S. Ambulatory venous pressure revisited. *J Vasc Surg.* 2000;31:1206-1213.
22. Cockett F. The role of the ankle perforating veins in the post-thrombotic syndrome and in primary hereditary varicose veins. In: Robert May, ed. *Perforating Veins*. Munchen: Urban & Schwarzenberg; 1981:106-108.
23. Hanrahan LM, Kechejian GJ, Cordts PR, et al. Patterns of venous insufficiency in patients with varicose veins. *Arch Surg.* 1991;126:687-690.
24. Jiang P, van Rij AM, Christie R, et al. Recurrent varicose veins: patterns of reflux and clinical severity. *Cardiovasc Surg.* 1999;7:332-339.
25. Labropoulos N, Touloupakis E, Giannoukas AD, et al. Recurrent varicose veins: investigation of the pattern and extent of reflux with color flow duplex scanning. *Surgery.* 1996;119:406-409.
26. May R. The clinical importance of incompetent perforating veins in primary varicosis. In: Robert May, ed. *Perforating Veins*. Munchen: Urban & Schwarzenberg; 1981:118-122.
27. Rutherford EE, Kianifard B, Cook SJ, et al. Incompetent perforating veins are associated with recurrent varicose veins. *Eur J Vasc Endovasc Surg.* 2001;21:458-460.
28. Allegra C, Antignani PL, Carlizza A. Recurrent varicose veins following surgical treatment: our experience with five years follow-up. *Eur J Vasc Endovasc Surg.* 2007;33:751-756.
29. Iafrati MD, Pare GJ, O'Donnell TF, et al. Is the nihilistic approach to surgical reduction of superficial and perforator vein incompetence for venous ulcer justified? *J Vasc Surg.* 2002;36:1167-1174.
30. Gloviczki P, Bergan JJ, Rhodes JM, et al. Mid-term results of endoscopic perforator vein interruption for chronic venous insufficiency: lessons learned from the North American Subfascial Endoscopic Perforator Surgery Registry. The North

- American Study Group. *J Vasc Surg*. 1999;29:489-502.
31. van Gent WB, Hop WC, van Praag MC, et al. Conservative versus surgical treatment of venous leg ulcers: a prospective, randomized, multicenter trial. *J Vasc Surg*. 2006;44:563-571.
  32. Schafer K. The course, structure and passage through the fascia of the perforating veins. In: Robert May, ed. *Perforating Veins*. Munchen: Urban & Schwarzenberg; 1981:37-45.
  33. Lurie F, Kessler D, Puggioni A, et al. Blood flow in perforating arteries can change after obliteration of incompetent perforating veins—preliminary ultrasound observations. *Praktika Flebologie (Czech Republic)*. 2005;14:55-56.
  34. Caggiati A, Bergan JJ, Gloviczki P, et al. Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus statement. *J Vasc Surg*. 2002;36:416-422.
  35. O'Donnell TF Jr, Burnand KG, Clemenson G, et al. Doppler examination vs clinical and phlebographic detection of the location of incompetent perforating veins: a prospective study. *Arch Surg*. 1977;112:31-35.
  36. Masuda EM, Kistner RL, Eklof B. Prospective study of duplex scanning for venous reflux: comparison of Valsalva and pneumatic cuff techniques in the reverse Trendelenburg and standing positions. *J Vasc Surg*. 1994;20:711-720.
  37. Sandri JL, Barros FS, Pontes S, et al. Diameter-reflux relationship in perforating veins of patients with varicose veins. *J Vasc Surg*. 1999;30:867-874.
  38. Blomgren L, Johansson G, Dahlberg-Akerman A, et al. Changes in superficial and perforating vein reflux after varicose vein surgery. *J Vasc Surg*. 2005;42:315-320.
  39. Barwell JR, Davies CE, Deacon J, et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. *Lancet* 2004;363:1854-1859.
  40. Kianifard B, Holdstock J, Allen C, et al. Randomized clinical trial of the effect of adding subfascial endoscopic perforator surgery to standard great saphenous vein stripping. *Br J Surg*. 2007;94:1075-1080.
  41. van Rij AM, Hill G, Gray C, et al. A prospective study of the fate of venous leg perforators after varicose vein surgery. *J Vasc Surg*. 2005;42:1156-1162.
  42. Hauer G. Endoscopic subfascial discussion of perforating veins—preliminary report. *Vasa*. 1985;14:59-61.
  43. Rhodes JM, Gloviczki P, Canton LG, et al. Endoscopic perforator vein division with ablation of superficial reflux improves venous hemodynamics. *J Vasc Surg*. 1998;28:839-847.
  44. Scriven JM, Bianchi V, Hartshorne T, et al. A clinical and haemodynamic investigation into the role of calf perforating vein surgery in patients with venous ulceration and deep venous incompetence. *Eur J Vasc Endovasc Surg*. 1998;16:148-152.
  45. Tenbrook JA Jr, Iafrati MD, O'donnell TF Jr, et al. Systematic review of outcomes after surgical management of venous disease incorporating subfascial endoscopic perforator surgery. *J Vasc Surg*. 2004;39:583-589.
  46. de Rijcke PA, Schenk T, van Gent WB, et al. Surgical anatomy for subfascial endoscopic perforating vein surgery of laterally located perforating veins. *J Vasc Surg*. 2003;38:1349-1352.
  47. Padberg FTJ, Pappas PJ, Araki CT, et al. Hemodynamic and clinical improvement after superficial vein ablation in primary combined venous insufficiency with ulceration. *J Vasc Surg*. 1996;24:711-718.
  48. Ting AC, Cheng SW, Ho P, et al. Clinical outcomes and changes in venous hemodynamics after subfascial endoscopic perforating vein surgery. *Surg Endosc*. 2003;17:1314-1318.
  49. Lurie F, Creton D, Eklof B, et al. Prospective randomised study of endovenous radiofrequency obliteration (closure) versus ligation and vein stripping (EVOLVEs): two-year follow-up. *Eur J Vasc Endovasc Surg*. 2005;29:67-73.
  50. Elias S, Peden E. Ultrasound-guided percutaneous ablation for the treatment of perforating vein incompetence. *Vascular*. 2007;15:281-289.
  51. Proebstle TM, Herdemann S. Early results and feasibility of incompetent perforator vein ablation by endovenous laser treatment. *Dermatol Surg*. 2007;33:162-168.
  52. Eklof B, Kessler D, Kistner R, et al. Can Duplex-guided sclerotherapy replace SEPS in the treatment of incompetent perforating veins? *J Vasc Surg*. 2003;37:545-551.



53. Black CM, Hatch D, Brown D, et al. An endovenous approach to symptomatic perforator ablation. *J Vasc Interv Radiol*. 2007;18(Suppl 2):S23.

## 第 58 章

1. Coon WW, Willis PW, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. *Circulation*. 1973;48:839-846.
2. Baker SR, Stacey MC, Jopp-McKay AG, et al. Epidemiology of chronic venous ulcers. *Br J Surg*. 1988;78:864-867.
3. Heit JA, Rooke TW, Silverstein MD, et al. Trends in the incidence of venous stasis syndrome and venous ulcer: a 25-year population-based study. *J Vasc Surg*. 2001;33:1022-1027.
4. Nicolaides AN. Investigation of chronic venous insufficiency: a consensus statement. *Circulation*. 2000;102:e126-e163.
5. Mayberry JC, Moneta GL, Taylor LM Jr, et al. Fifteen-year results of ambulatory compression therapy for chronic venous ulcers. *Surgery*. 1991;109:575-581.
6. Erickson CA, Lanza DJ, Karp DL, et al. Healing of venous ulcers in an ambulatory care program: the roles of chronic venous insufficiency and patient compliance. *J Vasc Surg*. 1995;22:629-636.
7. Kalra M, Gloviczki P. Surgical treatment of venous ulcers: role of subfascial endoscopic perforator vein ligation. *Surg Clin North Am*. 2003;83:671-705.
8. Neglen P, Thrasher TL, Raju S. Venous outflow obstruction: an underestimated contributor to chronic venous disease. *J Vasc Surg*. 2003;38:879-885.
9. Raju S, Owen S Jr, Neglen P. The clinical impact of iliac venous stents in the management of chronic venous insufficiency. *J Vasc Surg*. 2002;35:8-15.
10. Plate G, Brudin L, Eklof B, et al. Physiologic and therapeutic aspects in congenital vein valve aplasia of the lower limb. *Ann Surg*. 1983;198:229-233.
11. Raju S, Fredericks RK, Hudson CA, et al. Venous valve station changes in "primary" and post-thrombotic reflux: an analysis of 149 cases. *Ann Vasc Surg*. 2000;14:193-199.
12. Budd TW, Meenaghan MA, Wirth J, et al. Histopathology of veins and venous valves of patients with venous insufficiency syndrome: ultrastructure. *J Med*. 1990;21:181-199.
13. Sandri JL, Barros FS, Pontes S, et al. Diameter-reflux relationship in perforating veins of patients with varicose veins. *J Vasc Surg*. 1999;30:867-875.
14. Clarke H, Smith SR, Vasdekis SN, et al. Role of venous elasticity in the development of varicose veins. *Br J Surg*. 1989;76:577-580.
15. O'Donnell TF. Chronic venous insufficiency: an overview of epidemiology, classification, and anatomic considerations. *Semin Vasc Surg*. 1988;1:60-65.
16. Kistner RL, Eklof B, Masuda EM. Deep venous valve reconstruction. *Cardiovasc Surg*. 1995;3:129-140.
17. Danielson G, Arfvidsson B, Eklof B, et al. Reflux from thigh to calf, the major pathology in chronic venous ulcer disease: surgery indicated in the majority of patients. *Vasc Endovasc Surg*. 2004;38:209-219.
18. Masuda EM, Kistner RL. Long-term results of venous valve reconstruction: a four to twenty-one year follow-up. *J Vasc Surg*. 1994;19:391-403.
19. Killewich LA, Bedford GR, Beach KW, et al. Spontaneous lysis of deep venous thrombi: rate and outcome. *J Vasc Surg*. 1989;9:89-97.
20. Masuda EM, Kessler DM, Kistner RL, et al. The natural history of calf vein thrombosis: lysis of thrombi and development of reflux. *J Vasc Surg*. 1998;28:67-73.
21. McLafferty RB, Moneta GL, Passman MA, et al. Late clinical and hemodynamic sequelae of isolated calf vein thrombosis. *J Vasc Surg*. 1998;27:50-56.
22. Eriksson I, Almgren B. Influence of the profunda femoris vein on venous hemodynamics of the limb: experience from

- thirty-one deep vein valve reconstructions. *J Vasc Surg.* 1986;4:390-395.
23. Queral LA, Whitehouse WM Jr, Flinn WR, et al. Surgical correction of chronic deep venous insufficiency by valvular transposition. *Surgery.* 1980;87:688-695.
  24. Raju S, Fountain T, Neglen P, et al. Axial transformation of the profunda femoris vein. *J Vasc Surg.* 1998;27:651-659.
  25. O'Donnell TF, Mackey WC, Shepard AD, et al. Clinical, hemodynamic, and anatomic follow-up of direct venous reconstruction. *Arch Surg.* 1987;122:474-482.
  26. Bry JD, Muto PA, O'Donnell TF, et al. The clinical and hemodynamic results after axillary-to-popliteal vein valve transplantation. *J Vasc Surg.* 1995;21:110-119.
  27. Raju S, Fredericks RK, Neglen PN, et al. Durability of venous valve reconstruction techniques for "primary" and post-thrombotic reflux. *J Vasc Surg.* 1996;23:357-367.
  28. Raju S. Multiple-valve reconstruction for venous insufficiency: indications, optimal technique, and results. In: Veith FJ, ed. *Current Critical Problems in Vascular Surgery.* 4th ed. St. Louis, MO: Quality Medical Publishing; 1992:122-125.
  29. Nicolaides AN (chair) and the Executive Committee of the ad hoc committee, American Venous Forum, 6th annual meeting. February 22-25, 1994, Maui, Hawaii: Classification and grading of chronic venous disease in the lower limbs: a consensus statement. In: Gloviczki P, Yao JST, eds. *Handbook of Venous Disorders.* London, England: Chapman & Hall; 2001:653-656.
  30. Porter JM, Moneta GL, and an International Consensus Committee on Chronic Venous Disease: Reporting standards in venous disease: an update. *J Vasc Surg.* 1995;21:634-645.
  31. Rutherford RB, Padberg FT Jr, Comerota AJ, et al. Venous severity scoring: an adjunct to venous outcome assessment. *J Vasc Surg.* 2000;31:1307-1312.
  32. Lamping DL, Schroter S, Kurz X, et al. Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. *J Vasc Surg.* 2003;37:410-419.
  33. Mattos MA, Summer D. Direct noninvasive tests (duplex scan) for the evaluation of chronic venous obstruction and valvular incompetence. In: Gloviczki P, Yao JST, eds. *Handbook of Venous Disorders.* London, England: Arnold; 2001:120-131.
  34. vanBemmelen PS, Bedford G, Beach K, et al. Quantitative segmental evaluation of venous valvular reflux with duplex ultrasound scanning. *J Vasc Surg.* 1989;10:425-431.
  35. Araki CT, Back TL, Padberg FT, et al. The significance of calf muscle pump function in venous ulceration. *J Vasc Surg.* 1994;20:872-877.
  36. Cordts PR, Hartono C, LaMorte WW, et al. Physiologic similarities between extremities with varicose veins and with chronic venous insufficiency utilizing air plethysmography. *Am J Surg.* 1992;164:260-264.
  37. Criado E, Farber MA, Marston WA, et al. The role of air plethysmography in the diagnosis of chronic venous insufficiency. *J Vasc Surg.* 1998;27:660-670.
  38. Raju S. New approaches to the diagnosis and treatment of venous obstruction. *J Vasc Surg.* 1986;4:42-54.
  39. Nicolaides AN, Hussein MK, Szendro G, et al. The relation of venous ulceration with ambulatory venous pressure measurements. *J Vasc Surg.* 1993;17:414-419.
  40. Neglen P, Raju S. Proximal lower extremity chronic venous outflow obstruction: recognition and treatment. *Semin Vasc Surg.* 2002;15:57-64.
  41. Kistner RL, Ferris EB, Randhawa G, et al. A method of performing descending venography. *J Vasc Surg.* 1986;4:464-468.
  42. Cheatile TR, Perrin M. Venous valve repair: early results in fifty-two cases. *J Vasc Surg.* 1994;19:404-413.
  43. Kistner RL, Sparkuhl MD. Surgery in acute and chronic venous disease. *Surgery.* 1979;85:31-43.
  44. Wang S, Hu Z, Li S, et al. Effect of external valvuloplasty of the deep vein in the treatment of chronic venous insufficiency of the lower extremity. *J Vasc Surg.* 2006;44:1296-1300.
  45. Us M, Basaran M, Sanioglu S, et al. The use of external banding increases the durability of transcommissural external deep

- venous valve repair. *Eur J Vasc Endovasc Surg*. 2007;33:494-501.
46. Camilli S, Guarnera G. External banding valvuloplasty of the superficial femoral vein in the treatment of primary deep valvular incompetence. *Int Angiol*. 1994;13:218-222.
  47. Raju S, Berry MA, Neglen P. Transcommissural valvuloplasty: technique and results. *J Vasc Surg*. 2000;32:969-976.
  48. Tripathi R, Sieunarine K, Abbas M, et al. Deep venous valve reconstruction for non-healing leg ulcers: techniques and results. *Aust N Z J Surg*. 2004;74:34-39.
  49. Rosales A, Slagsvold CE, Kroese AJ, et al. External venous valve plasty (EVVP) in patients with primary chronic venous insufficiency (PCVI). *Eur J Endovasc Surg*. 2006;32:570-576.
  50. May R. Anatomy. In: May R, Ebert PA, eds. *Surgery of the Veins of the Leg and Pelvis*, Vol 23. In: *Major Problems in Clinical Surgery*. London, England: WB Saunders; 1979:1-33.
  51. Valentine RJ, Wind GG. Vessels of the leg. In: Valentine RJ, Wind GG, eds. *Anatomic Exposures in Vascular Surgery*. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:467-522.
  52. Sun J, Zhang P. Anatomic and histologic studies on the valves of the venous system in lower extremities. *Vasc Surg*. 1990;24:85-90.
  53. Powell T, Lynn RB. The valves of the external iliac, femoral, and upper third of the popliteal veins. *Surg Gynecol Obstet*. 1951;92:453-455.
  54. Basmajian JV. The distribution of valves in the femoral, external iliac, and common iliac veins and their relationship to varicose veins. *Surg Gynecol Obstet*. 1952;95:537-542.
  55. Lane JL, Cuzzilla ML, McMahon DG. Intermediate to long-term results of repairing incompetent multiple deep venous valves using external valvular stenting. *Aust N Z J Surg*. 2003;73:267-274.
  56. Raju S, Hardy JD. Technical options in venous valve reconstruction. *Am J Surg*. 1997;173:301-307.
  57. Nishibe T, Kudo F, Flores J, et al. Femoral vein valve repair with angioscopy-assisted anterior valve sinus plication. Early results. *J Cardiovasc Surg (Torino)*. 2001;42:529-535.
  58. Kistner RL. Surgical repair of a venous valve. *Straub Clin Proc*. 1968;24:41-43.
  59. Raju S. Venous insufficiency of the lower limb and stasis ulceration: changing concepts and management. *Ann Surg*. 1983;197:688-697.
  60. Sottiurai VS. Technique in direct venous valvuloplasty. *J Vasc Surg*. 1988;8:646-648.
  61. Tripathi R, Ktenidis KD. Trapdoor internal valvuloplasty: a new technique for primary deep vein valvular incompetence. *Eur J Vasc Endovasc Surg*. 2001;22:86-89.
  62. Raju S, Fredericks R. Valve reconstruction procedures for nonobstructive venous insufficiency: rationale, techniques, and results in 107 procedures with two- to eight-year follow-up. *J Vasc Surg*. 1988;7:301-310.
  63. Kistner RL. Surgical technique of external venous valve repair. *Straub Found Proc*. 1990;55:15-16.
  64. Nishibe T, Kudo F, Miyazaki K, et al. Intermediate-term results of angioscopy-assisted anterior valve sinus plication for primary deep venous insufficiency. *J Cardiovasc Surg (Torino)*. 2007;48:21-25.
  65. Gloviczki P, Merrell SW, Bower TC. Femoral vein valve repair under direct vision without venotomy: a modified technique with use of angioscopy. *J Vasc Surg*. 1991;14:645-648.
  66. Belcaro G, Nicolaidis AN, Ricci A, et al. External femoral vein valvuloplasty with limited anterior plication (LAP): a 10-year randomized, follow-up study. *Angiology*. 1999;50:531-536.
  67. Jamieson WG, Chinnick B. Clinical results of deep venous valvular repair for chronic venous insufficiency. *Can J Surg*. 1997;40:294-299.
  68. Welch H, McLaughlin RL, O'Donnell TF. Femoral vein valvuloplasty: intraoperative angioscopic evaluation and hemodynamic improvement. *J Vasc Surg*. 1992;16:694-700.
  69. Taheri SA, Lazar L, Elias SM, et al. Vein valve transplant. *Surgery*. 1982;91:28-33.
  70. Raju S, Neglen P, Doolittle J, et al. Axillary vein transfer in trabeculated post-thrombotic veins. *J Vasc Surg*.

1999;29:1050-1064.

71. Sottiurai VS. Supravalvular incision for valve repair in primary valvular insufficiency. In: Bergan JJ, Kistner RL, eds. *Atlas of Venous Surgery*. Philadelphia, PA: WB Saunders; 1992:137-138.
72. Cardon JM, Cardon A, Joyeux A, et al. Use of ipsilateral greater saphenous vein as a valved transplant in management of post-thrombotic deep venous insufficiency: long-term results. *Ann Vasc Surg*. 1999;13:284-289.
73. Perrin M. Reconstructive surgery for deep venous reflux: a report on 144 cases. *Cardiovasc Surg*. 2000;8:246-255.
74. Poller L, McKernan A, Thomson JM, et al. Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. *Br Med J (Clin Res Ed)*. 1987;295:1309-1312.
75. Perrin M, Hiltbrand B, Bayon JM. Results of valvuloplasty in patients presenting with deep venous insufficiency and recurring ulceration. *Ann Vasc Surg*. 1999;13:524-532.
76. Kistner RL. Surgical repair of the incompetent femoral vein valve. *Arch Surg*. 1975;110:1336-1342.
77. Ferris EB, Kistner RL. Femoral vein reconstruction in the management of chronic venous insufficiency: a 14-year experience. *Arch Surg*. 1982;117:1571-1579.
78. Lurie F, Makarova NP, Hmelniker SM. Results of deep-vein reconstruction. *Vasc Surg*. 1997;31:275-276.
79. Perrin MR. Results of deep-vein reconstruction. *Vasc Surg*. 1997;31:273-275.
80. Guarnera G, Furgiuele S, Mascellari L, et al. External banding of the superficial femoral vein in the treatment of recurrent varicose veins. *Int Angiol*. 1998;17:268-271.
81. Taheri SA, Lazar L, Elias SM, et al. Vein valve transplant. *Surgery*. 1982;91:28-33.
82. Taheri SA, Elias SM, Yacobucci GN, et al. Indications and results of vein valve transplant. *J Cardiovasc Surg*. 1986;27:163-168.
83. Nash T. Long-term results of vein valve transplants placed in the popliteal vein for intractable post-phlebotic venous ulcers and pre-ulcer skin changes. *J Cardiovasc Surg*. 1988;29:712-716.
84. Rai DB, Lerner R. Chronic venous insufficiency disease: its etiology: a new technique for vein valve transplantation. *Int Surg*. 1991;76:174-178.
85. Sottiurai VS. Results of deep-vein reconstruction. *Vasc Surg*. 1997;31:276-278.
86. Eklof BG, Kistner RL, Masuda EM. Venous bypass and valve reconstruction: long-term efficacy. *Vasc Med*. 1998;3:157-164.
87. Johnson ND, Queral LA, Flinn WR, et al. Late objective assessment of venous valve surgery. *Arch Surg*. 1981;116:1461-1466.
88. Dalsing MC, Sawchuk AP, Lalka SG, et al. An early experience with endovascular venous valve transplantation. *J Vasc Surg*. 1996;24:903-905.
89. Lurie F, Kistner RL, Eklof B, et al. Mechanism of venous valve closure and role of the valve in circulation. A new concept. *J Vasc Surg*. 2003;38:955-961.
90. Ofenloch JC, Chen C, Hughes JD, et al. Endoscopic venous valve transplantation with a valve-stent device. *Ann Vasc Surg*. 1997;11:62-67.
91. Boudjemline Y, Bonnet D, Sidi D, et al. Is percutaneous implantation of a bovine venous valve in the inferior vena cava a reliable technique to treat chronic venous insufficiency syndrome? *Med Sci Monit*. 2004;10:61-66.
92. Kaya M, Grogan JB, Lentz D, et al. Glutaraldehyde-preserved venous valve transplantation in the dog. *J Surg Res*. 1988;45:294-297.
93. Gomez-Jorge J, Venbrux AC, Magee C. Percutaneous deployment of a valved bovine jugular vein in the swine venous system: a potential treatment for venous insufficiency. *J Vasc Interv Radiol*. 2000;11:931-936.
94. Gale SS, Shuman S, Beebe HG, et al. Percutaneous venous valve bioprosthesis: initial observations. *Vasc Endovasc Surg*. 2004;38:221-224.
95. Pavcnik D, Uchida BT, Timmermans HA, et al. Percutaneous bioprosthetic venous valve: a long-term study in sheep. *J*

- Vasc Surg.* 2002;35:598-602.
96. Brountzos E, Pavcnik D, Timmermans HA, et al. Remodeling of suspended small intestinal submucosa venous valve: an experimental study in sheep to assess the host cells' origin. *J Vasc Interv Radiol.* 2003;14:349-356.
  97. Pavcnik D, Kaufman J, Uchida B, et al. Second-generation percutaneous bioprosthetic valve: a short-term study in sheep. *J Vasc Surg.* 2004;40:1223-1227.
  98. Pavcnik D. Update on venous valve replacement: long-term clinical results. *Vascular.* 2006;14(Suppl 1):S106.
  99. Pavcnik D, Yin Q, Uchida D, et al. Percutaneous autologous venous valve transplantation: short-term feasibility study in an ovine model. *J Vasc Surg.* 2007;46:338-345.
  100. Calhoun AD, Baur GM, Porter JM, et al. Fresh and cryopreserved venous allografts in genetically characterized dogs. *J Surg Res.* 1977;22:687-696.
  101. Hill R, Schmidt S, Evancho M, et al. Development of a prosthetic venous valve. *J Biomed Mater Res.* 1985;19:827-832.
  102. Taheri SA, Rigan D, Wels P, et al. Experimental prosthetic vein valve. *Am J Surg.* 1988;156:111-114.
  103. Taheri SA, Schultz RO. Experimental prosthetic vein valve: long-term results. *Angiology.* 1995;46:299-303.
  104. Reeves TR, Cezeaux JL, Sackman JE, et al. Mechanical characteristics of lyophilized human saphenous vein valves. *J Vasc Surg.* 1997;26:823-828.
  105. Burkhardt HM, Fath SW, Dalsing MC, et al. Experimental repair of venous valvular insufficiency using a cryopreserved venous valve allograft aided by a distal arteriovenous fistula. *J Vasc Surg.* 1997;26:817-822.
  106. Dalsing MC, Raju S, Wakefield TW, et al. A multicenter, phase I evaluation of cryopreserved venous valve allografts for the treatment of chronic deep venous insufficiency. *J Vasc Surg.* 1999;30:854-866.
  107. Neglen P, Raju S. Venous reflux repair with cryopreserved vein valves. *J Vasc Surg.* 2003;37:552-557.
  108. Madden R, Lipkowitz G, Benedetto B, et al. Decellularized cadaver vein allografts used for hemodialysis access do not cause allosensitization or preclude kidney transplantation. *Am J Kidney Dis.* 2002;40:1240-1243.
  109. Teebken OE, Puschmann C, Aper T, et al. Tissue-engineered bioprosthetic venous valve: a long-term study in sheep. *Eur J Vasc Endovasc Surg.* 2003;25:305-312.
  110. Garcia-Rinaldi R, Soltero E, Gaviria J, et al. Implantation of cryopreserved allograft pulmonary monocusp patch: to treat nonthrombotic femoral vein incompetence. *Tex Heart Inst J.* 2002;29:92-99.
  111. Garcia-Rinaldi R. Regarding "Venous reflux repair with cryopreserved vein valves." *J Vasc Surg.* 2003;38:1139-1140.
  112. Dalsing MC, Lalka SG, Unthank JL, et al. Venous valvular insufficiency: influence of a single venous valve (native and experimental). *J Vasc Surg.* 1991;14:576-587.
  113. Rosenbloom MS, Schuler JJ, Bishara RA, et al. Early experimental experience with a surgically created, totally autogenous venous valve: a preliminary report. *J Vasc Surg.* 1988;7:642-646.
  114. Plagnol P, Ciostek P, Grimaud JP, et al. Autogenous valve reconstruction technique for post-thrombotic reflux. *Ann Vasc Surg.* 1999;13:339-342.
  115. Maleti O. Venous valvular reconstruction in post-thrombotic syndrome. A new technique. *J Mal Vasc.* 2002;27:218-221.
  116. Maleti O, Lugli M. Neovalve construction in postthrombotic syndrome. *J Vasc Surg.* 2006;43:794-799.
  117. Lugli M, Guerzoni S, Maleti O. Neovalve construction in deep venous incompetence: comparison between two subsequent case series and related technical details. Presented at the 20th Annual Meeting of the American Venous Forum, Charleston Place, Charleston, SC, February 20-23, 2008.
  118. Corcos L, Peruzzi G, Procacci T, et al. A new autologous venous valve by intimal flap. One case report. *Minerva Cardioangiol.* 2003;51:395-404.

## 第 59 章

1. Raju S. Venous insufficiency of the lower limb and stasis ulceration: changing concepts and management. *Ann Surg.* 1983;197:688-697.

2. Warren R, Thayer TR. Transplantation of the saphenous vein for postphlebotic stasis. *Surgery*. 1954;35:867-878.
3. Bergan JJ, Yao JS, Flinn WR, McCarthy WJ. Surgical treatment of venous obstruction and insufficiency. *J Vasc Surg*. 1986;3:174-181.
4. Rhee RY, Gloviczki P, Luthra HS, et al. Iliocaval complications of retroperitoneal fibrosis. *Am J Surg*. 1994;168:179-183.
5. Dzsinih C, Gloviczki P, van Heerden JA, et al. Primary venous leiomyosarcoma: a rare but lethal disease. *J Vasc Surg*. 1992;15:595-603.
6. Bower TC, Nagorney DM, Toomey BJ, et al. Vena cava replacement for malignant disease: is there a role? *Ann Vasc Surg*. 1993;7:51-62.
7. Bower TC. Primary and secondary tumors of the inferior vena cava. In: Gloviczki P, Yao JST, eds. *Handbook of Venous Disorders: Guidelines of the American Venous Forum*. London: Chapman & Hall; 1996:529-550.
8. Rich NM, Hughes CW. Popliteal artery and vein entrapment. *Am J Surg*. 1967;113:696-698.
9. Servelle M, Babilliot J. Syndrome du soléaire. *Phlebologie*. 1968;21:399-405.
10. Gullmo A. The strain obstruction syndrome of the femoral vein. *Acta Radiol*. 1957;47:119-137.
11. May R, Thurner J. Ein Gefäßsporn in der Vena iliaca communis sinistra als Ursache der ubiegend linksseitigen Beckenvenenthrombosen. *Z Kreislaufforschung*. 1956;45:912-922.
12. Cockett FB, Thomas ML. The iliac compression syndrome. *Br J Surg*. 1965;52:816-825.
13. David M, Striffling V, Brenot R, et al. Syndrome de Cockett acquis: a propos de trois cas opérés dont deux forés inhabituelles. *Ann Chir*. 1981;35:93-98.
14. Steinberg JB, Jacocks MA. May-Thurner syndrome: a previously unreported variant. *Ann Vasc Surg*. 1993;7:577-581.
15. Wang ZG, Zhu Y, Wang SH, et al. Recognition and management of Budd-Chiari syndrome: report of one hundred cases. *J Vasc Surg*. 1989;10:149-156.
16. Gloviczki P, Stanson AW, Stickler GB, et al. Klippel-Trenaunay syndrome: the risks and benefits of vascular interventions. *Surgery*. 1991;110:469-479.
17. Jacob AG, Driscoll DJ, Shaughnessy WJ, et al. Klippel-Trenaunay syndrome: spectrum and management. *Mayo Clin Proc*. 1998;73:28-36.
18. Schanzer H, Skladany M. Complex venous reconstruction for chronic iliofemoral vein obstruction. *Cardiovasc Surg*. 1996;4:837-840.
19. Raju S. New approaches to the diagnosis and treatment of venous obstruction. *J Vasc Surg*. 1986;4:42-54.
20. Negus D, Cockett FB. Femoral vein pressures in post-phlebotic iliac vein obstruction. *Br J Surg*. 1967;54:522-525.
21. May R. The Palma operation with Gottlob's endothelium preserving suture. In: May R, Weber J, eds. *Pelvic and Abdominal Veins: Progress in Diagnostics and Therapy. International Congress Series 550*. Amsterdam: Excerpta Medica; 1981:192-197.
22. Gloviczki P, Pairolero PC, Cherry KJ, Hallett JW Jr. Reconstruction of the vena cava and of its primary tributaries: a preliminary report. *J Vasc Surg*. 1990;11:373-381.
23. Gloviczki P, Pairolero PC, Toomey BJ, et al. Reconstruction of large veins for nonmalignant venous occlusive disease. *J Vasc Surg*. 1992;16:750-761.
24. Gruss JD. Venous bypass for chronic venous insufficiency. In: Bergan JJ, Yao JST, eds. *Venous Disorders*. Philadelphia, PA: WB Saunders; 1991:316-330.
25. Yamaguchi A, Eguchi S, Iwasaki T, Asano K. The influence of arteriovenous fistulae on the patency of synthetic inferior vena caval grafts. *J Cardiovasc Surg*. 1968;9:99-103.
26. Soyer T, Lempien M, Cooper P, et al. A new venous prosthesis. *Surgery*. 1972;72:864-872.
27. Chiu CJ, Terzis J, MacRae ML. Replacement of superior vena cava with the spiral composite vein graft. *Ann Thorac Surg*. 1974;17:555-560.
28. Wilson SE, Jabour A, Stone RT, Stanley TM. Patency of biologic prosthetic inferior vena cava grafts with distal limb

- fistula. *Arch Surg*. 1978;113:1174-1179.
29. Hobson RW 2nd, Wright CB. Peripheral side to side arteriovenous fistula. Hemodynamics and application in venous reconstruction. *Am J Surg*. 1978;126:411-414.
  30. Kunlin K, Kunlin A. Experimental venous surgery. In: May R, ed. *Surgery of the Veins of the Leg and Pelvis*. Philadelphia, PA: WB Saunders; 1979:37-75.
  31. Hutschenreiter S, Vollmar J, Loeprecht H, et al. Reconstructive interventions of the venous system: clinical evaluation of late results using functional and vascular anatomic criteria. *Chirurgica*. 1979;50:555-563.
  32. Fiore AC, Brown JW, Cromartie RS, et al. Prosthetic replacement for the thoracic vena cava. *J Thorac Surg*. 1982;84:560-568.
  33. Gloviczki P, Hollier LH, Dewanjee MK, et al. Experimental replacement of the inferior vena cava: factors affecting patency. *Surgery*. 1984;95:657-666.
  34. Plate G, Hollier LH, Gloviczki P, et al. Overcoming failure of venous vascular prostheses. *Surgery*. 1984;96:503-510.
  35. Chan EL, Bardin JA, Bernstein EF. Inferior vena cava bypass: experimental evaluation of externally supported grafts and initial clinical application. *J Vasc Surg*. 1984;95:657-680.
  36. Robison RJ, Peigh PS, Fiore AC, et al. Venous prostheses: improved patency with external stents. *J Surg Res*. 1984;36:306-311.
  37. Koveker GB, Burkel WE, Graham LM, et al. Endothelial cell seeding of expanded polytetrafluoroethylene vena cava conduits: effects of luminal production of prostacyclin, platelet adherence, and fibrinogen accumulation. *J Vasc Surg*. 1988;7:600-605.
  38. Akimaru K, Onda M, Tajiri T, et al. Reconstruction of the vena cava with the peritoneum. *Am J Surg*. 2000;179:289-293.
  39. Burkhart HM, Fath SW, Dalsing MC, et al. Experimental repair of venous valvular insufficiency using a cryopreserved venous valve allograft aided by a distal arteriovenous fistula. *J Vasc Surg*. 1997;26:817-822.
  40. Dalsing MC, Raju S, Wakefield TW, Taheri S. A multicenter, phase I evaluation of cryopreserved venous valve allografts for the treatment of chronic deep venous insufficiency. *J Vasc Surg*. 1999;30:854-864.
  41. Gloviczki P, Pairolero PC. Venous reconstruction for obstruction and valvular incompetence. *Perspect Vasc Surg*. 1988;1:75-93.
  42. Alimi YS, DiMauro P, Fabre D, Juhan C. Iliac vein reconstructions to treat acute and chronic venous occlusive disease. *J Vasc Surg*. 1997;25:673-681.
  43. Dale WA, Harris J, Terry RB. Polytetrafluoroethylene reconstruction of the inferior vena cava. *Surgery*. 1984;95:625-630.
  44. Gruss JD, Heimer W. Bypass procedures for venous obstruction: Palma and May-Husni bypasses, Raju perforator bypass, prosthetic bypasses, and primary and adjunctive arteriovenous fistulae. In: Raju S, Villavicencio JL, eds. *Surgical Management of Venous Disease*. Baltimore, MD: Williams & Wilkins; 1997:289-305.
  45. Gloviczki P, Berens E. Vena cava syndrome. In: Raju S, Villavicencio JL, eds. *Surgical Management of Venous Disease*. Baltimore, MD: Williams & Wilkins; 1997:397-420.
  46. Gloviczki P, Pairolero PC. Prosthetic replacement of large veins. In: Bergan JJ, Kistner RL, eds. *Atlas of Venous Surgery*. Philadelphia, PA: WB Saunders; 1992:191-214.
  47. Kieffer E, Bahnini A, Koskas F, et al. In-situ allograft replacement of infected infrarenal aortic prosthetic grafts: results in forty-three patients. *J Vasc Surg*. 1993;17:349-355; discussion 355-356.
  48. Kieffer E, Bahnini A, Koskas F. Nonthrombotic disease of the inferior vena cava: surgical management of 24 patients. In: Bergan JJ, Yao JST, eds. *Venous Disorders*. Philadelphia, PA: WB Saunders; 1991:501-516.
  49. Lalka SG. Venous bypass graft for chronic venous occlusive disease. In: Gloviczki P, Yao JST, eds. *Handbook of Venous Disorders: Guidelines of American Venous Forum*. London: Chapman & Hall; 1996:446-470.
  50. Wang ZG, Zhang H, Pu LQ, et al. Can endothelial seeding enhance patency and inhibit neointimal hyperplasia? Experimental studies and clinical trial of endothelial seeded venous prostheses. *Int Angiol*. 2003;19:259-269.

51. Meinhart JG, Deutsch M, Fischlein T, et al. Clinical autologous in vitro endothelialization of 153 infrainguinal ePTFE grafts. *Ann Thorac Surg.* 2001;71(5 Suppl):S327-S331.
52. Menawat SS, Gloviczki P, Mozes G, et al. Effect of a femoral arteriovenous fistula on lower extremity venous hemodynamics after femorocaval reconstruction. *J Vasc Surg.* 1996;24:793-799.
53. Jost CJ, Gloviczki P, Cherry KJ Jr, et al. Surgical reconstruction of iliofemoral veins and the inferior vena cava for nonmalignant occlusive disease. *J Vasc Surg.* 2001;33:320-327; discussion 327-328.
54. Hobson RW 2nd, Lee BC, Lynch TG, et al. Use of intermittent pneumatic compression of the calf in femoral venous reconstruction. *Surg Gynecol Obstet.* 1984;159:284-286.
55. Raju S, Owen S Jr, Neglen P. The clinical impact of iliac venous stents in the management of chronic venous insufficiency. *J Vasc Surg.* 2002;35:8-15.
56. O'Sullivan GJ, Semba CP, Bittner CA, et al. Endovascular management of iliac vein compression (May-Thurner) syndrome. *J Vasc Intervent Radiol.* 2000;11:823-836.
57. Hurst DR, Forauer AR, Bloom JR, et al. Diagnosis and endovascular treatment of ilio caval compression syndrome. *J Vasc Surg.* 2001;34:106-113.
58. Juhan C, Hartung O, Alimi Y, et al. Treatment of nonmalignant obstructive ilio caval lesions by stent placement: mid-term results. *Ann Vasc Surg.* 2001;15:227-232.
59. Husni EA. Clinical experience with femoropopliteal venous reconstruction. In: Bergan JJ, Yao JST, eds. *Venous Problems*. Chicago, IL: Year Book; 1978:485-491.
60. May R. Der Femoralisbypass beim ostthrombotischen Zustandsbild. *Vasa.* 1972;1:267-272.
61. Gruss JD. The saphenopopliteal bypass for chronic venous insufficiency (May-Husni operation). In: Bergan JJ, Yao JST, eds. *Surgery of the Veins*. Orlando, FL: Grune & Stratton; 1985:255-265.
62. Frileux C, Pillot-Bienayme P, Gillot C. Bypass of segmental obliterations of ilio-femoral venous axis by transposition of saphenous vein. *J Cardiovasc Surg.* 1972;13:409-414.
63. Dale WA. Reconstructive venous surgery. *Arch Surg.* 1979;114:1312-1318.
64. Husni EA. Reconstruction of veins: the need for objectivity. *J Cardiovasc Surg.* 1983;24:525-528.
65. Dale WA. Peripheral venous reconstruction. In: Dale WA, ed. *Management of Vascular Surgical Problems*. New York, NY: McGraw-Hill; 1985:493-521.
66. O'Donnell TF, Mackey WC, Shepard AD, Callow AD. Clinical, hemodynamic and anatomic follow-up of direct venous reconstruction. *Arch Surg.* 1987;122:474-482.
67. AbuRahma AF, Robinson PA, Boland JP. Clinical hemodynamic and anatomic predictors of long-term outcome of lower extremity venovenous bypasses. *J Vasc Surg.* 1991;14:635-644.
68. Danza R, Navarro T, Baldizan J. Reconstructive surgery in chronic venous obstruction of the lower limbs. *J Cardiovasc Surg.* 1991;32:98-103.
69. Smith DE, Trimble C. Surgical management of obstructive venous disease of the lower extremity. In: Rutherford RB, ed. *Vascular Surgery*. Philadelphia, PA: WB Saunders; 1977:1247-1268.
70. Palma EC, Riss F, Del Campo F, Tobler H. Tratamiento de los trastornos postflebiticos mediante anastomosis venosa safeno-femoral cotrolateral. *Bull Soc Surg Uruguay.* 1958;29:135-145.
71. Palma EC, Esperon R. Vein transplants and grafts in the surgical treatment of the postphlebotic syndrome. *J Cardiovasc Surg.* 1960;1:94-107.
72. Lalka SG. Management of chronic obstructive venous disease of the lower extremity. In: Rutherford RB, ed. *Vascular Surgery*. 4th ed. Philadelphia, PA: WB Saunders; 1995:1862-1882.
73. Lalka SG, Lash JM, Unthank JL, et al. Inadequacy of saphenous vein grafts for cross-femoral venous bypass. *J Vasc Surg.* 1991;13:622-630.
74. Dale WA, Harris J. Cross-over vein grafts for iliac and femoral venous occlusion. *J Cardiovasc Surg (Torino).*



1969;10:458-462.

75. Dale WA. Crossover vein grafts for iliac and femoral venous occlusion. *Resident Staff Physician*. 1983;58-64.
76. Halliday P, Harris J, May J. Femoro-femoral crossover grafts (Palma operation): a long-term follow-up study. In: Bergan JJ, Yao JST, eds. *Surgery of the Veins*. Orlando, FL: Grune & Stratton; 1985:241-254.
77. Husfeldt KJ. Venous replacement with Gore-Tex prosthesis: Experimental and first clinical results. In: May R, Weber J, eds. *Pelvic and Abdominal Veins: Progress in Diagnostics and Therapy. International Congress Series 550*. Amsterdam: Excerpta Medica; 1981:249-258.
78. Eklof B, Broome A, Einarsson E. Venous reconstruction in acute iliac vein obstruction using ePTFE grafts. In: May R, Weber J, eds. *Pelvic and Abdominal Veins: Progress in Diagnostics and Therapy. International Congress Series 550*. Amsterdam: Excerpta Medica; 1981:241-245.
79. Sottiurai VS, Gonzales J, Cooper M, et al. A new concept of arteriovenous fistula in venous bypass requiring no fistula interruption: surgical technique and long-term results. Unpublished data, 2000.
80. McMurrich JP. The occurrence of congenital adhesions in the common iliac veins and their relation to thrombosis of the femoral and iliac veins. *Am J Med Sci*. 1908;135:342-346.
81. May R, Thurner J. The cause of predominantly sinistral occurrence of thrombosis of the pelvic veins. *Angiology*. 1957;8:419-427.
82. Taheri SA, Williams J, Powell S, et al. Iliocaval compression syndrome. *Am J Surg*. 1987;154:169-172.
83. Cormier JM, Fichelle JM, Vennin J, et al. Atherosclerotic occlusive disease of the superior mesenteric artery: late results of reconstructive surgery. *Ann Vasc Surg*. 1991;5:510-518.
84. Trimble C, Bernstein EF, Pomerantz M, Eiseman B. A prosthetic bridging device to relieve iliac venous compression. *Surg Forum*. 1975;23:249.
85. Akers DLJ, Creado B, Hewitt RL. Iliac vein compression syndrome: case report and review of the literature. *J Vasc Surg*. 1996;24:477-481.
86. Rigas A, Vomvouranis A, Tsardakas E. Iliac compression syndrome. *J Cardiovasc Surg (Torino)*. 1970;11:389-392.
87. Reasbeck PG, Reasbeck JC. Iliac compression syndrome: a myth, a rarity or a condition frequently missed? *N Z Med J*. 1983;96:383-385.
88. Welter HF, Becker HM. Therapy of the pelvic venous spur and postoperative follow-up. In: May R, Weber J, eds. *Pelvic and Abdominal Veins: Progress in Diagnostics and Therapy. International Congress Series 550*. Amsterdam: Excerpta Medica; 1981:172.
89. Jaszczak P, Mathiesen FR. The iliac compression syndrome. *Acta Chir Scand*. 1978;144:133-136.
90. Victor S, Jayanthi V, Kandasamy I, et al. Retrohepatic cavoatrial bypass for coarctation of inferior vena cava with a polytetrafluoroethylene graft. *J Thorac Cardiovasc Surg*. 1986;91:99-105.
91. Richet NA. *Traite Practique D'anatomie Medico-Chirurgiale*. Paris: E. Chamerot, Libraire Editeur; 1857.
92. Taylor HC Jr. Vascular congestion and hyperemia: the effect on function in the female reproductive organs. Part I. Physiological basis and history of the concept. *Am J Obstet Gynecol*. 1949;57:211-230.
93. Mathias SD, Kuppermann M, Liberman RF, et al. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. *Obstet Gynecol*. 1996;87:321-327.
94. Soysal ME, Soysal S, Vicdan K, Ozer S. A randomized controlled trial of goserelin and medroxyprogesterone acetate in the treatment of pelvic congestion. *Hum Reprod*. 2001;16:931-939.
95. Belenky A, Bartal G, Atar E, et al. Ovarian varices in healthy female kidney donors: incidence, morbidity and clinical outcome. *Am J Roentgenol*. 2002;179:625-627.
96. Monedero JL, Ezpeleta SZ, Grimberg M, et al. Subdiaphragmatic venous insufficiency. Embolization treatment using mixed technique (coils and foam). *Phlebology*. 2004;45:269-275.
97. Gray H. *Anatomy of the Human Body*. Philadelphia, PA: Lea & Febiger; 1918. Available at Bartleby.com, 2000.

98. LePage PA, Villavicencio JL, Gomez ER, et al. The valvular anatomy of the iliac venous system and its clinical implications. *J Vasc Surg.* 1991;14:678-683.
99. Lechter A, Lopez G, Martinez C, Camacho J. Anatomy of the gonadal veins: a reappraisal. *Surgery.* 1991;109:735-739.
100. Kennedy A, Hemingway A. Radiology of varices. *Br J Hosp Med.* 1990;44:38-43.
101. Stancati E, Cricenti SV, Ambrosio JD. Anatomy of the valves of human ovarian veins. *Braz J Morphol Sci.* 2002;19:73-76.
102. Ahlberg NE, Bartley O, Chidekel N. Right and left gonadal veins: an anatomical and statistical study. *Acta Radiol Diagn.* 1966;4:595-601.
103. Hodgkinson CP. Physiology of the ovarian veins during pregnancy. *Obstet Gynecol.* 1953;1:26-37.
104. Reginald PW, Beard RW, Kooner JS, et al. Intravenous dihydroergotamine to relieve pelvic congestion pain in young women. *Lancet.* 1987;15:351-353.
105. Beard RW, Kennedy RG, Gangar KF, et al. Bilateral oophorectomy and hysterectomy in the treatment of intractable pelvic pain associated with pelvic congestion. *Br J Obstet Gynaecol.* 1991;98:988-992.
106. Park SJ, Lim JW, Ko YT, et al. Diagnosis of pelvic congestion syndrome using transabdominal and transvaginal sonography. *AJR Am J Roentgenol.* 2004;182:683-688.
107. Hartung O, Otero A, Boufi M, et al. Mid-term results of endovascular treatment for symptomatic chronic nonmalignant ilio caval venous occlusive disease. *J Vasc Surg.* 2005;42:1138-1144.
108. Hartung O, Grisoli D, Boufi M, et al. Endovascular stenting in the treatment of pelvic vein congestion caused by nutcracker syndrome: lessons learned from the first five cases. *J Vasc Surg.* 2005;42:275-280.
109. Beard RW, Reginald PW, Wadsworth J. Clinical features of women with chronic lower abdominal pain and pelvic congestion. *Br J Obstet Gynaecol.* 1988;95:153-161.
110. Giacchetto C, Cotroneo GB, Marincolo F, et al. Ovarian varicocele: ultrasonic and phlebographic evaluation. *J Clin Ultrasound.* 1990;18:551-555.
111. Coakley FV, Varghese SL, Hricak H. CT and MRI of pelvic varices in women. *J Comput Assist Tomogr.* 1999;23:429-434.
112. Rozenblit AM, Ricci ZJ, Tuvia J, Amis ES. Incompetent and dilated ovarian veins: a common CT finding in asymptomatic parous women. *AJR Am J Roentgenol.* 2001;176:119-122.
113. Kuligowska E, Deeds L, Lu K. Pelvic pain: overlooked and underdiagnosed gynaecologic conditions. *Radiographics.* 2005;25:3-20.
114. Creton D, Hennequin L, Kohler F, Allaert FA. Embolisation of symptomatic pelvic veins in women presenting with non-saphenous varicose veins of pelvic origin—three-year follow-up. *Eur J Vasc Endovasc Surg.* 2007;34:112-117.
115. Kim HS, Malhotra AD, Rowe PC, et al. Embolotherapy for pelvic congestion syndrome: long-term results. *J Vasc Interv Radiol.* 2006;17:289-297.
116. Chung MH, Huh CY. Comparison of treatments for pelvic congestion syndrome. *Tohoku J Exp Med.* 2003;201:131-138.
117. Faquhar CM, Rogers V, Franks S, et al. A randomized controlled trial of medroxyprogesterone acetate and psychotherapy for the treatment of pelvic congestion. *Br J Obstet Gynaecol.* 1989;96:1153-1162.
118. Gangar KF, Stones RW, Saunders D, et al. An alternative to hysterectomy? GnRH analogue combined with hormone replacement therapy. *Br J Obstet Gynaecol.* 1993;100:360-364.
119. Simsek M, Burak F, Taskin O. Effects of micronized purified flavonoid fraction (Daflon) on pelvic pain in women with laparoscopically diagnosed pelvic congestion syndrome: a randomized crossover trial. *Clin Exp Obstet Gynecol.* 2007;34:96-98.
120. Mathis BV, Miller JS, Lukens ML, Paluzzi MW. Pelvic congestion syndrome: a new approach to an unusual problem. *Am Surg.* 1995;61:1016-1018.
121. Rundquist F, Sandholm IE, Larsson G. Treatment of pelvic varicosities causing lower abdominal pain with extraperitoneal resection of the left ovarian vein. *Ann Chir Gynaecol.* 1984;73:339-341.
122. Grabham JA, Barrie WW. Laparoscopic approach to pelvic congestion syndrome. *Br J Surg.* 1997;84:1264.

123. Tourne G, Ducroux A, Bourbon M, Blinding H. The ovarian vein syndrome: 8 cases and review of the literature. *J Gynecol Obstet Biol Reprod.* 2002;31:471-477.
124. Scultetus AH, Villavicencio JL, Gillespie DL, et al. The pelvic venous syndromes: analysis of our experience of 57 patients. *J Vasc Surg.* 2002;36:881-888.
125. Gargiulo T, Mais V, Brokaj L, et al. Bilateral laparoscopic transperitoneal ligation of ovarian veins for treatment of pelvic congestion syndrome. *J Am Assoc Gynecol Laparosc.* 2003;10:501-504.
126. Richardson GD, Beckwith TC, Mykityowycz M, Lennox AF. Pelvic congestion syndrome—diagnosis and treatment. *Aust N Z J Phlebol.* 1999;3:51-56.
127. Cordts PR, Eclavea MC, Buckley PJ, et al. Pelvic congestion syndrome: early clinical results after transcatheter ovarian vein embolization. *J Vasc Surg.* 1998;28:862-868.
128. Maleux G, Stockx L, Wilms G, Marchal G. Ovarian vein embolization for the treatment of pelvic congestion syndrome: long-term technical and clinical results. *J Vasc Interv Radiol.* 2000;11:859-864.
129. Capasso P, Simons C, Trotteur G, et al. Treatment of symptomatic pelvic varices by ovarian vein embolization. *Cardiovasc Intervent Radiol.* 1997;20:107-111.
130. Tarazov PG, Prozorovskij KV, Ryzhkov VK. Pelvic pain syndrome caused by ovarian varices. Treatment by transcatheter embolization. *Acta Radiol.* 1997;38:1023-1025.
131. Machan L, Mowatt J, Hurwitz T, et al. Clinical outcome of women with chronic pelvic pain treated by ovarian vein embolization [abstract]. *J Vasc Intervent Radiol.* 1998;9(suppl):185.
132. Cotroneo AR, Di Stasi C, Tropeano G, et al. Percutaneous treatment of pelvic varicocele [abstract]. *Radiology.* 1998;209(Suppl):378-379.
133. Bachar GN, Belenky A, Greif F, et al. Initial experience with ovarian vein embolization for the treatment of chronic pelvic pain syndrome. *Isr Med Assoc J.* 2003;12:843-846.
134. Pieri S, Agresti P, Morucci M, de Medici L. Percutaneous treatment of pelvic congestion syndrome. *Radiol Med (Torino).* 2003;105:76-82.
135. Richardson GD, Driver B. Ovarian vein ablation: coils or surgery? *Phlebology.* 2006;21:16-23.
136. Lasry JL, Coppe G, Balian E, Borie H. Pelvi-perineal insufficiency and varicose veins of the lower limbs: duplex Doppler diagnosis and endoluminal treatment in thirty females. *J Mal Vasc.* 2007;32:23-31.
137. Kwon SH, Oh JH, Ko KR, et al. Transcatheter ovarian vein embolization using coils for the treatment of pelvic congestion syndrome. *Cardiovasc Intervent Radiol.* 2007;30:655-661.
138. Grant JCB. *Methods of Anatomy.* Baltimore, MD: Williams and Wilkins; 1937:158.
139. El Sadr AR, Mina A. Anatomical and surgical aspects of the operative management of varicoceles. *Urol Cutan Rev.* 1950;54:257-262.
140. De Schepper A. Nutcracker phenomenon of the renal vein causing left renal vein pathology. *J Belg Radiol.* 1972;55:507-511.
141. Satyapal KS. The renal veins: a review. *Eur J Anat.* 2003;7(Suppl 1):43-52.
142. Hohenfellner M, Steinbach F, Schultz-Lampel D, et al. The nutcracker syndrome: new aspects of pathophysiology, diagnosis and treatment. *J Urol.* 1991;146:685-688.
143. Shokeir AA, El-Diasty TA, Ghoniem MA. The nutcracker syndrome: new methods of diagnosis and treatment. *Br J Urol.* 1994;74:139-143.
144. Wendel RG, Crawford ED, Hehman KN. The nutcracker phenomenon: an unusual cause for renal varicosities with haematuria. *J Urol.* 1980;123:761-763.
145. Beinart C, Sniderman KW, Tamura S, et al. Left renal vein to inferior vena cava pressure relationship in humans. *J Urol.* 1982;127:1070-1071.
146. Nishimura Y, Fushiki M, Yoshida M, et al. Left renal vein hypertension in patients with left renal bleeding of unknown

origin. *Radiology*. 1986;59:663-667.

147. Shin JI, Park JM, Lee JS, Kim MJ. Effect of renal Doppler ultrasound on the detection of nutcracker syndrome in children with hematuria. *Eur J Pediatr*. 2007;166:399-404.
148. Frantz P, Jardin A, Aboulker J, Küss R. Responsibility of the left renal vein and inferior vena cava in certain cases of myelitis and syringomyelia. Value of ligation of the venous reno-spinal trunk. A propos of 30 cases. *Ann Urol*. 1986;20:137-141.
149. Takahashi Y, Ohta S, Sano A, et al. Does severe nutcracker phenomenon cause pediatric fatigue? *Clin Nephrol*. 2000;53:174-181.
150. Hilgard P, Oberholzer K, Meyer zum Büschenfelde KH, et al. Das "Nußknacker-Syndrom" der Vena renalis (Arteria-mesenterica-superior-Syndrom) als Ursache gastrointestinaler Beschwerden. *Dtsch Med Wochenschr*. 1998;123:936-940.
151. Kim SH, Cho SW, Kim HD, et al. Nutcracker syndrome: diagnosis with Doppler US. *Radiology*. 1996;198:93-97.
152. Takebayashi S, Ueki T, Ikeda N, Fujikawa A. Diagnosis of the nutcracker syndrome with color Doppler sonography: correlation with flow patterns on retrograde left renal venography. *AJR Am J Roentgenol*. 1999;172:39-43.
153. Hartung O, Grisoli D, Boufi M, et al. Endovascular stenting in the treatment of pelvic vein congestion caused by nutcracker syndrome: lessons learned from the first five cases. *J Vasc Surg*. 2005;42:275-280.
154. Fu W, Hong B, Xiao Y, et al. Diagnosis of the nutcracker phenomenon by multislice helical computed tomography angiography. *Chinese Med J*. 2004;117:1873-1875.
155. Andrianne R, Limet R, Waltregny D, de Leval J. Hematuria caused by nutcracker syndrome: preoperative confirmation of its presence. *Prog Urol*. 2002;12:1323-1326.
156. Tanaka H, Waga S. Spontaneous remission of persistent severe haematuria in an adolescent with nutcracker syndrome: seven years' observation. *Clin Exp Nephrol*. 2004;8:68-70.
157. Shin JI, Park JM, Lee SM, et al. Factors affecting spontaneous resolution of hematuria in childhood nutcracker syndrome. *Pediatr Nephrol*. 2005;20:609-613.
158. d'Archambeau O, Maes M, De Schepper AM. The pelvic congestion syndrome: role of the "nutcracker phenomenon" and results of endovascular treatment. *JBR-BTR*. 2004;87:1-8.
159. Rudloff U, Holmes RJ, Prem JT, et al. Mesoaortic compression of the left renal vein (nutcracker syndrome): case reports and review of the literature. *Ann Vasc Surg*. 2006;20:120-129.
160. Pallwein L, Pinggera G, Schuster AH, et al. The influence of left renal vein entrapment on outcome after surgical varicocele repair: a color Doppler sonographic demonstration. *J Ultrasound Med*. 2004;23:595-601.
161. Pastershank SP. Left renal vein obstruction by a superior mesenteric artery. *J Can Assoc Radiol*. 1974;25:52-54.
162. Stewart BH, Reiman G. Left renal venous hypertension "nutcracker" syndrome. Managed by direct renocaval reimplantation. *Urology*. 1982;20:365-369.
163. Ariyoshi A, Nagase K. Renal hematuria caused by "nutcracker" phenomenon: a more logical surgical management. *Urology*. 1990;35:168-170.
164. Ishidoya S, Chiba Y, Sakai K, Orikasa S. Nutcracker phenomenon: a case with surgical treatment and its diagnostic criteria. *Hinyokika Kiyo*. 1994;40:135-138.
165. Ohki T, Miyahara M, Nakajima Y, Matsumoto K. Nutcracker phenomenon treated with left renal vein transposition: a case report. *Hinyokika Kiyo*. 1999;45:183-186.
166. Hohenfellner M, D'Elia G, Hampel C, et al. Transposition of the left renal vein for treatment of the nutcracker phenomenon: long-term follow-up. *Urology*. 2002;59:354-357.
167. Ali-El-Dein B, Osman Y, Shehab El-Din AB, et al. Anterior and posterior nutcracker syndrome: a report on 11 cases. *Transplant Proc*. 2003;35:851-853.
168. Kim JY, Joh JH, Choi HY, et al. Transposition of the left renal vein in nutcracker syndrome. *Eur J Vasc Endovasc Surg*.

2006;31:80-82.

169. Rudloff U, Holmes RJ, Prem JT, et al. Mesoaortic compression of the left renal vein (nutcracker syndrome): case reports and review of the literature. *Ann Vasc Surg.* 2006;20:120-129.
170. Zhang H, Li M, Jin W, et al. The left renal entrapment syndrome: diagnosis and treatment. *Ann Vasc Surg.* 2007;21:198-203.
171. Gloviczki P, Kalra M, Duncan AA, et al. Nutcracker syndrome: left renal vein transposition. The first line treatment. In: Becquemin JB, Alimi YS, Gerard JL, eds. *Controversies and Updates in Vascular Surgery 2008*. Torino, Italy: Edizioni Minerva Medica; 2008:360-366.
172. Hartung O, Benmiloud F, Barthelemy P, et al. Late results of surgical venous thrombectomy with ilio caval stenting. *J Vasc Surg.* 2008;47:381-387.
173. Chuang CK, Chu SH, Lai PC. The nutcracker syndrome managed by autotransplantation. *J Urol.* 1997;157:1833-1834.
174. Shaper KR, Jackson JE, Williams G. The nutcracker syndrome: an uncommon cause of haematuria. *Br J Urol.* 1994;74:144-146.
175. Barnes RW, Fleisher HL 3rd, Redman JF, et al. Mesoaortic compression of the left renal vein (the so-called nutcracker syndrome): repair by a new stenting procedure. *J Vasc Surg.* 1988;8:415-421.
176. Scultetus AH, Villavicencio JL, Gillespie DL. The nutcracker syndrome: its role in the pelvic venous disorders. *J Vasc Surg.* 2001;34:812-819.
177. Thompson PN, Darling RC 3rd, Chang BB, et al. A case of nutcracker syndrome: treatment by mesoaortic transposition. *J Vasc Surg.* 1992;16:663-665.
178. Wendel RG, Crawford ED, Hehman KN. The "nutcracker" phenomenon: an unusual cause for renal varicosities with hematuria. *J Urol.* 1980;123:761-763.
179. Takahashi Y, Sano A, Matsuo M. An effective "transluminal balloon angioplasty" therapy for pediatric chronic fatigue syndrome with nutcracker phenomenon. *Clin Nephrol.* 2000;53:77-78.
180. Hartung O, Barthelemy P, Berdah SV, Alimi YS. Laparoscopy-assisted left ovarian vein transposition to treat one case of posterior nutcracker syndrome. *Ann Vasc Surg.* 2009;23:413.
181. Neste MG, Narasimham DL, Belcher KK. Endovascular stent placement as a treatment for renal venous hypertension. *J Vasc Interv Radiol.* 1996;7:859-861.
182. Segawa N, Azuma H, Iwamoto Y, et al. Expandable metallic stent placement for nutcracker phenomenon. *Urology.* 1999;53:631-633.
183. Park YB, Lim SH, Ahn JH, et al. Nutcracker syndrome: intravascular stenting approach. *Nephrol Dial Transplant.* 2000;15:99-101.
184. Chiesa R, Anzuini A, Marone EM, et al. Endovascular stenting for the nutcracker phenomenon. *J Endovasc Ther.* 2001;8:652-655.
185. van der Laan L, Vos JA, de Boer E, et al. The central-venous compression syndrome: rare, but adequately treatable with endovascular stenting. *Ned Tijdschr Geneesk.* 2004;148:433-437.
186. Chen W, Chu J, Yang J, et al. Endovascular stent placement for the treatment of nutcracker phenomenon in three pediatric patients. *J Vasc Interv Radiol.* 2005;16:1529-1533.
187. Kim SJ, Kim CW, Kim S, et al. Long-term follow-up after endovascular stent placement for treatment of nutcracker syndrome. *J Vasc Interv Radiol.* 2005;16:428-431.
188. Basile A, Tsetis D, Calcara G, et al. Percutaneous nitinol stent implantation in the treatment of nutcracker syndrome in young adults. *J Vasc Interv Radiol.* 2007;18:1042-1046.
189. Wei SM, Chen ZD, Zhou M. Intravenous stent placement for treatment of the nutcracker syndrome. *J Urol.* 2003;170:1934-1935.
190. Zhang H, Li M, Jin W, et al. The left renal entrapment syndrome: diagnosis and treatment. *Ann Vasc Surg.*

## 第 60 章

1. Neglén P, Hollis KC, Raju S. Combined saphenous ablation and iliac stent placement for complex severe chronic venous disease. *J Vasc Surg.* 2006;44:828-833.
2. Neglén P, Thrasher TL, Raju S. Venous outflow obstruction: an underestimated contributor to chronic venous disease. *J Vasc Surg.* 2003;38:879-885.
3. Johnson BF, Manzo RA, Bergelin RO, Strandness DE Jr. Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one- to six-year follow-up. *J Vasc Surg.* 1995;21:307-312; discussion 313.
4. Johnson BF, Manzo RA, Bergelin RO, Strandness DE Jr. The site of residual abnormalities in the leg veins in long-term follow-up after deep vein thrombosis and their relationship to the development of the post-thrombotic syndrome. *Int Angiol.* 1996;15:14-19.
5. Nicolaides AN, Hussein MK, Szendro G, et al. The relation of venous ulceration with ambulatory venous pressure measurements. *J Vasc Surg.* 1993;17:414-419.
6. Nicolaides AN, Sumner DS. *Investigations of Patients with Deep Vein Thrombosis and Chronic Venous Insufficiency.* Los Angeles, CA: Med-Orion Publishing; 1991.
7. Negus D, Fletcher EW, Cockett FB, Thomas ML. Compression and band formation at the mouth of the left common iliac vein. *Br J Surg.* 1968;55:369-374.
8. Akesson H, Brudin L, Dahlstrom JA, et al. Venous function assessed during a 5-year period after acute ilio-femoral venous thrombosis treated with anticoagulation. *Eur J Vasc Surg.* 1990;4:43-48.
9. Delis KT, Bountouroglou D, Mansfield AO. Venous claudication in iliofemoral thrombosis: long-term effects on venous hemodynamics, clinical status, and quality of life. *Ann Surg.* 2004;239:118-126.
10. Raju S, Neglén P. High prevalence of nonthrombotic iliac vein lesions in chronic venous disease: a permissive role in pathogenicity. *J Vasc Surg.* 2006;44:136-143; discussion 144.
11. Plate G, Akesson H, Einarsson E, et al. Long-term results of venous thrombectomy combined with a temporary arterio-venous fistula. *Eur J Vasc Surg.* 1990;4:483-489.
12. Rokitsansky C. *A Manual of Pathological Anatomy.* Vol 4 (Translation by Day GE), London: 1852:336.
13. May R, Thurner J. The cause of the predominantly sinistral occurrence of thrombosis of the pelvic veins. *Angiology.* 1957;8:419-427.
14. Ehrich WE, Krumbhaar EB. A frequent obstructive anomaly of the mouth of the left common iliac vein. *Am Heart J.* 1943;26:737-750.
15. McMurrich JP. The occurrence of congenital adhesions in the common iliac veins, and their relation to thrombosis of the femoral and iliac veins. *Am J Med Sci.* 1943;135:342-346.
16. Kibbe MR, Ujiki M, Goodwin AL, et al. Iliac vein compression in an asymptomatic patient population. *J Vasc Surg.* 2004;39:937-943.
17. Cockett FB, Thomas ML, Negus D. Iliac vein compression—Its relation to iliofemoral thrombosis and the post-thrombotic syndrome. *BMJ.* 1967;2:14-19.
18. Cockett FB, Thomas ML. The iliac compression syndrome. *Br J Surg.* 1965;52:816-821.
19. Strandness DE Jr, Sumner DS. The effect of geometry on arterial blood flow. In: *Hemodynamics for Surgeons.* New York: Grune & Stratton; 1975:96-119.
20. Neglén P, Raju S. Detection of outflow obstruction in chronic venous insufficiency. *J Vasc Surg.* 1993;17:583-589.
21. Labropoulos N, Volteas N, Leon M, et al. The role of venous outflow obstruction in patients with chronic venous dysfunction. *Arch Surg.* 1997;132:46-51.

22. Hurst DR, Forauer AR, Bloom JR, et al. Diagnosis and endovascular treatment of ilio caval compression syndrome. *J Vasc Surg.* 2001;34:106-113.
23. Albrechtsson U, Einarsson E, Eklof B. Femoral vein pressure measurements for evaluation of venous function in patients with postthrombotic iliac veins. *Cardiovasc Intervent Radiol.* 1981;4:43-50.
24. Negus D, Cockett FB. Femoral vein pressures in post-phlebotic iliac vein obstruction. *Br J Surg.* 1967;54:522-525.
25. Rigas A, Vomvourannis A, Giannoulis K, et al. Measurement of the femoral vein pressure in oedema of the lower extremities. Report of 50 cases. *J Cardiovasc Surg (Torino).* 1971;12:411-416.
26. Raju S, Owen S Jr, Neglén P. The clinical impact of iliac venous stents in the management of chronic venous insufficiency. *J Vasc Surg.* 2002;35:8-15.
27. Neglén P, Berry MA, Raju S. Endovascular surgery in the treatment of chronic primary and post-thrombotic iliac vein obstruction. *Eur J Vasc Endovasc Surg.* 2000;20:560-571.
28. Neglén P, Raju S. Intravascular ultrasound scan evaluation of the obstructed vein. *J Vasc Surg.* 2002;35:694-700.
29. Forauer AR, Gemmette JJ, Dasika NL, et al. Intravascular ultrasound in the diagnosis and treatment of iliac vein compression (May-Thurner) syndrome. *J Vasc Interv Radiol.* 2002;13:523-527.
30. Neglén P, Raju S. Balloon dilation and stenting of chronic iliac vein obstruction: technical aspects and early clinical outcome. *J Endovasc Ther.* 2000;7:79-91.
31. Ahmed HK, Hagspiel KD. Intravascular ultrasonographic findings in May-Thurner syndrome (iliac vein compression syndrome). *J Ultrasound Med.* 2001;20:251-256.
32. Satokawa H, Hoshino S, Iwaya F, et al. Intravascular imaging methods for venous disorders. *Int J Angiol.* 2000;9:117-121.
33. Neglén P, Raju S. Proximal lower extremity chronic venous outflow obstruction: recognition and treatment. *Semin Vasc Surg.* 2002;15:57-64.
34. Hartung O, Otero A, Boufi M, et al. Mid-term results of endovascular treatment for symptomatic chronic nonmalignant ilio caval venous occlusive disease. *J Vasc Surg.* 2005;42:1138-1144; discussion 1144.
35. Raju S, McAllister S, Neglén P. Recanalization of totally occluded iliac and adjacent venous segments. *J Vasc Surg.* 2002;36:903-911.
36. Marzo KP, Schwartz R, Glanz S. Early restenosis following percutaneous transluminal balloon angioplasty for the treatment of the superior vena caval syndrome due to pacemaker-induced stenosis. *Cathet Cardiovasc Diagn.* 1995;36:128-131.
37. Neglén P, al-Hassan HK, Endrys J, et al. Iliofemoral venous thrombectomy followed by percutaneous closure of the temporary arteriovenous fistula. *Surgery.* 1991;110:493-499.
38. Wisselink W, Money SR, Becker MO, et al. Comparison of operative reconstruction and percutaneous balloon dilatation for central venous obstruction. *Am J Surg.* 1993;166:200-204; discussion 204-205.
39. Walpole HT Jr, Lovett KE, Chuang VP, et al. Superior vena cava syndrome treated by percutaneous transluminal balloon angioplasty. *Am Heart J.* 1988;115:1303-1304.
40. Murphy KD. Mechanical thrombectomy for DVT. *Tech Vasc Interv Radiol.* 2004;7:79-85.
41. van Bemmelen PS, Bedford G, Beach K, Strandness DE. Quantitative segmental evaluation of venous valvular reflux with duplex ultrasound scanning. *J Vasc Surg.* 1989;10:425-431.
42. Neglén P, Tackett TP Jr, Raju S. Venous stenting across the inguinal ligament. *J Vasc Surg.* 2008;45:1255-1261.
43. Rector WG Jr, Xu YH, Goldstein L, et al. Membranous obstruction of the inferior vena cava in the United States. *Medicine (Baltimore).* 1985;64:134-143.
44. Lee BB, Villavicencio L, Kim YW, et al. Primary Budd-Chiari syndrome: outcome of endovascular management for suprahepatic venous obstruction. *J Vasc Surg.* 2006;43:101-108.
45. Harris RD. The etiology of inferior vena caval obstruction and compression. *CRC Crit Rev Clin Radiol Nucl Med.* 1976;8:57-86.
46. Raju S, Fredericks R. Venous obstruction: an analysis of one hundred thirty-seven cases with hemodynamic, venographic,

- and clinical correlations. *J Vasc Surg.* 1991;14:305-313.
47. van der Laan L, Vos JA, de Boer E, et al. [The central-venous compression syndrome: rare, but adequately treatable with endovascular stenting.] *Ned Tijdschr Geneesk.* 2004;148:433-437.
  48. Raju S, Hollis K, Neglén P. Obstructive lesions of the inferior vena cava: clinical features and endovenous treatment. *J Vasc Surg.* 2006;44:820-827.
  49. Farrell T, Lang EV, Barnhart W. Sharp recanalization of central venous occlusions. *J Vasc Interv Radiol.* 1999;10:149-154.
  50. Honnef D, Wingen M, Gunther RW, Haage P. Sharp central venous recanalization by means of a TIPS needle. *Cardiovasc Intervent Radiol.* 2005;28:673-676.
  51. Neglén P, Hollis KC, Olivier J, Raju S. Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic result. *J Vasc Surg.* 2007;46:979-990.
  52. Mewissen MW, Seabrook GR, Meissner MH, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. *Radiology.* 1999;211:39-49.
  53. Thorpe PE. Endovascular therapy for chronic venous obstruction. In: Ballard JL, Bergan JJ, eds. *Chronic Venous Insufficiency.* New York: Springer; 1999:179-219.
  54. O'Sullivan GJ, Semba CP, Bittner CA, et al. Endovascular management of iliac vein compression (May-Thurner) syndrome. *J Vasc Interv Radiol.* 2000;11:823-836.
  55. Knipp B, Ferguson E, Williams DM, et al. Factors associated with outcome after interventional treatment of symptomatic iliac vein compression syndrome. *J Vasc Surg.* 2007;46:743-749.
  56. Neglén P, Raju S. In-stent recurrent stenosis in stents placed in the lower extremity venous outflow tract. *J Vasc Surg.* 2004;39:181-187.
  57. Scott J, Huskisson EC. Accuracy of subjective measurements made with or without previous scores: an important source of error in serial measurement of subjective states. *Ann Rheum Dis.* 1979;38:558-559.
  58. Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. *Arch Intern Med.* 2002;162:1144-1148.
  59. Beyth RJ, Cohen AM, Landefeld CS. Long-term outcomes of deep-vein thrombosis. *Arch Intern Med.* 1995;155:1031-1037.
  60. MacKenzie RK, Paisley A, Allan PL, et al. The effect of long saphenous vein stripping on quality of life. *J Vasc Surg.* 2002;35:1197-1203.
  61. Launois R, Reboul-Marty J, Henry B. Construction and validation of a quality of life questionnaire in chronic lower limb venous insufficiency (CIVIQ). *Qual Life Res.* 1996;5:539-554.
  62. Delis KT, Bjarnason H, Wennberg PW, et al. Successful iliac vein and inferior vena cava stenting ameliorates venous claudication and improves venous outflow, calf muscle pump function, and clinical status in post-thrombotic syndrome. *Ann Surg.* 2007;245:130-139.

## 第 61 章

1. Wilson LD, Detterbeck FC, Yahalom J. Superior vena cava syndrome with malignant causes. *N Engl J Med.* 2007;356:1862.
2. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. *Medicine (Baltimore).* 2006;85:37.
3. Hunter W. The history of an aneurysm of the aorta with some remarks on aneurysms in general. *Med Obs Inq (Lond).* 1757;1:323.
4. Ahmann F. A reassessment of the clinical implications of the superior vena cava syndrome. *J Clin Oncol.* 1984;2:961.
5. Parish JM, Marschke RF Jr, Dines DE, Lee RE. Etiologic considerations in superior vena cava syndrome. *Mayo Clin Proc.* 1981;56:407.
6. Sculier JP, Feld R. Superior vena cava obstruction syndrome: recommendations for management. *Cancer Treat Rev.* 1985;12:209.



7. Chen J, Bongard F, Klein SR. A contemporary perspective on superior vena cava syndrome. *Am J Surg*. 1990;160:207.
8. Yellin A, Rosen A, Reichert N, Lieberman Y. Superior vena cava syndrome: the myth—the facts. *Am Rev Respir Dis*. 1990;141:1114.
9. Doty DB. Bypass of superior vena cava: six years' experience with spiral vein graft for obstruction of superior vena cava due to benign and malignant disease. *J Thorac Cardiovasc Surg*. 1982;83:326.
10. Doty DB, Doty JR, Jones KW. Bypass of superior vena cava: fifteen years' experience with spiral vein graft for obstruction of superior vena cava caused by benign disease. *J Thorac Cardiovasc Surg*. 1990;99:889.
11. Gloviczki P, Pairolero PC, Toomey BJ, et al. Reconstruction of large veins for nonmalignant venous occlusive disease. *J Vasc Surg*. 1992;16:750.
12. Gupta D, Mathur AS. Cervical and mediastinal fibrosis presenting with superior vena cava syndrome. *Indian Heart J*. 1979;31:302.
13. Dodds GA 3rd, Harrison JK, O'Laughlin MP, et al. Relief of superior vena cava syndrome due to fibrosing mediastinitis using the Palmaz stent. *Chest*. 1994;106:315.
14. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2007;115:e69.
15. Korkeila P, Nyman K, Ylitalo A, et al. Venous obstruction after pacemaker implantation. *Pacing Clin Electrophysiol*. 2007;30:199.
16. Laguna Del Estal P, Gazapo Navarro T, Murillas Angoititi J, et al. Superior vena cava syndrome: a study based on 81 cases. *An Med Interna*. 1998;15:470.
17. Alimi YS, Gloviczki P, Vrtiska TJ, et al. Reconstruction of the superior vena cava: benefits of postoperative surveillance and secondary endovascular interventions. *J Vasc Surg*. 1998;27:287.
18. Rizvi AZ, Kalra M, Bjarnason H, et al. Benign superior vena cava syndrome: stenting is now the first line of treatment. *J Vasc Surg*. 2008;47:372.
19. Kim HJ, Kim HS, Chung SH. CT diagnosis of superior vena cava syndrome: importance of collateral vessels. *AJR Am J Roentgenol*. 1993;161:539.
20. Yedlicka JW, Schultz K, Moncada R, Flisak M. CT findings in superior vena cava obstruction. *Semin Roentgenol*. 1989;24:84.
21. Bashist B, Parisi A, Frager DH, Suster B. Abdominal CT findings when the superior vena cava, brachiocephalic vein, or subclavian vein is obstructed. *AJR Am J Roentgenol*. 1996;167:1457.
22. Yamada T, Takahashi K, Shuke N, et al. Focal hepatic "hot spot" in superior vena cava obstruction: correlation between radiocolloid hepatic SPECT and contrast-enhanced CT. *Clin Nucl Med*. 1999;24:533.
23. Cihangiroglu M, Lin BH, Dachman AH. Collateral pathways in superior vena caval obstruction as seen on CT. *J Comput Assist Tomogr*. 2001;25:1.
24. Stanford W, Doty DB. The role of venography and surgery in the management of patients with superior vena cava obstruction. *Ann Thorac Surg*. 1986;41:158.
25. Gloviczki P, Pairolero PC, Cherry KJ, Hallett JW Jr. Reconstruction of the vena cava and of its primary tributaries: a preliminary report. *J Vasc Surg*. 1990;11:373.
26. Schindler N, Vogelzang RL. Superior vena cava syndrome: experience with endovascular stents and surgical therapy. *Surg Clin North Am*. 1999;79:683.
27. Kalra M, Gloviczki P, Andrews JC, et al. Open surgical and endovascular treatment of superior vena cava syndrome caused by nonmalignant disease. *J Vasc Surg*. 2003;38:215.
28. Moore W, Hollier LH. Reconstruction of the superior vena cava and central veins. In: Bergan J, Yao JST, eds. *Venous Disorders*. Philadelphia, PA: WB Saunders; 1991:517.
29. Bergeron P, Reggi M, Jausseran JM, et al. Our experience with surgery of the superior vena cava. *Ann Chir*. 1985;39:485.

30. Herreros J, Glock Y, de la Fuente A, et al. Superior vena cava compression syndrome. Our experience apropos of 26 cases. *Ann Chir.* 1985;39:495.
31. Ricci C, Benedetti Valentini F, Colini GF, et al. Reconstruction of the superior vena cava: 15 years' experience using various types of prosthetic material. *Ann Chir.* 1985;39:492.
32. Darteville PG, Chapelier AR, Pastorino U, et al. Long-term follow-up after prosthetic replacement of the superior vena cava combined with resection of mediastinal-pulmonary malignant tumors. *J Thorac Cardiovasc Surg.* 1991;102:259.
33. Magnan PE, Thomas P, Giudicelli R, et al. Surgical reconstruction of the superior vena cava. *Cardiovasc Surg.* 1994;2:598.
34. Kalra M, Bjarnason H, Gloviczki P. Surgical and endovenous treatment of superior vena cava syndrome. In Gloviczki P, ed. *Handbook of Venous Disorders.* 3rd ed. London, Edward Arnold; 2009:553.
35. Chen KN, Xu SF, Gu ZD, et al. Surgical treatment of complex malignant anterior mediastinal tumors invading the superior vena cava. *World J Surg.* 2006;30:162-170.
36. Inoue M, Minami M, Shiono H, et al. Efficient clinical application of percutaneous cardiopulmonary support for perioperative management of a huge anterior mediastinal tumor. *J Thorac Cardiovasc Surg.* 2006;131:755.
37. Kuehn A, Schmidt M, Hornung HM, et al. Resection of malignant tumors invading the vena cava: perioperative complications and long-term follow-up. *J Vasc Surg.* 2007;46:533.
38. Vincze K, Kulka F, Csorba L. Saphenous-jugular bypass as palliative therapy of superior vena cava syndrome caused by bronchial carcinoma. *J Thorac Cardiovasc Surg.* 1982;83:272.
39. Graham A, Anikin V, Curry R, McGuigan J. Subcutaneous jugulofemoral bypass: a simple surgical option for palliation of superior vena cava obstruction. *J Cardiovasc Surg.* 1995;36:615.
40. Panneton JM, Andrews JC, Hoter JM. Superior vena cava syndrome relief with a modified sapheno-jugular bypass graft. *J Vasc Surg.* 2001;34:360.
41. Dhaliwal RS, Das D, Luthra S, et al. Management of superior vena cava syndrome by internal jugular to femoral vein bypass. *Ann Thorac Surg.* 2006;82:310.
42. Wells JK, Hagino RT, Bargmann KM, et al. Venous morbidity after superficial femoral–popliteal vein harvest. *J Vasc Surg.* 1999;29:282-289, discussion 289, 1999.
43. Modrall JG, Hocking JA, Timaran CH, et al. Late incidence of chronic venous insufficiency after deep vein harvest. *J Vasc Surg.* 2007;46:520.
44. Gladstone DJ, Pillai R, Paneth M, Lincoln JC. Relief of superior vena caval syndrome with autologous femoral vein used as a bypass graft. *J Thorac Cardiovasc Surg.* 1985;89:750.
45. Chiu CJ, Terzis J, MacRae ML. Replacement of superior vena cava with the spiral composite vein graft: a versatile technique. *Ann Thorac Surg.* 1974;17:555.
46. Gloviczki P, Pairolero PC. Prosthetic replacement of large veins. In: Bergan J, Kistner RL, eds. *Atlas of Venous Surgery.* Philadelphia, PA: WB Saunders; 1992:191.
47. Meissner MH, Eklof B, Coleridge Smith P, et al. Secondary chronic venous disorders. *J Vasc Surg.* 2007;46:S68.
48. Bower TC, Nagorney DM, Cherry KJ, et al. Replacement of the inferior vena cava for malignancy: an update. *J Vasc Surg.* 2000;31:270.
49. Jost CJ, Gloviczki P, Cherry KJ, et al. Surgical reconstruction of iliofemoral veins and the inferior vena cava for nonmalignant occlusive disease. *J Vasc Surg.* 2001;33:320.
50. Marshall W, Kouchoukos NT. Management of recurrent superior vena caval syndrome with an externally supported femoral vein bypass graft. *Ann Thorac Surg.* 1988;46:239.
51. Rhee R, Gloviczki P, Steers JL, et al. Superior vena cava reconstruction using an ilio caval allograft. *Vasc Surg.* 1996;30:77.
52. Billing JS, Sudarshan CD, Schofield PM, et al. Aortic arch homograft as a bypass conduit for superior vena cava obstruction. *Ann Thorac Surg.* 2003;76:1296.
53. Zembala M, Kustrzycki A, Ostapczuk S, et al. Pericardial tube for obstruction of superior vena cava by malignant teratoma.

- J Thorac Cardiovasc Surg.* 1986;91:469.
54. Seelig MH, Oldenburg WA, Klingler PJ, et al. Superior vena cava syndrome caused by chronic hemodialysis catheters: autologous reconstruction with a pericardial tube graft. *J Vasc Surg.* 1998;28:556.
  55. Abdullah F, Adeeb S. Superior vena cava obstruction bypass—an alternative technique using bovine pericardial conduit: a case report. *Heart Surg Forum.* 2003;6:E50.
  56. Singh S, Sherif H, Reul GJ. Reconstruction of the superior vena cava with the aid of an extraluminal venovenous jugulo-atrial shunt. *Tex Heart Inst J.* 2000;27:38.
  57. Doty JR, Flores JH, Doty DB. Superior vena cava obstruction: bypass using spiral vein graft. *Ann Thorac Surg.* 1999;67:1111.
  58. Hagino RT, Bengtson TD, Fosdick DA, et al. Venous reconstructions using the superficial femoral-popliteal vein. *J Vasc Surg.* 1997;26:829.
  59. Wisselink W, Money SR, Becker MO, et al. Comparison of operative reconstruction and percutaneous balloon dilatation for central venous obstruction. *Am J Surg.* 1993;166:200.
  60. Shintani Y, Ohta M, Minami M, et al. Long-term graft patency after replacement of the brachiocephalic veins combined with resection of mediastinal tumors. *J Thorac Cardiovasc Surg.* 2005;129:809.

## 第 62 章

1. Kamiya K, Nakata Y, Naiki K, et al. Superior vena caval syndrome. Review of the literature and a case report. *Vasc Dis.* 1967;4:59.
2. Schechter MM. The superior vena cava syndrome. *Am J Med Sci.* 1954;227:46.
3. Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. *N Engl J Med.* 2007;356:1862.
4. Nieto AF, Doty DB. Superior vena cava obstruction: clinical syndrome, etiology, and treatment. *Curr Probl Cancer.* 1986;10:441.
5. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. *Clin Oncol (R Coll Radiol).* 2002;14:338.
6. Van Putten JW, Schlosser NJ, Vujaskovic Z, et al. Superior vena cava obstruction caused by radiation induced venous fibrosis. *Thorax.* 2000;55:245.
7. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. *Medicine (Baltimore).* 2006;85:37.
8. Slonim SM, Semba CP, Sze DY, et al. Placement of SVC stents over pacemaker wires for the treatment of SVC syndrome. *J Vasc Interv Radiol.* 2000;1:215.
9. Woodyard TC, Mellinger JD, Wann KG, et al. Acute superior vena cava syndrome after central venous catheter placement. *Cancer.* 1993;15:2621.
10. Laguna Del Estal P, Gazapo Navarro T, Murillas Angoitte J, et al. [Superior vena cava syndrome: a study based on 81 cases.] *An Med Interna.* 1998;15:470.
11. Fa Qin LV, Duan YY, Yuan LJ, et al. Doppler superior vena cava flow evolution and respiratory variation in superior vena cava syndrome. *Echocardiography.* 2008;25:360.
12. Eren S, Karaman A, Okur A. The superior vena cava syndrome caused by malignant disease. Imaging with multi-detector row CT. *Eur J Radiol.* 2006;59:93.
13. Cihangiroglu M, Lin BH, Dachman AH. Collateral pathways in superior vena caval obstruction as seen on CT. *J Comput Assist Tomogr.* 2001;25:1.
14. Thornton MJ, Ryan R, Varghese JC, et al. A three-dimensional gadolinium-enhanced MR venography technique for imaging central veins. *AJR Am J Roentgenol.* 1999;173:999.

15. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. *J Am Soc Nephrol*. 2006;17:2359.
16. Mahmud AM, Teshima T, Isawa T, et al. Follow-up of patients with superior vena cava syndrome by functional analysis of radionuclide venography. *Nucl Med Commun*. 1998;19:417.
17. Stanford W, Doty DB. The role of venography and surgery in the management of patients with superior vena cava obstruction. *Ann Thorac Surg*. 1986;41:158.
18. Bierdrager E, Lampmann LEH, Lohle PNM, et al. Endovascular stenting in neoplastic superior vena cava syndrome prior to chemotherapy or radiotherapy. *Neth J Med*. 2005;63:20.
19. Rosch J, Uchida BT, Hall LD, et al. Gianturco-Rosch expandable Z-stents in the treatment of superior vena cava syndrome. *Cardiovasc Intervent Radiol*. 1992;15:319.
20. Kim YI, Kim KS, Ko YC, et al. Endovascular stenting as a first choice for the palliation of superior vena cava syndrome. *J Korean Med Sci*. 2004;19:519.
21. Dyet JF, Cook A, Nicholson A. Use of the Wallstent in the treatment of malignant superior vena caval obstruction. *J Vasc Interv Radiol*. 1994;5:2.
22. Barshes NR, Annambhotla S, El Sayed HF, et al. Percutaneous stenting of superior vena cava syndrome: treatment outcome in patients with benign and malignant etiology. *Vascular*. 2007;15:314.
23. Tzifa A, Marshall A, McElhinney D, et al. Endovascular treatment for superior vena cava occlusion or obstruction in a pediatric and young adult population. *J Am Coll Cardiol*. 2007;49:1003.
24. Ariza GA, Gamboa P, Gimeno MJ, et al. Percutaneous treatment of superior vena cava syndrome using metallic stents. *Eur Radiol*. 2003;13:853.
25. Sheikh MA, Fernandez BB Jr, Gray BH, et al. Endovascular stenting of nonmalignant superior vena cava syndrome. *Cathet Cardiovasc Interv*. 2005;65:405.
26. Dinkel HP, Mettke B, Schmid F, et al. Endovascular treatment of malignant superior vena cava syndrome: is bilateral Wallstent placement superior to unilateral placement? *J Endovasc Ther*. 2003;10:788.
27. Williams DR, Demos NJ. Thrombosis of superior vena cava caused by pacemaker wire and managed with streptokinase. *J Thorac Cardiovasc Surg*. 1974;68:134.
28. Kee ST, Kinoshita L, Razavi MK, et al. Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. *Radiology*. 1998;206:187.
29. Kalman PG, Lindsay TF, Clarke K, et al. Management of upper extremity central venous obstruction using interventional radiology. *Ann Vasc Surg*. 1998;12:202.
30. Blackburn T, Dunn M. Pacemaker-induced superior vena cava syndrome: consideration of management. *Am Heart J*. 1988;116:893.
31. de Gregorio MA, Gimeno MJ. Interventional radiologic techniques in thoracic emergencies. *Arch Bronconeumol*. 2000;36:51-56.
32. Gray BH, Olin JW, Graor RA, et al. Safety and efficacy of thrombolytic therapy for superior vena cava syndrome. *Chest*. 1991;99:54.
33. Rosenblum J, Leef J, Messersmith R, et al. Intravascular stents in the management of acute superior vena cava obstruction of benign etiology. *JPEN J Parenter Enteral Nutr*. 1994;18:362.
34. Lin PH, Zhou W, Dardik A, et al. Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis. *Am J Surg*. 2006;192:782.
35. Courtheoux P, Alkofer B, El Refai M, et al. Stent placement in superior vena cava syndrome. *Ann Thorac Surg*. 2003;75:158.
36. Singh KP, Patel MR, Kandzari DE, et al. Peripheral arterial disease: an overview of endovascular therapies and contemporary treatment strategies. *Rev Cardiovasc Med*. 2006;7:55.

37. Shah R, Sabanathan S, Lowe RA, et al. Stenting in malignant obstruction of superior vena cava. *J Thorac Cardiovasc Surg.* 1996;112:335.
38. Petersen BD, Uchida BT. Long-term results of treatment of benign central venous obstructions unrelated to dialysis with expandable Z stents. *J Vasc Interv Radiol.* 1999;10:757.
39. Miller JH, McBride K, Little F, et al. Malignant superior vena cava obstruction: stent placement via the subclavian route. *Cardiovasc Intervent Radiol.* 2000;23:155.
40. Watkinson AF, Hansell DM. Expandable Wallstent for the treatment of obstruction of the superior vena cava. *Thorax.* 1993;48:915.
41. Edwards RD, Cassidy J, Taylor A. Case report: superior vena cava obstruction complicated by central venous thrombosis—treatment with thrombolysis and Gianturco-Z stents. *Clin Radiol.* 1992;45:278.
42. Gaines PA, Belli AM, Anderson PB, et al. Superior vena caval obstruction managed by the Gianturco Z stent. *Clin Radiol.* 1994;49:202.
43. Glanz S, Gordon D, Lipkowitz GS, et al. Axillary and subclavian vein stenosis: percutaneous angioplasty. *Radiology.* 1998;168:371.
44. Qanadli SD, El Hajjam M, Mignon F, et al. Subacute and chronic benign superior vena cava obstructions: endovascular treatment with self-expanding metallic stents. *Am J Roentgenol.* 1999;173:159.
45. Stock KW, Jacob AL, Proske M, et al. Treatment of malignant obstruction of the superior vena cava with the self-expanding Wallstent. *Thorax.* 1995;50:1151.
46. Gill K, Ettles DF, Nicholson AA. Recurrent superior vena caval obstruction due to invasion by malignant thymoma: treatment using a stent-graft. *Br J Radiol.* 2001;73:414.
47. Chin DH, Petersen BD, Timmermans H, et al. Stent-graft in the management of superior vena cava syndrome. *Cardiovasc Intervent Radiol.* 1996;19:302.
48. Hennequin LM, Fade O, Fays JG, et al. Superior vena cava stent placement: results with the Wallstent endoprosthesis. *Radiology.* 1995;196:353.
49. Rizvi AZ, Kalra M, Bjarnason H, et al. Benign superior vena cava syndrome: stenting is now the first line of treatment. *J Vasc Surg.* 2008;47:372.
50. Charnsangavej C, Carrasco CH, Wallace S, et al. Stenosis of the vena cava: preliminary assessment of treatment with expandable metallic stents. *Radiology.* 1986;161:295.
51. Schindler N, Vogelzang RL. Superior vena cava syndrome. Experience with endovascular stents and surgical therapy. *Surg Clin North Am.* 1999;79:683.
52. Oudkerk M, Kuijpers T, Schmitz P, et al. Self expanding metal stents for palliative treatment of superior vena caval syndrome. *Cardiovasc Intervent Radiol.* 1996;19:146.
53. Nicholson AA, Ettles DF, Arnold A, et al. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. *J Vasc Interv Radiol.* 1997;8:781.
54. Kovalik EC, Newman GE, Suhocki P, et al. Correction of central venous stenosis: use of angioplasty and vascular Wallstents. *Kidney Int.* 1994;45:1177.
55. Brant J, Peebles C, Kalra P, et al. Hemopericardium after superior vena cava stenting for malignant SVC obstruction: the importance of contrast-enhanced CT in the assessment of postprocedural collapse. *Cardiovasc Intervent Radiol.* 2001;24:353.
56. Martin M, Baumgartner I, Kolb M, et al. Fatal pericardial tamponade after Wallstent implantation for malignant superior vena cava syndrome. *J Endovasc Ther.* 2002;9:680.
57. Taylor JD, Lehmann ED, Belli AM, et al. Strategies for the management of SVC stent migration into the right atrium. *Cardiovasc Intervent Radiol.* 2007;30:1003.
58. Srinathan S, McCafferty I, Wilson I. Radiological management of superior vena caval stent migration and infection.

## 第 63 章

1. Bower TC, Nagorney DM, Cherry KJ Jr, et al. Replacement of the inferior vena cava for malignancy: an update. *J Vasc Surg.* 2000;31:270-281.
2. Bower TC. Evaluation and management of malignant tumors of the inferior vena cava. In: Rutherford RB, ed. *Rutherford's Vascular Surgery*. 6th ed. Philadelphia, PA: Elsevier Saunders; 2005:2345-2356.
3. Bower TC. Primary and secondary tumors of the vena cava and iliac veins. In: Gloviczki P, ed. *Handbook of Venous Disorders*. 3rd ed. London, Hodder Arnold; 2008.
4. Mingoli A, Feldhaus RJ, Cavallaro A, Stipa S. Leiomyosarcoma of the inferior vena cava: analysis and search of world literature on 141 patients and report of three new cases. *J Vasc Surg.* 1991;14:688-699.
5. Dzsinih C, Gloviczki P, van Heerden JA, et al. Primary venous leiomyosarcoma: a rare but lethal disease. *J Vasc Surg.* 1992;15:595-603.
6. Kieffer E, Alaoui M, Piette JC, et al. Leiomyosarcoma of the inferior vena cava: experience in 22 cases. *Ann Surg.* 2006;244:289-295.
7. Gloviczki P, Pairolero PC, Toomey BJ, et al. Reconstruction of large veins for nonmalignant venous occlusive disease. *J Vasc Surg.* 1992;16:750-761.
8. Bonardelli S, Nodari F, Maffei R, et al. Limb salvage in lower-extremity sarcomas and technical details about vascular reconstruction. *J Orthop Sci.* 2000;5:555-560.
9. Leggon RE, Huber TS, Scarborough MT. Limb salvage surgery with vascular reconstruction. *Clin Orthop Relat Res.* 2001;387:207-216.
10. Matsushita M, Kuzuya A, Mano N, et al. Sequelae after limb-sparing surgery with major vascular resection for tumor of the lower extremity. *J Vasc Surg.* 2001;33:694-699.
11. Schwarzbach MHM, Hormann Y, Hinz U, et al. Results of limb-sparing surgery with vascular replacement for soft tissue sarcoma in the lower extremity. *J Vasc Surg.* 2005;42:88-97.
12. Nishinari K, Wolosker N, Yazbek G, et al. Venous reconstructions in lower limbs associated with resection of malignancies. *J Vasc Surg.* 2006;44:1046-1050.
13. Ito H, Hornick JL, Bertagnolli MM, et al. Leiomyosarcoma of the inferior vena cava: survival after aggressive management. *Ann Surg Oncol.* 2007;14:3534-3542.
14. Illuminati G, Calio FG, D'Urso A, et al. Prosthetic replacement of the infrahepatic inferior vena cava for leiomyosarcoma. *Arch Surg.* 2006;141:919-924.
15. Bower TC, Nagorney DM, Toomey BJ, et al. Vena cava replacement for malignant disease: is there a role? *Ann Vasc Surg.* 1993;7:51-62.
16. Huguet C, Ferri M, Gavelli A. Resection of the suprarenal inferior vena cava: the role of prosthetic replacement. *Arch Surg.* 1995;130:793-797.
17. Sarkar R, Ellber FR, Gelabert HA, Quinones-Baldrich WJ. Prosthetic replacement of the inferior vena cava for malignancy. *J Vasc Surg.* 1998;28:75-83.
18. Sarmiento JM, Bower TC, Cherry KJ, et al. Is combined partial hepatectomy with segmental resection of the inferior vena cava justified for malignancy? *Arch Surg.* 2003;138:624-630.
19. Kuehnl A, Schmidt M, Hornung HM, et al. Resection of malignant tumors invading the vena cava: perioperative complications and long-term follow-up. *J Vasc Surg.* 2007;46:533-540.
20. Delis S, Madariaga J, Ciancio G. Combined liver and inferior vena cava resection for hepatic malignancy. *J Surg Oncol.* 2007;96:258-264.
21. Arai S, Teramoto K, Kawamura T, et al. Significance of hepatic resection combined with inferior vena cava resection and its

- reconstruction with expanded polytetrafluoroethylene for treatment of liver tumors. *J Am Coll Surg*. 2004;239:712-721.
22. Hemming AW, Reed AI, Langham MR, et al. Combined resection of the liver and inferior vena cava for hepatic malignancy. *Ann Surg*. 2004;239:712-721.
  23. Yoshidome H, Takeuchi D, Ito H, et al. Should the inferior vena cava be reconstructed after resection for malignant tumors? *Am J Surg*. 2005;189:419-424.
  24. Oldehafer KJ, Lang H, Schlitt HJ, et al. Long-term experience after ex situ liver surgery. *J Surg*. 2000;127:520-527.
  25. Lodge JPA, Ammori BJ, Prasad KR, Bellamy MC. Ex vivo and in situ resection of inferior vena cava with hepatectomy for colorectal metastases. *Ann Surg*. 2000;231:471-479.
  26. Miller CM, Schwartz ME, Nishizaki T. Combined hepatic and vena caval resection with autogenous caval graft replacement. *Arch Surg*. 1991;126:106-108.
  27. Praseedom RJ, Dhar P, Jamieson NV, et al. Leiomyosarcoma of the retrohepatic vena cava treated by excision and reconstruction with an aortic homograft: a case report and review of the literature. *Surg Innov*. 2007;14:287-291.
  28. Guerrero M, Cross CA, Lin PH, et al. Inferior vena cava reconstruction using fresh inferior vena cava allograft following caval resection for leiomyosarcoma: midterm results. *J Vasc Surg*. 2007;46:140-143.
  29. Spitz A, Wilson TG, Kawachi MH, et al. Vena caval resection for bulky metastatic germ cell tumors: an 18-year experience. *J Urol*. 1997;158:1813-1818.
  30. Beck SD, Lalka SG. Long-term results after inferior vena caval resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer. *J Vasc Surg*. 1998;28:808-814.
  31. Blute ML, Leibovich BC, Lohse CM, et al. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. *BJU Int*. 2004;94:33-41.
  32. Enzinger FM, Weiss SW. In: Gay SM, ed. *Soft Tissue Tumors*. 3<sup>rd</sup> ed. St. Louis, MO: Mosby-Year Book; 1995:505-510.
  33. Perl L. Ein Fall von Sarkom der Vena cava inferior. *Virchows Arch*. 1871;53:378-383.
  34. Hartman DS, Hayes WS, Choyke PL, Tibbetts GP. Leiomyosarcoma of the retroperitoneum and inferior vena cava: radiologic-pathologic correlation. *Radiographics*. 1992;12:1203-1220.
  35. Chang AE, Sondak VK. Clinical evaluation and treatment of soft tissue tumors. In: Gay SM, ed. *Soft Tissue Tumors*. 3<sup>rd</sup> ed. St. Louis, MO: Mosby-Year Book; 1995:17-38.
  36. Nesbitt JC, Soltero ER, Dinney CPN, et al. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. *Ann Thorac Surg*. 1997;63:1592-1600.
  37. Quek ML, Stein JP, Skinner DG. Surgical approaches to venous tumor thrombus. *Semin Urol Oncol*. 2001;19:88-97.
  38. Zisman A, Wieder JA, Pantuck AJ, et al. Renal cell carcinoma with tumor thrombus extension. Biology, role of nephrectomy and response to immunotherapy. *J Urol*. 2003;169:909.
  39. Gettman MT, Boelter CW, Cheville JC, et al. Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. *J Urol*. 2003;169:1282-1286.
  40. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis: the SSIGN score. *J Urol*. 2002;168:2395-2400.
  41. Leibovich BC, Cheville JC, Lohse C, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. *J Urol*. 2005;174:1759-1763.
  42. Haferkamp A, Bastian PJ, Jakobi H, et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term follow-up. *J Urol*. 2007;177:1703-1708.
  43. Ciancio G, Livingstone AS, Soloway M. Surgical management of renal cell carcinoma with tumor thrombus in the renal and inferior vena cava: the University of Miami experience in using liver transplantation techniques. *Eur Urol*. 2007;51:988-995.
  44. Terakawa T, Miyake H, Takemaka A, et al. Clinical outcome of surgical management for patients with renal cell carcinoma involving the inferior vena cava. *Int J Urol*. 2007;14:781-784.
  45. Zini L, Destrieux-Garnier L, Leroy X, et al. Renal vein ostium wall invasion of renal cell carcinoma with inferior vena cava

- tumor thrombus: prediction by renal and vena caval vein diameters and prognostic significance. *J Urol*. 2008;179:450-454.
46. Swanson DA, Wallace S, Johnson DE. The role of embolization and nephrectomy in the treatment of metastatic renal carcinoma. *J Urol Surg*. 1980;7:719-730.
  47. Phillips M, Bower T, Orszulak TO, Hartmann L. Intracardiac extension of an intracaval sarcoma of endometrial origin. *Ann Thorac Surg*. 1997;63:1592-1600.
  48. Chiche L, Dousset B, Kieffer E, Chapuis Y. Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature. *Surgery*. 2006;139:15-27.
  49. Kallman DA, King BF, Hattery RR, et al. Renal vein and inferior vena cava tumor thrombus in renal cell carcinoma: CT, US, MRI and venacavography. *J Comput Assist Tomogr*. 1992;16:240-247.
  50. Padovan RS, Perkov D, Smiljanic R, et al. Venous spread of renal cell carcinoma: MDCT. *Abdom Imaging*. 2007;32:530-537.
  51. Gohji K, Yamashita C, Ueno K, et al. Preoperative computerized tomography detection of extensive invasion of the inferior vena cava by renal cell carcinoma: possible indication for resection with partial cardiopulmonary bypass and patch grafting. *J Urol*. 1994;152:1993-1996.
  52. Welch TJ, LeRoy AJ. Helical and electron beam CT scanning in the evaluation of renal vein involvement in patients with renal cell carcinoma. *J Comput Assist Tomogr*. 1997;21:467-471.
  53. Laissey JP, Menegazzo D, Debray MP, et al. Renal carcinoma: diagnosis of venous invasion with Gd-enhanced MR venography. *Eur Radiol*. 2000;10:1138.
  54. Beahrs OH, Henson DE, Hutter RVP, et al. General rules for staging cancer. In: American Joint Commission on Cancer. *Manual for Staging of Cancer*. 3rd ed. Philadelphia, PA: JB Lippincott; 1988:9.
  55. Mingoli A, Sapienza P, Cavallaro A, et al. The effect of extension of caval resection in the treatment of inferior vena cava leiomyosarcoma. *Anticancer Res*. 1997;17:3877-3882.
  56. Blute ML, Boorjian SA, Leibovich BC, et al. Results of inferior vena caval interruption by Greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy. *J Urol*. 2007;178:440-445.
  57. McCullough DL, Gittes RF. Ligation of the renal in the solitary kidney: effects on renal function. *J Urol Surg*. 1975;113:295-299.
  58. Gloviczki P, Kalra M, Andrews JC. Surgical treatment of superior vena cava syndrome. In: Rutherford RB, ed. *Rutherford's Vascular Surgery*. 6th ed. Philadelphia, PA: Elsevier Saunders; 2005:2357-2371.
  59. Butany J, Singh G, Henry J, et al. Vascular smooth muscle tumors: 13 cases and a review of the literature. *Int J Angiol*. 2006;15:43-50.

## 第 64 章

1. DeWeese M. Nonoperative treatment of acute superficial thrombophlebitis and deep femoral venous thrombosis. In: Ernst CB, Stanley JS, eds. *Current Therapy in Vascular Surgery*. 2nd ed. Philadelphia, PA: Mosby; 1996.
2. Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. *Cochrane Database Syst Rev*. 2007;2:CD004982.
3. Coon WW, Willis PW 3rd, Keller JB. Venous thromboembolism and other venous disease in the Tecumseh community health study. *Circulation*. 1973;48:839-846.
4. Marchiori A, Mosena L, Prandoni P. Superficial vein thrombosis: risk factors, diagnosis, and treatment. *Semin Thromb Hemost*. 2006;32:737-743.
5. Leon L, Giannoukas AD, Dodd D, et al. Clinical significance of superficial vein thrombosis. *Eur J Vasc Endovasc Surg*. 2005;29:10-17.
6. Meissner MH, Wakefield TW, Ascher E, et al. Acute venous disease: venous thrombosis and venous trauma. *J Vasc Surg*. 2007;46(Suppl S):25S-53S.



7. Quenet S, Laporte S, Déous H, et al. Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis. *J Vasc Surg.* 2003;38:944-949.
8. Sarica-Kucukoglu R, Akdag-Kose A, Kayabal IM, et al. Vascular involvement in Behçet's disease: a retrospective analysis of 2319 cases. *Int J Dermatol.* 2006;45:919-921.
9. Olin JW, Shih A. Thromboangiitis obliterans (Buerger's disease). *Curr Opin Rheumatol.* 2006;18:18-24.
10. Hanson JN, Ascher E, DePippo P, et al. Saphenous vein thrombophlebitis (SVT): a deceptively benign disease. *J Vasc Surg.* 1998;27:677-680.
11. Marchiori A, Verlato F, Sabbion P, et al. Low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. *Haematologica.* 2002;87:523-527.
12. de Moerloose P, Wutschert R, Heinzmann M, et al. Superficial vein thrombosis of lower limbs: influence of factor V Leiden, factor II G20210A and overweight. *Thromb Haemost.* 1998;80:239-241.
13. Prouttjos P, Bastounis E, Hadjinikolaou L, et al. Superficial venous thrombosis of the lower extremities co-existing with deep venous thrombosis. A phlebographic study on 57 cases. *Int Angiol.* 1991;10:63-65.
14. Bergqvist D, Jaroszewski H. Deep vein thrombosis in patients with superficial thrombophlebitis of the leg. *Br Med J (Clin Res Ed).* 1986;292:658-659.
15. Lutter KS, Kerr TM, Roedersheimer LR, et al. Superficial thrombophlebitis diagnosed by duplex scanning. *Surgery.* 1991;110:42-46.
16. De Palma RG. Superficial thrombophlebitis. In: Rutherford R, ed. *Vascular Surgery.* 6th ed. Philadelphia, PA: Elsevier Saunders; 2005:2216-2220.
17. Hammond JS, Varas R, Ward CG. Suppurative thrombophlebitis: a new look at a continuing problem. *South Med J.* 1988;81:969-971.
18. Mayor M, Burón I, de Mora JC, et al. Mondor's disease. *Int J Dermatol.* 2000;39:922-925.
19. Sasso F, Gulino G, Basar M, et al. Penile Mondor's disease: an underestimated pathology. *Br J Urol.* 1996;77:729-732.
20. Ascher E, Hanson JN, Salles-Cunha S, et al. Lesser saphenous vein thrombophlebitis: its natural history and implications for management. *Vasc Endovascular Surg.* 2003;37:421-427.
21. Sassu GP, Chisholm CD, Howell JM, et al. A rare etiology for pulmonary embolism: basilic vein thrombosis. *J Emerg Med.* 1990;8:45-49.
22. Chengelis DL, Bendick PJ, Glover JL, et al. Progression of superficial venous thrombosis to deep vein thrombosis. *J Vasc Surg.* 1996;24:745-749.
23. Blumenberg RM, Barton E, Gelfand ML, et al. Occult deep venous thrombosis complicating superficial thrombophlebitis. *J Vasc Surg.* 1998;27:338-343.
24. Ludbrook J, Jamieson GG. Disorders of veins. In: Sabiston DC Jr, ed. *Textbook of Surgery.* 12th ed. Philadelphia, PA: WB Saunders; 1981:1808-1827.
25. Hobbs JT. Superficial thrombophlebitis. In: Hobbs JT, ed. *The Treatment of Venous Disorders.* Philadelphia, PA: JB Lippincott; 1977:414-427.
26. Belcaro G, Nicolaides AN, Errichi BM, et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study. *Angiology.* 1999;50:523-529.
27. Husni EA, Williams WA. Superficial thrombophlebitis of lower limbs. *Surgery.* 1982;91:70-73.
28. Lofgren EP, Lofgren KA. The surgical treatment of superficial thrombophlebitis. *Surgery.* 1981;90:49-54.
29. Gjores JE. Surgical therapy of ascending thrombophlebitis in the saphenous system. *Angiology.* 1962;13:241-243.
30. Plate G, Eklöf B, Jensen R, et al. Deep venous thrombosis, pulmonary embolism and acute surgery in thrombophlebitis of the long saphenous vein. *Acta Chir Scand.* 1985;151:241-244.
31. Ascher E, Lorensen E, Pollina RM, et al. Preliminary results of a nonoperative approach to saphenofemoral junction thrombophlebitis. *J Vasc Surg.* 1995;22:616-621.

32. Sullivan V, Denk PM, Sonnad SS, et al. Ligation versus anticoagulation: treatment of above-knee superficial thrombophlebitis not involving the deep venous system. *J Am Coll Surg*. 2001;193:556-562.
33. Hingorani AP, Ascher E, Markevich N, et al. Deep venous thrombosis after radiofrequency ablation of greater saphenous vein: a word of caution. *J Vasc Surg*. 2004;40:500-504.
34. Puggioni A, Kalra M, Carmo M, et al. Endovenous laser therapy and radiofrequency ablation of the great saphenous vein: analysis of early efficacy and complications. *J Vasc Surg*. 2005;42:488-493.

## 第 65 章

1. Browse NL, Stewart G. Lymphedema: pathophysiology and classification. *J Cardiovasc Surg*. 1985;26:91.
2. Schirger A, Harrison EG, Janes JM. Idiopathic lymphedema. Review of 131 cases. *JAMA*. 1962;182:124.
3. Kinmonth JB, Taylor GW, Tracy GD, et al. Primary lymphoedema: clinical and lymphangiographic studies of a series of 107 patients in which the lower limbs were affected. *Br J Surg*. 1957;45:1.
4. Kinmonth JB. The lymphoedemas: general considerations. In: Kinmonth JB, ed. *The Lymphatics: Surgery, Lymphography and Diseases of the Chyle and Lymph Systems*. London: Edward Arnold; 1982:83.
5. Allen EV. Lymphedema of the extremities: classification, etiology and differential diagnosis: a study of three hundred cases. *Arch Intern Med*. 1934;54:606.
6. Browse NL. The diagnosis and management of primary lymphedema. *J Vasc Surg*. 1986;3:181.
7. Browse NL. Primary lymphedema. In: Ernst C, Stanley J, eds. *Current Therapy in Vascular Surgery*. Philadelphia: BC Decker; 1987:454.
8. Kurland LT, Molgaard CA. The patient record in epidemiology. *Sci Am*. 1981;245:54.
9. Rockson SG. Lymphedema. *Am J Med*. 2001;110:288.
10. Smeltzer DM, Stickler GB, Schirger A. Primary lymphedema in children and adolescents: a follow-up study and review. *Pediatrics*. 1985;76:206.
11. Wolfe JHN, Kinmonth JB. The prognosis of primary lymphedema of the lower limbs. *Arch Surg*. 1981;116:1157.
12. Mendoza E, Schmid-Schonbein GW. A model for mechanics of primary lymphatic valves. *J Biomech Eng*. 2003;125:407.
13. Rockson S. Syndromic lymphedema: keys to the kingdom of lymphatic structure and function? *Lymphatic Res Biol*. 2003;1:181.
14. Milroy W. An undescribed variety of hereditary oedema. *NY Med J*. 1892;56:505.
15. Milroy W. Chronic hereditary edema: Milroy's disease. *JAMA*. 1928;91:1172.
16. Lewis JM, Wald ER. Lymphedema praecox. *J Pediatr*. 1984;104:641.
17. Dahlberg PJ, Borer WZ, Newcomer KL, Yutuc WR. Autosomal or X-linked recessive syndrome of congenital lymphedema, hypoparathyroidism, nephropathy, prolapsing mitral valve, and brachytelephalangy. *Am J Med Genet*. 1983;16:99.
18. Radhakrishnan K, Rockson SG. The clinical spectrum of lymphatic disease. *Ann N Y Acad Sci*. 2008;1131:155.
19. Mucke J, Hoepffner W, Scheers Schmidt G, et al. Early onset lymphoedema, recessive form—a new form of genetic lymphoedema syndrome. *Eur J Pediatr*. 1986;145:195.
20. Henriksen HM. Turners's syndrome associated with lymphoedema, diagnosed in the newborns. *Z Geburtshilfe Perinatol*. 1980;184:313.
21. White SW. Lymphedema in Noonan's syndrome. *Int J Dermatol*. 1984;23:656.
22. Venencie PY, Dicken CH. Yellow nail syndrome: report of five cases. *J Am Acad Dermatol*. 1984;10:187.
23. Wheeler ES, Chan V, Wassman R, et al. Familial lymphedema praecox: Meige's disease. *Plast Reconstr Surg*. 1981;67:362.
24. Abe R, Kimura M, Airosaki A, et al. Retroperitoneal lymphangiomyomatosis with lymphedema of the legs. *Lymphology*. 1980;13:62.
25. Bull LN, Roche E, Song EJ, et al. Mapping of the locus for cholestasis-lymphedema syndrome (Aagaens syndrome) to a 6.6-cM interval on chromosome 15q. *Am J Hum Genet*. 2000;67:994.

26. Karkkainen MJ, Ferrell RE, Lawrence EC, et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. *Nat Genet.* 2000;25:153.
27. Irrthum A, Karkkainen MJ, Devriendt K, et al. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. *Am J Hum Genet.* 2000;67:295.
28. Fang J, Dagenais SL, Erickson RP, et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome [In Process Citation]. *Am J Hum Genet.* 2000;67:1382.
29. Finegold DN, Kimak MA, Lawrence EC, et al. Truncating mutations in FOXC2 cause multiple lymphedema syndromes. *Hum Mol Genet.* 2001;10:1185.
30. Irrthum A, Devriendt K, Chitayat D, et al. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. *Am J Hum Genet.* 2003;72:1470.
31. Mak JW. Epidemiology of lymphatic filariasis. *Ciba Found Symp.* 1987;127:5.
32. Chernin E. The disappearance of bancroftian filariasis from Charleston, South Carolina. *Am J Trop Med Hyg.* 1987;37:111.
33. Case T, Leis B, Witte M, et al. Vascular abnormalities in experimental and human lymphatic filariasis. *Lymphology.* 1991;24:174.
34. Dandapat MC, Mohapatro SK, Dash DM. Management of chronic manifestations of filariasis. *J Indian Med Assoc.* 1986;84:210.
35. Casley-Smith JR, Földi M, Ryan TJ, et al. Lymphedema: Summary of the 10th International Congress of Lymphology Working Group Discussions and Recommendations, Adelaide, Australia, August 10-17:1985. *Lymphology.* 1985;18:175.
36. Schirger A. Lymphedema. In: Spittell JA Jr, ed. *Cardiovascular Clinics*. Philadelphia: FA Davis; 1983:293.
37. Chant ADB. Hypothesis: why venous oedema causes ulcers and lymphoedema does not. *Eur J Vasc Surg.* 1992;6:427.
38. Samman PD, White WF. The "yellow nail" syndrome. *Br J Dermatol.* 1964;76:153.
39. Taylor JS, Young JR. The swollen limb: cutaneous clues to diagnosis and treatment. *Cutis.* 1978;21:553.
40. Fields CL, Roy TM, Ossorio MA, Mercer PJ. Yellow nail syndrome: a perspective. *J Ky Med Assoc.* 1991;89:563.
41. Servelle M. Congenital malformation of the lymphatics of the small intestine. *J Cardiovasc Surg.* 1991;32:159.
42. Kinmonth JB, Cox SJ. Protein-losing enteropathy in lymphoedema: surgical investigation and treatment. *J Cardiovasc Surg.* 1975;16:111.
43. Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema: a report of six cases in elephantiasis chirurgica. *Cancer.* 1948;1:64.
44. Rockson SG, Miller LT, Senie R, et al. American Cancer Society Lymphedema Workshop. Workgroup III: Diagnosis and management of lymphedema. *Cancer.* 1998;83:2882.
45. Weissleder H, Weissleder R. Lymphedema: evaluation of qualitative and quantitative lymphoscintigraphy in 238 patients. *Radiology.* 1988;167:729.
46. Stewart G, Gaunt JJ, Croft DN, Browse NL. Isotope lymphography: a new method of investigating the role of the lymphatics in chronic limb oedema. *Br J Surg.* 1985;72:906.
47. Vaqueiro M, Gloviczki P, Fisher J, et al. Lymphoscintigraphy in lymphedema: an aid to microsurgery. *J Nucl Med.* 1986;27:1125.
48. Gloviczki P, Calcagno D, Schirger A, et al. Noninvasive evaluation of the swollen extremity: experiences with 190 lymphoscintigraphic examinations. *J Vasc Surg.* 1989;9:683.
49. Cambria RA, Gloviczki P, Naessens JM, Wahner HW. Noninvasive evaluation of the lymphatic system with lymphoscintigraphy: a prospective, semiquantitative analysis in 386 extremities. *J Vasc Surg.* 1993;18:773.
50. Kleinhans E, Baumeister RGH, Hahn D, et al. Evaluation of transport kinetics in lymphoscintigraphy: follow-up study in patients with transplanted lymphatic vessels. *Eur J Nucl Med.* 1985;10:349.
51. Gloviczki P, Stanson AW, Stickler GB, et al. Klippel-Trenaunay syndrome: the risks and benefits of vascular interventions. *Surgery.* 1991;110:469.

52. Gliviczki P, Noel AA, Hollier LH. Arteriovenous fistulas and vascular malformations. In: Ascher E, ed. *Haimovici's Vascular Surgery*. 5th ed. Malden, MA: Blackwell Publishing; 2004:991.
53. Olofsson B, Jeltsch M, Eriksson U, Alitalo K. Current biology of VEGF-B and VEGF-C. *Curr Opin Biotechnol*. 1999;10:528.
54. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. *Cancer Res*. 2000;60:203.
55. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. *Embo J*. 1996;15:1751.
56. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. *Proc Natl Acad Sci U S A*. 1995;92:3566.
57. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. *Science*. 1997;276:1423.
58. Oh SJ, Jeltsch MM, Birkenhager R, et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. *Dev Biol*. 1997;188:96.
59. Enholm B, Karpanen T, Jeltsch M, et al. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. *Circ Res*. 2001;88:623.
60. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. *Oncogene*. 2000;19:5598.
61. Karkkainen MJ, Saaristo A, Jussila L, et al. A model for gene therapy of human hereditary lymphedema. *Proc Natl Acad Sci U S A*. 2001;98:12677.
62. Szuba A, Skobe M, Karkkainen M, et al. Therapeutic lymphangiogenesis with human recombinant VEGF-C. *FASEB J*. 2002;16:U114.
63. Cheung L, Han J, Beilhack A, et al. An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis. *BioDrugs*. 2006;20:363.

## 第 66 章

1. Woods M, Tobin M, Mortimer P. The psychosocial morbidity of breast cancer patients with lymphoedema. *Cancer Nurs*. 1995;18:467-471.
2. Witte MH, Bernas MJ, Martin CP, Witte CL. Lymphangiogenesis and lymphangiodysplasia: from molecular to clinical lymphology. *Microsc Res Tech*. 2001;55:122-145.
3. Karpanen T, Alitalo K. Molecular biology and pathology of lymphangiogenesis. *Annu Rev Pathol*. 2008;3:367-397.
4. Smeltzer DM, Stickler G, Schirger A. Primary lymphedema in children and adolescents: a follow-up study and review. *Pediatrics*. 1985;76:206-218.
5. Mirolo BR, Bruce IH, Chapman M, et al. Psychosocial benefits of postmastectomy lymphedema therapy. *Cancer Nurs*. 1995;18:197-205.
6. Ferrell RE, Levinson KL, Esman JH, et al. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. *Hum Mol Genet*. 1998;7:2073-2078.
7. Connell F, Brice G, Mortimer P. Phenotypic characterization of primary lymphedema. *Ann N Y Acad Sci*. 2008;1131:140-146.
8. Hoerauf A. Control of filarial infections: not the beginning of the end, but more research is needed. *Curr Opin Infect Dis*. 2003;16:403-410.
9. Bockarie MJ, Tisch DJ, Kastens W, et al. Mass treatment to eliminate filariasis in Papua New Guinea. *N Engl J Med*. 2002;347:1841-1848.
10. Das PK, Ramaiah KD, Augustin DJ, Kumar A. Towards elimination of lymphatic filariasis in India. *Trends Parasitol*.

2001;17:457-460.

11. Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. *Bull World Health Organ.* 1997;75:491-503.
12. Meyrowitsch DW, Simonsen PE. Long-term effect of mass diethylcarbamazine chemotherapy on bancroftian filariasis. Results at four years after start of treatment. *Trans R Soc Trop Med Hyg.* 1998;92:98-103.
13. Ismail MM, Jayakody RL, Weil GJ, et al. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. *Trans R Soc Trop Med Hyg.* 1998;92:94-97.
14. Lammie PJ, Cuenco KT, Punkosdy GA. The pathogenesis of filarial lymphedema: is it the worm or is it the host? *Ann N Y Acad Sci.* 2002;979:131-142; discussion 188-196.
15. Vaqas B, Ryan TJ. Lymphoedema: Pathophysiology and management in resource-poor settings—relevance for lymphatic filariasis control programmes. *Filaria J.* 2003;2:4.
16. Semel JD, Goldin H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. *Clin Infect Dis.* 1996;23:1162-1164.
17. Scheinfeld NS. Obesity and dermatology. *Clin Dermatol.* 2004;22:303-309.
18. Babb RR, Spittell JA Jr, Martin WJ, Schirger A. Prophylaxis of recurrent lymphangitis complicating lymphedema. *JAMA.* 1966;195:871-873.
19. Baddour LM. Cellulitis syndromes: an update. *Int J Antimicrob Agents.* 2000;14:113-116.
20. Damstra RJ, van Steensel MA, Boomsma JH, et al. Erysipelas as a sign of subclinical primary lymphoedema: a prospective quantitative scintigraphic study of 40 patients with unilateral erysipelas of the leg. *Br J Dermatol.* 2008;158:1210-1215.
21. Wang JH, Liu YC, Cheng DL, et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. *Clin Infect Dis.* 1997;25:685-689.
22. Wrone DA, Tanabe KK, Cosimi AB, et al. Lymphedema after sentinel lymph node biopsy for cutaneous melanoma: a report of 5 cases. *Arch Dermatol.* 2000;136:511-514.
23. Sener SF, Winchester DJ, Martz CH, et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma. *Cancer.* 2001;92:748-752.
24. Kissin MW, Querci della Rovere G, Easton D, Westbury G. Risk of lymphoedema following the treatment of breast cancer. *Br J Surg.* 1986;73:580-584.
25. Markby R, Baldwin E, Kerr P. Incidence of lymphoedema in women with breast cancer. *Prof Nurse.* 1991;6:502-508.
26. Schunemann H, Willich N. Secondary lymphedema of the arm following primary therapy of breast carcinoma. *Zentralbl Chir.* 1992;117:220-225.
27. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. *Ann Surg.* 1994;220:391-398; discussion 398-401.
28. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. *JAMA.* 1996;276:1818-1822.
29. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. *Lancet.* 1997;349:1864-1867.
30. Park JH, Lee WH, Chung HS. Incidence and risk factors of breast cancer lymphoedema. *J Clin Nurs.* 2008;17:1450-1459.
31. Werner RS, McCormick B, Petrek J, et al. Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. *Radiology.* 1991;180:177-184.
32. Petrek J, Senie R, Peters M, Rosen P. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. *Cancer.* 2001;92:1368-1377.
33. Herd-Smith A, Russo A, Muraca MG, et al. Prognostic factors for lymphedema after primary treatment of breast carcinoma. *Cancer.* 2001;92:1783-1787.
34. Swedborg I, Norrefalk JR, Piller NB, Asard C. Lymphoedema post-mastectomy: is elevation alone an effective treatment?

*Scand J Rehabil Med.* 1993;25:79-82.

35. Stillwell GK, Redford JW. Physical treatment of postmastectomy lymphedema. *Mayo Clin Proc.* 1958;33:1-8.
36. Cooke JB, Frohlich ED. *Current Management of Hypertensive and Vascular Diseases*. Philadelphia, PA: Mosby-Year Book; 1992.
37. Leduc O, Peeters A, Bourgeois P. *Bandages: scintigraphic demonstration of its efficacy on colloidal protein reabsorption during muscular activity*. In: Nishi M, Uchino S, Yabuki S, eds. *Progress in Lymphology XI*. Amsterdam: Elsevier; 1990:421-423.
38. McKenzie DC, Kalda AL. Effect of upper extremity exercise on secondary lymphedema in breast cancer patients: a pilot study. *J Clin Oncol.* 2003;21:463-466.
39. Ahmed RL, Thomas W, Yee D, Schmitz KH. Randomized controlled trial of weight training and lymphedema in the breast cancer survivors. *J Clin Oncol.* 2006;24:2765-2772.
40. Kolden GG, Strauman TJ, Ward A, et al. A pilot study of group exercise training (GET) for women with primary breast cancer: feasibility and health benefits. *Psychooncology.* 2002;11:447-456.
41. Soria P, Cuesta A, Romero H, et al. Dietary treatment of lymphedema by restriction of long-chain tryglicerides. *Angiology.* 1994;45:703-707.
42. Shaw C, Mortimer P, Judd PA. Randomized controlled trial comparing a low-fat diet with a weight-reduction diet in breast cancer-related lymphedema. *Cancer.* 2007;109:1949-1956.
43. Casley-Smith JR, Casley-Smith JR. Lymphedema initiated by aircraft flights. *Aviat Space Environ Med.* 1996;67:52-56.
44. Stout Gergich NL, Pfalzer LA, McGarvey C, et al. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. *Cancer.* 2008;112:2809-2819.
45. Schirger A. Lymphedema. *Cardiovasc Clin.* 1983;13:293-305.
46. Földi E, Földi M, Weissleder H. Conservative treatment of lymphoedema of the limbs. *Angiology.* 1985;36:171-180.
47. Földi M, Földi E, Kubik S. *Textbook of Lymphology for Physicians and Lymphedema Therapists*. San Francisco: Urban & Fischer; 2003.
48. Mortimer PS. Therapy approaches for lymphedema. *Angiology.* 1997;48:87-91.
49. Casley-Smith JR. The pathophysiology of lymphedema and the action of benzo-pyrones in reducing it. *Lymphology.* 1988;21:190-194.
50. Piller NB. Macrophage and tissue changes in the developmental phases of secondary lymphoedema and during conservative therapy with benzopyrone. *Arch Histol Cytol.* 1990;53:209-218.
51. Casley-Smith JR, Wang CT, Casley-Smith JR, Zi-hai C. Treatment of filarial lymphoedema and elephantiasis with 5,6-benzo-alpha-pyrone (coumarin). *BMJ.* 1993;307:1037-1041.
52. Loprinzi CL, Kugler JW, Sloan JA, et al. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. *N Engl J Med.* 1999;340:346-350.
53. Pecking AP, Fevrier B, Wargon C, Pillion G. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). *Angiology.* 1997;48:93-98.
54. Olszewski W. Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema. *Angiology.* 2000;51:25-29.
55. Das L, Subramanyam Reddy G, Pani S. Some observations on the effect of daflon (micronized purified flavonoid fraction of Rutaceae aurantiae) in bancroftian filarial lymphoedema. *Filaria J.* 2003;2:5.
56. Fyfe NC, Rutt DL, Edwards JM, Kinmonth JB. Intralymphatic steroid therapy for lymphoedema: preliminary studies. *Lymphology.* 1982;15:23-28.
57. Katoh I, Harada K, Tsuda Y, et al. Intraarterial lymphocytes injection for treatment of lymphedema. *Jpn J Surg.* 1984;14:331-334.
58. Ogawa Y, Yoshizumi M, Kitagawa T, et al. Investigation of the mechanism of lymphocyte injection therapy in treatment of lymphedema with special emphasis on cell adhesion molecule (L-sectin). *Lymphology.* 1999;32:151-156.

59. Carati CJ, Anderson SN, Gannon BJ, Piller NB. Treatment of postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-controlled trial. *Cancer*. 2003;98:1114-1122.
60. Piller NB, Thelander A. Treatment of chronic postmastectomy lymphedema with low level laser therapy: a 2.5 year follow-up. *Lymphology*. 1998;31:74-86.
61. Kocak Z, Overgaard J. Risk factors for arm lymphedema in breast cancer patients. *Acta Oncol*. 2000;39:389-392.
62. Witte MH, Witte CL, Bernas M. ISL Consensus document revisited: Suggested modifications (summarized from discussions at the 16th ICL, Madrid, Spain, September 1997 and the Interim ISL Executive Committee meeting). *Lymphology*. 1998;31:138-140.
63. Consensus Document of the International Society of Lymphology. In *The Diagnosis and Treatment of Peripheral Lymphedema*. *Lymphology*. 2003;36:84-91.
64. Soo JK, Bicanic TA, Heenan S, Mortimer PS. Lymphatic abnormalities demonstrated by lymphoscintigraphy after lower limb cellulitis. *Br J Dermatol*. 2008;158:1350-1353.
65. Casley-Smith JR. Measuring and representing peripheral oedema and its alterations. *Lymphology*. 1994;27:56-70.
66. Collins CD, Mortimer PS. Computed tomography in the assessment of response to limb compression in unilateral lymphoedema. *Clin Radiol*. 1995;50:541-544.
67. Duewell S, Hagspiel KD, Zuber J, et al. Swollen lower extremities: role of MR imaging. *Radiology*. 1992;184:227-231.
68. Cornish BH, Bunce IH, Ward LC, et al. Bioelectrical impedance for monitoring the efficacy of lymphoedema treatment programmes. *Breast Cancer Res Treat*. 1996;38:169-176.
69. Stanton AW, Northfield JW, Holroyd B, et al. Validation of an optoelectronic limb volumeter (perometer). *Lymphology*. 1997;30:77-97.
70. Spillane AJ, Saw RP, Tucker M, et al. Defining lower limb lymphedema after inguinal or ilio-inguinal dissection in patients with melanoma using classification and regression tree analysis. *Ann Surg*. 2008;248:286-293.
71. O'Donnell TF, Howrigan DH. The diagnosis and management of lymphedema. In: Bell PRF, Jamieson CS, Ruckley CV, eds. *Surgical Management of Vascular Disease*. Sussex, UK: Bailliere Tindall; 1992.
72. Kasseroller RG. The Vodder School: the Vodder method. *Cancer*. 1998;83:(12 Suppl Amer):2840-2842.
73. Boris M, Weindorf S, Lasinski B, Boris G. Lymphedema reduction by noninvasive complex lymphedema therapy. *Oncology (Williston Park)*. 1994;8:95-106; discussion 109-110.
74. Boris M, Weindorf S, Lasinski S. Persistence of lymphedema reduction after noninvasive complex lymphedema therapy. *Oncology (Williston Park)*. 1997;11:99-109; discussion 110, 113-114.
75. Ko DS, Lerner R, Klose G, Cosimi AB. Effective treatment of lymphedema of the extremities. *Arch Surg*. 1998;133:452-458.
76. Daane S, Poltoratszy P, Rockwell WB. Postmastectomy lymphedema management: evolution of the complex decongestive therapy technique. *Ann Plast Surg*. 1998;40:128-134.
77. Murthy G, Ballard RE, Breit GA, et al. Intramuscular pressures beneath elastic and inelastic leggings. *Ann Vasc Surg*. 1994;8:543-548.
78. Szuba A, Cooke JP, Yousuf S, Rockson S. Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema. *Am J Med*. 2000;109:296-300.
79. Lymphology Association of North America (LANA) Certified Lymphedema Therapist. <<http://www.clt-lana.org/>>.
80. Johansson K, Lie E, Ekdahl C, Lindfeldt J. A randomized study comparing manual lymph drainage with sequential pneumatic compression for treatment of postoperative arm lymphedema. *Lymphology*. 1998;31:56-64.
81. Williams AF, Vadgama A, Franks PJ, Mortimer PS. A randomized controlled crossover study of manual lymphatic drainage therapy in women with breast cancer-related lymphoedema. *Eur J Cancer Care (Engl)*. 2002;11:254-261.
82. Cheville AL, McGarvey CL, Petrek JA, et al. Lymphedema management. *Semin Radiat Oncol*. 2003;13:290-301.
83. Thiadens S. *Advances in the Management of Lymphedema*. St. Louis: Quality Medical Publishing; 1990.

84. Zelikovski A, Deutsch A, Reiss R. The sequential pneumatic compression device in surgery for lymphedema of the limbs. *J Cardiovasc Surg (Torino)*. 1983;24:122-126.
85. Richmand DM, O'Donnell TF Jr, Zelikovski A. Sequential pneumatic compression for lymphedema. A controlled trial. *Arch Surg*. 1985;120:1116-1119.
86. Zanolla R, Monzeglio C, Balzarini A, Martino G. Evaluation of the results of three different methods of postmastectomy lymphedema treatment. *J Surg Oncol*. 1984;26:210-213.
87. Zelikovski A, Haddad M, Reiss R. The "Lympha-Press" intermittent sequential pneumatic device for the treatment of lymphoedema: five years of clinical experience. *J Cardiovasc Surg (Torino)*. 1986;27:288-290.
88. Pappas CJ, O'Donnell TF Jr. Long-term results of compression treatment for lymphedema. *J Vasc Surg*. 1992;16:555-562; discussion 562-554.
89. Klein MJ, Alexander MA, Wright JM, et al. Treatment of adult lower extremity lymphedema with the Wright linear pump: statistical analysis of a clinical trial. *Arch Phys Med Rehabil*. 1988;69:202-206.
90. McLeod A, Brooks D, Hale J, et al. A clinical report on the use of the three external pneumatic compression devices in the management of lymphedema in a pediatric population. *Physiother Can*. 1991;43:28-32.
91. Bergan JJ, Sparks S, Angle N. Lymphedema: a comparison of compression pumps in the treatment of lymphedema. *Vasc Surg*. 1998;32:455-462.
92. Dini D, Del Mastro L, Gozza A, et al. The role of pneumatic compression in the treatment of postmastectomy lymphedema. A randomized phase III study. *Ann Oncol*. 1998;9:187-190.
93. Segers P, Belgrado JP, Leduc A, et al. Excessive pressure in multichambered cuffs used for sequential compression therapy. *Phys Ther*. 2002;82:1000-1008.
94. Boris M, Weindorf S, Lasinski BB. The risk of genital edema after external pump compression for lower limb lymphedema. *Lymphology*. 1998;31:15-20.
95. Szuba A, Achalu R, Rockson S. Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression. *Cancer*. 2002;95:2260-2267.
96. Palme A, Macchiarema J, Braun A, et al. Compression therapy of limb edema using hydrostatic pressure of mercury. *Angiology*. 1991;42:533.
97. Wilburn O, Wilburn P, Rockson SG. A pilot, prospective evaluation of a novel alternative for maintenance therapy of breast cancer-associated lymphedema [ISRCTN76522412]. *BMC Cancer*. 2006;6:84.
98. Ridner SH, Dietrich MS. Self-reported comorbid conditions and medication usage in breast cancer survivors with and without lymphedema. *Oncol Nurs Forum*. 2008;35:57-63.
99. Mayrovitz HN. Interface pressures produced by two different types of lymphedema therapy devices. *Phys Ther*. 2007;87:1379-1388.
100. Pierson S, Pierson D, Swallow R, Johnson G Jr. Efficacy of graded elastic compression in the lower leg. *JAMA*. 1983;249:242-243.
101. Johnson G Jr. *Venous Disorders*. Philadelphia: WB Saunders; 1991.
102. Zhang DS, Huang WY, Hun LY. Heating and bandaging treatment of chronic lymphedema: report of 1045 cases. *Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]*. 1985;23:13-16, 61-62.
103. Chang TS, Gan JL, Fu KD, Huang WY. The use of 5,6 benzo-[alpha]-pyrone (coumarin) and heating by microwaves in the treatment of chronic lymphedema of the legs. *Lymphology*. 1996;29:106-111.
104. Gan JL, Li SL, Cai RX, Chang TS. Microwave heating in the management of postmastectomy upper limb lymphedema. *Ann Plast Surg*. 1996;36:576-580; discussion 580-581.
105. Cheville AL. Current and future trends in lymphedema management: implications for women's health. *Phys Med Rehabil Clin N Am*. 2007;18:539-553.



106. Servelle M. Surgical treatment of lymphedema: a report on 652 cases. *Surgery*. 1987;101:485-495.
107. Schmitz-Rixen T, Horsch S, Arnold G, Peters PE. Angiosarcoma in primary lymphedema of the lower extremity—Stewart-Treves syndrome. *Lymphology*. 1984;17:50-53.
108. Muller R, Hajdu SI, Brennan MF. Lymphangiosarcoma associated with chronic filarial lymphedema. *Cancer*. 1987;59:179-183.
109. Alessi E, Sala F, Berti E. Angiosarcomas in lymphedematous limbs. *Am J Dermatopathol*. 1986;8:371-378.
110. Benda JA, Al-Jurf AS, Benson AB 3rd. Angiosarcoma of the breast following segmental mastectomy complicated by lymphedema. *Am J Clin Pathol*. 1987;87:651-655.
111. Tatnall FM, Mann BS. Non-Hodgkin's lymphoma of the skin associated with chronic limb lymphoedema. *Br J Dermatol*. 1985;113:751-756.
112. Ruocco V, Astarita C, Guerrero V, et al. Kaposi's sarcoma on a lymphedematous immunocompromised limb. *Int J Dermatol*. 1984;23:56-60.
113. Shelley WB, Wood MG. Transformation of the common wart into squamous cell carcinoma in a patient with primary lymphedema. *Cancer*. 1981;48:820-824.
114. Epstein JI, Mendelsohn G. Squamous carcinoma of the foot arising in association with long-standing verrucous hyperplasia in a patient with congenital lymphedema. *Cancer*. 1984;54:943-947.
115. Barta AH, Pinsky CM. Malignant melanoma appearing in a post-mastectomy lymphedematous arm: a novel association of double primary tumors. *J Surg Oncol*. 1985;30:16-18.

## 第 67 章

1. Foeldi M, Foeldi E. *Foeldi's Textbook of Lymphology*. München: Elsevier Urban & Fischer; 2006.
2. Charles RH. *A System of Treatment Vol. 3*. In: Latham A, Churchill JMA, eds. London: 1912;504.
3. Deutschmann W, Scharnagl E. Long-term results in the surgical treatment of lymphedema. *Chir Plast*. 1980;5:109.
4. Pierer H. Die radikale Resektion beim chronischen Lymphoedem. *Langenbecks Arch Chir*. 1969;325:113.
5. Barinka L. Our experience with the treatment of lymphedema of the lower limb. *Acta Chir Plast*. 1967;9:218.
6. Barinka L. Employment of dermatome-super in the treatment of lower limb lymphedema. *Acta Chir Plast*. 1968;10:223.
7. Barinka L. The technique of the excisional operation of the lower extremity using a new instrument. In: *Lymphedema*. Stuttgart: Thieme; 1977.
8. Cobbett. Small vessel anastomoses. *Br J Plast Surg*. 1967;20:16.
9. Clodius L. Conservative management of postmastectomy lymphedema. *Ther Ggw*. 1979;118:229.
10. Mowlen R. The treatment of lymphedema. *Br J Plast Surg*. 1948;1:48.
11. VEDIAYEV JP, ANTONOV J, KHARITONOV J. Simplified method for elaboration of tissues excised for replantation during radical operations of elephantiasis. *Acta Chir Plast*. 1978;20:4.
12. Auchincloss H. New operation for elephantiasis. *Puerto Rico J Publ Health Trop Med*. 1930;6:1949.
13. Fontaine R, Fontaine JL. Die operative Therapie des Lymphoedems. *Langenbecks Arch Chir*. 1969;325:89.
14. Homans J. The treatment of elephantiasis of the legs. *N Engl J Med*. 1936;215:1099.
15. Servelle M. Chirurgie der Elephantiasis. In: Foeldi M, ed. *Erkrankungen des Lymphsystems*. Witzstrock: Baden-Baden; 1971.
16. Sistrunk WE. Further experiences with the Kondoleon operation for elephantiasis. *JAMA*. 1918;71:800.
17. Sistrunk WE. Certain modifications of the Kondoleon-operation for elephantiasis. *Ann Surg*. 1927;85:185.
18. Illouz YG. *Body Sculpturing by Lipoplasty*. Edinburgh: Churchill Livingstone; 1989.
19. Brorson H, Svensson H. Complete reduction of lymphoedema of the arm by liposuction after breast cancer. *Scand J Plast Reconstr Surg Hand Surg*. 1997;31:137.
20. Lanz O. Eroeffnung neuer Abflusswege bei Stauung im Bauch und unteren Extremitäten. *Zentralbl Chir*. 1911;38:153.

21. Kondoleon E. Die chirurgische Behandlung der elefantiasischen Oedeme durch eine neue Methode der Lymphableitung. *Muench Med Wochenschr.* 1912;59:2726.
22. Kondoleon E. Operative Behandlung der elefantiasischen Oedeme. *Zentralbl Chir.* 1912;30:1022.
23. Thompson N. Surgical treatment of chronic lymphedema in lower limb. *BMJ.* 1962;2:1566.
24. Thompson N. Surgical treatment of primary and secondary lymphoedema of the extremities by lymphatic transposition. *Proc R Soc Med.* 1965;38:1026.
25. Thompson N. Buried dermal flap operations for chronic lymphoedema of the extremities. *Surg Clin North Am.* 1967;47:245.
26. Thompson N. The late results of operative treatment of chronic lymphedema of the extremities using the buried dermis flap procedure. *J Cardiovasc Surg.* 1968;92:93.
27. Thompson N. Buried dermal flap operation for chronic lymphedema of the extremities. *Plast Reconstr Surg.* 1970;45:541.
28. Bohmert H, Baumeister RGH. Die operative Therapie des Armlymphoedems. In: *Ergebnisse der Angiologie.* Bd 6. Stuttgart: Thieme; 1973.
29. Bohmert H, Haas W. Zur Behandlung des Lymphoedems mit einer modifizierten Methode nach Thompson. *Ther Ggw.* 1974;113:842.
30. Bunchmann HH II, Blocher G, Larson DC, Lewis SR. Long term results with the use of the buried skin flap in lymphedemas. In: Clodius L, ed. *Lymphedema.* Stuttgart: Thieme; 1977.
31. Grenzmann M, Beltz L. Die lymphovenoesen Anastomosen. *Rofo.* 1968;109:564.
32. Gillies HD, Fraser FR. Treatment of lymphoedema by plastic operation. *BMJ.* 1935;1:96.
33. Mukherji M. Surgical treatment of filarial elephantiasis of legs by the lymph-bearing flap. In: Clodius L, ed. *Lymphedema.* Stuttgart: Thieme; 1977.
34. Smith JW, Conwag H. Selection of appropriate surgical procedures in lymphedema. Introduction of the hinged pedicle. *Plast Reconstr Surg.* 1962;30:10.
35. Wynn SA. Surgical approach to postmastectomy lymphoedematous extremity. *Arch Surg.* 1955;70:418.
36. Goldsmith HS, de los Santos R, Beattle EJ. Relief of chronic lymphedema by omental transposition. *Am Surg.* 1967;166:573.
37. Goldsmith HS. Long term evaluation of omental transposition for chronic lymphedema. *Ann Surg.* 1974;180:847.
38. Kinmonth JB, Hurst PA, Edwards JM, Rutt DL. Relief of lymph obstruction by use of mesentery and ileum. *Br J Surg.* 1978;65:829.
39. Holle J, Mandl H, Kreppler R. Ueberbrueckung eines Lymphgefäessdefektes mittels Veneninterposition—eine experimentelle Studie Vortr a.d. 2. Jahrestagung der deutschsprachigen Arbeitsgemeinschaft fuer Mikrochirurgie der peripheren Nerven und Gefaesse. Hamburg, 1979.
40. Mandl H, Holle J. Experimentelle Untersuchungen zur Mikrochirurgie der Lymphgefäße. Abstr XVIII. Wissenschaftl. Tagung der GV-SOLAS, Lausanne. 1980;28.5-30.5.
41. Campisi C, Boccardo F, Tacchella M. Reconstructive Microsurgery of Lymph Vessels: The Personal Method of Lymphatic-Venous-Lymphatic (LVL) Interpositional Grafted Shunt. *Microsurgery.* 1995;16:161.
42. Laine JB, Howard JM. Experimental lymphatic-venous anastomosis. *Surg Forum.* 1963;14:111.
43. Nielubowicz J, Olszewski W. Surgical lymphovenous shunts for decompression of secondary lymphoedema. *J Cardiovasc Surg.* 1966;7(Suppl 2):262-267.
44. Rivero OR, Calnan JS, Reis ND, Mercurius-Taylor L. Experimental lympho-venous communications. *Br J Plast Surg.* 1976;20:124.
45. Allen PJ, Taylor GW. The use of free lymph-node grafts as a method of producing peripheral lymphovenous shunts. *Br J Surg.* 1968;55:385.
46. Degni M. New technique of lymphatic-venous anastomosis for the treatment of lymphedema. *J Cardiovasc Surg (Turin).*

1978;19:577.

47. Fox U, Montorsi M, Romagnoli G. Surgical treatment of chronic oedema of the leg. *Proc R Soc Med.* 1950;43:1054.
48. O'Brien BM. Microlymphaticovenous surgery for obstructive lymphedema. *Aust N Z J Surg.* 1977;47:284.
49. O'Brien BM, Black MJ, Fogdestam I. Role of microlymphaticovenous surgery in obstructive lymphedema. *Clin Plast Surg.* 1978;5:293.
50. Campisi C, Eretta C, Pertile D, et al. Microsurgery for treatment of peripheral lymphedema: long-term outcome and future perspectives. *Microsurgery.* 2007;27:333.
51. Calnan JS, Reis ND, Rivero, DR, Copenhagen HJ. The natural history of lymph node to vein anastomosis in the dog. *Br J Plast Surg.* 1967;20:134.
52. Calnan JS, Reis ND, Pflug J. Attempts to create anastomoses between lymphatics and veins at peripheral sites. *Br J Surg.* 1968;55:385.
53. Calnan JS, Reis ND, Pflug J. The late results of lymph node to vein anastomosis in the dog. *J Cardiovasc Surg Spec.* 1968.
54. Firica A, Ray A, Murat J, Tomphino E. Alleviation of experimental lymphedema by lymphovenous anastomosis in dogs. *Am Surg.* 1972;37:409.
55. Yamada Y. The study on lymphatic venous anastomosis in lymphoedema. *Nagoya J Med Sci.* 1969;32:1.
56. Gloviczki P, Hollier LH, Nora FE, Kaye MP. The natural history of microsurgical lymphovenous anastomoses: an experimental study. *J Vasc Surg.* 1986;4:148.
57. Danese G, Howard JM. Postmastectomy lymphedema. *Surg Gynecol Obstet.* 1965;129:797.
58. Danese C, Georgalas-Bertakis M, Morales LE. A model of chronic postsurgical lymphedema in dog's limbs. *Surgery.* 1968;64:814.
59. Trevidic P, Cormier JM. Free axillary lymph node transfer. In: *Progress in Lymphology. Vol XIII.* Paris: Excerpta Medica; 1992.
60. Becker C, Assouad J, Riquet M, Hidden G. Postmastectomy lymphedema long-term results following microsurgical lymph node transplantation. *Ann Surg.* 2006;243:313.
61. Trevidic P, Pecking AP. Limb radionuclide lymphoscintigraphy prior and after a lymphatic bypass using an axillary flap. *Lymphology.* 1998;31(suppl):605.
62. Li S, Cao W, Cheng K, Chang TS. Microvascular transfer of a lymphatic bearing, flap in the treatment of obstructive lymphedema. *Plast Reconstr Surg.* 2008;121:150e.
63. Saumweber DM, Baumeister RGH, Liebich HG, Hammer C. Experiences in experimental reconstructive microsurgery of lymphatics. In: *Progress in Lymphology. Vol XI.* Amsterdam: Excerpta Medica; 1988.
64. Yuwono HS, Kloppe PJ. Comparison of lymphatic and venous interpositional autografts in experimental microsurgery of the canine lymphatics. *Plast Reconstr Surg.* 1990;85:752.
65. Acland RD, Smith P. Experimental lymphatic-lymphatic anastomoses. In: *Abstract Book VII.* Florence: International Congress of Lymphology; 1979.
66. Cordeiro AK, Baracat FF, Al Assal F. Transplantations of lymphatic ducts, preliminary and experimental report. In: *Abstract Book VII.* Florence: International Congress of Lymphology; 1979.
67. Baumeister RGH, Seifert J, Wiebecke B. Transplantation of lymph vessels on rats as well as first therapeutic application on the experimental lymphedema of the dog. *Eur Surg Res.* 1980;12(Suppl 21):7.
68. Baumeister RGH, Seifert J, Wiebecke B, Hahn D. Experimental basis and first application of clinical lymph vessel transplantation of secondary lymphedema. *World J Surg.* 1981;5:401.
69. Baumeister RGH, Siuda S. Treatment of lymphedema by microsurgical lymphatic grafting: what is proved? *Plast Reconstr Surg.* 1990;85:64.
70. Baumeister RGH, Frick A, Hofmann T. 10 years experience with autogenous microsurgical lymph vessel transplantation. *Eur J Lymphol.* 1991;6:62.

71. Baumeister RGH, Frick A. The microsurgical lymph vessel transplantation. *Handchir Mikrochir Plast Chir.* 2003;35:202.
72. Baumeister RGH, Seifert J, Wiebecke B. Homologous and autologous experimental lymph vessel transplantation: initial experience. *Int J Microsurg.* 1981;3:19.
73. Kinmonth JB. *The Lymphatics.* London: Edward Arnold; 1972.
74. Partsch H. Aspects of indirect lymphography and lymphoscintigraphy. *Lymphatic Res Biol.* 2003;1:71.
75. Lohrmann C, Foeldi E, Speck O, Langer M. High-resolution MR-lymphangiography in patients with primary and secondary lymphedema. *AJR Am J Roentgenol.* 2006;187:556.
76. Kleinhans E, Baumeister RGH, Hahn D, et al. Evaluation of transport kinetics in lymphoscintigraphy: follow-up study in patients with transplanted lymphatic vessels. *Eur J Nucl Med.* 1985;10:349.
77. Weiss M, Baumeister RGH, Hahn K. Planning and monitoring of autologous lymph vessel transplantation by means of nuclear medicine lymphography. *Handchir Mikrochir Plast Chir.* 2003;35:210.
78. Weissleder H, Brauer WJ. *Examination Methods in Lymphedema.* Essen: Viavital; 2008;
79. Kubik S. Zur klinischen Anatomie des Lymphsystems. *Verh Anat Ges.* 1975;69:109.
80. Baumeister RGH, Fink U, Tatsch K, Frick A. Microsurgical lymphatic grafting: first demonstration of patent grafts by indirect lymphography and long term follow-up studies. *Lymphology.* 1994;27(Suppl):787.
81. Weiss M, Baumeister RGH, Hahn K. Posttherapeutic lymphedema: scintigraphy before and after autologous lymph vessel transplantation—8 years long-term follow up. *Clin Nucl Med.* 2002;27:788.
82. Ho LCY, Lai MF, Kennedy PJ. Microlymphatic bypass in the treatment of obstructive lymphoedema of the arm: case report of a new technique *Br J Plast Surg.* 1983;36:350.
83. Mandl H. Experimentelle Untersuchungen zur mikrochirurgischen Rekonstruktion von Lymphgefäßdefekten. *Plast Chir.* 1981;5:70.
84. Danese C, Bower R, Howard J. Experimental anastomosis of lymphatics. *Arch Surg.* 1962;84:24.
85. Cambria RA, Gloviczki P, Naessens JM, Wahner HW. Noninvasive evaluation of the lymphatic system with lymphoscintigraphy: a prospective, semiquantitative analysis in 386 extremities. *J Vasc Surg.* 1993;18:773.
86. Gloviczki P, Fisher J, Hollier LH, et al. Microsurgical lymphovenous anastomosis for treatment of lymphedema: a critical review. *J Vasc Surg.* 1988;7:647.
87. O'Brien BM, Mellow CG, Khazanchi RK, et al. Long-term results after microlymphaticovenous anastomoses for the treatment of obstructive lymphedema. *Plast Reconstr Surg.* 1990;85:562.
88. Campisi C, Boccardo F, Zilli A, et al. Long-term results after lymphatic-venous anastomoses for the treatment of obstructive lymphedema. *Microsurgery.* 2001;21:135.
89. Campisi C, Boccardo F. Lymphedema and microsurgery. *Microsurgery.* 2002;22:74.
90. Koshima I, Nanba Y, Tsutsui T, et al. Long-term follow-up after lymphaticovenular anastomosis for lymphedema in the leg. *J Reconstr Microsurg.* 2003;19:209.
91. Vignes S, Boursier V, Priollet P, et al. Quantitative evaluation and qualitative results of surgical lymphovenous anastomosis in lower limb lymphedema [in French]. *J Malad Vasc.* 2003;28:30.
92. Brorson H, Svensson H. Liposuction combined with controlled compression therapy reduces arm lymphedema more effectively than controlled compression therapy alone. *Plast Reconstr Surg.* 1998;102:1058.
93. Heffel DF, Miller TA. Excisional operations for chronic lymphedema. In: Rutherford RB, ed. *Vascular Surgery.* 5th ed. Philadelphia: WB Saunders; 2000:2153-2159.
94. Miller TA. Surgical management of lymphedema of the extremity. *Plast Reconstr Surg.* 1975;56:633.
95. Miller TA. Surgical approach to lymphedema of the arm after mastectomy. *Am J Surg.* 1984;148:152.
96. Miller TA, Wyatt LE, Rudkin GH. Staged skin and subcutaneous excision for lymphedema: a favorable report of long-term results. *Plast Reconstr Surg.* 1998;102:1486; discussion, 1499.
97. Kinmonth JB. Chylous diseases and syndromes, including references to tropical elephantiasis. In: Kinmonth JB, ed. *The*

- Lymphatics: Surgery, Lymphography and Diseases of the Chyle and Lymph Systems*. 2nd ed. London: Edward Arnold; 1982:221-268.
98. Servelle M. Congenital malformation of the lymphatics of the small intestine. *J Cardiovasc Surg*. 1991;32:159.
  99. Kinmonth JB, Cox SJ. Protein losing enteropathy in lymphedema: Surgical investigation and treatment. *J Cardiovasc Surg*. 1975;16:111.
  100. Browse NL, Wilson NM, Russo F, et al. Aetiology and treatment of chylous ascites. *Br J Surg*. 1992;79:1145.
  101. Gloviczki P, Soltesz L, Solti F, et al. The surgical treatment of lymphedema caused by chylous reflux. In: Bartos V, Davidson JW, eds. *Advances in Lymphology. Proceedings of the 8th International Congress of Lymphology, Montreal, 1981*. Prague: Czechoslovak Medical Press; 1982:502-507.
  102. Sanders JS, Rosenow EC III, Piehler JM, et al. Chyloptysis (chylous sputum) due to thoracic lymphangiectasia with successful surgical correction. *Arch Intern Med*. 1988;148:1465.
  103. Servelle M, Deysson H. Reflux du chyle dans les lymphatiques jambiers. *Arch Mal Coeur*. 1949;12:1181.
  104. Browse NL. The surgery of lymphedema. In: Veith FJ, ed. *Current Critical Problems in Vascular Surgery*. St. Louis: Quality Medical Publishing; 1989:408-409.
  105. Molitch HI, Unger EC, Witte CL, van Sonnenberg E. Percutaneous sclerotherapy of lymphangiomas. *Radiology*. 1995;194:343.
  106. Noel AA, Gloviczki P, Bender CE, et al. Treatment of symptomatic primary chylous disorders. *J Vasc Surg*. 2001;34:785.
  107. Cope C, Salem R, Kaiser LR. Management of chylothorax by percutaneous catheterization and embolization of the thoracic duct: Prospective trial. *J Vasc Interv Radiol*. 1999;10:1248.
  108. Silk YN, Goumas WM, Douglass HO Jr, Huben RP. Chylous ascites and lymphocyst management by peritoneovenous shunt. *Surgery*. 1991;110:561.
  109. Engum SA, Rescorla FJ, West KW, et al. The use of pleuroperitoneal shunts in the management of persistent chylothorax in infants. *J Pediatr Surg*. 1999;34:286.
  110. Burnand GK, Gloviczki P, Browse N. Principles of surgical treatment. In: Browse N, Burnand GK, Mortimer PS, eds. *Diseases of the Lymphatics*. London: Arnold; 2003:179-204.
  111. Browse NL, Allen DR, Wilson NM. Management of chylothorax. *Br J Surg*. 1997;84:1711.
  112. Melduni RM, Oh JK, Bunch TJ, et al. Reconstruction of occluded thoracic duct for treatment of chylopericardium: a novel surgical therapy. *J Vasc Surg*. 2008;48:1600-1602.
  113. Campisi C, Bellini C, Eretta C, et al. Diagnosis and management of primary chylous ascites. *J Vasc Surg*. 2006;43:1244.
  114. Gloviczki P, Noel A. Surgical treatment of chronic lymphedema and primary chylous disorders. In: Rutherford RB, ed. *Vascular Surgery*. 6th ed. 2005:2428-2445.

## 第 68 章

1. Warkany J. Congenital malformations. Notes and Comments. In: *Part II, Etiologic Factors. Introduction*. Chicago, IL: Yearbook Medical Publ. Inc; 1971:55.
2. Persaud TVN. Problems of birth defects. From Hippocrates to Thalidomide and after. In: Persaud TVN, ed. *Part I Belief, Mythology, Magic and Superstition. Commentary*. Baltimore, MD: University Park Press Maryland Publishers; 1977:3-4.
3. Saint-Hilaire IG. *Histoire generale et particuliere des anomalies de l'organisation chez l'homme et les animaux*. Traite de Teratology. 3 vol and atlas. Paris: Bailliere; 1832-1837.
4. Meckel JF. *Handbuch der pathologischen Anatomie*. Leipzig, Germany: Reclam; 1812-1818; 2 vol.
5. Malan E. History and nosography. In: Malan E, ed. *Vascular Malformations (Angiodysplasias)*. Milan, Italy: Carlo Erba Foundation; 1974:15-19.
6. Belov S. Classification, terminology, and nosology of congenital vascular defects. In: Belov S, Loose DA, Weber J, eds. *Vascular Malformations*. Reinbek, Germany: Einhorn-Press; 1989:25-30.

7. Malan E, Puglionisi A. Congenital angiodysplasias of the extremities, note II: arterial, arterial and venous, and hemolymphatic dysplasias. *J Cardiovasc Surg (Torino)*. 1965;6:255-345.
8. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. *Plast Reconstr Surg*. 1982;69:412-420.
9. Mulliken JB. Cutaneous vascular anomalies. *Semin Vasc Surg*. 1993;6:204-218.
10. Mulliken JB. Classification of vascular birthmarks. In: Grainger RG, Allison DJ, eds. *Vascular Birthmarks, Haemangiomas, and Malformations*. Philadelphia, PA: WB Saunders; 1988:24-37.
11. Villavicencio JL. Congenital vascular malformations: historical background. *Special Issue: Phlebology*. 2007;22:247-248.
12. Gloveczki P, Driscoll DJ. Klippel-Trenaunay syndrome: current management. *Special Issue: Phlebology*. 2007;22:291-298.
13. Villavicencio JL, Conaway CW, Pikoulis E, Gannon MX. Congenital vascular malformations of venous predominance. The Klippel Trenaunay Syndrome. In: Raju S, Villavicencio JL, eds. *Surgical Management of Venous Disease*. Media, PA: Williams and Wilkins; 1997:445-467.
14. Bartels C, Claeys L, Ktenidis K, Horsch SFP. Weber syndrome associated with a brachial artery aneurysm. A case report. *Angiology*. 1995;46:1039-1042.
15. Ziyeh S, Spreer J, Rossler J, et al. Parkes Weber or Klippel-Trenaunay syndrome? Non-invasive diagnosis with MR projection angiography. *Eur Radiol*. 2004;14:2025-2029. Epub 2004.
16. Lee BB. Critical issues on the management of congenital vascular malformation. *Ann Vasc Surg*. 2004;18:380-392.
17. Lee BB, Laredo J, Lee TS, et al. Terminology and classification of congenital vascular malformations. *Phlebology*. 2007;22:249-252.
18. Belov ST. Anatomopathological classification of congenital vascular defects. *Semin Vasc Surg*. 1993;6:219-224.
19. Belov ST. Classification of congenital vascular defects. *Int Angiol*. 1990;9:141-146.
20. Lee BB, Laredo J, Lee SJ, et al. Congenital vascular malformations: general diagnostic principles. *Phlebology*. 2007;22:253-257.
21. Lee BB. New approaches to the treatment of congenital vascular malformations (CVMs)—a single center experience. *Eur J Vasc Endovasc Surg*. 2005;30:184-197.
22. Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. *World J Gastroenterol* 2007;13:5979-5984.
23. Puso C, Guillot B, Durand L, et al. Capillary malformations associated with cerebral cavernous malformation. *Ann Dermatol Venereol*. 2005;132:471-474.
24. Villavicencio JL, Scultetus AH, Lee BB. Congenital venous malformations: when and how to treat them. *Seminars Vasc Surg*. 2002;15:65-71.
25. Lee BB: Current concept of venous malformation (VM). *Phlebology*. 2003;43:197-203.
26. Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have “true” hemangiomas. *J Pediatr*. 1997;130:631-640.
27. Lee BB: Advanced management of congenital vascular malformation (CVM). *Int Angiol*. September 2002;21:209-213.
28. Zhang YJ, Barrow DL, Day AL. Extracranial-intracranial vein graft bypass for giant intracranial aneurysm surgery for pediatric patients: two technical case reports. *Neurosurgery*. 2002;50:663-668.
29. Kan P, Liu JK, Couldwell WT. Giant fusiform aneurysm in an adolescent with PHACES syndrome treated with a high-flow external carotid artery-M3 bypass. Case report and review of the literature. *J Neurosurg*. 2007 Jun;106(6 Suppl):495-500.
30. Lee BB, Kim DI, Huh S, et al. New experiences with absolute ethanol sclerotherapy in the management of a complex form of congenital venous malformation. *J Vasc Surg*. 2001;33:764-772.
31. Lee BB, Do YS, Byun HS, et al. Advanced management of venous malformation with ethanol sclerotherapy: mid-term results. *J Vasc Surg*. 2003;37:533-538.
32. Lee BB, Do YS, Yakes W, et al. Management of arterial-venous shunting malformations (AVM) by surgery and

- embolosclectherapy. A multidisciplinary approach. *J Vasc Surg.* 2004;39:590-600.
33. Lee BB. Arteriovenous malformation. In: Zelenock GB, Huber TS, Messina LM, et al., eds. *Mastery of Vascular and Endovascular Surgery*. Philadelphia: Lippincott, Williams and Wilkins, 2006:597-607.
  34. Lee BB, Kim YW, Seo JM, et al. Current concepts in lymphatic malformation (LM). *J Vasc Endovasc Surg.* 2005;39:67-81.
  35. Lee BB. Lymphedema-angiodysplasia syndrome: a prodigal form of lymphatic malformation (LM). *Phlebology.* 2005;47:324-332.
  36. Villavicencio JL. Congenital vascular malformations—predominantly venous? The syndrome of Klippel-Trenaunay. *Scope on Phlebology and Lymphology.* 2000;71:116-125.
  37. Lee BB. Lymphatic malformation. In: Lee BB, Simonian SJ, Blondeau B, and Tretbar LT, eds. *Lymphedema: Diagnosis and Treatment*. Great Britain: Springer-Verlag London Limited; 2008:31-42.
  38. Rutherford RB. Classification of peripheral congenital vascular malformations. In: Ernst C, Stanley J, eds. *Current Therapy in Vascular Surgery*. 3<sup>rd</sup> ed. St. Louis, Mo: Mosby; 1995:834-838.
  39. Lee BB, Kim HH, Mattassi R, et al. A new approach to the congenital vascular malformation with new concept—Seoul Consensus. *Int J Angiol.* 2003;12:248-251.
  40. Lee BB, Mattassi R, Loose D, et al. Consensus on Controversial Issues in Contemporary Diagnosis and Management of Congenital Vascular Malformation—Seoul Communication. *Int J Angiol.* 2004;13:182-192.
  41. Leu HJ. Pathomorphology of vascular malformations: analysis of 310 cases. *Int Angiol.* 1990;9:147-155.
  42. Bastide G, Lefebvre D. Anatomy and organogenesis and vascular malformations. In: Belov St, Loose DA, Weber J, eds. *Vascular Malformations*. Reinbek: Einhorn-Press Verlag GmbH; 1989:20-22.
  43. Lee BB. Advanced management of congenital vascular malformation (CVM). *Int Angiol.* 2002;21:209-213.
  44. Lee BB. Congenital vascular malformation. In: Geroulakos G, van Urk H, Hobson II RW, Calligaro K, eds. *Vascular Surgery: Cases, Questions and Commentaries*. Great Britain: Springer-Verlag London Limited; 2003:315-323.
  45. Kennedy WP. Epidemiologic aspects of the problem of congenital malformations. In: Persaud TNV, ed. *Problems of Birth Defects*. Maryland: Publisher University Park Press Baltimore; 1977:35-52.
  46. Stevenson AC, Johnston HA, Stewart MIP, Golding DR. Congenital malformations. A report of a study of series of consecutive births in 24 centres. *Bull WHO.* 1966;34(Suppl):9 and 100-102 (Extracts).
  47. Myrianthopoulos NC, Chung CS. Congenital malformations in singletons. Epidemiologic survey. In Bergsma D, ed. *Birth Defects*. Orig.Artic.Ser. 1974; Vol X, No II (Miami Symposia Specialists for the National Foundation-March of Dimes).
  48. Woolard HH. The development of the principal arterial stems in the forelimb of the pig. *Contrib Embryol.* 1922;14:139-154.
  49. DeTakats G. Vascular anomalies of the extremities. *Surg Gynecol Obstet.* 1932;55:227-237.
  50. Lee BB. Congenital vascular malformation. In: Geroulakos G, van Urk H, Hobson II RW, Calligaro K, eds. *Vascular Surgery: Cases, Questions and Commentaries*. 2nd ed. Great Britain: Springer-Verlag London Limited; 2005:377-392.
  51. Do YS, Yakes WF, Shin SW, et al. Ethanol embolization of arteriovenous malformations: interim results. *Radiology.* 2005;235:674-682.
  52. Kim JY, Kim DI, Do YS, et al: Surgical treatment for congenital arteriovenous malformation: 10 years' experience. *Eur J Vasc Endovasc Surg.* 2006;32:101-106. Epub 2006 Feb.
  53. Jeon YH, Do YS, Shin SW, et al. Ethanol embolization of arteriovenous malformations: results and complications of 33 cases. *J Kor Radiol Soc.* 2003;49:263-270.
  54. Lee BB. Current issue in management of chronic lymphedema: personal reflection on an experience with 1065 patients. Commentary, *Lymphology.* 2005;38:28-31.
  55. Mortimer PS. Evaluation of lymphatic function: abnormal lymph drainage in venous disease. *Int Angiol.* 1995 Sep;14(3 Suppl 1):32-35.
  56. Lee BB. Management of arteriovenous malformation. In: Davies AH, Mitchel AW, eds. *Vascular & Endovascular Surgery Highlights*, 2006-07 (Fast Facts). Oxford, UK: Health Press Limited; 2007:42-50.

57. Mattassi R. Differential diagnosis in congenital vascular-bone syndromes. *Semin Vasc Surg.* 1993;6:233-244.
58. Kim YW, Do YS, Lee SH, Lee BB. Risk factors for leg length discrepancy in patients with congenital vascular malformation. *J Vasc Surg.* 2006;44:545-553.
59. Mattassi R, Vaghi M. Vascular bone syndrome—angio-osteodystrophy: current concepts. *Special Issue: Phlebology.* 2007;22:283-286.
60. Rutherford RB. New approaches to the diagnosis of congenital vascular malformations. In: Belov S, Loose DA, Weber J, eds. *Vascular Malformations.* Vol 16. Reinbek, Germany: Einhorn-Press Verlag; 1989:60-65.
61. Henedige AA, Quaba AA, Al-Nakib K. Sturge-Weber syndrome and dermatomal facial port-wine stains: incidence, association with glaucoma, and pulsed tunable dye laser treatment effectiveness. *Plast Reconstr Surg.* 2008;121:1173-1180.
62. Lee BB, Bergan JJ: Advanced management of congenital vascular malformations: a multidisciplinary approach. *Cardiovasc Surg.* 2002;10:523-533.
63. Lee BB. Critical role of multidisciplinary team approach in the new field of vascular surgery—endovascular surgery. *J Kor Soc Vasc Surg.* 2003;19:121-123.
64. Lee BB, Laredo J, Kim YW, et al. Congenital vascular malformations: general treatment principles. *Phlebology.* 2007;22:258-263.
65. Rutherford RB. Congenital vascular malformations: diagnostic evaluation. *Semin Vasc Surg.* 1993;6:225-232.
66. Emanuel RB, Weiser MM, Shenoy SS, et al. Arteriovenous malformations as a cause of gastrointestinal bleeding: the importance of triple-vessel angiographic studies in diagnosis and prevention of rebleeding. *J Clin Gastroenterol.* 1985;7:237-246.
67. Takahane H, Yaegashi Y, Satomi S, et al. Systemic-to-pulmonary vascular malformation of lung visualized by computer-assisted 3-D reconstruction. *Histopathology.* 1997;31:252-257.
68. Pearce WH, Rutherford RB, Whitehill TA, Davis K. Nuclear magnetic resonance imaging in patients with congenital vascular malformations of the limbs. *J Vasc Surg.* 1988;8:64-70.
69. Lee BB, Choe YH, Ahn JM, et al. The new role of MRI (Magnetic Resonance Imaging) in the contemporary diagnosis of venous malformation: can it replace angiography? *J Am Coll Surg.* 2004;198:549-558.
70. Lee BB, Mattassi R, Choe YH, et al. Critical role of duplex ultrasonography for the advanced management of a venous malformation (VM). *Phlebology.* 2005;20:28-37.
71. Lee BB, Mattassi R, Kim BT, et al. Contemporary diagnosis and management of venous and AV shunting malformation by whole body blood pool scintigraphy (WBBPS). *Int. Angiol.* 2004;23:355-367.
72. Lee BB. Surgical management of lymphedema. In: Lee BB, Simonian SJ, Blondeau B, and Tretbar LT, eds. *Lymphedema: Diagnosis and Treatment.* Great Britain: Springer-Verlag London Limited; 2008:55-63.
73. Lee BB, Bergan, JJ. New clinical and laboratory staging systems to improve management of chronic lymphedema. *Lymphology.* 2005;38:122-129.
74. Lee BB, Mattassi R, Kim BT, Park JM. Advanced management of arteriovenous shunting malformation with Transarterial Lung Perfusion Scintigraphy (TLPS) for follow up assessment. *Int Angiol.* 2005;24:173-184.
75. Ching AS, Chan PN, Cheung H, et al. CT and DSA appearances of a ruptured congenital arteriovenous malformation of the posterior mediastinal aorta. *Br J Radiol.* 2001;74:565-567.
76. Papendieck CM. Lymphatic dysplasias in pediatrics. *Int Angiol.* 1999;18:6-9.
77. Tasnadi G. Epidemiology and etiology of congenital vascular malformations. *Semin Vasc Surg.* 1993;6:200-203.
78. Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. *Pediatrics.* 1976;58:218-222.
79. Malan E. Surgical problems in the treatment of congenital arteriovenous fistulae. *J Cardiovasc Surg.* 1965;6:251.
80. Szilagyi DE, Elliott JP, DeRusso FJ, Smith RF. Peripheral congenital arteriovenous fistulas. *Surgery.* 1965;57:61-81.
81. Szilagyi DE, Smith RF, Elliott JP, Hageman JH. Congenital arteriovenous anomalies of the limbs. *Arch Surg.* 1976;111:423-429.



82. Kim YW, Lee BB, Cho JH, et al. Haemodynamic and clinical assessment of lateral marginal vein excision in patients with a predominantly venous malformation of the lower extremity. *Eur J Vasc Endovasc Surg.* 2007;33:122-127.
83. Loose DA. Surgical management of venous malformations. *Special Issue: Phlebology.* 2007;22:276-282.
84. Rosenblatt M. Endovascular management of venous malformations. *Special Issue: Phlebology.* 2007;22:264-275.
85. Loose DA. Combined treatment of congenital vascular defects: indications and tactics. *Semin Vasc Surg.* 1993;6:279-296.
86. Shin BS, Lee BB, Do YS, et al. Multistage ethanol sclerotherapy of soft-tissue arteriovenous malformations: effect on pulmonary arterial pressure. *Radiology.* 2005;235:1072-1077.
87. Yakes WF, Haas DK, Parker SH, et al. Symptomatic vascular malformations: ethanol embolotherapy. *Radiology.* 1989;170:1059-1066.
88. Yakes WF, Parker SH, Gibson MD, et al. Alcohol embolotherapy of vascular malformations. *Semin Intervent Radiol.* 1989;6:146-161.
89. Alòs J, Carreño P, López JA, et al. Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. *Eur J Vasc Endovasc Surg.* 2006;31:101-107.
90. Siniluoto TM, Svendsen PA, Wikholm GM, et al. Percutaneous sclerotherapy of venous malformations of the head and neck using sodium tetradecyl sulfate (sotradecol) *Scand J Plast Reconstr Surg Hand Surg.* 1997;31:145-150.
91. Pascarella L, Mekenas L, Bergan J. Venous disorders: treatment with sclerosant foam. *J Cardiovasc Surg (Torino).* 2006;47:9-18.
92. Bergan J, Cheng V. Foam sclerotherapy of venous malformations. *Special Issue: Phlebology.* 2007;22:299-302.
93. Forlee M, Grouden M, Moore D, et al. Stroke after varicose vein foam injection sclerotherapy. *J Vasc Surg.* 2006;43:162-164.
94. Zanetti PH. Cyanoacrylate/iophenylate mixtures: modification and in vitro evaluation as embolic agents. *J Intervention Radiol.* 1987;2:65-68.
95. Cromwell LD, Kerber CW. Modification of cyano-acrylate for therapeutic embolization: preliminary experience. *AJR Am J Roentgenol.* 1979;132:799.
96. Gillespie DL, Villavicencio JL, Gallagher C, et al. Presentation and management of venous aneurysms. *J Vasc Surg.* 1997;845-852.
97. Lee BB: Klippel-Trenaunay syndrome and pregnancy. *Int Angiol.* 2003;22:328.

## 第 69 章

1. Szilagyi DE, Smith RF, Elliott JP, Hageman JH. Congenital arteriovenous anomalies of the limbs. *Arch Surg.* 1976;111:423.
2. Coursey G, Ivins JC, Barker NW. Congenital arteriovenous fistulas in the extremities: an analysis of 69 cases. *Angiology.* 1956;7:201.
3. Gomes MM, Bernatz PE. Arteriovenous fistulas: a review and ten-year experience at the Mayo Clinic. *Mayo Clinic Proc.* 1970;45:81.
4. Szilagyi DE, Elliot JP, DeRusso FJ, Smith RF. Peripheral congenital arteriovenous fistulas. *Surgery.* 1965;57:61.
5. Jacobowitz GR, Rosen RJ, Rockman CB, et al. Transcatheter embolization of complex pelvic malformations: results and long-term follow-up. *J Vasc Surg.* 2001;33:51.
6. Lee BB, Do YS, Yakes W, et al. Management of arteriovenous malformations: a multidisciplinary approach. *J Vasc Surg.* 2004;39:590.
7. Mendel T, Louis DS. Major vascular malformations of the upper extremity: long-term observation. *J Hand Surg.* 1997;22A:302.
8. Natali J, Merland JJ. Superselective arteriography and therapeutic embolization for vascular malformations (angiodysplasias). *J Cardiovasc Surg.* 1976;17:465.
9. Kaufman SL, Kumar AA, Roland JA, et al. Transcatheter embolization in the management of congenital arteriovenous

- malformations. *Radiology*. 1980;137:21.
10. Palmaz JC, Newton TH, Reuter SR, Bookstein JJ. Particulate intraarterial embolization in pelvic arteriovenous malformations. *AJR Am J Roentgenol*. 1981;137:117.
  11. Flye MW, Jordan BP, Schwartz MZ. Management of congenital arteriovenous malformations. *Surgery*. 1983;94:740.
  12. Olcott CIV, Newton TH, Stoney RJ, Ehrenfeld WK. Intra-arterial embolization in the management of arteriovenous malformations. *Surgery*. 1976;79:312.
  13. Widlus DM, Murray RR, White RI Jr, et al. Congenital arteriovenous malformations: tailored embolotherapy. *Radiology*. 1988;169:511.
  14. Rockman CR, Rosen RJ, Jacobowitz GR, et al. Transcatheter embolization of peripheral vascular malformations: the long-term success of multiple interventions. *Ann Vasc Surg*. 2003;17:417.
  15. Anderson PE, Kjeldsen AD. Occlusion of pulmonary arteriovenous malformations by use of vascular plug. *Acta Radiol*. 2007;48:496.
  16. Beck A, Dagan T, Matitiau A, Bruckheimer E. Transcatheter closure of pulmonary arteriovenous malformations with amplatzer devices. *Cathet Cardiovasc Intervent*. 2006;67:932.
  17. Osuga K, Hori S, Kitayoshi H, et al. Embolization of high flow arteriovenous malformations: experience with use of superabsorbent polymer microspheres. *J Vasc Interv Radiol*. 2002;13:1125.
  18. Yakes WF, Luethke JM, Merland JJ, et al. Ethanol embolization of arteriovenous fistulas: a primary model of therapy. *J Vasc Interv Radiol*. 1990;1:89.
  19. Yakes WF, Rossi P, Odink H. How I do it. Arteriovenous malformation management. *Cardiovasc Intervent Radiol*. 1996;19:65-71.
  20. Cho SK, Do YS, Sung W, et al. Arteriovenous malformations of the body and extremities: analysis of therapeutic outcomes and approaches according to a modified angiographic classification. *J Endovasc Ther*. 2006;13:527.
  21. Do YS, Yakes WF, Shin SW, et al. Ethanol embolization of arteriovenous malformations: interim results. *Radiology*. 2005;235:674.
  22. Kubota Y, Tsuchiya T, Kamei S, et al. Transcatheter arterial embolization with N-butyl 2-cyanoacrylate (Hystoacryl) in two treatments for huge renal arteriovenous malformation. *Acta Urol Japon*. 2007;53:307.
  23. Yamaki T, Nozaki M, Sasaki K. Color duplex-guided sclerotherapy for the treatment of venous malformations. *Dermatol Surg*. 2000;36:323.
  24. Yamaki T, Nozaki M, Sakurai H, et al. Prospective randomized efficacy of ultrasound-guided foam sclerotherapy compared with ultrasound-guided liquid sclerotherapy in the treatment of symptomatic venous malformations. *J Vasc Surg*. 2008;47:5778.
  25. Lee BB, Kim DI, Huh S, et al. New experiences with absolute ethanol sclerotherapy in the management of a complex form of congenital venous malformation. *J Vasc Surg*. 2001;33:764.
  26. Marrocco-Trischitta MM, Guerrini P, Abeni D, Stillo F. Reversible cardiac arrest after polidocanol sclerotherapy of peripheral venous malformation. *Dermatol Surg*. 2002;28:153.
  27. Pascarella L, Bergan JJ, Yamada C, Mekenas L. Venous angiomas: treatment with sclerosant foam. *Ann Vasc Surg*. 2005;19:457.
  28. Siniluoto TM, Svendsen PA, Wikholm GM, et al. Percutaneous sclerotherapy of venous malformations of the head and neck using sodium tetradecyl sulfate (Sotradecyl). *Scand J Plast Reconstr Hand Surg*. 1997;31:145.
  29. Berenguer B, Burrows PE, Zurakowski D, Mulliken JB. Sclerotherapy of craniofacial venous malformations: complications and results. *Plast Reconstr Surg*. 1999;104:111.
  30. Yakes W, Baker R. Cardiopulmonary collapse: sequelae of alcohol embolotherapy. *Radiology*. 1993;189:145.
  31. Mason KP, Michna E, Zurakowski D, et al. Serum ethanol level in children and adults after ethanol embolization or sclerotherapy for vascular anomalies. *Radiology*. 2000;217:127.

32. Burrows PE, Mason KP. Percutaneous treatment of low flow vascular malformations. *J Vasc Interv Radiol.* 2004;15:431.
33. Dobson MJ, Hartley RW, Ashleigh R, et al. MR angiography and MR imaging of symptomatic peripheral vascular malformations. *Clin Radiol.* 1997;52:595.
34. Lee BB, Choe YH, Ahn JM, et al. The new role of magnetic resonance imaging in the contemporary diagnosis of venous malformation: can it replace angiography? *J Am Coll Surg.* 2004;198:549.
35. Kim JY, Kim DI, Do YS, et al. Surgical treatment of congenital arteriovenous malformations: 10 years' experience. *Eur J Vasc Endovasc Surg.* 2006;32:101.
36. White RI Jr, Pollak J, Persin J, et al. Long-term outcome of embolotherapy and surgery for high-flow arteriovenous malformations. *J Vasc Interv Radiol.* 2000;11:1285.
37. Riles TS, Berenstein A, Fisher FA, et al. Reconstruction of the ligated external carotid artery for the embolization of cervicofacial arteriovenous malformations. *J Vasc Surg.* 1993;17:491.
38. Carr MM, Mahoney JL, Bowen CV. Extremity arteriovenous malformations: Review of a series. *Can J Surg.* 1994;27:392.

## 第 70 章

1. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. *Plast Reconstr Surg.* 1982;69:412.
2. Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. *J Pediatr Surg.* 1983;18:894.
3. Enjolras O, Mulliken JB. Vascular tumors and vascular malformations. *Adv Dermatol.* 1998;13:375.
4. Holmdahl K. Cutaneous hemangiomas in premature and mature infants. *Acta Paediatr Scand.* 1955;44:370.
5. Amir J, Metzker A, Krikler R, et al. Strawberry hemangioma in preterm infants. *Pediatr Dermatol.* 1986;3:331.
6. Mulliken, JB, Fishman SJ, Burrows PE. Vascular anomalies. *Curr Prob Surg.* 2000;37:519.
7. Bowers RE, Graham EA, Tomlinson KM. The natural history of the strawberry nevus. *Arch Dermatol.* 1960;82:667.
8. Cheung DSM, Warman ML, Mulliken JB. Hemangioma in twins. *Ann Plast Surg.* 1997;38:269.
9. Walter JW, Blei F, Anderson JL, et al. Genetic mapping of a novel familial form of infantile hemangioma. *Am J Med Genet.* 1999;82:77.
10. Boye E, Yu Y, Paranya G, et al. Clonality and altered behavior of endothelial cells from hemangiomas. *J Clin Invest.* 2001;107:745.
11. North PE, Waner M, Mizeracki A, et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. *Hum Pathol.* 2000;31:11.
12. North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. *Arch Dermatol.* 2001;137:559.
13. Barnes CM, Christison-Lagay EA, Folkman J. The placenta theory and the origin of infantile hemangioma. *Lymphat Res Biol.* 2007;5:245.
14. Barnes CM, Huang S, Kaipainen A, et al. Evidence by molecular profiling for a placental origin of infantile hemangioma. *Proc Natl Acad Sci U S A.* 2005;102:19097.
15. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. *J Pediatr.* 2007;150:291.
16. Kleinman ME, Tepper OM, Capla JM, et al. Increased circulating AC133+ CD34+ endothelial progenitor cells in children with hemangioma. *Lymphat Res Biol.* 2003;1:301.
17. Yu Y, Flint AF, Mulliken JB, et al. Endothelial progenitor cells in infantile hemangioma. *Blood.* 2004;103:1373.
18. Yu Y, Fuhr J, Boye E, et al. Mesenchymal stem cells and adipogenesis in hemangioma involution. *Stem Cells.* 2006;24:1605.
19. Khan ZA, Melero-Martin JM, Wu X, et al. Endothelial progenitor cells from infantile hemangioma and umbilical cord blood

- display unique cellular responses to endostatin. *Blood*. 2006;108:915.
20. Takahashi K, Mulliken JB, Kozakewich HPW, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. *J Clin Invest*. 1994;93:2357.
  21. Bielenberg DR, Bucana CD, Sanchez R, et al. Progressive growth of infantile cutaneous hemangiomas directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN- $\gamma$ . *Int J Oncol*. 1999;14:401.
  22. Razon MJ, Kraling BM, Mulliken JB, et al. Increased apoptosis coincides with onset of involution in infantile hemangioma. *Microcirculation*. 1998;5:189.
  23. Boon LM, Burrows PE, Paltiel HJ, et al. Hepatic vascular anomalies in infancy: a twenty-seven-year experience. *J Pediatr*. 1996;129:346.
  24. Christison-Lagay ER, Burrows PE, Alomari A, et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. *J Pediatr Surg*. 2007;42:62.
  25. Huang SA, Tu HM, Harney JW, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. *N Engl J Med*. 2000;343:185.
  26. Mulliken JB, Marler JJ, Burrows PE, et al. Reticular infantile hemangioma of the limb can be associated with ventral-caudal anomalies, refractory ulceration, and cardiac overload. *Pediatr Dermatol*. 2007;24:356.
  27. Freiden IJ, Reese V, Cohen D. PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects and eye abnormalities. *Arch Dermatol*. 1996;132:307.
  28. Metry DW, Haggstrom AN, Drolet BA, et al. A prospective study of PHACE syndrome in infantile hemangiomas: demographic features, clinical findings, and complications. *Am J Med Genet*. 2006;140A:975.
  29. Hersh JH, Waterfill D, Rutledge J, et al. Sternal malformation/vascular dysplasia association. *Am J Med Genet*. 1985;21:177.
  30. Gorlin RJ, Kantaputra P, Aughton DJ, et al. Marked female predilection in some syndromes associated with facial hemangioma. *Am J Med Genet*. 1994;52:130.
  31. Goldberg NS, Hebert AA, Esterly NB. Sacral hemangiomas and multiple congenital anomalies. *Arch Dermatol*. 1986;122:684.
  32. Albright AL, Gartner JC, Wiener ES. Lumbar cutaneous hemangiomas as indicators of tethered spinal cords. *Pediatrics*. 1989;83:977.
  33. Bouchard S, Yazbeck S, Lallier M. Perineal hemangioma, anorectal malformation, and genital anomaly: a new association? *J Pediatr Surg*. 1999;34:1133.
  34. Girard C, Bigorre M, Guillot B, et al. PELVIS syndrome. *Arch Dermatol*. 2006;142:884.
  35. Stockman A, Boralevi F, Taieb A, et al. SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urological anomalies, associated with an angioma of lumbosacral localization. *Dermatology*. 2007;214:40.
  36. Boon LM, Enjolras O, Mulliken JB. Congenital hemangioma: evidence of accelerated involution. *J Pediatr*. 1996;128:329.
  37. Berenguer B, Mulliken JB, Enjolras O, et al. Rapidly involuting congenital hemangioma: clinical and histopathologic features. *Pediatr Dev Pathol*. 2003;6:495.
  38. Enjolras O, Mulliken JB, Boon LM, et al. Noninvoluting congenital hemangioma: a rare cutaneous vascular anomaly. *Plast Reconstr Surg*. 2001;107:1647.
  39. Kasabach HH, Merritt KK. Capillary hemangioma with extensive purpura: report of a case. *Am J Dis Child*. 1940;59:1063.
  40. Zuckerberg LR, Nikoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood: an aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis. *Am J Surg Pathol*. 1993;17:321.
  41. Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. *J Pediatr*. 1997;130:631.
  42. Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with kaposiform hemangioendothelioma and not with common infantile hemangioma. *Plast Reconstr Surg*.

1997;100:1377.

43. Lyons LL, North PE, Mac-Moune Lai F, et al. Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. *Am J Surg Pathol*. 2004;28:559.
44. Debelenko LV, Perez-Atayde AR, Mulliken JB, et al. D2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendothelioma. *Mod Pathol*. 2005;18:1454.
45. Mulliken JB, Anupindi S, Ezekowitz RA, et al. Case 13-2004: a newborn girl with a large cutaneous lesion, thrombocytopenia, and anemia. *N Engl J Med*. 2004;350:1764.
46. Enjolras O, Mulliken JB, Wassef M, et al. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. *J Am Acad Dermatol*. 2000;42:225.
47. Jones EW, Orkin M. Tufted angioma (angioblastoma): a benign progressive angioma, not to be confused with Kaposi's sarcoma or low grade angiosarcoma. *J Am Acad Dermatol*. 1989;20:214.
48. Mentzel T, Mazzoleni G, Dei Tos A, et al. Kaposiform hemangioendothelioma in adults. Clinicopathologic and immunohistochemical analysis of three cases. *Am J Clin Pathol*. 1997;108:450.
49. Karnes JC, Lee BT, Phung T, et al. Adult-onset kaposiform hemangioendothelioma in a post-traumatic site. *Ann Plast Surg*. (in press).
50. Gruman A, Liang MG, Mulliken JB, et al. Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon. *J Am Acad Dermatol*. 2005;52:616.
51. Mills SE, Cooper PH, Fechner RE. Lobular capillary hemangioma: the underlying lesion of pyogenic granuloma. *Am J Surg Pathol*. 1980;35:92.
52. Patrice SJ, Wiss K, Mulliken JB. Pyogenic granuloma (lobular capillary hemangioma): a clinicopathologic study of 178 cases. *Pediatr Dermatol*. 1991;8:267.
53. Paltiel H, Burrows PE, Kozakewich HPW, et al. Soft-tissue vascular anomalies: utility of US for diagnosis. *Radiology*. 2000;214:747.
54. Burrows PE, Laor T, Paltiel H, et al. Diagnostic imaging in the evaluation of vascular birthmarks. *Dermatol Clin*. 1998;16:455.
55. Meyer JS, Joffer FA, Barnes PD, et al. Biological classification of soft-tissue vascular anomalies: MR correlation. *AJR Am J Roentgenol*. 1991;157:559.
56. Chung KC, Weiss SW, Kuzon WM Jr. Multifocal congenital hemangiopericytomas associated with Kasabach-Merritt syndrome. *Br J Plast Surg*. 1995;48:240.
57. Boon LM, Fishman SJ, Lund DP, et al. Congenital fibrosarcoma masquerading as congenital hemangioma: report of two cases. *J Pediatr Surg*. 1995;30:1378.
58. Margileth AM, Museles M. Cutaneous hemangiomas in children: diagnosis and conservative management. *JAMA*. 1965;194:523.
59. Greene AK, Rogers GF, Mulliken JB. Management of parotid hemangioma in 100 children. *Plast Reconstr Surg*. 2004;113:53.
60. Enjolras O, Gelbert F. Superficial hemangiomas: associations and management. *Pediatr Dermatol*. 1997;14:174.
61. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. *Science*. 1985;230:1375.
62. Sloan GM, Renisch JF, Nichter LS, et al. Intralesional corticosteroid therapy for infantile hemangiomas. *Plast Reconstr Surg*. 1989;83:459.
63. Ruttum MS, Abrams GW, Harris GJ, et al. Bilateral retinal embolization associated with intralesional steroid injection for capillary hemangioma of infancy. *J Pediatr Ophthalmol Strabismus*. 1993;30:407.
64. Bennett ML, Fleischer AB, Chamlin SL, et al. Oral corticosteroid use is effective for cutaneous hemangiomas. *Arch Dermatol*. 2001;137:1208.

65. Greene AK. Corticosteroid treatment for problematic infantile hemangioma: evidence does not support an increased risk for cerebral palsy. *Pediatrics*. 2008;126:1251.
66. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangiomas. *Plast Reconstr Surg*. 1999;104:1616.
67. Sadan N, Wolach B. Treatment of hemangiomas of infants with high doses of prednisone. *J Pediatr*. 1996;128:141.
68. White CW, Wolf SJ, Korones DN, et al. Treatment of childhood angiomatous diseases with recombinant interferon-alpha-2a. *J Pediatr*. 1991;118:59.
69. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon-alfa-2a therapy for life-threatening hemangiomas of infancy. *N Engl J Med*. 1992;326:1456.
70. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. *Science*. 1980;108:516.
71. Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. *J Natl Cancer Inst*. 1989;81:497.
72. Greinwald JH, Burke DK, Bonthius DJ, et al. An update on the treatment of hemangiomas in children with interferon-alfa-2a. *Arch Otolaryngol Head Neck Surg*. 1999;125:21.
73. Mulliken JB, Boon LM, Takahashi K, et al. Pharmacologic therapy for endangering hemangiomas. *Curr Opin Dermatol*. 1995;2:109.
74. Dubois J, Hershon L, Carmant L, et al. Toxicity profile of interferon-alfa-2b in children: a prospective evaluation. *J Pediatr*. 1999;135:782.
75. Deb G, Jenkner A, Donfrancesco A. Spastic diplegia and interferon. *J Pediatr*. 1999;134:382.
76. Barlow CF, Priebe C, Mulliken JB, et al. Spastic diplegia as a complication of interferon-alfa-2a treatment of hemangiomas of infancy. *J Pediatr*. 1998;132:527.
77. Haisley-Royster C, Enjolras O, Frieden IJ, et al. Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine. *J Pediatr Hematol Oncol*. 2002;24:459.
78. Scheepers JH, Quaba AA. Does the pulsed tunable dye laser have a role in the management of infantile hemangiomas: observations based on 3 years' experience. *Plast Reconstr Surg*. 1995;95:305.
79. Sie KC, McGill T, Healy GB. Subglottic hemangioma: ten years' experience with carbon dioxide laser. *Ann Otol Rhinol Laryngol*. 1994;103:167.
80. Scarcella JV, Dykes ER, Anderson R. Hemangiomas of the parotid gland. *Plast Reconstr Surg*. 1965;36:38.
81. Williams HB. Hemangiomas of the parotid gland in children. *Plast Reconstr Surg*. 1975;29:56.
82. Little KET, Cywes S, Davies MRQ, et al. Complicated giant hemangioma: excision using cardiopulmonary bypass and deep hypothermia. *J Pediatr Surg*. 1976;11:533.
83. Mulliken JB, Rogers GF, Marler JJ. Circular excision of hemangioma and purse-string closure: the smallest possible scar. *Plast Reconstr Surg*. 2002;109:1544.
84. Kirschner RE, Low DW. Treatment of pyogenic granuloma by shave excision and laser photocoagulation. *Plast Reconstr Surg*. 1999;104:1346.

## 第 71 章

1. Hunter WA. History of aneurysm of the aorta with some remarks of aneurysms in general. *Med Obs Inquiries*. 1757;1:323.
2. Eastcott HHG. Aneurysms and the surgeon: an historical review. In: Bergan JJ, Yao JST, eds. *Aneurysms. Diagnosis and Treatment*. New York: Grune & Stratton; 1982:3-14.
3. Barker WF. A history of vascular surgery. In: Moore WS, ed. *Vascular and Endovascular Surgery: A Comprehensive Review*. 7th ed. Philadelphia: Saunders; 2006:1-20.
4. Hughes CW. Arterial repair during the Korean War. *Ann Surg*. 1958;147:555-561.
5. Rich NM, Baugh JH, Hughes CW. Acute arterial injuries in Vietnam: 1,000 cases. *J Trauma*. 1970;10:359-369.

6. Fox CJ, Gillespie DL, O'Donnell SD, et al. Contemporary management of wartime vascular trauma. *J Vasc Surg.* 2005;41:638-644.
7. Clouse WD, Rasmussen TE, Peck MA, et al. In-theater management of vascular injury: 2 years of the balad vascular registry. *J Am Coll Surg.* 2007;204:625-632.
8. Bartlett CS, Helfet DL, Hausman MR, Strauss E. Ballistics and gunshot wounds: effects on musculoskeletal tissues. *J Am Acad Orthop Surg.* 2000;8:21-36.
9. Mattox KL, Feliciano DV, Burch J, et al. Five thousand seven hundred sixty cardiovascular injuries in 4459 patients. *Ann Surg.* 1989;209:698-705.
10. Feliciano DV, Bitondo CG, Mattox KL, et al. Civilian trauma in the 1980's. A 1-year experience with 456 vascular and cardiac injuries. *Ann Surg.* 1984;199:717-723.
11. Robbs JV, Carrim AA, Kadwa AM, Mars M. Traumatic arteriovenous fistula: experience with 202 patients. *Br J Surg.* 1994;81:1296-1299.
12. Rich NM, Hobson RW, Collins GJ. Traumatic arteriovenous fistulas and false aneurysms: a review of 558 lesions. *Surgery.* 1975;78:817-828.
13. Kelm M, Perings SM, Jax T, et al. Incidence and clinical outcome of iatrogenic femoral arteriovenous fistulas. *J Am Coll Cardiol.* 2002;40:291-297.
14. Kent KC, McArdle CR, Kennedy B, et al. A prospective study of the clinical outcome of femoral pseudoaneurysms and arteriovenous fistulas induced by arterial puncture. *J Vasc Surg.* 1993;17:125-133.
15. Ananthakrishnan G, DeNunzio M, Bungay P, et al. The occurrence of arterio-venous fistula during lower limb subintimal angioplasty: treatment and outcome. *Eur J Vasc Endovasc Surg.* 2006;32:675-679.
16. Samson RH, Sprayregen S, Veith FJ, et al. Management of angioplasty complications, unsuccessful procedures and early and late failures. *Ann Surg.* 1984;199:234-240.
17. Cronenwett JL, Walsh DB, Garrett HE. Tibial artery pseudoaneurysms: delayed complication of balloon catheter embolectomy. *J Vasc Surg.* 1988;8:483-488.
18. Dawson D. Management of iatrogenic injury and arteriovenous fistula. *Endovascular Today.* 2008;7:43-48.
19. Espinet A, Dunning J. Does ultrasound-guided central line insertion reduce complications and time to placement in elective patients undergoing cardiac surgery. *Interactive Cardiovasc Thorac Surg.* 2004;3:523-527.
20. Mansfield PF, Hohn DC, Fornage BD, et al. Complications and failures of subclavian-vein catheterization. *N Engl J Med.* 1994;26:1735-1738.
21. Tourarkissian B, Allen BT, Petrenic D, et al. Spontaneous closure of selected iatrogenic pseudoaneurysms and arteriovenous fistulae. *J Vasc Surg.* 1997;25:803-808.
22. Feliciano DV. Management of penetrating injuries to carotid artery. *World J. Surg.* 2001;25:1028-1035.
23. Kumar SR, Weaver FA, Yellin AE. Cervical vascular injuries. carotid and jugular venous injuries. *Surg Clin North Am.* 2001;81:1331-1343.
24. Demetriades D, Rabinowitz B, Pezikis A, et al. Subclavian vascular injuries. *Br J Surg.* 1987;74:1001-1003.
25. Demetriades D, Asensio JA. Subclavian and axillary vascular injuries. *Surg Clin North Am.* 2001;81:1357-1373.
26. Sato O, Tada Y, Sudo K, et al. Arteriovenous fistula following central line venous catheterization. *Arch Surg.* 1986;121:729-731.
27. du Toit DF, Lambrechts AV, Stark H, Warren BL. Long-term results of stent graft treatments of subclavian artery injuries: management of choice for stable patients? *J Vasc Surg.* 2008;47:739-743.
28. Graham JM, Mattox KL, Feliciano DV, DeBakey M. Vascular injuries of the axilla. *Ann Surg.* 1982;195:232-238.
29. Roberts LHY, Demetriades D. Vertebral artery injuries. *Surg Clin North Am.* 2001;81:1345-1355.
30. Vinchon M, Laurian VM, D'arrigo G, et al. Vertebral arteriovenous fistulas: a study of 49 cases and review of the literature. *Cardiovasc Surg.* 1994;2:359-369.

31. Tran HS, Burrows BJ, Zang WA, Han DC. Brachial arteriovenous fistula as a complication of placement of a peripherally inserted central venous catheter: a case report and review of the literature. *Am Surg.* 2006;72:833-836.
32. Dogan OF, Demericin M, Ucar I, et al. Iatrogenic brachial and femoral artery complications following venipuncture in children. *Heart Surg Forum.* 2006;9:E675-E680.
33. Agostoni P, Biondi-Zoccai GL, De Benedictis ML, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures: systematic overview and meta-analysis of randomized trials. *J Am Coll Cardiol.* 2004;44:349-356.
34. Hafez HM, Woolgar J, Robbs JV. Lower extremity arterial injury: results of 550 cases and review of risk factors associated with limb loss. *J Vasc Surg.* 2001;33:1212-1219.
35. Degiannis E, Bowley D, Bode F, et al. Ballistic arterial trauma to the lower extremity: recent South African experience. *Am Surg.* 2007;73:1136-1139.
36. Ilijevski N, Radak D, Radevic B, et al. Popliteal traumatic arteriovenous fistulas. *J Trauma.* 2002;52:739-744.
37. Mullen JD, Jabaji GJ. Popliteal pseudoaneurysm and arteriovenous fistula after arthroscopic meniscectomy. *Arthroscopy.* 2001;17:E1.
38. Abularrage CJ, Weiswasser JM, DeZee KJ, et al. Predictors of lower extremity arterial injury after total knee or total hip arthroplasty. *J Vasc Surg.* 2008;47:803-808.
39. Haddad FS, Prendergast CM, Dorrell JH, Platta AD. Arteriovenous fistula after fibular osteotomy leading to recurrent haemarthroses in total knee replacement. *J Bone Joint Surg.* 1996;78-B:458-460.
40. Davidson JT. Peroneal arteriovenous fistula. A complication of Fogarty catheter thromboembolectomy. *Am Surg.* 1989;55:616-620.
41. Mattox KL, Whisennaud HH, Espada R, Beall AC Jr. Management of acute combined injuries to the aorta and inferior vena cava. *Am J Surg.* 1975;130:720-724.
42. Fletcher JP, Klineberg PL, Hawker FH, et al. Arteriovenous fistula following lumbar disc surgery—the use of total cardiopulmonary bypass during repair. *Aust N Z J Surg.* 1986;56:631-633.
43. Spencer TA, Smyth SH, Wittich G, Hunter GC. Delayed presentation of traumatic aorto-caval fistula: a report of two cases and a review of the associated compensatory hemodynamic and structural changes. *J Vasc Surg.* 2006;43:836-840.
44. Machiedo GW, Jain KM, Swan KG, et al. Traumatic aorto-caval fistula. *J Trauma.* 1983;23:243-247.
45. Kwon TW, Sung KB, Cho YP, et al. Large vessel injury following operations for a herniated lumbar disc. *Ann Vasc Surg.* 2003;17:438-444.
46. Schwart A, Hiss M, Gwinner W, et al. Course and relevance of arteriovenous fistulas after renal transplant biopsies. *Am J Transplantation.* 2008;8:826-831.
47. Harrison KL, Nghlern HV, Coldwell DM, Davis CL. Renal dysfunction due to an arteriovenous fistula in a transplant recipient. *J Am Soc Nephrol.* 1994;5:1300-1306.
48. Aravanis C, Michaelides G, Alivizatos CN, Lazarides D. Renal arterio-venous fistula following nephrectomy. *Ann Surg.* 1962;156:749-751.
49. Tiplitsky SI, Milhoua PM, Patel MB, et al. Intrarenal arteriovenous fistula after ureteroscopic stone extraction with holmium laser lithotripsy. *J Endourol.* 2007;21:530-531.
50. Tomczak R, Heimberger T, Gorich J, et al. Abdominal arteriovenous and arterio-portal fistulas: etiology, diagnosis, therapeutic possibilities. *Z Gastroenterol.* 1997;35:555-562.
51. Williams DB, Payne WS, Foulk WT, Johnson CM. Splenic arteriovenous fistula. *Mayo Clin Proc.* 1980;55:383-386.
52. Kakizawa H, Toyota N, Naito A, et al. Super-selective transcatheter arterial embolization of a traumatic splenic arteriovenous fistula. *Radiat Med.* 2004;22:364-367.
53. Brothers TE, Stanley JC, Zelenock GB. Splenic arteriovenous fistula. *Int Surg.* 1995;80:189-194.
54. Gartside R, Gamelli RL. Splenic arteriovenous fistula. *J Trauma.* 1987;27:671-673.



55. Strodel WE, Eckhauser FE, Lemmer JH, et al. Presentation and perioperative management of arterioportal fistulas. *Arch Surg*. 1987;122:563-571.
56. Falkenstein K, Flynn L, Dunn S, Baldrige A. Arterial-venous fistula following pediatric liver transplant case studies. *Pediatr Transplant*. 2007;11:683-638.
57. Okuda K, Musha H, Nakajima Y, et al. Frequency of intrahepatic arteriovenous fistula as a sequel to percutaneous needle puncture of the liver. *Gastroenterology*. 1978;74:1204-1207.
58. Lumsden AB, Allen RC, Sreeram S, et al. Hepatic arterioportal fistula. *Am Surg*. 1993;59:722-726.
59. Pietri J, Remond A, Reix T, et al. Arterioportal fistulas: twelve cases. *Ann Vasc Surg*. 1990;4:533-539.
60. Guzman EA, McCahill LE, Rogers FB. Arterioportal fistulas: introduction of a novel classification with therapeutic implications. *J Gastrointest Surg*. 2006;10:543-550.
61. Schwartz RA, Teitelbaum GP, Katz MD, Pentecost MJ. Effectiveness of transcatheter embolization in the control of hepatic injuries. *J Vasc Radiol*. 1993;4:359-365.
62. Rosenthal D, Ellison RG, Luke JP, et al. Traumatic superior mesenteric arteriovenous fistula: report of a case and review of the literature. *J Vasc Surg*. 1987;5:486-491.
63. Okada K, Furusyo N, Sawayama Y, et al. Inferior mesenteric arteriovenous fistula eight years after sigmoidectomy. *Intern Med*. 2002;41:543-548.
64. Bingol H, Cingoz F, Yilmaz AT, et al. Vascular complications related to lumbar disc surgery. *J Neurosurg*. 2004;100(3 Suppl Spine):249-253.
65. Papadoulas S, Konstantinou D, Kourea HP, et al. Vascular injury complicating lumbar disc surgery: a systematic review. *Eur J Vasc Endovasc Surg*. 2002;24:189-195.
66. Birkeland EW, Taylor TKF. Major vascular injuries in lumbar disc surgery. *J Bone Joint Surgery*. 1969;51-B:4-9.
67. Datta JC, Janssen ME, Beckham R, Ponce C. The use of computed tomography angiography to define the prevertebral vascular anatomy prior to anterior lumbar procedures. *Spine*. 2007;32:113-119.
68. Ward AS, Carty NJ, O'Rourke NA. Arteriovenous fistulae complicating orthopaedic procedures. *Aust N Z J Surg*. 1995;65:905-907.
69. Wolf JW, Tegtmeier CJ, Whitehill R, Wang G. Arteriovenous fistula of the popliteal artery associated with subtrochanteric fracture: report of a case. *Clin Orthop Relat Res*. 1978;133:227-229.
70. Ritchie DA, Hill D, Fullarton GM, Calvert MH. Ultrasound diagnosis of profunda femoris pseudo-aneurysm for plate fixation of a transcervical femoral fracture. *Br J Radiol*. 1987;60:502-504.
71. Syme J. Case of spontaneous varicose aneurysms. *Edin Med J*. 1831;36:104-105.
72. Brewster DG, Camibria RP, Moncirol A, et al. Aortocaval and iliac arteriovenous fistulas: recognition and treatment. *J Vasc Surg*. 1991;13:258-265.
73. Scher LA, Veith F. Arteriovenous fistulas of the aorto-iliac territory. In: Bergan JJ, Yao JST, eds. *Aneurysms: Diagnosis and Treatment*. New York: Grune & Stratton; 1982:599-610.
74. Cinara IS, Davidovic LB, Kostic DM, et al. Arto-caval fistulas: a review of eighteen years of experience. *Acta Chir Belg*. 2005;105:616-620.
75. Davis PM, Gloviczki P, Cherry KJ Jr, et al. Aorta-caval and ilio-iliac arteriovenous fistulae. *Am J Surg*. 1998;176:115-118.
76. Mansour MA, Rutherford RB, Metcalf RK, Pearce WH. Spontaneous aorta-left renal vein fistula: the "abdominal pain, hematuria, silent left kidney" syndrome. *Surgery*. 1991;109:101-106.
77. Meyerson SL, Haider SA, Gupta N, et al. Abdominal aortic aneurysm with aorta-left renal vein fistula with left varicocele. *J Vasc Surg*. 2000;31:802-805.
78. Rangel A, Albarran H, Gomez-Orta F, et al. A case of giant arteriovenous shunt in a renal carcinoma. *Rev Invest Clin*. 1997;49:277-280.
79. Izaki K, Sugimoto K, Sugimura K, Hirota S. Transcatheter arterial embolization for advanced tumor thrombus with marked

- arterioportal or arteriovenous shunt complicating hepatocellular carcinoma. *Radiat Med.* 2004;22:155-162.
80. Nair R, Chetty R, Woolgar J, et al. Spontaneous arteriovenous fistula resulting from HIV arteritis. *J Vasc Surg.* 2001;33:186-187.
  81. Sumner DS. Hemodynamics and pathophysiology of arteriovenous fistulae. In: Rutherford RB, ed. *Vascular Surgery*. 5th ed. Philadelphia: Saunders; 2000:1400-1425.
  82. Holman E. Clinical and experimental observations of arteriovenous fistulae. *Ann Surg.* 1940;112:840-878.
  83. Holman E, Taylor G. Problems in the dynamics of blood flow. Pressure relations at the site of arteriovenous fistula. *Angiology.* 1952;3:415-430.
  84. Ramacciotti E, Galego SJ, Gomes M, et al. Fistula size and hemodynamics: an experimental model in canine femoral arteriovenous fistulas. *J Vasc Access.* 2007;8:33-43.
  85. Solberg LA, Harkness RD, Ingebrigtsen R. Hypertrophy of the median coat of the artery in experimental arteriovenous fistula. *Acta Chis Scand.* 1970;136:575-578.
  86. Stehbens WE. Blood vessel changes in chronic experimental arteriovenous fistulas. *Surg Gynecol Obstet.* 1968;127:327-338.
  87. D'Silva J, Fouche RF. The effect of changes in flow on the caliber of the large arteriese. *J Physiol.* 1960;150:23P-24P.
  88. Khoury G, Sfeir R, Nabbout G, et al. Traumatic arteriovenous fistulae: "the Lebanese war experience." *Eur J. Vasc Surg.* 1994;8:171-173.
  89. Kotelis D, Klemm K, Tengg-Kobligk H, et al. Intermittent claudication secondary to a traumatic arteriovenous fistula. *VASA.* 2007;36:285-287.
  90. Fry WR, Dort JA, Smith S, et al. Duplex scanning replaces arteriography and operative exploration in the diagnosis of potential cervical vascular injury. *Am J Surg.* 1994;168:693-696.
  91. Mutze S, Rademacher G, Matthes G, et al. Blunt cerebrovascular injury in patients with blunt multiple trauma: diagnostic accuracy of duplex Doppler US and early CT angiography. *Radiology.* 2005;237:884-892.
  92. Roubidoux MA, Hertzberg BS, Carroll BA, Hedgpeeth CA. Colorflow and image-directed Doppler ultrasound evaluation of iatrogenic arteriovenous fistulas in the groin. *J Clin Ultrasound.* 1990;18:463-469.
  93. Munera F, Soto JA, Palacio D, et al. Diagnosis of arterial injuries caused by penetrating trauma to the neck: comparison of helical CT angiography and conventional angiography. *Radiology.* 2000;216:356-362.
  94. Soto JA, Munera F, Morales C, et al. Focal arterial injuries of the proximal extremities: helical CT arteriography as the initial method of diagnosis. *Radiology.* 2001;218:188-194.
  95. Ofer A, Nitecki SS, Braun J, et al. CT angiography of the carotid arteries in trauma to the neck. *Eur J Vasc Endovasc Surg.* 2001;21:401-407.
  96. Nunez DZB, Torres-Leon M, Munera F. Vascular injuries of the neck and thoracic inlet: helical CT angiographic correlation. *Radiographics.* 2004;24:1087-1100.
  97. Miller-Thomas MM, West OC, Cohen AM. Diagnosing traumatic arterial injury in the extremities with CT angiography: pearls and pitfalls. *Radiographics.* 2005;25:S133-S142.
  98. Gaa J, Bohm C, Richter A, et al. Aortocaval fistula complicating abdominal aortic aneurysm: diagnosis with gadolinium-enhanced three-dimensional MR angiography. *Eur Radiol.* 1999;9:1438-1440.
  99. Hatch WD, Pentecost MJ, Colletti PM, Weaver FA. Magnetic resonance imaging of a post-traumatic arteriovenous fistula in the lower extremity. *Magn Reson Imaging.* 1991;9:459-462.
  100. Soto JA, Munera F, Cardoso N, et al. Diagnostic performance of Helical CT angiography in trauma to large arteries of the extremities. *J Comput Assist Tomogr.* 1999;23:188-196.
  101. Rieker O, Duber C, Neufang A, et al. CT angiography versus intraarterial digital subtraction angiography for assessment of aortoiliac occlusive disease. *AJR Am J Roentgenol.* 1997;169:1133-1138.
  102. Sclafani SJA, Cooper R, Shaftan G, et al. Arterial trauma: diagnostic and therapeutic angiography. *Radiology.*

1986;161:165-172.

103. Rajan DK, Croteau DL, Kazmers A. Aortocaval fistula: diagnosis with carbon dioxide angiography. *Abdom Imaging*. 1999;24:301-303.
104. White RA, Donayre CE, Walot I, et al. Preliminary clinical outcome and imaging criterion for endovascular prosthesis development in high-risk patients who have aortoiliac and traumatic arterial lesions. *J Vasc Surg*. 1996;24:556-571.
105. Norris GW. Varicose aneurysm at the bend of the arm; ligature of the artery above and below the scapula; secondary hemorrhages with a return of aneurysmal thrill at the tenth day; cure. *Am J Med Sci*. 1843;5:27.
106. Soubbotitch V. Military experiences of traumatic aneurysms. *Lancet*. 1913;2:720-721.
107. Lexer E. 20 Jahre Transplantation forschung in der Chirurgie. *Arch Klin Chir*. 1925;138:251-305.
108. Rich NM, Rhee P. An historical tour of vascular injury management from its inception to the new millennium. *Surg Clin North Am*. 2001;81:1199-1215.
109. Ruebben A, Tettoni S, Muratore P, et al. Arteriovenous fistulas induced by femoral arterial catheterization: percutaneous treatment. *Radiology*. 1998;209:729-734.
110. Thalhammer C, Kircherr AS, Uhlich F, et al. Postcatheterization pseudoaneurysms and arteriovenous fistulas: repair with percutaneous implantation of endovascular covered stents. *Radiology*. 2000;2:127-131.
111. Fellmeth BD, Roberts AC, Bookstein JJ, et al. Postangiographic femoral artery injuries: nonsurgical repair with ultrasound guided compression. *Radiology*. 1991;178:671-675.
112. Schaub F, Theiss W, Heinz M, et al. New aspects in ultrasound-guided compression repair of postcatheterization femoral artery injuries. *Circulation*. 1994;90:1861-1865.
113. Feld R, Patton GM, Carabasi RA, et al. Treatment of iatrogenic femoral artery injuries with ultrasound guided compression. *J Vasc Surg*. 1992;16:832-840.
114. Parodi JC. Endovascular repair of aortic aneurysms, arteriovenous fistulas and false aneurysms. *World J Surg*. 1996;20:655-663.
115. Marin ML, Vieth FJ, Cynamon J, et al. Initial experience with transluminally placed endovascular grafts for the treatment of complex vascular lesions. *Ann Surg*. 1995;222:449-469.
116. Schonholz CJ, Uflacker R, Gregorio DE, Parodi JC. Stent-graft treatment of trauma to the supra-aortic arteries. *J Cardiovasc Surg*. 2007;48:537-549.
117. Jayaraman MV, Do HM, Marks MP. Treatment of traumatic cervical arteriovenous fistulas with N-Butyl-2-cyanoacrylate. *AJNR Am J Neuroradiol*. 2007;28:352-354.
118. Ben-Menachem Y, Fields WS, Cadavid G, et al. Vertebral trauma: transcatheter embolization. *AJNR Am J Neuroradiol*. 1987;8:501-507.
119. Trocciola SM, Chaer RA, Lin SC, et al. Embolization of renal artery aneurysm and arteriovenous fistulas. A case report. *Vasc Endovasc Surg*. 2005;39:525-529.
120. Dinkel HP, Danuser H, Triller J. Blunt renal trauma: minimally invasive management with microcatheter embolization—experience in nine patients. *Radiology*. 2002;223:723-730.
121. Bozgeyik Z, Ozdemir H, Orhau I, et al. Pseudoaneurysm and renal arteriovenous fistula after nephrectomy: two cases treated by transcatheter coil embolization. *Emerg Radiol*. 2008;15:119-122.
122. Uchiyama D, Loganemaru M, Abe T, et al. Coil embolization of splenic artery aneurysm with preservation of the parent artery using a neck remodeling technique. *J Vasc Interv Radiol*. 2007;18:447-450.
123. Stanziale SF, Wholey M, Makaroun MS. Large hepatic artery aneurysm with portal vein fistula. *J Vasc Surg*. 2006;43:631.
124. Uflacker R, Saado J. Transcatheter embolization of superior mesenteric arteriovenous fistula. *AJR Am J Roentgenol*. 1982;139:1212-1214.
125. Lookstein RA, Guller J. Embolization of complex vascular lesions. *Mt Sinai J Med*. January 2004;71:17-28.
126. Gabelmann A, Görich J, Merkle EM. Endovascular treatment of visceral artery aneurysms. *J Endovasc Ther*. 2002;9:38-47.

127. Amar AP, Teitelbaum GP, Giannotta SL, Larsen DW. Covered stent-graft repair of the brachiocephalic arteries: technical note. *Neurosurgery*. 2002;51:247-253.
128. du Toit DF, Leith JG, Strauss DC, et al. Endovascular management of traumatic cervicothoracic arteriovenous fistula. *Br J Surg*. 2003;90:1516-1521.
129. Sakoda T, Nishimukai A, Tsujino T, et al. Two giant renal aneurysms and renal arteriovenous fistula associated with cardiac insufficiency and a sustained elevation of atrial natriuretic peptide and brain natriuretic peptide. *Am J Med Sci*. 2007;333:300-304.
130. Xenos ES, Freeman M, Stevens S, et al. Covered stents for injuries of subclavian and axillary arteries. *J Vasc Surg*. 2003;38:451-454.
131. Onal B, Koar S, Gumus T, et al. Postcatherization femoral arteriovenous fistulas: endovascular treatment with stent-grafts. *Cardiovasc Intervent Radiol*. 2004;27:453-458.
132. Papvassiliou VG, Dervisis CI, Argitis VP, et al. Endovascular repair of a traumatic popliteal arteriovenous fistula. *VASA*. 2006;35:53-55.
133. Lau LL, O'Reilly MJ, Johnston LC, Lee B. Endovascular stent-graft repair of primary aortocaval fistula with an abdominal aortoiliac aneurysm. *J Vasc Surg*. 2001;33:425-428.
134. Waldrop JL Jr, Dart BWT, Barker DE. Endovascular stent graft treatment of a traumatic aortocaval fistula. *Ann Vasc Surg*. 2005;19:562-565.
135. Umscheid T, Steltlter WJ. Endovascular treatment of an aortic aneurysm ruptured into the inferior vena cava. *J Endovasc Ther*. 2000;7:31-35.
136. Kwon SH, Oh JH, Park SJ, Park HC. Endovascular repair of a spontaneous right common iliac artery—inferior vena cava fistula due to infrarenal aortoiliac aneurysm. *Vasc Endovasc Surg*. 2008;42:279-283.
137. Scheinert D, Schröder M, Steinkamp H, et al. Treatment of iliac artery aneurysms by percutaneous implantation of stent grafts. *Circulation*. 2000;102(suppl III):III-253-III-258.
138. Huang Y, Gloviczki P, Duncan AA, et al. Common iliac artery aneurysm: expansion rate and results of open surgical and endovascular repair. *J Vasc Surg*. 2008;47:1203-1211.e2.
139. Sprouse LR, Hamilton IN. The endovascular treatment of renal arteriovenous fistula: placement of a covered stent. *J Vasc Surg*. 2002;26:1006-1008.
140. Wu CG, Li YD, Li MH. Post-traumatic superior mesenteric arteriovenous fistula: endovascular treatment with a covered stent. *J Vasc Surg*. 2008;47:654-656.
141. Stanley JC. *Renal Artery Aneurysm. Current Therapy in Vascular Surgery*. 3rd ed. Philadelphia: Mosby; 1999:813-817.
142. McKinley AG, Carrim AT, Robbs JV. Management of proximal axillary and subclavian artery injuries. *Br J Surg*. 2000;87:79-85.
143. Nitecki SS, Karram T, Hoffman A, Bass A. Venous trauma in the Lebanon War—2006. *Interactive Cardiovasc Thorac Surg*. 2007;6:647-651.
144. Parry NG, Feliciano DV, Burke RM, et al. Management and short-term patency of lower extremity venous injuries with various repairs. *Am J Surg*. 2003;186:631-635.
145. Nikolsky E, Mehran R, Halkin A, et al. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. *J Am Coll Cardiol*. 2004;44:1200-1209.
146. Koreny M, Riedmuller E, Nikfardjam M, et al. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. *JAMA*. 2004;291:350-357.
147. Lins S, Guffey D, VanRiper S, Kline-Rogers E. Decreasing vascular complications after percutaneous coronary interventions. *Crit Care Nurse*. 2006;26:38-45.
148. Tulsyan N, Kashyap VS, Greenburg RK, et al. The endovascular management of visceral artery aneurysms and pseudoaneurysms. *J Vasc Surg*. 2007;45:276-283.

149. Pasha SF, Gloviczki P, Stanson AW, Kamath PS. Splanchnic artery aneurysms. *Mayo Clin Proc.* 2007;82:472-479.
150. Louis MM, Shanley CJ. Visceral artery aneurysms. *Surg Clin North Am.* 1997;77:425-442.
151. English WP, Pearce JD, Craven TE, et al. Surgical management of renal artery aneurysms. *J Vasc Surg.* 2004;40:53-60.
152. Pfeiffer T, Reiher L, Grabitz K, et al. Reconstruction for renal artery aneurysm: operative techniques and long term results. *J Vasc Surg.* 2003;37:293-300.

## 第 72 章

1. <http://www.cdc.gov/nchs/gastats/deaths.htm>
2. Incidence & Prevalence. In U.S. Renal Data System, USRDS 2007 Annual Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, 2007. ([http://www.usrds.org/2007/view/02\\_incid\\_prev.asp](http://www.usrds.org/2007/view/02_incid_prev.asp)); Accessed 6/18/08.
3. Costs of CKD & ESRD. In U.S. Renal Data System, USRDS 2007 Annual Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, 2007. ([http://www.usrds.org/2007/view/11\\_econ](http://www.usrds.org/2007/view/11_econ)); Accessed 6/18/08.
4. <http://www.kidney.org/professionals/KDOQI/guidelines.cfm>; Accessed 4/25/08.
5. <http://www.fistulafirst.org>; Accessed 4/25/2008.
6. Sidawy AN, Gray R, Besarab A, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. *J Vasc Surg.* 2002;35:603-610.
7. Sidawy AN, Spergel LM, Besarab A, et al; Society for Vascular Surgery. The Society for Vascular Surgery: clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access. *J Vasc Surg.* 2008;48(5 Suppl):2S-25S.
8. Oliver MJ, Rothwell DM. Late creation of vascular access for hemodialysis and increased risk of sepsis. *J Vasc Interv Radiol.* 2004;15:1490.
9. Lenz O, Sadhu S, Fornoni A, et al. Overutilization of central venous catheters in incident hemodialysis patients: reasons and potential resolution strategies. *Semin Dial.* 2006;19:543-550.
10. Mallory DL, McGee WT, Shawker TH, et al. Ultrasound guidance improves the success rate of internal jugular vein cannulation. A prospective, randomized trial. *Chest.* 1990;98:157-160.
11. Fry WR, Clagett GC, O'Rourke, Terrence P. Ultrasound-guided central venous access. *Arch Surg.* 1999;134:738-741.
12. Salgado OJ, Urdaneta B, Colmenares B, et al. Right versus left internal jugular vein catheterization for hemodialysis: complications and impact on ipsilateral access creation. *Artif Organs.* 2004;28:728-733.
13. Moss AH, McLaughlin MM, Lempert KD, Holley JL. Use of a silicone catheter with a Dacron cuff for dialysis short-term vascular access. *Am J Kidney Dis.* 1988;12:492-498.
14. Spinowitz BS, Galler M, Golden RA, et al. Subclavian vein stenosis as a complication of subclavian catheterization for hemodialysis. *Arch Intern Med.* 1987;147:305-307.
15. Jefferys A, Chow J, Suranyi M. Acute vascular access catheters for haemodialysis: complications limiting technique survival. *Nephrology.* 2003;8:16-20.
16. Cimochowski GE, Worley E, Rutherford WE, et al. Superiority of the internal jugular over the subclavian access for temporary dialysis. *Nephron.* 1990;54:154-161.
17. Schillinger F, Schillinger D, Montagnac R, Milcent T. Post catheterisation vein stenosis in haemodialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. *Nephrol Dial Transplant.* 1991;6:722-724.
18. Gray R, Levitin A, Buck D, et al. Percutaneous fibrin sheath stripping versus transcatheter urokinase infusion for malfunctioning well-positioned tunneled central venous dialysis catheters: a prospective, randomized trial. *J Vasc Interv Radiol.* 2000;11:1121-1129.
19. Stevenson KB, Adcox MJ, Mallea MC, et al. Standardized surveillance of hemodialysis vascular access infections: 18-month

- experience at an outpatient, multifacility hemodialysis center. *Infect Control Hosp Epidemiol*. 2000;21:200-203.
20. Weijmer MC, Vervloet MG, ter Wee PM. Compared to tunneled cuffed haemodialysis catheters, temporary untunneled catheters are associated with more complications already within 2 weeks of use. *Nephrol Dial Transplant*. 2004;19:670-677.
  21. Saad T. Bacteremia associated with tunneled, cuffed hemodialysis catheters. *Am J Kidney Dis*. 1999;34:1114-1124.
  22. Little MA, O'Riordan A, Lucey B, et al. A prospective study of complications associated with cuffed, tunneled haemodialysis catheters. *Nephrol Dial Transplant*. 2001;16:2194-2200.
  23. Silva MB, Hobson RW, Pappas PJ, et al. A strategy for increasing use of autogenous hemodialysis access procedures: impact of preoperative noninvasive evaluation. *J Vasc Surg*. 1998;27:302-308.
  24. Kimmel M, Butscheid M, Brenner S, et al. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc—preliminary results. *Nephrol Dial Transplant*. 2008;23:1241-1245.
  25. Stenstrom DA, Muldoon LL, Armijo-Medina H, et al. N-Acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase III trials. *J Vasc Interv Radiol*. 2008;19:309-318.
  26. Kelly AM, Kwamena B, Cronin P, et al. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. *Ann Intern Med*. 2008;148:284-294.
  27. Morcos SK. Prevention of contrast media-induced nephrotoxicity after angiographic procedures. *J Vasc Interv Radiol*. 2005;16:13-23.
  28. Mendes RR, Farber MA, Marston WA, et al. Prediction of wrist arteriovenous fistula maturation with preoperative vein mapping with ultrasonography. *J Vasc Surg*. 2002;36:460-463.
  29. Huber T, Ozaki C, Flynn TC, et al. Prospective validation of an algorithm to maximize native arteriovenous fistulae for chronic hemodialysis access. *J Vasc Surg*. 2002;36:452-459.
  30. Passman MA, Criado E, Farber MA, et al. Efficacy of color flow duplex imaging for proximal upper extremity venous outflow obstruction in hemodialysis patients. *J Vasc Surg*. 1998;28:869-875.
  31. Arroyo MR, Sideman MJ, Spergel L, Jennings WC. Primary and staged transposition arteriovenous fistulas. *J Vasc Surg*. 2008;47:1279-1283.
  32. McLafferty RB, Pryor RW, Johnson CM, et al. Outcome of a comprehensive follow-up program to enhance maturation of autogenous arteriovenous hemodialysis access. *J Vasc Surg*. 2007;45:981-985.
  33. Berman SS, Gentile AT. Impact of secondary procedures in autogenous arteriovenous fistula maturation and maintenance. *J Vasc Surg*. 2001;34:866-871.
  34. Choe HM, Lal B, Cerveira JJ, et al. Durability and cumulative functional patency of transposed and nontransposed arteriovenous fistulas. *J Vasc Surg*. 2003;38:1206-1212.
  35. Huber TS, Carter JW, Carter RL, Seeger JM. Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review. *J Vasc Surg*. 2003;38:1005-1011.
  36. Silva MB, Hobson RW, Pappas PJ, et al. Vein transposition in the forearm for autogenous hemodialysis access. *J Vasc Surg*. 1997;26:981-988.
  37. Obialo CI, Tagoe AT, Martin PC, Asche-Crowe PE. Adequacy and survival of autogenous arteriovenous fistula in African American hemodialysis patients. *ASAIO J*. 2003;49:435-439.
  38. Rooijens PP, Tordoir JH, Stijnen T, et al. Radiocephalic wrist arteriovenous fistula for hemodialysis: meta-analysis indicates a high primary failure rate. *Eur J Vasc Endovasc Surg*. 2004;28:583-589.
  39. Keuter XH, van der Sande FM, Kessels AG, et al. Excellent performance of one-stage brachial-basilic arteriovenous fistula. *Nephrol Dial Transplant*. 2005;20:2168-2171.
  40. Hodges TC, Fillinger MF, Zwolak RM, et al. Longitudinal comparison of dialysis access methods: risk factors for failure. *J Vasc Surg*. 1997;26:1009-1019.
  41. Ascher E, Gade P, Hingorani A, et al. Changes in the practice of angioaccess surgery: impact of dialysis outcome and quality

- initiative recommendations. *J Vasc Surg.* 2000;31:84-92.
42. Gibson KD, Gillen DL, Capt MT, et al. Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System dialysis morbidity and mortality study. *J Vasc Surg.* 2001;34:694-700.
  43. Kalman PG, Pope M, Bhola C, et al. A practical approach to vascular access for hemodialysis and predictors of success. *J Vasc Surg.* 1999;30:727-733.
  44. Wolford HY, Hsu J, Rhodes JM, et al. Outcome after autogenous brachial-basilic upper arm transpositions in the post-National Kidney Foundation Dialysis Outcomes Quality Initiative era. *J Vasc Surg.* 2005;42:951-956.
  45. Rao, RK, Azin GD, Hood D, et al. Basilic vein transposition fistula: a good option for maintaining hemodialysis access site options? *J Vasc Surg.* 2004;39:1043-1047.
  46. Casey K, Tonnessen BH, Mannava K, et al. Brachial versus basilic vein dialysis fistulas: a comparison of maturation and patency rates. *J Vasc Surg.* 2008;47:402-406.
  47. Arroyo MR, Sideman MJ, Spergel L, Jennings WC. Primary and stage transposition arteriovenous fistulas. *J Vasc Surg.* 2008;47:1279-1283.
  48. Hossny A. Brachio-basilic arteriovenous fistula: different surgical techniques and their effects on fistula patency and dialysis-related complications. *J Vasc Surg.* 2003;37:821-826.
  49. Patel ST, Hughes J, Mills JL. Failure of arteriovenous fistula maturation: an unintended consequence of exceeding Dialysis Outcome Quality Initiative guidelines for hemodialysis access. *J Vasc Surg.* 2003;38:439-445.
  50. Hakaim AG, Nalbandian M, Scott T. Superior maturation and patency of primary brachiocephalic and transposed basilic vein arteriovenous fistulae in patients with diabetes. *J Vasc Surg.* 1998;27:154-157.

## 第 73 章

1. Kendall TW, Cull DL, Carsten CG, et al. The prosthetic axillo-axillary loop access: indications, technique, and outcomes. *J Vasc Surg.* 2008;48:389-393.
2. Vascular Access Work Group. Clinical practice guidelines for vascular access. *Am J Kidney Dis.* 2006;48:S248-S278.
3. De Meester JD, Vanholder R, De Roose J, Ringoir S. Factors and complications affecting catheter and technique survival with permanent single-lumen dialysis catheters. *Nephrol Dial Transplant.* 1994;9:678-683.
4. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. *Am J Kidney Dis.* 1999;34:1114-1124.
5. Cull JD, Cull DL, Taylor SM, et al. Prosthetic thigh arteriovenous access: outcome with SVS/AAVS reporting standards. *J Vasc Surg.* 2004;39:381-386.
6. Quinn SF, Schuman ES, Demlow TA, et al. Percutaneous transluminal angioplasty versus endovascular stent placement in the treatment of venous stenoses in patients undergoing hemodialysis: intermediate results. *J Vasc Interv Radiol.* 1995;6:851-855.
7. May J, Harris J, Fletcher J. Long-term results of saphenous vein graft arteriovenous fistulas. *Am J Surg.* 1980;140:387-390.
8. Bhandari S, Wilkinson A, Sellars L. Saphenous vein forearm grafts and Goretex thigh grafts as alternative forms of vascular access. *Clin Nephrol.* 1995;44:325-328.
9. Huber TS, Hirneise CM, Lee WA, et al. Outcomes after autogenous brachial-axillary translocated superficial femoropopliteal vein hemodialysis access. *J Vasc Surg.* 2004;40:311-318.
10. Bazan HA, Schanzer H. Transposition of the brachial vein: a new source for autologous arteriovenous fistulas. *J Vasc Surg.* 2004;40:184-186.
11. Elwakeel HA, Saad EM, Elkiran YM, Awad I. Unusual vascular access for hemodialysis: transposed venae comitantes of the brachial artery. *Ann Vasc Surg.* 2007;21:560-563.
12. Angle N, Chandra A. The two stage brachial artery-brachial vein autogenous fistula for hemodialysis: an alternative autogenous option for hemodialysis access. *J Vasc Surg.* 2005;42:806-810.

13. Casey K, Tonnessen BH, Mannava K, et al. Brachial versus basilica vein dialysis fistulas: a comparison of maturation and patency rates. *J Vasc Surg.* 2008;47:402-406.
14. May J, Tiller D, Johnson J, et al. Saphenous vein arteriovenous fistula in regular dialysis treatment. *N Engl J Med.* 1969;280:770.
15. Pierre-Paul D, Williams S, Lee T, Gahtan V. Saphenous vein loop to femoral artery arteriovenous fistula: a practical alternative. *Ann Vasc Surg.* 2004;18:223-227.
16. Gorski TF, Nguyen HQ, Gorski YC, et al. Lower-extremity saphenous vein transposition arteriovenous fistula: an alternative for hemodialysis access in AIDS patients. *Am Surg.* 1998;64:338-340.
17. Illig KA, Orloff M, Lyden SP, Green RM. Transposed saphenous vein arteriovenous fistula revisited: new technology for an old idea. *Cardiovasc Surg.* 2002;10:212-215.
18. Gradman WS, Cohen W, Haji-Aghaii M. Arteriovenous fistula construction in the thigh with transposed superficial femoral vein: our initial experience. *J Vasc Surg.* 2001;35:968-975.
19. Gradman WS, Laub J, Cohen W. Femoral vein transposition for arteriovenous hemodialysis access: improved patient selection and intraoperative measures reduce postoperative ischemia. *J Vasc Surg.* 2005;41:279-284.
20. Jackson MR. The superficial femoral-popliteal vein transposition fistula: description of a new vascular access procedure. *J Am Coll Surg.* 2000;191:581-584.
21. Bronder CM, Cull DL, Kuper SG, et al. The fistula elevation procedure: experience with 295 consecutive cases over a seven year period. *J Am Coll Surg.* In Press.
22. Chuang FR, Hsieh MJ, Lee CH, et al. Axillary artery to contralateral axillary vein graft fistula in chronic hemodialysis patients. *Ren Fail.* 2003;25:871-878.
23. McCann RL. Axillary grafts for difficult hemodialysis access. *J Vasc Surg.* 1996;24:457-462.
24. Jean-Baptiste E, Hassen-Khodja R, Haudebourg P, et al. Axillary loop grafts for hemodialysis access: midterm results from a single-center study. *J Vasc Surg.* 2008;47:138-143.
25. Vega D, Polo JR, Polo J, et al. Brachial-jugular expanded PTFE grafts for dialysis. *Ann Vasc Surg.* 2001;15:553-556.
26. Korets A, Ori, Y, Baytner S, et al. The femoral artery-femoral vein polytetrafluoroethylene graft: a 14-year retrospective study. *Nephrol Dial Transplant.* 1998;13:1215-1220.
27. Englesbe MJ, Al-Holou WN, Moyer AT, et al. Single center review of femoral arteriovenous grafts for hemodialysis. *World J Surg.* 2006;30:171-175.
28. Khadra MH, Dwyer AJ, Thompson JF. Advantages of polytetrafluoroethylene arteriovenous loops in the thigh for hemodialysis access. *Am J Surg.* 1997;173:280-283.
29. Tashjian DB, Lipkowitz GS, Madden RL, et al. Safety and efficacy of femoral-based hemodialysis access grafts. *J Vasc Surg.* 2002;35:691-693.
30. Miller CD, Robbin ML, Barker J, Allon M. Comparison of arteriovenous grafts in the thigh and upper extremities in hemodialysis patients. *J Am Soc Nephrol.* 2003;14:2942-2947.
31. Taylor SM, Eaves GL, Weatherford DA, et al. Results and complications of arteriovenous access dialysis grafts in the lower extremity: a five year review. *Am Surg.* 1996;62:188-191.
32. Flarup S, Hadimeri H. Arteriovenous PTFE dialysis access in the lower extremity: a new approach. *Ann Vasc Surg.* 2003;17:581-584.
33. Scott JD, Cull DL, Kalbaugh CA, et al. The mid-thigh loop arteriovenous graft: patient selection, technique, and results. *Am Surg.* 2006;72:825-828.
34. Karp SJ, Hawxby A, Burdick JF. Axillorenal arteriovenous graft: a new approach for dialysis access. *J Vasc Surg.* 2004;40:379-380.
35. Kopriva D, Moustapha A. Axillary artery to right atrium shunt for hemodialysis access in a patient with advanced central vein thrombosis: a case report. *Ann Vasc Surg.* 2006;20:418-421.



36. Bunger CM, Kroger J, Kock L, et al. Axillary-axillary interarterial chest loop conduit as an alternative for chronic hemodialysis access. *J Vasc Surg.* 2005;42:290-295.
37. Zanow J, Kruger U, Petzold M, et al. Arterioarterial prosthetic loop: a new approach for hemodialysis access. *J Vasc Surg.* 2005;41:1007-1012.
38. Wellons ED, Matsuura J, Lai KM, et al. Transthoracic cuffed hemodialysis catheters: a method for difficult hemodialysis access. *J Vasc Surg.* 2005;42:286-289.
39. Rajan DK, Croteau DL, Sturza SG, et al. Translumbar placement of inferior vena caval catheters: a solution for challenging hemodialysis access. *Radiographics.* 1998;18:1155-1170.
40. Lund GB, Trerotola SO, Scheel PJ Jr. Percutaneous translumbar inferior vena cava cannulation for hemodialysis. *Am J Kidney Dis.* 1995;25:732-737.
41. Stavropoulos SW, Pan JJ, Clark TW, et al. Percutaneous transhepatic venous access for hemodialysis. *J Vasc Interv Radiol.* 2003;14:1187-1190.
42. Smith TP, Ryan JM, Reddan DN. Transhepatic catheter access for hemodialysis. *Radiology.* 2004;232:246-251.
43. U.S. Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007.
44. Bagolan P, Spagnoli A, Ciprandi G, et al. A ten-year experience of Brescia-Cimino arteriovenous fistula in children: technical evolution and refinements. *J Vasc Surg.* 1998;27:640-644.
45. Bourquelot P, Raynaud F, Pirozzi N. Microsurgery in children for creation of arteriovenous fistulas in renal and non-renal diseases. *Ther Apher Dial.* 2003;7:498-503.
46. Sanabia J, Polo JR, Morales MD, et al. Microsurgery in gaining paediatric vascular access for haemodialysis. *Microsurgery.* 1993;14:276-279.
47. Gradman WS, Lerner G, Mentser M, et al. Experience with autogenous arteriovenous access for hemodialysis in children and adolescents. *Ann Vasc Surg.* 2005;19:609-612.
48. Sheth RD, Brandt ML, Brewer ED, et al. Permanent hemodialysis vascular access survival in children and adolescents with end-stage renal disease. *Kidney Int.* 2002;62:1864-1869.
49. Davis JB, Howell CG, Humphries AL Jr. Hemodialysis access: elevated basilic vein arteriovenous fistula. *J Pediatr Surg.* 1986;21:1182-1183.

## 第 74 章

1. Taber TE, Maikranz PS, Haag BW, et al. Maintenance of adequate hemodialysis access. Prevention of neointimal hyperplasia. *ASAIO J.* 1995;41:842-846.
2. Kelly BS, Heffelfinger SC, Whiting JF, et al. Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. *Kidney Int.* 2002;62:2272-2280.
3. Roy-Chaudhury P, Kelly BS, Narayana A, et al. Hemodialysis vascular access dysfunction from basic biology to clinical intervention. *Adv Ren Replace Ther.* 2002;9:74-84.
4. Sprouse LR 2nd, Lesar CJ, Meier GH 3rd, et al. Percutaneous treatment of symptomatic central venous stenosis (corrected). *J Vasc Surg.* 2004;39:578-582.
5. Altman SD. A practical approach for diagnosis and treatment of central venous stenosis and occlusion. *Semin Vasc Surg.* 2007;20:189-194.
6. Daugirdas JT, Schneditz D, Leehey DJ. Effect of access recirculation on the modeled urea distribution volume. *Am J Kidney Dis.* 1996;27:512-518.
7. Marshall MR, Santamaria P, Collins JF. Biostat 1000 and Daugirdas blood-based hemodialysis quantification: agreement and reproducibility. *Am J Kidney Dis.* 1998;31:1011-1018.

8. Suri RS, Nesrallah GE, Mainra R, et al. Daily hemodialysis: a systematic review. *Clin J Am Soc Nephrol*. 2006;1:33-42.
9. Suri RS, Nesrallah GE, Mainra R, et al. Predictive measures of vascular access thrombosis: a prospective study. *Kidney Int*. 1997;52:1656-1662.
10. Back MR, Maynard M, Winkler A, Bandyk DF. Expected flow parameters within hemodialysis access and selection for remedial intervention of nonmaturing conduits. *Vasc Endovasc Surg*. 2008;42:150-158.
11. Hassell DR, van der Sande FM, Kooman JP, et al. Optimizing dialysis dose by increasing blood flow rate in patients with reduced vascular-access flow rate. *Am J Kidney Dis*. 2001;38:948-955.
12. Collins DM, Lambert MB, Middleton JP, et al. Fistula dysfunction: effect on rapid hemodialysis. *Kidney Int*. 1992;41:1292-1296.
13. Berkoben M, Schwab SJ. Maintenance of permanent hemodialysis vascular access patency. *Anna J*. 1995;22:17-24.
14. Sherman RA, Kapoian T. Recirculation, urea disequilibrium, and dialysis efficiency: peripheral arteriovenous versus central venovenous vascular access. *Am J Kidney Dis*. 1997;29:479-489.
15. Rafique Z, Abbas G, Shafi T. Comparison of arteriovenous fistula recirculation by thermodilution and urea-based method. *J Coll Physicians Surg Pak*. 2007;17:603-606.
16. Chan MR, Young HN, Becker YT, Yevzlin AS. Obesity as a predictor of vascular access outcomes: analysis of the USRDS DMMS Wave II study. *Semin Dial*. 2008;21:274-279.
17. Kats M, Hawxby AM, Barker J, Allon M. Impact of obesity on arteriovenous fistula outcomes in dialysis patients. *Kidney Int*. 2007;71:39-43.
18. Plumb TJ, Adelson AB, Groggel GC, et al. Obesity and hemodialysis vascular access failure. *Am J Kidney Dis*. 2007;50:450-454.
19. Berman SS, Gentile AT. Impact of secondary procedures in autogenous arteriovenous fistula maturation and maintenance. *J Vasc Surg*. 2001;34:866-871.
20. Cull DL, Taylor SM, Carsten CG, et al. The fistula elevation procedure: a valuable technique for maximizing arteriovenous fistula utilization. *Ann Vasc Surg*. 2002;16:84-88.
21. McLafferty RB, Pryor RW 3rd, Johnson CM, et al. Outcome of a comprehensive follow-up program to enhance maturation of autogenous arteriovenous hemodialysis access. *J Vasc Surg*. 2007;45:981-985.
22. Weyde W, Krajewska M, Letachowicz W, Klinger M. Superficialization of the wrist native arteriovenous fistula for effective hemodialysis vascular access construction. *Kidney Int*. 2002;61:1170-1173.
23. Weyde W, Krajewska M, Letachowicz W, et al. Obesity is not an obstacle for successful autogenous arteriovenous fistula creation in haemodialysis. *Nephrol Dial Transplant*. 2008;23:1318-1322.
24. Abularrage CJ, Sidawy AN, Weiswasser JM, et al. Medical factors affecting patency of arteriovenous access. *Semin Vasc Surg*. 2004;17:25-31.
25. Albers FJ. Causes of hemodialysis access failure. *Adv Ren Replace Ther*. 1994;1:107-118.
26. Allon M, Bailey R, Ballard R, et al. A multidisciplinary approach to hemodialysis access: prospective evaluation. *Kidney Int*. 1998;53:473-479.
27. Bay WH, Van Cleef S, Owens M. The hemodialysis access: preferences and concerns of patients, dialysis nurses and technicians, and physicians. *Am J Nephrol*. 1998;18:379-383.
28. Hakim R, Himmelfarb J. Hemodialysis access failure: a call to action. *Kidney Int*. 1998;54:1029-1040.
29. Hodges TC, Fillinger MF, Zwolak RM, et al. Longitudinal comparison of dialysis access methods: risk factors for failure. *J Vasc Surg*. 1997;26:1009-1019.
30. Criado E, Marston WA, Jaques PF, et al. Proximal venous outflow obstruction in patients with upper extremity arteriovenous dialysis access. *Ann Vasc Surg*. 1994;8:530-535.
31. Guillou PJ, Leveson SH, Kester RC. The complications of arteriovenous grafts for vascular access. *Br J Surg*. 1980;67:517-521.

32. Maher J, Rivero A, Zaim S, et al. Massive arm edema following arteriovenous dialysis shunt creation in a patient with ipsilateral permanent pacemaker. *J Clin Ultrasound*. 2008;36:321-324.
33. Agarwal R, Davis JL. Monitoring interposition graft venous pressures at higher blood-flow rates improves sensitivity in predicting graft failure. *Am J Kidney Dis*. 1999;34:212-217.
34. Besarab A, Asif A, Roy-Chaudhury P, et al. The native arteriovenous fistula in 2007. Surveillance and monitoring. *J Nephrol*. 2007;20:656-667.
35. Dember LM, Holmberg EF, Kaufman JS. Value of static venous pressure for predicting arteriovenous graft thrombosis. *Kidney Int*. 2002;61:1899-1904.
36. Dinwiddie LC, Frauman AC, Jaques PF, et al. Comparison of measures for prospective identification of venous stenoses. *Anna J*. 1996;23:593-600.
37. Kleinekofort W, Kraemer M, Rode C, Wizemann V. Extracorporeal pressure monitoring and the detection of vascular access stenosis. *Int J Artif Organs*. 2002;25:45-50.
38. Sands JJ, Jabyac PA, Miranda CL, Kapsick BJ. Intervention based on monthly monitoring decreases hemodialysis access thrombosis. *ASAIO J*. 1999;45:147-150.
39. Singh N, Ahmad S, Wienckowski JR, Murray BM. Comparison of access blood flow and venous pressure measurements as predictors of arteriovenous graft thrombosis. *J Vasc Access*. 2006;7:66-73.
40. Schuman E, Ronfeld A, Barclay C, Heintz P. Comparison of clinical assessment with ultrasound flow for hemodialysis access surveillance. *Arch Surg*. 2007;142:1129-1133.
41. Krivitski N, Schneditz D. Arteriovenous vascular access flow measurement: accuracy and clinical implications. *Contrib Nephrol*. 2004;142:269-284.
42. Basile C, Ruggieri G, Vernaglione L, et al. A comparison of methods for the measurement of hemodialysis access recirculation. *J Nephrol*. 2003;16:908-913.
43. Barril G, Besada E, Cirugeda A, et al. Hemodialysis vascular assessment by an ultrasound dilution method (transonic) in patients older than 65 years. *Int Urol Nephrol*. 2001;32:459-462.
44. Krivitski NM, MacGibbon D, Gleed RD, Dobson A. Accuracy of dilution techniques for access flow measurement during hemodialysis. *Am J Kidney Dis*. 1998;31:502-508.
45. Sands J, Glidden D, Miranda C. Access flow measured during hemodialysis. *ASAIO J*. 1996;42:M530-M532.
46. Depner TA. Techniques for prospective detection of venous stenosis. *Adv Ren Replace Ther*. 1994;1:119-130.
47. Sherman RA. The measurement of dialysis access recirculation. *Am J Kidney Dis*. 1993;22:616-621.
48. Depner TA, Krivitski NM, MacGibbon D. Hemodialysis access recirculation measured by ultrasound dilution. *ASAIO J*. 1995;41:M749-M753.
49. Sherman RA, Kapoian T. The role of recirculation in access monitoring. *ASAIO J*. 1998;44:40-41.
50. Cinat ME, Hopkins J, Wilson SE. A prospective evaluation of PTFE graft patency and surveillance techniques in hemodialysis access. *Ann Vasc Surg*. 1999;13:191-198.
51. Lemaitre P, Ackman CF, O'Regan S, et al. Polytetrafluoroethylene (PTFE) grafts for hemodialysis. 18 months' experience. *Clin Nephrol*. 1978;10:27-31.
52. Treacy PJ, Ragg JL, Snelling P, et al. Prediction of failure of native arteriovenous fistulas using "on-line" fistula flow measurements. *Nephrology (Carlton)*. 2005;10:136-141.
53. NKF-DOQI clinical practice guidelines for vascular access. National Kidney Foundation-Dialysis Outcomes Quality Initiative. *Am J Kidney Dis*. 1997;30(4 Suppl 3):S150-S191.
54. Lumsden AB, MacDonald MJ, Kikeri D, et al. Prophylactic balloon angioplasty fails to prolong the patency of expanded polytetrafluoroethylene arteriovenous grafts: results of a prospective randomized study. *J Vasc Surg*. 1997;26:382-390; discussion 390-392.
55. Bacchini G, La Milia V, Andrucci S, Locatelli F. Color Doppler ultrasonography percutaneous transluminal angioplasty of

- vascular access grafts. *J Vasc Access*. 2007;8:81-85.
56. Kakkos SK, Haddad R, Haddad GK, et al. Results of aggressive graft surveillance and endovascular treatment on secondary patency rates of Vectra Vascular Access Grafts. *J Vasc Surg*. 2007;45:974-980.
  57. Duijm LE, Liem YS, van der Rijt RH, et al. Inflow stenoses in dysfunctional hemodialysis access fistulae and grafts. *Am J Kidney Dis*. 2006;48:98-105.
  58. Falk A. Maintenance and salvage of arteriovenous fistulas. *J Vasc Interv Radiol*. 2006;17:807-813.
  59. Schwarz C, Mitterbauer C, Boczula M, et al. Flow monitoring: performance characteristics of ultrasound dilution versus color Doppler ultrasound compared with fistulography. *Am J Kidney Dis*. 2003;42:539-545.
  60. Raju S. PTFE grafts for hemodialysis access. Techniques for insertion and management of complications. *Ann Surg*. 1987;206:666-673.
  61. Wellington JL. Salvage of thrombosed polytetrafluoroethylene dialysis fistulas by interposition grafting. *Can J Surg*. 1983;26:463-465.
  62. Schainfeld RM. Cutting balloon angioplasty: is it the key to access? *Catheter Cardiovasc Interv*. 2008;71:255-257.
  63. Marks N, Ascher E, Hingorani AP. Duplex-guided repair of failing or nonmaturing arterio-venous access for hemodialysis. *Perspect Vasc Surg Endovasc Ther*. 2007;19:50-55.
  64. Vesely TM, Siegel JB. Use of the peripheral cutting balloon to treat hemodialysis-related stenoses. *J Vasc Interv Radiol*. 2005;16:1593-1603.
  65. Funaki B. Cutting balloon angioplasty in arteriovenous fistulas. *J Vasc Interv Radiol*. 2005;16:5-7.
  66. Wu CC, Wen SC. Cutting balloon angioplasty for resistant venous stenoses of dialysis access: immediate and patency results. *Catheter Cardiovasc Interv*. 2008;71:250-254.
  67. Peregrin JH, Rocek M. Results of a peripheral cutting balloon prospective multicenter European registry in hemodialysis vascular access. *Cardiovasc Interv Radiol*. 2007;30:212-215.
  68. Kariya S, Tanigawa N, Kojima H, et al. Primary patency with cutting and conventional balloon angioplasty for different types of hemodialysis access stenosis. *Radiology*. 2007;243:578-587.
  69. Bhat R, McBride K, Chakraverty S, et al. Primary cutting balloon angioplasty for treatment of venous stenoses in native hemodialysis fistulas: long-term results from three centers. *Cardiovasc Interv Radiol*. 2007;30:1166-1170; discussion 1171-1172.
  70. Kariya S, Tanigawa N, Kojima H, et al. Percutaneous transluminal cutting-balloon angioplasty for hemodialysis access stenoses resistant to conventional balloon angioplasty. *Acta Radiol*. 2006;47:1017-1021.
  71. Carrafiello G, Laganà D, Mangini M, et al. Cutting balloon angioplasty for the treatment of haemodialysis vascular accesses: midterm results. *Radiol Med (Torino)*. 2006;111:724-732.
  72. Sreenarasimhaiah VP, Margassery SK, Martin KJ, Bander SJ. Cutting balloon angioplasty for resistant venous anastomotic stenoses. *Semin Dial*. 2004;17:523-527.
  73. Song HH, Kim KT, Chung SK, et al. Cutting balloon angioplasty for resistant venous stenoses of Brescia-Cimino fistulas. *J Vasc Interv Radiol*. 2004;15:1463-1467.
  74. Ryan JM, Dumbleton SA, Smith TP. Technical innovation. Using a cutting balloon to treat resistant high-grade dialysis graft stenosis. *AJR Am J Roentgenol*. 2003;180:1072-1074.
  75. Turmel-Rodrigues L, Mouton A, Birmel éB, et al. Salvage of immature forearm fistulas for haemodialysis by interventional radiology. *Nephrol Dial Transplant*. 2001;16:2365-2371.
  76. Song HH, Won YD, Kim YO, Yoon SA. Salvaging and maintaining non-maturing Brescia-Cimino haemodialysis fistulae by percutaneous intervention. *Clin Radiol*. 2006;61:404-409.
  77. Beathard GA. Gianturco self-expanding stent in the treatment of stenosis in dialysis access grafts. *Kidney Int*. 1993;43:872-877.
  78. Shemesh D, Goldin I, Zaghal I, et al. Angioplasty with stent graft versus bare stent for recurrent cephalic arch stenosis in

- autogenous arteriovenous access for hemodialysis: a prospective randomized clinical trial. *J Vasc Surg.* 2008;48:1524-1531, 1531 e1-2.
79. Naoum JJ, Irwin C, Hunter GC. The use of covered nitinol stents to salvage dialysis grafts after multiple failures. *Vasc Endovasc Surg.* 2006;40:275-279.
  80. Vesely TM. Use of stent grafts to repair hemodialysis graft-related pseudoaneurysms. *J Vasc Interv Radiol.* 2005;16:1301-1307.
  81. Rhodes ES, Silas AM. Dialysis needle puncture of Wallgrafts placed in polytetrafluoroethylene hemodialysis grafts. *J Vasc Interv Radiol.* 2005;16:1129-1134.
  82. Chen MC, Liang HL, Wu DK, et al. Percutaneous vein graft reanastomosis with use of a covered stent to salvage a thrombosed hemodialysis graft. *J Vasc Interv Radiol.* 2005;16:1385-1389.
  83. Ryan JM, Dumbleton SA, Smith TP. Technical innovation. Using a covered stent (Wallgraft) to treat pseudoaneurysms of dialysis grafts and fistulas. *AJR Am J Roentgenol.* 2003;180:1067-1071.
  84. Quinn SF, Kim J, Sheley RC. Transluminally placed endovascular grafts for venous lesions in patients on hemodialysis. *Cardiovasc Interv Radiol.* 2003;26:365-369.
  85. Lin PH, Johnson CK, Pullium JK, et al. Transluminal stent graft repair with Wallgraft endoprosthesis in a porcine arteriovenous graft pseudoaneurysm model. *J Vasc Surg.* 2003;37:175-181.
  86. Gross KA. Covered stents for the treatment of venous-to-graft stenosis: one year later. *J Vasc Nurs.* 2003;21:114-116.
  87. Najibi S, Bush RL, Terramani TT, et al. Covered stent exclusion of dialysis access pseudoaneurysms. *J Surg Res.* 2002;106:15-19.
  88. Farber A, Barbey MM, Grunert JH, Gmelin E. Access-related venous stenoses and occlusions: treatment with percutaneous transluminal angioplasty and Dacron-covered stents. *Cardiovasc Interv Radiol.* 1999;22:214-218.
  89. Rabindranauth P, Shindelman L. Transluminal stent-graft repair for pseudoaneurysm of PTFE hemodialysis grafts. *J Endovasc Surg.* 1998;5:138-141.
  90. Palmer RM, Cull DL, Kalbaugh C, et al. Is surgical thrombectomy to salvage failed autogenous arteriovenous fistulae worthwhile? *Am Surg.* 2006;72:1231-1233.
  91. Diskin CJ, Stokes TJ, Panus LW, et al. The importance of timing of surgery for hemodialysis vascular access thrombectomy. *Nephron.* 1997;75:233-237.
  92. Rajan DK, Clark TW, Simons ME, et al. Procedural success and patency after percutaneous treatment of thrombosed autogenous arteriovenous dialysis fistulas. *J Vasc Interv Radiol.* 2002;13:1211-1218.
  93. Turmel-Rodrigues L. Application of percutaneous mechanical thrombectomy in autogenous fistulae. *Tech Vasc Interv Radiol.* 2003;6:42-48.
  94. Shatsky JB, Berns JS, Clark TW, et al. Single-center experience with the Arrow-Trerotola Percutaneous Thrombectomy Device in the management of thrombosed native dialysis fistulas. *J Vasc Interv Radiol.* 2005;16:1605-1611.
  95. Biuckians A, Scott EC, Meier GH, et al. The natural history of autologous fistulas as first-time dialysis access in the KDOQI era. *J Vasc Surg.* 2008;47:415-421; discussion 420-421.
  96. Glanz S, Gordon D, Butt KM, et al. Dialysis access fistulas: treatment of stenoses by transluminal angioplasty. *Radiology.* 1984;152:637-642.
  97. Mahon BR. Ultrasound guidance to gain access for the "lyse and wait" technique. *J Vasc Interv Radiol.* 1999;10:833.
  98. Turmel-Rodrigues LA. Hemodialysis graft declotting with the "lyse and wait" technique: a new name for an old recipe. *J Vasc Interv Radiol.* 1999;10:96-98.
  99. Vogel PM, Bansal V, Marshall MW. Thrombosed hemodialysis grafts: lyse and wait with tissue plasminogen activator or urokinase compared to mechanical thrombolysis with the Arrow-Trerotola Percutaneous Thrombolytic Device. *J Vasc Interv Radiol.* 2001;12:1157-1165.
  100. Cynamon J, Lakritz PS, Wahl SI, et al. Hemodialysis graft declotting: description of the "lyse and wait" technique. *J Vasc*

- Interv Radiol.* 1997;8:825-829.
101. Enea NA, Swank MD. Hemodialysis graft declotting: "lyse and wait" and watch. *J Vasc Interv Radiol.* 1998;9:660-661.
  102. Smits HF, Van Rijk PP, Van Isselt JW, et al. Pulmonary embolism after thrombolysis of hemodialysis grafts. *J Am Soc Nephrol.* 1997;8:1458-1461.
  103. Vesely TM, Williams D, Weiss M, et al. Comparison of the angiojet rheolytic catheter to surgical thrombectomy for the treatment of thrombosed hemodialysis grafts. Peripheral AngioJet Clinical Trial. *J Vasc Interv Radiol.* 1999;10:1195-1205.
  104. Vesely TM, Hovsepian DM, Darcy MD, et al. Angioscopic observations after percutaneous thrombectomy of thrombosed hemodialysis grafts. *J Vasc Interv Radiol.* 2000;11:971-977.
  105. Kakkos SK, Haddad GK, Haddad J, Scully MM. Percutaneous rheolytic thrombectomy for thrombosed autogenous fistulae and prosthetic arteriovenous grafts: outcome after aggressive surveillance and endovascular management. *J Endovasc Ther.* 2008;15:91-102.
  106. Marston WA, Mauro MA, Keagy BA. Re: comparison of the AngioJet rheolytic catheter to surgical thrombectomy for the treatment of thrombosed hemodialysis grafts. *J Vasc Interv Radiol.* 2000;11:1095-1096.
  107. Smits HF, Smits JH, Wüst AF, et al. Percutaneous thrombolysis of thrombosed haemodialysis access grafts: comparison of three mechanical devices. *Nephrol Dial Transplant.* 2002;17:467-473.
  108. Sofocleous CT, Schur I, Koh E, et al. Percutaneous treatment of complications occurring during hemodialysis graft recanalization. *Eur J Radiol.* 2003;47:237-246.
  109. Falk A, Vesely TM. Re: Single-center experience with the Arrow-Trerotola percutaneous thrombectomy device in the management of thrombosed native dialysis fistulas. *J Vasc Interv Radiol.* 2006;17:1210-1212; author reply 1212-1213.
  110. Lazzaro CR, Trerotola SO, Shah H, et al. Modified use of the Arrow-Trerotola percutaneous thrombolytic device for the treatment of thrombosed hemodialysis access grafts. *J Vasc Interv Radiol.* 1999;10:1025-1031.
  111. Trerotola SO, Vesely TM, Lund GB, et al. Treatment of thrombosed hemodialysis access grafts: Arrow-Trerotola percutaneous thrombolytic device versus pulse-spray thrombolysis. Arrow-Trerotola Percutaneous Thrombolytic Device Clinical Trial. *Radiology.* 1998;206:403-414.
  112. Pattynama PM, van Baalen J, Verburgh CA, et al. Revascularization of occluded haemodialysis fistulae with the Hydrolyser thrombectomy catheter: description of the technique and report of six cases. *Nephrol Dial Transplant.* 1995;10:1224-1227.
  113. Martinez JF, Momblanch T, Pallares M, et al. New approach to vascular access revascularisation: the Hydrolyser thrombectomy catheter. *Edna Erca J.* 1996;22:26-28.
  114. Overbosch EH, Pattynama PM, Aarts HJ, et al. Occluded hemodialysis shunts: Dutch multicenter experience with the Hydrolyser catheter. *Radiology.* 1996;201:485-488.
  115. Rousseau H, Sapoval M, Ballini P, et al. Percutaneous recanalization of acutely thrombosed vessels by hydrodynamic thrombectomy (Hydrolyser). *Eur Radiol.* 1997;7:935-941.
  116. Criado E, Marston WA, Ligush J, et al. Endovascular repair of peripheral aneurysms, pseudoaneurysms, and arteriovenous fistulas. *Ann Vasc Surg.* 1997;11:256-263.
  117. Criado E, Marston WA, Ligush J, et al. Thrombosed polytetrafluoroethylene hemodialysis fistulas: salvage with combined thrombectomy and angioplasty. *Radiology.* 1989;171:507-508.
  118. Ko PJ, Liu YH, Hsieh HC, et al. Initial experience during balloon angioplasty assisted surgical thrombectomy for thrombosed hemodialysis grafts. *Chang Gung Med J.* 2003;26:178-183.
  119. Dougherty MJ, Calligaro KD, Schindler N, et al. Endovascular versus surgical treatment for thrombosed hemodialysis grafts: a prospective, randomized study. *J Vasc Surg.* 1999;30:1016-1023.

## 第 75 章

1. KDOQI Guidelines 2006 Updates, (<http://www.kidney.org/professionals/kdoqi/guidelineupHD-PD>).

2. Sidawy AN, Gray R, Besarab A, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. *J Vasc Surg.* 2002;35:603-610.
3. Akpolat T, Ozdemir O, Arik N, et al. Effect of desmopressin (DDAVP) on protein C and protein C inhibitors in uremia. *Nephron.* 1993;64:232-234.
4. Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? *Blood.* 1999;94:2569-2574.
5. Andrassy K, Ritz E. Uremia as a cause of bleeding. *Am J Nephrol.* 1985;5:313-319.
6. Sood P, Sinson GP, Cohen EP. Subdural hematomas in chronic dialysis patients: significant and increasing. *Clin J Am Soc Nephrol.* 2007;956-959.
7. Crowther MA, Clase CM, Margetts PJ, et al. Low intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. *J Am Soc Nephrol.* 2002;13:2331-2337.
8. Kaufman JS, O'Connor TZ, Zhang JH, et al. Veterans Affairs Cooperative Study Group on hemodialysis access graft thrombosis: randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. *J Am Soc Nephrol.* 2003;14:2313-2321.
9. Andrassy K, Weischedel E, Ritz E, et al. Bleeding in uremic patients after carbenicillin. *Thromb Haemost.* 1976;36:115-126.
10. Ng HJ, Koh LP, Lee LH. Successful control of post-surgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. *Ann Hematol.* 2003;82:257-258.
11. Livio M, Gotti E, Marchesi D, et al. Uremic bleeding: role of anaemia and beneficial effect of red cell transfusions. *Lancet.* 1982;2:1013-1015.
12. Steiner RW, Coggins C, Carvalho ACA. Bleeding time in uremia: a useful test to assess clinical bleeding. *Am J Hematol.* 1979;7:107-117.
13. Janssen MJ, van der Meulen J. The bleeding risk in chronic haemodialysis: preventive strategies in high-risk patients. *Neth J Med.* 1996;48:198-207.
14. Sloand JA. Long-term therapy for uremic bleeding. *Int J Artif Organs.* 1996;19:439-440.
15. Salvati F, Liani M, Golato M. Long-term therapy for uremic bleeding: effects of conjugate estrogens on the expression of platelet surface receptors for von Willebrand factor and fibrinogen (GPIb and GPIIb/IIIa glycoproteins). *Int J Artif Organs.* 1997;20:184-185.
16. Gawaz MP, Dobos G, Spath M, et al. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. *J Am Soc Nephrol.* 1994;5:36-46.
17. Sloand EM, Sloand JA, Prodouk K, et al. Reduction of platelet glycoprotein Ib in uremia. *Br J Haematol.* 1991;77:375-381.
18. KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients, ([http://www.kidney.org/professionals/KDOQI/guidelines\\_cvd/aspirin.htm](http://www.kidney.org/professionals/KDOQI/guidelines_cvd/aspirin.htm)).
19. Holden RM, Harman GJ, Wang M, et al. Major bleeding in hemodialysis patients. *Clin J Am Soc Nephrol.* 2008;3:105-110.
20. Wolfson AB, Singer I. Hemodialysis-related emergencies: II. *J Emerg Med.* 1987;6:61-70.
21. Dember LM. Critical care issues in the patient with chronic renal failure. *Crit Care Clin.* 2002;18:421-440.
22. Sloand JA, Schiff MJ. Beneficial effect of low-dose transdermal estrogen on bleeding time and clinical bleeding in uremia. *Am J Kidney Dis.* 1995;26:22-26.
23. Zoja C, Noris M, Coma D, et al. L-Arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia. *Lab Invest.* 1991;65:479-483.
24. Livio M, Mannucci PM, Vigano G, et al. Conjugated estrogens for the management of bleeding associated with renal failure. *N Engl J Med.* 1986;315:731-735.
25. Ryan JM. Using a covered stent (Wallgraft) to treat pseudoaneurysms of dialysis grafts and fistulas. *AJR Am J Roentgenol.* 2002;180:1067-1071.
26. Najibi S, Bush RL, Terremani TT, et al. Covered stent exclusion of dialysis access pseudoaneurysms. *J Surg Res.*

2002;106:15-19.

27. Zibari GB, Rohr MS, Landreneau MD, et al. Complications from permanent hemodialysis vascular access. *Surgery*. 1988;104:681-686.
28. Hausegger KA, Tiessenhausen K, Klimpfinger M, et al. Aneurysms of hemodialysis access grafts: treatment with covered stents—a report of three cases. *Cardiovasc Intervent Radiol*. 1998;21:334-337.
29. Vesely TM. Use of stent grafts to repair hemodialysis graft-related pseudoaneurysms. *J Vasc Interv Radiol*. 2005;16:1301-1307.
30. Barshes NR, Annamhotla S, Bechara C, et al. Endovascular repair of hemodialysis graft-related pseudoaneurysm: an alternative treatment strategy in salvaging failing dialysis access. *Vasc Endovasc Surg*. 2008 Mar 28; [Epub ahead of print].
31. Moszkowicz A, Behrens G, Gueyikian S, et al. Occlusion of a rapidly expanding hemodialysis graft with placement of a stent graft. *Semin Interv Radiol*. 2007;24:34-37.
32. Lin PH, Johnson CK, Pullium JK, et al. Transluminal stent graft repair with Wallgraft endoprosthesis in a porcine arteriovenous graft pseudoaneurysm model. *J Vasc Surg*. 2003;37:175-181.
33. Kronung G. Plastic deformation of Cimino fistula by repeated puncture. *Dial Transplant*. 1984;13:635-638.
34. Pierce GE, Thomas JH, Fenton JR. Novel repair of venous aneurysms secondary to arteriovenous dialysis fistulae. *Vasc Endovasc Surg*. 2007;41:55-60.
35. Bolton W, Cannon JA. Seroma formation associated with PTFE vascular grafts used as arteriovenous fistulae. *Dial Transplant*. 1981;10:60-68.
36. Schanzer H. Overview of complications and management after vascular access creation. In: Gray RJ, ed. *Dialysis Access*. Philadelphia: Lippincott Williams & Wilkins; 2002:93-97.
37. Blumenberg RM, Galfand ML, Dale WA. Perigraft seromas complicating arterial grafts. *Surgery*. 1985;97:194-203.
38. Borrero E, Doscher W. Chronic perigraft seromas in PTFE grafts. *J Cardiovasc Surg*. 1988;29:46-49.
39. Ahn SS, Machleder HI, Gupta R, et al. Perigraft seroma: clinical, histologic, and serologic correlates. *Am J Surg*. 1987;154:173-178.
40. Dauria DM, Dyk P, Garvin P. Incidence and management of seroma after arteriovenous graft placement. *J Am Coll Surg*. 2006;203:506-511.
41. Rhodes VJ. Perigraft seroma: simple solution to a difficult problem. *J Vasc Surg*. 1986;3:939.
42. Blumenberg RM. Invited commentary in lymph fistulas and seromas. In: Dale WA, ed. *Management of Vascular Surgical Problems*. New York: McGraw-Hill; 1985:293-298.
43. Ahn SS, Williams DE, Thye DA, et al. The isolation of a fibroblast growth inhibitor associated with perigraft seroma. *J Vasc Surg*. 1994;20:202-208.
44. Lewis P, Wolfe JHN. Lymphatic fistula and perigraft seroma. *Br J Surg*. 1993;80:410-411.
45. Eid A, Lyass S. Acute perigraft seroma simulating anastomotic bleeding of a PTFE graft applied as an arteriovenous shunt for hemodialysis. *Ann Vasc Surg*. 1996;10:290-291.
46. Claessens F, Van den Brande P. Treatment of two cases of perigraft seroma with fistulization to the skin. *Acta Chir Belg*. 1994;94:116-119.
47. Gargiulo NJ, Veith FJ, Scher LA, et al. Experience with covered stents for the management of hemodialysis polytetrafluoroethylene graft seromas. *J Vasc Surg*. 2008;48:216-217.
48. Storey BG, George CR, Stewart JH, et al. Embolic and ischemic complications after anastomosis of radial artery to cephalic vein. *Surgery*. 1969;66:325-327.
49. Berman SS, Gentile AT, Glickman MH, et al. Distal revascularization-interval ligation for limb salvage and maintenance of dialysis access in ischemic steal syndrome. *J Vasc Surg*. 1997;26:393-404.
50. Schanzer H, Skadany M, Haimov M. Treatment of angioaccess-induced ischemia by revascularization. *J Vasc Surg*. 1992;16:861-866.



51. Kwun KB. Hemodynamic evaluation of angioaccess procedures for hemodialysis. *Vasc Surg*. 1979;13:170-177.
52. Duncan H, Ferguson L, Faris I. Incidence of the radial steal syndrome in malades with Brescia fistula hemodialysis: its clinical significance. *J Vasc Surg*. 1986;4:144-147.
53. Schanzer H. Overview of complications and management after vascular access creation. In: Gray RJ, ed. *Dialysis Access*. Philadelphia: Lippincott Williams & Wilkins; 2002:93-97.
54. Miles AM. Upper limb ischemia after vascular access surgery: differential diagnosis and management. *Semin Dial*. 2000;13:312-315.
55. Tordoir JH, Dammers R, van der Sande FM. Upper extremity ischemia and hemodialysis vascular access. *Eur J Vasc Endovasc Surg*. 2004;27:1-5.
56. Morsy AH, Kulbaski M, Chen C, et al. Incidence and characteristics of patients with hand ischemia after a hemodialysis access procedure. *J Surg Res*. 1998;74:8-10.
57. Rutherford RB. The value of noninvasive testing before and after hemodialysis access in the prevention and management of complications. *Semin Vasc Surg*. 1997;10:157-161.
58. Goff CD, Sato DT, Bloch PHS, et al. Steal syndrome complicating hemodialysis access procedures: can it be predicted? *Ann Vasc Surg*. 2000;14:138-144.
59. Lazarides MK, Staamos DN, Panagopoulos GN, et al. Indications for surgical treatment of angioaccess-induced arterial "steal." *J Am Coll Surg*. 1998;187:422-426.
60. Knox RC, Berman SS, Hughes JD, et al. Distal revascularization-interval ligation: a durable and effective treatment for ischemic steal syndrome after hemodialysis. *J Vasc Surg*. 2002;36:250-256.
61. Sessa C, Pecher M, Maurizi-Balsan J, et al. Critical hand ischemia after angioaccess surgery: diagnosis and treatment. *Ann Vasc Surg*. 2000;14:583-593.
62. Rivers SP, Scher LA, Veith FJ. Correction of steal syndrome secondary to hemodialysis access fistulas: a simplified quantitative technique. *Surgery*. 1992;112:593-597.
63. Miles AM. Vascular steal syndrome and ischemic monomelic neuropathy: two variants of upper limb ischemia after hemodialysis vascular access surgery. *Nephrol Dial Transplant*. 1999;14:297-300.
64. Wixon CL, Hughes JD, Mills JL. Understanding strategies for the treatment of ischemic steal syndrome after hemodialysis access. *J Am Coll Surg*. 2000;191:301-310.
65. Sivanesan S, How TV, Bakran A. Characterizing flow distributions in AV fistulae for haemodialysis access. *Nephrol Dial Transplant*. 1998;13:3108-3110.
66. Lazarides MK, Stamos DN, Kopadis G, et al. Onset of arterial "steal" following proximal angioaccess: immediate and delayed types. *Nephrol Dial Transplant*. 2003;18:2387-2390.
67. Schanzer H, Schwartz M, Harrington E, Haimov M. Treatment of ischemia due to "steal" by arteriovenous fistula with distal artery ligation and revascularization. *J Vasc Surg*. 1998;7:770-773.
68. Pirzada NA, Morgenlander JC. Peripheral neuropathy in patients with chronic renal failure: a treatable source of discomfort and disability. *Postgrad Med*. 1997;102:249-261.
69. Wilbourn AJ, Furlan AJ, Hulley W, et al. Ischemic monomelic neuropathy. *Neurology*. 1983;33:447-451.
70. Hye RJ, Wolf YG. Ischemic monomelic neuropathy: an under-recognized complication of hemodialysis access. *Ann Vasc Surg*. 1994;8:578-582.
71. Mattson WJ. Recognition and treatment of vascular steal secondary to hemodialysis prostheses. *Am J Surg*. 1987;154:198-201.
72. Katz S, Kohl RD. The treatment of hand ischemia by arterial ligation and upper extremity bypass after angioaccess surgery. *J Am Coll Surg*. 1996;183:239-242.
73. Halevy A, Halpern Z, Negri M, et al. Pulse oximetry in the evaluation of the painful hand after arteriovenous fistula creation. *Vasc Surg*. 1991;14:537-539.

74. Schanzer H, Schwartz M, Harrington E, et al. Treatment of ischemia due to "steal" by arteriovenous fistula with distal artery ligation and revascularization. *J Vasc Surg.* 1988;7:770-773.
75. Zanow J, Petzold M, Petzold K, et al. Diagnosis and differentiated treatment of ischemia in patients with arteriovenous vascular access. In: Henry ML, ed. *Vascular Access for Hemodialysis-VII.* Chicago: Gore; 2001;201-209.
76. Zanow J, Kruger U, Scholz H. Proximalization of the arterial inflow: a new technique to treat access-related ischemia. *J Vasc Surg.* 2006;43:1216-1221.
77. Thermann F, Wollert U. Proximalization of the arterial inflow: new treatment of choice in patients with advanced dialysis shunt-associated steal syndrome? *Ann Vasc Surg.* 2009;23:485-490.
78. Mwipatayi BP, Bowles T, Balakrishnan S, et al. Ischemic steal syndrome: a case series and review of current management. *Current Surgery.* 2006;63:130-135.
79. Odland MD, Kelly PH, Ney AL, et al. Management of dialysis-associated steal syndrome complicating upper extremity arteriovenous fistulas: use of intraoperative digital photoplethysmography. *Surgery.* 1991;110:664-669.
80. DeCaprio JD, Valentine RJ, Kakish HB, et al. Steal syndrome complicating hemodialysis access. *Cardiovasc Surg.* 1997;5:648-653.
81. Goel N, Miller GA, Jotwani MC, et al. Minimally invasive limited ligation endoluminal-assisted revision (MILLER) for treatment of dialysis access-associated steal syndrome. *Kidney International* 2006;70:765-770.
82. Minion DJ, Moore E, Endean E. Revision using distal inflow: a novel approach to dialysis-associated steal syndrome. *Ann Vasc Surg.* 2005;19:625-628.
83. Vanherweghem JL, Yassine T, Goldman M, et al. Subclavian vein thrombosis: a frequent complication of subclavian vein cannulation for hemodialysis. *Clin Nephrol.* 1986;26:235-238.
84. Beathard GA. Percutaneous transvenous angioplasty in the treatment of vascular access stenosis. *Kidney Int.* 1992;42:1390-1397.
85. Schwab SJ, Quarles LD, Middleton JP, et al. Hemodialysis-associated subclavian vein stenosis. *Kidney Int.* 1988;33:1156-1159.
86. Haage P, Vorwerk D, Piroth W, et al. Treatment of hemodialysis-related central stenosis or occlusion: results of primary Wall-stent placement and follow-up in 50 patients. *Radiology.* 1999;121:175-180.
87. Barrett N, Spencer S, McIvor J, et al. Subclavian stenosis: a major complication of subclavian dialysis catheters. *Nephrol Dial Transplant.* 1988;3:423-425.
88. Surratt RF, Picus D, Hicks ME, et al. The importance of preoperative evaluation of the subclavian vein in dialysis access planning. *AJR Am J Roentgenol.* 1991;156:623-625.
89. Bambauer R, Inniger R, Pirrung KJ, et al. Complications and side effects associated with large bore catheters in the subclavian and internal jugular veins. *Artif Organs.* 1994;18:318-321.
90. Cimochoowski GE, Worley E, Rutherford WE, et al. Superiority of the internal jugular over the subclavian access for temporary dialysis. *Nephron.* 1990;54:154-161.
91. Schillinger F, Schillinger D, Montagnac R, et al. Post catheterization vein stenosis in hemodialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. *Nephrol Dial Transplant.* 1991;6:722-724.
92. NKF-DOQI clinical practice guidelines for vascular access. National Kidney Foundation-Dialysis Outcomes Quality Initiative. *Am J Kidney Dis.* 1997;4(Suppl 3):S150-S191.
93. Gray RJ, Dolmach BL, Buick MK. Directional atherectomy treatment for dialysis access: early results. *J Vasc Interv Radiol.* 1992;3:497-503.
94. Wisselink W, Money SR, Becker MO, et al. Comparison of operative reconstruction and percutaneous balloon dilatation for central venous obstruction. *Am J Surg.* 1993;166:200-204.
95. Fillinger MF, Reinitz ER, Schwartz RA, et al. Graft geometry and venous intimal-medial hyperplasia in arteriovenous loop grafts. *J Vasc Surg.* 1990;11:556-566.

96. Dethlefsen SM, Shepro D, D'Amore PA. Comparison of the effects of mechanical stimulation on venous and arterial smooth muscle cells in vitro. *J Vasc Res.* 1996;33:405-413.
97. Davis RP, Lipsig LJ, Connolly MM, et al. Varicose ulcer of the upper extremity. *Surgery.* 1985;98:616-618.
98. Hernandez D, Diaz F, Rufino M, et al. Subclavian vascular access stenosis in dialysis patients: natural history and risk factors. *J Am Soc Nephrol.* 1998;9:1507-1510.
99. Beathard GA. Physical examination: The forgotten tool. In: Gray RJ, Sands JJ, eds. *Dialysis Access: A Multidisciplinary Approach.* Philadelphia: Lippincott Williams & Wilkins; 2002:111-118.
100. Elseviers MM, Van Waelegheem JP. Identifying vascular access complications among ESRD patients in Europe. A prospective, multicenter study. *Nephrol News Issues.* 2003;17:61-64, 66-68.
101. Paulson WD, Ram SJ, Zibari GB. Vascular access: anatomy, examination, management. *Semin Nephrol.* 2002;22:183-194.
102. Rutherford RB. The value of noninvasive testing before and after hemodialysis access in the prevention and management of complications. *Semin Vasc Surg.* 1997;10:157-161.
103. Malik J, Slavikova M, Malikova H, Maskova J. Many clinically silent access stenoses can be identified by ultrasonography. *J Nephrol.* 2002;15:661-665.
104. Lockhart ME, Robbin ML. Hemodialysis access ultrasound. *Ultrasound Q.* 2001;17:157-167.
105. Haimov M, Baez A, Noff M, et al. Complications of arteriovenous fistulae for hemodialysis. *Arch Surg.* 1975;110:708-712.
106. Irvine C, Holt P. Hand venous hypertension complicating arterio-venous fistula construction for haemodialysis. *Clin Exp Dermatol.* 1989;14:289-290.
107. Brakman M, Faber WR, Zeegelaar JE, et al. Venous hypertension of the hand caused by hemodialysis shunt: immunofluorescence studies of pericapillary cuffs. *J Am Acad Dermatol.* 1994;31:23-26.
108. Deshmukh N. Venous ulceration of the hand secondary to a Cimino fistula. *Mil Med.* 1993;158:752-753.
109. Bogaert AM, Vanholder R, De Roose J. Pseudo-Kaposi's sarcoma as a complication of Cimino-Brescia arteriovenous fistulas in hemodialysis patients. *Nephron.* 1987;46:170-173.
110. Wood ML, Reilly GD, Smith GT. Ulceration of the hand secondary to a radial arteriovenous fistula: a model for varicose ulceration. *BMJ.* 1983;287:1167-1168.
111. Davidson CJ, Newman GE, Sheikh KH, et al. Mechanisms of angioplasty in hemodialysis fistula stenoses evaluated by intravascular ultrasound. *Kidney Int.* 1991;40:91-95.
112. Kovalik EC, Newman GE, Suhocki P, et al. Correction of central venous stenoses: use of angioplasty and vascular Wallstents. *Kidney Int.* 1994;45:1177-1181.
113. Maskova J, Komarkova J, Kivanek J, et al. Endovascular treatment of central vein stenoses and/or occlusions in hemodialysis patients. *Cardiovasc Interv Radiol.* 2003;26:27-30.
114. Oderich GS, Treiman GS, Schneider P, Bhirangi K. Stent placement for treatment of central and peripheral venous obstruction: a long-term multi-institutional experience. *J Vasc Surg.* 2000;32:760-769.
115. Shoenfeld R, Hermans H, Novick A, et al. Stenting of proximal venous obstructions to maintain hemodialysis access. *J Vasc Surg.* 1994;19:532-538; discussion 538-539.
116. Vesely TM, Hovsepian DM, Pilgram TK, et al. Upper extremity central venous obstruction in hemodialysis patients: treatment with Wallstents. *Radiology.* 1997;204:343-348.
117. Kovalik EC, Raymond JR, Albers FJ, et al. A clustering of epidural abscesses in chronic hemodialysis patients: risks of salvaging access catheters in cases of infection. *J Am Soc Nephrol.* 1996;7:2264-2267.
118. Lund GB, Trerotola SO, Scheel PJ Jr. Percutaneous translumbar inferior vena cava cannulation for hemodialysis. *Am J Kidney Dis.* 1995;25:732-737.
119. Forauer AR, Glockner JF. Importance of US findings in access planning during jugular vein hemodialysis catheter placements. *J Vasc Interv Radiol.* 2000;11:233-238.
120. Atherikul K, Schwab SJ, Conlon PJ. Adequacy of haemodialysis with cuffed central-vein catheters. *Nephrol Dial*

*Transplant.* 1998;13:745-749.

121. Baumann M, Witzke O, Dietrich R, et al. Prolonged catheter survival in intermittent hemodialysis using a less thrombogenic micropatterned polymer modification. *ASAIO J.* 2003;49:708-712.
122. Cetinkaya R, Odabas AR, Unlu Y, et al. Using cuffed and tunneled central venous catheters as permanent vascular access for hemodialysis: a prospective study. *Ren Fail.* 2003;25:431-438.
123. Wisselink W, Money SR, Becker MO, et al. Comparison of operative reconstruction and percutaneous balloon dilation for central venous obstruction. *Am J Surg.* 1993;166:200-205.
124. Kamran T, Zaheer K, Khan AA, et al. Applications and complications of subclavian vein catheterization for hemodialysis. *J Coll Physicians Surg Pak.* 2003;13:40-43.
125. Stavropoulos SW, Pan JJ, Clark TW, et al. Percutaneous transhepatic venous access for hemodialysis. *J Vasc Interv Radiol.* 2003;14:1187-1190.
126. Perini S, LaBerge JM, Pearl JM, et al. Tesio catheter: radiologically guided placement, mechanical performance, and adequacy of delivered dialysis. *Radiology.* 2000;215:129-137.
127. Schwab SJ, Beathard G. The hemodialysis catheter conundrum: hate living with them, but can't live without them. *Kidney Int.* 1999;56:1-17.
128. Depner TA. Catheter performance. *Semin Dial.* 2001;14:425-431.
129. Twardowski ZJ, Haynie JD. Measurements of hemodialysis catheter blood flow in vivo. *Int J Artif Organs.* 2002;25:276-280.
130. Bakken AM, Protack CD, Saad WE, et al. Long-term outcomes of primary angioplasty and primary stenting of central venous stenosis in hemodialysis patients. *J Vasc Surg.* 2007;45:776-783.
131. Ayarragaray JE. Surgical treatment of hemodialysis-related central venous stenosis or occlusion: another option to maintain vascular access. *J Vasc Surg.* 2003;37:1043-1046.
132. Doty DB, Baker WH. Bypass of superior vena cava with spiral vein graft. *Ann Thorac Surg.* 1976;22:490-493.
133. El-Sabroun RA, Duncan JM. Right atrial bypass grafting for central venous obstruction associated with dialysis access: another treatment option. *J Vasc Surg.* 1999;30:582-584.
134. Hoballah JJ, Eid GM, Nazzal MM, et al. Contralateral internal jugular vein interposition for salvage of a functioning arteriovenous fistula. *Ann Vasc Surg.* 2000;14:679-682.
135. Puskas JD, Gertler JP. Internal jugular to axillary vein bypass for subclavian vein thrombosis in the setting of brachial arteriovenous fistula. *J Vasc Surg.* 1994;19:939-942.
136. Currier CB Jr, Widder S, Ali A, et al. Surgical management of subclavian and axillary vein thrombosis in patients with a functioning arteriovenous fistula. *Surgery.* 1985;100:25-28.
137. Hamish M, Shalhoub J, Rodd CD, Davies AH. Axillo-iliac conduit for haemodialysis vascular access. *Eur J Vasc Endovasc Surg.* 2006;31:530-534.
138. Kavallieratos N, Kokkinos A, Kalocheritis P. Axillary to saphenous vein bypass for treatment of central venous obstruction in patients receiving dialysis. *J Vasc Surg.* 2004;40:640-643.
139. Robson JS. Uremic neuropathy. In: Robertson RF, ed. *Some Aspects of Neurology.* Edinburgh: Royal College of Physicians; 1968:74-84.
140. Bolton CF. Peripheral neuropathy associated with chronic renal failure. *Can J Neurol Sci.* 1980;7:89-96.
141. Asbury AK. Uremic neuropathy. In: Dyck PJ, Thomas PK, Lambert EH, eds. *Peripheral Neuropathy.* 2nd ed. Philadelphia: Saunders; 1984:1811-1825.
142. Hassan K, Simri W, Rubinchik I, et al. The effect of erythropoietin therapy on polyneuropathy in predialytic patients. *J Nephrol.* 2003;16:121-125.
143. Adams RD, Victor M. *Disease of the peripheral nerves.* In: Principles of Neurology. 5th ed. New York: McGraw-Hill; 1993:1144-1145.

144. Burn DJ, Bates D. Neurology and the kidney. *J Neurol Neurosurg Psychiatry*. 1998;65:810-821.
145. Ahonen RE. Peripheral neuropathy in uremic patients and in renal transplant recipients. *Acta Neuropathol*. 1981;54:43-53.
146. Bolton CF, McKeown MJ, Chen R, et al. Sub-acute uremic and diabetic polyneuropathy. *Muscle Nerve*. 1997;20:59-64.
147. Rosales RL, Navarro J, Izumo S, et al. Sural nerve morphology in asymptomatic uremia. *Eur Neurol*. 1988;28:156-160.
148. Said G, Boudier L, Selva J, et al. Different patterns of uremic polyneuropathy: clinicopathologic studies. *Neurology*. 1983;33:567-574.
149. Ogura T, Makinodan A, Kubo T, et al. Electrophysiological course of uraemic neuropathy in hemodialysis patients. *Postgrad Med J*. 2001;77:451-454.
150. Nielson VK. The peripheral nerve function in chronic renal failure: VIII. Longitudinal course during terminal renal failure and regular hemodialysis. *Acta Med Scand*. 1974;195:155-162.
151. Bolton CF, Lindsay RM, Linton AL. The course of uremic neuropathy during chronic hemodialysis. *Can J Neurol Sci*. 1975;2:332-333.
152. Bolton CF, Baltzan MA, Baltzan BR. Effects of renal transplantation on uremic neuropathy: a clinical and electrophysiologic study. *N Engl J Med*. 1971;284:1170-1175.
153. Aminoff MJ, ed. *Neurological Aspects of Renal Failure*. New York: Churchill Livingstone; 1989.
154. Mondelli M, Giannini F, Giacchi M. Carpal tunnel syndrome incidence in a general population. *Neurology*. 2002;58:289-294.
155. Warren DJ, Otieno LS. Carpal tunnel syndrome in patients on intermittent haemodialysis. *Postgrad Med J*. 1975;51:450-452.
156. Borman H, Akinbingol G, Maral T, et al. Entrapment neuropathy of the upper extremity in hemodialysis patients. *Plast Reconstr Surg*. 2002;109:2598-2599.
157. Jadoul M, Garbar C, Noel H, et al. Histological prevalence of beta-2 microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. *Kidney Int*. 1997;51:1928-1932.
158. Bicknell JM, Lim AC, Raroque HG Jr, et al. Carpal tunnel syndrome, subclinical median mononeuropathy, and peripheral polyneuropathy: common early complications of chronic peritoneal dialysis and hemodialysis. *Arch Phys Med Rehabil*. 1991;72:378-381.
159. Gejyo F, Odani S, Yamada T, et al. Beta-2 microglobulin: a new form of amyloid protein associated with chronic hemodialysis. *Kidney Int*. 1986;30:385-390.
160. Tzamaloukas A. Carpal tunnel syndrome in patients on chronic hemodialysis. *Dial Transplant*. 1988;17:525-526.
161. Kessler M, Netter P, Azoulay E, et al. Dialysis-associated arthropathy: a multicentre survey of 171 patients receiving hemodialysis for over 10 years. *Br J Rheumatol*. 1992;31:157-162.
162. Kuchle C, Fricke H, Held E, et al. High-flux hemodialysis postpones clinical manifestations of dialysis-related amyloidosis. *Am J Nephrol*. 1996;16:484-488.
163. Reyat Y, Robinson C, Salama A, Levy J. Neurological complications from brachial arteriovenous fistulae. *Nephrol Dial Transplant*. 2004;19:1923-1924.
164. Webb A, Abdalla M, Harden PN, Russell GI. Use of the Tesio catheter for hemodialysis in patients with end-stage renal failure: a 2-year prospective study. *Clin Nephrol*. 2002;58:128-133.
165. Halter SK, DeLisa JA, Stolov WC, et al. Carpal tunnel syndrome in chronic renal dialysis patients. *Arch Phys Med Rehabil*. 1981;62:197-201.
166. Borgatti PP, Lusenti T, Franco V, et al. Guyon's syndrome in a long-term hemodialysis patient. *Nephrol Dial Transplant*. 1991;6:734-735.
167. Konishiike T, Hashizume H, Nishida K, et al. Cubital tunnel syndrome in a patient on long-term haemodialysis. *J Hand Surg Br*. 1994;19:636-637.
168. Kaku DA, Malamut RI, Frey DJ, et al. Conduction block as an early sign of reversible injury in ischemic monomelic

- neuropathy. *Neurology*. 1993;43:1126-1130.
169. Ballard JL, Bunt TJ, Malone JM. Major complications of angio-access surgery. *Am J Surg*. 1992;164:229-232.
  170. Wilbourn AJ, Furlan AJ, Hulley W, et al. Ischemic monomelic neuropathy. *Neurology*. 1983;33:447-451.
  171. Honet JC, Wajszczuk WJ, Rubenfire M, et al. Neurological abnormalities in the legs after use of intra-aortic balloon pump: report of six cases. *Arch Phys Med Rehabil*. 1975;56:346-352.
  172. Levin KH. AAEM case no. 19: Ischemic monomelic neuropathy. *Muscle Nerve*. 1989;12:791-795.
  173. Bolton CF, Driedger AA, Lindsay RM. Ischaemic neuropathy in uraemic patients caused by bovine arteriovenous shunt. *J Neurol Neurosurg Psychiatry*. 1979;42:810-814.
  174. Wytrzes L, Markley HG, Fisher M, et al. Brachial neuropathy after brachial artery-antecubital vein shunts for chronic hemodialysis. *Neurology*. 1987;37:1398-1400.
  175. Horlocker TT, Kufner RP, Bishop AT, et al. The risk of persistent paresthesia is not increased with repeated axillary block. *Anesth Analg*. 1999;88:382-387.
  176. Dyck PJ, Conn DL, Okazaki H. Necrotizing angiopathic neuropathy: three-dimensional morphology of fiber degeneration related to the sites of occluded vessels. *Mayo Clin Proc*. 1972;47:461-475.
  177. Redfern AB, Zimmerman NB. Neurologic and ischemic complications of upper extremity vascular access for dialysis. *J Hand Surg*. 1995;20A:199-204.
  178. London GM, Marchais SJ, Guerin AP, Metivier F. Contributive factors to cardiovascular hypertrophy in renal failure. *Am J Hypertens*. 1989;2:261S-265S.
  179. Abassi Z, Nakhoul F, Khankin E, et al. Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. *Curr Opin Nephrol Hypertens*. 2006;15:353-360.
  180. Wijnen E, Keuter XH, Planken NR, et al. The relation between vascular access flow and different types of vascular access with systemic hemodynamics in hemodialysis patients. *Artif Organs*. 2005;29:960-964.
  181. Tellis VA, Veith FJ, Soberman RJ, et al. Internal arteriovenous fistula for hemodialysis. *Surg Gynecol Obstet*. 1971;132:866-870.
  182. Abbott KC, Trespalacios FC, Agodoa LY. Arteriovenous fistula use and heart disease in long-term elderly hemodialysis patients: analysis of United States Renal Data System dialysis morbidity and mortality wave II. *J Nephrol*. 2003;16:822-830.
  183. Butt KM. Blood access. *Clin Nephrol*. 1978;9:138-143.
  184. Chemla ES, Morsy M, Anderson L, Whitmore A. Inflow reduction by distalization of anastomosis treats efficiently high-inflow high-cardiac output vascular access for hemodialysis. *Semin Dial*. 2007;20:68-72.
  185. Yigla M, Nakhoul F, Sabag A, et al. Pulmonary hypertension in patients with end-stage renal disease. *Chest*. 2003;123:1577-1582.
  186. Havlucu Y, Kursat S, Ekmekci C, et al. Pulmonary hypertension in patients with chronic renal failure. *Respiration*. 2007;74:503-510.
  187. Nakhoul F, Yigla M, Gilman R, et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. *Nephrol Dial Transplant*. 2005;20:1686-1692.
  188. Harp RJ, Stavropoulos W, Wasserstein A, Clark T. Pulmonary hypertension among end-stage renal failure patients following hemodialysis access thrombectomy. *Cardiovasc Intervent Radiol*. 2005;28:17-22.
  189. Suhoki P, Conlon P, Knelson M, et al. Silastic cuffed catheters for hemodialysis catheter access. *Am J Kidney Dis*. 1996;28:379-386.
  190. Marr KA, Sexton DJ, Conlon PJ, et al. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. *Ann Intern Med*. 1997;127:275-280.
  191. Dittmen ID, Sharp D, McNulty AM, et al. A prospective study of central venous hemodialysis catheter colonization and peripheral bacteremia. *Clin Nephrol*. 1999;51:34-39.

192. Almirall J, Gonzales J, Rello J, et al. Infection of hemodialysis catheters: incidence and mechanism. *Am J Nephrol*. 1989;9:454-459.
193. Schwartz RD, Messana JM, Boyer CJ, et al. Successful use of cuffed central hemodialysis catheters inserted percutaneously. *J Am Soc Nephrol*. 1994;4:1719-1725.
194. Lund GB, Treretola SO, Scheel PJ, et al. Outcome of tunneled hemodialysis catheters placed by radiologists. *Radiology*. 1996;198:467-472.
195. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. *Am J Kidney Dis*. 1999;34:1114-1124.
196. Oliver MJ, Callery SM, Thorpe KE, et al. Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: a prospective study. *Kidney Int*. 2000;58:2543-2545.
197. Nassar GM, Ayus JC. Infectious complications of the hemodialysis access. *Kidney Int*. 2001;60:1-13.
198. Fan ST, Teoh-Chan CH, Lau KF. Evaluation of central venous catheter sepsis by differential quantitative blood culture. *Eur J Clin Microbiol Infect Dis*. 1989;8:142-144.
199. Schaffer D. Catheter-related sepsis complicating long-term, tunneled central venous dialysis catheters: management by guidewire exchange. *Am J Kidney Dis*. 1995;25:593-596.
200. Carlisle EJ, Blake P, McCarthy F, et al. Septicemia in long-term jugular hemodialysis catheters: eradicating infection by changing the catheter over a guidewire. *Int J Artif Organs*. 1991;14:150-153.
201. Robinson D, Subock P, Schwab SJ. Treatment of infected tunneled venous access hemodialysis catheters with guide wire exchange. *Kidney Int*. 1998;53:1792-1794.
202. Beathard GA. Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. *J Am Soc Nephrol*. 1999;10:1045-1049.
203. Borgu R, Dubrow AJ, Levin NW, et al. Adjunctive antibiotic/anticoagulant lock therapy in the treatment of bacteremia associated with the use of a subcutaneously implanted hemodialysis access device. *ASAIO J*. 2000;46:767-770.
204. Krishnasami Z, Carlton D, Bimbo L, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. *Kidney Int*. 2002;61:1136-1142.
205. Poole CV, Carlton D, Bimbo L, Allon M. Treatment of catheter-related bacteremia with an antibiotic lock protocol: effect of bacterial pathogen. *Nephrol Dial Transplant*. 2004;19:1237-1244.
206. Moss AH, Vasilakis C, Holley JL, et al. Use of a silicone dual-lumen catheter with a Dacron cuff as a long term vascular access for hemodialysis patients. *Am J Kidney Dis*. 1990;26:211-215.
207. Gibson SP, Mosquera D. Five year experience with the Quinton Permcath for vascular access. *Nephrol Dial Transplant*. 1991;6:269-274.
208. McDowell DE, Moss AH, Vasilakis C, et al. Percutaneously placed dual lumen silicone catheters for long term hemodialysis. *Am Surg*. 1993;59:569-573.
209. Alomari AI, Falk A. The natural history of tunneled hemodialysis catheters removed or exchanged: a single-institution experience. *J Vasc Interv Radiol*. 2007;18:227-235.
210. Hwang FR, Stavropoulos SW, Shlansky-Goldberg RD, et al. Tunneled infusion catheter breakage: frequency and repair kit outcomes. *J Vasc Interv Radiol*. 2008;19:201-206.
211. Schwab SJ, Buller GL, McCann RL, et al. Prospective evaluation of a Dacron cuffed hemodialysis catheter for prolonged use. *Am J Kidney Dis*. 1988;11:166-169.
212. Falk A, Samson W, Uribarri J, Vassalotti JA. Efficacy of reteplase in poorly functioning hemodialysis catheters. *Clin Nephrol*. 2004;61:47-53.
213. Paulsen D, Reiasather A, Aasen M, et al. Use of tissue plasminogen activator for reopening of clotted dialysis catheters. *Nephron*. 1993;64:468-470.
214. Dowling K, Sansivero G, Stainken B, et al. The use of tissue plasminogen activator infusion to reestablish function of tunneled hemodialysis catheters. *Nephrol Nurs J*. 2004;31:199-200.

215. Savader SJ, Ehrman KO, Porter DJ, et al. Treatment of hemodialysis catheter-associated fibrin sheaths by rt-PA infusion: critical analysis of 124 procedures. *J Vasc Interv Radiol*. 2001;12:711-715.
216. Trerotola SO, Johnson MS, Harris VJ, et al. Outcome of tunneled hemodialysis catheters placed via the right internal jugular vein by radiologists. *Am J Kidney Dis*. 1996;28:379-386.
217. Brismar BO, Hardstedt C, Jacobson S. Diagnosis of thrombosis by catheter phlebography after prolonged central venous catheterization. *Ann Surg*. 1981;194:779-783.
218. Rockal AG, Harris A, Wetton CWN, et al. Stripping of failing hemodialysis catheters using the Amplatz gooseneck snare. *Clin Radiol*. 1997;52:616-620.
219. Duszak R, Haskal ZJ, Thomas-Hawkins C, et al. Replacement of failing tunneled hemodialysis catheters through preexisting subcutaneous tunnels: a comparison of catheter function and infection rates for de novo placements and over-the-wire exchanges. *J Vasc Interv Radiol*. 1998;9:321-327.
220. Garofalo RS, Zaleski GX, Lorenz JM, et al. Exchange of poorly functioning tunneled permanent hemodialysis catheters. *AJR Am J Roentgenol*. 1999;173:321-327.
221. Merport M, Murphy TP, Eglin TK et al. Fibrin sheath stripping versus catheter exchange for the treatment of failed tunneled hemodialysis catheters: randomized clinical trial. *J Vasc Interv Radiol*. 2000;11:1115-1120.
222. Brady PS, Spence LD, Levitin A, et al. Efficacy of percutaneous fibrin sheath stripping in restoring patency of tunneled hemodialysis catheters. *AJR Am J Roentgenol*. 1999;173:1023-1027.
223. Crain, MR, Mewissen MW, Ostrowski GJ, et al. Fibrin sleeve stripping for salvage of failing hemodialysis catheters: technique and initial results. *Radiology*. 1996;198:41-44.
224. Haskal ZJ, Leen VH, Thomas-Hawkins C, et al. Transvenous removal of fibrin sheaths from tunneled hemodialysis catheters. *J Vasc Interv Radiol*. 1996;7:513-517.
225. Gray RJ, Levitin A, Buck D, et al. Percutaneous fibrin sheath stripping versus transcatheter urokinase infusion for malfunctioning well-positioned tunneled central venous dialysis catheters. *J Vasc Interv Radiol*. 2000;11:1121-1129.
226. Winn MP, McDermott VG, Schwab SJ, et al. Dialysis catheter “fibrin sheath stripping”: a cautionary tale. *Nephrol Dial Transplant*. 1997;12:1048-1050.
227. Johnstone RD, Stewart GA, Akoh JA, et al. Percutaneous fibrin sheath stripping of failing hemodialysis catheters. *Nephrol Dial Transplant*. 1999;14:688-691.
228. Robinson D, Suhocki P, Schwab SJ. Treatment of infected tunneled venous access hemodialysis catheters with guidewire exchange. *Kidney Int*. 1998;53:1792-1794.
229. Janne d’Othee B, Tham JC, Sheiman RG. Restoration of patency in failing tunneled hemodialysis catheters: a comparison of catheter exchange, exchange and balloon disruption of the fibrin sheath, and femoral stripping. *J Vasc Interv Radiol*. 2006;17:1011-1015.
230. Angle JF, Shilling AT, Schenk WG, et al. Utility of percutaneous intervention in the management of tunneled hemodialysis catheters. *Cardiovasc Intervent Radiol*. 2003;26:9-18.
231. Obialo CI, Conner AC, Lebon LF. Maintaining patency of tunneled hemodialysis catheters—efficacy of aspirin compared to warfarin. *Scand J Urol Nephrol*. 2003;37:172-176.
232. Mokrzycki MH, Jean-Jerome K, Rush H, et al. A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. *Kidney Int*. 2001;59:1935-1942.
233. Pepper RJ, Gale DP, Wajed J, et al. Inadvertent postdialysis anticoagulation due to heparin line locks. *Hemodial Int*. 2007;11:430-434.
234. Yevzlin AS, Sanchez RJ, Hiatt JG, et al. Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement. *Semin Dial*. 2007;20:351-354.



1. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum.* 1994;37:187-192.
2. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. *N Engl J Med.* 2002;347:261-271.
3. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica. *Best Pract Res Clin Rheumatol.* 2004;18:705-722.
4. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. *Ann Intern Med.* 1995;123:192-194.
5. Bengtsson BA, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. *Arthritis Rheum.* 1981;24:899-904.
6. Nordborg E, Bengtsson BA. Epidemiology of biopsy-proven giant cell arteritis (GCA). *J Intern Med.* 1990;227:233-236.
7. Kobayashi S, Yano T, Matsumoto Y, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. *Arthritis Rheum.* 2003;49:594-598.
8. Salvarani C, Crowson CS, O'Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. *Arthritis Rheum.* 2004;51:264-268.
9. Gonzalez-Gay MA, Garcia-Porrúa C, Rivas MJ, et al. Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period. *Ann Rheum Dis.* 2001;60:367-371.
10. Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. *Arthritis Rheum.* 1991;34:351-356.
11. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. *J Clin Invest.* 1992;90:2355-2361.
12. Gonzalez-Gay MA, Amoli MM, Garcia-Porrúa C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. *Semin Arthritis Rheum.* 2003;33:38-48.
13. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. *Arthritis Rheum.* 1995;38:369-373.
14. Weyand CM, Ma-Krupa W, Pryshchep O, et al. Vascular dendritic cells in giant cell arteritis. *Ann N Y Acad Sci.* 2005;1062:195-208.
15. Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. *Autoimmun Rev.* 2004;3:46-53.
16. Weyand CM, Schonberger J, Oppitz U, et al. Distinct vascular-lesions in giant-cell arteritis share identical T-cell clonotypes. *J Exp Med.* 1994;179:951-960.
17. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. *Ann Intern Med.* 2003;139:505-515.
18. Smetana GW, Shmerling RH. Does this patient have temporal arteritis? *JAMA.* 2002;287:92-101.
19. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. *Arthritis Rheum.* 1990;33:1122-1128.
20. Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. *Arthritis Rheum.* 1999;42:311-317.
21. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. *N Engl J Med.* 2003;349:160-169.
22. Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. *Arthritis Rheum.* 2003;48:3522-3531.
23. Bongartz T, Matteson EL. Large-vessel involvement in giant cell arteritis. *Curr Opin Rheumatol.* 2006;18:10-17.
24. Schmidt WA, Seifert A, Gromnica-Ihle E, et al. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. *Rheumatology (Oxford).* 2008;47:96-101.

25. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. *Ann Intern Med.* 1995;122:502-507.
26. Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. *Arthritis Rheum.* 2003;48:3532-3537.
27. Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? *Ann Intern Med.* 1994;120:987-992.
28. Ray-Chaudhuri N, Kine DA, Tijani SO, et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. *Br J Ophthalmol.* 2002;86:530-532.
29. Warrington KJ, Matteson EL. Management guidelines and outcome measures in giant cell arteritis (GCA). *Clin Exp Rheumatol.* 2007;25(6 Suppl 47):137-141.
30. Pipitone N, Salvarani C. Improving therapeutic options for patients with giant cell arteritis. *Curr Opin Rheumatol.* 2008;20:17-22.
31. Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. *Ann Intern Med.* 1975;82:613-618.
32. Chan CC, Paine M, O'Day J. Steroid management in giant cell arteritis. *Br J Ophthalmol.* 2001;85:1061-1064.
33. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. *Arthritis Rheum.* 2004;50:1332-1337.
34. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. *Arthritis Rheum.* 2006;54:3306-3309.
35. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. *Arthritis Rheum.* 2007;56:2789-2797.
36. Hoffman GS, Cid MC, Rndt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. *Ann Intern Med.* 2007;146:621-630.
37. Both M, Aries PM, Muller-Hulsbeck S, et al. Balloon angioplasty of arteries of the upper extremities in patients with extracranial giant-cell arteritis. *Ann Rheum Dis.* 2006;65:1124-1130.
38. Zehr KJ, Mathur A, Orszulak TA, et al. Surgical treatment of ascending aortic aneurysms in patients with giant cell aortitis. *Ann Thorac Surg.* 2005;79:1512-1517.
39. Rojo-Leyva F, Ratliff NB, Cosgrove DM 3rd, Hoffman GS. Study of 52 patients with idiopathic aortitis from a cohort of 1204 surgical cases. *Arthritis Rheum.* 2000;43:901-907.
40. Kerr LD, Chang YJ, Spiera H, Fallon JT. Occult active giant cell aortitis necessitating surgical repair. *J Thorac Cardiovasc Surg.* 2000;120:813-815.
41. Miller DV, Isotalo PA, Weyand CM, et al. Surgical pathology of noninfectious ascending aortitis: a study of 45 cases with emphasis on an isolated variant. *Am J Surg Pathol.* 2006;30:1150-1158.
42. Guillevin L, Pagnoux C, Teixeira L. Polyarteritis Nodosa. In: Ball GV, Bridges SL, eds. *Vasculitis*. 2nd ed. Oxford; 2008:335-353.
43. Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. *Arthritis Rheum.* 1990;33:1088-1093.
44. Watts RA, Lane SE, Scott DG, et al. Epidemiology of vasculitis in Europe. *Ann Rheum Dis.* 2001;60:1156-1157.
45. Guillevin L, Le Thi Huong D, Godeau P, et al. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angitis: a study in 165 patients. *Br J Rheumatol.* 1988;27:258-264.
46. Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. *Medicine (Baltimore).* 2005;84:313-322.
47. Guillevin L, Lhote F, Cohen P, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term

- observation of 41 patients. *Medicine (Baltimore)*. 1995;74:238-253.
48. Calabrese LH. Vasculitis and infection with the human immunodeficiency virus. *Rheum Dis Clin North Am*. 1991;17:131-147.
  49. Hasler P, Kistler H, Gerber H. Vasculitides in hairy cell leukemia. *Semin Arthritis Rheum*. 1995;25:134-142.
  50. Bonsib SM. Polyarteritis nodosa. *Semin Diagn Pathol*. 2001;18:14-23.
  51. Guillevin L, Ronco P, Verroust P. Circulating immune complexes in systemic necrotizing vasculitis of the polyarteritis nodosa group. Comparison of HBV-related polyarteritis nodosa and Churg Strauss angiitis. *J Autoimmun*. 1990;3:789-792.
  52. Chanseaud Y, Tamby MC, Guilpain P, et al. Analysis of autoantibody repertoires in small- and medium-sized vessels vasculitides. Evidence for specific perturbations in polyarteritis nodosa, microscopic polyangiitis, Churg-Strauss syndrome and Wegener's granulomatosis. *J Autoimmun*. 2005;24:169-179.
  53. Panegyres PK, Blumbergs PC, Leong AS, Bourne AJ. Vasculitis of peripheral nerve and skeletal muscle: clinicopathological correlation and immunopathic mechanisms. *J Neurol Sci*. 1990;100:193-202.
  54. Moore PM, Calabrese LH. Neurologic manifestations of systemic vasculitides. *Semin Neurol*. 1994;14:300-306.
  55. Camilleri M, Pusey CD, Chadwick VS, Rees AJ. Gastrointestinal manifestations of systemic vasculitis. *Q J M*. 1983;52:141-149.
  56. Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. *Medicine (Baltimore)*. 2005;84:115-128.
  57. Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. *Medicine (Baltimore)*. 2005;84:323-330.
  58. Hachulla E, Bourdon F, Taieb S, et al. Embolization of two bleeding aneurysms with platinum coils in a patient with polyarteritis nodosa. *J Rheumatol*. 1993;20:158-161.
  59. Lupoli S, Gargiulo A, Rossi R, Ames PR. Myositis as a presenting feature of polyarteritis nodosa. *Clin Exp Rheumatol*. 2004;22:507-508.
  60. Fortin PR, Larson MG, Watters AK, et al. Prognostic factors in systemic necrotizing vasculitis of the polyarteritis nodosa group—a review of 45 cases. *J Rheumatol*. 1995;22:78-84.
  61. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. *Medicine (Baltimore)*. 1996;75:17-28.
  62. Ha HK, Lee SH, Rha SE, et al. Radiologic features of vasculitis involving the gastrointestinal tract. *Radiographics*. 2000;20:779-794.
  63. Miller DL. Angiography in polyarteritis nodosa. *AJR Am J Roentgenol*. 2000;175:1747-1748.
  64. Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. *Am J Med*. 1979;67:941-947.
  65. Guillevin L, Lhote F. Treatment of polyarteritis nodosa and microscopic polyangiitis. *Arthritis Rheum*. 1998;41:2100-2105.
  66. Cohen RD, Conn DL, Ilstrup DM. Clinical features, prognosis, and response to treatment in polyarteritis. *Mayo Clin Proc*. 1980;55:146-155.
  67. Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. *N Engl J Med*. 1979;301:235-238.
  68. Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. *Arthritis Rheum*. 2003;49:93-100.
  69. Guillevin L, Lhote F, Jarrousse B, Fain O. Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis

- of 3 prospective controlled trials including 182 patients over 12 years. *Ann Med Interne (Paris)*. 1992;143:405-416.
70. Satou GM, Giamelli J, Gewitz MH. Kawasaki disease: diagnosis, management, and long-term implications. *Cardiol Rev*. 2007;15:163-169.
  71. Newburger JW, Fulton DR. Kawasaki disease. *Curr Opin Pediatr*. 2004;16:508-514.
  72. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Circulation*. 2004;110:2747-2771.
  73. Jennette JC, Falk RJ. Small-vessel vasculitis. *N Engl J Med*. 1997;337:1512-1523.
  74. Lane SE, Watts R, Scott DG. Epidemiology of systemic vasculitis. *Curr Rheumatol Rep*. 2005;7:270-275.
  75. Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. *Curr Opin Rheumatol*. 2008;20:55-60.
  76. Gross W, Csernok E. Wegener's granulomatosis: clinical and immunodiagnostic aspects. In: Ball GV, Bridges SL, eds. *Vasculitis*. 2nd ed. Oxford; 2008:403-413.
  77. Guillevin L, Pagnoux C, Teixeira L. Microscopic polyangiitis. In: Ball GV, Bridges SL, eds. *Vasculitis*. 2nd ed. Oxford; 2008:355-364.
  78. Abril A, Calamia KT, Cohen MD. The Churg Strauss syndrome (allergic granulomatous angiitis): review and update. *Semin Arthritis Rheum*. 2003;33:106-114.
  79. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. *Arthritis Rheum*. 2005;52:2926-2935.
  80. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. *Arthritis Rheum*. 1990;33:1101-1107.
  81. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). *Arthritis Rheum*. 1990;33:1094-1100.
  82. Finkelstein JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. *Ann Intern Med*. 2007;147:611-619.
  83. Langford CA. Small-vessel vasculitis: therapeutic management. *Curr Rheumatol Rep*. 2007;9:328-335.
  84. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med*. 1992;116:488-498.
  85. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med*. 2003;349:36-44.
  86. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. *J Am Soc Nephrol*. 2007;18:2180-2188.
  87. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum*. 2005;52:2461-2469.
  88. Keogh KA, Specks U. Churg-Strauss syndrome: update on clinical, laboratory and therapeutic aspects. *Sarcoidosis Vasc Diffuse Lung Dis*. 2006;23:3-12.
  89. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's Disease. *N Engl J Med*. 1999;341:1284-1291.
  90. Yurdakul S, Gunaydin I, Tuzun Y, et al. The prevalence of Behcet's syndrome in a rural area in northern Turkey. *J Rheumatol*. 1988;15:820-822.
  91. Azizlerli G, Kose AA, Sarica R, et al. Prevalence of Behcet's disease in Istanbul, Turkey. *Int J Dermatol*. 2003;42:803-806.
  92. Mizuki N, Inoko H, Ohno S. Pathogenic gene responsible for the predisposition of Behcet's disease. *Int Rev Immunol*. 1997;14:33-48.
  93. Krause I, Weinberger A. Behcet's disease. *Curr Opin Rheumatol*. 2008;20:82-87.
  94. Ben Ahmed M, Houman H, Miled M, et al. Involvement of chemokines and Th1 cytokines in the pathogenesis of

- mucocutaneous lesions of Behcet's disease. *Arthritis Rheum.* 2004;50:2291-2295.
95. Fresko I, Melikoglu M, Kural-Seyahi E, Yazici H. Behcet's syndrome: pathogenesis, clinical manifestations and treatment. In: Ball GV, Bridges SL, eds. *Vasculitis*. 2nd ed. Oxford; 2008:461-479.
  96. Whallett AJ, Thurairajan G, Hamburger J, et al. Behcet's syndrome: a multidisciplinary approach to clinical care. *QJM.* 1999;92:727-740.
  97. Nussenblatt RB. Uveitis in Behcet's disease. *Int Rev Immunol.* 1997;14:67-79.
  98. Chou SJ, Chen VT, Jan HC, et al. Intestinal perforations in Behcet's disease. *J Gastrointest Surg.* 2007;11:508-514.
  99. Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behcet disease. *Curr Opin Rheumatol.* 2005;17:1-8.
  100. Le Thi Huong D, Wechsler B, Papo T, et al. Arterial lesions in Behcet's disease. A study in 25 patients. *J Rheumatol.* 1995;22:2103-2113.
  101. Ko GY, Byun JY, Choi BG, Cho SH. The vascular manifestations of Behcet's disease: angiographic and CT findings. *Br J Radiol.* 2000;73:1270-1274.
  102. Kizilkilic O, Albayram S, Adaletli I, et al. Endovascular treatment of Behcet's disease-associated intracranial aneurysms: report of two cases and review of the literature. *Neuroradiology.* 2003;45:328-334.
  103. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. *Lancet.* 1990;335:1078-1080.
  104. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med.* 1998;128:443-450.
  105. Kaklamani VG, Kaklamanis PG. Treatment of Behcet's disease—an update. *Semin Arthritis Rheum.* 2001;30:299-312.
  106. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease—review and basis for recommendations. *Rheumatology (Oxford).* 2007;46:736-741.
  107. Bautista-Hernandez V, Gutierrez F, Capel A, et al. Endovascular repair of concomitant celiac trunk and abdominal aortic aneurysms in a patient with Behcet's disease. *J Endovasc Ther.* 2004;11:222-225.
  108. Calamia KT, Balabanova M. Vasculitis in systemic lupus erythematosus. *Clin Dermatol.* 2004;22:148-156.
  109. Ramos-Casals M, Nardi N, Lagrutta M, et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. *Medicine (Baltimore).* 2006;85:95-104.
  110. Hughes BL. Vasculitis in primary connective tissue diseases. In: Ball GV, Bridges SL, eds. *Vasculitis*. 2nd ed. Oxford; 2008:439-460.
  111. Gergely P, Poór G. Relapsing polychondritis. *Best Pract Res Clin Rheumatol.* 2004;18:723-738.
  112. Mazlumzadeh M, Matteson EL. Cogan's syndrome: an audiovestibular, ocular, and systemic autoimmune disease. *Rheum Dis Clin North Am.* 2007;33:855-874, vii-viii.
  113. Gluth MB, Baratz KH, Matteson EL, Driscoll CL. Cogan syndrome: a retrospective review of 60 patients throughout a half century. *Mayo Clin Proc.* 2006;81:483-488.
  114. Moritz MW, Higgins RF, Jacobs JR. Duplex imaging and incidence of carotid radiation injury after high-dose radiotherapy for tumors of the head and neck. *Arch Surg.* 1990;125:1181-1183.
  115. Aoki S, Hayashi N, Abe O, et al. Radiation-induced arteritis: thickened wall with prominent enhancement on cranial MR images report of five cases and comparison with 18 cases of Moyamoya disease. *Radiology.* 2002;223:683-688.
  116. White D. *An Atlas of Radiation Histopathology*. Springfield: VA; 1975.
  117. Rhodes JM, Cherry KJ Jr, Clark RC, et al. Aortic-origin reconstruction of the great vessels: risk factors of early and late complications. *J Vasc Surg.* 2000;31:260-269.
  118. Leseche G, Castier Y, Chataigner O, et al. Carotid artery revascularization through a radiated field. *J Vasc Surg.* 2003;38:244-250.
  119. Protack CD, Bakken AM, Saad WA, et al. Radiation arteritis: a contraindication to carotid stenting? *J Vasc Surg.* 2007;45:110-117.
  120. Chassaing N, Martin L, Calvas P, et al. Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update

- including 11 novel ABCC6 mutations. *J Med Genet.* 2005;42:881-892.
121. Bergen AAB, Plomp AS, Hu X, et al. ABCC6 and pseudoxanthoma elasticum. *Pflugers Arch.* 2007;453:685-691.
  122. Gorgels TGMF, Hu X, Scheffer GL, et al. Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticum. *Hum Mol Genet.* 2005;14:1763-1773.
  123. Klement JF, Matsuzaki Y, Jiang Q-J, et al. Targeted ablation of the abcc6 gene results in ectopic mineralization of connective tissues. *Mol Cell Biol.* 2005;25:8299-8310.
  124. Navarro-Lopez F, Llorian A, Ferrer-Roca O, et al. Restrictive cardiomyopathy in pseudoxanthoma elasticum. *Chest.* 1980;78:113-115.
  125. Iliopoulos J, Manganas C, Jepson N, Newman D. Pseudoxanthoma elasticum: is the left internal mammary artery a suitable conduit for coronary artery bypass grafting? *Ann Thorac Surg.* 2002;73:652-653.
  126. Bacharach JM, Colville DS, Lie JT. Accelerated atherosclerosis, aneurysmal disease, and aortitis: possible pathogenetic association with cocaine abuse. *Int Angiol.* 1992;11:83-86.
  127. Perez JA Jr, Arsura EL, Strategos S. Methamphetamine-related stroke: four cases. *J Emerg Med.* 1999;17:469-471.
  128. Kempczinski RF, Buckley CJ, Darling RC. Vascular insufficiency secondary to ergotism. *Surgery.* 1976;79:597-600.
  129. Carliner N, Denune DP, Finch CS Jr, Goldberg LI. Sodium nitroprusside treatment of ergotamine-induced peripheral ischemia. *JAMA.* 1974;227:308-309.
  130. Bilku DK, Brammer CV. A case of hypersensitivity vasculitis after vinorelbine injection in a patient with metastatic breast cancer. *Clin Oncol.* 2007;19:363-364.
  131. Adisen E, Dizbay M, Hizel K, Ilter N. Leukocytoclastic vasculitis during pegylated interferon and ribavirin treatment of hepatitis C virus infection. *Indian J Dermatol Venereol Leprol.* 2008;74:60-62.
  132. Turken O, Karagoz B, Bilgi O, et al. Oral etoposide-induced leucocytoclastic vasculitis in a patient with lung carcinoma. *J Eur Acad Dermatol Venereol.* 2007;21:1297-1298.
  133. Shah P, Chillag S. Leukocytoclastic vasculitis due to hydrochlorthiazide. *J S C Med Assoc.* 2007;103:194-196.
  134. Glass GE, Greig AV, Weir J, Waterhouse N. Nasal tip necrosis—an unusual presentation of rheumatoid vasculitis. *Clin Rheumatol.* 2007;26:1943-1945.
  135. Yildirim ND, Ayer M, Kucukkaya RD, et al. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma. *Jpn J Clin Oncol.* 2007;37:704-707.
  136. Shah D, Rowbottom AW, Thomas CL, et al. Hypocomplementaemic urticarial vasculitis associated with non-Hodgkin lymphoma and treatment with intravenous immunoglobulin. *Br J Dermatol.* 2007;157:392-393.
  137. Merkel PA. Drug-induced vasculitis. *Rheum Dis Clin North Am.* 2001;27:849-862.
  138. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. *Arch Neurol.* 1988;45:575-578.
  139. Lin AE, Birch PH, Korf BR, et al. Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. *Am J Med Genet.* 2000;95:108-117.
  140. Friedman JM, Arbiser J, Epstein JA, et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. *Genet Med.* 2002;4:105-111.
  141. Oderich GS, Sullivan TM, Bower TC, et al. Vascular abnormalities in patients with neurofibromatosis syndrome type I: clinical spectrum, management, and results. *J Vasc Surg.* 2007;46:475-484.
  142. Friedman JM. Neurofibromatosis 1: clinical manifestations and diagnostic criteria. *J Child Neurol.* 2002;17:548-554; discussion 71-2.
  143. Kral CA, Han DC, Edwards WD, et al. Obstructive external iliac arteriopathy in avid bicyclists: new and variable histopathologic features in four women. *J Vasc Surg.* 2002;36:565-570.
  144. Scheerder MJ, Schutte PR, Schnater JM. [A 26-year-old cyclist with intermittent claudication]. [see comment]. *Ned Tijdschr Geneesk.* 2006;150:1518-1522.

145. Chevalier JM, Enon B, Walder J, et al. Endofibrosis of the external iliac artery in bicycle racers: an unrecognized pathological state. *Ann Vasc Surg.* 1986;1:297-303.
146. Korsten-Reck U, Rocker K, Schmidt-Trucksass A, et al. External iliac artery occlusion in a young female cyclist. *J Sports Med Phys Fitness.* 2007;47:91-95.
147. Teh LG, Sieunarine K, Van Schie G, Vasudevan T. Spontaneous common iliac artery dissection after exercise. *J Endovasc Ther.* 2003;10:163-166.
148. Fernandez-Garcia B, Alvarez Fernandez J, Vega Garcia F, et al. Diagnosing external iliac endofibrosis by postexercise ankle to arm index in cyclists. *Med Sci Sports Exerc.* 2002;34:222-227.
149. Giannoukas AD, Berczi V, Anoop U, et al. Endofibrosis of iliac arteries in high-performance athletes: diagnostic approach and minimally invasive endovascular treatment. *Cardiovasc Intervent Radiol.* 2006;29:866-869.

## 第 77 章

1. Shionoya S. *Buerger's disease: pathology, diagnosis and treatment.* Nagoya: University of Nagoya Press; 1990:1-3.
2. von Winiwarter F. Ueber eine eigenthümliche Form von Endarteriitis und Endophlebitis mit Gangrän des Fusses. *Arch Klin Chir.* 1879;23:202-226.
3. Buerger L. Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene. *Am J Med Sci.* 1908;136:567-580.
4. Buerger L. *The Circulatory Disturbances of the Extremities: Including Gangrene, Vasomotor, and Trophic Disorders.* Philadelphia: WB Saunders; 1924.
5. Allen EV, Brown GE. Thrombo-angiitis obliterans: a clinical study of 200 cases. *Ann Intern Med.* 1928;1:535-549.
6. Gore I, Burrows S. A reconsideration of the pathogenesis of Buerger's disease. *Am J Clin Pathol.* 1958;29:319-330.
7. Wessler S, Ming S, Gurewich V, et al. A critical evaluation of thromboangiitis obliterans. The case against Buerger's disease. *N Engl J Med.* 1960;262:1149-1160.
8. Wessler S. Thromboangiitis obliterans: fact or fancy. *Circulation.* 1961;23:165-167.
9. Horwitz O. Buerger's disease retrieved. *Ann Intern Med.* 1961;55:341-344.
10. McKusick VA, Harris WS, Ottesen OE. Buerger's disease, a distinct clinical and pathologic entity. *JAMA.* 1962;181:93-100.
11. McPherson JR, Juergens JL, Gifford RW Jr. Thromboangiitis obliterans and arteriosclerosis obliterans. Clinical and prognostic differences. *Ann Intern Med.* 1963;59:288-296.
12. Abramson DI, Zayas AM, Canning JR, et al. Thromboangiitis obliterans: a true clinical entity. *Am J Cardiol.* 1963;12:107-118.
13. Szilagyi DE, Derusso FJ, Elliott JP Jr. Thromboangiitis obliterans. clinico-angiographic correlations. *Arch Surg.* 1964;88:824-835.
14. Shionoya S. What is Buerger's disease? *World J Surg.* 1983;7:544-551.
15. Lie JT. The rise and fall and resurgence of thromboangiitis obliterans (Buerger's disease). *Acta Pathol Jpn.* 1989;39:153-158.
16. Olin JW. Thromboangiitis obliterans (Buerger's disease). *N Engl J Med.* 2000;343:864-869.
17. Mills JL Sr. Buerger's disease in the 21st century: diagnosis, clinical features, and therapy. *Semin Vasc Surg.* 2003;16:179-189.
18. Olin JW. Thromboangiitis obliterans (Buerger's disease). In: Rutherford RB, ed. *Vascular Surgery.* 6th ed. Philadelphia: Elsevier Saunders; 2005:404-419.
19. Ansari A. Thromboangiitis obliterans: current perspectives and future directions. *Tex Heart Inst J.* 1990;17:112-117.
20. Puechal X, Fiessinger JN. Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist. *Rheumatology (Oxford).* 2007;46:192-199.

21. Lie JT. Thromboangiitis obliterans (Buerger's disease) in women. *Medicine (Baltimore)*. 1987;66:65-72.
22. Williams G. Recent views on Buerger's disease. *J Clin Pathol*. 1969;22:573-578.
23. Olin JW, Young JR, Graor RA, et al. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). *Circulation*. 1990;82:IV3-IV8.
24. Aqel MB, Olin JW. Thromboangiitis obliterans (Buerger's disease). *Vasc Med*. 1997;2:61-66.
25. Shionoya S. Diagnostic criteria of Buerger's disease. *Int J Cardiol*. 1998;66(Suppl 1):S243-S245.
26. Olin JW, Shih A. Thromboangiitis obliterans (Buerger's disease). *Curr Opin Rheumatol*. 2006;18:18-24.
27. O'Dell JR, Linder J, Markin RS, et al. Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. *Arthritis Rheum*. 1987;30:1054-1056.
28. Joyce JW. Buerger's disease (thromboangiitis obliterans). *Rheum Dis Clin North Am*. 1990;16:463-470.
29. Kjeldsen K, Mozes M. Buerger's disease in Israel. Investigations on carboxyhemoglobin and serum cholesterol levels after smoking. *Acta Chir Scand*. 1969;135:495-498.
30. Laohapensang K, Rerkasem K, Kattipattanapong V. Decrease in the incidence of Buerger's disease recurrence in northern Thailand. *Surg Today*. 2005;35:1060-1065.
31. Matsushita M, Nishikimi N, Sakurai T, et al. Decrease in prevalence of Buerger's disease in Japan. *Surgery*. 1998;124:498-502.
32. Buerger's Disease Research Committee of Ministry of Health and Welfare of Japan: Annual Report 1976. Tokyo, The Ministry.
33. Nishikimi N, Shionoya S, Mizuno S. Result of national epidemiological study of Buerger's disease. *J Jpn Coll Angiol*. 1987;27:1125-1130.
34. Kobayashi M, Nishikimi N, Komori K. Current pathological and clinical aspects of Buerger's disease in Japan. *Ann Vasc Surg*. 2006;20:148-156.
35. Nielubowicz J, Rosnowski A, Pruszyński B, et al. Natural history of Buerger's disease. *J Cardiovasc Surg (Torino)*. 1980;21:529-540.
36. Mills JL, Porter JM. Buerger's disease (thromboangiitis obliterans). *Ann Vasc Surg*. 1991;5:570-572.
37. Cutler DA, Runge MS. 86 years of Buerger's disease—what have we learned? *Am J Med Sci*. 1995;309:74-75.
38. Wysokinski WE, Kwiatkowska W, Sapien-Raczkowska B, et al. Sustained classic clinical spectrum of thromboangiitis obliterans (Buerger's disease). *Angiology*. 2000;51:141-150.
39. Lie JT. Thromboangiitis obliterans (Buerger's disease) revisited. *Pathol Annu*. 1988;23:257-291.
40. Adar R, Papa MZ, Halpern Z, et al. Cellular sensitivity to collagen in thromboangiitis obliterans. *N Engl J Med*. 1983;308:1113-1116.
41. Hagen B, Lohse S. Clinical and radiologic aspects of Buerger's disease. *Cardiovasc Intervent Radiol*. 1984;7:283-293.
42. Cachovan M. Epidemiologic und geographisches Verteilungsmuster der Thromboangiitis obliterans. In: Heidrich H, ed. *Thromboangiitis obliterans Morbus Winiwarter-Buerger*. Stuttgart: Georg Thieme; 1988:31-36.
43. Dehaine-Bamberger N, Amar R, Touboul C, et al. Buerger disease, clinical and prognostic aspects. 83 cases. *Presse Med*. 1993;22:945-948.
44. Bozkurt AK, Besirli K, Koksall C, et al. Surgical treatment of Buerger's disease. *Vascular*. 2004;12:192-197.
45. Shionoya S, Ban I, Nakata Y, et al. Diagnosis, pathology, and treatment of Buerger's disease. *Surgery*. 1974;75:695-700.
46. Ishikawa K. *Annual report of the Buerger's disease research committee of Ministry of Health and Welfare of Japan*. Tokyo: Ministry of Health and Welfare. 1976:3-15, 89-97.
47. Matsushita M, Kuzuya A, Kobayashi M, et al. Buerger's disease in a 19-year-old woman. *J Vasc Surg*. 2003;38:175-179.
48. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *Eur J Vasc Endovasc Surg*. 2007;33(Suppl 1):S1-75.
49. Yorukoglu Y, Ilgit E, Zengin M, et al. Thromboangiitis obliterans (Buerger's disease) in women (a reevaluation).



*Angiology*. 1993;44:527-532.

50. Mills JL, Taylor LM Jr, Porter JM. Buerger's disease in the modern era. *Am J Surg*. 1987;154:123-129.
51. Jimenez-Ruiz CA, Dale LC, Astray MJ, et al. Smoking characteristics and cessation in patients with thromboangiitis obliterans. *Monaldi Arch Chest Dis*. 2006;65:217-221.
52. Casellas M, Perez A, Cabero L, et al. Buerger's disease and antiphospholipid antibodies in pregnancy. *Ann Rheum Dis*. 1993;52:247-248.
53. Kikuchi N, Kanai M, Kita N, et al. Pregnancy complicated with Buerger's disease. *Int J Gynaecol Obstet*. 2006;94:62-66.
54. Young SG, Hanson FW, Kahn BB. Pregnancy in a young woman with Buerger's disease. A case report. *J Reprod Med*. 1983;28:694-696.
55. Zelikovsky A, Urca I, Kessler E. Thromboangiitis obliterans in a woman. Report of a case. *Angiology*. 1973;24:169-174.
56. Shionoya S. Buerger's disease: diagnosis and management. *Cardiovasc Surg*. 1993;1:207-214.
57. Szuba A, Cooke JP. Thromboangiitis obliterans. An update on Buerger's disease. *West J Med*. 1998;168:255-260.
58. Silbert S. Etiology of thromboangiitis obliterans. *JAMA*. 1945;129:5-9.
59. Matsushita M, Shionoya S, Matsumoto T. Urinary cotinine measurement in patients with Buerger's disease—effects of active and passive smoking on the disease process. *J Vasc Surg*. 1991;14:53-58.
60. Harkavy J. Tobacco sensitivities in thromboangiitis obliterans, migratory phlebitis, and coronary artery disease. *Bull N Y Acad Med*. 1933;9:318-322.
61. Smolen JS, Youngchaiyud U, Weidinger P, et al. Autoimmunological aspects of thromboangiitis obliterans (Buerger's disease). *Clin Immunol Immunopathol*. 1978;11:168-177.
62. Smolen JS, Weidinger P, Menzel EJ. Sensitivity to collagen in thromboangiitis obliterans. *N Engl J Med*. 1983;309:857-858.
63. Hada M, Sakihama T, Kamiya K, et al. Cellular and humoral immune responses to vascular components in thromboangiitis obliterans. *Angiology*. 1993;44:533-540.
64. Gulati SM, Singh KS, Thusoo TK, et al. Immunological studies in thromboangitis obliterans (Buerger's disease). *J Surg Res*. 1979;27:287-293.
65. Gulati SM, Madhra K, Thusoo TK, et al. Autoantibodies in thromboangiitis obliterans (Buerger's disease). *Angiology*. 1982;33:642-651.
66. Roncon de Albuquerque R, Delgado L, Correia P, et al. Circulating immune complexes in Buerger's disease. Endarteritis obliterans in young men. *J Cardiovasc Surg (Torino)*. 1989;30:821-825.
67. Papa MZ, Bass A, Adar R, et al. Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex. *Surgery*. 1992;111:527-531.
68. Kobayashi M, Ito M, Nakagawa A, et al. Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans). *J Vasc Surg*. 1999;29:451-458.
69. Jimenez-Paredes CA, Canas-Davila CA, Sanchez A, et al. Buerger's disease at the "San Juan De Dios" Hospital, Santa Fe De Bogota, Colombia. *Int J Cardiol*. 1998;66(Suppl 1):S267-S272.
70. Maslowski L, McBane R, Alexewicz P, et al. Antiphospholipid antibodies in thromboangiitis obliterans. *Vasc Med*. 2002;7:259-264.
71. Olin JW. Are anticardiolipin antibodies really important in thromboangiitis obliterans (Buerger's disease)? *Vasc Med*. 2002;7:257-258.
72. de Godoy JM, Braile DM, Godoy MF. Buerger's disease and anticardiolipin antibodies: a worse prognosis? *Clin Appl Thromb Hemost*. 2002;8:85-86.
73. Heper G, Kose S, Akkoc O, et al. Two female nonsmoker Buerger's disease cases with anticardiolipin autoantibodies and a poor prognosis. *Int Heart J*. 2005;46:563-569.
74. Vasugi Z, Danda D. Systemic lupus erythematosus with antiphospholipid antibody syndrome: a mimic of Buerger's disease.

*J Postgrad Med.* 2006;52:132-133.

75. Halacheva KS, Manolova IM, Petkov DP, et al. Study of anti-neutrophil cytoplasmic antibodies in patients with thromboangiitis obliterans (Buerger's disease). *Scand J Immunol.* 1998;48:544-550.
76. Eichhorn J, Sima D, Lindschau C, et al. Antiendothelial cell antibodies in thromboangiitis obliterans. *Am J Med Sci.* 1998;315:17-23.
77. Wysokinski WE, Kwiatkowska W, Maslowski L, et al. Buerger's disease in two brothers: iliac artery occlusion by thromboangiitis obliterans—case reports. *Angiology.* 1998;49:409-414.
78. Tashiro T. Epidemiological studies on Buerger's disease in Japan [in Japanese]. *Gendai Iryo.* 1976;8:1231-1237.
79. McLoughlin GA, Helsby CR, Evans CC, et al. Association of HLA-A9 and HLA-B5 with Buerger's disease. *BMJ.* 1976;2:1165-1166.
80. Aerbajinai W, Tsuchiya T, Kimura A, et al. HLA class II DNA typing in Buerger's disease. *Int J Cardiol.* 1996;54(Suppl):S167-S172.
81. Kimura A, Kobayashi Y, Takahashi M, et al. MICA gene polymorphism in Takayasu's arteritis and Buerger's disease. *Int J Cardiol.* 1998;66(Suppl 1):S107-S113.
82. Mehra NK, Jaini R. Immunogenetics of peripheral arteriopathies. *Clin Hemorheol Microcirc.* 2000;23:225-232.
83. Makita S, Nakamura M, Murakami H, et al. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease). *Circulation.* 1996;94:II211-II215.
84. Glueck CJ, Haque M, Winarska M, et al. Stromelysin-1 5A/6A and eNOS T-786C polymorphisms, MTHFR C677T and A1298C mutations, and cigarette-cannabis smoking: a pilot, hypothesis-generating study of gene-environment pathophysiological associations with Buerger's disease. *Clin Appl Thromb Hemost.* 2006;12:427-439.
85. Brodmann M, Renner W, Stark G, et al. Prothrombotic risk factors in patients with thrombangitis obliterans. *Thromb Res.* 2000;99:483-486.
86. Choudhury NA, Pietraszek MH, Hachiya T, et al. Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease). *Thromb Res.* 1992;66:321-329.
87. Avcu F, Akar E, Demirkilic U, et al. The role of prothrombotic mutations in patients with Buerger's disease. *Thromb Res.* 2000;100:143-147.
88. Stammler F, Diehm C, Hsu E, et al. The prevalence of hyperhomocysteinemia in thromboangiitis obliterans. Does homocysteine play a role pathogenetically? *Dtsch Med Wochenschr.* 1996;121:1417-1423.
89. Mercie P, Baste JC, Sassoust G, et al. Factor V Leiden, mild hyperhomocyst(e)inemia and Buerger's disease. *Microvasc Res.* 1998;55:271-272.
90. Diehm C, Stammler F. Thromboangiitis obliterans (Buerger's disease). *N Engl J Med.* 2001;344:230-231.
91. Di Micco P, Niglio A, Scudiero O, et al. A case of Buerger's disease associated with MTHFR C677T mutation homozygosity: a possible therapeutic support. *Nutr Metab Cardiovasc Dis.* 2004;14:225-226.
92. Carr ME Jr, Hackney MH, Hines SJ, et al. Enhanced platelet force development despite drug-induced inhibition of platelet aggregation in patients with thromboangiitis obliterans—two case reports. *Vasc Endovasc Surg.* 2002;36:473-480.
93. Iwai T, Inoue Y, Umeda M, et al. Oral bacteria in the occluded arteries of patients with Buerger disease. *J Vasc Surg.* 2005;42:107-115.
94. Lee T, Seo JW, Sumpio BE, et al. Immunobiologic analysis of arterial tissue in Buerger's disease. *Eur J Vasc Endovasc Surg.* 2003;25:451-457.
95. Tanaka K. Pathology and pathogenesis of Buerger's disease. *Int J Cardiol.* 1998;66(Suppl 1):S237-S242.
96. Kurata A, Machinami R, Schulz A, et al. Different immunophenotypes in Buerger's disease. *Pathol Int.* 2003;53:608-615.
97. Kurata A, Franke FE, Machinami R, et al. Thromboangiitis obliterans: classic and new morphological features. *Virchows Arch.* 2000;436:59-67.
98. Sasaki S, Sakuma M, Yasuda K. Current status of thromboangiitis obliterans (Buerger's disease) in Japan. *Int J Cardiol.*

2000;75(Suppl 1):S175-S181.

99. Ates A, Yekeler I, Ceviz M, et al. One of the most frequent vascular diseases in northeastern of Turkey: thromboangiitis obliterans or Buerger's disease (experience with 344 cases). *Int J Cardiol.* 2006;111:147-153.
100. Fazeli B, Modaghegh H, Ravrai H, et al. Thrombophlebitis migrans as a footprint of Buerger's disease: a prospective-descriptive study in north-east of Iran. *Clin Rheumatol.* 2008;27:55-57.
101. Ohta T, Shionoya S. Fate of the ischaemic limb in Buerger's disease. *Br J Surg.* 1988;75:259-262.
102. Hirai M, Shinonoya S. Intermittent claudication in the foot and Buerger's disease. *Br J Surg.* 1978;65:210-213.
103. Mishima Y. Thromboangiitis obliterans (Buerger's disease). *Int J Cardiol.* 1996;54(Suppl):S155-S157.
104. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *Circulation.* 2006;113:e463-e654.
105. Chopra BS, Zakariah T, Sodhi JS, et al. Thromboangiitis obliterans: a clinical study with special emphasis on venous involvement. *Angiology.* 1976;27:126-132.
106. Stone JH. Vasculitis: a collection of pearls and myths. *Rheum Dis Clin North Am.* 2007;33:691-739.
107. Puechal X, Fiessinger JN, Kahan A, et al. Rheumatic manifestations in patients with thromboangiitis obliterans (Buerger's disease). *J Rheumatol.* 1999;26:1764-1768.
108. Quenneville JG, Gossard D. Subungueal-splinter hemorrhage an early sign of thromboangiitis obliterans. *Angiology.* 1981;32:424-432.
109. Farberow NL, Nehemkis AM. Indirect self-destructive behavior in patients with Buerger's disease. *J Pers Assess.* 1979;43:86-96.
110. Sasaki S, Sakuma M, Kuniyama T, et al. Current trends in thromboangiitis obliterans (Buerger's disease) in women. *Am J Surg.* 1999;177:316-320.
111. Shionoya S. Buerger's disease (thromboangiitis obliterans). In: Rutherford RB, ed. *Vascular Surgery*. 3rd ed. Philadelphia: WB Saunders; 1989:207-217.
112. Sasaki S, Sakuma M, Kuniyama T, et al. Distribution of arterial involvement in thromboangiitis obliterans (Buerger's disease): results of a study conducted by the Intractable Vasculitis Syndromes Research Group in Japan. *Surg Today.* 2000;30:600-605.
113. Herrington JL Jr, Grossman LA. Surgical lesions of the small and large intestine resulting from Buerger's disease. *Ann Surg.* 1968;168:1079-1087.
114. Wolf EA Jr, Sumner DS, Strandness DE Jr. Disease of the mesenteric circulation in patients with thromboangiitis obliterans. *Vasc Surg.* 1972;6:218-223.
115. Rosenberger A, Munk J, Schramek A, et al. The angiographic appearance of thromboangiitis obliterans (Buerger's disease) in the abdominal visceral vessels. *Br J Radiol.* 1973;46:337-343.
116. Guay A, Janower ML, Bain RW, et al. A case of Buerger's disease causing ischemic colitis with perforation in a young male. *Am J Med Sci.* 1976;271:239-240.
117. Sachs IL, Klima T, Frankel NB. Thromboangiitis obliterans of the transverse colon. *JAMA.* 1977;238:336-337.
118. Sobel RA, Ruebner BH. Buerger's disease involving the celiac artery. *Hum Pathol.* 1979;10:112-115.
119. Deitch EA, Sikkema WW. Intestinal manifestation of Buerger's disease: case report and literature review. *Am Surg.* 1981;47:326-328.

120. Soo KC, Hollinger-Vernea S, Miller G, et al. Buerger's disease of the sigmoid colon. *Aust N Z J Surg*. 1983;53:111-112.
121. Rosen N, Sommer I, Knobel B. Intestinal Buerger's disease. *Arch Pathol Lab Med*. 1985;109:962-963.
122. Iyer KR, Mair WS. Buerger's disease of the rectum: case report and literature review. *J R Coll Surg Edinb*. 1991;36:409-410.
123. Ito M, Nihei Z, Ichikawa W, et al. Intestinal ischemia resulting from Buerger's disease: report of a case. *Surg Today*. 1993;23:988-992.
124. Broide E, Scapa E, Peer A, et al. Buerger's disease presenting as acute small bowel ischemia. *Gastroenterology*. 1993;104:1192-1195.
125. Schellong SM, Bernhards J, Ensslen F, et al. Intestinal type of thromboangiitis obliterans (Buerger's disease). *J Intern Med*. 1994;235:69-73.
126. Sauvaget F, Debray M, Herve de Sigalony JP, et al. Colonic ischemia reveals thromboangiitis obliterans (Buerger's disease). *Gastroenterology*. 1996;110:900-903.
127. Lie JT. Visceral intestinal Buerger's disease. *Int J Cardiol*. 1998;66(Suppl 1):S249-S256.
128. Iwai T. Buerger's disease with intestinal involvement. *Int J Cardiol*. 1998;66(Suppl 1):S257-S263.
129. Hassoun Z, Lacrosse M, De Ronde T. Intestinal involvement in Buerger's disease. *J Clin Gastroenterol*. 2001;32:85-89.
130. Kobayashi M, Kurose K, Kobata T, et al. Ischemic intestinal involvement in a patient with Buerger disease: case report and literature review. *J Vasc Surg*. 2003;38:170-174.
131. Cho YP, Kwon YM, Kwon TW, et al. Mesenteric Buerger's disease. *Ann Vasc Surg*. 2003;17:221-223.
132. Cho YP, Kang GH, Han MS, et al. Mesenteric involvement of acute-stage Buerger's disease as the initial clinical manifestation: report of a case. *Surg Today*. 2005;35:499-501.
133. Leung DK, Haskal ZJ. SIR 2006 film panel case: mesenteric involvement and bowel infarction due to Buerger disease. *J Vasc Interv Radiol*. 2006;17:1087-1089.
134. Lippmann HI. Cerebrovascular thrombosis in patients with Buerger's disease. *Circulation*. 1952;5:680-692.
135. Zulch KJ. The cerebral form of von Winiwarter-Buerger's disease: does it exist? *Angiology*. 1969;20:61-69.
136. Berlit P, Kessler C, Reuther R, et al. New aspects of thromboangiitis obliterans (von Winiwarter-Buerger's disease). *Eur Neurol*. 1984;23:394-399.
137. Bozikas VP, Vlaikidis N, Petrikis P, et al. Schizophrenic-like symptoms in a patient with thrombo-angiitis obliterans (Winiwarter-Buerger's disease). *Int J Psychiatry Med*. 2001;31:341-346.
138. No YJ, Lee EM, Lee DH, et al. Cerebral angiographic findings in thromboangiitis obliterans. *Neuroradiology*. 2005;47:912-915.
139. Ohno H, Matsuda Y, Takashiba K, et al. Acute myocardial infarction in Buerger's disease. *Am J Cardiol*. 1986;57:690-691.
140. Mautner GC, Mautner SL, Lin F, et al. Amounts of coronary arterial luminal narrowing and composition of the material causing the narrowing in Buerger's disease. *Am J Cardiol*. 1993;71:486-490.
141. Donatelli F, Triggiani M, Nascimbene S, et al. Thromboangiitis obliterans of coronary and internal thoracic arteries in a young woman. *J Thorac Cardiovasc Surg*. 1997;113:800-802.
142. Hoppe B, Lu JT, Thistlewaite P, et al. Beyond peripheral arteries in Buerger's disease: angiographic considerations in thromboangiitis obliterans. *Cathet Cardiovasc Interv*. 2002;57:363-366.
143. Becit N, Unlu Y, Kocak H, et al. Involvement of the coronary artery in a patient with thromboangiitis obliterans. A case report. *Heart Vessels*. 2002;16:201-203.
144. Hong TE, Faxon DP. Coronary artery disease in patients with Buerger's disease. *Rev Cardiovasc Med*. 2005;6:222-226.
145. Tamura A, Aso N, Kadota J. Corkscrew appearance in the right coronary artery in a patient with Buerger's disease. *Heart*. 2006;92:944.
146. Hsu PC, Lin TH, Su HM, et al. Frequent accelerated idioventricular rhythm in a young male of Buerger's disease with acute myocardial infarction. *Int J Cardiol*. 2008;127:e64-e66.

147. Abe M, Kimura T, Furukawa Y, et al. Coronary Buerger's disease with a peripheral arterial aneurysm. *Eur Heart J*. 2007;28:928.
148. Harten P, Muller-Huelsbeck S, Regensburger D, et al. Multiple organ manifestations in thromboangiitis obliterans (Buerger's disease). A case report. *Angiology*. 1996;47:419-425.
149. Calguneri M, Ozturk MA, Ay H, et al. Buerger's disease with multisystem involvement. A case report and a review of the literature. *Angiology*. 2004;55:325-328.
150. Lie JT. Thromboangiitis obliterans (Buerger's disease) in a saphenous vein arterial graft. *Hum Pathol*. 1987;18:402-404.
151. Lie JT, Michet CJ Jr. Thromboangiitis obliterans with eosinophilia (Buerger's disease) of the temporal arteries. *Hum Pathol*. 1988;19:598-602.
152. Bernardezykowska A, Zawilski J. Fundus oculi changes in chronic ischemia of the lower extremities. *Klin Oczna*. 1991;93:291-292.
153. Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. *Prog Retin Eye Res*. 2001;20:319-349.
154. Ohguro I, Ohguro H, Ohta T, et al. A case of normal tension glaucoma associated with Buerger's disease. *Tohoku J Exp Med*. 2006;209:49-52.
155. Goktas S, Bedir S, Bozlar U, et al. Intrarenal arterial stenosis in a patient with thromboangiitis obliterans. *Int J Urol*. 2006;13:1243-1244.
156. Negredo E, Lopez-Contreras J, De Llobet JM, et al. Impotence as a cardinal sign in the thromboangiitis obliterans diagnosis. *Clin Rheumatol*. 1995;14:711-712.
157. Yavas US, Calisir C, Kaya T. Vasculogenic impotence as a symptom in late-onset Buerger's disease. *J Clin Ultrasound*. 2007;35:469-472.
158. Remy P, Jacquot C, Nochy D, et al. Buerger's disease associated with IgA nephropathy: report of two cases. *BMJ (Clin Res Ed)*. 1988;296:683-684.
159. Takanashi T, Horigome R, Okuda Y, et al. Buerger's disease manifesting nodular erythema with livedo reticularis. *Intern Med*. 2007;46:1815-1819.
160. Laohapensang K, Rerkasem K, Kattipattanapong V. Seasonal variation of Buerger's disease in northern part of Thailand. *Eur J Vasc Endovasc Surg*. 2004;28:418-420.
161. Tavakoli H, Rezaei J, Esfandiari K, et al. Buerger's disease: a 10-year experience in Tehran, Iran. *Clin Rheumatol*. 2008;27:369-371.
162. Adar R, Papa MZ. The definition of Buerger's disease. *World J Surg*. 1984;8:423-424.
163. Adar R, Papa MZ, Schneiderman J. Thromboangiitis obliterans: an old disease in need of a new look. *Int J Cardiol*. 2000;75(Suppl 1):S167-S170.
164. Kroger K. Buerger's disease: what has the last decade taught us? *Eur J Intern Med*. 2006;17:227-234.
165. Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger's disease. *Eur J Vasc Endovasc Surg*. 1996;11:335-339.
166. Mills JL, Porter JM. Buerger's disease: a review and update. *Semin Vasc Surg*. 1993;6:14-23.
167. Papa MZ, Adar R. A critical look at thromboangiitis obliterans (Buerger's disease). *Perspect Vasc Surg*. 1992;5:1-21.
168. Fujii Y, Nishioka K, Yoshizumi M, et al. Images in cardiovascular medicine. Corkscrew collaterals in thromboangiitis obliterans (Buerger's disease). *Circulation*. 2007;116:e539-e540.
169. Jargiello T, Wronski J, Drelich-Zbroja A, et al. Preliminary report on Doppler quantification of peripheral vascular resistance in patients with thromboangiitis obliterans; the diagnostic value of high resistance index—HRI. *Pol J Radiol*. 2003;68:75-80.
170. Jaccard Y, Walther S, Anderson S, et al. Influence of secondary infection on amputation in chronic critical limb ischemia. *Eur J Vasc Endovasc Surg*. 2007;33:605-609.

171. Combemale P, Consort T, Denis-Thelis L, et al. Cannabis arteritis. *Br J Dermatol*. 2005;152:166-169.
172. Marder VJ, Mellinghoff IK. Cocaine and Buerger disease: is there a pathogenetic association? *Arch Intern Med*. 2000;160:2057-2060.
173. Disdier P, Granel B, Serratrice J, et al. Cannabis arteritis revisited—ten new case reports. *Angiology*. 2001;52:1-5.
174. Noel B. Regarding “cannabis arteritis revisited—ten new case reports.” *Angiology*. 2001;52:505-506.
175. Noel B. Vascular complications of cocaine use. *Stroke*. 2002;33:1747-1748.
176. Noel B. Cocaine and arsenic-induced Raynaud’s phenomenon. *Clin Rheumatol*. 2002;21:343-344.
177. Lazarides MK, Georgiadis GS, Papas TT, et al. Diagnostic criteria and treatment of Buerger’s disease: a review. *Int J Low Extrem Wounds*. 2006;5:89-95.
178. Dean SM, Satiani B. Three cases of digital ischemia successfully treated with cilostazol. *Vasc Med*. 2001;6:245-248.
179. Cooper LT, Tse TS, Mikhail MA, et al. Long-term survival and amputation risk in thromboangiitis obliterans (Buerger’s disease). *J Am Coll Cardiol*. 2004;44:2410-2411.
180. Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. *J Vasc Surg*. 2004;39:176-180.
181. Cooper LT, Henderson SS, Ballman KV, et al. A prospective, case-control study of tobacco dependence in thromboangiitis obliterans (Buerger’s disease). *Angiology*. 2006;57:73-78.
182. Hooten WM, Bruns HK, Hays JT. Inpatient treatment of severe nicotine dependence in a patient with thromboangiitis obliterans (Buerger’s disease). *Mayo Clin Proc*. 1998;73:529-532.
183. Rahman M, Chowdhury AS, Fukui T, et al. Association of thromboangiitis obliterans with cigarette and bidi smoking in Bangladesh: a case-control study. *Int J Epidemiol*. 2000;29:266-270.
184. Lie JT. Thromboangiitis obliterans (Buerger’s disease) and smokeless tobacco. *Arthritis Rheum*. 1988;31:812-813.
185. Paraskevas KI, Liapis CD, Briana DD, et al. Thromboangiitis obliterans (Buerger’s disease): searching for a therapeutic strategy. *Angiology*. 2007;58:75-84.
186. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. *Arterioscler Thromb Vasc Biol*. 2001;21:1712-1719.
187. Calabro P, Yeh ET. The pleiotropic effects of statins. *Curr Opin Cardiol*. 2005;20:541-546.
188. Liao JK. Clinical implications for statin pleiotropy. *Curr Opin Lipidol*. 2005;16:624-629.
189. Della BS, Molteni M, Mocellin C, et al. Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. *Prostaglandins Other Lipid Mediat*. 2001;65:73-83.
190. Fiessinger JN, Schafer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. *Lancet*. 1990;335:555-557.
191. Oral iloprost in the treatment of thromboangiitis obliterans (Buerger’s disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. *Eur J Vasc Endovasc Surg*. 1998;15:300-307.
192. Bozkurt AK, Koksall C, Demirbas MY, et al. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger’s disease. *Int Angiol*. 2006;25:162-168.
193. Swainston Harrison T, Plosker GL. Limaprost. *Drugs*. 2007;67:109-118.
194. Olshwang D, Beer G, Magora F. Intravenous regional guanethidine treatment in peripheral vascular disease. *Angiology*. 1980;31:639-645.
195. Stumpfen A, Ahmadi A, Attender M, et al. Effects of transvenous regional guanethidine block in the treatment of critical finger ischemia. *Angiology*. 2000;51:115-122.
196. Paraskevas KI, Trigka AA, Samara M. Successful intravenous regional sympathetic blockade (Bier’s block) with guanethidine and lidocaine in a patient with advanced Buerger’s disease (thromboangiitis obliterans)—a case report. *Angiology*. 2005;56:493-496.
197. Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger’s disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. *J Vasc Surg*. 1998;28:964-973.

198. Brodmann M, Renner W, Stark G, et al. Vascular endothelial growth factor expression in patients suffering from thrombngitis obliterans. *Int J Cardiol.* 2001;80:185-186.
199. Lang EV, Bookstein JJ. Accelerated thrombolysis and angioplasty for hand ischemia in Buerger's disease. *Cardiovasc Intervent Radiol.* 1989;12:95-97.
200. Hussein EA, el Dorri A. Intra-arterial streptokinase as adjuvant therapy for complicated Buerger's disease: early trials. *Int Surg.* 1993;78:54-58.
201. Hodgson TJ, Gaines PA, Beard JD. Thrombolysis and angioplasty for acute lower limb ischemia in Buerger's disease. *Cardiovasc Intervent Radiol.* 1994;17:333-335.
202. Kubota Y, Kichikawa K, Uchida H, et al. Superselective urokinase infusion therapy for dorsalis pedis artery occlusion in Buerger's disease. *Cardiovasc Intervent Radiol.* 1997;20:380-382.
203. Reekers JA, Bolia A. Percutaneous intentional extraluminal (subintimal) recanalization: how to do it yourself. *Eur J Radiol.* 1998;28:192-198.
204. Reekers JA. Percutaneous intentional extraluminal (subintimal) revascularization (PIER) for critical lower limb ischemia: too good to be true? *J Endovasc Ther.* 2002;9:419-421.
205. Reekers JA. The feasibility of a percutaneous temporary pedal bypass. *Eur J Vasc Endovasc Surg.* 2007;34:50-52.
206. Ingle H, Nasim A, Bolia A, et al. Subintimal angioplasty of isolated infragenicular vessels in lower limb ischemia: long-term results. *J Endovasc Ther.* 2002;9:411-416.
207. Roncon-Albuquerque R, Serrao P, Vale-Pereira R, et al. Plasma catecholamines in Buerger's disease: effects of cigarette smoking and surgical sympathectomy. *Eur J Vasc Endovasc Surg.* 2002;24:338-343.
208. Lau H, Cheng SW. Buerger's disease in Hong Kong: a review of 89 cases. *Aust N Z J Surg.* 1997;67:264-269.
209. Watarida S, Shiraishi S, Fujimura M, et al. Laparoscopic lumbar sympathectomy for lower-limb disease. *Surg Endosc.* 2002;16:500-503.
210. Chander J, Singh L, Lal P, et al. Retroperitoneoscopic lumbar sympathectomy for Buerger's disease: a novel technique. *JSLs.* 2004;8:291-296.
211. Komori K, Kawasaki K, Okazaki J, et al. Thoracoscopic sympathectomy for Buerger's disease of the upper extremities. *J Vasc Surg.* 1995;22:344-346.
212. De Giacomo T, Rendina EA, Venuta F, et al. Thoracoscopic sympathectomy for symptomatic arterial obstruction of the upper extremities. *Ann Thorac Surg.* 2002;74:885-888.
213. Rizzo M, Balderson SS, Harpole DH, et al. Thoracoscopic sympathectomy in the management of vasomotor disturbances and complex regional pain syndrome of the hand. *Orthopedics.* 2004;27:49-52.
214. Iwase S, Okamoto T, Mano T, et al. Skin sympathetic outflow in Buerger's disease. *Auton Neurosci.* 2001;87:286-292.
215. Sasajima T, Kubo Y, Izumi Y, et al. Plantar or dorsalis pedis artery bypass in Buerger's disease. *Ann Vasc Surg.* 1994;8:248-257.
216. Inada K, Iwashima Y, Okada A, et al. Nonatherosclerotic segmental arterial occlusion of the extremity. *Arch Surg.* 1974;108:663-667.
217. Dilege S, Aksoy M, Kayabali M, et al. Vascular reconstruction in Buerger's disease: is it feasible? *Surg Today.* 2002;32:1042-1047.
218. Nakajima N. The change in concept and surgical treatment on Buerger's disease—personal experience and review. *Int J Cardiol.* 1998;66(Suppl 1):S273-S280.
219. Sayin A, Bozkurt AK, Tuzun H, et al. Surgical treatment of Buerger's disease: experience with 216 patients. *Cardiovasc Surg.* 1993;1:377-380.
220. Sasajima T, Kubo Y, Inaba M, et al. Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience. *Eur J Vasc Endovasc Surg.* 1997;13:186-192.
221. Chang H, Hasegawa T, Moteki K, et al. A challenging treatment for an ischaemic ulcer in a patient with Buerger's disease:

- vascular reconstruction and local flap coverage. *Br J Plast Surg*. 2001;54:76-79.
222. Van Landuyt K, Monstrey S, Tonnard P, et al. Free flap coverage of a gangrenous forefoot in a patient with Buerger's disease: a case report. *Ann Plast Surg*. 1996;36:154-157.
  223. Maurya SD, Singhal S, Gupta HC, et al. Pedicled omental grafts in the revascularization of ischemic lower limbs in Buerger's disease. *Int Surg*. 1985;70:253-255.
  224. Singh I, Ramteke VK. The role of omental transfer in Buerger's disease: New Delhi's experience. *Aust N Z J Surg*. 1996;66:372-376.
  225. Bhargava JS, Makker A, Bhargava K, et al. Pedicled omental transfer for ischaemic limbs—a 5-year experience. *J Indian Med Assoc*. 1997;95:100-102.
  226. Talwar S, Jain S, Porwal R, et al. Free versus pedicled omental grafts for limb salvage in Buerger's disease. *Aust N Z J Surg*. 1998;68:38-40.
  227. Talwar S, Jain S, Porwal R, et al. Pedicled omental transfer for limb salvage in Buerger's disease. *Int J Cardiol*. 2000;72:127-132.
  228. Talwar S, Prasad P. Single-stage lumbar sympathectomy and omentopexy: a new surgical approach towards patients with Buerger's disease. *Trop Doct*. 2001;31:73-75.
  229. Talwar S, Choudhary SK. Omentopexy for limb salvage in Buerger's disease: indications, technique and results. *J Postgrad Med*. 2001;47:137-142.
  230. Swigris JJ, Olin JW, Mekhail NA. Implantable spinal cord stimulator to treat the ischemic manifestations of thromboangiitis obliterans (Buerger's disease). *J Vasc Surg*. 1999;29:928-935.
  231. Chierichetti F, Mambrini S, Bagliani A, et al. Treatment of Buerger's disease with electrical spinal cord stimulation—review of three cases. *Angiology*. 2002;53:341-347.
  232. Pace AV, Saratzis N, Karokis D, et al. Spinal cord stimulation in Buerger's disease. *Ann Rheum Dis*. 2002;61:1114.
  233. Manfredini R, Boari B, Gallerani M, et al. Thromboangiitis obliterans (Buerger disease) in a female mild smoker treated with spinal cord stimulation. *Am J Med Sci*. 2004;327:365-368.
  234. Donas KP, Schulte S, Ktenidis K, et al. The role of epidural spinal cord stimulation in the treatment of Buerger's disease. *J Vasc Surg*. 2005;41:830-836.
  235. Boari B, Salmi R, Manfredini R. Buerger's disease: spinal cord stimulation may represent a useful tool for delaying amputation in young patients. *Eur J Intern Med*. 2007;18:259.
  236. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. *Science*. 1997;275:964-967.
  237. Kalka C, Masuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc Natl Acad Sci U S A*. 2000;97:3422-3427.
  238. Iba O, Matsubara H, Amano K, et al. Augmented angiogenesis in hindlimb ischemia by intramuscular implantation of peripheral blood mononuclear cells and platelets, but not polymorphonuclear leukocytes. *Circulation*. 2002;106:64.
  239. Iba O, Matsubara H, Nozawa Y, et al. Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. *Circulation*. 2002;106:2019-2025.
  240. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. *Lancet*. 2002;360:427-435.
  241. Taguchi A, Ohtani M, Soma T, et al. Therapeutic angiogenesis by autologous bone-marrow transplantation in a general hospital setting. *Eur J Vasc Endovasc Surg*. 2003;25:276-278.
  242. Durdu S, Akar AR, Arat M, et al. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. *J Vasc Surg*. 2006;44:732-739.
  243. Miyamoto K, Nishigami K, Nagaya N, et al. Unblinded pilot study of autologous transplantation of bone marrow



- mononuclear cells in patients with thromboangiitis obliterans. *Circulation*. 2006;114:2679-2684.
244. Saito Y, Sasaki K, Katsuda Y, et al. Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger's disease. *Circ J*. 2007;71:1187-1192.
  245. Kim SW, Han H, Chae GT, et al. Successful stem cell therapy using umbilical cord blood-derived multipotent stem cells for Buerger's disease and ischemic limb disease animal model. *Stem Cells*. 2006;24:1620-1626.
  246. Akar R, Durdu S, Arat M, et al. Therapeutic angiogenesis by autologous transplantation of bone-marrow mononuclear cells for Buerger's patients with retractable limb ischaemia. A preliminary report. *Turk J Haematol*. 2004;21:13-21.
  247. Akar AR, Durdu S, Baran C. Letter by Akar et al regarding article, "Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger's disease." *Circ J*. 2008;72:684.
  248. Inan M, Alat I, Kutlu R, et al. Successful treatment of Buerger's disease with intramedullary K-wire: the results of the first 11 extremities. *Eur J Vasc Endovasc Surg*. 2005;29:277-280.
  249. Kim DI, Kim MJ, Joh JH, et al. Angiogenesis facilitated by autologous whole bone marrow stem cell transplantation for Buerger's disease. *Stem Cells*. 2006;24:1194-1200.
  250. Akar AR, Durdu S, Corapcioglu T, et al. Regenerative medicine for cardiovascular disorders. New milestones: adult stem cells. *Artif Organs*. 2006;30:213-232.
  251. Foley S, Gibbs H, Muir J. Painful digital infarction in a male smoker treated as Buerger's disease. *Australas J Dermatol*. 2008;49:94-97.
  252. Nielsen SL, Lassen NA. Measurement of digital blood pressure after local cooling. *J Appl Physiol*. 1977;43:907-910.
  253. Batsis JA, Casey KK. Thromboangiitis obliterans (Buerger disease). *Mayo Clin Proc*. 2007;82:448.
  254. Montori VM, Kavros SJ, Walsh EE, et al. Intermittent compression pump for nonhealing wounds in patients with limb ischemia. The Mayo Clinic experience (1998-2000). *Int Angiol*. 2002;21:360-366.
  255. Boyd ST, Fremming BA. Update on rimonabant—a selective cannabinoid CB1 antagonist. *Ann Pharmacother*. 2006;40:994.
  256. Boyd ST, Fremming BA. Rimonabant—a selective CB1 antagonist. *Ann Pharmacother*. 2005;39:684-690.
  257. Canter HI, Isci E, Erk Y. Vacuum-assisted wound closure for the management of a foot ulcer due to Buerger's disease. *J Plast Reconstr Aesthet Surg*. 2007;62:250-253.

## 第 78 章

1. Giordano JM. Surgical treatment of Takayasu's disease. *Cleve Clin J Med*. 2002;69(Suppl 2):SII146-SII148.
2. Hall S, Barr W, Lie JT, et al. Takayasu arteritis: a study of 32 North American patients. *Medicine*. 1985;64:89-99.
3. DiGiacomo V. A case of Takayasu's disease occurred over 200 years ago. *Angiology*. 1984;35:750-754.
4. Numano F. The story of Takayasu arteritis. *Rheumatology (Oxford)*. 2002;41:103-106.
5. Numano F. Introductory remarks for this special issue on Takayasu arteritis. *Heart Vessels Suppl*. 1992;7:3-5.
6. Shinmi Y. A case of Takayasu's arteritis. *Sogo Gannka*. 1942;36:1404-1410.
7. Kerr GS. Takayasu's arteritis. *Rheum Dis Clin North Am*. 1995;21:1041-1058.
8. Nasu T. Takayasu's truncoarteritis in Japan. A statistical observation of 76 autopsy cases. *Pathol Microbiol (Basel)*. 1975;43:140-146.
9. González-Gay MA, García-Porrúa C. Epidemiology of the vasculitides. *Rheum Dis Clin North Am*. 2001;27:729-749.
10. Waern AU, Andersson P, Hemmingsson A. Takayasu's arteritis: a hospital-region based study on occurrence, treatment and prognosis. *Angiology*. 1983;34:311-320.
11. Kumar S, Subramanyan R, Mandalam KR, et al. Aneurysmal form of aortoarteritis (Takayasu's disease): analysis of thirty cases. *Clin Radiol*. 1990;42:342-347.
12. Zheng D, Fan D, Liu L. Takayasu arteritis in China: a report of 530 cases. *Heart Vessels Suppl*. 1992;7:32-36.
13. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. *Ann Intern Med*. 1994;120:919-929.

14. Di Giacomo V, Meloni F, Transi MG, et al. Takayasu's disease in middle-aged women. A clinicopathologic study. *Angiology*. 1985;36:70-74.
15. Nakao K, Ikeda M, Kimata S, et al. Takayasu's arteritis. Clinical report of eighty-four cases and immunological studies of seven cases. *Circulation*. 1967;35:1141-1155.
16. Ishikawa K. Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu's arteriopathy. *J Am Coll Cardiol*. 1988;12:964-972.
17. Zheng DY, Liu LS, Fan DJ. Clinical studies in 500 patients with aortoarteritis. *Chin Med J (Engl)*. 1990;103:536-540.
18. Liang P, Tan-Ong M, Hoffman GS. Takayasu's arteritis: vascular interventions and outcomes. *J Rheumatol*. 2004;31:102-106.
19. Park MC, Lee SW, Park YB, et al. Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. *Scand J Rheumatol*. 2005;34:284-292.
20. Vanoli M, Daina E, Salvarani C, et al. Takayasu's arteritis: a study of 104 Italian patients. *Arthritis Rheum*. 2005;53:100-107.
21. Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. *Circulation*. 1994;90:1855-1860.
22. Subramanyan R, Joy J, Balakrishnan KG. Natural history of aortoarteritis (Takayasu's disease). *Circulation*. 1989;80:429-437.
23. Lupi-Herrera E, Sánchez-Torres G, Marcushamer J, et al. Takayasu's arteritis. Clinical study of 107 cases. *Am Heart J*. 1977;93:94-103.
24. Numano F. Hereditary factors of Takayasu arteritis. *Heart Vessels Suppl*. 1992;7:68-72.
25. Jeeva I, Sajid J, Ali O, et al. Atypical Takayasu arteritis: a family with five affected siblings. *Med Sci Monit*. 2007;13:CS101-CS105.
26. Isohisa I, Numano F, Maezawa H, et al. HLA-Bw52 in Takayasu disease. *Tissue Antigens*. 1978;12:246-248.
27. Numano F, Ohta N, Sasazuki T. HLA and clinical manifestations in Takayasu disease. *Jpn Circ J*. 1982;46:184-189.
28. Lee SW, Kwon OJ, Park MC, et al. HLA alleles in Korean patients with Takayasu arteritis. *Clin Exp Rheumatol*. 2007;25(1 Suppl 44):S18-S22.
29. Girona E, Yamamoto-Furusho JK, Cutiño T, et al. HLA-DR6 (possibly DRB1\*1301) is associated with susceptibility to Takayasu arteritis in Mexicans. *Heart Vessels*. 1996;11:277-280.
30. Khraishi MM, Gladman DD, Dagenais P, et al. HLA antigens in North American patients with Takayasu arteritis. *Arthritis Rheum*. 1992;35:573-575.
31. Numano F, Kobayashi Y, Maruyama Y, et al. Takayasu arteritis: clinical characteristics and the role of genetic factors in its pathogenesis. *Vasc Med*. 1996;1:227-233.
32. Korkmaz C, Zubaroglu I, Kaya T, et al. Takayasu's arteritis associated with rheumatoid arthritis: a case report and review of the literature. *Rheumatology*. 2001;40:1420-1422.
33. Saxe PA, Altman RD. Takayasu's arteritis syndrome associated with systemic lupus erythematosus. *Semin Arthritis Rheum*. 1992;21:295-305.
34. Reny JL, Paul JF, Lefèvre C, et al. Association of Takayasu's arteritis and Crohn's disease. Results of a study on 44 Takayasu patients and review of the literature. *Ann Med Interne*. 2003;154:85-90.
35. Lai KN, Chan KW, Ho CP. Glomerulonephritis associated with Takayasu's arteritis: report of three cases and review of literature. *Am J Kidney Dis*. 1986;7:197-204.
36. Chauhan SK, Singh M, Nityanand S. Reactivity of gamma/delta T cells to human 60-kd heat-shock protein and their cytotoxicity to aortic endothelial cells in Takayasu arteritis. *Arthritis Rheum*. 2007;56:2798-2802.
37. Chauhan SK, Tripathy NK, Sinha N, et al. T-cell receptor repertoire of circulating gamma delta T-cells in Takayasu's

- arteritis. *Clin Immunol.* 2006;118:243-249.
38. Chauhan SK, Tripathy NK, Nityanand S. Antigenic targets and pathogenicity of anti-aortic endothelial cell antibodies in Takayasu arteritis. *Arthritis Rheum.* 2006;54:2326-2333.
  39. Eichhorn J, Sima D, Thiele B, et al. Anti-endothelial cell antibodies in Takayasu arteritis. *Circulation.* 1996;94:2396-2401.
  40. Dhingra R, Talwar KK, Chopra P, et al. An enzyme linked immunosorbent assay for detection of anti-aorta antibodies in Takayasu arteritis patients. *Int J Cardiol.* 1993;40:237-242.
  41. Numano F, Shimamoto T. Hypersecretion of estrogen in Takayasu's disease. *Am Heart J.* 1971;81:591-596.
  42. Berginer VM, Paran E, Hirsch M, et al. Klinefelter's and Takayasu's syndromes in one patient—a pure coincidence? *Angiology.* 1983;34:170-175.
  43. Maffei S, Di Renzo M, Bova G, et al. Takayasu's arteritis: a review of the literature. *Intern Emerg Med.* 2006;1:105-112.
  44. Hotchi M. Pathological studies on Takayasu arteritis. *Heart Vessels Suppl.* 1992;7:11-17.
  45. Inder SJ, Bobryshev YV, Cherian SM, et al. Immunophenotypic analysis of the aortic wall in Takayasu's arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. *Cardiovasc Surg.* 2000;8:141-148.
  46. Numano F, Kishi Y, Tanaka A, et al. Inflammation and atherosclerosis. Atherosclerotic lesions in Takayasu arteritis. *Ann N Y Acad Sci.* 2000;902:65-76.
  47. Abularrage CJ, Slidell MB, Sidawy AN, et al. Quality of life of patients with Takayasu's arteritis. *J Vasc Surg.* 2008;47:131-137.
  48. Dabague J, Reyes PA. Takayasu arteritis in Mexico: a 38-year clinical perspective through literature review. *Int J Cardiol.* 1996;54(Suppl):S103-S109.
  49. Jain S, Kumari S, Ganguly NK, et al. Current status of Takayasu arteritis in India. *Int J Cardiol.* 1996;54(Suppl):S111-S116.
  50. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. *Arthritis Rheum.* 2007;56:1000-1009.
  51. Ueda H, Morooka S, Ito I, et al. Clinical observation of 52 cases of aortitis syndrome. *Jpn Heart J.* 1969;10:277-288.
  52. Yamato M, Lecky JW, Hiramatsu K, et al. Takayasu arteritis: radiographic and angiographic findings in 59 patients. *Radiology.* 1986;161:329-334.
  53. Cipriano PR, Silverman JF, Perlroth MG, et al. Coronary arterial narrowing in Takayasu's aortitis. *Am J Cardiol.* 1977;39:744-750.
  54. Morooka S, Tanaka S, Ohya T, et al. Mitral regurgitation associated with aortitis syndrome. *Jpn Heart J.* 1983;24:471-480.
  55. Gupta SK, Khanna MN, Lahiri TK, et al. Involvement of cardiac valves in Takayasu's arteritis. Report of seven cases. *Indian Heart J.* 1980;32:147-155.
  56. Yamada I, Shibuya H, Matsubara O, et al. Pulmonary artery disease in Takayasu's arteritis: angiographic findings. *AJR Am J Roentgenol.* 1992;159:263-269.
  57. Sharma S, Kamalakar T, Rajani M, et al. The incidence and patterns of pulmonary artery involvement in Takayasu's arteritis. *Clin Radiol.* 1990;42:177-181.
  58. Talwar KK, Chopra P, Narula J, et al. Myocardial involvement and its response to immunosuppressive therapy in nonspecific aortoarteritis (Takayasu's disease)—a study by endomyocardial biopsy. *Int J Cardiol.* 1988;21:323-334.
  59. Suwanwela N, Piyachon C. Takayasu arteritis in Thailand: clinical and imaging features. *Int J Cardiol.* 1996;54(Suppl):S117-S134.
  60. Sharma BK, Sagar S, Chugh KS, et al. Spectrum of renovascular hypertension in the young in north India: a hospital based study on occurrence and clinical features. *Angiology.* 1985;36:370-378.
  61. Chugh KS, Jain S, Sakhuja V, et al. Renovascular hypertension due to Takayasu's arteritis among Indian patients. *QJM.* 1992;85:833-843.

62. Sen PK, Kinare SG, Engineer SD, et al. The middle aortic syndrome. *Br Heart J*. 1963;25:610-618.
63. Katsumura T. A report on the diagnostic criteria and therapeutic strategy of aortitis syndrome. In: 1991 Annual Report of the Intractable Arteritis Research Committee of Japan Organized by the Ministry of Health and Welfare, Tokyo, Japan. 1991;9-12.
64. Cohen JR, Birnbaum E. Coarctation of the abdominal aorta. *J Vasc Surg*. 1988;8:160-164.
65. Connolly JE, Wilson SE, Lawrence PL, et al. Middle aortic syndrome: distal thoracic and abdominal coarctation, a disorder with multiple etiologies. *J Am Coll Surg*. 2002;194:774-781.
66. Uwabe K, Okada O, Harada M. Ascending to descending aorta bypass for middle aortic syndrome. *Circ J*. 2007;71:1162-1163.
67. Janzen J, Vuong PN, Rothenberger-Janzen K. Takayasu's arteritis and fibromuscular dysplasia as causes of acquired atypical coarctation of the aorta: retrospective analysis of seven cases. *Heart Vessels*. 1999;14:277-282.
68. Esato K, Noma F, Kurata S, et al. Mesenteric infarction in Takayasu's arteritis treated by thromboendarterectomy and intestinal resection. *Jpn J Surg*. 1982;12:130-134.
69. Nussbaum O, Bouttier S, Duchatelle JP, et al. Mesenteric infarction in Takayasu's disease. *Ann Vasc Surg*. 1990;4:117-121.
70. Robbs JV, Abdool-Carrim AT, Kadwa AM. Arterial reconstruction for non-specific arteritis (Takayasu's disease): medium to long term results. *Eur J Vasc Surg*. 1994;8:401-407.
71. Matsumura K, Hirano T, Takeda K, et al. Incidence of aneurysms in Takayasu's arteritis. *Angiology*. 1991;42:308-315.
72. Weaver FA, Yellin AE, Campen DH, et al. Surgical procedures in the management of Takayasu's arteritis. *J Vasc Surg*. 1990;12:429-437.
73. Francès C, Boissac S, Blot O, et al. Cutaneous manifestations of Takayasu arteritis. A retrospective study of 80 cases. *Dermatologica*. 1990;181:266-272.
74. Perniciaro CV, Winkelmann RK, Hunder GG. Cutaneous manifestations of Takayasu's arteritis. A clinicopathologic correlation. *J Am Acad Dermatol*. 1987;17:998-1005.
75. Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. *Arthritis Rheum*. 1990;33:1129-1134.
76. Sharma BK, Siveski-Iliskovic N, Singal PK. Takayasu arteritis may be underdiagnosed in North America. *Can J Cardiol*. 1995;11:311-316.
77. Sharma BK, Jain S, Suri S, et al. Diagnostic criteria for Takayasu arteritis. *Int J Cardiol*. 1996;54(Suppl):S141-S147.
78. Hoffman GS. Takayasu arteritis: lessons from the American National Institutes of Health experience. *Int J Cardiol*. 1996;54(Suppl):S99-S102.
79. Takai Y, Wong GG, Clark SC, et al. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. *J Immunol*. 1988;140:508-512.
80. Okada M, Kitahara M, Kishimoto S, et al. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. *J Immunol*. 1988;141:1543-1549.
81. Schall TJ, Bacon K, Toy KJ, et al. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. *Nature*. 1990;347:669-671.
82. Noris M, Daina E, Gamba S, et al. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? *Circulation*. 1990;100:55-60.
83. Matsuyama A, Sakai N, Ishigami M, et al. Matrix metalloproteinases as novel disease markers in Takayasu arteritis. *Circulation*. 2003;108:1469-1473.
84. Tripathy NK, Sinha N, Nityanand S. Interleukin-8 in Takayasu's arteritis: plasma levels and relationship with disease activity. *Clin Exp Rheumatol*. 2004;22(6 Suppl 36):S27-S30.
85. Park MC, Lee SW, Park YB, et al. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. *Rheumatology (Oxford)*. 2006;45:545-548.

86. Tripathy NK, Gupta PC, Nityanand S. High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu's arteritis. *Clin Immunol.* 2006;118:154-158.
87. Grollman JH Jr., Hanafee W. The roentgen diagnosis of Takayasu's arteritis. *Radiology.* 1964;83:387-395.
88. Park JH, Chung JW, Im JG, et al. Takayasu arteritis: evaluation of mural changes in the aorta and pulmonary artery with CT angiography. *Radiology.* 1995;196:89-93.
89. Park SH, Chung JW, Lee JW, et al. Carotid artery involvement in Takayasu's arteritis: evaluation of the activity by ultrasonography. *J Ultrasound Med.* 2001;20:371-378.
90. Taniguchi N, Itoh K, Honda M, et al. Comparative ultrasonographic and angiographic study of carotid arterial lesions in Takayasu's arteritis. *Angiology.* 1997;48:9-20.
91. Kim SY, Park JH, Chung JW, et al. Follow-up CT evaluation of the mural changes in active Takayasu arteritis. *Korean J Radiol.* 2007;8:286-294.
92. Chung JW, Kim HC, Choi YH, et al. Patterns of aortic involvement in Takayasu arteritis and its clinical implications: evaluation with spiral computed tomography angiography. *J Vasc Surg.* 2007;45:906-914.
93. Park JH, Chung JW, Lee KW, et al. CT angiography of Takayasu arteritis: comparison with conventional angiography. *J Vasc Interv Radiol.* 1997;8:393-400.
94. Choe YH, Kim DK, Koh EM, et al. Takayasu arteritis: diagnosis with MR imaging and MR angiography in acute and chronic active stages. *J Magn Reson Imaging.* 1999;10:751-757.
95. Choe YH, Lee WR. Magnetic resonance imaging diagnosis of Takayasu arteritis. *Int J Cardiol.* 1998;66(Suppl 1):S175-S179.
96. Yamada I, Nakagawa T, Himeno Y, et al. Takayasu arteritis: diagnosis with breath-hold contrast-enhanced three-dimensional MR angiography. *J Magn Reson Imaging.* 2000;11:481-487.
97. Tso E, Flamm SD, White RD, et al. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. *Arthritis Rheum.* 2002;46:1634-1642.
98. Meave A, Soto ME, Reyes PA, et al. Pre-pulseless Takayasu's arteritis evaluated with 18F-FDG positron emission tomography and gadolinium-enhanced magnetic resonance angiography. *Tex Heart Inst J.* 2007;34:466-469.
99. Webb M, Chambers A, Al-Nahhas A, et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. *Eur J Nucl Med Mol Imaging.* 2004;31:627-634.
100. Lande A, Rossi P. The value of total aortography in the diagnosis of Takayasu's arteritis. *Radiology.* 1975;114:287-297.
101. Leavitt RY, Fauci AS. Takayasu's arteritis. In: Lichtenstein LM, Fauci AS, eds. *Current Therapy in Allergy, Immunology and Rheumatology.* 4th ed. Philadelphia: BC Decker; 1992:218.
102. Ueno A, Awane Y, Wakabayashi A, et al. Successfully operated obliterative brachiocephalic arteritis (Takayasu) associated with the elongated coarctation. *Jpn Heart J.* 1967;8:538-544.
103. Ishikawa K. Natural history and classification of occlusive thromboaropathy (Takayasu's disease). *Circulation.* 1978;57:27-35.
104. Hata A, Noda M, Moriwaki R, et al. Angiographic findings of Takayasu arteritis: new classification. *Int J Cardiol.* 1996;54(Suppl):S155-S163.
105. Fields CE, Bower TC, Cooper LT, et al. Takayasu's arteritis: operative results and influence of disease activity. *J Vasc Surg.* 2006;43:64-71.
106. Fraga A, Mintz G, Valle L, et al. Takayasu's arteritis: frequency of systemic manifestations (study of 22 patients) and favorable response to maintenance steroid therapy with adrenocorticosteroids (12 patients). *Arthritis Rheum.* 1972;15:617-624.
107. Shetty AK, Stopa AR, Gedalia A. Low-dose methotrexate as a steroid-sparing agent in a child with Takayasu's arteritis. *Clin Exp Rheumatol.* 1998;16:335-336.
108. Mevorach D, Leibowitz G, Brezis M, et al. Induction of remission in a patient with Takayasu's arteritis by low dose pulses

of methotrexate. *Ann Rheum Dis.* 1992;51:904-905.

109. Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. *Arthritis Rheum.* 1994;37:578-582.
110. Shelhamer JH, Volkman DJ, Parrillo JE, et al. Takayasu's arteritis and its therapy. *Ann Intern Med.* 1985;103:121-126.
111. Ozen S, Duzova A, Bakkaloglu A, et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. *J Pediatr.* 2007;150:72-76.
112. Valsakumar AK, Valappil UC, Jorapur V, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. *J Rheumatol.* 2003;30:1793-1798.
113. Daina E, Schieppati A, Remuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. *Ann Intern Med.* 1999;130:422-426.
114. Shinjo SK, Pereira RM, Tizziani VA, et al. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. *Clin Rheumatol.* 2007;26:1871-1875.
115. Seko Y. Takayasu arteritis. In: Hoffman GS, Weyand C, eds. *Inflammatory Diseases of the Blood Vessels*. New York: Marcel Dekker; 2002:443-453.
116. Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. *Arthritis Rheum.* 2004;50:2296-2304.
117. Molloy ES, Langford CA, Clark TM, et al. Anti-tumor necrosis factor therapy in patients with refractory Takayasu's arteritis: long-term follow-up. *Ann Rheum Dis.* 2008;67:1567-1569.
118. Tanaka F, Kawakami A, Iwanaga N, et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. *Intern Med.* 2006;45:313-316.
119. Karageorgaki ZT, Mavragani CP, Papathanasiou MA, et al. Infliximab in Takayasu arteritis: a safe alternative? *Clin Rheumatol.* 2007;26:984-987.
120. Tatò F, Rieger J, Hoffmann U. Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. *Int Angiol.* 2005;24:304-307.
121. Pajari R, Hekali P, Harjola PT. Treatment of Takayasu's arteritis: an analysis of 29 operated patients. *Thorac Cardiovasc Surg.* 1986;34:176-181.
122. Sharma S, Rajani M, Kaul U, et al. Initial experience with percutaneous transluminal angioplasty in the management of Takayasu's arteritis. *Br J Radiol.* 1990;63:517-522.
123. Kumar S, Mandalam KR, Rao VR, et al. Percutaneous transluminal angioplasty in nonspecific aortoarteritis (Takayasu's disease): experience of 16 cases. *Cardiovasc Intervent Radiol.* 1989;12:321-325.
124. Tyagi S, Verma PK, Gambhir DS, et al. Early and long-term results of subclavian angioplasty in aortoarteritis (Takayasu disease): comparison with atherosclerosis. *Cardiovasc Intervent Radiol.* 1998;21:219-224.
125. Fava MP, Foradori GB, García CB, et al. Percutaneous transluminal angioplasty in patients with Takayasu arteritis: five-year experience. *J Vasc Interv Radiol.* 1993;4:649-652.
126. Park MC, Lee SW, Park YB, et al. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. *Rheumatology (Oxford).* 2006;45:600-605.
127. Sharma S, Shrivastava S, Kothari SS, et al. Influence of angiographic morphology on the acute and longer-term outcome of percutaneous transluminal angioplasty in patients with aortic stenosis due to nonspecific aortitis. *Cardiovasc Intervent Radiol.* 1994;17:147-151.
128. Nakano S, Shimazaki Y, Kaneko M, et al. Transaortic patch angioplasty for left coronary ostial stenosis in a patient with Takayasu's aortitis. *Ann Thorac Surg.* 1992;53:694-696.
129. Amano J, Suzuki A. Coronary artery involvement in Takayasu's arteritis. Collective review and guideline for surgical treatment. *J Thorac Cardiovasc Surg.* 1991;102:554-560.
130. Maksimowicz-McKinnon K, Hoffman GS. Takayasu arteritis: what is the long-term prognosis? *Rheum Dis Clin North Am.*

2007;33:777-786.

131. Weaver FA, Kumar SR, Yellin AE, et al. Renal revascularization in Takayasu arteritis-induced renal artery stenosis. *J Vasc Surg.* 2004;39:749-757.
132. Keith DS, Markey B, Schiedler M. Successful long-term stenting of an atypical descending aortic coarctation. *J Vasc Surg.* 2002;35:166-167.
133. Perrone-Filardi P, Costanzo P, Cesarano P, et al. Long abdominal aortic stenosis: a rare presentation of Takayasu arteritis treated with percutaneous stent implantation. *J Thorac Cardiovasc Surg.* 2007;133:1647-1648.
134. Heinemann MK, Ziemer G, Wahlers T, et al. Extraanatomic thoracic aortic bypass grafts: indications, techniques, and results. *Eur J Cardiothorac Surg.* 1997;11:169-175.
135. Taketani T, Miyata T, Morota T, et al. Surgical treatment of atypical aortic coarctation complicating Takayasu's arteritis—experience with 33 cases over 44 years. *J Vasc Surg.* 2005;41:597-601.
136. Pokrovsky AV, Tsereshkin DM, Golossovskaya MA. Pathology of nonspecific aortoarteritis. *Angiology.* 1980;31:549-557.
137. Miyata T, Sato O, Deguchi J, et al. Anastomotic aneurysms after surgical treatment of Takayasu's arteritis: a 40-year experience. *J Vasc Surg.* 1998;27:438-445.
138. Miyata T, Sato O, Koyama H, et al. Long-term survival after surgical treatment of patients with Takayasu's arteritis. *Circulation.* 2003;108:1474-1480.
139. Gronemeyer PS, deMello DE. Takayasu's disease with aneurysm of right common iliac artery and ilio caval fistula in a young infant: case report and review of the literature. *Pediatrics.* 1982;69:626-631.
140. Cotch MF. The socioeconomic impact of vasculitis. *Curr Opin Rheumatol.* 2000;12:20-23.
141. Ware JE Jr, Kosinski M, Gandek B. *SF-36 Health Survey: Manual and interpretation guide.* Lincoln, RI: Quality Metric Incorporated; 2000.
142. Akar S, Can G, Binicier O, et al. Quality of life in patients with Takayasu's arteritis is impaired and comparable with rheumatoid arthritis and ankylosing spondylitis patients. *Clin Rheumatol.* 2008;27:859-865.
143. Gamba S, Cicci L, Stefanov R. Quality of life in patients with unusual diseases: experience of nurses at the clinical research center for unusual diseases Aldo e Cele Daccò Assist Inferm Ric. 2003;22:144-150.

## 第 79 章

1. Brodowski W. Primares sarkom der aorta thoracica mit verbreitung des neugebildes in der unteren Korperhalfte. *Jahresb Leistung Fortschr ges Med.* 1873;8:243-246.
2. Weickert U, Puschel W, Langenscheidt P, Remberger K. Intimal sarcoma of the left iliac artery. *Histopathology.* 1998;33:286-287.
3. Novak K, Hajek M, Pesek M, Chudacek Z. Successful surgical treatment of the brachial plexus paresis in leiomyosarcoma of the subclavian artery. *Int Surg.* 1999;84:78-80.
4. Mikami Y, Manabe T, Lie JT, et al. Intramural sarcoma of the carotid artery with adventitial inflammation and fibrosis resembling "inflammatory aneurysm." *Pathol Int.* 1997;47:569-574.
5. Whyte R, Joseph M, Bennett W, et al. Angiosarcoma of the carotid artery: a case report. *Head Neck Surg.* 1988;10:264-268.
6. Gill IS, Hobart MG, Kaouk JH, et al. Leiomyosarcoma of the main renal artery treated by laparoscopic radical nephrectomy. *Urology.* 2000;56:669.
7. Rohde H, Riesener K, Buttner R, Schumpelick V. Leiomyosarcoma of the splenic artery [German]. *Chirurg.* 2001;72:844-846.
8. Kogon B, Kabeer M, Sawchuk AP, et al. Angiosarcoma presenting as an occluded popliteal artery pseudoaneurysm. *J Vasc Surg.* 1998;27:970-973.
9. Burns A, Kanhoun S, Tillman L, et al. Fibrosarcoma occurring at the site of a plastic vascular graft. *Cancer.* 1972;29:66-72.
10. O'Connell T, Fee H, Golding A. Sarcoma associated with Dacron prosthetic material. *J Thorac Cardiovasc Surg.*

- 1976;72:94-96.
11. Fehrenbacher J, Bowers W, Strate R, Pittman J. Angiosarcoma of the aorta associated with a Dacron graft. *Ann Thorac Surg.* 1981;32:297-301.
  12. Weinberg D, Maini B. Primary sarcoma of the aorta associated with a vascular prosthesis: a case report. *Cancer.* 1980;46:398-402.
  13. Weiss W, Riles T, Gouge T, Mizrachi H. Angiosarcoma at the site of a Dacron vascular prosthesis: a case report and literature review. *J Vasc Surg.* 1991;14:87-91.
  14. Oppenheimer B, Oppenheimer E, Stout A. Sarcomas induced in rats by implanting cellophane. *Proc Soc Exp Biol Med.* 1948;67:33-34.
  15. Oppenheimer B, Oppenheimer E, Stout A, et al. The latent period in carcinogenesis by plastics in rats and its relation to the presarcomatous stage. *Cancer.* 1958;11:204-212.
  16. Salm R. Primary fibrosarcoma of aorta. *Cancer.* 1972;29:73-83.
  17. Wright E, Glick A, Virmani R, Page D. Aortic intimal sarcoma with embolic metastases. *Am J Surg Pathol.* 1985;9:890-897.
  18. Morasch M, Shanik G. Tumor embolus: a case report and review of the literature. *Ann Vasc Surg.* 2003;17:210-213.
  19. Ghanem N, Riede U, Uhrmeister P, et al. Epithelioid angiosarcoma of the aorta. *Vasa.* 2002;31:269-273.
  20. Miracco C, Laurini L, Santopietro R, et al. Intimal-type primary sarcoma of the aorta: report of a case with evidence of rhabdomyosarcomatous differentiation [comment]. *Virchows Arch.* 1999;435:62-66.
  21. Neri E, Miracco C, Luzi P, et al. Intimal-type primary sarcoma of the thoracic aorta presenting as a saccular false aneurysm: report of a case with evidence of rhabdomyosarcomatous differentiation. *J Thorac Cardiovasc Surg.* 1999;118:371-372.
  22. Szekely E, Kulka J, Miklos I, Kaliszky P. Leiomyosarcomas of great vessels. *Pathol Oncol Res.* 2000;6:233-236.
  23. Yasuda T, Yamamoto S, Yamaguchi S, Ishida Y. Leiomyosarcoma of the thoracic aorta. *Jpn J Thorac Cardiovasc Surg.* 1999;47:510-513.
  24. Rhee M, Myong N, Park Y. Primary intimal sarcoma of the aorta: role of transesophageal echocardiography. *Circulation.* 2002;66:111-113.
  25. Mohsen NA, Haber M, Urrutia VC, Nunes LW. Intimal sarcoma of the aorta. *AJR Am J Roentgenol.* 2000;175:1289-1290.
  26. Mirzachi IB, Trobe JD, Deeb MG, et al. Multiple brain infarcts and Balint syndrome in aortic arch angiosarcoma. *J Neuro Ophthalmol.* 2006;26:107-112.
  27. Seelig MH, Klingler PJ, Oldenburg WA, Blackshear JL. Angiosarcoma of the aorta: report of a case and review of the literature. *J Vasc Surg.* 1998;28:732-737.
  28. Brand CU, Yawalker N, van Briel C, Hunziker T. Combined surgical and X-ray treatment for angiosarcoma of the scalp: report of a case with a favourable outcome. *Br J Dermatol.* 1996;134:763-765.
  29. Shuster TA, Dall'Olmo CA, Spadone D, Silver D. Abdominal aortic sarcoma: report of a case with long-term survival and review of the literature. *Ann Vasc Surg.* 2002;16:545-549.

## 第 80 章

1. Leriche R. Des oblitérations artérielle hautes (obliteration de la termination de l'aorte) comme cause de insufficances circulatoire des membres inferiors [abstract]. *Bull Mem Soc Chir.* 1923;49:1401.
2. DePalma RG, Levine SB, Feldman S. Preservation of erectile function after aortoiliac reconstruction. *Arch Surg.* 1978;113:958.
3. DePalma RG, Kedia K, Persky L. Surgical options in the correction of vasculogenic impotence. *Vasc Surg.* 1980;14:92.
4. Cronenwett JL, Gooch JB, Garrett HE. Internal iliac artery revascularization during aortofemoral bypass. *Arch Surg.* 1982;117:638.
5. May AG, DeWeese JA, Rob CG. Changes in sexual function following operation on the abdominal aorta. *Surgery.* 1969;65:41.



6. Process of Care Consensus Panel, position paper. The process of care model for evaluation and treatment of erectile dysfunction. *Int J Impot Res*. 1999;11:59.
7. Hultgren R, Sjogren B, Soderberg M, et al. Sexual function in women suffering from aortoiliac occlusive disease. *Eur J Vasc Endovasc Surg*. 1999;17:306.
8. Laumann EO, Nicolosi A, Glasser DB, et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. *J Urol*. 2005;173:39.
9. Brock G, Moreira ED Jr, Glasser DB, et al. Sexual disorders and associated help-seeking in Canada. *Can J Urol*. 2006;13:2953.
10. Falkensammer J, Hakaim AG, Falkensammer CE, et al. Prevalence of erectile dysfunction in vascular surgery patients. *Vasc Med*. 2007;12:17.
11. Kapur V, Schwartz ER. The relationship between erectile dysfunction and cardiovascular disease. *Rev Cardiovasc Med*. 2007;8:214.
12. Stuckey BG, Walsh JP, Ching HL, et al. Erectile dysfunction predicts generalized cardiovascular disease: evidence from a case control study. *Atherosclerosis*. 2007;94:458.
13. Brindley GS. Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis. *Br J Pharmacol*. 1986;87:495.
14. DePalma RG, Olding M, Yu GW, et al. Vascular interventions for impotence: lessons learned. *J Vasc Surg*. 1995;21:576.
15. DePalma RG. Vascular surgery for impotence: a review. *Int J Impot Res*. 1997;9:61.
16. DePalma RG, Emsellem HA, Edwards CM, et al. A screening sequence for vasculogenic impotence. *J Vasc Surg*. 1987;5:228.
17. DePalma RG, Schwab FJ, Emsellem HA, et al. Noninvasive assessment of impotence. *Surg Clin North Am*. 1990;70:119.
18. Grading Recommendations According to Evidence. *Chest*. 2006;129:124.
19. Rosen AB, DePalma RG, Victor Y. Risk factors in peripheral atherosclerosis. *Arch Surg*. 1973;107:303.
20. Berman L, Dardik A, Bradley EH, et al. Informed consent for abdominal aortic aneurysm repair: assessing variations in surgical opinion through a national survey. *J Vasc Surg*. 2008;47:287.
21. Emsellem HA, Bergsrud DW, DePalma RG, Edwards CM. Pudendal evoked potentials in the evaluation of impotence. *J Clin Neurophysiol*. 1998;5:359.
22. Fisher-Santos BL, DeDues Viera AL, dos Santos ES. Bulbocavernosus reflex and evoked potentials in evidently normal males. *Int J Impot Res*. 1994;4:A12.
23. Canning JR, Bowers LM, Lloyd FA, et al. Genital vascular insufficiency and impotence. *Surg Forum*. 1963;14:298.
24. Britt DB, Kemmerer WT, Robison JR. Penile blood flow determination by mercury strain gauge plethysmography. *Invest Urol*. 1971;8:673.
25. Abelson D. Diagnostic value of the penile pulse and blood pressure: a Doppler study of impotence in diabetics. *J Urol*. 1975;113:636.
26. Gaskell P. The importance of penile blood pressure in cases of impotence. *Can Med Assoc J*. 1971;105:1047.
27. Kempczinski RF. Role of the vascular diagnostic laboratory in the evaluation of male impotence. *Am J Surg*. 1979;138:278.
28. Merchant RF Jr, DePalma RG. Effects of femorofemoral grafts on postoperative sexual function: correlation with penile pulse volume recordings. *Surgery*. 1981;90:962.
29. Stauffer D, DePalma RG. A comparison of penile-brachial index (PBI) and penile pulse volume recordings (PVR) for diagnosis of vasculogenic impotence. *Bruit*. 1983;7:29.
30. Lue TF, Hricak H, Marich RW, Tanago EA. Vasculogenic impotence evaluated by high-resolution ultrasonography and published Doppler spectrum analysis. *Radiology*. 1985;155:777.
31. Sanchez-Ortiz RF, Broderick GA. Vascular evaluation of erectile dysfunction. In: Mulcahy JJ, ed. *Male Sexual Function: A Guide to Clinical Management*. Towata, NJ: Humana Press; 2001:167.

32. Flanigan DP, Schuler JJ, Keifer T, et al. Elimination of iatrogenic impotence and improvement of sexual dysfunction after aortoiliac revascularization. *Arch Surg*. 1982;117:544.
33. Hallbrook T, Holmquist B. Sexual disturbances following dissection of the aorta and the common iliac arteries. *J Cardiovasc Surg*. 1970;11:255.
34. Harris JD, Jepson RP. Aorto-iliac stenosis: a comparison of two procedures. *Aust J Surg*. 1965;34:211.
35. Castaneda-Zuniga WR, Smith A, Kaye K, et al. Transluminal angioplasty for treatment of vasculogenic impotence. *AJR Am J Roentgenol*. 1982;139:371.
36. Miles JR, Miles DG, Johnson G Jr. Aortoiliac operations and sexual dysfunction. *Arch Surg*. 1982;117:1177.
37. Sabri S, Cotton LT. Sexual function following aortoiliac reconstruction. *Lancet*. 1971;2:1218.
38. Spiro M, Cotton LT. Aorto-iliac thrombo-endarterectomy. *Br J Surg*. 1979;57:161.
39. Weinstein MH, Machleder HI. Sexual function after aortoiliac surgery. *Ann Surg*. 1975;181:787.
40. DePalma RG. Impotence as a complication in aortoiliac reconstruction. In: Bernhard VM, Towne JB, eds. *Complications in Vascular Surgery*. New York: Grune & Stratton; 1980:427.
41. Nevelsteen A, Beyens G, Duchateau J, Suy R. Aortofemoral reconstruction and sexual function: a prospective study. *Eur J Vasc Surg*. 1990;4:247.
42. Karkos CD, Wood A, Bruce IA, et al. Erectile dysfunction after open versus angioplasty aortoiliac procedures; a questionnaire survey. *Vasc Endovasc Surg*. 2004;38:157.
43. Tessier DJ, Stone WM, Harold KL, et al. Sexual function and quality of life in women after elective aortic surgery. *Ann Vasc Surg*. 2004;18:428.
44. Prinssen M, Buskens E, Nolthenius RP, et al. Sexual dysfunction after conventional and endovascular AAA repair: results of the DREAM trial. *J Endovasc Ther*. 2004;11:613.
45. DePalma RG. Impotence in vascular disease: relationship to vascular surgery. *Br J Surg*. 1982;69:514.
46. Fredberg U, Mouritzen C. Sexual dysfunction as a symptom of arteriosclerosis and a complication to reconstruction of the aorto-iliac segment. *J Cardiovasc Surg (Torino)*. 1988;29:148.
47. Laumann EO, Paik A, Rosen RC. The epidemiology of erectile dysfunction: results from the National Health and Social Life Survey. *Int J Impot Res*. 1999;11(Suppl):S60.
48. McCullough AR Jr. Ejaculatory disorders. In: Mulcahy JJ, ed. *Male Sexual Function: A Guide to Clinical Management*. Totowa, NJ: Humana Press; 2001:351.
49. Queral LA, Flinn WR, Bergan JJ, et al. Pelvic hemodynamics after aortoiliac reconstruction. *Surgery*. 1979;86:799.
50. Saini J, Kuczynski E, Gretz HF III, Sills ES. Supracervical hysterectomy versus total abdominal hysterectomy: perceived effects on sexual function. *BMC Women's Health*. 2002;2:1.
51. Graesslin O, Martin-Morille C, Leguillier-Armour MC, et al. Local investigation concerning psychic and sexual functioning a short time after hysterectomy. *Gynecol Obstet Fertil*. 2002;6:474.
52. Trimbo JB, Maas CP, DeRuiter MC, et al. A nerve-sparing radical hysterectomy: guidelines and feasibility in Western patients. *Int J Gynecol Cancer*. 2001;11:180.
53. Berman JR, Berman L, Lin H, Goldstein I. Female sexual dysfunction: epidemiology, physiology, and treatment. In: Mulcahy JJ, ed. *Male Sexual Function: A Guide to Clinical Management*. Totowa, NJ: Humana Press; 2001:123.
54. Ballard JL, Abou-Zamzam AM Jr, Teruya TH, et al. Retroperitoneal aortic aneurysm repair: long term follow up regarding wound complications and erectile dysfunction. *Ann Vasc Surg*. 2006;20:195.
55. van Schaik J, van Baalen JM, Visser MJT, DeRuiter MC. Nerve-preserving aortoiliac surgery: anatomical study and surgical approach. *J Vasc Surg*. 2001;33:983.
56. El-Assmy A, El-Bahnasawy MS, Dawood A, et al. Vasculogenic erectile dysfunction in renal transplant recipients—assessment of potential risk factors. *Scand J Urol Nephrol*. 2004;38:511.
57. DePalma RG. Iliac artery occlusive disease: impotence and colon ischemia. In: Moore WS, Ahn SS, eds. *Endovascular*

- Surgery*. 3rd ed. Philadelphia: WB Saunders; 2001:355.
58. Urigo F, Pischedda A, Maiore M, et al. The role of arteriography and percutaneous transluminal angioplasty in the treatment of arteriogenic impotence. *Radiol Med (Torino)*. 1994;88:80.
  59. Valji K, Bookstein JJ. Transluminal angioplasty in the treatment of arteriogenic impotence. *Cardiovasc Intervent Radiol*. 1988;11:245.
  60. Lin P, Bush RL, Chen C, et al. A prospective evaluation of hypogastric artery embolization in endovascular aortoiliac aneurysm repair. *J Vasc Surg*. 2002;36:500.
  61. Lin PH, Bush RL, Lumsden AB. Sloughing of scrotal skin subsequent to bilateral hypogastric artery embolization for endovascular aortoiliac aneurysm repair. *J Vasc Surg*. 2001;34:748.
  62. Schoder M, Zaunbauer L, Holzenbein T, et al. Internal iliac artery embolization before endovascular repair of abdominal aortic aneurysms: frequency, efficiency, and clinical results. *AJR Am J Roentgenol*. 2001;177:599.
  63. Engelke C, Elford J, Morgan RA, Belli AM. Internal iliac artery embolization with bilateral occlusion before aortoiliac aneurysm repair—clinical outcome of simultaneous and sequential intervention. *J Interv Radiol*. 2002;13:667.
  64. Zander T, Baldi S, Rabellino M, et al. Bilateral hypogastric artery occlusion in endovascular repair of abdominal aortic aneurysms and its clinical significance. *J Vasc Interv Radiol*. 2007;18:1481.
  65. Kawai M. Pelvic hemodynamics before and after aortoiliac vascular reconstruction: the significance of penile blood pressure. *Jpn J Surg*. 1988;18:514.
  66. Iliopoulos JJ, Horowitz PE, Pierce GE, et al. The critical hypogastric circulation. *Am J Surg*. 1987;154:671.
  67. Iliopoulos JJ, Hermreck AS, Thomas JH, et al. Hemodynamics of the hypogastric arterial circulation. *J Vasc Surg*. 1989;9:637.
  68. Ohshiro T, Kosaki G. Sexual function after aorto-iliac vascular reconstruction: which is more important, the internal iliac artery or hypogastric nerve? *J Cardiovasc Surg (Torino)*. 1984;25:47.
  69. Metz P, Fridmodt-Moller C, Matheisen FR. Erectile function before and after reconstructive arterial surgery in men with occlusive arterial leg disease. *Scand J Thorac Cardiovasc Surg*. 1983;17:45.
  70. Lee CW, Kaufman JA, Fan CM, et al. Clinical outcome of internal iliac occlusions during endovascular treatment of aortoiliac aneurysmal disease. *J Vasc Interv Radiol*. 2000;11:567.
  71. Whitelaw GP, Smithwick RH. Some secondary effects of sympathectomy. *N Engl J Med*. 1951;245:121.
  72. Levine SM. Marital sexual dysfunction: erectile dysfunction. *Ann Intern Med*. 1976;85:342.
  73. DePalma RG. New developments in the diagnosis and treatment of impotence. *West J Med*. 1996;164:54.
  74. Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic neurotransmission. *N Engl J Med*. 1992;326:90.
  75. Azadzi KM, Nehra A, Siroky MB. Effects of cavernosal hypoxia and oxygenation on penile erection [abstract]. *Int J Impot Res*. 1994;6(Suppl I):D4.
  76. Brock GB, Zvara P, Sioufi R, et al. Nitric oxide synthase is testosterone dependent [abstract]. *Int J Impot Res*. 1994;6(Suppl I):D42.
  77. Burnett AL. Role of nitric oxide in the physiology of erection. *Biol Reprod*. 1995;52:485.
  78. Gingell C, Ballard SA, Tang K, et al. Cyclic nucleotide phosphodiesterase and erectile function. *Int J Impot Res*. 1997;9(Suppl I):510.
  79. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implication of multiple isoforms. *Physiol Rev*. 1995;75:725.
  80. Goldstein I, Lue TE, Padma Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. *N Engl J Med*. 1998;338:1397.
  81. Padma-Nathan H, Guiliano F. Oral Pharmacotherapy. In: Mulcahy JJ, ed. *Male Sexual Function: A Guide to Clinical Management*. Totowa, NJ: Humana Press; 2001:203.
  82. Bella AJ, Deyoung LX, Al-Numi M, Brock GB. Daily administration of phosphodiesterase type 5 inhibitors for urological

- and non urological indications. *Eur Urol.* 2007;52:990.
83. Nijland E, Davis S, Laan E, Schultz WW. Female sexual satisfaction and pharmaceutical intervention: a critical review of the drug intervention studies in female sexual dysfunction. *J Sex Med.* 2006;3:763.
  84. Frank JE, Mistretta P, Will J. Diagnosis and treatment of female sexual dysfunction. *Am Fam Physician.* 2008;77:635.
  85. Clayton AH. Epidemiology and neurobiology of female sexual dysfunction. *J Sex Med.* 2007;(suppl 4):260.
  86. Hartley H. The “pinking” of the viagra culture: drug industry efforts to create and repackage sex drugs for women. *Sexualities.* 2006;9:363.
  87. Yang CC, Cao YY, Guan QY, et al. Influence of PDE5 inhibitor on MRI measurement of clitoral volume response in women with FSAD: a feasibility study of a potential technique for evaluating drug response. *Int J Impot Res.* 2008;20:105.
  88. Shabsigh R. Intracorporal therapy. In: Mulcahy JJ, ed. *Male Sexual Function: A Guide to Clinical Management.* Totowa, NJ: Humana Press; 2001:245.
  89. Hairston JC, Becher EF, McVary KT. Topical and intraurethral therapy. In: Mulcahy JJ, ed. *Male Sexual Function: A Guide to Clinical Management.* Totowa, NJ: Humana Press; 2001:225.
  90. Donatucci CF. Vacuum erection devices. In: Mulcahy JJ, ed. *Male Sexual Function: A Guide to Clinical Management.* Totowa, NJ: Humana Press; 2001:253.
  91. Wang R, Lewis RW. Penile implants: types and current indications. In: Mulcahy JJ, ed. *Male Sexual Function: A Guide to Clinical Management.* Totowa, NJ: Humana Press; 2001:263.

## 第 81 章

1. Bartus CL, Margolis DJ. Reducing the incidence of diabetic foot ulceration and amputation in diabetes. *Curr Diab Rep.* 2004;4:413.
2. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. *Lancet.* 2003;381:1545.
3. Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. *Front Biosci.* 2004;9:283.
4. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. *Wound Repair Regen.* 1996;4:411.
5. Bettinger DA, Pellicane JV, Wallace TC, et al. The role of inflammatory cytokines in wound healing: accelerated healing in endotoxin-resistant mice. *J Trauma.* 1994;36:810.
6. Gill SE, Parks WC. Metalloproteinases and their inhibitors: regulators of wound healing. *Int J Biochem Cell Biol.* 2008;40:1344.
7. Krishnamoorthy L, Morris HL, Harding KG. Specific growth factors and the healing of chronic wounds. *J Wound Care.* 2001;10:173.
8. Li J, Zhang YP, Kirsner RS. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. *Microsc Res Tech.* 2003;60:107.
9. Mace KA, Yuh DH, Paydar KZ, et al. Sustained expression of Hif-1alpha in the diabetic environment promotes angiogenesis and cutaneous wound repair. *Wound Repair Regen.* 2007;15:636.
10. Rundhaug JE. Matrix metalloproteinases and angiogenesis. *J Cell Mol Med.* 2005;9:267.
11. Raja, Sivamani K, Garcia MS, Isseroff RR. Wound re-epithelialization: modulating keratinocyte migration in wound healing. *Front Biosci.* 2007;12:2849.
12. Broughton G 2nd, Janis JE, Attinger CE. The basic science of wound healing. *Plast Reconstr Surg.* 2006;117:12S.
13. Trengrove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. *Wound Repair Regen.* 2000;8:13.
14. Trengrove NJ, Stacey MC, MacAuley S. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. *Wound Repair Regen.* 1999;7:442.
15. Ladwig GP, Robson MC, Liu R, et al. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix

- metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. *Wound Repair Regen.* 2002;10:26.
16. Drinkwater SL, Smith A, Sawyer BM, et al. Effect of venous ulcer exudates on angiogenesis in vitro. *Br J Surg.* 2002;89:709.
  17. Drinkwater SL, Burnand KG, Ding R, et al. Increased but ineffectual angiogenic drive in nonhealing venous ulcers. *J Vasc Surg.* 2003;38:1106.
  18. Palmer-Kazen U, Wariaro D, Luo F, et al. Vascular endothelial growth factor and fibroblast growth factor 2 expression in patients with critical limb ischemia. *J Vasc Surg.* 2004;39:621.
  19. Galkowska H, Wojewodzka U, Olszewski WL. Chemokines, cytokines and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. *Wound Repair Regen.* 2006;14:558.
  20. Lal BK, Saito S, Pappas PJ, et al. Altered proliferative responses of dermal fibroblasts to TGF-beta1 may contribute to chronic venous stasis ulcer. *J Vasc Surg.* 2003;37:1285.
  21. Mendez MV, Raffetto JD, Phillips T, et al. The proliferative capacity of neonatal skin fibroblasts is reduced after exposure to venous ulcer wound fluid: a potential mechanism for senescence in venous ulcers. *J Vasc Surg.* 1999;30:734.
  22. Lobmann R, Zemlin C, Motzkau M, et al. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. *J Diabetes Complications.* 2006;20:329.
  23. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. *Arch Surg.* 2002;137:822.
  24. Beidler SK, Douillet CD, Berndt DF, et al. Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy. *J Vasc Surg.* 2009;49:1013.
  25. Treiman GS, Copland S, McNamara RM, et al. Factors influencing ulcer healing in patients with combined arterial and venous insufficiency. *J Vasc Surg.* 2001;33:1158.
  26. Marston WA, Carlin RE, Passman MA, et al. Healing rates and cost efficacy of outpatient compression treatment for leg ulcers associated with venous insufficiency. *J Vasc Surg.* 1999;30:491.
  27. Marston WA, Davies SW, Armstrong B, et al. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. *J Vasc Surg.* 2006;44:108.
  28. Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. *Wound Repair Regen.* 2003;11:S1.
  29. Stanley AC, Fernandez NN, Lounsbery KM, et al. Pressure-induced cellular senescence: a mechanism linking venous hypertension to venous ulcers. *J Surg Res.* 2005;124:112.
  30. Steed DL, Donohoe D, Webster MW, et al. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. *J Am Coll Surg.* 1996;183:61.
  31. Sherman RA. Maggot versus conservative debridement therapy for the treatment of pressure ulcers. *Wound Repair Regen.* 2002;10:208.
  32. Ennis WJ, Foremann P, Mozen N, et al. Ultrasound for recalcitrant diabetic foot ulcers: results of a randomized, double-blind, controlled multicenter study. *Ostomy Wound Manage.* 2005;51:24.
  33. Marston WA, Hanft J, Norwood P, et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. *Diabetes Care.* 2003;26:1701.
  34. Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. *Diabetes Care.* 2001;24:290.
  35. Edwards R, Harding KG. Bacteria and wound healing. *Curr Opin Infect Dis.* 2004;17:91.
  36. James GA, Swogger E, Wolcott R, et al. Biofilms in chronic wounds. *Wound Repair Regen.* 2008;16:37.
  37. Robson MC, Heggors JP. Bacterial quantification of open wounds. *Mil Med.* 1969;134:19.

38. Vermeulen H, van Hattem JM, Storm-Versloot MN, Ubbink DT. Topical silver for treating infected wounds. *Cochrane Database Syst Rev*. 2007 Jan;24:CD005486.
39. Jorgensen B, Price P, Andersen KE, et al. The silver-releasing foam dressing, Contreet Foam, promotes faster healing of critically colonized venous leg ulcers: a randomized, controlled trial. *Int Wound J*. 2005;2:64.
40. Mosher BA, Cuddigan J, Thomas DR, Boudreau DM. Outcomes of 4 methods of debridement using a decision analysis methodology. *Adv Wound Care*. 1999;12:81.
41. Jull A, Waters J, Arroll B. Pentoxifylline for treatment of venous leg ulcers: a systematic review. *Lancet*. 2002;359:1550.
42. Falanga V, Fujitani RM, Diaz C, et al. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized placebo-controlled trial. *Wound Repair Regen*. 1999;7:208.
43. Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind randomized, controlled versus placebo trial in 107 patients. *Angiology*. 1997;48:77.
44. Glinski W, Chodyncka B, Roszkiewicz J, et al. Effectiveness of a micronized purified flavonoid fraction (MPFF) in the healing process of lower limb ulcers. An open multicentre study, controlled and randomized. *Minerva Cardioangiol*. 2001;49:107.
45. Gohel MS, Barwell JR, Taylor M, et al. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomized controlled trial. *BMJ*. 2007;335:83.
46. Mayberry JC, Moneta GL, Taylor LM, et al. Fifteen-year results of ambulatory compression therapy for chronic venous ulcers. *Surgery*. 1991;109:575.
47. Jones JE, Nelson EA. Skin grafting for venous leg ulcers. *Cochrane Database Syst Rev*. 2007:CD001737.
48. Streit M, Braathen LR. Apligraf—a living human skin equivalent for the treatment of chronic wounds. *Int J Artif Organs*. 2000;23:831.
49. Falanga V, Sabolinski M. A bilayered living skin construct (APIGRAF) accelerates complete closure of hard-to-heal venous ulcers. *Wound Repair Regen*. 1999;7:201.
50. Sibbald RG, Torrance GW, Walker V, et al. Cost-effectiveness of Apligraf in the treatment of venous leg ulcers. *Ostomy Wound Manage*. 2001;47:36.
51. Al-Kurdi D, Bell-Syer SE, Flemming K. Therapeutic ultrasound for venous leg ulcers. *Cochrane Database Syst Rev*. 2008:CD001180.
52. Smiell JM, Wieman TJ, Steed DL, et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. *Wound Repair Regen*. 1999;7:355.
53. Kantor J, Margolis DL. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. *Dermatol Surg*. 2001;27:347.
54. FDA Web site June 6, 2008. <www.fda.gov>
55. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. *Artif Organs*. 1997;21:1203.
56. Mansbridge J, Liu K, Patch R, et al. Three-dimensional fibroblast culture implant for the treatment of diabetic foot ulcers: metabolic activity and therapeutic range. *Tissue Engineering*. 1998;4:403.
57. Eaglstein WH. Dermagraft treatment of diabetic ulcers. *J Dermatol*. 1998;25:803.
58. Marston WA, Dermagraft Diabetic Foot Ulcer Study Group. Risk factors associated with healing chronic diabetic foot ulcers: the importance of hyperglycemia. *Ostomy Wound Manage*. 2006;52:26.
59. Telles GS, Campbell WB, Wood RF, et al. Prostaglandin E1 in severe lower limb ischaemia: a double-blind controlled trial. *Br J Surg*. 1984;71:506.
60. Altstaedt HO, Berzewski B, Breddin HK, et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. *Prostaglandins Leukot Essent Fatty Acids*.

1993;49:573.

61. Gowdak LH, Poliakova L, Li Z, et al. Induction of angiogenesis by cationic lipid-mediated VEGF165 gene transfer in the rabbit ischemic hindlimb model. *J Vasc Surg.* 2000;32:343.
62. Comerato AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase 1 trial. *J Vasc Surg.* 2002;35:930.
63. Vella A, Carlson L, Blier B, et al. Circulator boot therapy alters the natural history of ischemic limb ulceration. *Vasc Medicine.* 2000;5:21.
64. Labropoulos N, Watson WC, Mansour MA, et al. Acute effects of intermittent pneumatic compression on popliteal artery blood flow. *Arch Surg.* 1998;133:1072.
65. Morris RJ, Woodcock JP. Effects of supine intermittent compression on arterial inflow to the lower limb. *Arch Surg.* 2002;137:1269.
66. Delis KT, Husmann MW, Cheshire NJ, et al. Effects of intermittent pneumatic compression of the calf and thigh on arterial calf inflow: a study of normals, claudicants, and grafted arteriopathies. *Surgery.* 2001;129:188.
67. Delis KT, Nicolaides AN, Labropoulos N, et al. The acute effects of intermittent pneumatic foot versus calf versus simultaneous foot and calf compression on popliteal artery hemodynamics: a comparative study. *J Vasc Surg.* 2000;32:284.
68. Delis CT, Nicolaides AN, Wolfe JH, et al. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up. *J Vasc Surg.* 2000;31:650.
69. Louridas G, Sadia R, Spelay J, et al. The ArtAssist device in chronic lower limb ischemia. A pilot study. *Int Angiol.* 2002;21:28.
70. Armstrong DG, Lavery LA, Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. *Lancet.* 2005;366:1704.
71. Blume PA, Walters J, Payne W, et al. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomised controlled trial. *Diabetes Care.* 2008;31:631.
72. Apelqvist J, Armstrong DG, Lavery LA, Boulton AJ. Resource utilization and economic costs of care based on a randomized trial of vacuum-assisted closure therapy in the treatment of diabetic foot wounds. *Am J Surg.* 2008;195:782.
73. Knighton DR, Silver IA, Hunt TK. Regulation of wound-healing angiogenesis-effect of oxygen gradients and inspired oxygen concentration. *Surgery.* 1981;90:262.
74. Abidia A, Kuhan G, Bahia H, et al. Microvascular reflexes are influenced by oxygen in diabetic patients with peripheral arterial disease. *Br J Surg.* 2001;88:749.
75. Wunderlich RP, Peters EJ, Lavery LA. Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot. *Diabetes Care.* 2000;23:1551.
76. Abidia A, Laden G, Kuhan G, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomized-controlled trial. *Eur J Vasc Endovasc Surg.* 2003;25:513.
77. Kalani M, Jornwakog G, Naderi N, et al. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers. Long-term follow-up. *J Diabetes Complications.* 2002;16:153.
78. Kranke P, Bennett M, Roeckl-Wiedmann I, Debus S. Hyperbaric oxygen therapy for chronic wounds. *Cochrane Database Syst Rev.* 2004.
79. Grolman RE, Wilkerson DK, Taylor J, et al. Transcutaneous oxygen measurements predict a beneficial response to hyperbaric oxygen therapy in patients with nonhealing wounds and critical limb ischemia. *Am Surg.* 2001;67:1072.
80. Fife CE, Buyukcakil C, Otto GH, et al. The predictive value of transcutaneous oxygen tension measurement in diabetic lower extremity ulcers treated with hyperbaric oxygen therapy: a retrospective analysis of 1,144 patients. *Wound Repair Regen.* 2002;10:198.

81. Chuck AW, Hailey D, Jacobs P, Perry DC. Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers. *Int J Technol Assess Health Care*. 2008;24:178.
82. Gottrup F, Holstein P, Jorgensen B, et al. A new concept of a multidisciplinary wound healing center and a national expert function of wound healing. *Arch Surg*. 2001;136:765.

## 第 82 章

1. Carpenter N. Spondylolisthesis. *Br J Surg*. 1932;19:374-386.
2. Hodgson AR, Stock FE. Anterior spinal fusion a preliminary communication on the radical treatment of Pott's disease and Pott's paraplegia. *Br J Surg*. 1956;44:266-275.
3. Foley KT, Holly LT, Schwender JD. Minimally invasive lumbar fusion. *Spine*. 2003;28:S26-S35.
4. Bianchi C, Ballard JL, Abou-Zamzam Jr AM, Teruya TH. Anterior retroperitoneal lumbosacral spine exposure: operative technique and results. *Ann Vasc Surg*. 2003;17:137-142.
5. Bergey DL, Villavicencio AT, Goldstein T, Regan JJ. Endoscopic lateral transpsoas approach to the lumbar spine. *Spine*. 2004;29:1681-1688.
6. Kleeman TJ, Michael Ahn U, Clutterbuck WB, et al. Laparoscopic anterior lumbar interbody fusion at L4-L5: an anatomic evaluation and approach classification. *Spine*. 2002;27:1390-1395.
7. Gumbs AA, Shah RV, Yue JJ, Sumpio B. The open anterior paramedian retroperitoneal approach for spine procedures. *Arch Surg*. 2005;140:339-343.
8. Zdeblick TA, David SM. A prospective comparison of surgical approach for anterior L4-L5 fusion: laparoscopic versus mini anterior lumbar interbody fusion. *Spine*. 2000;25:2682-2687.
9. Kaiser MG, Haid RW Jr, Subach BR, et al. Comparison of the mini-open versus laparoscopic approach for anterior lumbar interbody fusion: a retrospective review. *Neurosurgery*. 2002;51:97-103; discussion 103-105.
10. Gumbs AA, Bloom ND, Bitan FD, Hanan SH. Open anterior approaches for lumbar spine procedures. *Am J Surg*. 2007;194:98-102.
11. Shen FH, Samartzis D, Khanna AJ, Anderson DG. Minimally invasive techniques for lumbar interbody fusions. *Orthop Clin North Am*. 2007;38:373-386.
12. Tiusanen H, Seitsalo S, Osterman K. Retrograde ejaculation after anterior interbody lumbar fusion. *Eur Spine J*. 1995;4:339-342.
13. Rajaraman V, Vingan R, Roth P. Visceral and vascular complications resulting from anterior lumbar interbody fusion. *J Neurosurg*. 1999;91:S60-S64.
14. Cohn EB, Ignatoff JM, Keeler TC, et al. Exposure of the anterior spine: technique and experience with 66 patients. *J Urol*. 2000;164:416-418.
15. Sasso RC, Kenneth Burkus J, LeHuec JC. Retrograde ejaculation after anterior lumbar interbody fusion: transperitoneal versus retroperitoneal exposure. *Spine*. 2003;28:1023-1026.
16. Katkhouda N, Campos GM, Mavor E. Is laparoscopic approach to lumbar spine fusion worthwhile? *Am J Surg*. 1999;178:458-461.
17. Ballard JL, Yonemoto H, Killeen JD. Cost effective aortic exposure: a retroperitoneal experience. *Ann Vasc Surg*. 2000;14:1-5.
18. Ballard JL. Anatomy and surgical exposure of the vascular system. In: Moore WS, ed. *Vascular Surgery: A Comprehensive Review*. 7th Ed. Philadelphia: W.B. Saunders; 2005:46-68.
19. Brockstein B, Johns L, Gewertz BL. Blood supply to the spinal cord: anatomic and physiologic correlations. *Ann Vasc Surg*. 1994;8:394-399.
20. Amrani DL, Diorio JP, Delmotte Y. Wound healing: role of commercial fibrin sealants. *Ann N Y Acad Sci*. 2001;936:566-579.



21. Brau S. Mini-open approach to the spine for anterior lumbar interbody fusion: description of the procedure, results and complications. *Spine J.* 2002;2:216-223.
22. Wagner WH, Regan JJ, Leary SP, et al. Access strategies for revision or explantation of the Charité lumbar artificial disc replacement. *J Vasc Surg.* 2006;44:1266-1272.

## 下卷

### 第 83 章

1. Rutherford RB. *Atlas of Vascular Surgery: Basic Techniques and Exposures*. Philadelphia: WB Saunders; 1993.
2. Henry AK. *Extensile Exposure*. 3rd Revised ed. New York: Churchill Livingstone; 1995.
3. Hoballah JJ. *Vascular Reconstructions: Anatomy, Exposures, and Techniques*. New York: Springer-Verlag; 2000.
4. Valentine RJ, Wind GG. *Anatomic Exposures in Vascular Surgery*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2003.
5. Parsons RE, Marin ML, Veith FJ, et al. Fluoroscopically assisted thromboembolectomy: an improved method for treating acute arterial occlusions. *Ann Vasc Surg.* 1996;10:201.
6. Hoballah JJ, Mohan CR, Chalmers RTA, et al. Does the geometry of a distal anastomosis affect patency? *Vasc Surg.* 1996;30:371.
7. Sotturai VS, Batson RC. Use of nonreversed, translocated saphenous vein graft. In: Bergan JJ, Yao JST, eds. *Techniques in Arterial Surgery*. Philadelphia: WB Saunders; 1990:184-191.
8. Taylor LM, Porter JM. Technique of reversed vein bypass to distal leg arteries. In: Bergan JJ, Yao JST, eds. *Techniques in Arterial Surgery*. Philadelphia: WB Saunders; 1990:109-121.
9. Kirklin JW, Barratt-Boyes BG. Ischemic heart disease. In: *Cardiac Surgery*. 2nd ed. New York: Churchill-Livingstone; 1993:309.
10. Hamsho A, Nott D, Harris PL. Prospective randomised trial of distal arteriovenous fistula as an adjunct to femoro-infrapopliteal PTFE bypass. *Eur J Vasc Endovasc Surg.* 1999;17:197-201.
11. Siegman FA. The use of the venous cuff for graft anastomosis. *Surg Gynecol Obstet.* 1979;148:930.
12. Wolfe J, Tyrell M. Venous patches, collars, and boots improve the patency rates of polytetrafluoroethylene grafts. *Adv Vasc Surg.* 1995;3:134-143.
13. Neville RF, Tempesta B, Sidawy AN. Tibial bypass for limb salvage using polytetrafluoroethylene and a distal vein patch. *J Vasc Surg.* 2001;33:266-272.
14. Taylor RS, Loh A, McFarland RJ, et al. Improved technique for polytetrafluoroethylene bypass grafting: long-term results using anastomotic vein patches. *Br J Surg.* 1992;79:348-354.
15. Miller JH, Foreman RK, Ferguson L, Faris A. Interposition vein cuff for anastomosis of prostheses to small artery. *Aust N Z J Surg.* 1984;54:283-285.

### 第 84 章

1. Gibson M, Foale R, Spyrou N, al-Kutoubi A. Retrieval of detached coating of a hydrophilic guidewire from the profunda femoris artery using an Amplatz gooseneck snare. *Cathet Cardiovasc Diagn.* 1997;42:310-312.
2. Reagan K, Matsumoto AH, Teitelbaum GP. Comparison of the hydrophilic guidewire in double- and single-wall entry needles: potential hazards. *Cathet Cardiovasc Diagn.* 1991;24:205-208.
3. Kim JK, Kang HK. Percutaneous retrieval of the peeled-off plastic coating from a guide wire. *J Vasc Intervent Radiol.* 1994;5:657-658.
4. Hessel SJ, Adams DF, Abrams HL. Complications of angiography. *Radiology.* 1981;138:273-281.
5. Illescas FF, Baker ME, McCann R, et al. CT evaluation of retroperitoneal hemorrhage associated with femoral arteriography.

- AJR Am J Roentgenol.* 1981;137:799-802.
6. Altin RS, Flicker S, Naidech HJ. Pseudoaneurysm and arteriovenous fistula after femoral artery catheterization: association with low femoral punctures. *AJR Am J Roentgenol.* 1989;152:629-631.
  7. Sidawy AN, Neville RF, Adib H, Curry KM. Femoral arteriovenous fistula following cardiac catheterization: an anatomic explanation. *Cardiovasc Surg.* 1993;1:134-137.
  8. Hunt JA, Harris JP. Is the mid-inguinale point an accurate landmark for the common femoral artery in vascular patients? *Aust N Z J Surg.* 1996;66:43-45.
  9. Rupp SB, Vogelzang RL, Nemcek AA Jr, Yungbluth MM. Relationship of the inguinal ligament to pelvic radiographic landmarks: anatomic correlation and its role in femoral arteriography. *J Vasc Intervent Radiol.* 1993;4:409-413.
  10. Grier D, Hartnell G. Percutaneous femoral artery puncture: practice and anatomy. *Br J Radiol.* 1990;63:602-604.
  11. Dotter CT, Rosch J, Robinson M. Fluoroscopic guidance in femoral artery puncture. *Radiology.* 1978;127:266-267.
  12. Hughes P, Scott C, Bodenham A. Ultrasonography of the femoral vessels in the groin: implications for vascular access. *Anaesthesia.* 2000;55:1198-1202.
  13. Wacker F, Wolf KJ, Fobbe F. Percutaneous vascular access guided by color-duplex sonography. *Eur Radiol.* 1997;7:1501-1504.
  14. Hessel SJ, Sequeira JC. Femoral artery catheterization and vessel tortuosity. *Cardiovasc Intervent Radiol.* 1981;4:80-82.
  15. Nice C, Timmons G, Bartholemew P, Uberoi R. Retrograde versus antegrade puncture for infrainguinal angioplasty. *Cardiovasc Intervent Radiol.* 2003;26:370-374.
  16. Hartnell G. An improved reversal technique from retrograde to antegrade femoral artery cannulation. *Cardiovasc Intervent Radiol.* 2003;21:512-513.
  17. Giavroglou CE. "Retroantegrade" catheterization of the branches of the femoral artery: technical note. *Cardiovasc Intervent Radiol.* 1989;12:337-339.
  18. Shenoy SS. Sidewinder catheter for conversion of retrograde into antegrade catheterization. *Cardiovasc Intervent Radiol.* 1983;6:112-113.
  19. Yilmaz S, Sindel T, Luleci E. Bilateral transpopliteal approach for treatment of complex SFA and iliac occlusions. *Eur Radiol.* 2002;12:911-914.
  20. Villas PA, Cohen G, Goyal A, et al. The merits of percutaneous transluminal angioplasty of a superficial femoral artery stenosis via a retrograde popliteal artery approach. *J Vasc Intervent Radiol.* 1999;10:325-328.
  21. Botti CF Jr, Ansel GM, Silver MJ, et al. Percutaneous retrograde tibial access in limb salvage. *J Endovasc Ther.* 2003;10:614-618.
  22. Montero-Baker M, Schmidt A, Bräunlich S, et al. Retrograde approach for complex popliteal and tibioperoneal occlusions. *J Endovasc Ther.* 2008;15:594-604.
  23. Hildick-Smith DJ, Khan ZI, Shapiro LM, Petch MC. Occasional-operator percutaneous brachial coronary arteriography: first, do no arm. *Cathet Cardiovasc Interv.* 2002;57:161-165.
  24. Andros G, Harris RW, Dulawa LB, et al. Subclavian artery catheterization: a new approach for endovascular procedures. *J Vasc Surg.* 1994;20:566-574.
  25. Westcott JL, Taylor PT. Transaxillary selective four-vessel arteriography. *Radiology.* 1972;104:277-281.
  26. McIvor J, Rhymer JC. Two hundred forty-five transaxillary arteriograms in arteriopathic patients: success rate and complications. *Clin Radiol.* 1992;45:390-394.
  27. Chitwood RW, Shepard AD, Shetty PC, et al. Surgical complications of transaxillary arteriography: a case-control study. *J Vasc Surg.* 1996;23:844-849.
  28. O'Keefe DM. Brachial plexus injury following axillary arteriography: case report and review of the literature. *J Neurosurg.* 1980;53:853-857.
  29. Armstrong PJ, Han DC, Baxter JA, et al. Complication rates of percutaneous brachial artery access in peripheral vascular

- angiography. *Ann Vasc Surg*. 2003;17:107-110.
30. Campeau L. Percutaneous radial artery approach for coronary angiography. *Cathet Cardiovasc Diagn*. 1989;16:3-7.
  31. Katz SG, Abando A. The use of closure devices. *Surg Clin N Am*. 2004;84:1267-1280.
  32. Michalis LK, Rees MR, Patsouras D, et al. A prospective randomized trial comparing the safety and efficacy of three commercially available closure devices (Angioseal, VasoSeal and Duett). *Cardiovasc Intervent Radiol*. 2002;25:423-429.
  33. Slaughter PM, Chetty R, Flintoft VF, et al. A single center randomized trial assessing use of a vascular hemostasis device vs. conventional manual compression following PTCA: what are the potential resource savings? *Cathet Cardiovasc Diagn*. 1995;34:210-214.
  34. Chamberlin JR, Lardi AB, McKeever LS, et al. Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring abciximab (ReoPro). *Cathet Cardiovasc Interv*. 1999;47:143-147.
  35. Starnes BW, O'Donnell SD, Gillespie DL, et al. Percutaneous arterial closure in peripheral vascular disease: a prospective randomized evaluation of the Perclose device. *J Vasc Surg*. 2003;38:263-271.
  36. Boston US, Panneton JM, Hofer JM, et al. Infectious and ischemic complications from percutaneous closure devices used after vascular access. *Ann Vasc Surg*. 2003;17:66-71.
  37. Mackrell PJ, Kalbaugh CA, Langan EM 3<sup>rd</sup>, et al. Can the Perclose suture-mediated closure system be used safely in patients undergoing diagnostic and therapeutic angiography to treat chronic lower extremity ischemia? *J Vasc Surg*. 2003;38:1305-1308.
  38. Singh H, Cardella JF, Cole PE, et al. Quality improvement guidelines for diagnostic arteriography. *J Vasc Intervent Radiol*. 2003;14:S283-S288.

## 第 85 章

1. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. Description of a new technic and a preliminary report of its application. *Circulation*. 1964;30:654-670.
2. Gruntzig A, Kumpe DA. Technique of percutaneous transluminal angioplasty with the Gruntzig balloon catheter. *AJR Am J Roentgenol*. 1979;132:547-552.
3. Engelke C, Sandhu C, Morgan RA, Belli AM. Using 6-mm cutting balloon angioplasty in patients with resistant peripheral artery stenosis: preliminary results. *AJR Am J Roentgenol*. 2002;179:619-623.
4. Ansel GM, Sample NS, Botti IC Jr, et al. Cutting balloon angioplasty of the popliteal and infrapopliteal vessels for symptomatic limb ischemia. *Catheter Cardiovasc Interv*. 2004;61:1-4.
5. Laird J, Jaff MR, Biamino G, et al. Cryoplasty for the treatment of femoropopliteal arterial disease: results of a prospective, multicenter registry. *J Vasc Interv Radiol*. 2005;16:1067-1073.
6. Joye JD. The clinical application of cryoplasty for infrainguinal peripheral arterial disease. *Tech Vasc Interv Radiol*. 2005;8:160-164.
7. Dotter CT. Transluminally-placed coilspring endarterial tube grafts. Long-term patency in canine popliteal artery. *Invest Radiol*. 1969;4:329-332.
8. Dotter CT, Buschmann RW, McKinney MK, Rosch J. Transluminal expandable nitinol coil stent grafting: preliminary report. *Radiology*. 1983;147:259-260.
9. Cragg A, Lund G, Rysavy J, et al. Nonsurgical placement of arterial endoprostheses: a new technique using nitinol wire. *Radiology*. 1983;147:261-263.
10. Palmaz JC, Sibbitt RR, Reuter SR, et al. Expandable intraluminal graft: a preliminary study. Work in progress. *Radiology*. 1985;156:73-77.
11. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. *N Engl J Med*. 1994;331:489-495.

12. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. *N Engl J Med*. 1994;331:496-501.
13. Leung DA, Spinosa DJ, Hagspiel KD, et al. Selection of stents for treating iliac arterial occlusive disease. *J Vasc Interv Radiol*. 2003;14:137-152.
14. Palmaz JC, Laborde JC, Rivera FJ, et al. Stenting of the iliac arteries with the Palmaz stent: experience from a multicenter trial. *Cardiovasc Intervent Radiol*. 1992;15:291-297.
15. Murphy KD, Encarnacion CE, Le VA, Palmaz JC. Iliac artery stent placement with the Palmaz stent: follow-up study. *J Vasc Interv Radiol*. 1995;6:321-329.
16. Henry M, Amor M, Ethevenot G, et al. Palmaz stent placement in iliac and femoropopliteal arteries: primary and secondary patency in 310 patients with 2-4-year follow-up. *Radiology*. 1995;197:167-174.
17. Ohki T, Marin ML, Lyon RT, et al. Ex vivo human carotid artery bifurcation stenting: correlation of lesion characteristics with embolic potential. *J Vasc Surg*. 1998;27:463-471.
18. Powell RJ, Alessi C, Nolan B, et al. Comparison of embolization protection device-specific technical difficulties during carotid artery stenting. *J Vasc Surg*. 2006;44:56-61.
19. Eskandari MK. Cerebral embolic protection. *Semin Vasc Surg*. 2005;18:95-100.
20. Iyer V, de Donato G, Deloose K, et al. The type of embolic protection does not influence the outcome in carotid artery stenting. *J Vasc Surg*. 2007;46:251-256.
21. Tubler T, Schluter M, Dirsch O, et al. Balloon-protected carotid artery stenting: relationship of periprocedural neurological complications with the size of particulate debris. *Circulation*. 2001;104:2791-2796.
22. Ohki T, Roubin GS, Veith FJ, et al. Efficacy of a filter device in the prevention of embolic events during carotid angioplasty and stenting: an ex vivo analysis. *J Vasc Surg*. 1999;30:1034-1044.
23. Muller-Hulsbeck S, Jahnke T, Liess C, et al. Comparison of various cerebral protection devices used for carotid artery stent placement: an in vitro experiment. *J Vasc Interv Radiol*. 2003;14:613-620.
24. Whitlow PL, Lylyk P, Londero H, et al. Carotid artery stenting protected with an emboli containment system. *Stroke*. 2002;33:1308-1314.
25. Macdonald S, Venables GS, Cleveland TJ, Gaines PA. Protected carotid stenting: safety and efficacy of the MedNova NeuroShield filter. *J Vasc Surg*. 2002;35:966-972.
26. Reimers B, Sievert H, Schuler GC, et al. Proximal endovascular flow blockage for cerebral protection during carotid artery stenting: results from a prospective multicenter registry. *J Endovasc Ther*. 2005;12:156-165.
27. Kindel M, Spiller P. Transient occlusion of an Angioguard protection system by massive embolization during angioplasty of a degenerated aortocoronary saphenous vein graft. *Catheter Cardiovasc Interv*. 2002;55:501-504.
28. Mauri L, Cox D, Hermiller J, et al. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. *J Am Coll Cardiol*. 2007;50:1442-1449.
29. Cremonesi A, Manetti R, Liso A, et al. Endovascular treatment of soft carotid plaques: a single-center carotid stent experience. *J Endovasc Ther*. 2006;13:190-195.
30. Parodi JC. Is flow reversal the best method of protection during carotid stenting? *J Endovasc Ther*. 2005;12:166-168; discussion 168-170.
31. Parodi JC, Schonholz C, Parodi FE, et al. Initial 200 cases of carotid artery stenting using a reversal-of-flow cerebral protection device. *J Cardiovasc Surg (Torino)*. 2007;48:117-124.
32. Adelman AG, Cohen EA, Kimball BP, et al. A comparison of directional atherectomy with balloon angioplasty for lesions of the left anterior descending coronary artery. *N Engl J Med*. 1993;329:228-233.
33. Tielbeek AV, Vroegindeweij D, Buth J, Landman GH. Comparison of balloon angioplasty and Simpson atherectomy for lesions in the femoropopliteal artery: angiographic and clinical results of a prospective randomized trial. *J Vasc Interv*

- Radiol.* 1996;7:837-844.
34. Ramaiah V, Gammon R, Kies S, et al. Midterm outcomes from the TALON Registry: treating peripherals with SilverHawk: outcomes collection. *J Endovasc Ther.* 2006;13:592-602.
  35. Scheinert D, Laird JR Jr, Schroder M, et al. Excimer laser-assisted recanalization of long, chronic superficial femoral artery occlusions. *J Endovasc Ther.* 2001;8:156-166.
  36. Visona A, Perissinotto C, Lusiani L, et al. Percutaneous excimer laser angioplasty of lower limb vessels: results of a prospective 24-month follow-up. *Angiology.* 1998;49:91-98.
  37. Laird JR, Zeller T, Gray BH, et al. Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. *J Endovasc Ther.* 2006;13:1-11.
  38. Fogarty TJ, Cranley JJ, Krause RJ, et al. A method for extraction of arterial emboli and thrombi. *Surg Gynecol Obstet.* 1963;116:241-244.
  39. Sniderman KW, Bodner L, Saddekni S, et al. Percutaneous embolectomy by transcatheter aspiration. Work in progress. *Radiology.* 1984;150:357-361.
  40. Starck EE, McDermott JC, Crummy AB, et al. Percutaneous aspiration thromboembolectomy. *Radiology.* 1985;156:61-66.
  41. Kasirajan K, Haskal ZJ, Ouriel K. The use of mechanical thrombectomy devices in the management of acute peripheral arterial occlusive disease. *J Vasc Interv Radiol.* 2001;12:405-411.
  42. Vesely TM, Hovsepian DM, Darcy MD, et al. Angioscopic observations after percutaneous thrombectomy of thrombosed hemodialysis grafts. *J Vasc Interv Radiol.* 2000;11:971-977.
  43. Bolia A, Brennan J, Bell PR. Recanalisation of femoro-popliteal occlusions: improving success rate by subintimal recanalisation. *Clin Radiol.* 1989;40:325.

## 第 86 章

1. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysm. *Ann Vasc Surg.* 1991;5:491-499.
2. Balko A, Piasecki GJ, Shah DM, et al. Transfemoral placement of intraluminal polyurethane prosthesis for abdominal aortic aneurysm. *J Surg Res.* 1986;40:305-309.
3. Lawrence DD, Chansangavej C, Wright KC, et al. Percutaneous endovascular graft: experimental evaluation. *Radiology.* 1987;163:357-360.
4. Moore WS, Rutherford RB. Transfemoral endovascular repair of abdominal aortic aneurysm: results of the North American EVT phase 1 trial. EVT Investigators. *J Vasc Surg.* 1996;23:543-553.
5. Zarins CK, White RA, Schwarten D, et al. AneuRx stent graft versus open surgical repair of abdominal aortic aneurysms: multicenter prospective clinical trial. *J Vasc Surg.* 1999;29:292-305.
6. Broeders IA, Blankensteijn JD, Wever JJ, Eikelboom BC. Mid-term fixation stability of the EndoVascular Technologies endograft. EVT Investigators. *Eur J Vasc Endovasc Surg.* 1999;18:300-307.
7. Greenberg RK, Chuter TA, Sternbergh WC III, Fearnot NE, for the Zenith Investigators. Zenith AAA endovascular graft: intermediate-term results of the US multi-center trial. *J Vasc Surg.* 2004;39:1209-1218.
8. Matsumura JS, Brewster DC, Makaroun MS, Naftel DC. A multicenter controlled trial of open versus endovascular treatment of abdominal aortic aneurysms. *J Vasc Surg.* 2003;37:262-271.
9. Carpenter JP, Endologix Investigators. Midterm results of the multicenter trial of the powerlink bifurcated system for endovascular aortic aneurysm repair. *J Vasc Surg.* 2004;40:849-859.
10. Prinssen M, Verhoeven EL, Buth J, et al. Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. *N Engl J Med.* 2004;351:1607-1618.
11. Greenhalgh RM, Brown LC, Kwong GP, et al. Comparison of endovascular aneurysm repair with open repair in patients

- with abdominal aortic aneurysm (EVAR trial 1), 30-day mortality results: randomised control trial. *Lancet*. 2004;364:843-848.
12. Schermerhorn ML, O'Malley AJ, Jhaveri A, et al. Endovascular vs open repair of abdominal aortic aneurysm in the Medicare population. *N Engl J Med*. 2008;358:464-474.
  13. Makaroun MS, Dillavou ED, Wheatley GH, Cambria RP; the Gore Investigators. Five-year results of endovascular treatment with the Gore TAG device compared with open repair of thoracic aortic aneurysms. *J Vasc Surg*. 2008;47:912-918
  14. Matsumura JS, Cambria RP, Dake MD, et al. International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft: 1 year results. *J Vasc Surg*. 2008;47:247-257.
  15. Faries PL, Briggs VL, Rhee JY, et al. Failure of endovascular aorto-aortic tube grafts; a plea for preferential use of bifurcated grafts. *J Vasc Surg*. 2002;35:868-873.
  16. York JW, Sternbergh WC III, Lepore M, Money SR. Endovascular exclusion of saccular abdominal aortic aneurysms using "Stacked" AneuRx aortic cuffs. *J Endovasc Ther*. 2002;9:295-298.
  17. Conners MS III, Sternbergh WC III, Carter G, et al. Endograft migration 1-4 years after endovascular AAA repair with the AneuRx device: a cautionary note. *J Vasc Surg*. 2002;36:476-484.
  18. Sternbergh WC III, Money SR, Greenberg RK, Chuter TAM, for the Zenith Investigators. Influence of endograft oversizing on device migration, endoleak, aneurysm shrinkage and aortic neck dilation: results from the Zenith multi-center trial. *J Vasc Surg*. 2004;39:20-25.
  19. Sternbergh WC III, Carter G, York J, et al. Aortic neck angulation predicts adverse outcome after endovascular abdominal aortic aneurysm repair. *J Vasc Surg*. 2002;35:482-486.
  20. FDA public health notification: Updated data on mortality associated with the Medtronic AneuRx stent graft system. Posted March 17, 2008. <http://www.fda.gov/cdrh/safety/031808-medtronic.html>.
  21. Fultin JJ, Farber MA, Sanchez LA, et al. Effect of challenging neck anatomy on mid-term migration rates in AneuRx endografts. *J Vasc Surg*. 2006;44:932-937.
  22. Stanley BM, Semmens JB, Mai Q, et al. Evaluation of patient selection guidelines for endoluminal AAA repair with the Zenith stent-graft: the Australasian experience. *J Endovasc Ther*. 2001;8:457-464.
  23. Haddad F, Greenberg RK, Walker E, et al. Fenestrated endovascular grafting: the renal side of the story. *J Vasc Surg*. 2005;41:181-190.
  24. Knott AW, Kalra M, Duncan AA, et al. Open repair of juxtarenal aortic aneurysms (JAA) remains a safe option in the era of fenestrated endografts. *J Vasc Surg*. 2008;47:695-701.
  25. Lee WA, Brown MP, Nelson PR, Huber TS. Total percutaneous access for endovascular aortic aneurysm repair ("preclose technique"). *J Vasc Surg*. 2007;45:1095-1101.
  26. Starnes BW, Andersen CA, Ronsivalle JA, et al. Totally percutaneous aortic aneurysm repair: experience and prudence. *J Vasc Surg*. 2006;43:270-276.
  27. Arthurs ZM, Benjamin SW, Jason P, et al. Ultrasound-guided access improves rate of access-related complication for totally percutaneous aortic aneurysm repair. *Ann Vasc Surg*. 2008;22:736-741.
  28. Abu-Ghaida AM, Clair DG, Greenberg RK, et al. Broadening the applicability of endovascular aneurysm repair: the use of iliac conduits. *J Vasc Surg*. 2002;31:1-7.
  29. Peterson BG, Matsumura JS. Internal endoconduit: an innovative technique to address unfavorable iliac artery anatomy encountered during thoracic endovascular aortic repair. *J Vasc Surg*. 2008;47:441-445.
  30. Hinchliffe RJ, Ivancev K, Sonesson B, Malina M. "Paving and cracking": an endovascular technique to facilitate the introduction of aortic stent-grafts through stenosed iliac arteries. *J Endovasc Ther*. 2007;14:630-633.
  31. Sternbergh WC III, Money SR, Yoselevitz M. External manipulation of abdominal vessels: a useful adjunct with endovascular abdominal aortic aneurysm repair. *J Vasc Surg*. 2001;33:886-887.
  32. Minion DJ, Yancey A, Patterson DE, et al. The endowedge and kilt techniques to achieve additional juxtarenal seal during

- deployment of the Gore Excluder endoprosthesis. *Ann Vasc Surg.* 2006;20:472-477.
33. Benharash P, Lee JT, Abilez OJ, et al. Iliac fixation inhibits migration of both suprarenal and infrarenal aortic endografts. *J Vasc Surg.* 2007;45:250-257.
  34. Sivamurthy N, Scheider DB, Reilly LM, et al. Adjunctive primary stenting of Zenith endograft limbs during endovascular abdominal aortic aneurysm repair: implication for limb patency. *J Vasc Surg.* 2006;43:662-670.
  35. Kim JM, Tonnessen BH, Noll ER Jr, Sternbergh WC III. A technique for increased accuracy in the placement of giant Palmaz stents for treatment of type I endoleaks following EVAR. *J Vasc Surg.* 2008;48:755-777.
  36. Kritpracha B, Pigott JP, Price CI, et al. Distal internal iliac artery embolization: a procedure to avoid. *J Vasc Surg.* 2003;37:943-948.
  37. Tefera G, Turnipseed WD, Carr SC, et al. Is coil embolization of hypogastric artery necessary during endovascular treatment of aortoiliac aneurysms? *J Vasc Surg.* 2004;18:143-146.
  38. Farahmand P, Becquemin JP, Desgranges P, et al. Is hypogastric artery embolization during endovascular aneurysm repair (EVAR) innocuous and useful? *Eur J Vasc Endovasc Surg.* 2008;35:429-435.
  39. Ziegler P, Avgerinos ED, Umscheid T, et al. Branched iliac bifurcation: 6 years experience with endovascular preservation of internal iliac artery flow. *J Vasc Surg.* 2007;46:204-210.
  40. Minion DJ, Xenos E, Sorial E, et al. The trifurcated endograft technique for hypogastric preservation during endovascular aneurysm repair. *J Vasc Surg.* 2008;47:658-661.
  41. Bergamini TM, Rachel ES, Kinney EV, et al. External iliac artery-to-internal iliac artery endograft: a novel approach to preserve pelvic inflow in aortoiliac stent grafting. *J Vasc Surg.* 2002;35:120-124.
  42. Lee WA, Nelson PR, Berceli SA, et al. Outcome after hypogastric artery bypass and embolization during endovascular aneurysm repair. *J Vasc Surg.* 2006;44:1162-1168.
  43. Veith FJ, Gargiulo NJ. Endovascular aortic repair should be the gold standard for ruptured AAAs, and all vascular surgeons should be prepared to perform them. *Perspect Vasc Surg Endovasc Ther.* 2007;19:275-282.
  44. Ockert S, Schumacher H, Bockler D, et al. Early and midterm results after open and endovascular repair of ruptured abdominal aortic aneurysms in a comparative analysis. *J Endovasc Ther.* 2007;14:324-332.
  45. Greco G, Egorova N, Anderson PL, et al. Outcomes of endovascular treatment of ruptured abdominal aortic aneurysms. *J Vasc Surg.* 2006;43:453-459.
  46. Lee WA, Hirneise CM, Tayyarah M, et al. Impact of endovascular repair on early outcomes of ruptured abdominal aortic aneurysms. *J Vasc Surg.* 2004;40:211-215.
  47. Mehta M, Taggart J, Darling RC III, et al. Establishing a protocol for endovascular treatment of ruptured abdominal aortic aneurysms: outcomes of a prospective analysis. *J Vasc Surg.* 2006;44:1-8.
  48. Moore R, Nutley M, Cina CS, et al. Improved survival after introduction of an emergency endovascular therapy protocol for ruptured abdominal aortic aneurysms. *J Vasc Surg.* 2007;45:443-450.
  49. Cheung AT, Pochettino A, McGarvey ML, et al. Strategies to manage paraplegia risk after endovascular stent repair of descending thoracic aortic aneurysms. *Ann Thorac Surg.* 2005;80:1280-1288.
  50. Riesenman PJ, Farber MA, Mendes RR, et al. Coverage of the left subclavian artery during thoracic endovascular aortic repair. *J Vasc Surg.* 2007;45:90-95.
  51. Buth J, Harris PL, Hobo R, et al. Neurologic complications associated with endovascular repair of thoracic aortic pathology: incidence and risk factors. A study from the EUROSTAR registry. *J Vasc Surg.* 2007;46:1103-1110.
  52. Reece TB, Gazoni LM, Cherry KJ, et al. Reevaluating the need for left subclavian artery revascularization with thoracic endovascular aortic repair. *Ann Thorac Surg.* 2007;84:1201-1205.
  53. Criado FJ. A percutaneous technique for preservation of arch branch patency during thoracic endovascular repair (TEVAR): retrograde catheterization and stenting. *J Endovasc Surg.* 2007;14:54-55.
  54. Baldwin ZK, Chute TA, Hiramoto JS, et al. Double-barrel technique for endovascular exclusion of an aortic arch aneurysm

- without sternotomy. *J Endovasc Ther.* 2008;15:161-165.
55. Lee WA, Brown MP, Martin TD, et al. Early results after staged hybrid repair of thoracoabdominal aortic aneurysms. *J Am Coll Surg.* 2007;205:420-431.
  56. Greenberg RK, Lytle B. Endovascular repair of thoracoabdominal aneurysms. *Circulation.* 2008;29:2288-2296
  57. Chuter TA, Rapp JH, Hiramoto JS, et al. Endovascular treatment of thoracoabdominal aortic aneurysms. *J Vasc Surg.* 2008;47:6-16.

## 第 87 章

1. Dos Santos JC. Sur la desobstruction des thromboses arterielle anciennes. *Mem Acad Chir.* 1944;73:409-411.
2. Kunlin JL. Le traitement de l'arterite oblitterante par le greffe veineuse. *Arch Mal Coeur Vaiss.* 1949;42:371-374.
3. Mannick JA. Presidential address: remembrance of things past—New England surgeons and infrainguinal reconstruction. *J Vasc Surg.* 1996;24:1-5.
4. Linton RR, Darling RC. Autogenous saphenous vein bypass grafts in femoropopliteal obliterative arterial disease. *Surgery.* 1962;51:62-73.
5. Couch NP, Wheeler HB, Hyatt DF, et al. Factors influencing limb survival after femoropopliteal reconstruction. *Arch Surg.* 1967;95:163-169.
6. Dale WA. Grafting small arteries. Experience with 19 shunts below the knee. *Arch Surg.* 1963;86:22-33.
7. Mannick JA, Hume DM. Salvage of extremities by vein graft in far-advanced peripheral vascular disease. *Surgery.* 1964;55:154-164.
8. Mannick JA, Jackson BT, Coffman JD, Hume DM. Success of bypass vein grafts in patients with isolated popliteal artery segments. *Surgery.* 1967;61:17-25.
9. Pomposelli FB, Kansal N, Hamdan AD, et al. A decade of experience with dorsalis pedis artery bypass: analysis of outcome in more than 1000 cases. *J Vasc Surg.* 2003;37:307-315.
10. Campbell DR, Hoar CS Jr, Gibbons GW. The use of arm veins in femoral-popliteal bypass grafts. *Ann Surg.* 1979;190:740-742.
11. Donaldson MC, Whittemore AD, Mannick JA. Further experience with an all-autogenous tissue policy for infrainguinal reconstruction. *J Vasc Surg.* 1993;18:41-48.
12. Berceli SA, Borovetz HS, Shepeck RA, et al. Mechanisms of vein graft atherosclerosis: LDL metabolism and endothelial actin reorganization. *J Vasc Surg.* 1991;13:336-347.
13. Kevil CG, Okayama N, Trocha SD, et al. Expression of zonula occludens and adherens junctional proteins in human venous and arterial endothelial cells: role of occludin in endothelial solute barriers. *Microcirculation.* 1998;5:197-210.
14. Davies MG, Klyachkin ML, Dalen H, et al. The integrity of experimental vein graft endothelium—implications on the etiology of early graft failure. *Eur J Vasc Surg.* 1993;7:156-165.
15. Berceli SA, Showalter DP, Shepeck RA, et al. Biomechanics of the venous wall under simulated arterial conditions. *J Biomech.* 1990;23:985-989.
16. Kouzi-Koliakos K, Kanellaki-Kyparissi M, Marinov G, et al. Prebypass histological and ultrastructural evaluation of the long saphenous vein as a predictor of early graft failure. *Cardiovasc Pathol.* 2006;15:336-346.
17. Marin ML, Veith FJ, Panetta TF, et al. Saphenous vein biopsy: a predictor of vein graft failure. *J Vasc Surg.* 1993;18:407-414.
18. Giannoukas AD, Labropoulos N, Stavridis G, et al. Pre-bypass quality assessment of the long saphenous vein wall with ultrasound and histology. *Eur J Vasc Endovasc Surg.* 1997;14:37-40.
19. Caggiati A, Bergan JJ, Gloviczki P, et al. Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus statement. *J Vasc Surg.* 2002;36:416-422.
20. Mozes G, Gloviczki P. New discoveries in anatomy and new terminology of leg veins: clinical implications. *Vasc*



*Endovasc Surg.* 2004;38:367-374.

21. Thomson H. The surgical anatomy of the superficial and perforating veins of the lower limb. *Ann R Coll Surg Engl.* 1979;61:198-205.
22. Clagett GP, Valentine RJ, Hagino RT. Autogenous aortoiliac/femoral reconstruction from superficial femoral-popliteal veins: feasibility and durability. *J Vasc Surg.* 1997;25:255-266.
23. Smith ST, Clagett GP. Femoral vein harvest for vascular reconstructions: pitfalls and tips for success. *Semin Vasc Surg.* 2008;21:35-40.
24. Veith FJ, Moss CM, Sprayregen S, Montefusco C. Preoperative saphenous venography in arterial reconstructive surgery of the lower extremity. *Surgery.* 1979;85:253-256.
25. Leopold PW, Shandall AA, Corson JD, et al. Initial experience comparing B-mode imaging and venography of the saphenous vein before in situ bypass. *Am J Surg.* 1986;152:206-210.
26. Salles-Cunha SX, Andros G, Harris RW, et al. Preoperative noninvasive assessment of arm veins to be used as bypass grafts in the lower extremities. *J Vasc Surg.* 1986;3:813-816.
27. Seeger JM, Schmidt JH, Flynn TC. Preoperative saphenous and cephalic vein mapping as an adjunct to reconstructive arterial surgery. *Ann Surg.* 1987;205:733-739.
28. Buchbinder D, Semrow C, Friedell ML, et al. B-mode ultrasonic imaging in the preoperative evaluation of saphenous vein. *Am Surg.* 1987;53:368-372.
29. Panetta TF, Marin ML, Veith FJ, et al. Unsuspected preexisting saphenous vein disease: an unrecognized cause of vein bypass failure. *J Vasc Surg.* 1992;15:102-110.
30. Meissner MH, Moneta G, Burnand K, et al. The hemodynamics and diagnosis of venous disease. *J Vasc Surg.* 2007;46(Suppl S):4S-24S.
31. Towne JB, Schmitt DD, Seabrook GR, Bandyk DF. The effect of vein diameter on patency of in situ grafts. *J Cardiovasc Surg (Torino).* 1991;32:192-196.
32. Schanzer A, Hevelone N, Owens CD, et al. Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. *J Vasc Surg.* 2007;46:1180-1190.
33. Buxton B, Lambert RP, Pitt TT. The significance of vein wall thickness and diameter in relation to the patency of femoropopliteal saphenous vein bypass grafts. *Surgery.* 1980;87:425-431.
34. Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts). *N Engl J Med.* 1976;295:420-425.
35. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). *N Engl J Med.* 1976;295:369-377.
36. Ross R. The pathogenesis of atherosclerosis—an update. *N Engl J Med.* 1986;314:488-500.
37. Conte MS, Mann MJ, Simosa HF, et al. Genetic interventions for vein bypass graft disease: a review. *J Vasc Surg.* 2002;36:1040-1052.
38. Quist WC, LoGerfo FW. Prevention of smooth muscle cell phenotypic modulation in vein grafts: a histomorphometric study. *J Vasc Surg.* 1992;16:225-231.
39. Adcock GD, Adcock OT Jr, Wheeler JR, et al. Arterialization of reversed autogenous vein grafts: quantitative light and electron microscopy of canine jugular vein grafts harvested and implanted by standard or improved techniques. *J Vasc Surg.* 1987;6:283-295.
40. Eslami MH, Gangadharan SP, Belkin M, et al. Monocyte adhesion to human vein grafts: a marker for occult intraoperative injury? *J Vasc Surg.* 2001;34:923-929.
41. Abbott WM, Wieland S, Austen WG. Structural changes during preparation of autogenous venous grafts. *Surgery.* 1974;76:1031-1040.
42. Gundry SR, Jones M, Ishihara T, Ferrans VJ. Optimal preparation techniques for human saphenous vein grafts. *Surgery.* 1980;88:785-794.
43. Gundry SR, Jones M, Ishihara T, Ferrans VJ. Intraoperative trauma to human saphenous veins: scanning electron

- microscopic comparison of preparation techniques. *Ann Thorac Surg*. 1980;30:40-47.
44. Gottlob R. The preservation of the venous endothelium by “dissection without touching” and by an atraumatic technique of vascular anastomosis. The importance for arterial and venous surgery. *Minerva Chir*. 1977;32:693-700.
  45. Taylor LM Jr, Edwards JM, Phinney ES, Porter JM. Reversed vein bypass to infrapopliteal arteries. Modern results are superior to or equivalent to in-situ bypass for patency and for vein utilization. *Ann Surg*. 1987;205:90-97.
  46. Mamode N, Scott RN. Graft type for femoro-popliteal bypass surgery. *Cochrane Database Syst Rev*. 2000;2:CD001487.
  47. Dashwood MR, Savage K, Dooley A, et al. Effect of vein graft harvesting on endothelial nitric oxide synthase and nitric oxide production. *Ann Thorac Surg*. 2005;80:939-944.
  48. Souza DS, Christofferson RH, Bomfim V, Filbey D. “No-touch” technique using saphenous vein harvested with its surrounding tissue for coronary artery bypass grafting maintains an intact endothelium. *Scand Cardiovasc J*. 1999;33:323-329.
  49. Souza DSR, Dashwood MR, Tsui JCS, et al. Improved patency in vein grafts harvested with surrounding tissue: results of a randomized study using three harvesting techniques. *Ann Thorac Surg*. 2002;73:1189-1195.
  50. Souza DSR, Johansson B, Bojo L, et al. Harvesting the saphenous vein with surrounding tissue for CABG provides long-term graft patency comparable to the left internal thoracic artery: Results of a randomized longitudinal trial. *J Thorac Cardiovasc Surg*. 2006;132:373.
  51. Ramos JR, Berger K, Mansfield PB, Sauvage LR. Histologic fate and endothelial changes of distended and nondistended vein grafts. *Ann Surg*. 1976;183:205-228.
  52. Angelini GD, Passani SL, Breckenridge IM, Newby AC. Nature and pressure dependence of damage induced by distension of human saphenous vein coronary artery bypass grafts. *Cardiovasc Res*. 1987;21:902-907.
  53. Bush HL Jr, McCabe ME, Nabseth DC. Functional injury of vein graft endothelium. Role of hypothermia and distention. *Arch Surg*. 1984;119:770-774.
  54. LoGerfo FW, Quist WC, Crawshaw HM, Haudenschild C. An improved technique for preservation of endothelial morphology in vein grafts. *Surgery*. 1981;90:1015-1024.
  55. Zhao J, Jesper Andreasen J, Yang J, et al. Manual pressure distension of the human saphenous vein changes its biomechanical properties—implication for coronary artery bypass grafting. *J Biomech*. 2007;40:2268-2276.
  56. Galea J, Armstrong J, Francis SE, et al. Alterations in c-fos expression, cell proliferation and apoptosis in pressure distended human saphenous vein. *Cardiovasc Res*. 1999;44:436-448.
  57. Sotturrai VS, Stanley JC, Fry WJ. Ultrastructure of human and transplanted canine veins: effects of different preparation media. *Surgery*. 1983;93:28-38.
  58. Cavallari N, Abebe W, Mingoli A, et al. Functional and morphological evaluation of canine veins following preservation in different storage media. *J Surg Res*. 1997;68:106-115.
  59. Cavallari N, Abebe W, Mingoli A, et al. Short-term preservation of autogenous vein grafts: effectiveness of University of Wisconsin solution. *Surgery*. 1997;121:64-71.
  60. LoGerfo FW, Quist WC, Cantelmo NL, Haudenschild CC. Integrity of vein grafts as a function of initial intimal and medial preservation. *Circulation*. 1983;68:III17-III24.
  61. Lawrie GM, Weilbacher DE, Henry PD. Endothelium-dependent relaxation in human saphenous vein grafts. Effects of preparation and clinicopathologic correlations. *J Thorac Cardiovasc Surg*. 1990;100:612-620.
  62. Cook JM, Cook CD, Marlar R, et al. Thrombomodulin activity on human saphenous vein grafts prepared for coronary artery bypass. *J Vasc Surg*. 1991;14:147-151.
  63. Bush J, McCabe ME, Nabseth DC. Functional injury of vein graft endothelium. Role of hypothermia and distention. *Arch Surg*. 1984;119:770-774.
  64. LoGerfo FW, Haudenschild CC, Quist WC. A clinical technique for prevention of spasm and preservation of endothelium in saphenous vein grafts. *Arch Surg*. 1984;119:1212-1214.

65. Adcock OT Jr, Adcock GL, Wheeler JR, et al. Optimal techniques for harvesting and preparation of reversed autogenous vein grafts for use as arterial substitutes: a review. *Surgery*. 1984;96:886-894.
66. Roubos N, Rosenfeldt FL, Richards SM, et al. Improved preservation of saphenous vein grafts by the use of glyceryl trinitrate-verapamil solution during harvesting. *Circulation*. 1995;92:31-36.
67. Reifsnnyder T, Bandyk D, Seabrook G, et al. Wound complications of the in situ saphenous vein bypass technique. *J Vasc Surg*. 1992;15:843-848.
68. Wengrovitz M, Atnip RG, Gifford RR, et al. Wound complications of autogenous subcutaneous infrainguinal arterial bypass surgery: predisposing factors and management. *J Vasc Surg*. 1990;11:156-161.
69. Kiaii B, Moon BC, Massel D, et al. A prospective randomized trial of endoscopic versus conventional harvesting of the saphenous vein in coronary artery bypass surgery. *J Thorac Cardiovasc Surg*. 2002;123:204-212.
70. Wang S, Tang H, Wilkinson V, et al. Saphenous vein harvest with SaphLITE system versus conventional technique: a prospective, randomized study. *Ann Thorac Surg*. 2005;79:2018-2023.
71. Yun KL, Wu Y, Aharonian V, et al. Randomized trial of endoscopic versus open vein harvest for coronary artery bypass grafting: six-month patency rates. *J Thorac Cardiovasc Surg*. 2005;129:496-503.
72. Fabricius AM, Diegeler A, Doll N, et al. Minimally invasive saphenous vein harvesting techniques: morphology and postoperative outcome. *Ann Thorac Surg*. 2000;70:473-478.
73. Meyer DM, Rogers TE, Jessen ME, et al. Histologic evidence of the safety of endoscopic saphenous vein graft preparation. *Ann Thorac Surg*. 2000;70:487-491.
74. Erdoes LS, Milner TP. Encouraging results with endoscopic vein harvest for infrainguinal bypass. *J Vasc Surg*. 2005;42:442-448.
75. Gazoni LM, Carty R, Skinner J, et al. Endoscopic versus open saphenous vein harvest for femoral to below the knee arterial bypass using saphenous vein graft. *J Vasc Surg*. 2006;44:282-287.
76. Illig KA, Rhodes JM, Sternbach Y, Green RM. Financial impact of endoscopic vein harvest for infrainguinal bypass. *J Vasc Surg*. 2003;37:323-330.
77. Jordan WD Jr, Alcocer F, Voellinger DC, Wirthlin DJ. The durability of endoscopic saphenous vein grafts: a 5-year observational study. *J Vasc Surg*. 2001;34:434-439.
78. Pullatt R, Brothers TE, Robison JG, Elliott BM. Compromised bypass graft outcomes after minimal-incision vein harvest. *J Vasc Surg*. 2006;44:289-294.
79. Erdoes LS. Endoscopic vein harvest in peripheral vascular surgery. *J Vasc Surg*. 2006;44:417-418.
80. Jimenez JC, Lawrence PF, Rigberg DA, Quinones-Baldrich WJ. Technical modifications in endoscopic vein harvest techniques facilitate their use in lower extremity limb salvage procedures. *J Vasc Surg*. 2007;45:549-553.
81. Holzenbein TJ, Pomposelli FB Jr, Miller A, et al. Results of a policy with arm veins used as the first alternative to an unavailable ipsilateral greater saphenous vein for infrainguinal bypass. *J Vasc Surg*. 1996;23:130-140.
82. Chew DK, Owens CD, Belkin M, et al. Bypass in the absence of ipsilateral greater saphenous vein: safety and superiority of the contralateral greater saphenous vein. *J Vasc Surg*. 2002;35:1085-1092.
83. Poletti LF, Matsuura JH, Dattilo JB, et al. Should vein be saved for future operations? A 15-year review of infrainguinal bypasses and the subsequent need for autogenous vein. *Ann Vasc Surg*. 1998;12:143-147.
84. Robin C, Lermusiaux P, Bleuet F, Martinez R. Distal bypass for limb salvage: should the contralateral great saphenous vein be harvested? *Ann Vasc Surg*. 2006;20:761-766.
85. Tarry WC, Walsh DB, Birkmeyer NJO, et al. Fate of the contralateral leg after infrainguinal bypass. *J Vasc Surg*. 1998;27:1039-1048.
86. Masser PA, Taylor LM Jr, Moneta GL, Porter JM. Technique of reversed vein bypass for lower extremity ischemia. *Ann Vasc Surg*. 1996;10:190-200.
87. Armstrong PA, Bandyk DF, Wilson JS, et al. Optimizing infrainguinal arm vein bypass patency with duplex ultrasound

- surveillance and endovascular therapy. *J Vasc Surg.* 2004;40:724-731.
88. Belkin M, Conte MS, Donaldson MC, et al. Preferred strategies for secondary infrainguinal bypass: lessons learned from 300 consecutive reoperations. *J Vasc Surg.* 1995;21:282-293.
  89. Faries PL, LoGerfo FW, Arora S, et al. A comparative study of alternative conduits for lower extremity revascularization: all-autogenous conduit versus prosthetic grafts. *J Vasc Surg.* 2000;32:1080-1090.
  90. Faries PL, Arora S, Pomposelli FB Jr, et al. The use of arm vein in lower-extremity revascularization: results of 520 procedures performed in eight years. *J Vasc Surg.* 2000;31:50-59.
  91. Kent KC, Whittemore AD, Mannick JA. Short-term and midterm results of an all-autogenous tissue policy for infrainguinal reconstruction. *J Vasc Surg.* 1989;9:107-114.
  92. Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. *J Vasc Surg.* 2006;43:742-751.
  93. Mills JL, Fujitani RM, Taylor SM. The characteristics and anatomic distribution of lesions that cause reversed vein graft failure: a five-year prospective study. *J Vasc Surg.* 1993;17:195-204.
  94. McCaughan JJ Jr, Walsh DB, Edgcomb LP, Garrett HE. In vitro observations of greater saphenous vein valves during pulsatile and nonpulsatile flow and following lysis. *J Vasc Surg.* 1984;1:356-361.
  95. Chin AK, Mayer DN, Goldman RK, et al. The effect of valvulotomy on the flow rate through the saphenous vein graft: clinical implications. *J Vasc Surg.* 1988;8:316-320.
  96. Ku DN, Klapft JM, Gewertz BL, Zarins CK. The contribution of valves to saphenous vein graft resistance. *J Vasc Surg.* 1987;6:274-279.
  97. Walsh DB, Downing S, Ahmed SW, Wallace RB. Valvular obstruction of blood flow through saphenous veins. *J Surg Res.* 1987;42:39-42.
  98. Tullis MJ, Primozech J, Strandness DE Jr. Detection of "functional" valves in reversed saphenous vein bypass grafts: identification with duplex ultrasonography. *J Vasc Surg.* 1997;25:522-527.
  99. Vesti BR, Primozech J, Bergelin RO, Strandness DE Jr. Follow-up of valves in saphenous vein bypass grafts with duplex ultrasonography. *J Vasc Surg.* 2001;33:369-374.
  100. Vantinen E, Inberg MV, Scheinin TM. Femoropopliteal and femorotibial arterial reconstructive surgery. Special reference to the autogenous venous bypass procedure using unreversed vein after eversion valvectomy. *Acta Chir Scand.* 1975;141:341-352.
  101. Banz M, Stierli P, Aeberhard P. Infrainguinal arterial reconstruction with non-reversed autologous vein after angioscopy guided valvulotomy ex situ. *Eur J Vasc Endovasc Surg.* 1995;10:211-214.
  102. Neale ML, Graham JC, Lane RJ, et al. The influence of graft type on patency of infrainguinal arterial bypass grafts. *J Am Coll Surg.* 1994;178:155-163.
  103. Belkin M, Knox J, Donaldson MC, et al. Infrainguinal arterial reconstruction with nonreversed greater saphenous vein. *J Vasc Surg.* 1996;24:957-962.
  104. Stierli P, Banz M, Wigger P, Aeberhard P. Angioscopy guided in situ bypass versus angioscopy guided non reversed bypass for infrainguinal arterial reconstructions. A comparison of outcome. *J Cardiovasc Surg (Torino).* 1995;36:211-217.
  105. May AG, DeWesse JA, Rob CG. Arterialized in situ saphenous vein. *Arch Surg.* 1965;91:743-750.
  106. Hall KV. The great saphenous vein used in situ as an arterial shunt after extirpation of the vein valves. A preliminary report. *Surgery.* 1962;51:492-495.
  107. Leather RP, Powers SR, Karmody AM. A reappraisal of the in situ saphenous vein arterial bypass: its use in limb salvage. *Surgery.* 1979;86:453-461.
  108. Leather RP, Shah DM, Buchbinder D, et al. Further experience with the saphenous vein used in situ for arterial bypass. *Am J Surg.* 1981;142:506-510.
  109. Wengerter KR, Veith FJ, Gupta SK, et al. Prospective randomized multicenter comparison of in situ and reversed vein

- infrapopliteal bypasses. *J Vasc Surg.* 1991;13:189-197.
110. Jackson ZS, Gotlieb AI, Langille BL. Wall tissue remodeling regulates longitudinal tension in arteries. *Circ Res.* 2002;90:918-925.
  111. Veith FJ, Gupta SK, Wengerter KR, Farrell E. Short vein grafts in limb-saving arterial reconstructions. *J Vasc Interv Radiol.* 1990;1:57-61.
  112. Mills NL, Ochsner JL. Valvulotomy of valves in the saphenous vein graft before coronary artery bypass. *J Thorac Cardiovasc Surg.* 1976;71:878-879.
  113. LeMaitre GD, Arakelian MJ. In situ grafting made easy. Modification of a technique. *Arch Surg.* 1988;123:101-103.
  114. Skagseth E, Hall KV. In situ vein bypass. Experiences with new vein valve strippers. *Scand J Thorac Cardiovasc Surg.* 1973;7:53-58.
  115. Leather RP, Shah DM, Corson JD, Karmody AM. Instrumental evolution of the valve incision method of in situ saphenous vein bypass. *J Vasc Surg.* 1984;1:113-123.
  116. Alback A, Kantonen I, Ihlberg L, Lepantalo M. Valvulotomy of non-reversed saphenous vein bypass grafts: a randomised, blinded, angioscopy-controlled study. *Eur J Vasc Endovasc Surg.* 1999;18:144-148.
  117. Parent FN III, Gandhi RH, Wheeler JR, et al. Angioscopic evaluation of valvular disruption during in situ saphenous vein bypass. *Ann Vasc Surg.* 1994;8:24-30.
  118. Malmstedt J, Takolander R, Wahlberg E. A randomized prospective study of valvulotomy efficacy in in situ reconstructions. *Eur J Vasc Endovasc Surg.* 2005;30:52-56.
  119. Gilbertson JJ, Walsh DB, Zwolak RM, et al. A blinded comparison of angiography, angioscopy, and duplex scanning in the intraoperative evaluation of in situ saphenous vein bypass grafts. *J Vasc Surg.* 1992;15:121-127.
  120. Clair DG, Golden MA, Mannick JA, et al. Randomized prospective study of angioscopically assisted in situ saphenous vein grafting. *J Vasc Surg.* 1994;19:992-999.
  121. Maini BS, Andrews L, Salimi T, et al. A modified, angioscopically assisted technique for in situ saphenous vein bypass: impact on patency, complications, and length of stay. *J Vasc Surg.* 1993;17:1041-1047.
  122. Sales CM, Goldsmith J, Veith FJ. Prospective study of the value of prebypass saphenous vein angioscopy. *Am J Surg.* 1995;170:106-108.
  123. Wilson YG, Davies AH, Currie IC, et al. Angioscopically-assisted in situ saphenous vein bypass for infrainguinal revascularisation. *Eur J Vasc Endovasc Surg.* 1996;12:223-229.
  124. Lundell A, Nyborg K. Do residual arteriovenous fistulae after in situ saphenous vein bypass grafting influence patency? *J Vasc Surg.* 1999;30:99-105.
  125. van Dijk LC, van Urk H, Lam éris JS, Wittens CH. Residual arteriovenous fistulae after "closed" in situ bypass grafting: an overrated problem. *Eur J Vasc Endovasc Surg.* 1997;13:439-442.
  126. Rosenthal D, Herring MB, O'Donovan TG, et al. Endovascular infrainguinal in situ saphenous vein bypass: a multicenter preliminary report. *J Vasc Surg.* 1992;16:453-458.
  127. van Dijk LC, van Urk H, du Bois NA, et al. A new "closed" in situ vein bypass technique results in a reduced wound complication rate. *Eur J Vasc Endovasc Surg.* 1995;10:162-167.
  128. Taylor LM Jr, Edwards JM, Porter JM. Present status of reversed vein bypass grafting: five-year results of a modern series. *J Vasc Surg.* 1990;11:193-205.
  129. Faries PL, LoGerfo FW, Arora S, et al. Arm vein conduit is superior to composite prosthetic-autogenous grafts in lower extremity revascularization. *J Vasc Surg.* 2000;31:1119-1127.
  130. Holzenbein TJ, Pomposelli FB, Miller A, et al. The upper arm basilic-cephalic loop for distal bypass grafting: technical considerations and follow-up. *J Vasc Surg.* 1995;21:586-594.
  131. LoGerfo FW, Paniszyn CW, Menzoian J. A new arm vein graft for distal bypass. *J Vasc Surg.* 1987;5:889-891.
  132. Marcaccio EJ, Miller A, Tannenbaum GA, et al. Angioscopically directed interventions improve arm vein bypass grafts. *J*

*Vasc Surg.* 1993;17:994-1002.

133. Seeger JM, Pretus HA, Carlton LC, et al. Potential predictors of outcome in patients with tissue loss who undergo infrainguinal vein bypass grafting. *J Vasc Surg.* 1999;30:427-435.
134. Conte MS, Lorenz TJ, Bandyk DF, et al. Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure. *Vasc Endovasc Surg.* 2005;39:15-23.
135. Alback A, Biancari F, Saarinen O, Lepantalo M. Prediction of the immediate outcome of femoropopliteal saphenous vein bypass by angiographic runoff score. *Eur J Vasc Endovasc Surg.* 1998;15:220-224.
136. Blankensteijn JD, Gertler JP, Brewster DC, et al. Intraoperative determinants of infrainguinal bypass graft patency: a prospective study. *Eur J Vasc Endovasc Surg.* 1995;9:375-382.
137. Taylor LM Jr, Chitwood RW, Dalman RL, et al. Antiphospholipid antibodies in vascular surgery patients. A cross-sectional study. *Ann Surg.* 1994;220:544-550.
138. Berceli SA, Hevelone ND, Lipsitz SR, et al. Surgical and endovascular revision of infrainguinal vein bypass grafts: analysis of midterm outcomes from the PREVENT III trial. *J Vasc Surg.* 2007;46:1173-1179.
139. Szilagyi DE, Elliott JP, Hageman JH, et al. Biologic fate of autogenous vein implants as arterial substitutes: clinical, angiographic and histopathologic observations in femoro-popliteal operations for atherosclerosis. *Ann Surg.* 1973;178:232-246.
140. Roddy SP, Darling RC, Maharaj D, et al. Gender-related differences in outcome: an analysis of 5880 infrainguinal arterial reconstructions. *J Vasc Surg.* 2003;37:399-402.
141. Glagov S, Bassiouny HS, Sakaguchi Y, et al. Mechanical determinants of plaque modeling, remodeling and disruption. *Atherosclerosis.* 1997;(Suppl 131):S13-S14.
142. Owens CD, Wake N, Jacot JG, et al. Early biomechanical changes in lower extremity vein grafts—distinct temporal phases of remodeling and wall stiffness. *J Vasc Surg.* 2006;44:740-746.
143. Owens CD, Rybicki FJ, Wake N, et al. Early remodeling of lower extremity vein grafts: inflammation influences biomechanical adaptation. *J Vasc Surg.* 2008;47:1235-1242.
144. Bulkley BH, Hutchins GM. Accelerated “atherosclerosis.” A morphologic study of 97 saphenous vein coronary artery bypass grafts. *Circulation.* 1977;55:163-169.
145. Garratt KN, Edwards WD, Kaufmann UP, et al. Differential histopathology of primary atherosclerotic and restenotic lesions in coronary-arteries and saphenous-vein bypass grafts—analysis of tissue obtained from 73 patients by directional atherectomy. *J Am Coll Cardiol.* 1991;17:442-448.
146. Kalan JM, Roberts WC. Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1 year: necropsy analysis of 53 patients, 123 saphenous veins, and 1865 five-millimeter segments of veins. *Am Heart J.* 1990;119:1164-1184.
147. Walts AE, Fishbein MC, Sustaita H, Matloff JM. Ruptured atheromatous plaques in saphenous vein coronary artery bypass grafts: a mechanism of acute, thrombotic, late graft occlusion. *Circulation.* 1982;65:197-201.
148. Pregowski J, Tyczynski P, Mintz GS, et al. Incidence and clinical correlates of ruptured plaques in saphenous vein grafts: an intravascular ultrasound study. *J Am Coll Cardiol.* 2005;45:1974-1979.
149. Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial. *Circulation.* 2000;102:157-165.
150. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. *Circulation.* 1998;97:916-931.
151. Shah SJ, Waters DD, Barter P, et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. *J Am Coll Cardiol.* 2008;51:1938-1943.
152. Walton KW, Slaney G, Ashton F. Atherosclerosis in vascular grafts for peripheral vascular disease. Part 1. Autogenous

vein grafts. *Atherosclerosis*. 1985;54:49-64.

153. Nielsen TG, Laursen H, Gronholdt MLM, Schroeder TV. Histopathological features of in situ vein bypass stenoses. *Eur J Vasc Endovasc Surg*. 1997;14:492-498.
154. Mann MJ, Gibbons GH, Kernoff RS, et al. Genetic-engineering of vein grafts resistant to atherosclerosis. *Proc Natl Acad Sci U S A*. 1995;92:4502-4506.
155. Mann MJ. Novel strategies for the prevention of bypass graft failure. *Biodrugs*. 2004;18:1-8.
156. Stept LL, Flinn WR, Carthyl WJ III. Technical defects as a cause of early graft failure after femorodistal bypass. *Arch Surg*. 1987;122:599-604.
157. Walsh DB, Zwolak RM, McDaniel MD, et al. Intraoperative drug infusion as an adjunct to balloon catheter thrombectomy for salvage of thrombosed infragenic vein grafts: a preliminary report. *J Vasc Surg*. 1990;11:753-759.
158. Johnson BL, Bandyk DF, Back MR, et al. Intraoperative duplex monitoring of infrainguinal vein bypass procedures. *J Vasc Surg*. 2000;31:678-690.
159. Robinson KD, Sato DT, Gregory RT, et al. Long-term outcome after early infrainguinal graft failure. *J Vasc Surg*. 1997;26:425-438.
160. Liebman PR, Menzoian JO, Mannick JA, et al. Intraoperative arteriography in femoropopliteal and femorotibial bypass grafts. *Arch Surg*. 1981;116:1019-1021.
161. Sato O, Miyata T, Deguchi JO, et al. Completion arteriography paramalleolar bypasses: effect of configurational changes, with special reference to spasm, on long-term outcome. *Int Angiol*. 1996;15:219-224.
162. Sugawara Y, Sato O, Miyata T, et al. Significance of arterial defects on completion arteriograms following infrainguinal bypasses. *Vasc Surg*. 1998;32:33-41.
163. Samson RH, Gupta SK, Scher LA, Veith FJ. Arterial spasm complicating distal vascular bypass procedures. *Arch Surg*. 1982;117:973-975.
164. Mills JL, Fujitani RM, Taylor SM, Burch JM. Contribution of routine intraoperative completion arteriography to early infrainguinal bypass patency. *Am J Surg*. 1992;164:506-511.
165. Dalman RL, Harris EJ, Zarins CK. Is completion arteriography mandatory after reversed-vein bypass grafting? *J Vasc Surg*. 1996;23:637-644.
166. Schwierz T, Harnoncourt F, Havlicek W, et al. Interpretation of the results of Doppler ultrasound flow volume measurements of infrainguinal vein bypasses. *Eur J Vasc Endovasc Surg*. 2005;29:452-456.
167. Wolfle KD, Bruijnen H, Morski A, et al. The importance of graft blood flow and peripheral outflow resistance for early patency in infrainguinal arterial reconstructions. *Vasa*. 1999;28:34-41.
168. Alback A, Roth WD, Ihlberg L, et al. Preoperative angiographic score and intraoperative flow as predictors of the mid-term patency of infrapopliteal bypass grafts. *Eur J Vasc Endovasc Surg*. 2000;20:447-453.
169. Stirnemann P, Ris HB, Do D, Hammerli R. Intraoperative flow measurement of distal runoff: a valid predictor of outcome of infrainguinal bypass surgery. *Eur J Surg Acta Chir*. 1994;160:431-436.
170. Ihlberg LHM, Albäck NA, Lassila R, Lepäntalo M. Intraoperative flow predicts the development of stenosis in infrainguinal vein grafts. *J Vasc Surg*. 2001;34:269-276.
171. Brennan JA, Thrush AJ, Evans DH, Bell PRF. Perioperative monitoring of blood flow in femoroinfragenic vein grafts with Doppler ultrasonography: a preliminary report. *J Vasc Surg*. 1991;13:468-474.
172. Schwartz LB, Belkin M, Donaldson MC, et al. Validation of a new and specific intraoperative measurement of vein graft resistance. *J Vasc Surg*. 1997;25:1033-1043.
173. Bandyk DF, Jorgensen RA, Towne JB. Intraoperative assessment of in situ saphenous vein arterial grafts using pulsed Doppler spectral analysis. *Arch Surg*. 1986;121:292-299.
174. Bandyk DF, Mills JL, Gahtan V, et al. Intraoperative duplex scanning of arterial reconstructions: fate of repaired and unrepaired defects. *J Vasc Surg*. 1994;20:426-433.

175. Papanicolaou G, Aziz I, Yellin AE, Weaver FA. Intraoperative color duplex scanning for infrainguinal vein grafts. *Ann Vasc Surg.* 1996;10:347-355.
176. Sawaqed RS, Podbielski FJ, Rodriguez HE, et al. Prospective comparison of intraoperative angiography with duplex scanning in evaluating lower-extremity bypass grafts in a community hospital. *Am Surg.* 2001;67:601-604.
177. Bandyk DF, Johnson BL, Gupta AK, Esses GE. Nature and management of duplex abnormalities encountered during infrainguinal vein bypass grafting. *J Vasc Surg.* 1996;24:430-438.
178. Rzucidlo EM, Walsh DB, Powell RJ, et al. Prediction of early graft failure with intraoperative completion duplex ultrasound scan. *J Vasc Surg.* 2002;36:975-981.
179. Baxter BT, Rizzo RJ, Flinn WR, et al. A comparative study of intraoperative angioscopy and completion arteriography following femorodistal bypass. *Arch Surg.* 1990;125:997-1002.
180. Woelfle KD, Kugelmann U, Bruijnen H, et al. Intraoperative imaging techniques in infrainguinal arterial bypass grafting: completion angiography versus vascular endoscopy. *Eur J Vasc Surg.* 1994;8:556-561.
181. Miller A, Marcaccio EJ, Tannenbaum GA, et al. Comparison of angioscopy and angiography for monitoring infrainguinal bypass vein grafts: results of a prospective randomized trial. *J Vasc Surg.* 1993;17:382-398.
182. Eagleton MJ, Erez O, Srivastava SD, et al. Outcome of surgical and endoluminal intervention for infrainguinal bypass anastomotic strictures. *Vasc Endovasc Surg.* 2006;40:11-22.
183. Caps MT, Cantwell-Gab K, Bergelin RO, Strandness DE Jr. Vein graft lesions: time of onset and rate of progression. *J Vasc Surg.* 1995;22:466-474.
184. Ihlberg LHM, Mätzke S, Albäck NA, et al. Transfer function index of pulse volume recordings: a new method for vein graft surveillance. *J Vasc Surg.* 2001;33:546-553.
185. Bandyk DF, Seabrook GR, Moldenhauer P, et al. Hemodynamics of vein graft stenosis. *J Vasc Surg.* 1988;8:688-695.
186. Bandyk DF, Cato RF, Towne JB. A low flow velocity predicts failure of femoropopliteal and femorotibial bypass grafts. *Surgery.* 1985;98:799-809.
187. Mills JL, Harris EJ, Taylor LM Jr, et al. The importance of routine surveillance of distal bypass grafts with duplex scanning: a study of 379 reversed vein grafts. *J Vasc Surg.* 1990;12:379-386.
188. Grigg MJ, Nicolaides AN, Wolfe JH. Detection and grading of femorodistal vein graft stenoses: duplex velocity measurements compared with angiography. *J Vasc Surg.* 1988;8:661-666.
189. Sladen JG, Reid JD, Cooperberg PL, et al. Color flow duplex screening of infrainguinal grafts combining low- and high-velocity criteria. *Am J Surg.* 1989;158:107-112.
190. Bandyk DF. Infrainguinal vein bypass graft surveillance: how to do it, when to intervene, and is it cost-effective? *J Am Coll Surg.* 2002;194(Suppl 1):S40-S50.
191. Gahtan V, Payne LP, Roper LD, et al. Duplex criteria for predicting progression of vein graft lesions: which stenoses can be followed? *J Vasc Technol.* 1995;19:211-215.
192. Mills JL, Wixon CL, James DC, et al. The natural history of intermediate and critical vein graft stenosis: recommendations for continued surveillance or repair. *J Vasc Surg.* 2001;33:273-280.
193. Westerband A, Mills JL, Kistler S, et al. Prospective validation of threshold criteria for intervention in infrainguinal vein grafts undergoing duplex surveillance. *Ann Vasc Surg.* 1997;11:44-48.
194. Idu MM, Blankenstein JD, De Gier P, et al. Impact of a color-flow duplex surveillance program on infrainguinal vein graft patency: a five-year experience. *J Vasc Surg.* 1993;17:42-53.
195. Mattos MA, Van Bemmelen PS, Hodgson KJ, et al. Does correction of stenoses identified with color duplex scanning improve infrainguinal graft patency? *J Vasc Surg.* 1993;17:54-66.
196. Moody P, Gould DA, Harris PL. Vein graft-surveillance improves patency in femoro-popliteal bypass. *Eur J Vasc Surg.* 1990;4:117-121.
197. Visser K, Idu MM, Buth J, et al. Duplex scan surveillance during the first year after infrainguinal autologous vein bypass



- grafting surgery: costs and clinical outcomes compared with other surveillance programs. *J Vasc Surg.* 2001;33:123-130.
198. Wixon CL, Mills JL, Westerband A, et al. An economic appraisal of lower extremity bypass graft maintenance. *J Vasc Surg.* 2000;32:1-12.
  199. Mills JL, Bandyk DF, Gahtan V, Esses GE. The origin of infrainguinal vein graft stenosis: a prospective study based on duplex surveillance. *J Vasc Surg.* 1995;21:16-22.
  200. Erickson CA, Towne JB, Seabrook GR, et al. Ongoing vascular laboratory surveillance is essential to maximize long-term in situ saphenous vein bypass patency. *J Vasc Surg.* 1996;23:18-26, discussion 27.
  201. Passman MA, Moneta GL, Nehler MR, et al. Do normal early color-flow duplex surveillance examination results of infrainguinal vein grafts preclude the need for late graft revision? *J Vasc Surg.* 1995;22:476-481.
  202. Lundell A, Lindblad B, Bergqvist D, Hansen F. Femoropopliteal-crural graft patency is improved by an intensive surveillance program: a prospective randomized study. *J Vasc Surg.* 1995;21:26-34.
  203. Ihlberg L, Luther M, Alback A, et al. Does a completely accomplished duplex-based surveillance prevent vein-graft failure? *Eur J Vasc Endovasc Surg.* 1999;18:395-400.
  204. Davies AH, Hawdon AJ, Sydes MR, Thompson SG. Is duplex surveillance of value after leg vein bypass grafting? Principal results of the vein graft surveillance randomised trial (VGST). *Circulation.* 2005;112:1985-1991.
  205. Lindsay TF, Dueck AD. Vascular viewpoint. *Vasc Med.* 2006;11:137-138.
  206. Mills JL Sr. Is duplex surveillance of value after leg vein bypass grafting? Principal results of the Vein Graft Surveillance Randomised Trial (VGST). *Perspect Vasc Surg Endovasc Ther.* 2006;18:194-196.
  207. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S5-S67.

## 第 88 章

1. Voorhees A, Jaretski A, Blakemore A. The use of tubes constructed from vinyon "N" cloth in bridging arterial defects. *Ann Surg.* 1952;135:332.
2. Edwards WS, Tapp JS. Chemically treated nylon tubes as arterial grafts. *Surgery.* 1955;38:61.
3. Harrison JH. Synthetic materials as vascular prostheses. II. A comparative study of nylon, Dacron, Orlon, Ivalon sponge and Teflon in large blood vessels with tensile strength studies. *Am J Surg.* 1958;95:16.
4. Abbott WM, Green RM, Matsumoto T, et al. Prosthetic above-knee femoropopliteal bypass grafting: results of a multicenter randomized prospective trial. Above-knee femoropopliteal study group. *J Vasc Surg.* 1997;25:19.
5. Noon G, DeBakey M. DeBakey Dacron prosthesis and filamentous velour graft. In: Sawyer PN, Kaplitt MJ, eds. *Vascular Grafts*. New York, NY: Appleton-Century-Crofts; 1978:177.
6. Sawyer PN, Kaplitt MJ, eds. *Vascular Grafts*. New York: Appleton-Century-Crofts; 1978.
7. Snyder R, Botzko KM. Woven, knitted, and externally supported Dacron vascular prostheses. In: Stanley JC, ed. *Biologic and Synthetic Vascular Prostheses*. New York: Grune & Stratton; 1982.
8. Hake U, Gabbert H, Iversen S, et al. Evaluation of the healing of precoated vascular Dacron prostheses. *Langenbecks Arch Chir.* 1991;376:323.
9. Salzmänn DL, Kleinert LB, Berman SS, et al. Inflammation and neovascularization associated with clinically used vascular prosthetic materials. *Cardiovasc Pathol.* 1999;8:63.
10. Jonas RA, Ziemer G, Schoen FJ, et al. A new sealant for knitted Dacron prostheses: minimally cross-linked gelatin. *J Vasc Surg.* 1988;7:414.
11. Scott SM, Gaddy LR, Sahmel R, et al. A collagen coated vascular prosthesis. *J Cardiovasc Surg (Torino).* 1987;28:498.
12. Cziperle DJ, Joyce KA, Tattersall CW, et al. Albumin impregnated vascular grafts: albumin resorption and tissue reactions. *J Cardiovasc Surg (Torino).* 1992;33:407.
13. De Mol Van Otterloo JC, Van Bockel JH, Ponfoort ED, et al. Systemic effects of collagen-impregnated aortoiliac Dacron

- vascular prostheses on platelet activation and fibrin formation. *J Vasc Surg.* 1991;14:59.
14. Shindo S, Motohashi S, Katsu M, et al. Coated prostheses are associated with prolonged inflammation in aortic surgery: a cost analysis. *Artif Organs.* 2008;32:183.
  15. Prager M, Polteraue P, Bohmig HJ, et al. Collagen versus gelatin-coated Dacron versus stretch polytetrafluoroethylene in abdominal aortic bifurcation graft surgery: results of a seven-year prospective, randomized multicenter trial. *Surgery.* 2001;130:408.
  16. Prager MR, Hoblaj T, Nanobashvili J, et al. Collagen- versus gelatin-coated Dacron versus stretch PTFE bifurcation grafts for aortoiliac occlusive disease: long-term results of a prospective, randomized multicenter trial. *Surgery.* 2003;134:80.
  17. Goldman M, McCollum CN, Hawker RJ, et al. Dacron arterial grafts: the influence of porosity, velour, and maturity on thrombogenicity. *Surgery.* 1982;92:947.
  18. Eiberg JP, Røder O, Stahl-Madsen M, et al. Fluoropolymer-coated Dacron versus PTFE grafts for femorofemoral crossover bypass: randomised trial. *Eur J Vasc Endovasc Surg.* 2006;32:431.
  19. Nunn DB, Freeman MH, Hudgins PC. Postoperative alterations in size of Dacron aortic grafts: an ultrasonic evaluation. *Ann Surg.* 1979;189:741.
  20. Pourdeyhi B, Text C. A review of structural and material properties of vascular grafts. *J Biomater Appl.* 1987;2:163.
  21. Nunn DB. Structural failure of Dacron arterial grafts. *Semin Vasc Surg.* 1999;12:83.
  22. Wilson SE, Krug R, Mueller G, et al. Late disruption of Dacron aortic grafts. *Ann Vasc Surg.* 1997;11:383.
  23. Van Damme H, Deprez M, Creemers E, et al. Intrinsic structural failure of polyester (Dacron) vascular grafts. A general review. *Acta Chir Belg.* 2005;105:249.
  24. Soyer T, Lempinen M, Cooper P, et al. A new venous prosthesis. *Surgery.* 1972;72:864.
  25. Campbell CD, Brooks DH, Webster MW, et al. The use of expanded microporous polytetrafluoroethylene for limb salvage: a preliminary report. *Surgery.* 1976;79:485.
  26. Greisler HP. *New Biologic and Synthetic Vascular Prostheses.* Austin, TX: RG Landes; 1991.
  27. Clowes AW, Kirkman TR, Reidy MA. Mechanisms of arterial graft healing. Rapid transmural capillary ingrowth provides a source of intimal endothelium and smooth muscle in porous PTFE prostheses. *Am J Pathol.* 1986;123:220.
  28. Lenz BJ, Veldenz HC, Dennis JW, et al. A three-year follow-up on standard versus thin wall ePTFE grafts for hemodialysis. *J Vasc Surg.* 1998;28:464.
  29. Hamlin GW, Rajah SM, Crow MJ, et al. Evaluation of the thrombogenic potential of three types of arterial graft studied in an artificial circulation. *Br J Surg.* 1978;65:272.
  30. Goldman M, Hall C, Dykes J, et al. Does <sup>111</sup>indium-platelet deposition predict patency in prosthetic arterial grafts? *Br J Surg.* 1983;70:635.
  31. Allen BT, Mathias CJ, Sicard GA, et al. Platelet deposition on vascular grafts. The accuracy of in vivo quantitation and the significance of in vivo platelet reactivity. *Ann Surg.* 1986;203:318.
  32. Shepard AD, Gelfand JA, Callow AD, et al. Complement activation by synthetic vascular prostheses. *J Vasc Surg.* 1984;1:829.
  33. Griffiths GD, Nagy J, Black D, et al. Randomized clinical trial of distal anastomotic interposition vein cuff in infrainguinal polytetrafluoroethylene bypass grafting. *Br J Surg.* 2004;91:560.
  34. Panneton JM, Hollier LH, Hofer JM. Multicenter randomized prospective trial comparing a pre-cuffed polytetrafluoroethylene graft to a vein cuffed polytetrafluoroethylene graft for infragenicular arterial bypass. *Ann Vasc Surg.* 2004;18:199.
  35. Pinchuk L. A review of the biostability and carcinogenicity of polyurethanes in medicine and the new-generation of biostable polyurethanes. *J Biomater Sci Polym Ed.* 1994;6:225.
  36. Webb LX, Schmidt U. Vacuum therapy for wound management. *Unfallchirurg.* 2001;104:918.
  37. Uchida N, Kambic H, Emoto H, et al. Compliance effects on small-diameter polyurethane graft patency. *J Biomed Mater*

*Res.* 1993;27:1269.

38. Santerre JP, Labow RS, Duguay DG, et al. Biodegradation evaluation of polyether and polyester-urethanes with oxidative and hydrolytic enzymes. *J Biomed Mater Res.* 1994;28:1187.
39. Zhang Z, Marois Y, Guidoin RG, et al. Vascugraft polyurethane arterial prosthesis as femoro-popliteal and femoro-peroneal bypasses in humans: pathological, structural and chemical analyses of four excised grafts. *Biomaterials.* 1997;18:113.
40. Brinton LA, Brown SL. Breast implants and cancer. *J Natl Cancer Inst.* 1997;89:1341.
41. Glickman MH, Stokes GK, Ross JR, et al. Multicenter evaluation of a polyurethaneurea vascular access graft as compared with the expanded polytetrafluoroethylene vascular access graft in hemodialysis applications. *J Vasc Surg.* 2001;34:465.
42. Farrar DJ. Development of a prosthetic coronary artery bypass graft. *Heart Surg Forum.* 2000;3:36.
43. Salacinski HJ, Tai NR, Carson RJ, et al. In vitro stability of a novel compliant poly(carbonate-urea) urethane to oxidative and hydrolytic stress. *J Biomed Mater Res.* 2002;59:207.
44. Seifalian AM, Salacinski HJ, Tiwari A, et al. In vivo biostability of a poly(carbonate-urea)urethane graft. *Biomaterials.* 2003;24:2549.
45. Edwards A, Carson RJ, Szycher M, et al. In vitro and in vivo biodegradability of a compliant microporous vascular graft. *J Biomater Appl.* 1998;13:23.
46. Wilson GJ, MacGregor DC, Klement P, et al. The composite Corethane/Dacron vascular prosthesis. Canine in vivo evaluation of 4 mm diameter grafts with 1 year follow-up. *ASAIO Trans.* 1991;37:M475.
47. Cinar B, Goksel OS, Yekeler I. Midterm results with the use of polycarbonate urethane heterografts for dialysis access. *Tohoku J Exp Med.* 2005;207:233.
48. Ricco J-B. InterGard silver bifurcated graft: Features and results of a multicenter clinical study. *J Vasc Surg.* 2006;44:339.
49. Caldarelli G, Minervini A, Guerra M, et al. Prosthetic replacement of the inferior vena cava and the iliofemoral vein for urologically related malignancies. *BJU Int.* 2002;90:368.
50. Bosiers M, Deloose K, Verbist J, et al. Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results. *J Vasc Surg.* 2006;43:313.
51. Jensen LP, Lepäntalo M, Fossdal JE, et al. Dacron or PTFE for above-knee femoropopliteal bypass. A multicenter randomised study. *Eur J Vasc Endovasc Surg.* 2007;34:44.
52. Scharn DM, Dirven M, Barendregt WB, et al. Human umbilical vein versus heparin-bonded polyester for femoro-popliteal bypass: 5-year results of a prospective randomized multicentre trial. *Eur J Vasc Endovasc Surg.* 2008;35:61.
53. Laurila K, Lepäntalo M, Teittinen K, et al. Does an adjuvant AV-fistula improve the patency of a femorocrural PTFE bypass with distal vein cuff in critical leg ischaemia? A prospective randomised multicentre trial. *Eur J Vasc Endovasc Surg.* 2004;27:180.
54. Kapfer X, Meichelboeck W, Groegler FM. Comparison of carbon-impregnated and standard ePTFE prostheses in extra-anatomical anterior tibial artery bypass: a prospective randomized multicenter study. *Eur J Vasc Endovasc Surg.* 2006;32:155.
55. Sauvage LR, Smith JC, Davis CC, et al. Dacron arterial grafts: comparative structures and basis for successive use of current prostheses. In: Kambic HE, Kantrowitz A, Sung P, eds. *Vascular Graft Update: Safety and Performance.* Philadelphia, PA: American Society for Testing and Materials; 1986.
56. Schmitt DD, Bandyk DF, Pequet AJ, et al. Bacterial adherence to vascular prostheses. A determinant of graft infectivity. *J Vasc Surg.* 1986;3:732.
57. Harris JM, Martin LF. An in vitro study of the properties influencing *Staphylococcus epidermidis* adhesion to prosthetic vascular graft materials. *Ann Surg.* 1987;206:612.
58. Budd JS, Langdon I, Brennan J, et al. Above-knee prosthetic grafts do not compromise the ipsilateral long saphenous vein. *Br J Surg.* 1991;78:1379.

59. Sterpetti AV, Schultz RD, Feldhaus RJ, et al. 7-year experience with polytetrafluoroethylene as above-knee femoropopliteal bypass graft: is it worthwhile to preserve the autologous saphenous vein? *J Vasc Surg.* 1985;2:907.
60. Whittemore AD, Clowes AW, Couch NP, et al. Secondary femoropopliteal reconstruction. *Ann Surg.* 1981;193:35.
61. Taylor LM Jr, Edwards JM, Porter JM. Present status of reversed vein bypass grafting: five-year results of a modern series. *J Vasc Surg.* 1990;11:193.
62. Jackson MR, Belott TP, Dickason T, et al. The consequences of a failed femoropopliteal bypass grafting: comparison of saphenous vein and PTFE grafts. *J Vasc Surg.* 2000;32:498.
63. Ballotta E, Renon L, Toffano M, et al. Prospective randomized study on bilateral above-knee femoropopliteal revascularization: polytetrafluoroethylene graft versus reversed saphenous vein. *J Vasc Surg.* 2003;38:1051.
64. Klinkert P, Schepers A, Burger DH, et al. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trial. *J Vasc Surg.* 2003;37:149.
65. Veith FJ, Gupta SK, Ascer E, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. *J Vasc Surg.* 1986;3:104.
66. AbuRahma AF, Robinson PA, Holt SM. Prospective controlled study of polytetrafluoroethylene versus saphenous vein in claudicant patients with bilateral above knee femoropopliteal bypasses. *Surgery.* 1999;126:594.
67. Berglund J, Björck M, Elfström J, et al. Long-term results of above knee femoro-popliteal bypass depend on indication for surgery and graft-material. *Eur J Vasc Endovasc Surg.* 2005;29:412.
68. Robinson BI, Fletcher JP, Tomlinson P, et al. A prospective randomized multicentre comparison of expanded polytetrafluoroethylene and gelatin-sealed knitted Dacron grafts for femoropopliteal bypass. *Cardiovasc Surg.* 1999;7:214.
69. Green RM, Abbott WM, Matsumoto T, et al. Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial. *J Vasc Surg.* 2000;31:417.
70. Post S, Kraus T, Muller-Reinartz U, et al. Dacron vs. polytetrafluoroethylene grafts for femoropopliteal bypass: a prospective randomised multicentre trial. *Eur J Vasc Endovasc Surg.* 2001;22:226.
71. Devine C, McCollum C. Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. *J Vasc Surg.* 2004;40:924.
72. Bennion RS, Williams RA, Stabile BE, et al. Patency of autogenous saphenous vein versus polytetrafluoroethylene grafts in femoropopliteal bypass for advanced ischemia of the extremity. *Surg Gynecol Obstet.* 1985;160:239.
73. Veterans Administration Cooperative Study Group 141. Comparative evaluation of prosthetic, reversed, and in situ vein bypass grafts in distal popliteal and tibial-peroneal revascularization. *Arch Surg.* 1988;123:434.
74. Charlesworth PM, Brewster DC, Darling RC, et al. The fate of polytetrafluoroethylene grafts in lower limb bypass surgery: a six year follow-up. *Br J Surg.* 1985;72:896.
75. Whittemore AD, Kent KC, Donaldson MC, et al. What is the proper role of polytetrafluoroethylene grafts in infrainguinal reconstruction? *J Vasc Surg.* 1989;10:299.
76. Davies MG, Feeley TM, O'Malley MK, et al. Infrainguinal polytetrafluoroethylene grafts: saved limbs or wasted effort? A report on ten years' experience. *Ann Vasc Surg.* 1991;5:519.
77. Faries PL, LoGerfo FW, Arora S, et al. A comparative study of alternative conduits for lower extremity revascularization: all-autogenous conduit versus prosthetic grafts. *J Vasc Surg.* 2000;32:1080.
78. Stonebridge PA, Prescott RJ, Ruckley CV. Randomized trial comparing infrainguinal polytetrafluoroethylene bypass grafting with and without vein interposition cuff at the distal anastomosis. The Joint Vascular Research Group. *J Vasc Surg.* 1997;26:543.
79. Batson RC, Sottiurai VS, Craighead CC. Linton patch angioplasty. An adjunct to distal bypass with polytetrafluoroethylene grafts. *Ann Surg.* 1984;199:684.
80. Taylor RS, Loh A, McFarland RJ, et al. Improved technique for polytetrafluoroethylene bypass grafting: long-term results using anastomotic vein patches. *Br J Surg.* 1992;79:348.

81. Christenson JT, Broome A, Norgren L, et al. The late results after axillo-femoral bypass grafts in patients with leg ischaemia. *J Cardiovasc Surg (Torino)*. 1986;27:131.
82. el-Massry S, Saad E, Sauvage LR, et al. Axillofemoral bypass with externally supported, knitted Dacron grafts: a follow-up through twelve years. *J Vasc Surg*. 1993;17:107.
83. Landry GJ, Moneta GL, Taylor LM Jr, et al. Axillobifemoral bypass. *Ann Vasc Surg*. 2000;14:296.
84. Berce M, Sayers RD, Miller JH. Femorofemoral crossover grafts for claudication: a safe and reliable procedure. *Eur J Vasc Endovasc Surg*. 1996;12:437.
85. Ziomek S, Quinones-Baldrich WJ, Busuttil RW, et al. The superiority of synthetic arterial grafts over autologous veins in carotid-subclavian bypass. *J Vasc Surg*. 1986;3:140.
86. Perler BA, Williams GM. Carotid-subclavian bypass—a decade of experience. *J Vasc Surg*. 1990;12:716.
87. van der Vliet JA, Palamba HW, Scharn DM, et al. Arterial reconstruction for subclavian obstructive disease: a comparison of extrathoracic procedures. *Eur J Vasc Endovasc Surg*. 1995;9:454.
88. Huguet C, Ferri M, Gavelli A. Resection of the suprarenal inferior vena cava. The role of prosthetic replacement. *Arch Surg*. 1995;130:793.
89. Bower TC, Nagorney DM, Cherry KJ Jr, et al. Replacement of the inferior vena cava for malignancy: an update. *J Vasc Surg*. 2000;31:270.
90. Sarkar R, Eilber FR, Gelabert HA, et al. Prosthetic replacement of the inferior vena cava for malignancy. *J Vasc Surg*. 1998;28:75.
91. Comerota AJ, Harwick RD, White JV. Jugular venous reconstruction: a technique to minimize morbidity of bilateral radical neck dissection. *J Vasc Surg*. 1986;3:322.
92. Norton L, Eiseman B. Replacement of portal vein during pancreatectomy for carcinoma. *Surgery*. 1975;77:280.
93. Sarfeh II, Rypins EB, Mason GR. A systematic appraisal of portacaval h-graft diameters. Clinical and hemodynamic perspectives. *Ann Surg*. 1986;204:356.
94. Collins JC, Ong MJ, Rypins EB, et al. Partial portacaval shunt for variceal hemorrhage: longitudinal analysis of effectiveness. *Arch Surg*. 1998;133:590.
95. Bird RB, Stewart WE, Lightfoot EN. *Transport Phenomena*. 2nd ed. New York: Wiley; 2002.
96. Welty JR. *Fundamentals of Momentum, Heat, and Mass Transfer*. 5th ed. Hoboken, NJ: Wiley; 2008.
97. Vroman L. Methods of investigating protein interactions on artificial and natural surfaces. *Ann N Y Acad Sci*. 1987;516:300.
98. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. *Biomaterials*. 2004;25:5681.
99. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. *Biochemistry (Mosc)*. 1991;30:10363.
100. Coughlin SR. Thrombin signalling and protease-activated receptors. *Nature*. 2000;407:258.
101. Missirlis YF, Wautier JL. *The Role of Platelets in Blood-Biomaterial Interactions*. Boston, MA: Kluwer; 1993.
102. Morrell CN, Sun H, Swaim AM, et al. Platelets an inflammatory force in transplantation. *Am J Transplant*. 2007;7:2447.
103. Ito RK, Rosenblatt MS, Contreras MA, et al. Monitoring platelet interactions with prosthetic graft implants in a canine model. *ASAIO Trans*. 1990;36:M175.
104. McCollum CN, Kester RC, Rajah SM, et al. Arterial graft maturation: the duration of thrombotic activity in Dacron aortobifemoral grafts measured by platelet and fibrinogen kinetics. *Br J Surg*. 1981;68:61.
105. Stratton JR, Thiele BL, Ritchie JL. Platelet deposition on Dacron aortic bifurcation grafts in man: quantitation with indium-111 platelet imaging. *Circulation*. 1982;66:1287.
106. Stratton JR, Thiele BL, Ritchie JL. Natural history of platelet deposition on Dacron aortic bifurcation grafts in the first year after implantation. *Am J Cardiol*. 1983;52:371.

107. Stratton JR, Ritchie JL. Reduction of indium-111 platelet deposition on Dacron vascular grafts in humans by aspirin plus dipyridamole. *Circulation*. 1986;73:325.
108. Mazur C, Tschopp JF, Faliakou EC, et al. Selective alpha IIb beta 3 receptor blockage with peptide tp9201 prevents platelet uptake on Dacron vascular grafts without significant effect on bleeding time. *J Lab Clin Med*. 1994;124:589.
109. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration—the multistep paradigm. *Cell*. 1994;76:301.
110. Plow EF, Zhang L. A MAC-1 attack: Integrin functions directly challenged in knockout mice. *J Clin Invest*. 1997;99:1145.
111. Diacovo TG, Roth SJ, Buccola JM, et al. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta(2)-integrin CD11b/CD18. *Blood*. 1996;88:146.
112. Wang YM, Sakuma M, Chen ZP, et al. Leukocyte engagement of platelet glycoprotein Ib alpha via the integrin MAC-1 is critical for the biological response to vascular injury. *Circulation*. 2005;112:2993.
113. Bevilacqua MP, Nelson RM, Mannori G, et al. Endothelial-leukocyte adhesion molecules in human-disease. *Annu Rev Med*. 1994;45:361.
114. Sluiter W, Pietersma A, Lamers MJ, et al. Leukocyte adhesion molecules on the vascular endothelium—their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. *J Cardiovasc Pharmacol*. 1993;22:S37.
115. De La Cruz C, Haimovich B, Greco RS. Immobilized IgG and fibrinogen differentially affect the cytoskeletal organization and bactericidal function of adherent neutrophils. *J Surg Res*. 1998;80:28.
116. Bellon JM, Bujan J, Contreras LA, et al. Similarity in behavior of polytetrafluoroethylene (ePTFE) prostheses implanted into different interfaces. *J Biomed Mater Res*. 1996;31:1.
117. Kelly BS, Heffelfinger SC, Whiting JF, et al. Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. *Kidney Int*. 2002;62:2272.
118. Bonfield TL, Colton E, Marchant RE, et al. Cytokine and growth-factor production by monocytes/macrophages on protein preadsorbed polymers. *J Biomed Mater Res*. 1992;26:837.
119. Swartbol P, Truedsson L, Parsson H, et al. Tumor necrosis factor-alpha and interleukin-6 release from white blood cells induced by different graft materials in vitro are affected by pentoxifylline and iloprost. *J Biomed Mater Res*. 1997;36:400.
120. Greisler HP, Petsikas D, Cziperle DJ, et al. Dacron stimulation of macrophage transforming growth factor-beta release. *Cardiovasc Surg*. 1996;4:169.
121. Mattana J, Effiong C, Kapasi A, et al. Leukocyte-polytetrafluoroethylene interaction enhances proliferation of vascular smooth muscle cells via tumor necrosis factor-alpha secretion. *Kidney Int*. 1997;52:1478.
122. Greisler HP, Dennis JW, Endean ED, et al. Derivation of neointima in vascular grafts. *Circulation*. 1988;78:16.
123. Golden MA, Hanson SR, Kirkman TR, et al. Healing of polytetrafluoroethylene arterial grafts is influenced by graft porosity. *J Vasc Surg*. 1990;11:838.
124. Hazama K, Miura H, Shimada T, et al. Relationship between fibril length and tissue ingrowth in the healing of expanded polytetrafluoroethylene grafts. *Surg Today*. 2004;34:685.
125. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nat Med*. 1999;5:434.
126. Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. *J Exp Med*. 2001;193:1005.
127. Chavakis E, Carmona G, Urbich C, et al. Phosphatidylinositol-3-kinase-gamma is integral to homing functions of progenitor cells. *Circ Res*. 2008;102:942.
128. Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. *Blood*. 1998;92:362.
129. Greisler H. Regulation of vascular graft healing by induction of tissue incorporation. In: Wise D, Trantolo D, Altobelli D, et al, eds. *Human Biomaterials Applications*. Totowa, NJ: Humana; 1996:227.

130. Rotmans JJ, Heyligers JMM, Verhagen HJM, et al. In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. *Circulation*. 2005;112:12.
131. Pitsch RJ, Minion DJ, Goman ML, et al. Platelet-derived growth factor production by cells from Dacron grafts implanted in a canine model. *J Vasc Surg*. 1997;26:70.
132. Patel R, Cardneau JD, Colles SM, et al. Synthetic smooth muscle cell phenotype is associated with increased nicotinamide adenine dinucleotide phosphate oxidase activity: effect on collagen secretion. *J Vasc Surg*. 2006;43:364.
133. van Aalst JA, Pitsch RJ, Absood A, et al. Mechanism of Dacron-activated monocytic cell oxidation of low density lipoprotein. *J Vasc Surg*. 2000;31:171.
134. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. *J Pathol*. 2000;190:300.
135. Schepers A, Eefting D, Bonta PI, et al. Anti-mcp-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. *Arterioscler Thromb Vasc Biol*. 2006;26:2063.
136. Szilagyi DE, Smith RF, Elliott JP, et al. Infection in arterial reconstruction with synthetic grafts. *Ann Surg*. 1972;176:321.
137. Liekweg WG Jr, Greenfield LJ. Vascular prosthetic infections: collected experience and results of treatment. *Surgery*. 1977;81:335.
138. Goldstone J, Moore WS. Infection in vascular prostheses. Clinical manifestations and surgical management. *Am J Surg*. 1974;128:225.
139. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. *Science*. 1999;284:1318.
140. Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. *Clin Microbiol Rev*. 2002;15:167.
141. Edmiston CE Jr, Goheen MP, Seabrook GR, et al. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. *Am J Surg*. 2006;192:344.
142. D'Addato M, Curti T, Freyrie A. Prophylaxis of graft infection with rifampicin-bonded Gelseal graft: 2-year follow-up of a prospective clinical trial. Italian investigators group. *Cardiovasc Surg*. 1996;4:200.
143. Vicaretti M, Hawthorne W, Ao PY, et al. Does in situ replacement of a staphylococcal infected vascular graft with a rifampicin impregnated gelatin sealed Dacron graft reduce the incidence of subsequent infection? *Int Angiol*. 2000;19:158.
144. Earnshaw JJ, Whitman B, Heather BP. Two-year results of a randomized controlled trial of rifampicin-bonded extra-anatomic Dacron grafts. *Br J Surg*. 2000;87:758.
145. Batt M, Magne JL, Alric P, et al. In situ revascularization with silver-coated polyester grafts to treat aortic infection: early and midterm results. *J Vasc Surg*. 2003;38:983.
146. Sawyer PN, Kaplitt MJ, National Institutes of Health (U.S.). *Vascular Grafts*. New York, NY: Appleton-Century-Crofts; 1978.
147. Cameron BL, Tsuchida H, Connall TP, et al. High porosity PTFE improves endothelialization of arterial grafts without increasing early thrombogenicity. *J Cardiovasc Surg (Torino)*. 1993;34:281.
148. Isaka M, Nishibe T, Okuda Y, et al. Experimental study on stability of a high-porosity expanded polytetrafluoroethylene graft in dogs. *Ann Thorac Cardiovasc Surg*. 2006;12:37.
149. Clowes AW, Kohler T. Graft endothelialization: the role of angiogenic mechanisms. *J Vasc Surg*. 1991;13:734.
150. Abbott WM, Megerman J, Hasson JE, et al. Effect of compliance mismatch on vascular graft patency. *J Vasc Surg*. 1987;5:376.
151. Salacinski HJ, Goldner S, Giudiceandrea A, et al. The mechanical behavior of vascular grafts: a review. *J Biomater Appl*. 2001;15:241.
152. Tiwari A, Salacinski H, Seifalian AM, et al. New prostheses for use in bypass grafts with special emphasis on polyurethanes. *Cardiovasc Surg*. 2002;10:191.

153. Greenwald SE, Berry CL. Improving vascular grafts: the importance of mechanical and haemodynamic properties. *J Pathol.* 2000;190:292.
154. Kissin M, Kansal N, Pappas PJ, et al. Vein interposition cuffs decrease the intimal hyperplastic response of polytetrafluoroethylene bypass grafts. *J Vasc Surg.* 2000;31:69.
155. Gentile AT, Mills JL, Gooden MA, et al. Vein patching reduces neointimal thickening associated with prosthetic graft implantation. *Am J Surg.* 1998;176:601.
156. Kohler TR, Kirkman TR, Kraiss LW, et al. Increased blood flow inhibits neointimal hyperplasia in endothelialized vascular grafts. *Circ Res.* 1991;69:1557.
157. Mattsson EJ, Kohler TR, Vergel SM, et al. Increased blood flow induces regression of intimal hyperplasia. *Arterioscler Thromb Vasc Biol.* 1997;17:2245.
158. Suggs WD, Henriques HF, DePalma RG. Vein cuff interposition prevents juxta-anastomotic neointimal hyperplasia. *Ann Surg.* 1988;207:717.
159. Norberto JJ, Sidawy AN, Trad KS, et al. The protective effect of vein cuffed anastomoses is not mechanical in origin. *J Vasc Surg.* 1995;21:558.
160. Sumpio BE. *Hemodynamic Forces and Vascular Cell Biology.* Austin, TX: RG Landes; 1993.
161. Verrier ED, Boyle EM Jr. Endothelial cell injury in cardiovascular surgery. *Ann Thorac Surg.* 1996;62:915.
162. Kipshidze N, Dangas G, Tsapenko M, et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. *J Am Coll Cardiol.* 2004;44:733.
163. Loth F, Fischer PF, Bassiouny HS. Blood flow in end-to-side anastomoses. *Annu Rev Fluid Mechanics.* 2008;40:367.
164. Caro CG, Cheshire NJ, Watkins N. Preliminary comparative study of small amplitude helical and conventional ePTFE arteriovenous shunts in pigs. *J R Soc Interface.* 2005;2:261.
165. Huijbregts HJ, Blankstijn PJ, Caro CG, et al. A helical PTFE arteriovenous access graft to swirl flow across the distal anastomosis: results of a preliminary clinical study. *Eur J Vasc Endovasc Surg.* 2007;33:472.
166. Merrill EW, Salzman EW. Polyethylene oxide as a biomaterial. *ASAIO J.* 1983;6:1.
167. Lee JH, Lee HB, Andrade JD. Blood compatibility of polyethylene oxide surfaces. *Progr Polymer Sci.* 1995;20:1043.
168. Lyman D, Klein K, Brash J, et al. Platelet interaction with protein coated surfaces. *Thromb Diath Haemor Proc.* 1970;42:6.
169. Kim SW, Lee RG, Oster H, et al. Platelet adhesion to polymer surfaces. *Trans Am Soc Artif Intern Organs B.* 1974;20:449.
170. Lee ES, Kim SW. Adsorbed glycoproteins in platelet-adhesion onto polymer surfaces—significance of terminal galactose units. *Trans Am Soc Artif Intern Organs.* 1979;25:124.
171. Park K, Mosher DF, Cooper SL. Acute surface-induced thrombosis in the canine ex vivo model—importance of protein-composition of the initial monolayer and platelet activation. *J Biomed Mater Res.* 1986;20:589.
172. Ishikawa Y, Sasakawa S, Takase M, et al. Effect of albumin immobilization by plasma polymerization on platelet activity. *Thromb Res.* 1984;35:193.
173. Kang IK, Kwon BK, Lee JH, et al. Immobilization of proteins on poly(methyl methacrylate) films. *Biomaterials.* 1993;14:787.
174. Kamath KR, Demeo D, Park K. Albumin grafting on polymer surfaces by gamma-irradiation. *Abstracts of Papers of the American Chemical Society.* 1993;206:202.
175. Munro MS, Quattrone AJ, Ellsworth SR, et al. Alkyl substituted polymers with enhanced albumin affinity. *Trans Am Soc Artif Intern Organs.* 1981;27:499.
176. Eberhart RC, Munro MS, Frautschi JR, et al. Influence of endogenous albumin binding on blood-material interactions. *Ann N Y Acad Sci.* 1987;516:78.
177. Eberhart RC. Surface treatments to improve the albumin affinity and blood compatibility of polymers. *IEEE Eng Med Biol Mag.* 1989;8:26.
178. Eberhart RC, Huo HH, Nelson K. Cardiovascular materials. *MRS Bull.* 1991;16:50.



179. Frautschi JR, Eberhart RC, Hubbell JA. Alkylated cellulosic membranes with enhanced albumin affinity: influence of competing proteins. *J Biomater Sci Polym Ed.* 1995;7:563.
180. Nelson KD, Eisenbaumer R, Pomerantz M, et al. High affinity polyethylene oxide for improved biocompatibility. *ASAIO J.* 1996;42:M884.
181. Guidoin RG, Awad J, Brassard A, et al. Blood compatibility of silicone-rubber chemically coated with cross-linked albumin. *Biomater Med Devices Artif Organs.* 1976;4:205.
182. Guidoin RG, King MW, Awad J, et al. Albumin coated and critical-point dried polyester prostheses as substitutes in the thoracic aorta of dogs. *Trans Am Soc Artif Intern Organs.* 1983;29:290.
183. Kottke-Marchant K, Anderson JM, Umemura Y, Marchant RE. Effect of albumin coating on the in vitro blood compatibility of Dacron arterial prostheses. *Biomaterials.* 1989;10:147.
184. Marois Y, Chakfe N, Guidoin R, et al. An albumin-coated polyester arterial graft: in vivo assessment of biocompatibility and healing characteristics. *Biomaterials.* 1996;17:3.
185. Al Khaffaf H, Charlesworth D. Albumin-coated vascular prostheses: A five-year follow-up. *J Vasc Surg.* 1996;23:686.
186. Kudo FA, Nishibe T, Miyazaki K, et al. Albumin-coated knitted Dacron aortic prostheses. *Int Angiol.* 2002;21:214.
187. Gott VL, Koepke DE, Daggett RL, et al. The coating of intravascular plastic prostheses with colloidal graphite. *Surgery.* 1961;50:382.
188. Gott VL. Heparin bonding on colloidal graphite surfaces. *Science.* 1963;142:1297.
189. Olcott EL. Pyrolytic biocarbon materials. *J Biomed Mater Res.* 1974;8:209.
190. Goldfarb D, Houk JA, Moore JL, et al. Graphite-expanded polytetrafluoroethylene—improved small artery prosthesis. *Trans Am Soc Artif Intern Organs.* 1977;23:268.
191. Debski R, Borovetz H, Haubold A, et al. Polytetrafluoroethylene grafts coated with ULTI carbon. *Trans Am Soc Artif Intern Organs.* 1982;28:456.
192. Scott SM, Gaddy LR, Parra S. Pyrolytic carbon-coated vascular prostheses. *J Surg Res.* 1980;29:395.
193. Tsuchida H, Cameron BL, Marcus CS, et al. Modified polytetrafluoroethylene—In-111 labeled platelet deposition on carbon-lined and high-porosity polytetrafluoroethylene grafts. *J Vasc Surg.* 1992;16:643.
194. Arabi H, Mirzadeh H, Ahmadi SH, et al. In vitro and in vivo hemocompatibility evaluation of graphite coated polyester vascular grafts. *Int J Artif Organs.* 2004;27:691.
195. Tegoulia VA, Rao WS, Kalambur AT, et al. Surface properties, fibrinogen adsorption, and cellular interactions of a novel phosphorylcholine-containing self-assembled monolayer on gold. *Langmuir.* 2001;17:4396.
196. Lu JR, Murphy EF, Su TJ, et al. Reduced protein adsorption on the surface of a chemically grafted phospholipid monolayer. *Langmuir.* 2001;17:3382.
197. Glasmaster K, Larsson C, Hook F, et al. Protein adsorption on supported phospholipid bilayers. *J Colloid Interface Sci.* 2002;246:40.
198. Andersson AS, Glasmaster K, Sutherland D, et al. Cell adhesion on supported lipid bilayers. *J Biomed Mater Res A.* 2003;64A:622.
199. Vermette P, Gauvreau V, Pezolet M, et al. Albumin and fibrinogen adsorption onto phosphatidylcholine monolayers investigated by Fourier transform infrared spectroscopy. *Colloids Surf B Biointerfaces.* 2003;29:285.
200. Winger TM, Ludovice PJ, Chaikof EL. Formation and stability of complex membrane-mimetic monolayers on solid supports. *Langmuir.* 1999;15:3866.
201. Kaladhar K, Sharma CP. Supported cell mimetic monolayers and their interaction with blood. *Langmuir.* 2004;20:11115.
202. Kaladhar K, Sharma C. Cell mimetic lateral stabilization of outer cell mimetic bilayer on polymer surfaces by peptide bonding and their blood compatibility. *J Biomed Mater Res A.* 2006;79A:23.
203. Stine R, Pishko MV, Hampton JR, et al. Heat-stabilized phospholipid films: film characterization and the production of protein-resistant surfaces. *Langmuir.* 2005;21:11352.

204. Marra KG, Winger TM, Hanson SR, et al. Cytomimetic biomaterials. 1. In-situ polymerization of phospholipids on an alkylated surface. *Macromolecules*. 1997;30:6483.
205. Marra KG, Kidani DDA, Chaikof EL. Cytomimetic biomaterials. 2. In-situ polymerization of phospholipids on a polymer surface. *Langmuir*. 1997;13:5697.
206. Orban JM, Faucher KM, Dluhy RA, et al. Cytomimetic biomaterials. 4. In-situ photopolymerization of phospholipids on an alkylated surface. *Macromolecules*. 2000;33:4205.
207. Ross EE, Rozanski LJ, Spratt T, et al. Planar supported lipid bilayer polymers formed by vesicle fusion. 1. Influence of diene monomer structure and polymerization method on film properties. *Langmuir*. 2003;19:1752.
208. Ross EE, Spratt T, Liu SC, et al. Planar supported lipid bilayer polymers formed by vesicle fusion. 2. Adsorption of bovine serum albumin. *Langmuir*. 2003;19:1766.
209. Kim HK, Kim K, Byun Y. Preparation of a chemically anchored phospholipid monolayer on an acrylated polymer substrate. *Biomaterials*. 2005;26:3435.
210. Iwasaki Y, Ishihara K. Phosphorylcholine-containing polymers for biomedical applications. *Anal Bioanal Chem*. 2005;381:534.
211. Lewis AL, Stratford PW. Phosphorylcholine-coated stents. *J Long Term Eff Med Implants*. 2002;12:231.
212. Yoneyama T, Ishihara K, Nakabayashi N, et al. Short-term in vivo evaluation of small-diameter vascular prosthesis composed of segmented poly(etherurethane)/2-methacryloyloxyethyl phosphorylcholine polymer blend. *J Biomed Mater Res*. 1998;43:15.
213. Ishihara K, Fujita H, Yoneyama T, et al. Antithrombogenic polymer alloy composed of 2-methacryloyloxyethyl phosphorylcholine polymer and segmented polyurethane. *J Biomater Sci Polym Ed*. 2000;11:1183.
214. Yoneyama T, Sugihara K, Ishihara K, et al. The vascular prosthesis without pseudointima prepared by antithrombogenic phospholipid polymer. *Biomaterials*. 2002;23:1455.
215. Chen CY, Lumsden AB, Ofenloch JC, et al. Phosphorylcholine coating of ePTFE grafts reduces neointimal hyperplasia in canine model. *Ann Vasc Surg*. 1997;11:74.
216. Chen C, Ofenloch JC, Yianni YP, et al. Phosphorylcholine coating of ePTFE reduces platelet deposition and neointimal hyperplasia in arteriovenous grafts. *J Surg Res*. 1998;77:119.
217. Jordan SW, Faucher KM, Caves JM, et al. Fabrication of a phospholipid membrane-mimetic film on the luminal surface of an ePTFE vascular graft. *Biomaterials*. 2006;27:3473.
218. Chandy T, Das GS, Wilson RF, et al. Use of plasma glow for surface-engineering biomolecules to enhance blood compatibility of Dacron and PTFE vascular prosthesis. *Biomaterials*. 2000;21:699.
219. Baumgartner HR, Muggli R, Tschopp TB, et al. Platelet-adhesion, release and aggregation in flowing blood: effects of surface properties and platelet-function. *Thromb Haemost*. 1976;35:124.
220. Barnes MJ, Macintyre DE. Platelet-reactivity of isolated constituents of the blood-vessel wall. *Haemostasis*. 1979;8:158.
221. Ito S, Ishimaru S, Wilson SE. Application of coacervated alpha-elastin to arterial prostheses for inhibition of anastomotic intimal hyperplasia. *ASAIO J*. 1998;44:M501.
222. Huang L, McMillan RA, Apkarian RP, et al. Generation of synthetic elastin-mimetic small diameter fibers and fiber networks. *Macromolecules*. 2000;33:2989.
223. McPherson DT, Morrow C, Minehan DS, et al. Production and purification of a recombinant elastomeric polypeptide, g-(VPGVG)<sub>19</sub>-VPGV, from *Escherichia coli*. *Biotechnol Prog*. 1992;8:347.
224. Daniell H, Guda C, McPherson DT, et al. Hyperexpression of a synthetic protein-based polymer gene. *Methods Mol Biol*. 1997;63:359.
225. Trabbic-Carlson K, Setton LA, Chilkoti A. Swelling and mechanical behaviors of chemically cross-linked hydrogels of elastin-like polypeptides. *Biomacromolecules*. 2003;4:572.
226. Nagapudi K, Brinkman WT, Leisen J, et al. Protein-based thermoplastic elastomers. *Macromolecules*. 2005;38:345.

227. Lim DW, Nettles DL, Setton LA, et al. In situ cross-linking of elastin-like polypeptide block copolymers for tissue repair. *Biomacromolecules*. 2008;9:222.
228. Defife KM, Hagen KM, Clapper DL, et al. Photochemically immobilized polymer coatings: effects on protein adsorption, cell adhesion, and leukocyte activation. *J Biomater Sci Polym Ed*. 1999;10:1063.
229. Woodhouse KA, Klement P, Chen V, et al. Investigation of recombinant human elastin polypeptides as non-thrombogenic coatings. *Biomaterials*. 2004;25:4543.
230. Jordan SW, Haller CA, Sallach RE, et al. The effect of a recombinant elastin-mimetic coating of an ePTFE prosthesis on acute thrombogenicity in a baboon arteriovenous shunt. *Biomaterials*. 2007;28:1191.
231. Clagett GP, Burkel WE, Sharefkin JB, et al. Platelet reactivity in vivo in dogs with arterial prostheses seeded with endothelial cells. *Circulation*. 1984;69:632.
232. Hess F, Steeghs S, Jerusalem R, et al. Patency and morphology of fibrous polyurethane vascular prostheses implanted in the femoral artery of dogs after seeding with subcultivated endothelial cells. *Eur J Vasc Surg*. 1993;7:402.
233. Pasic M, Muller-Glauser W, von Segesser L, et al. Endothelial cell seeding improves patency of synthetic vascular grafts: manual versus automatized method. *Eur J Cardiothorac Surg*. 1996;10:372.
234. Sugitachi A, Takagi K. Antithrombogenicity of immobilized urokinase: Clinical application. *Int J Artif Organs*. 1978;1:88.
235. Aoshima R, Kanda Y, Takada A, et al. Sulfonated poly(vinylidene fluoride) as a biomaterial: immobilization of urokinase and biocompatibility. *J Biomed Mater Res*. 1982;16:289.
236. Kitamoto Y, Tomita M, Kiyama S, et al. Antithrombotic mechanisms of urokinase immobilized polyurethane. *Thromb Haemost*. 1991;65:73.
237. Lai ZF, Imamura T, Koike N, et al. Urokinase immobilization suppresses inflammatory responses to polyurethane tubes implanted in rabbit muscles. *J Biomed Mater Res A*. 2006;76A:81.
238. vonSegesser LK. Heparin-bonded surfaces in extracorporeal membrane oxygenation for cardiac support. *Ann Thorac Surg*. 1996;61:330.
239. Hsu LC. Heparin-coated cardiopulmonary bypass circuits: current status. *Perfusion*. 2001;16:417.
240. Hubbell JA. Pharmacological modification of materials. *Cardiovasc Pathol*. 1993;2:S121.
241. Olsson P, Sanchez J, Mollnes TE, et al. On the blood compatibility of end-point immobilized heparin. *J Biomater Sci Polym Ed*. 2000;11:1261.
242. Tanzi MC. Bioactive technologies for hemocompatibility. *Expert Rev Med Devices*. 2005;2:473.
243. Sperling C, Schweiss RB, Streller U, et al. In vitro hemocompatibility of self-assembled monolayers displaying various functional groups. *Biomaterials*. 2005;26:6547.
244. Huang LY, Yang MC. Hemocompatibility of layer-by-layer hyaluronic acid/heparin nanostructure coating on stainless steel for cardiovascular stents and its use for drug delivery. *J Nanosci Nanotechnol*. 2006;6:3163.
245. Laredo J, Xue L, Husak VA, et al. Silyl-heparin adsorption improves the in vivo thromboresistance of carbon-coated polytetrafluoroethylene vascular grafts. *Am J Surg*. 2003;186:556.
246. Laredo J, Xue L, Husak VA, et al. Silyl-heparin bonding improves the patency and in vivo thromboresistance of carbon-coated polytetrafluoroethylene vascular grafts. *J Vasc Surg*. 2004;39:1059.
247. Li YL, Neoh KG, Kang ET. Plasma protein adsorption and thrombus formation on surface functionalized polypyrrole with and without electrical stimulation. *J Colloid Interface Sci*. 2004;275:488.
248. Chen H, Chen Y, Sheardown H, et al. Immobilization of heparin on a silicone surface through a heterobifunctional PEG spacer. *Biomaterials*. 2005;26:7418.
249. Wang AF, Cao T, Tang HY, et al. Immobilization of polysaccharides on a fluorinated silicon surface. *Colloids Surf B Biointerfaces*. 2006;47:57.
250. Keuren JFW, Wielders SJH, Driessen A, et al. Covalently-bound heparin makes collagen thromboresistant. *Arterioscler Thromb Vasc Biol*. 2004;24:613.

251. Luong-Van E, Grondahl L, Chua KN, et al. Controlled release of heparin from poly(epsilon-caprolactone) electrospun fibers. *Biomaterials*. 2006;27:2042.
252. Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. *Biomater Med Devices Artif Organs*. 1983;11:161.
253. Pasche B, Elgue G, Olsson P, et al. Binding of antithrombin to immobilized heparin under varying flow conditions. *Artif Organs*. 1991;15:481.
254. Elgue G, Blomback M, Olsson P, et al. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin. *Thromb Haemost*. 1993;70:289.
255. Walluscheck KP, Bierkandt S, Brandt M, et al. Infrainguinal ePTFE vascular graft with bioactive surface heparin bonding—first clinical results. *J Cardiovasc Surg (Torino)*. 2005;46:425.
256. Peeters P, Verbist J, Deloose K, et al. Results with heparin bonded polytetrafluoroethylene grafts for femorodistal bypasses. *J Cardiovasc Surg (Torino)*. 2006;47:407.
257. Kishida A, Ueno Y, Fukudome N, et al. Immobilization of human thrombomodulin onto poly(ether urethane urea) for developing antithrombogenic blood-contacting materials. *Biomaterials*. 1994;15:848.
258. Kishida A, Ueno Y, Maruyama I, et al. Immobilization of human thrombomodulin on biomaterials: evaluation of the activity of immobilized human thrombomodulin. *Biomaterials*. 1994;15:1170.
259. Kishida A, Akatsuka Y, Yanagi M, et al. In vivo and ex vivo evaluation of the antithrombogenicity of human thrombomodulin immobilized biomaterials. *ASAIO J*. 1995;41:M369.
260. Vasilets VN, Hermel G, Konig U, et al. Microwave CO<sub>2</sub> plasma-initiated vapour phase graft polymerization of acrylic acid onto polytetrafluoroethylene for immobilization of human thrombomodulin. *Biomaterials*. 1997;18:1139.
261. Li JM, Singh MJ, Nelson PR, et al. Immobilization of human thrombomodulin to expanded polytetrafluoroethylene. *J Surg Res*. 2002;105:200.
262. Sperling C, Konig U, Hermel G, et al. Immobilization of human thrombomodulin onto PTFE. *J Mater Sci Mater Med*. 1997;8:789.
263. Sperling C, Salchert K, Steller U, et al. Covalently immobilized thrombomodulin inhibits coagulation and complement activation of artificial surfaces in vitro. *Biomaterials*. 2004;25:5101.
264. Han HS, Yang SL, Yeh HY, et al. Studies of a novel human thrombomodulin immobilized substrate: surface characterization and anticoagulation activity evaluation. *J Biomater Sci Polym Ed*. 2001;12:1075.
265. Cazalis CS, Haller CA, Sease-Cargo L, et al. C-terminal site-specific PEGylation of a truncated thrombomodulin mutant with retention of full bioactivity. *Bioconjug Chem*. 2004;15:1005.
266. Sun XL, Stabler CL, Cazalis CS, et al. Carbohydrate and protein immobilization onto solid surfaces by sequential diels-alder and azide-alkyne cycloadditions. *Bioconjug Chem*. 2006;17:52.
267. Tseng PY, Jordan SW, Sun XL, et al. Catalytic efficiency of a thrombomodulin-functionalized membrane-mimetic film in a flow model. *Biomaterials*. 2006;27:2768.
268. Feng J, Tseng PY, Faucher KM, et al. Functional reconstitution of thrombomodulin within a substrate-supported membrane-mimetic polymer film. *Langmuir*. 2002;18:9907.
269. Seifert B, Romaniuk P, Groth T. Covalent immobilization of hirudin improves the haemocompatibility of polylactide-polyglycolide in vitro. *Biomaterials*. 1997;18:1495.
270. Phaneuf MD, Berceli SA, Bide MJ, et al. Covalent linkage of recombinant hirudin to poly(ethylene terephthalate) (Dacron): creation of a novel antithrombin surface. *Biomaterials*. 1997;18:755.
271. Berceli SA, Phaneuf MD, LoGerfo PW. Evaluation of a novel hirudin-coated polyester graft to physiologic flow conditions: hirudin bioavailability and thrombin uptake. *J Vasc Surg*. 1998;27:1117.
272. Phaneuf MD, Dempsey DJ, Bide MJ, et al. Bioengineering of a novel small diameter polyurethane vascular graft with covalently bound recombinant hirudin. *ASAIO J*. 1998;44:M653.

273. Phaneuf MD, Szycher M, Berceli SA, et al. Covalent linkage of recombinant hirudin to a novel ionic poly(carbonate) urethane polymer with protein binding sites: determination of surface antithrombin activity. *Artif Organs*. 1998;22:657.
274. Wyers MC, Phaneuf MD, Rzucidlo EM, et al. In vivo assessment of a novel Dacron surface with covalently bound recombinant hirudin. *Cardiovasc Pathol*. 1999;8:153.
275. Tangelder MJD, Algra A, Lawson JA, et al. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (the Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. *Lancet*. 2000;355:346.
276. Chandy T, Sharma CP. The antithrombotic effect of prostaglandin E<sub>1</sub> immobilized on albuminated polymer matrix. *J Biomed Mater Res*. 1984;18:1115.
277. Joseph G, Sharma CP. Prostacyclin immobilized albuminated surfaces. *J Biomed Mater Res*. 1987;21:937.
278. Aldenhoff YBJ, Pijpers AP, Koole LH. Synthesis of a new photoreactive derivative of dipyridamole and its use in the manufacture of artificial surfaces with low thrombogenicity. *Bioconj Chem*. 1997;8:296.
279. Aldenhoff YBJ, van der Veen FH, ter Woorst J, et al. Performance of a polyurethane vascular prosthesis carrying a dipyridamole (Persantin) coating on its luminal surface. *J Biomed Mater Res*. 2001;54:224.
280. Aldenhoff YB, Koole LH. Platelet adhesion studies on dipyridamole coated polyurethane surfaces. *Eur Cell Mater*. 2003;5:61.
281. Paul W, Sharma CP. Acetylsalicylic acid loaded poly(vinyl alcohol) hemodialysis membranes: effect of drug release on blood compatibility and permeability. *J Biomater Sci Polym Ed*. 1997;8:755.
282. Vasudev SC, Chandy T, Sharma CP. Development of chitosan/polyethylene vinyl acetate co-matrix: controlled release of aspirin-heparin for preventing cardiovascular thrombosis. *Biomaterials*. 1997;18:375.
283. Rodriguez G, Gallardo A, San Roman J, et al. New resorbable polymeric systems with antithrombogenic activity. *J Mater Sci Mater Med*. 1999;10:873.
284. Rodriguez G, Gallardo A, Fernandez M, et al. Hydrophilic polymer drug from a derivative of salicylic acid: synthesis, controlled release studies and biological behavior. *Macromol Biosci*. 2004;4:579.
285. SanRoman J, Bujan J, Bellon JM, et al. Experimental study of the antithrombogenic behavior of Dacron vascular grafts coated with hydrophilic acrylic copolymers bearing salicylic acid residues. *J Biomed Mater Res*. 1996;32:19.
286. Viscardi PJ, Page EA, Clark HG, et al. Iloprost in alginate decreases the thrombogenicity of expanded polytetrafluoroethylene. *J Reconstr Microsurg*. 1997;13:303.
287. Groves PH, Banning AP, Penny WJ, et al. The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty. *Cardiovasc Res*. 1995;30:87.
288. Kibbe M, Billiar T, Tzeng E. Inducible nitric oxide synthase and vascular injury. *Cardiovasc Res*. 1999;43:650.
289. Keefer LK. Nitric oxide (NO)- and nitroxyl (HNO)-generating diazeniumdiolates (nonoates): emerging commercial opportunities. *Curr Top Med Chem*. 2005;5:625.
290. Smith DJ, Chakravarthy D, Pulfer S, et al. Nitric oxide-releasing polymers containing the [N(O)NO](-) group. *J Med Chem*. 1996;39:1148.
291. Pulfer SK, Ott D, Smith DJ. Incorporation of nitric oxide-releasing crosslinked polyethyleneimine microspheres into vascular grafts. *J Biomed Mater Res*. 1997;37:182.
292. Taite LJ, Yang P, Jun HW, et al. Nitric oxide-releasing polyurethane-PEG copolymer containing the YIGSR peptide promotes endothelialization with decreased platelet adhesion. *J Biomed Mater Res B Appl Biomater*. 2008;84B:108.
293. Jun HW, Taite LJ, West JL. Nitric oxide-producing polyurethanes. *Biomacromolecules*. 2005;6:838.
294. Mowery KA, Schoenfisch MH, Saavedra JE, et al. Preparation and characterization of hydrophobic polymeric films that are thromboresistant via nitric oxide release. *Biomaterials*. 2000;21:9.
295. Batchelor MM, Reoma SL, Fleser PS, et al. More lipophilic dialkyldiamine-based diazeniumdiolates: synthesis, characterization, and application in preparing thromboresistant nitric oxide release polymeric coatings. *J Med Chem*. 2003;46:5153.

296. Frost MC, Batchelor MM, Lee YM, et al. Preparation and characterization of implantable sensors with nitric oxide release coatings. *Microchem J*. 2003;74:277.
297. Fleser PS, Nuthakki VK, Malinzak LE, et al. Nitric oxide-releasing biopolymers inhibit thrombus formation in a sheep model of arteriovenous bridge grafts. *J Vasc Surg*. 2004;40:803.
298. Jourdain D, Hallen K, Feelisch M, et al. Dynamic state of S-nitrosothiols in human plasma and whole blood. *Free Radic Biol Med*. 2000;28:409.
299. Rafikova O, Rafikov R, Nudler E. Catalysis of S-nitrosothiols formation by serum albumin: the mechanism and implication in vascular control. *Proc Natl Acad Sci U S A*. 2002;99:5913.
300. Bohl KS, West JL. Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation. *Biomaterials*. 2000;21:2273.
301. Oh BK, Meyerhoff ME. Spontaneous catalytic generation of nitric oxide from S-nitrosothiols at the surface of polymer films doped with lipophilic copper(II) complex. *J Am Chem Soc*. 2003;125:9552.
302. Oh BK, Meyerhoff ME. Catalytic generation of nitric oxide from nitrite at the interface of polymeric films doped with lipophilic Cu(II)-complex: a potential route to the preparation of thromboresistant coatings. *Biomaterials*. 2004;25:283.
303. Duan XB, Lewis RS. Improved haemocompatibility of cysteine-modified polymers via endogenous nitric oxide. *Biomaterials*. 2002;23:1197.
304. Gappa-Fahlenkamp H, Duan X, Lewis RS. Analysis of immobilized L-cysteine on polymers. *J Biomed Mater Res A*. 2004;71:519.
305. Hwang S, Meyerhoff ME. Organodisulfide-tethered polymers that spontaneously generate nitric oxide when in contact with fresh blood. *J Mater Chem*. 2008;18:1784.
306. Herring M, Gardner A, Glover J. Single-staged technique for seeding vascular grafts with autogenous endothelium. *Surgery*. 1978;84:498.
307. Zilla P, Fasol R, Deutsch M, et al. Endothelial cell seeding of polytetrafluoroethylene vascular grafts in humans: a preliminary report. *J Vasc Surg*. 1987;6:535.
308. Herring M, Smith J, Dalsing M, et al. Endothelial seeding of polytetrafluoroethylene femoral popliteal bypasses: the failure of low-density seeding to improve patency. *J Vasc Surg*. 1994;20:650.
309. Jensen N, Lindblad B, Bergqvist D. Endothelial cell seeded Dacron aortobifurcated grafts: platelet deposition and long-term follow-up. *J Cardiovasc Surg (Torino)*. 1994;35:425.
310. Lindblad B, Wright SW, Sell RL, et al. Alternative techniques of seeding cultured endothelial cells to ePTFE grafts of different diameters, porosities, and surfaces. *J Biomed Mater Res*. 1987;21:1013.
311. Graham LM, Vinter DW, Ford JW, et al. Cultured autogenous endothelial cell seeding of prosthetic vascular grafts. *Surg Forum*. 1979;30:204.
312. Zilla P, Deutsch M, Meinhart J, et al. Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. *J Vasc Surg*. 1994;19:540.
313. Deutsch M, Meinhart J, Fischlein T, et al. Clinical autologous in vitro endothelialization of infrainguinal ePTFE grafts in 100 patients: a 9-year experience. *Surgery*. 1999;126:847.
314. Meinhart JG, Deutsch M, Fischlein T, et al. Clinical autologous in vitro endothelialization of 153 infrainguinal ePTFE grafts. *Ann Thorac Surg*. 2001;71:S327.
315. Laube HR, Duwe J, Rutsch W, et al. Clinical experience with autologous endothelial cell-seeded polytetrafluoroethylene coronary artery bypass grafts. *J Thorac Cardiovasc Surg*. 2000;120:134.
316. Seeger JM, Klingman N. Improved endothelial cell seeding with cultured cells and fibronectin-coated grafts. *J Surg Res*. 1985;38:641.
317. Kesler KA, Herring MB, Arnold MP, et al. Enhanced strength of endothelial attachment on polyester elastomer and polytetrafluoroethylene graft surfaces with fibronectin substrate. *J Vasc Surg*. 1986;3:58.

318. Jarrell BE, Speicher L, Carabasi RA, et al. Use of an endothelial monolayer on a vascular graft prior to implantation—temporal dynamics and compatibility with the operating-room. *Ann Surg.* 1986;203:671.
319. Anderson JS, Price TM, Hanson SR, et al. In vitro endothelialization of small-caliber vascular grafts. *Surgery.* 1987;101:577.
320. Greisler HP, Klosak JJ, Dennis JW, et al. Biomaterial pretreatment with ECGF to augment endothelial-cell proliferation. *J Vasc Surg.* 1987;5:393.
321. Radomski JS, Jarrell BE, Williams SK, et al. Initial adherence of human capillary endothelial cells to Dacron. *J Surg Res.* 1987;42:133.
322. Mazzucotelli JP, Kleinsoyer C, Beretz A, et al. Endothelial cell seeding: coating Dacron and expanded polytetrafluoroethylene vascular grafts with a biological glue allows adhesion and growth of human saphenous vein endothelial cells. *Int J Artif Organs.* 1991;14:482.
323. Steele JG, Johnson G, McFarland C, et al. Roles of serum vitronectin and fibronectin in initial attachment of human vein endothelial cells and dermal fibroblasts on oxygen-containing and nitrogen-containing surfaces made by radiofrequency plasmas. *J Biomater Sci Polym Ed.* 1994;6:511.
324. Gosselin C, Vorp DA, Warty V, et al. ePTFE coating with fibrin glue, FGF-1, and heparin: effect on retention of seeded endothelial cells. *J Surg Res.* 1996;60:327.
325. Kaehler J, Zilla P, Fasol R, et al. Precoating substrate and surface configuration determine adherence and spreading of seeded endothelial cells on polytetrafluoroethylene grafts. *J Vasc Surg.* 1989;9:535.
326. Lin HB, García-Echeverría C, Asakura S, et al. Endothelial-cell adhesion on polyurethanes containing covalently attached RGD-peptides. *Biomaterials.* 1992;13:905.
327. Massia SP, Hubbell JA. Vascular endothelial-cell adhesion and spreading promoted by the peptide REDV of the IIICS region of plasma fibronectin is mediated by integrin  $\alpha$ -4- $\beta$ -1. *J Biol Chem.* 1992;267:14019.
328. Jun HW, West J. Development of a YIGSR-peptide-modified polyurethaneurea to enhance endothelialization. *J Biomater Sci Polym Ed.* 2004;15:73.
329. Salacinski HJ, Tiwari A, Hamilton G, et al. Cellular engineering of vascular bypass grafts: role of chemical coatings for enhancing endothelial cell attachments. *Med Biol Eng Comput.* 2001;39:609.
330. Bowlin GL, Meyer A, Fields C, et al. The persistence of electrostatically seeded endothelial cells lining a small diameter expanded polytetrafluoroethylene vascular graft. *J Biomater Appl.* 2001;16:157.
331. Fields C, Cassano A, Makhoul RG, et al. Evaluation of electrostatically endothelial cell seeded expanded polytetrafluoroethylene grafts in a canine femoral artery model. *J Biomater Appl.* 2002;17:135.
332. Ballermann BJ, Ott MJ. Adhesion and differentiation of endothelial cells by exposure to chronic shear-stress: a vascular graft model. *Blood Purif.* 1995;13:125.
333. Isenberg BC, Williams C, Tranquillo RT. Endothelialization and flow conditioning of fibrin-based media-equivalents. *Ann Biomed Eng.* 2006;34:971.
334. Dichek DA, Anderson J, Kelly AB, et al. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. *Circulation.* 1996;93:301.
335. Vonderleyen HE, Gibbons GH, Morishita R, et al. Gene-therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. *Proc Natl Acad Sci U S A.* 1995;92:1137.
336. Fujita Y, Hong-De Wu M, Ishida A, et al. Accelerated healing of Dacron grafts seeded by preclotting with autologous bone marrow blood. *Ann Vasc Surg.* 1999;13:402.
337. Bhattacharya V, McSweeney PA, Shi Q, et al. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells. *Blood.* 2000;95:581.
338. Griese DP, Ehsan A, Melo LG, et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts. Implications for cell-based vascular therapy. *Circulation.* 2003;108:2710.

339. Tiwari A, Kidane A, Punshon G, et al. Extraction of cells for single-stage seeding of vascular-bypass grafts. *Biotechnol Appl Biochem*. 2003;38:35.
340. Pasic M, Muller Glauser W, Von Segesser LK, et al. Superior late patency of small-diameter Dacron grafts seeded with omental microvascular cells—an experimental study. *Ann Thorac Surg*. 1994;58:677.
341. Jarrell BE, Williams SK, Stokes G, et al. Use of freshly isolated capillary endothelial cells for the immediate establishment of a monolayer on a vascular graft at surgery. *Surgery*. 1986;100:392.
342. Pasic M, Muller Glauser W, Odermatt B, et al. Seeding with omental cells prevents late neointimal hyperplasia in small-diameter Dacron grafts. *Circulation*. 1995;92:2605.
343. Greisler HP, Cziperle DJ, Kim DU, et al. Enhanced endothelialization of expanded polytetrafluoroethylene grafts by fibroblast growth-factor type-1 pretreatment. *Surgery*. 1992;112:244.
344. Greisler HP, Gosselin C, Ren DW, et al. Biointeractive polymers and tissue engineered blood vessels. *Biomaterials*. 1996;17:329.
345. Gray JL, Kang SS, Zenni GC, et al. FGF-1 affixation stimulates ePTFE endothelialization without intimal hyperplasia. *J Surg Res*. 1994;57:596.
346. Doi K, Matsuda T. Enhanced vascularization in a microporous polyurethane graft impregnated with basic fibroblast growth factor and heparin. *J Biomed Mater Res*. 1997;34:361.
347. Dahl SLM, Koh J, Prabhakar V, et al. Decellularized native and engineered arterial scaffolds for transplantation. *Cell Transplant*. 2003;12:659.
348. Schmidt CE, Baier JM. Acellular vascular tissues: natural biomaterials for tissue repair and tissue engineering. *Biomaterials*. 2000;21:2215.
349. Uchimura E, Sawa Y, Taketani S, et al. Novel method of preparing acellular cardiovascular grafts by decellularization with poly(ethylene glycol). *J Biomed Mater Res A*. 2003;67A:834.
350. Tamura N, Nakamura T, Terai H, et al. A new acellular vascular prosthesis as a scaffold for host tissue regeneration. *Int J Artif Organs*. 2003;26:783.
351. Khor E. Methods for the treatment of collagenous tissues for bioprostheses. *Biomaterials*. 1997;18:95.
352. Courtman DW, Errett BF, Wilson GJ. The role of crosslinking in modification of the immune response elicited against xenogenic vascular acellular matrices. *J Biomed Mater Res*. 2001;55:576.
353. Huang Lee LLH, Cheung DT, Nimni ME. Biochemical changes and cytotoxicity associated with the degradation of polymeric glutaraldehyde derived cross-links. *J Biomed Mater Res*. 1990;24:1185.
354. Marois Y, Chakfe N, Deng XY, et al. Carbodiimide cross-linked gelatin—new coating for porous polyester arterial prostheses. *Biomaterials*. 1995;16:1131.
355. Hurt AV, Batellocruz M, Skipper BJ, et al. Bovine carotid-artery heterografts versus polytetrafluoroethylene grafts. A prospective, randomized study. *Am J Surg*. 1983;146:844.
356. Sciacca V, Walter G, Becker HM. Biogenic grafts in arterial surgery—long-term results. 1. The homologous vein. 2. The modified heterologous bovine carotid-artery. 3. The human umbilical vein. *Thorac Cardiovasc Surg*. 1984;32:157.
357. Holdsworth RJ, Naidu S, Gervaz P, et al. Glutaraldehyde-tanned bovine carotid artery graft for infrainguinal vascular reconstruction: 5-year follow-up. *Eur J Vasc Endovasc Surg*. 1997;14:208.
358. Conklin BS, Richter ER, Kreutziger KL, et al. Development and evaluation of a novel decellularized vascular xenograft. *Med Eng Phys*. 2002;24:173.
359. Amiel GE, Komura M, Shapira O, et al. Engineering of blood vessels from acellular collagen matrices coated with human endothelial cells. *Tissue Eng*. 2006;12:2355.
360. Conklin BS, Wu HK, Lin PH, et al. Basic fibroblast growth factor coating and endothelial cell seeding of a decellularized heparin-coated vascular graft. *Artif Organs*. 2004;28:668.
361. McFetridge PS, Bodamyali T, Horrocks M, et al. Endothelial and smooth muscle cell seeding onto processed ex vivo



- arterial scaffolds using 3D vascular bioreactors. *ASAIO J.* 2004;50:591.
362. Kaushal S, Amiel GE, Guleserian KJ, et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. *Nat Med.* 2001;7:1035.
  363. Shimizu K, Ito A, Arinobe M, et al. Effective cell-seeding technique using magnetite nanoparticles and magnetic force onto decellularized blood vessels for vascular tissue engineering. *J Biosci Bioeng.* 2007;103:472.
  364. Cho SW, Lim SH, Kim IK, et al. Small-diameter blood vessels engineered with bone marrow-derived cells. *Ann Surg.* 2005;241:506.
  365. DiMuzio P, Fischer L, McIlhenny S, et al. Development of a tissue-engineered bypass graft seeded with stem cells. *Vascular.* 2006;14:338.
  366. Badyalak SF, Lantz GC, Coffey A, et al. Small intestinal submucosa as a large diameter vascular graft in the dog. *J Surg Res.* 1989;47:74.
  367. Marshall SE, Tweedt SM, Greene CH, et al. An alternative to synthetic aortic grafts using jejunum. *J Invest Surg.* 2000;13:333.
  368. Weinberg CB, Bell E. A blood-vessel model constructed from collagen and cultured vascular cells. *Science.* 1986;231:397.
  369. van Buul-Wortelboer MF, Brinkman HJ, Dingemans KP, et al. Reconstitution of the vascular wall in vitro. A novel model to study interactions between endothelial and smooth muscle cells. *Exp Cell Res.* 1986;162:151.
  370. L'Heureux N, Germain L, Labbe R, et al. In vitro construction of a human blood vessel from cultured vascular cells: a morphologic study. *J Vasc Surg.* 1993;17:499.
  371. Ziegler T, Nerem RM. Tissue engineering a blood vessel: regulation of vascular biology by mechanical stresses. *J Cell Biochem.* 1994;56:204.
  372. Hirai J, Matsuda T. Self-organized, tubular hybrid vascular tissue composed of vascular cells and collagen for low-pressure-loaded venous system. *Cell Transplant.* 1995;4:597.
  373. Barocas VH, Girtan TS, Tranquillo RT. Engineered alignment in media equivalents: magnetic prealignment and mandrel compaction. *J Biomech Eng.* 1998;120:660.
  374. Girtan TS, Oegema TR, Grassl ED, et al. Mechanisms of stiffening and strengthening in media-equivalents fabricated using glycation. *J Biomech Eng.* 2000;122:216.
  375. Elbjairami WM, Yonter EO, Starcher BC, et al. Enhancing mechanical properties of tissue-engineered constructs via lysyl oxidase crosslinking activity. *J Biomed Mater Res A.* 2003;66A:513.
  376. Seliktar D, Black RA, Vito RP, et al. Dynamic mechanical conditioning of collagen-gel blood vessel constructs induces remodeling in vitro. *Ann Biomed Eng.* 2000;28:351.
  377. Isenberg BC, Tranquillo RT. Long-term cyclic distention enhances the mechanical properties of collagen-based media-equivalents. *Ann Biomed Eng.* 2003;31:937.
  378. Greisler HP. Arterial regeneration over absorbable prostheses. *Arch Surg.* 1982;117:1425.
  379. Greisler HP, Tattersall CW, Klosak JJ, et al. Partially bioresorbable vascular grafts in dogs. *Surgery.* 1991;110:645.
  380. Zenni GC, Ellinger J, Lam TM, et al. Biomaterial-induced macrophage activation and monokine release. *J Invest Surg.* 1994;7:135.
  381. Shinoka T, Shum-Tim D, Ma PX, et al. Creation of viable pulmonary artery autografts through tissue engineering. *J Thorac Cardiovasc Surg.* 1998;115:536.
  382. Shum-Tim D, Stock U, Hrkach J, et al. Tissue engineering of autologous aorta using a new biodegradable polymer. *Ann Thorac Surg.* 1999;68:2298.
  383. Shin'oka T, Imai Y, Ikada Y. Transplantation of a tissue-engineered pulmonary artery. *N Engl J Med.* 2001;344:532.
  384. Shin'oka T, Matsumura G, Hibino N, et al. Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. *J Thorac Cardiovasc Surg.* 2005;129:1330.
  385. L'Heureux N, Paquet S, Labbe R, et al. A completely biological tissue-engineered human blood vessel. *FASEB J.*

- 1998;12:47.
386. L'Heureux N, Dusserre N, Konig G, et al. Human tissue-engineered blood vessels for adult arterial revascularization. *Nat Med*. 2006;12:361.
  387. L'Heureux N, Dusserre N, Marini A, et al. Technology insight: the evolution of tissue-engineered vascular grafts—from research to clinical practice. *Nat Clin Pract Cardiovasc Med*. 2007;4:389.
  388. Sparks CH. Autogenous grafts made to order. *Ann Thorac Surg*. 1969;8:104.
  389. Sparks CH. Silicone mandril method for growing reinforced autogenous femoro-popliteal artery grafts in situ. *Ann Surg*. 1973;177:293.
  390. Campbell JH, Efendy JL, Campbell GR. Novel vascular graft grown within recipient's own peritoneal cavity. *Circ Res*. 1999;85:1173.
  391. Chue WL, Campbell GR, Caplice N, et al. Dog peritoneal and pleural cavities as bioreactors to grow autologous vascular grafts. *J Vasc Surg*. 2004;39:859.
  392. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—II: maintenance of vascular graft or arterial patency by antiplatelet therapy. *BMJ*. 1994;308:159.
  393. Tangelder MJD, Lawson JA, Algra A, et al. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. *J Vasc Surg*. 1999;30:701.
  394. Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. *J Vasc Surg*. 2002;35:413.
  395. Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease. *Chest*. 2004;126:609S.

## 第 89 章

1. Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. *N Engl J Med*. 1986;314:1.
2. Hayward PA, Hare DL, Gordon I, et al. Which arterial conduit? Radial artery versus free right internal thoracic artery: six-year clinical results of a randomized controlled trial. *Ann Thorac Surg*. 2007;84:493.
3. Hirose H, Amano A, Takanashi S, et al. Coronary artery bypass grafting using the gastroepiploic artery in 1,000 patients. *Ann Thorac Surg*. 2002;73:1371.
4. Piercy KT, Hundley JC, Stafford JM, et al. Renovascular disease in children and adolescents. *J Vasc Surg*. 2005;41:973.
5. Patterson R, Smail D. Radial artery as conduit for distal renal artery reconstruction. *J Vasc Surg*. 2003;38:609.
6. Amin-Hanjani S, Butler WE, Ogilvy CS, et al. Extracranial-intracranial bypass in the treatment of occlusive cerebrovascular disease and intracranial aneurysms in the United States between 1992 and 2001: a population-based study. *J Neurosurg*. 2005;103:794.
7. Pomposelli FB, Kansal N, Hamdan AD, et al. A decade of experience with dorsalis pedis artery bypass: analysis of outcome in more than 1000 cases. *J Vasc Surg*. 2003;37:307.
8. Hughes K, Hamdan A, Schermerhorn M, et al. Bypass for chronic ischemia of the upper extremity: results in 20 patients. *J Vasc Surg*. 2007;46:303.
9. Synn AY, Chalmers RT, Sharp WJ, et al. Is there a conduit of preference for a bypass between the carotid and subclavian arteries? *Am J Surg*. 1993;166:157.
10. Modrall JG, Sadjadi J, Joiner DR, et al. Comparison of superficial femoral vein and saphenous vein as conduits for mesenteric arterial bypass. *J Vasc Surg*. 2003;37:362.
11. NKF-K/DOQI clinical practice guidelines for vascular access: update 2006. *Am J Kidney Dis*. 2006;48(Suppl 1):S176.

12. Prager M, Polterauer P, Bohmig HJ, et al. Collagen versus gelatin coated Dacron versus stretch polytetrafluoroethylene in abdominal aortic bifurcation graft surgery: results of a seven year prospective randomized multicenter trial. *Surgery*. 2001;130:408.
13. Faries PL, LoGerfo FW, Arora S, et al. A comparative study of alternative conduits for lower extremity revascularization: all autogenous conduit versus prosthetic grafts. *J Vasc Surg*. 2000;32:1080.
14. Carrel A. Ultimate results of aortic transplantations. *J Exp Med*. 1912;15:389.
15. Jeger E. Zur Technik der Blutgefassnaht. *Beitr Klin Chir*. 1915;97:553.
16. Gross RE, Hurwitt ES, Bill AH, et al. Preliminary observations of the use of human arterial grafts in the treatment of certain cardiovascular defects. *N Engl J Med*. 1948;239:578.
17. Linton RB. Some practical considerations in the surgery of blood vessel grafts. *Surgery*. 1955;38:817.
18. Boren CH, Roon AJ, Moore WS. Maintenance of viable arterial allografts by cryopreservation. *Surgery*. 1977;83:382.
19. L'Italien GJ, Maloney RD, Abbott WM. The preservation of the mechanical properties of venous allografts by freezing. *J Surg Res*. 1979;27:239.
20. Faggioli GL, Ricotta JJ. The role of cryopreserved vein allografts in infrainguinal reconstructions. *Adv Vasc Surg*. 1995;3:173.
21. Rosenberg N, Martinez A, Sawyer PN, et al. Tanned collagen arterial prosthesis of bovine carotid origin in man. *Ann Surg*. 1966;164:247.
22. Dardik H, Dardik I. Successful arterial substitution with modified human umbilical vein. *Ann Surg*. 1976;183:252.
23. Barner HB, DeWeese JA, Schenk EA. Fresh and frozen homologous venous grafts for arterial repair. *Angiology*. 1966;17:389.
24. Perloff LJ, Reckard CR, Rowlands DT, et al. The venous homograft: An immunological question. *Surgery*. 1972;72:961.
25. Ochsner JL, DeCamp PT, Leonard GL. Experience with fresh venous allografts as arterial substitute. *Ann Surg*. 1971;173:933.
26. Mirelli M, Buzzi G, Pasquinelli PL, et al. Fresh and cryopreserved arterial homografts: immunological and clinical results. *Transplant Proc*. 2005;37:2688.
27. Weber TR, Dent TL, Salles CA, et al. Cryopreservation of venous homografts. *Surg Forum*. 1975;26:291.
28. Bortolotti U, Casarotto D, Frugoni C, et al. Coronary artery bypass with glycerol-preserved saphenous vein allografts. *Bull Tex Heart Inst*. 1981;8:250.
29. Balderman SC, Montes M, Schwartz K, et al. Preparation of venous allografts: a comparison of techniques. *Ann Surg*. 1984;200:117.
30. Stephen M, Sheil AGR, Wong J. Allograft vein arterial bypass. *Arch Surg*. 1978;113:591.
31. Livan GG. Mechanism of cryoinjury in biological systems. *Cryobiology*. 1972;9:182.
32. Mazur P. The freezing of biological systems. *Science*. 1970;168:929.
33. Faggioli GL, Gargiulo M, Pasquinelli G. Long-term cryopreservation of autologous veins in rabbits. *Cardiovasc Surg*. 1994;2:259.
34. Brockbank KGM. Effects of cryopreservation upon vein function in vivo. *Cryobiology*. 1994;31:71.
35. Pukacki F, Jankowski T, Pukacki F, et al. The mechanical properties of fresh and cryopreserved arterial homografts. *Eur J Vasc Endovasc Surg*. 2000;20:21.
36. Bia D, Pessana F, Armentano R, et al. Cryopreservation pressure does not modify human carotid homograft mechanical properties: an isobaric and dynamic analysis. *Cell Tissue Banking*. 2006;7:183.
37. Malone JM, Moore WS, Kischer CW, et al. Venous cryopreservation: endothelial fibrinolytic activity and histology. *J Surg Res*. 1980;29:209.
38. Bambang LS, Mazzucotelli JP, Beaujean F, et al. Effects of cryopreservation on the proliferation and anticoagulant activity of human saphenous vein endothelial cells. *J Thorac Cardiovasc Surg*. 1995;110:998.

39. Brockbank KGM, Donovan TJ, Ruby ST, et al. Functional analysis of cryopreserved veins: preliminary report. *J Vasc Surg.* 1990;11:94.
40. Ligush J, Berceli SA, Moosa HH, et al. First results on the functional characteristics of cryopreserved human saphenous vein. *Cells Materials.* 1991;1:359.
41. Ku DD, Willis WL, Caulfield JB. Retention of endothelium-dependent vasodilatory responses in canine coronary arteries following cryopreservation. *Cryobiology.* 1990;27:511.
42. Elmore JR, Gloviczki P, Brockbank KGM, et al. Cryopreservation affects endothelial and smooth muscle function of canine saphenous vein grafts. *J Vasc Surg.* 1991;13:584.
43. Alonso M, Segura RJ, Prada C, et al. Cryopreserved arterial homografts: preliminary results in infrainguinal arterial reconstructions. *Ann Vasc Surg.* 1999;13:261.
44. Schmitz-Rixen T, Megerman J, Colvin RB, et al. Immunosuppressive treatment of aortic allografts. *J Vasc Surg.* 1988;7:82.
45. Schwartz SI, Kutner FR, Neistadt A, et al. Antigenicity of homografted veins. *Surgery.* 1967;61:474.
46. Tice DA, Zerbino V. Clinical experience with preserved human allografts for vascular reconstruction. *Surgery.* 1972;72:260.
47. Pober JS, Gimbrone MA, Collins T, et al. Interactions of T lymphocytes with human vascular endothelial cells: role of endothelial cell surface antigens. *Immunobiol.* 1984;168:483.
48. Balzer KM, Luther B, Sandmann W, et al. Donor-specific sensitization by cadaveric venous allografts used for arterial occlusive vascular disease. *Tissue Antigens.* 2004;64:13.
49. Bank HL, Schmehl MK, Warner R, et al. Transplantation of cryopreserved canine venous allografts. *J Surg Res.* 1991;50:57.
50. Carpenter JP, Tomaszewski JE. Human saphenous vein allograft bypass grafts: immune response. *J Vasc Surg.* 1998;27:492.
51. Axthelm SC, Porter JM, Strickland S, et al. Antigenicity of venous allografts. *Ann Surg.* 1979;189:290.
52. Cochran RP, Kunzelman, KS. Cryopreservation does not alter antigenic expression of aortic allografts. *J Surg Res.* 1989;46:597.
53. Miller VM, Bergman RT, Gloviczki P, et al. Cryopreserved venous allografts: effects of immunosuppression and antiplatelet therapy on patency and function. *J Vasc Surg.* 1993;18:216.
54. Augelli NV, Lupinetti FM, el Khatib H, et al. Allograft vein patency in a canine model: additive effects of cryopreservation and cyclosporine. *Transplantation.* 1991;52:466.
55. Carpenter JP, Tomaszewski JE. Immunosuppression for human saphenous allograft bypass surgery: a prospective randomized trial. *J Vasc Surg.* 1997;26:32.
56. Posner MP, Makhoul RG, Altman M, et al. Early results of infrageniculate arterial reconstruction using cryopreserved homograft saphenous conduit (CADVEIN) and combination low-dose systemic immunosuppression. *J Am Coll Surg.* 1996;183:208.
57. Benedetto B, Lipkowitz G, Madden R, et al. Use of cryopreserved cadaveric vein allograft for hemodialysis access precludes kidney transplantation because of allosensitization. *J Vasc Surg.* 2001;34:139.
58. Madden R, Lipkowitz G, Benedetto B, et al. Decellularized cadaver vein allografts used for hemodialysis access do not cause allosensitization or preclude kidney transplantation. *Am J Kidney Dis.* 2002;10:1240.
59. Holdsworth RJ, Naidu S, Gervaz P, et al. Glutaraldehyde-tanned bovine carotid artery graft for infrainguinal vascular reconstruction: 5 year follow up. *Eur J Vasc Endovasc Surg.* 1997;14:208.
60. Rosenberg N. The modified bovine arterial graft. *Arch Surg.* 1972;105:547.
61. Katzman HE, Glickman MH, Schild AF, et al. Multicenter evaluation of the bovine mesenteric vein bioprosthesis for hemodialysis access in patients with an earlier failed prosthetic graft. *J Am Coll Surg.* 2005;201:223.
62. Dardik H, Ibrahim IM, Sprayregen S, et al. Clinical experience with modified human umbilical cord vein for arterial bypass.

*Surgery*. 1976;79:618.

63. Roedersheimer LR, Feins RH, Schwartz SI, et al. Comparison of platelet adherence and aggregation in modified human umbilical vein and autogenous vein grafts. *Am J Surg*. 1980;140:591.
64. Schechter I. Prolonged survival of glutaraldehyde treated skin homografts. *Proc Nat Acad Sci U S A*. 1971;68:1590.
65. Love C, Zeelnicov T, Dahl T, et al. Rapid intraoperative construction of autologous small caliber blood vessels. *ASAIO J*. 1998;44:M648.
66. Lantz GC, Badylak SF, Coffey AC, et al. Small intestinal submucosa as a small-diameter arterial graft in a dog. *J Invest Surg*. 1990;3:217.
67. Uematsu M, Okada M. A modified human ureter graft tanned by a new crosslinking agent polyepoxy compound for small diameter arterial substitutions: an experimental preliminary study. *Artif Organs*. 1998;22:1525.
68. Ketharanathan V, Christie BA. Bovine ureter as a vascular prosthesis: a preliminary report of an experimental study in dogs. *Aust N Z J Surg*. 1982;52:590.
69. Field PL. The chemically treated bovine ureter—clinical performance of a novel biological vascular prosthesis. *Cardiovasc Surg*. 2003;11:30.
70. Taylor LM, Edwards JM, Porter JM. Present status of reversed vein bypass grafting: five-year results of a modern series. *J Vasc Surg*. 1990;11:193-206.
71. Shah DM, Darling RC, Chang BB, et al. Long term results of in situ saphenous vein bypass. Analysis of 2058 cases. *Ann Surg*. 1995;222:438.
72. Faries PL, Arora S, Pomposelli FB, et al. The use of arm vein in lower-extremity revascularization: result of 520 procedures performed in eight years. *J Vasc Surg*. 2000;31:50.
73. Chang BB, Paty PS, Shah DM, et al. The lesser saphenous vein: an underappreciated source of autogenous vein. *J Vasc Surg*. 1992;15:152.
74. Londrey GL, Boshier LP, Brown PW, et al. Infrainguinal reconstruction with arm vein, lesser saphenous vein and remnants of greater saphenous vein: a report of 257 cases. *J Vasc Surg*. 1994;20:451.
75. Veith FJ, Gupta SK, Ascer E, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstruction. *J Vasc Surg*. 1986;3:104.
76. Hobson RW, Lynch TG, Jamil, Z, et al. Results of revascularization in severe lower extremity ischemia: a five year clinical experience. *J Vasc Surg*. 1985;2:174.
77. Pappas PJ, Hobson RW, Meyers MG, et al. Patency of infrainguinal polytetrafluoroethylene grafts with distal interposition vein cuffs. *Cardiovasc Surg*. 1998;6:19.
78. Neville RF, Tempesta B, Sidway AN. Tibial bypass for limb salvage using polytetrafluoroethylene and a distal vein patch. *J Vasc Surg*. 2000;33:266.
79. Dardik H, Silvestri F, Alasio T, et al. Improved method to create the common ostium variant of the distal arteriovenous fistula for enhancing crural prosthetic graft patency. *J Vasc Surg*. 1996;24:240.
80. Farber A, Major K, Wagner WH, et al. Cryopreserved saphenous vein allografts in infrainguinal revascularization: analysis of 240 grafts. *J Vasc Surg*. 2003;38:15.
81. Dardik H, Miller N, Dardik A, et al. A decade of experience with the glutaraldehyde-tanned human umbilical cord vein graft for revascularization of the lower limb. *J Vasc Surg*. 1988;7:336.
82. Kovalic AJ, Beattie DK, Davies AH. Outcome of ProCol, a bovine mesenteric vein graft, in infrainguinal reconstruction. *Eur J Vasc Endovasc Surg*. 2002;24:533.
83. Owen WF. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement. *J Am Soc Nephrol*. 2003;14:S76.
84. Xue JL, Ma JZ, Louis TA, et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. *J Am Soc Nephrol*. 2001;12:2753.

85. Patel ST, Hughes J, Mills JL. Failure of arteriovenous fistula maturation: an unintended consequence of exceeding Dialysis Outcome Quality Initiative guidelines for hemodialysis access. *J Vasc Surg.* 2003;38:439.
86. Woo K, Farber A, Doros G, et al. Evaluation of the efficacy of the transposed upper arm arteriovenous fistula: a single institutional review of 190 basilic and cephalic vein transposition procedures. *J Vasc Surg.* 2007;46:94.
87. Matsuura JH, Johansen KH, Rosenthal D, et al. Cryopreserved femoral vein grafts for difficult hemodialysis access. *Ann Vasc Surg.* 2000;14:50.
88. Hutchin P, Jacobs JR, Devin JB, et al. Bovine graft arteriovenous fistulas for maintenance hemodialysis. *Surg Gynecol Obstet.* 1975;141:255.
89. O'Hara PJ, Hertzner N, Beven EG, et al. Surgical management of abdominal aortic grafts: review of 25 year experience. *J Vasc Surg.* 1986;3:725.
90. Hayes PD, Nasim A, London NJ, et al. In situ replacement of infected aortic grafts with rifampicin-bonded prostheses: the Leicester experience (1992-98). *J Vasc Surg.* 1999;30:92.
91. Clagett GP, Valentine RJ, Hagino RT. Autogenous aortoiliac/femoral reconstruction from superficial femoral-popliteal veins: feasibility and durability. *J Vasc Surg.* 1997;25:255.
92. Kieffer E, Gomes D, Chiche L, et al. Allograft replacement for infrarenal aortic graft infection: early and late results in 179 patients. *J Vasc Surg.* 2004;39:1009.
93. Quinones-Baldrich WJ, Hernandez JJ, Moore WS. Long-term results following surgical management of aortic graft infection. *Arch Surg.* 1991;126:507.
94. Knosalla C, Goeau-Brissonniere O, Leflon V, et al. Treatment of vascular infection by in situ replacement with cryopreserved aortic allografts: an experimental study. *J Vasc Surg.* 1998;27:689.
95. Zhou W, Lin PH, Bush RL, et al. In situ reconstruction with cryopreserved arterial allografts for management of mycotic aneurysms or aortic prosthetic graft infections: a multi-institutional experience. *Tex Heart Inst J.* 2006;33:14.
96. Matsuura JH, Rosenthal D, Wellons ED, et al. Hemodialysis graft infections treated with cryopreserved femoral vein. *Cardiovasc Surg.* 2002;10:561.
97. Fujitani RM, Bassiouny HS, Gewertz BL, et al. Cryopreserved saphenous vein allogeneic homografts: an alternative conduit in lower extremity arterial reconstruction in infected fields. *J Vasc Surg.* 1992;15:519.
98. Buzzi M, Mirelli M, Vaselli C, et al. Vascular tissue banking: state of the art. *Transplant Proc.* 2005;37:2428.
99. Vogt PR, Brunner-LaRocca HP, Lachat M, et al. Technical details with the use of cryopreserved arterial allografts for aortic infection: influence on early and midterm mortality. *J Vasc Surg.* 2002;35:80.
100. Dardik H. A 30-year odyssey with the umbilical vein graft. *J Am Coll Surg.* 2006;203:582.
101. Harris L, O'Brien-Irr M, Ricotta JJ. Long term assessment of cryopreserved bypass grafting success. *J Vasc Surg.* 2001;33:528.
102. Harris RW, Schneider PA, Andros G, et al. Allograft vein bypass: is it an acceptable alternative for infrapopliteal revascularization? *J Vasc Surg.* 1993;18:553.
103. Leseche G, Penna C, Bouttier S, et al. Femorodistal bypass using cryopreserved venous allografts for limb salvage. *Ann Vasc Surg.* 1997;11:230.
104. Martin RS, Edwards WH, Mulherin JL, et al. Cryopreserved saphenous vein allografts for below-knee lower extremity revascularization. *Ann Surg.* 1994;219:664.
105. Shah RM, Faggioli GL, Mangione S, et al. Early results with cryopreserved saphenous vein allografts for infrainguinal bypass. *J Vasc Surg.* 1993;18:965.
106. Walker PJ, Mitchell RS, McFadden PM, et al. Early experience with cryopreserved saphenous vein allografts as a conduit for complex limb-salvage procedures. *J Vasc Surg.* 1993;18:561.
107. Buckley CJ, Abernathy S, Lee SD, et al. Suggested treatment protocol for improving patency of femoral-infrapopliteal cryopreserved saphenous vein allografts. *J Vasc Surg.* 2000;32:731.

108. Dalsing MC, White JV, Yao JS, et al. Infrapopliteal bypass for established gangrene of the forefoot or toes. *J Vasc Surg.* 1985;2:669.
109. Sellke FW, Meng RL, Rossi NP. Cryopreserved saphenous vein homografts for femoral-distal vascular reconstruction. *J Cardiovasc Surg.* 1989;30:838.
110. Lin PH, Brinkman WT, Terramini YY, et al. Management of infected hemodialysis access grafts using cryopreserved human vein allografts. *Am J Surg.* 2002;184:31.
111. Madden RL, Lipkowitz GS, Browne BJ, et al. Experience with cryopreserved cadaveric femoral vein allografts used for hemodialysis access. *Ann Vasc Surg.* 2004;18:453.
112. Bolton WD, Cull DL, Taylor SM, et al. The use of cryopreserved femoral vein grafts for hemodialysis in patients at high risk for infection: a word of caution. *J Vasc Surg.* 2002;36:464.
113. Castier Y, Leseche G, Palombi T, et al. Early experience with cryopreserved arterial allografts in below-knee revascularization for limb salvage. *Am J Surg.* 1999;177:197.
114. Albertini JN, Barral X, Branchereau A, et al. Long-term results of arterial allograft below-knee bypass for limb salvage: a retrospective multicenter study. *J Vasc Surg.* 2000;31:426.
115. Kieffer E, Sabatier J, Plissonnier D. Prosthetic graft infection after descending thoracic/thoracoabdominal aortic aneurysmectomy: management with in situ arterial allografts. *J Vasc Surg.* 2001;33:671.
116. Chiesa R, Astore D, Piccolo G, et al. Fresh and cryopreserved arterial homografts in the treatment of prosthetic graft infections: experience of the Italian Collaborative Vascular Homograft Group. *Ann Vasc Surg.* 1998;12:457.
117. Locati P, Novali C, Socrate M, et al. The use of arterial allografts in aortic graft infection: a three year experience on eighteen patients. *J Cardiovasc Surg.* 1998;39:735.
118. Noel AA, Gloviczki P, Cherry KJ, et al. Abdominal aortic reconstruction in infected fields: early results in the United States Cryopreserved Aortic Allograft Registry. *J Vasc Surg.* 2002;35:847.
119. Verhelst R, Lacroix V, Vraux H, et al. Use of cryopreserved arterial homografts for management of infected prosthetic grafts: a multicenter study. *Ann Vasc Surg.* 2000;14:602.
120. Nevelsteen A, Feryn T, Lacroix H, et al. Experience with cryopreserved arterial allografts in the treatment of prosthetic graft infections. *Cardiovasc Surg.* 1998;6:378.
121. Yeager RA, Taylor LMJ, Moneta GL, et al. Improved results with conventional management of infrarenal aortic infection. *J Vasc Surg.* 1999;30:76.
122. Dardik H, Wengerter K, Qin F, et al. Comparative decades of experience with glutaraldehyde-tanned human umbilical cord vein graft for lower limb revascularization: an analysis of 1275 cases. *J Vasc Surg.* 2002;35:64.
123. Neufang A, Espinola-Klein C, Dorweiler B, et al. Femoropopliteal prosthetic bypass with glutaraldehyde stabilized human umbilical vein (HUV). *J Vasc Surg.* 2007;46:280.
124. Neufang A, Espinola-Klein C, Dorweiler B, et al. Infrapopliteal composite bypass with autologous vein and second generation glutaraldehyde stabilized human umbilical vein (HUV) for critical limb ischemia. *Eur J Vasc Endovasc Surg.* 2007;34:583.
125. Neufang A, Espinola-Klein C, Dorweiler B, et al. Sequential femorodistal composite bypass with second generation glutaraldehyde stabilized human umbilical vein (HUV). *Eur J Vasc Endovasc Surg.* 2005;30:176.
126. Batt M, Gagliardi JM, Avril G, et al. Human umbilical vein grafts as infrainguinal bypasses: long-term clinical follow up and pathological investigation of explanted grafts. *Clin Invest Med.* 1990;13:155.
127. Sato O, Okamoto H, Tagaki A, et al. Biodegradation of glutaraldehyde-tanned human umbilical vein grafts. *Surg Today.* 1995;25:901.
128. Sommeling CA, Buth J, Jakimowicz JJ. Long-term behavior of modified human umbilical vein grafts: late aneurysmal degeneration established by colour-duplex scanning. *Eur J Vasc Endovasc Surg.* 1990;4:89.
129. Johnson WC, Lee KK. A comparative evaluation of polytetrafluoroethylene, umbilical vein, and saphenous vein bypass for

- femoral-popliteal above-knee revascularization: a prospective randomized Department of Veterans Affairs cooperative study. *J Vasc Surg.* 2000;32:268.
130. Cranley JJ, Hafner CD. Revascularization of the femoropopliteal arteries using saphenous vein, polytetrafluoroethylene, and umbilical vein grafts. *Arch Surg.* 1982;117:1543.
  131. Eickhoff JH, Broome A, Ericsson BF, et al. Four years' results of a prospective, randomized clinical trial comparing polytetrafluoroethylene and modified human umbilical vein for below-knee femoropopliteal bypass. *J Vasc Surg.* 1987;6:506.
  132. Johnson WC, Squires JW. Axillofemoral (PTFE) and infrainguinal revascularization (PTFE and umbilical vein). *J Cardiovasc Surg.* 1991;32:344.
  133. Aalders GJ, Vroonhoven TJMV. Polytetrafluoroethylene versus human umbilical vein in above knee femoropopliteal bypass: six-year results of a randomized clinical trial. *J Vasc Surg.* 1992;16:816.
  134. Chinitz JL, Yokoyama T, Bower R, et al. Self-sealing prosthesis for arteriovenous fistula in man. *Trans Am Soc Artif Intern Organs.* 1972;18:452.
  135. Sabanayagam P, Schwartz AB, Soricelli RR, et al. A comparative study of 402 bovine heterografts and 225 reinforced expanded PTFE grafts as AVF in the ESRD patient. *Trans Am Soc Artif Intern Organs.* 1980;26:88.
  136. Anderson C, Richardson CJ, Ney AL, et al. Renewed interest in bovine heterograft for vascular access: a comparison between polytetrafluoroethylene and bovine. In: Henry ML, ed. *Vascular Access for Hemodialysis IX*. Los Angeles, CA: Bonus Books; 2005:185-193.
  137. Anderson CB, Sicard GA, Etheredge EE. Bovine carotid artery and expanded polytetrafluoroethylene grafts for hemodialysis vascular access. *J Surg Res.* 1980;29:184.
  138. Butler HG, Baker LD, Johnson JM. Vascular access for chronic hemodialysis: polytetrafluoroethylene versus bovine heterograft. *Am J Surg.* 1977;134:791.
  139. Kaplan MS, Mirahmadi KS, Winer RL, et al. Comparison of PTFE and bovine grafts for blood access in dialysis patients. *Trans Am Soc Artif Intern Organs.* 1976;22:388.
  140. Tellis VA, Kohlberg WI, Bhat DJ, et al. Expanded polytetrafluoroethylene graft fistula for chronic hemodialysis. *Ann Surg.* 1979;189:101.
  141. Lilly L, Nghiem D, Mendez-Picon G, et al. Comparison between bovine heterograft and expanded PTFE grafts for dialysis access. *Am Surg.* 1980;46:694.
  142. Hurt AV, Batello-Cruz M, Skipper BJ. Bovine carotid artery heterografts versus polytetrafluoroethylene grafts: a prospective, randomized study. *Am J Surg.* 1983;146:844.
  143. Scott EC, Glickman MH. Conduits for hemodialysis access. *Semin Vasc Surg.* 2007;20:158.
  144. Hertzner NR, Beven EG. Venous access using the bovine heterograft: techniques, results, and complications in 75 patients. *Arch Surg.* 1978;113:696.
  145. Broyn T, Oddbjorn C, Fossdal JT, et al. Early complications with a new bovine arterial graft (Solcograft P). *Acta Chir Scand.* 1986;152:263.
  146. Wagner WH, Levin PM, Treiman RL, et al. Early results of infrainguinal arterial reconstruction with a modified biological conduit. *Ann Vasc Surg.* 1992;6:325.
  147. Bourquelot P. ProCol bioprosthetic vascular grafts for dialysis access. In: Henry ML, ed. *Vascular Access for Hemodialysis VI*. Chicago, IL: Precept Press; 1999:223-229.
  148. Widmer MK, Aregger F, Stauffer E, et al. Intermediate outcome and risk factor assessment of bovine vascular heterografts used as AV-fistulas for hemodialysis access. *Eur J Vasc Endovasc Surg.* 2004;27:660.
  149. Schmidli J, Savolainen H, Heller G, et al. Bovine mesenteric graft (ProCol) in critical limb ischaemia with tissue loss and infection. *Eur J Vasc Endovasc Surg.* 2004;27:251.
  150. Dahl SLM, Koh J, Prabhakar V, et al. Decellularized native and engineered arterial scaffolds for transplantation. *Cell*



*Transplant.* 2003;12:659.

151. Conklin BS, Richter ER, Kreutziger KL, et al. Development and evaluation of a novel decellularized vascular xenograft. *Med Eng Phys.* 2002;24:173.
152. Jo WM, Sohn YS, Choi YH, et al. Modified acellularization for successful vascular xenotransplantation. *J Korean Med Sci.* 2007;22:262.
153. Carnagey J, Hern-Anderson D, Ranieri J, et al. Rapid endothelialization of PhotoFix natural biomaterial vascular grafts. *J Biomed Mater Res.* 2003;65B:171.
154. Teebken OE, Bader A, Steinhoff G, et al. Tissue engineering of vascular grafts: human cell seeding of decellularized porcine matrix. *Eur J Vasc Endovasc Surg.* 2000;19:381.

## 第 90 章

1. Volodos NL, Shekhanin VE, Karpovich IP, et al. Self-fixing synthetic prosthesis for endoprosthetics of the vessels. *Vestnik Khirurgii (Russia).* 1986;137:123-125.
2. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. *Ann Vasc Surg.* 1991;5:491-499.
3. Ivancev K, Malina M, Lindblad B, et al. Abdominal aortic aneurysms: experience with the Ivancev-Malmo endovascular system for aortomonoiliac stent-grafts. *J Endovasc Ther.* 1997;4:242-251.
4. Ohki T, Veith FJ, Sanchez LA, et al. Varying strategies and devices for endovascular repair of abdominal aortic aneurysms. *Semin Vasc Surg.* 1997;10:242-256.
5. May J, White GH, Yu W, et al. Concurrent comparison of endoluminal versus open repair in the treatment of abdominal aortic aneurysms: analysis of 303 patients by the life table method. *J Vasc Surg.* 1998;27:213-221.
6. Mohan IV, Harris PL, Van Marrewijk CJ, et al. Factors and forces influencing stent-graft migration after endovascular aortic aneurysm repair. *J Endovasc Ther.* 2002;9:748-755.
7. Resch T, Malina M, Linblad B, et al. The impact of stent design on proximal stent-graft fixation in the abdominal aorta: an experimental study. *Eur J Vasc Endovasc Surg.* 2000;20:190-195.
8. Zarins CK, Bloch DA, Crabtree T, et al. Stent graft migration after endovascular aneurysm repair: importance of proximal fixation. *J Vasc Surg.* 2003;38:1264-1272.
9. Malina M, Lindblad B, Ivancev K, et al. Endovascular AAA exclusion: will stents with hooks and barbs prevent stent-graft migration? *J Endovasc Surg.* 1998;5:310-317.
10. Pearce WH, Slaughter MS, Lemaire S, et al. Aortic diameter as a function of age, gender, and body surface area. *Surgery.* 1993;114:691-697.
11. Walker SR, Macierewicz J, Elmarasy NM, et al. A prospective study to assess changes in proximal aortic neck dimensions after endovascular repair of abdominal aortic aneurysms. *J Vasc Surg.* 1999;29:625-630.
12. Walsh SR, Tang TY, Boyle JR. Renal consequences of endovascular abdominal aortic aneurysm repair. *J Endovasc Ther.* 2008;15:73-82.
13. Cho J, Dillavou ED, Rhee RY, et al. Late abdominal aortic aneurysm enlargement after endovascular repair with the Excluder device. *J Vasc Surg.* 2004;39:1236-1242.
14. Risberg B, Delle M, Lonn L, et al. Management of aneurysm sac hygroma. *J Endovasc Ther.* 2004;11:191-195.
15. Matsumura JS, Ryu RK, Ouriel K. Identification and implications of transgraft microleaks after endovascular repair of aortic aneurysms. *J Vasc Surg.* 2001;34:190-197.
16. Dattilo JB, Brewster DC, Fan CM, et al. Clinical failures of endovascular abdominal aortic aneurysm repair: incidence, causes, and management. *J Vasc Surg.* 2002;35:1137-1144.
17. Conner MS, Sternbergh WC, Carter G, et al. Secondary procedures after endovascular aortic aneurysm repair. *J Vasc Surg.* 2002;36:992-996.

18. Bernhard VM, Mitchell RS, Matsumura JS, et al. Ruptured abdominal aortic aneurysm after endovascular repair. *J Vasc Surg.* 2002;35:1155-1162.
19. FDA Public Health Notification. Problems with endovascular grafts for treatment of abdominal aortic aneurysm. Food and Drug Administration. April 27, 2001.
20. FDA Public Health Notification: Updated data on mortality associated with Medtronic AVE AneuRx stent graft system. Food and Drug Administration. December 17, 2003.
21. FDA Public Health Notification: Updated data on mortality associated with Medtronic AneuRx stent graft system. Food and Drug Administration. March 17, 2008.
22. White GH, May J, Waugh RC, et al. Type II and type IV endoleak: toward a complete definition of blood flow in the sac after endoluminal AAA repair. *J Endovasc Surg.* 1998;5:305-309.
23. Ebaugh JL, Eskandari MK, Finkelstein A, et al. Caudal migration of endoprostheses after treatment of abdominal aortic aneurysms. *J Surg Res.* 2002;107:14-17.
24. Lee JT, Lee J, Aziz I, et al. Stent-graft migration following endovascular repair of aneurysms with large proximal necks: anatomical risk factors and long-term sequelae. *J Endovasc Ther.* 2002;9:652-664.
25. Sternbergh WC, Money SR, Greenberg RK, et al. Influence of endograft oversizing on device migration, endoleak, aneurysm shrinkage, and aortic neck dilation: results from the Zenith multicenter trial. *J Vasc Surg.* 2004;39:20-26.
26. Albertini J, Kalliafas S, Travis S, et al. Anatomical risk factors for proximal perigraft endoleak and graft migration following endovascular repair of abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg.* 2000;19:308-312.
27. Sternbergh WC, Carter G, York JW, et al. Aortic neck angulation predicts adverse outcome with endovascular abdominal aortic aneurysm repair. *J Vasc Surg.* 2002;35:482-486.
28. Matsumura JS, Chaikof E; EVT Investigators. Continued expansion of aortic necks after endovascular repair of abdominal aortic aneurysm. *J Vasc Surg.* 1998;28:422-431.
29. Hassoun HT, Mitchell RS, Makaroun MS, et al. Aortic neck morphology after endovascular repair of descending thoracic aneurysms. *J Vasc Surg.* 2006;43:26-31.
30. Coppi G, Silingardi R, Saitta G, Gennai S. Single-center experience with the Talent LPS endograft in patients with at least 5 years of follow-up. *J Endovasc Ther.* 2008;15:23-32.
31. Rutherford RB, Krupski WC. Current status of open versus endovascular stent-graft repair of abdominal aortic aneurysm. *J Vasc Surg.* 2004;39:1129-1139.
32. Jacobs TS, Won J, Gravereaux EC, et al. Mechanical failure of prosthetic human implants: a 10-year experience with aortic stent graft devices. *J Vasc Surg.* 2003;37:16-26.
33. Schoder M, Zaunbauer L, Holzenbein T, et al. Internal iliac artery embolization before endovascular repair of abdominal aortic aneurysms: frequency, efficacy, and clinical results. *AJR Am J Roentgenol.* 2001;177:599-605.
34. Kritpracha B, Pigott JP, Russel TE, et al. Bell-bottom aortoiliac endografts: an alternative that preserves pelvic blood flow. *J Vasc Surg.* 2002;35:874-881.
35. Moore WS, Matsumura JS, Makaroun MS, et al. Five-year interim comparison of the Guidant bifurcated endograft with open repair of abdominal aortic aneurysm. *J Vasc Surg.* 2003;38:46-55.
36. Fransen GAJ, Desgranges P, Laheij RJF, et al. Frequency, predictive factors, and consequences of stent-graft kink following endovascular AAA repair. *J Endovasc Ther.* 2002;10:913-918.
37. Carroccio A, Faries PL, Morrissey NJ, et al. Predicting iliac limb occlusions after bifurcated aortic stent grafting: anatomic and device related causes. *J Vasc Surg.* 2002;36:679-684.
38. Dawson DL, Hellinger JC, Terramani TT, et al. Iliac artery kinking with endovascular therapies: technical considerations. *J Vasc Interv Radiol.* 2002;13:729-733.
39. Mehta M, Veith FJ, Ohki T, et al. Significance of endotension, endoleak, and aneurysm pulsatility after endovascular repair. *J Vasc Surg.* 2003;37:842-846.

40. Peterson BG, Matsumura JS, Brewster DC, Makaroun MS; Excluder Investigators. Five-year report of a multicenter controlled clinical trial of open versus endovascular treatment of abdominal aortic aneurysms. *J Vasc Surg.* 2007;45:885-890.
41. Haider S, Najjar SF, Cho J-S, et al. Sac behavior following aneurysm treatment with the Gore Excluder low-permeability aortic endoprosthesis: twelve-month comparison to the original Excluder device. *J Vasc Surg.* 2006;44:694-700.
42. Fillinger M. Outcomes of original and low-permeability Gore Excluder endoprosthesis for endovascular abdominal aortic aneurysm repair. *J Vasc Surg.* 2007;45:243-249.
43. Muhs BE, Balm R, White GH, Verhagen HJ. Anatomic factors associated with acute endograft collapse after Gore TAG treatment of thoracic aortic dissection or traumatic rupture. *J Vasc Surg.* 2007;45:655-661.
44. Zarins CK, for the AneuRx Clinical Investigators. The US AneuRx clinical trial: 6-year clinical update 2002. *J Vasc Surg.* 2003;37:904-908.
45. Greenberg RK, Chuter TA, Sternbergh WC, et al. Zenith AAA endovascular graft: intermediate-term results of the US multicenter trial. *J Vasc Surg.* 2004;39:1209-1218.
46. Carpenter J, for the Endologix Investigators. Midterm results of the multicenter trial of the PowerLink bifurcated system for endovascular aortic aneurysm repair. *J Vasc Surg.* 2004;40:849-859.
47. Criado FJ, Fairman RM, Becker GJ. Talent LPS AAA stent graft: results of a pivotal clinical trial. *J Vasc Surg.* 2003;37:709-715.
48. Blankensteijn JD, de Jong SECA, Prinssen M, et al, for the Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. *N Engl J Med.* 2005;352:2398-2405.
49. EVAR trial participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. *Lancet.* 2005;365:2179-2186.
50. Schermerhorn ML, O'Malley AJ, Jhaveri A, et al. Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population. *N Engl J Med.* 2008;358:464-474.
51. Anderson PL, Arons RR, Moskowitz AJ, et al. A statewide experience with endovascular abdominal aortic aneurysm repair: rapid diffusion with excellent early results. *J Vasc Surg.* 2004;10:18; discussion 18-19.
52. Lee WA, Carter JW, Upchurch G, et al. Perioperative outcomes after open and endovascular repair of intact abdominal aortic aneurysms in the United States during 2001. *J Vasc Surg.* 2004;39:491-496.
53. Minion DJ. The endowedge and kilt techniques to achieve additional juxtarenal seal during deployment of the Gore Excluder endoprosthesis. *Ann Vasc Surg.* 2006;20:472-477.
54. Makaroun MS, Dillavou ED, Wheatley GH, Cambria RP, for the Gore TAG Investigators. Five-year results of endovascular treatment with the Gore TAG device compared with open repair of thoracic aortic aneurysms. *J Vasc Surg.* 2008;47:912-918.
55. Fattori R, Nienaber CA, Rousseau H, et al. Results of endovascular repair of the thoracic aorta with the Talent thoracic stent-graft: the Talent thoracic retrospective registry. *J Thorac Cardiovasc Surg.* 2006;132:332-339.
56. Matsumura JS, Cambria RP, Dake MD, et al, for the TX2 Clinical Trial Investigators. International controlled clinical trial of TEVAR with the TX2: One-year results. *J Vasc Surg.* 2008;47:247-257; discussion 257.
57. Chuter TAM, Rapp JH, Hiramoto JS, et al. Endovascular treatment of thoracoabdominal aortic aneurysms. *J Vasc Surg.* 2008;47:6-16.
58. Kawaguchi S, Yokoi Y, Shimazaki T, et al. Thoracic endovascular aneurysm repair in Japan: experience with fenestrated stent grafts in the treatment of distal arch aneurysms. *J Vasc Surg.* 2008;48:24S-29S.
59. McWilliams RG, Murphy M, Hartley D, et al. In situ stent-graft fenestration to preserve the left subclavian artery. *J Endovasc Ther.* 2004;11:170-174.
60. Baldwin ZK, Chuter TAM, Hiramoto JS, et al. Double-barrel technique for endovascular exclusion of an aortic arch

- aneurysm without sternotomy. *J Endovasc Ther.* 2008;15:161-165.
61. Criado FJ. A percutaneous technique for preservation of arch branch patency during thoracic endovascular aortic repair (TEVAR). *J Endovasc Ther.* 2007;14:54-58.

## 第 91 章

1. Lee ES, Steenson CC, Trimble KE, et al. Comparing patency rates between external iliac and common iliac artery stents. *J Vasc Surg.* 2000;31:889-894.
2. Ward MR, Kanellakis P, Ramsey D, et al. Response to balloon injury is vascular bed specific: a consequence of de novo vessel structure? *Atherosclerosis.* 2000;151:407-414.
3. Schillinger M, Exner M, Mlekusch W, et al. Inflammatory response to stent implantation: differences in femoropopliteal, iliac, and carotid arteries. *Radiology.* 2002;224:529-535.
4. Gruentzig AR, King SB 3rd, Schlumpf M, Siegenthaler W. Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. *N Engl J Med.* 1987;316:1127-1132.
5. Nobuyoshi M, Kimura T, Nosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. *J Am Coll Cardiol.* 1988;12:616-623.
6. Nobuyoshi M, Kimura T, Ohishi H, et al. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. *J Am Coll Cardiol.* 1991;17:433-439.
7. Isles CG, Robertson S, Hill D. Management of renovascular disease: a review of renal artery stenting in ten studies. *QJM.* 1999;92:159-167.
8. Kandarpa K, Becker GJ, Ferguson RD, et al. Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: part II. *J Vasc Interv Radiol.* 2001;12:807-812.
9. Gray BH, Sullivan TM, Childs MB, et al. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. *J Vasc Surg.* 1997;25:74-83.
10. Schillinger M, Haumer M, Schlerka G, et al. Restenosis after percutaneous transluminal angioplasty in the femoropopliteal segment: the role of inflammation. *J Endovasc Ther.* 2001;8:477-483.
11. Sullivan TM, Ainsworth SD, Langan EM, et al. Effect of endovascular stent strut geometry on vascular injury, myointimal hyperplasia, and restenosis. *J Vasc Surg.* 2002;36:143-149.
12. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. *Circulation.* 1999;99:44-52.
13. Whelan DM, van Beusekom HM, van der Giessen WJ. Foreign body contamination during stent implantation. *Cathet Cardiovasc Diagn.* 1997;40:328-332.
14. LaDisa JF Jr, Olson LE, Guler I, et al. Stent design properties and deployment ratio influence indexes of wall shear stress: a three-dimensional computational fluid dynamics investigation within a normal artery. *J Appl Physiol.* 2004;97:424-430.
15. LaDisa JF Jr, Olson LE, Molthen RC, et al. Alterations in wall shear stress predict sites of neointimal hyperplasia after stent implantation in rabbit iliac arteries. *Am J Physiol Heart Circ Physiol.* 2005;288:H2465-H2475.
16. Sprague EA, Luo J, Palmaz JC. Human aortic endothelial cell migration onto stent surfaces under static and flow conditions. *J Vasc Interv Radiol.* 1997;8:83-92.
17. Palmaz JC, Benson A, Sprague EA. Influence of surface topography on endothelialization of intravascular metallic material. *J Vasc Interv Radiol.* 1999;10:439-444.
18. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. *Circulation.* 2001;103:2816-2821.
19. Shih CC, Lin SJ, Chen YL, et al. The cytotoxicity of corrosion products of nitinol stent wire on cultured smooth muscle cells. *J Biomed Mater Res.* 2000;52:395-403.
20. Palmaz JC, Bailey S, Marton D, Sprague E. Influence of stent design and material composition on procedure outcome. *J*

- Vasc Surg.* 2002;36:1031-1039.
21. Flueckiger F, Sternthal H, Klein GE, et al. Strength, elasticity, and plasticity of expandable metal stents: in vitro studies with three types of stress. *J Vasc Interv Radiol.* 1994;5:745-750.
  22. Hart J, Peeters P, Verbist J, et al. Do device characteristics impact outcome in carotid artery stenting? *J Vasc Surg.* 2006;44:725-730.
  23. Schillinger M, Gschwendtner M, Reimers B, et al. Does carotid stent cell design matter? *Stroke.* 2008;39:905-909.
  24. Dyet JF, Watts WG, Ettles DF, Nicholson AA. Mechanical properties of metallic stents: how do these properties influence the choice of stent for specific lesions? *Cardiovasc Intervent Radiol.* 2000;23:47-54.
  25. Grenacher L, Deutsch J, Lubinski A, Richter GM. Resistance to hoop stress in balloon expandable stents: evaluation in an ex vivo model. *Invest Radiol.* 2003;38:65-72.
  26. Grenacher L, Rohde S, Ganger E, et al. In vitro comparison of self-expanding versus balloon-expandable stents in a human ex vivo model. *Cardiovasc Intervent Radiol.* 2006;29:249-254.
  27. Schoder M, Cejna M, Häzenbein T, et al. Elective and emergent endovascular treatment of subclavian artery aneurysms and injuries. *J Endovasc Ther.* 2003;10:58-65.
  28. Edwards MS, Corriere MA, Craven TE, et al. Atheroembolism during percutaneous renal artery revascularization. *J Vasc Surg.* 2007;46:55-61.
  29. Lam RC, Shah S, Faries PL, et al. Incidence and clinical significance of distal embolization during percutaneous interventions involving the superficial femoral artery. *J Vasc Surg.* 2007;46:1155-1159.
  30. Rapp JH, Wakil L, Sawhney R, et al. Subclinical embolization after carotid artery stenting: new lesions on diffusion-weighted magnetic resonance imaging occur postprocedure. *J Vasc Surg.* 2007;45:867-872; discussion 872-874.
  31. Kedora J, Hohmann S, Garrett W, et al. Randomized comparison of percutaneous Viabahn stent grafts vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral arterial occlusive disease. *J Vasc Surg.* 2007;45:10-16; discussion 16.
  32. Biasi GM, Froio A., Diethrich EB. Carotid plaque echolucency increases the risk of stroke in carotid stenting: The Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) study. *Circulation.* 2004;110:756-762.
  33. Altaf N, Daniels L, Morgan PS, et al. Detection of intraplaque hemorrhage by magnetic resonance imaging in symptomatic patients with mild to moderate carotid stenosis predicts recurrent neurological events. *J Vasc Surg.* 2008;47:337-342.
  34. Coury AJ, Levy RJ, Ratner BD, et al. Degradation of materials in the biological environment. In: *Biomaterials Science: An Introduction to Materials in Medicine.* San Diego, CA: Elsevier Academic Press; 2004:411-454.
  35. Rondelli G, Vicentini B. Localized corrosion behaviour in simulated human body fluids of commercial Ni-Ti orthodontic wires. *Biomaterials.* 1999;20:785-792.
  36. Shih CC, Shih CM, Chou KY, et al. Electrochemical and SEM characterization of gold-coated stents in vitro. *J Electrochem Soc.* 2007;154:C326-C330.
  37. Thomas KA, Cook SD, Harding AF, Haddad RJ, Jr. Tissue reaction to implant corrosion in 38 internal fixation devices. *Orthopedics.* 1988;11:441-451.
  38. Cook SD, Thomas KA, Harding AF, et al. The in vivo performance of 250 internal fixation devices: a follow-up study. *Biomaterials.* 1987;8:177-184.
  39. Eliades T, Pratsinis H, Kleisas D, et al. Characterization and cytotoxicity of ions released from stainless steel and nickel-titanium orthodontic alloys. *Am J Orthod Dentofacial Orthop.* 2004;125:24-29.
  40. Shih CC, Lin SJ, Chen YL, et al. The cytotoxicity of corrosion products of nitinol stent wire on cultured smooth muscle cells. *J Biomed Mater Res.* 2000;52:395-403.
  41. Mauri L, Hsieh W, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. *N Engl J Med.* 2007;356:1020-1029.
  42. Duda SH, Bosiers M, Lammers J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the

- superficial femoral artery: long-term results from the SIROCCO trial. *J Endovasc Ther*. 2006;13:701-710.
43. <http://clinicaltrials.gov/ct2/show/NCT00120406>.
  44. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. *Lancet*. 2008;371:899-907.
  45. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. *Circulation*. 2000;102:399-404.
  46. Tsuji T, Tamai H, Igaki K, et al. Four year follow up of the biodegradable stent (IGAKI-TAMAI Stent) [abstract]. *Circ J*. 2004;68(suppl I):135.
  47. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. *N Engl J Med*. 2008;358:689-699.
  48. Shafique S, Nachreiner RD, Murphy MP, et al. Recanalization of infrainguinal vessels: SilverHawk, laser, and the remote superficial femoral artery endarterectomy. *Semin Vasc Surg*. 2007;20:29-36.
  49. Rastan A, Sixt S, Schwarzwälder U, et al. Initial experience with directed laser atherectomy using the CLiRpath photoablation atherectomy system and bias sheath in superficial femoral artery lesions. *J Endovasc Ther*. 2007;14:365-373.
  50. Zhou W, Bush RL, Lin PH, et al. Laser atherectomy for lower extremity revascularization: an adjunctive endovascular treatment option. *Vasc Endovascular Surg*. 2006;40:268-274.
  51. Lam RC, Shah S, Faries PL, et al. Incidence and clinical significance of distal embolization during percutaneous interventions involving the superficial femoral artery. *J Vasc Surg*. 2007;46:1155-1159.
  52. Yiu WK, Cheng SW, Sumpio BE. Direct comparison of endothelial cell and smooth muscle cell response to supercooling and rewarming. *J Vasc Surg*. 2007;46:557-564.
  53. McCaslin JE, Macdonald S, Stansby G. Cryoplasty for peripheral vascular disease. *Cochrane Database of Systematic Reviews*. 2007;4:CD005507.

## 第 92 章

1. Gowers WR. On a case of simultaneous embolism of central retinal and middle cerebral arteries. *Lancet*. 1875;2:794-796.
2. Chiari H. Ueber Verhalten Teilungswinkels der Carotis communis bei der Endarteritis chronica deformans. *Verh Dtsch Pathol Ges*. 1905;9:326-330.
3. Hunt JR. The role of the carotid arteries in the causation of vascular lesions of the brain with remarks on special features of the symptomatology. *Am J Med Sci*. 1914;147:704-713.
4. Moniz E, Lima A, deLacerda R. Hemiplegies par thrombose de la carotide interne. *Presse Med*. 1937;45:977-980.
5. Carrea R, Molins M, Murphy G. Surgical treatment of spontaneous thrombosis of the internal carotid artery in the neck: carotid-carotideal anastomosis. Report of a case. *Acta Neurol Latinoamer*. 1955;1:71-78.
6. LeFevre H. Sur un cas de plaie du bulbe carotidien per balle, traitee par la ligature de la carotid primitive, et l'anastomose bout et bout de la carotid externe avec la carotid interne. *Bull Mem Soc Chir*. 1918;44:923-928.
7. Eastcott HHG, Pickering GW, Rob CG. Reconstruction of internal carotid artery in a patient with intermittent attacks of hemiplegia. *Lancet*. 1954;2:994-996.
8. Debakey ME. Successful carotid endarterectomy for cerebrovascular insufficiency: nineteen year follow-up. *JAMA*. 1975;233:1083-1085.
9. Rowe WF. An early successful carotid endarterectomy, not previously reported. Paper presented at the Annual Meeting of the Southern California Vascular Surgical Society, September 18th, 1993, Coronado, CA.
10. Cooley DA, Al-Naaman YD, Carton CA. Surgical treatment of arteriosclerotic occlusion of the common carotid artery. *J Neurosurg*. 1956;13:500-506.
11. Bauer RB, Meyer JS, Fields WS, et al. Joint Study of Extracranial Arterial Occlusion III. Progress report of controlled study of long-term survival in patients with and without operation. *JAMA*. 1969;208:509-518.

12. Thompson JE, Talkington CM. Carotid endarterectomy. *Ann Surg.* 1976;184:1-15.
13. Callow AD, Mackey WC. Long term follow-up of surgically managed carotid bifurcation atherosclerosis. Justification for an aggressive approach. *Ann Surg.* 1989;210:308-316.
14. Easton JD, Sherman DG. Stroke and mortality rate in carotid endarterectomy: 228 consecutive operations. *Stroke.* 1977;8:565-568.
15. Brott T, Thalinger K. The practice of carotid endarterectomy in a large metropolitan area. *Stroke.* 1984;15:950-955.
16. Barnett HJM, Plum F, Walton JN. Carotid endarterectomy—an expression of concern. *Stroke.* 1984;15:941-943.
17. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. *N Engl J Med.* 1991;325:445-453.
18. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. *N Engl J Med.* 1998;339:1415-1425.
19. European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: interim results for patients with severe (70-99%) or mild (0-29%) carotid stenosis. *Lancet.* 1991;337:1235-1243.
20. Executive Committee of the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. *JAMA.* 1995;273:1421-1428.
21. ACST Collaborators Group. The International Asymptomatic Carotid Surgery Trial (ACST). *Lancet.* 2004;363:1491-1502.
22. Centers for Disease Control and Prevention (CDC). Stroke facts and statistics; 2/9/2007. Available at [http://www.cdc.gov/stroke/stroke\\_facts.htm](http://www.cdc.gov/stroke/stroke_facts.htm).
23. Centers for Disease Control and Prevention (CDC). Prevalence of stroke—United States. *MMWR Morb Mortal Wkly Rep.* 2005;56:469-674. Available at <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5619a2.htm>.
24. White H, Boden-Albala B, Wang C, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the northern Manhattan experience. *Circulation.* 2005;111:1327-1331.
25. Mathiesen EB, Joakimsen O, Bonna KH. Prevalence of and risk factors associated with carotid artery stenosis: the Tromsø Study. *Cerebrovasc Dis.* 2001;12:44-51.
26. Ghilardi G. Carotid stenotic-obliterative lesions. Distribution in 16,379 subjects 45-75 years of age. *Minerva Cardioangiol.* 1994;42:345-350.
27. Kiechl S, Willeit J, Rungger G, et al. Quantitative assessment of carotid atherosclerosis in a healthy population. *Neuroepidemiology.* 1994;13:314-317.
28. Mineva PP, Manchev IC, Hadjiev DI. Prevalence and outcome of asymptomatic carotid stenosis: a population based ultrasonographic study. *Eur J Neurol.* 2002;9:383-388.
29. Alexandrova NA, Gibson WC, Norris JW, Maggiano R. Carotid artery stenosis in peripheral vascular disease. *J Vasc Surg.* 1996;23:645-649.
30. Ascher E, DePippo P, Salles-Cunha S, et al. Carotid screening with duplex ultrasound in elderly asymptomatic patients referred to a vascular surgeon: is it worthwhile? *Ann Vasc Surg.* 1999;13:164-168.
31. Rosamund W, Flegal K, Friday G, et al. Heart Disease and Stroke Statistics—2007: a report from The American Heart Association Statistics Committee and Stroke Statistics Committee. *Circulation.* 2007;115:e69-e171.
32. Kissela B, Schneider A, Kleindorfer D, et al. Stroke in a biracial population, the excess burden of stroke among blacks. *Stroke.* 2004;35:426-431.
33. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. *Stroke.* 1991;22:312-318.
34. Curb JD, Abbott RD, Rodriguez BL, et al. High density lipoprotein cholesterol and the risk of stroke in elderly men, the Honolulu Heart Program. *Am J Epidemiol.* 2004;160:150-157.
35. Collins R, for the Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high risk conditions. *Lancet.*

- 2004;363:757-767.
36. Hill MD, Yiannakoulias N, Jeerakathil T, et al. The high risk of stroke immediately after transient ischemic attack: a population based study. *Neurology*. 2004;62:2015-2020.
  37. Kleindorfer D, Panagos P, Pancioli A, et al. Incidence and short-term prognosis after transient ischemic attack in a population based study. *Stroke*. 2005;36:720-723.
  38. Johnston SC, Fayad PB, Gorelick PB, et al. Prevalence and knowledge of transient ischemic attack among US adults. *Neurology*. 2003;60:1429-1434.
  39. Lisabeth LD, Ireland JK, Risser JM, et al. Stroke risk after transient ischemic attack in a population based setting. *Stroke*. 2004;35:1842-1846.
  40. Coull AJ, Lovett JK, Rothwell PM; Oxford Vascular Study. Population based study of early risk of stroke after transient ischemic attack or minor stroke: implications for public education and organization of services. *BMJ*. 2004;328:326.
  41. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. *JAMA*. 2000;284:2901-2906.
  42. Clark TG, Murphy MF, Rothwell PM. Long-term risks of stroke, myocardial infarction, and vascular death in "low-risk" patients with a non-recent transient ischemic attack. *J Neurol Neurosurg Psychiatry*. 2003;74:577-580.
  43. Chambers BR, Norris JW. Outcome in patients with asymptomatic neck bruits. *N Engl J Med*. 1986;315:860-865.
  44. Nicolaides AN, Kakkos SK, Griffin M, et al., for the Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Severity of asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: results from the ACSRS study. *Eur J Vasc Endovasc Surg*. 2005;30:275-284.
  45. O'Holleran LW, Kennelly MM, McClurken M, Johnson JM. Natural history of asymptomatic carotid plaque. *Am J Surg*. 1987;154:659-662.
  46. El Barghouty N, Geroulakos G, Nicolaides A, et al. Computer assisted carotid plaque characterization. *Eur J Vasc Endovasc Surg*. 1995;9:389-393.
  47. Mathiesen EB, Børnaa KH, Joakimsen O. Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the Tromsø study. *Circulation*. 2001;103:2171-2175.
  48. Roederer GO, Langlois YE, Jager KA, et al. The natural history of carotid arterial disease in asymptomatic patients with cervical bruits. *Stroke*. 1984;15:605-613.
  49. Hobson RW, Weiss DG, Fields WS, et al. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. *N Engl J Med*. 1993;328:221-227.
  50. Crouse JR, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. *Arch Intern Med*. 1997;157:1305-1310.
  51. Steering Committee of the Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing Physicians' Health Study. *N Engl J Med*. 1988;318:262-264.
  52. CAPRIE Steering Committee. A randomized blinded trial of clopidogrel vs aspirin in patients at risk of ischemic events (CAPRIE). *Lancet*. 1996;348:1329-1339.
  53. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. *N Engl J Med*. 1978;299:53-59.
  54. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. *Stroke*. 1977;8:301-315.
  55. Bousser MG, Eschwege E, Hagenau M, et al. "AICLA" controlled trial of aspirin and dipyridamole in secondary prevention of athero-thrombotic cerebral ischemia. *Stroke*. 1983;14:5-14.
  56. Ross R. The pathogenesis of atherosclerosis: an update. *N Engl J Med*. 1986;314:488-500.
  57. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med*. 1999;340:115-126.
  58. Takaya N, Yuan C, Chu B, et al. Association between carotid plaque characteristics and subsequent cerebrovascular events. *Stroke*. 2006;37:818-823.



59. Alvarez B, Ruiz C, Chacon P, et al. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. *J Vasc Surg.* 2004;40:469-475.
60. Alvarez Garcia B, Ruiz C, Chacon P, et al. High sensitivity C-reactive protein in high grade carotid stenosis: risk marker for unstable plaque. *J Vasc Surg.* 2003;38:1018-1024.
61. Arthurs ZM, Andersen C, Starnes BW, et al. A prospective evaluation of C-reactive protein in the progression of carotid artery stenosis. *J Vasc Surg.* 2008;47:744-751.
62. Hollenhorst RW. Significance of bright plaques in the retinal arterioles. *JAMA.* 1961;178:23.
63. Fisher CM. Observations of the fundus oculi in transient monocular blindness. *Neurology.* 1959;9:333-338.
64. Eklof B, Schwartz SI. Effects of subclavian steal and compromised cephalic blood flow on cerebral circulation. *Surgery.* 1969;68:431.
65. Cioffi FA, Meduri M, Tomasello F. Kinking and coiling of the internal carotid artery: clinical-statistical observations and surgical perspectives. *J Neurol Surg Sci.* 1975;19:15-22.
66. Gray SW, Skandalakis JE: The thoracic aorta. In: Gray SW, Skandalakis JE, eds. *Embryology for Surgeons, the Embryologic Basis for the Treatment of Congenital Defects.* Philadelphia, PA: WB Saunders; 1972:809-857.
67. Vannix RS, Joergenson EJ, Carter R. Kinking of the internal carotid artery: clinical significance and surgical management. *Am J Surg.* 1977;134:82-89.
68. Ballotta E, Thiene G, Baracchini C, et al. Surgical versus medical treatment for isolated internal carotid elongation with coiling or kinking in symptomatic patients: A prospective randomized clinical study. *J Vasc Surg.* 2005;42:838-846.
69. Chen CS, Miller NR. Ocular ischemic syndrome: review of clinical presentations, etiology, investigation, and management. *Compr Ophthalmol Update.* 2007;8:17-28.
70. Toole JF, Dibert SW, Harpold GJ. Transient ischemic attacks and stroke in the distribution of the carotid artery: clinical manifestations. In: Moore WS, ed. *Surgery for Cerebrovascular Disease.* 2nd ed. Philadelphia, PA: WB Saunders; 1996:73.
71. Murros KE, Evans GW, Toole JF, et al. Cerebral infarction in patients with transient ischemic attacks. *J Neurol.* 1989;236:182-186.
72. Schlegel DJ, Tanne D, Demchuk AM, et al. Prediction of hospital disposition after thrombolysis for acute ischemic stroke using the National Institutes of Health Stroke Scale. *Arch Neurol.* 2004;61:1061-1064.
73. Tejada J, Diez-Tejedor E, Hernandez-Echebarria L. Does a relationship exist between carotid stenosis and lacunar infarction? *Stroke.* 2003;34:1404-1411.
74. Roquer J, Rodriguez CA, Gomis M. Association of lacunar infarcts with small artery and large artery disease: a comparative study. *Arch Neurol Scand.* 2004;110:350-354.
75. Haque A, Meyer JS, Rauch GM. Epidemiology of vascular dementia. In: Meyer JS, Rauch GM, Lechner H, Loeb C, eds. *Vascular Dementia.* Armonk, NY: Futura; 2001:1-18.
76. Johnston SC, O'Meara ES, Manolio TA. Cognitive impairment and decline are associated with carotid artery disease in patients without clinically evident cerebrovascular disease. *Ann Intern Med.* 2004;140:237-247.
77. Mathiesen EB, Waterloo K, Joakimsen O, et al. Reduced neuropsychological test performance in asymptomatic carotid stenosis: the Tromsø Study. *Neurology.* 2004;62:695-701.
78. Fearn SJ, Hutchinson S, Riding G, et al. Carotid endarterectomy improves cognitive function in patients with exhausted cerebrovascular reserve. *Eur J Vasc Surg.* 2003;26:529-536.
79. Gillilan L. Anatomy and embryology of the arterial system of the brainstem and cerebellum. In: Vinken P, Bruyn G, eds. *Handbook of Clinical Neurology.* Vol 11. Amsterdam: North Holland; 1972:24.
80. Caplan LR, Wityk RJ. Transient ischemic attacks and stroke in the distribution of the vertebrobasilar system: clinical manifestations. In: Moore WS, ed. *Surgery for Cerebrovascular Disease.* 2nd ed. Philadelphia, PA: WB Saunders; 1996:78-95.

## 第 93 章

1. Rothwell PM, Eliasziw M, Gutnikov SA, et al, for the Carotid Endarterectomy Trialists Collaboration. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. *Lancet*. 2004;363:915.
2. Wardlaw JM, Chappell FM, Stevenson M, et al. Accurate, practical and cost-effective assessment of carotid stenosis in the UK. *Health Technology Assessment*. 2006;10. Available at: <http://www.hta.ac.uk/fullmono/mon1030.pdf>.
3. Loftus IM, McCarthy MJ, Pau H, et al. Carotid endarterectomy without angiography does not compromise operative outcome. *Eur J Vasc Endovasc Surg*. 1998;16:489.
4. US Preventive Services Task Force. Screening for carotid artery stenosis: US Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2007;147:854.
5. Naylor AR, Mehta Z, Rothwell PM, et al. Stroke during coronary artery bypass surgery: a critical review of the role of carotid artery disease. *Eur J Vasc Endovasc Surg*. 2002;23:283.
6. Walker J, Naylor AR. Ultrasound based diagnosis of "carotid stenosis >70%": an audit of UK practice. *Eur J Vasc Endovasc Surg*. 2006;31:487.
7. Gray-Weale AC, Graham JC, Burnett JR, et al. Carotid artery atheroma: comparison of pre-operative B-mode ultrasound appearance with carotid endarterectomy specimen pathology. *J Cardiovasc Surg*. 1988;29:676.
8. Geroulakos G, Ramaswami G, Nicolaides AN, et al. Characterisation of symptomatic and asymptomatic carotid plaques in high-resolution real time ultrasonography. *Br J Surg*. 1993;80:1274.
9. Asymptomatic Carotid Surgery Trial Collaborators. The MRC Asymptomatic Carotid Surgery Trial (ACST): carotid endarterectomy prevents disabling and fatal carotid territory strokes. *Lancet*. 2004;363:1491.
10. Nicolaides AN, Kakkos S, Griffin M, et al. Effect of image normalisation on carotid plaque classification and the risk of ipsilateral ischemic events: results from the Asymptomatic Carotid Stenosis and Risk of Stroke Study. *Vascular*. 2005;13:211.
11. Griffin M, Nicolaides AN, Kyriacou E. Normalisation of ultrasonic images of atherosclerotic plaques and reproducibility of gray scale median using dedicated software. *Int Angiol*. 2007;26:372.
12. Biasi GM, Froio A, Dietrich EB, et al. Carotid plaque echolucency increases the risk of stroke in carotid stenting: the Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) Study. *Circulation*. 2004;110:756.
13. Rockman CB, Halm EA. Intra-operative imaging: does it really improve peri-operative outcomes of carotid endarterectomy? *Semin Vasc Surg*. 2007;20:236.
14. Naylor AR, Chng S, Awad S. Redo carotid intervention: the role of carotid stenting. In: *Endovascular Therapies: Current Evidence*. Shrewsbury: TFM Publishing; 2006.
15. Spies C, Doshi R, Spoon J, et al. Carotid artery stent type influences duplex ultrasonography derived peak systolic velocity: findings of an in-vitro model. *Catheter Cardiovasc Interv*. 2007;70:304.
16. Lazaris A, Sayers RD, Thompson MM, et al. Patch corrugation on duplex ultrasonography may be an early warning of prosthetic patch infection. *Eur J Vasc Endovasc Surg*. 2005;29:91.
17. Grant EG, Benson CB, Moneta GL, et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis: Society of Radiologists in Ultrasound Consensus Conference. *Radiology*. 2003;229:340.
18. Schneider PA, Kasirajan KK. Difficult anatomy: what characteristics are critical to good outcomes of either CEA or CAS? *Semin Vasc Surg*. 2007;20:216.
19. Hatsukami TS, Ross R, Polissar NL, et al. Visualization of fibrous cap thickness and rupture in human atherosclerotic plaque in vivo with high resolution magnetic resonance imaging. *Circulation*. 2000;102:959.
20. Cai J, Hatsukami TS, Ferguson MS, et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high resolution, contrast enhanced magnetic resonance imaging and histology. *Circulation*. 2005;112:3437.
21. Altaf N, MacSweeney ST, Gladman J, et al. Carotid intraplaque haemorrhage predicts recurrent symptoms in patients with

- high-grade carotid stenosis. *Stroke*. 2007;38:1633.
22. Altaf N, Beech A, Goode S, et al. Magnetic resonance imaging detected carotid intraplaque haemorrhage predicts embolisation during carotid endarterectomy. *J Vasc Surg*. 2007;46:31.
  23. Altaf N, MacSweeney ST, Gladman J, et al. Detection of intraplaque haemorrhage by magnetic resonance imaging in symptomatic patients with mild to moderate carotid stenosis predicts recurrent neurological events. *J Vasc Surg*. 2008;47:337.
  24. Altaf N, Daniels L, Morgan PS, et al. Cerebral white matter hyperintense lesions are associated with unstable carotid plaques. *Eur J Vasc Endovasc Surg*. 2006;31:8.
  25. Harrison M, Marshall J. The finding of thrombus at carotid endarterectomy and its relationship to the timing of surgery. *Br J Surg*. 1977;64:511.
  26. Macdonald S. Brain injury secondary to carotid intervention. *J Endovasc Ther*. 2007;14:219.
  27. Naylor AR, Evans J, Thompson MM, et al. Seizures after carotid endarterectomy: hyperperfusion, dysautoregulation or hypertensive encephalopathy? *Eur J Vasc Endovasc Surg*. 2003;26:39.
  28. Kuo PH, Kanal E, Abu-Alfa AK, et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. *Radiology*. 2007;242:647.
  29. Powers WJ, Zazulia AR. The use of positron emission tomography in cerebrovascular disease. *Neuroimaging Clin N Am*. 2003;13:741.
  30. Van der Vaart MG, Meerwaldt R, Slart RHJA, et al. Application of PET/SPECT imaging in vascular disease. *Eur J Vasc Endovasc Surg*. 2008;35:507.
  31. Lell MM, Anders K, Uder M, et al. New techniques in CT angiography. *Radiographics*. 2006;26:S45.
  32. Bartlett ES, Walters TD, Symons SP. Quantification of carotid stenosis on CT angiography. *AJNR Am J Neuroradiol*. 2006;27:13.
  33. De Weert TT, Ouhlous M, Meijerling E, et al. Characterisation and quantification of atherosclerotic plaque components with multidetector computed tomography and histopathological correlation. *Arterioscler Thromb Vasc Biol*. 2006;26:2366.
  34. Nandalur KR, Baskurt E, Hagspiel K, et al. Calcified carotid atherosclerotic plaque is associated less with ischemic symptoms than is non-calcified plaque on MDCT. *AJR Am J Roentgenol*. 2005;184:295.
  35. Randoux B, Marro B, Koskas F, et al. Carotid artery stenosis: prospective comparison of CT, 3-dimensional gadolinium enhanced MR, and conventional angiography. *Radiology*. 2001;220:179.
  36. Saba L, Caddeo G, Sanfilippo R, et al. CT and US in the study of ulcerated carotid plaque compared to surgical results: advantages of multidetector-row CT angiography. *AJNR Am J Neuroradiol*. 2007;28:1061.
  37. Baptista MV, Maeder P, Dewarrrat A, et al. Conflicting images. *Lancet*. 1998;351:414.
  38. Kaufman TJ, Huston J, Mandrekar JN. Complications of diagnostic cerebral angiography: evaluation of 19,826 consecutive patients. *Radiology*. 2007;243:812.
  39. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. *JAMA*. 1995;273:1421.
  40. Tripp HF, Fail PJ, Beyer MG, et al. New approach to preoperative vascular exclusion for carotid body tumor. *J Vasc Surg*. 2003;38:389.
  41. Naylor AR, Rothwell PM, Bell PRF. Overview of the principal results and secondary analyses from the European and the North American randomised trials of carotid endarterectomy. *Eur J Vasc Endovasc Surg*. 2003;26:115.
  42. Smith JL, Evans DH, Naylor AR. Differentiation between emboli and artefacts using dual gated transcranial Doppler ultrasound. *Ultrasound Med Biol*. 1996;22:1031.
  43. Abbott AL, Chambers BR, Stork JL, et al. Embolic signals and prediction of ipsilateral stroke or transient ischaemic attack in asymptomatic carotid stenosis: a multicentre prospective cohort study. *Stroke*. 2005;36:1128.
  44. Naylor AR. Prevention of operation related stroke: are we asking the right questions? *Cardiovasc Surg*. 1999;7:155.

45. Naylor AR, Hayes PD, Allroggen H, et al. Reducing the risk of carotid surgery: a seven year audit of the role of monitoring and quality control assessment. *J Vasc Surg.* 2000;32:750.
46. Ghali R, Palazzo EG, Rodriguez DI, et al. Transcranial Doppler intra-operative monitoring during carotid endarterectomy: experience with regional or general anaesthesia, with and without shunting. *Ann Vasc Surg.* 1997;11:9.
47. Gaunt ME, Smith JL, Martin PJ, et al. A comparison of quality control methods applied to carotid endarterectomy. *Eur J Vasc Endovasc Surg* 1996;11:4.
48. Hayes PD, Box H, Tull S, et al. The patients thrombo-embolic response following carotid endarterectomy is related to enhanced platelet sensitivity to ADP. *J Vasc Surg.* 2003;38:1226.
49. Naylor AR, Goodall AH. *Preventing Strokes after CEA: A New Look at the Roles of Aspirin and Heparin.* London: BIBA Publishing; 2008:98-107.
50. Rangi PS, Markus HS, Punter MN, Clifton A. The use of intraoperative monitoring and treatment of symptomatic microemboli in carotid artery stenting: case report and discussion. *Neuroradiology.* 2007;49:265.
51. Krupinski J, Turu MM, Slevin M, Martinez-Gonzalez J. Carotid plaque, stroke pathogenesis, and CRP: treatment of ischemic stroke. *Curr Treat Options Cardiovasc Med.* 2007;9:2295.
52. Loftus I, Naylor AR, Bell PRF, Thompson MM. Plasma MMP-9: a marker of carotid plaque instability. *Eur J Vasc Endovasc Surg.* 2001;21:17.
53. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. *Am J Cardiol.* 2001;88:230.
54. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. *Circulation.* 2003;17:2908.
55. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. *Circulation.* 2004;109:3171.

## 第 94 章

1. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. *JAMA.* 1995;273:1421-1428.
2. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. *Lancet.* 2004;363:1491-1502.
3. Kresowik TF, Bratzler DW, Kresowik RA, et al. Multistate improvement in process and outcomes of carotid endarterectomy. *J Vasc Surg.* 2004;39:372-380.
4. Halliday AW, Thomas D, Mansfield A. The Asymptomatic Carotid Surgery Trial (ACST). Rationale and design. Steering Committee. *Eur J Vasc Surg.* 1994;8:703-710.
5. Curley PJ, Norrie L, Nicholson A, et al. Accuracy of carotid duplex is laboratory specific and must be determined by internal audit. *Eur J Vasc Endovasc Surg.* 1998;15:511-514.
6. Biller J, Feinberg WM, Castaldo JE, et al. Guidelines for carotid endarterectomy: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. *Circulation.* 1998;97:501-509.
7. Moore WS, Barnett HJM, Beebe HG, et al. Guidelines for carotid endarterectomy: a multidisciplinary consensus statement from the Ad Hoc Committee, American Heart Association. *Stroke.* 1995;26:188-201.
8. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *N Engl J Med.* 1991;325:445-453.
9. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). *Lancet.* 1998;351:1379-1387.
10. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *N Engl J Med.*

1998;339:1415-1425.

11. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. *Arterioscler Thromb Vasc Biol.* 2000;20:1262-1275.
12. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med.* 2005;352:1685-1695.
13. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery plaque: current imaging methods and new perspectives. *Stroke.* 2005;36:2764-2772.
14. Fisher M, Paganini-Hill A, Martin A, et al. Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis. *Stroke.* 2005;36:253-257.
15. Bertges DJ, Muluk V, Whittle J, et al. Relevance of carotid stenosis progression as a predictor of ischemic neurological outcomes. *Arch Intern Med.* 2003;163:2285-2289.
16. Sabeti S, Schlager O, Exner M, et al. Progression of carotid stenosis detected by duplex ultrasonography predicts adverse outcomes in cardiovascular high-risk patients. *Stroke.* 2007;38:2887-2894.
17. Ferguson GG, Eliasziw M, Barr HW, et al. The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 1415 patients. *Stroke.* 1999;30:1751-1758.
18. Grant EG, Benson CB, Moneta GL, et al. Carotid artery stenosis: grayscale and Doppler ultrasound diagnosis—Society of Radiologists in Ultrasound consensus conference. *Ultrasound Q.* 2003;19:190-198.
19. Rothwell PM, Eliasziw M, Gutnikov SA, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. *Lancet.* 2004;363:915-924.
20. Rothwell PM, Gutnikov SA, Warlow CP. Reanalysis of the final results of the European Carotid Surgery Trial. *Stroke.* 2003;34:514-523.
21. Naylor AR. Delay may reduce procedural risk, but at what price to the patient? *Eur J Vasc Endovasc Surg.* 2008;35:383-391.
22. Bond R, Rerkasem K, Rothwell PM. Systematic review of the risks of carotid endarterectomy in relation to the clinical indication for and timing of surgery. *Stroke.* 2003;34:2290-2301.
23. Naylor AR. Occam's razor: intervene early to prevent more strokes! *J Vasc Surg.* 2008;48:1053-1059.
24. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. *Lancet Neurol.* 2007;6:1063-1072.
25. Rockman CB, Maldonado TS, Jacobowitz GR, et al. Early carotid endarterectomy in symptomatic patients is associated with poorer perioperative outcomes. *J Vasc Surg.* 2006;44:480-487.
26. Buchan A, Gates P, Pelz D, Barnett HJ. Intraluminal thrombus in the cerebral circulation. Implications for surgical management. *Stroke.* 1988;19:681-687.
27. Karkos CD, McMahon G, McCarthy MJ, et al. The value of urgent carotid surgery for crescendo transient ischemic attacks. *J Vasc Surg.* 2007;45:1148-1154.
28. Nehler MR, Moneta GL, McConnell DB, et al. Anticoagulation followed by elective carotid surgery in patients with repetitive transient ischemic attacks and high-grade carotid stenosis. *Arch Surg.* 1993;128:1117-1121; discussion 1121-1123.
29. Biller J, Adams HP, Jr., Boarini D, et al. Intraluminal clot of the carotid artery. A clinical-angiographic correlation of nine patients and literature review. *Surg Neurol.* 1986;25:467-477.
30. Khuri SF, Henderson WG. The case against volume as a measure of quality of surgical care. *World J Surg.* 2005;29:1222-1229.
31. Christian CK, Gustafson ML, Betensky RA, et al. The leapfrog volume criteria may fall short in identifying high-quality surgical centers. *Ann Surg.* 2003;238:447-455; discussion 455.
32. Akers DL, Markowitz IA, Kerstein MD. The value of aortic arch study in the evaluation of cerebrovascular insufficiency. *Am J Surg.* 1987;154:230-232.

33. Akers DL, Bell WH 3rd, Kerstein MD. Does intracranial dye study contribute to evaluation of carotid artery disease? *Am J Surg*. 1988;156:87-90.
34. Kadwa AM, Robbs JV, Abdool-Carrim AT. Aortic arch angiography prior to carotid endarterectomy. Is its continued use justified? *Eur J Vasc Endovasc Surg*. 1997;13:527-530.
35. Mattos MA, Hodgson KJ, Faught WE, et al. Carotid endarterectomy without angiography: is color-flow duplex scanning sufficient? *Surgery*. 1994;116:776-782; discussion 782.
36. David LD, Zierler RE, Strandness DE, et al. The role of duplex scanning and arteriography before carotid endarterectomy: a prospective study. *J Vasc Surg* 1993;18:673-683.
37. Golledge J, Wright R, Pugh N, Lane IF. Colour-coded duplex assessment alone before carotid endarterectomy. *Br J Surg*. 1996;83:1234-1237.
38. Mackey WC, O'Donnell TF, Jr., Callow AD. Carotid endarterectomy in patients with intracranial vascular disease: short-term risk and long-term outcome. *J Vasc Surg*. 1989;10:432-438.
39. Kappelle LJ, Eliasziw M, Fox AJ, et al. Importance of intracranial atherosclerotic disease in patients with symptomatic stenosis of the internal carotid artery. The North American Symptomatic Carotid Endarterectomy Trial. *Stroke*. 1999;30:282-286.
40. Grego F, Frigatti P, Lepidi S, et al. Synchronous carotid endarterectomy and retrograde endovascular treatment of brachiocephalic or common carotid artery stenosis. *Eur J Vasc Endovasc Surg*. 2003;26:392-395.
41. Payne DA, Hayes PD, Bolia A, et al. Cerebral protection during open retrograde angioplasty/stenting of common carotid and innominate artery stenoses. *Br J Surg*. 2006;93:187-190.
42. Allie DE, Hebert CJ, Lirtzman MD, et al. Intraoperative innominate and common carotid intervention combined with carotid endarterectomy: a "true" endovascular surgical approach. *J Endovasc Ther*. 2004;11:258-262.
43. Kragsternan B, Logason K, Ahari A, et al. Risk factors for complications after carotid endarterectomy—a population-based study. *Eur J Vasc Endovasc Surg*. 2004;28:98-103.
44. Reed AB, Gaccione P, Belkin M, et al. Preoperative risk factors for carotid endarterectomy: defining the patient at high risk. *J Vasc Surg*. 2003;37:1191-1199.
45. Halm EA, Hannan EL, Rojas M, et al. Clinical and operative predictors of outcomes of carotid endarterectomy. *J Vasc Surg*. 2005;42:420-428.
46. Baker WH, Howard VJ, Howard G, Toole JF. Effect of contralateral occlusion on long-term efficacy of endarterectomy in the asymptomatic carotid atherosclerosis study (ACAS). ACAS Investigators. *Stroke*. 2000;31:2330-2334.
47. Frericks H, Kievit J, van Baalen JM, van Bockel JH. Carotid recurrent stenosis and risk of ipsilateral stroke: a systematic review of the literature. *Stroke*. 1998;29:244-250.
48. Lattimer CR, Burnand KG. Recurrent carotid stenosis after carotid endarterectomy. *Br J Surg*. 1997;84:1206-1219.
49. Moore WS, Kempczinski RF, Nelson JJ, Toole JF. Recurrent carotid stenosis: results of the asymptomatic carotid atherosclerosis study. *Stroke*. 1998;29:2018-2025.
50. Thomas M, Otis SM, Rush M, et al. Recurrent carotid artery stenosis following endarterectomy. *Ann Surg*. 1984;200:74-79.
51. O'Donnell TF Jr., Callow AD, Scott G, et al. Ultrasound characteristics of recurrent carotid disease: hypothesis explaining the low incidence of symptomatic recurrence. *J Vasc Surg*. 1985;2:26-41.
52. Schwarcz TH, Yates GN, Ghobrial M, Baker WH. Pathologic characteristics of recurrent carotid artery stenosis. *J Vasc Surg*. 1987;5:280-288.
53. Hellings WE, Moll FL, de Vries JP, et al. Histological characterization of restenotic carotid plaques in relation to recurrence interval and clinical presentation: a cohort study. *Stroke*. 2008;39:1029-1032.
54. Carballo RE, Towne JB, Seabrook GR, et al. An outcome analysis of carotid endarterectomy: the incidence and natural history of recurrent stenosis. *J Vasc Surg*. 1996;23:749-753; discussion 753.
55. O'Donnell TF, Jr., Rodriguez AA, Fortunato JE, et al. Management of recurrent carotid stenosis: should asymptomatic

lesions be treated surgically? *J Vasc Surg.* 1996;24:207-212.

56. Samson RH, Showalter DP, Yunis JP, et al. Hemodynamically significant early recurrent carotid stenosis: an often self-limiting and self-reversing condition. *J Vasc Surg.* 1999;30:446-452.
57. Stoner MC, Cambria RP, Brewster DC, et al. Safety and efficacy of reoperative carotid endarterectomy: a 14-year experience. *J Vasc Surg.* 2005;41:942-949.
58. Das MB, Hertzner NR, Ratliff NB, et al. Recurrent carotid stenosis. A five-year series of 65 reoperations. *Ann Surg.* 1985;202:28-35.
59. Nitzberg RS, Mackey WC, Prendiville E, et al. Long-term follow-up of patients operated on for recurrent carotid stenosis. *J Vasc Surg.* 1991;13:121-126; discussion 126-127.
60. Mansour MA, Kang SS, Baker WH, et al. Carotid endarterectomy for recurrent stenosis. *J Vasc Surg.* 1997;25:877-883.
61. Brown KR. Treatment of concomitant carotid and coronary artery disease. Decision-making regarding surgical options. *J Cardiovasc Surg (Torino).* 2003;44:395-399.
62. Ricotta JJ, Wall LP, Blackstone E. The influence of concurrent carotid endarterectomy on coronary bypass: a case-controlled study. *J Vasc Surg.* 2005;41:397-401; discussion 401.
63. Lewis BS, Albert HB, Robert WK, et al. Asymptomatic carotid artery stenosis and stroke in patients undergoing cardiopulmonary bypass. *J Vasc Surg.* 1995;21:146-153.
64. Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral outcomes after coronary bypass surgery. *N Engl J Med.* 1996;335:1857-1864.
65. Nussmeier NA. A review of risk factors for adverse neurologic outcome after cardiac surgery. *J Extra Corpor Technol.* 2002;34:4-10.
66. Kougas P, Kappa JR, Sewell DH, et al. Simultaneous carotid endarterectomy and coronary artery bypass grafting: results in specific patient groups. *Ann Vasc Surg.* 2007;21:408-414.
67. Dubinsky RM, Lai SM. Mortality from combined carotid endarterectomy and coronary artery bypass surgery in the US. *Neurology.* 2007;68:195-197.
68. Kolh PH, Comte L, Tchana-Sato V, et al. Concurrent coronary and carotid artery surgery: factors influencing perioperative outcome and long-term results. *Eur Heart J.* 2006;27:49-56.
69. Byrne J, Darling RC 3rd, Roddy SP, et al. Combined carotid endarterectomy and coronary artery bypass grafting in patients with asymptomatic high-grade stenoses: an analysis of 758 procedures. *J Vasc Surg.* 2006;44:67-72.
70. Hill MD, Shrive FM, Kennedy J, et al. Simultaneous carotid endarterectomy and coronary artery bypass surgery in Canada. *Neurology.* 2005;64:1435-1437.
71. Naylor R, Cuffe RL, Rothwell PM, et al. A systematic review of outcome following synchronous carotid endarterectomy and coronary artery bypass: influence of surgical and patient variables. *Eur J Vasc Endovasc Surg.* 2003;26:230-241.
72. Brown KR, Kresowik TF, Chin MH, et al. Multistate population-based outcomes of combined carotid endarterectomy and coronary artery bypass. *J Vasc Surg.* 2003;37:32-39.
73. Hertzner NR, Mascha EJ. A personal experience with coronary artery bypass grafting, carotid patching, and other factors influencing the outcome of carotid endarterectomy. *J Vasc Surg.* 2006;43:959-968.
74. Rerkasem K, Bond R, Rothwell PM. Local versus general anaesthesia for carotid endarterectomy. *Cochrane Database Syst Rev.* 2004;2:CD000126.
75. Guay J. Regional or general anesthesia for carotid endarterectomy? Evidence from published prospective and retrospective studies. *J Cardiothorac Vasc Anesth.* 2007;21:127-132.
76. Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. *BMJ.* 2000;321:1493.
77. Borger MA, Fries SE, Weisel RD, et al. Coronary bypass and carotid endarterectomy: does a combined approach increase risk? A metaanalysis. *Ann Thorac Surg.* 1999;68:14-20.

78. Barnett HJM. A modern approach to posterior circulation ischemic stroke. *Arch Neurol*. 2002;59:359-360.
79. Caplan LR, Wityk RJ, Glass TA, et al. New England Medical Center Posterior Circulation Registry. *Ann Neurol*. 2004;56:389-398.
80. Ricotta JJ, O'Brien MS, DeWeese JA. Carotid endarterectomy for non-hemispheric ischaemia: long-term follow-up. *Cardiovasc Surg*. 1994;2:561-566.
81. Delaney CP, Couse NF, Mehigan D, Keaveny TV. Investigation and management of subclavian steal syndrome. *Br J Surg*. 1994;81:1093-1095.
82. Reivich M, Holling HE, Roberts B, Toole JF. Reversal of blood flow through the vertebral artery and its effect on cerebral circulation. *N Engl J Med*. 1961;265:878-885.
83. Savitz SI, Caplan LR. Vertebrobasilar disease. *N Engl J Med*. 2005;352:2618-2626.
84. Takach TJ, Reul GJ, Cooley DA, et al. Myocardial thievery: the coronary-subclavian steal syndrome. *Ann Thorac Surg*. 2006;81:386-392.
85. Elian D, Gerniak A, Guetta V, et al. Subclavian coronary steal syndrome: an obligatory common fate between subclavian artery, internal mammary graft and coronary circulation. *Cardiology*. 2002;97:175-179.
86. Rogers JH, Calhoun RF 2nd. Diagnosis and management of subclavian artery stenosis prior to coronary artery bypass grafting in the current era. *J Card Surg*. 2007;22:20-25.
87. Hobson RW 2nd. Randomized clinical trials: How will results influence clinical practice in the management of symptomatic and asymptomatic extracranial carotid occlusive disease? *J Vasc Surg*. 2007;45(6, Suppl 1):A158-A163.
88. Touze E, Calvet D, Chatellier G, Mas JL. Carotid stenting. *Curr Opin Neurol*. 2008;21:56-63.
89. Ringleb PA, Chatellier G, Hacke W, et al. Safety of endovascular treatment of carotid artery stenosis compared with surgical treatment: a meta-analysis. *J Vasc Surg*. 2008;47:350-355.
90. Brahmanandam S, Ding EL, Conte MS, et al. Clinical results of carotid artery stenting compared with carotid endarterectomy. *J Vasc Surg*. 2008;47:343-349.
91. Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. *N Engl J Med*. 2004;351:1493-1501.
92. Cayne NS, Faries PL, Trocciola SM, et al. Carotid angioplasty and stent-induced bradycardia and hypotension: impact of prophylactic atropine administration and prior carotid endarterectomy. *J Vasc Surg*. 2005;41:956-961.
93. Hobson RW 2nd, Howard VJ, Roubin GS, et al. Carotid artery stenting is associated with increased complications in octogenarians: 30-day stroke and death rates in the CREST lead-in phase. *J Vasc Surg*. 2004;40:1106-1111.
94. Park B, Mavanur A, Dahn M, Menzoian J. Clinical outcomes and cost comparison of carotid artery angioplasty with stenting versus carotid endarterectomy. *J Vasc Surg*. 2006;44:270-276.
95. Pawaskar M, Satiani B, Balkrishnan R, Starr JE. Economic evaluation of carotid artery stenting versus carotid endarterectomy for the treatment of carotid artery stenosis. *J Am Coll Surg*. 2007;205:413-419.
96. Ecker RD, Brown RD Jr., Nichols DA, et al. Cost of treating high-risk symptomatic carotid artery stenosis: stent insertion and angioplasty compared with endarterectomy. *J Neurosurg*. 2004;101:904-907.
97. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. *Stroke*. 2006;37:577-617.
98. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events. A systematic review. *Stroke*. 2003;34:2741-2748.
99. Enseleit F, Hurlimann D, Luscher TF. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. *J Cardiovasc Pharmacol*. 2001;37:S21-S30.
100. Iadecola C, Gorelick PB. Hypertension, angiotensin, and stroke: beyond blood pressure. *Stroke*. 2004;35:348-350.



101. Crouse JR. Effects of statins on carotid disease and stroke. *Curr Opin Lipidol*. 1999;10:535-541.
102. Crouse JR, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. *Atherosclerosis*. 1998;138:11-24.
103. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. *JAMA*. 2007;297:1344-1353.
104. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med*. 2006;355:549-559.
105. Perler BA. The effect of statin medications on perioperative and long-term outcomes following carotid endarterectomy or stenting. *Semin Vasc Surg*. 2007;20:252-258.
106. You RX, Thrift AG, McNeil JJ, et al. Ischemic stroke risk and passive exposure to spouses' cigarette smoking. Melbourne Stroke Risk Factor Study (MERFS) Group. *Am J Public Health*. 1999;89:572-575.
107. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002;324:71-86.
108. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *J Neurol Sci*. 1996;143:1-13.
109. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. the Dutch TIA Trial Study Group. *N Engl J Med*. 1991;325:1261-1266.
110. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. *Lancet*. 1991;338:1345-1349.
111. Halkes PHA, Algra A. Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient? *Cerebrovasc Dis*. 2007;24:107-111.
112. Hass WK, Easton JD, Adams HP, Jr., et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. *N Engl J Med*. 1989;321:501-507.
113. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. *JAMA*. 2003;289:2947-2957.
114. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. *Lancet*. 1989;1:1215-1220.
115. Zakarija A, Bandarenko N, Pandey DK, et al. Clopidogrel-associated TTP. An update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. *Stroke*. 2004;35:533-538.
116. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet*. 1996;348:1329-1339.
117. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet*. 2004;364:331-337.
118. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med*. 2006;354:1706-1717.
119. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the charisma trial. *J Am Coll Cardiol*. 2007;49:1982-1988.
120. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection. *Circulation*. 2006;111:2233-2240.
121. Kennedy J, Hill MD, Ryckborst KJ, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (faster): a randomised controlled pilot trial. *Lancet Neurol*. 2007;6:961-969.
122. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. *N*

*Engl J Med.* 2008;359:1238-1251.

123. Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. *Lancet Neurol.* 2007;6:115-124.
124. Algra A, De Schryver EL, van Gijn J, et al. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischemic attack or minor stroke of presumed arterial origin. *Stroke.* 2003;34:234-235.
125. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. *N Engl J Med.* 2005;352:1305-1316.
126. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. *N Engl J Med.* 2001;345:1444-1451.
127. Adams HP Jr. Emergent use of anticoagulation for treatment of patients with ischemic stroke. *Stroke.* 2002;33:856-861.
128. Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. *Stroke.* 2007;38:1655-1711.
129. Kidwell CS, Shephard T, Tonn S, et al. Establishment of primary stroke centers. A survey of physician attitudes and hospital resources. *Neurology.* 2003;60:1452-1456.
130. Schwamm LH, Pancioli A, Acker JE, et al. Recommendations for the establishment of stroke systems of care. Recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. *Stroke.* 2005;36:690-703.
131. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med.* 1995;333:1581-1587.
132. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. *Lancet.* 2008;369:275-282.
133. The NINDA t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. *Stroke.* 1997;28:2109-2118.
134. Furlan AJ, Higashida R, Wechsler L, Schultz G, for the PROACT Investigators. PROACT II. Recombinant prourokinase (r-ProUK) in acute cerebral thromboembolism. Initial trial results. *Stroke.* 1999;30:234.
135. Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI Trial. *Stroke.* 2008;39:1205-1212.
136. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke. Results of the MERCI trial. *Stroke.* 2005;36:1432-1440.

## 第 95 章

1. Eastcott HHG, Pickering GW, Rob CG. Reconstruction of internal carotid artery in a patient with intermittent attacks of hemiplegia. *Lancet.* 1954;264:994-996.
2. DeBakey ME, Crawford ES, Cooley DA, Morris GC. Surgical considerations of occlusive disease of innominate, carotid, subclavian, and vertebral arteries. *Ann Surg.* 1959;149:690-710.
3. Busuttill RW, Baker JD, Davidson RK, Machleder HI. Carotid-artery stenosis—hemodynamic significance and clinical course. *JAMA.* 1981;245:1438-1441.
4. Kartchner MM, Mcrae LP. Noninvasive evaluation and management of asymptomatic carotid bruit. *Surgery.* 1977;82:840-847.
5. Moore DJ, Miles RD, Gooley NA, Sumner DS. Noninvasive assessment of stroke risk in asymptomatic and

- nonhemispheric patients with suspected carotid disease—5-year follow-up of 294 unoperated and 81 operated patients. *Ann Surg.* 1985;202:491-504.
6. Roederer GO, Langlois YE, Jager KA, et al. The natural-history of carotid arterial-disease in asymptomatic patients with cervical bruits. *Stroke.* 1984;15:605-613.
  7. Bauer RB, Meyer JS, Fields WS, et al. Joint study of extracranial arterial occlusion. *JAMA.* 1969;208:509-518.
  8. Easton JD, Sherman DG. Stroke and mortality-rate in carotid endarterectomy—228 consecutive operations. *Stroke.* 1977;8:565-568.
  9. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *N Engl J Med.* 1991;325:445-453.
  10. MRC European Carotid Surgery Trial: Interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. *Lancet.* 1991;337:1235-1243.
  11. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. *JAMA.* 1995;273:1421-1428.
  12. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). *Lancet.* 1998;351:1379-1387.
  13. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet.* 2006;367:1747-1757.
  14. Mathers CD, Boerma T, Fat DM. *The Global Burden of Disease: 2004 Update.* Geneva, Switzerland: World Health Organization Press; 2008:1-160.
  15. European Carotid Surgery Trialists' Collaborative Group. Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC European Carotid Surgery Trial. *Lancet.* 1996;347:1591-1593.
  16. Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. *Lancet.* 2004;363:1491-1502.
  17. Clinical alert—benefit of carotid endarterectomy for patients with high-grade stenosis of the internal carotid-artery—National Institute of Neurological Disorders and Stroke and Trauma Division. *Stroke.* 1991;22:816-817.
  18. Barnett HJM, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. *N Engl J Med.* 1998;339:1415-1425.
  19. Binaghi S, Maeder P, Uske A, et al. Three-dimensional computed tomography angiography and magnetic resonance angiography of carotid bifurcation stenosis. *Eur Neurol.* 2001;46:25-34.
  20. Jenkins RH, Mahal R, MacEneaney PM. Noninvasive imaging of carotid artery disease: critically appraised topic. *Can Assoc Radiol J.* 2003;54:121-123.
  21. Magarelli N, Scarabino T, Simeone AL, et al. Carotid stenosis: a comparison between MR and spiral CT angiography. *Neuroradiology.* 1998;40:367-373.
  22. Nonent M, Serfaty JM, Nighoghossian N, et al. Concordance rate differences of 3 noninvasive imaging techniques to measure carotid stenosis in clinical routine practice—results of the CARMEDAS Multicenter Study. *Stroke.* 2004;35:682-686.
  23. Patel SG, Collie DA, Wardlaw JM, et al. Outcome, observer reliability, and patient preferences if CTA, MRA, or Doppler ultrasound were used, individually or together, instead of digital subtraction angiography before carotid endarterectomy. *J Neurol Neurosurg Psychiatry.* 2002;73:21-28.
  24. Randoux B, Marro B, Koskas F, et al. Carotid artery stenosis: prospective comparison of CT, three-dimensional gadolinium-enhanced MR, and conventional angiography. *Radiology.* 2001;220:179-185.
  25. Wardlaw JM, Chappell FM, Best JJK, et al. Non-invasive imaging compared with intra-arterial angiography in the diagnosis of symptomatic carotid stenosis: a meta-analysis. *Lancet.* 2006;367:1503-1512.
  26. Collaborative overview of randomized trials of antiplatelet therapy. 1. Prevention of death, myocardial-infarction, and

stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ*. 1994;308:81-106. Erratum in: *BMJ*. 1994;308:1540.

27. Baigent C, Sudlow C, Collins R, Peto R. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002;324:71-86.
28. Lindblad B, Persson NH, Takolander R, Bergqvist D. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. *Stroke*. 1993;24:1125-1128.
29. Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. *Lancet*. 1999;353:2179-2184.
30. Payne DA, Jones CI, Hayes PD, et al. Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. *Circulation*. 2004;109:1476-1481.
31. Engelter S, Lyrer P. Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy. *Stroke*. 2004;35:1227-1228.
32. Sandercock P, Collins R, Counsell C, et al. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. *Lancet*. 1997;349:1569-1581.
33. Nehler MR, Moneta GL, McConnell DB, et al. Anticoagulation followed by elective carotid surgery in patients with repetitive transient ischemic attacks and high-grade carotid stenosis. *Arch Surg*. 1993;128:1117-1123.
34. Huang ZS, Teng CM, Lee TK, et al. Combined use of aspirin and heparin inhibits invivo acute carotid thrombosis. *Stroke*. 1993;24:829-838.
35. Paty PSK, Clement Darling R, Kreienberg PB, et al. The use of low-dose heparin is safe in carotid endarterectomy and avoids the use of protamine sulfate. *Cardiovasc Surg*. 1999;7:39-43.
36. Fearn SJ, Parry AD, Picton AJ, et al. Should heparin be reversed after carotid endarterectomy? A randomised prospective trial. *Eur J Vasc Endovasc Surg*. 1997;13:394-397.
37. Treiman RL, Cossman DV, Foran RF, et al. The influence of neutralizing heparin after carotid endarterectomy on postoperative stroke and wound hematoma. *J Vasc Surg*. 1990;12:440-446.
38. Levison JA, Faust GR, Halpern VJ, et al. Relationship of protamine dosing with postoperative complications of carotid endarterectomy. *Ann Vasc Surg*. 1999;13:67-72.
39. Mauney MC, Buchanan SA, Lawrence WA, et al. Stroke rate is markedly reduced after carotid endarterectomy by avoidance of protamine. *J Vasc Surg*. 1995;22:264-270.
40. Dellagrammaticas D, Lewis SC, Gough MJ. Is heparin reversal with protamine after carotid endarterectomy dangerous? *Eur J Vasc Endovasc Surg*. 2008;36:41-44.
41. Sobel M, Adelman B, Greenfield LJ. Dextran 40 reduces heparin-mediated platelet aggregation. *J Surg Res*. 1986;40:382-387.
42. Lennard N, Smith J, Dumville J, et al. Prevention of postoperative thrombotic stroke after carotid endarterectomy: the role of transcranial Doppler ultrasound. *J Vasc Surg*. 1997;26:579-584.
43. Lennard N, Smith JL, Hayes P, et al. Transcranial Doppler directed dextran therapy in the prevention of carotid thrombosis: three hour monitoring is as effective as six hours. *Eur J Vasc Endovasc Surg*. 1999;17:301-305.
44. Lennard NS, Vijayasekar C, Tiivas C, et al. Control of emboli in patients with recurrent or crescendo transient ischaemic attacks using preoperative transcranial Doppler-directed dextran therapy. *Br J Surg*. 2003;90:166-170.
45. Hayes PD, Lloyd AJ, Lennard N, et al. Transcranial Doppler-directed dextran-40 therapy is a cost-effective method of preventing carotid thrombosis after carotid endarterectomy. *Eur J Vasc Endovasc Surg*. 2000;19:56-61.
46. Amarenco P, Labreuche J, Laval é P, Touboul PJ. Statins of stroke prevention and carotid atherosclerosis: systemic review and up-to-date meta-analysis. *Stroke*. 2004;35:2902-2909.
47. Amarenco P. Effect of statins in stroke prevention. *Curr Opin Lipidol*. 2005;16:614-618.
48. Becker K, Chopp M. Role of statins in the treatment and prevention of stroke introduction. *Stroke*. 2004;35:2706-2707.

49. Berwanger O, Avezum A, Fernandes J, et al. Statins for the prevention and treatment of stroke: a meta-analysis of randomized controlled trials. *Stroke*. 2006;37:664-745.
50. Callahan A. Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention. *Am J Cardiol*. 2001;88:33J-37J.
51. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis—The METEOR trial. *JAMA*. 2007;297:1344-1353.
52. Gedikli O, Baykan M. Statins in stroke prevention. *Anadolu Kardiyoloji Dergisi—Anatolian J Cardiol*. 2008;8:217-222.
53. Guerra LC, Moreno MCF, Hernandez MDJ, Chozas JML. Current role of statins in the stroke prevention. *Rev Clin Esp*. 2007;207:83-85.
54. Squizzato A, Dentali F, Romualdi E, Ageno W. Statins and secondary prevention of ischemic and hemorrhagic stroke. *Stroke*. 2008;39:E113.
55. Furberg CD, Adams HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. *Circulation*. 1994;90:1679-1687.
56. Probstfield JL, Margitic SE, Byington RP, et al. Results of the primary outcome measure and clinical events from the asymptomatic carotid-artery progression study. *Am J Cardiol*. 1995;76:C47-C53.
57. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy—pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. *Circulation*. 1995;92:2419-2425.
58. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*. 2004;364:685-696.
59. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med*. 2006;355:549-559.
60. White HD, Simes RJ, Watson J, et al. The LIPID trial: impact of lipid lowering therapy with pravastatin on the risk of stroke. *J Am Coll Cardiol*. 1998;31:282A.
61. White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. *N Engl J Med*. 2000;343:317-326.
62. Durazzo AES, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. *J Vasc Surg*. 2004;39:967-975.
63. Lindenauer PK, Pekow P, Wang KJ, et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. *JAMA*. 2004;291:2092-2099.
64. O'Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery—the Statins for Risk Reduction in Surgery (StaRRS) Study. *J Am Coll Cardiol*. 2005;45:336-342.
65. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. *Circulation*. 2003;107:1848-1851.
66. McGirt MJ, Perler BA, Brooke BS, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. *J Vasc Surg*. 2005;42:829-835.
67. Kennedy J, Quan H, Buchan AM, et al. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. *Stroke*. 2005;36:2072-2076.
68. Lamuraglia GM, Stoner MC, Brewster DC, et al. Determinants of carotid endarterectomy anatomic durability: effects of serum lipids and lipid-lowering drugs. *J Vasc Surg*. 2005;41:762-768.
69. Guay J. Regional or general anesthesia for carotid endarterectomy? Evidence from published prospective and retrospective studies. *J Cardiothorac Vasc Anesth*. 2007;21:127-132.
70. Rerkasem K, Rothwell PM. Local versus general anaesthesia for carotid endarterectomy. *Cochrane Database Syst Rev*. 2008;4:CD000126.

71. Tangkanakul C, Counsell C, Warlow C. Local versus general anaesthesia for carotid endarterectomy. *Cochrane Database Syst Rev*. 2000;2:CD000126.
72. GALA Trial Collaborative Group, Lewis SC, Warlow CP, Bodenham AR, et al. General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial. *Lancet*. 2008;372:2132-2142.
73. Collins GJ, Lough F, Rich NM, et al. An expedient shunt for the small internal carotid artery. *Am J Surg*. 1980;139:880-882.
74. Wilkinson JM, Rochester JR, Sivaguru A, et al. Middle cerebral artery blood velocity, embolisation, and neurological outcome during carotid endarterectomy: a prospective comparison of the Javid and the Pruitt-Inahara shunts. *Eur J Vasc Endovasc Surg*. 1997;14:399-402.
75. Ascher E, Hingorani A, Markevich N, et al. Carotid surgery without external carotid endarterectomy: a 6-year clinical experience with 1027 cases. *Eur J Vasc Endovasc Surg*. 2003;25:458-461.
76. Moore WS, Kempczinski RF, Nelson JJ, Toole JF. Recurrent carotid stenosis: results of the Asymptomatic Carotid Atherosclerosis Study. *Stroke*. 1998;29:2018-2025.
77. AbuRahma AF, Hannay RS, Khan JH, et al. Prospective randomized study of carotid endarterectomy with polytetrafluoroethylene versus collagen-impregnated Dacron (Hemashield) patching: perioperative (30-day) results. *J Vasc Surg*. 2002;35:125-130.
78. Etheredge SN. A simple technic for carotid endarterectomy. *Am J Surg*. 1970;120:275-278.
79. Kieny R, Hirsch D, Seiller C, et al. Does carotid eversion endarterectomy and reimplantation reduce the risk of restenosis? *Ann Vasc Surg*. 1993;7:407-413.
80. Cao P, Giordano G, De Rango P, et al. Eversion versus conventional carotid endarterectomy: a prospective study. *J Vasc Surg*. 1997;14:96-104.
81. Cao P, Giordano G, De Rango P, et al. Eversion versus conventional carotid endarterectomy: late results of a prospective multicenter randomized trial. *J Vasc Surg*. 2000;31:19-30.
82. Entz L, Jaranyi Z, Nemes A. Comparison of perioperative results obtained with carotid eversion endarterectomy and with conventional patch plasty. *Cardiovasc Surg*. 1997;5:16-20.
83. Ballotta E, Renon L, Da Giau G, et al. A prospective randomized study on bilateral carotid endarterectomy: patching versus eversion. *Ann Surg*. 2000;232:119-125.
84. Littooy FN, Gagovic V, Sandu C, et al. Comparison of standard carotid endarterectomy with Dacron patch angioplasty versus eversion carotid endarterectomy during a 4-year period. *Am Surg*. 2004;70:181-185.
85. Crawford RS, Chung TK, Hodgman T, et al. Restenosis after eversion vs patch closure carotid endarterectomy. *J Vasc Surg*. 2007;46:41-48.
86. Boontje AH. Carotid endarterectomy without a temporary indwelling shunt: results and analysis of back pressure measurements. *Cardiovasc Surg*. 1994;2:549-554.
87. Frawley JE, Hicks RG, Gray LJ, Niesche JW. Carotid endarterectomy without a shunt for symptomatic lesions associated with contralateral severe stenosis or occlusion. *J Vasc Surg*. 1996;23:421-427.
88. Samson RH, Showalter DP, Yunis JP. Routine carotid endarterectomy without a shunt, even in the presence of a contralateral occlusion. *Cardiovasc Surg*. 1998;6:475-484.
89. Hamdan AD, Pomposelli FB Jr, Gibbons GW, et al. Perioperative strokes after 1001 consecutive carotid endarterectomy procedures without an electroencephalogram: incidence, mechanism, and recovery. *Arch Surg*. 1999;134:412-415.
90. Thompson J. Complications of endarterectomy and their prevention. *World J Surg*. 1979;3:155-165.
91. Javid H, Julian O, Dye W, et al. Seventeen year experience with routine shunting in carotid artery surgery. *World J Surg*. 1979;3:167-177.
92. Hertzner NR, Ohara PJ, Mascha EJ, et al. Early outcome assessment for 2228 consecutive carotid endarterectomy procedures: the Cleveland Clinic experience from 1989 to 1995. *J Vasc Surg*. 1997;26:1-10.

93. Rockman CB, Cappadona C, Riles TS, et al. Causes of the increased stroke rate after carotid endarterectomy in patients with previous strokes. *Ann Vasc Surg.* 1997;11:28-34.
94. Steed DL, Peitzman AB, Grundy BL, Webster MW. Causes of stroke in carotid endarterectomy. *Surgery.* 1982;92:634-641.
95. Whitney EG, Brophy CM, Kahn EM, Whitney DG. Inadequate cerebral perfusion is an unlikely cause of perioperative stroke. *Ann Vasc Surg.* 1997;11:109-114.
96. Riles T, Imparato A, Jacobowitz G, et al. The cause of perioperative stroke after carotid endarterectomy. *J Vasc Surg.* 1994;19:206-216.
97. McKinsey JF, Desia TR, Bassiouny H, et al. Mechanisms of neurologic deficits and mortality with carotid endarterectomy. *Arch Surg.* 1996;131:526-532.
98. McDowell HA Jr, Gross GM, Halsey JH. Carotid endarterectomy monitored with transcranial Doppler. *Ann Surg.* 1992;215:514-518.
99. Halsey JH. Risks and benefits of shunting in carotid endarterectomy. *Stroke.* 1992;23:1583-1587.
100. Hertzner N, Beven E. A retrospective comparison of the use of shunts during carotid endarterectomy. *Surg Gynecol Obstet.* 1980;151:81-84.
101. Gumerlock MK, Neuwelt EA. Carotid endarterectomy: to shunt or not to shunt. *Stroke.* 1988;19:1485-1490.
102. Cao P, Giordano G, De Rango P, et al. A randomized study on eversion versus standard carotid endarterectomy: study design and preliminary results: the Everest Trial. *J Vasc Surg.* 1998;27:595-605.
103. Michal V, Hejnal J, Hejhal L, Firt P. Zeitweilige Shunts in der vaskularen Chirurgie. *Thoraxchirurgie.* 1966;14:35.
104. Hays RJ, Levinson SA, Wylie EJ. Intraoperative measurement of carotid back pressure as a guide to operative management for carotid endarterectomy. *Surgery.* 1972;72:953-960.
105. Kelly JJ, Callow AD, O'Donnell TF, et al. Failure of carotid stump pressures. Its incidence as a predictor for a temporary shunt during carotid endarterectomy. *Arch Surg.* 1979;114:1361-1366.
106. Harada RN, Comerota AJ, Good GM, et al. Stump pressure, electroencephalographic changes, and the contralateral carotid artery: another look at selective shunting. *Am J Surg.* 1995;170:148-153.
107. Brewster DC, O'Hara PJ, Darling RC, Hallett JW Jr. Relationship of intraoperative EEG monitoring and stump pressure measurements during carotid endarterectomy. *Circulation.* 1980;62:14-17.
108. Finocchi C, Gandolfo C, Carissimi T, et al. Role of transcranial Doppler and stump pressure during carotid endarterectomy. *Stroke.* 1997;28:2448-2452.
109. Fletcher JP, Morris JG, Little JM, Kershaw LZ. EEG monitoring during carotid endarterectomy. *Aust N Z J Surg.* 1988;58:285-288.
110. Cho I, Smullens S, Streletz L, Fariello R. The value of intraoperative EEG monitoring during carotid endarterectomy. *Ann Neurol.* 1986;20:508-512.
111. Plestis KA, Loubser P, Mizrahi EM, et al. Continuous electroencephalographic monitoring and selective shunting reduces neurologic morbidity rates in carotid endarterectomy. *J Vasc Surg.* 1997;25:620-628.
112. Salvian AJ, Taylor DC, Hsiang YN, et al. Selective shunting with EEG monitoring is safer than routine shunting for carotid endarterectomy. *Cardiovasc Surg.* 1997;5:481-485.
113. Facco E, Deriu GP, Dona B, et al. EEG monitoring of carotid endarterectomy with routine patch-graft angioplasty: an experience in a large series. *Neurophysiol Clin.* 1992;22:437-446.
114. Phillips MR, Johnson WC, Scott RM, et al. Carotid endarterectomy in the presence of contralateral carotid occlusion: the role of EEG and intraluminal shunting. *Arch Surg.* 1979;114:1232-1239.
115. Blume W, Ferguson G, Mcneil D. Significance of EEG changes at carotid endarterectomy. *Stroke.* 1986;8:891-897.
116. Tempelhoff R, Modica PA, Grubb RL Jr, et al. Selective shunting during carotid endarterectomy based on two-channel computerized electroencephalographic/compressed spectral array analysis. *Neurosurgery.* 1989;24:339-344.
117. Amantini A, De Scisciolo G, Bartelli M, et al. Selective shunting based on somatosensory evoked potential monitoring

- during carotid endarterectomy. *Int Angiol.* 1987;6:387-390.
118. Dinkel M, Schweiger H, Goerlitz P. Monitoring during carotid surgery: somatosensory evoked potentials vs. carotid stump pressure. *J Neurosurg Anesthesiol.* 1992;4:167-175.
  119. Fiori L, Parenti G. Electrophysiological monitoring for selective shunting during carotid endarterectomy. *J Neurosurg Anesthesiol.* 1995;7:168-173.
  120. Lam AM, Manninen PH, Ferguson GG, Nantau W. Monitoring electrophysiologic function during carotid endarterectomy: a comparison of somatosensory evoked potentials and conventional electroencephalogram. *Anesthesiology.* 1991;75:15-21.
  121. Manninen PH, Tan TK, Sarjeant RM. Somatosensory evoked potential monitoring during carotid endarterectomy in patients with a stroke. *Anesth Analg.* 2001;93:39-44.
  122. Wober C, Zeitlhofer J, Asenbaum S, et al. Monitoring of median nerve somatosensory evoked potentials in carotid surgery. *J Clin Neurophysiol.* 1998;15:429-438.
  123. Schneider P, Rossman M, Torem S, et al. Transcranial Doppler in the management of extracranial cerebrovascular disease: implications in diagnosis and monitoring. *J Vasc Surg.* 1988;7:1583-1587.
  124. Visser GH, Wieneke GH, van Huffelen AC, Eikelboom BC. The use of preoperative transcranial Doppler variables to predict which patients do not need a shunt during carotid endarterectomy. *Eur J Vasc Endovasc Surg.* 2000;19:226-232.
  125. Jansen C, Vriens EM, Eikelboom BC, et al. Carotid endarterectomy with transcranial Doppler and electroencephalographic monitoring. A prospective study in 130 operations. *Stroke.* 1993;24:665-669.
  126. Smith JL, Evans DH, Gaunt ME, et al. Experience with transcranial Doppler monitoring reduces the incidence of particulate embolization during carotid endarterectomy. *Br J Surg.* 1998;85:56-59.
  127. Belardi P, Lucertini G, Ermirio D. Stump pressure and transcranial Doppler for predicting shunting in carotid endarterectomy. *Eur J Vasc Endovasc Surg.* 2003;25:164-167.
  128. Benjamin ME, Silva MB Jr, Watt C, et al. Awake patient monitoring to determine the need for shunting during carotid endarterectomy. *Surgery.* 1993;114:673-679.
  129. Illig KA, Sternbach Y, Zhang R, et al. EEG changes during awake carotid endarterectomy. *Ann Vasc Surg.* 2002;16:6-11.
  130. Lawrence PF, Alves JC, Jicha D, et al. Incidence, timing, and causes of cerebral ischemia during carotid endarterectomy with regional anesthesia. *J Vasc Surg.* 1998;27:329-334.
  131. McCarthy RJ, Walker R, McAteer P, et al. Patient and hospital benefits of local anaesthesia for carotid endarterectomy. *Eur J Vasc Endovasc Surg.* 2001;22:13-18.
  132. McCleary AJ, Maritati G, Gough MJ. Carotid endarterectomy; local or general anaesthesia? *Eur J Vasc Endovasc Surg.* 2001;22:1-12.
  133. Stoughton J, Nath RL, Abbott WM. Comparison of simultaneous electroencephalographic and mental status monitoring during carotid endarterectomy with regional anesthesia. *J Vasc Surg.* 1998;28:1014-1021.
  134. Wellman BJ, Loftus CM, Kresowik TF, et al. The differences in electroencephalographic changes in patients undergoing carotid endarterectomies while under local versus general anesthesia. *Neurosurgery.* 1998;43:769-773.
  135. Calligaro KD, Dougherty MJ. Correlation of carotid artery stump pressure and neurologic changes during 474 carotid endarterectomies performed in awake patients. *J Vasc Surg.* 2005;42:684-689.
  136. Hans SS, Jareunpoon O. Prospective evaluation of electroencephalography, carotid artery stump pressure, and neurologic changes during 314 consecutive carotid endarterectomies performed in awake patients. *J Vasc Surg.* 2007;45:511-515.
  137. Sternbach Y, Illig KA, Zhang R, et al. Hemodynamic benefits of regional anesthesia for carotid endarterectomy. *J Vasc Surg.* 2002;35:333-339.
  138. Eibes T, Gross WS. The influence of anesthetic technique on perioperative blood pressure control after carotid endarterectomy. *Am Surg.* 2000;66:641-647.
  139. Bowyer M, Zierold D, Loftus J, et al. Carotid endarterectomy: a comparison of regional versus general anesthesia in 500 operations. *Ann Vasc Surg.* 2000;14:145-151.



140. Back M, Harward T, Huber T, et al. Improving the cost-effectiveness of carotid endarterectomy. *J Vasc Surg.* 1997;26:456-464.
141. Bond R, Warlow CP, Naylor AR, Rothwell PM. Variation in surgical and anaesthetic technique and associations with operative risk in the European Carotid Surgery Trial: implications for trials of ancillary techniques. *Eur J Vasc Endovasc Surg.* 2002;23:117-126.
142. Halsey JH Jr. Risks and benefits of shunting in carotid endarterectomy. The International Transcranial Doppler Collaborators. *Stroke.* 1992;23:1583-1587.
143. Parsson HN, Lord RS, Scott K, Zemack G. Maintaining carotid flow by shunting during carotid endarterectomy diminishes the inflammatory response mediating ischaemic brain injury. *Eur J Vasc Endovasc Surg.* 2000;19:124-130.
144. Sundt T, Sharbrough F, Piepgras D, et al. Correlation of cerebral blood flow and electroencephalographic changes during carotid endarterectomy. *Mayo Clin Proc.* 1981;56:533-543.
145. De Vleeschauwer P, Wirthle W, Holler L, et al. Is venous patch grafting after carotid endarterectomy able to reduce the rate of restenosis? Prospective randomized pilot study with stratification. *Acta Chir Belg.* 1987;87:242-246.
146. Katz MM, Jones GT, Degenhardt J, et al. The use of patch angioplasty to alter the incidence of carotid restenosis following thromboendarterectomy. *J Cardiovasc Surg (Torino).* 1987;28:2-8.
147. Eikelboom BC, Ackerstaff RG, Hoenefeld H, et al. Benefits of carotid patching: a randomized study. *J Vasc Surg.* 1988;7:240-247.
148. O'Hara PJ, Hertzner NR, Krajewski LP, Beven EG. Saphenous vein patch rupture after carotid endarterectomy. *J Vasc Surg.* 1992;15:504-509.
149. Scott EW, Dolson L, Day AL, Seeger JM. Carotid endarterectomy complicated by vein patch rupture. *Neurosurgery.* 1992;31:373-376.
150. Riles TS, Lamparello PJ, Giangola G, Imparato AM. Rupture of the vein patch—a rare complication of carotid endarterectomy. *Surgery.* 1990;107:10-12.
151. Lord RS, Raj TB, Stary DL, et al. Comparison of saphenous vein patch, polytetrafluoroethylene patch, and direct arteriotomy closure after carotid endarterectomy. Part I. Perioperative results. *J Vasc Surg.* 1989;9:521-529.
152. Archie JP Jr, Green JJ Jr. Saphenous vein rupture pressure, rupture stress, and carotid endarterectomy vein patch reconstruction. *Surgery.* 1990;107:389-396.
153. Archie JP. Carotid endarterectomy saphenous vein patch rupture revisited: selective use on the basis of vein diameter. *J Vasc Surg.* 1996;24:346-351.
154. Katz D, Snyder SO, Gandhi RH, et al. Long-term follow-up for recurrent stenosis: a prospective randomized study of expanded polytetrafluoroethylene patch angioplasty versus primary closure after carotid endarterectomy. *J Vasc Surg.* 1994;19:198-203.
155. AbuRahma AF, Robinson PA, Saiedy S, et al. Prospective randomized trial of bilateral carotid endarterectomies: primary closure versus patching. *Stroke.* 1999;30:1185-1189.
156. Bond R, Rerkasem K, Naylor AR, et al. Systematic review of randomized controlled trials of patch angioplasty versus primary closure and different types of patch materials during carotid endarterectomy. *J Vasc Surg.* 2004;40:1126-1135.
157. Counsell CE, Salinas R, Naylor R, Warlow CP. A systematic review of the randomised trials of carotid patch angioplasty in carotid endarterectomy. *Eur J Vasc Endovasc Surg.* 1997;13:345-354.
158. Rockman CB, Halm EA, Wang JJ, et al. Primary closure of the carotid artery is associated with poorer outcomes during carotid endarterectomy. *J Vasc Surg.* 2005;42:870-877.
159. Kresowik TF, Bratzler D, Karp HR, et al. Multistate utilization, processes, and outcomes of carotid endarterectomy. *J Vasc Surg.* 2001;33:227-234.
160. Al-Rawi PG, Turner CL, Waran V, et al. A randomized trial of synthetic patch versus direct primary closure in carotid endarterectomy. *Neurosurgery.* 2006;59:822-828; discussion 828-829.

161. Grego F, Antonello M, Lepidi S, et al. Prospective, randomized study of external jugular vein patch versus polytetrafluoroethylene patch during carotid endarterectomy: perioperative and long-term results. *J Vasc Surg.* 2003;38:1232-1240.
162. Marien BJ, Raffetto JD, Seidman CS, et al. Bovine pericardium vs Dacron for patch angioplasty after carotid endarterectomy: a prospective randomized study. *Arch Surg.* 2002;137:785-788.
163. Goldman KA, Su WT, Riles TS, et al. A comparative-study of saphenous-vein, internal jugular-vein, and knitted Dacron patches for carotid-artery endarterectomy. *Ann Vasc Surg.* 1995;9:71-79.
164. Jacobowitz GR, Rockman CB, Lamparello PJ, et al. Causes of perioperative stroke after carotid endarterectomy: special considerations in symptomatic patients. *Ann Vasc Surg.* 2001;15:19-24.
165. AbuRahma AF, Khan JH, Robinson PA, et al. Prospective randomized trial of carotid endarterectomy with primary closure and patch angioplasty with saphenous vein, jugular vein, and polytetrafluoroethylene: perioperative (30-day) results. *J Vasc Surg.* 1996;24:998-1007.
166. AbuRahma AF, Robinson PA, Saiedy S, et al. Prospective randomized trial of carotid endarterectomy with primary closure and patch angioplasty with saphenous vein, jugular vein, and polytetrafluoroethylene: long-term follow-up. *J Vasc Surg.* 1998;27:222-232.
167. AbuRahma AF, Hopkins ES, Robinson PA, et al. Prospective randomized trial of carotid endarterectomy with polytetrafluoroethylene versus collagen-impregnated Dacron (Hemashield) patching: late follow-up. *Ann Surg.* 2003;237:885-892.
168. AbuRahma AF, Stone PA, Flaherty SK, AbuRahma Z. Prospective randomized trial of ACUSEAL (Gore-Tex) versus Hemashield-Finesse patching during carotid endarterectomy: early results. *J Vasc Surg.* 2007;45:881-884.
169. Margovsky AI, Meek AC, Lord RSA. Acute platelet deposition after carotid endarterectomy in sheep: vein patch compared with gelatin-sealed Dacron and polytetrafluoroethylene patch closure. *J Vasc Surg.* 1996;24:200-206.
170. Golledge J, Cumming R, Davies AH, Greenhalgh RM. Outcome of selective patching following carotid endarterectomy. *Eur J Vasc Endovasc Surg.* 1996;11:458-463.
171. Cikrit DF, Larson DM, Sawchuk AP, et al. Discretionary carotid patch angioplasty leads to good results. *Am J Surg.* 2006;192:e46-e50.
172. Pappas D, Hines GL, Yoonah KE. Selective patching in carotid endarterectomy: is patching always necessary? *J Cardiovasc Surg (Torino).* 1999;40:555-559.
173. Kinney EV, Seabrook GR, Kinney LY, et al. The importance of intraoperative detection of residual flow abnormalities after carotid artery endarterectomy. *J Vasc Surg.* 1993;17:912-922.
174. Westerband A, Mills JL, Berman SS, Hunter GC. The influence of routine completion arteriography on outcome following carotid endarterectomy. *Ann Vasc Surg.* 1997;11:14-19.
175. Rockman CB, Haim EA. Intraoperative imaging: does it really improve perioperative outcomes of carotid endarterectomy? *Semin Vasc Surg.* 2007;20:236-243.
176. Diethrich EB, Koopot R, Pierce SA. Carotid-cavernous fistula complicating thromboendarterectomy for an occluded internal carotid-artery. *Vasc Surg.* 1981;15:287-296.
177. Perler BA, Murphy K, Sternbach Y, et al. Immediate postoperative thrombolytic therapy: an aggressive strategy for neurologic salvage when cerebral thromboembolism complicates carotid endarterectomy. *J Vasc Surg.* 2000;31:1033-1037.
178. Bellon RJ, Putman CM, Budzik RF, et al. Rheolytic thrombectomy of the occluded internal carotid artery in the setting of acute ischemic stroke. *AJNR Am J Neuroradiol.* 2001;22:526-530.
179. Flint AC, Duckwiler GR, Budzik RF, et al. Mechanical thrombectomy of intracranial internal carotid occlusion—Pooled results of the MERCI and multi MERCI part I trials. *Stroke.* 2007;38:1274-1280.
180. Imai K, Mori T, Izumoto H, et al. Clot removal therapy by aspiration and extraction for acute embolic carotid occlusion. *AJNR Am J Neuroradiol.* 2006;27:1521-1527.

181. Stead LG, Gilmore RM, Bellolio MF, et al. Percutaneous clot removal devices in acute ischemic stroke. *Arch Neurol*. 2008;65:1024-1030.
182. Tomsick T, Broderick J, Carrozella J, et al. Revascularization results in the Interventional Management of Stroke II Trial. *AJNR Am J Neuroradiol*. 2008;29:582-587.
183. Sorimachi T, Fujii Y, Tsuchiya N, et al. Recanalization by mechanical embolus disruption during intra-arterial thrombolysis in the carotid territory. *AJNR Am J Neuroradiol*. 2004;25:1391-1402.
184. Bush RL, Bhama JK, Lin PH, Lumsden AB. Transient ischemic attack due to early carotid stent thrombosis: successful rescue with rheolytic thrombectomy and systemic abciximab. *J Endovasc Ther*. 2003;10:870-874.
185. Saqqur M, Uchino K, Demchuk AM, et al. Site of arterial occlusion identified by transcranial doppler predicts the response to intravenous thrombolysis for stroke. *Stroke*. 2007;38:948-954.
186. Rubin JR, Goldstone J, McIntyre KE, et al. The value of carotid endarterectomy in reducing the morbidity and mortality of recurrent stroke. *J Vasc Surg*. 1986;4:443-449.
187. Takolander RJ, Bergentz SE, Ericsson BF. Carotid-artery surgery in patients with minor stroke. *Br J Surg*. 1983;70:13-16.
188. Thompson JE. Don't throw out the baby with the bath water—a perspective on carotid endarterectomy. *J Vasc Surg*. 1986;4:543-545.
189. Matsumoto N, Whisnant JP, Kurland LT, Okazaki H. Natural history of stroke in Rochester, Minnesota, 1955 through 1969: an extension of a previous study, 1945 through 1954. *Stroke*. 1973;4:20-29.
190. Imparato AM, Ramirez A, Riles T, Mintzer R. Cerebral protection in carotid surgery. *Arch Surg*. 1982;117:1073-1078.
191. Hertzner NR. Carotid endarterectomy—a crisis in confidence. *J Vasc Surg*. 1988;7:611-619.
192. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. *Lancet*. 2004;363:1491-1502.
193. Lamuraglia GM, Brewster DC, Moncure AC, et al. Carotid endarterectomy at the millennium: what interventional therapy must match. *Ann Surg*. 2004;240:535-544.
194. Maxwell JG, Rutledge R, Covington DL, et al. A statewide, hospital-based analysis of frequency and outcomes in carotid endarterectomy. *Am J Surg*. 1997;174:655-660.
195. Greenstein AJ, Chassin MR, Wang J, et al. Association between minor and major surgical complications after carotid endarterectomy: results of the New York Carotid Artery Surgery study. *J Vasc Surg*. 2007;46:1138-1146.
196. Matsen SL, Chang DC, Perler BA, et al. Trends in the in-hospital stroke rate following carotid endarterectomy in California and Maryland. *J Vasc Surg*. 2006;44:488-495.
197. Weiss JS, Dumas P, Cha C, et al. Safety of carotid endarterectomy in a high-risk population: lessons from the VA and Connecticut. *J Am Coll Surg*. 2006;203:277-282.
198. Karp HR, Flanders WD, Shipp CC, et al. Carotid endarterectomy among Medicare beneficiaries: a statewide evaluation of appropriateness and outcome. *Stroke*. 1998;29:46-52.
199. Goodney PP, Siewers AE, Stukel TA, et al. Is surgery getting safer? National trends in operative mortality. *J Am Coll Surg*. 2002;195:219-227.
200. Sheikh K, Bullock C. Variation and changes in state-specific carotid endarterectomy and 30-day mortality rates, United States, 1991-2000. *J Vasc Surg*. 2003;38:779-784.
201. Wennberg DE, Lucas FL, Birkmeyer JD, et al. Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics. *JAMA*. 1998;279:1278-1281.
202. Stoner MC, Abbott WM, Wong DR, et al. Defining the high-risk patient for carotid endarterectomy: an analysis of the prospective National Surgical Quality Improvement Program database. *J Vasc Surg*. 2006;43:285-295.
203. McPhee JT, Hill JS, Ciocca RG, et al. Carotid endarterectomy was performed with lower stroke and death rates than carotid artery stenting in the United States in 2003 and 2004. *J Vasc Surg*. 2007;46:1112-1118.
204. Jacobowitz GR, Adelman MA, Riles TS, et al. Long-term follow-up of patients undergoing carotid endarterectomy in the

- presence of a contralateral occlusion. *Am J Surg*. 1995;170:165-167.
205. Ballotta E, Meneghetti G, Manara R, Baracchini C. Long-term survival and stroke-free survival after eversion carotid endarterectomy for asymptomatic severe carotid stenosis. *J Vasc Surg*. 2007;46:265-270.
  206. Healy DA, Clowes AW, Zierler RE, et al. Immediate and long-term results of carotid endarterectomy. *Stroke*. 1989;20:1138-1142.
  207. Vermassen F, Flamme A, De Roose J, et al. Long-term results after carotid endarterectomy for carotid artery stenosis with contralateral occlusion. *Ann Vasc Surg*. 1990;4:323-327.
  208. Kazmers A, Cerqueira MD, Zierler RE. The role of preoperative radionuclide left ventricular ejection fraction for risk assessment in carotid surgery. *Arch Surg*. 1988;123:416-419.
  209. Hertzner NR, Lees CD. Fatal myocardial infarction following carotid endarterectomy: three hundred thirty-five patients followed 6-11 years after operation. *Ann Surg*. 1981;194:212-218.
  210. O'Donnell TF Jr, Callow AD, Willet C, et al. The impact of coronary artery disease on carotid endarterectomy. *Ann Surg*. 1983;198:705-712.
  211. Hertzner NR, Arison R. Cumulative stroke and survival ten years after carotid endarterectomy. *J Vasc Surg*. 1985;2:661-668.
  212. Nunn DB. Carotid endarterectomy: an analysis of 234 operative cases. *Ann Surg*. 1975;182:733-738.
  213. Deweese JA, Rob CG, Satran R, et al. Results of carotid endarterectomies for transient ischemic attacks—five years later. *Ann Surg*. 1973;178:258-264.
  214. Hertzner NR, Loop FD, Taylor PC, Beven EG. Staged and combined surgical approach to simultaneous carotid and coronary vascular disease. *Surgery*. 1978;84:803-811.
  215. Hertzner NR, Beven EG, Young JR, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. *Ann Surg*. 1984;199:223-233.
  216. Deweese JA, Rob CG, Satran R, et al. Results of carotid endarterectomies for transient ischemic attacks-five years later. *Ann Surg*. 1973;178:258-264.
  217. Gelabert HA, Moore WS. Carotid endarterectomy: current status. *Curr Probl Surg*. 1991;28:181-262.
  218. Forssell C, Takolander R, Bergqvist D, et al. Cranial nerve injuries associated with carotid endarterectomy. A prospective study. *Acta Chir Scand*. 1985;151:595-598.
  219. Schaubert MD, Fontenelle LJ, Solomon JW, Hanson TL. Cranial/cervical nerve dysfunction after carotid endarterectomy. *J Vasc Surg*. 1997;25:481-487.
  220. Evans WE, Mendelowitz DS, Liapis C, et al. Motor speech deficit following carotid endarterectomy. *Ann Surg*. 1982;196:461-464.
  221. Cunningham EJ, Bond R, Mayberg MR, et al. Risk of persistent cranial nerve injury after carotid endarterectomy. *J Neurosurg*. 2004;101:445-448.
  222. Rosenbloom M, Friedman SG, Lamparello PJ, et al. Glossopharyngeal nerve injury complicating carotid endarterectomy. *J Vasc Surg*. 1987;5:469-471.
  223. Tucker JA, Gee W, Nicholas GG, et al. Accessory nerve injury during carotid endarterectomy. *J Vasc Surg*. 1987;5:440-444.
  224. Bageant TE, Tondini D, Lysons D. Bilateral hypoglossal-nerve palsy following a second carotid endarterectomy. *Anesthesiology*. 1975;43:595-596.
  225. Hertzner NR. Postoperative management and complications following extracranial carotid reconstruction. In: Rutherford RB, ed. *Vascular Surgery*. 2nd ed. Philadelphia, PA: WB Saunders; 1984:1300.
  226. Verta MJ Jr, Applebaum EL, McClusky DA, et al. Cranial nerve injuring during carotid endarterectomy. *Ann Surg*. 1977;185:192-195.
  227. Matsumoto GH, Cossman D, Callow AD. Hazards and safeguards during carotid endarterectomy—technical considerations. *Am J Surg*. 1977;133:458-462.

228. Dehn TC, Taylor GW. Cranial and cervical nerve damage associated with carotid endarterectomy. *Br J Surg*. 1983;70:365-368.
229. Pine R, Avellone JC, Hoffman M, et al. Control of postcarotid endarterectomy hypotension with baroreceptor blockade. *Am J Surg*. 1984;147:763-765.
230. Lehv MS, Salzman EW, Silen W. Hypertension complicating carotid endarterectomy. *Stroke*. 1970;1:307-313.
231. Angell-James JE, Lumley JS. The effects of carotid endarterectomy on the mechanical properties of the carotid sinus and carotid sinus nerve activity in atherosclerotic patients. *Br J Surg*. 1974;61:805-810.
232. Bove EL, Fry WJ, Gross WS, Stanley JC. Hypotension and hypertension as consequences of baroreceptor dysfunction following carotid endarterectomy. *Surgery*. 1979;85:633-637.
233. Ranson JH, Imparato AM, Clauss RH, et al. Factors in the mortality and morbidity associated with surgical treatment of cerebrovascular insufficiency. *Circulation*. 1969;39(5 Suppl 1):I269-I274.
234. Thompson JE. Complications of carotid endarterectomy and their prevention. *World J Surg*. 1979;3:155-165.
235. Towne JB, Bernhard VM. The relationship of postoperative hypertension to complications following carotid endarterectomy. *Surgery*. 1980;88:575-580.
236. Ascher E, Markevich N, Schutzer RW, et al. Cerebral hyperperfusion syndrome after carotid endarterectomy: predictive factors and hemodynamic changes. *J Vasc Surg*. 2003;37:769-777.
237. Karapanayiotides T, Meuli R, Devuyst G, et al. Postcarotid endarterectomy hyperperfusion or reperfusion syndrome. *Stroke*. 2005;36:21-26.
238. Abou-Chebl A, Yadav JS, Reginelli JP, et al. Intracranial hemorrhage and hyperperfusion syndrome following carotid artery stenting—risk factors, prevention, and treatment. *J Am Coll Cardiol*. 2004;43:1596-1601.
239. Kaku Y, Yoshimura S, Kokuzawa J. Factors predictive of cerebral hyperperfusion after carotid angioplasty and stent placement. *AJNR Am J Neuroradiol*. 2004;25:1403-1408.
240. Perler BA, Williams GM. Post-carotid-endarterectomy intracerebral hemorrhage: a continuing challenge—Case reports. *Vasc Surg*. 1996;30:71-75.
241. Hafner DH, Smith RB, King OW, et al. Massive intracerebral hemorrhage following carotid endarterectomy. *Arch Surg*. 1987;122:305-307.
242. Nielsen TG, Sillesen H, Schroeder TV. Seizures following carotid endarterectomy in patients with severely compromised cerebral circulation. *Eur J Vasc Endovasc Surg*. 1995;9:53-57.
243. Jorgensen LG, Schroeder TV. Defective cerebrovascular autoregulation after carotid endarterectomy. *Eur J Vasc Surg*. 1993;7:370-379.
244. Schroeder T, Sillesen H, Sorensen O, Engell HC. Cerebral hyperperfusion following carotid endarterectomy. *J Neurosurg*. 1987;66:824-829.
245. Ascher E, Markevich N, Schutzer RW, et al. Cerebral hyperperfusion syndrome after carotid endarterectomy: predictive factors and hemodynamic changes. *J Vasc Surg*. 2003;37:769-777.
246. Nouraei SA, Al Rawi PG, Sigaudo-Roussel D, et al. Carotid endarterectomy impairs blood pressure homeostasis by reducing the physiologic baroreflex reserve. *J Vasc Surg*. 2005;41:631-637.
247. Myers SI, Valentine RJ, Chervu A, et al. Saphenous-vein patch versus primary closure for carotid endarterectomy—long-term assessment of a randomized prospective-study. *J Vasc Surg*. 1994;19:15-22.
248. Perler BA, Ursin F, Shanks U, Williams GM. Carotid Dacron patch angioplasty: immediate and long-term results of a prospective series. *Cardiovasc Surg*. 1995;3:631-636.
249. Rosenthal D, Archie JP Jr, Garcia-Rinaldi R, et al. Carotid patch angioplasty: immediate and long-term results. *J Vasc Surg*. 1990;12:326-333.
250. Rainer WG, Guillen J, Bloomquist CD, McCrory CB. Carotid artery surgery. Morbidity and mortality in 257 operations. *Am J Surg*. 1968;116:78-81.

251. Sundt TM, Sandok BA, Whisnant JP. Carotid endarterectomy. Complications and preoperative assessment of risk. *Mayo Clin Proc.* 1975;50:301-306.
252. Kunkel JM, Gomez ER, Spebar MJ, et al. Wound hematomas after carotid endarterectomy. *Am J Surg.* 1984;148:844-847.
253. Sadideen H, Taylor PR, Padayachee TS. Restenosis after carotid endarterectomy. *Int J Clin Pract.* 2006;60:1625-1630.
254. Callow AD. Recurrent stenosis after carotid endarterectomy. *Arch Surg.* 1982;117:1082-1085.
255. Salvian A, Baker JD, Machleder HI, et al. Cause and noninvasive detection of restenosis after carotid endarterectomy. *Am J Surg.* 1983;146:29-34.
256. Zierler RE, Bandyk DF, Thiele BL, Strandness DE Jr. Carotid artery stenosis following endarterectomy. *Arch Surg.* 1982;117:1408-1415.
257. Lattimer CR, Burnand KG. Recurrent carotid stenosis after carotid endarterectomy. *Br J Surg.* 1997;84:1206-1219.
258. Frericks H, Kievit J, van Baalen JM, van Bockel JH. Carotid recurrent stenosis and risk of ipsilateral stroke: a systematic review of the literature. *Stroke.* 1998;29:244-250.
259. Ballotta E, Da Giau G, Piccoli A, Baracchini C. Durability of carotid endarterectomy for treatment of symptomatic and asymptomatic stenoses. *J Vasc Surg.* 2004;40:270-278.
260. Healy DA, Zierler E, Nicholls SC, et al. Long-term follow-up and clinical outcome of carotid restenosis. *J Vasc Surg.* 1989;10:662-669.
261. Zierler RE, Bandyk DF, Thiele BL, Strandness DE. Carotid-artery stenosis following endarterectomy. *Arch Surg.* 1982;117:1408-1415.
262. Reina-Gutierrez T, Serrano-Hernando FJ, Sanchez-Hervas L, et al. Recurrent carotid artery stenosis following endarterectomy: natural history and risk factors. *Eur J Vasc Endovasc Surg.* 2005;29:334-341.
263. AbuRahma AF, Jennings TG, Wulu JT, et al. Redo carotid endarterectomy versus primary carotid endarterectomy. *Stroke.* 2001;32:2787-2792.
264. Mehta M, Roddy SP, Darling RC, et al. Safety and efficacy of eversion carotid endarterectomy for the treatment of recurrent stenosis: 20-year experience. *Ann Vasc Surg.* 2005;19:492-498.
265. AbuRahma AF, Bates MC, Wulu JT, Stone PA. Early postsurgical carotid restenosis: redo surgery versus angioplasty/stenting. *J Endovasc Ther.* 2002;9:566-572.
266. Bowser AN, Bandyk DF, Evans A, et al. Outcome of carotid stent-assisted angioplasty versus open surgical repair of recurrent carotid stenosis. *J Vasc Surg.* 2003;38:432-438.
267. Stoner MC, Cambria RP, Brewster DC, et al. Safety and efficacy of reoperative carotid endarterectomy: a 14-year experience. *J Vasc Surg.* 2005;41:942-949.
268. Archie JP. Reoperations for carotid artery stenosis: role of primary and secondary reconstructions. *J Vasc Surg.* 2001;33:495-503.
269. Cho JS, Pandurangi K, Conrad MF, et al. Safety and durability of redo carotid operation: an 11-year experience. *J Vasc Surg.* 2004;39:155-161.
270. Brener BJ, Brief DK, Alpert J, et al. The risk of stroke in patients with asymptomatic carotid stenosis undergoing cardiac-surgery—a follow-up-study. *J Vasc Surg.* 1987;5:269-279.
271. Barnes RW, Liebman PR, Marszalek PB, et al. The natural-history of asymptomatic carotid disease in patients undergoing cardiovascular-surgery. *Surgery.* 1981;90:1075-1083.
272. Tunio AM, Hingorani A, Ascher E. The impact of an occluded internal carotid artery on the mortality and morbidity of patients undergoing coronary artery bypass grafting. *Am J Surg.* 1999;178:201-205.
273. Naylor AR, Mehta Z, Rothwell PM, Bell PRF. Carotid artery disease and stroke during coronary artery bypass: a critical review of the literature. *Eur J Vasc Endovasc Surg.* 2002;23:283-294.
274. Hertzner NR, Loop FD, Beven EG, et al. Surgical staging for simultaneous coronary and carotid disease: a study including prospective randomization. *J Vasc Surg.* 1989;9:455-463.

275. Takach TJ, Reul GJ, Cooley DA, et al. Is an integrated approach warranted for concomitant carotid and coronary artery disease? *Ann Thorac Surg*. 1997;64:16-22.
276. Evagelopoulos N, Trenz MT, Beckmann A, Krian A. Simultaneous carotid endarterectomy and coronary artery bypass grafting in 313 patients. *Cardiovasc Surg*. 2000;8:31-40.
277. Mishra Y, Wasir H, Kohli V, et al. Concomitant carotid endarterectomy and coronary bypass surgery: outcome of on-pump and off-pump techniques. *Ann Thorac Surg*. 2004;78:2037-2043.
278. Minami K, Fukahara K, Boethig D, et al. Long-term results of simultaneous carotid endarterectomy and myocardial revascularization with cardiopulmonary bypass used for both procedures. *J Thorac Cardiovasc Surg*. 2000;119:764-772.
279. Darling RC, Dylewski M, Chang BB, et al. Combined carotid endarterectomy and coronary artery bypass grafting does not increase the risk of perioperative stroke. *Cardiovasc Surg*. 1998;6:448-452.
280. Plestis KA, Ke S, Jiang ZD, Howell JF. Combined carotid endarterectomy and coronary artery bypass: immediate and long-term results. *Ann Vasc Surg*. 1999;13:84-92.
281. Cambria RP, Ivarsson BL, Akins CW, et al. Simultaneous carotid and coronary-disease—safety of the combined approach. *J Vasc Surg*. 1989;9:56-64.
282. Perler BA, Burdick JF, Williams GM. The safety of carotid endarterectomy at the time of coronary artery bypass surgery: analysis of results in a high-risk patient population. *J Vasc Surg*. 1985;2:558-563.
283. Coyle KA, Gray BC, Smith RB, et al. Morbidity and mortality associated with carotid endarterectomy—effect of adjunctive coronary revascularization. *Ann Vasc Surg*. 1995;9:21-27.
284. Giangola G, Migaly J, Riles TS, et al. Perioperative morbidity and mortality in combined vs. staged approaches to carotid and coronary revascularization. *Ann Vasc Surg*. 1996;10:138-142.
285. Ghosh J, Murray D, Khwaja N, et al. The influence of asymptomatic significant carotid disease on mortality and morbidity in patients undergoing coronary artery bypass surgery. *Eur J Vasc Endovasc Surg*. 2005;29:88-90.
286. Durand DJ, Perler BA, Roseborough GS, et al. Mandatory versus selective preoperative carotid screening: a retrospective analysis. *Ann Thorac Surg*. 2004;78:159-166.
287. Borger MA, Fremes SE, Weisel RD, et al. Coronary bypass and carotid endarterectomy: does a combined approach increase risk? A metaanalysis. *Ann Thorac Surg*. 1999;68:14-20.
288. Naylor AR, Cuffe RL, Rothwell PM, Bell PRF. A systematic review of outcomes following staged and synchronous carotid endarterectomy and coronary artery bypass. *Eur J Vasc Endovasc Surg*. 2003;25:380-389.
289. Naylor R, Cuffe RL, Rothwell PM, et al. A systematic review of outcome following synchronous carotid endarterectomy and coronary artery bypass: influence of surgical and patient variables. *Eur J Vasc Endovasc Surg*. 2003;26:230-241.
290. Byrne J, Darling RC, Roddy SP, et al. Combined carotid endarterectomy and coronary artery bypass grafting in patients with asymptomatic high-grade stenoses: an analysis of 758 procedures. *J Vasc Surg*. 2006;44:67-72.
291. Brown KR, Kresowik TF, Chin MH, et al. Multistate population-based outcomes of combined carotid endarterectomy and coronary artery bypass. *J Vasc Surg*. 2003;37:32-39.
292. Meharwal ZS, Mishra A, Trehan N. Safety and efficacy of one stage off-pump coronary artery operation and carotid endarterectomy. *Ann Thorac Surg*. 2002;73:793-797.
293. Ziada KM, Yadav JS, Mukherjee D, et al. Comparison of results of carotid stenting followed by open heart surgery versus combined carotid endarterectomy and open heart surgery (coronary bypass with or without another procedure). *Am J Cardiol*. 2005;96:519-523.
294. Abbasi K, Araghi MF, Zafarghandi M, et al. Concomitant carotid endarterectomy and coronary artery bypass grafting versus staged carotid stenting followed by coronary artery bypass grafting. *J Cardiovasc Surg*. 2008;49:285-288.
295. Guzman LA, Costa MA, Angiolillo DJ, et al. A systematic review of outcomes in patients with staged carotid artery stenting and coronary artery bypass graft surgery. *Stroke*. 2008;39:361-365.
296. Timaran CH, Rosero EB, Smith ST, et al. Trends and outcomes of concurrent carotid revascularization and coronary bypass.

*J Vasc Surg.* 2008;48:355-361.

297. Narins CR, Illig KA. Patient selection for carotid stenting versus endarterectomy: a systematic review. *J Vasc Surg.* 2006;44:661-672.
298. Perler BA, Dardik A, Burleyson GP, et al. Influence of age and hospital volume on the results of carotid endarterectomy: a statewide analysis of 9918 cases. *J Vasc Surg.* 1998;27:25-31.
299. Teso D, Edwards RE, Frattini JC, et al. Safety of carotid endarterectomy in 2,443 elderly patients: lessons from nonagenarians—are we pushing the limit? *J Am Coll Surg.* 2005;200:734-741.
300. Pruner G, Castellano R, Jannello AM, et al. Carotid endarterectomy in the octogenarian: outcomes of 345 procedures performed from 1995-2000. *Cardiovasc Surg.* 2003;11:105-112.
301. Cartier B. Carotid surgery in octogenarians: why not? *Ann Vasc Surg.* 2002;16:751-755.
302. O'Hara PJ, Hertzner NR, Mascha EJ, et al. Carotid endarterectomy in octogenarians: early results and late outcome. *J Vasc Surg.* 1998;27:860-871.
303. Sternbach Y, Perler BA. The influence of female gender on the outcome of carotid endarterectomy: a challenge to the ACAS findings. *Surgery.* 2000;127:272-275.
304. Harthun NL, Kongable GL, Baglioni J, et al. Examination of sex as an independent risk factor for adverse events after carotid endarterectomy. *J Vasc Surg.* 2005;41:223-230.
305. Kapral MK, Wang H, Austin PC, et al. Sex differences in carotid endarterectomy outcomes—results from the Ontario Carotid Endarterectomy Registry. *Stroke.* 2003;34:1120-1124.
306. Lucas FL, Stukel TA, Morris AM, et al. Race and surgical mortality in the United States. *Ann Surg.* 2006;243:281-286.
307. Kennedy BS. Does race predict short-term mortality after carotid surgery? The results of a meta-analysis. *J Natl Med Assoc.* 2002;94:25-30.
308. Dardik A, Bowman HM, Gordon TA, et al. Impact of race on the outcome of carotid endarterectomy—a population-based analysis of 9,842 recent elective procedures. *Ann Surg.* 2000;232:704-709.
309. Horner RD, Oddone EZ, Stechuchak KM, et al. Racial variations in postoperative outcomes of carotid endarterectomy—evidence from the Veterans Affairs National Surgical Quality Improvement Program. *Med Care.* 2002;40:35-43.
310. Conrad MF, Shepard AD, Pandurangi K, et al. Outcome of carotid endarterectomy in African Americans: is race a factor? *J Vasc Surg.* 2003;38:129-137.
311. Bogousslavsky J, Regli F, Hungerbuhler JP, Chrzanowski R. Transient ischemic attacks and external carotid artery. A retrospective study of 23 patients with an occlusion of the internal carotid artery. *Stroke.* 1981;12:627-630.
312. Connolly JE, Stemmer EA. Endarterectomy of external carotid-artery—its importance in surgical management of extracranial cerebrovascular occlusive disease. *Arch Surg.* 1973;106:799-802.
313. Boontje AH. External carotid-artery revascularization—indications, operative techniques and results. *J Cardiovasc Surg.* 1992;33:315-318.
314. Hertzner NR. External carotid endarterectomy. *Surg Gynecol Obstet.* 1981;153:186-190.
315. Sekhar LN, Heros RC, Dujovny M, et al. External carotid endarterectomy for cerebral and ocular ischemia. *Vasc Surg.* 1982;16:185-203.
316. Gattuso R, Irace L, Gossetti B, Martinelli O. External carotid-artery repair in cerebrovascular insufficiency. *J Mal Vasc.* 1993;18:262-264.
317. Fisher DF, Valentine RJ, Patterson CB, et al. Is external carotid endarterectomy a durable procedure? *Am J Surg.* 1986;152:700-703.
318. Nicolosi A, Klinger D, Bandyk D, Towne J. External carotid endarterectomy in the treatment of symptomatic patients with internal carotid artery occlusion. *Ann Vasc Surg.* 1988;2:336-339.
319. Street DL, Ricotta JJ, Green RM, Deweese JA. The role of external carotid revascularization in the treatment of ocular



- ischemia. *J Vasc Surg.* 1987;6:280-282.
320. O'Hara PJ, Hertzner NR, Beven EG. External carotid revascularization: review of a ten-year experience. *J Vasc Surg.* 1985;2:709-714.
  321. Rush DS, Holloway WO, Fogartie JE, et al. The safety, efficacy, and durability of external carotid endarterectomy. *J Vasc Surg.* 1992;16:407-413.
  322. Lesèche G, Castier Y, Chataigner O, et al. Carotid artery revascularization through a radiated field. *J Vasc Surg.* 2003;38:244-250.
  323. Kashyap VS, Moore WS, Quinones-Baldrich WJ. Carotid artery repair for radiation-associated atherosclerosis is a safe and durable procedure. *J Vasc Surg.* 1999;29:90-99.
  324. Holt PJE, Poloniecki JD, Loftus IM, Thompson MM. Meta-analysis and systematic review of the relationship between hospital volume and outcome following carotid endarterectomy. *Eur J Vasc Endovasc Surg.* 2007;33:645-651.
  325. Manheim LM, Sohn MW, Feinglass J, et al. Hospital vascular surgery volume and procedure mortality rates in California, 1982-1994. *J Vasc Surg.* 1998;28:45-58.
  326. Peck C, Peck J, Peck A. Comparison of carotid endarterectomy at high- and low-volume hospitals. *Am J Surg.* 2001;181:450-453.
  327. Moore WS, Barnett HJM, Beebe HG, et al. Guidelines for Carotid Endarterectomy: a multidisciplinary consensus statement from the Ad Hoc Committee, American Heart Association. *Circulation.* 1995;91:566-579.

## 第 96 章

1. Mathias K. A new catheter system for percutaneous transluminal angioplasty (PTA) of carotid artery stenoses. *Fortschr Med.* 1977;95:1007-1011.
2. Mathias K, Mittermayer CH, Ensinger H, et al. Percutaneous catheter dilatation of carotid stenoses. *Rofo.* 1980;133:258-261.
3. Kerber CW, Cromwell LD, Loehden OL. Catheter dilatation of proximal carotid stenosis during distal bifurcation endarterectomy. *AJNR Am J Neuroradiol.* 1980;1:348-349.
4. Diethrich EB, Ndiaye M, Reid DB. Stenting in the carotid artery: initial experience in 110 patients. *J Endovasc Surg.* 1996;3:42-62.
5. Marks MP, Dake MD, Steinberg GK, et al. Stent placement for arterial and venous cerebrovascular disease: preliminary experience. *Radiology.* 1994;191:441-446.
6. Roubin GS, Yadav S, Iyer SS, Vitek J. Carotid stent-supported angioplasty: a neurovascular intervention to prevent stroke. *Am J Cardiol.* 1996;78:8-12.
7. Roubin GS, New G, Iyer SS, et al. Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis. *Circulation.* 2001;30:103:532-537.
8. Theron J, Courtheoux P, Alachkar F, et al. New triple coaxial catheter system for carotid angioplasty with cerebral protection. *AJNR Am J Neuroradiol.* 1990;11:869-874.
9. Sacco RL, Adams R, Albers G, et al., for the American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. *Stroke.* 2006;37:577-617.
10. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. *Stroke.* 2008;39:1647-1652.
11. American College of Cardiology Foundation; American Society of Interventional & Therapeutic Neuroradiology; Society

- for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology, et al. ACCF/SCAI/SVMB/SIR/ASITN 2007 clinical expert consensus document on carotid stenting: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on Carotid Stenting). *J Am Coll Cardiol*. 2007;49:126-170.
12. Narins CR, Illig KA. Patient selection for carotid stenting versus endarterectomy: a systematic review. *J Vasc Surg*. 2006;44:661-672.
  13. Roubin GS, Iyer S, Halkin A, et al. Realizing the potential of carotid artery stenting: proposed paradigms for patient selection and procedural technique. *Circulation*. 2006;113:2021-2030.
  14. Mas JL, Chatellier G, Beyssen B, et al., for the EVA-3S Investigators. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. *N Engl J Med*. 2006;355:1660-1671.
  15. SPACE Collaborative Group, Ringleb PA, Allenberg J, Brückmann H, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. *Lancet*. 2006;368:1239-1247.
  16. Rothwell PM, Eliasziw M, Gutnikov SA, et al., for the Carotid Endarterectomy Trialists Collaboration. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. *Lancet*. 2004;363:915-924.
  17. Topakian R, Strasak AM, Sonnberger M, et al. Timing of stenting of symptomatic carotid stenosis is predictive of 30-day outcome. *Eur J Neurol*. 2007;14:672-678.
  18. Setacci C, de Donato G, Chisci E, et al., on behalf of the Submarine Registry Group. Deferred urgency carotid artery stenting in symptomatic patients: clinical lessons and biomarker patterns from a prospective registry. *Eur J Vasc Endovasc Surg*. 2008;35:644-651.
  19. Manolio TA, Kronmal RA, Burke GL, et al. Short-term predictors of incident stroke in older adults. The Cardiovascular Health Study. *Stroke*. 1996;27:1479-1486.
  20. Hobson RW 2nd, Howard VJ, Roubin GS, et al., for the CREST Investigators. Carotid artery stenting is associated with increased complications in octogenarians: 30-day stroke and death rates in the CREST lead-in phase. *J Vasc Surg*. 2004;40:1106-1111.
  21. Stinge R, Berger J, Alfke K, et al., for the SPACE investigators. Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. *Lancet Neurol*. 2008;7:216-222.
  22. The Asymptomatic Carotid Atherosclerosis Study Group. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. *JAMA*. 1995;273:1421-1428.
  23. European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70% to 99%) or with mild (0% to 29%) carotid stenosis. *Lancet*. 1991;337:1235-1243.
  24. Halliday A, Mansfield A, Marro J, et al., for the MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. *Lancet*. 2004;363:1491-1502.
  25. Kastrup A, Gröschel K, Schulz JB, et al. Clinical predictors of transient ischemic attack, stroke, or death within 30 days of carotid angioplasty and stenting. *Stroke*. 2005;36:787-791.
  26. Goessens BMB, Visserens FLJ, Kappelle LJ, et al., for the SMART Study. Asymptomatic carotid artery stenosis and the risk of new vascular events in patients with manifest arterial disease. The SMART Study. *Stroke*. 2007;38:1470-1475.
  27. Moussa ID, Mohr JP. Epidemiology and natural history of asymptomatic carotid artery stenosis. In: *Asymptomatic Carotid Artery Stenosis, Risk Stratification and Management*. London: Informa Healthcare; 2007:1-18.
  28. Ferguson GG, Eliasziw M, Barr HWK, et al. The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 1415 patients. *Stroke*. 1999;30:1751-1758.

29. Yadav JS, Wholey MH, Kuntz RE, et al., for the Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy Investigators. Protected carotid-artery stenting versus endarterectomy in high-risk patients. *N Engl J Med*. 2004;351:1493-1501.
30. Gates PC, Eliasziw M, Algra A, et al. Identifying patients with symptomatic carotid artery disease at high and low risk of severe myocardial infarction and cardiac death. *Stroke*. 2002;33:2413-2416.
31. Chimowitz MI, Poole RM, Starling MR, et al. Frequency and severity of asymptomatic coronary disease in patients with different causes of stroke. *Stroke*. 1997;28:941-945.
32. Kallikazaros I, Tsioufis C, Sideris S, et al. Carotid artery disease as a marker for the presence of severe coronary artery disease in patients evaluated for chest pain. *Stroke*. 1999;30:1002-1007.
33. Brown KR, Kresowik TF, Chin MH, et al. Multistate population-based outcomes of combined carotid endarterectomy and coronary artery bypass. *J Vasc Surg*. 2003;37:32-39.
34. Ouriel K, Hertzner NR, Beven EG, et al. Preprocedural risk stratification: identifying an appropriate population for carotid stenting. *J Vasc Surg*. 2001;33:728-732.
35. Naylor R, Cuffe RL, Rothwell PM, et al. A systematic review of outcome following synchronous carotid endarterectomy and coronary artery bypass: influence of surgical and patient variables. *Eur J Vasc Endovasc Surg*. 2003;26:230-241.
36. Ziada KM, Yadav JS, Mukherjee D, et al. Comparison of results of carotid stenting followed by open heart surgery versus combined carotid endarterectomy and open heart surgery (coronary bypass with or without another procedure). *Am J Cardiol*. 2005;96:519-523.
37. Van der Heyden J, Suttrop MJ, Bal ET, et al. Staged carotid angioplasty and stenting followed by cardiac surgery in patients with severe asymptomatic carotid artery stenosis: early and long-term results. *Circulation*. 2007;116:2036-2042.
38. Guzman LA, Costa MA, Angiolillo DJ, et al. A systematic review of outcomes in patients with staged carotid artery stenting and coronary artery bypass graft surgery. *Stroke*. 2008;39:361-365.
39. Roffi M. Management of patients with concomitant severe coronary and carotid artery disease: is there a perfect solution? *Circulation*. 2007;116:2002-2004.
40. Kramer J, Abraham J, Jones PA. Carotid artery stenting before CABG: a better alternative to treat concomitant coronary and carotid artery disease [letter]. *Stroke*. 2006;37:1359.
41. Mendiz O, Fava C, Valdivieso L, et al. Synchronous carotid stenting and cardiac surgery: an initial single-center experience. *Catheter Cardiovasc Interv*. 2006;68:424-428.
42. Chiariello L, Tomai F, Zeitani J, Versaci F. Simultaneous hybrid revascularization by carotid stenting and coronary artery bypass grafting. *Ann Thorac Surg*. 2006;81:1883-1885.
43. Eagle KA, Guyton RA, Davidoff R, et al., for the American College of Cardiology; American Heart Association. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). *Circulation*. 2004;110:e340-437.
44. Atkins MD, Bush RL. Embolic protection devices for carotid artery stenting: have they made a significant difference in outcomes? *Semin Vasc Surg*. 2007;20:244-251.
45. El-Koussy M, Schroth G, Do DD, et al. Periprocedural embolic events related to carotid artery stenting detected by diffusion-weighted MRI: comparison between proximal and distal embolus protection devices. *J Endovasc Ther*. 2007;14:293-303.
46. Piñero P, González A, Mayol A, et al. Silent ischemia after neuroprotected percutaneous carotid stenting: a diffusion-weighted MRI study. *AJNR Am J Neuroradiol*. 2006;27:1338-1345.
47. Nicolaides AN, Kakkos SK, Griffin M, et al., for the Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Severity of asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: results from the ACSRS study. *Eur J Vasc Endovasc Surg*. 2005;30:275-284.

48. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004;351:1296-1305.
49. Osbourne A. Aortic arch and great vessels. In: Osbourne A, ed. *Diagnostic Cerebral Angiography*. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:12-16.
50. Redgrave JN, Lovett JK, Gallagher PJ, Rothwell PM. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford plaque study. *Circulation*. 2006;113:2320-2328.
51. Tedesco MM, Lee JT, Dalman RL, et al. Postprocedural microembolic events following carotid surgery and carotid angioplasty and stenting. *J Vasc Surg*. 2007;46:244-250.
52. Hellings WE, Ackerstaff RG, Pasterkamp G, et al. The carotid atherosclerotic plaque and microembolisation during carotid stenting. *J Cardiovasc Surg (Torino)*. 2006;47:115-126.
53. Biasi GM, Froio A, Diethrich EB, et al. Carotid plaque echolucency increases the risk of stroke in carotid stenting: the Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) study. *Circulation*. 2004;110:756-762.
54. Nicolaides AN, Kakkos SK, Griffin M, et al., for the Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Effect of image normalization on carotid plaque classification and the risk of ipsilateral hemispheric ischemic events: results from the Asymptomatic Carotid Stenosis and Risk of Stroke Study. *Vascular*. 2005;13:211-221.
55. Lovett JK, Redgrave JN, Rothwell PM. A critical appraisal of the performance, reporting, and interpretation of studies comparing carotid plaque imaging with histology. *Stroke*. 2005;36:1091-1097.
56. Virmani R, Ladich ER, Burke AP, Kolodgie FD. Histopathology of carotid atherosclerotic disease. *Neurosurgery*. 2006;59(5 Suppl 3):S219-S227.
57. Kolodgie FD, Nakazawa G, Sangiorgi G, et al. Pathology of atherosclerosis and stenting. *Neuroimaging Clin N Am*. 2007;17:285-301.
58. Sangiorgi G, Mauriello A, Kolodgie F, et al. Pathobiology of the asymptomatic atherosclerotic carotid plaque. In: *Asymptomatic Carotid Artery Stenosis, Risk Stratification and Management*. London: Informa Healthcare; 2007:19-38.
59. Sangiorgi G, Mauriello A, Bonanno E, et al. Pregnancy-associated plasma protein-a is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events. *J Am Coll Cardiol*. 2006;47:2201-2211.
60. Suzue A, Uno M, Kitazato KT, et al. Comparison between early and late carotid endarterectomy for symptomatic carotid stenosis in relation to oxidized low-density lipoprotein and plaque vulnerability. *J Vasc Surg*. 2007;46:870-875.
61. Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. *Arterioscler Thromb Vasc Biol*. 2002;22:1649-1654.
62. Uno M, Kitazato KT, Suzue A, et al. Contribution of an imbalance between oxidant-antioxidant systems to plaque vulnerability in patients with carotid artery stenosis. *J Neurosurg*. 2005;103:518-525.
63. Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. *Lancet*. 1999;353:2179-2184.
64. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002;324:71-86.
65. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. *Lancet*. 1991;338:1345-1349.
66. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. *J Neurol Neurosurg Psychiatry*. 1991;54:1044-1054.
67. Assadian A, Lax J, Meixner-Loicht U, et al. Aspirin resistance among long-term aspirin users after carotid endarterectomy and controls: flow cytometric measurement of aspirin-induced platelet inhibition. *J Vasc Surg*. 2007;45:1142-1147.
68. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. *Eur Heart J*.

2006;27:647-654.

69. Eshaghian S, Kaul S, Amin S, et al. Role of clopidogrel in managing atherothrombotic cardiovascular disease. *Ann Intern Med.* 2007;146:434-441.
70. Brener SJ, Steinhubl SR, Berger PB, et al., for the CREDO Investigators. Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial. *J Invasive Cardiol.* 2007;19:287-290.
71. Steinhubl SR, Berger PB, Brennan DM, Topol EJ, for the CREDO Investigators. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. *J Am Coll Cardiol.* 2006;47:939-943.
72. Mukherjee D, Topol EJ, Moliterno DJ, et al., for the CREDO Investigators. Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment. *Heart.* 2006;92:49-51.
73. Weintraub WS, Mahoney EM, Lamy A, et al., for the CURE Study Investigators. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. *J Am Coll Cardiol.* 2005;45:838-845.
74. Keller TT, Squizzato A, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. *Cochrane Database Syst Rev.* 2007;3:CD005158.
75. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. *Arch Intern Med.* 2004;164:2106-2110.
76. Sabatine MS, Cannon CP, Gibson CM, et al., for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med.* 2005;352:1179-1189.
77. Chen ZM, Jiang LX, Chen YP, et al., for the COMMIT (CLOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet.* 2005;366:1607-1621.
78. Liao JK. Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? *Circulation.* 2007;115:1615-1621.
79. Diener HC, Bogousslavsky J, Brass LM, et al., for the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet.* 2004;364:331-337.
80. Bhatt DL, Fox KA, Hacke W, et al., for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med.* 2006;354:1706-1717.
81. Wang TH, Bhatt DL, Fox KA, et al., for the CHARISMA Investigators. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. *Eur Heart J.* 2007;28:2200-2207.
82. Dittrich R, Ritter MA, Kaps M, et al. The use of embolic signal detection in multicenter trials to evaluate antiplatelet efficacy: signal analysis and quality control mechanisms in the CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid Stenosis) trial. *Stroke.* 2006;37:1065-1069.
83. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al., for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). *Circulation.* 2006;113:e166-e286.
84. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. *Circulation.* 2008;117:261-295.

85. Silber S, Albertsson P, Avilés FF, et al., for the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. *Eur Heart J*. 2005;26:804-847.
86. Cremonesi A, Manetti R, Setacci F, et al. Protected carotid stenting: clinical advantages and complications of embolic protection devices in 442 consecutive patients. *Stroke*. 2003;34:1936-1941.
87. Anderson JL, Adams CD, Antman EM, et al., for the American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *Circulation*. 2007;116:e148-304.
88. McKeivitt FM, Randall MS, Cleveland TJ, et al. The benefits of combined anti-platelet treatment in carotid artery stenting. *Eur J Vasc Endovasc Surg*. 2005;29:522-527.
89. Sacco RL, Prabhakaran S, Thompson JL, et al., for the WARSS Investigators. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. *Cerebrovasc Dis*. 2006;22:4-12.
90. Kasner SE, Chimowitz MI, Lynn MJ, et al., for the Warfarin Aspirin Symptomatic Intracranial Disease Trial Investigators. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. *Circulation*. 2006;113:555-563.
91. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? *Eur J Vasc Endovasc Surg*. 2006;32:286-293.
92. Perler BA. The effect of statin medications on perioperative and long-term outcomes following carotid endarterectomy or stenting. *Semin Vasc Surg*. 2007;20:252-258.
93. Brooke BS, McGirt MJ, Woodworth GF, et al. Preoperative statin and diuretic use influence the presentation of patients undergoing carotid endarterectomy: results of a large single-institution case-control study. *J Vasc Surg*. 2007;45:298-303.
94. Kennedy J, Quan H, Buchan AM, et al. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. *Stroke*. 2005;36:2072-2076.
95. Gröschel K, Ernemann U, Schulz JB, et al. Statin therapy at carotid angioplasty and stent placement: effect on procedure-related stroke, myocardial infarction, and death. *Radiology*. 2006;240:145-151.
96. Cieri E, De Rango P, Maccaroni MR, et al. Is haemodynamic depression during carotid stenting a predictor of peri-procedural complications? *Eur J Vasc Endovasc Surg*. 2008;35:399-404.
97. Gupta R, Abou-Chebl A, Bajzer CT, et al. Rate, predictors, and consequences of hemodynamic depression after carotid artery stenting. *J Am Coll Cardiol*. 2006;47:1538-1543.
98. Nonaka T, Oka S, Miyata K, et al. Prediction of prolonged postprocedural hypotension after carotid artery stenting. *Neurosurgery*. 2005;57:472-477.
99. Im SH, Han MH, Kim SH, Kwon BJ. Transcutaneous temporary cardiac pacing in carotid stenting: noninvasive prevention of angioplasty-induced bradycardia and hypotension. *J Endovasc Ther*. 2008;15:110-116.
100. Mlekusch W, Schillinger M, Sabeti S, et al. Hypotension and bradycardia after elective carotid stenting: frequency and risk factors. *J Endovasc Ther*. 2003;10:851-859.
101. Demirci M, Saribas O, Uluç K, et al. Carotid artery stenting and endarterectomy have different effects on heart rate

variability. *J Neurol Sci.* 2006;241:45-51.

102. Bush RL, Lin PH, Bianco CC, et al. Reevaluation of temporary transvenous cardiac pacemaker usage during carotid angioplasty and stenting: a safe and valuable adjunct. *Vasc Endovasc Surg.* 2004;38:229-235.
103. Basic identification criteria of Doppler microembolic signals. Consensus Committee of the Ninth International Cerebral Hemodynamic Symposium. *Stroke.* 1995;26:1123.
104. Ringelstein EB, Droste DW, Babikian VL, et al. Consensus on microembolus detection by TCD. International Consensus Group on Microembolus Detection. *Stroke.* 1998;29:725-729.
105. Moehring MA, Klepper JR. Pulse Doppler ultrasound detection, characterization and size estimation of emboli in flowing blood. *IEEE Trans Biomed Eng.* 1994;41:35-44.
106. Ditttrich R, Ritter MA, Kaps M, et al. The use of embolic signal detection in multicenter trials to evaluate antiplatelet efficacy: signal analysis and quality control mechanisms in the CARESS (Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid Stenosis) trial. *Stroke.* 2006;37:1065-1069.
107. Naylor AR, Hayes PD, Allroggen H, et al. Reducing the risk of carotid surgery: a 7-year audit of the role of monitoring and quality control assessment. *J Vasc Surg.* 2000;32:750-759.
108. Ackerstaff RG, Vos JA, for the Antonius Carotid Endarterectomy, Angioplasty, and Stenting Study Group. TCD-detected cerebral embolism in carotid endarterectomy versus angioplasty and stenting of the carotid bifurcation. *Acta Chir Belg.* 2004;104:55-59.
109. Markus HS, MacKinnon A. Asymptomatic embolization detected by Doppler ultrasound predicts stroke risk in symptomatic carotid artery stenosis. *Stroke.* 2005;36:971-975.
110. Forteza AM, Babikian VL, Hyde C, et al. Effect of time and cerebrovascular symptoms of the prevalence of microembolic signals in patients with cervical carotid stenosis. *Stroke.* 1996;27:687-690.
111. van Heesewijk HP, Vos JA, Louwerse ES, et al., for the Carotid PTA and Stenting Collaborative Research Group. New brain lesions at MR imaging after carotid angioplasty and stent placement. *Radiology.* 2002;224:361-365.
112. Rapp JH, Pan XM, Sharp FR, et al. Atheroemboli to the brain: size threshold for causing acute neuronal cell death. *J Vasc Surg.* 2000;32:68-76.
113. Vos JA, van den Berg JC, Ernst SM, et al. Carotid angioplasty and stent placement: comparison of transcranial Doppler US data and clinical outcome with and without filtering cerebral protection devices in 509 patients. *Radiology.* 2005;234:493-499.
114. Russell D, Brucher R. Online automatic discrimination between solid and gaseous cerebral microemboli with the first multifrequency transcranial Doppler. *Stroke.* 2002;33:1975-1980.
115. Wholey MH, Al-Mubarek N, Wholey MH. Updated review of the global carotid artery stent registry. *Catheter Cardiovasc Interv.* 2003;60:259-266.
116. Kastrup A, Gröschel K, Krapf H, et al. Early outcome of carotid angioplasty and stenting with and without cerebral protection devices: a systematic review of the literature. *Stroke.* 2003;34:813-819.
117. Sztriha LK, Vörös E, Sas K, et al. Favorable early outcome of carotid artery stenting without protection devices. *Stroke.* 2004;35:2862-2866.
118. Atkins MD, Bush RL. Embolic protection devices for carotid artery stenting: have they made a significant difference in outcomes? *Semin Vasc Surg.* 2007;20:244-251.
119. Ohki T, Veith FJ. Critical analysis of distal protection devices. *Semin Vasc Surg.* 2003;16:317-325.
120. Schonholz CJ, Uflacker R, Parodi JC, et al. Is there evidence that cerebral protection is beneficial? *Clinical data. J Cardiovasc Surg (Torino).* 2006;47:137-141.
121. Macdonald S. The evidence for cerebral protection: an analysis and summary of the literature. *Eur J Radiol.* 2006;60:20-25.
122. Barbato JE, Dillavou E, Horowitz MB, et al. A randomized trial of carotid artery stenting with and without cerebral protection. *J Vasc Surg.* 2008;47:760-765.

123. Reimers B, Schlüter M, Castriota F, et al. Routine use of cerebral protection during carotid artery stenting: results of a multicenter registry of 753 patients. *Am J Med.* 2004;116:217-222.
124. Rhee-Moore SJ, Derubertis BG, Lam RC, et al. Periprocedural complication rates are equivalent between symptomatic and asymptomatic patients undergoing carotid angioplasty and stenting. *Ann Vasc Surg.* 2008;22:233-237.
125. Reimers B, Corvaja N, Moshiri S, et al. Cerebral protection with filter devices during carotid artery stenting. *Circulation.* 2001;104:12-15.
126. Jaeger H, Mathias K, Drescher R, et al. Clinical results of cerebral protection with a filter device during stent implantation of the carotid artery. *Cardiovasc Intervent Radiol.* 2001;24:249 -256.
127. Kachel R. Results of balloon angioplasty in the carotid arteries. *J Endovasc Surg.* 1996;3:22-30.
128. Parodi JC, La Mura R, Ferreira LM, et al. Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices. *J Vasc Surg.* 2000;32:1127-1136.
129. Reimers B, Sievert H, Schuler GC, et al. Proximal endovascular flow blockage for cerebral protection during carotid artery stenting: results from a prospective multicenter registry. *J Endovasc Ther.* 2005;12:156-165.
130. Henry M, Amor M, Henry I, et al. Carotid stenting with cerebral protection: first clinical experience using the PercuSurge GuardWire system. *J Endovasc Surg.* 1999;6:321-331.
131. Iyer V, de Donato G, Deloose K, et al. The type of embolic protection does not influence the outcome in carotid artery stenting. *J Vasc Surg.* 2007;46:251-256.
132. Powell RJ, Alessi C, Nolan B, et al. Comparison of embolization protection device-specific technical difficulties during carotid artery stenting. *J Vasc Surg.* 2006;44:56-61.
133. El-Koussy M, Schroth G, Do DD, et al. Periprocedural embolic events related to carotid artery stenting detected by diffusion-weighted MRI: comparison between proximal and distal embolus protection devices. *J Endovasc Ther.* 2007;14:293-303.
134. Al-Mubarak N, Roubin GS, Vitek JJ, et al. Effect of the distal-balloon protection system on microembolization during carotid stenting. *Circulation.* 2001;104:1999-2002.
135. Bosiers M, de Donato G, Deloose K, et al. Does free cell area influence the outcome in carotid artery stenting? *Eur J Vasc Endovasc Surg.* 2007;33:135-141.
136. Schillinger M, Gschwendtner M, Reimers B, et al. Does carotid stent cell design matter? *Stroke.* 2008;39:905-909.
137. Cremonesi A, Setacci C, Bignamini A, et al. Carotid artery stenting: first consensus document of the ICCS-SPREAD Joint Committee. *Stroke.* 2006;37:2400-2409.
138. Schneider PA. Management of the complications of carotid interventions. In: *Carotid Interventions.* New York, NY: Marcel Dekker; 2004:275-283.
139. Verzini F, Cao P, De Rango P, et al. Appropriateness of learning curve for carotid artery stenting: an analysis of periprocedural complications. *J Vasc Surg.* 2006;44:1205-1212.
140. Ahmadi R, Willfort A, Lang W, et al. Carotid artery stenting: effect of learning curve and intermediate-term morphological outcome. *J Endovasc Ther.* 2001;8:539-546.
141. Abou-Chebl A, Reginelli J, Bajzer CT, Yadav JS. Intensive treatment of hypertension decreases the risk of hyperperfusion and intracerebral hemorrhage following carotid artery stenting. *Catheter Cardiovasc Interv.* 2007;69:690-696.
142. Coutts SB, Hill MD, Hu WY. Hyperperfusion syndrome: toward a stricter definition. *Neurosurgery.* 2003;53:1053-1058.
143. Naylor AR, Bolia A, Abbott RJ, et al. Randomized study of carotid angioplasty and stenting versus carotid endarterectomy: a stopped trial. *J Vasc Surg.* 1998;28:326-334.
144. Alberts MJ. Results of a multicentre prospective randomized trial of carotid artery stenting vs carotid endarterectomy [abstract]. *Stroke.* 2001;32:325-d.
145. CAVATAS Investigators. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. *Lancet.* 2001;357:1729-1737.



146. Brooks WH, McClure RR, Jones MR, et al. Carotid angioplasty and stenting versus carotid endarterectomy: randomized trial in a community hospital. *J Am Coll Cardiol*. 2001;38:1589-1595.
147. Brooks WH, McClure RR, Jones MR, et al. Carotid angioplasty and stenting versus carotid endarterectomy for treatment of asymptomatic carotid stenosis: a randomized trial in a community hospital. *Neurosurgery*. 2004;54:318-324.
148. Becquemin JP, Ben El Kadi H, Desgranges P, Kobeiter H. Carotid stenting versus carotid surgery: a prospective cohort study. *J Endovasc Ther*. 2003;10:687-694.
149. Bosiers M, Peeters P, Verbist J, et al. Belgian experience with FilterWire EX in the prevention of embolic events during carotid stenting. *J Endovasc Ther*. 2003;10:695-701.
150. Cernetti C, Reimers B, Picciolo A, et al. Carotid artery stenting with cerebral protection in 100 consecutive patients: immediate and two-year follow-up results. *Ital Heart J*. 2003;4:695-700.
151. Hobson RW 2nd, Lal BK, Chakhtoura E, et al. Carotid artery stenting: analysis of data for 105 patients at high risk. *J Vasc Surg*. 2003;37:1234-1239.
152. Kastrup A, Skalej M, Krapf H, et al. Early outcome of carotid angioplasty and stenting versus carotid endarterectomy in a single academic center. *Cerebrovasc Dis*. 2003;15:84-89.
153. Lal BK, Hobson RW 2nd, Goldstein J, et al. In-stent recurrent stenosis after carotid artery stenting: life table analysis and clinical relevance. *J Vasc Surg*. 2003;38:1162-1168.
154. Tan KT, Cleveland TJ, Berci V, et al. Timing and frequency of complications after carotid artery stenting: what is the optimal period of observation? *J Vasc Surg*. 2003;38:236-243.
155. Henry M, Polydorou A, Henry I, et al. Carotid angioplasty under cerebral protection with the PercuSurge GuardWire System. *Catheter Cardiovasc Interv*. 2004;61:293-305.
156. Sganzerla P, Bocciarelli M, Savasta C, et al. The treatment of carotid artery bifurcation stenoses with systematic stenting: experience of first 100 consecutive cardiological procedures. *J Invasive Cardiol*. 2004;16:592-595.
157. Bush RL, Kougiass P, Guerrero MA, et al. A comparison of carotid artery stenting with neuroprotection versus carotid endarterectomy under local anesthesia. *Am J Surg*. 2005;190:696-700.
158. Yen MH, Lee DS, Kapadia S, et al. Symptomatic patients have similar outcomes compared with asymptomatic patients after carotid artery stenting with emboli protection. *Am J Cardiol*. 2005;95:297-300.
159. Cao P, De Rango P, Verzini F, et al. Outcome of carotid stenting versus endarterectomy: a case-control study. *Stroke*. 2006;37:1221-1226.
160. Zhou W, Lin PH, Bush RL, et al. Management of in-sent restenosis after carotid artery stenting in high-risk patients. *J Vasc Surg*. 2006;43:305-312.
161. Younis GA, Gupta K, Mortazavi A, et al. Predictors of carotid stent restenosis. *Catheter Cardiovasc Interv*. 2007;69:673-682.
162. Setacci C, Chisci E, de Donato G, et al. Carotid artery stenting in a single center: are six years of experience enough to achieve the standard of care? *Eur J Vasc Endovasc Surg*. 2007;34:655-662.
163. Eskandari MK, Najjar SF, Matsumura JS, et al. Technical limitations of carotid filter embolic protection devices. *Ann Vasc Surg*. 2007;21:403-407.
164. Theiss W, Hermanek P, Mathias K, et al., for the German Societies of Angiology and Radiology. Pro-CAS: a prospective registry of carotid angioplasty and stenting. *Stroke*. 2004;35:2134-2139.
165. Ouriel K, Wholey MH, Fayad P, et al. Feasibility trial of carotid stenting with and without an embolus protection device. *J Endovasc Ther*. 2005;12:525-537.
166. Zahn R, Ischinger T, Hochadel M, et al., for the Arbeitsgemeinschaft Leitende Kardiologische Krankenhaus ärzte. Carotid artery stenting in octogenarians: results from the ALKK Carotid Artery Stent (CAS) Registry. *Eur Heart J*. 2007;28:370-375.
167. Phatourous CC, Higashida RT, Malek AM, et al. Carotid artery stent placement for atherosclerotic disease: rationale,

- technique, and current status. *Radiology*. 2000;217:26-41.
168. Goodney PP, Schermerhorn ML, Powell RJ. Current status of carotid artery stenting. *J Vasc Surg*. 2006;43:406-411.
  169. Burton KR, Lindsay TF. Assessment of short-term outcomes for protected carotid angioplasty with stents using recent evidence. *J Vasc Surg*. 2005;42:1094-1100.
  170. CaRESS Steering Committee. Carotid Revascularization Using Endarterectomy or Stenting Systems (CaRESS) phase I clinical trial: 1-year results. *J Vasc Surg*. 2005;42:213-219.
  171. Gray WA, Hopkins LN, Yadav S, et al., for the ARChER Trial Collaborators. Protected carotid stenting in high-surgical-risk patients: the ARChER results. *J Vasc Surg*. 2006;44:258-268.
  172. Iyer SS, White CJ, Hopkins LN, et al., for the BEACH Investigators. Carotid artery revascularization in high-surgical-risk patients using the Carotid WALLSTENT and FilterWire EX/EZ: 1-year outcomes in the BEACH Pivotal Group. *J Am Coll Cardiol*. 2008;51:427-434.
  173. [http://salesandmarketingnetwork.com/news\\_release.php?ID=2000813&key=TCT](http://salesandmarketingnetwork.com/news_release.php?ID=2000813&key=TCT). Accessed Oct 15, 2005.
  174. Safian RD, Bacharach JM, Ansel GM, Criado FJ. Carotid stenting with a new system for distal embolic protection and stenting in high-risk patients: the Carotid Revascularization with ev3 Arterial Technology Evolution (CREATE) feasibility trial. *Catheter Cardiovasc Interv*. 2004;63:1-6.
  175. Roubin G, Clark W, Chakhtoura E, et al. Low complication rates for carotid artery stenting in the credentialing phase of the Carotid Revascularization Endarterectomy Versus Stenting Trial [abstract]. *Stroke*. 2006;37:620.
  176. Ramee SR, Higashida R, MAVERIC Investigators. Evaluation of the Medtronic self-expanding carotid stent system with distal protection in the treatment of carotid artery stenosis: The MAVERIC trial phase II 30-day update. *Am J Cardiol*. 2004;94(Suppl. 6A):61E.
  177. Coppi G, Moratto R, Silingardi R, et al. PRIAMUS—proximal flow blockage cerebral protection during carotid stenting: results from a multicenter Italian registry. *J Cardiovasc Surg (Torino)*. 2005;46:219-227.
  178. Whitlow P, SECURITY Investigators. Registry study to evaluate the Neuroshield bare wire cerebral protection system and X-Act stent in patients at high risk for carotid endarterectomy (SECURITY). Available at [www.tctmd.com/csportal/appmanager/tctmd/main?\\_nfpb1/4true&\\_pageLabel1/4TCTMDContent&hdCon1/4862458](http://www.tctmd.com/csportal/appmanager/tctmd/main?_nfpb1/4true&_pageLabel1/4TCTMDContent&hdCon1/4862458); 209. [http://www.clevelandclinic.org/heartcenter/pub/news/archive/2003/security9\\_17.asp](http://www.clevelandclinic.org/heartcenter/pub/news/archive/2003/security9_17.asp). Accessed Oct 15, 2005.
  179. Gray WA, Yadav JS, Verta P, et al. The CAPTURE registry: results of carotid stenting with embolic protection in the post approval setting. *Catheter Cardiovasc Interv*. 2007;69:341-348.
  180. Katzen BT, Criado FJ, Ramee SR, et al., for the CASES-PMS Investigators. Carotid Artery Stenting with Emboli Protection Surveillance Study: thirty-day results of the CASES-PMS Study. *Catheter Cardiovasc Interv*. 2007;70:316-323.
  181. Gray WA, Hopkins LN, Yadav S, et al., for the ARChER Trial Collaborators. Protected carotid stenting in high-surgical-risk patients: the ARChER results. *J Vasc Surg*. 2006;44:258-268.
  182. Gurm HS, Yadav JS, Fayad P, et al., for the SAPHIRE Investigators. Long-term results of carotid stenting versus endarterectomy in high-risk patients. *N Engl J Med*. 2008;358:1572-1579.
  183. Ederle J, Featherstone RL, Brown MM. Percutaneous transluminal angioplasty and stenting for carotid artery stenosis. *Cochrane Database Syst Rev*. 2007;4:CD000515.
  184. Halliday A. Asymptomatic Carotid Surgery Trial 2 (ACST-2): surgery versus stenting. Paper presented at the UK Stroke Forum Conference, Harrogate, UK, 2006.
  185. [www.ptca.org/pr\\_abbott/20050118.html](http://www.ptca.org/pr_abbott/20050118.html) (accessed 11 April 2007).
  186. International Carotid Stenting Study. Available at [http://www.ion.ucl.ac.uk/cavatas\\_icss/](http://www.ion.ucl.ac.uk/cavatas_icss/).
  187. Featherstone RL, Brown MM, Coward LJ, ICSS Investigators. International Carotid Stenting Study: protocol for a randomised clinical trial comparing carotid stenting with endarterectomy in symptomatic carotid artery stenosis. *Cerebrovascular Diseases*. 2004;18:69-74.
  188. Rundback JH, MacDonald S. Asymptomatic CAS Trial Designs. *Endovasc Today Sept*. 2007;59-64.

189. Barr JD, Connors JJ 3rd, Sacks D, et al. for the American Society of Interventional and Therapeutic Neuroradiology; American Society of Neuroradiology; Society of Interventional Radiology. Quality improvement guidelines for the performance of cervical carotid angioplasty and stent placement. *J Vasc Interv Radiol*. 2003;14:S321-S335.
190. Lin PH, Bush RL, Peden EK, et al. Carotid artery stenting with neuroprotection: assessing the learning curve and treatment outcome. *Am J Surg*. 2005;190:850-857.
191. Patel AD, Gallagher AG, Nicholson WJ, Cates CU. Learning curves and reliability measures for virtual reality simulation in the performance assessment of carotid angiography. *J Am Coll Cardiol*. 2006;47:1796-1802.
192. Rosenfield K, Babb JD, Cates CU, et al. Clinical competence statement on carotid stenting: training and credentialing for carotid stenting—multispecialty consensus recommendations: a report of the SCAI/SVMB/SVS Writing Committee to Develop a Clinical Competence Statement on Carotid Interventions. *J Am Coll Cardiol*. 2005;45:165-174.
193. Rosenfield KM, SCAI/SVMB/SVS Writing Committee. Clinical competence statement on carotid stenting: training and credentialing for carotid stenting—multispecialty consensus recommendations. *J Vasc Surg*. 2005;41:160-168.
194. Connors JJ 3rd, Sacks D, Furlan AJ, et al., for the American Academy of Neurology; American Association of Neurological Surgeons; American Society of Interventional and Therapeutic Neuroradiology; American Society of Neuroradiology; Congress of Neurological Surgeons; AANS/CNS Cerebrovascular Section; Society of Interventional Radiology; NeuroVascular Coalition Writing Group. Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology. *Neurology*. 2005;64:190-198.
195. Gröschel K, Riecker A, Schulz JB, et al. Systematic review of early recurrent stenosis after carotid angioplasty and stenting. *Stroke*. 2005;36:367-373.
196. de Borst GJ, Zanen P, de Vries JP, et al. Durability of surgery for restenosis after carotid endarterectomy. *J Vasc Surg*. 2008;47:363-371.
197. Frericks H, Kievit J, van Baalen JM, van Bockel JH. Carotid recurrent stenosis and risk of ipsilateral stroke: a systematic review of the literature. *Stroke*. 1998;29:244-250.
198. Setacci C, de Donato G, Setacci F, et al. In-stent restenosis after carotid angioplasty and stenting: a challenge for the vascular surgeon. *Eur J Vasc Endovasc Surg*. 2005;29:601-607.
199. Skelly CL, Gallagher K, Fairman RM, et al. Risk factors for restenosis after carotid artery angioplasty and stenting. *J Vasc Surg*. 2006;44:1010-1015.
200. de Borst GJ, Ackerstaff RG, de Vries JP, et al. Carotid angioplasty and stenting for postendarterectomy stenosis: long-term follow-up. *J Vasc Surg*. 2007;45:118-123.
201. Brajesh K, Lal MD. Recurrent carotid stenosis after CEA and CAS: Diagnosis and management. *Semin Vasc Surg*. 2007;20:259-266.
202. Zhou W, Felkai DD, Evans M, et al. Ultrasound criteria for severe in-stent restenosis following carotid artery stenting. *J Vasc Surg*. 2008;47:74-80.
203. Lal BK, Hobson RW 2nd, Tofighi B, et al. Duplex ultrasound velocity criteria for the stented carotid artery. *J Vasc Surg*. 2008;47:63-73.
204. AbuRahma AF, Maxwell D, Eads K, et al. Carotid duplex velocity criteria revisited for the diagnosis of carotid in-stent restenosis. *Vascular*. 2007;15:119-125.
205. Chahwan S, Miller MT, Pigott JP, et al. Carotid artery velocity characteristics after carotid artery angioplasty and stenting. *J Vasc Surg*. 2007;45:523-526.
206. Telman G, Kouperberg E, Sprecher E, et al. Duplex ultrasound verified by angiography in patients with severe primary and restenosis of internal carotid artery. *Ann Vasc Surg*. 2006;20:478-481.

207. Reimers B, Tübler T, de Donato G, et al. Endovascular treatment of in-stent restenosis after carotid artery stenting: immediate and midterm results. *J Endovasc Ther.* 2006;13:429-435.

## 第 97 章

1. Slovut DP, Olin JW. Fibromuscular dysplasia. *N Engl J Med.* 2004;350:1862-1871.
2. Zhou W, Bush RL, Lin PL, Lumsden AB. Fibromuscular dysplasia of the carotid artery. *J Am Coll Surg.* 2005;200:807.
3. Begelman SM, Olin JW. Nonatherosclerotic arterial disease of the extracranial cerebrovasculature. *Semin Vasc Surg.* 2000;13:153-164.
4. Osborn AG, Anderson RE. Angiographic spectrum of cervical and intracranial fibromuscular dysplasia. *Stroke.* 1977;8:617-626.
5. Houser OW, Baker HL Jr: Fibrovascular dysplasia and other uncommon diseases of the cervical carotid artery: angiographic aspects. *AJR Am J Roentgenol.* 1968;104:201-212.
6. Stanley JC, Fry WJ, Seeger JF, et al. Extracranial internal carotid and vertebral artery fibrodysplasia. *Arch Surg.* 1974;109:215-222.
7. Moreau P, Albat B, Thevenet A. Fibromuscular dysplasia of the internal carotid artery: long-term results. *J Cardiovasc Surg.* 1993;34:465-472.
8. Taylor SM, Langan EM, Snyder BA, et al. Nonendarterectomy procedures of the carotid artery: a five-year review. *Am Surg.* 1999;65:323-327.
9. Mettinger KL, Ericson K. Fibromuscular dysplasia and the brain: I. Observations on angiographic, clinical, and genetic characteristics. *Stroke.* 1982;13:46-52.
10. Schievink WI, Bjornsson J. Fibromuscular dysplasia of the internal carotid artery: a clinicopathological study. *Clin Neuropathol.* 1996;15:2-6.
11. Furie DM, Tien RD. Fibromuscular dysplasia of arteries of the head and neck: imaging findings. *AJR Am J Roentgenol.* 1994;162:1205-1209.
12. So EL, Toole JF, Dalal P, Moody DM. Cephalic fibromuscular dysplasia in 32 patients: clinical findings and radiologic features. *Arch Neurol.* 1981;38:619-622.
13. Corrin LS, Sandok BA, Houser OW. Cerebral ischemic events in patients with carotid artery fibromuscular dysplasia. *Arch Neurol.* 1981;38:616-618.
14. Fisicaro M, Tonizzo M, Mucelli RP, et al. Fibromuscular dysplasia: a case report of multivessel vascular involvement. *Int Angiol.* 1994;13:347-350.
15. Stahlfeldt KR, Means JR, Didomenico P. Carotid artery fibromuscular dysplasia. *Am J Surg.* 2007;193:71-72.
16. Miyauchi M, Shionoya S. Aneurysm of the extracranial internal carotid artery caused by fibromuscular dysplasia. *Eur J Vasc Surg.* 1991;5:587-591.
17. Coffin O, Maiza D, Galateau-Salle F, et al. Results of surgical management of internal carotid artery aneurysm by the cervical approach. *Ann Vasc Surg.* 1997;11:482-490.
18. Rhee RY, Gloviczki P, Cherry KJ, et al. Two unusual variants of internal carotid artery aneurysms due to fibromuscular dysplasia. *Ann Vasc Surg.* 1996;10:481-485.
19. Edgell RC, Abou-Chebl A, Yadav JS. Endovascular management of spontaneous carotid dissection. *J Vasc Surg.* 2005;42:854-860.
20. Luscher TF, Lie JT, Stanson AW, et al. Arterial fibromuscular dysplasia. *Mayo Clin Proc.* 1987;62:931-952.
21. Muller BT, Luther B, Hort W, et al. Surgical treatment of 50 carotid dissections: Indications and results. *J Vasc Surg.* 2000;31:980-988.
22. DeOcampo J, Brillman J, Levy DI. Stenting: a new approach to carotid dissection. *J Neuroimaging.* 1997;7:187-190.
23. Manninen HU, Koivisto T, Saari T, et al. Dissecting aneurysms of all four cervicocranial arteries in fibromuscular dysplasia:

- treatment with self-expanding endovascular stents, coil embolization, and surgical ligation. *AJNR Am J Neuroradiol*. 1997;18:1216-1220.
24. Klufas RA, Hsu L, Barnes PD, et al. Dissection of the carotid and vertebral arteries: imaging with MR angiography. *AJR Am J Roentgenol*. 1995;164:673-677.
  25. Chiche L, Bahnini A, Koskas F, et al. Occlusive fibromuscular disease of the arteries supplying the brain: results of surgical treatment. *Ann Vasc Surg*. 1997;11:496-504.
  26. Haldeman S, Kohlbeck FJ, McGregor M. Risk factors and precipitating neck movements causing vertebrobasilar artery dissection after trauma and spinal manipulation. *Spine*. 1999;15:785-794.
  27. Stewart MT, Moritz MW, Smith RB 3rd, et al. The natural history of carotid fibromuscular dysplasia. *J Vasc Surg*. 1986;3:305-310.
  28. Cloft HJ, Kallmes DF, Snider R, et al. Idiopathic supraclinoid and internal carotid bifurcation steno-occlusive disease in young American adults. *Neuroradiology*. 1999;41:772-776.
  29. Schneider PA, Cunningham CG, Ehrenfeld WK, et al. Fibromuscular dysplasia of the carotid artery. In: Veith FJ, Hobson RW, Williams RA, Wilson SE, eds. *Vascular Surgery: Principles and Practice*. New York, NY. McGraw-Hill; 1994:711-717.
  30. Starr DS, Lawrie GM, Morris GC. Fibromuscular disease of carotid arteries: long-term results of graduated internal dilatation. *Stroke*. 1981;12:196-199.
  31. Collins GJ Jr, Rich NM, Clagett GP, et al. Fibromuscular dysplasia of the internal carotid arteries: clinical experience and follow-up. *Ann Surg*. 1981;194:89-96.
  32. Arning C. Nonatherosclerotic disease of the cervical arteries: role of ultrasonography for diagnosis. *Vasa*. 2001;30:160-167.
  33. Russo CP, Smoker WRK. Nonatheromatous carotid artery disease. *Neuroimaging Clin North Am*. 1996;6:811-830.
  34. Patman RD, Thompson JE, Talkington CM, Garrett WV. Natural history of fibromuscular dysplasia of the carotid artery [abstract]. *Stroke*. 1980;2:135.
  35. Smith LL, Smith DC, Killeen JD, et al. Operative balloon angioplasty in the treatment of internal carotid artery fibromuscular dysplasia. *J Vasc Surg*. 1987;6:482-487.
  36. de Smul G, Bostoen H. Operative balloon dilatation of fibromuscular dysplasia of the internal carotid artery: two case reports. *Acta Chir Belg*. 1995;95:139-143.
  37. Ballard JL, Guinn JE, Killeen D, et al. Open operative balloon angioplasty of the internal carotid artery: a technique in evolution. *Ann Vasc Surg*. 1995;9:390-393.
  38. Lord RSA, Graham AR, Benn IV. Radiologic control of operative carotid dilation: aneurysm formation following balloon dilation. *Cardiovasc Surg*. 1986;27:158-161.
  39. Brown MM. Balloon angioplasty for cerebrovascular disease. *Neurol Res*. 1992;14:159-163.
  40. Motarjeme A. Percutaneous transluminal angioplasty of the supra-aortic vessels. *J Endovasc Surg*. 1996;3:171-181.
  41. Hasso AN, Bird CR, Zinke DE, et al. Fibromuscular dysplasia of the internal carotid artery: percutaneous transluminal angioplasty. *AJNR Am J Neuroradiol*. 1981;2:175-180.
  42. Tsai FY, Matovich V, Hiesheima G, et al. Percutaneous transluminal angioplasty of the carotid artery. *AJNR Am J Neuroradiol*. 1986;7:349-358.
  43. Theron JG, Payelle GG, Coskun O, et al. Carotid artery stenosis: treatment with protected balloon angioplasty and stent placement. *Radiology*. 1996;201:627-636.
  44. Jooma R, Bradshaw JR, Griffith HB. Intimal dissection following percutaneous transluminal carotid angioplasty for fibromuscular hyperplasia. *Neuroradiology*. 1985;27:181-182.

## 第 98 章

1. McCormick WF, Acosta-Rua GJ. The size of intracranial saccular aneurysms. An autopsy study. *J Neurosurg*.

- 1970;33:422-427.
2. Dell S. Asymptomatic cerebral aneurysm: assessment of its risk of rupture. *Neurosurgery*. 1982;10:162-166.
  3. El-Sabroun R, Cooley DA. Extracranial carotid artery aneurysms: Texas Heart Institute experience. *J Vasc Surg*. 2000;31:702-712.
  4. Schechter DC. Cervical carotid aneurysms: Part I. *N Y State J Med*. 1979;79:892-901.
  5. Schechter DC. Cervical carotid aneurysms. Part II. *N Y State J Med*. 1979;79:1042-1048.
  6. Johnston KW, Rutherford RB, Tilson MD, et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. *J Vasc Surg*. 1991;13:452-458.
  7. de Jong KP, Zondervan PE, van Urk H. Extracranial carotid artery aneurysms. *Eur J Vasc Surg*. 1989;3:557-562.
  8. Cooper A. Account of the first successful operation performed on the common carotid artery for aneurysm, in the year 1808: with the post-mortem examination, in 1821. *Guys Hosp Rep*. 1836;1:53-59.
  9. Winslow N. Extracranial aneurysm of the internal carotid artery: history and analysis of the cases registered up to Aug 1, 1925. *Arch Surg*. 1926;689-729.
  10. Bower TC, Pairorero PC, Hallett JW Jr, et al. Brachiocephalic aneurysm: the case for early recognition and repair. *Ann Vasc Surg*. 1991;5:125-132.
  11. Welling RE, Taha A, Goel T, et al. Extracranial carotid artery aneurysms. *Surgery*. 1983;93:319-323.
  12. McCollum CH, Wheeler WG, Noon GP, DeBakey ME. Aneurysms of the extracranial carotid artery. Twenty-one years' experience. *Am J Surg*. 1979;137:196-200.
  13. Zwolak RM, Whitehouse WM Jr, Knake JE, et al. Atherosclerotic extracranial carotid artery aneurysms. *J Vasc Surg*. 1984;1:415-422.
  14. Rhodes EL, Stanley JC, Hoffman GL, et al. Aneurysms of extracranial carotid arteries. *Arch Surg*. 1976;111:339-343.
  15. Pratschke E, Schafer K, Reimer J, et al. Extracranial aneurysms of the carotid artery. *Thorac Cardiovasc Surg*. 1980;28:354-358.
  16. Krupski WC, Effeney DJ, Ehrenfeld WK, Stoney RJ. Aneurysms of the carotid arteries. *Aust N Z J Surg*. 1983;53:521-525.
  17. Moreau P, Albat B, Thevenet A. Surgical treatment of extracranial internal carotid artery aneurysm. *Ann Vasc Surg*. 1994;8:409-416.
  18. Faggioli GL, Freyrie A, Stella A, et al. Extracranial internal carotid artery aneurysms: results of a surgical series with long-term follow-up. *J Vasc Surg*. 1996;23:587-594; discussion 594-595.
  19. Sundt TM Jr, Pearson BW, Piepgras DG, et al. Surgical management of aneurysms of the distal extracranial internal carotid artery. *J Neurosurg*. 1986;64:169-182.
  20. Schievink WI, Piepgras DG, McCaffrey TV, Mokri B. Surgical treatment of extracranial internal carotid artery dissecting aneurysms. *Neurosurgery*. 1994;35:809-815; discussion 15-16.
  21. Pulli R, Gatti M, Credi G, et al. Extracranial carotid artery aneurysms. *J Cardiovasc Surg (Torino)* 1997;38:339-346.
  22. Zhou W, Lin PH, Bush RL, et al. Carotid artery aneurysm: evolution of management over two decades. *J Vasc Surg*. 2006;43:493-496; discussion 497.
  23. Lesley WS, Chaloupka JC, Weigle JB, et al. Preliminary experience with endovascular reconstruction for the management of carotid blowout syndrome. *AJNR Am J Neuroradiol*. 2003;24:975-981.
  24. Painter TA, Hertzner NR, Beven EG, O'Hara PJ. Extracranial carotid aneurysms: report of six cases and review of the literature. *J Vasc Surg*. 1985;2:312-318.
  25. Pourhassan S, Grottemeyer D, Fokou M, et al. Extracranial carotid arteries aneurysms in children: single-center experiences in 4 patients and review of the literature. *J Pediatr Surg*. 2007;42:1961-1968.
  26. Rosset E, Albertini JN, Magnan PE, et al. Surgical treatment of extracranial internal carotid artery aneurysms. *J Vasc Surg*. 2000;31:713-723.

27. Berne JD, Reuland KS, Villarreal DH, et al. Sixteen-slice multi-detector computed tomographic angiography improves the accuracy of screening for blunt cerebrovascular injury. *J Trauma*. 2006;60:1204-1209; discussion 1209-1210.
28. Rich NM, Baugh JH, Hughes CW. Acute arterial injuries in Vietnam: 1,000 cases. *J Trauma*. 1970;10:359-369.
29. Stonebridge PA, Clason AE, Jenkins AM. Traumatic aneurysm of the extracranial internal carotid artery due to hyperextension of the neck. *Eur J Vasc Surg*. 1990;4:423-425.
30. Biffl WL, Moore EE, Offner PJ, et al. Blunt carotid arterial injuries: implications of a new grading scale. *J Trauma*. 1999;47:845-853.
31. Fabian TC, Patton JH Jr, Croce MA, et al. Blunt carotid injury. Importance of early diagnosis and anticoagulant therapy. *Ann Surg*. 1996;223:513-522; discussion 522-525.
32. Coldwell DM, Novak Z, Ryu RK, et al. Treatment of posttraumatic internal carotid arterial pseudoaneurysms with endovascular stents. *J Trauma*. 2000;48:470-472.
33. Coffin O, Maiza D, Galateau-Salle F, et al. Results of surgical management of internal carotid artery aneurysm by the cervical approach. *Ann Vasc Surg*. 1997;11:482-490.
34. Xu C, Zarins CK, Glagov S. Aneurysmal and occlusive atherosclerosis of the human abdominal aorta. *J Vasc Surg*. 2001;33:91-96.
35. Zarins CK, Xu C, Glagov S. Atherosclerotic enlargement of the human abdominal aorta. *Atherosclerosis*. 2001;155:157-164.
36. Shipley AM, Winslow N, Walker WW. Aneurysm in the cervical portion of the internal carotid artery: an analytical study of the cases recorded in the literature between August 1, 1925, and July 31, 1936. Report of two new cases. *Ann Surg*. 1937;105:673-699.
37. Mokri B, Piepgras DG, Sundt TM Jr, Pearson BW. Extracranial internal carotid artery aneurysms. *Mayo Clin Proc*. 1982;57:310-321.
38. Goldstone J. Aneurysms of the extracranial carotid artery. In: Rutherford RB, ed. *Vascular Surgery*. 6th ed. Philadelphia, PA: Elsevier Saunders; 2005.
39. Kato K, Tomura N, Takahashi S, et al. Balloon occlusion test of the internal carotid artery: correlation with stump pressure and <sup>99m</sup>Tc-HMPAO SPECT. *Acta Radiol*. 2006;47:1073-1078.
40. Dare AO, Chaloupka JC, Putman CM, et al. Failure of the hypotensive provocative test during temporary balloon test occlusion of the internal carotid artery to predict delayed hemodynamic ischemia after therapeutic carotid occlusion. *Surg Neurol*. 1998;50:147-155; discussion 155-156.
41. Linskey ME, Jungreis CA, Yonas H, et al. Stroke risk after abrupt internal carotid artery sacrifice: accuracy of preoperative assessment with balloon test occlusion and stable xenon-enhanced CT. *AJNR Am J Neuroradiol*. 1994;15:829-843.
42. Watson WL, Silverstone SM. Ligature of the common carotid artery in cancer of the head and neck. *Ann Surg*. 1939;109:1-27.
43. Brackett CE Jr. The complications of carotid artery ligation in the neck. *J Neurosurg*. 1953;10:91-106.
44. Kirby CK, Johnson J, Donald JG. Aneurysm of the common carotid artery. *Ann Surg*. 1949;130:913-920.
45. Pemberton JD, Livermore GR Jr. Surgical treatment of carotid body tumors: value of anticoagulants in carotid ligation. *Ann Surg*. 1951;133:837-852.
46. Ehrnefeld WK, Stoney RJ, Wylie EJ. Relation of carotid stump pressure to safety of carotid artery ligation. *Surgery*. 1983;93:299-305.
47. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. The EC/IC Bypass Study Group. *N Engl J Med*. 1985;313:1191-1200.
48. Candon E, Marty-Ane C, Pieuchot P, Frerebeau P. Cervical-to-petrous internal carotid artery saphenous vein in situ bypass for the treatment of a high cervical dissecting aneurysm: technical case report. *Neurosurgery*. 1996;39:863-866.
49. Skau T, Hillman J, Harder H, Magnuson B. Surgical treatment of distal extracranial internal carotid artery aneurysms involving the base of the skull—a multidisciplinary approach. *Eur J Vasc Endovasc Surg*. 2000;20:308-311.

50. Dimitza A. Aneurysms of the carotid arteries. Report of 2 cases. *Angiology*. 1956;7:218-227.
51. Beall AC Jr, Crawford ES, Cooley DA, DeBakey ME. Extracranial aneurysms of the carotid artery. Report of seven cases. *Postgrad Med*. 1962;32:93-102.
52. Callow AD. *Surgery of the Carotid and Vertebral Arteries for the Prevention of Stroke*. Baltimore, MD: Williams & Wilkins; 1996.
53. Hertzner NR. Extracranial carotid aneurysms: a new look at an old problem. *J Vasc Surg*. 2000;31:823-825.
54. Bush RL, Lin PH, Dodson TF, et al. Endoluminal stent placement and coil embolization for the management of carotid artery pseudoaneurysms. *J Endovasc Ther*. 2001;8:53-61.
55. Hori Y, Kiyosue H, Kashiwagi J, et al. Double stent technique for the treatment of an internal carotid artery pseudoaneurysm caused by zone III stab injury. *J Vasc Interv Radiol*. 2007;18:1300-1304.
56. Marotta TR, Buller C, Taylor D, et al. Autologous vein-covered stent repair of a cervical internal carotid artery pseudoaneurysm: technical case report. *Neurosurgery*. 1998;42:408-412; discussion 412-413.
57. Zimmerman MC, Mickel RA, Kessler DJ, et al. Treatment of impending carotid rupture with detachable balloon embolization. *Arch Otolaryngol Head Neck Surg*. 1987;113:1169-1175.
58. Kubaska SM 3rd, Greenberg RK, Clair D, et al. Internal carotid artery pseudoaneurysms: treatment with the Wallgraft endoprosthesis. *J Endovasc Ther*. 2003;10:182-189.
59. Holder R, Hilton D, Martin J, et al. Percutaneous thrombin injection of carotid artery pseudoaneurysm. *J Endovasc Ther*. 2002;9:25-28.
60. Baril DT, Ellozy SH, Carroccio A, et al. Endovascular repair of an infected carotid artery pseudoaneurysm. *J Vasc Surg*. 2004;40:1024-1027.
61. Saatci I, Cekirge HS, Ozturk MH, et al. Treatment of internal carotid artery aneurysms with a covered stent: experience in 24 patients with mid-term follow-up results. *AJNR Am J Neuroradiol*. 2004;25:1742-1749.
62. Comerota AJ, Thakur S. Antiplatelet therapy for vascular interventions. *Perspect Vasc Surg Endovasc Ther*. 2008;20:28-35.
63. McGirt MJ, Perler BA, Brooke BS, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. *J Vasc Surg*. 2005;42:829-836; discussion 836-837.
64. Kennedy J, Quan H, Buchan AM, et al. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. *Stroke*. 2005;36:2072-2076.
65. Groschel K, Ernemann U, Schulz JB, et al. Statin therapy at carotid angioplasty and stent placement: effect on procedure-related stroke, myocardial infarction, and death. *Radiology*. 2006;240:145-151.

## 第 99 章

1. Bogousslavsky J, Regli F. Ischemic stroke in adults younger than 30 years of age. Cause and prognosis. *Arch Neurol*. 1987;44:479-482.
2. Lee VH, Brown RD, Jr, Mandrekar JN, et al. Incidence and outcome of cervical artery dissection: a population-based study. *Neurology*. 2006;67:1809-1812.
3. Schievink WI, Roiter V. Epidemiology of cervical artery dissection. *Front Neurol Neurosci*. 2005;20:12-15.
4. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. *N Engl J Med*. 2001;344:898-906.
5. Schievink WI, Mokri B, O'Fallon WM. Recurrent spontaneous cervical-artery dissection. *N Engl J Med*. 1994;330:393-397.
6. Haneline MT, Croft AC, Frishberg BM. Association of internal carotid artery dissection and chiropractic manipulation. *Neurologist*. 2003;9:35-44.
7. Pezzini A, Caso V, Zanferrari C, et al. Arterial hypertension as risk factor for spontaneous cervical artery dissection. A case-control study. *J Neurol Neurosurg Psychiatry*. 2006;77:95-97.
8. Mokri B, Piepgras DG, Wiebers DO, et al. Familial occurrence of spontaneous dissection of the internal carotid artery.



*Stroke*. 1987;18:246-251.

9. Grau AJ, Brandt T, Buggle F, et al. Association of cervical artery dissection with recent infection. *Arch Neurol*. 1999;56:851-856.
10. Paciaroni M, Georgiadis D, Arnold M, et al. Seasonal variability in spontaneous cervical artery dissection. *J Neurol Neurosurg Psychiatry*. 2006;77:677-679.
11. Guillon B, Tzourio C, Biousse V, et al. Arterial wall properties in carotid artery dissection: an ultrasound study. *Neurology*. 2000;55:663-666.
12. Chandra A, Suliman A, Angle N. Spontaneous dissection of the carotid and vertebral arteries: the 10-year UCSD experience. *Ann Vasc Surg*. 2007;21:178-185.
13. Baumgartner RW, Bogousslavsky J. Clinical manifestations of carotid dissection. *Front Neurol Neurosci*. 2005;20:70-76.
14. Davis JW, Holbrook TL, Hoyt DB, et al. Blunt carotid artery dissection: incidence, associated injuries, screening, and treatment. *J Trauma*. 1990;30:1514-1517.
15. Laitt RD, Lewis TT, Bradshaw JR. Blunt carotid arterial trauma. *Clin Radiol*. 1996;51:117-122.
16. Nedeltchev K, Baumgartner RW. Traumatic cervical artery dissection. *Front Neurol Neurosci*. 2005;20:54-63.
17. Hughes KM, Collier B, Greene KA, et al. Traumatic carotid artery dissection: a significant incidental finding. *Am Surg*. 2000;66:1023-1027.
18. Rommel O, Niedeggen A, Tegenthoff M, et al. Carotid and vertebral artery injury following severe head or cervical spine trauma. *Cerebrovasc Dis*. 1999;9:202-209.
19. Fabian TC, Patton JH, Jr, Croce MA, et al. Blunt carotid injury. Importance of early diagnosis and anticoagulant therapy. *Ann Surg*. 1996;223:513-522.
20. Biffl WL, Moore EE, Ryu RK, et al. The unrecognized epidemic of blunt carotid arterial injuries: early diagnosis improves neurologic outcome. *Ann Surg*. 1998;228:462-470.
21. Biffl WL, Moore EE, Offner PJ, et al. Optimizing screening for blunt cerebrovascular injuries. *Am J Surg*. 1999;178:517-522.
22. Adkins AL, Zelenock GB, Bendick PJ, et al. Duplex ultrasound recognition of spontaneous carotid dissection—a case report and review of the literature. *Vasc Endovascular Surg*. 2004;38:455-460.
23. Biffl WL. Diagnosis of blunt cerebrovascular injuries. *Curr Opin Crit Care*. 2003;9:530-534.
24. Stallmeyer MJ, Morales RE, Flanders AE. Imaging of traumatic neurovascular injury. *Radiol Clin North Am*. 2006;44:13-39, vii.
25. Miller PR, Fabian TC, Croce MA, et al. Prospective screening for blunt cerebrovascular injuries: analysis of diagnostic modalities and outcomes. *Ann Surg*. 2002;236:386-393.
26. Biffl WL, Ray CE, Jr, Moore EE, et al. Noninvasive diagnosis of blunt cerebrovascular injuries: a preliminary report. *J Trauma*. 2002;53:850-856.
27. Eastman AL, Chason DP, Perez CL, et al. Computed tomographic angiography for the diagnosis of blunt cervical vascular injury: is it ready for primetime? *J Trauma*. 2006;60:925-929; discussion 929.
28. Sturzenegger M, Mattle HP, Rivoir A, et al. Ultrasound findings in carotid artery dissection: analysis of 43 patients. *Neurology*. 1995;45:691-698.
29. Touze E, Gauvrit JY, Meder JF, et al. Prognosis of cervical artery dissection. *Front Neurol Neurosci*. 2005;20:129-139.
30. Mokri B. Traumatic and spontaneous extracranial internal carotid artery dissections. *J Neurol*. 1990;237:356-361.
31. Milhaud D, de Freitas GR, van Melle G, et al. Occlusion due to carotid artery dissection: a more severe disease than previously suggested. *Arch Neurol*. 2002;59:557-561.
32. Norris JW. Extracranial arterial dissection: anticoagulation is the treatment of choice. *Stroke*. 2005;36:2041-2042.
33. Lyrer P, Engelter S. Antithrombotic drugs for carotid artery dissection. *Cochrane Database Syst Rev*. 2003;000255.
34. Antiplatelet therapy vs. anticoagulation in cervical artery dissection: rationale and design of the Cervical Artery Dissection

- in Stroke Study (CADISS). *Int J Stroke*. 2007;2:292-296.
35. Muller BT, Luther B, Hort W, et al. Surgical treatment of 50 carotid dissections: indications and results. *J Vasc Surg*. 2000;31:980-988.
  36. Edgell RC, Abou-Chebl A, Yadav JS. Endovascular management of spontaneous carotid artery dissection. *J Vasc Surg*. 2005;42:854-860; discussion 860.
  37. Cohen JE, Ben-Hur T, Rajz G, et al. Endovascular stent-assisted angioplasty in the management of traumatic internal carotid artery dissections. *Stroke*. 2005;36:e45-e47.
  38. Schievink WI, Piepgras DG, McCaffrey TV, et al. Surgical treatment of extracranial internal carotid artery dissecting aneurysms. *Neurosurgery*. 1994;35:809-815; discussion 815-816.
  39. Ehrnefeld WK, Stoney RJ, Wylie EJ. Relation of carotid stump pressure to safety of carotid artery ligation. *Surgery*. 1983;93:299-305.
  40. Georgiadis D, Baumgartner RW. Thrombolysis in cervical artery dissection. *Front Neurol Neurosci*. 2005;20:140-146.
  41. Lavalley PC, Mazighi M, Saint-Maurice JP, et al. Stent-assisted endovascular thrombolysis versus intravenous thrombolysis in internal carotid artery dissection with tandem internal carotid and middle cerebral artery occlusion. *Stroke*. 2007;38:2270-2274.
  42. Nikas D, Reimers B, Elisabetta M, et al. Percutaneous interventions in patients with acute ischemic stroke related to obstructive atherosclerotic disease or dissection of the extracranial carotid artery. *J Endovasc Ther*. 2007;14:279-288.
  43. Hoppe H, Barnwell SL, Nesbit GM, et al. Stent-grafts in the treatment of emergent or urgent carotid artery disease: review of 25 cases. *J Vasc Interv Radiol*. 2008;19:31-41.
  44. Saket RR, Razavi MK, Sze DY, et al. Stent-graft treatment of extracranial carotid and vertebral arterial lesions. *J Vasc Interv Radiol*. 2004;15:1151-1156.
  45. Lin PH, Bush RL, Lumsden AB. Endovascular treatment for symptomatic carotid artery dissection. *J Vasc Surg*. 2005;41:555.
  46. Biondi A, Katz JM, Vallabh J, et al. Progressive symptomatic carotid dissection treated with multiple stents. *Stroke*. 2005;36:e80-e82.
  47. Janjua N, Qureshi AI, Kirmani J, et al. Stent-supported angioplasty for acute stroke caused by carotid dissection. *Neurocrit Care*. 2006;4:47-53.
  48. Bejjani GK, Monsein LH, Laird JR, et al. Treatment of symptomatic cervical carotid dissections with endovascular stents. *Neurosurgery*. 1999;44:755-760; discussion 760-761.
  49. Malek AM, Higashida RT, Phatouros CC, et al. Endovascular management of extracranial carotid artery dissection achieved using stent angioplasty. *AJNR Am J Neuroradiol*. 2000;21:1280-1292.
  50. Baysal BE, Myers EN. Etiopathogenesis and clinical presentation of carotid body tumors. *Microsc Res Tech*. 2002;59:256-261.
  51. Athanasiou A, Liappis CD, Rapidis AD, et al. Carotid body tumor: review of the literature and report of a case with a rare sensorineural symptomatology. *J Oral Maxillofac Surg*. 2007;65:1388-1393.
  52. Sajid MS, Hamilton G, Baker DM, et al. A multicenter review of carotid body tumour management. *Eur J Vasc Endovasc Surg*. 2007;34:127-130.
  53. Luna-Ortiz K, Rascon-Ortiz M, Villavicencio-Valencia V, et al. Carotid body tumors: review of a 20-year experience. *Oral Oncol*. 2005;41:56-61.
  54. Hallett JW Jr, Nora JD, Hollier LH, et al. Trends in neurovascular complications of surgical management for carotid body and cervical paragangliomas: a fifty-year experience with 153 tumors. *J Vasc Surg*. 1988;7:284-291.
  55. Kohn JS, Raftery KB, Jewell ER. Familial carotid body tumors: a closer look. *J Vasc Surg*. 1999;29:649-653.
  56. Torres Patino F, Gomez Acosta F, Guzman Patraca C, et al. [Carotid body tumor. Analysis of 96 cases]. *Rev Invest Clin*. 1991;43:119-123.

57. Chedid A, Jao W. Hereditary tumors of the carotid bodies and chronic obstructive pulmonary disease. *Cancer*. 1974;33:1635-1641.
58. Netterville JL, Jackson CG, Miller FR, et al. Vagal paraganglioma: a review of 46 patients treated during a 20-year period. *Arch Otolaryngol Head Neck Surg*. 1998;124:1133-1140.
59. Pawlu C, Bausch B, Neumann HP. Mutations of the SDHB and SDHD genes. *Fam Cancer*. 2005;4:49-54.
60. Rinaldo A, Myssiorek D, Devaney KO, et al. Which paragangliomas of the head and neck have a higher rate of malignancy? *Oral Oncol*. 2004;40:458-460.
61. Lee JH, Barich F, Karnell LH, et al. National Cancer Data Base report on malignant paragangliomas of the head and neck. *Cancer*. 2002;94:730-737.
62. Shamblyn WR, ReMine WH, Sheps SG, et al. Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. *Am J Surg*. 1971;122:732-739.
63. Westerband A, Hunter GC, Cintora I, et al. Current trends in the detection and management of carotid body tumors. *J Vasc Surg*. 1998;28:84-92.
64. Jansen JC, van den Berg R, Kuiper A, et al. Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. *Cancer*. 2000;88:2811-2816.
65. Stoeckli SJ, Schuknecht B, Alkadhi H, et al. Evaluation of paragangliomas presenting as a cervical mass on color-coded Doppler sonography. *Laryngoscope*. 2002;112:143-146.
66. Boedeker CC, Ridder GJ, Schipper J. Paragangliomas of the head and neck: diagnosis and treatment. *Fam Cancer*. 2005;4:55-59.
67. Kafie FE, Freischlag JA. Carotid body tumors: the role of preoperative embolization. *Ann Vasc Surg*. 2001;15:237-242.
68. Kasper GC, Welling RE, Wladis AR, et al. A multidisciplinary approach to carotid paragangliomas. *Vasc Endovasc Surg*. 2006;40:467-474.
69. Boedeker CC, Neumann HP, Maier W, et al. Malignant head and neck paragangliomas in SDHB mutation carriers. *Otolaryngol Head Neck Surg*. 2007;137:126-129.
70. Borges LF, Heros RC, DeBrun G. Carotid body tumors managed with preoperative embolization. Report of two cases. *J Neurosurg*. 1983;59:867-870.
71. DuBois J, Kelly W, McMenamin P, et al. Bilateral carotid body tumors managed with preoperative embolization: a case report and review. *J Vasc Surg*. 1987;5:648-650.
72. Little VR, Reilly LM, Ramos TK. Preoperative embolization of carotid body tumors: when is it appropriate? *Ann Vasc Surg*. 1996;10:464-468.
73. Elshaikh MA, Mahmoud-Ahmed AS, Kinney SE, et al. Recurrent head-and-neck chemodectomas: a comparison of surgical and radiotherapeutic results. *Int J Radiat Oncol Biol Phys*. 2002;52:953-956.
74. Filippone JD, Bisognano JD. Baroreflex stimulation in the treatment of hypertension. *Curr Opin Nephrol Hypertens*. 2007;16:403-408.
75. O'Mahony D. Pathophysiology of carotid sinus hypersensitivity in elderly patients. *Lancet*. 1995;346:950-952.
76. McIntosh SJ, Lawson J, Kenny RA. Clinical characteristics of vasodepressor, cardioinhibitory, and mixed carotid sinus syndrome in the elderly. *Am J Med*. 1993;95:203-208.
77. Strasberg B, Sagie A, Erdman S, et al. Carotid sinus hypersensitivity and the carotid sinus syndrome. *Prog Cardiovasc Dis*. 1989;31:379-391.
78. Schellack J, Fulenwider JT, Olson RA, et al. The carotid sinus syndrome: a frequently overlooked cause of syncope in the elderly. *J Vasc Surg*. 1986;4:376-383.
79. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. *Hypertension*. 2004;44:398-404.
80. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement

from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. *Hypertension*. 2008;51:1403-1419.

81. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002;288:2981-2997.
82. Alper AB, Jr, Calhoun DA. Contemporary management of refractory hypertension. *Curr Hypertens Rep*. 1999;1:402-407.
83. Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. *J Hypertens*. 2001;19:2063-2070.
84. Chobanian AV, Bakris GL, Black HR, et al., for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*. 2003;42:1206-1252.
85. Krieger EM. Neurogenic mechanisms in hypertension: resetting of baroreceptors. *Hypertension*. 1986;8:1-7.
86. Lohmeier TE, Hildebrandt DA, Warren S, et al. Recent insights into the interactions between the baroreflex and the kidneys in hypertension. *Am J Physiol Regul Integr Comp Physiol*. 2005;288:R828-R836.
87. Thrasher TN. Unloading arterial baroreceptors causes neurogenic hypertension. *Am J Physiol Regul Integr Comp Physiol*. 2002;282:R1044-R1053.
88. Lohmeier TE, Irwin ED, Rossing MA, et al. Prolonged activation of the baroreflex produces sustained hypotension. *Hypertension*. 2004;43:306-311.
89. Lohmeier TE, Dwyer TM, Hildebrandt DA, et al. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. *Hypertension*. 2005;46:1194-1200.
90. Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. *J Vasc Surg*. 2006;44:1213-1218.
91. Hering HE. Compression of carotid artery. *Munch Med Wochenschr*. 1923;70:1287.
92. McCubbin JW, Green JH, Page IH. Baroreceptor function in renal hypertension. *Circ Res*. 1956;4:205-210.
93. Carlsten A, Folkow B, Grimby G, et al. Cardiovascular effects of direct stimulation of the carotid sinus nerve in man. *Acta Physiol Scand*. 1958;44:138-145.
94. Schwartz SI, Griffith LSC, Neistadt A, et al. Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. *Am J Surg*. 1967;114:5-15.
95. Tordoir JH, Scheffers I, Schmidli J, et al. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. *Eur J Vasc Endovasc Surg*. 2007;33:414-421.
96. Lohmeier TE, Barrett AM, Irwin ED. Prolonged activation of the baroreflex: a viable approach for the treatment of hypertension? *Curr Hypertens Rep*. 2005;7:193-198.
97. Scheffers I, Schmidli J, Kroon AA, et al. Sustained blood pressure reduction by baroreflex hypertension therapy with a chronically implanted system: long term data from the Rheos DEBUT-HT study in patients with resistant hypertension [abstract]. *J Hypertens*. 2007;25:S141-S142.
98. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. *N Engl J Med*. 2003;349:160-169.
99. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. *Ann Intern Med*. 1994;120:919-929.
100. Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. *J Clin Pathol*. 2002;55:481-486.
101. Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. *Curr Opin Rheumatol*. 2005;17:16-24.
102. Liang P, Tan-Ong M, Hoffman GS. Takayasu's arteritis: vascular interventions and outcomes. *J Rheumatol*.

2004;31:102-106.

103. Park MC, Lee SW, Park YB, et al. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. *Rheumatology*. 2006;45:600-605.
104. Tabata M, Kitagawa T, Saito T, et al. Extracranial carotid aneurysm in Takayasu's arteritis. *J Vasc Surg*. 2001;34:739-742.
105. Odero A, Regina G. Regarding "Extracranial carotid aneurysm in Takayasu's arteritis." *J Vasc Surg*. 2002;36:201.
106. Both M, Aries PM, Muller-Hulsbeck S, et al. Balloon angioplasty of arteries of the upper extremities in patients with extracranial giant-cell arteritis. *Ann Rheum Dis*. 2006;65:1124-1130.
107. Amann-Vesti BR, Koppensteiner R, Rainoni L, et al. Immediate and long-term outcome of upper extremity balloon angioplasty in giant cell arteritis. *J Endovasc Ther*. 2003;10:371-375.
108. Fajardo LF, Berthrong M. Vascular lesions following radiation. *Pathol Annu*. 1988;23:297-330.
109. Himmel PD, Hassett JM. Radiation-induced chronic arterial injury. *Semin Surg Oncol*. 1986;2:225-247.
110. Zidar N, Ferluga D, Hvala A, et al. Contribution to the pathogenesis of radiation-induced injury to large arteries. *J Laryngol Otol*. 1997;111:988-990.
111. Dubec JJ, Munk PL, Tsang V, et al. Carotid artery stenosis in patients who have undergone radiation therapy for head and neck malignancy. *Br J Radiol*. 1998;71:872-875.
112. Steele SR, Martin MJ, Mullenix PS, et al. Focused high-risk population screening for carotid arterial stenosis after radiation therapy for head and neck cancer. *Am J Surg*. 2004;187:594-598.
113. Cheng SW, Ting AC, Lam LK, et al. Carotid stenosis after radiotherapy for nasopharyngeal carcinoma. *Arch Otolaryngol Head Neck Surg*. 2000;126:517-521.
114. Carmody BJ, Arora S, Avena R, et al. Accelerated carotid artery disease after high-dose head and neck radiotherapy: is there a role for routine carotid duplex surveillance? *J Vasc Surg*. 1999;30:1045-1051.
115. Qureshi AI, Alexandrov AV, Tegeler CH, et al. Highlights of the guidelines for screening of extracranial carotid artery disease: a statement for healthcare professionals from the Multidisciplinary Practice Guidelines Committee of the American Society of Neuroimaging; cosponsored by the Society of Vascular and Interventional Neurology. *J Endovasc Ther*. 2007;14:469-474.
116. Haynes JC, Machtay M, Weber RS, et al. Relative risk of stroke in head and neck carcinoma patients treated with external cervical irradiation. *Laryngoscope*. 2002;112:1883-1887.
117. Meeske KA, Nelson MD, Lavey RS, et al. Premature carotid artery disease in long-term survivors of childhood cancer treated with neck irradiation: a series of 5 cases. *J Pediatr Hematol Oncol*. 2007;29:480-484.
118. Hassen-Khodja R, Sala F, Declémy S, et al. Surgical management of atherosclerotic carotid artery stenosis after cervical radiation therapy. *Ann Vasc Surg*. 2000;14:608-611.
119. Rockman CB, Riles TS, Fisher FS, et al. The surgical management of carotid artery stenosis in patients with previous neck irradiation. *Am J Surg*. 1996;172:191-195.
120. Friedell ML, Joseph BP, Cohen MJ, et al. Surgery for carotid artery stenosis following neck irradiation. *Ann Vasc Surg*. 2001;15:13-18.
121. Leseche G, Castier Y, Chataigner O, et al. Carotid artery revascularization through a radiated field. *J Vasc Surg*. 2003;38:244-250.
122. Protack CD, Bakken AM, Saad WA, et al. Radiation arteritis: a contraindication to carotid stenting? *J Vasc Surg*. 2007;45:110-117.
123. Metz H, Murray-Leslie RM, Bannister RG, et al. Kinking of the internal carotid artery. *Lancet*. 1961;1:424-426.
124. Ballotta E, Thiene G, Baracchini C, et al. Surgical vs medical treatment for isolated internal carotid artery elongation with coiling or kinking in symptomatic patients: a prospective randomized clinical study. *J Vasc Surg*. 2005;42:838-846.
125. Aleksic M, Schutz G, Gerth S, et al. Surgical approach to kinking and coiling of the internal carotid artery. *J Cardiovasc Surg*. 2004;45:43-48.

126. Vannix RS, Joergenson EJ, Carter R. Kinking of the internal carotid artery. Clinical significance and surgical management. *Am J Surg*. 1977;134:82-89.
127. Cairney J. Tortuosity of the cervical segment of the internal carotid artery. *J Anat*. 1924;59:87-96.
128. Weibel J, Fields WS. Tortuosity, coiling, and kinking of the internal carotid artery. II. Relationship of morphological variation to cerebrovascular insufficiency. *Neurology*. 1965;15:462-468.
129. Illuminati G, Ricco JB, Calio FG, et al. Results in a consecutive series of 83 surgical corrections of symptomatic stenotic kinking of the internal carotid artery. *Surgery*. 2008;143:134-139.
130. Nissim O, Bakon M, Ben Zeev B, et al. Moyamoya disease—diagnosis and treatment: indirect cerebral revascularization at the Sheba Medical Center. *Isr Med Assoc J*. 2005;7:661-666.
131. Fukui M. Current state of study on moyamoya disease in Japan. *Surg Neurol*. 1997;47:138-143.
132. Fung LW, Thompson D, Ganesan V. Revascularisation surgery for paediatric moyamoya: a review of the literature. *Childs Nerv Syst*. 2005;21:358-364.
133. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. The EC/IC Bypass Study Group. *N Engl J Med*. 1985;313:1191-1200.
134. Garrett MC, Komotar RJ, Merkow MB, et al. The extracranial-intracranial bypass trial: implications for future investigations. *Neurosurg Focus*. 2008;24:e4.
135. Grubb RL, Jr, Powers WJ, Derdeyn CP, et al. The Carotid Occlusion Surgery Study. *Neurosurg Focus*. 2003;14:e9.
136. Ogasawara K, Ogawa A. [JET study (Japanese EC-IC Bypass Trial).] *Nippon Rinsho—Jpn J Clin Med*. 2006;64:524-527.
137. Jakubowski J, Kendall B. Coincidental aneurysms with tumours of pituitary origin. *J Neurol Neurosurg Psychiatry*. 1978;41:972-979.
138. Unruptured intracranial aneurysms—risk of rupture and risks of surgical intervention. International Study of Unruptured Intracranial Aneurysms Investigators. *N Engl J Med*. 1998;339:1725-1733.
139. Komotar RJ, Mocco J, Solomon RA. Guidelines for the surgical treatment of unruptured intracranial aneurysms: the first annual J. Lawrence Pool Memorial Research Symposium—controversies in the management of cerebral aneurysms. *Neurosurgery*. 2008;62:183-193.
140. Mitchell P, Jakubowski J. Risk analysis of treatment of unruptured aneurysms. *J Neurol Neurosurg Psychiatry*. 2000;68:577-580.

## 第 100 章

1. Bergman RA. *Compendium of Human Anatomic Variation: Text, Atlas, and World Literature*. Baltimore, MD: Urban & Schwarzenberg; 1988.
2. Berguer R, Morasch MD, Kline RA. Transthoracic repair of innominate and common carotid artery disease: immediate and long-term outcome for 100 consecutive surgical reconstructions. *J Vasc Surg*. 1998;27:34-41.
3. Berguer R, Morasch MD, Kline RA, et al. Cervical reconstruction of the supra-aortic trunks: a 16-year experience. *J Vasc Surg*. 1999;29:239-246.
4. Fisher CM. A new vascular syndrome—"the subclavian steal." *N Engl J Med*. 1961;265:912-913.
5. Marshall WG Jr. The coronary-subclavian steal syndrome: report of a case and recommendations for prevention and management. *Ann Thorac Surg*. 1988;46:93-96.
6. Mozersky DJ, Barnes RW, Sumner DS, Strandness DE Jr. Hemodynamics of innominate artery occlusion. *Ann Surg*. 1973;178:123-127.
7. Berguer R, Caplan LR. *Vertebrobasilar Arterial Disease*. St. Louis, MO: Quality Medical; 1992.
8. Savitz SI, Caplan LR. Vertebrobasilar disease. *N Engl J Med*. 2005;352:2618-2626.
9. Toursarkissian B. Surgical treatment of patients with symptomatic vertebrobasilar insufficiency. *Ann Vasc Surg*. 1998;12:28-33.

10. Daniel RA Jr. Syphilitic aneurysm of the subclavian artery. *Ann Surg.* 1951;134:251-258.
11. Johnston RH Jr, Wall MJ Jr, Mattox KL. Innominate artery trauma: a thirty-year experience. *J Vasc Surg.* 1993;17:134-139.
12. Mathes SJ, Salam AA. Subclavian artery aneurysm; sequela of thoracic outlet syndrome. *Surgery.* 1974;76:506-510.
13. Pairolero PC, Walls JT, Payne WS, et al. Subclavian-axillary artery aneurysms. *Surgery.* 1981;90:757-763.
14. Bower TC, Pairolero PC, Hallett JW, et al. Brachiocephalic aneurysm: the case for early recognition and repair. *Ann Vasc Surg.* 1991;5:125-132.
15. Hall S, Barr W, Lie JT, et al. Takayasu arteritis. A study of 32 North American patients. *Medicine (Baltimore).* 1985;64:89-99.
16. Weinberger J, Azhar S, Danisi F, et al. A new noninvasive technique for imaging atherosclerotic plaque in the aortic arch of stroke patients by transcutaneous real-time B-mode ultrasonography: an initial report. *Stroke.* 1998;29:673-676.
17. Yip PK, Liu HM, Hwang BS, Chen RC. Subclavian steal phenomenon: a correlation between duplex sonographic and angiographic findings. *Neuroradiology.* 1992;34:279-282.
18. Estol CJ, Kase CS. Intracerebral hemorrhage after carotid revascularization procedures. *Semin Cerebrovasc Dis Stroke.* 2005;5:194-201.
19. Kieffer E, Sabatier J, Koskas F, Bahnini A. Atherosclerotic innominate artery occlusive disease: early and long-term results of surgical reconstruction. *J Vasc Surg.* 1995;21:326-337.
20. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *J Am Coll Cardiol.* 2007;50:e159-e241.
21. Vaduganathan P, Ewton A, Nagueh SF, et al. Pathologic correlates of aortic plaques, thrombi and mobile "aortic debris" imaged in vivo with transesophageal echocardiography. *J Am Coll Cardiol.* 1997;30:357-363.
22. Sylivris S, Calafiore P, Matalanis G, et al. The intraoperative assessment of ascending aortic atheroma: epiaortic imaging is superior to both transesophageal echocardiography and direct palpation. *J Cardiothorac Vasc Anesth.* 1997;11:704-707.
23. Cherry KJ. Direct reconstruction of the innominate artery. *Cardiovasc Surg.* 2002;10:383-388.
24. Takach TJ, Reul GJ, Gregoric I, et al. Concomitant subclavian and coronary artery disease. *Ann Thorac Surg.* 2001;71:187-189.
25. Nicholls SC, Koutlas TC, Strandness DE. Clinical significance of retrograde flow in the vertebral artery. *Ann Vasc Surg.* 1991;5:331-336.
26. Estrera AL, Miller CC III, Madisetty J, et al. Ascending and transverse aortic arch repair: the impact of glomerular filtration rate on mortality. *Ann Surg.* 2008;247:524-529.
27. DeBakey ME, Morris GC Jr, Jordan GL Jr, Cooley DA. Segmental thrombo-obliterative disease of branches of aortic arch; successful surgical treatment. *JAMA.* 1958;166:998-1003.
28. Crawford ES, DeBakey ME, Morris GC Jr, Cooley DA. Thrombo-obliterative disease of the great vessels arising from the aortic arch. *Thorac Cardiovasc Surg.* 1962;43:38-53.
29. Crawford ES, Stowe CL, Powers RW Jr. Occlusion of the innominate, common carotid, and subclavian arteries: long-term results of surgical treatment. *Surgery.* 1983;94:781-791.
30. Rhodes JM, Cherry KJ, Clark RC, et al. Aortic-origin reconstruction of the great vessels: risk factors of early and late complications. *J Vasc Surg.* 2000;31:260-269.
31. Crawford ES, DeBakey ME, Morris GC Jr, Howell JF. Surgical treatment of occlusion of the innominate, common carotid, and subclavian arteries: a 10-year experience. *Surgery.* 1969;65:17-31.

32. Edwards WH Jr, Tapper SS, Edwards WH Sr, et al. Subclavian revascularization. A quarter century experience. *Ann Surg.* 1994;219:673-677; discussion 677-678.
33. Schardey HM, Meyer G, Rau HG, et al. Subclavian carotid transposition: an analysis of a clinical series and a review of the literature. *Eur J Vasc Endovasc Surg.* 1996;12:431-436.
34. Cinà CS, Safar HA, Laganr A, et al. Subclavian carotid transposition and bypass grafting: consecutive cohort study and systematic review. *J Vasc Surg.* 2002;35:422-429.
35. AbuRahma AF, Robinson PA, Jennings TG. Carotid-subclavian bypass grafting with polytetrafluoroethylene grafts for symptomatic subclavian artery stenosis or occlusion: A 20-year experience. *J Vasc Surg.* 2000;32:411-419.
36. Diethrich EB, Garrett HE, Ameriso J, et al. Occlusive disease of the common carotid and subclavian arteries treated by carotid-subclavian bypass. Analysis of 125 cases. *Am J Surg.* 1967;114:800-808.
37. Law MM, Colburn MD, Moore WS, et al. Carotid-subclavian bypass for brachiocephalic occlusive disease choice of conduit and long-term follow-up. *Stroke.* 1995;26:1565-1571.
38. Perler BA, Williams GM. Carotid-subclavian bypass—a decade of experience. *J Vasc Surg.* 1990;12:716-722.
39. Salam TA, Lumsden AB, Smith RB 3rd. Subclavian artery revascularization: a decade of experience with extrathoracic bypass procedures. *J Surg Res.* 1994;56:387-392.
40. Vitti MJ, Thompson BW, Read RC, et al. Carotid-subclavian bypass: a twenty-two-year experience. *J Vasc Surg.* 1994;20:411-417.
41. Ziomek S, Quinones-Baldrich WJ, Busuttil RW, et al. The superiority of synthetic arterial grafts over autologous veins in carotid-subclavian bypass. *J Vasc Surg.* 1986;3:140-145.
42. Mingoli A, Feldhaus RJ, Farina C, et al. Comparative results of carotid-subclavian bypass and axillo-axillary bypass in patients with symptomatic subclavian disease. *Eur J Vasc Surg.* 1992;6:26-30.
43. Chang JB, Stein TA, Liu JP, Dunn ME. Long-term results with axillo-axillary bypass grafts for symptomatic subclavian artery insufficiency. *J Vasc Surg.* 1997;25:173-178.
44. Mingoli A, Sapienza P, Feldhaus RJ, et al. Long-term results and outcomes of crossover axilloaxillary bypass grafting: a 24-year experience. *J Vasc Surg.* 1999;29:894-901.
45. Berguer R, Gonzalez JA. Revascularization by the retropharyngeal route for extensive disease of the extracranial arteries. *J Vasc Surg.* 1994;19:217-224.
46. Ozsvath KJ, Roddy SP, Darling RC, et al. Carotid-carotid crossover bypass: is it a durable procedure? *J Vasc Surg.* 2003;37:582-585.
47. Salam TA, Smith RB 3rd, Lumsden AB. Extrathoracic bypass procedures for proximal common carotid artery lesions. *Am J Surg.* 1993;166:163-166.
48. Byrne J, Darling RC, Roddy SP, et al. Long-term outcome for extra-anatomic arch reconstruction. An analysis of 143 procedures. *Eur J Vasc Endovasc Surg.* 2007;34:444-450.
49. Leurs LJ, Bell R, Degrieck Y, et al. Endovascular treatment of thoracic aortic diseases: combined experience from the EUROSTAR and United Kingdom Thoracic Endograft registries. *J Vasc Surg.* 2004;40:670-679.
50. Buth J, Harris PL, Hobo R, et al. Neurologic complications associated with endovascular repair of thoracic aortic pathology: incidence and risk factors. A study from the European Collaborators on Stent/Graft Techniques for Aortic Aneurysm Repair (EUROSTAR) Registry. *J Vasc Surg.* 2007;46:1103-1111.
51. Peterson BG, Eskandari MK, Gleason TG, Morasch MD. Utility of left subclavian artery revascularization in association with endoluminal repair of acute and chronic thoracic aortic pathology. *J Vasc Surg.* 2006;43:433-439.
52. Kato M, Kaneko M, Kuratani T, et al. New operative method for distal aortic arch aneurysm: combined cervical branch bypass and endovascular stent-graft implantation. *J Thorac Cardiovasc Surg.* 1999;117:832-834.
53. Bergeron P, Coulon P, De Chaumaray T, et al. Great vessels transposition and aortic arch exclusion. *J Cardiovasc Surg.* 2005;46:141-147.



54. Saleh HM. Hybrid repair of aortic arch aneurysm. *Acta Chir Belg.* 2007;107:173-180.
55. Saleh HM, Inglese L. Combined surgical and endovascular treatment of aortic arch aneurysms. *J Vasc Surg.* 2006;44:460-466.
56. Schumacher H, Von Tengg-Kobligk H, Ostovic M, et al. Hybrid aortic procedures for endoluminal arch replacement in thoracic aneurysms and type B dissections. *J Cardiovasc Surg (Torino).* 2006;47:509-517.
57. Szeto WY, Bavaria JE, Bowen FW, et al. The hybrid total arch repair: brachiocephalic bypass and concomitant endovascular aortic arch stent graft placement. *J Card Surg.* 2007;22:97-102.
58. Czerny M, Cejna M, Hutschala D, et al. Stent-graft placement in atherosclerotic descending thoracic aortic aneurysms: midterm results. *Eur J Cardiothorac Surg.* 2007;11:26-32.
59. Estrera AL, Miller CC 3rd, Lee TY, et al. Ascending and transverse aortic arch repair: the impact of retrograde cerebral perfusion. *Circulation* 2008;118(14 Suppl):S160-S166.
60. Estrera AL, Miller CC, Huynh TT, et al. Replacement of the ascending and transverse aortic arch: determinants of long-term survival. *Ann Thorac Surg.* 2002;74:1058-1065.
61. Safi HJ, Letsou GV, Iliopoulos DC, et al. Impact of retrograde cerebral perfusion on ascending aortic and arch aneurysm repair. *Ann Thorac Surg.* 1997;63:1601-1607.

## 第 101 章

1. DeBakey ME, Morris GC Jr, Jordan GL Jr, Cooley DA. Segmental thrombo-obliterative disease of the branches of the aortic arch. *JAMA.* 1958;166:998-1003.
2. Carlson RE, Ehrenfeld WK, Stoney RJ, Wylie EJ. Innominate artery endarterectomy: a 16 year history. *Arch Surg.* 1977;112:1389-1393.
3. Motarjeme A, Keifer JW, Zuska AJ. Percutaneous transluminal angioplasty of the brachiocephalic arteries. *AJR Am J Roentgenol.* 1982;138:457-462.
4. Galichia JP, Bajaj AK, Vine DL, Roberts RW. Subclavian artery stenosis treated by transluminal angioplasty: six cases. *Cardiovasc Intervent Radiol.* 1983;6:78-81.
5. Theron J, Courtheoux P, Henriot JP, et al. Angioplasty of supraaortic arteries. *J Neuroradiol.* 1984;11:187-200.
6. Vitek JJ, Keller FS, Duvall ER, et al. Brachiocephalic artery dilation by percutaneous transluminal angioplasty. *Radiology.* 1986;158:779-785.
7. Fields W, Lemak N. Joint study of extracranial arterial occlusion. VII. Subclavian steal—a review of 168 cases. *JAMA.* 1972;222:1139-1143.
8. Wiley E, Effenev D. Surgery of the aortic arch branches and vertebral arteries. *Surg Clin North Am.* 1979;59:669-680.
9. Kadwa A, Robbs J, Abdool-Carrim AT. Aortic arch angiography prior to carotid endarterectomy. Is its continued use justified? *Eur J Vasc Endovasc Surg.* 1997;13:527-530.
10. Long S, Kern J, Fiser S, et al. Carotid arteriography impacts carotid stenosis management. *Vasc Surg.* 2001;35:251-256.
11. English J, Carell E, Guidera S, Tripp H. Angiographic prevalence and clinical predictors of left subclavian stenosis in patients undergoing diagnostic cardiac catheterization. *Cathet Cardiovasc Diagn.* 2001;54:8-11.
12. Shadman R, Criqui M, Bundens W, et al. Subclavian artery stenosis: prevalence, risk factors, and association with cardiovascular diseases. *J Am Coll Cardiol.* 2004;44:618-623.
13. Feit A, Reddy C, Cowley C, et al. Internal mammary artery angiography should be a routine component of diagnostic coronary angiography. *Cathet Cardiovasc Diagn.* 1992;25:85-90.
14. Osborn L, Vernon S, Reynolds B, et al. Screening for subclavian artery stenosis in patients who are candidates for coronary bypass surgery. *Cathet Cardiovasc Diagn.* 2002;56:162-165.
15. Hass W, Fields W, North R, et al. Joint study of extracranial arterial occlusion II. Arteriography, techniques, sites and complications. *JAMA.* 1968;203:961-968.

16. Vogt D, Hertzner N, O'Hara P, Beven EG. Brachiocephalic arterial reconstruction. *Ann Surg.* 1982;196:541-552.
17. Kieffer E, Sabatier J, Koskas F, Bahnini A. Atherosclerotic innominate artery occlusive disease: early and long-term results of surgical reconstruction. *J Vasc Surg.* 1995;21:326-337.
18. Berguer R, Morasch M, Kline R, et al. Cervical reconstruction of the supra-aortic trunks: a 16 year experience. *J Vasc Surg.* 1999;29:239-246.
19. Owens L, Tinsley E, Criado E, et al. Extrathoracic reconstruction of arterial occlusive disease involving the supraaortic trunks. *J Vasc Surg.* 1995;22:217-222.
20. Bergman R, Thompson S, Afifi A, et al. *Compendium of Human Anatomic Variation: Text, Atlas and World Literature.* Baltimore, MD: Urban & Schularzenberg; 1988.
21. Mahajan A, Crowley R, Ho J, et al. Imaging the ascending aorta and aortic arch using transesophageal echocardiography: the expanded aortic view. *Echocardiography.* 2008;25:408-413.
22. Kumar K, Dorros G, Bates MC, et al. Primary stent deployment in occlusive subclavian artery disease. *Cathet Cardiovasc Diagn.* 1995;34:281-285.
23. Brountzos EN, Petersen B, Binkert C, et al. Primary stenting of subclavian and innominate artery occlusive disease: a single center's experience. *Cardiovasc Intervent Radiol.* 2004;27:616-623.
24. Przewlocki T, Kablak-Ziembicka A, Pieniazek P, et al. Determinants of immediate and long-term results of subclavian and innominate artery angioplasty. *Catheter Cardiovasc Interv.* 2006;67:519-526.
25. Patel SN, White C, Collins T, et al. Catheter-based treatment of the subclavian and innominate arteries. *Catheter Cardiovasc Interv.* 2008;71:969-971.
26. Moore TS, Russell WF, Parent AD, et al. Percutaneous transluminal angioplasty in subclavian steal syndrome: recurrent stenosis and retreatment in two patients. *Neurosurgery.* 1982;11:512-517.
27. Damuth HD Jr, Diamond AB, Rappoport AS, Renner JW. Angioplasty of subclavian artery stenosis proximal to the vertebral origin. *AJNR Am J Neuroradiol.* 1983;4:1239-1242.
28. Higashida RT, Hieshima GB, Tsai FY, et al. Percutaneous transluminal angioplasty of the subclavian and vertebral arteries. *Acta Radiol Suppl.* 1986;369:124-126.
29. Erbstein RA, Wholey MH, Smoot S. Subclavian artery steal syndrome: treatment by percutaneous transluminal angioplasty. *AJR Am J Roentgenol.* 1988;151:291-294.
30. Wilms G, Baert A, Dewaele D, et al. Percutaneous transluminal angioplasty of the subclavian artery: early and late results. *Cardiovasc Intervent Radiol.* 1987;10:123-128.
31. Henry M, Henry I, Polydorou A, et al. Percutaneous transluminal angioplasty of the subclavian arteries. *Int Angiol.* 2007;26:324-340.
32. Bates MC, Broce M, Lavigne PS, Stone P. Subclavian artery stenting: factors influencing long-term outcome. *Catheter Cardiovasc Interv.* 2004;61:5-11.
33. Al-Mubarak N, Liu MW, Dean LS, et al. Immediate and late outcomes of subclavian artery stenting. *Catheter Cardiovasc Interv.* 1999;46:169-172.
34. Lyon RD, Shonnard KM, McCarter DL, et al. Supra-aortic arterial stenoses: management with Palmaz balloon-expandable intraluminal stents. *J Vasc Interv Radiol.* 1996;7:825-835.
35. Hadjipetrou P, Cox S, Piemonte T, Eisenhauer A. Percutaneous revascularization of atherosclerotic obstruction of aortic arch vessels. *J Am Coll Cardiol.* 1999;33:1238-1245.
36. Sullivan TM, Gray BH, Bacharach JM, et al. Angioplasty and primary stenting of the subclavian, innominate, and common carotid arteries in 83 patients. *J Vasc Surg.* 1998;28:1059-1065.
37. Rodriguez-Lopez JA, Werner A, Martinez R, et al. Stenting for atherosclerotic occlusive disease of the subclavian artery. *Ann Vasc Surg.* 1999;13:254-260.
38. Mathias KD, Luth I, Haarmann P. Percutaneous transluminal angioplasty of proximal subclavian artery occlusions.

- Cardiovasc Intervent Radiol.* 1993;16:214-218.
39. Schillinger M, Haumer M, Schillinger S, et al. Risk stratification for subclavian artery angioplasty: is there an increased rate of restenosis after stent implantation? *J Endovasc Ther.* 2001;8:550-557.
  40. Boulos AS, Agner C, Deshaies EM. Preliminary evidence supporting the safety of drug-eluting stents in neurovascular disease. *Neurol Res.* 2005;27(Suppl 1):S95-102.
  41. Ewings E, Wittgen C, Paletta C. Prolonged success with a covered endovascular stent after emergent use in radiation-induced subclavian artery blowout: a case report. *Vasc Endovasc Surg.* 2008;42:187-191.
  42. Hilfiker PR, Razavi MK, Kee ST, et al. Stent-graft therapy for subclavian artery aneurysms and fistulas: single-center mid-term results. *J Vasc Interv Radiol.* 2000;11:578-584.
  43. Bates MC, Campbell J. Emergent stent graft isolation of a knife-related subclavian arterial venous fistula: lessons learned during long-term follow-up. *Catheter Cardiovasc Interv.* 2005;66:483-486.
  44. Schoder M, Cejna M, Holzenbein T, et al. Elective and emergent endovascular treatment of subclavian artery aneurysms and injuries. *J Endovasc Ther.* 2003;10:58-65.
  45. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). *J Vasc Surg.* 2000;31:S1-S296.
  46. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet.* 1996;348:1329-1339.
  47. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. *Circulation.* 2005;111:2233-2240.
  48. Bhatt DL, Kapadia SR, Bajzer CT, et al. Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. *J Invasive Cardiol.* 2001;13:767-771.
  49. McKevitt FM, Randall MS, Cleveland TJ, et al. The benefits of combined anti-platelet treatment in carotid artery stenting. *Eur J Vasc Endovasc Surg.* 2005;29:522-527.
  50. Qureshi AI, Suri MF, Ali Z, et al. Carotid angioplasty and stent placement: a prospective analysis of perioperative complications and impact of intravenously administered abciximab. *Neurosurgery.* 2002;50:466-473; discussion 473-475.
  51. Hofmann R, Kerschner K, Steinwender C, et al. Abciximab bolus injection does not reduce cerebral ischemic complications of elective carotid artery stenting: a randomized study. *Stroke.* 2002;33:725-727.
  52. Zahn R, Ischinger T, Hochadel M, et al. Glycoprotein IIb/IIIa antagonists during carotid artery stenting: results from the carotid artery stenting (CAS) registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). *Clin Res Cardiol.* 2007;96:730-737.
  53. Katzen BT, Ardid MI, MacLean AA, et al. Bivalirudin as an anticoagulation agent: safety and efficacy in peripheral interventions. *J Vasc Interv Radiol.* 2005;16:1183-1187; quiz 1187.
  54. Bush RL, Lin PH, Mureebe L, et al. Routine bivalirudin use in percutaneous carotid interventions. *J Endovasc Ther.* 2005;12:521-522.
  55. Gimelli G, Tefera G, Turnipseed WD. Vertebral artery embolic protection via ipsilateral brachial approach during left subclavian artery angioplasty and stenting—a case report. *Vasc Endovasc Surg.* 2006;40:235-238.
  56. Ringelstein EB, Zeumer H. Delayed reversal of vertebral artery blood flow following percutaneous transluminal angioplasty for subclavian steal syndrome. *Neuroradiology.* 1984;26:189-198.
  57. Kobin GS, Bergmann H Jr. Angioplasty in stenosis of the innominate artery. *Cardiovasc Intervent Radiol.* 1983;6:82-85.
  58. Gordon RL, Haskell L, Hirsch M, et al. Transluminal dilatation of the subclavian artery. *Cardiovasc Intervent Radiol.* 1985;8:14-19.
  59. De Vries JP, Jager LC, Van den Berg JC, et al. Durability of percutaneous transluminal angioplasty for obstructive lesions of proximal subclavian artery: long-term results. *J Vasc Surg.* 2005;41:19-23.

60. Motarjeme A. Percutaneous transluminal angioplasty of supra-aortic vessels. *J Endovasc Surg.* 1996;3:171-181.
61. AbuRahma AF, Bates MC, Stone P, et al. Angioplasty and stenting versus carotid-subclavian bypass for the treatment of isolated subclavian artery disease. *J Endovasc Ther.* 2007;14:698-704.
62. Palchik E, Bakken AM, Wolford HY, et al. Subclavian artery revascularization: an outcome analysis based on mode of therapy and presenting symptoms. *Ann Vasc Surg.* 2008;22:70-78.
63. Modarai B, Ali T, Dourado R, et al. Comparison of extra-anatomic bypass grafting with angioplasty for atherosclerotic disease of the supra-aortic trunks. *Br J Surg.* 2004;91:1453-1457.

## 第 102 章

1. Wityk RJ, Chang HM, Rosengart A, et al. Proximal extracranial vertebral artery disease in the New England Medical Center Posterior Circulation registry. *Arch Neurol.* 1998;55:470-478.
2. Cartlidge NE, Whisnant JP, Elveback LR. Carotid and vertebral-basilar transient cerebral ischemic attacks. A community study, Rochester, Minnesota. *Mayo Clin Proc.* 1977;52:117-120.
3. Heyman A, Wilkinson WE, Hurwitz BJ, et al. Clinical and epidemiologic aspects of vertebrobasilar and nonfocal cerebral ischemia. In: Berguer R, Bauer RB, eds. *Vertebrobasilar Arterial Occlusive Disease. Medical and Surgical Management.* New York, NY: Raven Press; 1984:27-36.
4. Whisnant JP, Cartlidge NE, Elveback LR. Carotid and vertebral-basilar transient ischemic attacks: effect of anticoagulants, hypertension, and cardiac disorders on survival and stroke occurrence—a population study. *Ann Neurol.* 1978;3:107-115.
5. Jones HR Jr, Millikan CH, Sandok BA. Temporal profile (clinical course) of acute vertebrobasilar system cerebral infarction. *Stroke.* 1980;11:173-177.
6. McDowell FH, Potes J, Groch S. The natural history of internal carotid and vertebral-basilar artery occlusion. *Neurology.* 1961;11:153-157.
7. Patrick BK, Ramirez-Lassepas M, Synder BD. Temporal profile of vertebrobasilar territory infarction. Prognostic implications. *Stroke.* 1980;11:643-648.
8. Caplan LR, Wityk RJ, Glass TA, et al. New England Medical Center Posterior Circulation registry. *Ann Neurol.* 2004;56:389-398.
9. Caplan L, Tettenborn B. Embolism in the posterior circulation. In: Berguer R, Caplan L, eds. *Vertebrobasilar Arterial Disease.* St. Louis, MO: Quality Medical; 1992:52-65.
10. Pessin M. Posterior cerebral artery disease and occipital ischemia. In: Berguer R, Caplan L, eds. *Vertebrobasilar Arterial Disease.* St. Louis, MO: Quality Medical; 1992:66-75.
11. Bauer R. Mechanical compression of the vertebral arteries. In: Berguer R, Bauer R, eds. *Vertebrobasilar Arterial Occlusive Disease: Medical and Surgical Management.* New York, NY: Raven; 1984:45-71.
12. Berguer R, Higgins R, Nelson R. Noninvasive diagnosis of reversal of vertebral-artery blood flow. *N Engl J Med.* 1980;302:1349-1351.
13. Ruotolo C, Hazan H, Rancurel G, Kieffer E. Dynamic arteriography. In: Berguer R, Caplan L, eds. *Vertebrobasilar Arterial Disease.* St. Louis, MO: Quality Medical; 1992:116-123.
14. Berguer R. Distal vertebral artery bypass: technique, the “occipital connection,” and potential uses. *J Vasc Surg.* 1985;2:621-626.
15. Berguer R, Kieffer E. *Surgery of the Arteries to the Head.* New York, NY: Springer-Verlag; 1992.
16. Edwards WH, Mulherin JL Jr. The surgical approach to significant stenosis of vertebral and subclavian arteries. *Surgery.* 1980;87:20-28.
17. Roon AJ, Ehrenfeld WK, Cooke PB, Wylie EJ. Vertebral artery reconstruction. *Am J Surg.* 1979;138:29-36.
18. Berguer R, Andaya LV, Bauer RB. Vertebral artery bypass. *Arch Surg.* 1976;111:976-979.
19. Berguer R, Bauer RB. Vertebral artery reconstruction. A successful technique in selected patients. *Ann Surg.*

- 1981;193:441-447.
20. McNamara MF, Berguer R. Simultaneous carotid-vertebral reconstruction. *J Cardiovasc Surg (Torino)*. 1989;30:161-164.
  21. Kieffer E, Rancurel G, Richart T. Reconstruction of the distal cervical vertebral artery. In: Bergeron P, Bauer RB, eds. *Vertebrobasilar Arterial Occlusive Disease: Medical and Surgical Management*. New York, NY: Raven; 1984:265-289.
  22. Berguer R. Revascularization of the vertebral arteries. In: Nyhus L, Baker R, Fischer J, eds. *Mastery of Surgery*. Boston, MA: Little, Brown; 1997:1937.
  23. Berguer R. Complex carotid and vertebral revascularizations. In: Pearce WH, Matsumura JS, Yao JST, eds. *Vascular Surgery in the Endovascular Era*. Evanston, IL: Greenwood Academic; 2008:344-352.
  24. Berguer R. Suboccipital approach to the distal vertebral artery. *J Vasc Surg*. 1999;30:344-349.
  25. Berguer R, Morasch MD, Kline RA. A review of 100 consecutive reconstructions of the distal vertebral artery for embolic and hemodynamic disease. *J Vasc Surg*. 1998;27:852-859.
  26. Thevenet A, Ruotolo C. Surgical repair of vertebral artery stenoses. *J Cardiovasc Surg (Torino)*. 1984;25:101-110.
  27. Berguer R, Flynn LM, Kline RA, Caplan L. Surgical reconstruction of the extracranial vertebral artery: management and outcome. *J Vasc Surg*. 2000;31:9-18.
  28. Cloud GC, Crawley F, Clifton A, et al. Vertebral artery origin angioplasty and primary stenting: safety and restenosis rates in a prospective series. *J Neurol Neurosurg Psychiatry*. 2003;74:586-590.
  29. Dabus G, Gerstle RJ, Derdeyn CP, et al. Endovascular treatment of the vertebral artery origin in patients with symptoms of vertebrobasilar ischemia. *Neuroradiology*. 2006;48:917-923.
  30. Hauth EA, Gissler HM, Drescher R, et al. Angioplasty or stenting of extra- and intracranial vertebral artery stenoses. *Cardiovasc Intervent Radiol*. 2004;27:51-57.
  31. Henry M, Polydorou A, Henry I, et al. Angioplasty and stenting of extracranial vertebral artery stenosis. *Int Angiol*. 2005;311-324.
  32. Janssens E, Leclerc X, Gautier C, et al. Percutaneous transluminal angioplasty of proximal vertebral artery stenosis: long-term clinical follow-up of 16 consecutive patients. *Neuroradiology*. 2004;46:81-84.
  33. Jenkins JS, White CJ, Ramee SR, et al. Vertebral artery stenting. *Catheter Cardiovasc Interv*. 2001;54:1-5.
  34. Kim HY, Kang HS, Roh HG, et al. Transient global amnesia following vertebral artery angioplasty and stenting. *Eur Neurol*. 2006;56:133-135.
  35. Levy EI, Horowitz MB, Koebbe CJ, et al. Transluminal stent-assisted angioplasty of the intracranial vertebrobasilar system for medically refractory, posterior circulation ischemia: early results. *Neurosurgery*. 2001;48:1215-1221; discussion 1221-1223.
  36. Lin YH, Liu YC, Tseng WY, et al. The impact of lesion length on angiographic restenosis after vertebral artery origin stenting. *Eur J Vasc Endovasc Surg*. 2006;32:379-385.
  37. Mukherjee D, Roffi M, Kapadia SR, et al. Percutaneous intervention for symptomatic vertebral artery stenosis using coronary stents. *J Invasive Cardiol*. 2001;13:363-366.
  38. Piotin M, Spelle L, Martin JB, et al. Percutaneous transluminal angioplasty and stenting of the proximal vertebral artery for symptomatic stenosis. *AJNR Am J Neuroradiol*. 2000;21:727-731.
  39. Wehman JC, Hanel RA, Guidot CA, et al. Atherosclerotic occlusive extracranial vertebral artery disease: indications for intervention, endovascular techniques, short-term and long-term results. *J Interv Cardiol*. 2004;17:219-232.
  40. Coward LJ, Featherstone RL, Brown MM. Percutaneous transluminal angioplasty and stenting for vertebral artery stenosis. *Cochrane Database Syst Rev*. 2005;2:CD000516.

## 第 103 章

1. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease. *JAMA*. 2001;286:1599-1606.
2. Levien LJ. Popliteal artery entrapment syndrome. *Semin Vasc Surg*. 2003;16:223-231.

3. Turnipseed WD. Diagnosis and management of chronic compartment syndrome. *Surgery*. 2002;132:613-617.
4. Kannel WB, Skinner JJ Jr, Schwartz MJ, et al. Intermittent claudication: incidence in the Framingham Study. *Circulation*. 1970;41:875-883.
5. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. *Circulation*. 1985;71:510-515.
6. Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. *Int J Epidemiol*. 1991;20:384-392.
7. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease)—Summary of Recommendations. *J Vasc Interv Radiol*. 2006;17:1383-1397.
8. Feringa HH, Jax JJ, van Waning VH, et al. The long-term prognostic value of resting and postexercise ankle-brachial index. *Arch Intern Med*. 2006;166:529-535.
9. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey 1999-2000. *Circulation*. 2004;110:738-743.
10. Collins TC, Suarez-Almazor M, Bush RL, Petersen NJ. Gender and peripheral arterial disease. *J Am Board Fam Med*. 2006;19:132-140.
11. Ostchega Y, Paulose-Ram R, Dillon CF, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. *J Am Geriatr Soc*. 2007;55:583-589.
12. Leng GC, Lee AJ, Fowkes FGR, et al. Incidence, natural history, and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. *Int J Epidemiol*. 1996;25:1172-1181.
13. Garg P, Tian L, Criqui MH, et al. Physical activity during daily life and mortality in patients with peripheral arterial disease. *Circulation*. 2006;114:242-248.
14. Jonason J, Ringqvist I. Factors of prognostic importance for subsequent rest pain in patients with intermittent claudication. *Acta Med Scand*. 1985;218:27-33.
15. Aquino R, Johnides C, Makaroun M, et al. Natural history of claudication: long-term serial follow-up study of 1244 claudicants. *J Vasc Surg*. 2001;34:962-970.
16. deVries M, Ouwendijk R, Kessels A, et al. Comparison of generic and disease-specific questionnaires for the assessment of quality of life in patients with peripheral arterial disease. *J Vasc Surg*. 2005;41:261-268.
17. Bosch JL, Hunink MGM. The relationship between descriptive and valuations quality-of-life measures in patients with intermittent claudication. *Med Decis Making*. 1996;16:217-225.
18. Dumville JC, Lee AJ, Smith FB, Fowkes FG. The health-related quality of life of people with peripheral arterial disease in the community: the Edinburgh Artery Study. *Br J Gen Pract*. 2004;54:826-831.
19. Izquierdo-Porrera AM, Gardner AW, Bradham DD, et al. Relationship between objective measures of peripheral arterial disease severity to self-reported quality of life in older patients with intermittent claudication. *J Vasc Surg*. 2005;41:625-630.
20. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. *JAMA*. 2001;286:1317-1324.
21. Muluk SC, Muluk VS, Kelley ME, et al. Outcome events in patients with claudication: a 15-year study in 2777 patients. *J Vasc Surg*. 2001;33:251-258.
22. Weatherley BD, Nelson JJ, Heiss G, et al. The association of the ankle-brachial index with incident coronary heart disease:

- the Atherosclerotic Risk in Communities (ARIC) study, 1987-2001. *BMC Cardiovasc Disord.* 2007;7:3.
23. Matzke S, Lepantalo M. Claudication does not always precede critical limb ischemia. *Vasa Med.* 2001;6:77-80.
  24. Schuler JJ, Flanigan DP, Holcroft JW, et al. Efficacy of prostaglandin E1 in the treatment of lower extremity ulcers secondary to peripheral vascular occlusive disease: results of a prospective randomized, double-blind multi-center clinical trial. *J Vasc Surg.* 1984;1:160-170.
  25. Telles GS, Campbell WE, Wood RFM, et al. Prostaglandin E1 in severe lower extremity ischaemia: a double-blind controlled trial. *Br J Surg.* 1984;71:506-508.
  26. Lepantalo M, Matzke S. Outcome of unreconstructed chronic critical leg ischaemia. *Eur J Vasc Endovasc Surg.* 1996;11:153-157.
  27. Norgren L, Alwark A, Angqvist KA, et al. A stable prostacyclin analog (Iloprost) in the treatment of ischaemic ulcers of the lower limb: a Scandinavian-Polish placebo controlled randomized multi-centre study. *Eur J Vasc Endovasc Surg.* 1990;4:463-467.
  28. Bowers BL, Valentine RJ, Myers SI, et al. The natural history of patients with claudication with toe pressures of 40 mm Hg or less. *J Vasc Surg.* 1993;18:506-511.
  29. Marston WA, Davies SW, Armstrong B, et al. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. *J Vasc Surg.* 2006;44:108-114.
  30. Wolfe JN, Wyatt MG. Critical and subcritical ischaemia. *Eur J Vasc Endovasc Surg.* 1997;13:578-582.
  31. Dormandy JA, Rutherford RB. The TransAtlantic Inter-Society Consensus on the management of peripheral arterial disease. *J Vasc Surg.* 2000;31.
  32. I.C.A.I. Group. Long-term mortality and its predictors in patients with critical limb ischaemia. *Eur J Vasc Endovasc Surg.* 1997;14:91-95.
  33. Stoffers HE, Kester AD, Kaiser V, et al. The diagnostic value of signs and symptoms associated with peripheral arterial occlusive disease in general practice: a multivariate approach. *Med Decis Making.* 1997;17:61-70.
  34. Kannel WB, McGee DL. Update on some epidemiological features of intermittent claudication. *J Am Geriatr Soc.* 1985;33:13-18.
  35. Fowkes GR, Housley E, Riemersa RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. *Am J Epidemiol.* 1992;135:331-340.
  36. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication: a risk profile from the Framingham Heart Study. *Circulation.* 1997;96:44-49.
  37. Powell JT, Edwards RJ, Worrell PC, et al. Risk factors associated with the development of peripheral arterial disease in smokers: a case control study. *Atherosclerosis.* 1997;129:41-48.
  38. McCully KS. Atherosclerosis, serum cholesterol and the homocysteine theory: a study of 194 consecutive autopsies. *Am J Med Sci.* 1990;299:217-221.
  39. Boushey CJ, Beresford SAA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. *JAMA.* 1995;274:1049-1057.
  40. Ray SA, Rowley MR, Loh A, et al. Hypercoagulable states in patients with leg ischemia. *Br J Surg.* 1994;81:811-814.
  41. Cournot M, Boccalon H, Cambou JP, et al. Accuracy of the screening physical examination to identify subclinical atherosclerosis and peripheral arterial disease in asymptomatic subjects. *J Vasc Surg.* 2007;46:1215-1221.
  42. Hirsch AT, Gotto AM Jr. Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction. *Vasc Med.* 2002;7:323-331.
  43. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. *JAMA.* 2002;287:2570-2581.
  44. Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis. *Cochrane Database Syst Rev*

- 2000;2:CD000123.
45. McDermott MM, Green D, Greenland P, et al. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. *Am J Cardiol*. 2003;92:194-199.
  46. Tzoulaki I, Murray GD, Lee AJ, et al. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. *Circulation*. 2005;112:976-983.
  47. Guillard JC, Favier A, Potier de Courcy G, et al. Hyperhomocysteinemia: an independent risk factor or a simple marker of vascular disease? *Pathol Biol*. 2003;51:101-110.
  48. Cook JW, Taylor LM, Orloff SL, et al. Homocysteine and arterial disease: experimental mechanisms. *Vasc Pharmacol*. 2002;38:293-300.
  49. Assanelli D, Grassi M, Bonanome A, et al. Premature arterial and venous events in three families: effects of folate levels and MTHFR mutation mediated by family/generation and homocysteine level. *Thromb Res*. 2002;105:109-115.
  50. Taylor LM, DeFrang RD, Harris EJ Jr, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. *J Vasc Surg*. 1991;13:128-136.
  51. Valentine RJ, Kaplan HS, Green R, et al. Lipoprotein (a), homocysteine, and hypercoagulable state in young men with premature peripheral atherosclerosis: a prospective, controlled analysis. *J Vasc Surg*. 1996;23:53-63.
  52. Darius H, Pittrow D, Haberl R, et al. Are elevated homocysteine plasma levels related to peripheral arterial disease? Results from a cross-sectional study of 6880 primary care patients. *Eur J Clin Invest*. 2003;33:751-757.
  53. Tofler GH, D'Agostino RB, Jacques PF, et al. Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk. *Thromb Hemost*. 2002;88:799-804.
  54. Hooi JD, Stoffers HE, Kester AD, et al. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease. The Limburgh PAOD study. *Scand J Prim Health Care*. 1998;16:177-182.
  55. Mukherjee D, Lingam P, Chetcuti S, et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-Q12). *Circulation*. 2002;106:1909-1912.
  56. Sonecha TN, Delis KT. Prevalence and distribution of coronary artery disease in claudicants using 12-lead precordial stress electrocardiography. *Eur J Vasc Endovasc Surg*. 2003;25:519-526.
  57. Fleisher LA, Beckman JA, Brown KA, et al. Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Writing Committee to revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery]. *J Am Coll Cardiol*. 2007;50:1707-1732.
  58. Pasternack PF, Imperato AM, Riles TS, et al. The value of the radionuclide angiogram in the prediction of perioperative myocardial infarction in patients undergoing lower extremity revascularization procedures. *Circulation*. 1985;72:1113-1117.
  59. Gentile AT, Taylor LM Jr, Moneta GL, Porter JM. Prevalence of asymptomatic carotid stenosis in patients undergoing infrainguinal bypass surgery. *Arch Surg*. 1995;130:900-904.
  60. De Virgilio C, Toosie K, Arnell T, et al. Asymptomatic carotid artery stenosis screening in patients with lower extremity atherosclerosis: a prospective study. *Ann Vasc Surg*. 1997;11:374-377.
  61. Wolf YG, Otis SM, Schwend RB, Bernstein EF. Screening for abdominal aortic aneurysms during lower extremity arterial evaluation in the vascular laboratory. *J Vasc Surg*. 1995;22:417-421.
  62. Cornuz J, Sidoti Pinto C, Tevaearai H, Egger M. Risk factors for asymptomatic abdominal aortic aneurysm: systematic review and meta-analysis of population-based screening studies. *Eur J Public Health*. 2004;14:343-349.
  63. Alund M, Mani K, Wanhainen A. Selective screening for abdominal aortic aneurysm among patients referred to the vascular laboratory. *Eur J Vasc Endovasc Surg*. 2008;35:669-674.
  64. Gahtan V. The noninvasive laboratory. *Surg Clin North Am*. 1998;78:507-518.
  65. Nordness P, Money S. Evaluation of claudication. In: Mansour MA, Labropoulos N, eds. *Vascular Diagnosis*. Philadelphia: Elsevier, Inc.; 2004.



66. Cossman DV, Ellison JE, Wagner WH, et al. Comparison of contrast arteriography to arterial mapping with color-flow duplex imaging in the lower extremities. *J Vasc Surg*. 1989;10:522-528.
67. Aly S, Sommerville K, Adiseshiah M, et al. Comparison of duplex imaging and arteriography in the evaluation of lower limb arteries. *Br J Surg*. 1998;85:1099-1102.
68. Wain RA, Berdejo GL, Delvalle WN, et al. Can duplex scan arterial mapping replace contrast arteriography as the test of choice before infrainguinal revascularization? *J Vasc Surg*. 1999;29:100-107.
69. Ascher E, Hingorani A, Markevich N, et al. Lower extremity revascularization without preoperative contrast arteriography: experience with duplex ultrasound arterial mapping in 485 cases. *Acta Radiol*. 2000;41:125-132.
70. Lundin P, Svensson A, Henriksen E, et al. Imaging of aortoiliac arterial disease: duplex ultrasound and MR angiography versus digital subtraction angiography. *Acta Radiol*. 2000;41:125-132.
71. Bonn J. Percutaneous vascular interventions: the value of hemodynamic measurements. *Radiology*. 1996;201:18-20.
72. Bettmann MA, Heeren T, Greenfield A, et al. SCVIR contrast agent registry report. *Radiology*. 1997;203:611-620.
73. Waugh JR, Sacharias N. Arteriographic complications in the DSA era. *Radiology*. 1992;182:243-246.
74. Kreitner KF, Kalden P, Neufang A, et al. Diabetes and peripheral arterial occlusive disease: prospective comparison of contrast-enhanced three-dimensional MR angiography with conventional digital subtraction angiography. *Am J Radiol*. 2000;174:171-179.
75. Lundin P, Svensson A, Henriksen E, et al. Imaging of aortoiliac disease: duplex ultrasound and MR angiography versus digital subtraction angiography. *Acta Radiol*. 2000;41:125-132.
76. Koelemay MJ, Lijmer JG, Stoker J, et al. Magnetic resonance angiography for the evaluation of lower extremity arterial disease: a meta-analysis. *JAMA*. 2001;285:1338-1345.
77. Sam AD, Morasch MD, Collins J, et al. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. *J Vasc Surg*. 2003;38:313-318.
78. Othersen JB, Maize JC, Woolson RF, Budisavlievic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. *Nephrol Dial Transplant*. 2007;22:3179-3185.
79. Heijenbrok-Kal MH, Kock MC, Hunink MG. Lower extremity arterial disease: multidetector CT angiography—meta-analysis. *Radiology*. 2007;245:433-439.
80. Willmann JK, Baumert B, Schertler T, et al. Aortoiliac and lower extremity arteries assessed with 16-detector row CT angiography: prospective comparison with digital subtraction angiography. *Radiology*. 2005;236:1083-1093.
81. Ota H, Takase K, Igarashi K, et al. MDCT compared with digital subtraction angiography for assessment of lower extremity arterial occlusive disease: importance of reviewing cross-sectional images. *Am J Roentgenol*. 2004;182:201-209.
82. Ouwendijk R, Kock MC, van Dijk LC, et al. Vessel wall calcifications at multi-detector row CT angiography in patients with peripheral arterial disease: effect on clinical utility and clinical predictors. *Radiology*. 2006;241:603-608.
83. Back MR, Caridi JG, Hawkins IF, Seeger JM. Angiography with carbon dioxide (CO<sub>2</sub>). *Surg Clin North Am*. 1998;78:575-591.
84. Visser K, Kuntz KM, Donaldson MC, et al. Pretreatment imaging workup for patients with intermittent claudication: a cost-effectiveness analysis. *J Vasc Interv Radiol*. 2003;14:53-62.
85. Collins R, Cranny G, Burch J, et al. Duplex ultrasonography, magnetic resonance angiography, and computerized tomography for the diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review. *BMJ*. 2007;334:1257.
86. Antiplatelet Trialists. Collaborative review of randomized trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ*. 1994;308:81-106.
87. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002;324:71-86.
88. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial

- disease in the CARISMA trial. *J Am Coll Cardiol*. 2007;49:1982-1988.
89. Kabir Z, Connolly GN, Clancy L, et al. Coronary heart disease deaths and decreased smoking prevalence in Massachusetts, 1993-2003. *Am J Public Health*. 2008;98:1468-1469.
  90. Willigendael EM, Teijink JA, Bartelink ML, et al. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. *J Vasc Surg*. 2005;42:67-74.
  91. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking and smoking cessation in relation to mortality in women. *JAMA*. 2008;299:2037-2047.
  92. Grundy SM, Cleeman JI, Brewer HB Jr, et al. Implications of recent clinical trials for the National Cholesterol Education Program. Adult Treatment Panel III Guidelines. *J Am Coll Cardiol*. 2004;44:720-732.
  93. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. *Arch Intern Med*. 1991;151:1705-1707.
  94. Norgren L, Hiatt WR, Dormandy JA, et al. Fowkes FGR on behalf of the TASC II Working Group. Inter-Society Consensus for the management of peripheral arterial disease (TASC II). *J Vasc Surg*. 2007;45:S5-S67.

## 第 104 章

1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. *Circulation*. 2004;110:738-743.
2. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg*. 2007;45(Suppl S):S5-S67.
3. O'Riordan DS, O'Donnell JA. Realistic expectations for the patient with intermittent claudication. *Br J Surg*. 1991;78:861-863.
4. Cox GS, Hertzner NR, Young JR, et al. Non-operative treatment of superficial femoral artery disease: long term follow-up. *J Vasc Surg*. 1993;17:172-181.
5. Muluk SC, Muluk VS, Kelley ME, et al. Outcome events in patients with claudication: a 15 year study in 2777 patients. *J Vasc Surg*. 2001;33:251-257.
6. Hirsch A, Criqui M, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness and treatment in primary care. *JAMA*. 2001;286:1317-1324.
7. Bhatt D, Steg P, Ohman E, et al. International prevalence, recognition, and treatment of cardiovascular risk factors and outpatients with atherothrombosis. *JAMA*. 2006;295:180-189.
8. Hirsch AT, Murphy TP, Lovell MB, et al. Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey. *Circulation*. 2007;116:2086-2094.
9. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. *N Engl J Med*. 2001;344:1608-1621.
10. Hawkey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. *JAMA*. 2006;295:547-553.
11. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg*. 2007;45(Suppl S):S14.
12. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg*. 2007;45(Suppl S):S30.
13. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease: the San Luis Valley Diabetes Study. *Circulation*. 1995;91:1472-1479.
14. Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication: a risk profile from The Framingham Heart Study. *Circulation*. 1997;96:44-49.
15. Vogt MT, Cauley JA, Kuller LH, et al. Prevalence and correlates of lower extremity arterial disease in elderly women. *Am J Epidemiol*. 1993;137:559-568.
16. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of

Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S9.

17. Creager MA, Jones DW, Easton JD. Atherosclerotic Vascular Disease Conference: Writing Group V: Medical decision making and therapy. *Circulation.* 2004;109:2634-2642.
18. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. *Acta Med Scand.* 1987;221:253-260.
19. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. *Med J Aust.* 1983;1:217-219.
20. Couch NP. On the arterial consequences of smoking. *J Vasc Surg.* 1986;3:807-812.
21. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of smoking cessation intervention on 1, 4, 5-year mortality: a randomized clinical trial. *Ann Intern Med.* 2005;142:233-239.
22. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S15.
23. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. *Eur Heart J.* 2003;24:946-955.
24. Gonzales D, Rennard SI, Nides M, et al. Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA* 2006;296:47-55.
25. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. *JAMA.* 1979;241:2035-2038.
26. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham study. *J Am Geriatr Soc.* 1985;33:13-18.
27. Kannel WB, D'Agostino RB, Wilson PW, et al. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. *Am Heart J.* 1990;120:672-676.
28. Hooi JD, Kester AD, Stoffers HE, et al. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. *Am J Epidemiol.* 2001;153:666-672.
29. American Diabetes Association. Peripheral arterial disease in people with diabetes. *Diabetes Care.* 2003;26:3333-3341.
30. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. *Am J Cardiol.* 1995;75:894-903.
31. Nathan DM, Lachin J, Cleary P, et al; Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. *N Engl J Med.* 2003;348:2294-2303.
32. Adler AI, Stevens RJ, Neil A, et al. UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. *Diabetes Care.* 2002;25:894-899.
33. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S17.
34. Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. *Am Heart J.* 2002;143:961-965.
35. Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. *Atherosclerosis.* 2004;172:95-105.
36. Chobanian AV, Bakris GL, Black HR, et al. seventh report of the Joint National Committee on Prevention, Detection, Valuation, and Treatment of High Blood Pressure. *Hypertension.* 2003;42:1206-1252.
37. ESH/ESC European Society of Hypertension—European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens.* 2003;21:1000-1053.
38. Mehler PS, Coll JR, Estacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. *Circulation.* 2003;107:753-756.

39. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*. 2000;342:145-153.
40. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. *Lancet*. 1986;2:933-936.
41. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. *N Engl J Med*. 1990;322:1700-1707.
42. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. *Circulation*. 1989;79:8-15.
43. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360:7-22.
44. Moreno PR, Fuster V. The year in atherothrombosis. *J Am Coll Cardiol*. 2004;44:2099-2110.
45. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344:1383-1389.
46. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med*. 1998;339:1349-1357.
47. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360:7-22.
48. Feringa HH, Karagiannis SE, van Waning VH, et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. *J Vasc Surg*. 2007;45:936-943.
49. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. *Circulation*. 2004;110:3512-3517.
50. Mohler ER III, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. *Circulation*. 2003;108:1481-1486.
51. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention and clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Atherosclerosis*. 2004;173:381-391.
52. Grundy SM, Cleeman JI, Merz CN, et al. Applications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004;110:227-239.
53. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and American College of Cardiology. *Circulation*. 2001;104:1577-1579.
54. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg*. 2007;45(Suppl S):S16.
55. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *JAMA*. 1995;274:1049-1057.
56. Wald DS, Bishop L, Wald NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. *Arch Intern Med*. 2001;161:695-700.
57. Robinson K, Arheart K, Refsum H, et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. *Circulation*. 1998;97:437-443.
58. Refsum H, Ueland PM, Nygård O, et al. Homocysteine and cardiovascular disease. *Annu Rev Med*. 1998;49:31-62.
59. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent

- stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. *JAMA*. 2004;291:565-575.
60. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al. Secondary prevention with folic acid: effects on clinical outcomes. *J Am Coll Cardiol*. 2003;41:2105-2113.
  61. Wronce EM, Hornberger JM, Zehnder JL, et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. *J Am Soc Nephrol*. 2004;15:420-426.
  62. ATC. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. *BMJ*. 1994;308:81-106.
  63. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet*. 1996;348:1329-1339.
  64. Neri Serneri GG, Coccheri S, Marubini E, et al; Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. *Eur Heart J*. 2004;25:1845-1852.
  65. Stewart KJ, Hiatt WR, Regensteiner JG, et al. Exercise training for claudication. *N Engl J Med*. 2002;347:1941-1951.
  66. Laufs U, Werner N, Link A, et al. Physical training increases collateral-dependent muscle flow in aged rats. *Am J Physiol*. 1990;258:H759-H765.
  67. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. *JAMA*. 1995;274:975-980.
  68. Aquino R, Johnnides C, Makaroun M, et al. Natural history of claudication: long term follow-up study of 1244 claudicants. *J Vasc Surg*. 2001;34:962-970.
  69. Sakamoto S, Yokyama N, Kasai S, et al. Long-term clinical outcome of supervised exercise rehabilitation among patients with peripheral arterial disease. *J Am Coll Cardiol*. 2007;49:351A.
  70. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery, Society for Vascular Surgery, Society for Cardiovascular Angiography and Intervention, Society for Vascular Medicine and Biology, Society for Interventional Radiology and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *J Am Coll Cardiol*. 2006;47:1239-1312.
  71. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg*. 2007;45(Suppl S):S27.
  72. Samlaska CP, Winfield EA. Pentoxifylline. *J Am Acad Dermatol*. 1994;30:604-621.
  73. Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. *Am Heart J*. 1982;104:66-72.
  74. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. *Am J Med*. 2000;109:523-530.
  75. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. *CMAJ*. 1996;155:1053-1059.
  76. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. *Circulation*. 1999;100:21-26.
  77. Barnett AH, Bradbury AW, Brittenden J, et al. The role of cilostazol in the treatment of intermittent claudication. *Curr Med*

*Res Opin.* 2004;20:1661-1670.

78. Regensteiner J, Ware JJ, McCarthy W, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. *J Am Geriatr Soc.* 2002;50:1939-1946.
79. Lee TM, Su SF, Tsai CH, et al. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. *Clin Sci (Lond).* 2001;101:305-311.
80. Moody AP, al-Khaffaf HS, Leher P, et al. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. *J Cardiovasc Pharmacol.* 1994;23:S44-S47.
81. Leher P, Comte S, Gamand S, et al. Naftidrofuryl in intermittent claudication: a retrospective analysis. *J Cardiovasc Pharmacol.* 1994;23:S48-S52.
82. Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. *Am J Med.* 2001;110:616-622.
83. Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. *Am J Med.* 2003;114:359-364.
84. Mohler ER III, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. *Circulation.* 2003;108:1481-1486.
85. De Backer TL, Vander Stichele RH, Bogaert MG. Buflomedil for intermittent claudication. *Cochrane Database Syst Rev.* 2001;CD000988.
86. De Backer TL, Vander Stichele RH, Warie HH, et al. Oral vasoactive medication in intermittent claudication: utile or futile? *Eur J Clin Pharmacol.* 2000;56:199-206.
87. Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. *Vasc Med.* 2000;5:11-19.
88. Böger RH, Bode-Böger SM, Thiele W, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. *J Am Coll Cardiol.* 1998;32:1336-1344.
89. PACK Claudication Substudy Investigators. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants. Changes in claudication distance and ankle systolic pressure. PACK Claudication Substudy. *Circulation.* 1989;80:1544-1548.
90. Belch J, Bell P, Creissen D, et al. Randomized, placebo-controlled, double-blind study of evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug in patients with intermittent claudication. *Circulation.* 1997;95:2298-2302.
91. Diehm C, Balzer K, Bisler H, et al. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double-blind trial. *J Vasc Surg.* 1997;25:537-544.
92. Lièvre M, Morand S, Besse B, et al. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. *Circulation.* 2000;102:426-431.
93. Mohler ER III, Hiatt WR, Olin JW, et al. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. *J Am Coll Cardiol.* 2003;41:1679-1686.
94. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): A randomised trial. *Lancet.* 2000;355:346-351.
95. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S29.
96. Labropoulos N, Leon LR Jr, Bhatti A, et al. Hemodynamic effects of intermittent pneumatic compression in patients with critical limb ischemia. *J Vasc Surg.* 2005;42:710-716.

97. TASC. Management of Peripheral Arterial Disease (PAD) Transatlantic Inter-Society Consensus (TASC). *J Vasc Surg.* 2000;31:S23.
98. Kavros SJ, Delis KT, Turner NS, et al. Improving limb salvage in critical ischemia with intermittent pneumatic compression: a controlled study with 18-month follow-up. *J Vasc Surg.* 2008;47:543-549.
99. Opie SR, Dib N. Local endovascular delivery, gene therapy, and cell transplantation for peripheral arterial disease. *J Endovasc Ther.* 2004;11(Suppl 2):II151-II162.
100. Tongers J, Roncalli JG, Losordo DW. Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. *Circulation.* 2008;118:9-16.
101. Rajagopalan S, Mohler EI, Lederman R, et al. Regional angiogenesis with vascular endothelial growth factor peripheral arterial disease: a phase II randomized double-blind control study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. *Circulation.* 2003;108:1933-1938.
102. Lederman RJ, Mendelsohn FO, Anderson RD, et al; TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. *Lancet.* 2002;359:2053-2058.
103. Nikol S, Baumgartner I, Van Belle E, et al; TALISMAN 201 Investigators. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. *Mol Ther.* 2008;16:972-978.
104. Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. *Circulation.* 2008;118:58-65.
105. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis using cell transplantation (TACT) study investigators. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone marrow cells; a pilot study and a randomized controlled trial. *Lancet.* 2002;360:427-435.
106. TASC. Management of Peripheral Arterial Disease (PAD) Transatlantic Inter-Society Consensus (TASC). *J Vasc Surg.* 2000;31:S1-S287.
107. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S25-S35.
108. Schadt DC, Hines EA Jr, Juergens JL, et al. Chronic atherosclerotic occlusion of the femoral artery. *JAMA.* 1961;175:937-940.
109. McAllister FF. The fate of patients with intermittent claudication managed nonoperatively. *Am J Surg.* 1976;132:593-595.
110. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S10.
111. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S15.
112. Whyman MR, Fowkes FG, Kerracher EM, et al. Is intermittent claudication improved by percutaneous transluminal angioplasty? A randomized controlled trial. *J Vasc Surg.* 1997;26:551-557.
113. Taylor SM, Kalbaugh CA, Healy MG, et al. Do current outcomes justify more liberal use of revascularization for vasculogenic claudication? A single center experience of 1000 consecutively treated limbs. *J Am Coll Surg.* 2008;6:1053-1064.
114. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S25.
115. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S47-S53.
116. Johnston KW, Rae M, Hogg-Johnston SA, et al. 5-year results of a prospective study of percutaneous transluminal angioplasty. *Ann Surg.* 1987;206:403-413.

117. Taylor SM, Kalbaugh CA, Gray BH, et al. The LEGS Score: a proposed scoring system to direct treatment of chronic lower extremity ischemia. *Ann Surg.* 2003;237:812-819.
118. Kalbaugh CA, Taylor SM, Cull DL, et al. Invasive treatment of chronic limb ischemia according to the Lower Extremity Grading System (LEGS) score: a 6-month report. *J Vasc Surg.* 2004;39:1268-1276.
119. Androes MP, Kalbaugh CA, Taylor SM, et al. Does a standardization tool to direct invasive therapy for symptomatic lower extremity peripheral arterial disease improve outcomes? *J Vasc Surg.* 2004;40:907-915.
120. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S29-S30.
121. The I.C.A.I. Group. Long-term mortality as predictors in patients with critical leg ischemia. *Eur J Vasc Endovasc Surg.* 1997;14:91-95.
122. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S38-S39.
123. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S23.
124. Taylor SM, Kalbaugh CA, Blackhurst DW, et al. Preoperative clinical factors predict postoperative functional outcomes after major lower limb amputation: an analysis of 553 consecutive patients. *J Vasc Surg.* 2005;42:227-235.
125. Taylor SM, Kalbaugh CA, Blackhurst DW, et al. Determinants of functional outcome after revascularization for critical limb ischemia: an analysis of 1000 consecutive vascular interventions. *J Vasc Surg.* 2006;44:747-756.
126. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S47-S60.
127. Alber M, Romiti M, Brochado-Neto FC, Pereira CAB. Meta-analysis of alternate autogenous vein bypass grafts to infrapopliteal arteries. *J Vasc Surg.* 2005;42:449-455.
128. Wolfle KD, Bruijnen H, Loeprecht H, et al. Graft patency and clinical outcome of femorodistal arterial reconstruction in diabetic and non-diabetic patients: results of a multi-centre comparative analysis. *Eur J Vasc Endovasc Surg.* 2003;25:229-234.
129. van der Zaag ES, Legemate DA, Prins MH, et al. Angioplasty or bypass for superficial femoral artery disease? A randomised controlled trial. *Eur J Vasc Endovasc Surg.* 2004;28:32-37.
130. Hobbs SD, Yapanis M, Burns PJ, et al. Peri-operative myocardial injury in patients undergoing surgery for critical limb ischaemia. *Eur J Vasc Endovasc Surg.* 2005;29:301-304.
131. Visser K, Idu MM, Buth J, et al. Duplex scan surveillance during the first year after infrainguinal autogenous vein bypass grafting surgery: cost and clinical outcomes compared with other surveillance programs. *J Vasc Surg.* 2001;33:123-130.
132. Wixon CL, Mills JL, Westerband A, et al. An economic appraisal of lower extremity bypass graft maintenance. *J Vasc Surg.* 2000;32:1-12.
133. Davies AH, Hawdon AJ, Sydes MR, Thompson SG. Is duplex scan surveillance of value after leg bypass grafting? Principal results of the Vein Graft Surveillance Randomized Trial (VGST). *Circulation.* 2005;112:1985-1991.
134. Giswold ME, Landry GJ, Sexto GJ, et al. Modifiable patient factors are associated with reverse vein graft occlusion in the era of duplex scan surveillance. *J Vasc Surg.* 2003;37:47-53.
135. Nguyen LL, Conte MS, Menard MT, et al. Infrainguinal vein bypass graft revision: factors affecting long term outcome. *J Vasc Surg.* 2004;40:916-923.
136. Papavassiliou VG, Walker SR, Bolia A, et al. Techniques for the endovascular management of complications following lower limb percutaneous transluminal angioplasty. *Eur J Vasc Endovasc Surg.* 2003;25:125-130.
137. Lipsitz EC, Ohki T, Veith FJ, et al. Fate of collateral vessels following subintimal angioplasty. *J Endovasc Ther.* 2004;11:269-273.
138. Lipsitz EC, Veith FJ, Ohki T. The value of subintimal angioplasty in the management of critical lower extremity ischemia:



failure is not always associated with a rethreatened limb. *J Cardiovasc Surg*. 2004;45:231-237.

139. Bradberry AW; BASIL Trial Participants. Bypass versus angioplasty in severe ischemia of the leg (BASIL): multicenter, randomized controlled trial. *Lancet*. 2005;366:1925-1934.
140. Mills JL Sr. Open bypass and endoluminal therapy: complementary techniques for revascularization in diabetic patients with critical limb ischemia. *Diabetes Metab Res Rev*. 2008;24(Suppl 1):S34-S39.
141. Landry GJ. Functional outcome of critical limb ischemia. *J Vasc Surg*. 2007;45:141A-148A.
142. Nehler MR, Hiatt WR, Taylor LM. Is revascularization and limb salvage always the best treatment for critical limb ischemia. *J Vasc Surg*. 2003;37:704-708.
143. Abou-Zamzam AM Jr, Lee RW, Moneta GI, et al. Functional outcome after infrainguinal bypass for limb salvage. *J Vasc Surg*. 1997;25:287-297.
144. Nicoloff AD, Taylor LM Jr, McLafferty RB, et al. Patient recovery after infrainguinal bypass grafting for limb salvage. *J Vasc Surg*. 1998;27:256-266.
145. Goshima KR, Mills JL, Hughes JD. A new look at outcomes after infrainguinal bypass surgery: traditional reporting standards systematically underestimate the expenditure of effort required to attain limb salvage. *J Vasc Surg*. 2004;29:330-335.
146. Feinglass J, McCarthy WJ, Slavensky R, et al. Functional status and walking ability after lower extremity bypass grafting or angioplasty for intermittent claudication: results from a prospective outcomes study. *J Vasc Surg*. 2000;31:93-103.
147. Kalbaugh CA, Taylor SM, Blackhurst DW. One year prospective quality-of-life outcomes in patients treated with angioplasty for symptomatic peripheral arterial disease. *J Vasc Surg*. 2006;44:296-303.
148. Kukkonen T, Junnila J, Aittola V, Mäkinen K. Functional outcome of distal bypasses for lower limb ischemia. *Eur J Vasc Endovasc Surg*. 2006;31:258-261.
149. Tangelder MJD, McDonnell J, Van Busschbach JJ, et al. Quality of life after infrainguinal bypass grafting surgery. *J Vasc Surg*. 2002;29:913-919.
150. Nguyen LL, Moneta GL, Conte MS, et al. Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical ischaemia. *J Vasc Surg*. 2006;44:977-984.
151. Holtzman J, Caldwell M, Walvatne C, Kane R. Long-term functional status and quality of life after lower extremity revascularization. *J Vasc Surg*. 1999;29:395-402.
152. Litwin MS. Health-related quality of life. In: Penson DF, Wie JT, eds. *Clinical research methods for surgeons*. Totowa, NJ: Humana Press; 2006:237-253.
153. deVries M, Ouwendijk R, Kessels AG, et al. Comparison of generic and disease-specific questionnaires for the assessment of quality of life in patients with peripheral arterial disease. *J Vasc Surg*. 2005;41:261-268.
154. Morgan MBF, Crayford T, Murrin B, et al. Developing the vascular quality-of-life questionnaire: a new disease specific quality-of-life measure for the use of lower extremity ischemia. *J Vasc Surg*. 2001;33:679-687.
155. Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. *J Vasc Surg*. 2006;43:742-751.
156. Taylor SM, Cull DL, Kalbaugh CA, et al. Critical analysis of clinical success after surgical bypass for lower extremity ischemic tissue loss using a standardized definition combining multiple parameters: a new paradigm of outcome assessment. *J Am Coll Surg*. 2007;204:831-839.
157. Kleivsgard R, Hallberg IR, Risberg B, Thomsen MB. Quality of life associated with varying degrees of chronic lower limb ischaemia: comparison with a healthy sample. *Eur J Vasc Endovasc Surg*. 1999;17:319-325.
158. Johnson BF, Evans L, Drury R, et al. Surgery for limb threatening ischaemia: a reappraisal of the costs and benefits. *Eur J Vasc Endovasc Surg*. 1995;9:181-188.
159. Luther M. Surgical treatment for chronic critical leg ischaemia: a 5 year follow-up of socioeconomic outcome. *Eur J Vasc Endovasc Surg*. 1997;13:452-459.

160. Cheshire NJ, Wolfe JH, Noone MA, et al. The economics of femorocrural reconstruction for critical leg ischemia with and without autologous vein. *J Vasc Surg.* 1992;15:167-174.
161. Sullivan TM, Taylor SM, Blackhurst DW, et al. Has endovascular surgery reduced the number of open vascular operations performed by an established surgical practice? *J Vasc Surg.* 2002;36:514-519.

## 第 105 章

1. Gray EA. *Portrait of a surgeon. A biography of John Hunter.* London: Robert Hale; 1952.
2. dos Santos JC. Sur la desobstion des thromboses arterielles anciennes. *Mem Acad Chir.* 1947;73:409.
3. Wylie EJ, Kerr E, Davies O. Experimental and clinical experiences with the use of fascia lata applied as a graft about major arteries after thromboendarterectomy and aneurysmorrhaphy. *Surg Gynecol Obstet.* 1951;93:257.
4. Back MR, Johnson BL, Shames ML, et al. Evolving complexity of open aortofemoral reconstruction done for occlusive disease in the endovascular era. *Ann Vasc Surg.* 2003;17:596.
5. Imparata AM, Kim G, Davidson T, et al. Intermittent claudication: its natural course. *Surgery.* 1975;78:795.
6. Starrett RW, Stoney RJ. Juxta-renal aortic occlusion. *Surgery.* 1974;76:890.
7. Reilly LM, Sauer L, Weinstein ES, et al. Infrarenal aortic occlusion: does it threaten renal perfusion or function? *J Vasc Surg.* 1990;11:216.
8. Wingo JP, Nix ML, Greenfield LJ, Barnes RW. The blue toe syndrome: hemodynamic and therapeutic correlates of outcome. *J Vasc Surg.* 1986;3:475.
9. Karmody AM, Powers SR, Monaco VJ, et al. "Blue toe" syndrome. *Arch Surg.* 1976;111:1263.
10. Darling RC, Brewster DC, Hallett JW Jr, et al. Aortoiliac reconstruction. *Surg Clin North Am.* 1979;59:565.
11. Malone JM, Moore WS, Goldstone J. Life expectancy following aortofemoral arterial grafting. *Surgery.* 1977;81:551.
12. Brewster DC, Perler BA, Robison JG, et al. Aortofemoral graft for multilevel occlusive disease: predictors of success and need for distal bypass. *Arch Surg.* 1982;117:1593.
13. Krug RT, Calligaro KD, Dougherty MJ. Claudication in the young patient. *Perspect Vasc Surg.* 2000;13:27.
14. Cronenwett JL, Davis JT, Gooch JB, et al. Aortoiliac occlusive disease in women. *Surgery.* 1980;88:775.
15. Caes F, Cham B, Van den Brande P, et al. Small artery syndrome in women. *Surg Gynecol Obstet.* 1985;161:165.
16. Flanagan DP, Schuler JJ, Keifer T, et al. Elimination of iatrogenic impotence and improvement of sexual dysfunction after aortoiliac revascularization. *Arch Surg.* 1982;117:544.
17. Leriche R, Morel A. The syndrome of thrombotic obliteration of the aortic bifurcation. *Ann Surg.* 1948;127:193.
18. Berman JR, Berman LA, Goldstein I. Female sexual dysfunction: incidence, pathophysiology, evaluation and treatment options. *Urology.* 1999;54:385.
19. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease. *J Am Coll Cardiol.* 2006;47:1239.
20. Yao JST. Hemodynamic studies in peripheral arterial disease. *Br J Surg.* 1970;57:761.
21. Radermacher J, Chavan A, Bleck J, et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. *N Engl J Med.* 2001;344:410.
22. Platt JF. Doppler ultrasound of the kidney. *Semin Ultrasound CT MR.* 1997;18:22.
23. Soares GM, Murphy TP, Singha MS, et al. Renal artery duplex ultrasonography as a screening and surveillance tool to detect renal artery stenosis: a comparison with current reference standard imaging. *J Ultrasound Med.* 2006;25:293.
24. Holland GA, Dougherty L, Carpenter JP, et al. Breath-hold ultrafast three-dimensional gadolinium-enhanced MR angiography of the aorta and renal and other visceral abdominal arteries. *AJR Am J Roentgenol.* 1996;166:971.
25. Gaa J, Laub G, Edelman RR, et al. [First clinical results of ultrafast, contrast-enhanced 2-phase 3D-angiography of the abdomen.] *Rofo.* 1998;169:135.
26. Adriaansen ME, Kock MC, Stijnen T, et al. Peripheral arterial disease: therapeutic confidence of CT versus digital

- subtraction angiography and effects on additional imaging recommendations. *Radiology*. 2004;233:385.
27. Catalano C, Fraioli F, Laghi A, et al. Infra renal aortic and lower extremity arterial disease: diagnostic performance of multi-detector row CT angiography. *Radiology*. 2004;231:555.
  28. Bostrom AA, Karacagil S, Hellberg A, et al. Surgical reconstruction without preoperative angiography in patients with aortoiliac occlusive disease. *Ann Vasc Surg*. 2002;16:273.
  29. Koelemay MJ, Lijmer JG, Stoker J, et al. Magnetic resonance angiography for the evaluation of lower extremity arterial disease: a meta-analysis. *JAMA*. 2001;285:1338.
  30. Armstrong P, Han D, Baxter J, et al. Complication rates of percutaneous brachial artery access in peripheral vascular angiography. *Ann Vasc Surg*. 2003;17:107.
  31. Udoff EJ, Barth KH, Harrington DP, et al. Hemodynamic significance of iliac artery stenosis: pressure measurements during angiography. *Radiology*. 1979;132:289.
  32. Brewster DC. Current controversies in the management of aortoiliac occlusive disease. *J Vasc Surg*. 1997;25:365.
  33. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg*. 2007;45:S5A.
  34. Upchurch GR, Dimick JB, Wainess RM, et al. Diffusion of new technology in health care: the case of aorto-iliac occlusive disease. *Surgery*. 2004;136:812.
  35. Knipp BS, Dimick JB, Eliason JL, et al. Diffusion of new technology for the treatment of renovascular hypertension in the United States: surgical revascularization versus catheter-based therapy, 1988-2001. *J Vasc Surg*. 2004;40:717.
  36. Hertzner NR, Bena JF, Karafa MT. A personal experience with direct reconstruction and extra-anatomic bypass for aortobifemoral occlusive disease. *J Vasc Surg*. 2007;45:527.
  37. Chang RW, Goodney PP, Baek JH, et al. Long-term results of combined common femoral endarterectomy and iliac stenting/stent grafting for occlusive disease. *J Vasc Surg*. Jun: epub, 2008.
  38. Dawber TR. *Framingham Study*. London: Harvard University Press; 1980.
  39. Walsh DB, Gilbertson JJ, Zwolak RM, et al. The natural history of superficial femoral artery stenoses. *J Vasc Surg*. 1991;14:299.
  40. Rutherford RB. Evaluation and selection of patients for vascular interventions. In: *Vascular Surgery*. 5th ed. Philadelphia, PA: Saunders; 2000.
  41. Boyd AM. The natural course of the arteriosclerosis of the lower extremities. *Proc R Soc Med*. 1962;55:591.
  42. Chaer RA, Faries PL, Lin S, et al. Successful percutaneous treatment of gluteal claudication secondary to isolated bilateral hypogastric stenoses. *J Vasc Surg*. 2006;43:165.
  43. Halperin JL. Evaluation of patients with peripheral vascular disease. *Thromb Res*. 2002;106:303-311.
  44. Illuminati G, Bresadola L, D'Urso A, et al. Simultaneous stent grafting of the descending thoracic aorta and aortofemoral bypass for "shaggy aorta" syndrome. *Can J Surg*. 2007;10:50.
  45. Reed AB, Conte MS, Donaldson MC, et al. The impact of patient age and aortic size on the results of aortobifemoral bypass grafting. *J Vasc Surg*. 2003;37:1219.
  46. Lawrence VA, Page CP, Harris GD. Preoperative spirometry before abdominal operations. A critical appraisal of its predictive value. *Arch Intern Med*. 1989;149:280.
  47. Hertzner NR, Beven EG, Young JR, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. *Ann Surg*. 1984;199:223.
  48. Whittemore AD, Clowes AW, Hechtman HB, et al. Aortic aneurysm repair: reduced operative mortality associated with maintenance of optimal cardiac performance. *Ann Surg*. 1971;173:940.
  49. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. *J Am Coll Cardiol*. 2000;35:1288.
  50. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on perioperative cardiovascular evaluation and

- care for noncardiac surgery. *J Am Coll Cardiol*. 2007;50:159.
51. Stevens RD, Burri H, Tramer MR. Pharmacologic myocardial protection in patients undergoing noncardiac surgery: a quantitative systematic review. *Anesth Analg*. 2003;97:623.
  52. Hoeks SE, Scholte Op Reimer WJ, van Urk H, et al. Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients. *Eur J Vasc Endovasc Surg*. 2007;33:13.
  53. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. *J Am Coll Cardiol*. 2002;40:231.
  54. Connolly JE, Price T. Aortoiliac endarterectomy: a lost art? *Ann Vasc Surg*. 2006;20:56.
  55. DePalma RG, Emsellem HA, Edwards CM, et al. A screening sequence for vasculogenic impotence. *J Vasc Surg*. 1987;5:228.
  56. Van der Akker PJ, van Schilfaarde R. Long-term results of prosthetic and non-prosthetic reconstruction for obstructive aorto-iliac disease. *Eur J Vasc Surg*. 1992;6:53.
  57. Stoney RJ, Reilly LM. Endarterectomy for aortoiliac occlusive disease. In Ernst CB, Stanley JC, eds. *Current Therapy in Vascular Therapy*. Philadelphia: BC Decker; 1987:157.
  58. Inahara T. Evaluation of endarterectomy for aortoiliac and aortoilio-femoral occlusive disease. *Arch Surg*. 1975;110:1458.
  59. Brewster DC, Darling RC. Optimal methods of aortoiliac reconstruction. *Surgery*. 1978;84:739.
  60. Haimovici H. Endarterectomy. In: Ascher E, Haimovici H, Strandness DE, eds. *Vascular Surgery Principles and Techniques*. 5th ed. Malden: Norwalk, CT: Blackwell Publishing; 2004:237.
  61. Inahara T. Endarterectomy for occlusive disease of the aortoiliac and common femoral arteries. *Am J Surg*. 1972;124:235.
  62. Harrison JH, Jordan WD, Perez AR. Eversion thromboendarterectomy. *Surgery*. 1967;61:26.
  63. Huber TS, McGorray SP, Carlton LC, et al. Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: a decision analysis model. *J Vasc Surg*. 1997;25:984.
  64. Bush Jr HL, Hydo LJ, Fischer E, et al. Hypothermia during elective abdominal aortic aneurysm repair: the high price of avoidable morbidity. *J Vasc Surg*. 1995;21:392.
  65. Nunn DB, Carter MM, Donohue MT, et al. Postoperative dilation of knitted Dacron aortic bifurcation. *J Vasc Surg*. 1990;12:291.
  66. Robbs JV, Wylie EJ. Factors contributing to recurrent limb ischemia following bypass surgery for aortoiliac occlusive disease and their management. *Arch Surg*. 1981;193:346.
  67. Sanders RJ, Kempczinski RF, Hammond W, et al. The significance of graft diameter. *Surgery*. 1980;88:856.
  68. Juleff RS, Brown OW, McKain MM, et al. The influence of competitive flow on graft patency. *J Cardiovasc Surg*. 1992;33:415.
  69. Pierce GE, Turrentine M, Stringfield S, et al. Evaluation of end-to-side v end-to-end proximal anastomosis in aortobifemoral bypass. *Arch Surg*. 1982;117:1580.
  70. Jaquinandi V, Picquet J, Saumet JL, et al. Functional assessment at the buttock level of the effect of aortobifemoral bypass surgery. *Ann Surg*. 2008;247:869.
  71. Jaquinandi V, Picquet J, Bouye P, et al. High prevalence of proximal claudication among patients with patent aortobifemoral bypasses. *J Vasc Surg*. 2007;45:312.
  72. Gloviczki P, Cross SA, Stanson AW, et al. Ischemic injury to the spinal cord or lumbosacral plexus after aorto-iliac reconstruction. *Am J Surg*. 1991;162:131.
  73. Malone JM, Goldstone J, Moore WS. Autogenous profundaplasty: the key to long-term patency in secondary repair of aortofemoral graft occlusion. *Ann Surg*. 1978;188:817.
  74. Morris GC Jr, Edwards W, Cooley DA, et al. Surgical importance of profunda femoris artery. *Arch Surg*. 1961;82:32.
  75. Bernhard VM, Ray LI, Militello JP. The role of angioplasty in the profunda femoris artery in revascularization of the ischemic limb. *Surg Gynecol Obstet*. 1976;142:840.

76. Malone JM, Goldstone J, Moore WS. Autogenous profundaplasty: the key to long-term success and need for distal bypass. *Arch Surg*. 1982;117:1593.
77. Berguer R, Higgins RF, Cotton LT. Geometry, blood flow, and reconstruction of the deep femoral artery. *Am J Surg*. 1975;130:68.
78. Baird RJ, Feldman P, Miles JT, et al. Subsequent downstream repair after aorta-iliac and aorta-femoral bypass operations. *Surgery*. 1977;82:785.
79. Nevelsteen A, Wouters L, Suy R. Aorto-femoral Dacron reconstruction for aortoiliac occlusive disease: a 25 year survey. *Eur J Vasc Surg*. 1991;5:179.
80. Ballard JL, Bergan JJ, Singh P, et al. Aortoiliac stent deployment versus surgical reconstruction: analysis of outcome and cost. *J Vasc Surg*. 1998;28:94.
81. Madiba TE, Mars M, Robbs JV. Aortobifemoral bypass in the presence of superficial femoral artery occlusion: does the profunda femoris artery provide adequate runoff? *J R Coll Surg Edinb*. 1998;43:310.
82. Faries PL, LoGerfo FW, Hook SC, et al. The impact of diabetes on arterial reconstructions for multilevel arterial occlusive disease. *Am J Surg*. 2001;181:251.
83. Martinez BD, Hertzner NR, Beven EG. Influence of distal arterial occlusive disease on prognosis following aortobifemoral bypass. *Surgery*. 1980;88:795.
84. Hill DA, McGrath MA, Lord RSA, et al. The effect of superficial femoral artery occlusion on the outcome of aortofemoral bypass for intermittent claudication. *Surgery*. 1980;87:133.
85. Nypaver TJ, Ellenby MI, Mendoza O, et al. A comparison of operative approaches and parameters of success in multilevel arterial occlusive disease. *J Am Coll Surg*. 1994;179:449.
86. Dalman RL, Taylor Jr LM, Moneta GL, et al. Simultaneous operative repair of multilevel lower extremity occlusive disease. *J Vasc Surg*. 1991;13:211.
87. Benjamin ME, Hansen KJ, Craven TE, et al. Combined aortic and renal artery surgery: a contemporary experience. *Ann Surg*. 1996;223:555.
88. Cambria RP, Brewster DC, L'Italien G, et al. Simultaneous aortic and renal artery reconstruction: evolution of an eighteen-year experience. *J Vasc Surg*. 1995;21:916.
89. Mehta M, Darling RC, Roddy SP, et al. Outcome of concomitant renal artery reconstructions in patients with aortic aneurysm and occlusive disease. *Vascular*. 2004;12:381.
90. Cherr GS, Hansen KJ, Craven TE, et al. Surgical management of atherosclerotic renovascular disease. *J Vasc Surg*. 2002;35:236.
91. Wong JM, Hansen KJ, Oskin TC, et al. Surgery after failed percutaneous renal artery angioplasty. *J Vasc Surg*. 1999;30:468.
92. Leather RP, Shar DM, Kaufman JL, et al. Comparative analysis of retroperitoneal and transperitoneal aortic replacement for aneurysm. *Surg Gynecol Obstet*. 1989;168:387.
93. Sicard GA, Reilly JM, Rubin BE, et al. Transabdominal versus retroperitoneal incision for abdominal aortic surgery: report of a prospective randomized trial. *J Vasc Surg*. 1995;21:174.
94. Cambria RP, Brewster DC, Abbott WM, et al. Transperitoneal versus retroperitoneal approach for aortic reconstruction: a randomized prospective study. *J Vasc Surg*. 1990;11:314.
95. Turnipseed WD, Carr SC, Tefera G, et al. Minimal incision aortic surgery. *Ann Surg*. 2001;34:47.
96. Stadler P, Matous P, Vitasek P, Spacek M. Robot-assisted aortoiliac reconstruction: a review of 30 cases. *J Vasc Surg*. 2006;44:915.
97. Di Centa I, Coggia M, Cerceau P, et al. Total laparoscopic aortobifemoral bypass: short- and middle-term results. *Ann Vasc Surg*. 2008;22:227.
98. de Vries SO, Hunink MGM. Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis. *J Vasc*

- Surg.* 1997;26:558.
99. McDaniel MD, Macdonald PD, Haver RA, et al. Published results of surgery for aortoiliac occlusive disease. *Ann Vasc Surg.* 1997;11:425.
  100. Onohara T, Komori K, Kume M, et al. Multivariate analysis of long-term results after an axillobifemoral and aortobifemoral bypass in patients with aortoiliac disease. *J Cardiovasc Surg.* 2000;41:905.
  101. Mingoli A, Sapienza P, Feldhaus RJ, et al. Comparison of femorofemoral and aortofemoral bypass for aortoiliac occlusive disease. *J Cardiovasc Surg.* 2001;42:381.
  102. Dimick JB, Cowan JA, Henke PK, et al. Hospital volume-related difference in aorto-bifemoral bypass operative mortality in the United States. *J Vasc Surg.* 2003;37:970.
  103. Zannetti S, L'Italien GJ, Cambria RP. Functional outcomes after surgical treatment for intermittent claudication. *J Vasc Surg.* 1996;24:65.
  104. Crawford ES, Bomberger RA, Glaeser DH, et al. Aortoiliac occlusive disease: factors influencing survival and function following reconstructive operation over a twenty-five year period. *Surgery.* 1981;90:1055.
  105. Szilagyi DE, Hageman JH, Smith RF, et al. A thirty-year survey of the reconstructive surgical treatment of aortoiliac occlusive disease. *J Vasc Surg.* 1986;3:421.
  106. Brewster DC. Complications of aortic and lower extremity procedures. In Strandness Jr DE, van Breda A, eds. *Vascular Disease: Surgical and Interventional Therapy*. New York: Churchill Livingstone; 1994:1151.
  107. Garibaldi RA, Britt MR, Coleman ML, et al. Risk factors for postoperative pneumonia. *Am J Med.* 1981;70:677.
  108. Powell RJ, Roddy SP, Meier GH, et al. Effect of renal insufficiency on outcome following infrarenal aortic surgery. *Am J Surg.* 1997;174:126.
  109. Picone AL, Green RM, Ricotta JR. Spinal cord ischemia following operations on the abdominal aorta. *J Vasc Surg.* 1986;3:94.
  110. Gloviczki P, Cross SA, Stanson AW, et al. Ischemic injury to the spinal cord or lumbosacral plexus after aorto-iliac reconstruction. *Am J Surg.* 1991;162:131.
  111. Steele SR. Ischemic colitis complicating major vascular surgery. *Surg Clin North Am.* 2007;87:1099.
  112. Seeger JM, Doe DA, Kaelin LD, et al. Routine reimplantation of patent inferior mesenteric arteries limits colon infarction after aortic reconstruction. *J Vasc Surg.* 1992;15:635.
  113. Nevelsteen A, Suy R. Graft occlusion following aortofemoral Dacron bypass. *Ann Vasc Surg.* 1991;5:32.
  114. Hagino RT, Taylor SM, Fuitani RM, et al. Proximal anastomotic failure following infrarenal aortic reconstruction: late development of true aneurysms, pseudoaneurysms, and occlusive disease. *Ann Vasc Surg.* 1993;7:8.
  115. O'Connor S, Andrew P, Batt M, Becquemin JP. A systematic review and meta-analysis of treatments for aortic graft infection. *J Vasc Surg.* 2006;44:38-45.
  116. Armstrong PA, Back MR, Wilson JS, et al. Improved outcomes in the recent management of secondary aortoenteric fistula. *J Vasc Surg.* 2005;42:660.

## 第 106 章

1. Staple TW. The solitary aortoiliac lesion. *Surgery.* 1968;64:569-576.
2. Darling RC, Brewster DC, Hallett JW Jr, Darling RC 3rd. Aorto-iliac reconstruction. *Surg Clin North Am.* 1979;59:565-579.
3. Cronenwett JL, Davis JT Jr, Gooch JB, Garrett HE. Aortoiliac occlusive disease in women. *Surgery.* 1980;88:775-784.
4. Johnston KW, Rae M, Hogg-Johnston SA, et al. 5-year results of a prospective study of percutaneous transluminal angioplasty. *Ann Surg.* 1987;206:403-413.
5. Johnston KW. Factors that influence the outcome of aortoiliac and femoropopliteal percutaneous transluminal angioplasty. *Surg Clin North Am.* 1992;72:843-850.

6. Johnston KW. Iliac arteries: reanalysis of results of balloon angioplasty. *Radiology*. 1993;186:207-212.
7. Kalman PG, Johnston KW, Sniderman KW. Indications and results of balloon angioplasty for arterial occlusive lesions. *World J Surg*. 1996;20:630-634.
8. Yacyshyn VJ, Thatipelli MR, Lennon RJ, et al. Predictors of failure of endovascular therapy for peripheral arterial disease. *Angiology*. 2006;57:403-417.
9. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg*. 2007;45(Suppl S):S5-S67.
10. Davies AH, Ramarakha P, Collin J, Morris PJ. Recent changes in the treatment of aortoiliac occlusive disease by the Oxford Regional Vascular Service. *Br J Surg*. 1990;77:1129-1131.
11. Whiteley MS, Ray-Chaudhuri SB, Galland RB. Changing patterns in aortoiliac reconstruction: a 7-year audit. *Br J Surg*. 1996;83:1367-1369.
12. Liapis CD, Tzortzis EA. Advances in the management of iliac artery occlusive disease: a short review. *Vasc Endovasc Surg*. 2004;38:541-545.
13. Freeman NE, Leeds FH. Operations on large arteries; application of recent advances. *Calif Med*. 1952;77:229-233.
14. Oudot J, Beaconsfield P. Thrombosis of the aortic bifurcation treated by resection and homograft replacement; report of five cases. *Arch Surg*. 1953;66:365-369.
15. Vetto RM. The treatment of unilateral iliac artery obstruction with a trans-abdominal, subcutaneous, femoro-femoral graft. *Surgery*. 1962;52:342-345.
16. Lewis CD. A subclavian artery as the means of blood-supply to the lower half of the body. *Br J Surg*. 1961;48:574-575.
17. Daily PO, Trueblood HW, Stinson EB, et al. Management of acute aortic dissections. *Ann Thorac Surg*. 1970;10:237-247.
18. Blaisdell FW, Hall AD. Axillary-femoral artery bypass for lower extremity ischemia. *Surgery*. 1963;54:563-568.
19. Louw JH. Splenic-to-femoral and axillary-to-femoral bypass grafts in diffuse atherosclerotic occlusive disease. *Lancet*. 1963;281:1401-1402.
20. Blaisdell FW, Hall AD, Lim RC Jr, Moore WC. Aorto-iliac arterial substitution utilizing subcutaneous grafts. *Ann Surg*. 1970;172:775-780.
21. Blaisdell FW. Extraanatomical bypass procedures. *World J Surg*. 1988;12:798-804.
22. Shaw RS, Baue AE. Management of sepsis complicating arterial reconstructive surgery. *Surgery*. 1963;53:75-86.
23. Courbier R, Monties R. Les possibilités de pontage ilio-fémoral à travers le trou obturateur. [Possibilities of ilio-femoral by-pass through the obturator foramen.] *Mars Chir*. 1960;12:244-246.
24. Stevenson JK, Sauvage LR, Harkins HN. A bypass homograft from thoracic aorta to femoral arteries for occlusive vascular disease: case report. *Ann Surg*. 1961;27:632-637.
25. Fry WJ, Lindenauer SM. Infection complicating the use of plastic arterial implants. *Arch Surg*. 1967;94:600-609.
26. Second European Consensus Document on chronic critical leg ischemia. *Circulation*. 1991;84:IV1-IV26.
27. Lepäntalo M, Mäzke S. Outcome of unreconstructed chronic critical leg ischaemia. *Eur J Vasc Endovasc Surg*. 1996;11:153-157.
28. Hertzner NR, Bena JF, Karafa MT. A personal experience with direct reconstruction and extra-anatomic bypass for aortoiliofemoral occlusive disease. *J Vasc Surg*. 2007;45:527-535.
29. Brewster DC, Darling RC. Optimal methods of aortoiliac reconstruction. *Surgery*. 1978;84:739-748.
30. Piotrowski JJ, Pearce WH, Jones DN, et al. Aortobifemoral bypass: the operation of choice for unilateral iliac occlusion? *J Vasc Surg*. 1988;8:211-218.
31. Rutherford RB. Aortobifemoral bypass, the gold standard: technical considerations. *Semin Vasc Surg*. 1994;7:11-16.
32. Brewster DC. Current controversies in the management of aortoiliac occlusive disease. *J Vasc Surg*. 1997;25:365-379.
33. Rutherford RB. Options in the surgical management of aorto-iliac occlusive disease: a changing perspective. *Cardiovasc Surg*. 1999;7:5-12.

34. Kretschmer G, Niederle B, Schemper M, Polterauer P. Extra-anatomic femoro-femoral crossover bypass (FF) vs. unilateral orthotopic ilio-femoral bypass (IF): an attempt to compare results based on data matching. *Eur J Vasc Surg.* 1991;5:75-82.
35. Couch NP, Clowes AW, Whittemore AD, et al. The iliac-origin arterial graft: a useful alternative for iliac occlusive disease. *Surgery.* 1985;97:83-87.
36. Sidawy AN, Menzoian JO, Cantelmo NL, LoGerfo FW. Retroperitoneal inflow procedures for iliac occlusive vascular disease. *Arch Surg.* 1985;120:794-796.
37. Kalman PG, Hosang M, Johnston KW, Walker PM. Unilateral iliac disease: the role of iliofemoral bypass. *J Vasc Surg.* 1987;6:139-143.
38. Cham C, Myers KA, Scott DF, et al. Extraperitoneal unilateral iliac artery bypass for chronic lower limb ischaemia. *Aust N Z J Surg.* 1988;58:859-863.
39. Ricco J-B. Unilateral iliac artery occlusive disease: a randomized multicenter trial examining direct revascularization versus crossover bypass. Association Universitaire de Recherche en Chirurgie. *Ann Vasc Surg.* 1992;6:209-219.
40. Harrington ME, Harrington EB, Haimov M, et al. Iliofemoral versus femorofemoral bypass: the case for an individualized approach. *J Vasc Surg.* 1992;16:841-854.
41. Oliveira M, Wilson SE, Williams R, Freischlag JA. Iliofemoral bypass: a 10-year review. *Cardiovasc Surg.* 1993;1:103-106.
42. Harrington ME, Harrington EB. Options in the management of unilateral iliac occlusive disease. *Semin Vasc Surg.* 1994;7:45-53.
43. Nazzari MM, Hoballah JJ, Jacobovitz C, et al. A comparative evaluation of femorofemoral crossover bypass and iliofemoral bypass for unilateral iliac artery occlusive disease. *Angiology.* 1998;49:259-265.
44. Ricco J-B, Probst H. Long-term results of a multicenter randomized study on direct versus crossover bypass for unilateral iliac artery occlusive disease. *J Vasc Surg.* 2008;47:45-54.
45. van der Vliet JA, Scharn DM, de Waard J-WD, et al. Unilateral vascular reconstruction for iliac obstructive disease. *J Vasc Surg.* 1994;19:610-614.
46. May J, White G, Waugh R, et al. Treatment of complex abdominal aortic aneurysms by a combination of endoluminal and extraluminal aortofemoral grafts. *J Vasc Surg.* 1994;19:924-933.
47. Yusuf SW, Baker DM, Hind RE, et al. Endoluminal transfemoral abdominal aortic aneurysm repair with aorto-uni-iliac graft and femorofemoral bypass. *Br J Surg.* 1995;82:916.
48. Yusuf SW, Whitaker SC, Chuter TA, et al. Early results of endovascular aortic aneurysm surgery with aortouniiliac graft, contralateral iliac occlusion, and femorofemoral bypass. *J Vasc Surg.* 1997;25:165-172.
49. Thompson MM, Sayers RD, Nasim A, et al. Aortomonoiliac endovascular grafting: difficult solutions to difficult aneurysms. [see comment]. *J Endovasc Surg.* 1997;4:174-181.
50. Walker SR, Braithwaite B, Tennant WG, et al. Early complications of femorofemoral crossover bypass grafts after aorta uni-iliac endovascular repair of abdominal aortic aneurysms. *J Vasc Surg.* 1998;28:647-650.
51. Chuter TA, Faruqi RM, Reilly LM, et al. Aortomonoiliac endovascular grafting combined with femorofemoral bypass: an acceptable compromise or a preferred solution? *Semin Vasc Surg.* 1999;12:176-181.
52. Ohki T, Veith FJ, Sanchez LA, et al. Endovascular graft repair of ruptured aortoiliac aneurysms. *J Am Coll Surg.* 1999;189:102-113.
53. Rehring TF, Brewster DC, Cambria RP, et al. Utility and reliability of endovascular aortouniiliac with femorofemoral crossover graft for aortoiliac aneurysmal disease. *J Vasc Surg.* 2000;31:1135-1141.
54. Moore WS, Brewster DC, Bernhard VM. Aorto-uni-iliac endograft for complex aortoiliac aneurysms compared with tube/bifurcation endografts: results of the EVT/Guidant trials. *J Vasc Surg.* 2001;33:S11-S20.
55. Hinchliffe RJ, Alric P, Wenham PW, Hopkinson BR. Durability of femorofemoral bypass grafting after aortouniiliac endovascular aneurysm repair. *J Vasc Surg.* 2003;38:498-503.



56. Clouse WD, Brewster DC, Marone LK, et al. Durability of aortouniiliac endografting with femorofemoral crossover: 4-year experience in the EVT/Guidant trials. *J Vasc Surg.* 2003;37:1142-1149.
57. Schneider JR. Femorofemoral bypass. In: Bell RH Jr, Kaufman DB, eds. *Northwestern Handbook of Surgical Procedures.* Georgetown, TX: Landes; 2005:297-299.
58. Tyson RR, Reichle FA. Retropubic femorofemoral bypass: a new route through the space of Retzius. *Surgery.* 1972;72:401-403.
59. Mosley JG, Marston A. Long term results of 66 femoral-to-femoral by-pass grafts: a 9-year follow-up. *Br J Surg.* 1983;70:631-634.
60. Hubert J, Mourey E, Hirsch JJ, Mangin P. An unusual urological complication due to vascular surgery: transvesical polytetrafluoroethylene iliofemoral graft. *J Urol.* 1996;156:2004-2005.
61. Häcker A, Uysal Z, Badawi K, et al. Ein Corpus alienum in der Harnblase nach gefäßchirurgischem Eingriff. [Foreign body in the urinary bladder after vascular surgery.] *Aktuelle Urologie.* 2005;36:249-251.
62. Wertheimer P, Sautot J, Sisteron A, Descotes J. Les dérivations artérielles contro-latérales. A propos de 6 observations. [Contralateral arterial by-passes. Apropos of 6 cases.] *Lyon Chir.* 1963;59:350-357.
63. Paineau J, Pelleray C. Pontages ilio ou fémoro-fémoraux extra-anatomiques. [Extra-anatomic ilio- or femoro-femoral bypass.] *J Chir (Paris).* 1985;122:3-7.
64. Brouwer MH, Biemans RG, Donders HP. Long-term results of 44 cross-over bypasses. *J Cardiovasc Surg (Torino).* 1988;29:290-295.
65. Hanafy M, McLoughlin GA. Comparison of iliofemoral and femorofemoral crossover bypass in the treatment of unilateral iliac arterial occlusive disease. [see comment]. *Br J Surg.* 1991;78:1001-1002.
66. Defraigne JO, Vazquez C, Limet R. Crossover iliofemoral bypass grafting for treatment of unilateral iliac atherosclerotic disease. *J Vasc Surg.* 1999;30:693-700.
67. do Carmo G, Moura CM, Sarmento C, et al. A new approach for the surgical management of unilateral iliac artery occlusive disease: the iliofemoral crossover transposition. *J Vasc Surg.* 2002;36:404-407.
68. Ng RL, Gillies TE, Davies AH, et al. Iliofemoral versus femorofemoral bypass: a 6-year audit. [see comment]. *Br J Surg.* 1992;79:1011-1013.
69. McCaughan JJ Jr, Kahn SF. Cross-over graft for unilateral occlusive disease of the ilio-femoral arteries. *Ann Surg.* 1960;151:26-28.
70. Goetz RH, Lord JW Jr. Crossover femoropopliteal shunt. *Surgery.* 1968;64:681-684.
71. Schuler JJ, Flanagan DP, Ryan TJ, et al. Crossover femorofemoropopliteal sequential bypass for combined ipsilateral iliac and femoropopliteal occlusive disease. *Arch Surg.* 1984;119:456-461.
72. Dalman RL, Taylor LM Jr, Moneta GL, et al. Simultaneous operative repair of multilevel lower extremity occlusive disease. *J Vasc Surg.* 1991;13:211-221.
73. Ellenby MI, Sawchuk AP, Schwarcz TH, et al. A nine-year experience with crossover femoro-femoro-popliteal sequential bypass. *Am J Surg.* 1991;161:672-676.
74. Hardy JD, Bane JW. Arterial injury and massive blood loss: a case report of management of pelvic gunshot injury with femoro-subscrotal-femoral bypass and 116 units of blood. *Ann Surg.* 1975;181:245-246.
75. Kieffer E, Laurian C, Surugue P, Natali J. Pontage veineux fémoro-fémoral par le périnée (6 observations). [Femoro-femoral venous bypass via the perineum (6 cases)]. *Chirurgie.* 1976;102:420-428.
76. Laurian C, Martino A, Cormier JM. Pontages périnéaux. Technique. Indications à propos de douze cas. [Subscrotal bypass. Technique and indications. A report on twelve cases.] *Ann Chir.* 1981;35:455-459.
77. Lawrence PF, Albo D Jr. Femorofemoral bypass with an infrascrotal perineal approach for the patient with an infected groin wound. *J Vasc Surg.* 1985;2:485-487.
78. Baird RN. Subscrotal bypass for the infected groin. In: Greenhalgh RM, ed. *Vascular and Endovascular Surgical*

*Techniques*. London: WB Saunders; 1994:257-259.

79. Branchereau A, Ciosi G, Bordeaux J, et al. Femorofemoral bypass through the perineum for infection complicating arterial revascularization of the lower limb. *Ann Vasc Surg*. 1988;2:43-49.
80. Ray LI, O'Connor JB, Davis CC, et al. Axillofemoral bypass: a critical reappraisal of its role in the management of aortoiliac occlusive disease. *Am J Surg*. 1979;138:117-128.
81. Archie JP. The value of donor iliac artery pressure gradients in predicting the outcome of femorofemoral bypass. *J Vasc Surg*. 1996;23:383-393.
82. Ehrenfeld WK, Levin SM, Wylie EJ. Venous crossover bypass grafts for arterial insufficiency. *Ann Surg*. 1968;167:287-291.
83. Jepson RP, Harris JD, Miller J. Femoro-femoral cross-over grafts. *Aust N Z J Surg*. 1970;39:345-348.
84. Trimble IR, Stonesifer GL Jr, Shaw Wilgis EF, Montague AC. Criteria for femoro-femoral bypass from clinical and hemodynamic studies. *Ann Surg*. 1972;175:985-993.
85. Warren WD, Fomon JJ. Rerouting arterial flow to relieve ischemia: femoro-femoral, axillary femoral and carotid-carotid artery bypasses. *Ann Surg*. 1966;163:131-136.
86. Devolve C, Adeleine P, Henrie M, et al. Ilio-femoral and femoro-femoral crossover grafting. Analysis of an 11-year experience. *J Cardiovasc Surg (Torino)*. 1983;24:634-640.
87. Hakaim AG, Hertzner NR, O'Hara PJ, et al. Autogenous vein grafts for femorofemoral revascularization in contaminated or infected fields. *J Vasc Surg*. 1994;19:912-915.
88. Mingoli A, Sapienza P, Feldhaus RJ, et al. Femorofemoral bypass grafts: Factors influencing long-term patency rate and outcome. *Surgery*. 2001;129:451-458.
89. Pai M, Handa A, Hands L, Collin J. Femoro-femoral arterial bypass is an effective and durable treatment for symptomatic unilateral iliac artery occlusion. *Ann R Coll Surg Engl*. 2003;85:88-90.
90. D'Addio V, Ali A, Timaran C, et al. Femorofemoral bypass with femoral popliteal vein. *J Vasc Surg*. 2005;42:35-39.
91. Schneider JR, Besso SR, Walsh DB, et al. Femorofemoral versus aortobifemoral bypass: outcome and hemodynamic results. *J Vasc Surg*. 1994;19:43-57.
92. Schneider JR, McDaniel MD, Walsh DB, et al. Axillofemoral bypass: outcome and hemodynamic results in high-risk patients. *J Vasc Surg*. 1992;15:952-963.
93. Johnson WC, Lee KK. Comparative evaluation of externally supported Dacron and polytetrafluoroethylene prosthetic bypasses for femorofemoral and axillofemoral arterial reconstructions. Veterans Affairs Cooperative Study #141. *J Vasc Surg*. 1999;30:1077-1083.
94. Brener BJ, Brief DK, Alpert J, et al. Femorofemoral bypass: a twenty-five year experience. In: Yao JST, Pearce WH, eds. *Long-term Results in Vascular Surgery*. East Norwalk: Appleton & Lange; 1993:385-393.
95. Criado E, Burnham SJ, Tinsley EA Jr, et al. Femorofemoral bypass graft: analysis of patency and factors influencing long-term outcome. *J Vasc Surg*. 1993;18:495-505.
96. Criado E, Farber MA. Femorofemoral bypass: appropriate application based on factors affecting outcome. *Semin Vasc Surg*. 1997;10:34-41.
97. Plecha FR, Plecha FM. Femorofemoral bypass grafts: ten-year experience. *J Vasc Surg*. 1984;1:555-561.
98. Lamerton AJ, Nicolaidis AN, Eastcott HH. The femorofemoral graft. Hemodynamic improvement and patency rate. *Arch Surg*. 1985;120:1274-1278.
99. Rutherford RB, Patt A, Pearce WH. Extra-anatomic bypass: a closer view. *J Vasc Surg*. 1987;6:437-446.
100. Farber MA, Hollier LH, Eubanks R, et al. Femorofemoral bypass: a profile of graft failure. *South Med J*. 1990;83:1437-1443.
101. Perler BA, Burdick JF, Williams GM. Femoro-femoral or ilio-femoral bypass for unilateral inflow reconstruction? *Am J Surg*. 1991;161:426-430.

102. Self SB, Richardson JD, Klamer TW, et al. Utility of femorofemoral bypass. Comparison of results with indications for operation. *Am Surg*. 1991;57:602-606.
103. Pursell R, Sideso E, Magee TR, Galland RB. Critical appraisal of femorofemoral crossover grafts. *Br J Surg*. 2005;92:565-569.
104. Kim YW, Lee JH, Kim HG, Huh S. Factors affecting the long-term patency of crossover femorofemoral bypass graft. *Eur J Vasc Endovasc Surg*. 2005;30:376-380.
105. Mii S, Eguchi D, Takenaka T, et al. Role of femorofemoral crossover bypass grafting for unilateral iliac atherosclerotic disease: a comparative evaluation with anatomic bypass. *Surg Today*. 2005;35:453-458.
106. Vetto RM. The femorofemoral shunt. An appraisal. *Am J Surg*. 1966;112:162-165.
107. Papadopoulos CD. Cross-over femorofemoral bypass. *Am J Surg*. 1966;111:216-219.
108. da Gama AD. The fate of the donor artery in extraanatomic revascularization. *J Vasc Surg*. 1988;8:106-111.
109. Wylie EJ. Comment on Vetto RM. The femorofemoral shunt. An appraisal. *Am J Surg*. 1966;112:165.
110. Foley WJ, Dow RW, Fry WJ. Crossover femoro-femoral bypass grafts. *Arch Surg*. 1969;99:83-87.
111. Stone PA, Armstrong PA, Bandyk DF, et al. Duplex ultrasound criteria for femorofemoral bypass revision. *J Vasc Surg*. 2006;44:496-502.
112. Lyons JH Jr, Weismann RE. Surgical management of late closure of aortofemoral reconstruction grafts. *N Engl J Med*. 1968;278:1035-1037.
113. Bernhard VM, Ray LI, Towne JB. The reoperation of choice for aortofemoral graft occlusion. *Surgery*. 1977;82:867-874.
114. Laurendeau F, Lassonde J, Ennabli K. Extra-anatomic bypass grafting in the lower extremity. *Can J Surg*. 1983;26:335-338.
115. Littooy FN, Widerborg KA, Greisler HP, Baker WH. Effect of prior arterial reconstruction on the outcome of femorofemoral bypass. *Am Surg*. 1987;53:446-450.
116. Kalman PG, Hosang M, Johnston KW, Walker PM. The current role for femorofemoral bypass. *J Vasc Surg*. 1987;6:71-76.
117. Gazzola LM, Hirsch SA, Kaufer GI. Femorofemoral bypass. *Surgery*. 1974;76:841-844.
118. Sethi GK, Crawford FA, Scott SM, Takaro T. Femorofemoral bypass graft: choice or compromise? *Am Surg*. 1975;41:61-66.
119. Crawford FA, Sethi GK, Scott SM, Takaro T. Femorofemoral grafts for unilateral occlusion of aortic bifurcation grafts. *Surgery*. 1975;77:150-153.
120. François F, Picard E, Nicaud P, et al. Femorofemoral crossover bypass for noninfective complications of aortoiliac surgery. *Ann Vasc Surg*. 1991;5:46-49.
121. Nolan KD, Benjamin ME, Murphy TJ, et al. Femorofemoral bypass for aortofemoral graft limb occlusion: a ten-year experience. *J Vasc Surg*. 1994;19:851-857.
122. Cohn LH, Moore WS, Hall AD. Extra-abdominal management of late aortofemoral graft thrombosis. *Surgery*. 1970;67:775-779.
123. Najafi H, Dye WS, Javid H, et al. Late thrombosis affecting one limb of aortic bifurcation graft. *Arch Surg*. 1975;110:409-412.
124. Stanton PE Jr, Lamis PA, Gross WS, McCluskey D. Correction of late aortic-bifemoral graft failures. *Am Surg*. 1977;43:497-502.
125. Benhamou AC, Kieffer E, Tricot JF, et al. "Redo" surgery for late aorto-femoral graft occlusive failures. *J Cardiovasc Surg (Torino)*. 1984;25:118-125.
126. Parsonnet V, Alpert J, Brief DK. Femorofemoral and axillofemoral grafts—compromise or preference. *Surgery*. 1970;67:26-33.
127. Mannick JA. Are there practical alternatives to aortoiliac reconstruction? *Am J Surg*. 1971;122:344-346.
128. Sheiner NM, Zeltzer J. Axillofemoral and femorofemoral bypass: an alternative to conventional aortoiliac revascularization.

*Can J Surg.* 1973;16:338-342.

129. Descotes J, Baulieux J, Boulez J. Les pontages contro-latéraux: procédé de sauvetage ou méthode de choix dans le traitement des oblitérations des artères iliaques? (A propos de 28 observations). [Contralateral shunts: salvage procedure or method of choice in the treatment of occlusion of the iliac arteries? (Apropos of 28 cases)]. *J Chir (Paris)*. 1974;107:537-554.
130. Dick LS, Brief DK, Alpert J, et al. A 12-year experience with femorofemoral crossover grafts. *Arch Surg*. 1980;115:1359-1365.
131. Davis RC, O'Hara ET, Mannick JA, et al. Broadened indications for femorofemoral grafts. *Surgery*. 1972;72:990-994.
132. Biancari F, Lepäntalo M. Extra-anatomic bypass surgery for critical leg ischemia. A review. *J Cardiovasc Surg (Torino)*. 1998;39:295-301.
133. Schneider JR. Femorofemoral bypass. *Perspect Vasc Surg*. 1999;11:113-123.
134. Mingoli A, Sapienza P, Feldhaus RJ, et al. Comparison of femorofemoral and aortofemoral bypass for aortoiliac occlusive disease. *J Cardiovasc Surg (Torino)*. 2001;42:381-387.
135. Eiberg JP, Røder O, Stahl-Madsen M, et al. Fluoropolymer-coated Dacron versus PTFE grafts for femorofemoral crossover bypass: randomised trial. *Eur J Vasc Endovasc Surg*. 2006;32:431-438.
136. Lau H, Cheng SW. Is the preferential use of ePTFE grafts in femorofemoral bypass justified? *Ann Vasc Surg*. 2001;15:383-387.
137. Ehrenfeld WK, Harris JD, Wylie EJ. Vascular "steal" phenomenon. An experimental study. *Am J Surg*. 1968;116:192-197.
138. Sumner DS, Strandness DE Jr. The hemodynamics of the femorofemoral shunt. *Surg Gynecol Obstet*. 1972;134:629-636.
139. Nicholson ML, Beard JD, Horrocks M. Intra-operative inflow resistance measurement: a predictor of steal syndromes following femoro-femoral bypass grafting. *Br J Surg*. 1988;75:1064-1066.
140. Flanigan DP, Pratt DG, Goodreau JJ, et al. Hemodynamic and angiographic guidelines in selection of patients for femorofemoral bypass. *Arch Surg*. 1978;113:1257-1262.
141. Livesay JJ, Atkinson JB, Baker JD, et al. Late results of extra-anatomic bypass. *Arch Surg*. 1979;114:1260-1267.
142. Donor limb vascular events following femoro-femoral bypass surgery. A Veterans Affairs Cooperative Study. *Arch Surg*. 1991;126:681-686.
143. Harris JP, Flinn WR, Rudo ND, et al. Assessment of donor limb hemodynamics in femorofemoral bypass for claudication. *Surgery*. 1981;90:764-773.
144. Moore WS, Hall AD. Unrecognized aortoiliac stenosis. A physiologic approach to the diagnosis. *Arch Surg*. 1971;103:633-638.
145. Sethi GK, Scott SM, Takaro T. Multiple-plane angiography for more precise evaluation of aortoiliac disease. *Surgery*. 1975;78:154-159.
146. Gupta SK, Veith FJ, Kram HB, Wengerter KA. Significance and management of inflow gradients unexpectedly generated after femorofemoral, femoropopliteal, and femoroinfrapopliteal bypass grafting. *J Vasc Surg*. 1990;12:278-283.
147. Sako Y. Papavarine test in peripheral arterial disease. *Surg Forum*. 1966;17:141-143.
148. Flanigan DP, Ryan TJ, Williams LR, et al. Aortofemoral or femoropopliteal revascularization? A prospective evaluation of the papaverine test. *J Vasc Surg*. 1984;1:215-223.
149. Brief DK, Brener BJ, Alpert J, Parsonnet V. Crossover femorofemoral grafts followed up five years or more. An analysis. *Arch Surg*. 1975;110:1294-1299.
150. Deruyter L, Caes F, Van den Brande P, et al. Femorofemoral bypass grafting in high-risk patients. *Acta Chir Belg*. 1986;86:271-276.
151. Buchbinder D, Pasch AR, Schuler JJ, et al. Efficacy of femorofemoral bypass for intermittent claudication. Clinical and hemodynamic assessment. *Am J Surg*. 1986;152:215-219.
152. Porter JM, Eidemiller LR, Dotter CT, et al. Combined arterial dilatation and femorofemoral bypass for limb salvage. *Surg*

*Gynecol Obstet.* 1973;137:409-412.

153. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. Description of a new technic and a preliminary report of its application. *Circulation.* 1964;30:654-670.
154. Grüntzig A, Hopff H. Perkutane Rekanalisation chronischer arterieller Verschlüsse mit einem neuen Dilatationskatheter. Modifikation der Dotter-Technik [Percutaneous recanalization after chronic arterial occlusion with a new dilator-catheter (modification of the Dotter technique)]. *Dtsch Med Wochenschr.* 1974;99:2502-2510.
155. Grüntzig A, Kumpe DA. Technique of percutaneous transluminal angioplasty with the Grüntzig balloon catheter. *AJR Am J Roentgenol.* 1979;132:547-552.
156. Howell HS, Ingram CH, Parham AR, et al. Transluminal angioplasty of the iliac artery combined with femorofemoral bypass. *South Med J.* 1983;76:49-51.
157. Brewster DC, Cambria RP, Darling RC, et al. Long-term results of combined iliac balloon angioplasty and distal surgical revascularization. *Ann Surg.* 1989;210:324-331.
158. Walker PJ, Harris JP, May J. Combined percutaneous transluminal angioplasty and extraanatomic bypass for symptomatic unilateral iliac artery occlusion with contralateral iliac artery stenosis. *Ann Vasc Surg.* 1991;5:209-217.
159. Shah RM, Peer RM, Upson JF, et al. Donor iliac angioplasty and crossover femorofemoral bypass. *Am J Surg.* 1992;164:295-298.
160. Katz SG, Kohl RD, Yellin A. Iliac angioplasty as a prelude to distal arterial bypass. *J Am Coll Surg.* 1994;179:577-582.
161. Perler BA, Williams GM. Does donor iliac artery percutaneous transluminal angioplasty or stent placement influence the results of femorofemoral bypass? Analysis of 70 consecutive cases with long-term follow-up. *J Vasc Surg.* 1996;24:363-370.
162. Lopez-Galarza LA, Ray LI, Rodriguez-Lopez J, Diethrich EB. Combined percutaneous transluminal angioplasty, iliac stent deployment, and femorofemoral bypass for bilateral aortoiliac occlusive disease. *J Am Coll Surg.* 1997;184:249-258.
163. AbuRahma AF, Robinson PA, Cook CC, Hopkins ES. Selecting patients for combined femorofemoral bypass grafting and iliac balloon angioplasty and stenting for bilateral iliac disease. *J Vasc Surg.* 2001;33:S93-S99.
164. Leeds FH, Gilfillan RS. Importance of profunda femoris artery in the revascularization of the ischemic limb. *Arch Surg.* 1961;82:25-31.
165. Morris GC Jr, Edwards E, Cooley DA, et al. Surgical importance of profunda femoris artery. Analysis of 102 cases with combined aortoiliac and femoropopliteal occlusive disease treated by revascularization of deep femoral artery. *Arch Surg.* 1961;82:32-37.
166. Healey SJ, Wheeler HB, Crane C, Warren R. Reconstructive operations for aortoiliac obliterative disease. Results and reflections from an eleven-year experience. *N Engl J Med.* 1964;271:1386-1391.
167. Haid SP, Jurayj MN, Trippel OH. Innovative applications of extra-anatomic reconstruction. *Surg Clin North Am.* 1974;54:123-135.
168. Todd GJ, Voorhees AB, Nowygrod R, Reemtsma K. Femorofemoral bypass for unilateral iliac artery occlusion in the presence of bilateral superficial femoral artery occlusions. *J Cardiovasc Surg (Torino).* 1985;26:12-14.
169. McDonald PT, Rich NM, Collins GJ Jr, et al. Femorofemoral grafts: the role of concomitant extended profundaplasty. *Am J Surg.* 1978;136:622-628.
170. Prendiville EJ, Burke PE, Colgan MP, et al. The profunda femoris: a durable outflow vessel in aortofemoral surgery. *J Vasc Surg.* 1992;16:23-29.
171. Whitmore KE, Billig DM, Pavlides C, Matsumoto T. Special considerations in the revascularization for aortoiliac occlusive disease: anatomic and extraanatomic bypass. *Am Surg.* 1980;46:279-288.
172. Farkas P, Lüdecke G, Akintürk H, Weidner W. Transvesical placement of one limb of an aortobifemoral bypass graft as a complication of aortic bypass surgery. *Urol Int.* 2001;66:227-228.
173. Connery CP, DeWeese JA, Eisenberg BK, Moss AJ. Treatment of aortic coarctation by axillofemoral bypass grafting in the

- high-risk patient. *Ann Thorac Surg*. 1991;52:1281-1284.
174. Harada T, Nakayama K, Kitano T, et al. Axillofemoral bypass for recurrent atypical coarctation of the thoracic aorta. Woman in childbearing age. *Jpn J Thorac Cardiovasc Surg*. 1999;47:460-464.
  175. Attenhofer Jost CH, Schaff HV, Connolly HM, et al. Spectrum of reoperations after repair of aortic coarctation: importance of an individualized approach because of coexistent cardiovascular disease. *Mayo Clin Proc*. 2002;77:646-653.
  176. Ehrenfeld WK, Lord RS, Stoney RJ, Wylie EJ. Subcutaneous arterial bypass grafts in the management of fistulae between the bowel and plastic arterial prostheses. *Ann Surg*. 1968;168:29-35.
  177. Kleinman LH, Towne JB, Bernhard VM. A diagnostic and therapeutic approach to aortoenteric fistulas: clinical experience with twenty patients. *Surgery*. 1979;86:868-880.
  178. Raithel D. Late results after extra-anatomic bypass routes. *J Cardiovasc Surg (Torino)*. 1979;20:487-492.
  179. Reilly LM, Altman H, Lusby RJ, et al. Late results following surgical management of vascular graft infection. *J Vasc Surg*. 1984;1:36-44.
  180. Lorentzen JE, Nielsen OM, Arendrup H, et al. Vascular graft infection: an analysis of sixty-two graft infections in 2411 consecutively implanted synthetic vascular grafts. *Surgery*. 1985;98:81-86.
  181. O'Hara PJ, Hertzner NR, Beven EG, Krajewski LP. Surgical management of infected abdominal aortic grafts: review of a 25-year experience. *J Vasc Surg*. 1986;3:725-731.
  182. Schmitt DD, Seabrook GR, Bandyk DF, Towne JB. Graft excision and extra-anatomic revascularization: the treatment of choice for the septic aortic prosthesis. *J Cardiovasc Surg (Torino)*. 1990;31:327-332.
  183. Ricotta JJ, Faggioli GL, Stella A, et al. Total excision and extra-anatomic bypass for aortic graft infection. *Am J Surg*. 1991;162:145-149.
  184. Seeger JM, Pretus HA, Welborn MB, et al. Long-term outcome after treatment of aortic graft infection with staged extra-anatomic bypass grafting and aortic graft removal. *J Vasc Surg*. 2000;32:451-461.
  185. Bandyk DF, Bergamini TM, Kinney EV, et al. In situ replacement of vascular prostheses infected by bacterial biofilms. *J Vasc Surg*. 1991;13:575-583.
  186. Kieffer E, Bahnini A, Koskas F, et al. In situ allograft replacement of infected infrarenal aortic prosthetic grafts: results in forty-three patients. *J Vasc Surg*. 1993;17:349-356.
  187. Clagett GP, Valentine RJ, Hagino RT. Autogenous aortoiliac/femoral reconstruction from superficial femoral-popliteal veins: feasibility and durability. *J Vasc Surg*. 1997;25:255-270.
  188. Bandyk DF, Novotney ML, Johnson BL, et al. Use of rifampin-soaked gelatin-sealed polyester grafts for in situ treatment of primary aortic and vascular prosthetic infections. *J Surg Res*. 2001;95:44-49.
  189. Vogt PR, Brunner-LaRocca H-P, Lachat M, et al. Technical details with the use of cryopreserved arterial allografts for aortic infection: influence on early and midterm mortality. *J Vasc Surg*. 2002;35:80-86.
  190. Gorman JF, Douglass FM. Axillary-femoral artery bypass. *Arch Surg*. 1965;91:509-512.
  191. DeAvila R, Doyle J, Heaney JP. Axillary-femoral bypass. *Arch Surg*. 1966;92:118-119.
  192. Sauvage LR, Wood SJ. Unilateral axillary bilateral femoral bifurcation graft: a procedure for the poor risk patient with aortoiliac disease. *Surgery*. 1966;60:573-577.
  193. Pierangeli A, Guernelli N. The axillo-femoral by-pass as a treatment of the obstruction of the aorto-iliac junction in the poor risk patients. *J Cardiovasc Surg (Torino)*. 1967;8:353-360.
  194. Mannick JA, Nabseth DC. Axillofemoral bypass graft. A safe alternative to aortoiliac reconstruction. *N Engl J Med*. 1968;278:461-466.
  195. Mannick JA, Williams LE, Nabseth DC. The late results of axillofemoral grafts. *Surgery*. 1970;68:1038-1043.
  196. Bliss BP, Barrett GS. Axillo-femoral and axillo-profunda bypass grafts. Their use for limb salvage in the bad-risk patient with occlusion or infection of the abdominal aorta and iliac arteries. *Ann R Coll Surg Engl*. 1972;50:268-273.
  197. Pollock AV. Axillary-femoral by-pass grafts in the treatment of aorto-iliac occlusive disease. *Br J Surg*. 1972;59:704-707.

198. Lamis PA, Stanton PE, Wilson JP, Letton AH. Axillofemoral and femorofemoral bypass grafts: safe surgical alternatives in aortoiliac occlusive disease. *South Med J*. 1973;66:1263-1266.
199. Richardson JV, McDowell HA Jr. Extra-anatomic bypass grafting in aortoiliac occlusive disease: a seven-year experience. *South Med J*. 1977;70:1287-1291.
200. Campbell CD, Brooks DH, Siewers RD, et al. Extra-anatomic bypass with expanded polytetrafluoroethylene. *Surg Gynecol Obstet*. 1979;148:525-530.
201. Devolve C, Adeleine P, Violet F, Descotes J. La revascularisation des membres inférieurs à partir de l'artère axillaire est-elle fiable? Analyse informatique de 98 pontages. *Lyon Chir*. 1981;77:88-93.
202. Burrell MJ, Wheeler JR, Gregory RT, et al. Axillofemoral bypass: a ten-year review. *Ann Surg*. 1982;195:796-799.
203. Glock Y, Benallou A, Puel P. Les pontages extra-anatomiques destinés aux membres inférieurs. A propos d'une série de 51 cas consécutifs. [Extra-anatomical shunts in the lower limbs. Apropos of a series of 51 consecutive cases]. *J Chir (Paris)*. 1984;121:593-598.
204. Johnson WC. Comment on Schneider JR, et al. Axillofemoral bypass: outcome and hemodynamic results in high-risk patients. *J Vasc Surg*. 1992;15:962.
205. Hepp W, de Jonge K, Pallua N. Late results following extra-anatomic bypass procedures for chronic aortoiliac occlusive disease. *J Cardiovasc Surg (Torino)*. 1988;29:181-185.
206. Schneider JR. Axillofemoral bypass. In: Bell RH Jr, Kaufman DB, eds. *Northwestern Handbook of Surgical Procedures*. Georgetown, TX: Landes; 2005:292-296.
207. Calligaro KD, Ascer E, Veith FJ, et al. Unsuspected inflow disease in candidates for axillofemoral bypass operations: a prospective study. *J Vasc Surg*. 1990;11:832-837.
208. Urdaneta LF, Visudh-Arom K, Delaney JP, Castaneda AR. Use of bilateral axillofemoral bypass prosthesis for the management of infected aortic bifurcation grafts: report of a case with extended follow-up. *Surgery*. 1969;65:753-756.
209. Louw JH. The treatment of combined aortoiliac and femoropopliteal occlusive disease by splenofemoral and axillofemoral bypass grafts. *Surgery*. 1964;55:387-395.
210. Blaisdell FW. Late axillary artery thrombosis in patients with occluded axillary-femoral bypass grafts. *J Vasc Surg*. 1985;2:925-926.
211. Sullivan LP, Davidson PG, D'Anna JA Jr, Sithian N. Disruption of the proximal anastomosis of axillobifemoral grafts: two case reports. *J Vasc Surg*. 1989;10:190-192.
212. Bunt TJ, Moore W. Optimal proximal anastomosis/tunnel for axillofemoral grafts. *J Vasc Surg*. 1986;3:673-676.
213. Taylor LM Jr, Park TC, Edwards JM, et al. Acute disruption of polytetrafluoroethylene grafts adjacent to axillary anastomoses: a complication of axillofemoral grafting. *J Vasc Surg*. 1994;20:520-528.
214. Ward RE, Holcroft JW, Conti S, Blaisdell FW. New concepts in the use of axillofemoral bypass grafts. *Arch Surg*. 1983;118:573-576.
215. Rutherford RB, Rainer W. A modified technique for performing axillobifemoral bypass grafting. *J Vasc Surg*. 1989;10:468-469.
216. Wittens CHA, van Houtte HJKP, van Urk H. Winner of the ESVS Prize 1991. European Prospective Randomised Multi-centre Axillo-bifemoral Trial. *Eur J Vasc Surg*. 1992;6:115-123.
217. Wittens CHA. *Haemodynamics in Axillobifemoral Bypass Graft*. Rotterdam: Department of General Surgery, University Hospital; 1992.
218. Moore WS, Hall AD, Blaisdell FW. Late results of axillary-femoral bypass grafting. *Am J Surg*. 1971;122:148-154.
219. Pietri P, Pancrazio F, Adovasio R, et al. Long term results of extra anatomical bypasses. *Int Angiol*. 1987;6:429-433.
220. Schneider JR, Golan JF. The role of extraanatomic bypass in the management of bilateral aortoiliac occlusive disease. *Semin Vasc Surg*. 1994;7:35-44.
221. Passman MA, Taylor LM, Moneta GL, et al. Comparison of axillofemoral and aortofemoral bypass for aortoiliac occlusive

- disease. *J Vasc Surg*. 1996;23:263-271.
222. Oblath RW, Green RM, DeWeese JA, Rob CG. Extra-anatomic bypass of the abdominal aorta: management of postoperative thrombosis. *Ann Surg*. 1978;187:647-652.
  223. Bacourt F, Koskas F. Axillobifemoral bypass and aortic exclusion for vascular septic lesions: a multicenter retrospective study of 98 cases. French University Association for Research in Surgery. *Ann Vasc Surg*. 1992;6:119-126.
  224. Savrin RA, Record GT, McDowell DE. Axillofemoral bypass. Expectations and results. *Arch Surg*. 1986;121:1016-1020.
  225. Agee JM, Kron IL, Flanagan T, Tribble CG. The risk of axillofemoral bypass grafting for acute vascular occlusion. *J Vasc Surg*. 1991;14:190-194.
  226. Johnson WC, Leger FW, Vollman RW, et al. Is axillo-bilateral femoral graft an effective substitute for aortic-bilateral iliac/femoral graft? An analysis of ten years experience. *Ann Surg*. 1977;186:123-129.
  227. LoGerfo FW, Johnson WC, Corson JD, et al. A comparison of the late patency rates of axillobilateral femoral and axillounilateral femoral grafts. *Surgery*. 1977;81:33-40.
  228. Schneider JR. Comment on Passman et al. Comparison of axillofemoral and aortofemoral bypass for aortoiliac occlusive disease. *J Vasc Surg*. 1996;23:270.
  229. Harris EJ Jr, Taylor LM Jr, McConnell DB, et al. Clinical results of axillobifemoral bypass using externally supported polytetrafluoroethylene. *J Vasc Surg*. 1990;12:416-421.
  230. El-Massry S, Saad E, Sauvage LR, et al. Axillofemoral bypass with externally supported, knitted Dacron grafts: a follow-up through twelve years. *J Vasc Surg*. 1993;17:107-115.
  231. Corbett CR, Taylor PR, Chilvers AS, Edwards JM. Axillofemoral bypass in poor risk patients with critical ischaemia. *Ann R Coll Surg Engl*. 1984;66:170-172.
  232. Dé P, Hepp W. Present role of extraanatomic bypass graft procedures for aortoiliac occlusive disease. *Int Angiol*. 1991;10:224-228.
  233. Harris KA, Niesowska V, Carroll SE, et al. Extra-anatomic bypass grafting: a rational approach. *Can J Surg*. 1989;32:113-116.
  234. Urayama H, Ohtake H, Yokoi K, et al. Long-term results of endarterectomy, anatomic bypass and extraanatomic bypass for aortoiliac occlusive disease. *Surg Today*. 1998;28:151-155.
  235. Eugene J, Goldstone J, Moore WS. Fifteen year experience with subcutaneous bypass grafts for lower extremity ischemia. *Ann Surg*. 1977;186:177-183.
  236. Allison HF, Terblanche J, Immelman EJ, et al. Axillofemoral bypass. A 2-decade experience reviewed. *S Afr Med J*. 1985;68:559-562.
  237. Ascer E, Veith FJ, Gupta SK, et al. Comparison of axillounifemoral and axillobifemoral bypass operations. *Surgery*. 1985;97:169-175.
  238. Donaldson MC, Louras JC, Bucknam CA. Axillofemoral bypass: a tool with a limited role. *J Vasc Surg*. 1986;3:757-763.
  239. Kalman PG, Hosang M, Cina C, et al. Current indications for axillounifemoral and axillobifemoral bypass grafts. *J Vasc Surg*. 1987;5:828-832.
  240. Naylor AR, Ah-See AK, Engeset J. Axillofemoral bypass as a limb salvage procedure in high risk patients with aortoiliac disease. *Br J Surg*. 1990;77:659-661.
  241. Rutherford RB, Flanagan DP, Gupta SK, et al. Suggested standards for reports dealing with lower extremity ischemia. [erratum appears in *J Vasc Surg* 1986;4:350]. *J Vasc Surg*. 1986;4:80-94.
  242. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version.[erratum appears in *J Vasc Surg* 2001;33:805]. *J Vasc Surg*. 1997;26:517-538.
  243. Jämsä T, Tulla H, Lopenen P. Axillofemoral bypass operations in Kuopio University Hospital 1985-1996. *Ann Chir Gynaecol*. 1999;88:269-275.
  244. Onohara T, Komori K, Kume M, et al. Multivariate analysis of long-term results after an axillobifemoral and



- aortobifemoral bypass in patients with aortoiliac occlusive disease. *J Cardiovasc Surg (Torino)*. 2000;41:905-910.
245. Angle N, Dorafshar AH, Farooq MM, et al. The evolution of the axillofemoral bypass over two decades. *Ann Vasc Surg*. 2002;16:742-745.
  246. Tueche SG. Extra-anatomic bypass shunting in aorto-iliac occlusive disease. Clinical results and risk factors in a Belgian population. *Ann Med Interne (Paris)*. 2003;154:489-492.
  247. Mason RA, Smirnov VB, Newton GB, Giron F. Alternative procedures to aortobifemoral bypass grafting. *J Cardiovasc Surg (Torino)*. 1989;30:192-197.
  248. Musicant SE, Giswold ME, Olson CJ, et al. Postoperative duplex scan surveillance of axillofemoral bypass grafts. *J Vasc Surg*. 2003;37:54-61.
  249. Foster MC, Mikulin T, Hopkinson BR, Makin GS. A review of 155 extra-anatomic bypass grafts. *Ann R Coll Surg Engl*. 1986;68:216-218.
  250. Sanchez LA, Suggs WD, Veith FJ, et al. Is surveillance to detect failing polytetrafluoroethylene bypasses worthwhile? Twelve-year experience with ninety-one grafts. *J Vasc Surg*. 1993;18:981-990.
  251. Calligaro KD, Musser DJ, Chen AY, et al. Duplex ultrasonography to diagnose failing arterial prosthetic grafts. *Surgery*. 1996;120:455-459.
  252. Stipa S. Axillofemoral bypass graft with saphenous, cephalic, and basilic veins. *Surg Gynecol Obstet*. 1971;133:297-300.
  253. Wojciechowski J, Znaniecki L, Zelechowski P. Superficial femoral vein and superficial femoral artery as replacement for infected axillofemoral graft. *Ann Vasc Surg*. 2006;20:544-546.
  254. Kenney DA, Sauvage LR, Wood SJ, et al. Comparison of noncrimped, externally supported (EXS) and crimped, nonsupported Dacron prostheses for axillofemoral and above-knee femoropopliteal bypass. *Surgery*. 1982;92:931-946.
  255. Schultz GA, Sauvage LR, Mathisen SR, et al. A five- to seven-year experience with externally-supported Dacron prostheses in axillofemoral and femoropopliteal bypass. *Ann Vasc Surg*. 1986;1:214-224.
  256. Pradhan DJ, Juanteguy JM, Michelson E, Abosch O. Extra-anatomic bypass: review of 60 cases using PTFE grafts. *Am Surg*. 1982;48:258-260.
  257. Orringer MB, Rutherford RB, Skinner DB. An unusual complication of axillofemoral artery bypass. *Surgery*. 1972;72:769-771.
  258. Onoe M, Watarida S, Sugita T, et al. Disruption of the expanded polytetrafluoroethylene (EPTFE) graft of axillofemoral by-pass. *J Cardiovasc Surg (Torino)*. 1994;35:165-168.
  259. Courbier R, Jausseran JM, Bergeron P. Axillo-femoral bypass material of choice. In: Greenhalgh RM, ed. *Extra-anatomic Secondary Arterial Reconstruction*. Bath: Pittman; 1982:122-130.
  260. Christenson JT, Broomè A, Norgren L, Eklof B. The late results after axillo-femoral bypass grafts in patients with leg ischaemia. *J Cardiovasc Surg (Torino)*. 1986;27:131-135.
  261. Taylor LM. Clinical results of axillofemoral bypass using externally supported polytetrafluoroethylene (reply). *J Vasc Surg*. 1991;13:564-565.
  262. Jarowenko MV, Buchbinder D, Shah DM. Effect of external pressure on axillofemoral bypass grafts. *Ann Surg*. 1981;193:274-276.
  263. Cavallaro A, Sciacca V, di Marzo L, et al. The effect of body weight compression on axillo-femoral by-pass patency. *J Cardiovasc Surg (Torino)*. 1988;29:476-479.
  264. Graham JC, Cameron AE, Ismail HI, et al. Axillofemoral and femorofemoral grafts: a 6-year experience with emphasis on the relationship of peroperative flow measurement to graft survival. *Br J Surg*. 1983;70:326-331.
  265. Field JP, Musson AM, Zwolak RM, et al. Duplex arterial flow measurements in normal lower extremities. *J Vasc Technol*. 1989;13:13-19.
  266. Stoney RJ, Ehrenfeld WK, Wylie EJ. Revascularization methods in chronic visceral ischemia caused by atherosclerosis. *Ann Surg*. 1977;186:468-476.

267. Cina C, Ameli FM, Kalman P, Provan JL. Indications and role of axillofemoral bypass in high-risk patients. *Ann Vasc Surg.* 1988;2:237-241.
268. Illuminati G, Calio FG, Mangialardi N, et al. Results of axillofemoral by-passes for aorto-iliac occlusive disease. *Langenbecks Arch Chir.* 1996;381:212-217.
269. Schroe H, Nevelsteen A, Suy R. Extra-anatomical grafting for aorto-occlusive disease: the outcome in 133 procedures. *Acta Chir Belg.* 1990;90:240-243.
270. Mohan CR, Sharp WJ, Hoballah JJ, et al. A comparative evaluation of externally supported polytetrafluoroethylene axillobifemoral and axillofemoral bypass grafts. *J Vasc Surg.* 1995;21:801-809.
271. Bastounis E, Panayiotopoulos YP, Papalambros EL, Balas P. Axillodistal bypass on critical limb ischaemia. *Eur J Vasc Surg.* 1993;7:263-270.
272. McCarthy WJ, McGee GS, Lin WW, et al. Axillary-popliteal artery bypass provides successful limb salvage after removal of infected aortofemoral grafts. *Arch Surg.* 1992;127:974-978.
273. Ascer E, Veith FJ, Gupta S. Axillopopliteal bypass grafting: indications, late results, and determinants of long-term patency. *J Vasc Surg.* 1989;10:285-291.
274. Keller MP, Hoch JR, Harding AD, et al. Axillopopliteal bypass for limb salvage. *J Vasc Surg.* 1992;15:817-822.
275. Kempczinski R, Penn I. Upper extremity complications of axillofemoral grafts. *Am J Surg.* 1978;136:209-211.
276. Alexander RH, Selby JH. Axillofemoral bypass grafts using polytetrafluoroethylene. *South Med J.* 1980;73:1325-1329, 1332.
277. White GH, Donayre CE, Williams RA, et al. Exertional disruption of axillofemoral graft anastomosis. "The axillary pullout syndrome." *Arch Surg.* 1990;125:625-627.
278. Anderson LS, Davis RJ, Simonet M, et al. New mechanism for disruption of axillofemoral bypass. *J Vasc Surg.* 1992;15:255-256.
279. Brophy CM, Quist WC, Kwolek C, LoGerfo FW. Disruption of proximal axillobifemoral bypass graft anastomosis. *J Vasc Surg.* 1992;15:218-220.
280. Bandyk DF, Thiele BL, Radke HM. Upper-extremity emboli secondary to axillofemoral graft thrombosis. *Arch Surg.* 1981;116:393-395.
281. Hartman AR, Fried KS, Khalil I, Riles TS. Late axillary artery thrombosis in patients with occluded axillary-femoral bypass grafts. *J Vasc Surg.* 1985;2:285-287.
282. Khalil IM, Hoballah JJ. Late upper extremity embolic complications of occluded axillofemoral grafts. *Ann Vasc Surg.* 1991;5:375-380.
283. McLafferty RB, Taylor LM Jr, Moneta GL, et al. Upper extremity thromboembolism caused by occlusion of axillofemoral grafts. [erratum appears in *Am J Surg* 1995;170:406]. *Am J Surg.* 1995;169:492-495.
284. Mawatari K, Muto Y, Funahashi S, et al. The potential risk for upper extremity thromboembolism in patients with occluded axillofemoral bypass grafts: two case reports. *Vasc Surg.* 2001;35:67-71.
285. Yeager RA, Taylor LM Jr. Axillary artery anastomosis to avoid axillofemoral bypass disruption. *Semin Vasc Surg.* 2000;13:74-76.
286. Marston WA, Risley GL, Criado E, et al. Management of failed and infected axillofemoral grafts. *J Vasc Surg.* 1994;20:357-366.
287. de Virgilio C, Cherry KJ Jr, Gloviczki P, et al. Infected lower extremity extra-anatomic bypass grafts: management of a serious complication in high-risk patients. *Ann Vasc Surg.* 1995;9:459-466.
288. Mahoney WD, Whelan TJ. Use of obturator foramen in iliofemoral artery grafting: case reports. *Ann Surg.* 1966;163:215-220.
289. DePalma RG, Hubay CA. Arterial bypass via the obturator foramen. An alternative in complicated vascular problems. *Am J Surg.* 1968;115:323-328.

290. Spiro M, Cotton LT. The obturator canal as a route for iliofemoral by-pass. *Br J Surg*. 1970;57:168-172.
291. Kunlin J. Le pontage ou bypass en chirurgie artérielle restauratrice des membres. *Aktuelle Probl Angiol*. 1968;105-113.
292. Tilson MD, Sweeney T, Gusberg RJ, Stansel HC. Obturator canal bypass grafts for septic lesions of the femoral artery. *Arch Surg*. 1979;114:1031-1033.
293. Fromm SH, Lucas CE. Obturator bypass for mycotic aneurysm in the drug addict. *Arch Surg*. 1970;100:82-83.
294. Patel KR, Semel L, Clauss RH. Routine revascularization with resection of infection femoral pseudoaneurysms from substance abuse. *J Vasc Surg*. 1988;8:321-328.
295. Mentha C, Launois B, Delaere J. Les pontages artériels ilio-fémoraux par le trou obturateur [Ilio-femoral arterial bridging by the obturator foramen]. *J Chir (Paris)*. 1965;90:131-140.
296. Donahoe PK, Froio RA, Nabseth DC. Obturator bypass graft in radical excision of inguinal neoplasm. *Ann Surg*. 1967;166:147-149.
297. Wood RF. Arterial grafting through the obturator foramen in secondary hemorrhage from the femoral vessels. *Angiology*. 1982;33:385-392.
298. Hegarty JC, Linton PC, McSweeney ED Jr. Revascularization of the lower extremity through the obturator canal. *Arch Surg*. 1969;98:35-38.
299. Größ JD, Heisel W. Der Obturator-Bypass. Indikation-Technik-Ergebnisse [The obturator bypass. Indication-technic-results]. *Thoraxchir Vask Chir*. 1971;19:483-488.
300. van Det RJ, Brands LC. The obturator foramen bypass: an alternative procedure in iliofemoral artery revascularization. *Surgery*. 1981;89:543-547.
301. Reddy DJ, Smith RF, Elliott JP Jr, et al. Infected femoral artery false aneurysms in drug addicts: evolution of selective vascular reconstruction. *J Vasc Surg*. 1986;3:718-724.
302. Reddy DJ. Treatment of drug-related infected false aneurysm of the femoral artery—is routine revascularization justified? *J Vasc Surg*. 1988;8:344-345.
303. Padberg F Jr, Hobson R 2nd, Lee B, et al. Femoral pseudoaneurysm from drugs of abuse: ligation or reconstruction? *J Vasc Surg*. 1992;15:642-648.
304. Arora S, Weber MA, Fox CJ, et al. Common femoral artery ligation and local debridement: a safe treatment for infected femoral artery pseudoaneurysms. *J Vasc Surg*. 2001;33:990-993.
305. Nevelsteen A, Mees U, Deleersnijder J, Suy R. Obturator bypass: a sixteen year experience with 55 cases. *Ann Vasc Surg*. 1987;1:558-563.
306. Panetta T, Sottiurai VS, Batson RC. Obturator bypass with nonreversed translocated saphenous vein. *Ann Vasc Surg*. 1989;3:56-62.
307. Reddy DJ, Shin LH. Obturator bypass: technical considerations. *Semin Vasc Surg*. 2000;13:49-52.
308. Benjamin ME, Cohn EJ Jr, Purtill WA, et al. Arterial reconstruction with deep leg veins for the treatment of mycotic aneurysms. *J Vasc Surg*. 1999;30:1004-1015.
309. Guida PM, Moore SW. Obturator bypass technique. *Surg Gynecol Obstet*. 1969;128:1307-1316.
310. Diethrich EB, Noon GP, Liddicoat JE, De Bakey ME. Treatment of infected aortofemoral arterial prosthesis. *Surgery*. 1970;68:1044-1052.
311. Rawson HD. Arterial grafting through the obturator foramen. *Aust N Z J Surg*. 1986;56:127-130.
312. Patel A, Taylor SM, Langan EM 3rd, et al. Obturator bypass: a classic approach for the treatment of contemporary groin infection. *Am Surg*. 2002;68:653-659.
313. Millis JM, Ahn SS. Transobturator aorto-profunda femoral artery bypass using the direct medial thigh approach. *Ann Vasc Surg*. 1993;7:384-390.
314. Plate G, Qvarfordt P, Oredsson S, Stigsson L. Obturator bypass to the distal profunda femoris artery using a medial approach—long-term results. *Eur J Vasc Endovasc Surg*. 1998;16:164-168.

315. Kerdiles Y, Baudry F, Rouxel P, et al. Le pontage par le trou obturateur dans la chirurgie artérielle restauratrice des membres inférieurs [Bypass graft through the foramen obturatum in the restorative arterial surgery of the lower limbs]. *Ann Chir Thorac Cardiovasc*. 1974;13:335-341.
316. Pearce WH, Ricco JB, Yao JS, et al. Modified technique of obturator bypass in failed or infected grafts. *Ann Surg*. 1983;197:344-347.
317. Berguer R, Feldman AJ. Infected groin aneurysms from heroin addiction. In: Bergan JJ, Yao JST, eds. *Aneurysms: Diagnosis and Treatment*. New York: Grune & Stratton; 1981:643-655.
318. Rudich M, Gutierrez IZ, Gage AA. Obturator foramen bypass in the management of infected vascular prostheses. *Am J Surg*. 1979;137:657-660.
319. Calligaro KD, Veith FJ, Schwartz ML, et al. Are gram-negative bacteria a contraindication to selective preservation of infected prosthetic arterial grafts? *J Vasc Surg*. 1992;16:337-346.
320. Sautner T, Niederle B, Herbst F, et al. The value of obturator canal bypass. A review. *Arch Surg*. 1994;129:718-722.
321. Taylor SM, Weatherford DA, Langan EM 3rd, Lokey JS. Outcomes in the management of vascular prosthetic graft infections confined to the groin: a reappraisal. *Ann Vasc Surg*. 1996;10:117-122.
322. Kretschmer G, Niederle B, Huk I, et al. Groin infections following vascular surgery: obturator bypass (BYP) versus "biologic coverage" (TRP)—a comparative analysis. *Eur J Vasc Surg*. 1989;3:25-29.
323. Macpherson AI. Iliofemoral arterial by-pass through the obturator foramen. *Br J Surg*. 1967;54:946-947.
324. Mercier C, Juhan C, Chauvin G, Bourde J. Faux an érysme suppuré du triangle de Scarpa. Pontage ilio-femoral par le trou obturateur. *Mars Chir*. 1967;19:249-252.
325. Brücke VP, Piza F. Zur Indikation des Obturator-Bypass [On indications for the obturator bypass]. *Zentralbl Chir*. 1968;93:489-493.
326. Bell CL, Ali AT, Brawley JG, et al. Arterial reconstruction of infected femoral artery pseudoaneurysms using superficial femoral-popliteal vein. *J Am Coll Surg*. 2005;200:831-836.
327. Smith RF, Szilagyi DE, Colville JM. Surgical treatment of mycotic aneurysms. *Arch Surg*. 1962;85:663-674.
328. Leather RP, Karmody AM. A lateral route for extra-anatomical bypass of the femoral artery. *Surgery*. 1977;81:307-309.
329. Trout HH 3rd, Smith CA. Lateral iliopopliteal arterial bypass as an alternative to obturator bypass. *Am Surg*. 1982;48:63-64.
330. Katsamouris AN, Giannoukas AD, Alamanos E, et al. Experience with new techniques for extraanatomic arterial reconstruction of the lower limb. *Ann Vasc Surg*. 2000;14:444-449.
331. Brzezinski W, Callaghan JC. Transiliac bypass for infected femoral end of an aortofemoral graft. *Can J Surg*. 1989;32:121-123.
332. Favre J-P, Gournier J-P, Barral X. Trans-osseous ilio-femoral by-pass. A new extra-anatomical by-pass. *J Cardiovasc Surg (Torino)*. 1993;34:455-459.
333. Schneider JR, Oskin SI, Verta MJ Jr. Superficial femoral vein graft interposition in-situ repair for femoral mycotic aneurysm. *Ann Vasc Surg*. 2009;23:147-149.
334. Ali AT, Bell C, Modrall JG, et al. Graft-associated hemorrhage from femoropopliteal vein grafts. *J Vasc Surg*. 2005;42:667-672.
335. Meyer JP, Durham JR, Schwarcz TH, et al. The use of sartorius muscle rotation-transfer in the management of wound complications after infrainguinal vein bypass: a report of eight cases and description of the technique. *J Vasc Surg*. 1989;9:731-735.
336. Hasen KV, Gallegos ML, Dumanian GA. Extended approach to the vascular pedicle of the gracilis muscle flap: anatomical and clinical study. *Plast Reconstr Surg*. 2003;111:2203-2208.
337. Sheiner NM, Sigman H, Stilman A. An unusual complication of obturator foramen arterial bypass. *J Cardiovasc Surg (Torino)*. 1969;10:324-328.

338. Blaisdell FW, Demattei GA, Gauder PJ. Extraperitoneal thoracic aorta to femoral bypass graft as replacement for an infected aortic bifurcation prosthesis. *Am J Surg.* 1961;102:583-585.
339. DeLaurentis DA. The descending thoracic aorta in reoperative aortic surgery. In: Bergan JJ, Yao JST, eds. *Reoperative Arterial Surgery*. Orlando: Grune & Stratton; 1986:195-203.
340. Sapienza P, Mingoli A, Feldhaus RJ, et al. Descending thoracic aorta-to-femoral artery bypass grafts. *Am J Surg.* 1997;174:662-666.
341. Fulenwider JT, Smith RB 3rd, Johnson RW, et al. Reoperative abdominal arterial surgery—a ten-year experience. *Surgery.* 1983;93:20-27.
342. Reilly LM, Ehrenfeld WK, Stoney RJ. Delayed aortic prosthetic reconstruction after removal of an infected graft. *Am J Surg.* 1984;148:234-239.
343. DiMuzio PJ, Reilly LM, Stoney RJ. Redo aortic grafting after treatment of aortic graft infection. *J Vasc Surg.* 1996;24:328-337.
344. Nunn DB, Kamal MA. Bypass grafting from the thoracic aorta to femoral arteries for high aortoiliac occlusive disease. *Surgery.* 1972;72:749-755.
345. Passman MA, Farber MA, Criado E, et al. Descending thoracic aorta to iliofemoral artery bypass grafting: a role for primary revascularization for aortoiliac occlusive disease? *J Vasc Surg.* 1999;29:249-258.
346. Crawford ES, De Bakey ME, Morris GC Jr, et al. Aneurysm of the abdominal aorta. *Surg Clin North Am.* 1966;46:963-978.
347. Qvarfordt PG, Stoney RJ, Reilly LM, et al. Management of pararenal aneurysms of the abdominal aorta. *J Vasc Surg.* 1986;3:84-93.
348. Nypaver TJ, Shepard AD, Reddy DJ, et al. Supraceliac aortic cross-clamping: determinants of outcome in elective abdominal aortic reconstruction. *J Vasc Surg.* 1993;17:868-876.
349. Schneider JR, Gottner RJ, Golan JF. Supraceliac versus infrarenal aortic cross-clamp for repair of non-ruptured infrarenal and juxtarenal abdominal aortic aneurysm. *Cardiovasc Surg.* 1997;5:279-285.
350. Cormier JM, Uhl JF. Revascularisation antérograde des artères digestives par pontage implanté sur l'aorte sus-rénale. *Nouv Presse Med.* 1979;8:2195-2197.
351. Williams GM, Ricotta J, Zinner M, Burdick J. The extended retroperitoneal approach for treatment of extensive atherosclerosis of the aorta and renal vessels. *Surgery.* 1980;88:846-855.
352. Crawford ES, Manning LG, Kelly TF. "Redo" surgery after operations for aneurysm and occlusion of the abdominal aorta. *Surgery.* 1977;81:41-52.
353. May J, Patrick W, Harris J. Transabdominal exposure of the thoracic aorta. *Surg Gynecol Obstet.* 1980;151:803-805.
354. Canepa CS, Schubart PJ, Taylor LM Jr, Porter JM. Supraceliac aortofemoral bypass. *Surgery.* 1987;101:323-328.
355. May J, Harris JP. Use of the supraceliac aorta for repeat aortic surgery. In: Bergan JJ, Yao JST, eds. *Reoperative Arterial Surgery*. New York: Grune & Stratton; 1986:175-193.
356. Mills JL, Fujitani RM, Taylor SM. The retroperitoneal, left flank approach to the supraceliac aorta for difficult and repeat aortic reconstructions. *Am J Surg.* 1991;162:638-642.
357. Barral X, Youvarlakis P, Boissier C, Cavallo G. Supraceliac aorta-to-lower extremity arterial bypass. *Ann Vasc Surg.* 1986;1:30-35.
358. Bacourt F. Revascularization des membres et des artères viscérales à partir de l'aorte thoracique par vois abdominale. Nouvelle technique. *J Chir (Paris).* 1982;119:749-752.
359. Frantz SL, Kaplitt MJ, Beil AR Jr, Stein HL. Ascending aorta-bilateral femoral artery bypass for the totally occluded infrarenal abdominal aorta. *Surgery.* 1974;75:471-475.
360. Baird RJ, Ropchan GV, Oates TK, et al. Ascending aorta to bifemoral bypass—a ventral aorta. *J Vasc Surg.* 1986;3:405-410.
361. Veith FJ, Hartsuck JM, Crane C. Management of aortoiliac reconstruction complicated by sepsis and hemorrhage. *N Engl J*

- Med.* 1964;270:1389-1391.
362. Frøysaker T, Skagseth E, Dundas P, Hall KV. Bypass procedures in the treatment of obstructions of the abdominal aorta. *J Cardiovasc Surg (Torino)*. 1973;14:317-321.
  363. Cevese PG, Gallucci V. Thoracic aorta-to-femoral artery by-pass. For the treatment of complete obstruction of the abdominal aorta at the level of the renal arteries. *J Cardiovasc Surg (Torino)*. 1975;16:432-438.
  364. Buxton B, Simpson L, Johnson N, Myers K. Descending thoracic aortofemoral bypass for distal aortic reconstruction after removal of an infected Dacron prosthesis. *Med J Aust.* 1976;2:133-136.
  365. Lakner G, Lukács L. High aortoiliac occlusion: treatment with thoracic aorta to femoral arterial bypass. *J Cardiovasc Surg (Torino)*. 1983;24:532-534.
  366. Ochsner JL. Use of thoracic aorta in revascularization of the lower extremity. In: Bergan JJ, Yao JST, eds. *Evaluation and Treatment of Upper and Lower Extremity Circulatory Disorders*. Orlando: Grune & Stratton; 1984:361-368.
  367. Feldhaus RJ, Sterpetti AV, Schultz RD, Peetz DJ Jr. Thoracic aorta-femoral artery bypass: indications, technique, and late results. *Ann Thorac Surg.* 1985;40:588-592.
  368. Haas KL, Moulder PV, Kerstein MD. Use of thoracic aortobifemoral artery bypass grafting as an alternative procedure for occlusive aortoiliac disease. *Am Surg.* 1985;51:573-576.
  369. Rosenfeld JC, Savarese RP, DeLaurentis DA. Distal thoracic aorta to femoral artery bypass: a surgical alternative. *J Vasc Surg.* 1985;2:747-750.
  370. Enon B, Chevalier JM, Moreau P, et al. Revascularisation des membres inférieurs à partir de l'aorte thoracique descendante. [Revascularization of the lower limbs starting from the descending thoracic aorta]. *J Chir (Paris)*. 1985;122:539-543.
  371. McCarthy WJ, Rubin JR, Flinn WR, et al. Descending thoracic aorta-to-femoral artery bypass. *Arch Surg.* 1986;121:681-688.
  372. Schultz RD, Sterpetti AV, Feldhaus RJ. Thoracic aorta as source of inflow in reoperation for occluded aortoiliac reconstruction. *Surgery.* 1986;100:635-645.
  373. Amjad Hussain S. Descending thoracic aorta to bifemoral by-pass graft without laparotomy. *Int Surg.* 1988;73:260-263.
  374. Schellack J, Fulenwider JT, Smith RB 3rd. Descending thoracic aortofemoral-femoral bypass: a remedial alternative for the failed aortobifemoral bypass. *J Cardiovasc Surg (Torino)*. 1988;29:201-204.
  375. Bowes DE, Youkey JR, Pharr WP, et al. Long term follow-up of descending thoracic aorto-iliac/femoral bypass. *J Cardiovasc Surg (Torino)*. 1990;31:430-437.
  376. Branchereau A, Espinoza H, Rudondy P, et al. Descending thoracic aorta as an inflow source for late occlusive failures following aortoiliac reconstruction. *Ann Vasc Surg.* 1991;5:8-15.
  377. Kalman PG, Johnston KW, Walker PM. Descending thoracic aortofemoral bypass as an alternative for aortoiliac revascularization. *J Cardiovasc Surg (Torino)*. 1991;32:443-446.
  378. O'Brien DP, Waldron RP, McCabe JP, Courtney DF. Descending thoracic aorto-bifemoral bypass graft: a safe alternative in the high risk patients. *Ir Med J.* 1991;84:58-59.
  379. McCarthy WJ, Mesh CL, McMillan WD, et al. Descending thoracic aorta-to-femoral artery bypass: ten years' experience with a durable procedure. *J Vasc Surg.* 1993;17:336-348.
  380. Carrel T, Pasic M, Niederhäuser U, Turina M. Le pontage extra-anatomique thoraco-bifémoral: une excellente alternative à la reconstruction in situ lors de revascularisation iterative des membres inférieurs. [Extra-anatomic thoraco-bifemoral bypass: an excellent alternative to in-situ reconstruction for repeat revascularization of the lower limbs]. *Schweiz Med Wochenschr.* 1994;124:961-965.
  381. Criado E. Descending thoracic aorta to femoral artery bypass: surgical technique. *Ann Vasc Surg.* 1997;11:206-215.
  382. Kalman PG. Thoracofemoral bypass: proximal exposure and tunneling. *Semin Vasc Surg.* 2000;13:65-69.
  383. Passman MA. Descending thoracic aorta to femoral artery bypass. *Perspect Vasc Surg.* 1999;11:69-81.
  384. Kalman PG. Thoracofemoral bypass: a useful addition to a vascular surgeon's armamentarium. *Perspect Vasc Surg*

*Endovasc Ther.* 2004;16:59-64.

385. McMillan WD, McCarthy WJ. Minimally invasive thoracoscopic thoraco-femoral bypass: a case report. *Cardiovasc Surg.* 1999;7:251-254.
386. Elkins R, DeMeester TR, Brawley RK. Surgical exposure of the upper abdominal aorta and its branches. *Surgery.* 1971;70:622-627.
387. O'Mara CS, Williams GM. Expanded retroperitoneal approach for abdominal aortic aneurysm repair. In: Bergan JJ, Yao JST, eds. *Aneurysms, Diagnosis and Treatment*. New York: Grune & Stratton; 1982:327-343.
388. Sicard GA, Reilly JM. Left retroperitoneal approach to the aorta and its branches: Part I. *Ann Vasc Surg.* 1994;8:212-219.
389. Wolf YG, Sasson T, Wolf DG, et al. Thoracic aorta transobturator bipopliteal bypass as eventual durable reconstruction after removal of an infected aortofemoral graft. *J Vasc Surg.* 1997;26:693-696.

## 第 107 章

1. TASC working group. TransAtlantic Inter-Society Consensus. *J Vasc Surg.* 2007;45:S214-S217.
2. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *Circulation.* 2006;113:e463-e654.
3. De Vries SO, Hunink MG. Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis. *J Vasc Surg.* 1997;26:558-569.
4. Galland RB. Mortality following elective infrarenal aortic reconstruction: a joint Vascular Research Group study. *Br J Surg.* 1998;85:633-636.
5. Cau J, Ricco JB, Marchand C, et al. Total laparoscopic aortic repair for occlusive and aneurysmal disease: first 95 cases. *Eur J Vasc Endovasc Surg.* 2006;31:567-574.
6. Dooner J, Lee S, Griswold W, et al. Laparoscopic aortic reconstruction: early experience. *Am J Surg.* 2006;191:691-695.
7. Olinde AJ, Mcneil JW, Sam A, et al. Totally laparoscopic aortobifemoral bypass: a review of 22 cases. *J Vasc Surg.* 2005;42:27-34.
8. Rouers A, Meurisse N, Lavigne JP, et al. Potential benefits of laparoscopic aorto-bifemoral bypass surgery. *Acta Chir Belg.* 2005;105:610-615.
9. Remy P, Deprez AF, D'hont CH, et al. Total laparoscopic aortobifemoral bypass. *Eur J Vasc Endovasc Surg.* 2005;29:22-27.
10. Barbera L, Geier B, Kemen M, et al. Clinical experiences with 43 cases of laparoscopic reconstruction in aortoiliac occlusive diseases: analysis of morbidity, effectiveness and treatment results. *Zentralbl Chir.* 2001;126:134-137.
11. Kolvenbach R, Puerschel A, Fajer S, et al. Total laparoscopic aortic surgery versus minimal access techniques: review of more than 600 patients. *Vascular.* 2006;14:186-192.
12. Dion YM, Griselli F, Douville Y, et al. Early and mid-term results of totally laparoscopic surgery for aortoiliac disease: lessons learned. *Surg Laparosc Endosc Percutan Tech.* 2004;14:328-334.
13. Alimi YS, Hartung O, Orsoni P, et al. Abdominal aortic laparoscopic surgery: retroperitoneal or transperitoneal approach? *Eur J Vasc Endovasc Surg.* 2000;19:21-26.
14. Dion YM, Gracia CR. A new technique for laparoscopic aortobifemoral grafting in occlusive aortoiliac disease. *J Vasc Surg.* 1997;26:685-692.
15. Dion YM, Thaveau F, Fearn SJ. Current modifications to totally laparoscopic apron technique. *J Vasc Surg.*

- 2003;38:403-406.
16. Stadler P, Sebesta P, Vitasek P, et al. A modified technique of transperitoneal direct approach for totally laparoscopic aortoiliac surgery. *Eur J Vasc Endovasc Surg.* 2006;32:266-269.
  17. Alimi YS, Hartung O, Cavalero C, et al. Intestinal retractor for transperitoneal laparoscopic aortoiliac reconstruction: experimental study on human cadavers and initial clinical experience. *Surg Endosc.* 2000;14:915-919.
  18. Barbera L, Ludemann R, Grossefeld M, et al. Newly designed retraction devices for intestine control during laparoscopic aortic surgery: a comparative study in an animal model. *Surg Endosc.* 2000;14:63-66.
  19. Cau J, Ricco JB, Deelchand A, et al. Totally laparoscopic aortic repair: a new device for direct transperitoneal approach. *J Vasc Surg.* 2005;41:902-906.
  20. Said S, Mall J, Peter F, et al. Laparoscopic aorto-femoral bypass grafting: human cadaveric and initial clinical experiences. *J Vasc Surg.* 1999;29:639-648.
  21. Coggia M, Bourriez A, Javerliat I, et al. Totally laparoscopic aortobifemoral bypass: a new and simplified approach. *Eur J Vasc Endovasc Surg.* 2002;24:274-275.
  22. Coggia M, Di Centa I, Javerliat I, et al. Total laparoscopic aortic surgery: transperitoneal left retrorenal approach. *Eur J Vasc Endovasc Surg.* 2004;28:619-622.
  23. Di Centa I, Coggia M, Javerliat I, et al. Total laparoscopic aortic surgery: transperitoneal direct approach. *Eur J Vasc Endovasc Surg.* 2005;30:494-496.
  24. Castronuovo JJ Jr, James KV, Resnikoff M, et al. Laparoscopic-assisted abdominal aortic aneurysmectomy. *J Vasc Surg.* 2000;32:224-233.
  25. Javerliat I, Coggia M, Di Centa I, et al. Total videoscopic aortic surgery: left retroperitoneoscopic approach. *Eur J Vasc Endovasc Surg.* 2005;29:244-246.
  26. Javerliat I, Coggia M, Bourriez A, et al. Total laparoscopic aortomesenteric bypass. *Vascular.* 2004;12:126-129.
  27. Alimi YS, Di Molfetta L, Hartung O, et al. Laparoscopy-assisted abdominal aortic aneurysm endoaneurysmorrhaphy: early and mid-term results. *J Vasc Surg.* 2003;37:744-749.
  28. Coggia M, Javerliat I, Di Centa I, et al. Total laparoscopic bypass for aortoiliac occlusive lesions: a 93 cases experience. *J Vasc Surg.* 2004;40:899-906.
  29. Di Centa I, Coggia M, Cerceau P, et al. Total laparoscopic aortobifemoral bypass: short- and middle-term results. *Ann Vasc Surg.* 2008;22:227-232.
  30. Adye B, Luna G. Incidence of abdominal wall hernia in aortic surgery. *Am J Surg.* 1998;175:400-402.
  31. Raffetto JDD, Cheung Y, Fisher JB, et al. Incision and abdominal wall hernias in patients with aneurysm or occlusive aortic disease. *J Vasc Surg.* 2003;37:1150-1154.
  32. Schermerhorn ML, O'Malley AJ, et al. Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population. *N Engl J Med.* 2008;358:464-474.
  33. Chapron CM, Pierre F, Lacroix S, et al. Major vascular injuries during gynecologic laparoscopy. *J Am Coll Surg.* 1997;185:461-465.
  34. Bonjer HJ, Hazebroek EJ, Kazemier G, et al. Open versus closed establishment of pneumoperitoneum in laparoscopic surgery. *Br J Surg.* 1997;84:599-602.
  35. Dion YM, Gracia CR, Estakhri M, et al. Totally laparoscopic aortobifemoral bypass. A review of ten patients. *Surg Laparosc Endosc.* 1998;8:165-170.
  36. Usual H, Sayad P, Hayek N, et al. Major vascular injuries during laparoscopic cholecystectomy. *Surg Endosc.* 1998;12:960-962.
  37. Alimi YS, Harting O, Valerio N, et al. Laparoscopic aorto-iliac surgery for aneurysm and occlusive disease: when should a minilaparotomy be performed? *J Vasc Surg.* 2001;33:469-475.
  38. Sternberg A, Alfici R, Bronek S, et al. Laparoscopic surgery and splanchnic vessel thrombosis. *J Laparoendosc Adv Surg*



- Tech.* 1998;8:65-68.
39. Richmond BK, Lucente FC, Boland JP. Laparoscopy-associated mesenteric vascular events: description of an evolving clinical syndrome. *J Laparoendosc Adv Surg Tech.* 1997;7:363-367.

## 第 108 章

1. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. Description of a new technic and a preliminary report of its application. *Circulation.* 1964;30:654-670.
2. Palmaz JC, Richter GM, Noeldge G, et al. Intraluminal stents in atherosclerotic iliac artery stenosis: preliminary report of a multicenter study. *Radiology.* 1988;168:727-731.
3. Palmaz JC, Sibbitt RR, Reuter SR, et al. Expandable intraluminal graft: a preliminary study. Work in progress. *Radiology.* 1985;156:73-77.
4. Palmaz JC, Sibbitt RR, Tio FO, et al. Expandable intraluminal vascular graft: a feasibility study. *Surgery.* 1986;99:199-205.
5. McCready RA, Vincent AE, Schwartz RW, et al. Atherosclerosis in the young: a virulent disease. *Surgery.* 1984;96:863-869.
6. Najafi H, Ostermiller WE, Ardekani RG, et al. Aortoiliac reconstruction in patients 32 to 45 years of age. *Arch Surg.* 1970;101:780-784.
7. Olsen PS, Gustafsen J, Rasmussen L, Lorentzen JE. Long-term results after arterial surgery for arteriosclerosis of the lower limbs in young adults. *Eur J Vasc Surg.* 1988;2:15-18.
8. Reed AB, Conte MS, Donaldson MC, et al. The impact of patient age and aortic size on the results of aortobifemoral bypass grafting. *J Vasc Surg.* 2003;37:1219-1225.
9. Kumins NH, Owens EL, Oglevie SB, et al. Early experience using the Wallgraft in the management of distal microembolism from common iliac artery pathology. *Ann Vasc Surg.* 2002;16:181-186.
10. Matchett WJ, McFarland DR, Eidt JF, Moursi MM. Blue toe syndrome: treatment with intra-arterial stents and review of therapies. *J Vasc Interv Radiol.* 2000;11:585-592.
11. Renshaw A, McCowen T, Waltke EA, et al. Angioplasty with stenting is effective in treating blue toe syndrome. *Vasc Endovasc Surg.* 2002;36:155-159.
12. Briguori C, Airolidi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. *Circulation.* 2007;115:1211-1217.
13. Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. *Eur Heart J.* 2004;25:206-211.
14. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. *JAMA.* 2004;291:2328-2334.
15. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S5-S67.
16. Leville CD, Kashyap VS, Clair DG, et al. Endovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter-Society Consensus class C and D patients. *J Vasc Surg.* 2006;43:32-39.
17. Voiculescu A, Hollenbeck M, Plum J, et al. Iliac artery stenosis proximal to a kidney transplant: clinical findings, duplex-sonographic criteria, treatment, and outcome. *Transplantation.* 2003;76:332-339.
18. Polak JF. Arterial sonography: efficacy for the diagnosis of arterial disease of the lower extremity. *AJR Am J Roentgenol.* 1993;161:235-243.
19. Rosfors S, Eriksson M, Hoglund N, Johansson G. Duplex ultrasound in patients with suspected aorto-iliac occlusive disease. *Eur J Vasc Surg.* 1993;7:513-517.
20. Rzucidlo EM, Powell RJ, Zwolak RM, et al. Early results of stent-grafting to treat diffuse aortoiliac occlusive disease. *J Vasc Surg.* 2003;37:1175-1180.
21. Morcos SK. Contrast media-induced nephrotoxicity—questions and answers. *Br J Radiol.* 1998;71:357-365.

22. Sprout IA. *Percutaneous transluminal balloon angioplasty of the aorta and the iliac arteries*. In: Darcy MD, Vedantham S, eds. *SCVIR Syllabus. Peripheral and Vascular Interventions*. 2nd ed; 2001:179-204.
23. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). *Eur Radiol*. 1999;9:1602-1613.
24. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. *N Engl J Med*. 2003;348:491-499.
25. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. *Radiology*. 1993;188:171-178.
26. Eisenberg RL, Bank WO, Hedgcock MW. Renal failure after major angiography can be avoided with hydration. *AJR Am J Roentgenol*. 1981;136:859-861.
27. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. *J Am Coll Cardiol*. 2006;48:924-930.
28. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. *J Am Coll Cardiol*. 2006;48:692-699.
29. Kelly AM, Dwamena B, Cronin P, et al. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. *Ann Intern Med*. 2008;148:284-294.
30. Bakris GL, Lass N, Gaber AO, et al. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. *Am J Physiol*. 1990;258:F115-F120.
31. Lindinger MI, Franklin TW, Lands LC, et al. NaHCO<sub>3</sub> and KHCO<sub>3</sub> ingestion rapidly increases renal electrolyte excretion in humans. *J Appl Physiol*. 2000;88:540-550.
32. Smith JC, Watkins GE, Taylor FC, et al. Angioplasty or stent placement in the proximal common iliac artery: is protection of the contralateral side necessary? *J Vasc Interv Radiol*. 2001;12:1395-1398.
33. Leung DA, Spinosa DJ, Hagspiel KD, et al. Selection of stents for treating iliac arterial occlusive disease. *J Vasc Interv Radiol*. 2003;14:137-152.
34. Nelson PR, Powell RJ, Schermerhorn ML, et al. Early results of external iliac artery stenting combined with common femoral artery endarterectomy. *J Vasc Surg*. 2002;35:1107-1113.
35. Tetteroo E, van der Graaf Y, Bosch JL, et al. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. *Lancet*. 1998;351:1153-1159.
36. Tetteroo E, van Engelen AD, Spithoven JH, et al. Stent placement after iliac angioplasty: comparison of hemodynamic and angiographic criteria. Dutch Iliac Stent Trial Study Group. *Radiology*. 1996;201:155-159.
37. Parsons RE, Suggs WD, Lee JJ, et al. Percutaneous transluminal angioplasty for the treatment of limb threatening ischemia: do the results justify an attempt before bypass grafting? *J Vasc Surg*. 1998;28:1066-1071.
38. Korogi Y, Takahashi M. Percutaneous transluminal angioplasty of totally occluded iliac arteries in high-risk patients. *Br J Radiol*. 1986;59:1167-1170.
39. Ring EJ, Freiman DB, McLean GK, Schwarz W. Percutaneous recanalization of common iliac artery occlusions: an unacceptable complication rate? *AJR Am J Roentgenol*. 1982;139:587-589.
40. Haulon S, Mounier-Vehier C, Gaxotte V, et al. Percutaneous reconstruction of the aortoiliac bifurcation with the "kissing stents" technique: long-term follow-up in 106 patients. *J Endovasc Ther*. 2002;9:363-368.
41. Klein WM, van der Graaf Y, Seegers J, et al. Long-term cardiovascular morbidity, mortality, and reintervention after endovascular treatment in patients with iliac artery disease: The Dutch Iliac Stent Trial Study. *Radiology*. 2004;232:491-498.
42. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. *Radiology*. 1997;204:87-96.

43. Murphy TP. *The role of stents in aorto-iliac occlusive disease*. New York: Thieme; 1998.
44. Schurmann K, Mahnken A, Meyer J, et al. Long-term results 10 years after iliac arterial stent placement. *Radiology*. 2002;224:731-738.
45. Galaria II, Davies MG. Percutaneous transluminal revascularization for iliac occlusive disease: long-term outcomes in TransAtlantic Inter-Society Consensus A and B lesions. *Ann Vasc Surg*. 2005;19:352-360.
46. de Vries SO, Hunink MG. Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis. *J Vasc Surg*. 1997;26:558-569.
47. Carnevale FC, De Blas M, Merino S, et al. Percutaneous endovascular treatment of chronic iliac artery occlusion. *Cardiovasc Intervent Radiol*. 2004;27:447-452.
48. Dyet JF, Gaines PA, Nicholson AA, et al. Treatment of chronic iliac artery occlusions by means of percutaneous endovascular stent placement. *J Vasc Interv Radiol*. 1997;8:349-353.
49. Henry M, Amor M, Ethevenot G, et al. Percutaneous endoluminal treatment of iliac occlusions: long-term follow-up in 105 patients. *J Endovasc Surg*. 1998;5:228-235.
50. Uher P, Nyman U, Lindh M, et al. Long-term results of stenting for chronic iliac artery occlusion. *J Endovasc Ther*. 2002;9:67-75.
51. Scheinert D, Schroder M, Ludwig J, et al. Stent-supported recanalization of chronic iliac artery occlusions. *Am J Med*. 2001;110:708-715.
52. Chang RW, Goodney PP, Baek JH, et al. Long-term results of combined common femoral endarterectomy and iliac stenting/stent grafting for occlusive disease. *J Vasc Surg*. 2008;48:362-367.
53. Powell RJ, Fillinger M, Bettmann M, et al. The durability of endovascular treatment of multisegment iliac occlusive disease. *J Vasc Surg*. 2000;31:1178-1184.
54. Powell RJ, Fillinger M, Walsh DB, et al. Predicting outcome of angioplasty and selective stenting of multisegment iliac artery occlusive disease. *J Vasc Surg*. 2000;32:564-569.
55. Timaran CH, Stevens SL, Freeman MB, Goldman MH. Predictors for adverse outcome after iliac angioplasty and stenting for limb-threatening ischemia. *J Vasc Surg*. 2002;36:507-513.
56. Timaran CH, Stevens SL, Freeman MB, Goldman MH. External iliac and common iliac artery angioplasty and stenting in men and women. *J Vasc Surg*. 2001;34:440-446.
57. Reyes R, Carreira JM, Gude F, et al. Long-term follow-up of iliac wallstents. *Cardiovasc Intervent Radiol*. 2004;27:624-631.
58. Lammer J, Dake MD, Bleyn J, et al. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent-graft. International Trial Study Group. *Radiology*. 2000;217:95-104.
59. Schurmann K, Vorwerk D, Uppenkamp R, et al. Iliac arteries: plain and heparin-coated Dacron-covered stent-grafts compared with noncovered metal stents—an experimental study. *Radiology*. 1997;203:55-63.
60. Cynamon J, Marin ML, Veith FJ, et al. Stent-graft repair of aorto-iliac occlusive disease coexisting with common femoral artery disease. *J Vasc Interv Radiol*. 1997;8:19-26.
61. Lacroix H, Stockx L, Wilms G, Nevelsteen A. Transfemoral treatment for iliac occlusive disease with endoluminal stent-grafts. *Eur J Vasc Endovasc Surg*. 1997;14:204-207.
62. Nevelsteen A, Lacroix H, Stockx L, Wilms G. Stent grafts for iliofemoral occlusive disease. *Cardiovasc Surg*. 1997;5:393-397.
63. Krajcer Z, Sioco G, Reynolds T. Comparison of Wallgraft and Wallstent for treatment of complex iliac artery stenosis and occlusion. Preliminary results of a prospective randomized study. *Tex Heart Inst J*. 1997;24:193-199.
64. Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. *Semin Vasc Surg*. 1999;12:123-137.
65. Dormandy J, Heeck L, Vig S. Lower-extremity arteriosclerosis as a reflection of a systemic process: implications for concomitant coronary and carotid disease. *Semin Vasc Surg*. 1999;12:118-122.
66. Dormandy J, Heeck L, Vig S. Peripheral arterial occlusive disease: clinical data for decision making. Introduction. *Semin*

- Vasc Surg.* 1999;12:95.
67. Harris RA, Hardman DT, Fisher C, et al. Aortic reconstructive surgery for limb ischaemia: immediate and long-term follow-up to provide a standard for endovascular procedures. *Cardiovasc Surg.* 1998;6:256-261.
  68. Long-term mortality and its predictors in patients with critical leg ischaemia. The I.C.A.I. Group (Gruppo di Studio dell'Ischemia Cronica Critica degli Arti Inferiori). The Study Group of Critical Chronic Ischemia of the Lower Extremities. *Eur J Vasc Endovasc Surg.* 1997;14:91-95.
  69. Crawford ES, Bomberger RA, Glaeser DH, et al. Aortoiliac occlusive disease: factors influencing survival and function following reconstructive operation over a twenty-five-year period. *Surgery.* 1981;90:1055-1067.
  70. Malone JM, Moore WS, Goldstone J. The natural history of bilateral aortofemoral bypass grafts for ischemia of the lower extremities. *Arch Surg.* 1975;110:1300-1306.
  71. Nevelsteen A, Wouters L, Suy R. Aortofemoral dacron reconstruction for aorto-iliac occlusive disease: a 25-year survey. *Eur J Vasc Surg.* 1991;5:179-186.
  72. Poulis GE, Doundoulakis N, Prombonas E, et al. Aorto-femoral bypass and determinants of early success and late favourable outcome. Experience with 1000 consecutive cases. *J Cardiovasc Surg (Torino).* 1992;33:664-678.
  73. Szilagyi DE, Elliott JP Jr, Smith RF, et al. A thirty-year survey of the reconstructive surgical treatment of aortoiliac occlusive disease. *J Vasc Surg.* 1986;3:421-436.
  74. Starnes BW, O'Donnell SD, Gillespie DL, et al. Percutaneous arterial closure in peripheral vascular disease: a prospective randomized evaluation of the Perclose device. *J Vasc Surg.* 2003;38:263-271.
  75. Bosch JL, van der Graaf Y, Hunink MG. Health-related quality of life after angioplasty and stent placement in patients with iliac artery occlusive disease: results of a randomized controlled clinical trial. The Dutch Iliac Stent Trial Study Group. *Circulation.* 1999;99:3155-3160.

## 第 109 章

1. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S5-S67.
2. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). *J Vasc Surg.* 2000;31:S1-S296.
3. *Dartmouth Atlas of Vascular Healthcare.* Chicago: Health Forum, AHA Press; 2000.
4. Fontaine R, Kim M, Kieny R. Surgical treatment of peripheral circulation disorders. *Helv Chir Acta.* 1954;21:499-533.
5. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. *J Vasc Surg.* 1997;26:517-538.
6. Rutherford RB, Becker GJ. Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. *Radiology.* 1991;181:277-281.
7. Suggested standards for reports dealing with lower extremity ischemia. Prepared by the Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery. *J Vasc Surg.* 1986;4:80-94.
8. Second European consensus document on chronic critical leg ischemia. *Eur J Vasc Surg.* 1992;6(Suppl A):1-32.
9. Wolfe JH, Wyatt MG. Critical and subcritical ischaemia. *Eur J Vasc Endovasc Surg.* 1997;13:578-582.
10. Marek JM, Mills JL. Risk factor assessment and indications for reconstruction. In: Mills JL, ed. *Management of Chronic Lower Limb Ischemia.* London, UK: Arnold; 2000:30-44.
11. Hertzner NR, Beven EG, Young JR, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. *Ann Surg.* 1984;199:223-233.
12. Abramson BL, Huckell V, Anand S, et al. Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease—executive summary. *Can J Cardiol.* 2005;21:997-1006.

13. Shaw LJ, Eagle KA, Gersh BJ, Miller DD. Meta-analysis of intravenous dipyridamole-thallium-201 imaging (1985 to 1994) and dobutamine echocardiography (1991 to 1994) for risk stratification before vascular surgery. *J Am Coll Cardiol.* 1996;27:787-798.
14. Taylor LM Jr, Yeager RA, Moneta GL, et al. The incidence of perioperative myocardial infarction in general vascular surgery. *J Vasc Surg.* 1992;15:52-59; discussion 59-61.
15. Cook DJ, Guyatt GH, Laupacis A, Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. *Chest.* 1992;102(4 Suppl):305S-311S.
16. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. *N Engl J Med.* 1999;341:1789-1794.
17. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. *N Engl J Med.* 1996;335:1713-1720.
18. Bolsin S, Colson M, Conroy M. Beta blockers and statins in non-cardiac surgery. *BMJ.* 2007;334:1283-1284.
19. Hamdan AD, Saltzberg SS, Sheahan M, et al. Lack of association of diabetes with increased postoperative mortality and cardiac morbidity: results of 6565 major vascular operations. *Arch Surg.* 2002;137:417-421.
20. Monahan TS, Shrikhande GV, Pomposelli FB, et al. Preoperative cardiac evaluation does not improve or predict perioperative or late survival in asymptomatic diabetic patients undergoing elective infrainguinal arterial reconstruction. *J Vasc Surg.* 2005;41:38-45.
21. Krupski WC, Nehler MR, Whitehill TA, et al. Negative impact of cardiac evaluation before vascular surgery. *Vasc Med.* 2000;5:3-9.
22. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. *N Engl J Med.* 2004;351:2795-2804.
23. Ouwendijk R, Kock MC, van Dijk LC, et al. Vessel wall calcifications at multi-detector row CT angiography in patients with peripheral arterial disease: effect on clinical utility and clinical predictors. *Radiology.* 2006;241:603-608.
24. Dorweiler B, Neufang A, Kreitner KF, et al. Magnetic resonance angiography unmasks reliable target vessels for pedal bypass grafting in patients with diabetes mellitus. *J Vasc Surg.* 2002;35:766-772.
25. Kreitner KF, Kunz RP, Herber S, et al. MR angiography of the pedal arteries with gadobenate dimeglumine, a contrast agent with increased relaxivity, and comparison with selective intraarterial DSA. *J Magn Reson Imaging.* 2008;27:78-85.
26. Diehm N, Kickuth R, Baumgartner I, et al. Magnetic resonance angiography in infrapopliteal arterial disease: prospective comparison of 1.5 and 3 Tesla magnetic resonance imaging. *Invest Radiol.* 2007;42:467-476.
27. Janka R, Fellner C, Wenkel E, et al. Contrast-enhanced MR angiography of peripheral arteries including pedal vessels at 1.0 T: feasibility study with dedicated peripheral angiography coil. *Radiology.* 2005;235:319-326.
28. Ruhl KM, Katoh M, Langer S, et al. Time-resolved 3D MR angiography of the foot at 3 T in patients with peripheral arterial disease. *AJR Am J Roentgenol.* 2008;190:W360-364.
29. Binkert CA, Baker PD, Petersen BD, et al. Peripheral vascular disease: blinded study of dedicated calf MR angiography versus standard bolus-chase MR angiography and film hard-copy angiography. *Radiology.* 2004;232:860-866.
30. Mazzariol F, Ascher E, Hingorani A, et al. Lower-extremity revascularisation without preoperative contrast arteriography in 185 cases: lessons learned with duplex ultrasound arterial mapping. *Eur J Vasc Endovasc Surg.* 2000;19:509-515.
31. Pemberton M, London NJ. Colour flow duplex imaging of occlusive arterial disease of the lower limb. *Br J Surg.* 1997;84:912-919.
32. Cohen MI, Vogelzang RL. A comparison of techniques for improved visualization of the arteries of the distal lower extremity. *AJR Am J Roentgenol.* 1986;147:1021-1024.
33. Kozak BE, Bedell JE, Rosch J. Small vessel leg angiography for distal vessel bypass grafts. *J Vasc Surg.* 1988;8:711-715.
34. Pomposelli FB Jr, Jepsen SJ, Gibbons GW, et al. Efficacy of the dorsal pedal bypass for limb salvage in diabetic patients:

short-term observations. *J Vasc Surg.* 1990;11:745-751.

35. Kunlin J. Le traitement de l'arterite oblitérante par le greffe veineuse. *Arch Mal Coeur Vaiss.* 1949;42:371-372.
36. Testart J, Jean Kunlin (1904-1991). *Ann Vasc Surg.* 1995;9(Suppl):S1-S6.
37. Donaldson MC, Whittemore AD, Mannick JA. Further experience with an all-autogenous tissue policy for infrainguinal reconstruction. *J Vasc Surg.* 1993;18:41-48.
38. Taylor LM Jr, Edwards JM, Porter JM. Present status of reversed vein bypass grafting: five-year results of a modern series. *J Vasc Surg.* 1990;11:193-205.
39. Shah DM, Chang BB, Leopold PW, et al. The anatomy of the greater saphenous venous system. *J Vasc Surg.* 1986;3:273-283.
40. Leopold PW, Shandall A, Kupinski AM, et al. Role of B-mode venous mapping in infrainguinal in situ vein-arterial bypasses. *Br J Surg.* 1989;76:305-307.
41. Bagi P, Schroeder T, Sillesen H, Lorentzen JE. Real time B-mode mapping of the greater saphenous vein. *Eur J Vasc Surg.* 1989;3:103-105.
42. Blebea J, Schomaker WR, Hod G, et al. Preoperative duplex venous mapping: a comparison of positional techniques in patients with and without atherosclerosis. *J Vasc Surg.* 1994;20:226-233.
43. Illig KA, Rhodes JM, Sternbach Y, et al. Reduction in wound morbidity rates following endoscopic saphenous vein harvest. *Ann Vasc Surg.* 2001;15:104-109.
44. Erdoes LS. Endoscopic vein harvest in peripheral vascular surgery. *J Vasc Surg.* 2006;44:417-418.
45. Erdoes LS, Milner TP. Encouraging results with endoscopic vein harvest for infrainguinal bypass. *J Vasc Surg.* 2005;42:442-448.
46. Pullatt R, Brothers TE, Robison JG, Elliott BM. Compromised bypass graft outcomes after minimal-incision vein harvest. *J Vasc Surg.* 2006;44:289-294.
47. Gazoni LM, Carty R, Skinner J, et al. Endoscopic versus open saphenous vein harvest for femoral to below the knee arterial bypass using saphenous vein graft. *J Vasc Surg.* 2006;44:282-287; discussion 287-288.
48. Imparato AM, Kim GE, Madayag M, Haveson SP. The results of tibial artery reconstruction procedures. *Surg Gynecol Obstet.* 1974;138:33-38.
49. Reichle FA, Martinson MW, Rankin KP. Infrapopliteal arterial reconstruction in the severely ischemic lower extremity. A comparison of long-term results of peroneal and tibial bypasses. *Ann Surg.* 1980;191:59-65.
50. Szilagyi DE, Hageman JH, Smith RF, et al. Autogenous vein grafting in femoropopliteal atherosclerosis: the limits of its effectiveness. *Surgery.* 1979;86:836-851.
51. Mills JL, Taylor SM. Results of infrainguinal revascularization with reversed vein conduits: a modern control series. *Ann Vasc Surg.* 1991;5:156-162.
52. Taylor LM Jr, Edwards JM, Phinney ES, Porter JM. Reversed vein bypass to infrapopliteal arteries. Modern results are superior to or equivalent to in-situ bypass for patency and for vein utilization. *Ann Surg.* 1987;205:90-97.
53. Beard JD, Wyatt M, Scott DJ, et al. The non-reversed vein femoro-distal bypass graft: a modification of the standard in situ technique. *Eur J Vasc Surg.* 1989;3:55-60.
54. Bandyk DF, Kaebnick HW, Stewart GW, Towne JB. Durability of the in situ saphenous vein arterial bypass: a comparison of primary and secondary patency. *J Vasc Surg.* 1987;5:256-268.
55. Bergamini TM, Towne JB, Bandyk DF, et al. Experience with in situ saphenous vein bypasses during 1981 to 1989: determinant factors of long-term patency. *J Vasc Surg.* 1991;13:137-147.
56. Donaldson MC, Mannick JA, Whittemore AD. Femoral-distal bypass with in situ greater saphenous vein. Long-term results using the Mills valvulotome. *Ann Surg.* 1991;213:457-464.
57. Hall KV. The great saphenous vein used in situ as an arterial shunt after extirpation of the vein valves. A preliminary report. *Surgery.* 1962;51:492-495.

58. Harris RW, Andros G, Dulawa LB, et al. The transition to "in situ" vein bypass grafts. *Surg Gynecol Obstet.* 1986;163:21-28.
59. Leather RP, Powers SR, Karmody AM. A reappraisal of the in situ saphenous vein arterial bypass: its use in limb salvage. *Surgery.* 1979;86:453-461.
60. Leather RP, Shah DM, Chang BB, Kaufman JL. Resurrection of the in situ saphenous vein bypass. 1000 cases later. *Ann Surg.* 1988;208:435-442.
61. Leather RP, Shan DM, Karmody AM. Infrapopliteal arterial bypass for limb salvage: increased patency and utilization of the saphenous vein used "in situ." *Surgery.* 1981;90:1000-1008.
62. May AG, DeWesse JA, Rob CG. Arterialized in situ saphenous vein. *Arch Surg.* 1965;91:743-750.
63. Boren CH, Towne JB, Bernhard VM, Salles-Cunha S. Profundapopliteal collateral index. A guide to successful profundaplasty. *Arch Surg.* 1980;115:1366-1372.
64. Flanigan DP, Williams LR, Schwartz JA, et al. Hemodynamic evaluation of the aortoiliac system based on pharmacologic vasodilatation. *Surgery.* 1983;93:709-714.
65. Tweedie JH, Ballantyne KC, Callum KG. Direct arterial pressure measurements during operation to assess adequacy of arterial reconstruction in lower limb ischaemia. *Br J Surg.* 1986;73:879-881.
66. Edwards WH, Jenkins JM, Mulherin JL Jr, et al. Extended profundoplasty to minimize pelvic and distal tissue loss. *Ann Surg.* 1990;211:694-701.
67. Hansen AK, Bille S, Nielsen PH, Egeblad K. Profundaplasty as the only reconstructive procedure in patients with severe ischemia of the lower extremity. *Surg Gynecol Obstet.* 1990;171:47-50.
68. Kalman PG, Johnston KW, Walker PM. The current role of isolated profundaplasty. *J Cardiovasc Surg (Torino).* 1990;31:107-111.
69. Schwartz JA, Flanigan DP, Williams LR, et al. Preoperative hemodynamic evaluation of aortoiliac occlusive disease: correlation with intraoperative measurements. *Curr Surg.* 1983;40:278-281.
70. Karacagil S, Almgren B, Bowald S, Eriksson I. Bypass grafting to the popliteal artery in limbs with occluded crural arteries. *Am J Surg.* 1991;162:19-23.
71. Belkin M, Welch HJ, Mackey WC, O'Donnell TF Jr. Clinical and hemodynamic results of bypass to isolated tibial artery segments for ischemic ulceration of the foot. *Am J Surg.* 1992;164:281-284; discussion 284-285.
72. Darke S, Lamont P, Chant A, et al. Femoro-popliteal versus femoro-distal bypass grafting for limb salvage in patients with an "isolated" popliteal segment. *Eur J Vasc Surg.* 1989;3:203-207.
73. Kram HB, Gupta SK, Veith FJ, et al. Late results of two hundred seventeen femoropopliteal bypasses to isolated popliteal artery segments. *J Vasc Surg.* 1991;14:386-390.
74. Loh A, Chester JF, Taylor RS. PTFE bypass grafting to isolated popliteal segments in critical limb ischaemia. *Eur J Vasc Surg.* 1993;7:26-30.
75. Samson RH, Showalter DP, Yunis JP. Isolated femoropopliteal bypass graft for limb salvage after failed tibial reconstruction: a viable alternative to amputation. *J Vasc Surg.* 1999;29:409-412.
76. Elliott BM, Robison JG, Brothers TE, Cross MA. Limitations of peroneal artery bypass grafting for limb salvage. *J Vasc Surg.* 1993;18:881-888.
77. Bergamini TM, George SM Jr, Massey HT, et al. Pedal or peroneal bypass: which is better when both are patent? *J Vasc Surg.* 1994;20:347-355.
78. Plecha EJ, Seabrook GR, Bandyk DF, Towne JB. Determinants of successful peroneal artery bypass. *J Vasc Surg.* 1993;17:97-105; discussion 105-106.
79. Raftery KB, Belkin M, Mackey WC, O'Donnell TF. Are peroneal artery bypass grafts hemodynamically inferior to other tibial artery bypass grafts? *J Vasc Surg.* 1994;19:964-968; discussion 968-969.
80. Gentile AT, Berman SS, Reinke KR, et al. A regional pedal ischemia scoring system for decision analysis in patients with

- heel ulceration. *Am J Surg*. 1998;176:109-114.
81. Mills JL, Gahtan V, Fujitani RM, et al. The utility and durability of vein bypass grafts originating from the popliteal artery for limb salvage. *Am J Surg*. 1994;168:646-650.
  82. Shah DM, Darling RC 3rd, Chang BB, et al. Is long vein bypass from groin to ankle a durable procedure? An analysis of a ten-year experience. *J Vasc Surg*. 1992;15:402-407; discussion 407-408.
  83. Farley HH, Kiser JC, Hitchcock CR. Profunda femoris-popliteal shunt. *Ann Surg*. 1964;160:23-25.
  84. Stabile BE, Wilson SE. The profunda femoris-popliteal artery bypass. *Arch Surg*. 1977;112:913-918.
  85. Nunez AA, Veith FJ, Collier P, et al. Direct approaches to the distal portions of the deep femoral artery for limb salvage bypasses. *J Vasc Surg*. 1988;8:576-581.
  86. Mills JL, Taylor SM, Fujitani RM. The role of the deep femoral artery as an inflow site for infrainguinal revascularization. *J Vasc Surg*. 1993;18:416-423.
  87. Veith FJ, Gupta SK, Samson RH, et al. Superficial femoral and popliteal arteries as inflow sites for distal bypasses. *Surgery*. 1981;90:980-990.
  88. Veith FJ, Ascer E, Gupta SK, Wengerter KR. Lateral approach to the popliteal artery. *J Vasc Surg*. 1987;6:119-123.
  89. Mukherjee D. Posterior approach to the peroneal artery. *J Vasc Surg*. 1994;19:174-178.
  90. Ouriel K. Posterior exposure for popliteal-crural bypass: a useful approach. *Semin Vasc Surg*. 1997;10:23-30.
  91. Bernhard VM, Boren CH, Towne JB. Pneumatic tourniquet as a substitute for vascular clamps in distal bypass surgery. *Surgery*. 1980;87:709-713.
  92. Chew DK, Owens CD, Belkin M, et al. Bypass in the absence of ipsilateral greater saphenous vein: safety and superiority of the contralateral greater saphenous vein. *J Vasc Surg*. 2002;35:1085-1092.
  93. Chang BB, Paty PS, Shah DM, Leather RP. The lesser saphenous vein: an underappreciated source of autogenous vein. *J Vasc Surg*. 1992;15:152-156; discussion 156-157.
  94. Weaver FA, Barlow CR, Edwards WH, et al. The lesser saphenous vein: autogenous tissue for lower extremity revascularization. *J Vasc Surg*. 1987;5:687-692.
  95. Schulman ML, Badhey MR, Yatco R. Superficial femoral-popliteal veins and reversed saphenous veins as primary femoropopliteal bypass grafts: a randomized comparative study. *J Vasc Surg*. 1987;6:1-10.
  96. Faries PL, Arora S, Pomposelli FB Jr, et al. The use of arm vein in lower-extremity revascularization: results of 520 procedures performed in eight years. *J Vasc Surg*. 2000;31:50-59.
  97. Londrey GL, Boshier LP, Brown PW, et al. Infrainguinal reconstruction with arm vein, lesser saphenous vein, and remnants of greater saphenous vein: a report of 257 cases. *J Vasc Surg*. 1994;20:451-456; discussion 456-457.
  98. Harris RW, Andros G, Dulawa LB, et al. Successful long-term limb salvage using cephalic vein bypass grafts. *Ann Surg*. 1984;200:785-792.
  99. Holzenbein TJ, Pomposelli FB Jr, Miller A, et al. Results of a policy with arm veins used as the first alternative to an unavailable ipsilateral greater saphenous vein for infrainguinal bypass. *J Vasc Surg*. 1996;23:130-140.
  100. Holzenbein TJ, Pomposelli FB Jr, Miller A, et al. The upper arm basilic-cephalic loop for distal bypass grafting: technical considerations and follow-up. *J Vasc Surg*. 1995;21:586-592.
  101. Kakkar VV. The cephalic vein as a peripheral vascular graft. *Surg Gynecol Obstet*. 1969;128:551-556.
  102. Taylor SM, Langan EM 3rd, Snyder BA, Crane MM. Superficial femoral artery eversion endarterectomy: a useful adjunct for infrainguinal bypass in the presence of limited autogenous vein. *J Vasc Surg*. 1997;26:439-445.
  103. Farber A, Major K, Wagner WH, et al. Cryopreserved saphenous vein allografts in infrainguinal revascularization: analysis of 240 grafts. *J Vasc Surg*. 2003;38:15-21.
  104. Fujitani RM, Bassiouny HS, Gewertz BL, et al. Cryopreserved saphenous vein allogenic homografts: an alternative conduit in lower extremity arterial reconstruction in infected fields. *J Vasc Surg*. 1992;15:519-526.
  105. Harris RW, Schneider PA, Andros G, et al. Allograft vein bypass: is it an acceptable alternative for infrapopliteal



- revascularization? *J Vasc Surg.* 1993;18:553-559; discussion 559-560.
106. Leshnower BG, Leshnower LE, Leshnower AC. Adjunctive uses of the radial artery for emergency infrapopliteal bypass in patients presenting with acute limb-threatening ischemia. *Vasc Endovasc Surg.* 2007;41:348-351.
  107. Treiman GS, Lawrence PF, Rockwell WB. Autogenous arterial bypass grafts: durable patency and limb salvage in patients with inframalleolar occlusive disease and end-stage renal disease. *J Vasc Surg.* 2000;32:13-22.
  108. Ihnat DM, Mills JL, Dawson DL, et al. The correlation of early flow disturbances with the development of infrainguinal graft stenosis: a 10-year study of 341 autogenous vein grafts. *J Vasc Surg.* 1999;30:8-15.
  109. Faries PL, Logerfo FW, Arora S, et al. Arm vein conduit is superior to composite prosthetic-autogenous grafts in lower extremity revascularization. *J Vasc Surg.* 2000;31:1119-1127.
  110. Gentile AT, Lee RW, Moneta GL, et al. Results of bypass to the popliteal and tibial arteries with alternative sources of autogenous vein. *J Vasc Surg.* 1996;23:272-279; discussion 279-280.
  111. LoGerfo FW, Paniszyn CW, Menzoian J. A new arm vein graft for distal bypass. *J Vasc Surg.* 1987;5:889-891.
  112. Green RM, Abbott WM, Matsumoto T, et al. Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial. *J Vasc Surg.* 2000;31:417-425.
  113. Post S, Kraus T, Muller-Reinartz U, et al. Dacron vs polytetrafluoroethylene grafts for femoropopliteal bypass: a prospective randomised multicentre trial. *Eur J Vasc Endovasc Surg.* 2001;22:226-231.
  114. Robinson BI, Fletcher JP, Tomlinson P, et al. A prospective randomized multicentre comparison of expanded polytetrafluoroethylene and gelatin-sealed knitted Dacron grafts for femoropopliteal bypass. *Cardiovasc Surg.* 1999;7:214-218.
  115. Devine C, Hons B, McCollum C. Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass grafting: a multicenter trial. *J Vasc Surg.* 2001;33:533-539.
  116. Devine C, McCollum C. Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. *J Vasc Surg.* 2004;40:924-931.
  117. Stonebridge PA, Prescott RJ, Ruckley CV. Randomized trial comparing infrainguinal polytetrafluoroethylene bypass grafting with and without vein interposition cuff at the distal anastomosis. The Joint Vascular Research Group. *J Vasc Surg.* 1997;26:543-550.
  118. Yeung KK, Mills JL Sr, Hughes JD, et al. Improved patency of infrainguinal polytetrafluoroethylene bypass grafts using a distal Taylor vein patch. *Am J Surg.* 2001;182:578-583.
  119. Sayers RD, Raptis S, Berce M, Miller JH. Long-term results of femorotibial bypass with vein or polytetrafluoroethylene. *Br J Surg.* 1998;85:934-938.
  120. Taylor RS, Loh A, McFarland RJ, et al. Improved technique for polytetrafluoroethylene bypass grafting: long-term results using anastomotic vein patches. *Br J Surg.* 1992;79:348-354.
  121. Tyrrell MR, Chester JF, Vipond MN, et al. Experimental evidence to support the use of interposition vein collars/patches in distal PTFE anastomoses. *Eur J Vasc Surg.* 1990;4:95-101.
  122. Tyrrell MR, Wolfe JH. New prosthetic venous collar anastomotic technique: combining the best of other procedures. *Br J Surg.* 1991;78:1016-1017.
  123. Neufang A, Espinola-Klein C, Dorweiler B, et al. Infrapopliteal composite bypass with autologous vein and second generation glutaraldehyde stabilized human umbilical vein (HUV) for critical lower limb ischaemia. *Eur J Vasc Endovasc Surg.* 2007;34:583-589.
  124. Dardik H, Wengerter K, Qin F, et al. Comparative decades of experience with glutaraldehyde-tanned human umbilical cord vein graft for lower limb revascularization: an analysis of 1275 cases. *J Vasc Surg.* 2002;35:64-71.
  125. Hamsho A, Nott D, Harris PL. Prospective randomised trial of distal arteriovenous fistula as an adjunct to femoro-infrapopliteal PTFE bypass. *Eur J Vasc Endovasc Surg.* 1999;17:197-201.
  126. Walluscheck KP, Bierkandt S, Brandt M, Cremer J. Infrainguinal ePTFE vascular graft with bioactive surface heparin

- bonding. First clinical results. *J Cardiovasc Surg (Torino)*. 2005;46:425-430.
127. Heyligers JM, Verhagen HJ, Rotmans JI, et al. Heparin immobilization reduces thrombogenicity of small-caliber expanded polytetrafluoroethylene grafts. *J Vasc Surg*. 2006;43:587-591.
  128. Heyligers JM, Lisman T, Verhagen HJ, et al. A heparin-bonded vascular graft generates no systemic effect on markers of hemostasis activation or detectable heparin-induced thrombocytopenia-associated antibodies in humans. *J Vasc Surg*. 2008;47:324-329.
  129. Bosiers M, Deloose K, Verbist J, et al. Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoropopliteal and femorocrural bypass grafting: 1-year results. *J Vasc Surg*. 2006;43:313-318; discussion 318-319.
  130. Dorigo W, Di Carlo F, Troisi N, et al. Lower limb revascularization with a new bioactive prosthetic graft: early and late results. *Ann Vasc Surg*. 2008;22:79-87.
  131. Dorrucchi V, Griselli F, Petralia G, et al. Heparin-bonded expanded polytetrafluoroethylene grafts for infragenicular bypass in patients with critical limb ischemia: 2-year results. *J Cardiovasc Surg (Torino)*. 2008;49:145-149.
  132. Peeters P, Verbist J, Deloose K, Bosiers M. Results with heparin bonded polytetrafluoroethylene grafts for femorodistal bypasses. *J Cardiovasc Surg (Torino)*. 2006;47:407-413.
  133. Ballotta E, Renon L, Toffano M, Da Giau G. Prospective randomized study on bilateral above-knee femoropopliteal revascularization: polytetrafluoroethylene graft versus reversed saphenous vein. *J Vasc Surg*. 2003;38:1051-1055.
  134. Pereira CE, Albers M, Romiti M, et al. Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. *J Vasc Surg*. 2006;44:510-517.
  135. Robinson BI, Fletcher JP. Fluoropolymer coated Dacron or polytetrafluoroethylene for femoropopliteal bypass grafting: a multicentre trial. *Aust N Z J Surg*. 2003;73:95-99.
  136. Aalders GJ, van Vroonhoven TJ. Polytetrafluoroethylene versus human umbilical vein in above-knee femoropopliteal bypass: six-year results of a randomized clinical trial. *J Vasc Surg*. 1992;16:816-823.
  137. McCollum C, Kenchington G, Alexander C, et al. PTFE or HUV for femoro-popliteal bypass: a multi-centre trial. *Eur J Vasc Surg*. 1991;5:435-443.
  138. Klinkert P, Schepers A, Burger DH, et al. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trial. *J Vasc Surg*. 2003;37:149-155.
  139. Mills JL Sr. P values may lack power: the choice of conduit for above-knee femoropopliteal bypass graft. *J Vasc Surg*. 2000;32:402-405.
  140. Johnson WC, Lee KK. A comparative evaluation of polytetrafluoroethylene, umbilical vein, and saphenous vein bypass grafts for femoral-popliteal above-knee revascularization: a prospective randomized Department of Veterans Affairs cooperative study. *J Vasc Surg*. 2000;32:268-277.
  141. Eickhoff JH, Broome A, Ericsson BF, et al. Four years' results of a prospective, randomized clinical trial comparing polytetrafluoroethylene and modified human umbilical vein for below-knee femoropopliteal bypass. *J Vasc Surg*. 1987;6:506-511.
  142. Gupta SK, Veith FJ, Kram HB, Wengerter KR. Prospective, randomized comparison of ringed and nonringed polytetrafluoroethylene femoropopliteal bypass grafts: a preliminary report. *J Vasc Surg*. 1991;13:163-172.
  143. Whittemore AD, Clowes AW, Couch NP, Mannick JA. Secondary femoropopliteal reconstruction. *Ann Surg*. 1981;193:35-42.
  144. Edwards JE, Taylor LM Jr, Porter JM. Treatment of failed lower extremity bypass grafts with new autogenous vein bypass grafting. *J Vasc Surg*. 1990;11:136-144.
  145. Scharn DM, Dirven M, Barendregt WB, et al. Human umbilical vein versus heparin-bonded polyester for femoro-popliteal bypass: 5-year results of a prospective randomized multicentre trial. *Eur J Vasc Endovasc Surg*. 2008;35:61-67.
  146. Kapfer X, Meichelboeck W, Groegler FM. Comparison of carbon-impregnated and standard ePTFE prostheses in extra-anatomical anterior tibial artery bypass: a prospective randomized multicenter study. *Eur J Vasc Endovasc Surg*.

2006;32:155-168.

147. Mills JL. Reversed vein bypass. In: Mills JL, ed. *Management of Chronic Lower Limb Ischemia*. London: Arnold; 2000:76-83.
148. Knox JB, Belkin M. In situ bypass. In: Mills JL, ed. *Management of Chronic Lower Limb Ischemia*. London: Arnold; 2000:84-91.
149. Shah DM, Darling RC 3rd, Chang BB, et al. Long-term results of in situ saphenous vein bypass. Analysis of 2058 cases. *Ann Surg*. 1995;222:438-446.
150. Bandyk DF, Jorgensen RA, Towne JB. Intraoperative assessment of in situ saphenous vein arterial grafts using pulsed Doppler spectral analysis. *Arch Surg*. 1986;121:292-299.
151. Spencer TD, Goldman MH, Hyslop JW, et al. Intraoperative assessment of in situ saphenous vein bypass grafts with continuous-wave Doppler probe. *Surgery*. 1984;96:874-877.
152. Mills JL, Fujitani RM, Taylor SM. Contribution of routine intraoperative completion arteriography to early infrainguinal bypass patency. *Am J Surg*. 1992;164:506-510.
153. Renwick S, Royle JP, Martin P. Operative angiography after femoropopliteal arterial reconstruction-its influence on early failure rate. *Br J Surg*. 1968;55:134-136.
154. Sayers RD, Naylor AR, London NJ, et al. The additional value of intraoperative angiography in infragenicular reconstruction. *Eur J Vasc Endovasc Surg*. 1995;9:211-217.
155. Bandyk DF, Mills JL, Gahtan V, Esses GE. Intraoperative duplex scanning of arterial reconstructions: fate of repaired and unrepaired defects. *J Vasc Surg*. 1994;20:426-432.
156. Johnson BL, Bandyk DF, Back MR, et al. Intraoperative duplex monitoring of infrainguinal vein bypass procedures. *J Vasc Surg*. 2000;31:678-690.
157. Towne JB, Bernhard VM. Vascular endoscopy: useful tool or interesting toy. *Surgery*. 1977;82:415-419.
158. Wilson YG, Davies AH, Currie IC, et al. Angioscopy for quality control of saphenous vein during bypass grafting. *Eur J Vasc Endovasc Surg*. 1996;11:12-18.
159. Stonebridge PA, Miller A, Tsoukas A, et al. Angioscopy of arm vein infrainguinal bypass grafts. *Ann Vasc Surg*. 1991;5:170-175.
160. Sales CM, Marin ML, Veith FJ, et al. Saphenous vein angioscopy: a valuable method to detect unsuspected venous disease. *J Vasc Surg*. 1993;18:198-204.
161. Sales CM, Goldsmith J, Veith FJ. Prospective study of the value of prebypass saphenous vein angioscopy. *Am J Surg*. 1995;170:106-108.
162. Miller A, Stonebridge PA, Tsoukas AI, et al. Angioscopically directed valvulotomy: a new valvulotome and technique. *J Vasc Surg*. 1991;13:813-820; discussion 821.
163. Miller A, Stonebridge PA, Jepsen SJ, et al. Continued experience with intraoperative angioscopy for monitoring infrainguinal bypass grafting. *Surgery*. 1991;109:286-293.
164. Miller A, Marcaccio EJ, Tannenbaum GA, et al. Comparison of angioscopy and angiography for monitoring infrainguinal bypass vein grafts: results of a prospective randomized trial. *J Vasc Surg*. 1993;17:382-396.
165. Marcaccio EJ, Miller A, Tannenbaum GA, et al. Angioscopically directed interventions improve arm vein bypass grafts. *J Vasc Surg*. 1993;17:994-1002; discussion 1003-1004.
166. Gilbertson JJ, Walsh DB, Zwolak RM, et al. A blinded comparison of angiography, angioscopy, and duplex scanning in the intraoperative evaluation of in situ saphenous vein bypass grafts. *J Vasc Surg*. 1992;15:121-127; discussion 127-129.
167. Davies AH, Magee TR, Thompson JF, et al. Preliminary experience of angioscopy in femorodistal bypass. *Ann R Coll Surg Engl*. 1993;75:178-180.
168. Clair DG, Golden MA, Mannick JA, et al. Randomized prospective study of angioscopically assisted in situ saphenous vein grafting. *J Vasc Surg*. 1994;19:992-999; discussion 999-1000.

169. Baxter BT, Rizzo RJ, Flinn WR, et al. A comparative study of intraoperative angioscopy and completion arteriography following femorodistal bypass. *Arch Surg*. 1990;125:997-1002.
170. Rzcudlo EM, Walsh DB, Powell RJ, et al. Prediction of early graft failure with intraoperative completion duplex ultrasound scan. *J Vasc Surg*. 2002;36:975-981.
171. Rosenthal D, Arous EJ, Friedman SG, et al. Endovascular-assisted versus conventional in situ saphenous vein bypass grafting: cumulative patency, limb salvage, and cost results in a 39-month multicenter study. *J Vasc Surg*. 2000;31:60-68.
172. Rosenthal D, Dickson C, Rodriguez FJ, et al. Infrainguinal endovascular in situ saphenous vein bypass: ongoing results. *J Vasc Surg*. 1994;20:389-394.
173. Rosenthal D, Herring MB, O'Donovan TG, et al. Endovascular infrainguinal in situ saphenous vein bypass: a multicenter preliminary report. *J Vasc Surg*. 1992;16:453-458.
174. Wengrovitz M, Atnip RG, Gifford RR, et al. Wound complications of autogenous subcutaneous infrainguinal arterial bypass surgery: predisposing factors and management. *J Vasc Surg*. 1990;11:156-161.
175. Schwartz ME, Harrington EB, Schanzer H. Wound complications after in situ bypass. *J Vasc Surg*. 1988;7:802-807.
176. Reifsnnyder T, Bandyk D, Seabrook G, et al. Wound complications of the in situ saphenous vein bypass technique. *J Vasc Surg*. 1992;15:843-848; discussion 848-850.
177. Patel VI, Hamdan AD, Schermerhorn ML, et al. Lower extremity arterial revascularization in obese patients. *J Vasc Surg*. 2007;46:738-742.
178. Nguyen LL, Brahmanandam S, Bandyk DF, et al. Female gender and oral anticoagulants are associated with wound complications in lower extremity vein bypass: an analysis of 1404 operations for critical limb ischemia. *J Vasc Surg*. 2007;46:1191-1197.
179. Wilson YG, Davies AH, Currie IC, et al. Angioscopically-assisted in situ saphenous vein bypass for infrainguinal revascularisation. *Eur J Vasc Endovasc Surg*. 1996;12:223-229.
180. van Dijk LC, van Urk H, du Bois NA, et al. A new "closed" in situ vein bypass technique results in a reduced wound complication rate. *Eur J Vasc Endovasc Surg*. 1995;10:162-167.
181. Thorne J, Danielsson G, Danielsson P, et al. Intraoperative angioscopy may improve the outcome of in situ saphenous vein bypass grafting: a prospective study. *J Vasc Surg*. 2002;35:759-765.
182. Rosenthal D, Tucker JG, Atkins CP, et al. Extraluminal endoscopic-assisted ligation of venous tributaries for infrainguinal in situ saphenous vein bypass: a preliminary report. *Cardiovasc Surg*. 1996;4:512-514.
183. Rosenthal D, Matsuura JH, Clark MD. Current developments in endovascular in situ bypass grafting. *Ann Vasc Surg*. 1999;13:637-640.
184. Rosenthal D, Martin JD, Kirby LB, Matsuura JH. Minimally invasive in situ bypass. *Surg Clin North Am*. 1999;79:645-652.
185. Maini BS, Andrews L, Salimi T, et al. A modified, angioscopically assisted technique for in situ saphenous vein bypass: impact on patency, complications, and length of stay. *J Vasc Surg*. 1993;17:1041-1047; discussion 1047-1049.
186. Cikrit DF, Fiore NF, Dalsing MC, et al. A comparison of endovascular assisted and conventional in situ bypass grafts. *Ann Vasc Surg*. 1995;9:37-43.
187. Suggested standards for reports dealing with lower extremity ischemia. *J Vasc Surg*. 1987;5:501-503.
188. Marin ML, Veith FJ, Panetta TF, et al. Saphenous vein biopsy: a predictor of vein graft failure. *J Vasc Surg*. 1993;18:407-414.
189. Panetta TF, Marin ML, Veith FJ, et al. Unsuspected preexisting saphenous vein disease: an unrecognized cause of vein bypass failure. *J Vasc Surg*. 1992;15:102-110.
190. Varty K, London NJ, Brennan JA, et al. Infragenicular in situ vein bypass graft occlusion: a multivariate risk factor analysis. *Eur J Vasc Surg*. 1993;7:567-571.
191. Idu MM, Buth J, Hop WC, et al. Factors influencing the development of vein-graft stenosis and their significance for

- clinical management. *Eur J Vasc Endovasc Surg*. 1999;17:15-21.
192. Wengerter KR, Veith FJ, Gupta SK, et al. Influence of vein size (diameter) on infrapopliteal reversed vein graft patency. *J Vasc Surg*. 1990;11:525-531.
  193. Schanzer A, Hevelone N, Owens CD, et al. Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. *J Vasc Surg*. 2007;46:1180-1190.
  194. Mills JL. In-situ versus reversed vein grafts: is there a difference? *Vasc Endovasc Surg*. 1999;31:679-684.
  195. Biancari F, Kantonen I, Alback A, et al. Limits of infrapopliteal bypass surgery for critical leg ischemia: when not to reconstruct. *World J Surg*. 2000;24:727-733.
  196. Seeger JM, Pretus HA, Carlton LC, et al. Potential predictors of outcome in patients with tissue loss who undergo infrainguinal vein bypass grafting. *J Vasc Surg*. 1999;30:427-435.
  197. Ramdev P, Rayan SS, Sheahan M, et al. A decade experience with infrainguinal revascularization in a dialysis-dependent patient population. *J Vasc Surg*. 2002;36:969-974.
  198. Peltonen S, Biancari F, Lindgren L, et al. Outcome of infrainguinal bypass surgery for critical leg ischaemia in patients with chronic renal failure. *Eur J Vasc Endovasc Surg*. 1998;15:122-127.
  199. Meyerson SL, Skelly CL, Curi MA, et al. Long-term results justify autogenous infrainguinal bypass grafting in patients with end-stage renal failure. *J Vasc Surg*. 2001;34:27-33.
  200. Maithel SK, Pomposelli FB, Williams M, et al. Creatinine clearance but not serum creatinine alone predicts long-term postoperative survival after lower extremity revascularization. *Am J Nephrol*. 2006;26:612-620.
  201. Kantonen I, Lepantalo M, Luther M, et al. Factors affecting the results of surgery for chronic critical leg ischemia-a nationwide survey. Finnvasc Study Group. *J Vasc Surg*. 1998;27:940-947.
  202. Jones WB, Cull DL, Kalbaugh CA, et al. Surgical revascularization in patients with end-stage renal disease: results using a new paradigm in outcomes assessment. *Am Surg*. 2007;73:598-605.
  203. Chang BB, Paty PS, Shah DM, et al. Results of infrainguinal bypass for limb salvage in patients with end-stage renal disease. *Surgery*. 1990;108:742-746; discussion 746-747.
  204. Schanzer A, Mega J, Meadows J, et al. Risk stratification in critical limb ischemia: derivation and validation of a model to predict amputation-free survival using multicenter surgical outcomes data. *J Vasc Surg*. 2008;48:1464-1471.
  205. Taylor SM, Cull DL, Kalbaugh CA, et al. Critical analysis of clinical success after surgical bypass for lower-extremity ischemic tissue loss using a standardized definition combining multiple parameters: a new paradigm of outcomes assessment. *J Am Coll Surg*. 2007;204:831-838; discussion 838-839.
  206. Christopherson R, Beattie C, Frank SM, et al. Perioperative morbidity in patients randomized to epidural or general anesthesia for lower extremity vascular surgery. Perioperative Ischemia Randomized Anesthesia Trial Study Group. *Anesthesiology*. 1993;79:422-434.
  207. Pierce ET, Pomposelli FB Jr, Stanley GD, et al. Anesthesia type does not influence early graft patency or limb salvage rates of lower extremity arterial bypass. *J Vasc Surg*. 1997;25:226-232; discussion 232-223.
  208. Comparative evaluation of prosthetic, reversed, and in situ vein bypass grafts in distal popliteal and tibial-peroneal revascularization. Veterans Administration Cooperative Study Group 141. *Arch Surg*. 1988;123:434-438.
  209. Harris PL, How TV, Jones DR. Prospectively randomized clinical trial to compare in situ and reversed saphenous vein grafts for femoropopliteal bypass. *Br J Surg*. 1987;74:252-255.
  210. Harris PL, Veith FJ, Shanik GD, et al. Prospective randomized comparison of in situ and reversed infrapopliteal vein grafts. *Br J Surg*. 1993;80:173-176.
  211. Lawson JA, Tangelder MJ, Algra A, Eikelboom BC. The myth of the in situ graft: superiority in infrainguinal bypass surgery? *Eur J Vasc Endovasc Surg*. 1999;18:149-157.
  212. Moody AP, Edwards PR, Harris PL. In situ versus reversed femoropopliteal vein grafts: long-term follow-up of a prospective, randomized trial. *Br J Surg*. 1992;79:750-752.

213. Watelet J, Cheysson E, Poels D, et al. In situ versus reversed saphenous vein for femoropopliteal bypass: a prospective randomized study of 100 cases. *Ann Vasc Surg.* 1987;1:441-452.
214. Watelet J, Soury P, Menard JF, et al. Femoropopliteal bypass: in situ or reversed vein grafts? Ten-year results of a randomized prospective study. *Ann Vasc Surg.* 1997;11:510-519.
215. Wengerter KR, Veith FJ, Gupta SK, et al. Prospective randomized multicenter comparison of in situ and reversed vein infrapopliteal bypasses. *J Vasc Surg.* 1991;13:189-197.
216. Dalman RL. Expected outcome: Early results, life table patency, limb salvage. In: Mills JL, ed. *Management of Chronic Lower Limb Ischemia*. London: Arnold; 2000:106-112.
217. Albers M, Battistella VM, Romiti M, et al. Meta-analysis of polytetrafluoroethylene bypass grafts to infrapopliteal arteries. *J Vasc Surg.* 2003;37:1263-1269.
218. Roll S, Muller-Nordhorn J, Keil T, et al. Dacron vs PTFE as bypass materials in peripheral vascular surgery—systematic review and meta-analysis. *BMC Surg.* 2008;8:22.
219. Albers M, Romiti M, Pereira CA, et al. Meta-analysis of allograft bypass grafting to infrapopliteal arteries. *Eur J Vasc Endovasc Surg.* 2004;28:462-472.
220. Albers M, Romiti M, De Luccia N, et al. An updated meta-analysis of infrainguinal arterial reconstruction in patients with end-stage renal disease. *J Vasc Surg.* 2007;45:536-542.
221. Albers M, Romiti M, Brochado-Neto FC, Pereira CA. Meta-analysis of alternate autologous vein bypass grafts to infrapopliteal arteries. *J Vasc Surg.* 2005;42:449-455.
222. Albers M, Romiti M, Brochado-Neto FC, et al. Meta-analysis of popliteal-to-distal vein bypass grafts for critical ischemia. *J Vasc Surg.* 2006;43:498-503.
223. Albers M, Romiti M, Braganca Pereira CA, et al. A meta-analysis of infrainguinal arterial reconstruction in patients with end-stage renal disease. *Eur J Vasc Endovasc Surg.* 2001;22:294-300.
224. Nicoloff AD, Taylor LM Jr, McLafferty RB, et al. Patient recovery after infrainguinal bypass grafting for limb salvage. *J Vasc Surg.* 1998;27:256-263.
225. Golledge J, Iannos J, Walsh JA, et al. Critical assessment of the outcome of infrainguinal vein bypass. *Ann Surg.* 2001;234:697-701.
226. Abou-Zamzam AM Jr, Lee RW, Moneta GL, et al. Functional outcome after infrainguinal bypass for limb salvage. *J Vasc Surg.* 1997;25:287-295.
227. Goshima KR, Mills JL Sr, Hughes JD. A new look at outcomes after infrainguinal bypass surgery: traditional reporting standards systematically underestimate the expenditure of effort required to attain limb salvage. *J Vasc Surg.* 2004;39:330-335.
228. Wixon CL, Mills JL, Westerband A, et al. An economic appraisal of lower extremity bypass graft maintenance. *J Vasc Surg.* 2000;32:1-12.
229. Albers M, Fratezi AC, De Luccia N. Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease. *J Vasc Surg.* 1992;16:54-59.
230. Chetter IC, Spark JJ, Scott DJ, et al. Prospective analysis of quality of life in patients following infrainguinal reconstruction for chronic critical ischaemia. *Br J Surg.* 1998;85:951-955.
231. Kleivsgard R, Hallberg IR, Risberg B, Thomsen MB. Quality of life associated with varying degrees of chronic lower limb ischaemia: comparison with a healthy sample. *Eur J Vasc Endovasc Surg.* 1999;17:319-325.
232. Nehler MR, McDermott MM, Treat-Jacobson D, et al. Functional outcomes and quality of life in peripheral arterial disease: current status. *Vasc Med.* 2003;8:115-126.
233. Nehler MR, Moneta GL, Edwards JM, et al. Surgery for chronic lower extremity ischemia in patients eighty or more years of age: operative results and assessment of postoperative independence. *J Vasc Surg.* 1993;18:618-624.
234. O'Brien TS, Lamont PM, Crow A, et al. Lower limb ischaemia in the octogenarian: is limb salvage surgery worthwhile?

*Ann R Coll Surg Engl.* 1993;75:445-447.

235. Singh S, Evans L, Datta D, et al. The costs of managing lower limb-threatening ischaemia. *Eur J Vasc Endovasc Surg.* 1996;12:359-362.
236. Taylor SM, Kalbaugh CA, Blackhurst DW, et al. Postoperative outcomes according to preoperative medical and functional status after infrainguinal revascularization for critical limb ischemia in patients 80 years and older. *Am Surg.* 2005;71:640-645; discussion 645-646.
237. Taylor SM, Kalbaugh CA, Blackhurst DW, et al. Preoperative clinical factors predict postoperative functional outcomes after major lower limb amputation: an analysis of 553 consecutive patients. *J Vasc Surg.* 2005;42:227-235.
238. Taylor SM, Kalbaugh CA, Blackhurst DW, et al. A comparison of percutaneous transluminal angioplasty versus amputation for critical limb ischemia in patients unsuitable for open surgery. *J Vasc Surg.* 2007;45:304-310.
239. Taylor SM, Kalbaugh CA, Gray BH, et al. The LEGS score: a proposed grading system to direct treatment of chronic lower extremity ischemia. *Ann Surg.* 2003;237:812-818; discussion 818-819.
240. Berceli SA, Hevelone ND, Lipsitz SR, et al. Surgical and endovascular revision of infrainguinal vein bypass grafts: analysis of midterm outcomes from the PREVENT III trial. *J Vasc Surg.* 2007;46:1173-1179.
241. Conte MS, Bandyk DF, Clowes AW, et al. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. *J Vasc Surg.* 2005;42:456-464.
242. Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. *J Vasc Surg.* 2006;43:742-751.
243. Conte MS, Lorenz TJ, Bandyk DF, et al. Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure. *Vasc Endovasc Surg.* 2005;39:15-23.
244. Davies AH, Hawdon AJ, Sydes MR, Thompson SG. Is duplex surveillance of value after leg vein bypass grafting? Principal results of the Vein Graft Surveillance Randomised Trial (VGST). *Circulation.* 2005;112:1985-1991.
245. Nguyen LL, Lipsitz SR, Bandyk DF, et al. Resource utilization in the treatment of critical limb ischemia: the effect of tissue loss, comorbidities, and graft-related events. *J Vasc Surg.* 2006;44:971-975; discussion 975-976.
246. Nguyen LL, Moneta GL, Conte MS, et al. Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia. *J Vasc Surg.* 2006;44:977-983.
247. Gibbons GW, Burgess AM, Guadagnoli E, et al. Return to well-being and function after infrainguinal revascularization. *J Vasc Surg.* 1995;21:35-44.
248. Gulati S, Coughlin PA, Hatfield J, Chetter IC. Quality of life in patients with lower limb ischemia; revised suggestions for analysis. *J Vasc Surg.* 2009;49:122-126.
249. Klevsgard R, Hallberg IR, Risberg B, Thomsen MB. The effects of successful intervention on quality of life in patients with varying degrees of lower-limb ischaemia. *Eur J Vasc Endovasc Surg.* 2000;19:238-245.
250. Klevsgard R, Risberg BO, Thomsen MB, Hallberg IR. A 1-year follow-up quality of life study after hemodynamically successful or unsuccessful surgical revascularization of lower limb ischemia. *J Vasc Surg.* 2001;33:114-122.
251. Nguyen HV, Ngian V, Cordato D, et al. Quality of life in a random sample of community dwelling older patients with essential tremor. *Acta Neurol Scand.* 2007;116:289-292.
252. Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. *Lancet.* 2005;366:1925-1934.
253. Beard JD. Which is the best revascularization for critical limb ischemia: endovascular or open surgery? *J Vasc Surg.* 2008;48(6 Suppl):11S-16S.
254. Mills JL Sr. Open bypass and endoluminal therapy: complementary techniques for revascularization in diabetic patients with critical limb ischaemia. *Diabetes Metab Res Rev.* 2008;24(Suppl 1):S34-S39.
255. Watson HR, Belcher G, Horrocks M. Adjuvant medical therapy in peripheral bypass surgery. *Br J Surg.* 1999;86:981-991.
256. Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial disease: a critical review. *Am J*

*Med.* 2002;112:49-57.

257. Montalescot G. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease. *Clin Cardiol.* 2000;23(Suppl 6):VI-18-22.
258. Hackam DG, Eikelboom JW. Antithrombotic treatment for peripheral arterial disease. *Heart.* 2007;93:303-308.
259. Girolami B, Bernardi E, Prins MH, et al. Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis. *Eur J Vasc Endovasc Surg.* 2000;19:370-380.
260. Gardner AW, Afaq A. Management of lower extremity peripheral arterial disease. *J Cardiopulm Rehabil Prev.* 2008;28:349-357.
261. Collins TC, Soucek J, Beyth RJ. Benefits of antithrombotic therapy after infrainguinal bypass grafting: a meta-analysis. *Am J Med.* 2004;117:93-99.
262. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ.* 2002;324:71-86.
263. Collaborative overview of randomised trials of antiplatelet therapy-II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. *BMJ.* 1994;308:159-168.
264. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. *BMJ.* 1994;308:81-106.
265. Antiplatelet therapy in peripheral arterial disease. Consensus statement. *Eur J Vasc Endovasc Surg.* 2003;26:1-16.
266. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet.* 1996;348:1329-1339.
267. Kretschmer G, Herbst F, Prager M, et al. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. *Arch Surg.* 1992;127:1112-1115.
268. Tangelder MJ, McDonnell J, Van Busschbach JJ, et al. Quality of life after infrainguinal bypass grafting surgery. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. *J Vasc Surg.* 1999;29:913-919.
269. Tangelder MJ, Algra A, Lawson JA, et al. Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. *J Vasc Surg.* 2001;33:522-527.
270. Oostenbrink JB, Tangelder MJ, Busschbach JJ, et al. Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. *J Vasc Surg.* 2001;34:254-262.
271. Sarac TP, Huber TS, Back MR, et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. *J Vasc Surg.* 1998;28:446-457.
272. Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. *J Vasc Surg.* 2002;35:413-421.
273. Shoenfeld NA, O'Donnell TF, Bush HL Jr, et al. The management of early in situ saphenous vein bypass occlusions. *Arch Surg.* 1987;122:871-875.
274. Szilagyi DE, Elliott JP, Hageman JH, et al. Biologic fate of autogenous vein implants as arterial substitutes: clinical, angiographic and histopathologic observations in femoro-popliteal operations for atherosclerosis. *Ann Surg.* 1973;178:232-246.
275. Mills JL, Fujitani RM, Taylor SM. The characteristics and anatomic distribution of lesions that cause reversed vein graft failure: a five-year prospective study. *J Vasc Surg.* 1993;17:195-204.
276. Mills JL. Mechanisms of vein graft failure: the location, distribution, and characteristics of lesions that predispose to graft failure. *Semin Vasc Surg.* 1993;6:78-91.
277. Donaldson MC, Mannick JA, Whittemore AD. Causes of primary graft failure after in situ saphenous vein bypass grafting.



- J Vasc Surg.* 1992;15:113-118; discussion 118-120.
278. Dunlop P, Hartshorne T, Bolia A, et al. The long-term outcome of infrainguinal vein graft surveillance. *Eur J Vasc Endovasc Surg.* 1995;10:352-355.
  279. Ferris BL, Mills JL Sr, Hughes JD, et al. Is early postoperative duplex scan surveillance of leg bypass grafts clinically important? *J Vasc Surg.* 2003;37:495-500.
  280. Grigg MJ, Nicolaides AN, Wolfe JH. Detection and grading of femorodistal vein graft stenoses: duplex velocity measurements compared with angiography. *J Vasc Surg.* 1988;8:661-666.
  281. Grigg MJ, Nicolaides AN, Wolfe JH. Femorodistal vein bypass graft stenoses. *Br J Surg.* 1988;75:737-740.
  282. Gupta AK, Bandyk DF, Cheanvechai D, Johnson BL. Natural history of infrainguinal vein graft stenosis relative to bypass grafting technique. *J Vasc Surg.* 1997;25:211-220.
  283. Hagino RT, Sheehan MK, Jung I, et al. Target lesion characteristics in failing vein grafts predict the success of endovascular and open revision. *J Vasc Surg.* 2007;46:1167-1172.
  284. Mills JL Sr. Is duplex surveillance of value after leg vein bypass grafting? Principal results of the Vein Graft Surveillance Randomised Trial (VGST). *Perspect Vasc Surg Endovasc Ther.* 2006;18:194-196.
  285. Mills JL, Bandyk DF, Gahtan V, Esses GE. The origin of infrainguinal vein graft stenosis: a prospective study based on duplex surveillance. *J Vasc Surg.* 1995;21:16-22.
  286. Mills JL, Harris EJ, Taylor LM Jr, et al. The importance of routine surveillance of distal bypass grafts with duplex scanning: a study of 379 reversed vein grafts. *J Vasc Surg.* 1990;12:379-386.
  287. Mills JL Sr, Wixon CL, James DC, et al. The natural history of intermediate and critical vein graft stenosis: recommendations for continued surveillance or repair. *J Vasc Surg.* 2001;33:273-278; discussion 278-280.
  288. Olojugba DH, McCarthy MJ, Naylor AR, et al. At what peak velocity ratio value should duplex-detected infrainguinal vein graft stenoses be revised? *Eur J Vasc Endovasc Surg.* 1998;15:258-260.
  289. Visser K, Idu MM, Buth J, et al. Duplex scan surveillance during the first year after infrainguinal autologous vein bypass grafting surgery: costs and clinical outcomes compared with other surveillance programs. *J Vasc Surg.* 2001;33:123-130.
  290. Lundell A, Lindblad B, Bergqvist D, Hansen F. Femoropopliteal-crural graft patency is improved by an intensive surveillance program: a prospective randomized study. *J Vasc Surg.* 1995;21:26-33.
  291. Lalak NJ, Hanel KC, Hunt J, Morgan A. Duplex scan surveillance of infrainguinal prosthetic bypass grafts. *J Vasc Surg.* 1994;20:637-641.
  292. Dunlop P, Sayers RD, Naylor AR, et al. The effect of a surveillance programme on the patency of synthetic infrainguinal bypass grafts. *Eur J Vasc Endovasc Surg.* 1996;11:441-445.
  293. Avino AJ, Bandyk DF, Gonsalves AJ, et al. Surgical and endovascular intervention for infrainguinal vein graft stenosis. *J Vasc Surg.* 1999;29:60-70.
  294. Gonsalves C, Bandyk DF, Avino AJ, Johnson BL. Duplex features of vein graft stenosis and the success of percutaneous transluminal angioplasty. *J Endovasc Surg.* 1999;6:66-72.
  295. Schneider PA, Caps MT, Nelken N. Infrainguinal vein graft stenosis: cutting balloon angioplasty as the first-line treatment of choice. *J Vasc Surg.* 2008;47:960-966.
  296. Kasirajan K, Schneider PA. Early outcome of "cutting" balloon angioplasty for infrainguinal vein graft stenosis. *J Vasc Surg.* 2004;39:702-708.
  297. Mills JL, Wixon CL. Pathobiology, detection and treatment of vein graft stenosis. In: Mills JL, ed. *Management of Chronic Lower Limb Ischemia*. London: Arnold; 2000:113-129.
  298. Tilanus HW, Obertop H, Van Urk H. Saphenous vein or PTFE for femoropopliteal bypass. A prospective randomized trial. *Ann Surg.* 1985;202:780-782.
  299. Veith FJ, Gupta SK, Ascer E, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. *J Vasc Surg.* 1986;3:104-114.

300. Sharp WJ, Shamma AR, Kresowik TF, Corson JD. Use of terminal T-junctions for in situ bypass in the lower extremity. *Surg Gynecol Obstet.* 1991;172:151-152.
301. Ouriel K. The posterior approach to popliteal-crural bypass. *J Vasc Surg.* 1994;19:74-79; discussion 79-80.
302. Miller JH, Foreman RK, Ferguson L, Faris I. Interposition vein cuff for anastomosis of prosthesis to small artery. *Aust N Z J Surg.* 1984;54:283-285.

## 第 110 章

1. Markose G, Bolia A. Subintimal angioplasty in the management of lower limb ischaemia. *J Cardiovasc Surg (Torino).* 2006;47:399-406.
2. Parsons RE, Suggs WD, Lee JJ, et al. Percutaneous transluminal angioplasty for the treatment of limb threatening ischemia: do the results justify an attempt before bypass grafting? *J Vasc Surg.* 1998;28:1066-1071.
3. Treiman GS, Treiman RL, Ichikawa L, Van Allan R. Should percutaneous transluminal angioplasty be recommended for treatment of infrageniculate popliteal artery or tibioperoneal trunk stenosis? *J Vasc Surg.* 1995;22:457-463; discussion 464-465.
4. Rogers JH, Laird JR. Overview of new technologies for lower extremity revascularization. *Circulation.* 2007;116:2072-2085.
5. Hobbs SD, Yapanis M, Burns PJ, et al. Peri-operative myocardial injury in patients undergoing surgery for critical limb ischaemia. *Eur J Vasc Endovasc Surg.* 2005;29:301-304.
6. Papavassiliou VG, Walker SR, Bolia A, et al. Techniques for the endovascular management of complications following lower limb percutaneous transluminal angioplasty. *Eur J Vasc Endovasc Surg.* 2003;25:125-130.
7. Menard MT, Belkin M. Infrapopliteal intervention for the treatment of the claudicant. *Semin Vasc Surg.* 2007;20:42-53.
8. Met R, Van Lienden KP, Koelemay MJ, et al. Subintimal angioplasty for peripheral arterial occlusive disease: a systematic review. *Cardiovasc Intervent Radiol.* 2008.
9. Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. *Radiology.* 2001;221:137-145.
10. Pentecost MJ, Criqui MH, Dorros G, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association. *Circulation.* 1994;89:511-531.
11. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). *J Vasc Surg.* 2000;31:S1-S296.
12. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S5-67.
13. Currie IC, Wakeley CJ, Cole SE, et al. Femoropopliteal angioplasty for severe limb ischaemia. *Br J Surg.* 1994;81:191-193.
14. Martin EC, Katzen BT, Benenati JF, et al. Multicenter trial of the wallstent in the iliac and femoral arteries. *J Vasc Interv Radiol.* 1995;6:843-849.
15. Ray SA, Minty I, Buckenham TM, et al. Clinical outcome and restenosis following percutaneous transluminal angioplasty for ischaemic rest pain or ulceration. *Br J Surg.* 1995;82:1217-1221.
16. Brosi P, Dick F, Do DD, et al. Revascularization for chronic critical lower limb ischemia in octogenarians is worthwhile. *J Vasc Surg.* 2007;46:1198-1207.
17. Conrad MF, Cambria RP, Stone DH, et al. Intermediate results of percutaneous endovascular therapy of femoropopliteal occlusive disease: a contemporary series. *J Vasc Surg.* 2006;44:762-769.
18. Clair DG, Dayal R, Faries PL, et al. Tibial angioplasty as an alternative strategy in patients with limb-threatening ischemia.

*Ann Vasc Surg.* 2005;19:63-68.

19. Romiti M, Albers M, Brochado-Neto FC, et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. *J Vasc Surg.* 2008;47:975-981.
20. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. *J Vasc Surg.* 1997;26:517-538.
21. Diehm N, Baumgartner I, Jaff M, et al. A call for uniform reporting standards in studies assessing endovascular treatment for chronic ischaemia of lower limb arteries. *Eur Heart J.* 2007;28:798-805.
22. Laxdal E, Jenssen GL, Pedersen G, Aune S. Subintimal angioplasty as a treatment of femoropopliteal artery occlusions. *Eur J Vasc Endovasc Surg.* 2003;25:578-582.
23. Hynes N, Akhtar Y, Manning B, et al. Subintimal angioplasty as a primary modality in the management of critical limb ischemia: comparison to bypass grafting for aortoiliac and femoropopliteal occlusive disease. *J Endovasc Ther.* 2004;11:460-471.
24. Vraux H, Bertoncello N. Subintimal angioplasty of tibial vessel occlusions in critical limb ischaemia: a good opportunity? *Eur J Vasc Endovasc Surg.* 2006;32:663-667.
25. Desgranges P, Boufi M, Lapeyre M, et al. Subintimal angioplasty: feasible and durable. *Eur J Vasc Endovasc Surg.* 2004;28:138-141.
26. Myers KA. Reporting standards and statistics for evaluating intervention. *Cardiovasc Surg.* 1995;3:455-461.
27. Shaw MB, DeNunzio M, Hinwood D, et al. The results of subintimal angioplasty in a district general hospital. *Eur J Vasc Endovasc Surg.* 2002;24:524-527.
28. Treiman GS, Treiman R, Whiting J. Results of percutaneous subintimal angioplasty using routine stenting. *J Vasc Surg.* 2006;43:513-519.
29. Vraux H, Hammer F, Verhelst R, et al. Subintimal angioplasty of tibial vessel occlusions in the treatment of critical limb ischaemia: mid-term results. *Eur J Vasc Endovasc Surg.* 2000;20:441-446.
30. Florenes T, Bay D, Sandbaek G, et al. Subintimal angioplasty in the treatment of patients with intermittent claudication: long term results. *Eur J Vasc Endovasc Surg.* 2004;28:645-650.
31. Yilmaz S, Sindel T, Yegin A, Luleci E. Subintimal angioplasty of long superficial femoral artery occlusions. *J Vasc Interv Radiol.* 2003;14:997-1010.
32. Lipsitz EC, Ohki T, Veith FJ, et al. Does subintimal angioplasty have a role in the treatment of severe lower extremity ischemia? *J Vasc Surg.* 2003;37:386-391.
33. McCarthy RJ, Neary W, Roobottom C, et al. Short-term results of femoropopliteal subintimal angioplasty. *Br J Surg.* 2000;87:1361-1365.
34. Lazaris AM, Tsiamis AC, Fishwick G, et al. Clinical outcome of primary infrainguinal subintimal angioplasty in diabetic patients with critical lower limb ischemia. *J Endovasc Ther.* 2004;11:447-453.
35. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. *Circulation.* 1990;82:1925-1931.
36. Spinoso DJ, Leung DA, Harthun NL, et al. Simultaneous antegrade and retrograde access for subintimal recanalization of peripheral arterial occlusion. *J Vasc Interv Radiol.* 2003;14:1449-1454.
37. Tisi PV, Mirnezami A, Baker S, et al. Role of subintimal angioplasty in the treatment of chronic lower limb ischaemia. *Eur J Vasc Endovasc Surg.* 2002;24:417-422.
38. DeRubertis BG, Pierce M, Chaer RA, et al. Lesion severity and treatment complexity are associated with outcome after percutaneous infra-inguinal intervention. *J Vasc Surg.* 2007;46:709-716.
39. Baim DS, Leon MB, Popma JJ, et al. Problems in the evaluation of new devices for coronary intervention: what have we learned since 1989? *Am J Cardiol.* 1997;80:3K-9K.
40. Radke PW, Kaiser A, Frost C, Sigwart U. Outcome after treatment of coronary in-stent restenosis; results from a systematic

review using meta-analysis techniques. *Eur Heart J*. 2003;24:266-273.

41. Kudo T, Chandra FA, Ahn SS. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. *J Vasc Surg*. 2005;41:423-435; discussion 435.
42. Ruef J, Hofmann M, Haase J. Endovascular interventions in iliac and infrainguinal occlusive artery disease. *J Interv Cardiol*. 2004;17:427-435.
43. Haider SN, Kavanagh EG, Forlee M, et al. Two-year outcome with preferential use of infrainguinal angioplasty for critical ischemia. *J Vasc Surg*. 2006;43:504-512.
44. DeRubertis BG, Faries PL, McKinsey JF, et al. Shifting paradigms in the treatment of lower extremity vascular disease: a report of 1000 percutaneous interventions. *Ann Surg*. 2007;246:415-422; discussion 422-424.
45. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. *Circulation*. 1991;83(2 Suppl):I70-I80.
46. Johnston KW. Factors that influence the outcome of aortoiliac and femoropopliteal percutaneous transluminal angioplasty. *Surg Clin North Am*. 1992;72:843-850.
47. Stanley B, Teague B, Raptis S, et al. Efficacy of balloon angioplasty of the superficial femoral artery and popliteal artery in the relief of leg ischemia. *J Vasc Surg*. 1996;23:679-685.
48. Jeans WD, Armstrong S, Cole SE, et al. Fate of patients undergoing transluminal angioplasty for lower-limb ischemia. *Radiology*. 1990;177:559-564.
49. Krepel VM, van Andel GJ, van Erp WF, Breslau PJ. Percutaneous transluminal angioplasty of the femoropopliteal artery: initial and long-term results. *Radiology*. 1985;156:325-328.
50. Jorgensen B, Tonnesen KH, Holstein P. Late hemodynamic failure following percutaneous transluminal angioplasty for long and multifocal femoropopliteal stenoses. *Cardiovasc Intervent Radiol*. 1991;14:290-292.
51. Cotroneo AR, Iezzi R, Marano G, et al. Hybrid therapy in patients with complex peripheral multifocal steno-obstructive vascular disease: two-year results. *Cardiovasc Intervent Radiol*. 2007;30:355-361.
52. Almahameed A, Bhatt DL. Contemporary management of peripheral arterial disease: III. Endovascular and surgical management. *Cleve Clin J Med*. 2006;73(Suppl 4):S45-S51.
53. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. *N Engl J Med*. 1992;326:381-386.
54. Vogt MT, Wolfson SK, Kuller LH. Segmental arterial disease in the lower extremities: correlates of disease and relationship to mortality. *J Clin Epidemiol*. 1993;46:1267-1276.
55. Conte MS, Belkin M, Upchurch GR, et al. Impact of increasing comorbidity on infrainguinal reconstruction: a 20-year perspective. *Ann Surg*. 2001;233:445-452.
56. Olojugba DH, McCarthy MJ, Reid A, et al. Infrainguinal revascularisation in the era of vein-graft surveillance—do clinical factors influence long-term outcome? *Eur J Vasc Endovasc Surg*. 1999;17:121-128.
57. Enzler MA, Ruoss M, Seifert B, Berger M. The influence of gender on the outcome of arterial procedures in the lower extremity. *Eur J Vasc Endovasc Surg*. 1996;11:446-452.
58. Rueda CA, Nehler MR, Perry DJ, et al. Patterns of artery disease in 450 patients undergoing revascularization for critical limb ischemia: implications for clinical trial design. *J Vasc Surg*. 2008;47:995-1000.
59. Davies AH, Cole SE, Magee TR, et al. The effect of diabetes mellitus on the outcome of angioplasty for lower limb ischaemia. *Diabet Med*. 1992;9:480-481.
60. Stokes KR, Strunk HM, Campbell DR, et al. Five-year results of iliac and femoropopliteal angioplasty in diabetic patients. *Radiology*. 1990;174:977-982.
61. Joels CS, York JW, Kalbaugh CA, et al. Surgical implications of early failed endovascular intervention of the superficial femoral artery. *J Vasc Surg*. 2008;47:562-565.
62. Taylor SM, Kalbaugh CA, Blackhurst DW, et al. Determinants of functional outcome after revascularization for critical

- limb ischemia: an analysis of 1000 consecutive vascular interventions. *J Vasc Surg*. 2006;44:747-755; discussion 755-756.
63. Jansen TS, Manninen HI, Tulla HE, et al. Infrainguinal revascularization because of claudication: total long-term outcome of endovascular and surgical treatment. *J Vasc Surg*. 2003;37:808-815.
  64. Ascher E, Marks NA, Hingorani AP, et al. Duplex-guided endovascular treatment for occlusive and stenotic lesions of the femoral-popliteal arterial segment: a comparative study in the first 253 cases. *J Vasc Surg*. 2006;44:1230-1237; discussion 1237-1238.
  65. Trocciola SM, Chaer R, Dayal R, et al. Comparison of results in endovascular interventions for infrainguinal lesions: claudication versus critical limb ischemia. *Am Surg*. 2005;71:474-479; discussion 479-480.
  66. Treiman GS, Ichikawa L, Treiman RL, et al. Treatment of recurrent femoral or popliteal artery stenosis after percutaneous transluminal angioplasty. *J Vasc Surg*. 1994;20:577-585; discussion 585-587.
  67. Kudo T, Chandra FA, Kwun WH, et al. Changing pattern of surgical revascularization for critical limb ischemia over 12 years: endovascular vs. open bypass surgery. *J Vasc Surg*. 2006;44:304-313.
  68. Sniderman KW. Noncoronary vascular stenting. *Prog Cardiovasc Dis*. 1996;39:141-164.
  69. Muller-Hulsbeck S, Order BM, Jahnke T. Interventions in infrainguinal bypass grafts. *Cardiovasc Intervent Radiol*. 2006;29:17-28.
  70. Hunink MG, Donaldson MC, Meyerovitz MF, et al. Risks and benefits of femoropopliteal percutaneous balloon angioplasty. *J Vasc Surg*. 1993;17:183-192; discussion 192-194.
  71. Matsi PJ, Manninen HI, Vanninen RL, et al. Femoropopliteal angioplasty in patients with claudication: primary and secondary patency in 140 limbs with 1-3-year follow-up. *Radiology*. 1994;191:727-733.
  72. London NJ, Srinivasan R, Naylor AR, et al. Subintimal angioplasty of femoropopliteal artery occlusions: the long-term results. *Eur J Vasc Surg*. 1994;8:148-155.
  73. Rush DS, Gewertz BL, Lu CT, et al. Limb salvage in poor-risk patients using transluminal angioplasty. *Arch Surg*. 1983;118:1209-1212.
  74. Wolf GL, Wilson SE, Cross AP, et al. Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial. Principal investigators and their associates of Veterans Administration Cooperative Study Number 199. *J Vasc Interv Radiol*. 1993;4:639-648.
  75. Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. *Lancet*. 2005;366:1925-1934.
  76. Bergeron P, Pinot JJ, Poyen V, et al. Long-term results with the Palmaz stent in the superficial femoral artery. *J Endovasc Surg*. 1995;2:161-167.
  77. Do Dai D, Triller J, Walpoth BH, et al. A comparison study of self-expandable stents vs balloon angioplasty alone in femoropopliteal artery occlusions. *Cardiovasc Intervent Radiol*. 1992;15:306-312.
  78. Rousseau HP, Raillat CR, Joffre FG, et al. Treatment of femoropopliteal stenoses by means of self-expandable endoprostheses: midterm results. *Radiology*. 1989;172:961-964.
  79. Sapoval MR, Long AL, Raynaud AC, et al. Femoropopliteal stent placement: long-term results. *Radiology*. 1992;184:833-839.
  80. White GH, Liew SC, Waugh RC, et al. Early outcome and intermediate follow-up of vascular stents in the femoral and popliteal arteries without long-term anticoagulation. *J Vasc Surg*. 1995;21:270-279; discussion 279-281.
  81. Vroegindeweij D, Vos LD, Tielbeek AV, et al. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: a comparative randomized study. *Cardiovasc Intervent Radiol*. 1997;20:420-425.
  82. Grimm J, Muller-Hulsbeck S, Jahnke T, et al. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. *J Vasc Interv Radiol*. 2001;12:935-942.
  83. Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a

- multicenter prospective randomized study. *J Vasc Interv Radiol*. 2001;12:23-31.
84. Becquemin JP, Favre JP, Marzelle J, et al. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. *J Vasc Surg*. 2003;37:487-494.
  85. Conroy RM, Gordon IL, Tobis JM, et al. Angioplasty and stent placement in chronic occlusion of the superficial femoral artery: technique and results. *J Vasc Interv Radiol*. 2000;11:1009-1020.
  86. Lugmayr HF, Holzer H, Kastner M, et al. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a midterm follow-up. *Radiology*. 2002;222:37-43.
  87. Mewissen MW. Self-expanding nitinol stents in the femoropopliteal segment: technique and mid-term results. *Tech Vasc Interv Radiol*. 2004;7:2-5.
  88. Sabeti S, Schillinger M, Amighi J, et al. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis. *Radiology*. 2004;232:516-521.
  89. Vogel TR, Shindelman LE, Nackman GB, Graham AM. Efficacious use of nitinol stents in the femoral and popliteal arteries. *J Vasc Surg*. 2003;38:1178-1184.
  90. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. *N Engl J Med*. 2006;354:1879-1888.
  91. Ingle H, Nasim A, Bolia A, et al. Subintimal angioplasty of isolated infragenicular vessels in lower limb ischemia: long-term results. *J Endovasc Ther*. 2002;9:411-416.
  92. Krankenberg H, Sorge I, Zeller T, Tubler T. Percutaneous transluminal angioplasty of infrapopliteal arteries in patients with intermittent claudication: acute and one-year results. *Catheter Cardiovasc Interv*. 2005;64:12-17.
  93. Feiring AJ, Wesolowski AA, Lade S. Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: early and one-year outcomes. *J Am Coll Cardiol*. 2004;44:2307-2314.
  94. Bosiers M, Hart JP, Deloose K, et al. Endovascular therapy as the primary approach for limb salvage in patients with critical limb ischemia: experience with 443 infrapopliteal procedures. *Vascular*. 2006;14:63-69.
  95. Armstrong MW, Torrie EP, Galland RB. Consequences of immediate failure of percutaneous transluminal angioplasty. *Ann R Coll Surg Engl*. 1992;74:265-268.
  96. Treiman GS. Subintimal angioplasty for infrainguinal occlusive disease. *Surg Clin North Am*. 2004;84:1365-1380, viii.
  97. Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(3 Suppl):609S-626S.
  98. Rzucidlo EM, Martin KA, Powell RJ. Regulation of vascular smooth muscle cell differentiation. *J Vasc Surg*. 2007;45(Suppl A):A25-A32.
  99. Lumsden AB, Rice TW, Chen C, et al. Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management. *World J Surg*. 2007;31:695-704.
  100. Schneider PA, Andros G. Role of balloon angioplasty and stents in the management of failed arterial reconstructions. *Semin Vasc Surg*. 1994;7:178-182.
  101. Ryer EJ, Trocciola SM, DeRubertis B, et al. Analysis of outcomes following failed endovascular treatment of chronic limb ischemia. *Ann Vasc Surg*. 2006;20:440-446.
  102. Henry M, Amor M, Ethevenot G, et al. Palmaz stent placement in iliac and femoropopliteal arteries: primary and secondary patency in 310 patients with 2-4-year follow-up. *Radiology*. 1995;197:167-174.
  103. Jakobs TF, Wintersperger BJ, Becker CR. MDCT-imaging of peripheral arterial disease. *Semin Ultrasound CT MR*. 2004;25:145-155.
  104. Koelemay MJ, Lijmer JG, Stoker J, et al. Magnetic resonance angiography for the evaluation of lower extremity arterial disease: a meta-analysis. *JAMA*. 2001;285:1338-1345.
  105. Cowper SE. Nephrogenic systemic fibrosis: an overview. *J Am Coll Radiol*. 2008;5:23-28.
  106. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral

- arterial disease. A meta-analysis of randomized controlled trials. *Arch Intern Med*. 1991;151:1769-1776.
107. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*. 2000;342:145-153.
  108. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med*. 2006;354:1706-1717.
  109. Girolami B, Bernardi E, Prins MH, et al. Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis. *Eur J Vasc Endovasc Surg*. 2000;19:370-380.
  110. Stricker H, Jacomella V. Stent-assisted angioplasty at the level of the common femoral artery bifurcation: midterm outcomes. *J Endovasc Ther*. 2004;11:281-286.
  111. Schneider PA, Abcarian PW, Ogawa DY, et al. Should balloon angioplasty and stents have any role in operative intervention for lower extremity ischemia? *Ann Vasc Surg*. 1997;11:574-580.
  112. Nelson PR, Powell RJ, Schermerhorn ML, et al. Early results of external iliac artery stenting combined with common femoral artery endarterectomy. *J Vasc Surg*. 2002;35:1107-1113.
  113. Dosluoglu HH, Harris LM, Cherr GS. Recanalization of concomitant iliac artery and common femoral artery occlusions using an antegrade hybrid (open/endovascular) approach. *Vasc Endovasc Surg*. 2007;41:130-134.
  114. Motarjeme A, Keifer JW, Zuska AJ. Percutaneous transluminal angioplasty of the deep femoral artery. *Radiology*. 1980;135:613-617.
  115. Waltman AC. Percutaneous transluminal angioplasty: iliac and deep femoral arteries. *AJR Am J Roentgenol*. 1980;135:921-925.
  116. Silva JA, White CJ, Ramee SR, et al. Percutaneous profundaplasty in the treatment of lower extremity ischemia: results of long-term surveillance. *J Endovasc Ther*. 2001;8:75-82.
  117. Savolainen H, Hansen A, Diehm N, et al. Small is beautiful: why profundaplasty should not be forgotten. *World J Surg*. 2007;31:2058-2061.
  118. Mossop PJ, Amukotuwa SA, Whitbourn RJ. Controlled blunt microdissection for percutaneous recanalization of lower limb arterial chronic total occlusions: a single center experience. *Catheter Cardiovasc Interv*. 2006;68:304-310.
  119. Joye JD, Serry R, St. Goar FG, Zetterlund P. Clinical success in 100 consecutive endovascular occlusion cases using re-entry catheters for failed sub-intimal approach. *J Am Coll Cardiol*. 2006;47(suppl 2):31B.
  120. Saket RR, Razavi MK, Padidar A, et al. Novel intravascular ultrasound-guided method to create transintimal arterial communications: initial experience in peripheral occlusive disease and aortic dissection. *J Endovasc Ther*. 2004;11:274-280.
  121. Hoffmann R, Guagliumi G, Musumeci G, et al. Vascular response to sirolimus-eluting stents delivered with a nonaggressive implantation technique: comparison of intravascular ultrasound results from the multicenter, randomized E-SIRIUS, and SIRIUS trials. *Catheter Cardiovasc Interv*. 2005;66:499-506.
  122. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. *Circulation*. 2002;106:1505-1509.
  123. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. *J Vasc Interv Radiol*. 2005;16:331-338.
  124. Siablis D, Karnabatidis D, Katsanos K, et al. Sirolimus-eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit. *J Endovasc Ther*. 2007;14:241-250.
  125. Katzen B. *Zilver Stent trial update*. *International Symposium on Endovascular Therapy*. Miami Beach, FL, 2006.
  126. Kedora J, Hohmann S, Garrett W, et al. Randomized comparison of percutaneous Viabahn stent grafts vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral arterial occlusive disease. *J Vasc Surg*. 2007;45:10-16; discussion 16.

127. Zeller T, Rastan A, Sixt S, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. *J Am Coll Cardiol.* 2006;48:1573-1578.
128. Kandzari DE, Kiesz RS, Allie D, et al. Procedural and clinical outcomes with catheter-based plaque excision in critical limb ischemia. *J Endovasc Ther.* 2006;13:12-22.
129. Scheinert D, Laird JR Jr, Schroder M, et al. Excimer laser-assisted recanalization of long, chronic superficial femoral artery occlusions. *J Endovasc Ther.* 2001;8:156-166.
130. Laird JR, Zeller T, Gray BH, et al. Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. *J Endovasc Ther.* 2006;13:1-11.
131. Yiu WK, Cheng SW, Sumpio BE. Vascular smooth muscle cell apoptosis induced by "supercooling" and rewarming. *J Vasc Interv Radiol.* 2006;17:1971-1977.
132. Laird J, Jaff MR, Biamino G, et al. Cryoplasty for the treatment of femoropopliteal arterial disease: results of a prospective, multicenter registry. *J Vasc Interv Radiol.* 2005;16:1067-1073.
133. Das T. *1-Year results from the Below-the-Knee (BTK) CHILL Study. 56th Annual American College of Cardiology Scientific Session.* New Orleans, LA, 2007.
134. Chalmers RT, Hoballah JJ, Kresowik TF, et al. Late results of a prospective study of direct intra-arterial urokinase infusion for peripheral arterial and bypass graft occlusions. *Cardiovasc Surg.* 1995;3:293-297.
135. Wholey MH, Maynar MA, Pulido-Duque JM, et al. Comparison of thrombolytic therapy of lower-extremity acute, subacute, and chronic arterial occlusions. *Cathet Cardiovasc Diagn.* 1998;44:159-169.
136. Wholey MH, Toursarkissian B, Postoak D, et al. Early experience in the application of distal protection devices in treatment of peripheral vascular disease of the lower extremities. *Catheter Cardiovasc Interv.* 2005;64:227-235.
137. Vikram R, Ross RA, Bhat R, et al. Cutting balloon angioplasty versus standard balloon angioplasty for failing infra-inguinal vein grafts: comparative study of short- and mid-term primary patency rates. *Cardiovasc Intervent Radiol.* 2007;30:607-610.
138. Ansel GM, Sample NS, Botti IC Jr, et al. Cutting balloon angioplasty of the popliteal and infrapopliteal vessels for symptomatic limb ischemia. *Catheter Cardiovasc Interv.* 2004;61:1-4.

## 第 111 章

1. Levien LJ. Nonatheromatous causes of popliteal artery disease. In: Rutherford RB, ed. *Vascular Surgery*. 6th ed. Philadelphia: Elsevier Saunders Inc; 2005:1236-1255.
2. di Marzo L, Cavallaro A. Popliteal vascular entrapment. *World J Surg.* 2005;29:S43-S45.
3. Atkins HJB, Key JA. A case of myxomatous tumor arising in the adventitia of the left external iliac artery. *Br J Surg.* 1947;34:426.
4. Tsilimparis N, Hanack U, Yousefi S, et al. Cystic adventitial disease of the popliteal artery: an argument for the developmental theory. *J Vasc Surg.* 2007;45:1249-1252.
5. Ortiz MWR, Lopera JE, Gimenez CR, et al. Bilateral adventitial cystic disease of the popliteal artery: a case report. *Cardiovasc Intervent Radiol.* 2006;29:306-310.
6. Gagnon J, Doyle DL. Adventitial cystic disease of common femoral artery. *Ann Vasc Surg.* 2007;21:84-86.
7. Levien LJ, Benn CA. Adventitial cystic disease: a unifying hypothesis. *J Vasc Surg.* 1998;28:193-205.
8. Dix FP, McDonald M, Obomighie J, et al. Cystic adventitial disease of the femoral vein presenting as deep vein thrombosis: a case report and review of the literature. *J Vasc Surg.* 2006;44:871-874.
9. Flanigan DP, Burnham SJ, Goodreau JJ, Bergan JJ. Summary of cases of adventitial cystic disease of the popliteal artery. *Ann Surg.* 1979;189:165-175.
10. Ishikawa K. Cystic adventitial disease of the popliteal artery and of other stem vessels in the extremities. *Jpn J Surg.* 1987;17:221-229.



11. Tsolakis IA, Walvatne CS, Caldwell MD. Cystic adventitial disease of the popliteal artery: diagnosis and treatment. *Eur J Vasc Endovasc Surg*. 1998;15:188-194.
12. Schramek A, Hashmonai M. Subadventitial haematoma of the popliteal artery. *J Cardiovasc Surg (Torino)*. 1973;14:447-451.
13. Vasudevan A, Halak M, Lee S, et al. Cystic adventitial disease: a case report and literature review. *Aust N Z J Surg*. 2005;75:1120-1122.
14. Schroe H, Van Opstal C, De Leersnijder J, et al. Baker's cyst connected to popliteal artery cyst. *Ann Vasc Surg*. 1988;2:385-389.
15. Leaf G. Amino-acid analysis of protein present in a popliteal artery cyst. *BMJ* 1967;3:415-417.
16. Jay GD, Ross FL, Mason RA, Giron F. Clinical and chemical characterization of an adventitial popliteal cyst. *J Vasc Surg*. 1989;3:448-455.
17. Linquette M, Mesmacque R, Beghin B, et al. Degenerescence colloide de l'adventice de l'artere poplitee. *Semaine Hop (Paris)*. 1967;43:3005-3013.
18. Chiche L, Barranger B, Cordoliani YS, et al. Two cases of cystic adventitial disease of the popliteal artery. Current diagnostic approach. *J Mal Vasc*. 1994;19:57-61.
19. Galle C, Cavenaile JC, Hoang AD, et al. Adventitial cystic disease of the popliteal artery communicating with the knee joint. A case report. *J Vasc Surg*. 1998;28:738-741.
20. Buijsrogge MP, van der Meij S, Korte JH, Fritschy WM. "Intermittent claudication intermittence" as a manifestation of adventitial cystic disease communicating with the knee joint. *Ann Vasc Surg*. 2006;20:687-689.
21. Pursell R, Torrie EP, Gibson M, Galland RB. Spontaneous and permanent resolution of cystic adventitial disease of the popliteal artery. *J R Soc Med*. 2004;97:77-78.
22. Vanhoenacker FM, Vandevenne JE, De Schepper AM, De Leersnijder J. Regarding "Adventitial cystic disease: a unifying hypothesis." *J Vasc Surg*. 2000;31:621-622.
23. Stapff J, Zoller WG, Spengel FA. Image-directed Doppler ultrasound findings in adventitial cystic disease of the popliteal artery. *J Clin Ultrasound*. 1989;17:689-691.
24. Rizzo RJ, Flinn WR, Yao JST, et al. Computed tomography for evaluation of arterial disease in the popliteal fossa. *J Vasc Surg*. 1990;11:112-119.
25. Crolla R, Steyling J, Hennipman A, et al. A case of cystic adventitial disease of the popliteal artery: confirmation with MR imaging. *J Vasc Surg*. 1993;18:1052-1055.
26. Khoury M. Failed angioplasty of a popliteal artery stenosis secondary to cystic adventitial disease: a case report. *Vasc Endovasc Surg*. 2004;38:277-280.
27. Wilbur AC, Spigos DG. Adventitial cyst of the popliteal artery: CT-guided percutaneous aspiration. *J Comput Assist Tomogr*. 1986;10:161-163.
28. Ohta T, Kato R, Sugimoto I, Kondo M. Recurrence of cystic adventitial disease in an interposed vein graft. *Surgery*. 1994;116:587-592.
29. Love JW, Whelan TJ. Popliteal artery entrapment syndrome. *Am J Surg*. 1965;109:620-624.
30. Gibson MHL, Mills JG, Johnson GE, Downs AR. Popliteal entrapment syndrome. *Ann Surg*. 1977;185:341-348.
31. Murray A, Halliday M, Croft RJ. Popliteal artery entrapment syndrome. *Br J Surg*. 1991;78:1414-1419.
32. Rossett E, Hartung O, Brunet C. Popliteal artery entrapment syndrome. Anatomic and embryologic bases, diagnostic and therapeutic considerations following a series of 15 cases with a review of the literature. *Surg Radiol Anat*. 1995;17:161-169.
33. Henry MF, Wilkins DC, Lambert AW. Popliteal artery entrapment syndrome. *Curr Treat Options Cardiovasc Med*. 2004;6:113-120.
34. Bron C, Haller C, Calanca L, et al. Popliteal artery entrapment syndrome: 3 unusual features in the same patient. *Eur J Vasc Endovasc Surg Extra*. 2007;14:51-53.

35. Levien LJ, Veller MG. Popliteal artery entrapment syndrome: more common than previously recognized. *J Vasc Surg.* 1999;30:587-598.
36. McAree BJ, O'Donnell ME, Davison GW, et al. Bilateral popliteal artery occlusion in a competitive bike rider: case report and clinical review. *Vasc Endovasc Surg.* 2008;42:380-385.
37. Hoelting T, Schuermann G, Allenberg JR. Entrapment of the popliteal artery and its surgical management in a 20-year period. *Br J Surg* 1997;84:338-341.
38. Akkersdijk WL, de Ruyter JW, Lapham R, et al. Colour duplex ultrasonographic and provocation of popliteal artery compression. *Eur J Vasc Endovasc Surg.* 1995;10:342-345.
39. Pillai J, Levien LJ, Haagensen M, et al. Assessment of the medial head of the gastrocnemius muscle in functional compression of the popliteal artery. *J Vasc Surg.* 2008;48:1189-1196.
40. Levien LJ. Popliteal artery thrombosis caused by popliteal artery entrapment syndrome. In: Greenhalgh RM, Powell JT, eds. *Inflammatory and Thrombotic Problems in Vascular Surgery.* London: WB Saunders Co Ltd; 1997:159-168.
41. di Marzo L, Cavallaro A, Sciacca V. Diagnosis of popliteal artery entrapment syndrome: the role of duplex scanning. *J Vasc Surg.* 1991;13:434-438.
42. Steurer J, Hoffmann U, Schneider E, et al. A new therapeutic approach to popliteal artery entrapment syndrome (PAES). *Eur J Vasc Endovasc Surg.* 1995;10:243-247.
43. Beseth BD, Moore WS. The posterior approach for repair of popliteal artery aneurysms. *J Vasc Surg.* 2006;43:940-945.
44. Lambert AW, Wilkins DC. Popliteal artery entrapment syndrome. *Br J Surg.* 1999;86:1365-1370.

## 第 112 章

1. Lavery LA, van Houtum WH. In-hospital mortality and disposition of diabetic amputees in the Netherlands. *Diabet Med.* 1996;13:192-197.
2. Lavery LA, Ashry HR, van Houtum WH, Pugh J. Variation in the incidence and proportion of diabetes related amputations in minorities. *Diabetes Care.* 1996;19:48-52.
3. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. *JAMA.* 2005;293:217-228.
4. Armstrong DG, Lavery LA. Surgical morbidity and the risk of amputation due to infected puncture wounds in diabetic versus nondiabetic adults. *South Med J.* 1997;90:384-389.
5. Lavery LA, van Houtum WH, Ashry HR, et al. Diabetes-related lower-extremity amputations disproportionately affect blacks and Mexican Americans. *South Med J.* 1999;92:593-599.
6. Armstrong DG, Lavery LA, eds. *Clinical Care of the Diabetic Foot.* Alexandria, VA: American Diabetes Association Press; 2005.
7. *National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2003.* Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services; 2004. NIH Publication No. 05-3892.
8. Lavery LA, Armstrong DG, Wunderlich RP, et al. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. *Diabetes Care.* 2003;26:1435-1438.
9. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *Eur J Vasc Endovasc Surg.* 2007;11:S8.
10. Lim TS, Finlayson A, Thorpe JM, et al. Outcomes of a contemporary amputation series. *Aust N Z J Surg.* 2006;76:300-305.
11. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. *Diabetes Care.* 1990;13:513-521.
12. Lavery LA, Wunderlich RP, Tredwell J. Disease management for the diabetic foot: effectiveness of a diabetic foot prevention program to reduce amputations and hospitalizations. *Diabetes Res Clin Pract.* 2005;70:31-37.

13. Lavery LA, Armstrong DG, Wunderlich RP, et al. Risk factors for foot infections in individuals with diabetes. *Diabetes Care*. 2006;29:1288.
14. Lavery LA, Peters EJ, Williams JR, et al. Reevaluating the way we classify the diabetic foot: restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. *Diabetes Care*. 2008;31:154-156.
15. Peters EJ, Lavery LA. Effectiveness of the Diabetic Foot Risk Classification System of the International Working Group on the Diabetic Foot. *Diabetes Care*. 2001;24:1442-1447.
16. Mayfield JA, Reiber GE, Nelson RG, Greene T. A foot risk classification system to predict diabetic amputation in Pima Indians. *Diabetes Care*. 1996;19:704-709.
17. Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders: a clinical practice guideline (2006 revision). *J Foot Ankle Surg*. 2006;45(5 Suppl):S1-S66.
18. Lavery LA, Armstrong DG, Wunderlich RP, et al. Predictive value of foot pressure assessment as part of a population-based diabetes disease management program. *Diabetes Care*. 2003;26:1069-1073.
19. Boulton AJ, Armstrong DG, Albert SF, et al; American Diabetes Association; American Association of Clinical Endocrinologists. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. *Diabetes Care*. 2008;31:1679-1685.
20. Andros G. Diagnostic and therapeutic arterial interventions in the ulcerated diabetic foot. *Diabetes Metab Res Rev*. 2004;20(Suppl 1):S29-S33.
21. Andros G. Bypass grafts to the ankle and foot. A personal perspective. *Surg Clin North Am*. 1995;75:715-729.
22. LoGerfo FW, Coffman JD. Current concepts. Vascular and microvascular disease of the foot in diabetes. Implications for foot care. *N Engl J Med*. 1984;311:1615-1619.
23. Andros G, Harris RW, Salles-Cunha SX, et al. Bypass grafts to the ankle and foot. *J Vasc Surg*. 1988;7:785-794.
24. Belkin M, Welch HJ, Mackey WC, O'Donnell TF Jr. Clinical and hemodynamic results of bypass to isolated tibial artery segments for ischemic ulceration of the foot. *Am J Surg*. 1992;164:281-284.
25. Faglia E, Dalla Paola L, Clerici G, et al. Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. *Eur J Vasc Endovasc Surg*. 2005;29:620-627.
26. Berceli SA, Chan AK, Pomposelli FB Jr, et al. Efficacy of dorsal pedal artery bypass in limb salvage for ischemic heel ulcers. *J Vasc Surg*. 1999;30:499-508.
27. Gentile AT, Berman SS, Reinke KR, et al. A regional pedal ischemia scoring system for decision analysis in patients with heel ulceration. *Am J Surg*. 1998;176:109-114.
28. West KM. Epidemiology of Diabetes and Its Vascular Lesions. Philadelphia: Elsevier, Inc.; 1978.
29. Carter SA, Tate RB. The relationship of the transcutaneous oxygen tension, pulse waves and systolic pressures to the risk for limb amputation in patients with peripheral arterial disease and skin ulcers or gangrene. *Int Angiol*. 2006;25:67-72.
30. Faris I, Duncan H. Skin perfusion pressure in the prediction of healing in diabetic patients with ulcers or gangrene of the foot. *J Vasc Surg*. 1985;2:536-540.
31. Kalani M, Brismar K, Fagrell B, et al. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. *Diabetes Care*. 1999;22:147-151.
32. Yamada T, Ohta T, Ishibashi H, et al. Clinical reliability and utility of skin perfusion pressure measurement in ischemic limbs—comparison with other noninvasive diagnostic methods. *J Vasc Surg*. 2008;47:318-323.
33. Karanfilian RG, Lynch TG, Zirul VT, et al. The value of laser Doppler velocimetry and transcutaneous oxygen tension determination in predicting healing of ischemic forefoot ulcerations and amputations in diabetic and nondiabetic patients. *J Vasc Surg*. 1986;4:511-516.
34. Ubbink DT, Spincemaille GH, Reneman RS, Jacobs MJ. Prediction of imminent amputation in patients with

- non-reconstructible leg ischemia by means of microcirculatory investigations. *J Vasc Surg*. 1999;30:114-121.
35. Apelqvist J, Castenfors J, Larsson J, et al. Prognostic value of systolic ankle and toe blood pressure levels in outcome of diabetic foot ulcer. *Diabetes Care*. 1989;12:373-378.
  36. Ballard JL, Eke CC, Bunt TJ, Killeen JD. A prospective evaluation of transcutaneous oxygen measurements in the management of diabetic foot problems. *J Vasc Surg*. 1995;22:485-490.
  37. Adera HM, James K, Castronuovo JJ Jr, et al. Prediction of amputation wound healing with skin perfusion pressure. *J Vasc Surg*. 1995;21:823-828; discussion 828-829.
  38. Armstrong DG, Lavery LA, Quebedeaux TL, et al. Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration. *Arch Intern Med*. 1998;158:289-292.
  39. Apelqvist J, Bakker K, Van Houtum WH, et al, eds. *International Working Group on the Diabetic Foot: International Consensus on the Diabetic Foot*. Maastricht: International Working Group on the Diabetic Foot; 1999.
  40. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. *Diabetes Metab Res Rev*. 2004;20(Suppl 1):S90-S95.
  41. Lipsky BA, Berendt AR, Deery HG, et al. IDSA guidelines: diagnosis and treatment of diabetic foot infections. *Clin Infect Dis*. 2004;39:885-910.
  42. Armstrong DG, Lavery LA, eds. *Clinical Care of the Diabetic Foot*. Alexandria, VA: American Diabetes Association Press; 2005:72-77.
  43. Grayson ML, Gibbons GW, Balogh K, et al. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. *JAMA*. 1995;273:721-723.
  44. Lavery LA, Armstrong DG, Peters EJG, Lipsky BA. Probe to bone test for diagnosing osteomyelitis: reliable or relic? *Diabetes Care*. 2007;30:270-274.
  45. Shone A, Burnside J, Chipchase S, et al. Probing the validity of the probe-to-bone test in the diagnosis of osteomyelitis of the foot in diabetes. *Diabetes Care*. 2006;29:945.
  46. Khan NA, Rahim SA, Anand SS, et al. Does the clinical examination predict lower extremity peripheral arterial disease? *JAMA*. 2006;295:536-546.
  47. Laughlin TJ, Armstrong DG, Caporusso J, Lavery LA. Soft tissue and bone infections from puncture wounds in children. However, most puncture related infections in persons with diabetes are due to *Staphylococcus* and *Streptococcus* species. *West J Med*. 1997;166:126-128.
  48. Lavery LA, Walker SC, Felder-Johnson KL, Harkless LB. Infected puncture wounds in diabetic and non-diabetic adults. Limb threatening infections classically present with a mixed bacterial flora of gram positive and gram negative aerobic and anaerobic pathogens. *Diabetes Care*. 1995;18:1588-1591.
  49. Meggitt B. Surgical management of the diabetic foot. *Br J Hosp Med*. 1976;227-232.
  50. Wagner FW Jr. The dysvascular foot: a system for diagnosis and treatment. *Foot Ankle*. 1981;2:64-122.
  51. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system: the contribution of depth, infection and ischemia to risk of amputation. *Diabetes Care*. 1998;21:855-859.
  52. Andros G, Harris RW, Dulawa LB, et al. Indications for distal arterial reconstruction in the presence of palpable pedal pulses. *Arch Surg*. 1984;119:1260-1263.
  53. Armstrong DG, Peters EJG. Charcot's arthropathy of the foot. *J Am Podiatr Med Assoc*. 2003;92:390-394.
  54. Ulbrecht J, Wukich D. The Charcot foot: medical and surgical therapy. *Curr Diabetes Rep*. 2008;8:444-451.

## 第 113 章

1. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. *JAMA*. 2005;293:217-228.
2. Lavery LA, Armstrong DG, Wunderlich RP, et al. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. *Diabetes Care*.

- 2003;26:1435-1438.
3. *National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2003*. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services; 2004. NIH Publication No. 05-3892.
  4. Goldner MG. The fate of the second leg in the diabetic amputee. *Diabetes*. 1960;9:100-103.
  5. Armstrong DG, Wrobel J, Robbins JM. Guest editorial: are diabetes-related wounds and amputations worse than cancer? *Int Wound J*. 2007;4:286-287.
  6. Rogers LC, Lavery LA, Armstrong DG. The right to bear legs—an amendment to healthcare; how preventing amputations can save billions to the US healthcare system. *J Am Podiatr Med Assoc*. 2008;98:166-168.
  7. Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. *Diabetes Care*. 1999;22:157-162.
  8. Brand PW, Yancey P. *The Gift of Pain*. Grand Rapids: Zondervan; 1997.
  9. Fernando DJS, Masson EA, Veves A, Boulton AJM. Relationship of limited joint mobility to abnormal foot pressures and diabetic foot ulceration. *Diabetes Care*. 1991;14:8-11.
  10. Grant WP, Foreman EJ, Wilson AS, et al. Evaluation of Young's modulus in Achilles tendons with diabetic neuroarthropathy. *J Am Podiatr Med Assoc*. 2005;95:242-246.
  11. Lavery LA, Armstrong DG, Vela SA, et al. Practical criteria for screening patients at high risk for diabetic foot ulceration. *Arch Intern Med*. 1998;158:158-162.
  12. Murdoch DP, Armstrong DG, Dacus JB, et al. The natural history of great toe amputations. *J Foot Ankle Surg*. 1997;36:204-208.
  13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependant diabetes mellitus. *N Engl J Med*. 1993;329:966-986.
  14. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. *Br J Clin Pharmacol*. 1999;48:643-648.
  15. Dellon AL. Diabetic neuropathy: review of a surgical approach to restore sensation, relieve pain, and prevent ulceration and amputation. *Foot Ankle Int*. 2004;25:749-755.
  16. Chaudhry V, Stevens JC, Kincaid J, So YT. Practice advisory: utility of surgical decompression for treatment of diabetic neuropathy: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2006;66:1805-1808.
  17. Lavery LA, Murdoch DP, Williams J, Lavery DC. Does anodyne light therapy improve peripheral neuropathy in diabetes? A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy. *Diabetes Care*. 2008;31:316-321.
  18. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. *Diabetes Care*. 2006;29:2365-2370.
  19. Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. *Cochrane Database Syst Rev*. 2007;CD004572.
  20. Ashry HR, Lavery LA, Murdoch DP, et al. Effectiveness of diabetic insoles to reduce foot pressures. *J Foot Ankle Surg*. 1997;36:268-271; discussion 328-329.
  21. Bus SA, Ulbrecht JS, Cavanagh PR. Pressure relief and load redistribution by custom-made insoles in diabetic patients with neuropathy and foot deformity. *Clin Biomech (Bristol, Avon)*. 2004;19:629-638.
  22. Uccioli L, Faglia E, Monticone G, et al. Manufactured shoes in the prevention of diabetic foot ulcers. *Diabetes Care*. 1995;18:1376-1378.
  23. Reiber GE, Smith DG, Wallace C, et al. Effect of therapeutic footwear on foot reulceration in patients with diabetes: a

- randomized controlled trial. *JAMA*. 2002;287:2552-2558.
24. Balkin SW, Kaplan L. Injectable silicone and the diabetic foot: a 25 year report. *Foot*. 1991;2:83-88.
  25. Armstrong DG, Holtz-Neiderer K, Wendel C, et al. Skin temperature monitoring reduces the risk for diabetic foot ulceration in high-risk patients. *Am J Med*. 2007;120:1042-1046.
  26. Lavery LA, Higgins KR, Lancot DR, et al. Home monitoring of foot skin temperatures to prevent ulceration. *Diabetes Care*. 2004;27:2642-2647.
  27. Lavery LA, Armstrong DG. Temperature monitoring to assess, predict, and prevent diabetic foot complications. *Curr Diab Rep*. 2007;7:416-419.
  28. Lavery LA, Higgins KR, Lancot DR, et al. Preventing diabetic foot ulcer recurrence in high-risk patients: use of temperature monitoring as a self-assessment tool. *Diabetes Care*. 2007;30:14-20.
  29. Canavan RJ, Unwin NC, Kelly WF, Connolly VM. Diabetes and non-diabetes related lower extremity amputation incidence before and after the introduction of better organized diabetes foot care. Continuous longitudinal monitoring using a standard method. *Diabetes Care*. 2008;31:459-463.
  30. Dargis V, Pantelejeva O, Jonushaite A, et al. Benefits of a multidisciplinary approach in the management of recurrent diabetic foot ulceration in Lithuania: a prospective study. *Diabetes Care*. 1999;22:1428-1431.
  31. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. *Diabetes Care*. 1990;13:513-521.
  32. Armstrong DG, Lavery LA, Sariaya M, Ashry H. Leukocytosis is a poor indicator of acute osteomyelitis of the foot in diabetes mellitus. *J Foot Ankle Surg*. 1996;35:280-283.
  33. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. *Clin Infect Dis*. 2004;39:885-910.
  34. Lavery LA, Armstrong DG, Murdoch DP, et al. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. *Clin Infect Dis*. 2007;44:562-565.
  35. Lavery LA, Armstrong DG, Wunderlich RP, et al. Predictive value of foot pressure assessment as part of a population-based diabetes disease management program. *Diabetes Care*. 2003;26:1069-1073.
  36. Armstrong DG, Nguyen HC, Lavery LA, et al. Off-loading the diabetic foot wound: a randomized clinical trial. *Diabetes Care*. 2001;24:1019-1022.
  37. Armstrong DG, Lavery LA, Wu S, Boulton AJ. Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomized controlled trial. *Diabetes Care*. 2005;28:551-554.
  38. Wu SC, Crews RT, Armstrong DG. The pivotal role of offloading in the management of neuropathic foot ulceration. *Curr Diab Rep*. 2005;5:423-429.
  39. Berner A, Sage R, Niemela J. Keller procedure for the treatment of resistant plantar ulceration of the hallux. *J Foot Ankle Surg*. 2005;44:133-136.
  40. Willrich A, Angrasa AK, Sage RA. Percutaneous tendo Achillis lengthening to promote healing of diabetic plantar foot ulceration. *J Am Podiatr Med Assoc*. 2005;95:281-284.
  41. Mueller MJ, Sinacore DR, Hastings MK, et al. Effect of Achilles tendon lengthening on neuropathic plantar ulcers. A randomized clinical trial. *J Bone Joint Surg*. 2003;85A:1436-1445.
  42. Armstrong DG, Frykberg RG. Classification of diabetic foot surgery: toward a rational definition. *Diabet Med*. 2003;20:329-331.
  43. Armstrong DG, Lavery LA, Frykberg RG, et al. Validation of a diabetic foot surgery classification. *Int Wound J*. 2006;3:240-246.
  44. Armstrong DG, Lavery LA, Stern S, Harkless LB. Is prophylactic diabetic foot surgery dangerous? *J Foot Ankle Surg*. 1996;35:585-589.
  45. Baravarian B, Van Gils CC. Arthrodesis of the Charcot foot and ankle. *Clin Podiatr Med Surg North Am*. 2004;21:271-289.

46. Rosenblum BI, Giurini JM, Chrzan JS, Habershaw GM. Preventing loss of the great toe with the hallux interphalangeal joint arthroplasty. *J Foot Ankle Surg.* 1994;33:557-560.
47. Lavery LA, Armstrong DG, Boulton AJM. Ankle equinus deformity and its relationship to high plantar pressure in a large population with diabetes mellitus. *J Am Podiatr Med Assoc.* 2002;92:479-482.
48. Armstrong DG, Stacpoole-Shea S, Nguyen H, Harkless LB. Lengthening of the Achilles tendon in diabetic patients who are at high risk for ulceration of the foot. *J Bone Joint Surg Am.* 1999;81:535-538.
49. Lin SS, Lee TH, Wapner KL. Plantar forefoot ulceration with equinus deformity of the ankle in diabetic patients: the effect of tendo-achilles lengthening and total contact casting. *Orthopaedics.* 1996;19:465-475.
50. Nielson DL, Armstrong DG. The natural history of Charcot's neuroarthropathy. *Clin Podiatr Med Surg.* 2008;25:53-62, vi.
51. Armstrong DG, Todd WF, Lavery LA, et al. The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. *Diabet Med.* 1997;14:357-363.
52. Catanzariti AR, Mendicino R, Haverstock B. Osteotomy for diabetic neuroarthropathy involving the midfoot. *J Foot Ankle Surg.* 2000;39:291-300.
53. Bevilacqua NJ, Rogers LC. Surgical management of charcot midfoot deformities. *Clin Podiatr Med Surg.* 2008;25:81-94.
54. Armstrong DG, Lavery LA, Nixon BP, Boulton AJ. It's not what you put on, but what you take off: techniques for debriding and off-loading the diabetic foot wound. *Clin Infect Dis.* 2004;39(Suppl 2):S92-S99.
55. Cardinal M, Eisenbud DE, Armstrong DG, et al. Serial surgical debridement: a retrospective study on clinical outcomes in chronic lower extremity wounds. *Wound Repair & Regeneration.* 2009;17:306-311.
56. Attinger CE, Janis JE, Steinberg J, et al. Clinical approach to wounds: debridement and wound bed preparation including the use of dressings and wound-healing adjuvants. *Plast Reconstr Surg.* 2006;117(7Suppl):72S-109S.
57. Armstrong DG, Mossel J, Nixon BP, et al. Maggot debridement therapy: a primer. *J Am Podiatr Med Assoc.* 2002;92:398-401.
58. Armstrong DG, Salas P, Short B, et al. Maggot therapy in "lower-extremity hospice" wound care: fewer amputations and more antibiotic-free days. *J Am Podiatr Med Assoc.* 2005;95:254-257.
59. Courtenay M. The use of larval therapy in wound management in the UK. *J Wound Care.* 1999;8:177-179.
60. Hinman CD, Maibach H. Effect of air exposure and occlusion on experimental human skin wounds. *Nature.* 1963;200:377-378.
61. Eginton MT, Brown KR, Seabrook GR, et al. A prospective randomized evaluation of negative-pressure wound dressings for diabetic foot wounds. *Ann Vasc Surg.* 2003;17:645-649.
62. Armstrong DG, Lavery LA. Negative pressure wound after partial diabetic foot amputation: a multicentre, randomised controlled trial. *Lancet.* 2005;366:1704-1710.
63. Frykberg RG, Williams DV. Negative-pressure wound therapy and diabetic foot amputations: a retrospective study of payer claims data. *J Am Podiatr Med Assoc.* 2007;97:351-359.
64. Robson MC, Mustoe TA, Hunt TK. The future of recombinant growth factors in wound healing. *Am J Surg.* 1998;176(2A Suppl):80S-82S.
65. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. *Diabetes Care.* 1998;21:822-827.
66. Steed DL, Donohoe D, Webster MW, Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic ulcer study group. *J Am Coll Surg.* 1996;183:61-64.
67. Badiavas EV, Abedi M, Butmarc J, et al. Participation of bone marrow derived cells in cutaneous wound healing. *J Cell Physiol.* 2003;196:245-250.
68. Rogers LC. Marrow-derived stem cells to augment chronic wound healing. Paper presented at: American Podiatric Medical Association Oral Abstracts 2007; Philadelphia, PA.

69. Badiavas EV, Falanga V. Treatment of chronic wounds with bone marrow-derived cells. *Arch Dermatol*. 2003;139:510-516.
70. Falanga V, Iwamoto S, Chartier M, et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. *Tissue Eng*. 2007;13:1299-1312.
71. Vojtassak J, Danisovic L, Kubes M, et al. Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot. *Neuro Endocrinol Lett*. 2006;27(Suppl 2):134-137.
72. Roukis TS, Zgonis T. Skin grafting techniques for soft-tissue coverage of diabetic foot and ankle wounds. *J Wound Care*. 2005;14:173-176.
73. Puttirutvong P. Meshed skin graft versus split thickness skin graft in diabetic ulcer coverage. *J Med Assoc Thai*. 2004;87:66-72.
74. Korber A, Franckson T, Grabbe S, Dissemond J. Vacuum assisted closure device improves the take of mesh grafts in chronic leg ulcer patients. *Dermatology*. 2008;216:250-256.
75. Banis JC. Glabrous skin grafts for plantar defects. *Foot Ankle Clin*. 2001;6:827-837, viii.
76. Kalbermatten DF, Kalbermatten NT, Haug M, et al. Use of a combined pedicled toe fillet flap. *Scand J Plast Reconstr Surg Hand Surg*. 2004;38:301-305.
77. Ozkan O, Coskunfirat OK, Ozgentas HE. Reliability of free-flap coverage in diabetic foot ulcers. *Microsurgery*. 2005;25:107-112.
78. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Apligraf diabetic foot ulcer study. *Diabetes Care*. 2001;24:290-295.
79. Gentzkow GD, Iwasaki SD, Hershon KS. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. *Diabetes Care*. 1996;19:350-354.
80. Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. *Diabetes Care*. 2003;26:1701-1705.
81. Brigido SA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. *Int Wound J*. 2006;3:181-187.
82. Mahmoud SM, Mohamed AA, Mahdi SE, Ahmed ME. Split-skin graft in the management of diabetic foot ulcers. *J Wound Care*. 2008;17:303-306.

## 第 114 章

1. Nowygrod R, Egorova N, Greco G, et al. Trends, complications, and mortality in peripheral vascular surgery. *J Vasc Surg*. 2006;43:205.
2. DeFrang RD, Taylor LM, Porter JM. Basic data related to amputations. *Ann Vasc Surg*. 1991;5:202.
3. Feinglass J, Brown JL, LoSasso A, et al. Rates of lower-extremity amputation and arterial reconstruction in the United States, 1979 to 1996. *Am J Public Health*. 1999;89:1222.
4. Group TG. Epidemiology of lower extremity amputation in centres in Europe, North America and East Asia. The Global Lower Extremity Amputation Study Group. *Br J Surg*. 2000;87:328.
5. Connelly J, Airey M, Chell S. Variation in clinical decision making is a partial explanation for geographical variation in lower extremity amputation rates. *Br J Surg*. 2001;88:529.
6. Kazmers A, Perkins AJ, Jacobs LA. Major lower extremity amputation in Veterans Affairs medical centers. *Ann Vasc Surg*. 2000;14:216.
7. Kantonen I, Lepantalo M, Luther M, et al. Factors affecting the results of surgery for chronic critical leg ischemia—a nationwide survey. Finnvasc Study Group. *J Vasc Surg*. 1998;27:940.
8. Ho V, Wirthlin D, Yun H, et al. Physician supply, treatment, and amputation rates for peripheral arterial disease. *J Vasc Surg*. 2005;42:81.



9. Bruckner M, Mangan M, Godin S, Pogach L. Project LEAP of New Jersey: lower extremity amputation prevention in persons with type 2 diabetes. *Am J Manag Care*. 1999;5:609.
10. Huber TS, Wang JG, Wheeler KG, et al. Impact of race on the treatment for peripheral arterial occlusive disease. *J Vasc Surg*. 1999;30:417.
11. Resnick HE, Valsania P, Phillips CL. Diabetes mellitus and nontraumatic lower extremity amputation in black and white Americans: the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, 1971-1992. *Arch Intern Med*. 1999;159:2470.
12. Tunis SR, Bass EB, Klag MJ, Steinberg EP. Variation in utilization of procedures for treatment of peripheral arterial disease. A look at patient characteristics. *Arch Intern Med*. 1993;153:991.
13. Eslami MH, Zayaruzny M, Fitzgerald GA. The adverse effects of race, insurance status, and low income on the rate of amputation in patients presenting with lower extremity ischemia. *J Vasc Surg*. 2007;45:55.
14. Feinglass J, Rucker-Whitaker C, Lindquist L, et al. Racial differences in primary and repeat lower extremity amputation: results from a multihospital study. *J Vasc Surg*. 2005;41:823.
15. Hallett JW Jr, Byrne J, Gayari MM, et al. Impact of arterial surgery and balloon angioplasty on amputation: a population-based study of 1155 procedures between 1973 and 1992. *J Vasc Surg*. 1997;25:29.
16. Eskelinen E, Luther M, Eskelinen A, Lepantalo M. Infrapopliteal bypass reduces amputation incidence in elderly patients: a population-based study. *Eur J Vasc Endovasc Surg*. 2003;26:65.
17. Taylor SM, Kalbaugh CA, Blackhurst DW, et al. A comparison of percutaneous transluminal angioplasty versus amputation for critical limb ischemia in patients unsuitable for open surgery. *J Vasc Surg*. 2007;45:304.
18. Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. *Lancet*. 2005;366:1925.
19. Norgren L, Hiatt WR, Dormandy JA, et al. TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). *J Vasc Surg*. 2007;45S:S5.
20. Malone JM. Lower extremity amputations. In: Moore WS, ed. *Vascular Surgery: A Comprehensive Review*. Philadelphia: WB Saunders; 2002:875.
21. Abou-Zamzam Jr AM, Teruya TH, Killeen JD, Ballard JL. Major lower extremity amputation in an academic vascular center. *Ann Vasc Surg*. 2003;17:86.
22. Nehler MR, Coll JR, Hiatt WR, et al. Functional outcome in a contemporary series of major lower extremity amputations. *J Vasc Surg*. 2003;38:7.
23. Amirhamzeh MMR. The decision to amputate. *Surgery Rounds* Feb 2003;86.
24. Bailey CM, Saha S, Magee TR, Galland RB. A 1 year prospective study of management and outcome of patients presenting with critical lower limb ischaemia. *Eur J Vasc Endovasc Surg*. 2003;25:131.
25. Abou-Zamzam AM, Gomez NR, Molkara A, et al. A prospective analysis of critical limb ischemia: factors leading to major primary amputation versus revascularization. *Ann Vasc Surg*. 2007;21:458.
26. Taylor SM, Kalbaugh CA, Blackhurst DW, et al. Preoperative clinical factors predict postoperative functional outcomes after major lower limb amputation: an analysis of 553 consecutive patients. *J Vasc Surg*. 2005;42:227.
27. Nehler MR, Hiatt WR, Taylor LM Jr. Is revascularization and limb salvage always the best treatment for critical limb ischemia? *J Vasc Surg*. 2003;37:704.
28. Edwards JM, Taylor LM Jr, Porter JM. Limb salvage in end-stage renal disease (ESRD). Comparison of modern results in patients with and without ESRD. *Arch Surg*. 1998;123:1164.
29. Leers SA, Reifsnnyder T, Delmonte R, Caron M. Realistic expectations for pedal bypass grafts in patients with end-stage renal disease. *J Vasc Surg*. 1998;28:976.
30. Krupski WC, Nehler MR, Whitehill TA, et al. Negative impact of cardiac evaluation before vascular surgery. *Vasc Med*. 2000;5:3.

31. Taylor LM, Yeager RA, Moneta GL, et al. The incidence of perioperative myocardial infarction in general vascular surgery. *J Vasc Surg.* 1991;15:52.
32. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *Circulation.* 2007;116:1971.
33. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group [published erratum appears in *N Engl J Med* 1997;336(14):1039]. *N Engl J Med.* 1996;335:1713.
34. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. *N Engl J Med.* 1999;341:1789.
35. Yeager RA, Moneta GL, Edwards JM, et al. Deep vein thrombosis associated with lower extremity amputation. *J Vasc Surg.* 1995;22:612.
36. Bani-Hani M, Titi M, Al-Khaffaf H. Deep venous thrombosis after arterial surgery: a literature review. *Eur J Vasc Endovasc Surg.* 2008;36:565.
37. Fisher DF Jr, Clagett GP, Fry RE, et al. One-stage versus two-stage amputation for wet gangrene of the lower extremity: a randomized study. *J Vasc Surg.* 1988;8:428.
38. Hunsaker RH, Schwartz JA, Keagy BA, et al. Dry ice cryoamputation: a twelve-year experience. *J Vasc Surg.* 1985;2:812.
39. Winburn GB, Wood MC, Hawkins ML, et al. Current role of cryoamputation. *Am J Surg.* 1991;162:647.
40. Barone JE, Tucker JB, Rassias D, Corvo PR. Routine perioperative pulmonary artery catheterization has no effect on rate of complications in vascular surgery: a meta-analysis. *Am Surg.* 2001;67:674.
41. de Virgilio C, Toosie K, Elbassir M, et al. Dipyridamole-thallium/sestamibi before vascular surgery: a prospective blinded study in moderate-risk patients. *J Vasc Surg.* 2000;32:77.
42. de Virgilio C, Wall DB, Ephraim L, et al. An abnormal dipyridamole thallium/sestamibi fails to predict long-term cardiac events in vascular surgery patients. *Ann Vasc Surg.* 2001;15:267.
43. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. *N Engl J Med.* 2004;351:2795.
44. Malone JM, Moore W, Leal JM, Childers SJ. Rehabilitation for lower extremity amputation. *Arch Surg.* 1981;116:93.
45. McWhinnie DL, Gordon AC, Collin J, et al. Rehabilitation outcome 5 years after 100 lower-limb amputations. *Br J Surg.* 1994;81:1596.
46. Toursarkissian B, Shireman PK, Harrison A, et al. Major lower-extremity amputation: contemporary experience in a single Veterans Affairs institution. *Am Surg.* 2002;68:606.
47. Keagy BA, Schwartz JA, Kotb M, et al. Lower extremity amputation: the control series. *J Vasc Surg.* 1986;4:321.
48. Ballard JL, Eke CC, Bunt TJ, Killeen JD. A prospective evaluation of transcutaneous oxygen measurements in the management of diabetic foot problems. *J Vasc Surg.* 1995;22:485.
49. Dwars BJ, van den Broek TA, Rauwerda JA, Bakker FC. Criteria for reliable selection of the lowest level of amputation in peripheral vascular disease. *J Vasc Surg.* 1992;15:536.
50. Wagner WH, Keagy BA, Kotb MM, et al. Noninvasive determination of healing of major lower extremity amputation: the continued role of clinical judgment. *J Vasc Surg.* 1988;8:703.
51. Spence VA, Walker WF, Troup IM, Murdoch G. Amputation of the ischemic limb: selection of the optimum site by thermography. *Angiology.* 1981;32:155.

52. Marston WA, Davies SW, Armstrong B, et al. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. *J Vasc Surg.* 2006;44:108.
53. Vitti MJ, Robinson DV, Hauer-Jensen M, et al. Wound healing in forefoot amputations: the predictive value of toe pressure. *Ann Vasc Surg.* 1994;8:99.
54. Malone JM, Anderson GG, Lalka SG, et al. Prospective comparison of noninvasive techniques for amputation level selection. *Am J Surg.* 1987;154:179.
55. Malone JM, Leal JM, Moore WS, et al. The “gold standard” for amputation level selection xenon-133 clearance. *J Surg Res.* 1981;30:449.
56. Sarikaya A, Top H, Aygit AC, et al. Predictive value of (99m)Tc-sestamibi scintigraphy for healing of extremity amputation. *Eur J Nucl Med Mol Imaging.* 2006;33:1500.
57. Ballard JL, Bianchi C. Transcutaneous oxygen tension: principles and application. In: Abu-Rhama AF, Bergan JJ, eds. *Noninvasive Vascular Diagnosis.* New York: Springer; 2000:403.
58. Scheffler A, Rieger H. A comparative analysis of transcutaneous oximetry (tcPO<sub>2</sub>) during oxygen inhalation and leg dependency in severe peripheral arterial occlusive disease. *J Vasc Surg.* 1992;16:218.
59. Jorreskog G, Djavani K, Brismar K. Day-to-day variability of transcutaneous oxygen tension in patients with diabetes mellitus and peripheral arterial occlusive disease. *J Vasc Surg.* 2001;34:277.
60. Bunt TJ, Holloway GA. TcPO<sub>2</sub> as an accurate predictor of therapy in limb salvage. *Ann Vasc Surg.* 1996;10:224.
61. Bacharach JM, Rooke TW, Osmundson PJ, Gloviczki P. Predictive value of transcutaneous oxygen pressure and amputation success by use of supine and elevation measurements. *J Vasc Surg.* 1992;15:558.
62. Gibbons GW. Lower extremity bypass in patients with diabetic foot ulcers. *Surg Clin North Am.* 2003;83:659.
63. Yamada T, Ohta T, Ishibashi H, et al. Clinical reliability and utility of skin perfusion pressure measurement in ischemic limbs—comparison with other noninvasive diagnostic methods. *J Vasc Surg.* 2008;47:318.
64. Ziegler-Graham K, MacKenzie EJ, Ephraim PL, et al. Estimating the prevalence of limb loss in the United States: 2005 to 2050. *Arch Phys Med Rehabil.* 2008;89:422.
65. Tang PCY, Ravji K, Key JJ, et al. Let them walk! Current prosthesis options for leg and foot amputees. *J Am Coll Surg.* 2008;206:548.
66. Walsh TL. Custom removable immediate postoperative prosthesis. *J Prosthet Orthot.* 2003;15:158.
67. Moore WS. Below-knee amputation. In: Moore WS, Malone JM, eds. *Lower Extremity Amputation.* Philadelphia: WB Saunders Company; 1989:118.
68. Falsom D, King T, Rubin JR. Lower-extremity amputation with immediate postoperative prosthetic placement. *Am J Surg.* 1992;164:320.
69. Schon LC, Short KW, Soupiou O, et al. Benefits of early prosthetic management of transtibial amputees: A prospective clinical study of a prefabricated prosthesis. *Foot Ankle Int.* 2002;23:509.
70. Taylor L, Cavenett S, Stephien JM, Crotty M. Removable rigid dressings: a retrospective case-note audit to determine the validity of post-amputation application. *Prosthet Orthot Int.* 2008;32:223.
71. Michael JW. Modern prosthetic knee mechanisms. *Clin Orthop Relat Res.* 1999;361:39.
72. Francis W, Renton CJ. Mobility after major limb amputation for arterial occlusive disease. *Prosthet Orthot Int.* 1987;11:85.
73. Robinson K. Amputation in vascular disease. *Ann Royal Coll Surg Engl.* 1980;62:87.
74. Pinzur MS, Gold J, Schwartz D, et al. Energy demands for walking in dysvascular amputees as related to level of amputation. *Orthopedics.* 1992;15:1033.
75. Gosselin S, Desrosiers J, Corriveau H, et al. Outcomes during and after inpatient rehabilitation: comparison between adults and older adults. *J Rehabil Med.* 2008;40:55.
76. Stasik CN, Berceli SA, Nelson PR, et al. Functional outcome after redo below-knee amputation. *World J Surg* Mar 2008;1 [Epub ahead of print].

77. Stewart CP, Jain AS, Ogston SA: Lower-limb amputee survival. *Prosthet Orthot Int.* 1992;16:11.
78. Dormandy J, Heeck L, Vig S. Major amputations: clinical patterns and predictors. *Semin Vasc Surg.* 1999;12:154.
79. Frank RG, Kashani JH, Kashani SR, et al. Psychological response to amputation as a function of age and time since amputation. *Br J Psychiatry.* 1984;144:493.
80. Parkes CM. Psycho-social transitions: comparison between reactions to loss of a limb and loss of a spouse. *Br J Psychiatry.* 1975;127:204.
81. Schubert DS, Burns R, Paras W, Sioson E. Decrease of depression during stroke and amputation rehabilitation. *Gen Hosp Psychiatry.* 1992;14:135.
82. Donovan-Hall MK, Yardley L, Watts RJ. Engagement in activities revealing the body and psychosocial adjustment in adults with a trans-tibial prosthesis. *Prosthet Orthot Int.* 2002;26:15.
83. Gallagher P, MacLachlan M. Psychological adjustment and coping in adults with prosthetic limbs. *Behav Med.* 1999;25:117.
84. Rybarczyk BD, Nyenhuis DL, Nicholas JJ, et al. Social discomfort and depression in a sample of adults with leg amputations. *Arch Phys Med Rehabil.* 1992;73:1169.

## 第 115 章

1. Sachs M, Bojunga J, Encke A. Historical evolution of limb amputation. *World J Surg.* 1999;23:1088-1093.
2. Choksy S, Chong P, Smith C, et al. A randomised controlled trial of the use of a tourniquet to reduce blood loss during transtibial amputation for peripheral arterial disease. *Eur J Vasc Endovasc Surg.* 2006;31:646-650.
3. Jaegers S, Arendzen J, DeJongh H. Changes in hip muscles after above knee amputation. *Clin Orthop Relat Res.* 1995;319:276-285.
4. Lastória S, Rollo HA, Yoshida WB, et al. Prophylaxis of deep-vein thrombosis after lower extremity amputation: comparison of low molecular weight heparin with unfractionated heparin. *Acta Cirurgica Brasileira.* 2006;21:184-186.
5. Sadat U, Chaudhuri A, Hayes PD, et al. Five day antibiotic prophylaxis for major lower limb amputation reduces wound infection rates and the length of in-hospital stay. *Eur J Vasc Endovasc Surg.* 2008;35:75-78.
6. McIntyre KE Jr, Bailey SA, Malone JM, Goldstone J. Guillotine amputation in the treatment of nonsalvageable lower-extremity infections. *Arch Surg.* 1984;119:450-453.
7. Fisher DF Jr, Clagett GP, Fry RE. One-stage versus two-stage amputation for wet gangrene of the lower extremity: a randomized study. *J Vasc Surg.* 1988;8:428-433.
8. Desai Y, Robbs JV, Keenan JP. Staged below-knee amputations for septic peripheral lesions due to ischaemia. *Br J Surg.* 1986;73:392-394.
9. Payne JE, Breust M, Bradbury R. Reduction in amputation stump infection by antiseptic preoperative preparation. *Aust N Z J Surg.* 1989;59:637-640.
10. Scher KS, Steele FJ. The septic foot in patients with diabetes. *Surgery.* 1988;104:661-666.
11. Murdoch D, Armstrong D, Dacus J, et al. The natural history of great toe amputations. *J Foot Ankle Surg.* 1997;36:204-208.
12. Bowker J. Amputations and disarticulations. In: MS M. *Foot and Ankle Disorders.* Philadelphia: WB Saunders; 2000:466-503.
13. Dalla Paola L, Faglia E, Caminiti M, et al. Ulcer recurrence following first ray amputation in diabetic patients: a cohort prospective study. *Diabetes Care.* 2003;26:1874-1878.
14. Funk C, Young G. Subtotal pedal amputations. *J Am Podiatr Med Assoc.* 2001;91:6-12.
15. Izumi Y, Satterfield K, Lee S, Harkless LB. Risk of reamputation in diabetic patients stratified by limb and level of amputation: a 10-year observation. *Diabetes Care.* 2006;29:566-570.
16. Dillingham TR, Pezzin LE, Shore AD. Reamputation, mortality, and health care costs among persons with dysvascular lower-limb amputations. *Arch Phys Med Rehabil.* 2005;86:480-486.
17. Early JS. Transmetatarsal and midfoot amputations. *Clin Orthop Rel Res.* 1999;361:85-90.

18. Blume P, Salonga C, Garbalosa J, et al. Predictors for the healing of transmetatarsal amputations: retrospective study of 91 amputations. *Vascular*. 2007;15:126-133.
19. Pollard J, Hamilton GA, Rush SM, Ford LA. Mortality and morbidity after transmetatarsal amputation: retrospective review of 101 cases. *J Foot Ankle Surg*. 2006;45:91-97.
20. Mwipatayi BP, Naidoo NG, Jeffery PC, et al. Transmetatarsal amputation: three-year experience at Groote Schuur Hospital. *World J Surg*. 2005;29:245-248.
21. Thomas SRYW, Perkins JMT, Magee TR, Galland RB. Transmetatarsal amputation: an 8-year experience. *Ann R Coll Surg Engl*. 2001;83:164-166.
22. Armstrong DG, Lavery LA. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. *Lancet*. 2005;366:1704-1710.
23. Pinzur MS, Kaminsky M, Sage R. Amputations at the middle level of the foot. *J Bone Joint Surg Am*. 1986;68:1061-1064.
24. Schweihberger M, Roukis T. Soft-tissue and osseous techniques to balance forefoot and midfoot amputations. *Clin Podiatr Med Surg*. 2008;25:623-639.
25. Sanders L. Transmetatarsal and midfoot amputations. *Clin Podiatr Med Surg*. 1997;14:741-762.
26. Stone PA, Back MR, Armstonrg PA, et al. Midfoot amputations expand limb salvage rates for diabetic foot infections. *Ann Vasc Surg*. 2005;19: 805-811.
27. Chang B, Bock D, Jacobs R, et al. Increased limb salvage by the use of unconventional foot amputations. *J Vasc Surg*. 1994;19:341-348.
28. Armstrong D, Stacpoole-Shea S, Nguyen H, Harkless L. Lengthening of Achilles tendon in diabetic patients who are at high risk for ulceration of the foot. *J Bone Joint Surg*. 1999;81:535-538.
29. Blanc CH, Borens O. Amputations of the lower limb—an overview on technical aspects. *Acta Chir Belg*. 2004;104:388-392.
30. Hatt R, Lamphier T. Triple hemisection: a simplified procedure for lengthening the Achilles tendon *N Engl J Med*. 1947;236:166-169.
31. Hulnick A, Highsmith C, Boutin FJ. Amputations for failure in reconstructive surgery. *J Bone Joint Surg Am*. 1949;31:639-649.
32. Richardson D. Amputations of the foot. In: Canale S, Beaty J, eds. *Campbell's Operative Orthopedics*. Philadelphia: Elsevier; 2008:595-596.
33. Humzah M, Gilbert P. Fasciocutaneous blood supply in below-knee amputation. *J Bone Joint Surg*. 1997;79:441-443.
34. Burgess EM, Romano RL, Zettl JH, Schrock RDJ. Amputations of the leg for peripheral vascular insufficiency. *J Bone Joint Surg Am*. 1971;53:874-890.
35. Allcock PA, Jain AS. Revisiting transtibial amputation with the long posterior flap. *Br J Surg*. 2001;88:683-686.
36. Smith DG, Ferguson JR. Transtibial amputations. *Clin Orthop Rel Res*. 1999;361:108-115.
37. Assal M, Blanck R, Smith D. Extended posterior flap for transtibial amputation. *Orthopedics* 2005;28:542-546.
38. Persson BM. Sagittal incision for below-knee amputation in ischaemic gangrene. *J Bone Joint Surg Br*. 1974;56:110.
39. Termansen N. Below knee amputation for ischaemic gangrene: prospective, randomized comparison of a transverse and a sagittal operative technique. *Acta Orthop Scand*. 1977;48:311-316.
40. Robinson KP. Amputations in vascular patients. In: Bell PRF, ed. *Surgical Management of Vascular Disease*. London: W. B. Saunders; 1992:609-635.
41. Jain AS, Steward CPU, Turner MS. Transtibial amputation using a medially-based flap. *J R Coll Surg Edinb*. 1995;40:263-265.
42. Tisi PV, Callam MJ. Type of incision for below knee amputation (Review). *Cochrane Database Syst Rev*. 2004;1-23.
43. Brinker MR, Timberlake GA, Goff JM. Below-knee physiologic cryoanesthesia in the critically ill patient. *J Vasc Surg*. 1988;7:433-438.
44. Bunt TJ. Physiologic amputation: preliminary cryoamputation of the gangrenous extremity. *AORN J*. 1991;54:1220-1224.

45. Hunsaker RH, Schwartz JA, Keagy BA. Dry ice cryoamputation: a twelve-year experience. *J Vasc Surg.* 1985;2:812-816.
46. Winburn GB, Wood MC, Hawkins ML. Current role of cryoamputation. *Am J Surg.* 1991;1991.
47. Nehler MR, Coll JR, Hiatt WR, et al. Functional outcome in a contemporary series of major lower extremity amputations. *J Vasc Surg.* 2003;38:7-14.
48. Cull DL, Taylor SM, Hamontree SE, et al. A reappraisal of a modified through-knee amputation in patients with peripheral vascular disease. *Am J Surg.* 2001;182:44-48.
49. Mazet RJ, Hennessy CA. Knee disarticulation: a new technique and a new knee-joint mechanism. *J Bone Joint Surg Am.* 1966;48:126-139.
50. Faber DC, Fielding P. Gritti-Stokes (through-knee) amputation: should it be reintroduced? *South Med J.* 2001;94:997-1001.
51. Huston CC, Bivins BA, Ernst CB, Griffen WO Jr. Morbid implications of above-knee amputations: report of a series and review of the literature. *Arch Surg.* 1980;115:165-167.
52. Sugarbaker PH, Chretien PB. A surgical technique for hip disarticulation. *Surgery.* 1981;90:546.
53. Tang PCY, Ravji K, Key JJ, et al. Let them walk! Current prosthesis options for leg and foot amputees. *J Am Coll Surg.* 2008;206:548-560.
54. Nawijn SE, van der Linde H, Emmelot CH, Hofstad CJ. Stump management after trans-tibial amputation: a systematic review. *Prosthet Orthot Int.* 2005;29:13-26.
55. Berlemont M, Weber R, Willot JP. Ten years of experience with the immediate application of prosthetic devices to amputees of the lower extremities on the operating table. *Prosthet Int.* 1969;3:8-18.
56. Burgess EM, Romano RL, Zetl CP. Amputation management utilising immediate postsurgical prosthetic fitting. *Prosthet Int.* 1969;3:28-37.
57. Bunt TJ. Gangrene of the immediate postoperative above-knee amputation stump: role of emergency revascularization in preventing death. *J Vasc Surg.* 1985;2:874-877.
58. Kane TJ, Pollack EW. The rigid versus soft postoperative dressing controversy: a controlled study in vascular below-knee amputees. *Am Surg.* 1980;46:244-247.
59. Otterman MG, Stahlgren LH. Evaluation of factors which influence mortality and morbidity following major lower extremity amputations for atherosclerosis. *Surg Gynecol Obstet.* 1965;120:1217.
60. Eidemiller LR, Awe W, Peterson CG. Amputation of the ischemic extremity. *Am Surg.* 1968;34:491.
61. Rosenberg N, Adiarte E, Bujdoso LJ, Backwinkel KD. Mortality factors in major limb amputations for vascular disease: a study of 176 procedures. *Surgery.* 1970;67:437-441.
62. Nowygrod R, Egorova N, Greco G, et al. Trends, complications, and mortality in peripheral vascular surgery. *J Vasc Surg.* 2006;43:205-216.
63. Abou-Zamzam AM, Teruya TH, Killeen JD, Ballard JL. Major lower extremity amputation in an academic vascular center. *Ann Vasc Surg.* 2003;17:86-90.
64. Ploeg AJ, Lardenoye JW, Vrancken Peeters MPFM, Breslau PJ. Contemporary series of morbidity and mortality after lower limb amputation. *Eur J Vasc Endovasc Surg.* 2005;29:633-637.
65. Dillingham T, Pezzin L, MacKenzie E. Limb amputation and limb deficiency: epidemiology and recent trends in the United States. *South Med J.* 2002;95:875-883.
66. Heikkinen M, Saarinen J, Suominen VP, et al. Lower limb amputations: differences between the genders and long-term survival. *Prosthet Orthot Int.* 2007;31:277-286.
67. Aulivola B, Hile CN, Hamdan AD, et al. Major lower extremity amputation: outcome of a modern series. *Arch Surg.* 2004;139:395-399.
68. Sandnes DK, Sobel M, Flum DR. Survival after lower-extremity amputation. *J Am Coll Surg.* 2004;199:394-402.
69. Ebskov B. Relative mortality and long term survival for the non-diabetic lower limb amputee with vascular insufficiency. *Prosthet Orthot Int.* 1999;23:209-216.

70. Feinglass J, Pearce WH, Martin GJ. Postoperative and late survival outcomes after major amputation: findings from the Department of Veterans Affairs National Surgical Quality Improvement Program. *Surgery*. 2001;130:21-29.
71. Feinglass J, Rucker-Whitaker C, Lindquist L, et al. Racial differences in primary and repeat lower extremity amputation: results from a multihospital study. *J Vasc Surg*. 2005;41:823-829.
72. Lavery LA, van Houtum WH, Armstrong DG, et al. Mortality following lower extremity amputation in minorities with diabetes mellitus. *Diabetes Res Clin Pract*. 1997;37:41-47.
73. Schofield C, Libby G, Brennan G, et al. Mortality and hospitalization in patients after amputation. *Diabetes Care*. 2006;29:2252-2256.
74. Mayfield JA, Reiber GE, Maynard C, et al. Survival following lower-limb amputation in a veteran population. *J Rehabil Res Dev*. 2001;38:341-345.
75. Pohjolainen T, Alaranta H. Ten-year survivals of Finnish lower limb amputees. *Prosthet Orthot Int*. 1998;22:10-16.
76. Ziegler-Graham K, MacKenzie EJ, Ephraim PL, et al. Estimating the prevalence of limb loss in the United States: 2005 to 2050. *Arch Phys Med Rehabil*. 2008;89:422-429.
77. Bo Ebskov L. Dysvascular amputations and long-term survival in a 20-year follow-up study. *Int J Rehabil Res*. 2006;29:325-328.
78. Toursarkissian B, Shireman PK, Harrison A. Major lower-extremity amputation: contemporary experience in a single Veterans Affairs institution. *Am Surg*. 2002;68:606-610.
79. Schoppen T, Boonstra A, Groothoff JW, et al. Physical, mental, and social predictors of functional outcome in unilateral lower-limb amputees. *Arch Phys Med Rehabil*. 2003;84:803-811.
80. Taylor SM, Kalbaugh CA, Blackhurst DW, et al. Preoperative clinical factors predict postoperative functional outcomes after major lower limb amputation: an analysis of 553 consecutive patients. *J Vasc Surg*. 2005;42:227-234.
81. Cruz CP, Eidt JF, Capps C, et al. Major lower extremity amputations at a Veterans Affairs hospital. *Am J Surg*. 2003;186:449-454.
82. Davies B, Datta, D. Mobility outcome following unilateral lower limb amputation. *Prosthet Orthot Int*. 2003;27:186-190.
83. Stone P, Flaherty S, Hayes J, AbuRahma A. Lower extremity amputation: a contemporary series. *W V Med J*. 2007;103:14-18.
84. Berridge DC, Slack RCB, Hopkinson BR, Makin GS. A bacteriological survey of amputation wound sepsis. *J Hosp Infect*. 1989;13:167-172.
85. Rubin JR, Marmen C, Rhodes, RS. Management of failed prosthetic grafts at the time of major lower extremity amputation. *J Vasc Surg*. 1988;7:673-676.
86. Wasiak K, Paczkowski P, Garlicki J. Surgical results of leg amputation according to Ghormley's technique in the treatment of chronic lower limb ischaemia. *Acta Chir Belg*. 2006;106:52-54.
87. Huang ME, Johns JS, White J, Sanford K. Venous thromboembolism in a rehabilitation setting after major lower-extremity amputation. *Arch Phys Med Rehabil*. 2005;86:73-78.
88. Burke B, Kumar R, Vickers V, et al. Deep vein thrombosis after lower limb amputation. *Am J Phys Med Rehabil*. 2000;79:145-149.
89. Yeager RA, Moneta GL, Edwards JM, et al. Deep vein thrombosis associated with lower extremity amputation. *J Vasc Surg*. 1995;22:612-615.
90. Defrang RD, Taylor LMJ, Porter JM. Amputation. *Curr Probl Surg*. 1991;28:140.
91. Bhuvaneswar CG, Epstein LA, Stern TA. Reactions to amputation: recognition and treatment. *Prim Care Companion J Clin Psychiatry*. 2007;9:303-308.
92. Kashani JH, Frank RG, Kashani SR. Depression among amputees. *J Clin Psychiatry*. 1983;44:256-258.
93. Ephraim PL, Wegener ST, MacKenzie EJ, et al. Phantom pain, residual limb pain, and back pain in amputees: results of a national survey. *Arch Phys Med Rehabil*. 2005;86:1910-1919.

94. Katz J. Phantom limb pain. *Lancet*. 1997;350:1338-1339.
95. Sherman RA, Sherman CJ, Parker L. Chronic phantom and stump pain among American veterans: results of a survey. *Pain*. 1984;18:83-95.
96. Hanley MA, Jensen MP, Smith DG, et al. Preamputation pain and acute pain predict chronic pain after lower extremity amputation. *J Pain*. 2007;8:102-109.
97. Gehling M, Tryba M. Prophylaxe von Phantomschmerzen: Sind regionale Analgesieverfahren unwirksam? *Der Schmerz*. 2003;17:11-19.
98. Robinson LR, Czerniecki JM, Ehde DM, et al. Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study. *Arch Phys Med Rehabil*. 2004;85:1-6.

## 第 116 章

1. Casey RG, Richards S, O'Donohoe M. Vascular surgery of the upper limb: the first year of a new vascular service. *Ir Med J*. 2002;95:104-105.
2. Bartelink ML, Wollersheim H, van de Lisdonk E, et al. Prevalence of Raynaud's phenomenon. *Neth J Med*. 1992;41:149-152.
3. Edwards JM, Porter JM. Associated diseases with Raynaud's syndrome. *Vasc Med Rev*. 1990;1:51-58.
4. Johnson SR, Feldman BM, Hawker GA. Classification criteria for systemic sclerosis subsets. *J Rheumatol*. 2007;34:1855-1863.
5. Raynaud M. On local asphyxia and symmetrical gangrene of the extremities. In: *Selected Monographs*. London: New Sydenham Society; 1888.
6. McLafferty RB, Edwards JM, Taylor LM Jr, Porter JM. Diagnosis and long-term clinical outcome in patients presenting with hand ischemia. *J Vasc Surg*. 1995;22:361-393.
7. Mills JL, Porter JM. Buerger's disease (thromboangiitis obliterans). *Ann Vasc Surg*. 1992;5:570-572.
8. Puechal X, Fiessinger JN. Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist. *Rheumatology*. 2007;46:192-199.
9. Schneider HJ, Jha S, Burnand KG. Progressive arteritis associated with cannabis use. *Eur J Vasc Endovasc Surg*. 1999;18:366-367.
10. Loriga G. Pneumatic tools: occupation and health. *Boll Inspett Labor*. 1911;2:35.
11. Hamilton A. A study of spastic anemia in the hands of stonecutters. Effect of the air hammer on the hands of the stonecutters. *U S Bureau Labor Stat Bull*. 1918;236:53-66.
12. McLafferty RB, Edwards JM, Ferris BL, et al. Raynaud's syndrome in workers who use vibrating pneumatic air knives. *J Vasc Surg*. 1999;30:1-7.
13. Schatz IJ. Occlusive disease on the hand due to occupational trauma. *N Engl J Med*. 1963;268:281-284.
14. Cherniack M, Brammer AJ, Lundstrom R, et al. The Hand-Arm Vibration International Consortium (HAVIC): prospective studies on the relationship between power tool exposure and health effects. *J Occup Environ Med*. 2007;49:289-301.
15. Yeager RA, Edwards JM, Moneta GL, et al. Relationship of hemodialysis access to finger gangrene in end stage renal disease patients. *J Vasc Surg*. 2002;36:245-249.
16. Edwards JM, Antonius JJ, Porter JM. Critical hand ischemia caused by forearm fibromuscular dysplasia. *J Vasc Surg*. 1985;2:459-463.
17. Friedman SA, Bienenstock H, Richter IH. Malignancy and arteriopathy. *Angiology*. 1969;20:136-143.
18. Vayssairat M, Fiessinger JN, Bordet F, Housset E. Rapports entre necroses digitales du membre superieur et affections malignes. *Nouv Presse Med*. 1978;7:1279-1282.
19. Taylor LM Jr, Hauty MG, Edwards JM, Porter JM. Digital ischemia as a manifestation of malignancy. *Ann Surg*. 1987;206:62-68.



20. Stonebridge PA, Clason AE, Duncan AJ, et al. Acute ischaemia of the upper limb compared with acute lower limb ischaemia; a 5-year review. *Br J Surg*. 1989;76:515-516.
21. Walcher J, Strecker R, Goldacker S, et al. High resolution 3 tesla contrast-enhanced MR angiography of the hands in Raynaud's disease. *Clin Rheumatol*. 2007;26:587-589.
22. Landry GJ, Edwards JM, Taylor LM Jr, Porter JM. Long-term outcome of prospectively analyzed patients with Raynaud's syndrome. *J Vasc Surg*. 1996;23:76-86.
23. Maga P, Kuzdzal J, Nizankowski R, et al. Long-term effects of thoracic sympathectomy on microcirculation in the hands of patients with primary Raynaud disease. *J Thorac Cardiovasc Surg*. 2007;133:1428-1433.
24. El-Gammal T, Blair F. Digital periarterial sympathectomy for ischaemic digital pain and ulcers. *J Hand Surg (Edinburgh)*. 1991;16:382-385.
25. Ortensi A, Salsano F, Trinchi S, et al. Microsurgical distal sympathectomy in chronic vasospastic syndromes of the hand. *Int Surg*. 2005;90:88-92.
26. Kiowski W, Erne P, Buhler FR. Use of nifedipine in hypertension and Raynaud's phenomenon. *Cardiovasc Drugs Ther Suppl*. 1994;5:935-940.
27. Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. *Arthritis Rheum*. 1999;42:2646-2655.

## 第 117 章

1. McCarthy WJ, Flinn WR, Yao JS, et al. Result of bypass grafting for upper limb ischemia. *J Vasc Surg*. 1986;3:741-746.
2. Stonebridge PA, Clason AE, Duncan AJ, et al. Acute ischaemia of the upper limb compared with acute lower limb ischaemia; a 5-year review. *Br J Surg*. 1989;76:515-516.
3. Wirsing P, Andriopoulos A, Botticher R. Arterial embolectomies in the upper extremity after acute occlusion. Report on 79 cases. *J Cardiovasc Surg (Torino)*. 1983;24:40-42.
4. Hernandez-Richter T, Angele MK, Helmberger T, et al. Acute ischemia of the upper extremity: long-term results following thromboembolectomy with the Fogarty catheter. *Langenbecks Arch Surg*. 2001;386:261-266.
5. Baird RJ, Lajos TZ. Emboli to the arm. *Ann Surg*. 1964;160:905-909.
6. Savelyev VS, Zatevakhin II, Stepanov NV. Artery embolism of the upper limbs. *Surgery*. 1977;81:367-375.
7. Galbraith K, Collin J, Morris PJ, Wood RF. Recent experience with arterial embolism of the limbs in a vascular unit. *Ann R Coll Surg Engl*. 1985;67:30-33.
8. Chang BB, Roddy SP, Darling RC 3rd, et al. Upper extremity bypass grafting for limb salvage in end-stage renal failure. *J Vasc Surg*. 2003;38:1313-1315.
9. Nehler MR, Dalman RL, Harris EJ, et al. Upper extremity arterial bypass distal to the wrist. *J Vasc Surg*. 1992;16:633-640; discussion 640-2.
10. Coates T, Kirkland GS, Dymock RB, et al. Cutaneous necrosis from calcific uremic arteriopathy. *Am J Kidney Dis*. 1995;32:384-391.
11. Roddy SP, Darling RC 3rd, Chang BB, et al. Brachial artery reconstruction for occlusive disease: a 12-year experience. *J Vasc Surg*. 2001;33:802-805.
12. Hughes K, Hamdan A, Schermerhorn M, et al. Bypass for chronic ischemia of the upper extremity: results in 20 patients. *J Vasc Surg*. 2007;46:303-307.
13. Xenos ES, Freeman M, Stevens S, et al. Covered stents for injuries of subclavian and axillary arteries. *J Vasc Surg*. 2003;38:451-454.
14. Amann-Vesti BR, Koppensteiner R, Rainoni L, et al. Immediate and long-term outcome of upper extremity balloon angioplasty in giant cell arteritis. *J Endovasc Ther*. 2003;10:371-375.
15. Pride YB, Pinto DS, Garcia LA. A novel approach using atherectomy for chronic total occlusion of the brachial artery: a

- case report. *Vasc Med*. 2007;12:207-210.
16. Dineen S, Smith S, Arko FR. Successful percutaneous angioplasty and stenting of the radial artery in a patient with chronic upper extremity ischemia and digital gangrene. *J Endovasc Ther*. 2007;14:426-428.
  17. Cohen ES, Holtzman RB, Johnson GW Jr. Axillobrachial artery bypass grafting with in situ cephalic vein for axillary artery occlusion: a case report. *J Vasc Surg*. 1989;10:683-687.
  18. Jain KM, Simoni EJ, Munn JS, Madson DL Jr. Long-term follow-up of bypasses to the brachial artery across the shoulder joint. *Am J Surg*. 1996;172:127-129.
  19. Marone L, Nigri G, LaMuraglia GM. A novel technique of upper extremity revascularization: the retrohumeral approach. *J Vasc Surg*. 2002;35:1277-1279.
  20. Evers P, Earnshaw JJ. Acute non-traumatic arm ischaemia. *Br J Surg*. 1998;85:1340-1346.
  21. De Giacomo T, Rendina EA, Venuta F, et al. Thoracoscopic sympathectomy for symptomatic arterial obstruction of the upper extremities. *Ann Thorac Surg*. 2002;74:885-888.
  22. el-Gammal TA, Blair WF. Digital periarterial sympathectomy for ischaemic digital pain and ulcers. *J Hand Surg [Br]*. 1991;16:382-385.
  23. Widlus DM, Venbrux AC, Benenati JF, et al. Fibrinolytic therapy for upper-extremity arterial occlusions. *Radiology*. 1990;175:393-399.
  24. Cejna M, Salomonowitz E, Wohlschlagel H, et al. rt-PA thrombolysis in acute thromboembolic upper-extremity arterial occlusion. *Cardiovasc Intervent Radiol*. 2001;24:218-223.
  25. Zeller T, Frank U, Bürgelin K, et al. Treatment of acute embolic occlusions of the subclavian and axillary arteries using a rotational thrombectomy device. *Vasa*. 2003;32:111-116.
  26. Babu SC, Piccorelli GO, Shah PM, et al. Incidence and results of arterial complications among 16,350 patients undergoing cardiac catheterization. *J Vasc Surg*. 1989;10:113-116.
  27. Slogoff S, Keats AS, Arlund C. On the safety of radial artery cannulation. *Anesthesiology*. 1983;59:42-47.
  28. Aptekar E, Pernes JM, Chabane-Chaouch M, et al. Transulnar versus transradial artery approach for coronary angioplasty: the PCVI-CUBA study. *Catheter Cardiovasc Interv*. 2006;67:711-720.
  29. Myers SI, Harward TR, Maher DP, et al. Complex upper extremity vascular trauma in an urban population. *J Vasc Surg*. 1990;12:305-309.
  30. Meyer J, Walsh J, Schuler J, et al. The early fate of venous repair after civilian vascular trauma. A clinical, hemodynamic, and venographic assessment. *Ann Surg*. 1987;206:458-464.
  31. Sabharwal S, Tredwell SJ, Beauchamp RD, et al. Management of pulseless pink hand in pediatric supracondylar fractures of humerus. *J Pediatr Orthop*. 1997;17:303-310.
  32. Luria S, Sucar A, Eylon S, et al. Vascular complications of supracondylar humeral fractures in children. *J Pediatr Orthop B*. 2007;16:133-143.
  33. Ninet JP, Bachet P, Dumontet CM, et al. Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica. *Am J Med*. 1990;88:13-20.
  34. Weaver FA, Yellin AE, Campen DH, et al. Surgical procedures in the management of Takayasu's arteritis. *J Vasc Surg*. 1990;12:429-437; discussion 438-9.

## 第 118 章

1. Ziegler-Graham K, MacKenzie EJ, Ephraim PL, et al. Estimating the prevalence of limb loss in the United States: 2005 to 2050. *Arch Phys Med Rehabil*. 2008;89:422-429.
2. Dillingham TR, Pezzin LE, MacKenzie ED. Limb amputation and limb deficiency: epidemiology and recent trends in the United States. *South Med J*. 2002;95:875-883.
3. Mackaay AJC, Beks PJ, Dur AHM, et al. The distribution of peripheral vascular disease in a Dutch Caucasian population:

- comparison of type II diabetic and non-diabetic subjects. *Eur J Vasc Endovasc Surg*. 1995;9:170-175.
4. Hughes K, Hamdan A, Schermerhorn M, et al. Bypass for chronic ischemia of the upper extremity: results in 20 patients. *J Vasc Surg*. 2007;46:303-307.
  5. McCarty WJ, Flinn WR, Yao JS, et al. Results of bypass grafting for upper limb ischemia. *J Vasc Surg*. 1986;3:741-746.
  6. Deguara J, Ali T, Modarai B, et al. Upper limb ischemia: 20-years experience from a single center. *Vascular*. 2005;13:84-91.
  7. Stansbury LG, Lalliss SJ, Branstetter JG, et al. Amputations in U.S. military personnel in the current conflicts in Afghanistan and Iraq. *J Trauma*. 2008;22:43-46.
  8. Clouse WD, Rasmussen TE, Perlstein J, et al. Upper extremity vascular injury: a current in-theater report from Operation Iraqi Freedom. *Ann Vasc Surg*. 2006;20:429-434.
  9. Clouse WD, Rasmussen TE, Peck MA, et al. In-theater management of vascular injury: 2 years of the Balad vascular registry. *J Am Coll Surg*. 2007;204:625-632.
  10. Weber MA, Fox CJ, Adams E, et al. Upper extremity arterial combat injury management. *Perspect Vasc Surg Endovasc Ther*. 2006;18:141-145.
  11. Orcutt MB, Levine BA, Gaskill HV, et al. Civilian vascular trauma of the upper extremity. *J Trauma*. 1986;26:63-67.
  12. Cicrit DF, Dalsing MC, Bryant BJ, et al. An experience with upper extremity vascular trauma. *Am J Surg*. 1990;160:229-233.
  13. Menakuru SR, Behera A, Jindal R, et al. Extremity vascular trauma in civilian population: a seven-year review from north India. *Injury*. 2005;36:400-406.
  14. Manford JD, Garrard L, Kline DG, et al. Management of severe proximal vascular and neural injury of the upper extremity. *J Vasc Surg*. 1998;27:43-49.
  15. Shanmugam V, Velu RB, Subramaniyan SR, et al. Management of upper limb arterial injury without angiography—Chennai experience. *Injury*. 2004;35:61-64.
  16. Myers SI, Hayward TRS, Maher DP, et al. Complex upper extremity trauma in an urban population. *J Vasc Surg*. 1990;12:305-309.
  17. Zellweger R, Hess F, Nicol A, et al. An analysis of 124 surgically managed brachial artery injuries. *Am J Surg*. 2004;188:240-245.
  18. Brown KR, Jean-Claude J, Seabrook GR, et al. Determinates of functional disability after complex upper extremity trauma. *Ann Vasc Surg*. 2001;15:43-48.
  19. Shaw AD, Milne AA, Christie J, et al. Vascular trauma of the upper limb and associated nerve injuries. *Injury*. 1995;26:515-518.
  20. Stanec S, Tonkovic I, Stanec Z, et al. Treatment of upper limb nerve war injuries associated with vascular trauma. *Injury*. 1997;28:463-468.
  21. Hanel DP, Chin SH. Wrist level and proximal-upper extremity replantation. *Hand Clin*. 2007;23:13-21.
  22. Wood MB, Cooney WP. Above elbow limb replantation: functional results. *J Hand Surg*. 1986;11:682-687.
  23. McKeever FM. Upper extremity amputations and prostheses. *J Bone Joint Surg Am*. 1944;26:660-706.
  24. Peck MA, Clouse WD, Cox MW, et al. The complete management of extremity vascular injury in a local population: a wartime report from the 332nd Expeditionary Medical Group/Air Force Theater Hospital, Balad Air Base, Iraq. *J Vasc Surg*. 2007;45:1197-1205.
  25. Huckstep RL, Sherry E. Replacement of the proximal humerus in primary bone tumors. *Aust N Z J Surg*. 1996;66:97-100.
  26. Yajima H, Tamai S, Ono H, Kizaki K. Vascularized bone grafts to the upper extremities. *Plast Reconstr Surg*. 1998;101:727-737.
  27. Ilizarov GA. The principles of the Ilizarov method. *Bull Hosp Joint Dis*. 1997;56:33-49.
  28. Alekberov C, Karatosun V, Baran Ö, et al. Lengthening of congenital below-elbow amputation stumps by the Ilizarov technique. *J Bone Joint Surg Br*. 2000;82:239-241.

29. Bernstein RM, Watts HG, Setoguchi Y. The lengthening of short upper extremity amputation stumps. *J Pediatr Orthop*. 2008;28:86-90.
30. Baccarani A, Follmar KE, De Santis G, et al. Free vascularized tissue transfer to preserve upper extremity amputation levels. *Plast Reconstr Surg*. 2007;120:971-981.
31. Lanzetta M, Petruzzo P, Margreiter R, et al. The international registry on hand and composite tissue transplantation. *Transplantation*. 2005;79:1210-1214.
32. O'Shaughnessy KD, Dumanian GA, Lipschutz RD, et al. Targeted reinnervation to improve prosthesis control in transhumeral amputees. *J Bone Joint Surg Am*. 2008;90:393-400.
33. Rosslin R, Simmen BR. Finger tip amputations in children. *Handchir Mikrochir Plast Chir*. 1991;23:312-317.
34. Horton TC, Sauerland S, Davis TRC. The effect of flexor digitorum profundus quadriga on grip strength. *J Hand Surg [Br]*. 2007;32:130-134.
35. Chase RA. Functional levels of amputation of the hand. *Surg Clin North Am*. 1960;40:415-423.
36. Kutler W. New method for fingertip amputation. *JAMA*. 1947;133:29-30.
37. Atasoy E, Ioakimidis E, Kasdan M, et al. Reconstruction of the amputated fingertip with a triangular volar flap. A new surgical procedure. *J Bone Joint Surg Am*. 1970;52:921-926.
38. Snow JW. The use of a volar flap for repair of fingertip amputations: a preliminary report. *Plast Reconstr Surg*. 1973;52:299.
39. Venkataswami R, Subramanian N. Oblique triangular flap: a new method of repair for oblique amputations of the fingertip and thumb. *Plast Reconstr Surg*. 1980;66:296-300.
40. Bowen CV, Beveridge J, Milliken RG, Johnston GH. Rotating shaft avulsion amputations of the thumb. *J Hand Surg [Am]*. 1991;16:117-121.
41. Leupin P, Weil J, Buchler U. The dorsal middle phalangeal finger flap: mid-term results of 43 cases. *J Hand Surg [Br]*. 1997;22:362-371.
42. Tubiana R. Krukenberg's operation. *Orthop Clin North Am*. 1981;12:819-826.
43. Gu YD, Zhang LY, Zheng YL. Introduction of a modified Krukenberg operation. *Plast Reconstr Surg*. 1996;97:222-226.
44. Neusel E, Traub M, Blasius K, Marquardt E. Results of humeral stump angulation osteotomy. *Arch Orthop Trauma Surg*. 1997;116:263-265.
45. Cleveland KB. Amputation of upper extremity. In: Canale ST, Beaty JH, eds. *Campbell's Operative Orthopaedics*. 11th ed. St. Louis, MO: Elsevier Mosby; 2008:625-670.
46. Smith DG. Amputations about the shoulder: surgical management. In: Smith DG, Michael JW, Bowker JH, eds. *Atlas of Amputations and Limb Deficiencies: Surgical, Prosthetic, and Rehabilitative Principles*. 3rd ed. Rosemont, IL: American Academy of Orthopedics; 2004:251-262.
47. Berger P. *L'amputation du Membre Supérieur dans la Contiguïté du Tronc (Amputation Interscapulo-Thoracique)*. Paris: G Masson; 1887.
48. Littlewood H. Amputations at the shoulder and at the hip. *BMJ*. 1922;1:381-383.
49. Gusenhoff JA, Vega SJ, Jiang S, et al. Free tissue transfer: comparison of outcomes between university hospitals and community hospitals. *Plast Reconstr Surg*. 2006;118:671-675.
50. Ehde DM, Smith DG. Chronic pain management. In: Smith DG, Michael JW, Bowker JH, eds. *Atlas of Amputations and Limb Deficiencies: Surgical, Prosthetic, and Rehabilitative Principles*. 3rd ed. Rosemont, IL: American Academy of Orthopedics; 2004:711-726.
51. Hompland S. Pain management for upper extremity amputation. In: Meier RH, Atkins DJ, eds. *Functional Recovery of Adults and Children with Upper Extremity Amputation*. New York, NY: Demos Medical Publishing; 2004:89-111.
52. Ebrahimzadeh MH, Fattahi AS, Nejad AB. Long-term follow-up of Iranian veteran upper extremity amputees from the Iran-Iraq War (1980-1988). *J Trauma*. 2006;61:886-888.
53. Dettmers C, Rzanny T, van Schayak R, et al. Increased excitability in the primary motor cortex and supplementary motor

- area in patients with phantom limb pain after upper limb amputation. *Neurosci Lett*. 2001;307:109-112.
54. Ugur F, Akin A, Esmaoglu A, et al. Comparison of phantom limb pain or phantom extremity sensations of upper and lower extremity amputations. *Agri*. 2007;19:50-56.
  55. Van Dorsten B. Integrating psychological and medical care: practice recommendations for amputation. In: Meier RH, Atkins DJ, eds. *Functional Recovery of Adults and Children with Upper Extremity Amputation*. New York, NY: Demos Medical Publishing; 2004:73-88.
  56. Meier RH, Atkins DJ. Postoperative and preprosthetic preparation. In: Meier RH, Atkins DJ, eds. *Functional Recovery of Adults and Children with Upper Extremity Amputation*. New York, NY: Demos Medical Publishing; 2004:135-138.
  57. Williams TW. Control of powered upper extremity prostheses. In: Meier RH, Atkins DJ, eds. *Functional Recovery of Adults and Children with Upper Extremity Amputation*. New York, NY: Demos Medical Publishing; 2004:207-224.
  58. Childress DS, Weir RF. Control of limb prostheses. In: Smith DG, Michael JW, Bowker JH, eds. *Atlas of Amputations and Limb Deficiencies: Surgical, Prosthetic, and Rehabilitative Principles*. 3rd ed. Rosemont, IL: American Academy of Orthopedics; 2004:711-726.
  59. Pasquina PF. Rehabilitation of the OIF injured patient. Paper presented at the 33rd Annual Meeting of the Society for Military Vascular Surgery. Bethesda, MD, December 1-3, 2005.
  60. Kuiken TA, Miller LA, Lipschutz R, et al. Targeted reinnervation for enhanced prosthetic arm function in woman with a proximal amputation. *Lancet*. 2007;369:371-380.
  61. Schwartz AB. Cortical neural prosthetics. *Annu Rev Neurosci*. 2004;27:487-507.
  62. Datta D, Selvarajah K, Davey N. Functional outcome of patients with proximal upper limb deficiency—acquired and congenital. *Clin Rehabil*. 2004;18:172-177.
  63. Burger H, Maver T, Marincek C. Partial hand amputation and work. *Disabil Rehabil*. 2007;29:1317-1321.
  64. Weed R, Atkins DJ. Return to work issues for the upper extremity amputee. In: Meier RH, Atkins DJ, eds. *Functional Recovery of Adults and Children with Upper Extremity Amputation*. New York, NY: Demos Medical Publishing; 2004:89-111.
  65. Weed R, Kirkscey M, Mullins G, et al. Return to work rates in case of amputation. *J Rehabil Outcomes Measurement*. 1997;1:35-39.

## 第 119 章

1. Raynaud M. *De L'asphyxie locale et de la gangrene symetrique des extremities [Selected Monographs 121, London Translation]*. London: Sydenham Society; 1862.
2. Blunt RJ, Porter JM. Raynaud syndrome. *Semin Arthritis Rheum*. 1981;10:282.
3. Heslop J, Coggon D, Acheson ED. The prevalence of intermittent digital ischaemia (Raynaud's phenomenon) in a general practice. *J R Coll Gen Pract*. 1983;33:85.
4. Maricq HR, Weinrich MC, Keil JE, et al. Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire. *J Chron Dis*. 1986;39:423.
5. Leppert J, Aberg H, Ringqvist I, et al. Raynaud's phenomenon in a female population: prevalence and association with other conditions. *Angiology*. 1987;38:871.
6. Silman A, Holligan S, Brennan P, et al. Prevalence of symptoms of Raynauds phenomenon in general practice. *BMJ*. 1990;301:590.
7. Weinrich MC, Maricq HR, Keil JE, et al. Prevalence of Raynaud phenomenon in the adult population of South Carolina. *J Clin Epidemiol*. 1990;43:1343.
8. Harada N, Ueda A, Takegata S. Prevalence of Raynaud's phenomenon in Japanese males and females. *J Clin Epidemiol*. 1991;44:649.
9. O'Keeffe ST, Tsapatsaris NP, Beetham WP. Color chart assisted diagnosis of Raynaud's phenomenon in an unselected

- hospital employee population. *J Rheumatol*. 1992;19:1415.
10. Bartelink ML, Wollersheim H, van de Lisdonk E, et al. Prevalence of Raynaud's phenomenon. *Neth J Med*. 1992;41:149.
  11. Riera G, Vilardell M, Vaque J, et al. Prevalence of Raynaud's phenomenon in a healthy Spanish population. *J Rheumatol*. 1993;20:66.
  12. Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA vs Tarentaise Savoie France. *J Rheumatol*. 1993;20:70.
  13. Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. *J Rheumatol*. 1997;24:879.
  14. Valter I, Maricq HR. Prevalence of Raynaud's phenomenon in Tartu and Tartumaa, southern Estonia. *Scand J Rheumatol*. 1997;26:117.
  15. Brand FN, Larson MG, Kannel WB, et al. The occurrence of Raynaud's phenomenon in a general population: the Framingham Study. *Vasc Med*. 1997;2:296.
  16. Gelber AC, Wigley FM, Stallings RY, et al. Symptoms of Raynaud's phenomenon in an inner-city African-American community: prevalence and self-reported cardiovascular comorbidity. *J Clin Epidemiol*. 1999;52:441.
  17. Palmer KT, Griffin MJ, Syddall H, et al. Prevalence of Raynaud's phenomenon in Great Britain and its relation to hand transmitted vibration: a national postal survey. *Occup Environ Med*. 2000;57:448.
  18. Voulgari PV, Alamanos T, Papazisi D, et al. Prevalence of Raynaud's phenomenon in a healthy Greek population. *Ann Rheum Dis*. 2000;59:206.
  19. Roman Ivorra JA, Gonzalez Perales JL, Fernandez Carballido C, et al. Prevalence of Raynaud's phenomenon in general practice in the east of Spain. *Clin Rheum*. 2001;20:88.
  20. De Angelis R, Salaffi F, Grassi W. Raynaud's phenomenon: prevalence in an Italian population sample. *Clin Rheumatol*. 2006;25:506.
  21. Carpentier PH, Satger B, Poensin D, et al. Incidence and natural history of Raynaud phenomenon: a long-term follow-up (14 years) of a random sample from the general population. *J Vasc Surg*. 2006;44:1023.
  22. Suter LG, Murabito JM, Felson DT, et al. The incidence and natural history of Raynaud's phenomenon in the community. *Arthritis Rheum*. 2005;52:1259.
  23. Koman LA, Smith BP, Smith TL. Stress testing in the evaluation of upper-extremity perfusion. *Hand Clin*. 1993;9:59.
  24. Coleman S, Anson B. Arterial patterns in the hand based upon a study of 650 specimens. *Surg Gynecol Obstet*. 1961;113:409.
  25. Greenfield A, Shepherd J. A quantitative study of the response to cold of the circulation through the fingers of normal subjects. *Clin Sci*. 1950;9:323.
  26. Coffman JD. Total and nutritional blood flow in the finger. *Clin Sci*. 1972;42:243.
  27. Hummers LK, Wigley FM. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. *Rheum Dis Clin North Am*. 2003;29:293.
  28. Greenfield A, Shepherd J. The loss of heat from the hands and from the fingers immersed in cold water. *J Physiol (Lond)*. 1950;112:459.
  29. Coffman JD, Cohen AS. Total and capillary fingertip blood flow in Raynaud's phenomenon. *N Engl J Med*. 1971;285:259.
  30. Coffman JD, Cohen RA. Alpha-adrenergic and serotonergic mechanisms in the human digit. *J Cardiovasc Pharmacol*. 1988;11(Suppl 1):S49.
  31. Lewis T. Observations upon reactions of vessels of human skin to cold. *Heart*. 1930;15:177.
  32. Burton A, Taylor R. A study of the adjustment of peripheral vascular tone to the requirements of the regulation of body temperature. *Am J Physiol*. 1940;129:565.
  33. Engelhart M, Kristensen JK. Raynaud's phenomenon: blood supply to fingers during indirect cooling, evaluated by laser Doppler flowmetry. *Clin Physiol*. 1986;6:481-488.

34. Marshall R, Shepherd J, Thompson I. Vascular responses in patients with high serum titres of cold agglutinins. *Clin Sci*. 1953;12:155.
35. Lewis T. Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease. *Heart*. 1929;15:7.
36. Herrick AL. Pathogenesis of Raynaud's phenomenon. *Rheumatology*. 2005;44:587.
37. Furchgott R, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. *FASEB J*. 1989;3:2007.
38. Luscher T, Vanhoutte PM. *The Endothelium: Modulator of Cardiovascular Function*. Boca Raton, FL: CRC Press; 1990.
39. Shepherd JT, Vanhoutte PM. Endothelium-derived relaxing (EDRF) and contracting factors (EDCF) in the control of cardiovascular homeostasis: the pioneering observations. In: Rubanyi GM, ed. *Cardiovascular Significance of Endothelium-Derived Vasoactive Factors*. Mount Kisco, NY: Futura; 1991.
40. Cooke JP, Marshall JM. Mechanisms of Raynaud's disease. *Vasc Med*. 2005;10:293.
41. Romero LI, Zhang DN, Cooke JP, et al. Differential regulation (expression) of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. *Vasc Med*. 2000;5:147.
42. Rajagopalan S, Pfenninger D, Kehrer C, et al. Increased asymmetric dimethyl-arginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. *Arthritis Rheum*. 2003;48:1992.
43. Singh S, De Trafford JC, Baskerville PA, et al. Response of digital arteries to endothelium-dependent and -independent vasodilators in patients with Raynaud's phenomenon. *Eur J Clin Invest*. 1995;25:182.
44. Biondi ML, Marasini B, Bianchi E, et al. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon. *Int J Cardiol*. 1988;19:335.
45. Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. *Prog Cardiovasc Dis*. 1995;38:105.
46. Yang ZH, Richard V, von Segesser L, et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries: a new mechanism of vasospasm? *Circulation*. 1990;82:188.
47. Fyhrquist F. Raised plasma endothelin-1 concentration following cold pressor test. *Biochem Biophys Res Commun*. 1990;169:217.
48. Leppert J, Ringqvist A, Karlberg BE, et al. Whole-body cooling increases plasma endothelin-1 levels in women with primary Raynaud's phenomenon. *Clin Physiol*. 1998;18:420.
49. Zamora MR, O'Brien RF, Rutherford RB, et al. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. *Lancet*. 1990;336:1144.
50. Kawaguchi Y, Takagi K, Hara M, et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. *Arthritis Rheum*. 2004;50:216.
51. Coppo M, Boddi M, Poggesi L, et al. Exaggerated local hand sympathetic but not renin-angiotensin system activation in patients with primary Raynaud's phenomenon. *Microvasc Res*. 2006;71:128.
52. Rösch J, Porter JM. Cryodynamic hand angiography in the diagnosis and management of Raynaud's syndrome. *Circulation*. 1977;55:807.
53. Flavahan NA, Lindblad LE, Verbeuren TJ, et al. Cooling and alpha1- and alpha-adrenergic responses in cutaneous veins: role of receptor reserve. *Am J Physiol*. 1985;249:H950.
54. Flavahan NA, Cooke JP, Shepherd JT, et al. Human postjunctional alpha1- and alpha2-adrenoceptors: differential distribution in arteries of the limbs. *J Pharmacol Exp Ther*. 1987;241:361.
55. Cooke JP, Creager SJ, Scales KM, et al. Role of digital artery adrenoceptors in Raynaud's disease. *Vasc Med*. 1997;2:1.
56. Flavahan NA, Flavahan S, Mitra S, et al. The vasculopathy of Raynaud's phenomenon and scleroderma. *Rheum Dis Clin North Am*. 2003;29:275.
57. Bailey SR, Eid AH, Mitra S, et al. Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2c-adrenoceptor translocation. *Circ Res*. 2004;94:1367.

58. Bunker CB, Terengi G, Springall DR, et al. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon and systemic sclerosis. *Lancet*. 1990;336:1530.
59. Bunker CB, Reavley C, O'Shaughnessy DJ, et al. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon. *Lancet*. 1993;342:80.
60. Merritt WH. Comprehensive management of Raynaud's syndrome. *Clin Plast Surg*. 1997;24:133.
61. Coffman JD, Cohen RA. Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenon. *Clin Sci*. 1994;86:269.
62. Seibold JR, Terrigino CA. Selective antagonism of 5<sub>2</sub>-serotonergic receptors relieves but does not prevent cold-induced vasoconstriction in primary Raynaud's phenomenon. *J Rheumatol*. 1986;13:337.
63. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. *Rheumatology (Oxford)*. 2001;40:1038.
64. Ames PR, Lupoli S, Alves J, et al. The coagulation/fibrinolytic balance in systemic sclerosis: evidence for a haematologic stress syndrome. *Br J Rheumatol*. 1997;36:1045.
65. Solans R, Motta C, Sola R, et al. Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis. *Arthritis Rheum*. 2000;43:894.
66. Ziegler S, Zöck C, Gschwandtner M, et al. Thermoregulation and rheologic properties of blood in primary Raynaud's phenomenon and the vibration-induced white-finger syndrome. *Int Arch Occup Environ Health*. 2005;78:218.
67. Fraenkel L, Zhang Y, Chaisson CE, et al. The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. *Ann Intern Med*. 1998;129:208.
68. Cooke JP, Creager MA, Osmundson PJ, et al. Sex differences in control of cutaneous blood flow. *Circulation*. 1990;82:1607.
69. Eid AH, Maiti K, Mitra S, et al. Estrogen increases smooth muscle cell expression of alpha<sub>2c</sub>-adrenoceptors and cold-induced constriction of cutaneous arteries. *AJP-Heart Circ Physiol*. 2007;293:H1955.
70. Freedman RR, Mayes MD. Familial aggregation of primary Raynaud's disease. *Arthritis Rheum*. 1996;39:1189.
71. Cherkas LF, Williams FMK, Carter L, et al. Heritability of Raynaud's phenomenon and vascular responsiveness to cold: a study of adult female twins. *Arthritis Rheum*. 2007;57:524.
72. Maricq HR, Weinrich MC, Keil JC, et al. Prevalence of Raynaud phenomenon in the general population: a preliminary study by questionnaire. *J Chron Dis*. 1986;39:423.
73. Allen E, Brown G. Raynaud's disease: A critical review of minor requisites for diagnosis. *Am J Med Sci*. 1932;183:187.
74. Nigrovic PA, Fuhlbrigge RC, Sundel RP. Raynaud's phenomenon in children: a retrospective review of 123 patients. *Pediatrics*. 2003;111:715.
75. Fulcher SM, Koman LA, Smith BP, et al. The effect of transdermal nicotine on digital perfusion in reformed habitual smokers. *J Hand Surg [Am]*. 1998;23:79.
76. Suter LG, Murabito JM, Felson DT, et al. Smoking, alcohol consumption, and Raynaud's phenomenon in middle age. *Am J Med*. 2007;120:264.
77. Di Castelnuovo A, Rotondo S, Iacoviello L, et al. Meta-analysis of wine and beer consumption in relation to vascular risk. *Circulation*. 2002;105:2836.
78. Spittell PC, Spittell JA. Occlusive arterial disease of the hand due to repetitive blunt trauma: a review with illustrative cases. *Int J Cardiol*. 1993;38:281.
79. Hamilton G. Effect of the air hammer on the hands of the stonecutters. *U.S. Bureau Labor Stat Bull*. 1918;236:53.
80. Griffin MJ, Bovenzi M, Nelson CM. Dose-response patterns for vibration-induced white finger. *Occup Environ Med*. 2003;60:16.
81. Seyring M. Maladies from work with compressed air drills. *Bull Hyg*. 1931;6:25.
82. McLafferty RB, Edwards JM, Ferris BL, et al. Raynaud's syndrome in workers who use vibrating pneumatic air knives. *J*



- Vasc Surg.* 1999;30:1.
83. Liapina M, Tzvetkov D, Vodenitcharov E. Pathophysiology of vibration-induced white fingers—current opinion: A review. *Centr Eur J Public Health.* 2002;10:16.
  84. Stoyneva Z, Lyapina M, Tzvetkov D, et al. Current pathophysiological views on vibration-induced Raynaud's phenomenon. *Cardiovasc Res.* 2003;57:615.
  85. Nilsson T, Burstrom L, Hagberg M. Risk assessment of vibration exposure and white fingers among platers. *Int Arch Occup Environ Health.* 1989;61:473.
  86. Feleke E, Lyngstam O, Rastam L, et al. Complaints of cold extremities among patients on antihypertensive treatment. *Acta Med Scand.* 1983;213:381.
  87. Adverse reactions to bendroflumazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. *Lancet.* 1981;2:539.
  88. van der Veur E, ten Berge BS, Wouda AA, et al. Effects of atenolol, labetalol, and propranolol on the peripheral circulation in hypertensive patients without obstructive vascular disease. *Eur J Clin Pharmacol.* 1985;28:131.
  89. Steiner JA, Cooper R, Gear JS, et al. Vascular symptoms in patients with primary Raynaud's phenomenon are not exacerbated by propranolol or labetalol. *Br J Clin Pharmacol.* 1979;7:401.
  90. Coffman JD, Rasmussen HM. Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud's phenomenon. *Circulation.* 1985;72:466.
  91. Franssen C, Wollersheim H, de Haan A, et al. The influence of different beta-blocking drugs on the peripheral circulation in Raynaud's phenomenon and in hypertension. *J Clin Pharmacol.* 1992;32:652.
  92. Grau JJ, Grau M, Milla A, et al. Cancer chemotherapy and Raynaud's phenomenon. *Ann Intern Med.* 1983;98:258.
  93. Scheulen ME, Schmidt CG. Raynaud's phenomenon and cancer chemotherapy. *Ann Intern Med.* 1982;96:256.
  94. Clowse ME, Wigley FM. Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. *J Rheumatol.* 2003;30:1341.
  95. Al-Zahrani H, Gupta V, Minden MD, et al. Vascular events associated with alpha interferon therapy. *Leuk Lymphoma.* 2003;44:471.
  96. Shepherd RFJ. Ergotism. In: White R, Hollier L, eds. *Vascular Surgery*. Philadelphia, PA: JB Lippincott; 1994.
  97. Bowen JS, Davis GB, Kearney TE, et al. Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion. *JAMA.* 1983;249:1477.
  98. Balbir-Gurman A, Braun-Moscovici Y, Nahir AM. Cocaine-induced Raynaud's phenomenon and ischaemic finger necrosis. *Clin Rheumatol.* 2001;20:376.
  99. Coffman J. *Raynaud's Phenomenon*. New York, NY: Oxford University Press; 1989.
  100. Nadir A, Smith JW, Matter B, et al. Type 2 cryoglobulinemia and hepatitis C virus: its recognition and treatment. *J Okla State Med Assoc.* 1994;87:449.
  101. McLeod BC, Sassetti RJ. Plasmapheresis with return of cryoglobulin-depleted autologous plasma (cryoglobulinpheresis) in cryoglobulinemia. *Blood.* 1980;55:866.
  102. Wong AS, Hon Yoon K. Paraneoplastic Raynaud phenomenon and idiopathic thrombocytopenic purpura in non-small-cell lung cancer. *Am J Clin Oncol.* 2003;26:26.
  103. Fam AG. Paraneoplastic rheumatic syndromes. *Best Pract Res Clin Rheumatol.* 2000;14:515.
  104. Taillan B, Castanet J, Garnier G, et al. Paraneoplastic Raynaud's phenomenon. *Clin Rheumatol.* 1993;12:281.
  105. DeCross AJ, Sahasrabudhe DM. Paraneoplastic Raynaud's phenomenon. *Am J Med.* 1992;92:571.
  106. Kohli M, Bennett RM. Raynaud's phenomenon as a presenting sign of ovarian adenocarcinoma. *J Rheumatol.* 1995;22:1393.
  107. Gifford R, Heins E. Raynaud's disease among women and girls. *Circulation.* 1957;16:1012.
  108. Maricq HR, Weinrich MC. Diagnosis of Raynaud's phenomenon assisted by color charts. *J Rheumatol.* 1988;15:454.

109. Chikura B, Moore TL, Manning JB, et al. Sparing of the thumb in Raynaud's phenomenon. *Rheumatology*. 2008;47:219.
110. Garrison CP. Nipple vasospasms, Raynaud's syndrome, and nifedipine. *J Hum Lactat*. 2002;18:382.
111. Miller D, Waters DD, Warnica W, et al. Is variant angina the coronary manifestation of a generalized vasospastic disorder? *N Engl J Med*. 1981;304:763.
112. Landry GJ, Edwards JM, McLafferty RB, et al. Long-term outcome of Raynaud's syndrome in a prospectively analyzed patient cohort. *J Vasc Surg*. 1996;23:76.
113. Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes. *Curr Opin Rheumatol*. 2002;14:737.
114. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. *Rheum Dis Clin North Am*. 2003;29:255.
115. White B. Systemic sclerosis and related syndromes: A. Epidemiology, pathology, and pathogenesis. In: Klippel JH, ed. *Primer on the Rheumatic Diseases*. Atlanta, GA: Arthritis Foundation; 2001.
116. Wigley FM. Systemic sclerosis and related syndromes: B. Clinical features. In: Klippel JH, ed. *Primer on the Rheumatic Diseases*. Atlanta, GA: Arthritis Foundation; 2001.
117. Grader-Beck T, Wigley RM. Raynaud's phenomenon in mixed connective tissue disease. *Rheum Dis Clin North Am*. 2005;31:465.
118. De Angelis R, Cerioni A, Del Medico P, et al. Raynaud's phenomenon in undifferentiated connective tissue disease (UCTD). *Clin Rheumatol*. 2005;24:145.
119. Bhatt SP, Gulati GS, Sharma S, et al. Peripheral vascular disease in systemic lupus erythematosus. *Lupus*. 2007;16:720.
120. Garcia-Carrasco M, Siso A, Ramos-Casals M, et al. Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. *J Rheumatol*. 2002;29:726.
121. Zimmerman NB. Occlusive vascular disorders of the upper extremity. *Hand Clin*. 1993;9:139.
122. Olin JW. Thromboangiitis obliterans (Buerger's disease). *N Engl J Med*. 2000;343:864.
123. Joyce JW. Buerger's disease (thromboangiitis obliterans). *Rheum Dis Clin North Am*. 1990;16:463.
124. Berlin AL, Pehr K. Coexistence of erythromelalgia and Raynaud's phenomenon. *J Am Acad Dermatol*. 2004;50:456.
125. Sunahara JF, Gora-Harper ML, Nash KS. Possible erythromelalgia-like syndrome associated with nifedipine in a patient with Raynaud's phenomenon. *Ann Pharmacother*. 1996;30:484.
126. Wigley FM. Raynaud's phenomenon. *New Engl J Med*. 2002;347:1001.
127. LeRoy EC, Medsger TA. Raynaud's phenomenon: a proposal for classification. *Clin Exp Rheumatol*. 1992;10:485.
128. Ouriel K. Noninvasive diagnosis of upper extremity vascular disease. *Semin Vasc Surg*. 1998;11:54.
129. Greenfield LJ, Rajagopalan S, Olin JW. Upper extremity arterial disease. *Cardiol Clin*. 2002;20:623.
130. Leesmans E, Bartelink ML, Wollersheim H, et al. The relationship between subjective vasospastic complaints and finger blood flow measurements in Raynaud's phenomenon. *Neth J Med*. 1993;43:13.
131. Hirai M, Nielsen SL, Lassen NA. Blood pressure measurement of all five fingers by strain gauge plethysmography. *Scand J Clin Lab Invest*. 1976;36:627.
132. Krahenbuhl B, Nielsen SL, Lassen NA. Closure of digital arteries in high vascular tone states as demonstrated by measurement of systolic blood pressure in the fingers. *Scand J Clin Lab Invest*. 1977;37:71.
133. Sumner D, Strandness DE. An abnormal finger pulse associated with cold sensitivity. *Ann Surg*. 1972;175:294.
134. Porter JM, Snider RL, Bardana EJ, et al. The diagnosis and treatment of Raynaud's phenomenon. *Surgery*. 1975;77:11.
135. Bartelink ML, Wollersheim H, Jansen RW, et al. Reproducibility of the finger cooling test. *Microvasc Res*. 1993;45:65.
136. Bartelink ML, Wollersheim H, Leesmans E, et al. A standardized finger cooling test for Raynaud's phenomenon: diagnostic value and sex differences. *Eur Heart J*. 1993;14:614.
137. Nielsen SL, Lassen NA. Measurement of digital blood pressure after local cooling. *J Appl Physiol*. 1977;43:907.
138. Nielsen SL. Raynaud phenomena and finger systolic pressure during cooling. *Scand J Clin Lab Invest*. 1978;38:765.

139. Gates KH, Tyburczy J, Zupan J, et al. The non-invasive quantification of digital vasospasm. *Bruit*. 1984;8:34.
140. Keberle M, Tony HP, Jahns R, et al. Assessment of microvascular changes in Raynaud's phenomenon and connective tissue disease using colour Doppler ultrasound. *Rheumatology (Oxford)*. 2000;39:1206.
141. Lee SI, Lee SY, Yoo WH. The usefulness of power Doppler ultrasonography in differentiating primary and secondary Raynaud's phenomenon. *Clin Rheumatol*. 2006;25:814.
142. Foerster J, Wittstock S, Fleischanderl S, et al. Infrared-monitored cold response in the assessment of Raynaud's phenomenon. *Clin Exp Dermatol*. 2005;31:6.
143. Foerster J, Kuerth A, Niederstrasser E, et al. A cold-response index for the assessment of Raynaud's phenomenon. *J Dermatol Sci*. 2007;45:113.
144. Del Bianco E, Magini B, Muscarella G, et al. Raynaud's phenomenon (primary or secondary to systemic sclerosis): the usefulness of laser-Doppler flowmetry in the diagnosis. *Int Angiol*. 2001;20:307.
145. Engelhart M, Nielsen HV, Kristensen JK. The blood supply to fingers during Raynaud's attack: a comparison of laser-Doppler flowmetry with other techniques. *Clin Physiol*. 1985;5:447.
146. Cesarone MR, Laurora G, Smith SR, et al. Laser-Doppler flowmetry in the assessment of "mild" Raynaud's phenomenon and its treatment. *Painminerva Med*. 1990;32:151.
147. Hahn M, Klyszcz T, Junger M, et al. Local cold exposure test as therapy control in patients with Raynaud's phenomenon: comparison between laser Doppler fluxmetry and simultaneous red blood cell viscosity measurements in nailfold capillaries. *Br J Dermatol*. 1995;133:704.
148. Kido M, Takeuchi S, Hayashida S, et al. Assessment of abnormal blood flow and efficacy of treatment in patients with systemic sclerosis using a newly developed microwireless laser Doppler flowmeter and arm-raising test. *Br J Dermatol*. 2007;157:690.
149. Murray AK, Herrick AL, King TA. Laser Doppler imaging: a developing technique for application in the rheumatic diseases. *Rheumatology*. 2004;43:1210.
150. Bornmyr S, Castenfors F, Evander E, et al. Effect of local cold provocation on systolic blood pressure and skin flow in the finger. *Clin Physiol*. 2001;21:570.
151. Clark S, Campbell F, Moore T, et al. Laser Doppler imaging—a new technique for quantifying microcirculatory flow in patients with primary Raynaud's phenomenon and systemic sclerosis. *Microvasc Res*. 1999;57:284.
152. Anderson ME, Moore TL, Hollis S, et al. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. *Rheumatology*. 2002;41:324.
153. Seifalian AM, Stansby G, Jackson A, et al. Comparison of laser Doppler perfusion imaging, laser Doppler flowmetry, and thermographic imaging for the assessment of blood flow in human skin. *Eur J Vasc Surg*. 1994;8:65.
154. Clark S, Dunn G, Moore T, et al. Comparison of thermography and laser Doppler imaging in the assessment of Raynaud's phenomenon. *Microvasc Res*. 2003;66:73.
155. Rofsky NM. MR angiography of the hand and wrist. *Magn Reson Imaging Clin N Am*. 1995;3:345.
156. Miller LM, Morgan RF. Vasospastic disorders: etiology, recognition, and treatment. *Hand Clin*. 1993;9:171.
157. Cutolo M, Grassi W, Cerinic MM. Raynaud's phenomenon and the role of capillaroscopy. *Arthritis Rheum*. 2003;48:3023.
158. Maricq HR. Capillary abnormalities, Raynaud's phenomenon, and systemic sclerosis in patients with localized scleroderma. *Arch Dermatol*. 1992;128:630.
159. Dolezalova P, Young SP, Bacon PA, et al. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. *Ann Rheum Dis*. 2003;62:444.
160. Meli M, Gitzelmann G, Koppensteiner R, et al. Predictive value of nailfold capillaroscopy in patients with Raynaud's phenomenon. *Clin Rheumatol*. 2006;25:153.
161. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. *Ann Intern Med*. 2007;146:797.

162. Ziegler S, Brunner M, Eigenbauer E, et al. Long-term outcome of primary Raynaud's phenomenon and its conversion to connective tissue disease: a 12-year retrospective patient analysis. *Scand J Rheumatol*. 2003;32:343.
163. Hirschl M, Hirschl K, Lenz M, et al. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. *Arthritis Rheum*. 2006;54:1974.
164. Kempson GE, Coggon D, Acheson ED. Electrically heated gloves for intermittent digital ischaemia. *BMJ*. 1983;286:268.
165. Ko GD, Berbrayer D. Effect of ceramic-impregnated "ThermoFlow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. *Altern Med Rev*. 2002;4:32.
166. Goodfield MJ, Hume A, Rowell NR. The acute effects of cigarette smoking on cutaneous blood flow in smoking and non-smoking subjects with and without Raynaud's phenomenon. *Br J Rheumatol*. 1990;29:89.
167. Karavidas MK, Tsai PS, Yucha C, et al. Thermal biofeedback for primary Raynaud's phenomenon: a review of the literature. *Appl Psychophys Biofeedback*. 2006;31:203.
168. Freedman RR. Physiological mechanisms of temperature biofeedback. *Biofeedback Self-Regulat*. 1991;16:95.
169. Freedman RR, Sabharwal SG, Ianni P, et al. Nonneural beta-adrenergic vasodilating mechanism in temperature biofeedback. *Psychosom Med*. 1988;50:394.
170. Surwit RS, Pilon RN, Fenton CH. Behavioral treatment of Raynaud's disease. *J Behav Med*. 1978;1:323.
171. Keefe FJ, Surwit RS, Pilon RN. Biofeedback, autogenic training, and progressive relaxation in the treatment of Raynaud's disease: a comparative study. *J Appl Behav Anal*. 1980;13:3.
172. Raynaud's Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon: results from a randomized clinical trial with 1-year follow-up. *Arch Intern Med*. 2000;160:1101.
173. Belch JJ, Ho M. Pharmacotherapy of Raynaud's phenomenon. *Drugs*. 1996;52:682.
174. Schmidt JF, Valentin N, Nielsen SL. The clinical effect of felodipine and nifedipine in Raynaud's phenomenon. *Eur J Clin Pharmacol*. 1989;37:191.
175. Gjørup T, Hartling OJ, Kelbaek H, et al. Controlled double-blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon. *Eur J Clin Pharmacol*. 1986;31:387.
176. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. *Rheumatology*. 2005;44:145.
177. Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. *Arthritis Rheum*. 2001;44:1841.
178. Weber A, Bounameaux H. Effects of low-dose nifedipine on a cold provocation test in patients with Raynaud's disease. *J Cardiovasc Pharmacol*. 1990;15:853.
179. Maricq HR, Jennings JR, Valter I, et al. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators. *Vasc Med*. 2000;5:135.
180. La Civita L, Pitaro N, Rossi M, et al. Amlodipine in the treatment of Raynaud's phenomenon. *Br J Rheumatol*. 1993;32:524.
181. Ferri C, Cecchetti R, Cini G, et al. Slow-releasing nicardipine in the treatment of Raynaud's phenomena without underlying diseases. *Clin Rheumatol*. 1992;11:76.
182. Wollersheim H, Thien T. Double-blind placebo-controlled crossover study of nicardipine in the treatment of Raynaud's phenomenon. *J Cardiovasc Pharmacol*. 1991;18:813.
183. van Heereveld H, Wollersheim H, Gough K, et al. Intravenous nicardipine in Raynaud's phenomenon: a controlled trial. *J Cardiovasc Pharmacol*. 1988;11:68.
184. Pope J, Fenlon D, Thompson A, et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. *Cochrane Database Syst Rev*. 2000;2:CD000956.

185. Wollersheim H, Thien T. Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects. *J Clin Pharmacol.* 1988;28:1089.
186. Wollersheim H, Thien T, Fennis J, et al. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon. *Clin Pharmacol Ther.* 1986;40:219.
187. Paterna S, Pinto A, Arrostuto A, et al. Raynaud's phenomenon: effects of terazosin. *Minerva Cardioangiol.* 1997;45:215.
188. Wise RA, Wigley FM, White B, et al. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. *Arthritis Rheum.* 2004;50:3994.
189. Teh LS, Manning J, Moore T, et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. *Br J Rheumatol.* 1995;7:636.
190. Franks AG. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. *Lancet.* 1982;1:76.
191. Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud's phenomenon. *Ann Pharmacother.* 2006;40:1998.
192. Tosi S, Marchesoni A, Messina K, et al. Treatment of Raynaud's phenomenon with captopril. *Drugs Exp Clin Res.* 1987;13:37.
193. Rustin MH, Almond NE, Beacham JA, et al. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon. *Br J Dermatol.* 1987;117:751.
194. Janini SD, Scott DG, Coppock JS, et al. Enalapril in Raynaud's phenomenon. *J Clin Pharm Ther.* 1988;13:145.
195. Gliddon AE, Dore CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon. *Arthritis Rheum.* 2007;56:3837.
196. Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. *Arthritis Rheum.* 1999;42:2646.
197. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. *Rheumatology.* 2001;40:1038.
198. Colakoglu M, Cobankara V, Akpolat T. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma. *Ann Pharmacother.* 2007;41:1544.
199. Halcox JPI, Nour KRA, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. *J Am Coll Cardiol.* 2002;40:1232.
200. Levien TL. Phosphodiesterase inhibitors in Raynaud's phenomenon. *Ann Pharmacol.* 2006;40:1388.
201. Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. *Circulation.* 2005;112:2980.
202. Zamiri B, Koman AL, Smith BP, et al. Double-blind, placebo-controlled trial of sildenafil for the management of primary Raynaud's phenomenon [abstract]. *Ann Rheum Dis.* 2004;63(suppl 1):484.
203. Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. *Arch Intern Med.* 2006;166:231.
204. Carlino G. Treatment of Raynaud's phenomenon with tadalafil, a phosphodiesterase-5 inhibitor [abstract]. *Ann Rheum Dis.* 2005;64(suppl 3):258.
205. Rajagopalan S, Pfenninger D, Somers E, et al. Effects of cilostazol in patients with Raynaud's syndrome. *Am J Cardiol.* 2003;92:1310.
206. Selenko-Gebauer N, Duschek N, Minimair G, et al. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan. *Rheumatology.* 2006;45:iii45.
207. Hettema ME, Zhang D, Bootsma H, et al. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. *Ann Rheum Dis.* 2007;66:1398.
208. Kingma K, Wollersheim H, Thien T. Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics

- in severe Raynaud's phenomenon: the acute vasodilatory effect is not sustained. *J Cardiovasc Pharmacol*. 1995;26:388.
209. Torley HI, Madhok R, Capell HA, et al. A double-blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. *Ann Rheum Dis*. 1991;50:800.
  210. Balbir-Gurman A, Braun-Moscovici Y, Livshitz V, et al. Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis. *Clin Rheumatol*. 2007;26:1517.
  211. Wigley FM, Siebold JR, Wise RA, et al. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. *J Rheumatol*. 1992;19:1407.
  212. Scorza R, Caronni M, Mascagni B, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon: a randomized, controlled study. *Clin Exp Rheumatol*. 2001;19:503.
  213. Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomised study. *BMJ*. 1989;298:561.
  214. Marasini B, Massarotti M, Bottasso B, et al. Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon. *Scand J Rheumatol*. 2004;33:253.
  215. Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. *Arthritis Rheum*. 1998;41:670.
  216. Black CM, Halkier-Sorensen L, Belch JJ, et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. *Br J Rheumatol*. 1998;37:952.
  217. Digiacomo R, Kremer J, Shaw D. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. *Am J Med*. 1989;86:158.
  218. Freedman RR, Girgis R, Mayes MD. Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma. *Lancet*. 1999;354:739.
  219. Khan F, Litchfield SJ, McLaren M, et al. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon. *Arthritis Rheum*. 1997;40:352.
  220. Khan F, Belch JJ. Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: effects of oral L-arginine supplementation. *J Rheumatol*. 1999;26:2389.
  221. Muir AH, Robb R, McLaren M, et al. The use of *Ginkgo biloba* in Raynaud's disease: a double-blind placebo-controlled trial. *Vasc Med*. 2002;7:265.
  222. Kashiba H, Ueda Y. Acupuncture to the skin induces release of substance P and calcitonin gene-related peptide from peripheral terminals of primary sensory neurons in the rat. *Am J Chin Med*. 1991;19:189.
  223. Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. *J Intern Med*. 1997;241:119.
  224. Hirschl M, Katzenschlager R, Francesconi C, et al. Low level laser therapy in primary Raynaud's phenomenon—results of a placebo-controlled, double blind intervention study. *J Rheumatol*. 2004;31:2408.
  225. Kaada B. Vasodilation induced by transcutaneous nerve stimulation in peripheral ischemia (Raynaud's phenomenon and diabetic polyneuropathy). *Eur Heart J*. 1982;3:303.
  226. Sibell DM, Colantonio AJ, Stacey BR. Successful use of spinal cord stimulation in the treatment of severe Raynaud's disease of the hands. *Anesthesiology*. 2005;102:225.
  227. Benyamin R, Kramer J, Vallejo R. A case of spinal cord stimulation in Raynaud's phenomenon: can subthreshold sensory stimulation have an effect? *Pain Physician*. 2007;10:43.
  228. Lowell RC, Gloviczki P, Cherry KJ Jr, et al. Cervicothoracic sympathectomy for Raynaud's syndrome. *Int Angiol*. 1993;12:168.
  229. Thune TH, Ladegaard L, Licht PB. Thoracoscopic sympathectomy for Raynaud's phenomenon—a long term follow-up study. *Eur J Vasc Endovasc Surg*. 2006;32:198.

230. Maga P, Kuzdzal J, Nizankowski R, et al. Long-term effects of thoracic sympathectomy on microcirculation in the hands of patients with primary Raynaud disease. *J Thorac Cardiovasc Surg.* 2007;133:1428.
231. Matsumoto Y, Ueyama T, Endo M, et al. Endoscopic thoracic sympathectomy for Raynaud's phenomenon. *J Vasc Surg.* 2002;36:57.
232. Janoff KA, Phinney ES, Porter JM. Lumbar sympathectomy for lower extremity vasospasm. *Am J Surg.* 1985;150:147.
233. Watarida S, Shiraishi S, Fujimura M, et al. Laparoscopic lumbar sympathectomy for lower-limb disease. *Surg Endosc.* 2002;16:500.
234. Balogh B, Mayer W, Vesely M, et al. Adventitial stripping of the radial and ulnar arteries in Raynaud's disease. *J Hand Surg [Am].* 2002;27:1073.
235. Ortensi A, Salsano F, Trinchì S, et al. Microsurgical distal sympathectomy in chronic vasospastic syndromes of the hand. *Int Surg.* 2005;90:88.
236. Gofeld M, Faclier G. Bilateral pain relief after unilateral thoracic percutaneous sympathectomy. *Can J Anesth.* 2006;53:258.
237. Han KR, Kim C, Park EJ. Successful treatment of digital ulcers in a scleroderma patient with continuous bilateral thoracic sympathetic block. *Pain Physician.* 2008;11:91.
238. Van Beek AL, Lim PK, Gear AJL, et al. Management of vasospastic disorders with botulinum toxin A. *Plast Reconstr Surg.* 2007;119:217.

## 第 120 章

1. Buckle PW. Fortnightly review: work factors and upper limb disorders. *BMJ.* 1997;315:1360.
2. *Bureau of Labor Statistics Reports on Survey of Occupational Injuries and Illness in 1977-1989.* Washington, DC: Bureau of Labor Statistics, U.S. Department of Labor; 1990.
3. Rempel DM, Harrison RJ, Barnhart S. Work-related cumulative trauma disorders of the upper extremity. *JAMA.* 1992;267:838.
4. Loriga G. Il lavoro con i martelli pneumatici boll. *Ispett Lavoro.* 1911;2:35.
5. Cottingham CE. Effects of use of air hammer on hands of Indiana stone cutters. *U.S. Bureau of Labor Statistics.* 1918;19:125.
6. Taylor W, Pelmear PL, eds. *Vibration White Finger in Industry.* New York, NY: Academic Press; 1975.
7. Ashe WF, Cook WT, Old JW. Raynaud's phenomenon of occupational origin. *Arch Environ Health.* 1962;5:63.
8. Griffin MJ. *Vibration Injuries of the Hand and Arm: Their Occurrence and the Evolution of Standards and Limits.* London: Her Majesty's Stationery Office; 1980.
9. Yodaiken RE, Jones E, Kunicki R. The Raynaud phenomenon of occupational origin. In: Altura BM, Davis E, eds. *Advances in Microcirculation.* Vol. 12. Basel, Switzerland: Karger; 1985:6.
10. Newem RM. Vibration-induced arterial shear stress: the relationship to Raynaud's phenomenon of occupational origin. *Arch Environ Health.* 1973;26:105.
11. Bovenzi M. Some pathophysiological aspects of vibration-induced white finger. *Eur J Appl Physiol.* 1986;55:381.
12. Pearce WH, Yao JST, Bergan JJ. Noninvasive vascular diagnostic testing. In: Ravitch MM, ed. *Current Problems in Surgery.* Vol. 20. Chicago, IL: Year Book Medical Publishers; 1983.
13. Sumner DS. Vascular laboratory diagnosis and assessment of upper extremity vascular disorders. In: Machleder HI, ed. *Vascular Disorders of the Upper Extremity.* Mt. Kisco, NY: Futura; 1983:1.
14. Nasu Y, Kurozawa Y, Fujiwara Y, et al. Multicenter study on finger systolic blood pressure test for diagnosis of vibration-induced white finger. *Int Arch Occup Environ Health.* 2008;81:639.
15. Payne KM, Blackburn DR, Peterson LK, et al. B-mode imaging of the arteries of the hand and upper extremity. *Bruit.* 1986;10:168.

16. Barker NW, Hines EA Jr. Arterial occlusion in the hands and fingers associated with repeated occupational trauma. *Mayo Clin Proc.* 1944;19:345.
17. Shatz JJ. Occlusive arterial disease in the hand due to occupational trauma. *N Engl J Med.* 1963;268:281.
18. Ashe WF, Williams N. Occupational Raynaud's: II. Further studies of this disorder in uranium mine workers. *Arch Environ Health.* 1964;9:425.
19. Wegelius U. Angiography of the hand: clinical and postmortem investigations. *Acta Radiol Suppl (Stockh).* 1972;315:1.
20. Griffin MJ, Bovenzi M, Nelson CM. Dose-response patterns for vibration-induced white finger. *Occup Environ Med.* 2003;60:16.
21. Bartel P, Blackburn D, Peterson L, et al. The value of noninvasive tests in occupational trauma of the hands and fingers. *Bruitt.* 1984;8:15.
22. Threshold limit values approved by ACGIH for hand-arm vibration. *Noise Regul Report.* 1984;11:3.
23. Kahan A, Amor B, Menkes CJ. Nifedipine and allied substances in the treatment of Raynaud's phenomenon. In: Altura BM, Davis E, eds. *Advances in Microcirculation.* Vol. 12. Basel, Switzerland: Karger; 1985:95.
24. Chetter IC, Kent PJ, Kester RC. The hand arm vibration syndrome: a review. *Cardiovasc Surg.* 1998;6:1.
25. Kleinert HE, Burget GC, Morgan JA, et al. Aneurysms of the hand. *Arch Surg.* 1973;106:554.
26. Conn J, Bergan JJ, Bell JL. Hypothenar hammer syndrome: post-traumatic digital ischemia. *Surgery.* 1970;68:1122.
27. Von Rosen S. Ein Fall von Thrombose in der Arteria ulnaris nach Einwirkung von stumpfer Gewalt. *Acta Chir Scand.* 1934;73:500.
28. Short DW. Occupational aneurysm of the palmar arch. *Lancet.* 1948;2:217.
29. Pineda CJ, Weisman MH, Bookstein JJ, et al. Hypothenar hammer syndrome: form of reversible Raynaud's phenomenon. *Am J Med.* 1985;79:561.
30. Little JM, Ferguson DA. The incidence of the hypothenar hammer syndrome. *Arch Surg.* 1972;105:684.
31. Ferris BL, Taylor LM Jr, Oyama K, et al. Hypothenar hammer syndrome: proposed etiology. *J Vasc Surg.* 2000;31:104.
32. Winterer JT, Ghanem N, Roth M, et al. Diagnosis of the hypothenar hammer syndrome by high-resolution contrast-enhanced MR angiography. *Eur Radiol.* 2002;12:2457.
33. Blum AG, Zabel JP, Kohlmann R, et al. Pathologic conditions of the hypothenar eminence: evaluation with multidetector CT and MR imaging. *Radiographics.* 2006;26:1021.
34. Marie I, Hervé F, Primard E, et al. Long-term follow up of hypothenar hammer syndrome: a series of 47 patients. *Medicine (Baltimore).* 2007;86:334.
35. Vayssairat M, Debure C, Cormier J, et al. Hypothenar hammer syndrome: seventeen cases with long-term follow-up. *J Vasc Surg.* 1987;5:838.
36. Wilson R, McCormick W, Tattum C, et al. Occupational acro-osteolysis. *JAMA.* 1967;201:577.
37. Bookstein JJ. Arteriography. In: Poznanski AK, ed. *The Hand in Radiologic Diagnosis with Gamuts and Pattern Profiles.* Vol. 1. 2nd ed. Philadelphia, PA: WB Saunders; 1984:97.
38. Veltman G. Raynaud's syndrome in vinylchloride disease. In: Heidrich H, ed. *Raynaud's Phenomenon.* Berlin: TM-Verlag; 1979:11.
39. Falappa P, Magnavita N, Bergamaschi A, et al. Angiographic study of digital arteries in workers exposed to vinyl chloride. *Br J Ind Med.* 1982;39:169.
40. d'Amato TA, Kaplan IB, Britt LD. High-voltage electrical injury: a role for mandatory exploration of deep muscle compartments. *J Natl Med Assoc.* 1994;86:535.
41. Wang X, Roberts BB, Zapata-Sirvent RL, et al. Early vascular grafting to prevent upper extremity necrosis after electrical burns: commentary on indications for surgery. *Burns.* 1985;11:359.
42. Kaminski M, Bourguin M, Zins M, et al. Risk factors for Raynaud's phenomenon among workers in poultry slaughterhouses and canning factories. *Int J Epidemiol.* 1997;26:371.



43. Mackiewicz Z, Piskorz A. Raynaud's phenomenon following long-term repeated action or great differences of temperature. *J Cardiovasc Surg (Torino)*. 1977;18:151.
44. Tullos HS, Erwin WD, Woods GW, et al. Unusual lesions of the pitching arm. *Clin Orthop Relat Res*. 1972;88:169.
45. Fields WS, Lemak NA, Ben-Menachem Y. Thoracic outlet syndrome: review and reference to stroke in a major league pitcher. *AJNR Am J Neuroradiol*. 1986;7:73.
46. Green DP. True and false traumatic aneurysms in the hand: report of two cases and review of the literature. *J Bone Joint Surg Am*. 1973;55:120.
47. Ho PK, Dellon AL, Wilgis EFS. True aneurysms of the hand resulting from athletic injury: report of two cases. *Am J Sports Med*. 1985;13:136.
48. Arko FR, Harris EJ, Zarins CK, Olcott C IV. Vascular complications in high-performance athletes. *J Vasc Surg*. 2001;33:935.
49. Noel B, Hayoz D. A tennis player with hand claudication. *Vasa*. 2000;29:151.
50. Buckhout BC, Warner MA. Digital perfusion of handball players: effects of repeated ball impact on structures of the hand. *Am J Sports Med*. 1980;8:206.
51. McCue FC III, Miller GA. Soft-tissue injuries to the hand. In: Pettrone FA, ed. *Upper Extremity Injuries in Athletes*. St Louis, MO: CV Mosby; 1986:85.
52. Lowrey CW. Digital vessel trauma from repetitive impacts in baseball catchers. *J Hand Surg*. 1976;1:236.
53. Itoh Y, Wakano K, Takeda T, Murakami T. Circulatory disturbances in the throwing hand of baseball pitchers. *Am J Sports Med*. 1987;15:264.
54. Cahill B, Palmer R. Quadriateral space syndrome. *J Hand Surg*. 1983;8:65.
55. McLelland D, Paxinos A. The anatomy of the quadriateral space with reference to quadriateral space syndrome. *J Shoulder Elbow Surg*. 2008;17:162.
56. McAdams TR, Dillingham MF. Surgical decompression of the quadriateral space in overhead athletes. *Am J Sports Med*. 2008;36:528.
57. McLeod WD. The pitching mechanism. In: Zarins B, Andrews JR, Carson WG Jr, eds. *Injuries to the Throwing Arm*. Philadelphia, PA: WB Saunders; 1985:22.
58. Sain J, Andrews JR. Proper pitching techniques. In: Zarins B, Andrews JR, Carson WG Jr, eds. *Injuries to the Throwing Arm*. Philadelphia, PA: WB Saunders; 1985:34.
59. Strukel RJ, Garrick JG. Thoracic outlet compression in athletes: a report of four cases. *Am J Sports Med*. 1978;6:35.
60. Fields WS. Neurovascular syndromes of the neck and shoulders. *Semin Neurol*. 1981;1:301.
61. McCarthy WJ, Yao JST, Schafer MF, et al. Upper extremity arterial injury in athletes. *J Vasc Surg*. 1989;9:317.
62. Jones HH, Priest JD, Hayes WC, et al. Humeral hypertrophy in response to exercise. *J Bone Joint Surg Am*. 1977;59:204.
63. Nijhuis HHAM, Muller-Wiefel H. Occlusion of the brachial artery by thrombus dislodged from a traumatic aneurysm of the anterior humeral circumflex artery. *J Vasc Surg*. 1991;13:408.
64. Rohrer MJ, Cardullo PA, Pappas AM, et al. Axillary artery compression and thrombosis in throwing athletes. *J Vasc Surg*. 1990;11:761.
65. Reekers JA, den Hartog BMG, Kuyper CF, et al. Traumatic aneurysm of the posterior circumflex humeral artery: a volleyball player's disease? *J Vasc Interv Radiol*. 1993;4:405.
66. Kee ST, Dake MD, Wolfe-Johnson B, et al. Ischemia of the throwing hand in major league baseball pitchers: embolic occlusion from aneurysms of axillary artery branches. *J Vasc Interv Radiol*. 1995;6:979.
67. Durham JR, Yao JST, Pearce WH, et al. Arterial injuries in the thoracic outlet syndrome. *J Vasc Surg*. 1995;21:57.
68. Dale WA. Thoracic outlet compression syndrome. In: Dale WA, ed. *Management of Vascular Surgical Problems*. New York, NY: McGraw-Hill; 1985:562.
69. Baker CL, Thornberry R. Neurovascular syndromes. In: Zarins B, Andrews JR, Carson WG Jr, eds. *Injuries to the Throwing*

- Arm. Philadelphia, PA: WB Saunders; 1985:176.
70. Vogel CM, Jensen JE. "Effort" thrombosis of the subclavian vein in a competitive swimmer. *Am J Sports Med.* 1985;13:269.
  71. Ishitobi K, Moteki K, Nara S, et al. Extra-anatomic bypass graft for management of axillary artery occlusion in pitchers. *J Vasc Surg.* 2001;33:797.
  72. Lee WA, Hill B, Harris EJ Jr, et al. Surgical intervention is not required for all patients with subclavian vein thrombosis. *J Vasc Surg.* 2000;32:57.
  73. Azakie A, McElhinney DB, Thompson RW, et al. Surgical management of subclavian-vein effort thrombosis as a result of thoracic outlet compression. *J Vasc Surg.* 1998;28:777.
  74. Kreienberg PB, Chang BB, Darling RC III, et al. Long-term results in patients treated with thrombolysis, thoracic inlet decompression, and subclavian vein stenting for Paget-Schroetter syndrome. *J Vasc Surg.* 2001;33:S100.
  75. AbuRahma AF, Robinson PA. Effort subclavian vein thrombosis: Evolution of management. *J Endovasc Ther.* 2000;7:302.

## 第 121 章

1. Langley JN. Observations on the medullated fibres of the sympathetic system and chiefly on those of the grey rami communicantes. *J Physiol.* 1896;20:55.
2. Alexander W. *The Treatment of Epilepsy*. Edinburgh: YJ Pentland; 1889.
3. Jonnesco T. Resección totala și bilaterală a simpaticului cervical în cazuri de epilepsie și gusa exoftalmică. *România Măd.* 1896;4:479.
4. Jaboulay M. Le traitement de quelques troubles trophiques du pied et de la jambe par la dénudation de l'artère fémorale et la distension des nerfs vasculaires. *Lyon Med.* 1899;91:467.
5. Jonnesco T. *Le Sympathique Cervico-thoracique*. Paris: Mason; 1923.
6. Kotzareff A. Résection partielle du tronc sympathique cervical droit pour hyperhidrose unilatérale (régions faciale, cervicale, thoracique et brachiale droites). *Rev Med Suisse Rom.* 1920;40:111.
7. Hunter J. The influence of the sympathetic nervous system in the genesis of the rigidity of striated muscles in spastic paralysis. *Surg Gynecol Obstet.* 1924;39:721.
8. Diez J. Un nuevo método de simpatectomía periférica para el tratamiento de las afecciones tróficas y gangrenosas de los miembros. *Biol Soc Cir Buenos Aires.* 1924;8:792.
9. Telford ED. The technique of sympathectomy. *Br J Surg.* 1935;23:448.
10. Atkins HJB. Sympathectomy by the axillary approach. *Lancet.* 1954;1:538.
11. Adson AW, Brown GE. Treatment of Raynaud's disease of the upper extremities; successful treatment by resection of the sympathetic cervicothoracic and second thoracic ganglions and the intervening trunk. *JAMA.* 1929;92:444.
12. Cloward RB. Hyperhidrosis. *J Neurosurg.* 1969;30:545.
13. Goetz RH, Marr JAS. Importance of the second thoracic ganglion for sympathetic supply of the upper extremities with a description of 2 new approaches for its removal in cases of vascular surgery. *Clin Proc.* 1944;3:102.
14. Jacobaeus HC. Possibility of the use of the cystoscope for the investigation of serous cavities. *Munch Med Wochenschr.* 1910;57:2090.
15. Hughes J. Endothoracic sympathectomy. *Proc R Soc Med.* 1942;35:585.
16. Kux E. 1239 Cases of thorascopic sympathectomy and vagotomy; preliminary report. *Dtsch Med Wochenschr.* 1953;78:1590.
17. Lin CC. A new method of thorascopic sympathectomy in hyperhidrosis palmaris. *Surg Endosc.* 1990;4:224-226.
18. Lee LS, Ng SM, Lin CC. Single-lumen endotracheal intubated anaesthesia for thorascopic sympathectomy—experience of 719 cases. *Eur J Surg.* 1994;(Suppl.)27-31.
19. Albazaz R, Wong YT, Homer-Vanniasinkam S. Complex regional pain syndrome: a review. *Ann Vasc Surg.* 2008;22:297.
20. Stephenson EA, Berul CI. Electrophysiological interventions for inherited arrhythmia syndromes. *Circulation.*

2007;116:1062.

21. Maga P, Kuzdzal J, Nizankowski R, et al. Long-term effects of thoracic sympathectomy on microcirculation in the hands of patients with primary Raynaud disease. *J Thorac Cardiovasc Surg.* 2007;133:1428.
22. Adar R, Kurchin A, Zweig A, et al. Palmar hyperhidrosis and its surgical treatment. *Ann Surg.* 1977;186:34.
23. Strutton DR, Kowalski JW, Glaser DA, et al. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. *J Am Acad Dermatol.* 2004;51:241.
24. Bonde P, Nwaejike N, Fullerton C, et al. An objective assessment of the sudomotor response after thoracoscopic sympathectomy. *J Thorac Cardiovasc Surg.* 2008;135:635-641.
25. Hamm H, Naumann MK, Kowalski JW, et al. Primary focal hyperhidrosis: disease characteristics and functional impairment. *Dermatology.* 2006;212:343.
26. Hurley HJ: Diseases of the eccrine sweat glands. In: Moschella SL, Hurley HJ, eds. *Dermatology*. 3rd ed. Philadelphia, PA: WB Saunders; 1992:1514.
27. Neumayer C, Panhofer P, Zacherl J, et al. Effect of endoscopic thoracic sympathetic block on plantar hyperhidrosis. *Arch Surg.* 2005;140:676.
28. Licht PB, OléDJ, Ladegaard L, et al. Thoracoscopic sympathectomy for axillary hyperhidrosis: the influence of T4. *Ann Thorac Surg.* 2005;80:455.
29. Drott C, Claes G, Olsson-Rex L, et al. Successful treatment of facial blushing by endoscopic transthoracic sympathectomy. *Br J Dermatol.* 1998;138:639.
30. Nyamekye IK. Current therapeutic options for treating primary hyperhidrosis. *Eur J Vasc Endovasc Surg.* 2004;27:571.
31. Kauffman P, de Campos JRM, Wolosker N, et al. Thoracoscopic cervicothoracic sympathectomy: an eight-year experience. *J Vasc Bras.* 2003;2:22.
32. Paraskevas KI. Treatment-of-choice for Buerger's disease (thromboangiitis obliterans): still an unresolved issue. *Clin Rheumatol.* 2008;27:547.
33. Olin JW, Shih A. Thromboangiitis obliterans (Buerger's disease). *Curr Opin Rheumatol.* 2006;18:18.
34. Sayin A, Bozkurt AK, Tüzün H, et al. Surgical treatment of Buerger's disease: experience with 216 patients. *Cardiovasc Surg.* 1993;1:377.
35. Merskey H, Bogduk N. *Classification of Chronic Pain*. 2nd ed. Seattle, WA: IASP Press; 1994.
36. Osenbach RK. Complex regional pain syndromes. *Semin Neurosurg.* 2004;15:81.
37. Hassantash SA, Afrakhteh M, Maer RV. Causalgia: a meta-analysis of the literature. *Arch Surg.* 2003;138:1226.
38. Singh B, Moodley J, Shaik AS, et al. Sympathectomy for complex regional pain syndrome. *J Vasc Surg.* 2003;37:508.
39. Cepeda MS, Carr DB, Lau J. Local anesthetic sympathetic blockade for complex regional pain syndrome. *Cochrane Database Syst Rev.* 2005;4:CD004598.
40. Koulousakis A, Kuchta J, Bayarassou A, et al. Intrathecal opioids for intractable pain syndromes. *Acta Neurochir Suppl.* 2007;97:43.
41. Cruccu G, Aziz TZ, Garcia-Larrea L, et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. *Eur J Neurol.* 2007;14:952.
42. Furlan AD, Lui PW, Mailis A. Chemical sympathectomy for neuropathic pain: does it work? Case report and systematic literature review. *Clin J Pain.* 2001;17:327.
43. Schwartz PJ, Locati EH, Moss AJ, et al. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. *Circulation.* 1991;84:503.
44. Han PP, Kenny K, Dickman CA. Thoracoscopic approaches to the thoracic spine: experience with 241 surgical procedures. *Neurosurgery.* 2002;51(5 Suppl):S88.
45. Goetz RH. Sympathectomy for the upper extremities. In: Dale WA, ed. *Management of Arterial Occlusive Disease*. Chicago. IL: Year Book Medical Publishers; 1971:431.

46. Kauffman P, Cinelli M Jr, Wolosker M, et al. Treatment of palmar hyperhidrosis by cervico-thoracic sympathectomy. *Rev Assoc Med Bras.* 1978;24:29.
47. Krasna MJ. Thoracoscopic sympathectomy: a standardized approach to therapy for hyperhidrosis. *Ann Thorac Surg.* 2008;85:S764.
48. Harris RJ, Benveniste G, Pfitzner J. Cardiovascular collapse caused by carbon insufflation during one-lung anesthesia for thoracoscopic dorsal sympathectomy. *Anaesth Intensive Care.* 2002;30:86.
49. Lin TS. Video-assisted thoracoscopic “resympathicotomy” for palmar hyperhidrosis: analysis of 42 cases. *Ann Thorac Surg.* 2001;72:895-898.
50. Reisfeld R. Azygos lobe in endoscopic thoracic sympathectomy for hyperhidrosis. *Surg Endosc.* 2005;19:964.
51. Assalia A, Bahouth H, Ilivitzki A, et al. Thoracoscopic sympathectomy for primary palmar hyperhidrosis: resection versus transection—a prospective trial. *World J Surg.* 2007;31:1978.
52. Lin CC, Mo LR, Lee LS, et al. Thoracoscopic T2 block by clipping: a better and reversible operation for the treatment of hyperhidrosis palmaris: experience with 326 cases. *Eur J Surg.* 1998;164(Suppl 580):13.
53. Whitson BA, Andrade RS, Dahlberg PS, et al. Evolution of clipping for thoracoscopic sympathectomy in symptomatic hyperhidrosis. *Surg Laparosc Endosc Percutan Tech.* 2007;17:287.
54. Lee AD, Agarwal S, Sadhu D. A 7-year experience with thoracoscopic sympathectomy for critical upper limb ischemia. *World J Surg.* 2006;30:1644.
55. de Campos JR, Wolosker N, Takeda FR, et al. The body mass index and level of resection: predictive factors for compensatory sweating after sympathectomy. *Clin Auton Res.* 2005;15:116.
56. Lin TS, Wang NP, Huang LC. Pitfalls and complication avoidance associated with transthoracic endoscopic sympathectomy for primary hyperhidrosis (analysis of 2200 cases). *Int J Surg Invest.* 2001;2:377.
57. Amjadi K, Alvarez GG, Vanderhelst E, et al. The prevalence of blebs or bullae among young healthy adults: a thoracoscopic investigation. *Chest.* 2007;132:1140.
58. Shachor D, Jedeikin R, Olsfanger D, et al. Endoscopic transthoracic sympathectomy in the treatment of primary hyperhidrosis. A review of 290 sympathectomies. *Clin Auton Res.* 1992;2:349.
59. Atherton WG, Morgan WE. False aneurysm of an intercostal artery after thoracoscopic sympathectomy. *Ann R Coll Surg Engl.* 1997;79:229.
60. Serra Mitjans M, Callejas Pérez MA, Rubio Garay M. Chylothorax after thoracic sympathectomy by videothorascopy *Arch Bronconeumol.* 2002;38:198.
61. Jedeikin R, Olsfanger D, Shachor D. Intraoperative anaesthetic management of hypoxaemia during transthoracic endoscopic sympathectomy. *Eur J Surg Suppl.* 1994;572:23.
62. Noppen M, Dendale P, Hagers Y, et al. Changes in cardiocirculatory anatomic function after thoracoscopic upper dorsal sympaticolysis for essential hyperhidrosis. *J Auton Nerv Syst.* 1996;60:115.
63. Lin CC, Mo LR, Hwang MH. Intraoperative cardiac arrest: a rare complication of T2,3-sympathicotomy for treatment of hyperhidrosis palmaris. Two case reports. *Eur J Surg Suppl.* 1994;572:43.
64. Herbst F, Plas EG, Fugger R, et al. Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limbs. A critical analysis and long-term results of 480 operations. *Ann Surg.* 1994;220:86.
65. Chon SH, Suk Choi MS. Brachial plexus injury with emphasis on axillary nerve paralysis after thoracoscopic sympathectomy for axillary hyperhidrosis. *Surg Laparosc Endosc Percutan Tech.* 2006;16:432.
66. Gossot D, Kabiri H, Caliendo R, et al. Early complications of thoracic endoscopic sympathectomy: a prospective study of 940 procedures. *Ann Thoracic Surg.* 2001;71:1116.
67. Chung K, Chung JM. Sympathetic sprouting in the dorsal root ganglion after spinal nerve ligation: evidence of regenerative collateral sprouting. *Brain Res.* 2001;895:204.
68. Murray JG, Thompson JW. Collateral sprouting in autonomic nervous system. *Br Med Bull.* 1957;13:213.

69. Singh B, Moodley J, Allopi L, et al. Horner syndrome after sympathectomy in the thoracoscopic era. *Surg Laparosc Endosc Percutan Tech.* 2006;16:222.
70. Chung IH, Oh CS, Koh KS, et al. Anatomic variations of the T2 nerve root (including the nerve of Kuntz) and their implications for sympathectomy. *J Thorac Cardiovasc Surg.* 2002;123:498.
71. Yano M, Kiriya M, Fukai I, et al. Endoscopic thoracic sympathectomy for palmar hyperhidrosis: efficacy of T2 and T3 ganglion resection. *Surgery.* 2005;138:40.
72. Yazbek G, Wolosker N, de Campos JR, et al. Palmar hyperhidrosis—which is the best level of denervation using video-assisted thoracoscopic sympathectomy: T2 or T3 ganglion? *J Vasc Surg.* 2005;42:281.
73. Wolosker N, Yazbek G, Ishy A, et al. Is sympathectomy at T4 level better than at T3 level for treating palmar hyperhidrosis? *J Laparoendosc Adv Surg Tech A.* 2008;18:102.
74. Yoon DH, Ha Y, Park YG, et al. Thoracoscopic limited T-3 sympathicotomy for primary hyperhidrosis: prevention for compensatory hyperhidrosis. *J Neurosurg.* 2003;99(1 Suppl):39.
75. Lin CC, Mo LR, Lee LS, et al. Thoracoscopic T2 block by clipping: a better and reversible operation for the treatment of hyperhidrosis palmaris: experience with 326 cases. *Eur J Surg.* 1998;164(Suppl 580):13.
76. Whitson BA, Andrade RS, Dahlberg PS, et al. Evolution of clipping for thoracoscopic sympathectomy in symptomatic hyperhidrosis. *Surg Laparosc Endosc Percutan Tech.* 2007;17:287.
77. Reisfeld R, Nguyen R, Phini A. Endoscopic thoracic sympathectomy for hyperhidrosis: experience with both cauterization and clamping methods. *Surg Laparosc Endosc Percutan Tech.* 2002;12:255.
78. Ribas Milanez de Campos J, Kauffman P, Wolosker N, et al. Axillary hyperhidrosis: T3/T4 versus T4 thoracic sympathectomy in a series of 276 cases. *J Laparoendosc Adv Surg Tech A.* 2006;16:598.
79. Munia MA, Wolosker N, Kauffman P, et al. A randomized trial of T3-T4 versus T4 sympathectomy for isolated axillary hyperhidrosis. *J Vasc Surg.* 2007;45:130.
80. Kwong KF, Hobbs JL, Cooper LB, et al. Stratified analysis of clinical outcomes in thoracoscopic sympathicotomy for hyperhidrosis. *Ann Thorac Surg.* 2008;85:390.
81. Kao MC. Thoracoscopic sympathectomy for craniofacial hyperhidrosis. *Eur J Cardiothorac Surg.* 2001;19:951.
82. Telaranta T. Secondary sympathetic chain reconstruction after endoscopic thoracic sympathicotomy. *Eur J Surg.* 1998;164:17.
83. Lin CC, Wu HH. Endoscopic T4-sympathetic block by clamping (ESB4) in treatment of hyperhidrosis palmaris and axillaries: experiences of 165 cases. *Ann Chir Gynaecol.* 2001;90:167.
84. Ouriel K, Moss AJ. Long QT syndrome: an indication for cervicothoracic sympathectomy. *Cardiovasc Surg.* 1995;3:475.
85. Doolabh N, Horswell S, Williams M, et al. Thoracoscopic sympathectomy for hyperhidrosis: indications and results. *Ann Thorac Surg.* 2004;77:410.
86. Dumont P, Denoyer A, Robin P. Long-term results of thoracoscopic sympathectomy for hyperhidrosis. *Ann Thorac Surg.* 2005;78:1801.
87. Dewey TM, Herbert MA, Hill SL, et al. One year follow-up after thoracoscopic sympathectomy for hyperhidrosis: outcomes and consequences. *Ann Thorac Surg.* 2006;81:1227.
88. Gossot D, Debrosse D, Grunenwald D. Endoscopic thoracic sympathectomy for isolated axillary hyperhidrosis. *Ann Dermatol Venereol.* 2000;127:1065.
89. Lin TS, Fang HY. Transthoracic endoscopic sympathectomy for craniofacial hyperhidrosis: analysis of 46 cases. *J Laparoendosc Adv Surg Tech A.* 2000;10:243.
90. de Campos JR, Kauffman P, Wolosker N, et al. Quality of life, before and after thoracic sympathectomy: report on 378 operated patients. *Ann Thorac Surg.* 2003;76:886.
91. Wolosker N, Yazbek G, Milanez de Campos JR, et al. Evaluation of plantar hyperhidrosis in patients undergoing video-assisted thoracoscopic sympathectomy. *Clin Auton Res.* 2007;17:172.

92. Asking B, Svartholm E. Degeneration activity: a transient effect following sympathectomy for hyperhidrosis. *Eur J Surg.* 1994;572:41.
93. Licht PB, Pilegaard HK. Gustatory side effects after thoracoscopic sympathectomy. *Ann Thorac Surg.* 2006;81:1043.
94. Libson S, Kirshtein B, Mizrahi S, et al. Evaluation of compensatory sweating after bilateral thoracoscopic sympathectomy for palmar hyperhidrosis. *Surg Laparosc Endosc Percutan Tech.* 2007;17:511.
95. Steiner Z, Kleiner O, HersHKovitz Y, et al. Compensatory sweating after thoracoscopic sympathectomy: an acceptable trade-off. *J Pediatr Surg.* 2007;42:1238.
96. Baumgartner F, Konecny J. Compensatory hyperhidrosis after sympathectomy: level of resection versus location of hyperhidrosis. *Ann Thorac Surg.* 2007;84:1422.
97. Steiner Z, Cohen Z, Kleiner O, et al. Do children tolerate thoracoscopic sympathectomy better than adults? *Pediatr Surg Int.* 2008;24:343.
98. Sanni A, Hamid A, Dunning J. Is sympathectomy of benefit in critical leg ischaemia not amenable to revascularisation? *Interact Cardiovasc Thorac Surg.* 2005;4:478.
99. Ishibashi H, Hayakawa N, Yamamoto H, et al. Thoracoscopic sympathectomy for Buerger's disease: a report on the successful treatment of four patients. *Surg Today.* 1995;25:180.
100. De Giacomo T, Rendina EA, Venuta F, et al. Thoracoscopic sympathectomy for symptomatic arterial obstruction of the upper extremities. *Ann Thorac Surg.* 2002;74:885.
101. Krasna MJ, Jiao X, Sonett J, et al. Thoracoscopic sympathectomy. *Surg Laparosc Endosc Percutan Tech.* 2000;10:314.
102. Ouriel K, Moss AJ. Long QT syndrome: an indication for cervicothoracic sympathectomy. *Cardiovasc Surg.* 1995;3:475.
103. Matsumoto Y, Ueyama T, Endo M, et al. Endoscopic thoracic sympathicotomy for Raynaud's phenomenon. *J Vasc Surg.* 2002;36:57.
104. Thune TH, Ladegaard L, Licht PB. Thoracoscopic sympathectomy for Raynaud's phenomenon: a long term follow-up study. *Eur J Vasc Endovasc Surg.* 2006;32:198.
105. Coffman JD. Raynaud's phenomenon. *Curr Treat Options Cardiovasc Med.* 2000;2:219.

## 第 122 章

1. Cooper A. On exostosis. In: Cooper AP, Travers B, eds. *Surgical Essays*. 3<sup>rd</sup> ed. 1821:128.
2. Coote H. Exostosis of the left transverse process of the seventh cervical vertebra, surrounded by blood vessels and nerves; successful removal. *Lancet.* 1861;1:360-361.
3. Hodgson. *Diseases of Arteries and Veins*. 1815:262.
4. Cooper AP, Travers B. *Surgical Essay*. 1818:173.
5. Benedik L. Raynaudscher symptomkomplex bei Halsrippe. *Dtsche Z Nervenhe.* 1924;82:217.
6. Billington W. Excision of subclavian aneurysm associated with cervical rib. *Br J Surg.* 1924;19:334.
7. Luke CJ, Fountain EM. Vasospasm and occlusive arterial changes in the fingers due to cervical rib. *CMAJ.* 1950;62:379.
8. Schein CJ, Haimovici H, Young H. Recent advances in surgery: arterial thrombosis associated with cervical ribs: surgical considerations. Report of a case and review of the literature. *Surgery.* 1956;40:428-443.
9. Halsted WH. An experimental study of circumscribed dilation of an artery immediately distal to a partially occluded band, and its bearing on the dilation of the subclavian artery observed in certain cases of cervical rib. *J Exp Med.* 1916;24:271-286.
10. Roach MR. Changes in arterial distensibility as a cause of poststenotic dilatation. *Am J Cardiol.* 1963;12:802-815.
11. Petronio R. Su un caso di trombosi della subclavia in soggetto concosta cervicale. *Ospedale Maggiore (Milano).* 1952;40:488.
12. Judy KL, Heymann RL. Vascular complications thoracic outlet syndrome. *Am J Surg.* 1972;123:521-531.
13. Peet RM, Hendriksen JD, Anderson TP, Martin GM. Thoracic outlet syndrome: evaluation of a therapeutic exercise program. *Proc Mayo Clin.* 1956;31:281-287.

14. Hunauld. Sur le nombre des cotes, moindre ou plus grand qu a l'ordinaire. *Hist Acad Roy d Sc de Paris*, 1740.
15. Gruber W. *Ueber die Halsrippen des Menschen mit Vergleichend-anatomischen*. St. Petersburg: Bemerkungen; 1869.
16. Todd TW. The descent of the shoulder after birth: its significance in the production of pressure-symptoms on the lowest brachial trunk. *Anat Anz*. 1912;41:385-397.
17. Jones FW. Discussion on cervical ribs: the anatomy of cervical ribs. *Proc R Soc Med*. 1913;6:95-112.
18. Murphy JB. Cervical rib excision: collective review on surgery of cervical rib. *Clin John B Murphy*. 1916;5:227-240.
19. Law AA. Adventitious ligaments simulating cervical ribs. *Ann Surg*. 1920;72:497-499.
20. Roos DB. Congenital anomalies associated with thoracic outlet syndrome: anatomy, symptoms, diagnosis and treatment. *Am J Surg*. 1976;132:771-778.
21. Adson AW, Coffey JR. Cervical rib: a method of anterior approach for relief of symptoms by division of the scalenus anticus. *Ann Surg*. 1927;85:839-857.
22. Adson AW. Surgical treatment for symptoms produced by cervical ribs and the scalenus anticus muscle. *Surg Gynecol Obstet*. 1947;85:687-700.
23. Ochsner A, Gage M, Debaquey M. Scalenus anticus (Naffziger) syndrome. *Am J Surg*. 1935;28:669-695.
24. Naffziger HC, Grant WT. Neuritis of the brachial plexus mechanical in origin: the scalenus origin. *Surg Gynecol Obstet*. 1938;67:722-729.
25. Eden KC. Complications of cervical rib: vascular complications of cervical ribs and first thoracic rib abnormalities. *Br J Surg*. 1939-40;27:111-139.
26. Falconer MA, Weddell G. Costoclavicular compression of the subclavian artery and vein. *Lancet*. 1943;2:539-543.
27. Gage M, Parnell H. Scalenus anticus syndrome. *Am J Surg*. 1947;73:252-268.
28. Lord JW Jr. Surgical management of shoulder girdle syndromes: new operative procedure for hyperabduction, costoclavicular, cervical rib, and scalenus syndromes. *Arch Surg*. 1953;60:69-83.
29. Pairolero PC, Walls JT, Payne WS, et al. Subclavian-axillary artery aneurysms. *Surgery*. 1981;90:757-763.
30. Bramwell E. Lesion of the first dorsal nerve root. *Rev Neurol Psychiatry*. 1903;1:236-239.
31. Murphy T. Brachial neuritis caused by pressure of first rib. *Aust Med J*. 1910;15:582-585.
32. Stopford JS, Telford ED. Compression of the lower trunk of the brachial plexus by a first dorsal rib: with a note on the surgical treatment. *Br J Surg*. 1919;7:168-177.
33. Keen WW. The symptomatology, diagnosis, and surgical treatment of cervical ribs. *Am J Med Sci*. 1907;133:173-218.
34. Sanders RJ, Haug CE. *Thoracic Outlet Syndrome: A Common Sequela of Neck Injuries*. Philadelphia, PA: JB Lippincott; 1991:226.
35. Telford ED, Mottershead S. The costoclavicular syndrome. *BMJ*. 1947;1:325-328.
36. Telford ED, Mottershead S. Pressure at the cervico-brachial junction: an operative and anatomical study. *J Bone Joint Surg*. 1948;30:249-265.
37. Kirgis HD, Reed AF. Significant anatomic relations in the syndrome of the scalene muscles. *Ann Surg*. 1948;127:1182-1201.
38. Wright IS. The neurovascular syndrome produced by hyperabduction of the arms. The immediate changes produced in 150 normal controls, and the effects on same persons of prolonged hyperabduction of the arms, as in sleeping, and in certain occupations. *Am Heart J*. 1945;29:1-19.
39. Rob CG, Standeven A. Arterial occlusion complicating thoracic outlet compression syndrome. *BMJ*. 1958;2:709-712.
40. Clagett OT. Presidential address: research and prosearch. *J Thorac Cardiovasc Surg*. 1962;44:153-166.
41. Roos DB. Transaxillary approach for first rib resection to relieve thoracic outlet syndrome. *Ann Surg*. 1966;163:354-358.
42. Gol A, Patrick DW, McNeel DP. Relief of costoclavicular syndrome by infraclavicular removal of first rib. *J Neurosurg*. 1968;28:81-84.
43. Thomas GI, Jones TW, Stavney LS, Manhas DR. The middle scalene muscle and its contribution to the TOS. *Am J Surg*. 1983;145:589-592.

44. Sanders RJ, Monsour JW, Gerber FG, et al. Scaleneotomy versus first rib resection for treatment of the thoracic outlet syndrome. *Surgery*. 1979;85:109-121.
45. Sanders RJ, Pearce WH. The treatment of thoracic outlet syndrome: a comparison of different operations. *J Vasc Surg*. 1989;10:626-634.
46. Gu YD, Zhang GM, Chen DS, et al. Thoracic outlet syndrome. *Chin Med J*. 1988;101:689-694.
47. Loh CS, Wu AVO, Stevenson IM. Surgical decompression for thoracic outlet syndrome. *J R Coll Surg Edinb*. 1989;34:66-68.
48. Cikrit DF, Haefner R, Nichols WK, Silver D. Transaxillary or supraclavicular decompression for the thoracic outlet syndrome: a comparison of the risks and benefits. *Am Surg*. 1989;55:347-352.
49. Graham GG, Lincoln BM. Anterior resection of first rib for thoracic outlet syndrome. *Am J Surg*. 1973;126:803-806.
50. Thompson JB, Hernandez IA. The thoracic outlet syndrome: a second look. *Am J Surg*. 1979;138:251-253.
51. Hempel GK, Rucher AH Jr, Wheeler CG, et al. Supraclavicular resection of the first rib for thoracic outlet syndrome. *Am J Surg*. 1981;141:213-215.
52. Reilly LM, Stoney RJ. Supraclavicular approach for thoracic outlet decompression. *J Vasc Surg*. 1988;8:329-334.
53. Lang EK. Roentgenographic diagnosis of the neurovascular compression syndromes. *Radiology*. 1962;79:58-63.
54. Winsor T, Brow R. Costoclavicular syndrome: its diagnosis and treatment. *JAMA*. 1966;196:109-111.
55. Caldwell JW, Crane CR, Krusen EM. Nerve conduction studies: an aid in the diagnosis of the thoracic outlet syndrome. *South Med J*. 1971;64:210-212.
56. Hongladthrom T. "F"-wave conduction velocity in thoracic outlet syndrome. *N Engl J Med*. 1976;295:1382-1383.
57. Glover JL, Worth RM, Bendick PJ, et al. Evoked responses in the diagnosis of thoracic outlet syndrome. *Surgery*. 1981;89:86-93.
58. Seror O. Medial antebrachial cutaneous nerve conduction study, a new tool to demonstrate mild lower brachial plexus lesions. A report of 16 cases. *Clin Neurophysiol*. 2004;115:2316-2322.
59. Machleder HI, Moll F, Verity A. The anterior scalene muscle in thoracic outlet compression syndrome: histochemical and morphometric studies. *Arch Surg*. 1986;121:1141-1144.
60. Sanders RJ, Jackson CGR, Banchero N, Pearce WH. Scalene muscle abnormalities in traumatic thoracic outlet syndrome. *Am J Surg*. 1990;159:231-236.
61. Paget J. *Clinical Lectures and Essays*. 1875.
62. von Schrotter L. *Handbuch der allgemeinen Pathologie und Therapie (Nothnagel)*. Berlin: A. Hirschwald; 1884:533. Cited by Sampson JJ: *Am Heart J*. 1943;25:313.
63. Hughes ESR. Venous obstruction in the upper extremity. *Br J Surg*. 1948;36: 155-163.
64. Hovelacque A, Monod O, Evrard H, Beuzart J. Etude anatomique du nerf phrenique pre-veineux. *Ann Anat Pathol*. 1936;13:518-522.
65. Cucci CE, Bottino CG, Ciampa V. Venous obstruction of the upper extremity caused by a malformed valve of the subclavian vein. *Circulation*. 1963;27:275-278.
66. Cassada DC, Lipscomb AL, Stevens SL, et al. The importance of thrombophilia in the treatment of Paget-Schroetter syndrome. *Ann Vasc Surg*. 2006;20:596-601.
67. Głowiczki P, Kazmier FJ, Hollier LH. Axillary subclavian venous occlusion: the morbidity of a nonlethal disease. *J Vasc Surg*. 1986;4:333-337.
68. Lowenstein PS. Thrombosis of the axillary vein: an anatomical study. *JAMA*. 1924;82:854-857.
69. DeWeese JA, Rogoff SM. Phlebography of upper extremity. In: *Vascular Roentgenology*. New York, NY: Macmillan; 1964:482.
70. Male C, Chait P, Ginsberg JS, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. *Thromb Haemost*. 2002;87:593-598.



71. McCleery RS, Kesterson JE, Kirtley JA, Love RB. Subclavius and anterior scalene muscle compression as a cause of intermittent obstruction of the subclavian vein. *Ann Surg.* 1951;133:588-602.
72. Adams JT, McEvoy RK, DeWeese JA. Primary deep venous thrombosis of upper extremity. *Arch Surg.* 1965;91:29-42.
73. Coon WW, Willis PW. Thrombosis of axillary and subclavian veins. *Arch Surg.* 1967;94:657-663.
74. Witte CL, Smith CA. Single anastomosis vein bypass for subclavian vein obstruction. *Arch Surg.* 1966;93:664-666.
75. Sanders, RJ, Haug C. Subclavian vein obstruction and thoracic outlet syndrome: a review of etiology and management. *Ann Vasc Surg.* 1990;4:397-410.
76. Inahara T. Surgical treatment of "effort" thrombosis of the axillary and subclavian veins. *Am Surg.* 1968;34:479-483.
77. Bazy L. Thrombose de la veine axillaire droit. *Bull Soc Chir Paris.* 1926;52:529.
78. Horowitz O, Zinsser HF Jr. Subclavian vein obstruction. *JAMA.* 1953;151:997-999.
79. Mahorner H, Castelberry JW, Coleman WD. To restore function in major veins which are sites of massive thrombosis. *Ann Surg.* 1957;146:510.
80. Drapanas T, Curran WL. Thrombectomy in the treatment of "effort" thrombosis of the axillary and subclavian veins. *J Trauma.* 1966;6:107-119.
81. DeWeese JA, Adams JT, Gaiser DL. Subclavian venous thrombectomy. *Circulation.* 1970;41 and 42(suppl. II):158-164.
82. Bryant MF, Lazenby, WD, Howard JM. Experimental replacement of short segments of veins. *Arch Surg.* 1958;76:289.
83. Holt MH, Lewis FJ. Experimental grafts of the superior vena cava with temporary arteriovenous shunts. *J Thoracic Cardiovasc Surg.* 1965;49:818.
84. Scheinin TM, Jude JR, Blalock A. Experimental replacement of the superior vena cava: effect of temporary increase in blood flow. *J Thoracic Cardiovasc Surg.* 1964;48:781.
85. Dean RE, Read RC. The influence of increased blood flow on thrombosis in prosthetic grafts. *Surgery.* 1964;55:581.
86. Yamaguchi A, Eguchi S, Iwasaki T, Asano K. The influence of arteriovenous fistulae on the patency of synthetic inferior vena caval grafts. *J Cardiovasc Surg.* 1968;9:99.
87. Johnson V, Eiseman B. Evaluation of arteriovenous shunt to maintain patency of venous autograft. *Am J Surg.* 1969;118:915-920.
88. Adams JT, DeWeese JA, Mahoney EB, Rob CG. Intermittent subclavian vein obstruction without thrombosis. *Surgery.* 1968;63:147-165.
89. Siegel RS, Steichen FM. Cervicothoracic outlet syndrome: vascular compression caused by congenital abnormality of thoracic ribs; a case report. *J Bone Joint Surg Am.* 1967;49:1187-1192.
90. Adams JT, DeWeese JA, Mahoney EB, Rob CG. Intermittent subclavian vein obstruction without thrombosis. *Surgery.* 1968;63:147-165. Discussion pp 164-165.
91. Mercier CP, Branchereau A, Dimarino V, et al. Venous thrombosis of the upper limb: effort or compression. *J Cardiovasc Surg (Torino).* 1973;Spec. No:519-522.
92. Campbell CB, Chandler JG, Tegtmeier CJ, Bernstein EF. Axillary, subclavian, and brachiocephalic vein obstruction. *Surgery.* 1977;82:816-826.
93. Molina JE. A new surgical approach to the innominate and subclavian vein. *J Vasc Surg.* 1998;27:576-581.
94. Taylor LM Jr, McAllister WR, Dennis DL, Porter JM. Thrombolytic therapy followed by first rib resection for spontaneous ("effort") subclavian vein thrombosis. *Am J Surg.* 1985;149: 644-647.
95. Druy EM, Trout HH, Giordano JM, Hix WR. Lytic therapy in the treatment of axillary and subclavian vein thrombosis. *J Vasc Surg.* 1985;2:821-827.
96. Vogel CM, Jensen JE. "Effort" Thrombosis of the subclavian vein in a competitive swimmer. *Am J Sports Med.* 1985;13:269-272.
97. Galabert HA, Jimenez JC, Rigberg DA. Comparison of Retavase and urokinase for management of spontaneous subclavian vein thrombosis. *Ann Vasc Surg.* 2007;21:149-154.

98. Perler BA, Mitchell SE. Percutaneous transluminal angioplasty and transaxillary first rib resection: a multidisciplinary approach to the thoracic outlet syndrome. *Am Surg*. 1986;52:485-488.
99. Kunkel JM, Machleder HI. Treatment of Paget-Schroetter syndrome: a staged, multidisciplinary approach. *Arch Surg*. 1989;124:1153-1158.

## 第 123 章

1. Sanders RJ. *Thoracic Outlet Syndrome: A Common Sequela of Neck Injuries*. Philadelphia, PA: JB Lippincott; 1991.
2. Lindgren KA, Oksala I. Long-term outcome of surgery for thoracic outlet syndrome. *Am J Surg*. 1995;169:358-360.
3. Hempel GK, Shutze WP, Anderson JF, Bukhari HI. 770 consecutive supraclavicular first rib resections for thoracic outlet syndrome. *Ann Vasc Surg*. 1996;10:456-463.
4. Wilbourn AJ. The thoracic outlet syndrome is overdiagnosed. *Arch Neurol*. 1990;47:328-330.
5. Wilbourn AJ. Thoracic outlet syndromes: a plea for conservatism. *Neurosurg Clin N Am*. 1991;2:235-245.
6. Lindgren KA. Thoracic outlet syndrome with special reference to the first rib. *Ann Chir Gynaecol*. 1993;82:218-230.
7. Roos DB. Congenital anomalies associated with thoracic outlet syndrome. *Am J Surg*. 1976;132:771-778.
8. Juvonen T, Satta J, Laitala P, et al. Anomalies at the thoracic outlet are frequent in the general population. *Am J Surg*. 1995;170:33-37.
9. Demondion X, Herbinet P, Van Sint Jan S, et al. Imaging assessment of thoracic outlet syndrome. *Radiographics*. 2006;26:1735-1750.
10. Demondion X, Bacqueville E, Paul C, et al. Thoracic outlet: assessment with MR imaging in asymptomatic and symptomatic populations. *Radiology*. 2003;227:461-468.
11. Sanders RJ, Hammond SL. Management of cervical ribs and anomalous first ribs causing neurogenic thoracic outlet syndrome. *J Vasc Surg*. 2002;36:51-56.
12. Machleder HI, Moll F, Verity MA. The anterior scalene muscle in thoracic outlet compression syndrome: histochemical and morphometric studies. *Arch Surg*. 1986;121:1141-1144.
13. Sanders RJ, Jackson CG, Banchero N, Pearce WH. Scalene muscle abnormalities in traumatic thoracic outlet syndrome. *Am J Surg*. 1990;159:231-236.
14. Sanders RJ, Hammond SL, Rao NM. Diagnosis of thoracic outlet syndrome. *J Vasc Surg*. 2007;46:601-604.
15. Raskin NH, Howard MW, Ehrenfeld WK. Headache as the leading symptom of the thoracic outlet syndrome. *Headache*. 1985;25:208-210.
16. Filler AG, Kliot M, Howe FA, et al. Application of magnetic resonance neurography in the evaluation of patients with peripheral nerve pathology. *J Neurosurg*. 1996;85:299-309.
17. Filler AG, Maravilla KR, Tsuruda JS. MR neurography and muscle MR imaging for image diagnosis of disorders affecting the peripheral nerves and musculature. *Neurol Clin*. 2004;22:643-682.
18. Komanetsky RM, Novak CB, Mackinnon SE, et al. Somatosensory evoked potentials fail to diagnose thoracic outlet syndrome. *J Hand Surg [Am]*. 1996;21:662-666.
19. Machanic BI, Sanders RJ. Medial antebrachial cutaneous nerve measurements to diagnose neurogenic thoracic outlet syndrome. *Ann Vasc Surg*. 2008;22:248-254.
20. Jordan SE, Machleder HI. Diagnosis of thoracic outlet syndrome using electrophysiologically guided anterior scalene blocks. *Ann Vasc Surg*. 1998;12:260-264.
21. Gage M. Scalenus anticus syndrome: a diagnostic and confirmatory test. *Surgery*. 1939;5:599-601.
22. Sanders RJ, Monsour JW, Gerber FG, et al. Scaleneotomy versus first rib resection for treatment of the thoracic outlet syndrome. *Surgery*. 1979;85:109-121.
23. Jordan SE, Ahn SS, Freischlag JA, et al. Selective botulinum chemodenervation of the scalene muscles for treatment of neurogenic thoracic outlet syndrome. *Ann Vasc Surg*. 2000;14:365-369.

24. Jordan SE, Ahn SS, Gelabert HA. Differentiation of thoracic outlet syndrome from treatment-resistant cervical brachial pain syndromes: development and utilization of a questionnaire, clinical examination and ultrasound evaluation. *Pain Physician*. 2007;10:441-452.
25. Wilbourn AJ, Porter JM. Neurogenic thoracic outlet syndrome: surgical versus conservative therapy. *J Vasc Surg*. 1992;15:880-882.
26. Edgelow P. Neurovascular consequences of cumulative trauma disorders affecting the thoracic outlet: a patient centered treatment approach. In: Donatelli R, ed. *Physical Therapy of the Shoulder*. New York, NY: Churchill Livingstone; 2004:205-238.
27. Lindgren KA. Conservative treatment of thoracic outlet syndrome: a 2-year follow-up. *Arch Phys Med Rehabil*. 1997;78:373-378.
28. Mueller MJ, Maluf KS. Tissue adaptation to physical stress: a proposed "Physical Stress Theory" to guide physical therapist practice, education, and research. *Phys Ther*. 2002;82:383-403.
29. Sahrmann S. *Diagnosis and Treatment of Movement Impairment Syndromes*. St. Louis, MO: CV Mosby; 2002.
30. Aligne C, Barral X. Rehabilitation of patients with thoracic outlet syndrome. *Ann Vasc Surg*. 1992;6:381-389.
31. Walsh MT. Therapist management of thoracic outlet syndrome. *J Hand Ther*. 1994;7:131-144.
32. Novak CB. Conservative management of thoracic outlet syndrome. *Semin Thorac Cardiovasc Surg*. 1996;8:201-207.
33. Novak CB. Thoracic outlet syndrome. *Clin Plast Surg*. 2003;30:175-188.
34. Mackinnon SE, Novak CB. Thoracic outlet syndrome. *Curr Probl Surg*. 2002;39:1070-1145.
35. Coote H. Exostosis of the left transverse process of the seventh cervical vertebra, surrounded by blood vessels and nerves; successful removal. *Lancet*. 1861;1:360-361.
36. Adson AW, Coffey JR. Cervical rib: a method of anterior approach for relief of symptoms by division of the scalenus anticus. *Ann Surg*. 1927;85:839-857.
37. Peet RM, Hendriksen JD, Anderson TP, Martin GM. Thoracic outlet syndrome: evaluation of a therapeutic exercise program. *Proc Mayo Clin*. 1956;31:281-287.
38. Clagett OT. Presidential address: research and proresearch. *J Thorac Cardiovasc Surg*. 1962;44:153-166.
39. Roos DB. Transaxillary approach for first rib resection to relieve thoracic outlet syndrome. *Ann Surg*. 1966;163:354-358.
40. Dale A. Thoracic outlet compression syndrome: critique in 1982. *Arch Surg*. 1982;117:1437-1445.
41. Sanders RJ, Monsour JW, Gerber WJ. Recurrent thoracic outlet syndrome following first rib resection. *Vasc Surg*. 1979;13:325-330.
42. Qvarfordt PG, Ehrenfeld WK, Stoney RJ. Supraclavicular radical scalenectomy and transaxillary first rib resection for the thoracic outlet syndrome: a combined approach. *Am J Surg*. 1984;148:111-116.
43. Sanders RJ, Raymer S. The supraclavicular approach to scalenectomy and first rib resection: description of technique. *J Vasc Surg*. 1985;2:751-756.
44. Reilly LM, Stoney RJ. Supraclavicular approach for thoracic outlet decompression. *J Vasc Surg*. 1988;8:329-334.
45. Fantini GA. Reserving supraclavicular first rib resection for vascular complications of thoracic outlet syndrome. *Am J Surg*. 1996;172:200-204.
46. Machleder HI. Transaxillary operative management of thoracic outlet syndrome. In: Ernst CB, Stanley JC, eds. *Current Therapy in Vascular Surgery*. 2nd ed. Philadelphia, PA: BC Decker; 1991:227-230.
47. Annersten S. Studies on the scalenus anticus syndrome. *Acta Surg Scand*. 1947;95:419-439.
48. Holden WD, Murphy JA, Portmann AF. Scalene anticus syndrome: unusual diagnostic and therapeutic aspects. *Am J Surg*. 1951;81:411-416.
49. Raaf J. Surgery for cervical rib and scalenus anticus syndrome. *JAMA*. 1955;157:219-223.
50. Shenkin HA, Somach FM. Scalenotomy in patients with and without cervical ribs. *Arch Surg*. 1963;87:30-34.
51. deBruin TR. Costoclavicular space enlargement: eight methods for relief of neurovascular compression. *Int Surg*.

- 1966;46:340-360.
52. Urschel HC, Razzuk MA, Wood RE, et al. Objective diagnosis (ulnar nerve conduction velocity) and current therapy of the thoracic outlet syndrome. *Ann Thorac Surg.* 1971;12:608-620.
  53. Narakas A, Bonnard C, Egloff DV. The cervico-thoracic outlet syndrome. *Ann Chir Main.* 1986;5:185-207.
  54. Takagi K, Yamaga M, Morisawa K, Kitagawa T. Management of thoracic outlet syndrome. *Arch Orthop Trauma Surg.* 1987;106:78-81.
  55. Adson AW. Surgical treatment for symptoms produced by cervical ribs and the scalenus anticus muscle. *Surg Gynecol Obstet.* 1947;85:687-700.
  56. Stowell A. The scalenus anticus syndrome. *J Int Coll Surg.* 1956;26:711-717.
  57. Woods WW. Thoracic outlet syndrome. *West J Med.* 1978;128:9-12.
  58. Gu YD, Wu M, Zheng Y, et al. Combined supra-infraclavicular approach for excision of the first rib in the treatment of the thoracic outlet syndrome. *Chung Hua Wai Ko Tsa Chih.* 1984;22:692-693.
  59. Loh CS, Wu AVO, Stevenson IM. Surgical decompression for thoracic outlet syndrome. *J R Coll Surg Edinb.* 1989;34:66-68.
  60. Cikrit DF, Haefner R, Nichols WK, Silver D. Transaxillary or supraclavicular decompression for the thoracic outlet syndrome: a comparison of the risks and benefits. *Am Surg.* 1989;55:347-352.
  61. Sanders RJ, Monsour JW, Baer SB. Transaxillary first rib resection for the thoracic outlet syndrome. *Arch Surg.* 1968;97:1014-1023.
  62. Roeder DK, Mills M, McHale JJ, et al. First rib resection in the treatment of thoracic outlet syndrome: transaxillary and posterior thoracoplasty approaches. *Ann Surg.* 1973;178:49-52.
  63. Hoofner WD, Burnett AD. Thoracic outlet relief. *J Kansas Med Soc.* 1973;74:329-331.
  64. Dale WA. Management of thoracic outlet syndrome. *Ann Surg.* 1975;181:575-585.
  65. Kremer RM, Ahlquist REJ. Thoracic outlet compression syndrome. *Am J Surg.* 1975;130:612-616.
  66. McGough EC, Pearce MB, Byrne JP. Management of thoracic outlet syndrome. *J Ther Card Med.* 1979;77:169-174.
  67. Youmans CRJ, Smiley RH. Thoracic outlet syndrome with negative Adson's and hyperabduction maneuvers. *Vasc Surg.* 1980;14:318-329.
  68. Roos DB. The place for scalenectomy and first-rib resection in thoracic outlet syndrome. *Surgery.* 1982;92:1077-1085.
  69. Batt M, Griffet J, Scotti L, LeBas P. Le syndrome de la transverse cervico-brachiale: a propos de 112 cas: vers une attitude tactique plus nuancee. *J Chir Paris.* 1983;120:687-691.
  70. Sallstrom J, Gjores JE. Surgical treatment of the thoracic outlet syndrome. *Acta Chir Scand.* 1983;149:555-560.
  71. Heughan C. Thoracic outlet syndrome. *Can J Surg.* 1984;27:35-36.
  72. Davies AL, Messerschmidt W. Thoracic outlet syndrome: a therapeutic approach based on 115 consecutive cases. *Del Med J.* 1988;60:307-310.
  73. Selke FW, Kelly TR. Thoracic outlet syndrome. *Am J Surg.* 1988;156:54-57.
  74. Stanton PEJ, Vo NM, Haley T, et al. Thoracic outlet syndrome: a comprehensive evaluation. *Am Surg.* 1988;54:129-133.
  75. Wood VE, Twito R, Verska JM. Thoracic outlet syndrome: the results of first rib resection in 100 patients. *Orthop Clin North Am.* 1988;19:131-146.
  76. Lindgren SHS, Ribbe EB, Norgren LEH. Two year follow-up of patients operated on for thoracic outlet syndrome: effects on sick-leave incidence. *Eur J Vasc Surg.* 1989;3:411-415.
  77. Lepantalo M, Lindgren KA, Leino E, et al. Long term outcome after resection of the first rib for thoracic outlet syndrome. *Br J Surg.* 1989;76:1255-1256.
  78. Jamieson WG, Chinnick B. Thoracic outlet syndrome: fact or fancy? A review of 409 consecutive patients who underwent operation. *Can J Surg.* 1996;39:321-326.
  79. Graham GG, Lincoln BM. Anterior resection of the first rib for thoracic outlet syndrome. *Am J Surg.* 1973;126:803-806.

80. Thompson JB, Hernandez IA. The thoracic outlet syndrome: a second look. *Am J Surg.* 1979;138:251-253.
81. Thomas GI, Jones TW, Stavney LS, Manhas DR. The middle scalene muscle and its contribution to the TOS. *Am J Surg.* 1983;145:589-592.
82. Axelrod DA, Proctor MC, Geisser ME, et al. Outcomes after surgery for thoracic outlet syndrome. *J Vasc Surg.* 2001;33:1220-1225.
83. Sanders RJ, Pearce WH. The treatment of thoracic outlet syndrome: a comparison of different operations. *J Vasc Surg.* 1989;10:626-634.
84. Sanders RJ. Results of the surgical treatment for thoracic outlet syndrome. *Semin Thorac Cardiovasc Surg.* 1996;8:221-228.
85. Franklin GM, Fulton-Kehoe D, Bradley C, Smith-Weller T. Outcome of surgery for thoracic outlet syndrome in Washington state workers' compensation. *Neurology.* 2000;54:1252-1257.

## 第 124 章

1. Mayo H. Exostosis of the first rib with strong pulsations of the subclavian artery. *London Med Phys J.* 1831;11:40.
2. Coote H. Exostosis of the transverse process of the seventh cervical vertebra, surrounded by blood vessels and nerves: successful removal. *Lancet.* 1861;1:360-361.
3. Naffziger HC, Grant WT. Neuritis of the brachial plexus mechanical in origin. *Surg Gynecol Obstet.* 1938;67:722-730.
4. Peet RM, Hendriksen JD, Anderson TP, Martin GM. Thoracic outlet syndrome: evaluation of the therapeutic exercise program. *Proc Mayo Clin.* 1956;31:281-287.
5. Green RM. Vascular manifestations of the thoracic outlet syndrome. *Semin Vasc Surg.* 1988;11:67-76.
6. Durham JR, Yao ST, Pearce WH, et al. Arterial injuries in the thoracic outlet syndrome. *J Vasc Surg.* 1995;21:57-70.
7. Casbas L, Chauffour X, Cau J, et al. Post-traumatic thoracic outlet syndromes. *Ann Vasc Surg.* 2005;19:25-28.
8. Cormier JM, Amrane M, Ward A, et al. Arterial complications of the thoracic outlet syndrome: fifty five operative cases. *J Vasc Surg.* 1989;9:778-787.
9. Nehler MR, Taylor LM, Moneta GL, Porter JM. Upper extremity ischemia from subclavian artery aneurysm caused by bony abnormalities of the thoracic outlet. *Arch Surg.* 1997;132:527-532.
10. Sanders RJ, Haug C. Review of arterial thoracic outlet syndrome with a report of five new instances. *Surg Gynecol Obstet.* 1991;173:415-425.
11. Urschel HC Jr, Kourlis H Jr. Thoracic outlet syndrome: a 50-year experience at Baylor University Medical Center. *Proc Bayl Univ Med Cent.* 2007;20:125-135.
12. Makhoul RG, Machleder HI. Developmental anomalies at the thoracic outlet: an analysis of 200 consecutive cases. *J Vasc Surg.* 1992;16:534-545.
13. Sanders RJ, Hammond SL, Rao NM. Diagnosis of thoracic outlet syndrome. *J Vasc Surg.* 2007;46:601-604.
14. Gelabert HA, Machleder HI. Diagnosis and management of arterial compression at the thoracic outlet. *Ann Vasc Surg.* 1997;11:359-366.
15. Lee TS, Hines GL. Cerebral embolic stroke and arm ischemia in a teenager with arterial thoracic outlet syndrome: a case report. *Vasc Endovascular Surg.* 2007;41:254-257.
16. Hugl B, Oldenburg A, Hakaim AG, Persellin ST. Unusual etiology of upper extremity ischemia in a scleroderma patient: thoracic outlet syndrome with arterial embolization. *J Vasc Surg.* 2007;45:1259-1261.
17. Fields W, Lemak N, Ben-Menachem Y. Thoracic outlet syndrome: review and reference to stroke in a major league pitcher. *AJNR Am J Neuroradiol.* 1986;146:809-814.
18. Symonds CP. Two cases of thrombosis of subclavian artery with contralateral hemiplegia of sudden onset, probably embolic. *Brain.* 1927;50:259-260.
19. Naz I, Ziad S. Cerebral embolism: distal subclavian disease as a rare etiology. *J Pak Med Assoc.* 2006;56:186-188.
20. Adson AW. Surgical treatment for symptoms produced by cervical ribs and the scalenus anticus muscle. *Surg Gynecol*

- Obstet.* 1947;85:687-700.
21. Gergoudis R, Barnes RW. Thoracic outlet arterial compression: prevalence in normal persons. *Angiology.* 1980;31:538-541.
  22. Warrens A, Heaton JM. Thoracic outlet compression syndrome: the lack of reliability of its clinical assessment. *Ann R Coll Surg Engl.* 1987;69:203-204.
  23. Colon E, Westdrop R. Vascular compression in the thoracic outlet: age dependent normative values in noninvasive testing. *J Cardiovasc Surg.* 1988;29:166-171.
  24. Plewa MC, Delinger M. The false-positive rate of thoracic outlet syndrome shoulder maneuvers in healthy subjects. *Acad Emerg Med.* 1998;5:337-342.
  25. Roos DB, Owens JC. Thoracic outlet syndrome. *Arch Surg.* 1966;93:71-74.
  26. Demondion X, Vidal C, Herbinet P, et al. Ultrasonographic assessment of arterial cross-sectional area in the thoracic outlet on postural maneuvers measured with power Doppler ultrasonography in both asymptomatic and symptomatic populations. *J Ultrasound Med.* 2006;25:217-224.
  27. Stapleton C, Herrington L, George K. Sonographic evaluation of the subclavian artery during thoracic outlet syndrome shoulder manoeuvres. *Man Ther.* 2009;14:19-27.
  28. Longley DG, Yedlicka JW, Monina EJ, et al. Thoracic outlet syndrome: evaluation of the subclavian vessels by color duplex sonography. *AJR Am J Roentgenol.* 1992;158:623-630.
  29. Matsumura JS, Rilling WS, Pearce WH, et al. Helical computed tomography of the normal thoracic outlet. *J Vasc Surg.* 1997;26:776-783.
  30. Charon JP, Milne W, Sheppard DG, Houston JG. Evaluation of MR angiographic technique in the assessment of thoracic outlet syndrome. *Clin Radiol.* 2004;59:588-595.
  31. Jamieson WG, Chinnick B. Thoracic outlet syndrome: fact or fantasy? A review of 409 consecutive patients who underwent operation. *Can J Surg.* 1996;39:321-326.
  32. Degeorges R, Reynaud C, Becquemin JP. Thoracic outlet syndrome surgery: long-term functional results. *Ann Vasc Surg.* 2004;18:558-565.
  33. Reeser JC. Diagnosis and management of vascular injuries of the shoulder girdle of the overhead athlete. *Curr Sports Med Rep.* 2007;6:322-327.
  34. Dobrin PB. Poststenotic dilatation. *Surg Gynecol Obstet.* 1991;172:503-508.
  35. Short DW. The subclavian artery in 16 patients with complete cervical ribs. *J Cardiovasc Surg (Torino).* 1975;16:135-141.
  36. Scher LA, Veith FJ, Haimovichi H, et al. Staging of arterial complications of cervical rib: guidelines for surgical management. *Surgery.* 1984;95:664-669.
  37. Thompson RW, Petrinc D. Surgical treatment of thoracic outlet compression syndromes: diagnostic considerations and transaxillary first rib resection. *Ann Vasc Surg.* 1997;11:315-323.
  38. Robicsek F, Eastman D. "Above-under" exposure of the first rib: a modified approach for the treatment of thoracic outlet syndrome. *Ann Vasc Surg.* 1997;11:304-306.
  39. Modrall JG, Joiner DR, Seidel SA, et al. Superficial femoral-popliteal vein as a conduit for brachiocephalic arterial reconstructions. *Ann Vasc Surg.* 2002;16:17-23.
  40. Reilly LM, Stoney RJ. Supraclavicular approach for thoracic outlet decompression. *J Vasc Surg.* 1988;8:329-334.
  41. Malliet C, Fourneau I, Daenens K, et al. Endovascular stent-graft and first rib resection for thoracic outlet syndrome complicated by an aneurysm of the subclavian artery. *Acta Chir Belg.* 2005;105:194-197.
  42. Meyer T, Merkel S, Lang W. Combined operative and endovascular treatment of a post-traumatic embolizing aneurysm of the subclavian artery. *J Endovasc Surg.* 1998;5:52-55.
  43. Sitsen ME, Gwan HH, Blankensteijn JD. Deformation of self-expanding stent-grafts complicating endovascular peripheral aneurysm repair. *J Endovasc Surg.* 1999;6:288-292.
  44. Hood DB, Kuehne J. Vascular complications of thoracic outlet syndrome. *Am Surg.* 1997;63:913-917.

45. Davidovic LB, Kostic DM, Jakovljevic NS, et al. Vascular thoracic outlet syndrome. *World J Surg*. 2003;27:545-550.

## 第 125 章

1. Hughes ES. Venous obstruction in the upper extremity; Paget-Schroetter's syndrome; a review of 320 cases. *Surg Gynecol Obstet*. 1949;88:89-127.
2. Paget J. *Clinical Lectures and Essays*. London: Longmans Green & Co; 1875.
3. von Schroetter L. *Erkrankungen der gefasse. Nathnagel Handbuch de Pathologie and Therapie*. Vienna: Holder; 1884.
4. Joffe HV, Goldhaber SZ. Upper-extremity deep vein thrombosis. *Circulation*. 2002;106:1874-1880.
5. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Old and new risk factors for upper extremity deep venous thrombosis. *J Thromb Haemost*. 2005;3:2471-2478.
6. Malhotra S, Punia VP. Upper extremity deep vein thrombosis. *J Assoc Physicians India*. 2004;52:237-241.
7. Kroger K, Schelo C, Gocke C, Rudofsky G. Colour Doppler sonographic diagnosis of upper limb venous thromboses. *Clin Sci (Lond)*. 1998;94:657-661.
8. McDonough JJ, Altemeier WA. Subclavian venous thrombosis secondary to indwelling catheters. *Surg Gynecol Obstet*. 1971;133:397-400.
9. Adelman MA, Stone DH, Riles TS, et al. A multidisciplinary approach to the treatment of Paget-Schroetter syndrome. *Ann Vasc Surg*. 1997;11:149-154.
10. Adams JT, DeWeese JA. "Effort" thrombosis of the axillary and subclavian veins. *J Trauma*. 1971;11:923-930.
11. Kommareddy A, Zaroukian MH, Hassouna HI. Upper extremity deep venous thrombosis. *Semin Thromb Hemost*. 2002;28:89-99.
12. Schneider DB, Azakie A, Messina LM, Stoney RJ. Management of vascular thoracic outlet syndrome. *Chest Surg Clin North Am*. 1999;6:781-803.
13. Drury EM, Trout HH 3rd, Giordano JM, Hix WR. Lytic therapy in the treatment of axillary and subclavian vein thrombosis. *J Vasc Surg*. 1985;2:821-827.
14. Daskalakis E, Bouhoutsos J. Subclavian and axillary vein compression of musculoskeletal origin. *Br J Surg*. 1980;67:573-576.
15. Demondion X, Boutry N, Drizenko A, et al. Thoracic outlet: anatomic correlation with MR imaging. *AJR Am J Roentgenol*. 2000;175:417-422.
16. Crowell DL. Effort thrombosis of the subclavian and axillary veins: review of the literature and case report with two-year follow-up with venography. *Ann Intern Med*. 1960;52:1337-1343.
17. Hagspiel KD, Spinosa DJ, Angle JF, Matsumoto AH. Diagnosis of vascular compression at the thoracic outlet using gadolinium-enhanced high-resolution ultrafast MR angiography in abduction and adduction. *Cardiovasc Intervent Radiol*. 2000;23:152-154.
18. Kunkel JM, Machleder HI. Treatment of Paget-Schroetter syndrome. A staged, multidisciplinary approach. *Arch Surg*. 1989;124:1153-1157; discussion 1157-1158.
19. Stevenson IM, Parry EW. Radiological study of the aetiological factors in venous obstruction of the upper limb. *J Cardiovasc Surg (Torino)*. 1975;16:580-585.
20. Strange-Vognsen HH, Hauch O, Andersen J, Struckmann J. Resection of the first rib, following deep arm vein thrombolysis in patients with thoracic outlet syndrome. *J cardiovasc Surg*. 1989;30:430-433.
21. Becker GJ, Holden RW, Rabe FE, et al. Local thrombolytic therapy for subclavian and axillary vein thrombosis. Treatment of the thoracic inlet syndrome. *Radiology*. 1983;149:419-423.
22. Glanz S, Gordon DH, Lipkowitz GS, et al. Axillary and subclavian vein stenosis: percutaneous angioplasty. *Radiology*. 1988;168:371-373.
23. Kerr TM, Lutter KS, Moeller DM, et al. Upper extremity venous thrombosis diagnosed by duplex scanning. *Am J Surg*.

- 1990;160:202-206.
24. Lindblad B, Tengborn L, Bergqvist D. Deep vein thrombosis of the axillary-subclavian veins: epidemiologic data, effects of different types of treatment and late sequelae. *Eur J Vasc Surg.* 1988;2:161-165.
  25. Sharafuddin MJ, Sun S, Hoballah JJ. Endovascular management of venous thrombotic diseases of the upper torso and extremities. *J Vasc Interv Radiol.* 2002;13:975-990.
  26. Tilney ML, Griffiths HJ, Edwards EA. Natural history of major venous thrombosis of the upper extremity. *Arch Surg.* 1970;101:792-796.
  27. Urschel HC Jr, Razzuk MA. Paget-Schroetter syndrome: what is the best management? *Ann Thorac Surg.* 2000;69:1663-1668; discussion 1668-1669.
  28. Swinton NW Jr, Edgett JW Jr, Hall RJ. Primary subclavian-axillary vein thrombosis. *Circulation.* 1968;38:737-745.
  29. Hingorani A, Ascher E, Lorenson E, et al. Upper extremity deep venous thrombosis and its impact on morbidity and mortality rates in a hospital-based population. *J Vasc Surg.* 1997;26:853-860.
  30. Azakie A, McElhinney DB, Thompson RW, et al. Surgical management of subclavian-vein effort thrombosis as a result of thoracic outlet compression. *J Vasc Surg.* 1998;28:777-786.
  31. Monreal M, Raventos A, Lerma R, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines—a prospective study. *Thromb Haemost.* 1994;72:548-550.
  32. Chandrasekar R, Nott DM, Enabi L, et al. Upper limb venous gangrene, a lethal condition. *Eur J Vasc Surg.* 1993;7:475-477.
  33. Haire WD, Lynch TG, Lund GB, et al. Limitations of magnetic resonance imaging and ultrasound-directed (duplex) scanning in the diagnosis of subclavian vein thrombosis. *J Vasc Surg.* 1991;13:391-397.
  34. Baxter GM, Kincaid W, Jeffrey RF, et al. Comparison of colour Doppler ultrasound with venography in the diagnosis of axillary and subclavian vein thrombosis. *Br J Radiol.* 1991;64:777-781.
  35. Koksoy C, Kuzu A, Kutlay J, et al. The diagnostic value of colour Doppler ultrasound in central venous catheter related thrombosis. *Clin Radiol.* 1995;50:687-689.
  36. Passman MA, Criado E, Farber MA, et al. Efficacy of color flow duplex imaging for proximal upper extremity venous outflow obstruction in hemodialysis patients. *J Vasc Surg.* 1998;28:869-875.
  37. Baarslag HJ, van Beek EJ, Koopman MM, Reekers JA. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. *Ann Intern Med.* 2002;136:865-872.
  38. Lee JT, Karwowski JK, Harris EJ, et al. Long-term thrombotic recurrence after nonoperative management of Paget-Schroetter syndrome. *J Vasc Surg.* 2006;43:1236-1243.
  39. Demondion X, Herbinet P, Van Sint Jan S, et al. Imaging assessment of thoracic outlet syndrome. *Radiographics.* 2006;26:1735-1750.
  40. Gomez E, Bastida R, Oleaga L, et al. Diagnosis of thoracic outlet syndrome by angio-MRI. *Radiologia.* 2006;48:295-300.
  41. Demondion X, Bacqueville E, Paul C, et al. Thoracic outlet: assessment with MR imaging in asymptomatic and symptomatic populations. *Radiology.* 2003;227:461-468.
  42. DeWeese JA, Adams JT, Gaiser DL. Subclavian venous thrombectomy. *Circulation.* 1970;41:II158-64.
  43. Melby SJ, Vedantham S, Narra VR, et al. Comprehensive surgical management of the competitive athlete with effort thrombosis of the subclavian vein (Paget-Schroetter syndrome). *J Vasc Surg.* 2008;47:809-820.
  44. Doyle A, Wolford HY, Davies MG, et al. Management of effort thrombosis of the subclavian vein: today's treatment. *Ann Vasc Surg.* 2007;21:723-729.
  45. Molina JE, Hunter DW, Dietz CA. Paget-Schroetter syndrome treated with thrombolytics and immediate surgery. *J Vasc Surg.* 2007;45:328-334.
  46. Schneider DB, Dimuzio PJ, Martin ND, et al. Combination treatment of venous thoracic outlet syndrome: open surgical decompression and intraoperative angioplasty. *J Vasc Surg.* 2004;40:599-603.



47. Zimmermann R, Morl H, Harenberg J, et al. Urokinase therapy of subclavian-axillary vein thrombosis. *Klin Wochenschr.* 1981;59:851-856.
48. Arko FR, Davis CM 3rd, Murphy EH, et al. Aggressive percutaneous mechanical thrombectomy of deep venous thrombosis: early clinical results. *Arch Surg.* 2007;142:513-518; discussion 518-519.
49. Schneider DB, Curry TK, Eichler CM, et al. Percutaneous mechanical thrombectomy for the management of venous thoracic outlet syndrome. *J Endovasc Ther.* 2003;10:336-340.
50. Hilleman DE, Razavi MK. Clinical and economic evaluation of the Trellis-8 infusion catheter for deep vein thrombosis. *J Vasc Interv Radiol.* 2008;19:377-383.
51. de Leon R, Chang DC, Busse C, et al. First rib resection and scalenectomy for chronically occluded subclavian veins: what does it really do? *Ann Vasc Surg.* 2008;22:395-401.
52. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126:401S-428S.
53. Machleder HI. Evaluation of a new treatment strategy for Paget-Schroetter syndrome: spontaneous thrombosis of the axillary-subclavian vein. *J Vasc Surg.* 1993;17:305-315; discussion 316-317.
54. Bjarnason H, Hunter DW, Crain MR, et al. Collapse of a Palmaz stent in the subclavian vein. *AJR Am J Roentgenol.* 1993;160:1123-1124.
55. Meier GH, Pollak JS, Rosenblatt M, et al. Initial experience with venous stents in exertional axillary-subclavian vein thrombosis. *J Vasc Surg.* 1996;24:974-981; discussion 981-983.
56. Urschel HC Jr, Patel AN. Paget-Schroetter syndrome therapy: failure of intravenous stents. *Ann Thorac Surg.* 2003;75:1693-1696; discussion 1696.
57. Lee MC, Grassi CJ, Belkin M, et al. Early operative intervention after thrombolytic therapy for primary subclavian vein thrombosis: an effective treatment approach. *J Vasc Surg.* 1998;27:1101-1107; discussion 1107-1108.
58. Angle N, Gelabert HA, Farooq MM, et al. Safety and efficacy of early surgical decompression of the thoracic outlet for Paget-Schroetter syndrome. *Ann Vasc Surg.* 2001;15:37-42.
59. Urschel HC Jr, Razzuk MA. Improved management of the Paget-Schroetter syndrome secondary to thoracic outlet compression. *Ann Thorac Surg.* 1991;52:1217-1221.
60. Hurlbert SN, Rutherford RB. Primary subclavian-axillary vein thrombosis. *Ann Vasc Surg.* 1995;9:217-223.
61. Pittam MR, Darke SG. The place of first rib resection in the management of axillary-subclavian vein thrombosis. *Eur J Vasc Surg.* 1987;1:5-10.
62. Roos DB, Edgar J. Poth Lecture. Thoracic outlet syndromes: update 1987. *Am J Surg.* 1987;154:568-573.
63. Kreienberg PB, Chang BB, Darling RC 3rd, et al. Long-term results in patients treated with thrombolysis, thoracic inlet decompression, and subclavian vein stenting for Paget-Schroetter syndrome. *J Vasc Surg.* 2001;33:S100-S105.
64. McGee DC, Gould MK. Preventing complications of central venous catheterization. *N Engl J Med.* 2003;348:1123-1133.
65. Lee AY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. *J Clin Oncol.* 2006;24:1404-1408.
66. Prandoni P, Bernardi E. Upper extremity deep vein thrombosis. *Curr Opin Pulm Med.* 1999;5:222-226.
67. Petrakis IE, Sciacca V, Katsamouris AN. Upper extremities deep venous thrombosis: comparison of light reflection rheography and colour duplex ultrasonography for diagnosis and follow-up. *Painminerva Med.* 2001;43:69-75.
68. Sajid MS, Ahmed N, Desai M, et al. Upper limb deep vein thrombosis: a literature review to streamline the protocol for management. *Acta Haematol.* 2007;118:10-18.
69. Gould JR, Carlsson HW, Skinner WL. Groshong catheter-associated subclavian venous thrombosis. *Am J Med.* 1993;95:419-423.
70. Timsit JF, Farkas JC, Boyer JM, et al. Central vein catheter-related thrombosis in intensive care patients: incidence, risks factors, and relationship with catheter-related sepsis. *Chest.* 1998;114:207-213.

71. DaCosta SS, Scalabrini Neto A, Costa R, et al. Incidence and risk factors of upper extremity deep vein lesions after permanent transvenous pacemaker implant: a 6-month follow-up prospective study. *Pacing Clin Electrophysiol.* 2002;25:1301-1306.
72. Mustafa BO, Rathbun SW, Whitsett TL, Raskob GE. Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. *Arch Intern Med.* 2002;162:401-404.
73. Ascher E, Hingorani A, Tsemekhin B, et al. Lessons learned from six years clinical experience with superior vena cava Greenfield Filters. *J Vasc Surg.* 2000;32:881-887.
74. Hann CL, Streiff MB. The role of vena caval filters in the management of venous thromboembolism. *Blood Rev.* 2005;19:179-202.
75. Boraks P, Seale J, Price J, et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. *Br J Haematol.* 1998;101:483-486.
76. Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices—prophylaxis with a low molecular weight heparin (Fragmin). *Thromb Haemost.* 1996;75:251-253.
77. Karthaus M, Kretzschmar A, Kroning H, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. *Ann Oncol.* 2006;17:289-296.
78. Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. *J Clin Oncol.* 2005;23:4063-4069.
79. Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. *J Clin Oncol.* 2005;23:4057-4062.
80. Young AM, Begum G, Billingham LJ, et al. WARP—a multicentre prospective randomized controlled trial of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters [abstract]. *J Clin Oncol.* 2005;23:8004.
81. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest.* 2004;126:338S-400S.

## 第 126 章

1. Johnston KW, Rutherford RB, Tilson MD, et al, for the Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. Suggested standards for reporting on arterial aneurysms. *J Vasc Surg.* 1991;13:452-458.
2. Pedersen OM, Aslaksen A, Vik-Mo H. Ultrasound measurement of the luminal diameter of the abdominal aorta and iliac arteries in patients without vascular disease. *J Vasc Surg.* 1993;17:596-601.
3. Cordell AR. A lasting legacy: the life and work of Rudolph Matas. *J Vasc Surg.* 1985;2:613-619.
4. Friedman SG. The 50th anniversary of abdominal aortic reconstruction. *J Vasc Surg.* 2001;33:895-898.
5. Blakemore AH, Voorhees AB. The use of tubes constructed from Vinyon “N” cloth in bridging arterial defects—experimental and clinical. *Ann Surg.* 1954;140:324-333.
6. Cooley DA, DeBakey ME. Resection of the thoracic aorta with replacement by homograft for aneurysms and constrictive lesions. *J Thorac Surg.* 1955;29:66-100; discussion 100-104.
7. Parodi JC, Palmaz JC, Barone HD. Endovascular repair of abdominal aortic aneurysms and other arterial lesions. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. *Ann Vasc Surg.* 1991;5:491-499.
8. Hill JS, McPhee JT, Messina LM, et al. Regionalization of abdominal aortic aneurysm repair: evidence of a shift to high-volume centers in the endovascular era. *J Vasc Surg.* 2008;48:29-36.
9. Belardi P, Lucertini G, De Caro G. Type I aneurysm: complementary index for diagnosis. *Vascular.* 2005;13:5-11.
10. Fillinger MF, Racusin J, Baker RK, et al. Anatomic characteristics of ruptured abdominal aortic aneurysm on conventional CT scans: implications for rupture risk. *J Vasc Surg.* 2004;39:1243-1252.
11. Ouriel K, Green RM, Donayre C, et al. An evaluation of new methods of expressing aortic aneurysm size: relationship to

- rupture. *J Vasc Surg.* 1992;15:12-18; discussion 19-20.
12. Zarins CK, Glagov S, Vesselinovitch D, Wissler RW. Aneurysm formation in experimental atherosclerosis: relationship to plaque evolution. *J Vasc Surg.* 1990;12:246-256.
  13. Xu C, Zarins CK, Glagov S. Aneurysmal and occlusive atherosclerosis of the human abdominal aorta. *J Vasc Surg.* 2001;33:91-96.
  14. Brophy CM, Marks WH, Reilly JM, Tilson MD. Decreased tissue inhibitor of metalloproteinases (TIMP) in abdominal aortic aneurysm tissue: a preliminary report. *J Surg Res.* 1991;50:653-657.
  15. Rasmussen TE, Hallett JW, Schutte S, et al. Genetic similarity in inflammatory and degenerative abdominal aortic aneurysms: a study of human leukocyte antigen class II disease risk genes. *J Vasc Surg.* 2001;34:84-89.
  16. Williams LR, Flanigan DP, O'Connor RJA, Schuler JJ. Persistent sciatic artery: clinical aspects and operative management. *Am J Surg.* 1983;145:687-693.
  17. Brantley SK, Rigdon EE, Raju S. Persistent sciatic artery: embryology, pathology, and treatment. *J Vasc Surg.* 1993;18:242-248.
  18. Brown SL, Busuttill RW, Baker JD, Machleder HI, et al. Bacteriologic and surgical determinants of survival in patients with mycotic aneurysms. *J Vasc Surg.* 1984;1:541-547.
  19. Nair R, Abdool-Carrim ATO, Chetty R, Robbs JV. Arterial aneurysms in patients infected with human immunodeficiency virus: a distinct clinicopathology entity? *J Vasc Surg.* 1999;29:600-607.
  20. Stahl RD, Lawrence PF, Bhirangi K. Left subclavian artery aneurysm: two cases of rare congenital etiology. *J Vasc Surg.* 1999;29:715-718.
  21. Jones TR, Frusha JD, Stromeyer FW. Brachial artery aneurysm in an infant: case report and review of the literature. *J Vasc Surg.* 1988;7:439-442.
  22. Svensjö S, Bengtsson H, Bergqvist D. Thoracic and thoracoabdominal aortic aneurysm and dissection: an investigation based on autopsy. *Br J Surg.* 1996;83:68-71.
  23. Lawrence PF, Gazak C, Bhirangi L, et al. The epidemiology of surgically repaired aneurysms in the United States. *J Vasc Surg.* 1999;30:632-640.
  24. Rigberg DA, Zingmond DS, McGory ML, et al. Age stratified, perioperative, and one-year mortality after abdominal aortic aneurysm repair: a statewide experience. *J Vasc Surg.* 2006;43:224-229.
  25. Rigberg DA, McGory ML, Zingmond DS, et al. Thirty-day mortality statistics underestimate the risk of repair of thoracoabdominal aortic aneurysms: a statewide experience. *J Vasc Surg.* 2006;43:217-222; discussion 223.
  26. Brunkwall J, Hauksson H, Bengtsson H, et al. Solitary aneurysms of the iliac arterial system: an estimate of their frequency of occurrence. *J Vasc Surg.* 1989;10:381-384.
  27. Krupski WC, Selzman CH, Florida R, et al. Contemporary management of isolated iliac aneurysms. *J Vasc Surg.* 1998;28:1-13.
  28. Olsen DM, Rodriguez JA, Vranic M, et al. A prospective study of ultrasound scan-guided thrombin injection of femoral pseudoaneurysm: a trend toward minimal medication. *J Vasc Surg.* 2002;36:779-782.
  29. Diwan A, Sarkar R, Stanley JC, et al. Incidence of femoral and popliteal artery aneurysms in patients with abdominal aortic aneurysms. *J Vasc Surg.* 2000;31:863-869.
  30. Crawford ES, Cohen ES. Aortic aneurysm: a multifocal disease. Presidential Address. *Arch Surg.* 1982;117:1393-1400.
  31. Gloviczki P, Pairolero P, Welch T, et al. Multiple aortic aneurysms: the results of surgical management. *J Vasc Surg.* 1990;11:19-27; discussion 27-28.
  32. Whitehouse WM Jr, Wakefield TW, Graham LM, et al. Limb-threatening potential of arteriosclerotic popliteal artery aneurysms. *Surgery.* 1983;93:694-699.
  33. Harbuzariu C, Duncan AA, Bower TC, et al. Profunda femoris artery aneurysms: association with aneurysmal disease and limb ischemia. *J Vasc Surg.* 2008;47:31-34; discussion 34-35.

34. Hollier LH, Stanson AW, Gloviczki P, et al. Arteriomegaly: classification and morbid implications of diffuse aneurysmal disease. *Surgery*. 1983;93:700-708.
35. Lawrence PF, Wallis C, Dobrin PB, et al. Peripheral aneurysms and arteriomegaly: is there a familial pattern? *J Vasc Surg*. 1999;28:599-605.
36. Ogata T, MacKean GL, Cole CW, et al. The lifetime prevalence of abdominal aortic aneurysms among siblings of aneurysm patients is eightfold higher than among siblings of spouses: an analysis of 187 aneurysm families in Nova Scotia, Canada. *J Vasc Surg*. 2005;42:891-897.
37. Biddinger A, Rocklin M, Coselli J, Milewicz DM. Familial thoracic aortic dilatations and dissections: a case control study. *J Vasc Surg*. 1997;25:506-511.
38. Darling RC 3rd, Brewster DC, Darling RC, et al. Are familial abdominal aortic aneurysms different? *J Vasc Surg*. 1989;10:39-43.

## 第 127 章

1. Johnston KW, Rutherford RB, Tilson MD, et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. *J Vasc Surg*. 1991;13:452-458.
2. Pearce WH, Slaughter MS, LeMaire S, et al. Aortic diameter as a function of age, gender, and body surface area. *Surgery*. 1993;114:691-697.
3. Lederle FA, Johnson GR, Wilson SE, et al. Relationship of age, gender, race, and body size to infrarenal aortic diameter. The Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Investigators. *J Vasc Surg*. 1997;26:595-601.
4. Olsen PS, Schroeder T, Agerskov K, et al. Surgery for abdominal aortic aneurysms. A survey of 656 patients. *J Cardiovasc Surg (Torino)*. 1991;32:636-642.
5. Back MR, Bandyk M, Bradner M, et al. Critical analysis of outcome determinants affecting repair of intact aneurysms involving the visceral aorta. *Ann Vasc Surg*. 2005;19:648-656.
6. Brunkwall J, Hauksson H, Bengtsson H, et al. Solitary aneurysms of the iliac arterial system: an estimate of their frequency of occurrence. *J Vasc Surg*. 1989;10:381-384.
7. Crawford ES, Cohen ES. Aortic aneurysm: a multifocal disease. Presidential address. *Arch Surg*. 1982;117:1393-1400.
8. Cho JS, Gloviczki P, Martelli E, et al. Long-term survival and late complications after repair of ruptured abdominal aortic aneurysms. *J Vasc Surg*. 1998;27:813-819; discussion 819-820.
9. Dent TL, Lindenauer SM, Ernst CB, Fry WJ. Multiple arteriosclerotic arterial aneurysms. *Arch Surg*. 1972;105:338-344.
10. Silverberg E, Boring CC, Squires TS. Cancer statistics, 1990. *CA Cancer J Clin*. 1990;40:9-26.
11. Prevention CfDcA. Leading causes of death, United States, 2000-2005. cdc.gov. 2008.
12. Gillum RF. Epidemiology of aortic aneurysm in the United States. *J Clin Epidemiol*. 1995;48:1289-1298.
13. Bengtsson H, Bergqvist D. Ruptured abdominal aortic aneurysm: a population-based study. *J Vasc Surg*. 1993;18:74-80.
14. Heller JA, Weinberg A, Arons R, et al. Two decades of abdominal aortic aneurysm repair: have we made any progress? *J Vasc Surg*. 2000;32:1091-1100.
15. Adam DJ, Mohan IV, Stuart WP, et al. Community and hospital outcome from ruptured abdominal aortic aneurysm within the catchment area of a regional vascular surgical service. *J Vasc Surg*. 1999;30:922-928.
16. Bown MJ, Sutton AJ, Bell PR, Sayers RD. A meta-analysis of 50 years of ruptured abdominal aortic aneurysm repair. *Br J Surg*. 2002;89:714-730.
17. Hallin A, Bergqvist D, Holmberg L. Literature review of surgical management of abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg*. 2001;22:197-204.
18. Heikkinen M, Salenius JP, Auvinen O. Ruptured abdominal aortic aneurysm in a well-defined geographic area. *J Vasc Surg*.

2002;36:291-296.

19. Kantonen I, Lepantalo M, Brommels M, et al. Mortality in ruptured abdominal aortic aneurysms. The Finnvasc Study Group. *Eur J Vasc Endovasc Surg.* 1999;17:208-212.
20. Lesperance K, Andersen C, Singh N, et al. Expanding use of emergency endovascular repair for ruptured abdominal aortic aneurysms: disparities in outcomes from a nationwide perspective. *J Vasc Surg.* 2008;47:1165-1170; discussion 1170-1171.
21. Nowygrod R, Egorova N, Greco G, et al. Trends, complications, and mortality in peripheral vascular surgery. *J Vasc Surg.* 2006;43:205-216.
22. Craig SR, Wilson RG, Walker AJ, Murie JA. Abdominal aortic aneurysm: still missing the message. *Br J Surg.* 1993;80:450-452.
23. Pasch AR, Ricotta JJ, May AG, et al. Abdominal aortic aneurysm: the case for elective resection. *Circulation.* 1984;70:II-14.
24. Breckwoldt WL, Mackey WC, O'Donnell TF Jr. The economic implications of high-risk abdominal aortic aneurysms. *J Vasc Surg.* 1991;13:798-803; discussion 803-804.
25. Katz DJ, Stanley JC, Zelenock GB. Operative mortality rates for intact and ruptured abdominal aortic aneurysms in Michigan: an eleven-year statewide experience. *J Vasc Surg.* 1994;19:804-815; discussion 816-817.
26. LaMorte WW, Scott TE, Menzoian JO. Racial differences in the incidence of femoral bypass and abdominal aortic aneurysmectomy in Massachusetts: relationship to cardiovascular risk factors. *J Vasc Surg.* 1995;21:422-431.
27. Blanchard JF. Epidemiology of abdominal aortic aneurysms. *Epidemiol Rev.* 1999;21:207-221.
28. Wilmink AB, Hubbard CS, Day NE, Quick CR. The incidence of small abdominal aortic aneurysms and the change in normal infrarenal aortic diameter: implications for screening. *Eur J Vasc Endovasc Surg.* 2001;21:165-170.
29. Lederle FA, Johnson GR, Wilson SE, et al. Yield of repeated screening for abdominal aortic aneurysm after a 4-year interval. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. *Arch Intern Med.* 2000;160:1117-1121.
30. Melton LJ 3rd, Bickerstaff LK, Hollier LH, et al. Changing incidence of abdominal aortic aneurysms: a population-based study. *Am J Epidemiol.* 1984;120:379-386.
31. Bengtsson H, Bergqvist D, Sternby NH. Increasing prevalence of abdominal aortic aneurysms. A necropsy study. *Eur J Surg.* 1992;158:19-23.
32. McFarlane MJ. The epidemiologic necropsy for abdominal aortic aneurysm. *JAMA.* 1991;265:2085-2088.
33. Wilmink AB, Quick CR. Epidemiology and potential for prevention of abdominal aortic aneurysm. *Br J Surg.* 1998;85:155-162.
34. Choksy SA, Wilmink AB, Quick CR. Ruptured abdominal aortic aneurysm in the Huntingdon district: a 10-year experience. *Ann R Coll Surg Engl.* 1999;81:27-31.
35. Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. *Ann Intern Med.* 1997;126:441-449.
36. Alcorn HG, Wolfson SK Jr, Sutton-Tyrrell K, et al. Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. *Arterioscler Thromb Vasc Biol.* 1996;16:963-970.
37. Lee AJ, Fowkes FG, Carson MN, et al. Smoking, atherosclerosis and risk of abdominal aortic aneurysm. *Eur Heart J.* 1997;18:671-676.
38. Franks PJ, Edwards RJ, Greenhalgh RM, Powell JT. Risk factors for abdominal aortic aneurysms in smokers. *Eur J Vasc Endovasc Surg.* 1996;11:487-492.
39. Lederle FA, Johnson GR, Wilson SE, et al. The Aneurysm Detection and Management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. *Arch Intern Med.* 2000;160:1425-1430.

40. O'Kelly TJ, Heather BP. General practice-based population screening for abdominal aortic aneurysms: a pilot study. *Br J Surg*. 1989;76:479-480.
41. Pleumeekers HJ, Hoes AW, van der Does E, et al. Aneurysms of the abdominal aorta in older adults. The Rotterdam Study. *Am J Epidemiol*. 1995;142:1291-1299.
42. Smith FC, Grimshaw GM, Paterson IS, et al. Ultrasonographic screening for abdominal aortic aneurysm in an urban community. *Br J Surg*. 1993;80:1406-1409.
43. Vardulaki KA, Walker NM, Day NE, et al. Quantifying the risks of hypertension, age, sex and smoking in patients with abdominal aortic aneurysm. *Br J Surg*. 2000;87:195-200.
44. Reed D, Reed C, Stemmermann G, Hayashi T. Are aortic aneurysms caused by atherosclerosis? *Circulation*. 1992;85:205-211.
45. Rodin MB, Daviglus ML, Wong GC, et al. Middle age cardiovascular risk factors and abdominal aortic aneurysm in older age. *Hypertension*. 2003;42:61-68.
46. Singh K, Bona KH, Jacobsen BK, et al. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: the Tromsø Study. *Am J Epidemiol*. 2001;154:236-244.
47. Strachan DP. Predictors of death from aortic aneurysm among middle-aged men: the Whitehall study. *Br J Surg*. 1991;78:401-404.
48. Wilmsink TB, Quick CR, Day NE. The association between cigarette smoking and abdominal aortic aneurysms. *J Vasc Surg*. 1999;30:1099-1105.
49. Lederle FA, Nelson DB, Joseph AM. Smokers' relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. *J Vasc Surg*. 2003;38:329-334.
50. Tornwall ME, Virtamo J, Haukka JK, et al. Life-style factors and risk for abdominal aortic aneurysm in a cohort of Finnish male smokers. *Epidemiology*. 2001;12:94-100.
51. Grimshaw GM, Thompson JM, Hamer JD. Prevalence of abdominal aortic aneurysm associated with hypertension in an urban population. *J Med Screen*. 1994;1:226-228.
52. Lindholt JS, Henneberg EW, Fasting H, Juul S. Mass or high-risk screening for abdominal aortic aneurysm. *Br J Surg*. 1997;84:40-42.
53. Wilmsink AB, Vardulaki KA, Hubbard CS, et al. Are antihypertensive drugs associated with abdominal aortic aneurysms? *J Vasc Surg*. 2002;36:751-757.
54. Cronenwett JL, Likosky DS, Russell MT, et al. A regional registry for quality assurance and improvement: the Vascular Study Group of Northern New England (VSGNNE). *J Vasc Surg*. 2007;46:1093-1101; discussion 1101-1102.
55. Darling RC 3rd, Brewster DC, Darling RC, et al. Are familial abdominal aortic aneurysms different? *J Vasc Surg*. 1989;10:39-43.
56. Johansen K, Koepsell T. Familial tendency for abdominal aortic aneurysms. *JAMA*. 1986;256:1934-1936.
57. Verloes A, Sakalihasan N, Koulischer L, Limet R. Aneurysms of the abdominal aorta: familial and genetic aspects in three hundred thirteen pedigrees. *J Vasc Surg*. 1995;21:646-655.
58. Webster MW, Ferrell RE, St Jean PL, et al. Ultrasound screening of first-degree relatives of patients with an abdominal aortic aneurysm. *J Vasc Surg*. 1991;13:9-13; discussion 13-14.
59. Baird PA, Sadovnick AD, Yee IM, et al. Sibling risks of abdominal aortic aneurysm. *Lancet*. 1995;346:601-604.
60. Frydman G, Walker PJ, Summers K, et al. The value of screening in siblings of patients with abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg*. 2003;26:396-400.
61. Salo JA, Soisalon-Soininen S, Bondestam S, Mattila PS. Familial occurrence of abdominal aortic aneurysm. *Ann Intern Med*. 1999;130:637-642.
62. Powell JT, Greenhalgh RM. Multifactorial inheritance of abdominal aortic aneurysm. *Eur J Vasc Surg*. 1987;1:29-31.
63. Muluk SC, Gertler JP, Brewster DC, et al. Presentation and patterns of aortic aneurysms in young patients. *J Vasc Surg*.

1994;20:880-886; discussion 887-888.

64. Baxter BT, McGee GS, Flinn WR, et al. Distal embolization as a presenting symptom of aortic aneurysms. *Am J Surg*. 1990;160:197-201.
65. Kvilekval KH, Best IM, Mason RA, et al. The value of computed tomography in the management of symptomatic abdominal aortic aneurysms. *J Vasc Surg*. 1990;12:28-33.
66. Sullivan CA, Rohrer MJ, Cutler BS. Clinical management of the symptomatic but unruptured abdominal aortic aneurysm. *J Vasc Surg*. 1990;11:799-803.
67. Lucarotti ME, Heather BP, Shaw E, Poskitt KR. Psychological morbidity associated with abdominal aortic aneurysm screening. *Eur J Vasc Endovasc Surg*. 1997;14:499-501.
68. Lederle FA, Walker JM, Reinke DB. Selective screening for abdominal aortic aneurysms with physical examination and ultrasound. *Arch Intern Med*. 1988;148:1753-1756.
69. Lederle FA, Simel DL. The rational clinical examination. Does this patient have abdominal aortic aneurysm? *JAMA*. 1999;281:77-82.
70. Beede SD, Ballard DJ, James EM, et al. Positive predictive value of clinical suspicion of abdominal aortic aneurysm. Implications for efficient use of abdominal ultrasonography. *Arch Intern Med*. 1990;150:549-551.
71. Chervu A, Clagett GP, Valentine RJ, et al. Role of physical examination in detection of abdominal aortic aneurysms. *Surgery*. 1995;117:454-457.
72. Jaakkola P, Hippelainen M, Farin P, et al. Interobserver variability in measuring the dimensions of the abdominal aorta: comparison of ultrasound and computed tomography. *Eur J Vasc Endovasc Surg*. 1996;12:230-237.
73. Shuman WP, Hastrup W Jr, Kohler TR, et al. Suspected leaking abdominal aortic aneurysm: use of sonography in the emergency room. *Radiology*. 1988;168:117-119.
74. Pavone P, Di Cesare E, Di Renzi P, et al. Abdominal aortic aneurysm evaluation: comparison of US, CT, MRI, and angiography. *Magn Reson Imaging*. 1990;8:199-204.
75. Lederle FA, Wilson SE, Johnson GR, et al. Variability in measurement of abdominal aortic aneurysms. Abdominal Aortic Aneurysm Detection and Management Veterans Administration Cooperative Study Group. *J Vasc Surg*. 1995;21:945-952.
76. Thomas PR, Shaw JC, Ashton HA, et al. Accuracy of ultrasound in a screening programme for abdominal aortic aneurysms. *J Med Screen*. 1994;1:3-6.
77. Sprouse LR 2nd, Meier GH 3rd, Lesar CJ, et al. Comparison of abdominal aortic aneurysm diameter measurements obtained with ultrasound and computed tomography: Is there a difference? *J Vasc Surg*. 2003;38:466-471; discussion 471-472.
78. Bengtsson H, Bergqvist D, Ekberg O, Janzon L. A population based screening of abdominal aortic aneurysms (AAA). *Eur J Vasc Surg*. 1991;5:53-57.
79. Morris GE, Hubbard CS, Quick CR. An abdominal aortic aneurysm screening programme for all males over the age of 50 years. *Eur J Vasc Surg*. 1994;8:156-160.
80. Scott RA, Ashton HA, Kay DN. Abdominal aortic aneurysm in 4237 screened patients: prevalence, development and management over 6 years. *Br J Surg*. 1991;78:1122-1125.
81. Heather BP, Poskitt KR, Earnshaw JJ, et al. Population screening reduces mortality rate from aortic aneurysm in men. *Br J Surg*. 2000;87:750-753.
82. Vardulaki KA, Walker NM, Couto E, et al. Late results concerning feasibility and compliance from a randomized trial of ultrasonographic screening for abdominal aortic aneurysm. *Br J Surg*. 2002;89:861-864.
83. Scott RA, Bridgewater SG, Ashton HA. Randomized clinical trial of screening for abdominal aortic aneurysm in women. *Br J Surg*. 2002;89:283-285.
84. Lindholt JS, Juul S, Fasting H, Henneberg EW. Hospital costs and benefits of screening for abdominal aortic aneurysms. Results from a randomised population screening trial. *Eur J Vasc Endovasc Surg*. 2002;23:55-60.

85. Ashton HA, Buxton MJ, Day NE, et al, for the Multicentre Aneurysm Screening Study G. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. *Lancet*. 2002;360:1531-1539.
86. Norman PE, Semmens JB, Lawrence-Brown MM. Long-term relative survival following surgery for abdominal aortic aneurysm: a review. *Cardiovasc Surg*. 2001;9:219-224.
87. Lederle FA. Ultrasonographic screening for abdominal aortic aneurysms. *Ann Intern Med*. 2003;139:516-522.
88. Wilmink TB, Quick CR, Hubbard CS, Day NE. The influence of screening on the incidence of ruptured abdominal aortic aneurysms. *J Vasc Surg*. 1999;30:203-208.
89. Scott RA, Wilson NM, Ashton HA, Kay DN. Influence of screening on the incidence of ruptured abdominal aortic aneurysm: 5-year results of a randomized controlled study. *Br J Surg*. 1995;82:1066-1070.
90. Bohm N, Wales L, Dunkley M, et al. Objective risk-scoring systems for repair of abdominal aortic aneurysms: applicability in endovascular repair? *Eur J Vasc Endovasc Surg*. 2008;36:172-177.
91. Health service costs and quality of life for early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. UK Small Aneurysm Trial Participants. *Lancet*. 1998;352:1656-1660.
92. Khaira HS, Herbert LM, Crowson MC. Screening for abdominal aortic aneurysms does not increase psychological morbidity. *Ann R Coll Surg Engl*. 1998;80:341-342.
93. Lindholt JS, Vammen S, Fasting H, Henneberg EW. Psychological consequences of screening for abdominal aortic aneurysm and conservative treatment of small abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg*. 2000;20:79-83.
94. Shaw C, Abrams K, Marteau TM. Psychological impact of predicting individuals' risks of illness: a systematic review. *Soc Sci Med*. 1999;49:1571-1598.
95. Multicentre Aneurysm Screening Study (MASS). Cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial. *BMJ*. 2002;325:1135.
96. Fleming C, Whitlock EP, Beil TL, Lederle FA. Screening for abdominal aortic aneurysm: a best-evidence systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2005;142:203-211.
97. Screening for abdominal aortic aneurysm: recommendation statement. *Ann Intern Med*. 2005;142:198-202.
98. Fillinger M. Commentary. Screening for abdominal aortic aneurysm: recommendation statement. *Perspect Vasc Surg Endovasc Ther*. 2006;18:71-73.
99. Kent KC, Zwolak RM, Jaff MR, et al. Screening for abdominal aortic aneurysm: a consensus statement. *J Vasc Surg*. 2004;39:267-269.
100. Crow P, Shaw E, Earnshaw JJ, et al. A single normal ultrasonographic scan at age 65 years rules out significant aneurysm disease for life in men. *Br J Surg*. 2001;88:941-944.
101. Scott RA, Vardulaki KA, Walker NM, et al. The long-term benefits of a single scan for abdominal aortic aneurysm (AAA) at age 65. *Eur J Vasc Endovasc Surg*. 2001;21:535-540.
102. Katz DA, Littenberg B, Cronenwett JL. Management of small abdominal aortic aneurysms. Early surgery vs watchful waiting. *JAMA*. 1992;268:2678-2686.
103. Brewster DC, Cronenwett JL, Hallett JW Jr, et al. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. *J Vasc Surg*. 2003;37:1106-1117.
104. Estes JE Jr. Abdominal aortic aneurysm; a study of one hundred and two cases. *Circulation*. 1950;2:258-264.
105. Schatz IJ, Fairbairn JF 2nd, Juergens JL. Abdominal aortic aneurysms. A reappraisal. *Circulation*. 1962;26:200-205.
106. Darling RC, Messina CR, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms. The case for early resection. *Circulation*. 1977;56(3 Suppl):II161-II164.
107. Sterpetti AV, Cavallaro A, Cavallari N, et al. Factors influencing the rupture of abdominal aortic aneurysms. *Surg Gynecol Obstet*. 1991;173:175-178.



108. Szilagyi DE, Smith RF, DeRusso FJ, et al. Contribution of abdominal aortic aneurysmectomy to prolongation of life. *Ann Surg.* 1966;164:678-699.
109. Foster JH, Bolasny BL, Gobbel WG Jr, Scott HW Jr. Comparative study of elective resection and expectant treatment of abdominal aortic aneurysm. *Surg Gynecol Obstet.* 1969;129:1-9.
110. Reed WW, Hallett JW Jr, Damiano MA, Ballard DJ. Learning from the last ultrasound. A population-based study of patients with abdominal aortic aneurysm. *Arch Intern Med.* 1997;157:2064-2068.
111. Limet R, Sakalihassan N, Albert A. Determination of the expansion rate and incidence of rupture of abdominal aortic aneurysms. *J Vasc Surg.* 1991;14:540-548.
112. Guirguis EM, Barber GG. The natural history of abdominal aortic aneurysms. *Am J Surg.* 1991;162:481-483.
113. Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. *Ann Surg.* 1999;230:289-296; discussion 296-297.
114. Conway KP, Byrne J, Townsend M, Lane IF. Prognosis of patients turned down for conventional abdominal aortic aneurysm repair in the endovascular and sonographic era: Szilagyi revisited? *J Vasc Surg.* 2001;33:752-757.
115. Lederle FA, Johnson GR, Wilson SE, et al. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. *JAMA.* 2002;287:2968-2972.
116. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. *Lancet.* 2005;365:2187-2192.
117. Fillinger MF, Racusin J, Baker RK, et al. Anatomic characteristics of ruptured abdominal aortic aneurysm on conventional CT scans: implications for rupture risk. *J Vasc Surg.* 2004;39:1243-1252.
118. Ouriel K, Green RM, Donayre C, et al. An evaluation of new methods of expressing aortic aneurysm size: relationship to rupture. *J Vasc Surg.* 1992;15:12-18; discussion 19-20.
119. Stringfellow MM, Lawrence PF, Stringfellow RG. The influence of aorta-aneurysm geometry upon stress in the aneurysm wall. *J Surg Res.* 1987;42:425-433.
120. Mower WR, Baraff LJ, Sneyd J. Stress distributions in vascular aneurysms: factors affecting risk of aneurysm rupture. *J Surg Res.* 1993;55:155-161.
121. Inzoli F, Boschetti F, Zappa M, et al. Biomechanical factors in abdominal aortic aneurysm rupture. *Eur J Vasc Surg.* 1993;7:667-674.
122. Elger DF, Blackketter DM, Budwig RS, Johansen KH. The influence of shape on the stresses in model abdominal aortic aneurysms. *J Biomech Eng.* 1996;118:326-332.
123. Raghavan ML, Webster MW, Vorp DA. Ex vivo biomechanical behavior of abdominal aortic aneurysm: assessment using a new mathematical model. *Ann Biomed Eng.* 1996;24:573-582.
124. Vorp DA, Raghavan ML, Webster MW. Mechanical wall stress in abdominal aortic aneurysm: influence of diameter and asymmetry. *J Vasc Surg.* 1998;27:632-639.
125. Fillinger MF, Raghavan ML, Marra SP, et al. In vivo analysis of mechanical wall stress and abdominal aortic aneurysm rupture risk. *J Vasc Surg.* 2002;36:589-597.
126. Venkatasubramanian AK, Fagan MJ, Mehta T, et al. A comparative study of aortic wall stress using finite element analysis for ruptured and non-ruptured abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg.* 2004;28:168-176.
127. Fillinger MF, Marra SP, Raghavan ML, Kennedy FE. Prediction of rupture risk in abdominal aortic aneurysm during observation: wall stress versus diameter. *J Vasc Surg.* 2003;37:724-732.
128. Truijers M, Pol JA, Schultzeekool LJ, et al. Wall stress analysis in small asymptomatic, symptomatic and ruptured abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg.* 2007;33:401-407.
129. Heng MS, Fagan MJ, Collier JW, et al. Peak wall stress measurement in elective and acute abdominal aortic aneurysms. *J Vasc Surg.* 2008;47:17-22; discussion 22.
130. Vande Geest JP, Di Martino ES, Bohra A, et al. A biomechanics-based rupture potential index for abdominal aortic

aneurysm risk assessment: demonstrative application. *Ann N Y Acad Sci.* 2006;1085:11-21.

131. Hunter GC, Smyth SH, Aguirre ML, et al. Incidence and histologic characteristics of blebs in patients with abdominal aortic aneurysms. *J Vasc Surg.* 1996;24:93-101.
132. Faggioli GL, Stella A, Gargiulo M, et al. Morphology of small aneurysms: definition and impact on risk of rupture. *Am J Surg.* 1994;168:131-135.
133. Fillinger MF, Marra SP, Chen D, Kennedy FE. The effect of calcification and focal stress artifacts on aortic aneurysm wall stress and rupture risk. *J Vasc Surg.* 2008.
134. Li ZY, U-King-Im J, Tang TY, et al. Impact of calcification and intraluminal thrombus on the computed wall stresses of abdominal aortic aneurysm. *J Vasc Surg.* 2008;47:928-935.
135. Speelman L, Bohra A, Bosboom EM, et al. Effects of wall calcifications in patient-specific wall stress analyses of abdominal aortic aneurysms. *J Biomech Eng.* 2007;129:105-109.
136. Di Martino E, Mantero S, Inzoli F, et al. Biomechanics of abdominal aortic aneurysm in the presence of endoluminal thrombus: experimental characterisation and structural static computational analysis. *Eur J Vasc Endovasc Surg.* 1998;15:290-299.
137. Mower WR, Quinones WJ, Gambhir SS. Effect of intraluminal thrombus on abdominal aortic aneurysm wall stress. *J Vasc Surg.* 1997;26:602-608.
138. Raghavan ML, Vorp DA. Toward a biomechanical tool to evaluate rupture potential of abdominal aortic aneurysm: identification of a finite strain constitutive model and evaluation of its applicability. *J Biomech.* 2000;33:475-482.
139. Schurink GW, van Baalen JM, Visser MJ, van Bockel JH. Thrombus within an aortic aneurysm does not reduce pressure on the aneurysmal wall. *J Vasc Surg.* 2000;31:501-506.
140. Wolf YG, Thomas WS, Brennan FJ, et al. Computed tomography scanning findings associated with rapid expansion of abdominal aortic aneurysms. *J Vasc Surg.* 1994;20:529-535; discussion 535-538.
141. Cronenwett JL, Murphy TF, Zelenock GB, et al. Actuarial analysis of variables associated with rupture of small abdominal aortic aneurysms. *Surgery.* 1985;98:472-483.
142. Nicholls SC, Gardner JB, Meissner MH, Johansen HK. Rupture in small abdominal aortic aneurysms. *J Vasc Surg.* 1998;28:884-888.
143. Nevitt MP, Ballard DJ, Hallett JW Jr. Prognosis of abdominal aortic aneurysms. A population-based study. *N Engl J Med.* 1989;321:1009-1014.
144. Brown PM, Pattenden R, Vernooy C, et al. Selective management of abdominal aortic aneurysms in a prospective measurement program. *J Vasc Surg.* 1996;23:213-220; discussion 221-222.
145. Lederle FA, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med.* 2002;346:1437-1444.
146. Szilagyi DE, Elliott JP, Smith RF. Clinical fate of the patient with asymptomatic abdominal aortic aneurysm and unfit for surgical treatment. *Arch Surg.* 1972;104:600-606.
147. Cronenwett JL, Sargent SK, Wall MH, et al. Variables that affect the expansion rate and outcome of small abdominal aortic aneurysms. *J Vasc Surg.* 1990;11:260-268; discussion 268-269.
148. Bengtsson H, Nilsson P, Bergqvist D. Natural history of abdominal aortic aneurysm detected by screening. *Br J Surg.* 1993;80:718-720.
149. Grimshaw GM, Thompson JM. The abnormal aorta: a statistical definition and strategy for monitoring change. *Eur J Vasc Endovasc Surg.* 1995;10:95-100.
150. Hirose Y, Hamada S, Takamiya M. Predicting the growth of aortic aneurysms: a comparison of linear vs exponential models. *Angiology.* 1995;46:413-419.
151. Schewe CK, Schweikart HP, Hammel G, et al. Influence of selective management on the prognosis and the risk of rupture of abdominal aortic aneurysms. *Clin Invest.* 1994;72:585-591.

152. Hatakeyama T, Shigematsu H, Muto T. Risk factors for rupture of abdominal aortic aneurysm based on three-dimensional study. *J Vasc Surg.* 2001;33:453-461.
153. Brady AR, Thompson RW, Greenhalgh RM, et al. Cardiovascular risk factors and abdominal aortic aneurysm expansion: only smoking counts [Abstract]. *Br J Surg.* 2003;90:492.
154. Santilli SM, Littooy FN, Cambria RA, et al. Expansion rates and outcomes for the 3.0-cm to the 3.9-cm infrarenal abdominal aortic aneurysm. *J Vasc Surg.* 2002;35:666-671.
155. Krupski WC, Bass A, Thurston DW, et al. Utility of computed tomography for surveillance of small abdominal aortic aneurysms. Preliminary report. *Arch Surg.* 1990;125:1345-1349; discussion 1349-1350.
156. Blankensteijn JD, Lindenburg FP, Van der Graaf Y, Eikelboom BC. Influence of study design on reported mortality and morbidity rates after abdominal aortic aneurysm repair. *Br J Surg.* 1998;85:1624-1630.
157. Brady AR, Fowkes FG, Greenhalgh RM, et al. Risk factors for postoperative death following elective surgical repair of abdominal aortic aneurysm: results from the UK Small Aneurysm Trial. On behalf of the UK Small Aneurysm Trial participants. *Br J Surg.* 2000;87:742-749.
158. Cronenwett JL, Birkmeyer JD. *The Dartmouth Atlas of Vascular Healthcare.* Chicago, IL: AHA Press; 2000.
159. Johnston KW. Multicenter prospective study of nonruptured abdominal aortic aneurysm. Part II. Variables predicting morbidity and mortality. *J Vasc Surg.* 1989;9:437-447.
160. Steyerberg EW, Kievit J, de Mol Van Otterloo JC, et al. Perioperative mortality of elective abdominal aortic aneurysm surgery. A clinical prediction rule based on literature and individual patient data. *Arch Intern Med.* 1995;155:1998-2004.
161. Nesi F, Leo E, Biancari F, et al. Preoperative risk stratification in patients undergoing elective infrarenal aortic aneurysm surgery: evaluation of five risk scoring methods. *Eur J Vasc Endovasc Surg.* 2004;28:52-58.
162. Biancari F, Leo E, Ylonen K, et al. Value of the Glasgow Aneurysm Score in predicting the immediate and long-term outcome after elective open repair of infrarenal abdominal aortic aneurysm. *Br J Surg.* 2003;90:838-844.
163. Biancari F, Hobo R, Juvonen T. Glasgow Aneurysm Score predicts survival after endovascular stenting of abdominal aortic aneurysm in patients from the EUROSTAR registry. *Br J Surg.* 2006;93:191-194.
164. L'Italien GJ, Paul SD, Hendel RC, et al. Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates. *J Am Coll Cardiol.* 1996;27:779-786.
165. Dimick JB, Cowan JA Jr, Stanley JC, et al. Surgeon specialty and provider volumes are related to outcome of intact abdominal aortic aneurysm repair in the United States. *J Vasc Surg.* 2003;38:739-744.
166. Anderson PL, Arons RR, Moskowitz AJ, et al. A statewide experience with endovascular abdominal aortic aneurysm repair: rapid diffusion with excellent early results. *J Vasc Surg.* 2004;39:10-19.
167. Lee WA, Carter JW, Upchurch G, et al. Perioperative outcomes after open and endovascular repair of intact abdominal aortic aneurysms in the United States during 2001. *J Vasc Surg.* 2004;39:491-496.
168. Dillavou ED, Muluk SC, Makaroun MS. Improving aneurysm-related outcomes: nationwide benefits of endovascular repair. *J Vasc Surg.* 2006;43:446-451; discussion 451-452.
169. Hua HT, Cambria RP, Chuang SK, et al. Early outcomes of endovascular versus open abdominal aortic aneurysm repair in the National Surgical Quality Improvement Program—Private Sector (NSQIP-PS). *J Vasc Surg.* 2005;41:382-389.
170. Baas AF, Janssen KJ, Prinssen M, et al. The Glasgow Aneurysm Score as a tool to predict 30-day and 2-year mortality in the patients from the Dutch Randomized Endovascular Aneurysm Management trial. *J Vasc Surg.* 2008;47:277-281.
171. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. *Lancet.* 2005;365:2179-2186.
172. Blankensteijn JD, de Jong SE, Prinssen M, et al. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. *N Engl J Med.* 2005;352:2398-2405.
173. Schermerhorn ML, O'Malley AJ, Jhaveri A, et al. Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population. *N Engl J Med.* 2008;358:464-474.

174. Bosch JL, Beinfeld MT, Halpern EF, et al. Endovascular versus open surgical elective repair of infrarenal abdominal aortic aneurysm: predictors of patient discharge destination. *Radiology*. 2001;220:576-580.
175. Williamson WK, Nicoloff AD, Taylor LM Jr, et al. Functional outcome after open repair of abdominal aortic aneurysm. *J Vasc Surg*. 2001;33:913-920.
176. Aquino RV, Jones MA, Zullo TG, et al. Quality of life assessment in patients undergoing endovascular or conventional AAA repair. *J Endovasc Ther*. 2001;8:521-528.
177. Harris PL, Vallabhaneni SR, Desgranges P, et al. Incidence and risk factors of late rupture, conversion, and death after endovascular repair of infrarenal aortic aneurysms: the EUROSTAR experience. European Collaborators on Stent/Graft Techniques for Aortic Aneurysm Repair. *J Vasc Surg*. 2000;32:739-749.
178. Prinssen M, Verhoeven EL, Buth J, et al. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. *N Engl J Med*. 2004;351:1607-1618.
179. Schermerhorn M. Should usual criteria for intervention in abdominal aortic aneurysms be “downsized,” considering reported risk reduction with endovascular repair? *Ann N Y Acad Sci*. 2006;1085:47-58.
180. Schermerhorn ML, Finlayson SR, Fillinger MF, et al. Life expectancy after endovascular versus open abdominal aortic aneurysm repair: results of a decision analysis model on the basis of data from EUROSTAR. *J Vasc Surg*. 2002;36:1112-1120.
181. Aune S, Amundsen SR, Evjensvold J, Trippstad A. Operative mortality and long-term relative survival of patients operated on for asymptomatic abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg*. 1995;9:293-298.
182. Batt M, Staccini P, Pittaluga P, et al. Late survival after abdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg*. 1999;17:338-342.
183. Johnston KW. Nonruptured abdominal aortic aneurysm: six-year follow-up results from the multicenter prospective Canadian aneurysm study. Canadian Society for Vascular Surgery Aneurysm Study Group. *J Vasc Surg*. 1994;20:163-170.
184. Smoking, lung function and the prognosis of abdominal aortic aneurysm. The UK Small Aneurysm Trial Participants. *Eur J Vasc Endovasc Surg*. 2000;19:636-642.
185. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. *Lancet*. 1998;352:1649-1655.
186. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med*. 2002;346:1445-1452.
187. Powell JT, Brown LC, Forbes JF, et al. Final 12-year follow-up of surgery versus surveillance in the UK Small Aneurysm Trial. *Br J Surg*. 2007;94:702-708.
188. Valentine RJ, Decaprio JD, Castillo JM, et al. Watchful waiting in cases of small abdominal aortic aneurysms—appropriate for all patients? *J Vasc Surg*. 2000;32:441-448; discussion 448-450.
189. Norman PE, Powell JT. Abdominal aortic aneurysm: the prognosis in women is worse than in men. *Circulation*. 2007;115:2865-2869.
190. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *Circulation*. 2002;105:1257-1267.
191. Hertzner NR, Young JR, Kramer JR, et al. Routine coronary angiography prior to elective aortic reconstruction: results of selective myocardial revascularization in patients with peripheral vascular disease. *Arch Surg*. 1979;114:1336-1344.
192. Eagle KA, Coley CM, Newell JB, et al. Combining clinical and thallium data optimizes preoperative assessment of cardiac risk before major vascular surgery. *Ann Intern Med*. 1989;110:859-866.
193. Fagevik Olsen M, Hahn I, Nordgren S, et al. Randomized controlled trial of prophylactic chest physiotherapy in major abdominal surgery. *Br J Surg*. 1997;84:1535-1538.

194. Indes JE, Lipsitz EC, Veith FJ, et al. Incidence and significance of nonaneurysmal-related computed tomography scan findings in patients undergoing endovascular aortic aneurysm repair. *J Vasc Surg.* 2008;48:286-290.
195. Wyers MC, Fillinger MF, Schermerhorn ML, et al. Endovascular repair of abdominal aortic aneurysm without preoperative arteriography. *J Vasc Surg.* 2003;38:730-738.
196. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. *AJR Am J Roentgenol.* 2008;190:736-741.
197. Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. *AJR Am J Roentgenol.* 2008;190:1060-1068.
198. Greenhalgh RM, Powell JT. Screening men for aortic aneurysm. *BMJ.* 2002;325:1123-1124.
199. Becquemin JP, Chemla E, Chatellier G, et al. Perioperative factors influencing the outcome of elective abdominal aorta aneurysm repair. *Eur J Vasc Endovasc Surg.* 2000;20:84-89.
200. Cronenwett JL. Variables that affect the expansion rate and rupture of abdominal aortic aneurysms. *Ann N Y Acad Sci.* 1996;800:56-67.
201. Finlayson SR, Birkmeyer JD, Fillinger MF, Cronenwett JL. Should endovascular surgery lower the threshold for repair of abdominal aortic aneurysms? *J Vasc Surg.* 1999;29:973-985.
202. Bush RL, Johnson ML, Collins TC, et al. Open versus endovascular abdominal aortic aneurysm repair in VA hospitals. *J Am Coll Surg.* 2006;202:577-587.
203. Sicard GA, Zwolak RM, Sidawy AN, et al. Endovascular abdominal aortic aneurysm repair: long-term outcome measures in patients at high-risk for open surgery. *J Vasc Surg.* 2006;44:229-236.
204. Zarins CK, Crabtree T, Bloch DA, et al. Endovascular aneurysm repair at 5 years: does aneurysm diameter predict outcome? *J Vasc Surg.* 2006;44:920-929; discussion 929-931.
205. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. *Circulation.* 2008;117:1883-1889.
206. Brown LC, Thompson SG, Greenhalgh RM, Powell JT. Fit patients with small abdominal aortic aneurysms (AAAs) do not benefit from early intervention. *J Vasc Surg.* 2008;48:1375-1381.
207. Iribarren C, Darbinian JA, Go AS, et al. Traditional and novel risk factors for clinically diagnosed abdominal aortic aneurysm: the Kaiser multiphasic health checkup cohort study. *Ann Epidemiol.* 2007;17:669-678.
208. Brady AR, Thompson SG, Fowkes FG, et al. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. *Circulation.* 2004;110:16-21.
209. Yeung JJ, Kim HJ, Abbruzzese TA, et al. Aortoiliac hemodynamic and morphologic adaptation to chronic spinal cord injury. *J Vasc Surg.* 2006;44:1254-1265.
210. Vollmar JF, Paes E, Pauschinger P, et al. Aortic aneurysms as late sequelae of above-knee amputation. *Lancet.* 1989;2:834-835.
211. Brophy CM, Tilson JE, Tilson MD. Propranolol stimulates the crosslinking of matrix components in skin from the aneurysm-prone blotchy mouse. *J Surg Res.* 1989;46:330-332.
212. Ricci MA, Slaiby JM, Gadowski GR, et al. Effects of hypertension and propranolol upon aneurysm expansion in the Anidjar/Dobrin aneurysm model. *Ann N Y Acad Sci.* 1996;800:89-96.
213. Simpson CF. Sotalol for the protection of turkeys from the development of  $\beta$ -aminopropionitrile-induced aortic ruptures. *Br J Pharmacol.* 1972;45:385-390.
214. Simpson CF, Boucek RJ. The  $\beta$ -aminopropionitrile-fed turkey: a model for detecting potential drug action on arterial tissue. *Cardiovasc Res.* 1983;17:26-32.
215. Simpson CF, Boucek RJ, Noble NL. Influence of *d*-, *l*-, and *dl*-propranolol, and practolol on beta-amino-propionitrile-induced aortic ruptures of turkeys. *Toxicol Appl Pharmacol.* 1976;38:169-175.
216. Englund R, Hudson P, Hanel K, Stanton A. Expansion rates of small abdominal aortic aneurysms. *Aust N Z J Surg.*

1998;68:21-24.

217. Gadowski GR, Pilcher DB, Ricci MA. Abdominal aortic aneurysm expansion rate: effect of size and beta-adrenergic blockade. *J Vasc Surg.* 1994;19:727-731.
218. Leach SD, Toole AL, Stern H, et al. Effect of beta-adrenergic blockade on the growth rate of abdominal aortic aneurysms. *Arch Surg.* 1988;123:606-609.
219. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. *J Vasc Surg.* 2002;35:72-79.
220. Wilmink AB, Hubbard CS, Day NE, Quick CR. Effect of propranolol on the expansion of abdominal aortic aneurysms: a randomized study. *Br J Surg.* 2000;87:499.
221. Kertai MD, Boersma E, Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. *Eur J Vasc Endovasc Surg.* 2004;28:343-352.
222. Schouten O, Lever TM, Welten GM, et al. Long-term cardiac outcome in high-risk patients undergoing elective endovascular or open infrarenal abdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg.* 2008;36:646-652.
223. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. *Lancet.* 2006;368:659-665.
224. Schouten O, van Laanen JH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. *Eur J Vasc Endovasc Surg.* 2006;32:21-26.
225. Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. *J Vasc Surg.* 2002;36:1-12.
226. Giulini SM, Bonardelli S, Portolani N, et al. Suprarenal aortic cross-clamping in elective abdominal aortic aneurysm surgery. *Eur J Vasc Endovasc Surg.* 2000;20:286-289.
227. Mosorin M, Juvonen J, Biancari F, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. *J Vasc Surg.* 2001;34:606-610.
228. Vammen S, Lindholt JS, Ostergaard L, et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. *Br J Surg.* 2001;88:1066-1072.
229. Juvonen J, Juvonen T, Laurila A, et al. Demonstration of *Chlamydia pneumoniae* in the walls of abdominal aortic aneurysms. *J Vasc Surg.* 1997;25:499-505.
230. Petersen E, Boman J, Persson K, et al. *Chlamydia pneumoniae* in human abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg.* 1998;15:138-142.
231. Vammen S, Lindholt JS, Andersen PL, et al. Antibodies against *Chlamydia pneumoniae* predict the need for elective surgical intervention on small abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg.* 2001;22:165-168.
232. Curci JA, Mao D, Bohnert DG, et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. *J Vasc Surg.* 2000;31:325-342.
233. Curci JA, Petrincic D, Liao S, et al. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. *J Vasc Surg.* 1998;28:1082-1093.
234. Petrincic D, Liao S, Holmes DR, et al. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. *J Vasc Surg.* 1996;23:336-346.
235. Schlosser FJ, Tangelder MJ, Verhagen HJ, et al. Growth predictors and prognosis of small abdominal aortic aneurysms. *J Vasc Surg.* 2008;47:1127-1133.
236. Sukhija R, Aronow WS, Sandhu R, et al. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. *Am J Cardiol.* 2006;97:279-280.
237. Evans J, Powell JT, Schwalbe E, et al. Simvastatin attenuates the activity of matrix metalloproteinase-9 in aneurysmal aortic tissue. *Eur J Vasc Endovasc Surg.* 2007;34:302-303.

238. Abisi S, Burnand KG, Humphries J, et al. Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms. *Br J Surg*. 2008;95:333-337.
239. Mosorin M, Niemela E, Heikkinen J, et al. The use of statins and fate of small abdominal aortic aneurysms. *Interact Cardiovasc Thorac Surg*. 2008;7:578-581.

## 第 128 章

1. Crawford ES, Saleh SA, Babb JW 3rd, et al. Infra renal abdominal aortic aneurysm: factors influencing survival after operation performed over a 25-year period. *Ann Surg*. 1981;193:699-709.
2. Ernst CB. Abdominal aortic aneurysm. *N Engl J Med*. 1993;328:1167-1172.
3. Zarins CK, Harris EJ Jr. Operative repair for aortic aneurysms: the gold standard. *J Endovasc Surg*. 1997;4:232-241.
4. Hertzner NR, Mascha EJ, Karafa MT, et al. Open infra renal abdominal aortic aneurysm repair: the Cleveland Clinic experience from 1989 to 1998. *J Vasc Surg*. 2002;35:1145-1154.
5. Wilt TJ, Lederle FA, Macdonald R, et al. Comparison of endovascular and open surgical repairs for abdominal aortic aneurysm. *Evid Rep Technol Assess (Full Rep)*. 2006;1-113.
6. Anderson PL, Arons RR, Moskowitz AJ, et al. A statewide experience with endovascular abdominal aortic aneurysm repair: rapid diffusion with excellent early results. *J Vasc Surg*. 2004;39:10-19.
7. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. *Ann Vasc Surg*. 1991;5:491-499.
8. Cowan JA Jr, Dimick JB, Henke PK, et al. Epidemiology of aortic aneurysm repair in the United States from 1993 to 2003. *Ann N Y Acad Sci*. 2006;1085:1-10.
9. Dillavou ED, Muluk SC, Makaroun MS. Improving aneurysm-related outcomes: nationwide benefits of endovascular repair. *J Vasc Surg*. 2006;43:446-451; discussion 451-452.
10. Carpenter JP, Baum RA, Barker CF, et al. Impact of exclusion criteria on patient selection for endovascular abdominal aortic aneurysm repair. *J Vasc Surg*. 2001;34:1050-1054.
11. Wolf YG, Fogarty TJ, Olcott C IV, et al. Endovascular repair of abdominal aortic aneurysms: eligibility rate and impact on the rate of open repair. *J Vasc Surg*. 2000;32:519-523.
12. West CA, Noel AA, Bower TC, et al. Factors affecting outcomes of open surgical repair of para renal aortic aneurysms: a 10-year experience. *J Vasc Surg*. 2006;43:921-927; discussion 927-928.
13. Sarac TP, Clair DG, Hertzner NR, et al. Contemporary results of juxtarenal aneurysm repair. *J Vasc Surg*. 2002;36:1104-1111.
14. Arko FR, Lee WA, Hill BB, et al. Impact of endovascular repair on open aortic aneurysm surgical training. *J Vasc Surg*. 2001;34:885-891.
15. Costin JA, Watson DR, Duff SB, et al. Evaluation of the complexity of open abdominal aneurysm repair in the era of endovascular stent grafting. *J Vasc Surg*. 2006;43:915-920; discussion 920.
16. Wolff KS, Prusa AM, Polterauer P, et al. Endografting increases total volume of AAA repairs but not at the expense of open surgery: experience in more than 1000 patients. *J Endovasc Ther*. 2005;12:274-279.
17. Choi ET, Wyble CW, Rubin BG, et al. Evolution of vascular fellowship training in the new era of endovascular techniques. *J Vasc Surg*. 2001;33(2 Suppl):S106-S110.
18. Johnston KW, Rutherford RB, Tilson MD, et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. *J Vasc Surg*. 1991;13:452-458.
19. Olsen PS, Schroeder T, Agerskov K, et al. Surgery for abdominal aortic aneurysms. A survey of 656 patients. *J Cardiovasc Surg (Torino)*. 1991;32:636-642.
20. Crawford ES, Crawford JL, Safi HJ, et al. Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors

determining immediate and long-term results of operations in 605 patients. *J Vasc Surg.* 1986;3:389-404.

21. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. *Lancet.* 1998;352:1649-1655.
22. Lederle FA, Johnson GR, Wilson SE, et al. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. *Arch Intern Med.* 2000;160:1425-1430.
23. Brewster DC, Cronenwett JL, Hallett JW Jr, et al. Guidelines for the treatment of abdominal aortic aneurysms. Report of a subcommittee of the Joint Council of the American Association for Vascular Surgery and Society for Vascular Surgery. *J Vasc Surg.* 2003;37:1106-1117.
24. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. *Lancet.* 2005;365:2187-2192.
25. Sicard GA, Zwolak RM, Sidawy AN, et al. Endovascular abdominal aortic aneurysm repair: long-term outcome measures in patients at high-risk for open surgery. *J Vasc Surg.* 2006;44:229-236.
26. Johnston KW. Multicenter prospective study of nonruptured abdominal aortic aneurysm. II. Variables predicting morbidity and mortality. *J Vasc Surg.* 1989;9:437-447.
27. Steyerberg EW, Kievit J, de Mol Van Otterloo JC, et al. Perioperative mortality of elective abdominal aortic aneurysm surgery. A clinical prediction rule based on literature and individual patient data. *Arch Intern Med.* 1995;155:1998-2004.
28. Brady AR, Fowkes FG, Greenhalgh RM, et al. Risk factors for postoperative death following elective surgical repair of abdominal aortic aneurysm: results from the UK Small Aneurysm Trial. On behalf of the UK Small Aneurysm Trial participants. *Br J Surg.* 2000;87:742-749.
29. Beck AW, Goodney PP, Nolan BW, et al. Predicting one year mortality after elective AAA repair. *J Vasc Surg* 2009;4:838-843, discussion 843-844.
30. Errington ML, Ferguson JM, Gillespie IN, et al. Complete pre-operative imaging assessment of abdominal aortic aneurysm with spiral CT angiography. *Clin Radiol.* 1997;52:369-377.
31. Fukuhara R, Ishiguchi T, Ikeda M, et al. Evaluation of abdominal aortic aneurysm for endovascular stent-grafting with volume-rendered CT images of vessel lumen and thrombus. *Radiat Med.* 2004;22:332-341.
32. Filis KA, Arko FR, Rubin GD, Zarins CK. Three-dimensional CT evaluation for endovascular abdominal aortic aneurysm repair. Quantitative assessment of the infrarenal aortic neck. *Acta Chir Belg.* 2003;103:81-86.
33. Van Hoe L, Baert AL, Gryspeerdt S, et al. Supra- and juxtarenal aneurysms of the abdominal aorta: preoperative assessment with thin-section spiral CT. *Radiology.* 1996;198:443-448.
34. Boules TN, Compton CN, Stanziale SF, et al. Can computed tomography scan findings predict "impending" aneurysm rupture? *Vasc Endovascular Surg.* 2006;40:41-47.
35. Lutz AM, Willmann JK, Pfammatter T, et al. Evaluation of aortoiliac aneurysm before endovascular repair: comparison of contrast-enhanced magnetic resonance angiography with multidetector row computed tomographic angiography with an automated analysis software tool. *J Vasc Surg.* 2003;37:619-627.
36. Petersen MJ, Cambria RP, Kaufman JA, et al. Magnetic resonance angiography in the preoperative evaluation of abdominal aortic aneurysms. *J Vasc Surg.* 1995;21:891-898; discussion 899.
37. Prince MR, Narasimham DL, Stanley JC, et al. Gadolinium-enhanced magnetic resonance angiography of abdominal aortic aneurysms. *J Vasc Surg.* 1995;21:656-669.
38. Vosschenrich R, Fischer U. Contrast-enhanced MR angiography of abdominal vessels: is there still a role for angiography? *Eur Radiol.* 2002;12:218-230.
39. Schoenberg SO, Essig M, Hallscheidt P, et al. Multiphase magnetic resonance angiography of the abdominal and pelvic arteries: results of a bicenter multireader analysis. *Invest Radiol.* 2002;37:20-28.
40. Cambria RP, Kaufman JL, Brewster DC, et al. Surgical renal artery reconstruction without contrast arteriography: the role



of clinical profiling and magnetic resonance angiography. *J Vasc Surg.* 1999;29:1012-1021.

41. Tennant WG, Hartnell GG, Baird RN, Horrocks M. Radiologic investigation of abdominal aortic aneurysm disease: comparison of three modalities in staging and the detection of inflammatory change. *J Vasc Surg.* 1993;17:703-709.
42. Alimi YS, Hartung O, Orsoni P, Juhan C. Abdominal aortic laparoscopic surgery: retroperitoneal or transperitoneal approach? *Eur J Vasc Endovasc Surg.* 2000;19:21-26.
43. Edoga JK, Asgarian K, Singh D, et al. Laparoscopic surgery for abdominal aortic aneurysms. Technical elements of the procedure and a preliminary report of the first 22 patients. *Surg Endosc.* 1998;12:1064-1072.
44. Dion YM, Gracia CR, Ben El Kadi HH. Totally laparoscopic abdominal aortic aneurysm repair. *J Vasc Surg.* 2001;33:181-185.
45. Dion YM, Griselli F, Douville Y, Langis P. Early and mid-term results of totally laparoscopic surgery for aortoiliac disease: lessons learned. *Surg Laparosc Endosc Percutan Tech.* 2004;14:328-334.
46. Tefera G, Carr SC, Turnipseed WD. Endovascular aortic repair or minimal incision aortic surgery: which procedure to choose for treatment of high-risk aneurysms? *Surgery.* 2004;136:748-753.
47. Turnipseed W, Tefera G, Carr S. Comparison of minimal incision aortic surgery with endovascular aortic repair. *Am J Surg.* 2003;186:287-291.
48. Turnipseed WD, Carr SC, Hoch JR, Cohen JR. Minimal incision aortic surgery (MIAS). *Ann Vasc Surg.* 2003;17:180-184.
49. Kawaharada N, Morishita K, Fukada J, et al. Minilaparotomy abdominal aortic aneurysm repair versus the retroperitoneal approach and standard open surgery. *Surg Today.* 2004;34:837-841.
50. Calligaro KD, Savarese RP, McCombs PR, DeLaurentis DA. Division of the left renal vein during aortic surgery. *Am J Surg.* 1990;160:192-196.
51. AbuRahma AF, Robinson PA, Boland JP, Lucente FC. The risk of ligation of the left renal vein in resection of the abdominal aortic aneurysm. *Surg Gynecol Obstet.* 1991;173:33-36.
52. Sicard GA, Reilly JM, Rubin BG, et al. Transabdominal versus retroperitoneal incision for abdominal aortic surgery: report of a prospective randomized trial. *J Vasc Surg.* 1995;21:174-181; discussion 181-183.
53. Todd GJ, DeRose JJ Jr. Retroperitoneal approach for repair of inflammatory aortic aneurysms. *Ann Vasc Surg.* 1995;9:525-534.
54. Cambria RP, Brewster DC, Abbott WM, et al. Transperitoneal versus retroperitoneal approach for aortic reconstruction: a randomized prospective study. *J Vasc Surg.* 1990;11:314-324; discussion 324-325.
55. Arko FR, Bohannon WT, Mettauer M, et al. Retroperitoneal approach for aortic surgery: is it worth it? *Cardiovasc Surg.* 2001;9:20-26.
56. Darling C 3rd, Shah DM, Chang BB, et al. Current status of the use of retroperitoneal approach for reconstructions of the aorta and its branches. *Ann Surg.* 1996;224:501-506; discussion 506-508.
57. Sieunarine K, Lawrence-Brown MM, Goodman MA. Comparison of transperitoneal and retroperitoneal approaches for infrarenal aortic surgery: early and late results. *Cardiovasc Surg.* 1997;5:71-76.
58. Mason RA, Kvilekval KH, Hartman A, Giron F. The retroperitoneal approach to aortic surgery associated with horseshoe kidney. *J Cardiovasc Surg (Torino).* 1991;32:763-766.
59. Eze AR, White JV, Pathak AS, Grabowski MW. "Pancake kidney": a renal anomaly complicating aortic reconstruction. *Ann Vasc Surg.* 1998;12:278-281.
60. Huber D, Griffin A, Niesche J, et al. Aortic aneurysm surgery in the presence of a horseshoe kidney. *Aust N Z J Surg.* 1990;60:963-966.
61. Faggioli G, Freyrie A, Pilato A, et al. Renal anomalies in aortic surgery: contemporary results. *Surgery.* 2003;133:641-646.
62. Crawford ES, Coselli JS, Safi HJ, et al. The impact of renal fusion and ectopia on aortic surgery. *J Vasc Surg.* 1988;8:375-383.
63. O'Hara PJ, Hakaim AG, Hertzner NR, et al. Surgical management of aortic aneurysm and coexistent horseshoe kidney:

- review of a 31-year experience. *J Vasc Surg*. 1993;17:940-947.
64. de Virgilio C, Gloviczki P. Aortic reconstruction in patients with horseshoe or ectopic kidneys. *Semin Vasc Surg*. 1996;9:245-252.
  65. Stroosma OB, Kootstra G, Schurink GW. Management of aortic aneurysm in the presence of a horseshoe kidney. *Br J Surg*. 2001;88:500-509.
  66. Gökseel O, Cinar B, Kämürçü G, et al. Surgical treatment of abdominal aortic aneurysms associated with horseshoe kidney. *Vascular*. 2006;14:27-31.
  67. Frego M, Bianchera G, Angriman I, et al. Abdominal aortic aneurysm with coexistent horseshoe kidney. *Surg Today*. 2007;37:626-630.
  68. Gelman S. The pathophysiology of aortic cross-clamping and unclamping. *Anesthesiology*. 1995;82:1026-1060.
  69. Wozniak MF, LaMuraglia GM, Musch G. Anesthesia for open abdominal aortic surgery. *Int Anesthesiol Clin*. 2005;43:61-78.
  70. Roizen MF, Beaupre PN, Alpert RA, et al. Monitoring with two-dimensional transesophageal echocardiography. Comparison of myocardial function in patients undergoing supraceliac, suprarenal-infraceliac, or infrarenal aortic occlusion. *J Vasc Surg*. 1984;1:300-305.
  71. Attia RR, Murphy JD, Snider M, et al. Myocardial ischemia due to infrarenal aortic cross-clamping during aortic surgery in patients with severe coronary artery disease. *Circulation*. 1976;53:961-965.
  72. Green RM, Ricotta JJ, Ouriel K, DeWeese JA. Results of supraceliac aortic clamping in the difficult elective resection of infrarenal abdominal aortic aneurysm. *J Vasc Surg*. 1989;9:124-134.
  73. Miller DC, Myers BD. Pathophysiology and prevention of acute renal failure associated with thoracoabdominal or abdominal aortic surgery. *J Vasc Surg*. 1987;5:518-523.
  74. Bicknell CD, Cowan AR, Kerle MI, et al. Renal dysfunction and prolonged visceral ischaemia increase mortality rate after suprarenal aneurysm repair. *Br J Surg*. 2003;90:1142-1146.
  75. Wahlberg E, Dimuzio PJ, Stoney RJ. Aortic clamping during elective operations for infrarenal disease: the influence of clamping time on renal function. *J Vasc Surg*. 2002;36:13-18.
  76. Gamulin Z, Forster A, Morel D, et al. Effects of infrarenal aortic cross-clamping on renal hemodynamics in humans. *Anesthesiology*. 1984;61:394-399.
  77. Paul MD, Mazer CD, Byrick RJ, et al. Influence of mannitol and dopamine on renal function during elective infrarenal aortic clamping in man. *Am J Nephrol*. 1986;6:427-434.
  78. Gilbert TB, Hasnain JU, Flinn WR, et al. Fenoldopam infusion associated with preserving renal function after aortic cross-clamping for aneurysm repair. *J Cardiovasc Pharmacol Ther*. 2001;6:31-36.
  79. Halpenny M, Rushe C, Breen P, et al. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. *Eur J Anaesthesiol*. 2002;19:32-39.
  80. Tallgren M, Niemi T, Pöyhiä R, et al. Acute renal injury and dysfunction following elective abdominal aortic surgery. *Eur J Vasc Endovasc Surg*. 2007;33:550-555.
  81. Ochsner JL, Mills NL, Gardner PA. A technique for renal preservation during suprarenal abdominal aortic operations. *Surg Gynecol Obstet*. 1984;159:388-390.
  82. Allen BT, Anderson CB, Rubin BG, et al. Preservation of renal function in juxtarenal and suprarenal abdominal aortic aneurysm repair. *J Vasc Surg*. 1993;17:948-958; discussion 958-959.
  83. Yeung KK, Jongkind V, Coveliers HM, et al. Routine continuous cold perfusion of the kidneys during elective juxtarenal aortic aneurysm repair. *Eur J Vasc Endovasc Surg*. 2008;35:446-451.
  84. Svensson LG, Crawford ES, Hess KR, et al. Thoracoabdominal aortic aneurysms associated with celiac, superior mesenteric, and renal artery occlusive disease: methods and analysis of results in 271 patients. *J Vasc Surg*. 1992;16:378-389; discussion 389-390.

85. Hassoun HT, Miller CC 3rd, Huynh TT, et al. Cold visceral perfusion improves early survival in patients with acute renal failure after thoracoabdominal aortic aneurysm repair. *J Vasc Surg.* 2004;39:506-512.
86. K  soy C, LeMa  re SA, Curling PE, et al. Renal perfusion during thoracoabdominal aortic operations: cold crystalloid is superior to normothermic blood. *Ann Thorac Surg.* 2002;73:730-738.
87. Cohen JR, Angus L, Asher A, et al. Disseminated intravascular coagulation as a result of supraceliac clamping: implications for thoracoabdominal aneurysm repair. *Ann Vasc Surg.* 1987;1:552-557.
88. Cohen JR, Sardari F, Paul J, et al. Increased intestinal permeability: implications for thoracoabdominal aneurysm repair. *Ann Vasc Surg.* 1992;6:433-437.
89. Cohen JR, Schroder W, Leal J, Wise L. Mesenteric shunting during thoracoabdominal aortic clamping to prevent disseminated intravascular coagulation in dogs. *Ann Vasc Surg.* 1988;2:261-267.
90. Safi HJ, Miller CC 3rd, Yawn DH, et al. Impact of distal aortic and visceral perfusion on liver function during thoracoabdominal and descending thoracic aortic repair. *J Vasc Surg.* 1998;27:145-152; discussion 152-153.
91. Gertler JP, Cambria RP, Brewster DC, et al. Coagulation changes during thoracoabdominal aneurysm repair. *J Vasc Surg.* 1996;24:936-943; discussion 943-945.
92. Money SR, Ballinger BA, Crockett DE Jr, et al. The effects of supraceliac aortic clamping on the anticoagulant effects of heparin. *Am J Surg.* 1996;172:155-157.
93. Illig KA, Green RM, Ouriel K, et al. Primary fibrinolysis during supraceliac aortic clamping. *J Vasc Surg.* 1997;25:244-251; discussion 252-254.
94. Anagnostopoulos PV, Shepard AD, Pipinos II, et al. Hemostatic alterations associated with supraceliac aortic cross-clamping. *J Vasc Surg.* 2002;35:100-108.
95. Ernst CB, Hagihara PF, Daugherty ME, Griffen WO Jr. Inferior mesenteric artery stump pressure: a reliable index for safe IMA ligation during abdominal aortic aneurysmectomy. *Ann Surg.* 1978;187:641-646.
96. Pittaluga P, Batt M, Hassen-Khodja R, et al. Revascularization of internal iliac arteries during aortoiliac surgery: a multicenter study. *Ann Vasc Surg.* 1998;12:537-543.
97. K  ttil   K, Perttil   J, V  nttinen E, Niinikoski J. Tonometric assessment of sigmoid perfusion during aortobifemoral reconstruction for arteriosclerosis. *Eur J Surg.* 1994;160:491-495.
98. Van Damme H, Creemers E, Limet R. Ischaemic colitis following aortoiliac surgery. *Acta Chir Belg.* 2000;100:21-27.
99. Schiedler MG, Cutler BS, Fiddian-Green RG. Sigmoid intramural pH for prediction of ischemic colitis during aortic surgery. A comparison with risk factors and inferior mesenteric artery stump pressures. *Arch Surg.* 1987;122:881-886.
100. Pronovost PJ, Jenckes MW, Dorman T, et al. Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery. *JAMA.* 1999;281:1310-1317.
101. Pronovost PJ, Dang D, Dorman T, et al. Intensive care unit nurse staffing and the risk for complications after abdominal aortic surgery. *Eff Clin Pract.* 2001;4:199-206.
102. Hadjianastassiou VG, Tekkis PP, Athanasiou T, et al. Comparison of mortality prediction models after open abdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg.* 2007;33:536-543.
103. Hadjianastassiou VG, Tekkis PP, Goldhill DR, Hands LJ. Quantification of mortality risk after abdominal aortic aneurysm repair. *Br J Surg.* 2005;92:1092-1098.
104. Le Manach Y, Perel A, Coriat P, et al. Early and delayed myocardial infarction after abdominal aortic surgery. *Anesthesiology.* 2005;102:885-891.
105. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. *N Engl J Med.* 1996;335:1713-1720.
106. Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. *N Engl J Med.* 2005;353:349-361.
107. Shammash JB, Trost JC, Gold JM, et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients.

*Am Heart J.* 2001;141:148-153.

108. Olin JW, Graor RA, O'Hara P, Young JR. The incidence of deep venous thrombosis in patients undergoing abdominal aortic aneurysm resection. *J Vasc Surg.* 1993;18:1037-1041.
109. Bani-Hani MG, Al-Khaffaf H, Titi MA, Jaradat I. Interventions for preventing venous thromboembolism following abdominal aortic surgery. *Cochrane Database Syst Rev.* 2008;1:CD005509.
110. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008;133(6 Suppl):381S-453S.
111. Blankensteijn JD, Lindenburg FP, Van der Graaf Y, Eikelboom BC. Influence of study design on reported mortality and morbidity rates after abdominal aortic aneurysm repair. *Br J Surg.* 1998;85:1624-1630.
112. Menard MT, Chew DK, Chan RK, et al. Outcome in patients at high risk after open surgical repair of abdominal aortic aneurysm. *J Vasc Surg.* 2003;37:285-292.
113. Hertzer NR, Mascha EJ. A personal experience with factors influencing survival after elective open repair of infrarenal aortic aneurysms. *J Vasc Surg.* 2005;42:898-905.
114. Krupski WC, Rutherford RB. Update on open repair of abdominal aortic aneurysms: the challenges for endovascular repair. *J Am Coll Surg.* 2004;199:946-960.
115. Johnston KW, Scobie TK. Multicenter prospective study of nonruptured abdominal aortic aneurysms. I. Population and operative management. *J Vasc Surg.* 1988;7:69-81.
116. Lawrence PF, Gazak C, Bhirangi L, et al. The epidemiology of surgically repaired aneurysms in the United States. *J Vasc Surg.* 1999;30:632-640.
117. Dimick JB, Stanley JC, Axelrod DA, et al. Variation in death rate after abdominal aortic aneurysmectomy in the United States: impact of hospital volume, gender, and age. *Ann Surg.* 2002;235:579-585.
118. Rigberg DA, Zingmond DS, McGory ML, et al. Age stratified, perioperative, and one-year mortality after abdominal aortic aneurysm repair: a statewide experience. *J Vasc Surg.* 2006;43:224-229.
119. Heller JA, Weinberg A, Arons R, et al. Two decades of abdominal aortic aneurysm repair: have we made any progress? *J Vasc Surg.* 2000;32:1091-1100.
120. Galland RB. Mortality following elective infrarenal aortic reconstruction: a Joint Vascular Research Group study. *Br J Surg.* 1998;85:633-636.
121. Bradbury AW, Adam DJ, Makhdooni KR, et al. A 21-year experience of abdominal aortic aneurysm operations in Edinburgh. *Br J Surg.* 1998;85:645-647.
122. Bayly PJ, Matthews JN, Dobson PM, et al. In-hospital mortality from abdominal aortic surgery in Great Britain and Ireland: Vascular Anaesthesia Society audit. *Br J Surg.* 2001;88:687-692.
123. Kazmers A, Jacobs L, Perkins A, et al. Abdominal aortic aneurysm repair in Veterans Affairs medical centers. *J Vasc Surg.* 1996;23:191-200.
124. Huber TS, Wang JG, Derrow AE, et al. Experience in the United States with intact abdominal aortic aneurysm repair. *J Vasc Surg.* 2001;33:304-310; discussion 310-311.
125. Dardik A, Lin JW, Gordon TA, et al. Results of elective abdominal aortic aneurysm repair in the 1990s: a population-based analysis of 2335 cases. *J Vasc Surg.* 1999;30:985-995.
126. Akkersdijk GJ, van der Graaf Y, van Bockel JH, et al. Mortality rates associated with operative treatment of infrarenal abdominal aortic aneurysm in The Netherlands. *Br J Surg.* 1994;81:706-709.
127. Schermerhorn ML, O'Malley AJ, Jhaveri A, et al. Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population. *N Engl J Med.* 2008;358:464-474.
128. Hallin A, Bergqvist D, Holmberg L. Literature review of surgical management of abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg.* 2001;22:197-204.
129. Norman PE, Powell JT. Abdominal aortic aneurysm: the prognosis in women is worse than in men. *Circulation.*

2007;115:2865-2869.

130. Katz DJ, Stanley JC, Zelenock GB. Gender differences in abdominal aortic aneurysm prevalence, treatment, and outcome. *J Vasc Surg.* 1997;25:561-568.
131. Dimick JB, Cowan JA Jr, Stanley JC, et al. Surgeon specialty and provider volumes are related to outcome of intact abdominal aortic aneurysm repair in the United States. *J Vasc Surg.* 2003;38:739-744.
132. Young EL, Holt PJ, Poloniecki JD, et al. Meta-analysis and systematic review of the relationship between surgeon annual caseload and mortality for elective open abdominal aortic aneurysm repairs. *J Vasc Surg.* 2007;46:1287-1294.
133. Cronenwett JL, Birkmeyer JD, eds. *The Dartmouth Atlas of Vascular Health Care*. Chicago: AHA Press; 2000.
134. Dimick JB, Pronovost PJ, Cowan JA, et al. The volume-outcome effect for abdominal aortic surgery: differences in case-mix or complications? *Arch Surg.* 2002;137:828-832.
135. Greenhalgh RM, Brown LC, Kwong GP, et al. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. *Lancet.* 2004;364:843-848.
136. Prinssen M, Verhoeven EL, Buth J, et al. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. *N Engl J Med.* 2004;351:1607-1618.
137. Lederle FA, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med.* 2002;346:1437-1444.
138. Qvarfordt PG, Stoney RJ, Reilly LM, et al. Management of pararenal aneurysms of the abdominal aorta. *J Vasc Surg.* 1986;3:84-93.
139. Crawford ES, Beckett WC, Greer MS. Juxtarenal infrarenal abdominal aortic aneurysm. Special diagnostic and therapeutic considerations. *Ann Surg.* 1986;203:661-670.
140. Poulidas GE, Doundoulakis N, Skoutas B, et al. Juxtarenal abdominal aneurysmectomy. *J Cardiovasc Surg (Torino).* 1992;33:324-330.
141. Nypaver TJ, Shepard AD, Reddy DJ, et al. Repair of pararenal abdominal aortic aneurysms. An analysis of operative management. *Arch Surg.* 1993;128:803-811; discussion 811-813.
142. Faggioli G, Stella A, Freyrie A, et al. Early and long-term results in the surgical treatment of juxtarenal and pararenal aortic aneurysms. *Eur J Vasc Endovasc Surg.* 1998;15:205-211.
143. Martin GH, O'Hara PJ, Hertzner NR, et al. Surgical repair of aneurysms involving the suprarenal, visceral, and lower thoracic aortic segments: early results and late outcome. *J Vasc Surg.* 2000;31:851-862.
144. Chiesa R, Marone EM, Brioschi C, et al. Open repair of pararenal aortic aneurysms: operative management, early results, and risk factor analysis. *Ann Vasc Surg.* 2006;20:739-746.
145. Jean-Claude JM, Reilly LM, Stoney RJ, Messina LM. Pararenal aortic aneurysms: the future of open aortic aneurysm repair. *J Vasc Surg.* 1999;29:902-912.
146. Knott AW, Kalra M, Duncan AA, et al. Open repair of juxtarenal aortic aneurysms (JAA) remains a safe option in the era of fenestrated endografts. *J Vasc Surg.* 2008;47:695-701.
147. Koskas F, Kieffer E. Long-term survival after elective repair of infrarenal abdominal aortic aneurysm: results of a prospective multicentric study. Association for Academic Research in Vascular Surgery (AURC). *Ann Vasc Surg.* 1997;11:473-481.
148. Johnston KW. Nonruptured abdominal aortic aneurysm: six-year follow-up results from the multicenter prospective Canadian aneurysm study. Canadian Society for Vascular Surgery Aneurysm Study Group. *J Vasc Surg.* 1994;20:163-170.
149. Batt M, Staccini P, Pittaluga P, et al. Late survival after abdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg.* 1999;17:338-342.
150. Feinglass J, Cowper D, Dunlop D, et al. Late survival risk factors for abdominal aortic aneurysm repair: experience from fourteen Department of Veterans Affairs hospitals. *Surgery.* 1995;118:16-24.

151. Illig KA, Green RM, Ouriel K, et al. Fate of the proximal aortic cuff: implications for endovascular aneurysm repair. *J Vasc Surg.* 1997;26:492-499; discussion 499-501.
152. Hallett JW Jr, Naessens JM, Ballard DJ. Early and late outcome of surgical repair for small abdominal aortic aneurysms: a population-based analysis. *J Vasc Surg.* 1993;18:684-691.
153. Aune S, Amundsen SR, Evjensvold J, Trippstad A. Operative mortality and long-term relative survival of patients operated on for asymptomatic abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg.* 1995;9:293-298.
154. Zöllner N, Zoller WG, Spengel F, et al. The spontaneous course of small abdominal aortic aneurysms. Aneurysmal growth rates and life expectancy. *Klin Wochenschr.* 1991;69:633-639.
155. Williamson WK, Nicoloff AD, Taylor LM Jr, et al. Functional outcome after open repair of abdominal aortic aneurysm. *J Vasc Surg.* 2001;33:913-920.
156. Arko FR, Hill BB, Reeves TR, et al. Early and late functional outcome assessments following endovascular and open aneurysm repair. *J Endovasc Ther.* 2003;10:2-9.
157. Prinssen M, Buskens E, Blankensteijn JD. Quality of life endovascular and open AAA repair. Results of a randomised trial. *Eur J Vasc Endovasc Surg.* 2004;27:121-127.
158. Plate G, Hollier LA, O'Brien P, et al. Recurrent aneurysms and late vascular complications following repair of abdominal aortic aneurysms. *Arch Surg.* 1985;120:590-594.
159. Conrad MF, Crawford RS, Pedraza JD, et al. Long-term durability of open abdominal aortic aneurysm repair. *J Vasc Surg.* 2007;46:669-675.
160. Papia G, Klein D, Lindsay TF. Intensive care of the patient following open abdominal aortic surgery. *Curr Opin Crit Care.* 2006;12:340-345.
161. Longo WE, Lee TC, Barnett MG, et al. Ischemic colitis complicating abdominal aortic aneurysm surgery in the U.S. veteran. *J Surg Res.* 1996;60:351-354.
162. Björck M, Bergqvist D, Troeng T. Incidence and clinical presentation of bowel ischaemia after aortoiliac surgery—2930 operations from a population-based registry in Sweden. *Eur J Vasc Endovasc Surg.* 1996;12:139-144.
163. Brewster DC, Franklin DP, Cambria RP, et al. Intestinal ischemia complicating abdominal aortic surgery. *Surgery.* 1991;109:447-454.
164. Levison JA, Halpern VJ, Kline RG, et al. Perioperative predictors of colonic ischemia after ruptured abdominal aortic aneurysm. *J Vasc Surg.* 1999;29:40-45; discussion 45-47.
165. Champagne BJ, Darling RC 3rd, Daneshmand M, et al. Outcome of aggressive surveillance colonoscopy in ruptured abdominal aortic aneurysm. *J Vasc Surg.* 2004;39:792-796.
166. Kehlet H, Moesgaard F. Prophylaxis against postoperative complications in gastroenterology. *Scand J Gastroenterol Suppl.* 1996;216:218-224.
167. Bast TJ, van der Biezen JJ, Scherpenisse J, et al. Ischaemic disease of the colon and rectum after surgery for abdominal aortic aneurysm: a prospective study of the incidence and risk factors. *Eur J Vasc Surg.* 1990;4:253-257.
168. Brandt CP, Piotrowski JJ, Alexander JJ. Flexible sigmoidoscopy. A reliable determinant of colonic ischemia following ruptured abdominal aortic aneurysm. *Surg Endosc.* 1997;11:113-115.
169. Boley SJ, Brandt LJ, Veith FJ. Ischemic disorders of the intestines. *Curr Probl Surg.* 1978;15:1-85.
170. Boley SJ. 1989 David H. Sun lecture. Colonic ischemia—25 years later. *Am J Gastroenterol.* 1990;85:931-934.
171. Fanti L, Masci E, Mariani A, et al. Is endoscopy useful for early diagnosis of ischaemic colitis after aortic surgery? Results of a prospective trial. *Ital J Gastroenterol Hepatol.* 1997;29:357-360.
172. Welch M, Baguneid MS, McMahon RF, et al. Histological study of colonic ischaemia after aortic surgery. *Br J Surg.* 1998;85:1095-1098.
173. Connolly JE. Prevention of paraplegia secondary to operations on the aorta. *J Cardiovasc Surg (Torino).* 1986;27:410-417.
174. Szilagyi DE, Hageman JH, Smith RF, Elliott JP. Spinal cord damage in surgery of the abdominal aorta. *Surgery.*

1978;83:38-56.

175. Ferguson LR, Bergan JJ, Conn J Jr, Yao JS. Spinal ischemia following abdominal aortic surgery. *Ann Surg.* 1975;181:267-272.
176. Golden GT, Sears HF, Wellons HA Jr, Muller WH Jr. Paraplegia complicating resection of aneurysms of the infrarenal abdominal aorta. *Surgery.* 1973;73:91-96.
177. Sher MH, Healy EH. Paraplegia following infrarenal aneurysmorrhaphy. *Vasc Surg.* 1971;5:171-176.
178. Joseph MG, Langsfeld MA, Lusby RJ. Infrarenal aortic aneurysm: unusual cause of paraparesis. *Aust N Z J Surg.* 1989;59:743-744.
179. Dormal PA, Delberghe X, Roeland A. Infrarenal aortic aneurysm and spinal cord ischaemia. A new case and review of the literature. *Acta Chir Belg.* 1995;95:136-138.
180. Defraigne JO, Otto B, Sakalihan N, Limet R. Spinal ischaemia after surgery for abdominal infrarenal aortic aneurysm. Diagnosis with nuclear magnetic resonance. *Acta Chir Belg.* 1997;97:250-256.
181. Fernandez Alonso L, Agundez Gomez I. Transient paraplegia following elective infrarenal aortic aneurysm repair. Case report. *J Cardiovasc Surg (Torino).* 1999;40:707-709.
182. Clouse WD, Cambria RP. Complex aortic aneurysm: pararenal, suprarenal and thoracoabdominal. In: Hallett JW Jr, Mills JL, Earnshaw JJ, Reekers JA, et al, eds. *Comprehensive Vascular and Endovascular Surgery.* Edinburgh: CV Mosby; 2004:445-478.
183. Rosenthal D. Spinal cord ischemia after abdominal aortic operation: is it preventable? *J Vasc Surg.* 1999;30:391-397.
184. Takagi H, Sugimoto M, Kato T, et al. Postoperative incision hernia in patients with abdominal aortic aneurysm and aortoiliac occlusive disease: a systematic review. *Eur J Vasc Endovasc Surg.* 2007;33:177-181.
185. Liapis CD, Dimitroulis DA, Kakisis JD, et al. Incidence of incisional hernias in patients operated on for aneurysm or occlusive disease. *Am Surg.* 2004;70:550-552.
186. Papadimitriou D, Pitoulis G, Papaziogas B, et al. Incidence of abdominal wall hernias in patients undergoing aortic surgery for aneurysm or occlusive disease. *Vasa.* 2002;31:111-114.
187. Hall KA, Peters B, Smyth SH, et al. Abdominal wall hernias in patients with abdominal aortic aneurysmal versus aortoiliac occlusive disease. *Am J Surg.* 1995;170:572-575; discussion 575-576.
188. Gardner GP, Josephs LG, Rosca M, et al. The retroperitoneal incision. An evaluation of postoperative flank "bulge." *Arch Surg.* 1994;129:753-756.
189. Matsen SL, Krosnick TA, Roseborough GS, et al. Preoperative and intraoperative determinants of incisional bulge following retroperitoneal aortic repair. *Ann Vasc Surg.* 2006;20:183-187.
190. Ballard JL, Abou-Zamzam AM Jr, Teruya TH, et al. Retroperitoneal aortic aneurysm repair: long-term follow-up regarding wound complications and erectile dysfunction. *Ann Vasc Surg.* 2006;20:195-199.
191. Edwards JM, Teefey SA, Zierler RE, Kohler TR. Intraabdominal paraanastomotic aneurysms after aortic bypass grafting. *J Vasc Surg.* 1992;15:344-350; discussion 351-353.
192. Hallett JW Jr, Marshall DM, Petterson TM, et al. Graft-related complications after abdominal aortic aneurysm repair: reassurance from a 36-year population-based experience. *J Vasc Surg.* 1997;25:277-284; discussion 285-286.
193. Kalman PG, Rappaport DC, Merchant N, et al. The value of late computed tomographic scanning in identification of vascular abnormalities after abdominal aortic aneurysm repair. *J Vasc Surg.* 1999;29:442-450.
194. Cappeller WA, Häzel D, Hinz MH, Lauterjung L. Ten-year results following elective surgery for abdominal aortic aneurysm. *Int Angiol.* 1998;17:234-240.
195. Mukai S, Yao H, Miyamoto T, et al. The long-term follow-up results of elective surgical treatment for abdominal aortic aneurysms. *Ann Thorac Cardiovasc Surg.* 2002;8:38-41.
196. Biancari F, Ylönen K, Anttila V, et al. Durability of open repair of infrarenal abdominal aortic aneurysm: a 15-year follow-up study. *J Vasc Surg.* 2002;35:87-93.

197. Crawford JL, Stowe CL, Safi HJ, et al. Inflammatory aneurysms of the aorta. *J Vasc Surg.* 1985;2:113-124.
198. Pennell RC, Hollier LH, Lie JT, et al. Inflammatory abdominal aortic aneurysms: a thirty-year review. *J Vasc Surg.* 1985;2:859-869.
199. Sterpetti AV, Hunter WJ, Feldhaus RJ, et al. Inflammatory aneurysms of the abdominal aorta: incidence, pathologic, and etiologic considerations. *J Vasc Surg.* 1989;9:643-649; discussion 649-650.
200. Thompson RW. Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem. *Curr Opin Cardiol.* 1996;11:504-518.
201. Stella A, Gargiulo M, Faggioli GL, et al. Postoperative course of inflammatory abdominal aortic aneurysms. *Ann Vasc Surg.* 1993;7:229-238.
202. Nitecki SS, Hallett JW Jr, Stanson AW, et al. Inflammatory abdominal aortic aneurysms: a case-control study. *J Vasc Surg.* 1996;23:860-868; discussion 868-869.
203. Hechelhammer L, Wildermuth S, Lachat ML, Pfammatter T. Endovascular repair of inflammatory abdominal aneurysm: a retrospective analysis of CT follow-up. *J Vasc Interv Radiol.* 2005;16:737-741.
204. Bonamigo TP, Bianco C, Becker M, Puricelli Faccini F. Inflammatory aneurysms of infra-renal abdominal aorta. A case-control study. *Minerva Cardioangiol.* 2002;50:253-258.
205. Moosa HH, Peitzman AB, Steed DL, et al. Inflammatory aneurysms of the abdominal aorta. *Arch Surg.* 1989;124:673-675.
206. Speziale F, Sbarigia E, Grossi R, et al. Inflammatory aneurysms of the abdominal aorta involving the ureters: is combined treatment really necessary? *J Urol.* 2001;165:27-31.
207. Lacquet JP, Lacroix H, Nevelsteen A, Suy R. Inflammatory abdominal aortic aneurysms. A retrospective study of 110 cases. *Acta Chir Belg.* 1997;97:286-292.
208. Lindblad B, Almgren B, Bergqvist D, et al. Abdominal aortic aneurysm with perianeurysmal fibrosis: experience from 11 Swedish vascular centers. *J Vasc Surg.* 1991;13:231-237; discussion 237-239.
209. Baskerville PA, Blakeney CG, Young AE, Browse NL. The diagnosis and treatment of peri-aortic fibrosis ("inflammatory" aneurysms). *Br J Surg.* 1983;70:381-385.
210. Reddy DJ, Shepard AD, Evans JR, et al. Management of infected aortoiliac aneurysms. *Arch Surg.* 1991;126:873-878; discussion 878-879.
211. Ewart JM, Burke ML, Bunt TJ. Spontaneous abdominal aortic infections. Essentials of diagnosis and management. *Am Surg.* 1983;49:37-50.
212. Oderich GS, Panneton JM, Bower TC, et al. Infected aortic aneurysms: aggressive presentation, complicated early outcome, but durable results. *J Vasc Surg.* 2001;34:900-908.
213. Miller DV, Oderich GS, Aubry MC, et al. Surgical pathology of infected aneurysms of the descending thoracic and abdominal aorta: clinicopathologic correlations in 29 cases (1976 to 1999). *Hum Pathol.* 2004;35:1112-1120.
214. Gomes MN, Choyke PL, Wallace RB. Infected aortic aneurysms. A changing entity. *Ann Surg.* 1992;215:435-442.
215. Woon CY, Sebastian MG, Tay KH, Tan SG. Extra-anatomic revascularization and aortic exclusion for mycotic aneurysms of the infrarenal aorta and iliac arteries in an Asian population. *Am J Surg.* 2008;195:66-72.
216. Utsumi T, Ohtsuka M, Uchida E, et al. Abdominal aortic pseudoaneurysm caused by prolonged methicillin-resistant *Staphylococcus aureus* sepsis. *Int J Cardiol.* 2008;128:294-295.
217. Chen IM, Chang HH, Hsu CP, et al. Ten-year experience with surgical repair of mycotic aortic aneurysms. *J Chin Med Assoc.* 2005;68:265-271.
218. Hsu RB, Chen RJ, Wang SS, Chu SH. Infected aortic aneurysms: clinical outcome and risk factor analysis. *J Vasc Surg.* 2004;40:30-35.
219. Farkas JC, Fichelle JM, Laurian C, et al. Long-term follow-up of positive cultures in 500 abdominal aortic aneurysms. *Arch Surg.* 1993;128:284-288.
220. Lehner S, Wittgen C. Infections of the aorta: case report and review of treatment. *Vascular.* 2005;13:252-256.



221. Rubin BG, German ML. *Candida* infection with aneurysm formation in the juxtarenal aorta. *J Vasc Surg.* 1994;20:311-314.
222. Truty MJ, Bower TC. Congenital anomalies of the inferior vena cava and left renal vein: implications during open abdominal aortic aneurysm reconstruction. *Ann Vasc Surg.* 2007;21:186-197.
223. Brener BJ, Darling RC, Frederick PL, Linton RR. Major venous anomalies complicating abdominal aortic surgery. *Arch Surg.* 1974;108:159-165.
224. Baldrige ED Jr, Canos AJ. Venous anomalies encountered in aortoiliac surgery. *Arch Surg.* 1987;122:1184-1188.
225. Karkos CD, Bruce IA, Thomson GJ, Lambert ME. Retroaortic left renal vein and its implications in abdominal aortic surgery. *Ann Vasc Surg.* 2001;15:703-708.
226. Bartle EJ, Pearce WH, Sun JH, Rutherford RB. Infraarenal venous anomalies and aortic surgery: avoiding vascular injury. *J Vasc Surg.* 1987;6:590-593.
227. Hafez KS, El Fettouh HA, Novick AC, Ouriel K. Management of synchronous renal neoplasm and abdominal aortic aneurysm. *J Vasc Surg.* 2000;32:1102-1110.
228. Ginsberg DA, Modrall JG, Esrig D, et al. Concurrent abdominal aortic aneurysm and urologic neoplasm: an argument for simultaneous intervention. *Ann Vasc Surg.* 1995;9:428-433.
229. Fry RE, Fry WJ. Cholelithiasis and aortic reconstruction: the problem of simultaneous surgical therapy. Conclusions from a personal series. *J Vasc Surg.* 1986;4:345-350.
230. Ouriel K, Ricotta JJ, Adams JT, Deweese JA. Management of cholelithiasis in patients with abdominal aortic aneurysm. *Ann Surg.* 1983;198:717-719.
231. Swanson RJ, Littooy FN, Hunt TK, Stoney RJ. Laparotomy as a precipitating factor in the rupture of intra-abdominal aneurysms. *Arch Surg.* 1980;115:299-304.
232. Durham SJ, Steed DL, Moosa HH, et al. Probability of rupture of an abdominal aortic aneurysm after an unrelated operative procedure: a prospective study. *J Vasc Surg.* 1991;13:248-251; discussion 251-252.
233. Brunkwall J, Hauksson H, Bengtsson H, et al. Solitary aneurysms of the iliac arterial system: an estimate of their frequency of occurrence. *J Vasc Surg.* 1989;10:381-384.
234. Best IM, Vansandani G, Bumpers HL. Complications of isolated bilateral iliac artery aneurysms. *Am Surg.* 2001;67:767-771.
235. McCready RA, Pairolero PC, Gilmore JC, et al. Isolated iliac artery aneurysms. *Surgery.* 1983;93:688-693.
236. Richardson JW, Greenfield LJ. Natural history and management of iliac aneurysms. *J Vasc Surg.* 1988;8:165-171.
237. Krupski WC, Selzman CH, Florida R, et al. Contemporary management of isolated iliac aneurysms. *J Vasc Surg.* 1998;28:1-11; discussion 11-13.
238. Santilli SM, Wernsing SE, Lee ES. Expansion rates and outcomes for iliac artery aneurysms. *J Vasc Surg.* 2000;31:114-121.
239. Nachbur BH, Inderbitzi RG, Bar W. Isolated iliac aneurysms. *Eur J Vasc Surg.* 1991;5:375-381.
240. Bolin T, Lund K, Skau T. Isolated aneurysms of the iliac artery: what are the chances of rupture? *Eur J Vasc Surg.* 1988;2:213-215.
241. Kasirajan V, Hertzner NR, Beven EG, et al. Management of isolated common iliac artery aneurysms. *Cardiovasc Surg.* 1998;6:171-177.
242. Sandhu RS, Pipinos II. Isolated iliac artery aneurysms. *Semin Vasc Surg.* 2005;18:209-215.
243. Batt M, Ricco JB, Staccini P. Do internal iliac arteries contribute to vascularization of the descending colon during abdominal aortic aneurysm surgery? An intraoperative hemodynamic study. *Ann Vasc Surg.* 2001;15:171-174.
244. Mehta M, Veith FJ, Ohki T, et al. Unilateral and bilateral hypogastric artery interruption during aortoiliac aneurysm repair in 154 patients: a relatively innocuous procedure. *J Vasc Surg.* 2001;33(2 Suppl):S27-S32.
245. Deb B, Benjamin M, Comerota AJ. Delayed rupture of an internal iliac artery aneurysm following proximal ligation for abdominal aortic aneurysm repair. *Ann Vasc Surg.* 1992;6:537-540.

## 第 129 章

1. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysm. *Ann Vasc Surg.* 1991;5:491-499.
2. Blakemore A. Progressive, constrictive occlusion of the abdominal aorta with wiring and electrothermic coagulation: one-stage operation for arteriosclerotic aneurysm of the abdominal aorta. *Ann Surg.* 1951;94:591-597.
3. Dotter CT. Transluminally-placed coil-spring endarterial tube grafts: long-term patency in canine popliteal artery. *Invest Radiol.* 1969;4:329-332.
4. Cragg AH, Lund G, Rysavy JA, et al. Percutaneous arterial grafting. *Radiology.* 1984;150:45-49.
5. Balko A, Piasecki GJ, Shah DM, et al. Transfemoral placement of intraluminal polyurethane prosthesis for abdominal aortic aneurysm. *J Surg Res.* 1986;40:305-309.
6. Lawrence DD, Charnsangavey C, Wright KC, et al. Percutaneous endovascular graft: experimental evaluation. *Radiology.* 1987;163:357-360.
7. Yoshioka T, Wright KC, Wallace S, et al. Self expanding endovascular graft: an experimental study in dogs. *Am J Radiol.* 1988;151:673-676.
8. Laborde JC, Parodi JC, Clem MF, et al. Intraluminal bypass of abdominal aortic aneurysm: feasibility study. *Radiology.* 1992;184:185-190.
9. Chuter TA, Green RM, Ouriel K, Fiore WM, DeWeese JA. Transfemoral endovascular aortic graft placement. *J Vasc Surg.* 1993;18:185-195.
10. Volodos NL, Shekhanin VE, Karpovich IP, et al. A self-fixing synthetic blood vessel endoprosthesis. *Vestn Khir Im I I Grek.* 1986;137:123-125.
11. Franks SC, Sutton AJ, Bown MJ, Sayers RD. Systematic review and meta-analysis of 12 years of endovascular abdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg.* 2007;33:154-171.
12. Brewster DC, Jones JE, Chung TK, et al. Long-term outcomes after endovascular abdominal aortic aneurysm repair: the first decade. *Ann Surg.* 2006;244:426-438.
13. Torrela F, for the EUROSTAR collaborators. Effect of improved endograft design on outcome of endovascular aneurysm repair. *J Vasc Surg.* 2004;40:216-221.
14. May J, White GH, Yu W, et al. Endoluminal grafting of abdominal aortic aneurysms: causes of failure and their prevention. *J Endovasc Surg.* 1994;1:44-52.
15. Chuter TA, Donayre C, Wendt G. Bifurcated stent-grafts for endovascular repair of abdominal aortic aneurysm. Preliminary case reports. *Surg Endosc.* 1994;8:800-802.
16. Blum U, Voshage G, Lammer J, et al. Endoluminal stent-grafts for infrarenal abdominal aortic aneurysms. *N Engl J Med.* 1997;336:13-20.
17. May J, White GH, Yu W, et al. Importance of graft configuration in outcome of endoluminal aortic aneurysm repair: a 5-year analysis by the life table method. *Eur J Vasc Endovasc Surg.* 1998;15:406-411.
18. Faries PL, Biggs VL, Rhee JY, et al. Failure of endovascular aortoortic tube grafts: a plea for preferential use of bifurcated grafts. *J Vasc Surg.* 2002;35:868-873.
19. Chuter TA, Green RM, Ouriel K, DeWeese JA. Infrarenal aortic aneurysm structure: implications for transfemoral repair. *J Vasc Surg.* 1994;20:44-49.
20. Chuter TAM, Risberg B, Hopkinson BR, et al. Clinical experience with a bifurcated endovascular graft for abdominal aortic aneurysm repair. *J Vasc Surg.* 1996;24:655-666.
21. Alric P, Hinchcliffe RJ, Wenham PW, et al. Lessons learned from the long-term follow-up of a first-generation aortic stent graft. *J Vasc Surg.* 2003;37:367-373.
22. Wang GJ, Carpenter JP; Endologix Investigators. The PowerLink system for endovascular abdominal aortic aneurysm

- repair: six-year results. *J Vasc Surg.* 2008;48:535-545.
23. Becquemin JP, Poussier B, Allaire E, et al. Endograft fabric disintegration simulating a type II endoleak. *J Endovasc Ther.* 2002;9:203-207.
  24. Beebe HG, Cronenwett JL, Katzen BT, et al. Results of an aortic endograft trial: impact of device failure beyond 12 months. *J Vasc Surg.* 2001;33:55-63.
  25. Guidoin R, Marois Y, Douville Y, et al. First-generation aortic endografts: analysis of explanted Stentor devices from the EUROSTAR Registry. *J Endovasc Ther.* 2000;7:105-122.
  26. AneuRx Clinical Investigators, Zarins CK. The US AneuRx clinical trial: 6-year clinical update 2002. *J Vasc Surg.* 2003;37:904-908.
  27. Zarins CK, Bloch DA, Crabtree T, et al. Stent graft migration after endovascular aneurysm repair: importance of proximal fixation. *J Vasc Surg.* 2003;38:1264-1272.
  28. Zarins CK, Bloch DA, Crabtree T, et al. Aneurysm enlargement following endovascular aneurysm repair: AneuRx clinical trial. *J Vasc Surg.* 2004;39:109-117.
  29. Tanski W 3rd, Fillinger M. Outcomes of original and low-permeability Gore Excluder endoprosthesis for endovascular abdominal aortic aneurysm repair. *J Vasc Surg.* 2007;45:243-249.
  30. Carpenter JP, Baum RA, Barker CF, et al. Impact of exclusion criteria on patient selection for endovascular abdominal aortic aneurysm repair. *J Vasc Surg.* 2001;34:1050-1054.
  31. Armon MP, Yusuf SW, Latief K, et al. Anatomical suitability of abdominal aortic aneurysms for endovascular repair. *Br J Surg.* 1997;84:178-180.
  32. Wolf YG, Fogarty TJ, Olcott C IV, et al. Endovascular repair of abdominal aortic aneurysms: eligibility rate and impact on the rate of open repair. *J Vasc Surg.* 2000;32:519-523.
  33. Arko FR, Filis KA, Seidel SA, et al. How many patients with infrarenal aneurysms are candidates for endovascular repair? The Northern California experience. *J Endovasc Ther.* 2004;11:33-40.
  34. Treiman GS, Lawrence FP, Edwards WH Jr, et al. An assessment of the current applicability of the EVT endovascular graft for treatment of patients with an infrarenal abdominal aortic aneurysm. *J Vasc Surg.* 1999;30:68-75.
  35. Browne TF, Hartley D, Purchas S, et al. A fenestrated covered suprarenal aortic stent. *Eur J Vasc Endovasc Surg.* 1999;18:445-449.
  36. Anderson JL, Berce M, Hartley DE. Endoluminal aortic grafting with renal and superior mesenteric artery incorporation by graft fenestration. *J Endovasc Ther.* 2001;8:3-15.
  37. Hosakawa H, Iwase T, Sato M, et al. Successful endovascular repair of juxtarenal and suprarenal aortic aneurysms with a branched stent-graft. *J Vasc Surg.* 2001;33:1087-1092.
  38. Inoue K, Iwase T, Sato M, et al. Transluminal endovascular branched graft placement for a pseudoaneurysm: reconstruction of the descending thoracic aorta including the celiac axis. *J Thorac Cardiovasc Surg.* 1997;114:859-861.
  39. Imai M, Kimura T, Toma M, et al. Inoue stent-graft implantation for thoracoabdominal aortic aneurysm involving the visceral arteries. *Eur J Vasc Endovasc Surg.* 2008;35:462-465.
  40. Anderson JL, Adam DJ, Berce M, Hartley DE. Repair of thoracoabdominal aortic aneurysms with fenestrated and branched endovascular stent-grafts. *J Vasc Surg.* 2005;42:600-607.
  41. Chuter TAM, Gordon RL, Reilly LM, et al. An endovascular system for thoracoabdominal aortic aneurysm repair. *J Endovasc Ther.* 2001;8:25-33.
  42. Chuter TA, Rapp JH, Hiramoto JS, et al. Endovascular treatment of thoracoabdominal aortic aneurysms. *J Vasc Surg.* 2008;47:6-16.
  43. Greenberg RK. Aortic aneurysm, thoracoabdominal aneurysm, juxtarenal aneurysm, fenestrated endografts, branched endografts and endovascular aneurysm repair. *Ann N Y Acad Sci.* 2006;1085:187-196.
  44. Mohan IV, Harris PL, van Marrewijk CJ, et al. Factors and forces influencing stent-graft migration after endovascular

- aortic aneurysm repair. *J Endovasc Ther*. 2002;9:748-755.
45. Sternbergh WC, Carter G, York JW, et al. Aortic neck angulation predicts adverse outcome with endovascular abdominal aortic aneurysm repair. *J Vasc Surg*. 2002;35:482-486.
  46. Cao P, Verzini F, Parlani G, et al. Predictive factors and clinical consequences of proximal aortic neck dilatation in 230 patients undergoing abdominal aorta aneurysm repair with self-expandable stent-graft. *J Vasc Surg*. 2003;37:1200-1205.
  47. Sicard GA, Zwolak RM, Sidaway AN, et al, for the Society for Vascular Surgery Outcomes Committee. Endovascular abdominal aortic aneurysm repair: long-term outcome measures in patients at high-risk for open surgery. *J Vasc Surg*. 2006;44:229-236.
  48. Chuter T, Ivancev K, Malina M, et al. Aneurysm pressure following endovascular exclusion. *Eur J Vasc Endovasc Surg*. 1997;13:85-87.
  49. Ellozy SH, Carroccio A, Lookstein RA, et al. First experience in human beings with a permanently implantable intrasac pressure transducer for monitoring endovascular repair of abdominal aortic aneurysms. *J Vasc Surg*. 2004;40:405-412.
  50. Ohki T, Ouriel K, Silveira PG, et al. Initial results of wireless pressure sensing for endovascular aneurysm repair: the APEX Trial—Acute Pressure Measurement to Confirm Aneurysm Sac EXclusion. *J Vasc Surg*. 2007;45:236-242.
  51. Dias NV, Ivancev K, Malina M, et al. Intra-aneurysm sac pressure measurements after endovascular aneurysm repair: differences between shrinking, unchanged, and expanding aneurysms with and without endoleaks. *J Vasc Surg*. 2004;39:1229-1235.
  52. Ellozy SH, Carroccio A, Lookstein RA, et al. Abdominal aortic aneurysm sac shrinkage after endovascular aneurysm repair: correlation with chronic sac pressure measurement. *J Vasc Surg*. 2006;43:2-7.
  53. Baum RA, Carpenter JP, Cope C, et al. Aneurysm sac pressure measurements after endovascular repair of abdominal aortic aneurysms. *J Vasc Surg*. 2001;33:32-41.
  54. Dias NV, Ivancev K, Resch TA, et al. Endoleaks after endovascular aneurysm repair lead to nonuniform intra-aneurysm sac pressure. *J Vasc Surg*. 2007;46:197-203.
  55. White GH, Yu W, May J, et al. Endoleak as a complication of endoluminal grafting of abdominal aortic aneurysms: classification, incidence, diagnosis, and management. *J Endovasc Surg*. 1997;4:152-168.
  56. White GH, May J, Waugh RC, et al. Type III and type IV endoleak: Toward a complete definition of blood flow in the sac after endoluminal AAA repair. *J Endovasc Surg*. 1998;5:305-309.
  57. Chaikof EL, Blankensteijn JD, Harris PL, et al. Reporting standards for endovascular aortic aneurysm repair. *J Vascular Surg*. 2002;35:1048-1060.
  58. Harris PL, Vallabhaneni SR, Desgranges P. Incidence and risk factors of late rupture, conversion and death after endovascular repair of infrarenal aortic aneurysms: the EUROSTAR experience. *J Vasc Surg*. 2000;32:739-749.
  59. van Marrewijk C, Bluth J, Harris PL, et al. Significance of endoleaks after endovascular repair of abdominal aortic aneurysms: the EUROSTAR experience. *J Vasc Surg*. 2002;35:461-473.
  60. Gilling Smith G, Brennan J, Harris P, et al. Endotension after endovascular aneurysm repair: definition, classification, and strategies for surveillance and intervention. *J Endovasc Surg*. 1999;6:305-307.
  61. White GH, May J, Petrsek P, et al. Endotension: an explanation for continued AAA growth after successful endoluminal repair. *J Endovasc Surg*. 1999;6:308-315.
  62. Zarins CK, Arko FR, Crabtree T, et al. Explant analysis of AneuRx stent grafts: relationship between structural findings and clinical outcome. *J Vasc Surg*. 2004;40:1-11.
  63. Arko FR, Lee WA, Hill BB, et al. Aneurysm-related death: primary endpoint analysis for comparison of open and endovascular repair. *J Vasc Surg*. 2002;36:297-304.
  64. Greenhalgh RM, Brown LC, Kwong GP, et al, for the EVAR trial participants. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomized controlled trial. *Lancet*. 2004;364:843-848.

65. Blankensteijn JD, de Jong S, Prinssen M, van der Ham A. Two year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. *N Engl J Med*. 2005;352:2398-2405.
66. EVAR trial participants. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. *Lancet*. 2005;365:2187-2192.
67. Bush RL, Hedayati N, Johnson ML, et al. Performance of endovascular aortic aneurysm repair in high-risk patients: results from the VA National Surgical Quality Improvement Program. *J Vasc Surg*. 2007;45:227-233.
68. Buth J, van Marrewijk CJ, Harris PL, et al, for the EUROSTAR Collaborators. Outcome of endovascular abdominal aortic aneurysm repair in patients with conditions considered unfit for an open procedure: a report on the EUROSTAR experience. *J Vasc Surg*. 2002;35:211-221.
69. Moore WS, Rutherford RB. Transfemoral endovascular repair of abdominal aortic aneurysms: results of the North-American EVT phase 1 trial. *J Vasc Surg*. 1996;23:543-553.
70. Moore WS, Matsumura JS, Makaroun MS, et al, for the EVT/Guidant Investigators. Five-year interim comparison of the Guidant bifurcated endograft with open repair of abdominal aortic aneurysm. *J Vasc Surg*. 2003;38:46-55.
71. Greenberg RK, Chuter TA, Cambria RP, et al. Zenith abdominal aortic aneurysm endovascular graft. *J Vasc Surg*. 2008;48:1-9.
72. Criado FJ, Fairman RM, Becker GJ, for the Talent LPS Pivotal Clinical Trial investigators. Talent LPS AAA stent graft: results of a pivotal clinical trial. *J Vasc Surg*. 2003;37:709-715.
73. Matsumura JS, Brewster DC, Makaroun MS, Naftel DC. A multicenter controlled clinical trial of open versus endovascular treatment of abdominal aortic aneurysm. *J Vasc Surg*. 2003;37:262-271.
74. Boyle JR, Thompson JP, Thompson MM, et al. Improved respiratory function and analgesia control after endovascular AAA repair. *J Endovasc Surg*. 1997;4:62-65.
75. Baxendale BR, Baker DM, Hutchinson A, et al. Haemodynamic and metabolic response to endovascular repair of infra-renal aortic aneurysms. *Br J Anaesth*. 1996;77:581-585.
76. Cuypers PW, Gardien M, Buth J, et al. Randomized study comparing cardiac response in endovascular and open abdominal aortic aneurysm repair. *Br J Surg*. 2001;88:1059-1065.
77. Elmarasy NM, Soong CV, Walker SR, et al. Sigmoid ischemia and the inflammatory response following endovascular abdominal aortic aneurysm repair. *J Endovasc Ther*. 2000;7:21-30.
78. Thompson JP, Boyle JR, Thompson MM, et al. Cardiovascular and catecholamine responses during endovascular and conventional abdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg*. 1999;17:326-333.
79. Galle C, De Maertelaer V, Motte S, et al. Early inflammatory response after elective abdominal aortic aneurysm repair: a comparison between endovascular procedure and conventional surgery. *J Vasc Surg*. 2000;32:234-246.
80. Boyle JR, Goodall S, Thompson JP, et al. Endovascular AAA repair attenuates the inflammatory and renal responses associated with conventional surgery. *J Endovasc Ther*. 2000;7:359-371.
81. Becquemin JP, Bourriez A, D'Audiffret A, et al. Mid-term results of endovascular versus open repair for abdominal aortic aneurysm in patients anatomically suitable for endovascular repair. *Eur J Vasc Endovasc Surg*. 2000;19:656-661.
82. Brewster DC, Geller SC, Kaufman JA, et al. Initial experience with endovascular aneurysm repair: comparison of early results with outcome of conventional open repair. *J Vasc Surg*. 1998;27:992-1003.
83. May J, White GH, Waugh R, et al. Improved survival after endoluminal repair with second-generation prosthesis compared with open repair in the treatment of abdominal aortic aneurysms: a five-year concurrent comparison using life-table method. *J Vasc Surg*. 2001;33:S21-S26.
84. Makaroun MS, Chaikof EL, Naslund T, Matsumura JS. Efficacy of a bifurcated endograft versus open repair of abdominal aortic aneurysms: a reappraisal. *J Vasc Surg*. 2002;35:203-210.
85. Maher MM, McNamara AM, MacEneaney PM, et al. Abdominal aortic aneurysms: elective endovascular repair versus conventional surgery—evaluation with evidence-based medicine techniques. *Radiology*. 2003;228:647-658.

86. Moore WS, Kashyap VS, Vescera CL, Quinones-Baldrich WJ. Abdominal aortic aneurysm: six-year comparison of endovascular versus transabdominal repair. *Ann Surg.* 1999;230:298-308.
87. Wolf YG, Arko FR, Hill BR, et al. Gender differences in endovascular abdominal aortic aneurysm repair with the AneuRx stent-graft. *J Vasc Surg.* 2002;35:882-886.
88. Shames ML, Sanchez LA, Rubin BG, et al. Delayed complications after endovascular AAA repair in women. *J Endovasc Ther.* 2003;10:10-15.
89. Hugl B, Hakaim AG, Biebl M, et al. Impact of gender on the outcome of endovascular aortic aneurysm repair using the Zenith stent-graft: midterm results. *J Endovasc Ther.* 2007;14:115-121.
90. Parlani G, Verzini F, Zannetti S, et al. Does gender influence outcome of AAA endoluminal repair? *Eur J Vasc Endovasc Surg.* 2003;26:69-73.
91. Peppelenbosch N, Buth J, Harris PL, et al, for the EUROSTAR Collaborators. Diameter of AAA and outcome of endovascular aneurysm repair. Does size matter? A report from the EUROSTAR. *J Vasc Surg.* 2004;39:288-297.
92. Ouriel K, Srivastava SD, Sarac TP, et al. Disparate outcome after endovascular treatment of small versus large abdominal aortic aneurysm. *J Vasc Surg.* 2003;37:1206-1212.
93. Schermerhorn ML, Finlayson SRG, Fillinger MF, et al. Life expectancy after endovascular versus open abdominal aortic aneurysm repair: results of a decision analysis model on the basis of data from EUROSTAR. *J Vasc Surg.* 2002;36:1112-1120.
94. Laheij RJF, Van Marrewijk CJ, Buth J, Harris PL, for the EUROSTAR Collaborators. The influence of team experience on outcomes of endovascular stenting of abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg.* 2002;24:128-133.
95. Lee WA, Wolf YG, Hill BW, et al. The first 150 endovascular AAA repairs at a single institution: how steep is the learning curve? *J Endovasc Ther.* 2002;9:269-276.
96. Lobato AC, Rodrigues-Lopez J, Diethrich EB. Learning curve for endovascular abdominal aortic aneurysm repair: evaluation of a 277-patient single-center experience. *J Endovasc Ther.* 2002;9:262-268.
97. Van Marrewijk CJ, Leurs LJ, Vallabhaneni SR, et al. Risk-adjusted outcome analysis of endovascular abdominal aortic aneurysm repair. *J Endovasc Ther.* 2005;12:417-429.
98. Siami FS. Lifeline Registry of EVAR Publications Committee. Lifeline registry of endovascular aneurysm repair: long-term primary outcome measures. *J Vasc Surg.* 2005;42:1-10.
99. United Kingdom Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med.* 2002;346:1445-1452.
100. Johnston KW, for the Canadian Society for Vascular Surgery Aneurysm Study Group. Nonruptured abdominal aortic aneurysm: six-year follow-up results from the multicenter prospective Canadian aneurysm study. *J Vasc Surg.* 1994;20:163-170.
101. Lederle FA, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med.* 2002;346:1437-1444.
102. Hiramoto JS, Reilly LM, Schneider DB, et al. Long-term outcome and reintervention after endovascular abdominal aortic aneurysm repair using the Zenith stent graft. *J Vasc Surg.* 2007;45:461-465.
103. Ohki T, Veith FJ, Shaw P, et al. Increasing incidents of mid-term and long-term complications after endovascular graft repair of abdominal aortic aneurysms: a note of caution based on a 9-year experience. *Ann Surg.* 2001;234:323-335.
104. Anderson PL, Arons RR, Moskowitz AJ, et al. A statewide experience with endovascular abdominal aortic aneurysm repair: rapid diffusion with excellent early results. *J Vasc Surg.* 2004;39:10-19.
105. Lee WA, Carter JW, Upchurch G, et al. Perioperative outcomes after open and endovascular repair of intact abdominal aortic aneurysms in the United States during 2001. *J Vasc Surg.* 2004;39:491-496.
106. Schermerhorn ML, O'Malley AJ, Jhaveri A, et al. Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population. *N Engl J Med.* 2008;358:464-474.

107. Chuter TAM, Reilly RM, Farqui RM, et al. Endovascular aneurysm repair in high-risk patients. *J Vasc Surg.* 2000;31:122-133.
108. Abbruzzese TA, Kwolek CJ, Brewster DC, et al. Outcomes following endovascular abdominal aortic aneurysm repair (EVAR): an anatomic and device-specific analysis. *J Vasc Surg.* 2008;48:19-28.
109. Lederle FA, Johnson GR, Wilson SE, et al. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. *JAMA.* 2002;287:2968-2972.
110. Chuter TA, Faruqi RM, Sawhney R, et al. Endoleak after endovascular repair of abdominal aortic aneurysm. *J Vasc Surg.* 2001;34:98-105.
111. Buth J, Harris PL, van Marrewijk C, Fransen G. The significance and management of different types of endoleaks. *Semin Vasc Surg.* 2003;16:95-102.
112. Van Marrewijk C, Buth J, Harris PL, et al. Significance of endoleaks after end vascular repair of abdominal aortic aneurysms: the EUROSTAR experience. *J Vasc Surg.* 2002;35:461-473.
113. Resch T, Ivancev K, Lindh M, et al. Persistent collateral perfusion of abdominal aortic aneurysm after endovascular repair does not lead to progressive change in aneurysm diameter. *J Vasc Surg.* 1998;28:242-249.
114. Görich J, Rilinger N, Sokiranski R, et al. Embolisation of type II endoleaks fed by the inferior mesenteric artery: using the superior mesenteric artery approach. *J Endovasc Ther.* 2000;7:297-301.
115. Baum RA, Carpenter JP, Golden MA, et al. Treatment of type II endoleaks after endovascular repair of abdominal aortic aneurysms: comparison of transarterial and translumbar techniques. *J Vasc Surg.* 2002;35:23-29.
116. Greenberg RK, Chuter TA, Lawrence-Brown M, et al., for the Zenith Investigators. Analysis of renal function after aneurysm repair with a device using suprarenal fixation (Zenith AAA Endovascular Graft) in contrast to open surgical repair. *J Vasc Surg.* 2004;39:1219-1228.
117. Brenner DJ, Hall EJ. Computed tomography, an increasing source of radiation exposure. *N Engl J Med.* 2007;357:2277-2284.
118. Pitton MB, Schweitzer H, Herber S, et al. MRI versus helical CT for endoleak detection after endovascular aneurysm repair. *AJR Am J Roentgenol.* 2005;185:1275-1281.
119. van der Laan MJ, Bartels LW, Viergever MA, Blankensteijn JD. Computed tomography versus magnetic resonance imaging of endoleaks after EVAR. *Eur J Vasc Endovasc Surg.* 2006;32:361-365.
120. McLafferty RB, McCrary BS, Mattos MA, et al. The use of color-flow duplex scan for the detection of endoleaks. *J Vasc Surg.* 2002;36:100-104.
121. Manning BJ, O'Neill SM, Haider SN, et al. Duplex ultrasound in aneurysm surveillance following endovascular aneurysm repair: a comparison with computed tomography aortography. *J Vasc Surg.* 2009;49:60-65.
122. Sandford RM, Bown MJ, Fishwick G, et al. Duplex ultrasound scanning is reliable in the detection of endoleak following endovascular aneurysm repair. *Eur J Vasc Endovasc Surg.* 2006;32:537-541.
123. AbuRahma AF, Welch CA, Mullins BB, Dyer B. Computed tomography versus color duplex ultrasound for surveillance of abdominal aortic stent-grafts. *J Endovasc Ther.* 2005;12:568-573.
124. Hiramoto JS, Reilly LM, Schneider DB, et al. The effect of magnetic resonance imaging on stainless-steel Z-stent-based abdominal aortic prosthesis. *J Vasc Surg.* 2007;45:472-474.
125. Kim JK, Noll RE Jr, Tonnessen BH, Sternbergh WC 3rd. A technique for increased accuracy in the placement of the "giant" Palmaz stent for treatment of type IA endoleak after endovascular abdominal aneurysm repair. *J Vasc Surg.* 2008;48:755-757.
126. Varcoe RL, Laird MP, Frawley JE. A novel alternative to open conversion for type I endoleak resulting in ruptured aneurysm. *Vasc Endovascular Surg.* 2008;42:391-393.
127. Timaran CH, Ohki T, Rhee SJ, et al. Predicting aneurysm enlargement in patients with persistent type II endoleaks. *J Vasc Surg.* 2004;39:1157-1162.

128. Arko FR, Filis KA, Siedel SA, et al. Intrasc flow velocities predict sealing of type II endoleaks after endovascular abdominal aortic aneurysm repair. *Vasc Surg*. 2003;37:8-15.
129. Parent FN, Meier GH, Godziachvili V, et al. The incidence and natural history of type I and II endoleak: a 5-year follow-up assessment with color duplex ultrasound scan. *J Vasc Surg*. 2002;35:474-478.
130. Hiramoto JS, Howell B, Reilly LM, Chuter TA. Effect of systemic blood pressure on aneurysm size in the presence of a type II endoleak: *Vascular*. 2008;16:321-325.
131. Barbiero G, Baratto A, Ferro F, et al. Strategies of endoleak management following endoluminal treatment of abdominal aortic aneurysms in 95 patients: how, when and why. *Radiol Med (Torino)*. 2008;113:1029-1042.
132. Wales L, Dunckley M, Bohm N, et al. Device-specific outcomes following endovascular aortic aneurysm repair. *Eur J Vasc Endovasc Surg*. 2008;36:661-667.
133. Brown KE, Heyer KS, Matsumura JS, Eskandari MK. Late type III endoleak and graft failure of an Ancure stent-graft. *J Vasc Interv Radiol*. 2008;19:1506-1508.
134. Wanhainen A, Nyman R, Eriksson MO, Björck M. First report of a late type III endoleak from fabric tears of a Zenith stent graft. *J Vasc Surg*. 2008;48:723-726.
135. Lee WA, Huber TS, Seeger JM. Late type III endoleak from graft erosion of an Excluder stent graft: a case report. *J Vasc Surg*. 2006;44:183-185.
136. Raffi BY, Abilez OJ, Benharash P, Zarins CK. Lateral movement of endografts within the aneurysm sac is an indicator of stent-graft instability. *J Endovasc Ther*. 2008;15:335-343.
137. Zarins CK, Arko FR, Crabtree T, et al. Explant analysis of AneuRx stent grafts: relationship between structural findings and clinical outcome. *J Vasc Surg*. 2004;40:1-11.
138. Cornelissen SA, Verhagen HJ, Prokop M, et al. Visualizing type IV endoleak using magnetic resonance imaging with a blood pool contrast agent. *J Vasc Surg*. 2008;47:861-864.
139. Thoo CH, Bourke BM, May J. Symptomatic sac enlargement and rupture due to seroma after open abdominal aortic aneurysm repair with polytetrafluoroethylene graft: implications for endovascular repair and endotension. *J Vasc Surg*. 2004;40:1089-1094.
140. Curci JA, Fillinger, Naslund TC, Rubin BG, for the Excluder Bifurcated Endoprosthesis Investigators. Clinical trial results of a modified Gore Excluder endograft: comparison with open repair and original device design. *Ann Vasc Surg*. 2007;21:328-338.
141. Hoppe H, Segall JA, Liem TK, et al. Aortic aneurysm sac pressure measurements after endovascular repair using an implantable remote sensor: initial experience and short-term follow-up. *Eur Radiol*. 2008;18:957-965.
142. Vallabhaneni SR, Gilling-Smith GL, Brennan J, et al. Can intrasac pressure monitoring reliably predict failure of endovascular aneurysm repair? *J Endovasc Ther*. 2003;10:524-530.
143. Goodney PP, Fillinger MF. The effect of endograft relining on sac expansion after endovascular aneurysm repair with the original-permeability Gore Excluder abdominal aortic aneurysm endoprosthesis. *J Vasc Surg*. 2007;45:686-693.
144. Resch T, Malina M, Lindblad B, et al. The impact of stent design on proximal stent-graft fixation in the abdominal aorta: an experimental study. *Eur J Vasc Endovasc Surg*. 2000;20:190-195.
145. Malina M, Brunkwall J, Ivancev K, et al. Endovascular healing is inadequate for fixation of Dacron stent-grafts in human aortoiliac vessels. *Eur J Vasc Endovasc Surg*. 2000;19:5-11.
146. Connors MS, Sternbergh WC, Carter G, et al. Endograft migration 1 to 4 years after endovascular abdominal aortic aneurysm repair with the AneuRx device: a cautionary note. *J Vasc Surg*. 2002;36:476-484.
147. May J, White GH, Yu W, Sieunarine K. Importance of plain x-ray in endoluminal aortic graft surveillance. *Eur J Vasc Endovasc Surg*. 1997;13:202-206.
148. Murphy M, Hodgson R, Harris PL, et al. Plain radiographic surveillance of abdominal aortic stent-grafts: the Liverpool/Perth protocol. *J Endovasc Ther*. 2003;10:911-912.



149. Sivamurthy N, Schneider DB, Reilly LM, et al. Adjunctive primary stenting of Zenith endograft limbs during endovascular abdominal aortic aneurysm repair: implications for limb patency. *J Vasc Surg.* 2006;43:662-670.
150. Cochenne F, Becquemin JP, Desgranges P, et al. Limb graft occlusion following EVAR: clinical pattern outcomes and predictive factors of occurrence. *Eur J Vasc Endovasc Surg.* 2007;34:59-65.
151. Parent FN 3rd, Godziachvili V, Meier GH 3rd, et al. Endograft limb occlusion and stenosis after ANCURE endovascular abdominal aneurysm repair. *J Vasc Surg.* 2002;35:686-690.
152. Erzurum VZ, Sampram ESK, Sarac TP, et al. Initial management and outcome of aortic endograft limb occlusion. *J Vasc Surg.* 2004;40:419-423.
153. Bove PG, Long GW, Shanley CJ, et al. Transrenal fixation of endovascular stent-grafts for infrarenal aortic aneurysm repair: Mid-term results. *J Vasc Surg.* 2003;37:938-942.
154. Burks JA, Faries PL, Gravereaux EC, et al. Endovascular repair of abdominal aortic aneurysms: stent-graft fixation across the visceral arteries. *J Vasc Surg.* 2002;35:109-113.
155. Walsh SR, Boyle JR, Lynch AG, et al. Suprarenal endograft fixation and medium-term renal function: systematic review and meta-analysis. *J Vasc Surg.* 2008;47:1364-1370.
156. Palombo D, Valenti D, Ferri M, et al. Changes in the proximal neck of abdominal aortic aneurysms early after endovascular treatment. *Ann Vasc Surg.* 2003;17:408-410.
157. Liapis C, Kakisis J, Kaperonis E, et al. Changes of the infrarenal aortic segment after conventional abdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg.* 2000;19:643-647.
158. Malas MB, Ohki T, Veith FJ, et al. Absence of proximal neck dilatation and graft migration after endovascular aneurysm repair with balloon-expandable stent-based endografts. *J Vasc Surg.* 2005;42:639-644.
159. May J, White GH, Ly CN, et al. Endoluminal repair of abdominal aortic aneurysm prevents enlargement of the proximal neck: a 9-year life table and 5-year longitudinal study. *J Vasc Surg.* 2003;37:86-90.
160. Ingle H, Fiskwick G, Thompson MM, Bell PRF. Endovascular repair of wide neck AAA—preliminary report on feasibility and complications. *Eur J Vasc Endovasc Surg.* 2002;24:123-127.
161. Gitlitz DB, Ramaswami G, Kaplan D, et al. Endovascular stent-grafting in the presence of aortic neck filling defects: early clinical experience. *J Vasc Surg.* 2001;33:340-344.
162. Fiorani P, Speziale F, Calisi A, et al. Endovascular graft infection: preliminary results of an international enquiry. *J Endovasc Ther.* 2003;10:919-927.
163. Criado FJ, Wilson EP, Velazquez OC, et al. Safety of coil embolization of the internal iliac artery in endovascular grafting of abdominal aortic aneurysms. *J Vasc Surg.* 2000;32:684-688.
164. Arko FR, Lee WA, Hill BB, et al. Hypogastric artery bypass to preserve pelvic circulation: improved outcome after endovascular abdominal aortic aneurysm repair. *J Vasc Surg.* 2004;39:404-408.
165. Rayt HS, Bown MJ, Lambert KV, et al. Buttock claudication and erectile dysfunction after internal iliac artery embolization in patients prior to endovascular aortic aneurysm repair. *Cardiovasc Intervent Radiol.* 2008;31:728-734.
166. Geraghty PJ, Sanchez LA, Rubin BG, et al. Overt ischemic colitis after endovascular repair of aortoiliac aneurysms. *J Vasc Surg.* 2004;40:413-418.
167. Dadian N, Ohki T, Veith FJ, et al. Overt colon ischemia after endovascular aneurysm repair: the importance of microembolization as an etiology. *J Vasc Surg.* 2001;34:986-996.
168. Lee ES, Bass A, Arko FR, et al. Intraoperative colon mucosal oxygen saturation during aortic surgery. *J Surg Res.* 2006;136:19-24.
169. Karch LA, Hodgson KJ, Mattos MA, et al. Adverse consequences of internal iliac artery occlusion during endovascular repair of abdominal aortic aneurysms. *J Vasc Surg.* 2000;32:676-683.
170. Mehta M, Veith FJ, Ohki T, et al. Unilateral and bilateral hypogastric artery interruption during aortoiliac aneurysm repair in 154 patients: a relatively innocuous procedure. *J Vasc Surg.* 2001;33:S27-S32.

171. Huang Y, Gloviczki P, Duncan AA, et al. Common iliac artery aneurysm: expansion rate and results of open surgical and endovascular repair. *J Vasc Surg.* 2008;47:1203-1210.
172. England A, Butterfield JS, McCollum CN, Ashleigh RJ. Endovascular aortic aneurysm repair with the Talent stent-graft: outcomes in patients with large iliac arteries. *Cardiovasc Intervent Radiol.* 2008;31:723-727.
173. Haulon S, Greenberg RK, Pfaff K, et al. Branched grafting for aortoiliac aneurysms. *Eur J Vasc Endovasc Surg.* 2007;33:567-574.
174. Najibi S, Steinberg J, Katzen BT, et al. Detection of isolated hook fractures 36 months after implantation of the Ancure endograft: a cautionary note. *J Vasc Surg.* 2001;34:353-356.
175. Dias NV, Ivancev K, Malina M, et al. Strut failure in the body of the Zenith abdominal endoprosthesis. *Eur J Vasc Endovasc Surg.* 2007;33:507.
176. Roos JE, Hellinger JC, Hallet R, et al. Detection of endograft fractures with multidetector row computed tomography. *J Vasc Surg.* 2005;42:1002-1006.
177. Hinnen JW, Rixen DJ, Koning OH, et al. Aneurysm sac pressure monitoring: does the direction of pressure measurement matter in fibrinous thrombus? *J Vasc Surg.* 2007;45:812-816.
178. Go MR, Barbato JE, Rhee RY, Makaroun MS. What is the clinical utility of a 6-month computed tomography in the follow-up of endovascular aneurysm repair patients? *J Vasc Surg.* 2008;47:1181-1186.
179. Sternbergh WC 3rd, Greenberg RK, Chuter TA, Tonnessen BH, for the Zenith Investigators. Redefining postoperative surveillance after endovascular aneurysm repair: recommendations based on 5-year follow-up in the US Zenith multicenter trial. *J Vasc Surg.* 2008;48:278-284.
180. Bos WT, Tielliu IF, Zeebregts CJ, et al. Results of endovascular abdominal aortic aneurysm repair with the Zenith stent-graft. *Eur J Vasc Endovasc Surg.* 2008;36:653-660.
181. Hiramoto JS, Chang CK, Reilly LM, et al. Outcome of renal stenting for renal artery coverage during endovascular aortic aneurysm repair. *J Vasc Surg.* 2009;49:1100-1106.
182. Ohrlander T, Sonesson B, Ivancev K, et al. The chimney graft: a technique for preserving or rescuing aortic branch vessels in stent-graft sealing zones. *J Endovasc Ther.* 2008;15:427-432.
183. Sun Z, Mwipatayi BP, Semmens JB, Lawrence-Brown MM. Short to midterm outcomes of fenestrated endovascular grafts in the treatment of abdominal aortic aneurysms: a systematic review. *J Endovasc Ther.* 2006;13:747-753.
184. O'Neill S, Greenberg RK, Haddad F, et al. A prospective analysis of fenestrated endovascular grafting: intermediate-term outcomes. *Eur J Vasc Endovasc Surg.* 2006;32:115-123.
185. Haddad F, Greenberg RK, Walker E, et al. Fenestrated endovascular grafting: the renal side of the story. *J Vasc Surg.* 2005;41:181-190.
186. Sarac TP, Clair DG, Hertzner NR, et al. Contemporary results of juxtarenal aneurysm repair. *J Vasc Surg.* 2002;36:1104-1111.
187. West CA, Noel AA, Bower TC, et al. Factors affecting outcomes of open surgical repair of pararenal aortic aneurysms: a 10-year experience. *J Vasc Surg.* 2006;43:921-927.
188. Jean-Claude JM, Reilly LM, Stoney RJ, Messina LM. Pararenal aortic aneurysms: the future of open aortic aneurysm repair. *J Vasc Surg.* 1999;29:902-912.
189. Rigberg DA, McGory ML, Zingmond DS, et al. Thirty day mortality statistics underestimate the risk of repair of thoracoabdominal aortic aneurysms: a statewide experience. *J Vasc Surg.* 2006;43:217-223.
190. Cowan JA Jr, Dimick JB, Henke PK, et al. Surgical treatment of intact thoracoabdominal aortic aneurysms in the United States: hospital and surgeon volume-related outcomes. *J Vasc Surg.* 2003;37:1169-1174.
191. Gloviczki P. Surgical repair of thoracoabdominal aneurysms: patient selection, techniques and results. *Cardiovascular Surg.* 2002;10:434-441.
192. Coselli JS, LeMaire SA, Miller CC 3rd, et al. Mortality and paraplegia after thoracoabdominal aortic aneurysm repair: a

- risk factor analysis. *Ann Thorac Surg*. 2000;69:409-414.
193. Black SA, Wolfe JH, Clark M, et al. Complex thoracoabdominal aortic aneurysms: endovascular exclusion with visceral revascularization. *J Vasc Surg*. 2006;43:1081-1089.
  194. Böckler D, Kotelis D, Geisbüsch P, et al. Hybrid procedures for thoracoabdominal aortic aneurysms and chronic aortic dissections—a single center experience in 28 patients. *J Vasc Surg*. 2008;47:724-732.
  195. Armon MP, Wenham PW, et al. Common iliac artery aneurysms in patients with abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg*. 1998;15:255-257.
  196. Richardson JW, Greenfield LJ. Natural history and management of iliac aneurysms. *J Vasc Surg*. 1988;8:165-171.
  197. Levi N, Schroeder TV. Isolated iliac artery aneurysms: *Eur J Vasc Endovasc Surg*. 1998;16:342-344.
  198. Pitoulis GA, Donas KP, Schute S, et al. Isolated iliac artery aneurysms: endovascular versus open elective repair. *J Vasc Surg*. 2007;46:648-654.
  199. Chaer RA, Barbato JE, Lin SC, et al. Isolated iliac artery aneurysms: a contemporary comparison of endovascular and open repair. *J Vasc Surg*. 2008;47:708-713.
  200. Boules TN, Selzer F, Stanziale SF, et al. Endovascular management of isolated iliac artery aneurysms. *J Vasc Surg*. 2006;44:29-37.
  201. Noll RE Jr, Tonnessen BH, Mannava K, et al. Long-term postplacement cost after endovascular aneurysm repair. *J Vasc Surg*. 2007;46:9-15.
  202. Collin J, Murie JA. Endovascular treatment of abdominal aortic aneurysm: a failed experiment. *Br J Surg*. 2001;88:1281-1282.
  203. Hill JS, McPhee JT, Messina LM, et al. Regionalization of abdominal aortic aneurysm repair: evidence of a shift to high-volume centers in the endovascular era. *J Vasc Surg*. 2008;48:29-36.
  204. Brooke BS, Perler BA, Dominici F, et al. Reduction of in-hospital mortality among California hospitals meeting Leapfrog evidence-based standards for abdominal aortic aneurysm repair. *J Vasc Surg*. 2008;47:1155-1156.
  205. Dimick JB, Upchurch GR Jr. Endovascular technology, hospital volume, and mortality with abdominal aortic aneurysm surgery. *J Vasc Surg*. 2008;47:1150-1154.
  206. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. *Circulation*. 2008;117:1883-1889.
  207. Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicenter study. *J Vasc Surg*. 2002;36:1-12.
  208. Schlösser FJ, Tangelder MJ, Verhagen HJ, et al, for the SMART study group: growth predictors and prognosis of small abdominal aortic aneurysms. *J Vasc Surg*. 2008;47:1127-1133.
  209. Mosorin M, Niemelä E, Heikkinen J, et al. The use of statins and fate of small abdominal aortic aneurysms. *Interact Cardiovasc Thorac Surg*. 2008;7:578-581.

## 第 130 章

1. Hoorweg LL, Storm-Versloot MN, Ubbink DT, et al. Meta analysis on mortality of ruptured abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg*. 2008;35:558-570.
2. Bown MJ, Sutton AJ, Bell PR, Sayers RD. A meta-analysis of 50 years of ruptured abdominal aortic aneurysm repair. *Br J Surg*. 2002;89:714-730.
3. Cooley DA, DeBakey ME. Ruptured aneurysms of the abdominal aorta; excision and homograft replacement. *Postgrad Med*. 1954;16:334-342.
4. Dillavou ED, Muluk SC, Makaroun MS. A decade of change in abdominal aortic aneurysm repair in the United States: have we improved outcomes equally between men and women? *J Vasc Surg*. 2006;43:230-238.
5. Mureebe L, Egorova N, Giacovelli JK, et al. National trends in the repair of ruptured abdominal aortic aneurysms. *J Vasc*

*Surg.* 2008;48:1101-1107

6. Johansen K, Kohler TR, Nicholls SC, et al. Ruptured abdominal aortic aneurysm: the Harborview experience. *J Vasc Surg.* 1991;13:240-245, discussion 245-247.
7. Bengtsson H, Bergqvist D. Ruptured abdominal aortic aneurysm: a population-based study. *J Vasc Surg.* 1993;18:74-80.
8. Lindsay TF, Walker PM, Romaschin A. Acute pulmonary injury in a model of ruptured abdominal aortic aneurysm. *J Vasc Surg.* 1995;22:1-8.
9. Lindsay TF, Luo XP, Lehotay DC, et al. Ruptured abdominal aortic aneurysm, a “two-hit” ischemia/reperfusion injury: evidence from an analysis of oxidative products. *J Vasc Surg.* 1999;30:219-228.
10. Lesperance K, Andersen C, Singh N, et al. Expanding use of emergency endovascular repair for ruptured abdominal aortic aneurysms: disparities in outcomes from a nationwide perspective. *J Vasc Surg.* 2008;47:1165-1170; discussion 1170-1211.
11. McPhee JT, Hill JS, Eslami MH. The impact of gender on presentation, therapy, and mortality of abdominal aortic aneurysm in the United States, 2001-2004. *J Vasc Surg.* 2007;45:891-899.
12. Dillavou ED, Muluk SC, Makaroun MS. Improving aneurysm-related outcomes: nationwide benefits of endovascular repair. *J Vasc Surg.* 2006;43:446-451.
13. Gloviczki P, Pairolero PC, Mucha P Jr, et al. Ruptured abdominal aortic aneurysms: repair should not be denied. *J Vasc Surg.* 1992;15:851-857, discussion 857-859.
14. Antonello M, Lepidi S, Kechagias A, et al. Glasgow Aneurysm Score predicts the outcome after emergency open repair of symptomatic, unruptured abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg.* 2007;33:272-276.
15. Greco G, Egorova N, Anderson PL, et al. Outcomes of endovascular treatment of ruptured abdominal aortic aneurysms. *J Vasc Surg.* 2006;43:453-459.
16. Giles KA, Pomposelli F, Hamsdan A, et al. Decrease in total aneurysm related deaths in the era of endovascular aneurysm repair *J Vasc Surg.* 2009;49:543-550; discussion 550-551.
17. Mastracci TM, Garrido-Olivares L, et al. Endovascular repair of ruptured abdominal aortic aneurysms: a systematic review and meta-analysis. *J Vasc Surg.* 2008;47:214-221.
18. Harkin DW, Dillon M, Blair PH, et al. Endovascular ruptured abdominal aortic aneurysm repair (EVRAR): a systematic review. *Eur J Vasc Endovasc Surg.* 2007;34:673-681.
19. Takagi H, Kawai N, Umemoto T. Regarding “Endovascular repair of ruptured abdominal aortic aneurysms.” *J Vasc Surg.* 2008;48:253-254
20. <http://www.cdc.gov/releases/02facts/final.htm> 2008.
21. Filipovic M, Goldacre MJ, Roberts SE, et al. Trends in mortality and hospital admission rates for abdominal aortic aneurysm in England and Wales, 1979-1999. *Br J Surg.* 2005;92:968-975.
22. Heller JA, Weinberg A, Arons R, et al. Two decades of abdominal aortic aneurysm repair: have we made any progress? *J Vasc Surg.* 2000;32:1091-1100.
23. Ashton HA, Buxton MJ, Day NE, et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. *Lancet.* 2002;360:1531-1539.
24. Kim LG, Scott RA, Ashton HA, et al. A sustained mortality benefit from screening for abdominal aortic aneurysm. *Ann Intern Med.* 2007;146:699-706.
25. Lederle FA, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med.* 2002;346:1437-1444.
26. Powell JT, Brown LC, Forbes JF, et al. Final 12-year follow-up of surgery versus surveillance in the UK Small Aneurysm Trial. *Br J Surg.* 2007;94:702-708.
27. Brown PM, Zelt DT, Sobolev B. The risk of rupture in untreated aneurysms: the impact of size, gender, and expansion rate. *J Vasc Surg.* 2003;37:280-284.
28. Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small

- Aneurysm Trial Participants. *Ann Surg.* 1999;230:289-296.
29. Choke E, Cockerill G, Wilson WR, et al. A review of biological factors implicated in abdominal aortic aneurysm rupture. *Eur J Vasc Endovasc Surg.* 2005;30:227-244.
  30. Raghavan ML, Webster MW, Vorp DA. Ex vivo biomechanical behavior of abdominal aortic aneurysm: assessment using a new mathematical model. *Ann Biomed Eng.* 1996;24:573-582.
  31. Vorp DA, Raghavan ML, Muluk SC, et al. Wall strength and stiffness of aneurysmal and nonaneurysmal abdominal aorta. *Ann N Y Acad Sci.* 1996;800:274-276.
  32. Fillinger MF, Raghavan ML, Marra SP, et al. In vivo analysis of mechanical wall stress and abdominal aortic aneurysm rupture risk. *J Vasc Surg.* 2002;36:589-597.
  33. Raghavan ML, Vorp DA, Federle MP, et al. Wall stress distribution on three-dimensionally reconstructed models of human abdominal aortic aneurysm. *J Vasc Surg.* 2000;31:760-769.
  34. Fillinger MF, Marra SP, Raghavan ML, Kennedy FE. Prediction of rupture risk in abdominal aortic aneurysm during observation: wall stress versus diameter. *J Vasc Surg.* 2003;37:724-732.
  35. Heng MS, Fagan MJ, Collier JW, et al. Peak wall stress measurement in elective and acute abdominal aortic aneurysms. *J Vasc Surg.* 2008;47:17-22.
  36. Di Martino ES, Bohra A, Vande Geest JP, et al. Biomechanical properties of ruptured versus electively repaired abdominal aortic aneurysm wall tissue. *J Vasc Surg.* 2006;43:570-576.
  37. Fillinger MF, Racusin J, Baker RK, et al. Anatomic characteristics of ruptured abdominal aortic aneurysm on conventional CT scans: implications for rupture risk. *J Vasc Surg.* 2004;39:1243-1252.
  38. Vorp DA, Lee PC, Wang DH, et al. Association of intraluminal thrombus in abdominal aortic aneurysm with local hypoxia and wall weakening. *J Vasc Surg.* 2001;34:291-299.
  39. Vande Geest JP, Wang DH, Wisniewski SR, et al. Towards a noninvasive method for determination of patient-specific wall strength distribution in abdominal aortic aneurysms. *Ann Biomed Eng.* 2006;34:1098-1106.
  40. Kleinstreuer C, Li Z. Analysis and computer program for rupture-risk prediction of abdominal aortic aneurysms. *Biomed Eng Online.* 2006;5:19.
  41. Bown MJ, McCarthy MJ, Bell PR, Sayers RD. Low atmospheric pressure is associated with rupture of abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg.* 2003;25:68-71.
  42. Harkin DW, O'Donnell M, Butler J, et al. Periods of low atmospheric pressure are associated with high abdominal aortic aneurysm rupture rates in Northern Ireland. *Ulster Med J.* 2005;74:113-121.
  43. Wilson WR, Anderton M, Schwalbe EC, et al. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. *Circulation.* 2006;113:438-445.
  44. Wilson WR, Anderton M, Choke EC, et al. Elevated plasma MMP1 and MMP9 are associated with abdominal aortic aneurysm rupture. *Eur J Vasc Endovasc Surg.* 2008.
  45. Marston WA, Ahlquist R, Johnson G Jr, Meyer AA. Misdiagnosis of ruptured abdominal aortic aneurysms. *J Vasc Surg.* 1992;16:17-22.
  46. Khaw H, Sotturai VS, Craighead CC, Batson RC. Ruptured abdominal aortic aneurysm presenting as symptomatic inguinal mass: report of six cases. *J Vasc Surg.* 1986;4:384-389.
  47. Linsell JC, Rowe PH, Owen WJ. Rupture of an aortic aneurysm into the renal vein presenting as a left-sided varicocele. Case report. *Acta Chir Scand.* 1987;153:477-478.
  48. Rose J, Civil I, Koelmeyer T, et al. Ruptured abdominal aortic aneurysms: clinical presentation in Auckland 1993-1997. *Aust N Z J Surg.* 2001;71:341-344.
  49. Akkersdijk GJ, van Bockel JH. Ruptured abdominal aortic aneurysm: initial misdiagnosis and the effect on treatment. *Eur J Surg.* 1998;164:29-34.
  50. Loughran CF. A review of the plain abdominal radiograph in acute rupture of abdominal aortic aneurysms. *Clin Radiol.*

1986;37:383-387.

51. Korner M, Krotz MM, Degenhart C, et al. Current role of emergency US in patients with major trauma. *Radiographics*. 2008;28:225-242.
52. Shuman WP, Hastrup WJ, Kohler TR, et al. Suspected leaking abdominal aortic aneurysm: use of sonography in the emergency room. *Radiology*. 1988;168:117-119.
53. Knaut AL, Kendall JL, Patten R, Ray C. Ultrasonographic measurement of aortic diameter by emergency physicians approximates results obtained by computed tomography. *J Emerg Med*. 2005;28:119-126.
54. Dent B, Kendall RJ, Boyle AA, Atkinson PR. Emergency ultrasound of the abdominal aorta by UK emergency physicians: a prospective cohort study. *Emerg Med J*. 2007;24:547-549.
55. Weinbaum FI, Dubner S, Turner JW, Pardes JG. The accuracy of computed tomography in the diagnosis of retroperitoneal blood in the presence of abdominal aortic aneurysm. *J Vasc Surg*. 1987;6:11-16.
56. Hoonweg LL, Wisselink W, Vahl AC, et al. Interobserver and intraobserver variability of interpretation of CT-angiography in patients with a suspected abdominal aortic aneurysm rupture. *Eur J Vasc Endovasc Surg*. 2008;35:295-300.
57. Lloyd GM, Bown MJ, Norwood MG, et al. Feasibility of preoperative computer tomography in patients with ruptured abdominal aortic aneurysm: a time-to-death study in patients without operation. *J Vasc Surg*. 2004;39:788-791.
58. Boyle JR, Gibbs PJ, Kruger A, et al. Existing delays following the presentation of ruptured abdominal aortic aneurysm allow sufficient time to assess patients for endovascular repair. *Eur J Vasc Endovasc Surg*. 2005;29:505-509.
59. Hoonweg LL, Wisselink W, Vahl A, Balm R. The Amsterdam Acute Aneurysm Trial: suitability and application rate for endovascular repair of ruptured abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg*. 2007;33:679-683.
60. Hinchliffe RJ, Bruijstens L, MacSweeney ST, Braithwaite BD. A randomised trial of endovascular and open surgery for ruptured abdominal aortic aneurysm—results of a pilot study and lessons learned for future studies. *Eur J Vasc Endovasc Surg*. 2006;32:506-513.
61. Mehta M, Taggart J, Darling RC III, et al. Establishing a protocol for endovascular treatment of ruptured abdominal aortic aneurysms: outcomes of a prospective analysis. *J Vasc Surg*. 2006;44:1-8.
62. Moore R, Nutley M, Cina CS, et al. Improved survival after introduction of an emergency endovascular therapy protocol for ruptured abdominal aortic aneurysms. *J Vasc Surg*. 2007;45:443-450.
63. Hames H, Forbes TL, Harris JR, et al. The effect of patient transfer on outcomes after rupture of an abdominal aortic aneurysm. *Can J Surg*. 2007;50:43-47.
64. Crawford ES. Ruptured abdominal aortic aneurysm [editorial]. *J Vasc Surg*. 1991;13:348-350.
65. Bickell WH, Wall MJ Jr, Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. *N Engl J Med*. 1994;331:1105-1109.
66. Roberts K, Revell M, Youssef H, et al. Hypotensive resuscitation in patients with ruptured abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg*. 2006;31:339-344.
67. Kim SH, Stezoski SW, Safar P, et al. Hypothermia and minimal fluid resuscitation increase survival after uncontrolled hemorrhagic shock in rats. *J Trauma*. 1997;42:213-222.
68. Holmes JF, Sakles JC, Lewis G, Wisner DH. Effects of delaying fluid resuscitation on an injury to the systemic arterial vasculature. *Acad Emerg Med*. 2002;9:267-274.
69. Revell M, Porter K, Greaves I. Fluid resuscitation in prehospital trauma care: a consensus view. *Emerg Med J*. 2002;19:494-498.
70. Alric P, Ryckwaert F, Picot MC, et al. Ruptured aneurysm of the infrarenal abdominal aorta: impact of age and postoperative complications on mortality. *Ann Vasc Surg*. 2003;17:277-283.
71. Peppelenbosch N, Yilmaz N, van Marrewijk C, et al. Emergency treatment of acute symptomatic or ruptured abdominal aortic aneurysm. Outcome of a prospective intent-to-treat by EVAR protocol. *Eur J Vasc Endovasc Surg*. 2003;26:303-310.

72. Hinchliffe RJ, Alric P, Rose D, et al. Comparison of morphologic features of intact and ruptured aneurysms of infrarenal abdominal aorta. *J Vasc Surg.* 2003;38:88-92.
73. Badger SA, O'Donnell ME, Makar RR, et al. Aortic necks of ruptured abdominal aneurysms dilate more than asymptomatic aneurysms after endovascular repair. *J Vasc Surg.* 2006;44:244-249.
74. Hinchliffe RJ, Braithwaite BD, European Bifab Study Collaborators. A modular aortouniiliac endovascular stent-graft is a useful device for the treatment of symptomatic and ruptured infrarenal abdominal aortic aneurysms: one-year results from a multicentre study. *Eur J Vasc Endovasc Surg.* 2007;34:291-298.
75. Najjar SF, Mueller KH, Ujiki MB, et al. Percutaneous endovascular repair of ruptured abdominal aortic aneurysms. *Arch Surg.* 2007;142:1049-1052.
76. Champagne BJ, Darling RC III, Daneshmand M, et al. Outcome of aggressive surveillance colonoscopy in ruptured abdominal aortic aneurysm. *J Vasc Surg.* 2004;39:792-796.
77. Champagne BJ, Lee EC, Valerian B, et al. Incidence of colonic ischemia after repair of ruptured abdominal aortic aneurysm with endograft. *J Am Coll Surg.* 2007;204:597-602.
78. Orend KH, Kotsis T, Scharrer-Pamler R, et al. Endovascular repair of aortic rupture due to trauma and aneurysm. *Eur J Vasc Endovasc Surg.* 2002;23:61-67.
79. Lachat ML, Pfammatter T, Witzke HJ, et al. Endovascular repair with bifurcated stent-grafts under local anaesthesia to improve outcome of ruptured aortoiliac aneurysms. *Eur J Vasc Endovasc Surg.* 2002;23:528-536.
80. Nguyen AT, De Virgilio C. Transperitoneal approach should be considered for suspected ruptured abdominal aortic aneurysms. *Ann Vasc Surg.* 2007;21:129-132.
81. Bown MJ, Nicholson ML, Bell PR, Sayers RD. The systemic inflammatory response syndrome, organ failure, and mortality after abdominal aortic aneurysm repair. *J Vasc Surg.* 2003;37:600-606.
82. Darling C 3rd, Shah DM, Chang BB, et al. Current status of the use of retroperitoneal approach for reconstructions of the aorta and its branches. *Ann Surg.* 1996;224:501-506, discussion 506-508.
83. Chang BB, Paty PK, Shah DM, Leather RP. Selective use of retroperitoneal aortic exposure in the emergency treatment of ruptured and symptomatic abdominal aortic aneurysms. *Ann J Surg.* 1988;156:108-110.
84. Veith FJ, Ohki T, Lipsitz EC, et al. Endovascular grafts and other catheter-directed techniques in the management of ruptured abdominal aortic aneurysms. *Semin Vasc Surg.* 2003;16:326-331.
85. Marty-Ane CH, Alric P, Picot MC, et al. Ruptured abdominal aortic aneurysm: influence of intraoperative management on surgical outcome. *J Vasc Surg.* 1995;22:780-786.
86. Posacioglu H, Apaydin AZ, Islamoglu F, et al. Adverse effects of cell saver in patients undergoing ruptured abdominal aortic aneurysm repair. *Ann Vasc Surg.* 2002;16:450-455.
87. Serracino-Inglott F, Awad S, Barclay A, Nasim A. The use of a cell saver during repair of ruptured abdominal aortic aneurysms increases early survival. *Ann R Coll Surg Engl.* 2005;87:475.
88. Szalay D, Wong D, Lindsay T. Impact of red cell salvage on transfusion requirements during elective abdominal aortic aneurysm repair. *Ann Vasc Surg.* 1999;13:576-581.
89. Huber TS, McGorray SP, Carlton LC, et al. Intraoperative autologous transfusion during elective infrarenal aortic reconstruction: a decision analysis model. *J Vasc Surg.* 1997;25:984-993.
90. Frank SM, Fleisher LA, Breslow MJ, et al. Perioperative maintenance of normothermia reduces the incidence of morbid cardiac events. A randomized clinical trial. *JAMA.* 1997;277:1127-1134.
91. Vogel TR, Nackman GB, Brevetti LS, et al. Resource utilization and outcomes: effect of transfer on patients with ruptured abdominal aortic aneurysms. *Ann Vasc Surg.* 2005;19:149-153.
92. Aljabri B, MacDonald PS, Satin R, et al. Incidence of major venous and renal anomalies relevant to aortoiliac surgery as demonstrated by computed tomography. *Ann Vasc Surg.* 2001;15:615-618.
93. De Virgilio C, Gloviczki P. Aortic reconstruction in patients with horseshoe or ectopic kidneys. *Semin Vasc Surg.*

1996;9:245-252.

94. Sekhon CS, Sekhon BK, Singh I, et al. Attenuation of renal ischemia/reperfusion injury by a triple drug combination therapy. *J Nephrol*. 2003;16:63-74.
95. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. *J Am Coll Cardiol*. 2002;40:298-303.
96. Rasmussen TE, Hallett JW Jr, Noel AA, et al. Early abdominal closure with mesh reduces multiple organ failure after ruptured abdominal aortic aneurysm repair: guidelines from a 10-year case-control study. *J Vasc Surg*. 2002;35:246-253.
97. An G, West MA. Abdominal compartment syndrome: a concise clinical review. *Crit Care Med*. 2008;36:1304-1310.
98. Loftus IM, Thompson MM. The abdominal compartment syndrome following aortic surgery. *Eur J Vasc Endovasc Surg*. 2003;25:97-109.
99. Papavassiliou V, Anderton M, Loftus IM, et al. The physiological effects of elevated intra-abdominal pressure following aneurysm repair. *Eur J Vasc Endovasc Surg*. 2003;26:293-298.
100. Mehta M, Darling RC III, Roddy SP, et al. Factors associated with abdominal compartment syndrome complicating endovascular repair of ruptured abdominal aortic aneurysms. *J Vasc Surg*. 2005;42:1047-1051.
101. Akers DL Jr, Fowl RJ, Kempczinski RF, et al. Temporary closure of the abdominal wall by use of silicone rubber sheets after operative repair of ruptured abdominal aortic aneurysms. *J Vasc Surg*. 1991;14:48-52.
102. Foy HM, Nathens AB, Maser B, et al. Reinforced silicone elastomer sheeting, an improved method of temporary abdominal closure in damage control laparotomy. *Am J Surg*. 2003;185:498-501.
103. Johnston KW. Ruptured abdominal aortic aneurysm: six-year follow-up results of a multicenter prospective study. Canadian Society for Vascular Surgery Aneurysm Study Group. *J Vasc Surg*. 1994;19:888-900.
104. Becquemin JP, Majewski M, Fermani N, et al. Colon ischemia following abdominal aortic aneurysm repair in the era of endovascular abdominal aortic repair. *J Vasc Surg*. 2008;47:258-263.
105. Peppelenbosch N, Cuypers PW, Vahl AC, et al. Emergency endovascular treatment for ruptured abdominal aortic aneurysm and the risk of spinal cord ischemia. *J Vasc Surg*. 2005;42:608-614.
106. Rosenthal D. Spinal cord ischemia after abdominal aortic operation: is it preventable? *J Vasc Surg*. 1999;30:391-397.
107. Harris LM, Faggioli GL, Fiedler R, et al. Ruptured abdominal aortic aneurysms: factors affecting mortality rates. *J Vasc Surg*. 1991;14:812-818, discussion 819-820.
108. Katz DJ, Stanley JC, Zelenock GB. Operative mortality rates for intact and ruptured abdominal aortic aneurysms in Michigan: an eleven-year statewide experience. *J Vasc Surg*. 1994;19:804-815, discussion 816-817.
109. Bauer EP, Redaelli C, von Segesser LK, Turina MI. Ruptured abdominal aortic aneurysms: predictors for early complications and death. *Surgery*. 1993;114:31-35.
110. El Sabrout RA, Reul GJ. Suprarenal or supraceliac aortic clamping during repair of infrarenal abdominal aortic aneurysms. *Tex Heart Inst J*. 2001;28:254-264.
111. Tilney NL, Bailey GL, Morgan AP. Sequential system failure after rupture of abdominal aortic aneurysms: an unsolved problem in postoperative care. *Ann Surg*. 1973;178:117-122.
112. Hermreck AS, Proberts KS, Thomas JH. Severe jaundice after rupture of abdominal aortic aneurysm. *Am J Surg*. 1977;134:745-748.
113. Maziak DE, Lindsay TF, Marshall JC, Walker PM. The impact of multiple organ dysfunction on mortality following ruptured abdominal aortic aneurysm repair. *Ann Vasc Surg*. 1998;12:93-100.
114. Bown MJ, Nicholson ML, Bell PR, Sayers RD. Cytokines and inflammatory pathways in the pathogenesis of multiple organ failure following abdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg*. 2001;22:485-495.
115. Bown MJ, Nicholson ML, Bell PR, Sayers RD. The systemic inflammatory response syndrome, organ failure, and mortality after abdominal aortic aneurysm repair. *J Vasc Surg*. 2003;37:600-606.
116. Fan J, Marshall JC, Jimenez M, et al. Hemorrhagic shock primes for increased expression of cytokine-induced neutrophil



- chemoattractant in the lung: role in pulmonary inflammation following lipopolysaccharide. *J Immunol.* 1998;161:440-447.
117. Vedder NB, Winn RK, Rice CL, et al. A monoclonal antibody to the adherence-promoting leukocyte glycoprotein, CD18, reduces organ injury and improves survival from hemorrhagic shock and resuscitation in rabbits. *J Clin Invest.* 1988;81:939-944.
  118. Forbes TL, Harris KA, Jamieson WG, et al. Leukocyte activity and tissue injury following ischemia-reperfusion in skeletal muscle. *Microvasc Res.* 1996;51:275-287.
  119. Boyd AJ, Walker PM, Romaschin A, et al. Monoclonal antibody against CD18 reduces intestinal and pulmonary injury in a model of ruptured abdominal aortic aneurysm. *J Vasc Interv Radiol.* 1998;9:708-709.
  120. Shahani R, Marshall JG, Rubin BB, et al. Role of TNF-alpha in myocardial dysfunction after hemorrhagic shock and lower-torso ischemia. *Am J Physiol Heart Circ Physiol.* 2000;278:H942-H950.
  121. Lindsay TF, Memari N, Ghanekar A, et al. Rupture of an abdominal aortic aneurysm causes priming of phagocytic oxidative burst. *J Vasc Surg.* 1997;25:599-610.
  122. Harkin DW, Romaschin A, Taylor SM, et al. Complement C5a receptor antagonist attenuates multiple organ injury in a model of ruptured abdominal aortic aneurysm. *J Vasc Surg.* 2004;39:196-206.
  123. Haveman JW, van den Berg AP, Verhoeven EL, et al. HLA-DR expression on monocytes and systemic inflammation in patients with ruptured abdominal aortic aneurysms. *Crit Care.* 2006;10:R119.
  124. Dardik A, Burleyson GP, Bowman H, et al. Surgical repair of ruptured abdominal aortic aneurysms in the state of Maryland: factors influencing outcome among 527 recent cases. *J Vasc Surg.* 1998;28:413-420.
  125. Sadat U, Boyle JR, Walsh SR, et al. Endovascular vs open repair of acute abdominal aortic aneurysms—a systematic review and meta-analysis. *J Vasc Surg.* 2008;48:227-236.
  126. Tambyraja AL, Murie JA, Chalmers RT. Prediction of outcome after abdominal aortic aneurysm rupture. *J Vasc Surg.* 2008;47:222-230.
  127. Tambyraja AL, Lee AJ, Murie JA, Chalmers RT. Prognostic scoring in ruptured abdominal aortic aneurysm: a prospective evaluation. *J Vasc Surg.* 2008;47:282-286.
  128. AbuRahma AF, Woodruff BA, Stuart SP, et al. Early diagnosis and survival of ruptured abdominal aortic aneurysms. *Am J Emerg Med.* 1991;9:118-121.
  129. Dardik A, Burleyson GP, Bowman H, et al. Surgical repair of ruptured abdominal aortic aneurysms in the state of Maryland: factors influencing outcome among 527 recent cases. *J Vasc Surg.* 1998;28:413-420.
  130. Heller JA, Weinberg A, Arons R, et al. Two decades of abdominal aortic aneurysm repair: have we made any progress? *J Vasc Surg.* 2000;32:1091-1100.
  131. Wakefield TW, Whitehouse WM Jr, Wu SC, Zelenock GB, et al. Abdominal aortic aneurysm rupture: statistical analysis of factors affecting outcome of surgical treatment. *Surgery.* 1982;91:586-596.
  132. Halpern VJ, Kline RG, D'Angelo AJ, Cohen JR. Factors that affect the survival rate of patients with ruptured abdominal aortic aneurysms. *J Vasc Surg.* 1997;26:939-945.
  133. Boxer LK, Dimick JB, Wainess RM, et al. Payer status is related to differences in access and outcomes of abdominal aortic aneurysm repair in the United States. *Surgery.* 2003;134:142-145.
  134. Chen JC, Hildebrand HD, Salvian AJ, et al. Predictors of death in nonruptured and ruptured abdominal aortic aneurysms. *J Vasc Surg.* 1996;24:614-620.
  135. Noel AA, Gloviczki P, Cherry KJ Jr, et al. Ruptured abdominal aortic aneurysms: the excessive mortality rate of conventional repair. *J Vasc Surg.* 2001;34:41-46.
  136. Piper G, Patel NA, Chandela S, et al. Short-term predictors and long-term outcome after ruptured abdominal aortic aneurysm repair. *Am Surg.* 2003;69:703-709.
  137. Cho JS, Gloviczki P, Martelli E, et al. Long-term survival and late complications after repair of ruptured abdominal aortic aneurysms. *J Vasc Surg.* 1998;27:813-819.

138. Kazmers A, Perkins AJ, Jacobs LA. Aneurysm rupture is independently associated with increased late mortality in those surviving abdominal aortic aneurysm repair. *J Surg Res.* 2001;95:50-53.
139. Korhonen SJ, Kantonen I, Pettila V, et al. Long-term survival and health-related quality of life of patients with ruptured abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg.* 2003;25:350-353.
140. Hinchliffe RJ, Braithwaite BD. Ruptured abdominal aortic aneurysm: endovascular repair does not confer any long-term survival advantage over open repair. *Vascular.* 2007;15:191-196.
141. Anain PM, Anain JM Sr, Tiso M, et al. Early and mid-term results of ruptured abdominal aortic aneurysms in the endovascular era in a community hospital. *J Vasc Surg.* 2007;46:898-905.
142. Hechelhammer L, Lachat ML, Wildermuth S, et al. Midterm outcome of endovascular repair of ruptured abdominal aortic aneurysms. *J Vasc Surg.* 2005;41:752-757.
143. Visser JJ, Bosch JL, Hunink MG, et al. Endovascular repair versus open surgery in patients with ruptured abdominal aortic aneurysms: clinical outcomes with 1-year follow-up. *J Vasc Surg.* 2006;44:1148-1155.
144. Ockert S, Schumacher H, Bockler D, et al. Early and midterm results after open and endovascular repair of ruptured abdominal aortic aneurysms in a comparative analysis. *J Endovasc Ther.* 2007;14:324-332.
145. Coppi G, Silingardi R, Gennai S, et al. A single-center experience in open and endovascular treatment of hemodynamically unstable and stable patients with ruptured abdominal aortic aneurysms. *J Vasc Surg.* 2006;44:1140-1147.
146. Hill AB, Palerme LP, Brandys T, et al. Health-related quality of life in survivors of open ruptured abdominal aortic aneurysm repair: a matched, controlled cohort study. *J Vasc Surg.* 2007;46:223-229.
147. Laukontaus SJ, Pettila V, Kantonen I, et al. Utility of surgery for ruptured abdominal aortic aneurysm. *Ann Vasc Surg.* 2006;20:42-48.
148. Hinterseher I, Saeger HD, Koch R, et al. Quality of life and long-term results after ruptured abdominal aortic aneurysm. *Eur J Vasc Endovasc Surg.* 2004;28:262-269.

## 第 131 章

1. National Center for Health Statistics (NHCS), National Vital Statistics System, WISQARS Query: 20 Leading Causes of Death, United States, 1999-2004, All Races, Both Sexes. Available at <http://webappa.cdc.gov/sasweb/ncipc/leadcaus10.html>; Accessed July 25, 2007.
2. Bickerstaff LK, Pairolero PC, Hollier LH, et al. Thoracic aortic aneurysms: a population-based study. *Surgery.* 1982;92:1103-1108.
3. Lam CR, Aram HH. Resection of the descending thoracic aorta for aneurysm; a report of the use of a homograft in a case and an experimental study. *Ann Surg.* 1951;134:743-752.
4. De Bakey ME, Cooley DA. Successful resection of aneurysm of thoracic aorta and replacement by graft. *J Am Med Assoc.* 1953;152:673-676.
5. Etheredge SN, Yee J, Smith JV, et al. Successful resection of a large aneurysm of the upper abdominal aorta and replacement with homograft. *Surgery.* 1955;38:1071-1081.
6. Creech O Jr, DeBakey ME, Morris GC Jr. Aneurysm of thoracoabdominal aorta involving the celiac, superior mesenteric, and renal arteries; report of four cases treated by resection and homograft replacement. *Ann Surg.* 1956;144:549-573.
7. Crawford ES. Thoraco-abdominal and abdominal aortic aneurysms involving renal, superior mesenteric, celiac arteries. *Ann Surg.* 1974;179:763-772.
8. Cowan JA Jr, Dimick JB, Henke PK, et al. Surgical treatment of intact thoracoabdominal aortic aneurysms in the United States: hospital and surgeon volume-related outcomes. *J Vasc Surg.* 2003;37:1169-1174.
9. Cowan JA Jr, Dimick JB, Wainess RM, et al. Ruptured thoracoabdominal aortic aneurysm treatment in the United States: 1988 to 1998. *J Vasc Surg.* 2003;38:319-322.
10. Dake MD, Miller DC, Semba CP, et al. Transluminal placement of endovascular stent-grafts for the treatment of

descending thoracic aortic aneurysms. *N Engl J Med*. 1994;331:1729-1734.

11. Mitchell RS, Miller DC, Dake MD, et al. Thoracic aortic aneurysm repair with an endovascular stent graft: the "first generation." *Ann Thorac Surg*. 1999;67:1971-1974; discussion 1979-1980.
12. Volodos NL, Karpovich IP, Troyan VI, et al. Clinical experience of the use of self-fixing synthetic prostheses for remote endoprosthetics of the thoracic and the abdominal aorta and iliac arteries through the femoral artery and as intraoperative endoprosthesis for aorta reconstruction. *Vasa Suppl*. 1991;33:93-95.
13. Buffolo E, da Fonseca JH, de Souza JA, Alves CM. Revolutionary treatment of aneurysms and dissections of descending aorta: the endovascular approach. *Ann Thorac Surg*. 2002;74:S1815-S1817; discussion S1825-S1832.
14. Dake MD, Miller DC, Mitchell RS, et al. The "first generation" of endovascular stent-grafts for patients with aneurysms of the descending thoracic aorta. *J Thorac Cardiovasc Surg*. 1998;116:689-703; discussion 703-704.
15. Greenberg R, Resch T, Nyman U, et al. Endovascular repair of descending thoracic aortic aneurysms: an early experience with intermediate-term follow-up. *J Vasc Surg*. 2000;31:147-156.
16. Makaroun MS, Dillavou ED, Kee ST, et al. Endovascular treatment of thoracic aortic aneurysms: results of the phase II multicenter trial of the GORE TAG thoracic endoprosthesis. *J Vasc Surg*. 2005;41:1-9.
17. Gawenda M, Brunkwall J. Device-specific outcomes with endografts for thoracic aortic aneurysms. *J Cardiovasc Surg (Torino)*. 2005;46:113-120.
18. Leurs LJ, Bell R, Degrieck Y, et al. Endovascular treatment of thoracic aortic diseases: combined experience from the EUROSTAR and United Kingdom Thoracic Endograft registries. *J Vasc Surg*. 2004;40:670-679; discussion 679-680.
19. Orend KH, Scharrer-Pamler R, Kapfer X, et al. Endovascular treatment in diseases of the descending thoracic aorta: 6-year results of a single center. *J Vasc Surg*. 2003;37:91-99.
20. Rachel ES, Bergamini TM, Kinney EV, et al. Endovascular repair of thoracic aortic aneurysms: a paradigm shift in standard of care. *Vasc Endovasc Surg*. 2002;36:105-113.
21. Semba CP, Kato N, Kee ST, et al. Acute rupture of the descending thoracic aorta: repair with use of endovascular stent-grafts. *J Vasc Interv Radiol*. 1997;8:337-342.
22. Kato N, Dake MD, Miller DC, et al. Traumatic thoracic aortic aneurysm: treatment with endovascular stent-grafts. *Radiology*. 1997;205:657-662.
23. Semba CP, Sakai T, Slonim SM, et al. Mycotic aneurysms of the thoracic aorta: repair with use of endovascular stent-grafts. *J Vasc Interv Radiol*. 1998;9:33-40.
24. Bavaria JE, Appoo JJ, Makaroun MS, et al. Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: a multicenter comparative trial. *J Thorac Cardiovasc Surg*. 2007;133:369-377.
25. Matsumura JS, Cambria RP, Dake MD, et al. International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft: 1-year results. *J Vasc Surg*. 2008;47:247-257; discussion 257.
26. Fairman RM, Criado F, Farber M, et al. Pivotal results of the Medtronic Vascular Talent Thoracic Stent Graft System: the VALOR Trial. *J Vasc Surg*. 2008;48:546-554.
27. Roselli EE, Greenberg RK, Pfaff K, et al. Endovascular treatment of thoracoabdominal aortic aneurysms. *J Thorac Cardiovasc Surg*. 2007;133:1474-1482.
28. Chuter TA, Rapp JH, Hiramoto JS, et al. Endovascular treatment of thoracoabdominal aortic aneurysms. *J Vasc Surg*. 2008;47:6-16.
29. Fulton JJ, Farber MA, Marston WA, et al. Endovascular stent-graft repair of pararenal and type IV thoracoabdominal aortic aneurysms with adjunctive visceral reconstruction. *J Vasc Surg*. 2005;41:191-198.
30. Lee WA, Brown MP, Martin TD, et al. Early results after staged hybrid repair of thoracoabdominal aortic aneurysms. *J Am Coll Surg*. 2007;205:420-431.
31. Santilli JD, Santilli SM. Diagnosis and treatment of abdominal aortic aneurysms. *Am Fam Physician*. 1997;56:1081-1090.
32. Vasan RS, Larson MG, Benjamin EJ, Levy D. Echocardiographic reference values for aortic root size: the Framingham

- Heart Study. *J Am Soc Echocardiogr*. 1995;8:793-800.
33. Dapunt OE, Galla JD, Sadeghi AM, et al. The natural history of thoracic aortic aneurysms. *J Thorac Cardiovasc Surg*. 1994;107:1323-1332; discussion 1332-1333.
  34. Agmon Y, Khandheria BK, Meissner I, et al. Is aortic dilatation an atherosclerosis-related process? Clinical, laboratory, and transesophageal echocardiographic correlates of thoracic aortic dimensions in the population with implications for thoracic aortic aneurysm formation. *J Am Coll Cardiol*. 2003;42:1076-1083.
  35. Garcier JM, Petitcolin V, Filaire M, et al. Normal diameter of the thoracic aorta in adults: a magnetic resonance imaging study. *Surg Radiol Anat*. 2003;25:322-329.
  36. Hager A, Kaemmerer H, Rapp-Bernhardt U, et al. Diameters of the thoracic aorta throughout life as measured with helical computed tomography. *J Thorac Cardiovasc Surg*. 2002;123:1060-1066.
  37. Liddington MI, Heather BP. The relationship between aortic diameter and body habitus. *Eur J Vasc Surg*. 1992;6:89-92.
  38. Brady AR, Thompson SG, Fowkes FG, et al. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. *Circulation*. 2004;110:16-21.
  39. Roman MJ, Rosen SE, Kramer-Fox R, Devereux RB. Prognostic significance of the pattern of aortic root dilation in the Marfan syndrome. *J Am Coll Cardiol*. 1993;22:1470-1476.
  40. Pleumeekers HJ, Hoes AW, van der Does E, et al. Aneurysms of the abdominal aorta in older adults. The Rotterdam Study. *Am J Epidemiol*. 1995;142:1291-1299.
  41. Biddinger A, Rocklin M, Coselli J, Milewicz DM. Familial thoracic aortic dilatations and dissections: a case control study. *J Vasc Surg*. 1997;25:506-511.
  42. Coady MA, Davies RR, Roberts M, et al. Familial patterns of thoracic aortic aneurysms. *Arch Surg*. 1999;134:361-367.
  43. Hasham SN, Willing MC, Guo DC, et al. Mapping a locus for familial thoracic aortic aneurysms and dissections (TAAD2) to 3p24-25. *Circulation*. 2003;107:3184-3190.
  44. Guo DC, Papke CL, He R, Milewicz DM. Pathogenesis of thoracic and abdominal aortic aneurysms. *Ann N Y Acad Sci*. 2006;1085:339-352.
  45. Coady MA, Rizzo JA, Goldstein LJ, Elefteriades JA. Natural history, pathogenesis, and etiology of thoracic aortic aneurysms and dissections. *Cardiol Clin*. 1999;17:615-635; vii.
  46. Moreno-Cabral CE, Miller DC, Mitchell RS, et al. Degenerative and atherosclerotic aneurysms of the thoracic aorta. Determinants of early and late surgical outcome. *J Thorac Cardiovasc Surg*. 1984;88:1020-1032.
  47. Cambria RP, Davison JK, Zannetti S, et al. Thoracoabdominal aneurysm repair: perspectives over a decade with the clamp-and-sew technique. *Ann Surg*. 1997;226:294-303; discussion 303-305.
  48. Juvonen T, Ergin MA, Galla JD, et al. Risk factors for rupture of chronic type B dissections. *J Thorac Cardiovasc Surg*. 1999;117:776-786.
  49. McNamara JJ, Pressler VM. Natural history of arteriosclerotic thoracic aortic aneurysms. *Ann Thorac Surg*. 1978;26:468-473.
  50. Pressler V, McNamara JJ. Aneurysm of the thoracic aorta. Review of 260 cases. *J Thorac Cardiovasc Surg*. 1985;89:50-54.
  51. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. *Ann Thorac Surg*. 2002;73:17-27; discussion 27-28.
  52. Crawford ES, DeNatale RW. Thoracoabdominal aortic aneurysm: observations regarding the natural course of the disease. *J Vasc Surg*. 1986;3:578-582.
  53. Cronenwett JL, Murphy TF, Zelenock GB, et al. Actuarial analysis of variables associated with rupture of small abdominal aortic aneurysms. *Surgery*. 1985;98:472-483.
  54. Cambria RA, Gloviczki P, Stanson AW, et al. Outcome and expansion rate of 57 thoracoabdominal aortic aneurysms managed nonoperatively. *Am J Surg*. 1995;170:213-217.
  55. Griep RB, Ergin MA, Galla JD, et al. Natural history of descending thoracic and thoracoabdominal aneurysms. *Ann*

*Thorac Surg.* 1999;67:1927-1930; discussion 1953-1928.

56. Coady MA, Rizzo JA, Hammond GL, et al. What is the appropriate size criterion for resection of thoracic aortic aneurysms? *J Thorac Cardiovasc Surg.* 1997;113:476-491; discussion 489-491.
57. Masuda Y, Takanashi K, Takasu J, et al. Expansion rate of thoracic aortic aneurysms and influencing factors. *Chest.* 1992;102:461-466.
58. Rizzo JA, Coady MA, Elefteriades JA. Procedures for estimating growth rates in thoracic aortic aneurysms. *J Clin Epidemiol.* 1998;51:747-754.
59. Juvonen T, Ergin MA, Galla JD, et al. Prospective study of the natural history of thoracic aortic aneurysms. *Ann Thorac Surg.* 1997;63:1533-1545.
60. Clouse WD, Hallett JW Jr, Schaff HV, et al. Improved prognosis of thoracic aortic aneurysms: a population-based study. *JAMA.* 1998;280:1926-1929.
61. Olsson C, Thelin S, Stahle E, et al. Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. *Circulation.* 2006;114:2611-2618.
62. LaRoy LL, Cormier PJ, Matalon TA, et al. Imaging of abdominal aortic aneurysms. *AJR Am J Roentgenol.* 1989;152:785-792.
63. Barbour JR, Spinale FG, Ikonomidis JS. Proteinase systems and thoracic aortic aneurysm progression. *J Surg Res.* 2007;139:292-307.
64. Milewicz DM, Chen H, Park ES, et al. Reduced penetrance and variable expressivity of familial thoracic aortic aneurysms/dissections. *Am J Cardiol.* 1998;82:474-479.
65. Guo DC, Pannu H, Tran-Fadulu V, et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. *Nat Genet.* 2007;39:1488-1493.
66. Pannu H, Tran-Fadulu V, Papke CL, et al. MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. *Hum Mol Genet.* 2007;16:2453-2462.
67. Wang Y, Barbacioru CC, Shiffman D, et al. Gene expression signature in peripheral blood detects thoracic aortic aneurysm. *PLoS ONE.* 2007;2:e1050.
68. Andreotti L, Bussotti A, Cammelli D, et al. Aortic connective tissue in ageing—a biochemical study. *Angiology.* 1985;36:872-879.
69. Wolinsky H, Glagov S. A lamellar unit of aortic medial structure and function in mammals. *Circ Res.* 1967;20:99-111.
70. Ikonomidis JS, Barbour JR, Amani Z, et al. Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. *Circulation.* 2005;112(9 Suppl):I242-248.
71. Sinha I, Bethi S, Cronin P, et al. A biologic basis for asymmetric growth in descending thoracic aortic aneurysms: a role for matrix metalloproteinase 9 and 2. *J Vasc Surg.* 2006;43:342-348.
72. Erdheim J. Medionecrosis aortae idiopathica cystica. *Virchows Arch.* 1930;276:187.
73. Klima T, Spjut HJ, Coelho A, et al. The morphology of ascending aortic aneurysms. *Hum Pathol.* 1983;14:810-817.
74. Schlatmann TJ, Becker AE. Histologic changes in the normal aging aorta: implications for dissecting aortic aneurysm. *Am J Cardiol.* 1977;39:13-20.
75. Carlson RG, Lillehei CW, Edwards JE. Cystic medial necrosis of the ascending aorta in relation to age and hypertension. *Am J Cardiol.* 1970;25:411-415.
76. Cambria RP. Thoracoabdominal aortic aneurysms. In Rutherford R, ed. *Vascular Surgery*. 5th ed. Philadelphia, PA: WB Saunders; 2000.
77. LeMaire SA, Carter SA, Volguina IV, et al. Spectrum of aortic operations in 300 patients with confirmed or suspected Marfan syndrome. *Ann Thorac Surg.* 2006;81:2063-2078; discussion 2078.
78. Kang N, Clarke AJ, Nicholson IA, Chard RB. Circulatory arrest for repair of postcoarctation site aneurysm. *Ann Thorac*

*Surg.* 2004;77:2029-2033.

79. Heikkinen L, Ala-Kulju K. Long-term results of direct aortoplasty for repair of aortic coarctation in adults. *Ann Thorac Surg.* 1990;49:948-950.
80. Ala-Kulju K, Heikkinen L. Aneurysms after patch graft aortoplasty for coarctation of the aorta: long-term results of surgical management. *Ann Thorac Surg.* 1989;47:853-856.
81. Kan CD, Lee HL, Yang YJ. Outcome after endovascular stent graft treatment for mycotic aortic aneurysm: a systematic review. *J Vasc Surg.* 2007;46:906-912.
82. Kpodonu J, Williams JP, Ramaiah VG, Diethrich EB. Endovascular management of a descending thoracic mycotic aneurysm: mid-term follow-up. *Eur J Cardiothorac Surg.* 2007;32:178-179.
83. Crawford ES, Crawford JL, Safi HJ, et al. Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. *J Vasc Surg.* 1986;3:389-404.
84. Svensson LG, Crawford ES, Hess KR, et al. Experience with 1509 patients undergoing thoracoabdominal aortic operations. *J Vasc Surg.* 1993;17:357-368; discussion 368-370.
85. Safi HJ, Miller CC 3rd, Huynh TT, et al. Distal aortic perfusion and cerebrospinal fluid drainage for thoracoabdominal and descending thoracic aortic repair: ten years of organ protection. *Ann Surg.* 2003;238:372-380; discussion 380-381.
86. Panneton JM, Hollier LH. Nondissecting thoracoabdominal aortic aneurysms: Part I. *Ann Vasc Surg.* 1995;9:503-514.
87. Cooke JC, Cambria RP. Simultaneous tracheobronchial and esophageal obstruction caused by a descending thoracic aneurysm. *J Vasc Surg.* 1993;18:90-94.
88. Furukawa H, Tsuchiya K, Osawa H, et al. Saccular descending thoracic aortic aneurysm with dysphagia. *Jpn J Thorac Cardiovasc Surg.* 1999;47:277-280.
89. Arnold SE, Biller J. Spontaneous cerebral embolism from descending thoracic aortic aneurysm—a case report. *Angiology.* 1991;42:69-72.
90. Fann JJ. Descending thoracic and thoracoabdominal aortic aneurysms. *Coron Artery Dis.* 2002;13:93-102.
91. Svensjo S, Bengtsson H, Bergqvist D. Thoracic and thoracoabdominal aortic aneurysm and dissection: an investigation based on autopsy. *Br J Surg.* 1996;83:68-71.
92. Crawford ES, Cohen ES. Aortic aneurysm: a multifocal disease. Presidential address. *Arch Surg.* 1982;117:1393-1400.
93. Coselli JS, Poli de Figueiredo LF, LeMaire SA. Impact of previous thoracic aneurysm repair on thoracoabdominal aortic aneurysm management. *Ann Thorac Surg.* 1997;64:639-650.
94. Clouse WD, Marone LK, Davison JK, et al. Late aortic and graft-related events after thoracoabdominal aneurysm repair. *J Vasc Surg.* 2003;37:254-261.
95. Schoenhoff FS, Schmidli J, Eckstein FS, et al. The frozen elephant trunk: an interesting hybrid endovascular-surgical technique to treat complex pathologies of the thoracic aorta. *J Vasc Surg.* 2007;45:597-599.
96. Abou-Zamzam AM Jr, Zhang W, Wang N, Razzouk A. Endovascular repair of a ruptured descending thoracic aortic aneurysm in a patient with an ascending aortic aneurysm: hybrid open arch reconstruction with simultaneous thoracic stent-graft deployment within elephant trunk. *Ann Vasc Surg.* 2008;22:168-172.
97. Resch TA, Greenberg RK, Lyden SP, et al. Combined staged procedures for the treatment of thoracoabdominal aneurysms. *J Endovasc Ther.* 2006;13:481-489.
98. Williams GM, Roseborough GS, Webb TH, et al. Preoperative selective intercostal angiography in patients undergoing thoracoabdominal aneurysm repair. *J Vasc Surg.* 2004;39:314-321.
99. Hemminger BM, Molina PL, Egan TM, et al. Assessment of real-time 3D visualization for cardiothoracic diagnostic evaluation and surgery planning. *J Digit Imaging.* 2005;18:145-153.
100. Loutsidis A, Koukis I, Argiriou M, Bellenis I. Incidental finding of lung cancer in a patient with thoracic aortic aneurysm—simultaneous management. A case report. *Eur J Cancer Care (Engl).* 2007;16:387-389.
101. Morimoto Y, Kuratani T, Tanaka Y, Kaneko M. Surgical strategy for advanced gastric cancer with a concomitant

- thoracoabdominal aortic aneurysm requiring arterial reconstruction of the visceral branches. *Surg Today*. 2007;37:817-821.
102. El-Hajjar M, Bashir I, Khan M, et al. Incidence of contrast-induced nephropathy in patients with chronic renal insufficiency undergoing multidetector computed tomographic angiography treated with preventive measures. *Am J Cardiol*. 2008;102:353-356.
  103. Schweiger MJ, Chambers CE, Davidson CJ, et al. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. *Catheter Cardiovasc Interv*. 2007;69:135-140.
  104. Meschi M, Detrenis S, Musini S, et al. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. *Crit Care Med*. 2006;34:2060-2068.
  105. Nijenhuis RJ, Jacobs MJ, Jaspers K, et al. Comparison of magnetic resonance with computed tomography angiography for preoperative localization of the Adamkiewicz artery in thoracoabdominal aortic aneurysm patients. *J Vasc Surg*. 2007;45:677-685.
  106. Kaufman JA, Geller SC, Petersen MJ, et al. MR imaging (including MR angiography) of abdominal aortic aneurysms: comparison with conventional angiography. *AJR Am J Roentgenol*. 1994;163:203-210.
  107. Clorius S, Technau K, Watter T, et al. Nephrogenic systemic fibrosis following exposure to gadolinium-containing contrast agent. *Clin Nephrol*. 2007;68:249-252.
  108. Schillinger M, Domanovits H, Ignatescu M, et al. Lipoprotein (a) in patients with aortic aneurysmal disease. *J Vasc Surg*. 2002;36:25-30.
  109. Lases EC, Schepens MA, Haas FJ, et al. Clinical prospective study of biochemical markers and evoked potentials for identifying adverse neurological outcome after thoracic and thoracoabdominal aortic aneurysm surgery. *Br J Anaesth*. 2005;95:651-661.
  110. Suzuki T, Distant A, Zizza A, et al. Preliminary experience with the smooth muscle troponin-like protein, calponin, as a novel biomarker for diagnosing acute aortic dissection. *Eur Heart J*. 2008;29:1439-1445.
  111. Touat Z, Lepage L, Ollivier V, et al. Dilation-dependent activation of platelets and prothrombin in human thoracic ascending aortic aneurysm. *Arterioscler Thromb Vasc Biol*. 2008;28:940-946.
  112. Mamiya S, Endo Y, Miura AB, et al. Disseminated intravascular coagulation accompanying thoracic and abdominal aortic aneurysm; report of three cases. *Jpn J Med*. 1988;27:91-95.
  113. Wheat MW Jr, Palmer RF. Dissecting aneurysms of the aorta: present status of drug versus surgical therapy. *Prog Cardiovasc Dis*. 1968;11:198-210.
  114. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. *N Engl J Med*. 1994;330:1335-1341.
  115. Moursi MM, Beebe HG, Messina LM, et al. Inhibition of aortic aneurysm development in blotchy mice by beta adrenergic blockade independent of altered lysyl oxidase activity. *J Vasc Surg*. 1995;21:792-799; discussion 799-800.
  116. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. *J Vasc Surg*. 2002;35:72-79.
  117. Ejiri J, Inoue N, Tsukube T, et al. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker. *Cardiovasc Res*. 2003;59:988-996.
  118. Steinmetz EF, Buckley C, Shames ML, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. *Ann Surg*. 2005;241:92-101.
  119. Nagashima H, Aoka Y, Sakomura Y, et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. *J Vasc Surg*. 2002;36:158-163.
  120. Schouten O, van Laanen JH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. *Eur J Vasc Endovasc Surg*. 2006;32:21-26.
  121. Diehm N, Becker G, Katzen B, et al. Statins are associated with decreased mortality in abdominal, but not in thoracic aortic aneurysm patients undergoing endovascular repair: propensity score-adjusted analysis. *Vasa*. 2008;37:241-249.

122. Cannon DJ, Read RC. Blood elastolytic activity in patients with aortic aneurysm. *Ann Thorac Surg.* 1982;34:10-15.
123. Rasmussen TE, Hallett Jr JW, Tazelaar HD, et al. Human leukocyte antigen class II immune response genes, female gender, and cigarette smoking as risk and modulating factors in abdominal aortic aneurysms. *J Vasc Surg.* 2002;35:988-993.
124. Wilmink TB, Quick CR, Day NE. The association between cigarette smoking and abdominal aortic aneurysms. *J Vasc Surg.* 1999;30:1099-1105.
125. Coady MA, Rizzo JA, Elefteriades JA. Developing surgical intervention criteria for thoracic aortic aneurysms. *Cardiol Clin.* 1999;17:827-839.
126. Greenberg RK, Clair D, Srivastava S, et al. Should patients with challenging anatomy be offered endovascular aneurysm repair? *J Vasc Surg.* 2003;38:990-996.
127. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. *Lancet.* 1998;352:1649-1655.
128. Lederle FA, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med.* 2002;346:1437-1444.
129. Davies RR, Gallo A, Coady MA, et al. Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. *Ann Thorac Surg.* 2006;81:169-177.
130. Svensson LG. Device discordancy: lost cords, quick-fix seekers, quality, and ethics. *J Thorac Cardiovasc Surg.* 2006;131:261-263.
131. Coselli JS, LeMaire SA, Miller CC 3rd, et al. Mortality and paraplegia after thoracoabdominal aortic aneurysm repair: a risk factor analysis. *Ann Thorac Surg.* 2000;69:409-414.
132. Crawford ES, Hess KR, Cohen ES, et al. Ruptured aneurysm of the descending thoracic and thoracoabdominal aorta. Analysis according to size and treatment. *Ann Surg.* 1991;213:417-425; discussion 425-426.
133. Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. *Ann Thorac Surg.* 2002;74:S1877-1880; discussion S1892-S1898.
134. Hertzner NR, Young JR, Kramer JR, et al. Routine coronary angiography prior to elective aortic reconstruction: results of selective myocardial revascularization in patients with peripheral vascular disease. *Arch Surg.* 1979;114:1336-1344.
135. Young JR, Hertzner NR, Beven EG, et al. Coronary artery disease in patients with aortic aneurysm: a classification of 302 coronary angiograms and results of surgical management. *Ann Vasc Surg.* 1986;1:36-42.
136. Estrera AL, Rubenstein FS, Miller CC 3rd, et al. Descending thoracic aortic aneurysm: surgical approach and treatment using the adjuncts cerebrospinal fluid drainage and distal aortic perfusion. *Ann Thorac Surg.* 2001;72:481-486.
137. Upchurch GR Jr, Proctor MC, Henke PK, et al. Predictors of severe morbidity and death after elective abdominal aortic aneurysmectomy in patients with chronic obstructive pulmonary disease. *J Vasc Surg.* 2003;37:594-599.
138. Cambria RP, Clouse WD, Davison JK, et al. Thoracoabdominal aneurysm repair: results with 337 operations performed over a 15-year interval. *Ann Surg.* 2002;236:471-479; discussion 479.
139. Coselli JS, Conklin LD, LeMaire SA. Thoracoabdominal aortic aneurysm repair: review and update of current strategies. *Ann Thorac Surg.* 2002;74:S1881-1884; discussion S1892-S1888.
140. Kashyap VS, Cambria RP, Davison JK, L'Italien GJ. Renal failure after thoracoabdominal aortic surgery. *J Vasc Surg.* 1997;26:949-955; discussion 955-957.
141. Kouchoukos NT, Masetti P, Rokkas CK, et al. Safety and efficacy of hypothermic cardiopulmonary bypass and circulatory arrest for operations on the descending thoracic and thoracoabdominal aorta. *Ann Thorac Surg.* 2001;72:699-707; discussion 707-708.
142. Safi HJ. Thoracoabdominal aortic aneurysm. In Rutherford R, ed. *Vascular Surgery*. 6th ed. Philadelphia, PA: Elsevier Saunders; 2005.
143. Svensson LG, Coselli JS, Safi HJ, et al. Appraisal of adjuncts to prevent acute renal failure after surgery on the thoracic or thoracoabdominal aorta. *J Vasc Surg.* 1989;10:230-239.



144. Huynh TT, van Eps RG, Miller CC, 3rd, et al. Glomerular filtration rate is superior to serum creatinine for prediction of mortality after thoracoabdominal aortic surgery. *J Vasc Surg.* 2005;42:206-212.
145. Svensson LG, Crawford ES, Hess KR, et al. Thoracoabdominal aortic aneurysms associated with celiac, superior mesenteric, and renal artery occlusive disease: methods and analysis of results in 271 patients. *J Vasc Surg.* 1992;16:378-389; discussion 389-390.
146. LeMaire SA, Jamison AL, Carter SA, et al. Deployment of balloon expandable stents during open repair of thoracoabdominal aortic aneurysms: a new strategy for managing renal and mesenteric artery lesions. *Eur J Cardiothorac Surg.* 2004;26:599-607.
147. Sullivan TM, Hertzner NR. Stenting of the renal artery to improve renal function prior to thoracoabdominal aneurysm repair. *J Endovasc Surg.* 1998;5:56-59.
148. Woodcock NP, Sudheer V, El-Barghouti N, et al. Bacterial translocation in patients undergoing abdominal aortic aneurysm repair. *Br J Surg.* 2000;87:439-442.
149. Hua HT, Cambria RP, Chuang SK, et al. Early outcomes of endovascular versus open abdominal aortic aneurysm repair in the National Surgical Quality Improvement Program-Private Sector (NSQIP-PS). *J Vasc Surg.* 2005;41:382-389.
150. Zierer A, Melby SJ, Lubahn JG, et al. Elective surgery for thoracic aortic aneurysms: late functional status and quality of life. *Ann Thorac Surg.* 2006;82:573-578.
151. Dick F, Hinder D, Immer FF, et al. Outcome and quality of life after surgical and endovascular treatment of descending aortic lesions. *Ann Thorac Surg.* 2008;85:1605-1612.
152. Rigberg DA, Zingmond DS, McGory ML, et al. Age stratified, perioperative, and one-year mortality after abdominal aortic aneurysm repair: a statewide experience. *J Vasc Surg.* 2006;43:224-229.
153. Crawford RS, Pedraza JD, Chung TK, et al. Functional outcome after thoracoabdominal aneurysm repair. *J Vasc Surg.* 2008;48:828-835.
154. Barbato JE, Kim JY, Zenati M, et al. Contemporary results of open repair of ruptured descending thoracic and thoracoabdominal aortic aneurysms. *J Vasc Surg.* 2007;45:667-676.
155. Heijmen RH, Deblier IG, Moll FL, et al. Endovascular stent-grafting for descending thoracic aortic aneurysms. *Eur J Cardiothorac Surg.* 2002;21:5-9.
156. Black SA, Wolfe JH, Clark M, et al. Complex thoracoabdominal aortic aneurysms: endovascular exclusion with visceral revascularization. *J Vasc Surg.* 2006;43:1081-1089; discussion 1089.
157. Makaroun MS, Dillavou ED, Wheatley GH, Cambria RP. Five-year results of endovascular treatment with the Gore TAG device compared with open repair of thoracic aortic aneurysms. *J Vasc Surg.* 2008;47:912-918.
158. Walsh SR, Tang TY, Sadat U, et al. Endovascular stenting versus open surgery for thoracic aortic disease: systematic review and meta-analysis of perioperative results. *J Vasc Surg.* 2008;47:1094-1098.
159. Svensson LG, Kouchoukos NT, Miller DC, et al. Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts. *Ann Thorac Surg.* 2008;85(1 Suppl):S1-S41.
160. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. *Lancet.* 2005;365:2187-2192.
161. Patel HJ, Shillingford MS, Williams DM, et al. Survival benefit of endovascular descending thoracic aortic repair for the high-risk patient. *Ann Thorac Surg.* 2007;83:1628-1633; discussion 1633-1634.

## 第 132 章

1. Crafoord C, Nylin G. Congenital coarctation of the aorta and its surgical treatment. *J Thorac Surg.* 1945;14:347-361.
2. Lam CR, Aram HH. Resection of the descending thoracic aorta for aneurysm; a report of the use of a homograft in a case and an experimental study. *Ann Surg.* 1951;134:743-752.
3. Etheredge SN, Yee J, Smith JV, et al. Successful resection of large aneurysm of the upper abdominal aorta and replacement

- with homograft. *Surgery*. 1955;38:1071-1081.
4. Shumacker HB Jr. Innovation in the operative management of the thoracoabdominal aortic aneurysm. *Surg Gynecol Obstet*. 1973;136:793-794.
  5. DeBakey ME, Cooley DA, Crawford ES, Morris GC Jr. Clinical application of a new flexible knitted Dacron arterial substitute. *Am Surg*. 1958;24:862-869.
  6. Crawford ES. Thoraco-abdominal and abdominal aortic aneurysms involving renal, superior mesenteric, celiac arteries. *Ann Surg*. 1974;179:763-772.
  7. Crawford ES, Crawford JL, Safi HJ, et al. Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. *J Vasc Surg*. 1986;3:389-404.
  8. Juvonen T, Ergin MA, Galla JD, et al. Prospective study of the natural history of thoracic aortic aneurysms. *Ann Thorac Surg*. 1997;63:1533-1545.
  9. Koomen E, Schurink GW, Mochtar B, et al. Repair of thoracic aortic aneurysm associated with tracheal and right mainstem bronchus compression. *J Cardiothorac Vasc Anesth*. 2007;21:88-90.
  10. Pattison CW, Dorricott NJ, Matthews HR. Oesophageal obstruction due to saccular aneurysm of the distal thoracic aorta. *Scand J Thorac Cardiovasc Surg*. 1984;18:279-282.
  11. Mehta VK, Lafaro RJ, De Vincenzo S. Successful management of an aneurysmal aortoesophageal fistula. *J Cardiovasc Surg (Torino)*. 2000;41:721-723.
  12. Kouchoukos NT, Dougenis D. Surgery of the thoracic aorta. *N Engl J Med*. 1997;336:1876-1888.
  13. Jacobs MJ, Mommertz G, Koeppel TA, et al. Surgical repair of thoracoabdominal aortic aneurysms. *J Cardiovasc Surg (Torino)*. 2007;48:49-58.
  14. Black JH 3rd, Cambria RP. Contemporary results of open surgical repair of descending thoracic aortic aneurysms. *Semin Vasc Surg*. 2006;19:11-17.
  15. Coady MA, Rizzo JA, Goldstein LJ, Elefteriades JA. Natural history, pathogenesis, and etiology of thoracic aortic aneurysms and dissections. *Cardiol Clin*. 1999;17:615-635; vii.
  16. Coady MA, Rizzo JA, Hammond GL, et al. What is the appropriate size criterion for resection of thoracic aortic aneurysms? *J Thorac Cardiovasc Surg*. 1997;113:476-491; discussion 489-491.
  17. Davies RR, Gallo A, Coady MA, et al. Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. *Ann Thorac Surg*. 2006;81:169-177.
  18. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. *Ann Thorac Surg*. 2002;73:17-27; discussion 27-28.
  19. Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. *Ann Thorac Surg*. 2002;74:S1877-S1880; discussion S1892-S1898.
  20. Griep RB, Ergin MA, Galla JD, et al. Natural history of descending thoracic and thoracoabdominal aneurysms. *Ann Thorac Surg*. 1999;67:1927-1930; discussion 1953-1958.
  21. Pitt MP, Bonser RS. The natural history of thoracic aortic aneurysm disease: an overview. *J Card Surg*. 1997;12:270-278.
  22. Dapunt OE, Galla JD, Sadeghi AM, et al. The natural history of thoracic aortic aneurysms. *J Thorac Cardiovasc Surg*. 1994;107:1323-1332; discussion 1332-1333.
  23. Juvonen T, Ergin MA, Galla JD, et al. Risk factors for rupture of chronic type B dissections. *J Thorac Cardiovasc Surg*. 1999;117:776-786.
  24. Perko MJ, Norgaard M, Herzog TM, et al. Unoperated aortic aneurysm: a survey of 170 patients. *Ann Thorac Surg*. 1995;59:1204-1209.
  25. Bonser RS, Pagano D, Lewis ME, et al. Clinical and patho-anatomical factors affecting expansion of thoracic aortic aneurysms. *Heart*. 2000;84:277-283.
  26. Cambria RA, Gloviczki P, Stanson AW, et al. Outcome and expansion rate of 57 thoracoabdominal aortic aneurysms

- managed nonoperatively. *Am J Surg*. 1995;170:213-217.
27. Masuda Y, Takanashi K, Takasu J, et al. Expansion rate of thoracic aortic aneurysms and influencing factors. *Chest*. 1992;102:461-466.
  28. Lobato AC, Puech-Leao P. Predictive factors for rupture of thoracoabdominal aortic aneurysm. *J Vasc Surg*. 1998;27:446-453.
  29. Hirose Y, Hamada S, Takamiya M, et al. Aortic aneurysms: growth rates measured with CT. *Radiology*. 1992;185:249-252.
  30. Cambria RP, Davison JK, Zannetti S, et al. Thoracoabdominal aneurysm repair: perspectives over a decade with the clamp-and-sew technique. *Ann Surg*. 1997;226:294-303; discussion 303-305.
  31. Coselli JS, Bozinovski J, LeMaire SA. Open surgical repair of 2286 thoracoabdominal aortic aneurysms. *Ann Thorac Surg*. 2007;83:S862-S864; discussion S890-S892.
  32. Finkbohner R, Johnston D, Crawford ES, et al. Marfan syndrome. Long-term survival and complications after aortic aneurysm repair. *Circulation*. 1995;91:728-733.
  33. Mommertz G, Sigala F, Langer S, et al. Thoracoabdominal aortic aneurysm repair in patients with Marfan syndrome. *Eur J Vasc Endovasc Surg*. 2008;35:181-186.
  34. Kalkat MS, Rahman I, Kotidis K, et al. Presentation and outcome of Marfan's syndrome patients with dissection and thoraco-abdominal aortic aneurysm. *Eur J Cardiothorac Surg*. 2007;32:250-254.
  35. Estrera AL, Miller CC 3rd, Chen EP, et al. Descending thoracic aortic aneurysm repair: 12-year experience using distal aortic perfusion and cerebrospinal fluid drainage. *Ann Thorac Surg*. 2005;80:1290-1296; discussion 1296.
  36. Huynh TT, Porat EE, Miller CC 3rd, et al. The effect of aortic dissection on outcome in descending thoracic and thoracoabdominal aortic aneurysm repair. *Semin Vasc Surg*. 2002;15:108-115.
  37. Sueyoshi E, Sakamoto I, Hayashi K, et al. Growth rate of aortic diameter in patients with type B aortic dissection during the chronic phase. *Circulation*. 2004;110:II256-II261.
  38. Hirose H, Svensson LG. Chronic posttraumatic aneurysm of descending aorta with fistulous communication into pulmonary artery. *J Vasc Surg*. 2004;40:564-566.
  39. Bickerstaff LK, Pairolero PC, Hollier LH, et al. Thoracic aortic aneurysms: a population-based study. *Surgery*. 1982;92:1103-1108.
  40. Chan FY, Crawford ES, Coselli JS, et al. In situ prosthetic graft replacement for mycotic aneurysm of the aorta. *Ann Thorac Surg*. 1989;47:193-203.
  41. Muller BT, Wegener OR, Grabitz K, et al. Mycotic aneurysms of the thoracic and abdominal aorta and iliac arteries: experience with anatomic and extra-anatomic repair in 33 cases. *J Vasc Surg*. 2001;33:106-113.
  42. Ucer E, Oner AO, Erdinler IC. Uncommon presentation of Behçet's syndrome: aortic aneurysm and dissection due to Behçet's syndrome. *Acta Cardiol*. 2006;61:356-358.
  43. Umehara N, Saito S, Ishii H, et al. Rupture of thoracoabdominal aortic aneurysm associated with Behçet's disease. *Ann Thorac Surg*. 2007;84:1394-1396.
  44. Seo JW, Park IA, Yoon DH, et al. Thoracic aortic aneurysm associated with aortitis—case reports and histological review. *J Korean Med Sci*. 1991;6:75-82.
  45. Kieffer E, Chiche L, Bertal A, et al. Descending thoracic and thoracoabdominal aortic aneurysm in patients with Takayasu's disease. *Ann Vasc Surg*. 2004;18:505-513.
  46. Stanson AW, Kazmier FJ, Hollier LH, et al. Penetrating atherosclerotic ulcers of the thoracic aorta: natural history and clinicopathologic correlations. *Ann Vasc Surg*. 1986;1:15-23.
  47. Tittle SL, Lynch RJ, Cole PE, et al. Midterm follow-up of penetrating ulcer and intramural hematoma of the aorta. *J Thorac Cardiovasc Surg*. 2002;123:1051-1059.
  48. Cho KR, Stanson AW, Potter DD, et al. Penetrating atherosclerotic ulcer of the descending thoracic aorta and arch. *J Thorac Cardiovasc Surg*. 2004;127:1393-1399; discussion 1399-1401.

49. Kieffer E, Leschi JP, Chiche L. Open repair of chronic post-traumatic aneurysms of the aortic isthmus: the value of direct aorto-aortic anastomosis. *J Vasc Surg.* 2005;41:931-935; discussion 935.
50. Langer S, Mommertz G, Koeppel TA, et al. Surgical correction of failed thoracic endovascular aortic repair. *J Vasc Surg.* 2008;47:1195-1202.
51. Crawford ES, Coselli JS. Thoracoabdominal aneurysm surgery. *Semin Thorac Cardiovasc Surg.* 1991;3:300-322.
52. Girardi LN, Krieger KH, Mack CA, et al. Does cross-clamping the arch increase the risk of descending thoracic and thoracoabdominal aneurysm repair? *Ann Thorac Surg.* 2005;79:133-137; discussion 137-138.
53. Kay GL, Cooley DA, Livesay JJ, et al. Surgical repair of aneurysms involving the distal aortic arch. *J Thorac Cardiovasc Surg.* 1986;91:397-404.
54. Coselli JS, Bozinovski J, Cheung C. Hypothermic circulatory arrest: safety and efficacy in the operative treatment of descending and thoracoabdominal aortic aneurysms. *Ann Thorac Surg.* 2008;85:956-963; discussion 964.
55. Safi HJ, Miller CC 3rd, Subramaniam MH, et al. Thoracic and thoracoabdominal aortic aneurysm repair using cardiopulmonary bypass, profound hypothermia, and circulatory arrest via left side of the chest incision. *J Vasc Surg.* 1998;28:591-598.
56. Svensson LG, Crawford ES. Aortic dissection and aortic aneurysm surgery: clinical observations, experimental investigations, and statistical analyses. Part II. *Curr Probl Surg.* 1992;29:913-1057.
57. Sundt TM. Intramural hematoma and penetrating atherosclerotic ulcer of the aorta. *Ann Thorac Surg.* 2007;83:S835-S841; discussion S846-S850.
58. Takasu J, Masuda Y, Watanabe S, et al. Progression and regression of atherosclerotic findings in the descending thoracic aorta detected by enhanced computed tomography. *Atherosclerosis.* 1994;110:175-184.
59. Katzberg RW, Haller C. Contrast-induced nephrotoxicity: clinical landscape. *Kidney Int Suppl.* 2006; S3-S7.
60. Roberts DA. Magnetic resonance imaging of thoracic aortic aneurysm and dissection. *Semin Roentgenol.* 2001;36:295-308.
61. Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. *N Engl J Med.* 2007;357:2277-2284.
62. Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. *AJR Am J Roentgenol.* 2008;190:1060-1068.
63. Thron A. Anatomy of the spinal cord blood supply. In: Thron A, ed. *Vascular Anatomy of the Spinal Cord.* New York, NY: Springer-Verlag; 1988:8-12.
64. Lasjaunias P, Bernstein A. Spinal and spinal cord arteries and veins. In: Lasjaunias P, Bernstein A, eds. *Surgical Neuroangiography.* New York, NY: Springer-Verlag; 1990:15-87.
65. Nijenhuis RJ, Jacobs MJ, Schurink GW, et al. Magnetic resonance angiography and neuromonitoring to assess spinal cord blood supply in thoracic and thoracoabdominal aortic aneurysm surgery. *J Vasc Surg.* 2007;45:71-77; discussion 77-78.
66. Kieffer E, Fukui S, Chiras J, et al. Spinal cord arteriography: a safe adjunct before descending thoracic or thoracoabdominal aortic aneurysmectomy. *J Vasc Surg.* 2002;35:262-268.
67. Nijenhuis RJ, Jacobs MJ, Jaspers K, et al. Comparison of magnetic resonance with computed tomography angiography for preoperative localization of the Adamkiewicz artery in thoracoabdominal aortic aneurysm patients. *J Vasc Surg.* 2007;45:677-685.
68. Yamada N, Takamiya M, Kuribayashi S, et al. MRA of the Adamkiewicz artery: a preoperative study for thoracic aortic aneurysm. *J Comput Assist Tomogr.* 2000;24:362-368.
69. Yoshioka K, Niinuma H, Ohira A, et al. MR angiography and CT angiography of the artery of Adamkiewicz: noninvasive preoperative assessment of thoracoabdominal aortic aneurysm. *Radiographics.* 2003;23:1215-1225.
70. Jacobs MJ, de Mol BA, Elenbaas T, et al. Spinal cord blood supply in patients with thoracoabdominal aortic aneurysms. *J Vasc Surg.* 2002;35:30-37.
71. Backes WH, Nijenhuis RJ, Mess WH, et al. Magnetic resonance angiography of collateral blood supply to spinal cord in

- thoracic and thoracoabdominal aortic aneurysm patients. *J Vasc Surg.* 2008;48:261-271.
72. Cambria RP, Clouse WD, Davison JK, et al. Thoracoabdominal aneurysm repair: results with 337 operations performed over a 15-year interval. *Ann Surg.* 2002;236:471-479; discussion 479.
  73. Svensson LG, Crawford ES, Hess KR, et al. Experience with 1509 patients undergoing thoracoabdominal aortic operations. *J Vasc Surg.* 1993;17:357-368; discussion 368-370.
  74. Brooks MJ, Mayet J, Glenville B, et al. Cardiac investigation and intervention prior to thoraco-abdominal aneurysm repair: coronary angiography in 35 patients. *Eur J Vasc Endovasc Surg.* 2001;21:437-444.
  75. Suzuki S, Davis CA 3rd, Miller CC 3rd, et al. Cardiac function predicts mortality following thoracoabdominal and descending thoracic aortic aneurysm repair. *Eur J Cardiothorac Surg.* 2003;24:119-124; discussion 124.
  76. Coselli JS, LeMaire SA, Conklin LD, et al. Morbidity and mortality after extent II thoracoabdominal aortic aneurysm repair. *Ann Thorac Surg.* 2002;73:1107-1115; discussion 1115-1116.
  77. Jacobs MJ, de Mol BA, Legemate DA, et al. Retrograde aortic and selective organ perfusion during thoracoabdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg.* 1997;14:360-366.
  78. Miller DC, Myers BD. Pathophysiology and prevention of acute renal failure associated with thoracoabdominal or abdominal aortic surgery. *J Vasc Surg.* 1987;5:518-523.
  79. Coselli JS, LeMaire SA, Miller CC 3rd, et al. Mortality and paraplegia after thoracoabdominal aortic aneurysm repair: a risk factor analysis. *Ann Thorac Surg.* 2000;69:409-414.
  80. LeMaire SA, Miller CC 3rd, Conklin LD, et al. A new predictive model for adverse outcomes after elective thoracoabdominal aortic aneurysm repair. *Ann Thorac Surg.* 2001;71:1233-1238.
  81. Jacobs MJ, Eijssman L, Meylaerts SA, et al. Reduced renal failure following thoracoabdominal aortic aneurysm repair by selective perfusion. *Eur J Cardiothorac Surg.* 1998;14:201-205.
  82. Safi HJ, Harlin SA, Miller CC, et al. Predictive factors for acute renal failure in thoracic and thoracoabdominal aortic aneurysm surgery. *J Vasc Surg.* 1996;24:338-344; discussion 344-345.
  83. Kieffer E, Koskas F, Walden R, et al. Hypothermic circulatory arrest for thoracic aneurysmectomy through left-sided thoracotomy. *J Vasc Surg.* 1994;19:457-464.
  84. Kouchoukos NT, Masetti P, Rokkas CK, Murphy SF. Hypothermic cardiopulmonary bypass and circulatory arrest for operations on the descending thoracic and thoracoabdominal aorta. *Ann Thorac Surg.* 2002;74:S1885-S1887; discussion S1892-S1898.
  85. Verdant A, Cossette R, Page A, et al. Aneurysms of the descending thoracic aorta: three hundred sixty-six consecutive cases resected without paraplegia. *J Vasc Surg.* 1995;21:385-390; discussion 390-391.
  86. Comerota AJ, White JV. Reducing morbidity of thoracoabdominal aneurysm repair by preliminary axillofemoral bypass. *Am J Surg.* 1995;170:218-222.
  87. Cambria RP, Davison JK, Giglia JS, Gertler JP. Mesenteric shunting decreases visceral ischemia during thoracoabdominal aneurysm repair. *J Vasc Surg.* 1998;27:745-749.
  88. Conrad MF, Crawford RS, Davison JK, Cambria RP. Thoracoabdominal aneurysm repair: a 20-year perspective. *Ann Thorac Surg.* 2007;83:S856-S861; discussion S890-S892.
  89. Estrera AL, Miller CC 3rd, Huynh TT, et al. Neurologic outcome after thoracic and thoracoabdominal aortic aneurysm repair. *Ann Thorac Surg.* 2001;72:1225-1230; discussion 1230-1231.
  90. Jacobs MJ, Meylaerts SA, de Haan P, et al. Strategies to prevent neurologic deficit based on motor-evoked potentials in type I and II thoracoabdominal aortic aneurysm repair. *J Vasc Surg.* 1999;29:48-57; discussion 57-59.
  91. Cambria RP, Giglia JS. Prevention of spinal cord ischaemic complications after thoracoabdominal aortic surgery. *Eur J Vasc Endovasc Surg.* 1998;15:96-109.
  92. Laschinger JC, Owen J, Rosenbloom M, et al. Direct noninvasive monitoring of spinal cord motor function during thoracic aortic occlusion: use of motor evoked potentials. *J Vasc Surg.* 1988;7:161-171.

93. Robertazzi RR, Cunningham JN Jr. Monitoring of somatosensory evoked potentials: a primer on the intraoperative detection of spinal cord ischemia during aortic reconstructive surgery. *Semin Thorac Cardiovasc Surg.* 1998;10:11-17.
94. Meylaerts SA, Jacobs MJ, van Iterson V, et al. Comparison of transcranial motor evoked potentials and somatosensory evoked potentials during thoracoabdominal aortic aneurysm repair. *Ann Surg.* 1999;230:742-749.
95. Dong CC, MacDonald DB, Janusz MT. Intraoperative spinal cord monitoring during descending thoracic and thoracoabdominal aneurysm surgery. *Ann Thorac Surg.* 2002;74:S1873-S1876; discussion S1892-S1898.
96. Galla JD, Ergin MA, Lansman SL, et al. Use of somatosensory evoked potentials for thoracic and thoracoabdominal aortic resections. *Ann Thorac Surg.* 1999;67:1947-1952; discussion 1953-1958.
97. Stinson LW Jr, Murray MJ, Jones KA, et al. A computer-controlled, closed-loop infusion system for infusing muscle relaxants: its use during motor-evoked potential monitoring. *J Cardiothorac Vasc Anesth.* 1994;8:40-44.
98. Jacobs MJ, Mess W, Mochtar B, et al. The value of motor evoked potentials in reducing paraplegia during thoracoabdominal aneurysm repair. *J Vasc Surg.* 2006;43:239-246.
99. Etz CD, Halstead JC, Spielvogel D, et al. Thoracic and thoracoabdominal aneurysm repair: is reimplantation of spinal cord arteries a waste of time? *Ann Thorac Surg.* 2006;82:1670-1677.
100. Safi HJ, Estrera AL, Azizzadeh A, et al. Progress and future challenges in thoracoabdominal aortic aneurysm management. *World J Surg.* 2008;32:355-360.
101. Coselli JS. The use of left heart bypass in the repair of thoracoabdominal aortic aneurysms: current techniques and results. *Semin Thorac Cardiovasc Surg.* 2003;15:326-332.
102. Rokkas CK, Kouchoukos NT. Profound hypothermia for spinal cord protection in operations on the descending thoracic and thoracoabdominal aorta. *Semin Thorac Cardiovasc Surg.* 1998;10:57-60.
103. Cambria RP, Davison JK, Carter C, et al. Epidural cooling for spinal cord protection during thoracoabdominal aneurysm repair: A five-year experience. *J Vasc Surg.* 2000;31:1093-1102.
104. Kouchoukos NT, Rokkas CK. Hypothermic cardiopulmonary bypass for spinal cord protection: rationale and clinical results. *Ann Thorac Surg.* 1999;67:1940-1942; discussion 1953-1958.
105. Svensson LG, Hess KR, D'Agostino RS, et al. Reduction of neurologic injury after high-risk thoracoabdominal aortic operation. *Ann Thorac Surg.* 1998;66:132-138.
106. Killen DA, Edwards RH, Tinsley EA, Boehm FH. Effect of low molecular weight dextran, heparin, urea, cerebrospinal fluid drainage, and hypothermia on ischemic injury of the spinal cord secondary to mobilization of the thoracic aorta from the posterior parietes. *J Thorac Cardiovasc Surg.* 1965;50:882-887.
107. McCullough JL, Hollier LH, Nugent M. Paraplegia after thoracic aortic occlusion: influence of cerebrospinal fluid drainage. Experimental and early clinical results. *J Vasc Surg.* 1988;7:153-160.
108. Saether OD, Juul R, Aadahl P, et al. Cerebral haemodynamics during thoracic- and thoracoabdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg.* 1996;12:81-85.
109. Coselli JS, Lemaire SA, K  soy C, et al. Cerebrospinal fluid drainage reduces paraplegia after thoracoabdominal aortic aneurysm repair: results of a randomized clinical trial. *J Vasc Surg.* 2002;35:631-639.
110. Acher CW, Wynn MM, Mell MW, et al. A quantitative assessment of the impact of intercostal artery reimplantation on paralysis risk in thoracoabdominal aortic aneurysm repair. *Ann Surg.* 2008;248:529-540.
111. Cheung AT, Weiss SJ, McGarvey ML, et al. Interventions for reversing delayed-onset postoperative paraplegia after thoracic aortic reconstruction. *Ann Thorac Surg.* 2002;74:413-419; discussion 420-421.
112. Reiher L, Vosberg H, Sandmann W. Kidney protection in preventing post-ischaemic renal failure during thoracoabdominal aortic aneurysm repair: does prostaglandin E<sub>1</sub> together with cooling provide more protection than cooling alone? *Vasa.* 2001;30:21-23.
113. K  soy C, LeMaire SA, Curling PE, et al. Renal perfusion during thoracoabdominal aortic operations: cold crystalloid is superior to normothermic blood. *Ann Thorac Surg.* 2002;73:730-738.

114. Coselli JS, Jones MM, Carter SA, et al. Cold blood and cold crystalloid renal perfusion afford similar protection against acute renal injury during thoracoabdominal aortic aneurysm repair: results of a randomized trial. Vascular Annual Meeting, SVS, San Diego, CA, 2008.
115. Hassoun HT, Miller CC 3rd, Huynh TT, et al. Cold visceral perfusion improves early survival in patients with acute renal failure after thoracoabdominal aortic aneurysm repair. *J Vasc Surg.* 2004;39:506-512.
116. Morishita K, Yokoyama H, Inoue S, et al. Selective visceral and renal perfusion in thoracoabdominal aneurysm repair. *Eur J Cardiothorac Surg.* 1999;15:502-507.
117. Griep RB, Griep EB. Spinal cord perfusion and protection during descending thoracic and thoracoabdominal aortic surgery: the collateral network concept. *Ann Thorac Surg.* 2007;83:S865-S869; discussion S890-S892.
118. Safi HJ, Miller CC 3rd. Spinal cord protection in descending thoracic and thoracoabdominal aortic repair. *Ann Thorac Surg.* 1999;67:1937-1939; discussion 1953-1958.
119. DeBakey ME, Beall AC Jr, Cooley DA, et al. Dissecting aneurysms of the aorta. *Surg Clin North Am.* 1966;46:1045-1055.
120. Williams GM, Roseborough GS, Webb TH, et al. Preoperative selective intercostal angiography in patients undergoing thoracoabdominal aneurysm repair. *J Vasc Surg.* 2004;39:314-321.
121. Azizzadeh A, Estrera AL, Porat EE, et al. The hybrid elephant trunk procedure: a single-stage repair of an ascending, arch, and descending thoracic aortic aneurysm. *J Vasc Surg.* 2006;44:404-407.
122. Baraki H, Hagl C, Khaladj N, et al. The frozen elephant trunk technique for treatment of thoracic aortic aneurysms. *Ann Thorac Surg.* 2007;83:S819-S823; discussion S824-S831.
123. Bozinovski J, Coselli JS. Outcomes and survival in surgical treatment of descending thoracic aorta with acute dissection. *Ann Thorac Surg.* 2008;85:965-970; discussion 970-971.
124. Coselli JS, LeMaire SA, Conklin LD, Adams GJ. Left heart bypass during descending thoracic aortic aneurysm repair does not reduce the incidence of paraplegia. *Ann Thorac Surg.* 2004;77:1298-1303; discussion 1303.
125. Patel HJ, Shillingford MS, Mihalik S, et al. Resection of the descending thoracic aorta: outcomes after use of hypothermic circulatory arrest. *Ann Thorac Surg.* 2006;82:90-95; discussion 95-96.
126. Svensson LG, Kouchoukos NT, Miller DC, et al. Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts. *Ann Thorac Surg.* 2008;85:S1-S41.
127. Schermerhorn ML, Giles KA, Hamdan AD, et al. Population-based outcomes of open descending thoracic aortic aneurysm repair. *J Vasc Surg.* 2008;48:821-827.
128. Bavaria JE, Appoo JJ, Makaroun MS, et al. Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: a multicenter comparative trial. *J Thorac Cardiovasc Surg.* 2007;133:369-377.
129. Fairman RM, Criado F, Farber M, et al. Pivotal results of the Medtronic Vascular Talent Thoracic Stent Graft System: the VALOR trial. *J Vasc Surg.* 2008;48:546-554.
130. Matsumura JS, Cambria RP, Dake MD, et al. International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft: 1-year results. *J Vasc Surg.* 2008;47:247-257; discussion 257.
131. Rigberg DA, McGory ML, Zingmond DS, et al. Thirty-day mortality statistics underestimate the risk of repair of thoracoabdominal aortic aneurysms: a statewide experience. *J Vasc Surg.* 2006;43:217-222; discussion 223.
132. Rectenwald JE, Huber TS, Martin TD, et al. Functional outcome after thoracoabdominal aortic aneurysm repair. *J Vasc Surg.* 2002;35:640-647.
133. Coselli JS, Conklin LD, LeMaire SA. Thoracoabdominal aortic aneurysm repair: review and update of current strategies. *Ann Thorac Surg.* 2002;74:S1881-S1884; discussion S1892-S1898.
134. Kouchoukos NT, Masetti P, Murphy SF. Hypothermic cardiopulmonary bypass and circulatory arrest in the management of extensive thoracic and thoracoabdominal aortic aneurysms. *Semin Thorac Cardiovasc Surg.* 2003;15:333-339.
135. Cowan JA Jr, Dimick JB, Henke PK, et al. Surgical treatment of intact thoracoabdominal aortic aneurysms in the United States: hospital and surgeon volume-related outcomes. *J Vasc Surg.* 2003;37:1169-1174.

136. Clouse WD, Marone LK, Davison JK, et al. Late aortic and graft-related events after thoracoabdominal aneurysm repair. *J Vasc Surg.* 2003;37:254-261.
137. LeMaire SA, Carter SA, Volguina IV, et al. Spectrum of aortic operations in 300 patients with confirmed or suspected Marfan syndrome. *Ann Thorac Surg.* 2006;81:2063-2078; discussion 2078.
138. Dardik A, Krosnick T, Perler BA, et al. Durability of thoracoabdominal aortic aneurysm repair in patients with connective tissue disorders. *J Vasc Surg.* 2002;36:696-703.
139. Svensson LG, Hess KR, Coselli JS, et al. A prospective study of respiratory failure after high-risk surgery on the thoracoabdominal aorta. *J Vasc Surg.* 1991;14:271-282.
140. Fransen E, Maessen J, Dentener M, et al. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. *Chest.* 1999;116:1233-1239.
141. Kashyap VS, Cambria RP, Davison JK, L'Italien GJ. Renal failure after thoracoabdominal aortic surgery. *J Vasc Surg.* 1997;26:949-955; discussion 955-957.
142. Achouh PE, Madsen K, Miller CC 3rd, et al. Gastrointestinal complications after descending thoracic and thoracoabdominal aortic repairs: a 14-year experience. *J Vasc Surg.* 2006;44:442-446.
143. Etz CD, Luehr M, Kari FA, et al. Paraplegia after extensive thoracic and thoracoabdominal aortic aneurysm repair: does critical spinal cord ischemia occur postoperatively? *J Thorac Cardiovasc Surg.* 2008;135:324-330.
144. Wong DR, Coselli JS, Amerman K, et al. Delayed spinal cord deficits after thoracoabdominal aortic aneurysm repair. *Ann Thorac Surg.* 2007;83:1345-1355; discussion 1355.
145. Azizzadeh A, Huynh TT, Miller CC 3rd, et al. Postoperative risk factors for delayed neurologic deficit after thoracic and thoracoabdominal aortic aneurysm repair: a case-control study. *J Vasc Surg.* 2003;37:750-754.
146. Dardik A, Perler BA, Roseborough GS, Williams GM. Subdural hematoma after thoracoabdominal aortic aneurysm repair: an underreported complication of spinal fluid drainage? *J Vasc Surg.* 2002;36:47-50.
147. Weaver KD, Wiseman DB, Farber M, et al. Complications of lumbar drainage after thoracoabdominal aortic aneurysm repair. *J Vasc Surg.* 2001;34:623-627.
148. Piciche M, De Paulis R, Fabbri A, Chiariello L. Postoperative aortic fistulas into the airways: etiology, pathogenesis, presentation, diagnosis, and management. *Ann Thorac Surg.* 2003;75:1998-2006.
149. Favre JP, Gournier JP, Adham M, et al. Aortobronchial fistula: report of three cases and review of the literature. *Surgery.* 1994;115:264-270.
150. Svensson LG, Crawford ES, Hess KR, et al. Variables predictive of outcome in 832 patients undergoing repairs of the descending thoracic aorta. *Chest.* 1993;104:1248-1253.
151. Miller CC 3rd, Porat EE, Estrera AL, et al. Number needed to treat: analyzing of the effectiveness of thoracoabdominal aortic repair. *Eur J Vasc Endovasc Surg.* 2004;28:154-157.

## 第 133 章

1. Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. *Ann Vasc Surg.* 1991;5:491-499.
2. Dake MD, Miller DC, Semba CP, et al. Transluminal placement of endovascular stent-grafts for the treatment of descending thoracic aortic aneurysms. *N Engl J Med.* 1994;331:1729-1734.
3. Inoue K, Iwase T, Sato M, et al. Transluminal endovascular branched graft placement for a pseudoaneurysm: reconstruction of the descending thoracic aorta including the celiac axis. *J Thorac Cardiovasc Surg.* 1997;114:859-861.
4. Anderson JL, Berce M, Hartley DE. Endoluminal aortic grafting with renal and superior mesenteric artery incorporation by graft fenestration. *J Endovasc Ther.* 2001;8:3-15.
5. Stanley BM, Semmens JB, Lawrence-Brown MM, et al. Fenestration in endovascular grafts for aortic aneurysm repair: new horizons for preserving blood flow in branch vessels. *J Endovasc Ther.* 2001;8:16-24.



6. Chuter TAM, Gordon RL, Reilly LM, et al. An endovascular system for thoracoabdominal aortic aneurysm repair. *J Endovasc Ther.* 2001;8:25-33.
7. Chuter TAM, Gordon RL, Reilly LM, et al. Multi-branched stent-graft for type III thoracoabdominal aortic aneurysm. *J Vasc Interv Radiol.* 2001;12:391-392.
8. Brooks M, Loftus I, Morgan R, Thompson M. The Valiant thoracic endograft. *J Cardiovasc Surg (Torino).* 2006;47:269-278.
9. Makaroun MS, Dillavou ED, Wheatley GH, Cambria RA. Five-year results of endovascular treatment with the Gore TAG device compared to open repair of thoracic aortic aneurysms. *J Vasc Surg.* 2008;47:912-918.
10. Svensson LG, Kouchoukos NT, Miller DC, et al. Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts. *Ann Thorac Surg.* 2008;85:S1-S41.
11. Criado FJ, bul-Khoudoud OR, Domer GS, et al. Endovascular repair of the thoracic aorta: lessons learned. *Ann Thorac Surg.* 2005;80:857-863.
12. Mitchell RS, Ishimaru S, Ehrlich MP, et al. First International Summit on Thoracic Aortic Endografting: roundtable on thoracic aortic dissection as an indication for endografting. *J Endovasc Ther.* 2002;9(Suppl 2):II98-II105.
13. Dillavou ED, Buck DG, Muluk SC, Makaroun MS. Two-dimensional versus three-dimensional CT scan for aortic measurement. *J Endovasc Ther.* 2003;10:531-538.
14. Feezor RJ, Martin TD, Hess PJ, et al. Risk factors for perioperative stroke during thoracic endovascular aortic repairs (TEVAR). *J Endovasc Ther.* 2007;14:568-573.
15. Cho JS, Haider S, Makaroun MS. US multi-center trials of endoprostheses for the endovascular treatment of descending thoracic aneurysms. *J Vasc Surg.* 2006;43(Suppl A):12A-19A.
16. Sunder-Plassmann L, Scharrer-Pamler R, Liewald F, et al. Endovascular exclusion of thoracic aortic aneurysms: mid-term results of elective treatment and in contained rupture. *J Card Surg.* 2003;18:367-374.
17. Rehders TC, Petzsch M, Ince H, et al. Intentional occlusion of the left subclavian artery during stent-graft implantation in the thoracic aorta: risk and relevance. *J Endovasc Ther.* 2004;11:659-666.
18. Caronno R, Piffaretti G, Tozzi M, et al. Intentional coverage of the left subclavian artery during endovascular stent graft repair for thoracic aortic disease. *Surg Endosc.* 2006;20:915-918.
19. Thompson M, Ivaz S, Cheshire N, et al. Early results of endovascular treatment of the thoracic aorta using the Valiant endograft. *Cardiovasc Intervent Radiol.* 2007;30:1130-1138.
20. Burks JA Jr, Faries PL, Gravereaux EC, et al. Endovascular repair of thoracic aortic aneurysms: stent-graft fixation across the aortic arch vessels. *Ann Vasc Surg.* 2002;16:24-28.
21. Peterson BG, Eskandari MK, Gleason TG, Morasch MD. Utility of left subclavian artery revascularization in association with endoluminal repair of acute and chronic thoracic aortic pathology. *J Vasc Surg.* 2006;43:433-439.
22. Buth J, Harris PL, Hobo R, et al. Neurologic complications associated with endovascular repair of thoracic aortic pathology: Incidence and risk factors. a study from the European Collaborators on Stent/Graft Techniques for Aortic Aneurysm Repair (EUROSTAR) registry. *J Vasc Surg.* 2007;46:1103-1110.
23. Biglioli P, Roberto M, Cannata A, et al. Upper and lower spinal cord blood supply: the continuity of the anterior spinal artery and the relevance of the lumbar arteries. *J Thorac Cardiovasc Surg.* 2004;127:1188-1192.
24. Giglia JS, Zelenock GB, D'Alecy L. Prevention of paraplegia during thoracic aortic cross-clamping: importance of patent internal mammary arteries. *J Vasc Surg.* 1994;19:1044-1051.
25. Criado FJ. A percutaneous technique for preservation of arch branch patency during thoracic endovascular aortic repair (TEVAR): retrograde catheterization and stenting. *J Endovasc Ther.* 2007;14:54-58.
26. Riesenman PJ, Farber MA, Mendes RR, et al. Coverage of the left subclavian artery during thoracic endovascular aortic repair. *J Vasc Surg.* 2007;45:90-94.
27. Kurimoto Y, Ito T, Harada R, et al. Management of left subclavian artery in endovascular stent-grafting for distal aortic

arch disease. *Circ J*. 2008;72:449-453.

28. Manninen H, Tulla H, Vanninen R, Ronkainen A. Endangered cerebral blood supply after closure of left subclavian artery: postmortem and clinical imaging studies. *Ann Thorac Surg*. 2008;85:120-125.
29. Makaroun MS, Dillavou ED, Kee ST, et al. Endovascular treatment of thoracic aortic aneurysms: results of the phase II multicenter trial of the GORE TAG thoracic endoprosthesis. *J Vasc Surg*. 2005;41:1-9.
30. Cina CS, Safar HA, Lagana A, et al. Subclavian carotid transposition and bypass grafting: consecutive cohort study and systematic review. *J Vasc Surg*. 2002;35:422-429.
31. Reece TB, Gazoni LM, Cherry KJ, et al. Reevaluating the need for left subclavian artery revascularization with thoracic endovascular aortic repair. *Ann Thorac Surg*. 2007;84:1201-1205.
32. Sunder-Plassmann L, Orend KH. Stent-grafting of the thoracic aorta—complications. *J Cardiovasc Surg (Torino)*. 2005;46:121-130.
33. Vaddineni SK, Taylor SM, Patterson MA, Jordan WD, Jr. Outcome after celiac artery coverage during endovascular thoracic aortic aneurysm repair: preliminary results. *J Vasc Surg*. 2007;45:467-471.
34. Darling RC, III, Mehta M, Roddy SP, et al. Coverage of celiac artery during thoracic endovascular aneurysm repair: outcomes of a prospective analysis. Paper presented at the Society for Vascular Surgery Annual Meeting, June 5, 2008, San Diego, CA.
35. Weaver KD, Wiseman DB, Farber M, et al. Complications of lumbar drainage after thoracoabdominal aortic aneurysm repair. *J Vasc Surg*. 2001;34:623-627.
36. Chiesa R, Melissano G, Marrocco-Trischitta MM, et al. Spinal cord ischemia after elective stent-graft repair of the thoracic aorta. *J Vasc Surg*. 2005;42:11-17.
37. Acher CW. Multifactorial nature of spinal cord circulation. *Semin Thorac Cardiovasc Surg*. 1998;10:7-10.
38. Acher CW, Wynn MM, Hoch JR, et al. Combined use of cerebral spinal fluid drainage and naloxone reduces the risk of paraplegia in thoracoabdominal aneurysm repair. *J Vasc Surg*. 1994;19:236-246.
39. Lee WA, Brown MP, Nelson PR, et al. Midterm outcomes of femoral arteries after percutaneous endovascular aortic repair using the Perclose technique. *J Vasc Surg*. 2008;47:919-923.
40. Kasirajan K. Thoracic endografts: procedural steps, technical pitfalls and how to avoid them. *Semin Vasc Surg*. 2006;19:3-10.
41. Stone DH, Brewster DC, Kwolek CJ, et al. Stent-graft versus open-surgical repair of the thoracic aorta: mid-term results. *J Vasc Surg*. 2006;44:1188-1197.
42. Criado FJ, Clark NS, Barnatan MF. Stent graft repair in the aortic arch and descending thoracic aorta: a 4-year experience. *J Vasc Surg*. 2002;36:1121-1128.
43. Demers P, Miller DC, Mitchell RS, et al. Midterm results of endovascular repair of descending thoracic aortic aneurysms with first-generation stent grafts. *J Thorac Cardiovasc Surg*. 2004;127:664-673.
44. Ricco JB, Cau J, Marchand C, et al. Stent-graft repair for thoracic aortic disease: results of an independent nationwide study in France from 1999 to 2001. *J Thorac Cardiovasc Surg*. 2006;131:131-137.
45. Riesenman PJ, Farber MA, Mendes RR, et al. Endovascular repair of lesions involving the descending thoracic aorta. *J Vasc Surg*. 2005;42:1063-1074.
46. Leurs LJ, Bell R, Degrieck Y, et al. Endovascular treatment of thoracic aortic diseases: combined experience from the EUROSTAR and United Kingdom Thoracic Endograft registries. *J Vasc Surg*. 2004;40:670-679.
47. Cho JS, Haider S, Makaroun MS. Endovascular therapy of thoracic aneurysms: Gore TAG trial results. *Semin Vasc Surg*. 2006;19:18-24.
48. Matsumura JS, Cambria RP, Dake MD, et al. International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft: 1-year results. *J Vasc Surg*. 2008;47:247-257.
49. Fairman RM, Farber M, Kwolek CJ, et al. Pivotal results of the Medtronic Vascular Talent Thoracic Stent Graft System for

- patients with thoracic aortic disease: the VALOR trial. *J Vasc Surg.* 2008;48:546-554.
50. Bavaria JE, Appoo JJ, Makaroun MS, et al. Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: a multicenter comparative trial. *J Thorac Cardiovasc Surg.* 2007;133:369-377.
  51. Chaikof EL, Blankensteijn JD, Harris PL, et al. Reporting standards for endovascular aortic aneurysm repair. *J Vasc Surg.* 2002;35:1048-1060.
  52. Greenberg RK, Resch T, Nyman U, et al. Endovascular repair of descending thoracic aortic aneurysms: an early experience with intermediate-term follow-up. *J Vasc Surg.* 2000;31:147-156.
  53. Matsumura JS, Cambria RP, Dake MD, et al. Early results of an international controlled trial of TEVAR. Paper presented at the Annual Meeting of the Society for Vascular Surgery, Baltimore, MD, June 8, 2007.
  54. Walsh SR, Tang TY, Sadat U, et al. Endovascular stenting versus open surgery for thoracic aortic disease: systematic review and meta-analysis of perioperative results. *J Vasc Surg.* 2008;47:1094-1098.
  55. Glade GJ, Vahl AC, Wisselink W, et al. Mid-term survival and costs of treatment of patients with descending thoracic aortic aneurysms; endovascular vs. open repair: a case-control study. *Eur J Vasc Endovasc Surg.* 2005;29:28-34.
  56. Bell RE, Taylor PR, Aukett M, et al. Mid-term results for second-generation thoracic stent grafts. *Br J Surg.* 2003;90:811-817.
  57. Fattori R, Nienaber CA, Rousseau H, et al. Results of endovascular repair of the thoracic aorta with the Talent Thoracic stent graft: the Talent Thoracic Retrospective Registry. *J Thorac Cardiovasc Surg.* 2006;132:332-339.
  58. Czerny M, Cejna M, Hutschala D, et al. Stent-graft placement in atherosclerotic descending thoracic aortic aneurysms: midterm results. *J Endovasc Ther.* 2004;11:26-32.
  59. Neuhauser B, Perkmann R, Greiner A, et al. Mid-term results after endovascular repair of the atherosclerotic descending thoracic aortic aneurysm. *Eur J Vasc Endovasc Surg.* 2004;28:146-153.
  60. Appoo JJ, Moser WG, Fairman RM, et al. Thoracic aortic stent grafting: improving results with newer generation investigational devices. *J Thorac Cardiovasc Surg.* 2006;131:1087-1094.
  61. Estrera AL, Miller CC, III, Chen EP, et al. Descending thoracic aortic aneurysm repair: 12-year experience using distal aortic perfusion and cerebrospinal fluid drainage. *Ann Thorac Surg.* 2005;80:1290-1296.
  62. Coselli JS, LeMaire SA, Conklin LD, Adams GJ. Left heart bypass during descending thoracic aortic aneurysm repair does not reduce the incidence of paraplegia. *Ann Thorac Surg.* 2004;77:1298-1303.
  63. Kieffer E, Chiche L, Cormier E, Guegan H. Recurrent spinal cord ischemia after endovascular stent grafting for chronic traumatic aneurysm of the aortic isthmus. *J Vasc Surg.* 2007;45:831-833.
  64. Cho JS, Rhee RY, Makaroun MS. Delayed paraplegia 10 months after endovascular repair of thoracic aortic aneurysm. *J Vasc Surg.* 2008;47:625-628.
  65. Dake MD, Miller DC, Mitchell RS, et al. The "first generation" of endovascular stent-grafts for patients with aneurysms of the descending thoracic aorta. *J Thorac Cardiovasc Surg.* 1998;116:689-703.
  66. Gravereaux EC, Faries PL, Burks JA, et al. Risk of spinal cord ischemia after endograft repair of thoracic aortic aneurysms. *J Vasc Surg.* 2001;34:997-1003.
  67. Mitchell RS, Miller DC, Dake MD, et al. Thoracic aortic aneurysm repair with an endovascular stent graft: the "first generation." *Ann Thorac Surg.* 1999;67:1971-1974.
  68. Coselli JS, LeMaire SA, Miller CC, Schmittling ZC, et al. Mortality and paraplegia after thoracoabdominal aortic aneurysm repair: a risk factor analysis. *Ann Thorac Surg.* 2000;69:409-414.
  69. Khoynzhad A, Donayre CE, Bui H, et al. Risk factors of neurologic deficit after thoracic aortic endografting. *Ann Thorac Surg.* 2007;83:S882-889.
  70. Jacobs MJ, de Moll BA, Elenbass T, et al. Spinal cord blood supply in patients with thoracoabdominal aortic aneurysms. *J Vasc Surg.* 2002;35:30-37.
  71. Sheehan MK, Ouriel K, Greenberg R, et al. Are type II endoleaks after endovascular aneurysm repair endograft dependent?

*J Vasc Surg.* 2006;43:657-661.

72. Moore WS, Matsumura JS, Makaroun MS, et al. Five-year interim comparison of the Guidant bifurcated endograft with open repair of abdominal aortic aneurysm. *J Vasc Surg.* 2003;38:46-55.
73. Cho JS, Dillavou ED, Rhee RY, Makaroun MS. Late abdominal aortic aneurysm enlargement after endovascular repair with the Excluder device. *J Vasc Surg.* 2004;39:1236-1241.
74. Haider SE, Najjar SF, Cho JS, et al. Sac behavior after aneurysm treatment with the Gore Excluder low-permeability aortic endoprosthesis: 12-month comparison to the original Excluder device. *J Vasc Surg.* 2006;44:694-700.
75. Resch T, Koul B, Dias N, et al. Changes in aneurysm morphology and stent-graft configuration after endovascular repair of aneurysms of the descending thoracic aorta. *J Thorac Cardiovasc Surg.* 2001;122:47-52.
76. Gorich J, Asquan Y, Seifarth H, et al. Initial experience with intentional stent-graft coverage of the subclavian artery during endovascular thoracic aortic repairs. *J Endovasc Ther.* 2002;9(Suppl 2):II39-II43.
77. Hassoun HT, Mitchell RS, Makaroun MS, et al. Aortic neck morphology after endovascular repair of descending thoracic aortic aneurysms. *J Vasc Surg.* 2006;43:26-31.
78. Ellozy SH, Carroccio A, Minor M, et al. Challenges of endovascular tube graft repair of thoracic aortic aneurysm: midterm follow-up and lessons learned. *J Vasc Surg.* 2003;38:676-683.
79. Svensson LG, Hess KR, Coselli JS, et al. A prospective study of respiratory failure after high-risk surgery on the thoracoabdominal aorta. *J Vasc Surg.* 1991;14:271-282.
80. Juvonen T, Ergin MA, Galla JD, et al. Prospective study of the natural history of thoracic aortic aneurysms [erratum appears in *Ann Thorac Surg* 1997 Aug;64(2):594]. *Ann Thorac Surg.* 1997;63:1533-1545.
81. Black SA, Wolfe JH, Clark M, et al. Complex thoracoabdominal aortic aneurysms: endovascular exclusion with visceral revascularization. *J Vasc Surg.* 2006;43:1081-1089.
82. Chuter TA, Rapp JH, Hiramoto JS, et al. Endovascular treatment of thoracoabdominal aortic aneurysms. *J Vasc Surg.* 2008;47:6-16.
83. Chiesa R, Tshomba Y, Melissano G, et al. Hybrid approach to thoracoabdominal aortic aneurysms in patients with prior aortic surgery. *J Vasc Surg.* 2007;45:1128-1135.
84. Bäckler D, Kotelis D, Geisbusch P, et al. Hybrid procedures for thoracoabdominal aortic aneurysms and chronic aortic dissections—A single center experience in 28 patients. *J Vasc Surg.* 2008;47:724-732.
85. Resch TA, Greenberg RK, Lyden SP, et al. Combined staged procedures for the treatment of thoracoabdominal aneurysms. *J Endovasc Ther.* 2006;13:481-489.
86. Zhou W, Reardon M, Peden EK, et al. Hybrid approach to complex thoracic aortic aneurysms in high-risk patients: surgical challenges and clinical outcomes. *J Vasc Surg.* 2006;44:688-693.
87. Cho JS, Gloviczki P, Martelli E, et al. Long-term survival and late complications after repair of ruptured abdominal aortic aneurysms. *J Vasc Surg.* 1998;27:813-819; discussion 819-820.
88. Greenberg RK, Lytle B. Endovascular repair of thoracoabdominal aneurysms. *Circulation.* 2008;117:2288-2296.
89. Anderson JL, Adam DJ, Berce M, Hartley DE. Repair of thoracoabdominal aortic aneurysms with fenestrated and branched endovascular stent grafts. *J Vasc Surg.* 2005;42:600-607.
90. Muhs BE, Verhoeven EL, Zeebregts CJ, et al. Mid-term results of endovascular aneurysm repair with branched and fenestrated endografts. *J Vasc Surg.* 2006;44:9-15.
91. Roselli EE, Greenberg RK, Pfaff K, et al. Endovascular treatment of thoracoabdominal aortic aneurysms. *J Thorac Cardiovasc Surg.* 2007;133:1474-1482.
92. Bley J, Schol F, Vanhandenhove I, Vercaeren P. Side-branched modular endograft system for thoracoabdominal aortic aneurysm repair. *J Endovasc Ther.* 2002;9:838-841.
93. Adam DJ, Berce M, Hartley DE, et al. Repair of recurrent visceral aortic patch aneurysm after thoracoabdominal aortic aneurysm repair with a branched endovascular stent graft. *J Vasc Surg.* 2007;45:183-185.

94. Haddad F, Greenberg RK, Walker E, et al. Fenestrated endovascular grafting: the renal side of the story. *J Vasc Surg.* 2005;41:181-190.
95. Alric P, Hinchliffe RJ, Picot MC, et al. Long-term renal function following endovascular aneurysm repair with infrarenal and suprarenal aortic stent-grafts. *J Endovasc Ther.* 2003;10:397-405.
96. Kvilekval KH, Yunis JP, Mason RA, Giron F. After the blue toe: prognosis of noncardiac arterial embolization in the lower extremities. *J Vasc Surg.* 1993;17:328-334.
97. Choukroun EM, Labrousse LM, Madonna FP, Deville C. Mobile thrombus of the thoracic aorta: diagnosis and treatment in 9 cases. *Ann Vasc Surg.* 2002;16:714-722.
98. Rossi PJ, Desai TR, Skelly CL, et al. Paravisceral aortic thrombus as a source of peripheral embolization—report of three cases and review of the literature. *J Vasc Surg.* 2002;36:839-843.
99. Lozano P, Gomez FT, Julia J, et al. Recurrent embolism caused by floating thrombus in the thoracic aorta. *Ann Vasc Surg.* 1998;12:609-611.
100. Machleder HI, Takiff H, Lois JF, Holburt E. Aortic mural thrombus: an occult source of arterial thromboembolism. *J Vasc Surg.* 1986;4:473-478.
101. Scolari F, Tardanico R, Zani R, et al. Cholesterol crystal embolism: a recognizable cause of renal disease. *Am J Kidney Dis.* 2000;36:1089-1109.
102. Baumann DS, McGraw D, Rubin BG, et al. An institutional experience with arterial atheroembolism. *Ann Vasc Surg.* 1994;8:258-265.
103. Bojar RM, Payne DD, Murphy RE, et al. Surgical treatment of systemic atheroembolism from the thoracic aorta. *Ann Thorac Surg.* 1996;61:1389-1393.
104. Kumins NH, Owens EL, Oglevie SB, et al. Early experience using the Wallgraft in the management of distal microembolism from common iliac artery pathology. *Ann Vasc Surg.* 2002;16:181-186.
105. Carroccio A, Olin JW, Ellozy SH, et al. The role of aortic stent grafting in the treatment of atheromatous embolization syndrome: results after a mean of 15 months follow-up. *J Vasc Surg.* 2004;40:424-429.
106. Fueglistaler P, Wolff T, Guerke L, et al. Endovascular stent graft for symptomatic mobile thrombus of the thoracic aorta. *J Vasc Surg.* 2005;42:781-783.
107. Criado E, Wall P, Lucas P, et al. Transesophageal echo-guided endovascular exclusion of thoracic aortic mobile thrombi. *J Vasc Surg.* 2004;39:238-242.
108. Zhang WW, bou-Zamzam AM, Hashisho M, et al. Staged endovascular stent grafts for concurrent mobile/ulcerated thrombi of thoracic and abdominal aorta causing recurrent spontaneous distal embolization. *J Vasc Surg.* 2008;47:193-196.

## 第 134 章

1. Svensson L, Crawford ES. *Cardiovascular and Vascular Disease of the Aorta*. Philadelphia, PA: WB Saunders; 1996.
2. Robinson BL, Nadolny EM, Entrup MH, Svensson LG. Management of right-sided aortic aneurysms. *Ann Thorac Surg.* 2001;1764-1765.
3. Celoria G, Patton R. Congenital absence of the aortic arch. *Am Heart J.* 1959;58:407-413.
4. Ruigrok YM, Elias R, Wijmenga C, Rinkel GJ. A comparison of genetic chromosomal loci for intracranial, thoracic aortic, and abdominal aortic aneurysms in search of common genetic risk factors. *Cardiovasc Pathol.* 2008;17:40-47.
5. Svensson LG, Blackstone EH, Feng J, et al. Are Marfan syndrome and marfanoid patients distinguishable on long-term follow-up? *Ann Thorac Surg.* 2007;83:1067-1074.
6. Svensson LG, Labib SB, Eisenhauer AC, Butterly JR. Intimal tear without hematoma: an important variant of aortic dissection that can elude current imaging techniques. *Circulation.* 1999;99:1331-1336.
7. Svensson LG, Hess KR, Coselli JS, et al. A prospective study of respiratory failure after high-risk surgery on the thoracoabdominal aorta. *J Vasc Surg.* 1991;14:271-282.

8. Svensson LG, Nadolny EM, Penney DL, et al. Prospective randomized neurocognitive and S-100 study of hypothermic circulatory arrest, retrograde brain perfusion, and antegrade brain perfusion for aortic arch operations. *Ann Thorac Surg.* 2001;71:1905-1912.
9. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. *Ann Thorac Surg.* 2002;73:17-27.
10. Coady MA, Rizzo JA, Hammond GL, et al. What is the appropriate size criterion for resection of thoracic aortic aneurysms? *J Thorac Cardiovasc Surg.* 1997;113:476-491.
11. Svensson LG, Kouchoukos NT, Miller DC, et al. Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts. *Ann Thorac Surg.* 2008;85(1 Suppl):S1-S41.
12. Kpodonu J, Preventza O, Ramaiah VG, et al. Retrograde type A dissection after endovascular stenting of the descending thoracic aorta. Is the risk real? *Eur J Cardiothorac Surg.* 2008;33:1014-1018.
13. Svensson LG, Khitin L. Aortic cross-sectional area/height ratio timing of aortic surgery in asymptomatic patients with Marfan syndrome. *J Thorac Cardiovasc Surg.* 2002;123:360-361.
14. Griep RB, Stinson EB, Hollingsworth JF, Buehler D. Prosthetic replacement of the aortic arch. *J Thorac Cardiovasc Surg.* 1975;70:1051-1063.
15. Svensson LG, Husain A, Penney DL, et al. A prospective randomized study of neurocognitive function and S-100 protein after antegrade or retrograde brain perfusion with hypothermic arrest for aortic surgery. *J Thorac Cardiovasc Surg.* 2000;119:163-167.
16. Svensson LG, Crawford ES, Hess KR, et al. Deep hypothermia with circulatory arrest. Determinants of stroke and early mortality in 656 patients. *J Thorac Cardiovasc Surg.* 1993;106:19-28.
17. Augoustides JG, Pochettino A, McGarvey ML, et al. Clinical predictors for mortality in adults undergoing thoracic aortic surgery requiring deep hypothermic circulatory arrest. *Ann Card Anaesth.* 2006;9:114-119.
18. Valeri CR, Khabbaz K, Khuri SF, et al. Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass. *J Thorac Cardiovasc Surg.* 1992;104:108-116.
19. Valeri CR, Feingold H, Cassidy G, et al. Hypothermia-induced reversible platelet dysfunction. *Ann Surg.* 1987;205:175-181.
20. Kettner SC, Kozek SA, Groetzner JP, et al. Effects of hypothermia on thrombelastography in patients undergoing cardiopulmonary bypass. *Br J Anaesth.* 1998;80:313-317.
21. Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. *N Engl J Med.* 1996;334:1209-1215.
22. Apostolakis E, Koletsis EN, Dedeilias P, et al. Antegrade versus retrograde cerebral perfusion in relation to postoperative complications following aortic arch surgery for acute aortic dissection type A. *J Card Surg.* 2008;23:480-487.
23. Harrington DK, Bonser M, Moss A, et al. Neuropsychometric outcome following aortic arch surgery: a prospective randomized trial of retrograde cerebral perfusion. *J Thorac Cardiovasc Surg.* 2003;126:638-644.
24. Ehrlich M, Grabenwoger M, Cartes-Zumelzu F, et al. Operations on the thoracic aorta and hypothermic circulatory arrest: is aprotinin safe? *J Thorac Cardiovasc Surg.* 1998;115:220-225.
25. Bonser RS, Wong CH, Harrington D, et al. Failure of retrograde cerebral perfusion to attenuate metabolic changes associated with hypothermic circulatory arrest. *J Thorac Cardiovasc Surg.* 2002;123:943-950.
26. Svensson LG, Nadolny EM, Kimmel WA. Multimodal protocol influence on stroke and neurocognitive deficit prevention after ascending/arch aortic operations. *Ann Thorac Surg.* 2002;74:2040-2046.
27. Dorotta I, Kimball-Jones P, Applegate R. Deep hypothermia and circulatory arrest in adults. *Semin Cardiothorac Vasc Anesth.* 2007;11:66-76.
28. Immer FF, Moser B, Krahenbuhl ES, et al. Arterial access through the right subclavian artery in surgery of the aortic arch improves neurologic outcome and mid-term quality of life. *Ann Thorac Surg.* 2008;85:1614-1618.
29. Gulbins H, Pritisanac A, Ennker J. Axillary versus femoral cannulation for aortic surgery: enough evidence for a general

- recommendation? *Ann Thorac Surg*. 2007;83:1219-1224.
30. Augoustides JG, Harris H, Pochettino A. Direct innominate artery cannulation in acute type A dissection and severe thoracic aortic atheroma. *J Cardiothorac Vasc Anesth*. 2007;21:727-729.
  31. Kamiya H, Klima U, Hagl C, et al. Cerebral microembolization during antegrade selective cerebral perfusion. *Ann Thorac Surg*. 2006;81:519-521.
  32. Coselli JS, Bozinovski J, Cheung C. Hypothermic circulatory arrest: safety and efficacy in the operative treatment of descending and thoracoabdominal aortic aneurysms. *Ann Thorac Surg*. 2008;85:956-963.
  33. Appoo JJ, Augoustides JG, Pochettino A, et al. Perioperative outcome in adults undergoing elective deep hypothermic circulatory arrest with retrograde cerebral perfusion in proximal aortic arch repair: evaluation of protocol-based care. *J Cardiothorac Vasc Anesth*. 2006;20:3-7.
  34. Svensson LG. Antegrade perfusion during suspended animation? *J Thorac Cardiovasc Surg*. 2002;124:1068-1070.
  35. Augoustides JG, Pochettino A, Ochroch EA, et al. Renal dysfunction after thoracic aortic surgery requiring deep hypothermic circulatory arrest: definition, incidence, and clinical predictors. *J Cardiothorac Vasc Anesth*. 2006;20:673-677.
  36. Svensson LG, Blackstone EH, Rajeswaran J, et al. Does the arterial cannulation site for circulatory arrest influence stroke risk? *Ann Thorac Surg*. 2004;78:1274-1284.
  37. Shuhaiber JH. Evaluating the quality of trials of hypothermic circulatory arrest aortic surgery. *Asian Cardiovasc Thorac Ann*. 2007;15:449-452.
  38. Greenberg RK, Haddad F, Svensson L, et al. Hybrid approaches to thoracic aortic aneurysms: the role of endovascular elephant trunk completion. *Circulation*. 2005;112:2619-2626.
  39. Borst HG, Walterbusch G, Schaps D. Extensive aortic replacement using "elephant trunk" prosthesis. *Thorac Cardiovasc Surg*. 1983;31:37-40.
  40. Safi HJ, Miller CC, III, Estrera AL, et al. Staged repair of extensive aortic aneurysms: long-term experience with the elephant trunk technique. *Ann Surg*. 2004;240:677-684.
  41. Svensson LG, Kim KH, Blackstone EH, et al. Elephant trunk procedure: newer indications and uses. *Ann Thorac Surg*. 2004;78:109-116.
  42. Melissano G, Civilini E, Bertoglio L, et al. Results of endografting of the aortic arch in different landing zones. *Eur J Vasc Endovasc Surg*. 2007;33:561-566.
  43. Szeto WY, Bavaria JE, Bowen FW, et al. The hybrid total arch repair: brachiocephalic bypass and concomitant endovascular aortic arch stent graft placement. *J Card Surg*. 2007;22:97-102.
  44. Schumacher H, Von Tengg-Kobligh H, Ostovic M, et al. Hybrid aortic procedures for endoluminal arch replacement in thoracic aneurysms and type B dissections. *J Cardiovasc Surg (Torino)*. 2006;47:509-517.
  45. Bergeron P, Mangialardi N, Costa P, et al. Great vessel management for endovascular exclusion of aortic arch aneurysms and dissections. *Eur J Vasc Endovasc Surg*. 2006;32:38-45.
  46. Akasaka J, Tabayashi K, Saiki Y, et al. Stent grafting technique using Matsui-Kitamura (MK) stent for patients with aortic arch aneurysm. *Eur J Cardiothorac Surg*. 2005;27:649-653.
  47. Czerny M, Gottardi R, Zimpfer D, et al. Mid-term results of supraaortic transpositions for extended endovascular repair of aortic arch pathologies. *Eur J Cardiothorac Surg*. 2007;31:623-627.
  48. Baraki H, Hagl C, Khaladj N, et al. The frozen elephant trunk technique for treatment of thoracic aortic aneurysms. *Ann Thorac Surg*. 2007;83:S819-S823.
  49. Gorlitzer M, Weiss G, Thalmann M, et al. Combined surgical and endovascular repair of complex aortic pathologies with a new hybrid prosthesis. *Ann Thorac Surg*. 2007;84:1971-1976.
  50. Mizuno T, Toyama M, Tabuchi N, et al. Stented elephant trunk procedure combined with ascending aorta and arch replacement for acute type A aortic dissection. *Eur J Cardiothorac Surg*. 2002;22:504-509.
  51. Chavan A, Karck M, Hagl C, et al. Hybrid endograft for one-step treatment of multisegment disease of the thoracic aorta. *J*

- Vasc Interv Radiol.* 2005;16:823-829.
52. Usui A, Fujimoto K, Ishiguchi T, et al. Cerebrospinal dysfunction after endovascular stent-grafting via a median sternotomy: the frozen elephant trunk procedure. *Ann Thorac Surg.* 2002;74:S1821-S1824.
  53. Kato M, Kuratani T, Kaneko M, et al. The results of total arch graft implantation with open stent-graft placement for type A aortic dissection. *J Thorac Cardiovasc Surg.* 2002;124:531-540.
  54. Inoue K, Hosokawa H, Iwase T, et al. Aortic arch reconstruction by transluminally placed endovascular branched stent graft. *Circulation.* 1999;100(19 Suppl):II316-II321.
  55. Ferreira M, Chuter T, Hartley D, et al. Hybrid repair of aortic arch aneurysms: a totally extrathoracic approach with branched endografts in two patients. *Vascular.* 2007;15:79-83.
  56. Schneider DB, Curry TK, Reilly LM, et al. Branched endovascular repair of aortic arch aneurysm with a modular stent-graft system. *J Vasc Surg.* 2003;38:855.
  57. Safi HJ, Miller CC, III, Estrera AL, et al. Staged repair of extensive aortic aneurysms: long-term experience with the elephant trunk technique. *Ann Surg.* 2004;240:677-684.
  58. Wong CH, Wyatt MG, Jackson R, Hasan A. A dual strategic approach to mega-aortic aneurysms. *Eur J Cardiothorac Surg.* 2001;19:528-530.
  59. Ishihara H, Uchida N, Yamasaki C, et al. Extensive primary repair of the thoracic aorta in Stanford type A acute aortic dissection by means of a synthetic vascular graft with a self-expandable stent. *J Thorac Cardiovasc Surg.* 2002;123:1035-1040.
  60. Uchida N, Ishihara H, Sakashita M, et al. Repair of the thoracic aorta by transaortic stent grafting (open stenting). *Ann Thorac Surg.* 2002;73:444-448.
  61. Diethrich EB, Ghazoul M, Wheatley GH, et al. Surgical correction of ascending type A thoracic aortic dissection: simultaneous endoluminal exclusion of the arch and distal aorta. *J Endovasc Ther.* 2005;12:660-666.
  62. Buth J, Penn O, Tielbeek A, Mersman M. Combined approach to stent-graft treatment of an aortic arch aneurysm. *J Endovasc Surg.* 1998;5:329-332.
  63. Noor N, Sadat U, Hayes PD, et al. Management of the left subclavian artery during endovascular repair of the thoracic aorta. *J Endovasc Ther.* 2008;15:168-176.
  64. Reece TB, Gazoni LM, Cherry KJ, et al. Reevaluating the need for left subclavian artery revascularization with thoracic endovascular aortic repair. *Ann Thorac Surg.* 2007;84:1201-1205.
  65. Buth J, Harris PL, Hobo R, et al. Neurologic complications associated with endovascular repair of thoracic aortic pathology: incidence and risk factors. a study from the European Collaborators on Stent/Graft Techniques for Aortic Aneurysm Repair (EUROSTAR) registry. *J Vasc Surg.* 2007;46:1103-1110.
  66. Palchik E, Bakken AM, Wolford HY, et al. Subclavian artery revascularization: an outcome analysis based on mode of therapy and presenting symptoms. *Ann Vasc Surg.* 2008;22:70-78.
  67. Byrne J, Darling RC, III, Roddy SP, et al. Long term outcome for extra-anatomic arch reconstruction. An analysis of 143 procedures. *Eur J Vasc Endovasc Surg.* 2007;34:444-450.
  68. Greenberg RK, Clair D, Srivastava S, et al. Should patients with challenging anatomy be offered endovascular aneurysm repair? *J Vasc Surg.* 2003;38:990-996.
  69. Baldwin ZK, Chuter TA, Hiramoto JS, et al. Double-barrel technique for endovascular exclusion of an aortic arch aneurysm without sternotomy. *J Endovasc Ther.* 2008;15:161-165.
  70. Hiramoto JS, Schneider DB, Reilly LM, Chuter TA. A double-barrel stent-graft for endovascular repair of the aortic arch. *J Endovasc Ther.* 2006;13:72-76.
  71. Criado FJ. A percutaneous technique for preservation of arch branch patency during thoracic endovascular aortic repair (TEVAR): retrograde catheterization and stenting. *J Endovasc Ther.* 2007;14:54-58.
  72. Inoue K, Sato M, Iwase T, et al. Clinical endovascular placement of branched graft for type B aortic dissection. *J Thorac*



- Cardiovasc Surg.* 1996;112:1111-1113.
73. Chuter TA, Schneider DB, Reilly LM, et al. Modular branched stent graft for endovascular repair of aortic arch aneurysm and dissection. *J Vasc Surg.* 2003;38:859-863.
  74. O'Neill S, Greenberg R, Haddad F, et al. A prospective analysis of fenestrated endovascular grafting: intermediate-term outcomes. *Eur J Vasc Endovasc Surg.* 2006;32:115-123.
  75. McWilliams RG, Fearn SJ, Harris PL, et al. Retrograde fenestration of endoluminal grafts from target vessels: feasibility, technique, and potential usage. *J Endovasc Ther.* 2003;10:946-952.
  76. McWilliams RG, Murphy M, Hartley D, et al. In situ stent-graft fenestration to preserve the left subclavian artery. *J Endovasc Ther.* 2004;11:170-174.
  77. Kruger AJ, Holden AH, Hill AA. Endoluminal repair of a thoracic arch aneurysm using a scallop-edged stent-graft. *J Endovasc Ther.* 2003;10:936-939.
  78. Ishimaru S. Endografting of the aortic arch. *J Endovasc Ther.* 2004;11(Suppl 2):II62-II71.

## 第 135 章

1. Shekelton J. Healed dissecting aneurysm. *Dublin Hosp Rep.* 1922;3:231-232.
2. Kouchoukos NT, Dougenis D. Surgery of the thoracic aorta. *N Engl J Med.* 1997;336:1876-1888.
3. Bickerstaff LK, Pairolero PC, Hollier LH, et al. Thoracic aortic aneurysms: a population-based study. *Surgery.* 1982;92:1103-1108.
4. Crawford ES, Crawford JL, Safi HJ, et al. Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. *J Vasc Surg.* 1986;3:389-404.
5. Clouse WD, Hallett JW Jr, Schaff HV, et al. Acute aortic dissection: population-based incidence compared with degenerative aortic aneurysm rupture. *Mayo Clin Proc.* 2004;79:176-180.
6. Khan IA, Nair CK. Clinical, diagnostic, and management perspectives of aortic dissection. *Chest.* 2002;122:311-328.
7. Cambria RP. Surgical treatment of complicated distal aortic dissection. *Semin Vasc Surg.* 2002;15:97-107.
8. Mehta RH, Suzuki T, Hagan PG, et al. Predicting death in patients with acute type A aortic dissection. *Circulation.* 2002;105:200-206.
9. Lauterbach SR, Cambria RP, Brewster DC, et al. Contemporary management of aortic branch compromise resulting from acute aortic dissection. *J Vasc Surg.* 2001;33:1185-1192.
10. Cambria RP, Brewster DC, Gertler J, et al. Vascular complications associated with spontaneous aortic dissection. *J Vasc Surg.* 1988;7:199-209.
11. Hagan PG, Nienaber CA, Isselbacher EM, et al. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. *JAMA.* 2000;283:897-903.
12. Tsai TT, Evangelista A, Nienaber CA, et al. Long-term survival in patients presenting with type A acute aortic dissection: insights from the International Registry of Acute Aortic Dissection (IRAD). *Circulation.* 2006;114(1 Suppl):I350-I356.
13. Tsai TT, Fattori R, Trimarchi S, et al. Long-term survival in patients presenting with type B acute aortic dissection: insights from the International Registry of Acute Aortic Dissection. *Circulation.* 2006;114:2226-2231.
14. Crawford ES. The diagnosis and management of aortic dissection. *JAMA.* 1990;264:2537-2541.
15. DeBakey ME, Henly WS, Cooley DA, et al. Surgical management of dissecting aneurysms of the aorta. *Thorac Cardiovasc Surg.* 1965;49:130-149.
16. Daily PO, Trueblood HW, Stinson EB, et al. Management of acute aortic dissection. *Ann Thorac Surg.* 1970;10:237-246.
17. Meszaros I, Morocz J, Szilavi J, et al. Epidemiology and clinicopathology of aortic dissection. *Chest.* 2000;117:1271-1278.
18. Januzzi JL, Isselbacher EM, Fattori R, et al. Characterizing the young patient with aortic dissection: results from the International Registry of Aortic Dissection (IRAD). *J Am Coll Cardiol.* 2004;43:665-669.
19. Willich SN, Levy D, Rocco MB, et al. Circadian variation in the incidence of sudden cardiac death in the Framingham

- Heart Study population. *Am J Cardiol*. 1987;60:801-806.
20. Willich SN, Lowel H, Lewis M, et al. Weekly variation of acute myocardial infarction. Increased Monday risk in the working population. *Circulation*. 1994;90:87-93.
  21. Mehta RH, Manfredini R, Hassan F, et al. Chronobiological patterns of acute aortic dissection. *Circulation*. 2002;106:1110-1115.
  22. Mehta RH, Manfredini R, Bossone E, et al. The winter peak in the occurrence of acute aortic dissection is independent of climate. *Chronobiol Int*. 2005;22:723-729.
  23. Spittell PC, Spittell JA Jr, Joyce JW, et al. Clinical features and differential diagnosis of aortic dissection: experience with 236 cases (1980 through 1990). *Mayo Clin Proc*. 1993;68:897-903.
  24. Larson EW, Edwards WD. Risk factors for aortic dissection: a necropsy study of 161 patients. *Am J Cardiology*. 1984;53:849-855.
  25. Williams GM, Gott VL, Brawley RK, et al. Aortic disease associated with pregnancy. *J Vasc Surg*. 1988;8:470-475.
  26. Elkayam U, Ostrzega E, Shotan A, Mehra A. Cardiovascular problems in pregnant women with the Marfan syndrome. *Ann Intern Med*. 1995;123:117-122.
  27. Eagle KA, Isselbacher EM, DeSanctis RW. Cocaine-related aortic dissection in perspective. *Circulation*. 2002;105:1529-1530.
  28. Daniel JC, Huynh TT, Zhou W, et al. Acute aortic dissection associated with use of cocaine. *J Vasc Surg*. 2007;46:427-433.
  29. Hsue PY, Salinas CL, Bolger AF, et al. Acute aortic dissection induced by crack cocaine. *Circulation*. 2002;105:1592-1595.
  30. Wilson SK, Hutchins GM. Aortic dissecting aneurysms: causative factors in 204 subjects. *Arch Pathol Lab Med*. 1982;106:175-180.
  31. Hirst AE Jr, Johns VJ Jr, Kime SW Jr. Dissecting aneurysm of the aorta: a review of 505 cases. *Medicine (Baltimore)*. 1958;37:217-279.
  32. Wheat MW Jr. Acute dissection of the aorta. *Cardiovasc Clin*. 1987;17:241-262.
  33. O'Gara PT, DeSanctis RW. Acute aortic dissection and its variants. Toward a common diagnostic and therapeutic approach. *Circulation*. 1995;92:1376-1378.
  34. Marsalese DL, Moodie DS, Lytle BW, et al. Cystic medial necrosis of the aorta in patients without Marfan's syndrome: surgical outcome and long-term follow-up. *J Am Coll Cardiol*. 1990;16:68-73.
  35. Reed D, Reed C, Stemmerman G, et al. Are aortic aneurysms caused by atherosclerosis? *Circulation*. 1992;205-211.
  36. Nienaber CA, Fattori R, Mehta RH, et al. Gender-related differences in acute aortic dissection. *Circulation*. 2004;109:3014-3021.
  37. Jex RK, Schaff HV, Piehler JM, et al. Early and late results following repair of dissections of the descending thoracic aorta. *J Vasc Surg*. 1986;3:226-237.
  38. Cambria RP, Brewster DC, Moncure AC, et al. Spontaneous aortic dissection in the presence of coexistent or previously repaired atherosclerotic aortic aneurysm. *Ann Surg*. 1988;208:619-624.
  39. Barnes DM, Williams DM, Dasika NL, et al. A single-center experience treating renal malperfusion after aortic dissection with central aortic fenestration and renal artery stenting. *J Vasc Surg*. 2008;47:903-910; discussion 910-911.
  40. DeBakey ME, McCollum CH, Crawford ES, et al. Dissection and dissecting aneurysms of the aorta: twenty year follow-up of five hundred twenty seven patients treated surgically. *Surgery*. 1982;92:1118-1134.
  41. Fann JJ, Smith JA, Miller DC, et al. Surgical management of aortic dissection during a 30 year period. *Circulation*. 1995;92(Suppl II):113-121.
  42. Williams DM, LePage MA, Lee DY. The dissected aorta: part I. Early anatomic changes in an in vitro model. *Radiology*. 1997;203:23-31.
  43. Greenberg R, Khwaja J, Haulon S, Fulton G. Aortic dissections: new perspectives and treatment paradigms. *Eur J Vasc*

*Endovasc Surg.* 2003;26:579-586.

44. Williams DM, Lee DY, Hamilton BH, et al. The dissected aorta: percutaneous treatment of ischemic complications—principles and results. *J Vasc Interv Radiol.* 1997;8:605-625.
45. Chung JW, Elkins C, Sakai T, et al. True-lumen collapse in aortic dissection: Part II. Evaluation of treatment methods in phantoms with pulsatile flow. *Radiology.* 2000;214:99-106.
46. Young JR, Kramer J, Humphries AW. The ischemic leg: a clue to dissecting aneurysm. *Cardiovasc Clin.* 1975;7:201-205.
47. Williams DM, Lee DY, Hamilton BH, et al. The dissected aorta: part III. Anatomy and radiologic diagnosis of branch-vessel compromise. *Radiology.* 1997;203:37-44.
48. Nienaber CA, Eagle KA. Aortic dissection: new frontiers in diagnosis and management: Part II. Therapeutic management and follow-up. *Circulation.* 2003;108:772-778.
49. Januzzi JL, Movsowitz HD, Choi J, et al. Significance of recurrent pain in acute type B aortic dissection. *Am J Cardiol.* 2001;87:930-933.
50. Nallamothu BK, Saint S, Kolia TJ, Eagle KA. Clinical problem-solving. Of nicks and time. *N Engl J Med.* 2001;345:359-363.
51. Nallamothu BK, Mehta RH, Saint S, et al. Syncope in acute aortic dissection: diagnostic, prognostic, and clinical implications. *Am J Med.* 2002;113:468-471.
52. Slater EE. Aortic dissection: presentation and diagnosis. In: Dorogahzi RM, Slater EE, eds. *Aortic Dissection*. New York, NY: McGraw-Hill; 1983:13-53.
53. Sanders JS, Ferguson DW, Mark AL. Arterial baroreflex control of sympathetic nerve activity during elevation of blood pressure in normal man: dominance of aortic baroreflexes. *Circulation.* 1988;77:279-288.
54. Syed MA, Fiad TM. Transient paraplegia as a presenting feature of aortic dissection in a young man. *Emerg Med J.* 2002;19:174-175.
55. Khan IW, Wattanasauwan N, Ansari AW. Painless aortic dissection presenting as hoarseness of voice: cardiovocal syndrome, Ortner's syndrome. *Am J Emerg Med.* 1999;17:361-363.
56. Greenwood WR, Robinson MD. Painless dissection of the thoracic aorta. *Ann Emerg Med.* 1986;4:330-333.
57. Lefebvre V, Leduc JJ, Choteau PH. Painless ischemic lumbosacral plexopathy and aortic dissection. *J Neurol Neurosurg Psychiatry.* 1995;58:641.
58. Isselbacher EM. Diseases of the aorta. In: Braunwald E, ed. *Heart Disease*. WB Saunders: Philadelphia; 2002:1422-1455.
59. Januzzi JL, Sabatine MS, Choi JC, et al. Refractory systemic hypertension following type B aortic dissection. *Am J Cardiol.* 2001;88:686-688.
60. Bossone E, Rampoldi V, Nienaber CA, et al. Usefulness of pulse deficit to predict in-hospital complications and mortality in patients with acute type A aortic dissection. *Am J Cardiol.* 2002;89:851-855.
61. Burt C. Summary statistics for acute cardiac ischemia and chest pain visits to the United States EDs, 1995-1996. *Am J Emerg Med.* 1999;17:552-559.
62. Barbant S, Eisenberg, MJ, Schiller NB. The diagnostic value of imaging techniques for aortic dissection. *Am Heart J.* 1992;124:541-543.
63. Rosman HS, Patel S, Borzak S, et al. Quality of history taking in patients with aortic dissection. *Chest.* 1998;114:793-795.
64. Moore AG, Eagle KA, Bruckman D, et al. Choice of computed tomography, transesophageal echocardiography, magnetic resonance imaging, and aortography in acute aortic dissection: International Registry of Acute Aortic Dissection (IRAD). *Am J Cardiol.* 2002;89:1235-1238.
65. Hata N, Tanaka K, Imaizumi T, et al. Clinical significance of pleural effusion in acute aortic dissection. *Chest.* 2002;121:825-830.
66. Dinsmore RE, Wedeen VJ, Miller SW, et al. MRI of dissection of the aorta: recognition of the intimal tear and differential flow velocities. *AJR Am J Roentgenol.* 1986;146:1286-1288.

67. Guthaner DF, Miller DC. Digital subtraction angiography of aortic dissection. *AJR Am J Roentgenol*. 1983;141:157-161.
68. Petasnick JP. Radiologic evaluation of aortic dissection. *Radiology*. 1991;180:297-305.
69. Mugge A, Daniel WG, Laas J, et al. False-negative diagnosis of proximal aortic dissection by computed tomography or angiography and possible explanations based on transesophageal echocardiographic findings. *Am J Cardiol*. 1990;65:527-529.
70. Ince H, Nienaber CA. Diagnosis and management of patients with aortic dissection. *Heart*. 2007;93:266-270.
71. Fisher ER, Stern EJ, Godwin JD 2nd, et al. Acute aortic dissection: typical and atypical imaging features. *Radiographics*. 1994;14:1263-1271; discussion 1271-1274.
72. Hartnell G, Costello P. The diagnosis of thoracic aortic dissection by noninvasive imaging procedures. *N Engl J Med*. 1993;328:1637; author reply 1638.
73. Clague J, Magee P, Mills P. Diagnostic techniques in suspected thoracic aortic dissection. *Br Heart J*. 1992;67:428-429.
74. LePage MA, Quint LE, Sonnad SS, et al. Aortic dissection: CT features that distinguish true lumen from false lumen. *AJR Am J Roentgenol*. 2001;177:207-211.
75. Rampoldi V, Trimarchi S, Eagle KA, et al. Simple risk models to predict surgical mortality in acute type A aortic dissection: the International Registry of Acute Aortic Dissection score. *Ann Thorac Surg*. 2007;83:55-61.
76. Erbel R, Engberding R, Daniel W, et al. Echocardiography in diagnosis of aortic dissection. *Lancet*. 1989;1:457-461.
77. Victor MF, Mintz GS, Kotler MN, et al. Two dimensional echocardiographic diagnosis of aortic dissection. *Am J Cardiol*. 1981;48:1155-1159.
78. Granato JE, Dee P, Gibson RS. Utility of two-dimensional echocardiography in suspected ascending aortic dissection. *Am J Cardiol*. 1985;56:123-129.
79. Adachi H, Omoto R, Kyo S, et al. Diagnosis of acute aortic dissection with transesophageal echocardiography and results of surgical treatment. *Nippon Kyobu Geka Gakkai Zasshi*. 1991;39:1987-1994.
80. Keren A, Kim CB, Hu BS, et al. Accuracy of biplane and multiplane transesophageal echocardiography in diagnosis of typical acute aortic dissection and intramural hematoma. *J Am Coll Cardiol*. 1996;28:627-636.
81. Vignon P, Spencer KT, Rambaud G, et al. Differential transesophageal echocardiographic diagnosis between linear artifacts and intraluminal flap of aortic dissection or disruption. *Chest*. 2001;119:1778-1790.
82. Erbel R. Role of transesophageal echocardiography in dissection of the aorta and evaluation of degenerative aortic disease. *Cardiol Clin*. 1993;11:461-473.
83. Erbel R, Bednarczyk I, Pop T, et al. Detection of dissection of the aortic intima and media after angioplasty of coarctation of the aorta. An angiographic, computed tomographic, and echocardiographic comparative study. *Circulation*. 1990;81:805-814.
84. Movsowitz HD, Levine RA, Hilgenberg AD, Isselbacher EM. Transesophageal echocardiographic description of the mechanisms of aortic regurgitation in acute type A aortic dissection: implications for aortic valve repair. *J Am Coll Cardiol*. 2000;36:884-890.
85. Fruehwald FX, Neuhold A, Fezoulidis J, et al. Cine-MR in dissection of the thoracic aorta. *Eur J Radiol*. 1989;9:37-41.
86. Tomiguchi S, Morishita S, Nakashima R, et al. Usefulness of turbo-FLASH dynamic MR imaging of dissecting aneurysms of the thoracic aorta. *Cardiovasc Intervent Radiol*. 1994;17:17-21.
87. Prince MR, Narasimham DL, Jacoby WT, et al. Three-dimensional gadolinium-enhanced MR angiography of the thoracic aorta. *AJR Am J Roentgenol*. 1996;166:1387-1397.
88. Wheat M Jr, Palmer, RF. Dissecting aneurysms of the aorta: present status of drug versus surgical therapy. *Prog Cardiovasc Dis*. 1968;11:198-210.
89. Isselbacher E, Cigarroa JE, Eagle KA. Cardiac tamponade complicating proximal aortic dissection: is pericardiocentesis harmful? *Circulation*. 1994;90:2375-2379.
90. Isselbacher EM. Thoracic and abdominal aortic aneurysms. *Circulation*. 2005;111:816-828.

91. Patel HJ, Williams DM, Dasika NL, et al. Operative delay for peripheral malperfusion syndrome in acute type A aortic dissection: a long-term analysis. *J Thorac Cardiovasc Surg.* 2008;135:1288-1295; discussion 1295-1296.
92. Fann JJ, Sarris GE, Mitchell RS, et al. Treatment of patients with aortic dissection presenting with peripheral vascular complications. *Ann Surg.* 1990;212:705-713.
93. Davies RR, Coe MP, Mandapati D, et al. Thoracic Surgery Directors Association Award. What is the optimal management of late-presenting survivors of acute type A aortic dissection? *Ann Thorac Surg.* 2007;83:1593-1601; discussion 1601-1602.
94. Trimarchi S, Nienaber CA, Rampoldi V, et al. Contemporary results of surgery in acute type A aortic dissection: the International Registry of Acute Aortic Dissection experience. *J Thorac Cardiovasc Surg.* 2005;129:112-122.
95. Bavaria J, Pochettino A, Brinster DR, et al. New paradigms and improved results for the surgical treatment of acute type A dissection. *Ann Surg.* 2001;234:236-242.
96. Lai DT, Robbins RC, Mitchell RS, et al. Does profound hypothermic circulatory arrest improve survival in patients with acute type A aortic dissection? *Circulation.* 2002;106(12 Suppl 1):I218-I228.
97. Bakhtiary F, Dogan S, Zierer A, et al. Antegrade cerebral perfusion for acute type A aortic dissection in 120 consecutive patients. *Ann Thorac Surg.* 2008;85:465-469.
98. Knipp BS, Deeb GM, Prager RL, et al. A contemporary analysis of outcomes for operative repair of type A aortic dissection in the United States. *Surgery.* 2007;142:524-528; discussion 528 e1.
99. Apaydin AZ, Buket S, Posacioglu H, et al. Perioperative risk factors for mortality in patients with acute type A aortic dissection. *Ann Thorac Surg.* 2002;74:2034-2039; discussion 2039.
100. Mehta RH, O'Gara PT, Bossone E, et al. Acute type A aortic dissection in the elderly: clinical characteristics, management, and outcomes in the current era. *J Am Coll Cardiol.* 2002;40:685-692.
101. Zierer A, Voeller RK, Hill KE, et al. Aortic enlargement and late reoperation after repair of acute type A aortic dissection. *Ann Thorac Surg.* 2007;84:479-486; discussion 486-487.
102. Crawford ES, Kirklin JW, Naftel DC, et al. Surgery for acute dissection of ascending aorta. Should the arch be included? *J Thorac Cardiovasc Surg.* 1992;104:46-59.
103. Kazui T, Yamashita K, Washiyama N, et al. Impact of an aggressive surgical approach on surgical outcome in type A aortic dissection. *Ann Thorac Surg.* 2002;74:S1844-S1847; discussion S1857-S1863.
104. Schor JS, Yerlioglu ME, Galla JD, et al. Selective management of acute type B aortic dissection: long-term follow-up. *Ann Thorac Surg.* 1996;61:1339-1341.
105. Safi HJ, Miller CC 3rd, Reardon MJ, et al. Operation for acute and chronic aortic dissection: recent outcome with regard to neurologic deficit and early death. *Ann Thorac Surg.* 1998;66:402-411.
106. Sasaki S, Yasuda K, Kuniyama T, et al. Surgical results of Stanford type B aortic dissection. Comparisons between partial and subtotal replacement of the dissected aorta. *J Cardiovasc Surg (Torino).* 2000;41:227-232.
107. Lansman SL, Hagl C, Fink D, et al. Acute type B aortic dissection: surgical therapy. *Ann Thorac Surg.* 2002;74:S1833-S1835; discussion S1857-S1863.
108. Coselli JS. Thoracoabdominal aortic aneurysms: experience with 372 patients. *J Card Surg.* 1994;9:638-647.
109. Neya K, Omoto R, Kyo S, et al. Outcome of Stanford type B acute aortic dissection. *Circulation.* 1992;86(5 Suppl):III-7.
110. Svensson LG, Crawford ES, Hess KR, et al. Dissection of the aorta and dissecting aortic aneurysms. Improving early and long-term surgical results. *Circulation.* 1990;82(5 Suppl):IV24-38.
111. Trimarchi S, Nienaber CA, Rampoldi V, et al. Role and results of surgery in acute type B aortic dissection: insights from the International Registry of Acute Aortic Dissection (IRAD). *Circulation.* 2006;114(1 Suppl):I357-I364.
112. Verdant A, Cossette R, Page A, et al. Aneurysms of the descending thoracic aorta: three hundred sixty-six consecutive cases resected without paraplegia. *J Vasc Surg.* 1995;21:385-390; discussion 390-391.
113. Ahmed AA, Mahadevan VS, Webb SW, MacGowan SW. Glue aortoplasty repair of aortic dissection after coronary

- angioplasty. *Ann Thorac Surg.* 2001;72:922-924.
114. Dake MD, Kato N, Mitchell RS, et al. Endovascular stent-graft placement for the treatment of acute aortic dissection. *N Engl J Med.* 1999;340:1546-1552.
  115. Nienaber CA, Fattori R, Lund G, et al. Nonsurgical reconstruction of thoracic aortic dissection by stent-graft placement. *N Engl J Med.* 1999;340:1539-1545.
  116. Onitsuka S, Akashi H, Tayama K, et al. Long-term outcome and prognostic predictors of medically treated acute type B aortic dissections. *Ann Thorac Surg.* 2004;78:1268-1273.
  117. Erbel R, Oelert H, Meyer J, et al. Effect of medical and surgical therapy on aortic dissection evaluated by transesophageal echocardiography. Implications for prognosis and therapy. The European Cooperative Study Group on Echocardiography. *Circulation.* 1993;87:1604-1615.
  118. Hata M, Shiono M, Inoue T, et al. Optimal treatment of type B acute aortic dissection: long-term medical follow-up results. *Ann Thorac Surg.* 2003;75:1781-1784.
  119. Winnekqvist A, Lockowandt U, Rasmussen E, Radegran K. A prospective study of medically treated acute type B aortic dissection. *Eur J Vasc Endovasc Surg.* 2006;32:349-355.
  120. Auer J. Aortic dissection: incidence, natural history and impact of surgery. *J Clin Basic Cardiol.* 2002;3:151-154.
  121. Bernard Y, Zimmermann H, Chocron S, et al. False lumen patency as a predictor of late outcome in aortic dissection. *Am J Cardiol.* 2001;87:1378-1382.
  122. Erbel R, Alfonso F, Boileau C, et al. Diagnosis and management of aortic dissection. *Eur Heart J.* 2001;22:1642-1681.
  123. Tsai TT, Evangelista A, Nienaber CA, et al. Partial thrombosis of the false lumen in patients with acute type B aortic dissection. *N Engl J Med.* 2007;357:349-359.
  124. Sueyoshi E, Sakamoto I, Hayashi K, et al. Growth rate of aortic diameter in patients with type B aortic dissection during the chronic phase. *Circulation.* 2004;110(11 Suppl 1):II256-261.
  125. Greenberg R. Treatment of aortic dissections with endovascular stent grafts. *Semin Vasc Surg.* 2002;15:122-127.
  126. Kato N, Hirano T, Takeda K, et al. Treatment of aortic dissections with a percutaneous intravascular endoprosthesis: comparison of covered and bare stents. *J Vasc Interv Radiol.* 1994;5:805-812.
  127. Moon MR, Dake MD, Pelc LR, et al. Intravascular stenting of acute experimental type B dissections. *J Surg Res.* 1993;54:381-388.
  128. Trent MS, Parsonnet V, Shoenfeld R, et al. A balloon-expandable intravascular stent for obliterating experimental aortic dissection. *J Vasc Surg.* 1990;11:707-717.
  129. Greenberg RK, Haulon S, Khwaja J, et al. Contemporary management of acute aortic dissection. *J Endovasc Ther.* 2003;10:476-485.
  130. Greenberg RK, Khwaja J, Haulon S, et al. Endovascular grafting for aortic dissections with life-threatening complications: early and mid-term results. August 2003. Unpublished data.
  131. Slonim SM, Miller DC, Mitchell RS, et al. Percutaneous balloon fenestration and stenting for life-threatening ischemic complications in patients with acute aortic dissection. *J Thorac Cardiovasc Surg.* 1999;117:1118-1126.
  132. Lopera J, Patino JH, Urbina C, et al. Endovascular treatment of complicated type-B aortic dissection with stent-grafts: midterm results. *J Vasc Interv Radiol.* 2003;14:195-203.
  133. Duebener LF, Lorenzen P, Richardt G, et al. Emergency endovascular stent-grafting for life-threatening acute type B aortic dissections. *Ann Thorac Surg.* 2004;78:1261-1266; discussion 1266-1267.
  134. Schoder M, Czerny M, Cejna M, et al. Endovascular repair of acute type B aortic dissection: long-term follow-up of true and false lumen diameter changes. *Ann Thorac Surg.* 2007;83:1059-1066.
  135. Leurs LJ, Bell R, Degrieck Y, et al. Endovascular treatment of thoracic aortic diseases: combined experience from the EUROSTAR and United Kingdom Thoracic Endograft registries. *J Vasc Surg.* 2004;40:670-679; discussion 679-680.
  136. Eggebrecht H, Nienaber CA, Neuhauser M, et al. Endovascular stent-graft placement in aortic dissection: a meta-analysis.

*Eur Heart J.* 2006;27:489-498.

137. Xu SD, Huang FJ, Yang JF, et al. Endovascular repair of acute type B aortic dissection: early and mid-term results. *J Vasc Surg.* 2006;43:1090-1095.
138. Mossop PJ, McLachlan CS, Amukotuwa SA, Nixon IK. Staged endovascular treatment for complicated type B aortic dissection. *Nat Clin Pract Cardiovasc Med.* 2005;2:316-321; quiz 322.
139. Elefteriades JA, Hammond GL, Gusberg RJ, et al. Fenestration revisited. A safe and effective procedure for descending aortic dissection. *Arch Surg.* 1990;125:786-790.
140. Clair DG. Aortic dissection with branch vessel occlusion: percutaneous treatment with fenestration and stenting. *Semin Vasc Surg.* 2002;15:116-121.
141. Elefteriades JA, Hartleroad J, Gusberg RJ, et al. Long-term experience with descending aortic dissection: the complication-specific approach. *Ann Thorac Surg.* 1992;53:11-20; discussion 20-21.
142. Chavan A, Hausmann D, Dresler C, et al. Intravascular ultrasound-guided percutaneous fenestration of the intimal flap in the dissected aorta. *Circ.* 1997;96:2124-2127.
143. Bartel T, Eggebrecht H, Ebradlidze T, et al. Images in cardiovascular medicine. Optimal guidance for intimal flap fenestration in aortic dissection by transvenous two-dimensional and Doppler ultrasonography. *Circulation.* 2003;107:e17-e18.
144. Beregi JP, Prat A, Gaxotte V, et al. Endovascular treatment for dissection of the descending aorta. *Lancet.* 2000;356:482-483.
145. Lookstein RA, Mitty H, Falk A, et al. Aortic intimal dehiscence: a complication of percutaneous balloon fenestration for aortic dissection. *J Vasc Interv Radiol.* 2001;12:1347-1350.
146. Chung JW, Elkins C, Sakai T, et al. True-lumen collapse in aortic dissection: part I. Evaluation of causative factors in phantoms with pulsatile flow. *Radiology.* 2000;214:87-98.
147. Fann JJ, Smith JA, Miller DC, et al. Surgical management of aortic dissection during a 30-year period. *Circulation.* 1995;92(9 Suppl):III113-121.
148. Beregi JP, Haulon S, Otal P, et al. Endovascular treatment of acute complications associated with aortic dissection: midterm results from a multicenter study. *J Endovasc Ther.* 2003;10:486-493.
149. Shaw RS. Acute dissecting aortic aneurysm; treatment by fenestration of the internal wall of the aneurysm. *N Engl J Med.* 1955;253:331-333.
150. DeBakey ME, Henly WS, Cooley DA, et al. Surgical management of dissecting aneurysms of the aorta. *J Thorac Cardiovasc Surg.* 1965;49:130-149.
151. Crawford ES, Crawford JL, Stowe CL, Safi HJ. Total aortic replacement for chronic aortic dissection occurring in patients with and without Marfan's syndrome. *Ann Surg.* 1984;199:358-362.
152. Coselli JS, LeMaire SA, de Figueiredo LP, Kirby RP. Paraplegia after thoracoabdominal aortic aneurysm repair: is dissection a risk factor? *Ann Thorac Surg.* 1997;63:28-35; discussion 35-36.
153. Safi HJ, Bartoli S, Hess KR, et al. Neurologic deficit in patients at high risk with thoracoabdominal aortic aneurysms: the role of cerebral spinal fluid drainage and distal aortic perfusion. *J Vasc Surg.* 1994;20:434-444; discussion 442-443.
154. Deeb GM, Williams DM, Bolling SF, et al. Surgical delay for acute type A dissection with malperfusion. *Ann Thorac Surg.* 1997;64:1669-1675; discussion 1675-1677.
155. Webb TH, Williams GM. Abdominal aortic tailoring for renal, visceral, and lower extremity malperfusion resulting from acute aortic dissection. *J Vasc Surg.* 1997;26:474-480; discussion 480-481.
156. Oderich GS, Panneton JM. Acute aortic dissection with side branch vessel occlusion: open surgical options. *Semin Vasc Surg.* 2002;15:89-96.
157. Panneton JM, Teh SH, Cherry KJ Jr, et al. Aortic fenestration for acute or chronic aortic dissection: an uncommon but effective procedure. *J Vasc Surg.* 2000;32:711-721.

158. Panneton JM, Hollier LH. Dissecting descending thoracic and thoracoabdominal aortic aneurysms: Part II. *Ann Vasc Surg.* 1995;9:596-605.
159. Hollier LH, Symmonds JB, Pairolero PC, et al. Thoracoabdominal aortic aneurysm repair. Analysis of postoperative morbidity. *Arch Surg.* 1988;123:871-875.
160. Cambria RP, Davison JK, Zannetti S, et al. Thoracoabdominal aneurysm repair: perspectives over a decade with the clamp-and-sew technique. *Ann Surg.* 1997;226:294-303; discussion 303-305.
161. White RA, Donayre CE, Walot I, Kopchok GE. Intraprocedural imaging: thoracic aortography techniques, intravascular ultrasound, and special equipment. *J Vasc Surg.* 2006;43(Suppl A):53A-61A.
162. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. *N Engl J Med.* 1994;330:1335-1341.
163. Chuter T, Hartley D, Rapp J, et al. Totally endovascular thoracoabdominal aneurysm repair. Paper presented at the Society for Vascular Surgery Annual Meeting. Baltimore, MD, 2007, pp 106-107.
164. Nienaber CA, von Kodolitsch Y, Petersen B, et al. Intramural hemorrhage of the thoracic aorta. Diagnostic and therapeutic implications. *Circulation.* 1995;92:1465-1472.
165. von Kodolitsch Y, Csoos SK, Koschik DH, et al. Intramural hematoma of the aorta: predictors of progression to dissection and rupture. *Circulation.* 2003;107:1158-1163.
166. Muluk SC, Kaufman JA, Torchiana DF, et al. Diagnosis and treatment of thoracic aortic intramural hematoma. *J Vasc Surg.* 1996;24:1022-1029.
167. Cho KR, Stanson AW, Potter DD, et al. Penetrating atherosclerotic ulcer of the descending thoracic aorta and arch. *J Thorac Cardiovasc Surg.* 2004;127:1393-1399; discussion 1399-1401.
168. Sundt TM. Intramural hematoma and penetrating atherosclerotic ulcer of the aorta. *Ann Thorac Surg.* 2007;83:S835-S841; discussion S846-S850.
169. Ohmi M, Tabayashi K, Moizumi Y, et al. Extremely rapid regression of aortic intramural hematoma. *J Thorac Cardiovasc Surg.* 1999;118:968-969.
170. Evangelista A, Mukherjee D, Mehta RH, et al. Acute intramural hematoma of the aorta: a mystery in evolution. *Circulation.* 2005;111:1063-1070.
171. Sueyoshi E, Imada T, Sakamoto I, et al. Analysis of predictive factors for progression of type B aortic intramural hematoma with computed tomography. *J Vasc Surg.* 2002;35:1179-1183.
172. Tittle SL, Lynch RJ, Cole PE, et al. Midterm follow-up of penetrating ulcer and intramural hematoma of the aorta. *J Thorac Cardiovasc Surg.* 2002;123:1051-1059.

## 第 136 章

1. Aulivola B, Hamdan AD, Hile CN, et al. Popliteal artery aneurysms: a comparison of outcomes in elective versus emergent repair. *J Vasc Surg.* 2004;39:1171-1177.
2. Johnston KW, Rutherford RB, Tilson MD, et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. *J Vasc Surg.* 1991;13:452-458.
3. Sandgren T, Sonesson B, Ryden A, Lanne T. Arterial dimensions in the lower extremities of patients with abdominal aortic aneurysms—no indications of a generalized dilating diathesis. *J Vasc Surg.* 2001;34:1079-1084.
4. Cutler BS, Darling RC. Surgical management of arteriosclerotic femoral aneurysms. *Surgery.* 1973;74:764-773.
5. Graham LM, Zelenock GB, Whitehouse WM Jr, et al. Clinical significance of arteriosclerotic femoral artery aneurysms. *Arch Surg.* 1980;115:502-507.
6. Kalko Y, Basaran M, Aydin U, et al. The surgical treatment of arterial aneurysms in Behçet disease: a report of 16 patients. *J Vasc Surg.* 2005;42:673-677.



7. Sasaki S, Yasuda K, Takigami K, et al. Surgical experiences with peripheral arterial aneurysms due to vasculo-Beçet's disease. *J Cardiovasc Surg (Torino)*. 1998;39:147-150.
8. Kasirajan K, Marek JM, Langsfeld M. Beçet's disease: endovascular management of a ruptured peripheral arterial aneurysm. *J Vasc Surg*. 2001;34:1127-1129.
9. Yamamoto T, Kurosaka M, Sugimoto T. A true aneurysm of the femoral artery in acromegaly. *Clin Imaging*. 2001;25:126-129.
10. Hollier LH, Stanson AW, Gloviczki P, et al. Arteriomegaly: classification and morbid implications of diffuse aneurysmal disease. *Surgery*. 1983;93:700-708.
11. Adiseshiah M, Bailey DA. Aneurysms of the femoral artery. *Br J Surg*. 1977;64:174-176.
12. Baird RJ, Gurry JF, Kellam J, Plume SK. Arteriosclerotic femoral artery aneurysms. *Can Med Assoc J*. 1977;117:1306-1307.
13. Levi N, Schroeder TV. Arteriosclerotic femoral artery aneurysms. A short review. *J Cardiovasc Surg (Torino)*. 1997;38:335-338.
14. Pappas G, Janes JM, Bernatz PE, Schirger A. Femoral aneurysms. Review of surgical management. *JAMA*. 1964;190:489-493.
15. Sapienza P, Mingoli A, Feldhaus RJ, et al. Femoral artery aneurysms: long-term follow-up and results of surgical treatment. *Cardiovasc Surg*. 1996;4:181-184.
16. Dent TL, Lindenauer SM, Ernst CB, Fry WJ. Multiple arteriosclerotic arterial aneurysms. *Arch Surg*. 1972;105:338-344.
17. Diwan A, Sarkar R, Stanley JC, et al. Incidence of femoral and popliteal artery aneurysms in patients with abdominal aortic aneurysms. *J Vasc Surg*. 2000;31:863-869.
18. Savolainen H, Widmer MK, Heller G, et al. Common femoral artery—uncommon aneurysms. *Scand J Surg*. 2003;92:203-205.
19. McCann RL. Basic data related to peripheral artery aneurysms. *Ann Vasc Surg*. 1990;4:411-414.
20. Davis RP, Neiman HL, Yao JS, Bergan JJ. Ultrasound scan in diagnosis of peripheral aneurysms. *Arch Surg*. 1977;112:55-58.
21. Pilcher DB, Ricci MA. Vascular ultrasound. *Surg Clin North Am*. 1998;78:273-293.
22. Berkmen T. MR angiography of aneurysms in Behçet disease: a report of four cases. *J Comput Assist Tomogr*. 1998;22:202-206.
23. Rubin GD, Walker PJ, Dake MD, et al. Three-dimensional spiral computed tomographic angiography: an alternative imaging modality for the abdominal aorta and its branches. *J Vasc Surg*. 1993;18:656-664; discussion 665.
24. Lagana D, Carrafiello G, Mangini M, et al. Endovascular treatment of femoropopliteal aneurysms: a five-year experience. *Cardiovasc Intervent Radiol*. 2006;29:819-825.
25. Tolstedt GE, Radke HM, Bell JW. Late sequela of arteriosclerotic femoral aneurysms. *Angiology*. 1961;12:601-602.
26. Corriere MA, Guzman RJ. True and false aneurysms of the femoral artery. *Semin Vasc Surg*. 2005;18:216-223.
27. Hands LJ, Collin J. Infra-inguinal aneurysms: outcome for patient and limb. *Br J Surg*. 1991;78:996-998.
28. Hessel SJ, Adams DF, Abrams HL. Complications of angiography. *Radiology*. 1981;138:273-281.
29. Kresowik TF, Khoury MD, Miller BV, et al. A prospective study of the incidence and natural history of femoral vascular complications after percutaneous transluminal coronary angioplasty. *J Vasc Surg*. 1991;13:328-333; discussion 333-335.
30. Lumsden AB, Miller JM, Kosinski AS, et al. A prospective evaluation of surgically treated groin complications following percutaneous cardiac procedures. *Am Surg*. 1994;60:132-137.
31. Katzenschlager R, Ugurluoglu A, Ahmadi A, et al. Incidence of pseudoaneurysm after diagnostic and therapeutic angiography. *Radiology*. 1995;195:463-466.
32. McCann RL, Schwartz LB, Pieper KS. Vascular complications of cardiac catheterization. *J Vasc Surg*. 1991;14:375-381.
33. Morgan R, Belli AM. Current treatment methods for postcatheterization pseudoaneurysms. *J Vasc Interv Radiol*.

2003;14:697-710.

34. Rivers SP, Lee ES, Lyon RT, et al. Successful conservative management of iatrogenic femoral arterial trauma. *Ann Vasc Surg.* 1992;6:45-49.
35. Toursarkissian B, Allen BT, Petrincec D, et al. Spontaneous closure of selected iatrogenic pseudoaneurysms and arteriovenous fistulae. *J Vasc Surg.* 1997;25:803-808; discussion 808-809.
36. Kent KC, McArdle CR, Kennedy B, et al. A prospective study of the clinical outcome of femoral pseudoaneurysms and arteriovenous fistulas induced by arterial puncture. *J Vasc Surg.* 1993;17:125-131; discussion 131-133.
37. Coughlin BF, Paushter DM. Peripheral pseudoaneurysms: evaluation with duplex US. *Radiology.* 1988;168:339-342.
38. Imsand D, Hayoz D. Current treatment options of femoral pseudoaneurysms. *Vasa.* 2007;36:91-95.
39. Fellmeth BD, Roberts AC, Bookstein JJ, et al. Postangiographic femoral artery injuries: nonsurgical repair with US-guided compression. *Radiology.* 1991;178:671-675.
40. Coley BD, Roberts AC, Fellmeth BD, et al. Postangiographic femoral artery pseudoaneurysms: further experience with US-guided compression repair. *Radiology.* 1995;194:307-311.
41. Eisenberg L, Paulson EK, Kliewer MA, et al. Sonographically guided compression repair of pseudoaneurysms: further experience from a single institution. *AJR Am J Roentgenol.* 1999;173:1567-1573.
42. Gorge G, Kunz T, Kirstein M. A prospective study on ultrasound-guided compression therapy or thrombin injection for treatment of iatrogenic false aneurysms in patients receiving full-dose anti-platelet therapy. *Z Kardiol.* 2003;92:564-570.
43. Knight CG, Healy DA, Thomas RL. Femoral artery pseudoaneurysms: risk factors, prevalence, and treatment options. *Ann Vasc Surg.* 2003;17:503-508.
44. Hye RJ. Compression therapy for acute iatrogenic femoral pseudoaneurysms. *Semin Vasc Surg.* 2000;13:58-61.
45. Chatterjee T, Do DD, Mahler F, Meier B. Pseudoaneurysm of femoral artery after catheterisation: treatment by a mechanical compression device guided by colour Doppler ultrasound. *Heart.* 1998;79:502-504.
46. Cope C, Zeit R. Coagulation of aneurysms by direct percutaneous thrombin injection. *AJR Am J Roentgenol.* 1986;147:383-387.
47. Kang SS, Labropoulos N, Mansour MA, Baker WH. Percutaneous ultrasound guided thrombin injection: a new method for treating postcatheterization femoral pseudoaneurysms. *J Vasc Surg.* 1998;27:1032-1038.
48. Grewe PH, Mugge A, Germing A, et al. Occlusion of pseudoaneurysms using human or bovine thrombin using contrast-enhanced ultrasound guidance. *Am J Cardiol.* 2004;93:1540-1542.
49. Sadiq S, Ibrahim W. Thromboembolism complicating thrombin injection of femoral artery pseudoaneurysm: management with intraarterial thrombolysis. *J Vasc Interv Radiol.* 2001;12:633-636.
50. Weinmann EE, Chayen D, Kobzantzev ZV, et al. Treatment of postcatheterisation false aneurysms: ultrasound-guided compression vs ultrasound-guided thrombin injection. *Eur J Vasc Endovasc Surg.* 2002;23:68-72.
51. Khoury M, Rebecca A, Greene K, et al. Duplex scanning-guided thrombin injection for the treatment of iatrogenic pseudoaneurysms. *J Vasc Surg.* 2002;35:517-521.
52. Loose HW, Haslam PJ. The management of peripheral arterial aneurysms using percutaneous injection of fibrin adhesive. *Br J Radiol.* 1998;71:1255-1259.
53. Morrison SL, Obrand DA, Steinmetz OK, Montreuil B. Treatment of femoral artery pseudoaneurysms with percutaneous thrombin injection. *Ann Vasc Surg.* 2000;14:634-639.
54. Sheiman RG, Brophy DP. Treatment of iatrogenic femoral pseudoaneurysms with percutaneous thrombin injection: experience in 54 patients. *Radiology.* 2001;219:123-127.
55. Tisi PV, Callam MJ. Surgery versus non-surgical treatment for femoral pseudoaneurysms. *Cochrane Database Syst Rev.* 2006;1:CD004981.
56. Paulson EK, Nelson RC, Mayes CE, et al. Sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms: further experience of a single institution. *AJR Am J Roentgenol.* 2001;177:309-316.

57. Forbes TL, Millward SF. Femoral artery thrombosis after percutaneous thrombin injection of an external iliac artery pseudoaneurysm. *J Vasc Surg.* 2001;33:1093-1096.
58. Kurz DJ, Jungius KP, Luscher TF. Delayed femoral vein thrombosis after ultrasound-guided thrombin injection of a postcatheterization pseudoaneurysm. *J Vasc Interv Radiol.* 2003;14:1067-1070.
59. Pope M, Johnston KW. Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: recommendations for prevention. *J Vasc Surg.* 2000;32:190-191.
60. Roseman JM, Wyche D. True aneurysm of the profunda femoris artery. Literature review, differential diagnosis, management. *J Cardiovasc Surg (Torino).* 1987;28:701-705.
61. Van Bockel JH, Hamming JF. Lower extremity aneurysms. In: Rutherford RB, ed. *Vascular Surgery*. 5th ed. Philadelphia, PA: Elsevier Saunders; 2005:1534-1551.
62. Tait WF, Vohra RK, Carr HM, et al. True profunda femoris aneurysms: are they more dangerous than other atherosclerotic aneurysms of the femoropopliteal segment? *Ann Vasc Surg.* 1991;5:92-95.
63. Harbuzariu C, Duncan AA, Bower TC, et al. Profunda femoris artery aneurysms: association with aneurysmal disease and limb ischemia. *J Vasc Surg.* 2008;47:31-34; discussion 34-35.
64. Posner SR, Wilensky J, Dimick J, Henke PK. A true aneurysm of the profunda femoris artery: a case report and review of the English language literature. *Ann Vasc Surg.* 2004;18:740-746.
65. Taricco A. Ruptured aneurysm of profunda femoris; complications successfully treated by cross-over femoropopliteal bypass with double velour Dacron. *N Y State J Med.* 1980;80:960-962.
66. Wiest JW, Mukherjee D, Inahara T. Ruptured aneurysm of the profunda femoris artery. *J Vasc Surg.* 1986;4:406-409.
67. Williams IM, Baildam AD, Eyers P, McCollum CN. Rupture of a true profunda femoris artery aneurysm. *Br J Surg.* 1993;80:721-722.
68. Terada Y, Wanibuchi Y. [A case of ruptured aneurysm of the profunda femoris artery treated successfully by transcatheter embolization.] *Nippon Geka Gakkai Zasshi.* 1989;90:1278-1281.
69. Cantasdemir M, Kantarci F, Mihmanli I, Numan F. Embolization of profunda femoris artery branch pseudoaneurysms with ethylene vinyl alcohol copolymer (onyx). *J Vasc Interv Radiol.* 2002;13:725-728.
70. Jarrett F, Makaroun MS, Rhee RY, Bertges DJ. Superficial femoral artery aneurysms: an unusual entity? *J Vasc Surg.* 2002;36:571-574.
71. Rigdon EE, Monajjem N. Aneurysms of the superficial femoral artery: a report of two cases and review of the literature. *J Vasc Surg.* 1992;16:790-793.
72. Wolf YG, Kobzantsev Z, Zelmanovich L. Size of normal and aneurysmal popliteal arteries: a duplex ultrasound study. *J Vasc Surg.* 2006;43:488-492.
73. Dawson I, Sie RB, van Bockel JH. Atherosclerotic popliteal aneurysm. *Br J Surg.* 1997;84:293-299.
74. Huang Y, Gloviczki P, Noel AA, et al. Early complications and long-term outcome after open surgical treatment of popliteal artery aneurysms: is exclusion with saphenous vein bypass still the gold standard? *J Vasc Surg.* 2007;45:706-713; discussion 713-715.
75. Lawrence PF, Lorenzo-Rivero S, Lyon JL. The incidence of iliac, femoral, and popliteal artery aneurysms in hospitalized patients. *J Vasc Surg.* 1995;22:409-415; discussion 415-416.
76. Ebaugh JL, Matsumura JS, Morasch MD, et al. Morphometric analysis of the popliteal artery for endovascular treatment. *Vasc Endovascular Surg.* 2003;37:23-26.
77. MacSweeney ST, Skidmore C, Turner RJ, et al. Unravelling the familial tendency to aneurysmal disease: popliteal aneurysm, hypertension and fibrillin genotype. *Eur J Vasc Endovasc Surg.* 1996;12:162-166.
78. Dawson I, van Bockel JH, Brand R, Terpstra JL. Popliteal artery aneurysms. Long-term follow-up of aneurysmal disease and results of surgical treatment. *J Vasc Surg.* 1991;13:398-407.
79. Selvam A, Shetty K, James NV, et al. Giant popliteal aneurysm presenting with foot drop. *J Vasc Surg.* 2006;44:882-883.

80. Varga ZA, Locke-Edmunds JC, Baird RN. A multicenter study of popliteal aneurysms. Joint Vascular Research Group. *J Vasc Surg.* 1994;20:171-177.
81. Galland RB, Magee TR. Popliteal aneurysms: distortion and size related to symptoms. *Eur J Vasc Endovasc Surg.* 2005;30:534-538.
82. Dawson I, Sie R, van Baalen JM, van Bockel JH. Asymptomatic popliteal aneurysm: elective operation versus conservative follow-up. *Br J Surg.* 1994;81:1504-1507.
83. Rosenberg MW, Shah DM. Bilateral blue toe syndrome. A case report. *JAMA.* 1980;243:365-366.
84. Mandolino T, Canciglia A, D'Alfonso M, Mangano S. [Popliteal aneurysms: comparison of the results of elective and emergent treatment.] *Chir Ital.* 2007;59:113-116.
85. Pulli R, Dorigo W, Troisi N, et al. Surgical management of popliteal artery aneurysms: which factors affect outcomes? *J Vasc Surg.* 2006;43:481-487.
86. Ravn H, Wanhainen A, Bjorck M. Surgical technique and long-term results after popliteal artery aneurysm repair: results from 717 legs. *J Vasc Surg.* 2007;46:236-243.
87. Mahmood A, Salaman R, Sintler M, et al. Surgery of popliteal artery aneurysms: a 12-year experience. *J Vasc Surg.* 2003;37:586-593.
88. Anton GE, Hertzner NR, Beven EG, et al. Surgical management of popliteal aneurysms. Trends in presentation, treatment, and results from 1952 to 1984. *J Vasc Surg.* 1986;3:125-134.
89. Carpenter JP, Barker CF, Roberts B, et al. Popliteal artery aneurysms: current management and outcome. *J Vasc Surg.* 1994;19:65-72; discussion 73.
90. Reilly MK, Abbott WM, Darling RC. Aggressive surgical management of popliteal artery aneurysms. *Am J Surg.* 1983;145:498-502.
91. Shortell CK, DeWeese JA, Ouriel K, Green RM. Popliteal artery aneurysms: a 25-year surgical experience. *J Vasc Surg.* 1991;14:771-776; discussion 776-779.
92. Ascher E, Markevich N, Schutzer RW, et al. Small popliteal artery aneurysms: are they clinically significant? *J Vasc Surg.* 2003;37:755-760.
93. Bowyer RC, Cawthorn SJ, Walker WJ, Giddings AE. Conservative management of asymptomatic popliteal aneurysm. *Br J Surg.* 1990;77:1132-1135.
94. Galland RB, Magee TR. Management of popliteal aneurysm. *Br J Surg.* 2002;89:1382-1385.
95. Schellack J, Smith RB 3rd, Perdue GD. Nonoperative management of selected popliteal aneurysms. *Arch Surg.* 1987;122:372-375.
96. Perry MO. John Hunter—triumph and tragedy. *J Vasc Surg.* 1993;17:7-14.
97. Jones WT 3rd, Hagino RT, Chiou AC, et al. Graft patency is not the only clinical predictor of success after exclusion and bypass of popliteal artery aneurysms. *J Vasc Surg.* 2003;37:392-398.
98. Ebaugh JL, Morasch MD, Matsumura JS, et al. Fate of excluded popliteal artery aneurysms. *J Vasc Surg.* 2003;37:954-959.
99. Mehta M, Champagne B, Darling RC 3rd, et al. Outcome of popliteal artery aneurysms after exclusion and bypass: significance of residual patent branches mimicking type II endoleaks. *J Vasc Surg.* 2004;40:886-890.
100. van Santvoort HC, de Vries JP, van de Mortel R, et al. Rupture of a popliteal artery aneurysm 10 years after surgical repair. *Vascular.* 2006;14:227-230.
101. Beseth BD, Moore WS. The posterior approach for repair of popliteal artery aneurysms. *J Vasc Surg.* 2006;43:940-944; discussion 944-945.
102. Mahmood A, Hardy R, Garnham A, et al. Microtibial embolectomy. *Eur J Vasc Endovasc Surg.* 2003;25:35-39.
103. Ravn H, Bjorck M. Popliteal artery aneurysm with acute ischemia in 229 patients. Outcome after thrombolytic and surgical therapy. *Eur J Vasc Endovasc Surg.* 2007;33:690-695.
104. Thompson JF, Beard J, Scott DJ, Earnshaw JJ. Intraoperative thrombolysis in the management of thrombosed popliteal

- aneurysm. *Br J Surg*. 1993;80:858-859.
105. Ravn H, Wanhainen A, Bjorck M. Risk of new aneurysms after surgery for popliteal artery aneurysm. *Br J Surg*. 2008;95:571-575.
  106. Marty B, Wicky S, Ris HB, et al. Success of thrombolysis as a predictor of outcome in acute thrombosis of popliteal aneurysms. *J Vasc Surg*. 2002;35:487-493.
  107. Kropman RH, van Santvoort HC, Teijink J, et al. The medial versus the posterior approach in the repair of popliteal artery aneurysms: a multicenter case-matched study. *J Vasc Surg*. 2007;46:24-30.
  108. Blanco E, Serrano-Hernando FJ, Monux G, et al. Operative repair of popliteal aneurysms: effect of factors related to the bypass procedure on outcome. *Ann Vasc Surg*. 2004;18:86-92.
  109. Marin ML, Veith FJ, Panetta TF, et al. Transfemoral endoluminal stented graft repair of a popliteal artery aneurysm. *J Vasc Surg*. 1994;19:754-757.
  110. Gerasimidis T, Sfyroeras G, Papazoglou K, et al. Endovascular treatment of popliteal artery aneurysms. *Eur J Vasc Endovasc Surg*. 2003;26:506-511.
  111. Tiellu IF, Verhoeven EL, Zeebregts CJ, et al. Endovascular treatment of popliteal artery aneurysms: results of a prospective cohort study. *J Vasc Surg*. 2005;41:561-567.
  112. Curi MA, Geraghty PJ, Merino OA, et al. Mid-term outcomes of endovascular popliteal artery aneurysm repair. *J Vasc Surg*. 2007;45:505-510.
  113. Rajasinghe HA, Tzilinis A, Keller T, et al. Endovascular exclusion of popliteal artery aneurysms with expanded polytetrafluoroethylene stent-grafts: early results. *Vasc Endovascular Surg*. 2006;40:460-466.
  114. Antonello M, Frigatti P, Battocchio P, et al. Open repair versus endovascular treatment for asymptomatic popliteal artery aneurysm: results of a prospective randomized study. *J Vasc Surg*. 2005;42:185-193.
  115. Lee WA, Brown MP, Nelson PR, Huber TS. Total percutaneous access for endovascular aortic aneurysm repair ("Preclose" technique). *J Vasc Surg*. 2007;45:1095-1101.
  116. Lovegrove RE, Javid M, Magee TR, Galland RB. Endovascular and open approaches to non-thrombosed popliteal aneurysm repair: a meta-analysis. *Eur J Vasc Endovasc Surg*. 2008;36:96-100.
  117. Edwards H, Martin E, Nowygrod R. Nonoperative management of a traumatic peroneal artery false aneurysm. *J Trauma*. 1982;22:323-326.
  118. Paul MA, Patka P, van Heuzen EP, et al. Vascular injury from external fixation: case reports. *J Trauma*. 1992;33:917-920.
  119. Cronenwett JL, Walsh DB, Garrett HE. Tibial artery pseudoaneurysms: delayed complication of balloon catheter embolectomy. *J Vasc Surg*. 1988;8:483-488.
  120. Neary WD, Tottle AJ, Earnshaw JJ. False aneurysm of the posterior tibial artery after femoral embolectomy. *Eur J Vasc Endovasc Surg*. 2002;23:460-461.
  121. Rowe P, Taylor P, Franklin A, et al. Unusual causes of calf swelling—1. Unusual presentation of a tibial artery false aneurysm. *Postgrad Med J*. 1987;63:649-652.

## 第 137 章

1. Dent TL, Lindenauer SM, Ernst CB, Fry WJ. Multiple arteriosclerotic arterial aneurysms. *Arch Surg*. 1972;105:338.
2. Greenough J. Operations of the innominate artery: report of a successful ligation. *Arch Surg*. 1929;19:1484.
3. Bjork VO. Aneurysm and occlusion of the right subclavian artery. *Acta Chir Scand Suppl*. 1965;356:103.
4. Halsted WS. Ligation of the first portion of the left subclavian artery and excision of a subclavio-axillary aneurysm. *Johns Hopkins Hosp Bull*. 1892;24:93.
5. Muller GP. Subclavian aneurysm with report of a case. *Ann Surg*. 1935;101:568.
6. Pairolero PC, Walls JT, Payne WS, et al. Subclavian-axillary artery aneurysms. *Surgery*. 1981;90:757.
7. McCollum CH, Da Gama AD, Noon GP, DeBakey ME. Aneurysm of the subclavian artery. *J Cardiovasc Surg (Torino)*.

1979;20:159.

8. Fry WR, Clagett GC, O'Rourke PT. Ultrasound-guided central venous access. *Arch Surg*. 1999;134:738.
9. Wolfe TJ, Smith TP, Alexander MJ, Zaidat OO. Endovascular treatment of inadvertent cannulation of the vertebro-subclavian arterial junction. *Neurocrit Care*. 2007;6:113.
10. Shetty SV, Kwolek CJ, Garasic JM. Percutaneous closure after inadvertent subclavian artery cannulation. *Catheter Cardiovasc Interv*. 2007;69:1050.
11. Fraizer MC, Chu WW, Gudjonsson T, Wolff MR. Use of a percutaneous vascular suture device for closure of an inadvertent subclavian artery puncture. *Catheter Cardiovasc Interv*. 2003;59:369.
12. Kieffer E, Chiche L, Koskas F, Bahnini A. Aneurysms of the innominate artery: surgical treatment of 27 patients. *J Vasc Surg*. 2001;34:222.
13. Bower TC, Pairolero PC, Hallett JW Jr, et al. Brachiocephalic aneurysm: the case for early recognition and repair. *Ann Vasc Surg*. 1991;5:125.
14. El-Sabrou R, Cooley DA. Extracranial carotid artery aneurysms: Texas Heart Institute experience. *J Vasc Surg*. 2000;31:702.
15. Hertzner NR. Extracranial carotid aneurysms: a new look at an old problem. *J Vasc Surg*. 2000;31:823.
16. Longo GM, Kibbe MR. Aneurysms of the carotid artery. *Semin Vasc Surg*. 2005;18:178.
17. Tabata M, Kitagawa T, Saito T, et al. Extracranial carotid aneurysm in Takayasu's arteritis. *J Vasc Surg*. 2001;34:739.
18. Cil BE, Ucar I, Ozsoy F, et al. Successful endovascular treatment of a left common carotid artery aneurysm following failed surgery of a right common carotid artery aneurysm. *Cardiovasc Intervent Radiol*. 2005;28:367.
19. Temple LJ. Aneurysm of the first part of the left subclavian artery; review of the literature and a case history. *J Thorac Surg*. 1950;19:412.
20. Elefteriades JA, Kay HA, Stansel HC Jr, Geha AS. Extraanatomical reconstruction for bilateral intrathoracic subclavian artery aneurysms. *Ann Thorac Surg*. 1983;35:188.
21. Criado E, Marston WA, Ligush J, et al. Endovascular repair of peripheral aneurysms, pseudoaneurysms, and arteriovenous fistulas. *Ann Vasc Surg*. 1997;11:256.
22. May J, White G, Waugh R, et al. Transluminal placement of a prosthetic graft-stent device for treatment of subclavian artery aneurysm. *J Vasc Surg*. 1993;18:1056.
23. Davidian M, Kee ST, Kato N, et al. Aneurysm of an aberrant right subclavian artery: treatment with PTFE covered stentgraft. *J Vasc Surg*. 1998;28:335.
24. Szeimies U, Kueffer G, Stoeckelhuber B, Steckmeier B. Successful exclusion of subclavian aneurysms with covered nitinol stents. *Cardiovasc Intervent Radiol*. 1998;21:246.
25. Hilfiker PR, Razavi MK, Kee ST, et al. Stent-graft therapy for subclavian artery aneurysms and fistulas: single-center mid-term results. *J Vasc Interv Radiol*. 2000;11:578.
26. Chambers CM, Curci JA. Treatment of nonaortic aneurysms in the endograft era: aneurysms of the innominate and subclavian arteries. *Semin Vasc Surg*. 2005;18:184.
27. Becker GJ, Benenati JF, Zemel G, et al. Percutaneous placement of a balloon-expandable intraluminal graft for life-threatening subclavian arterial hemorrhage. *J Vasc Interv Radiol*. 1991;2:225.
28. Marston WA, Criado E, Mauro MA, Keagy BA. Transbrachial endovascular exclusion of an axillary artery pseudoaneurysm with PTFE-covered stents. *J Endovasc Surg*. 1995;2:172.
29. Marin ML, Veith FJ, Cynamon J, et al. Initial experience with transluminally placed endovascular grafts for the treatment of complex vascular lesions. *Ann Surg*. 1995;222:449.
30. Patel AV, Marin ML, Veith FJ, et al. Endovascular graft repair of penetrating subclavian artery injuries. *J Endovasc Surg*. 1996;3:382.
31. Ohki T, Veith FJ, Kraas C, et al. Endovascular therapy for upper extremity injury. *Semin Vasc Surg*. 1998;11:106.

32. Schoder M, Cejna M, Holzenbein T, et al. Elective and emergent endovascular treatment of subclavian artery aneurysms and injuries. *J Endovasc Ther.* 2003;10:58.
33. Kasirajan K, Matteson B, Marek JM, Langsfeld M. Covered stents for true subclavian aneurysms in patients with degenerative connective tissue disorders. *J Endovasc Ther.* 2003;10:647.
34. Mathur A, Dorros G, Iyer SS, et al. Palmaz stent compression in patients following carotid artery stenting. *Cathet Cardiovasc Diagn.* 1997;41:137.
35. Rosenfield K, Schainfeld R, Pieczek A, et al. Restenosis of endovascular stents from stent compression. *J Am Coll Cardiol.* 1997;29:328.
36. Bush RL, Lin PH, Najibi S, et al. Coil embolization combined with carotid-subclavian bypass for treatment of subclavian artery aneurysm. *J Endovasc Ther.* 2002;9:308.
37. Bergeron P, Mangialardi N, Costa P, et al. Great vessel management for endovascular exclusion of aortic arch aneurysms and dissections. *Eur J Vasc Endovasc Surg.* 2006;32:38.
38. du Toit DF, Strauss DC, Blaszczyk M, et al. Endovascular treatment of penetrating thoracic outlet arterial injuries. *Eur J Vasc Endovasc Surg.* 2000;19:489.
39. Austin EH, Wolfe WG. Aneurysm of aberrant subclavian artery with a review of the literature. *J Vasc Surg.* 1985;2:571.
40. Valentine RJ, Carter DJ, Clagett GP. A modified extrathoracic approach to the treatment of dysphagia lusoria. *J Vasc Surg.* 1987;5:498.
41. Simon RW, Lachat M, Pfammatter T, Mann-Vesti BR. Giant aneurysm of an aberrant right subclavian artery from the left aortic arch. *J Thorac Cardiovasc Surg.* 2006;132:1478.
42. McCallen AM, Schaff B. Aneurysm of an anomalous right subclavian artery. *Radiology.* 1956;66:561.
43. Kieffer E, Bahnini A, Koskas F. Aberrant subclavian artery: surgical treatment in thirty-three adult patients. *J Vasc Surg.* 1994;19:100.
44. Cina CS, Althani H, Pasenau J, Abouzahr L. Kommerell's diverticulum and right-sided aortic arch: a cohort study and review of the literature. *J Vasc Surg.* 2004;39:131.
45. Kopp R, Wizgall I, Kreuzer E, et al. Surgical and endovascular treatment of symptomatic aberrant right subclavian artery (arteria lusoria). *Vascular.* 2007;15:84.
46. Hunter JA, Dye WS, Javid H, et al. Arteriosclerotic aneurysm of anomalous right subclavian artery. *J Thorac Cardiovasc Surg.* 1970;59:754.
47. Campbell CF. Repair of an aneurysm of an aberrant retroesophageal right subclavian artery arising from Kommerell's diverticulum. *J Thorac Cardiovasc Surg.* 1971;62:330.
48. Stoney WS, Alford WC, Burrus GR, Thomas CS Jr. Aberrant right subclavian artery aneurysm. *Ann Thorac Surg.* 1975;19:460.
49. Shennib H, Diethrich EB. Novel approaches for the treatment of the aberrant right subclavian artery and its aneurysms. *J Vasc Surg.* 2008;47:1066.
50. Munneke GJ, Loosemore TM, Belli AM, et al. Aneurysm of an aberrant right subclavian artery successfully excluded by a thoracic aortic stent graft with supra-aortic bypass of three arch vessels. *Cardiovasc Intervent Radiol.* 2005;28:653.
51. Corral JS, Zuniga CG, Sanchez JB, et al. Treatment of aberrant right subclavian artery aneurysm with endovascular exclusion and adjunctive surgical bypass. *J Vasc Interv Radiol.* 2003;14:789.
52. Waltham M, Agrawal V, Bowman L, et al. Right arm ischemia following intentional stent-graft coverage of an anomalous right subclavian artery. *J Endovasc Ther.* 2005;12:110.
53. Lacroix V, Astarci P, Philippe D, et al. Endovascular treatment of an aneurysmal aberrant right subclavian artery. *J Endovasc Ther.* 2003;10:190.
54. Weinberger G, Randall PA, Parker FB, Kieffer SA. Involvement of an aberrant right subclavian artery in dissection of the thoracic aorta: diagnostic and therapeutic implications. *AJR Am J Roentgenol.* 1977;129:653.

55. Attmann T, Brandt M, Muller-Hulsbeck S, Cremer J. Two-stage surgical and endovascular treatment of an aneurysmal aberrant right subclavian (Lusoria) artery. *Eur J Cardiothorac Surg*. 2005;27:1125.
56. Li QL, Zhang XM, Zhang XM. Aortic dissection originating from an aberrant right subclavian artery. *J Vasc Surg*. 2007;46:1270.
57. Hoppe H, Hohenwarter EJ, Kaufman JA, Petersen B. Percutaneous treatment of aberrant right subclavian artery aneurysm with use of the Amplatzer septal occluder. *J Vasc Interv Radiol*. 2006;17:889.
58. Ho PK, Weiland AJ, McClinton MA, Wilgis EF. Aneurysms of the upper extremity. *J Hand Surg [Am]*. 1987;12:39.
59. Applebaum RE, Caniano DA, Sun CC, et al. Synchronous left subclavian and axillary artery aneurysms associated with melorheostosis. *Surgery*. 1986;99:249.
60. Perry SP, Massey CW. Bilateral aneurysms of the subclavian and axillary arteries; report of a case. *Radiology*. 1953;61:53.
61. Todd GJ, Benvenisty AI, Hershon S, Bigliani LU. Aneurysms of the mid axillary artery in major league baseball pitchers—a report of two cases. *J Vasc Surg*. 1998;28:702.
62. Baumgarten KM, Dines JS, Winchester PA, et al. Axillary artery aneurysm with distal embolization in a major league baseball pitcher. *Am J Sports Med*. 2007;35:650.
63. Gallen J, Wiss DA, Cantelmo N, Menzoin JO. Traumatic pseudoaneurysm of the axillary artery: report of three cases and literature review. *J Trauma*. 1984;24:350.
64. Majeed L. Pulsatile haemarthrosis of the shoulder joint associated with false aneurysm of the axillary artery as a late complication of anterior dislocation of the shoulder. *Injury*. 1985;16:566.
65. Rob CG, Standeven A. Closed traumatic lesions of the axillary and brachial arteries. *Lancet*. 1956;270:597.
66. Brooks AL, Fowler SB. Axillary artery thrombosis after prolonged use of crutches. *J Bone Joint Surg Am*. 1964;46:863.
67. Abbott WM, Darling RC. Axillary artery aneurysms secondary to crutch trauma. *Am J Surg*. 1973;125:515.
68. McCarthy WJ, Flinn WR, Yao JS, et al. Result of bypass grafting for upper limb ischemia. *J Vasc Surg*. 1986;3:741.
69. Tetik O, Yilik L, Besir Y, et al. Surgical treatment of axillary artery aneurysm. *Tex Heart Inst J*. 2005;32:186.
70. Sullivan TM, Bacharach JM, Perl J, Gray B. Endovascular management of unusual aneurysms of the axillary and subclavian arteries. *J Endovasc Surg*. 1996;3:389.
71. Stahnke M, Duddy MJ. Endovascular repair of a traumatic axillary pseudoaneurysm following anterior shoulder dislocation. *Cardiovasc Intervent Radiol*. 2006;29:298.
72. Gray RJ, Stone WM, Fowl RJ, et al. Management of true aneurysms distal to the axillary artery. *J Vasc Surg*. 1998;28:606.
73. Matas R. An operation for the radical cure of aneurysm based on arteriorrhaphy. *Ann Surg*. 1903;37:161.
74. Leon LR, Psalms SB, Labropoulos N, Mills JL. Infected upper extremity aneurysms: a review. *Eur J Vasc Endovasc Surg*. 2008;35:320.
75. Barabas AP. Vascular complications in the Ehlers-Danlos syndrome, with special reference to the “arterial type” or Sack’s syndrome. *J Cardiovasc Surg (Torino)*. 1972;13:160.
76. Short DW. Multiple congenital aneurysms in childhood: report of a case. *Br J Surg*. 1978;65:509.
77. Nitsure MY, Hiremath MS, Grant PK, et al. Kawasaki syndrome with multiple arterial aneurysms. *Indian Pediatr*. 1988;25:881.
78. Giler S, Zelikovski A, Goren G, Urca I. Aneurysm of the radial artery in a patient with Buerger’s disease. *Vasa*. 1979;8:147.
79. Baxt S, Mori K, Hoffman S. Aneurysm of the hand secondary to Kaposi’s sarcoma. Case report. *J Bone Joint Surg Am*. 1975;57:995.
80. Absoud EM. Recurrent cystic adventitial disease of the radial artery. *Angiology*. 1984;35:257.
81. Fox CJ, Gillespie DL, O’Donnell SD, et al. Contemporary management of wartime vascular trauma. *J Vasc Surg*. 2005;41:638.
82. Buda SJ, Johanning JM. Brachial, radial, and ulnar arteries in the endovascular era: choice of intervention. *Semin Vasc Surg*. 2005;18:191.



83. Babu SC, Piccorelli GO, Shah PM, et al. Incidence and results of arterial complications among 16,350 patients undergoing cardiac catheterization. *J Vasc Surg.* 1989;10:113.
84. Armstrong PJ, Han DC, Baxter JA, et al. Complication rates of percutaneous brachial artery access in peripheral vascular angiography. *Ann Vasc Surg.* 2003;17:107.
85. Chatzioannou A, Ladopoulos C, Mourikis D, et al. Complications of lower-extremity outpatient arteriography via low brachial artery. *Cardiovasc Intervent Radiol.* 2004;27:31.
86. Fransson SG, Nylander E. Vascular injury following cardiac catheterization, coronary angiography, and coronary angioplasty. *Eur Heart J.* 1994;15:232.
87. Barnett FJ, Lecky DM, Freiman DB, Montecalvo RM. Cerebrovascular disease: outpatient evaluation with selective carotid DSA performed via a transbrachial approach. *Radiology.* 1989;170:535.
88. Krueger K, Zaehring M, Strohe D, et al. Postcatheterization pseudoaneurysm: results of US-guided percutaneous thrombin injection in 240 patients. *Radiology.* 2005;236:1104.
89. Sheiman RG, Brophy DP, Perry LJ, Akbari C. Thrombin injection for the repair of brachial artery pseudoaneurysms. *AJR Am J Roentgenol.* 1999;173:1029.

## 第 138 章

1. Wagner WH, Allins AD, Treiman RL, et al. Ruptured visceral artery aneurysms. *Ann Vasc Surg.* 1997;11:342-347.
2. Beaussier M. Sur un aneurisme de l'artère splénique: dont les parois se sont ossifiées. *J Med Clin Pharm.* 1770;32:157.
3. DeBakey ME, Cooley DA. Successful resection of mycotic aneurysm of superior mesenteric artery; case report and review of literature. *Am Surg.* 1953;19:202-212.
4. Parfitt J, Chalmers RT, Wolfe JH. Visceral aneurysms in Ehlers-Danlos syndrome: case report and review of the literature. *J Vasc Surg.* 2000;31:1248-1251.
5. Saltzberg SS, Maldonado TS, Lamparello PJ, et al. Is endovascular therapy the preferred treatment for all visceral artery aneurysms? *Ann Vasc Surg.* 2005;19:507-515.
6. Tessier DJ, Abbas MA, Fowl RJ, et al. Management of rare mesenteric arterial branch aneurysms. *Ann Vasc Surg.* 2002;16:586-590.
7. Messina LM, Shanley CJ. Visceral artery aneurysms. *Surg Clin North Am.* 1997;77:425-442.
8. Nosher JL, Chung J, Brevetti LS, et al. Visceral and renal artery aneurysms: a pictorial essay on endovascular therapy. *Radiographics.* 2006;26:1687-1704; quiz 1687.
9. Shanley CJ, Shah NL, Messina LM. Uncommon splanchnic artery aneurysms: pancreaticoduodenal, gastroduodenal, superior mesenteric, inferior mesenteric, and colic. *Ann Vasc Surg.* 1996;10:506-515.
10. Carr SC, Mahvi DM, Hoch JR, et al. Visceral artery aneurysm rupture. *J Vasc Surg.* 2001;33:806-811.
11. Welling TH, Williams DM, Stanley JC. Excessive oral amphetamine use as a possible cause of renal and splanchnic arterial aneurysms: a report of two cases. *J Vasc Surg.* 1998;28:727-731.
12. Funahashi S, Yukizane T, Yano K, et al. An aneurysm of the right gastroepiploic artery. *J Cardiovasc Surg (Torino)* 1997;38:385-388.
13. De Angelis M, Vogel C, Horowitz B, et al. Ruptured gastroepiploic aneurysm. *J Clin Gastroenterol.* 1994;18:261-262.
14. Walter M, Opitz I, Lohr G. Symptomatic aneurysm of the right gastroepiploic artery. Case report and review of the literature. *Chirurg.* 2001;72:437-440.
15. Dave SP, Reis ED, Hossain A, et al. Splenic artery aneurysm in the 1990s. *Ann Vasc Surg.* 2000;14:223-229.
16. Sadat U, Noor N, Tang T, Varty K. Emergency endovascular repair of ruptured visceral artery aneurysms. *World J Emerg Surg.* 2007;2:17.
17. Hassen-Khodja R, Declémy S, Batt M, et al. Visceral artery aneurysms in von Recklinghausen's neurofibromatosis. *J Vasc Surg.* 1997;25:572-575.

18. Stanley JC, Wakefield TW, Graham LM, et al. Clinical importance and management of splanchnic artery aneurysms. *J Vasc Surg.* 1986;3:836-840.
19. Sellke FW, Williams GB, Donovan DL, Clarke RE. Management of intra-abdominal aneurysms associated with periarteritis nodosa. *J Vasc Surg.* 1986;4:294-298.
20. Mogle P, Halperin Y, Kobrin I, Ilisar M. Rapid regression of aneurysms in polyarteritis nodosa. *Br J Radiol.* 1982;55:536-538.
21. Freeman RK, Swegle J, Sise MJ. The surgical complications of Ehlers-Danlos syndrome. *Am Surg.* 1996;62:869-873.
22. Matsumoto K, Ohgami M, Shirasugi N, et al. A first case report of the successful laparoscopic repair of a splenic artery aneurysm. *Surgery.* 1997;121:462-464.
23. Arca MJ, Gagner M, Heniford BT, et al. Splenic artery aneurysms: methods of laparoscopic repair. *J Vasc Surg.* 1999;30:184-188.
24. McDermott VG, Shlansky-Goldberg R, Cope C. Endovascular management of splenic artery aneurysms and pseudoaneurysms. *Cardiovasc Intervent Radiol.* 1994;17:179-184.
25. Baggio E, Migliara B, Lipari G, Landoni L. Treatment of six hepatic artery aneurysms. *Ann Vasc Surg.* 2004;18:93-99.
26. Bratby MJ, Lehmann ED, Bottomley J, et al. Endovascular embolization of visceral artery aneurysms with ethylene-vinyl alcohol (Onyx): a case series. *Cardiovasc Intervent Radiol.* 2006;29:1125-1128.
27. Saad NE, Saad WE, Davies MG, et al. Pseudoaneurysms and the role of minimally invasive techniques in their management. *Radiographics.* 2005;25(Suppl 1):S173-S189.
28. Lagana D, Carrafiello G, Mangini M, et al. Multimodal approach to endovascular treatment of visceral artery aneurysms and pseudoaneurysms. *Eur J Radiol.* 2006;59:104-111.
29. Jenssen GL, Wirsching J, Pedersen G, et al. Treatment of a hepatic artery aneurysm by endovascular stent-grafting. *Cardiovasc Intervent Radiol.* 2007;30:523-525.
30. Drescher R, Köster O, von Rothenburg T. Superior mesenteric artery aneurysm stent graft. *Abdom Imaging.* 2006;31:113-116.
31. Rossi M, Rebonato A, Greco L, et al. Endovascular exclusion of visceral artery aneurysms with stent-grafts: technique and long-term follow-up. *Cardiovasc Intervent Radiol.* 2008;31:36-42.
32. Karaman K, Onat L, Sirvanci M, Olga R. Endovascular stent graft treatment in a patient with splenic artery aneurysm. *Diagn Interv Radiol.* 2005;11:119-121.
33. Tsai HY, Yang TL, Wann SR, et al. Successful angiographic stent-graft treatment for spontaneously dissecting broad-base pseudoaneurysm of the superior mesenteric artery. *J Chin Med Assoc.* 2005;68:397-400.
34. Moore SW, Guida PM, Schumacher HW. Splenic artery aneurysm. *Bull Soc Int Chir.* 1970;29:210-218.
35. Bedford PD, Lodge B. Aneurysm of the splenic artery. *Gut.* 1960;1:312-320.
36. Stanley JC, Fry WJ. Pathogenesis and clinical significance of splenic artery aneurysms. *Surgery.* 1974;76:898-909.
37. Pescarus R, Montreuil B, Bendavid Y. Giant splenic artery aneurysms: case report and review of the literature. *J Vasc Surg.* 2005;42:344-347.
38. Lee PC, Rhee RY, Gordon RY, et al. Management of splenic artery aneurysms: the significance of portal and essential hypertension. *J Am Coll Surg.* 1999;189:483-490.
39. Trastek VF, Pairolero PC, Joyce JW, et al. Splenic artery aneurysms. *Surgery.* 1982;91:694-699.
40. Busuttil RW, Brin BJ. The diagnosis and management of visceral artery aneurysms. *Surgery.* 1980;88:619-624.
41. Pomerantz RA, Eckhauser FE, Strodel WE, et al. Splenic aneurysm rupture in cirrhotic patients. *Arch Surg.* 1986;121:1095-1096.
42. Ayalon A, Wiesner RH, Perkins JD, et al. Splenic artery aneurysms in liver transplant patients. *Transplantation.* 1988;45:386-389.
43. Tazawa K, Shimoda M, Nagata T, et al. Splenic artery aneurysm associated with systemic lupus erythematosus: report of a

case. *Surg Today*. 1999;29:76-79.

44. Sidhu PS, Khaw KT, Belli AM. Anomalous splenic artery aneurysm: demonstration on CT scanning and angiography. *Postgrad Med J*. 1995;71:49-51.
45. Tochii M, Ogino H, Sasaki H, et al. Successful surgical treatment for aneurysm of splenic artery with anomalous origin. *Ann Thorac Cardiovasc Surg*. 2005;11:346-349.
46. Tessier DJ, Fowl RJ, Stone WM, et al. Iatrogenic hepatic artery pseudoaneurysms: an uncommon complication after hepatic, biliary, and pancreatic procedures. *Ann Vasc Surg*. 2003;17:663-669.
47. Hallett JW Jr. Splenic artery aneurysms. *Semin Vasc Surg*. 1995;8:321-326.
48. Mattar SG, Lumsden AB. The management of splenic artery aneurysms: experience with 23 cases. *Am J Surg*. 1995;169:580-584.
49. de Vries JE, Schattenkerk ME, Malt RA. Complications of splenic artery aneurysm other than intraperitoneal rupture. *Surgery*. 1982;91:200-204.
50. Lambert CJ, Jr, Williamson JW. Splenic artery aneurysm. A rare cause of upper gastrointestinal bleeding. *Am Surg*. 1990;56:543-545.
51. Sendra F, Safran DB, McGee G. A rare complication of splenic artery aneurysm. Mesenteric steal syndrome. *Arch Surg*. 1995;130:669-672.
52. Rao S, Sivina M, Willis I, et al. Massive lower gastrointestinal tract bleeding due to splenic artery aneurysm: a case report. *Ann Vasc Surg*. 2007;21:388-391.
53. Sandblom P. Gastrointestinal hemorrhage through the pancreatic duct. *Ann Surg*. 1970;171:61-66.
54. Holdsworth RJ, Gunn A. Ruptured splenic artery aneurysm in pregnancy. A review. *Br J Obstet Gynaecol*. 1992;99:595-597.
55. Barrett JM, Van Hooydonk JE, Boehm FH. Pregnancy-related rupture of arterial aneurysms. *Obstet Gynecol Surv*. 1982;37:557-566.
56. Abbas MA, Stone WM, Fowl RJ, et al. Splenic artery aneurysms: two decades experience at Mayo Clinic. *Ann Vasc Surg*. 2002;16:442-449.
57. Mastracci TM, Cadeddu M, Colopinto RF, Cina C. A minimally invasive approach to the treatment of aberrant splenic artery aneurysms: a report of two cases. *J Vasc Surg*. 2005;41:1053-1057.
58. Huang IH, Zuckerman DA, Matthews JB. Occlusion of a giant splenic artery pseudoaneurysm with percutaneous thrombin-collagen injection. *J Vasc Surg*. 2004;40:574-577.
59. Carroccio A, Jacobs TS, Faries P, et al. Endovascular treatment of visceral artery aneurysms. *Vasc Endovasc Surg*. 2007;41:373-382.
60. Tulsyan N, Kashyap VS, Greenberg RK, et al. The endovascular management of visceral artery aneurysms and pseudoaneurysms. *J Vasc Surg*. 2007;45:276-283; discussion 283.
61. Sachdev U, Baril DT, Ellozy SH, et al. Management of aneurysms involving branches of the celiac and superior mesenteric arteries: a comparison of surgical and endovascular therapy. *J Vasc Surg*. 2006;44:718-724.
62. Berceli SA. Hepatic and splenic artery aneurysms. *Semin Vasc Surg*. 2005;18:196-201.
63. Kibbler CC, Cohen DL, Cruickshank JK, et al. Use of CAT scanning in the diagnosis and management of hepatic artery aneurysm. *Gut*. 1985;26:752-756.
64. Arneson MA, Smith RS. Ruptured hepatic artery aneurysm: case report and review of literature. *Ann Vasc Surg*. 2005;19:540-545.
65. Hiramoto JS, Messina LM. Visceral artery aneurysms. *Curr Treat Options Cardiovasc Med*. 2005;7:109-117.
66. Luebke T, Heckenkamp J, Gawenda M, et al. Combined endovascular-open surgical procedure in a great hepatic artery aneurysm. *Ann Vasc Surg*. 2007;21:807-812.
67. Abbas MA, Fowl RJ, Stone WM, et al. Hepatic artery aneurysm: factors that predict complications. *J Vasc Surg*.

2003;38:41-45.

68. Zachary K, Geier S, Pellecchia C, Irwin G. Jaundice secondary to hepatic artery aneurysm: radiological appearance and clinical features. *Am J Gastroenterol.* 1986;81:295-298.
69. Harlaftis NN, Akin JT. Hemobilia from ruptured hepatic artery aneurysm. Report of a case and review of the literature. *Am J Surg.* 1977;133:229-232.
70. O'Driscoll D, Olliff SP, Olliff JF. Hepatic artery aneurysm. *Br J Radiol.* 1999;72:1018-1025.
71. Haimovici H, Sprayregen S, Eckstein P, Veith FJ. Celiac artery aneurysmectomy: case report with review of the literature. *Surgery.* 1976;79:592-596.
72. Graham LM, Stanley JC, Whitehouse WM, Jr, et al. Celiac artery aneurysms: historic (1745-1949) versus contemporary (1950-1984) differences in etiology and clinical importance. *J Vasc Surg.* 1985;2:757-764.
73. Hossain A, Reis ED, Dave SP, et al. Visceral artery aneurysms: experience in a tertiary-care center. *Am Surg.* 2001;67:432-437.
74. Carmeci C, McClenathan J. Visceral artery aneurysms as seen in a community hospital. *Am J Surg.* 2000;179:486-489.
75. Stone WM, Abbas MA, Gloviczki P, et al. Celiac arterial aneurysms: a critical reappraisal of a rare entity. *Arch Surg.* 2002;137:670-674.
76. Deterling RA, Jr. Aneurysm of the visceral arteries. *J Cardiovasc Surg (Torino)* 1971;12:309-322.
77. Woolard JD, Ammar AD. Spontaneous dissection of the celiac artery: a case report. *J Vasc Surg.* 2007;45:1256-1258.
78. Ailawadi G, Cowles RA, Stanley JC, et al. Common celiacomesenteric trunk: aneurysmal and occlusive disease. *J Vasc Surg.* 2004;40:1040-1043.
79. Kalra M, Panneton JM, Hofer JM, Andrews JC. Aneurysm and stenosis of the celiomesenteric trunk: a rare anomaly. *J Vasc Surg.* 2003;37:679-682.
80. McIntyre TP, Simone ST, Stahlfeld KR. Intraoperative thrombin occlusion of a visceral artery aneurysm. *J Vasc Surg.* 2002;36:393-395.
81. Miller DW, Jr, Royster TS. Celiac artery aneurysm: rationale for celiac axis ligation with excisional treatment. *Vasc Surg.* 1971;5:42-47.
82. Risher WH, Hollier LH, Bolton JS, Ochsner JL. Celiac artery aneurysm. *Ann Vasc Surg.* 1991;5:392-395.
83. Stone WM, Abbas M, Cherry KJ, et al. Superior mesenteric artery aneurysms: is presence an indication for intervention? *J Vasc Surg.* 2002;36:234-237; discussion 237.
84. D'Ayala M, Deitch JS, deGraft-Johnson J, et al. Giant celiac artery aneurysm with associated visceral occlusive disease. *Vascular.* 2004;12:390-393.
85. Rodrigus IE, Berry MC, Gdeedo A, et al. Surgical management of concurrent, coeliac and bilateral iliac artery aneurysms. *Cardiovasc Surg.* 1995;3:501-503.
86. Glickerman DJ, Hathaway PB, Hatsukami T, et al. Transluminal treatment of a celiac artery pseudoaneurysm with a stent graft occlusion device. *Cardiovasc Intervent Radiol.* 1997;20:466-469.
87. Matsukura I, Iwai T, Inoue Y. Celiac artery aneurysm: report of two surgical cases. *Surg Today.* 1999;29:948-952.
88. Atkins BZ, Ryan JM, Gray JL. Treatment of a celiac artery aneurysm with endovascular stent grafting—a case report. *Vasc Endovasc Surg.* 2003;37:367-373.
89. Waldenberger P, Bendix N, Petersen J, et al. Clinical outcome of endovascular therapeutic occlusion of the celiac artery. *J Vasc Surg.* 2007;46:655-661.
90. Dinter DJ, Rexin M, Kaehler G, Neff W. Fatal coil migration into the stomach 10 years after endovascular celiac aneurysm repair. *J Vasc Interv Radiol.* 2007;18:117-120.
91. Lorelli DR, Cambria RA, Seabrook GR, Towne JB. Diagnosis and management of aneurysms involving the superior mesenteric artery and its branches—a report of four cases. *Vasc Endovasc Surg.* 2003;37:59-66.
92. Komori K, Mori E, Yamaoka T, et al. Successful resection of superior mesenteric artery aneurysm. A case report and

review of the literature. *J Cardiovasc Surg (Torino)* 2000;41:475-478.

93. Lindberg CG, Stridbeck H. Aneurysms of the superior mesenteric artery and its branches. *Gastrointest Radiol.* 1992;17:132-134.
94. Brown SL, Busuttill RW, Baker JD, et al. Bacteriologic and surgical determinants of survival in patients with mycotic aneurysms. *J Vasc Surg.* 1984;1:541-547.
95. Ballard JL, Reiss J, Abou-Zamzam AM, et al. Two-graft repair of very proximal superior mesenteric artery aneurysms: a technical note. *Ann Vasc Surg.* 2005;19:465-469.
96. Solis MM, Ranval TJ, McFarland DR, Eidt JF. Surgical treatment of superior mesenteric artery dissecting aneurysm and simultaneous celiac artery compression. *Ann Vasc Surg.* 1993;7:457-462.
97. Cormier F, Ferry J, Artru B, et al. Dissecting aneurysms of the main trunk of the superior mesenteric artery. *J Vasc Surg.* 1992;15:424-430.
98. Patchefsky AS, Paplanus SH. Fibromuscular hyperplasia and dissecting aneurysm of the hepatic artery. *Arch Pathol.* 1967;83:141-144.
99. Takehara Y, Takahashi M, Fukaya T, et al. Computed tomography of isolated dissecting aneurysm of superior mesenteric artery. *J Comput Assist Tomogr.* 1988;12:678-680.
100. Leung DA, Schneider E, Kubik-Huch R, et al. Acute mesenteric ischemia caused by spontaneous isolated dissection of the superior mesenteric artery: treatment by percutaneous stent placement. *Eur Radiol.* 2000;10:1916-1919.
101. Yoon YW, Choi D, Cho SY, Lee DY. Successful treatment of isolated spontaneous superior mesenteric artery dissection with stent placement. *Cardiovasc Intervent Radiol.* 2003;26:475-478.
102. Froment P, Alerci M, Vandoni RE, et al. Stenting of a spontaneous dissection of the superior mesenteric artery: a new therapeutic approach? *Cardiovasc Intervent Radiol.* 2004;27:529-532.
103. Iyomasa S, Matsuzaki Y, Hiei K, et al. Pancreaticoduodenal artery aneurysm: a case report and review of the literature. *J Vasc Surg.* 1995;22:161-166.
104. Bageacu S, Cuilleron M, Kaczmarek D, Porcheron J. True aneurysms of the pancreaticoduodenal artery: successful non-operative management. *Surgery.* 2006;139:608-616.
105. Chiou AC, Josephs LG, Menzoian JO. Inferior pancreaticoduodenal artery aneurysm: report of a case and review of the literature. *J Vasc Surg.* 1993;17:784-789.
106. Mandel SR, Jaques PF, Sanofsky S, Mauro MA. Nonoperative management of peripancreatic arterial aneurysms. A 10-year experience. *Ann Surg.* 1987;205:126-128.
107. Hildebrand P, Esnaashari H, Franke C, et al. Surgical management of pancreaticoduodenal artery aneurysms in association with celiac trunk occlusion or stenosis. *Ann Vasc Surg.* 2007;21:10-15.
108. Eckhauser FE, Stanley JC, Zelenock GB, et al. Gastroduodenal and pancreaticoduodenal artery aneurysms: a complication of pancreatitis causing spontaneous gastrointestinal hemorrhage. *Surgery.* 1980;88:335-344.
109. Stanley JC, Frey CF, Miller TA, et al. Major arterial hemorrhage: a complication of pancreatic pseudocysts and chronic pancreatitis. *Arch Surg.* 1976;111:435-440.
110. White AF, Baum S, Buranasiri S. Aneurysms secondary to pancreatitis. *AJR Am J Roentgenol.* 1976;127:393-396.
111. Sugiyama K, Takehara Y. Analysis of five cases of splanchnic artery aneurysm associated with coeliac artery stenosis due to compression by the median arcuate ligament. *Clin Radiol.* 2007;62:688-693.
112. Quandalle P, Chambon JP, Marache P, et al. Pancreaticoduodenal artery aneurysms associated with celiac axis stenosis: report of two cases and review of the literature. *Ann Vasc Surg.* 1990;4:540-545.
113. Granke K, Hollier LH, Bowen JC. Pancreaticoduodenal artery aneurysms: changing patterns. *South Med J.* 1990;83:918-921.
114. Teng W, Sarfati MR, Mueller MT, Kraiss LW. A ruptured pancreaticoduodenal artery aneurysm repaired by combined endovascular and open techniques. *Ann Vasc Surg.* 2006;20:792-795.

115. Moore E, Matthews MR, Minion DJ, et al. Surgical management of peripancreatic arterial aneurysms. *J Vasc Surg.* 2004;40:247-253.
116. Krmpotich PT, Makdisi WF. Superior pancreaticoduodenal artery aneurysm rupture presenting with hemorrhage from the ampulla of Vater into the gastrointestinal tract. *Am J Gastroenterol.* 1995;90:2046-2047.
117. Gangahar DM, Carveth SW, Reese HE, et al. True aneurysm of the pancreaticoduodenal artery: a case report and review of the literature. *J Vasc Surg.* 1985;2:741-742.
118. Sessa C, Tinelli G, Porcu P, et al. Treatment of visceral artery aneurysms: description of a retrospective series of 42 aneurysms in 34 patients. *Ann Vasc Surg.* 2004;18:695-703.
119. Boudghene F, L'Hermine C, Bigot JM. Arterial complications of pancreatitis: diagnostic and therapeutic aspects in 104 cases. *J Vasc Interv Radiol.* 1993;4:551-558.
120. Neschis DG, Safford SD, Golden MA. Management of pancreaticoduodenal artery aneurysms presenting as catastrophic intraabdominal bleeding. *Surgery.* 1998;123:8-12.
121. de Perrot M, Berney T, Deleaval J, et al. Management of true aneurysms of the pancreaticoduodenal arteries. *Ann Surg.* 1999;229:416-420.
122. Huang YK, Hsieh HC, Tsai FC, et al. Visceral artery aneurysm: risk factor analysis and therapeutic opinion. *Eur J Vasc Endovasc Surg.* 2007;33:293-301.
123. Manazer JR, Monzon JR, Dietz PA, et al. Treatment of pancreatic pseudoaneurysm with percutaneous transabdominal thrombin injection. *J Vasc Surg.* 2003;38:600-602.
124. Rohatgi A, Cherian T. Spontaneous rupture of a left gastroepiploic artery aneurysm. *J Postgrad Med.* 2002;48:288-289.
125. Montisci R, Cuccu G, Serra F, et al. Spontaneous rupture of an aneurysm of the left gastroepiploic artery. *Eur J Vasc Surg.* 1992;6:95-97.
126. Jani ND, McGrath KM. Left gastric artery aneurysm. *Gastrointest Endosc.* 2008;67:154-155; commentary 155.
127. Chandran S, Parvaiz A, Karim A, et al. Ruptured left gastric artery aneurysm successfully treated by thrombin injection: case report and literature review. *Sci World J.* 2005;5:20-23.
128. Carr SC, Pearce WH, Vogelzang RL, et al. Current management of visceral artery aneurysms. *Surgery.* 1996;120:627-633; discussion 633-634.
129. Dietrich NA, Cacioppo JC, Ying DP. Massive gastrointestinal hemorrhage caused by rupture of a jejunal branch artery aneurysm. *J Vasc Surg.* 1988;8:187-189.
130. Mandeville KL, Bicknell C, Narula S, Renton S. Inferior mesenteric artery aneurysm with occlusion of the superior mesenteric artery, coeliac trunk and right renal artery. *Eur J Vasc Endovasc Surg.* 2008;35:312-313.
131. Araj O, Barquero JM, Marcos F, Infantes C. Inferior mesenteric artery aneurysm associated with occlusion of the superior mesenteric and celiac arteries. *Ann Vasc Surg.* 2001;15:399-401.
132. Sugrue ME, Mehigan D, Hederman WP. Inferior mesenteric artery aneurysm. *J Cardiovasc Surg (Torino)* 1990;31:380-381.
133. Goffi L, Chan R, Boccoli G, et al. Aneurysm of a jejunal branch of the superior mesenteric artery in a patient with Marfan's syndrome. *J Cardiovasc Surg (Torino)* 2000;41:321-323.
134. Naito A, Toyota N, Ito K. Embolization of a ruptured middle colic artery aneurysm. *Cardiovasc Intervent Radiol.* 1995;18:56-58.
135. Pulli R, Dorigo W, Troisi N, et al. Surgical treatment of visceral artery aneurysms: a 25-year experience. *J Vasc Surg.* 2008;48:334-342.
136. Gabelmann A, Gorich J, Merkle EM. Endovascular treatment of visceral artery aneurysms. *J Endovasc Ther.* 2002;9:38-47.
137. Kasirajan K, Greenberg RK, Clair D, Ouriel K. Endovascular management of visceral artery aneurysm. *J Endovasc Ther.* 2001;8:150-155.
138. Salam TA, Lumsden AB, Martin LG, Smith RB 3rd. Nonoperative management of visceral aneurysms and

- pseudoaneurysms. *Am J Surg*. 1992;164:215-219.
139. Ghassemi A, Javit D, Dillon EH. Thrombin injection of a pancreaticoduodenal artery pseudoaneurysm after failed attempts at transcatheter embolization. *J Vasc Surg*. 2006;43:618-622.
  140. Gulati GS, Gulati MS, Makharia G, et al. Percutaneous glue embolization of a visceral artery pseudoaneurysm in a case of sickle cell anemia. *Cardiovasc Intervent Radiol*. 2006;29:665-668.
  141. Krueger K, Zaehring M, Lackner K. Percutaneous treatment of a splenic artery pseudoaneurysm by thrombin injection. *J Vasc Interv Radiol*. 2005;16:1023-1025.
  142. Szopinski P, Ciostek P, Pleban E, et al. Percutaneous thrombin injection to complete SMA pseudoaneurysm exclusion after failing of endograft placement. *Cardiovasc Intervent Radiol*. 2005;28:509-514.
  143. Schwartz RA, Nichols WK, Silver D. Is thrombosis of the infrarenal abdominal aortic aneurysm an acceptable alternative? *J Vasc Surg*. 1986;3:448-455.
  144. Schanzer H, Papa MC, Miller CM. Rupture of surgically thrombosed abdominal aortic aneurysm. *J Vasc Surg*. 1985;2:278-280.
  145. Onohara T, Okadome K, Mii S, et al. Rupture of embolised coeliac artery pseudoaneurysm into the stomach: is coil embolisation an effective treatment for coeliac anastomotic pseudoaneurysm? *Eur J Vasc Surg*. 1992;6:330-332.

## 第 139 章

1. Osler W. The Gulstonian lectures on malignant endocarditis. *BMJ*. 1885;1:467.
2. Stengel A, Wolferth CC. Mycotic (bacterial) aneurysms of intravascular origin. *Arch Intern Med*. 1923;31:527.
3. Sommerville RI, Allen EV, Edwards JE. Bland and infected arteriosclerotic abdominal aortic aneurysms: a clinicopathologic study. *Medicine (Baltimore)*. 1959;38:207.
4. Kyriakides GK, Simmons RL, Najarian JS. Mycotic aneurysms in transplant patients. *Arch Surg*. 1976;111:472.
5. Johansen K, Devin J. Spontaneous healing of mycotic aortic aneurysm. *J Cardiovasc Surg*. 1980;21:625.
6. Gouny P, Valverde A, Vincent D. Human immunodeficiency virus and infected aneurysm of the abdominal aorta: report of three cases. *Ann Vasc Surg*. 1992;6:239.
7. Soderstrom CA, Wasserman DJ, Ransom KJ, et al. Infected false femoral artery aneurysms secondary to monitoring catheters. *J Cardiovasc Surg*. 1983;24:63.
8. Baker WH, Moran JM, Dormer DB. Infected aortic aneurysm following arteriography. *J Cardiovasc Surg*. 1979;20:313.
9. Eshaghy B, Scanlon RJ, Amirparviz F, et al. Mycotic aneurysm of brachial artery: a complication of retrograde catheterization. *JAMA*. 1974;228:1574.
10. Anderson CB, Butcher HR Jr, Ballinger WF, et al. Mycotic aneurysms. *Arch Surg*. 1974;109:712.
11. Johnson JR, Ledgerwood AM, Lucas CE. Mycotic aneurysm: new concepts in surgery. *Arch Surg*. 1983;118:577.
12. Padberg F, Hobson R II, Lee B, et al. Femoral pseudoaneurysm from drugs of abuse: ligation or reconstruction? *J Vasc Surg*. 1992;15:642.
13. Patel KR, Semel L, Clauss RH. Routine revascularization with resection of infected femoral pseudoaneurysms from substance abuse. *J Vasc Surg*. 1988;8:321.
14. Reddy DJ, Smith RF, Elliott JP Jr, et al. Infected femoral artery false aneurysms in drug addicts: evolution of selective vascular reconstruction. *J Vasc Surg*. 1986;3:718.
15. Wilson SE, Van Wagenen P, Passaro E Jr. Arterial infection. *Curr Probl Surg*. 1978;15:5.
16. Samore MH, Wessolossky MA, Lewis SM, et al. Frequency, risk factors, and outcome for bacteremia after percutaneous transluminal coronary angioplasty. *Am J Cardiol*. 1997;79:873.
17. Noel AA, Gloviczki P, Cherry KJ Jr, et al. Abdominal aortic reconstruction in infected fields: early results of the United States cryopreserved aortic allograft registry. *J Vasc Surg*. 2002;35:847.
18. Vogt PR, Brunner-LaRocca HP, Lachat M, et al. Technical details with the use of cryopreserved arterial allograft for aortic

- infection: influence on early and mid term mortality. *J Vasc Surg.* 2002;35:80.
19. Lewis D, Schrager J. Embolomycotic aneurysms. *JAMA.* 1909;63:1808.
  20. Revell STR. Primary mycotic aneurysms. *Ann Intern Med.* 1943;22:431.
  21. Jarrett F, Darling RC, Mundth ED, et al. Experience with infected aneurysms of the abdominal aorta. *Arch Surg.* 1975;10:1281.
  22. Feldman AJ, Berguer R. Management of an infected aneurysm of the groin secondary to drug abuse. *Surg Gynecol Obstet.* 1983;157:519.
  23. Reid MR. Studies on abnormal arteriovenous communications, acquired and congenital: I. Report of a series of cases. *Arch Surg.* 1925;10:601.
  24. Akers DL Jr, Fowl RJ, Kempczinski RF. Mycotic aneurysm of the tibioperoneal trunk: case report and review of the literature. *J Vasc Surg.* 1992;16:71.
  25. Chen YF, Lin PY, Yen HW, et al. Double mycotic aneurysm of the ascending aorta. *Ann Thorac Surg.* 1997;63:529.
  26. D'Angelo V, Fiumara E, Gorgoglione L, et al. Surgical treatment of a cerebral mycotic aneurysm using the stereo-angiographic localizer. *Surg Neurol.* 1995;44:263.
  27. Huebl HC, Read RC. Aneurysmal abscess. *Minn Med.* 1966;49:11.
  28. Senocak F, Cekirge S, Senocak ME, et al. Hepatic artery aneurysm in a 10-year-old boy as a complication of infective endocarditis. *J Pediatr Surg.* 1996;31:1570.
  29. Willemsen P, De Roover D, Kockx M, et al. Mycotic common carotid artery aneurysm in an immunosuppressed pediatric patient: case report. *J Vasc Surg.* 1997;25:784.
  30. Magilligan DJ Jr, Quinn EL, eds. *Endocarditis. Medical and Surgical Management.* New York, NY: Marcel Dekker; 1986.
  31. Brown SL, Busutill RW, Baker JD, et al. Bacteriologic and surgical determinants of survival in patients with mycotic aneurysms. *J Vasc Surg.* 1984;1:541.
  32. Hsu RB, Tsay YG, Wang SS, Chu SH. Surgical treatment for primary infected aneurysm of the descending thoracic aorta, abdominal aorta and iliac arteries. *J Vasc Surg.* 2002;36:746.
  33. Moneta GL, Taylor LM, Yeager RA, et al. Surgical treatment of infected aortic aneurysm. *Am J Surg.* 1998;175:396.
  34. Muller BT, Wegener OR, Grabitz K, et al. Mycotic aneurysms of the thoracic and abdominal aorta and iliac arteries: experience with anatomic and extra-anatomic repair in 33 cases. *J Vasc Surg.* 2001;33:106.
  35. Oderich GS, Panneton JM, Bower TC, et al. Infected aortic aneurysms: aggressive presentation, complicated early outcome but durable results. *J Vasc Surg.* 2001;34:900.
  36. Sessa C, Farah I, Voirin L, et al. Infected aneurysms of the infrarenal abdominal aorta: diagnostic criteria and therapeutic strategy. *Ann Vasc Surg.* 1997;11:453.
  37. Sriussadaporn S. Infected abdominal aortic aneurysms: experience with 14 consecutive cases. *Int Surg.* 1996;81:395.
  38. Bitseff EL, Edwards WA, Mulherin JL Jr, Kaiser AB. Infected abdominal aortic aneurysms. *South Med J.* 1987;80:309.
  39. Reddy DJ, Shepard AD, Evans JR, et al. Management of infected aortoiliac aneurysms. *Arch Surg.* 1991;126:873.
  40. Bennett DE, Cherry JK. Bacterial infection of aortic aneurysms: a clinicopathologic study. *Am J Surg.* 1967;113:321.
  41. Chan YF, Crawford ES, Coselli JS, et al. In situ prosthetic graft replacement for mycotic aneurysms of the aorta. *Ann Thorac Surg.* 1989;47:193.
  42. Mundth ED, Darling RC, Alvarado RH, et al. Surgical management of mycotic aneurysms and the complications of infection in vascular reconstructive surgery. *Am J Surg.* 1969;117:460.
  43. Nabseth DC, Deterling RA. Surgical management of mycotic aneurysms. *Surgery.* 1961;50:347.
  44. Patel S, Johnson KW. Classification and management of mycotic aneurysm. *Surg Gynecol Obstet.* 1977;144:691.
  45. Schrandt-van de Meer AM, Guit GL, van Bockel JH. Mycotic aneurysm of the suprarenal abdominal aorta. *Neth J Med.* 1994;44:23.
  46. Har Shai Y, Schein M, Molek AD, et al. Ruptured mycotic aneurysm of the subclavian artery after irradiation: a case report.



*Eur J Surg.* 1993;159:59.

47. Garb M. Appendicitis: an unusual cause of infected abdominal aortic aneurysm. *Australas Radiol.* 1994;38:68.
48. Rubery PT, Smith MD, Cammisa FP, et al. Mycotic aortic aneurysm in patients who have lumbar vertebral osteomyelitis: a report of two cases. *J Bone Joint Surg Am.* 1995;77:1729.
49. Sailors DM, Barone GW, Gagne PJ, et al. *Candida* arteritis: are GI endoscopic procedures a source of vascular infections? *Am Surg.* 1996;62:472.
50. Suddleson EA, Katz SG, Kohl RD. Mycotic suprarenal aortic aneurysm. *Ann Vasc Surg.* 1987;1:426.
51. Chan P, Tsai CW, Huang JJ, et al. Salmonellosis and mycotic aneurysm of the aorta: a report of 10 cases. *J Infect.* 1995;30:129.
52. Flamand F, Harris KA, DeRose G, et al. Arteritis due to *Salmonella* with aneurysm formation: two cases. *Can J Surg.* 1992;35:248.
53. Malanoski GJ, Samore MH, Pefanis A, et al. *Staphylococcus aureus* catheter-associated bacteremia: minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. *Arch Intern Med.* 1995;155:1161.
54. Oskoui R, Davis WA, Gomes MN. *Salmonella* aortitis: a report of a successfully treated case with a comprehensive review of the literature. *Arch Intern Med.* 1993;153:517.
55. Gauto AR, Cone LA, Woodard DR, et al. Arterial infections due to *Listeria monocytogenes*: report of four cases and review of world literature. *Clin Infect Dis.* 1992;14:23.
56. Lamothe M, Simmons B, Gelfand M, et al. *Listeria monocytogenes* causing endovascular infection. *South Med J.* 1992;85:193.
57. Tatebe S, Kanazawa H, Yamazaki Y, et al. Mycotic aneurysm of the internal iliac artery caused by *Klebsiella pneumoniae*. *Vasa.* 1996;25:184.
58. Montoya FJ, Weinstein-Moreno LF, Johnson CC. Mycotic thoracic aneurysm due to *Clostridium septicum* and occult adenocarcinoma of the cecum. *Clin Infect Dis.* 1997;24:785.
59. Murphy DP, Glazier DB, Krause TJ. Mycotic aneurysm of the thoracic aorta caused by *Clostridium septicum*. *Ann Thorac Surg.* 1996;62:1835.
60. Sailors DM, Eidt JF, Gagne PJ, et al. Primary *Clostridium septicum* aortitis: a rare cause of necrotizing suprarenal aortic infection: a case report and review of the literature. *J Vasc Surg.* 1996;23:714.
61. Smith FC, Rees E, Elliott TS, et al. A hazard of immunosuppression: *Aspergillus niger* infection of abdominal aortic aneurysm. *Eur J Vasc Surg.* 1994;8:369.
62. Ernst CB, Campbell C Jr, Daugherty ME, et al. Incidence and significance of intra-operative bacterial cultures during abdominal aortic aneurysmectomy. *Ann Surg.* 1977;185:626.
63. Williams RD, Fisher FW. Aneurysm contents as a source of graft infection. *Arch Surg.* 1977;112:415.
64. Steed DL, Higgins RS, Pasculle A, et al. Culture of intraluminal thrombus during abdominal aortic aneurysm resection: significant contamination is rare. *Cardiovasc Surg.* 1993;1:494.
65. Fourneau I, Nivelsteen A, Lacroix H, et al. Microbiological monitoring of aortic aneurysm sac contents during abdominal aneurysmectomy: results in 176 patients and review of the literature. *Acta Chir Belg.* 1996;96:119.
66. Mostovych M, Johnson L, Cambria RP. Aortic sepsis from an appendiceal abscess. *Cardiovasc Surg.* 1994;2:67.
67. Parodi JC. Endovascular repair of abdominal aortic aneurysms and other arterial lesions. *J Vasc Surg.* 1995;21:549.
68. Greenberg R, Chuer TA, Sternbergh UC 3<sup>rd</sup>, Fearnot NE. Zenith AAA endovascular graft: intermediate-term results of the US multicenter trial. *J Vasc Surg.* 2004;39:1209.
69. Monson RL, Alexander RH. Vein reconstruction of a mycotic internal carotid aneurysm. *Ann Surg.* 1980;191:47.
70. Pipkin W, Brophy C, Nesbit R, Mondy JS III. Early experience with infectious complications of percutaneous femoral artery closure devices. *J Vasc Surg.* 2000;32:205.
71. Gomes MN, Choyke PL, Wallace RB. Infected aortic aneurysms: a changing entity. *Ann Surg.* 1992;215:435.

72. Byard RW, Leduc JR, Chambers J, Walley VM. The rapid evolution of a large mycotic aneurysm of the abdominal aorta. *J Can Assoc Radiol.* 1988;39:62.
73. Thompson TR, Tilleli J, Johnson DE, et al. Umbilical artery catheterization complicated by mycotic aortic aneurysm in neonates. *Adv Pediatr.* 1980;27:275.
74. Millar AJ, Gilbert RD, Brown RA, et al. Abdominal aortic aneurysms in children. *J Pediatr Surg.* 1996;31:1624.
75. Bennett DE. Primary mycotic aneurysms of the aorta. *Arch Surg.* 1967;94:758.
76. Vogelzang RL, Sohaey R. Infected aortic aneurysms: CT appearance. *J Comput Assist Tomogr.* 1988;12:109.
77. Van Damme H, Belachew M, Damas P, et al. Mycotic aneurysm of the upper abdominal aorta ruptured into the stomach. *Arch Surg.* 1992;127:478.
78. Yao JST, McCarthy WJ. Contained rupture of a thoracoabdominal aneurysm. *Contemp Surg.* 1988;33:47.
79. Zak FG, Strauss L, Saphra I. Rupture of diseased large arteries in the course of enterobacterial (*Salmonella*) infection. *N Engl J Med.* 1958;258:824.
80. Mendelowitz DS, Ramstedt R, Yao JST, et al. Abdominal aortic salmonellosis. *Surgery.* 1979;85:514.
81. Miller BM, Waterhouse G, Alford RH, et al. *Histoplasma* infection of abdominal aortic aneurysms. *Ann Surg.* 1983;197:57.
82. Taylor LM Jr, Deitz DM, McConnell DB, Porter JM. Treatment of infected abdominal aneurysms by extra-anatomic bypass, aneurysm excision, and drainage. *Am J Surg.* 1988;155:655.
83. Szilagyi DE, Elliott JP, Smith RF. Ruptured abdominal aneurysms simulating sepsis. *Arch Surg.* 1965;91:263.
84. Gomes MN, Schellinger D, Hufnagel CA. Abdominal aortic aneurysms: diagnostic review and new techniques. *Ann Thorac Surg.* 1979;27:479.
85. Gomes MH, Choyke PL. Infected aortic aneurysms: CT diagnosis. *J Cardiovasc Surg.* 1992;33:684.
86. Lee MH, Chan P, Chiou HJ, et al. Diagnostic imaging of *Salmonella*-related mycotic aneurysm of aorta by CT. *Clin Imaging.* 1996;20:26.
87. Rozenblit A, Bennett J, Suggs W. Evolution of the infected abdominal aneurysm: CT observation of early aortitis. *Abdom Imaging.* 1996;21:512.
88. Moriarity JA, Edelman RR, Tumei SS. CT and MRI mycotic aneurysms of the abdominal aorta. *J Comput Assist Tomogr.* 1992;16:941.
89. Walsh DW, Ho VB, Haggerty MF. Mycotic aneurysm of the aorta: MRI and MRA features. *J Magn Reson Imaging.* 1997;7:312.
90. Brunner MC, Mitchell RS, Baldwin JC, et al. Prosthetic graft infection: limitations of indium white blood cell scanning. *J Vasc Surg.* 1986;3:42.
91. Chen P, Lamski L, Raval B. Indium-111 leukocyte appearance of *Salmonella* mycotic aneurysm. *Clin Nucl Med.* 1994;19:646.
92. Van der Wall H, Palmer A, Thomas M, Chu J. Bone and leukocyte scintigraphy of a complicated case of ruptured mycotic aneurysm of the aorta: a case history. *Angiology.* 1994;45:315.
93. Weintraub RA, Abrams HL. Mycotic aneurysm. *AJR Am J Roentgenol.* 1968;102:354.
94. Crawford ES, Crawford JL, eds: *Diseases of the Aorta Including an Atlas of Angiographic Pathology and Surgical Techniques.* Baltimore, MD: Williams & Wilkins; 1984.
95. Cates JE, Christie RV. Subacute bacterial endocarditis. *QJM.* 1951;24:93.
96. Cooke PA, Ehrenfeld WK. Successful management of mycotic aortic aneurysm: report of a case. *Surgery.* 1974;75:132.
97. Atnip RG. Mycotic aneurysms of the suprarenal abdominal aorta: prolonged survival after in situ aortic and visceral reconstruction. *J Vasc Surg.* 1989;10:635.
98. Ewart JM, Burke ML, Bunt TJ. Spontaneous abdominal aortic infections: essentials of diagnosis and management. *Am Surg.* 1983;49:37.
99. Johansen K, Devin J. Mycotic aortic aneurysms: a reappraisal. *Arch Surg.* 1983;118:583.

100. Oz MC, Brener BJ, Buda JA, et al. A ten-year experience with bacterial aortitis. *J Vasc Surg.* 1989;10:439.
101. Pasic M, Segesser L, Turina M. Implantation of antibiotic-releasing carriers and in situ reconstruction for treatment of mycotic aneurysm. *Arch Surg.* 1992;127:745.
102. Reddy DJ. Letter to editor. *J Vasc Surg.* 1989;10:358.
103. Trairatvorakul P, Sriphojanart S, Sathapatayavongs B. Abdominal aortic aneurysms infected with *Salmonella*: problems of treatment. *J Vasc Surg.* 1990;12:16.
104. Elliott JP, Smith RF, Szilagyi DE. Aortoenteric and paraprosthetic-enteric fistulas. *Arch Surg.* 1974;114:1041.
105. Reddy DJ, Lee RE, Oh HK. Suprarenal mycotic aortic aneurysm: surgical management and follow-up. *J Vasc Surg.* 1986;3:917.
106. Bacourt F, Koskas F. Axillofemoral artery bypass and aortic exclusion for vascular septic lesions: a multi-centered retrospective study of 98 cases. *Ann Vasc Surg.* 1992;6:119-126.
107. Mcbeth GA, Rubin JR, McIntyre KE, et al. The relevance of arterial wall microbiology in the treatment of prosthetic graft infections: graft infection versus arterial infection. *J Vasc Surg.* 1984;1:750.
108. Yeager RA, Taylor LM, Moneta GL, et al. Improved results with conventional management of infrarenal aortic infection. *J Vasc Surg.* 1999;30:76.
109. McCready RA, Bryant MA, Divelbiss JL, et al. Arterial infections in the new millennium: an old problem revisited. *Ann Vasc Surg.* 2006;20:590.
110. Chan FY, Crawford ES, Coselli JS, et al. In situ prosthetic graft replacement for mycotic aneurysm of the aorta. *Ann Thor Surg.* 1989;47:193-203.
111. Alonso M, Caeiro S, Cachaldora J. Infected abdominal aortic aneurysm: in situ replacement with cryopreserved arterial homograft. *J Cardiovasc Surg.* 1997;38:371.
112. Koskas F, Plissonnier D, Bahnini A, et al. In situ arterial allografting graft infection: a 6-year experience. *Cardiovasc Surg.* 1996;4:495.
113. Knosalla C, Weng Y, Yanakh AC, et al. Using aortic allograft material to treat mycotic aneurysms of the thoracic aorta. *Ann Thorac Surg.* 1996;61:1053.
114. Pagano D, Guest P, Bonser RS. Homograft replacement of thoraco-abdominal segment of the aorta for leaking mycotic aneurysm. *Eur J Cardiothorac Surg.* 1996;10:383.
115. Pasic M, Carrel T, von Segesser L, et al. In situ repair of mycotic aneurysm of the ascending aorta. *J Thorac Cardiovasc Surg.* 1993;105:321.
116. Vogt PR, von Segesser LK, Goffin Y. Cryopreserved arterial homografts for in situ reconstruction of mycotic aneurysms and prosthetic graft infections. *Eur J Cardiothorac Surg.* 1995;9:502.
117. Vogt PR, von Segesser LK, Goffin Y. Eradication of aortic infections with the use of cryopreserved arterial homografts. *Ann Thorac Surg.* 1996;62:640.
118. von Segesser LK, Vogt P, Genoni M, et al. The infected aorta. *J Card Surg.* 1997;12:256.
119. Clagett GP, Valentine RJ, Hagino RT. Autogenous aortoiliac/femoral reconstruction from superficial femoral-popliteal veins: Feasibility and durability. *J Vasc Surg.* 1997;25:255.
120. Benjamin ME, Cohn EJ, Purtill WA, et al. Arterial reconstruction with deep leg veins for the treatment of mycotic aneurysms. *J Vasc Surg.* 1999;30:1004.
121. Beck AW, Murphy EH, Hocking TA, et al. Aortic reconstruction with femoral-popliteal vein: graft stenosis incidence, risk and reintervention. *J Vasc Surg.* 2008;47:36; discussion 44.
122. Modrall JG, Hocking JA, Timaran CH, et al. Late incidence of chronic venous insufficiency after deep vein harvest. *J Vasc Surg.* 2007;46:520.
123. Lopera JE, Trimmer CK, Josephs S, et al. Neo-aortoiliac reconstructions using femoropopliteal veins: MDCT angiography findings. *AJR Am J Roentgenol.* 2008;191:569.

124. Beck AW, Murphy EH, Hocking JA, et al. Aortic reconstruction with femoral-popliteal vein: graft stenosis incidence, risk and reintervention. *J Vasc Surg.* 2008;47:36.
125. Koskas F, Goeau-Brissoniere O, Nicolas MH, et al. Arteries from human beings are less infectible by *Staphylococcus aureus* than polytetrafluoroethylene in an aortic dog model. *J Vasc Surg.* 1996;23:472.
126. Gupta AK, Bandyk DF, Johnson BL. In situ repair of mycotic abdominal aortic aneurysms with rifampin-bonded gelatin impregnated Dacron grafts: a preliminary case report. *J Vasc Surg.* 1996;24:472.
127. Yokoyama H, Maida K, Takahashi S, et al. Purulently infected abdominal aortic aneurysm: in situ reconstruction with transmesocolic omental transposition technique. *Cardiovasc Surg.* 1994;2:78.
128. Kan C, Lee H, Yang Y. Outcome after endovascular stent graft treatment for mycotic aortic aneurysm: a systematic review. *J Vasc Surg.* 2007;46:906.
129. Bell RE, Taylor PR, Aukett M, et al. Successful endoluminal repair of an infected thoracic pseudoaneurysm caused by methicillin-resistant *Staphylococcus aureus*. *J Endovasc Ther.* 2003;10:29.
130. Kinney EV, Kaebnick HW, Mitchell RA, et al. Repair of mycotic paravisceral aneurysm with a fenestrated stent-graft. *J Endovasc Ther.* 2000;7:192.
131. Kotzampassakis N, Delanaye P, Masy F, Creemers E. Endovascular stent-graft for thoracic aorta aneurysm caused by *Salmonella*. *Eur J Cardiothorac Surg.* 2004;26:225.
132. Gonzalez-Fajardo J, Gutierrez V, Martin-Pedrosa M, et al. Endovascular repair in the presence of aortic infection. *Ann Vasc Surg.* 2005;19:94.
133. Forbes T, Harding G. Endovascular repair of *Salmonella*-infected abdominal aortic aneurysms: a word of caution. *J Vasc Surg.* 2006;44:198.
134. Koeppl T, Gahlen J, Deihl S, et al. Mycotic aneurysm of the abdominal aorta with retroperitoneal abscess: successful endovascular repair. *J Vasc Surg.* 2004;40:164.
135. Pasic M, Carrel T, Tonz M, et al. Mycotic aneurysm of the abdominal aorta: extra-anatomic versus in situ reconstruction. *Cardiovasc Surg.* 1993;1:48.
136. Marty-An   C, Alric P, Prudhomme M, et al. Bilateral splenorenal bypass and axillofemoral graft for management of juxtarenal mycotic aneurysm. *Cardiovasc Surg.* 1996;4:331.
137. Chiba Y, Muraoka R, Ihaya A, et al. Surgical treatment of infected thoracic and abdominal aortic aneurysms. *Cardiovasc Surg.* 1996;4:476.
138. Robinson JA, Johansen K. Aortic sepsis: is there a role for in situ graft reconstruction? *J Vasc Surg.* 1991;13:677.
139. Cordero JA Jr, Darling RC 3rd, Chang BB, et al. In situ prosthetic graft replacement for mycotic thoracoabdominal aneurysms. *Am Surg.* 1996;62:35.
140. Hollier LH, Money SR, Creely B, et al. Direct repair of mycotic thoracoabdominal aneurysms. *J Vasc Surg.* 1993;18:477.
141. Pasic M, Carrel T, Vogt M, et al. Treatment of mycotic aneurysms of the aorta and its branches: the location determines the operative technique. *Eur J Vasc Surg.* 1992;6:419.
142. Jones K, Bell R, Sabharwal T, et al. Treatment of mycotic aortic aneurysms with endoluminal grafts. *Eur J Vasc Endovasc Surg.* 2005;29:139.
143. Hegenscheid M, Alveizacos P, Hepp W. Autogene Rekonstruktion bei mykotischem inquinalem Aneurysma-Langzeitergebnis. *Vasa.* 1994;23:159.
144. Reddy DJ, Shin LH. Obturator bypass: technical considerations. *Semin Vasc Surg.* 2000;13:49.
145. Arora S, Weber MA, Fox CJ, et al. Common femoral artery ligation and local debridement: a safe treatment for infected femoral artery pseudoaneurysms. *J Vasc Surg.* 2001;33:990.
146. Gan JP, Leiberman DP, Pollock JG. Outcome after ligation of infected false femoral aneurysms in intravenous drug abusers. *Eur J Vasc Endovasc Surg.* 2000;19:158.
147. Reddy DJ. Treatment of drug-related infected false aneurysms of the femoral artery: is routine revascularization justified? *J*

- Vasc Surg.* 1988;8:344.
148. Tsao JW, Marder SR, Goldstone J, et al. Presentation, diagnosis and management of arterial mycotic pseudoaneurysms in injection drug users. *Ann Vasc Surg.* 2002;16:652.
  149. Zainal AA, Yusha AW. A 3 year audit of infected pseudoaneurysms in intravenous drug users managed surgically in the Vascular Unit, Hospital Kuala Lumpur. *Med J Malay.* 1998;53:372.
  150. Howell HS, Barburao T, Graziano J. Mycotic cervical carotid aneurysm. *Surgery.* 1977;81:357.
  151. Ledgerwood AM, Lucas CE. Mycotic aneurysm of the carotid artery. *Arch Surg.* 1974;109:496.
  152. Samson DS, Gewertz BL, Beyer CW Jr, et al. Saphenous vein interposition grafts in the microsurgical treatment of cerebral ischemia. *Arch Surg.* 1981;116:1578.
  153. Avellone JC, Ahmad MY. Cervical internal carotid aneurysm from syphilis: an alternative to resection. *JAMA.* 1979;241:238.
  154. Ehrenfeld WR, Stoney RJ, Wylie EJ. Relation of carotid stump pressure to safety of carotid arterial ligation. *Surgery.* 1983;93:299.
  155. Khalil I, Nawfal G. Mycotic aneurysms of the carotid artery: ligation vs. reconstruction—case report and review of the literature. *Eur J Vasc Surg.* 1993;7:588.
  156. Michielsen D, Van Hee R, Discart H. Mycotic aneurysm of the carotid artery: a case report and review of the literature. *Acta Chir Belg.* 1997;97:44.
  157. Stanley JC, Thompson NW, Fry WJ. Splanchnic artery aneurysms. *Arch Surg.* 1970;101:689.
  158. Hashemi HA, Comerota AJ, Dempsey DT. Foregut revascularization via retrograde splenic artery perfusion after resection of a juxtaceliac mycotic aneurysm: complicated by pancreatic infarction because of cholesterol emboli. *J Vasc Surg.* 1995;21:530.
  159. Viglione G, Younes GA, Coste P, et al. Mycotic aneurysm of the celiac trunk: radical resection and reconstruction without prosthetic material. *J Cardiovasc Surg.* 1993;34:73.
  160. Paré A. Of aneurismas. In *The Apologie and Treatise Containing the Voyages Made into Divers Places with Many of His Writings upon Surgery.* Birmingham, AL: The Classics of Surgery Library; 1984.
  161. Rokitsky CF. *Handbuch der Pathologischen Anatomie*, 2<sup>nd</sup> ed. Austria, 1844:55.
  162. Koch R. Ueber aneurysma der arteria mesenterica superior [About an aneurysm of the superior mesenteric artery]. In Erlangen JJ, ed. *Inaug Dural-Abhandlung.* Barfus'schen: Universitaets-Buchdruckerei; 1851.
  163. Tufnell J. On the influence of vegetation of the valves of the heart in the production of secondary arterial disease. *Dublin Q J Med.* 1885;15:371.
  164. Barker WF. Mycotic aneurysms. *Ann Surg.* 1954;139:84.
  165. Davies OG, Thorburn JD, Powell P. Cryptic mycotic abdominal aortic aneurysms. *Am J Surg.* 1978;136:96.
  166. Fromm SH, Lucas CE. Obturator bypass for mycotic aneurysm of the drug addict. *Arch Surg.* 1970;100:82.
  167. Eppinger H. Pathogenesis (histogenesis und aetiologie) der anerysmen eimschliesslich des aneurysma equi verminosum. *Arch Klin Chir.* 1887;35:404.
  168. Crane AR. Primary multilocular mycotic aneurysm of the aorta. *Arch Pathol.* 1937;24:634.
  169. Dupont JR, Bonavita JA, DiGiovanni RJ, et al. Acquired immunodeficiency syndrome and mycotic abdominal aortic aneurysms: a new challenge? Report of a case. *J Vasc Surg.* 1989;10:254.
  170. Yellin AE. Ruptured mycotic aneurysm. *Arch Surg.* 1977;112:981.

## 第 140 章

1. McKusick V. *Heritable Disorders of Connective Tissue.* St. Louis, MO: CV Mosby; 1956.
2. Marfan A-B. Un cas de deformation congenitale des quarte members plus prononcee aux extremités caracterisee par l'allongement des os avec un certain degre d'amincissement. *Bull Mem Soc Med Hop Par (Ser 3).* 1896;13:220-226.

3. Mery H, Baboneix L. Un cas de deformation congenitale des quatres members: hyperchondroplasie. *Bull Mem Soc Med Hop Par (Ser 3)*. 1902;19:671-676.
4. Baer RW, Taussig HB, Oppenheimer EH. Congenital aneurysmal dilatation of the aorta associated with arachnodactyly. *Bull Johns Hopkins Hosp*. 1943;72:309-331.
5. Judge DP, Dietz HC. Marfan's syndrome. *Lancet*. 2005;366:1965-1976.
6. Gray JR, Bridges AB, Faed MJ, et al. Ascertainment and severity of Marfan syndrome in a Scottish population. *J Med Genet*. 1994;31:51-54.
7. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de-novo missense mutation in the fibrillin gene. *Nature*. 1991;352:337-339.
8. Kinoshita N, Mimura J, Obayashi C, et al. Aortic root dilatation among young competitive athletes: echocardiographic screening of 1929 athletes between 15 and 34 years of age. *Am Heart J*. 2000;139:723-728.
9. Murdoch JL, Walker BA, Halpern BL, et al. Life expectancy and causes of death in the Marfan syndrome. *N Engl J Med*. 1972;286:804-808.
10. Silverman DJ, Burton KL, Gray J, et al. Life expectancy in the Marfan syndrome. *Am J Cardiol*. 1995;75:157-160.
11. McKusick VA. The cardiovascular aspects of Marfan syndrome: a heritable disorder of connective tissue. *Circulation*. 1955;11:321-342.
12. Halme T, Savunen T, Aho H, et al. Elastin and collagen in the aortic wall: changes in the Marfan syndrome and annuloaortic ectasia. *Exp Mol Pathol*. 1985;43:1-12.
13. Tsuji T. Marfan syndrome: demonstration of abnormal elastic fibers in skin. *J Cutan Pathol*. 1986;13:144-153.
14. Fahrenbach WH, Sandberg LB, Cleary EG. Ultrastructural studies on early elastogenesis. *Anat Rec*. 1966;155:563-576.
15. Ross R, Bornstein P. The elastic fiber: the separation and partial characterization of its macromolecular components. *J Cell Biol*. 1969;40:366-381.
16. Sakai LY, Keen DR, Engvall E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. *J Cell Biol*. 1986;103:2499-2509.
17. Kainulainen K, Pulkkinen L, Savolainen A, et al. Location of chromosome 15 of the gene defect causing Marfan syndrome. *N Engl J Med*. 1990;323:935-939.
18. Collod-Beroud G, Beroud C, Ades L, et al. Marfan database: new mutations and new routines for the software. *Nucleic Acids Res*. 1998;26:229-233.
19. Putnam EA, Cho M, Zinn AB, et al. Delineation of the Marfan phenotype associated with mutations in exons 23-32 of the FBN-1 gene. *Am J Med Genet*. 1996;62:233-242.
20. Corson GM, Chalberg SC, Dietz HC, et al. Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5' end. *Genomics*. 1993;17:476-484.
21. Biery NJ, Eldadah ZA, Moore CS. Revised genomic organization of FBN1 and significance for regulated gene expression. *Genomics*. 1999;56:70-77.
22. Halliday D, Hutchinson S, Kettle S, et al. Molecular analysis of eight mutations in FBN1. *Hum Genet*. 1999;105:587-597.
23. Pereira L, Andrikopoulos K, Tian J, et al. Targeting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. *Nat Genet*. 1997;17:218-222.
24. Pereira L, Lee SY, Gayraud B, et al. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. *Proc Natl Acad Sci U S A*. 1999;96:3819-3823.
25. Bunton TE, Biery NJ, Gayraud B. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. *Circ Res*. 2001;88:37-43.
26. Saharinen J, Hyttianen M, Taipale J, et al. Latent transforming growth factor  $\beta$  binding proteins (LTBPs)—structural extracellular matrix proteins for targeting TGF- $\beta$  action. *Cytokine Growth Factor Rev*. 1999;10:99-107.
27. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF- $\beta$  activation contributes to pathogenesis in Marfan

- syndrome. *Nat Genet* 2003. 2003;33:407-411.
28. Ng CM, Cheng A, Myers LA, et al. TGF- $\beta$  dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. *J Clin Invest*. 2004;114:1586-1592.
  29. Beighton P, de Paepe A, Danks D, et al. International Nosology of Heritable Disorders of Connective Tissue, Berlin, 1986. *Am J Med Genet*. 1988;29:581-594.
  30. De Paepe A, Devereaux RV, Dietz HC, et al. Revised diagnostic criteria for the Marfan syndrome. *Am J Med Genet*. 1996;62:417-426.
  31. Milewicz DM, Dietz HC, Miller C. Treatment of aortic disease in patients with Marfan syndrome. *Circulation*. 2005;111:e150-e157.
  32. Loeys B, Nuytinck L, Delvaux I, et al. Genotype and phenotype analysis of 171 patients referred for the molecular study of the fibrillin-1 gene because of suspected Marfan syndrome. *Arch Intern Med*. 2001;161:2447-2554.
  33. Loeys B, De Backer J, Van Acker P, et al. Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. *Hum Mutat*. 2004;24:140-146.
  34. Glesby MJ, Pyeritz RE. Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum. *JAMA*. 1989;262:523-528.
  35. Nijbroek G, Sood S, McIntosh I, et al. Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons. *Am J Hum Genet*. 1995;57:8-21.
  36. Sood S, Eldadah ZA, Dietz HC, et al. Mutation in fibrillin-1 and the marfanoid caranosynostosis (Schprintzen-Goldberg) syndrome. *Nat Genet*. 1996;12:209-211.
  37. Wang M, Clericuzio CL, Godfrey M. Familial occurrence of typical and lethal congenital contractural arachnodactyly caused by misplacing of exon 34 in FBN2. *Am J Hum Genet*. 1997;59:1027-1034.
  38. Pyeritz RE, Wappel MA. Mitral valve dysfunction in Marfan syndrome. Clinical and echocardiographic study of prevalence and natural history. *Am J Med*. 1983;74:797-807.
  39. Meijboom LJ, Timmermans J, van Tintelen JP, et al. Evaluation of left ventricular dimensions and function in Marfan syndrome with significant valvular regurgitation. *Am J Cardiol*. 2005;95:795-797.
  40. Roman MJ, Devereux RB, Kramer-Fox R, et al. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. *Am J Cardiol*. 1989;95:795-797.
  41. Gott VL, Greene PS, Alejo DE, et al. Replacement of the aortic root in patients with Marfan syndrome. *N Engl J Med*. 1999;340:1307-1313.
  42. Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young athletes: clinical, demographic, and pathologic profiles. *JAMA*. 1996;276:199-204.
  43. Yeatman AT, Bornemeier RA, McCrindle BW, et al. Long-term outcome in patients with Marfan syndrome: is aortic dissection the only cause of death? *J Am Coll Cardiol*. 2003;41:329-332.
  44. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. *Circulation*. 2004;109:2807-2816.
  45. Maron BJ, Mitten MJ, Quandt EF, et al. Competitive athletes with cardiovascular disease: the case of Nicholas Knapp. *N Engl J Med*. 1998;339:1632-1635.
  46. Shores J, Berger KR, Murphy EA, et al. Progression of aortic dilatation and the benefit of long-term  $\beta$ -blockade in Marfan syndrome. *N Engl J Med*. 1994;330:1335-1341.
  47. Rossi-Foulkes R, Roman MJ, Rosen SE, et al. Phenotypic features and impact of  $\beta$ -blockade or calcium antagonist therapy on aortic lumen size in Marfan syndrome. *Am J Cardiol*. 1999;83:1364-1368.
  48. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT-1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. *Science*. 2006;312:117-121.
  49. Matt P, Habashi JP, Carrel T, et al. Recent advances in Marfan syndrome: should we now treat surgical patients with

- losartan? *J Cardiovasc Thor Surg*. 2008;135:389-394.
50. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysm: simple prediction based on size. *Ann Thor Surg*. 2003;73:17-27.
  51. Lemaire SA, Carter SA, Volguina IV, et al. Spectrum of aortic operations in 300 patients with confirmed or suspected Marfan syndrome. *Ann Thor Surg*. 2006;81:2063-2078.
  52. Bentall H, De Bono A. A technique for complete replacement of the ascending aorta. *Thorax*. 1968;23:338-339.
  53. deOliviera NC, David TE, Ivanov J, et al. Results of surgery for aortic root aneurysm in patients with Marfan syndrome. *J Thorac Cardiovasc Surg*. 2003;125:789-796.
  54. Bethea BT, Fitton TP, Alejo DE, et al. Results of aortic valve-sparing operations: experience with remodeling and reimplantation procedures in 65 patients. *Ann Thorac Surg*. 2004;78:767-772.
  55. Crawford ES. Marfan's syndrome: broad spectral surgical treatment of cardiovascular manifestations. *Ann Surg*. 1983;198:487-505.
  56. Coselli JS, LeMaire SA, Buket S. Marfan syndrome: the variability and outcome of operative management. *J Vasc Surg*. 1995;21:432-443.
  57. Dardik A, Krosnick T, Perler BA, et al. Durability of thoracoabdominal aortic aneurysm repair in patients with connective tissue disorders. *J Vasc Surg*. 2002;36:696-703.
  58. Dardik A, Perler BA, Roseborough GS, et al. Aneurysmal expansion of the visceral patch after thoracoabdominal aortic replacement: an argument for limiting patch size? *J Vasc Surg*. 2001;34:405-410.
  59. Expert consensus document on the treatment of descending thoracic aortic disease using endovascular grafts. *Ann Thor Surg*. 2008;85:S1-41.
  60. Geisbusch P, Kotelis D, von Tengg-Kobligk H, et al. Thoracic aortic endografting in patients with connective tissue diseases. *J Endovasc Ther*. 2008;15:144-149.
  61. Steinman B, Royce PM, Superti-Furga A. *Ehlers-Danlos Syndrome, in Connective Tissue and its Heritable Disorders*. New York, NY: Wiley-Liss; 2002:431-523.
  62. Superti-Furga A, Steinman B, Byers PH. Type III collagen deficiency. *Lancet*. 1989;1:903-904.
  63. Pope FM, Martin GR, McKusick VA. Inheritance of Ehlers-Danlos type IV syndrome. *J Med Genet*. 1977;14:200-204.
  64. Milewicz DM, Witz AM, Smith AC, et al. Parental somatic and germ-line mosaicism for a mult exon deletion with unusual endpoints in a type III collagen (COL3A1) allele produces Ehlers-Danlos syndrome type IV in the heterozygous offspring. *Am J Hum Genet*. 1993;53:62-70.
  65. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos type IV, the vascular type. *N Engl J Med*. 2000;342:673-680.
  66. Pope FM, Narcisi P, Nicholls AC, et al. COL3A1 mutations cause variable clinical phenotypes including acrogeria and vascular rupture. *Br J Dermatol*. 1996;135:163-181.
  67. Prockop DJ. Osteogenesis imperfecta: phenotypic heterogeneity, protein suicide, short and long collagen. *Am J Hum Genet*. 1984;36:499-505.
  68. Clark JG, Kuhn C, Uitto J. Lung collagen in type IV Ehlers-Danlos syndrome. *Am Rev Respir Dis*. 1980;122:971-978.
  69. Nerlich AG, Stoss H, Lehman H, et al. Pathomorphological and biochemical alterations in Ehlers-Danlos syndrome type IV. *Pathol Res Pract*. 1994;190:697-706.
  70. Epstein EH.  $\alpha 1(\text{III})$  human skin collagen, release by pepsin digestion and preponderance in fetal life. *J Biol Chem*. 1974;249:3225-3231.
  71. Holbrook KA, Byers PH. Ultrastructural characteristics of the skin in a form of the Ehlers-Danlos syndrome type IV. *Lab Invest*. 1981;44:342-350.
  72. Crowther MA, Lach B, Dunmore PJ, et al. Vascular collagen fibril morphology in type IV Ehlers-Danlos syndrome. *Connect Tissue Res*. 1990;25:209-217.



73. Beighton P, De Paepe A, Danks D, et al. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. *Am J Med Genet.* 1997;77:31-37.
74. Nuytinck L, Narcisi P, Renard JP, et al. Detection and characterization of an overmodified type III collagen by analysis of non-connective tissues in a patient with Ehlers-Danlos syndrome IV. *J Med Genet.* 1992;29:375-380.
75. Roberts DL, Pope FM, Nicholls AC, et al. Ehlers-Danlos syndrome type IV mimicking non-accidental injury in a child. *Br J Dermatol.* 1984;111:341-345.
76. Leblanc R, Lorenzo A, van der Rest M. Type III collagen mutations and cerebral aneurysms. *Stroke.* 1989;20:1432-1433.
77. Dolan P, Sisko F, Riley E. Anesthetic considerations for Ehlers-Danlos syndrome. *Anesthesiology.* 1980;52:266-269.
78. Freeman RK, Swegle J, Sise MJ. The surgical complications of Ehlers-Danlos syndrome. *Am Surg.* 1996;62:869-873.
79. Cikrit DF, Miles JH, Silver D. Spontaneous arterial perforation: the Ehlers-Danlos specter. *J Vasc Surg.* 1987;5:248-255.
80. Germain DP. Clinical genetic features of vascular Ehlers-Danlos syndrome. *Ann Vasc Surg.* 2002;16:391-397.
81. Berqvist D. Ehlers-Danlos type IV syndrome: a review from a vascular surgical point of view. *Eur J Surg.* 1996;162:163-170.
82. Oderich GS, Panneton JM, Bower TC. The spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV. A 30 year experience. *J Vasc Surg.* 2005;42:98-106.
83. Weinbaum PJ, Cassidy SB, Campbell WA. Pregnancy management and successful outcome of Ehlers-Danlos syndrome type IV. *Am J Perinatol.* 1987;4:134-137.
84. Loeys BL, Schwarze U, Holm T. Aneurysm syndromes caused by mutations in the TGF- $\beta$  receptor. *N Engl J Med.* 2006;355:788-798.
85. Loeys B, Chen J, Neptune E, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive, and skeletal development caused by mutations in TGFBR1 and TGFBR2. *Nat Genet.* 2005;37:275-281.
86. Williams JA, Loeys BL, Nwakanma LU, et al. Early surgical experience with Loeys-Dietz: a new syndrome of aggressive thoracic aortic aneurysm disease. *Ann Thorac Surg.* 2007;83:s757-s763.
87. Coucke PJ, Willaert A, Wessels MW, et al. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. *Nat Genet.* 2006;38:452-457.
88. Black JH, Loeys BL, Oswald G, Dietz HC. Peripheral vascular manifestations of Loeys-Dietz syndrome. Paper presented at the annual meeting of the Society for Vascular Surgery, 2008, San Diego, CA.
89. Lemaire SA, Pannu H, Tran-Fadulu V, et al. Severe aortic and arterial aneurysms associated with TGFBR2 mutation. *Nat Clin Pract Cardiovasc Med.* 2007;4:167-171.
90. Albornoz G, Coady MA, Roberts M, et al. Familial thoracic aortic aneurysms and dissections—incidence, modes of inheritance, and phenotypic patterns. *Ann Thorac Surg.* 2006;82:1400-1406.
91. Biddinger AM, Rocklin J, Coselli JS, et al. Familial thoracic aortic dilatations and dissections: a case control study. *J Vasc Surg.* 1997;25:506-511.
92. Pannu H, Avidian N, Tran-Fadulu V, et al. Genetic basis of thoracic aortic aneurysms and dissections, potential relevance to abdominal aortic aneurysms. *Ann N Y Acad Sci.* 2006;1085:242-255.
93. Pannu H, Tran-Fadulu V, Papke C, et al. MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin 2. *Hum Mol Genet.* 2007;16:2453-2462.
94. Guo D, Hasham SQ, Kuang SQ, et al. Familial thoracic aortic aneurysms and dissections: genetic heterogeneity with major locus mapping to 5q13-14. *Circulation.* 2001;103:2461-2468.
95. Tran-Fadulu V, Chen JH, Lemuth D, et al. Familial thoracic aortic aneurysms and dissections: three families with early-onset ascending and descending aortic dissections in women. *Am J Med Genet.* 2006;140A:1196-1202.
96. Kakko S, Raisanen T, Tamminen M, et al. Candidate locus analysis of familial ascending aortic aneurysms and dissections confirms the linkage to chromosome 5q13-14 in Finnish families. *J Thorac Cardiovasc Surg.* 2003;126:106-113.
97. Hasham SN, Willing MC, Guo DC, et al. Mapping a locus for familial thoracic aortic aneurysms and dissections (TAAD2)

- to 3p24-25. *Circulation*. 2003;107:3184-3190.
98. Pannu H, Tran-Fadulu V, Chang J, et al. Mutations in transforming growth factor  $\beta$  receptor type II cause familial thoracic aortic aneurysms and dissections. *Circulation*. 2005;112:513-520.
  99. Zhu L, Vranckx R, Khau Van Kien P, et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. *Nat Genet*. 2006;38:343-349.
  100. Guo DC, Pannu H, Tran-Fadulu V, et al. Mutations in smooth muscle  $\alpha$ -actin (ACTA-2) lead to thoracic aortic aneurysms and dissections. *Nat Genet*. 2007;39:1488-1493.

## 第 141 章

1. Edwards MS, Hansen KJ, Craven TE, et al. Relationships between renovascular disease, blood pressure, and renal function in the elderly: a population-based study. *Am J Kidney Dis*. 2003;41:990-996.
2. Piercy KT, Hundley JC, Stafford JM, et al. Renovascular disease in children and adolescents. *J Vasc Surg*. 2005;41:973-982.
3. Stanley JC, Criado E, Upchurch GR Jr, et al. Pediatric renovascular hypertension: 132 primary and 30 secondary operations in 97 children. *J Vasc Surg*. 2006;44:1219-1228; discussion 1228-1229.
4. Dorros G, Jaff M, Mathiak L, et al. Four-year follow-up of Palmaz-Schatz stent revascularization as treatment for atherosclerotic renal artery stenosis. *Circulation*. 1998;98:642-647.
5. Johansson M, Herlitz H, Jensen G, et al. Increased cardiovascular mortality in hypertensive patients with renal artery stenosis. Relation to sympathetic activation, renal function and treatment regimens. *J Hypertens*. 1999;17:1743-1750.
6. Tigerstedt R, Bergman PG. Niere und Kreislauf. *Skand Arch Physiol*. 1899;8:223.
7. Katzenstein M, Experimenteller Beirag zur Erkenntnis der bei Nephritis auftretenden Hypertrophie des linken Herzens. *Virchows Arch*. 1905;182:327.
8. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension. *J Exp Med*. 1934;59:347-379.
9. Leadbetter WFG, Burkland C. Hypertension in unilateral renal disease. *J Urol*. 1938;39:611.
10. Smith HW. Unilateral nephrectomy in hypertensive disease. *J Urol*. 1956;76:685-701.
11. Freeman NE, Leeds FH, Elliott WG, et al. Thromboendarterectomy for hypertension due to renal artery occlusion. *JAMA*. 1954;156:1077-1079.
12. Abelson DS, Haimovich H, Hurwitt ES, Seidenberg B. Splenorenal arterial anastomoses. *Circulation*. 1956;14:532-539.
13. Decamp PT, Birchall R. Recognition and treatment of renal arterial stenosis associated with hypertension. *Surgery*. 1958;43:134-151; discussion 151-152.
14. Luke JC, Levitan BA. Revascularization of the kidney in hypertension due to renal artery stenosis. *AMA Arch Surg*. 1959;79:269-275.
15. Morris GC Jr, De Bakey ME, Cooley DA. Surgical treatment of renal failure of renovascular origin. *JAMA*. 1962;182:609.
16. Morris GC Jr, Cooley DA, Crawford ES, et al. Renal revascularization for hypertension. Clinical and physiological studies in 32 cases. *Surgery*. 1960;48:95-110.
17. Braun-Meriendez E, Fasciolo JC, Leloir LF, et al. La substancia hipertensora de la sangre del rinon, isquemiado. *Rev Soc Argent Biol*. 1939;15:420.
18. Lentz KE, Skeggs LT Jr, Woods KR, et al. The amino acid composition of hypertensin II and its biochemical relationship to hypertensin I. *J Exp Med*. 1956;104:183-191.
19. Paige IH, Helmes OM. A crystalline pressor substance (angiotensin) resulting from the reaction between renin and renin activator. *J Exp Med*. 1940;71.
20. Tobian L. Relationship of juxtaglomerular apparatus to renin and angiotensin. *Circulation*. 1962;25:189-192.
21. Hansen KJ, Cherr GS, Dean RH. Dialysis-free survival after surgical repair of ischemic nephropathy. *Cardiovasc Surg*. 2002;10:400-404.

22. Bengtsson U, Bergentz SE, Norback B. Surgical treatment of renal artery stenosis with impending uremia. *Clin Nephrol*. 1974;2:222-229.
23. Dean RH, Englund R, Dupont WD, et al. Retrieval of renal function by revascularization. Study of preoperative outcome predictors. *Ann Surg*. 1985;202:367-375.
24. Dean RH, Lawson JD, Hollifield JW, et al. Revascularization of the poorly functioning kidney. *Surgery*. 1979;85:44-52.
25. Libertino JA, Zinman L. Revascularization of the poorly functioning and nonfunctioning kidney. In: Novick AC, Stratton RA, eds. *Vascular Problems in Urologic Surgery*. Philadelphia: WB Saunders; 1982:173.
26. Novick AC, Pohl MA, Schreiber M, et al. Revascularization for preservation of renal function in patients with atherosclerotic renovascular disease. *J Urol*. 1983;129:907-912.
27. Kaylor WM, Novick AC, Ziegelbaum M, Vidt DG. Reversal of end stage renal failure with surgical revascularization in patients with atherosclerotic renal artery occlusion. *J Urol*. 1989;141:486-488.
28. Hansen KJ, Thomason RB, Craven TE, et al. Surgical management of dialysis-dependent ischemic nephropathy. *J Vasc Surg*. 1995;21:197-209; discussion 209-211.
29. Ascer E, Gennaro M, Rogers D. Unilateral renal artery revascularization can salvage renal function and terminate dialysis in selected patients with uremia. *J Vasc Surg*. 1993;18:1012-1018.
30. Bloch MJ, Basile J. Clinical insights into the diagnosis and management of renovascular disease. An evidence-based review. *Minerva Med*. 2004;95:357-373.
31. Chonchol M, Linas S. Diagnosis and management of ischemic nephropathy. *Clin J Am Soc Nephrol*. 2006;1:172-181.
32. Gruntzig A, Kuhlmann U, Vetter W, et al. Treatment of renovascular hypertension with percutaneous transluminal dilatation of a renal-artery stenosis. *Lancet*. 1978;1:801-802.
33. Joffe F, Bernadet P, Rousseau H, et al. Usefulness of a percutaneous endoprosthesis in the treatment of renal artery stenoses. *Arch Mal Coeur Vaiss*. 1989;82:1199-1204.
34. Murphy TP, Soares G, Kim M. Increase in utilization of percutaneous renal artery interventions by medicare beneficiaries, 1996-2000. *AJR Am J Roentgenol*. 2004;183:561-568.
35. Hansen KJ, Edwards MS, Craven TE, et al. Prevalence of renovascular disease in the elderly: a population-based study. *J Vasc Surg*. 2002;36:443-451.
36. Alhaddad IA, Blum S, Heller EN, et al. Renal artery stenosis in minority patients undergoing diagnostic cardiac catheterization: prevalence and risk factors. *J Cardiovasc Pharmacol Ther*. 2001;6:147-153.
37. Schwartz CJ, White TA. Stenosis of renal artery: an unselected necropsy study. *BMJ*. 1964;2:1415-1421.
38. Holley KE, Hunt JC, Brown AL Jr, et al. Renal artery stenosis. A clinical-pathologic study in normotensive and hypertensive patients. *Am J Med*. 1964;37:14-22.
39. Jean WJ, al-Bitar I, Zwicke DL, et al. High incidence of renal artery stenosis in patients with coronary artery disease. *Cathet Cardiovasc Diagn*. 1994;32:8-10.
40. Miralles M, Corominas A, Cotillas J, et al. Screening for carotid and renal artery stenoses in patients with aortoiliac disease. *Ann Vasc Surg*. 1998;12:17-22.
41. Appel RG, Bleyer AJ, Reavis S, Hansen KJ. Renovascular disease in older patients beginning renal replacement therapy. *Kidney Int*. 1995;48:171-176.
42. Davis RP, Pearce JD, Craven TE, et al. Atherosclerotic renovascular disease among hypertensive adults. *J Vasc Surg*. 2009;50:564-570, 571.e1-3; discussion 571.
43. Lawson JD, Boerth R, Foster JH, Dean RH. Diagnosis and management of renovascular hypertension in children. *Arch Surg*. 1977;112:1307-1316.
44. Rihal CS, Textor SC, Breen JF, et al. Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography. *Mayo Clin Proc*. 2002;77:309-316.
45. Harding MB, Smith LR, Himmelstein SI, et al. Renal artery stenosis: prevalence and associated risk factors in patients

undergoing routine cardiac catheterization. *J Am Soc Nephrol*. 1992;2:1608-1616.

46. Kawarada O, Yokoi Y, Morioka N, Takemoto K. Renal artery stenosis in cardio-and cerebrovascular disease: renal duplex ultrasonography as an initial screening examination. *Circ J*. 2007;71:1942-1947.
47. Nakamura S, Iihara K, Matayoshi T, et al. The incidence and risk factors of renal artery stenosis in patients with severe carotid artery stenosis. *Hypertens Res*. 2007;30:839-844.
48. Greco BA, Breyer JA. The natural history of renal artery stenosis: who should be evaluated for suspected ischemic nephropathy? *Semin Nephrol*. 1996;16:2-11.
49. O'Neil EA, Hansen KJ, Canzanello VJ, et al. Prevalence of ischemic nephropathy in patients with renal insufficiency. *Am Surg*. 1992;58:485-490.
50. Mailloux LU, Napolitano B, Bellucci AG, et al. Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: a 20-year clinical experience. *Am J Kidney Dis*. 1994;24:622-629.
51. Guo H, Kalra PA, Gilbertson DT, et al. Atherosclerotic renovascular disease in older US patients starting dialysis, 1996 to 2001. *Circulation*. 2007;115:50-58.
52. Cherr GS, Hansen KJ, Craven TE, et al. Surgical management of atherosclerotic renovascular disease. *J Vasc Surg*. 2002;35:236-245.
53. Dean RH, Kieffer RW, Smith BM, et al. Renovascular hypertension: anatomic and renal function changes during drug therapy. *Arch Surg*. 1981;116:1408-1415.
54. Schreiber MJ, Pohl MA, Novick AC. The natural history of atherosclerotic and fibrous renal artery disease. *Urol Clin North Am*. 1984;11:383-392.
55. Tollefson DF, Ernst CB. Natural history of atherosclerotic renal artery stenosis associated with aortic disease. *J Vasc Surg*. 1991;14:327-331.
56. Crowley JJ, Santos RM, Peter RH, et al. Progression of renal artery stenosis in patients undergoing cardiac catheterization. *Am Heart J*. 1998;136:913-918.
57. Zierler RE, Bergelin RO, Isaacson JA, Strandness DE Jr. Natural history of atherosclerotic renal artery stenosis: a prospective study with duplex ultrasonography. *J Vasc Surg*. 1994;19:250-257; discussion 257-258.
58. Caps MT, Perissinotto C, Zierler RE, et al. Prospective study of atherosclerotic disease progression in the renal artery. *Circulation*. 1998;98:2866-2872.
59. Chabova V, Schirger A, Stanson AW, et al. Outcomes of atherosclerotic renal artery stenosis managed without revascularization. *Mayo Clin Proc*. 2000;75:437-444.
60. Baboolal K, Evans C, Moore RH. Incidence of end-stage renal disease in medically treated patients with severe bilateral atherosclerotic renovascular disease. *Am J Kidney Dis*. 1998;31:971-977.
61. Pearce JD, Craven BL, Craven TE, et al. Progression of atherosclerotic renovascular disease: a prospective population-based study. *J Vasc Surg*. 2006;44:955-962; discussion 962-963.
62. Losito A, Fagugli RM, Zampi I, et al. Comparison of target organ damage in renovascular and essential hypertension. *Am J Hypertens*. 1996;9:1062-1067.
63. Valentine RJ, Clagett GP, Miller GL, et al. The coronary risk of unsuspected renal artery stenosis. *J Vasc Surg*. 1993;18:433-439; discussion 439-440.
64. Conlon PJ, Athirakul K, Kovalik E, et al. Survival in renal vascular disease. *J Am Soc Nephrol*. 1998;9:252-256.
65. Edwards MS, Hansen KJ, Craven TE, et al. Associations between renovascular disease and prevalent cardiovascular disease in the elderly: a population-based study. *Vasc Endovasc Surg*. 2004;38:25-35.
66. Ovrehus KA, Andersen PE, Jacobsen IA. Treatment of renovascular hypertension by transluminal angioplasty-13 years experience in a single centre. *Blood Press*. 2007;16:335-340.
67. Ruchin PE, Baron DW, Wilson SH, et al. Long-term follow-up of renal artery stenting in an Australian population. *Heart Lung Circ*. 2007;16:79-84.

68. Bettmann MA, Dake MD, Hopkins LN, et al. Atherosclerotic Vascular Disease Conference: Writing Group VI: revascularization. *Circulation*. 2004;109:2643-2650.
69. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. *Pharmacol Rev*. 2007;59:251-287.
70. Bader M, Ganten D. Update on tissue renin-angiotensin systems. *J Mol Med*, 2008.
71. Fleming I, Kohlstedt K, Busse R. The tissue renin-angiotensin system and intracellular signalling. *Curr Opin Nephrol Hypertens*. 2006;15:8-13.
72. Belova LA. Angiotensin II-generating enzymes. *Biochemistry (Mosc)*. 2000;65:1337-1345.
73. Raines EW. PDGF and cardiovascular disease. *Cytokine Growth Factor Rev*. 2004;15:237-254.
74. Perazella MA, Setaro JF. Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders. *J Nucl Cardiol*. 2003;10:184-196.
75. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. *Am J Physiol Cell Physiol*. 2007;292:C82-C97.
76. Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. *Heart Fail Rev*. 2005;10:7-13.
77. Cowley AWJ, Roman RJ. The pressure-diuresis-natriuresis mechanism in normal and hypertensive states. In: Zanchetti A, Tarazi RC, eds. *Handbook of Hypertension*. London: Elsevier; 1986:295-314.
78. Guyton AC, Coleman TG, Bower JD, Granger HJ. Circulatory control in hypertension. *Circ Res*. 1970;27(Suppl 2).
79. Hobbs SD, Thomas ME, Bradbury AW. Manipulation of the renin angiotensin system in peripheral arterial disease. *Eur J Vasc Endovasc Surg*. 2004;28:573-582.
80. Ferrario CM. Contribution of cardiac output and peripheral resistance to experimental renal hypertension. *Am J Physiol*. 1974;226:711-717.
81. Pipinos II, Nypaver TJ, Moshin SK, et al. Response to angiotensin inhibition in rats with sustained renovascular hypertension correlates with response to removing renal artery stenosis. *J Vasc Surg*. 1998;28:167-177.
82. Folkow B. Physiological aspects of primary hypertension. *Physiol Rev*. 1982;62:347-504.
83. Rizzoni D, Porteri E, Guefi D, et al. Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. *Hypertension*. 2000;35:931-935.
84. Mortsell D, Malmqvist K, Held C, Kahan T. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. *J Intern Med*. 2007;261:472-479.
85. Dielis AW, Smid M, Spronk HM, et al. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. *Hypertension*. 2005;46:1236-1242.
86. Strawn WB, Ferrario CM. Mechanisms linking angiotensin II and atherogenesis. *Curr Opin Lipidol*. 2002;13:505-512.
87. Textor SC, Tarazi RC, Novick AC, et al. Regulation of renal hemodynamics and glomerular filtration in patients with renovascular hypertension during converting enzyme inhibition with captopril. *Am J Med*. 1984;76:29-37.
88. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? *Circulation*. 1994;89:493-498.
89. Textor SC, Wilcox CS. Renal artery stenosis: a common, treatable cause of renal failure? *Annu Rev Med*. 2001;52:421-442.
90. Weder AB. Renal protective effects of angiotensin converting enzyme inhibitors. *Am J Hypertens*. 1990;3:273S-277S.
91. Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. *Am J Med Sci*. 2003;326:15-24.
92. Chade AR, Rodriguez-Porcel M, Grande JP, et al. Distinct renal injury in early atherosclerosis and renovascular disease. *Circulation*. 2002;106:1165-1171.
93. Kobayashi S, Ishida A, Moriya A, et al. Angiotensin II receptor blockade limits kidney injury in two-kidney, one-clip Goldblatt hypertensive rats with special reference to phenotypic changes. *J Lab Clin Med*. 1999;133:134-143.
94. Kim S, Ohta K, Hamaguchi A, et al. Contribution of renal angiotensin II type I receptor to gene expressions in

- hypertension-induced renal injury. *Kidney Int.* 1994;46:1346-1358.
95. Johnson RJ, Alpers CE, Yoshimura A, et al. Renal injury from angiotensin II-mediated hypertension. *Hypertension.* 1992;19:464-474.
  96. Eddy AA. Molecular insights into renal interstitial fibrosis. *J Am Soc Nephrol.* 1996;7:2495-2508.
  97. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. *N Engl J Med.* 1996;334:939-945.
  98. Scoble JE. Atherosclerotic nephropathy. *Kidney Int.* 1999;71(Suppl.):S106-S109.
  99. Tullus K, Brennan E, Hamilton G, et al. Renovascular hypertension in children. *Lancet.* 2008;371:1453-1463.
  100. Cohen MG, Pascua JA, Garcia-Ben M, et al. A simple prediction rule for significant renal artery stenosis in patients undergoing cardiac catheterization. *Am Heart J.* 2005;150:1204-1211.
  101. Cheung CM, Hegarty J, Kalra PA. Dilemmas in the management of renal artery stenosis. *Br Med Bull.* 2005;73-74:35-55.
  102. Young WF Jr. Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism. *Rev Endocr Metab Disord.* 2007;8:309-320.
  103. Hansen KJ, Tribble RW, Reavis SW, et al. Renal duplex sonography: evaluation of clinical utility. *J Vasc Surg.* 1990;12:227-236.
  104. Radermacher J, Chavan A, Schaffer J, et al. Detection of significant renal artery stenosis with color Doppler sonography: combining extrarenal and intrarenal approaches to minimize technical failure. *Clin Nephrol.* 2000;53:333-343.
  105. Hua HT, Hood DB, Jensen CC, et al. The use of color flow duplex scanning to detect significant renal artery stenosis. *Ann Vasc Surg.* 2000;14:118-124.
  106. Nazzal MM, Hoballah JJ, Miller EV, et al. Renal hilar Doppler analysis is of value in the management of patients with renovascular disease. *Am J Surg.* 1997;174:164-168.
  107. Miralles M, Cairois M, Cotillas J, et al. Value of Doppler parameters in the diagnosis of renal artery stenosis. *J Vasc Surg.* 1996;23:428-435.
  108. Motew SJ, Cherr GS, Craven TE, et al. Renal duplex sonography: main renal artery versus hilar analysis. *J Vasc Surg.* 2000;32:462-469; 469-471.
  109. Strandness DE Jr. Duplex imaging for the detection of renal artery stenosis. *Am J Kidney Dis.* 1994;24:674-678.
  110. Mollo M, Pelet V, Mouawad J, et al. Evaluation of colour duplex ultrasound scanning in diagnosis of renal artery stenosis, compared to angiography: a prospective study on 53 patients. *Eur J Vasc Endovasc Surg.* 1997;14:305-309.
  111. Olin JW, Piedmonte MR, Young JR, et al. The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. *Ann Intern Med.* 1995;122:833-838.
  112. Kawarada O, Yokoi Y, Takemoto K, et al. The performance of renal duplex ultrasonography for the detection of hemodynamically significant renal artery stenosis. *Catheter Cardiovasc Interv.* 2006;68:311-318.
  113. de Haan MW, Kroon AA, Flobbe K, et al. Renovascular disease in patients with hypertension: detection with duplex ultrasound. *J Hum Hypertens.* 2002;16:501-507.
  114. Johansson M, Jensen G, Aurell M, et al. Evaluation of duplex ultrasound and captopril renography for detection of renovascular hypertension. *Kidney Int.* 2000;58:774-782.
  115. Ioannou G, Thorpe RJ, MacKechnie SG, et al. Duplex sonography in detection of renal artery stenosis: a simplified approach using new parameters. *Australas Radiol.* 1993;37:386-388.
  116. Radermacher J, Chavan A, Bleck J, et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. *N Engl J Med.* 2001;344:410-417.
  117. Fraioli F, Catalano C, Bertolotti L, et al. Multidetector-row CT angiography of renal artery stenosis in 50 consecutive patients: prospective interobserver comparison with DSA. *Radiol Med.* 2006;111:459-468.
  118. Kemerink GJ, de Haan MW, Vasbinder GB, et al. The effect of equipment set up on patient radiation dose in conventional

- and CT angiography of the renal arteries. *Br J Radiol.* 2003;76:625-630.
119. Leiner T, de Haan MW, Nelemans PJ, et al. Contemporary imaging techniques for the diagnosis of renal artery stenosis. *Eur Radiol.* 2005;15:2219-2229.
  120. Schoenberg SO, Rieger J, Weber CH, et al. High-spatial-resolution MR angiography of renal arteries with integrated parallel acquisitions: comparison with digital subtraction angiography and US. *Radiology.* 2005;235:687-698.
  121. Kaatee R, Beek FJ, de Lange EE, et al. Renal artery stenosis: detection and quantification with spiral CT angiography versus optimized digital subtraction angiography. *Radiology.* 1997;205:121-127.
  122. Equine O, B é é é JP, Mounier-V é é é C, et al. Importance of the echo-doppler and helical angioscanner of the renal arteries in the management of renovascular diseases. Results of a retrospective study in 113 patients. *Arch Mal Coeur Vaiss.* 1999;92:1043-1045.
  123. Wittenberg G, Kenn W, Tschammler A, et al. Spiral CT angiography of renal arteries: comparison with angiography. *Eur Radiol.* 1999;9:546-551.
  124. Korst MB, Joosten FB, Postma CT, et al. Accuracy of normal-dose contrast-enhanced MR angiography in assessing renal artery stenosis and accessory renal arteries. *AJR Am J Roentgenol.* 2000;174:629-634.
  125. Bongers V, Bakker J, Beutler JJ, et al. Assessment of renal artery stenosis: comparison of captopril renography and gadolinium-enhanced breath-hold MR angiography. *Clin Radiol.* 2000;55:346-353.
  126. De Cobelli F, Venturini M, Vanzulli A, et al. Renal arterial stenosis: prospective comparison of color Doppler US and breath-hold, three-dimensional, dynamic, gadolinium-enhanced MR angiography. *Radiology.* 2000;214:373-380.
  127. Voiculescu A, Hofer M, Hetzel GR, et al. Noninvasive investigation for renal artery stenosis: contrast-enhanced magnetic resonance angiography and color Doppler sonography as compared to digital subtraction angiography. *Clin Exp Hypertens.* 2001;23:521-531.
  128. Vasbinder GB, Nelemans PJ, Kessels AG, et al. Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis. *Ann Intern Med.* 2004;141:674-682; discussion 682.
  129. Beregi JP, Louveigny S, Gautier C, et al. Fibromuscular dysplasia of the renal arteries: comparison of helical CT angiography and arteriography. *AJR Am J Roentgenol.* 1999;172:27-34.
  130. Rountas C, Vlychou M, Vassiou K, et al. Imaging modalities for renal artery stenosis in suspected renovascular hypertension: prospective intraindividual comparison of color Doppler US, CT angiography, GD-enhanced MR angiography, and digital subtraction angiography. *Ren Fail.* 2007;29:295-302.
  131. Vossenhilch R, Fischer U. Contrast-enhanced MR angiography of abdominal vessels: is there still a role for angiography? *Eur Radiol.* 2002;12:218-230.
  132. Giroletti E, Corbucci G. Cardiac magnetic resonance imaging: patient safety considerations. *Phys Med.* 2005;21:5-13.
  133. Marcos HB, Choyke PL. Magnetic resonance angiography of the kidney. *Semin Nephrol.* 2000;20:450-455.
  134. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. *Lancet.* 2000;356:1000-1001.
  135. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). *Curr Opin Rheumatol.* 2006;18:614-617.
  136. Cowper SE. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. *Adv Dermatol.* 2007;23:131-154.
  137. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. *AJR Am J Roentgenol.* 2007;188:586-592.
  138. Penfield JG, Reilly RF Jr. What nephrologists need to know about gadolinium. *Nat Clin Pract Nephrol.* 2007;3:654-668.
  139. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. *Acta Radiol.* 2001;42:339-341.
  140. Cinat ME, Casalmé C, Wilson SE, et al. Computed tomography angiography validates duplex sonographic evaluation of

- carotid artery stenosis. *Am Surg*. 2003;69:842-847.
141. Marro B, Zouaoui A, Koskas F, et al. Computerized tomographic angiography scan following carotid endarterectomy. *Ann Vasc Surg*. 1998;12:451-456.
  142. Davis BA, Crook JE, Vestal RE, Oates JA. Prevalence of renovascular hypertension in patients with grade III or IV hypertensive retinopathy. *N Engl J Med*. 1979;301:1273-1276.
  143. Campbell NR, Drouin D, Feldman RD. The 2001 Canadian hypertension recommendations: take-home messages. *CMAJ*. 2002;167:661-668.
  144. Kane GC, Stanson AW, Kalnicka D, et al. Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes. *Nephrol Dial Transplant*. 2008;23:1233-1240.
  145. Mannebach PC, Dieter RS, Marks DS. Use of gadolinium-based angiography for renal artery stenting in a patient with renal insufficiency: a case report. *Angiology*. 2006;57:526-529.
  146. Edwards MS, Corriere MA, Craven TE, et al. Atheroembolism during percutaneous renal artery revascularization. *J Vasc Surg*. 2007;46:55-61.
  147. Silva JA, Chan AW, White CJ, et al. Elevated brain natriuretic peptide predicts blood pressure response after stent revascularization in patients with renal artery stenosis. *Circulation*. 2005;111:328-333.
  148. Michaely HJ, Schoenberg SO, Oesingmann N, et al. Renal artery stenosis: functional assessment with dynamic MR perfusion measurements-feasibility study. *Radiology*. 2006;238:586-596.
  149. Farmer CK, Reidy J, Kalra PA, et al. Individual kidney function before and after renal angioplasty. *Lancet*. 1998;352:288-289.
  150. Jonker GJ, de Zeeuw D, Huisman RM, et al. Angiotensin converting enzyme inhibition improves diagnostic procedures for renovascular hypertension in dogs. *Hypertension*. 1988;12:411-419.
  151. Eklof H, Ahlstrom H, Magnusson A, et al. A prospective comparison of duplex ultrasonography, captopril renography, MRA, and CTA in assessing renal artery stenosis. *Acta Radiol*. 2006;47:764-774.
  152. van Jaarsveld BC, Krijnen P, Derkx FH, et al. The place of renal scintigraphy in the diagnosis of renal artery stenosis. Fifteen years of clinical experience. *Arch Intern Med*. 1997;157:1226-1234.
  153. Geyskes GG, de Bruyn AJ. Captopril renography and the effect of percutaneous transluminal angioplasty on blood pressure in 94 patients with renal artery stenosis. *Am J Hypertens*. 1991;4:685S-689S.
  154. Taylor A. Radionuclide renography: a personal approach. *Semin Nucl Med*. 1999;29:102-127.
  155. Erbsloh-Moller B, Dumas A, Roth D, et al. Furosemide-131I-hippuran renography after angiotensin-converting enzyme inhibition for the diagnosis of renovascular hypertension. *Am J Med*. 1991;90:23-29.
  156. Vaughan ED Jr, Buhler FR, Laragh JH, et al. Renovascular hypertension: renin measurements to indicate hypersecretion and contralateral suppression, estimate renal plasma flow, and score for surgical curability. *Am J Med*. 1973;55:402-414.
  157. Voiculescu A, Schmitz M, Plum J, et al. Duplex ultrasound and renin ratio predict treatment failure after revascularization for renal artery stenosis. *Am J Hypertens*. 2006;19:756-763.
  158. de Leeuw PW. On the significance of renal vein renins in renovascular hypertension. *J Hypertens*. 2002;20:843-845.
  159. Anderson CA, Hansen KJ, Benjamin ME, et al. Renal artery fibromuscular dysplasia: results of current surgical therapy. *J Vasc Surg*. 1995;22:207-215; discussion 215-216.
  160. Hansen KJ, Cherr GS, Craven TE, et al. Management of ischemic nephropathy: dialysis-free survival after surgical repair. *J Vasc Surg*. 2000;32:472-481; discussion 481-482.
  161. Edwards MS, Craven TE, Burke GL, et al. Renovascular disease and the risk of adverse coronary events in the elderly: a prospective, population-based study. *Arch Intern Med*. 2005;165:207-213.
  162. Wollenweber J, Sheps SG, Davis GD. Clinical course of atherosclerotic renovascular disease. *Am J Cardiol*. 1968;21:60-71.
  163. Meaney TF, Dustan HP, McCormack LJ. Natural history of renal arterial disease. *Radiology*. 1968;91:881-887.



164. Zierler RE, Bergelin RO, Davidson RC, et al. A prospective study of disease progression in patients with atherosclerotic renal artery stenosis. *Am J Hypertens*. 1996;9:1055-1061.
165. Webster J, Marshall F, Abdalla M, et al. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. *J Hum Hypertens*. 1998;12:329-335.
166. van Jaarsveld BC, Krijnen P. Prospective studies of diagnosis and intervention: the Dutch experience. *Semin Nephrol*. 2000;20:463-473.
167. Pearce JD, Edwards MS, Craven TE, et al. Renal duplex parameters, blood pressure, and renal function in elderly people. *Am J Kidney Dis*. 2005;45:842-850.
168. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). *Am J Cardiol*. 1996;78:902-907.
169. Cheung CM, Patel A, Shaheen N, et al. The effects of statins on the progression of atherosclerotic renovascular disease. *Nephron Clin Pract*. 2007;107:c35-c42.
170. Khong TK, Missouris CG, Belli AM, MacGregor GA. Regression of atherosclerotic renal artery stenosis with aggressive lipid lowering therapy. *J Hum Hypertens*. 2001;15:431-433.
171. Duffield RG, Lewis B, Miller NE, et al. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial. *Lancet*. 1983;2:639-642.
172. Byington RP, Furberg CD, Crouse JR 3rd, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). *Am J Cardiol*. 1995;76:54C-59C.
173. de Groot E, Jukema JW, van Boven AJ, et al. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. *Am J Cardiol*. 1995;76:40C-46C.
174. Stanley JC, David M. Hume memorial lecture. Surgical treatment of renovascular hypertension. *Am J Surg*. 1997;174:102-110.
175. Hansen KJ, O'Neil EA, Reavis SW, et al. Intraoperative duplex sonography during renal artery reconstruction. *J Vasc Surg*. 1991;14:364-374.
176. Cambria RP, Brewster DC, L'Italien GJ, et al. Renal artery reconstruction for the preservation of renal function. *J Vasc Surg*. 1996;24:371-380; discussion 380-382.
177. Darling RC 3rd, Kreienberg PB, Chang BB, et al. Outcome of renal artery reconstruction: analysis of 687 procedures. *Ann Surg*. 1999;230:524-530; discussion 530-532.
178. Fergany A, Kolettis P, Novick AC. The contemporary role of extra-anatomical surgical renal revascularization in patients with atherosclerotic renal artery disease. *J Urol*. 1995;153:1798-1801; discussion 1801-1802.
179. Geroulakos G, Wright JG, Tober JC, et al. Use of the splenic and hepatic artery for renal revascularization in patients with atherosclerotic renal artery disease. *Ann Vasc Surg*. 1997;11:85-89.
180. Grigoryants V, Henke PK, Watson NC, et al. Iliorenal bypass: indications and outcomes following 41 reconstructions. *Ann Vasc Surg*. 2007;21:1-9.
181. Marone LK, Clouse WD, Dorer DJ, et al. Preservation of renal function with surgical revascularization in patients with atherosclerotic renovascular disease. *J Vasc Surg*. 2004;39:322-329.
182. Corriere MA, Edwards MS, Hansen KJ. Abdominal aortic aneurysm and renal artery stenosis. *Vasc Dis Management*. 2008;5:16-21.
183. Wong JM, Hansen KJ, Oskin TC, et al. Surgery after failed percutaneous renal artery angioplasty. *J Vasc Surg*. 1999;30:468-482.
184. Wykrzykowska JJ, Williams M, Laham RJ. Stabilization of renal function, improvement in blood pressure control and pulmonary edema symptoms after opening a totally occluded renal artery. *J Invasive Cardiol*. 2008;20:E26-E29.
185. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal

- failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). *Lancet*. 1997;349:1857-1863.
186. Ivanovic V, McKusick MA, Johnson CM 3rd, et al. Renal artery stent placement: complications at a single tertiary care center. *J Vasc Interv Radiol*. 2003;14:217-225.
  187. Textor SC. Atherosclerotic renal artery stenosis: overtreated but underrated? *J Am Soc Nephrol*. 2008;19:656-659.
  188. Korsakas S, Mohaupt MG, Kinkel HP, et al. Delay of dialysis in end-stage renal failure: prospective study on percutaneous renal artery interventions. *Kidney Int*. 2004;65:251-258.
  189. van de Ven PJ, Kaatee R, Beutler JJ, et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial. *Lancet*. 1999;353:282-286.
  190. Leertouwer TC, Gussenhoven EJ, Bosch JL, et al. Stent placement for renal arterial stenosis: where do we stand? A meta-analysis. *Radiology*. 2000;216:78-85.

## 第 142 章

1. Goldblatt H. Studies on experimental hypertension. *J Exp Med*. 1934;59:346.
2. Leadbetter WFG, Burkland CE. Hypertension in unilateral renal disease. *J Urol*. 1938;39:611.
3. Smith HW. Unilateral nephrectomy in hypertensive disease. *J Urol*. 1956;76:685.
4. Freeman N. Thromboendarterectomy for hypertension due to renal artery occlusion. *JAMA*. 1954;157:1077.
5. Abelson DS, Haimovici H, Hurwitt ES, Seidenberg B. Splenorenal arterial anastomoses. *Circulation*. 1956;14:532-539.
6. DeCamp PT, Birchall R. Recognition and treatment of renal arterial stenosis associated with hypertension. *Surgery*. 1958;43:134-151.
7. Luke JC, Levitan BA. Revascularization of the kidney in hypertension due to renal artery stenosis. *Arch Surg*. 1959;79:269-275.
8. Morris GC, Cooley DA, Crawford ES, et al. Renal revascularization for hypertension. Clinical and physiological studies in 32 cases. *Surgery*. 1960;48:95-110.
9. Howard JE, Connor TB. Use of differential renal function studies in the diagnosis of renovascular hypertension. *Am J Surg*. 1964;107:58-66.
10. Stamey TA, Nudelman IJ, Good PH, et al. Functional characteristics of renovascular hypertension. *Medicine (Baltimore)*. 1961;40:347-394.
11. Page IH, Helmes OM. A crystalline pressor substance (angiotensin) resulting from the reaction between renin and renin activator. *J Exp Med*. 1940;71:29.
12. Bruan-Memendez E, Fasciolo JC, Lelois LF, et al. La substancia hipertensora de la sangre del rinon, isquemiado. *Rev Soc Argent Biol*. 1939;15:420.
13. Lentz KE, Skeggs LT, Woods KR, et al. The amino acid composition of hypertensin II and its biochemical relationship to hypertensin I. *J Exp Med*. 1956;104:183-191.
14. Tobian L. Relationship of juxtaglomerular apparatus to renin and angiotensin. *Circulation*. 1962;25:189-192.
15. Morris GC, Deakey ME, Cooley DA. Surgical treatment of renal failure of renovascular origin. *JAMA*. 1962;182:609.
16. Dean RH, Lawson JD, Hollifield JW, et al. Revascularization of the poorly functioning kidney. *Surgery*. 1979;85:44-52.
17. Dean RH, Englund R, Dupont WD, et al. Retrieval of renal function by revascularization. Study of preoperative outcome predictors. *Ann Surg*. 1985;202:367-375.
18. Libertino JA, Zinman L. Revascularization of the poorly functioning and nonfunctioning kidney. In: Novick AC, Stratton RA, eds. *Vascular Problems In Urologic Surgery*. Philadelphia: WB Saunders Co., 1982:173.
19. Novick AC, Pohl MA, Schreiber M, et al. Revascularization for preservation of renal function in patients with atherosclerotic renovascular disease. *J Urol*. 1983;129:907-912.
20. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? *Circulation*. 1994;89:493-498.

21. Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenoses or renal artery stenosis in a solitary kidney. *N Engl J Med*. 1983;308:373-376.
22. Kobayashi S, Ishida A, Moriya H, et al. Angiotensin II receptor blockade limits kidney injury in two-kidney, one-clip Goldblatt hypertensive rats with special reference to phenotypic changes. *J Lab Clin Med*. 1999;133:134-143.
23. Eddy AA. Molecular insights into renal interstitial fibrosis. *J Am Soc Nephrol*. 1996;7:2495-2508.
24. Johnson RJ, Alpers CE, Yoshimura A, et al. Renal injury from angiotensin II-mediated hypertension. *Hypertension*. 1992;19:464-474.
25. Kim S, Ohta K, Hamaguchi A, et al. Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. *Kidney Int*. 1994;46:1346-1358.
26. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. *N Engl J Med*. 1996;334:939-945.
27. Scoble JE. Atherosclerotic nephropathy. *Kidney Int Suppl*. 1999;71:S106-S109.
28. Hansen KJ, Cherr GS, Craven TE, et al. Management of ischemic nephropathy: dialysis-free survival after surgical repair. *J Vasc Surg*. 2000;32:472-481.
29. Cherr GS, Hansen KJ, Craven TE, et al. Surgical management of atherosclerotic renovascular disease. *J Vasc Surg*. 2002;35:236-245.
30. Stanley JC, Fry WJ. Surgical treatment of renovascular hypertension. *Arch Surg* 1977;112:1291-1297.
31. Hansen KJ, Starr SM, Sands RE, et al. Contemporary surgical management of renovascular disease. *J Vasc Surg*. 1992;16:319-330.
32. Cohn EJ, Benjamin ME, Sandager GP, et al. Can intrarenal duplex waveform analysis predict successful renal artery revascularization? *J Vasc Surg*. 1998;28:471-480.
33. Radermacher J, Chavan A, Bleck J, et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. *N Engl J Med*. 2001;344:410-417.
34. Crutchley TA, Pearce JD, Craven TE, et al. Branch renal artery repair with cold perfusion protection. *J Vasc Surg*. 2007;46:405-412.
35. Hansen KJ, Thomason RB, Craven TE, et al. Surgical management of dialysis-dependent ischemic nephropathy. *J Vasc Surg*. 1995;21:197-209.
36. Hansen KJ, Benjamin ME, Appel RG, et al. Renovascular hypertension in the elderly: results of surgical management. *Geriatr Nephrol Urol*. 1996;6:3-11.
37. Oskin TC, Hansen KJ, Deitch JS, et al. Chronic renal artery occlusion: nephrectomy versus revascularization. *J Vasc Surg*. 1999;29:140-149.
38. Piercy KT, Mostafavi K, Craven TE, et al. Open operative management of dialysis-dependent ischemic nephropathy. *Dial Transplant*. 2007;36:192-204.
39. Caps MT, Perissinotto C, Zierler RE, et al. Prospective study of atherosclerotic disease progression in the renal artery. *Circulation*. 1998;98:2866-2872.
40. Caps MT, Zierler RE, Polissar NL, et al. Risk of atrophy in kidneys with atherosclerotic renal artery stenosis. *Kidney Int*. 1998;53:735-742.
41. Dean RH, Kieffer RW, Smith BM, et al. Renovascular hypertension: anatomic and renal function changes during drug therapy. *Arch Surg*. 1981;116:1408-1415.
42. Dean RH, Tribble RW, Hansen KJ, et al. Evolution of renal insufficiency in ischemic nephropathy. *Ann Surg*. 1991;213:446-455.
43. Hansen KJ, Reavis SW, Dean RH. Duplex scanning in renovascular disease. *Geriatr Nephrol Urol*. 1996;6:89.
44. Jacobson HR. Ischemic renal disease: an overlooked clinical entity? *Kidney Int*. 1988;34:729-743.

45. Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure. *Ann Intern Med.* 1993;118:712-719.
46. Zierler RE, Bergelin RO, Isaacson JA, Strandness DE. Natural history of atherosclerotic renal artery stenosis: a prospective study with duplex ultrasonography. *J Vasc Surg.* 1994;19:250-257.
47. Zierler RE, Bergelin RO, Davidson RC, et al. A prospective study of disease progression in patients with atherosclerotic renal artery stenosis. *Am J Hypertens.* 1996;9:1055-1061.
48. Pearce JD, Craven BL, Craven TE, et al. Progression of atherosclerotic renovascular disease: a prospective population-based study. *J Vasc Surg.* 2006;44:955-963.
49. Benjamin ME, Hansen KJ, Craven TE, et al. Combined aortic and renal artery surgery. A contemporary experience. *Ann Surg.* 1996;223:555-565.
50. Hansen KJ, Deitch JS, Oskin TC, et al. Renal artery repair: consequence of operative failures. *Ann Surg.* 1998;227:678-689.
51. Hansen KJ, O'Neil EA, Reavis SW, et al. Intraoperative duplex sonography during renal artery reconstruction. *J Vasc Surg.* 1991;14:364-374.
52. Proceedings from The Medicare Evidence Development and Coverage Advisory Committee Meeting on Percutaneous Transluminal Angioplasty and Stenting of Renal Arteries. Centers for Medicare and Medicaid Services. 2008.
53. Corriere MA, Hansen KJ. The role of embolic protection devices in renal artery stenting. A commentary. *Pers Vasc Surg Endovasc Ther.* 2007;19:272-274.
54. Piercy KT, Hundley JC, Stafford JM, et al. Renovascular disease in children and adolescents. *J Vasc Surg.* 2005;41:973-982.
55. Stanley JC, Criado E, Upchurch GR Jr, et al. Pediatric renovascular hypertension: 132 primary and 30 secondary operation in 97 children. *J Vasc Surg.* 2006;44:1219-1229.
56. English WP, Pearce JD, Craven TE, et al. Surgical management of renal artery aneurysms. *J Vasc Surg.* 2004;40:53-60.
57. Fry RE, Fry WJ. Supraceliac aortorenal bypass with saphenous vein for renovascular hypertension. *Surg Gynecol Obstet.* 1989;168:180-182.
58. Novick AC. Use of the thoracic aorta for renal revascularization. *Urol Clin North Am.* 1994;21:355-360.
59. Dean RH, Benjamin ME, Hansen KJ. Surgical management of renovascular hypertension. *Curr Probl Surg.* 1997;34:209-308.
60. Stoney RJ, Olofsson PA. Aortorenal arterial autografts: the last two decades. *Ann Vasc Surg.* 1988;2:169-173.
61. Fry WJ, Ernst CB, Stanley JC, Brink B. Renovascular hypertension in the pediatric patient. *Arch Surg.* 1973;107:692-698.
62. Moncure AC, Brewster DC, Darling RC, et al. Use of the splenic and hepatic arteries for renal revascularization. *J Vasc Surg.* 1986;3:196-203.
63. Fergany A, Kolettis P, Novick AC. The contemporary role of extra-anatomical surgical renal revascularization in patients with atherosclerotic renal artery disease. *J Urol.* 1995;153:1798-1801.
64. Desai MM, Gill IS, Ramani AP, et al. The impact of warm ischaemia on renal function after laparoscopic partial nephrectomy. *BJU Int.* 2005;95:377-383.
65. Thompson RH, Leibovich BC, Lohse CM, et al. Complications of contemporary open nephron sparing surgery: a single institution experience. *J Urol.* 2005;174:855-858.
66. Novick AC. Renal hypothermia: in vivo and ex vivo. *Urol Clin North Am.* 1983;10:637-644.
67. Yossepowitch O, Eggener SE, Serio A, et al. Temporary renal ischemia during nephron sparing surgery is associated with short-term but not long-term impairment in renal function. *J Urol.* 2006;176:1339-1343.
68. Van der Werf WJ, D'Alessandro AM, Hoffmann RM, Knechtle SJ. Procurement, preservation, and transport of cadaver kidneys. *Surg Clin North Am.* 1998;78:41-54.
69. Mitchell RM. Renal cooling and ischaemia. *Br J Surg.* 1959;46:593-597.
70. Green CJ, Pegg DE. Mechanism of action of "intracellular" renal preservation solutions. *World J Surg.* 1979;3:115-120.
71. Collins GM, Green RD, Boyer D, Halasz NA. Protection of kidneys from warm ischemic injury. Dosage and timing of

- mannitol administration. *Transplantation*. 1980;29:83-84.
72. Dishart MK, Kellum JA. An evaluation of pharmacological strategies for the prevention and treatment of acute renal failure. *Drugs*. 2000;59:79-91.
73. Zacharias M, Gilmore IC, Herbison GP, et al. Interventions for protecting renal function in the perioperative period. *Cochrane Database Syst Rev*. 2005;20:CD003590.
74. Ahmad N, Pratt JR, Potts DJ, Lodge JP. Comparative efficacy of renal preservation solutions to limit functional impairment after warm ischemic injury. *Kidney Int*. 2006;69:884-893.
75. Karam G, Compagnon P, Hourmant M, et al. A single solution for multiple organ procurement and preservation. *Transpl Int*. 2005;18:657-663.
76. Salvatierra O, Olcott C, Stoney RJ. Ex vivo renal artery reconstruction using perfusion preservation. *J Urol*. 1978;119:16-19.
77. Dean RH, Wilson JP, Burko H, Foster JH. Saphenous vein aortorenal bypass grafts: serial arteriographic study. *Ann Surg*. 1974;180:469-478.
78. Dean RH. Complications of renal revascularization. In: Bernhard VM, Towne JB, editors. *Complications in Vascular Surgery*. Orlando, FL: Grune & Stratton; 1985:229-246.
79. Stanley JC, Ernst CB, Fry WJ. Fate of 100 aortorenal vein grafts: characteristics of late graft expansion, aneurysmal dilatation, and stenosis. *Surgery*. 1973;74:931-944.
80. Dean RH, Krueger TC, Whiteneck JM, et al. Operative management of renovascular hypertension. Results after a follow-up of fifteen to twenty-three years. *J Vasc Surg*. 1984;1:234-242.
81. Courbier R, Jausseran JM, Reggi M. Detecting complications of direct arterial surgery: the role of intraoperative arteriography. *Arch Surg*. 1977;112:1115-1118.
82. Plecha FR, Pories WJ. Intraoperative angiography in the immediate assessment of arterial reconstruction. *Arch Surg*. 1972;105:902-907.
83. Goldstone J. Intraoperative assessment of renal and visceral arterial reconstruction using Doppler and duplex imaging. In: Ernst CB, Stanley JC, editors. *Current Therapy in Vascular Surgery*. Philadelphia: BC Decker; 1991:872.
84. Okuhn SP, Reilly LM, Bennett JB, et al. Intraoperative assessment of renal and visceral artery reconstruction: the role of duplex scanning and spectral analysis. *J Vasc Surg*. 1987;5:137-147.
85. Stanley JC, Whitehouse WM Jr, Zelenock GB, et al. Reoperation for complications of renal artery reconstructive surgery undertaken for treatment of renovascular hypertension. *J Vasc Surg*. 1985;2:133-144.

## 第 143 章

1. Marik PE, Varon J. Hypertensive crises: challenges and management. *Chest*. 2007;131:1949-1962.
2. Cherr GS, Hansen KJ, Craven TE, et al. Surgical management of atherosclerotic renovascular disease. *J Vasc Surg*. 2002;35:236-245.
3. Hansen KJ, Cherr GS, Craven TE, et al. Management of ischemic nephropathy: dialysis-free survival after surgical repair. *J Vasc Surg*. 2000;32:472-481.
4. Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy. *Circulation*. 2005;112:1362-1374.
5. Kashyap VS, Sepulveda RN, Bena JF, et al. The management of renal artery atherosclerosis for renal salvage: does stenting help? *J Vasc Surg*. 2007;45:101-108.
6. Giroux MF, Soulez G, Therasse E, et al. Percutaneous revascularization of the renal arteries: predictors of outcome. *J Vasc Interv Radiol*. 2000;11:713-720.
7. Rocha-Singh KJ, Mishkel GJ, Katholi RE, et al. Clinical predictors of improved long-term blood pressure control after successful stenting of hypertensive patients with obstructive renal artery atherosclerosis. *Catheter Cardiovasc Interv*. 1999;47:167-172.
8. Zeller T, Frank U, Muller C, et al. Predictors of improved renal function after percutaneous stent-supported angioplasty of

severe atherosclerotic ostial renal artery stenosis. *Circulation*. 2003;108:2244-2249.

9. Krijnen P, van Jaarsveld BC, Deinum J, et al. Which patients with hypertension and atherosclerotic renal artery stenosis benefit from immediate intervention? *J Hum Hypertens*. 2004;18:91-96.
10. Knipp BS, Dimick JB, Eliason JL, et al. Diffusion of new technology for the treatment of renovascular hypertension in the United States: surgical revascularization versus catheter-based therapy, 1988-2001. *J Vasc Surg*. 2004;40:717-723.
11. Murphy TP, Soares G, Kim M. Increase in utilization of percutaneous renal artery interventions by Medicare beneficiaries, 1996-2000. *AJR Am J Roentgenol*. 2004;183:561-568.
12. Crowley JJ, Santos RM, Peter RH, et al. Progression of renal artery stenosis in patients undergoing cardiac catheterization. *Am Heart J*. 1998;136:913-918.
13. Zierler RE, Bergelin RO, Isaacson JA, Strandness DE Jr. Natural history of atherosclerotic renal artery stenosis: a prospective study with duplex ultrasonography. *J Vasc Surg*. 1994;19:250-257.
14. Zierler RE, Bergelin RO, Davidson RC, et al. A prospective study of disease progression in patients with atherosclerotic renal artery stenosis. *Am J Hypertens*. 1996;9:1055-1061.
15. Caps MT, Perissinotto C, Zierler RE, et al. Prospective study of atherosclerotic disease progression in the renal artery. *Circulation*. 1998;98:2866-2872.
16. Pearce JD, Craven BL, Craven TE, et al. Progression of atherosclerotic renovascular disease: a prospective population-based study. *J Vasc Surg*. 2006;44:955-962.
17. van Jaarsveld BC, Krijnen P. Prospective studies of diagnosis and intervention: the Dutch experience. *Semin Nephrol*. 2000;20:463-473.
18. Webster J, Marshall F, Abdalla M, et al. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. *J Hum Hypertens*. 1998;12:329-335.
19. Hansen KJ, Tribble RW, Reavis SW, et al. Renal duplex sonography: evaluation of clinical utility. *J Vasc Surg*. 1990;12:227-236.
20. Corriere MA, Pearce JD, Edwards MS, et al. Endovascular management of atherosclerotic renal artery stenosis: early results following primary intervention. *J Vasc Surg*. 2008;48:580-587.
21. Lederman RJ, Mendelsohn FO, Santos R, et al. Primary renal artery stenting: characteristics and outcomes after 363 procedures. *Am Heart J*. 2001;142:314-323.
22. Baumgartner I, von Aesch K, Do DD, et al. Stent placement in ostial and nonostial atherosclerotic renal arterial stenoses: a prospective follow-up study. *Radiology*. 2000;216:498-505.
23. Henry M, Amor M, Henry I, et al. Stents in the treatment of renal artery stenosis: long-term follow-up. *J Endovasc Surg*. 1999;6:42-51.
24. White CJ, Ramee SR, Collins TJ, et al. Renal artery stent placement: utility in lesions difficult to treat with balloon angioplasty. *J Am Coll Cardiol*. 1997;30:1445-1450.
25. Blum U, Krumme B, Flugel P, et al. Treatment of ostial renal-artery stenoses with vascular endoprosthesis after unsuccessful balloon angioplasty. *N Engl J Med*. 1997;336:459-465.
26. Boisclair C, Therasse E, Oliva VL, et al. Treatment of renal angioplasty failure by percutaneous renal artery stenting with Palmaz stents: midterm technical and clinical results. *AJR Am J Roentgenol*. 1997;168:245-251.
27. Iannone LA, Underwood PL, Nath A, et al. Effect of primary balloon expandable renal artery stents on long-term patency, renal function, and blood pressure in hypertensive and renal insufficient patients with renal artery stenosis. *Cathet Cardiovasc Diagn*. 1996;37:243-250.
28. Leertouwer TC, Gussenhoven EJ, Bosch JL, et al. Stent placement for renal arterial stenosis: where do we stand? A meta-analysis. *Radiology*. 2000;216:78-85.
29. Taliencio CP, Vlietstra RE, Fisher LD, Burnett JC. Risks for renal dysfunction with cardiac angiography. *Ann Intern Med*. 1986;104:501-504.

30. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. *Am J Cardiol.* 2002;90:1068-1073.
31. Nikolsky E, Aymong ED, Dangas G, Mehran R. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. *Rev Cardiovasc Med.* 2003;4(Suppl 1):S7-S14.
32. Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. *Kidney Int.* 2005;67:706-713.
33. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. *Jama.* 2006;295:2765-2779.
34. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation.* 2002;105:2259-2264.
35. Bartholomew BA, Harjai KJ, Dukkupati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. *Am J Cardiol.* 2004;93:1515-1519.
36. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol.* 2004;44:1393-1399.
37. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. *Am J Med.* 1997;103:368-375.
38. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. *N Engl J Med.* 2003;348:491-499.
39. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. *Kidney Int.* 1995;47:254-261.
40. Barrett BJ, Parfrey PS, McDonald JR, et al. Nonionic low-osmolality versus ionic high-osmolality contrast material for intravenous use in patients perceived to be at high risk: randomized trial. *Radiology.* 1992;183:105-110.
41. Harris KG, Smith TP, Cragg AH, Lemke JH. Nephrotoxicity from contrast material in renal insufficiency: ionic versus nonionic agents. *Radiology.* 1991;179:849-852.
42. Sharma SK, Kini A. Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials. *Catheter Cardiovasc Interv.* 2005;65:386-393.
43. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. *N Engl J Med.* 2006;354:379-386.
44. Back MR, Caridi JG, Hawkins IF Jr, Seeger JM. Angiography with carbon dioxide (CO<sub>2</sub>). *Surg Clin North Am.* 1998;78:575-591.
45. Seeger JM, Self S, Harward TR, et al. Carbon dioxide gas as an arterial contrast agent. *Ann Surg.* 1993;217:688-697.
46. Hannedouche T, Godin M, Fries D, Fillastre JP. Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension. *Nephron.* 1991;57:230-231.
47. Johansen TL, Kjaer A. Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. *BMC Nephrol.* 2001;2:1.
48. Wynckel A, Ebikili B, Melin JP, et al. Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors. *Am J Hypertens.* 1998;11:1080-1086.
49. van de Ven PJ, Kaatee R, Beutler JJ, et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial. *Lancet.* 1999;353:282-286.
50. Grollman JH Jr, Marcus R. Transbrachial arteriography: techniques and complications. *Cardiovasc Intervent Radiol.* 1988;11:32-35.
51. Burket MW, Cooper CJ, Kennedy DJ, et al. Renal artery angioplasty and stent placement: predictors of a favorable outcome. *Am Heart J.* 2000;139:64-71.
52. Edwards MS, Corriere MA, Craven TE, et al. Atheroembolism during percutaneous renal artery revascularization. *J Vasc*

- Surg.* 2007;46:55-61.
53. Cooper CJ, Haller ST, Colyer W, et al. Embolic protection and platelet inhibition during renal artery stenting. *Circulation.* 2008;117:2752-2760.
  54. Corriere MA, Crutchley TA, Edwards MS. Is embolic protection during renal artery intervention really necessary? *J Cardiovasc Surg (Torino).* 2007;48:443-453.
  55. Hiramoto J, Hansen KJ, Pan XM, et al. Atheroemboli during renal artery angioplasty: an ex vivo study. *J Vasc Surg.* 2005;41:1026-1030.
  56. Edwards MS, Craven BL, Stafford J, et al. Distal embolic protection during renal artery angioplasty and stenting. *J Vasc Surg.* 2006;44:128-135.
  57. Henry M, Amor M, Henry I, et al. Stent placement in the renal artery: three-year experience with the Palmaz stent. *J Vasc Interv Radiol.* 1996;7:343-350.
  58. Rundback JH, Jacobs JM. Percutaneous renal artery stent placement for hypertension and azotemia: pilot study. *Am J Kidney Dis.* 1996;28:214-219.
  59. Wong JM, Hansen KJ, Oskin TC, et al. Surgery after failed percutaneous renal artery angioplasty. *J Vasc Surg.* 1999;30:468-482.
  60. Munneke GJ, Engelke C, Morgan RA, Belli AM. Cutting balloon angioplasty for resistant renal artery in-stent restenosis. *J Vasc Interv Radiol.* 2002;13:327-331.
  61. Ivanovic V, McKusick MA, Johnson CM III, et al. Renal artery stent placement: complications at a single tertiary care center. *J Vasc Interv Radiol.* 2003;14:217-225.
  62. Morris CS, Bonnevie GJ, Najarian KE. Nonsurgical treatment of acute iatrogenic renal artery injuries occurring after renal artery angioplasty and stenting. *AJR Am J Roentgenol.* 2001;177:1353-1357.
  63. Axelrod DJ, Freeman H, Pukin L, et al. Guide wire perforation leading to fatal perirenal hemorrhage from transcortical collaterals after renal artery stent placement. *J Vasc Interv Radiol.* 2004;15:985-987.
  64. Rundback JH, Sacks D, Kent KC, et al. Guidelines for the reporting of renal artery revascularization in clinical trials. American Heart Association. *Circulation.* 2002;106:1572-1585.
  65. Dean RH, Kieffer RW, Smith BM, et al. Renovascular hypertension: anatomic and renal function changes during drug therapy. *Arch Surg.* 1981;116:1408-1415.
  66. Cooper CJ, Murphy TP, Matsumoto A, et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. *Am Heart J.* 2006;152:59-66.
  67. Mistry S, Ives N, Harding J, et al. Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far. *J Hum Hypertens.* 2007;21:511-515.
  68. Tobe SW, Atri M, Perkins N, et al. Renal atherosclerotic revascularization evaluation (RAVE study): study protocol of a randomized trial [NCT00127738]. *BMC Nephrol.* 2007;8:4.
  69. Dorros G, Jaff M, Jain A, et al. Follow-up of primary Palmaz-Schatz stent placement for atherosclerotic renal artery stenosis. *Am J Cardiol.* 1995;75:1051-1055.
  70. MacLeod M, Taylor AD, Baxter G, et al. Renal artery stenosis managed by Palmaz stent insertion: technical and clinical outcome. *J Hypertens.* 1995;13:1791-1795.
  71. van de Ven PJ, Beutler JJ, Kaatee R, et al. Transluminal vascular stent for ostial atherosclerotic renal artery stenosis. *Lancet.* 1995;346:672-674.
  72. Harden PN, MacLeod MJ, Rodger RS, et al. Effect of renal-artery stenting on progression of renovascular renal failure. *Lancet.* 1997;349:1133-1136.
  73. Dorros G, Jaff M, Mathiak L, et al. Four-year follow-up of Palmaz-Schatz stent revascularization as treatment for atherosclerotic renal artery stenosis. *Circulation.* 1998;98:642-647.



74. Fiala LA, Jackson MR, Gillespie DL, et al. Primary stenting of atherosclerotic renal artery ostial stenosis. *Ann Vasc Surg.* 1998;12:128-133.
75. Gross CM, Kramer J, Waigand J, et al. Ostial renal artery stent placement for atherosclerotic renal artery stenosis in patients with coronary artery disease. *Cathet Cardiovasc Diagn.* 1998;45:1-8.
76. Rundback JH, Gray RJ, Rozenblit G, et al. Renal artery stent placement for the management of ischemic nephropathy. *J Vasc Interv Radiol.* 1998;9:413-420.
77. Tuttle KR, Chouinard RF, Webber JT, et al. Treatment of atherosclerotic ostial renal artery stenosis with the intravascular stent. *Am J Kidney Dis.* 1998;32:611-622.
78. Rodriguez-Lopez JA, Werner A, Ray LI, et al. Renal artery stenosis treated with stent deployment: indications, technique, and outcome for 108 patients. *J Vasc Surg.* 1999;29:617-624.
79. Bush RL, Najibi S, MacDonald MJ, et al. Endovascular revascularization of renal artery stenosis: technical and clinical results. *J Vasc Surg.* 2001;33:1041-1049.
80. Henry M, Klonaris C, Henry I, et al. Protected renal stenting with the PercuSurge GuardWire device: a pilot study. *J Endovasc Ther.* 2001;8:227-237.
81. Rocha-Singh KJ, Ahuja RK, Sung CH, Rutherford J. Long-term renal function preservation after renal artery stenting in patients with progressive ischemic nephropathy. *Catheter Cardiovasc Interv.* 2002;57:135-141.
82. Gill KS, Fowler RC. Atherosclerotic renal arterial stenosis: clinical outcomes of stent placement for hypertension and renal failure. *Radiology.* 2003;226:821-826.
83. Holden A, Hill A. Renal angioplasty and stenting with distal protection of the main renal artery in ischemic nephropathy: early experience. *J Vasc Surg.* 2003;38:962-968.
84. Kennedy DJ, Colyer WR, Brewster PS, et al. Renal insufficiency as a predictor of adverse events and mortality after renal artery stent placement. *Am J Kidney Dis.* 2003;42:926-935.
85. Zeller T, Frank U, Muller C, et al. Stent-supported angioplasty of severe atherosclerotic renal artery stenosis preserves renal function and improves blood pressure control: long-term results from a prospective registry of 456 lesions. *J Endovasc Ther.* 2004;11:95-106.
86. Nolan BW, Schermerhorn ML, Rowell E, et al. Outcomes of renal artery angioplasty and stenting using low-profile systems. *J Vasc Surg.* 2005;41:46-52.
87. Holden A, Hill A, Jaff MR, Pilmore H. Renal artery stent revascularization with embolic protection in patients with ischemic nephropathy. *Kidney Int.* 2006;70:948-955.
88. Bush RL, Martin LG, Lin PH, et al. Endovascular revascularization of renal artery stenosis in the solitary functioning kidney. *Ann Vasc Surg.* 2001;15:60-66.
89. Henry M, Henry I, Klonaris C, et al. Renal angioplasty and stenting under protection: the way for the future? *Catheter Cardiovasc Interv.* 2003;60:299-312.
90. Silva JA, Chan AW, White CJ, et al. Elevated brain natriuretic peptide predicts blood pressure response after stent revascularization in patients with renal artery stenosis. *Circulation.* 2005;111:328-333.
91. Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis—A randomized trial. *Hypertension.* 1998;31:823-829.
92. van Jaarsveld BC, Krijnen P, Pieterman H, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. *N Engl J Med.* 2000;342:1007-1014.
93. Weibull H, Bergqvist D, Bergentz SE, et al. Percutaneous transluminal renal angioplasty versus surgical reconstruction of atherosclerotic renal artery stenosis: a prospective randomized study. *J Vasc Surg.* 1993;18:841-850.
94. Balk E, Raman G, Chung M, et al. Effectiveness of management strategies for renal artery stenosis: a systematic review. *Ann Intern Med.* 2006;145:901-912.
95. Bax L, Mali WP, Buskens E, et al. The benefit of STent placement and blood pressure and lipid-lowering for the prevention

- of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design. *J Nephrol*. 2003;16:807-812.
96. Arthurs Z, Starnes B, Cuadrado D, et al. Renal artery stenting slows the rate of renal function decline. *J Vasc Surg*. 2007;45:726-731.
  97. Hanzel G, Balon H, Wong O, et al. Prospective evaluation of aggressive medical therapy for atherosclerotic renal artery stenosis, with renal artery stenting reserved for previously injured heart, brain, or kidney. *Am J Cardiol*. 2005;96:1322-1327.
  98. Pizzolo F, Mansueto G, Minniti S, et al. Renovascular disease: effect of ACE gene deletion polymorphism and endovascular revascularization. *J Vasc Surg*. 2004;39:140-147.
  99. Nolan BW, Schermerhorn ML, Powell RJ, et al. Restenosis in gold-coated renal artery stents. *J Vasc Surg*. 2005;42:40-46.
  100. Yutan E, Glickerman DJ, Caps MT, et al. Percutaneous transluminal revascularization for renal artery stenosis: Veterans Affairs Puget Sound Health Care System experience. *J Vasc Surg*. 2001;34:685-693.
  101. Bates MC, Rashid M, Campbell JE, et al. Factors influencing the need for target vessel revascularization after renal artery stenting. *J Endovasc Ther*. 2006;13:569-577.
  102. Kane GC, Hambly N, Textor SC, et al. Restenosis following percutaneous renal artery revascularization. *Nephron Clin Pract*. 2007;107:c63-c69.
  103. Vignali C, Bargellini I, Lazzereschi M, et al. Predictive factors of in-stent restenosis in renal artery stenting: a retrospective analysis. *Cardiovasc Intervent Radiol*. 2005;28:296-302.
  104. Shammas NW, Kapalis MJ, Dippel EJ, et al. Clinical and angiographic predictors of restenosis following renal artery stenting. *J Invasive Cardiol*. 2004;16:10-13.
  105. Bates MC, Campbell JE, Stone PA, et al. Factors affecting long-term survival following renal artery stenting. *Catheter Cardiovasc Interv*. 2007;69:1037-1043.

## 第 144 章

1. Leadbetter WF, Burkland CE. Hypertension in unilateral renal disease. *J Urol*. 1938;39:611-626.
2. Palubinskas AJ, Ripley HR. Fibromuscular hyperplasia in extrarenal arteries. *Radiology*. 1964;82:451-455.
3. Plouin PF, Perdu J, La Batide-Alanore A, et al. Fibromuscular dysplasia. *Orphanet J Rare Dis*. 2007;2:28.
4. Cragg AH, Smith TP, Thompson BH, et al. Incidental fibromuscular dysplasia in potential renal donors: long-term clinical follow-up. *Radiology*. 1989;172:145-147.
5. Andreoni KA, Weeks SM, Gerber DA, et al. Incidence of donor renal fibromuscular dysplasia: does it justify routine renal angiography? *Transplantation*. 2002;73:1112-1116.
6. Slovut DP, Olin JW. Fibromuscular dysplasia. *N Engl J Med*. 2004;350:1862-1871.
7. Stanley JC, Criado E, Upchurch GR Jr, et al. Pediatric renovascular hypertension: 132 primary and 30 secondary operations in 97 children. *J Vasc Surg*. 2006;44:1219-1229.
8. Bayazit AK, Yalcinkaya F, Cakar N, et al. Reno-vascular hypertension in childhood: a nationwide survey. *Pediatr Nephrol*. 2007;22:1327-1333.
9. De Fraissinette B, Garcier JUM, Dieu V, et al. Percutaneous transluminal angioplasty of dysplastic stenoses of the renal artery: results on 70 adults. *Cardiovasc Intervent Radiol*. 2003;26:46-51.
10. Pascual A, Bush HS, Copley JB. Renal fibromuscular dysplasia in elderly persons. *Am J Kidney Dis*. 2005;45:e63-e66.
11. Prieto LN, Dyer CB, Thompson PM, Whigham C Jr. The oldest reported patient with fibromuscular dysplasia of the renal artery. *South Med J*. 1996;89:405-408.
12. Pannier-Moreau I, Grimbart P, Fiquet-Kempf B, et al. Possible familial origin of multifocal renal artery fibromuscular dysplasia. *J Hypertens*. 1997;15:1797-1801.
13. Jyoti Das C, Neyaz Z, Thapa P, et al. Fibromuscular dysplasia of the renal arteries: a radiological review. *Int Urol Nephrol*.

2007;39:233-238.

14. Stanley JC, Whitehouse WM, Graham LM, et al. Operative treatment of renovascular hypertension. *Br J Surg*. 1982;69(Suppl 1):S63-S66.
15. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension. *Eur Heart J*. 2007;28:1462-1536.
16. Davis BA, Crook JE, Vestal RE, Oates JA. Prevalence of renovascular hypertension in patients with grade III or IV hypertensive retinopathy. *N Engl J Med*. 1979;301:1273-1276.
17. Labropoulos N, Ayuste B, Leon LR Jr. Renovascular disease among patients referred for renal duplex ultrasonography. *J Vasc Surg*. 2007;46:731-737.
18. Zeller T. Renal artery stenosis: epidemiology, clinical manifestation, and percutaneous endovascular therapy. *J Intervent Cardiol*. 2005;18:497-506.
19. Tyagi S, Kaul UA, Satsangi DK, Arora R. Percutaneous transluminal angioplasty for renovascular hypertension in children: initial and long-term results. *Pediatrics*. 1997;99:44-49.
20. Tortoledo F, Izaguirre L, Tortoledo MA. Experiences and controversies related to the endovascular treatment of renovascular hypertension. *Int Congr Series*. 2002;1237:63-73.
21. Kim HJ, Do YS, Shin SW, et al. Percutaneous transluminal angioplasty of renal artery fibromuscular dysplasia: mid-term results. *Kor J Radiol*. 2008;9:38-44.
22. Keith TA 3<sup>rd</sup>. Renovascular hypertension in black patients. *Hypertension*. 1982;4:438-443.
23. Lüscher TF, Keller HM, Imhof HG, et al. Fibromuscular hyperplasia: extension of the disease and therapeutic outcome. Results of the University Hospital Zurich Cooperative Study on Fibromuscular Hyperplasia. *Nephron*. 1986;44(Suppl. 1):109-114.
24. Stokes JB, Bonsib SM, McBride JW. Diffuse intimal fibromuscular dysplasia with multiorgan failure. *Arch Intern Med*. 1996;156:2611-2614.
25. Andersen CA, Hansen KJ, Benjamin ME, et al. Renal artery fibromuscular dysplasia: results of current surgical therapy. *J Vasc Surg*. 1995;22:207-216.
26. Vuong PN, Desooutter P, Mickley V, et al. Fibromuscular dysplasia of the renal artery responsible for renovascular hypertension: a histological presentation based on a series of 102 patients. *Vasa*. 2004;33:13-18.
27. Shroff R, Roebuck DJ, Gordon I, et al. Angioplasty for renovascular hypertension in children: 20-year experience. *Pediatrics*. 2006;118:268-275.
28. Lüscher TF, Lie JT, Stanson AW, et al. Arterial fibromuscular dysplasia. *Mayo Clin Proc*. 1987;62:931-952.
29. Alhadad A, Mattiasson I, Ivancev K, et al. Revascularisation of renal artery stenosis caused by fibromuscular dysplasia: effects on blood pressure during 7-year follow-up are influenced by duration of hypertension and branch artery stenosis. *J Hum Hypertens*. 2005;19:761-767.
30. Sang CN, Whelton PK, Hamper UM, et al. Etiologic factors in renovascular fibromuscular dysplasia. A case-control study. *Hypertension*. 1989;14:472-479.
31. Sarkar R, Messina LM. Renovascular disease: pathology of renal artery occlusive disease. In: Ernst CB, Stanley JC, eds. *Current Therapy of Vascular Surgery*. 3rd ed. St. Louis, CV Mosby, 1985, p 764.
32. Sotturrai V, Fry WJ, Stanley JC. Ultrastructural characteristics of experimental arterial medial fibroplasia induced by vasa vasorum occlusion. *J Surg Res*. 1978;24:167-177.
33. Janzen J, Lanzer P, Rothenberger-Janzen K, Vuong PN. The transitional zone in the tunica media of renal arteries has a maximal length of 10 millimetres. *Vasa*. 2000;29:168-172.
34. Kaufman JJ, Maxwell MH. Upright aortography in the study of nephroptosis, stenotic lesions of the renal artery, and hypertension. *Surgery*. 1963;53:736-742.
35. Hågg A, Åberg H, Eriksson I, et al. Fibromuscular dysplasia of the renal artery—management and outcome. *Acta Chir*

*Scand.* 1987;153:15-20.

36. Nicholson JP, Teichman SL, Alderman MH, et al. Cigarette smoking and renovascular hypertension. *Lancet.* 1983;2:765-766.
37. Bofinger A, Hawley C, Fisher P, et al. Increased severity of multifocal renal arterial fibromuscular dysplasia in smokers. *J Hum Hypertens.* 1999;13:517-520.
38. Bigazzi R, Bianchi S, Quilici N, et al. Bilateral fibromuscular dysplasia in identical twins. *Am J Kidney Dis.* 1998;32:E4.
39. Rushton AR. The genetics of fibromuscular dysplasia. *Arch Intern Med.* 1980;140:233-236.
40. Boutouyrie P, Gimenez-Roqueplo AP, Fine E, et al. Evidence for carotid and radial artery wall subclinical lesions in renal fibromuscular dysplasia. *J Hypertens.* 2003;21:2287-2295.
41. Perdu J, Boutouyrie P, Bourgain C, et al. Inheritance of arterial lesions in renal fibromuscular dysplasia. *J Hum Hypertens.* 2007;21:393-400.
42. Bofinger A, Hawley C, Fisher P, et al. Polymorphisms of the renin-angiotensin system in patients with multifocal renal arterial fibromuscular dysplasia. *J Hum Hypertens.* 2001;15:185-190.
43. Schievink WI, Limburg M. Angiographic abnormalities mimicking fibromuscular dysplasia in a patient with Ehlers-Danlos syndrome, type IV. *Neurosurgery.* 1989;25:482-483.
44. Qunibi WJ, Taylor TK, Knight TF, et al. Pheochromocytoma and fibromuscular hyperplasia. *South Med J.* 1979;72:1481-1482.
45. Schievink WI, Bjornsson J, Piegras DG. Coexistence of fibromuscular dysplasia and cystic medial necrosis in a patient with Marfan's syndrome and bilateral carotid artery dissections. *Stroke.* 1994;25:2492-2496.
46. Hudgins LB, Limbacher JP II. Fibromuscular dysplasia in Alport's syndrome. *J Tenn Med Assoc.* 1982;75:733-735.
47. Janzen J, Vong PN, Rothenberger-Janzen K. Takayasu's arteritis and fibromuscular dysplasia as causes of acquired atypical coarctation of the aorta: retrospective analysis of seven cases. *Heart Vessels.* 1999;14:277-282.
48. Bol A, Missault L, Dewilde W. Renovascular hypertension associated with neurofibromatosis. *Acta Clin Belg.* 2007;62:61-63.
49. Booth C, Preston R, Clark G, Reidy J. Management of renal vascular disease in neurofibromatosis type 1 and the role of percutaneous transluminal angioplasty. *Nephrol Dial Transplant.* 2002;17:1235-1240.
50. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. *JAMA.* 1997;278:51-57.
51. Germain DP, Herrera-Guzman Y. Vascular Ehlers-Danlos syndrome. *Ann Genet.* 2004;47:1-9.
52. Lacolley P, Boutouyrie P, Glukhova M, et al. Disruption of the elastin gene in adult Williams syndrome is accompanied by a paradoxical reduction in arterial stiffness. *Clin Sci (Lond).* 2002;103:21-29.
53. Jaff MR, Olin JW, Young JR. Failure of acute phase reactants to predict disease activity in Takayasu's arteritis. *J Vasc Med Biol.* 1993;4:223-227.
54. Leung DY, Glagov S, Mathews MB. Cyclic stretching stimulates synthesis of matrix components by arterial smooth muscle cells in vitro. *Science.* 1976;191:475-477.
55. Fievez ML. Fibromuscular dysplasia of arteries: a spastic phenomenon? *Med Hypotheses.* 1984;13:341-349.
56. Julien LM. The occurrence of fibromuscular dysplasia in the arteries of domestic turkeys. *Am J Pathol.* 1980;101:415-424.
57. Stanley JC, Gewertz BL, Bove EL, et al. Arterial fibrodysplasia histopathologic character and current etiologic concepts. *Arch Surg.* 1975;110:561-566.
58. Harrison EG, McCormack LJ. Pathologic classification of renal arterial disease in renovascular hypertension. *Mayo Clin Proc.* 1971;46:161-167.
59. Begelman SM, Olin JW. Fibromuscular dysplasia. *Curr Opin Rheumatol.* 2000;12:41-47.
60. Higashi Y, Sasaki S, Nakagawa K, et al. Endothelial function and oxidative stress in renovascular hypertension. *N Engl J Med.* 2002;346:1954-1962.

61. Morishita R, Higaki J, Miyazaki M, Ogihara T. Possible role of the renin-angiotensin system in hypertension and vascular hypertrophy. *Hypertension*. 1992;19(Suppl II):1162-1167.
62. Alhadad A, Guron G, Fortuna-Nowakowska E, et al. Transient rise in high sensitivity C-reactive protein and interleukin-6, and long term decrease in endothelin-1 after angioplasty of renal artery stenosis. *J Hypertens*. 2007;25:1907-1914.
63. Mounier-Vehier C, Lions C, Jaboureck O, et al. Parenchymal consequences of fibromuscular dysplasia renal artery stenosis. *Am J Kidney Dis*. 2002;40:1138-1145.
64. Lerman LO, Taler SJ, Textor SC, et al. Computed tomography-derived intrarenal blood flow in renovascular and essential hypertension. *Kidney Int*. 1996;49:846-854.
65. Safian RD. Atherosclerotic renal artery stenosis. *Curr Treat Options Cardiovasc Med*. 2003;5:91-101.
66. Ramsay LE, Waller PC. Blood pressure response to percutaneous transluminal angioplasty for renovascular hypertension: an overview of published series. *BMJ*. 1980;300:569-572.
67. Pohl MA, Novick AC. Natural history of atherosclerotic and fibrous renal artery disease: clinical implications. Hypertension and the Kidney. Proceedings of a Symposium: A120-A130, 1985.
68. Schreiber MJ, Pohl MA, Novick AC. The natural history of atherosclerotic and fibrous renal artery disease. *Urol Clin North Am*. 1984;11:383-392.
69. Goncharenko V, Gerlock Jr AJ, Shaff MI, Hollifield JW. Progression of renal artery fibromuscular dysplasia in 42 patients as seen on angiography. *Radiology*. 1981;139:45-51.
70. Stanley JC, Graham LM, Whitehouse WM Jr, et al. Developmental occlusive disease of the abdominal aorta and the splanchnic and renal arteries. *Am J Surg*. 1981;142:190-196.
71. Crutchley TA, Pearce JD, Craven TE, et al. Branch renal artery repair with cold perfusion protection. *J Vasc Surg*. 2007;46:405-412.
72. Ropponen KM, Alafuzoff I. A case of sudden death caused by fibromuscular dysplasia. *J Clin Pathol*. 1999;52:541-542.
73. Sinnamon K, McNally D, Harty J. Fibromuscular dysplasia presenting as renal infarction. *Kidney Int*. 2007;72:1295-1296.
74. Mestres CA, Campistol JM, Ninot S, et al. Improvement of renal function in azotaemic hypertensive patients after surgical revascularization. *Br J Surg*. 1988;75:578-580.
75. Nemcek AA, Holmburg CE. Reversible renal fibromuscular dysplasia. *AJR Am J Roentgenol*. 1986;147:737-738.
76. Elliott WJ. Secondary hypertension: renovascular hypertension. In: Black H, Elliott W, eds. *Hypertension: A Companion to Braunwald's Heart Disease*. Philadelphia: Saunders Elsevier; 2007:93-105.
77. Bloch MJ, Trost DW, Pickering TG, et al. Prevention of recurrent pulmonary edema in patients with bilateral renovascular disease through renal artery stent placement. *Am J Hypertens*. 1999;12:1-7.
78. Weatherford DA, Freeman MB, Register RF, et al. Surgical management of flash pulmonary edema secondary to renovascular hypertension. *Am J Surg*. 1997;174:160-163.
79. Mansoor S, Shah A, Scoble JE. "Flash pulmonary edema" a diagnosis for both the cardiologist and the nephrologist? *Nephrol Dial Transplant*. 2001;16:1311-1313.
80. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. *JAMA*. 2003;203:2560-2572.
81. Safian RD, Textor SC. Renal artery stenosis. *N Engl J Med*. 2001;344:431-442.
82. Krumme W, Blum U, Schwertfeger E, et al. Diagnosis of renovascular disease by intra-extrarenal Doppler scanning. *Kidney Int*. 1996;50:1288-1292.
83. Radermacher J, Chavan A, Bleck J, et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal artery stenosis. *N Engl J Med*. 2001;344:410-417.
84. Hansen KJ, Tribble RW, Reavis SW, et al. Renal duplex sonography: evaluation of clinical utility. *J Vasc Surg*. 1990;12:227-236.
85. Gowda MS, Loeb AL, Crouse LJ, Kramer PH. Complementary roles of color-flow duplex imaging and intravascular

- ultrasound in the diagnosis of renal artery fibromuscular dysplasia. *J Am Coll Cardiol*. 2003;41:1305-1311.
86. Woolfson RG, Neild GH. The true clinical significance of renography in nephrourology. *Eur J Nucl Med*. 1997;24:557-570.
  87. Eklöf H, Ahlström H, Magnusson A, et al. A prospective comparison of duplex ultrasonography, captopril renography, MRA, and CTA in assessing renal artery stenosis. *Acta Radiol*. 2006;47:764-774.
  88. Vasbinder BGC, Nelemans PJ, Kessels AGH, et al. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. *Ann Intern Med*. 2001;135:401-411.
  89. Leung DA, Hoffmann U, Pfammatter T, et al. Magnetic resonance angiography versus duplex sonography for diagnosing renovascular disease. *Hypertension*. 1999;33:726-731.
  90. Sabharwal T, Fotiadis N, Adam A. Modern trends in interventional radiology. *Br Med Bull*. 2007;81-82:167-182.
  91. Tetteroo E, Haaring C, van der Graaf Y, et al. Intraarterial pressure gradients after randomized angioplasty or stenting of iliac artery lesions. Dutch Iliac Stent Trial Study Group. *Cardiovasc Intervent Radiol*. 1996;19:411-417.
  92. Martin LG, Rundback JH, Sacks D, et al. Quality improvement guidelines for angiography, angioplasty and stent placement in the diagnosis and treatment of renal artery stenosis in adults. *J Vasc Interv Radiol*. 2002;13:1069-1083.
  93. Nahman NS Jr, Maniam P, Hernandez RA Jr, et al. Renal artery pressure gradients in patients with angiographic evidence of atherosclerotic renal artery stenosis. *Am J Kidney Dis*. 1994;24:695-699.
  94. Gross CM, Kramer J, Weingärtner O, et al. Determination of renal arterial stenosis severity: comparison of pressure gradient and vessel diameter. *Radiology*. 2001;220:751-756.
  95. De Bruyne B, Manoharan G, Pijls NH, et al. Assessment of renal artery stenosis severity by pressure measurements. *J Am Coll Cardiol*. 2006;48:1851-1855.
  96. Mahmud E, Brocato M, Palakodeti V, Tsimikas S. Fibromuscular dysplasia of renal arteries: percutaneous revascularisation based on hemodynamic assessment with a pressure measurement guidewire. *Catheter Cardiovasc Intervent*. 2006;67:434-437.
  97. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*. 2003;362:1527-1535.
  98. Ramos F, Kotliar C, Alvarez D, et al. Renal function and outcome of PTR and stenting for atherosclerotic renal artery stenosis. *Kidney Int*. 2003;63:276-282.
  99. Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney. *N Engl J Med*. 1983;308:373-376.
  100. Knipp BS, Dimick JB, Eliason JL, et al. Diffusion of new technology for the treatment of renovascular hypertension in the United States: surgical revascularization versus catheter-based therapy, 1988-2001. *J Vasc Surg*. 2004;40:717-723.
  101. Davidson RA, Barri Y, Wilcox CS. Predictors of cure of hypertension in fibromuscular renovascular disease. *Am J Kidney Dis*. 1996;28:334-338.
  102. Unsal A, Parildar M, Oran I, et al. Treatment of renal artery bifurcation stenosis due to fibromuscular dysplasia by kissing balloon technique and intrarenal stent deployment: a case report. *Int J Angiol*. 2002;11:86-88.
  103. Cluzel P, Raynaud A, Beyssen B, et al. Stenoses of renal branch arteries in fibromuscular dysplasia: results of percutaneous transluminal angioplasty. *Radiology*. 1994;193:227-232.
  104. Adams CW, Reidy J. Renal arterial pathology after percutaneous transluminal angioplasty. *Atherosclerosis*. 1987;63:153-157.
  105. Mach F. Toward new therapeutic strategies against neointimal formation in restenosis. *Arterioscler Thromb Vasc Biol*. 2000;20:1699-1700.
  106. Bonelli FS, McKusick MA, Textor SC, et al. Renal artery angioplasty: technical results and clinical outcome in 320 patients. *Mayo Clin Proc*. 1995;70:1041-1052.

107. Jensen G, Zachrisson B-F, Delin K, et al. Treatment of renovascular hypertension: one year results of renal angioplasty. *Kidney Int.* 1995;48:1936-1945.
108. Birrer M, Do DD, Mahler F, et al. Treatment of renal artery fibromuscular dysplasia with balloon angioplasty: a prospective follow-up study. *Eur J Vasc Endovasc Surg.* 2002;23:146-152.
109. Sos TA, Pickering TG, Phil D, et al. Percutaneous transluminal renal angioplasty in renovascular hypertension due to atheroma or fibromuscular dysplasia. *N Eng J Med.* 1983;309:274-279.
110. Oguzkurt L, Tercan F, Gulcan O, Turkoz R. Rupture of the renal artery after cutting balloon angioplasty in a young women with fibromuscular dysplasia. *Cardiovasc Intervent Radiol.* 2005;28:360-363.
111. Lupattelli T, Nano G, Inglese L. Regarding cutting balloon angioplasty of renal fibromuscular dysplasia: a word of caution. *J Vasc Surg.* 2005;42:1038-1039.
112. Tanaka R, Higashi M, Naito H. Angioplasty for non-arteriosclerotic renal artery stenosis: the efficacy of cutting balloon angioplasty versus conventional angioplasty. *Cardiovasc Intervent Radiol.* 2007;30:601-606.
113. Tanemoto M, Abe T, Chaki T, et al. Cutting balloon angioplasty of resistant renal artery stenosis caused by fibromuscular dysplasia. *J Vasc Surg.* 2005;41:898-901.
114. Surowiec SM, Sivamurthy N, Rhodes JM, et al. Percutaneous therapy for renal artery fibromuscular dysplasia. *Ann Vasc Surg.* 2003;17:650-655.
115. Simonetti G, Bonomo L, Cornalba GP, et al. L'angioplastica renale percutanea transluminale. Esperienza italiana in 13 centri. *Radiol Med.* 1993;86:503-508.
116. Rundback JH, Sacks D, Kent KC, et al. Guidelines for the reporting of renal artery revascularization in clinical trials. *Circulation.* 2002;106:1572-1585.
117. Wong JM, Hansen KJ, Oskin TC, et al. Surgery after failed percutaneous renal artery angioplasty. *J Vasc Surg.* 1999;38:468-483.
118. Lacombe M. Place de la chirurgie dans le traitement de l'hypertension réno-vasculaire de l'enfant. *Bull Acad Natl Med* 2003;187:1081-1094.
119. Chiche L, Kieffer E, Sabatier J, et al. Renal autotransplantation for vascular disease: late outcome according to etiology. *J Vasc Surg.* 2003;37:353-361.
120. Novick AC, Ziegelbaum M, Vidt DG, et al. Trends in surgical revascularization for renal artery disease. Ten years' experience. *JAMA.* 1987;257:498-501.
121. Lacombe M, Ricco J-B. Surgical revascularization of renal artery after complicated or failed percutaneous transluminal renal angioplasty. *J Vasc Surg.* 2006;44:537-544.
122. Carmo M, Bower TC, Mozes G, et al. Surgical management of renal fibromuscular dysplasia: challenges in the endovascular era. *Ann Vasc Surg.* 2005;19:208-217.
123. Pfeiffer T, Reiher L, Grabitz K, et al. Reconstruction for renal artery aneurysm: operative techniques and long-term results. *J Vasc Surg.* 2003;37:293-300.
124. English WP, Pearce JD, Craven TE, et al. Surgical management of renal artery aneurysms. *J Vasc Surg.* 2004;40:53-60.
125. Hardy JD. High uretral injury; management by autotransplantation of the kidney. *JAMA.* 1963;184:97-101.
126. Woodruff MFA. Experience with transplantation of the kidney in man. *Ann R Coll Surg Engl.* 1966;39:178-183.
127. Murray SP, Kent C, Salvatierra O, Stoney RJ. Complex branch renovascular disease: management options and late results. *J Vasc Surg.* 1994;20:338-345.
128. Sevmis S, Karakayali H, Boyvat F, et al. Renal autotransplantation for the treatment of complex renovascular hypertension. *Transplant Proc.* 2006;38:3412-3415.
129. Marekovic Z, Mokos I, Krhen I, et al. Long-term outcome after surgical kidney revascularization for fibromuscular dysplasia and atherosclerotic renal artery stenosis. *J Urol.* 2004;171:1043-1045.
130. Buda JA, Baer L, Parra-Carrillo JZ, et al. Predictability of surgical response in renovascular hypertension. *Arch Surg.*

1976;111:1243-1248.

131. Bergentz S-E, Ericsson BF, Husberg B. Technique and complications in the surgical treatment of renovascular hypertension. *Acta Chir Scand*. 1979;145:143-148.
132. Reiher L, Pfeiffer T, Sandemann W. Long-term results after surgical reconstruction for renal artery fibromuscular dysplasia. *Eur J Vasc Endovasc Surg*. 2000;20:556-559.
133. Van Bockel JH, van Schilfgaarde R, Felthuis W, et al. Long-term results of in situ and extracorporeal surgery for renovascular hypertension caused by fibrodysplasia. *J Vasc Surg*. 1987;6:355-364.
134. Jakubowski HD, Eigler FW, Montag H. Results of surgery in fibrodysplastic renal artery stenosis. *World J Surg*. 1981;5:859-861.
135. Dean RH, Wilson JP, Burko H, Foster JH. Saphenous vein aortorenal bypass grafts: serial arteriographic study. *Ann Surg*. 1974;180:469-478.
136. Stoney RJ, Silane M, Salvatierra O Jr. Ex vivo renal artery reconstruction. *Arch Surg*. 1978;113:1272-1278.
137. Stanley JC, Ernst CB, Fry WJ. Fate of 100 aortorenal vein grafts: characteristics of late graft expansion, aneurysmal dilatation, and stenosis. *Surgery*. 1973;74:931-944.
138. Courtel JV, Soto B, Niaudet P, et al. Percutaneous transluminal angioplasty of renal artery stenosis in children. *Pediatr Radiol*. 1998;28:59-63.
139. Lacombe M. Traitement chirurgical des lésions artérielles rénales chez l'enfant. *Chirurgie*. 1999;124:264-271.
140. Stanley JC, Zelenock GB, Messina LM, Wakefield TW. Pediatric renovascular hypertension: a thirty-year experience of operative treatment. *J Vasc Surg*. 1995;21:212-227.
141. O'Neill JA Jr. Long-term outcome with surgical treatment of renovascular hypertension. *J Pediatr Surg*. 1998;33:106-111.
142. Chalmers RTA, Dhadwal A, Deal JE, et al. The surgical management of renovascular hypertension in children and young adults. *Eur J Vasc Endovasc Surg*. 2000;19:400-405.
143. Estepa R, Gallego N, Orte L, et al. Renovascular hypertension in children. *Scand J Urol Nephrol*. 2000;35:388-392.
144. Piercy KT, Hundely JC, Stafford JM, et al. Renovascular disease in children and adolescents. *J Vasc Surg*. 2005;41:973-982.
145. McTaggart SJ, Gelati S, Walker RG, et al. Evaluation and long-term outcome of pediatric renovascular hypertension. *Pediatr Nephrol*. 2000;14:1022-1029.
146. Mali WTM, Puillaert CBA, Kouwenberg HJ, et al. Percutaneous transluminal angioplasty in children and adolescents. *Radiology*. 1987;165:391-394.
147. Stoney RJ, Cooke PA, String ST. Surgical treatment of renovascular hypertension in children. *J Pediatr Surg*. 1975;10:631-639.
148. Lawson JD, Boerth R, Foster JH, Dean RH. Diagnosis and management of renovascular hypertension in children. *Arch Surg*. 1977;112:1307-1316.
149. Novick AC, Straffon RA, Stewart BH, Benjamin S. Surgical treatment of renovascular hypertension in the pediatric patient. *J Urol*. 1978;119:794-799.
150. Stoney RJ, De Luccia N, Ehrenfeld WK, Wylie EJ. Aortorenal arterial autografts. Long-term assessment. *Arch Surg*. 1981;116:1416-1421.
151. Stanley JC, Rhodes EL, Gewertz BL, et al. Renal artery aneurysms. Significance of macroaneurysms exclusive of dissection and fibrodysplastic mural dilatations. *Arch Surg*. 1975;110:1327-1333.
152. Huang Y, Duncan AA, McKusick MA, et al. Renal artery intervention in pediatric and adolescent patients: a 20-year experience. *Vasc Endovasc Surg*. 2008;41:490-499.
153. Serter S, Oran I, Parildar M, Memis A. Fibromuscular dysplasia-related renal artery stenosis associated with aneurysm: successive endovascular therapy. *Cardiovasc Intervent Radiol*. 2007;30:297-299.
154. Bisschops RHC, Popma JJ, Meyerovitz MF. Treatment of fibromuscular dysplasia and renal artery aneurysm with the use



- of a stent-graft. *J Vasc Interv Radiol*. 2001;12:757-760.
155. Bui BT, Olivia VL, Leclerc G, et al. Renal artery aneurysm: treatment with percutaneous placement of a stent-graft. *Radiology*. 1995;195:181-182.
  156. Martin LG, Price RB, Casarella WJ, et al. Percutaneous angioplasty in clinical management of renovascular hypertension: initial and long-term results. *Radiology*. 1985;155:629-633.
  157. Baert AL, Wilms G, Amery A, et al. Percutaneous transluminal renal angioplasty: initial results and long-term follow-up in 202 patients. *Cardiovasc Intervent Radiol*. 1990;13:22-28.
  158. Tegtmeier CJ, Selby JB, Hartwell GD, et al. Results and complications of angioplasty in fibromuscular disease. *Circulation*. 1991;83(Suppl I):I155-I161.
  159. Rodríguez-Pérez JC, Plaza C, Reyes R, et al. Treatment of renovascular hypertension with percutaneous transluminal angioplasty: experience in Spain. *J Vasc Interv Radiol*. 1994;5:101-109.
  160. Jagose JT, Bailey RR, Young AT. Fibromuscular dysplasia of the renal artery: management and outcome. *Nephrology*. 1998;4:95-99.
  161. Klow N-E, Paulsen D, Vatne K, et al. Percutaneous transluminal renal artery angioplasty using the coaxial technique. Ten years experience from 591 procedures in 419 patients. *Acta Radiol*. 1998;39:594-603.
  162. Lovaria A, Nicolini A, Mereaglia D, et al. Interventional radiology in the treatment of renal artery stenosis. *Ann Urol*. 1999;33:146-155.
  163. Fremuth J, McKusick MA, Stanson AA, et al. Does angioplasty (PTRA) benefit older patients with fibromuscular disease (FMD)? Results of PTRA in 97 patients treated 1996-2000. *Am Heart J*. 2002;15:19A.
  164. Kumar A, Dubey D, Bansal P, et al. Surgical and radiological management of renovascular hypertension in a developing country. *J Urol*. 2003;170:727-730.
  165. Hughes RJ, Scoble JE, Reidy JF. Renal angioplasty in non-atheromatous renal artery stenosis: technical results and clinical outcome in 43 patients. *Cardiovasc Intervent Radiol*. 2004;7:435-440.
  166. Lawrie GM, Morris Jr GC, Soussou ID, et al. Late results of reconstructive surgery for renovascular disease. *Ann Surg*. 1980;191:528-533.
  167. Hansen KJ, Starr SM, Sands RE, et al. Contemporary surgical management of renovascular disease. *J Vasc Surg*. 1992;16:319-331.
  168. Fallo F, Oberfield SE, Levine LS, et al. Evaluation of percutaneous transluminal renal angioplasty in childhood hypertension. *Int J Pediatr Nephrol*. 1985;6:261-266.
  169. Simunic S, Winter-Fidric I, Radanovic B, et al. Percutaneous transluminal renal angioplasty (PTRA) as a method of therapy for renovascular hypertension in children. *Eur J Radiol*. 1990;10:143-146.
  170. Casalini E, Sfondrini MS, Fossali E. Two-year clinical follow-up of children and adolescents after percutaneous transluminal angioplasty for renovascular hypertension. *Invest Radiol*. 1995;30:40-43.
  171. Sharma S, Thatai D, Saxena A, et al. Renovascular hypertension resulting from nonspecific aortoarteritis in children: midterm results of percutaneous transluminal renal angioplasty and predictors of restenosis. *AJR Am J Roentgenol*. 1996;166:157-162.
  172. Fossali E, Signorini E, Intermite RC, et al. Renovascular disease and hypertension in children with neurofibromatosis. *Pediatr Nephrol*. 2000;14:806-810.
  173. Alfonzo JP, Ugarte C, Banasco J, et al. Hipertensión vasculorenal en niños y adolescentes: diagnóstico y tratamiento durante 19 años. *Nefrología*. 2006;26:573-580.
  174. Towbin RB, Pelchovitz DJ, Baskin KM, et al. Cutting balloon angioplasty in children with resistant renal artery stenosis. *J Vasc Intervent Radiol*. 2007;5:663-669.
  175. Martinez A, Novick AC, Cunningham R, Goormastic M. Improved results of vascular reconstruction in pediatric and young adult patients with renovascular hypertension. *J Urol*. 1990;144:717-720.

## 第 145 章

1. Martin RS III, Meacham PW, Ditesheim JA, et al. Renal artery aneurysm: selective treatment for hypertension and prevention of rupture. *J Vasc Surg*. 1989;9:26.
2. Stanley JC. Natural history of renal artery stenosis and aneurysms. In: Calligaro KD, Dougherty MJ, Dean RH, eds. *Modern Management of Renovascular Hypertension and Renal Salvage*. Baltimore: Williams & Wilkins; 1996:15.
3. Charron J, Belanger R, Vaclair R, et al. Renal artery aneurysm: polyaneurysmal lesion of kidney. *Urology*. 1975;5:1.
4. Erdsman G. Angionephrography and suprarenal angiography. *Acta Radiol*. 1957;155(Suppl):104.
5. Tham G, Ekelund L, Herrlin K, et al. Renal artery aneurysms: natural history and prognosis. *Ann Surg*. 1983;197:348.
6. Zhang LJ, Yang GF, Qi J, Shen W. Renal artery aneurysm: diagnosis and surveillance with multidetector-row computed tomography. *Acta Radiol*. 2007;48:274.
7. Cinat M, Yoon P, Wilson SE. Management of renal artery aneurysms. *Semin Vasc Surg*. 1996;9:236.
8. Fry WF. Renal artery aneurysm. In: Ernst CB, Stanley JC, eds. *Current Therapy in Vascular Surgery*. Philadelphia: BC Decker; 1987:363.
9. Lumsden AB, Salam TA, Walton KG. Renal artery aneurysm: a report of 28 cases. *Cardiovasc Surg*. 1996;4:185.
10. Stanley JC, Rhodes EL, Gewertz BL, et al. Renal artery aneurysms: significance of macroaneurysms exclusive of dissections and fibrodysplastic mural dilations. *Arch Surg*. 1975;110:1327.
11. Pliskin MJ, Dresner ML, Hassell LH, et al. A giant renal artery aneurysm diagnosed postpartum. *J Urol*. 1990;144:1459.
12. Bernhardt J, Zwicker C, Hering M, et al. A major renal artery aneurysm as the cause of a hydronephrosis with renovascular hypertension. *Urol Int*. 1996;57:237.
13. Dzsinih C, Gloviczki P, McKusick MA, et al. Fibromuscular dysplasia and surgical management of renal artery aneurysm. *Cardiovasc Surg*. 1993;1:243.
14. Poutasse EF. Renal artery aneurysms: their natural history and surgery. *J Urol*. 1966;95:297.
15. Poutasse EF. Renal artery aneurysms. *J Urol*. 1975;43:113.
16. Mattar SG, Kumar AG, Lumsden AB. Vascular complications in Ehlers-Danlos syndrome. *Am Surg*. 1994;60:827.
17. Gewertz BL, Stanley JC, Fry WJ. Renal artery dissections. *Arch Surg*. 1977;112:409.
18. Hare WSC, Kincaid-Smith P. Dissecting aneurysms of the renal artery. *Radiology*. 1970;97:255.
19. Kaufman JJ, Coulson WF, Lecky JW, et al. Primary dissecting aneurysms of renal artery: report of a case causing reversible renal hypertension. *Ann Surg*. 1973;177:259.
20. McCormack LJ, Poutasse EF, Meaney TF, et al. A pathologic arteriographic correlation of renal arterial disease. *Am Heart J*. 1966;72:188.
21. Hekali P, Kivisaara L, Standerskjold-Nordenstam CG, et al. Renal complications of polyarteritis nodosa: CT findings. *J Comput Assist Tomogr*. 1985;9:333.
22. Sellar RJ, Mackay IG, Buist TA. The incidence of microaneurysms in polyarteritis nodosa. *Cardiovasc Intervent Radiol*. 1986;9:123.
23. Henriksson C, Bjorkerud S, Nilson AE, et al. Natural history of renal artery aneurysm elucidated by repeated angiography and pathoanatomic studies. *Eur Urol*. 1985;11:244.
24. Hageman JH, Smith RF, Szilagyi DD, et al. Aneurysms of the renal artery: problems of prognosis and surgical management. *Surgery*. 1978;84:563.
25. Hubert JP Jr, Pairolo PC, Kazmier FJ. Solitary renal artery aneurysms. *Surgery*. 1980;88:557.
26. Harrow BR, Sloane JA. Aneurysm of renal artery: report of five cases. *J Urol*. 1959;81:35.
27. McCarron JP Jr, Marshall VF, Whitsell JC II. Indications for surgery on renal artery aneurysms. *J Urol*. 1975;114:177.
28. Panayiotopoulos YP, Assadourian R, Taylor PR. Aneurysms of the visceral and renal arteries. *Ann R Coll Surg Engl*. 1996;78:412.

29. Hidai H, Kinoshita Y, Murayama T, et al. Rupture of renal artery aneurysm. *Eur Urol.* 1985;11:249.
30. Cohen JR, Shamash FS. Ruptured renal artery aneurysms during pregnancy. *J Vasc Surg.* 1987;6:51.
31. Sicard GA, Reilly JM, Picus DD, et al. Alternatives in renal revascularization. *Curr Probl Surg.* 1995;32:569.
32. Stanley JC, Zelenock GB. Splanchnic artery aneurysms. In: Rutherford RB, ed. *Vascular Surgery*. 4th ed. Philadelphia: WB Saunders; 1995:1124.
33. Van Way CW III. Renal artery aneurysms and arteriovenous fistulae. In: Rutherford RB, ed. *Vascular Surgery*. 4th ed. Philadelphia: WB Saunders; 1995:1438.
34. Chivate J, Blewitt R. Congenital renal arteriovenous fistula: case report. *Br J Urol.* 1993;71:358.
35. Arroyo Bielsa A, Porto Rodriguez J, Gesto Castromil R. Extraparenchymal renal artery aneurysms: is hypertension an indication for revascularization surgery? *Ann Vasc Surg.* 2002;16:339.
36. Turpin S, Lambert R, Querin S, et al. Radionuclide captopril renography in postpartum renal artery aneurysms. *J Nucl Med.* 1996;37:1368.
37. Vaughan TJ, Barry WF, Jeffords DL, et al. Renal artery aneurysms and hypertension. *Radiology.* 1971;99:287.
38. Routh WD, Keller FS, Gross GM. Transcatheter thrombosis of a leaking saccular aneurysm of the main renal artery with preservation of renal blood flow. *AJR Am J Roentgenol.* 1990;154:1097.
39. Murray SP, Kent C, Salvatierra O, et al. Complex branch renovascular disease: management options and late results. *J Vasc Surg.* 1994;20:338.
40. Brayman KL, Gincherman Y, Levy MM, et al. Ex vivo reconstruction of the renal artery for aneurysm and other abnormalities of renal vascular anatomy. In: Calligaro KD, Dougherty MJ, Dean RH, eds. *Modern Management of Renovascular Hypertension and Renal Salvage*. Baltimore: Williams & Wilkins; 1996:269.
41. Dubernard JM, Martin X, Gelet A, et al. Aneurysms of the renal artery: surgical management with special reference to extracorporeal surgery and autotransplantation. *Eur Urol.* 1985;11:26.
42. Dean RH, Meachum PW, Weaver FA. Ex vivo renal artery reconstructions: indications and techniques. *J Vasc Surg.* 1986;4:546.
43. Lacombe M. Ex situ repair of complex renal artery lesions. *Cardiovasc Surg.* 1994;2:767.
44. Seki T, Koyanagi T, Togashi M, et al. Experience with revascularizing renal artery aneurysms: is it feasible, safe, and worth attempting? *J Urol.* 1997;158:357.
45. English WP, Pearce JD, Craven TE, et al. Surgical management of renal artery aneurysms. *J Vasc Surg.* 2004;40:53.
46. Pfeiffer T, Reiher L, Grabitz K, et al. Reconstruction for renal artery aneurysm: operative techniques and long-term results. *J Vasc Surg.* 2003;37:293.
47. Toshino A, Oka A, Kitajima K, et al. Ex vivo surgery for renal artery aneurysms. *Int J Urol.* 1996;3:421.
48. Gill IS, Murphy DP, Hsu TH, et al. Laparoscopic repair of renal artery aneurysm. *J Urol.* 2001;166:202.
49. Luke P, Knudsen BE, Ngan CY, et al. Robot-assisted laparoscopic renal artery aneurysm reconstruction. *J Vasc Surg.* 2006;44:651.
50. Bui BT, Oliva VL, Leclerc G, et al. Renal artery aneurysm: treatment with percutaneous placement of a stent-graft. *Radiology.* 1995;195:181.
51. Klein GE, Szolar DH, Breinl E, et al. Endovascular treatment of renal artery aneurysm with conventional non-detachable microcoils and Guglielmi detachable coils. *Br J Urol.* 1997;79:852.
52. Tateno T, Kubota Y, Sasagawa I, et al. Successful embolization of a renal artery aneurysm with preservation of renal blood flow. *Int Urol Nephrol.* 1996;28:283.
53. Tshomba Y, Deleo G, Ferrari S, et al. Renal artery aneurysm: improved renal function after coil embolization. *J Endovasc Ther.* 2002;9:54.
54. Soga Y, Sakai K, Nobuyoshi M. Renal artery aneurysm treatment with coil embolization. *Catheter Cardiovasc Interv.* 2007;69:697.

55. Pall AA, Reid AW, Allsion MEM. Renal artery aneurysm six years after percutaneous renal biopsy: successful treatment by embolization. *Nephrol Dial Transplant*. 1992;7:883.
56. Rautio R, Haapanen A. Transcatheter embolization of a renal artery aneurysm using ethylene vinyl alcohol copolymer. *Cardiovasc Intervent Radiol*. 2007;30:300.
57. Lupattelli T, Abubacker Z, Morgan R, Belli AM. Embolization of a renal artery aneurysm using ethylene vinyl alcohol copolymer (Onyx). *J Endovasc Ther*. 2003;10:366.
58. Gandini R, Spinelli A, Pampana E, et al. Bilateral renal artery aneurysm: percutaneous treatment with stent-graft placement. *Cardiovasc Intervent Radiol*. 2006;29:875.
59. Andersen PE, Rohr N. Endovascular exclusion of renal artery aneurysm. *Cardiovasc Intervent Radiol*. 2005;28:665.
60. Klonaris C, Katsargyris A, Bakoyannis C, et al. Renal artery aneurysm endovascular repair. *Int Angiol*. 2007;26:189.
61. Bruce M, Kuan YM. Endoluminal stent-graft repair of a renal artery aneurysm. *J Endovasc Ther*. 2002;9:359.
62. Sahin S, Okbay M, Cinar B, Uzunlulu N. Wide-necked renal artery aneurysm: endovascular treatment with stent-graft. *Diagn Interv Radiol*. 2007;13:42.
63. Kyle VN. Renal artery aneurysms. *Can Med Assoc J*. 1968;98:815.
64. Sachs D, Langevitz P, Moraq B, et al. Polyarteritis nodosa and familial Mediterranean fever. *Br J Rheumatol*. 1987;26:139.
65. Motta J, Breslin D, Vogel F, et al. Congenital renal arteriovenous malformation in pregnancy presenting with hypertension: case report. *Urology*. 1994;44:911.
66. Cho KJ, Stanley JC. Non-neoplastic congenital and acquired renal arteriovenous malformations and fistulas. *Radiology*. 1978;129:333.
67. Kearse W Jr, Joseph A, Sabanegh E Jr. Transcatheter embolization of large idiopathic renal arteriovenous fistula: case report. *J Urol*. 1994;151:967.
68. McAlhany JC Jr, Black HC Jr, Hanback LD Jr, Yarbrough DR III. Renal arteriovenous fistula as a cause of hypertension. *Am J Surg*. 1971;122:117.
69. Piquet P, Trainier P, Garibotti F, et al. Aneurysmes des arteres renales et fistules arterioveineuses renales. In: Kieffer E, ed. *Chirurgie des Arteres Renales*. Paris: AERCv; 1993:237.
70. Gopalakrishnan G, Al-Awadi K, Bhatia V, Mahmoud A. Renal arteriovenous malformation presenting as haematuria in pregnancy: case report. *Br J Urol*. 1995;75:110.
71. Fogazzi G, Moriggi M, Fontanella U. Spontaneous renal arteriovenous fistula as a cause of haematuria. *Nephrol Dial Transplant*. 1997;12:350.
72. Morimoto A, Nakatani A, Matsui K, et al. A unique case of renovascular hypertension caused by combined renal artery disease: case report. *Hypertens Res*. 1995;18:255.
73. Imray TJ, Cohen AJ, Hahn L. Renal arteriovenous fistula associated with fibromuscular dysplasia. *Urology*. 1989;23:378.
74. Vasavada S, Manion S, Flanigan RC, et al. Renal arteriovenous malformations masquerading as renal cell carcinoma. *Urology*. 1995;46:716.
75. Crotty K, Orihuela E, Warren M. Recent advances in the diagnosis and treatment of renal arteriovenous malformations and fistulas. *J Urol*. 1993;150:1355.
76. Robinson D, Teitelbaum G, Pentecost M, et al. Transcatheter embolization of an aortocaval fistula caused by residual renal artery stump from previous nephrectomy: a case report. *J Vasc Surg*. 1993;17:794.
77. Steffens J, Defreyne L, Kramann B, et al. Selective transcatheter embolization of a pediatric postnephrectomy arteriovenous fistula: case report. *Urol Int*. 1994;53:99.
78. van der Zee J, van den Hoek J, Weerts J. Traumatic renal arteriovenous fistula in a 3-year-old girl, successfully treated by percutaneous transluminal embolization. *J Pediatr Surg*. 1995;30:1513.
79. Huppert P, Duda S, Erley C, et al. Embolization of renal vascular lesions: clinical experience with microcoils and tracker catheters. *Cardiovasc Intervent Radiol*. 1993;16:361.

80. Lawen JD, van Buren CT, Lewis RM, Kahan BD. Arteriovenous fistulas after renal allograft biopsy: a serious complication in patients beyond one year. *Clin Transplant*. 1990;4:357.
81. Thistlethwaite JR Jr, Woodle ES, Mayes JT, et al. Aggressive needle biopsy protocol prevents loss of renal allografts to undetected rejection during early post-transplant dysfunction. *Transplant Proc*. 1989;21:1890.
82. Merkus J, Zeebregts C, Hoitsma A, et al. High incidence of arteriovenous fistula after biopsy of kidney allografts. *Br J Surg*. 1993;80:310.
83. Reilly K, Shapiro M, Haskal Z. Angiographic embolization of a penetrating traumatic renal arteriovenous fistula. *J Trauma*. 1996;41:763.
84. Ozbek S, Memis A, Killi R, et al. Image-directed and color Doppler ultrasonography in the diagnosis of postbiopsy arteriovenous fistulas of native kidneys. *J Clin Ultrasound*. 1995;23:239.
85. Rollino C, Garofalo G, Roccatello D, et al. Colour-coded Doppler sonography in monitoring native kidney biopsies. *Nephrol Dial Transplant*. 1994;9:1260.
86. Kolb L, Velosa J, Bergstralh E, Offord K. Percutaneous renal allograft biopsy: a comparison of two needle types and analysis of risk factors. *Transplantation*. 1994;57:1742.
87. Riehl J, Maigatter S, Kierdorf H, et al. Percutaneous renal biopsy: comparison of manual and automated puncture techniques with native and transplant kidneys. *Nephrol Dial Transplant*. 1994;9:1568.
88. Mori K, Koga S, Nishikido M, et al. Spontaneous rupture of an aneurysmal intrarenal arteriovenous fistula. *Urol Int*. 2003;70:83.
89. Schmid T, Sandbichler P, Ausserwinkler M, et al. Vascular lesions after percutaneous biopsies of renal allografts. *Transplant Int*. 1989;2:56.
90. Harrison K, Nghiem H, Coldwell D, Davis C. Renal dysfunction due to an arteriovenous fistula in a transplant recipient. *J Am Soc Nephrol*. 1994;5:1300.
91. Beaujeux R, Saussine C, Al-Fakir A, et al. Superselective endovascular treatment of renal vascular lesions. *J Urol*. 1995;153:14.
92. Yeo E, Low J. Intrarenal arteriovenous fistula simulating a hypervascular renal tumor on radionuclide renal imaging. *Clin Nucl Med*. 1995;20:549.
93. Peces R, Gorostidi M, Garcia-Gala J, et al. Giant saccular aneurysm of the renal artery presenting as malignant hypertension. *J Hum Hypertens*. 1991;5:465.
94. Bagga H, Bis KG. Contrast-enhanced MR angiography in the assessment of arteriovenous fistula after renal transplant biopsy. *AJR Am J Roentgenol*. 1999;172:1509.
95. Gainza F, Minguela I, Lopez-Vidaur I, et al. Evaluation of complications due to percutaneous renal biopsy in allografts and native kidneys with color-coded Doppler sonography. *Clin Nephrol*. 1995;43:303.
96. Beaujeux R, Boudjema K, Ellero B, et al. Endovascular treatment of renal allograft postbiopsy arteriovenous fistula with platinum microcoils. *Transplantation*. 1994;57:311.
97. Messing E, Kessler R, Kavaney PB. Renal arteriovenous fistulas. *Urology*. 1976;8:101.
98. Kumar U, German K, Blackford H, Dux A. Perioperative use of a balloon-occluding arterial catheter in renal arteriovenous malformation. *Br J Urol*. 1996;77:312.
99. Takatera H, Nakamura M, Nakano E, et al. Renal arteriovenous fistula associated with a huge renal vein dilatation. *J Urol*. 1987;137:722.
100. Torres G, Terramani T, Weaver F. Ex vivo repair of a large renal artery aneurysm and associated arteriovenous fistula. *Ann Vasc Surg*. 2002;16:141.
101. Takebayashi S, Hosaka M, Kubota Y, et al. Transarterial embolization and ablation of renal arteriovenous malformations: efficacy and damages in 30 patients with long-term followup. *J Urol*. 1998;159:696.
102. Cursio R, Choquenot C, Brunner P. Successful transarterial embolization of idiopathic renal arteriovenous fistula. *Minerva*

- Chir.* 2001;56:321.
103. Wikholm G, Svendsen P, Herlitz H, et al. Superselective transarterial embolization of renal arteriovenous malformations of cryptogenic origin. *Scand J Urol Nephrol.* 1994;28:29.
  104. Saliou C, Raynaud A, Blanc F, et al. Idiopathic renal arteriovenous fistula: treatment with embolization. *Ann Vasc Surg.* 1998;12:75.
  105. Defrayne L, Govaere F, Vanlangenhove P, et al. Cirroid renal arteriovenous malformation treated by endovascular embolization with N-butyl 2-cyanoacrylate. *Eur Radiol.* 2000;10:772.
  106. Nakamura H, Uchida H, Kuroda C, et al. Renal aorto-venous malformations: transcatheter embolization and follow-up. *AJR Am J Roentgenol.* 1981;137:113.
  107. Lord RSA, Cherian SM, Ozmen J. Massive renal arteriovenous fistula presenting as a pulsatile abdominal mass. *Cardiovasc Surg.* 2000;8:164.
  108. Ziani M, Valignat C, Lopez J, et al. Renal arteriovenous malformation requiring surgery in Rendu-Osler-Weber disease (hereditary hemorrhagic telangiectasia). *J Urol.* 2000;164:1292.
  109. Gralino BJ, Bricker DL. Staged endovascular occlusion of giant idiopathic renal arteriovenous fistula with platinum microcoils and silk suture threads. *J Vasc Interv Radiol.* 2002;13:747.
  110. Kamai T, Saito K, Hirokawa M, et al. A case of gross hematuria arising during embolization for renal arteriovenous malformation. *Urol Int.* 1997;58:55.

## 第 146 章

1. Desai TR, Gupta N, Gewertz BL. Acute renovascular occlusive events. In: Rutherford RB, ed. *Vascular Surgery*. Philadelphia: Elsevier Saunders; 2005:1871-1877.
2. Wright MP, Persad RA, Cranston DW. Renal artery occlusion. *BJU Int.* 2001;87:9-12.
3. Hurwitt ES, Seiderberg B, Haimovici H, Abelson D. Splenorenal anastomosis. *Circulation.* 1956;14:532-539.
4. Morton JR, Crawford ES. Bilateral traumatic renal artery thrombosis. *Ann Surg.* 1972;176:62-67.
5. Spanos PK, Terhorst TR, Sako Y. Acute prolonged renal arterial infarction. Return of function after thromboendarterectomy. *Am J Surg.* 1975;129:579-582.
6. Selli C, Turini D, Berni G. Embolism in a single functioning kidney: report of two cases. *Br J Urol.* 1976;48:419-425.
7. Gruntzig A, Kuhlman U, Vetter W, et al. Treatment of renovascular hypertension with percutaneous transluminal dilatation of a renal artery stenosis. *Lancet.* 1978;i:801-802.
8. Korzets Z, Plotkin E, Bernheim J, Zissin R. The clinical spectrum of acute renal infarction. *Isr Med Assoc J.* 2002;4:781-784.
9. Hazanov N, Somin M, Attali M, et al. Acute renal embolism. Forty-four cases of renal infarction in patients with atrial fibrillation. *Medicine (Baltimore).* 2004;83:292-299.
10. Moolenaar W, Lamers CB. Cholesterol crystal embolization in the Netherlands. *Arch Intern Med.* 1996;156:653-657.
11. Scolari F, Ravani P, Gaggi R, et al. The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors. *Circulation.* 2007;116:298-304.
12. Caps MT, Perissinotto C, Zierler RE, et al. Prospective study of atherosclerotic disease progression in the renal artery. *Circulation.* 1998;98:2866-2872.
13. Ames PR, Cianciaruso B, Bellizzi V, et al. Bilateral renal artery occlusion in a patient with primary antiphospholipid antibody syndrome: thrombosis, vasculitis or both? *J Rheumatol.* 1992;19:1802-1806.
14. Le Moine A, Chauveau D, Grunfeld JP. Acute renal artery thrombosis associated with factor V Leiden mutation. *Nephrol Dial Transplant.* 1996;11:2067-2069.
15. Uthman I, Khamashta M. Antiphospholipid syndrome and the kidneys. *Semin Arthritis Rheum.* 2006;35:360-367.
16. Fukuda T, Hayashi K, Sakamoto I, Mori M. Acute renal infarction caused by Behcet's disease. *Abdom Imaging.*

- 1995;20:264-266.
17. Smith BM, Holcomb GW III, Richie RE, Dean RH. Renal artery dissection. *Ann Surg.* 1984;200:134-146.
18. Brown MF, Graham JM, Mattox KL, et al. Renovascular trauma. *Am J Surg.* 1980;140:802-805.
19. Sullivan MJ, Smalley R, Banowsky LH. Renal artery occlusion secondary to blunt abdominal trauma. *J Trauma.* 1972;12:509-515.
20. Sharples EJ, Sobeh M, Matson M, Yaqoob MM. Renal artery dissection after blunt abdominal trauma: a rare cause of acute cortical necrosis. *Am J Kidney Dis.* 2002;40:E11.
21. Peterson NE. Traumatic bilateral renal infarction. *J Trauma.* 1989;29:158-167.
22. Knudson MM, Harrison PB, Hoyt DB, et al. Outcome after major renovascular injuries: a Western Trauma Association multicenter report. *J Trauma.* 2000;49:1116-1122.
23. Asghar M, Ahmed K, Shah SS, et al. Renal vein thrombosis. *Eur J Vasc Endovasc Surg.* 2007;34:217-223.
24. Lau KK, Stoffman JM, Williams S, et al. Neonatal renal vein thrombosis: review of the English-language literature between 1992 and 2006. *Pediatrics.* 2007;120:e1278-e1284.
25. Witz M, Kantarovsky A, Morag B, Shifrin EG. Renal vein occlusion: a review. *J Urol.* 1996;155:1173-1179.
26. Novick AC. Renal hypothermia: in vivo and ex vivo. *Urol Clin North Am.* 1983;10:637-644.
27. Semb C. Partial resection of the kidney: anatomical, physiological and clinical aspects. *Ann R Coll Surg Engl.* 1956;19:137-155.
28. Laven BA, Orvieto MA, Chuang MS, et al. Renal tolerance to prolonged warm ischemia time in a laparoscopic versus open surgery porcine model. *J Urol.* 2004;172:2471-2474.
29. Lohse JR, Shore RM, Belzer FO. Acute renal artery occlusion: the role of collateral circulation. *Arch Surg.* 1982;117:801-804.
30. Schefft P, Novick AC, Stewart BH, Straffon RA. Renal revascularization in patients with total occlusion of the renal artery. *J Urol.* 1980;124:184-186.
31. Flye MW, Anderson RW, Fish JC, Silver D. Successful surgical treatment of anuria caused by renal artery occlusion. *Ann Surg.* 1982;195:346-353.
32. Yune HY, Klatte EC. Collateral circulation to an ischemic kidney. *Radiology.* 1976;119:539-546.
33. Hietala SO, Kunz R. Collateral circulation in stenosis or occlusion of the renal artery. *Cardiovasc Radiol.* 1979;2:249-255.
34. Abrams HL, Cornell SH. Patterns of collateral flow in renal ischemia. *Radiology.* 1965;84:1001-1012.
35. Pagtalunan ME, Olson JL, Tilney NL, Meyer TW. Late consequences of acute ischemic injury to a solitary kidney. *J Am Soc Nephrol.* 1999;10:366-373.
36. Textor SC. Pathophysiology of renal failure in renovascular disease. *Am J Kidney Dis.* 1994;24:642-651.
37. Zager RA, Alpers CE. Effects of aging on expression of ischemic acute renal failure in rats. *Lab Invest.* 1989;61:290-294.
38. Shi H, Patschan D, Epstein T, et al. Delayed recovery of renal regional blood flow in diabetic mice subjected to acute ischemic kidney injury. *Am J Physiol Renal Physiol.* 2007;293:F1512-F1517.
39. Johnson SR, Khwaja K, Pavlakis M, et al. Older living donors provide excellent quality kidneys: a single center experience (older living donors). *Clin Transplant.* 2005;19:600-606.
40. Eckel H. Acute renal artery occlusion: problems of diagnosis and treatment. *Urologe Ausgabe B.* 1980;20:268-272.
41. Dell'Aria JC, Petrilli R, Schwartz E. Acute occlusion of the left renal artery manifested by hypertensive crisis. *J Emerg Med.* 1988;6:23-27.
42. Platz G. Acute kidney artery occlusion as important differential diagnosis of acute flank pain—diagnosis, course and therapy. Extended case report and review of the literature. *Urologe Ausgabe B.* 1998;38:358-362.
43. Hall SK. Acute renal vascular occlusion: an uncommon mimic. *J Emerg Med.* 1993;11:691-700.
44. Kasinath BS, Corwin HL, Bidani AK, et al. Eosinophilia in the diagnosis of atheroembolic renal disease. *Am J Nephrol.* 1987;7:173-177.

45. Winzelberg GG, Hull JD, Agar JW, et al. Elevation of serum lactate dehydrogenase levels in renal infarction. *JAMA*. 1979;242:268-269.
46. Mulligan SA, Koslin DB, Berland LL. Duplex evaluation of native renal vessels, inferior vena cava and renal allografts. In: Zwiebel WJ, ed. *Introduction to Vascular Ultrasound*. Philadelphia: W.B. Saunders; 1992:387-407.
47. Fleischmann D. Multiple detector-row CT angiography of the renal and mesenteric vessels. *Eur J Radiol*. 2003;45(Suppl 1):S79-S87.
48. Lupetin AR, Mainwaring BL, Daffner RH. CT diagnosis of renal artery injury caused by blunt abdominal trauma. *AJR Am J Roentgenol*. 1989;153:1065-1068.
49. Nunez D Jr, Becerra JL, Fuentes D, Pagson S. Traumatic occlusion of the renal artery: helical CT diagnosis. *AJR Am J Roentgenol*. 1996;167:777-780.
50. Kawashima A, Sandler CM, Ernst RD, et al. CT evaluation of renovascular disease. *Radiographics*. 2000;20:1321-1340.
51. Ouriel K, Andrus CH, Ricotta JJ, et al. Acute renal artery occlusion: when is revascularization justified? *J Vasc Surg*. 1987;5:348-355.
52. Pavlock GS, Southard JH, Lutz MF, et al. Effects of mannitol and chlorpromazine pretreatment of rabbits on kidney mitochondria following in vivo ischemia and reflow. *Life Sci*. 1981;29:2667-2672.
53. Didlake R, Kirchner KA, Lewin J, et al. Attenuation of ischemic renal injury with fructose 1,6-diphosphate. *J Surg Res*. 1989;47:220-226.
54. Lopez-Marti J, Sola A, Pi F, et al. Nucleotides modulate renal ischaemia-reperfusion injury by different effects on nitric oxide and superoxide. *Clin Exp Pharmacol Physiol*. 2003;30:242-248.
55. Rhoden EL, Pereira-Lima L, Rhoden CR, et al. Role of the L-arginine/nitric oxide pathway in renal ischaemia-reperfusion in rats. *Eur J Surg*. 2001;167:224-228.
56. Torsello G, Schror K, Szabo Z, et al. Winner of the ESVS Prize 1988. Effects of prostaglandin E1 (PGE1) on experimental renal ischaemia. *Eur J Vasc Surg*. 1989;3:5-13.
57. Abbott WM, Austen WG. The reversal of renal cortical ischemia during aortic occlusion by mannitol. *J Surg Res*. 1974;16:482-489.
58. Collins GM, Green RD, Boyer D, Halasz NA. Protection of kidneys from warm ischemic injury. Dosage and timing of mannitol administration. *Transplantation*. 1980;29:83-84.
59. Zigman A, Yazbeck S, Emil S, Nguyen L. Renal vein thrombosis: a 10-year review. *J Pediatr Surg*. 2000;35:1540-1542.
60. Lacombe M. Acute non-traumatic obstructions of the renal artery. *J Cardiovasc Surg (Torino)*. 1992;33:163-168.
61. Salam TA, Lumsden AB, Martin LG. Local infusion of fibrinolytic agents for acute renal artery thromboembolism: report of ten cases. *Ann Vasc Surg*. 1993;7:21-26.
62. Contractor FM, Leicht JP. Intraarterial infusion of low-dose streptokinase after acute thromboembolization of the right renal artery. *Cardiovasc Intervent Radiol*. 1984;7:21-23.
63. Blum U, Billmann P, Krause T, et al. Effect of local low-dose thrombolysis on clinical outcome in acute embolic renal artery occlusion. *Radiology*. 1993;189:549-554.
64. Kadir S, Watson A, Burrow C. Percutaneous transcatheter recanalization in the management of acute renal failure due to sudden occlusion of the renal artery to a solitary kidney. *Am J Nephrol*. 1987;7:445-449.
65. Pineo GF, Thorndyke WC, Steed BL. Spontaneous renal artery thrombosis: successful lysis with streptokinase. *J Urol*. 1987;138:1223-1225.
66. Blum U, Billmann P, Krause T, et al. Effect of local low-dose thrombolysis on clinical outcome in acute embolic renal artery occlusion. *Radiology*. 1993;189:549-554.
67. Gluck G, Croitoru M, Deleanu D, Platon P. Local thrombolytic treatment for renal arterial embolism. *Eur Urol*. 2000;38:339-343.
68. Cheng BC, Ko SF, Chuang FR, et al. Successful management of acute renal artery thromboembolism by intra-arterial



- thrombolytic therapy with recombinant tissue plasminogen activator. *Ren Fail.* 2003;25:665-670.
69. Schneider JR, Wright A, Mitchell RS. Successful percutaneous balloon catheter treatment of renal artery occlusion and anuria. *Ann Vasc Surg.* 1992;6:533-536.
  70. Lutkevich C, Hall JR, Lewis JV, et al. Percutaneous transluminal angioplasty of an acute traumatic renal artery occlusion. *Tenn Med.* 2000;93:140-141.
  71. Rha SW, Wani SP, Suh SY, et al. Images in cardiovascular medicine. Successful percutaneous renal intervention in a patient with acute traumatic renal artery thrombosis. *Circulation.* 2006;114:e583-e585.
  72. Morris CS, Bonnevie GJ, Najarian KE. Nonsurgical treatment of acute iatrogenic renal artery injuries occurring after renal artery angioplasty and stenting. *AJR Am J Roentgenol.* 2001;177:1353-1357.
  73. Kim HS, Fine DM, Atta MG. Catheter-directed thrombectomy and thrombolysis for acute renal vein thrombosis. *J Vasc Interv Radiol.* 2006;17:815-822.
  74. Benjamin ME, Dean RH. Techniques in renal artery reconstruction: Part I. *Ann Vasc Surg.* 1996;10:306-314.
  75. Benjamin ME, Dean RH. Techniques in renal artery reconstruction: Part II. *Ann Vasc Surg.* 1996;10:409-414.
  76. van Weel V, van Bockel JH, van Wissen R, van Baalen JM. Intraoperative renal duplex sonography: a valuable method for evaluating renal artery reconstructions. *Eur J Vasc Endovasc Surg.* 2000;20:268-272.
  77. Lacombe M. Surgical versus medical treatment of renal artery embolism. *J Cardiovasc Surg (Torino).* 1977;18:281-290.
  78. Bouttier S, Valverde JP, Lacombe M, et al. Renal artery emboli: the role of surgical treatment. *Ann Vasc Surg.* 1988;2:161-168.
  79. Higgins RM, Goldsmith DJ, Charlesworth D, et al. Elective rather than emergency intervention for acute renal artery occlusion with anuria. *Nephron.* 1994;68:265-267.
  80. Ross WB, Markham NI, Salaman JR. Autotransplantation for renovascular hypertension with complete renal artery occlusion. *Ann R Coll Surg Engl.* 1989;71:233-235.
  81. Van Damme H, Rorive G, Limet R. Reversal of acute renal failure by kidney revascularisation. *Eur J Vasc Endovasc Surg.* 1996;11:134-139.
  82. Smith SD, Gardner MJ, Rowe MI. Renal artery occlusion in pediatric blunt abdominal trauma—decreasing the delay from injury to treatment. *J Trauma.* 1993;35:861-864.
  83. Haas CA, Spirnak JP. Traumatic renal artery occlusion: a review of the literature. *Tech Urol.* 1998;4:1-11.
  84. van Rooden CJ, van Baalen JM, van Bockel JH. Spontaneous dissection of renal artery: long-term results of extracorporeal reconstruction and autotransplantation. *J Vasc Surg.* 2003;38:116-122.
  85. Reilly LM, Cunningham CG, Maggisano R, et al. The role of arterial reconstruction in spontaneous renal artery dissection. *J Vasc Surg.* 1991;14:468-477.
  86. Lacombe M. Isolated spontaneous dissection of the renal artery. *J Vasc Surg.* 2001;33:385-391.
  87. Muller BT, Reiher L, Pfeiffer T, et al. Surgical treatment of renal artery dissection in 25 patients: indications and results. *J Vasc Surg.* 2003;37:761-768.

## 第 147 章

1. Allbutt C, Rolleston RS. *System of Medicine*. London: WH Welch; 1909.
2. Baccelli F, cited by Goodman EH. Angina abdominis. *Am J Med Sci.* 1918;155:524-528.
3. Cokkinis AJ. *Mesenteric Vascular Occlusion*. London: Bailliere, Tindall and Cox; 1926.
4. Dunphy JE. Abdominal pain of vascular origin. *Am J Med Sci.* 1936;192:109-113.
5. Klass AA. Embolectomy in acute mesenteric occlusion. *Ann Surg.* 1951;134:913-917.
6. Shaw RS, Maynard EP III. Acute and chronic thrombosis of the mesenteric arteries associated with malabsorption. A report of two cases successfully treated with thromboendarterectomy. *N Engl J Med.* 1958;258:874.
7. Morris GC, Crawford ES, Cooley DA, et al. Revascularization of the celiac and superior mesenteric arteries. *Arch Surg.*

- 1962;84:113-125.
8. Stoney RJ, Wylie WJ. Recognition and surgical management of visceral ischaemic syndromes. *Ann Surg.* 1966;164:714-722.
9. Furrer J, Gruntzig A, Kugelmeier J, et al. Treatment of abdominal angina with percutaneous dilatation of an arteria mesenterica superior stenosis. Preliminary communication. *Cardiovasc Intervent Radiol.* 1980;3:43-44.
10. Rosenblum JD, Boyle CM, Schwartz LB. The mesenteric circulation: anatomy and physiology. *Surg Clin North Am.* 1997;77:289-306.
11. Perko MJ, Nielsen HB, Skak C, et al. Mesenteric, celiac and splanchnic blood flow in humans during exercise. *J Physiol.* 1998;513:907-913.
12. Wilson DB, Mostavi K, Craven TE, et al. Clinical course of mesenteric artery stenosis in elderly Americans. *Arch Intern Med.* 2006;166:2095-2100.
13. Foley MI, Moneta GL, Abou-Zamzam AM, et al. Revascularization of the superior mesenteric artery alone for treatment of intestinal ischemia. *J Vasc Surg.* 2000;32:37-47.
14. Stoney RJ, Cunningham CG. Acute mesenteric ischemia. *Surgery.* 1993;114:489-490.
15. McKinsey JF, Gewertz BL. Acute mesenteric ischemia. *Surg Clin North Am.* 1997;77:307-318.
16. Park WM, Gloviczki P, Cherry KJ Jr, et al. Contemporary management of acute mesenteric ischemia: factors associated with survival. *J Vasc Surg.* 2002;35:445-452.
17. McMillan WD, McCarthy WJ, Bresticker MR, et al. Mesenteric artery bypass: objective patency determination. *J Vasc Surg.* 1995;21:721-749.
18. Bradbury AW, Brittenden J, McBride K, et al. Mesenteric ischaemia: a multidisciplinary approach. *Br J Surg.* 1995;82:1446-1459.
19. Mansour MA. Management of acute mesenteric ischemia. *Arch Surg.* 1999;134:328-330.
20. Oldenburg WA, Lau LL, Rodenburg TJ. Acute mesenteric ischemia: a clinical review. *Arch Intern Med.* 2004;164:1054-1062.
21. Schoots IG, Koffeman GI, Legemate DA, et al. Systematic review of survival after acute mesenteric ischaemia according to disease aetiology. *Br J Surg.* 2004;91:17-27.
22. Acosta S, Ogren M, Sternby NH, et al. Clinical implications for the management of acute thromboembolic occlusion of the superior mesenteric artery: autopsy findings in 213 patients. *Ann Surg.* 2005;241:516-522.
23. Thomas JH, Blake K, Pierce GE, et al. The clinical course of asymptomatic mesenteric arterial stenosis. *J Vasc Surg.* 1998;27:840-844.
24. Deitch EA, Morrison J, Berg R, et al. Effect of hemorrhagic shock on bacterial translocation, intestinal morphology, and intestinal permeability in conventional and antibiotic-decontaminated rats. *Crit Care Med.* 1990;18:529-536.
25. Grendell JH, Ockner RK. Mesenteric venous thrombosis. *Gastroenterology.* 1982;82:35-72.
26. Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. *N Engl J Med.* 2001;345:1683-1688.
27. Schwartz LB, Gewertz BL. Mesenteric ischemia. *Surg Clin North Am.* 1997;77:275-507.
28. Rhee RY, Gloviczki P, Mendonca CT, et al. Mesenteric venous thrombosis: still a lethal disease in the 1990's. *J Vasc Surg.* 1994;20:688-697.
29. Park WM, Cherry KJ, Chua HK, et al. Current results of open revascularization for chronic mesenteric ischemia: a standard for comparison. *J Vasc Surg.* 2002;35:853-859.
30. Dietrich CF, Jedrzejczyk M, Ignee A. Sonographic assessment of splanchnic arteries and the bowel wall. *Eur J Radiol.* 2007;64:202-212.
31. Moneta GL, Lee RW, Yeager RA, et al. Mesenteric duplex scanning: a blinded prospective study. *J Vasc Surg.* 1993;17:79-84.
32. Moneta GL, Yeager RA, Dalman R, et al. Duplex ultrasound criteria for diagnosis of splanchnic artery stenosis or occlusion. *J Vasc Surg.* 1991;14:511-518.

33. Geelkerken RH, Delahunt TA, Schultze Kool LJ, et al. Pitfalls in the diagnosis of origin stenosis of the celiac and superior mesenteric arteries with transabdominal color duplex examination. *Ultrasound Med Biol*. 1996;22:695-700.
34. Rosow DE, Sahani D, Strobel O, et al. Imaging of acute mesenteric ischemia using multidetector CT and CT angiography in a porcine model. *J Gastrointest Surg*. 2005;9:1262-1275.
35. Kirkpatrick ID, Kroeker MA, Greenberg HM, et al. Biphasic CT with mesenteric CT angiography in the evaluation of acute mesenteric ischemia: initial experience. *Radiology*. 2003;221:91-98.
36. Ernst O, Asnar V, Sergeant G, et al. Comparing contrast-enhanced breath-hold MR angiography and conventional angiography in the evaluation of mesenteric circulation. *AJR Am J Roentgenol*. 2000;174:433-439.
37. Jamieson WG, Pliagus G, Marchuk S, et al. Effect of antibiotic and fluid resuscitation upon survival time in experimental intestinal ischemia. *Surg Gynecol Obstet*. 1988;167:103-108.
38. Silva JA, White CJ, Collins TJ, et al. Endovascular therapy for chronic mesenteric ischemia. *J Am Coll Cardiol*. 2006;47:944-950.
39. Sivamurthy N, Rhodes JM, Lee D, et al. Endovascular versus open mesenteric revascularization: immediate benefits do not equate with short-term functional outcomes. *J Am Coll Surg*. 2006;202:859-867.
40. Sharafuddin MJ, Olson CH, Sun S, et al. Endovascular treatment of celiac and mesenteric arteries stenosis: applications and results. *J Vasc Surg*. 2003;38:692-698.
41. Sarac TP, Altinel O, Kashyap V, et al. Endovascular treatment of stenotic and occluded visceral arteries for chronic mesenteric ischemia. *J Vasc Surg*. 2008;47:485-491.
42. Kasirajan K, O'Hara PJ, Gray BH, et al. Chronic mesenteric ischemia: open surgery versus percutaneous angioplasty and stenting. *J Vasc Surg*. 2001;33:63-71.
43. Brown DJ, Schermerhorn ML, Powell RJ, et al. Mesenteric stenting for chronic mesenteric ischemia. *J Vasc Surg*. 2005;42:268-274.
44. Atkins MD, Kwolek CJ, LaMuraglia GM, et al. Surgical revascularization versus endovascular therapy for chronic mesenteric ischemia: a comparative experience. *J Vasc Surg*. 2007;45:1162-1171.
45. Milner R, Woo EY, Carpenter JP. Superior mesenteric artery angioplasty and stenting via a retrograde approach in a patient with bowel ischemia: a case report. *Vasc Endovasc Surg*. 2004;38:89-91.
46. Wyers MC, Powell RJ, Nolan BW, et al. Retrograde mesenteric stenting during laparotomy for acute occlusive mesenteric ischemia. *J Vasc Surg*. 2007;45:269-275.
47. Moyes LH, McCarter DHA, Vass DG, et al. Intraoperative retrograde mesenteric angioplasty for acute occlusive mesenteric ischemia: a case series. *Eur J Endovasc Surg*. 2008;38:203-206.
48. Klepczyk L, Keeling WB, Stone PA, et al. Superior mesenteric artery stent fracture producing stenosis and recurrent chronic mesenteric ischemia: case report. *Vasc Endovasc Surg*. 2008;41:79-81.
49. Moore M, McSweeney S, Fulton G, et al. Reperfusion hemorrhage following superior mesenteric artery stenting. *Cardiovasc Intervent Radiol*. 2008;31:(Suppl 2):S57-61.
50. Bergman RT, Glociczki P, Welch TJ, et al. The role of intravenous fluorescein in the detection of colon ischemia during aortic reconstruction. *Ann Vasc Surg*. 1992;6:74-79.
51. Cunningham CG, Reilly LM, Rapp JH, et al. Chronic visceral ischemia. Three decades of progress. *Ann Surg*. 1991;214:276-287.
52. Lau H, Chew DK, Whittemore AD, et al. Transaortic endarterectomy for primary mesenteric revascularization. *Vasc Endovasc Surg*. 2002;36:335-341.
53. Rapp JH, Reilly LM, Qvarfordt PG, et al. Durability of endarterectomy and antegrade grafts in the treatment of chronic visceral ischemia. *J Vasc Surg*. 1986;3:799-806.
54. Jimenez JG, Huber TS, Ozaki K, et al. Durability of antegrade synthetic aortomesenteric bypass for chronic mesenteric ischemia. *J Vasc Surg*. 2002;35:1078-1084.

55. English WP, Pearce JP, Craven TE, et al. Chronic visceral ischemia: symptom-free survival after open surgical repair. *Vasc Endovasc Surg*. 2004;38:493-503.
56. Wylie EJ, Stoney RJ, Ehrenfeld WK. *Manual of Vascular Surgery*. New York: Springer-Verlag NY, Inc; 1980:211.
57. Kansal N, LoGerfo FW, Belfield AK, et al. A comparison of antegrade and retrograde mesenteric bypass. *Ann Vasc Surg*. 2002;16:591-596.
58. Horton JW, White DJ. Free radical scavengers prevent intestinal ischemia-reperfusion-mediated cardiac dysfunction. *J Surg Res*. 1993;55:282-289.
59. Horton JW, White DJ. Cardiac contractile injury after intestinal ischemia-reperfusion. *Am J Physiol*. 1991;261:H1164-H1170.
60. Horton JW, Walker PB. Oxygen radicals, lipid peroxidation, and permeability changes after intestinal ischemia and reperfusion. *J Appl Physiol*. 1993;74:1515-1520.
61. Gerkin TM, Oldham KT, Guice KS, et al. Intestinal ischemia-reperfusion injury causes pulmonary endothelial cell ATP depletion. *Ann Surg*. 1993;217:48-56.
62. Schoenberg MH, Beger HG. Oxygen radicals in intestinal ischemia and reperfusion. *Chem-Biol Interactions*. 1990;76:141-161.
63. Schmeling DJ, Caty MG, Oldham KT, et al. Evidence for neutrophil-related acute lung injury after intestinal ischemia-reperfusion. *Surgery*. 1989;106:195-202.
64. Kougiass P, Lau D, El Sayed HF, et al. Determinants of mortality and treatment outcome following surgical interventions for acute mesenteric ischemia. *J Vasc Surg*. 2007;46:467-474.
65. Mateo RB, O'Hara PJ, Hertzer NR, et al. Elective surgical treatment of symptomatic chronic mesenteric occlusive disease: early results and late outcomes. *J Vasc Surg*. 1999;821-832.
66. Kang H, Manasia A, Rajamani S, et al. Intravenous iloprost increases mesenteric blood flow in experimental acute nonocclusive mesenteric ischemia. *Crit Care Med*. 2002;30:2528-2534.
67. Mitsuyoshi A, Obama K, Shinkura N, et al. Survival in nonocclusive mesenteric ischemia: early diagnosis by multidetector row computed tomography and early treatment with continuous intravenous high-dose prostaglandin E1. *Ann Surg*. 2007;246:229-235.
68. Lopera JE, Correa G, Brazzini A, et al. Percutaneous transhepatic treatment of symptomatic mesenteric venous thrombosis. *J Vasc Surg*. 2002;36:1058-1061.
69. Kim HS, Patra A, Khan J, et al. Transhepatic catheter-directed thrombectomy and thrombolysis of acute superior mesenteric venous thrombosis. *J Vasc Interv Radiol*. 2005;1685-1691.
70. Zhou W, Choi L, Lin PH, et al. Percutaneous transhepatic thrombectomy and pharmacologic thrombolysis of mesenteric venous thrombosis. *Vascular*. 2007;1:41-45.
71. Grisham A, Lohr J, Guenther JM, et al. Deciphering mesenteric venous thrombosis: imaging and treatment. *Vasc Endovasc Surg*. 2005;39:473-479.
72. Semiz-Oysu A, Keussen I, Cwikiel W. Interventional radiological management of prehepatic obstruction of [corrected] the splanchnic venous system. *Cardiovasc Interv Radiol*. 2007;30:688-695.

## 第 148 章

1. Derrow AE, Seeger JM, Dame DA, et al. The outcome in the United States after thoracoabdominal aortic aneurysm repair, renal artery bypass, and mesenteric revascularization. *J Vasc Surg*. 2001;34:54-61.
2. Fara JW. Postprandial mesenteric hyperemia. In: Shepard AP, Granger DN, eds. *Physiology of the Intestinal Circulation*. New York: Raven Press; 1984:99.
3. Moneta GL, Taylor DC, Helton WS, et al. Duplex ultrasound measurement of postprandial intestinal blood flow: effect of meal composition. *Gastroenterology*. 1988;95:1294-1301.

4. Siregar H, Chou CC. Relative contribution of fat, protein, carbohydrate, and ethanol to intestinal hyperemia. *Am J Physiol.* 1982;242:G27-G31.
5. Bond JH, Prentiss RA, Levitt MD. The effects of feeding on blood flow to the stomach, small bowel, and colon of the conscious dog. *J Lab Clin Med.* 1979;93:594-599.
6. Li KC, Whitney WS, McDonnell CH, et al. Chronic mesenteric ischemia: evaluation with phase-contrast cine MR imaging. *Radiology.* 1994;190:175-179.
7. Johnston KW, Lindsay TF, Walker PM, Kalman PG. Mesenteric arterial bypass grafts: early and late results and suggested surgical approach for chronic and acute mesenteric ischemia. *Surgery.* 1995;118:1-7.
8. Mikkelsen WP. Intestinal angina: its surgical significance. *Am J Surg.* 1957;94:262-2267.
9. Carrick RP, Borge MA, Labropoulos N, Rodriguez H. Chronic mesenteric ischemia resulting from isolated lesions of the superior mesenteric artery—a case report. *Angiology.* 2005;56:785-788.
10. Taylor LM, Moneta GL, Porter JM. Treatment of chronic visceral ischemia. In: Rutherford RB, ed. *Vascular Surgery*. 5th ed. Philadelphia: WB Saunders; 2000:1532.
11. Foley MI, Moneta GL, Abou-Zamzam AM Jr, et al. Revascularization of the superior mesenteric artery alone for treatment of intestinal ischemia. *J Vasc Surg.* 2000;32:37-47.
12. Wilson DB, Mostafavi K, Craven TE, et al. Clinical course of mesenteric artery stenosis in elderly americans. *Arch Intern Med.* 2006;166:2095-2100.
13. Croft RJ, Menon GP, Marston A. Does “intestinal angina” exist? A critical study of obstructed visceral arteries. *Br J Surg.* 1981;68:316-318.
14. Valentine RJ, Martin JD, Myers SI, et al. Asymptomatic celiac and superior mesenteric artery stenoses are more prevalent among patients with unsuspected renal artery stenoses. *J Vasc Surg.* 1991;14:195-199.
15. Thomas JH, Blake K, Pierce GE, et al. The clinical course of asymptomatic mesenteric arterial stenosis. *J Vasc Surg.* 1998;27:840-844.
16. Levy PJ, Krausz MM, Manny J. Acute mesenteric ischemia: improved results—a retrospective analysis of ninety-two patients. *Surgery.* 1990;107:372-380.
17. Stoney RJ, Cunningham CG. Acute mesenteric ischemia. *Surgery.* 1993;114:489-490.
18. Connolly JE, Stemmer EA. Intestinal gangrene as the result of mesenteric arterial steal. *Am J Surg.* 1973;126:197-204.
19. Poole JW, Sammartano RJ, Boley SJ. Hemodynamic basis of the pain of chronic mesenteric ischemia. *Am J Surg.* 1987;153:171-176.
20. Marston A, Clarke JM, Garcia GJ, Miller AL. Intestinal function and intestinal blood supply: a 20 year surgical study. *Gut.* 1985;26:656-666.
21. Jimenez JG, Huber TS, Ozaki CK, et al. Durability of antegrade synthetic aortomesenteric bypass for chronic mesenteric ischemia. *J Vasc Surg.* 2002;35:1078-1084.
22. Matsumoto AH, Angle JF, Spinosa DJ, et al. Percutaneous transluminal angioplasty and stenting in the treatment of chronic mesenteric ischemia: results and longterm followup. *J Am Coll Surg.* 2002;194(1 Suppl):S22-S31.
23. Kruger AJ, Walker PJ, Foster WJ, et al. Open surgery for atherosclerotic chronic mesenteric ischemia. *J Vasc Surg.* 2007;46:941-945.
24. Calderon M, Reul GJ, Gregoric ID, et al. Long-term results of the surgical management of symptomatic chronic intestinal ischemia. *J Cardiovasc Surg (Torino).* 1992;33:723-728.
25. Hollier LH, Bernatz PE, Pairolero PC, et al. Surgical management of chronic intestinal ischemia: a reappraisal. *Surgery.* 1981;90:940-946.
26. Mateo RB, O'Hara PJ, Hertzner NR, et al. Elective surgical treatment of symptomatic chronic mesenteric occlusive disease: early results and late outcomes. *J Vasc Surg.* 1999;29:821-831.
27. Rapp JH, Reilly LM, Qvarfordt PG, et al. Durability of endarterectomy and antegrade grafts in the treatment of chronic

- visceral ischemia. *J Vasc Surg.* 1986;3:799-806.
28. Van Damme H, Jacquet N, Belaiche J, et al. Chronic ischaemic gastritis: an unusual form of splanchnic vascular insufficiency. *J Cardiovasc Surg (Torino).* 1992;33:451-453.
  29. Sales J, Norton L, Nolan P, et al. Gastric mucosal ischemia in experimental stress ulcer. *J Surg Res.* 1975;18:65-74.
  30. Shirazi S, Mueller TM, Hardy BM. Canine gastric acid secretion and blood flow measurement in hemorrhagic shock. *Gastroenterology.* 1977;73:75-78.
  31. Moneta GL, Lee RW, Yeager RA, et al. Mesenteric duplex scanning: a blinded prospective study. *J Vasc Surg.* 1993;17:79-84.
  32. Mitchell EL, Moneta GL. Mesenteric duplex scanning. *Perspect Vasc Surg Endovasc Ther.* 2006;18:175-183.
  33. Zwolak RM, Fillinger MF, Walsh DB, et al. Mesenteric and celiac duplex scanning: a validation study. *J Vasc Surg.* 1998;27:1078-1087.
  34. Boley SJ, Brandt LJ, Veith FJ, et al. A new provocative test for chronic mesenteric ischemia. *Am J Gastroenterol.* 1991;86:888-891.
  35. Gentile AT, Moneta GL, Lee RW, et al. Usefulness of fasting and postprandial duplex ultrasound examinations for predicting high-grade superior mesenteric artery stenosis. *Am J Surg.* 1995;169:476-479.
  36. Flinn WR, Rizzo RJ, Park JS, Sandager GP. Duplex scanning for assessment of mesenteric ischemia. *Surg Clin North Am.* 1990;70:99-107.
  37. Fenwick JL, Wright IA, Buckenham TM. Endovascular repair of chronic mesenteric occlusive disease: the role of duplex surveillance. *Aust N Z J Surg.* 2007;77:60-63.
  38. Liem TK, Segall JA, Wei W, et al. Duplex scan characteristics of bypass grafts to mesenteric arteries. *J Vasc Surg.* 2007;45:922-927.
  39. Lee PC, Rhee RY, Gordon RY, et al. Management of splenic artery aneurysms: the significance of portal and essential hypertension. *J Am Coll Surg.* 1999;189:483-490.
  40. Cademartiri F, Raaijmakers RH, Kuiper JW, et al. Multi-detector row CT angiography in patients with abdominal angina. *Radiographics.* 2004;24:969-984.
  41. Hagspiel KD, Leung DA, Angle JF, et al. MR angiography of the mesenteric vasculature. *Radiol Clin North Am.* 2002;40:867-886.
  42. Laissy JP, Trillaud H, Douek P. MR angiography: noninvasive vascular imaging of the abdomen. *Abdom Imaging.* 2002;27:488-506.
  43. Wildermuth S, Leschka S, Alkadhi H, Marincek B. Multislice CT in the pre- and postinterventional evaluation of mesenteric perfusion. *Eur Radiol.* 2005;15:1203-1210.
  44. Zandrino F, Musante F, Gallesio I, Benzi L. Assessment of patients with acute mesenteric ischemia: multislice computed tomography signs and clinical performance in a group of patients with surgical correlation. *Minerva Gastroenterol Dietol.* 2006;52:317-325.
  45. Saba L, Mallarini G. Spiral computed tomography imaging of bowel ischemia: a literature review. *Panminerva Med.* 2007;49:35-41.
  46. Shih MC, Hagspiel KD. CTA and MRA in mesenteric ischemia: part 1, Role in diagnosis and differential diagnosis. *AJR Am J Roentgenol.* 2007;188:452-461.
  47. Shih MC, Angle JF, Leung DA, et al. CTA and MRA in mesenteric ischemia: part 2, Normal findings and complications after surgical and endovascular treatment. *AJR Am J Roentgenol.* 2007;188:462-471.
  48. Rheidasil JM, Stewart MT, Schellack JV, et al. Surgical treatment of chronic mesenteric arterial insufficiency. *J Vasc Surg.* 1988;8:495-500.
  49. Biebl M, Oldenburg WA, Paz-Fumagalli R, et al. Surgical and interventional visceral revascularization for the treatment of chronic mesenteric ischemia—when to prefer which? *World J Surg.* 2007;31:562-568.

50. Schaefer PJ, Schaefer FK, Hinrichsen H, et al. Stent placement with the monorail technique for treatment of mesenteric artery stenosis. *J Vasc Interv Radiol.* 2006;17:637-643.
51. Silva JA, White CJ, Collins TJ, et al. Endovascular therapy for chronic mesenteric ischemia. *J Am Coll Cardiol.* 2006;47:944-950.
52. Brown DJ, Schermerhorn ML, Powell RJ, et al. Mesenteric stenting for chronic mesenteric ischemia. *J Vasc Surg.* 2005;42:268-274.
53. Atkins MD, Kwolek CJ, LaMuraglia GM, et al. Surgical revascularization versus endovascular therapy for chronic mesenteric ischemia: a comparative experience. *J Vasc Surg.* 2007;45:1162-1171.
54. Sivamurthy N, Rhodes JM, Lee D, et al. Endovascular versus open mesenteric revascularization: immediate benefits do not equate with short-term functional outcomes. *J Am Coll Surg.* 2006;202:859-867.
55. Park WM, Cherry KJ Jr, Chua HK, et al. Current results of open revascularization for chronic mesenteric ischemia: a standard for comparison. *J Vasc Surg.* 2002;35:853-859.
56. Kihara TK, Blebea J, Anderson KM, et al. Risk factors and outcomes following revascularization for chronic mesenteric ischemia. *Ann Vasc Surg.* 1999;13:37-44.
57. McMillan WD, McCarthy WJ, Bresticker MR, et al. Mesenteric artery bypass: objective patency determination. *J Vasc Surg.* 1995;21:729-740.
58. Modrall JG, Sadjadi J, Joiner DR, et al. Comparison of superficial femoral vein and saphenous vein as conduits for mesenteric arterial bypass. *J Vasc Surg.* 2003;37:362-366.
59. Hertzberg BS, Kliewer MA, DeLong DM, et al. Sonographic assessment of lower limb vein diameters: implications for the diagnosis and characterization of deep venous thrombosis. *AJR Am J Roentgenol.* 1997;168:1253-1257.
60. Sarac TP, Altinel O, Kashyap V, et al. Endovascular treatment of stenotic and occluded visceral arteries for chronic mesenteric ischemia. *J Vasc Surg.* 2008;47:485-491.
61. Robken J, Shammas NW. Treatment of a totally occluded superior mesenteric artery facilitated by retrograde crossing via collaterals from the celiac artery. *J Endovasc Ther.* 2007;14:745-747.
62. Hertzner NR, Beven EG, Young JR, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. *Ann Surg.* 1984;199:223-233.
63. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *Circulation.* 2007;116:1971-1996.
64. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *J Am Coll Cardiol.* 2001;38:1581-1583.
65. Cho KJ, Varma MK. Arteriographic evaluation of splanchnic artery occlusive disease. In: Ernst CB, Stanley JC, eds. *Current Therapy in Vascular Surgery.* 4th ed. St. Louis: Mosby, Inc.; 2001:661.
66. Oderich GS, Panneton JM, Macedo TA, et al. Intraoperative duplex ultrasound of visceral revascularizations: optimizing technical success and outcome. *J Vasc Surg.* 2003;38:684-691.
67. Kagan SA, Myers SI. Acute embolic and thrombotic mesenteric ischemia. In: Ernst CB, Stanley JC, eds. *Current Therapy in Vascular Surgery.* 4th ed. St. Louis: Mosby, Inc.; 2001:675.
68. Kazmers A. Operative management of acute mesenteric ischemia. Part 1. *Ann Vasc Surg.* 1998;12:187-197.
69. Harward TR, Brooks DL, Flynn TC, Seeger JM. Multiple organ dysfunction after mesenteric artery revascularization. *J Vasc*

- Surg.* 1993;18:459-467.
70. Howd A, Loose H, Chamberlain J. Transluminal angioplasty in the treatment of mesenteric vein graft stenosis. *Cardiovasc Intervent Radiol.* 1987;10:43-45.
  71. Levy PJ, Haskell L, Gordon RL. Percutaneous transluminal angioplasty of splanchnic arteries: an alternative method to elective revascularisation in chronic visceral ischaemia. *Eur J Radiol.* 1987;7:239-242.
  72. Landis MS, Rajan DK, Simons ME, et al. Percutaneous management of chronic mesenteric ischemia: outcomes after intervention. *J Vasc Interv Radiol.* 2005;16:1319-1325.
  73. Matsumoto AH, Angle JF, Spinosa DJ, et al. Percutaneous transluminal angioplasty and stenting in the treatment of chronic mesenteric ischemia: results and longterm followup. *J Am Coll Surg.* 2002;194(1 Suppl):S22-S31.
  74. Sharafuddin MJ, Olson CH, Sun S, et al. Endovascular treatment of celiac and mesenteric arteries stenoses: applications and results. *J Vasc Surg.* 2003;38:692-698.
  75. Cho JS, Carr JA, Jacobsen G, et al. Long-term outcome after mesenteric artery reconstruction: a 37-year experience. *J Vasc Surg.* 2002;35:453-460.
  76. English WP, Pearce JD, Craven TE, et al. Chronic visceral ischemia: symptom-free survival after open surgical repair. *Vasc Endovascular Surg.* 2004;38:493-503.
  77. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S5-S67.
  78. Kaminsky O, Yampolski I, Aranovich D, et al. Does a second-look operation improve survival in patients with peritonitis due to acute mesenteric ischemia? A five-year retrospective experience. *World J Surg.* 2005;29:645-648.
  79. McAfee MK, Cherry KJ Jr, Naessens JM, et al. Influence of complete revascularization on chronic mesenteric ischemia. *Am J Surg.* 1992;164:220-224.
  80. Lindner HH, Kemprud E. A clinicoanatomical study of the arcuate ligament of the diaphragm. *Arch Surg.* 1971;103:600-605.
  81. Taylor DC, Moneta GL, Cramer MM. Extrinsic compression of the celiac artery by the median arcuate ligament of the diaphragm: diagnosis by duplex ultrasound. *J Vasc Tech.* 1987;11:236.
  82. Głowiczki P, Duncan AA. Treatment of celiac artery compression syndrome: does it really exist? *Perspect Vasc Surg Endovasc Ther.* 2007;19:259-263.
  83. Reilly LM, Ammar AD, Stoney RJ, Ehrenfeld WK. Late results following operative repair for celiac artery compression syndrome. *J Vasc Surg.* 1985;2:79-91.
  84. Dordoni L, Tshomba Y, Giacomelli M, et al. Celiac artery compression syndrome: successful laparoscopic treatment—a case report. *Vasc Endovasc Surg.* 2002;36:317-321.
  85. Gíswold ME, Landry GJ, Taylor LM Jr, Moneta GL. Outcomes after redo procedures for failed mesenteric revascularization. *Vasc Endovasc Surg.* 2004;38:315-319.
  86. Karkos CD, McMahon GS, Markose G, et al. Axillomesenteric bypass: an unusual solution to a difficult problem. *J Vasc Surg.* 2007;45:404-407.
  87. Chiche L, Kieffer E. Use of the ascending aorta as bypass inflow for treatment of chronic intestinal ischemia. *J Vasc Surg.* 2005;41:457-461.
  88. Schneider DB, Nelken NA, Messina LM, Ehrenfeld WK. Isolated inferior mesenteric artery revascularization for chronic visceral ischemia. *J Vasc Surg.* 1999;30:51-58.
  89. Golden DA, Ring EJ, McLean GK, Freiman DB. Percutaneous transluminal angioplasty in the treatment of abdominal angina. *AJR Am J Roentgenol.* 1982;139:247-249.
  90. Casella IB, Bosch MA, Sousa WO Jr. Isolated spontaneous dissection of the superior mesenteric artery treated by percutaneous stent placement: case report. *J Vasc Surg.* 2008;47:197-200.
  91. Nagai T, Torishima R, Uchida A, et al. Spontaneous dissection of the superior mesenteric artery in four cases treated with



- anticoagulation therapy. *Intern Med*. 2004;43:473-478.
92. Sakamoto I, Ogawa Y, Sueyoshi E, et al. Imaging appearances and management of isolated spontaneous dissection of the superior mesenteric artery. *Eur J Radiol*. 2007;64:103-110.
93. Takayama T, Miyata T, Shirakawa M, Nagawa H. Isolated spontaneous dissection of the splanchnic arteries. *J Vasc Surg*. 2008;48:329-333.
94. Sparks SR, Vasquez JC, Bergan JJ, Owens EL. Failure of nonoperative management of isolated superior mesenteric artery dissection. *Ann Vasc Surg*. 2000;14:105-109.

## 第 149 章

1. Klass AA. Embolectomy in acute mesenteric occlusion. *Ann Surg*. 1951;134:913-917.
2. Shaw RS, Maynard EP 3rd. Acute and chronic thrombosis of the mesenteric arteries associated with malabsorption; a report of two cases successfully treated by thromboendarterectomy. *N Engl J Med*. 1958;258:874-878.
3. Boley SJ, Brandt LJ. Selective mesenteric vasodilators. A future role in acute mesenteric ischemia? *Gastroenterology*. 1986;91:247-249.
4. Boley SJ, Sprayregen S, Veith FJ, Siegelman SS. An aggressive roentgenologic and surgical approach to acute mesenteric ischemia. *Surg Annu*. 1973;5:355-378.
5. Clark RA, Colley DP, Jacobson ED, et al. Superior mesenteric angiography and blood flow measurement following intra-arterial injection of prostaglandin E1. *Radiology*. 1980;134:327-333.
6. Clark RA, Gallant TE. Acute mesenteric ischemia: angiographic spectrum. *AJR Am J Roentgenol*. 1984;142:555-562.
7. Kassahun WT, Schulz T, Richter O, Hauss J. Unchanged high mortality rates from acute occlusive intestinal ischemia: six year review. *Langenbecks Arch Surg*. 2008;393:163-171.
8. Oldenburg WA, Lau LL, Rodenberg TJ, et al. Acute mesenteric ischemia: a clinical review. *Arch Intern Med*. 2004;164:1054-1062.
9. Acosta S, Nilsson TK, Björck M. D-dimer testing in patients with suspected acute thromboembolic occlusion of the superior mesenteric artery. *Br J Surg*. 2004;91:991-994.
10. Mamode N, Pickford I, Leiberman P. Failure to improve outcome in acute mesenteric ischaemia: seven-year review. *Eur J Surg*. 1999;165:203-208.
11. Kougiass P, Lau D, El Sayed HF, et al. Determinants of mortality and treatment outcome following surgical interventions for acute mesenteric ischemia. *J Vasc Surg*. 2007;46:467-474.
12. Boley SJ, Feinstein FR, Sammartano R, et al. New concepts in the management of emboli of the superior mesenteric artery. *Surg Gynecol Obstet*. 1981;153:561-569.
13. Boley SJ. Early diagnosis of acute mesenteric ischemia. *Hosp Pract (Off Ed)*. 1981;16:63-71.
14. Schoots IG, Levi MM, Reekers JA, et al. Thrombolytic therapy for acute superior mesenteric artery occlusion. *J Vasc Interv Radiol*. 2005;16:317-329.
15. Lock G. Acute intestinal ischaemia. *Best Pract Res Clin Gastroenterol*. 2001;15:83-98.
16. Batellier J, Kieny R. Superior mesenteric artery embolism: eighty-two cases. *Ann Vasc Surg*. 1990;4:112-116.
17. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. *J Am Coll Cardiol*. 2001;38:1231-1266.
18. Mansour MA. Management of acute mesenteric ischemia. *Arch Surg*. 1999;134:328-330.
19. Li KC, Hopkins KL, Dalman RL, Song CK. Simultaneous measurement of flow in the superior mesenteric vein and artery with cine phase-contrast MR imaging: value in diagnosis of chronic mesenteric ischemia. Work in progress. *Radiology*.

- 1995;194:327-330.
20. Valentine RJ, Martin JD, Myers SI, et al. Asymptomatic celiac and superior mesenteric artery stenoses are more prevalent among patients with unsuspected renal artery stenoses. *J Vasc Surg.* 1991;14:195-199.
  21. Kaleya RN, Boley SJ. Acute mesenteric ischemia: an aggressive diagnostic and therapeutic approach. 1991 Roussel Lecture. *Can J Surg.* 1992;35:613-623.
  22. Kaleya RN, Sammartano RJ, Boley SJ. Aggressive approach to acute mesenteric ischemia. *Surg Clin North Am.* 1992;72:157-182.
  23. Endean ED, Barnes SL, Kwolek CJ, et al. Surgical management of thrombotic acute intestinal ischemia. *Ann Surg.* 2001;233:801-808.
  24. Thomas JH, Blake K, Pierce GE, et al. The clinical course of asymptomatic mesenteric arterial stenosis. *J Vasc Surg.* 1998;27:840-844.
  25. Haglund U, Lundgren O. Non-occlusive acute intestinal vascular failure. *Br J Surg.* 1979;66:155-158.
  26. Cohen EB. Infarction of the stomach; report of three cases of total gastric infarction and one case of partial infarction. *Am J Med.* 1951;11:645-652.
  27. Wilson R, Qualheim RE. A form of acute hemorrhagic enterocolitis afflicting chronically ill individuals; a description of twenty cases. *Gastroenterology.* 1954;27:431-444.
  28. Ende N. Infarction of the bowel in cardiac failure. *N Engl J Med.* 1958;258:879-881.
  29. Boley SJ. Persistent vasoconstriction: a major factor in nonocclusive mesenteric ischemia. *Curr Top Surg Res.* 1971;425-430.
  30. Boley SJ, Brandt LJ, Veith FJ. Ischemic disorders of the intestines. *Curr Probl Surg.* 1978;15:1-85.
  31. Howard TJ, Plaskon LA, Wiebke EA, et al. Nonocclusive mesenteric ischemia remains a diagnostic dilemma. *Am J Surg.* 1996;171:405-408.
  32. Wilcox MG, Howard TJ, Plaskon LA, et al. Current theories of pathogenesis and treatment of nonocclusive mesenteric ischemia. *Dig Dis Sci.* 1995;40:709-716.
  33. Bailey RW, Bulkley GB, Hamilton SR, et al. Pathogenesis of nonocclusive ischemic colitis. *Ann Surg.* 1986;203:590-599.
  34. McNeill JR, Stark RD, Greenway CV. Intestinal vasoconstriction after hemorrhage: roles of vasopressin and angiotensin. *Am J Physiol.* 1970;219:1342-1347.
  35. Studer W, Wu X, Siegemund M, Seeberger M. Resuscitation from cardiac arrest with adrenaline/epinephrine or vasopressin: effects on intestinal mucosal tonometer pCO<sub>2</sub> during the postresuscitation period in rats. *Resuscitation.* 2002;53:201-207.
  36. Gewertz BL, Zarins CK. Postoperative vasospasm after antegrade mesenteric revascularization: a report of three cases. *J Vasc Surg.* 1991;14:382-385.
  37. Clark ET, Gewertz BL. Intermittent ischemia potentiates intestinal reperfusion injury. *J Vasc Surg.* 1991;13:601-606.
  38. Harlan JM, Killen PD, Senecal FM, et al. The role of neutrophil membrane glycoprotein GP-150 in neutrophil adherence to endothelium in vitro. *Blood.* 1985;66:167-178.
  39. Luscinskas FW, Brock AF, Arnaout MA, Gimbrone MA Jr. Endothelial-leukocyte adhesion molecule-1-dependent and leukocyte (CD11/CD18)-dependent mechanisms contribute to polymorphonuclear leukocyte adhesion to cytokine-activated human vascular endothelium. *J Immunol.* 1989;142:2257-2263.
  40. Mileski WJ, Winn RK, Harlan JM, Rice CL. Transient inhibition of neutrophil adherence with the anti-CD18 monoclonal antibody 60.3 does not increase mortality rates in abdominal sepsis. *Surgery.* 1991;109:497-501.
  41. Granger DN, Richardson PD, Kvietys PR, Mortillaro NA. Intestinal blood flow. *Gastroenterology.* 1980;78:837-863.
  42. Rosenblum JD, Boyle CM, Schwartz LB. The mesenteric circulation. Anatomy and physiology. *Surg Clin North Am.* 1997;77:289-306.
  43. Desai TR, Sisley AC, Brown S, Gewertz BL. Defining the critical limit of oxygen extraction in the human small intestine. *J Vasc Surg.* 1996;23:832-837.

44. Kolkman JJ, Groeneveld AB. Occlusive and non-occlusive gastrointestinal ischaemia: a clinical review with special emphasis on the diagnostic value of tonometry. *Scand J Gastroenterol Suppl.* 1998;225:3-12.
45. Kurland B, Brandt LJ, Delany HM. Diagnostic tests for intestinal ischemia. *Surg Clin North Am.* 1992;72:85-105.
46. Kurt Y, Akin ML, Demirbas S, et al. D-dimer in the early diagnosis of acute mesenteric ischemia secondary to arterial occlusion in rats. *Eur Surg Res.* 2005;37:216-219.
47. Gollin G, Marks C, Marks WH. Intestinal fatty acid binding protein in serum and urine reflects early ischemic injury to the small bowel. *Surgery.* 1993;113:545-551.
48. Kanda T, Fujii H, Tani T, et al. Intestinal fatty acid-binding protein is a useful diagnostic marker for mesenteric infarction in humans. *Gastroenterology.* 1996;110:339-343.
49. Smerud MJ, Johnson CD, Stephens DH. Diagnosis of bowel infarction: a comparison of plain films and CT scans in 23 cases. *AJR Am J Roentgenol.* 1990;154:99-103.
50. Fleischmann D. Multiple detector-row CT angiography of the renal and mesenteric vessels. *Eur J Radiol.* 2003;45:S79-S87.
51. Horton KM, Fishman EK. Multidetector CT angiography in the diagnosis of mesenteric ischemia. *Radiol Clin North Am.* 2007;45:275-288.
52. Lee R, Tung HKS, Tung PHM, et al. CT in acute mesenteric ischaemia. *Clin Radiol.* 2003;58:279-287.
53. Zandrino F, Musante F, Gallesio I, Benzi L. Assessment of patients with acute mesenteric ischemia: multislice computed tomography signs and clinical performance in a group of patients with surgical correlation. *Minerva Gastroenterol Dietol.* 2006;52:317-325.
54. Kirkpatrick ID, Kroeker MA, Greenberg HM. Biphasic CT with mesenteric CT angiography in the evaluation of acute mesenteric ischemia: initial experience. *Radiology.* 2003;229:91-98.
55. Taourel PG, Deneuille M, Pradel JA, et al. Acute mesenteric ischemia: diagnosis with contrast-enhanced CT. *Radiology.* 1996;199:632-636.
56. Aschoff AJ, Stuber G, Becker BW, et al. Evaluation of acute mesenteric ischemia: accuracy of biphasic mesenteric multi-detector CT angiography. *Abdom Imaging.* 2009;34:345-357.
57. Meilahn JE, Morris JB, Ceppa EP, Bulkley GB. Effect of prolonged selective intramesenteric arterial vasodilator therapy on intestinal viability after acute segmental mesenteric vascular occlusion. *Ann Surg.* 2001;234:107-115.
58. Savassi-Rocha PR, Veloso LF. Treatment of superior mesenteric artery embolism with a fibrinolytic agent: case report and literature review. *Hepatogastroenterology.* 2002;49:1307-1310.
59. Kasirajan K, O'Hara PJ, Gray BH, et al. Chronic mesenteric ischemia: open surgery versus percutaneous angioplasty and stenting. *J Vasc Surg.* 2001;33:63-71.
60. Burkart DJ, Johnson CD, Reading CC, Ehman RL. MR measurements of mesenteric venous flow: prospective evaluation in healthy volunteers and patients with suspected chronic mesenteric ischemia. *Radiology.* 1995;194:801-806.
61. Wasser MN, Geelkerken RH, Kouwenhoven M, et al. Systolically gated 3D phase contrast MRA of mesenteric arteries in suspected mesenteric ischemia. *J Comput Assist Tomogr.* 1996;20:262-268.
62. Carlos RC, Stanley JC, Stafford-Johnson D, Prince MR. Interobserver variability in the evaluation of chronic mesenteric ischemia with gadolinium-enhanced MR angiography. *Acad Radiol.* 2001;8:879-887.
63. Meaney JF, Prince MR, Nostrant TT, Stanley JC. Gadolinium-enhanced MR angiography of visceral arteries in patients with suspected chronic mesenteric ischemia. *J Magn Reson Imaging.* 1997;7:171-176.
64. Kam DM, Scheeres DE. Fluorescein-assisted laparoscopy in the identification of arterial mesenteric ischemia. *Surg Endosc.* 1993;7:75-78.
65. McGinty JJ Jr, Hogle N, Fowler DL. Laparoscopic evaluation of intestinal ischemia using fluorescein and ultraviolet light in a porcine model. *Surg Endosc.* 2003;17:1140-1143.
66. Paral J, Ferko A, Plodr M, et al. Laparoscopic diagnostics of acute bowel ischemia using ultraviolet light and fluorescein

- dye: an experimental study. *Surg Laparosc Endosc Percutan Tech.* 2007;17:291-295.
67. Sauerland S, Agresta F, Bergamaschi R, et al. Laparoscopy for abdominal emergencies: evidence-based guidelines of the European Association for Endoscopic Surgery. *Surg Endosc.* 2006;20:14-29.
  68. Siegelman SS, Sprayregen S, Boley SJ. Angiographic diagnosis of mesenteric arterial vasoconstriction. *Radiology.* 1974;112:533-542.
  69. Luckner G, Jochberger S, Mayr VD, et al. Vasopressin as adjunct vasopressor for vasodilatory shock due to non-occlusive mesenteric ischemia. *Anaesthesist.* 2006;55:283-286.
  70. Niederhauser U, Genoni M, von Segesser LK, et al. Mesenteric ischemia after a cardiac operation: conservative treatment with local vasodilation. *Ann Thorac Surg.* 1996;61:1817-1819.
  71. Mitsuyoshi A, Obama K, Shinkura N, et al. Survival in nonocclusive mesenteric ischemia: early diagnosis by multidetector row computed tomography and early treatment with continuous intravenous high-dose prostaglandin E<sub>1</sub>. *Ann Surg.* 2007;246:229-235.
  72. Hollier LH, Bernatz PE, Pairolero PC, et al. Surgical management of chronic intestinal ischemia: a reappraisal. *Surgery.* 1981;90:940-946.
  73. Modrall JG, Sadjadi J, Joiner DR, et al. Comparison of superficial femoral vein and saphenous vein as conduits for mesenteric arterial bypass. *J Vasc Surg.* 2003;37:362-366.
  74. Kazmers A. Operative management of acute mesenteric ischemia. *Ann Vasc Surg.* 1998;12:187-197.
  75. Bulkley GB, Zuidema GD, Hamilton SR, et al. Intraoperative determination of small intestinal viability following ischemic injury: a prospective, controlled trial of two adjuvant methods (Doppler and fluorescein) compared with standard clinical judgment. *Ann Surg.* 1981;193:628-637.
  76. Wright CB, Hobson RW 2nd. Prediction of intestinal viability using Doppler ultrasound techniques. *Am J Surg.* 1975;129:642-645.
  77. Cooperman M, Pace WG, Martin EW Jr, et al. Determination of viability of ischemic intestine by Doppler ultrasound. *Surgery.* 1978;83:705-710.
  78. O'Donnell JA, Hobson RW 2nd. Operative confirmation of Doppler ultrasound in evaluation of intestinal ischemia. *Surgery.* 1980;87:109-112.
  79. Dyess DL, Bruner BW, Donnell CA, et al. Intraoperative evaluation of intestinal ischemia: a comparison of methods. *South Med J.* 1991;84:966-969, 974.
  80. Carter MS, Fantini GA, Sammartano RJ, et al. Qualitative and quantitative fluorescein fluorescence in determining intestinal viability. *Am J Surg.* 1984;147:117-123.
  81. Redaelli CA, Schilling MK, Carrel TP. Intraoperative assessment of intestinal viability by laser Doppler flowmetry for surgery of ruptured abdominal aortic aneurysms. *World J Surg.* 1998;22:283-289.
  82. Whitehill TA, Pearce WH, Rosales C, et al. Detection thresholds of nonocclusive intestinal hypoperfusion by Doppler ultrasound, photoplethysmography, and fluorescein. *J Vasc Surg.* 1988;8:28-32.
  83. Brountzos EN, Critselis A, Magoulas D, et al. Emergency endovascular treatment of a superior mesenteric artery occlusion. *Cardiovasc Intervent Radiol.* 2001;24:57-60.
  84. Demirpolat G, Oran I, Tamsel S, et al. Acute mesenteric ischemia: endovascular therapy. *Abdom Imaging.* 2007;32:299-303.
  85. Turégano Fuentes F, Simó Muerza G, Echenagusia Belda A, et al. Successful intraarterial fragmentation and urokinase therapy in superior mesenteric artery embolisms. *Surgery.* 1995;117:712-714.
  86. Gartenschlaeger S, Bender S, Maeurer J, Schroeder RJ. Successful percutaneous transluminal angioplasty and stenting in acute mesenteric ischemia. *Cardiovasc Intervent Radiol.* 2008;31:398-400.
  87. Hladik P, Raupach J, Lojik M, et al. Treatment of acute mesenteric thrombosis/ischemia by transcatheter thromboaspiration. *Surgery.* 2005;137:122-123.

88. Kawarada O, Sonomura T, Yokoi Y. Direct aspiration using rapid-exchange and low-profile device for acute thrombo-embolic occlusion of the superior mesenteric artery. *Cathet Cardiovasc Interv*. 2006;68:862-866.
89. Leduc FJ, Pestieau SR, Detry O, et al. Acute mesenteric ischaemia: minimal invasive management by combined laparoscopy and percutaneous transluminal angioplasty. *Eur J Surg*. 2000;166:345-347.
90. Loomer DC, Johnson SP, Diffin DC, DeMaio CB. Superior mesenteric artery stent placement in a patient with acute mesenteric ischemia. *J Vasc Interv Radiol*. 1999;10:29-32.
91. Regan F, Karlstad RR, Magnuson TH. Minimally invasive management of acute superior mesenteric artery occlusion: combined urokinase and laparoscopic therapy. *Am J Gastroenterol*. 1996;91:1019-1021.
92. Wang G, Lu W, Xia Q, et al. Superior mesenteric arterial embolism: a retrospective study of local thrombolytic treatment with urokinase in west China. *Int J Clin Pract*. 2003;57:588-591.
93. Biehl M, Oldenburg WA, Paz-Fumagalli R, et al. Endovascular treatment as a bridge to successful surgical revascularization for chronic mesenteric ischemia. *Am Surg*. 2004;70:994-998.
94. Brown DJ, Schermerhorn ML, Powell RJ, et al. Mesenteric stenting for chronic mesenteric ischemia. *J Vasc Surg*. 2005;42:268-274.
95. Matsumoto AH, Angle JF, Spinoso DJ, et al. Percutaneous transluminal angioplasty and stenting in the treatment of chronic mesenteric ischemia: results and longterm followup. *J Am Coll Surg*. 2002;194:S22-S31.
96. Sharafuddin MJ, Olson CH, Sun S, et al. Endovascular treatment of celiac and mesenteric arteries stenoses: applications and results. *J Vasc Surg*. 2003;38:692-698.
97. Langner S, Kobarg I, Puls R, et al. Acute mesenteric ischemia caused by spontaneous isolated dissection of the superior mesenteric artery: treatment by intra-arterial thrombolysis and percutaneous stent placement. *Eur J Radiol Extra*. 2007;61:69-72.
98. Wyers MC, Powell RJ, Nolan BW, Cronenwett JL. Retrograde mesenteric stenting during laparotomy for acute occlusive mesenteric ischemia. *J Vasc Surg*. 2007;45:269-275.
99. Milner R, Woo EY, Carpenter JP. Superior mesenteric artery angioplasty and stenting via a retrograde approach in a patient with bowel ischemia—a case report. *Vasc Endovasc Surg*. 2004;38:89-91.
100. Park WM, Gloviczki P, Cherry KJ Jr, et al. Contemporary management of acute mesenteric ischemia: factors associated with survival. *J Vasc Surg*. 2002;35:445-452.
101. Boley SJ, Sprayregen S, Sammartano RJ, et al. The pathophysiologic basis for the angiographic signs of vascular ectasias of the colon. *Radiology*. 1977;125:615-621.
102. Cronenwett JL, Ayad M, Kazmers A. Effect of intravenous glucagon on the survival of rats after acute occlusive mesenteric ischemia. *J Surg Res*. 1985;38:446-452.
103. Kazmers A, Zwolak R, Appelman HD, et al. Pharmacologic interventions in acute mesenteric ischemia: improved survival with intravenous glucagon, methylprednisolone, and prostacyclin. *J Vasc Surg*. 1984;1:472-481.
104. Liem TK, Segall JA, Wei W, et al. Duplex scan characteristics of bypass grafts to mesenteric arteries. *J Vasc Surg*. 2007;45:922-927.
105. Moneta GL, Lee RW, Yeager RA, et al. Mesenteric duplex scanning: a blinded prospective study. *J Vasc Surg*. 1993;17:79-84.
106. Perko MJ, Just S, Schroeder TV. Importance of diastolic velocities in the detection of celiac and mesenteric artery disease by duplex ultrasound. *J Vasc Surg*. 1997;26:288-293.
107. Zwolak RM, Fillingim MF, Walsh DB, et al. Mesenteric and celiac duplex scanning: a validation study. *J Vasc Surg*. 1998;27:1078-1087.

## 第 150 章

1. Elliott JW. The operative relief of gangrene of the intestine due to occlusion of the mesenteric vessels. *Ann Surg*. 1895;21:9.

2. Warren S, Eberhard TP. Mesenteric venous thrombosis. *Surg Gynecol Obstet.* 1935;61:102-121.
3. Morasch M, Ebaugh J, Chiou A, et al. Mesenteric venous thrombosis: a changing clinical entity. *J Vasc Surg.* 2001;34:680-684.
4. Acosta S, Alhadad A, Svensson P, Ekberg O. Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. *Br J Surg.* 2008;95:1245-1251.
5. Acosta S, Ögren M, Sternby N-H, et al. Mesenteric venous thrombosis with transmural intestinal infarction: a population-based study. *J Vasc Surg.* 2005;41:59-63.
6. Acosta S, Ögren M, Sternby N-H, et al. Incidence of acute thrombo-embolic occlusion of the superior mesenteric artery—a population-based study. *Eur J Vasc Endovasc Surg.* 2004;27:145-150.
7. Rhee Ry, Gloviczki P, Mendonca CT, et al. Mesenteric venous thrombosis: still a lethal disease in the 1990s. *J Vasc Surg.* 1994;20:688-697.
8. Brunaud L, Antunes L, Collinet-Adler S, et al. Acute mesenteric venous thrombosis: case for nonoperative management. *J Vasc Surg.* 2001;34:673-679.
9. Karagulle E, Turk E, Gokturk H, et al. Prothrombin 20210 G/A defect as a cause of mesenteric venous infarction: report of a case. *Surg Today.* 2007;37:251-253.
10. Shibahara K, Tatsuta K, Orita H, et al. Superior mesenteric and portal vein thrombosis caused by congenital antithrombin III deficiency: report of a case. *Surg Today.* 2007;37:308-310.
11. Bergenfeldt M, Svensson PJ, Borgström A. Mesenteric vein thrombosis due to factor V Leiden gene mutation. *Br J Surg.* 1999;86:1059-1062.
12. Famularo G, Minisola G, Nicotra G, de Simone C. Mesenteric and portal vein thrombosis associated with hyperhomocysteinemia and heterozygosity for factor V leiden mutation. *World J Gastroenterol.* 2005;11:7700-7701.
13. Lijfering W, Sprenger H, van Son W, van der Meer J. Mesenteric vein thrombosis associated with primary cytomegalovirus infection: a case report. *Blood Coag Fibrin.* 2007;18:509-511.
14. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. *N Engl J Med.* 1994;330:517-522.
15. Samama MM, Simon D, Horellou MH, et al. Diagnosis and clinical characteristics of inherited activated protein C resistance. *Haemostasis.* 1996;26(Suppl 4):315-330.
16. Ikeda M, Sekimoto M, Takiguchi S, et al. High incidence of thrombosis of the portal venous system after laparoscopic splenectomy. A prospective study with contrast-enhanced CT scan. *Ann Surg.* 2005;241:208-216.
17. Ögren M, Bergqvist D, Björck M, et al. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23796 consecutive autopsies. *World J Gastroenterol.* 2006;12:2115-2119.
18. Amitrano L, Guardascione M, Scaglione M, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. *Am J Gastroenterol.* 2007;102:2464-2470.
19. Rhee RY, Gloviczki P. Mesenteric venous thrombosis. *Surg Clin North Am.* 1997;77:327-338.
20. Acosta S, Ögren M, Sternby N-H, et al. Clinical implications for the management of acute thromboembolic occlusion of the superior mesenteric artery. Autopsy findings in 213 patients. *Ann Surg.* 2005;241:516-522.
21. Horton K, Fishman E. Multidetector CT angiography in the diagnosis of mesenteric ischemia. *Radiol Clin North Am.* 2007;45:275-288.
22. Levy A. Mesenteric ischemia. *Radiol Clin North Am.* 2007;45:593-599.
23. Acosta S, Alhadad A, Ekberg O. High sensitivity for multi-detector row CT with portal phase enhancement in patients with mesenteric venous thrombosis. (Submitted manuscript.)
24. Cho YP, Jung SM, Han MS, et al. Role of diagnostic laparoscopy in managing acute mesenteric venous thrombosis. *Surg Laparosc Endosc Percutan Tech.* 2003;13:215-217.
25. Chong AK, So JB, Ti TK. Use of laparoscopy in the management of mesenteric venous thrombosis. *Surg Endosc.*

- 2001;15:1042.
26. Acosta S, Nilsson TK, Björck M. D-Dimer testing in patients with suspected acute thromboembolic occlusion of the superior mesenteric artery. *Br J Surg.* 2004;91:991-994.
  27. Hrštic I, Kalauz M, Cukovic-Cavka S, et al. Treatment of extensive subacute portal, mesenteric and ileocolic vein thrombosis with recombinant tissue plasminogen activator. *Blood Coagul Fibrinolysis.* 2007;18:581-583.
  28. Takahashi N, Kuroki K, Yanaga K. Percutaneous transhepatic mechanical thrombectomy for acute mesenteric venous thrombosis. *J Endovasc Ther.* 2005;12:508-511.
  29. Ozdogan M, Gurer A, Gokahim A, et al. Thrombolysis via an operatively placed mesenteric catheter for portal and superior mesenteric vein thrombosis: report of a case. *Surg Today.* 2006;36:846-848.
  30. Kernagis LY, Levine MS, Jacobs JE. Pneumatosis intestinalis in patients with ischemia: correlation of CT findings with viability of the bowel. *AJR Am J Roentgenol.* 2003;180:733-736.
  31. Mousa SA. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. *Semin Thromb Hemostat.* 2007;33:524-533.
  32. Ferro C, Rossi UG, Bovio G, et al. Transjugular intrahepatic portosystemic shunt, mechanical aspiration thrombectomy, and direct thrombolysis in the treatment of acute portal and superior mesenteric vein thrombosis. *Cardiovasc Interv Radiol.* 2007;30:1070-1074.
  33. Zhou W, Choi L, Liu P, et al. Percutaneous transhepatic thrombectomy and pharmacologic thrombolysis of mesenteric venous thrombosis. *Vascular.* 2007;15:41-45.
  34. Hollingshead M, Burke C, Mauro M, et al. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. *J Vasc Interv Radiol.* 2005;16:651-661.
  35. Marini M, Gomez-Gutierrez M, Cao I, et al. Endovascular treatment of splenomesenteric-portal vein thromboses during orthotopic liver transplantation. *J Vasc Interv Radiol.* 2005;16:1135-1142.
  36. Kim H, Patra A, Khan J, et al. Transhepatic catheter-directed thrombectomy and thrombolysis of acute superior mesenteric venous thrombosis. *J Vasc Interv Radiol.* 2005;16:1685-1691.

## 第 151 章

1. Bonnie RJ, Fulco CE, Liverman CT. *Magnitude and Costs. Reducing the Burden of Injury. Advancing Prevention and Treatment.* Chapter 2, pp 41-59. Washington, DC: National Academy Press; 1999.
2. National Center for Injury and Prevention Control. Overall injury and adverse-event-related deaths and rate per 100,000. E800-E999. On line. National Center for Injury and Prevention Control, Centers for Disease Control and Prevention 1995.
3. Baker S. *The Injury Fact Book.* New York: Oxford University Press; 1992.
4. Rice DP, MacKenzie EJ, et al, eds. *Cost of Injury in the United States: A Report to Congress.* Atlanta: Centers for Disease Control; 1989.
5. National Highway Traffic Safety Administration (NHTSA). *The incidence and role of drugs in fatally injured drivers.* Traffic Tech. Washington, DC: NHTSA; 1993.
6. DeBakey ME, Simeone FA. Battle injuries of the arteries in World War II: an analysis of 2,471 cases. *Ann Surg.* 1946;123:534-579.
7. Rich NM, Spencer FC. *Vascular Trauma.* Philadelphia, PA: WB Saunders; 1978.
8. Rich NM, Baugh JH, Hughes CW. Acute arterial injuries in Vietnam: 1,000 cases. *J Trauma.* 1970;10:359-369.
9. Oller DW, Rutledge R, Clancy T, et al. Vascular injuries in a rural state: a review of 978 patients from a state trauma registry. *J Trauma.* 1992;32:740-746.
10. Mattox KL, Feliciano DV, Burch J, et al. Five thousand seven hundred sixty cardiovascular injuries in 4459 patients: epidemiologic evolution 1958 to 1987. *Ann Surg.* 1989;209:698-705.
11. Frykberg ER, Dennis JW, Bishop K, et al. The reliability of physical examination in the evaluation of penetrating extremity

- trauma from vascular injury: results at one year. *J Trauma*. 1991;31:502-511.
12. Gupta R, Rao S, Sieunarine K. An epidemiological view of vascular trauma in western Australia: a 5-year study. *Aust N Z J Surg*. 2001;71:461-466.
  13. Beebe GW, DeBakey ME. *Battle Casualties: Incidence, Mortality, and Logistic Considerations*. Springfield, IL: Charles C Thomas; 1952.
  14. Hughes CW. Arterial repair during the Korean War. *Ann Surg*. 1958;147:555-561.
  15. Nanobashvili J, Kopadze T, Tvaladze M, et al. War injuries of major extremity arteries. *World J Surg*. 2003;27:134-139.
  16. Frykberg ER. Vascular Trauma: history, general principles, and extremity injuries. In: Callow AD, Ernst CB, eds. *Vascular Surgery. Theory and Practice*. Stamford, CT: Appleton & Lange, 1996:985-1037.
  17. Stain SC, Yellin AE, Weaver FA, et al. Selective management of nonocclusive arterial injuries. *Arch Surg*. 1989;124:1136-1141.
  18. Frykberg ER, Vines FS, Alexander RH. The natural history of clinically occult arterial injuries: a prospective evaluation. *J Trauma*. 1989;29:577-583.
  19. Frykberg ER, Crump JM, Dennis JW, et al. Nonoperative observation of clinically occult arterial injuries: a prospective evaluation. *Surgery*. 1991;109: 85-96.
  20. Neville RF, Hobson RW, Watanabe B, et al. A prospective evaluation of arterial intimal injuries in an experimental model. *J Trauma*. 1991;31:669-675.
  21. Panetta TF, Sales CM, Marin ML, et al. Natural history, duplex characteristics, and histopathologic correlation of arterial injuries in a canine model. *J Vasc Surg*. 1992;16:867-876.
  22. Hoffer EK, Sclafani SJ, Herzkowitz MM, Scalea TM. Natural history of arterial injuries diagnosed with arteriography. *J Vasc Interv Radiol*. 1997;8:43-53.
  23. Dennis JW, Frykberg ER, Veldenz HC, et al. Validation of nonoperative management of occult vascular injuries and accuracy of physical examination alone in penetrating extremity trauma: 5- to 10-year follow-up. *J Trauma*. 1998;44:243-253.
  24. Hoyt DB, Coimbra R. Trauma. In: Greenfield LJ, Mulholland MW, et al. eds. *Surgery: Scientific Principles and Practice*. 3<sup>rd</sup> ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:271-280.
  25. Beitsch P, Weigelt JA, Flynn E, Easley S. Physical examination and arteriography in patients with penetrating zone II neck wounds. *Arch Surg*. 1994;129:577.
  26. Fabian TC, Patton JH, Croce MA, et al. Blunt carotid injury. Importance of early diagnosis and anticoagulant therapy. *Ann Surg*. 1996;223:513.
  27. Eachempati SR, Vaslef SN, Sebastian MW, et al. Blunt vascular injuries of the head and neck: is heparinization necessary? *J Trauma*. 1998;45:997.
  28. Byrne MP, Welling RE. Penetrating and blunt extracranial carotid artery injuries. In: Ernst CB, Stanley JC, eds. *Current Therapy in Vascular Surgery*. St. Louis: Mosby-Year Book; 1995:598-603.
  29. Ballard JL, Bunt TJ, Fitzpatrick B, Malone JM. Bilateral traumatic internal carotid artery dissections: case report. *J Vasc Surg*. 1992;15:431-435.
  30. Cogbill TH, Moore EE, Meissner M, et al. The spectrum of blunt injury to the carotid artery: a multicenter perspective. *J Trauma*. 1994;37:473-479.
  31. Hellner D, Thie A, Lachenmayer L, et al. Blunt trauma lesions of the extracranial internal carotid artery in patients with head injury. *J Craniomaxillofac Surg*. 1993;21:234-238.
  32. Pretre R, Reverdin A, Kalonji T, Faidutti B. Blunt carotid artery injury: difficult therapeutic approaches for an under-recognized entity. *Surgery*. 1994;115:375-381.
  33. Li MS, Smith BM, Espinosa J, et al. Nonpenetrating trauma to the carotid artery: seven cases and a literature review. *J Trauma*. 1994;36:265-272.



34. Sanzone AG, Torres H, Soundoulakis SH. Blunt trauma to the carotid arteries. *Am J Emerg Med.* 1995;13:327-330.
35. Fabian TC, Patton JH, Croce MA, et al. Blunt carotid injury: importance of early diagnosis and anticoagulant therapy. *Ann Surg.* 1996;223:513-525.
36. Parikh AA, Luchett FA, Valente JF, et al. Blunt carotid artery injuries. *J Am Coll Surg.* 1997;185:80-86.
37. McKevitt EC, Kirkpatrick AW, Vertesi L, et al. Blunt vascular neck injuries: diagnosis and outcomes of extracranial vessel injury. *J Trauma.* 2002;52:472-476.
38. Kraus RR, Bergstein JM, DeBord JR. Diagnosis, treatment, and outcome of blunt carotid arterial injuries. *Am J Surg.* 1999;178:190-193.
39. Miller PR, Fabian TC, Bee TK, et al. Blunt cerebrovascular injuries: diagnosis and treatment. *J Trauma.* 2001;51:279-286.
40. Biffl WL, Moore EE, Offner PJ, et al. Blunt carotid arterial injuries: implications of a new grading scale. *J Trauma.* 1999;47:845-853.
41. Biffl WL, Ray CE Jr, Moore EE, et al. Treatment-related outcomes from blunt cerebrovascular injuries: importance of routine follow-up arteriography. *Ann Surg.* 2002;235:699-707.
42. Fakhry S, Jacques PF, Proctor H. Cervical vessel injury after blunt trauma. *J Vasc Surg.* 1988;8:501.
43. Roberts LH, Demetriades D. Vertebral artery injuries. *Surg Clin North Am.* 2001;81:1345-1356.
44. DeBehnke DJ, Brady W. Vertebral artery dissection due to minor neck trauma. *J Emerg Med.* 1994;12:27.
45. Egnor MR, Page LK, David C. Vertebral artery aneurysm: a unique hazard of head banging by heavy metal rockers. *Pediatr Neurosurg.* 1991;17:135.
46. Wall MJ, Hirshberg A, LeMaire SA, et al. Thoracic aortic and thoracic vascular injuries. *Surg Clin North Am.* 2001;81:1375-1394.
47. Demetriades D, Chahwan S, Gomez H, et al. Penetrating injuries to the subclavian artery and axillary vessels. *J Am Coll Surg.* 1999;188:290-295.
48. Lin PH, Koffron AJ, Guske PJ, et al. Penetrating injuries of the subclavian artery. *Am J Surg.* 2003;185:580-584.
49. Demetriades D, Asensio JA. Subclavian and axillary injuries. *Surg Clin North Am.* 2001;81:1357-1374.
50. Asensio TA, Chahwan S, Hanpeter D, et al. Operative management and outcomes of 302 abdominal vascular injuries. *Am J Surg.* 2000;180:528-534.
51. Asensio JA, Forno W, Roldan G, et al. Abdominal vascular injuries: injuries to the aorta. *Surg Clin North Am.* 2001;81:1395-1416.
52. Cox EF. Blunt abdominal trauma: A 5-year analysis of 870 patients requiring celiotomy. *Ann Surg.* 1984;199:467-474.
53. Coimbra R, Hoyt D, Winchell R, et al. The ongoing challenge of retroperitoneal vascular injuries. *Am J Surg.* 1996;172:541-545.
54. Mattox KL, McCollum WB, Jordan GL, et al. Management of upper abdominal vascular trauma. *Am J Surg.* 1974;128:823-828.
55. Coimbra R, Aguida HC, Soler W, et al. Penetrating abdominal aortic injuries. *Rev Col Bras Cir.* 1993;20:128-132.
56. Coimbra R, Prado PA, Araujo LHB, et al. Factors related to mortality in inferior vena cava injuries. A 5-year experience. *Int Surg.* 1994;79:138-141.
57. Stewart MT, Stone HH. Injuries of the inferior vena cava. *Am Surg.* 1896;52:9-13.
58. Maul KI, Rozycki GS, Vinsant GO, Pedigo RE. Retroperitoneal injuries: pitfalls in diagnosis and management. *South Med J.* 1987;80:1111-1115.
59. Lopez-Viego MA, Snyder WH, Valentine RJ, Clagett GP. Penetrating abdominal aortic trauma: a report of 129 cases. *J Vasc Surg.* 1992;16:332-336.
60. Burch JM, Feliciano DV, Mattox KL, Edelman M. Injuries of the inferior vena cava. *Am J Surg.* 1988;156:548-552.
61. Lock JS, Huffman AD, Johnson RC. Blunt trauma to the abdominal aorta. *J Trauma.* 1987;27:674-677.
62. Naude GP, Back M, Perry MO, Bongard FS. Blunt disruption of the abdominal aorta: report of a case and review of the

- literature. *J Vasc Surg.* 1997;25:931-935.
63. Coimbra R, Aguida HC, Soler W, et al. Penetrating abdominal aortic injuries. *Rev Col Bras Cir.* 1993;20:128-132.
  64. Coimbra R, Yang J, Hoyt DB. Injuries of the abdominal aorta and inferior vena cava injuries in association with thoracolumbar fractures: a lethal combination. *J Trauma.* 1996;41:533-535.
  65. Demetriades D, Theodorou D, Murray J, et al. Mortality and prognostic factors in penetrating injuries of the aorta. *J Trauma.* 1996;40:761-763.
  66. Mattox KL, Espada R, Beall AR Jr. Traumatic injury to the portal vein. *Ann Surg.* 1975;181:519-522.
  67. Stone HH, Fabian TC, Turkleson ML. Wounds of the portal venous system. *World J Surg.* 1982;6:335-341.
  68. Ivatury RR, Nallathambi M, Lankin DH, et al. Portal vein injuries. Noninvasive follow-up of venorrhaphy. *Ann Surg.* 1987;206:733-737.
  69. Dawson DL, Johansen KH, Jurkovich GJ. Injuries to the portal triad. *Am J Surg.* 1991;161:545-551.
  70. Coimbra R, Filho AR, Nesser RA, Rasslan S. Outcome from traumatic injury of the portal and superior mesenteric veins. *Vasc Endovasc Surg.* 2004;38:249-255.
  71. Asensio JA, Petrone P, Garcia-Nuñez L, et al. Superior mesenteric venous injuries: to ligate or to repair remains the question. *J Trauma.* 2007;62:668-675.
  72. Jurkovich GJ, Hoyt DB, Moore FA, et al. Portal triad injuries. *J Trauma.* 1995;39:426-434.
  73. Pearl J, Chao A, Kennedy S, et al. Traumatic injuries to the portal vein: case study. *J Trauma.* 2004;56:779-782.
  74. Sheldon GF, Lim RC, Yee ES, Petersen SR. Management of injuries to the porta hepatis. *Ann Surg.* 1985;202:539-545.
  75. Fraga GP, Mantovani M, Hirano ES, Leal RF. Portal vein injury. *Rev Col Bras Cir.* 2003;30:43-50.
  76. Bruce LM, Croce MA, Santaniello JM, et al. Blunt renal artery injury: incidence, diagnosis, and management. *Am Surg.* 2001;67:550-556.
  77. Spinak JP, Resnick MI. Revascularization of traumatic thrombosis of the renal artery. *Surg Gynecol Obstet.* 1987;164:22-26.
  78. Clark DE, Georgitis JW, Ray FS. Renal arterial injuries caused by blunt trauma. *Surgery.* 1981;90:87-96.
  79. Tillou A, Romero J, Asensio JA, et al. Renal vascular injuries. *Surg Clin North Am.* 2001;81:1417-1430.
  80. Velmahos GC, Demetriades D, Cornwell EE, et al. Selective management of renal gunshot wounds. *Br J Surg.* 1998;85:1121-1124.
  81. Lock JS, Carraway RP, Hudson HC, Laws ML. Proper management of renal artery injury from blunt trauma. *South Med J.* 1985;78:406-410.
  82. Kuehne J, Frankhouse J, Modrall G, et al. Determinants of survival after inferior vena cava trauma. *Am Surg.* 1999;65:976-981.
  83. Buckman RF, Pathak AS, Badelino MM, Bradley KM. Injuries of the inferior vena cava. *Surg Clin North Am.* 2001;81:1431-1447.
  84. Bongard FS, Dubrow T, Klein SR. Vascular injuries in the urban battleground: experience at a metropolitan trauma center. *Ann Vasc Surg.* 1990;4:415-418.
  85. Demetriades D, Murray JA, Asensio JA. In: Rich N, Mattox KL, Hirshberg A, eds. *Vascular Trauma*. Philadelphia: Saunders; 2004:339-351.
  86. Smith RF, Elliott JP, Hageman JH, et al. Acute penetrating arterial injuries of the neck and limbs. *Arch Surg.* 1974;109:198-205.
  87. Dennis JW, Frykberg ER, Crump JM, et al. New perspectives on the management of penetrating trauma in proximity to major limb arteries. *J Vasc Surg.* 1990;11:84-93.
  88. Robbs JV, Baker LW. Major arterial trauma: review of experience with 267 injuries. *Br J Surg.* 1978;65:532-538.
  89. Carillo EH, Spain DA, Miller FB, Richardson JD. Femoral vessel injuries. *Surg Clin North Am.* 2002;82:49-66.
  90. Frykberg ER. Popliteal vascular injuries. *Surg Clin North Am.* 2002;82:67-90.
  91. Ordog GJ, Balasubramanian S, Wasserberger J, et al. Extremity gunshot wounds: I. Identification and treatment of patients

at high risk of vascular injury. *J Trauma*. 1994;36:358-368.

## 第 152 章

1. du Toit DF, van Schalkwyk GD, Wade SA, et al. Neurologic outcome after penetrating extracranial arterial trauma. *J Vasc Surg*. 2003;38:257-262.
2. Monson DO, Saletta JD, Freeark RJ. Carotid vertebral trauma. *J Trauma*. 1969;9:987-999.
3. Demetriades D, Theodorou D, Cornwell E, et al. Evaluation of penetrating injuries of the neck: prospective study of 223 patients. *World J Surg*. 1997;21:41-47; discussion 47-48.
4. Demetriades D, Charalambides D, Lakhoo M. Physical examination and selective conservative management in patients with penetrating injuries of the neck. *Br J Surg*. 1993;80:1534-1536.
5. Wylie EJ, Hein MF, Adams JE. Intracranial hemorrhage following surgical revascularization for treatment of acute strokes. *J Neurosurg*. 1964;21:212-215.
6. Cohen CA, Brief D, Mathewson C Jr. Carotid artery injuries. An analysis of eighty-five cases. *Am J Surg*. 1970;120:210-214.
7. Bradley EL 3rd. Management of penetrating carotid injuries: an alternative approach. *J Trauma*. 1973;13:248-255.
8. Kuehne JP, Weaver FA, Papanicolaou G, et al. Penetrating trauma of the internal carotid artery. *Arch Surg*. 1996;131:942-947; discussion 947-948.
9. Weaver FA, Yellin AE, Wagner WH, et al. The role of arterial reconstruction in penetrating carotid injuries. *Arch Surg*. 1988;123:1106-1111.
10. Richardson R, Obeid FN, Richardson JD, et al. Neurologic consequences of cerebrovascular injury. *J Trauma*. 1992;32:755-758; discussion 758-760.
11. Meyer JP, Barrett JA, Schuler JJ, et al. Mandatory vs selective exploration for penetrating neck trauma. A prospective assessment. *Arch Surg*. 1987;122:592-597.
12. Nunez DB Jr, Torres-Leon M, Munera F. Vascular injuries of the neck and thoracic inlet: helical CT-angiographic correlation. *Radiographics*. 2004;24:1087-1098; discussion 1099-1100.
13. Munera F, Soto JA, Nunez D. Penetrating injuries of the neck and the increasing role of CTA. *Emerg Radiol*. 2004;10:303-309.
14. Ginzburg E, Montalvo B, LeBlang S, et al. The use of duplex ultrasonography in penetrating neck trauma. *Arch Surg*. 1996;131:691-693.
15. Coldwell DM, Novak Z, Ryu RK, et al. Treatment of posttraumatic internal carotid arterial pseudoaneurysms with endovascular stents. *J Trauma*. 2000;48:470-472.
16. Duane TM, Parker F, Stokes GK, et al. Endovascular carotid stenting after trauma. *J Trauma*. 2002;52:149-153.
17. Ellis PK, Kennedy PT, Barros D'Sa AA. Successful exclusion of a high internal carotid pseudoaneurysm using the Wallgraft endoprosthesis. *Cardiovasc Intervent Radiol*. 2002;25:68-69.
18. McNeil JD, Chiou AC, Gunlock MG, et al. Successful endovascular therapy of a penetrating zone III internal carotid injury. *J Vasc Surg*. 2002;36:187-190.
19. Jacobs JR, Arden RL, Marks SC, et al. Carotid artery reconstruction using superficial femoral arterial grafts. *Laryngoscope*. 1994;104:689-693.
20. Biffi WL, Moore EE, Ryu RK, et al. The unrecognized epidemic of blunt carotid arterial injuries: early diagnosis improves neurologic outcome. *Ann Surg*. 1998;228:462-470.
21. Fabian TC, Patton JH Jr, Croce MA, et al. Blunt carotid injury. Importance of early diagnosis and anticoagulant therapy. *Ann Surg*. 1996;223:513-522; discussion 522-525.
22. Berne JD, Norwood SH, McAuley CE, et al. The high morbidity of blunt cerebrovascular injury in an unscreened population: more evidence of the need for mandatory screening protocols. *J Am Coll Surg*. 2001;192:314-321.

23. Crissey MM, Bernstein EF. Delayed presentation of carotid intimal tear following blunt craniocervical trauma. *Surgery*. 1974;75:543-549.
24. Lee KP, Carlini WG, McCormick GF, et al. Neurologic complications following chiropractic manipulation: a survey of California neurologists. *Neurology*. 1995;45:1213-1215.
25. Traflet RF, Babaria AR, Bell RD, et al. Vertebral artery dissection after rapid head turning. *AJNR Am J Neuroradiol*. 1989;10:650-651.
26. Yamada S, Kindt GW, Youmans JR. Carotid artery occlusion due to nonpenetrating injury. *J Trauma*. 1967;7:333-342.
27. Davis JW, Holbrook TL, Hoyt DB, et al. Blunt carotid artery dissection: incidence, associated injuries, screening, and treatment. *J Trauma*. 1990;30:1514-1517.
28. Biffl WL, Ray CE Jr, Moore EE, et al. Treatment-related outcomes from blunt cerebrovascular injuries: importance of routine follow-up arteriography. *Ann Surg*. 2002;235:699-706; discussion 706-707.
29. Cogbill TH, Moore EE, Meissner M, et al. The spectrum of blunt injury to the carotid artery: a multicenter perspective. *J Trauma*. 1994;37:473-479.
30. Perry MO, Snyder WH, Thal ER. Carotid artery injuries caused by blunt trauma. *Ann Surg*. 1980;192:74-77.
31. Cothren CC, Moore EE, Biffl WL, et al. Anticoagulation is the gold standard therapy for blunt carotid injuries to reduce stroke rate. *Arch Surg*. 2004;139:540-545; discussion 545-546.
32. Miller PR, Fabian TC, Croce MA, et al. Prospective screening for blunt cerebrovascular injuries: analysis of diagnostic modalities and outcomes. *Ann Surg*. 2002;236:386-393; discussion 393-395.
33. DiPerna CA, Rowe VL, Terramani TT, et al. Clinical importance of the "seat belt sign" in blunt trauma to the neck. *Am Surg*. 2002;68:441-445.
34. Biffl WL, Moore EE, Offner PJ, et al. Optimizing screening for blunt cerebrovascular injuries. *Am J Surg*. 1999;178:517-522.
35. Mutze S, Rademacher G, Matthes G, et al. Blunt cerebrovascular injury in patients with blunt multiple trauma: diagnostic accuracy of duplex Doppler US and early CT angiography. *Radiology*. 2005;237:884-892.
36. Biffl WL, Moore EE, Offner PJ, et al. Blunt carotid arterial injuries: implications of a new grading scale. *J Trauma*. 1999;47:845-853.
37. Biffl WL, Ray CE Jr, Moore EE, et al. Noninvasive diagnosis of blunt cerebrovascular injuries: a preliminary report. *J Trauma*. 2002;53:850-856.
38. Bub LD, Hollingworth W, Jarvik JG, et al. Screening for blunt cerebrovascular injury: evaluating the accuracy of multidetector computed tomographic angiography. *J Trauma*. 2005;59:691-697.
39. Biffl WL, Eggin T, Benedetto B, et al. Sixteen-slice computed tomographic angiography is a reliable noninvasive screening test for clinically significant blunt cerebrovascular injuries. *J Trauma*. 2006;60:745-751; discussion 751-752.
40. Eastman AL, Chason DP, Perez CL, et al. Computed tomographic angiography for the diagnosis of blunt cervical vascular injury: is it ready for primetime? *J Trauma*. 2006;60:925-929; discussion 929.
41. Bousson V, Levy C, Brunereau L, et al. Dissections of the internal carotid artery: three-dimensional time-of-flight MR angiography and MR imaging features. *AJR Am J Roentgenol*. 1999;173:139-143.
42. Bok AP, Peter JC. Carotid and vertebral artery occlusion after blunt cervical injury: the role of MR angiography in early diagnosis. *J Trauma*. 1996;40:968-972.
43. Levy C, Laissy JP, Raveau V, et al. Carotid and vertebral artery dissections: three-dimensional time-of-flight MR angiography and MR imaging versus conventional angiography. *Radiology* 1994;190:97-103.
44. Eachempati SR, Vaslef SN, Sebastian MW, et al. Blunt vascular injuries of the head and neck: is heparinization necessary? *J Trauma*. 1998;45:997-1004.
45. Miller PR, Fabian TC, Bee TK, et al. Blunt cerebrovascular injuries: diagnosis and treatment. *J Trauma*. 2001;51:279-285; discussion 285-286.

46. Wahl WL, Brandt MM, Thompson BG, et al. Antiplatelet therapy: an alternative to heparin for blunt carotid injury. *J Trauma*. 2002;52:896-901.
47. Edwards NM, Fabian TC, Claridge JA, et al. Antithrombotic therapy and endovascular stents are effective treatment for blunt carotid injuries: results from long-term followup. *J Am Coll Surg*. 2007;204:1007-1013; discussion 1014-1015.
48. Mokri B. Traumatic and spontaneous extracranial internal carotid artery dissections. *J Neurol*. 1990;237:356-361.
49. Duke BJ, Ryu RK, Coldwell DM, et al. Treatment of blunt injury to the carotid artery by using endovascular stents: an early experience. *J Neurosurg*. 1997;87:825-829.
50. Pretre R, Kursteiner K, Reverdin A, et al. Blunt carotid artery injury: devastating consequences of undetected pseudoaneurysm. *J Trauma*. 1995;39:1012-1014.
51. Cohen JE, Ben-Hur T, Rajz G, et al. Endovascular stent-assisted angioplasty in the management of traumatic internal carotid artery dissections. *Stroke*. 2005;36:e45-e47.
52. Bejjani GK, Monsein LH, Laird JR, et al. Treatment of symptomatic cervical carotid dissections with endovascular stents. *Neurosurgery*. 1999;44:755-760; discussion 760-761.
53. Liu AY, Paulsen RD, Marcellus ML, et al. Long-term outcomes after carotid stent placement treatment of carotid artery dissection. *Neurosurgery*. 1999;45:1368-1373; discussion 1373-1374.
54. Parodi JC, Schonholz C, Ferreira LM, et al. Endovascular stent-graft treatment of traumatic arterial lesions. *Ann Vasc Surg*. 1999;13:121-129.
55. Horowitz MB, Miller G 3rd, Meyer Y, et al. Use of intravascular stents in the treatment of internal carotid and extracranial vertebral artery pseudoaneurysms. *AJNR Am J Neuroradiol*. 1996;17:693-696.
56. McCready RA, Divelbiss JL, Bryant MA, et al. Endoluminal repair of carotid artery pseudoaneurysms: a word of caution. *J Vasc Surg*. 2004;40:1020-1023.
57. de Vries JP, Meijer RW, van den Berg JC, et al. Stent fracture after endoluminal repair of a carotid artery pseudoaneurysm. *J Endovasc Ther*. 2005;12:612-615.
58. Bhatt DL, Kapadia SR, Bajzer CT, et al. Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. *J Invasive Cardiol*. 2001;13:767-771.
59. Cothren CC, Moore EE, Ray CE Jr, et al. Carotid artery stents for blunt cerebrovascular injury: risks exceed benefits. *Arch Surg*. 2005;140:480-485; discussion 485-486.
60. Ramadan F, Rutledge R, Oller D, et al. Carotid artery trauma: a review of contemporary trauma center experiences. *J Vasc Surg*. 1995;21:46-55; discussion 55-56.
61. Schievink WI, Piepgras DG, McCaffrey TV, et al. Surgical treatment of extracranial internal carotid artery dissecting aneurysms. *Neurosurgery*. 1994;35:809-815; discussion 815-816.
62. Reid JD, Weigelt JA. Forty-three cases of vertebral artery trauma. *J Trauma*. 1988;28:1007-1012.
63. Cothren CC, Moore EE, Biffl WL, et al. Cervical spine fracture patterns predictive of blunt vertebral artery injury. *J Trauma*. 2003;55:811-813.
64. Biffl WL, Moore EE, Elliott JP, et al. The devastating potential of blunt vertebral arterial injuries. *Ann Surg*. 2000;231:672-681.
65. Mwipatayi BP, Jeffery P, Beningfield SJ, et al. Management of extra-cranial vertebral artery injuries. *Eur J Vasc Endovasc Surg*. 2004;27:157-162.
66. Thomas GI, Anderson KN, Hain RF. The significance of anomalous vertebral-basilar artery communications in operation on the heart and great vessels. *Surgery*. 1959;46:747-757.
67. Bruneau M, Cornelius JF, George B. Antero-lateral approach to the V3 segment of the vertebral artery. *Neurosurgery*. 2006;58(1 Suppl): ONS29-ONS35; discussion ONS29-35.
68. Demetriades D, Rabinowitz B, Pezikis A, et al. Subclavian vascular injuries. *Br J Surg*. 1987;74:1001-1003.
69. Demetriades D, Chahwan S, Gomez H, et al. Penetrating injuries to the subclavian and axillary vessels. *J Am Coll Surg*.

- 1999;188:290-295.
70. du Toit DF, Lambrechts AV, Stark H, et al. Long-term results of stent graft treatment of subclavian artery injuries: management of choice for stable patients? *J Vasc Surg.* 2008;47:739-743.
  71. Xenos ES, Freeman M, Stevens S, et al. Covered stents for injuries of subclavian and axillary arteries. *J Vasc Surg.* 2003;38:451-454.
  72. Abouljoud MS, Obeid FN, Horst HM, et al. Arterial injuries of the thoracic outlet: a ten-year experience. *Am Surg.* 1993;59:590-595.
  73. Hyre CE, Cikrit DF, Lalka SG, et al. Aggressive management of vascular injuries of the thoracic outlet. *J Vasc Surg.* 1998;27:880-884; discussion 884-885.
  74. Nair R, Robbs JV, Muckart DJ. Management of penetrating cervicomedial venous trauma. *Eur J Vasc Endovasc Surg.* 2000;19:65-69.
  75. Nitecki SS, Karram T, Hoffman A, et al. Venous trauma in the Lebanon War—2006. *Interact Cardiovasc Thorac Surg.* 2007;6:647-650.
  76. Jeroukhimov I, Altshuler A, Peer A, et al. Endovascular stent-graft is a good alternative to traditional management of subclavian vein injury. *J Trauma.* 2004;57:1329-1330.
  77. Kumar V. Endovascular treatment of penetrating injury of axillary vein with Viabahn endoprosthesis. *J Vasc Surg.* 2004;40:1243-1244.
  78. Comerota AJ, Harwick RD, White JV. Jugular venous reconstruction: a technique to minimize morbidity of bilateral radical neck dissection. *J Vasc Surg.* 1986;3:322-329.

## 第 153 章

1. Mattox K, Feliciano D, Beal A. Five thousand seven hundred and sixty cardiovascular injuries in 4459 patients. Epidemiologic evolution 1958-1988. *Ann Surg.* 1989;209:698-705.
2. Williams JS, Graff JA, Uku JM, et al. Aortic injury in vehicular trauma. *Ann Thorac Surg.* 1994;57:726-730.
3. Feczko J, Lynch L, Pless J, et al. An autopsy case review of 142 nonpenetrating (blunt) injuries of the aorta. *J Trauma.* 1992;33:846-849.
4. Mirvis S, Bidwell J, Buddemeyer E, et al. Value of chest radiography in excluding traumatic aortic rupture. *Radiology.* 1987;163:487-493.
5. Mattox K, Wall M, LeMaire S. Injury to the great thoracic vessels. In: Mattox K, Feliciano D, Moore K, eds. *Trauma*. New York: McGraw-Hill; 2000.
6. Ho R, Blackmore C, Bloch R. Can we rely on mediastinal widening on chest radiography to identify subjects with aortic injury? *Emerg Radiol.* 2002;9:183-187.
7. Nzewi O, Slight R, Zamvar V. Management of blunt thoracic aortic injury. *Eur J Vasc Endovasc Surg.* 2006;31:18-27.
8. Miller F, Richardson J, Thomas H. Role of CT in diagnosis of major arterial injury after blunt thoracic trauma. *Surgery.* 1989;106:596-602.
9. Mirvis S. Thoracic vascular injury. *Radiol Clin North Am.* 2006;44:181-197.
10. Rivas LA, Munera F, Fishman JE. Multidetector-row computerized tomography of aortic injury. *Semin Roentgenol.* 2006;41:226-236.
11. Fishman J, Nunez D, Kane A. Direct versus indirect signs of traumatic aortic injury revealed by helical CT: performance characteristics and interobserver agreement. *AJR Am J Roentgenol.* 1999;172:1027-1031.
12. Mirvis S, Shanmugathan K, Miller B. Traumatic aortic injury: diagnosis with contrast enhanced CT—five-year experience at a major trauma center. *Radiology.* 1996;200:413-422.
13. Dyer D, Moore E, Mestek M. Can chest CT be used to exclude aortic injury? *Radiology.* 1999;213:195-202.
14. Mirvis S, Shanmugathan K. *Imaging in Trauma and Critical Care*. Philadelphia, PA: Saunders; 2003.

15. Dyer D, Moore E, Ilke D. Thoracic aortic injury: how predictive is mechanism and is chest tomography a reliable screening tool? *J Trauma Injury Crit Care*. 2000;48:673-682.
16. Scaglione M, Pinto A, Pinto F. Role of contrast-enhanced helical CT in the evaluation of acute thoracic aortic injuries after blunt chest trauma. *Eur Radiol*. 2001;11:2444-2448.
17. Minard G, Schurr M, Croce M. A prospective analysis of transesophageal echocardiography in the diagnosis of aortic disruption in trauma patients without enlarged mediastinum. *J Trauma*. 1996;40:225-230.
18. Chirillo F, Totis O, Cavarzerani A. Usefulness of transthoracic and transesophageal echocardiography in recognition and management of cardiovascular injuries after blunt trauma. *Heart*. 1996;75:301-306.
19. Cinnella G, Dambrosio M, Brienza N, et al. Transesophageal echocardiography for diagnosis of traumatic aortic injury: an appraisal of the evidence. *J Trauma*. 2004;57:1246-1255.
20. Goarin J, Cluzel P, Gosgnach M, et al. Evaluation of transesophageal echocardiography for the diagnosis of traumatic aortic injury. *Anesthesiology*. 2000;93:1373-1377.
21. Vignon P, Boncoeur MP, Francoi B, et al. Comparison of multiplane transesophageal echocardiography and contrast-enhanced helical CT in the diagnosis of blunt traumatic cardiovascular injuries. *Anesthesiology*. 2001;94:615-622.
22. Molloy M, Felner J. Transesophageal echocardiography in the evaluation of cardiothoracic trauma. *Am Heart J*. 1996;132:841-849.
23. Ahrar K, Smith D, Bansal R. Angiography in blunt thoracic injury. *J Trauma Injury Crit Care*. 1997;42:665-669.
24. Morse S, Glickman M, Greenwood L. Traumatic aortic rupture: false-positive aortographic diagnosis due to atypical ductus diverticulum. *AJR Am J Roentgenol*. 1988;150:793-796.
25. Sturm J, Hankins D, Young G. Thoracic aortography following blunt chest trauma. *Am J Emerg Med*. 1990;8:92-96.
26. Pozzato C, Gedriga E, Donatelli F, Gattoni F. Acute posttraumatic rupture of the thoracic aorta: the role of angiography in a 7-year review. *Cardiovasc Intervent Radiol*. 1991;14:338-341.
27. Fattori R, Celletti F, Bertacchini P. Delayed surgery of traumatic aortic rupture: role of magnetic resonance imaging. *Circulation*. 1996;94:2865-2870.
28. Gavelli G, Canini R, Bertaccini G, et al. Traumatic injuries: imaging of thoracic injuries. *Eur Radiol*. 2002;12:1273-1294.
29. Nagy K, Fabian T, Rodman G, et al. Guidelines for the diagnosis and management of blunt aortic injury: an EAST Practice Management Guidelines Work Group. *J Trauma*. 2000;48:1128-1143.
30. Fabian T, Richardson J, Croce M. Prospective study of blunt aortic injury: Multicenter Trial of the American Association for the Surgery of Trauma. *J Trauma*. 1997;42:374-380.
31. Vesalius A. Sepulchrethum sive Anatomia Practica ex Cadaveribus Morbo. In: Beonetus T, ed. 1700.
32. Passaro E, Pace W. Traumatic rupture of the aorta. *Surgery*. 1957;46:787.
33. Steinberg I. Chronic traumatic aneurysm of the thoracic aorta: report of five cases, with a plea for conservative treatment. *N Engl J Med*. 1957;257:913-918.
34. Parmley L, Mattingly T, Manion T. Nonpenetrating traumatic injury of the aorta. *Circulation*. 1958;17:1086-1101.
35. Richens D, Field M, Neale M, et al. The mechanism of injury in blunt traumatic rupture of the aorta. *Eur J Cardiothorac Surg*. 2002;21:288-293.
36. Brundage S, Harruff R, Jurkovich G, Maier R. The epidemiology of thoracic aortic injuries in pedestrians. *J Trauma Injury Infect Crit Care*. 1998;45:1010-1014.
37. Arajärvi E, Santavirta S, Tolonen J. Aortic ruptures in seat belt wearers. *J Thorac Cardiovasc Surg*. 1989;98:355-361.
38. Rabinsky I, Sidhu G, Wagner R. Mid-descending aortic traumatic aneurysms. *Ann Thorac Surg*. 1990;50:155-160.
39. Lundevall J. Traumatic rupture of the aorta, with special reference to road accidents. *Acta Pathol Microbiol Scand*. 1964;62:29-33.
40. Mohan D, Melvin J. Failure properties of passive human aortic tissue. *J Biomech*. 1982;15:887-902.
41. Symbas P. *Cardiothoracic traumas*. London: WB Saunders; 1989.

42. Kirklin J, Barrett-Boyes B. *Cardiac Surgery*. London: Churchill Livingstone; 1993.
43. Crass J, Cohen A, Motta A, et al. A proposed new mechanism of traumatic aortic rupture: the osseous pinch. *Radiology*. 1990;176:645-649.
44. Symbas P. Fundamentals of clinical cardiology: great vessel injury. *Am Heart J*. 1977;93:518-522.
45. Ray G, Liu Y, Davids N. Wall stress in curved aorta in blunt-chest trauma. In: 28th Annual Conference on Engineering in Medicine and Biology, Vol. 17: Alliance for Engineering in Medicine and Biology. 1975:412.
46. Richens D, Kotidis K, Neale M, et al. Rupture of the aorta following road traffic accidents in the United Kingdom 1992-1999. The results of the co-operative crash injury study. *Eur J Cardiothorac Surg*. 2003;23:143-148.
47. Dischinger P, Cowley R, Shankar B. The incidence of ruptured aorta among vehicle fatalities. *Proc Assoc Adv Automot Med Conf*. 1988;32:15.
48. Greendyke RM. Traumatic rupture of aorta; special reference to automobile accidents. *JAMA*. 1966;195:527-530.
49. Newgard CD, Lewis RJ, Kraus JF, et al. Steering wheel deformity and serious thoracic or abdominal injury among drivers and passengers involved in motor vehicle crashes. [see comment]. *Ann Emerg Med*. 2005;45:43-50.
50. Hilgenberg A, Logan D, Akins C, et al. Blunt injuries of the thoracic aorta. *Ann Thorac Surg*. 1992;53:233.
51. Pate J, Fabian T, Walker W. Acute traumatic rupture of the aortic isthmus: repair with cardiopulmonary bypass. *Ann Thorac Surg*. 1995;59:90-99.
52. Tatou E, Steinmetz E, Jazayeri S, et al. Surgical outcome of traumatic rupture of the thoracic aorta. *Ann Thorac Surg*. 2000;69:70-73.
53. Gammie J, Shah A, Hattler B, et al. Traumatic aortic rupture: diagnosis and management. *Ann Thorac Surg*. 1998;66:1295-1300.
54. Galli R, Pacini D, Di Bartolomeo R, et al. Surgical indications and timing of repair of traumatic ruptures of the thoracic aorta. *Ann Thorac Surg*. 1998;65:461-464.
55. Camp P, Shackford S. The Western Trauma Association Multicenter Group. Outcome after blunt traumatic aortic laceration: identification of a high-risk cohort. *J Trauma Injury Infect Crit Care*. 1997;43:413-422.
56. Maggisano R, Nathens A, Alexandrova N, et al. Traumatic rupture of the thoracic aorta: should one always operate immediately? *Ann Vasc Surg*. 1995;9:44-52.
57. Holmes J, Bloch R, Hall A, et al. Natural history of traumatic rupture of the thoracic aorta managed nonoperatively: a longitudinal analysis. *Ann Thorac Surg*. 2002;73:1149-1154.
58. Pate J, Gavant M, Weiman D, Fabian T. Traumatic rupture of the aortic isthmus: program of selective management. *World J Surg*. 1999;23:59-63.
59. Pate J, Fabian T, Walker W. Traumatic rupture of the aortic isthmus: an emergency? *World J Surg*. 1995;19:119-126.
60. Fabian T, Devis K, Gavant M, et al. Prospective study of blunt aortic injury. Helical CT is diagnostic and antihypertensive therapy reduces rupture. *Ann Surg*. 1998;227:666-677.
61. Simon B, Leslie C. Factors predicting early hospital death in blunt thoracic aortic injury. *J Trauma Injury Infect Crit Care*. 2001;51:906-911.
62. Moore WM Jr, Hollier LH. The influence of severity of spinal cord ischemia in the etiology of delayed-onset paraplegia. *Ann Surg*. 1991;213:427-431; discussion 431-432.
63. Von Oppell U, Dunne T, DeGroot M, Zilla P. Traumatic aortic rupture: twenty-year meta analysis of mortality and risk of paraplegia. *Ann Thorac Surg*. 1994;58:585-593.
64. Adams H, Von Geertruyden H. Neurologic complications of aortic surgery. *Ann Surg*. 1956;144:574.
65. Gharagozloo F, Larson J, Dausmann MJ, et al. Spinal cord protection during surgical procedures on the descending thoracic and thoracoabdominal aorta: review of current techniques. *Chest*. 1996;109:799-809.
66. Cambria R, Davidson J, Zannetti S, et al. Clinical experience with epidural cooling for spinal cord protection during thoracic and thoracoabdominal aortic aneurysm repair. *J Vasc Surg*. 1997;25:234-243.



67. Kouchoukos N, Daily B, Rokkas C, et al. Hypothermic bypass and circulatory arrest for operations on the descending aorta and thoracoabdominal aorta. *Ann Thorac Surg.* 1995;60:67-77.
68. Fowl R, Patterson R, Gewirtz R, Anderson D. Protection against spinal cord injury using a new 21-aminosteroid. *J Surg Res.* 1990;48:597-600.
69. Archer C, Wynn M, Hoch J, et al. Combined use of cerebral spinal drainage and naloxone reduces the risk of paraplegia in thoracoabdominal aortic aneurysm repair. *J Vasc Surg.* 1994;19:236-248.
70. Quayumi A, Janusz M, Jamieson W, Lyster D. Pharmacologic interventions for the prevention of spinal cord injury caused by aortic cross-clamping. *J Thorac Cardiovasc Surg.* 1992;104:256-261.
71. Svensson L, Hess K, D'Agostino R, et al. Reduction of neurologic injury after high-risk thoracoabdominal aortic operation. *Ann Thorac Surg.* 1998;66:132-138.
72. Safi H, Miller C, Carr C, et al. Importance of intercostal artery reattachment during thoracoabdominal aortic aneurysm repair. *J Vasc Surg.* 1998;27:58-66.
73. Coselli J, LeMaire S, Koksoy C, et al. Cerebrospinal fluid drainage reduced paraplegia after thoracoabdominal aortic aneurysm repair: results of a randomized clinical trial. *J Vasc Surg.* 2002;35:631-639.
74. Mauney MC, Blackburne LH, Langenburg SE, et al. Prevention of spinal cord injury after repair of the thoracic or thoracoabdominal aorta. *Ann Thorac Surg.* 1995;59:245-252.
75. Svensson L, Loop F. Prevention of spinal cord ischemia in aortic surgery. In: Bergan J, Yao J, eds. *Arterial Surgery: New Diagnostic and Operative Techniques*. New York: Grune and Stratton; 1988:273-285.
76. Gott V. Heparinized shunts for thoracic vascular operation. *Ann Thorac Surg.* 1972;14:219-220.
77. Molina J, Cogordan J, Einzig S, et al. Adequacy of ascending aortic descending aortic shunt during cross-clamping of the thoracic aorta from prevention of spinal cord injury. *J Thorac Cardiovasc Surg.* 1985;90:126-136.
78. Oliver H, Maher T, Liebler G, et al. Use of the Biomedicus centrifugal pump in traumatic tear of the thoracic aorta. *Ann Thorac Surg.* 1984;38:586-591.
79. Duke B, Moore E, Moore F, et al. Posterior circulation cerebral infarcts associated with repair of thoracic aortic disruptions using partial left heart bypass. *J Trauma.* 1997;42:1135-1139.
80. Weisman D, Garbuz A, Gursky A, et al. Comparison of spinal cord protection utilizing left atrial-femoral with femoral-femoral bypass in patients with traumatic rupture of the aortic isthmus. *World J Surg.* 2006;30:1638-1641.
81. Von Oppell U, Dunne T, DeGroot M, Zilla P. Spinal cord protection in the absence of collateral circulation: a meta-analysis of mortality and paraplegia. *J Cardiac Surg.* 1994;9:685-691.
82. Schumacher H, Bockler D, von Tengg-Kobligh H, et al. Acute traumatic aortic tear: open versus stent-graft repair. *Semin Vasc Surg.* 2006;19:48-59.
83. Appoo JJ, Moser WG, Fairman RM, et al. Thoracic aortic stent grafting: improving results with newer generation investigational devices. *J Thorac Cardiovasc Surg.* 2006;131:1087-1094.
84. Brooks M, Loftus I, Morgan R, Thompson M. The Valiant thoracic endograft. *J Cardiovasc Surg (Torino).* 2006;47:269-278.
85. Fattori R, Nienaber CA, Rousseau H, et al. Results of endovascular repair of the thoracic aorta with the Talent Thoracic stent graft: the Talent Thoracic Retrospective Registry. *J Thorac Cardiovasc Surg.* 2006;132:332-339.
86. Kaya A, Heijmen RH, Overtom TT, et al. Thoracic stent grafting for acute aortic pathology. *Ann Thorac Surg.* 2006;82:560-565.
87. Khamaisi M, Anner H, Marincheva G, et al. Stent graft in treatment of penetrating thoracic aortic ulcer. *J Am Soc Echocardiogr.* 2006;19:835 e4-835 e6.
88. Onitsuka S, Tanaka A, Akashi H, et al. Initial and midterm results for repair of aortic diseases with handmade stent grafts. *Circ J.* 2006;70:726-732.
89. Wheatley GH 3rd, Gurbuz AT, Rodriguez-Lopez JA, et al. Midterm outcome in 158 consecutive Gore TAG thoracic

- endoprostheses: single center experience. *Ann Thorac Surg.* 2006;81:1570-1577; discussion 1577.
90. Song H, Slater M, Kaufman J. *Technique for Percutaneous Transfemoral Stent Graft Repair of Traumatic Aortic Transection.* In: Tolis G, ed. [http://www.ctsnet.org/sections/clinicalresources/adultcardiac/expert\\_tech-24.html](http://www.ctsnet.org/sections/clinicalresources/adultcardiac/expert_tech-24.html). Baltimore, MD: CTSNet Publishing; 2007.
  91. Walls JT, Curtis JJ, McKenney-Knox CA, Schmaltz RA. Centrifugal pump support for distal aortic perfusion during repair of traumatic thoracic aortic injury. *Artif Organs.* 2002;26:991-993.
  92. Forbes AD, Ashbaugh DG. Mechanical circulatory support during repair of thoracic aortic injuries improves morbidity and prevents spinal cord injury. *Arch Surg.* 1994;129:494-497; discussion 497-498.
  93. Read RA, Moore EE, Moore FA, et al. Partial left heart bypass for thoracic aorta repair. Survival without paraplegia. *Arch Surg.* 1993;128:746-750; discussion 750-752.
  94. Sweeney M, Young D, Frazier O, et al. Traumatic aortic transections: eight year experience with the "clamp-sew" technique. *Ann Thorac Surg.* 1997;64:384.
  95. Leurs LJ, Bell R, Degrieck Y, et al. Endovascular treatment of thoracic aortic diseases: combined experience from the EUROSTAR and United Kingdom Thoracic Endograft registries. *J Vasc Surg.* 2004;40:670-679; discussion 679-680.
  96. Reed AB, Thompson JK, Crafton CJ, et al. Timing of endovascular repair of blunt traumatic thoracic aortic transections. *J Vasc Surg.* 2006;43:684-688.
  97. Tehrani HY, Peterson BG, Katariya K, et al. Endovascular repair of thoracic aortic tears. *Ann Thorac Surg.* 2006;82:873-877; discussion 877-878.
  98. Orford VP, Atkinson NR, Thomson K, et al. Blunt traumatic aortic transection: the endovascular experience. *Ann Thorac Surg.* 2003;75:106-111; discussion 111-112.
  99. Peterson BG, Longo GM, Matsumura JS, et al. Endovascular repair of thoracic aortic pathology with custom-made devices. *Surgery.* 2005;138:598-605; discussion 605.
  100. Marty-Ane CH, Berthet JP, Branchereau P, et al. Endovascular repair for acute traumatic rupture of the thoracic aorta. *Ann Thorac Surg.* 2003;75:1803-1807.
  101. Kondo N, Koyama M, Wakayama F, et al. Surgical repair for chronic traumatic thoracic aneurysm after 12-year follow-up. *Jpn J Thorac Cardiovasc Surg.* 2004;52:586-588.
  102. Bacharach JM, Garratt KN, Rooke TW, et al. Chronic traumatic thoracic aneurysm: report of two cases with the question of timing for surgical intervention. *J Vasc Surg.* 1993;17:780-783.
  103. Katsumata T, Shinfeld A, Westaby S, et al. Operation for chronic traumatic aortic aneurysm: when and how? *Ann Thorac Surg.* 1998;66:774-778.
  104. Hirose H, Svensson LG. Chronic posttraumatic aneurysm of descending aorta with fistulous communication into pulmonary artery. *J Vasc Surg.* 2004;40:564-566.
  105. Pantaleo P, Prothero T, Banning AP, et al. Aorto-bronchial fistula resulting from an accidental fall one year earlier. *Int J Cardiol.* 1999;68:239-240.
  106. Fernandez Gonzalez AL, Montero JA, Luna D, et al. Aortobronchial fistula secondary to chronic post-traumatic thoracic aneurysm. *Tex Heart Inst J.* 1996;23:174-177.
  107. Baba M, Yamashita A, Sugimoto S, et al. [A case of a chronic traumatic thoracic aneurysm with compression of left main bronchus at the isthmus]. *Kyobu Geka.* 1998;51:860-863.
  108. Gawenda M, Landwehr P, Brunkwall J, et al. Stent-graft replacement of chronic traumatic aneurysm of the thoracic aorta after blunt chest trauma. *J Cardiovasc Surg.* 2002;43:705-709.
  109. Stone D, Brewster D, Kwolek C, et al. Stent-graft versus open-surgical repair of the thoracic aorta: mid-term results. *J Vasc Surg.* 2006;44:1188-1197.
  110. Symbas P, Horsley W, Symbas P. Rupture of the ascending aorta caused by blunt trauma. *Ann Thorac Surg.* 1998;66:113-117.

111. Serna D, Miller J, Chen E. Aortic reconstruction after complex injury of the mid-transverse arch. *Ann Thorac Surg.* 2006;81:1112-1114.
112. Graham J, Feliciano D, Mattox K. Innominant vascular injury. *J Trauma.* 1982;22:647.
113. Brown M, Graham J, Feliciano D, et al. Carotid artery injuries. *Am J Surg.* 1982;144:748.
114. Graham J, Feliciano D, Mattox K, et al. Management of subclavian vascular injuries. *J Trauma.* 1980;20:537.
115. Joo J, Ahn J, Chung Y, et al. Therapeutic endovascular treatments for traumatic carotid artery injuries. *J Trauma.* 2005;58:1159-1166.
116. Diaz-Daza O, Arraiza F, Barkley J, et al. Endovascular therapy of traumatic vascular lesions of the head and neck. *Cardiovasc Intervent Radiol.* 2003;26:213-221.
117. Duke B, Ryu R, Coldwell D, et al. Treatment of blunt injury to the carotid artery by using endovascular stents: an early experience. *J Neurosurg.* 1997;87:825-829.
118. Gomez C, May A, Terry J, et al. Endovascular therapy of traumatic injuries of the extracranial cerebral arteries. *Crit Care Clin.* 1999;15:789-809.
119. Parodi J, Schonholz C, Ferreira L, et al. Endovascular stent-graft treatment of traumatic arterial lesions. *Ann Vasc Surg.* 1999;13:121-129.
120. Leon M, Baim D, Popma J, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting. *N Engl J Med.* 1998;339:1665-1671.
121. Graham J, Feliciano D, Mattox K. Management of subclavian vascular injuries. *J Trauma.* 1980;20:537.
122. Mattox K. Approaches to trauma involving the major vessels of the thorax. *Surg Clin North Am.* 1989;69:77.
123. Elkin D, Cooper F. Resection of the clavicle in vascular surgery. *J Bone Joint Surg.* 1946;28:117.
124. Szeto W, Fairman R, Acker M, et al. Emergency endovascular deployment of stent graft in the ascending aorta for contained rupture of innominate artery pseudoaneurysm in a pediatric patient. *Ann Thorac Surg.* 2006;81:1872-1875.
125. Chandler T, Fishwick G, Bell P. Endovascular repair of a traumatic innominant artery aneurysm. *Eur J Vasc Endovasc Surg.* 1999;18:80-82.
126. Axisa B, Loftus I, Fishwick G, et al. Endovascular repair of an innominate artery false aneurysm following blunt trauma. *J Endovasc Ther.* 2000;7:245-250.
127. Castelli P, Caronno R, Piffaretti G, et al. Endovascular repair of traumatic injuries of the subclavian and axillary arteries. *Injury.* 2005;36:778-782.
128. Fang R, Miller OL, Cai T, et al. Blunt avulsion of the right inferior pulmonary vein. *J Trauma Injury Infect Crit Care.* 2004;56:191-193.
129. Kemmerrer W, Eckert W, Gathright J, et al. Patterns of thoracic injuries in fatal traffic accidents. *J Trauma.* 1961;1:595-599.
130. DiMarco RF, Layton TR, Manzetti GW, et al. Blunt traumatic rupture of the right atrium and the right superior pulmonary vein. *J Trauma Injury Infect Crit Care.* 1983;23:353-355.
131. Leeson P, Dass S, Mitchell AR, et al. A transesophageal echocardiography study: traumatic left atrial appendage and left upper pulmonary vein dissection. *J Am Soc Echocardiogr.* 2007;20:537.e3-537.e5.
132. McKeown PP, Rosemurgy A, Conant P, et al. Blunt traumatic rupture of pulmonary vein, left atrium, and bronchus. *Ann Thorac Surg.* 1991;52:1171-1172.
133. Varghese D, Patel H, Cameron EW, et al. Repair of pulmonary vein rupture after deceleration injury. *Ann Thorac Surg.* 2000;70:656-658.
134. Fuller J, Clark TC. Repair of traumatic aneurysm of the pulmonary artery with arteriovenous fistula. *Minn Med.* 1987;70:521-522.
135. Hubler B, Earls JP, Stevens K, et al. Traumatic pulmonary arterial and venous pseudoaneurysms. *AJR Am J Roentgenol.* 1997;169:1354.

136. Ito T, Sakamoto T, Norio H, et al. An arteriovenous fistula between the internal mammary artery and the pulmonary vein following blunt chest trauma. *Cardiovasc Intervent Radiol*. 2005;28:120-123.
137. Mills T, Gupta S, Helmcke F, et al. Posttraumatic pulmonary arteriovenous fistula presenting as multiple embolic strokes. *Echocardiography*. 2007;24:79-82.
138. Couves C, Heughan C. Laceration of superior vena cava due to blunt trauma: successful surgical management. *Can J Surg*. 1981;24:402-403.
139. Van de Wal H, Draaisma J, Vincent J, Goris R. Rupture of the supradiaphragmatic inferior vena cava by blunt decelerating trauma: case report. *J Trauma*. 1990;30:111-113.
140. Clements R, Fischer P. Blunt injury of the intrapericardial great vessels. *J Trauma*. 2001;50:129-132.
141. Frezza E, Valenziano C. Blunt traumatic avulsion of the inferior vena cava. *J Trauma*. 1997;42:141-143.
142. Rozycki G, Feliciano D, Schmidt J, et al. The role of surgeon performed ultrasound in patients with possible cardiac wounds. *Ann Surg*. 1996;223:737-774.
143. Kudsk KA, Sheldon GF, Lim RC Jr, et al. Atrial-caval shunting (ACS) after trauma. *J Trauma Injury Infect Crit Care*. 1982;22:81-85.

## 第 154 章

1. Asensio TA, Chahwan S, Hanpeter D, et al. Operative management and outcomes of 302 abdominal vascular injuries. *Am J Surg*. 2000;180:528-534.
2. Demetriades D, Velmahos G, Cornwell EE, et al. Selective nonoperative management of gunshot wounds of the anterior abdomen. *Arch Surg*. 1997;132:178-183.
3. Feliciano DV, Burch JM, Graham JM. Abdominal vascular injury. In: Mattox KL, Feliciano DV, Moore EE, eds. *Trauma*. 4th ed. New York: McGraw-Hill; 2000:783-806.
4. Cox EF. Blunt abdominal trauma: a 5-year analysis of 870 patients requiring celiotomy. *Ann Surg*. 1984;199:467-474.
5. Bickell WH, Wall MJ, Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso trauma. *N Engl J Med*. 1994;27:1105-1109.
6. Dutton RP, Mackenzie CF, Scalea TM. Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality. *J Trauma*. 2002;52:1141-1146.
7. Stern SA, Dronen SC, Birrer P, Wang X. Effect of blood pressure on hemorrhage volume and survival in a near-fatal hemorrhage model incorporating a vascular injury. *Ann Emerg Med*. 1993;22:155-163.
8. Bickell WH, Bruttig SC, Millnamow GA, et al. The detrimental effects of intravenous crystalloid after aortotomy in swine. *Surgery*. 1991;110:529-536.
9. Capone AC, Safar P, Stezoski SW, et al. Improved outcome with fluid restriction in treatment of uncontrolled hemorrhagic shock. *J Am Coll Surg*. 1995;180:49-56.
10. Leppaniemi A, Solter R, Burris D, et al. Fluid resuscitation in a model of uncontrolled hemorrhage: too much too early, or too little too late? *J Surg Res*. 1996;63:413-418.
11. Ledgerwood AM, Kazmers M, Lucas CE. The role of thoracic aortic occlusion for massive hemoperitoneum. *J Trauma*. 1976;16:610-615.
12. Millikan JS, Moore EE. Outcome of resuscitative thoracotomy and descending aortic occlusion performed in the operating room. *J Trauma*. 1984;24:387-392.
13. Brotman S, Oster-Granite M, Cox EF. Failure of cross-clamping the thoracic aorta to control intra-abdominal bleeding. *Ann Emerg Med*. 1982;11:147-148.
14. Fry WR, Fry EE, Fry WJ. Operative exposure of the abdominal arteries for trauma. *Arch Surg*. 1991;126:289-291.
15. Voellinger DC, Saddakni S, Melton SM, et al. Endovascular repair of a traumatic infrarenal aortic dissection: a case report and review. *Vasc Surg*. 2001;35:385-389.

16. Inaba K, Kirkpatrick AW, Finkelstein J, et al. Blunt abdominal aortic trauma in association with thoracolumbar spine fractures. *Injury*. 2001;32:201-207.
17. Naude GP, Back M, Perry MO, Bongard FS. Blunt disruption of the abdominal aorta: report of a case and review of the literature. *J Vasc Surg*. 1997;25:931-935.
18. Demetriades D, Theodorou D, Murray J, et al. Mortality and prognostic factors in penetrating injuries of the aorta. *J Trauma*. 1996;40:761-763.
19. Lopez-Viego MA, Snyder WH, Valentine RJ, Clagett GP. Penetrating abdominal aortic trauma: a report of 129 cases. *J Vasc Surg*. 1992;16:332-335.
20. Picard E, Marty-Ane CH, Vernhet H, et al. Endovascular management of traumatic infrarenal abdominal aortic dissection. *Ann Vasc Surg*. 1998;12:515-521.
21. Vernhet H, Marty-Ane CH, Lesnik A, et al. Dissection of the abdominal aorta in blunt trauma: management by percutaneous stent placement. *Cardiovasc Intervent Radiol*. 1997;20:473-476.
22. Accola KD, Feliciano DV, Mattox KL, et al. Management of injuries to the suprarenal aorta. *Am J Surg*. 1987;154:613-618.
23. Degiannis E, Levy RD, Florizone MG, et al. Gunshot injuries of the abdominal aorta: a continuing challenge. *Injury*. 1997;28:195-197.
24. Asensio JA, Forno W, Roldan G, et al. Visceral vascular injuries. *Surg Clin North Am*. 2002;82:1-20.
25. Mullins RJ, Huckfeldt R, Trunkey DD. Abdominal vascular injuries. *Surg Clin North Am*. 1996;76:813-832.
26. Asensio JA, Berne JD, Chahwan S, et al. Traumatic injury to the superior mesenteric artery. *Am J Surg*. 1999;178:235-239.
27. Accola KD, Feliciano DV, Mattox KL, et al. Management of injuries to the superior mesenteric artery. *J Trauma*. 1986;26:313-319.
28. Lucas AE, Richardson JD, Flint LM, Polk HC. Traumatic injury of the proximal superior mesenteric artery. *Ann Surg*. 1981;193:30-34.
29. Reilly PM, Rotondo MF, Carpenter JP, et al. Temporary vascular continuity during damage control: intraluminal shunting for proximal superior mesenteric artery injury. *J Trauma*. 1995;39:757-760.
30. Sirinek KR, Gaskill HV, Root HD, Levine BA. Truncal vascular injury: factors influencing survival. *J Trauma*. 1983;23:372-377.
31. Sangthong B, Demetriades D, Martin M, et al. Management and hospital outcomes of blunt renal artery injuries: analysis of 517 patients from the National Trauma Data Bank. *J Am Coll Surg*. 2006;203:612-617.
32. Haas CA, Sprinak JP. Traumatic renal artery occlusion: a review of the literature. *Tech Urol*. 1998;4:1-11.
33. Spinak JP, Resnick MI. Revascularization of traumatic thrombosis of the renal artery. *Surg Gynecol Obstet*. 1987;164:22-26.
34. Clark DE, Georgitis JW, Ray FS. Renal arterial injuries caused by blunt trauma. *Surgery*. 1981;90:87-96.
35. Tillou A, Romero J, Asensio JA, et al. Renal vascular injuries. *Surg Clin North Am*. 2001;81:1417-1430.
36. Villas PA, Cohen G, Putnam SG. Wallstent placement in a renal artery after blunt abdominal trauma. *J Trauma*. 1999;46:1137-1139.
37. Sprouse LR II, Hamilton IN Jr. The endovascular treatment of a renal arteriovenous fistula: placement of covered stent. *Vasc Surg*. 2002;36:1066-1068.
38. Lee JT, White RA. Endovascular management of blunt traumatic renal artery dissection. *J Endovasc Ther*. 2002;9:354-358.
39. Velmahos GC, Demetriades D, Cornwell EE, et al. Selective management of renal gunshot wounds. *Br J Surg*. 1998;85:1121-1124.
40. Lock JS, Carraway RP, Hudson HC, Laws ML. Proper management of renal artery injury from blunt trauma. *South Med J*. 1985;78:406-410.
41. Maggio AJ, Brosman S. Renal artery trauma. *Urology*. 1978;11:125-130.
42. Demetriades D, Murray JA, Asensio JA. Iliac vessel injuries. In: Rich N, Mattox KL, Hirshberg A, eds. *Vascular Trauma*. Philadelphia: WB Saunders; 2004:339-351.

43. Kennedy F, Cornwell EE, Lockett C, Demetriades D. Blunt injury to the left common iliac artery. *Am Surg.* 1995;61:360-362.
44. Balogh Z, Voros E, Suveges G, Simonka JA. Stent-graft treatment of an external iliac artery injury associated with pelvic fractures: a case report. *J Bone Joint Surg Am.* 2003;85:919-922.
45. Lyden SP, Srivastava SD, Waldman DL, Green RM. Common iliac artery dissection after blunt trauma: case report of endovascular repair and literature review. *J Trauma.* 2001;50:339-342.
46. Burch JM, Richardson RJ, Martin RR, Mattox KL. Penetrating iliac vascular injuries: recent experience with 233 consecutive patients. *J Trauma.* 1990;30:1450-1459.
47. Lee JT, Bongard FS. Iliac vessel injuries. *Surg Clin North Am.* 2002;82:21-48.
48. Velmahos GC, Theodorou D, Demetriades D, et al. Complications and nonclosure rates of fasciotomy for trauma and related risk factors. *World J Surg.* 1997;21:247-253.
49. Shah DM, Bock DE, Darling RC, et al. Beneficial effects of hypertonic mannitol in acute ischemia-reperfusion injuries in humans. *Cardiovasc Surg.* 1996;4:97-100.
50. Oredsson S, Plate G, Qvarfordt P. The effect of mannitol on reperfusion injury and postischemic compartment pressure in skeletal muscle. *Eur J Surg.* 1994;8:326-331.
51. Kuene J, Frankhouse J, Modrall G, et al. Determinants of survival after inferior vena cava trauma. *Am Surg.* 1999;65:976-981.
52. Buckman RF, Pathak AS, Badelino MM, Bradley KM. Injuries of the inferior vena cava. *Surg Clin North Am.* 2001;81:1431-1447.
53. Yellin AE, Chaffee CB, Donovan AJ. Vascular isolation in the treatment of juxtahepatic venous injuries. *Arch Surg.* 1971;102:566-573.
54. Shrock T, Blaisdell FW, Mathewson C. Management of blunt trauma to the liver and hepatic veins. *Arch Surg.* 1968;95:698-704.
55. Mattox KL, Espada R, Beall AR. Traumatic injury to the portal vein. *Ann Surg.* 1975;181:519-522.
56. Buckman RF, Pathak AS, Badelino MM, Bradley KM. Portal vein injuries. *Surg Clin North Am.* 2001;81:1449-1462.
57. Pachter HL, Drager S, Godfrey N, Lefleur R. Traumatic injuries in the portal vein: the role of acute ligation. *Ann Surg.* 1979;189:383-385.
58. Stone HH, Fabian TC, Turkelson ML. Wounds of the portal venous system. *World J Surg.* 1982;6:335-341.

## 第 155 章

1. Rich NM. Surgeon's response to battlefield vascular trauma. *Am J Surg.* 1993;166:91.
2. DeBakey E, Simeone CF. Battle injuries of the arteries in World War II: an analysis of 2471 cases. *Ann Surg.* 1946;123:534.
3. Hughes CH. Arterial repair during the Korean War. *Ann Surg.* 1958;147:555.
4. Rich NA, Baugh JH, Hughes CW. Acute arterial injuries in Vietnam: 1000 cases. *J Trauma.* 1970;10:359.
5. Melton SM, Croce MA, Patton JH, et al. Popliteal artery trauma. *Ann Surg.* 1997;225:518.
6. Wagner WH, Caulkins E, Weaver FA, et al. Blunt popliteal artery trauma: 100 consecutive cases. *J Vasc Surg.* 1988;7:736.
7. Wagner WH, Yellin AE, Weaver FA, et al. Acute treatment of popliteal artery trauma: the importance of soft tissue injury. *Ann Vasc Surg.* 1994;8:557.
8. Weaver FA, Papanicolaou G, Yellin AE. Difficult peripheral vascular injuries. *Surg Clin North Am.* 1996;76:843.
9. Pasch AR, Bishara RA, Lim LT, et al. Optimal limb salvage in penetrating civilian vascular trauma. *J Vasc Surg.* 1986;3:189.
10. Fackler ML. Wound ballistics: a review of common misconceptions. *JAMA.* 1988;259:2730.
11. Amato JJ, Billy LJ, Gruber RP, et al. Vascular injuries: an experimental study of high and low velocity missile wounds.

*Arch Surg.* 1970;101:167.

12. Mayer JP, Lim LT, Schuler JJ, et al. Peripheral vascular trauma from close-range shotgun injuries. *Arch Surg.* 1985;120:1126.
13. White RA, Scher LA, Samson RH, et al. Peripheral vascular injuries associated with falls from heights. *J Trauma.* 1987;27:411.
14. Guede JW, Hobson RW, Padberg FT, et al. The role of contrast arteriography in suspected arterial injuries of the extremities. *Am Surg.* 1985;51:89.
15. Abou-Sayed H, Berger DL. Blunt lower-extremity trauma and popliteal artery injuries. Revisiting the case for selective arteriography. *Arch Surg.* 2002;137:585.
16. Conrad MF, Patton Jr JH, Parikshak M, et al. Evaluation of vascular injury in penetrating extremity trauma: angiographers stay home. *Am Surg.* 2002;68:269.
17. Dennis JW, Jagger C, Butcher JL, et al. Reassessing the role of arteriograms in the management of posterior knee dislocations. *J Trauma.* 1993;35:692.
18. Weaver FA, Yellin AE, Bauer M, et al. Is arterial proximity a valid indication for arteriography in penetrating extremity trauma? A prospective analysis. *Arch Surg.* 1990;125:1256.
19. Schwartz MR, Weaver FA, Yellin AE, et al. Refining the indications for arteriography in penetrating extremity trauma: a prospective analysis. *J Vasc Surg.* 1993;17:166.
20. Applebaum R, Yellin AE, Weaver FA, et al. The role of routine arteriography in blunt lower extremity trauma. *Am J Surg.* 1990;160:221.
21. Treiman GS, Yellin AE, Weaver FA, et al. Examination of the patient with knee dislocation: the case for selective arteriography. *Arch Surg.* 1992;127:1056.
22. Dennis JW, Frykberg ER, Veldenz HC, et al. Validation of nonoperative management of occult vascular injuries and accuracy of physical examination alone in penetrating extremity trauma: 5- to 10-year follow up. *J Trauma.* 1998;44:243.
23. Lynch K, Johansen K. Can Doppler pressure measurement replace "exclusion" arteriography in the diagnosis of occult extremity arterial trauma? *Ann Surg.* 1991;214:737.
24. Hood DB, Yellin AE, Weaver FA. Vascular trauma. In: Dean R, ed. *Current Vascular Surgical Diagnosis and Treatment*. Norwalk, CT: Appleton & Lange; 1995:405.
25. Meissner M, Paun M, Johansen K. Duplex scanning for arterial trauma. *Am J Surg.* 1991;161:552.
26. Bynoe RP, Miles WS, Bell RM, et al. Noninvasive diagnosis of vascular trauma by duplex ultrasonography. *J Vasc Surg.* 1991;14:346.
27. Fry WR, Smith RS, Sayers DV, et al. The success of duplex ultrasonographic scanning in diagnosis of extremity vascular proximity trauma. *Arch Surg.* 1993;128:1368.
28. Bergstein JM, Blair JF, Edwards J, et al. Pitfalls in the use of color-flow duplex ultrasound for screening of suspected arterial injuries in penetrated extremities. *J Trauma.* 1992;33:395.
29. Gagne PJ, Cone JB, McFarland D, et al. Proximity penetrating extremity trauma: the role of duplex ultrasound in the detection of occult venous injuries. *J Trauma.* 1995;39:1157.
30. Ordog GJ, Balasubramaniam S, Wasserber J, et al. Extremity gunshot wounds: I. Identification and treatment of patients at high risk of vascular injury. *J Trauma.* 1994;36:358.
31. Schwartz M, Weaver F, Yellin A, Ralls P. The utility of color flow Doppler examination in penetrating extremity arterial trauma. *Am Surg.* 1993;59:375.
32. Rubel IF, Potter H, Barie P, et al. Magnetic resonance venography to evaluate deep venous thrombosis in patients with pelvic and acetabular trauma. *J Trauma.* 2001;51:622.
33. Soto JA, Múnera F, Cardoso N, et al. Diagnostic performance of helical CT angiography in trauma to large arteries of the extremities. *J Comput Assist Tomogr.* 1999;23:188.

34. Busqu s AR, Acosta JA, Col n E, et al. Helical computed tomographic angiography for the diagnosis of traumatic arterial injuries of the extremities. *J Trauma*. 2004;56:625.
35. Fleiter TR, Mervis S. The role of 3D-CTA in the assessment of peripheral vascular lesions in trauma patients. *Eur J Radiol*. 2007;64:92.
36. Peng PD, Spain DA, Tataria M, et al. CT angiography effectively evaluates extremity vascular trauma. *Am Surg*. 2008;74:103.
37. Weaver FA, Yellin AE. Complications of missed arterial injuries. *J Vasc Surg*. 1993;18:1077.
38. Stain SC, Yellin AE, Weaver FA, et al. Selective management of nonocclusive arterial injuries. *Arch Surg*. 1989;124:1136.
39. Frykberg EP. Advances in the diagnosis and treatment of extremity vascular trauma. *Surg Clin North Am*. 1995;75:207
40. Knudson MM, Lewis FR, Atkinson K, et al. The role of duplex ultrasound arterial imaging in patients with penetrating extremity trauma. *Arch Surg*. 1993;128:1033.
41. Reuben BC, Whitten MG, Sarfati M, Kraiss LW. Increasing use of endovascular therapy in acute arterial injuries: analysis of the National Trauma Data Bank. *J Vasc Surg*. 2007;46:1222.
42. McNeese S, Fink E, Yellin AE. Definitive treatment of selected vascular injuries and post-traumatic arteriovenous fistulas by arteriographic embolization. *Am J Surg*. 1980;140:252.
43. Marin ML, Veith FJ, Panetta TF, et al. Transluminally placed endovascular stented graft repair for arterial trauma. *J Vasc Surg*. 1994;20:466.
44. Risberg B, L nn L. Management of vascular injuries using endovascular techniques. *Eur J Surg*. 2000;166:196.
45. Shah SH, Ledgerwood AM, Lucas CE. Successful endovascular stenting for common iliac artery injury associated with pelvic fracture. *J Trauma*. 2003;55:383.
46. Sternberg W 3rd, Connors MS 3rd, Ojeda MA, et al. Acute bilateral iliac artery occlusion secondary to blunt trauma: successful endovascular treatment. *J Vasc Surg*. 2003;38:589.
47. Xenos ES, Freeman M, Stevens S, et al. Covered stents for injuries of subclavian and axillary arteries. *J Vasc Surg*. 2003;38:451.
48. Eger M, Golcman L, Goldstein A, et al. The use of a temporary shunt in the management of arterial vascular injuries. *Surg Gynecol Obstet*. 1971;123:67.
49. Nichols JG, Svoboda JA, Parks SN. Use of temporary intraluminal shunts in selected peripheral arterial injuries. *J Trauma*. 1986;26:1094.
50. Reber PU, Patel AG, Sapio NLD, et al. Selective use of temporary intravascular shunts in coincident vascular and orthopedic upper and lower limb trauma. *J Trauma*. 1999;47:72.
51. Rasmussen TE, Clouse WD, Jenkins DH, et al. The use of temporary vascular shunts as a damage control adjunct in the management of wartime vascular injury. *J Trauma*. 2006;61:8.
52. Aldridge SD, Badellino MM, Malaspina PJ, et al. Extended intravascular shunting in an experimental model of vascular injury. *J Cardiovasc Surg*. 1997;38:183.
53. Dawson DL, Putnam AT, Light JT, et al. Temporary arterial shunts to maintain limb perfusion after arterial injury: an animal study. *J Trauma*. 1999;47:64.
54. Granchi T, Schmittling Z, Vasquez J, et al. Prolonged use of intraluminal arterial shunts without systemic anticoagulation. *Am J Surg*. 2000;180:493.
55. Sriussadaporn S, Pak-art R. Temporary intravascular shunt in complex extremity vascular injuries. *J Trauma*. 2002;52:1129.
56. Barros D'Sa AA, Harkin DW, Blair PH, et al. The Belfast approach to managing complex lower limb vascular injuries. *Eur J Vasc Endovasc Surg*. 2006;32:246.
57. Chambers LW, Green DJ, Sample K, et al. Tactical surgical intervention with temporary shunting of peripheral vascular trauma sustained during Operation Iraqi Freedom: one unit's experience. *J Trauma*. 2006;61:824.



58. Stain SC, Weaver FA, Yellin AE. Extra-anatomical bypass of failed traumatic arterial repairs. *J Trauma*. 1991;31:575.
59. Vaughn GD, Mattox KL, Feliciano DV, et al. Surgical experience with expanded polytetrafluoroethylene (PTFE) as a replacement graft for traumatized vessels. *J Trauma*. 1979;19:403.
60. Veith FJ, Gupta SK, Ascer E, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. *J Vasc Surg*. 1986;3:104.
61. Feliciano DV, Mattox K, Graham JM, Bitondo CG. Five year experience with PTFE grafts in vascular wounds. *J Trauma*. 1985;25:71.
62. Martin LC, McKenney MG, Sossa JL, et al. Management of lower extremity arterial trauma. *J Trauma*. 1994;37:591.
63. Hafez HM, Woolgar J, Robbs JV. Lower extremity arterial injury: results of 550 cases and review of risk factors associated with limb loss. *J Vasc Surg*. 2001;33:112.
64. Dorweiler B, Neufang A, Schmiedt W, et al. Limb trauma with arterial injury: long-term performance of venous interpositions grafts. *Thorac Cardiovasc Surg*. 2003;51:67.
65. Odeh M. Mechanisms of disease: The role of reperfusion-induced injury in the pathogenesis of the crush syndrome. *N Engl J Med*. 1991;324:1417.
66. Wright JG, Kerr JC, Valeri CR, et al. Heparin decreases ischemia-reperfusion injury in isolated canine gracilis model. *Arch Surg*. 1988;123:470.
67. Guerrero A, Gibson K, Kralovich KA, et al. Limb loss following lower extremity arterial trauma: what can be done proactively? *Injury*. 2002;33:765.
68. Johnson SB, Weaver FA, Yellin AE, et al. Clinical results of decompressive dermatomy-fasciotomy. *Am J Surg*. 1992;164:286.
69. Demetriades D, Chahwan S, Gomez H, et al. Penetrating injuries to the subclavian and axillary vessels. *J Am Coll Surg*. 1999;188:290.
70. Lin PH, Koffron AJ, Guske PJ, et al. Penetrating injuries of the subclavian artery. *Am J Surg*. 2003;185:580.
71. D'Othee BJ, Rousseau H, Otal P, et al. Noncovered stent placement in a blunt traumatic injury of the right subclavian artery. *Cardiovasc Intervent Radiol*. 1999;22:424.
72. Graham JM, Feliciano DV, Mattox KL, et al. Management of subclavian vascular injuries. *J Trauma*. 1980;20:537.
73. Dutor DF, Strauss DC, Blaszczyk M, et al. Endovascular treatment of penetrating thoracic outlet arterial injuries. *Eur J Vasc Endovasc Surg*. 2000;19:489.
74. Coleman SS, Anson BJ. Arterial patterns in the hand based upon a study of 650 specimens. *Surg Gynecol Obstet*. 1961;113:408.
75. Ikeda A, Ugawa A, Kazihara Y, Hamada N. Arterial pattern in the hand on a three-dimensional analysis of 220 cadaver hands. *J Hand Surg*. 1988;13:501.
76. Burch JM, Richardson RJ, Martin RR, et al. Penetrating iliac vascular injuries: recent experience with 233 consecutive patients. *J Trauma*. 1990;30:1450.
77. Carrillo EH, Spain DA, Wilson MA, et al. Alternatives in the management of penetrating injuries to the iliac vessels. *J Trauma*. 1998;44:1024.
78. Asensio JA, Petrone P, Roldan G, et al. Analysis of 185 iliac vessel injuries. Risk factors and predictors of outcome. *Arch Surg*. 2003;138:1187.
79. Gorman JF. Combat arterial trauma analysis of 106 limb-threatening injuries. *Arch Surg*. 1969;98:160.
80. Johansen K, Daines M, Howey T, et al. Objective criteria accurately predict amputation following lower extremity trauma. *J Trauma*. 1990;30:568.
81. Dar AM, Ahanger AG, Wani RA, et al. Popliteal artery injuries: the Kashmir experience. *J Trauma*. 2003;55:362.
82. Shah DM, Corson JD, Karmody AM, et al. Optimal management of tibial arterial trauma. *J Trauma*. 1988;28:228.
83. Whitman GR, McCroskey BL, Moore EE, et al. Traumatic popliteal and trifurcation vascular injuries: determinants of

- functional limb salvage. *Am J Surg*. 1987;154:681.
84. DeVirgilio C, Mercado PD, Arnell T, et al. Noniatrogenic pediatric vascular trauma: a ten-year experience at a level 1 trauma center. *Am Surg*. 1997;63:781.
  85. Fayiga YJ, Valentine RJ, Myers SI, et al. Blunt pediatric vascular trauma: analysis of forty-one consecutive patients undergoing operative intervention. *J Vasc Surg*. 1994;20:419.
  86. Harris LM, Hordines J. Major vascular injuries in the pediatric population. *Ann Vasc Surg*. 2003;17:266.
  87. Myers SI, Reed MK, Black CT, et al. Noniatrogenic pediatric vascular trauma. *J Vasc Surg*. 1989;10:258.
  88. Smith C, Green RM. Pediatric vascular injuries. *Surgery*. 1981;90:20.
  89. Meyer J, Walsh J, Schuler J, et al. The early fate of venous repair after civilian vascular trauma. *Ann Surg*. 1987;206:458.
  90. Timberlake GA, O'Connell R, Kerstein M. Venous injury. To repair or ligate, the dilemma. *J Vasc Surg*. 1986;4:553.
  91. Timberlake GA, Kerstein MD. Venous injury: to repair or ligate, the dilemma revisited. *Am Surg*. 1995;61:139.
  92. Kuralay E, Demirkilic U, Özal E, et al. A quantitative approach to lower extremity vein repair. *J Vasc Surg*. 2002;36:1213.
  93. Weaver FA, Rosenthal RE, Waterhouse G, et al. Combined vascular and skeletal injuries of the lower extremities. *Am Surg*. 1984;50:189.
  94. Atteberry LR, Dennis JW, Russo-Alesi R, et al. Changing patterns of arterial injuries associated with fractures and dislocations. *J Am Coll Surg*. 1996;183:377.
  95. Cone JB. Vascular injury associated with fracture-dislocations of the lower extremity. *Clin Orthop*. 1989;243:30.
  96. Frykberg ER, Crump JM, Dennis JW, et al. Nonoperative observation of clinically occult arterial injuries: a prospective evaluation. *Surgery*. 1991;109:85.
  97. Lange RH, Bach AW, Hansen ST, et al. Open tibial fractures with associated vascular injuries: prognosis for limb salvage. *J Trauma*. 1985;25:204.
  98. Johansen K, Bandyk D, Thiele B, et al. Temporary intraluminal shunts: resolution of a management dilemma in complex vascular injuries. *J Trauma*. 1982;22:395.
  99. Howe HH, Poole GV, Hansen KJ, et al. Salvage of lower extremities following combined orthopedic and vascular trauma: a predictive salvage index. *Ann Surg*. 1987;53:205.
  100. Durham RM, Mistry BM, Mazuski JE, Shapiro M, Jacobs D. Outcome and utility of scoring systems in the management of the mangled extremity. *Am J Surg*. 1996;172:569.
  101. Bonanni F, Rhodes M, Lucke JF. The futility of predictive scoring of mangled lower extremities. *J Trauma*. 1993;34:99.
  102. Miller HH, Welch CS. Quantitative studies on the time factor in arterial injuries. *Ann Surg*. 1949;130:428.
  103. Manord JD, Garrard CL, Kline DG, et al. Management of severe proximal vascular and neural injury of the upper extremity. *J Vasc Surg*. 1998;27:43.
  104. Treiman GS, Yellin AE, Weaver FA. An effective treatment protocol for intra-arterial drug injection. *J Vasc Surg*. 1990;456.
  105. Yellin AE, Frankhouse JH, Weaver FA. Vascular injury secondary to drug abuse. In: Ernst CB, Stanley JC, eds. *Current Therapy in Vascular Surgery*. 3rd ed. St Louis: Mosby Year Book, 1995;637.
  106. Silverman SH, Turner WW Jr. Intraarterial drug abuse: new treatment options. *J Vasc Surg*. 1991;14:111.
  107. Padberg F Jr, Hobson II R, Lee B, et al. Femoral pseudoaneurysm from drugs of abuse: ligation or reconstruction? *J Vasc Surg*. 1992;15:642.

## 第 156 章

1. Holcomb JB, McMullin NR, Pearse L, et al. Causes of death in US Special Operations Forces in the global war on terrorism 2001-2004. *Ann Surg*. 2007;245:986-991.
2. Starnes BW, Beekley AC, Sebesta JA, et al. Extremity vascular injuries on the battlefield: tips for surgeons deploying to war. *J Trauma*. 2006;60:432-442.

3. Gawande A. Casualties of war—military care for the wounded from Iraq and Afghanistan. *N Engl J Med*. 2004;351:2471-2475.
4. DeBakey ME, Simeone MC. Battle injuries of the arteries in World War II: an analysis of 2,471 cases. *Ann Surg*. 1946;123:534-579.
5. Spencer FC. Historical vignette: the introduction of arterial repair into the US Marine Corps, US Naval Hospital, in July-August 1952. *J Trauma*. 2006;60:906-909.
6. Hughes CW. Arterial repair during the Korean War. *Ann Surg*. 1958;147:555-561.
7. Jahnke EJ, Howard JM. Primary repair of major arterial injuries; report of fifty-eight casualties. *AMA Arch Surg*. 1953;66:646-649.
8. Jahnke EJ, Seeley SF. Acute vascular injuries in the Korean War. *Ann Surg*. 1953;138:158-177.
9. Rich NM, Baugh JH, Hughes CW. Significance of complications associated with vascular repairs performed in Vietnam. *Arch Surg*. 1970;100:646-651.
10. Rich NM. Management of venous injuries. *Ann Surg*. 1970;171:724-730.
11. Rich NM, Baugh JH, Hughes CW. Acute arterial injuries in Vietnam: 1,000 cases. *J Trauma*. 1970;10:359-369.
12. Rich NM, Collins GJ, Andersen CA, McDonald PT. Autogenous venous interposition grafts in repair of major venous injuries. *J Trauma*. 1977;17:512-520.
13. Rich NM, Rhee P. An historical tour of vascular injury management: from its inception to the new millennium. *Surg Clin North Am*. 2001;81:1199-1215.
14. Walters TJ, Wenke JC, Kauvar DS, et al. Effectiveness of self-applied tourniquets in human volunteers. *Prehosp Emerg Care*. 2005;9:416-422.
15. Walters TJ, Mabry RL. Issues related to the use of tourniquets on the battlefield. *Mil Med*. 2005;170:770-775.
16. Wenke JC, Walters TJ, Greydanus DJ, et al. Physiological evaluation of the U.S. Army one-handed tourniquet. *Mil Med*. 2005;170:776-781.
17. Beekley AC. United States military surgical response to modern large-scale conflicts: the ongoing evolution of a trauma system. *Surg Clin North Am*. 2006;86:689-709.
18. Sebesta J. Special lessons learned from Iraq. *Surg Clin North Am*. 2006;86:711-726.
19. Fox CJ, Gillespie DL, O'Donnell SD, et al. Contemporary management of wartime vascular injury. *J Vasc Surg*. 2005;41:638-644.
20. Clouse WD, Rasmussen TE, Peck MA. In-theater management of vascular injury: 2 years of the Balad Vascular Registry. *J Am Coll Surg*. 2007;204:625-632.
21. Fox CJ, Starnes MW. Vascular surgery in the modern battlefield. *Surg Clin North Am*. 2007;87:1193-1211.
22. Woodward EB, Clouse WD, Eliason JL, et al. Penetrating femoropopliteal injury during modern warfare: experience from the Balad Vascular Registry. *J Vasc Surg*. 2008;47:1259-1265.
23. Rasmussen TE, Clouse WD, Jenkins DH, et al. The use of temporary vascular shunts as a damage control adjunct in the management of wartime vascular injury. *J Trauma*. 2006;61:8-12.
24. Rasmussen TE, Clouse WD, Jenkins DH, et al. Echelons of care and the management of wartime vascular injury: a report from the 332nd EMDG/Air Force Theater Hospital Balad Air Base Iraq. *Perspect Vasc Surg Endovasc Ther*. 2006;18:91-99.
25. Peck MA, Clouse WD, Cox MW, et al. The complete management of extremity vascular injury in a local population: a wartime report from the 332nd Expeditionary Medical Group/Air Force Theater Hospital, Balad Air Base, Iraq. *J Vasc Surg*. 2007;45:1197-1204.
26. Rasmussen TE, Clouse WD, Peck MA, et al. Development and implementation of endovascular capabilities in wartime. *J Trauma*. 2008;64:1169-1176.
27. Johnson ON, Fox CJ, O'Donnell SD, et al. Arteriography in the delayed evaluation of wartime extremity injuries. *Vasc Endovasc Surg*. 2007;41:217-224.

28. Coppola CP, Leininger BE, Rasmussen TE, Smith DL. Children treated at an expeditionary military hospital in Iraq. *Arch Pediatr Adolesc Med.* 2006;160:972-976.
29. *Emergency War Surgery*. Third United States Revision Emergency War Surgery NATO Handbook 2004.
30. Ward KR, Tiba MH, Holbert WH, et al. Comparison of a new hemostatic agent to current hemostatic agents in a Swine model of lethal extremity arterial hemorrhage. *J Trauma.* 2007;63:276-283.
31. Acheson EM, Kheirabadi BS, Deguzman R, et al. Comparison of hemorrhage control agents applied to lethal extremity arterial hemorrhages in swine. *J Trauma.* 2005;59:865-874.
32. Alam HB, Chen Z, Jaskille A, et al. Application of a zeolite hemostatic agent achieves 100% survival in a lethal model of complex groin injury in swine. *J Trauma.* 2004;56:974-983.
33. Chambers LW, Rhee P, Baker BC, et al. Initial experience of US Marine Corps forward resuscitative surgical system during Operation Iraqi Freedom. *Arch Surg.* 2005;140:26-32.
34. Rich NM. Vietnam missile wounds evaluated in 750 patients. *Mil Med.* 1968;133:9-22.
35. Dawson DL, Putnam AT, Light JT, et al. Temporary arterial shunts to maintain limb perfusion after arterial injury: an animal study. *J Trauma.* 1999;47:64-71.
36. Cox MW, Whittaker DR, Martinez C, et al. Traumatic pseudoaneurysms of the head and neck: early endovascular intervention. *J Vasc Surg.* 2007;46:1227-1233.
37. Kragh JF Jr, Walters TJ, Baer DG, et al. Practical use of emergency tourniquets to stop bleeding in major limb trauma. *J Trauma.* 2008;64(2 Suppl):S38-S49.
38. Fox CJ, Gillespie DL, Cox ED, et al. The effectiveness of a damage control resuscitation strategy for vascular injury in a combat support hospital: results of a case control study. *J Trauma.* 2008;64(2 Suppl):S99-S106.
39. Kauvar DS, Holcomb JB, Norris GC, Hess JR. Fresh whole blood transfusion: a controversial military practice. *J Trauma.* 2006;61:181-184.
40. Lavenson GS Jr, Rich NM, Strandness DE Jr. Ultrasonic flow detector value in combat vascular injuries. *Arch Surg.* 1971;103:644-647.
41. Johansen K, Daines M, Howey T, et al. Objective criteria accurately predict amputation following lower extremity trauma. *J Trauma.* 1990;30:568-572.
42. Porter JM, Ivatury RR, Nassoura ZE. Extending the horizons of "damage control" in unstable trauma patients beyond the abdomen and gastrointestinal tract. *J Trauma.* 1997;42:559-561.
43. Rich NM, Hughes CW. The fate of prosthetic material used to repair vascular injuries in contaminated wounds. *J Trauma.* 1972;12:459-467.
44. Feliciano DV, Mattox KL, Graham JM, Bitondo CG. Five-year experience with PTFE grafts in vascular wounds. *J Trauma.* 1985;25:71-82.
45. Vaughan GD, Mattox KL, Feliciano DV, et al. Surgical experience with expanded polytetrafluoroethylene (PTFE) as a replacement graft for traumatized vessels. *J Trauma.* 1979;19:403-408.
46. Martin TD, Mattox KL, Feliciano DV. Prosthetic grafts in vascular trauma: a controversy. *Compr Ther.* 1985;11:41-45.
47. Leininger BE, Rasmussen TE, Smith DL, et al. Experience with wound VAC and delayed primary closure of contaminated soft tissue injuries in Iraq. *J Trauma.* 2006;61:1207-1211.
48. Clouse WD, Rasmussen TE, Perlstein J, et al. Upper extremity vascular injury: a current in-theater wartime report from Operation Iraqi Freedom. *Ann Vasc Surg.* 2006;20:429-434.
49. Brigham RA, Eddleman WL, Clagett GP, Rich NM. Isolated venous injury produced by penetrating trauma to the lower extremity. *J Trauma.* 1983;23:255-257.
50. Quan RW, Adams ED, Cox MW, et al. The management of trauma venous injury: civilian and wartime experiences. *Perspect Vasc Surg Endovasc Ther.* 2006;18:149-156.
51. Quan RW, Gillespie DL, Stuart BS, et al. The effect of vein repair on the risk of venous thromboembolic events: a review of

- more than 100 traumatic military venous injuries. *J Vasc Surg*. 2008;47:571-577.
52. Eger M, Golcman L, Goldstein A, et al. The use of a temporary shunt in the management of arterial vascular injuries. *Surg Gynecol Obstet*. 1971;32:67-70.
53. Hossny A. Blunt popliteal artery injury with complete lower limb ischemia: is routine use of temporary intraluminal arterial shunt justified? *J Vasc Surg*. 2004;40:61-66.
54. Sriussadaporn S, Pak-art R. Temporary intravascular shunt in complex extremity vascular injuries. *J Trauma*. 2002;52:1129-1133.
55. Reber PU, Patel AG, Sapio N, et al. Selective use of temporary intravascular shunts in coincident vascular and orthopedic upper and lower limb trauma. *J Trauma*. 1999;47:72-76.
56. Rueben BC, Whitten MG, Sarfati M, Kraiss LW. An increasing use of endovascular therapy in acute arterial injuries: analysis of the national trauma data bank. *J Vasc Surg*. 2007;46:1222-1226.
57. White R, Krajcer Z, Johnson M, et al. Results of a multicenter trial for the treatment of traumatic vascular injury with a covered stent. *J Trauma*. 2006;60:1189-1195.
58. Starnes BW, Arthurs ZM. Endovascular management of vascular trauma. *Perspect Vasc Surg Endovasc Ther*. 2006;18:114-129.
59. Ohki T, Veith FJ, Marin ML, et al. Endovascular approaches for traumatic arterial lesions. *Semin Vasc Surg*. 1997;10:272-285.
60. Patel AV, Marin ML, Veith FJ, et al. Endovascular graft repair of penetrating subclavian artery injuries. *J Endovasc Surg*. 1996;3:382-388.
61. Marin ML, Veith FJ, Panetta TF, et al. Transluminally placed endovascular stented graft repair for arterial trauma. *J Vasc Surg*. 1994;20:466-472.
62. Lin PH, Bush RL, Zhou W, et al. Endovascular treatment of traumatic thoracic aortic injury—should this be the new standard of treatment? *J Vasc Surg*. 2006;43(Suppl A):22A-29A.
63. Johannigman JA. Critical care aeromedical teams (CCATT): then, now and what's next. *J Trauma*. 2007;62(6 Suppl):S35.

## 第 157 章

1. Haimovici H. Peripheral arterial embolism. *Angiology*. 1950;1:2-45.
2. Abbott WM, Maloney RD, McCabe CC, et al. Arterial embolism: a 44 year perspective. *Am J Surg*. 1982;143:460-464.
3. Tawes RL Jr, Harris EJ, Brown WH, et al. Peripheral arterial embolism: a 20 year perspective. *Arch Surg*. 1985;120:595-599.
4. Ward R, Jones D, Haponik E. Paradoxical embolism: an under-recognized problem. *Chest*. 1995;108:549-558.
5. Swartz MF, Lutz CJ, Chandan VS, et al. Atrial myxomas: pathologic types, tumor location, and presenting symptoms. *J Card Surg*. 2006;21:435-440.
6. Mackman N. Triggers, targets and treatments for thrombosis. *Nature*. 2008;451:914-918.
7. Javid M, Magee TR, Galland RB. Arterial thrombosis associated with malignant disease. *Eur J Vasc Endovasc Surg*. 2008;35:84-87.
8. Bowdish ME, Weaver FA, Liebman HA, et al. Anticoagulation is an effective treatment of aortic mural thrombi. *J Vasc Surg*. 2002;36:713-719.
9. Henke PK, Williams DM, Upchurch GR Jr, et al. Acute limb ischemia associated with type B aortic dissection: clinical relevance and therapy. *Surgery*. 2006;140:532-539.
10. Davies B, Braithwaite BD, Birch PA, et al. Acute leg ischaemia in Gloucestershire. *Br J Surg*. 1997;84:504-508.
11. Dryjski M, Swedenborg J. Acute ischemia of the extremities in a metropolitan area during one year. *J Cardiovasc Surg (Torino)*. 1984;25:518-522.
12. Campbell WB, Ridler BM, Szymanska TH. Current management of acute leg ischaemia: results of an audit by the Vascular

- Surgical Society of Great Britain and Ireland. *Br J Surg*. 1998;85:1498-1503.
13. Jivegard L, Wingren U. Management of acute limb ischaemia over two decades: the Swedish experience. *Eur J Vasc Endovasc Surg*. 1999;18:93-95.
  14. Ljungman C, Adami HO, Bergqvist D, et al. Time trends in incidence rates of acute, non-traumatic extremity ischaemia: a population-based study during a 19-year period. *Br J Surg*. 1991;78:857-860.
  15. Cambria RP, Abbott WM. Acute arterial thrombosis of the lower extremity. Its natural history contrasted with arterial embolism. *Arch Surg*. 1984;119:784-787.
  16. Dale W. Differential management of acute peripheral arterial ischaemia. *J Vasc Surg*. 1984;1:269-278.
  17. Jivegård L, Bergqvist D, Holm J. When is urgent revascularization unnecessary for acute lower limb ischaemia? *Eur J Vasc Endovasc Surg*. 1995;9:448-453.
  18. Earnshaw JJ, Hopkinson BR, Makin GS. Acute critical ischaemia of the limb: a prospective evaluation. *Eur J Vasc Surg*. 1990;4:365-368.
  19. Suggested standards for reports dealing with lower extremity ischemia. Prepared by the Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery. *J Vasc Surg*. 1986;4:80-94.
  20. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. *J Vasc Surg*. 1997;26:517-538.
  21. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg*. 2007;45(suppl):S5-S67.
  22. Littooy FN, Baker WH. Acute aortic occlusion: a multifaceted catastrophe. *J Vasc Surg*. 1986;4:211-216.
  23. Galland RB. Popliteal aneurysms: from John Hunter to the 21st century. *Ann R Coll Surg Engl*. 2007;87:466-471.
  24. Mahmood A, Hardy R, Garnham A, et al. Microtibial embolectomy. *Eur J Vasc Endovasc Surg*. 2003;25:35-39.
  25. Gossage JA, Ali T, Chambers J, Burnand KG. Peripheral arterial embolism: prevalence, outcome, and the role of echocardiography in management. *Vasc Endovasc Surg*. 2006;40:280-286.
  26. Egeblad H, Anderson K, Hartiala J, et al. Role of echocardiography in systemic arterial embolism. A review with recommendations. *Scand Cardiovasc J*. 1998;32:323-342.
  27. Berridge DC, Hopkinson BR, Makin GS. Acute lower limb arterial ischaemia: a role for continuous oxygen inhalation. *Br J Surg*. 1989;76:1021-1023.
  28. Linnemann B, Schindewolf M, Zgouras D, et al. Are patients with thrombophilia and previous thromboembolism at higher risk to arterial thrombosis? *Thromb Res*. 2007;3:743-750.
  29. Lijfering WM, Coppens M, van der Poel MH, et al. The risk of arterial and venous thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. *Thromb Haemost*. 2007;98:457-463.
  30. Deitcher SR, Carman TL, Sheikh MA, Gomes M. Hypercoagulable syndromes: evaluation and management strategies for acute limb ischaemia. *Semin Vasc Surg*. 2001;14:74-85.
  31. de Moerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective view. *Semin Haematol*. 2007;44:106-113.
  32. Murray GDW. Heparin in thrombosis and embolism. *Br J Surg*. 1940;27:567-598.
  33. Blaisdell FW, Steele M, Allen RE. Management of acute lower extremity arterial ischaemia due to embolism and thrombosis. *Surgery*. 1978;84:822-834.
  34. Campbell WB, Ridler BM, Szymanska TH. Two year follow-up after acute thromboembolic limb ischaemia: the importance of anticoagulation. *Eur J Vasc Endovasc Surg*. 2000;19:169-173.
  35. Fogarty T, Cranley J, Krause R. A method for extraction of arterial emboli and thrombi. *Surg Gynecol Obstet*. 1963;116:241-244.
  36. Jivegard L, Wingren U. Management of acute limb ischaemia over two decades: the Swedish experience. *Eur J Vasc Endovasc Surg*. 1999;18:93-95.

37. Ljungman C, Holmberg L, Bergqvist D, et al. Amputation risk and survival after embolectomy for acute arterial ischaemia. Time trends in a defined Swedish population. *Eur J Vasc Endovasc Surg*. 1996;11:176-182.
38. Clason AE, Stonebridge PA, Duncan AJ, et al. Acute ischaemia of the lower limb: the effect of centralizing vascular surgical services on morbidity and mortality. *Br J Surg*. 1989;76:592-593.
39. Braithwaite BD, Birch PA, Poskitt KR, et al. Accelerated thrombolysis with high dose bolus t-PA extends the role of peripheral thrombolysis but may increase the risks. *Clin Radiol*. 1995;50:747-750.
40. Armon M, Yusuf SW, Whitaker SC, et al. Results of 100 cases of pulse-spray thrombolysis for acute and sub-acute leg ischaemia. *Br J Surg*. 1997;84:47-50.
41. Ouriel K, Veith FJ, Sasahara AA, for the Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. *N Engl J Med*. 1998;338:1105-1111.
42. Whitman B, Foy C, Earnshaw JJ, on behalf of the Thrombolysis Study Group. National Audit of Thrombolysis of Acute Leg Ischemia (NATALI): clinical factors associated with early outcome. *J Vasc Surg*. 2004;39:1018-1025.
43. Palfreyman SJ, Booth A, Michaels JA. A systematic review of intra-arterial thrombolytic therapy for acute leg ischaemia. *Eur J Vasc Endovasc Surg*. 2000;19:143-157.
44. Whitman B, Parkin D, Earnshaw JJ. Management of acute leg ischaemia. In: Beard JD, eds. *Murray's Pathways of Care in Vascular Surgery*. Vol 12. Shropshire: Tfm Publishing Ltd; 2002:99-102.
45. Ouriel K, Veith FJ. Acute lower limb ischemia: determinants of outcome. *Surgery*. 1998;124:336-341.
46. Jivegard L, Arfvidsson B, Frid I, et al. Cardiac output in patients with acute lower limb ischaemia of presumed embolic origin—a predictor of severity and outcome? *Eur J Vasc Surg*. 1990;4:401-407.
47. Ljungman C, Adami HO, Bergqvist D, et al. Risk factors for early lower limb loss after embolectomy for acute arterial occlusion: a population-based case-control study. *Br J Surg*. 1991;78:1482-1485.
48. Neary B, Whitman B, Foy C, et al. Value of POSSUM scoring to assess outcome after intra-arterial thrombolysis for acute leg ischaemia. *Br J Surg*. 2001;88:1344-1345.
49. Braithwaite BD, Davies B, Birch PA, et al. Management of acute leg ischaemia in the elderly. *Br J Surg*. 1998;85:217-220.
50. Campbell WB. Non intervention and palliative care in vascular patients. *Br J Surg*. 2000;87:1601-1602.
51. Stonebridge PA, Clason AE, Duncan AJ, et al. Acute ischaemia of the upper limb compared with acute lower limb ischaemia; a 5-year review. *Br J Surg*. 1989;76:515-516.
52. Evers P, Earnshaw JJ. Acute non-traumatic arm ischaemia. *Br J Surg*. 1998;85:1340-1346.
53. Joshi V, Harding GE, Bottoni DA, et al. Determination of functional outcome following upper extremity arterial trauma. *Vasc Endovasc Surg*. 2007;41:111-114.
54. Hernandez-Richter T, Angele MK, Helmberger T, et al. Acute ischemia of the upper extremity: long-term results following thromboembolectomy with the Fogarty catheter. *Langenbecks Arch Surg*. 2001;386:261-266.

## 第 158 章

1. Rutherford RB, Baker DJ, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. *J Vasc Surg*. 1997;26:517-538.
2. Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. *J Vasc Surg*. 1994;19:1021-1030.
3. Blaisdell FW, Steele M, Allen RE. Management of acute lower extremity arterial ischemia due to embolism and thrombosis. *Surgery*. 1978;84:822-834.
4. Campbell WB, Rider BMF, Szymanska TH. Current management of acute leg ischemia: results of audit by the Vascular Surgical Society of Great Britain and Ireland. *Br J Surg*. 1998;85:1498-1503.
5. Nypaver TJ, Whyte BR, Endean ED, et al. Nontraumatic lower-extremity acute arterial ischemia. *Am J Surg*.

- 1998;176:147-152.
6. Pemberton M, Varty K, Nydahl S, Bell PR. The surgical management of acute limb ischemia due to native vessel occlusion. *Eur J Vasc Endovasc Surg.* 1999;17:72-76.
  7. Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of a thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. *J Vasc Surg.* 1994;19:1021-1030.
  8. The STILE Trial: results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. *Ann Surg.* 1994;220:251-266.
  9. Ouriel K, Veith FJ, Sasahara AA, for the Thrombolysis or Peripheral Arterial Surgery (TOPAS) investigators. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. *N Engl J Med.* 1998;338:1105-1111.
  10. Wagner H-J, Müller-Hülsbeck S, Pitton MB, et al. Rapid thrombectomy with a hydrodynamic catheter: results from a prospective, multicenter trial. *Radiology.* 1997;205:675-681.
  11. Silva JA, Ramee SR, Collins TJ, et al. Rheolytic thrombectomy in the treatment of acute limb-threatening ischemia: immediate results and six-month follow-up of the multicenter Angiojet registry. *Cathet Cardiovasc Diagn.* 1998;45:386-393.
  12. Henry M, Amor M, Henry I, et al. The Hydrolyser thrombectomy catheter: a single-center experience. *J Endovasc Surg.* 1998;5:24-31.
  13. Sharafuddin MJ, Hicks ME, Jennson ML, et al. Rheolytic thrombectomy with the Angiojet-F105 catheter: preclinical evaluation of safety. *J Vasc Interv Radiol.* 1996;7:445-449.
  14. Castañeda F, Smouse HB, Swischuk JL, et al. Pharmacological thrombolysis with use of the brush catheter in canine thrombosed femoropopliteal arterial PTFE bypass grafts. *J Vasc Interv Radiol.* 2000;11:503-508.
  15. Trerotola SO, Davidson DD, Filo R, et al. Preclinical in vivo testing of a rotational mechanical thrombectomy device. *J Vasc Interv Radiol.* 1996;7:717-723.
  16. Rilinger N, Görich J, Scharrer-Palmer R, et al. Short-term results with use of the Amplatz thrombectomy device in the treatment of acute lower limb occlusion. *J Vasc Interv Radiol.* 1997;8:343-348.
  17. Tadavarthy SM, Murray PD, Inampudi S, et al. Mechanical thrombectomy with the Amplatz device: human experience. *J Vasc Interv Radiol.* 1994;5:715-724.
  18. Kasirajan K, Ramaiah VG, Diethrich EB. The Trellis Thrombectomy System in the treatment of acute limb ischemia. *J Endovasc Ther.* 2003;10:317-321.
  19. Tsetis DK, Katsamouris AN, Androulakakis Z, et al. Use of the Trellis Peripheral Infusion System for enhancement of rt-PA thrombolysis in acute lower limb ischemia. *Cardiovasc Intervent Radiol.* 2003;26:572-575.
  20. Francis CW, Blinc A, Lee S, Cox C. Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. *Ultrasound Med Biol.* 1995;21:419-424.
  21. Wissgott C, Richter A, Kamusella P, Steinkamp HJ. Treatment of critical limb ischemia using ultrasound-enhanced thrombolysis (PARES Trial): final results. *J Endovasc Ther.* 2007;14:438-443.
  22. Braithwaite BD, Davies B, Birch PA, et al. Management of acute leg ischemia in the elderly. *Br J Surg.* 1998;85:217-220.
  23. Kasirajan K, Gray B, Beavers FP, et al. Rheolytic thrombectomy in the management of acute and subacute limb threatening ischemia. *J Vasc Interv Radiol.* 2001;12:413-421.
  24. Hilleman D, Arko FR, Zarins CK, Ouriel K. Clinical and economic evaluation of the Trellis thrombectomy device for arterial occlusions: preliminary analysis. *J Vasc Surg.* 2004;39:556-559.
  25. Höpfner W, Vicol C, Bohndorf K, Loeprecht H. Shredding embolectomy thrombectomy catheter for treatment of acute lower-limb ischemia. *Ann Vasc Surg.* 1999;13:426-435.
  26. Müller-Hülsbeck S, Kalinowski M, Heller M, et al. Rheolytic hydrodynamic thrombectomy for percutaneous treatment of acutely occluded infra-aortic native arteries and bypass grafts: midterm follow-up results. *Invest Radiol.* 2000;35:131-140.
  27. Kasirajan K, Ouriel K. Management of acute lower extremity ischemia; treatment strategies and outcomes. *Curr Intervent*



- Cardiol Rep.* 2000;2:119-129.
28. Reekers JA, Kromhout JG, Spithoven HG, et al. Arterial thrombosis below the inguinal ligament: percutaneous treatment with a thrombosuction catheter. *Radiology.* 1996;198:49-53.
  29. Henry M, Amor M, Henry I, et al. The Hydrolyser thrombectomy catheter: a single-center experience. *J Endovasc Surg.* 1998;5:24-31.
  30. Görich J, Rilinger N, Sokiranski R, et al. Mechanical thrombectomy of acute occlusions of both the superficial and the deep femoral arteries using a thrombectomy device. *AJR Am J Roentgenol.* 1998;170:1177-1180.
  31. Fogarty TJ, Cranley JJ, Krause RJ, et al. A method for extraction of arterial emboli and thrombi. *Surg Gynecol Obstet.* 1963;116:241-244.

## 第 159 章

1. Hargens AR, Akeson WH, Mubarak SJ, et al. Fluid balance with the canine anterolateral compartment and its relationship to compartment syndromes. *J Bone Joint Surg Am.* 1978;60:499-505.
2. Matsen FA III. Compartment syndrome: a unified concept. *Clin Orthop.* 1975;113:8-14.
3. Hartsock LA, O'Farrell D, Seaber AV, Urbaniak JR. Effect of increased compartment pressure on the microcirculation of skeletal muscle. *Microsurgery.* 1998;18:67-71.
4. Vollmar B, Westernmann S, Menger MD. Microvascular response to compartment syndrome-like external pressure elevation: an in vivo fluorescence microscopic study in the hamster striated muscle. *J Trauma.* 1999;46:91-96.
5. Hargens AR, Schmidt DA, Evans KL, et al. Quantitation of skeletal-muscle necrosis in a model compartment syndrome. *J Bone Joint Surg Am.* 1981;63:631-636.
6. Rydevik B, Lundborg G, Bagge U. Effects of graded compression on intraneural blood flow. An in vivo study on rabbit tibial nerve. *J Hand Surg (Am).* 1981;6:3-12.
7. Lundborg G, Myers R, Powell H. Nerve compression injury and increased endoneurial fluid pressure: a "miniature compartment syndrome." *J Neurol Neurosurg Psychiatry.* 1983;46:1119-1124.
8. Heppenstall RB, Sapega AA, Scott R, et al. The compartment syndrome. An experimental and clinical study of muscular energy metabolism using phosphorus nuclear magnetic resonance spectroscopy. *Clin Orthop.* 1988;226:138-155.
9. Heckman MM, Whitesides TE Jr, Grewe SR, et al. Histologic determination of the ischemic threshold of muscle in the canine compartment syndrome model. *J Orthop Trauma.* 1993;7:199-210.
10. McQueen MM, Court-Brown CM. Compartment monitoring in tibial fractures. The pressure threshold for decompression. *J Bone Joint Surg Br.* 1996;78:99-104.
11. Papalambros EL, Panayiotopoulos YP, Bastounis E, et al. Prophylactic fasciotomy of the legs following acute arterial occlusion procedures. *Int Angiol.* 1989;8:120-124.
12. Bates GJ, Askew AR. Arterial embolectomy: a review of 100 cases. *Aust N Z J Surg.* 1984;54:137-140.
13. Sexton WL, Korthuis RJ, Laughlin MH. Ischemia-reperfusion injury in isolated rat hindquarters. *J Appl Physiol.* 1990;68:387-392.
14. Abouezzi Z, Nassoura Z, Ivatury RR, et al. A critical reappraisal of indications for fasciotomy after extremity vascular trauma. *Arch Surg.* 1998;133:547-551.
15. Qvaeford PG, Eklof B, Ohlin P. Intramuscular pressure in the lower leg in deep vein thrombosis and plegmasia cerulea dolens. *Ann Surg.* 1983;197:450-453.
16. Modrall JG, Sadjadi J, Ali AT, et al. Deep vein harvest: predicting need for fasciotomy. *J Vasc Surg.* 2004;39:387-394.
17. Illig KA, Eagleton MJ, Shortell CK, et al. Ruptured popliteal artery aneurysm. *J Vasc Surg.* 1998;27:783-787.
18. Nadeem RD, Clift BA, Martindale JP, et al. Acute compartment syndrome of the thigh after joint replacement with anticoagulation. *J Bone Joint Surg Br.* 1998;80:866-868.
19. McQueen MM, Christie J, Court-Brown CM. Acute compartment syndrome in tibial diaphyseal fractures. *J Bone Joint Surg*

- Br. 1996;78:95-98.
20. Blick SS, Brumback RJ, Poka A, et al. Compartment syndrome in open tibial fractures. *J Bone Joint Surg Am.* 1986;68:1348-1353.
  21. Mullet H, Al Abed K, Prasad CV, O'Sullivan M. Outcome of compartment syndrome following intramedullary nailing of tibial diaphyseal fractures. *Injury.* 2001;32:411-413.
  22. Malinoski DJ, Slater MS, Mullins RJ. Crush injury and rhabdomyolysis. *Crit Care Clin.* 2004;20:171-192.
  23. Mubarak S, Owen CA. Compartmental syndrome and its relation to the crush syndrome: a spectrum of disease. A review of 11 cases of prolonged limb compression. *Clin Orthop.* 1975;113:81-89.
  24. Ward MM. Factors predictive of acute renal failure in rhabdomyolysis. *Arch Intern Med.* 1988;148:1553-1557.
  25. Ouellette EA, Kelly R. Compartment syndromes in the hand. *J Bone Joint Surg Am.* 1996;78:1515-1522.
  26. Luce EA, Futrell JW, Wilgis EF, Hoopes JE. Compression neuropathy following brachial arterial puncture in anticoagulated patients. *J Trauma.* 1976;16:717-721.
  27. Seiler JG, Valadie AL, Drvaric DM, et al. Perioperative compartment syndrome. A report of four cases. *J Bone Joint Surg Am.* 1996;78:600-602.
  28. Wassenaar EB, van den Brand JG, van der Werken C. Compartment syndrome of the lower leg after surgery in the modified lithotomy position: report of seven cases. *Dis Colon Rectum.* 2006;49:1449-1453.
  29. Chow CE, Friedell ML, Freeland MB, Dejesus S. A pitfall of protracted surgery in the lithotomy position: lower extremity compartment syndrome. *Am Surg.* 2007;73:19-21.
  30. Tremblay LN, Feliciano DV, Rozycki GS. Secondary extremity compartment syndrome. *J Trauma.* 2002;53:833-837.
  31. Jensen SL, Sandermann J. Compartment syndrome and fasciotomy in vascular surgery. A review of 57 cases. *Eur J Vasc Endovasc Surg.* 1997;13:48-53.
  32. Gelberman RH, Garfin SR, Hergenroeder PT, et al. Compartment syndromes of the forearm: diagnosis and treatment. *Clin Orthop.* 1981;161:252-261.
  33. Ulmer T. The clinical diagnosis of compartment syndrome of the lower legs: Are clinical findings predictive of the disorder? *J Orthop Trauma.* 2002;16:572-577.
  34. Boody AR, Wongworawat MD. Accuracy in the measurement of compartment pressures: a comparison of three commonly used devices. *J Bone Joint Surg Am.* 2005;87:2415-2422.
  35. Giannotti G, Cohn SM, Brown M, et al. Utility of near-infrared spectroscopy in the diagnosis of lower extremity compartment syndrome. *J Trauma.* 2000;48:399-401.
  36. Abraham P, Leftheriotis G, Saumet JL. Laser Doppler flowmetry in the diagnosis of chronic compartment syndrome. *J Bone Joint Surg Br.* 1998;80:365-369.
  37. Spinner M, Aiache A, Silver L, Barsky AJ. Impending ischemic contracture of the hand. Early diagnosis and management. *Plast Reconstr Surg.* 1972;50:341-349.
  38. McQueen MM, Gaston P, Court-Brown CM. Acute compartment syndrome. Who is at risk? *J Bone Joint Surg Br.* 2000;82:200-203.
  39. Mithöfer K, Lhowe DW, Vrahas MS, et al. Clinical spectrum of acute compartment syndrome of the thigh and its relation to associated injuries. *Clin Orthop.* 2004;425:223-229.
  40. Nau T, Menth-Chiari WA, Seitz H, Vecsei V. Acute compartment syndrome of the thigh associated with exercise. *Am J Sports Med.* 2000;28:120-122.
  41. Su WT, Stone DH, Lamparello PJ, Rockman CB. Gluteal compartment syndrome following elective unilateral internal iliac artery embolization before endovascular abdominal aortic aneurysm repair. *J Vasc Surg.* 2004;39:672-675.
  42. Determination of the compartment pressure threshold of muscle ischemia in a canine model. *J Trauma.* 1994;37:50-58.
  43. Heyn J, Ladurner R, Ozimek A, et al. Gluteal compartment syndrome after prostatectomy caused by incorrect positioning. *Eur J Med Res.* 2006;11:170-173.

44. Pai VS. Compartment syndrome of the buttock following a total hip arthroplasty. *J Arthroplasty*. 1996;11:609-610.
45. Perler BA, Tohmeh AG, Bulkey GB. Inhibition of the compartment syndrome by the ablation of free radical-mediated reperfusion injury. *Surgery*. 1990;108:40-47.
46. Hutton M, Rhodes RS, Chapman G. Lowering of postischemic compartment pressures with mannitol. *J Surg Res*. 1982;32:239-242.
47. Ricci MA, Graham AM, Corbisiero R, et al. Are free radical scavengers beneficial in the treatment of compartment syndrome after acute arterial ischemia? *J Vasc Surg*. 1989;9:244-250.
48. Dabby D, Greif F, Yaniv M, et al. Thromboxane A2 in postischemic acute compartment syndrome. *Arch Surg*. 1998;133:953-956.
49. Buchbinder D, Karmody AM, Leather RP, Shah DM. Hypertonic mannitol: its use in the prevention of revascularization syndrome after acute arterial ischemia. *Arch Surg*. 1981;116:414-421.
50. Shah DM, Boch DE, Darling RC, et al. Beneficial effects of hypertonic mannitol in acute ischemia-reperfusion injuries in humans. *Cardiovasc Surg*. 1996;4:97-100.
51. Mars M, Hadley GP. Raised intracompartmental pressure and compartment syndromes. *Injury*. 1998;6:403-411.
52. Oda J, Tanaka H, Yoshioka T, et al. Analysis of 372 patients with crush syndrome caused by Hanshin-Awaji earthquake. *J Trauma*. 1997;42:470-476.
53. Forni L, Hilton P. Continuous hemofiltration in the treatment of acute renal failure. *N Engl J Med*. 1997;336:1303-1309.
54. Zager R. Studies of mechanisms and protein maneuvers in myoglobinuric acute renal injury. *Lab Invest*. 1989;60:619-629.
55. Odeh M. The role of reperfusion-induced injury in the pathogenesis of the crush syndrome. *N Engl J Med*. 1991;324:1417-1422.
56. Adiseshiah M, Round J, Jones D. Reperfusion injury in skeletal muscle: a prospective study in patients with acute limb ischemia and claudication treated by revascularization. *Br J Surg*. 1992;79:1026-1029.
57. Brown C, Rhee P, Chan L, et al. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference? *J Trauma*. 2004;56:1191-1196.
58. Zager R. Rhabdomyolysis and myohemoglobinuric acute renal failure. *Kidney Int*. 1996;49:314-326.
59. Curry S, Change D, Connor D. Drug and toxin-induced rhabdomyolysis. *Ann Emerg Med*. 1989;18:1068-1084.
60. Ron D, Taitelman U, Michaelson M, et al. Prevention of acute renal failure in traumatic rhabdomyolysis. *Arch Intern Med*. 1984;144:277-280.
61. Amyot SL, Leblanc M, Thibeault Y, et al. Myoglobin clearance and removal during continuous venovenous hemofiltration. *Intensive Care Med*. 1999;25:1169-1172.
62. Cooper GG. A method of single-incision, four compartment fasciotomy of the leg. *Eur J Vasc Surg*. 1992;6:659-661.
63. Mubarak SJ, Owens CA. Double-incision fasciotomy of the leg for decompression in compartment syndromes. *J Bone Joint Surg Am*. 1977;59:184-187.
64. Davey JR, Rorabeck CH, Fowler PJ. The tibialis posterior muscle compartment: an unrecognized cause of exertional compartment syndrome. *Am J Sports Med*. 1984;12:391-397.
65. Cohen MS, Garfin SR, Hargens AR, Mubarak SJ. Acute compartment syndrome. Effect of dermatomy on fascial decompression in the leg. *J Bone Joint Surg Br*. 1991;73:287-290.
66. Patman RD. Compartmental syndromes in peripheral vascular surgery. *Clin Orthop*. 1975;113:103-110.
67. Tarlow SD, Achterman CA, Hayhurst J, Ovadia DN. Acute compartment syndrome in the thigh complicating fracture of the femur. *J Bone Joint Surg Am*. 1986;68:1439-1443.
68. Myerson MS. Experimental decompression of the fascial compartments of the foot—the basis for fasciotomy in acute compartment syndromes. *Foot Ankle*. 1988;8:308-314.
69. Myerson MS. Management of compartment syndromes of the foot. *Clin Orthop*. 1991;271:239-248.
70. Owen CA, Woody PR, Mubarak SJ, Hargens AR. Gluteal compartment syndromes. A report of three cases and management

- utilizing the wick catheter. *Clin Orthop*. 1978;132:57-60.
71. Schmalzried TP, Neal WC, Eckardt JJ. Gluteal compartment syndrome and crush syndromes. Report of three cases and review of the literature. *Clin Orthop*. 1992;277:161-165.
  72. Gelberman RH, Zakaib GS, Mubarak SJ, et al. Decompression of forearm compartment syndromes. *Clin Orthop*. 1978;134:225-229.
  73. Johnson SB, Weaver FA, Yellin AE, et al. Clinical results of decompressive dermatomy-fasciotomy. *Am J Surg*. 1992;164:286-290.
  74. Velmahos GC, Theodorou D, Demetriades D, et al. Complications and nonclosure rates of fasciotomy for trauma and related risk factors. *World J Surg*. 1997;21:247-253.
  75. Wiger P, Tkaczuk P, Styf J. Secondary wound closure following fasciotomy for acute compartment syndrome increases intramuscular pressure. *J Orthop Trauma*. 1998;12:117-121.
  76. van der Velde M, Hudson DA. VADER (vacuum-assisted dermal recruitment): a new method of wound closure. *Ann Plast Surg*. 2005;55:660-664.
  77. Weiland DE. Fasciotomy closure using simultaneous vacuum-assisted closure and hyperbaric oxygen. *Am Surg*. 2007;73:261-266.
  78. Gomoll AH, Lin A, Harris MB. Incisional vacuum-assisted closure therapy. *J Orthop Trauma*. 2006;20:705-709.
  79. Narayanan K, Futrell J, Bentz M, Hurwitz D. Comparative clinical study of the Sure-Closure device with conventional wound closure techniques. *Ann Plast Surg*. 1995;35:485-491.
  80. Janzing HMJ, Broos PLO. Dematotraction: an effective technique for the closure of fasciotomy wounds: a preliminary report of fifteen patients. *J Orthop Trauma*. 2001;15:438-441.
  81. Barnea Y, Gur E, Amir A, et al. Our experience with Wisebands: a new skin and soft-tissue stretch device. *Plast Reconstr Surg*. 2004;113:862-869.
  82. Zorrilla P, Marin A, Gomez LA, Salido JA. Shoelace technique for gradual closure of fasciotomy wounds. *J Trauma*. 2005;59:1515-1517.
  83. Berman SS, Schilling JD, McIntyre KE, et al. Shoelace technique for delayed primary closure of fasciotomies. *Am J Surg*. 1994;167:435-436.
  84. Sheridan GW, Matsen FA III. Fasciotomy in the treatment of the acute compartment syndrome. *J Bone Joint Surg Am*. 1976;58:112-115.
  85. Fitzgerald AM, Gaston P, Wilson Y, et al. Long-term sequelae of fasciotomy wounds. *Br J Plast Surg*. 2000;53:690-693.
  86. Heemskerk J, Kitslaar P. Acute compartment syndrome of the lower leg: retrospective study on prevalence, technique, and outcome of fasciotomies. *World J Surg*. 2003;27:744-747.
  87. Finkelstein JA, Hunter GA, Hu RW. Lower limb compartment syndrome: course after delayed fasciotomy. *J Trauma*. 1996;40:342-344.
  88. Bermudez K, Knudeson MM, Morabito D, Kessel O. Fasciotomy, chronic venous insufficiency, and calf muscle pump. *Arch Surg*. 1998;133:1356-1361.
  89. Akmal M, Massry S. Reversible hepatic dysfunction associated with rhabdomyolysis. *Am J Nephrol*. 1990;10:49-52.
  90. Rush DS, Frame SB, Bell RM, et al. Does open fasciotomy contribute to morbidity and mortality after acute lower extremity ischemia and revascularization? *J Vasc Surg*. 1989;10:343-350.
  91. Lagerstrom CF, Reed RL, Rowlands BJ, Fischer RP. Early fasciotomy for acute clinically evident posttraumatic compartment syndrome. *Am J Surg*. 1989;158:36-39.
  92. Williams AB, Luchette FA, Papacontantinou HT, et al. The effect of early versus late fasciotomy in the management of extremity trauma. *Surgery*. 1997;122:861-866.
  93. Mubarak SJ, Carroll NC. Volkmann's contracture in children: aetiology and prevention. *J Bone Joint Surg Br*. 1997;61:285-293.

94. Tsuge K. Treatment of established Volkmann's contracture. *J Bone Joint Surg Am.* 1975;57:925-929.
95. Blackman PG. A review of chronic exertional compartment syndrome in the leg. *Med Sci Sports Exerc.* 2000;32:S4-S10.
96. Turnipseed WD. Clinical review of patients treated for atypical claudication: a 28-year experience. *J Vasc Surg.* 2008;40:79-85.
97. Mohler LR, Styf JR, Pedowitz RA, et al. Intramuscular deoxygenation during exercise in patients who have chronic anterior compartment syndrome of the leg. *J Bone Joint Surg Am.* 1997;79:844-849.
98. Edmundsson D, Toolanen G, Sojka P. Chronic compartment syndrome also affects non-athletic subjects. *Acta Orthop.* 2007;78:136-142.
99. Pedowitz RA, Hargens AR, Mubarak SJ, Geschuni DH. Modified criteria for the objective diagnosis of chronic compartment syndrome of the leg. *Am J Sports Med.* 1990;18:35-40.

## 第 160 章

1. Olin JW. Atheroembolic renal disease: underdiagnosed and misunderstood. *Catheter Cardiovasc Interv.* 2007;70:789-790.
2. Moolenaar W, Lamers CB. Cholesterol crystal embolization in the Netherlands. *Arch Intern Med.* 1996;156:653-657.
3. Cross SS. How common is cholesterol embolism? *J Clin Pathol.* 1991;44:859-861.
4. Rhodes JM. Cholesterol crystal embolism: an important "new" diagnosis for the general physician. *Lancet.* 1996;347:1641.
5. Ghannem M, Philippe J, Ressay A, et al. Systemic cholesterol embolism. *Ann Cardiol Angeiol (Paris).* 1995;44:422-426.
6. Moolenaar W, Lamers CB. Gastrointestinal blood loss due to cholesterol crystal embolization. *J Clin Gastroenterol.* 1995;21:220-223.
7. Blauth CI, Cosgrove DM, Webb BW, et al. Atheroembolism from the ascending aorta. An emerging problem in cardiac surgery. *J Thorac Cardiovasc Surg.* 1992;103:1104-1111.
8. Ramirez G, O'Neill WM Jr, Lambert R, Bloomer HA. Cholesterol embolization: a complication of angiography. *Arch Intern Med.* 1978;138:1430-1432.
9. Belenfant X, Meyrier A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. *Am J Kidney Dis.* 1999;33:840-850.
10. Hollenhorst RW. Vascular status of patients who have cholesterol emboli in the retina. *Am J Ophthalmol.* 1966;61:1159-1165.
11. Mayo RR, Swartz RD. Redefining the incidence of clinically detectable atheroembolism. *Am J Med.* 1996;100:524-529.
12. Scolari F, Tardanico R, Zani R, et al. Cholesterol crystal embolism: a recognizable cause of renal disease. *Am J Kidney Dis.* 2000;36:1089-1109.
13. Lie JT. Cholesterol atheromatous embolism. The great masquerader revisited. *Pathol Annu.* 1992;27:17-50.
14. Panum P. Experimentelle Beiträge zur Lehre von der Embolie. *Arch Pathol Anat Physiol Klin Med.* 1862;25:308-310.
15. Flory C. Arterial occlusions produced by emboli from eroded aortic atheromatous plaques. *Am J Pathol.* 1945;21:549-565.
16. Arroyo LH, Lee RT. Mechanisms of plaque rupture: mechanical and biologic interactions. *Cardiovasc Res.* 1999;41:369-375.
17. Bartholomew JR, Olin JW. Atheromatous embolization. In: Young JR, Olin JW, Bartholomew JR, eds. *Peripheral Vascular Diseases*. 2nd ed. St. Louis: C.V. Mosby; 1996.
18. Pennington M, Yeager J, Skelton H, Smith KJ. Cholesterol embolization syndrome: cutaneous histopathological features and the variable onset of symptoms in patients with different risk factors. *Br J Dermatol.* 2002;146:511-517.
19. Jones DB, Iannaccone PM. Atheromatous emboli in renal biopsies. An ultrastructural study. *Am J Pathol.* 1975;78:261-276.
20. Kang K, Botella R, White CR, Jr. Subtle clues to the diagnosis of cholesterol embolism. *Am J Dermatopathol.* 1996;18:380-384.
21. Thadhani RI, Camargo CA Jr, Xavier RJ, et al. Atheroembolic renal failure after invasive procedures. Natural history based

- on 52 histologically proven cases. *Medicine (Baltimore)*. 1995;74:350-358.
22. Fabbian F, Catalano C, Lambertini D, et al. A possible role of corticosteroids in cholesterol crystal embolization. *Nephron*. 1999;83:189-190.
  23. Mittal BV, Alexander MP, Rennke HG, Singh AK. Atheroembolic renal disease: a silent masquerader. *Kidney Int*. 2008;73:126-130.
  24. Scolari F, Ravani P, Gaggi R, et al. The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors. *Circulation*. 2007;116:298-304.
  25. Piriou V, Claudel JP, Bastien O, et al. Severe systemic cholesterol embolization after open heart surgery. *Br J Anaesth*. 1996;77:277-280.
  26. Doty JR, Wilentz RE, Salazar JD, et al. Atheroembolism in cardiac surgery. *Ann Thorac Surg*. 2003;75:1221-1226.
  27. Scolari F, Bracchi M, Valzorio B, et al. Cholesterol atheromatous embolism: an increasingly recognized cause of acute renal failure. *Nephrol Dial Transplant*. 1996;11:1607-1612.
  28. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 24-1998. A 76-year-old woman with cardiac and renal failure and gastrointestinal bleeding. *N Engl J Med*. 1998;339:329-337.
  29. Moll S, Huffman J. Cholesterol emboli associated with warfarin treatment. *Am J Hematol*. 2004;77:194-195.
  30. Turnbull RG, Hayashi AH, McLean DR. Multiple spontaneous intestinal perforations from atheroembolism after thrombolytic therapy: a case report. *Can J Surg*. 1994;37:325-328.
  31. Rivera-Manrique E, Castro-Salomó A, Azón-Masoliver A, Marin LM. Cholesterol embolism: a fatal complication after thrombolytic therapy for acute myocardial infarction. *Arch Intern Med*. 1998;158:1575.
  32. Izumi C, Kondo H, Tamura T, et al. [Clinical evaluation of cholesterol embolization syndrome after cardiac catheterization]. *J Cardiol*. 1998;31:201-206.
  33. Adorati M, Pizzolitto S, Franzon R, et al. Cholesterol embolism and acute interstitial nephritis: two adverse effects of streptokinase thrombolytic therapy in the same patient. *Nephrol Dial Transplant*. 1998;13:1262-1264.
  34. Sarwar S, Al Absi A, Wall BM. Catastrophic cholesterol crystal embolization after endovascular stent placement for peripheral vascular disease. *Am J Med Sci*. 2008;335:403-406.
  35. Edwards MS, Corriere MA, Craven TE, et al. Atheroembolism during percutaneous renal artery revascularization. *J Vasc Surg*. 2007;46:55-61.
  36. Hiramoto J, Hansen KJ, Pan XM, et al. Atheroemboli during renal artery angioplasty: an ex vivo study. *J Vasc Surg*. 2005;41:1026-1030.
  37. Keeley EC, Grines CL. Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases. *J Am Coll Cardiol*. 1998;32:1861-1865.
  38. Eggebrecht H, Oldenburg O, Dirsch O, et al. Potential embolization by atherosclerotic debris dislodged from aortic wall during cardiac catheterization: histological and clinical findings in 7,621 patients. *Catheter Cardiovasc Interv*. 2000;49:389-394.
  39. Drost H, Buis B, Haan D, Hillers JA. Cholesterol embolism as a complication of left heart catheterisation. Report of seven cases. *Br Heart J*. 1984;52:339-342.
  40. Colt HG, Begg RJ, Saporito JJ, et al. Cholesterol emboli after cardiac catheterization. Eight cases and a review of the literature. *Medicine (Baltimore)*. 1988;67:389-400.
  41. Saklayen MG, Gupta S, Suryaprasad A, Azmeh W. Incidence of atheroembolic renal failure after coronary angiography. A prospective study. *Angiology*. 1997;48:609-613.
  42. Fukumoto Y, Tsutsui H, Tsuchihashi M, et al. Cholesterol Embolism Study (CHEST) Investigators. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. *J Am Coll Cardiol*. 2003;42:211-216.
  43. Shmuely H, Zoldan J, Sagie A, et al. Acute stroke after coronary angiography associated with protruding mobile thoracic

- aortic atheromas. *Neurology*. 1997;49:1689-1691.
44. The French Study of Aortic Plaques in Stroke Group. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. *N Engl J Med*. 1996;334:1216-1221.
  45. Farah B, Prendergast B, Garbarz E, et al. Antegrade transseptal coronary angiography: an alternative technique in severe vascular disease. *Catheter Cardiovasc Interv*. 1998;43:444-446.
  46. Kiemeneij F, Laarman GJ, Odekerken D, et al. A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches: the Access Study. *J Am Coll Cardiol*. 1997;29:1269-1275.
  47. Kiemeneij F, Laarman GJ, Slagboom T, van der Wieken R. Outpatient coronary stent implantation. *J Am Coll Cardiol*. 1997;29:323-327.
  48. Safian RD, Freed MS. *The Manual of Interventional Cardiology*. Boston: Physicians' Press, 2001.
  49. Johnson LW, Esente P, Giambartolomei A, et al. Peripheral vascular complications of coronary angioplasty by the femoral and brachial techniques. *Cathet Cardiovasc Diagn*. 1994;31:165-172.
  50. Rosansky SJ. Multiple cholesterol emboli syndrome after angiography. *AJR Am J Roentgenol*. 1984;143:683.
  51. Feldman RL, Wargovich TJ, Bittl JA. No-touch technique for reducing aortic wall trauma during renal artery stenting. *Catheter Cardiovasc Interv*. 1999;46:245-248.
  52. Lin PH, Bush RL, Conklin BS, et al. Late complication of aortoiliac stent placement—atheroembolization of the lower extremities. *J Surg Res*. 2002;103:153-159.
  53. Toogood GJ, Torrie EP, Magee TR, Galland RB. Early experience with stenting for iliac occlusive disease. *Eur J Vasc Endovasc Surg*. 1998;15:165-168.
  54. Ballard JL, Bergan JJ, Singh P, et al. Aortoiliac stent deployment versus surgical reconstruction: analysis of outcome and cost. *J Vasc Surg*. 1998;28:94-103.
  55. Kawarada O, Yokoi Y, Takemoto K. The characteristics of dissemination of embolic materials during renal artery stenting. *Catheter Cardiovasc Interv*. 2007;70:784-788.
  56. Roubin GS, New G, Iyer SS, et al. Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis. *Circulation*. 2001;103:532-537.
  57. Henry M, Henry I, Polydorou A, et al. Endovascular treatment of a renal artery stenosis: techniques, indications, results. Role of embolic protection devices (part 4). *Angiol Sosud Khir*. 2007;13:57-66.
  58. Henry M, Henry I, Polydorou A, et al. Recent advances in renal artery stenting. *J Cardiovasc Surg (Torino)*. 2007;48:411-442.
  59. Henry M, Polydorou A, Henry I, et al. New distal embolic protection device—the FiberNet 3 dimensional filter: first carotid human study. *Catheter Cardiovasc Interv*. 2007;69:1026-1035.
  60. Henry M, Klonaris C, Henry I, et al. Protected renal stenting with the PercuSurge GuardWire Device: a pilot study. *J Endovasc Ther*. 2001;8:227-237.
  61. Holden A, Hill A, Jaff MR, Pilmore H. Renal artery stent revascularization with embolic protection in patients with ischemic nephropathy. *Kidney Int*. 2006;70:948-955.
  62. Cooper CJ, Haller ST, Colyer W, et al. Embolic protection and platelet inhibition during renal artery stenting. *Circulation*. 2008;117:2752-2760.
  63. Dubel GJ, Murphy TP. Distal embolic protection for renal arterial interventions. *Cardiovasc Intervent Radiol*. 2008;31:14-22.
  64. Thurlbeck WM, Castleman B. Atheromatous emboli to the kidneys after aortic surgery. *N Engl J Med*. 1957;257:442-447.
  65. Kolh PH, Torchiana DF, Buckley MJ. Atheroembolization in cardiac surgery. The need for preoperative diagnosis. *J Cardiovasc Surg (Torino)*. 1999;40:77-81.
  66. Davila-Roman VG, Westerhausen D, Hopkins WE, et al. Transesophageal echocardiography in the detection of cardiovascular sources of peripheral vascular embolism. *Ann Vasc Surg*. 1995;9:252-260.

67. Tenenbaum A, Garniek A, Shemesh J, et al. Dual-helical CT for detecting aortic atheromas as a source of stroke: comparison with transesophageal echocardiography. *Radiology*. 1998;208:153-158.
68. Kaufman JL. Atheroembolism and microthromboembolic syndromes (blue toe syndrome and disseminated atheroembolism). In: Rutherford RB, ed. *Vascular Surgery*. 5th ed. Philadelphia: WB Saunders; 2000:836-845.
69. Kassirer JP. Atheroembolic renal disease. *N Engl J Med*. 1969;280:812-818.
70. Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. *Angiology*. 1987;38:769-784.
71. Lye WC, Cheah JS, Sinniah R. Renal cholesterol embolic disease. Case report and review of the literature. *Am J Nephrol*. 1993;13:489-493.
72. Saleem S, Lakkis FG, Martinez-Maldonado M. Atheroembolic renal disease. *Semin Nephrol*. 1996;16:309-318.
73. Dahlberg PJ, Frecentese DF, Cogbill TH. Cholesterol embolism: experience with 22 histologically proven cases. *Surgery*. 1989;105:737-746.
74. Blackshear JL, Oldenburg WA, Cohen MD. Making the diagnosis when the patient has "blue toes." *Geriatrics*. 1994;49:37-39, 43-45.
75. Blankenship JC, Butler M, Garbes A. Prospective assessment of cholesterol embolization in patients with acute myocardial infarction treated with thrombolytic vs conservative therapy. *Chest*. 1995;107:662-668.
76. Donohue K, Saap L, Falanga V. Cholesterol crystal embolization: an atherosclerotic disease with frequent and varied cutaneous manifestations. *J Eur Acad Dermatol Venereol*. 2003;17:504-511.
77. Saklayen MG. Atheroembolic renal disease: preferential occurrence in whites only. *Am J Nephrol*. 1989;9:87-88.
78. Meyrier A. Cholesterol crystal embolism: diagnosis and treatment. *Kidney Int*. 2006;69:1308-1312.
79. Rose R, Bartholomew JR, Olin JW. Atheromatous embolization syndrome. Rutherford RB, ed. *Vascular Surgery*. 6th ed. Philadelphia: WB Saunders; 2005:986-999.
80. Falanga V, Fine MJ, Kapoor WN. The cutaneous manifestations of cholesterol crystal embolization. *Arch Dermatol*. 1986;122:1194-1198.
81. Jugla A, Moreso F, Muniesa C, et al. Cholesterol embolism: still an unrecognized entity with a high mortality rate. *J Am Acad Dermatol*. 2006;55:786-793.
82. Chaudhary K, Wall BM, Rasberry RD. Livedo reticularis: an underutilized diagnostic clue in cholesterol embolization syndrome. *Am J Med Sci*. 2001;321:348-351.
83. Callen JP, Greer KE, Paller AS, Swinyer LJ. *Color Atlas of Dermatology*. 2nd ed. Philadelphia: WB Saunders; 2000.
84. Schanz S, Metzler G, Metzger S, et al. Cholesterol embolism: an often unrecognized cause of leg ulcers. *Br J Dermatol*. 2002;146:1107-1108.
85. Rosansky SJ. Multiple cholesterol emboli syndrome. *South Med J*. 1982;75:677-680.
86. Modi KS, Rao VK. Atheroembolic renal disease. *J Am Soc Nephrol*. 2001;12:1781-1787.
87. Ripple MG, Charney D, Nadasdy T. Cholesterol embolization in renal allografts. *Transplantation*. 2000;69:2221-2225.
88. Dalakos TG, Streeten DH, Jones D, Obeid A. "Malignant" hypertension resulting from atheromatous embolization predominantly of one kidney. *Am J Med*. 1974;57:135-138.
89. Thériault J, Agharazzi M, Dumont M, et al. Atheroembolic renal failure requiring dialysis: potential for renal recovery? A review of 43 cases. *Nephron Clin Pract*. 2003;94:c11-c18.
90. Górriz JL, Sancho A, Garc   R, et al. Recovery of renal function after renal failure due to cholesterol crystal embolism. *Nephrol Dial Transplant*. 1999;14:2261-2262.
91. Scolari F, Ravani P, Pola A, et al. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. *J Am Soc Nephrol*. 2003;14:1584-1590.
92. Moolenaar W, Lamers CB. Cholesterol crystal embolisation to the alimentary tract. *Gut*. 1996;38:196-200.
93. Ben-Horin S, Bardan E, Barshack I, et al. Cholesterol crystal embolization to the digestive system: characterization of a



- common, yet overlooked presentation of atheroembolism. *Am J Gastroenterol*. 2003;98:1471-1479.
94. Paraf F, Jacquot C, Bloch F, et al. Cholesterol crystal embolization demonstrated on GI biopsy. *Am J Gastroenterol*. 2001;96:3301-3304.
  95. Matsukuma S, Suda K, Abe H. Histopathological study of pancreatic ischemic lesions induced by cholesterol emboli: fresh and subsequent features of pancreatic ischemia. *Hum Pathol*. 1998;29:41-46.
  96. Lawson JM. Cholesterol crystal embolization: more common than we thought? *Am J Gastroenterol*. 2001;96:3230-3232.
  97. Masuda J, Yutani C, Ogata J, et al. Atheromatous embolism in the brain: a clinicopathologic analysis of 15 autopsy cases. *Neurology*. 1994;44:1231-1237.
  98. Beal MF, Williams RS, Richardson EP Jr, Fisher CM. Cholesterol embolism as a cause of transient ischemic attacks and cerebral infarction. *Neurology*. 1981;31:860-865.
  99. Colucciello M. Images in clinical medicine. Retinal arteriolar cholesterol emboli. *N Engl J Med*. 2008;358:826.
  100. Dunlap AB, Kosmorsky GS, Kashyap VS. The fate of patients with retinal artery occlusion and Hollenhorst plaque. *J Vasc Surg*. 2007;46:1125-1129.
  101. Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal emboli in an older population. *Stroke*. 2006;37:908-910.
  102. Wang JJ, Cugati S, Knudtson MD, et al. Retinal arteriolar emboli and long-term mortality: pooled data analysis from two older populations. *Stroke*. 2006;37:1833-1836.
  103. Laloux P, Brucher JM. Lacunar infarctions due to cholesterol emboli. *Stroke*. 1991;22:1440-1444.
  104. Ezzeddine MA, Primavera JM, Rosand J, et al. Clinical characteristics of pathologically proved cholesterol emboli to the brain. *Neurology*. 2000;54:1681-1683.
  105. Desnuelle C, Lanteri-Minet M, Hofman P, et al. Cholesterol emboli with neurologic manifestation in the spinal cord. *Rev Neurol (Paris)*. 1992;148:715-718.
  106. Teja K, Crampton RS. Intramural coronary arteritis from cholesterol emboli: a rare cause of unstable angina preceding sudden death. *Am Heart J*. 1985;110:168-170.
  107. Sabatine MS, Oelberg DA, Mark EJ, Kanarek D. Pulmonary cholesterol crystal embolization. *Chest*. 1997;112:1687-1692.
  108. Walton TJ, Samani NJ, Andrews R. Systemic cholesterol crystal embolisation with pulmonary involvement: a fatal combination after coronary angiography. *Postgrad Med J*. 2002;78:288-289.
  109. Hillion D, Durst P, Baglin A, et al. Syndrome of alveolar hemorrhage associated with systemic cholesterol embolism. *Ann Med Interne (Paris)*. 1986;137:660-662.
  110. Sijpkens Y, Westendorp R, van Kemenade F, et al. Vasculitis due to cholesterol embolism. *Am J Med*. 1997;102:302-303.
  111. Reuter MD, Chor PJ, Dehlendorf A, Alpert MA. Spontaneous cholesterol crystal embolization to bone marrow. *South Med J*. 2007;100:533-536.
  112. Olin JW. Syndromes that mimic vasculitis. *Curr Opin Cardiol*. 1991;6:768-774.
  113. Anderson WR, Richards AM. Evaluation of lower extremity muscle biopsies in the diagnosis of atheroembolism. *Arch Pathol*. 1968;86:535-541.
  114. Cecioni I, Fassio F, Gori S, et al. Eosinophilia in cholesterol atheroembolic disease. *J Allergy Clin Immunol*. 2007;120:1470-1471.
  115. Low complement in atheroembolic disease. *Lancet*. 1985;2:136.
  116. Haqqie SS, Urizar RE, Singh J. Nephrotic-range proteinuria in renal atheroembolic disease: report of four cases. *Am J Kidney Dis*. 1996;28:493-501.
  117. Greenberg A, Bastacky SI, Iqbal A, et al. Focal segmental glomerulosclerosis associated with nephrotic syndrome in cholesterol atheroembolism: clinicopathological correlations. *Am J Kidney Dis*. 1997;29:334-344.
  118. Mieszczańska H, Lazar J, Marzo KP, Cunha BA. Cholesterol emboli mimicking acute bacterial endocarditis. *Heart Lung*. 2002;31:452-454.

119. Peat DS, Mathieson PW. Cholesterol emboli may mimic systemic vasculitis. *BMJ*. 1996;313:546-547.
120. Wilson DM, Salazer TL, Farkouh ME. Eosinophiluria in atheroembolic renal disease. *Am J Med*. 1991;91:186-189.
121. Siddiqui S, Norbury M, Robertson S, et al. Recovery of renal function after 90 d on dialysis: implications for transplantation in patients with potentially reversible causes of renal failure. *Clin Transplant*. 2008;22:136-140.
122. Liew YP, Bartholomew JR. Atheromatous embolization. *Vasc Med*. 2005;10:309-326.
123. Mann SJ, Sos TA. Treatment of atheroembolization with corticosteroids. *Am J Hypertens*. 2001;14:831-834.
124. Nakahama H, Sakaguchi K. Small dose oral corticosteroid treatment rapidly improved renal function in a patient with an acute aggravation of chronic renal failure due to cholesterol embolism. *Nephrol Dial Transplant*. 2001;16:872-873.
125. Matsumura T, Matsumoto A, Ohno M, et al. A case of cholesterol embolism confirmed by skin biopsy and successfully treated with statins and steroids. *Am J Med Sci*. 2006;331:280-283.
126. Yücel AE, Kart-Köseoglu H, Demirhan B, Ozdemir FN. Cholesterol crystal embolization mimicking vasculitis: success with corticosteroid and cyclophosphamide therapy in two cases. *Rheumatol Int*. 2006;26:454-460.
127. Koga J, Ohno M, Okamoto K, et al. Cholesterol embolization treated with corticosteroids—two case reports. *Angiology*. 2005;56:497-501.
128. Finch TM, Ryatt KS. Livedo reticularis caused by cholesterol embolization may improve with simvastatin. *Br J Dermatol*. 2000;143:1319-1320.
129. Woolfson RG, Lachmann H. Improvement in renal cholesterol emboli syndrome after simvastatin. *Lancet*. 1998;351:1331-1332.
130. Cabili S, Hochman I, Goor Y. Reversal of gangrenous lesions in the blue toe syndrome with lovastatin—a case report. *Angiology*. 1993;44:821-825.
131. Tunick PA, Nayar AC, Goodkin GM, et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. *Am J Cardiol*. 2002;90:1320-1325.
132. Elinav E, Chajek-Shaul T, Stern M. Improvement in cholesterol emboli syndrome after iloprost therapy. *BMJ*. 2002;324:268-269.
133. Minatohara K. Renal failure associated with blue toe syndrome: effective treatment with intravenous prostaglandin E-1. *Acta Derm Venereol*. 2006;86:364-365.
134. Hasegawa M, Kawashima S, Shikano M, et al. The evaluation of corticosteroid therapy in conjunction with plasma exchange in the treatment of renal cholesterol embolic disease. A report of 5 cases. *Am J Nephrol*. 2000;20:263-267.
135. Muso E, Mune M, Fujii Y, et al. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. *Nephron*. 2001;89:408-415.
136. Zuccala A, Zucchelli P. A renal disease frequently found at postmortem, but rarely diagnosed in vivo. *Nephrol Dial Transplant*. 1997;12:1762-1767.
137. Carr ME Jr, Sanders K, Todd WM. Pain relief and clinical improvement temporally related to the use of pentoxifylline in a patient with documented cholesterol emboli—a case report. *Angiology*. 1994;45:65-69.
138. Hankey GJ. Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE? *Stroke*. 2003;34:354-356.
139. Arnold JM, Yusuf S, Young J, et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. *Circulation*. 2003;107:1284-1290.
140. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med*. 2000;342:145-153.
141. Cannon CP. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). *Am J Cardiol*. 2002;90:760-762.
142. Collaboration, Antithrombotic Trialists. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002;324:71-86.

143. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360:7-22.
144. Keen RR, McCarthy WJ, Shireman PK, et al. Surgical management of atheroembolization. *J Vasc Surg*. 1995;21:773-780.
145. Baumann DS, McGraw D, Rubin BG, et al. An institutional experience with arterial atheroembolism. *Ann Vasc Surg*. 1994;8:258-265.
146. Dougherty MJ, Calligaro KD. Endovascular treatment of embolization of aortic plaque with covered stents. *J Vasc Surg*. 2002;36:727-731.
147. Friedman SG, Krishnasastri KV. External iliac ligation and axillary-bifemoral bypass for blue toe syndrome. *Surgery*. 1994;115:27-30.
148. Kaufman JL, Saifi J, Chang BB, et al. The role of extraanatomic exclusion bypass in the treatment of disseminated atheroembolism syndrome. *Ann Vasc Surg*. 1990;4:260-263.
149. Brewer ML, Kinnison ML, Perler BA, White RI Jr. Blue toe syndrome: treatment with anticoagulants and delayed percutaneous transluminal angioplasty. *Radiology*. 1988;166:31-36.
150. Sharma PV, Babu SC, Shah PM, Nassoura ZE. Changing patterns of atheroembolism. *Cardiovasc Surg*. 1996;4:573-579.
151. Clugston RA, Eisenhauer AC, Matthews RV. Atherectomy of the distal aorta using a "kissing-balloon" technique for the treatment of blue toe syndrome. *AJR Am J Roentgenol*. 1992;159:125-127.
152. Dolmatch BL, Rholl KS, Moskowitz LB, et al. Blue toe syndrome: treatment with percutaneous atherectomy. *Radiology*. 1989;173:799-804.
153. Matchett WJ, McFarland DR, Eidt JF, Moursi MM. Blue toe syndrome: treatment with intra-arterial stents and review of therapies. *J Vasc Interv Radiol*. 2000;11:585-592.
154. Murphy KD, Encarnacion CE, Le VA, Palmaz JC. Iliac artery stent placement with the Palmaz stent: follow-up study. *J Vasc Interv Radiol*. 1995;6:321-329.
155. Ohki T, Marin ML, Lyon RT, et al. Ex vivo human carotid artery bifurcation stenting correlation of lesion characteristics with embolic potential. *J Vasc Surg*. 1998;27:463-471.
156. Renshaw A, McCowen T, Waltke EA, et al. Angioplasty with stenting is effective in treating blue toe syndrome. *Vasc Endovasc Surg*. 2002;36:155-159.
157. Kumins NH, Owens EL, Oglevie SB, et al. Early experience using the Wallgraft in the management of distal microembolism from common iliac artery pathology. *Ann Vasc Surg*. 2002;16:181-186.
158. Carroccio A, Olin JW, Ellozy SH, et al. The role of aortic stent grafting in atheromatous embolization syndrome. Results after a mean of 15 months follow-up. *J Vasc Surg*. 2004;40:424-429.
159. Lee BY, Madden JL, Thoden WR, McCann WJ. Lumbar sympathectomy for toe gangrene. Long-term follow-up. *Am J Surg*. 1983;145:398-401.
160. Ghilardi G, Massaro F, Gobatti D, et al. Temporary spinal cord stimulation for peripheral cholesterol embolism. *J Cardiovasc Surg (Torino)*. 2002;43:255-258.
161. Tunick PA, Perez JL, Kronzon I. Protruding atheromas in the thoracic aorta and systemic embolization. *Ann Intern Med*. 1991;115:423-427.
162. Amarencu P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. *N Engl J Med*. 1994;331:1474-1479.
163. Amarencu P, Duyckaerts C, Tzourio C, et al. The prevalence of ulcerated plaques in the aortic arch in patients with stroke. *N Engl J Med*. 1992;326:221-225.
164. Kronzon I, Tunick PA. Aortic atherosclerotic disease and stroke. *Circulation*. 2006;114:63-75.
165. Molishe TA, Tunick PA, Kronzon I. Complications of aortic atherosclerosis: atheroemboli and thromboemboli. *Curr Treat Options Cardiovasc Med*. 2007;9:137-147.
166. Dávila-Román VG, Murphy SF, Nickerson NJ, et al. Atherosclerosis of the ascending aorta is an independent predictor of

- long-term neurologic events and mortality. *J Am Coll Cardiol*. 1999;33:1308-1316.
167. Tunick PA, Rosenzweig BP, Katz ES, et al. High risk for vascular events in patients with protruding aortic atheromas: a prospective study. *J Am Coll Cardiol*. 1994;32:1085-1090.
  168. Mitusch R, Doherty C, Wucherpfennig H, et al. Vascular events during follow-up in patients with aortic arch atherosclerosis. *Stroke*. 1997;28:36-39.
  169. Cohen A, Amarenco P. Atherosclerosis of the thoracic aorta: from risk stratification to treatment. *Am J Cardiol*. 2002;90:1333-1335.
  170. Laperche T, Laurian C, Roudaut R, Steg PG. Mobile thromboses of the aortic arch without aortic debris: a transesophageal echocardiographic finding associated with unexplained arterial embolism. *Circulation*. 1997;96:288-294.
  171. Dressler FA, Craig WR, Castello R, Labovitz AJ. Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. *J Am Coll Cardiol*. 1998;31:134-138.
  172. Ferrari E, Vidal R, Chevallier T, Baudouy M. Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: benefit of oral anticoagulants. *J Am Coll Cardiol*. 1999;33:1317-1322.
  173. Salem DN, Levine HJ, Pauker SG, et al. Antithrombotic therapy in valvular heart disease. *Chest*. 1998;114:590S-601S.
  174. Bojar RM, Payne DD, Murphy RE, et al. Surgical treatment of systemic atheroembolism from the thoracic aorta. *Ann Thorac Surg*. 1996;61:1389-1393.
  175. Stern A, Tunick PA, Culliford AT, et al. Protruding aortic arch atheromas: risk of stroke during heart surgery with and without aortic arch endarterectomy. *Am Heart J*. 1999;138:746-752.

## 第 161 章

1. Bonica JJ. *The Management of Pain*. 2nd ed. Philadelphia: Lea & Febiger; 1990:221-233.
2. Kozin F. The painful shoulder and reflex sympathetic dystrophy syndrome. In: McCarty DJ, ed. *Arthritis and Allied Conditions*. 10<sup>th</sup> ed. Philadelphia: Lea & Febiger; 1985.
3. Davis SW. Shoulder-hand syndrome in a hemiplegic population: 5-year retrospective study. *Arch Phys Med Rehabil*. 1977;8:353-356.
4. Gellman H, Keenan MA, Stone L, et al. Reflex sympathetic dystrophy in brain-injured patients. *Pain*. 1992;51:307-311.
5. Bryant PR, Kim CT, Millan R. The rehabilitation of causalgia (complex regional pain syndrome—type II). *Phys Med Rehabil Clin N Am*. 2002;13:137-157.
6. Wasner G, Schattschneider J, Binder A, Baron R. Complex regional pain syndrome—diagnostic, mechanisms, CNS involvement and therapy. *Spinal Cord*. 2003;41:61-75.
7. Hassantash SA, Afrkhteh M, Maier RV. Causalgia: a meta-analysis of the literature. *Arch Surg*. 2003;138:1226-1231.
8. Kozin F. Reflex sympathetic dystrophy syndrome. *Bull Rheum Dis*. 1986;36:1-8.
9. Mitchell SW, Morehouse GR, Keen WW. *Gunshot Wounds and Other Injuries of Nerves*. Philadelphia: JB Lippincott; 1864:164.
10. Stanton-Hicks M, Janig W, Hassenbusch S, et al. Reflex sympathetic dystrophy: changing concepts and taxonomy. *Pain*. 1995;63:127-133.
11. Haddox JD. A call for clarity. In: *Pain 1996-An Updated Review: IASP Refresher Courses on Pain Management held in conjunction with the 8th World Congress on Pain*. Seattle: IASP Press; 1996:97-99.
12. Stanton-Hicks M, Baron R, Boas R, et al. Complex regional pain syndromes: guidelines for therapy. *Clin J Pain*. 1998;14:155-166.
13. Merskey H, Bogduk N. *Classification of Chronic Pain*. 2nd ed. Seattle: IASP Press; 1994.
14. Doupe J, Cullen CH, Chance GQ. Post-traumatic pain and the causalgic syndrome. *J Neurol Psychiatry*. 1944;7:33-48.
15. Bergan JJ, Conn J. Sympathectomy for pain relief. *Med Clin North Am*. 1968;52:147-159.
16. Ramos M, Almazan A, Lozano F, et al. Phenol lumbar sympathectomy in severe arterial disease of the lower limb: a

- hemodynamic study. *Int Surg*. 1983;68:127-130.
17. Livingston WK. *Pain Mechanisms: A Physiological Interpretation of Causalgia and Its Related States*. New York: Macmillan; 1943:83-113.
  18. Thompson JE. The diagnosis and management of post-traumatic pain syndromes (causalgia). *Aust N Z J Surg*. 1979;49:299-304.
  19. Christensen K, Jensen EM, Noer I. The reflex dystrophy syndrome response to treatment with systemic corticosteroids. *Acta Chir Scand*. 1982;148:653-655.
  20. Huygen FJ, de Bruijn AG, de Bruin MT, et al. Evidence for local inflammation in complex regional pain syndrome type I. *Mediators Inflamm*. 2002;11:47-51.
  21. Schwartzman RJ, Grothusen J, Kiefer TR, Rohr P. Neuropathic central pain: epidemiology, etiology, and treatment options. *Arch Neurol*. 2001;58:1547-1550.
  22. Mailis A, Wade JA. Genetic considerations in CRPS. In: Harden RN, Baron R, Janig W, eds. *Progress in Pain Research and Management, Vol. 22, Complex regional pain syndrome*. Seattle: IASP Press; 2001:227-238.
  23. Roberts WJ. A hypothesis on the physiological basis for causalgia and related pain. *Pain*. 1986;24:297-311.
  24. Campbell JN. Complex regional pain syndrome and the sympathetic nervous system. In: *Pain 1996-An Updated Review. IASP Refresher Courses on Pain Management held in conjunction with the 8th World Congress on Pain*. Seattle: IASP Press; 1996:89-96.
  25. Bernstein BH, Singsen BH, Kent JT. Reflex neurovascular dystrophy in childhood. *J Pediatr*. 1978;93:211-215.
  26. Silber TJ, Majd M. Reflex sympathetic dystrophy syndrome in children and adolescents: report of 18 cases and review of the literature. *Am J Dis Child*. 1988;142:1325-1330.
  27. Drucker WR, Hubay CA, Holden WD, et al. Pathogenesis of posttraumatic sympathetic dystrophy. *Am J Surg*. 1959;97:454-465.
  28. Veldman PHJM, Reynen HM, Arntz IE, et al. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. *Lancet*. 1993;342:1012-1016.
  29. Bruehl S, Harden RN, Galer BS, et al. External validation of IASP diagnostic criteria for complex regional pain syndrome and proposed research diagnostic criteria. *Pain*. 1999;81:147-154.
  30. Schurmann M, Gradl G, Rommel O. Early diagnosis in post-traumatic complex regional pain syndrome. *Orthopedics*. 2007;30:450-456.
  31. Schondorf R. The role of the sympathetic skin response in the assessment of autonomic function. In: Low PA, ed. *Clinical Autonomic Disorders*. Boston: Little, Brown; 1993:231-241.
  32. Fealey RD. The thermoregulatory sweat test. In: Low PA, ed. *Clinical Autonomic Disorders*. Boston: Little, Brown; 1993:217-229.
  33. Low PA, Pfeifer MD. Standardization of clinical tests for practice and clinical trials. In: Low PA, ed. *Clinical Autonomic Disorders*. Boston: Little, Brown; 1993:287-296.
  34. Low PA, Wilson PR, Sandroni P, et al. Reflex sympathetic dystrophy: A reappraisal, progress. In: Janig W, Stanton-Hicks M, eds. *Pain Research and Management. Vol 6*. Seattle: IASP Press; 1996:40-43, 212-213.
  35. Longmire DR. An electrophysiological approach to the evaluation of regional sympathetic dysfunction: a proposed classification. *Pain Physician*. 2006;9:69-82.
  36. Birklein F, Schmeltz M, Schifter S, Weber M. The important role of neuropeptides in complex regional pain syndrome. *Neurology*. 2001;57:2179-2184.
  37. Sudeck P. Acute bone atrophy after inflammation or trauma of the extremities [in German]. *Dtsch Med Wochenschr*. 1902;28:336-338.
  38. Davidoff G, Werner R, Cremer S, et al. Predictive value of the three-phase technetium bone scan in diagnosis of reflex sympathetic dystrophy syndrome. *Arch Phys Med Rehabil*. 1989;70:135-137.

39. Kozin F, Ryan LM, Carerra GF, et al. The reflex sympathetic dystrophy syndrome: III. Scintigraphic studies, further evidence for the therapeutic efficacy of systemic corticosteroids and proposed diagnostic criteria. *Am J Med.* 1981;70:23-30.
40. AbuRahma AF, Robinson PA, Powell M, et al. Sympathectomy for reflex sympathetic dystrophy: factors affecting outcome. *Ann Vasc Surg.* 1994;8:372-379.
41. Loh L, Nathan PW. Painful peripheral states and sympathetic blocks. *J Neurol Neurosurg Psychiatry.* 1978;41:664-671.
42. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. *Pain.* 1997;73:123-139.
43. Perez RS, Kwakkel G, Zuurmond WW, de Lange JJ. Treatment of reflex sympathetic dystrophy (CRPS type I): a research synthesis of 21 randomized clinical trials. *J Pain Symptom Manage.* 2001;21:511-526.
44. Hogan CJ, Hurwitz SR. Treatment of complex regional pain syndrome of the lower extremity. *J Am Acad Orthop Surg.* 2002;10:281-289.
45. McCabe CS, Haigh RC, Ring EF, et al. A controlled pilot study of the utility of mirror visual feedback in the treatment of complex regional pain syndrome. *Rheumatology (Oxford).* 2003;42:97-101.
46. Dowd GSE, Hussein R, Khanduja V, Ordman AJ. Complex regional pain syndrome with special emphasis on the knee. *J Bone Joint Surg Br.* 2007;89:285-290.
47. Meyer GA, Fields HL. Causalgia treated by selective large fiber stimulation of peripheral nerve. *Brain.* 1972;95:163-168.
48. Wilson RL. Management of pain following peripheral nerve injuries. *Orthop Clin North Am.* 1981;12:343-359.
49. Chan CS, Chow SP. Electroacupuncture in the treatment of post-traumatic sympathetic dystrophy (Sudeck's atrophy). *Br J Anaesth.* 1981;53:899-901.
50. Benson WF. Discussion of RG Chuinard at Annual Meeting, American Society for Surgery of the Hand, Atlanta, 1980.
51. Raja SN, Treede RD, David KD, Campbell JN. Systemic alpha-adrenergic blockade with phentolamine: a diagnostic test for sympathetically maintained pain. *Anesthesiology.* 1991;74:691-698.
52. Malik VK, Inchiosa MA Jr, Mustafa K, et al. Intravenous regional phenoxybenzamine in the treatment of reflex sympathetic dystrophy. *Anesthesiology.* 1998;88:823-827.
53. Muizelaar JP, Kleyer M, Hertogs IA, et al. Complex regional pain syndrome (reflex sympathetic dystrophy and causalgia): management with the calcium channel blocker nifedipine and/or the alpha-sympathetic blocker phenoxybenzamine in 59 patients. *Clin Neurol Neurosurg.* 1997;99:26-30.
54. Adami S, Fossaluzza V, Gatti D, et al. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. *Ann Rheum Dis.* 1997;56:201-204.
55. Chabal C, Jacobson L, Mariano A, et al. The use of oral mexiletine for the treatment of pain after peripheral nerve injury. *Anesthesiology.* 1992;76:513-517.
56. Teasdall RD, Koman A, Wessinger P, et al. Reflex sympathetic dystrophy of the foot and ankle. *Foot Ankle Clin.* 1998;3:485-510.
57. Schott GD. Interrupting the sympathetic outflow in causalgia and reflex sympathetic dystrophy. *BMJ.* 1998;316:792-793.
58. Ochoa JL. Truths, errors, and lies around "reflex sympathetic dystrophy" and "complex regional pain syndrome." *J Neurol.* 1999;246:875-879.
59. Verdugo RJ, Ochoa JL. "Sympathetically maintained pain." I. Phentolamine block questions the concept. *Neurology.* 1994;44:1003-1010.
60. Cepeda MS, Carr DB, Lau J. Local anesthetic sympathetic blockade for complex regional pain syndrome. *Cochrane Database Syst Rev.* 2005; Oct 19;(4):CD004598.
61. Noe CE, Haynsworth RF Jr. Lumbar radiofrequency sympathectomy. *J Vasc Surg.* 1993;17:801-806.
62. Becker WJ, Ablett DP, Harris CJ, Dold ON. Long-term treatment of intractable reflex sympathetic dystrophy with intrathecal morphine. *Am J Neurol Sci.* 1995;22:153-159.
63. Cooper DE, DeLee JC, Ramamurthy S. Reflex sympathetic dystrophy of the knee: treatment using continuous epidural

- anesthesia. *J Bone Joint Surg Am.* 1989;71:365-369.
64. Van Hilten BJ, van de Beek WJ, Hoff JI, et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. *N Engl J Med.* 2000;343:625-630.
  65. Kemler MA, Barendse GA, van Kleef M, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. *N Engl J Med.* 2000;343:618-624.
  66. Taylor RS. Spinal cord stimulation in complex regional pain syndrome and refractory neuropathic back and leg pain/failed back surgery syndrome: results of a systematic review and meta-analysis. *J Pain Symptom Manage.* 2006;31:S13-S19.
  67. Cooney WP. Somatic versus sympathetic mediated chronic limb pain: experience and treatment options. *Hand Clin.* 1997;13:355-361.
  68. Mockus MB, Rutherford RB, Rosales C, et al. Sympathectomy for causalgia: patient selection and long-term results. *Arch Surg.* 1987;122:668-672.
  69. Flowthrow PG. Anterior extraperitoneal approach to the lumbar sympathetic nerves. *Am J Surg.* 1948;127:953.
  70. Adson AW, Brown CE. Treatment of Raynaud's disease by lumbar ramisection and ganglionectomy and perivascular sympathectomy neurectomy of the common iliac arteries. *JAMA.* 1925;84:1908.
  71. Cheshire NJ, Darzi AW. Retroperitoneoscopic lumbar sympathectomy. *Br J Surg.* 1997;84:1094.
  72. Beglaibter N, Berlatzky Y, Zamir O, et al. Retroperitoneoscopic lumbar sympathectomy. *J Vasc Surg.* 2002;35:815-817.
  73. Kathouda N, Wattanasirichaigoon S, Tang E, et al. Laparoscopic lumbar sympathectomy. *Surg Endosc.* 1997;11:257.
  74. Spurling RG. Causalgia of the upper extremity: treatment by dorsal sympathetic ganglionectomy. *Arch Neurol Psychiatry (Chir).* 1930;23:704.
  75. Kwan ST. The treatment of causalgia by thoracic sympathetic ganglionectomy. *Ann Surg.* 1935;101:222.
  76. Olcott C, Eltherington LG, Wilcosky BR, et al. Reflex sympathetic dystrophy: the surgeon's role in management. *J Vasc Surg.* 1991;14:488-492.
  77. Bandyk DF, Johnson BL, Kirkpatrick AF, et al. Surgical sympathectomy for reflex sympathetic dystrophy syndromes. *J Vasc Surg.* 2002;35:269-277.
  78. Singh B, Moodley J, Shaik AS, Robbs JV. Sympathectomy for complex regional pain syndrome. *J Vasc Surg.* 2003;37:508-511.
  79. Litwin MS. Post-sympathectomy neuralgia. *Arch Surg.* 1962;84:591.
  80. Quale JB. Sexual function after bilateral lumbar sympathectomy and aortoiliac bypass surgery. *J Cardiovasc Surg.* 1980;21:215.
  81. Bergan JJ, Trippell OH. Arteriograms in ischemic limbs worsened after lumbar sympathectomy. *Arch Surg.* 1962;85:135.
  82. Katz MM, Hungerford DS. Reflex sympathetic dystrophy affecting the knee. *J Bone Joint Surg Br.* 1987;69:797-803.
  83. Hamamci N, Dursun E, Ural C, Cakci A. Calcitonin treatment in reflex sympathetic dystrophy: a preliminary study. *Br J Clin Pract.* 1996;50:373-375.
  84. Ogilvie-Harris DJ, Roscoe M. Reflex sympathetic dystrophy of the knee. *J Bone Joint Surg Br.* 1987;69:804-806.
  85. Grabow TS, Tella PK, Raja SN. Spinal accord stimulation for complex regional pain syndrome: an evidence-based medicine review of the literature. *Clin J Pain.* 2003;19:371-383.
  86. Lindenfeld TN, Bach BR, Wojtys EM. Reflex sympathetic dystrophy and pain dysfunction in the lower extremity. *J Bone Joint Surg Am.* 1996;78:1936-1944.